Medicines Information Services

Information on any aspect of drug therapy can be obtained from Regional and District Medicines Information Services. Details regarding the local services provided within your Region can be obtained by telephoning the following numbers.

England
Birmingham: (0121) 424 7298
Bristol: (0117) 342 2867
Ipswich: (01473) 704 431
Leeds: (0113) 206 5377
Leicester: (0116) 255 779/258 3491
Liverpool: (0151) 794 8113/4/5/7, or (0151) 795 8206
London: Guy’s Hospital (020) 7188 8750, or (020) 7188 3849, or (020) 7188 3855
Northwick Park Hospital (020) 8869 2761, or (020) 8869 3973
Newcastle: (0191) 282 4631
Southampton: (023) 8120 6908/9

Wales
Cardiff: (029) 2074 2979, or (029) 2074 2251

Scotland
Aberdeen: (01224) 552 316
Dundee: (01382) 632 351, or (01382) 660 111 Extn 32351
Edinburgh: (0131) 242 2920
Glasgow: (0141) 211 4407

Northern Ireland
Belfast: (028) 9063 2032, or (028) 9063 3847

Republic of Ireland
Dublin: (Dublin) 473 0589, or (Dublin) 453 7941 Extn 2348

United Kingdom Medicines Information Pharmacists Group (UKMIPG) website
www.ukmi.nhs.uk

Telephone numbers and email addresses of manufacturers listed in BNF Publications are shown in Index of Proprietary Manufacturers

UK Teratology Information Service
Information on drug and chemical exposures in pregnancy.
Tel: 0844 892 0909

Information on drug therapy relating to dental treatment can be obtained by telephoning
Liverpool: (0151) 794 8206

Driver and Vehicle Licensing Agency (DVLA)
Information on the national medical guidelines of fitness to drive is available from: www.gov.uk/government/publications/at-a-glance

Patient Information Lines
NHS Urgent Care Services 111

Poisons Information Services
UK National Poisons Information Service 0844 892 0111

Sport
Information on substances currently permitted or prohibited is provided in a card supplied by UK Anti-doping.
Further information regarding medicines in sport is available from: www.ukad.org.uk
Tel: (020) 7766 7350
information@ukad.org.uk

Travel Immunisation
Up-to-date information on travel immunisation requirements may be obtained from:
National Travel Health Network and Centre (for healthcare professionals only) 0845 602 6712 (09.00–12.00 and 14.00–16.30 hours weekdays)
Travel Medicine Team, Health Protection Scotland (0141) 300 1130 (14.00–16.00 hours weekdays)
www.travax.nhs.uk (for registered users of the NHS website Travax only)
Welsh Government Switchboard English language 0300 0603300 (09.00–17.30 hours weekdays only)
Welsh Government Switchboard Yr Iaith Gymraeg 0300 0604400 (09.00–17.30 hours weekdays only)
Department of Health and Social Services (Belfast) (028) 9052 2118 (weekdays)

List of Registered Medical Practitioners
Details on whether doctors are registered and hold a licence to practise medicine in the UK can be obtained from the General Medical Council.
Tel: (0161) 923 6602
www.gmc-uk.org/register

Travel Immunisation
Up-to-date information on travel immunisation requirements may be obtained from:
National Travel Health Network and Centre (for healthcare professionals only) 0845 602 6712 (09.00–12.00 and 14.00–16.30 hours weekdays)
Travel Medicine Team, Health Protection Scotland (0141) 300 1130 (14.00–16.00 hours weekdays)
www.travax.nhs.uk (for registered users of the NHS website Travax only)
Welsh Government Switchboard English language 0300 0603300 (09.00–17.30 hours weekdays only)
Welsh Government Switchboard Yr Iaith Gymraeg 0300 0604400 (09.00–17.30 hours weekdays only)
Department of Health and Social Services (Belfast) (028) 9052 2118 (weekdays)

List of Registered Medical Practitioners
Details on whether doctors are registered and hold a licence to practise medicine in the UK can be obtained from the General Medical Council.
Tel: (0161) 923 6602
www.gmc-uk.org/register
Access the BNF your way

The British National Formulary (BNF) and BNF for Children are updated monthly online via MedicinesComplete, ensuring healthcare professionals always have the latest prescribing advice.

You can be alerted to all the latest updates by signing up to the BNF eNewsletter at www.bnf.org/newsletter.

**ONLINE**

BNF on MedicinesComplete
Access BNF and BNF for Children on MedicinesComplete and receive the very latest drug information through monthly online updates.

BNF on FormularyComplete
Create, edit and manage your own local formulary content built upon the trusted prescribing advice of the BNF and BNF for Children.

BNF on Evidence Search
Search the BNF and BNF for Children alongside other authoritative clinical and non-clinical evidence and best practice at http://evidence.nhs.uk from NICE.

**MOBILE**

BNF app – Stay up to date anywhere with the BNF app available for iOS, Android and Blackberry.
BNF eBook – Available as an ePDF via a range of suppliers. See www.pharmpress.com/bnf.
BNF on MedicinesComplete – Now mobile responsive.

**PRINT**

BNF subscription – if you prefer to access BNF in print, take advantage of our subscription option. We will send you the new BNF as soon as the book is published. One or two year packages (including or excluding BNFC) are available. Discounted pricing is also available on bulk sales.
How to purchase

Purchase direct from Pharmaceutical Press by visiting www.pharmpress.com/bnf

For enquiries about the BNF or BNFC in print, contact direct@macmillan.co.uk
Tel: +44 (0) 1256 302 699

For enquiries concerning MedicinesComplete, BNF on FormularyComplete, or bulk orders of the print edition, contact pharmpress@rpharms.com
Tel: +44 (0) 20 7572 2266

Download mobile apps by visiting your appropriate app store.
Available for iOS, Android and Blackberry

For pricing information please visit the website at www.pharmpress.com/bnf

For international sales contact your local sales agent.
Contact details at www.pharmpress.com/agents

Stay up to date – sign up to the BNF eNewsletter at www.bnf.org/newsletter
Preface

The BNF is a joint publication of the British Medical Association and the Royal Pharmaceutical Society. It is published under the authority of a Joint Formulary Committee which comprises representatives of the two professional bodies, the UK Health Departments, the Medicines and Healthcare products Regulatory Agency, and a national guideline producer. The Dental Advisory Group oversees the preparation of advice on the drug management of dental and oral conditions; the Group includes representatives of the British Dental Association and a representative from the UK Health Departments. The Nurse Prescribers’ Advisory Group advises on the content relevant to nurses and includes representatives from different parts of the nursing community and from the UK Health Departments.

The BNF aims to provide prescribers, pharmacists, and other healthcare professionals with sound up-to-date information about the use of medicines.

The BNF includes key information on the selection, prescribing, dispensing and administration of medicines. Medicines generally prescribed in the UK are covered and those considered less suitable for prescribing are clearly identified. Little or no information is included on medicines promoted for purchase by the public.

Information on drugs is drawn from the manufacturers’ product literature, medical and pharmaceutical literature, UK health departments, regulatory authorities, and professional bodies. Advice is constructed from clinical literature and reflects, as far as possible, an evaluation of the evidence from diverse sources. The BNF also takes account of authoritative national guidelines and emerging safety concerns. In addition, the editorial team receives advice on all therapeutic areas from expert clinicians; this ensures that the BNF’s recommendations are relevant to practice.

The BNF is designed as a digest for rapid reference and it may not always include all the information necessary for prescribing and dispensing. Also, less detail is given on areas such as obstetrics, malignant disease, and anaesthesia since it is expected that those undertaking treatment will have specialist knowledge and access to specialist literature. BNF for Children should be consulted for detailed information on the use of medicines in children. The BNF should be interpreted in the light of professional knowledge and supplemented as necessary by specialised publications and by reference to the product literature. Information is also available from medicines information services, see Medicines Information Services.

It is important to use the most recent BNF information for making clinical decisions. The print edition of the BNF is updated in March and September each year. Monthly updates are provided online via Medicines Complete and the NHS Evidence portal. The more important changes are listed under Changes; changes listed online are cumulative (from one print edition to the next), and can be printed off each month to show the main changes since the last print edition as an aide memoire for those using print copies.

The BNF Publications website (www.bnf.org) includes additional information of relevance to healthcare professionals. Other digital formats of the BNF—including versions for mobile devices and integration into local formularies—are also available.
Contents

Preface page iii
Acknowledgements v
How BNF publications are constructed ix
How to use the BNF xi
Changes xv
Guidance on Prescribing 1
Prescription writing 4
Emergency supply of medicines 6
Controlled drugs and drug dependence 7
Adverse reactions to drugs 11
Guidance on intravenous infusions 14
Prescribing for children 16
Prescribing in hepatic impairment 17
Prescribing in renal impairment 17
Prescribing in pregnancy 19
Prescribing in breast-feeding 19
Prescribing in palliative care 20
Prescribing for the elderly 25
Drugs and sport 26
Prescribing in dental practice 27

NOTES ON DRUGS AND PREPARATIONS

1 Gastro-intestinal system page 32
2 Cardiovascular system 84
3 Respiratory system 209
4 Nervous system 262
5 Infection 438
6 Endocrine system 574
7 Genito-urinary system 667
8 Malignant disease 715
9 Blood and nutrition 822
10 Musculoskeletal system 891
11 Eye 943
12 Ear, nose and oropharynx 976
13 Skin 998
14 Vaccines 1059
15 Anaesthesia 1093
16 Emergency treatment of poisoning 1123

APPENDICES AND INDICES

Appendix 1 Interactions 1137
Appendix 2 Borderline substances 1260
Appendix 3 Cautionary and advisory labels for dispensed medicines 1291
Appendix 4 Wound management products and elasticated garments 1294
Dental Practitioners’ Formulary 1320
Nurse Prescribers’ Formulary 1322
Non-medical prescribing 1325
index of proprietary manufacturers 1326
Special-order Manufacturers 1335
Index 1337
Medical emergencies in the community inside back cover
Acknowledgements

The Joint Formulary Committee is grateful to individuals and organisations that have provided advice and information to the BNF.

The principal contributors for this update were:

Expert advice on the management of oral and dental conditions was kindly provided by M. Addy, P. Coulthard, A. Crighton, M.A.O. Lewis, J.G. Meechan, N.D. Robb, C. Scully, R.A. Seymour, R. Welbury, and J.M. Zakrzewska. S. Kaur provided valuable advice on dental prescribing policy.

Members of the British Association of Dermatologists’ Therapy & Guidelines Subcommittee, D.A. Buckley, M. Cork, E. Duarte Williams, M. Griffiths, T. Leslie, E. Mallon, P. McHenry, P. Hunzehally, I. Nasr, C. Saunders, V. Swale, S. Ungureanu, S. Wakelin, A. Brain (Secretariat), and M.F. Mohd Mustapa (Secretariat) have provided valuable advice.

Members of the Advisory Committee on Malaria Prevention, R.H. Behrens, D. Bell, P.L. Chiodini, V. Field, F. Genasi, L. Goodyer, A. Green, J. Jones, G. Kassianos, D.G. Lalloo, D. Patel, H. Patel, M. Powell, D.V. Shingadia, N.O. Subair, C.J.M. Whitty, M. Blaze (Secretariat), and V. Smith (Secretariat) have provided valuable advice.

The UK Ophthalmic Pharmacy Group have also provided valuable advice.

The MHRA have provided valuable assistance.

Correspondents in the pharmaceutical industry have provided information on new products and commented on products in the BNF.

Numerous doctors, pharmacists, nurses, and others have sent comments and suggestions.

BNF interactions are provided by C.L. Preston, S.L. Jones, H.K. Sandhu, and S. Sutton.

The BNF has valuable access to the Martindale data banks by courtesy of A. Brayfield and staff.

J. Macdonald and staff provided valuable technical assistance.

K.K. Cheema, M.E. Elnaeem, H.G. Hesketh, M. Khalid, and E. Laughton provided considerable assistance during the production of this update of the BNF.

BNF Staff

BNF DIRECTOR
Karen Baxter
BSc, MSc, MRPharmS

HEAD OF CONTENT
Kate Towers
BPharm (AU), GCClinPharm

CONTENT MANAGERS
Jessica A. Forrest
BPharm (AU), GradDipHlthEcon (AU)
Kristina Fowlie
MPharm, CertPharmPract, MRPharmS
Heenaben Patel
MPharm, DipClinPharm, MRPharmS

QUALITY AND PROCESS MANAGER
Angela M.G. McFarlane
BSc, DipClinPharm

CLINICAL WRITERS
Thomas Corbett
BSc (Pharm), MPharm
Joyce Donnelly
MPharm, MRPharmS
Serena Frau
MPharm (IT), DipHospPharm (IT), CertScientMethod (IT)
Belén Granell Villén
BSc, DipClinPharm
Maeve A.M. Lynn
MPharm
Claire McSherry
BPharm (NZ), PGCertClinPharm (NZ)
Kere Odumah
MPharm
Katie L. Page
MPharm, MRPharmS
Roushin Patel
MPharm, MRPharmS
Paridhi K. Prashar
MPharm, MRPharmS
Dominique Shakir
MPharm, MRPharmS, IP, PGDip
Jyoti A. Sood
MPharm, MRPharmS, CertPharmPract

CLINICAL ASSISTANTS
Basma Hossin
MPharm, PhD
Elizabeth King

SENIOR BNF ADMINISTRATOR
Heidi Homar
BA

MANAGING DIRECTOR, PHARMACEUTICAL PRESS
Alina Lourie
B.Ed, MSc

SENIOR MEDICAL ADVISER
Derek G. Waller
BSc, MB, BS, DM, FRCP

CONTRIBUTORS TO BNF 70

SENIOR CLINICAL WRITER
Manjula Halai
BScChem, MPharm

CLINICAL WRITER
Sarah Mohamad
MPharm, MRPharmS

EDITORIAL ASSISTANT
Rhiannon Howe
BMedSc
Joint Formulary Committee 2015–2016

CHAIR
Derek G. Waller
BSc, MB BS, DM, FRCP

DEPUTY CHAIR
Alison Blenkinsopp
BPharm, PhD, FRPharmS, OBE

COMMITTEE MEMBERS
Julie Beynon
MB ChB, FRCA, FFPM
Carmel M. Darcy
BSc, MSc, IP, MPSNI, MRPharmS
Sue Faulding
BPharm, MSc, FRPharmS
Matt Griffiths
BA, FAETC, RGN, Cert A&E, NISP
Tracy Hall
BSc, MSc, Cert N, Dip N, RGN, DN
W. Moira Kinnear
BSc, MSc, MRPharmS
Mark P. Lythgoe
MB BS, MRPharmS
Louise Picton
BSc, DipCommPharm, MSc, MRPharmS
Michael J. Stewart
MB ChB, MD, FRCP(Ed), FRCP
Esther Wong
BSc, MPharm, MSc, DipEthics, DipPharmPract, IP, MRPharmS

LAY MEMBERS
Andy Burman
Elaine Keen

EXECUTIVE SECRETARY
Heidi Homar
BA

Dental Advisory Group 2015–2016

CHAIR
Sarah Manton
BDS, FDSRCS Ed, FHEA, PhD

COMMITTEE MEMBERS
Christine Arnold
BDS, DDPhRCS, MCDH
Karen Baxter
BSc, MSc, MRPharmS
Andrew K. Brewer
BSc, BchD
Barry Cockerston
BDS, FDSRCS (Eng)
Lesley P. Longman
BSc, BDS, FDSRCS Ed, PhD
Michelle Moffat
BDS, MFDS RCS Ed, M Paed Dent RCPS, FDS (Paed Dent) RCS Ed
Sarah Mohamad
MPharm, MRPharmS

SECRETARY
Arianne J. Matlin
MA, MSc, PhD

EXECUTIVE SECRETARY
Heidi Homar
BA

ADVICE ON DENTAL PRACTICE
The British Dental Association has contributed to the advice on medicines for dental practice through its representatives on the Dental Advisory Group.
Nurse Prescribers’ Advisory Group 2015-2016

CHAIR
Molly Courtenay
PhD, MSc, Cert Ed, BSc, RGN

COMMITTEE MEMBERS
Karen Baxter
BSc, MSc, MRPharmS
Penny M. Franklin
RN, RCN, RSCPHN(HV), MA, PGCE
Belen Granell Villen
BSc, PGDipClinPharm
Tracy Hall
BSc, MSc, RGN, DN, Dip N, Cert N
Joan Myers
MSc, BSc, RGN, RSCN, Dip DN
Kathy Radley
BSc, RGN
John Wright

EXECUTIVE SECRETARY
Heidi Homar
BA
How BNF publications are constructed

The BNF is unique in bringing together authoritative, independent guidance on best practice with clinically validated drug information, enabling healthcare professionals to select safe and effective medicines for individual patients.

Information in the BNF has been validated against emerging evidence, best-practice guidelines, and advice from a network of clinical experts.

Hundreds of changes are made between print editions, and are published monthly in some digital formats. The most clinically significant updates are listed under Changes p. xv.

Joint Formulary Committee
The Joint Formulary Committee (JFC) is responsible for the content of the BNF. The JFC includes doctors appointed by the BMJ Group, pharmacists appointed by the Royal Pharmaceutical Society, nursing and lay representatives; there are also representatives from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK Health Departments, and a national guideline producer.

The JFC decides on matters of policy and reviews amendments to the BNF in the light of new evidence and expert advice.

Dental Advisory Group
The Dental Advisory Group oversees the preparation of advice on the drug management of dental and oral conditions; the group includes representatives from the British Dental Association and a representative from the UK Health Departments.

Nurse Prescribers’ Advisory Group
The Nurse Prescribers’ Advisory Group oversees the list of drugs approved for inclusion in the Nurse Prescribers’ Formulary; the group includes representatives from a range of nursing disciplines and stakeholder organisations.

Editorial Team
BNF clinical writers have all worked as pharmacists and have a sound understanding of how drugs are used in clinical practice. Each clinical writer is responsible for editing, maintaining, and updating BNF content. During the publication cycle the clinical writers review information in the BNF against a variety of sources.

Amendments to the text are drafted when the clinical writers are satisfied that any new information is reliable and relevant. The draft amendments are passed to expert advisers for comment and then presented to the Joint Formulary Committee for consideration. Additionally, sections are regularly chosen for thorough review. These planned reviews aim to verify all the information in the selected sections and to draft any amendments to reflect the current best practice.

Clinical writers prepare the text for publication and undertake a number of checks on the knowledge at various stages of the production.

Expert advisers
The BNF uses about 60 expert clinical advisers (including doctors, pharmacists, nurses, and dentists) throughout the UK to help with clinical content. The role of these expert advisers is to review existing text and to comment on amendments drafted by the clinical writers. These clinical experts help to ensure that the BNF remains reliable by:

- commenting on the relevance of the text in the context of best clinical practice in the UK;
- checking draft amendments for appropriate interpretation of any new evidence;
- providing expert opinion in areas of controversy or when reliable evidence is lacking;
- advising on areas where the BNF diverges from summaries of product characteristics;
- providing independent advice on drug interactions, prescribing in hepatic impairment, renal impairment, pregnancy, breast-feeding, children, the elderly, palliative care, and the emergency treatment of poisoning.

In addition to consulting with regular advisers, the BNF calls on other clinical specialists for specific developments when particular expertise is required.

The BNF works closely with a number of expert bodies that produce clinical guidelines. Drafts or pre-publication copies of guidelines are routinely received for comment and for assimilation into the BNF.

Sources of BNF information
The BNF uses a variety of sources for its information; the main ones are shown below.

Summaries of product characteristics
The BNF receives summaries of product characteristics (SPCs) of all new products as well as revised SPCs for existing products. The SPCs are the principal source of product information and are carefully processed, despite the ever-increasing volume of information being issued by the pharmaceutical industry. Such processing involves:

- verifying the approved names of all relevant ingredients including ‘non-active’ ingredients (the BNF is committed to using approved names and descriptions as laid down by the Human Medicines Regulations 2012);
- comparing the indications, cautions, contra-indications, and side-effects with similar existing drugs. Where these are different from the expected pattern, justification is sought for their inclusion or exclusion;
- seek independent data on the use of drugs in pregnancy and breast-feeding;
- incorporating the information into the BNF using established criteria for the presentation and inclusion of the data;
- checking interpretation of the information by a second clinical writer before submitting to a content manager; changes relating to doses receive an extra check;
- identifying potential clinical problems or omissions and seeking further information from manufacturers or from expert advisers;
- careful validation of any areas of divergence of the BNF from the SPC before discussion by the Committee (in the light of supporting evidence);
- constructing, with the help of expert advisers, a comment on the role of the drug in the context of similar drugs.

Much of this processing is applicable to the following sources as well.

Expert advisers
The role of expert clinical advisers in providing the appropriate clinical context for all BNF information is discussed above.

Literature
Clinical writers monitor core medical and pharmaceutical journals. Research papers and reviews relating to drug therapy are carefully processed. When a difference between the advice in the BNF and the paper is noted, the new information is assessed for reliability and relevance to UK clinical practice. If necessary, new text is drafted and discussed with expert advisers and the Joint Formulary Committee. The BNF enjoys a close working relationship with a number of national information providers.

Systematic reviews
The BNF has access to various databases of systematic reviews (including the Cochrane Library and various web-
based resources). These are used for answering specific queries, for reviewing existing text, and for constructing new text. Clinical writers receive training in critical appraisal, literature evaluation, and search strategies. Reviews published in Clinical Evidence are used to validate BNF advice.

Consensus guidelines
The advice in the BNF is checked against consensus guidelines produced by expert bodies. A number of bodies make drafts or pre-publication copies of the guidelines available to the BNF; it is therefore possible to ensure that a consistent message is disseminated. The BNF routinely processes guidelines from the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the Scottish Intercollegiate Guidelines Network (SIGN).

Reference sources
Textbooks and reference sources are used to provide background information for the review of existing text or for the construction of new text. The BNF team works closely with the editorial team that produces Martindale: The Complete Drug Reference. The BNF has access to Martindale information resources and each team keeps the other informed of significant developments and shifts in the trends of drug usage.

Statutory information
The BNF routinely processes relevant information from various Government bodies including Statutory Instruments and regulations affecting the Prescriptions only Medicines Order. Official compendia such as the British Pharmacopoeia and its addenda are processed routinely to ensure that the BNF complies with the relevant sections of the Human Medicines Regulations 2012.

The BNF maintains close links with the Home Office (in relation to controlled drug regulations) and the Medicines and Healthcare products Regulatory Agency (including the British Pharmacopoeia Commission). Safety warnings issued by the Commission on Human Medicines (CHM) and guidelines on drug are issued by the UK health departments are processed as a matter of routine.

Relevant professional statements issued by the Royal Pharmaceutical Society are included in the BNF as are guidelines from bodies such as the Royal College of General Practitioners.

The BNF reflects information from the Drug Tariff, the Scottish Drug Tariff, and the Northern Ireland Drug Tariff.

Medicines and devices
NHS Prescription Services (from the NHS Business Services Authority) provides non-clinical, categorical information (including prices) on the medicines and devices included in the BNF.

Comments from readers
Readers of the BNF are invited to send in comments. Numerous letters and emails are received by the BNF team. Such feedback helps to ensure that the BNF provides practical and clinically relevant information. Many changes in the presentation and scope of the BNF have resulted from comments sent in by users.

Comments from industry
Close scrutiny of BNF by the manufacturers provides an additional check and allows them an opportunity to raise issues about BNF’s presentation of the role of various drugs; this is yet another check on the balance of BNF’s advice. All comments are looked at with care and, where necessary, additional information and expert advice are sought.

Market research
Market research is conducted at regular intervals to gather feedback on specific areas of development, such as drug interactions or changes to the way information is presented in digital formats.

Overview
The BNF is an independent professional publication that is kept up-to-date and addresses the day-to-day prescribing information needs of healthcare professionals. Use of this resource throughout the health service helps to ensure that medicines are used safely, effectively, and appropriately.
How to use the BNF

This edition of the BNF marks a fundamental change to the structure of the content. The changes have been made to bring consistency and clarity to BNF content, and to the way that the content is arranged within print and digital products, increasing the ease with which information can be found.

For this print edition, the most notable changes include:

— Drug monographs – where possible, all information that relates to a single drug is now contained within its drug monograph, moving information previously contained in the prescribing notes. Drug monographs have also changed structurally: additional sections have been added, ensuring greater regularity around where information is located within the publication.

— Drug-class monographs – where substantial amounts of information is common to all drugs within a drug class (e.g. macrolides, p. 469), a drug-class monograph has been created to contain the common information.

— Medicines – categorical information about marketed medicines, such as price and pack size, continues to be sourced directly from the Dictionary of Medicines and Devices provided by the NHS Business Services Authority. However, clinical information curated by the BNF team has been clearly separated from the categorical pricing and pack size information and is included in the relevant section of the drug monograph.

— Section numbering – the BNF section numbering has been removed. This section numbering tied the content to a rigid structure and enforced the retention of defunct classifications, such as mercurial diuretics, and hindered the relocation of drugs where therapeutic use had altered. It also caused constraints between the BNF and BNF for Children, where drugs had different therapeutic uses in children.

— Appendix 4 – the content has been moved to individual drug monographs. The introductory notes have been replaced with a new guidance section, Guidance on intravenous infusions, p. 14.

Introduction

In order to achieve the safe, effective, and appropriate use of medicines, healthcare professionals must be able to use the BNF effectively, and keep up to date with significant changes in the BNF that are relevant to their clinical practice. This How to Use the BNF is key in introducing the new structure of the BNF to all healthcare professionals involved with prescribing, monitoring, supplying, and administering medicines, as well as supporting the learning of students training to join these professions.

Structure of the BNF

This new BNF broadly follows the high-level structure of previous editions:

Front matter, comprising information on how to use the BNF, the significant content changes in each edition, and guidance on various prescribing matters (e.g. prescription writing, the use of intravenous drugs, particular considerations for special patient populations);

Chapters, containing drug monographs describing the uses, doses, safety issues and other considerations involved in the use of drugs; class monographs; and treatment summaries, covering guidance on the selection of drugs. Monographs and treatment summaries are divided into chapters based on specific aspects of medical care, such as Chapter 5, Infections, or Chapter 16, Emergency treatment of poisoning; or drug use related to a particular system of the body, such as Chapter 2, Cardiovascular.

Within each chapter, content is organised alphabetically by therapeutic use (e.g. Respiratory disease, obstructive), with the treatment summaries first (e.g. asthma), followed by the monographs of the drugs used to manage the conditions discussed in the treatment summary. Within each therapeutic use, the drugs are organised alphabetically by classification (e.g. Antimuscarinics, Beta-agonist bronchodilators) and then alphabetically within each classification (e.g. Acetazolamide, Glycopyrronium bromide, Ipratropium bromide).

Appendices, covering interactions, borderline substances, cautionary and advisory labels, and woundcare.

Back matter, covering the lists of medicines approved by the NHS for Dental and Nurse Practitioner prescribing, proprietary and specials manufacturer’s contact details, and the index. Yellow cards are also included, to facilitate the reporting of adverse events, as well as quick reference guides for life support and key drug doses in medical emergencies, for ease of access.

Navigating the BNF

The contents page provides the high-level layout of information within the BNF; and in addition, each chapter begins with a small contents section, describing the therapeutic uses covered within that chapter. Once in a chapter, location is guided by the side of the page showing the chapter number (the thumbnail), alongside the chapter title. The top of the page includes the therapeutic use (the running head) alongside the page number.

On one page, visual cues aid navigation: treatment summary information is in black type, with therapeutic use titles similarly styled in black, whereas the use of colour indicates drug-related information, including drug classification titles, class monographs, and drug monographs.

Although navigation is possible by browsing, primarily access to the information is via the index, which covers the titles of drug class monographs, drug monographs, and treatment summaries; as well as the names of branded medicines and other topics of relevance, such as abbreviations, guidance sections, tables, and images.

Content types

Treatment summaries

Treatment summaries are of three main types;

— an overview of delivering a drug to a particular body system (e.g. Skin conditions, management, p. 998),
— a comparison between a group or groups of drugs (e.g. Beta-adrenoceptor blocking drugs, p. 139),
— an overview of the drug management or prophylaxis of common conditions intended to facilitate rapid appraisal of options (e.g. Hypertension, p. 121, or Malaria, prophylaxis, p. 528).

In order to select safe and effective medicines for individual patients, information in the treatment summaries must be used in conjunction with other prescribing details about the drugs and knowledge of the patient’s medical and drug history.

Monographs

Overview

In previous editions, a systemically administered drug with indications for use in different body systems was split across the chapters relating to those body systems body systems. So, for example, codeine phosphate was found in chapter 1, for its antiinflammatory effects and chapter 4 for its analgesic effects. However, the monograph in chapter 1 contained only the dose and some selected safety precautions.

In this new BNF all of the information for the systemic use of a drug is contained within one monograph, so codeine phosphate is now included in chapter 4. This
carries the advantage of providing all of the information in one place, so the user does not need to flick back and forth across several pages to find all of the relevant information for that drug. Cross references are included in chapter 1, where the management of diarrhoea is discussed, to the drug monograph to assist navigation.

Where drugs have systemic and local uses, for example, chloramphenicol, and the considerations around drug use are markedly different according to the route of administration, the monograph is split, as with previous editions, into the relevant chapters.

This means that the majority of drugs will still be placed in the same chapters and sections as previous editions, and although there may be some variation in order, all of the relevant information will be easier to locate.

One of the most significant changes to the monograph structure is the increased granularity, with a move from around 9 sections to over 20 sections; sections are only included when relevant information has been identified. The following information describes these sections and their uses in more detail.

**Nomenclature**

Monograph titles follow the convention of recommended international non-proprietary names (rINNs), or, in the absence of a rINN, British Approved Names. Relevant synonyms are included below the title. In some instances a brief description of the drug action is included. Over future editions these drug action statements will be rolled out for all drugs.

In some monographs, immediately below the nomenclature or drug action, there are a number of cross references or flags used to signpost the user to any additional information they need to consider about a drug.

This is most common for drugs formulated in combinations, where users will be signposted to the monographs for the individual ingredients (e.g. Ispaghula husk with senna, p. 54) or for drugs that are related to a class monograph (see Class monographs, below).

**Indication and dose**

User feedback has highlighted that one of the main uses of the BNF is identifying indications and doses of drugs. Therefore in this edition, indication and dose information has been promoted to the top of the monograph and highlighted by a coloured panel to aid quick reference.

The indication and dose section is more highly structured than in previous editions, giving greater clarity around which doses should be used for which indications and by which route. In addition, if the dose varies with a specific preparation or formulation that dosing information has been moved out of the preparations section and in to the indication and dose panel, under a heading of the preparation name.

Doses are either expressed in terms of a definite frequency (e.g. 1 g 4 times daily) or in the total daily dose format (e.g. 6 g daily in 3 divided doses); the total daily dose should be divided into individual doses (in the second example, the patient should receive 2 g 3 times daily).

Doses for specific patient groups (e.g. the elderly) may be included if they are different to the standard dose. Doses for children can be identified by the relevant age range and may vary according to their age or body-weight.

In previous editions of the BNF, age ranges and weight ranges overlapped. For clarity and to aid selection of the correct dose, wherever possible the age and weight ranges now do not overlap. When interpreting age ranges it is important to understand that a patient is considered to be 64 up until the point of their 65th birthday, meaning that an age range of adult 18 to 64 is applicable to a patient from the day of their 18th birthday until the day before their 65th birthday. All age ranges should be interpreted in this way. Similarly, when interpreting weight ranges, it should be understood that a weight range of 35 to 59kg is applicable to a patient as soon as they tip the scales at 35kg right up until, but not including, the point that the scales tip to 60kg. All weight ranges should be interpreted in this way.

In all circumstances, it is important to consider the patient in question and their physical condition, and select the dose most appropriate for the individual.

**Other information relevant to Indication and dose**

The dose panel also contains, where known, an indication of pharmacokinetic considerations that may affect the choice of dose, and dose equivalence information, which may aid the selection of dose when switching between drugs or preparations.

The BNF includes unlicensed use of medicines when the clinical need cannot be met by licensed medicines; such use should be supported by appropriate evidence and experience. When the BNF recommends an unlicensed medicine or the ‘off-label’ use of a licensed medicine, this is shown below the indication and dose panel in the unlicensed use section.

**Minimising harm and drug safety**

The drug chosen to treat a particular condition should minimise the patient’s susceptibility to adverse effects and, where co-morbidities exist, have minimal detrimental effects on the patient’s other diseases. To achieve this, the Contra-indications, Cautions and Side-effects of the relevant drug should be reviewed.

The information under Cautions can be used to assess the risks of using a drug in a patient who has co-morbidities that are also included in the Cautions for that drug—if a safer alternative cannot be found, the drug may be prescribed while monitoring the patient for adverse-effects or deterioration in the co-morbidity. Contra-indications are far more restrictive than Cautions and mean that the drug should be avoided in a patient with a condition that is contra-indicated.

The impact that potential side-effects may have on a patient’s quality of life should also be assessed. For instance, in a patient who has difficulty sleeping, it may be preferable to avoid a drug that frequently causes insomnia. Clinically relevant Side-effects for drugs are included in the monographs or class monographs. Side-effects are listed in order of frequency, where known, and arranged alphabetically.

The frequency of side-effects follows the regulatory standard:

- Very common — occurs more frequently than 1 in 10 administrations of a drug
- Common — occurs between 1 in 10 and 1 in 100 administrations of a drug
- Uncommon — between 1 in 100 and 1 in 1,000 administrations of a drug
- Rare — between 1 in 1,000 and 1 in 10,000 administrations of a drug
- Very rare — occurs less than 1 in 10,000 administrations of a drug
- Frequency not known

An exhaustive list of side-effects is not included, particularly for drugs that are used by specialists (e.g. cytotoxic drugs and drugs used in anaesthesia). The BNF also omits effects that are likely to have little clinical consequence (e.g. transient increase in liver enzymes). Recognising that hypersensitivity reactions can occur with virtually all medicines, this effect is generally not listed, unless the drug carries an increased risk of such reactions, when the information is included under Allergy and cross sensitivity.

The Important safety advice section in the BNF, delineated by a coloured outline box, highlights important safety concerns, often those raised by regulatory authorities or guideline producers. Safety warnings issued by the Commission on Human Medicines (CHM) or Medicines and
Healthcare products Regulatory Agency (MHRA) are found here. Drug selection should aim to minimise drug interactions. If it is necessary to prescribe a potentially serious combination of drugs, patients should be monitored appropriately. The mechanisms underlying drug interactions are explained in Appendix 1 p. 1137, followed by details of drug interactions.

Use of drugs in specific patient populations
Drug selection should aim to minimise the potential for drug accumulation, adverse drug reactions, and exacerbation of pre-existing hepatic or renal disease. If it is necessary to prescribe drugs whose effect is altered by hepatic or renal disease, appropriate drug dose adjustments should be made, and patients should be monitored adequately. The general principles for prescribing are outlined under Prescribing in Hepatic Impairment p. 17, and Prescribing in Renal Impairment p. 17. Information about drugs that should be avoided or used with caution in hepatic disease or renal impairment can be found in drug monographs under Hepatic Impairment and Renal impairment (e.g. fluconazole p. 518).

Similarly, drug selection should aim to minimise harm to the fetus, nursing infant, and mother. The infant should be monitored for potential side-effects of drugs used by the mother during pregnancy or breast-feeding. The general principles for prescribing are outlined under Prescribing in Pregnancy p. 19 and Prescribing in Breast-feeding p. 19. The Treatment Summaries provide guidance on the drug treatment of common conditions that can occur during pregnancy and breast-feeding (e.g. asthma p. 210).

Information about the use of specific drugs during pregnancy and breast-feeding can be found in their drug monographs under Pregnancy, and Breast-feeding (e.g. fluconazole p. 518).

In this edition a new section, Conception and contraception, containing information around considerations for females of childbearing potential or men who might father a child (e.g. isotretinoin p. 1045) has been included.

Administration and monitoring
When selecting the most appropriate drug, it may be necessary to screen the patient for certain genetic markers or metabolic states. This information is included within a section called Pre-treatment screening (e.g. abacavir, p. 561). This section covers one-off tests required to assess the suitability of a patient for a particular drug.

Once the drug has been selected, it needs to be given in the most appropriate manner. A new Directions for administration section contains the information about intravenous administration previously located in Appendix 4. This provides practical information on the preparation of intravenous drug infusions, including compatibility of drugs with standard intravenous infusion fluids, method of dilution or reconstitution, and administration rates. In addition, general advice relevant to other routes of administration is provided within this section (e.g. fentanyl, p. 362).

After selecting and administering the most appropriate drug by the most appropriate route, patients should be monitored to ensure they are achieving the expected benefits from drug treatment without any unwanted side-effects. The Monitoring section specifies any special monitoring requirements, including information on monitoring the plasma concentration of drugs with a narrow therapeutic index (e.g. theophylline, p. 238). Monitoring may, in certain cases, be affected by the impact of a drug on laboratory tests (e.g. hydroxocobalamin, p. 837), and this information is included in Effects on laboratory tests.

In some cases, when a drug is withdrawn, further monitoring or precautions may be advised (e.g. clonidine, p. 137): these are covered under Treatment cessation.

Choice and supply
The prescriber and the patient should agree on the health outcomes that the patient desires and on the strategy for achieving them (see Taking Medicines to Best Effect, p. 1). Taking the time to explain to the patient (and carers) the rationale and the potential adverse effects of treatment may improve adherence. For some medicines there is a special need for counselling (e.g. appropriate posture during administration of doxycycline, p. 496); this is shown in Patient and carer advice.

Other information contained in the latter half of the monograph also helps prescribers and those dispensing medicines choose medicinal forms (by indicating information such as flavour or when branded products may not be interchangeeable e.g. Diltiazem, p. 149), assess the suitability of a drug for prescribing, understand the NHS funding status for a drug (e.g. sildenafil, p. 656, or assess when a patient may be able to purchase a drug without prescription (e.g. loperamide hydrochloride, p. 56).

Medicinal forms
In the BNF, preparations follow immediately after the monograph for the drug that is their main ingredient. In previous editions, when a particular preparation had safety information, dose advice or other clinical information specific to the product, it was contained within the preparations record. This information has now been moved to the relevant section in the main body of the monograph under a heading of the name of the specific medicinal form (e.g. peppermint oil), p. 40.

In the new BNF, the medicinal forms (formerly preparations) record provides information on the type of formulation (e.g. tablet), the amount of active drug in a solid dosage form, and the concentration of active drug in a liquid dosage form. The legal status is shown for prescription-only medicines and controlled drugs, as well as pharmacy medicines and medicines on the general sales list. Practitioners are reminded, by a statement at the top of the monograph that not all products containing a specific drug ingredient may be similarly licensed. To be clear on the precise licensing status of specific medicinal forms, practitioners should check the product literature for the particular product being prescribed or dispensed.

Patients should be prescribed a preparation that complements their daily routine, and that provides the right dose of drug for the right indication and route of administration. When dispensing liquid preparations, a sugar-free preparation should always be used in preference to one containing sugar. Patients receiving medicines containing cariogenic sugars should be advised of the importance of good oral hygiene, and so this information is now covered at the level of the dose form (e.g. peppermint oil). It is not possible to keep abreast of all of the generic products available on the UK market, and so this information serves as a reminder to the healthcare professional that, if the presence of a particular excipient is of concern, they should check the product literature for the particular product being prescribed or dispensed.

Cautionary and advisory labels that pharmacists are recommended to add when dispensing are included in the medicinal forms (formerly Preparations) record. Details of these labels can be found in Appendix 3, p. 1291. As these labels have now been applied at the level of the dose form, a full list of medicinal products with their relevant labels would be extensive. This list has therefore been removed, but the information is retained within the monograph.
In the case of compound preparations, the prescribing information for all constituents should be taken into account.

**Prices in the BNF**

Basic NHS net prices are given in the BNF to provide an indication of relative cost. Where there is a choice of suitable preparations for a particular disease or condition the relative cost may be used in making a selection. Cost-effective prescribing must, however, take into account other factors (such as dose frequency and duration of treatment) that affect the total cost. The use of more expensive drugs is justified if it will result in better treatment of the patient, or a reduction of the length of an illness, or the time spent in hospital.

Prices are regularly updated using the Drug Tariff and proprietary price information published by the NHS dictionary of medicines and devices (dm+d, www.dmd.nhs.uk). The weekly updated dm+d data (including prices) can be accessed using the dm+d browser of the NHS Business Services Authority (www.ppa.org.uk/systems/pddbrowseerv2.3new/browser.jsp). Prices have been calculated from the net cost used in pricing NHS prescriptions in June 2015 and generally reflect whole dispensing packs. Prices for extemporaneously prepared preparations are not provided in the BNF as prices vary between different manufacturers.

In Appendix 5 prices stated are per dressing or bandage. BNF prices are not suitable for quoting to patients seeking private prescriptions or contemplating over-the-counter purchases because they do not take into account VAT, professional fees, and other overheads.

A fuller explanation of costs to the NHS may be obtained from the Drug Tariff. Separate drug tariffs are applicable to England and Wales (www.ppa.org.uk/ppta/edt_introt.htm), Scotland (www.isdscotland.org/HealthTopics/Prescribing-and-Medicines/Scottish-Drug-Tariff/), and Northern Ireland (www.dhsspsni.gov.uk/pas-tariff); prices in the different tariffs may vary.

**Drug-class monographs**

In previous editions of the BNF, information relating to a class of drug sharing the same properties (e.g. tetracyclines, p. 496), was contained within the prescribing notes. In this new edition, drug-class monographs have been created to contain the common information; this ensures such information is easier to find, and has a more regularised structure.

For consistency and ease of use, the class monograph follows the same structure as a drug monograph. Class monographs are indicated by the presence of a flag (e.g. Beta blockers, systemic, p. 140). If a drug monograph has a corresponding class monograph, that needs to be considered in tandem, in order to understand the full information about a drug, the monograph is also indicated by a flag (e.g. metoprolol, p. 144). Where the drug monographs run on from a class monograph no further cross referencing is given. However, occasionally, due to differences in therapeutic use, the drug monograph may not directly follow the class monograph. In this situation the need to consider a class monograph is still indicated by a flag, but a cross reference is also provided to help navigate the user to the class monograph (e.g. sotalol, p. 93).

**Other content**

**Nutrition**

Appendix 2, p. 1260 includes tables of ACBS-approved enteral feeds and nutritional supplements based on their energy and protein content. There are separate tables for specialised formulae for specific clinical conditions. Classified sections on foods for special diets and nutritional supplements for metabolic diseases are also included.

**Wound dressings**

A table on wound dressings in Appendix 4 (previously Appendix 5), p. 1294 allows an appropriate dressing to be selected based on the appearance and condition of the wound. Further information about the dressing can be found by following the cross-reference to the relevant classified section in the Appendix.

**Advanced wound contact dressings** have been classified in order of increasing absorbency.

**Other useful information**

**Finding significant changes in the BNF**

- **Changes**, p. xv, provides a list of significant changes, dose changes, classification changes, new names, and new preparations that have been incorporated into the BNF, as well as a list of preparations that have been discontinued and removed from the BNF. Changes listed online are cumulative (from one print edition to the next), and can be printed off each month to show the main changes since the last print edition as an aide memoire for those using print copies. So many changes are made for each update of the BNF, that not all of them can be accommodated in the Changes section. We encourage healthcare professionals to review regularly the prescribing information on drugs that they encounter frequently.

- **Changes to the Dental Practitioners’ Formulary**, p. 27, are located at the end of the Dental List.

- **E-newsletter**, the BNF & BNFC e-newsletter service is available free of charge. It alerts healthcare professionals to details of significant changes in the clinical content of these publications and to the way that this information is delivered. Newsletters also review clinical case studies, provide tips on using these publications effectively, and highlight forthcoming changes to the publications. To sign up for e-newsletters go to www.bnfn.org.

- An e-learning programme developed in collaboration with the Centre for Pharmacy Postgraduate Education (CPPPE), enables pharmacists to identify and assess how significant changes in the BNF affect their clinical practice. The module can be found at www.cpppe.ac.uk.

**Using other sources for medicines information**

The BNF is designed as a digest for rapid reference. Less detail is given on areas such as obstetrics, malignant disease, and anaesthesia since it is expected that those undertaking treatment will have specialist knowledge and access to specialist literature. BNF for Children should be consulted for detailed information on the use of medicines in children. The BNF should be interpreted in the light of professional knowledge and supplemented as necessary by specialised publications and by reference to the product literature. Information is also available from medicines information services.
Changes

Monthly updates are provided online via MedicinesComplete and the NHS Evidence portal. The changes listed below are cumulative (from one print edition to the next).

**Significant changes**
Significant changes made since release of data for the print edition of BNF 69 (March–September 2015):
- Aceclofenac p. 916: updated cardiovascular advice—new contra-indications in certain established cardiovascular diseases [MHRA advice].
- Apixaban p. 108 for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism [NICE guidance].
- Axitinib p. 802 for treating advanced renal cell carcinoma after failure of prior systemic treatment [NICE guidance].
- Codeine phosphate p. 360 for cough and cold: restricted use in children [MHRA advice].
- Dabigatran etexilate p. 117 for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism [NICE guidance].
- Diclofenac potassium p. 920, 12.5 mg tablets no longer available over the counter [MHRA advice].
- Dimethyl fumarate p. 727: risk of lymphopenia and potential risk of progressive multifocal leukoencephalopathy [MHRA advice].
- Empagliflozin p. 610 in combination therapy for treating type 2 diabetes [NICE guidance].
- Hydroxyzine hydrochloride p. 248: risk of QT interval prolongation and Torsade de Pointes [MHRA advice].
- Indinavir p. 906, adalimumab p. 901 and golimumab p. 904 for treating moderately to severely active ulcerative colitis after the failure of conventional therapy [NICE guidance].
- Obinutuzumab p. 739 in combination with chlorambucil for untreated chronic lymphocytic leukaemia [NICE guidance].
- Ofatumumab p. 740 in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia [NICE guidance].
- Omalizumab p. 235 for previously treated chronic spontaneous urticaria [NICE guidance].
- Pomalidomide p. 797 for relapsed and refractory multiple myeloma previously treated with lenalidomide p. 796 and bortezomib p. 801 [NICE guidance].
- Rivaroxaban p. 109 for preventing adverse outcomes after acute management of acute coronary syndrome [NICE guidance].
- Rifaximin p. 495 for preventing episodes of overt hepatic encephalopathy [NICE guidance].
- Simeprevir p. 548 in combination with peginterferon alfa p. 542 and ribavirin p. 545 for treating genotypes 1 and 4 chronic hepatitis C [NICE guidance].
- Sofosbuvir p. 546 for treating chronic hepatitis C [NICE guidance].
- Ustekinumab p. 899 for treating active psoriatic arthritis [NICE guidance].

**Dose changes**
Changes in dose statements made since release of data for the print edition of BNF 69 (March–September 2015):
- Eprosartan p. 133
- Lisdexamfetamine mesilate p. 271 [dose in renal impairment]
- Tetrastarch p. 854 [Volulyte®]
- Tetrastarch p. 854 [Voluven®]
- Tamadol hydrochloride p. 373 [oral dose for acute and chronic pain]

**Classification changes**
Classification changes made since release of data for the print edition of BNF 69 (March–September 2015):

**New names**
Name changes introduced since release of data for the print edition of BNF 69 (March–September 2015):

**Deleted preparations**
Preparations discontinued since release of data for the print edition of BNF 69 (March–September 2015):
- Anafranil SR®
- BindRen®
- Brexidol®
- Calcium-Sandoz®
- Calmrdic HC®
- Didronel®
- Eporatio®
- Fularix®
- Froben®
- Ortho-Gynest®
- Penbritin® syrup
- Pneumovax® II
- Rienso®
- Rupafin®
- Vantax®
- Vistabel®

**New preparations**
New preparations included since release of data for the print edition of BNF 69 (March–September 2015):
- Bydureon® pre-filled pen [exenatide p. 599]
- DuoResp Spirironax® [budesonide with formoterol p. 229]
- Envarsus® [tacrolimus p. 720]
- Fostair NEXTThaler® [beclometasone with formoterol p. 221]
- Jaydless® [levonorgestrel p. 692]
- Ketoconazole HRA® [ketoconazole p. 587]
- Lonquex® [lipecifilgrastim p. 842]
- Salofalk® 1 g suppositories [mesalamine p. 34]
Guidance on prescribing

General guidance
Medicines should be prescribed only when they are necessary, and in all cases the benefit of administering the medicine should be considered in relation to the risk involved. This is particularly important during pregnancy, when the risk to both mother and fetus must be considered. It is important to discuss treatment options carefully with the patient to ensure that the patient is content to take the medicine as prescribed. In particular, the patient should be helped to distinguish the adverse effects of prescribed drugs from the effects of the medical disorder. When the beneficial effects of the medicine are likely to be delayed, the patient should be advised of this.

Taking medicines to best effect
Difficulties in adherence to drug treatment occur regardless of age. Factors contributing to poor compliance with prescribed medicines include:

- prescription not collected or not dispensed;
- purpose of medicine not clear;
- perceived lack of efficacy;
- real or perceived adverse effects;
- patients’ perception of the risk and severity of side-effects may differ from that of the prescriber;
- instructions for administration not clear;
- physical difficulty in taking medicines (e.g. swallowing the medicine, handling small tablets, or opening medicine containers);
- unattractive formulation (e.g. unpleasant taste);
- complicated regimen.

The prescriber and the patient should agree on the health outcomes that the patient desires and on the strategy for achieving them (‘concordance’). The prescriber should be sensitive to religious, cultural, and personal beliefs that can affect a patient’s acceptance of medicines. Taking the time to explain to the patient (and relatives) the rationale and the potential adverse effects of treatment may improve adherence. Reinforcement and elaboration of the physician’s instructions by the pharmacist and other members of the healthcare team also helps. Advising the patient of the possibility of alternative treatments may encourage the patient to seek advice rather than merely abandon unacceptable treatment.

Simplifying the drug regimen may help; the need for frequent administration may reduce adherence, although there appears to be little difference in adherence between once-daily and twice-daily administration. Combination products reduce the number of drugs taken but at the expense of the ability to titrate individual doses.

Biosimilar medicines
A biosimilar medicine is a new biological product that is similar to a medicine that has already been authorised to be marketed (the biological reference medicine) in the European Union. The active substance of a biosimilar medicine is similar, but not identical, to the biological reference medicine. Biological products are different from standard chemical products in terms of their complexity and although theoretically there should be no important differences between the biosimilar and the biological reference medicine in terms of safety or efficacy, when prescribing biological products, it is good practice to use the brand name. This will ensure that substitution of a biosimilar medicine does not occur when the medicine is dispensed. Biosimilar medicines have black triangle status at the time of initial marketing. It is important to report suspected adverse reactions to biosimilar medicines using the Yellow Card Scheme. For biosimilar medicines, adverse reaction reports should clearly state the brand name and the batch number of the suspected medicine.

Complementary and alternative medicine
An increasing amount of information on complementary and alternative medicine is becoming available. The scope of the BNF is restricted to the discussion of conventional medicines but reference is made to complementary treatments if they affect conventional therapy (e.g. interactions with St John’s wort). Further information on herbal medicines is available at www.mhra.gov.uk.

Abbreviation of titles
In general, titles of drugs and preparations should be written in full. Unofficial abbreviations should not be used as they may be misinterpreted.

Non-proprietary titles
Where non-proprietary (‘generic’) titles are given, they should be used in prescribing. This will enable any suitable product to be dispensed, thereby saving delay to the patient and sometimes expense to the health service. The only exception is where there is a demonstrable difference in clinical effect between each manufacturer’s version of the formulation, making it important that the patient should always receive the same brand; in such cases, the brand name or the manufacturer should be stated. Non-proprietary titles should not be invented for the purposes of prescribing generically since this can lead to confusion, particularly in the case of compound and modified-release preparations.

Titles used as headings for monographs may be used freely in the United Kingdom but in other countries may be subject to restriction. Many of the non-proprietary titles used in this book are titles of monographs in the European Pharmacopoeia, British Pharmacopoeia, or British Pharmaceutical Codex 1973. In such cases the preparations must comply with the standard (if any) in the appropriate publication, as required by the Human Medicines Regulations 2012.

Proprietary titles
Names followed by the symbol® are or have been used as proprietary names in the United Kingdom. These names may in general be applied only to products supplied by the owners of the trade marks.

Marketing authorisation and BNF advice
In general the doses, indications, cautions, contra-indications, and side-effects in the BNF reflect those in the manufacturers’ data sheets or Summaries of Product Characteristics (SPCs) which, in turn, reflect those in the corresponding marketing authorisations (formerly known as Product Licences). The BNF does not generally include proprietary medicines that are not supported by a valid Summary of Product Characteristics or when the marketing authorisation holder has not been able to supply essential information. When a preparation is available from more than one manufacturer, the BNF reflects advice that is the most clinically relevant regardless of any variation in the marketing authorisations. Unlicensed products can be obtained from ‘special-order’ manufacturers or specialist importing companies.

Where an unlicensed drug is included in the BNF, this is indicated in square brackets after the entry. When the BNF
Guidance on prescribing

2 Guidance on prescribing

suggested a use (or route) that is outside the licensed indication of a product ('off-label' use), this too is indicated. Unlicensed use of medicines becomes necessary if the clinical need cannot be met by licensed medicines; such use should be supported by appropriate evidence and experience.

The doses stated in the BNF are intended for general guidance and represent, unless otherwise stated, the usual range of doses that are generally regarded as being suitable for adults.

Prescribing unlicensed medicines

Prescribing medicines outside the recommendations of their marketing authorisation alters (and probably increases) the prescriber’s professional responsibility and potential liability. The prescriber should be able to justify and feel competent in using such medicines, and also inform the patient or the patient’s carer that the prescribed medicine is unlicensed.

Oral syringes

An oral syringe is supplied when oral liquid medicines are prescribed in doses other than multiples of 5 mL. The oral syringe is marked in 0.5 mL divisions from 1 to 5 mL to measure doses of less than 5 mL (other sizes of oral syringe may also be available). It is provided with an adaptor and an instruction leaflet. The 5–5 mL spoon is used for doses of 5 mL (or multiples thereof).

Important To avoid inadvertent intravenous administration of oral liquid medicines, only an appropriate oral or enteral syringe should be used to measure an oral liquid medicine (if a medicine spoon or graduated measure cannot be used); these syringes should not be compatible with intravenous or other parenteral devices. Oral or enteral syringes should be clearly labelled ‘Oral’ or ‘Enteral’ in a large font size; it is the healthcare practitioner’s responsibility to label the syringe with this information if the manufacturer has not done so.

Excipients

Branded oral liquid preparations that do not contain fructose, glucose, or sucrose are described as ‘sugar-free’ in the BNF. Preparations containing hydrogenated glucose syrup, mannitol, maltitol, sorbitol, or xylitol are also marked ‘sugar-free’ since there is evidence that they do not cause dental caries. Patients receiving medicines containing cariogenic sugars should be advised of appropriate dental hygiene measures to prevent caries. Sugar-free preparations should be used whenever possible.

Where information on the presence of aspartame, gluten, sulfites, tartrazine, arachis (peanut) oil or sesame oil is available, this is indicated in the BNF against the relevant preparation.

Information is provided on selected excipients in skin preparations, in vaccines, and on selected preparations and excipients in eye drops and injections.

The presence of benzyl alcohol and polyoxyl castor oil (polyethoxylated castor oil) in injections is indicated in the BNF. Benzyl alcohol has been associated with a fatal toxic syndrome in preterm neonates, and therefore, parenteral preparations containing the preservative should not be used in neonates. Polyoxyl castor oils, used as vehicles in intravenous injections, have been associated with severe anaphylactoid reactions.

The presence of propylene glycol in oral or parenteral medicines is indicated in the BNF; it can cause adverse effects if its elimination is impaired, e.g. in renal failure, in neonates and young children, and in slow metabolisers of the substance. It may interact with disulfiram p. 428 and metronidazole p. 475.

The lactose content in most medicines is too small to cause problems in most lactose-intolerant patients. However in severe lactose intolerance, the lactose content should be determined before prescribing. The amount of lactose varies according to manufacturer, product, formulation, and strength.

Important In the absence of information on excipients in the BNF and in the product literature (available at www.medicines.org.uk/emc), contact the manufacturer (see Index of Proprietary Manufacturers) if it is essential to check details.

Extemporaneous preparation

A product should be dispensed extemporaneously only when no product with a marketing authorisation is available.

The BP direction that a preparation must be freshly prepared indicates that it must be made not more than 24 hours before it is issued for use. The direction that a preparation should be recently prepared indicates that deterioration is likely if the preparation is stored for longer than about 4 weeks at 15–25°C.

The term water used without qualification means either potable water freshly drawn direct from the public supply and suitable for drinking or freshly boiled and cooled purified water. The latter should be used if the public supply is from a local storage tank or if the potable water is unsuitable for a particular preparation (Water for injections).

Drugs and driving

Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

A new offence of driving, attempting to drive, or being in charge of a vehicle, with certain specified controlled drugs in excess of specified limits, came into force on 2nd March 2015. This offence is an addition to the existing rules on drug impaired driving and fitness to drive, and applies to two groups of drugs—commonly abused drugs, including cannabis, cocaine, and ketamine p. 1110, and drugs used mainly for medical reasons, such as opioids and benzodiazepines. Amfetamines are also expected to be added to the legislation later in 2015. Anyone found to have any of the drugs (including related drugs, for example, apomorphine hydrochloride p. 332) above specified limits in their blood will be guilty of an offence, whether their driving was impaired or not. This also includes prescribed drugs which metabolise to those included in the offence, for example, selegiline hydrochloride p. 340. However, the legislation provides a statutory “medical defence” for patients taking drugs for medical reasons in accordance with instructions, if their driving was not impaired—it continues to be an offence to drive if actually impaired.

Patients should therefore be advised to continue taking their medicines as prescribed, and when driving, to carry suitable evidence that the drug was prescribed, or sold, to treat a medical or dental problem, and that it was taken according to the instructions given by the prescriber, or information provided with the medicine (e.g. a repeat prescription form or the medicine’s patient information leaflet). Further information is available from the Department for Transport at www.gov.uk/government/collections/drug-driving.

Patents

In the BNF, certain drugs have been included notwithstanding the existence of actual or potential patent rights. In so far as such substances are protected by Letters
Patent, their inclusion in this Formulary neither conveys, nor implies, licence to manufacture.

**Health and safety**

When handling chemical or biological materials particular attention should be given to the possibility of allergy, fire, explosion, radiation, or poisoning. Substances such as corticosteroids, some antimicrobials, phenothiazines, and many cytotoxics, are irritant or very potent and should be handled with caution. Contact with the skin and inhalation of dust should be avoided.

**Safety in the home**

Patients must be warned to keep all medicines out of the reach of children. All solid dose and all oral and external liquid preparations must be dispensed in a reclosable child-resistant container unless:

- the medicine is in an original pack or patient pack such as to make this inadvisable;
- the patient will have difficulty in opening a child-resistant container;
- a specific request is made that the product shall not be dispensed in a child-resistant container;
- no suitable child-resistant container exists for a particular liquid preparation.

All patients should be advised to dispose of unwanted medicines by returning them to a supplier for destruction.

**Labelling of prescribed medicines**

There is a legal requirement for the following to appear on the label of any prescribed medicine:

- name of the patient;
- name and address of the person dispensing the medicine;
- date of dispensing;
- name of the medicine;
- directions for use of the medicine;
- precautions relating to the use of the medicine.

The Royal Pharmaceutical Society recommends that the following also appears on the label:

- the words 'Keep out of the sight and reach of children';
- where applicable, the words 'Use this medicine only on your skin'.

A pharmacist can exercise professional skill and judgement to amend or include more appropriate wording for the name of the medicine, the directions for use, or the precautions relating to the use of the medicine.

**Non-proprietary names of compound preparations**

Non-proprietary names of compound preparations which appear in the BNF are those that have been compiled by the British Pharmacopoeia Commission or another recognised body; whenever possible they reflect the names of the active ingredients.

Prescribers should avoid creating their own compound names for the purposes of generic prescribing; such names do not have an approved definition and can be misinterpreted.

Special care should be taken to avoid errors when prescribing compound preparations; in particular the hyphen in the prefix ‘co-’ should be retained.

Special care should also be taken to avoid creating generic names for modified-release preparations where the use of these names could lead to confusion between formulations with different lengths of action.

**EEA and Swiss prescriptions**

Pharmacists can dispense prescriptions issued by doctors and dentists from the European Economic Area (EEA) or Switzerland (except prescriptions for controlled drugs in Schedules 1, 2, or 3, or for drugs without a UK marketing authorisation). Prescriptions should be written in ink or otherwise so as to be indelible, should be dated, should state the name of the patient, should state the address of the prescriber, should contain particulars indicating whether the prescriber is a doctor or dentist, and should be signed by the prescriber.

**Security and validity of prescriptions**

The Councils of the British Medical Association and the Royal Pharmaceutical Society have issued a joint statement on the security and validity of prescriptions. In particular, prescription forms should:

- not be left unattended at reception desks;
- not be left in a car where they may be visible; and
- when not in use, be kept in a locked drawer within the surgery and at home.

Where there is any doubt about the authenticity of a prescription, the pharmacist should contact the prescriber.

If this is done by telephone, the number should be obtained from the directory rather than relying on the information on the prescription form, which may be false.

**Patient group direction (PGD)**

In most cases, the most appropriate clinical care will be provided on an individual basis by a prescriber to a specific individual patient. However, a Patient Group Direction for supply and administration of medicines by other healthcare professionals can be used where it would benefit patient care without compromising safety.

A Patient Group Direction is a written direction relating to the supply and administration (or administration only) of a licensed prescription-only medicine (including some Controlled Drugs in specific circumstances) by certain classes of healthcare professionals; the Direction is signed by a doctor (or dentist) and by a pharmacist. Further information on Patient Group Directions is available in Health Service Circular HSC 2000/026 (England), HDL (2001) 7 (Scotland), and WHC (2000) 116 (Wales); see also the Human Medicines Regulations 2012.

**NICE and Scottish Medicines Consortium**

Advice issued by the National Institute for Health and Care Excellence (NICE) is included in the BNF when relevant. The BNF also includes advice issued by the Scottish Medicines Consortium (SMC) when a medicine is restricted or not recommended for use within NHS Scotland. If advice within a NICE Single Technology Appraisal differs from SMC advice, the Scottish Executive expects NHS Boards within NHS Scotland to comply with the SMC advice. Details of the advice together with updates can be obtained from www.nice.org.uk and from www.scottishmedicines.org.uk.
Prescription writing

Shared care
In its guidelines on responsibility for prescribing (circular EL (51) 127) between hospitals and general practitioners, the Department of Health has advised that legal responsibility for prescribing lies with the doctor who signs the prescription.

Prescriptions should be written legibly in ink or otherwise so as to be indelible (it is permissible to issue carbon copies of NHS prescriptions as long as they are signed in ink), should be dated, should state the name and address of the patient, the address of the prescriber, an indication of the type of prescriber, and should be signed in ink by the prescriber (computer-generated facsimile signatures do not meet the legal requirement). The age and the date of birth of the patient should preferably be stated, and it is a legal requirement in the case of prescription-only medicines to state the age for children under 12 years. These recommendations are acceptable for prescription-only medicines. Prescriptions for controlled drugs have additional legal requirements.

Wherever appropriate the prescriber should state the current weight of the child to enable the dose prescribed to be checked. Consideration should also be given to including the dose per unit mass e.g. mg/kg or the dose per m$^2$ body-surface area e.g. mg/m$^2$ where this would reduce error.

The following should be noted:

- The strength or quantity to be contained in capsules, lozenges, tablets etc. should be stated by the prescriber. In particular, strength of liquid preparations should be clearly stated (e.g. 125 mg/5 mL).
- The unnecessary use of decimal points should be avoided, e.g. 3 mg, not 3.0 mg.
- Quantities of 1 gram or more should be written as 1 g etc.
- Quantities less than 1 gram should be written in milligrams, e.g. 500 mg, not 0.5 g.
- Quantities less than 1 mg should be written in micrograms, e.g. 100 micrograms, not 0.1 mg.
- When decimals are unavoidable a zero should be written in front of the decimal point where there is no other figure, e.g. 0.5 mL, not .5 mL.
- Use of the decimal point is acceptable to express a range, e.g. 0.5 to 1 g.
- Micrograms and ‘nanograms’ should not be abbreviated. Similarly ‘units’ should not be abbreviated.
- The term ‘millilitre’ (ml or mL) is used in medicine and pharmacy, and cubic centimetre, c.c., or cm$^3$ should not be used. (The use of capital ‘L’ in mL is a printing convention throughout the BNF; both ‘ml’ and ‘mL’ are recognised SI abbreviations).
- Dose and dose frequency should be stated; in the case of preparations to be taken ‘as required’ a minimum dose interval should be specified.
- Care should be taken to ensure children receive the correct dose of the active drug. Therefore, the dose should normally be stated in terms of the mass of the active drug (e.g. ‘125 mg 3 times daily’); terms such as ‘5 mL’ or ‘1 tablet’ should be avoided except for compound preparations.
- When doses other than multiples of 5 mL are prescribed for oral liquid preparations the dose-volume will be provided by means of an oral syringe, (except for preparations intended to be measured with a pipette). Suitable quantities: Elixirs, Linctuses, and Paediatric Mixtures (5-mL dose), 50, 100, or 150 mL.
- Adult Mixtures (10-mL dose), 200 or 300 mL

Ear Drops, Eye drops, and Nasal Drops, 10 mL (or the manufacturer’s pack)
Eye Lotions, Gargles, and Mouthwashes, 200 mL
- The names of drugs and preparations should be written clearly and not abbreviated, using approved titles only; avoid creating generic titles for modified-release preparations.
- The quantity to be supplied may be stated by indicating the number of days of treatment required in the box provided on NHS forms. In most cases the exact amount will be supplied. This does not apply to items directed to be used as required—if the dose and frequency are not given then the quantity to be supplied needs to be stated.
- When several items are ordered on one form the box can be marked with the number of days of treatment provided the quantity is added for any item for which the amount cannot be calculated.
- Although directions should preferably be in English without abbreviation, it is recognised that some Latin abbreviations are used, for details, see Inside Back Cover.

Sample prescription

Prescribing by dentists Until new prescribing arrangements are in place for NHS prescriptions, dentists should use form FP10D (GPI4 in Scotland, WP10D in Wales) to prescribe only those items listed in the Dental Practitioners’ Formulary. The Human Medicines Regulations 2012 does not set any limitations upon the number and variety of substances which the dentist may administer to patients in the surgery or may order by private prescription—provided the relevant legal requirements are observed the dentist may use or order whatever is required for the clinical
situation. There is no statutory requirement for the dentist to communicate with a patient’s medical practitioner when prescribing for dental use. There are, however, occasions when this would be in the patient’s interest and such communication is to be encouraged.

**Computer-issued prescriptions**

For computer-issued prescriptions the following advice, based on the recommendations of the Joint GP Information Technology Committee, should also be noted:

1. The computer must print out the date, the patient’s surname, one forename, other initials, and address, and may also print out the patient’s title and date of birth. The age of children under 12 years and of adults over 60 years must be printed in the box available; the age of children under 5 years should be printed in years and months. A facility may also exist to print out the age of patients between 12 and 60 years.

2. The doctor’s name must be printed at the bottom of the prescription form; this will be the name of the doctor responsible for the prescription (who will normally sign it). The doctor’s surgery address, reference number, and Primary Care Trust (PCT, Health Board in Scotland, Local Health Board in Wales) are also necessary. In addition, the surgery telephone number should be printed.

3. When prescriptions are to be signed by general practitioner registrars, assistants, locums, or deputising doctors, the name of the doctor printed at the bottom of the form must still be that of the responsible principal.

4. Names of medicines must come from a dictionary held in the computer memory, to provide a check on the spelling and to ensure that the name is written in full. The computer can be programmed to recognise both the non-proprietary and the proprietary name of a particular drug and to print out the preferred choice, but must not print out both names. For medicines not in the dictionary, separate checks are required—the user must be warned that no check was possible and the entire prescription must be entered in the lexicon.

5. The dictionary may contain information on the usual doses, formulations, and pack sizes to produce standard predetermined prescriptions for common preparations, and to provide a check on the validity of an individual prescription on entry.

6. The prescription must be printed in English without abbreviation; information may be entered or stored in abbreviated form. The dose must be in numbers, the frequency in words, and the quantity in numbers in brackets, thus: 40 mg four times daily (112). It must also be possible to prescribe by indicating the length of treatment required.

7. The BNF recommendations should be followed as listed above.

8. Checks may be incorporated to ensure that all the information required for dispensing a particular drug has been filled in. For instructions such as ‘as directed’ and ‘when required’, the maximum daily dose should normally be specified.

9. Numbers and codes used in the system for organising and retrieving data must never appear on the form.

10. Supplementary warnings or advice should be written in full, should not interfere with the clarity of the prescription itself, and should be in line with any warnings or advice in the BNF; numerical codes should not be used.

11. A mechanism (such as printing a series of nonspecific characters) should be incorporated to cancel out unused space, or wording such as ‘no more items on this prescription’ may be added after the last item.

Otherwise the doctor should delete the space manually.

12. To avoid forgery the computer may print on the form the number of items to be dispensed (somewhere separate from the box for the pharmacist). The number of items per form need be limited only by the ability of the printer to produce clear and well-demarcated instructions with sufficient space for each item and a spacer line before each fresh item.

13. Handwritten alterations should only be made in exceptional circumstances—it is preferable to print out a new prescription. Any alterations must be made in the doctor’s own handwriting and countersigned; computer records should be updated to fully reflect any alteration. Prescriptions for drugs used for contraceptive purposes (but which are not promoted as contraceptives) may need to be marked in handwriting with the symbol ‘D’, (or endorsed in another way to indicate that the item is prescribed for contraceptive purposes).

14. Prescriptions for controlled drugs can be printed from the computer, but the prescriber’s signature must be handwritten (See Controlled Drugs and Drug Dependence; the prescriber may use a date stamp).

15. The strip of paper on the side of the FP10SS (GP10SS in Scotland, WP10SS in Wales) may be used for various purposes but care should be taken to avoid including confidential information. It may be advisable for the patient’s name to appear at the top, but this should be preceded by ‘confidential’.

16. In rural dispensing practices prescription requests (or details of medicines dispensed) will normally be entered in one surgery. The prescriptions (or dispensed medicines) may then need to be delivered to another surgery or location; if possible the computer should hold up to 10 alternatives.

17. Prescription forms that are reprinted or issued as a duplicate should be labelled clearly as such.
Emergency supply of medicines

Emergency supply requested by member of the public

Pharmacists are sometimes called upon by members of the public to make an emergency supply of medicines. The Human Medicines Regulations 2012 allows exemptions from the Prescription Only requirements for emergency supply to be made by a person lawfully conducting a retail pharmacy business provided:

a) that the pharmacist has interviewed the person requesting the prescription-only medicine and is satisfied:
   i) that there is immediate need for the prescription-only medicine and that it is impracticable in the circumstances to obtain a prescription without undue delay;
   ii) that treatment with the prescription-only medicine has on a previous occasion been prescribed for the person requesting it;
   iii) as to the dose that it would be appropriate for the person to take;
b) that no greater quantity shall be supplied than will provide 5 days’ treatment of phenobarbital p. 409, phenobarbital sodium, or Controlled Drugs in Schedules 4 or 5 doctors or dentists from the European Economic Area and Switzerland, or their patients, cannot request an emergency supply of Controlled Drugs in Schedules 1, 2, or 3, or drugs that do not have a UK marketing authorisation (or 30 days’ treatment for other prescription-only medicines, except when the prescription-only medicine is:
   i) insulin, an ointment or cream, or a preparation for the relief of asthma in an aerosol dispenser when the smallest pack can be supplied;
   ii) an oral contraceptive when a full cycle may be supplied;
   iii) an antibiotic in liquid form for oral administration when the smallest quantity that will provide a full course of treatment can be supplied;
c) that an entry shall be made by the pharmacist in the prescription book stating:
   i) the date of supply;
   ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
   iii) the name and address of the patient;
   iv) the nature of the emergency;
d) that the container or package must be labelled to show:
   i) the date of supply;
   ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
   iii) the name of the patient;
   iv) the name and address of the pharmacy;
   v) the words ‘Emergency supply’;
   vi) the words ‘Keep out of the reach of children’ (or similar warning);
e) that the prescription-only medicine is not a substance specifically excluded from the emergency supply provision, and does not contain a Controlled Drug specified in Schedules 1, 2, or 3 to the Misuse of Drugs Regulations 2001 except for phenobarbital p. 409 or phenobarbital sodium for the treatment of epilepsy: for details see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition); (Doctors or dentists from the European Economic Area and Switzerland, or their patients, cannot request an emergency supply of Controlled Drugs in Schedules 1, 2, or 3, or drugs that do not have a UK marketing authorisation).

Emergency supply requested by prescriber

Emergency supply of a prescription-only medicine may also be made at the request of a doctor, a dentist, a supplementary prescriber, a community practitioner nurse prescriber, a nurse, pharmacist, or optometrist independent prescriber, or a doctor or dentist from the European Economic Area or Switzerland, provided:

a) that the pharmacist is satisfied that the prescriber by reason of some emergency is unable to furnish a prescription immediately;
b) that the prescriber has undertaken to furnish a prescription within 72 hours;
c) that the medicine is supplied in accordance with the directions of the prescriber requesting it;
d) that the medicine is not a Controlled Drug specified in Schedules 1, 2, or 3 to the Misuse of Drugs Regulations 2001 except for phenobarbital p. 409 or phenobarbital sodium for the treatment of epilepsy: for details see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition); (Doctors or dentists from the European Economic Area and Switzerland, or their patients, cannot request an emergency supply of Controlled Drugs in Schedules 1, 2, or 3, or drugs that do not have a UK marketing authorisation).
e) that an entry shall be made in the prescription book stating:
   i) the date of supply;
   ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
   iii) the name and address of the practitioner requesting the emergency supply;
   iv) the name and address of the patient;
   v) the date on the prescription;
   vi) when the prescription is received the entry should be amended to include the date on which it is received.

Royal Pharmaceutical Society’s guidelines

1. The pharmacist should consider the medical consequences of not supplying a medicine in an emergency.
2. If the pharmacist is unable to make an emergency supply of a medicine the pharmacist should advise the patient how to obtain essential medical care.

For conditions that apply to supplies made at the request of a patient see Medicines, Ethics and Practice, London Pharmaceutical Press, (always consult latest edition).
Controlled drugs and drug dependence

The Misuse of Drugs Act, 1971 prohibits certain activities in relation to ‘Controlled Drugs’, in particular their manufacture, supply, and possession. The penalties applicable to offences involving the different drugs are graded broadly according to the harmfulness attributable to a drug when it is misused and for this purpose the drugs are defined in the following three classes:


**Class C** includes: certain drugs related to the amphetamines such as benzphetamine and chlorphentermine, buprenorphine p. 434, diethylpropion, mazindol, meptobarbital p. 265 pemeoline, pipradrol, most benzodiazipines, tramadol hydrochloride p. 373, zaleplon p. 422, zolpidem tartrate p. 423, zopiclone p. 423, and zopiclone p. 423 which are subject to minimal control. Part II includes androgenic and anabolic steroids, clenbuterol, chionic gonadotrophin (HCG), non-human chionic gonadotrophin, somatotropin, somatrem, and somatropin p. 642. Controlled drug prescription requirements do not apply and Schedule 4 Controlled Drugs are not subject to safe custody requirements.

**Schedule 5** includes those preparations which, because of their strength, are exempt from virtually all Controlled Drug requirements other than retention of invoices for two years.

**Prescriptions**

Preparations in Schedules 1, 2, 3, 4 of the Misuse of Drugs Regulations 2001 (and subsequent amendments) are identified throughout the BNF and BNF for children using the following symbols:

| CD1 | for preparations in Schedule 1 |
| CD2 | for preparations in Schedule 2 |
| CD3 | for preparations in Schedule 3 |
| CD4-1 | for preparations in Schedule 4 (Part I) |
| CD4-2 | for preparations in Schedule 4 (Part II) |

The principal legal requirements relating to medical prescriptions are listed below.

**Prescription requirements**

Prescriptions for Controlled Drugs that are subject to prescription requirements, (all preparations in Schedules 2 and 3, except temazepam p. 420), must be indelible, (a machine-written prescription is acceptable; the prescriber’s signature must be handwritten), and must be signed by the prescriber, be dated, and specify the prescriber’s address. The prescription must always state:

- the name and address of the patient;
- in the case of a preparation, the form, (the dosage form e.g. tablets must be included on a Controlled Drugs prescription irrespective of whether it is implicit in the proprietary name e.g. MST Continus or whether only one form is available), and where appropriate the strength of the preparation (when more than one strength of a preparation exists the strength required must be specified);
- for liquids, the total volume in millilitres (in both words and figures) of the preparation to be supplied; for dosage units, the number (in both words and figures) of dosage units to be supplied; in any other case, the total quantity (in both words and figures) of the Controlled Drug to be supplied;
- the dose (the instruction ‘one as directed’ constitutes a dose but ‘as directed’ does not);
- the words ‘for dental treatment only’ if issued by a dentist.

A pharmacist is not allowed to dispense a Controlled Drug unless all the information required by law is given on the prescription. In the case of a prescription for a Controlled Drug in Schedule 2 or 3, a pharmacist can amend the prescription if it specifies the total quantity only in words or
Controlled drugs and drug dependence

Instalments and ‘repeats’

A prescription may order a Controlled Drug to be dispensed by instalments; the amount of instalments and the intervals to be observed must be specified. A total of 14 days’ treatment by instalment of any drug listed in Schedule 2 of the Misuse of Drugs Regulations, buprenorphine p. 434, and diazepam p. 267 may be prescribed in England. In England, forms FP10(MDA) (blue) and FP10H(MDA) (blue) should be used. In Scotland, forms GP10 (peach), HBP (blue), or HBPA (pink) should be used. In Wales a total of 14 days’ treatment by instalment of any drug listed in Schedules 2–5 of the Misuse of Drugs Regulations may be prescribed. In Wales, form WP10(MDA) or form WP10HP(AD) should be used. Instalment prescriptions must be dispensed in accordance with the directions in the prescription. However, the Home Office has approved specific wording which may be included in an instalment prescription to cover certain situations; for example, if a pharmacy is closed on the day when an instalment is due. For details, see Prescribing of diamorphine (heroin), dipipanone, or cocaine for addicts, see Prescribing of diamorphine (heroin), dipipanone, and cocaine for addicts. Despite marked reduction in the prescribing of amphetamines, there is concern that abuse of illicit amfetamine and related compounds is widespread. Benzodiazepines are commonly misused. However, the misuse of barbiturates is now uncommon, in line with declining medicinal use and consequent availability. Cannabis (Indian hemp) has no approved medicinal use and consequent availability. Lysergide (bysergic acid diethylamide, LSD) is a much more potent hallucinogen; its use can lead to severe psychotic states which can be life-threatening. There are concerns over increases in the availability and misuse of other drugs with variously combined hallucinogenic, anaesthetic, or sedative properties. These include ketamine p. 1110 and gamma-hydroxybutyrate (sodium oxybate, GHB).

Supervised consumption

Individuals prescribed opioid substitution therapy can take their daily dose under the supervision of a doctor, nurse, or pharmacist during the dose stabilisation phase (usually the first 3 months of treatment), after a relapse or period of...
instability, or if there is a significant increase in the dose of methadone. Supervised consumption should continue (in accordance with local protocols) until the prescriber is confident that the patient is compliant with their treatment.

**Prescribing drugs likely to cause dependence or misuse**

The prescriber has three main responsibilities:

- **To avoid creating dependence by introducing drugs to patients without sufficient reason.** In this context, the proper use of the morphine-like drugs is well understood. The dangers of other Controlled Drugs are less clear because recognition of dependence is not easy and its effects, and those of withdrawal, are less obvious.
- **To see that the patient does not gradually increase the dose of a drug, given for good medical reasons, to the point where dependence becomes more likely.** This tendency is seen especially with hypnotics and anxiolytics. The prescriber should keep a close eye on the amount prescribed to prevent patients from accumulating stocks. A minimal amount should be prescribed in the first instance, or when seeing a new patient for the first time.
- **To avoid being used as an unwitting source of supply for addicts and being vigilant to methods for obtaining medicines.** Methods include visiting more than one doctor, fabricating stories, and forging prescriptions.

Patients under temporary care should be given only small supplies of drugs unless they present an unequivocal letter from their own doctor. Doctors should also remember that their own patients may be attempting to collect prescriptions from other prescribers, especially in hospitals. It is sensible to reduce dosages steadily or to issue weekly or even daily prescriptions for small amounts if it is apparent that dependence is occurring. The stealing and misuse of prescription forms could be minimised by the following precautions:

- do not leave unattended or if called away from the consulting room or reception desks; do not leave in a car where they may be visible; when not in use, keep in a locked drawer within the surgery and at home;
- draw a diagonal line across the blank part of the form under the prescription;
- write the quantity in words and figures when prescribing drugs prone to abuse; this is obligatory for controlled drugs;
- alterations are best avoided but if any are made they should be clear and unambiguous; add initials against altered items;
- if prescriptions are left for collection they should be left in a safe place in a sealed envelope.

**Travelling abroad**

Prescribed drugs listed in Schedule 4 Part II (CD Anab) and Schedule 5 of the Misuse of Drugs Regulations 2001 are not subject to export or import licensing. However, patients intending to travel abroad for more than 3 months carrying any amount of drugs listed in Schedules 2, 3, or 4 Part I (CD Benz) will require a personal export/import licence. Further details can be obtained at www.gov.uk/controlled-drugs-licences-fees-and-returns or from the Home Office by contacting licensing.enquiry.aadu@homeoffice.gsi.gov.uk

In cases of emergency, telephone (020) 7035 6330

Applications must be supported by a covering letter from the prescriber and should give details of:

- the patient’s name and address;
- the quantities of drugs to be carried;
- the strength and form in which the drugs will be dispensed;
- the country or countries of destination;
- the dates of travel to and from the United Kingdom.

Applications for licences should be sent to the Home Office, Drugs Licensing & Compliance Unit, Fry Building, 2 Marsham Street, SW1P 4DF. Alternatively, completed application forms can be emailed to dlcucommsofficer@homeoffice.gsi.gov.uk with a copy of the covering letter from the prescriber as a pdf. A minimum of two weeks should be allowed for processing the application.

Patients travelling for less than 3 months do not require a personal export/import licence for carrying Controlled Drugs, but are advised to carry a letter from the prescribing doctor. Those travelling for more than 3 months are advised to make arrangements to have their medication prescribed by a practitioner in the country they are visiting.

Doctors who want to take Controlled Drugs abroad while accompanying patients may similarly be issued with licences. Licences are not normally issued to doctors who want to take Controlled Drugs abroad solely in case a family emergency should arise.

Personal export/import licences do not have any legal status outside the UK and are issued only to comply with the Misuse of Drugs Act and to facilitate passage through UK Customs and Excise control. For clearance in the country to be visited it is necessary to approach that country’s consular in the UK.

**Notification of patients receiving structured drug treatment for substance dependence**

In **England**, doctors should report cases where they are providing structured drug treatment for substance dependence to their local National Drug Treatment Monitoring System (NDTMS) Team. General information about NDTMS can be found at www.nta.nhs.uk/ndtms.aspx.

Enquiries about NDTMS, and how to submit data, should initially be directed to:

Malcom Roxburgh, NTA Information Manager
Tel: (020) 7972 1964
malcolm.roxburgh@nta-nhs.org.uk

In **Scotland**, doctors should report cases to the Substance Misuse Programme (SMP).

Tel: (0131) 275 6348

In **Northern Ireland**, the Misuse of Drugs (Notification of Supply to Addicts) (Northern Ireland) Regulations 1973 require doctors to send particulars of persons whom they consider to be addicted to certain controlled drugs to the Chief Medical Officer of the Department of Health and Social Services. The Northern Ireland contacts are:

Medical contact:
Dr Ian McMaster,
C3 Castle Buildings
Belfast BT4 3FQ
Tel: (028) 9052 2421
Fax: (028) 9052 0718
ian.mcmaster@dhsspsni.gov.uk

Administrative contact:
Public Health Information & Research Branch
Annex 2
Castle Building
Belfast BT4 3SQ
Tel: (028) 9052 2520

Public Health Information & Research Branch also maintains the Northern Ireland Drug Misuse Database (NIDMD) which collects detailed information on those presenting for treatment, on drugs misused and injecting behaviour; participation is not a statutory requirement.

In **Wales**, doctors should report cases where they are providing structured drug treatment for substance dependence.
dependence on the Welsh National Database for Substance Misuse; enquiries should be directed to: substance.misuse-queries@wales.nhs.uk.

Prescribing of diamorphine (heroin), dipipanone, and cocaine for addicts

The Misuse of Drugs (Supply to Addicts) Regulations 1997 require that only medical practitioners who hold a special licence issued by the Home Secretary may prescribe, administer, or supply diamorphine hydrochloride p. 361, dipipanone (Diconal®), or cocaine in the treatment of drug addiction; other practitioners must refer any addict who requires these drugs to a treatment centre. Whenever possible the addict will be introduced by a member of staff from the treatment centre to a pharmacist whose agreement has been obtained and whose pharmacy is conveniently sited for the patient. Prescriptions for weekly supplies will be sent to the pharmacy by post and will be dispensed on a daily basis as indicated by the doctor. If any alterations of the arrangements are requested by the addict, the portion of the prescription affected must be represcribed and not merely altered.

General practitioners and other doctors do not require a special licence for prescribing diamorphine hydrochloride p. 361, dipipanone, and cocaine for patients (including addicts) for relieving pain from organic disease or injury.
Adverse reactions to drugs

Any drug may produce unwanted or unexpected adverse reactions. Rapid detection and recording of adverse drug reactions is of vital importance so that unrecognised hazards are identified promptly and appropriate regulatory action is taken to ensure that medicines are used safely. Healthcare professionals and coroners are urged to report suspected adverse drug reactions directly to the Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card Scheme using the electronic form at www.mhra.gov.uk/yellowcard. Alternatively, prepaid Yellow Cards for reporting are available from the address below and are also bound in the inside back cover of the BNF.

Send Yellow Cards to:
FREEPOST YELLOW CARD
(No other address details required).
Tel: 0800 731 6789

Suspected adverse drug reactions to any therapeutic agent should be reported, including drugs (self-medication as well as those prescribed), blood products, vaccines, radiographic contrast media, complementary and herbal products. For biosimilar medicines and vaccines, adverse reaction reports should clearly state the brand name and the batch number of the suspected medicine or vaccine.

Suspected adverse drug reactions should be reported through the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. Yellow Cards can be used for reporting suspected adverse drug reactions to medicines, vaccines, herbal or complementary products, whether self-medicated or prescribed. This includes suspected adverse drug reactions associated with misuse, overdose, medication errors or from use of unlicensed and off-label medicines. Yellow Cards can also be used to report medical device incidents, defective medicines, and suspected fake medicines.

Spontaneous reporting is particularly valuable for recognising possible new hazards rapidly. An adverse reaction should be reported even if it is not certain that the drug has caused it, or if the reaction is well recognised, or if other drugs have been given at the same time. Reports of overdoses (deliberate or accidental) can complicate the assessment of adverse drug reactions, but provide important information on the potential toxicity of drugs.

A freephone service is available to all parts of the UK for advice and information on suspected adverse drug reactions; contact the National Yellow Card Information Service at the MHRA on 0800 731 6789. Outside office hours a telephone-answering machine will take messages. The following Yellow Card Centres can be contacted for further information:

Yellow Card Centre West Midlands
City Hospital
Dudley Road
Birmingham B18 7QH
Tel: (0121) 507 5672

Yellow Card Centre Scotland
CARDS, Royal Infirmary of Edinburgh
51 Little France Crescent
Old Dalkeith Road
Edinburgh EH16 4SA
Tel: (0131) 242 2919
YCCScotland@luht.scot.nhs.uk

The MHRA’s database facilitates the monitoring of adverse drug reactions. More detailed information on reporting and a list of products currently under additional monitoring can be found on the MHRA website: www.mhra.gov.uk.

MHRA Drug Safety Update

Drug Safety Update is a monthly newsletter from the MHRA and the Commission on Human Medicines (CHM); it is available at www.mhra.gov.uk/drugsafetyupdate.

Self-reporting

Patients and their carers can also report suspected adverse drug reactions to the MHRA. Reports can be submitted directly to the MHRA through the Yellow Card Scheme using the electronic form at www.mhra.gov.uk/yellowcard, by telephone on 0808 100 3352, or by downloading the Yellow Card form from www.mhra.gov.uk. Alternatively, patient Yellow Cards are available from pharmacies and GP surgeries. Information for patients about the Yellow Card Scheme is available in other languages at www.mhra.gov.uk/yellowcard.

Prescription-event monitoring

In addition to the MHRA’s Yellow Card Scheme, an independent scheme monitors the safety of new medicines using a different approach. The Drug Safety Research Unit identifies patients who have been prescribed selected new medicines and collects data on clinical events in these patients. The data are submitted on a voluntary basis by general practitioners on green forms. More information about the scheme and the Unit’s educational material is available from www.dsru.org.

Newer drugs and vaccines

Only limited information is available from clinical trials on the safety of new medicines. Further understanding about the safety of medicines depends on the availability of information from routine clinical practice. The black triangle symbol identifies newly licensed medicines that require additional monitoring by the European Medicines Agency. Such medicines include new active substances, biosimilar medicines, and medicines that the European Medicines Agency consider require additional monitoring. The black triangle symbol also appears in the Patient Information Leaflets for relevant medicines, with a brief explanation of what it means. Products usually retain a black triangle for 5 years, but this can be extended if required.

Spontaneous reporting is particularly valuable for recognising possible new hazards rapidly. For medicines showing the black triangle symbol, the MHRA asks that all suspected reactions (including those considered not to be serious) are reported through the Yellow Card Scheme. An adverse reaction should be reported even if it is not certain that the drug has caused it, or if the reaction is well...
recognised, or if other drugs have been given at the same time.

Established drugs and vaccines
Healthcare professionals and coroners are asked to report all suspected reactions to established drugs (including over-the-counter, herbal, and unlicensed medicines and medicines used off-label) and vaccines that are serious, medically significant, or result in harm. Serious reactions include those that are fatal, life-threatening, disabling, incapacitating, or which result in or prolong hospitalisation, or a congenital abnormality; they should be reported even if the effect is well recognised. Examples include anaphylaxis, blood disorders, endocrine disturbances, effects on fertility, haemorrhage from any site, renal impairment, jaundice, ophthalmic disorders, severe CNS effects, severe skin reactions, reactions in pregnant women, and any drug interactions. Reports of serious adverse reactions are required to enable comparison with other drugs of a similar class. Reports of overdoses (deliberate or accidental) can compromise the assessment of adverse drug reactions, but provide important information on the potential toxicity of drugs.

For established drugs there is no need to report well-known, relatively minor side-effects, such as dry mouth with tricyclic antidepressants or constipation with opioids.

Medication errors
Adverse drug reactions where harm occurs as a result of a medication error are reportable as a Yellow Card or through the local risk management systems into the National Reporting and Learning System (NRLS). If reported to the NRLS, these will be shared with the MHRA. If the NRLS is not available and harm occurs, report using a Yellow Card.

Adverse reactions to medical devices
Suspected adverse reactions to medical devices including dental or surgical materials, intra-uterine devices, and contact lens fluids should be reported. Information on reporting these can be found at: www.mhra.gov.uk.

Side-effects in the BNF
The BNF includes clinically relevant side-effects for most drugs; an exhaustive list is not included for drugs that are used by specialists (e.g. cytotoxic drugs and drugs used in anaesthesia). Where causality has not been established, side-effects in the manufacturers’ literature may be omitted from the BNF.

Recognising that hypersensitivity reactions can occur with virtually all medicines, this effect is not generally listed, unless the drug carries an increased risk of such reactions. The BNF also omits effects that are likely to have little clinical consequence (e.g. transient increase in liver enzymes).

Side-effects are generally listed in order of frequency and arranged broadly by body systems. Occasionally a rare side-effect might be listed first if it is considered to be particularly important because of its seriousness. In the product literature the frequency of side-effects is generally described as follows:

<table>
<thead>
<tr>
<th>Description of the frequency of side-effects</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>greater than 1 in 10</td>
</tr>
<tr>
<td>Common</td>
<td>1 in 100 to 1 in 10</td>
</tr>
<tr>
<td>Uncommon (formerly ‘less commonly’ in BNF publications)</td>
<td>1 in 1000 to 1 in 100</td>
</tr>
<tr>
<td>Rare</td>
<td>1 in 10 000 to 1 in 10 000</td>
</tr>
<tr>
<td>Very rare</td>
<td>less than 1 in 10 000</td>
</tr>
</tbody>
</table>

Special problems
Delayed drug effects Some reactions (e.g. cancers, chloroquine retinopathy, and retroperitoneal fibrosis) may become manifest months or years after exposure. Any suspicion of such an association should be reported directly to the MHRA through the Yellow Card Scheme.

The elderly Particular vigilance is required to identify adverse reactions in the elderly.

Congenital abnormalities When an infant is born with a congenital abnormality or there is a malformed aborted fetus doctors are asked to consider whether this might be an adverse reaction to a drug and to report all drugs (including self-medications) taken during pregnancy.

Children Particular vigilance is required to identify and report adverse reactions in children, including those resulting from the unlicensed use of medicines; all suspected reactions should be reported directly to the MHRA through the Yellow Card Scheme (see also Adverse Drug Reactions in Children).

Prevention of adverse reactions
Adverse reactions may be prevented as follows:

• never use any drug unless there is a good indication. If the patient is pregnant do not use a drug unless the need for it is imperative;
• allergy and idiosyncrasy are important causes of adverse drug reactions. Ask if the patient had previous reactions to the drug or formulation;
• ask if the patient is already taking other drugs including self-medications, drug supplements, complementary and alternative therapies; interactions may occur;
• age and hepatic or renal disease may alter the metabolism or excretion of drugs, so that much smaller doses may be needed. Genetic factors may also be responsible for variations in metabolism, and therefore for the adverse effect of the drug; notably of isoniazid p. 506 and the tricyclic antidepressants;
• prescribe as few drugs as possible and give very clear instructions to the elderly or any patient likely to misunderstand complicated instructions;
• whenever possible use a familiar drug; with a new drug, be particularly alert for adverse reactions or unexpected events;
• consider if excipients (e.g. colouring agents) may be contributing to the adverse reaction. If the reaction is minor, a trial of an alternative formulation of the same drug may be considered before abandoning the drug;
• warn the patient if serious adverse reactions are liable to occur.

Oral side-effects of drugs
Drug-induced disorders of the mouth may be due to a local action on the mouth or to a systemic effect manifested by oral changes. In the latter case urgent referral to the patient’s medical practitioner may be necessary.
Adverse reactions to drugs 13

Oral mucosa Medicaments left in contact with or applied directly to the oral mucosa can lead to inflammation or ulceration; the possibility of allergy should also be borne in mind. Aspirin p. 104 tablets allowed to dissolve in the sulcus for the treatment of toothache can lead to a white patch followed by ulceration. Flavouring agents, particularly essential oils, may sensitise the skin, but mucosal swelling is not usually prominent. The oral mucosa is particularly vulnerable to ulceration in patients treated with cytotoxic drugs, e.g. methotrexate p. 762. Other drugs capable of causing oral ulceration include ACE inhibitors, gold, nicorandil p. 185, NSAIDs, pancreatein p. 81, penicillamine p. 896, proguanil hydrochloride p. 539, and protease inhibitors. Erythema multiforme or Stevens-Johnson syndrome may follow the use of a wide range of drugs including antibacterials, antiretrovirals, sulfonamide derivatives, and anticonvulsants; the oral mucosa may be extensively ulcerated, with characteristic target lesions on the skin. Oral lesions of toxic epidermal necrolysis have been reported with a similar range of drugs. Lichenoid eruptions are associated with ACE inhibitors, NSAIDs methylprednisolone p. 138, chloroquine p. 536, oral antidiabetics, thiazide diuretics, and gold. Candidiasis can complicate treatment with antibacterials and immunosuppressants and is an occasional side-effect of corticosteroid inhalers.

Teeth and jaw Brown staining of the teeth frequently follows the use of chlorhexidine p. 989 mouthwash, spray or gel, but can readily be removed by polishing. Iron salts in liquid form can stain the enamel black. Superficial staining has been reported rarely with co-amoxiclav p. 484 suspension. Intrinsic staining of the teeth is most commonly caused by tetracyclines. They will affect the teeth if given at any time from about the fourth month in utero until the age of twelve years; they are contra-indicated during pregnancy, in breast-feeding women, and in children under 12 years. All tetracyclines can cause permanent, unsightly staining in children, the colour varying from yellow to grey. Excessive ingestion of fluoride leads to dental fluorosis with mottling of the enamel and areas of hypoplasia or pitting; fluoride supplements occasionally cause mild mottling (white patches) if the dose is too large for the child’s age (taking into account the fluoride content of the local drinking water and of toothpaste). The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget’s disease. All patients receiving bisphosphonates should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. Patients with cancer receiving cevacinumab p. 736 or sunitinib p. 817 may also be at risk of osteonecrosis of the jaw. Periodontium Gingival overgrowth (gingival hyperplasia) is a side-effect of phenytoin p. 398 and sometimes of ciclosporin p. 717 or of nifedipine p. 154 (and some other calcium-channel blockers). Thrombocytopenia may be drug related and may cause bleeding at the gingival margins, which may be spontaneous or may follow mild trauma (such as toothbrushing).

Salivary glands The most common effect that drugs have on the salivary glands is to reduce flow (xerostomia). Patients with a persistently dry mouth may have poor oral hygiene; they are at an increased risk of dental caries and oral infections (particularly candidiasis). Many drugs have been implicated in xerostomia, particularly antimuscarinics (anticholinergics), antidepressants (including tricyclic antidepressants, and selective serotonin re-uptake inhibitors), alpha-blockers, antihistamines, antipsychotics, bicalutamid p. 914, bupropion hydrochloride p. 433, clonidine hydrochloride p. 137, 5HT agonists, opioids, and tizanidine p. 913. Excessive use of diuretics can also result in xerostomia. Some drugs (e.g. clozapine p. 313, neostigmine p. 912) can increase saliva production but this is rarely a problem unless the patient has associated difficulty in swallowing. Pain in the salivary glands has been reported with some antihypertensives (e.g. clonidine hydrochloride p. 137, methyldopa p. 138) and with vinca alkaloids. Swelling of the salivary glands can occur with iodides, antithyroid drugs, phenothiazines, and sulfonamides.

Taste There can be decreased taste acuity or alteration in taste sensation. Many drugs are implicated, including amiodarone hydrochloride p. 88, calcitonin, ACE inhibitors, carbimazole p. 664, clarithromycin p. 470, gold, griseofulvin p. 1012, lithium salts, metformin hydrochloride p. 594, metronidazole p. 475, penicillamine p. 896, phenindione p. 120, propafenone hydrochloride p. 92, protease inhibitors, terbinafine p. 214, and zopiclone p. 423.

Defective medicines During the manufacture or distribution of a medicine an error or accident may occur whereby the finished product does not conform to its specification. While such a defect may impair the therapeutic effect of the product and could adversely affect the health of a patient, it should not be confused with an Adverse Drug Reaction where the product conforms to its specification.

The Defective Medicines Report Centre assists with the investigation of problems arising from licensed medicinal products thought to be defective and co-ordinates any necessary protective action. Reports on suspect defective medicinal products should include the brand or the non-proprietary name, the name of the manufacturer or supplier, the strength and dosage form of the product, the product licence number, the batch number or numbers of the product, the nature of the defect, and an account of any action already taken in consequence. The Centre can be contacted at:

The Defective Medicines Report Centre
Medicines and Healthcare products Regulatory Agency
151 Buckingham Palace Road
London SW1W 9SZ
Tel: (020) 3080 6588
info@mhra.gsi.gov.uk
Guidance on intravenous infusions

Intravenous additives policies
A local policy on the addition of drugs to intravenous fluids should be drawn up by a multi-disciplinary team in each strategic health authority (or equivalent) and issued as a document to the members of staff concerned. Centralised additive services are provided in a number of hospital pharmacy departments and should be used in preference to making additions on wards.

The information that follows should be read in conjunction with local policy documents.

Guidelines
- Drugs should only be added to infusion containers when constant plasma concentrations are needed or when the administration of a more concentrated solution would be harmful.
- In general, only one drug should be added to any infusion container and the components should be compatible. Ready-prepared solutions should be used whenever possible. Drugs should not normally be added to blood products, mannitol, or sodium bicarbonate.
- Only specially formulated additives should be used with fat emulsions or amino-acid solutions.
- Solutions should be thoroughly mixed by shaking and checked for absence of particulate matter before use.
- Strict asepsis should be maintained throughout and in general the giving set should not be used for more than 24 hours (for drug admixtures).
- The infusion container should be labelled with the patient’s name, the name and quantity of additives, and the date and time of addition (and the new expiry date or time). Such additional labelling should not interfere with information on the manufacturer’s label that is still valid. When possible, containers should be retained for a period after use in case they are needed for investigation.
- It is good practice to examine intravenous infusions from time to time while they are running. If cloudiness, crystallisation, change of colour, or any other sign of interaction or contamination is observed the infusion should be discontinued.

Problems
Microbial contamination The accidental entry and subsequent growth of micro-organisms converts the infusion fluid pathway into a potential vehicle for infection with micro-organisms, particularly species of Candida, Enterobacter, and Klebsiella. Ready-prepared infusions containing the additional drugs, or infusions prepared by an additive service (when available) should therefore be used in preference to making extemporaneous additions to infusion containers on wards etc. However, when this is necessary strict aseptic procedure should be followed.

Incompatibility Physical and chemical incompatibilities may occur with loss of potency, increase in toxicity, or other adverse effect. The solutions may become opalescent or precipitation may occur, but in many instances there is no visual indication of incompatibility. Interaction may take place at any point in the infusion fluid pathway, and the potential for incompatibility is increased when more than one substance is added to the infusion fluid.

Common incompatibilities Precipitation reactions are numerous and varied and may occur as a result of pH, concentration changes, ‘salting-out’ effects, complexation or other chemical changes. Precipitation or other particle formation must be avoided since, apart from lack of control of dosage on administration, it may initiate or exacerbate adverse effects. This is particularly important in the case of drugs which have been implicated in either thrombophlebitis (e.g. diazepam) or in skin sloughing or necrosis caused by extravasation (e.g. sodium bicarbonate and certain cytotoxic drugs). It is also especially important to effect solution of colloidal drugs and to prevent their subsequent precipitation in order to avoid a pyrogenic reaction (e.g. amphotericin).

It is considered undesirable to mix beta-lactam antibiotics, such as semi-synthetic penicillins and cephalosporins, with proteinaceous materials on the grounds that immunogenic and allergenic conjugates could be formed.

A number of preparations undergo significant loss of potency when added singly or in combination to large volume infusions. Examples include ampicillin in infusions that contain glucose or lactates. The breakdown products of dacarbazine have been implicated in adverse effects.

Blood Because of the large number of incompatibilities, drugs should not normally be added to blood and blood products for infusion purposes. Examples of incompatibility with blood include hypertonic mannitol solutions (irreversible crenation of red cells), dextran (routelux formation and interference with cross-matching), glucose (clumping of red cells), and oxytocic (inactivation).

If the giving set is not changed after the administration of blood, but used for other infusion fluids, a fibrin clot may form which, apart from blocking the set, increases the likelihood of microbial growth.

Intravenous fat emulsions These may break down with coalescence of fat globules and separation of phases when additions such as antibacterials or electrolytes are made, thus increasing the possibility of embolism. Only specially formulated products such as Vitlipid N® may be added to appropriate intravenous fat emulsions.

Other infusions Infusions that frequently give rise to incompatibility include amino acids, mannitol, and sodium bicarbonate.

Bactericides Bactericides such as chlorocresol 0.1% or phenylmercuric nitrate 0.001% are present in some injection solutions. The total volume of such solutions added to a container for infusion on one occasion should not exceed 15 ml.

Method
Ready-prepared infusions should be used whenever available. Potassium chloride is usually available in concentrations of 20, 27, and 40 mmol/litre in sodium chloride intravenous infusion (0.9%), glucose intravenous infusion (5%) or sodium chloride and glucose intravenous infusion. Lidocaine hydrochloride is usually available in concentrations of 0.1 or 0.2% in glucose intravenous infusion (5%).

When addition is required to be made extemporaneously, any product reconstitution instructions such as those relating to concentration, vehicle, mixing, and handling precautions should be strictly followed using an aseptic technique throughout. Once the product has been reconstituted, addition to the infusion fluid should be made immediately in order to minimise microbial contamination and, with certain products, to prevent degradation or other formulation change which may occur; e.g. reconstituted ampicillin injection degrades rapidly on standing, and also may form polymers which could cause sensitivity reactions. It is also important in certain instances that an infusion fluid of specific pH be used (e.g. furosemide injection requires dilution in infusions of pH greater than 5.5). When drug additions are made it is important to mix thoroughly; additions should not be made to an infusion container that has been connected to a giving set, as mixing
is hampered. If the solutions are not thoroughly mixed a concentrated layer of the additive may form owing to differences in density. Potassium chloride is particularly prone to this ‘layering’ effect when added without adequate mixing to infusions packed in non-rigid infusion containers; if such a mixture is administered it may have a serious effect on the heart.

A time limit between addition and completion of administration must be imposed for certain admixtures to guarantee satisfactory drug potency and compatibility. For admixtures in which degradation occurs without the formation of toxic substances, an acceptable limit is the time taken for 10% decomposition of the drug. When toxic substances are produced stricter limits may be imposed. Because of the risk of microbial contamination a maximum time limit of 24 hours may be appropriate for additions made elsewhere than in hospital pharmacies offering central additive service.

Certain injections must be protected from light during continuous infusion to minimise oxidation, e.g. dacarbazine and sodium nitroprusside.

Dilution with a small volume of an appropriate vehicle and administration using a motorised infusion pump is advocated for preparations such as unfractionated heparin where strict control over administration is required. In this case the appropriate dose may be dissolved in a convenient volume (e.g. 24–48 mL) of sodium chloride intravenous infusion (0.9%).

**Information provided in the BNF**

The *BNF* gives information about preparations given by three methods:

- continuous infusion;
- intermittent infusion;
- addition via the drip tubing.

Drugs for continuous infusion must be diluted in a large volume infusion. Penicillins and cephalosporins are not usually given by continuous infusion because of stability problems and because adequate plasma and tissue concentrations are best obtained by intermittent infusion. Where it is necessary to administer them by continuous infusion, detailed literature should be consulted.

Drugs that are both compatible and clinically suitable may be given by intermittent infusion in a relatively small volume of infusion over a short period of time, e.g. 100 mL in 30 minutes. The method is used if the product is incompatible or unstable over the period necessary for continuous infusion; the limited stability of ampicillin or amoxicillin in large volume glucose or lactate infusions may be overcome in this way.

Intermittent infusion is also used if adequate plasma and tissue concentrations are not produced by continuous infusion as in the case of drugs such as dacarbazine, gentamicin, and ticarcillin. An in-line burette may be used for intermittent infusion techniques in order to achieve strict control over the time and rate of administration, especially for infants and children and in intensive care units. Intermittent infusion may also make use of the ‘piggy-back’ technique provided that no additions are made to the primary infusion. In this method the drug is added to a small secondary container connected to a Y-type injection site on the primary infusion giving set; the secondary solution is usually infused within 30 minutes.

**Addition via the drip tubing** is indicated for a number of cytotoxic drugs in order to minimise extravasation. The preparation is added aseptically via the rubber septum of the injection site of a fast-running infusion. In general, drug preparations intended for a bolus effect should be given directly into a separate vein where possible. Failing this, administration may be made via the drip tubing provided that the preparation is compatible with the infusion fluid when given in this manner.

**Drugs given by intravenous infusion** The *BNF* includes information on addition of drugs to *Glucose intravenous infusion* 5 and 10%, and *Sodium chloride intravenous infusion* 0.9%. Compatibility with glucose 5% and with sodium chloride 0.9% indicates compatibility with *Sodium chloride and glucose intravenous infusion*. Infusion of a large volume of hypotonic solution should be avoided therefore care should be taken if water for injections is used. The information relates to the proprietary preparations indicated; for other preparations suitability should be checked with the manufacturer.

Information provided in the BNF The *BNF* gives information about preparations given by three methods:

- continuous infusion;
- intermittent infusion;
- addition via the drip tubing.

Drugs for continuous infusion must be diluted in a large volume infusion. Penicillins and cephalosporins are not usually given by continuous infusion because of stability problems and because adequate plasma and tissue concentrations are best obtained by intermittent infusion. Where it is necessary to administer them by continuous infusion, detailed literature should be consulted.

Drugs that are both compatible and clinically suitable may be given by intermittent infusion in a relatively small volume of infusion over a short period of time, e.g. 100 mL in 30 minutes. The method is used if the product is incompatible or unstable over the period necessary for continuous infusion; the limited stability of ampicillin or amoxicillin in large volume glucose or lactate infusions may be overcome in this way.

Intermittent infusion is also used if adequate plasma and tissue concentrations are not produced by continuous infusion as in the case of drugs such as dacarbazine, gentamicin, and ticarcillin. An in-line burette may be used for intermittent infusion techniques in order to achieve strict control over the time and rate of administration, especially for infants and children and in intensive care units. Intermittent infusion may also make use of the ‘piggy-back’ technique provided that no additions are made to the primary infusion. In this method the drug is added to a small secondary container connected to a Y-type injection site on the primary infusion giving set; the secondary solution is usually infused within 30 minutes.

**Addition via the drip tubing** is indicated for a number of cytotoxic drugs in order to minimise extravasation. The preparation is added aseptically via the rubber septum of the injection site of a fast-running infusion. In general, drug preparations intended for a bolus effect should be given directly into a separate vein where possible. Failing this, administration may be made via the drip tubing provided that the preparation is compatible with the infusion fluid when given in this manner.

**Drugs given by intravenous infusion** The *BNF* includes information on addition of drugs to *Glucose intravenous infusion* 5 and 10%, and *Sodium chloride intravenous infusion* 0.9%. Compatibility with glucose 5% and with sodium chloride 0.9% indicates compatibility with *Sodium chloride and glucose intravenous infusion*. Infusion of a large volume of hypotonic solution should be avoided therefore care should be taken if water for injections is used. The information relates to the proprietary preparations indicated; for other preparations suitability should be checked with the manufacturer.
Prescribing for children

For detailed advice on medicines used for children, consult BNF for Children.

Children, and particularly neonates, differ from adults in their response to drugs. Special care is needed in the neonatal period (first 28 days of life) and doses should always be calculated with care. At this age, the risk of toxicity is increased by reduced drug clearance and differing target organ sensitivity.

Whenever possible, intramuscular injections should be avoided in children because they are painful.

Where possible, medicines for children should be prescribed within the terms of the marketing authorisation (product licence). However, many children may require medicines outside the limits of the licence, the Human Medicines Regulations 2012 does not prohibit the use of unlicensed medicines. It is recognised that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications ('off-label' use) is often necessary in paediatric practice.

Adverse drug reactions in children

Suspected adverse drug reactions in children and young adults under 18 years should be reported through the Yellow Card Scheme. Yellow cards can be used for reporting suspected adverse drug reactions to medicines, vaccines, herbal or complementary products, whether self-medicating or prescribed. This includes suspected adverse drug reactions associated with misuse, overdose, medication errors or from use of unlicensed and off-label medicines. Yellow Cards can also be used to report medical device incidents, defective medicines, and suspected fake medicines.

Report all suspected adverse drug reactions that are:

- serious, medically significant or result in harm.
- associated with newer drugs and vaccines; the most up to date list of black triangle medicines is available at: www.mhra.gov.uk/blacktriangle.

If in doubt whether to report a suspected adverse drug reaction, please complete a Yellow Card.

The identification and reporting of adverse reactions to drugs in children and neonates is particularly important because:

- the action of the drug and its pharmacokinetics in children (especially in the very young) may be different from that in adults;
- drugs may not have been extensively tested in children;
- many drugs are not specifically licensed for use in children and are used either 'off-label' or as unlicensed products;
- drugs may affect the way a child grows and develops or may cause delayed adverse reactions which do not occur in adults;
- suitable formulations may not be available to allow precise dosing in children or they may contain excipients that should be used with caution in children;
- the nature and course of illnesses and adverse drug reactions may differ between adults and children.

Even if reported through the British Paediatric Surveillance Unit’s Orange Card Scheme, any identified suspected adverse drug reactions should also be submitted to the Yellow Card Scheme.

Adverse drug reactions where harm occurs as a result of a medication error are reportable as a Yellow Card or through the local risk management systems into the National Reporting and Learning System (NRLS). If reported to the NRLS, these will be shared with the MHRA. If the NRLS is not available and harm occurs, report using a Yellow Card.

Prescription writing

Prescriptions should be written according to the guidelines in Prescription Writing. Inclusion of age is a legal requirement in the case of prescription-only medicines for children under 12 years of age, but it is preferable to state the age for all prescriptions for children.

It is particularly important to state the strengths of capsules or tablets. Although liquid preparations are particularly suitable for children, they may contain sugar which encourages dental decay. Sugar-free medicines are preferred for long-term treatment.

Many children are able to swallow tablets or capsules and may prefer a solid dose form; involving the child and parents in choosing the formulation is helpful.

When a prescription for a liquid oral preparation is written and the dose ordered is smaller than 5 mL, an oral syringe will be supplied. Parents should be advised not to add any medicines to the infant’s feed, since the drug may interact with the milk or other liquid in it; moreover the ingested dosage may be reduced if the child does not drink all the contents.

Parents must be warned to keep all medicines out of reach of children.

Rare paediatric conditions

Information on substances such as biotin and sodium benzoate used in rare metabolic conditions is included in BNF for Children; further information can be obtained from:

Alder Hey Children’s Hospital
Drug Information Centre
Liverpool L12 2AP
Tel: (0151) 252 5381

Great Ormond Street Hospital for Children
Pharmacy
Great Ormond St
London WC1N 3JH
Tel: (020) 7405 9200

Dosage in children

Children’s doses in the BNF are stated in the individual drug entries or a cross-reference is provided to BNF for Children.

Doses are generally based on body-weight (in kilograms) or specific age ranges, e.g. first month (neonate), 1–5 years, 6–11 years, 12–17 years.

Dose calculation

Many children’s doses are standardised by weight (and therefore require multiplying by the body-weight in kilograms to determine the child’s dose); occasionally, the doses have been standardised by body surface area (in m²).

These methods should be used rather than attempting to calculate a child’s dose on the basis of doses used in adults. For most drugs the adult maximum dose should not be exceeded. For example if the dose is stated as 8 mg/kg (max. 300 mg), a child weighing 10 kg should receive 80 mg but a child weighing 40 kg should receive 300 mg (rather than 320 mg).

Young children may require a higher dose per kilogram than adults because of their higher metabolic rates. Other problems need to be considered. For example, calculation by body-weight in the overweight child may result in much higher doses being administered than necessary; in such cases, dose should be calculated from an ideal weight, related to height and age.

Body surface area (BSA) estimates are sometimes preferable to body-weight for calculation of paediatric doses.
since many physiological phenomena correlate better with body surface area. Body surface area can be estimated from weight. For more information, refer to BNF for Children. Where the dose for children is not stated, prescribers should consult BNF for Children or seek advice from a medicines information centre.

Dose frequency
Antibacterials are generally given at regular intervals throughout the day. Some flexibility should be allowed in children to avoid waking them during the night. For example, the night-time dose may be given at the child’s bedtime. Where new or potentially toxic drugs are used, the manufacturers’ recommended doses should be carefully followed.

Prescribing in hepatic impairment

Liver disease may alter the response to drugs in several ways as indicated below, and drug prescribing should be kept to a minimum in all patients with severe liver disease. The main problems occur in patients with jaundice, ascites, or evidence of encephalopathy.

Impaired drug metabolism
Metabolism by the liver is the main route of elimination for many drugs, but hepatic reserve is large and liver disease has to be severe before important changes in drug metabolism occur. Routine liver-function tests are a poor guide to the capacity of the liver to metabolise drugs, and in the individual patient it is not possible to predict the extent to which the metabolism of a particular drug may be impaired.

A few drugs, e.g. rifampicin p. 508 and fusidic acid p. 463, are excreted in the bile unchanged and can accumulate in patients with intrahepatic or extrahepatic obstructive jaundice.

Hypoproteinaemia
The hypoalbuminaemia in severe liver disease is associated with reduced protein binding and increased toxicity of some highly protein-bound drugs such as phenytoin p. 398 and prednisolone p. 585.

Reduced clotting
Reduced hepatic synthesis of blood-clotting factors, indicated by a prolonged prothrombin time, increases the sensitivity to oral anticoagulants such as warfarin sodium p. 121 and phenindione p. 120.

Hepatic encephalopathy
In severe liver disease many drugs can further impair cerebral function and may precipitate hepatic encephalopathy. These include all sedative drugs, opioid analgesics, those diuretics that produce hypokalaemia, and drugs that cause constipation.

Fluid overload
Oedema and ascites in chronic liver disease can be exacerbated by drugs that give rise to fluid retention e.g. NSAIDs and corticosteroids.

Hepatotoxic drugs
Hepatotoxicity is either dose-related or unpredictable (idiosyncratic). Drugs that cause dose-related toxicity may do so at lower doses in the presence of hepatic impairment than in individuals with normal liver function, and some drugs that produce reactions of the idiosyncratic kind do so more frequently in patients with liver disease. These drugs should be avoided or used very carefully in patients with liver disease. Where care is needed when prescribing in hepatic impairment, this is indicated under the relevant drug in the BNF.

Prescribing in renal impairment

The use of drugs in patients with reduced renal function can give rise to problems for several reasons:

- reduced renal excretion of a drug or its metabolites may cause toxicity;
- sensitivity to some drugs is increased even if elimination is unimpaired;
- many side-effects are tolerated poorly by patients with renal impairment;
- some drugs are not effective when renal function is reduced.

Many of these problems can be avoided by reducing the dose or by using alternative drugs.

Principles of dose adjustment in renal impairment

The level of renal function below which the dose of a drug must be reduced depends on the proportion of the drug eliminated by renal excretion and its toxicity. For many drugs with only minor or no dose-related side-effects very precise modification of the dose regimen is unnecessary and a simple scheme for dose reduction is sufficient.

For more toxic drugs with a small safety margin or patients at extremes of weight, dose regimens based on creatinine clearance should be used. When both efficacy and toxicity are closely related to plasma-drug concentration, recommended regimens should be regarded only as a guide to initial treatment; subsequent doses must be adjusted.
Prescribing in renal impairment

The total daily maintenance dose of a drug can be reduced either by reducing the size of the individual doses or by increasing the interval between doses. For some drugs, although the size of the maintenance dose is reduced it is important to give a loading dose if an immediate effect is required. This is because it takes about five times the half-life of the drug to achieve steady-state plasma concentrations. Because the plasma half-life of drugs excreted by the kidney is prolonged in renal impairment it can take many doses for the reduced dosage to achieve a therapeutic plasma concentration. The loading dose should usually be the same size as the initial dose for a patient with normal renal function.

Nephrotoxic drugs should, if possible, be avoided in patients with renal disease because the consequences of nephrotoxicity are likely to be more serious when renal reserve is already reduced. Dose recommendations are based on the severity of renal impairment.

Renal function is measured either in terms of estimated glomerular filtration rate (eGFR) calculated from a formula derived from the Modification of Diet in Renal Disease study (‘MDRD formula’ that uses serum creatinine, age, sex, and race (for Afro-Caribbean patients)) or it can be expressed as creatinine clearance (best derived from a 24-hour urine collection but often calculated from the Cockcroft and Gault formula (CG)).

**Cockcroft and Gault Formula**

\[
\text{Estimated Creatinine Clearance} = \frac{(140 - \text{Age}) \times \text{Weight} \times \text{Constant}}{\text{Serum creatinine}} \text{ in } \text{mL/minute}
\]

Age in years  
Weight in kilograms; use ideal body-weight  
Serum creatinine in micromol/litre  
Constant = 1.23 for men; 1.04 for women

The serum-creatinine concentration is sometimes used instead as a measure of renal function but it is only a rough guide to drug dosing.

**Important** Renal function in adults is increasingly being reported on the basis of estimated glomerular filtration rate (eGFR) normalised to a body surface area of 1.73 m² and derived from the Modification of Diet in Renal Disease (MDRD) formula. However, published information on the effects of renal impairment on drug elimination is usually stated in terms of creatinine clearance as a surrogate for glomerular filtration rate (GFR).

The information on dosage adjustment in the BNF is expressed in terms of eGFR, rather than creatinine clearance, for most drugs (exceptions include toxic drugs and patients at extremes of weight). Although the two measures of renal function are not interchangeable, in practice, for most drugs and for most patients (over 18 years) of average build and height, eGFR (MDRD ‘formula’) can be used to determine dosage adjustments in place of creatinine clearance. An individual’s absolute glomerular filtration rate can be calculated from the eGFR as follows:

\[
\text{GFR Absolute} = \text{eGFR} \times (\text{individual’s body surface area}/1.73)
\]

**Toxic drugs** For potentially toxic drugs with a small safety margin, creatinine clearance (calculated from the Cockcroft and Gault formula) should be used to adjust drug dosages in addition to plasma-drug concentration and clinical response.

**Patients at extremes of weight** In patients at both extremes of weight (BMI of less than 18.5 kg/m² or greater than 30 kg/m²) the absolute glomerular filtration rate or creatinine clearance (calculated from the Cockcroft and Gault formula) should be used to adjust drug dosages.

In the BNF, values for eGFR, creatinine clearance (for toxic drugs), or another measure of renal function are included where possible. However, where such values are not available, the BNF reflects the terms used in the published information.

### Chronic kidney disease in adults: UK guidelines for identification, management and referral (March 2006) define renal function as follows:

<table>
<thead>
<tr>
<th>Degree of impairment</th>
<th>eGFR mL/minute/1.73 m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal - Stage 1</td>
<td>More than 90 (with other evidence of kidney damage)</td>
</tr>
<tr>
<td>Mild - Stage 2</td>
<td>60–89 (with other evidence of kidney damage)</td>
</tr>
<tr>
<td>Moderate - Stage 3</td>
<td>30–59</td>
</tr>
<tr>
<td>Severe - Stage 4</td>
<td>15–29</td>
</tr>
<tr>
<td>Established renal failure - Stage 5</td>
<td>Less than 15</td>
</tr>
</tbody>
</table>

1. NICE clinical guideline 73 (September 2008)—Chronic kidney disease: Stage 3a eGFR 45–59, Stage 3b eGFR 30–44

**Dialysis**

For prescribing in patients on continuous ambulatory peritoneal dialysis (CAPD) or haemodialysis, consult specialist literature.

Drug prescribing should be kept to the minimum in all patients with severe renal disease. If even mild renal impairment is considered likely on clinical grounds, renal function should be checked before prescribing any drug which requires dose modification. Where care is needed when prescribing in renal impairment, this is indicated under the relevant drug in the BNF.
Prescribing in pregnancy

Drugs can have harmful effects on the embryo or fetus at any time during pregnancy. It is important to bear this in mind when prescribing for a woman of childbearing age or for men trying to father a child.

During the first trimester drugs can produce congenital malformations (teratogenesis), and the period of greatest risk is from the third to the eleventh week of pregnancy. During the second and third trimesters drugs can affect the growth or functional development of the fetus, or they can have toxic effects on fetal tissues.

Drugs given shortly before term or during labour can have adverse effects on labour or on the neonate after delivery. Not all the damaging effects of intra-uterine exposure to drugs are obvious at birth, some may only manifest later in life. Such late-onset effects include malignancy, e.g. adenocarcinoma of the vagina after puberty in females exposed to diethylstilbestrol in the womb, and adverse effects on intellectual, social, and functional development.

The amount of drug transferred in breast milk is rarely sufficient to produce a discernible effect on the infant. This applies particularly to drugs that are poorly absorbed and need to be given parenterally. However, there is a theoretical possibility that a small amount of drug present in breast milk can induce a hypersensitivity reaction. A clinical effect can occur in the infant if a pharmacologically significant quantity of the drug is present in milk. For some drugs (e.g. fluvastatin p. 180), the ratio between the concentration in milk and that in maternal plasma may be high enough to expose the infant to adverse effects. Some infants, such as those born prematurely or who have jaundice, are at a slightly higher risk of toxicity. Some drugs inhibit the infant’s sucking reflex (e.g. phenobarbital p. 409) while others can affect lactation (e.g. bromocriptine p. 333).

Important

Drugs should be prescribed in pregnancy only if the expected benefit to the mother is thought to be greater than the risk to the fetus, and all drugs should be avoided if possible during the first trimester. Drugs which have been extensively used in pregnancy and appear to be usually safe should be prescribed in preference to new or untried drugs; and the smallest effective dose should be used. Few drugs have been shown conclusively to be teratogenic in humans, but no drug is safe beyond all doubt in early pregnancy. Screening procedures are available when there is a known risk of certain defects.

Absence of information does not imply safety. It should be noted that the BNF and BNF for Children provide independent advice and may not always agree with the product literature.

Information on drugs and pregnancy is also available from the UK Teratology Information Service. www.uktis.org

Tel: 0844 892 0909 (09.00–17.00 Monday to Friday; urgent enquiries only outside these hours).

Prescribing in breast-feeding

Breast-feeding is beneficial; the immunological and nutritional value of breast milk to the infant is greater than that of formula feeds.

Although there is concern that drugs taken by the mother might affect the infant, there is very little information on this. In the absence of evidence of an effect, the potential for harm to the infant can be inferred from:

- the amount of drug or active metabolite of the drug delivered to the infant (dependent on the pharmacokinetic characteristics of the drug in the mother);
- the efficiency of absorption, distribution, and elimination of the drug by the infant (infant pharmacokinetics);
- the nature of the effect of the drug on the infant (pharmacodynamic properties of the drug in the infant).

The amount of drug transferred in breast milk is rarely sufficient to produce a discernible effect on the infant. This applies particularly to drugs that are poorly absorbed and need to be given parenterally. However, there is a theoretical possibility that a small amount of drug present in breast milk can induce a hypersensitivity reaction. A clinical effect can occur in the infant if a pharmacologically significant quantity of the drug is present in milk. For some drugs (e.g. fluvastatin p. 180), the ratio between the concentration in milk and that in maternal plasma may be high enough to expose the infant to adverse effects. Some infants, such as those born prematurely or who have jaundice, are at a slightly higher risk of toxicity. Some drugs inhibit the infant’s sucking reflex (e.g. phenobarbital p. 409) while others can affect lactation (e.g. bromocriptine p. 333).

Important

For many drugs insufficient evidence is available to provide guidance and it is advisable to administer only essential drugs to a mother during breast-feeding. Because of the inadequacy of information on drugs in breast-feeding, absence of information does not imply safety.
Prescribing in palliative care

Palliative care is an approach that improves the quality of life of patients and their families facing life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual. Careful assessment of symptoms and needs of the patient should be undertaken by a multidisciplinary team. Specialist palliative care is available in most areas as day hospice care, home-care teams (often known as Macmillan teams), in-patient hospice care, and hospital teams. Many acute hospitals and teaching centres now have consultative, hospital-based teams. Hospice care of terminally ill patients has shown the importance of symptom control and psychosocial support of the patient and family. Families should be included in the care of the patient if they wish. Many patients wish to remain at home with their families. Although some families may at first be afraid of caring for the patient at home, support can be provided by community nursing services, social services, voluntary agencies and hospices together with the general practitioner. The family may be reassured by the knowledge that the patient will be admitted to a hospital or hospice if the family cannot cope.

Drug treatment The number of drugs should be as few as possible, for even the taking of medicine may be an effort. Oral medication is usually satisfactory unless there is severe nausea and vomiting, dysphagia, weakness, or coma, when parenteral medication may be necessary.

Pain Pain management in palliative care is focused on achieving control of pain by administering the right drug in the right dose at the right time. Analgesics can be divided into three broad classes: non-opioid (paracetamol p. 354, NSAID), opioid (e.g. codeine phosphate p. 360 ‘weak’, morphine p. 367 ‘strong’) and adjuvant (e.g. antidepressants, antiepileptics). Drugs from the different classes are used alone or in combination according to the type of pain and response to treatment. Analgesics are more effective in preventing pain than in the relief of established pain; it is important that they are given regularly. Paracetamol or a NSAID given regularly will often be sufficient to manage mild pain. If non-opioid analgesics alone are not sufficient, then an opioid analgesic alone or in combination with a non-opioid analgesic at an adequate dosage, may be helpful in the control of moderate pain. Codeine phosphate or tramadol hydrochloride p. 373 can be considered for moderate pain. If these preparations do not control the pain then morphine is the most useful opioid analgesic. Alternatives to morphine, including transdermal buprenorphine p. 434, transdermal fentanyl p. 362, hydromorphone hydrochloride p. 366, methadone hydrochloride p. 436, or oxycodone hydrochloride p. 369, should be initiated by those with experience in palliative care. Initiation of an opioid analgesic should not be delayed by concern over a theoretical likelihood of psychological dependence (addiction).

Bone metastases In addition to the above approach, radiotherapy, bisphosphonates, and radioactive isotopes of strontium ranelate p. 626 (Metastron® available from GE Healthcare) may be useful for pain due to bone metastases.

Neuropathic pain Patients with neuropathic pain may benefit from a trial of a tricyclic antidepressant. An antiepileptic may be added or substituted if pain persists; gabapentin p. 392 and pregabalin p. 400 are licensed for neuropathic pain. Ketamine p. 1110 is sometimes used under specialist supervision for neuropathic pain that responds poorly to opioid analgesics. Pain due to nerve compression may be reduced by a corticosteroid such as dexamethasone p. 947, which reduces oedema around the tumour, thus reducing compression. Nerve blocks or regional anaesthesia techniques (including the use of epidural and intrathecal catheters) can be considered when pain is localised to a specific area.

Pain management with opioids

Oral route Treatment with morphine p. 367 is given by mouth as immediate-release or modified-release preparations. During the titration phase the initial dose is based on the previous medication used, the severity of the pain, and other factors such as presence of renal impairment, increasing age, or frailty. The dose is given either as an immediate-release preparation 4-hourly or as a modified-release preparation 12-hourly, in addition to rescue doses.

If pain occurs between regular doses of morphine (‘breakthrough pain’), an additional dose (‘rescue dose’) of immediate-release morphine should be given. An additional dose should also be given 30 minutes before an activity that causes pain, such as wound dressing. The standard dose of a strong opioid for breakthrough pain is usually one-tenth to one-sixth of the regular 24-hour dose, repeated every 2–4 hours as required (up to hourly may be needed if pain is severe or in the last days of life). Review pain management if rescue analgesic is required frequently (twice daily or more). Each patient should be assessed on an individual basis. Formulations of fentanyl p. 362 that are administered nasally, buccally or sublingually are also licensed for breakthrough pain. When adjusting the dose of morphine, the number of rescue doses required and the response to them should be taken into account; increments of morphine should not exceed one-third to one-half of the total daily dose every 24 hours. Thereafter, the dose should be adjusted with careful assessment of the pain, and the use of adjuvant analgesics should also be considered. Upward titration of the dose of morphine stops when either the pain is relieved or unacceptable adverse effects occur, after which it is necessary to consider alternative measures. Morphine immediate-release 30mg 4-hourly (or modified-release 100mg 12-hourly) is usually adequate for most patients; some patients require morphine immediate-release up to 200mg 4-hourly (or modified-release 600mg 12-hourly), occasionally more is needed. Once their pain is controlled, patients started on 4-hourly immediate-release morphine can be transferred to the same total 24-hour dose of morphine given as the modified-release preparation for 12-hourly or 24-hourly administration. The first dose of the modified-release preparation is given with, or within 4 hours of, the last dose of the immediate-release preparation. For preparations suitable for 12-hourly or 24-hourly administration see modified-release preparations under morphine p. 367. Increments should be made to the dose, not to the frequency of administration. The patient must be monitored closely for efficacy and side-effects, particularly constipation, and nausea and vomiting. A suitable laxative should be prescribed routinely.
Oxycodone hydrochloride p. 369 can be used in patients who require an opioid but cannot tolerate morphine. If the patient is already receiving an opioid, oxycodone hydrochloride should be started at a dose equivalent to the current analgesic (see below). Oxycodone hydrochloride immediate-release preparations can be given for breakthrough pain.

### Equivalent doses of opioid analgesics

This table is only an approximate guide (doses may not correspond with those given in clinical practice); patients should be carefully monitored after any change in medication and dose titration may be required.

<table>
<thead>
<tr>
<th>Analgesic</th>
<th>Route</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
<td>PO</td>
<td>100 mg</td>
</tr>
<tr>
<td>Diamorphine</td>
<td>IM, IV, SC</td>
<td>3 mg</td>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td>PO</td>
<td>100 mg</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>PO</td>
<td>2 mg</td>
</tr>
<tr>
<td>Morphine</td>
<td>PO</td>
<td>5 mg</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>PO</td>
<td>6.6 mg</td>
</tr>
<tr>
<td>Tramadol</td>
<td>PO</td>
<td>100 mg</td>
</tr>
</tbody>
</table>

PO = by mouth; IM = intramuscular; IV = intravenous; SC = subcutaneous

### Parenteral route

The equivalent parenteral dose of morphine p. 367 (subcutaneous, intramuscular, or intravenous) is about half of the oral dose. If the patient becomes unable to swallow, generally morphine is administered as a continuous subcutaneous infusion (for details, see Continuous Subcutaneous Infusions below). Diamorphine hydrochloride p. 361 is sometimes preferred, because being more soluble, it can be given in a smaller volume. The equivalent subcutaneous dose of dihydromorphone hydrochloride is about one-third of the oral dose of morphine.

If the patient can resume taking medicines by mouth, then oral morphine may be substituted for subcutaneous infusion of morphine or diamorphine hydrochloride, see table above of approximate equivalent doses of morphine and dihydromorphone hydrochloride. The infusion is discontinued when the first oral dose of morphine is given.

### Rectal route

Morphine p. 367 is also available for rectal administration as suppositories; alternatively oxycodone hydrochloride suppositories p. 369 can be obtained on special order.

### Transdermal route

Transdermal preparations of fentanyl p. 362 and buprenorphine p. 434 are available, they are not suitable for acute pain or in patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Prescribers should ensure that they are familiar with the correct use of transdermal preparations, see under buprenorphine p. 434 and fentanyl p. 362 (inappropriate use has caused fatalities). Immediate-release morphine can be given for breakthrough pain.

The following 24-hour oral doses of morphine are considered to be approximately equivalent to the buprenorphine and fentanyl patches shown, however when switching due to possible opioid-induced hyperalgesia, reduce the calculated equivalent dose of the new opioid by one-quarter to one-half.

### Buprenorphine patches are approximately equivalent to the following 24-hour doses of oral morphine

<table>
<thead>
<tr>
<th>Analgesic</th>
<th>Route</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>12 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>24 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>48 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>84 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>126 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>168 mg daily</td>
</tr>
<tr>
<td>fentanyl '12' patch</td>
<td>BuTrans® 5' patch</td>
<td>7-day patches</td>
</tr>
<tr>
<td>fentanyl '25' patch</td>
<td>BuTrans® 10' patch</td>
<td>7-day patches</td>
</tr>
<tr>
<td>fentanyl '50' patch</td>
<td>BuTrans® 20' patch</td>
<td>7-day patches</td>
</tr>
<tr>
<td>fentanyl '75' patch</td>
<td>Transect® 35' patch</td>
<td>4-day patches</td>
</tr>
<tr>
<td>fentanyl '100' patch</td>
<td>Transect® 52.5' patch</td>
<td>4-day patches</td>
</tr>
<tr>
<td>fentanyl '100' patch</td>
<td>Transect® 70' patch</td>
<td>4-day patches</td>
</tr>
</tbody>
</table>

Conversion ratios vary and these figures are a guide only. Morphine equivalents for transdermal opioid preparations have been approximated to allow comparison with available preparations of oral morphine.

### 72-hour Fentanyl patches are approximately equivalent to the following 24-hour doses of oral morphine

<table>
<thead>
<tr>
<th>Analgesic</th>
<th>Route</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>30 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>60 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>120 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>180 mg daily</td>
</tr>
<tr>
<td>morphine salt</td>
<td>PO</td>
<td>240 mg daily</td>
</tr>
<tr>
<td>fentanyl '12' patch</td>
<td>fentanyl '12' patch</td>
<td>240 mg daily</td>
</tr>
<tr>
<td>fentanyl '25' patch</td>
<td>fentanyl '25' patch</td>
<td>240 mg daily</td>
</tr>
<tr>
<td>fentanyl '50' patch</td>
<td>fentanyl '50' patch</td>
<td>240 mg daily</td>
</tr>
<tr>
<td>fentanyl '75' patch</td>
<td>fentanyl '75' patch</td>
<td>240 mg daily</td>
</tr>
</tbody>
</table>

Fentanyl equivalents in this table are for patients on well-tolerated opioid therapy for long periods; for patients who are opioid naive or who have been stable on oral morphine or other immediate release opioid for only several weeks, see Transdermal Route above. Conversion ratios vary and these figures are a guide only. Morphine equivalents for transdermal opioid preparations have been approximated to allow comparison with available preparations of oral morphine.

### Prescribing in palliative care

**Symptom control**

Several recommendations in this section involve unlicensed indications or routes.

**Anorexia** Anorexia may be helped by prednisolone p. 979 or dexamethasone p. 947.

**Bowel colic and excessive respiratory secretions** Bowel colic and excessive respiratory secretions may be reduced by a subcutaneous injection of hyoscine butylbromide p. 344, hyoscine butylbromide p. 73, or glycopyrronium bromide p. 1100. These antimuscarinics are generally given every 4 hours when required, but hourly use is occasionally necessary, particularly in excessive respiratory secretions. If symptoms persist, they can be given regularly via a continuous infusion device. Care is required to avoid the discomfort of dry mouth.

**Capillary bleeding** Capillary bleeding can be treated with tranexamic acid p. 95 by mouth; treatment is usually discontinued one week after the bleeding has stopped, or, if necessary, it can be continued at a reduced dose. Alternatively, gauze soaked in tranexamic acid 100 mg/mL p. 95 or adrenaline/epinephrine solution 1 mg/mL (1 in 1000) p. 196 can be applied to the affected area. Vitamin K may be useful for the treatment and prevention of bleeding associated with prolonged clotting in liver.
disease. In severe chronic cholestasis, absorption of vitamin K may be impaired; either parenteral or water-soluble oral vitamin K (see phytomenadione p. 889) should be considered.

**Constipation**

Constipation is a common cause of distress and is almost invariable after administration of an opioid analgesic. It should be prevented if possible by the regular administration of laxatives; a faecal softener with a peristaltic stimulant (e.g. co-danthramer p. 52) or lactulose p. 47 solution with a senna p. 53 preparation should be used. Methylaltrexone bromide p. 47 is licensed for the treatment of opioid-induced constipation.

**Convulsions**

Patients with cerebral tumours or uraemia may be susceptible to convulsions. Prophylactic treatment with phenytoin p. 398 or carbamazepine p. 387 should be considered. When oral medication is no longer possible, diazepam p. 267 given rectally, or phenobarbital p. 409 by injection is continued as prophylaxis. For the use of midazolam p. 414 by subcutaneous infusion using a continuous infusion device see below.

**Dry mouth**

Dry mouth may be relieved by good mouth care and measures such as chewing sugar-free gum, sucking ice or pineapple chunks, or the use of artificial saliva, dry mouth associated with candidiasis can be treated by oral preparations of nystatin p. 997 or miconazole p. 997; alternatively, fluconazole p. 518 can be given by mouth. Dry mouth may be caused by certain medications including opioids, antimuscarinic drugs (e.g. hyoscine), antidepressants and some antiemetics; if possible, an alternative preparation should be considered.

**Dysphagia**

A corticosteroid such as dexamethasone p. 947 may help, temporarily, if there is an obstruction due to tumour. See also Dry mouth, above.

**Dyspnoea**

Breathlessness at rest may be relieved by regular oral morphine p. 367 in carefully titrated doses. Diazepam p. 267 may be helpful for dyspnoea associated with anxiety. A corticosteroid, such as dexamethasone p. 947, may also be helpful if there is bronchospasm or partial obstruction.

**Fungating tumours**

Fungating tumours can be treated by regular dressing and antibacterial drugs; systemic treatment with metronidazole p. 475 is often required to reduce malodour but topical metronidazole is also used.

**Gastro-intestinal pain**

The pain of bowel colic may be reduced by loperamide hydrochloride p. 56. Hyoscine butylbromide may also be helpful, given sublingually as *Kwells®* tablets. Subcutaneous injections of hyoscine butylbromide p. 73, hyoscine hydrobromide p. 344, and glycopyrronium bromide p. 1100 can also be used to treat bowel colic. Gastric distension pain due to pressure on the stomach may be helped by a preparation incorporating an antacid with an antiflatulent and a prokinetic such as domperidone p. 346 before meals.

**Hiccups**

Hiccups due to gastric distension may be helped by a preparation incorporating an antacid with an antiflatulent. If this fails, metoclopramide hydrochloride p. 347 by mouth or by subcutaneous or intramuscular injection can be added; if this also fails, baclofen p. 914, or nifedipine p. 154, or chlorpromazine hydrochloride p. 304 can be tried.

**Insomnia**

Patients with advanced cancer may not sleep because of discomfort, cramps, night sweats, joint stiffness, or fear. There should be appropriate treatment of these problems before hypnotics are used. Benzodiazepines, such as temazepam p. 420, may be useful.

**Intractable cough**

Intractable cough may be relieved by moist inhalations or by regular administration of oral morphine p. 367. Methadone hydrochloride p. 436 linctus should be avoided because it has a long duration of action and tends to accumulate.

**Muscle spasm**

The pain of muscle spasm can be helped by a muscle relaxant such as diazepam p. 267 or baclofen p. 914.

**Nausea and vomiting**

Nausea and vomiting are common in patients with advanced cancer. Ideally, the cause should be determined before treatment with an antiemetic is started. A prokinetic antiemetic may be a preferred choice for first-line therapy.

Nausea and vomiting may occur with opioid therapy particularly in the initial stages but can be prevented by giving an antiemetic such as haloperidol p. 306 or metoclopramide hydrochloride p. 347. An antiemetic is usually necessary only for the first 4 or 5 days and therefore combined preparations containing an opioid with an antiemetic are not recommended because they lead to unnecessary antiemetic therapy (and associated side-effects when used long-term).

Metoclopramide hydrochloride has a prokinetic action and is used by mouth for nausea and vomiting associated with gastritis, gastric stasis, and functional bowel obstruction. Drugs with antimuscarinic effects antagonise prokinetic drugs and, if possible, should not be used concurrently. Haloperidol is used by mouth for most metabolic causes of vomiting (e.g. hypercalcaemia, renal failure).

Cyclizine p. 343 is given by mouth. It is used for nausea and vomiting due to mechanical bowel obstruction, raised intracranial pressure, and motion sickness. Levomepromazine p. 345 is used as an antiemetic; it is given by mouth or by subcutaneous injection at bedtime. For the dose by subcutaneous infusion see below. Dexamethasone p. 947 by mouth can be used as an adjunct.

Antiemetic therapy should be reviewed every 24 hours; it may be necessary to substitute the antiemetic or to add another one.

For the administration of antiemetics by subcutaneous infusion using a continuous infusion device, see below. For the treatment of nausea and vomiting associated with cancer chemotherapy see Cytotoxic drugs p. 744.

**Pruritus**

Pruritus, even when associated with obstructive jaundice, often responds to simple measures such as application of emollients. In the case of obstructive jaundice, further measures include administration of colestyramine p. 173).

**Raised intracranial pressure**

Headache due to raised intracranial pressure often responds to a high dose of a corticosteroid, such as dexamethasone p. 947 and should be given before 6 p.m. to reduce the risk of insomnia.

**Restlessness and confusion**

Restlessness and confusion may require treatment with an antipsychotic, e.g. haloperidol p. 306 or levomepromazine p. 345, by mouth or by subcutaneous injection, both repeated every 2 hours if required. The dose and frequency is adjusted according to the level of patient distress and the response. A regular maintenance dose should also be considered, given twice daily either by mouth or by subcutaneous injection; alternatively use a continuous infusion device.

Levomepromazine is licensed to treat pain in palliative care—this use is reserved for distressed patients with severe pain unresponsive to other measures (seek specialist advice).
Continuous subcutaneous infusions

Although drugs can usually be administered by mouth to control the symptoms of advanced cancer, the parenteral route may sometimes be necessary. Repeated administration of intramuscular injections can be difficult in a cachectic patient. This has led to the use of portable continuous infusion devices, such as syringe drivers, to give a continuous subcutaneous infusion, which can provide good control of symptoms with little discomfort or inconvenience to the patient.

Indications for the parenteral route are:
- the patient is unable to take medicines by mouth owing to nausea and vomiting, dysphagia, severe weakness, or coma
- there is malignant bowel obstruction in patients for whom further surgery is inappropriate (avoiding the need for an intravenous infusion or for insertion of a nasogastric tube)
- occasionally when the patient does not wish to take regular medication by mouth.

Syringe driver rate settings Staff using syringe drivers should be adequately trained and different rate settings should be clearly identified and differentiated; incorrect use of syringe drivers is a common cause of medication errors.

Bowel colic and excessive respiratory secretions Hyoscine hydrobromide p. 344 effectively reduces respiratory secretions and bowel colic and is sedative (but occasionally causes paradoxical agitation). Hyoscine butylbromide p. 72 is used for bowel colic and for excessive respiratory secretions, and is less sedative than hyoscine hydrobromide. Glycopyrronium bromide p. 1100 may also be used to treat bowel colic or excessive respiratory secretions.

Confusion and restlessness Haloperidol p. 306 has little sedative effect. Levomepromazine p. 345 has a sedative effect. Midazolam p. 414 is a sedative and an antiepileptic that may be used in addition to an antipsychotic drug in a very restless patient. Midazolam is also used for myoclonus.

Convolusions If a patient has previously been receiving an antiepileptic drug or has a primary or secondary cerebral tumour or is at risk of convulsion (e.g. owing to uraemia) antiepileptic medication should not be stopped. Midazolam is the benzodiazepine antiepileptic of choice for continuous subcutaneous infusion.

Nausea and vomiting Haloperidol p. 306 and levomepromazine p. 345 can both be given as a subcutaneous infusion but sedation can limit the dose of levomepromazine. Cyclizine is particularly likely to precipitate if mixed with diamorphine or other drugs (see under Mixing and Compatibility, below).

Mixing and compatibility The general principle that injections should be given into separate sites (and should not be mixed) does not apply to the use of syringe drivers in palliative care. Provided that there is evidence of compatibility, selected injections can be mixed in syringe drivers. Not all types of medication can be used in a subcutaneous infusion. In particular, chlorpromazine hydrochloride p. 304, prochlorperazine p. 309, and diazepam p. 267 are contra-indicated as they cause skin reactions at the injection site; to a lesser extent cyclizine p. 343 and levomepromazine p. 345 also sometimes cause local irritation.

In theory injections dissolved in water for injections are more likely to be associated with pain (possibly owing to their hypotonicity). The use of physiological saline (sodium chloride 0.9% p. 953) however increases the likelihood of precipitation when more than one drug is used; moreover subcutaneous infusion rates are slow (0.1–0.3 mL/hour) that pain is not usually a problem when water is used as a diluent.

Diamorphine can be given by subcutaneous infusion in a strength of up to 250 mg/mL; up to a strength of 40 mg/mL either water for injections or physiological saline (sodium chloride 0.9%) is a suitable diluent—above that strength only water for injections is used (to avoid precipitation). The following can be mixed with diamorphine:
- Cyclizine, may precipitate at concentrations above 10 mg/mL or in the presence of sodium chloride 0.9% or as the concentration of diamorphine relative to cyclizine increases; mixtures of diamorphine and cyclizine are also likely to precipitate after 24 hours.
- Dexamethasone, special care is needed to avoid precipitation of dexamethasone when preparing it.
- Haloperidol, mixtures of haloperidol and diamorphine are likely to precipitate after 24 hours if haloperidol concentration is above 2 mg/mL.
- Hyoscine butylbromide
- Hyoscine hydrobromide
- Levomepromazine
- Metoclopramide, under some conditions infusions containing metoclopramide become discoloured; such solutions should be discarded.
- Midazolam Subcutaneous infusion solution should be monitored regularly both to check for precipitation (and discoloration) and to ensure that the infusion is running at the correct rate.

Problems encountered with syringe drivers The following are problems that may be encountered with syringe drivers and the action that should be taken:
- if the subcutaneous infusion runs too quickly check the rate setting and the calculation;
- if the subcutaneous infusion runs too slowly check the start button, the battery, the syringe driver, the cannula, and make sure that the injection site is not inflamed;
- if there is an injection site reaction make sure that the site does not need to be changed—firmness or swelling at the site of injection is not in itself an indication for change, but pain or obvious inflammation is.
Equivalent doses of morphine sulfate and diamorphine hydrochloride given over 24 hours

These equivalences are *approximate only* and should be adjusted according to response

<table>
<thead>
<tr>
<th>MORPHINE</th>
<th>PARENTERAL DIAMORPHINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral morphine sulfate</td>
<td>Subcutaneous infusion of morphine sulfate</td>
</tr>
<tr>
<td>over 24 hours</td>
<td>over 24 hours</td>
</tr>
<tr>
<td>30 mg</td>
<td>15 mg</td>
</tr>
<tr>
<td>60 mg</td>
<td>30 mg</td>
</tr>
<tr>
<td>90 mg</td>
<td>45 mg</td>
</tr>
<tr>
<td>120 mg</td>
<td>60 mg</td>
</tr>
<tr>
<td>180 mg</td>
<td>90 mg</td>
</tr>
<tr>
<td>240 mg</td>
<td>120 mg</td>
</tr>
<tr>
<td>360 mg</td>
<td>180 mg</td>
</tr>
<tr>
<td>480 mg</td>
<td>240 mg</td>
</tr>
<tr>
<td>600 mg</td>
<td>300 mg</td>
</tr>
<tr>
<td>780 mg</td>
<td>390 mg</td>
</tr>
<tr>
<td>960 mg</td>
<td>480 mg</td>
</tr>
<tr>
<td>1200 mg</td>
<td>600 mg</td>
</tr>
</tbody>
</table>

If breakthrough pain occurs give a subcutaneous (preferable) or intramuscular injection equivalent to one-tenth to one-sixth of the total 24-hour subcutaneous infusion dose. It is kinder to give an intermittent bolus injection subcutaneously—absorption is smoother so that the risk of adverse effects at peak absorption is avoided (an even better method is to use a subcutaneous butterfly needle). To minimise the risk of infection no individual subcutaneous infusion solution should be used for longer than 24 hours.
Prescribing for the elderly

Old people, especially the very old, require special care and consideration from prescribers. Medicines for Older People, a component document of the National Service Framework for Older People (Department of Health. National Service Framework for Older People. London: Department of Health, March 2001), describes how to maximise the benefits of medicines and how to avoid excessive, inappropriate, or inadequate consumption of medicines by older people.

Appropriate prescribing

Elderly patients often receive multiple drugs for their multiple diseases. This greatly increases the risk of drug interactions as well as adverse reactions, and may affect compliance. The balance of benefit and harm of some medicines may be altered in the elderly. Therefore, elderly patients’ medicines should be reviewed regularly and medicines which are not of benefit should be stopped. Non-pharmacological measures may be more appropriate for symptoms such as headache, sleeplessness, and light-headedness when associated with social stress as in widowhood, loneliness, and family dispersal.

In some cases prophylactic drugs are inappropriate if they are likely to complicate existing treatment or introduce unnecessary side-effects, especially in elderly patients with poor prognosis or with poor overall health. However, elderly patients should not be denied medicines which may help them, such as anticoagulants or antiplatelet drugs for atrial fibrillation, antihypertensives, statins, and drugs for osteoporosis.

Form of medicine

Frail elderly patients may have difficulty swallowing tablets; if left in the mouth, ulceration may develop. They should always be encouraged to take their tablets or capsules with enough fluid, and whilst in an upright position to avoid the possibility of oesophageal ulceration. It can be helpful to discuss with the patient the possibility of taking the drug as a liquid if available.

Manifestations of ageing

In the very old, manifestations of normal ageing may be mistaken for disease and lead to inappropriate prescribing. In addition, age-related muscle weakness and difficulty in maintaining balance should not be confused with neurological disease. Disorders such as light-headedness not associated with postural or postprandial hypotension are unlikely to be helped by drugs.

Sensitivity

The nervous system of elderly patients is more sensitive to many commonly used drugs, such as opioid analgesics, benzodiazepines, antipsychotics, and antiparkinsonian drugs, all of which must be used with caution. Similarly, other organs may also be more susceptible to the effects of drugs such as anti-hypertensives and NSAIDs.

Pharmacokinetics

Pharmacokinetic changes can markedly increase the tissue concentration of a drug in the elderly, especially in debilitated patients. The most important effect of age is reduced renal clearance. Many aged patients thus excrete drugs slowly, and are highly susceptible to nephrotoxic drugs. Acute illness can lead to rapid reduction in renal clearance, especially if accompanied by dehydration. Hence, a patient stabilised on a drug with a narrow margin between the therapeutic and the toxic dose (e.g. digoxin p. 94) can rapidly develop adverse effects in the aftermath of a myocardial infarction or a respiratory-tract infection. The hepatic metabolism of lipid soluble drugs is reduced in elderly patients because there is a reduction in liver volume. This is important for drugs with a narrow therapeutic window.

Adverse reactions

Adverse reactions often present in the elderly in a vague and non-specific fashion. Confusion is often the presenting symptom (caused by almost any of the commonly used drugs). Other common manifestations are constipation (with antimuscarinics and many tranquillisers) and postural hypotension and falls (with diuretics and many psychotropics).

Hypnotics

Many hypnotics with long half-lives have serious hangover effects, including drowsiness, unsteady gait, slurred speech, and confusion. Hypnotics with short half-lives should be used but they too can present problems. Short courses of hypnotics are occasionally useful for helping a patient through an acute illness or some other crisis but every effort must be made to avoid dependence. Benzodiazepines impair balance, which can result in falls.

Diuretics

Diuretics are overprescribed in old age and should not be used on a long-term basis to treat simple gravitational oedema which will usually respond to increased movement, raising the legs, and support stockings. A few days of diuretic treatment may speed the clearing of the oedema but it should rarely need continued drug therapy.

NSAIDs

Bleeding associated with aspirin and other NSAIDs is more common in the elderly who are more likely to have a fatal or serious outcome. NSAIDs are also a special hazard in patients with cardiac disease or renal impairment which may again place older patients at particular risk. Owing to the increased susceptibility of the elderly to the side-effects of NSAIDs the following recommendations are made:

- for osteoarthritis, soft-tissue lesions, and back pain, first try measures such as weight reduction (if obese), warmth, exercise, and use of a walking stick;
- for osteoarthritis, soft-tissue lesions, back pain, and pain in rheumatoid arthritis, paracetamol p. 354 should be used first and can often provide adequate pain relief;
- alternatively, a low-dose NSAID (e.g. ibuprofen p. 927 up to 1.2 g daily) may be given;
- for pain relief when either drug is inadequate, paracetamol in a full dose plus a low-dose NSAID may be given;
- if necessary, the NSAID dose can be increased or an opioid analgesic given with paracetamol p. 354;
- do not give two NSAIDs at the same time.

Prophylaxis of NSAID-induced peptic ulcers may be required if continued NSAID treatment is necessary see NSAID-associated ulcers under Peptic ulceration p. 61.

Other drugs

Other drugs which commonly cause adverse reactions are antiparkinsonian drugs, antihypertensives, psychotropics, and digoxin p. 94. The usual maintenance dose of digoxin p. 94 in very old patients is 125 micrograms daily (62.5 micrograms in those with renal disease); lower doses are often inadequate but toxicity is common in those given 250 micrograms daily. Drug-induced blood disorders are much more common in the elderly. Therefore drugs with a tendency to cause bone marrow depression (e.g. co-trimoxazole p. 461, mianserin...
hydrochloride p. 290) should be avoided unless there is no acceptable alternative. The elderly generally require a lower maintenance dose of warfarin sodium p. 121 than younger adults; once again, the outcome of bleeding tends to be more serious.

**Guidelines**

Always consider whether a drug is indicated at all.

**Limit range** It is a sensible policy to prescribe from a limited range of drugs and to be thoroughly familiar with their effects in the elderly.

**Reduce dose** Dosage should generally be substantially lower than for younger patients and it is common to start with about 50% of the adult dose. Some drugs (e.g. long-acting antidiabetic drugs such as glibenclamide p. 611) should be avoided altogether.

**Review regularly** Review repeat prescriptions regularly. In many patients it may be possible to stop some drugs, provided that clinical progress is monitored. It may be necessary to reduce the dose of some drugs as renal function declines.

**Simplify regimens** Elderly patients benefit from simple treatment regimens. Only drugs with a clear indication should be prescribed and whenever possible given once or twice daily. In particular, regimens which call for a confusing array of dosage intervals should be avoided.

**Explain clearly** Write full instructions on every prescription (including repeat prescriptions) so that containers can be properly labelled with full directions. Avoid imprecisions like 'as directed'. Child-resistant containers may be unsuitable.

**Repeats and disposal** Instruct patients what to do when drugs run out, and also how to dispose of any that are no longer necessary. Try to prescribe matching quantities. If these guidelines are followed most elderly people will cope adequately with their own medicines. If not then it is essential to enrol the help of a third party, usually a relative or a friend.

---

**Drugs and sport**

UK Anti-Doping, the national body responsible for the UK’s anti-doping policy, advises that athletes are personally responsible should a prohibited substance be detected in their body. An advice card listing examples of permitted and prohibited substances is available from:

UK Anti-doping
Oceanic House
1a Cockspur Street
London SW1Y 5BG
Tel: (020) 7766 7350
information@ukad.org.uk
www.ukad.org.uk

**General Medical Council’s advice** Doctors who prescribe or collude in the provision of drugs or treatment with the intention of improperly enhancing an individual’s performance in sport contravene the GMC’s guidance, and such actions would usually raise a question of a doctor’s continued registration. This does not preclude the provision of any care or treatment where the doctor’s intention is to protect or improve the patient’s health.
Prescribing in dental practice

Advice on the drug management of dental and oral conditions has been integrated into the main text. For ease of access, guidance on such conditions is usually identified by means of a relevant heading (e.g. Dental and Orofacial Pain) in the appropriate sections of the BNF.

The following is a list of topics of particular relevance to dentists.

**General guidance**

- Prescribing by dentists, see Prescription writing p. 4
- Oral side-effects of drugs, see Adverse reactions to drugs p. 11
- Medical emergencies in dental practice (below)
- Medical problems in dental practice p. 30

**Drug management of dental and oral conditions**

- Dental and orofacial pain, see Analgesics p. 352
- Neuropathic pain p. 382
- Non-opioid analgesics and compound analgesic preparations, see Analgesics p. 352
- Opioid analgesics, see Analgesics p. 352
- Non-steroidal anti-inflammatory drugs p. 915

**Oral infections**

- Bacterial infections, see Antibacterials, principles of therapy p. 438
- Phenoxymethylpenicillin p. 481
- Broad-spectrum penicillins (amoxicillin p. 482 and ampicillin p. 483)
- Cephalosporins (cefalexin p. 456 and cefadroxil p. 458)
- Tetracyclines p. 496
- Macrolides (clarithromycin p. 470, erythromycin p. 471 and azithromycin p. 955)
- Clindamycin p. 467
- Metronidazole p. 475
- Fusidic acid p. 956

**Fungal infections**

- Local treatment, Oropharynx infections, fungal p. 996
- Systemic treatment, Antifungals, systemic use p. 512
- Viral infections
- Herpetic gingivostomatitis, local treatment, see Oropharynx infections, viral p. 997
- Herpetic gingivostomatitis, systemic treatment, see Oropharynx infections, viral p. 997

**Anaesthetics, anxiolytics and hypnotics**

- Anaesthesia, sedation, and resuscitation in dental practice p. 1094
- Hypnotics, see Hypnotics and anxiolytics p. 416
- Sedation for dental procedures, see Hypnotics and anxiolytics p. 416
- Local anaesthesia p. 1111

**Oral ulceration and inflammation p. 992**

- Mouthwashes, gargles and dentifrices, see Mouthwashes and other preparations for oropharyngeal use p. 989
- Dry mouth, see Treatment of dry mouth p. 987
- Aromatic inhalations, see Aromatic inhalations, cough preparations and systemic nasal decongestants p. 258
- Nasal decongestants, see Aromatic inhalations, cough preparations and systemic nasal decongestants p. 258

**Dental Practitioners’ Formulary p. 1520**

**Changes to Dental Practitioners’ Formulary, see Dental Practitioners’ Formulary p. 1520**

**Medical emergencies in dental practice**

This section provides guidelines on the management of the more common medical emergencies which may arise in dental practice. Dentists and their staff should be familiar with standard resuscitation procedures, but in all circumstances it is advisable to summon medical assistance as soon as possible. See also algorithm of the procedure for Cardiopulmonary resuscitation p. 195.

**The drugs referred to in this section include:**

- Adrenaline/epinephrine Injection, adrenaline 1 in 1000, (adrenaline 1 mg/mL as acid tartrate), 1 mL amp p. 196
- Aspirin Dispersible Tablets 300 mg p. 104
- Glucagon Injection, glucagon (as hydrochloride), 1-unit vial (with solvent) p. 618
- Glucagon (as hydrochloride), 1-unit vial p. 618
- Oxygen
- Salbutamol Aerosol Inhalation, salbutamol 100 micrograms/metered inhalation p. 222

**Adrenal insufficiency**

Adrenal insufficiency may follow prolonged therapy with corticosteroids and can persist for years after stopping. A patient with adrenal insufficiency may become hypotensive under the stress of a dental visit (important: see also Adrenal suppression for details of corticosteroids (systemic) p. 579 cover before dental surgical procedures under general anaesthesia).

**Management**

- Lay the patient flat
- Give oxygen
- Transfer patient urgently to hospital

**Anaphylaxis**

A severe allergic reaction may follow oral or parenteral administration of a drug. Anaphylactic reactions in dentistry may follow the administration of a drug or contact with substances such as latex in surgical gloves. In general, the more rapid the onset of the reaction the more profound it tends to be. Symptoms may develop within minutes and rapid treatment is essential.

Anaphylactic reactions may also be associated with additives and excipients in foods and medicines. Refined arachis (peanut) oil, which may be present in some medicinal products, is unlikely to cause an allergic reaction—nevertheless it is wise to check the full formula of preparations which may contain allergens (including those for topical application, particularly if they are intended for use in the mouth or for application to the nasal mucosa).

**Symptoms and signs**

- Paraesthesia, flushing, and swelling of face
- Generalised itching, especially of hands and feet
- Bronchospasm and laryngospasm (with wheezing and difficulty in breathing)
- Rapid weak pulse together with fall in blood pressure and pallor; finally cardiac arrest

**Management**

First-line treatment includes securing the airway, restoration of blood pressure (laying the patient flat and raising the feet, or in the recovery position if unconscious or nauseous and at risk of vomiting), and administration of adrenaline/epinephrine injection p. 196. This is given intramuscularly in a dose of 500 micrograms (0.5 mL adrenaline injection 1 in 1000); a dose of 300 micrograms (0.3 mL adrenaline injection 1 in 1000) may be appropriate for immediate self-administration. The dose is repeated if...
necessarily at 5-minute intervals according to blood pressure, pulse, and respiratory function. Oxygen administration is also of primary importance. Arrangements should be made to transfer the patient to hospital urgently.

**Asthma**

Patients with asthma may have an attack while at the dental surgery. Most attacks will respond to 2 puffs of the patient’s short-acting beta, agonist inhaler such as salbutamol 100 micrograms/puff p. 222; further puffs are required if the patient does not respond rapidly. If the patient is unable to use the inhaler effectively, further puffs should be given through a large-volume spacer device (or, if not available, through a plastic or paper cup with a hole in the bottom for the inhaler mouthpiece). If the response remains unsatisfactory, or if further deterioration occurs, then the patient should be transferred urgently to hospital. Whilst awaiting transfer, oxygen should be given with salbutamol 5 mg or terbutaline sulfate 10 mg p. 225 by nebuliser; if a nebuliser is unavailable, then 2–10 puffs of salbutamol 100 micrograms/metered inhalation should be given (preferably by a large-volume spacer), and repeated every 10–20 minutes if necessary. If asthma is part of a more generalised anaphylactic reaction, an intramuscular injection of adrenaline/epinephrine p. 196 (as detailed under Anaphylaxis) should be given.

Patients with severe chronic asthma or whose asthma has deteriorated previously during a dental procedure may require an increase in their prophylactic medication before a dental procedure. This should be discussed with the patient’s medical practitioner and may include increasing the dose of inhaled or oral corticosteroid.

**Cardiac emergencies**

If there is a history of angina the patient will probably carry glyceryl trinitrate spray or tablets p. 190 (or isosorbide dinitrate tablets p. 191) and should be allowed to use them. Hospital admission is not necessary if symptoms are mild and resolve rapidly with the patient’s own medication. See also Coronary Artery Disease p. 29.

Arrhythmias may lead to a sudden reduction in cardiac output with loss of consciousness. Medical assistance should be summoned. For advice on pacemaker interference, see also Pacemakers p. 30.

The pain of myocardial infarction is similar to that of angina but generally more severe and more prolonged.

**Symptoms and signs of myocardial infarction**

- Progressive onset of severe, crushing pain across front of chest; pain may radiate towards the shoulder and down arm, or into neck and jaw
- Skin becomes pale and clammy
- Nausea and vomiting are common
- Pulse may be weak and blood pressure may fall
- Breathlessness

**Initial management of myocardial infarction**

Call immediately for medical assistance and an ambulance, as appropriate. Allow the patient to rest in the position that feels most comfortable; in the presence of breathlessness this is likely to be sitting position, whereas the syncopal patient should be laid flat; often an intermediate position (dictated by the patient) will be most appropriate. Oxygen may be administered.

Sublingual glyceryl trinitrate p. 190 may relieve pain. Intramuscular injection of drugs should be avoided because absorption may be too slow (particularly when cardiac output is reduced) and pain relief is inadequate. Intramuscular injection also increases the risk of local bleeding into the muscle if the patient is given a thrombolytic drug. Reassure the patient as much as possible to relieve further anxiety. If available, aspirin p. 104 in a single dose of 300 mg should be given. A note (to say that aspirin has been given) should be sent with the patient to the hospital. For further details on the initial management of myocardial infarction, see Management of ST-Segment Elevation Myocardial Infarction p. 186.

If the patient collapses and loses consciousness attempt standard resuscitation measures. See also algorithm of the procedure for Cardiopulmonary resuscitation p. 195.

**Epileptic seizures**

Patients with epilepsy must continue with their normal dosage of anticonvulsant drugs when attending for dental treatment. It is not uncommon for epileptic patients not to volunteer the information that they are epileptic but there should be little difficulty in recognising a tonic-clonic (grand mal) seizure.

**Symptoms and signs**

- There may be a brief warning (but variable)
- Sudden loss of consciousness, the patient becomes rigid, falls, may give a cry, and becomes cyanotic (tonic phase)
- After 30 seconds, there are jerking movements of the limbs; the tongue may be bitten (clonic phase)
- There may be frothing from mouth and urinary incontinence
- The seizure typically lasts a few minutes; the patient may then become flaccid but remain unconscious. After a variable time the patient regains consciousness but may remain confused for a while

**Management**

During a convulsion try to ensure that the patient is not at risk from injury but make no attempt to put anything in the mouth or between the teeth (in mistaken belief that this will protect the tongue). Give oxygen to support respiration if necessary. Do not attempt to restrain convulsive movements.

After convulsive movements have subsided place the patient in the coma (recovery) position and check the airway.

After the convulsion the patient may be confused (postictal confusion) and may need reassurance and sympathy. The patient should not be sent home until fully recovered. Seek medical attention or transfer the patient to hospital if it was the first episode of epilepsy, or if the convulsion was atypical, prolonged (or repeated), or if injury occurred. Medication should only be given if convulsive seizures are prolonged (convulsive movements lasting 5 minutes or longer) or repeated rapidly.

Midazolam oromucosal solution p. 414 can be given by the buccal route in adults as a single dose of 10 mg [unlicensed]. For further details on the management of status epilepticus, including details of paediatric doses of midazolam, see Drugs used in status epilepticus (Epilepsy p. 383). Focal seizures similarly need very little active management (in an automatism only a minimum amount of restraint should be applied to prevent injury). Again, the patient should be observed until post-ictal confusion has completely resolved.

**Hypoglycaemia**

Insulin-treated diabetic patients attending for dental treatment under local anaesthesia should inject insulin and eat meals as normal. If food is omitted the blood glucose will fall to an abnormally low level (hypoglycaemia). Patients can often recognise the symptoms themselves and this state responds to sugar in water or a few lumps of sugar. Children may not have such prominent changes but may appear unduly lethargic.

**Symptoms and signs**

- Shaking and trembling
- Sweating
If the patient has systemic disease or is taking other medication, the matter may need to be discussed with the patient’s general practitioner or hospital consultant.

**Allergy**
Patients should be asked about any history of allergy; those with a history of atopic allergy (asthma, eczema, hay fever, etc.) are at special risk. Those with a history of a severe allergy or of anaphylactic reactions are at high risk—it is essential to confirm that they are not allergic to any medication, or to any dental materials or equipment (including latex gloves). See also Anaphylaxis p. 242.

**Arrhythmias**
Patients, especially those who suffer from heart failure or who have sustained a myocardial infarction, may have irregular cardiac rhythm. Atrial fibrillation is a common arrhythmia even in patients with normal hearts and is of little concern except that dentists should be aware that such patients may be receiving anticoagulant therapy. The patient’s medical practitioner should be asked whether any special precautions are necessary. Premedication (e.g. with temazepam p. 420) may be useful in some instances for very anxious patients.

See also Cardiac emergencies and Dental Anaesthesia (Local anaesthesia p. 1111).

**Cardiac prostheses**
For an account of the risk of infective endocarditis in patients with prosthetic heart valves, see Infective Endocarditis p. 29. For advice on patients receiving anticoagulants, see Thromboembolic disease p. 30.

**Coronary artery disease**
Patients are vulnerable for at least 4 weeks following a myocardial infarction or following any sudden increase in the symptoms of angina. It would be advisable to check with the patient’s medical practitioner before commencing treatment. See also Cardiac Emergencies p. 28. Treatment with low-dose aspirin (75 mg daily), clopidogrel p. 106, or dipyridamole p. 107 should not be stopped routinely nor should the dose be altered before dental procedures.

A Working Party of the British Society for Antimicrobial Chemotherapy has not recommended antibiotic prophylaxis for patients following coronary artery bypass surgery.

**Cyanotic heart disease**
Patients with cyanotic heart disease are at risk in the dental chair, particularly if they have pulmonary hypertension. In such patients a syncopal reaction increases the shunt away from the lungs, causing more hypoxia which worsens the syncopal reaction—a vicious circle that may prove fatal. The advice of the cardiologist should be sought on any patient with congenital cyanotic heart disease. Treatment in hospital is more appropriate for some patients with this condition.

**Hypertension**
Patients with hypertension are likely to be receiving antihypertensive drugs. Their blood pressure may fall dangerously low under general anaesthesia, see also under Dental Anaesthesia (Local anaesthesia p. 1111).

**Immunosuppression and indwelling intraperitoneal catheters**
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who are immunosuppressed (including transplant patients) and patients with indwelling intraperitoneal catheters do not require antibiotic prophylaxis for dental treatment provided there is no other indication for prophylaxis.
Prescribing in dental practice

The Working Party has commented that there is little evidence that dental treatment is followed by infection in immunosuppressed and immunodeficient patients nor is there evidence that dental treatment is followed by infection in patients with indwelling intraperitoneal catheters.

**Infective endocarditis**
While almost any dental procedure can cause bacteraemia, there is no clear association with the development of infective endocarditis. Routine daily activities such as tooth brushing also produce a bacteraemia and may present a greater risk of infective endocarditis than a single dental procedure.

Antibacterial prophylaxis and chlorhexidine p. 989 mouthwash are not recommended for the prevention of endocarditis in patients undergoing dental procedures. Such prophylaxis may expose patients to the adverse effects of antimicrobials when the evidence of benefit has not been proven.

**Reduction of oral bacteraemia** Patients at risk of endocarditis include those with valve replacement, acquired valvular heart disease with stenosis or regurgitation, structural congenital heart disease (including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices considered to be endothelialised), hypertrophic cardiomyopathy, or a previous episode of infective endocarditis, should be advised to maintain the highest possible standards of oral hygiene in order to reduce the:
- need for dental extractions or other surgery;
- chances of severe bacteraemia if dental surgery is needed;
- possibility of ‘spontaneous’ bacteraemia.

**Postoperative care** Patients at risk of endocarditis include those with valve replacement, acquired valvular heart disease with stenosis or regurgitation, structural congenital heart disease (including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices considered to be endothelialised), hypertrophic cardiomyopathy, or a previous episode of infective endocarditis, should be warned to report to the doctor or dentist any unexplained illness that develops after dental treatment.

Any infection in patients at risk of endocarditis should be investigated promptly and treated appropriately to reduce the risk of endocarditis.

**Patients on anticoagulant therapy**
For general advice on dental surgery in patients receiving oral anticoagulant therapy see Thromboembolic Disease (below).

**Joint prostheses**
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients with prosthetic joint implants (including total hip replacements) do not require antibiotic prophylaxis for dental treatment. The Working Party considers that it is unacceptable to expose patients to the adverse effects of antibiotics when there is no evidence that such prophylaxis is of any benefit, but that those who develop any intercurrent infection require prompt treatment with antibiotics to which the infecting organisms are sensitive.

The Working Party has commented that joint infections have rarely been shown to follow dental procedures and are even more rarely caused by oral streptococci.

**Pacemakers**
Pacemakers prevent asystole or severe bradycardia. Some ultrasonic scalers, electronic apex locators, electroanalgesic devices, and electrocautery devices interfere with the normal function of pacemakers (including shielded pacemakers) and should not be used. The manufacturer’s literature should be consulted whenever possible. If severe bradycardia occurs in a patient fitted with a pacemaker, electrical equipment should be switched off and the patient placed supine with the legs elevated. If the patient loses consciousness and the pulse remains slow or is absent, cardiopulmonary resuscitation may be needed. Call immediately for medical assistance and an ambulance, as appropriate.


**Thromboembolic disease**
Patients receiving a heparin or an oral anticoagulant such as warfarin sodium p. 121, acenocoumarol p. 120 (nicoumalone), phenindione p. 120, apixaban p. 108, dabigatran etexilate p. 117 or rivaroxaban p. 109 may be liable to excessive bleeding after extraction of teeth or other dental surgery. Often dental surgery can be delayed until the anticoagulant therapy has been completed.

For a patient requiring long-term therapy with warfarin sodium, the patient’s medical practitioner should be consulted and the International Normalised Ratio (INR) should be assessed 72 hours before the dental procedure. This allows sufficient time for dose modification if necessary. In those with an unstable INR (including those who require weekly monitoring of their INR, or those who have had some INR measurements greater than 4.0 in the last 2 months), the INR should be assessed within 24 hours of the dental procedure. Patients requiring minor dental procedures (including extractions) who have an INR below 4.0 may continue warfarin sodium without dose adjustment.

There is no need to check the INR for a patient requiring a non-invasive dental procedure.

If it is necessary to remove several teeth, a single extraction should be done first; if this goes well further teeth may be extracted at subsequent visits (two or three at a time).

Measures should be taken to minimise bleeding during and after the procedure. This includes the use of sutures and a haemostatic such as oxidised cellulose, collagen sponge or resorbable gelatin sponge. Scaling and root planing should initially be restricted to a limited area to assess the potential for bleeding.

For a patient on long-term warfarin sodium, the advice of the clinician responsible for the patient’s anticoagulation should be sought if:
- the INR is unstable, or if the INR is greater than 4.0;
- the patient has thrombocytopenia, haemophilia, or other disorders of haemostasis, or suffers from liver impairment, alcoholism, or renal failure;
- the patient is receiving antiplatelet drugs, cytotoxic drugs or radiotherapy.

Intramuscular injections are contra-indicated in patients taking anticoagulants with an INR above the therapeutic range, and in those with any disorder of haemostasis. In patients taking anticoagulants who have a stable INR within the therapeutic range, intramuscular injections should be avoided if possible; if an intramuscular injection is necessary, the patient should be informed of the increased risk of localised bleeding and monitored carefully.

A local anaesthetic containing a vasoconstrictor should be given by infiltration, or by intraligamentary or mental nerve injection if possible. If regional nerve blocks cannot be avoided the local anaesthetic should be given cautiously using an aspirating syringe.
Drugs which have potentially serious interactions with anticoagulants include aspirin and other NSAIDs, carbamazepine p. 387, imidazole and triazole antifungals (including miconazole p. 1011), erythromycin p. 471, clarithromycin p. 470, and metronidazole p. 475; for details of these and other interactions with anticoagulants, see Appendix 1 (dabigatran etexilate, heparins, phenindione, rivaroxaban, and coumarins).

Although studies have failed to demonstrate an interaction, common experience in anticoagulant clinics is that the INR can be altered following a course of an oral broad-spectrum antibiotic, such as ampicillin p. 483 or amoxicillin p. 482. Information on the treatment of patients who take anticoagulants is available at www.npsa.nhs.uk/patientsafety/alerts-and-directives/alerts/anticoagulant.

Liver disease
Liver disease may alter the response to drugs and drug prescribing should be kept to a minimum in patients with severe liver disease. Problems are likely mainly in patients with jaundice, ascites, or evidence of encephalopathy. For guidance on prescribing for patients with hepatic impairment, see Prescribing in hepatic impairment p. 17. Where care is needed when prescribing in hepatic impairment, this is indicated under the relevant drug in the BNF.

Renal impairment
The use of drugs in patients with reduced renal function can give rise to many problems. Many of these problems can be avoided by reducing the dose or by using alternative drugs. Special care is required in renal transplantation and immunosuppressed patients; if necessary such patients should be referred to specialists. For guidance on prescribing in patients with renal impairment, see Prescribing in renal impairment p. 17. Where care is needed when prescribing in renal impairment, this is indicated under the relevant drug in the BNF.

Pregnancy
Drugs taken during pregnancy can be harmful to the fetus and should be prescribed only if the expected benefit to the mother is thought to be greater than the risk to the fetus; all drugs should be avoided if possible during the first trimester. For guidance on prescribing in pregnancy, see Prescribing in pregnancy p. 19. Where care is needed when prescribing in pregnancy, this is indicated under the relevant drug in the BNF.

Breast-feeding
Some drugs taken by the mother whilst breast-feeding can be transferred to the breast milk, and may affect the infant. For guidance on prescribing in breast-feeding, see Prescribing in breast-feeding p. 19. Where care is needed when prescribing in breast-feeding, this is indicated under the relevant drug in the BNF.
Chapter 1
Gastro-intestinal system

1 Chronic bowel disorders

Chronic bowel disorders

Once tumours are ruled out individual symptoms of chronic bowel disorders need specific treatment including dietary manipulation as well as drug treatment and the maintenance of a liberal fluid intake.

Clostridium difficile infection

Clostridium difficile infection is caused by colonisation of the colon with Clostridium difficile and production of toxin. It often follows antibiotic therapy and is usually of acute onset, but may become chronic. It is a particular hazard of ampicillin, amoxicillin, co-amoxiclav, second- and third-generation cephalosporins, clindamycin, and quinolones, but few antibiotics are free of this side-effect. Treatment options include metronidazole p. 475, vancomycin p. 485, and fidaxomicin p. 468.

Diverticular disease

Diverticular disease is treated with a high-fibre diet, bran supplements, and bulk-forming drugs. Antispasmodics may provide symptomatic relief when colic is a problem. Antibacterials are used only when the diverticula in the intestinal wall become infected. Antimotility drugs which slow intestinal motility, e.g. codeine phosphate p. 360, diphenoxylate, and loperamide hydrochloride p. 56 could possibly exacerbate the symptoms of diverticular disease and are contra-indicated.

Irritable bowel syndrome

Irritable bowel syndrome can present with pain, constipation, or diarrhea. In some patients there may be important psychological aggravating factors which respond to reassurance and possibly specific treatment e.g. with an antidepressant.

The fiber intake of patients with irritable bowel syndrome should be reviewed. If an increase in dietary fibre is required, soluble fibre (e.g. ispaghula husk p. 45, sterculia p. 46, or oats) is recommended; insoluble fibre (e.g. bran) may exacerbate symptoms and its use should be discouraged. A laxative can be used to treat constipation. An osmotic laxative, such as a macrogol, is preferred; lactulose p. 47 may cause bloating. Linaclootide p. 40 is licensed for the treatment of moderate to severe irritable bowel syndrome associated with constipation. Stimulant laxatives should be avoided or used only occasionally. Loperamide hydrochloride p. 56 may relieve diarrhoea and antispasmodic drugs may relieve pain. Opioids with a central action, such as codeine phosphate p. 360, are better avoided because of the risk of dependence.

A tricyclic antidepressant can be used for abdominal pain or discomfort [unlicensed indication] in patients who have not responded to laxatives, loperamide hydrochloride p. 56, or antispasmodics. A selective serotonin reuptake inhibitor may be considered in those who do not respond to a tricyclic antidepressant [unlicensed indication].

Malabsorption syndromes

Individual conditions need specific management and also general nutritional consideration. Coeliac disease (gluten enteropathy) usually needs a gluten-free diet and pancreatic insufficiency needs pancreatic supplements.

See further information on foods for special diets (ACBS), see Borderline substances p. 1260.

1.1 Inflammatory bowel disease

Inflammatory bowel disease

Chronic inflammatory bowel diseases include ulcerative colitis and Crohn’s disease. Effective management requires drug therapy, attention to nutrition, and in severe or chronic active disease, surgery.

Aminosalicylates (balsalazide sodium p. 34, mesalazine p. 34, olsalazine sodium p. 37, and sulfasalazine p. 37), corticosteroids (hydrocortisone p. 583, beclometasone dipropionate p. 38, budesonide p. 38, and prednisolone p. 585), and drugs that affect the immune response are used in the treatment of inflammatory bowel disease.

Treatment of acute ulcerative colitis and Crohn’s disease

Acute mild to moderate disease affecting the rectum (proctitis) or the recto-sigmoid is treated initially with local application of an aminosalicylate; alternatively, a local corticosteroid can be used but it is less effective. A combination of a local aminosalicylate and a local
corticosteroid can be used for proctitis that does not respond to a local aminosalicylate alone. Foam preparations and suppositories are especially useful when patients have difficulty retaining liquid enemas.

Diffuse inflammatory bowel disease or disease that does not respond to local therapy requires oral treatment. Mild disease affecting the proximal colon can be treated with an oral aminosalicylate alone; a combination of a local and an oral aminosalicylate can be used in proctitis or distal colitis. Refractory or moderate inflammatory bowel disease usually requires adjunctive use of an oral corticosteroid such as prednisolone for 4–8 weeks. Modified-release budesonide is licensed for Crohn’s disease affecting the ileum and the ascending colon; it causes fewer systemic side-effects than oral prednisolone but may be less effective. Beclometasone dipropionate by mouth is licensed as an adjunct to mesalazine for mild to moderate ulcerative colitis, but it is not known whether it is as effective as other corticosteroids.

Severe inflammatory bowel disease or disease that is not responding to an oral corticosteroid requires hospital admission and treatment with an intravenous corticosteroid (such as hydrocortisone p. 583 or methylprednisolone p. 584); other therapy may include intravenous fluid and electrolyte replacement, and possibly parenteral nutrition. Specialist supervision is required for patients who fail to respond adequately to these measures. Patients with severe ulcerative colitis that has not responded to intravenous corticosteroids, may benefit from a short course of intravenous ciclosporin p. 717 [unlicensed indication]. Patients with unresponsive or chronically active Crohn’s disease may benefit from azathioprine p. 716, mercaptopurine p. 762 [unlicensed indication], or once-weekly methotrexate p. 762 [unlicensed indication]; these drugs have a slower onset of action.

Infliximab p. 906 is licensed for the management of severe active Crohn’s disease and severe ulcerative colitis in patients whose condition has not responded adequately to treatment with a corticosteroid and a conventional drug that affects the immune response, or who are intolerant of them.

Adalimumab p. 901 is licensed for the treatment of severe active Crohn’s disease and severe ulcerative colitis in patients whose condition has not responded adequately to treatment with a corticosteroid and a conventional drug that affects the immune response, or who are intolerant of them. For inducing remission, adalimumab can be used in combination with a corticosteroid, but it may be given alone if a corticosteroid is inappropriate or is not tolerated. Adalimumab may also be used for Crohn’s disease in patients who have relapsed while taking infliximab or who cannot tolerate infliximab because of hypersensitivity reactions.

Golimumab p. 904 is licensed for the treatment of severe ulcerative colitis in patients whose condition has not responded adequately to conventional therapy, or who are intolerant of it.

Vedolizumab p. 39 is licensed for the treatment of moderate to severe active Crohn’s disease and ulcerative colitis in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor.

Maintenance of remission of acute ulcerative colitis and Crohn’s disease

Smoking cessation reduces the risk of relapse in Crohn’s disease and should be encouraged. Aminosalicylates are efficacious in the maintenance of remission of ulcerative colitis, but there is no evidence of efficacy in the maintenance of remission of Crohn’s disease.

Corticosteroids are not suitable for maintenance treatment because of their side-effects. In resistant or frequently relapsing cases either azathioprine p. 716 or mercaptopurine p. 762 [unlicensed indication], given under close supervision may be helpful. Methotrexate p. 762 is tried in Crohn’s disease if azathioprine or mercaptopurine cannot be used [unlicensed indication]. Maintenance therapy with infliximab p. 906 should be considered for patients with Crohn’s disease or ulcerative colitis who respond to the initial induction course of infliximab; fixed-interval dosing is superior to intermittent dosing. Adalimumab p. 901 is licensed for maintenance therapy in Crohn’s disease and ulcerative colitis. Golimumab p. 904 is licensed for maintenance therapy in ulcerative colitis.

Fistulating Crohn’s disease

Treatment may not be necessary for simple, asymptomatic perianal fistulas. Metronidazole p. 475 or ciprofloxacin p. 490 can improve symptoms of fistulating Crohn’s disease but complete healing occurs rarely [unlicensed indication]. Metronidazole is usually given for 1 month but no longer than 3 months because of concerns about peripheral neuropathy. Ciprofloxacin by mouth is given twice daily. Other antibacterials should be given if specifically indicated (e.g. sepsis associated with fistulas and perianal disease) and for managing bacterial overgrowth in the small bowel. Fistulas may also require surgical exploration and local drainage.

Either azathioprine p. 716 or mercaptopurine p. 762 is used as a second-line treatment for fistulating Crohn’s disease and continued for maintenance [unlicensed indication]. Infliximab p. 906 is used for fistulating Crohn’s disease refractory to conventional treatments; fixed-interval dosing is superior to intermittent dosing. Maintenance therapy with infliximab should be considered for patients who respond to the initial induction course of infliximab. Adalimumab p. 901 can be used if there is intolerance to infliximab p. 906 [unlicensed indication].

Adjunctive treatment of inflammatory bowel disease

Due attention should be paid to diet; high-fibre or low-residue diets should be used as appropriate.

Antimitoty drugs such as codeine phosphate p. 360 and loperamide hydrochloride p. 56, and antispasmodic drugs may precipitate paralytic ileus and megacolon in active ulcerative colitis; treatment of the inflammation is more logical. An osmotic laxative, such as a macrogol, may be required in proctitis. Diarrhoea resulting from the loss of bile-salt absorption (e.g. in terminal ileal disease or bowel resection) may improve with colestyramine p. 173, which binds bile salts.

Drugs used in chronic bowel disorders

Aminosalicylates
Sulfasalazine p. 37 is a combination of 5-aminosalicylic acid (‘5-ASA’) and sulfapyridine; sulfapyridine acts only as a carrier to the colonic site of action but still causes side-effects. In the newer aminosalicylates, mesalazine p. 34 (5-aminosalicylic acid), balsalazide sodium p. 34 (a prodrug of 5-aminosalicylic acid) and olsalazine sodium p. 37 (a dimer of 5-aminosalicylic acid which cleaves in the lower bowel), the sulfonamide-related side-effects of sulfasalazine are avoided, but 5-aminosalicylic acid alone can still cause side-effects including blood disorders and lupus-like syndrome also seen with sulfasalazine.

Drugs affecting the immune response
Azathioprine p. 716, ciclosporin p. 717, mercaptopurine p. 762, and methotrexate p. 762 have a role in the treatment of inflammatory bowel disease.

Folic acid p. 836 should be given to reduce the possibility of methotrexate toxicity [unlicensed indication]. Folic acid is usually given once weekly on a different day to the methotrexate; alternative regimens may be used in some settings.
Cytokine modulators
Infliximab p. 906, adalimumab p. 901, and golimumab p. 904 are monoclonal antibodies which inhibit the pro-
flammatory cytokine, tumour necrosis factor alpha. They should be used under specialist supervision. Adequate
resuscitation facilities must be available when infliximab is used.

AMINOSALICYLATES

Aminosalicylates

SIDE-EFFECTS
• Rare Acute pancreatitis · agranulocytosis · alopecia · aplastic anaemia · arthralgia · blood disorders · eosinophilia · fibrosing alveolitis · hepatitis · interstitial nephritis · leucopenia · lung disorders · lupus erythematosus-like syndrome · methaemoglobinemia · myalgia · myocarditis · nephrotic syndrome · neutropenia · pericarditis · peripheral neuropathy · renal dysfunction · skin reactions · Stevens-Johnson syndrome · thrombocytopenia
• Frequency not known Abdominal pain · diarrhoea · exacerbation of symptoms of colitis · headache · hypersensitivity reactions · nausea · rash · urticaria · vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Blood Disorders A blood count should be performed and the drug stopped immediately if there is suspicion of a
blood dyscrasia.
• ALLERGY AND CROSS-SENSITIVITY Contraindicated in salicylate hypersensitivity.
• RENAL IMPAIRMENT Renal function should be monitored more frequently in renal impairment.
• MONITORING REQUIREMENTS Renal function should be monitored before starting an oral aminosalicylate, at 3
months of treatment, and then annually during treatment.
• PATIENT AND CARER ADVICE Blood disorders Patients receiving aminosalicylates, and their
carers, should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise
that occurs during treatment.

Balsalazide sodium

INDICATIONS AND DOSE
Treatment of mild to moderate ulcerative colitis (acute attack)
BY MOUTH
• Adult: 2.25 g 3 times a day until remission occurs or for
up to maximum of 12 weeks
Maintenance of remission of ulcerative colitis
BY MOUTH
• Adult: 1.5 g twice daily (max. per dose 3 g), adjusted
good response; maximum 6 g per day

CAUTIONS History of asthma
SIDE-EFFECTS Cholelithiasis
PREGNANCY Manufacturer advises avoid.
BREAST FEEDING Diarrhoea may develop in the infant. Monitor breast-fed infants for diarrhoea.
HEPATIC IMPAIRMENT Avoid in severe impairment.
RENAL IMPAIRMENT Manufacturer advises avoid in moderate to severe impairment.

Mesalazine

INDICATIONS AND DOSE
PENTASA® TABLETS
Treatment of mild to moderate ulcerative colitis, acute attack
BY MOUTH
• Adult: Up to 4 g once daily, alternatively up to 4 g daily
in 2–3 divided doses
Maintenance of remission of ulcerative colitis
BY MOUTH
• Adult: 2 g once daily
MEZAVANT® XL
Treatment of mild to moderate ulcerative colitis, acute attack
BY MOUTH
• Adult: 2.4 g once daily
ASACOL® MR 800MG TABLETS
Treatment of mild to moderate ulcerative colitis, acute attack
BY MOUTH
• Adult: 2.4–4.8 g daily in divided doses
Maintenance of remission of ulcerative colitis
BY MOUTH
• Adult: Up to 2.4 g once daily, alternatively up to 4.8 g
daily in divided doses
Maintenance of remission of Crohn’s ileo-colitis
BY MOUTH
• Adult: Up to 2.4 g daily in divided doses
ASACOL® MR 400MG TABLETS
Treatment of mild to moderate ulcerative colitis, acute attack
BY MOUTH
• Child 12–17 years: 800 mg 3 times a day
• Adult: 2.4 g daily in divided doses
Maintenance of remission of ulcerative colitis and Crohn’s ileo-colitis
BY MOUTH
• Child 12–17 years: 400–800 mg 3 times a day
• Adult: 1.2–2.4 g daily in divided doses
OCTASA®
Treatment of mild to moderate ulcerative colitis, acute attack
BY MOUTH
• Adult: 2.4–4.8 g once daily, alternatively 2.4–4.8 g
daily in divided doses, dose over 2.4 g daily in divided
doses only
Maintenance of remission of ulcerative colitis and Crohn’s ileo-colitis
BY MOUTH
• Adult: 1.2–2.4 g once daily, alternatively daily in divided doses

MEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.

Capsule
CAUTIONARY AND ADVISORY LABELS 21, 25
• Colazide (Almirall Ltd)
Balsalazide disodium 750 mg Colazide 750mg capsules 1
130 capsule pack £30.42 DT price = £30.42

Mesalazine
**SALOFALK® TABLETS**

Treatment of mild to moderate ulcerative colitis, acute attack

- **BY MOUTH**
  - Child 5-17 years (body-weight up to 39 kg): 10–20 mg/kg 3 times a day
  - Child 5-17 years (body-weight 40 kg and above): 0.5–1 g 3 times a day
  - Adult: 0.5–1 g 3 times a day

Maintenance of remission of ulcerative colitis

- **BY MOUTH**
  - Child 5-17 years (body-weight up to 39 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses
  - Child 5-17 years (body-weight 40 kg and above): 500 mg 3 times a day
  - Adult: 500 mg 3 times a day

**IPOCOL®**

Treatment of mild to moderate ulcerative colitis, acute attack

- **BY MOUTH**
  - Adult: 2.4 g daily in divided doses

Maintenance of remission of ulcerative colitis

- **BY MOUTH**
  - Adult: 1.2–2.4 g daily in divided doses

**PENTASA GRANULES**

Treatment of mild to moderate ulcerative colitis, acute attack

- **BY MOUTH**
  - Child 5-17 years (body-weight up to 40 kg): 10–20 mg/kg 3 times a day
  - Child 5-17 years (body-weight 41 kg and above): 1–2 g twice daily, total daily dose may alternatively be given in 3–4 divided doses
  - Adult: Up to 4 g once daily, alternatively up to 4 g daily in 2–4 divided doses

Maintenance of remission of ulcerative colitis

- **BY MOUTH**
  - Child 5-17 years (body-weight up to 40 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses
  - Child 5-17 years (body-weight 41 kg and above): 2 g once daily
  - Adult: 2 g once daily

**SALOFALK® GRANULES**

Treatment of mild to moderate ulcerative colitis, acute attack

- **BY MOUTH**
  - Child 5-17 years (body-weight up to 40 kg): 30–50 mg/kg once daily, dose preferably given in the morning, alternatively 10–20 mg/kg 3 times a day
  - Child 5-17 years (body-weight 41 kg and above): 1.5–3 g once daily, dose preferably given in the morning, alternatively 0.5–1 g 3 times a day
  - Adult: 1.5–3 g once daily, dose preferably taken in the morning, alternatively 0.5–1 g 3 times a day

Maintenance of remission of ulcerative colitis

- **BY MOUTH**
  - Child 5-17 years (body-weight up to 40 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses
  - Child 5-17 years (body-weight 41 kg and above): 500 mg 3 times a day
  - Adult: 500 mg 3 times a day

**SALOFALK® RECTAL FOAM**

Treatment of mild ulcerative colitis affecting sigmoid colon and rectum

- **BY RECTUM**
  - Child 12-17 years: 2 g once daily, dose to be administered into the rectum at bedtime, alternatively 2 g daily in 2 divided doses
  - Adult: 2 g once daily, dose to be administered into the rectum at bedtime, alternatively 2 g daily in 2 divided doses

**ASACOL® FOAM ENEMA**

Treatment of acute attack of mild to moderate ulcerative colitis, affecting the rectosigmoid region

- **BY RECTUM**
  - Adult: 1 g daily for 4–6 weeks, to be administered into the rectum

**SALOFALK® SUPPOSITORIES**

Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectum, sigmoid colon and descending colon

- **BY RECTUM**
  - Adult: 0.5–1 g 2–3 times a day, adjusted according to response, dose to be given using 500 mg suppositories

**ASACOL® SUPPOSITORIES**

Treatment of acute attack of mild to moderate ulcerative colitis and maintenance of remission

- **BY RECTUM**
  - Adult: 0.75–1.5 g daily in divided doses, last dose to be administered at bedtime

**PENTASA® SUPPOSITORIES**

Treatment of acute attack, ulcerative proctitis

- **BY RECTUM**
  - Child 15-17 years: 1 g daily for 2–4 weeks
  - Adult: 1 g daily for 2–4 weeks

Maintenance, ulcerative proctitis

- **BY RECTUM**
  - Child 15-17 years: 1 g daily
  - Adult: 1 g daily

**PENTASA® RETENTION ENEMA**

Treatment of acute attack of mild to moderate ulcerative colitis or maintenance of remission

- **BY RECTUM**
  - Adult: 1 g once daily, dose to be administered at bedtime

**SALOFALK® ENEMA**

Treatment of acute attack of mild to moderate ulcerative colitis or maintenance of remission

- **BY RECTUM**
  - Adult: 2 g once daily, dose to be administered at bedtime

**CAUTIONS**

- Elderly
- Pulmonary disease
PRESCRIBING AND DISPENSING INFORMATION

DIRECTIONS FOR ADMINISTRATION

RENAL IMPAIRMENT

SIDE-EFFECTS

CAUTIONARY AND ADVISORY LABELS

Very rare

Rare

Negligible quantities cross placenta.

Avoid in severe impairment.

Dizziness

Negligible amounts of mesalazine detected in infants, but negligible quantities of mesalazine detected in breast milk. Monitor breast-fed infant for diarrhoea.

Dizziness

EXCIPIENTS: May contain Aspartame

Salofalk

Mesalazine 400 mg gastro-resistant tablets | 90 tablet P Dod £47.50 | 180 tablet P Dod £95.00 DT price = £117.62

Salofalk (Dr. Falk Pharma UK Ltd)

Mesalazine 250 mg Salofalk 250mg gastro-resistant tablets | 100 tablet P Dod £16.19

Mesalazine 500 mg Salofalk 500mg gastro-resistant tablets | 100 tablet P Dod £32.38

Modified-release granules

CAUTIONARY AND ADVISORY LABELS 25

EXCIPIENTS: May contain Aspartame

Pentasa (Ferring Pharmaceuticals Ltd)

Mesalazine 1 gram Pentasa 1g modified-release granules sachets (sugar-free) | 50 satchet P Dod £30.74 DT price = £30.74

Mesalazine 2 gram Pentasa 2g modified-release granules sachets (sugar-free) | 60 satchet P Dod £73.78 DT price = £73.78

Mesalazine 4 gram Pentasa 4g modified-release granules sachets (sugar-free) | 30 satchet P Dod £73.78

Salofalk (Dr. Falk Pharma UK Ltd)

Mesalazine 500 mg Salofalk 500mg gastro-resistant modified-release granules sachets (sugar-free) | 100 satchet P Dod £28.74

Mesalazine 1 gram Salofalk 1g gastro-resistant modified-release granules sachets (sugar-free) | 50 satchet P Dod £28.74 DT price = £28.74

Mesalazine 1.5 gram Salofalk 1.5g gastro-resistant modified-release granules sachets (sugar-free) | 60 satchet P Dod £48.85 DT price = £48.85

Mesalazine 3 gram Salofalk 3g gastro-resistant modified-release granules sachets (sugar-free) | 60 satchet P Dod £97.70 DT price = £97.70

Foam

EXCIPIENTS: May contain Ceteostearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens), polysorbates, propylene glycol, sodium metabisulphite

Mesalazine (Non-proprietary)

Mesalazine 1 gram per 1 application Mesalazine 1g/application foam enema | 14 dose P Dod no price available

Asacol (Dr. Falk Pharma UK Ltd)

Mesalazine 1 gram per 1 application Asacol 1g/application foam enema | 14 dose P Dod £26.72

Salofalk (Dr. Falk Pharma UK Ltd)

Mesalazine 1 gram per 1 application Salofalk 1g/application foam enema | 14 dose P Dod £30.17

Suppository

Mesalazine (Non-proprietary)

Mesalazine 250 mg Mesalazine 250mg suppositories | 20 suppository P Dod no price available

Mesalazine 500 mg Mesalazine 500mg suppositories | 10 suppository P Dod no price available | 20 suppository P Dod no price available

Asacol (Dr. Falk Pharma UK Ltd)

Mesalazine 250 mg Asacol 250mg suppositories | 20 suppository P Dod £4.82

Mesalazine 500 mg Asacol 500mg suppositories | 10 suppository P Dod £4.82

Pentasa (Ferring Pharmaceuticals Ltd)

Mesalazine 1 gram Pentasa 1g suppositories | 28 suppository P Dod £40.01 DT price = £40.01

Salofalk (Dr. Falk Pharma UK Ltd)

Mesalazine 500 mg Salofalk 500mg suppositories | 30 suppository P Dod £14.81

Mesalazine 1 gram Salofalk 1g suppositories | 30 suppository P Dod £29.62

Enema

Mesalazine (Non-proprietary)

Mesalazine 33.9 mg per 1 ml Mesalazine 2g/59ml enema | 7 enema P Dod no price available

Pentasa (Ferring Pharmaceuticals Ltd)

Mesalazine 10 mg per 1 ml Pentasa Mesalazine 1g/100ml enema | 7 enema P Dod £17.73 DT price = £17.73

Salofalk (Dr. Falk Pharma UK Ltd)

Mesalazine 33.9 mg per 1 ml Salofalk 2g/59ml enema | 7 enema P Dod £29.92

INTERACTIONS

The manufacturers of some mesalazine gastro-resistant and modified-release medicines (Asacol® MR tablets, Ipocol®, Salofalk® granules) suggest that preparations that lower stool pH (e.g. lactulose) may prevent the release of mesalazine.

SIDE-EFFECTS

Rare Dizziness

Very rare Oligospermia (reversible)

PREGNANCY

Negligible quantities cross placenta.

BREAST FEEDING

Diarrhoea reported in breast-fed infants, but negligible amounts of mesalazine detected in breast milk. Monitor breast-fed infant for diarrhoea.

HEPATIC IMPAIRMENT

Avoid in severe impairment.

RENAL IMPAIRMENT

Use with caution. Avoid if eGFR less than 20 ml/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION

PENTASA® TABLETS

Tablets may be halved, quartered, or dispersed in water, but should not be chewed.

PENTASA® GRANULES

Granules should be placed on tongue and washed down with water without chewing.

In children Contents of one sachet should be weighed and divided immediately before use; discard any remaining granules.

SALOFALK® GRANULES

Granules should be placed on tongue and washed down with water without chewing.

PRESCRIBING AND DISPENSING INFORMATION

Flavours of granule formulations of Salofalk® may include vanilla. There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary.

PATIENT AND CAREER ADVICE

If it is necessary to switch a patient to a different brand of mesalazine, the patient should be advised to report any changes in symptoms. Some products may require special administration advice; patients and carers should be informed.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 21, 25

Mezavant XL (Shire Pharmaceuticals Ltd)

Mesalazine 1.2 gram Mezavant XL 1200mg tablets | 60 tablet P Dod £62.44 DT price = £62.44

Pentasa (Ferring Pharmaceuticals Ltd)

Mesalazine 500 mg Pentasa 500mg modified-release tablets | 100 tablet P Dod £30.74 DT price = £30.74

Mesalazine 1 gram Pentasa 1g modified-release tablets | 60 tablet P Dod £36.89 DT price = £36.89

Gastro-resistant tablet

CAUTIONARY AND ADVISORY LABELS 5, 25

Mesalazine (Non-proprietary)

Mesalazine 400 mg Mesalazine 400mg gastro-resistant tablets | 90 tablet P Dod £29.41 DT price = £29.41 | 120 tablet P Dod £39.21

Mesalazine 800 mg Mesalazine 800mg gastro-resistant tablets | 90 tablet P Dod £58.81

Asacol MR (Warner Chilcott UK Ltd)

Mesalazine 400 mg Asacol 400mg MR gastro-resistant tablets | 90 tablet P Dod £29.41 DT price = £29.41 | 120 tablet P Dod £39.21

Mesalazine 800 mg Asacol 800mg MR gastro-resistant tablets | 180 tablet P Dod £117.62 DT price = £117.62

Ipocol (Sanofi Ltd)

Mesalazine 400 mg Ipocol 400mg gastro-resistant tablets | 120 tablet P Dod £17.68

Octasa MR (Tillets Pharma Ltd)

Mesalazine 400 mg Octasa 400mg MR gastro-resistant tablets | 90 tablet P Dod £19.50 DT price = £29.41 | 120 tablet P Dod £26.00
**Olsalazine sodium**

**INDICATIONS AND DOSE**

Treatment of acute attack of mild ulcerative colitis

**BY MOUTH**

- Adult: 1 g daily in divided doses, doses to be taken after meals, then increased if necessary up to 3 g daily in divided doses (max. per dose 1 g), dose to be increased over 1 week.

**Maintenance of remission of mild ulcerative colitis**

**BY MOUTH**

- Adult: Maintenance 500 mg twice daily, dose to be taken after food.

**SIDE-EFFECTS**

- **Common or very common** Watery diarrhoea
- **Frequency not known** Blurred vision - palpitation - photosensitivity - pyrexia - tachycardia

**PREGNANCY**

Manufacturer advises avoid unless potential benefit outweighs risk.

**BREAST FEEDING**

Monitor breast-fed infants for diarrhoea.

**RENAL IMPAIRMENT**

Use with caution; manufacturer advises avoid in significant impairment.

**DIRECTIONS FOR ADMINISTRATION**

Capsules can be opened and contents sprinkled on food.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 21
  - Olsalazine sodium 500 mg Olsalazine 500mg tablets | 60 tablet [POD] £85.00 DT price = £85.00

**Capsule**

- **CAUTIONARY AND ADVISORY LABELS** 21
  - Olsalazine sodium 250 mg Olsalazine 250mg capsules | 112 capsule [POD] £75.00 DT price = £75.00

---

**Sulfasalazine**  
*(Sulphasalazine)*

**INDICATIONS AND DOSE**

Treatment of acute attack of mild to moderate and severe ulcerative colitis | Active Crohn’s disease

**BY MOUTH**

- Adult: 1–2 g 4 times a day until remission occurs, corticosteroids may also be given, if necessary
- Adult: 0.5–1 g twice daily, administered alone or in conjunction with oral therapy, morning and night after a bowel movement

**Maintenance of remission of mild to moderate and severe ulcerative colitis**

**BY MOUTH**

- Adult: 500 mg 4 times a day

**BY RECTUM**

- Adult: 0.5–1 g twice daily, administered alone or in conjunction with oral therapy, morning and night after a bowel movement

**Active rheumatoid arthritis (administered on expert advice)**

**BY MOUTH**

- Adult: Initially 500 mg daily, increased in steps of 500 mg every 1 week, increased to 2–3 g daily in divided doses, enteric coated tablets to be administered

---

**INFLAMMATORY BOWEL DISEASE**  
**37**

**CONTRA-INDICATIONS**

Child under 2 years of age

**CAUTIONS**

Acute porphyrias p. 864 | G6PD deficiency | history of allergy | history of asthma | maintain adequate fluid intake | risk of haematological toxicity | risk of hepatic toxicity | slow acetylator status

**INTERACTIONS**

- Appendix 1 (aminosalicylates).

**SIDE-EFFECTS**

- **Common or very common** Blood disorders - cough - dizziness - fever - Heinz body anaemia - insomnia - megaloblastic anaemia - proteinuria - pruritus - stomatitis - taste disturbances - tinnitus
- **Uncommon** Alopecia - convulsions - depression - dysphoria - vasculitis
- **Frequency not known** Anaphylaxis - aseptic meningitis - ataxia - crystalluria - disturbances of smell - epidermal necrolysis - exfoliative dermatitis - gastro-intestinal intolerance - hallucinations - hypersensitivity reactions - leucopenia (especially in patients with rheumatoid arthritis) - loss of appetite - neutropenia (especially in patients with rheumatoid arthritis) - oligospermia - parotitis - photosensitivity - rashes - serum sickness - some soft contact lenses may be stained - thrombocytopenia (especially in patients with rheumatoid arthritis) - yellow-orange discoloration of other body fluids - yellow-orange discoloration of skin - yellow-orange discoloration of urine

**SIDE-EFFECTS, FURTHER INFORMATION**

**Gastro-intestinal side effects**

Upper gastro-intestinal side-effects common over 4 g daily.

**Blood disorders**

Haematological abnormalities occur usually in the first 3 to 6 months of treatment and are reversible on cessation of treatment.

**PREGNANCY**

Theoretical risk of neonatal haemolysis in third trimester; adequate folate supplements should be given to mother.

**BREAST FEEDING**

Small amounts in milk (1 report of bloody diarrhoea); theoretical risk of neonatal haemolysis especially in G6PD-deficient infants.

**HEPATIC IMPAIRMENT**

Use with caution.

**RENAI IMPAIRMENT**

Risk of toxicity, including crystalluria, in moderate impairment—ensure high fluid intake. Avoid in severe impairment.

**MONITORING REQUIREMENTS**

- Blood disorders Close monitoring of full blood counts (including differential white cell count and platelet count) is necessary initially, and at monthly intervals during the first 3 months.
- Renal function Although the manufacturer recommends renal function tests in rheumatic diseases, evidence of practical value is unsatisfactory.
- Liver function Liver function tests should be performed at monthly intervals for first 3 months.

**PATIENT AND CARER ADVICE**

Contact lenses Some soft contact lenses may be stained.

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 14
  - **SULFASALAZINE (Non-proprietary)**
    - Sulfasalazine 500 mg Sulfasalazine 500mg tablets | 112 tablet [POD] £18.00 DT price = £15.38
    - Salazopyrin (Pfizer Ltd) Sulfasalazine 500 mg Salazopyrin 500mg tablets | 112 tablet [POD] £16.97 DT price = £15.38
**Gastro-resistant tablet**

**CAUTIONARY AND ADVISORY LABELS 5, 14, 25**

- **SULFASALAZINE (Non-proprietary)**
  - Sulfasalazine 500 mg Sulfasalazine 500mg gastro-resistant tablets | 100 tablet [Post] £39.00 | 112 tablet [Post] £32.33 DT price = £12.33
- **Salazopyrin EN (Pfizer Ltd)**
  - Sulfasalazine 500 mg Sulfasalazine EN-Tabs 500mg | 112 tablet [Post] £8.43 DT price = £12.33
- **Sulazine EC (Genesis Pharmaceuticals Ltd, Teva UK Ltd)**
  - Sulfasalazine 500 mg Sulazine EC 500mg tablets | 100 tablet [Post] £7.14 | 112 tablet [Post] £8.00 DT price = £12.33

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 14**

EXCIPIENTS: May contain Alcohol

- **SULFASALAZINE (Non-proprietary)**
  - Sulfasalazine 50 mg per 1 ml Sulfasalazine 250mg/5ml oral suspension sugar free (sugar-free) | 500 ml [Post] £41.00 DT price = £14.00

**Suppository**

**CAUTIONARY AND ADVISORY LABELS 14**

- Salazopyrin (Pfizer Ltd)
  - Sulfasalazine 500 mg Salazopyrin 500mg suppositories | 10 suppository [Post] £3.30

**CORTICOSTEROIDS**

**Beclometasone dipropionate**  
*Beclometasone dipropionate*

The properties listed below are those particular to systemic use of the drug only. For properties common to the class, see Corticosteroids, systemic, p. 579.

**INDICATIONS AND DOSE**

**Adjunct to aminosalicylates in acute mild to moderate ulcerative colitis**

**BY MOUTH**

- Adult: 5 mg daily maximum duration of treatment of 4 weeks, dose to be taken in the morning

**SIDE-EFFECTS**

Constipation - drowsiness

**HEPATIC IMPAIRMENT**

Manufacturer advises avoid in severe impairment—no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream, ointment

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 25**

- Clipper (Chiesi Ltd)  
  - Beclometasone dipropionate 5 mg Clipper 5mg gastro-resistant modified-release tablets | 30 tablet [Post] £56.56

**Budesonide**

The properties listed below are those particular to the drug only. For properties common to the class, see corticosteroids (systemic), p. 579.

**INDICATIONS AND DOSE**

**ENTOCORT® CAPSULES**

Mild to moderate Crohn’s disease affecting the ileum or ascending colon | Chronic diarrhoea due to collagenous colitis

**BY MOUTH**

- Adult: 3 mg 3 times a day for up to 8 weeks, reduce dose for the last 2 weeks of treatment

Autoimmune hepatitis, induction of remission

**BY MOUTH**

- Adult: 3 mg 3 times a day

Autoimmune hepatitis, maintenance

**BY MOUTH**

- Adult: 3 mg twice daily

**ENTOCORT® GRANULES**

Mild to moderate Crohn’s disease affecting the ileum or ascending colon | Collagenous colitis

**BY MOUTH**

- Adult: 9 mg daily for up to 8 weeks, to be taken in the morning, dose to be reduced for the last 2 weeks of treatment

**ENTOCORT® RECTAL FOAM**

Ulcerative colitis affecting sigmoid colon and rectum

**BY RECTUM**

- Adult: 1 metered application once daily for up to 8 weeks

Dose equivalence and conversion

1 metered application is equivalent to budesonide 2 mg.

**ENTOCORT® ENEMA**

Ulcerative colitis involving rectal and recto-sigmoid disease

**BY RECTUM**

- Adult: 1 enema daily for 4 weeks, to be administered at bedtime

**CAUTIONS**

- With systemic use Autoimmune hepatitis

**HEPATIC IMPAIRMENT**

- With systemic use When used in autoimmune hepatitis liver function tests should be monitored every 2 weeks for 1 month, then at least every 3 months.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use Granules should be placed on tongue and washed down with water without chewing.

**ENTOCORT® GRANULES**

Granules should be placed on tongue and washed down with water without chewing.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of granule formulations may include lemon.

**ENTOCORT® CAPSULES**

Dispense in original container (contains dessicant).

**PATIENT AND CARER ADVICE**

- With oral use Patients or carers should be given advice on how to administer budesonide granules

**NATIONAL FUNDING/ACCESS DECISIONS**

**ENTOCORT® CAPSULES**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (April 2015) that Budesonide gastro-resistant capsules are accepted for restricted use within NHS Scotland for the treatment of autoimmune hepatitis in non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
**Vedolizumab**

**DRUG ACTION** Vedolizumab is a monoclonal antibody that binds specifically to the alpha_4 integrin, which is preferentially expressed on gut homing T helper lymphocytes.

**INDICATIONS AND DOSE**

Moderate to severe active ulcerative colitis in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)

**BY INTRAVENOUS INFUSION**

- Adult: Initially 300 mg, then 300 mg after 2 weeks, followed by 300 mg after 4 weeks, followed by 300 mg every 8 weeks, dose to be given over 30 minutes, if treatment is interrupted or response decreases, dosing frequency may be increased—consult product literature; review treatment if no response within 10 weeks of initial dose

Moderate to severe active Crohn’s disease in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)

**BY INTRAVENOUS INFUSION**

- Adult: Initially 300 mg, then 300 mg after 2 weeks, followed by 300 mg after 4 weeks, followed by 300 mg every 8 weeks, dose to be given over 30 minutes, if no response is observed, an additional dose of 300 mg may be given 10 weeks after initial dose; if treatment is interrupted or response decreases, dosing frequency may be increased—consult product literature; review treatment if no response within 14 weeks of initial dose

**CONTRA-INDICATIONS** Severe active infection

**CAUTIONS** Controlled chronic severe infection, history of recurring severe infection, previous treatment with natalizumab (wait at least 12 weeks between natalizumab use and initiation of vedolizumab unless potential benefit outweighs risk); previous treatment with rituximab

**CAUTIONS, FURTHER INFORMATION**

**Risk of infection** Patients must be screened for tuberculosis before starting treatment; if latent tuberculosis is diagnosed, appropriate treatment must be initiated prior to vedolizumab treatment; if tuberculosis is diagnosed during treatment, discontinue vedolizumab until infection is resolved.

Patients should be brought up to date with current immunisation schedule before initiating treatment.

**INTERACTIONS** → Appendix 1 (vedolizumab).

**SIDE-EFFECTS**

- **Common or very common** Acne, arthralgia, back pain, constipation, cough, dyspepsia, eczema, erythema, flatulence, gastroenteritis, headache, hypertension, infections, malaise, muscle spasms, muscular weakness, nasal congestion, nausea, night sweats, oropharyngeal pain, paraesthesia, pharyngitis, pruritus, pyrexia, rash, upper respiratory tract infection

- **Uncommon** Folliculitis, oral candidiasis, vulvovaginal candidiasis

- **Frequency not known** Dizziness, infusion-related reactions, listeria meningitis, salmonella sepsis, tuberculosis

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related reactions

- Infusion-related and hypersensitivity reactions have been reported. Patients should be observed continuously during each infusion for signs and symptoms of acute hypersensitivity reactions; they should also be observed for 2 hours after the initial two infusions, and for 1 hour after subsequent infusions. Discontinue treatment if a severe infusion-related or other severe reaction occurs and initiate appropriate treatment (e.g. adrenaline and antihistamines); if a mild to moderate infusion-related reaction occurs, interrupt infusion or reduce infusion rate and initiate appropriate treatment (if reaction subsides the infusion may be continued)—consider pretreatment with an antihistamine, hydrocortisone, and/or paracetamol prior to subsequent infusions in patients who experience mild to moderate infusion-related reactions.

**CONCEPTION AND CONTRACEPTION** Effective contraception required during and for at least 18 weeks after treatment.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**MONITORING REQUIREMENTS**

- Monitor closely for infection before, during and after treatment—potential increased risk of opportunistic infection.

- Monitor for new onset or worsening neurological signs and symptoms (withhold treatment if progressive multifocal leukoencephalopathy (PML) is suspected).

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Entyvio®), give intermittently in Sodium chloride 0.9%; allow vial to reach room temperature then reconstitute with 4.8 mL of water for injection (using a syringe with a 21–25 gauge needle); gently swirl vial for at least 15 seconds, do not shake vigorously or invert; allow to stand for up to 20 minutes (gently swirl vial if needed), leave for an additional 10 minutes if not dissolved; gently invert vial three times, withdraw 5 mL of reconstituted solution (using a syringe with a 21–25 gauge needle), and add to 250 mL of infusion fluid; gently mix and give over 30 minutes.

**PATIENT AND CARER ADVICE** Patients should be provided with a patient alert card.
## 40 Constipation and bowel cleansing

### 1.2 Irritable bowel syndrome

**Drugs used for Irritable bowel syndrome not listed below:**

- Alverine citrate, p. 74
- Mebeverine hydrochloride, p. 75

### ANTI spasmodics

**Peppermint oil**

**INDICATIONS AND DOSE**

**Colpermin®**

Relief of abdominal colic and distension, particularly in irritable bowel syndrome

**BY MOUTH**

- Child 15–17 years: 1–2 capsules 3 times a day for up to 3 months if necessary, capsule to be swallowed whole
- Adult: 1–2 capsules 3 times a day for up to 3 months if necessary, capsule to be swallowed whole with water

**Mintec®**

Relief of abdominal colic and distension, particularly in irritable bowel syndrome

**BY MOUTH**

- Adult: 1–2 capsules 3 times a day for up to 2–3 months if necessary, dose to be taken before meals, swallowed whole with water

### CAUTIONS

- Sensitivity to menthol

### SIDE-EFFECTS

- Rare  Allergic reactions - ataxia - bradycardia - headache - muscle tremor - rash
- Frequency not known  Heartburn - perianal irritation

### PREGNANCY

- Not known to be harmful.

### BREAST FEEDING

- Significant levels of menthol in breast milk unlikely.

### DIRECTIONS FOR ADMINISTRATION

Capsules should not be broken or chewed because peppermint oil may irritate mouth or oesophagus.

### MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: enema

- **Modified-release capsule**
  - Peppermint oil 200 microlitre  Colpermin gastro-resistant modified-release capsules | 20 capsule [**(G)**] £3.33 | 100 capsule [**(G)**] £12.18 DT price = £12.18
  - Gas tro-resistant capsule
    - PEPPERMINT OIL (Non-proprietary)
      - Peppermint oil 200 microlitre  Peppermint oil 0.2ml gastro-resistant capsules | 84 capsule [**(G)**] £7.04 DT price = £7.04
    - Brands may include Apercap, Mintec
  - Liquid
    - PEPPERMINT OIL (Non-proprietary)
      - Ethanol 90% 15 ml per 1 litre, Peppermint oil 5 ml per 1 litre, Purified water 9.5 ml per 1 litre  Peppermint oil BP 1973 | 100 ml [**(G)**] £5.95 | 100 ml £9.50

### CONTRA-INDICATIONS

- Gastro-intestinal obstruction - inflammatory bowel disease

### CAUTIONS

- Predisposition to fluid and electrolyte disturbances

### MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **Colpermin 290 microgram**  Constella 290microgram capsules | 28 capsule [**(P)**] £3.75

## 2 Constipation and bowel cleansing

### 2.1 Bowel cleansing

**Drugs used for Bowel cleansing not listed below:**

- Bisacodyl, p. 52
- Docusate sodium, p. 52
- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride, p. 48
- Magnesium sulfate, p. 858
- Phosphate, p. 861
- Sodium picosulfate, p. 54
**MAGNESIUM-CONTAINING DRUGS**

**Citric acid with magnesium carbonate**  
(Formulated as a bowel cleansing preparation)

### INDICATIONS AND DOSE

**Bowel evacuation for surgery, colonoscopy or radiological examination**  
**BY MOUTH**

- **Child 5-9 years:** One-third of a sachet to be given at 8 a.m. the day before the procedure and, one-third of a sachet to be given between 2 and 4 p.m. the day before the procedure.
- **Child 10-17 years:** 0.5–1 sachet, given at 8 a.m. the day before the procedure and 0.5–1 sachet, given between 2 and 4 p.m. the day before the procedure.
- **Adult:** 1 sachet, given 8 a.m. the day before the procedure and 1 sachet, given between 2 and 4 p.m. the day before the procedure, use half the dose in frail elderly patients.

### CONTRA-INDICATIONS

- Acute severe colitis - gastric retention - gastro-intestinal obstruction - gastro-intestinal perforation - toxic megacolon.

### CAUTIONS

- Children - colitis (avoid if acute severe colitis) - debilitated - elderly - hypovolaemia (should be corrected before administration of bowel cleansing preparations) - impaired gag reflex or possibility of regurgitation or aspiration - patients with fluid and electrolyte disturbances.

### CAUTIONS, FURTHER INFORMATION

- Adequate hydration should be maintained during treatment.

### INTERACTIONS

- Other oral drugs should not be taken one hour before or after administration of bowel cleansing preparations because absorption may be impaired. Consider withholding ACE inhibitors, angiotensin-II receptor antagonists, and NSAIDs on the day that bowel cleansing preparations are given and for up to 72 hours after the procedure. Also consider withholding diuretics on the day that bowel cleansing preparations are given.

### SIDE-EFFECTS

- **Common or very common** Abdominal distension - abdominal pain - nausea - vomiting
- **Uncommon** Dehydration - dizziness - electrolyte disturbances - headache

### SIDE-EFFECTS, FURTHER INFORMATION

- **Abdominal pain** Abdominal pain is usually transient and can be reduced by taking preparation more slowly.

### PREGNANCY

- Use with caution.

### BREAST FEEDING

- Use with caution.

### HEPATIC IMPAIRMENT

- Avoid in hepatic coma if risk of renal failure.

### RENAL IMPAIRMENT

- In adults: Avoid if eGFR less than 30 mL/minute/1.73 m² — risk of hypermagnesaemia.
- In children: Avoid if estimated glomerular filtration rate less than 30 mL/minute/1.73 m² — risk of hypermagnesaemia.

### MONITORING REQUIREMENTS

- Renal function should be measured before starting treatment in patients at risk of fluid and electrolyte disturbances.

### DIRECTIONS FOR ADMINISTRATION

- One sachet should be reconstituted with 200 mL of hot water; the solution should be allowed to cool for approx. 30 minutes before drinking.

### PRESCRIBING AND DISPENSING INFORMATION

- Reconstitution of one sachet containing 11.57 g magnesium carbonate and 17.79 g anhydrous citric acid produces a solution containing magnesium citrate with 118 mmol Mg²⁺. Flavours of oral powders may include lemon and lime.

### PATIENT AND CARER ADVICE

- Low residue or fluid only diet (e.g. water, fruit squash, clear soup, black tea or coffee) recommended before procedure (according to prescriber’s advice) and copious intake of clear fluids recommended until procedure. Patient or carers should be given advice on how to administer oral powder.

### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

#### Effervescent powder

- **CAUTIONARY AND ADVISORY LABELS** 13, 10
- **ELECTROLYTES:** Magnesium
- **Citramag** (Sanochemia Diagnostics UK Ltd)
  - Citric acid anhydrous 17.79 gram, Magnesium carbonate heavy 11.57 gram
  - Citramag effervescent powder sachets (sugar-free)  
  - 10 sachet [£] 18.92

### OSMOTIC LAXATIVES

**Macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride**  
(Polyethylene glycols)

### INDICATIONS AND DOSE

**MOVIPREP®**

- **Bowel evacuation for surgery, colonoscopy or radiological examination**  
  **BY MOUTH**
  - **Adult:** 1 litre daily for 2 doses: first dose of reconstituted solution taken on the evening before procedure and the second dose on the morning of procedure, alternatively 2 litres daily for 1 dose; reconstituted solution to be taken on the evening before the procedure, treatment should be completed at least 1 hour before colonoscopy.

### CONTRA-INDICATIONS


### CAUTIONS

- Colitis (avoid if acute severe colitis) - debilitated patients - elderly - fluid and electrolyte disturbances - heart failure - hypovolaemia (should be corrected before administration of bowel cleansing preparations) - impaired gag reflex or possibility of regurgitation or aspiration.

### INTERACTIONS

- Consider withholding ACE inhibitors, angiotensin-II receptor antagonists, and NSAIDs on the day that bowel cleansing preparations are given and for up to 72 hours after the procedure. Also consider withholding diuretics on the day that bowel cleansing preparations are given.

### SIDE-EFFECTS

- **Common or very common** Abdominal distension - abdominal pain - nausea - vomiting
- **Uncommon** Dehydration - dizziness - electrolyte disturbances - headache
- **Frequency not known** Anal discomfort - fatigue - sleep disturbances

### SIDE-EFFECTS, FURTHER INFORMATION

- **Abdominal pain** Abdominal pain is usually transient and can be reduced by taking preparation more slowly.
42 Constipation and bowel cleansing

Gastro-intestinal system

INTERACTIONS

CAUTIONS

CONTRA-INDICATIONS

(Formulated as a bowel cleansing preparation)

bicarbonate and sodium chloride

Macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride

(Macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride

(Formulated as a bowel cleansing preparation)

INDICATIONS AND DOSE

Bowel cleansing before radiological examination, colonoscopy, or surgery

INITIALLY BY MOUTH

Adult: Initially 2 litres daily for 2 doses: first dose of reconstituted solution taken on the evening before procedure and the second dose on the morning of procedure, alternatively (by mouth) initially 250 mL every 10–15 minutes, reconstituted solution to be administered, alternatively (by nasogastric tube) initially 20–30 mL/minute, starting on the day before procedure until 4 litres have been consumed

CONTRA-INDICATIONS

Acute severe colitis • gastric retention • gastro-intestinal obstruction • gastro-intestinal perforation • toxic megacolon

CAUTIONS

Colitis (avoid if acute severe colitis) • debilitated patients • elderly • fluid and electrolyte disturbances • heart failure • hypovolaemia (should be corrected before administration of bowel cleansing preparations) • impaired gag reflex or possibility of regurgitation or aspiration

INTERACTIONS

Consider withholding ACE inhibitors, angiotensin-II receptor antagonists, and NSAIDs on the day that bowel cleansing preparations are given and for up to 72 hours after the procedure. Also consider withholding diuretics on the day that bowel cleansing preparations are given.

SIDE-EFFECTS

Common or very common Abdominal distention • abdominal pain • nausea • vomiting

Uncommon Anal discomfort • dehydration • dizziness • electrolyte disturbances • fatigue • headache • sleep disturbances

SIDE-EFFECTS, FURTHER INFORMATION

Abdominal pain Abdominal pain is usually transient and can be reduced by taking preparation more slowly.

PREGNANCY

Manufacturers advise use only if essential—no information available.

BREAST FEEDING

Manufacturers advise use only if essential—no information available.

MONITORING REQUIREMENTS

Renal function should be measured before starting treatment in patients at risk of fluid and electrolyte disturbances.

DIRECTIONS FOR ADMINISTRATION

MOVIPREP®

One pair of sachets (A and B) should be reconstituted in 1 litre of water and taken over 1–2 hours.

1 litre of other clear fluid should also be taken during treatment.

PRESCRIBING AND DISPENSING INFORMATION

Flavours of oral powder formulations may include lemon or orange.

PATIENT AND CARER ADVICE

Patient information leaflet.

Solid food should not be taken during treatment until procedure completed.

Treatment can be stopped if bowel motions become watery and clear.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder

CAUTORY AND ADVISORY LABELS 10, 13
EXCIPENTS: May contain Aspartame
ELECTROLYTES: May contain Chloride, potassium, sodium

Moviprep (Norgine Pharmaceuticals Ltd)

Moviprep oral powder sachets (sugar-free) | 4 sachet £9.87

Macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride

(Formulated as a bowel cleansing preparation)

INDICATIONS AND DOSE

Bowel cleansing before radiological examination, colonoscopy, or surgery

INITIALLY BY MOUTH

Adult: Initially 2 litres daily for 2 doses: first dose of reconstituted solution taken on the evening before procedure and the second dose on the morning of procedure, alternatively (by mouth) initially 250 mL every 10–15 minutes, reconstituted solution to be administered, alternatively (by nasogastric tube) initially 20–30 mL/minute, starting on the day before procedure until 4 litres have been consumed

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder

CAUTORY AND ADVISORY LABELS 10, 13
EXCIPENTS: May contain Aspartame
ELECTROLYTES: May contain Bicarbonate, chloride, potassium, sodium

Klean-Prep (Norgine Pharmaceuticals Ltd)

Polyethylene glycol 3350 59 gram, Potassium chloride 1.465 gram, Sodium bicarbonate 1.685 gram, Sodium chloride 5.685 gram, Klean-Prep oral powder sachets (sugar-free) | 4 sachet £9.07

STIMULANT LAXATIVES

Magnesium citrate with sodium picosulfate

(Formulated as a bowel cleansing preparation)

INDICATIONS AND DOSE

CITRAFLEET® SACHETS

Bowel evacuation on day before radiological examination, endoscopy, or surgery

BY MOUTH

Adult: 1 sachet taken before 8 a.m, then 1 sachet after 6–8 hours

PHARMACOKINETICS

Acts within 3 hours of first dose.

PICOLAX® SACHETS

Bowel evacuation on day before radiological procedure, endoscopy, or surgery

BY MOUTH

Child 1 year: 0.25 sachet taken before 8 a.m, then 0.25 sachet after 6–8 hours

Child 2–3 years: 0.5 sachet taken before 8 a.m, then 0.5 sachet after 6–8 hours

Child 4–8 years: 1 sachet taken before 8 a.m, then 1.5 sachet after 6–8 hours

Child 9–17 years: 1 sachet taken before 8 a.m, then 1 sachet after 6–8 hours

Adult: 1 sachet taken before 8 a.m, then 1 sachet after 6–8 hours
2.2 Constipation

Constipation

Before prescribing laxatives it is important to be sure that the patient is constipated and that the constipation is not secondary to an underlying undiagnosed complaint. It is also important for those who complain of constipation to understand that bowel habit can vary considerably in frequency without doing harm. Some people tend to consider themselves constipated if they do not have a bowel movement each day. A useful definition of constipation is the passage of hard stools less frequently than the patient’s own normal pattern and this can be explained to the patient.

Misconceptions about bowel habits have led to excessive laxative use. Abuse may lead to hypokalaemia. Thus, laxatives should generally be avoided except where straining will exacerbate a condition (such as angina) or increase the risk of rectal bleeding as in haemorrhoids. Laxatives are also of value in drug-induced constipation, for the expulsion of parasites after anthelminthic treatment, and to clear the alimentary tract before surgery and radiological procedures. Prolonged treatment of constipation is sometimes necessary. Also see the prevention of opioid-induced constipation in palliative care.

The laxatives that follow have been divided into 5 main groups. This simple classification disguises the fact that some laxatives have a complex action.

Bulk-forming laxatives

Bulk-forming laxatives are of value if the diet is deficient in fibre. Bulk-forming laxatives are of particular value in those with small hard stools, but should not be required unless fibre cannot be increased in the diet. A balanced diet, including adequate fluid intake and fibre is of value in preventing constipation.

Bulk-forming laxatives can be used in the management of patients with colostomy, ileostomy, haemorrhoids, anal fissure, chronic diarrhoea associated with diverticular disease, irritable bowel syndrome, and as adjuncts in ulcerative colitis. Adequate fluid intake must be maintained to avoid intestinal obstruction. Unprocessed wheat bran, taken with food or fruit juice, is a most effective bulk-forming preparation. Finely ground bran, though more palatable, seems to have little advantage over coarse bran.

Methylcellulose also acts as a faecal softener. Methylcellulose p. 45, ispaghula husk p. 45, and sterculia p. 46 are useful in patients who cannot tolerate bran. Methylcellulose also acts as a faecal softener.

Stimulant laxatives

Stimulant laxatives include bisacodyl p. 52, sodium picosulfate p. 54, and members of the anthraquinone group, senna p. 53, co-danthramer p. 52 and co-danthrusate p. 51. The indications for co-danthramer and

Flavours of oral powder formulations may include lemon.

CAUTIONARY AND ADVISORY LABELS 10, 13

ELECTROLYTES: May contain Magnesium, potassium

CitraFleet® SACHETS
One sachet should be reconstituted with 150 mL (approx. half a glass) of cold water.

Picolax® SACHETS
One sachet should be reconstituted with 150 mL (approx. half a glass) of cold water.

Sodium picosulfate 10 mg
Citric acid anhydrous 12 gram, Magnesium oxide 3.5 gram, Sodium picosulfate 10 mg
CitraFleet oral powder 15.08g sachets (sugar-free) | 2 sachet £3.25

Picolax® Ferring Pharmaceuticals Ltd
CitraFleet oral powder 16.1g sachets (sugar-free) | 2 sachet £3.39

Pharmacokinetics

Acts within 3 hours of first dose.

Contra-indications

Acute severe colitis - ascites - congestive cardiac failure - gastric retention - gastro-intestinal obstruction - gastro-intestinal perforation - gastro-intestinal ulceration - toxic megacolon

Cautions

General cautions:
Cardiac disease (avoid in congestive cardiac failure) - children - colitis (avoid if acute severe colitis) - debilitated patients - elderly - fluid and electrolyte disturbances - hypovolaemia (should be corrected before administration) - impaired gag reflex or possibility of regurgitation or aspiration - recent gastro-intestinal surgery

Side-effects

Common or very common:
Abdominal distension - abdominal pain (usually transient—reduced by taking more slowly) - nausea - vomiting

Uncommon:
Dehydration - dizziness - electrolyte disturbances - headache

Frequency not known:
Anal discomfort - fatigue - rash - sleep disturbances

Pregnancy
Caution.

Breast feeding
Caution.

Hepatic impairment
Avoid in hepatic coma if risk of renal failure.

Renal impairment
Avoid if eGFR less than 30 mL/minute/1.73 m²—risk of hypermagnesaemia.

Directions for administration
One sachet of sodium picosulfate with magnesium citrate powder should be reconstituted with 150 mL (approx. half a glass) of cold water; patients should be warned that heat is generated during reconstitution and that the solution should be allowed to cool before drinking.

CitraFleet® SACHETS
One sachet should be reconstituted with 150 mL (approx. half a glass) of cold water.

Picolax® SACHETS
One sachet should be reconstituted with 150 mL (approx. half a glass) of cold water.

Prescribing and dispensing information
Flavours of oral powder formulations may include lemon.

Patient and carer advice
Low residue diet recommended on the day before procedure and copious intake of water or other clear fluids recommended during treatment. Patients or carers should be given advice on how to administer sodium picosulfate with magnesium citrate oral powder.

CitraFleet® SACHETS
Low residue diet recommended on the day before procedure and copious intake of water or other clear fluids recommended during treatment. Patients and carers should be given advice on how to administer oral powder; they should be warned that heat is generated during reconstitution and that the solution should be allowed to cool before drinking.

Picolax® SACHETS
Low residue diet recommended on the day before procedure and copious intake of water or other clear fluids recommended during treatment. Patients and carers should be given advice on how to administer oral powder; they should be warned that heat is generated during reconstitution and that the solution should be allowed to cool before drinking.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug.
Constipation and bowel cleansing

44
BNF 70

co-danthrussate are limited by its potential carcinogenicity (based on rodent carcinogenicity studies) and evidence of genotoxicity. Powerful stimulants such as cascara (an anthraquinone) and castor oil are obsolete. Docusate sodium p. 52 probably acts both as a stimulant and as a softening agent.

Stimulant laxatives increase intestinal motility and often cause abdominal cramp; they should be avoided in intestinal obstruction. Excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia; however, prolonged use may be justifiable in some circumstances.

Bulk laxatives and non-ionic surfactants are therefore useful in the treatment of osmotic diarrhoea of low faecal pH, and discourage the proliferation of ammonia-producing organisms. It is avoided as they may give rise to sodium and water retention salts, such as magnesium sulfate are useful where rapid bowel clearance before radiology, endoscopy, and surgery is necessary.

Bowel cleansing preparations

Bowel cleansing preparations are used before colonic surgery, colonoscopy, or radiological examination to ensure the bowel is free of solid contents. They are not treatments for constipation.

Pregnancy

If dietary and lifestyle changes fail to control constipation in pregnancy, moderate doses of poorly absorbed laxatives may be used. A bulk-forming laxative should be tried first. An osmotic laxative, such as lactulose p. 47, can also be used. Bisacodyl p. 52 or senna p. 53 may be suitable, if a stimulant effect is necessary.

Constipation in children

Laxatives should be prescribed by a healthcare professional experienced in the management of constipation in children. Delays of greater than 3 days between stools may increase the likelihood of pain on passing hard stools leading to anal fissure, anal spasm and eventually to a learned response to avoid defaecation.

In infants, increased intake of fluids, particularly fruit juice containing sorbitol (e.g. prune, pear, or apple), may be sufficient to soften the stool. In infants under 1 year of age with mild constipation, lactulose p. 47 can be used to soften the stool; either an oral preparation containing macrogols or, rarely, glycerol p. 53 suppositories can be used to clear faecal impaction. The infant should be referred to a hospital paediatrician if these measures fail.

The diet of children over 1 year of age should be reviewed to ensure that it includes an adequate intake of fibre and fluid. An osmotic laxative containing macrogols can also be used, particularly in children with chronic constipation; lactulose p. 47 is an alternative in children who cannot tolerate a macrogol. If there is an inadequate response to the osmotic laxative, a stimulant laxative can be added. Treatment of faecal impaction may initially increase symptoms of soiling and abdominal pain. In children over 1 year of age with faecal impaction, an oral preparation containing macrogols is used to clear faecal mass and to establish and maintain soft well-formed stools. If disimpaction does not occur after 2 weeks, a stimulant laxative can be added. If the impacted mass is not expelled following treatment with macrogols and a stimulant laxative, a sodium citrate p. 677 enema can be administered. Although rectal administration of laxatives may be effective, this route is frequently distressing for the child and may lead to persistence of withholding. A phosphate enema may be administered under specialist supervision if disimpaction does not occur after a sodium citrate enema; a bowel cleansing preparation is an alternative. Manual evacuation under anaesthetic may be necessary if disimpaction does not occur after oral and rectal treatment, or if the child is afraid.

Long-term regular use of laxatives is essential to maintain well-formed stools and prevent recurrence of faecal impaction; intermittent use may provoke relapses. In children with chronic constipation, laxatives should be continued for several weeks after a regular pattern of bowel movements or toilet training is established. The dose of laxatives should then be tapered gradually, over a period of...
months, according to response. Some children may require laxative therapy for several years.

**Chronic constipation**
For children with chronic constipation, it may be necessary to exceed the licensed doses of some laxatives. Parents and carers of children should be advised to adjust the dose of laxative in order to establish a regular pattern of bowel movements in which stools are soft, well-formed, and passed without discomfort. Laxatives should be administered at a time that produces an effect that is likely to fit in with the child’s toilet routine.

**BULK FORMING LAXATIVES**

**Ispaghula husk**

- **DRUG ACTION** Bulk-forming laxatives relieve constipation by increasing faecal mass which stimulates peristalsis.

### INDICATIONS AND DOSE

#### ISPAGEL® ORANGE

**Constipation**
- **BY MOUTH**
  - Child 6-11 years: 2.5–5 mL twice daily, dose to be given as a half or whole level spoonful in water, preferably after meals
  - Child 12-17 years: 1 sachet 1–3 times a day, dose to be given in water preferably after meals, alternatively 10 mL 1–3 times a day, dose to be given as level spoonfuls in water, preferably after meals
  - Adult: 1 sachet 1–3 times a day, dose to be made up in water, preferably taken after food

**Dose equivalence and conversion**
1 sachet equivalent to 2 level 5 mL spoonfuls.

#### FYBOGEL®

**Constipation**
- **BY MOUTH**
  - Child 6-11 years: 2.5–5 mL twice daily, dose to be given as a half or whole level spoonfuls in water, preferably after meals
  - Child 12-17 years: 1 sachet twice daily, dose to be made up in water, preferably taken after food, alternatively 10 mL twice daily, dose to be made up in water, preferably taken after food
  - Adult: 1 sachet twice daily, dose to be made up in water, preferably taken after food, alternatively 10 mL twice daily, dose to be made up in water, preferably taken after food

**Dose equivalence and conversion**
1 sachet equivalent to 2 level 5 mL spoonfuls.

- **CONTRA-INDICATIONS** Colonic atony - difficulty in swallowing - faecal impaction - infective bowel disease - intestinal obstruction
- **CAUTIONS** Adequate fluid intake should be maintained to avoid intestinal obstruction

**CAUTIONS, FURTHER INFORMATION**
It may be necessary to supervise elderly or debilitated patients or those with intestinal narrowing or decreased motility to ensure adequate fluid intake.

- **SIDE-EFFECTS** Abdominal distension (especially during the first few days of treatment) - flatulence (especially during the first few days of treatment) - gastro-intestinal impaction - gastro-intestinal obstruction - hypersensitivity

- **PRESCRIBING AND DISPENSING INFORMATION** Ispagel® Orange and Fybofel® effervescent granules are available as GSL medicines. Flavours of soluble granules formulations may include plain, lemon, or orange.

- **PATIENT AND CARER ADVICE** Patients and their carers should be advised that the full effect may take some days to develop. Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Granules

- **CAUTIONARY AND ADVISORY LABELS**
- **ISPAGHULA HUSK (Non-proprietary)**
  - Ispaghula husk 3.5 gram
  - Ispaghula husk granules sachets gluten free | 30 sachet GSK £2.29

#### Effervescent granules

- **CAUTIONARY AND ADVISORY LABELS**
- **ISPAGHULA HUSK (Non-proprietary)**
  - Ispaghula husk 3.5 gram
  - Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free (sugar-free) | 30 sachet price = £2.29

#### Powder

- **CAUTIONARY AND ADVISORY LABELS**
- **ISPAGHULA HUSK (Non-proprietary)**
  - Ispaghula husk 1 mg per 1 mg
  - Husk oral powder (sugar-free) | 200 gram GSK £5.24

Also available in combination with senna, p. 53

**Methycellulose**

- **DRUG ACTION** Bulk-forming laxatives relieve constipation by increasing faecal mass which stimulates peristalsis.

### INDICATIONS AND DOSE

**Constipation**
- **Diarrhoea**
  - **BY MOUTH USING TABLETS**
    - Adult: 3–6 tablets daily

- **CONTRA-INDICATIONS** Colonic atony - difficulty in swallowing - faecal impaction - infective bowel disease - intestinal obstruction

- **CAUTIONS** Adequate fluid intake should be maintained to avoid intestinal obstruction

**CAUTIONS, FURTHER INFORMATION**
It may be necessary to supervise elderly or debilitated patients or those with intestinal narrowing or decreased motility to ensure adequate fluid intake.

- **SIDE-EFFECTS** Abdominal distension (especially during the first few days of treatment) - flatulence (especially during the first few days of treatment) - gastro-intestinal impaction - gastro-intestinal obstruction - hypersensitivity

- **DIRECTIONS FOR ADMINISTRATION** In constipation the dose should be taken with at least 300 mL liquid. In diarrhoea, ileostomy, and colostomy control, avoid liquid intake for 30 minutes before and after dose.

- **PATIENT AND CARER ADVICE** Patients and their carers should be advised that the full effect may take some days to develop. Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, enema

#### Tablet

- **Celevac (AMCo)**
  - Methyccellulose "450" 500 mg Celevac 500mg tablets | 112 tablet £4.64 DT price = £3.22
**Sternula**

**INDICATIONS AND DOSE**

**CONSTIPATION**

**BY MOUTH**

- Child 6-11 years: 0.5–1 sachet 1–2 times a day, alternatively, half to one heaped 5-mL spoonful once or twice a day; washed down without chewing with plenty of liquid after meals.
- Child 12-17 years: 1–2 sachets 1–2 times a day, alternatively, one to two heaped 5-mL spoonfuls once or twice a day; washed down without chewing with plenty of liquid after meals.
- Adult: 1–2 sachets 1–2 times a day, alternatively, one to two heaped 5-mL spoonfuls once or twice a day; washed down without chewing with plenty of liquid after meals.

**CONTRA-INDICATIONS**

Colonic atony, difficulty in swallowing, faecal impaction, intestinal obstruction.

**CAUTIONS**

Adequate fluid intake should be maintained to avoid intestinal obstruction.

**SIDE-EFFECTS**

- Frequency not known: Hyperhidrosis, palpitation.
- Uncommon: Chest pain, muscle spasm, syncope, vomiting.

**PREGNANCY**

Manufacturer advises avoid—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

In moderate to severe impairment, initially 24 micrograms once daily; if tolerated, and if necessary, increased to 24 micrograms twice daily.

**PRESCRIBING AND DISPENSING INFORMATION**

Dispense capsules in original container; discard any capsules remaining 4 weeks after opening.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

Lubiprostone for treating chronic idiopathic constipation. (July 2014) NICE TA318

Lubiprostone is recommended as an option for treating chronic idiopathic constipation for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered. If treatment with lubiprostone is not effective after 2 weeks, the patient should be re-examined and the benefit of continuing treatment reconsidered.

Lubiprostone should only be prescribed by a clinician with experience of treating chronic idiopathic constipation, after careful review of the patient’s previous courses of laxative treatments. www.nice.org.uk/TA318

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (July 2014) that lubiprostone (Amitiza®) is not recommended for use within NHS Scotland.

**MAGNESIUM-CONTAINING DRUGS**

**Magnesium hydroxide**

**INDICATIONS AND DOSE**

**CONSTIPATION**

**BY MOUTH**

- Adult: 30–45 mL as required, dose to be given mixed with water at bedtime.

**CONTRA-INDICATIONS**

Acute gastro-intestinal conditions.

**CAUTIONS**

Debilitated patients, elderly.

**INTERACTIONS**

→ Appendix 1 (antacids).

**SIDE-EFFECTS**

Colic, abdominal pain, diarrhoea, dizziness, dyspepsia, dysphoria, flatulence, headache, hot flush, hyperhidrosis, nausea, oedema, palpitation, palpitation.

**PREGNANCY**

Manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

Avoid in hepatic coma if risk of renal failure.

**RENAI IMPAIRMENT**

Avoid reduce dose. Increased risk of toxicity in renal impairment.

**PRESCRIBING AND DISPENSING INFORMATION**

When prepared extemporaneously, the BP states Magnesium Hydroxide Mixture, BP consists of an aqueous suspension containing about 8% hydrated magnesium oxide.

**MAGNIFICENT FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 21**

- Amitiza (Sucampo Pharma Europe Ltd)
- Lubiprostone 24 microgram: Amitiza 24 microgram capsules
  - 28 capsule (PBS) £26.68
  - 56 capsule (PBS) £53.48

**Granules**

**CAUTIONARY AND ADVISORY LABELS 25, 27**

- Normacol (Norgine Pharmaceuticals Ltd)
- Sterculia 620 mg per 1 gram:
  - Normacol granules 7g sachets: 60 sachet (GS) £5.77 OT price = £5.77
  - Normacol granules: 500 gram (GS) £6.85 OT price = £6.85

**CHLORIDE-CHANNEL ACTIVATORS**

**Lubiprostone**

**INDICATIONS AND DOSE**

Chronic idiopathic constipation when response to lifestyle changes (including diet) inadequate.

**BY MOUTH**

- Adult: 24 micrograms twice daily for 2 weeks.

**CONTRA-INDICATIONS**

Gastro-intestinal obstruction.

**SIDE-EFFECTS**

- Common or very common: Abdominal pain, diarrhoea, dizziness, dyspepsia, dysphoria, flatulence, headache, hot flush, hyperhidrosis, nausea, oedema, palpitation.
OPIOID RECEPTOR ANTAGONISTS (PERIPHERAL)

Methylnaltrexone bromide

DRUG ACTION Peripheral acting opioid-receptor antagonist which does not alter the central analgesic effect of opioids.

INDICATIONS AND DOSE
Adjunct to other laxatives in opioid-induced constipation in terminally ill patients, when response to other laxatives is inadequate.

BY SUBCUTANEOUS INJECTION
- Adult (body-weight up to 38 kg): 150 micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.
- Adult (body-weight 38–62 kg): 8 mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.
- Adult (body-weight 62–114 kg): 12 mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.
- Adult (body-weight 115 kg and above): 150 micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.

PHARMACOKINETICS
May act with 30–60 minutes.

CONTRA-INDICATIONS Acute surgical abdominal conditions - gastrointestinal obstruction.

CAUTIONS Diverticular disease - faecal impaction - patients with colostomy - patients with peritoneal catheter.

SIDE-EFFECTS
- Common or very common Abdominal pain - diarrhoea - dizziness - flatulence - hyperhidrosis - injection site reactions - nausea.
- Frequency not known Gastro-intestinal perforation.
- PREGNANCY Toxicity at high doses in animal studies—manufacturer advises avoid unless essential.
- BREAST FEEDING Manufacturer advises use only if potential benefit outweighs risk—present in milk in animal studies.
- HEPATIC IMPAIRMENT Manufacturer advises avoid in severe hepatic impairment—no information available.
- RENAL IMPAIRMENT If eGFR less than 30 ml/minute/1.73 m², reduce dose as follows: body-weight under 62 kg, 75 micrograms/kg on alternate days; body-weight 62–114 kg, 8 mg on alternate days; body-weight over 114 kg, 75 micrograms/kg on alternate days.

DIRECTIONS FOR ADMINISTRATION Rotate injection site.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Relistor (TMC Pharma Services Ltd)
  Methylnaltrexone bromide 20 mg per 1 ml Relistor 12mg/0.6ml solution for injection vials 1 vial  21.05  7 vial  147.35

OSMOTIC LAXATIVES

Lactulose

INDICATIONS AND DOSE
Constipation
BY MOUTH
- Adult: Adjusted according to response to 30–50 mL 3 times a day, subsequently adjusted to produce 2–3 soft stools per day.

PHARMACOKINETICS
Lactulose may take up to 48 hours to act.

UNLICENSED USE
- In children Not licensed for use in children for hepatic encephalopathy.
- In adults Lactulose doses in the BNF may differ from those in product literature.

CONTRA-INDICATIONS Galactosaemia - intestinal obstruction.

CAUTIONS Lactose intolerance.

INTERACTIONS → Appendix 1 (lactulose).

SIDE-EFFECTS
- Common or very common Abdominal discomfort - cramps - flatulence - nausea - vomiting.

SIDE-EFFECTS, FURTHER INFORMATION
Nausea. Nausea can be reduced by administration with water, fruit juice or meals.

PREGNANCY Not known to be harmful.

PATIENT AND CARER ADVICE
Medicines for Children leaflet: Lactulose for constipation www.medicinesforchildren.org.uk/lactulose-for-constipation

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Oral solution
- LACTULOSE (Non-proprietary)
  Lactulose 666.667 mg per 1 ml Lactulose 10g/15ml oral solution 15ml sachets sugar free (sugar-free) 10 sachets  2.50 DT price = 2.50
  Lactulose 680 mg per 1 ml Lactulose 3.1-3.7g/5ml oral solution 300 ml  8.85  500 ml  14.50 DT price = 3.22
- Brands may include Duphalac oral solution, Lactagut oral solution.
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride

**INDICATIONS AND DOSE**

### Chronic constipation

**BY MOUTH**
- Child 12-17 years: 1–3 sachets daily in divided doses usually for up to 2 weeks; maintenance 1–2 sachets daily
- Adult: 1–3 sachets daily in divided doses usually for up to 2 weeks; maintenance 1–2 sachets daily

**Faecal impaction**

**BY MOUTH**
- Child 12-17 years: 4 sachets on first day, then increased in steps of 2 sachets daily, total daily dose to be drunk within a 6 hour period, after disimpaction, switch to maintenance laxative therapy if required; maximum 8 sachets per day
- Adult: 4 sachets on first day, then increased in steps of 2 sachets daily, total daily dose to be drunk within a 6 hour period, after disimpaction, switch to maintenance laxative therapy if required; maximum 8 sachets per day

**MOVICOL® LIQUID**

**Chronic constipation**

**BY MOUTH**
- Child 12-17 years: 25 mL 1–3 times a day usually for up to 2 weeks; maintenance 25 mL 1–2 times a day
- Adult: 25 mL 1–3 times a day usually for up to 2 weeks; maintenance 25 mL 1–2 times a day

**MOVICOL-PAEDIATRIC®**

**Chronic constipation | Prevention of faecal impaction**

**BY MOUTH**
- Child 2–5 years: 1 sachet daily, adjust dose to produce regular soft stools; maximum 4 sachets per day
- Child 6–11 years: 2 sachets daily, adjust dose to produce regular soft stools; maximum 4 sachets per day

**Faecal impaction**

**BY MOUTH**
- Child 5–11 years: Initially 4 sachets daily on first day, then increased in steps of 2 sachets daily, total daily dose to be taken over a 12-hour period, after disimpaction, switch to maintenance laxative therapy; maximum 12 sachets per day

**MOVICOL® ORAL POWDER**

**Chronic constipation**

**BY MOUTH**
- Child 12-17 years: 1–3 sachets daily in divided doses usually for up to 2 weeks; maintenance 1–2 sachets daily
- Adult: 1–3 sachets daily in divided doses usually for up to 2 weeks; maintenance 1–2 sachets daily

**Faecal impaction**

**BY MOUTH**
- Child 12-17 years: Initially 4 sachets daily on first day, then increased in steps of 2 sachets daily, total daily dose to be drunk within a 6 hour period, after disimpaction, switch to maintenance laxative therapy if required; maximum 8 sachets per day
- Adult: Initially 4 sachets daily on first day, then increased in steps of 2 sachets daily, total daily dose to be drunk within a 6 hour period, after disimpaction, switch to maintenance laxative therapy if required; maximum 8 sachets per day

**MOVICOL-HALF®**

**Chronic constipation**

**BY MOUTH**
- Child 12-17 years: 2–6 sachets daily in divided doses usually for up to 2 weeks; maintenance 2–4 sachets daily
- Adult: 2–6 sachets daily in divided doses usually for up to 2 weeks; maintenance 2–4 sachets daily

**Faecal impaction**

**BY MOUTH**
- Child 12-17 years: Initially 8 sachets daily on first day, then increased in steps of 4 sachets daily, total daily dose to be drunk within 6 hours, after disimpaction, switch to maintenance laxative therapy; maximum 16 sachets per day
- Adult: Initially 8 sachets daily on first day, then increased in steps of 4 sachets daily, total daily dose to be drunk within 6 hours, after disimpaction, switch to maintenance laxative therapy; maximum 16 sachets per day

**UNLICENSED USE**

**MOVICOL-PAEDIATRIC®**

Movicol® Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

**CONTRA-INDICATIONS**

- Crohn’s disease
- Intestinal obstruction
- Intestinal perforation
- Paralytic ileus
- Severe inflammatory conditions of the intestinal tract
- Toxic megacolon
- Ulcerative colitis

**MOVICOL-PAEDIATRIC®**

Cardiovascular impairment · renal impairment.

**CAUTIONS**

Cardiovascular impairment (should not take more than 2 ‘full-strength’ sachets or 4 ‘half-strength’ sachets in any one hour) · discontinue if symptoms of fluid and electrolyte disturbance

**MOVICOL-PAEDIATRIC®**

Impaired consciousness (with high doses) · impaired gag reflex (with high doses) · reflux oesophagitis (with high doses)

**INTERACTIONS**

- Appendix 1 (macrogols).

**SIDE-EFFECTS**

- Abdominal distention · abdominal pain · flatulence · nausea

**PREGNANCY**

Limited data, but manufacturer advises that it can be used.

**BREAST FEEDING**

Manufacturer advises that it can be used.

**DIRECTIONS FOR ADMINISTRATION**

Contents of each ‘full strength’ sachet of oral powder to be dissolved in half a glass (approx. 125 mL) of water; after reconstitution the solution should be kept in a refrigerator and discarded if unused after 6 hours.

**MOVICOL® LIQUID**

25 mL of oral concentrate to be diluted with half a glass (approx. 100 mL) of water. After dilution the solution should be discarded if unused after 24 hours.

**MOVICOL-PAEDIATRIC®**

Contents of each sachet to be dissolved in quarter of a glass (approx. 60–65 mL) of water; after reconstitution the solution should be kept in a refrigerator and discarded if unused after 24 hours.

**MOVICOL® ORAL POWDER**

Contents of each sachet to be dissolved in half a glass (approx. 125 mL) of water; after reconstitution the solution should be kept in a refrigerator and discarded if unused after 6 hours.

**MOVICOL-HALF®**

Contents of each sachet to be dissolved in quarter of a glass (approx. 60–65 mL) of water; after reconstitution...
Liquid paraffin with magnesium hydroxide

The properties listed below are those particular to the combination only. For the properties of the components please consider, liquid paraffin above, magnesium hydroxide p. 46.

**INDICATIONS AND DOSE**

**Conipation**
- **BY MOUTH**
  - Adult: 5–20 mL as required

**PRESCRIBING AND DISPENSING INFORMATION**
- Liquid paraffin and magnesium hydroxide preparations are on sale to the public. When prepared extemporaneously, the BP states Liquid Paraffin and Magnesium Hydroxide Oral Emulsion, BP consists of 25% liquid paraffin in aqueous suspension containing 6% hydrated magnesium oxide.
- **LESS SUITABLE FOR PRESCRIBING** Liquid paraffin with magnesium hydroxide is less suitable for prescribing.

**PRESCRIBING AND DISPENSING INFORMATION**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops
  - **L I Q U I D PA R A F F I N  ( N o n - p r o p r i e t a r y )**
    - Liquid paraffin 1 ml per 1 ml Liquid paraffin liquid | 150 ml £ 1.32–1.45

**PHOSPHATE-CONTAINING DRUGS**

**Sodium acid phosphate with sodium phosphate**

**INDICATIONS AND DOSE**

**Constipation (using Phosphates Enema BP Formula B)**
- Bowel evacuation before abdominal radiological procedures, endoscopy, and surgery (using Phosphates Enema BP Formula B)
  - **BY RECTUM**
    - Child 3–6 years: 45–65 mL once daily
    - Child 7–11 years: 65–100 mL once daily
    - Child 12–17 years: 100–128 mL once daily
    - Adult: 128 mL daily

**CONTRA-INDICATIONS** Children under 3 years

**CAUTIONS** Avoid prolonged use

**SIDE-EFFECTS** Anal irritation after prolonged use - anal seepage of paraffin after prolonged use - granulomatous reactions caused by absorption of small quantities of liquid paraffin (especially from the emulsion) - interference with the absorption of fat-soluble vitamins - lipid pneumonia

**PRESCRIBING AND DISPENSING INFORMATION**

- When prepared extemporaneously, the BP states Liquid Paraffin Oral Emulsion, BP consists of liquid paraffin 5 mL, vanillin 5 mg, chloroform 0.25 mL, benzoic acid solution 0.2 mL, methylcellulose-20 200 mg, saccharin sodium 500 micrograms, water to 10 mL...

**PATIENT AND CARER ADVICE**
- Oral emulsion should not be taken immediately before going to bed.

**MEDICINES FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops
  - **L I Q U I D PA R A F F I N  ( N o n - p r o p r i e t a r y )**
    - Liquid paraffin 1 ml per 1 ml Liquid paraffin liquid | 150 ml £ 1.32–1.45

**MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE (Non-proprietary)**

- Bicarbonate 17 mmol per 1 litre, Chloride 53 mmol per 1 litre, Macrogol 3350 13.125 gram, Potassium 5.4 mmol per 1 litre, Sodium 65 mmol per 1 litre
  - Movicol Liquid (sugar-free) | 500 ml £ 4.45
  - Powder
  - Liquid paraffin with magnesium hydroxide oral
  - MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE (Non-proprietary)
  - Bicarbonate 17 mmol per 1 litre, Chloride 53 mmol per 1 litre, Macrogol 3350 13.125 gram, Potassium 5.4 mmol per 1 litre, Sodium 65 mmol per 1 litre
  - Movicol Plain oral powder 13.7g sachets sugar free (sugar-free) | 20 sachet (£ 3.26–3.45, sugar-free) | 30 sachet (£ 4.68 DT price = £ 4.27)
  - Bicarbonate 17 mmol per 1 litre, Chloride 53 mmol per 1 litre, Macrogol 3350 13.125 gram, Potassium 5.4 mmol per 1 litre, Sodium 65 mmol per 1 litre
  - Movicol Plain oral powder 13.7g sachets sugar free (sugar-free) | 30 sachet (£ 4.68 DT price = £ 4.27)
  - Movicol (Norgine Pharmaceuticals Ltd)
  - Bicarbonate 17 mmol per 1 litre, Chloride 53 mmol per 1 litre, Macrogol 3350 13.125 gram, Potassium 5.4 mmol per 1 litre, Sodium 65 mmol per 1 litre
  - Movicol Plain oral powder 13.7g sachets sugar free (sugar-free) | 30 sachet (£ 6.68 DT price = £ 4.27)
  - Movicol oral powder 13.8g sachets lemon & lime (sugar-free) | 20 sachet (£ 4.45, sugar-free) | 30 sachet (£ 6.68 DT price = £ 4.27)
  - Bicarbonate 17 mmol per 1 litre, Chloride 53 mmol per 1 litre, Macrogol 3350 13.125 gram, Potassium 5.4 mmol per 1 litre, Sodium 65 mmol per 1 litre
  - Movicol-Half oral powder 6.9g sachets sugar free (sugar-free) | 20 sachet (£ 2.92, sugar-free) | 30 sachet (£ 4.38)
  - Movicol Paediatric Plain oral powder 6.9g sachets sugar free (sugar-free) | 30 sachet (£ 6.95)
  - Movicol Paediatric Chocolate oral powder 6.9g sachets sugar free (sugar-free) | 30 sachet (£ 6.95)
  - Brands may include Cosmoocol, Laxido, Macilax; Molaxole

**PARAFFINS**

**Liquid paraffin**

**INDICATIONS AND DOSE**

**Conipation**
- **BY MOUTH**
  - Adult: 10–30 mL daily if required, to be administered at night

- **CONTRA-INDICATIONS** Children under 3 years
- **CAUTIONS** Avoid prolonged use
- **SIDE-EFFECTS** Anal irritation after prolonged use - anal seepage of paraffin after prolonged use - granulomatous reactions caused by absorption of small quantities of liquid paraffin (especially from the emulsion) -
**FLEET® PHOSPHO-SODA**

Bowel evacuation before colonic surgery | Bowel evacuation before colonoscopy | Bowel evacuation before radiological examination

**BY MOUTH**
- Adult: 45 mL twice daily, each dose must be diluted with half a glass (120 mL) of cold water, followed by one full glass (240 mL) of cold water; timing of doses is dependent on the time of the procedure, for morning procedure, the first dose should be taken at 7 a.m. and second at 7 p.m. on day before the procedure; for afternoon procedure, first dose should be taken at 7 p.m. on day before and second dose at 7 a.m. on day of the procedure

**PHARMACOKINETICS**
Onset of action is within half to 6 hours of first dose.

**FLEET® READY-TO-USE ENEMA**
Constipation | Bowel evacuation before abdominal radiological procedures | Bowel evacuation before endoscopy | Bowel evacuation before surgery

**BY RECTUM**
- Adult: 118 mL.

#### CONTRA-INDICATIONS
- With oral use Acute severe colitis - ascites - congestive cardiac failure - gastric retention - gastro-intestinal obstruction - gastro-intestinal perforation - toxic megacolon
- With rectal use Conditions associated with increased colonic absorption - gastro-intestinal obstruction - inflammatory bowel disease

#### CAUTIONS
- With oral use Cardiac disease (avoid in congestive cardiac failure) - colitis (avoid if acute severe colitis) - elderly and debilitated patients - fluid and electrolyte disturbances - hypovolaemia (should be corrected before administration) - impaired gag reflex or possibility of regurgitation or aspiration
- With rectal use Ascites - congestive heart failure - elderly and debilitated patients - electrolyte disturbances - uncontrolled hypertension

#### INTERACTIONS
- With oral use Other oral drugs should not be taken one hour before or after administration of bowel cleansing preparations because absorption may be impaired. Consider withholding ACE inhibitors, angiotensin-II receptor antagonists, and NSAIDs on the day that bowel cleansing preparations are given and for up to 72 hours after the procedure. Also consider withholding diuretics on the day that bowel cleansing preparations are given.

#### SIDE-EFFECTS
- Common or very common
  - With oral use Abdominal distension - abdominal pain (usually transient - reduced by taking more slowly) - nausea - vomiting
  - Uncommon
    - With oral use Dehydration - dizziness - headache
    - Frequency not known
    - With oral use Arrhythmias - asthenia - chest pain - electrolyte disturbances - renal failure
    - With rectal use Electrolyte disturbances - local irritation
- Pregnancy
  - With oral use Caution.
  - Breast Feeding
    - With oral use Caution.
- Hepatic Impairment
  - Use with caution in cirrhosis.
- Renal Impairment
  - With oral use Avoid if eGFR less than 60 mL/minute/1.73 m².
  - With rectal use Use with caution.

#### MONITORING REQUIREMENTS
- With oral use Renal function should be measured before starting treatment in patients at risk of fluid and electrolyte disturbances.

#### DIRECTIONS FOR ADMINISTRATION
**FLEET® PHOSPHO-SODA**
Copious intake of water or other clear fluids (e.g. clear soup, strained fruit juice without pulp, black tea or coffee) recommended until midnight before morning procedure and until 8 a.m. after afternoon procedure. At least one glass (approx 240 mL) of water or other clear fluid should also be taken immediately before each dose.

#### PRESCRIBING AND DISPENSING INFORMATION
When prepared extemporaneously, the BP states Phosphates Enema BP Formula B consists of sodium dihydrogen phosphate dihydrate 12.8 g, disodium phosphate dodecahydrate 10.24 g, purified water, freshly boiled and cooled, to 128 mL.

#### PATIENT AND CARER ADVICE
**FLEET® PHOSPHO-SODA**
Intake of solid food should be stopped for at least 6 hours before starting treatment and until procedure completed. Patients or carers should be advised that adequate hydration should be maintained during treatment. Patients or carers should be given advice on administration of Fleet Phospho-soda® oral solution.

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Fleet Phospho-soda (Laboratorios Casen-Fleet S.L.U)**
- Disodium hydrogen phosphate dodecahydrate 240 mg per 1 ml, Sodium dihydrogen phosphate dihydrate 542 mg per 1 ml
- Fleet Phospho-soda oral solution (sugar-free) | 90 ml | £4.79

**Enema**
- Sodium Acid Phosphate with Sodium Phosphate (Non-proprietary)
  - Disodium hydrogen phosphate dodecahydrate 80 mg per 1 ml, Sodium dihydrogen phosphate dihydrate 100 mg per 1 ml
- Phosphates enema (Formula B) 128ml long tube | 1 enema | £1.93
  - Disodium hydrogen phosphate dodecahydrate 80 mg per 1 ml, Sodium dihydrogen phosphate dihydrate 181 mg per 1 ml
- Fleet Ready-to-use (Laboratorios Casen-Fleet S.L.U)
  - Sodium dihydrogen phosphate dihydrate 80 mg per 1 ml, Sodium dihydrogen phosphate dihydrate 181 mg per 1 ml
  - Fleet Ready-to-use 133ml enema | 1 enema | £0.68

#### SELECTIVE 5-HT4 RECEPTOR AGONISTS

**Prucalopride**

#### DRUG ACTION
A selective serotonin 5-HT4-receptor agonist with prokinetic properties.

#### INDICATIONS AND DOSE
Chronic constipation in women when other laxatives fail to provide an adequate response

**BY MOUTH**
- Adult: 2 mg once daily, review treatment if no response after 4 weeks
- Elderly: Initially 1 mg once daily, increased if necessary to 2 mg once daily, review treatment if no response after 4 weeks

#### CONTRA-INDICATIONS
Crohn’s disease - intestinal obstruction - intestinal perforation - severe inflammatory conditions of the intestinal tract - toxic megacolon - ulcerative colitis

#### CAUTIONS
History of arrhythmias - history of ischaemic heart disease - severe, unstable chronic illness
INTERACTIONS Caution with concomitant use of drugs that prolong QT interval.

SIDE-EFFECTS
- Common or very common Abdominal pain · diarrhoea · dizziness · dyspepsia · fatigue · flatulence · gastro-intestinal symptoms · headache · nausea · polyuria · rectal bleeding · vomiting
- Uncommon Anorexia · fever · palpitation · tremor

SIDE-EFFECTS, FURTHER INFORMATION
Side-effects generally occur at the start of treatment and are usually transient.

CONCEPTION AND CONTRACEPTION Manufacturer recommends effective contraception during treatment.

PREGNANCY Manufacturer advises avoid.

BREAST FEEDING
Manufacturer advises avoid—present in milk.

HEPATIC IMPAIRMENT In severe impairment, initially 1 mg once daily, increased if necessary to 2 mg once daily.

RENAL IMPAIRMENT Max. 1 mg daily if eGFR less than 30 ml/minute/1.73 m².

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Prucalopride for the treatment of chronic constipation in women (December 2010) NICE TA211
Prucalopride is recommended as an option for the treatment of chronic constipation in women for whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered. If treatment with prucalopride is not effective after 4 weeks, the patient should be re-examined and the benefit of continuing treatment reconsidered.

Prucalopride should only be prescribed by a clinician with experience of treating chronic constipation, after careful review of the patient’s previous courses of laxative treatments. www.nice.org.uk/TA211

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2010) that prucalopride (Resolor®) is not recommended for use within NHS Scotland because weaknesses in the clinical data prevent an assessment of its efficacy in the target population.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Resolor (Shire Pharmaceuticals Ltd)
  Prucalopride (as Prucalopride succinate) 1 mg Resolor 1mg tablets | 28 tablet (Ref) £38.69 DT price = £38.69
  Prucalopride (as Prucalopride succinate) 2 mg Resolor 2mg tablets | 28 tablet (Ref) £59.52 DT price = £59.52

Arachis oil

INDICATIONS AND DOSE
To soften impacted faeces
BY RECTUM
- Adult: 130 mL as required

CAUTIONS
- Hypersensitivity to soya · intestinal obstruction
- Allergy and Cross-Sensitivity Contraindicated if history of hypersensitivity to arachis oil or peanuts.
- DIRECTIONS FOR ADMINISTRATION Warm enema in warm water before use.

SOFTENING DRUGS

Co-danthrusate

INDICATIONS AND DOSE
Constipation in terminally ill patients
BY MOUTH USING CAPSULES
- Child 6–11 years: 1 capsule once daily, to be taken at night
- Child 12–17 years: 1–3 capsules once daily, to be taken at night
- Adult: 1–3 capsules once daily, to be taken at night

BY MOUTH USING ORAL SUSPENSION
- Child 6–11 years: 5 mL once daily, to be taken at night
- Child 12–17 years: 5–15 mL once daily, to be taken at night
- Adult: 5–15 mL once daily, to be taken at night

Dose equivalence and conversion
Co-danthrusate suspension contains dantron 50 mg and docusate 60 mg per 5 mL.
Co-danthrusate capsules contain dantron 50 mg and docusate 60 mg per capsule.

CONTRA-INDICATIONS
Acute abdominal conditions (in children) · acute inflammatory bowel disease · acute surgical abdominal conditions (in adults) · intestinal obstruction · severe dehydration

CAUTIONS
Rodent studies indicate potential carcinogenic risk · excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia · may cause local irritation

CAUTIONS, FURTHER INFORMATION
Local irritation Avoid prolonged contact with skin (as in incontinent patients or infants wearing nappies—risk of irritation and excoriation).

SIDE-EFFECTS Abdominal cramp · urine may be coloured red

PREGNANCY Manufacturers advise avoid—limited information available.

BREAST FEEDING Manufacturer’s advise avoid—no information available.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS

CO-DANTHRUSATE (Non-proprietary)
- Dantron 50 mg, Docusate sodium 60 mg Co-danthrusate 50mg/60mg capsules | 63 capsule (Ref) £42.50 DT price = £42.50
- Normax (Galen Ltd)
  Dantron 50 mg, Docusate sodium 60 mg Normax capsules | 63 capsule (Ref) £42.50 DT price = £42.50

Oral suspension

CAUTIONARY AND ADVISORY LABELS

Normax (Focus Pharmaceuticals Ltd)
- Dantron 10 mg per 1 mL, Docusate sodium 12 mg per 1 mL Normax oral suspension (sugar-free) | 200 mL (Ref) £89.92 DT price = £89.92
52 Constipation and bowel cleansing

**STIMULANT LAXATIVES**

**Bisacodyl**

**INDICATIONS AND DOSE**

Constitution

**BY MOUTH**

- Child 4–17 years: 5–20 mg once daily, adjusted according to response, dose to be taken before noon and evening
- Adult: 5–10 mg once daily increased if necessary up to 20 mg once daily, dose to be taken at night

**BY RECTUM**

- Child 2–17 years: 5–10 mg once daily, adjusted according to response
- Adult: 10 mg once daily, dose to be taken in the morning

**Bowel clearance before radiological procedures and surgery**

**INITIALLY BY MOUTH**

- Adult: 10 mg twice daily, dose to be taken in the morning and evening on the day before procedure and (by rectum) 10 mg, to be administered 1–2 hours before procedure the following day

**PHARMACOKINETICS**

Tablets act in 10–12 hours; suppositories act in 20–60 minutes.

**CONTRA-INDICATIONS**

- Acute abdominal conditions (in children) - acute inflammatory bowel disease - acute surgical abdominal conditions (in adults) - intestinal obstruction - severe dehydration

**CAUTIONS**

- Excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia - risk of electrolyte imbalance with prolonged use (in children)

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Abdominal cramp - colitis - nausea - vomiting

**SPECIFIC SIDE-EFFECTS**

- With rectal use Local irritation
- **PREGNANCY** May be suitable for constipation in pregnancy, if a stimulant effect is necessary.

**MEDIcINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, enema, suppository

**Gastro-resistant tablet**

**CAUTIONARY AND ADVISORY LABELS** 5, 25

- **BISACODYL (Non-proprietary)**
  - Bisacodyl 5 mg Bisacodyl 5mg gastro-resistant tablets | 60 tablet  £3.25 DT price = £2.30 | 100 tablet  £3.83–£5.40 | 500 tablet  £25.73 | 1000 tablet  £51.45

- **Suppository**
  - **BISACODYL (Non-proprietary)**
    - Bisacodyl 10 mg Bisacodyl 10mg suppositories | 12 suppository  £3.53 DT price = £3.53
  - Brains may include Dulco-Lax tablets and suppositories.

**Co-danthramer**

**INDICATIONS AND DOSE**

Constipation in terminally ill patients (standard strength capsules)

**BY MOUTH USING CAPSULES**

- Child 6–11 years: 1 capsule once daily, dose should be taken at night
- Child 12–17 years: 1–2 capsules once daily, dose should be taken at night
- Adult: 1–2 capsules once daily, dose should be taken at night

---

**Docsolate sodium** (Diocyl sodium sulphosuccinate)

**INDICATIONS AND DOSE**

**Chronic constipation**

**BY MOUTH**

- Child 6 months–1 year: 12.5 mg 3 times a day, adjusted according to response, use paediatric oral solution
- Child 2–11 years: 12.5–25 mg 3 times a day, adjusted according to response, use paediatric oral solution
- Child 12–17 years: Up to 500 mg daily in divided doses, adjusted according to response
- Adult: Up to 500 mg daily in divided doses, adjusted according to response

**BY RECTUM**

- Adult: 120 mg for 1 dose

**Adjunct in abdominal radiological procedures**

**BY MOUTH**

- Adult: 400 mg, to be administered with barium meal

**BY RECTUM**

- Adult: 120 mg for 1 dose

**PHARMACOKINETICS**

Oral preparations act within 1–2 days; response to rectal administration usually occurs within 20 minutes.

- **UNLICENSED USE**
  - With oral use in children *Adult oral solution and capsules* not licensed for use in children under 12 years.
  - **CONTRA-INDICATIONS** Avoid in intestinal obstruction
  - **CAUTIONS** Do not give with liquid paraffin - excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia - rectal preparations not indicated if haemorrhoids or anal fissure
  - **SIDE-EFFECTS** Abdominal cramp - diarrhoea (excessive use) - hypokalaemia - rash
  - **PREGNANCY** Not known to be harmful — manufacturer advises caution.
  - **BREAST FEEDING**
    - With oral use Present in milk following oral administration — manufacturer advises caution.
    - With rectal use Rectal administration not known to be harmful.

- **DIRECTIONS FOR ADMINISTRATION**
  - With oral use in children For administration by mouth, solution may be mixed with milk or squash.

- **MEDIcINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Capsule**
    - Diocyl (UCB Pharma Ltd)
      - Docsolate sodium 100 mg Docsolate 100mg capsules | 30 capsule  £2.09 DT price = £2.09 | 100 capsule  £6.98
  - **Oral solution**
    - Docusol (Typharm Ltd)
      - Docsolate sodium 2.5 mg per 1 ml
        - Docsol Paediatric 12.5mg/5ml oral solution (sugar-free) | 300 ml  £5.29 DT price = £5.29
      - Docsolate sodium 10 mg per 1 ml
        - Docsol Adult 50mg/5ml oral solution (sugar-free) | 300 ml  £5.49 DT price = £5.49
  - **Enema**
    - Norgalax (Norgine Pharmaceuticals Ltd)
      - Docsolate sodium 12 mg per 1 gram
        - Norgalax 120mg/10g enema | 6 enema  £3.97

---

**Docusate sodium**

**Use)**

Adjunct in abdominal radiological procedures}

solution may be mixed with milk or squash.
### Glycerol (Glycerin)

**INDICATIONS AND DOSE**

**Constipation**

- **BY RECTUM**
  - Child 1-11 months: 1 g as required
  - Child 1-11 years: 2 g as required
  - Child 12-17 years: 4 g as required
  - Adult: 4 g as required

- **DIRECTIONS FOR ADMINISTRATION**
  - Moisten suppositories with water before insertion.

**PRESCRIBING AND DISPENSING INFORMATION**

When prepared extemporaneously, the BP states Glycerol Suppositories, BP consists of gelatin 140 mg, glycerol 700 mg, purified water to 1 g.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Glycerin (glycerol) suppositories for constipation [www.medicinesforchildren.org.uk/glycerin-glycerol-suppositories-for-constipation](http://www.medicinesforchildren.org.uk/glycerin-glycerol-suppositories-for-constipation)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Suppository**
  - Glycerol (Non-proprietary)
    - Gelatin 140 mg per 1 gram, Glycerol 700 mg per 1 gram
    - Glycerol 2g suppositories | 12 suppository [GSL £1.65 DT price = £1.53]
    - Glycerol 3g suppositories | 12 suppository [GSL £1.60 DT price = £0.88]
    - Glycerol 4g suppositories | 12 suppository [GSL £3.72 DT price = £1.94]

**Senna**

**INDICATIONS AND DOSE**

**Constipation**

- **BY MOUTH USING TABLETS**
  - Child 6-17 years: 1–4 tablets once daily, adjusted according to response
  - Adult: 2–4 tablets daily, dose usually taken at night; initial dose should be low then gradually increased

- **BY MOUTH USING SYRUP**
  - Child 1 month–3 years: 2.5–10 mL once daily, adjusted according to response
  - Child 4-17 years: 2.5–20 mL once daily, adjusted according to response
  - Adult: 10–20 mL once daily, dose usually taken at bedtime

**PHARMACOKINETICS**

Onset of action 8–12 hours.

- **UNLICENSED USE**
  - Tablets not licensed for use in children under 6 years. Syrup not licensed for use in children under 2 years.

- **CONTRA-INDICATIONS**
  - Intestinal obstruction

- **CAUTIONS**
  - Excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia

- **SIDE-EFFECTS**
  - Abdominal cramp

- **PREGNANCY**
  - May be suitable for constipation in pregnancy if a stimulant effect is necessary.

- **BREAST FEEDING**
  - Not known to be harmful.

- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: Senna for constipation [www.medicinesforchildren.org.uk/senna-for-constipation](http://www.medicinesforchildren.org.uk/senna-for-constipation)
Ispaghula husk with senna
The properties listed below are those particular to the combination only. For the properties of the components please consider, ispaghula husk p. 45, senna p. 53.

**INDICATIONS AND DOSE**

**Constipation**
- **BY MOUTH**
  - Child 12-17 years: 5–10 mL once daily, to be taken at night, 5 mL equivalent to one level teaspoonful of granules
  - Adult: 5–10 mL once daily, to be taken at night, 5 mL equivalent to one level teaspoonful of granules

**DIRECTIONS FOR ADMINISTRATION** Take at night with at least 150 mL water, fruit juice, milk or warm drink.

**PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer ispaghula with senna granules.

**MEDICINAL FORMS**

**Granules**
- **CAUTIONARY AND ADVISORY LABELS** 25
- **EXCIPIENTS:** May contain Sucrose
- **Manufacturers** (IATA Healthcare Ltd)
- Ispaghula 542 mg per 1 gram, Senna fruit 124 mg per 1 gram Manevac granules | 400 gram | £9.50 DT price = £9.50

**Sodium picosulfate** (Sodium picosulphate)

**INDICATIONS AND DOSE**

**Constipation**
- **BY MOUTH**
  - Child 1 month-3 years: 2.5–10 mg once daily, adjusted according to response
  - Child 4-17 years: 2.5–20 mg once daily, adjusted according to response
  - Adult: 5–10 mg once daily, dose to be taken at night

**PHARMACOKINETICS**
Onset of action 6–12 hours.

**UNLICENSED USE**
- In children Sodium picosulfate elixir, licensed for use in children (age range not specified by manufacturer).
- In adults Sodium picosulfate doses in BNF may differ from those in product literature.

**CONTRA-INDICATIONS** Avoid in intestinal obstruction - severe dehydration.

**CAUTIONS**
- Active inflammatory bowel disease (avoid if fulminant) - excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia
- **SIDE-EFFECTS** Abdominal cramp - nausea - vomiting

**BRAND FEEDING**
- Not known to be present in milk but manufacturer advises avoid unless potential benefit outweighs risk.

**PATIENT AND CARER ADVICE**
- Medicines for Children leaflet: Sodium picosulfate for constipation [www.medicinesforchildren.org.uk/sodium-picosulfate-for-constipation](http://www.medicinesforchildren.org.uk/sodium-picosulfate-for-constipation)

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**
- **SENNA (Non-proprietary)**
- Sennoside B (as Sennosides) 7.5 mg | Senna 7.5mg tablets | 20 tablet | £0.99 | 60 tablet | £12.25 DT price = £3.52
- Oral solution no price available DT price = £3.52 | 100 tablet | £2.10 | 1000 tablet no price available | 1000 tablet | £47.50

**3 Diarrhoea**

**Acute diarrhoea**
The priority in acute diarrhoea, as in gastro-enteritis, is the prevention or reversal of fluid and electrolyte depletion. This is particularly important in infants and in frail and elderly patients. **Oral rehydration preparations** are used in the prevention or reversal of fluid and electrolyte depletion. Severe depletion of fluid and electrolytes requires immediate admission to hospital and urgent replacement.

**Antimotility drugs**

**Antimotility drugs** relieve symptoms of acute diarrhoea. They are used in the management of uncomplicated acute diarrhoea in adults; fluid and electrolyte replacement may be necessary in case of dehydration. However, antimotility drugs are not recommended for acute diarrhoea in young children.

Antimotility drugs prolong the duration of intestinal transit by binding to opioid receptors in the gastrointestinal tract. Loperamide hydrochloride p. 56 does not cross the blood-brain barrier readily. Antimotility drugs have a role in the management of uncomplicated *acute diarrhoea* in adults but not in young children. However, in severe cases, fluid and electrolyte replacement are of primary importance.

Antimotility drugs have a role in Inflammatory bowel disease p. 32 and in Stoma care p. 83.

Loperamide hydrochloride p. 56 can be used for faecal incontinence [unlicensed indication] after the underlying cause of incontinence has been addressed.

**Antispasmodics**

Antispasmodics are occasionally of value in treating abdominal cramp associated with diarrhoea but they should not be used for primary treatment. Antispasmodics and antiemetics should be avoided in young children with gastro-enteritis because they are rarely effective and have troublesome side-effects.

**Antibacterial drugs**
Antibacterial drugs are generally unnecessary in simple gastro-enteritis because the complaint usually resolves quickly without them, and infective diarrhoeas in the UK often have a viral cause. Systemic bacterial infection does, however, need appropriate systemic treatment.
Ciprofloxacin p. 490 is occasionally used for prophylaxis against travellers’ diarrhoea, but routine use is not recommended. Lactobacillus preparations have not been shown to be effective.

**Adsorbsents and bulk-forming drugs**

Adsorbsents such as kaolin p. 57 are not recommended for *acute diarrhoeas*. Bulk-forming drugs, such as ispaghula husk p. 45, methylcellulose p. 45, and stercula p. 46 are useful in controlling diarrhoea associated with diverticular disease.

Co-phenotrope p. 173 binds unabsorbed bile salts and provides symptomatic relief of diarrhoea following ileal disease or resection.

**Enkephalinase inhibitors**

Racecadotril p. 57 is a pro-drug of thiorphan. Thiorphan is an enkephalinase inhibitor that inhibits the breakdown of endogenous opioids, thereby reducing intestinal secretions. Racecadotril is licensed, as an adjunct to rehydration, for the symptomatic treatment of un-complicated acute diarrhoea; it should only be used in children over 3 months of age when usual supportive measures, including oral rehydration, are insufficient to control the condition. Racecadotril does not affect the duration of intestinal transit.

**Antimotility drugs**

### Co-phenotrope

**INDICATIONS AND DOSE**

**Adjunct to rehydration in acute diarrhoea**

**BY MOUTH**

- Child 4-8 years: 1 tablet 3 times a day
- Child 9-11 years: 1 tablet 4 times a day
- Child 12-15 years: 2 tablets 3 times a day
- Child 16-17 years: Initially 4 tablets, followed by 2 tablets every 6 hours until diarrhoea controlled
- Adult: Initially 4 tablets, followed by 2 tablets every 6 hours until diarrhoea controlled

**Control of faecal consistency after colostomy or ileostomy**

**BY MOUTH**

- Child 4-8 years: 1 tablet 3 times a day
- Child 9-11 years: 1 tablet 4 times a day
- Child 12-15 years: 2 tablets 3 times a day
- Child 16-17 years: Initially 4 tablets, then 2 tablets 4 times a day
- Adult: Initially 4 tablets, then 2 tablets 4 times a day

**UNLICENSED USE** Not licensed for use in children under 4 years.

**CONTRA-INDICATIONS** Gastro-intestinal obstruction - intestinal atony - myasthenia gravis (but some antimuscarinics may be used to decrease muscarinic side-effects of anticholinesterases) - paralytic ileus - prostatic enlargement (in adults) - pyloric stenosis - severe ulcerative colitis - significant bladder outflow obstruction - toxic megacolon - urinary retention

**CAUTIONS** Presence of subclinical doses of atropine may give rise to atropine side-effects in susceptible individuals or in overdosage - young children are particularly susceptible to overdosage; symptoms may be delayed and observation is needed for at least 48 hours after ingestion

**INTERACTIONS** » Appendix 1 (antimuscarinics, opioid analgesics).

**SIDE-EFFECTS**

- Very rare Angle-closure glaucoma
- Frequency not known Abdominal pain - anorexia - confusion (particularly in the elderly) - constipation - dilution of the pupils with loss of accomodation - dry mouth - dryness of the skin - fever - flushing - giddiness - nausea - photophobia - reduced bronchial secretions - transient bradycardia (followed by tachycardia, palpitation and arrhythmias) - urinary retention - urinary urgency - vomiting

**PREGNANCY** Manufacturer advises caution.

**BREAST FEEDING** May be present in milk.

**HEPATIC IMPAIRMENT** Avoid in jaundice.

**DIRECTIONS FOR ADMINISTRATION** For administration by mouth tablets may be crushed.

**PRESCRIBING AND DISPENSING INFORMATION** A mixture of diphenoxylate hydrochloride and atropine sulfate in the mass proportions 100 parts to 1 part respectively.

**EXCEPTIONS TO LEGAL CATEGORY** Co-phenotrope 2.5/0.025 can be sold to the public for adults and children over 16 years (provided packs do not contain more than 20 tablets) as an adjunct to rehydration in acute diarrhoea (max. daily dose 10 tablets).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

### Tablet

- **CO-PHENOTROPE (Non-proprietary)**
  - Atropine sulfate 25 microgram, Diphenoxylate hydrochloride 2.5 mg
  - Price = £74/100 tablets
  - Schedule 74 DT price = £10.74

### Kaolin with morphine

**INDICATIONS AND DOSE**

**Acute diarrhoea**

**BY MOUTH**

- Adult: 10 mL every 6 hours, dose to be given in water

**CONTRA-INDICATIONS** Acute abdomen - delayed gastric emptying - heart failure secondary to chronic lung disease - phaeochromocytoma

**CAUTIONS** Cardiac arrhythmias - pancreatitis - severe cor pulmonale


**BREAST FEEDING** Therapeutic doses unlikely to affect infant.

**RENAI IMPAIRMENT** Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Kaolin and Morphine Mixture, BP consists of light kaolin or light kaolin (natural) 20%, sodium bicarbonate 5%, and chloroform and morphine tincture 4% in a suitable vehicle. Contains anhydrous morphine 550–800 micrograms/10 mL.

**LESS SUITABLE FOR PRESCRIBING** Kaolin and Morphine Mixture, BP (Kaolin and Morphine Oral Suspension) is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
### Loperamide hydrochloride

**INDICATIONS AND DOSE**

**Symptomatic treatment of acute diarrhoea**

- **BY MOUTH**
  - Child 4–7 years: 1 mg 3–4 times a day for up to 3 days only
  - Child 8–11 years: 2 mg 4 times a day for up to 5 days
  - Child 12–17 years: Initially 4 mg, followed by 2 mg for up to 5 days, dose to be taken after each loose stool; usual dose 6–8 mg daily; maximum 16 mg per day
  - Adult: Initially 4 mg, followed by 2 mg for up to 5 days, dose to be taken after each loose stool; usual dose 6–8 mg daily; maximum 16 mg per day

**Chronic diarrhoea**

- **BY MOUTH**
  - Adult: Initially 4–8 mg daily in divided doses, adjusted according to response; maintenance up to 16 mg daily in 2 divided doses

**Faecal incontinence**

- **BY MOUTH**
  - Adult: Initially 500 micrograms daily, adjusted according to response, maximum daily dose to be given in divided doses; maximum 16 mg per day

**Pain of bowel colic in palliative care**

- **BY MOUTH**
  - Adult: 2–4 mg 4 times a day

**UNLICENSED USE** Capsules not licensed for use in children under 8 years. Syrup not licensed for use in children under 4 years.

**CONTRA-INDICATIONS** Active ulcerative colitis - antibiotic-associated colitis - conditions where abdominal distension develops - conditions where inhibition of peristalsis should be avoided

**CAUTIONS** Not recommended for children under 12 years

**INTERACTIONS** → Appendix 1 (loperamide).

**SIDE-EFFECTS**

- Common or very common: Dizziness, flatulence, headache, nausea

- Uncommon: Abdominal pain, drowsiness, dry mouth, dyspepsia, rash, vomiting

- Rare: Fatigue, hypertension, paralytic ileus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention

**PREGNANCY** Manufacturers advise avoid—no information available.

**BREAST FEEDING** Amount probably too small to be harmful.

**HEPATIC IMPAIRMENT** Risk of accumulation—manufacturer advises caution.

**PATIENT AND CARER ADVICE**


**EXCEPTIONS TO LEGAL CATEGORY** Loperamide can be sold to the public, provided it is licensed and labelled for the treatment of acute diarrhoea associated with irritable bowel syndrome (after initial diagnosis by a doctor) in adults over 18 years of age.

---

Loperamide can be sold to the public, for use in adults and children over 12 years, provided it is licensed and labelled for the treatment of acute diarrhoea.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Loperamide hydrochloride (non-proprietary)**
  - Loperamide hydrochloride 2 mg tablets | 30 tablet | £2.15 DT price = £2.15

**Orodispersible tablet**

- **Imodium (McNeil Products Ltd)**
  - Loperamide hydrochloride 2 mg | Imodium Instant Melts 2 mg | orodispersible tablets (sugar-free) | 12 tablet | £3.75 (sugar-free) | 18 tablet | £5.02

**Capsule**

- **Loperamide hydrochloride (non-proprietary)**
  - Loperamide hydrochloride 2 mg | Loperamide 2mg capsules | 6 capsule | £3.15 | 10 capsule | £4.76 | 12 capsule | £1.94 | 30 capsule | £3.19 DT price = £3.19

- **Imodium (McNeil Products Ltd)**
  - Loperamide hydrochloride 2 mg | Imodium IBS Relief 2 mg | capsules | 6 capsule | £2.23 | 12 capsule | £3.79

- **Imodium 2mg Soft capsules**
  - 12 capsule | £3.79

- **Imodium Classic 2mg capsules**
  - 12 capsule | £3.31 | 18 capsule | £4.13

**Oral solution**

- **Imodium (Janssen-Cilag Ltd)**
  - Loperamide hydrochloride 200 microgram per 1 ml | Imodium 1mg/5ml oral solution (sugar-free) | 100 ml | £1.17 DT price = £1.17

**Oral lypophilisate**

- **Imodium (McNeil Products Ltd)**
  - Loperamide hydrochloride 2 mg | Imodium Instant 2mg oral lypophilisates (sugar-free) | 6 tablet | £2.45 (sugar-free) | 12 tablet | £3.76

---

Loperamide with simeticone

The properties listed below are those particular to the combination only. For the properties of the components please consider, loperamide hydrochloride above, simeticone p. 60.

**INDICATIONS AND DOSE**

**Acute diarrhoea with abdominal colic**

- **INITIALLY BY MOUTH**
  - Child 12–17 years: Initially 1 tablet, then (by mouth) 1 tablet, after each loose stool, for up to 2 days; maximum 4 tablets per day

- Adult: Initially 2 tablets, then (by mouth) 1 tablet, after each loose stool, (by mouth) for up to 2 days; maximum 4 tablets per day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Imodium Plus (McNeil Products Ltd)**
  - Loperamide hydrochloride 2 mg, Dimeticon (as Simeticone) | 125 mg | Imodium Plus caplets | 12 tablet | £3.66
ENKEPHALINASE INHIBITORS

Racecadotril

**INDICATIONS AND DOSE**

Adjunct to rehydration, for the symptomatic treatment of uncomplicated acute diarrhoea

**BY MOUTH**

- Child 3 months–17 years (body-weight up to 9 kg): 10 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days
- Child 3 months–17 years (body-weight 9–13 kg): 20 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days
- Child 3 months–17 years (body-weight 13–27 kg): 30 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days
- Child 3 months–17 years (body-weight 28 kg and above): 60 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days
- Adult: Initially 100 mg, then 100 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days, dose to be taken preferably before food

**SIDE-EFFECTS**

- Common or very common: Headache
- Uncommon: Rash

**PREGNANCY**

Manufacturer advises avoid—no information available.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

- In adults: Manufacturer advises caution.
- In children: Manufacturer advises avoid.

**RENAL IMPAIRMENT**

- In adults: Manufacturer advises caution.
- In children: Manufacturer advises avoid.

**DIRECTIONS FOR ADMINISTRATION**

Granules may be added to food or mixed with water or bottle feeds and then taken immediately.

**PATIENT AND CARER ADVICE**

Patients and carers should be given advice on how to administer racecadotril granules.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium, has advised (July 2014) that racecadotril (Hidrasec®) is not recommended for use within NHS Scotland for the treatment of acute diarrhoea in children because there is insufficient evidence that it improves the recovery rate.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- Hidrasec (Lincoln Medical Ltd)
- Racecadotril 100 mg Hidrasec 100mg capsules | 20 capsule (£8.42

**Granules**

EXCipients: May contain Sucrose

- Hidrasec (Lincoln Medical Ltd)
- Racecadotril 10 mg Hidrasec Infants 10mg granules sachets | 20 sachet (£8.42
- Racecadotril 30 mg Hidrasec Children 30mg granules sachets | 20 sachet (£8.42

INTESTINAL ADSORBENTS

Kaolin

**INDICATIONS AND DOSE**

Diarrhoea (not recommended for acute diarrhoea)

**BY MOUTH**

- Adult: 10–20 mL every 4 hours

**INTERACTIONS**

- Appendix 1 (kaolin).

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral liquid formulations may include peppermint. When prepared extemporaneously, the BP states Kaolin Mixture, BP consists of light kaolin or light kaolin (natural) 20%, light magnesium carbonate 5%, sodium bicarbonate 5% in a suitable vehicle with a peppermint flavour.

**LESS SUITABLE FOR PRESCRIBING**

Kaolin Mixture BP is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- KAOLIN (Non-proprietary)
  - Kaolin light 200 mg per 1 ml, Magnesium carbonate light 50 mg per 1 ml, Sodium bicarbonate 50 mg per 1 ml | 80 ml (£6.50 DT price = £0.86
  - Kaolin mixture 200 mg per 1 gram | 100 ml (£0.78 DT price = £0.78

4 Disorders of gastric acid and ulceration

4.1 Dyspepsia

**Dyspepsia**

Dyspepsia covers upper abdominal pain, fullness, early satiety, bloating, and nausea. It can occur with gastric and duodenal ulceration and, gastric cancer, but most commonly it is of uncertain origin.

Urgent endoscopic investigation is required if dyspepsia is accompanied by ‘alarm features’ (e.g. bleeding, dysphagia, recurrent vomiting, or weight loss). Urgent investigation should also be considered for patients over 55 years with unexplained, recent-onset dyspepsia that has not responded to treatment.

Patients with dyspepsia should be advised about lifestyle changes (avoidance of excess alcohol and of aggravating foods such as fats); other measures include weight reduction, smoking cessation, and raising the head of the bed. Some medications may cause dyspepsia—these should be stopped, if possible.

Antacids may provide some symptomatic relief, however if symptoms persist in uninvestigated dyspepsia, treatment involves a proton pump inhibitor for up to 4 weeks. A proton pump inhibitor can be used intermittently to control symptoms long term. Patients with uninvestigated dyspepsia, who do not respond to an initial trial with a proton pump inhibitor, should be tested for Helicobacter pylori and given eradication therapy if H. pylori is present. Alternatively, particularly in populations where H. pylori infection is more likely, the ‘test and treat’ strategy for H. pylori can be used before a trial with a proton pump inhibitor.

If H. pylori is present in patients with functional (investigated, non-ulcer) dyspepsia, eradication therapy should be provided. If symptoms persist, treatment with
either a proton pump inhibitor or a histamine H₂-receptor antagonist can be given for 4 weeks. These antisecretory drugs can be used intermittently to control symptoms long term. However, most patients with functional dyspepsia do not benefit symptomatically from H. pylori eradication therapy or antisecretory drugs.

### Alginate

#### Indications and dose

**Gaviscon infant® powder sachets**

Management of gastro-oesophageal reflux disease

- **By mouth**
  - Infant: 12–24 months: 1 dose as required, to be mixed with feeds (or water, for breast-fed infants); maximum 6 doses per day
  - Child 1 month–2 years: 1 dose as required, to be mixed with feeds (or water, for breast-fed infants); maximum 12 doses per day

#### Contra-indications

- Intestinal obstruction - preterm neonates - where excessive water loss likely (e.g. fever, diarrhoea, vomiting, high room temperature)
- Interactions: Appendix 1 (antacids).
- Not to be used with other preparations containing thickening agents.
- Antacids should preferably not be taken at the same time as other drugs since they may impair absorption.
- Antacids may damage enteric coatings designed to prevent dissolution in the stomach.

#### Hepatic impairment

In patients with fluid retention, avoid antacids containing large amounts of sodium. Avoid antacids containing magnesium salts in hepatic coma if there is a risk of renal failure.

#### Renal impairment

In patients with fluid retention, avoid antacids containing large amounts of sodium.

#### Prescribing and dispensing information

- Each half of the dual-sachet is identified as ‘one dose’. To avoid errors prescribe with directions in terms of ‘dose’.
- There can be variation in the licensing of different medicines containing the same drug.

**Powder**

- **Electrolytes**: May contain Sodium
  - Gaviscon infant (Forum Health Products Ltd)
  - Magnesium alginate 825 mg, Sodium alginate 225 mg Gaviscon infant oral powder sachets (sugar-free) 15 dual dose sachet £3.99

### Calcium carbonate with sodium alginate and sodium bicarbonate

The properties listed below are those particular to the combination only. For the properties of the components please consider, alginic acid above.

#### Indications and dose

**Mild symptoms of gastro-oesophageal reflux disease**

- **By mouth**
  - Child 6–11 years: 5–10 mL, to be taken after meals and at bedtime
  - Child 12–17 years: 10–20 mL, to be taken after meals and at bedtime
  - Adult: 20–40 mL, to be taken after meals and at bedtime

#### Prescribing and dispensing information

- Flavours of oral liquid formulations may include aniseed or peppermint.

#### Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

**Chewable tablet**

- **Excipients**: May contain Aspartame
- **Electrolytes**: May contain Potassium, sodium
  - Potassium bicarbonate sodium alginate (non-proprietary)
    - Potassium bicarbonate 100 mg, Sodium alginate 500mg / Potassium bicarbonate 100mg chewable tablets sugar free (sugar-free) 60 tablet £6.05 no price available
  - Brands may include Gaviscon Advance

**Oral suspension**

- **Electrolytes**: May contain Potassium, sodium
  - Gaviscon advance (Reckitt Benckiser Healthcare (UK) Ltd)
    - Potassium bicarbonate 20 mg per 1 mL, Sodium alginate 100 mg per 1 mL Gaviscon advance oral suspension aniseed (sugar-free) 150 mL £3.23 (sugar-free) 250 mL £5.56 (sugar-free) 300 mL £5.82 (sugar-free) 500 mL £9.12 DT price = £5.12
Antacids

Antacids (usually containing aluminium or magnesium compounds) can often relieve symptoms in ulcer dyspepsia and in non-erosive gastro-oesophageal reflux; they are also sometimes used in functional (non-ulcer) dyspepsia but the evidence of benefit is uncertain. Antacids are best given when symptoms occur or are expected, usually between meals and at bedtime, although additional doses may be required. Conventional doses of liquid magnesium–aluminium antacids promote ulcer healing, but less well than antacids also containing bismuth; they tend to be constipating. They are recommended because absorbed bismuth can be neurotoxic, and prolonged high doses also cause hypophosphataemia and alkalosis, and can precipitate the milk-alkali syndrome. These colonic side-effects are less likely with less bismuth-containing antacids. The acid-neutralising capacity of preparations that contain more than one antacid may be the same as simpler antacids (e.g. aluminium hydroxide p. 859, and magnesium carbonate p. 60, hydroxide and magnesium trisilicate p. 61), being relatively insoluble in water, are long-acting if retained in the gastrointestinal tract. They are suitable for most antacid purposes. Magnesium-containing antacids tend to be laxative whereas aluminium-containing antacids may be constipating; antacids containing both magnesium and aluminium may reduce these colonic side-effects. Aluminium accumulation does not appear to be a risk if renal function is normal. The acid-neutralising capacity of preparations that contain more than one antacid may be the same as simpler preparations. Complexes such as hydrotalcite confer no special advantage.

Sodium bicarbonate p. 848 should no longer be prescribed alone for the relief of dyspepsia but it is present as an ingredient in many indigestion remedies. However, it retains a place in the management of urinary-tract disorders and acidosis.

Bismuth-containing antacids (unless chelates) are not recommended because absorbed bismuth can be neurotoxic, causing encephalopathy; they tend to be constipating.

Calcium-containing antacids can induce rebound acid secretion: with modest doses the clinical significance is doubtful, but prolonged high doses also cause hypercalcaemia and alkalosis, and can precipitate the milk-alkali syndrome.

Simeticone

Simeticone p. 60 (activated dimeticone) is added to an antacid as an antifoaming agent to relieve flatulence. These preparations may be useful for the relief of hiccup in palliative care.

Alginates

Alginates taken in combination with an antacid increases the viscosity of stomach contents and can protect the oesophageal mucosa from acid reflux. Some alginate-containing preparations form a viscous gel (‘raft’) that floats on the surface of the stomach contents, thereby reducing symptoms of reflux.

The amount of additional ingredient or antacid in individual preparations varies widely, as do their sodium content, so that preparations may not be freely interchangeable.

Co-magaldrox

The properties listed below are those particular to the combination only. For the properties of the components please consider, aluminium hydroxide p. 859, magnesium hydroxide p. 46.
**Disorders of gastric acid and ulceration**

**Gastro-intestinal system**

- **HEPATIC IMPAIRMENT** Avoid; can cause constipation which can precipitate coma. Avoid in hepatic coma; risk of renal failure.
- **RENAL IMPAIRMENT** Antacids containing magnesium salts should be avoided or used at a reduced dose because there is an increased risk of toxicity.
  - In adults There is a risk of accumulation and aluminium toxicity with antacids containing aluminium salts. Absorption of aluminium from aluminium salts is increased by citrates, which are contained in many effervescent preparations (such as effervescent analgesics).
  - In children Aluminium-containing antacids should not be used in children with renal impairment, because accumulation may lead to increased plasma-aluminium concentrations.
- **PRESCRIBING AND DISPENSING INFORMATION** Altacite Plus® is low in Na⁺.

**Magnesium carbonate**

**INDICATIONS AND DOSE**

**Dyspepsia**

**BY MOUTH USING ORAL SUSPENSION**

- Adult: 10 ml 3 times a day, dose to be taken in water

**CONTRA-INDICATIONS** Hypophosphataemia

**INTERACTIONS** → Appendix 1 (antacids).

Antacids should preferably not be taken at the same time as other drugs since they may impair absorption. Antacids may damage enteric coatings designed to prevent dissolution in the stomach.

**SIDE-EFFECTS** Belching due to liberated carbon dioxide - diarrhoea

**HEPATIC IMPAIRMENT** In patients with fluid retention, avoid antacids containing large amounts of sodium. Avoid antacids containing magnesium salts in hepatic coma if there is a risk of renal failure.

**RENAL IMPAIRMENT** Avoid or use at a reduced dose; increased risk of toxicity. Magnesium carbonate mixture has a high sodium content; avoid in patients with fluid retention.

**PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Aromatic Magnesium Carbonate Mixture, BP consists of light magnesium carbonate 3%, sodium bicarbonate 5%, in a suitable vehicle containing aromatic cardamom tincture.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule

- **Magnesite** (Ennogen Healthcare Ltd)
  - Magnesium carbonate heavy 500 mg Magnesite 500 mg capsules | 30 capsule £9.20

Also available in combination with calcium acetate, p. 61 - magnesium trisilicate and sodium bicarbonate, p. 61

**DEFOAMING DRUGS**

**Simeticone**

(Activated dimeticone)

**DRUG ACTION** Simeticone (activated dimeticone) is an antifoaming agent.

**INDICATIONS AND DOSE**

**INFACOL®**

- Colic | Wind pains
- **BY MOUTH**
  - Child 1 month-1 year: 0.5–1 mL, to be taken before feeds

**DENTINOX®**

- Colic | Wind pains
- **BY MOUTH**
  - Child 1 month-1 year: 2.5 mL, to be taken with or after each feed; may be added to bottle feed; maximum 6 doses per day

**PATIENT AND CARER ADVICE**

INFACOL®

Patients or carers should be given advice on use of the Infacol® dropper.

**LESS SUITABLE FOR PRESCRIBING**

INFACOL®

Infacol® is less suitable for prescribing (evidence of benefit in infantile colic uncertain).

DENTINOX®

Dentinox® colic drops are less suitable for prescribing (evidence of benefit in infantile colic uncertain).

**Aluminium hydroxide with magnesium hydroxide and simeticone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, aluminium hydroxide p. 859, simeticone above.

**INDICATIONS AND DOSE**

**Dyspepsia**

**BY MOUTH**

- Child 12-17 years: 5–10 mL 4 times a day, to be taken after meals and at bedtime, or when required
- Adult: 5–10 mL 4 times a day, to be taken after meals and at bedtime, or when required

**PRESCRIBING AND DISPENSING INFORMATION**

Maalox Plus® is low Na⁺.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- **Maalox Plus®** (Sanofi)
  - Aluminium hydroxide gel dried 44 mg per 1 mL, Magnesium hydroxide 39 mg per 1 mL, Simeticone 5 mg per 1 mL Maalox Plus oral suspension (sugar-free) | 500 ml GSK £3.90
Magnesium trisilicate

**INDICATIONS AND DOSE**

**Dyspepsia**

*By mouth using chewable tablets*

- **Adult**: 1–2 tablets as required

- **CONTRA-INDICATIONS** Hypophosphataemia
- **INTERACTIONS** → Appendix 1 (antacids). Antacids should preferably not be taken at the same time as other drugs since they may impair absorption. Antacids may damage enteric coatings designed to prevent dissolution in the stomach.
- **SIDE-EFFECTS** Belching due to liberated carbon dioxide - diarrhoea - silica-based renal stones (with long-term treatment)
- **HEPATIC IMPAIRMENT** Avoid in hepatic coma; risk of renal failure.
- **RENAL IMPAIRMENT** Avoid or used at a reduced dose (increased risk of toxicity).
- **MEDICINAL FORMS** Medicines not identified.

Magnesium carbonate with magnesium trisilicate and sodium bicarbonate

The properties listed below are those particular to the combination only. For the properties of the components please consider, magnesium carbonate p. 60, magnesium trisilicate above, sodium bicarbonate p. 848.

**INDICATIONS AND DOSE**

**Dyspepsia**

- **Child 5-11 years**: 5–10 mL 3 times a day or as required, dose to be made up with water
- **Child 12-17 years**: 10–20 mL 3 times a day or as required, dose to be made up with water
- **Adult**: 10–20 mL 3 times a day or as required, dose to be made up with water

- **HEPATIC IMPAIRMENT** In patients with fluid retention avoid antacids containing large amounts of sodium. Avoid antacids containing magnesium salts in hepatic coma if there is a risk of renal failure.
- **RENAL IMPAIRMENT** Magnesium trisilicate mixture has a high sodium content; avoid in patients with fluid retention.
- **PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Magnesium Trisilicate Mixture, BP consists of 5% each of magnesium trisilicate, light magnesium carbonate, and sodium bicarbonate in a suitable vehicle with a peppermint flavour.
- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

<table>
<thead>
<tr>
<th>Magnesium Carbonate with Magnesium Trisilicate and Sodium Bicarbonate (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium Carbonate light 50 mg per 1 mL, Magnesium trisilicate 50 mg per 1 mL, Sodium Bicarbonate 50 mg per 1 mL</td>
</tr>
</tbody>
</table>

4.2 Gastric and duodenal ulceration

**Peptic ulceration**

Peptic ulceration commonly involves the stomach, duodenum, and lower oesophagus; after gastric surgery it involves the gastro-enterostomy stoma. Healing can be promoted by general measures, stopping smoking and taking antacids and by antisecretory drug treatment, but relapse is common when treatment ceases. Nearly all duodenal ulcers and most gastric ulcers not associated with NSAIDs are caused by *Helicobacter pylori*.

**Helicobacter pylori infection**

Eradication of *Helicobacter pylori* reduces recurrence of gastric and duodenal ulcers and the risk of rebleeding. It also causes regression of most localised gastric mucosa associated lymphoid-tissue (MALT) lymphomas. The presence of *H. pylori* should be confirmed before starting eradication treatment. Acid inhibition combined with antibacterial treatment is highly effective in the eradication of *H. pylori*; re-infection is rare. Antibiotic associated colitis is an uncommon risk.

For initial treatment, a one-week triple-therapy regimen that comprises a proton pump inhibitor, clarithromycin p. 470, and *either* amoxicillin p. 482 or metronidazole p. 475 can be used. However, if a patient has been treated with metronidazole for other infections, a regimen containing a proton pump inhibitor, amoxicillin and clarithromycin is preferred for initial therapy. If a patient has been treated with a macrolide for other infections, a regimen containing a proton pump inhibitor, amoxicillin and metronidazole is preferred for initial therapy. These regimens eradicate *H. pylori* in about 85% of cases. There is usually no need to continue antisecretory treatment (with a proton pump inhibitor or H₂-receptor antagonist), however, if the ulcer is large, or complicated by haemorrhage or perforation, then antisecretory treatment is continued for a further 3 weeks. Treatment failure usually indicates antibacterial resistance or poor compliance. Resistance to amoxicillin is rare. However, resistance to clarithromycin and metronidazole is common and can develop during treatment.

Two-week triple-therapy regimens offer the possibility of higher eradication rates compared to one-week regimens, but adverse effects are common and poor compliance is likely to offset any possible gain.

Two-week dual-therapy regimens using a proton pump inhibitor and a single antibacterial are licensed, but produce low rates of *H. pylori* eradication and are not recommended.

Tinidazole p. 476 is also used occasionally for *H. pylori* eradication as an alternative to metronidazole; tinidazole should be combined with antisecretory drugs and other antibiotics.

Routine retesting, to confirm eradication, is not necessary unless the patient has gastric MALT lymphoma or complicated *H. pylori* associated peptic ulcer.

A two-week regimen comprising a proton pump inhibitor *plus* tripotassium dicitratobismuthate p. 63, *plus* tetracycline p. 496, *plus* metronidazole can be used for eradication failure. Alternatively, the patient can be referred for endoscopy and treatment based on the results of culture and sensitivity testing.

See under NSAID-associated ulcers for the role of *H. pylori* eradication therapy in patients starting or taking a NSAID.

Also see Dyspepsia p. 57 for *H. pylori* eradication in patients with dyspepsia.
Gastro-intestinal system

Overall risk of ulceration.

The most rapid healing; alternatively, the ulcer can be discontinued

The age

Children is available (Helicobacter Test INFAI for children of the age 3–11). However, the appropriateness of testing for H. pylori infection in children has not been established.

NSAID-associated ulcers

Gastro-intestinal bleeding and ulceration can occur with NSAID use. The risk of serious upper gastro-intestinal side-effects varies between individual NSAIDs. Whenever possible, the NSAID should be withdrawn if an ulcer occurs.

Patients at high risk of developing gastro-intestinal complications with a NSAID include those aged over 65 years, those with a history of peptic ulcer disease or serious gastro-intestinal complication, those taking other medicines that increase the risk of gastro-intestinal side-effects, or those with serious co-morbidity (e.g., cardiovascular disease, diabetes, renal or hepatic impairment). In those at risk of ulceration, a proton pump inhibitor can be considered for protection against gastric and duodenal ulcers associated with non-selective NSAIDs; a H₂-receptor antagonist such as ranitidine p. 65 given at twice the usual dose or misoprostol p. 710 are alternatives.

Colic and diarrhoea may limit the dose of misoprostol. Its use is most appropriate for the frail or very elderly from whom NSAIDs cannot be withdrawn. A combination of a cyclo-oxygenase-2 selective inhibitor with a proton pump inhibitor may be more appropriate for those with a history of upper gastro-intestinal bleeding or 3 or more risk factors for gastro-intestinal ulceration, but see NSAIDs and Cardiovascular Events.

NSAID use and H. pylori infection are independent risk factors for gastro-intestinal bleeding and ulceration. In patients already taking a NSAID, eradication of H. pylori is unlikely to reduce the risk of NSAID-induced bleeding or ulceration. However, in patients with dyspepsia or a history of gastric or duodenal ulcer, who are H₂-positives, and who are about to start long-term treatment with a non-selective NSAID, eradication of H. pylori may reduce the overall risk of ulceration.

In a patient who has developed an ulcer, if the NSAID can be discontinued, a proton pump inhibitor usually produces the most rapid healing; alternatively, the ulcer can be treated with a H₂-receptor antagonist or misoprostol p. 710.

On healing, patients should be tested for H. pylori and given eradication therapy if H. pylori is present (see also Test for Helicobacter pylori).

If treatment with a non-selective NSAID needs to continue, the following options are suitable:

- Treat ulcer with a proton pump inhibitor and on healing continue the proton pump inhibitor (dose not normally reduced because asymptomatic ulcer recurrence may occur);
- Treat ulcer with a proton pump inhibitor and on healing switch to misoprostol for maintenance therapy (colic and diarrhoea may limit the dose of misoprostol);
- Treat ulcer with a proton pump inhibitor and switch non-selective NSAID to a cyclo-oxygenase-2 selective inhibitor, but see NSAIDs and Cardiovascular Events; on healing, continuation of the proton pump inhibitor in patients with a history of upper gastro-intestinal bleeding may provide further protection against recurrence.

If treatment with a cyclo-oxygenase-2 selective inhibitor needs to continue, treat ulcer with a proton pump inhibitor; on healing continuation of the proton pump inhibitor in patients with a history of upper gastro-intestinal bleeding may provide further protection against recurrence.

GASTROPROTECTIVE COMPLEXES AND CHELATORS

Chelates and complexes

Tripotassium dichromatobismuthate p. 63 is a bismuth chelate effective in healing gastric and duodenal ulcers. See under Peptic ulceration p. 61 for the role of tripotassium dichromatobismuthate p. 63 in a Helicobacter pylori eradication regimen for those who have not responded to first-line regimens.

The bismuth content of tripotassium dichromatobismuthate p. 63 is low but absorption has been reported; encephalopathy (described with higher dose bismuth preparations) has not been reported.

Sucralfate p. 65 may act by protecting the mucosa from acid-pepsin attack in gastric and duodenal ulcers. It is a complex of aluminium hydroxide and sulfated sucrose but has minimal antacid properties.

Recommended regimens for Helicobacter pylori eradication

<table>
<thead>
<tr>
<th>Acid suppressant</th>
<th>Antibacterial</th>
<th>Price for 7-day course</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amoxicillin</td>
<td>Clarithromycin</td>
</tr>
<tr>
<td>Esomeprazole 20 mg</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
</tr>
<tr>
<td>twice daily</td>
<td></td>
<td>250 mg twice daily</td>
</tr>
<tr>
<td>Lansoprazole 30 mg</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
</tr>
<tr>
<td>twice daily</td>
<td>1 g twice daily</td>
<td>250 mg twice daily</td>
</tr>
<tr>
<td>Omeprazole 20 mg</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
</tr>
<tr>
<td>twice daily</td>
<td>500 mg 3 times a day</td>
<td>250 mg twice daily</td>
</tr>
<tr>
<td>Pantoprazole 40 mg</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
</tr>
<tr>
<td>twice daily</td>
<td></td>
<td>250 mg twice daily</td>
</tr>
<tr>
<td>Rabeprozole sodium 20</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
</tr>
<tr>
<td>mg twice daily</td>
<td></td>
<td>250 mg twice daily</td>
</tr>
</tbody>
</table>

Test for Helicobacter pylori

¹³C-Urea breath test kits are available for the diagnosis of gastro-duodenal infection with Helicobacter pylori. The test involves collection of breath samples before and after ingestion of an oral solution of ¹³C-Urea; the samples are sent for analysis by an appropriate laboratory. The test should not be performed within 4 weeks of treatment with an antibacterial or within 2 weeks of treatment with an antisecretory drug. A specific ¹³C-Urea breath test kit for children is available (Helicobacter Test INFAI for children of the age 3–11). However, the appropriateness of testing for H. pylori infection in children has not been established.
Sucralfate

**INDICATIONS AND DOSE**

**Benign gastric ulceration | Benign duodenal ulceration**

**BY MOUTH**

- Child 15-17 years: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day
- Adult: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day

**Chronic gastritis**

**BY MOUTH**

- Child 15-17 years: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day
- Adult: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day

**Prophylaxis of stress ulceration in child under intensive care**

**BY MOUTH**

- Child 15-17 years: 1 g 6 times a day; maximum 8 g per day

**Prophylaxis of stress ulceration**

**BY MOUTH**

- Adult: 1 g 6 times a day; maximum 8 g per day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, cream, powder, enema

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 5**

- **Antepsin** (Chugai Pharma UK Ltd)
  - Sucralfate 1 gram Antepsin 1g tablets | 50 tablet [P] £6.36 DT price = £6.36

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 5**

- **Antepsin** (Chugai Pharma UK Ltd)
  - Sucralfate 200 mg per 1 ml Antepsin 1g/5ml oral suspension (sugar-free) | 250 ml [P] £6.36 DT price = £6.36

**Tripotassium dicitratobismuthate**

**INDICATIONS AND DOSE**

Eradication failure of *Helicobacter pylori* infection (in combination with omeprazole, tetracycline and metronidazole)

**BY MOUTH**

- Adult: 120 mg 4 times a day for 2 weeks

**Benign gastric and duodenal ulceration**

**BY MOUTH**

- Adult: 240 mg twice daily, alternatively 120 mg 4 times a day both dosage regimens taken for 28 days followed by a further 28 days if necessary, maintenance dose not indicated but course may be repeated after interval of 1 month

**INTERACTIONS**

- Appendix 1 (tripotassium dicitratobismuthate).

**SIDE-EFFECTS**

- **Common or very common** May blacken faeces - may darken tongue
- **Uncommon** Constipation - diarrohea - nausea - pruritus - rash - vomiting
- **PREGNANCY** Manufacturer advises avoid on theoretical grounds.
- **BREAST FEEDING** No information available.
- **RENAL IMPAIRMENT** Avoid in severe impairment.

**DIRECTIONS FOR ADMINISTRATION**

To be swallowed with half a glass of water. Twice-daily dosage to be taken 30 minutes before breakfast and main evening meal. Four-times-daily dosage to be taken as follows: one dose 30 minutes before breakfast, midday meal and main evening meal, and one dose 2 hours after main evening meal.

**PATIENT AND CARER ADVICE**

Milk should not be drunk by itself during treatment but small quantities may be taken in tea or coffee or on cereal. Antacids, fruit, or fruit juice should not be taken half an hour before or after a dose. Patients and carers should be aware that the patient may develop darkened tongue and blackened faeces.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**ELECTROLYTES**: May contain Potassium

- **De-Noltab** (Astellas Pharma Ltd)
  - Tripotassium dicitratobismuthate 120 mg De-Noltab 120mg tablets | 112 tablet [P] £5.09

**Gastro-intestinal system**
H₂-RECEPTOR ANTAGONISTS

Histamine H₂-receptor antagonists heal gastric and duodenal ulcers by reducing gastric acid output as a result of histamine H₂-receptor blockade; they are also used to relieve symptoms of gastro-oesophageal reflux disease. H₂-receptor antagonists should not normally be used for Zollinger-Ellison syndrome because proton pump inhibitors are more effective.

Maintenance treatment with low doses for the prevention of peptic ulcer disease has largely been replaced in Helicobacter pylori positive patients by eradication regimens.

In adults, H₂-receptor antagonists are used for the treatment of functional dyspepsia and may be used for the treatment of uninvestigated dyspepsia without alarm features.

H₂-receptor antagonist therapy can promote healing of NSAID-associated ulcers (particularly duodenal).

Treatment with a H₂-receptor antagonist has not been shown to be beneficial in haematemesis and melaena, but prophylactic use reduces the frequency of bleeding from gastroduodenal erosions in hepatic coma, and possibly in other conditions requiring intensive care. H₂-receptor antagonists also reduce the risk of acid aspiration in obstetric patients at delivery (Mendelson’s syndrome).

H₂-receptor antagonists

- **CAUTIONS** Signs and symptoms of gastric cancer

**CAUTIONS, FURTHER INFORMATION**

Gastric cancer H₂-receptor antagonists might mask symptoms of gastric cancer; particular care is required in patients presenting with ‘alarm features’ in such cases gastric malignancy should be ruled out before treatment.

- **SIDE-EFFECTS**
  - Common or very common Diarrhoea · dizziness · headache
  - Uncommon Erythema multiforme · rash · toxic epidermal necrolysis
  - Rare Arthralgia · blood disorders · bradycardia · cholestatic jaundice · confusion · depression · hallucinations · hepatitis · leucopenia · myalgia · pancytopenia · psychiatric reactions · thrombocytopenia
  - Frequency not known Gynaecomastia · impotence

**SIDE-EFFECTS, FURTHER INFORMATION**

Psychiatric reactions Psychiatric reactions, including confusion, depression, and hallucinations occur particularly in the elderly or the very ill.

Cimetidine

**INDICATIONS AND DOSE**

**Benign duodenal ulceration**

- **BY MOUTH**
  - Adult: 400 mg twice daily for at least 4 weeks, to be taken with breakfast and at night, alternatively 800 mg once daily for at least 4 weeks, to be taken at night; increased if necessary up to 400 mg 4 times a day; maintenance 400 mg once daily for 6 weeks, to be taken at night; alternatively maintenance 400 mg twice daily, to be taken in the morning and at night

**Benign gastric ulceration**

- **BY MOUTH**
  - Adult: 400 mg twice daily for 6 weeks, to be taken with breakfast and at night, alternatively 800 mg daily for 6 weeks, to be taken at night; increased if necessary up to 400 mg 4 times a day; maintenance 400 mg once daily for 8 weeks, to be taken at night; increased if necessary up to 400 mg 4 times a day; maintenance 400 mg daily, to be taken at night, alternatively maintenance 400 mg twice daily, to be taken in the morning and at night

**NSAID-associated ulceration**

- **BY MOUTH**
  - Adult: 400 mg twice daily for 8 weeks, to be taken with breakfast and at night, alternatively 800 mg daily for 8 weeks, to be taken at night; increased if necessary up to 400 mg 4 times a day; maintenance 400 mg daily, to be taken at night, alternatively maintenance 400 mg twice daily, to be taken in the morning and at night

**Reflex oesophagitis**

- **BY MOUTH**
  - Adult: 400 mg 4 times a day for 4–8 weeks

**Prophylaxis of stress ulceration**

- **BY MOUTH**
  - Adult: 200–400 mg every 4–6 hours

**Gastric acid reduction in obstetrics**

- **BY MOUTH**
  - Adult: Initially 400 mg, to be administered at start of labour, then increased if necessary up to 400 mg every 4 hours, do not use syrup in prophylaxis of acid aspiration; maximum 2.4 g per day

**Gastric acid reduction during surgical procedures**

- **BY MOUTH**
  - Adult: 400 mg, to be given 90–120 minutes before induction of general anaesthesia

**Short-bowel syndrome**

- **BY MOUTH**
  - Adult: 400 mg twice daily, adjusted according to response, to be taken with breakfast and at bedtime

To reduce degradation of pancreatic enzyme supplements

- **BY MOUTH**
  - Adult: 0.8–1.6 g daily in 4 divided doses, dose to be taken 1–1½ hours before meals

**INTERACTIONS** → Appendix 1 (histamine H₂-antagonists).

**SIDE-EFFECTS**

- Common or very common Malaise
- Uncommon Tachycardia
- Rare Interstitial nephritis
- Very rare Alopecia · galactorrhoea · pancreatitis · vasculitis

**PREGNANCY** Manufacturer advises avoid unless essential.

**BREAST FEEDING** Significant amount present in milk—not known to be harmful but manufacturer advises avoid.

**HEPATIC IMPAIRMENT** Reduce dose. Increased risk of confusion.

**RENAL IMPAIRMENT** Occasional risk of confusion. Reduce dose to 200 mg 4 times daily if eGFR 30–50 mL/minute/1.73 m². Reduce dose to 200 mg 3 times daily if eGFR 15–30 mL/minute/1.73 m². Reduce dose to 200 mg twice daily if eGFR less than 15 mL/minute/1.73 m².

**EXCEPTIONS TO LEGAL CATEGORY** Cimetidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks’ supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity (max. single dose 200 mg, max. daily dose 800 mg), and for the prophylactic management of nocturnal heartburn (single night-time dose 100 mg).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Cimetidine (Non-proprietary) Cimetidine 200 mg Cimetidine 200 mg tablets | 60 tablet (£0.80 DT price = £5.04)
Nizatidine

**INDICATIONS AND DOSE**

**Benign gastric, duodenal or NSAID-associated ulceration**

**BY MOUTH**

- Adult: 300 mg once daily for 4–8 weeks; dose to be taken in the evening, alternatively 150 mg twice daily for 4–8 weeks; maintenance 150 mg once daily, dose to be taken at night.

**Gastro-oesophageal reflux disease**

**BY MOUTH**

- Adult: 150–300 mg twice daily for up to 12 weeks

**INTERACTIONS** → Appendix 1 (histamine H₂-antagonists).

**SIDE-EFFECTS**

- Common or very common Sweating
- Rare Fever · hyperuricaemia · nausea · vasculitis

**PREGNANCY** Manufacturer advises avoid unless essential.

**BREAST FEEDING** Amount too small to be harmful.

**HEPATIC IMPAIRMENT** Manufacturer advises caution.

**RENAL IMPAIRMENT** Use half normal dose if eGFR 20–50 mL/minute/1.73 m². Use one-quarter normal dose if eGFR less than 20 mL/minute/1.73 m².

**EXCEPTIONS TO LEGAL CATEGORY** Nizatidine can be sold to the public for the prevention and treatment of symptoms of food-related heartburn and meal-induced indigestion in adults and children over 16 years; max. single dose 75 mg, max. daily dose 150 mg for max. 14 days.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Capsule**

- **NIZATIDINE (Non-proprietary)**
  
  Nizatidine 150 mg Nizatidine 150mg capsules | 30 capsule £12.20 DT price = £5.40
  
  Nizatidine 300 mg Nizatidine 300mg capsules | 30 capsule £17.40 DT price = £11.43

Ranitidine

**INDICATIONS AND DOSE**

**Benign gastric ulceration | Duodenal ulceration**

**BY MOUTH**

- Child 1-5 years: 1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day)
- Child 6 months-2 years: 2–4 mg/kg twice daily
- Child 3-11 years: 2–4 mg/kg twice daily (max. per dose 150 mg) for 4–8 weeks
- Child 12-17 years: 150 mg twice daily for 4–8 weeks, alternatively 300 mg once daily for 4–8 weeks, dose to be taken at night
- Adult: 150 mg twice daily for 4–8 weeks, alternatively 300 mg once daily for 4–8 weeks, dose to be taken at night

**Chronic episodic dyspepsia**

**BY MOUTH**

- Child 12-17 years: 150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night
- Adult: 150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night
NSAID-associated gastric ulceration

**BY MOUTH**
- Child 12-17 years: 150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night
- Adult: 150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night

NSAID-associated duodenal ulcer

**BY MOUTH**
- Child 12-17 years: 300 mg twice daily for 4 weeks, to achieve a higher healing rate
- Adult: 300 mg twice daily

Gastro-oesophageal reflux disease

**BY MOUTH**
- Child 12-17 years: 150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night
- Adult: 150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night

**Moderate to severe gastro-oesophageal reflux disease**

**BY MOUTH**
- Child 12-17 years: 600 mg daily in 2–4 divided doses for up to 12 weeks
- Adult: 600 mg daily in 2–4 divided doses for up to 12 weeks

Long-term treatment of healed gastro-oesophageal reflux disease

**BY MOUTH**
- Child 3-11 years: 2.5–5 mg/kg twice daily (max. per dose 300 mg)
- Child 12-17 years: 150 mg twice daily
- Adult: 150 mg twice daily

Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics

**BY MOUTH**
- Child 12-17 years: 150 mg, dose to be given at onset of labour, then 150 mg every 6 hours
- Adult: 150 mg, dose to be given at onset of labour, then 150 mg every 6 hours

Gastric acid reduction (prophylaxis of acid aspiration) in surgical procedures

**INITIALLY BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION**
- Adult: 50 mg, to be given 45–60 minutes before induction of anaesthesia, intravenous injection diluted to 20 mL and given over at least 2 minutes, alternatively (by mouth) 150 mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening

Prophylaxis of stress ulceration

**INITIALLY BY SLOW INTRAVENOUS INJECTION**
- Adult: 50 mg every 8 hours, dose to be diluted to 20 mL and given over at least 2 minutes, then (by mouth) 150 mg twice daily, may be given when oral feeding commences

**Reflex oesophagitis and other conditions where gastric acid reduction is beneficial**

**BY MOUTH**
- Child 1-5 months: 1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day)
- Child 6-months-2 years: 2–4 mg/kg twice daily
- Child 3-11 years: 2–4 mg/kg twice daily (max. per dose 150 mg); increased to up to 5 mg/kg twice daily (max. per dose 300 mg), dose increase for severe gastro-oesophageal disease
- Child 12-17 years: 150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night, then increased if necessary to 300 mg twice daily for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease, alternatively increased if necessary to 150 mg 4 times a day for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease

**Conditions where reduction of gastric acidity is beneficial and oral route not available**

**BY INTRAMUSCULAR INJECTION**
- Adult: 50 mg every 6–8 hours

**BY SLOW INTRAVENOUS INJECTION**
- Adult: 50 mg, dose to be diluted to 20 mL and given over at least 2 minutes; may be repeated every 6–8 hours

- **UNLICENSED USE** Oral preparations not licensed for use in children under 3 years. Injection not licensed for use in children under 6 months.
- In adults Doses given for prophylaxis of NSAID-associated gastric or duodenal ulcer, and prophylaxis of stress ulceration, are not licensed.
- **INTERACTIONS** → Appendix 1 (histamine H₂-antagonists).
- **SIDE-EFFECTS**
  - Uncommon Blurred vision
  - Frequency not known Alopecia • interstitial nephritis • involuntary movement disorders • pancreatitis
- **PREGNANCY** Manufacturer advises avoid unless essential, but not known to be harmful.
- **BREAST FEEDING** Significant amount present in milk, but not known to be harmful.
- **RENAL IMPAIRMENT**
  - In adults Use half normal dose if eGFR less than 50 mL/minute/1.73 m².
  - In children Use half normal dose if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².
- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use in children For *slow intravenous injection* dilute to a concentration of 2.5 mg/mL with Glucose 5% or Sodium Chloride 0.9%; give over at least 3 minutes.
  - With intravenous use in adults For *intravenous infusion* (Zantac®), give intermittently in Glucose 5% or Sodium Chloride 0.9%.
- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: Ranitidine for acid reflux www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux
  - In fat malabsorption syndrome, give oral doses (usually half normal dose) after food to enhance effects of pancreatic enzyme replacement.
- **EXCEPTIONS TO LEGAL CATEGORY** Ranitidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks’ supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink (max. single dose 75 mg, max. daily dose 300 mg).
for gastric and duodenal ulceration

Proton pump inhibitors

Proton pump inhibitors are effective short-term treatments for gastric and duodenal ulcers; they are also used in combination with antibacterials for the eradication of Helicobacter pylori (see specific regimens). Following endoscopic treatment of severe peptic ulcer bleeding, an intravenous, high-dose proton pump inhibitor reduces the risk of rebleeding and the need for surgery. Proton pump inhibitors can be used for the treatment of dyspepsia and gastro-oesophageal reflux disease.

Proton pump inhibitors are also used for the prevention and treatment of NSAID-associated ulcers. In patients who need to continue NSAID treatment after an ulcer has healed, the dose of proton pump inhibitor should normally not be reduced because asymptomatic ulcer deterioration may occur.

A proton pump inhibitor can be used to reduce the degradation of pancreatic enzyme supplements in patients with cystic fibrosis. They can also be used to control excessive secretion of gastric acid in Zollinger–Ellison syndrome; high doses are often required.

DRUG ACTION Proton pump inhibitors inhibit gastric acid secretion by blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the ‘proton pump’) of the gastric parietal cell.

CAUTIONS Can increase the risk of fractures (particularly when used at high doses for over a year in the elderly) - may increase the risk of gastro-intestinal infections (including Clostridium difficile infection) - may mask the symptoms of gastric cancer - patients at risk of osteoporosis

CAUTIONS, FURTHER INFORMATION

Risk of osteoporosis Patients at risk of osteoporosis should maintain an adequate intake of calcium and vitamin D, and if necessary, receive other preventative therapy.

Gastric cancer Particular care is required in those presenting with ‘alarm features’, in such cases gastric malignancy should be ruled out before treatment.

SIDE-EFFECTS

Common or very common Abdominal pain - constipation - diarrhoea - flatulence - gastro-intestinal disturbances - headache - nausea - vomiting

Uncommon Arthralgia - dizziness - dry mouth - fatigue - myalgia - paraesthesia - peripheral oedema - pruritus - rash - sleep disturbances

Rare Alopecia - anaphylaxis - blood disorders - bronchospasm - confusion - depression - fever - gynaecomastia - hallucinations - hepatitis - hypersensitivity reactions - hypomagnesaemia (usually after 1 year of treatment, but sometimes after 5 months of treatment) - hypotension - intrastitial nephritis - jaundice - leucocytosis - leucopenia - pancytopenia - photosensitivity - Stevens-Johnson syndrome - stomatitis - sweating - taste disturbance - thrombocytopenia - toxic epidermal necrosis - visual disturbances

SIDE-EFFECTS, FURTHER INFORMATION

Rebound acid hypersecretion and protracted dyspepsia may occur after stopping prolonged treatment with a proton pump inhibitor.

MONITORING REQUIREMENTS Measurement of serum-magnesium concentrations should be considered before and during prolonged treatment with a proton pump inhibitor, especially when used with other drugs that cause hypomagnesaemia or with digoxin.

PRESCRIBING AND DISPENSING INFORMATION A proton pump inhibitor should be prescribed for appropriate indications at the lowest effective dose for the shortest period; the need for long-term treatment should be reviewed periodically.
Gastro-intestinal system

With intravenous use in adults

**DIRECTIONS FOR ADMINISTRATION**

**HEPATIC IMPAIRMENT**

- In adults: Severe hepatic impairment max. 20 mg daily. Severe peptic ulcer bleeding in severe hepatic impairment, initial intravenous infusion of 80 mg, then by continuous intravenous infusion, 4 mg/hour for 72 hours.
- In children 1–11 years max. 10 mg daily in severe impairment. 12–18 years max. 20 mg daily in severe impairment.

**RENA L IMPAIRMENT**

Manufacturer advises caution in severe renal insufficiency.

**DIRECTIONS FOR ADMINISTRATION**

**With intravenous use in adults** For *intravenous infusion*, dilute reconstituted solution to a concentration not exceeding 800 micrograms/mL with Sodium Chloride 0.9%; give over 10–30 minutes.

**With oral use** Do not chew or crush capsules; swallow whole or mix capsule contents in water and drink within 30 minutes. Do not crush or chew tablets; swallow whole or disperse in water and drink within 30 minutes. Disperse the contents of each sachet of gastro-resistant granules in approx. 15 mL water. Stir and leave to thicken for a few minutes; stir again before administration and use within 30 minutes; rinse container with 15 mL water to obtain full dose. For administration through a gastric tube, consult product literature.

**PATIENT AND CARER ADVICE**

- With oral use Counselling on administration of gastro-resistant capsules, tablets, and granules advised.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

### Gastro-resistant tablet

**ESOMEPRAZOLE (Non-proprietary)**

- **Esomeprazole (as Esomeprazole magnesium trihydrate)**
  - 20 mg Esomeprazole 20mg gastro-resistant tablets | 28 tablet [PO]
  - £18.50 DT price = £3.70

- **Esomeprazole (as Esomeprazole magnesium trihydrate)**
  - 40 mg Esomeprazole 40mg gastro-resistant tablets | 28 tablet [PO]
  - £25.19 DT price = £4.38

- **Nexium (AstraZeneca UK Ltd)**
  - Esomeprazole (as Esomeprazole magnesium trihydrate)
    - 20 mg Nexium 20mg gastro-resistant tablets | 28 tablet [PO]
    - £18.50 DT price = £3.70

  - **Esomeprazole (as Esomeprazole magnesium trihydrate)**
    - 40 mg Nexium 40mg gastro-resistant tablets | 28 tablet [PO]
    - £25.19 DT price = £4.38

### Gastro-resistant capsule

**ESOMEPRAZOLE (Non-proprietary)**

- **Esomeprazole (as Esomeprazole magnesium dihydrate)**
  - 20 mg Esomeprazole 20mg gastro-resistant capsules | 28 capsule [PO]
  - £12.95 DT price = £3.40

  - **Esomeprazole (as Esomeprazole magnesium dihydrate)**
    - 40 mg Esomeprazole 40mg gastro-resistant capsules | 28 capsule [PO]
    - £17.63 DT price = £3.96

  - **Emozul (Consilient Health Ltd)**
    - Esomeprazole (as Esomeprazole magnesium dihydrate)
      - 20 mg Emozul 20mg gastro-resistant capsules | 28 capsule [PO]
      - £13.40 DT price = £3.40

  - **Esomeprazole (as Esomeprazole magnesium dihydrate)**
    - 40 mg Emozul 40mg gastro-resistant capsules | 28 capsule [PO]
    - £13.96 DT price = £3.96

### Gastro-resistant granules

COUNTER AND ADVISORY LABELS 25

- **Nexium (AstraZeneca UK Ltd)**
  - Esomeprazole (as Esomeprazole magnesium trihydrate)
    - 10 mg Nexium 10mg gastro-resistant granules sachets | 28 sachet [PO]
    - £25.19 DT price = £25.19

Power for solution for injection

**ESOMEPRAZOLE (Non-proprietary)**

- **Esomeprazole (as Esomeprazole sodium) 40 mg**
  - Esomeprazole 40mg powder for solution for injection vials | 1 vial [PO] £3.07–£3.13 (Hospital only)

  - **Nexium (AstraZeneca UK Ltd)**
    - Esomeprazole (as Esomeprazole sodium) 40 mg Nexium IV 40mg powder for solution for injection vials | 1 vial [PO] £4.25 (Hospital only)
Lansoprazole

**INDICATIONS AND DOSE**

*Helicobacter pylori* eradication in combination with amoxicillin and clarithromycin; or in combination with amoxicillin and metronidazole; or in combination with clarithromycin and metronidazole

**BY MOUTH**

- Adult: 30 mg twice daily

**Benign gastric ulcer**

**BY MOUTH**

- Adult: 30 mg once daily for 8 weeks, dose to be taken in the morning

**Duodenal ulcer**

**BY MOUTH**

- Adult: 30 mg once daily for 4 weeks, dose to be taken in the morning; maintenance 15 mg once daily

**NSAID-associated duodenal ulcer | NSAID-associated gastric ulcer**

**BY MOUTH**

- Adult: 30 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed

**Prophylaxis of NSAID-associated duodenal ulcer | Prophylaxis of NSAID-associated gastric ulcer**

**BY MOUTH**

- Adult: 15–30 mg once daily

**Zollinger-Ellison syndrome (and other hypersecretory conditions)**

**BY MOUTH**

- Adult: Initially 60 mg once daily, adjusted according to response, daily doses of 120 mg or more given in two divided doses

**Gastro-oesophageal reflux disease**

**BY MOUTH**

- Adult: 30 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed; maintenance 15–30 mg once daily, doses to be taken in the morning

**Acid-related dyspepsia**

**BY MOUTH**

- Adult: 15–30 mg once daily for 2-4 weeks, doses to be taken in the morning

**UNLICENSED USE** Lansoprazole doses in BNF may differ from those in product literature.

**INTERACTIONS** → Appendix 1 (proton pump inhibitors).

**SIDE-EFFECTS**

- **Very rare** Collitis - raised serum cholesterol - raised triglycerides
- **Frequency not known** Anorexia - glossitis - impotence - pancreatitis - petechiae - purpura - restlessness - tremor
- **PREGNANCY** Manufacturer advises avoid.
- **BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Use half normal dose in moderate to severe liver disease.

**DIRECTIONS FOR ADMINISTRATION** Orodispersible tablets should be placed on the tongue, allowed to disperse and swallowed, or may be swallowed whole with a glass of water. Alternatively, tablets can be dispersed in a small amount of water and administered by an oral syringe or nasogastric tube.

**PATIENT AND CARER ADVICE** Counselling on administration of orodispersible tablet advised.

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulary

Lansoprazole capsules may be prescribed.

---

Omeprazole

**INDICATIONS AND DOSE**

*Helicobacter pylori* eradication in combination with amoxicillin and clarithromycin; or in combination with amoxicillin and metronidazole; or in combination with clarithromycin and metronidazole

**BY MOUTH**

- Adult: 20 mg twice daily

**Eradication failure of *Helicobacter pylori* infection in combination with tripotassium dicitratobismuthate, tetracycline and metronidazole**

**BY MOUTH**

- Adult: 20 mg twice daily

**Prevention of relapse in gastric ulcer**

**BY MOUTH**

- Adult: 20 mg once daily, increased if necessary to 40 mg once daily, in severe or recurrent cases

**Prevention of relapse in duodenal ulcer**

**BY MOUTH**

- Adult: 20 mg once daily, dose may range between 10–40 mg daily

**NSAID-associated duodenal ulcer | NSAID-associated gastric ulcer | NSAID-associated gastroduodenal erosions**

**BY MOUTH**

- Adult: 20 mg once daily for 4 weeks, continued for a further 4 weeks if not fully healed
Prophylaxis in patients with a history of NSAID-associated duodenal ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated gastric ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated gastroduodenal lesions who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated dyspeptic symptoms who require continued NSAID treatment

BY MOUTH
- Adult: 20 mg once daily

Gastro-oesophageal reflux disease

BY MOUTH
- Adult: 20 mg once daily for 4 weeks, continued for a further 4–8 weeks if not fully healed; maintenance 20 mg once daily

Gastro-oesophageal reflux disease refractory to other treatment

BY MOUTH
- Adult: 40 mg once daily for 8 weeks; maintenance 20 mg once daily

Acid reflux disease (long-term management)

BY MOUTH
- Adult: 10 mg once daily, increased to 20 mg once daily, dose only increased if symptoms return

Acid-related dyspepsia

BY MOUTH
- Adult: 10–20 mg once daily for 2–4 weeks according to response

Treatment and prevention of benign gastric ulcers | Treatment and prevention of duodenal ulcers | Treatment and prevention of NSAID-associated ulcers | Treatment and prevention of gastro-oesophageal reflux disease

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION
- Adult: 40 mg once daily until oral administration possible, injection to be given over 5 minutes, infusion to be given over 20–30 minutes

Major peptic ulcer bleeding (following endoscopic treatment)

INITIALLY BY INTRAVENOUS INFUSION
- Adult: Initially 80 mg, to be given over 40–60 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, subsequent dose then changed to oral therapy

Zollinger–Ellison syndrome

BY MOUTH
- Adult: Initially 60 mg once daily; usual dose 20–120 mg daily, total daily doses greater than 80 mg should be given in 2 divided doses

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION
- Adult: Initially 60 mg once daily, adjusted according to response, total daily doses greater than 60 mg should be given in 2 divided doses, injection to be given over 5 minutes, infusion to be given over 20–30 minutes

UNLICENSED USE
- Treatment of major peptic ulcer bleeding (following endoscopic treatment) is an unlicensed indication.

INTERACTIONS | Appendix 1 (proton pump inhibitors).

SIDE-EFFECTS
- Appetite - impotence

PREGNANCY
- Not known to be harmful.

BREAST FEEDING
- Present in milk but not known to be harmful.

HEPATIC IMPAIRMENT
- Not more than 20 mg daily should be needed.

DIRECTIONS FOR ADMINISTRATION
- For administration by mouth, swallow whole, or disperse Losec MUPS® tablets in water, or mix capsule contents or Losec MUPS® tablets with fruit juice or yoghurt. Preparations consisting of an e/c tablet within a capsule should not be opened.
- With intravenous use For intravenous infusion (Losec®), give intermittently or continuously in Glucose 5% or Sodium chloride 0.9%; reconstitute each 40 mg vial with infusion fluid and dilute to 100 mL; for intermittent infusion give 40 mg over 20–30 minutes; stable for 3 hours in glucose 5% or 12 hours in sodium chloride 0.9%.

PATIENT AND CARER ADVICE
- With oral use Counselling on administration advised.

PROFESSION SPECIFIC INFORMATION
- Dental practitioners’ formulary
- Gastro-resistant omeprazole capsules may be prescribed.

EXCEPTIONS TO LEGAL CATEGORY
- Omeprazole 10 mg tablets can be sold to the public for the short-term relief of reflux-like symptoms (e.g. heartburn) in adults over 18 years, max. daily dose 20 mg for max. 4 weeks, and a pack size of 28 tablets.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Gastro-resistant tablet

CAUTIONARY AND ADVISORY LABELS

OMEPAZOLE (Non-proprietary)

Omeprazole 10 mg Losec MUPS® gastro-resistant capsules | 28 tablet (PDT) £21.25
Omeprazole (as Omeprazole magnesium) 10 mg Losec MUPS® gastro-resistant capsules | 28 tablet (PDT) £11.60
Omeprazole (as Omeprazole magnesium) 20 mg Losec MUPS® gastro-resistant capsules | 7 tablet (PDT) £16.00
Omeprazole (as Omeprazole magnesium) 40 mg Losec MUPS® gastro-resistant capsules | 7 tablet (PDT) £35.00
Omeprazole (as Omeprazole magnesium) 40 mg Losec gastro-resistant tablets | 7 tablet (PDT) £5.80

MEPRADER capsules | 30 capsule (PDT) £21.65

OMEPAZOLE (Non-proprietary)

Omeprazole 10 mg Losec gastro-resistant capsules | 28 capsule (PDT) £18.91
Omeprazole 20 mg Losec gastro-resistant capsules | 28 capsule (PDT) £29.56
Omeprazole 40 mg Losec gastro-resistant capsules | 7 capsule (PDT) £4.93
Omeprazole (as Omeprazole magnesium) 10 mg Losec gastro-resistant capsules | 7 tablet (PDT) £5.80
Omeprazole (as Omeprazole magnesium) 20 mg Losec gastro-resistant capsules | 7 tablet (PDT) £11.60
Omeprazole (as Omeprazole magnesium) 40 mg Losec gastro-resistant capsules | 7 tablet (PDT) £5.80

Omeprazole (as Omeprazole magnesium) 10 mg Losec gastro-resistant capsules | 7 tablet (PDT) £5.80
Omeprazole (as Omeprazole magnesium) 20 mg Losec gastro-resistant capsules | 7 tablet (PDT) £11.60
Omeprazole (as Omeprazole magnesium) 40 mg Losec gastro-resistant capsules | 7 tablet (PDT) £5.80

Losec (AstraZeneca UK Ltd)

Omeprazole (as Omeprazole magnesium) 10 mg Losec MUPS® gastro-resistant capsules | 28 tablet (PDT) £7.75
Omeprazole (as Omeprazole magnesium) 20 mg Losec MUPS® gastro-resistant capsules | 28 tablet (PDT) £11.60
Omeprazole (as Omeprazole magnesium) 40 mg Losec MUPS® gastro-resistant capsules | 7 tablet (PDT) £4.93

Brands may include Mezzopram tablets;

Losec (AstraZeneca UK Ltd)

Omeprazole (as Omeprazole magnesium) 10 mg Losec gastro-resistant capsules | 28 capsule (PDT) £18.91
Omeprazole (as Omeprazole magnesium) 20 mg Losec gastro-resistant capsules | 28 capsule (PDT) £29.56
Omeprazole (as Omeprazole magnesium) 40 mg Losec gastro-resistant capsules | 7 capsule (PDT) £4.93

Omeprazole (as Omeprazole magnesium) 40 mg Mezzopram gastro-resistant capsules | 7 tablet (PDT) £4.93

Powder and solvent for solution for injection

Losec (AstraZeneca UK Ltd)

Omeprazole (as Omeprazole sodium) 40 mg Losec I.V. 40mg powder and solvent for solution for injection vials | 1 vial (PDT) £6.49

Powder for solution for infusion

OMEPAZOLE (Non-proprietary)

Omeprazole (as Omeprazole sodium) 40 mg Losec 40mg powder for solution for infusion vials | 5 vial (PDT) £6.47
Pantoprazole

**INDICATIONS AND DOSE**

*Helicobacter pylori* eradication in combination with amoxicillin and clarithromycin; or in combination with clarithromycin and metronidazole

**BY MOUTH**

- Adult: 40 mg daily for 8 weeks; increased if necessary up to 80 mg daily, dose increased in severe cases

**Benign gastric ulcer**

**BY MOUTH**

- Adult: 40 mg daily for 8 weeks; increased if necessary up to 80 mg daily, dose increased in severe cases

**Gastric ulcer**

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: 40 mg daily until oral administration can be resumed, injection to be given over at least 2 minutes

**Duodenal ulcer**

**BY MOUTH**

- Adult: 40 mg daily for 4 weeks; increased if necessary up to 80 mg daily, dose increased in severe cases

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: 40 mg daily until oral administration can be resumed, injection to be given over at least 2 minutes

**Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment (Prophylaxis of NSAID-associated duodenal ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment)**

**BY MOUTH**

- Adult: 20 mg daily

**Gastro-oesophageal reflux disease**

**BY MOUTH**

- Adult: 20–80 mg daily for 4 weeks, continued for further 4 weeks if not fully healed, dose to be taken in the morning; maintenance 20 mg daily and increased to 40 mg daily, increased only if symptoms return

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: 40 mg daily until oral administration can be resumed, injection to be given over at least 2 minutes

**Zollinger-Ellison syndrome (and other hypersecretary conditions)**

**BY MOUTH**

- Adult: Initially 80 mg daily (max. per dose 80 mg), adjusted according to response

- Elderly: 40 mg daily

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: Initially 80 mg, alternatively 160 mg in 2 divided doses, if rapid acid control required, then 80 mg once daily (max. per dose 80 mg), adjusted according to response

**INTERACTIONS** → Appendix 1 (proton pump inhibitors).

**SIDE-EFFECTS**

- Hyperlipidaemia - weight changes

- Pregnancy

  Manufacturer advises avoid unless potential benefit outweighs risk—fetotoxic in animals.

- Breast Feeding

  Manufacturer advises avoid unless potential benefit outweighs risk—small amount present in milk.

- Hepatic Impairment

  Max. 20 mg daily in severe impairment and cirrhosis. Monitor liver function in hepatic impairment (discontinue if deterioration).

- Renal Impairment

  Max. oral dose 40 mg daily.

**DIRECTIONS FOR ADMINISTRATION**

For *intravenous infusion* (*Protium*®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute 40 mg with 10 mL sodium chloride 0.9% and dilute with 100 mL of infusion fluid; give 40 mg over 15 minutes.

**EXCEPTIONS TO LEGAL CATEGORY**

Pantoprazole 20 mg tablets can be sold to the public for the short-term treatment of reflux symptoms (e.g. heartburn) in adults over 18 years, max. daily dose 20 mg for max. 4 weeks.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Gastro-resistant tablet**

CAUTIONARY AND ADVISORY LABELS 25

- **PANTOPRAZOLE (Non-proprietary)**
  - Pantoprazole (as Pantoprazole sodium sesquihydrate)
    - 20 mg Pantoprazole 20mg gastro-resistant tablets | 28 tablet [P] £11.83 DT price = £1.22
    - Pantoprazole (as Pantoprazole sodium sesquihydrate)
      - 40 mg Pantoprazole 40mg gastro-resistant tablets | 28 tablet [P] £20.57 DT price = £1.59
    - Pantoloc Control (Novartis Consumer Health UK Ltd)
      - Pantoprazole (as Pantoprazole sodium sesquihydrate)
        - 20 mg Pantoloc Control 20mg gastro-resistant tablets | 7 tablet [P] £4.11 | 14 tablet [P] £7.09

**Powder for solution for injection**

- **PANTOPRAZOLE (Non-proprietary)**
  - Pantoprazole (as Pantoprazole sodium sesquihydrate)
    - 40 mg Pantoprazole 40mg powder for solution for injection vials | 1 vial [P] £4.65-£5.00
    - Protium (Wycomed UK Ltd)
      - Pantoprazole (as Pantoprazole sodium sesquihydrate)
        - 40 mg Protium IV. 40mg powder for solution for injection vials | 5 vial [P] £25.53

Rabeprazole sodium

**INDICATIONS AND DOSE**

**Benign gastric ulcer**

**BY MOUTH**

- Adult: 20 mg daily for 8 weeks, dose to be taken in the morning

**Duodenal ulcer**

**BY MOUTH**

- Adult: 20 mg daily for 4 weeks, dose to be taken in the morning

**Gastro-oesophageal reflux disease**

**BY MOUTH**

- Adult: 20 mg once daily for 4–8 weeks; maintenance 10–20 mg daily

**Gastro-oesophageal reflux disease (symptomatic treatment in the absence of oesophagitis)**

**BY MOUTH**

- Adult: 10 mg daily for up to 4 weeks, then 10 mg daily if required

**Zollinger-Ellison syndrome**

**BY MOUTH**

- Adult: Initially 60 mg once daily, adjusted according to response, doses above 100 mg daily given in 2 divided doses; maximum 120 mg per day

*Helicobacter pylori* eradication in combination with amoxicillin or metronidazole and clarithromycin

**BY MOUTH**

- Adult: 20 mg twice daily

**INTERACTIONS** → Appendix 1 (proton pump inhibitors).

**SIDE-EFFECTS**

- Common or very common
  - Cough - influenza like syndrome - rhinitis
  - Uncommon
  - Chest pain - nervousness
4.3 Gastro-oesophageal reflux disease

Gastro-oesophageal reflux disease

Gastro-oesophageal reflux disease (including non-erosive gastro-oesophageal reflux and erosive oesophagitis) is associated with heartburn, acid regurgitation, and sometimes, difficulty in swallowing (dysphagia); oesophageal inflammation (oesophagitis), ulceration, and stricture formation may occur and there is an association with asthma.

The management of gastro-oesophageal reflux disease includes drug treatment, lifestyle changes and, in some cases, surgery. Initial treatment is guided by the severity of symptoms and treatment is then adjusted according to response. The extent of healing depends on the severity of the disease, the treatment chosen, and the duration of therapy.

Patients with gastro-oesophageal reflux disease should be advised about lifestyle changes (avoidance of excess alcohol and of aggravating foods such as fats); other measures associated with heartburn, acid regurgitation, and stricture formation may occur and there is an association with asthma.

For **mild symptoms** of gastro-oesophageal reflux disease, initial management may include the use of **antacids** and **alginates**. Alginate-containing antacids can form a ‘raft’ that floats on the surface of the stomach contents to reduce reflux and protect the oesophageal mucosa. **Histamine H2-receptor antagonists** may relieve symptoms and permit reduction in antacid consumption. However, **proton pump inhibitors** provide more effective relief of symptoms than H2-receptor antagonists. When symptoms abate, treatment is titrated down to a level which maintains remission (e.g. by giving treatment intermittently).

For **severe symptoms** of gastro-oesophageal reflux disease or for patients with a proven or severe pathology (e.g. oesophagitis, oesophageal ulceration, oesophagopharyngeal reflux, Barrett’s oesophagus), initial management involves the use of a **proton pump inhibitor**: patients need to be reassessed if symptoms persist despite treatment for 4–6 weeks with a proton pump inhibitor. When symptoms abate, treatment is titrated down to a level which maintains remission (e.g. by reducing the dose of the proton pump inhibitor or by giving it intermittently, or by substituting treatment with a histamine H2-receptor antagonist). However, for endoscopically confirmed erosive, ulcerative, or stricturing disease, or Barrett’s oesophagus, treatment with a proton pump inhibitor usually needs to be maintained at the minimum effective dose.

**Pregnancy**

If dietary and lifestyle changes fail to control gastro-oesophageal reflux disease in pregnancy, an antacid or an alginate can be used. If this is ineffective, ranitidine p. 65 can be tried. Omeprazole p. 69 is reserved for women with severe or complicated reflux disease.

**Gastro-oesophageal reflux disease in children**

Gastro-oesophageal reflux disease is common in infancy but most symptoms resolve without treatment between 12 and 18 months of age. In infants, mild or moderate reflux without complications can be managed initially by changing the frequency and volume of feed; a feed thickener or thickened formula feed can be used (with advice of a dietitian). If necessary, a suitable alginate-containing preparation can be used instead of thickened feeds. For older children, life-style changes similar to those for adults may be helpful followed if necessary by treatment with an alginate-containing preparation.

Children who do not respond to these measures or who have problems such as respiratory disorders or suspected oesophagitis need to be referred to hospital; an H2-receptor antagonist may be needed to reduce acid secretion. If the oesophagitis is resistant to H2-receptor blockade, the proton pump inhibitor omeprazole p. 69 can be tried.

4.4 Helicobacter pylori diagnosis

**DIAGNOSTICS**

**Urea (13C)**

**INDICATIONS AND DOSE**

Diagnosis of gastro-duodenal *Helicobacter pylori* infection

**BY MOUTH**

- Adult: (consult product literature)

**BY INTRAMUSCULAR INJECTION**

**Tablet**

- diabact UBT (Seahorse Laboratories Ltd)

**Urea (13-C) 50 mg** diabact UBT 50mg tablets | 1 tablet POM £21.25 | 10 tablet kit POM no price available (Hospital only)

**Soluble tablet**

- Pylobactel (Torbet Laboratories Ltd)

**Urea (13-C) 100 mg** Pylobactel breath test kit | 1 kit POM £20.75

**Powder**

- **UREA (13C) (Non-proprietary)**

**Urea (13-C) 45 mg** Helicobacter Test INFAI for children breath test kit (sugar-free) | 1 kit POM £19.20

**Urea (13-C) 75 mg** Helicobacter Test INFAI breath test kit (sugar-free) | 1 kit POM £19.20

5 Food allergy

**Food allergy**

Allergy with classical symptoms of vomiting, colic and diarrhoea caused by specific foods such as cow’s milk or shellfish should be managed by strict avoidance. The
condition should be distinguished from symptoms of occasional food intolerance in those with irritable bowel syndrome. Sodium cromoglicate p. 234 may be helpful as an adjunct to dietary avoidance.

6 Gastro-intestinal smooth muscle spasm

**ANTIMUSCARINICS**

Dicycloverine hydrochloride

(Dicylomine hydrochloride)

The properties listed below are those particular to the drug only. For properties common to the class, see antimuscarinics (systemic), p. 668.

### INDICATIONS AND DOSE

Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm

**BY MOUTH**
- Child 6 months-1 year: 5–10 mg 3–4 times a day, dose to be taken 15 minutes before feeds
- Child 2-11 years: 10 mg 3 times a day
- Child 12-17 years: 10–20 mg 3 times a day
- Adult: 10–20 mg 3 times a day

### CONTRA-INDICATIONS

Child under 6 months

### PREGNANCY

Not known to be harmful; manufacturer advises use only if essential.

### BREAST FEEDING

Avoid—present in milk; apnoea reported in infant.

### EXCEPTIONS TO LEGAL CATEGORY

Dicycloverine hydrochloride can be sold to the public provided that max. single dose is 10 mg and max. daily dose is 60 mg.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **DICYCLOVERINE HYDROCHLORIDE (Non-proprietary)**
  - Dicycloverine hydrochloride 10 mg: Dicycloverine 10mg tablets | 100 tablet [P] £141.68 DT price = £117.72
  - Dicycloverine hydrochloride 20 mg: Dicycloverine 20mg tablets | 84 tablet [P] £149.66 DT price = £123.91

**Oral solution**
- **DICYCLOVERINE HYDROCHLORIDE (Non-proprietary)**
  - Dicycloverine hydrochloride 2 mg per 1 ml: Dicycloverine 10mg/5ml oral solution | 100 ml [P] no price available | 120 ml [P] £138.30 DT price = £115.41 | 300 ml [P] no price available

### Aluminum hydroxide with dicycloverine hydrochloride, magnesium oxide and simeticone

The properties listed below are those particular to the combination only. For the properties of the components please consider, aluminium hydroxide p. 859, dicycloverine hydrochloride above, simeticone p. 60.

### INDICATIONS AND DOSE

Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm

**BY MOUTH**
- Child 12-17 years: 10–20 mL every 4 hours as required
- Adult: 10–20 mL every 4 hours as required

### Hyoscine butylbromide

The properties listed below are those particular to the drug only. For properties common to the class, see antimuscarinics (systemic), p. 668.

### INDICATIONS AND DOSE

Symptomatic relief of gastro-intestinal or genito-urinary disorders characterised by smooth muscle spasm

**BY MOUTH**
- Child 6-11 years: 10 mg 3 times a day
- Child 12-17 years: 20 mg 4 times a day
- Adult: 20 mg 4 times a day

**Irritable bowel syndrome**

**BY MOUTH**
- Adult: 10 mg 3 times a day; increased if necessary up to 20 mg 4 times a day

**Acute spasm** | Spasm in diagnostic procedures

**INITIALLY BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION**
- Adult: 20 mg, then (by intramuscular injection or by slow intravenous injection) 20 mg after 30 minutes if required, dose may be repeated more frequently in endoscopy; maximum 100 mg per day

**Excessive respiratory secretions (in palliative care)**

**BY MOUTH**
- Child 1 month-1 year: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
- Child 2-4 years: 5 mg 3–4 times a day
- Child 5-11 years: 10 mg 3–4 times a day
- Child 12-17 years: 10–20 mg 3–4 times a day

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**
- Child 1 month-3 years: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
- Child 5-11 years: 5–10 mg 3–4 times a day
- Child 12-17 years: 10–20 mg 3–4 times a day

**BY SUBCUTANEOUS INJECTION**
- Adult: 20 mg every 4 hours if required, increased according to response, up to 20 mg every hour

**BY SUBCUTANEOUS INFUSION**
- Adult: 20–120 mg/24 hours

**Bowel colic (in palliative care)**

**BY MOUTH**
- Child 1 month-1 year: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
- Child 2-4 years: 5 mg 3–4 times a day
- Child 5-11 years: 10 mg 3–4 times a day
- Child 12-17 years: 10–20 mg 3–4 times a day

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**
- Child 1 month-3 years: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
- Child 5-11 years: 5–10 mg 3–4 times a day
- Child 12-17 years: 10–20 mg 3–4 times a day

**BY SUBCUTANEOUS INJECTION**
- Adult: 20 mg every 4 hours if required, increased according to response, up to 20 mg every hour

**BY SUBCUTANEOUS INFUSION**
- Adult: 60–300 mg/24 hours

### PHARMACOKINETICS

Administration by mouth is associated with poor absorption.
Gastro-intestinal system

**RENAL IMPAIRMENT**

**HEPATIC IMPAIRMENT**

**BREAST FEEDING**

**UNLICENSED USE**


**PREGNANCY**

Manufacturer advises avoid.

**BREAST FEEDING**

Amount too small to be harmful.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use in children For administration by mouth, injection solution may be used; content of ampoule may be stored in a refrigerator for up to 24 hours after opening.
- With intravenous use in children For intravenous injection, may be diluted with Glucose 5% or Sodium Chloride 0.9%; give over at least 1 minute.

**EXCEPTIONS TO LEGAL CATEGORY**

Hyoscine butylbromide tablets can be sold to the public for medically confirmed irritable bowel syndrome, provided single dose does not exceed 20 mg, daily dose does not exceed 80 mg, and pack does not contain a total of more than 240 mg.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, tablets, solution for injection.

**Tablet**

- Buscopan (Boehringer Ingelheim Self-Medication Division, Boehringer Ingelheim Ltd)
  - Hyoscine butylbromide 10 mg
    - Buscopan Cramps 10mg tablets 120 tablet £2.64
    - Buscopan 10mg tablets 56 tablet £3.00 OT price = £3.00

**Solution for injection**

- Buscopan (Boehringer Ingelheim Ltd)
  - Hyoscine butylbromide 20 mg per 1 ml
    - Buscopan 20mg/1ml solution for injection ampoules 10 ampoule £2.92 OT price = £2.92

**Propantheline bromide**

The properties listed below are those particular to the drug only. For properties common to the class, see antimuscarinics (systemic), p.668.

**INDICATIONS AND DOSE**

Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm

**BY MOUTH**

- Child 12–17 years: 15 mg 3 times a day, dose to be taken at least one hour before food and 30 mg, dose to be taken at night; maximum 120 mg per day
- Adult: 15 mg 3 times a day, dose to be taken at least one hour before food and 30 mg, dose to be taken at night; maximum 120 mg per day

**Adult enuresis**

**BY MOUTH**

- Adult: Initially 15 mg 3 times a day, dose to be taken at least one hour before food and 30 mg, dose to be taken at bedtime, subsequently adjusted according to response; maximum 120 mg per day

**UNLICENSED USE**

Tablets not licensed for use in children under 12 years.

**SIDE-EFFECTS**

- Facial flushing
- Manufacturer advises avoid unless essential—no information available.
- May suppress lactation.
- Manufacturer advises caution.
- Manufacturer advises caution.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

**Tablet CAUTIONARY AND ADVISORY LABELS 23**

- Pro-Banthine (Archimedes Pharma UK Ltd)
  - Propantheline bromide 15 mg Pro-Banthine 15mg tablets 112 tablet £20.74 OT price = £20.74

**ANTISPASMODICS**

**Antispasmodics**

**Antimuscarinics**

The intestinal smooth muscle relaxant properties of antimuscarinic and other antispasmodic drugs may be useful in irritable bowel syndrome and in diverticular disease.

Antimuscarinics (formerly termed ‘anticholinergics’) reduce intestinal motility. They can be used for the management of irritable bowel syndrome and diverticular disease. However, their value has not been established and response varies.

Antimuscarinic drugs that are used for gastro-intestinal smooth muscle spasm include the tertiary amines atropine sulfate p.1099 and dicycloverine hydrochloride p.73 and the quaternary ammonium compounds propantheline bromide above and hyoscine butylbromide p.73. The quaternary ammonium compounds are less lipid soluble than atropine sulfate and are less likely to cross the blood–brain barrier; they are also less well absorbed from the gastro-intestinal tract.

Dicycloverine hydrochloride has a much less marked antimuscarinic action than atropine sulfate and may also have some direct action on smooth muscle. Hyoscine butylbromide is advocated as a gastro-intestinal antispasmodic, but it is poorly absorbed; the injection is useful in endoscopy and radiology. Atropine sulfate and the belladonna alkaloids are outmoded treatments, any clinical virtues being outweighed by atropinic side-effects.

Other indications for antimuscarinic drugs include arrhythmias, asthma and airways disease, motion sickness, parkinsonism, urinary incontinence, mydriasis and cycloplegia, premedication, and as an antidote to organophosphorus poisoning.

**Other antispasmodics**

Alverine citrate below, mebeverine hydrochloride p.75, and peppermint oil p.40 are believed to be direct relaxants of intestinal smooth muscle and may relieve pain in irritable bowel syndrome and diverticular disease. They have no serious adverse effects but, like all antispasmodics, should be avoided in paralytic ileus.

**Alverine citrate**

**INDICATIONS AND DOSE**

Adjunct in gastro-intestinal disorders characterised by smooth muscle spasm | Dysmenorrhoea

**BY MOUTH**

- Child 12–17 years: 60–120 mg 1–3 times a day
- Adult: 60–120 mg 1–3 times a day

**CONTRA-INDICATIONS**

Paralytic ileus

**SIDE-EFFECTS**

- Dizziness | dyspepsia | headache | hepatitis | nausea | pruritus | rash

**PREGNANCY**

Use with caution.

**BREAST FEEDING**

Manufacturer advises avoid—limited information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Mebeverine hydrochloride

INDICATIONS AND DOSE
Adjunct in gastrointestinal disorders characterised by smooth muscle spasm

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Child 10–17 years: 135–150 mg 3 times a day, dose preferably taken 20 minutes before meals
- Adult: 135–150 mg 3 times a day, dose preferably taken 20 minutes before meals

Irritable bowel syndrome

BY MOUTH USING MODIFIED-RELEASE MEDICINES
- Child 12–17 years: 200 mg twice daily
- Adult: 200 mg twice daily

- CONTRA-INDICATIONS Paralytic ileus
- SIDE-EFFECTS Allergic reactions • angioedema • rash • urticaria
- PREGNANCY Not known to be harmful — manufacturers advise avoid.
- BREAST FEEDING Manufacturers advise avoid — no information available.
- PATIENT AND CARER ADVICE Patients or carers should be given advice on the timing of administration of mebeverine hydrochloride tablets and oral suspension.

Medicines for Children leaflet: Mebeverine for intestinal spasm www.medicinesforchildren.org.uk/mebeverine-for-intestinal-spasms

EXCEPTIONS TO LEGAL CATEGORY Mebeverine hydrochloride can be sold to the public for symptomatic relief of irritable bowel syndrome provided that max. single dose is 135 mg and max. daily dose is 405 mg; for uses other than symptomatic relief of irritable bowel syndrome provided that max. single dose is 100 mg and max. daily dose is 300 mg.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: powder

**Tablet**

- **MEBEVERINE HYDROCHLORIDE (Non-proprietary)**
  - Mebeverine hydrochloride 135 mg Boots IBS Relief 135 mg tablets | 15 tablet | no price available
  - Mebeverine 135 mg tablets | 15 tablet | no price available | 15 tablet | £4.50 | 1 tablet | £2.67 DT price = £8.44
  - Colofac (BGP Products Ltd)
  - Mebeverine hydrochloride 135 mg Colofac 135 mg tablets | 100 tablet | £39.02 DT price = £8.44
  - Colofac IBS 135 mg tablets | 15 tablet | £2.83
  - Modified-release capsule
  - CAUTIONARY AND ADVISORY LABELS 25
  - Colofac MR (BGP Products Ltd)
  - Mebeverine hydrochloride 200 mg Colofac MR 200 mg capsules | 60 capsule | £6.92 DT price = £6.92

**Oral suspension**

- **MEBEVERINE HYDROCHLORIDE (Non-proprietary)**
  - Mebeverine hydrochloride (as Mebeverine pamoate) 10 mg per 1 ml Mebeverine 50 mg/5 ml oral suspension sugar free (sugar-free) | 300 ml | £143.42 DT price = £143.42

Ispaghula husk with mebeverine

The properties listed below are those particular to the combination only. For the properties of the components please consider, ispaghula husk p. 45, mebeverine hydrochloride above.

INDICATIONS AND DOSE

Irritable bowel syndrome

BY MOUTH
- Child 12–17 years: 1 sachet twice daily, in water, morning and evening, 30 minutes before food and 1 sachet daily if required, taken 30 minutes before midday meal
- Adult: 1 sachet twice daily, in water, morning and evening, 30 minutes before food and 1 sachet daily if required, taken 30 minutes before midday meal

DIRECTIONS FOR ADMINISTRATION
Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed.

PATIENT AND CARER ADVICE
Patients or carers should be given advice on how to administer ispaghula husk with mebeverine granules.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Effervescent granules

CAUTIONARY AND ADVISORY LABELS 13, 22
EXCIPIENTS: May contain Aspartame
ELECTROLYTES: May contain Potassium
- Fybogel Mebeverine (Forum Health Products Ltd)
  - Ispaghula husk 3.5 gram, Mebeverine hydrochloride 135 mg Fybogel Mebeverine effervescent granules sachets orange (sugar-free) | 10 sachet | £3.91 DT price = £3.91

Liver disorders and related conditions

7.1 Biliary disorders

Biliary disorders

Drugs affecting biliary composition and flow

The use of laparoscopic cholecystectomy and of endoscopic biliary techniques has limited the place of the bile acid ursodeoxycholic acid p. 76 in gallstone disease. Ursodeoxycholic acid is suitable for patients with unimpaired gall bladder function, small or medium-sized radiolucent stones, and whose mild symptoms are not amenable to other treatment. Long-term prophylaxis may be needed after complete dissolution of the gallstones has been confirmed because they may recur in up to 25% of patients within one year of stopping treatment. Ursodeoxycholic acid is also used in primary biliary cirrhosis; liver tests improve in most patients but the effect on overall survival is uncertain.

A terpene mixture (Rowachol) raises biliary cholesterol solubility. It is not considered to be a useful adjunct.
Bile acid sequestrants
Colestyramine p. 173 is an anion-exchange resin that is not absorbed from the gastro-intestinal tract. It relieves diarrhea and pruritus by forming an insoluble complex with bile acids in the intestine.

Pancreatin
Supplements of pancreatic enzymes are given by mouth to compensate for reduced or absent exocrine secretion in cystic fibrosis, and following pancreatectomy, gastrectomy, or chronic pancreatitis. Pancreatin may also be necessary if a tumour (e.g. pancreatic cancer) obstructs outflow from the pancreas.

Pancreatin preparations

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Protease units</th>
<th>Amylase units</th>
<th>Lipase units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creon® 10 000 capsule</td>
<td>600</td>
<td>8000</td>
<td>10 000</td>
</tr>
<tr>
<td>Creon® Micro e/c granules</td>
<td>200</td>
<td>3600</td>
<td>5000</td>
</tr>
<tr>
<td>Pancrex® granules</td>
<td>300</td>
<td>4000</td>
<td>5000</td>
</tr>
<tr>
<td>Pancrex V® capsule powder</td>
<td>430</td>
<td>9000</td>
<td>8000</td>
</tr>
<tr>
<td>Pancrex V® ’125®’ capsule</td>
<td>160</td>
<td>3300</td>
<td>2950</td>
</tr>
<tr>
<td>Pancrex V® e/c tablet</td>
<td>110</td>
<td>1700</td>
<td>1900</td>
</tr>
<tr>
<td>Pancrex V® Forte e/c tablet</td>
<td>330</td>
<td>5000</td>
<td>5600</td>
</tr>
<tr>
<td>Pancrex V® powder (gram)</td>
<td>1400</td>
<td>30000</td>
<td>25000</td>
</tr>
</tbody>
</table>

Higher-strength pancreatin preparations

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Protease units</th>
<th>Amylase units</th>
<th>Lipase units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creon® 25 000 capsule</td>
<td>1000</td>
<td>18 000</td>
<td>25 000</td>
</tr>
<tr>
<td>Creon® 40 000 capsule</td>
<td>1600</td>
<td>25 000</td>
<td>40 000</td>
</tr>
<tr>
<td>Nutrizym 22® capsule</td>
<td>1100</td>
<td>19 800</td>
<td>22 000</td>
</tr>
<tr>
<td>Pancrease HL® capsule</td>
<td>1250</td>
<td>22 500</td>
<td>25 000</td>
</tr>
</tbody>
</table>

Bile acids

Ursodeoxycholic acid

**INDICATIONS AND DOSE**

**Dissolution of gallstones**

**BY MOUTH**

- Adult: 8–12 mg/kg once daily, dose to be taken at bedtime, alternatively 8–12 mg/kg daily in 2 divided doses for up to 2 years; treatment is continued for 3–4 months after stones dissolve

**Primary biliary cirrhosis**

**BY MOUTH**

- Adult: 12–16 mg/kg daily in 3 divided doses for 3 months, then 12–16 mg/kg once daily, dose to be taken at bedtime

**SIDE-EFFECTS**

- Common or very common: Diarrhoea
- Very rare: Abdominal pain, gallstone calcification, urticaria
- Frequency not known: Nausea, pruritus, vomiting

**PREGNANCY**

No evidence of harm but manufacturer advises avoid.

**BREAST FEEDING**

Not known to be harmful but manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

Avoid in chronic liver disease (but used in primary biliary cirrhosis).

**MONITORING REQUIREMENTS**

In primary biliary cirrhosis, monitor liver function every 4 weeks for 3 months, then every 3 months.

**PATIENT AND CARER ADVICE**

Patients should be given dietary advice (including avoidance of excessive cholesterol and calories).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 21**

- **URSODEOXYCHOLIC ACID (Non-proprietary)**
  - Ursodeoxycholic acid 150 mg: Ursodeoxycholic acid 150 mg tablets | 60 tablet (Pos) £19.02 DT price = £19.01
  - Ursodeoxycholic acid 300 mg: Ursodeoxycholic acid 300 mg tablets | 60 tablet (Pos) £38.86 DT price = £38.86
  - Destolit (Norgine Pharmaceuticals Ltd)
  - Ursodeoxycholic acid 150 mg: Destolit 150 mg tablets | 60 tablet (Pos) £18.39 DT price = £19.01
  - Ursofalk (Dr. Falk Pharma UK Ltd)
  - Ursodeoxycholic acid 500 mg: Ursofalk 500 mg tablets | 100 tablet (Pos) £80.00
  - Ursogal (Galén Ltd)
  - Ursodeoxycholic acid 150 mg: Ursogal 150 mg tablets | 60 tablet (Pos) £14.49 DT price = £15.01

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 21**

- **URSODEOXYCHOLIC ACID (Non-proprietary)**
  - Ursodeoxycholic acid 250 mg: Ursodeoxycholic acid 250 mg capsules | 60 capsule (Pos) £25.29 DT price = £25.29
  - Ursofalk (Dr. Falk Pharma UK Ltd)
  - Ursodeoxycholic acid 250 mg: Ursofalk 250 mg capsules | 60 capsule (Pos) £30.17 DT price = £25.29 | 100 capsule (Pos) £31.88
  - Ursogal (Galén Ltd)
  - Ursodeoxycholic acid 250 mg: Ursofalk 250 mg capsules | 60 capsule (Pos) £25.93 DT price = £25.29

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 21**

- Ursofalk (Dr. Falk Pharma UK Ltd)
- Ursodeoxycholic acid 50 mg per 1 ml: Ursofalk 250 mg/5ml oral suspension (sugar-free) | 250 ml (Pos) £26.98 DT price = £26.98

**TERPENES**

**Borneol with camphene, cineole, menthol, menthone and pinene**

**INDICATIONS AND DOSE**

**Biliary disorders**

**BY MOUTH**

- Adult: 1–2 capsules 3 times a day, to be taken before food

**LESS SUITABLE FOR PRESCRIBING**

Rowachol® is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
### 7.2 Oesophageal varices

**VASOPRESSIN AND ANALOGUES**

Drugs used for Oesophageal varices not listed below; *Vasopressin*, p. 576

---

**Terlipressin acetate**

**INDICATIONS AND DOSE**

**GLYPRESSIN® INJECTION**

**Bleeding from oesophageal varices**

**BY INTRAVENOUS INJECTION**

- Adult (body-weight up to 50 kg): Initially 2 mg every 4 hours until bleeding controlled, then reduced to 1 mg every 4 hours if required, maximum duration 48 hours.
- Adult (body-weight 50 kg and above): Initially 2 mg every 4 hours until bleeding controlled, reduced if not tolerated to 1 mg every 4 hours, maximum duration 48 hours.

**VARIQUEL® INJECTION**

**Bleeding from oesophageal varices**

**BY INTRAVENOUS INJECTION**

- Adult (body-weight up to 49 kg): Initially 1 mg, then 1 mg every 4–6 hours for up to 72 hours, to be administered over 1 minute.
- Adult (body-weight 50–69 kg): Initially 1.5 mg, then 1 mg every 4–6 hours for up to 72 hours, to be administered over 1 minute.
- Adult (body-weight 70 kg and above): Initially 2 mg, then 1 mg every 4–6 hours for up to 72 hours, to be administered over 1 minute.

---

**CAUTIONS**


**INTERCTIONS**

- Caution with concomitant use of drugs that prolong the QT-interval.

**SIDE-EFFECTS**

- Common or very common: Abdominal cramps - arrhythmia - bradycardia - diarrhoea - headache - hypertension - hypotension - pallor - peripheral ischaemia.
- Rare: Dizziness.
- Very rare: Hyperglycaemia - stroke.
- Frequency not known: Heart failure - skin necrosis.

**PREGNANCY**

Avoid unless benefits outweigh risk—uterine contractions and increased intra-uterine pressure in early pregnancy, and decreased uterine blood flow reported.

**BREAST FEEDING**

Avoid unless benefits outweigh risk—no information available.

**RENAI IMPAIRMENT**

Use with caution in chronic renal failure.

---

**8 Obesity**

**Obesity**

Obesity is associated with many health problems including cardiovascular disease, diabetes mellitus, gallstones and osteoarthritis. Factors that aggravate obesity may include depression, other psychosocial problems, and some drugs.

The main treatment of the obese individual is a suitable diet, carefully explained to the individual, with appropriate support and encouragement; the individual should also be advised to increase physical activity. Smoking cessation (while maintaining body weight) may be worthwhile before attempting supervised weight loss since cigarette smoking may be more harmful than obesity. Attendance at weight loss groups helps some individuals.

Obesity should be managed in an appropriate setting by staff who have been trained in the management of obesity; the individual should receive advice on diet and lifestyle modification and be monitored for changes in weight as well as in blood pressure, blood lipids and other associated conditions.

An anti-obesity drug should be considered only for those with a body mass index (BMI, individual’s bodyweight divided by the square of the individual’s height) of 30 kg/m² or greater in whom at least 3 months of managed care involving supervised diet, exercise and behaviour modification fails to achieve a realistic reduction in weight. In the presence of associated risk factors, it may be appropriate to prescribe an anti-obesity drug to individuals with a BMI of 28 kg/m² or greater. Drugs should never be used as the sole element of treatment. The individual should be monitored on a regular basis; drug treatment should be discontinued if the individual regains weight at any time whilst receiving drug treatment.

Combination therapy involving more than one anti-obesity drug is contra-indicated by the manufacturers; there is no evidence-base to support such treatment.

Thyroid hormones have no place in the treatment of obesity except in biochemically proven hypothyroid patients. The use of diuretics, choriionic gonadotrophin, or amphetamines is not appropriate for weight reduction.

**Anti-obesity drugs acting on the gastro-intestinal tract**

Orlistat p. 78 should be used in conjunction with other lifestyle measures to manage obesity; treatment should only be continued beyond 12 months after discussing potential benefits and risks with the patient. On stopping orlistat, there may be a gradual reversal of weight loss.
Some of the weight loss in those taking orlistat below probably results from individuals reducing their fat intake to avoid severe gastro-intestinal effects including steatorrhoea. Methylcellulose p. 45 is claimed to reduce food intake by producing a feeling of satiety, but there is little evidence to support its use in the management of obesity.

**Centrally acting appetite suppressants**

Phentermine and diethylpropion are central stimulants; they are not recommended for the treatment of obesity. Phentermine has been associated with a risk of pulmonary hypertension. Sibutramine, dexfenfluramine, and fenfluramine have been withdrawn because the benefit of treatment does not outweigh the risk of serious adverse effects.

**LIPASE INHIBITORS**

Orlistat

- **DRUG ACTION** Orlistat, a lipase inhibitor, reduces the absorption of dietary fat.

**INDICATIONS AND DOSE**

Adjunct in obesity (in conjunction with a mildly hypocaloric diet in individuals with a body mass index (BMI) of 30 kg/m² or more or in individuals with a BMI of 28 kg/m² or more in the presence of other risk factors such as type 2 diabetes, hypertension, or hypercholesterolaemia)  

- **BY MOUTH**
  - Adult: 120 mg up to 3 times a day, dose to be taken immediately before, during, or up to 1 hour after each main meal, continue treatment beyond 12 weeks only if weight loss since start of treatment exceeds 5% (target for initial weight loss may be lower in patients with type 2 diabetes), if a meal is missed or contains no fat, the dose of orlistat should be omitted

- **CONTRA-INDICATIONS** Cholestasis • chronic malabsorption syndrome

- **CAUTIONS** Chronic kidney disease • may impair absorption of fat-soluble vitamins • volume depletion

- **CAUTIONS, FURTHER INFORMATION**
  - Vitamin supplementation (especially of vitamin D) may be considered if there is concern about deficiency of fat-soluble vitamins.

- **INTERACTIONS** → Appendix 1 (orlistat).
  - Multivitamins If a multivitamin supplement is required, it should be taken at least 2 hours after orlistat dose or at bedtime.

- **SIDE-EFFECTS**
  - Common or very common Abdominal distension (gastro-intestinal effects minimised by reduced fat intake) • abdominal pain (gastro-intestinal effects minimised by reduced fat intake) • anxiety • faecal incontinence • faecal urgency • flatulence • gingival disorders • headache • hypoglycaemia • liquid stools • malaise • menstrual disturbances • oily leakage from rectum • oily stools • respiratory infections • tooth disorders • urinary tract infection
  - Frequency not known Bullous eruptions • cholelithiasis • diverticulitis • hepatitis • hypothyroidism • oxalate nephropathy • rectal bleeding

- **PREGNANCY** Use with caution.

- **BREAST FEEDING** Avoid—no information available.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **ORLISTAT (Non-proprietary)**
  - Orlistat 120 mg Orlistat 120mg capsules | 84 capsule £26.51-£30.05 DT price = £26.51
  - Alli (GlaxoSmithKline Consumer Healthcare) Orlistat 60 mg Alli 60mg capsules | 42 capsule £19.20 | 84 capsule £29.10 | 120 capsule £36.32
  - Beacita (Actavis UK Ltd) Orlistat 120 mg Beacita 120mg capsules | 84 capsule £31.63 DT price = £26.51
  - Xenical (Roche Products Ltd) Orlistat 120 mg Xenical 120mg capsules | 84 capsule £31.63 DT price = £26.51

9 Rectal and anal disorders

**Rectal and anal disorders**

Anal and perianal pruritus, soreness, and excoriation are best treated by application of bland ointments and suppositories. These conditions occur commonly in patients suffering from haemorrhoids, fistulas, and proctitis. Cleansing with attention to any minor faecal soiling, adjustment of the diet to avoid hard stools, the use of bulk-forming materials such as bran and a high residue diet are helpful. In proctitis these measures may supplement treatment with corticosteroids or sulphasalazine p. 37.

When necessary, topical preparations containing local anaesthetics or corticosteroids are used, provided perianal thrush has been excluded. Perianal thrush is treated with a topical antifungal preparation.

**Soothing haemorrhoidal preparations**

Soothing preparations containing mild astringents such as bismuth subgallate, zinc oxide, and hamamelis may give symptomatic relief in haemorrhoids. Many proprietary preparations also contain lubricants, vasoconstrictors, or mild antiseptics.

Local anaesthetics are used to relieve pain associated with haemorrhoids and pruritus ani but good evidence is lacking. Lidocaine hydrochloride ointment is used before emptying the bowel to relieve pain associated with anal fissure. Alternative local anaesthetics include tetracaine, cinchocaine (dibucaine), and pramoxine (pramoxime), but they are more irritant. Local anaesthetic ointments can be absorbed through the rectal mucosa therefore excessive application should be avoided, particularly in infants and children. Preparations containing local anaesthetics should be used for short periods only (no longer than a few days) since they may cause sensitisation of the anal skin.

**Compound haemorrhoidal preparations with corticosteroids**

Corticosteroids are often combined with local anaesthetics and soothing agents in preparations for haemorrhoids. They are suitable for occasional short-term use after exclusion of infections, such as herpes simplex; prolonged use can cause atrophy of the anal skin.

**Rectal sclerosants**

Oily phenol injection is used to inject haemorrhoids particularly when unprolapsed.

**Anal fissures**

The management of anal fissures requires stool softening by increasing dietary fibre in the form of bran or by using a bulk-forming laxative. Short-term use of local anaesthetic preparations may help. If these measures are inadequate, the patient should be referred for specialist treatment in hospital. The use of a topical nitrate (e.g. glyceryl trinitrate 0.4% ointment p. 190) may be considered. Before considering surgery, topical dilutiazem hydrochloride 2%
may be used twice daily [unlicensed indication] in patients with chronic anal fissures unresponsive to topical nitrates.

**Rectal and anal disorders in children**

Haemorrhoids in children are rare. Treatment is usually symptomatic and the use of a locally applied cream is appropriate for short periods; however, local anaesthetics can cause stinging initially and this may aggravate the child’s fear of defaecation.

**9.1 Haemorrhoids**

**CORTICOSTEROIDS**

**Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide**

**INDICATIONS AND DOSE**

Haemorrhoids | Priritus ani
---|---
**BY RECTUM USING SUPPOSITORIES**
- Adult: Apply twice daily for no longer than 7 days, to be applied morning and night, an additional dose after a bowel movement

**CAUTIONS**
- Local anaesthetic component can be absorbed through the rectal mucosa (avoid excessive application, particularly in children and infants) - local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)
- Proprietary brand Anusol Plus HC® (ointment and suppositories) is on sale to the public.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**
- Benzyl benzoate with bismuth oxide, hydrocortisone acetate, peru balsam, pramocaine hydrochloride and zinc oxide (Non-proprietary)

Benzyl benzoate 12 mg per 1 gram, Bismuth oxide 8.75 mg per 1 gram, Hydrocortisone acetate 5 mg per 1 gram, Pramocaine hydrochloride 10 mg per 1 gram, Zinc oxide 123.5 mg per 1 gram Anugesic-HC cream | 30 gram (Pack) £3.71

**Ointment**
- Benzyl benzoate with bismuth oxide, hydrocortisone acetate, peru balsam and zinc oxide (Non-proprietary)

Benzyl benzoate 12.5 mg per 1 gram, Bismuth oxide 8.75 mg per 1 gram, Hydrocortisone acetate 2.5 mg per 1 gram, Peru Balsam 18.75 mg per 1 gram, Zinc oxide 107.5 mg per 1 gram Anusol Plus HC ointment | 15 gram (£) £3.03
Anusol HC ointment | 30 gram (Pack) £2.49

**Cinchoacaine hydrochloride with fluocortolone caproate and fluocortolone pivalate**

**INDICATIONS AND DOSE**

Haemorrhoids | Priritus ani
---|---
**BY RECTUM USING OINTMENT**
- Adult: Apply twice daily for 5–7 days, apply 3–4 times a day if required, on the first day of treatment, then apply once daily for a few days after symptoms have cleared

**BY RECTUM USING SUPPOSITORIES**
- Adult: Initially 1 suppository daily for 5–7 days, to be inserted after a bowel movement, then 1 suppository once daily on alternate days for 1 week

**CAUTIONS**
- Local anaesthetic component can be absorbed through the rectal mucosa (avoid excessive application, particularly in children and infants) - local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suppository**
- UltraprocT (Meadow Laboratories Ltd)

Cinchoacaine hydrochloride 1 mg, Fluocortolone caproate 630 microgram, Fluocortolone pivalate 610 microgram UltraprocT suppositories | 12 suppository (Pack) £2.15
Cinchoacaine with hydrocortisone

**INDICATIONS AND DOSE**

**UNIROID-HC® SUPPOSITORIES**

Haemorrhoids | Pruritus ani

- Child 12-17 years: 1 suppository, insert twice daily and after a bowel movement, do not use for longer than 7 days
- Adult: 1 suppository, insert twice daily and after a bowel movement, do not use for longer than 7 days

**UNIROID-HC® OINTMENT**

Haemorrhoids | Pruritus ani

- Child 12-17 years: Apply twice daily, and apply after a bowel movement, apply externally or by rectum, do not use for longer than 7 days
- Adult: Apply twice daily, and apply after a bowel movement, apply externally or by rectum, do not use for longer than 7 days

**Suppository**

- CINCHOCAINE WITH HYDROCORTISONE (Non-proprietary)
  - Cinchoacaine hydrochloride 5 mg, Hydrocortisone 5 mg per 1 gram, Fluocortolone caprate 950 microgram per 1 gram, Fluocortolone pivalate 920 microgram per 1 gram
  - Uniproct suppositories | 12 suppository no price available
  - Proctosedyl (Sanofi)
  - Cinchoacaine hydrochloride 5 mg, Hydrocortisone 5 mg per 1 gram, Fluocortolone caprate 950 microgram per 1 gram, Fluocortolone pivalate 920 microgram per 1 gram
  - Uniproct suppositories | 12 suppository no price available

**Ointment**

- CINCHOCAINE WITH HYDROCORTISONE (Non-proprietary)
  - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Cinchoacaine 0.9% / Hydrocortisone 0.9% ointment | 30 gram no price available
  - Proctosedyl (Sanofi)
  - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Proctosedyl ointment | 30 gram £10.34
  - Uniroid HC (Chemidex Pharma Ltd)
  - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Uniroid HC ointment | 30 gram £4.23

**CAUTIONS**

- Local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Suppository**

- Scheriproct (Bayer Plc)
  - Cinchoacaine hydrochloride 1 mg, Prednisolone hexanoate 1.3 mg Scheriproct suppositories | 12 suppository £1.38

**Ointment**

- Scheriproct (Bayer Plc)
  - Cinchoacaine hydrochloride 5 mg per 1 gram, Prednisolone hexanoate 1.9 mg per 1 gram Scheriproct ointment | 30 gram £2.94

**INDICATIONS AND DOSE**

Haemorrhoids | Pruritus ani

- Adult: Apply twice daily for 5–7 days, apply 3–4 times a day on the first day if necessary, then apply once daily for a few days after symptoms have cleared

**BY RECTUM USING SUPPOSITORIES**

- Adult: Initially 1 suppository daily for 5–7 days, to be inserted after a bowel movement

**Haemorrhoids (severe cases) | Pruritus ani (severe cases)**

- Initially by rectum using suppositories

- Adult: Initially 1 suppository 2–3 times a day, then (by rectum) 1 suppository daily for a total of 5–7 days, to be inserted after a bowel movement

**CAUTIONS**

- Local anaesthetic component may be absorbed through the rectal mucosa (avoid excessive application) - local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Suppository**

- CINCHOCAINE WITH HYDROCORTISONE (Non-proprietary)
  - Cinchoacaine hydrochloride 5 mg, Hydrocortisone 5 mg per 1 gram, Fluocortolone caprate 950 microgram per 1 gram, Fluocortolone pivalate 920 microgram per 1 gram
  - Uniproct suppositories | 12 suppository no price available
  - Proctosedyl (Sanofi)
  - Cinchoacaine hydrochloride 5 mg, Hydrocortisone 5 mg per 1 gram, Fluocortolone caprate 950 microgram per 1 gram, Fluocortolone pivalate 920 microgram per 1 gram
  - Uniproct suppositories | 12 suppository no price available

**Ointment**

- CINCHOCAINE WITH HYDROCORTISONE (Non-proprietary)
  - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Cinchoacaine 0.9% / Hydrocortisone 0.9% ointment | 30 gram no price available
  - Proctosedyl (Sanofi)
  - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Proctosedyl ointment | 30 gram £10.34
  - Uniroid HC (Chemidex Pharma Ltd)
  - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Uniroid HC ointment | 30 gram £4.23

**CAUTIONS**

- Local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: mouthwash
Hydrocortisone with pramocaine

INDICATIONS AND DOSE
Haemorrhoids | Proctitis
BY RECTUM
▶ Adult: 1 applicatorful 2–3 times a day and 1 applicatorful, after a bowel movement, do not use for longer than 7 days; maximum 4 applicatorfuls per day

CAUTIONS Local anaesthetic component can be absorbed through the rectal mucosa (avoid excessive application) • local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Foam
▶ Proctofoam HC (Meda Pharmaceuticals Ltd)
Hydrocortisone acetate 10 mg per 1 gram, Pramocaine hydrochloride 10 mg per 1 gram Proctofoam HC foam enema | 40 dose [DS] £6.07 DT price + £6.07

RECTAL SCLEROSANTS

Phenol

INDICATIONS AND DOSE
Haemorrhoids (particularly when unprolapsed)
BY SUBMUCOSAL INJECTION
▶ Adult: 2–3 mL, dose (using phenol 5%) to be injected into the submucosal layer at the base of the pile; several injections may be given at different sites, max. total injected 10 mL at any one time

SIDE-EFFECTS Irritation • tissue necrosis

PRESCRIBING AND DISPENSING INFORMATION When prepared extemporaneously, the BP states Oily Phenol Injection, BP consists of phenol 5% in a suitable fixed oil.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, cutaneous solution, liquid

Solution for injection
▶ PHENOL (Non-proprietary)
Phenol 50 mg per 1 ml Oily phenol 5% solution for injection 5ml ampoules | 10 ampoule [DS] £47.91-£50.00
Oily phenol 5% solution for injection 2ml ampoules | 10 ampoule [DS] £38.03
82 Reduced exocrine secretions

**NUTRIZYM 22°® GASTRO-RESISTANT CAPSULES**

Pancreatic insufficiency

**BY MOUTH**

- Adult: Initially 1–2 capsules, dose to be taken with meals and 1 capsule as required, dose to be taken with snacks, doses should be swallowed whole or contents taken with water or mixed with soft food (then swallowed immediately without chewing)

**CREON® 25000**

Pancreatic insufficiency

**BY MOUTH**

- Child 2-17 years: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)
- Adult: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)

**CREON® MICRO**

Pancreatic insufficiency

**BY MOUTH**

- Child: Initially 100 mg, to be taken before each feed or meal; granules can be mixed with a small amount of milk or soft food and administered immediately (manufacturer recommends mixing with acidic liquid or pureed fruit before administration), granules should not be chewed before swallowing
- Adult: Initially 100 mg, to be taken before each feed or meal; granules can be mixed with a small amount of milk or soft food and administered immediately (manufacturer recommends mixing with acidic liquid or pureed fruit before administration), granules should not be chewed before swallowing

**Dose equivalence and conversion**

100 mg granules = one measured scoopful (scoop supplied with product).

**PANCREX®**

Pancreatic insufficiency

**BY MOUTH**

- Child 2-17 years: 5–10 g, to be taken just before meals, washed down or mixed with milk or water
- Adult: 5–10 g, to be taken just before meals, washed down or mixed with milk or water

**PANCREX® V POWDER**

Pancreatic insufficiency

**BY MOUTH**

- Child: 0.5–2 g, to be taken before or with meals, washed down or mixed with milk or water
- Adult: 0.5–2 g, to be taken before or with meals, washed down or mixed with milk or water

**CONTRA-INDICATIONS**

- **PANCREATE H L®**: Should not be used in children aged 15 years or less with cystic fibrosis.

**CAUTIONS**

- Can irritate the perioral skin and buccal mucosa if retained in the mouth. Excessive doses can cause perianal irritation

**INTERACTIONS** → Appendix 1 (pancreatin).

**SIDE-EFFECTS**

- Abdominal discomfort • hyperuricaemia (associated with very high doses) • hyperuricosuria (associated with very high doses) • mucosal irritation • nausea • skin irritation • vomiting

**PREGNANCY**

- Not known to be harmful.

**DIRECTIONS FOR ADMINISTRATION**

- Enteric-coated preparations deliver a higher enzyme concentration in the duodenum (provided the capsule contents are swallowed whole without chewing). Since pancreatin is inactivated by heat, excessive heat should be avoided if preparations are mixed with liquids or food; the resulting mixtures should not be kept for more than one hour. Gastro-resistant granules should be mixed with milk, slightly acidic soft food or liquid such as apple juice, and then swallowed immediately without chewing. Any left-over food or liquid containing pancreatin should be discarded. Capsules containing enteric-coated granules can be opened and the granules administered in the same way. Pancreatin is inactivated by gastric acid therefore pancreatin preparations are best taken with food (or immediately before or after food). Gastric acid secretion may be reduced by giving cimetidine or ranitidine an hour beforehand. Concurrent use of antacids also reduces gastric acidity.

**HANDLING AND STORAGE**

- Hypersensitivity reactions occur occasionally and may affect those handling the powder.

**PATIENT AND CARER ADVICE**

- Patients or carers should be given advice on administration. It is important to ensure adequate hydration at all times in patients receiving higher-strength pancreatin preparations.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant tablet**

**CAUTIONARY AND ADVISORY LABELS 5, 25**

- Pancrex (Essential Pharmaceuticals Ltd)
  - Amylase 1700 unit, Lipase 1900 unit, Protease 110 unit Pancrex V gastro-resistant tablets | 300 tablet £38.79
  - Amylase 5000 unit, Lipase 5600 unit, Protease 330 unit Pancrex V Forte gastro-resistant tablets | 300 tablet £48.11

- Capsule
  - Pancrex (Essential Pharmaceuticals Ltd)
    - Amylase 3300 unit, Lipase 2950 unit, Protease 160 unit Pancrex V 125mg capsules | 300 capsule £42.07
    - Amylase 9000 unit, Lipase 8000 unit, Protease 430 unit Pancrex V capsules | 300 capsule £53.20

**Gastro-resistant capsule**

- Creon (BGP Products Ltd)
  - Amylase 8000 unit, Lipase 10000 unit, Protease 600 unit Creon 10000 gastro-resistant capsules | 100 capsule £12.93
  - Amylase 18000 unit, Lipase 25000 unit, Protease 1000 unit Creon 25000 gastro-resistant capsules | 100 capsule £28.25
  - Amylase 25000 unit, Lipase 40000 unit, Protease 1600 unit Creon 40000 gastro-resistant capsules | 100 capsule £41.80

- Nutrizym (Merck Serono Ltd)
  - Amylase 19800 unit, Lipase 22000 unit, Protease 110 unit Nutrizym 22 gastro-resistant capsules | 100 capsule £33.33

- Pancrease (Janssen-Cilag Ltd)
  - Amylase 22500 unit, Lipase 25000 unit, Protease 1250 unit Pancrease HL gastro-resistant capsules | 100 capsule £40.38

**Gastro-resistant granules**

**CAUTIONARY AND ADVISORY LABELS 25**

- Creon (BGP Products Ltd)
  - Amylase 3600 unit, Lipase 5000 unit, Protease 200 unit Creon Micro Pancreate 60.12mg gastro-resistant granules | 40 gram £31.50

- Pancrex (Essential Pharmaceuticals Ltd)
  - Amylase 4000 unit, Lipase 5000 unit, Protease 300 unit Pancrex gastro-resistant granules | 300 gram £57.00

**Powder**

- Pancrex (Essential Pharmaceuticals Ltd)
  - Amylase 30000 unit, Lipase 25000 unit, Protease 1400 unit Pancrex V oral powder (sugar-free) | 300 gram £58.88
11 Stoma care

Prescribing for patients with stoma calls for special care. The following is a brief account of some of the main points to be borne in mind.

Enteric-coated and modified-release preparations are unsuitable, particularly in patients with an ileostomy, as there may not be sufficient release of the active ingredient.

Laxatives
Enemas and washouts should not be prescribed for patients with an ileostomy as they may cause rapid and severe loss of water and electrolytes. Colostomy patients may suffer from constipation and whenever possible should be treated by increasing fluid intake or dietary fibre. Bulk-forming drugs should be tried. If they are insufficient, as small a dose as possible of senna p. 53 should be used.

Antidiarrhoeals
Drugs such as loperamide hydrochloride p. 56, codeine phosphate p. 360, or co-phenotrope p. 55 (diphenoxylate with atropine) are effective. Bulk-forming drugs may be tried but it is often difficult to adjust the dose appropriately. Antibacterials should not be given for an episode of acute diarrhoea.

Antacids
The tendency to diarrhoea from magnesium salts or constipation from aluminium salts may be increased in these patients.

Diuretics
Diuretics should be used with caution in patients with an ileostomy as they may become excessively dehydrated and potassium depletion may easily occur. It is usually advisable to use a potassium-sparing diuretic.

Digoxin
Patients with a stoma are particularly susceptible to hypokalaemia if on digoxin p. 94 therapy and potassium supplements or a potassium-sparing diuretic may be advisable.

Potassium supplements
Liquid formulations are preferred to modified-release formulations.

Analgesics
Opioid analgesics may cause troublesome constipation in colostomy patients. When a non-opioid analgesic is required paracetamol p. 354 is usually suitable but anti-inflammatory analgesics may cause gastric irritation and bleeding.

Iron preparations
Iron preparations may cause loose stools and sore skin in these patients. If this is troublesome and if iron is definitely indicated an intramuscular iron preparation should be used. Modified-release preparations should be avoided for the reasons given above.

Care of stoma
Patients are usually given advice about the use of cleansing agents, protective creams, lotions, deodorants, or sealants whilst in hospital, either by the surgeon or by stoma care nurses. Voluntary organisations offer help and support to patients with stoma.
Chapter 2

Cardiovascular system

1 Arrhythmias

Arrhythmias

Management of an arrhythmia requires precise diagnosis of the type of arrhythmia, and electrocardiography is essential; underlying causes such as heart failure require appropriate treatment.

Ectopic beats

If ectopic beats are spontaneous and the patient has a normal heart, treatment is rarely required and reassurance to the patient will often suffice. If they are particularly troublesome, beta-blockers are sometimes effective and may be safer than other suppressant drugs.

Atrial fibrillation

Treatment of patients with atrial fibrillation aims to reduce symptoms and prevent complications, especially stroke. All patients with atrial fibrillation should be assessed for their risk of stroke and thromboembolism. Atrial fibrillation can be managed by either controlling the ventricular rate (‘rate control’) or by attempting to restore and maintain sinus rhythm (‘rhythm control’). At any stage if treatment fails to control symptoms, or, if symptoms recur after cardioversion and specialised management is required, referral should be made within 4 weeks. If drug treatment fails to control the symptoms of atrial fibrillation or is unsuitable, ablation strategies can be considered. Review anticoagulation, stroke, and bleeding risk at least annually in all patients with atrial fibrillation.

Acute presentation

All patients with life-threatening haemodynamic instability caused by new-onset atrial fibrillation should undergo emergency electrical cardioversion without delaying to achieve anticoagulation. In patients presenting acutely but without life-threatening haemodynamic instability, rate or rhythm control can be offered if the onset of arrhythmia is less than 48 hours; rate control is preferred if onset is more than 48 hours or uncertain. Consideration of pharmacological or electrical cardioversion should be based on clinical circumstances. If pharmacological cardioversion has been agreed, intravenous amiodarone hydrochloride p. 88, or alternatively flecainide acetate p. 91, can be used (amiodarone hydrochloride is preferred if there is structural heart disease). If urgent rate control is required, a beta-blocker or verapamil hydrochloride p. 156 can be given intravenously.

Cardioversion

Sinus rhythm can be restored by electrical cardioversion, or pharmacological cardioversion with an oral or intravenous antiarrhythmic drug e.g. flecainide acetate or amiodarone hydrochloride. If atrial fibrillation has been present for more than 48 hours, electrical cardioversion is preferred and should not be attempted until the patient has been fully anticoagulated for at least 3 weeks; if this is not possible, parenteral anticoagulation should be commenced, and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks; prior to cardioversion, offer rate control as appropriate.

Drug treatment

Rate control is the preferred first-line drug treatment strategy for atrial fibrillation except in patients with new-onset atrial fibrillation, heart failure secondary to atrial fibrillation, atrial flutter suitable for an ablation strategy, atrial fibrillation with a reversible cause, or if rhythm control is more suitable based on clinical judgement. Ventricular rate can be controlled with a standard beta-blocker (not sotalol hydrochloride p. 93) or a rate-limiting calcium channel blocker such as diltiazem hydrochloride p. 149 [unlicensed indication], or verapamil hydrochloride p. 156 as monotherapy. Choice of drug should be based on individual symptoms, heart rate, comorbidities, and patient preference. Digoxin p. 94 is usually only effective for controlling the ventricular rate at rest, and should therefore only be used as monotherapy in predominantly sedentary patients with non-paroxysmal atrial fibrillation. When a single drug fails to adequately control the ventricular rate, a combination of two drugs including a beta-blocker, digoxin, or diltiazem hydrochloride can be used. If symptoms are not controlled with a combination of two drugs, a rhythm-control strategy should be considered. If ventricular function is diminished, the combination of a beta-blocker (that is licensed for use in heart failure) and digoxin is preferred. Digoxin is also used when atrial fibrillation is accompanied by congestive heart failure.

If drug treatment is required to maintain sinus rhythm (‘rhythm control’) post-cardioversion, a standard beta-
blocker is used. If a standard beta-blocker is not appropriate or is ineffective, consider an oral anti-arrhythmic drug such as sotalol hydrochloride p. 93, flecainide acetate p. 91, propafenone hydrochloride p. 92, or amiiodarone hydrochloride p. 88; dronedarone p. 50 may be considered in paroxysmal or persistent atrial fibrillation (see NICE guidance). If necessary, amiiodarone hydrochloride can be started 4 weeks before and continuing for up to 12 months after electrical cardioversion to increase success of the procedure, and to maintain sinus rhythm. Flecainide acetate or propafenone hydrochloride should not be given when there is known ischaemic or structural heart disease. Controlled trial data on rate control and its management in patients with left ventricular impairment or heart failure.

**Paroxysmal atrial fibrillation**

In symptomatic paroxysmal atrial fibrillation, ventricular rhythm is controlled with a standard beta-blocker. Alternatively, if symptoms persist or a standard beta-blocker is not appropriate, an oral anti-arrhythmic drug such as dronedarone p. 90 (see NICE guidance), sotalol hydrochloride p. 93, flecainide acetate p. 91, propafenone hydrochloride p. 92, or amiiodarone hydrochloride p. 88 can be given (see also Paroxysmal supraventricular tachycardia and Supraventricular arrhythmias). In selected patients with infrequent episodes of symptomatic paroxysmal atrial fibrillation, sinus rhythm can be restored using the ‘pill-in-the-pocket’ approach; this involves the patient taking oral flecainide acetate or propafenone hydrochloride to self-treat an episode of atrial fibrillation when it occurs.

**Stroke prevention**

All patients with atrial fibrillation should be assessed for their risk of stroke and the need for thromboprophylaxis; this needs to be balanced with the patient’s risk of bleeding; a NICE guideline (NICE clinical guideline 100 (June 2014). Atrial fibrillation: Management of atrial fibrillation) recommends using the CHA2DS2-VASc assessment tool for stroke risk and the HAS-BLED tool for bleeding risk prior to and during anticoagulation. Risk factors for stroke taken into account by CHA2DS2-VASc include prior ischaemic stroke, transient ischaemic attacks, or thromboembolic events, heart failure, left ventricular systolic dysfunction, vascular disease, diabetes, hypertension, females, and patients over 65 years. Patients with a very low risk of stroke (CHA2DS2-VASc score of 0 for men or 1 for women) do not require an antithrombotic for stroke prevention. Parenteral anticoagulation should be offered to patients with new-onset atrial fibrillation who are receiving subtherapeutic or no anticoagulation therapy until assessment is made, and appropriate anticoagulation is started. Oral anticoagulation should be offered to patients with confirmed diagnosis of atrial fibrillation in whom sinus rhythm has not been successfully restored within 48 hours of onset, patients who have had, or are at high risk of recurrence of atrial fibrillation such as those with structural heart disease, prolonged history of atrial fibrillation (more than 12 months), a history of failed attempts at cardioversion, and patients whom the risk of stroke outweighs the risk of bleeding. Anticoagulant treatment should not be withheld solely because of the risk of falls, and choice of treatment should be based on clinical features and patient preferences. Oral anticoagulation may be with a vitamin K antagonist (e.g warfarin sodium p. 121, or in non-valvular atrial fibrillation with apixaban p. 108, dabigatran etexilate p. 117, or rivaroxaban p. 109. Anticoagulants are also indicated during cardioversion procedures. Aspirin p. 104 is less effective than warfarin sodium at preventing emboli; the modest benefit is offset by the risk of bleeding, and aspirin should not be offered as monotherapy solely for stroke prevention in atrial fibrillation. If anticoagulant treatment is contraindicated or not tolerated, left atrial appendage occlusion can be considered.

**Atrial flutter**

Like atrial fibrillation, treatment options for atrial flutter involve either controlling the ventricular rate or attempting to restore and maintain sinus rhythm. However, atrial flutter generally responds less well to drug treatment than atrial fibrillation.

Control of the ventricular rate is usually an interim measure pending restoration of sinus rhythm. Ventricular rate can be controlled by administration of a beta-blocker, diltiazem hydrochloride p. 149 [unlicensed indication], or verapamil hydrochloride p. 156; an intravenous beta-blocker or verapamil hydrochloride is preferred for rapid control. Digoxin p. 94 can be added if rate control remains inadequate, and may be particularly useful in those with heart failure.

Conversion to sinus rhythm can be achieved by electrical cardioversion (by cardiac pacing or direct current), pharmacological cardioversion, or catheter ablation. If the duration of atrial flutter is unknown, or it has lasted for over 48 hours, cardioversion should not be attempted until the patient has been fully anticoagulated for at least 3 weeks; if this is not possible, parenteral anticoagulation should be commenced and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks.

Direct current cardioversion is usually the treatment of choice when rapid conversion to sinus rhythm is necessary (e.g. when atrial flutter is associated with haemodynamic compromise); catheter ablation is preferred for the treatment of recurrent atrial flutter. There is a limited role for anti-arrhythmic drugs as their use is not always successful. Flecainide acetate p. 91 or propafenone hydrochloride p. 92 can slow atrial flutter, resulting in 1:1 conduction to the ventricles, and should therefore be prescribed in conjunction with a ventricular rate controlling drug such as a beta-blocker, diltiazem hydrochloride p. 149 [unlicensed indication], or verapamil hydrochloride p. 156. Amiodarone hydrochloride p. 88 can be used when other drug treatments are contra-indicated or ineffective.

All patients should be assessed for their risk of stroke and the need for thromboprophylaxis; the choice of anticoagulant is based on the same criteria as for atrial fibrillation.

**Paroxysmal supraventricular tachycardia**

This will often terminate spontaneously or with reflex vagal stimulation such as a Valsalva manoeuvre, immersing the face in ice-cold water, or carotid sinus massage; such manoeuvres should be performed with ECG monitoring. If the effects of reflex vagal stimulation are transient or ineffective, or if the arrhythmia is causing severe symptoms, or if other drug treatments are contra-indicated or ineffective, treatment with direct current cardioversion is needed in haemodynamically unstable patients or when the above measures have failed to restore sinus rhythm (and an alternative diagnosis has not been found).

Recurrent episodes of paroxysmal supraventricular tachycardia can be treated by catheter ablation, or prevented with drugs such as diltiazem hydrochloride p. 149, verapamil hydrochloride p. 156, beta-blockers including sotalol hydrochloride p. 93, flecainide acetate p. 91 or propafenone hydrochloride p. 92.
86 Arrhythmias

Arterial hypertension

In patients with arterial hypertension related to sodium intake or intravascular volume, the use of an ACE inhibitor may reduce the need for anti-hypertensive therapy.

Cardiovascular system

worsening the condition.

Anti-arrhythmics can further prolong the QT interval, thus increasing the risk of asystole, or if the patient is unstable and has no response, direct current cardioversion or pacing should be considered.

intravenous infusion, and the dose adjusted according to haemodynamic stability.

Beta-blockers or sotalol hydrochloride p. 92 should be considered. Catheter ablation is an alternative if anti-arrhythmic drugs are ineffective. A beta-blocker (but not sotalol hydrochloride) is preferred drug. Flecainide acetate p. 91, propafenone hydrochloride p. 92, and, although less effective, lidocaine hydrochloride p. 91 have all been used. If sinus rhythm is not restored, direct current cardioversion of pacing should be considered. Catheter ablation is an alternative if cessation of the arrhythmia is not urgent. Non-sustained ventricular tachycardia can be treated with a beta-blocker.

All patients presenting with ventricular tachycardia should be referred to a specialist. Following restoration of sinus rhythm, patients who remain at high risk of cardiac arrest will require maintenance therapy. Most patients will be treated with an implantable cardioverter defibrillator. Beta-blockers or sotalol hydrochloride p. 93 (in place of a standard beta-blocker), or amiodarone hydrochloride (in combination with a standard beta-blocker), can be used in addition to the device in some patients; alternatively, they can be used alone when use of an implantable cardioverter defibrillator is not appropriate.

Torsade de pointes

Torsade de pointes is a form of ventricular tachycardia associated with a long QT syndrome (usually drug-induced, but other factors including hypokalaemia, severe bradycardia, and genetic predisposition are also implicated). Episodes are usually self-limiting, but are frequently recurrent and can cause impairment or loss of consciousness. If not controlled, the arrhythmia can progress to ventricular fibrillation and sometimes death. Intravenous infusion of magnesium sulfate p. 858 is usually effective. A beta-blocker (but not sotalol hydrochloride p. 93) and atrial (or ventricular) pacing can be considered. Anti-arrhythmics can further prolong the QT interval, thus worsening the condition.

Drugs for arrhythmias

Anti-arrhythmic drugs can be classified clinically into those that act on supraventricular arrhythmias (e.g. verapamil hydrochloride p. 156), those that act on both supraventricular and ventricular arrhythmias (e.g. amiodarone hydrochloride p. 88, and those that act on ventricular arrhythmias (e.g. lidocaine hydrochloride p. 91).

Anti-arrhythmic drugs can also be classified according to their effects on the electrical behaviour of myocardial cells during activity (the Vaughan Williams classification) although this classification is of less clinical significance:

- Class I: membrane stabilising drugs (e.g. lidocaine, flecainide)
- Class II: beta-blockers
- Class III: amiodarone, sotalol (also Class II)
- Class IV: calcium-channel blockers (includes verapamil but not dihydropyridines)

The negative inotropic effects of anti-arrhythmic drugs tend to be additive. Therefore special care should be taken if two or more are used, especially if myocardial function is impaired. Most drugs that are effective in countering arrhythmias can also provoke them in some circumstances; moreover, hypokalaemia enhances the arrhythmogenic (pro-arrhythmic) effect of many drugs.

Supraventricular arrhythmias

Adenosine p. 87 is usually the treatment of choice for terminating paroxysmal supraventricular tachycardia. As it has a very short duration of action (half-life only about 8 to 10 seconds, but prolonged in those taking dipyridamole p. 107), most side-effects are short-lived. Unlike verapamil hydrochloride p. 156, adenosine can be used after a beta-blocker. Verapamil hydrochloride may be preferable to adenosine in asthma.

Oral administration of a cardiac glycoside (such as digoxin p. 94) slows the ventricular response in cases of atrial fibrillation and atrial flutter. However, intravenous infusion of digoxin is rarely effective for rapid control of ventricular rate. Cardiac glycosides are contra-indicated in supraventricular arrhythmias associated with accessory conducting pathways (e.g. Wolff- Parkinson-White syndrome).

Verapamil hydrochloride is usually effective for supraventricular arrhythmias. An initial intravenous dose (important: serious beta-blocker interaction hazard) may be followed by oral treatment; hypotension may occur with large doses. It should not be used for tachyarrhythmias where the QRS complex is wide (i.e. broad complex) unless a supraventricular origin has been established beyond reasonable doubt. It is also contra-indicated in atrial fibrillation or atrial flutter associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome). It should not be used in children with arrhythmias without specialist advice; some supraventricular arrhythmias in childhood can be accelerated by verapamil hydrochloride with dangerous consequences.

Intravenous administration of a beta-blocker such as esmolol hydrochloride p. 143 or propranolol hydrochloride p. 146, can achieve rapid control of the ventricular rate. Drugs for both supraventricular and ventricular arrhythmias include amiodarone hydrochloride p. 88, beta-blockers, disopyramide p. 89, flecainide acetate p. 91, procainamide (available from ‘special-order’ manufacturers or specialist importing companies), and propafenone hydrochloride p. 92.

Supraventricular and ventricular arrhythmias

Amiodarone hydrochloride is used in the treatment of arrhythmias, particularly when other drugs are ineffective or contraindicated. It can be used for paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation and flutter, and ventricular fibrillation. It can also be used for tachyarrhythmias associated with Wolff-Parkinson-White syndrome. It should be initiated only under hospital or specialist supervision. Amiodarone hydrochloride may be given by intravenous infusion as well as by mouth, and has the advantage of causing little or no myocardial depression. Unlike oral amiodarone hydrochloride, intravenous amiodarone hydrochloride acts relatively rapidly.

Intravenous injection of amiodarone hydrochloride can be used in cardiopulmonary resuscitation for ventricular
fibrillation or pulseless tachycardia unresponsive to other interventions.

Amiodarone hydrochloride has a very long half-life (extending to several weeks) and only needs to be given once daily (but high doses can cause nausea unless divided). Many weeks or months may be required to achieve steady-state plasma-amiodarone concentration; this is particularly important when drug interactions are likely. **Beta-blockers** act as anti-arrhythmic drugs principally by attenuating the effects of the sympathetic system on automaticity and conductivity within the heart. Sotalol hydrochloride p. 93 has a role in the management of ventricular arrhythmias.

Disopyramide p. 89 can be given by intravenous injection to control arrhythmias after myocardial infarction (including those not responding to lidocaine hydrochloride p. 91), but it impairs cardiac contractility. Oral administration of disopyramide is useful, but it has an antimuscarinic effect which limits its use in patients susceptible to angle-closure glaucoma or with prostatic hyperplasia.

Flecainide acetate p. 91 belongs to the same general class as lidocaine hydrochloride p. 91 and may be of value for serious symptomatic ventricular arrhythmias. It may also be indicated for junctional re-entry tachycardias and for paroxysmal atrial fibrillation. However, it can precipitate serious arrhythmias in a small minority of patients (including those with otherwise normal hearts).

Propafenone hydrochloride p. 92 is used for the prophylaxis and treatment of ventricular arrhythmias and also for some supraventricular arrhythmias. It has complex mechanisms of action, including weak beta-blocking activity (therefore caution is needed in obstructive airways disease—contra-indicated if severe).

Drugs for supraventricular arrhythmias include adenosine below, **cardiac glycosides**, and verapamil hydrochloride p. 156. Drugs for ventricular arrhythmias include lidocaine hydrochloride.

Mexiletine and procainamide are both available from ‘special-order’ manufacturers or specialist importing companies. Mexiletine can be used for life-threatening ventricular arrhythmias; procainamide is given by intravenous injection to control ventricular arrhythmias.

**Ventricular arrhythmias**

Intravenous lidocaine hydrochloride can be used for the treatment of ventricular tachycardia in haemodynamically stable patients, and ventricular fibrillation and pulseless ventricular tachycardia in cardiac arrest refractory to defibrillation, however it is no longer the anti-arrhythmic drug of first choice.

Drugs for both supraventricular and ventricular arrhythmias include amiodarone hydrochloride, **beta-blockers**, disopyramide, flecainide acetate, **procainamide** (available from ‘special-order’ manufacturers or specialist importing companies), and propafenone hydrochloride.

**Mexiletine** is available from ‘special-order’ manufacturers or specialist importing companies for treatment of life-threatening ventricular arrhythmias.

---

**ANTIARRHYTHMICS**

**Adenosine**

**INDICATIONS AND DOSE**

**Rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory conducting pathways (e.g. Wolf-Parkinson-White syndrome)** | **Used to aid to diagnosis of broad or narrow complex supraventricular tachycardias**

**BY RAPID INTRAVENOUS INJECTION**

- Adult: Initially 6 mg, administer into central or large peripheral vein and give over 2 seconds, cardiac monitoring required, followed by 12 mg after 1–2 minutes if required, then 12 mg after 1–2 minutes if required, increments should not be given if high level AV block develops at any particular dose.

**Rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory conducting pathways (e.g. Wolf-Parkinson-White syndrome) in patients with a heart transplant** | **Aid to diagnosis of broad or narrow complex supraventricular tachycardias in patients with a heart transplant**

**BY RAPID INTRAVENOUS INJECTION**

- Adult: Initially 3 mg, administer into a central or large peripheral vein and give over 2 seconds, followed by 6 mg after 1–2 minutes if required, then 12 mg after 1–2 minutes if required, patients with a heart transplant are very sensitive to the effects of adenosine.

**Used in conjunction with radioisotope myocardial perfusion imaging in patients who cannot exercise adequately or for whom exercise is inappropriate**

**BY INTRAVENOUS INFUSION**

- Adult: (consult product literature)

**Dose adjustments due to interactions**

If essential to give with dipyridamole reduce adenosine dose to a quarter of the usual dose.

- **UNLICENSED USE** Adenosine doses in the BNF may differ from those in the product literature.

- **CONTRA-INDICATIONS** Asthma, chronic obstructive lung disease—decompensated heart failure—long QT syndrome—second- or third-degree AV block and sick sinus syndrome (unless pacemaker fitted)—severe hypotension.

- **CAUTIONS** Atrial fibrillation with accessory pathway (conduction down anomalous pathway may increase)—atrial flutter with accessory pathway (conduction down anomalous pathway may increase)—autonomic dysfunction—bundle branch block—first-degree AV block—heart transplant—left main coronary artery stenosis—left to right shunt—pericardial effusion—pericarditis—QT-interval prolongation—recent myocardial infarction—severe heart failure—stenotic carotid artery disease with cerebrovascular insufficiency—stenotic valvular heart disease—uncorrected hypovolaemia.

- **INTERACTIONS** | Appendix 1 (adenosine); also possibility of interaction with drugs tending to impair myocardial conduction.

- **SIDE-EFFECTS**

  - **Common or very common** Angina (discontinue)—apprehension—arrhythmia (discontinue if asystole or severe bradyarrhythmia occur)—AV block—dizziness—dyspnoea—flushing—headache—nausea—sinus pause.

  - **Uncommon** Blurred vision—hyperventilation—metallic taste—palpitation—sweating—weakness.

  - **Very rare** Bronchospasm—injection-site reactions—transient worsening of intracranial hypertension.

  - **Frequency not known** Cardiac arrest—convulsions—hypotension (discontinue if severe)—respiratory failure (discontinue)—syncope—vomiting.
Amiodarone hydrochloride

INDICATIONS AND DOSE
Treatment of arrhythmias, particularly when other drugs are ineffective or contra-indicated (including paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation and flutter, ventricular fibrillation, and tachyarrhythmias associated with Wolff-Parkinson-White syndrome (initiated in hospital or under specialist supervision) by mouth
- Adult: 200 mg 3 times a day for 1 week, then reduced to 200 mg twice daily for a further week, followed by maintenance dose, usually 200 mg daily or the minimum dose required to control arrhythmia by intravenous infusion
- Adult: Initially 5 mg/kg, to be given over 20–120 minutes with ECG monitoring, subsequent infusions given if necessary according to response; maximum 1.2 g per day

Ventricular fibrillation or pulseless ventricular tachycardia refractory to defibrillation initially by intravenous injection
- Adult: Initially 300 mg, dose to be considered after administration of adrenaline, dose should be given from a pre-filled syringe or diluted in 20 mL Glucose 5%, then (by intravenous injection) 150 mg if required, followed by (by intravenous infusion) 900 mg/24 hours

CONTRA-INDICATIONS
GENERAL CONTRA-INDICATIONS
Avoid in severe conduction disturbances (unless pacemaker fitted) - avoid in sinus node disease (unless pacemaker fitted) - iodine sensitivity - sino-atrial heart block (except in cardiac arrest) - sinus bradycardia (except in cardiac arrest) - thyroid dysfunction

SPECIFIC CONTRA-INDICATIONS
- With intravenous use Avoid bolus injection in cardiomyopathy - avoid bolus injection in congestive heart failure - avoid in circulatory collapse - avoid in severe arterial hypotension - avoid in severe respiratory failure

CAUTIONS
GENERAL CAUTIONS
Acute porphyrias p. 864 - conduction disturbances (in excessive dosage) - elderly - heart failure - hypokalaemia - severe bradycardia (in excessive dosage)

SPECIFIC CAUTIONS
- With intravenous use Moderate and transient fall in blood pressure (circulatory collapse precipitated by rapid administration or overdosage) - severe hepatocellular toxicity

INTERACTIONS → Appendix 1 (amiodarone).
Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped.

Use extreme caution or avoid concomitant use of drugs that prolong QT interval. Risk of severe bradycardia or heart block when amiodarone is used in combination with sofosbuvir and daclatasvir for hepatitis C.

SIDE-EFFECTS
GENERAL SIDE-EFFECTS
- Common or very common Bradycardia - hyperthyroidism - hypothyroidism - jaundice - nausea - persistent slate grey skin discoloration - phototoxicity - pulmonary toxicity (including pneumonitis and fibrosis) - raised serum transaminases (may require dose reduction or withdrawal if accompanied by acute liver disorders) - reversible corneal microdeposits (sometimes with night glare) - sleep disorders - taste disturbances - tremor - vomiting

- Uncommon Conduction disturbances - onset or worsening of arrhythmia - peripheral myopathy (usually reversible on withdrawal) - peripheral neuropathy (usually reversible on withdrawal)

- Very rare Alopecia - aplastic anaemia - ataxia - benign intracranial hypertension - bronchospasm (in patients with severe respiratory failure) - chronic liver disease - cirrhosis - epididymo-orchitis - exfoliative dermatitis - haemolytic anaemia - headache - hypersensitivity - impaired vision due to optic neuritis or optic neuropathy (including blindness) - impotence - rash - sinus arrest - thrombocytopenia - vasculitis - vertigo

- Frequency not known Hot flushes - hypotension - respiratory distress syndrome - sweating

SPECIFIC SIDE-EFFECTS
- Common or very common
- With intravenous use injection-site reactions
- Very rare
- With intravenous use anaphylaxis on rapid injection

SIDE-EFFECTS, FURTHER INFORMATION
Corneal microdeposits Most patients taking amiodarone develop corneal microdeposits (reversible on withdrawal of treatment); these rarely interfere with vision, but drivers may be dazzled by headlights at night. However, if vision is impaired or if optic neuritis or optic neuropathy occur, amiodarone must be stopped to prevent blindness and expert advice sought.

Thyroid function Amiodarone contains iodine and can cause disorders of thyroid function; both hypothyroidism and hyperthyroidism may occur. Thyrotoxicosis may be very refractory, and amiodarone should usually be withdrawn at least temporarily to help achieve control; treatment with carbimazole may be required.

Hypothyroidism can be treated with replacement therapy without withdrawing amiodarone if it is essential; careful supervision is required.

Hepatotoxicity Amiodarone is also associated with hepatotoxicity and treatment should be discontinued if
severe liver function abnormalities or clinical signs of liver disease develop.

**Pulmonary toxicity** Pneumonitis should always be suspected if new or progressive shortness of breath or cough develops in a patient taking amiodarone.

**Peripheral neuropathy** Fresh neurological symptoms should raise the possibility of peripheral neuropathy.

- **PREGNANCY** Possible risk of neonatal goitre; use only if no alternative.
- **BREAST FEEDING** Avoid; present in milk in significant amounts; theoretical risk of neonatal hypothyroidism from release of iodine.

**MONITORING REQUIREMENTS**

- Thyroid function tests should be performed before treatment and then every 6 months. Clinical assessment of thyroid function alone is unreliable. Thyroxine (T4) may be raised in the absence of hyperthyroidism; therefore tri-iodothyronine (T3), T4, and thyroid-stimulating hormone (thyrotrophin, TSH) should all be measured. A raised T3 and T4 with a very low or undetectable TSH concentration suggests the development of thyrotoxicosis.
- Liver function tests required before treatment and then every 6 months.
- Serum potassium concentration should be measured before treatment.
- Chest x-ray required before treatment.

If concomitant use of amiodarone with sofosbuvir and daclatasvir cannot be avoided because other anti-arrhythmics are not tolerated or contraindicated, patients should be closely monitored, particularly during the first weeks of treatment.

- Patients at high risk of bradycardia should be monitored continuously for 48 hours in an appropriate clinical setting after starting concomitant treatment.
- Patients who have stopped amiodarone within the last few months and need to start sofosbuvir and daclatasvir should be monitored.
- With intravenous use, ECG monitoring and resuscitation facilities must be available. Monitor liver transaminases closely.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For intravenous infusion (Cordarone X®), give continuously or intermittently in Glucose 5%. Suggested initial infusion volume 250 mL given over 20–120 minutes; for repeat infusions up to 1.2 g in max. 500 mL; should not be diluted to less than 600 micrograms/mL. See cardio-pulmonary resuscitation for details of infusion in extreme emergency. Incompatible with Sodium Chloride infusion fluids; avoid equipment containing the plasticizer di-2-ethylhexylphthalate (DEHP).
- With oral use For administration by mouth, tablets may be crushed and dispersed in water; injection solution should not be given orally (irritant).

**PATIENT AND CARER ADVICE** Because of the possibility of phototoxic reactions, patients should be advised to shield the skin from light during treatment and for several months after discontinuing amiodarone; a wide-spectrum sunscreen to protect against both long-wave ultraviolet and visible light should be used.

If taking amiodarone with sofosbuvir and daclatasvir, patients and their carers should be told how to recognise signs and symptoms of bradycardia and heart block and advised to seek immediate medical attention if symptoms such as shortness of breath, light-headedness, palpitations, fainting, unusual tiredness or chest pain develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder for suspension.

**CONTRA-INDICATIONS** Bundle-branch block associated with first-degree AV block - second- and third-degree AV block or bifascicular block (unless pacemaker fitted) - severe heart failure (unless secondary to arrhythmia) - severe sinus node dysfunction

**CAUTIONS** Atrial flutter or atrial tachycardia with partial block - avoid in Acute porphyrias p. 864 - elderly - heart failure (avoid if severe) - myasthenia gravis - prostatic enlargement - structural heart disease - susceptibility to angle-closure glaucoma

**INTERACTIONS** † Appendix 1 (disopyramide).

**SIDE-EFFECTS** Angle-closure glaucoma - antimuscarinic effects - AV block - blurred vision - cholestatic jaundice - dry mouth - gastro-intestinal irritation - hypoglycaemia - hypotension - myocardial depression - psychosis - urinary retention - ventricular tachycardia, ventricular fibrillation or torsade de pointes (usually associated with prolongation of QRS complex or QT interval)

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk; may induce labour if used in third trimester.

**BREAST FEEDING** Present in milk - use only if essential. Monitor infant for antimuscarinic effects.

**HEPATIC IMPAIRMENT** Half-life prolonged — may need dose reduction. Avoid modified-release preparation.

**RENAI IMPAIRMENT** Reduce dose by increasing dose interval; adjust according to response. Avoid modified-release preparation.

**SOLUTION FOR INJECTION**

- **EXCIPIENTS:** May contain Benzyl alcohol
- **AMIODARONE HYDROCHLORIDE (Non-proprietary)**
  - Amiodarone hydrochloride 100 mg Amiodarone 300mg tablets | 28 tablet (£4.25 DT price + £1.08)
  - Amiodarone hydrochloride 200 mg Amiodarone 200mg tablets | 28 tablet (£7.80 DT price + £2.04)
  - Cordarone X (Sanofi) Amiodarone hydrochloride 100 mg Cordarone X 100 tablets | 28 tablet (£4.28 DT price + £1.08)
  - Amiodarone hydrochloride 200 mg Cordarone X 200 tablets | 28 tablet (£6.99 DT price + £2.04)

**Arrhythmias 89**

**INDICATIONS AND DOSE**

Prevention and treatment of ventricular and supraventricular arrhythmias, including after myocardial infarction | Maintenance of sinus rhythm after cardioversion

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: 300–800 mg daily in divided doses

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adult: 250–375 mg every 12 hours

**Disopyramide**
MONITORING REQUIREMENTS
- Monitor for hypotension, hypoglycaemia, ventricular tachycardia, ventricular fibrillation or tordade de pointes (discontinue if occur).
- Monitor serum potassium.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 25
- **Rythmodan Retard** (Sanofi)
  - Disopyramide (as Disopyramide phosphate) 250 mg Rythmodan Retard 250mg tablets | 60 tablet [POT] £32.08 DT price = £32.08
- **DISOPYRAMIDE (Non-proprietary)**
  - Disopyramide 100 mg Disopyramide 100mg capsules | 84 capsule [POT] £25.00 DT price = £22.09
  - Disopyramide 150 mg Disopyramide 150mg capsules | 84 capsule [POT] £33.40 DT price = £27.58
- **Rythmodan** (Sanofi)
  - Disopyramide 100 mg Rythmodan 100mg capsules | 84 capsule [POT] £14.14 DT price = £22.09

Dronedarone

**DRUG ACTION** Dronedarone is a multi-channel blocking anti-arrhythmic drug.

**INDICATIONS AND DOSE**
Maintenance of sinus rhythm after cardioversion in clinically stable patients with paroxysmal or persistent atrial fibrillation, when alternative treatments are unsuitable (initiated under specialist supervision)

**MOUTH**
- Adult: 400 mg twice daily

CONTRA-INDICATIONS
- Atrial conduction defects - bradycardia - complete bundle branch block - to block - existing or previous heart failure or left ventricular systolic dysfunction - haemodynamically unstable patients
- liver toxicity associated with previous amiodarone use - permanent atrial fibrillation - prolonged QT interval - second - or third-degree AV block - sick sinus syndrome (unless pacemaker fitted) - sinus node dysfunction

CAUTIONS
- Coronary artery disease - correct hypokalaemia and hypomagnesaemia before starting and during treatment

INTERACTIONS
- Appendix 1 (dronedarone).

SIDE-EFFECTS
- Common or very common: Bradycardia - gastro-intestinal disturbances - heart failure - malaise - pruritus - QT-interval prolongation - raised serum creatinine - rash
- Uncommon: Dermatitis - eczema - erythema - interstitial lung disease (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed) - photosensitivity - pneumonitis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed) - pulmonary fibrosis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed) - taste disturbance
- Rare: Liver injury (including life-threatening acute liver failure)

SIDE-EFFECTS, FURTHER INFORMATION
- Liver injury: Liver injury, including life-threatening acute liver failure reported rarely; discontinue treatment if 2 consecutive alanine aminotransferase concentrations exceed 3 times upper limit of normal.

Heart failure: New onset or worsening heart failure reported. If heart failure or left ventricular systolic dysfunction develops, discontinue treatment.

PREGNANCY
- Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING
- Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
- Avoid in severe impairment.

RENAL IMPAIRMENT
- Avoid if eGFR less than 30 mL/minute/1.73 m².

MONITORING REQUIREMENTS
- Ongoing monitoring should occur under specialist supervision.
- Monitor for heart failure.
- Perform ECG at least every 6 months—consider discontinuation if atrial fibrillation reoccurs.
- Measure serum creatinine before treatment and 7 days after initiation—if raised, measure again after a further 7 days and consider discontinuation if creatinine continues to rise.
- Monitor liver function before treatment, 1 week and 1 month after initiation of treatment, then monthly for 6 months, then every 3 months for 6 months and periodically thereafter.

PATIENT AND CARER ADVICE
- Heart failure: Patients or their carers should be told how to recognise signs of heart failure and advised to seek prompt medical attention if symptoms such as weight gain, dependent oedema, or dyspnoea develop or worsen.
- Hepatic disorders: Patients or their carers should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as abdominal pain, anorexia, nausea, vomiting, fever, malaise, itching, dark urine, or jaundice develop.

NATIONAL FUNDING/ACCESS DECISIONS
**NICE technology appraisals (TAs)**
- **Dronedarone for the treatment of non-permanent atrial fibrillation (December 2012) NICE TA197**
  - Dronedarone is an option for the maintenance of sinus rhythm after successful cardioversion in paroxysmal or persistent atrial fibrillation which is not controlled by first-line therapy (usually including beta-blockers), and after alternative options have been considered in patients:
    - who have at least 1 of the following cardiovascular risk factors: hypertension requiring drugs of at least 2 different classes, diabetes mellitus, previous transient ischaemic attack, stroke or systemic embolism, left atrial diameter of 50 mm or greater, or age 70 years or older and
    - who do not have left ventricular systolic dysfunction nor a history of, or current, heart failure
  - Patients who do not meet the above criteria who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop. [www.nice.org.uk/TA197](http://www.nice.org.uk/TA197)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 21
- **DRONEDARONE (Non-proprietary)**
  - Dronedarone (as Dronedarone hydrochloride) 400 mg Dronedarone 400mg tablets | 60 tablet [POT] no price available
  - **Multaq** (Sanofi)
    - Dronedarone (as Dronedarone hydrochloride) 400 mg Multaq 400mg tablets | 20 tablet [POT] £22.50 | 60 tablet [POT] £67.50
Flecainide acetate

INDICATIONS AND DOSE
AV nodal reciprocating tachycardia, arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal atrial fibrillation in patients without left ventricular dysfunction (arrhythmias of recent onset will respond more readily) (specialist supervision in hospital)

Ventricular tachyarrhythmias resistant to other treatment (specialist supervision in hospital)

INITIALLY BY SLOW INTRAVENOUS INJECTION

- Adult: Initially 2 mg/kg (max. per dose 150 mg), to be given over 10–30 minutes with ECG monitoring, followed by (by intravenous infusion) 1.5 mg/kg/hour if required for 1 hour, then (by intravenous infusion) reduced to 100–250 micrograms/kg/hour for up to 24 hours, maximum cumulative dose of 600 mg in first 24 hours, then transfer to oral treatment

Supraventricular arrhythmias

INITIALLY BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 50 mg twice daily, (by mouth) increased if necessary up to 300 mg daily
- By mouth using modified-release medicines
- Adult: 200 mg daily

Ventricular arrhythmias (initiated under direction of hospital consultant)

- Adult: Initially 100 mg twice daily for 3–5 days, maximum 400 mg daily reserved for rapid control or in heavily built patients, then (by mouth) maintenance, reduce to the lowest dose that controls the arrhythmia

Dose equivalence and conversion
Patients stabilised on 200 mg daily immediate-release flecainide may be transferred to modified-release medicines.

- UNLICENSED USE Capsules, tablets and injections: AV nodal reciprocating tachycardia, arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal atrial fibrillation in patients without left ventricular dysfunction (arrhythmias of recent onset will respond more readily). Immediate-release tablets only: symptomatic sustained ventricular tachycardia, disabling symptoms of pre-mature ventricular contractions or non-sustained ventricular tachycardia in patients resistant to or intolerant of other therapy. Injection only: ventricular tachyarrhythmias resistant to other treatment.

- CONTRA-INDICATIONS Abnormal left ventricular function, atrial conduction defects (unless pacing rescue available) - bundle branch block (unless pacing rescue available) - control of arrhythmias in acute situations (for modified-release forms only) - distal block (unless pacing rescue available) - haemodynamically significant valvular heart disease - heart failure - history of myocardial infarction and either asymptomatic ventricular ectopics or asymptomatic non-sustained ventricular tachycardia - long-standing atrial fibrillation where conversion to sinus rhythm not attempted - second-degree or greater AV block (unless pacing rescue available) - sinus node dysfunction (unless pacing rescue available)

- CAUTIONS Atrial fibrillation following heart surgery - elderly (accumulation may occur) - patients with pacemakers (especially those who may be pacemaker dependent because stimulation threshold may rise appreciably)

- INTERACTIONS → Appendix 1 (flecainide).

SIDE-EFFECTS
- Common or very common Asthenia - dizziness - dyspnoea - fatigue - fever - oedema - pro-arrhythmic effects - visual disturbances
- Rare Amnesia - confusion - convulsions - depression - dyskinesia - hallucinations - peripheral neuropathy - pneumonitis

- PREGNANCY Used in pregnancy to treat maternal and fetal arrhythmias in specialist centres; toxicity reported in animal studies; infant hyperbilirubinaemia also reported.

- BREAST FEEDING Significant amount present in milk but not known to be harmful.

- HEPATIC IMPAIRMENT Avoid or reduce dose in severe impairment.

- RENAL IMPAIRMENT Reduce initial oral dose to max. 100 mg daily or reduce intravenous dose by 50%, if eGFR less than 35 mL/minute/1.73 m².

- MONITORING REQUIREMENTS
- With intravenous use ECG monitoring and resuscitation facilities must be available.

- DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Tambocor®), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%. Minimum volume in infusion fluids containing chlorides 500 mL.

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet
- FLECAINIDE ACETATE (Non-proprietary)
  - Flecainide acetate 50 mg Flecainide 50mg tablets | 60 tablet [POS] £19.50 DT price = £3.25
  - Flecainide acetate 100 mg Flecainide 100mg tablets | 60 tablet [POS] £29.00 DT price = £4.96
  - Tambocor (Meda Pharmaceuticals Ltd)
  - Flecainide acetate 50 mg Tambocor tablets 50mg | 60 tablet [POS] £11.57 DT price = £3.25
  - Flecainide acetate 100 mg Tambocor tablets 100mg | 60 tablet [POS] £16.53 DT price = £4.96
  - Modified-release capsule
  - CAUTIONARY AND ADVISORY LABELS 25
  - Tambocor XL (Meda Pharmaceuticals Ltd)
  - Flecainide acetate 200 mg Tambocor XL 200mg capsules | 30 capsule [POS] £14.77
  - Solution for injection
  - Tambocor (Meda Pharmaceuticals Ltd)
  - Flecainide acetate 10 mg per 1 ml Tambocor 10mg/1ml solution for injection ampoules | 3 ampoule [POS] £21.99

Lidocaine hydrochloride
(Lignocaine hydrochloride)

INDICATIONS AND DOSE
Cardiopulmonary resuscitation (as an alternative if amiodarone is not available)

BY INTRAVENOUS INJECTION
- Adult: 1 mg/kg, do not exceed 3 mg/kg over the first hour
Cardiovascular system

MEDICINAL FORMS

MONITORING REQUIREMENTS

RENAL IMPAIRMENT

HEPATIC IMPAIRMENT

PREGNANCY

Rare

CONTRA-INDICATIONS

All grades of atrioventricular block - severe myocardial depression - sino-atrial disorders

CAUTIONS

Acute prophyria (consider infusion with glucose for its anti-porphyrinic effects) - congestive cardiac failure (consider lower dose) - post cardiac surgery (consider lower dose)

INTERACTIONS

→ Appendix 1 (lidocaine).

SIDE-EFFECTS

Common or very common

Bradycardia (may lead to cardiac arrest) - confusion - convulsions - dizziness (particularly if injection too rapid) - hypotension (may lead to cardiac arrest) - paraesthesia (particularly if injection too rapid) - respiratory depression

Rare

Anaphylaxis

PREGNANCY

Crosses the placenta but not known to be harmful in animal studies—use if benefit outweighs risk.

BREAST FEEDING

Present in milk but amount too small to be harmful.

HEPATIC IMPAIRMENT

Caution—increased risk of side-effects.

RENAL IMPAIRMENT

Possible accumulation of lidocaine and active metabolite; caution in severe impairment.

MONITORING REQUIREMENTS

Monitor ECG and have resuscitation facilities available.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

Solution for injection

LIDOCAINE HYDROCHLORIDE (Non-proprietary)

Lidocaine hydrochloride 5 mg per 1 ml

Lidocaine hydrochloride 10 mg per 1 ml

Lidocaine hydrochloride 100 mg/10ml

92 Arrhythmias

Propafenone hydrochloride

INDICATIONS AND DOSE

Ventricular arrhythmias (specialist supervision in hospital) | Paroxysmal supraventricular tachyarrhythmias which include paroxysmal atrial flutter or fibrillation and paroxysmal re-entrant tachycardias involving the AV node or accessory pathway, where standard therapy ineffective or contra-indicated (specialist supervision in hospital)

BY MOUTH

Adult: Initially 150 mg 3 times a day, dose to be taken after food, monitor ECG and blood pressure, if QRS interval prolonged by more than 20%, reduce dose or discontinue until ECG returns to normal limits; increased if necessary to 300 mg twice daily (max. per dose 300 mg 3 times a day), dose to be increased at intervals of at least 3 days, reduce total daily dose for patients under 70 kg

Elderly: Initially 150 mg 3 times a day, dose to be taken after food, monitor ECG and blood pressure, if QRS interval prolonged by more than 20%, reduce dose or discontinue until ECG returns to normal limits; increased if necessary to 300 mg twice daily (max. per dose 300 mg 3 times a day), dose to be increased at intervals of at least 5 days, reduce total daily dose for patients under 70 kg

CONTRA-INDICATIONS

Atrial conduction defects (unless adequately paced) - Brugada syndrome - bundle branch block (unless adequately paced) - cardiogenic shock (except arrhythmia induced) - distal block (unless adequately paced) - electrolyte disturbances - marked hypotension - myasthenia gravis - myocardial infarction within last 3 months - second degree or greater AV block (unless adequately paced) - severe bradyarrhythmia - severe obstructive pulmonary disease (due to weak beta-blocking activity) - sinus node dysfunction (unless adequately paced) - uncontrolled congestive heart failure with left ventricular ejection fraction less than 35%
**BETA-ADRENOCEPTOR BLOCKERS**

**INDICATIONS AND DOSE**

- Symptomatic non-sustained ventricular tachyarrhythmias | Prophylaxis of paroxysmal atrial tachycardia or fibrillation, paroxysmal AV re-entrant tachycardias (both nodal and involving accessory pathways), and paroxysmal supraventricular tachycardia after cardiac surgery | Maintenance of sinus rhythm following cardioversion of atrial fibrillation or flutter

**BREAST FEEDING**

- Frequency not known
  - Uncommon
  - Common or very common

**INTERACTIONS** → Appendix 1 (propafenone).

**SIDE-EFFECTS**

- Common or very common

- Uncommon
  - Abdominal distension - anorexia - ataxia - erectile dysfunction - flatulence - hypotension - paraesthesia - pro-arrhythmic effects - rash - syncope - thrombocytopenia - vertigo

- Frequency not known
  - Agranulocytosis - cholestasis - confusion - convulsions - extrapyramidal symptoms - granulocytopenia - hepatitis - jaundice - leukopenia - lupus erythematosus-like syndrome - reduced sperm count (reversible on withdrawal) - restlessness

**PREGNANCY**

- Use only if potential benefit outweighs risk.

**BREAST FEEDING**

- Use with caution — present in milk.

**PATIENT AND CARER ADVICE**

- May affect performance of skilled tasks e.g. driving.

**RECOMMENDATIONS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 21, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propafenone hydrochloride 150 mg</td>
<td>Propafenone 150mg tablets</td>
</tr>
<tr>
<td>Propafenone hydrochloride 300 mg</td>
<td>Propafenone 300mg tablets</td>
</tr>
<tr>
<td>Arythmol (BGP Products Ltd)</td>
<td>Propafenone hydrochloride 150 mg</td>
</tr>
<tr>
<td>Propafenone hydrochloride 300 mg</td>
<td>Propafenone 300mg tablets</td>
</tr>
</tbody>
</table>

**BETA-ADRENOCEPTOR BLOCKERS**

**Sotalol hydrochloride**

- The properties listed below are those particular to the drug only. For properties common to the class, see Beta-blockers, p. 139.

**INDICATIONS AND DOSE**

- Symptomatic non-sustained ventricular tachyarrhythmias | Prophylaxis of paroxysmal atrial tachycardia or fibrillation, paroxysmal AV re-entrant tachycardias (both nodal and involving accessory pathways), and paroxysmal supraventricular tachycardia after cardiac surgery | Maintenance of sinus rhythm following cardioversion of atrial fibrillation or flutter

**BREAST FEEDING**

- Frequency not known
  - Uncommon
  - Common or very common

**INTERACTIONS**

- Extreme caution or avoid concomitant use of drugs that prolong QT interval.

**SIDE-EFFECTS**

- Arrhythmogenic (pro-arrhythmic) effect (torsade de pointes — increased risk in females)

**BREAST FEEDING**

- Water soluble beta-blockers such as sotalol are present in breast milk in greater amounts than other beta blockers.

**REMEDIAL ACTION**

- Use half normal dose if eGFR 30–60 mL/minute/1.73 m²; use one-quarter normal dose if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- Measurement of corrected QT interval, and monitoring of ECG and electrolytes required; correct hypokalaemia, hypomagnesaemia, or other electrolyte disturbances.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sotalol hydrochloride 40 mg</td>
<td>Sotalol 40mg tablets</td>
</tr>
<tr>
<td>Sotalol hydrochloride 80 mg</td>
<td>Sotalol 80mg tablets</td>
</tr>
<tr>
<td>Sotalol hydrochloride 160 mg</td>
<td>Sotalol 160mg tablets</td>
</tr>
<tr>
<td>Sotalol hydrochloride 200 mg</td>
<td>Sotalol 200mg tablets</td>
</tr>
<tr>
<td>Sotalol hydrochloride 320 mg</td>
<td>Beta-Cardone 320mg tablets</td>
</tr>
<tr>
<td>Sotalol hydrochloride 320 mg</td>
<td>Beta-Cardone 320mg tablets</td>
</tr>
<tr>
<td>Sotalol hydrochloride 320 mg</td>
<td>Beta-Cardone 320mg tablets</td>
</tr>
<tr>
<td>Sotalocor (Bristol-Myers Squibb Pharmaceuticals Ltd)</td>
<td>Sotalol hydrochloride 80 mg</td>
</tr>
<tr>
<td>Sotalocor (Bristol-Myers Squibb Pharmaceuticals Ltd)</td>
<td>Sotalol hydrochloride 80 mg</td>
</tr>
</tbody>
</table>

**CONTRA-INDICATIONS**

- Long QT syndrome (congenital or acquired) — torsade de pointes

**CAUTIONS**

- Diarrhoea (severe or prolonged)

**CARDIAC GLYCOSIDES**

**Cardiac glycosides**

**Digoxin-specific antibody**

- Serious cases of digoxin toxicity should be discussed with the National Poisons Information Service (see further information, under Emergency treatment of poisoning p. 1123). Digoxin-specific antibody p. 1132 fragments are indicated for the treatment of known or strongly suspected life-threatening digoxin toxicity associated with ventricular
**Arrhythmias**

Arrhythmias or bradycardias unresponsive to atropine sulfate p. 949 and when measures beyond the withdrawal of digoxin and correction of any electrolyte abnormalities are considered necessary.

Digoxin is most useful for controlling ventricular response in persistent and permanent atrial fibrillation and atrial flutter. Digoxin also has a role in heart failure.

For management of atrial fibrillation the maintenance dose of digoxin can usually be determined by the ventricular rate at rest, which should not usually be allowed to fall persistently below 60 beats per minute.

Digoxin is now rarely used for rapid control of heart rate (see management of supraventricular arrhythmias). Even with intravenous administration, response may take many hours; persistence of tachycardia is therefore not an indication for exceeding the recommended dose. The intramuscular route is not recommended.

In patients with heart failure who are in sinus rhythm a loading dose is not required, and a satisfactory plasma-digoxin concentration can be achieved over a period of about a week.

Digoxin has a long half-life and maintenance doses need to be given only once daily (although higher doses may be divided to avoid nausea); renal function is the most important determinant of digoxin dosage.

Unwanted effects depend both on the concentration of digoxin in the plasma and on the sensitivity of the conducting system or of the myocardium, which is often increased in heart disease. It can sometimes be difficult to distinguish between toxic effects and clinical deterioration because symptoms of both are similar. The plasma concentration alone cannot indicate toxicity reliably, but the likelihood of toxicity increases progressively through the range 1.5 to 3 micrograms/litre for digoxin. Digoxin should be used with special care in the elderly, who may be particularly susceptible to digitalis toxicity.

Regular monitoring of plasma-digoxin concentration during maintenance treatment is not necessary unless problems are suspected. Hypokalaemia predisposes the patient to digitalis toxicity; it is managed by giving a potassium-sparking diuretic or, if necessary, potassium supplementation.

If toxicity occurs, digoxin should be withdrawn; serious manifestations require urgent specialist management. Digoxin-specific antibody fragments are available for reversal of life-threatening overdosage.

**Digoxin**

**Drug Action** Digoxin is a cardiac glycoside that increases the force of myocardial contraction and reduces conductivity within the atrioventricular (AV) node.

**Indications and Dose**

Rapid digitalisation, for atrial fibrillation or flutter

**By Mouth**
- Adult: 0.75–1.5 mg in divided doses, dose to be given over 24 hours, reduce dose in the elderly

Maintenance, for atrial fibrillation or flutter

**By Mouth**
- Adult: Maintenance 125–250 micrograms daily, dose according to renal function and initial loading dose, reduce dose in the elderly

Heart failure (for patients in sinus rhythm)

**By Mouth**
- Adult: 62.5–125 micrograms once daily, reduce dose in the elderly

**Emergency loading dose, for atrial fibrillation or flutter**

**INITIALLY BY INTRAVENOUS INFUSION**
- Adult: Loading dose 0.75–1 mg, to be given over at least 2 hours, then (by mouth) maintenance, start on the following day, reduce dose in the elderly

**Dose equivalence and conversion**

Dose may need to be reduced if digoxin (or another cardiac glycoside) has been given in the preceding 2 weeks. When switching from intravenous to oral route may need to increase dose by 20–33% to maintain the same plasma-digoxin concentration.

**Unlicensed Use** Digoxin doses in the BNF may differ from those in product literature.

**Contra-Indications** Constrictive pericarditis (unless to control atrial fibrillation or improve systolic dysfunction—but use with caution) · hypertrophic cardiomyopathy (unless concomitant atrial fibrillation and heart failure— but use with caution) · intermittent complete heart block · myocardiatis · second degree AV block · supraventricular arrhythmias associated with accessory conducting pathways e.g. Wolff-Parkinson-White syndrome (although can be used in infancy) · ventricular tachycardia or fibrillation

**Caution**

Hypercalcaemia (risk of digitalis toxicity) · hypokalaemia (risk of digitalis toxicity) · hypomagnesaemia (risk of digitalis toxicity) · hypoxia (risk of digitalis toxicity) · recent myocardial infarction · severe respiratory disease · sick sinus syndrome · thyroid disease

**Interactions** → Appendix 1 (cardiac glycosides).

**Side-effects**

- Common or very common Arrhythmias · blurred vision · conduction disturbances · diarrhoea · dizziness · eosinophilia · nausea · rash · vomiting · yellow vision

- Uncommon · Depression

- Very rare · Anorexia · apathy · confusion · fatigue · gynaecomastia on long-term use · headache · intestinal ischaemia and necrosis · psychosis · thrombocytopenia · weakness

**Overdose** If toxicity occurs, digoxin should be withdrawn; serious manifestations require urgent specialist management.

- Pregnancy May need dosage adjustment.

- Breastfeeding Amount too small to be harmful.

- Renal Impairment Reduce dose. Monitor plasma-digoxin concentration in renal impairment.

**Monitoring Requirements**

- For plasma-digoxin concentration assay, blood should be taken at least 6 hours after a dose.

- Monitor serum electrolytes and renal function. Toxicity increased by electrolyte disturbances.

**Directions for Administration**

- With intravenous use Avoid rapid intravenous administration (risk of hypertension and reduced coronary flow). For intravenous infusion (Lanoxin®), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to a concentration of not more than 62.5 micrograms/mL. To be given over at least 2 hours.

- With oral use For oral administration, oral solution must not be diluted.

**Patient and Carer Advice** Patient counselling is advised for digoxin elixir (use pipette).

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral suspension, oral solution
2 Bleeding disorders

Antifibrinolytic drugs and haemostatics

Fibrin dissolution can be impaired by the administration of tranexamic acid, which inhibits fibrinolysis. It can be used to prevent bleeding or to treat bleeding associated with excessive fibrinolysis (e.g. in surgery, dental extraction, obstetric disorders, and traumatic haemophilia) and in the management of menorrhagia. Tranexamic acid below may also be used in hereditary angioedema, epistaxis, and in the management of obstetric disorders, and traumatic hyphaema) and in the management of heavy menstrual bleeding and its use in the management of heavy menstrual bleeding and its use is no longer recommended.

ANTIFIBRINOLYTICS

Tranexamic acid

INDICATIONS AND DOSE

Inhibition of fibrinolysis (local)

BY MOUTH

- Adult: 1–1.5 g 2–3 times a day, alternatively 15–25 mg/kg 2–3 times a day

INITIALLY BY SLOW INTRAVENOUS INJECTION

- Adult: 0.5–1 g 2–3 times a day, to be administered at a rate not exceeding 100 mg/minute, dose may be followed by continuous infusion; (by continuous intravenous infusion) 25–50 mg/kg, dose to be given over 24 hours

Menorrhagia

BY MOUTH

- Adult: 1 g 3 times a day for up to 4 days, to be initiated when menstruation has started; maximum 4 g per day

Hereditary angioedema

BY MOUTH

- Adult: 1–1.5 g 2–3 times a day, for short-term prophylaxis of hereditary angioedema, tranexamic acid is started several days before planned procedures which may trigger an acute attack of hereditary angioedema (e.g. dental work) and continued for 2–5 days afterwards

Epistaxis

BY MOUTH

- Adult: 1 g 3 times a day for 7 days

General fibrinolysis

BY SLOW INTRAVENOUS INJECTION

- Adult: 1 g every 6–8 hours, alternatively 15 mg/kg every 6–8 hours, dose to be given at a rate not exceeding 100 mg/minute

ADDITIONAL USE

Use of tranexamic acid by continuous intravenous infusion for treatment of local fibrinolysis is an unlicensed route of administration

CONTRA-INDICATIONS

Fibrinolytic conditions following disseminated intravascular coagulation (unless predominant activation of fibrinolytic system with severe bleeding) - history of convulsions - thromboembolic disease

CAUTIONS

Irregular menstrual bleeding (establish cause before initiating therapy) - massive haematuria (avoid if risk of ureteric obstruction) - patients receiving oral contraceptives (increased risk of thrombosis)

CAUTIONS, FURTHER INFORMATION

Menorrhagia

Before initiating treatment for menorrhagia, exclude structural or histological causes or fibroids causing distortion of uterine cavity.

SIDE-EFFECTS

- Common or very common Diarrhoea (reduce dose) - nausea - vomiting

- Uncommon Dermatitis

- Rare Impairment of colour vision (discontinue) - thromboembolic events - visual disturbances (discontinue)

- Frequency not known Convulsions (usually with high doses) - hypotension (on rapid intravenous injection) - malaise (on rapid intravenous injection)

PREGNANCY

No evidence of teratogenicity in animal studies; manufacturer advises use only if potential benefit outweighs risk—crosses the placenta.

BREAST FEEDING

Small amount present in milk—antifibrinolytic effect in infant unlikely.

RENAI IMPAIRMENT

Reduce dose—consult product literature for details.

MONITORING REQUIREMENTS

Regular liver function tests in long-term treatment of hereditary angioedema.

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (Cyklokapron®), give continuously in Glucose 5% or Sodium chloride 0.9%.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, mouthwash

Tablet

- TRANEXAMIC ACID (Non-proprietary)
  - Tranexamic acid 500 mg Tranexamic acid 500mg tablets | 60 tablet (PO) £18.87 DT price = £6.60
  - Cyklokapron (Meda Pharmaceuticals Ltd) Tranexamic acid 500 mg Cyklokapron 500mg tablets | 60 tablet (PO) £14.30 DT price = £6.60
HAEMOSTATICS

Etamsylate
(Ethamsylate)

**INDICATIONS AND DOSE**
- Short-term blood loss in menorrhagia

**CONTRA-INDICATIONS**
- Acute porphyrias

**CAUTIONS**
- Exclude structural or histological causes of menorrhagia, or fibroids causing distortion of the uterine cavity, before initiating treatment

**SIDE-EFFECTS**
- Diarrhoea - fever (discontinue treatment)
- Headache - nausea - rashes - vomiting

**BREAST FEEDING**
- Present in milk — manufacturer advises avoid.

**LESS SUITABLE FOR PRESCRIBING**
- Less suitable for prescribing.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

2.1 Coagulation factor deficiencies

BLOOD COAGULATION FACTORS

Dried prothrombin complex
(Human prothrombin complex)

**INDICATIONS AND DOSE**
- Treatment and peri-operative prophylaxis of haemorrhage in patients with congenital deficiency of factors II, VII, IX, or X (e.g. during warfarin treatment)

**CONTRA-INDICATIONS**
- Angina - history of heparin induced thrombocytopenia - recent myocardial infarction (except in life-threatening haemorrhage following overdosage of oral anticoagulants, and before induction of fibrinolytic therapy)

**CAUTIONS**
- Disseminated intravascular coagulation - history of myocardial infarction or coronary heart disease - postoperative use - risk of thrombosis

**SIDE-EFFECTS**
- Rare Headache

**Solution for injection**
- **TRANEXAMIC ACID (Non-proprietary)**
  - Tranexamic acid 100 mg per 1 ml Tranexamic acid 500mg/5ml solution for injection ampoules | 5 ampoules (£7.50) (Hospital only) | 10 ampoules (£14.95—£15.47) (Hospital only)
  - Cyklokapron (Pfizer Ltd)
    - Tranexamic acid 100 mg per 1 ml Cyklokapron 500mg/5ml solution for injection ampoules | 10 ampoule (£15.47)

**Factor IX fraction, dried**

**INDICATIONS AND DOSE**
- Treatment and prophylaxis of haemorrhage in congenital factor IX deficiency (haemophilia B)

**CONTRA-INDICATIONS**
- Disseminated intravascular coagulation

**CAUTIONS**
- Risk of thrombosis — principally with former low purity products

**SIDE-EFFECTS**
- Allergic reactions - chills - dizziness - fever - gastro-intestinal disturbances - headache

**PRESCRIBING AND DISPENSING INFORMATION**
- Dried factor IX fraction is prepared from human plasma by a suitable fractionation technique; it may also contain clotting factors II, VII, and X.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- **AlphaNine** (Grifols UK Ltd)
  - Factor IX high purity 500 unit AlphaNine 500 unit powder and solvent for solution for injection vials | 1 vial (£478.43) no price available
  - Factor IX high purity 1000 unit AlphaNine 1000 unit powder and solvent for solution for injection vials | 1 vial (£821.00) no price available
  - Factor IX high purity 1500 unit AlphaNine 1500 unit powder and solvent for solution for injection vials | 1 vial (£1651.80) no price available

- **Mononine** (CSL Behring UK Ltd)
  - Factor IX high purity 1000 unit Mononine 1000 unit powder and solvent for solution for injection vials | 1 vial (£607.15)

- **Repleline-VF** (Bio Products Laboratory Ltd)
  - Factor IX high purity 500 unit Repleline-VF 500 unit powder and solvent for solution for injection vials | 1 vial (£360.00) no price available
  - Factor IX high purity 1000 unit Repleline-VF 1000 unit powder and solvent for solution for injection vials | 1 vial (£792.00)

**Powder and solvent for solution for infusion**
- **BenefIX (Pfizer Ltd)**
  - Nonacog alfa 250 unit BenefIX 250 unit powder and solvent for solution for infusion vials | 1 vial (£151.80)
  - Nonacog alfa 500 unit BenefIX 500 unit powder and solvent for solution for infusion vials | 1 vial (£363.60)
  - Nonacog alfa 1000 unit BenefIX 1000 unit powder and solvent for solution for infusion vials | 1 vial (£607.20)
  - Nonacog alfa 2000 unit BenefIX 2000 unit powder and solvent for solution for infusion vials | 1 vial (£1214.40)
  - Nonacog alfa 3000 unit BenefIX 3000 unit powder and solvent for solution for infusion vials | 1 vial (£2282.00)

**BENEFIX® 2000®, 3000®**
- Available from CSL Behring (BeriPLEX® P/N) Octapharma (Octaplex®)
Factor VIIa (recombinant) (Eptacog alfa (activated))

**INDICATIONS AND DOSE**
Treatment and prophylaxis of haemorrhage in patients with factor VIII deficiency or Glanzmann's thrombasthenia

**SIDE-EFFECTS**
- **Uncommon** Deep vein thrombosis - fever - pulmonary embolism - rash - venous thromboembolic events
- **Rare** Angina - arterial thrombotic events - cerebrovascular accident - coagulation disorders - headache - myocardial infarction - nausea
- **Frequency not known** Anaphylaxis - angioedema - flushing

**CAUTIONS**
Disseminated intravascular coagulation - risk of thrombosis

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- **NovoSeven** (Novo Nordisk Ltd)
  - Eptacog alfa activated 250000 unit powder and solvent for solution for injection pre-filled vials | 1 vial (PSt) £525.20 (Hospital only)
  - Eptacog alfa activated 100000 unit powder and solvent for solution for injection pre-filled vials | 1 vial (PSt) £105.40 (Hospital only)
  - Eptacog alfa activated 50000 unit powder and solvent for solution for injection pre-filled vials | 1 vial (PSt) £42.62 (Hospital only)

**Octocog alfa activated 1500 unit**
- Powder and solvent for solution for infusion vials | 1 vial (PSt) £57.00
- Powder and solvent for solution for infusion vials | 1 vial (PSt) £65.00
- Powder and solvent for injection vials | 1 vial (PSt) £49.50

**Coagulation factor deficiencies 97**

**Factor VIII fraction, dried (Human coagulation factor VIII, dried)**

**INDICATIONS AND DOSE**
Treatment and prophylaxis of haemorrhage in patients with congenital factor VIII deficiency (haemophilia A), acquired factor VIII deficiency or von Willebrand’s disease

**SIDE-EFFECTS**

**MONITORING REQUIREMENTS**
Monitor for development of factor VIII inhibitors.

**PRESCRIBING AND DISPENSING INFORMATION**
Dried factor VIII fraction is prepared from human plasma by a suitable fractionation technique; it may also contain varying amounts of von Willebrand factor.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- **Advate** (Baxter Healthcare Ltd)
  - Octocog alfa 250 unit Advate 250unit powder and solvent for solution for injection vials | 1 vial (PSt) no price available
  - Octocog alfa 500 unit Advate 500unit powder and solvent for solution for injection vials | 1 vial (PSt) no price available
  - Octocog alfa 1000 unit Advate 1000unit powder and solvent for solution for injection vials | 1 vial (PSt) no price available
  - Octocog alfa 2000 unit Advate 2000unit powder and solvent for solution for injection vials | 1 vial (PSt) no price available

- **Fanhdi** (Grifols Ltd)
  - Factor VIII high purity 500 unit Fanhdi 500unit powder and solvent for solution for injection vials | 1 vial (PSt) £163.00 (Hospital only)
  - Factor VIII high purity 1000 unit Fanhdi 1000unit powder and solvent for solution for injection vials | 1 vial (PSt) £330.00 (Hospital only)
  - Factor VIII high purity 1500 unit Fanhdi 1500unit powder and solvent for solution for injection vials | 1 vial (PSt) £495.00

- **Helixate NexGen** (CSL Behring UK Ltd)
  - Octocog alfa 250 unit Helixate NexGen 250unit powder and solvent for solution for injection vials | 1 vial (PSt) £118.57
  - Octocog alfa 500 unit Helixate NexGen 500unit powder and solvent for solution for injection vials | 1 vial (PSt) £237.15
  - Octocog alfa 1000 unit Helixate NexGen 1000unit powder and solvent for solution for injection vials | 1 vial (PSt) £474.30
  - Octocog alfa 2000 unit Helixate NexGen 2000unit powder and solvent for solution for injection vials | 1 vial (PSt) £948.60

- **Kogenate** (Bayer Plc)
  - Octocog alfa 250 unit Kogenate Bayer 250unit powder and solvent for solution for injection vials | 1 vial (PSt) £115.75
  - Octocog alfa 500 unit Kogenate Bayer 500unit powder and solvent for solution for injection vials | 1 vial (PSt) £331.00
  - Octocog alfa 1000 unit Kogenate Bayer 1000unit powder and solvent for solution for injection vials | 1 vial (PSt) £630.00
  - Octocog alfa 2000 unit Kogenate Bayer 2000unit powder and solvent for solution for injection vials | 1 vial (PSt) £1,260.00

**Powder and solvent for solution for infusion**
- **Advate** (Baxter Healthcare Ltd)
  - Octocog alfa 1500 unit Advate 1500unit powder and solvent for solution for infusion vials | 1 vial (PSt) no price available
  - Octocog alfa 3000 unit Advate 3000unit powder and solvent for solution for infusion vials | 1 vial (PSt) no price available

- **Kogenate** (Bayer Plc)
  - Octocog alfa 3000 unit Kogenate Bayer 3000unit powder and solvent for solution for injection vials | 1 vial (PSt) £1,890.00

**Factor VIII inhibitor bypassing fraction**

**INDICATIONS AND DOSE**
Treatment and prophylaxis of haemorrhage in patients with congenital factor VIII deficiency (haemophilia A) and factor VIII inhibitors | Treatment of haemorrhage in non-haemophilic patients with acquired factor VIII inhibitors

**SIDE-EFFECTS**
Anaphylaxis - disseminated intravascular coagulation - flushing - hypersensitivity - hypotension - myocardial infarction - paraesthesia - pyrexia - rash - thrombosis - urticaria

**PRESCRIBING AND DISPENSING INFORMATION**
Preparations with factor VIII inhibitor bypassing activity are prepared from human plasma.
**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- FEIBA Imuno (Baxter Healthcare Ltd)
  - Factor VIII inhibitor bypassing fraction 500 unit
  - Factor VIII inhibitor bypassing fraction 1000 unit
  - FEIBA Imuno (Baxter Healthcare Ltd)

**Powder and solvent for solution for infusion**
- FEIBA Imuno (Baxter Healthcare Ltd)
  - Factor VIII inhibitor bypassing fraction 1000 unit

**SIDE-EFFECTS**
- Very rare

**PRESCRIBING AND DISPENSING INFORMATION**
Fibrinogen is prepared from human plasma.

**INDICATIONS AND DOSE**
Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- Adult: (consult haematologist)

**CONTRA-INDICATIONS**
Avoid use as a volume expander - IgA deficiency with confirmed antibodies to IgA

**CAUTIONS**
- Cardiac decompensation - need for compatibility - pulmonary oedema - severe protein S deficiency (avoid products with low protein S activity e.g. OctaplasLG®)

**SIDE-EFFECTS**
- Common or very common: Nausea, pruritus, rash
- Uncommon: Oedema, vomiting
- Rare: Agitation, allergic reactions - bronchospasms - cardiorespiratory collapse - chills - fever - tachycardia
- Very rare: Arrhythmia, hypertension, thromboembolism

**BLOOD PRODUCTS**

**Fresh frozen plasma**

**INDICATIONS AND DOSE**
Replacement of coagulation factors or other plasma proteins where their concentration or functional activity is critically reduced

**BY INTRAVENOUS INFUSION**
- Adult: (consult haematologist)

**Major bleeding in patients on warfarin following phytomenadione**
- Adult: 15 mL/kg

**Dose equivalence and conversion**
Fresh frozen plasma is prepared from the supernatant liquid obtained by centrifugation of one donation of whole blood.

**CONTRA-INDICATIONS**
Avoid use as a volume expander - IgA deficiency with confirmed antibodies to IgA

**CAUTIONS**
- Cardiac decompensation - need for compatibility - pulmonary oedema - severe protein S deficiency (avoid products with low protein S activity e.g. OctaplasLG®)

**SIDE-EFFECTS**
- Common or very common: Nausea, pruritus, rash
- Uncommon: Oedema, vomiting
- Rare: Agitation, allergic reactions - bronchospasms - cardiorespiratory collapse - chills, fever, tachycardia
- Very rare: Arrhythmia, hypertension, thromboembolism

**PROVIDING AND DISPENSING INFORMATION**
Fresh frozen plasma is prepared from the supernatant liquid obtained by centrifugation of one donation of whole blood. A preparation of solvent/detergent treated human plasma (frozen) from pooled donors is available from Octapharma (OctaplasLG®)

**Protein C concentrate**

**INDICATIONS AND DOSE**
Congenital protein C deficiency

**BY INTRAVENOUS INJECTION**
- Adult: (consult haematologist)

**CAUTIONS**
- Hypersensitivity to heparins

**SIDE-EFFECTS**
- Very rare: Bleeding, dizziness, fever, hypersensitivity reactions

**PROVIDING AND DISPENSING INFORMATION**
Protein C is prepared from human plasma.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for infusion**
- Ristap (CSL Behring UK Ltd)
  - Fibrinogen 1 gram
  - Ristap 1g powder for solution for infusion vials | 1 vial (PSt) £340.00

**Solution for sealant**
- FIBRINOGEN, DRIED (Non-proprietary)
  - Fibrinogen 91 mg
  - Fibrinogen 91mg powder for solution for sealant vials | 1 vial (PSt) no price available
  - Fibrinogen 182 mg
  - Fibrinogen 182mg powder for solution for sealant vials | 1 vial (PSt) no price available
  - Fibrinogen 70 mg per 1 mL
  - Fibrinogen 350mg/5ml solution for sealant vials | 1 vial (PSt) no price available (Hospital only)

**Fibrinogen 455 mg**
Fibrinogen 455mg powder for solution for sealant vials | 1 vial (PSt) no price available

**Fibrinogen, dried**
(Human fibrin-stabilising factor, dried)

**INDICATIONS AND DOSE**
Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- Adult: (consult haematologist)

**CAUTIONS**
- Risk of thrombosis

**SIDE-EFFECTS**
- Rare: Allergic reactions, fever
- Very rare: Myocardial infarction, pulmonary embolism, thromboembolic events

**PREGNANCY**
Manufacturer advises not known to be harmful - no information available.

**BREAST-FEEDING**
Manufacturer advises avoid - no information available.

**PROVIDING AND DISPENSING INFORMATION**
Fibrinogen is prepared from human plasma.
2.2 Subarachnoid haemorrhage

CALCIUM-CHANNEL BLOCKERS

Nimodipine

The properties listed below are those particular to the drug. For properties common to the class, see Calcium-channel blockers, p. 147.

DRUG ACTION Nimodipine is a dihydropyridine calcium-channel blocker.

INDICATIONS AND DOSE

Prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage

BY MOUTH

- Adult: 60 mg every 4 hours, to be started within 4 days of aneurysmal subarachnoid haemorrhage and continued for 21 days

Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage

BY INTRAVENOUS INFUSION

- Adult (body-weight up to 70 kg): Initially 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter

- Adult (body-weight 70 kg and above): Initially 1 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter

Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage in patients with unstable blood pressure

BY INTRAVENOUS INFUSION

- Adult: Initially up to 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter

CONTRA-INDICATIONS Acute porphyrias p. 864 • unstable angina • within 1 month of myocardial infarction

CAUTIONS Cerebral oedema • hypotension • severely raised intracranial pressure

INTERACTIONS → Appendix 1 (calcium-channel blockers, alcohol [infusion only]). Avoid concomitant administration with other calcium-channel blockers, beta-blocker and nephrotoxic drugs.

SIDE-EFFECTS Flushing • gastro-intestinal disorders • headache • hypotension • ileus • nausea • sweating and feeling of warmth • thrombocytopenia • variation in heart-rate

PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING Manufacturer advises avoid—present in milk.

HEPATIC IMPAIRMENT Elimination reduced in cirrhosis—monitor blood pressure.

RENAL IMPAIRMENT

- With intravenous use Manufacturer advises monitor renal function closely in renal impairment.

DIRECTIONS FOR ADMINISTRATION

Avoid concomitant administration of nimodipine infusion and tablets.

- With oral use For administration by mouth, tablets may be crushed or halved but are light sensitive—administer immediately.

- With intravenous use For intravenous infusion, give via drip tubing in Glucose 5% or Sodium chloride 0.9%. Not to be added to infusion container; administer via an infusion pump through a Y-piece into a central catheter; incompatible with polyvinyl chloride giving sets or containers; protect infusion from light. Polyethylene, polypropylene, or glass apparatus should be used. PVC should be avoided.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet

- Nimotop (Bayer PdC) Nimodipine 30 mg Nimotop 30mg tablets | 100 tablet $40.00

Solution for infusion

- Nimotop (Bayer PdC) Nimodipine 200 microgram per 1 ml Nimotop 0.02% solution for infusion 50ml vials | 5 vial $66.00 (Hospital only)

3 Blood clots

3.1 Blocked catheters and lines

Drugs used for Blocked catheters and lines not listed below; Heparin (unfractionated). p. 114 • Urokinase, p. 119

PROSTAGLANDINS (CARDIOVASCULAR)

Epoprostenol

(Prostacyclin)

DRUG ACTION Epoprostenol is a prostaglandin and a potent vasodilator. It is also a powerful inhibitor of platelet aggregation.

INDICATIONS AND DOSE

Inhibition of platelet aggregation during renal dialysis when heparins are unsuitable or contra-indicated | Treatment of primary pulmonary hypertension resistant to other treatments, usually with oral anti-coagulation (initiated by a specialist)

BY CONTINUOUS INTRAVENOUS INFUSION

- Adult: (consult product literature)

PHARMACOKINETICS

Short half-life of approximately 3 minutes, therefore it must be administered by continuous intravenous infusion.

CONTRA-INDICATIONS Severe left ventricular dysfunction

CAUTIONS Avoid abrupt withdrawal when used for primary pulmonary hypertension (risk of rebound pulmonary hypertension) • extreme caution in coronary artery disease • haemorrhagic diathesis • pulmonary veno-occlusive disease • reconstituted solution highly alkaline—avoid extravasation (irritant to tissues) • risk of pulmonary oedema (dose titration for pulmonary hypertension should be in hospital)

INTERACTIONS Caution with concomitant use of drugs that increase risk of bleeding.
2 MEDICINAL FORMS

2.1 Monitoring requirements

BREAST FEEDING

Frequency not known

▶ Very rare

▶ Uncommon

Common or very common

SIDE-EFFECTS

dilute further with glycine buffer diluent only

hypertension

for peripheral vein until central venous access established); diluent) provided to make a concentrate; may be diluted reconstitute using the filter and solvent (glycine buffer pulmonary hypertension).

intravenous infusion

sodium chloride

Flolan

EPOPROSTENOL (Non-proprietary)

▶ Powder and solvent for solution for infusion

EPROPENSTENOL (Non-proprietary)

Powder and solvent for solution for infusion vials | 1 vial (PST) £49.24

Powder and solvent for solution for infusion

EPROPENSTENOL (as Epoprostenol sodium) 50 microgram

Epoprostenol (as Epoprostenol sodium) 500 microgram powder and solvent for solution for infusion vials | 1 vial (PST) £24.44

Epoprostenol (as Epoprostenol sodium) 1.5 mg

Epoprostenol (as Epoprostenol sodium) 1.5 mg powder and solvent for solution for infusion vials | 1 vial (PST) £49.24

Flolan (GlasgowSmithKline UK Ltd)

Epoprostenol (as Epoprostenol sodium) 500 microgram

Epoprostenol (as Epoprostenol sodium) 500 microgram powder and solvent for solution for infusion vials | 1 vial (PST) £22.22

Epoprostenol (as Epoprostenol sodium) 1.5 mg

Epoprostenol (as Epoprostenol sodium) 1.5 mg powder and solvent for solution for infusion vials | 1 vial (PST) £44.76

3.2 Thromboembolism

Venous thromboembolism

Venous thromboembolism includes deep-vein thrombosis and pulmonary embolism, and occurs as a result of thrombus formation in a vein.

Prophylaxis of venous thromboembolism

All patients admitted to hospital should undergo a risk assessment for venous thromboembolism on admission. Patients considered to be at high risk include those anticipated to have a substantial reduction in mobility, those with obesity, malignant disease, history of venous thromboembolism, thrombophilic disorder, or patients over 60 years. Patients with risk factors for bleeding (e.g. acute stroke, thrombocytopaenia, acquired or untreated inherited bleeding disorders) should only receive pharmacological prophylaxis when the risk of bleeding does not outweigh the risk of venous thromboembolism. NICE clinical guideline 92 (January 2010) provides a full list of risk factors, and gives recommendations for prophylaxis. A venous thromboembolism risk assessment checklist is also available from the Department of Health (www.gov.uk/dh).

Patients scheduled for surgery should be offered mechanical prophylaxis (e.g. anti-embolism stockings) on admission if appropriate; prophylaxis should continue until the patient is sufficiently mobile. Choice of mechanical prophylaxis will depend on factors such as the type of surgery, suitability for the patient, and their condition.

Patients undergoing general or orthopaedic surgery, who are considered to be at high risk of venous thromboembolism, should be offered pharmacological prophylaxis. Choice of prophylaxis will depend on the type of surgery, suitability for the patient, and local policy. A low molecular weight heparin is suitable in all types of general and orthopaedic surgery; heparin (unfractionated) p. 114 is preferred for patients in renal failure. Fondaparinux sodium p. 109 is an option for patients undergoing hip or knee replacement surgery, hip fracture surgery, gastro-intestinal, bariatric, or day surgery procedures. The oral anticoagulants apixaban p. 108, dabigatran etexilate p. 117, and rivaroxaban p. 109 are indicated for thromboprophylaxis following hip or knee replacement surgery.

Pharmacological prophylaxis in general surgery should usually continue for 5–7 days, or until sufficient mobility has been re-established. Pharmacological prophylaxis should be extended to 28 days after major cancer surgery in the abdomen or pelvis. Hip or knee replacement surgery, and hip fracture surgery, require an extended duration of pharmacological prophylaxis, depending on the preparation used (consult product literature).

General medical patients who are considered to be at high risk of venous thromboembolism should be offered pharmacological prophylaxis on admission. Choice of prophylaxis will depend on the medical condition, suitability for the patient, and local policy. Patients should receive either a low molecular weight heparin, heparin (unfractionated) (if patient in renal failure), or fondaparinux sodium prophylaxis should continue until the patient is no longer considered to be at significant risk of venous thromboembolism. Mechanical prophylaxis (e.g. anti-embolism stockings) can be offered to medical patients in whom pharmacological prophylaxis is contra-indicated, and continued until the patient is sufficiently mobile.

Treatment of venous thromboembolism

For the initial treatment of deep-vein thrombosis and pulmonary embolism a low molecular weight heparin is used; alternatively, heparin (unfractionated) is given as an intravenous loading dose, followed by continuous intravenous infusion (using an infusion pump) or (for deep-vein thrombosis only) by intermittent subcutaneous injection. Intermittent intravenous injection of heparin (unfractionated) is no longer recommended. An oral anticoagulant (usually warfarin sodium p. 121) is started at the same time as unfractionated or low molecular weight heparin (the heparin needs to be continued for at least 5 days and until the INR is ≥2 for at least 24 hours). Laboratory monitoring for heparin (unfractionated),
preferably on a daily basis, is essential; determination of the activated partial thromboplastin time (APTT) is the most widely used measure (for heparin (unfractionated). A low molecular weight heparin or, in some circumstances, heparin (unfractionated) is also used in regimens for the management of myocardial infarction and unstable angina.

**Management of venous thromboembolism in pregnancy**

Heparins are used for the management of venous thromboembolism in pregnancy because they do not cross the placenta. Low molecular weight heparins are preferred because they have a lower risk of osteoporosis and of heparin-induced thrombocytopenia. Low molecular weight heparins are eliminated more rapidly in pregnancy, requiring alteration of the dosage regimen for drugs such as dalteparin sodium p. 112, enoxaparin sodium p. 113, and tinzaparin sodium p. 115. Treatment should be stopped at the onset of labour and advice sought from a specialist on continuing therapy after birth.

**Extracorporeal circuits**

Heparin (unfractionated) is also used in the maintenance of extracorporeal circuits in cardiopulmonary bypass and haemodialysis.

**Haemorrhage**

If haemorrhage occurs it is usually sufficient to withdraw unfractionated or low molecular weight heparin, but if rapid reversal of the effects of the heparin is required, protamine sulfate p. 113 is a specific antidote (but only partially reverses the effects of low molecular weight heparins).

**Management of stroke**

Stroke is associated with a significant risk of morbidity and mortality. Patients presenting with acute symptoms should be immediately transferred to hospital for accurate diagnosis of stroke type, and urgent initiation of appropriate treatment; patients should be managed by a specialist multidisciplinary stroke team.

The following notes give an overview of the initial and long-term management of transient ischaemic attack, ischaemic stroke, and intracerebral haemorrhage.

**Transient ischaemic attack**

Patients suspected of having a transient ischaemic attack should immediately receive aspirin p. 104 (patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor, should receive clopidogrel p. 106 [unlicensed use] as an alternative). Following a confirmed diagnosis, patients should receive treatment for secondary prevention (see Long-term Management, under Ischaemic Stroke).

**Ischaemic stroke**

**Initial management**

Alteplase p. 194 is recommended in the treatment of acute ischaemic stroke if it can be administered within 4.5 hours of symptom onset; it should be given by medical staff experienced in the administration of thrombolitics and the treatment of acute stroke, preferably within a specialist stroke centre. Treatment with aspirin should be initiated 24 hours after thrombolysis (or as soon as possible within 48 hours of symptom onset in patients not receiving thrombolysis); patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor, should receive clopidogrel [unlicensed use] as an alternative.

Anticoagulants are not recommended as an alternative to antiplatelet drugs in acute ischaemic stroke in patients who are in sinus rhythm. However, parenteral anticoagulants may be indicated in patients who are symptomatic of, or at high risk of developing, deep vein thrombosis or pulmonary embolism; warfarin sodium p. 121 should not be commenced in the acute phase of ischaemic stroke.

Anticoagulants should be considered after cardio-embolic ischaemic stroke in patients with atrial fibrillation, however patients presenting with atrial fibrillation following a disabling ischaemic stroke should receive aspirin before being considered for anticoagulant treatment. Patients already receiving anticoagulation for a prosthetic heart valve who experience a disabling ischaemic stroke and are at significant risk of haemorrhagic transformation, should have their anticoagulant treatment stopped for 7 days and substituted with aspirin.

Treatment of hypertension in the acute phase of ischaemic stroke can result in reduced cerebral perfusion, and should therefore only be instituted in the event of a hypertensive emergency, or in those patients considered for thrombolysis.

**Long-term management**

Patients should receive long-term treatment following a transient ischaemic attack or an ischaemic stroke to reduce the risk of further cardiovascular events.

Following a transient ischaemic attack, long-term treatment with modified-release dipyridamole in combination with aspirin is recommended. If patients are intolerant of aspirin, or it is contra-indicated, then modified-release dipyridamole p. 107 alone is recommended; if patients are intolerant of dipyridamole, or it is contra-indicated, then aspirin alone is recommended.

Patients who are intolerant of both aspirin and dipyridamole should receive clopidogrel alone [unlicensed use].

Following an ischaemic stroke (not associated with atrial fibrillation), clopidogrel is recommended as long-term treatment. If clopidogrel is contra-indicated or not tolerated, patients should receive modified-release dipyridamole in combination with aspirin; if both aspirin and clopidogrel are contra-indicated or not tolerated, then modified-release dipyridamole alone is recommended; if both dipyridamole and clopidogrel are contra-indicated or not tolerated, then aspirin alone is recommended.

Patients with stroke associated with atrial fibrillation should be reviewed for long-term treatment with warfarin sodium or an alternative anticoagulant (see Initial Management under Ischaemic Stroke).

Anticoagulants are not routinely recommended in the long-term prevention of recurrent stroke, except in patients with atrial fibrillation.

A statin should be initiated 48 hours after stroke symptom onset, irrespective of the patient’s serum-cholesterol concentration.

Following the acute phase of ischaemic stroke, blood pressure should be measured and treatment initiated to achieve a target blood pressure of < 130/80 mmHg. Beta-blockers should not be used in the management of hypertension following a stroke, unless they are indicated for a co-existing condition.

All patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight, alcohol intake, and smoking.

**Intracerebral haemorrhage**

**Initial Management**

Surgical intervention may be required following intracerebral haemorrhage to remove the haematoma and relieve intracranial pressure. Patients taking anticoagulants should have this treatment stopped for 7 days and substituted with aspirin.

Anticoagulant therapy has, however, been used in patients with intracerebral haemorrhage who are symptomatic of...
deep vein thrombosis or pulmonary embolism; placement of a caval filter is an alternative in this situation.

Long-term management
Aspirin therapy should only be given to patients at a high risk of a cardiac ischaemic event. Anticoagulant therapy is not recommended following an intracerebral haemorrhage, even in those with atrial fibrillation, unless the patient is at very high risk of an ischaemic stroke or cardiac ischaemic events; advice from a specialist should be sought in this situation. Blood pressure should be measured and treatment initiated where appropriate, taking care to avoid hypoperfusion. Statins should be avoided following intracerebral haemorrhage, however they can be used with caution when the risk of a vascular event outweighs the risk of further haemorrhage.

Oral anticoagulants
The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slower-moving venous side of the circulation, where the thrombus consists of a fibrin web enmeshed with platelets and red cells.

Anticoagulants are of less use in preventing thrombus formation in arteries, for in faster-flowing vessels thrombi are composed mainly of platelets with little fibrin.

Coumarins and phenindione
The oral anticoagulants warfarin sodium p. 121,acenocoumarol p. 120 and phenindione p. 120, antagonise the effects of vitamin K, and take at least 48 to 72 hours for the anticoagulant effect to develop fully; warfarin sodium is the drug of choice. If an immediate effect is required, unfractionated or low molecular weight heparin must be given concomitantly. These oral anticoagulants should not be used in cerebral artery thrombosis or peripheral artery occlusion as first-line therapy; aspirin p. 104 is more appropriate for reduction of risk in transient ischaemic attacks. Unfractionated or a low molecular weight heparin (see under Parenteral anticoagulants p. 104) is usually preferred for the prophylaxis of venous thromboembolism in patients undergoing surgery; alternatively, warfarin sodium can be continued in selected patients currently taking long-term warfarin sodium and who are at high risk of thromboembolism (seek expert advice).

Dose
The base-line prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.

Target INR
The following indications and target INRs for adults for warfarin take into account recommendations of the British Society for Haematology guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol 2011; 154: 311–324:

An INR which is within 0.5 units of the target value is generally satisfactory; larger deviations require dosage adjustment. Target values (rather than ranges) are now recommended.

INR 2.5 for:
- treatment of deep-vein thrombosis or pulmonary embolism (including those associated with antiphospholipid syndrome or for recurrence in patients no longer receiving warfarin sodium p. 121)
- atrial fibrillation
- cardioversion—target INR should be achieved at least 3 weeks before cardioversion and anticoagulation should continue for at least 4 weeks after the procedure (higher target values, such as an INR of 3, can be used for up to 4 weeks before the procedure to avoid cancellations due to low INR)
- dilated cardiomyopathy
- mitral stenosis or regurgitation in patients with either atrial fibrillation, a history of systemic embolism, a left atrial thrombus, or an enlarged left atrium
- bioprosthetic heart valves in the mitral position (treat for 3 months), or in patients with a history of systemic embolism (treat for at least 3 months), or with a left atrial thrombus at surgery (treat until clot resolves), or with other risk factors (e.g. atrial fibrillation or a low ventricular ejection fraction)
- acute arterial embolism requiring embolectomy (consider long-term treatment)
- myocardial infarction

INR 3.5 for:
- recurrent deep-vein thrombosis or pulmonary embolism in patients currently receiving anticoagulation and with an INR above 2:
  - Mechanical prosthetic heart valves:
    - the recommended target INR depends on the type and location of the valve, and patient-related risk factors
  - consider increasing the INR target or adding an antiplatelet drug, if an embolic event occurs whilst anticoagulated at the target INR.

Duration

- 6 weeks for isolated calf-vein deep-vein thrombosis
- 3 months for venous thromboembolism provoked by surgery or other transient risk factor (e.g. combined oral contraceptive use, pregnancy, plaster cast)
- at least 3 months for unprovoked proximal deep-vein thrombosis or pulmonary embolism; long-term anticoagulation may be required.

Haemorrhage
The main adverse effect of all oral anticoagulants is haemorrhage. Checking the INR and omitting doses when appropriate is essential; if the anticoagulant is stopped but not reversed, the INR should be measured 2–3 days later to ensure that it is falling. The cause of an elevated INR should be investigated. The following recommendations (which take into account the recommendations of the British Society for Haematology Guidelines on Oral Anticoagulation with Warfarin—fourth edition. Br J Haematol 2011; 154: 311–324) are based on the result of the INR and whether there is major or minor bleeding; the recommendations apply to adults taking warfarin:

- Major bleeding—stop warfarin sodium; give phytonadione p. 889 (vitamin K1) by slow intravenous injection; give dried prothrombin complex p. 96 (factors II, VII, IX, and X); if dried prothrombin complex unavailable, fresh frozen plasma can be given but is less effective; recombinant factor VIIa is not recommended for emergency anticoagulation reversal
- INR >8.0, minor bleeding—stop warfarin sodium p. 121; give phytonadione p. 889 (vitamin K1) by slow intravenous injection; repeat dose of phytonadione p. 889 if INR still too high after 24 hours; restart warfarin sodium when INR <5.0
- INR >8.0, no bleeding—stop warfarin sodium; give phytonadione (vitamin K1) by mouth using the intravenous preparation orally (fun of the use); repeat dose of phytonadione if INR still too high after 24 hours; restart warfarin when INR <5.0
Antiplatelet drugs

Antiplatelet drugs decrease platelet aggregation and inhibit thrombus formation in the arterial circulation, because in faster-flowing vessels, thrombi are composed mainly of platelets with little fibrin.

Use of aspirin p. 104 in primary prevention of cardiovascular events, in patients with or without diabetes, is of unproven benefit. Long-term use of aspirin is of benefit in established cardiovascular disease (secondary prevention); unduly high blood pressure must be controlled before aspirin is given. If the patient is at a high risk of gastro-intestinal bleeding, a proton pump inhibitor can be added.

Aspirin is given following coronary bypass surgery. It is also used in atrial fibrillation, for intermittent claudication, for stable angina and acute coronary syndromes, for use following placement of coronary stents and for use in stroke.

prasugrel p. 106 is licensed for the prevention of atherothrombotic events in patients with a history of symptomatic ischaemic disease. Clopidogrel, in combination with low-dose aspirin, is also licensed for acute coronary syndrome without ST-segment elevation; in these circumstances the combination is given for up to 12 months (most benefit occurs during the first 3 months; there is no evidence of benefit beyond 12 months). Clopidogrel, in combination with low-dose aspirin, is also licensed for acute myocardial infarction with ST-segment elevation; the combination is licensed for at least 4 weeks, but the optimum treatment duration has not been established. In patients undergoing percutaneous coronary intervention, clopidogrel is used as an adjunct with aspirin. Patients who are not already taking clopidogrel should receive a loading dose prior to procedure.

Clopidogrel is also licensed, in combination with low-dose aspirin, for the prevention of atherothrombotic and thromboembolic events in patients with atrial fibrillation (and at least one risk factor for a vascular event), and for whom warfarin sodium is unsuitable.

Use of clopidogrel with aspirin increases the risk of bleeding. Clopidogrel monotherapy may be an alternative when aspirin is contra-indicated, for example in those with aspirin hypersensitivity, or when aspirin is not tolerated despite the addition of a proton pump inhibitor (see also NICE guidance). Clopidogrel also has uses in stroke. Dipyridamole is used by mouth as an adjunct to oral antiplatelet therapy for prophylaxis of thromboembolism associated with prosthetic heart valves. Modified-release preparations are licensed for secondary prevention of ischaemic stroke and transient ischaemic attacks.

Prasugrel p. 188, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention; the combination is usually given for up to 12 months.

Ticagrelor p. 188, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome; the combination is usually given for up to 12 months.

Antiplatelet drugs and coronary stents

Patients selected for percutaneous coronary intervention, with the placement of a coronary stent, will require dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel, or ticagrelor. Aspirin therapy should continue indefinitely. Clopidogrel is recommended for 1 month following elective percutaneous coronary intervention with placement of a bare-metal stent, and for 12 months if percutaneous coronary intervention with placement of a bare-metal stent was for an acute coronary syndrome; clopidogrel should be given for 12 months following placement of a drug-eluting stent. Clopidogrel should not be discontinued prematurely in patients with a drug-eluting stent—there is an increased risk of stent thrombosis as a result of the eluted drug slowing the re-endothelialisation process. Patients considered to be at high risk of developing late stent thrombosis with a drug-eluting stent may require a longer duration of treatment with clopidogrel. Prasugrel or ticagrelor are alternatives to clopidogrel in certain patients undergoing percutaneous coronary intervention.

Glycoprotein Iib/IIia inhibitors

Glycoprotein Iib/IIia inhibitors prevent platelet aggregation by blocking the binding of fibrinogen to receptors on platelets. Abciximab p. 183 is a monoclonal antibody which binds to glycoprotein Iib/IIia receptors and to other related sites; it is licensed as an adjunct to heparin.
Cardiovascular system

Heparin (unfractionated) p. 114 and aspirin for the prevention of ischaemic complications in high-risk patients undergoing percutaneous transluminal coronary intervention. Abciximab should be used once only (to avoid additional risk of thrombocytopenia). Eptifibatide (in combination with heparin (unfractionated) and aspirin) and tiroliban p. 184 (in combination with heparin (unfractionated), aspirin, and clopidogrel) also inhibit glycoprotein IIb/IIIa receptors; they are licensed for use to prevent early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction. Tiroliban is also licensed for use in combination with heparin (unfractionated), aspirin, and clopidogrel, for the reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction intended for primary percutaneous coronary intervention. Abciximab, eptifibatide p. 183 and tiroliban should be used by specialists only.

Epoprostenol p. 99 is also used to inhibit platelet aggregation during renal dialysis when heparin is unsuitable or contra-indicated.

Parenteral anticoagulants

The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slower-moving venous side of the circulation, where the thrombus consists of a fibrin web enmeshed with platelets and red cells.

Anticoagulants are of less use in preventing thrombus formation in arteries, for in faster-flowing vessels thrombi are composed mainly of platelets with little fibrin.

Heparin

Heparin initiates anticoagulation rapidly but has a short duration of action. It is often referred to as ‘standard’ or heparin (unfractionated) p. 114 to distinguish it from the low molecular weight heparins, which have a longer duration of action. Although a low molecular weight heparin is generally preferred for routine use, heparin (unfractionated) can be used in those at high risk of bleeding because its effect can be terminated rapidly by stopping the infusion.

Low molecular weight heparins

Low molecular weight heparins (dalteparin sodium p. 112, enoxaparin sodium p. 113, and tinzaparin sodium p. 115) are usually preferred over heparin (unfractionated) in the prevention of Venous thromboembolism because they are as effective and they have a lower risk of heparin-induced thrombocytopenia. The standard prophylactic regimen does not require anticoagulant monitoring. The duration of action of low molecular weight heparins is longer than that of heparin (unfractionated) and once-daily subcutaneous administration is possible for some indications, making them convenient to use.

Low molecular weight heparins are generally preferred over heparin (unfractionated) in the treatment of deep vein thrombosis and pulmonary embolism, and are also used in the treatment of myocardial infarction, unstable coronary artery disease (see Acute coronary syndromes p. 186) and for the prevention of clotting in extracorporeal circuits.

Dalteparin sodium and tinzaparin sodium (only 20 000 unit/mL syringe) are also licensed for the extended treatment and prophylaxis of venous thromboembolism in patients with solid tumours; treatment is recommended for a duration of 6 months. Treatment should be initiated by healthcare professionals experienced in the treatment of venous thromboembolism.

Heparinoids

Danaparoid sodium p. 111 is a heparinoid used for prophylaxis of deep-vein thrombosis in patients undergoing general or orthopaedic surgery. Providing there is no evidence of cross-reactivity, it also has a role in patients who develop heparin-induced thrombocytopenia.

Argatroban

An oral anticoagulant can be given with argatroban monohydrate p. 116, but it should only be started once thrombocytopenia has substantially resolved.

Hirudins

Bivalirudin, a hirudin analogue, is a thrombin inhibitor which is licensed for unstable angina or non-ST-segment elevation myocardial infarction in patients planned for urgent or early intervention, and as an anticoagulant for patients undergoing percutaneous coronary intervention (including patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention—see also Myocardial infarction: ST-segment elevation p. 186).

Heparin flushes

The use of heparin flushes should be kept to a minimum. For maintaining patency of peripheral venous catheters, sodium chloride injection 0.9% is as effective as heparin flushes. The role of heparin flushes in maintaining patency of arterial and central venous catheters is unclear.

Epoprostenol

Epoprostenol (prostacyclin) p. 99 can be given to inhibit platelet aggregation during renal dialysis when heparins are unsuitable or contra-indicated. It is also licensed for the treatment of primary pulmonary hypertension resistant to other treatment, usually with oral anticoagulation; it should be initiated by specialists in pulmonary hypertension. Epoprostenol is a potent vasodilator. It has a short half-life of approximately 3 minutes and therefore it must be administered by continuous intravenous infusion.

Fondaparinux

Fondaparinux sodium p. 109 is a synthetic pentasaccharide that inhibits activated factor X.

Aspirin

(Acetylsalicylic Acid)

**INDICATIONS AND DOSE**

Cardiovascular disease (secondary prevention)

**BY MOUTH**

- Adult: 75 mg daily

Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) Management of ST-segment elevation myocardial infarction (STEMI)

**BY MOUTH**

- Adult: 300 mg

Suspected transient ischaemic attack

**BY MOUTH**

- Adult: 300 mg daily until diagnosis established

Transient ischaemic attack (long-term treatment following in combination with dipyridamole) Ischaemic stroke not associated with atrial fibrillation (in combination with dipyridamole if clopidogrel contraindicated or not tolerated)

**BY MOUTH**

- Adult: 75 mg daily
Acute ischaemic stroke

By mouth
- Adult: 300 mg daily for 14 days, to be initiated 24 hours after thrombolysis or as soon as possible within 48 hours of symptom onset in patients not receiving thrombolysis

Atrial fibrillation following a disabling ischaemic stroke

By mouth
- Adult: 300 mg daily for 14 days

Following disabling ischaemic stroke in patients receiving anticoagulation for a prosthetic heart valve

By mouth
- Adult: 300 mg daily, anticoagulant treatment stopped for 7 days and to be substituted with aspirin

Following coronary by-pass surgery

By mouth
- Adult: 75–300 mg daily

Mild to moderate pain

By mouth
- Adult: 300–900 mg every 4–6 hours as required; maximum 4 g per day

By rectum
- Adult: 450–900 mg every 4 hours; maximum 3.6 g per day

- CONTRA-INDICATIONS Active peptic ulceration - bleeding disorders (antiplatelet dose) - children under 16 years (risk of Reye’s syndrome) - haemophilia - previous peptic ulceration (analgesic dose) - severe cardiac failure (analgesic dose)

CONTRA-INDICATIONS, FURTHER INFORMATION
Reye’s syndrome. Owing to an association with Reye’s syndrome, aspirin-containing preparations should not be given to children under 16 years, unless specifically indicated, e.g., for Kawasaki disease.

- CAUTIONS Allergic disease - anaemia - asthma - dehydrogen - elderly - G6PD deficiency - preferably avoid during fever or viral infection in children (risk of Reye’s syndrome) - previous peptic ulceration (but manufacturers may advise avoidance of low-dose aspirin in history of peptic ulceration) - thyrotoxicosis - uncontrolled hypertension

- INTERACTIONS Appendix 1 (aspirin). Caution with concomitant use of drugs that increase risk of bleeding.

SIDE-EFFECTS. Blood disorders (with analgesic doses) - bronchospasm - confusion (with analgesic doses) - gastrointestinal haemorrhage (occasionally major) - gastrointestinal irritation (with slight asymptomatic blood loss at higher doses) - haemorrhage including subconjunctival haemorrhage (reported with antiplatelet doses) - increased bleeding time - skin reactions in hypersensitive patients - tinnitus (with analgesic doses)

Overdose The main features of salicylate poisoning are hyperventilation, tinnitus, deafness, vasodilatation, and sweating. Coma is uncommon but indicates very severe poisoning. For specific details on the management of poisoning, see Aspirin, under Emergency treatment of poisoning p. 1123.

- ALLERGY AND CROSS-SENSITIVITY Aspirin is contra-indicated in history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria, or rhinitis have been precipitated by aspirin or any other NSAID.

- PREGNANCY Use antiplatelet doses with caution during third trimester; impaired platelet function and risk of haemorrhage; delayed onset and increased duration of labour with increased blood loss; avoid analgesic doses if possible in last few weeks (low doses probably not harmful); high doses may be related to intra-uterine growth restriction, teratogenic effects, closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of newborn; kernicterus may occur in jaundiced neonates.

- BREAST FEEDING Avoid—possible risk of Reye’s syndrome; regular use of high doses could impair platelet function and produce hypoprothrombinemia in infant if neonatal vitamin K stores low.

- HEPATIC IMPAIRMENT Avoid in severe impairment—increased risk of gastro-intestinal bleeding.

- RENAL IMPAIRMENT Use with caution; avoid in severe impairment; sodium and water retention; deterioration in renal function; increased risk of gastro-intestinal bleeding.

- PRESCRIBING AND DISPENSING INFORMATION BP directs that when no strength is stated the 300 mg strength should be dispensed, and that when soluble aspirin tablets are prescribed, dispersible aspirin tablets shall be dispensed.

- PROFESSION SPECIFIC INFORMATION Dental practitioners’ formulary Aspirin Dispersible Tablets 300 mg may be prescribed.

- EXCEPTIONS TO LEGAL CATEGORY Can be sold to the public provided packs contain no more than 32 capsules or tablets; pharmacists can sell multiple packs up to a total quantity of 100 capsules or tablets in justifiable circumstances.

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder, capsule, liquid

Tablet
CAUTIONARY AND ADVISORY LABELS 21, 32
- ASPIRIN (Non-proprietary)
  - Aspirin 75 mg
    - Aspirin 75mg tablets | 28 tablet P|82 DT price = £0.82
  - Aspirin 300 mg
    - Aspirin 300mg tablets | 16 tablet GSL no price available | 28 tablet GSS £2.93 | 32 tablet GSS £0.31-0.33 DT price = £3.35 | 32 tablet P £3.35 DT price = £3.35 | 100 tablet P £10.67

Dispersible tablet
CAUTIONARY AND ADVISORY LABELS 13, 21, 32
- ASPIRIN (Non-proprietary)
  - Aspirin 75 mg
    - Aspirin 75mg dispersible tablets | 28 tablet P £0.90 DT price = £0.87 | 28 tablet GSS £0.87 DT price = £0.87 | 100 tablet P £3.12 DT price = £3.11 | 100 tablet GSL £3.11 DT price = £3.11 | 1000 tablet P £31.28
  - Pure Health Aspirin 75mg dispersible tablets | 28 tablet P £0.23 DT price = £0.87 | 100 tablet P £0.89 DT price = £3.11
  - Aspirin 300 mg
    - Aspirin 300mg dispersible tablets | 32 tablet P £1.37 DT price = £1.06 | 32 tablet P no price available DT price = £1.06 | 100 tablet P £0.94-€4.28 DT price = £3.31 | 1000 tablet P £33.10

Gastro-resistant tablet
CAUTIONARY AND ADVISORY LABELS 5, 25, 32
- ASPIRIN (Non-proprietary)
  - Aspirin 75 mg
    - Aspirin 75mg gastro-resistant tablets | 28 tablet P £0.93-€0.94 DT price = €0.94 | 28 tablet GSS £0.93 DT price = €0.94 | 56 tablet P £1.93 | 56 tablet GSS no price available
  - Boots Aspirin 75mg gastro-resistant tablets | 56 tablet P no price available
  - Aspirin 300 mg
    - Aspirin 300mg gastro-resistant tablets | 100 tablet P £20.34 DT price = £20.24
  - Micropirin (Dexcel-Pharma Ltd)
    - Aspirin 75 mg
      - Micropirin 75mg gastro-resistant tablets | 28 tablet P £1.45 DT price = £0.94 | 56 tablet P £2.87
  - Nu-Seals (Alliance Pharmaceuticals Ltd)
    - Aspirin 75 mg
      - Nu-Seals 75 gastro-resistant tablets | 56 tablet P £3.12
Suppository

CAUTIONARY AND ADVISORY LABELS 32

▶ ASPIRIN (Non-proprietary)

Aspirin 150 mg  Aspirin 150mg suppositories  |  10 suppository  £16.57–£21.95
Aspirin 300 mg  Aspirin 300mg suppositories  |  10 suppository  £32.63

Also available in combination with dipyridamole, p. 107

Clopidogrel

INDICATIONS AND DOSE

Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel

BY MOUTH

▶ Adult: Loading dose 300 mg, to be taken prior to the procedure, alternatively loading dose 600 mg, higher dose may produce a greater and more rapid inhibition of platelet aggregation

Transient ischaemic attack for patients with aspirin hypersensitivity, or those intolerant of aspirin / Acute ischaemic stroke for patients with aspirin hypersensitivity, or those intolerant of aspirin

BY MOUTH

▶ Adult: 75 mg once daily

Prevention of atherothrombotic events in peripheral arterial disease or within 35 days of myocardial infarction, or within 6 months of ischaemic stroke

BY MOUTH

▶ Adult: 75 mg once daily

Prevention of atherothrombotic events in acute coronary syndrome without ST-segment elevation (given with aspirin)

BY MOUTH

▶ Adult: Initially 300 mg, then 75 mg daily for up to 12 months

Prevention of atherothrombotic events in acute myocardial infarction with ST-segment elevation (given with aspirin)

BY MOUTH

▶ Adult 18-75 years: Initially 300 mg, then 75 mg for at least 4 weeks

▶ Adult 76 years and over: 75 mg daily

Prevention of atherothrombotic and thromboembolic events in patients with atrial fibrillation (with aspirin) and for whom warfarin is unsuitable

BY MOUTH

▶ Adult: 75 mg once daily

UNLICENSED USE 600 mg loading dose prior to percutaneous coronary intervention is an unlicensed dose. Use in transient ischaemic attack or acute ischaemic stroke, in patients with aspirin hypersensitivity or intolerant of aspirin, is unlicensed.

CONTRA-INDICATIONS  Active bleeding

CAUTIONS Discontinue 7 days before elective surgery if antiplatelet effect not desirable - patients at risk of increased bleeding from trauma, surgery, or other pathological conditions

INTERACTIONS → Appendix 1 (clopidogrel).

Caution with concomitant use of drugs that increase risk of bleeding.

SIDE-EFFECTS

▶ Common or very common  Abdominal pain - bleeding disorders (including gastro-intestinal and intracranial) - diarrhoea - dyspepsia


REACHED Rare  Vertigo


ALLERGY AND CROSS-SENSITIVITY  Caution with history of hypersensitivity reactions to thienopyridines (e.g. prasugrel).

PREGNANCY  Manufacturer advises avoid—no information available.

BREAST FEEDING  Manufacturer advises avoid.

HEPATIC IMPAIRMENT  Manufacturer advises caution (risk of bleeding). Avoid in severe impairment.

RENAL IMPAIRMENT  Manufacturer advises caution.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

▶ Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (December 2010) NICE TA210

The guidance applies to patients who have had an occlusive vascular event, or who have established peripheral arterial disease. The guidance does not apply to patients who have had, or are at risk of, stroke associated with atrial fibrillation, or who need prophylaxis for occlusive events following coronary revascularisation or carotid artery procedures. Clopidogrel monotherapy is recommended as an option to prevent occlusive vascular events in patients who have had:

▶ an ischaemic stroke, or who have peripheral arterial disease or multivascular disease, or

▶ a myocardial infarction, only if aspirin is contra-indicated or not tolerated. www.nice.org.uk/TA210

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2004) that clopidogrel be accepted for restricted use for the treatment of confirmed acute coronary syndrome (without ST-segment elevation), in combination with aspirin. Clopidogrel should be initiated in hospital inpatients only.

The Scottish Medicines Consortium has also advised (July 2007) that clopidogrel be accepted for restricted use for patients with ST-segment elevation acute myocardial infarction in combination with aspirin; treatment with clopidogrel is restricted to 4 weeks only.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, powder

Tablet

▶ CLOPIDOGREL (Non-proprietary)

Clopidogrel 75 mg  Clopidogrel 75mg tablets | 28 tablet  £30.54 DT price = £1.82 | 30 tablet  £32.71

Grepid (Beacon Pharmaceuticals Ltd)

Clopidogrel 75 mg  Grepid 75mg tablets | 30 tablet  £32.28

Plavix (Sanofi)

Clopidogrel 75 mg  Plavix 75mg tablets | 30 tablet  £35.64

Clopidogrel (as Clopidogrel hydrogen sulfate) 300 mg  Plavix 300mg tablets | 30 tablet  £142.54 DT price = £142.54
**Dipyridamole**

**INDICATIONS AND DOSE**
Secondary prevention of ischaemic stroke (not associated with atrial fibrillation) and transient ischaemic attacks (used alone or with aspirin) | Adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 200 mg twice daily, to be taken preferably with food

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 300–600 mg daily in 3–4 divided doses

- **BY INTRAVENOUS INJECTION**
  - Adult: (consult product literature)

**SIDE-EFFECTS**
Angioedema | dizziness | gastro-intestinal effects | hot flushes | hypersensitivity reactions | hypotension | increased bleeding after surgery | increased bleeding during surgery | myalgia | rash | severe bronchospasm | tachycardia | throbbing headache | urticaria | worsening symptoms of coronary heart disease

**PREGNANCY**
Not known to be harmful.

**BREAST FEEDING**
Manufacturers advise use only if essential—small amount present in milk.

**PRESCRIBING AND DISPENSING INFORMATION**
Modified-release capsules should be dispensed in original container (pack contains a desiccant) and any capsules remaining should be discarded 6 weeks after opening.

**NATIONAL FUNDING/ACCESS DECISIONS**
**NICE technology appraisals (TAs)**
- Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (December 2010) NICE TA210
  - The guidance applies to patients who have had an occlusive vascular event, or who have established peripheral arterial disease. The guidance does not apply to patients who have had, or are at risk of, stroke associated with atrial fibrillation, or who need prophylaxis for occlusive events following coronary revascularisation or carotid artery procedures.
  - Modified-release dipyridamole, in combination with aspirin, is recommended as an option to prevent occlusive vascular events in patients who have had:
    - a transient ischaemic attack, or
    - an ischaemic stroke, only if clopidogrel is contraindicated or not tolerated.
  - Modified-release dipyridamole monotherapy is recommended as an option to prevent occlusive vascular events in patients who have had:
    - an ischaemic stroke, only if aspirin and clopidogrel are contra-indicated or not tolerated, or
    - a transient ischaemic attack, only if aspirin is contraindicated or not tolerated. [www.nice.org.uk/TA210](http://www.nice.org.uk/TA210)

**MEDICATION FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

---

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**
- **DIPYRIDAMOLE (Non-proprietary)**
  - **Dipyridamole 25 mg**: Dipyridamole 25mg tablets | 84 tablet £4.14 DT price = £3.76
  - **Dipyridamole 100 mg**: Dipyridamole 100mg tablets | 84 tablet £6.30 DT price = £5.82

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS**
- **DIPYRIDAMOLE (Non-proprietary)**
  - **Dipyridamole 200 mg**: Dipyridamole 200mg modified-release capsules | 60 capsule £10.06 DT price = £9.66
  - **Attia (Dr Reddy’s Laboratories (UK) Ltd)**
    - **Dipyridamole 200 mg**: Attia 200mg modified-release capsules | 60 capsule £13.36 DT price = £12.95
  - **Ofcram PR (Focus Pharmaceuticals Ltd)**
    - **Dipyridamole 200 mg**: Ofcram PR 200mg capsules | 60 capsule £10.06 DT price = £9.66
    - **Persantin Retard (Boehringer Ingelheim Ltd, Consilient Health Ltd)**
      - **Dipyridamole 200 mg**: Persantin Retard 200mg capsules | 60 capsule £8.55-10.06 DT price = £7.78

**Oral suspension**

- **DIPYRIDAMOLE (Non-proprietary)**
  - **Dipyridamole 10 mg per 1 ml**: Dipyridamole 50mg/5ml oral suspension sugar free (sugar-free) | 150 ml £41.26 DT price = £38.06

**Solution for injection**

- **Persantin (Boehringer Ingelheim Ltd)**
  - **Dipyridamole 5 mg per 1 ml**: Persantin 10mg/2ml solution for injection ampoules | 5 ampoule £0.82

---

**Aspirin with dipyridamole**

The properties listed below are those particular to the combination only. For the properties of the components please consider, aspirin p. 104, dipyridamole above.

**INDICATIONS AND DOSE**
Secondary prevention of ischaemic stroke and transient ischaemic attacks

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 25/200 mg twice daily

**PRESCRIBING AND DISPENSING INFORMATION**
Dispense in original container (pack contains a desiccant) and discard any capsules remaining 6 weeks after opening.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS**
- **ASPIRIN WITH DIPYRIDAMOLE (Non-proprietary)**
  - **Aspirin 25 mg, Dipyridamole 200 mg**: Dipyridamole 200mg modified-release / Aspirin 25mg capsules | 100 capsule £16.40
  - **Asasantin Retard (Boehringer Ingelheim Ltd)**
    - **Aspirin 25 mg, Dipyridamole 200 mg**: Asasantin Retard capsules | 60 capsule £9.84 DT price = £9.44
  - **Molita (Dr Reddy’s Laboratories (UK) Ltd)**
    - **Aspirin 25 mg, Dipyridamole 200 mg**: Molita 200mg/25mg modified-release capsules | 100 capsule £3.35
**Cardiovascular system**

When used for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation (February 2013) NICE TA275

Apixaban is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in accordance with its licensed indication; with one or more of the following risk factors:

- previous stroke or transient ischaemic attack
- symptomatic heart failure
- age ≥ 75 years
- diabetes mellitus
- hypertension

The risks and benefits of apixaban compared to warfarin, dabigatran etexilate, and rivaroxaban should be discussed with the patient. www.nice.org.uk/TA275

**Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015) NICE TA341**

Apixaban is an option for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults. www.nice.org.uk/TA341

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Eliquis** (Bristol-Myers Squibb Pharmaceuticals Ltd) ▼

Apixaban 2.5 mg Eliquis 2.5mg tablets | 10 tablet | £10.98 |
20 tablet | £21.96 | 60 tablet | £65.90 | DT price = £65.90

Apixaban 5 mg Eliquis 5mg tablets | 28 tablet | £30.75 |
56 tablet | £61.50 | DT price = £61.50

**FACTOR Xa INHIBITORS**

**Apixaban**

**DRUG ACTION** Apixaban is a direct inhibitor of activated factor X (factor Xa).

**INDICATIONS AND DOSE**

**Prophylaxis of venous thromboembolism following knee replacement surgery**

**BY MOUTH**

- Adult: 2.5 mg twice daily for 10–14 days, to be started 12–24 hours after surgery

**Prophylaxis of venous thromboembolism following hip replacement surgery**

**BY MOUTH**

- Adult: 2.5 mg twice daily for 32–38 days, to be started 12–24 hours after surgery

**Treatment of deep-vein thrombosis | Treatment of pulmonary embolism**

**BY MOUTH**

- Adult: Initially 10 mg twice daily for 7 days, then maintenance 5 mg twice daily

**Prophylaxis of recurrent deep-vein thrombosis | Prophylaxis of recurrent pulmonary embolism**

**BY MOUTH**

- Adult: 2.5 mg twice daily, following completion of 6 months anticoagulant treatment

**Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor such as previous stroke or transient ischaemic attack, symptomatic heart failure, diabetes mellitus, hypertension, or age ≥ 75 years**

**BY MOUTH**

- Adult: 2.5 mg twice daily
- Adult 18-79 years: 5 mg twice daily
- Adult 80 years and over (body-weight up to 61 kg): 2.5 mg twice daily

**Dose equivalence and conversion**

For information on changing from, or to, other anticoagulants, consult product literature.

**CONTRA-INDICATIONS** Active bleeding • malignant neoplasms • oesophageal varices • recent brain surgery • recent gastro-intestinal ulcer • recent intracranial haemorrhage • recent ophthalmic surgery • recent spine surgery • significant risk of major bleeding • vascular aneurysm

**CAUTIONS** Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis—monitor neurological signs and wait 20–30 hours after apixaban dose before removing catheter and do not give next dose until at least 5 hours after catheter removal) • prosthetic heart valve (efficacy not established) • risk of bleeding

**INTERACTIONS** ◄ Appendix 1 (apixaban). Caution in concomitant use of drugs that increase risk of bleeding.

**SIDE-EFFECTS**

- **Common or very common** Anaemia • bruising • haemorrhage • nausea
- **Uncommon** Hypotension • rash • thrombocytopenia

**PREGNANCY** Manufacturer advises avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies

**HEPATIC IMPAIRMENT** Avoid in severe impairment and in hepatic disease associated with coagulopathy.

**RENAL IMPAIRMENT**

- When used for prophylaxis of stroke and systemic embolism in atrial fibrillation Reduce dose to 2.5 mg twice daily if creatinine clearance 15–29 mL/minute, or if serum-creatinine ≥ 133 micromol/litre and age ≥ 80 years or body-weight < 60 kg.
- When used for prophylaxis of venous thromboembolism following knee or hip replacement surgery, prophylaxis of recurrent deep-vein thrombosis or pulmonary embolism, and treatment of deep-vein thrombosis or pulmonary embolism Use with caution if creatinine clearance 15–29 mL/minute. Manufacturer advises avoid if creatinine clearance less than 15 mL/minute—no information available.

**MONITORING REQUIREMENTS**

- Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.
- No routine anticoagulant monitoring required (INR tests are unreliable).

**PRESCRIBING AND DISPENSING INFORMATION** Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilisation. Apixaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (Tas)**

- **Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults** (January 2012) NICE TA245

Apixaban is an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery. www.nice.org.uk/TA245

- **Apixaban for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation** (February 2013) NICE TA275

Apixaban is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in accordance with its licensed indication; with one or more of the following risk factors:

- previous stroke or transient ischaemic attack
- symptomatic heart failure
- age ≥ 75 years
- diabetes mellitus
- hypertension

Apixaban is an option for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in adults. www.nice.org.uk/TA341

**Tablet**

- **Eliquis** (Bristol-Myers Squibb Pharmaceuticals Ltd) ▼

Apixaban 2.5 mg Eliquis 2.5mg tablets | 10 tablet | £10.98 |
20 tablet | £21.96 | 60 tablet | £65.90 | DT price = £65.90

Apixaban 5 mg Eliquis 5mg tablets | 28 tablet | £30.75 |
56 tablet | £61.50 | DT price = £61.50
Fondaparinux sodium

**DRUG ACTION** Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X.

**INDICATIONS AND DOSE**

**Prophylaxis of venous thromboembolism in patients after undergoing major orthopaedic surgery of the hip or leg, or abdominal surgery**

**BY SUBCUTANEOUS INJECTION**
- **Adult:** Initially 2.5 mg, dose to be given 6 hours after surgery, then 2.5 mg once daily

**Prophylaxis of venous thromboembolism in medical patients immobilised because of acute illness**

**BY SUBCUTANEOUS INJECTION**
- **Adult:** 2.5 mg once daily

**Treatment of superficial-vein thrombosis**

**BY SUBCUTANEOUS INJECTION**
- **Adult (body-weight 50 kg and above):** 2.5 mg once daily for at least 30 days (max. 45 days if high risk of thromboembolic complications), treatment should be stopped 24 hours before surgery and restarted at least 6 hours post operatively

**Treatment of unstable angina and non-ST-segment elevation myocardial infarction**

**BY SUBCUTANEOUS INJECTION**
- **Adult:** 2.5 mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively

**Treatment of ST-segment elevation myocardial infarction**

**INITIALLY BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- **Adult:** Initially 2.5 mg daily for the first day, then (by subcutaneous injection) 2.5 mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively

**Treatment of deep-vein thrombosis and pulmonary embolism**

**BY SUBCUTANEOUS INJECTION**
- **Adult (body-weight up to 50 kg):** 5 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR ≥ 2 for at least 24 hours)
- **Adult (body-weight 50–100 kg):** 7.5 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR ≥ 2 for at least 24 hours)
- **Adult (body-weight 101 kg and above):** 10 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR ≥ 2 for at least 24 hours)

**CONTRA-INDICATIONS** Active bleeding - bacterial endocarditis

**CAUTIONS** Active gastro-intestinal ulcer disease - bleeding disorders - brain surgery - elderly patients - low body-weight - ophthalmic surgery - recent intracranial haemorrhage - risk of catheter thrombus during percutaneous coronary intervention - spinal or epidural anaesthesia - (risk of spinal haematoma - avoid if using treatment doses) - spinal surgery

**INTERACTIONS** → Appendix 1 (fondaparinux). Caution with concomitant use of drugs that increase risk of bleeding.

**SIDE-EFFECTS**
- Common or very common: Anaemia - bleeding - purpura
- Uncommon: Chest pain - dyspnoea - gastro-intestinal disturbances - hepatic impairment - oedema - pruritus - rash - thrombocythaemia - thrombocytopenia
- Rare: Anxiety - confusion - cough - dizziness - drowsiness - flushing - headache - hyperbilirubinaemia - hypokalaemia - hypotension - injection-site reactions - vertigo
- Frequency not known: Atrial fibrillation - pyrexia - tachycardia

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs possible risk — no information available.

**BREAST FEEDING** Present in milk in animal studies — manufacturer advises avoid.

**HEPATIC IMPAIRMENT** Caution in severe impairment (increased risk of bleeding).

**RENAL IMPAIRMENT** Increased risk of bleeding in renal impairment.

- When used for prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis: Reduce dose to 1.5 mg daily if eGFR 20–50 mL/minute/1.73 m².
- When used for treatment of acute coronary syndromes or prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis: Avoid if eGFR less than 20 mL/minute/1.73 m².
- When used for treatment of venous thromboembolism: Use with caution if eGFR 30–50 mL/minute/1.73 m², avoid if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Arixtra®), give intermittently in Sodium chloride 0.9%. For ST-segment elevation myocardial infarction, add requisite dose to 25–50 mL infusion fluid and give over 1–2 minutes.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Arixtra (Aspen Pharma Trading Ltd)
  - Fondaparinux sodium 5 mg per 1 ml Arixtra 2.5mg/0.5ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £62.79
  - Fondaparinux sodium 12.5 mg per 1 ml Arixtra 5mg/0.1ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £62.79 (Hospital only)

- Fondaparinux sodium 12.5 mg per 1 ml Arixtra 5mg/0.1ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £116.63

- Fondaparinux sodium 5 mg per 1 ml Arixtra 2.5mg/0.5ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £116.53

- Fondaparinux sodium 10mg/0.4ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £116.53

Rivaroxaban

**DRUG ACTION** Rivaroxaban is a direct inhibitor of activated factor X (factor Xa).

**INDICATIONS AND DOSE**

**Prophylaxis of venous thromboembolism following knee replacement surgery**

**BY MOUTH**
- **Adult:** 10 mg once daily for 2 weeks, to be started 6–10 hours after surgery

**Prophylaxis of venous thromboembolism following hip replacement surgery**

**BY MOUTH**
- **Adult:** 10 mg once daily for 5 weeks, to be started 6–10 hours after surgery

Manufacturer advises avoid unless potential benefit outweighs possible risk — no information available.

**HEPATIC IMPAIRMENT** Caution in severe impairment (increased risk of bleeding).

**SIDE-EFFECTS**
- Common or very common: Anaemia - bleeding - purpura
- Uncommon: Chest pain - dyspnoea - gastro-intestinal disturbances - hepatic impairment - oedema - pruritus - rash - thrombocythaemia - thrombocytopenia
- Rare: Anxiety - confusion - cough - dizziness - drowsiness - flushing - headache - hyperbilirubinaemia - hypokalaemia - hypotension - injection-site reactions - vertigo
- Frequency not known: Atrial fibrillation - pyrexia - tachycardia

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs possible risk — no information available.

**BREAST FEEDING** Present in milk in animal studies — manufacturer advises avoid.

**HEPATIC IMPAIRMENT** Caution in severe impairment (increased risk of bleeding).

**RENAL IMPAIRMENT** Increased risk of bleeding in renal impairment.

- When used for prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis: Reduce dose to 1.5 mg daily if eGFR 20–50 mL/minute/1.73 m².
- When used for treatment of acute coronary syndromes or prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis: Avoid if eGFR less than 20 mL/minute/1.73 m².
- When used for treatment of venous thromboembolism: Use with caution if eGFR 30–50 mL/minute/1.73 m², avoid if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** For oral use, give in water or food at any time of day. Do not give with antacids, milk or dairy products.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Arixtra (Aspen Pharma Trading Ltd)
  - Fondaparinux sodium 5 mg per 1 ml Arixtra 2.5mg/0.5ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £62.79
  - Fondaparinux sodium 12.5 mg per 1 ml Arixtra 5mg/0.1ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £62.79 (Hospital only)

- Fondaparinux sodium 12.5 mg per 1 ml Arixtra 5mg/0.1ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £116.63

- Fondaparinux sodium 10mg/0.4ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £116.53

- Fondaparinux sodium 10mg/0.4ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PFS) £116.53
Blood clots

Initial treatment of deep-vein thrombosis | Initial treatment of pulmonary embolism
BY MOUTH
- Adult: Initially 15 mg twice daily for 21 days, to be taken with food

Continued treatment of deep-vein thrombosis (following initial treatment) | Continued treatment of pulmonary embolism (following initial treatment) | Prophylaxis of recurrent deep-vein thrombosis | Prophylaxis of recurrent pulmonary embolism
BY MOUTH
- Adult: 20 mg once daily, to be taken with food

Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: congestive heart failure, hypertension, previous stroke or transient ischaemic attack, age ≥ 75 years, or diabetes mellitus

CONTRA-INDICATIONS
Active bleeding - in acute coronary syndrome—previous stroke - in acute coronary syndrome—transient ischaemic attack - malignant neoplasms - oesophageal varices - recent brain surgery - recent gastrointestinal ulcer - recent intracranial haemorrhage - recent ophthalmic surgery - recent spine surgery - significant risk of major bleeding - vascular aneurysm

CAUTIONS
Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis—monitor neurological signs and wait at least 18 hours after rivaroxaban dose before removing catheter and do not give next dose until at least 6 hours after catheter removal) - bronchiectasis - prostatic heart valve (efficacy not established) - risk of bleeding - rivaroxaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy - severe hypertension - vascular retinopathy

INTERACTIONS
Appendix 1 (rivaroxaban). Caution in concomitant use of drugs that increase risk of bleeding.

SIDE-EFFECTS
- Common or very common Abdominal pain - constipation - diarrhoea - dizziness - dyspepsia - haemorrhage - headache - hypotenion - nausea - pain in extremities - pruritus - rash - renal impairment - vomiting
- Uncommon Angioedema - dry mouth - malaise - syncope - tachycardia - thrombocythaemia
- Rare Jaundice - oedema

PREGNANCY
Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING
Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
Avoid in liver disease with coagulopathy.

RENAL IMPAIRMENT
When used for treatment of deep-vein thrombosis or pulmonary embolism and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism Initially 15 mg twice daily for 21 days, then 20 mg once daily (but consider reducing to 15 mg once daily if risk of bleeding outweighs risk of recurrent deep-vein thrombosis or pulmonary embolism) if creatinine clearance 15–49 mL/minute.

When used for prophylaxis of stroke and systemic embolism in atrial fibrillation Reduce dose to 15 mg once daily if creatinine clearance 15–49 mL/minute.

When used for prophylaxis of venous thromboembolism following knee or hip replacement surgery and prophylaxis of atherothrombotic events in acute coronary syndrome Use with caution if creatinine clearance 15–29 mL/minute. Use with caution if concomitant use of drugs that increase plasma-rivaroxaban concentration (consult product literature).

Avoid if creatinine clearance less than 15 mL/minute; manufacturer recommends Cockcroft and Gault formula to calculate creatinine clearance.

MONITORING REQUIREMENTS
- Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.
- No routine anticoagulant monitoring required (INR tests are unreliable).

DIRECTIONS FOR ADMINISTRATION
Tablets may be crushed and mixed with water or apple puree just before administration.

PRESCRIBING AND DISPENSING INFORMATION
Low-dose rivaroxaban, in combination with aspirin alone or aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers. Treatment should be started as soon as possible after the patient has been stabilised following the acute coronary event, at the earliest 24 hours after admission to hospital, and at the time when parenteral anticoagulation therapy would normally be discontinued; the usual duration of treatment is 12 months.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (April 2009) NICE TA170
- Rivaroxaban is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery. www.nice.org.uk/TA170
- Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation (May 2012) NICE TA256
- Rivaroxaban is an option for the prevention of stroke and systemic embolism (in accordance with its licensed indication) in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: previous stroke or transient ischaemic attack - congestive heart failure - age ≥ 75 years - diabetes mellitus - hypertension

The risks and benefits of rivaroxaban compared with warfarin should be discussed with the patient. www.nice.org.uk/TA256

- Rivaroxaban for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism (July 2012) NICE TA261
- Rivaroxaban is an option for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism in adults after diagnosis of acute deep-vein thrombosis. www.nice.org.uk/TA261
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013) NICE TA287
- Rivaroxaban is an option for treating pulmonary embolism and preventing recurrent deep-vein thrombosis and pulmonary embolism in adults. www.nice.org.uk/TA287
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015) NICE TA335

Rivaroxaban is an option within its marketing authorisation, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in patients who have had an acute coronary syndrome with elevated cardiac biomarkers.

The patient’s risk of bleeding should be carefully assessed before treatment is initiated and the risks and benefits of rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone, compared with aspirin plus clopidogrel or aspirin alone should be discussed with the patient.

A decision on continuation of treatment should be taken no later than 12 months after starting treatment. www.nice.org.uk/TA335

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2012) that rivaroxaban (Xarelto®) is accepted for restricted use within NHS Scotland for the prevention of stroke and systemic embolism in accordance with the licensed indication; use is restricted to patients with poor risk of bleeding.

There can be variation in the licensing of different medicines containing the same drug.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Xarelto (Bayer Plc)
  - Rivaroxaban 2.5 mg: Xarelto 2.5mg tablets | 56 tablet (POD) £58.80
  - Rivaroxaban 10 mg: Xarelto 10mg tablets | 10 tablet (POD) £21.00 | 30 tablet (POD) £63.00 | 100 tablet (POD) £210.00
  - Rivaroxaban 15 mg: Xarelto 15mg tablets | 14 tablet (POD) £29.40 | 28 tablet (POD) £58.80 | 42 tablet (POD) £88.20 | 100 tablet (POD) £210.00
  - Rivaroxaban 20 mg: Xarelto 20mg tablets | 28 tablet (POD) £58.80 | 100 tablet (POD) £210.00

HEPARINOIDS

Danaparoid sodium

INDICATIONS AND DOSE

Prevention of deep-vein thrombosis in general or orthopaedic surgery

BY SUBCUTANEOUS INJECTION

- Adult: 750 units twice daily for 7–10 days, initiate treatment before operation, with last pre-operative dose 1–4 hours before surgery

Thromboembolic disease in patients with history of heparin-induced thrombocytopenia

INITIALLY BY INTRAVENOUS INJECTION

- Adult (body-weight up to 55 kg): Initially 1250 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days

- Adult (body-weight 55–89 kg): Initially 2500 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days

- Adult (body-weight 90 kg and above): Initially 3750 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days

CONTRA-INDICATIONS

Active peptic ulcer (unless this is the reason for operation) - acute bacterial endocarditis - diabetics - clopidogrel - acute myocardial infarction (with treatment doses) - haemophilia and other haemorrhagic disorders - recent cerebral haemorrhage - severe hypertension - spinal anaesthesia (with treatment doses) - thrombocytopenia (unless patient has heparin-induced thrombocytopenia)

CAUTIONS

Antibodies to heparins (risk of antibody-induced thrombocytopenia) - body-weight over 90 kg - recent bleeding - risk of bleeding

INTERACTIONS

Appendix 1 (danaparoid).

Caution with concomitant use of drugs that increase risk of bleeding.

SIDE-EFFECTS

Bleeding - hypersensitivity reactions - rash

PREGNANCY

Manufacturer advises avoid—limited information available but not known to be harmful.

BREAST FEEDING

Amount probably too small to be harmful but manufacturer advises avoid.

HEPATIC IMPAIRMENT

Caution in moderate impairment (increased risk of bleeding). Avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.

RENAL IMPAIRMENT

Use with caution in moderate impairment. Avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available.

MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Orgaran (Aspen Pharma Trading Ltd)
  - Danaparoid sodium 1250 unit per 1 ml Orgaran 750units/0.6ml solution for injection ampoules | 10 ampoule (POD) £266.73

HEPARINS

Heparins

CONTRA-INDICATIONS

Acute bacterial endocarditis - after major trauma - epidural anaesthesia with treatment doses - haemophilia and other haemorrhagic disorders - peptic ulcer - recent cerebral haemorrhage - recent surgery to eye - recent surgery to nervous system - severe hypertension - spinal anaesthesia with treatment doses - thrombocytopenia (including history of heparin-induced thrombocytopenia)

CAUTIONS

Elderly

INTERACTIONS

Appendix 1 (heparins).

Caution with concomitant use of drugs that increase risk of bleeding.

SIDE-EFFECTS

Rare Alopecia (on prolonged use) - anaphylaxis - angioedema - hyperkalaemia - hypersensitivity reactions - injection-site reactions - osteoporosis (risk lower with low molecular weight heparins) - priapism - rebound hyperlipidaemia (following unfractionated heparin withdrawal) - skin necrosis - urticaria

Frequency not known Haemorrhage - thrombocytopenia
SIDE-EFFECTS, FURTHER INFORMATION

Haemorrhage If haemorrhage occurs it is usually sufficient to withdraw unfractionated or low molecular weight heparin, but if rapid reversal of the effects of the heparin is required, protamine sulfate is a specific antidote (but only partially reverses the effects of low molecular weight heparins).

Heparin-induced thrombocytopenia Clinically important heparin-induced thrombocytopenia is immune-mediated and does not usually develop until after 5–10 days; it can be complicated by thrombosis. Signs of heparin-induced thrombocytopenia include a 30% reduction of platelet count, thrombosis, or skin allergy. If heparin-induced thrombocytopenia is strongly suspected or confirmed, the heparin should be stopped and an alternative anticoagulant, such as danaparoid, should be given. Ensure platelet counts return to normal range in those who require warfarin.

Hyperkalaemia Inhibition of aldosterone secretion by unfractionated or low molecular weight heparin can result in hyperkalaemia; patients with diabetes mellitus, chronic renal failure, acidosis, raised plasma potassium or those taking potassium-sparing drugs seem to be more susceptible. The risk appears to increase with duration of therapy.

ALLERGY AND CROSS-SENSITIVITY Hypersensitivity to unfractionated or low molecular weight heparin.

MONITORING REQUIREMENTS

Heparin-induced thrombocytopenia Platelet counts should be measured just before treatment with unfractionated or low molecular weight heparin, and regular monitoring of platelet counts may be required if given for longer than 4 days. See the British Society for Haematology’s Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528–540.

Hyperkalaemia Plasma-potassium concentration should be measured in patients at risk of hyperkalaemia before starting the heparin and monitored regularly thereafter, particularly if treatment is to be continued for longer than 7 days.

Dalteparin sodium

INDICATIONS AND DOSE

FRAGMIN® GRADUATED SYRINGES

Unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction)

BY SUBCUTANEOUS INJECTION

Adult: 120 units/kg every 12 hours (max. per dose 10 000 units twice daily) for up to 8 days

Patients with unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction) awaiting angiography or revascularisation and having already had 8 days treatment with dalteparin

BY SUBCUTANEOUS INJECTION

Adult (body-weight up to 69 kg and male): 5000 units every 12 hours until the day of the procedure (max. 45 days)

Adult (body-weight up to 79 kg and female): 5000 units every 12 hours until the day of the procedure (max. 45 days)

Adult (body-weight 70 kg and above and male): 7500 units every 12 hours until the day of the procedure (max. 45 days)

Adult (body-weight 80 kg and above and female): 7500 units every 12 hours until the day of the procedure (max. 45 days)

Dalteparin sodium

INDICATIONS AND DOSE

FRAGMIN® GRADUATED SYRINGES

Unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction)

BY SUBCUTANEOUS INJECTION

Adult: 120 units/kg every 12 hours (max. per dose 10 000 units twice daily) for up to 8 days

Patients with unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction) awaiting angiography or revascularisation and having already had 8 days treatment with dalteparin

BY SUBCUTANEOUS INJECTION

Adult (body-weight up to 69 kg and male): 5000 units every 12 hours until the day of the procedure (max. 45 days)

Adult (body-weight up to 79 kg and female): 5000 units every 12 hours until the day of the procedure (max. 45 days)

Adult (body-weight 70 kg and above and male): 7500 units every 12 hours until the day of the procedure (max. 45 days)

Adult (body-weight 80 kg and above and female): 7500 units every 12 hours until the day of the procedure (max. 45 days)

Prophylaxis of deep-vein thrombosis in surgical patients—moderate risk

BY SUBCUTANEOUS INJECTION

Adult: Initially 2500 units for 1 dose, dose to be given 1–2 hours before surgery, then 2500 units every 24 hours

Prophylaxis of deep-vein thrombosis in surgical patients—high risk

BY SUBCUTANEOUS INJECTION

Adult: Initially 2500 units for 1 dose, dose to be administered 1–2 hours before surgery, followed by 2500 units after 8–12 hours, then 5000 units every 24 hours, alternatively initially 5000 units for 1 dose, dose to be given on the evening before surgery, followed by 5000 units after 24 hours, then 5000 units every 24 hours

Prophylaxis of deep-vein thrombosis in medical patients

BY SUBCUTANEOUS INJECTION

Adult: 5000 units every 24 hours

Treatment of deep-vein thrombosis, with oral anticoagulant treatment / Treatment of pulmonary embolism, with oral anticoagulant treatment

BY SUBCUTANEOUS INJECTION

Adult (body-weight up to 45 kg): 7500 units daily until adequate oral anticoagulation established

Adult (body-weight 46–56 kg): 10 000 units daily until adequate oral anticoagulation established

Adult (body-weight 57–68 kg): 12 500 units daily until adequate oral anticoagulation established

Adult (body-weight 69–82 kg): 15 000 units daily until adequate oral anticoagulation established

Adult (body-weight 85 kg and above): 18 000 units daily until adequate oral anticoagulation established

Extended treatment and prophylaxis of venous thromboembolism in patients with solid tumours

BY SUBCUTANEOUS INJECTION

Adult (body-weight 40–45 kg): 7500 units once daily for 30 days, then 7500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature

Adult (body-weight 46–56 kg): 10 000 units once daily for 30 days, then 7500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature

Adult (body-weight 57–68 kg): 12 500 units once daily for 30 days, then 10 000 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature

Adult (body-weight 69–82 kg): 15 000 units once daily for 30 days, then 12 500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature

Adult (body-weight 83 kg and above): 18 000 units once daily for 30 days, then 18 000 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature
Treatment of venous thromboembolism in pregnancy

BY SUBCUTANEOUS INJECTION
  ▶ Adult (body-weight up to 49 kg): 5000 units twice daily, use body-weight in early pregnancy to calculate the dose
  ▶ Adult (body-weight 50–69 kg): 6000 units twice daily, use body-weight in early pregnancy to calculate the dose
  ▶ Adult (body-weight 70–89 kg): 8000 units twice daily, use body-weight in early pregnancy to calculate the dose
  ▶ Adult (body-weight 90 kg and above): 10 000 units twice daily, use body-weight in early pregnancy to calculate the dose

FRAGMIN®

Treatment of deep-vein thrombosis, with oral anticoagulant treatment

BY SUBCUTANEOUS INJECTION
  ▶ Adult: 200 units/kg daily (max. per dose 18 000 units) until adequate oral anticoagulation established

Treatment of deep-vein thrombosis, with oral anticoagulant treatment (in patients at increased risk of haemorrhage)

BY SUBCUTANEOUS INJECTION
  ▶ Adult: 100 units/kg twice daily until adequate oral anticoagulation established

Unstable coronary artery disease

BY SUBCUTANEOUS INJECTION
  ▶ Adult: 120 units/kg every 12 hours (max. per dose 10 000 units twice daily) for 5–8 days

Prevention of clotting in extracorporeal circuits

TO THE DEVICE AS A FLUSH
  ▶ Adult: (consult product literature)

UNLICENSED USE

Not licensed for treatment of venous thromboembolism in pregnancy.

PREGNANCY

Not known to be harmful, low molecular weight heparins do not cross the placenta. Multidose vial contains benzyl alcohol—manufacturer advises avoid.

BREAST FEEDING

Due to the relatively high molecular weight and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible, however manufacturers advise avoid.

HEPATIC IMPAIRMENT

Dose reduction may be required in severe impairment—risk of bleeding may be increased.

RENAL IMPAIRMENT

Risk of bleeding may be increased—dose reduction may be required. Use of unfractionated heparin may be preferable.

MONITORING REQUIREMENTS

For monitoring during treatment of deep-vein thrombosis and of pulmonary embolism, blood should be taken 3–4 hours after a dose (recommended plasma concentration of anti-Factor Xa 0.5–1 unit/mL); monitoring not required for once-daily treatment regimen and not generally necessary for twice-daily regimen.

Routine monitoring of anti-Factor Xa activity is not usually required during treatment with dalteparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium (SMC) has advised (February 2011) that dalteparin (Fragnim®) is accepted for restricted use within NHS Scotland as extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

**EXCIPIENTS:** May contain Benzyl alcohol

- Fragmin (Pfizer Ltd)
  - Dalteparin sodium 2500 unit per 1 ml Fragmin 10,000 units/4ml solution for injection ampoules | 1 ampoule (P) £1.22
  - Dalteparin sodium 10000 unit per 1 ml Fragmin 10,000 units/1ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (P) £28.23
  - Fragmin 10,000 units/1ml solution for injection ampoules | 10 ampoule (P) £51.22
  - Dalteparin sodium 12500 unit per 1 ml Fragmin 2,500 units/0.2ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (P) £18.58

Dalteparin sodium 25000 unit per 1 ml

- Fragmin 18,000 units/0.72ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (P) £50.82
- Fragmin 15,000 units/0.6ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (P) £42.34
- Fragmin 5,000 units/0.2ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (P) £28.23
- Fragmin 12.500 units/0.5ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (P) £32.52
- Fragmin 7,500 units/0.3ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (P) £42.34
- Fragmin 100,000 units/4ml solution for injection vials | 1 vial (P) £68.66
- Fragmin 10,000 units/0.4ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (P) £28.23

Enoxaparin sodium

**INDICATIONS AND DOSE**

Treatment of venous thromboembolism in pregnancy

BY SUBCUTANEOUS INJECTION
  ▶ Adult (body-weight up to 50 kg): 40 mg twice daily, dose based on early pregnancy body-weight
  ▶ Adult (body-weight 50–69 kg): 60 mg twice daily, dose based on early pregnancy body-weight
  ▶ Adult (body-weight 70–89 kg): 80 mg twice daily, dose based on early pregnancy body-weight
  ▶ Adult (body-weight 90 kg and above): 100 mg twice daily, dose based on early pregnancy body-weight

Prophylaxis of deep-vein thrombosis, especially in surgical patients—moderate risk

BY SUBCUTANEOUS INJECTION
  ▶ Adult: 20 mg for 1 dose, dose to be given approximately 2 hours before surgery, then 20 mg every 24 hours

Prophylaxis of deep-vein thrombosis, especially surgical patients—high risk (e.g. orthopaedic surgery)

BY SUBCUTANEOUS INJECTION
  ▶ Adult: 40 mg for 1 dose, dose to be given 12 hours before surgery, then 40 mg every 24 hours

Prophylaxis of deep-vein thrombosis in medical patients

BY SUBCUTANEOUS INJECTION
  ▶ Adult: 40 mg every 24 hours

Treatment of deep-vein thrombosis | Treatment of pulmonary embolism

BY SUBCUTANEOUS INJECTION
  ▶ Adult: 1.5 mg/kg every 24 hours until adequate oral anticoagulation established

Treatment of acute ST-segment elevation myocardial infarction (patients not undergoing percutaneous coronary intervention)

INITIALLY BY INTRAVENOUS INJECTION
  ▶ Adult 18–74 years: Initially 30 mg, followed by (by subcutaneous injection) 1 mg/kg for 1 dose, then (by subcutaneous injection) 1 mg/kg every 12 hours
Solution for injection

**EXCIPIENTS:** May contain Benzyl alcohol

- **Clexane** (Sanofi)
  - Enoxaparin sodium 100 mg per 1 ml
    - Clexane 60mg/0.6ml solution for injection pre-filled syringes 10 pre-filled disposable injection (PFS) £45.65 DT price = £45.65
    - Clexane 300mg/3ml solution for injection multidose vials 1 vial (PFS) £21.33
    - Clexane 80mg/0.8ml solution for injection pre-filled syringes 10 pre-filled disposable injection (PFS) £46.86 DT price = £46.86
    - Clexane 40mg/0.4ml solution for injection pre-filled syringes 10 pre-filled disposable injection (PFS) £30.27 DT price = £30.27
    - Clexane 100mg/1ml solution for injection pre-filled syringes 10 pre-filled disposable injection (PFS) £80.33 DT price = £80.33
    - Clexane 20mg/0.2ml solution for injection pre-filled syringes 10 pre-filled disposable injection (PFS) £22.72 DT price = £22.72
  - Enoxaparin sodium 150 mg per 1 ml
    - Clexane Forte 120mg/0.8ml solution for injection pre-filled syringes 10 pre-filled disposable injection (PFS) £97.70 DT price = £97.70
    - Clexane Forte 150mg/1ml solution for injection pre-filled syringes 10 pre-filled disposable injection (PFS) £111.01 DT price = £111.01

**Heparin (unfractionated)**

**INDICATIONS AND DOSE**

- **Treatment of mild to moderate pulmonary embolism**
- **Treatment of unstable angina**
- **Treatment of acute peripheral arterial occlusion**

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: Loading dose 5000 units, alternatively (by intravenous injection) loading dose 75 units/kg, followed by (by continuous intravenous infusion) 18 units/kg/hour, laboratory monitoring essential—preferably on a daily basis, and dose adjusted accordingly

**Treatment of severe pulmonary embolism**

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: Loading dose 10 000 units, followed by (by continuous intravenous infusion) 18 units/kg/hour, laboratory monitoring essential—preferably on a daily basis, and dose adjusted accordingly

**Treatment of deep-vein thrombosis**

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: Loading dose 5000 units, alternatively (by intravenous injection) loading dose 75 units/kg, followed by (by continuous intravenous infusion) 18 units/kg/hour, alternatively (by subcutaneous injection) 15 000 units every 12 hours, laboratory monitoring essential—preferably on a daily basis, and dose adjusted accordingly

**Thromboprophylaxis in medical patients**

**BY SUBCUTANEOUS INJECTION**

- Adult: 5000 units every 8–12 hours

**Thromboprophylaxis in surgical patients**

**BY SUBCUTANEOUS INJECTION**

- Adult: 5000 units for 1 dose, to be taken 2 hours before surgery, then 5000 units every 8–12 hours

**Thromboprophylaxis during pregnancy**

**BY SUBCUTANEOUS INJECTION**

- Adult: 5000–10 000 units every 12 hours, to be administered with monitoring. Important: prevention of prosthetic heart-valve thrombosis in pregnancy calls for specialist management

**Haemodialysis**

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: Initially 1000–5000 units, followed by (by continuous intravenous infusion) 250–1000 units/hour

**Prevention of clotting in extracorporeal circuits**

**TO THE DEVICE AS A FLUSH**

- Adult: (consult product literature)
To maintain patency of catheters, cannulas, other indwelling intravenous infusion devices

**TO THE DEVICE AS A FLUSH**
- Adult: 10–200 units, to be flushed through every 4–8 hours, not for therapeutic use

- **PREGNANCY** Does not cross the placenta; maternal osteoporosis reported after prolonged use; multidose vials may contain benzyl alcohol—some manufacturers advise avoid.

- **BREAST FEEDING** Not excreted into milk due to high molecular weight.

- **HEPATIC IMPAIRMENT** Risk of bleeding increased—reduce dose or avoid in severe impairment (including oesophageal varices).

- **RENAL IMPAIRMENT** Risk of bleeding increased in severe impairment—dose may need to be reduced.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%; administration with a motorised pump is advisable.

- **PRESCRIBING AND DISPENSING INFORMATION**

Doses listed take into account the guidelines of the British Society for Haematology.

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, solution for injection, solution for infusion

**Solution for injection**

**EXCIPIENTS:** May contain Benzyl alcohol  
  - **HEPARIN (UNFRACTIONATED) (Non-proprietary)**
    - Heparin sodium 1000 unit per 1 ml Heparin sodium 1,000 units/ml solution for injection ampoule | 10 ampoule (PQM) £14.85
    - Heparin sodium 5,000 units/ml solution for injection vials | 10 vial (PQM) £16.50–£37.41
    - Heparin sodium 20,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £70.80–£70.88
    - Heparin sodium 5,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £37.45–£37.47
    - Heparin sodium 10,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £64.50–£64.59
    - Heparin sodium 5000 unit per 1 ml Heparin sodium 25,000 units/ml solution for injection vials | 10 vial (PQM) £45.00–£54.60
    - Heparin sodium 5,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £29.04
    - Heparin sodium 25,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £75.78
    - Heparin sodium 5000 unit per 1 ml Heparin sodium 5,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £39.12
    - Heparin sodium 25000 unit per 1 ml Heparin sodium 25,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £76.95
    - Heparin sodium 5,000 units/ml solution for injection ampoules | 10 ampoule (PQM) £37.35

**Infusion**

  - **HEPARIN (UNFRACTIONATED) (Non-proprietary)**
    - Heparin sodium 2 unit per 1 ml Heparin sodium 1,000 units/500ml infusion Viaflex bags | 1 bag (PQM) no price available
    - Heparin sodium 2,000 units/1,000ml infusion Viaflex bags | 1 bag (PQM) no price available
    - Heparin sodium 5 unit per 1 ml Heparin sodium 5,000 units/1 litre infusion Viaflex bags | 1 bag (PQM) no price available

**Intravenous Flush**

**EXCIPIENTS:** May contain Benzyl alcohol

  - **HEPARIN (UNFRACTIONATED) (Non-proprietary)**
    - Heparin sodium 10 unit per 1 ml Heparin sodium 50 units/5ml patency solution ampoules | 10 ampoule (PQM) £14.96
    - Heparin sodium 50 units/5ml I.V. flush solution ampoules | 10 ampoule (PQM) £14.96
    - Heparin sodium 100 unit per 1 ml Heparin sodium 200 units/2ml I.V. flush solution ampoules | 10 ampoule (PQM) £15.68

- **SIDE-EFFECTS**

  - Uncommon Headache

- **PREGNANCY** Not known to be harmful, low molecular weight heparins do not cross the placenta. Vials contain benzyl alcohol—manufacturer advises avoid.

- **BREAST FEEDING** Due to the relatively high molecular weight of tinzaparin and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible; however manufacturer advise avoid.

- **RENAL IMPAIRMENT** Risk of bleeding may be increased. Unfractionated heparin may be preferable. Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m². In renal impairment monitoring of anti-Factor Xa activity is not usually required during treatment with tinzaparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **INDICATIONS AND DOSE**

**INNOHEP® 10,000 UNITS/ML**

**Prophylaxis of deep-vein thrombosis (general surgery)**

**BY SUBCUTANEOUS INJECTION**

- Adult: 3500 units for 1 dose, dose to be given 2 hours before surgery, then 3500 units every 24 hours

**Prophylaxis of deep-vein thrombosis (orthopaedic surgery)**

**BY SUBCUTANEOUS INJECTION**

- Adult: Initially 50 units/kg for 1 dose, dose to be given 2 hours before surgery, then 50 units/kg every 24 hours, alternatively initially 4500 units for 1 dose, dose to be given 12 hours before surgery, then 4500 units every 24 hours

**Prevention of clotting in extracorporeal circuits**

**TO THE DEVICE AS A FLUSH**

- Adult: (consult product literature)

**INNOHEP® 20,000 UNITS/ML**

Extended treatment of venous thromboembolism in patients with solid tumours | Prophylaxis of venous thromboembolism in patients with solid tumours

**BY SUBCUTANEOUS INJECTION**

- Adult: 175 units/kg once daily for up to 6 months

**Treatment of deep-vein thrombosis | Treatment of pulmonary embolism**

**BY SUBCUTANEOUS INJECTION**

- Adult: 175 units/kg once daily, dose based on early pregnancy body-weight, treatment regimens do not require anticoagulation monitoring

**Thromboembolism**

**UNLICENSED USE** Not licensed for the treatment of venous thromboembolism in pregnancy.

**MONITORING REQUIREMENTS** Routine monitoring of anti-Factor Xa activity is not usually required during treatment with tinzaparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).
Solution for injection

EXCIPIENTS: May contain Benzyl alcohol, sulfites

- Innohep
  Tinzaparin sodium 10000 unit per 1 ml
  3.500units/0.35ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (£37.71)
  Innohep 4.500units/0.45ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (£35.63)
  Innohep 20.000units/2ml solution for injection vials | 10 vial (£105.66)
  Innohep 2.500units/0.25ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (£19.80)
  Tinzaparin sodium 20000 unit per 1 ml
  18.000units/0.9ml solution for injection pre-filled syringes | 2 pre-filled disposable injection (£31.42) | 6 pre-filled disposable injection (£42.25)
  Innohep 6.000units/0.4ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (£28.56) | 10 pre-filled disposable injection (£47.60)
  Innohep 4.000units/2ml solution for injection vials | 1 vial (£34.20)
  Innohep 16.000units/0.6ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (£57.12) | 10 pre-filled disposable injection (£95.20)
  Innohep 12.000units/0.6ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (£42.84) | 10 pre-filled disposable injection (£71.40)
  Innohep 14.000units/0.7ml solution for injection pre-filled syringes | 2 pre-filled disposable injection (£18.67) | 6 pre-filled disposable injection (£49.98)
  Innohep 10.000units/0.5ml solution for injection pre-filled syringes | 2 pre-filled disposable injection (£11.90) | 6 pre-filled disposable injection (£35.70)

THROMBIN INHIBITORS

Argatroban monohydrate

INDICATIONS AND DOSE

Anticoagulation in patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic treatment

INITIALLY BY CONTINUOUS INTRAVENOUS INFUSION

- Adult: Initially 2 micrograms/kg/minute, dose to be adjusted according to activated partial thromboplastin time, (by intravenous infusion) increased up to 10 micrograms/kg/minute maximum duration of treatment 14 days

Anticoagulation in patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic treatment (for dose in cardiac surgery, percutaneous coronary intervention, or critically ill patients)

BY CONTINUOUS INTRAVENOUS INFUSION

- Adult: (consult product literature)

Anticoagulation in patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic treatment (when initiating concomitant warfarin treatment)

BY CONTINUOUS INTRAVENOUS INFUSION

- Adult: Dose should be temporarily reduced to 2 micrograms/kg/minute, and INR measured after 4–6 hours; warfarin should be initiated at intended maintenance dose (do not give loading dose of warfarin); consult product literature for further details

CAUTIONS

- Bleeding disorders
- Diabetic retinopathy
- Gastro-intestinal ulceration
- Immediately after lumbar puncture
- Major surgery (especially of brain, spinal cord, or eye)
- Risk of bleeding
- Severe hypertension
- Spinal anaesthesia

INTERACTIONS

- Appendix 1 (argatroban).

Caution with concomitant use of drugs that increase risk of bleeding.

SIDE-EFFECTS

- Common or very common
  Haemorrhage - nausea - purpura
- Uncommon

PREGNANCY

Manufacturer advises avoid unless essential—limited information available.

BREAST FEEDING

Avoid—no information available.

HEPATIC IMPAIRMENT

Reduce initial dose to 500 nanograms/kg/minute in moderate impairment. Avoid in severe impairment or in patients with hepatic impairment undergoing percutaneous coronary intervention.

MONITORING REQUIREMENTS

Determine activated partial thromboplastin time 2 hours after start of treatment, then 2 or 4 hours after infusion rate altered (consult product literature), and at least once daily thereafter.

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (Exembol®) give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute each 2.5–ml vial with 250 ml infusion fluid.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

EXCIPIENTS: May contain Ethanol

- Exembol (Mitsubishi Pharma Europe Ltd)
  Argatroban monohydrate 100 mg per 1 ml
  Exembol 250mg/2.5ml concentrate for solution for infusion vials | 1 vial no price available

Bivalirudin

DRUG ACTION

Bivalirudin, a hirudin analogue, is a thrombin inhibitor.

INDICATIONS AND DOSE

Unstable angina or non-ST-segment elevation myocardial infarction in patients planned for urgent or early intervention (in addition to aspirin and clopidogrel)

INITIALLY BY INTRAVENOUS INJECTION

- Adult: Initially 100 micrograms/kg, then (by intravenous infusion) 250 micrograms/kg/hour (for up to 72 hours in medically managed patients)

Unstable angina or non-ST-segment elevation myocardial infarction (in addition to aspirin and clopidogrel) in patients proceeding to percutaneous coronary intervention or coronary artery bypass surgery without cardiopulmonary bypass

INITIALLY BY INTRAVENOUS INJECTION

- Adult: Initially 100 micrograms/kg for 1 dose, then (by intravenous injection) 500 micrograms/kg for 1 dose, then (by intravenous infusion) 1.75 mg/kg/hour for duration of procedure; (by intravenous infusion) reduced to 250 micrograms/kg/hour for 4–12 hours as necessary following percutaneous coronary intervention, for patients proceeding to coronary artery bypass surgery with cardiopulmonary bypass, discontinue intravenous infusion 1 hour before procedure and treat with unfractionated heparin
Anticoagulation in patients undergoing percutaneous coronary intervention including patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (in addition to aspirin and clopidogrel)

INITIALLY BY INTRAVENOUS INJECTION

- Adult: Initially 750 micrograms/kg, followed immediately by (by intravenous infusion) 1.75 mg/kg/hour during procedure and for up to 4 hours after procedure, then (by intravenous infusion) reduced to 250 micrograms/kg/hour may be continued for a further 4–12 hours if necessary.

CONTRA-INDICATIONS

- Active bleeding - bleeding disorders
- Severe hypertension - subacute bacterial endocarditis

CAUTIONS

- Brachytherapy procedures - previous exposure to lepirudin (theoretical risk from lepirudin antibodies)

INTERACTIONS

† Appendix 1 (bivalirudin).

SIDE-EFFECTS

- Common or very common - bleeding (discontinue)
- Common - ecchymosis
- Uncommon - anemia - headache - hypotension - isolated reports of anaphylaxis - nausea - thrombocytopenia
- Rare - back pain - bradycardia - dyspnoea - tachycardia - thrombosis - vomiting

PREGNANCY

Manufacturer advises caution—no information available.

BREAST FEEDING

Manufacturer advises caution—no information available.

RENAI IMPAIRMENT

Avoid if eGFR less than 30 mL/minute/1.73 m².

When used for percutaneous coronary intervention, reduce rate of infusion to 1.4 mg/kg/hour and monitor blood clotting parameters if eGFR 30–60 mL/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (Angiox®), give continuously in Glucose 5% or Sodium chloride 0.9%. Reconstitute each 250-mg vial with 5 mL water for injections then withdraw 1 mL from vial and dilute to 50 mL with infusion fluid.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)


Bivalirudin in combination with aspirin and clopidogrel is recommended for the treatment of adults with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. [www.nice.org.uk/TA230](http://www.nice.org.uk/TA230)

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (November 2008) that bivalirudin (Angiox®) is accepted for restricted use within NHS Scotland for patients with acute coronary syndromes planned for urgent or early intervention who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein IIb/IIIa inhibitor; it should not be used as an alternative to heparin alone.

The Scottish Medicines Consortium has advised (August 2010) that bivalirudin (Angiox®) is accepted for restricted use within NHS Scotland as an anticoagulant in patients undergoing percutaneous coronary intervention who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein IIb/IIIa inhibitor; it should not be used as an alternative to heparin alone.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

- Angiox (The Medicines Company UK Ltd)

Bivalirudin 250 mg Angiox 250mg powder for solution for injection vials | 10 vial (P339) no price available

Dabigatran etexilate

DRUG ACTION

Dabigatran etexilate is a direct thrombin inhibitor with a rapid onset of action.

INDICATIONS AND DOSE

Prophylaxis of venous thromboembolism following total knee replacement surgery

BY MOUTH

- Adult 18–74 years: 110 mg, to be taken 1–4 hours after surgery, followed by 220 mg once daily for 9 days, to be followed 12–24 hours after initial dose.
- Adult 75 years and over: 75 mg, to be taken 1–4 hours after surgery, followed by 150 mg once daily for 9 days, to be followed 12–24 hours after initial dose.

Prophylaxis of venous thromboembolism following total knee replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil

BY MOUTH

- Adult: 110 mg, to be taken 1–4 hours after surgery, followed by 150 mg once daily for 9 days, to be followed 12–24 hours after initial dose.

Prophylaxis of venous thromboembolism following total hip replacement surgery

BY MOUTH

- Adult 18–74 years: 110 mg, to be taken 1–4 hours after surgery, followed by 220 mg once daily for 27–34 days, to be followed 12–24 hours after initial dose.
- Adult 75 years and over: 75 mg, to be taken 1–4 hours after surgery, followed by 150 mg once daily for 27–34 days, to be followed 12–24 hours after initial dose.

Prophylaxis of venous thromboembolism following total hip replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil

BY MOUTH

- Adult: 110 mg, to be taken 1–4 hours after surgery, followed by 150 mg daily for 27–34 days, to be followed 12–24 hours after initial dose.

Treatment of deep-vein thrombosis | Treatment of pulmonary embolism | Prophylaxis of recurrent deep-vein thrombosis | Prophylaxis of recurrent pulmonary embolism

BY MOUTH

- Adult 18–74 years: 150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.
- Adult 75–79 years: 110–150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.
- Adult 80 years and over: 110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.
Treatment of deep-vein thrombosis in patients with moderate renal impairment

Prophylaxis of recurrent deep-vein thrombosis in patients at increased risk of bleeding

BY MOUTH
- Adult: 110–150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant

Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age ≥ 75 years, diabetes mellitus, or hypertension

BY MOUTH
- Adult: 110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant

Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age ≥ 75 years, diabetes mellitus, or hypertension in patients receiving concomitant treatment with verapamil

BY MOUTH
- Adult 80 years and over: 75 mg twice daily

Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age ≥ 75 years, diabetes mellitus, or hypertension in patients with moderate renal impairment

BY MOUTH
- Adult: 110–150 mg twice daily

Dose equivalence and conversion
For information on changing from, or to, other anticoagulants, consult product literature.

CONTRA-INDICATIONS
- Active bleeding; do not use as anticoagulant for prosthetic heart valve; malignant neoplasms; oesophageal varices; recent brain surgery; recent gastro-intestinal ulcer; recent intracranial haemorrhage; recent ophthalmic surgery; recent spine surgery; significant risk of major bleeding; vascular aneurysm

CAUTIONS
- Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis—give initial dose at least 2 hours after catheter removal and monitor neurological signs); bacterial endocarditis; bleeding disorders; body-weight less than 50 kg; elderly; gastritis; gastro-oesophageal reflux; oesophagitis; recent biopsy; recent major trauma; thrombocytopenia

INTERACTIONS
- Appendix 1 (dabigatran). Caution in concomitant use of drugs that increase risk of bleeding.

SIDE EFFECTS
- Common or very common Abdominal pain; anaemia; diarrhoea; dyspepsia; haemorrhage; nausea
- Uncommon Dysphagia; gastro-intestinal ulcer; gastro-oesophageal reflux; hepatobiliary disorders; oesophagitis; thrombocytopenia; vomiting

PREGNANCY
- Manufacturer advises avoid unless essential—toxicity in animal studies.

BREAST FEEDING
- Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
- Avoid in severe liver disease, especially if prothrombin time already prolonged.

RENAL IMPAIRMENT
- When used for prophylaxis of venous thromboembolism following knee or hip replacement surgery Reduce initial dose to 75 mg and subsequent doses to 150 mg once daily if creatinine clearance 30–50 mL/minute; reduce dose to 75 mg once daily if creatinine clearance 30–50 mL/minute and patient receiving concomitant treatment with verapamil.

- When used for treatment of deep-vein thrombosis and pulmonary embolism, prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation Consider reduced dose of 110 mg twice daily if creatinine clearance 30–50 mL/minute, based on individual assessment of thromboembolic risk and risk of bleeding. Avoid if creatinine clearance less than 30 mL/minute.

In renal impairment monitor renal function at least annually (manufacturer recommends Cockcroft and Gault formula to calculate creatinine clearance).

MONITORING REQUIREMENTS
- Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.

- No routine anticoagulant monitoring required (INR tests are unreliable).

- Assess renal function (manufacturer recommends Cockcroft and Gault formula to calculate creatinine clearance) before treatment in all patients and at least annually in elderly.

DIRECTIONS FOR ADMINISTRATION
- When given concomitantly with amiodarone or verapamil, doses should be taken at the same time.

PRESCRIBING AND DISPENSING INFORMATION
Dabigatran etexilate, is given orally for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery; it is also licensed for the treatment of deep-vein thrombosis and pulmonary embolism, and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism in adults. Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilisation, and longer duration of treatment should be based on permanent risk factors, or idiopathic deep-vein thrombosis or pulmonary embolism.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (September 2008) NICE TAs157

Dabigatran etexilate is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement surgery.
replacement or total knee replacement surgery. www.nice.org.uk/Ta157

- Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012) NICE TA249

Dabigatran etexilate is an option for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with one or more of the following risk factors:

- previous stroke, transient ischaemic attack, or systemic embolism
- left ventricular ejection fraction <40%
- symptomatic heart failure
- age >75 years
- age >65 years in patients with diabetes mellitus, coronary artery disease, or hypertension

The risks and benefits of dabigatran compared to warfarin should be discussed with the patient. www.nice.org.uk/Ta249

- Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (December 2014) NICE TA327

Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults. www.nice.org.uk/Ta327

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 25

- Pradaxa (Boehringer Ingelheim Ltd)
  Dabigatran etexilate (as Dabigatran etexilate mesilate)
  75 mg Pradaxa 75mg capsules | 10 capsule (PST) £10.98 | 60 capsule (PST) £65.90 DT price = £65.90
  Dabigatran etexilate (as Dabigatran etexilate mesilate)
  110 mg Pradaxa 110mg capsules | 10 capsule (PST) £10.98 | 60 capsule (PST) £65.90 DT price = £65.90
  Dabigatran etexilate (as Dabigatran etexilate mesilate)
  150 mg Pradaxa 150mg capsules | 60 capsule (PST) £65.90 DT price = £65.90

TISSUE PLASMINOGEN ACTIVATORS

Urokinase

The properties listed below are those particular to the drug only. For properties common to the class, see fibrinolytics, p. 154.

INDICATIONS AND DOSE

Deep-vein thrombosis (thromboembolic occlusive vascular disease)

BY INTRAVENOUS INFUSION

- Adult: Initially 4400 units/kg, to be given over 10–20 minutes, followed by 100 000 units/hour for 2–3 days

Pulmonary embolism (thromboembolic occlusive vascular disease)

BY INTRAVENOUS INFUSION

- Adult: Initially 4400 units/kg, to be given over 10–20 minutes, followed by 4400 units/kg/hour for 12 hours

Oclusive peripheral arterial disease (thromboembolic occlusive vascular disease)

BY INTRA-ARTERIAL INFUSION

- Adult: (consult product literature)

Occluded central venous catheters

BY INTRAVENOUS INJECTION

- Adult: Inject directly into occluded catheter, to be dissolved in sodium chloride 0.9% to a concentration of 5000 units/mL; use a volume sufficient to fill the catheter lumen; leave for 20–60 minutes then aspirate the lysate; repeat if necessary

Occluded arteriovenous haemodialysis shunts

BY INTRAVENOUS INFUSION OR BY INTRA-ARTERIAL INFUSION

SYNER-KINASE®

Deep-vein thrombosis (thromboembolic occlusive vascular disease)

BY INTRAVENOUS INFUSION

- Adult: Initially 4400 units/kg, to be given over 10 minutes, dose to be made up in 15 ml sodium chloride 0.9%, followed by 4400 units/kg/hour for 12–24 hours

Pulmonary embolism (thromboembolic occlusive vascular disease)

INITIALLY BY INTRAVENOUS INFUSION

- Adult: Initially 4400 units/kg, to be given over 10 minutes, dose to be made up in 15 ml sodium chloride 0.9%, followed by (by intravenous infusion) 4400 micrograms/kg/hour for 12 hours, alternatively (by intra-arterial injection) initially 15 000 units/kg, to be injected into pulmonary artery, subsequent doses adjusted according to response; maximum 3 doses per day

Occlusive peripheral arterial disease

BY INTRA-ARTERIAL INFUSION

- Adult: (consult product literature)

Occluded catheters and cannulas

BY INTRA-ARTERIAL INJECTION OR BY INTRAVENOUS INJECTION

- Adult: 5000–25 000 units, to be injected directly into catheter or cannula, dose dissolved in suitable volume of sodium chloride 0.9% to fill the catheter or cannula lumen; leave for 20–60 minutes then aspirate the lysate; repeat if necessary

- BREAST FEEDING Manufacturer advises avoid—no information available.

- HEPATIC IMPAIRMENT Dose reduction may be required.

- RENAL IMPAIRMENT Dose reduction may be required.

- DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Syner-KINASE®), give continuously or intermittently in sodium chloride 0.9%.

VITAMIN K ANTAGONISTS

Vitamin K antagonists

- CONTRA-INDICATIONS Avoid use within 48 hours postpartum - haemorrhagic stroke - significant bleeding

- CAUTIONS Bacterial endocarditis (use only if warfarin otherwise indicated) - conditions in which risk of bleeding
is increased · history of gastrointestinal bleeding · peptic ulcer · postpartum (delay warfarin until risk of haemorrhage is low—usually 5–7 days after delivery) · recent ischaemic stroke · recent surgery · uncontrolled hypertension

**INTERACTIONS** → Appendix 1 (coumarins, phenindione). Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may affect warfarin control. Caution if concomitant use of drugs that increase risk of bleeding. Avoid cranberry juice.

**SIDE-EFFECTS** Alopecia · diarrhoea · haemorrhage · hepatic dysfunction · jaundice · nausea · pancreatitis · purpura · pyrexia · rash · skin necrosis (increased risk in patients with protein C or protein S deficiency) · vomiting · ‘purple toes’

**CONCEPTION AND CONTRACEPTION** Women of childbearing age should be warned of the danger of teratogenicity.

**PREGNANCY** Should not be given in the first trimester of pregnancy. Warfarin, acenocoumarol, and phenindione cross the placenta with risk of congenital malformations, and placental, fetal, or neonatal haemorrhage, especially during the last few weeks of pregnancy and at delivery. Therefore, if at all possible, they should be avoided in pregnancy, especially in the first and third trimesters (difficult decisions may have to be made, particularly in women with prosthetic heart valves, atrial fibrillation, or with a history of recurrent venous thrombosis or pulmonary embolism). Stopping these drugs before the sixth week of gestation may largely avoid the risk of fetal abnormality.

**MONITORING REQUIREMENTS**
- The base-line prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.
- It is essential that the INR be determined daily or on alternate days in early days of treatment, then at longer intervals (depending on response), then up to every 12 weeks.
- Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing.

**PATIENT AND CARER ADVICE** Anticoagulant treatment booklets should be issued to all patients or their carers; these booklets include advice for patients on anticoagulant treatment, an alert card to be carried by the patient at all times, and a section for recording of INR results and dosage information. In England, Wales, and Northern Ireland, they are available for purchase from: 3M Security Print and Systems Limited Gorse Street, Chadderton Oldham OL9 9QH Tel: 0845 610 1112 GP practices can obtain supplies through their Local Area Team stores. NHS Trusts can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mm.com. In Scotland, treatment booklets and starter information packs can be obtained by emailing stockorders. dppas@theapsgroup.com or by fax on (0131) 6299 967 Electronic copies of the booklets and further advice are also available at www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant.

---

**Acenocoumarol**  
(Nicoumalone)

**INDICATIONS AND DOSE**  
Prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation | Prophylaxis after insertion of prosthetic heart valve | Prophylaxis and treatment of venous thrombosis and pulmonary embolism | Transient ischaemic attacks

**BY MOUTH**
- Adult: Initially 2–4 mg once daily for 2 days, alternatively initially 5 mg on day 1, then 4 mg on day 2; maintenance 1–8 mg daily, adjusted according to response, dose to be taken at the same time each day, lower doses may be required in patients over 65 years, liver disease, severe heart failure with hepatic congestion, and malnutrition

**SIDE-EFFECTS**
- Rare Anorexia
- Very rare Vasculitis

**BREAST FEEDING** Risk of haemorrhage; increased by vitamin K deficiency—manufacturer recommends prophylactic vitamin K for the infant (consult product literature).

**HEPATIC IMPAIRMENT** Use with caution in mild to moderate impairment. Avoid in severe impairment, especially if prothrombin time is already prolonged.

**RENAL IMPAIRMENT** Caution in mild to moderate impairment. Avoid in severe impairment.

**PATIENT AND CARER ADVICE** Anticoagulant card to be provided.

---

**Phenindione**

**INDICATIONS AND DOSE**  
Prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation | Prophylaxis after insertion of prosthetic heart valve | Prophylaxis and treatment of venous thrombosis and pulmonary embolism

**BY MOUTH**
- Adult: Initially 200 mg on day 1, then 100 mg on day 2, then, adjusted according to response; maintenance 50–150 mg daily

**SIDE-EFFECTS**
- Agranulocytosis · eosinophilia · exanthema · exfoliative dermatitis · fever · hypersensitivity reactions · leucopenia · micro-adenopathy · renal damage · urine coloured pink or orange

**BREAST FEEDING** Avoid. Risk of haemorrhage; increased by vitamin K deficiency.

**HEPATIC IMPAIRMENT** Avoid in severe impairment, especially if prothrombin time is already prolonged.

**RENAL IMPAIRMENT** Caution in mild to moderate impairment. Avoid in severe impairment.
Hypertension 121

4 Blood pressure conditions

4.1 Hypertension

Lowering raised blood pressure decreases the risk of stroke, coronary events, heart failure, and renal impairment. Advice on antihypertensive therapy in this section takes into account the recommendations of NICE clinical guidance 127 (August 2011), Hypertension—Clinical management of primary hypertension in adults.

Possible causes of hypertension (e.g. renal disease, endocrine causes), contributory factors, risk factors, and the presence of any complications of hypertension, such as left ventricular hypertrophy, should be established. Patients should be given advice on lifestyle changes to reduce blood pressure or cardiovascular risk; these include smoking cessation, weight reduction, reduction of excessive intake of alcohol and caffeine, reduction of dietary salt, reduction of total and saturated fat, increasing exercise, and increasing fruit and vegetable intake.

Thresholds and targets for treatment

Patients presenting with a blood pressure of 140/90 mmHg or higher when measured in a clinic setting, should be offered ambulatory blood pressure monitoring (or home blood pressure monitoring if ambulatory blood pressure monitoring is unsuitable) to confirm the diagnosis and stage of hypertension.

Stage 1 hypertension:

- Clinic blood pressure 140/90 mmHg or higher, and ambulatory daytime average or home blood pressure average 135/85 mmHg or higher
- Treat patients under 80 years who have stage 1 hypertension and target-organ damage (e.g. left ventricular hypertrophy, chronic kidney disease, hypertensive retinopathy), cardiovascular disease, renal disease, or diabetes, or a 10 year cardiovascular risk ≥20%; in the absence of these conditions, advise lifestyle changes and review annually. For patients under 40 years with stage 1 hypertension but no overt target-organ damage, cardiovascular disease, renal disease, or diabetes, consider seeking specialist advice for evaluation of secondary causes of hypertension

Stage 2 hypertension:

- Clinic blood pressure 160/100 mmHg or higher, and ambulatory daytime average or home blood pressure average 150/95 mmHg or higher
- Treat all patients who have stage 2 hypertension, regardless of age

Severe hypertension:

- Clinic systolic blood pressure >180 mmHg or clinic diastolic blood pressure >110 mmHg; treat promptly—see Hypertensive Crises p. 123.

A target clinic blood pressure below 140/90 mmHg is suggested for patients under 80 years; a target ambulatory or home blood pressure average (during the patient’s waking hours) of below 135/85 mmHg is suggested for patients under 80 years; see also Hypertension in the Elderly p. 122. A target clinic blood pressure below
130/80 mmHg should be considered for those with established atherosclerotic cardiovascular disease, or diabetes in the presence of kidney, eye, or cerebrovascular disease. In some individuals it may not be possible to reduce blood pressure below the suggested targets despite the use of appropriate therapy.

**Drug treatment of hypertension**

A single antihypertensive drug is often inadequate in the management of hypertension, and additional antihypertensive drugs are usually added in a step-wise manner until control is achieved. Unless it is necessary to lower the blood pressure urgently (see Hypertensive Crises), an interval of at least 4 weeks should be allowed to determine response; clinicians should ensure antihypertensive drugs are titrated to the optimum or maximum tolerated dose at each step of treatment.

Response to drug treatment may be affected by age and ethnicity.

**Patients under 55 years:**

- Step 1
  - ACE inhibitor; if not tolerated, offer an angiotensin-II receptor antagonist. If both ACE inhibitors and angiotensin-II receptor antagonists are contra-indicated or not tolerated, consider a beta-blocker; beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or at high risk of developing diabetes

- Step 2
  - ACE inhibitor or angiotensin-II receptor antagonist in combination with a calcium-channel blocker. If a calcium-channel blocker is not tolerated or if there is evidence of, or a high risk of, heart failure, give a thiazide-related diuretic (e.g. chlortalidone or indapamide). If a beta-blocker was given at Step 1, add a calcium channel blocker in preference to a thiazide-related diuretic (see Step 1)

- Step 3
  - ACE inhibitor or angiotensin-II receptor antagonist in combination with a calcium-channel blocker and a thiazide-related diuretic

- Step 4 (resistant hypertension)
  - Consider seeking specialist advice
  - Add low-dose spironolactone [unlicensed indication], or use high-dose thiazide related diuretic if plasma-potassium concentration above 4.5 mmol/litre
  - Monitor renal function and electrolytes
  - If additional diuretic therapy is contra-indicated, ineffective, or not tolerated, consider an alpha-blocker or a beta-blocker

**Patients over 55 years, and patients of any age who are of African or Caribbean family origin:**

- Step 1
  - Calcium-channel blocker; if not tolerated or if there is evidence of, or a high risk of, heart failure, give a thiazide-related diuretic (e.g. chlortalidone or indapamide)

- Step 2
  - Calcium-channel blocker or thiazide-related diuretic in combination with an ACE inhibitor or angiotensin-II receptor antagonist (an angiotensin-II receptor antagonist in combination with a calcium-channel blocker is preferred in patients of African or Caribbean family origin)

- Steps 3 and 4
  - Treat as for patients under 55 years

**Other measures to reduce cardiovascular risk**

Aspirin p. 104 reduces the risk of cardiovascular events and myocardial infarction. Unduly high blood pressure must be controlled before aspirin is given. Unless contra-indicated, aspirin is recommended for all patients with established cardiovascular disease. Use of aspirin in primary prevention, in those with or without diabetes, is of unproven benefit. Aspirin also has a role in the prevention of stroke in patients with atrial fibrillation.

Statins are also of benefit in cardiovascular disease or in those who are at high risk of developing cardiovascular disease.

**Hypertension in the elderly**

Benefit from antihypertensive therapy is evident up to at least 80 years of age, but it is probably inappropriate to apply a strict age limit when deciding on drug therapy. Patients who reach 80 years of age while taking antihypertensive drugs should continue treatment, provided that it continues to be of benefit and does not cause significant side-effects. If patients are aged over 80 years when diagnosed with stage 1 hypertension, the decision to treat should be based on the presence of other comorbidities; patients with stage 2 hypertension should be treated as for patients over 55 years. A target clinic blood pressure below 150/90 mmHg is suggested for patients over 80 years; the suggested target ambulatory or home blood pressure average (during the patient’s waking hours) is below 145/85 mmHg.

**Isolated systolic hypertension**

Isolated systolic hypertension (systolic pressure ≥160 mmHg, diastolic pressure <90 mmHg) is common in patients over 60 years, and is associated with an increased cardiovascular disease risk; it should be treated as for patients with both a raised systolic and diastolic blood pressure. Patients with severe postural hypotension should be referred to a specialist.

**Hypertension in diabetes**

For patients with diabetes, a target clinic blood pressure below 140/80 mmHg is suggested (below 130/80 mmHg is advised if kidney, eye, or cerebrovascular disease are also present). However, in some individuals, it may not be possible to achieve this level of control despite appropriate therapy. Most patients require a combination of antihypertensive drugs.

Hypertension is common in type 2 diabetes, and antihypertensive treatment prevents macrovascular and microvascular complications. In type 1 diabetes, hypertension usually indicates the presence of diabetic nephropathy. An ACE inhibitor (or an angiotensin-II receptor antagonist) may have a specific role in the management of diabetic nephropathy; in patients with type 2 diabetes, an ACE inhibitor (or an angiotensin-II receptor antagonist) can delay progression of microalbuminuria to nephropathy.

**Hypertension in renal disease**

A target clinic blood pressure below 140/90 mmHg is suggested (below 130/80 mmHg is advised in patients with chronic kidney disease and diabetes, or if proteinuria exceeds 1 g in 24 hours). An ACE inhibitor (or an angiotensin-II receptor antagonist) should be considered for patients with proteinuria; however, ACE inhibitors should be used with caution in renal impairment. Thiazide diuretics may be ineffective and high doses of loop diuretics may be required.

**Hypertension in pregnancy**

Hypertensive complications in pregnancy can be hazardous for both the mother and the fetus, and are associated with a significant risk of morbidity and mortality; complications can occur in pregnant women with pre-existing chronic hypertension, or in those who develop hypertension in the latter half of pregnancy.
Labetalol hydrochloride p. 143 is widely used for treating hypertension in pregnancy. Methyldopa p. 138 is considered safe for use in pregnancy. Modified-release preparations of nifedipine p. 154 [unlicensed] are also used.

The following advice takes into account the recommendations of NICE Clinical Guideline 107 (August 2010), Hypertension in Pregnancy.

Pregnant women with chronic hypertension who are already receiving antihypertensive treatment should have their drug therapy reviewed. In uncomplicated chronic hypertension, a target blood pressure of <150/100 mmHg is recommended; women with target-organ damage as a result of chronic hypertension, and in women with chronic hypertension who have given birth, a target blood pressure of <140/90 mmHg is advised. Long-term antihypertensive treatment should be reviewed 2 weeks following the birth. Women managed with methyldopa during pregnancy should discontinue treatment and restart their original antihypertensive medication within 2 days of the birth.

Pregnant women are at high risk of developing pre-eclampsia if they have chronic kidney disease, diabetes mellitus, autoimmune disease, chronic hypertension, or if they have had hypertension during a previous pregnancy; these women are advised to take aspirin p. 104 once daily [unlicensed indication] from week 12 of pregnancy until the baby is born. Women with more than one moderate risk factor (first pregnancy, aged ≥40 years, pregnancy interval >10 years, BMI ≥35 kg/m² at first visit, multiple pregnancy, or family history of pre-eclampsia) for developing pre-eclampsia are also advised to take aspirin once daily [unlicensed indication] from week 12 of pregnancy until the baby is born.

Women with pre-eclampsia or gestational hypertension who present with a blood pressure over 150/100 mmHg, should receive initial treatment with oral labetalol hydrochloride to achieve a target blood pressure of <150 mmHg systolic, and diastolic 80–100 mmHg. If labetalol hydrochloride is unsuitable, methyldopa or modified-release nifedipine may be considered. Women with gestational hypertension or pre-eclampsia who have been managed with methyldopa during pregnancy should discontinue treatment within 2 days of the birth. Women with a blood pressure of ≥160/110 mmHg who require critical care during pregnancy or after birth should receive immediate treatment with either oral or intravenous labetalol hydrochloride, intravenous hydralazine hydrochloride p. 157, or oral modified-release nifedipine to achieve a target blood pressure of <150 mmHg systolic, and diastolic 80–100 mmHg.

Also see use of magnesium sulfate in pre-eclampsia and eclampsia p. 858.

**Hypertensive crises**

If blood pressure is reduced too quickly in the management of hypertensive crises, there is a risk of reduced organ perfusion leading to cerebral infarction, blindness, deterioration in renal function, and myocardial ischaemia.

A **hypertensive emergency** is defined as severe hypertension with acute damage to the target organs (e.g. signs of papilloedema or retinal haemorrhage, or the presence of clinical conditions such as acute coronary syndromes, acute aortic dissection, acute pulmonary oedema, hypertensive encephalopathy, acute cerebral infarction, intracerebral or subarachnoid haemorrhage, eclampsia, or rapidly progressing renal failure); prompt treatment with intravenous antihypertensive therapy is generally required. Over the first few minutes or within 2 hours blood pressure should be reduced by 20–25%. When intravenous therapy is indicated, treatment options include sodium nitroprusside p. 161 [unlicensed], nicardipine hydrochloride p. 153, labetalol hydrochloride p. 143, glyceryl trinitrate p. 190, phentolamine mesilate p. 161, hydralazine hydrochloride p. 157, or esmolol hydrochloride p. 143; choice of drug is dependent on concomitant conditions and clinical status of the patient.

Severe hypertension (blood pressure >180/110 mmHg) without acute target-organ damage is defined as a hypertensive urgency; blood pressure should be reduced gradually over 24–48 hours with oral antihypertensive therapy, such as labetalol hydrochloride, or the calcium-channel blockers amloidipine p. 148 or felodipine p. 151. Use of sublingual nifedipine is not recommended.

Also see advice on short-term management of hypertensive episodes in preeclampsia and eclampsia p. 858.

**Phaeochromocytoma**

Long-term management of phaeochromocytoma involves surgery. However, surgery should not take place until there is adequate blockade of both alpha- and beta-adrenoceptors; the optimal choice of drug therapy remains unclear. Alpha-blockers are used in the short-term management of hypertensive episodes in phaeochromocytoma. Once alpha blockade is established, tachycardia can be controlled by the cautious addition of a beta-blocker; a cardioselective beta-blocker is preferred.

Phenoxybenzamine hydrochloride p. 161, a powerful alpha-blocker, is effective in the management of phaeochromocytoma but it has many side-effects. Phentolamine mesilate p. 161 is a short-acting alpha-blocker used mainly during surgery of phaeochromocytoma; its use for the diagnosis of phaeochromocytoma has been superseded by measurement of catecholamines in blood and urine.

Metirosine (available from ‘special-order’ manufacturers or specialist importing companies) inhibits the enzyme tyrosine hydroxylase, and hence the synthesis of catecholamines. It is rarely used in the pre-operative management of phaeochromocytoma, and long term in patients unsuitable for surgery; an alpha-adrenoceptor blocking drug may also be required. Metirosine should not be used to treat essential hypertension.

**Antihypertensive drugs**

**Vasodilator antihypertensive drugs**

Vasodilators have a potent hypotensive effect, especially when used in combination with a beta-blocker and a thiazide. **Important:** see Hypertension (hypertensive crises) for a warning on the hazards of a very rapid fall in blood pressure.

Hydralazine hydrochloride p. 157 is given by mouth as an adjunct to other antihypertensives for the treatment of resistant hypertension but is rarely used; when used alone it causes tachycardia and fluid retention.

Sodium nitroprusside p. 161 [unlicensed] is given by intravenous infusion to control severe hypertensive emergencies when parenteral treatment is necessary.

Minoxidil p. 158 should be reserved for the treatment of severe hypertension resistant to other drugs. Vasodilatation is accompanied by increased cardiac output and tachycardia and the patients develop fluid retention. For this reason the addition of a beta-blocker and a diuretic (usually furosemide p. 201, in high dosage) are mandatory. Hypertrichosis is troublesome and renders this drug unsuitable for females.

Prazosin p. 674, doxazosin p. 673, and terazosin p. 675 have alpha-blocking and vasodilator properties.

Ambrisentan p. 162, bosentan p. 163, iloprost p. 164, macitentan p. 163, sildenafil p. 699, and tadalafil p. 700 are licensed for the treatment of pulmonary arterial hypertension and should be used under specialist supervision. Epoprostenol p. 99 can be used in patients with primary pulmonary hypertension resistant to other
Drugs affecting the renin-angiotensin system

Angiotensin-converting enzyme inhibitors

Angiotensin-converting enzyme inhibitors (ACE inhibitors) inhibit the conversion of angiotensin I to angiotensin II. They have many uses and are generally well tolerated. The main indications of ACE inhibitors are shown below.

Heart Failure

ACE inhibitors are used in all grades of heart failure, usually combined with a beta-blocker. Potassium supplements and potassium-sparing diuretics should be discontinued before introducing an ACE inhibitor because of the risk of hyperkalaemia. However, a low dose of spironolactone p. 166 may be beneficial in severe heart failure and can be used with an ACE inhibitor provided serum potassium is monitored carefully. Profound first-dose hypotension may occur when ACE inhibitors are introduced to patients with heart failure who are already taking a high dose of a loop diuretic (e.g. furosemide p. 201 80 mg daily or more).

Temporary withdrawal of the loop diuretic reduces the risk, but may cause severe rebound pulmonary oedema. Therefore, for patients on high doses of loop diuretics, the ACE inhibitor may need to be initiated under specialist supervision. An ACE inhibitor can be initiated in the community in patients who are receiving a low dose of a diuretic or who are not otherwise at risk of serious hypotension; nevertheless, care is required and a very low dose of the ACE inhibitor is given initially.

Hypertension

An ACE inhibitor may be the most appropriate initial drug for hypertension in younger Caucasian patients; Afro-Caribbean patients, those aged over 55 years, and those with primary aldosteronism respond less well. ACE inhibitors are particularly indicated for hypertension in patients with type 1 diabetes with nephropathy. They may reduce blood pressure very rapidly in some patients particularly in those receiving diuretic therapy.

Diabetic nephropathy

ACE inhibitors have a role in the management of diabetic nephropathy.

Prophylaxis of cardiovascular events

ACE inhibitors are used in the early and long-term management of patients who have had a myocardial infarction. ACE inhibitors may also have a role in preventing cardiovascular events.

Initiation under specialist supervision

ACE inhibitors should be initiated under specialist supervision and with careful clinical monitoring in those with severe heart failure or in those:

- receiving multiple or high-dose diuretic therapy (e.g. more than 80 mg of furosemide daily or its equivalent);
- receiving concomitant angiotensin-II receptor antagonist or aliskiren;
- with hypovolaemia;
- with hyponatraemia (plasma-sodium concentration below 130 mmol/litre);
- with hypotension (systolic blood pressure below 90 mmHg);
- with unstable heart failure;
- receiving high-dose vasodilator therapy;
- known renovascular disease.

Renal effects

Renal function and electrolytes should be checked before starting ACE inhibitors (or increasing the dose) and monitored during treatment (more frequently if features mentioned below present); hyperkalaemia and other side-effects of ACE inhibitors are more common in those with impaired renal function and the dose may need to be reduced. Although ACE inhibitors now have a specialised role in some forms of renal disease, including chronic kidney disease, they also occasionally cause impairment of renal function which may progress and become severe in other circumstances (at particular risk are the elderly). A specialist should be involved if renal function is significantly reduced as a result of treatment with an ACE inhibitor.

Concomitant treatment with NSAIDs increases the risk of renal damage, and potassium-sparing diuretics (or potassium-containing salt substitutes) increase the risk of hyperkalaemia.

In patients with severe bilateral renal artery stenosis (or severe stenosis of the artery supplying a single functioning kidney), ACE inhibitors reduce or abolish glomerular filtration and are likely to cause severe and progressive renal failure. They are therefore not recommended in patients known to have these forms of critical renovascular disease.

ACE inhibitor treatment is unlikely to have an adverse effect on overall renal function in patients with severe...
unilateral renal artery stenosis and a normal contralateral kidney, but glomerular filtration is likely to be reduced (or even abolished) in the affected kidney and the long-term consequences are unknown.

ACE inhibitors are therefore best avoided in patients with known or suspected renovascular disease, unless the blood pressure cannot be controlled by other drugs. If ACE inhibitors are used, they should be initiated only under specialist supervision and renal function should be monitored regularly.

ACE inhibitors should also be used with particular caution in patients who may have undiagnosed and clinically silent renovascular disease. This includes patients with peripheral vascular disease or those with severe generalised atherosclerosis.

Cautions

ACE inhibitors need to be initiated with care in patients receiving diuretics.

Concomitant diuretics

ACE inhibitors can cause a very rapid fall in blood pressure in volume-depleted patients; treatment should therefore be initiated with very low doses. If the dose of diuretic is greater than 80 mg furosemide p. 201 or equivalent, the ACE inhibitor should be initiated under close supervision and in some patients the diuretic dose may need to be reduced or the diuretic discontinued at least 24 hours beforehand (may not be possible in heart failure—risk of pulmonary oedema). If high-dose diuretic therapy cannot be stopped, close observation is recommended after administration of the first dose of ACE inhibitor, for at least 2 hours or until the blood pressure has stabilised.

Combination products

Products incorporating an ACE inhibitor with a thiazide diuretic or a calcium-channel blocker are available for the management of hypertension. Use of these combination products should be reserved for patients whose blood pressure has not responded adequately to a single antihypertensive drug and who have been stabilised on the individual components of the combination in the same proportions.

Angiotensin-II receptor antagonists

Azilsartan medoxomil p. 132, candesartan cilexetil p. 133, eprosartan p. 133, ibrsartan p. 133, losartan potassium p. 134, olmesartan medoxomil p. 135, telmisartan p. 136, and valsartan p. 136 are angiotensin-II receptor antagonists with many properties similar to those of the ACE inhibitors. However, unlike ACE inhibitors, they do not inhibit the breakdown of bradykinin and other kinins, and thus are less likely to cause the persistent dry cough which can complicate ACE inhibitor therapy. They are therefore a useful alternative for patients who have to discontinue an ACE inhibitor because of persistent cough.

An angiotensin-II receptor antagonist may be used as an alternative to an ACE inhibitor in the management of heart failure or diabetic nephropathy. Candesartan cilexetil and valsartan are also licensed as adjuncts to ACE inhibitors under specialist supervision, in the management of heart failure when other treatments are unsuitable.

Renal effects

Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal effects under ACE Inhibitors, above).

Renin inhibitor

Aliskiren is a renin inhibitor that is licensed for the treatment of hypertension.

Concomitant use of drugs affecting the renin-angiotensin system

Combination therapy with two drugs affecting the renin-angiotensin system (ACE inhibitors, angiotensin-II receptor antagonists, and aliskiren p. 158 is not recommended due to an increased risk of hyperkalaemia, hypotension, and renal impairment, compared to use of a single drug. Patients with diabetic nephropathy are particularly susceptible to developing hyperkalaemia and should not be given an ACE inhibitor with an angiotensin-II receptor antagonist. There is some evidence that the benefits of combination use of an ACE inhibitor with candesartan or valsartan may outweigh the risks in selected patients with heart failure for whom other treatments are unsuitable, however, the concomitant use of this combination, together with an aldosterone antagonist or a potassium-sparing diuretic is not recommended.

For patients currently taking combination therapy, the need for continued combined therapy should be reviewed. If combination therapy is considered essential, it should be carried out under specialist supervision, with close monitoring of blood pressure, renal function, and electrolytes (particularly potassium); monitoring should be considered at the start of treatment, then monthly, and also after any change in dose or during intercurrent illness.

Drugs used for Hypertension not listed below;


ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Angiotensin-converting enzyme inhibitors

● CONTRA-INDICATIONS The combination of an ACE inhibitor with aliskiren is contra-indicated in patients with an eGFR less than 60 mL/minute/1.73 m² - the combination of an ACE inhibitor with aliskiren is contra-indicated in patients with diabetes mellitus

● CAUTIONS Afro-Caribbean patients (may respond less well to ACE inhibitors) - concomitant diuretics - first dose hypotension (especially in patients taking high doses of diuretics, on a low-sodium diet, on dialysis, dehydrated, or with heart failure) - peripheral vascular disease or generalised atherosclerosis (risk of clinically silent renovascular disease) - primary aldosteronism (patients may respond less well to ACE inhibitors) - the risk of agranulocytosis is possibly increased in collagen vascular disease (blood counts recommended) - use with care (or avoid) in those with a history of idiopathic or hereditary angioedema - use with care in patients with hypertrophic cardiomyopathy - use with care in patients with severe or symptomatic aortic stenosis (risk of hypotension)

CAUTIONS, FURTHER INFORMATION

Anaphylactoid reactions To prevent anaphylactoid reactions, ACE inhibitors should be avoided during dialysis with high-flux polycrylonitrile membranes and during low-density lipoprotein apheresis with dextran sulphate; they should also be withheld before desensitization with wasp or bee venom.

● INTERACTIONS → Appendix 1 (ACE inhibitors).

● SIDE-EFFECTS Pruritus - abdominal pain - altered liver function tests - angioedema (onset may be delayed; higher incidence reported in Afro-Caribbean patients) - arthralgia - blood disorders - bronchospasm - cholestatic jaundice -
constipation • diarrhea • dizziness • dyspepsia • eosinophilia • fatigue • fever • fulminant hepatic necrosis • haemolytic anaemia • headache • hepatic failure • hepatitis • hyperkalaemia • hypoglycaemia • leucocytosis • leucopenia • malaise • myalgia • nausea • neutropenia • pancreatitis • paraesthesia • persistent dry cough • photosensitivity • positive antinuclear antibody • profound hypotension • raised erythrocyte sedimentation rate • rash • renal impairment • rhinitis • serotonin • sinusitis • sore throat • taste disturbance • thrombocytopenia • urticaria • vasculitis • vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Hepatic effects
In light of reports of cholestatic jaundice, hepatic, fulminant hepatic necrosis, and hepatic failure, ACE inhibitors should be discontinued if marked elevation of hepatic enzymes or jaundice occur.

ALLERGY AND CROSS-SENSITIVITY
ACE inhibitors are contra-indicated in patients with hypersensitivity to ACE inhibitors (including angioedema).

PREGNANCY
ACE inhibitors should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported.

BREAST FEEDING
Information on the use of ACE inhibitors in breast-feeding is limited.

RENAL IMPAIRMENT
Use with caution, starting with low dose, and adjust according to response. Hyperkalaemia and other side-effects of ACE inhibitors are more common in those with impaired renal function and the dose may need to be reduced.

MONITORING REQUIREMENTS
Renal function and electrolytes should be checked before starting ACE inhibitors (or increasing the dose) and monitored during treatment (more frequently if side effects mentioned are present).

DIRECTIONS FOR ADMINISTRATION
For hypertension the first dose should preferably be given at bedtime.

Captopril

INDICATIONS AND DOSE

Hypertension
BY MOUTH
Adult: Initially 12.5–25 mg twice daily, then increased if necessary up to 150 mg daily in 2 divided doses, doses to be increased at intervals of at least 2 weeks, once-daily dosing may be appropriate if other concomitant antihypertensive drugs taken

Essential hypertension if used in volume depletion, cardiac decompensation, or renovascular hypertension
BY MOUTH
Adult: Initially 6.25–12.5 mg for 1 dose (under close medical supervision), then 6.25–12.5 mg twice daily; increased if necessary up to 100 mg daily in 1–2 divided doses, doses to be increased at intervals of at least 2 weeks, once-daily dosing may be appropriate if other concomitant antihypertensive drugs taken

Heart failure
BY MOUTH
Adult (under close medical supervision): Initially 6.25–12.5 mg 2–3 times a day, then increased if tolerated to up to 150 mg daily in divided doses, dose to be increased gradually at intervals of at least 2 weeks

Short-term treatment within 24 hours of onset of myocardial infarction in clinically stable patients
BY MOUTH
Adult: Initially 6.25 mg, then increased to 12.5 mg after 2 hours, followed by 25 mg after 12 hours, increased if tolerated to 50 mg twice daily for 4 weeks

Prophylaxis of symptomatic heart failure after myocardial infarction in clinically stable patients with asymptomatic left ventricular dysfunction (starting 3–16 days after infarction) (under close medical supervision)
BY MOUTH
Adult: Initially 6.25 mg daily, then increased to 12.5 mg 3 times a day for 2 days, then increased if tolerated to 25 mg 3 times a day, then increased if tolerated to 75–150 mg daily in 2–3 divided doses, doses to be increased gradually

Diabetic nephropathy
BY MOUTH
Adult: 75–100 mg daily in divided doses

SIDE-EFFECTS

Common or very common
Alopecia • dry mouth • dyspnoea • sleep disorder

Uncommon
Angina • arthralgia • flushing • pallor • palpitation • Raynaud’s syndrome • tachycardia

Rare
Anorexia • stomatitis

Very rare
Allergic alveolitis • blurred vision • cardiac arrest • cardiogenic shock • cerebrovascular events • confusion • depression • eosinophilic pneumonia • glossitis • gynaecomastia • hyponatraemia • impotence • peptic ulcer • photosensitivity • Stevens-Johnson syndrome • syncpe

BREAST FEEDING
Avoid in first few weeks after delivery, particularly in preterm infants—risk of profound neonatal hypotension; can be used in mothers breast-feeding older infants if essential but monitor infant’s blood pressure.

RENAL IMPAIRMENT
Reduce dose; max. initial dose 50 mg if eGFR above 40 mL/minute/1.73 m²; max. initial dose 25 mg daily (do not exceed 100 mg daily) if eGFR 20–40 mL/minute/1.73 m²; max. initial dose 12.5 mg daily (do not exceed 75 mg daily) if eGFR 10–20 mL/minute/1.73 m²; max. initial dose 6.25 mg daily (do not exceed 37.5 mg daily) if eGFR less than 10 mL/minute/1.73 m².

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution, powder, capsule

Tablet

Captopril (Non-proprietary)
Captopril 12.5 mg Captopril 12.5mg tablets | 56 tablet | £2.80 | DT price = £2.44 | 100 tablet | £5.00
Captopril 25 mg Captopril 25mg tablets | 56 tablet | £4.52 | DT price = £1.30 | 100 tablet | £8.07
Captopril 50 mg Captopril 50mg tablets | 56 tablet | £5.83 | DT price = £2.47 | 100 tablet | £10.41
Capoten (Bristol-Myers Squibb Pharmaceuticals Ltd)
Captopril 25 mg Capoten 25mg tablets | 28 tablet | £5.26
Ecosp ace (AMCo)
Captopril 12.5 mg Ecosp ace 12.5mg tablets | 56 tablet | £6.48 | DT price = £2.44
Captopril 25 mg Ecosp ace 25mg tablets | 56 tablet | £0.60 | DT price = £1.30
Captopril 50 mg Ecosp ace 50mg tablets | 56 tablet | £0.72 | DT price = £2.47

Oral solution

ELECTROLYTES: May contain Sodium
Noyada (Martindale Pharmaceuticals Ltd)
Captopril 1 mg per 1 mL Noyada 1mg/5ml oral solution (sugar-free) | 100 ml | £98.21 | DT price = £98.21
Co-zidocapt
The properties listed below are those particular to the combination only. For the properties of the components please consider, captopril p. 126, hydrochlorothiazide p. 160.

INDICATIONS AND DOSE
Mild to moderate hypertension in patients stabilised on the individual components in the same proportions
BY MOUTH
Adult: (consult product literature)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- CO-ZIDOCAPT (Non-proprietary)
  Captopril 5 mg, Hydrochlorothiazide 12.5 mg Co-zidocapt 12.5mg/25mg tablets | 28 tablet PSt £1.00
  Captopril 50 mg, Hydrochlorothiazide 25 mg Co-zidocapt 25mg/50mg tablets | 28 tablet PSt £4.00
- Capozide (Bristol-Myers Squibb Pharmaceuticals Ltd)
  Captopril 50 mg, Hydrochlorothiazide 25 mg Capozide 25mg/50mg tablets | 30 tablet PSt £7.52

Enalapril maleate

INDICATIONS AND DOSE
Hypertension
BY MOUTH
Adult: Initially 5 mg once daily, lower initial doses may be required when used in addition to diuretic or in renal impairment; maintenance 20 mg once daily; maximum 40 mg per day
Heart failure
BY MOUTH
Adult (under close medical supervision): Initially 2.5 mg once daily, increased if tolerated to 10–20 mg twice daily, dose to be increased gradually over 2–4 weeks
Prevention of symptomatic heart failure in patients with asymptomatic left ventricular dysfunction
BY MOUTH
Adult (under close medical supervision): Initially 2.5 mg once daily, increased if tolerated to 10–20 mg twice daily, dose to be increased gradually over 2–4 weeks

SIDE-EFFECTS
- Common or very common Asthenia · blurred vision · depression · dyspnoea
- Uncommon Alopecia · anorexia · arrhythmias · confusion · drowsiness · dry mouth · flushing · hypotension · impotence · insomnia · muscle cramps · nervousness · palpitation · peptic ulcer · sweating · tinnitus · vertigo
- Rare Abnormal dreams · allergic alveolitis · exfoliative dermatitis · glossitis · gynaecomastia · pemphigus · pulmonary infiltrates · Raynaud’s syndrome · Stevens-Johnson syndrome · stomatitis · toxic epidermal necrolysis
- Very rare Gastro-intestinal angioedema

BREAST FEEDING Avoid in first few weeks after delivery, particularly in preterm infants—risk of profound neonatal hypotension; can be used in mothers breast-feeding older infants if essential but monitor infant’s blood pressure.

HEPATIC IMPAIRMENT Enalapril is a prodrug and requires close monitoring in patients with hepatic impairment.

RENAL IMPAIRMENT Max. initial dose 2.5 mg daily if eGFR less than 30 mL/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION Tablets may be crushed and suspended in water immediately before use.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet
- ENALAPRIL MALEATE (Non-proprietary)
  Enalapril maleate 2.5 mg | 28 tablet PSt £2.84 DT price = £1.51
  Enalapril maleate 5 mg | 28 tablet PSt £4.13 DT price = £0.99
  Enalapril maleate 10 mg | 28 tablet PSt £5.64 DT price = £1.02
  Enalapril maleate 20 mg | 28 tablet PSt £6.63 DT price = £1.18
- Innovace (Merck Sharp & Dohme Ltd)
  Enalapril maleate 2.5 mg | 28 tablet PSt £5.35 DT price = £1.51
  Enalapril maleate 5 mg | 28 tablet PSt £7.51 DT price = £0.99
  Enalapril maleate 10 mg | 28 tablet PSt £10.51 DT price = £1.02
  Enalapril maleate 20 mg | 28 tablet PSt £12.51 DT price = £1.18

Enalapril with hydrochlorothiazide
The properties listed below are those particular to the combination only. For the properties of the components please consider, enalapril maleate above, hydrochlorothiazide p. 160.

INDICATIONS AND DOSE
Mild to moderate hypertension in patients stabilised on the individual components in the same proportions
BY MOUTH
Adult: (consult product literature)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- ENALAPRIL WITH HYDROCHLOROTHIAZIDE (Non-proprietary)
  Enalapril maleate 20 mg, Hydrochlorothiazide 12.5 mg Enalapril 20mg / Hydrochlorothiazide 12.5mg tablets | 28 tablet PSt £20.00 DT price = £13.94
  Innozide (Merck Sharp & Dohme Ltd)
  Enalapril maleate 20 mg, Hydrochlorothiazide 12.5 mg Innozide 20mg/12.5mg tablets | 28 tablet PSt £13.90 DT price = £19.94

Fosinopril sodium

INDICATIONS AND DOSE
Hypertension
BY MOUTH
Adult: Initially 10 mg daily for 4 weeks, then increased if necessary up to 40 mg daily, doses over 40 mg not shown to increase efficacy
Congestive heart failure (adjunct) (under close medical supervision)
BY MOUTH
Adult: Initially 10 mg once daily, then increased if tolerated to 40 mg once daily, doses to be increased gradually

SIDE-EFFECTS
Chest pain · musculoskeletal pain

BREAST FEEDING Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

HEPATIC IMPAIRMENT Fosinopril is a prodrug and requires close monitoring in patients with hepatic impairment.

BNF 70
Hypertension 127
Cardiovascular system
**Imidapril hydrochloride**

**INDICATIONS AND DOSE**

**Essential hypertension**
- **BY MOUTH**
  - Adult: Initially 2.5 mg daily, increased if necessary to 10 mg daily, dose to be increased at intervals of at least 3 weeks, to be taken before food; maximum 20 mg per day
  - Elderly: Initially 2.5 mg daily, increased if necessary to 10 mg daily, dose to be increased at intervals of at least 3 weeks

**Essential hypertension in patients with heart failure, angina or cerebrovascular disease, or in renal or hepatic impairment**
- **BY MOUTH**
  - Adult: Initially 2.5 mg daily, increased if necessary to 10 mg daily, dose to be increased at intervals of at least 3 weeks; maximum 20 mg per day

**SIDE-EFFECTS**
- Blurred vision, bronchitis, confusion, depression, dry mouth, dyspnoea, glossitis, ileus, impotence, sleep disturbances, tinnitus

**BREAST FEEDING**
- Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

**HEPATIC IMPAIRMENT**
- Imidapril is a prodrug and requires close monitoring in patients with hepatic impairment.

**RENAL IMPAIRMENT**
- Initial dose 2.5 mg daily if eGFR 30–80 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - Tanatril (Chiesi Ltd)
      - Imidapril hydrochloride 5 mg Tanatril 5mg tablets | 28 tablet £6.40 DT price = £6.40
      - Imidapril hydrochloride 10 mg Tanatril 10mg tablets | 28 tablet £7.22 DT price = £7.22
      - Imidapril hydrochloride 20 mg Tanatril 20mg tablets | 28 tablet £8.67 DT price = £8.67

**Lisinopril**

**INDICATIONS AND DOSE**

**Hypertension**
- **BY MOUTH**
  - Adult: Initially 10 mg once daily; maintenance 20 mg once daily; maximum 80 mg per day
  - Hypertension, when used in addition to diuretic, in cardiac decompensation or in volume depletion
  - Adult: Initially 2.5–5 mg once daily; maintenance 20 mg once daily; maximum 80 mg per day

**SIDE-EFFECTS**
- Uncommon: Raynaud’s syndrome, vertigo, asthma, cerebrovascular accident, confusion, impotence, mood changes, myocardial infarction, palpitation, sleep disturbances, tachycardia
  - Rare: Alopecia, dry mouth, gynaecomastia, psoriasis
  - Very rare: Allergic alveolitis, pemphigus, profuse sweating, pulmonary infiltrates, Stevens-Johnson syndrome, toxic epidermal necrolysis

**BREAST FEEDING**
- Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

**RENAL IMPAIRMENT**
- Max. initial doses 5–10 mg daily if eGFR 30–80 mL/minute/1.73 m² (max. 40 mg daily); 2.5–5 mg daily if eGFR 10–30 mL/minute/1.73 m² (max. 40 mg daily); 2.5 mg daily if eGFR less than 10 mL/minute/1.73 m².

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension
  - **Tablet**
    - Lisinopril (Non-proprietary)
      - Lisinopril 2.5 mg Lisinopril 2.5mg tablets | 28 tablet £6.16 DT price = £6.16
      - Lisinopril 5 mg Lisinopril 5mg tablets | 28 tablet £7.80 DT price = £7.80
      - Lisinopril 10 mg Lisinopril 10mg tablets | 28 tablet £9.60 DT price = £9.60
      - Lisinopril 20 mg Lisinopril 20mg tablets | 28 tablet £10.90 DT price = £10.90
      - Zestril (AstraZeneca UK Ltd)
        - Lisinopril 5 mg Zestril 5mg tablets | 28 tablet £4.71 DT price = £4.71

**Short-term treatment following myocardial infarction in haemodynamically stable patients—systolic blood pressure over 120 mmHg**
- **BY MOUTH**
  - Adult: Initially 5 mg, taken within 24 hours of myocardial infarction, followed by 5 mg, to be taken 24 hours after initial dose, then 10 mg once daily, to be taken 24 hours after second dose, then 10 mg once daily for 6 weeks (or continued if heart failure), temporarily reduce maintenance dose to 5 mg and if necessary 2.5 mg daily if systolic blood pressure 100 mmHg or less during treatment. Withdraw if prolonged hypotension occurs during treatment (systolic blood pressure less than 90 mmHg for more than 1 hour)

**Short-term treatment following myocardial infarction in haemodynamically stable patients—systolic blood pressure 100–120 mmHg**
- **BY MOUTH**
  - Adult: Initially 2.5 mg once daily, maintenance 5 mg once daily, should not be started after myocardial infarction if systolic blood pressure less than 100 mmHg, temporarily reduce maintenance dose to 5 mg and if necessary 2.5 mg daily if systolic blood pressure 100 mmHg or less during treatment. Withdraw if prolonged hypotension occurs (systolic blood pressure less than 90 mmHg for more than 1 hour)

**Renal complications of diabetes mellitus**
- **BY MOUTH**
  - Adult: Initially 2.5–5 mg once daily, adjusted according to response; maintenance 10–20 mg once daily

**Heart failure (adjunct) (under expert supervision)**
- **BY MOUTH**
  - Adult: Initially 2.5 mg once daily; increased in steps of up to 10 mg at least every 2 weeks; maximum 35 mg per day
Hydrochlorothiazide with lisinopril

The properties listed below are those particular to the combination only. For the properties of the components please consider, lisinopril p. 128, hydrochlorothiazide p. 160.

**INDICATIONS AND DOSE**

Mild to moderate hypertension in patients stabilised on the individual components in the same proportions

**BY MOUTH**

- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Zestoretic
- Carace Plus
- Hydrochlorothiazide 12.5 mg, Lisinopril 20 mg
- Hydrochlorothiazide 12.5 mg, Lisinopril 10 mg
- Perdix
- Coversyl Arginine
- Moexipril hydrochloride 7.5 mg
- Moexipril hydrochloride 15 mg

**SIDE-EFFECTS**

- Asthenia
- Mood disturbances
- Sleep disturbances
- Seizures
- Hyperuricaemia
- Impotence
- Myocardial infarction

**Hypertension, if used in addition to diuretic, or in renal impairment, cardiac decompensation or volume depletion**

**BY MOUTH**

- Adult: Initially 2.5 mg once daily, then, adjusted according to response; maximum 10 mg per day
- Elderly: Initially 2.5 mg once daily, then, adjusted according to response; maximum 10 mg per day

**Symptomatic heart failure (adjunct) (under close medical supervision)**

**BY MOUTH**

- Adult: Initially 2.5 mg once daily for 2 weeks, then increased if tolerated to 5 mg once daily, dose to be taken in the morning

**Prophylaxis of cardiac events following myocardial infarction or revascularisation in stable coronary artery disease**

**BY MOUTH**

- Adult: Initially 5 mg once daily for 2 weeks, then increased if tolerated to 10 mg once daily, dose to be taken in the morning
- Elderly: Initially 2.5 mg once daily for 1 week, then increased if tolerated to 5 mg once daily for 1 week, then increased if tolerated to 10 mg once daily, dose to be taken in the morning

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Coversyl Arginine (Servier Laboratories Ltd)
- Perindopril arginine 2.5 mg
- Perindopril arginine 5 mg
- Perindopril arginine 10 mg

**Moexipril hydrochloride**

**INDICATIONS AND DOSE**

Essential hypertension (monotherapy)

**BY MOUTH**

- Adult: Initially 7.5 mg once daily, adjusted according to response; maintenance 7.5–15 mg once daily; maximum 30 mg per day
- Elderly: Initially 3.75 mg once daily, adjusted according to response; maintenance 7.5–15 mg once daily; maximum 30 mg per day

**MEDICATIONS**

Significant mitral valve stenosis

**SIDE-EFFECTS**

- Very rare: Numbness
- Frequency not known: Alopecia, angina, appetite, arrhythmias, blurred vision, cerebrovascular accident, confusion, depression, drowsiness, dry mouth, dyspnœa, flushing, hyperuricaemia, impotence, myocardial infarction, palpitation, pemphigus, sleep disturbance, Stevens-Johnson syndrome, sweating, syncope, tachycardia, tinnitus, toxic epidermal necrolysis, weight changes

**BREAST FEEDING**

Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

**Hepatic Impairment**

Initial dose 3.75 mg once daily.

**Renal Impairment**

If eGFR less than 40 mL/minute/1.73 m², initial dose 3.75 mg once daily titrated to max. 15 mg once daily.

**Perindopril arginine**

**INDICATIONS AND DOSE**

Hypertension

**BY MOUTH**

- Adult: Initially 5 mg once daily for 1 month, then, adjusted according to response; maximum 10 mg per day
- Elderly: Initially 2.5 mg once daily, then, adjusted according to response; maximum 10 mg per day

**MEDICATIONS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Coversyl Arginine (Servier Laboratories Ltd)
- Perindopril arginine 2.5 mg
- Perindopril arginine 5 mg
- Perindopril arginine 10 mg
Indapamide with perindopril arginine

The properties listed below are those particular to the combination only. For the properties of the components please consider, perindopril arginine p. 129, indapamide p. 160.

### INDICATIONS AND DOSE

Hypertension not adequately controlled by perindopril alone

BY MOUTH
- Adult: (consult product literature)

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, powder

**Tablet**

**CAUTIONARY AND ADVISORY LABELS. 22**

**PERINDOPRIL ERBUMINE (Non-proprietary)**

Perindopril erbumine 2 mg | Perindopril erbumine 2mg tablets | 30 tablet [Ref] £4.41 DT price = £1.15 | 56 tablet [Ref] £3.34
60 tablet [Ref] £3.90

Perindopril erbumine 4 mg | Perindopril erbumine 4mg tablets | 30 tablet [Ref] £4.50 DT price = £1.56 | 56 tablet [Ref] £3.38
60 tablet [Ref] £27.80

Perindopril erbumine 8 mg | Perindopril erbumine 8mg tablets | 30 tablet [Ref] £5.95 DT price = £1.52 | 56 tablet [Ref] £3.88
60 tablet [Ref] £40.00

---

Quinapril

### INDICATIONS AND DOSE

Essential hypertension

BY MOUTH
- Adult: Initially 10 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day
- Elderly: Initially 2.5 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day

Essential hypertension if used in addition to diuretic

BY MOUTH
- Adult: Initially 2.5 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day

Heart failure (adjunct) (under close medical supervision)

BY MOUTH
- Adult: Initially 2.5 mg daily, increased if tolerated to 10–20 mg daily in 1–2 divided doses, doses to be increased gradually; maximum 40 mg per day

### SIDE-EFFECTS

Impotence · asthenia · back pain · blurred vision · chest pain · depression · flatulence · insomnia · nervousness · oedema

### BREAST FEEDING

Avoid in the first few weeks after delivery, particularly in preterm infants, due to the risk of profound neonatal hypotension; if essential, may be used in mothers breast-feeding older infants – the infant’s blood pressure should be monitored.

### HEPATIC IMPAIRMENT

Quinapril is a prodrug and requires close monitoring in patients with hepatic impairment.

### RENAL IMPAIRMENT

Max. initial dose 2.5 mg once daily if eGFR less than 40 mL/minute/1.73 m².

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**QUINAPRIL (Non-proprietary)**

Quinapril (as Quinapril hydrochloride) 5 mg | Quinapril 5mg tablets | 28 tablet [Ref] £8.59 DT price = £8.47
Quinapril (as Quinapril hydrochloride) 10 mg | Quinapril 10mg tablets | 28 tablet [Ref] £8.59 DT price = £8.46
Quinapril (as Quinapril hydrochloride) 20 mg | Quinapril 20mg tablets | 28 tablet [Ref] £6.00 DT price = £1.86
Quinapril (as Quinapril hydrochloride) 40 mg | Quinapril 40mg tablets | 28 tablet [Ref] £8.00 DT price = £2.41

**Accupro (Pfizer Ltd)**

Quinapril (as Quinapril hydrochloride) 5 mg | Accupro 5mg tablets | 28 tablet [Ref] £8.60 DT price = £8.47
Quinapril (as Quinapril hydrochloride) 10 mg | Accupro 10mg tablets | 28 tablet [Ref] £8.60 DT price = £8.46
Quinapril (as Quinapril hydrochloride) 20 mg | Accupro 20mg tablets | 28 tablet [Ref] £10.79 DT price = £1.86
Quinapril (as Quinapril hydrochloride) 40 mg | Accupro 40mg tablets | 28 tablet (PO) £9.75 DT price = £2.41

Hydrochlorothiazide with quinapril

The properties listed below are those particular to the combination only. For the properties of the components please consider, quinapril p. 130, hydrochlorothiazide p. 160.

INDICATIONS AND DOSE
Hypertension in patients stabilised on the individual components in the same proportions

BY MOUTH

Adult: (consult product literature)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROCHLOROTHIAZIDE WITH QUINAPRIL (Non-proprietary)</td>
</tr>
<tr>
<td>Hydrochlorothiazide 12.5 mg, Quinapril (as Quinapril hydrochloride) 10 mg</td>
</tr>
<tr>
<td>Tablet</td>
</tr>
<tr>
<td>Accuretic (Pfizer Ltd)</td>
</tr>
</tbody>
</table>

Ramipril

INDICATIONS AND DOSE
Hypertension

BY MOUTH

Adult: Initially 1.25–2.5 mg daily, increased if necessary up to 10 mg daily, dose to be increased at intervals of 1–2 weeks

Symptomatic heart failure (adjunct) (under close medical supervision)

BY MOUTH

Adult: Initially 1.25 mg daily, increased if necessary up to 10 mg daily, preferably taken in 2 divided doses, increase dose gradually at intervals of 1–2 weeks

Prophylaxis after myocardial infarction in patients with clinical evidence of heart failure (started at least 48 hours after infarction)

BY MOUTH

Adult: Initially 2.5 mg twice daily for 3 days, then increased to 5 mg twice daily

Prophylaxis after myocardial infarction in patients with clinical evidence of heart failure (started at least 48 hours after infarction) when initial dose not tolerated

BY MOUTH

Adult: Initially 1.25 mg twice daily for 2 days, then increased to 2.5 mg twice daily, then increased to 5 mg twice daily, withdraw treatment if dose cannot be increased to 2.5 mg twice daily

Prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease or with diabetes mellitus and at least one additional risk factor for cardiovascular disease

BY MOUTH

Adult: Initially 2.5 mg daily for 1–2 weeks, then increased to 5 mg daily for a further 2–3 weeks, then increased to 10 mg daily

Nephropathy (consult product literature)

BY MOUTH

Adult: Initially 1.25 mg daily for 2 weeks, then increased to 2.5 mg daily for a further 2 weeks, then increased if tolerated to 5 mg daily

SIDE-EFFECTS

- Common or very common Bronchitis · dyspnoea · muscle cramps · stomatitis · syncope
- Uncommon Angina · anxiety · arrhythmias · chest pain · decreased libido · depression · dry mouth · flushing · impotence · loss of appetite · myocardial infarction · nervousness · palpitations · peripheral oedema · sweating · tachycardia · visual disturbances
- Rare Confusion · conjunctivitis · impaired hearing · onycholysis · tinnitus · tremor
- Frequency not known Alopecia · cerebrovascular accident · erythema multiforme · gynaecomastia · hyponatraemia · pemphigoid exanthema · precipitation or exacerbation of Raynaud’s syndrome · skin reactions · sleep disturbance · Stevens-Johnson syndrome · toxic epidermal necrolysis

BREAST FEEDING
Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

HEPATIC IMPAIRMENT
Max. daily dose 2.5 mg. Ramipril is a prodrug and requires close monitoring in patients with hepatic impairment.

RENAL IMPAIRMENT
Max. daily dose 5 mg if eGFR 30–60 mL/minute/1.73 m²; max. initial dose 1.25 mg once daily (do not exceed 5 mg daily) if eGFR less than 30 mL/minute/1.73 m².

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution containing the same drug.

<table>
<thead>
<tr>
<th>Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAMIPRIL (Non-proprietary)</td>
</tr>
<tr>
<td>Ramipril 1.25 mg</td>
</tr>
<tr>
<td>Ramipril 2.5 mg</td>
</tr>
<tr>
<td>Ramipril 5 mg</td>
</tr>
<tr>
<td>Ramipril 10 mg</td>
</tr>
<tr>
<td>TRICTACE (Sanofi)</td>
</tr>
<tr>
<td>Ramipril 1.25 mg</td>
</tr>
<tr>
<td>Ramipril 2.5 mg</td>
</tr>
<tr>
<td>Ramipril 5 mg</td>
</tr>
<tr>
<td>Ramipril 10 mg</td>
</tr>
<tr>
<td>Capsule</td>
</tr>
<tr>
<td>RAMIPRIL (Non-proprietary)</td>
</tr>
<tr>
<td>Ramipril 1.25 mg</td>
</tr>
<tr>
<td>Ramipril 2.5 mg</td>
</tr>
<tr>
<td>Ramipril 5 mg</td>
</tr>
<tr>
<td>Ramipril 10 mg</td>
</tr>
</tbody>
</table>

Solution

<table>
<thead>
<tr>
<th>RAMIPRIL (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramipril 500 microgram per 1 ml Ramipril 2.5mg/5ml oral solution sugar free (sugar-free)</td>
</tr>
</tbody>
</table>

Felodipine with ramipril

The properties listed below are those particular to the combination only. For the properties of the components please consider, felodipine p. 151, ramipril above.
**INDICATIONS AND DOSE**

Hypertension in patients stabilised on the individual components in the same proportions

**BY MOUTH**
- **Adult:** (consult product literature)

**SIDE-EFFECTS**
- Alopecia
- angina
- arthralgia
- ashen
- bronchitis
- cerebral haemorrhage
- dry mouth
- dysphonia
- hot flushes
- ileus
- myocardial infarction
- nervousness
- palpitation
- psoriasis-like efflorescence
- skin reactions
- sleep disturbances
- Stevens-Johnson syndrome
- sweating
- syncope
- tachycardia
- toxic epidermal necrolysis
- transient ischaemic attacks

**SIDE-EFFECTS, FURTHER INFORMATION**

Symptomatic hypotension: If symptomatic hypotension develops during titration, do not increase dose further; if possible, reduce dose of any adjunctive treatment and if this is not effective or feasible, reduce dose of trandolapril.

**BREAST FEEDING**
Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

**HEPATIC IMPAIRMENT**
Trandolapril is a prodrug and requires close monitoring in patients with hepatic impairment.

**RENAL IMPAIRMENT**
Max. 2 mg daily if eGFR less than 10 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

- **Capsule**
  - **TRANDOLAPRIL (Non-proprietary)**
    - Trandolapril 500 microgram: 500 microgram capsules | 14 capsule [PO] £1.92 DT price = £1.87
    - Trandolapril 1 mg: 1 mg capsules | 28 capsule [PO] £20.00 DT price = £19.99
    - Trandolapril 2 mg: 2 mg capsules | 28 capsule [PO] £10.40 DT price = £7.60
    - Trandolapril 4 mg: 4 mg capsules | 28 capsule [PO] £14.19 DT price = £14.01

**ANGIOTENSIN-II RECEPTOR ANTAGONISTS**

**Angiotensin-II receptor antagonists**

- **CONTRA-INDICATIONS**
  The combination of an angiotensin-II receptor antagonist with aliskiren is contra-indicated in patients with an eGFR less than 60 mL/minute/1.73 m².

- **CAUTIONS**
  - Afro-Caribbean patients—particularly those with left ventricular hypertrophy (may not benefit from an angiotensin-II receptor antagonist).
  - aortic or mitral valve stenosis—elderly (lower initial doses may be appropriate).
  - hypertrophic cardiomyopathy—patients with a history of angioedema.

**INTERACTIONS**
Appendix 1 (angiotensin-II receptor antagonists).

**SIDE-EFFECTS**
- Hyperkalaemia
- angioedema (may be delayed onset).
- Symptomatic hypotension including dizziness (particularly in patients with intravascular volume depletion).
- Pregnancy
  - Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential.
  - They may adversely affect fetal and neonatal blood pressure control and renal function; neonatal skull defects and oligohydramnios have also been reported.

**BREAST FEEDING**
- Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited.
  - They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available.

**RENAL IMPAIRMENT**
- Use with caution, starting with low dose, and adjust according to response.

**MONITORING REQUIREMENTS**
- Monitor plasma-potassium concentration, particularly in the elderly and in patients with renal impairment.

**Azilsartan medoxomil**

**INDICATIONS AND DOSE**

Hypertension

**BY MOUTH**
- **Adult 18–74 years:** Initially 40 mg once daily, increased if necessary to 80 mg once daily
- **Adult 75 years and over:** Initially 20–40 mg once daily, increased if necessary to 80 mg once daily

**Hypertension with intravascular volume depletion**

**BY MOUTH**
- **Adult:** Initially 20–40 mg daily, increased if necessary to 80 mg daily

**SIDE-EFFECTS**
- **Common or very common**
  - Diarrhoea
  - Heart failure
  - Diarrhoea
  - Diarrhoea

**HEPATIC IMPAIRMENT**
- Manufacturer advises to consider initial dose of 20 mg in mild to moderate impairment (limited information available).

Manufacturer advises avoid in severe impairment (no information available). Manufacturer advises monitor closely in mild to moderate hepatic impairment (limited information available).
### Renal Impairment

The manufacturer advises caution in severe impairment—no information available.

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Edarbi** (Takeda UK Ltd)
  - Azilsartan medoxomil 20 mg | 28 tablet (PO) £16.80 DT price = £16.80
  - Azilsartan medoxomil 40 mg | 28 tablet (PO) £16.80 DT price = £16.80
  - Azilsartan medoxomil 80 mg | 28 tablet (PO) £19.95 DT price = £19.95

### Side-effects

- Common or very common: Headache, vertigo
- Very rare: Arthralgia, back pain, blood disorders, cough, hepatitis, hypotension, myalgia, nausea, pruritus, rash, urticaria

### Hepatic Impairment

Initially 4 mg once daily in mild or moderate impairment. Avoid in severe hepatic impairment.

### Renal Impairment

Initially 4 mg daily, use with caution if eGFR less than 30 mL/minute/1.73 m²—limited experience.

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- **Candesartan cilexetil 2 mg** | 7 tablet (PO) £5.53
- **Candesartan cilexetil 4 mg** | 7 tablet (PO) £8.88 DT price = £8.88
- **Candesartan cilexetil 8 mg** | 28 tablet (PO) £9.89 DT price = £9.89
- **Candesartan cilexetil 16 mg** | 28 tablet (PO) £12.72 DT price = £12.72
- **Candesartan cilexetil 32 mg** | 28 tablet (PO) £16.13 DT price = £16.13

**Amias** (Takeda UK Ltd)

- **Candesartan cilexetil 2 mg** | 7 tablet (PO) £3.58 DT price = £3.58
- **Candesartan cilexetil 4 mg** | 7 tablet (PO) £6.83 DT price = £6.83
- **Candesartan cilexetil 8 mg** | 28 tablet (PO) £9.78

### Contra-Indications

- Cholestasis

### Indications and Dose

**Hypertension**

**By Mouth**

- Adult: 600 mg once daily

**Side-effects**

- Common or very common: Headache, vertigo, fatigue, muscular-skeletal pain, nausea, vomiting

**Hepatic Impairment**

Caution in mild or moderate liver disease. Avoid in severe impairment.

**Renal Impairment**

Caution if eGFR less than 30 mL/minute/1.73 m².

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- **Eprosartan (as Eprosartan mesilate) 300 mg** | 28 tablet (PO) £7.31 DT price = £7.31
- **Eprosartan (as Eprosartan mesilate) 400 mg** | 56 tablet (PO) £25.98 DT price = £25.98
- **Eprosartan (as Eprosartan mesilate) 600 mg** | 28 tablet (PO) £14.31 DT price = £14.31

**Teveteen** (BGP Products Ltd)

- **Eprosartan (as Eprosartan mesilate) 300 mg** | 28 tablet (PO) £7.31 DT price = £7.31
- **Eprosartan (as Eprosartan mesilate) 600 mg** | 28 tablet (PO) £14.31 DT price = £14.31

### Indications and Dose

**Hypertension**

**By Mouth**

- Adult 18-74 years: Initially 150 mg once daily, increased if necessary to 300 mg once daily
- Adult 75 years and over: Initially 75–150 mg once daily, increased if necessary to 300 mg once daily

**Hypertension in patients receiving haemodialysis**

**By Mouth**

- Adult: Initially 75–150 mg once daily, increased if necessary to 300 mg once daily

**Renal disease in hypertensive type 2 diabetes mellitus**

**By Mouth**

- Adult 18-74 years: Initially 150 mg once daily, increased if tolerated to 300 mg once daily
- Adult 75 years and over: Initially 75–150 mg once daily, increased if tolerated to 300 mg once daily

**Renal disease in hypertensive type 2 diabetes mellitus in patients receiving haemodialysis**

**By Mouth**

- Adult: Initially 75–150 mg once daily, increased if tolerated to 300 mg once daily

### Side-effects

- Common or very common: Fatigue, muscular-skeletal pain, nausea, vomiting
- Uncommon: Chest pain, cough, diarrhoea, dyspepsia, flushing, sexual dysfunction, tachycardia
- Rare: Rash, urticaria

### Candesartan Cilexetil 16 mg

Amias 16mg tablets | 28 tablet (PO) £12.72 DT price = £1.57

### Candesartan Cilexetil 32 mg

Amias 32mg tablets | 28 tablet (PO) £16.13 DT price = £2.20

### Eprosartan

**Indications and Dose**

**Hypertension**

**By Mouth**

- Adult: 600 mg once daily

**Side-effects**

- Common or very common: Headache, vertigo, fatigue, muscular-skeletal pain, nausea, vomiting.

**Hepatic Impairment**

Caution in mild or moderate liver disease. Avoid in severe impairment.

**Renal Impairment**

Caution if eGFR less than 30 mL/minute/1.73 m².

### Irbesartan

**Indications and Dose**

**Hypertension**

**By Mouth**

- Adult 18-74 years: Initially 150 mg once daily, increased if necessary to 300 mg once daily
- Adult 75 years and over: Initially 75–150 mg once daily, increased if necessary to 300 mg once daily

**Hypertension in patients receiving haemodialysis**

**By Mouth**

- Adult: Initially 75–150 mg once daily, increased if necessary to 300 mg once daily

**Renal disease in hypertensive type 2 diabetes mellitus**

**By Mouth**

- Adult 18-74 years: Initially 150 mg once daily, increased if tolerated to 300 mg once daily
- Adult 75 years and over: Initially 75–150 mg once daily, increased if tolerated to 300 mg once daily

**Renal disease in hypertensive type 2 diabetes mellitus in patients receiving haemodialysis**

**By Mouth**

- Adult: Initially 75–150 mg once daily, increased if tolerated to 300 mg once daily

**Side-effects**

- Common or very common: Fatigue, muscular-skeletal pain, nausea, vomiting.
- Uncommon: Chest pain, cough, diarrhoea, dyspepsia, flushing, sexual dysfunction, tachycardia.
- Rare: Rash, urticaria.
Hydrochlorothiazide with irbesartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, irbesartan p. 133, hydrochlorothiazide p. 160.

INDICATIONS AND DOSE

Hypertension not adequately controlled with irbesartan alone

BY MOUTH

Adult: (consult product literature)

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

HYDROCHLOROTHIAZIDE WITH IRBESARTAN (Nonproprietary)

Hydrochlorothiazide 12.5 mg, Irbesartan 150 mg  Irbesartan 150 mg / Hydrochlorothiazide 12.5 mg tablets | 28 tablet (PO) £11.25 DT price = £1.60

Hydrochlorothiazide 25 mg, Irbesartan 300 mg  Irbesartan 300 mg / Hydrochlorothiazide 25 mg tablets | 28 tablet (PO) £11.53 DT price = £1.87

Hydrochlorothiazide 12.5 mg, Irbesartan 300 mg  Irbesartan 300 mg / Hydrochlorothiazide 12.5 mg tablets | 28 tablet (PO) £15.13 DT price = £2.00

CoAprovel (Sanofi)

Hydrochlorothiazide 12.5 mg, Irbesartan 150 mg  CoAprovel 150 mg/12.5 mg tablets | 28 tablet (PO) £11.84 DT price = £1.62

Hydrochlorothiazide 25 mg, Irbesartan 300 mg  CoAprovel 300 mg/25 mg tablets | 28 tablet (PO) £15.93 DT price = £2.35

Losartan potassium

INDICATIONS AND DOSE

Diabetic nephropathy in type 2 diabetes mellitus

BY MOUTH

Adult 18–75 years: Initially 50 mg once daily for several weeks, then increased if necessary to 100 mg once daily

Adult 76 years and over: Initially 25 mg once daily

Chronic heart failure when ACE inhibitors are unsuitable or contra-indicated

BY MOUTH

Adult: Initially 12.5 mg once daily, increased if tolerated up to 150 mg once daily, doses to be increased at weekly intervals

Hypertension

BY MOUTH

Adult 18–75 years: Initially 50 mg once daily for several weeks, then increased if necessary to 100 mg once daily

Adult 76 years and over: Initially 25 mg daily

Hypertension with intravascular volume depletion

BY MOUTH

Adult 18–75 years: Initially 25 mg once daily for several weeks, then increased if necessary up to 100 mg once daily

CAUTIONS

Severe heart failure

SIDE-EFFECTS

Common or very common  Vertigo

Uncommon  Angina, dyspnoea, gastro-intestinal disturbances, headache, malaise, oedema, palpitation, pruritus, rash, sleep disorders, urticaria

Rare  Atrial fibrillation, cerebrovascular accident, hepatitis, paraesthesia, syncope

Frequency not known  Anaemia, anaphylaxis, arthralgia, cough, depression, erectile dysfunction, Henoch–Schönlein purpura, hyponatraemia, myalgia, pancreatitis, photosensitivity, renal impairment, rhabdomyolysis, thrombocytopenia, tinnitus, vasculitis

HEPATIC IMPAIRMENT  Consider dose reduction in mild to moderate impairment. Manufacturer advises avoid in severe impairment—no information available.

PRESCRIBING AND DISPENSING INFORMATION

Flavours of oral liquid formulations may include berry-citrus.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

LOSARTAN POTASSIUM (Nonproprietary)

Losartan potassium 12.5 mg  Losartan 12.5 mg tablets | 28 tablet (PO) £7.48 DT price = £0.97

Losartan potassium 25 mg  Losartan 25 mg tablets | 28 tablet (PO) £16.18 DT price = £2.15

Losartan potassium 50 mg  Losartan 50 mg tablets | 28 tablet (PO) £16.18 DT price = £2.35

Losartan potassium 100 mg  Losartan 100 mg tablets | 28 tablet (PO) £16.18 DT price = £2.35

Cozaar (Merck Sharp & Dohme Ltd)

Losartan potassium 12.5 mg  Cozaar 12.5 mg tablets | 28 tablet (PO) £8.09 DT price = £1.15

Losartan potassium 25 mg  Cozaar 25 mg tablets | 28 tablet (PO) £16.18 DT price = £2.25

Losartan potassium 50 mg  Cozaar 50 mg tablets | 28 tablet (PO) £22.80 DT price = £3.14

Losartan potassium 100 mg  Cozaar 100 mg tablets | 28 tablet (PO) £16.18 DT price = £2.50

Cozaar (Merck Sharp & Dohme Ltd)

Losartan potassium 2.5 mg per 1 ml  Cozaar 2.5 mg/ml oral suspension (sugar-free) | 200 ml (PO) £3.68
Hydrochlorothiazide with losartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, losartan potassium p. 134, hydrochlorothiazide p. 160.

**INDICATIONS AND DOSE**

Hypertension not adequately controlled with losartan alone

**BY MOUTH**

- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- HYDROCHLOROTHIAZIDE WITH LOSARTAN (Non-proprietary)

  | Hydrochlorothiazide 12.5 mg, Losartan potassium |
  | 50 mg Losartan 50mg / Hydrochlorothiazide 12.5mg tablets | 28 tablet P trom £13.75 DT price = £1.65

  | Hydrochlorothiazide 25 mg, Losartan potassium |
  | 100 mg Losartan 100mg / Hydrochlorothiazide 25mg tablets | 28 tablet P trom £16.18 DT price = £2.06

  | Hydrochlorothiazide 12.5 mg, Losartan potassium |
  | 100 mg Losartan 100mg / Hydrochlorothiazide 12.5mg tablets | 28 tablet P trom £16.18 DT price = £13.69

- Cozaar-Comp (Merck Sharp & Dohme Ltd)

  | Hydrochlorothiazide 12.5 mg, Losartan potassium 50 mg |
  | Cozaar-Comp 50mg/12.5mg tablets | 28 tablet P trom £12.80 DT price = £1.65

  | Hydrochlorothiazide 25 mg, Losartan potassium 100 mg |
  | Cozaar-Comp 100mg/25mg tablets | 28 tablet P trom £16.18 DT price = £2.06

  | Hydrochlorothiazide 12.5 mg, Losartan potassium 100 mg |
  | Cozaar-Comp 100mg/12.5mg tablets | 28 tablet P trom £16.18 DT price = £13.69

**Olmesartan medoxomil**

**INDICATIONS AND DOSE**

Hypertension

**BY MOUTH**

- Adult: Initially 10 mg daily, increased if necessary to 20 mg daily; maximum 40 mg per day

**CONTRA-INDICATIONS**

Biliary obstruction

**SIDE-EFFECTS**

Common or very common

- Arthritis, chest pain, cough, fatigue, gastro-intestinal disturbances, haematuria, hypertriglyceridaemia, hyperuricaemia, influenza-like symptoms, musculoskeletal pain, peripheral oedema, pharyngitis, rhinitis, urinary-tract infection

- Uncommon

  | Angina, rash, vertigo |
  | Very rare |

  | Headache, myalgia, pruritus, thrombocytopenia, urticaria |

**HEPATIC IMPAIRMENT**

Dose should not exceed 20 mg daily in moderate impairment. Manufacturer advises avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**

Max. 20 mg daily if eGFR 20–60 mL/minute/1.73 m². Avoid if eGFR less than 20 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- Olmetec (Daichi Sankyo UK Ltd)

  | Olmesartan medoxomil 10 mg |
  | Olmetec 10mg tablets | 28 tablet P trom £10.95 DT price = £1.05

  | Olmesartan medoxomil 20 mg |
  | Olmetec 20mg tablets | 28 tablet P trom £12.95 DT price = £1.25

  | Olmesartan medoxomil 40 mg |
  | Olmetec 40mg tablets | 28 tablet P trom £17.50 DT price = £1.75

Amlodipine with olmesartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, amlodipine p. 148, olmesartan medoxomil p. 160.

**INDICATIONS AND DOSE**

Hypertension in patients stabilised on the individual components in the same proportions

**BY MOUTH**

- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Sevikar (Daichi Sankyo UK Ltd)

  | Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 20 mg |
  | Sevikar 20mg/5mg tablets | 28 tablet P trom £16.95

  | Amlodipine (as Amlodipine besilate) 10 mg, Olmesartan medoxomil 40 mg |
  | Sevikar 40mg/10mg tablets | 28 tablet P trom £16.95

  | Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 40 mg |
  | Sevikar 40mg/5mg tablets | 28 tablet P trom £16.95

Amlodipine with hydrochlorothiazide and olmesartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, amlodipine p. 148, olmesartan medoxomil, hydrochlorothiazide p. 160.

**INDICATIONS AND DOSE**

Hypertension in patients stabilised on the individual components in the same proportions, or for hypertension not adequately controlled with olmesartan and amlodipine

**BY MOUTH**

- Adult: (consult product literature)
136 Blood pressure conditions

Hydrochlorothiazide with olmesartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, olmesartan medoxomil p. 135, hydrochlorothiazide p. 160.

INDICATIONS AND DOSE

Hypertension not adequately controlled with olmesartan alone

BY MOUTH

Adult: (consult product literature)

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Olmec Plus (Daichi Sankyo UK Ltd)
  Hydrochlorothiazide 12.5 mg, Olmesartan medoxomil
  20 mg Olmec Plus 20mg/12.5mg tablets [28 tablet £12.95 DT price = £12.95
  Hydrochlorothiazide 25 mg, Olmesartan medoxomil
  20 mg Olmec Plus 20mg/25mg tablets [28 tablet £12.95 DT price = £12.95
  Hydrochlorothiazide 12.5 mg, Olmesartan medoxomil
  40 mg Olmec Plus 40mg/12.5mg tablets [28 tablet £17.50 DT price = £17.50

Telmisartan

INDICATIONS AND DOSE

Hypertension

BY MOUTH

Adult: Initially 20–40 mg once daily for at least 4 weeks, increased if necessary up to 80 mg once daily

Prevention of cardiovascular events in patients with established atherosclerotic cardiovascular disease, or type 2 diabetes mellitus with target-organ damage

BY MOUTH

Adult: 80 mg once daily

- SIDE-EFFECTS

  - Common or very common Arthralgia - back pain - chest pain - eczema - gastro-intestinal disturbances - influenza-like symptoms - leg cramps - myalgia - pharyngitis - sinusitis - urinary-tract infection
  - Uncommon Abnormal vision - anxiety - dry mouth - flatulence - increased sweating - tendinitis-like symptoms - vertigo
  - Rare Blood disorders - bradycardia - depression - dyspepsia - eosinophilia - increase in uric acid - insomnia - pruritus - rash - tachycardia
  - Frequency not known Asthenia - syncope

- HEPATIC IMPAIRMENT

20–40 mg once daily in mild or moderate impairment. Avoid in severe impairment or biliary obstruction.

- RENAL IMPAIRMENT

Manufacturer advises initial dose of 20 mg once daily in severe impairment.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- TELMISARTAN (Non-proprietary)
  Telmisartan 20 mg Telmisartan 20mg tablets [28 tablet £1.35–£12.93 DT price = £1.49
  Telmisartan 40 mg Telmisartan 40mg tablets [28 tablet £1.35–£12.93 DT price = £1.49
  Telmisartan 80 mg Telmisartan 80mg tablets [28 tablet £1.98–£16.15 DT price = £1.98
  Micardis (Boehringer Ingelheim Ltd)
  Telmisartan 20 mg Micardis 20mg tablets [28 tablet £11.10 DT price = £1.44

Hydrochlorothiazide with telmisartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, telmisartan above, hydrochlorothiazide p. 160.

INDICATIONS AND DOSE

Hypertension not adequately controlled by telmisartan alone

BY MOUTH

Adult: (consult product literature)

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- HYDROCHLOROTHIAZIDE WITH TELMISARTAN (Non-proprietary)
  Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg Telmisartan 40mg / Hydrochlorothiazide 12.5mg tablets [28 tablet £13.61 DT price = £13.61
  Hydrochlorothiazide 25 mg, Telmisartan 80 mg Telmisartan 80mg / Hydrochlorothiazide 25mg tablets [28 tablet £16.15–£17.00 DT price = £17.00
  Hydrochlorothiazide 12.5 mg, Telmisartan 80 mg Telmisartan 80mg / Hydrochlorothiazide 12.5mg tablets [28 tablet £16.15–£17.00 DT price = £17.00
  Actelsar HCT (Actavis UK Ltd)
  Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg Actelsar HCT 40mg/12.5mg tablets [28 tablet £13.61 DT price = £13.61
  Hydrochlorothiazide 25 mg, Telmisartan 80 mg Actelsar HCT 80mg/25mg tablets [28 tablet £17.00 DT price = £17.00
  Hydrochlorothiazide 12.5 mg, Telmisartan 80 mg Actelsar HCT 80mg/12.5mg tablets [28 tablet £17.00 DT price = £17.00
  MicardisPlus (Boehringer Ingelheim Ltd)
  Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg MicardisPlus 40mg/12.5mg tablets [28 tablet £13.61 DT price = £13.61
  Hydrochlorothiazide 25 mg, Telmisartan 80 mg MicardisPlus 80mg/25mg tablets [28 tablet £17.00 DT price = £17.00
  Toluna (Consilient Health Ltd)
  Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg Toluna 40mg/12.5mg tablets [28 tablet £13.61 DT price = £13.61
  Hydrochlorothiazide 25 mg, Telmisartan 80 mg Toluna 80mg/25mg tablets [28 tablet £17.00 DT price = £17.00

Valsartan

INDICATIONS AND DOSE

Hypertension

BY MOUTH

Adult: Initially 80 mg once daily, increased if necessary up to 320 mg daily, doses to be increased at intervals of 4 weeks

Hypertension with intravascular volume depletion

BY MOUTH

Adult: Initially 40 mg once daily, increased if necessary up to 320 mg daily, dose to be increased at intervals of 4 weeks
Heart failure when ACE inhibitors cannot be used, or in conjunction with an ACE inhibitor when a beta-blocker cannot be used | Heart failure, in conjunction with an ACE inhibitor when a beta-blocker cannot be used (under expert supervision)

**BY MOUTH**
- Adult: Initially 40 mg twice daily, increased to up to 160 mg twice daily, dose to be increased at intervals of at least 2 weeks

Myocardial infarction with left ventricular failure or left ventricular systolic dysfunction

**BY MOUTH**
- Adult: Initially 20 mg twice daily, increased if necessary up to 160 mg twice daily, dose to be increased over several weeks

**SIDE-EFFECTS**
- Common or very common Renal impairment
- Uncommon Acute renal failure - cough - fatigue - gastrointestinal disturbance - headache - syncope
- Frequency not known Hypersensitivity reactions - myalgia - neutropenia - pruritus - rash - serum sickness - thrombocytopenia - vasculitis

**HEPATIC IMPAIRMENT** Max. dose 80 mg daily in mild to moderate impairment. Avoid in severe hepatic impairment.

**RENAI IMPAIRMENT** Use with caution if eGFR less than 10 mL/minute/1.73 m² — no information available.

**CONTRA-INDICATIONS** Biliary cirrhosis - cholestasis

**ANTIHYPERTENSIVES (CENTRALLY ACTING)**

**Clonidine hydrochloride**

**INDICATIONS AND DOSE**

Hypertension not adequately controlled by valsartan alone

**BY MOUTH**
- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **HYDROCHLOROTHIAZIDE WITH VALSARTAN (Non-proprietary)**
  - Hydrochlorothiazide 12.5 mg, Valsartan 80 mg: Co-Diovan 80mg/12.5mg tablets | 28 tablet (POM) £13.97 DT price = £8.47
  - Hydrochlorothiazide 25 mg, Valsartan 160 mg: Co-Diovan 160mg/25mg tablets | 28 tablet DT price = £18.41 DT price = £11.21
  - Hydrochlorothiazide 12.5 mg, Valsartan 160 mg: Co-Diovan 160mg/12.5mg tablets | 28 tablet DT price = £18.41 DT price = £2.52

- **Co-Diovan (Novartis Pharmaceuticals UK Ltd)**
  - Hydrochlorothiazide 12.5 mg, Valsartan 80 mg: Co-Diovan 80mg/12.5mg tablets | 28 tablet (POM) £13.97 DT price = £8.47
  - Hydrochlorothiazide 25 mg, Valsartan 160 mg: Co-Diovan 160mg/25mg tablets | 28 tablet DT price = £18.41 DT price = £11.21
  - Hydrochlorothiazide 12.5 mg, Valsartan 160 mg: Co-Diovan 160mg/12.5mg tablets | 28 tablet DT price = £18.41 DT price = £2.52

**LENSAL IMPAIRMENT** Use with caution in severe impairment—reduce initial dose and increase gradually.

- **Common or very common** Constipation - depression - dizziness - drowsiness - dry mouth - headache - malaise - nausea - postural hypotension - salivary gland pain - sexual dysfunction - sleep disturbances - vomiting
- **Uncommon** Bradycardia - delusion - hallucination - paraesthesia - pruritus - rash - Raynaud’s syndrome - urticaria
- **Rare** Alopecia - AV block - colonic pseudo-obstruction - decreased lacrimation - gynaecomastia - nasal dryness
- **Frequency not known** Bradyarrhythmia - confusion - fluid retention - hepatitis - impaired visual accommodation
- **PREGNANCY** May lower fetal heart rate. Avoid oral use unless potential benefit outweighs risk. Avoid using injection.
- **BREAST FEEDING** Avoid—present in milk.

**CONTRA-INDICATIONS** Severe bradyarrhythmia secondary to second- or third-degree AV block or sick sinus syndrome

**CAUTIONS** Cerebrovascular disease - constipation - heart failure - history of depression - mild to moderate bradycardia - polynuropathy - Raynaud’s syndrome or other occlusive peripheral vascular disease

**INTERACTIONS** Appendix 1 (clonidine).

**SIDE-EFFECTS**
- **Common or very common** Constipation - depression - dizziness - drowsiness - dry mouth - headache - malaise - nausea - postural hypotension - salivary gland pain - sexual dysfunction - sleep disturbances - vomiting
- **Uncommon** Bradycardia - delusion - hallucination - paraesthesia - pruritus - rash - Raynaud’s syndrome - urticaria

**LUNG**

**IMMUNOSUPPRESSANTS**

**ANTIHYPERTENSIVES (CENTRALLY ACTING)**

**Clonidine hydrochloride**

**INDICATIONS AND DOSE**

Hypertension

**BY MOUTH**
- Adult: Initially 50-100 micrograms 3 times a day, increase initial dose every second or third day, usual maximum dose 1.2 mg daily

Prevention of recurrent migraine | Prevention of vascular headache

**BY MOUTH**
- Adult: Initially 50 micrograms twice daily for 2 weeks, then increased if necessary to 75 micrograms twice daily

**INDICATIONS AND DOSE**

Hypertension not adequately controlled by valsartan alone

**BY MOUTH**
- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **HYDROCHLOROTHIAZIDE WITH VALSARTAN (Non-proprietary)**
  - Hydrochlorothiazide 12.5 mg, Valsartan 80 mg: Co-Diovan 80mg/12.5mg tablets | 28 tablet (POM) £13.97 DT price = £8.47
  - Hydrochlorothiazide 25 mg, Valsartan 160 mg: Co-Diovan 160mg/25mg tablets | 28 tablet DT price = £18.41 DT price = £11.21
  - Hydrochlorothiazide 12.5 mg, Valsartan 160 mg: Co-Diovan 160mg/12.5mg tablets | 28 tablet DT price = £18.41 DT price = £2.52

- **Co-Diovan (Novartis Pharmaceuticals UK Ltd)**
  - Hydrochlorothiazide 12.5 mg, Valsartan 80 mg: Co-Diovan 80mg/12.5mg tablets | 28 tablet (POM) £13.97 DT price = £8.47
  - Hydrochlorothiazide 25 mg, Valsartan 160 mg: Co-Diovan 160mg/25mg tablets | 28 tablet DT price = £18.41 DT price = £11.21
  - Hydrochlorothiazide 12.5 mg, Valsartan 160 mg: Co-Diovan 160mg/12.5mg tablets | 28 tablet DT price = £18.41 DT price = £2.52

**CONTRA-INDICATIONS**

Severe bradyarrhythmia secondary to second- or third-degree AV block or sick sinus syndrome

**CAUTIONS**

Cerebrovascular disease - constipation - heart failure - history of depression - mild to moderate bradycardia - polynuropathy - Raynaud’s syndrome or other occlusive peripheral vascular disease

**INTERACTIONS** Appendix 1 (clonidine).

**SIDE-EFFECTS**

- **Common or very common**
  - Constipation - depression - dizziness - drowsiness - dry mouth - headache - malaise - nausea - postural hypotension - salivary gland pain - sexual dysfunction - sleep disturbances - vomiting

- **Uncommon**
  - Bradycardia - delusion - hallucination - paraesthesia - pruritus - rash - Raynaud’s syndrome - urticaria

- **Rare**
  - Alopecia - AV block - colonic pseudo-obstruction - decreased lacrimation - gynaecomastia - nasal dryness

- **Frequency not known**
  - Bradycardia - confusion - fluid retention - hepatitis - impaired visual accommodation

- **PREGNANCY**
  - May lower fetal heart rate. Avoid oral use unless potential benefit outweighs risk. Avoid using injection.

- **BREAST FEEDING**
  - Avoid—present in milk.

**RENAI IMPAIRMENT** Use with caution in severe impairment—reduce initial dose and increase gradually.
Cardiovascular system

INDICATIONS AND DOSE

Methyldopa

**INDICATIONS AND DOSE**

<table>
<thead>
<tr>
<th>Hypertension</th>
<th><strong>BY MOUTH</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: Initially 250 mg 2–3 times a day, dose should be increased gradually at intervals of at least 2 days; maximum 3 g per day</td>
<td>Elderly: Initially 125 mg twice daily, dose should be increased gradually; maximum 2 g per day</td>
</tr>
</tbody>
</table>

**SIDE-EFFECTS**


**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects are minimised if the daily dose is kept below 2 g.

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Amount too small to be harmful.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in history of liver disease. AVOID in active liver disease.

**Renal Impairment** Increased sensitivity to hypotensive and sedative effect. Start with small dose.

**MONITORING REQUIREMENTS** Monitor blood counts and liver-function before treatment and at intervals during first 6–12 weeks or if unexplained fever occurs.

**EFFECT ON LABORATORY TESTS** Interference with laboratory tests. Positive direct Coombs’ test in up to 20% of patients (may affect blood cross-matching).

**PATIENT AND CARER ADVICE**

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, solution for injection, oral suspension, solution for infusion, oral solution, transdermal patch.

**Tablet CAUTIONARY AND ADVISORY LABELS 3, 8**

- Methyldopa anhydrous 125 mg Methyldopa 125mg tablets | 56 tablet | £0.75–£12.10 DT price = £11.16
- Methyldopa anhydrous 250 mg Methyldopa 250mg tablets | 56 tablet | £13.25 DT price = £6.33
- Methyldopa anhydrous 500 mg Methyldopa 500mg tablets | 56 tablet | £18.05 DT price = £3.94
- Aldomet (Aspen Pharma Trading Ltd) Methyldopa anhydrous 250 mg Aldomet 250mg tablets | 60 tablet | £6.15
- Methyldopa anhydrous 500 mg Aldomet 500mg tablets | 30 tablet | £4.55

**Moxonidine**

**INDICATIONS AND DOSE**

Mild to moderate essential hypertension

**BY MOUTH**

- Adult: 200 micrograms once daily for 3 weeks, dose to be increased in the morning, then increased if necessary to 400 micrograms daily in 1–2 divided doses (max. per dose 400 micrograms); maximum 600 micrograms per day in 2 divided doses

**CONTRA-INDICATIONS**

- Bradycardia - conduction disorders - second- or third-degree AV block - severe heart failure - sick sinus syndrome - sino-atrial block

**CAUTIONS**

- First-degree AV block - moderate heart failure - severe coronary artery disease - unstable angina

**INTERACTIONS** → Appendix 1 (moxonidine).

**SIDE-EFFECTS**

- Common or very common Back pain - diarrhoea - dizziness - dry mouth - dyspepsia - insomnia - nausea - pruritus - rash - somnolence - vomiting
- Uncommon Angioedema - bradycardia - neck pain - nervousness - oedema - tinnitus

**PREGNANCY** Manufacturer advises avoidance—no information available.

**BREAST FEEDING** Present in milk—manufacturer advises avoidance.

**RENAL IMPAIRMENT** Max. single dose 200 micrograms and max. daily dose 400 micrograms if eGFR 30–60 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

**TREATMENT CESSION** Avoid abrupt withdrawal (if concomitant treatment with beta-blocker has to be stopped, discontinue beta-blocker first, then moxonidine after a few days).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet CAUTIONARY AND ADVISORY LABELS 3**

- **Moxonidine (Non-proprietary)**

  Moxonidine 200 microgram Moxonidine 200 microgram tablets | 28 tablet | £10.40 DT price = £2.20
  Moxonidine 300 microgram Moxonidine 300 microgram tablets | 28 tablet | £13.85 DT price = £2.26
  Moxonidine 400 microgram Moxonidine 400 microgram tablets | 28 tablet | £14.24 DT price = £2.38
Beta-adrenoceptor blocking drugs

Beta-adrenoceptor blocking drugs (beta-blockers) block the beta-adrenoceptors in the heart, peripheral vasculature, bronchi, pancreas, and liver.

Many beta-blockers are now available and in general they are all equally effective. There are, however, differences between them, which may affect choice in treating particular diseases or individual patients.

Intrinsic sympathomimetic activity (ISA, partial agonist activity) represents the capacity of beta-blockers to stimulate as well as to block adrenergic receptors. Oxprenolol hydrochloride p. 145, pindolol p. 146, acebutolol p. 141, and celiprolol hydrochloride p. 143 have intrinsic sympathomimetic activity; they tend to cause less bradycardia than the other beta-blockers and may also cause less coldness of the extremities.

Some beta-blockers are lipid soluble and some are water soluble. Atenolol p. 141, celiprolol hydrochloride, nadolol p. 145, and sotalol hydrochloride p. 93 are the most water-soluble; they are less likely to enter the brain, and may therefore cause less sleep disturbance and nightmares. Water-soluble beta-blockers are excreted by the kidneys and dosage reduction is often necessary in renal impairment.

Beta-blockers with a relatively short duration of action have to be given two or three times daily. Many of these are, however, available in modified-release formulations so that administration once daily is adequate for hypertension. For angina twice-daily treatment may sometimes be needed even with a modified-release formulation. Some beta-blockers, such as atenolol, bisoprolol fumarate p. 142, celiprolol hydrochloride, and nadolol, have an intrinsically longer duration of action and need to be given only once daily.

Beta-blockers slow the heart and can depress the myocardium; they are contra-indicated in patients with second- or third-degree heart block. Beta-blockers should also be avoided in patients with worsening unstable heart failure; care is required when initiating a beta-blocker in those with stable heart failure.

Labeltolol hydrochloride p. 143, celiprolol hydrochloride, carvedilol p. 142, and nebivolol p. 145 are beta-blockers that have, in addition, an arteriolar vasodilating action, by diverse mechanisms, and thus lower peripheral resistance. There is no evidence that these drugs have important advantages over other beta-blockers in the treatment of hypertension.

Beta-blockers can precipitate bronchospasm and should therefore usually be avoided in patients with a history of asthma. When there is no suitable alternative, it may be necessary for a patient with well-controlled asthma, or chronic obstructive pulmonary disease (without significant reversible airways obstruction), to receive treatment with a beta-blocker for a co-existing condition (e.g. heart failure or following myocardial infarction). In this situation, a cardioselective beta-blocker should be selected and initiated at a low dose by a specialist; the patient should be closely monitored for adverse effects. Atenolol, bisoprolol fumarate, metoprolol tartrate p. 144, nebivolol, and (to a lesser extent) acebutolol, have less effect on the beta-(bronchial) receptors and are, therefore, relatively cardioselective, but they are not cardioselective. They have a lesser effect on airways resistance but are not free of this side-effect.

Beta-blockers are also associated with fatigue, coldness of the extremities (may be less common with those with ISA), and sleep disturbances with nightmares (may be less common with the water-soluble beta-blockers).

Beta-blockers can affect carbohydrate metabolism, causing hypoglycaemia or hyperglycaemia in patients with or without diabetes; they can also interfere with metabolic and autonomic responses to hypoglycaemia, thereby masking symptoms such as tachycardia. However, beta-blockers are not contra-indicated in diabetes, although the cardioselective beta-blockers may be preferred. Beta-blockers should be avoided altogether in those with frequent episodes of hypoglycaemia. Beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or in those at high risk of developing diabetes.

Hypertension

The mode of action of beta-blockers in hypertension is not understood, but they reduce cardiac output, alter baroceptor reflex sensitivity, and block peripheral adrenoceptors. Some beta-blockers depress plasma renin secretion. It is possible that a central effect may also partly explain their mode of action.

Beta-blockers are effective for reducing blood pressure but other antihypertensives are usually more effective for reducing the incidence of stroke, myocardial infarction, and cardiovascular mortality, especially in the elderly. Other antihypertensives are therefore preferred for routine initial treatment of uncomplicated hypertension.

In general, the dose of a beta-blocker does not have to be high.

Beta-blockers can be used to control the pulse rate in patients with phaeochromocytoma. However, they should never be used alone as beta-blockade without concurrent alpha-blockade may lead to a hypertensive crisis. For this reason phenoxybenzamine hydrochloride p. 161 should always be used together with the beta-blocker.

Angina

By reducing cardiac work beta-blockers improve exercise tolerance and relieve symptoms in patients with angina (see management of stable angina and acute coronary syndromes for further details). As with hypertension there is no good evidence of the superiority of any one drug, although occasionally a patient will respond better to one beta-blocker than to another. There is some evidence that sudden withdrawal may cause an exacerbation of angina and therefore gradual reduction of dose is preferable when beta-blockers are to be stopped. There is a risk of precipitating heart failure when beta-blockers and verapamil are used together in established ischaemic heart disease.

Myocardial infarction

For specific comments see management of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction.

Several studies have shown that some beta-blockers can reduce the recurrence rate of myocardial infarction. However, uncontrolled heart failure, hypotension, bradycardias, and obstructive airways disease render beta-blockers unsuitable in some patients following a myocardial infarction. Atenolol p. 141 and metoprolol tartrate p. 144 may reduce early mortality after intravenous and subsequent oral administration in the acute phase, while acebutolol p. 141, metoprolol tartrate, propranolol hydrochloride p. 146, and timolol maleate p. 147 have protective value when started in the early convalescent phase. The evidence relating to other beta-blockers is less
Cardiovascular system

Heart failure; nebivolol p. may induce torsade de pointes in susceptible patients.

Coronary disease or cardiomyopathy. However, it may be more effective than lidocaine in the termination of non-sustained ventricular tachycardia. It has been shown to be cardioselective, should usually be avoided in patients with a history of obstructive airway disease.

Arrhythmias

Beta-blockers act as anti-arrhythmic drugs principally by attenuating the effects of the sympathetic system on automaticity and conductivity within the heart. They can be used in conjunction with digoxin to control the ventricular response in atrial fibrillation, especially in patients with thyrotoxicosis. Beta-blockers are also useful in the management of supraventricular tachycardias, and are used to control those following myocardial infarction.

Esmolol hydrochloride p. 143 is a relatively cardioselective beta-blocker with a very short duration of action, used intravenously for the short-term treatment of supraventricular arrhythmias, sinus tachycardia, or hypertension, particularly in the peri-operative period. It may also be used in other situations, such as acute myocardial infarction, when sustained beta-blockade might be hazardous.

Sotalol hydrochloride p. 93, a non-cardioselective beta-blocker with additional class III anti-arrhythmic activity, is used for prophylaxis in paroxysmal supraventricular arrhythmias. It also suppresses ventricular ectopic beats and non-sustained ventricular tachycardia. It has been shown to be more effective than lidocaine in the termination of spontaneous sustained ventricular tachycardia due to coronary disease or cardiomyopathy. However, it may induce torsade de pointes in susceptible patients.

Heart failure

Beta-blockers may produce benefit in heart failure by blocking sympathetic activity. Bisoprolol fumarate p. 142 and carvedilol p. 142 reduce mortality in any grade of stable heart failure; nebivolol p. 145 is licensed for stable mild to moderate heart failure in patients over 70 years. Treatment should be initiated by those experienced in the management of heart failure.

Thyrotoxicosis

Beta-blockers are used in pre-operative preparation for thyroidectomy. Administration of propranolol hydrochloride p. 146 can reverse clinical symptoms of thyrotoxicosis within 4 days. Routine tests of increased thyroid function remain unaltered. The thyroid gland is rendered less vascular thus making surgery easier.

Other uses

Beta-blockers have been used to alleviate some symptoms of anxiety; probably patients with palpitation, tremor, and tachycardia respond best. Beta-blockers are also used in the prophylaxis of migraine. Betaxolol p. 963, carteolol hydrochloride p. 963, levobunolol hydrochloride p. 964, and timolol maleate p. 965 are used topically in glaucoma.

beta-adrenoceptor blockers (systemic)

CONTRA-INDICATIONS Asthma, cardiogenic shock, hypotension, marked bradycardia, metabolic acidosis, phaeochromocytoma (apart from specific use with alpha-blockers); Prinzmetal’s angina - second-degree AV block severe peripheral arterial disease, sick sinus syndrome, third-degree AV block - uncontrolled heart failure

CONTRA-INDICATIONS, FURTHER INFORMATION

Bronchospasm Beta-blockers, including those considered to be cardioselective, should usually be avoided in patients with a history of asthma, bronchospasm or a history of obstructive airways disease. However, when there is no alternative, a cardioselective beta-blocker can be given to these patients with caution and under specialist supervision. In such cases the risk of inducing bronchospasm should be appreciated and appropriate precautions taken.

CAUTIONS Diabetes - first-degree AV block - history of obstructive airways disease (introduce cautiously); myasthenia gravis - portal hypertension (risk of deterioration in liver function); psoriasis - symptoms of hypoglycaemia may be masked - symptoms of thyrotoxicosis may be masked

INTERACTIONS → Appendix 1 (beta-blockers).

Verapamil and beta-blockers Verapamil injection should not be given to patients recently treated with beta-blockers because of the risk of hypotension and asystole. The suggestion that when verapamil injection has been given first, an interval of 30 minutes before giving a beta-blocker is sufficient has not been confirmed. It may also be hazardous to give verapamil and a beta-blocker together by mouth (should only be contemplated if myocardial function well preserved). There is a risk of precipitating heart failure when beta-blockers and verapamil are used together in established ischaemic heart disease.

SIDE-EFFECTS

Rare Dry eyes (reversible on withdrawal) - rashes (reversible on withdrawal)

Frequency not known Alopecia - bradycardia - bronchospasm - coldness of the extremities - conduction disorders - dizziness - dyspnoea - exacerbation of intermittent claudication - exacerbation of psoriasis - exacerbation of Raynaud’s phenomenon - fatigue - gastrointestinal disturbances - headache - heart failure - hyperglycaemia (in patients with or without diabetes) - hypoglycaemia (in patients with or without diabetes) - hypotension - paraesthesia - peripheral vasoconstriction - psychosis - purpura - sexual dysfunction - sleep disturbances (with nightmares) - symptoms of hypoglycaemia masked - thrombocytopenia - vertigo - visual disturbances

SIDE-EFFECTS, FURTHER INFORMATION

Bradycardia With administration by intravenous injection, excessive bradycardia can occur and may be countered with intravenous injection of atropine sulfate. Overdose Therapeutic overdosages with beta-blockers may cause lightheadedness, dizziness, and possibly syncope as a result of bradycardia and hypotension; heart failure may be precipitated or exacerbated. For details on the management of poisoning, see Beta-blockers, under Emergency treatment of poisoning p. 1123

ALLERGY AND CROSS-SENSITIVITY Caution is advised in patients with a history of hypersensitivity—may increase sensitivity to allergens and result in more serious hypersensitivity response. Furthermore beta-adrenoceptor blockers may reduce response to adrenaline (epinephrine).

PREGNANCY Beta-blockers may cause intra-uterine growth restriction, neonatal hypoglycaemia, and bradycardia; the risk is greater in severe hypertension.

BREAST FEEDING With systemic use in the mother, infants should be monitored as there is a risk of possible toxicity due to beta-blockade. However, the amount of most beta-blockers present in milk is too small to affect infants.

MONITORING REQUIREMENTS Monitor lung function (in patients with a history of obstructive airway disease).

TREATMENT CESSION Avoid abrupt withdrawal especially in ischaemic heart disease. Sudden cessation of a beta-blocker can cause a rebound worsening of myocardial ischaemia and therefore gradual reduction of dose is preferable when beta-blockers are to be stopped.
Acebutolol

INDICATIONS AND DOSE

Hypertension
BY MOUTH
- Adult: Initially 400 mg daily for 2 weeks, alternatively initially 200 mg twice daily for 2 weeks, then increased if necessary to 400 mg twice daily; maximum 1.2 g per day.

Arrhythmias
BY MOUTH
- Adult: Initially 400 mg daily, alternatively initially 200 mg twice daily; maximum 1.2 g per day

Angina
BY MOUTH
- Adult: Initially 400 mg daily, alternatively 200 mg twice daily; maximum 1.2 g per day

INDICATIONS AND DOSAGE

Acebutolol (as Acebutolol hydrochloride) 400 mg
ACEBUTOLOL (Non-proprietary)
Sectral
ACEBUTOLOL (Non-proprietary)
Tablet
8
Tablet
containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution and injection ampoules.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 8
- ACEBUTOLOL (Non-proprietary)
  - Acebutolol (as Acebutolol hydrochloride) 400 mg
  - Sectral (Sanofi)
  - Acebutolol (as Acebutolol hydrochloride) 400 mg
  - Sectral 400mg tablets | 28 tablet PIP 18.62 DT price = 18.62

Capsule
CAUTIONARY AND ADVISORY LABELS 8
- ACEBUTOLOL (Non-proprietary)
  - Acebutolol (as Acebutolol hydrochloride) 100 mg
  - Sectral (Sanofi)
  - Acebutolol (as Acebutolol hydrochloride) 100 mg
  - Sectral 100mg capsules | 28 capsule PIP 19.18 DT price = 19.18

Migraine prophylaxis
BY MOUTH
- Adult: 150 micrograms/kg every 12 hours if required, to be given over 20 minutes

Early intervention within 12 hours of myocardial infarction initially by intravenous injection
- Adult: Initially 5 mg, to be given over 5 minutes, followed by (by mouth) 50 mg after 15 minutes, then (by mouth) 50 mg after 12 hours, then (by mouth) 100 mg daily

Breastfeeding

Acebutolol and water soluble beta-blockers are present in breast milk in greater amounts than other beta-blockers.

RENAL IMPAIRMENT
- Halve dose if eGFR 25–50 mg/L/minute/1.73 m²; use quarter dose if eGFR less than 25 mL/minute/1.73 m²; do not administer more than once daily.

Breastfeeding

Acebutolol and water soluble beta-blockers are present in breast milk in greater amounts than other beta-blockers.

RENAL IMPAIRMENT
- With oral use Max. 50 mg daily if eGFR 15–35 mL/minute/1.73 m²; max. 25 mg daily or 50 mg on alternate days if eGFR less than 15 mL/minute/1.73 m².
- With intravenous use Max. 10 mg on alternate days if eGFR 15–35 mL/minute/1.73 m²; max. 10 mg every 4 days if eGFR less than 15 mL/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION
For intravenous infusion (Tenormin®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Suggested infusion time 20 minutes.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution and injection ampoules.

Tablet
CAUTIONARY AND ADVISORY LABELS 8
- ATENOLOL (Non-proprietary)
  - Atenolol 25 mg
  - Atenolol 50 mg
  - Atenolol 100 mg
  - Tenormin (AstraZeneca UK Ltd)
  - Tenormin 50 mg
  - Tenormin 100 mg
  - Tenormin 150 mg
  - Tenormin L5 50mg tablets | 28 tablet PIP 5.11 DT price = 5.11
  - Tenormin 100 mg
  - Tenormin 150 mg
  - Tenormin L5 100mg tablets | 28 tablet PIP 6.49 DT price = 6.99

Oral solution
- ATENOLOL (Non-proprietary)
  - Atenolol 5 mg
  - Tenormin 5mg/5ml solution for injection ampoules | 10 ampoule PIP £34.45 (Hospital only)

Solution for injection
- Tenormin (AstraZeneca UK Ltd)
  - Atenolol 500 microgram per 1 ml

Atenolol with nifedipine

The properties listed below are those particular to the combination only. For the properties of the components please consider, atenolol above, nifedipine p. 154.
Cardiovascular system

RENAL IMPAIRMENT

HEPATIC IMPAIRMENT

Uncommon

SIDE-EFFECTS

CAUTIONS

PRESCRIBING AND DISPENSING INFORMATION

Only indicated when calcium-channel blocker or beta-blocker alone proves inadequate.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS

8, 25

- Beta-Aralat (Bayer Plc)
- Tenif (AstraZeneca UK Ltd)

28 tablet $32.15 DT price = £1.12

Bisoprolol fumarate 2.5 mg Cardiacor 2.5mg tablets

28 tablet $32.15 DT price = £1.12

Bisoprolol fumarate 3.75 mg Cardiacor 3.75mg tablets

28 tablet $5.90 DT price = £1.72

Bisoprolol fumarate 5 mg Cardiacor 5mg tablets

28 tablet $5.90 DT price = £0.98

Bisoprolol fumarate 7.5 mg Cardiacor 7.5mg tablets

28 tablet $5.90 DT price = £4.32

Bisoprolol fumarate 10 mg Cardiacor 10mg tablets

28 tablet $5.90 DT price = £1.02

Congescor (Tillomed Laboratories Ltd)

Bisoprolol fumarate 1.25 mg Congescor 1.25mg tablets

28 tablet $5.90 DT price = £1.21

Bisoprolol fumarate 2.5 mg Congescor 2.5mg tablets

28 tablet $3.90 DT price = £1.12

Carvedilol

INDICATIONS AND DOSE

Hypertension

BY MOUTH

- Adult: Initially 12.5 mg once daily for 2 days, then increased to 25 mg once daily; increased if necessary up to 50 mg daily, dose to be increased at intervals of at least 2 weeks and can be given as a single dose or in divided doses
- Elderly: Initially 12.5 mg daily, initial dose may provide satisfactory control

Angina

BY MOUTH

- Adult: Initially 12.5 mg twice daily for 2 days, then increased to 25 mg twice daily

Adjunct to diuretics, digoxin, or ACE inhibitors in symptomatic chronic heart failure

BY MOUTH

- Adult: Initially 3.125 mg twice daily, dose to be taken with food, then increased to 6.25 mg twice daily, then increased to 12.5 mg twice daily, then increased to 25 mg twice daily, dose should be increased at intervals of at least 2 weeks up to the highest tolerated dose, max. 25 mg twice daily in patients with severe heart failure or body-weight less than 85 kg; max. 50 mg twice daily in patients over 85 kg

CONTRA-INDICATIONS

Acute or decompensated heart failure requiring intravenous inotropes - sino–atrial block

CAUTIONS

Ensure heart failure not worsening before increasing dose

SIDE-EFFECTS

- Uncommon Cramp - depression - muscle weakness
- Rare Hearing impairment - hypertriglyceridaemia - syncope
- Very rare Conjunctivitis

HEPATIC IMPAIRMENT Max. 10 mg daily in severe impairment.

RENAL IMPAIRMENT Reduce dose if eGFR less than 20 mL/minute/1.73 m² (max. 10 mg daily).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet

CAUTIONARY AND ADVISORY LABELS

8

- Bisoprolol Fumarate (Non-proprietary)
  - Bisoprolol fumarate 1.25 mg Bisoprolol 1.25mg tablets
    - 28 tablet $7.43 DT price = £1.21
  - Bisoprolol fumarate 2.5 mg Bisoprolol 2.5mg tablets
    - 28 tablet $4.39 DT price = £1.12
  - Bisoprolol fumarate 3.75 mg Bisoprol 3.75mg tablets
    - 28 tablet $6.50 DT price = £1.72
  - Bisoprolol fumarate 5 mg Bisoprol 5mg tablets
    - 28 tablet $5.89 DT price = £0.98
  - Bisoprolol fumarate 7.5 mg Bisoprol 7.5mg tablets
    - 28 tablet $5.89 DT price = £4.32
  - Bisoprolol fumarate 10 mg Bisoprol 10mg tablets
    - 28 tablet $5.89 DT price = £1.02
- Cardicor (Merck Serono Ltd)
  - Bisoprolol fumarate 1.25 mg Cardicor 1.25mg tablets
    - 28 tablet $2.35 DT price = £1.21

Bisoprolol fumarate 2.5 mg Cardicor 2.5mg tablets

28 tablet $2.35 DT price = £1.12

Bisoprolol fumarate 3.75 mg Cardicor 3.75mg tablets

28 tablet $4.90 DT price = £1.72

Bisoprolol fumarate 5 mg Cardicor 5mg tablets

28 tablet $5.90 DT price = £0.98

Bisoprolol fumarate 7.5 mg Cardicor 7.5mg tablets

28 tablet $5.90 DT price = £4.32

Bisoprolol fumarate 10 mg Cardicor 10mg tablets

28 tablet $5.90 DT price = £1.02

Carvedilol

INDICATIONS AND DOSE

Hypertension

BY MOUTH

- Adult: 5–10 mg once daily; maximum 20 mg per day

Adjunct in heart failure

BY MOUTH

- Adult: Initially 1.25 mg once daily for 1 week, dose to be taken in the morning, then increased if tolerated to 2.5 mg once daily for 1 week, then increased if tolerated to 3.75 mg once daily for 1 week, then increased if tolerated to 5 mg once daily for 4 weeks, then increased if tolerated to 7.5 mg once daily for 4 weeks, then increased if tolerated to 10 mg once daily; maximum 10 mg per day

CONTRA-INDICATIONS

Acute or decompensated heart failure requiring intravenous inotropes - sino–atrial block

CAUTIONS

Ensure heart failure not worsening before increasing dose

SIDE-EFFECTS

- Rare Hearing impairment - hypertriglyceridaemia - syncope
- Very rare Conjunctivitis

HEPATIC IMPAIRMENT Max. 10 mg daily in severe impairment.

RENAL IMPAIRMENT Reduce dose if eGFR less than 20 mL/minute/1.73 m² (max. 10 mg daily).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension
**Celiprolol hydrochloride**

**INDICATIONS AND DOSE**

Mild to moderate hypertension

- Adult: 200 mg once daily, dose to be taken in the morning, then increased if necessary to 400 mg once daily

**SIDE-EFFECTS**

- Rare: Depression, pneumonitis
- Frequency not known: Hot flushes
- BREAST FEEDING: Manufacturers advise avoidance.
- HEPATIC IMPAIRMENT: Consider dose reduction.
- RENAL IMPAIRMENT: Reduce dose by half if eGFR is 15–40 mL/minute/1.73 m². Avoid if eGFR less than 15 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **CO-TENIDONE (Non-proprietary)**
  - Atenolol 50 mg, Chlortalidone 12.5 mg

**CAUTIONARY AND ADVISORY LABELS**

- **CO-TENIDONE (Non-proprietary)**
  - Atenolol 50 mg, Chlortalidone 12.5 mg

**Esmolol hydrochloride**

**INDICATIONS AND DOSE**

Short-term treatment of supraventricular arrhythmias (including atrial fibrillation, atrial flutter, sinus tachycardia) Tachycardia and hypertension in peri-operative period

**BY INTRAVENOUS INFUSION**

- Adult: 50–200 micrograms/kg/minute, consult product literature for details of dose titration and doses during peri-operative period

**SIDE-EFFECTS**

- Thrombophlebitis, venous irritation
- BREAST FEEDING: Manufacturer advises avoidance.
- RENAL IMPAIRMENT: Manufacturer advises caution.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Brevibloc** (Baxter Healthcare Ltd)
  - Esmolol hydrochloride 10 mg per 1 ml
  - Esmolol hydrochloride 10 mg per 1 ml
  - 2.5g/250ml infusion bags
  - 5 vial (£9.20)

**Solution for infusion**

- **Brevibloc** (Baxter Healthcare Ltd)
  - Esmolol hydrochloride 10 mg per 1 ml

**Labetalol hydrochloride**

**INDICATIONS AND DOSE**

Controlled hypotension in anaesthesia

- Adult: (consult product literature or local protocols)

**Hypertension of pregnancy**

- Adult: (consult product literature or local protocols)

**Hypertension following myocardial infarction**

- Adult: 15 mg/hour, then increased to up to 120 mg/hour, dose to be increased gradually continued

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **CO-TENIDONE (Non-proprietary)**
  - Atenolol 50 mg, Chlortalidone 12.5 mg

**CAUTIONARY AND ADVISORY LABELS**

- **CO-TENIDONE (Non-proprietary)**
  - Atenolol 50 mg, Chlortalidone 12.5 mg
Hypertensive emergencies

**BY INTRAVENOUS INJECTION**
- Adult: 50 mg, to be given over at least 1 minute, then 50 mg every 5 minutes if required until a satisfactory response occurs; maximum 200 mg per course

**BY INTRAVENOUS INFUSION**
- Adult: Initially 2 mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50–200 mg

**Hypertension**

**BY MOUTH**
- Adult: Initially 100 mg twice daily, dose to be increased at intervals of 14 days; usual dose 200 mg twice daily, increased if necessary up to 800 mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3–4 divided doses; maximum 2.4 g per day
- Elderly: Initially 50 mg twice daily, dose to be increased at intervals of 14 days; usual dose 200 mg twice daily, increased if necessary up to 800 mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3–4 divided doses; maximum 2.4 g per day

**BY INTRAVENOUS INJECTION**
- Adult: 50 mg, dose to be given over at least 1 minute, then 50 mg after 5 minutes if required; maximum 200 mg per course

**BY INTRAVENOUS INFUSION**
- Adult: Initially 2 mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50–200 mg

---

**Metoprolol tartrate**

**INDICATIONS AND DOSE**

**Hypertension**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: Initially 100 mg daily, increased if necessary to 200 mg daily in 1–2 divided doses, high doses are rarely required; maximum 400 mg per day

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- Adult: 200 mg once daily

**Angina**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: 50–100 mg 2–3 times a day

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- Adult: 200–400 mg daily

**Arrhythmias**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: Usual dose 50 mg 2–3 times a day, then increased if necessary up to 300 mg daily in divided doses

**BY INTRAVENOUS INJECTION**
- Adult: Up to 5 mg, dose to be given at a rate of 1–2 mg/minute, then up to 5 mg after 5 minutes if required, total dose of 10–15 mg

**Migraine prophylaxis**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: 100–200 mg daily in divided doses

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- Adult: 200 mg daily

**Hyperthyroidism (adjunct)**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: 50 mg 4 times a day

**In surgery**

**BY SLOW INTRAVENOUS INJECTION**
- Adult: Initially 2–4 mg, given at induction or to control arrhythmias developing during anaesthesia, then 2 mg, repeated if necessary; maximum 10 mg per course

**Early intervention within 12 hours of infarction**

**INITIALLY BY INTRAVENOUS INJECTION**
- Adult: Initially 5 mg every 2 minutes to a max. of 15 mg, followed after 15 minutes by (by mouth) 50 mg every 6 hours for 48 hours; (by mouth) maintenance 200 mg daily in divided doses

---

**HEPATIC IMPAIRMENT** Reduce dose in severe impairment.

---

**Cautionary and Advisory Labels**

**Labetalol hydrochloride (non-proprietary)**

<table>
<thead>
<tr>
<th>Drug Form</th>
<th>Trade Name</th>
<th>BNF Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet</td>
<td>Trandate</td>
<td>£15.00</td>
</tr>
<tr>
<td>Tablet</td>
<td>Trandate</td>
<td>£9.79</td>
</tr>
<tr>
<td>Tablet</td>
<td>Trandate</td>
<td>£7.41</td>
</tr>
<tr>
<td>Tablet</td>
<td>Trandate</td>
<td>£9.89</td>
</tr>
<tr>
<td>Tablet</td>
<td>Trandate</td>
<td>£24.76</td>
</tr>
<tr>
<td>Tablet</td>
<td>Trandate</td>
<td>£3.14</td>
</tr>
</tbody>
</table>

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

---

**Side-effects**

- **Rare** Lichenoid rash
- **Frequency not known** Difficulty in micturition, epigastric pain, liver damage, nausea, postural hypotension, vomiting, weakness

**Pregnancy**

The use of labetalol in maternal hypertension is not known to be harmful, except possibly in the first trimester. If labetalol is used close to delivery, infants should be monitored for signs of alpha-blockade (as well as beta blockage).

**Breast feeding**

Infants should be monitored as there is a risk of possible toxicity due to alpha-blockade (in addition to beta-blockade).

**Hepatic impairment**

Avoid—severe hepatocellular injury reported.

**Renal impairment**

Dose reduction may be required.

**Monitoring requirements**

Liver damage Severe hepatocellular damage reported after both short-term and long-term treatment. Appropriate laboratory testing needed at first symptom of liver dysfunction and if laboratory evidence of damage (or if jaundice) labetalol should be stopped and not restarted.

**Effect on laboratory tests**

Interferes with laboratory tests for catecholamines.

**Directions for administration**

Avoid upright position during and for 3 hours after intravenous administration. For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride and glucose. Dilute to a concentration of 1 mg/mL; suggested volume 200 mL; adjust rate with in-line burette.

---

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.
### Nebivolol

**INDICATIONS AND DOSE**

**Essential hypertension**

**BY MOUTH**

- Adult: 5 mg daily
- Elderly: Initially 2.5 mg daily, then increased if necessary to 5 mg daily

**Hypertension in patient with renal impairment**

**BY MOUTH**

- Adult: Initially 2.5 mg once daily, then increased if necessary to 5 mg once daily

**Adjunct in stable mild to moderate heart failure**

**BY MOUTH**

- Adult 70 years and over: Initially 1.25 mg once daily for 1–2 weeks, then increased if tolerated to 2.5 mg once daily for 1–2 weeks, then increased if tolerated to 5 mg once daily for 1–2 weeks, then increased if tolerated to 10 mg once daily

### Oxprenolol hydrochloride

**INDICATIONS AND DOSE**

**Hypertension**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: 80–160 mg daily in 2–3 divided doses, then increased if necessary up to 320 mg daily

**Angina**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: 80–160 mg daily in 2–3 divided doses; maximum 320 mg per day

**Arrhythmias**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: 40–240 mg daily in 2–3 divided doses; maximum 240 mg per day

**Anxiety symptoms (short-term use)**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: 40–80 mg daily in 1–2 divided doses

**Hypertension | Angina**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adult: Initially 160 mg once daily, then increased if necessary up to 320 mg daily

**HEPATIC IMPAIRMENT**

Reduce dose.
## Propranolol hydrochloride

### INDICATIONS AND DOSE

#### Thyrotoxicosis
BY MOUTH
- Adult: 10–40 mg 3–4 times a day

#### Thyrotoxic crisis
BY INTRAVENOUS INJECTION
- Adult: 1 mg, to be given over 1 minute, dose may be repeated if necessary at intervals of 2 minutes, maximum total dose is 5 mg in anaesthesia; maximum 10 mg per course

#### Hypertension
BY MOUTH
- Adult: Initially 80 mg twice daily, dose should be increased at weekly intervals as required; maintenance 160–320 mg daily

#### Prophylaxis of variceal bleeding in portal hypertension
BY MOUTH
- Adult: Initially 40 mg twice daily, then increased to 80 mg twice daily (max. per dose 160 mg twice daily), dose to be adjusted according to heart rate

#### Phaeochromocytoma (only with an alpha-blocker) in preparation for surgery
BY MOUTH
- Adult: 60 mg daily for 3 days before surgery

#### Phaeochromocytoma (only with an alpha-blocker) in patients unsuitable for surgery
BY MOUTH
- Adult: 30 mg daily

#### Angina
BY MOUTH
- Adult: Initially 40 mg 2–3 times a day; maintenance 120–240 mg daily

#### Hypertrophic cardiomyopathy | Anxiety tachycardia
BY MOUTH
- Adult: 10–40 mg 3–4 times a day

#### Anxiety with symptoms such as palpitation, sweating and tremor
BY MOUTH
- Adult: 40 mg once daily, then increased if necessary to 40 mg 3 times a day

#### Prophylaxis after myocardial infarction
BY MOUTH
- Adult: Initially 40 mg 4 times a day for 2–3 days, then 80 mg twice daily, start treatment 5 to 21 days after infarction

#### Essential tremor
BY MOUTH
- Adult: Initially 40 mg 2–3 times a day; maintenance 80–160 mg daily

#### Migraine prophylaxis
BY MOUTH
- Adult: 80–240 mg daily in divided doses

#### Arrhythmias
BY INTRAVENOUS INJECTION
- Adult: 1 mg, to be given over 1 minute, dose may be repeated if necessary at intervals of 2 minutes, maximum total dose is 5 mg in anaesthesia; maximum 10 mg per course

#### SIDE-EFFECTS
- Rare Dry eyes (reversible on withdrawal)

#### HEPATIC IMPAIRMENT
Reduce oral dose.

#### RENAL IMPAIRMENT
Manufacturer advises caution; dose reduction may be required.
### Timolol maleate

#### INDICATIONS AND DOSE

**Hypertension**
- **BY MOUTH**
  - Adult: 10–20 mg daily in 1–2 divided doses

**Angina**
- **BY MOUTH**
  - Adult: Initially 5 mg twice daily, then increased in steps of 10 mg daily every 3–4 days (max. 30 mg twice daily)

**Prophylaxis after myocardial infarction**
- **BY MOUTH**
  - Adult: Initially 5 mg twice daily for 2 days, then increased if tolerated to 10 mg twice daily

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Adult:**
  - **BY MOUTH**
    - Hypertension

**PROPRANOLOL HYDROCHLORIDE (Non-proprietary)**
- Propranolol hydrochloride 10 mg
- Propranolol 10mg tablets | 28 tablet (P) £1.90 DT price = £1.69
- Propranolol hydrochloride 40 mg
- Propranolol 40mg tablets | 28 tablet (P) £4.50 DT price = £3.88
- Propranolol hydrochloride 80 mg
- Propranolol 80mg tablets | 28 tablet (P) no price available | 50 tablet (P) £9.33 DT price = £3.43
- Propranolol hydrochloride 160 mg
- Propranolol 160mg tablets | 56 tablet (P) £6.23 DT price = £5.57

**Modified-release capsule**

**PROPRANOLOL HYDROCHLORIDE (Non-proprietary)**
- Propranolol hydrochloride 80 mg
- Propranolol 80mg modified-release capsules | 28 capsule (P) £6.98 DT price = £6.58
- Propranolol hydrochloride 160 mg
- Propranolol 160mg modified-release capsules | 28 capsule (P) £4.88 DT price = £5.13
- Bedranol SR (Sandoz Ltd, Almus Pharmaceuticals Ltd)
- Bedranol hydrochloride 80 mg
- Bedranol SR 80mg capsules | 28 capsule (P) £4.16 DT price = £6.58
- Bedranol hydrochloride 160 mg
- Bedranol SR 160mg capsules | 28 capsule (P) £5.09 DT price = £5.13
- Beta-Prograne (Tillomed Laboratories Ltd, Actavis UK Ltd, Teva UK Ltd)
- Propranolol hydrochloride 160 mg
- Beta-Prograne 160mg modified-release capsules | 28 capsule (P) £4.31-$6.11 DT price = £5.13
- Half Beta-Prograne (Teva UK Ltd, Actavis UK Ltd, Tillomed Laboratories Ltd)
- Propranolol hydrochloride 80 mg
- Half Beta-Prograne 80mg modified-release capsules | 28 capsule (P) £4.67-$4.95 DT price = £4.98

**Oral solution**

**PROPRANOLOL HYDROCHLORIDE (Non-proprietary)**
- Propranolol hydrochloride 1 mg
- 1 ml
- Propranolol 5mg/5ml oral solution sugar free (sugar-free) | 150 ml (P) no price available
- Propranolol hydrochloride 2 mg
- 1 ml
- Propranolol 10mg/5ml oral solution sugar free (sugar-free) | 150 ml (P) no price available
- Propranolol hydrochloride 8 mg
- 1 ml
- Propranolol 40mg/5ml oral solution sugar free (sugar-free) | 150 ml (P) no price available
- Propranolol hydrochloride 10 mg
- 1 ml
- Propranolol 50mg/5ml oral solution sugar free (sugar-free) | 150 ml (P) no price available
- Brands may include Syprol

---

### Amiloride with hydrochlorothiazide and timolol

The properties listed below are those particular to the combination only. For the properties of the components please consider, amiloride hydrochloride p. 103, timolol maleate above.

#### INDICATIONS AND DOSE

**Hypertension**
- **BY MOUTH**
  - Adult: 1–2 tablets daily

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Adult:**
  - **BY MOUTH**
    - Hypertension

**AMILORIDE WITH HYDROCHLOROTHIAZIDE AND TIMOLOL (Non-proprietary)**
- Amiloride hydrochloride 2.5 mg, Hydrochlorothiazide 25 mg, Timolol maleate 10 mg
- Prestim 10 mg tablets | 42 tablet (P) £12.59 DT price = £10.66

**Amiloride hydrochloride 2.5 mg, Hydrochlorothiazide 25 mg, Timolol maleate 10 mg**
- Prestim 10 mg tablets | 28 tablet (P) £29.87

---

### Bendroflumethiazide with timolol

The properties listed below are those particular to the combination only. For the properties of the components please consider, timolol maleate above, bendroflumethiazide p. 159.

#### INDICATIONS AND DOSE

**Hypertension**
- **BY MOUTH**
  - Adult: 1–2 tablets daily; maximum 4 tablets per day

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Adult:**
  - **BY MOUTH**
    - Hypertension

**Bendroflumethiazide with timolol**
- Bendroflumethiazide 2.5 mg, Timolol maleate 10 mg
- Prestim tablets | 30 tablet (P) £3.49

---

### Calcium-channel blockers

Calcium-channel blockers differ in their predilection for the various possible sites of action and, therefore, their therapeutic effects are disparate, with much greater variation than those of beta-blockers. There are important...
Calcium-channel blockers

- **DRUG ACTION** Calcium-channel blockers (less correctly called 'calcium-antagonists') interfere with the inward displacement of calcium ions through the slow channels of active cell membranes. They influence the myocardial cells, the cells within the specialised conducting system of the heart, and the cells of vascular smooth muscle. Thus, myocardial contractility may be reduced, the formation and propagation of electrical impulses within the heart may be depressed, and coronary or systemic vascular tone may be diminished.

- **SIDE-EFFECTS**
  - **Overdose** Features of calcium-channel blocker poisoning include nausea, vomiting, dizziness, agitation, confusion, and coma in severe poisoning. Metabolic acidosis and hyperglycaemia may occur. For details on the management of poisoning, see Calcium-channel blockers, under Emergency treatment of poisoning p. 1123.
  - **TREATMENT CESSATION** There is some evidence that sudden withdrawal of calcium-channel blockers may be associated with an exacerbation of myocardial ischaemia.

### Amlodipine

- **DRUG ACTION** Amlodipine is a dihydropyridine calcium-channel blocker.

#### INDICATIONS AND DOSE

- **Angina**
  - **BY MOUTH**
  - **Adult:** Initially 5 mg once daily; maximum 10 mg per day

- **Hypertension**
  - **BY MOUTH**
  - **Adult:** Initially 5 mg once daily; maximum 10 mg per day

#### Dose equivalence and conversion

Tablets from various suppliers may contain different salts (e.g. amlodipine besilate, amlodipine maleate, and amlodipine mesilate) but the strength is expressed in terms of amlodipine (base); tablets containing different salts are considered interchangeable.

- **CONTRA-INDICATIONS** Cardiogenic shock · significant aortic stenosis · unstable angina
- **INTERACTIONS** Appendix 1 (calcium-channel blockers).
- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · dizziness · fatigue · flushing · headache · nausea · oedema · palpitation · sleep disturbances
  - **Uncommon** Alopecia · arthralgia · asthenia · back pain · chest pain · dry mouth · dyspnoea · gastro-intestinal disturbances · gynaecomastia · hypotension · impotence · mood changes · muscle cramps · myalgia · paraesthesia · pruritus · purpura · rashes · rhinitis · skin discoloration · sweating · syncope · taste disturbances · tinnitus · tremor · urinary disturbances · visual disturbances · weight changes
  - **Very rare** Angioedema · arrhythmias · cholestasis · coughing · gastritis · gingival hyperplasia · hepatitis · hyperglycaemia · jaundice · myocardial infarction · pancreatitis · peripheral neuropathy · tachycardia · thrombocytopения · urticaria · vasculitis
  - **Frequency not known** Erythema multiforme

- **Overdose** In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

- **PREGNANCY** No information available—manufacturer advises avoid, but risk to fetus should be balanced against risk of uncontrolled maternal hypertension.
Diltiazem hydrochloride

INDICATIONS AND DOSE
Angina
BY MOUTH
- Adult: Initially 60 mg 3 times a day, adjusted according to response; maximum 360 mg per day
- Elderly: Initially 60 mg twice daily, adjusted according to response; maximum 360 mg per day

Dose equivalence and conversion
The standard formulations containing 60 mg diltiazem hydrochloride are licensed as generics and there is no requirement for brand name dispensing. Although their means of formulation has called for the strict designation 'modified-release', their duration of action corresponds to that of tablets requiring administration more frequently.

TILDIE RETARDO®
Mild to moderate hypertension
BY MOUTH
- Adult: Initially 90–120 mg twice daily; increased if necessary to 360 mg daily in divided doses
- Elderly: Initially 120 mg daily; increased if necessary to 120 mg twice daily

Angina
BY MOUTH
- Adult: Initially 90–120 mg twice daily; increased if necessary to 480 mg daily in divided doses
- Elderly: Up to 120 mg twice daily, dose form not appropriate for initial dose titration

ADIZEM-SR® TABLETS
Mild to moderate hypertension
BY MOUTH
- Adult: 120 mg twice daily, dose form not appropriate for initial dose titration

Angina
BY MOUTH
- Adult: Initially 90 mg twice daily; increased if necessary to 180 mg twice daily, dose form not appropriate for initial dose titration in the elderly

ADIZEM-SR® CAPSULES
Mild to moderate hypertension
BY MOUTH
- Adult: 120 mg twice daily, dose form not appropriate for initial dose titration

Angina
BY MOUTH
- Adult: Initially 90 mg twice daily; increased if necessary to 360 mg daily; dose form not appropriate for initial dose titration in the elderly

TILDIE LA
Angina | Mild to moderate hypertension
BY MOUTH
- Adult: Initially 200 mg daily, to be taken with or before food, increased if necessary to 300–400 mg daily; maximum 500 mg per day
- Elderly: Initially 200 mg daily, increased if necessary to 300 mg daily

VIAZEM® XL
Angina | Mild to moderate hypertension
BY MOUTH
- Adult: Initially 180 mg once daily, adjusted according to response to 240 mg once daily; maximum 360 mg per day
- Elderly: Initially 120 mg once daily, adjusted according to response

DILZEM® XL
Angina | Mild to moderate hypertension
BY MOUTH
- Adult: Initially 180 mg daily; increased if necessary to 360 mg daily
- Elderly: Initially 120 mg daily; increased if necessary to 360 mg daily

Amlozin with valsartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, amlodipine p. 148, valsartan p. 136.

INDICATIONS AND DOSE
Hypertension in patients stabilised on the individual components in the same proportions
BY MOUTH
- Adult: (consult product literature)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Exforge (Novartis Pharmaceuticals UK Ltd)
- Amlodipine (as Amlodipine besilate) 5 mg, Valsartan 80 mg
- Exforge 5mg/80mg tablets | 28 tablet [P] £16.76 DT price = £16.76
- Amlodipine (as Amlodipine besilate) 10 mg, Valsartan 160 mg
- Exforge 10mg/160mg tablets | 28 tablet [P] £22.09 DT price = £22.09

Oral solution
- Amlodipine (Non-proprietary)
- Amlodipine 1 mg per 1 ml Amlodipine 5mg/5ml oral solution sugar free (sugar-free) | 150 ml [P] £110.00
- Amlodipine 2 mg per 1 ml Amlodipine 10mg/5ml oral solution sugar free (sugar-free) | 150 ml [P] £110.00

Also available in combination with olmesartan, p. 135 - hydrochlorothiazide and olmesartan, p. 135 - valsartan, below

Diltiazem hydrochloride

INDICATIONS AND DOSE
Angina
BY MOUTH
- Adult: Initially 60 mg 3 times a day, adjusted according to response; maximum 360 mg per day
- Elderly: Initially 60 mg twice daily, adjusted according to response; maximum 360 mg per day

Hypertension
BY MOUTH
- Adult: Initially 90–120 mg twice daily; increased if necessary to 360 mg daily in divided doses
- Elderly: Initially 120 mg daily; increased if necessary to 120 mg twice daily

HEPATIC IMPAIRMENT
May need dose reduction—half-life prolonged.

DIRECTIONS FOR ADMINISTRATION
Tablets may be dispersed in water.
**DILZEM® SR**

**Angina | Mild to moderate hypertension**

**BY MOUTH**
- **Adult:** Initially 90 mg twice daily; increased if necessary up to 180 mg twice daily
- **Elderly:** Initially 60 mg twice daily; increased if necessary up to 180 mg twice daily

---

**ADIZEM-XL®**

**Angina | Mild to moderate hypertension**

**BY MOUTH**
- **Adult:** Initially 240 mg daily, increased if necessary to 300 mg daily
- **Elderly:** Initially 120 mg daily, increased if necessary up to 300 mg daily

---

**ZEMTARD®**

**Angina**

**BY MOUTH**
- **Adult:** 180–300 mg daily, increased if necessary to 480 mg daily
- **Elderly:** Initially 120 mg daily, increased if necessary to 480 mg daily

---

**Mild to moderate hypertension**

**BY MOUTH**
- **Adult:** 180–300 mg daily, increased if necessary to 360 mg daily
- **Elderly:** Initially 120 mg daily, increased if necessary to 360 mg daily

---

**SLOZEM®**

**Angina | Mild to moderate hypertension**

**BY MOUTH**
- **Adult:** Initially 240 mg daily; increased if necessary to 360 mg daily
- **Elderly:** Initially 120 mg daily; increased if necessary to 360 mg daily

---

**DILCARDIA® SR**

**Angina | Mild to moderate hypertension**

**BY MOUTH**
- **Adult:** Initially 90 mg twice daily; increased if necessary to 180 mg twice daily
- **Elderly:** Initially 60 mg twice daily; increased if necessary to 90 mg twice daily

---

**REFERENCES**

- Acute porphyrias p. 864: left ventricular failure with pulmonary congestion. second- or third-degree AV block (unless pacemaker fitted): severe bradycardia: sick sinus syndrome
- Bradycardia (avoid if severe): first degree AV block: heart failure: prolonged PR interval: significantly impaired left ventricular function
- Appendix 1 (calcium-channel blockers).
Felodipine

- **DRUG ACTION** Felodipine is a dihydropyridine calcium-channel blocker.

## INDICATIONS AND DOSE

### Angina

#### BY MOUTH

- **Adult:** Initially 5 mg daily; increased if necessary to 10 mg daily, to be taken in the morning
- **Elderly:** Initially 2.5 mg daily; increased if necessary to 10 mg daily, to be taken in the morning

### Hypertension

#### BY MOUTH

- **Adult:** Initially 5 mg daily, to be taken in the morning; usual maintenance 5–10 mg once daily, doses above 20 mg daily rarely needed
- **Elderly:** Initially 2.5 mg daily, to be taken in the morning; usual maintenance 5–10 mg once daily, doses above 20 mg daily rarely needed

### CONTRA-INDICATIONS

Cardiac outflow obstruction - significant cardiac valvular obstruction (e.g. aortic stenosis) - uncontrolled heart failure - unstable angina - within 1 month of myocardial infarction
Cardiovascular system

Very rare

INTERACTIONS

SIDE-EFFECTS
- Common or very common Flushing • headache • peripheral oedema
- Uncommon Abdominal pain • dizziness • malaise • nausea • palpitation • paraesthesia • pruritus • rash • tachycardia
- Rare Arthralgia • impotence • myalgia • syncope • vomiting
- Very rare Gum hyperplasia • leucocytoclastic vasculitis • photosensitivity • urinary frequency

PREGNANCY
- Avoid; toxicity in animal studies; may inhibit labour.

BREAST FEEDING
- Present in milk but amount probably too small to be harmful.

HEPATIC IMPAIRMENT

BREAST FEEDING
- Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
- 1.25 mg twice daily, increased if necessary after 3–4 weeks according to response; maintenance dose of 2.5 mg or 5 mg once daily may be sufficient.

RENAL IMPAIRMENT
- Use with caution.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet
- ISRADIPINE (Non-proprietary) Isradipine 2.5 mg Isradipine 2.5mg tablets | 56 tablet £21.11-£21.11 DT price = £185.64

Lacidipine

- DRUG ACTION Lacidipine is a dihydropyridine calcium-channel blocker.

INDICATIONS AND DOSE

Hypertension

BY MOUTH
- Adult: Initially 2 mg daily; increased if necessary to 4 mg daily, then increased if necessary to 6 mg daily, dose increases should occur at intervals of 3–4 weeks, to be taken preferably in the morning

CONTRA-INDICATIONS
- Acute porphyrias p. 864 • aortic stenosis • avoid within 1 month of myocardial infarction • cardiogenic shock • unstable angina

CAUTIONS
- Cardiac conduction abnormalities • poor cardiac reserve

INTERACTIONS
- Appendix 1 (calcium-channel blockers).

SIDE-EFFECTS
- Common or very common Dizziness • flushing • headache • oedema • palpitation
- Rare Aggravation of angina • asthenia • erythema • gastrointestinal disturbances • gum hyperplasia • mood disturbances • muscle cramps • polyuria • pruritus • skin rash

Overdose
- In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

PREGNANCY
- Manufacturer advises avoid; may inhibit labour.

BREAST FEEDING
- Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
- Antihypertensive effect possibly increased.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet
- LACIDIPINE (Non-proprietary) Lacidipine 2 mg Lacidipine 2mg tablets | 28 tablet £2.95 DT price = £2.90

Isradipine

INDICATIONS AND DOSE

Hypertension

BY MOUTH
- Adult: 2.5 mg twice daily for 3–4 weeks, then increased if necessary to 5 mg twice daily, dose increased exceptionally up to 10 mg twice daily
- Elderly: 1.25 mg twice daily, increased if necessary after 3–4 weeks according to response; maintenance 2.5–5 mg once daily

CONTRA-INDICATIONS
- Acute porphyrias p. 864 • cardiogenic shock • during or within 1 month of myocardial infarction • unstable angina

CAUTIONS
- Chronic heart failure • poor cardiac reserve • severe aortic stenosis • sick sinus syndrome (if pacemaker not fitted)

INTERACTIONS
- Appendix 1 (calcium-channel blockers).

SIDE-EFFECTS
- Common or very common Abdominal discomfort • dizziness • dyspnoea • fatigue • flushing • headache • palpitation • peripheral oedema • polyuria • rash • tachycardia
- Uncommon Hypotension • weight gain
- Very rare Anaemia • anorexia • anxiety • arrhythmia • arthralgia • blood disorders • bradycardia • cough • depression • drowsiness • erectile dysfunction • gum hyperplasia • heart failure • hypersensitivity reactions • leucopenia • nausea • paraesthesia • thrombocytopenia • visual disturbance • vomiting

FREQUENCY NOT KNOWN Gynaecomastia • hepatitis

Overdose
- In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

PREGNANCY
- May inhibit labour. Risk to fetus should be balanced against risk of uncontrolled maternal hypertension.

BREAST FEEDING
- Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
- 1.25 mg twice daily, increased if necessary after 3–4 weeks according to response; maintenance dose of 2.5 mg or 5 mg once daily may be sufficient.

RENAL IMPAIRMENT
- Use with caution.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet
- ISRADIPINE (Non-proprietary) Isradipine 2.5 mg Isradipine 2.5mg tablets | 56 tablet £21.11-£21.11 DT price = £185.64
Lercanidipine hydrochloride

**DRUG ACTION** Lercanidipine is a dihydropyridine calcium-channel blocker.

**INDICATIONS AND DOSE**

**Mild to moderate hypertension**

**BY MOUTH**

- Adult: Initially 10 mg once daily; increased if necessary to 20 mg daily, dose can be adjusted after 2 weeks

**CONTRA-INDICATIONS**

- Acute porphyrias p. 864
- Aortic stenosis
- Uncontrolled heart failure
- Unstable angina
- Within 1 month of myocardial infarction

**CAUTIONS**

- Left ventricular dysfunction
- Sick sinus syndrome (if pacemaker not fitted)

**INTERACTIONS**

- Appendix 1 (calcium-channel blockers).

**SIDE-EFFECTS**

- **Uncommon**
  - Dizziness, flushing, headache, palpitation, peripheral oedema, tachycardia
  - Angina, asthenia, drowsiness, gastrointestinal disturbances, myalgia, polyuria, rash

- **Very rare**
  - Gingival hyperplasia
  - Hypotension - myocardial infarction

**OVERDOSE** In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

**PREGNANCY**

- Manufacturer advises avoid—no information available.

**BREAST FEEDING**

- Manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

- Avoid in severe disease.

**RENAL IMPAIRMENT**

- Avoid if eGFR less than 30 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- CAUTIONARY AND ADVISORY LABELS 22
  - Lercanidipine hydrochloride (Non-proprietary)
    - Lercanidipine hydrochloride 10 mg
      - Lercanidipine 10mg tablets | 28 tablet | £5.89 DT price = £1.57
      - Lercanidipine hydrochloride 20 mg
        - Lercanidipine 20mg tablets | 28 tablet | £10.82 DT price = £1.84
  - Zanidip (Recordati Pharmaceuticals Ltd)
    - Lercanidipine hydrochloride 10 mg
      - Zanidip 10mg tablets | 28 tablet | £5.70 DT price = £1.57
    - Lercanidipine hydrochloride 20 mg
      - Zanidip 20mg tablets | 28 tablet | £10.82 DT price = £1.84

Nicardipine hydrochloride

**DRUG ACTION** Nicardipine is a dihydropyridine calcium-channel blocker.

**INDICATIONS AND DOSE**

**Prophylaxis of angina**

- **BY MOUTH USE IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 20 mg 3 times a day, then increased to 30 mg 3 times a day, dose increased after at least 3 days; usual dose 60–120 mg daily

**CONTRA-INDICATIONS**

- Acute porphyrias p. 864
- Aortic stenosis
- Uncontrolled heart failure
- Unstable angina
- Within 1 month of myocardial infarction

**CAUTIONS**

- Left ventricular dysfunction
- Sick sinus syndrome (if pacemaker not fitted)

**INTERACTIONS**

- Appendix 1 (calcium-channel blockers).

**SIDE-EFFECTS**

- **Uncommon**
  - Dizziness, flushing, headache, palpitation, peripheral oedema, tachycardia
  - Angina, asthenia, drowsiness, gastrointestinal disturbances, myalgia, polyuria, rash

- **Very rare**
  - Gingival hyperplasia
  - Hypotension - myocardial infarction

**OVERDOSE** In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

**PREGNANCY**

- For treatment of acute life-threatening hypertension only. May inhibit labour. Not to be used in...
multiple pregnancy (twins or more) unless there is no other acceptable alternative. Toxicity in animal studies. Risk of severe maternal hypotension and fatal foetal hypoxia—avoid excessive decrease in blood pressure.

- **BREAST FEEDING** Manufacturer advises avoid—present in breast milk.
- **HEPATIC IMPAIRMENT**
  - With oral use Use with caution—consider using lowest initial dose and extending dosing interval according to individual response.
  - With intravenous use Use with caution—use lower initial dose.
- **RENAL IMPAIRMENT**
  - With oral use Consider using lowest initial dose and extending dosing interval according to individual response.
  - With intravenous use Use with caution—use lower initial dose.
- **MONITORING REQUIREMENTS**
  - With intravenous use Monitor blood pressure and heart rate at least every 5 minutes during intravenous infusion, and then until stable, and continue monitoring for at least 12 hours after end of infusion.
- **DIRECTIONS FOR ADMINISTRATION**
  - Intravenous nicardipine should only be administered under the supervision of a specialist and in a hospital or intensive care setting in which patients can be closely monitored. For *intravenous infusion* give continuously in Glucose 5%; dilute dose in infusion fluid to a final concentration of 100–200 micrograms/mL (undiluted solution via central venous line only) and give via volumetric infusion pump or syringe driver; protect from light; to minimise peripheral venous irritation, change site of infusion every 12 hours; risk of adsorption on to plastic of infusion set in the presence of saline solutions; incompatible with bicarbonate or alkaline solutions—consult product literature.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Capsule**
- NICARDIPINE HYDROCHLORIDE (Non-proprietary)
  - Nicardipine hydrochloride 20 mg Nicardipine 20mg capsules | 56 capsule  £8.38 DT price = £6.00
  - Nicardipine hydrochloride 30 mg Nicardipine 30mg capsules | 56 capsule  £9.73 DT price = £6.37
  - Cardene (Astellas Pharma Ltd)
    - Nicardipine hydrochloride 20 mg Cardene 20mg capsules | 56 capsule  £6.00 DT price = £6.00
    - Nicardipine hydrochloride 30 mg Cardene 30mg capsules | 56 capsule  £6.96 DT price = £6.37

**Modified-release capsule**
- CARDENE SR (Astellas Pharma Ltd)
  - Nicardipine hydrochloride 30 mg Cardene SR 30mg capsules | 56 capsule  £7.15 DT price = £7.15
  - Nicardipine hydrochloride 45 mg Cardene SR 45mg capsules | 56 capsule  £10.40 DT price = £10.40

**Solution for infusion**
- NICARDIPINE HYDROCHLORIDE (Non-proprietary)
  - Nicardipine hydrochloride 1 mg per 1 ml Nicardipine 10mg/10ml solution for injection ampoules | 5 ampoule  £50.00

---

**INDICATIONS AND DOSE**

**Raynaud’s syndrome**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 5 mg 3 times a day, then adjusted according to response to 20 mg 3 times a day

**Angina prophylaxis (not recommended)**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 5 mg 3 times a day, then adjusted according to response to 20 mg 3 times a day

**Postponement of premature labour**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 20 mg, followed by 10–20 mg 3–4 times a day, adjusted according to uterine activity

**Hiccups in palliative care**
- **BY MOUTH**
  - Adult: 10 mg 3 times a day

**ADALAT®**

**Angina prophylaxis (not recommended) | Raynaud’s phenomenon**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 5 mg 3 times a day, then adjusted according to response to 20 mg 3 times a day

**Dose equivalence and conversion**
Adalat liquid gel capsules contain 5 mg nifedipine in 0.17 mL and 10 mg nifedipine in 0.34 mL.

**ADALAT® LA**

**Hypertension**
- **BY MOUTH**
  - Adult: 20–30 mg once daily, increased if necessary up to 90 mg once daily

**Angina prophylaxis**
- **BY MOUTH**
  - Adult: 30 mg once daily, increased if necessary up to 90 mg once daily

**FORTIPINE® LA 40**

**Hypertension | Angina prophylaxis**
- **BY MOUTH**
  - Adult: Initially 40 mg once daily, increased if necessary up to 80 mg daily in 1–2 divided doses

**VALMI® XL**

**Severe hypertension | Prophylaxis of angina**
- **BY MOUTH**
  - Adult: 30 mg once daily, increased if necessary up to 90 mg once daily

**ADALAT RETARD®**

**Hypertension | Angina prophylaxis**
- **BY MOUTH**
  - Adult: 10 mg twice daily, adjusted according to response to 40 mg twice daily

**ADIPINE® XL**

**Hypertension | Angina prophylaxis**
- **BY MOUTH**
  - Adult: 30 mg daily, increased if necessary up to 90 mg daily

**ADIPINE® MR**

**Hypertension | Angina prophylaxis**
- **BY MOUTH**
  - Adult: 10 mg twice daily, adjusted according to response to 40 mg twice daily

**NIFEDI PRESS® MR**

**Hypertension | Angina prophylaxis**
- **BY MOUTH**
  - Adult: 10 mg twice daily, adjusted according to response to 40 mg twice daily

---

**Nifedipine**

- **DRUG ACTION** Nifedipine is a dihydropyridine calcium-channel blocker.
Hypertension

PREGNANCY

▶ Frequency not known

Rare

▶ Common or very common

SIDE-EFFECTS

INTERACTIONS

CAUTIONS

l UNLICENSED USE Not licensed for use in postponing premature labour.

l CONTRA-INDICATIONS Acute attacks of angina - cardiogenic shock - significant aortic stenosis - unstable angina - within 1 month of myocardial infarction

l CAUTIONS Diabetes mellitus - elderly - heart failure - poor cardiac reserve - severe hypotension - short-acting formulations are not recommended for angina or long-term management of hypertension; their use may be associated with large variations in blood pressure and reflex tachycardia - significantly impaired left ventricular function (heart failure deterioration observed) - withdrawn if ischaemic pain occurs or existing pain worsens shortly after initiating treatment

ADALAT® LA

Crohn’s disease - decreased lumen diameter of the gastro-intestinal tract - history of gastro-intestinal obstruction - inflammatory bowel disease

CAUTIONS, FURTHER INFORMATION

ADALAT® LA, VALNI® XL

Dose form not appropriate for use where there is a history of oesophageal or gastro-intestinal obstruction, decreased lumen diameter of the gastro-intestinal tract, or inflammatory bowel disease (including Crohn’s disease).

l INTERACTIONS ▶ Appendix 1 (calcium-channel blockers).

l SIDE-EFFECTS

▶ Common or very common Asthenia - dizziness - gastrointestinal disturbance - headache - hypotension - lethargy - oedema - palpitation - vasodilatation


▶ Rare Anorexia - gum hyperplasia - hyperglycaemia - male infertility - mood disturbances - photosensitivity reactions - purpura

▶ Frequency not known Agranulocytosis - anaphylaxis - bezoar formation (with some modified-release preparations) - dysphagia - gynaecomastia - intestinal obstruction - intestinal ulcer

Overdose In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

▶ PREGNANCY May inhibit labour; manufacturer advises avoid before week 20, but risk to fetus should be balanced against risk of uncontrolled maternal hypertension. Use only if other treatment options are not indicated or have failed.

l BREAST FEEDING Amount too small to be harmful but manufacturers advise avoid.

l HEPATIC IMPAIRMENT Dose reduction may be required in severe liver disease. Some modified-release formulations may not be suitable for dose titration in hepatic disease—consult product literature.

ADALAT® LA, VALNI® XL Dose form not appropriate.

l DIRECTIONS FOR ADMINISTRATION

FORTIPINE® LA 40 Take with or just after food, or a meal.

l PRESCRIBING AND DISPENSING INFORMATION Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed.

l PATIENT AND CARER ADVICE

ADALAT® LA Tablet membrane may pass through gastrointestinal tract unchanged, but being porous has no effect on efficacy.

l MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral drops

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

▶ NIFEDIPINE (Non-proprietary)

Nifedipine 10 mg Nifedipine 10mg modified-release tablets | 56 tablet (P) £7.34 DT price = £7.34

Nifedipine 20 mg Nifedipine 20mg modified-release tablets | 28 tablet (P) no price available | 56 tablet (P) £10.06

Nifedipine 30 mg Nifedipine 30mg modified-release tablets | 28 tablet (P) no price available DT price = £6.85

Nifedipine 40 mg Nifedipine 40mg modified-release tablets | 30 tablet (P) no price available

▶ Adalat LA (Bayer Plc)

Nifedipine 20 mg Nifedipine LA 20 tablets | 28 tablet (P) £5.27

Nifedipine 30 mg Nifedipine LA 30 tablets | 28 tablet (P) £6.85 DT price = £6.85

Nifedipine 60 mg Adalat LA 60 tablets | 28 tablet (P) £9.03 DT price = £9.03

▶ Adalat retard (Bayer Plc)

Nifedipine 10 mg Adalat retard 10mg tablets | 56 tablet (P) £7.34 DT price = £7.34

Nifedipine 20 mg Adalat retard 20mg tablets | 56 tablet (P) £8.81

▶ Adipine MR (Chiesi Ltd)

Nifedipine 10 mg Adipine MR 10 tablets | 56 tablet (P) £3.73 DT price = £3.73

Nifedipine 20 mg Adipine MR 20 tablets | 56 tablet (P) £5.21

▶ Adipine XL (Chiesi Ltd)

Nifedipine 30 mg Adipine XL 30mg tablets | 28 tablet (P) £4.70 DT price = £6.85

Nifedipine 60 mg Adipine XL 60mg tablets | 28 tablet (P) £7.10 DT price = £9.03

▶ Fortipine LA (AMCo)

Nifedipine 40 mg Fortipine LA 40 tablets | 30 tablet (P) £14.40

▶ Nifedipress MR (Descel-Pharma Ltd)

Nifedipine 10 mg Nifedipress MR 10 tablets | 56 tablet (P) £9.23 DT price = £7.34

Nifedipine 20 mg Nifedipress MR 20 tablets | 56 tablet (P) £10.06

▶ Tensipine MR (Genus Pharmaceuticals Ltd)

Nifedipine 10 mg Tensipine MR 10 tablets | 56 tablet (P) £4.30 DT price = £7.34

Nifedipine 20 mg Tensipine MR 20 tablets | 56 tablet (P) £5.49

▶ Valni XL (Zentiva)

Nifedipine 30 mg Valni XL 30mg tablets | 28 tablet (P) £7.29 DT price = £6.85

Nifedipine 60 mg Valni XL 60mg tablets | 28 tablet (P) £9.14 DT price = £9.03

Brands may include Adalaf Xl; Kentipine MR; Neozipine XL; Nifedipress Retard; Valni Retard

Capsule

▶ NIFEDIPINE (Non-proprietary)

Nifedipine 5 mg Nifedipine 5mg capsules | 84 capsule (P) £19.99 DT price = £15.20

BNF 70

Cardiovascular system
Verapamil hydrochloride

**INDICATIONS AND DOSE**

**Treatment of supraventricular arrhythmias**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 40–120 mg 3 times a day
  - Adult: 5–10 mg, to be given over 2 minutes, preferably with ECG monitoring
  - Elderly: 5–10 mg, to be given over 3 minutes, preferably with ECG monitoring

**Paroxysmal tachyarrhythmias**
- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: Initially 5–10 mg, followed by 5 mg after 5–10 minutes if required, to be given over 2 minutes, preferably with ECG monitoring
  - Elderly: Initially 5–10 mg, followed by 5 mg after 5–10 minutes if required, to be given over 3 minutes, preferably with ECG monitoring

**Angina**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 80–120 mg 3 times a day

**Hypertension**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 240–480 mg daily in 2–3 divided doses

**Prophylaxis of cluster headache (initiated under specialist supervision)**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 240–960 mg daily in 3–4 divided doses

**HALF SECURON® SR**

**Hypertension (in patients new to verapamil)**
- **BY MOUTH**
  - Adult: Initially 120 mg daily, increased if necessary up to 480 mg daily, doses above 240 mg daily as 2 divided doses

**Hypertension**
- **BY MOUTH**
  - Adult: 240 mg daily, increased if necessary up to 480 mg daily, doses above 240 mg daily as 2 divided doses

**Securion® SR**

**Hypertension (in patients new to verapamil)**
- **BY MOUTH**
  - Adult: Initially 120 mg daily, increased if necessary up to 480 mg daily, doses above 240 mg daily as 2 divided doses

**Prophylaxis after myocardial infarction where beta-blockers not appropriate**

**CAUTIONS**
- Acute phase of myocardial infarction (avoid if bradycardia, hypotension, left ventricular failure) - first-degree AV block

**INTERACTIONS**
- Appendix 1 (calcium-channel blockers).
Verapamil and beta-blockers Verapamil injection should not be given to patients recently treated with beta-blockers because of the risk of hypotension and asystole. The suggestion that when verapamil injection has been given first, an interval of 30 minutes before giving a beta-blocker is sufficient has not been confirmed.

It may also be hazardous to give verapamil and a beta-blocker together by mouth (should only be contemplated if myocardial function well preserved).

SIDE-EFFECTS
- Common or very common: Constipation
- Uncommon: Ankle oedema, dizziness, fatigue, flushing, headache, nausea, vomiting
- Rare: Allergic reactions, angioedema, arthralgia, asystole, bradycardia, erythema, erythroemalgia, gingival hyperplasia after long-term treatment, gynaecomastia after long-term treatment, heart block, heart failure, hypotension, increased prolactin concentration, myalgia, parasthesia, pruritus, Stevens-Johnson syndrome, urticaria

SIDE-EFFECTS, FURTHER INFORMATION
Intravenous administration or high doses Hypotension, heart failure, bradycardia, heart block, and asystole are side-effects associated with intravenous administration or high doses.

Overdose In overdose, verapamil has a profound cardiac depressant effect causing hypotension and arrhythmias, including complete heart block and asystole.

PREGNANCY May reduce uterine blood flow with fetal hypoxia. Manufacturer advises avoid in first trimester unless absolutely necessary. May inhibit labour.

BREAST FEEDING Amount too small to be harmful.

HEPATIC IMPAIRMENT Oral dose may need to be reduced.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet
- VERAPAMIL HYDROCHLORIDE (Non-proprietary)
  - Verapamil hydrochloride 40 mg Verapamil 40mg tablets [84 tablet (P) £3.18 DT price = £2.06]
  - Verapamil hydrochloride 80 mg Verapamil 80mg tablets [84 tablet (P) £3.65 DT price = £2.38]
  - Verapamil hydrochloride 120 mg Verapamil 120mg tablets [28 tablet (P) £2.80 DT price = £1.81]
  - Verapamil hydrochloride 160 mg Verapamil 160mg tablets [56 tablet (P) £2.90 DT price = £1.20]
  - Half Securon (BGP Products Ltd)
  - Verapamil hydrochloride 120 mg Half Securon SR 120mg tablets [28 tablet (P) £7.71 DT price = £5.55]
  - Securon SR (BGP Products Ltd)
  - Verapamil hydrochloride 240 mg Securon SR 240mg tablets [28 tablet (P) £5.95 DT price = £5.95]
  - Brands may include Vera-Til SR
  - Verapress MR (Dechel-Pharma Ltd)
  - Verapamil hydrochloride 240 mg Verapress MR 240mg tablets [28 tablet (P) £9.20 DT price = £5.55]
  - Vertab SR (Chiesi Ltd)
  - Verapamil hydrochloride 240 mg Vertab SR 240 tablets [28 tablet (P) £3.45 DT price = £3.55]
  - Brands may include Vera-Til SR

Modified-release tablet
- CAUTIONARY AND ADVISORY LABELS 25
  - VERAPAMIL HYDROCHLORIDE (Non-proprietary)
  - Verapamil hydrochloride 120 mg Verapamil 120mg modified-release tablets [28 tablet (P) £7.71 DT price = £7.71]
  - Verapamil hydrochloride 240 mg Verapamil 240mg modified-release tablets [28 tablet (P) £5.25 DT price = £5.55]
  - Half Securon (BGP Products Ltd)
  - Securon SR (BGP Products Ltd)
  - Verapamil hydrochloride 240 mg Securon SR 240mg tablets [28 tablet (P) £5.55 DT price = £5.95]
  - Brands may include Vera-Til SR

Contra-Indications Acute porphyrias p. 864 - cor pulmonale - dissecting aortic aneurysm - high output heart failure - idiopathic systemic lupus erythematosus - myocardial insufficiency due to mechanical obstruction - severe tachycardia

CAUTIONS Cerebrovascular disease - coronary artery disease (may provoke angina, avoid after myocardial infarction until stabilised) - occasionally blood pressure reduction too rapid even with low parenteral doses

INTERACTIONS → Appendix 1 (hydralazine).

SIDE-EFFECTS
- Rare: Rash
- Frequency not known Abnormal liver function - agitation - anorexia - anxiety - arthralgia - blood disorders - dizziness - dyspnoea - fever - fluid retention - flushing - gastro-intestinal disturbances - haematuria - haemolytic anaemia - headache - hypotension - increased lactation - jaundice - leucopenia - myalgia - nasal congestion - palpitation - paraesthesia - peripheral neuritis - polynuerritis - proteinuria - raised plasma creatinine - systemic lupus erythematosus-like syndrome after long-term therapy with over 100 mg daily (or less in women and in slow acetylator individuals) - tachycardia - thrombocytopenia

SIDE-EFFECTS, FURTHER INFORMATION
The incidence of side-effects is lower if the dose is kept below 100 mg daily, but systemic lupus erythematosus should be suspected if there is unexplained weight loss, arthritis, or any other unexplained ill health.

Hypertension

Verapamil hydrochloride 180 mg Univer 180mg modified-release capsules | 56 capsule (P) £11.38 DT price = £11.38
Verapamil hydrochloride 240 mg Univer 240mg modified-release capsules | 28 capsule (P) £6.67 DT price = £7.67

Oral solution
- VERAPAMIL HYDROCHLORIDE (Non-proprietary)
  - Verapamil hydrochloride 6 mg per 1 ml Verapamil 40mg/5ml oral solution sugar free (sugar-free) [150 ml (P) no price available]
  - Brands may include Zolvera

Solution for injection
- Securon (BGP Products Ltd)
  - Verapamil hydrochloride 2.5 mg per 1 ml Securon IV 5mg/2ml solution for injection ampoules | 5 ampoule (P) £5.41
  - Brands may include Zolvera

Peripheral Vasodilators

Hydralazine hydrochloride

INDICATIONS AND DOSE
Moderate to severe hypertension (adjunct)
- BY MOUTH
  - Adult: Initially 25 mg twice daily, increased if necessary up to 50 mg twice daily

Heart failure (with long acting nitrate) (initiated in hospital or under specialist supervision)
- BY MOUTH
  - Adult: Initially 25 mg 3–4 times a day, then increased if necessary to every 2 days; maintenance 50–75 mg 4 times a day

Hypertensive emergencies (including during pregnancy)
  - Hypertension with renal complications
  - BY INTRAVENOUS INFUSION
    - Adult: Initially 200–300 micrograms/minute; maintenance 50–150 micrograms/minute

Hypertensive emergencies (including during pregnancy)
  - Hypertension with renal complications
  - BY SLOW INTRAVENOUS INJECTION
    - Adult: 5–10 mg, to be diluted with 10 ml sodium chloride 0.9%, dose may be repeated after 20–30 minutes

Excipients: May contain Propylene glycol

Univer (Teva UK Ltd)
  - Verapamil hydrochloride 120 mg Univer 120mg modified-release capsules | 28 capsule (P) £2.86 DT price = £4.86
Cardiovascular system

Minoxidil

INDICATIONS AND DOSE
Severe hypertension, in addition to a diuretic and a beta-blocker

BY MOUTH
- Adult: Initially 5 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg, increased at intervals of at least 3 days, seldom necessary to exceed 50 mg daily; maximum 100 mg per day
- Elderly: Initially 2.5 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg, increased at intervals of at least 3 days, seldom necessary to exceed 50 mg daily; maximum 100 mg per day

CONTRA-INDICATIONS Phaeochromocytoma

CAUTIONS Acute porphyrias p. 864 - after myocardial infarction (until stabilised) - angina

INTERACTIONS Appendix 1 (vasodilator antihypertensives).

SIDE-EFFECTS Breast tenderness - gastro-intestinal disturbances - hypertrichosis - peripheral oedema - rashes - reversible rise in creatinine and blood urea nitrogen - sodium retention - tachycardia - water retention - weight gain

PREGNANCY Avoid - possible toxicity including reduced placental perfusion. Neonatal hirsutism reported.

BREAST FEEDING Present in milk but not known to be harmful.

RENAI IMPAIRMENT Use with caution in significant impairment.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Table
- Lonten (Pfizer Ltd)
  - Minoxidil 2.5 mg Lonten 2.5mg tablets | 60 tablet (P) £8.88 DT price = £8.88
  - Minoxidil 5 mg Lonten 5mg tablets | 60 tablet (P) £15.83 DT price = £15.83
  - Minoxidil 10 mg Lonten 10mg tablets | 60 tablet (P) £30.68 DT price = £30.68

RENN INHIBITORS

Aliskiren

DRUG ACTION Renin inhibitors inhibit renin directly; renin converts angiotensinogen to angiotensin I.

INDICATIONS AND DOSE
Essential hypertension either alone or in combination with other antihypertensives

BY MOUTH
- Adult: 150 mg once daily, increased if necessary to 300 mg once daily

CONTRA-INDICATIONS Concomitant treatment with an ACE inhibitor or an angiotensin-II receptor antagonist in patients with an eGFR less than 60 mL/minute/1.73 m² - concomitant treatment with an ACE inhibitor or an angiotensin-II receptor antagonist in patients with diabetes mellitus - hereditary angioedema - idiopathic angioedema

CAUTIONS Combination treatment with an ACE inhibitor - combination treatment with an angiotensin-II receptor antagonist - concomitant use of diuretics (first doses may cause hypotension—initiate with care) - history of angioedema - moderate to severe congestive heart failure - patients at risk of renal impairment - salt depletion (first doses may cause hypotension—initiate with care) - volume depletion (first doses may cause hypotension—initiate with care)

CAUTIONS, FURTHER INFORMATION
Concomitant use of drugs affecting the renin-angiotensin system Combination therapy with two drugs affecting the renin-angiotensin system (ACE inhibitors, angiotensin-II receptor antagonists, and aliskiren) is not recommended due to an increased risk of hyperkalaemia, hypotension, and renal impairment, compared to use of a single drug. Patients with diabetic nephropathy are particularly susceptible to developing hyperkalaemia and should not be given an ACE inhibitor with an angiotensin-II receptor antagonist. There is some evidence that the benefits of combination use of an ACE inhibitor with candesartan or valsartan may outweigh the risks in selected patients with heart failure for whom other treatments are unsuitable, however, the concomitant use of this combination, together with an aldosterone antagonist or a potassium-sparing diuretic is not recommended. For patients currently taking combination therapy, the need for continued combined therapy should be reviewed. If combination therapy is considered essential, it should be carried out under specialist supervision, with close monitoring of blood pressure, renal function, and electrolytes (particularly potassium); monitoring should be considered at the start of treatment, then monthly, and also after any change in dose or during intercurrent illness.

INTERACTIONS Appendix 1 (aliskiren).

SIDE-EFFECTS
- Common or very common Arthralgia - dizziness - hyperkalaemia - diarrhoea
- Uncommon Acute renal failure (reversible on discontinuation of treatment) - hypotension - palpitation - peripheral oedema - cough - pruritus - rash - Stevens-Johnson syndrome - toxic epidermal necrolysis - urticaria
Hypertension

Thiazides and related diuretics can exacerbate diabetes, gout, and systemic lupus erythematosus.

INTERACTIONS → Appendix 1 (diuretics).

SIDE-EFFECTS
- Common or very common Altered plasma–lipid concentrations - gout - hypercalcaemia - hyperglycaemia - hyperuricaemia - hypochloremic alkalosis - hypokalaemia - hypomagnesaemia - hyponatraemia - metabolic and electrolyte disturbances - mild gastrointestinal disturbances - postural hypotension
- Uncommon Agranulocytosis - blood disorders - impotence - leucopenia - thrombocytopenia
- Frequency not known Cardiac arrhythmias - dizziness - headache - hypersensitivity reactions - intrahepatic cholestasis - pancreatitis - paraesthesia - photosensitivity - pneumonitis - pulmonary oedema - severe skin reactions - visual disturbances

PREGNANCY Thiazides and related diuretics should not be used to treat gestational hypertension. They may cause neonatal thrombocytopenia, bone marrow suppression, jaundice, electrolyte disturbances, and hypoglycaemia; placental perfusion may also be reduced. Stimulation of labour, uterine inertia, and meconium staining have also been reported.

HEPATIC IMPAIRMENT Caution in mild to moderate impairment. Avoid in severe liver disease. Hypokalaemia may precipitate coma in hepatic impairment, although hypokalaemia can be prevented by using a potassium-sparing diuretic. There is an increased risk of hypomagnesaemia in alcoholic cirrhosis.

RENAL IMPAIRMENT Thiazides and related diuretics are ineffective if eGFR is less than 30 mL/minute/1.73 m² and should be avoided. Metolazone remains effective if eGFR is less than 30 mL/minute/1.73 m² but is associated with a risk of excessive diuresis. Electrolytes should be monitored in renal impairment.

MONITORING REQUIREMENTS Electrolytes should be monitored, particularly with high doses and long-term use.

Bendroflumethiazide (Bendrofluazide)

INDICATIONS AND DOSE
- Oedema BY MOUTH
  - Adult: Initially 5–10 mg once daily or on alternate days, dose to be taken in the morning, then maintenance 5–10 mg 1–3 times a week

- Hypertension BY MOUTH
  - Adult: 2.5 mg daily, dose to be taken in the morning, higher doses are rarely necessary

BREAST FEEDING The amount present in milk is too small to be harmful. Large doses may suppress lactation.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet
- BENDROFLUMETHIAZIDE (Non-proprietary)
  - Bendroflumethiazide 2.5 mg Bendroflumethiazide 2.5mg tablets | 28 tablet (PSt) £3.68 DT price + £0.86 | 500 tablet (PSt) £60.71
  - Bendroflumethiazide 5 mg Bendroflumethiazide 5mg tablets | 28 tablet (PSt) £7.36 DT price + £0.97 | 500 tablet (PSt) £73.60
- Aprinox (AMCo)
  - Bendroflumethiazide 2.5 mg Aprinox 2.5mg tablets | 500 tablet (PSt) £27.31

Existing conditions Thiazides and related diuretics are seldom necessary when thiazides are used in the elderly because they are particularly susceptible to the side-effects. The dose should then be adjusted according to renal function. Diuretics should not be used continuously on a long-term basis to treat simple gravitational oedema (which will usually respond to increased movement, raising the legs, and support stockings).
Cyclophreniazide with amiloride
The properties listed below are those particular to the
combination only. For the properties of the components please
consider, amiloride hydrochloride p. 203, cyclophreniazide
p. 204.

**INDICATIONS AND DOSE**

**Hypertension**

**BY MOUTH**

- Adult: 1–2 tablets daily, dose to be taken in the morning

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines
containing the same drug.

**Tablet**

- **Excipients:** May contain Gluten

- **Navispare (AMCo)**

  Amiloride hydrochloride 2.5 mg, Cyclophreniazide 250
  microgram Navispare 2.5mg/250microgram tablets | 28
  tablet £3.24 DT price = £3.24

---

Hydrochlorothiazide

**INDICATIONS AND DOSE**

Indications listed in combination monographs (available in
the UK only in combination with other drugs)

**BY MOUTH**

- Adult: Doses listed in combination monographs

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: tablet, oral solution, oral suspension
Also available in combination with

- amloididine and olmesartan, p. 135
- amiloride and timolol, p. 147
- triamterene, p. 204
- captopril, p. 127
- enalapril, p. 127
- ibesartan, p. 134
- lisinopril, p. 129
- losartan, p. 135
- olmesartan, p. 136
- quinapril, p. 131
- telmisartan, p. 136
- valsartan, p. 137

---

Indapamide

**INDICATIONS AND DOSE**

Essential hypertension

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: 2.5 mg daily, dose to be taken in the morning

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adult: 1.5 mg daily, dose to be taken preferably in the morning

**CAUTIONS**

- Acute porphyrias p. 864

**SIDE-EFFECTS**

- Diuresis (with doses above 2.5 mg daily)

**ALLERGY AND CROSS-SENSITIVITY**

- Contraindicated if history of hypersensitivity to sulfonamides.

**BREAST FEEDING**

- Present in milk—manufacturer advises avoid.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral suspension

**Tablet**

- **Indapamide (Non-proprietary)**

  Indapamide hemihydrate 2.5 mg Indapamide 2.5mg tablets | 28
  tablet £40.99 DT price = £1.56 | 30 tablet £27.99 | 56
  tablet £52.00
4.2 Hypertension associated with phaeochromocytoma

Drugs used for Hypertension associated with phaeochromocytoma not listed below; Propanolol hydrochloride, p. 146

ALPHA-ADRENOCEPTOR BLOCKERS

Phenoxybenzamine hydrochloride

INDICATIONS AND DOSE
Hypertension in phaeochromocytoma
BY MOUTH
Adult: Initially 10 mg daily, increased in steps of 10 mg daily until hypertension controlled or treatment not tolerated; maintenance 1–2 mg/kg daily in 2 divided doses

CONTRA-INDICATIONS History of cerebrovascular accident

CAUTIONS Avoid contact with skin (risk of contact sensitisation) - avoid in Acute porphyrias p. 864 - carcinogenic in animals - cerebrovascular disease - congestive heart failure - elderly - severe ischaemic heart disease

SIDE-EFFECTS
- Rare Gastro-intestinal disturbances
- Frequency not known Inhibition of ejaculation - lassitude - miosis - nasal congestion - postural hypotension (with dizziness and marked compensatory tachycardia)

PREGNANCY Hypotension may occur in newborn.

BREAST FEEDING May be present in milk.

RENAL IMPAIRMENT Use with caution.

HANDLING AND STORAGE Owing to risk of contact sensitisation healthcare professionals should avoid contamination of hands.

MEDICINAL FORMS Medicines not identified.

4.3 Hypertensive crises

PERIPHERAL VASODILATORS

Sodium nitroprusside

INDICATIONS AND DOSE
Hypertensive emergencies
BY INTRAVENOUS INFUSION
Adult: 0.5–1.5 micrograms/kg/minute, adjusted in steps of 500 nanograms/kg/minute every 5 minutes, usual dose 0.5–8 micrograms/kg/minute, use lower doses if already receiving other antihypertensives, stop if response unsatisfactory with max. dose in 10 minutes, lower initial dose of 300 nanograms/kg/minute has been used

Maintenance of blood pressure at 30–40% lower than pretreatment diastolic blood pressure
BY INTRAVENOUS INFUSION
Adult: 20–400 micrograms/minute, use lower doses for patients being treated with other antihypertensives

Controlled hypotension in anaesthesia during surgery
BY INTRAVENOUS INFUSION
Adult: Up to 1.5 micrograms/kg/minute

Heart failure
BY INTRAVENOUS INFUSION
Adult: Initially 10–15 micrograms/minute, increased every 5–10 minutes as necessary; usual dose 10–200 micrograms/minute normally for max. 3 days
Cardiovascular system

PREGNANCY

SIDE-EFFECTS

INTERACTIONS

GUANETHIDINE MONOSULFATE

INHIBITORS

SELECTIVE POSTGANGLIONIC ADRENERGIC INHIBITORS

Guanethidine monosulfate

INDICATIONS AND DOSE

Hypertensive crisis (but no longer recommended)

BY INTRAMUSCULAR INJECTION

► Adult: 10–20 mg, dose may be repeated after 3 hours if necessary

CONTRA-INDICATIONS

Heart failure • phaeochromocytoma

CAUTIONS

Asthma • cerebral arteriosclerosis • coronary arteriosclerosis • history of peptic ulceration

INTERACTIONS

Appendix 1 (adrenergic neurons blockers).

SIDE-EFFECTS

Diarrhoea • drowsiness • failure of ejaculation • fluid retention • headache • nasal congestion • postural hypotension

PREGNANCY

Postural hypotension and reduced uteroplacental perfusion. Should not be used to treat hypertension in pregnancy.

RENAL IMPAIRMENT

Reduce dose if eGFR 40–65 mL/minute/1.73 m². Avoid if eGFR less than 40 mL/minute/1.73 m².

LESS SUITABLE FOR PRESCRIBING

Guanethidine monosulfate is less suitable for prescribing.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

GUANETHIDINE MONOSULFATE (Non-proprietary)

Guanethidine monosulfate 10 mg per 1 ml

Guanethidine 10mg/1ml solution for injection ampoules | 5 ampoule

4.4 Pulmonary hypertension

Drugs used for Pulmonary Hypertension not listed below

Epoprostenol, p. 99 • Sildenafil, p. 699 • Tadalafil, p. 700

ENDOTHELIN RECEPTOR ANTAGONISTS

Ambrisentan

INDICATIONS AND DOSE

Pulmonary arterial hypertension

BY MOUTH

► Adult: 5 mg once daily, increased if necessary to 10 mg once daily

Dose adjustments due to interactions

Max. 5 mg daily with concomitant ciclosporin.

CONTRA-INDICATIONS

Idiopathic pulmonary fibrosis

CAUTIONS

Not to be initiated in significant anaemia

INTERACTIONS

Appendix 1 (ambrisentan).

SIDE-EFFECTS

► Common or very common Abdominal pain • anaemia • chest pain • constipation • diarrhoea • dizziness • dyspnoea • epistaxis • flushing • headache • heart failure • hypotension • malaise • nausea • palpitation • peripheral oedema • upper respiratory-tract disorders • vomiting

► Uncommon Autoimmune hepatitis • hepatic injury • syncope

CONCEPTION AND CONTRACEPTION

Exclude pregnancy before treatment and ensure effective contraception during treatment. Monthly pregnancy tests advised.

PREGNANCY

Avoid (teratogenic in animal studies).

BREAST FEEDING

Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT

Avoid in severe impairment.

RENAL IMPAIRMENT

Use with caution if eGFR less than 30 mL/minute/1.73 m².

MONITORING REQUIREMENTS

Monitor haemoglobin concentration or haematocrit before treatment and ensure effective contraception during treatment. Monthly pregnancy tests advised.

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2008) that ambrisentan (Volibris®) should be prescribed only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.
#### Macitentan

**INDICATIONS AND DOSE**

**Pulmonary arterial hypertension**

**BY MOUTH**

- Adult: Initially 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily (max. per dose 250 mg), maximum 500 mg per day.

**Systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers)**

**BY MOUTH**

- Adult: Initially 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily.

- **CONTRA-INDICATIONS** Acute porphyrias p. 864
- **CAUTIONS** Not to be initiated if systemic systolic blood pressure is below 85 mmHg.
- **INTERACTIONS** → Appendix 1 (bosentan).
- **SIDE-EFFECTS**
  - Common or very common Anaemia, diarrhoea, flushing, gastro-oesophageal reflux, headache, hypotension, oedema, palpititation, syncope.
  - Uncommon Leucopenia, neutropenia, thrombocytopenia.
  - Rare Liver cirrhosis, liver failure.
- **CONCEPTION AND CONTRACEPTION** Effective contraception required during administration (hormonal contraception not considered effective). Monthly pregnancy tests advised.
- **PREGNANCY** Avoid (teratogenic in animal studies).
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Avoid in moderate and severe impairment.
- **MONITORING REQUIREMENTS**
  - Monitor liver function before treatment, then monthly thereafter (discontinue if unexplained persistent raised serum transaminases or signs of hepatic injury—can restart on advice on hepatologist if liver function tests return to normal and no hepatic injury).
  - Monitor haemoglobin concentration before treatment and monthly.
- **PATIENT AND CARER ADVICE** Patient card should be provided. Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as dark urine, nausea, vomiting, fatigue, abdominal pain, or pruritus develop.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (March 2014) that macitentan (Opsumit®) should be initiated and prescribed only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Tracleer** (Actelion Pharmaceuticals UK Ltd)
  - Bosentan (as Bosentan monohydrate) 62.5 mg Tracleer 62.5mg tablets | 56 tablet [POM] £1,510.21
  - Bosentan (as Bosentan monohydrate) 125 mg Tracleer 125mg tablets | 56 tablet [POM] £1,510.21

#### Bosentan

**INDICATIONS AND DOSE**

**Pulmonary arterial hypertension**

**BY MOUTH**

- Adult: Initially 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily (max. per dose 250 mg), maximum 500 mg per day.

**Systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers)**

**BY MOUTH**

- Adult: Initially 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily.

- **CONTRA-INDICATIONS** Severe anaemia.
- **CAUTIONS** Patients over 75 years - pulmonary veno-occlusive disease.
- **INTERACTIONS** → Appendix 1 (macitentan).
- **SIDE-EFFECTS**
  - Common or very common Anaemia, bronchitis, headache, hypotension, upper respiratory-tract disorders, urinary-tract infection.
  - Frequency not known Leucopenia, thrombocytopenia.
- **CONCEPTION AND CONTRACEPTION** Manufacturer advises avoid pregnancy before treatment and ensure effective contraception during and for one month after stopping treatment. Monthly pregnancy tests advised.
- **PREGNANCY** Toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Do not initiate if serum transaminases exceed 3 times upper limit of normal. Avoid in moderate and severe impairment.
- **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment and avoid in patients undergoing dialysis (no information available).
- **SPECIAL FEATURES** In renal impairment consider monitoring blood pressure (risk of hypotension).
- **MONITORING REQUIREMENTS**
  - Monitor liver function before treatment, then monthly thereafter (discontinue if unexplained persistent raised serum transaminases or signs of hepatic injury—can restart on advice on hepatologist if liver function tests return to normal and no hepatic injury).
  - Monitor haemoglobin concentration before treatment and then as indicated.
  - **PATIENT AND CARER ADVICE** Patient card should be provided. Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as dark urine, nausea, vomiting, fatigue, abdominal pain, or pruritus develop.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (March 2014) that bosentan (Opsumit®) should be initiated and prescribed only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Tracleer** (Actelion Pharmaceuticals UK Ltd)
  - Bosentan (as Bosentan monohydrate) 62.5 mg Tracleer 62.5mg tablets | 30 tablet [POM] £1,618.08
  - Bosentan 10 mg Volibris 10mg tablets | 30 tablet [POM] £1,618.08
only if systolic blood pressure $\geq 95$ mmHg and no signs of hypotension, if treatment interrupted for 3 or more days, restart at $\geq 0.5$ mg three times daily for 2 weeks and titrate as before, during titration, reduce dose by $\geq 0.5$ mg three times daily if systolic blood pressure falls below $95$ mmHg and patient shows signs of hypotension

- **CONTRA-INDICATIONS** History of serious haemoptysis - previous bronchial artery embolisation - pulmonary veno-occlusive disease
- **CAUTIONS** Autonomic dysfunction - elderly (risk of hypotension) - hypotension (do not initiate if systolic blood pressure below $95$ mmHg) - hypovolaemia - severe left ventricular outflow obstruction

**CAUTIONS, FURTHER INFORMATION**

- **Smoking** Smoking cessation advised (response possibly reduced); dose adjustment may be necessary if smoking started or stopped during treatment.
- **INTERACTIONS** $\rightarrow$ Appendix 1 (riociguat).
- **SIDE-EFFECTS**
  - Common or very common: Anaemia - constipation - diarrhoea - dizziness - dyspepsia - dysphagia - epistaxis - gastritis - gastro-oesophageal reflux - haemoptysis - headache - hypotension - nasal congestion - nausea - palpitation - peripheral oedema - vomiting
  - Uncommon: Pulmonary haemorrhage
- **CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment. Monthly pregnancy tests advised.
- **PREGNANCY** Avoid—toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Titrate dose cautiously in moderate impairment. Manufacturer advises avoid in severe impairment—no information available.
- **RENAL IMPAIRMENT** Titrate dose cautiously—risk of hypotension. Manufacturer advises avoid if eGFR less than $30$ mL/minute/1.73 m$^2$—limited information available.
- **PATIENT AND CARER ADVICE** Smoking cessation advised (response possibly reduced). Patients should inform prescriber if smoking started or stopped during treatment; dose adjustment may be necessary.
- **NATIONAL FUNDING/ACCESS DECISIONS**

  **Scottish Medicines Consortium (SMC) Decisions**

  The Scottish Medicines Consortium has advised (November 2014) that riociguat (Adempas®) is accepted for restricted use within NHS Scotland for the treatment of chronic thromboembolic pulmonary hypertension in patients for whom a phosphodiesterase type-5 inhibitor is inappropriate, not tolerated, or ineffective, and should only be prescribed by specialists in the Scottish Pulmonary Vascular Unit.

  **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  - **Tablet**
    - Adempas (Bayer Plc)
      - Riociguat 500 microgram | Adempas 0.5mg tablets | 42 tablet | £997.36 | 84 tablet | £1,994.72
      - Riociguat 1 mg | Adempas 1mg tablets | 42 tablet | £997.36 | 84 tablet | £1,994.72
      - Riociguat 1.5 mg | Adempas 1.5mg tablets | 42 tablet | £997.36 | 84 tablet | £1,994.72
      - Riociguat 2 mg | Adempas 2mg tablets | 42 tablet | £997.36 | 84 tablet | £1,994.72
      - Riociguat 2.5 mg | Adempas 2.5mg tablets | 42 tablet | £997.36 | 84 tablet | £1,994.72

**PROSTAGLANDINS (CARDIOVASCULAR)**

**Iloprost**

**INDICATIONS AND DOSE**

Idiopathic or familial pulmonary arterial hypertension (initiated under specialist supervision)

- Adult: Initially 2.5 micrograms for 1 dose, increased to 5 micrograms for 1 dose, if tolerated maintain at 5 micrograms 6–9 times a day, according to response; reduced if higher dose not tolerated to 2.5 micrograms 6–9 times a day

**CONTRA-INDICATIONS** Conditions which increase risk of haemorrhage - congenital or acquired valvular defects of the myocardium - decompensated cardiac failure (unless under close medical supervision) - pulmonary veno-occlusive disease - severe arrhythmias - unstable angina - within 3 months of cerebrovascular events - within 6 months of myocardial infarction

**CAUTIONS**

- **GENERAL CAUTIONS** Hypotension (do not initiate if systolic blood pressure below 85 mmHg) - unstable pulmonary hypertension with advanced right heart failure - acute pulmonary infection - chronic obstructive pulmonary disease - severe asthma
- **INTERACTIONS** $\rightarrow$ Appendix 1 (Iloprost).
- **SIDE-EFFECTS**
  - Common or very common: Chest pain - cough - diarrhoea - dyspnoea - haemorrhage - headache - hypotension - jaw pain - nausea - oral irritation - rash - throat pain - vomiting
  - Frequency not known: Bronchospasm - taste disturbance - thrombocytopenia - wheezing
- **PREGNANCY** Use if potential benefit outweighs risk.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Elimination reduced. Initially 2.5 micrograms at intervals of 3–4 hours (max. 6 times daily), adjusted according to response (consult product literature).
- **DIRECTIONS FOR ADMINISTRATION** To minimise accidental exposure use only with nebulisers listed in Ventavis® product literature in a well ventilated room.
- **PRESCRIBING AND DISPENSING INFORMATION** Delivery characteristics of nebuliser devices may vary—only switch devices under medical supervision.
- **NATIONAL FUNDING/ACCESS DECISIONS**

  **Scottish Medicines Consortium (SMC) Decisions**

  The Scottish Medicines Consortium has advised (November 2005) that iloprost (Ventavis®) is accepted for restricted use within NHS Scotland in patients in whom bosentan is ineffective or not tolerated, and should only be prescribed by specialists in the Scottish Pulmonary Vascular Unit.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Nebuliser liquid**

- Ventavis (Bayer Plc)
  - Iloprost (as iloprost trometamol) 10 microgram per $1$ ml Ventavis 10micrograms/ml nebuliser solution $1$ml ampoules | 30 ampoule | £1,400.19 | 168 ampoule | £2,241.08
4.5 Hypotension and shock

Sympathomimetics

Inotropic sympathomimetics

Shock
Shock is a medical emergency associated with a high mortality. The underlying causes of shock such as haemorrhage, sepsis, or myocardial insufficiency should be corrected. The profound hypotension of shock must be treated promptly to prevent tissue hypoxia and organ failure. Volume replacement is essential to correct the hypovolaemia associated with haemorrhage and sepsis but may be detrimental in cardiogenic shock. Depending on haemodynamic status, cardiac output may be improved by the use of sympathomimetic inotropes such as adrenaline/epinephrine p. 196, dobutamine p. 193 or dopamine hydrochloride below. In septic shock, when fluid replacement and inotropic support fail to maintain blood pressure, the vasoconstrictor noradrenaline/norepinephrine p. 166 may be considered. In cardiogenic shock peripheral resistance is frequently high and to raise it further may worsen myocardial performance and exacerbate tissue ischaemia.

The use of sympathomimetic inotropes and vasoconstrictors should preferably be confined to the intensive care setting and undertaken with invasive haemodynamic monitoring.

See also advice on the management of anaphylactic shock p. 242.

Vasoconstrictor sympathomimetics

Vasoconstrictor sympathomimetics raise blood pressure transiently by acting on alpha-adrenergic receptors to constrict peripheral vessels. They are sometimes used as an emergency method of elevating blood pressure where other measures have failed.

The danger of vasoconstrictors is that although they raise blood pressure they also reduce perfusion of vital organs such as the kidney.

Spinal and epidural anaesthesia may result in sympathetic block with resultant hypotension. Management may include intravenous fluids (which are usually given prophylactically), oxygen, elevation of the legs, and injection of a pressor drug such as ephedrine hydrochloride p. 237. As well as constricting peripheral vessels ephedrine hydrochloride p. 237 also accelerates the heart rate (by acting on beta receptors). Use is made of this dual action of ephedrine hydrochloride p. 237 to manage associated bradycardia (although intravenous injection of atropine sulfate p. 949 may also be required if bradycardia persists).

Metaraminol

INDICATIONS AND DOSE
Acute hypotension
BY INTRAVENOUS INFUSION
Adult: 15–100 mg, adjusted according to response
Emergency treatment of acute hypotension
INITIALLY BY INTRAVENOUS INJECTION
Adult: Initially 0.5–5 mg, then (by intravenous infusion) 15–100 mg, adjusted according to response
Priapism (alternative to intracavernosal injections of phentolamine and adrenaline)
BY INTRACAVERNOSAL INJECTION
Adult: 1 mg every 15 minutes

Drugs used for Hypotension and shock not listed below; Dobutamine, p. 193 · Ephedrine hydrochloride, p. 237 · Labetalol hydrochloride, p. 143 · Sodium nitroprusside, p. 161

Dopamine hydrochloride

Drug action
Dopamine is a cardiac stimulant which acts on beta, receptors in cardiac muscle, and increases contractility with little effect on rate.

INDICATIONS AND DOSE
Cardiogenic shock in infarction or cardiac surgery
BY INTRAVENOUS INFUSION
Adult: Initially 2–5 micrograms/kg/minute

CONTRA-INDICATIONS
Phaeochromocytoma · tachyarrhythmia

CAUTIONS
Correct hypovolaemia · hyperthyroidism · low dose in shock due to acute myocardial infarction

INTERACTIONS
Appendix 1 (sympathomimetics).

SIDE-EFFECTS
Common or very common Chest pain · dyspnoea · headache · hypotension · nausea · palpitation · tachycardia · vasodilatation · vomiting

Uncommon Bradycardia · gangrene · hypertension · mydriasis

Rare Fatal ventricular arrhythmias

PREGNANCY
No evidence of harm in animal studies—manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING
May suppress lactation—not known to be harmful.

DIRECTIONS FOR ADMINISTRATION
For intravenous infusion give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to max. concentration of 3.2 mg/ml; incompatible with bicarbonate. Dopamine concentrate for intravenous infusion to be diluted before use.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from specialist-order manufacturers include: solution for infusion

Solution for infusion
DOPAMINE HYDROCHLORIDE (Non-proprietary)
Dopamine hydrochloride 100 mg per 1 ml
Dopamine hydrochloride 200 mg per 1 ml

DOPAMINE HYDROCHLORIDE (proprietary)

Dopamine hydrochloride 1 mg/mL; incompatible with bicarbonate. Dopamine concentrate for intravenous infusion to be diluted before use.

SYMPATHOMIMETICS (VASOCONSTRICTOR)

Metaraminol
vasoconstrictor response may cause a prolonged rise in blood pressure.

- **INTERACTIONS** → Appendix 1 (sympathomimetics).
- **SIDE-EFFECTS** Angle-closure glaucoma, anorexia, anxiety, arrhythmias, bradycardia, confusion, dyspnoea, fatal ventricular arrhythmia reported in Laennec’s cirrhosis, headache, hypotension, hypoxia, insomnia, nausea, palpititation, peripheral ischaemia, psychosis, tachycardia, tremor, urinary retention, vomiting, weakness.
- **PREGNANCY** May reduce placental perfusion—manufacturer advises use only if potential benefit outweighs risk.
- **BREAST FEEDING** Manufacturer advises caution—no information available.
- **MONITORING REQUIREMENTS** Monitor blood pressure and rate of flow frequently.
- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Aramine®), give continuously or via drip tubing in Glucose 5% or Sodium chloride 0.9%. Suggested volume 500 mL.
  - For **intracavernosal injection**, dilute 1 mg (0.1 mL of 10 mg/mL metaraminol injection to 50 mL with Sodium chloride injection 0.9% and give carefully by slow injection into the corpora in 5–10 mL injections.
- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

**Noradrenaline/norepinephrine**

**INDICATIONS AND DOSE**

**Acute hypotension**

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 0.16–0.33 mL/minute, adjusted according to response, to be given via central venous catheter, of a solution containing noradrenaline 40 micrograms/base/mL.

**Dose equivalence and conversion**

1 mg of noradrenaline base is equivalent to 2 mg of noradrenaline acid tartrate. **Doses expressed as the base.**

- **CONTRA-INDICATIONS** Hypertension
- **CAUTIONS** Coronary vascular thrombosis, diabetes mellitus, elderly, extravasation at injection site may cause necrosis, following myocardial infarction, hypercapnia, hyperthyroidism, hypoxia, mesenteric vascular thrombosis, peripheral vascular thrombosis, Prinzmetal’s variant angina, uncorrected hypovolaemia
- **INTERACTIONS** → Appendix 1 (sympathomimetics).
- **SIDE-EFFECTS** Angle-closure glaucoma, anorexia, anxiety, arrhythmias, bradycardia, confusion, dyspnoea, headache, hypertension, hypoxia, insomnia, nausea, palpitation, peripheral ischaemia, psychosis, tachycardia, tremor, urinary retention, vomiting, weakness.
- **PREGNANCY** Avoid—may reduce placental perfusion.
- **MONITORING REQUIREMENTS** Monitor blood pressure and rate of flow frequently.
- **DIRECTIONS FOR ADMINISTRATION** For treatment of acute hypotension in adults, use a solution containing noradrenaline 40 micrograms (base)/mL.
  - For intravenous infusion, give continuously in Glucose 5% or Sodium Chloride and glucose via a controlled infusion device. For administration via syringe pump, dilute 2 mg (2 mL of solution) noradrenaline base with 48 mL infusion fluid. For administration via drip counter dilute 20 mg (20 mL of solution) noradrenaline base with 480 mL

**Phenylephrine hydrochloride**

**INDICATIONS AND DOSE**

- **Acute hypotension**
  - **BY SUBCUTANEOUS INJECTION**
    - Adult: Initially 2–5 mg, followed by further doses of 1–10 mg, after at least 15 minutes if required.
  - **BY INTRAVENOUS INJECTION**
    - Adult: 100–500 micrograms, repeated as necessary after at least 15 minutes; a 1 mg/1 mL solution to be used.

- **Priapism**
  - **BY INTRACavernOSAL INJECTION**
    - Adult: 100–200 micrograms every 5–10 minutes; maximum 1 mg per course

- **UNLICENSED USE** Use of phenylephrine hydrochloride injection in priapism is an unlicensed indication.
- **CONTRA-INDICATIONS** Hypertension, Severe hyperthyroidism
- **CAUTIONS** Coronary disease, coronary vascular thrombosis, diabetes, elderly, extravasation at injection site may cause necrosis, following myocardial infarction, hypercapnia, hyperthyroidism, hypoxia, mesenteric vascular thrombosis, peripheral vascular thrombosis, Prinzmetal’s variant angina, susceptibility to angle-closure glaucoma, uncorrected hypovolaemia

**CAUTIONS, FURTHER INFORMATION**

**Hypertensive response** Phenylephrine has a longer duration of action than noradrenaline (norepinephrine), and an excessive vasoconstrictor response may cause a prolonged rise in blood pressure.

- **INTERACTIONS** → Appendix 1 (sympathomimetics). Phenylephrine may interact with systemically administered monoamine oxidase inhibitors.
- **SIDE-EFFECTS** Arrhythmias, hypertension, palpitation, tachycardia, angle-closure glaucoma, anorexia, anxiety, bradycardia (also reflex bradycardia), confusion, dyspnoea, headache, hypoxia, insomnia, nausea, peripheral ischaemia, psychosis, tremor, urinary retention, vomiting, weakness.
- **PREGNANCY** Avoid if possible; malformations reported following use in first trimester; fetal hypoxia and bradycardia reported in late pregnancy and labour.
5 Heart failure

Heart failure

Drug treatment of heart failure associated with a reduced left ventricular ejection fraction (left ventricular systolic dysfunction) is covered below; optimal management of heart failure with a preserved left ventricular ejection fraction has not been established.

The treatment of chronic heart failure aims to relieve symptoms, improve exercise tolerance, reduce the incidence of acute exacerbations, and reduce mortality. An ACE

inhibitor, titrated to a ‘target dose’ (or the maximum tolerated dose if lower), together with a beta-blocker, form the basis of treatment for all patients with heart failure due to left ventricular systolic dysfunction.

An ACE inhibitor is generally advised for patients with asymptomatic left ventricular systolic dysfunction or symptomatic heart failure. An angiotensin-II receptor antagonist may be a useful alternative for patients who, because of side-effects such as cough, cannot tolerate ACE inhibitors; a relatively high dose of the angiotensin-II receptor antagonist may be required to produce benefit. Candesartan cilexetil p. 133 or valsartan p. 136 may be given under specialist supervision as adjuncts to an ACE inhibitor in the treatment of heart failure when other treatments are unsuitable; the concomitant use of this combination, together with an aldosterone antagonist or a potassium-sparking diuretic is not recommended.

The beta-blockers bisoprolol fumarate p. 142 and carvedilol p. 142 are of value in any grade of stable heart failure due to left ventricular systolic dysfunction; nebivolol p. 145 is licensed for stable mild to moderate heart failure in patients over 70 years. Beta-blocker treatment should be started by those experienced in the management of heart failure, at a very low dose and titrated very slowly over a period of weeks or months. Symptoms may deteriorate initially, calling for adjustment of concomitant therapy.

The aldosterone antagonist spironolactone p. 168 can be added to an ACE inhibitor and a beta-blocker in patients who continue to remain symptomatic (particularly in those with moderate to severe heart failure); low doses of spironolactone reduce symptoms and mortality in these patients. If spironolactone cannot be used, eplerenone below may be considered for the management of heart failure after an acute myocardial infarction with evidence of left ventricular systolic dysfunction, or for chronic mild heart failure with left ventricular systolic dysfunction. Close monitoring of serum creatinine, eGFR, and potassium is necessary, particularly following any change in treatment or any change in the patient’s clinical condition.

Patients who cannot tolerate an ACE inhibitor or an angiotensin-II receptor antagonist, or in whom they are contra-indicated, may be given isosorbide dinitrate p. 191 with hydralazine hydrochloride p. 157 but this combination may be poorly tolerated. The combination of isosorbide dinitrate p. 191 and hydralazine hydrochloride p. 157 may be considered in addition to standard therapy with an ACE inhibitor and a beta-blocker in patients who continue to remain symptomatic (particularly in patients of African or Caribbean origin who have moderate to severe heart failure).

Digoxin p. 94 improves symptoms of heart failure and exercise tolerance and reduces hospitalisation due to acute exacerbations but it does not reduce mortality. Digoxin is reserved for patients with worsening or severe heart failure due to left ventricular systolic dysfunction who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker in combination with either an aldosterone antagonist, candesartan cilexetil, or isosorbide dinitrate with hydralazine hydrochloride.

Patients with fluid overload should also receive either a loop or a thiazide diuretic (with salt or fluid restriction where appropriate). A thiazide diuretic may be of benefit in patients with mild heart failure and good renal function; however, thiazide diuretics are ineffective in patients with poor renal function (eGFR less than 30 mL/minute/1.73 m²) and a loop diuretic is preferred. If diuresis with a single diuretic is insufficient, a combination of a loop diuretic and a thiazide diuretic may be tried; addition of metolazone p. 205 may also be considered but the resulting diuresis may be profound and care is needed to avoid potentially dangerous electrolyte disturbances.

Drugs used for Heart failure not listed below:
Candesartan cilexetil, p. 133. Captopril, p. 126.
Isosorbide mononitrate, p. 192. Ivalradine, p. 185.
Perindopril erbumine, p. 130. Prazosin, p. 674.
Valsartan, p. 136.

ALDOSTERONE ANTAGONISTS

Eplerenone

INDICATIONS AND DOSE
Adjunct in stable patients with left ventricular ejection fraction < 40% with evidence of heart failure, following myocardial infarction (start therapy within 3–14 days of event) | Adjunct in chronic mild heart failure with left ventricular ejection fraction ≤ 30%

BY MOUTH
Adult: Initially 25 mg daily, then increased to 50 mg daily, increased within 4 weeks of initial treatment.

CONTRA-INDICATIONS Hyperkalaemia
CAUTIONS Elderly
INTERACTIONS | Appendix 1 (diuretics).
Concomitant use of potassium-sparking diuretics or potassium supplements is contra-indicated.
SIDE-EFFECTS
Common or very common Azotaemia, constipation, cough, diarrhoea, dizziness, hyperkalaemia, hypotension.
Cardiovascular system

Spironolactone

INDICATIONS AND DOSE

Oedema | Ascites in cirrhosis of the liver
BY MOUTH
• Adult: 100–400 mg daily, adjusted according to response

Malignant ascites
BY MOUTH
• Adult: Initially 100–200 mg daily, then increased if necessary to 400 mg daily, maintenance dose adjusted according to response

Nephrotic syndrome
BY MOUTH
• Adult: 100–200 mg daily

Oedema in congestive heart failure
BY MOUTH
• Adult: Initially 100 mg daily, alternatively initially 25–200 mg daily, dose may be taken as a single dose or divided doses, maintenance dose adjusted according to response

Moderate to severe heart failure (adjunct)
BY MOUTH
• Adult: Initially 25 mg once daily, then adjusted according to response to 50 mg once daily

Resistant hypertension (adjunct)
BY MOUTH
• Adult: 25 mg once daily

Primary hyperaldosteronism in patients awaiting surgery
BY MOUTH
• Adult: 100–400 mg daily, may be used for long-term maintenance if surgery inappropriate, use lowest effective dose

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet
• EPLERENONE (Non-proprietary)
  Eplerenone 25 mg Eplerenone 25mg tablets | 28 tablet | £35.45-£42.72 DT price = £39.04
  Eplerenone 50 mg Eplerenone 50mg tablets | 28 tablet | £35.45-£42.72 DT price = £38.95
• Inspra (Pfizer Ltd)
  Eplerenone 25 mg Inspra 25mg tablets | 28 tablet | £42.72 DT price = £39.04
  Eplerenone 50 mg Inspra 50mg tablets | 28 tablet | £42.72 DT price = £38.95

Co-flumecine

The properties listed below are those particular to the combination only. For the properties of the components please consider, spironolactone above and Thiazides, p. 159.
PHOSPHODIESTERASE TYPE-3 INHIBITORS

Enoximone

**DRUG ACTION** Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.

**INDICATIONS AND DOSE**

**Congestive heart failure where cardiac output reduced and filling pressures increased**

**BY SLOW INTRAVENOUS INJECTION (RATE NOT EXCEEDING 12.5 ML/MINUTE)**

- Adult: Initially 0.5–1 mg/kg, then 500 micrograms/kg every 30 minutes until a satisfactory response is achieved or a total dose of 3 mg/kg is reached; maintenance, initial dose of up to 3 mg/kg every 3–6 hours as required

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 90 micrograms/kg/minute, dose to be given over 10–30 minutes, followed by 5–20 micrograms/kg/minute, dose to be given as either a continuous or intermittent infusion; maximum 24 mg/kg per day

**CAUTIONS** Heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction

**INTERACTIONS** → Appendix 1 (phosphodiesterase type-3 inhibitors).

**SIDE-EFFECTS**

- Chills · diarrhoea · ectopic beats · fever · headache · hypotension · insomnia · nausea · oliguria · supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias) · upper and lower limb pain · urinary retention · ventricular tachycardia (more likely in patients with pre-existing arrhythmias) · vomiting

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Dose reduction may be required.

**RENAL IMPAIRMENT** Consider dose reduction.

**MONITORING REQUIREMENTS** Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.

**DIRECTIONS FOR ADMINISTRATION** Incompatible with glucose solutions. Use only plastic containers or syringes; crystal formation if glass used. Avoid extravasation.

For intravenous infusion (Perfan®), give continuously or intermittently in Sodium chloride 0.9% or Water for injections; dilute to a concentration of 2.5 mg/mL.

**PRESCRIBING AND DISPENSING INFORMATION** Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**EXCipients:** May contain Alcohol, propylene glycol

- Perfan (Myogen GmbH)
  - Enoximone 5 mg per 1 ml. Perfan 100mg/20ml solution for injection ampoules | 10 ampoule (PBN) no price available (hospital only)

**Milorinone**

**DRUG ACTION** Milrinone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.

**INDICATIONS AND DOSE**

**Short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy (not immediately after myocardial infarction) / Acute heart failure, including low output states following heart surgery**

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: Initially 50 micrograms/kg, given over 10 minutes, followed by (by intravenous infusion) 375–750 nanograms/kg/minute usually given following surgery for up to 12 hours or in congestive heart failure for 48–72 hours; maximum 1.13 mg/kg per day

**CONTRA-INDICATIONS** Severe hypovolaemia

**CAUTIONS** Correct hypokalaemia · heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction

**INTERACTIONS** → Appendix 1 (phosphodiesterase type-3 inhibitors).

**SIDE-EFFECTS**

- Common or very common Ectopic beats · headache · hypotension · supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias) · ventricular tachycardia

- Uncommon Chest pain · hypokalaemia · thrombocytopenia · tremor · ventricular fibrillation

- Very rare Anaaphylaxis · bronchospasms · rash

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**RENAI IMPAIRMENT** Reduce dose and monitor response if eGFR less than 50 mL/minute/1.73 m²—consult product literature for details.

**MONITORING REQUIREMENTS** Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.

**DIRECTIONS FOR ADMINISTRATION** Avoid extravasation. For intravenous injection, may be given either undiluted or diluted before use. For intravenous infusion (Primacor®) give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to a suggested concentration of 200 micrograms/mL.
Hyperlipidaemia

6 Hyperlipidaemia

Primary and secondary prevention of cardiovascular disease

Preventative measures should be taken in individuals with a high risk of developing cardiovascular disease (primary prevention) and to prevent recurrence of events in those with established cardiovascular disease (secondary prevention).

Primary prevention

Individuals at high risk of developing cardiovascular disease include those who have diabetes mellitus, chronic kidney disease (eGFR < 60 mL/minute/1.73 m²) and/or albuminuria, and those with familial hypercholesterolaemia. The risk also increases with age; those aged 85 years and over are at particularly high risk, especially if they smoke or have hypertension. Preventative measures are also required for other individuals who are considered to be at high risk of developing atherosclerotic cardiovascular disease based on risk estimated using risk calculators (see Risk calculators); those with a 10-year risk of cardiovascular disease of 10% or more stand to benefit most from drug treatment. Patients with a 10-year cardiovascular risk of less than 10% may benefit from an assessment of their lifetime risk (using the JBS3 tool—see Risk calculators for more detail), discussion on the impact of lifestyle interventions and, if necessary, drug therapy.

Risk calculators

Risk assessment calculators are recommended by both NICE (clinical guideline 181 (July 2014). Lipid Modification—Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease) and JBS3 (Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease 2014). They should not be used in patients at high cardiovascular risk. Both calculators are unsuitable for assessing risk in those aged 85 years and over, and NICE advises against using a risk assessment tool in those with type 1 diabetes mellitus.

The QRSiK®2 risk calculator www.qrisk.org/ is recommended by NICE clinical guideline 181, and the JBS3 risk calculator www.jbs3risk.com/pages/risk_calculator.htm is endorsed by JBS3. Both tools assess cardiovascular risk—coronary heart disease (angina and myocardial infarction), stroke, and transient ischaemic attack, on the basis of lipid profile, systolic blood pressure, gender, age, ethnicity, smoking status, BMI, chronic kidney disease, diabetes mellitus, atrial fibrillation, treated hypertension, rheumatoid arthritis, or a family history of premature cardiovascular disease. Risk assessment tools underestimate risk in patients with additional risk due to existing conditions or medication, such as:

- serious mental disorder
- autoimmune disorders such as systemic lupus erythematosus and other systemic inflammatory disorders
- antiretroviral treatment
- medication causing dyslipidaemia as a side-effect e.g. antipsychotics, corticosteroids, or immunosuppressants
- triglyceride concentration > 4.5 mmol/litre

Cardiovascular disease risk is also underestimated in those who are already taking antihypertensive or lipid-regulating drugs, and in those who have recently stopped smoking. Severe obesity (BMI > 40 kg/m²) also increases cardiovascular risk; the need for further treatment of risk

Dopexamine hydrochloride

**Drug action**

Dopexamine acts on beta, receptors in cardiac muscle to produce a positive inotropic effect; and on peripheral dopamine receptors to increase renal perfusion; it is reported not to induce vasoconstriction.

**Indications and dose**

Inotropic support and vasodilator in exacerbations of chronic heart failure and in heart failure associated with cardiac surgery

**By intravenous infusion**

- Adult: 0.5 microgram/kg/minute, to be administered into central or large peripheral vein, then increased if necessary to 1 microgram/kg/minute, increased if necessary up to 6 micrograms/kg/minute, in increments of 0.5–1 microgram/kg/minute at intervals of not less than 15 minutes

**Contra-indications**

Aortic stenosis • hypertrophic cardiomyopathy • left ventricular outlet obstruction • phaeochromocytoma • thrombocytopenia

**Caution**

Correct hypovolaemia before starting and during treatment • hyperglycaemia • hyperthyroidism • hypokalaemia • myocardial infarction • recent angina

**Interactions**

- Appendix 1 (sympathomimetics).

**Side-effects**

- Common or very common Angina • arrhythmias • bradycardia • dyspnoea • headache • myocardial infarction • nausea • reversible thrombocytopenia • sweating • tachycardia • tremor • vomiting

**Pregnancy**

No information available—manufacturer advises avoid.

**Monitoring requirements**

Monitor blood pressure, pulse, plasma potassium, and blood glucose.

**Treatment cessation**

Avoid abrupt withdrawal.

**Directions for administration**

Concentrate for intravenous infusion to be diluted before use. For continuous intravenous infusion, dilute to a concentration of 400 or 800 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%; max. concentration via large peripheral vein 1 mg/mL, concentrations up to 4 mg/mL may be infused via central veins; give via infusion pump or other device which provides accurate control of rate; contact with metal in infusion apparatus should be minimised; incompatible with bicarbonate.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- Dopcard (Neva UK Ltd)
  - Dopexamine hydrochloride 10 mg per 1 ml Dopcard 50mg/5ml concentrate for solution for infusion ampoules | 10 ampoule £252.00 (Hospital only)
factors in patients below the cardiovascular risk threshold for treatment should be based on clinical judgement.

**Preventative measures for primary prevention**

All patients at high risk of cardiovascular disease should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight management, alcohol consumption, and smoking cessation.

Offer a statin as first-line drug treatment if lifestyle modifications are inappropriate or ineffective (see also Statins for the prevention of cardiovascular disease). Lipid-regulating drug treatment must be combined with advice on diet and lifestyle measures, and where appropriate, treatment of comorbidities and secondary causes of dyslipidaemia.

**Secondary prevention**

Statins should be offered to all patients, including the elderly, with cardiovascular disease such as those with coronary heart disease (including history of angina or acute myocardial infarction), occlusive arterial disease (including peripheral vascular disease, non-haemorrhagic stroke, or transient ischaemic attacks).

**Preventative measures for secondary prevention**

Patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight management, alcohol consumption, and smoking cessation, however, initiation of lipid-regulating drug treatment should not be delayed to manage modifiable risk factors, and must be combined with advice on diet and lifestyle measures, and where appropriate, treatment of comorbidities and secondary causes of dyslipidaemia.

**Statins for the prevention of cardiovascular disease**

A statin reduces the risk of cardiovascular disease events, and is the drug of first choice for primary and secondary prevention of cardiovascular disease. Before starting treatment with statins, secondary causes of dyslipidaemia should be addressed; these include uncontrolled diabetes mellitus, hepatic disease, nephrotic syndrome, and excessive alcohol consumption. Patients with hypothyroidism should receive adequate thyroid replacement therapy (before assessing the requirement for lipid-regulating treatment if for primary prevention) because correcting hypothyroidism itself may resolve the lipid abnormality. Untreated hypothyroidism increases the risk of myositis with lipid-regulating drugs.

For the purpose of reducing cardiovascular risk, NICE Clinical Guideline 181 (NICE clinical guideline 181 (July 2014). Lipid Modification—Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease)—see JBS3 recommendations for further details. In type 2 diabetes, assess level of risk using the risk calculator and treat for primary prevention if necessary.

Total cholesterol, HDL-cholesterol, and non-HDL cholesterol concentrations should be checked 3 months after starting treatment with a high intensity statin. NICE Clinical Guideline 181 recommends aiming for a reduction in non-HDL cholesterol concentration below 2.5 mmol/litre. If these are not achieved, ensure lifestyle modifications are optimised and consider increasing the dose of the statin if started on less than atorvastatin 80 mg and the patient is judged to be at higher risk because of comorbidities, risk score or, using clinical judgement.

Specialist advice should be sought about treatment options for patients at high risk of cardiovascular disease or those with existing cardiovascular disease, who are intolerant of three different statins.

**Fibrates** should not be routinely used for primary or secondary prevention. Nicotinic acid p. 177, bile acid sequestrants, and omega-3 fatty acid compounds are not recommended for primary or secondary prevention.

**Hypercholesterolaemia, hypertriglyceridaemia, and familial hypercholesterolaemia**

A statin is also the drug of first choice for treating hypercholesterolaemia and moderate hypertriglyceridaemia. Severe hypercholesterolaemia not adequately controlled with a maximal dose of a statin may require the use of an additional lipid-regulating drug such as ezetimibe p. 173; such treatment should generally be supervised by a specialist.

---

**Reduction in low-density lipoprotein cholesterol**

<table>
<thead>
<tr>
<th>Therapy intensity</th>
<th>Drug</th>
<th>Daily dose (reduction in LDL cholesterol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-intensity</td>
<td>Atorvastatin</td>
<td>20mg (43%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>40mg (49%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>80mg (55%)</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>10mg (43%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20mg (48%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>40mg (53%)</td>
<td></td>
</tr>
<tr>
<td>Simvastatin</td>
<td>80mg (42%)</td>
<td></td>
</tr>
<tr>
<td>Medium-intensity</td>
<td>Atorvastatin</td>
<td>10mg (37%)</td>
</tr>
<tr>
<td></td>
<td>Fluvastatin</td>
<td>80mg (33%)</td>
</tr>
<tr>
<td></td>
<td>Rosuvastatin</td>
<td>5mg (38%)</td>
</tr>
<tr>
<td>Low-intensity</td>
<td>Fluvastatin</td>
<td>20mg (21%)</td>
</tr>
<tr>
<td></td>
<td>Pravastatin</td>
<td>40mg (27%)</td>
</tr>
<tr>
<td></td>
<td>Pravastatin</td>
<td>20mg (24%)</td>
</tr>
<tr>
<td></td>
<td>Simvastatin</td>
<td>40mg (29%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10mg (27%)</td>
</tr>
</tbody>
</table>

Advice from the MHRA: there is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80 mg dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks.
A number of conditions, some familial, are characterised by very high LDL-cholesterol concentration, high triglyceride concentration, or both. Fenofibrate p. 175 may be added to statin therapy if triglycerides remain high even after the LDL-cholesterol concentration has been reduced adequately; nicotinic acid may also be used to further lower triglyceride or LDL-cholesterol concentration.

Combination of a statin with a fibrate with nicotinic acid carries an increased risk of side-effects (including rhabdomyolysis) and should be used under specialist supervision; monitoring of liver function and creatine kinase should also be considered. The concomitant administration of gemfibrozil with a statin increases the risk of rhabdomyolysis considerably—this combination should not be used.

A statin is recommended for all patients with familial hypercholesterolaemia. A ‘high-intensity’ statin (as defined in NICE Clinical Guideline 71, August 2008. Identification and management of familial hypercholesterolaemia) e.g. rosvuastatin p. 180 (initiated by a specialist) or atorvastatin should be considered in order to achieve the recommended reduction in LDL-cholesterol concentration of greater than 50% from baseline; a ‘high-intensity’ statin is one that produces a greater LDL-cholesterol reduction than simvastatin 40 mg. Patients with heterozygous familial hypercholesterolaemia who have contra-indications to, or are intolerant of, statins should receive ezetimibe p. 173. The combination of a statin and ezetimibe can be considered if a statin alone fails to provide adequate control (or if intolerance limits dose titration), and when a switch to an alternative statin is being considered. Patients for whom statins and ezetimibe are inappropriate, should be referred to a specialist for the consideration of treatment with a bile acid sequestrant, nicotinic acid, or a fibrate.

The prescribing of drug therapy in homozygous familial hypercholesterolaemia should be undertaken in a specialist centre.

Bile acid sequestrants
Bile acid sequestrants effectively reduce LDL-cholesterol but can aggravate hypertriglyceridaemia. Treatment with bile acid sequestrants may be inappropriate under specialist supervision if statins and ezetimibe are inappropriate, and when LDL-cholesterol is severely raised, for example in familial hypercholesterolaemia.

Fibrates
Fibrates are mainly used in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

Lomitapide
Lomitapide p. 176 is licensed as an adjunct to dietary measures and other lipid-regulating drugs for the treatment of homozygous familial hypercholesterolaemia.

Nicotinic acid group
The value of nicotinic acid p. 177 is limited by its side-effects, especially vasodilatation.

Nicotinic acid is used by specialists in combination with a statin if the statin alone cannot adequately control dyslipidaemia (raised LDL-cholesterol, triglyceridaemia, and low HDL-cholesterol).

Acipimox p. 177 seems to have fewer side-effects than nicotinic acid but may be less effective in its lipid-regulating capabilities.

Omega-3 fatty acid compounds
There is no evidence that omega-3 fatty acid compounds reduce the risk of cardiovascular disease.

Statins
Statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration but they are less effective than the fibrates in reducing triglyceride concentration. However, statins reduce cardiovascular disease events and total mortality irrespective of the initial cholesterol concentration.

Bile acid sequestrants

- **DRUG ACTION** Bile acid sequestrants act by binding bile acids, preventing their reabsorption; this promotes hepatic conversion of cholesterol into bile acids; the resultant increased LDL-receptor activity of liver cells increases the clearance of LDL-cholesterol from the plasma.

- **CAUTIONS** Interference with the absorption of fat-soluble vitamins (supplements of vitamins A, D, K, and folic acid may be required when treatment is prolonged).

- **SIDE-EFFECTS** Constipation · diarrhoea · gastro-intestinal discomfort · hypertriglyceridaemia (aggravation) · hypoprothrombinaemia associated with vitamin K deficiency · increased risk of bleeding · nausea · vomiting

- **PREGNANCY** Bile acid sequestrants should be used with caution as although the drugs are not absorbed, they may cause fat-soluble vitamin deficiency on prolonged use.

- **BREAST FEEDING** Bile acid sequestrants should be used with caution as although the drugs are not absorbed, they may cause fat-soluble vitamin deficiency on prolonged use.

Colesevelim hydrochloride

**INDICATIONS AND DOSE**
Primary hypercholesterolaemia as an adjunct to dietary measures (monotherapy)

渤

**CONTRA-INDICATIONS**
Biliary obstruction · bowel obstruction

**CAUTIONS**
Gastro-intestinal motility disorders · inflammatory bowel disease · major gastro-intestinal surgery

**INTERACTIONS** → Appendix 1 (colesevelim).

**SIDE-EFFECTS**
Headache · myalgia

**HEPATIC IMPAIRMENT**
Manufacturer advises caution.

**MONITORING REQUIREMENTS**
Patients receiving ciclosporin should have their blood-ciclosporin concentration monitored before, during, and after treatment with colesevelim.

**DIRECTIONS FOR ADMINISTRATION**
Other drugs should be taken at least 4 hours before or after colesevelim to reduce possible interference with absorption.

**PATIENT AND CARER ADVICE**
Patient counselling on administration is advised for colesevelim hydrochloride tablets (avoid other drugs at same time).
COLESTYRAMINE (Non-proprietary)

INDICATIONS AND DOSE

Hyperlipidaemias, particularly type IIa, in patients who have not responded adequately to diet and other appropriate measures

BY MOUTH

Adult: Initially 5 g 1–2 times a day, increased in steps of 5 g every 1 month if required, total daily dose may be given in 1–2 divided doses; maximum 30 g per day

INTERACTIONS → Appendix 1 (colestipol).

DIRECTIONS FOR ADMINISTRATION

The contents of each sachet should be mixed with at least 150 mL of water or other suitable liquid such as fruit juice, skimmed milk, thin soups, and pulpy fruits ensuring at least 100 mL of liquid is provided. Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption.

PATIENT AND CARER ADVICE

Patient counselling on administration is advised for colestipol hydrochloride granules (avoid other drugs at same time).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Granules

CAUTIONARY AND ADVISORY LABELS 13
- COLESTYRAMINE (Non-proprietary)

Colestipol hydrochloride 5 gram
- Colestid (Pfizer Ltd)

Colestipol hydrochloride 5 gram
- Colestid (Pfizer Ltd)

Colestipol hydrochloride 5 gram
- Colestid granules (sugar-free) 30 sachet (cost)
- £15.05

Colestid Orange 5g granules sachets (sugar-free) 30 sachet (cost)
- £15.05

CHOLESTEROL ABSORPTION INHIBITORS

Ezetimibe

DRUG ACTION

Ezetimibe inhibits the intestinal absorption of cholesterol. If used alone, it has a modest effect on lowering LDL-cholesterol, with little effect on other lipoproteins.

INDICATIONS AND DOSE

Adjunct to dietary measures and statin treatment in primary hypercholesterolaemia | Adjunct to dietary measures and statin in homozygous familial hypercholesterolaemia | Primary hypercholesterolaemia (if statin inappropriate or not tolerated) | Adjunct to dietary measures in homozygous sitosterolaemia

BY MOUTH

Adult: 10 mg daily

INTERACTIONS → Appendix 1 (ezetimibe).

There is an increased risk of rhabdomyolysis if ezetimibe is used in combination with a statin.

SIDE-EFFECTS

- Common or very common Fatigue · gastro-intestinal disturbances · headache · myalgia
Hyperlipidaemia

Bezafibrate

**INDICATIONS AND DOSE**

Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contra-indicated or not tolerated. Adjunct to diet and other appropriate measures in severe hypertriglyceridaemia.

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: 200 mg 3 times a day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

- Adult: 400 mg once daily, modified-release dose form is not appropriate in patients with renal impairment

**CONTRA-INDICATIONS**

- Gall bladder disease
- Hypoaalbuminaemia
- Nephrotic syndrome
- Photosensitivity to fibrates

**CAUTIONS**

Correct hypothyroidism before initiating treatment.

**INTERACTIONS**

Appendix 1 (fibrates).

Combination of a fibrate with a statin increases the risk of muscle effects (especially rhabdomyolysis) and should be used with caution.

**SIDE-EFFECTS**

- Common or very common: Abdominal distension ± anorexia ± diarrhoea ± nausea
- Uncommon: Alopecia ± cholestasis ± dizziness ± erectile dysfunction ± headache ± myotoxicity (with myasthenia, myalgia, or very rarely rhabdomyolysis)—special risk in renal impairment ± photosensitivity reactions ± pruritus ± rash ± renal failure ± urticaria
- Rare: Pancreatitis ± peripheral neuropathy
- Very rare: Anaemia ± gallstones ± increased platelet count ± interstitial lung disease ± leucopenia ± pancytopenia ± Stevens-Johnson syndrome ± thrombocytopenic purpura ± toxic epidermal necrolysis

**PREGNANCY**

Manufacturers advise avoid—no information available.

**SIDE-EFFECTS**

- Abdominal distension ± anorexia ± diarrhoea ± nausea

**PRESCRIBING AND DISPENSING INFORMATION**

Fibrates are mainly used in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.

**PRECAUTIONS AND ADVISORY LABELS**

- Consider monitoring of liver function and creatine kinase when fibrates are used in combination with a statin.

Ciprofibrate

**INDICATIONS AND DOSE**

Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contra-indicated or not tolerated. Adjunct to diet and other appropriate measures in severe hypertriglyceridaemia.

BY MOUTH

- Adult: 100 mg daily

**CONTRA-INDICATIONS**

- Gall bladder disease
- Hypoaalbuminaemia
- Nephrotic syndrome
- Photosensitivity to fibrates

**CAUTIONS**

Correct hypothyroidism before initiating treatment.

**INTERACTIONS**

Appendix 1 (fibrates).

Combination of a fibrate with a statin increases the risk of muscle effects (especially rhabdomyolysis) and should be used with caution.

**SIDE-EFFECTS**

- Abdominal distension ± anorexia ± diarrhoea ± nausea
• Uncommon Alopecia - cholestasis - dizziness - erectile dysfunction - headache - myotoxicity (with myasthenia, myalgia, or very rarely rhabdomyolysis)—special risk in renal impairment - photosensitivity reactions - pruritus - rash - renal failure - urticaria

• Rare Pancreatitis - peripheral neuropathy

• Very rare Anaemia - gallstones - increased platelet count - interstitial lung disease - leucopenia - pancyclopenia - Stevens-Johnson syndrome - thrombocytopenic purpura - toxic epidermal necrolysis

• Frequency not known Pneumonitis - pulmonary fibrosis

• PREGNANCY Manufacturers advise avoid—toxicity in animal studies.

• BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.

• HEPATIC IMPAIRMENT Use with caution in mild to moderate impairment. Avoid in severe impairment.

• RENAL IMPAIRMENT Reduce dose to 100 mg on alternate days in moderate impairment. Avoid in severe impairment.

Myotoxicity Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly.

• MONITORING REQUIREMENTS

• Liver function tests recommended every 3 months for first year (discontinue treatment if significantly raised).

• Consider monitoring liver function and creatine kinase when fibrates used in combination with a statin.

• PRESCRIBING AND DISPENSING INFORMATION Fibrates are mainly used in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

• MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

- CIPROFIBRATE (Non-proprietary)

  Ciprofibrate 100 mg  Ciprofibrate 100mg tablets  |  28 tablet  [P](69)
  [P](69) £11.72  [P](69) DT price = £105.31

Fenofibrate

• DRUG ACTION Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.

• INDICATIONS AND DOSE

Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contraindicated or not tolerated | Adjunct to diet and other appropriate measures in severe hypertriglyceridaemia | Adjunct to statin in mixed hyperlipidaemia if triglycerides and HDL-cholesterol inadequately controlled in patients at high cardiovascular risk

BY MOUTH USING CAPSULES

• Adult: Initially 200 mg daily, then increased if necessary to 267 mg daily, maximum 200 mg daily with concomitant statin; 200 mg capsules not appropriate for use in renal impairment; 267 mg capsules not appropriate for initial dose titration or in renal impairment

BY MOUTH USING TABLETS

• Adult: 160 mg daily, tablets not appropriate in renal impairment

• CONTRA-INDICATIONS Gall bladder disease - pancreatitis (unless due to severe hypertriglyceridaemia) - photosensitivity to ketoprofen

• CAUTIONS Correct hypothyroidism before initiating treatment

• INTERACTIONS → Appendix 1 (fibrates). Combination of a fibrate with a statin increases the risk of muscle effects (especially rhabdomyolysis) and should be used with caution.

• SIDE-EFFECTS

• Common or very common Abdominal distension - anorexia - diarrhoea - nausea

• Uncommon Alopecia - cholestasis - dizziness - erectile dysfunction - headache - myotoxicity (with myasthenia, myalgia, or very rarely rhabdomyolysis)—special risk in renal impairment - pancreatitis - photosensitivity reactions - pruritus - pulmonary embolism - rash - renal failure - urticaria

• Very rare Anaemia - gallstones - increased platelet count - interstitial lung disease - leucopenia - pancyclopenia - Stevens-Johnson syndrome - thrombocytopenic purpura - toxic epidermal necrolysis

• Frequency not known Interstitial pneumopathies

• PREGNANCY Avoid—embryotoxicity in animal studies.

• BREAST FEEDING Manufacturers advise avoid—no information available.

• HEPATIC IMPAIRMENT Avoid.

• RENAL IMPAIRMENT Reduce dose to 134 mg daily if eGFR less than 60 mL/minute/1.73 m². Reduce dose to 67 mg daily if eGFR less than 20 mL/minute/1.73 m². Avoid if eGFR less than 15 mL/minute/1.73 m².

Myotoxicity Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly.

• MONITORING REQUIREMENTS

• Liver function tests recommended every 3 months for first year (discontinue treatment if significantly raised).

• Consider monitoring liver function and creatine kinase when fibrates used in combination with a statin.

• PRESCRIBING AND DISPENSING INFORMATION Fibrates are mainly used in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

• MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

  • CAUTIONARY AND ADVISORY LABELS 21

  • FENOFIBRATE (Non-proprietary)

  Fenofibrate micronised 160 mg  Fenofibrate micronised 160mg tablets  |  28 tablet  [P](69) £6.69  [P](69) DT price = £66.9

  Supralip  (BGP Products Ltd)

  Fenofibrate micronised 160 mg  Supralip 160mg tablets  |  28 tablet  [P](69) £6.69  [P](69) DT price = £66.9

Capsule

  • CAUTIONARY AND ADVISORY LABELS 21

  • FENOFIBRATE (Non-proprietary)

  Fenofibrate micronised 67 mg  Fenofibrate micronised 67mg capsules  |  90 capsule  [P](69) £23.30  [P](69) DT price = £233.0

  Fenofibrate micronised 200 mg  Fenofibrate micronised 200mg capsules  |  28 capsule  [P](69) £21.75  [P](69) DT price = £217.5

  Fenofibrate micronised 267 mg  Fenofibrate micronised 267mg capsules  |  28 capsule  [P](69) £21.75  [P](69) DT price = £217.5

  Lipantil Micro  (BGP Products Ltd)

  Fenofibrate micronised 67 mg  Lipantil Micro 67 capsules  |  90 capsule  [P](69) £23.30  [P](69) DT price = £233.0

  Fenofibrate micronised 200 mg  Lipantil Micro 200 capsules  |  28 capsule  [P](69) £14.23  [P](69) DT price = £142.3

  Fenofibrate micronised 267 mg  Lipantil Micro 267 capsules  |  28 capsule  [P](69) £21.75  [P](69) DT price = £217.5
Gemfibrozil

**DRUG ACTION** Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.

**INDICATIONS AND DOSE**
- Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contra-indicated or not tolerated
- Adjunct to diet and other appropriate measures in primary hypercholesterolaemia if statin contra-indicated or not tolerated
- Adjunct to diet and other appropriate measures in severe hypertriglyceridaemia
- Adjunct to diet and other appropriate measures in primary prevention of cardiovascular disease in men with hyperlipidaemias if statin contra-indicated or not tolerated

**CONTRA-INDICATIONS** History of gall-bladder or biliary tract disease including gallstones - photosensitivity to light - photosensitivity to sunlight

**CAUTIONS** Correct hypothyroidism before initiating treatment - elderly

**INTERACTIONS** Appendix 1 (fibrates).

The combination of gemfibrozil and a statin should preferably be avoided; high risk of muscle effects (especially rhabdomyolysis).

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain - constipation - diarrhoea - dyspepsia - eczema - fatigue - flatulence - headache - nausea - rash - vertigo - vomiting
- **Uncommon** Atrial fibrillation
- **Rare** Hepatitis - paraesthesia - alopecia - anaemia - angioedema - appendicitis - blurring vision - bone-marrow suppression - cholestatic jaundice - depression - disturbances in hepatic function - dizziness - drowsiness - eosinophilia - exfoliative dermatitis - leucopenia - myalgia - myasthenia - myopathy - myositis accompanied by increase in creatine kinase (discontinue if raised significantly) - pancreatitis - photosensitivity - pruritus - sexual dysfunction - thrombocytopenia - urticaria
- **PREGNANCY** Manufacturers advise avoid unless essential - toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Avoid.
- **RENAL IMPAIRMENT** Initially 900 mg daily if eGFR 30–80 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS**
  - Monitor blood counts for first year.
  - Monitor liver-function (discontinue treatment if abnormalities persist).
  - Consider monitoring creatine kinase if used in combination with a statin.
- **PRESCRIBING AND DISPENSING INFORMATION** Fibrates are mainly used in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 22</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GEMFIBROZIL (Non-proprietary)</strong></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Lopid</strong> (Pfizer Ltd)</td>
</tr>
<tr>
<td>Gemfibrozil 600 mg</td>
</tr>
<tr>
<td><strong>Capsule</strong></td>
</tr>
<tr>
<td>CAUTIONARY AND ADVISORY LABELS 22</td>
</tr>
<tr>
<td>Lopid (Pfizer Ltd)</td>
</tr>
<tr>
<td>Gemfibrozol 300 mg</td>
</tr>
</tbody>
</table>

**MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS**

Lomitapide

**DRUG ACTION** Lomitapide, an inhibitor of microsomal triglyceride transfer protein (MTP), reduces lipoprotein secretion and circulating concentrations of lipoprotein-borne lipids such as cholesterol and triglycerides.

**INDICATIONS AND DOSE** Adjunct to dietary measures and other lipid-regulating drugs with or without low-dose lipoprotein apheresis in homozygous familial hypercholesterolaemia (under expert supervision)

**CONTRA-INDICATIONS** Significant or chronic bowel disease

**CAUTIONS** Concomitant use of hepatotoxic drugs - lomitapide can interfere with the absorption of fat-soluble nutrients and supplementation of vitamin E and fatty acids is required - patients over 65 years

**INTERACTIONS** Appendix 1 (lomitapide).

**SIDE-EFFECTS**
- **Common or very common** Bloating - abdominal pain - appetite changes - constipation - diarrhoea - dizziness - dyspepsia - eczema - eructation - eye swelling - gastro-oesophageal reflux disease - gastroenteritis - haemorrhoids - headache - hepatic steatosis - hepatomegaly - hypokalaemia - leucopenia - malaise - migraine - muscle spasms - nausea - neutropenia - raised serum transaminases - tenesmus - vomiting - weight loss
- **BY MOUTH**
  - Adult: Initially 5 mg daily for 2 weeks, dose to be taken at least 2 hours after evening meal, then increased if necessary to 10 mg daily, for at least 4 weeks, then increased to 20 mg daily for at least 4 weeks, then increased in steps of 20 mg daily, adjusted at intervals of at least 4 weeks; maximum 60 mg per day

**SIDE-EFFECTS, FURTHER INFORMATION**

Raised transaminases Reduce dose if serum transaminases raised during treatment (consult product literature).

**CONCEPTION AND CONTRACEPTION** Manufacturer advises exclude pregnancy before treatment and ensure effective contraception used.

**PREGNANCY** Avoid — teratogenicity and embryotoxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Reduce dose if serum transaminases raised during treatment (consult product literature). Max. 40 mg daily in mild impairment.
Avoid in moderate to severe impairment, or if unexplained persistent abnormal liver function tests.

- **RENAI L IMPAIRMENT** Max. 40 mg daily in end-stage renal disease.
- **MONITORING REQUIREMENTS**
  - Monitor liver function tests before treatment, then at least monthly and before each dose increase for first year, then at least every 3 months and before each dose increase thereafter.
  - Screen for hepatic steatosis and fibrosis before treatment, then annually thereafter.
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Capsule**
    - Lojuxta (Aegerion Pharmaceuticals Ltd)
      - Lomitapide 5 mg Lojuxta 5mg capsules | 28 capsule [POM] £17,765.00
      - Lomitapide 10 mg Lojuxta 10mg capsules | 28 capsule [POM] £17,765.00
      - Lomitapide 20 mg Lojuxta 20mg capsules | 28 capsule [POM] £17,765.00

### NICOTINIC ACID DERIVATIVES

### Acipimox

#### INDICATIONS AND DOSE

Adjunct or alternative treatment in hyperlipidaemias of types IIb and IV in patients who have not responded adequately to other lipid-regulating drugs such as a statin or fibrate, and lifestyle changes (including diet, exercise, and weight reduction)

**BY MOUTH**
- Adult: 250 mg 2–3 times a day

- **CONTRA-INDICATIONS** Peptic ulcer
- **SIDE-EFFECTS**
  - Common or very common Abdominal pain - dyspepsia - diarrhoea - flushing - headache - malaise - myalgia - myopathy - nausea - pruritus - rash
  - Uncommon Anaphylactoid reaction - arthralgia - bronchospasm - erythema - myalgia - myositis - pruritus - rash
  - Frequency not known Diarrhoea - dry eyes - vasodilatation
- **PREGNANCY** Manufacturer advises avoid—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAI L IMPAIRMENT** Reduce dose to 250 mg 1–2 times daily if eGFR 30–60 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Monitor hepatic and renal function.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Capsule**
    - Olbetam (Pfizer Ltd)
      - Acipimox 250 mg Olbetam 250mg capsules | 90 capsule [POM] £46.33 DT price = £46.33

### Nicotinic acid

- **DRUG ACTION** In doses of 1.5 to 3 g daily, it lowers both cholesterol and triglyceride concentrations by inhibiting synthesis; it also increases HDL-cholesterol.

---

**INDICATIONS AND DOSE**

Adjunct to statin in dyslipidaemia or used alone if statin not tolerated

**BY MOUTH**
- Adult: (consult product literature)

- **CONTRA-INDICATIONS** Active peptic ulcer disease - arterial bleeding
- **CAUTIONS** Acute myocardial infarction - diabetes mellitus - gout - history of peptic ulceration - unstable angina
- **INTERACTIONS** → Appendix 1 (nicotinic acid).

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain - diarrhoea - dyspepsia - flushing - nausea - pruritus - rash - vomiting
  - Uncommon Dizziness - headache - hypophosphataemia - increase in uric acid - palpititation - peripheral oedema - prolonged prothrombin time - reduced platelet count - shortness of breath - tachycardia
  - Rare Hypotension - insomnia - myalgia - myasthenia - myopathy - reduced glucose tolerance - rhinitis - syncope
  - Very rare Anorexia - rhabdomyolysis - visual disturbance
  - Frequency not known Jaundice

**SIDE-EFFECTS, FURTHER INFORMATION**

Prostaglandin-mediated symptoms (such as flushing) can be reduced by low initial doses taken with meals or, if patient taking aspirin, aspirin dose should be taken 30 minutes before nicotinic acid.

- **PREGNANCY** No information available—manufacturer advises avoid unless potential benefit outweighs risk.
- **BREAST FEEDING** Present in milk—avoid.
- **HEPATIC IMPAIRMENT** Avoid in severe impairment. Discontinue if severe abnormalities in liver function tests. Manufacturer advises monitor liver function in mild to moderate hepatic impairment.
- **RENAI L IMPAIRMENT** Manufacturer advises use with caution—no information available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, powder, tablet, capsule

### OMEGA-3 FATTY ACIDS

#### Omega-3-acid ethyl esters

- **INDICATIONS AND DOSE** Adjunct to diet and statin in type IIb or III hypertriglyceridaemia | Adjunct to diet in type IV hypertriglyceridaemia

**BY MOUTH**
- Adult: Initially 2 capsules daily, dose to be taken with food, increased if necessary to 4 capsules daily
- Adult: 1 capsule daily, dose to be taken with food

- **CAUTIONS** Anticoagulant treatment (bleeding time increased) - haemorrhagic disorders

- **SIDE-EFFECTS**
  - Common or very common Dyspepsia - headache - nausea
  - Uncommon Abdominal pain - dizziness - gastritis - taste disturbances
  - Rare Acne - headache - hepatic disorders - hyperglycaemia - rash
  - Very rare Gastro-intestinal haemorrhage - hypotension - increased white cell count - nasal dryness - urticaria
Cardiovascular system

PREGNANCY Manufacturers advise use only if potential benefit outweighs risk—no information available.

BREAST FEEDING Manufacturers advise avoid—no information available.

HEPATIC IMPAIRMENT Monitor liver function in hepatic impairment.

NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2002) that omega-3 acid ethyl esters are not recommended for use within NHS Scotland for the treatment of hypertriglyceridaemia.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS

OMEGA-3 ACID ETHYL ESTERS (Non-proprietary)
- Docosahexaenoic acid 380 mg, Eicosapentaenoic acid
  460 mg
  Omega 3 acid-ethyl esters 1000mg capsules | 28 capsule [Pax] £6.00 DT price = £14.24
  100 capsule [Pax] £21.00
  Omega 3 1000mg capsules | 28 capsule no price available DT price = £14.24

- Omacor (BP Products Ltd)
  Docosahexaenoic acid 380 mg, Eicosapentaenoic acid
  460 mg
  Omacor capsules | 28 capsule [Pax] £14.24 DT price = £14.24 | 100 capsule £50.84
  Prestylon (Teva UK Ltd)
  Docosahexaenoic acid 380 mg, Eicosapentaenoic acid
  460 mg
  Prestylon 1g capsules | 28 capsule [Pax] £10.68 DT price = £14.24 | 100 capsule [Pax] £38.13
  Teromeg (AMCo)
  Docosahexaenoic acid 380 mg, Eicosapentaenoic acid
  460 mg
  Teromeg 1000mg capsules | 28 capsule [Pax] £11.39 DT price = £14.24 | 100 capsule £40.67
  Brands may include Dualis, Nebbaro

STATINS

Statins

Drug action Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis, especially in the liver.

Caution Elderly - high alcohol intake - history of liver disease - hypothyroidism - patients at increased risk of muscle toxicity, including myopathy or rhabdomyolysis (e.g. those with a personal or family history of muscular disorders, previous history of muscular toxicity and a high alcohol intake)

Caution further information
Muscle effects Muscle toxicity can occur with all statins, however the likelihood increases with higher doses and in certain patients (see below). Statins should be used with caution in patients at increased risk of muscle toxicity, including those with a personal or family history of muscular disorders, previous history of muscular toxicity, a high alcohol intake, renal impairment or hypothyroidism.

In patients at increased risk of muscle effects, a statin should not usually be started if the baseline creatine kinase concentration is more than 5 times the upper limit of normal (some patients may present with an extremely elevated baseline creatine kinase concentration, for example because of a physical occupation or rigorous exercise—specialist advice should be sought regarding consideration of statin therapy in these patients).

Hypothyroidism Hypothyroidism should be managed adequately before starting treatment with a statin.

Interactions → Appendix 1 (statins).

There is an increased incidence of myopathy if a statin is given with a fibrate (the combination of a statin and gemfibrozil should preferably be avoided), with lipid-lowering doses of nicotinic acid, with fusidic acid (risk of rhabdomyolysis—the combination of a statin and fusidic acid should be avoided; temporarily discontinue statin and restart 7 days after last fusidic acid dose), or with drugs that increase the plasma-statin concentration, such as macrolide antibiotics, imidazole and triazole antifungals, and ciclosporin; close monitoring of liver function and, if muscular symptoms occur, of creatine kinase is necessary.

Side-effects

Rare Hepatitis, jaundice

Very rare Hepatic failure, interstitial lung disease, lupus erythematosus-like reactions, pancreatitis

Frequency not known Alopecia, altered liver function tests, anemia, arthralgia, asthenia, depression, dizziness, fatigue, gastro-intestinal disturbances, headache, hyperglycaemia, hypersensitivity reactions, may be associated with the development of diabetes mellitus (particularly in those already at risk of the condition), myalgia, myopathy, myositis, parasthesia, peripheral neuropathy, pruritus, rash, rhabdomyolysis, sexual dysfunction, sleep disturbance, thrombocytopenia, urticaria, visual disturbance

Side-effects, further information
Muscle effects The risk of myopathy, myositis, and rhabdomyolysis associated with statin use is rare. Although myalgia has been reported commonly in patients receiving statins, muscle toxicity truly attributable to statin use is rare. Muscle toxicity can occur with all statins, however the likelihood increases with higher doses.

If muscular symptoms or raised creatine kinase occur during treatment, other possible causes (e.g. rigorous physical activity, hypothyroidism, infection, recent trauma, and drug or alcohol addiction) should be excluded before statin therapy is implicated, particularly if statin treatment has previously been tolerated for more than 3 months. When a statin is suspected to be the cause of myopathy, and creatine kinase concentration is markedly elevated (more than 5 times upper limit of normal), or if muscular symptoms are severe, treatment should be discontinued. If symptoms resolve and creatine kinase concentrations return to normal, the statin should be reintroduced at a lower dose and the patient monitored closely; an alternative statin should be prescribed if unacceptable side-effects are experienced with a particular statin. Statins should not be discontinued in the event of small, asymptomatic elevations of creatine kinase. Routine monitoring of creatine kinase is unnecessary in asymptomatic patients.

Statins should not be discontinued if there is an increase in the blood-glucose concentration or HbA1c as the benefits continue to outweigh the risks.

Interstitial lung disease If patients develop symptoms such as dyspnoea, cough, and weight loss, they should seek medical attention.

Conception and contraception Adequate contraception is required during treatment and for 1 month afterwards.

Pregnancy Statins should be avoided in pregnancy (discontinue 3 months before attempting to conceive) as congenital anomalies have been reported and the decreased synthesis of cholesterol possibly affects fetal development.
PATIENT AND CARER ADVICE

▶ Diabetes Before starting treatment with statins, at least one full lipid profile (non-fasting) should be measured, including total cholesterol, HDL-cholesterol, non-HDL-cholesterol (calculated as total cholesterol minus HDL-cholesterol), and triglyceride concentrations, thyroid-stimulating hormone, and renal function should also be assessed.

▶ Liver function There is little information available on a rational approach to liver-function monitoring; however, NICE suggests that liver enzymes should be measured before treatment, and repeated within 3 months and at 12 months of starting treatment, unless indicated at other times by signs or symptoms suggestive of hepatotoxicity (NICE clinical guideline 181 (July 2014). Lipid Modification—Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease). Those with serum transaminases that are raised, but less than 3 times the upper limit of the reference range, should not be routinely excluded from statin therapy. Those with serum transaminases of more than 3 times the upper limit of the reference range should discontinue statin therapy.

▶ Creatine kinase Before initiation of statin treatment, creatine kinase concentration should be measured in patients who have had persistent, generalised, unexplained muscle pain (whether associated or not with previous lipid-regulating drugs); if the concentration is more than 5 times the upper limit of normal, a repeat measurement should be taken after 7 days. If the repeat concentration remains above 5 times the upper limit, statin treatment should not be started; if concentrations are still raised but less than 5 times the upper limit, the statin should be started at a lower dose.

▶ Diabetes Patients at high risk of diabetes mellitus should have fasting blood-glucose concentration or HbA1c checked before starting statin treatment, and then repeated after 3 months.

PATIENT AND CARER ADVICE Advise patients to report promptly unexplained muscle pain, tenderness, or weakness.

Atorvastatin

INDICATIONS AND DOSE

Primary hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures | Combined hyperlipidaemia in patients who have not responded adequately to diet in other appropriate measures

BY MOUTH

Adult: Usual dose 10 mg daily; increased if necessary up to 80 mg daily, dose to be increased at intervals of at least 4 weeks

Heterozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures | Homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures

BY MOUTH

Adult: Initially 10 mg daily for at least 4 weeks, then increased if necessary to 40 mg daily for at least a further 4 weeks, then increased if necessary up to 80 mg daily.

Primary prevention of cardiovascular events in patients at high risk of a first cardiovascular event

BY MOUTH

Adult: 20 mg daily, dose can be increased if necessary

Secondary prevention of cardiovascular events

BY MOUTH

Adult: 80 mg once daily

Dose adjustments due to interactions

Reduced dose required (max. 10 mg daily) with concomitant ciclosporin, or tipranavir combined with ritonavir—seek specialist advice.

Maximum dose of 40 mg once daily when combined with anion-exchange resin for heterozygous familial hypercholesterolaemia.

UNLICENSED USE Not licensed for use in secondary prevention of cardiovascular events. Starting dose of 20 mg once daily is not licensed for the primary prevention of cardiovascular events.

CAUTIONS Haemorrhagic stroke

SIDE-EFFECTS

▶ Common or very common Back pain - epistaxis - hyperglycaemia - nasopharyngitis - pharyngolaryngeal pain

▶ Uncommon Anorexia - blurred vision - chest pain - hypoglycaemia - malaise - neck pain - peripheral oedema - pyrexia - tinnitus - weight gain

▶ Rare Cholestasis - Stevens-Johnson syndrome - toxic epidermal necrolysis

▶ Very rare Cynaecomasia - hearing loss

BREAST FEEDING Manufacturer advises avoid—no information available.

RENAL IMPAIRMENT In chronic kidney disease, for primary and secondary prevention of cardiovascular events [unlicensed starting dose in primary prevention; unlicensed in secondary prevention], initially 20 mg once daily, increased if necessary (on specialist advice if eGFR < 30 mL/minute/1.73 m²); max. 80 mg once daily.

PATIENT AND CARER ADVICE Patient counselling is advised for atorvastatin tablets (muscle effects).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet

▶ ATORVASTATIN (Non-proprietary)

10 mg Atorvastatin 10mg tablets | 28 tablet (£3.13) DT price = £1.18 | 90 tablet (£25.31) DT price = £1.78

Atorvastatin (as Atorvastatin calcium trihydrate) 20 mg Atorvastatin 20mg tablets | 28 tablet (£3.04) DT price = £1.41 | 90 tablet (£8.79) DT price = £9.20

Atorvastatin (as Atorvastatin calcium trihydrate) 30 mg Atorvastatin 30mg tablets | 28 tablet (£3.25) DT price = £1.45

Atorvastatin (as Atorvastatin calcium trihydrate) 40 mg Atorvastatin 40mg tablets | 28 tablet (£4.17) DT price = £1.59 | 90 tablet (£12.23) DT price = £13.20

Atorvastatin (as Atorvastatin calcium trihydrate) 60 mg Atorvastatin 60mg tablets | 28 tablet (£5.00) DT price = £2.80

Atorvastatin (as Atorvastatin calcium trihydrate) 80 mg Atorvastatin 80mg tablets | 28 tablet (£7.50) DT price = £2.71 | 90 tablet (£25.87) DT price = £90.67

Lipitor (Pfizer Ltd)

Atorvastatin (as Atorvastatin calcium trihydrate) 10 mg Lipitor 10mg tablets | 28 tablet (£3.13) DT price = £1.18

Atorvastatin (as Atorvastatin calcium trihydrate) 20 mg Lipitor 20mg tablets | 28 tablet (£3.04) DT price = £1.41

Atorvastatin (as Atorvastatin calcium trihydrate) 40 mg Lipitor 40mg tablets | 28 tablet (£4.17) DT price = £1.59

Atorvastatin (as Atorvastatin calcium trihydrate) 80 mg Lipitor 80mg tablets | 28 tablet (£7.50) DT price = £2.71
Fluvastatin

**INDICATIONS AND DOSE**

Adjunct to diet in primary hypercholesterolaemia or combined (mixed) hyperlipidaemia (types IIa and IIb)

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: Initially 20–40 mg daily, dose to be taken in the evening, increased if necessary up to 80 mg daily in 2 divided doses, dose to be adjusted at intervals of at least 4 weeks

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adult: 80 mg daily

**Cautionary and Advisory Labels**

- **SIDE-EFFECTS**
  - Very rare  Vasculitis
  - **BREAST FEEDING**  Manufacturer advises avoid—no information available.
  - **RENAL IMPAIRMENT**  Manufacturer advises doses above 40 mg daily should be initiated with caution if eGFR less than 30 mL/minute/1.73 m².
  - **PATIENT AND CARER ADVICE**  Patient counselling is advised for pravastatin tablets/capsules (muscle effects).

**National Funding/Access Decisions**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2004) that fluvastatin is accepted for restricted use for the secondary prevention of coronary events after percutaneous coronary angioplasty; if the patient has previously been receiving another statin, then there is no need to change the statin.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

Cautionary and Advisory Labels 25

- **FLUVASTATIN (Non-proprietary)**
  - Fluvastatin (as Fluvastatin sodium) 80 mg  Fluvastatin 80mg modified-release tablets  |  28 tablet  $19.20 DT price = $19.20
  - Lescol XL (Novartis Pharmaceuticals UK Ltd)
    - Fluvastatin (as Fluvastatin sodium) 80 mg  Fluvastatin 80mg tablets  |  28 tablet  $19.20 DT price = $19.20
  - Brands may include Dorisin XL; Lescol XL; Luvinsta XL; Nandovar XL; Pinmactil; Stefluvin XL

**Capsule**

- **FLUVASTATIN (Non-proprietary)**
  - Fluvastatin (as Fluvastatin sodium) 20 mg  Fluvastatin 20mg capsules  |  28 capsule  $6.96 DT price = $2.48
  - Fluvastatin (as Fluvastatin sodium) 40 mg  Fluvastatin 40mg capsules  |  28 capsule  $7.42 DT price = $2.72
  - Lescol (Novartis Pharmaceuticals UK Ltd)
    - Fluvastatin (as Fluvastatin sodium) 20 mg  Fluvastatin 20mg capsules  |  28 capsule  $15.26 DT price = $2.48
    - Fluvastatin (as Fluvastatin sodium) 40 mg  Fluvastatin 40mg capsules  |  28 capsule  $15.26 DT price = $2.72

**Pravastatin sodium**

**INDICATIONS AND DOSE**

Adjunct to diet for primary hypercholesterolaemia or combined (mixed) hyperlipidaemias in patients who have not responded adequately to dietary control

**BY MOUTH**

- Adult: 10–40 mg daily, dose to be taken at night, dose to be adjusted at intervals of at least 4 weeks

Prevention of cardiovascular events in patients with previous myocardial infarction or unstable angina

**BY MOUTH**

- Adult: 40 mg daily, dose to be taken at night

Reduction of hyperlipidaemia in patients receiving immunosuppressive therapy following solid-organ transplantation

**BY MOUTH**

- Adult: Initially 20 mg daily, then increased if necessary up to 40 mg daily, dose to be taken at night, close medical supervision is required if dose is increased to maximum dose

**SIDE-EFFECTS**

- Uncommon  Abnormal urination • dysuria • nocturia • urinary frequency
  - **BREAST FEEDING**  Manufacturer advises avoid—small amount of drug present in breast milk.
  - **RENAL IMPAIRMENT**  Manufacturer advises initial dose of 10 mg once daily in moderate to severe impairment.
  - **PATIENT AND CARER ADVICE**  Patient counselling is advised for pravastatin tablets (muscle effects).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, powder tablet

- **PRAVASTATIN SODIUM (Non-proprietary)**
  - Pravastatin sodium 10 mg  Pravastatin 10mg tablets  |  28 tablet  $16.10 DT price = $1.31
  - Pravastatin sodium 20 mg  Pravastatin 20mg tablets  |  28 tablet  $29.60 DT price = $1.57
  - Pravastatin sodium 40 mg  Pravastatin 40mg tablets  |  28 tablet  $52.90 DT price = $1.33
  - Lipostat (Bristol-Myers Squibb Pharmaceuticals Ltd)
    - Pravastatin sodium 10 mg  Lipostat 10mg tablets  |  28 tablet  $14.18 DT price = $1.31
    - Pravastatin sodium 20 mg  Lipostat 20mg tablets  |  28 tablet  $26.01 DT price = $1.37
    - Pravastatin sodium 40 mg  Lipostat 40mg tablets  |  28 tablet  $26.01 DT price = $1.37

**Rosuvastatin**

**INDICATIONS AND DOSE**

Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures

**BY MOUTH**

- Adult 18–69 years: Initially 5–10 mg once daily, then increased if necessary to 20 mg once daily, dose to be increased at intervals of at least 4 weeks
  - Adult (patients of Asian origin): Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.
Primary hypercholesterolaemia (type IIA including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis

BY MOUTH

- Adult: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.
- Severe primary hypercholesterolaemia (type IIA including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures, in patients with high cardiovascular risk (under expert supervision).

Dose adjustments due to interactions

- Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.
- Doses above 20 mg once daily are used with caution if eGFR less than 60 mL/minute/1.73 m².

Prevention of cardiovascular events in patients at high risk of a first cardiovascular event

BY MOUTH

- Adult 18–69 years: 20 mg once daily.
- Adult (patients of Asian origin): Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.
- Adult 70 years and over: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.

Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis

BY MOUTH

- Adult: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.

Dose adjustments due to interactions

- Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.
- For dose adjustments with concomitant atazanavir, darunavir, dronedarone, eltrombopag, ezetimibe, itraconazole, lopinavir, or tipranavir, consult product information available.

Patient counselling is advised for rosuvastatin tablets (muscle effects).

้าย _existing hypothyroidism.

SIDE-EFFECTS

- Rare Anaemia
- Frequency not known Tendinopathy

BREAST FEEDING

Manufacturer advises avoid—no information available.

RENAL IMPAIRMENT

Doses above 10 mg daily should be used with caution if eGFR less than 30 mL/minute/1.73 m².

PATIENT AND CARER ADVICE

Patient counselling is advised for simvastatin tablets/oral suspension (muscle effects).

EXCEPTIONS TO LEGAL CATEGORY

Simvastatin 10 mg tablets can be sold to the public to reduce risk of first coronary event in individuals at moderate risk of coronary heart disease (approx. 10–15 % risk of major event in 10 years), max. daily dose 10 mg and pack size of 28 tablets; treatment should form part of a programme to reduce risk of coronary heart disease.

MEDIcINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet

- SIMVASTATIN (Non-proprietary) Simvastatin 10 mg Simvastatin 10mg tablets | 28 tablet £18.00 DT price = £0.90
- Simvastatin 20 mg Simvastatin 20mg tablets | 28 tablet £29.60 DT price = £1.02
Acute attacks of stable angina should be managed with risk of cardiovascular events. Management to prevent angina attacks and to reduce the long-term management of acute anginal pain, and long-term exertion and relieved by rest. Treatment involves oxygen supply to the heart; it is often precipitated by Stable angina angina.

**Ezetimibe with simvastatin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ezetimibe p. 173, simvastatin p. 181.

**INDICATIONS AND DOSE**

Homozygous familial hypercholesterolaemia, primary hypercholesterolaemia, and mixed hyperlipidaemia in patients stabilised on the individual components in the same proportions, or for patients not adequately controlled by statin alone.

**BY MOUTH**

- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**

  - Inegy (Merck Sharp & Dohme Ltd)
  - Ezetimibe 10 mg, Simvastatin 20 mg Inegy 10mg/20mg tablets | 28 tablet £33.42 DT price = £33.42
  - Ezetimibe 10 mg, Simvastatin 40 mg Inegy 10mg/40mg tablets | 28 tablet £38.98 DT price = £38.98
  - Ezetimibe 10 mg, Simvastatin 80 mg Inegy 10mg/80mg tablets | 28 tablet £41.21 DT price = £41.21

7  **Myocardial ischaemia**

**Stable angina**

It is important to distinguish stable angina from unstable angina. Stable angina usually results from atherosclerotic plaques in the coronary arteries that restrict blood flow and oxygen supply to the heart; it is often precipitated by exertion and relieved by rest. Treatment involves management of acute anginal pain, and long-term management to prevent angina attacks and to reduce the risk of cardiovascular events.

**Management**

Acute attacks of stable angina should be managed with sublingual glyceryl trinitrate p. 190 which can be taken immediately before performing activities that are known to bring on an attack. If attacks occur more than twice a week, regular drug therapy is required and should be introduced in a step-wise manner according to response.

Patients with stable angina should be given a beta-blocker or a calcium-channel blocker. In those with left-ventricular dysfunction, beta-blocker treatment should be started at a very low dose and titrated very slowly over a period of weeks or months. If a beta-blocker or a calcium-channel blocker alone fails to control symptoms adequately, a combination of a beta-blocker and a dihydropyridine calcium-channel blocker (e.g. amiodipine p. 148, felodipine p. 151, modified-release nifedipine p. 154) should be used; if this combination is not appropriate due to intolerance of, or contra-indication to, either beta-blockers or calcium-channel blockers, addition of a long-acting nitrate, ivabradine p. 185, nicorandil p. 185, or ranolazine p. 184 can be considered.

For those patients in whom both beta-blockers and calcium-channel blockers are not tolerated or are contra-indicated, monotherapy with a long-acting nitrate, ivabradine, nicorandil, or ranolazine should be considered.

Response to treatment should be assessed every 2–4 weeks after initiating or changing drug therapy; the drug should be titrated (according to symptom control) to the maximum tolerated dose. Consider referring the patient to a specialist if a combination of two drugs fails to control symptoms. Addition of a third antianginal drug should only be considered if symptom control is not achieved with two drugs and the patient is either due to undergo a revascularisation procedure, or a revascularisation procedure is considered inappropriate. See the use of antiplatelet drugs in patients undergoing coronary stenting.

For long-term prevention of cardiovascular events, see Prevention of cardiovascular events.

**Antiangular drugs**

Nitrites, calcium-channel blockers, and potassium channel activators (use in adults only) have a vasodilating and, consequently, blood pressure lowering effect. Vasodilators can act in heart failure by arteriolar dilatation which reduces both peripheral vascular resistance and left ventricular pressure during systole resulting in improved cardiac output. They can also cause venous dilatation which results in dilatation of capacitance vessels, increase of venous pooling, and diminution of venous return to the heart (decreasing left ventricular end-diastolic pressure). Nicorandil p. 185, a potassium-channel activator with a nitrate component, has both arterial and venous vasodilating properties and is licensed for the prevention and long-term treatment of angina. Nicorandil has similar efficacy to other antiangular drugs in controlling symptoms; it may produce additional symptomatic benefit in combination with other antiangular drugs [unlicensed indication].

Ivabradine p. 185 lowers the heart rate by its action on the sinus node. It is licensed for the treatment of angina in patients who are in normal sinus rhythm in combination with a beta-blocker, or when beta-blockers are contraindicated or not tolerated. Ivabradine, in combination with standard therapy including a beta-blocker (unless contra-indicated or not tolerated), is also licensed for mild to severe stable chronic heart failure in patients who are in sinus rhythm.

Ranolazine p. 184 is licensed as adjunctive therapy in patients who are inadequately controlled or intolerant of first-line antiangular drugs.
GLYkoprotein IIB/IIIA INHIBITORS

Abciximab

INdICATIONS AND DOSE
Prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (specialist use only)

INITIALLY BY INTRAVENOUS INJECTION

- Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. 10 micrograms/minute), to be started 10–60 minutes before percutaneous coronary intervention and continue for 12 hours

Short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention (specialist use only)

INITIALLY BY INTRAVENous INJECTION

- Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. 10 micrograms/minute), to be started up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention

- CONTRA-INDICATIONS Active internal bleeding - arteriovenous malformation or aneurysm - haemorrhagic diathesis - hypertensive retinopathy - intracranial neoplasm - intracranial or intraspinal surgery or trauma within last 2 months - major surgery within last 2 months - severe hypertension - stroke within last 2 years - thrombocytopenia - vasculitis

- CAUTIONS Discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed (consult product literature for details of procedures to minimise bleeding) - elderly

- INTERACTIONS Caution with concomitant use of drugs that increase risk of bleeding.

- SIDE-EFFECTS
  - Common or very common Back pain - bleeding manifestations - bradycardia - chest pain - fever - headache - hypotension - nausea - puncture site pain - thrombocytopenia - vomiting
  - Rare Adult respiratory distress - cardiac tamponade - hypersensitivity reactions

- PREGNANCY Manufacturer advises use only if potential benefit outweighs risk — no information available.

- BREAST FEEDING Manufacturer advises avoid—no information available.

- HEPATIC IMPAIRMENT Avoid in severe liver disease—increased risk of bleeding.

- RENAL IMPAIRMENT Caution in severe impairment—increased risk of bleeding.

- MONITORING REQUIREMENTS
  - Measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time, platelet count, haemoglobin, and haematocrit.
  - Monitor haemoglobin and haematocrit 12 hours and 24 hours after start of treatment and platelet count 2–4 hours and 24 hours after start of treatment.

- DIRECTIONS FOR ADMINISTRATION
  - For intravenous infusion (ReoPro®), give continuously in Glucose 5% or Sodium Chloride 0.9%. Dilute requisite dose in infusion fluid and give via infusion pump; filter upon dilution through a non-pyrogenic low protein-binding 0.2, 0.22, or 2.0 micron filter or upon administration through an in-line non-progenic low protein-binding 0.2 or 0.22 micron filter

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  Solution for injection
  - ReoPro (Eli Lilly and Company Ltd)
    Abciximab 2 mg per 1 ml ReoPro 10mg/5ml solution for injection vials | 1 vial £25.24

Eptifibatide

INdICATIONS AND DOSE
In combination with aspirin and unfractionated heparin for the prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction and with last episode of chest pain within 24 hours (specialist use only)

INITIALLY BY INTRAVENOUS INJECTION

- Adult: Initially 180 micrograms/kg, then (by intravenous infusion) 2 micrograms/kg/minute for up to 72 hours (up to 96 hours if percutaneous coronary intervention during treatment)

- CONTRA-INDICATIONS Abnormal bleeding within 30 days - aneurysm - arteriovenous malformation - haemorrhagic diathesis - history of haemorrhagic stroke - increased INR - increased prothrombin time - intracranial disease - major surgery or severe trauma within 6 weeks - neoplasm - severe hypertension - stroke within last 30 days - thrombocytopenia

- CAUTIONS Discontinue if emergency cardiac surgery necessary - discontinue if intra-aortic balloon pump necessary - discontinue if thrombolytic therapy necessary - risk of bleeding—discontinue immediately if uncontrolled serious bleeding

- INTERACTIONS Caution with concomitant drugs that increase risk of bleeding—discontinue immediately if uncontrolled serious bleeding.

- SIDE-EFFECTS
  - Common or very common Bleeding manifestations
  - Very rare Anaphylaxis - rash

- PREGNANCY Manufacturer advises use only if potential benefit outweighs risk — no information available.

- BREAST FEEDING Manufacturer advises avoid—no information available.

- HEPATIC IMPAIRMENT Avoid in severe liver disease—increased risk of bleeding.

- RENAL IMPAIRMENT Reduce infusion to 30–50 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

- MONITORING REQUIREMENTS
  - Measure baseline prothrombin time, activated partial thromboplastin time, platelet count, haemoglobin, haematocrit and serum creatinine.
  - Monitor haemoglobin, haematocrit and platelets within 6 hours after start of treatment, then at least once daily.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  Solution for injection
  - Integrilin (GlaxoSmithKline UK Ltd)
    Eptifibatide 2 mg per 1 ml Integrilin 20mg/10ml solution for injection vials | 1 vial £13.61 (Hospital only)

  Solution for infusion
  - Integrilin (GlaxoSmithKline UK Ltd)
    Eptifibatide 750 microgram per 1 ml Integril 75mg/100ml solution for infusion vials | 1 vial £42.79 (Hospital only)
Tirofiban

INDICATIONS AND DOSE
In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTE-MI) and with last episode of chest pain within 12 hours (with angiography planned for 4–48 hours after diagnosis (initiated under specialist supervision))

BY INTRAVENOUS INFUSION
- Adult: Initially 400 nanograms/kg/minute for 30 minutes, then 100 nanograms/kg/minute for at least 48 hours (continue during and for 12–24 hours after percutaneous coronary intervention), maximum duration of treatment 108 hours
In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTE-MI) and with last episode of chest pain within 12 hours (with angiography within 4 hours of diagnosis) (initiated under specialist supervision)

INITIALLY BY INTRAVENOUS INJECTION
- Adult: 25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12–24 hours, maximum duration of treatment 48 hours
In combination with unfractionated heparin, aspirin, and clopidogrel for reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PCI) (initiated under specialist supervision)

INITIALLY BY INTRAVENOUS INJECTION
- Adult: 25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12–24 hours, maximum duration of treatment 48 hours

CONTRA-INDICATIONS
Abnormal bleeding within 30 days - history of aneurysm - history of arteriovenous malformation - history of haemorrhagic stroke - history of intracranial disease - history of neoplasm - increased INR - increased prothrombin time - severe hypertension - stroke within 50 days - thrombocytopenia

CAUTIONS
Active peptic ulcer (within 3 months) - acute pericarditis - anaemia - aortic dissection - cardiogenic shock - discontinue if intra-aortic balloon pump necessary - discontinue if thrombolytic therapy necessary - discontinue immediately if serious or uncontrollable bleeding occurs - discontinue if emergency cardiac surgery necessary - elderly - faecal occult blood - haematuria - haemorrhagic retinopathy - low body-weight - major surgery within 3 months (avoid if within 6 weeks) - organ biopsy or lithotripsy within last 2 weeks - puncture of non-compressible vessel within 24 hours - risk of bleeding (within 3 months) - severe heart failure - severe trauma within 5 months (avoid if within 6 weeks) - traumatic or protracted cardiopulmonary resuscitation within last 2 weeks - uncontrolled severe hypertension - vasculitis

INTERACTIONS → Appendix 1 (tirofiban).
Concomitant drugs that increase risk of bleeding (including within 48 hours of thrombolytic administration)

SIDE-EFFECTS
Bleeding manifestations - fever - headache - nausea - reversible thrombocytopenia

PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk — no information available.

- BREAST FEEDING
  Manufacturer advises avoid — no information available.
- HEPATIC IMPAIRMENT
  Caution in mild to moderate liver disease. Avoid in severe liver disease — increased risk of bleeding.
- RENAL IMPAIRMENT
  Increased risk of bleeding. Use half normal dose if eGFR less than 30 mL/minute/1.73 m². Monitor carefully if eGFR less than 60 mL/minute/1.73 m².
- MONITORING REQUIREMENTS
  Monitor platelet count, haemoglobin and haematocrit before treatment, 2–6 hours after start of treatment and then at least once daily.
- DIRECTIONS FOR ADMINISTRATION
  For intravenous infusion (Aggrastat®), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 50 mL infusion fluid from 250 mL bag and replace with 50 mL tirofiban concentrate (250 micrograms/mL) to give a final concentration of 50 micrograms/mL.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Infusion
ELECTROLYTES: May contain Sodium
- Aggrastat (Correvio GmbH)
  Tirofiban (as Tirofiban hydrochloride) 50 microgram per 1 ml
  Aggrastat 12.5 mg/250 mL infusion bags | 1 bag £0 no price available (Hospital only)

Solution for infusion
ELECTROLYTES: May contain Sodium
- Aggrastat (Correvio GmbH)
  Tirofiban (as Tirofiban hydrochloride) 250 microgram per 1 ml
  Aggrastat 12.5 mg/50 mL concentrate for solution for infusion vials | 1 vial £0 no price available (Hospital only)

Piperazine derivatives

Ranolazine

INDICATIONS AND DOSE
As adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies

BY MOUTH
- Adult: Initially 375 mg twice daily for 2–4 weeks, then increased to 500 mg twice daily, then increased if necessary up to 750 mg twice daily; reduced if not tolerated to 375–500 mg twice daily

CAUTIONS
Body-weight less than 60 kg - elderly - moderate to severe congestive heart failure - QT interval prolongation

INTERACTIONS → Appendix 1 (ranolazine).

SIDE-EFFECTS
Common or very common
- Asthenia - constipation - dizziness - headache - nausea - vomiting
- Uncommon
- Rare
  - Allergic dermatitis - amnesia - angioedema - cold extremities - erectile dysfunction - errosive duodenitis - impaired hearing - loss of consciousness - pancreatitis - parosmia - rash - renal failure - throat tightness - urticaria

PREGNANCY
Manufacturer advises avoid unless essential — no information available.
**Potassium-channel openers**

Nicolandil

**Indications and dose**

Prophylaxis and treatment of stable angina (including risk reduction of acute coronary syndromes in patients at high risk)

- **By mouth**
  - Adult: Initially 10 mg twice daily, alternatively initially 5 mg twice daily, use lower initial dose regimen if susceptible to headache; usual dose 10–20 mg twice daily (max. per dose 30 mg twice daily)

- **Contra-indications** Cardiogenic shock - hypotension - left ventricular failure with low filling pressures

- **Caution** Acute myocardial infarction with acute left ventricular failure and low filling pressures - acute pulmonary oedema - hypovolaemia - low systolic blood pressure

- **Interactions** → Appendix 1 (nicorandil).

- **Side-effects**
  - Common or very common: Cutaneous vasodilation with flushing - dizziness - headache (especially on initiation, usually transitory) - increase in heart rate (at high doses) - nausea - rectal bleeding - vomiting - weakness
  - Uncommon: Angioedema - hypotension - myalgia - oral ulceration
  - Rare: Abdominal pain - anal ulceration - cholestasis - hepatitis - intestinal ulceration - jaundice - pruritus - rash - skin ulceration

- **Pregnancy** Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **Breastfeeding** No information available—manufacturer advises avoid.

- **Patient and Carer Advice** Patients should be warned not to drive or operate machinery until it is established that their performance is unimpaired.

- **Medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: powder

- **Scottish Medicines Consortium (SMC) Decisions**

- **National funding/access decisions**

**SELECTIVE SINUS NODE I F INHIBITORS**

Ivabradine

**Indications and dose**

Treatment of angina in patients in normal sinus rhythm

- **By mouth**
  - Adult: Initially 5 mg twice daily for 3–4 weeks, then increased if necessary to 7.5 mg twice daily; reduced if not tolerated to 2.5–5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute
  - Elderly: Initially 2.5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute

Mild to severe chronic heart failure

- **By mouth**
  - Adult: Initially 5 mg twice daily for 2 weeks, then increased if necessary to 7.5 mg twice daily; reduced if not tolerated to 2.5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute

**Contra-indications** Acute myocardial infarction - cardiogenic shock - congenital QT syndrome - do not initiate for angina if heart rate below 70 beats per minute - do not initiate for chronic heart failure if heart rate below 75 beats per minute - immediately after cerebrovascular accident - patients dependent on pacemaker - second- and third-degree heart block - severe hypotension - sick-sinus syndrome - sino-atrial block - unstable angina - unstable or acute heart failure

**Caution** Atrial fibrillation or other arrhythmias (treatment ineffective) - elderly - in angina, consider stopping if there is no or limited symptom improvement after 5 months - intraventricular conduction defects - mild to moderate hypotension (avoid if severe) - retinopathy pigmentosa

**Interactions** → Appendix 1 (ivabradine).

**Side-effects**

- Common or very common: Atrial fibrillation - blurred vision - bradycardia - dizziness - first-degree heart block - headache - hypotension - myalgia - oral ulceration - palpitations - raised plasma-creatinine concentration - rash - venous thrombolysis - vertigo

- Very rare: Second and third-degree heart block - sick sinus syndrome

**Pregnancy** Manufacturer advises avoid—toxicity in animal studies.

**Breastfeeding** Present in milk in animal studies—manufacturer advises avoid.

**Hepatic impairment** Manufacturer advises caution in moderate impairment. Avoid in severe impairment.
myocardial necrosis (less significant than with STEMI) will be evident. There is a risk of progression to STEMI or sudden death, particularly in patients who experience pain at rest.

Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)

These conditions are managed similarly; the aims of management are to provide supportive care and pain relief during the acute attack and to prevent further cardiac events and death. For advice on the management of patients with acute ST-segment elevation myocardial infarction (STEMI), see below.

Initial management

Oxygen should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hypoxia should be avoided and particular care is required in patients with chronic obstructive airways disease.

Nitrates are used to relieve ischaemic pain. If sublingual glyceryl trinitrate p. 190 is not effective, intravenous or buccal glyceryl trinitrate or intravenous isosorbide dinitrate p. 191 is given. If pain continues, dimorphine or hydrochloride p. 361 or morphine p. 367 can be given by slow intravenous injection; an antiemetic such as metoclopramide hydrochloride p. 347 should also be given. Aspirin p. 104 (chewed or dispersed in water) is given for its antiplatelet effect. If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. Clopidogrel p. 106 should also be given. Prasugrel p. 188 is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see NICE guidance p. 188). Ticagrelor p. 188 is also an alternative to clopidogrel (see NICE guidance p. 188). Patients should also receive either heparin (unfractionated) p. 114, a low molecular weight heparin, or fondaparinux sodium p. 109.

Patients without contra-indications should receive beta-blockers which should be continued indefinitely. In patients without left ventricular dysfunction and in whom beta-blockers are inappropriate, diltiazem hydrochloride p. 149 or verapamil hydrochloride p. 156 can be given. The glycoprotein IIB/IIIa inhibitors epifibatide p. 183 (in combination with heparin (unfractionated) p. 114 and aspirin) and tirofiban p. 184 (in combination with heparin (unfractionated) aspirin, and clopidogrel) can be used for unstable angina or for NSTEMI in patients at a high risk of either myocardial infarction or death.

In intermediate- and high-risk patients, abciximab or eptifibatide (in combination with heparin (unfractionated) and aspirin), or tirofiban (in combination with heparin (unfractionated), aspirin, and clopidogrel) can also be used in patients undergoing percutaneous coronary intervention, to reduce the immediate risk of vascular occlusion. In intermediate- and high-risk patients in whom early intervention is planned, bivalirudin p. 116 can be considered as an alternative to the combination of a glycoprotein IIB/IIIa inhibitor plus a heparin. Revascularisation procedures are often appropriate for patients with unstable angina or NSTEMI; the use of antiplatelet drugs in patients undergoing coronary stenting.

Long-term management

The need for long-term angina treatment or for coronary angiography should be assessed. Most patients will require standard angina treatment to prevent recurrence of symptoms.

ST-segment elevation myocardial infarction (STEMI)

This is an acute coronary syndrome where atheromatous plaque rupture leads to thrombosis and myocardial ischaemia, with irreversible necrosis of the heart muscle, often leading to long-term complications. STEMI can also
occasionally occur as a result of coronary spasm or embolism, arteritis, spontaneous thrombosis, or sudden severe elevation in blood pressure.

**Management of ST-segment elevation myocardial infarction (STEMI)** These notes give an overview of the initial and long-term management of myocardial infarction with ST segment elevation (STEMI). For advice on the management of non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina, see above. The aims of management of STEMI are to provide supportive care and pain relief, to promote reperfusion and to reduce mortality. Oxygen, nitrates, and dexamethasone hydrochloride p. 361 or morphine p. 367 can provide initial support and pain relief; aspirin and percutaneous coronary intervention or thrombolitics promote reperfusion; antiagulants help to reduce re-occlusion and systemic embolisation; long-term use of aspirin, beta-blockers, ACE inhibitors, and statins help to reduce mortality further.

Local guidelines for the management of myocardial infarction should be followed where they exist.

**Initial management**

**Oxygen** should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hyperoxia should be avoided and particular care is required in patients with chronic obstructive airways disease.

The pain (and anxiety) of myocardial infarction is managed with slow intravenous injection of dexamethasone hydrochloride or morphine; an aminetic such as metoclopramide hydrochloride p. 347 (or, if left ventricular function is not compromised, cyclazine p. 343) by intravenous injection should also be given. Aspirin (chewed or dispersed in water) is given for its antiplatelet effect. If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. Clopidogrel p. 106, should also be given. Prasugrel p. 188, is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see NICE guidance p. 188). Ticagrelor p. 188, is also an alternative to clopidogrel (see NICE guidance p. 188).

Patency of the occluded artery can be restored by percutaneous coronary intervention or by giving a thrombolytic drug, unless contra-indicated. Percutaneous coronary intervention is the preferred method; a **glycoprotein IIb/IIIa inhibitor** can be used to reduce the risk of immediate vascular occlusion in intermediate- and high-risk patients. Patients undergoing percutaneous coronary intervention should also receive either heparin (unfractionated) or a low molecular weight heparin (e.g. enoxaparin sodium p. 113); bivalirudin p. 116 is an alternative to the combination of a glycoprotein IIb/IIIa inhibitor plus a heparin (see also NICE guidance p. 117). In patients who cannot be offered percutaneous coronary intervention within 90 minutes of diagnosis, a thrombolytic drug should be administered along with either heparin (unfractionated) (for maximum 2 days), a low molecular weight heparin (e.g. enoxaparin sodium), or fondaparinux sodium. See use of antiplatelet drugs in patients undergoing coronary stenting p. 103.

Patients who do not receive reperfusion therapy (with percutaneous coronary intervention or a thrombolytic) should be treated with either fondaparinux sodium, enoxaparin sodium, or heparin (unfractionated). Prescribers should consult product literature and local protocols (where they exist) for details of antiagulants dose and duration.

**Nitrates** are used to relieve ischaemic pain. If sublingual glyceryl trinitrate p. 190 is not effective, intravenous glyceryl trinitrate or isosorbide dinitrate p. 191 is given. Early administration of some beta-blockers has been shown to be of benefit and should be given to patients without contra-indications.

**ACE inhibitors**, and angiotensin-II receptor antagonists if an ACE inhibitor cannot be used, are also of benefit to patients who have no contra-indications; in hypertensive and normotensive patients treatment with an ACE inhibitor, or an angiotensin-II receptor antagonist, can be started within 24 hours of the myocardial infarction and continued for at least 5–6 weeks (see below for long-term treatment).

All patients should be closely monitored for hyperglycaemia; those with diabetes or raised blood-glucose concentration should receive insulin p. 603.

**Long-term management**

Long-term management following STEMI involves the use of several drugs which should ideally be started before the patient is discharged from hospital.

Aspirin should be given to all patients, unless contra-indicated. The addition of clopidogrel has been shown to reduce morbidity and mortality. Prasugrel p. 188 or ticagrelor are alternatives to clopidogrel in certain patients. For those intolerant of clopidogrel, and who are at low risk of bleeding, the combination of warfarin sodium p. 121 and aspirin should be considered. In those intolerant of both aspirin and clopidogrel, warfarin sodium alone can be used. Warfarin sodium should be continued for those who are already being treated for another indication, such as atrial fibrillation, with the addition of aspirin if there is a low risk of bleeding. The combination of aspirin with clopidogrel or warfarin sodium increases the risk of bleeding. The combination of aspirin with clopidogrel or warfarin sodium increases the risk of bleeding. Low-dose rivaroxaban p. 109, in combination with aspirin alone or aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following STEMI—see Prevention of cardiovascular events p. 187. For details of antiplatelet drug duration following coronary stenting—see also Antiplatelet drugs and coronary stents p. 103.

**Beta-blockers** should be given to all patients in whom they are not contra-indicated. Acebutolol p. 141, metoprolol tartrate p. 144, propranolol hydrochloride p. 146 and timolol maleate p. 147 are suitable; for patients with left ventricular dysfunction, carvedilol p. 142, bisoprolol fumarate p. 142, or long-acting metoprolol tartrate may be appropriate.

Diltiazem hydrochloride p. 149 [unlicensed] or verapamil hydrochloride p. 156 can be considered if a beta-blocker cannot be used; however, they are contra-indicated in those with left ventricular dysfunction. Other calcium-channel blockers have no place in routine long-term management after a myocardial infarction.

An **ACE inhibitor** should be considered for all patients, especially those with evidence of left ventricular dysfunction. If an ACE inhibitor cannot be used, an angiotensin-II receptor antagonist may be used for patients with heart failure. A relatively high dose of either the ACE inhibitor or angiotensin-II receptor antagonist may be required to produce benefit.

**Nitrates** are used for patients with angina. Eplerenone p. 167 is licensed for use following a myocardial infarction in those with left ventricular dysfunction and evidence of heart failure. See also the role of **statins** in preventing recurrent cardiovascular events p. 178.

**Prevention of cardiovascular events**

Patients with stable angina, unstable angina, or NSTEMI should be given advice and treatments to reduce their cardiovascular risk. The importance of life-style changes, especially stopping smoking, should be emphasised. Aspirin should be given indefinitely. Antihypertensive treatment should be initiated if appropriate, and a **statin** should also be given.
In patients with stable angina, addition of an ACE inhibitor should be considered for patients with diabetes (and should be continued if indicated for a co-morbidity).

In patients with unstable angina or NSTEMI, clopidogrel is given, in combination with aspirin, for up to 12 months—most benefit occurs during the first 3 months. Prasugrel or ticagrelor below are alternatives to clopidogrel in certain patients. An ACE inhibitor should also be given.

Low-dose rivaroxaban p. 109, in combination with aspirin alone or aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers.

### Drugs used for Acute coronary syndromes not listed below
- Captopril, p. 126
- Clopidogrel, p. 106
- Dalteparin sodium, p. 112
- Enoxaparin sodium, p. 113
- Heparin (unfractionated), p. 114
- Lisinopril, p. 126
- Perindopril arginine, p. 129
- Perindopril erbumine, p. 130
- Ramipril, p. 131
- Trandolapril, p. 132
- Valsartan, p. 136

### Antiplatelets

#### Prasugrel

**INDICATIONS AND DOSE**

In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention

**BY MOUTH**

- Adult 18-74 years (body-weight up to 60 kg): Initially 60 mg for 1 dose, then 5 mg once daily usually for up to 12 months
- Adult 18-74 years (body-weight 60 kg and above): Initially 60 mg for 1 dose, then 10 mg once daily usually for up to 12 months
- Adult 75 years and over: Initially 60 mg for 1 dose, then 5 mg once daily usually for up to 12 months

**Patients undergoing coronary angiography within 48 hours of admission for unstable angina or NSTEMI**

**BY MOUTH**

- Adult: Initially 60 mg, to be administered at the time of percutaneous coronary intervention to minimise the risk of bleeding, maintenance dose of 10 mg or 5 mg daily should then be selected as appropriate

**Alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention by appropriate**

**BY MOUTH**

- Adult: 60 mg as a single dose

- **CONTRA-INDICATIONS** Active bleeding - history of stroke or transient ischaemic attack
- **CAUTIONS** Body-weight less than 60 kg - discontinue at least 7 days before elective surgery if antiplatelet effect not desirable - elderly - patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or active peptic ulcer disease)
- **INTERACTIONS** $\rightarrow$ Appendix 1 (prasugrel), Caution with concomitant use of drugs that increase risk of bleeding.
- **SIDE-EFFECTS**
  - Common or very common Anaemia - gastro-intestinal haemorrhage - haematoma - haematuria - haemorrhage - intracranial haemorrhage - rash
  - Uncommon Angioedema - hypersensitivity reactions
  - Rare Thrombocytopenia
  - Frequency not known Thrombotic thrombocytopenic purpura
- **ALLERGY AND CROSS-SENSITIVITY** Caution in patients with history of hypersensitivity reactions to thienopyridines (e.g. clopidogrel).

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.
- ** BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Use with caution in moderate impairment—increased risk of bleeding. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Use with caution—increased risk of bleeding.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (July 2014) NICE TA317
    - Prasugrel 10 mg in combination with aspirin is recommended as an option, within its marketing authorisation, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI)) having primary or delayed percutaneous coronary intervention. www.nice.org.uk/TA317
- **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (August 2009) that prasugrel (Efient®), in combination with aspirin, be accepted for restricted use within NHS Scotland for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention who are eligible to receive the 10 mg dose of prasugrel.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Efient** (Eli Lilly and Company Ltd)
  - Prasugrel (as Prasugrel hydrochloride) 5 mg $\rightarrow$ Efient 5 mg tablets $\rightarrow$ 28 tablet (BD) $\rightarrow$ £47.56 07 price = £47.56
  - Prasugrel (as Prasugrel hydrochloride) 10 mg Efient 10 mg tablets $\rightarrow$ 28 tablet (BD) $\rightarrow$ £47.56 07 price = £47.56

#### Ticagrelor

**INDICATIONS AND DOSE**

In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome

**BY MOUTH**

- Adult: Initially 180 mg for 1 dose, then 90 mg twice daily usually for up to 12 months

**Alternative to clopidogrel in patients undergoing percutaneous coronary intervention by mouth**

- Adult: 180 mg as a single dose

- **CONTRA-INDICATIONS** Active bleeding - history of intracranial haemorrhage
- **CAUTIONS** Asthma - bradycardia (unless pacemaker fitted) - chronic obstructive pulmonary disease - discontinue 7 days before elective surgery if antiplatelet effect not desirable - history of hyperuricaemia - patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or coagulation disorders) - second- or third-degree AV block (unless pacemaker fitted) - sick sinus syndrome (unless pacemaker fitted)

**INTERACTIONS** Caution with concomitant use of drugs that increase risk of bleeding.

**SIDE-EFFECTS**

- Common or very common Bruising - dyspnoea - haemorrhage
Acute coronary syndromes

Nitrates

CONTRA-INDICATIONS
- Aortic stenosis
- Cardiac tamponade
- Constrictive pericarditis
- Hypertrophic cardiomyopathy
- Hypotensive conditions
- Hypovolaemia
- Marked anaemia
- Mitral stenosis
- Raised intracranial pressure due to cerebral haemorrhage
- Raised intracranial pressure due to head trauma
- Toxoplasmosis

CAUTIONS
- Heart failure due to obstruction
- Hypothyroidism
- Hypoxaemia
- Malnutrition
- Metal-containing transdermal systems should be removed before magnetic resonance imaging procedures, cardioversion, or diathermy
- Recent history of myocardial infarction
- Susceptibility to angle-closure glaucoma
- Tolerance
- Ventilation and perfusion abnormalities

Nitrates have a useful role in angina. Although they are potent coronary vasodilators, their principal benefit follows from a reduction in venous return which reduces left ventricular work. Unwanted effects such as flushing, headache, and postural hypotension may limit therapy, especially when angina is severe or when patients are unusually sensitive to the effects of nitrates.

Sublingual glyceryl trinitrate p. 190 is one of the most effective drugs for providing rapid symptomatic relief of angina, but its effect lasts only for 20 to 30 minutes; the 300-microgram tablet is often appropriate when glyceryl trinitrate is first used. The aerosol spray provides an alternative method of rapid relief of symptoms for those who find difficulty in dissolving sublingual preparations. Duration of action may be prolonged by transdermal preparations (but tolerance may develop).

Isosorbide dinitrate p. 191 is active sublingually and is a more stable preparation for those who only require nitrates infrequently. It is also effective by mouth for prophylaxis; although the effect is slower in onset, it may persist for several hours. Duration of action of up to 12 hours is claimed for modified-release preparations. The activity of isosorbide dinitrate may depend on the production of active metabolites, the most important of which is isosorbide mononitrate. Isosorbide mononitrate itself is also licensed for angina prophylaxis; modified-release formulations (for once daily administration) are available.

Glyceryl trinitrate p. 190 or isosorbide dinitrate may be tried by intravenous injection when the sublingual form is ineffective in patients with chest pain due to myocardial infarction or severe ischaemia. Intravenous injections are also useful in the treatment of congestive heart failure.
Glyceryl trinitrate

### INDICATIONS AND DOSE

**Prophylaxis and treatment of angina**

**BY SUBLINGUAL ADMINISTRATION USING SUBLINGUAL TABLETS**
- Adult: 0.3–1 mg; dose may be repeated as required.

**Control of hypertension and myocardial ischaemia during and after cardiac surgery**
- Induction of controlled hypotension during surgery
- Congestive heart failure

**Unstable angina**
- **BY INTRAVENOUS INFUSION**
  - Adult: 10–200 micrograms/minute (max. per dose 400 micrograms/minute), adjusted according to response. Consult product literature for recommended starting doses specific to indication.

**Treatment or prophylaxis of angina**
- **BY SUBLINGUAL ADMINISTRATION USING AEROSOL SPRAY**
  - Adult: 1–2 sprays, dose be administered under tongue and then close mouth.

**NITRO-DUR®**

**Prophylaxis of angina**
- **BY TRANSDERMAL APPLICATION**
  - Adult: One ‘0.2mg/h’ patch to be applied to chest or outer upper arm and replaced every 24 hours, siting replacement patch on different area, dose adjusted according to response; maximum 15 mg per day.

**DEPONIT®**

**Prophylaxis of angina**
- **BY TRANSDERMAL APPLICATION**
  - Adult: One ‘0.5’ or one ‘10’ patch to be applied to lateral chest wall, upper arm, thigh, abdomen, or shoulder; increase to two ‘10’ patches every 24 hours if necessary, to be replaced every 24 hours, siting replacement patch on different area.

**MINITRAN®**

**Prophylaxis of angina**
- **BY TRANSDERMAL APPLICATION**
  - Adult: One ‘5’ patch to be applied to chest or upper arm; replace every 24 hours, siting replacement patch on different area, dose to be adjusted according to response.

**Maintenance of venous patency (‘5’ patch only)**
- **BY TRANSDERMAL APPLICATION**
  - Adult: (consult product literature)

### SIDE-EFFECTS

- **With rectal use**
  - Burning, diarrhoea, itching, rectal bleeding.
- **PREGNANCY**
  - Not known to be harmful.
- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use
    - Glass or polyethylene apparatus is preferable; loss of potency will occur if PVC is used.
    - For intravenous infusion (Nitrocin®, Nitronal®), give continuously in Glucose 5% or Sodium Chloride 0.9%. For Nitrocin®, suggested infusion concentration 100 micrograms/mL; incompatible with polyvinyl chloride infusion containers such as Viaflex® or Steriflex®; use glass or polyethylene containers or give via a syringe pump.
    - Glyceryl trinitrate 1 mg/ml to be diluted before use or given undiluted with syringe pump. Glyceryl trinitrate 5 mg/ml to be diluted before use.

### PRESCRIBING AND DISPENSING INFORMATION

- With sublingual use
  - Glyceryl trinitrate tablets should be supplied in glass containers of not more than 100 tablets, closed with a foil-lined cap, and containing no cotton wool wadding; they should be discarded after 8 weeks in use.
- **PATIENT AND CARER ADVICE**
  - Rectal ointment should be discarded 8 weeks after first opening.
- **PERCUTOL®**
  - Patients or carers should be given advice on how to administer glyceryl trinitrate ointment.

### NATIONAL FUNDING/ACCESS DECISIONS

#### Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2008) that glyceryl trinitrate 0.4% ointment (Rectogesic®) is not recommended for use within NHS Scotland for the relief of pain associated with chronic anal fissure.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment.
Ointment

EXCIPIENTS: May contain Wool fat and related substances including lanolin
- Percurtal (Aspire Pharma Ltd)
  Glyceryl trinitrate 20 mg per 1 gram Percurtal 2% ointment
  60 gram [PO] £79.00 DT price = £79.00

Rectal ointment
- Rectogesic (Prostrakan Ltd)
  Glyceryl trinitrate 4 mg per 1 gram Rectogesic 0.4% rectal ointment
  30 gram [PO] £39.30 DT price = £39.30

Isosorbide dinitrate

INDICATIONS AND DOSE

Prophylaxis and treatment of angina

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: 30–120 mg daily in divided doses

BY INTRAVENOUS INFUSION
- Adult: 2–10 mg/hour, increased if necessary up to 20 mg/hour

BY SUBLINGUAL ADMINISTRATION USING AEROSOL SPRAY
- Adult: 1–3 sprays, to be administered under tongue whilst holding breath, allow a 30 second interval between each dose

Left ventricular failure

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: 40–160 mg daily in divided doses, increased if necessary up to 240 mg daily in divided doses

BY INTRAVENOUS INFUSION
- Adult: Initially 2–10 mg/hour, increased if necessary up to 20 mg/hour

Prophylaxis of angina

BY MOUTH USING MODIFIED-RELEASE MEDICINES
- Adult: 40 mg daily in 1–2 divided doses, increased if necessary to 60–80 mg daily in 2–3 divided doses

PREGNANCY
May cross placenta—manufacturers advise avoid unless potential benefit outweighs risk.

DIRECTIONS FOR ADMINISTRATION
For intravenous infusion (Isoket 0.05%, Isoket 0.1%), give continuously in Glucose 5% or Sodium chloride 0.9%. Adsorbed to some extent by polyvinyl chloride infusion containers; preferably use glass or polyethylene containers or give via a syringe pump; Isoket 0.05%® can alternatively be administered undiluted using a syringe pump with a glass or rigid plastic syringe. Glass or polyethylene infusion apparatus is preferable; loss of potency if PVC used.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, solution for infusion, oral solution

Tablet
- ISOSORBIDE DINITRATE (Non-proprietary)
  Isosorbide dinitrate 10 mg
  Isosorbide dinitrate 10mg tablets
  56 tablet [PO] £30.00 DT price = £13.41
  Isosorbide dinitrate 20 mg
  Isosorbide dinitrate 20mg tablets
  56 tablet [PO] £36.60 DT price = £14.38

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS

Tablet
- ISOSORBIDE DINITRATE (Non-proprietary)
  Isosorbide dinitrate 20 mg
  Isosorbide dinitrate 20mg modified-release tablets
  56 tablet [PO] no price available
  Isosorbide dinitrate 40 mg
  Isosorbide dinitrate 40mg modified-release tablets
  56 tablet [PO] no price available
  Isoket Retard (UCB Pharma Ltd)
  Isosorbide dinitrate 20 mg
  Isoket Retard 20 tablets
  56 tablet [PO] £2.58
  Isosorbide dinitrate 40 mg
  Isoket Retard 40 tablets
  56 tablet [PO] £6.36

Cardiovascular system
Isosorbide mononitrate

INDICATIONS AND DOSE

Prophylaxis of angina | Adjunct in congestive heart failure

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: Initially 20 mg 2–3 times a day, alternatively initially 40 mg twice daily, increased if necessary up to 120 mg daily in divided doses

Prophylaxis of angina (for patients who have not previously had a nitrate) | Adjunct in congestive heart failure (for patients who have not previously had a nitrate)

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: Initially 10 mg twice daily, increased if necessary up to 120 mg daily in divided doses

MONOMIL® XL

Prophylaxis of angina

BY MOUTH

- Adult: Initially 0.5 tablet daily for 2–4 days, to minimise possibility of headache, then 1 tablet daily, increased if necessary to 2 tablets once daily, to be taken in the morning

ISOB® 60XL

Prophylaxis of angina

BY MOUTH

- Adult: Initially 0.5 tablet daily for 2–4 days, to be taken if headache occurs, then 1 tablet daily, increased if necessary to 2 tablets daily, dose to be taken in the morning

MONOSORB® XL60

Prophylaxis of angina

BY MOUTH

- Adult: Initially 0.5 tablet daily for the first 2–4 days, to minimise the possibility of headache, then 1 tablet daily, increased if necessary to 2 tablets daily, to be taken in the morning

IMDUR®

Prophylaxis of angina

BY MOUTH

- Adult: Initially 0.5 tablet daily, to be taken if headache occurs; 1 tablet daily, then increased if necessary to 2 tablets daily, dose to be taken in the morning

MONOMAX® XL

Prophylaxis of angina

BY MOUTH

- Adult: Initially 0.5 tablet daily for 2–4 days, to minimise possibility of headache, then 1 tablet daily, increased if necessary to 2 tablets daily, to be taken in the morning

ZEMON®

Prophylaxis of angina

BY MOUTH

- Adult: Initially 30 mg daily for 2–4 days, to minimise possibility of headache, then 40–60 mg daily, increased if necessary to 80–120 mg once daily, to be taken in the morning

ISOTARD®

Prophylaxis of angina

BY MOUTH

- Adult: 25–60 mg daily, if headaches occur with 60 mg tablet, half a 60 mg tablet may be given for 2–4 days, then increased if necessary to 50–120 mg daily, to be taken in the morning

MODISAL® XL

Prophylaxis of angina

BY MOUTH

- Adult: Initially 0.5 tablet once daily for 2–4 days, to minimise the possibility of headache; 1 tablet once daily, then increased if necessary to 2 tablets once daily, dose to be taken in the morning

CHEMYDUR® 60XL

Prophylaxis of angina

BY MOUTH

- Adult: 25–50 mg daily, then increased if necessary to 50–100 mg once daily, to be taken in the morning

MONOMAX® SR

Prophylaxis of angina

BY MOUTH

- Adult: 40–60 mg daily, increased if necessary to 120 mg daily, to be taken in the morning

PREGNANCY

Manufacturers advise avoid unless potential benefit outweighs risk.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 25

- ISOSORBIDE MONONITRATE (Non-proprietary)
  - Isosorbide mononitrate 10 mg: Isosorbide mononitrate 10 mg tablets | 56 tablet £48.25 DT price = £4.27
  - Isosorbide mononitrate 20 mg: Isosorbide mononitrate 20 mg tablets | 56 tablet [P] no price available DT price = £5.26 | 56 tablet [P] £62.25 DT price = £5.26
  - Isosorbide mononitrate 40 mg: Isosorbide mononitrate 40 mg tablets | 56 tablet [P] £36.75 DT price = £6.19 | 56 tablet [P] no price available DT price = £6.19
  - Brands may include Isomox

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

- ISOSORBIDE MONONITRATE (Non-proprietary)
  - Isosorbide mononitrate 40 mg: Isosorbide mononitrate 40 mg modified-release tablets | 28 tablet [P] no price available | 28 tablet [P] £50.64
  - Chemydur 60XL (AMCO)
    - Isosorbide mononitrate 60 mg: Chemydur 60XL tablets | 28 tablet [P] £3.49 DT price = £10.50
  - Imdur (AstraZeneca UK Ltd)
    - Isosorbide mononitrate 60 mg: Imdur 60 mg modified-release tablets | 28 tablet [P] £10.50 DT price = £10.50
  - Isib XL (Sinclair IS Pharma Pfc)
    - Isosorbide mononitrate 60 mg: Isib XL tablets | 28 tablet [P] £8.15 DT price = £10.50


**DRUG ACTION** Dobutamine is a cardiac stimulant which acts on beta, receptors in cardiac muscle, and increases contractility with little effect on rate.

**INDICATIONS AND DOSE**

Inotropic support in infarction, cardiac surgery, cardiomyopathies, septic shock, cardiogenic shock, and during positive end expiratory pressure ventilation

**BY INTRAVENOUS INFUSION**

- Adult: Usual dose 2.5–10 micrograms/kg/minute, adjusted according to response, alternatively 0.5–40 micrograms/kg/minute

**Cardiac stress testing**

**BY INTRAVENOUS INFUSION**

- Adult: (consult product literature)

**CONTRA-INDICATIONS** Phaeochromocytoma

**CAUTIONS** Acute heart failure - acute myocardial infarction - arrhythmias - correct hypercapnia before starting and during treatment - correct hypovolaemia before starting and during treatment - correct hypoxia before starting and during treatment - correct metabolic acidosis before starting and during treatment - diabetes mellitus - elderly - extravasation may cause tissue necrosis - extreme caution or avoid in marked obstruction of cardiac ejection (such as idiopathic hypertrophic subaortic stenosis) - hyperthyroidism - ischaemic heart disease - occlusive vascular disease - severe hypotension - susceptibility to angle-closure glaucoma - tachycardia - tolerance may develop with continuous infusions longer than 72 hours

**INTERACTIONS** → Appendix 1 (sympathomimetics).

**SIDE-EFFECTS**

- Rare Psychosis

- Very rare Angle-closure glaucoma - AV block - bradycardia - cardiac arrest - coronary artery spasm - hypokalaemia - myocardial infarction - petechial bleeding

- Frequency not known Anxiety - arrhythmias - bronchospasm - cerebral haemorrhage - chest pain - dyspnoea - eosinophilia - fever - headache - hypertension (marked increase in systolic blood pressure indicates overdose) - hypotension - increased urinary urgency - myoclonic spasm - nausea - palpitation - paraesthesia - phlebitis - puritus of scalp - pulmonary oedema - rash - reduced platelet aggregation (on prolonged use) - tachycardia - tremor - vomiting

**PREGNANCY** No evidence of harm in animal studies— manufacturers advise use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturers advise avoid—no information available.

**MONITORING REQUIREMENTS** Monitor serum-potassium concentration.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to a concentration of 0.5–1 mg/mL and give via an infusion pump; give higher concentration (max. 5 mg/mL) through central venous catheter; incompatible with bicarbonate and other strong alkaline solutions. Dobutamine injection should be diluted before use or given undiluted with syringe pump. Dobutamine concentrate for intravenous infusion should be diluted before use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

**EXCIPIENTS:** May contain Sulphites

- **DOBUTAMINE (Non-proprietary)**
  - Dobutamine (as Dobutamine hydrochloride) 5 mg per 1 mL Dobutamine 250mg/50ml solution for infusion vials | 1 vial (£0.195)
  - Dobutamine (as Dobutamine hydrochloride) 12.5 mg per 1 mL Dobutamine 250mg/20ml concentrate for solution for infusion ampoules | 5 ampoule (£0.06-£0.25)

**Fibrinolytic drugs**

The value of thrombolytic drugs for the treatment of myocardial infarction has been established. Streptokinase p. 195 and alteplase p. 194 have been shown to reduce mortality. Retepaase p. 195 and tenecteplase p. 195 are also licensed for acute myocardial infarction. Thrombolytic drugs are indicated for any patient with acute myocardial infarction for whom the benefit is likely to outweigh the risk of treatment. Trials have shown that the benefit is greatest
in those with ECG changes that include ST segment elevation (especially in those with anterior infarction) and in patients with bundle branch block. Patients should not be denied thrombolytic treatment on account of age alone because mortality in the elderly is high and the reduction in mortality is the same as in younger patients. Alteplase should be given within 6–12 hours of symptom onset, reteplase and streptokinase within 12 hours of symptom onset, but ideally all should be given within 1 hour; use after 12 hours requires specialist advice. Tenecteplase should be given as early as possible and usually within 6 hours of symptom onset.

Alteplase, streptokinase and urokinase p. 119 can be used for other thromboembolic disorders such as deep-vein thrombosis and pulmonary embolism. Alteplase is also used for acute ischaemic stroke.

Urokinase p. 119 is also licensed to restore the patency of occluded intravenous catheters and cannulas blocked with fibrin clots.

### Fibrinolytics

**Drug Action** Fibrinolytic drugs act as thrombolitics by activating plasminogen to form plasmin, which degrades fibrin and so breaks up thrombi.

**Contra-Indications** Active pulmonary disease with cavitation - acute pancreatitis - aneurysm - aortic dissection - bacterial endocarditis - bleeding diatheses - coagulation defects - coma - heavy vaginal bleeding - history of cerebrovascular disease (especially recent events or with any residual disability) - oesophageal varices - pericarditis - recent haemorrhage - recent surgery (including dental extraction) - recent symptoms of possible peptic ulceration - recent trauma - severe hypertension

**Caution** Conditions in which thrombolysis might give rise to embolic complications such as enlarged left atrium with atrial fibrillation (risk of dissolution of clot and subsequent embolisation) - elderly - external chest compression - hypertension - risk of bleeding (including that from venepuncture or invasive procedures)

**Interactions** Caution with recent or concomitant use of drugs that increase the risk of bleeding.

**Side-Effects** Allergic reactions - anaphylaxis - angina (when used in myocardial infarction) - back pain - bleeding - bleeding (usually limited to the site of injection, but can occur from other sites) - cerebral oedema (caused by reperfusion) - convulsions - fever - flushing - hypotension - intracerebral haemorrhage - nausea - pulmonary oedema (caused by reperfusion) - rash - recurrent ischaemia (when used in myocardial infarction) - reperfusion arrhythmias (when used in myocardial infarction) - urticaria - vomiting

**Side-Effects, Further Information**

**Bleeding** Serious bleeding calls for discontinuation of the thrombolytic and may require administration of coagulation factors and antifibrinolytic drugs (e.g. tranexamic acid). Rarely further embolism may occur (either due to clots that break away from the original thrombus or to cholesterol crystal emboli).

**Hypotension** Hypotension can usually be controlled by elevating the patient’s legs, or by reducing the rate of infusion or stopping it temporarily.

**Pregnancy** Thrombolytic drugs can possibly lead to premature separation of the placenta in the last 18 weeks of pregnancy. There is also a risk of maternal haemorrhage throughout pregnancy and post-partum, and also a theoretical risk of fetal haemorrhage throughout pregnancy.

**Hepatic Impairment** Avoid in severe hepatic impairment as there is an increased risk of bleeding.

---

### Alteplase

**(rt-PA; Tissue-type plasminogen activator)**

**Indications and Dose**

**Acute myocardial infarction, accelerated regimen**

- **Initially by intravenous injection**
  - Adult: Initially 10 mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 0.75 mg/kg, to be given over 30 minutes, then (by intravenous infusion) 0.5 mg/kg, to be given over 60 minutes, maximum total dose of 100 mg administered over 90 minutes
  - Adult: Initially 15 mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 50 mg, to be given over 30 minutes, then (by intravenous infusion) 35 mg, to be given over 60 minutes, maximum total dose of 100 mg administered over 90 minutes

**Acute myocardial infarction**

- **Initially by intravenous injection**
  - Adult: Initially 10 mg, to be initiated within 6–12 hours of symptom onset, followed by (by intravenous infusion) 50 mg, to be given over 60 minutes, then (by intravenous infusion) 10 mg for 4 infusions, each 10 mg infusion dose to be given over 30 minutes, total dose of 100 mg over 3 hours; maximum 1.5 mg/kg in patients less than 65 kg

**Pulmonary embolism**

- **Initially by intravenous injection**
  - Adult: Initially 10 mg, to be given over 1–2 minutes, followed by (by intravenous infusion) 90 mg, to be given over 2 hours, maximum 1.5 mg/kg in patients less than 65 kg

**Acute stroke (under specialist neurology physician only)**

- **By intravenous infusion**
  - Adult 18–79 years: Initially 900 micrograms/kg (max. per dose 90 mg), treatment must begin within 4.5 hours of symptom onset, to be given over 60 minutes, the initial 10% of dose to be administered by intravenous injection and the remainder by intravenous infusion

**Actilyse Cathflo**

**Thrombolytic treatment of occluded central venous access devices**

- **By intravenous injection**
  - Adult: (consult product literature)

**Contra-Indications**

- When used for acute ischaemic stroke: Convulsion accompanying stroke - history of stroke in patients with diabetes - hyperglycaemia - hypoglycaemia - severe stroke - stroke in last 3 months

**Interactions** Contra-indicated if concomitant treatment with oral anticoagulants.

**Side-Effects** Risk of cerebral bleeding increased in acute stroke

**Allergy and Cross-Sensitivity** Contra-indicated if history of hypersensitivity to gentamicin (residue from manufacturing process).

**Monitoring Requirements**

- When used for acute ischaemic stroke: Monitor for intracranial haemorrhage, and monitor blood pressure (antihypertensive recommended if systolic above 180 mmHg or diastolic above 105 mmHg).

**Directions for Administration** For intravenous infusion (Actilyse®), give intermittently or continuously in Sodium chloride 0.9%; dissolve in water for injections to a concentration of 1 mg/mL or 2 mg/mL and infuse intravenously; alternatively dilute the solution further in...
the infusion fluid to a concentration of not less than 200 microgram/mL; not to be infused in glucose solution.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - NICE technology appraisals (TAs)
    - Alteplase for the treatment of acute ischaemic stroke (September 2012) NICE TA264
    - Alteplase is recommended for the treatment of acute ischaemic stroke in adults in accordance with its licensed indication:
      - treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, and
      - intracranial haemorrhage has been excluded by appropriate imaging techniques. [www.nice.org.uk/TA264](http://www.nice.org.uk/TA264)

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

  - **Powder and solvent for solution for injection**
    - **Actilyse** (Boehringer Ingelheim Ltd)
      - Alteplase 10 mg Actilyse 10mg powder and solvent for solution for injection vials | 1 vial £144.00
      - Alteplase 20 mg Actilyse 20mg powder and solvent for solution for injection vials | 1 vial £246.00
    - **Actilyse Cathflo** (Boehringer Ingelheim Ltd)
      - Alteplase 2 mg Actilyse Cathflo 2mg powder and solvent for solution for injection vials | 5 vial £225.00 (Hospital only)

  - **Powder and solvent for solution for infusion**
    - **Actilyse** (Boehringer Ingelheim Ltd)
      - Alteplase 50 mg Actilyse 50mg powder and solvent for solution for infusion vials | 1 vial £360.00

### Reteplase

- **INDICATIONS AND DOSE**
  - Acute myocardial infarction
    - Adult: 10 units, initiated within 12 hours of onset of symptoms, dose to be given over not more than 2 minutes, followed by 10 units after 30 minutes

- **BREAST FEEDING**
  Manufacturer advises avoid breastfeeding for 24 hours after dose (express and discard milk during this time).

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  - **Powder and solvent for solution for injection**
    - **Rapilysin** (Actavis UK Ltd)
      - Rapilysin 10 unit Rapilysin 10unit powder and solvent for solution for injection vials | 2 vial £566.00

### Streptokinase

- **INDICATIONS AND DOSE**
  - Acute myocardial infarction
    - Adult: 1 500 000 units, to be initiated within 12 hours of symptom onset, dose to be given over 60 minutes
    - Deep-vein thrombosis | Pulmonary embolism | Acute arterial thromboembolism | Central retinal venous or arterial thrombosis
    - **BY INTRAVENTOUS INFUSION**
      - Adult: 250 000 units, dose to be given over 30 minutes, then 100 000 units every 1 hour for up to 12–72 hours, duration is adjusted according to condition with monitoring of clotting parameters (consult product literature)

- **SIDE-EFFECTS**
  - Rare Guillain-Barré syndrome

- **ALLERGY AND CROSS-SENSITIVITY**
  Contra-indicated if previous allergic reaction to either streptokinase or anistreplase (no longer available). Prolonged persistence of antibodies to streptokinase and anistreplase (no longer available) can reduce the effectiveness of subsequent treatment; therefore, streptokinase should not be used again beyond 4 days of first administration of either streptokinase or anistreplase.

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Streptase®), give continuously or intermittently; reconstitute with sodium chloride 0.9%, then dilute further with Glucose 5% or Sodium Chloride 0.9% after reconstitution.

### Medicines

- **Tenecteplase**

  - **INDICATIONS AND DOSE**
    - Acute myocardial infarction
      - Adult: 30–50 mg (max. per dose 50 mg), dose to be given over 10 seconds and initiated within 6 hours of symptom onset, dose varies according to body weight—consult product literature

  - **BREAST FEEDING**
    Manufacturer advises avoid breastfeeding for 24 hours after dose (express and discard milk during this time).

  - **MEDICINAL FORMS**
    There can be variation in the licensing of different medicines containing the same drug.

    - **Powder and solvent for solution for injection**
      - **Metalyse** (Boehringer Ingelheim Ltd)
        - Tenecteplase 8000 unit Metalyse 8,000unit powder and solvent for solution for injection vials | 1 vial £502.25
        - Tenecteplase 10000 unit Metalyse 10,000unit powder and solvent for solution for injection vials | 1 vial £502.25

### 7.2 Cardiac arrest

Cardiopulmonary resuscitation

The algorithm for cardiopulmonary resuscitation (Life support algorithm) reflects the most recent recommendations of the Resuscitation Council (UK). These guidelines are available at [www.resus.org.uk](http://www.resus.org.uk).

Cardiac arrest can be associated with ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity (electromechanical dissociation). Adrenaline/epinephrine p. 196 1 in 10000 (100 microgram/mL) is recommended by intravenous injection repeated every 3–5 minutes if necessary. Administration through a central line results in a faster response than peripheral administration, however placement of a central line must not interfere with chest

...
Cardiovascular system

**CARDIOVASCULAR SYSTEM**

**DRUG ACTION**

Adrenaline/epinephrine

- Acts on both alpha and beta receptors and increases both heart rate and contractility (beta, effects); it can cause peripheral vasodilation (a beta, effect) or vasoconstriction (an alpha effect).

**INDICATIONS AND DOSE**

**Cardiopulmonary resuscitation**

- **BY INTRAVENOUS INFUSION**
  - Adult: 1 mg every 3–5 minutes as required, a 1 in 10 000 (100 micrograms/mL) solution is recommended

**Acute hypotension**

- **BY CONTINUOUS INTRAVENOUS INFUSION**
  - Neonate: Initially 100 nanograms/kg/minute (up to 1.5 micrograms/kg/minute has been used), adjusted according to response
  - Child: Initially 100 nanograms/kg/minute (up to 1.5 micrograms/kg/minute has been used), adjusted according to response

**Emergency treatment of acute anaphylaxis (under expert supervision) Angioedema (if laryngeal oedema is present)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 1 month–5 years: 150 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the thigh, repeated if necessary, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, suitable syringe to be used for measuring small volume; injected preferably into the anterolateral aspect of the middle third of the thigh
  - Child 6–11 years: 300 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the thigh, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function
  - Child 12–17 years: 500 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the thigh, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, 300 micrograms (0.3 mL) to be administered if child small or prepubertal
  - Adult: 500 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the thigh, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function

**Acute hypotension**

- Adult 1 mg every 3–5 minutes as required, a 1 in 10 000 (100 micrograms/mL) solution is recommended

**Emergency treatment of acute anaphylaxis**

- Adult: 2–10 micrograms/minute, adjusted according to response

**EMERADE® 150 MICROGRAMS**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight up to 15 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required
  - Child (body-weight 15–30 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required, on the basis of a dose of 10 micrograms/kg, 300 micrograms may be more appropriate for some children

**EMERADE® 300 MICROGRAMS**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required
  - Adult (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required

**EMERADE® 500 MICROGRAMS**

**Acute anaphylaxis (for self-administration for patients at risk of severe anaphylaxis)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 12–17 years: 500 micrograms, then 500 micrograms after 5–15 minutes as required
  - Adult: 500 micrograms, then 500 micrograms after 5–15 minutes as required

**EPIPEN® JR AUTO-INJECTOR 0.15MG**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight up to 15 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required
  - Child (body-weight 15–30 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required, on the basis of a dose of 10 micrograms/kg, 300 micrograms may be more appropriate for some children

**EPIPEN® AUTO-INJECTOR 0.3MG**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required
  - Adult (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required

**JEXT® 150 MICROGRAMS**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight up to 15 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required
  - Child (body-weight 15–30 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required, on the basis of a dose of 10 micrograms/kg, 300 micrograms may be more appropriate for some children
JEXT® 300 MICROGRAMS

Acute anaphylaxis (for self-administration)

BY INTRAVENOUS INJECTION

- Child (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required
- Adult (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required

Priapism associated with alprostadil, if aspiration and lavage of corpora are unsuccessful (alternative to phenylephrine or metaraminol).

BY INTRACAVERNOSAL INJECTION

- Adult: 10–20 micrograms every 5–10 minutes, using a 20 microgram/mL solution, Important: if suitable strength of adrenaline not available may be specially prepared by diluting 0.1 mL of the adrenaline 1 in 1000 (1 mg/mL) injection to 5 mL with sodium chloride 0.9%, continuously monitor blood pressure and pulse; maximum 100 micrograms per course

UNLICENSED USE

- With intravenous use Adrenaline 1 in 1000 (1mg/mL) solution is not licensed for intravenous administration. Auto-injector delivering 150-microgram dose of adrenaline not licensed for use in children body-weight under 15 kg.

Important safety information

SAFE PRACTICE

Intravenous route should be used with extreme care by specialists only.

- CAUTIONS Arteriosclerosis, arrhythmias, cerebrovascular disease, cor pulmonale, diabetes mellitus, elderly, hypercalcaemia, hyperreflexia, hypertension, hyperthyroidism, hypokalaemia, ischaemic heart disease, obstructive cardiomyopathy, occlusive vascular disease, organic brain damage, phaeochromocytoma, prostate disorders, psychosis, severe aniga, susceptibility to angle-closure glaucoma

CAUTIONS, FURTHER INFORMATION

Cautions listed are only for non-life-threatening situations.

- INTERACTIONS Appendix 1 (sympathomimetics)

Severe anaphylaxis in patients taking beta-blockers may not respond to adrenaline—consider bronchodilator therapy. Furthermore, adrenaline can cause severe hypertension and bradycardia in those taking non-cardioselective beta-blockers.

- SIDE-EFFECTS Angina, angle-closure glaucoma, anorexia, anxiety, arrhythmias, cold extremities, confusion, difficulty in micturition, dizziness, dry mouth, dyspnoea, headache, hyperglycaemia, hypersalivation, hypertension (risk of cerebral haemorrhage), hypokalaemia, insomnia, metabolic acidosis, mydriasis, myocardial infarction, nausea, pallor, palpitation, psychosis, pulmonary oedema (on excessive dosage or extreme sensitivity), restlessness, sweating, tachycardia, tissue necrosis at injection site, tissue necrosis of bowel, tissue necrosis of extremities, tissue necrosis of kidneys, tissue necrosis of liver, tremor, urinary retention, vomiting, weakness

- PREGNANCY May reduce placental perfusion and cause tachycardia, cardiac irregularities, and extrasystoles in fetus. Can delay second stage of labour. Manufacturers advise use only if benefit outweighs risk.

- BREAST FEEDING Present in milk but unlikely to be harmful as poor oral bioavailability.

- RENAL IMPAIRMENT Manufacturers advise use with caution in severe impairment.

- MONITORING REQUIREMENTS Monitor blood pressure and ECG.

DIRECTIONS FOR ADMINISTRATION

- With intravenous use in children Acute hypotension (same text as above) For continuous intravenous infusion, dilute with Glucose 5% or Sodium Chloride 0.9% and give through a central venous catheter. Incompatible with bicarbonate and alkaline solutions. Neonatal intensive care, dilute 3 mg/kg body-weight to a final volume of 50 mL with infusion fluid; an intravenous infusion rate of 0.1 mL/hour provides a dose of 100 nanograms/kg/minute; infuse through a central venous catheter. Incompatible with bicarbonate and alkaline solutions. These infusions are usually made up with adrenaline 1 in 1000 (1 mg/mL) solutions.

- With intravenous use Administration through a central line results in a faster response than peripheral administration, however placement of a central line must not interfere with chest compressions; drugs administered peripherally must be followed by a flush of at least 20 mL. Sodium Chloride 0.9% injection to aid entry into the central circulation.

PRESCRIBING AND DISPENSING INFORMATION

It is important, in acute anaphylaxis where intramuscular injection might still succeed, time should not be wasted seeking intravenous access. Great vigilance is needed to ensure that the correct strength of adrenaline injection is used; anaphylactic shock kits need to make a very clear distinction between the 1 in 10 000 strength and the 1 in 1000 strength. Patients with severe allergy should be instructed in the self-administration of adrenaline by intramuscular injection.

Packs for self-administration need to be clearly labelled with instructions on how to administer adrenaline (intramuscularly, preferably at the midpoint of the outer thigh, through light clothing if necessary) so that in the case of rapid collapse someone else is able to give it. It is important to ensure individuals at risk and their carers understand that:

- two injection devices should be carried at all times to treat symptoms until medical assistance is available; if, after the first injection, the individual does not start to feel better, the second injection should be given 5 to 15 minutes after the first;
- an ambulance should be called after every administration, even if symptoms improve;
- the individual should lie down with their legs raised (unless they have breathing difficulties, in which case they should sit up) and should not be left alone.

Adrenaline for administration by intramuscular injection is available in ‘auto-injectors’ (e.g. Emerade®), EpiPen®, or Jext®), pre-assembled syringes fitted with a needle suitable for very rapid administration (if necessary by a bystander or a healthcare provider if it is the only preparation available); injection technique is device specific.

To ensure patients receive the auto-injector device that they have been trained to use, prescribers should specify the brand to be dispensed.

PATIENT AND CARER ADVICE

Individuals at considerable risk of anaphylaxis need to carry (or have available) adrenaline at all times and the patient, or their carers, need to be instructed in advance and how to inject it.

Medicines for Children leaflet: Adrenaline auto-injector for anaphylaxis www.medicinesforchildren.org.uk/adrenaline-for-anaphylaxis

EpiPen® AUTO-INJECTOR 0.15MG, 0.3MG

1.7 mL of the solution remains in the auto-injector device after use.

EMERADE® 500 MICROGRAMS

No solution remains in the auto-injector device after use.
EMERADE® 150 MICROGRAMS
0.35 mL of the solution remains in the auto-injector device after use.

EMERADE® 300 MICROGRAMS
0.2 mL of the solution remains in the auto-injector device after use.

JEXT® 300 MICROGRAMS
1.1 mL of the solution remains in the auto-injector device after use.

JEXT® 150 MICROGRAMS
1.25 mL of the solution remains in the auto-injector device after use.

Exceptions to legal category
POM restriction does not apply to the intramuscular administration of up to 1 mg of adrenaline injection 1 in 1000 (1 mg/mL) for the emergency treatment of anaphylaxis.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

Solution for injection
Excipients: May contain Sulfites

Adrenaline (as Adrenaline acid tartrate) 100 microgram per 1 ml
Adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection ampoules | 1 ampoule (PSB) £43.53 | 10 ampoule (PSB) £60.30
Adrenaline (base) 500micrograms/5ml (1 in 10,000) dilute solution for injection ampoules | 10 ampoule (PSB) £55.43

Adrenaline 100 microgram per 1 ml
Adrenaline (base) 100micrograms/1ml (1 in 10,000) dilute solution for injection ampoules | 1 ampoule (PSB) £52.03
Adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSB) £6.87–£25.20
Adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection Minijet pre-filled syringes | 1 pre-filled disposable injection (PSB) £6.99

Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 ml
Adrenaline (base) 5mg/5ml (1 in 1,000) solution for injection ampoules | 10 ampoule (PSB) £63.77
Adrenaline (base) 500micrograms/0.5ml (1 in 1,000) solution for injection ampoules | 10 ampoule (PSB) £50.57 DT price = £50.57
Adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection ampoules | 10 ampoule (PSB) £4.43 DT price = £4.41

Adrenaline 1 mg per 1 ml
Adrenaline (base) for anaphylaxis 1mg/1ml (1 in 1,000) solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSB) £10.40
Adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection Minijet pre-filled syringes 21 gauge | 1 pre-filled disposable injection (PSB) £15.00
Adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSB) £10.10–£10.40
Adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection Minijet pre-filled syringes 25 gauge | 1 pre-filled disposable injection (PSB) £13.90

Emerade (Imed Systems Ltd)

Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 ml
Emerade 150micrograms/0.15ml (1 in 1,000) solution for injection auto-injectors | 1 pre-filled disposable injection (PSB) £26.94
Emerade 500micrograms/0.5ml (1 in 1,000) solution for injection auto-injectors | 1 pre-filled disposable injection (PSB) £28.74

Adrenaline 1 mg per 1 ml
Emerade 300micrograms/0.3ml (1 in 1,000) solution for injection auto-injectors | 1 pre-filled disposable injection (PSB) £26.94

Epipen (Meda Pharmaceuticals Ltd)

Adrenaline 500 microgram per 1 ml
Epipen Jr. 150micrograms/0.3ml (1 in 2,000) solution for injection auto-injectors | 1 pre-filled disposable injection (PSB) £26.45 | 2 pre-filled disposable injection (PSB) £52.90
Adrenaline 1 mg per 1 ml
Epipen 300micrograms/0.3ml (1 in 1,000) solution for injection auto-injectors | 1 pre-filled disposable injection (PSB) £26.45 | 2 pre-filled disposable injection (PSB) £52.90

Jext (ALK-Abello Ltd)

Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 ml
Jext 150micrograms/0.15ml (1 in 1,000) solution for injection auto-injectors | 1 pre-filled disposable injection (PSB) £23.99

Adrenaline 1 mg per 1 ml
Jext 300micrograms/0.3ml (1 in 1,000) solution for injection auto-injectors | 1 pre-filled disposable injection (PSB) £23.99

8 Oedema

Diuretics

Overview
Thiazides are used to relieve oedema due to chronic heart failure and, in lower doses, to reduce blood pressure.

Loop diuretics are used in pulmonary oedema due to left ventricular failure and in patients with chronic heart failure. Combination diuretic therapy may be effective in patients with oedema resistant to treatment with one diuretic. Vigorous diuresis, particularly with loop diuretics, may induce acute hypotension; rapid reduction of plasma volume should be avoided.

Thiazides and related diuretics

Thiazides and related compounds are moderately potent diuretics; they inhibit sodium reabsorption at the beginning of the distal convoluted tubule. They act within 1 to 2 hours of oral administration and most have a duration of action of 12 to 24 hours; they are usually administered early in the day so that the diuresis does not interfere with sleep.

In the management of hypertension a low dose of a thiazide produces a maximal or near-maximal blood pressure lowering effect, with very little biochemical disturbance. Higher doses cause more marked changes in plasma potassium, sodium, uric acid, glucose, and lipids, with little advantage in blood pressure control.

Chlortalidone p. 204 and indapamide p. 160 are the preferred diuretics in the management of hypertension. Thiazides also have a role in chronic heart failure.

Bendroflumethiazide p. 159 can be used for mild or moderate heart failure; it is licensed for the treatment of hypertension but is no longer considered the first-line diuretic for this indication, although patients with stable and controlled blood pressure currently taking bendroflumethiazide can continue treatment.

Chlortalidone, a thiazide-related compound, has a longer duration of action than the thiazides and may be given on alternate days to control oedema. It is also useful if acute retention is liable to be precipitated by a more rapid diuresis or if patients dislike the altered pattern of micturition caused by other diuretics. Chlortalidone can also be used under close supervision for the treatment of ascites due to cirrhosis in stable patients.

Xipamide p. 205 and indapamide are chemically related to chlortalidone. Indapamide is claimed to lower blood pressure with less metabolic disturbance, particularly less aggravation of diabetes mellitus.

Metolazone p. 205 is particularly effective when combined with a loop diuretic (even in renal failure); profound diuresis can occur and the patient should therefore be monitored carefully.

The thiazide diuretics benzthiazide, clopamide, cyclopenthiazide p. 204, hydrochlorothiazide, and hydroflumethiazide do not offer any significant advantage over other thiazides and related diuretics.

Loop diuretics

Loop diuretics are used in pulmonary oedema due to left ventricular failure; intravenous administration produces relief of breathlessness and reduces pre-load sooner than would be expected from the time of onset of diuresis. Loop diuretics are also used in patients with chronic heart failure. Diuretic-resistant oedema (except lymphoedema and
Oedema due to peripheral venous stasis or calcium-channel blockers can be treated with a loop diuretic combined with a thiazide or related diuretic (e.g. bendroflumethiazide or metolazone).

If necessary, a loop diuretic can be added to antihypertensive treatment to achieve better control of blood pressure in those with resistant hypertension, or in patients with impaired renal function or heart failure.

Loop diuretics can exacerbate diabetes (but hyperglycaemia is less likely than with thiazides) and gout. If there is an enlarged prostate, urinary retention can occur, although this is less likely if small doses and less potent diuretics are used initially.

Furosemide and bumetanide are similar in activity; both act within 1 hour of oral administration and diuresis is complete within 6 hours so that, if necessary, they can be given twice in one day without interfering with sleep. Following intravenous administration furosemide has a peak effect within 30 minutes. The diuresis associated with these drugs is dose related.

Torasemide p. 202 has properties similar to those of furosemide and bumetanide, and is indicated for oedema and for hypertension.

Potassium-sparing diuretics and aldosterone antagonists

Amiloride hydrochloride p. 203 and triamterene p. 203 on their own are weak diuretics. They cause retention of potassium and are therefore given with thiazide or loop diuretics as a more effective alternative to potassium supplements. See compound preparations with thiazides or loop diuretics.

Potassium supplements must not be given with potassium-sparing diuretics. Administration of a potassium-sparing diuretic to a patient receiving an ACE inhibitor or an angiotensin-II receptor antagonist can also cause severe hyperkalaemia.

Aldosterone antagonists

Spironolactone p. 168 potentiates thiazide or loop diuretics by antagonising aldosterone; it is a potassium-sparing diuretic. Spironolactone is of value in the treatment of oedema and ascites caused by cirrhosis of the liver; furosemide can be used as an adjunct. Low doses of spironolactone are beneficial in moderate to severe heart failure and when used in resistant hypertension [unlicensed indication].

Spironolactone is also used in primary hyperaldosteronism (Conn’s syndrome). It is given before surgery or if surgery is not appropriate, in the lowest effective dose for maintenance.

Eplerenone p. 167 is licensed for use as an adjunct in left ventricular dysfunction with evidence of heart failure after a myocardial infarction; it is also licensed as an adjunct in chronic mild heart failure with left ventricular systolic dysfunction.

Potassium supplements must not be given with aldosterone antagonists

Potassium-sparing diuretics with other diuretics

Although it is preferable to prescribe thiazides and potassium-sparing diuretics separately, the use of fixed combinations may be justified if compliance is a problem. Potassium-sparing diuretics are not usually necessary in the routine treatment of hypertension, unless hypokalaemia develops.

Other diuretics

Mannitol p. 202 is an osmotic diuretic that can be used to treat cerebral oedema and raised intraocular pressure. Mercurial diuretics are effective but are now almost never used because of their nephrotoxicity.

The carbonic anhydrase inhibitor acetazolamide p. 965 is a weak diuretic and is little used for its diuretic effect. It is used for prophylaxis against mountain sickness [unlicensed indication] but is not a substitute for acclimatisation.

Acetazolamide and eye drops of dorzolamide p. 966 and brinzolamide p. 965 inhibit the formation of aqueous humour and are used in glaucoma.

Diuretics with potassium

Many patients on diuretics do not need potassium supplements. For many of those who do, the amount of potassium in combined preparations may not be enough, and for this reason their use is to be discouraged.

Diuretics with potassium and potassium-sparing diuretics should not usually be given together. Diuretics and potassium supplements should be prescribed separately for children.

LOOP DIURETICS

Loop diuretics

- **DRUG ACTION** Loop diuretics inhibit reabsorption from the ascending limb of the loop of Henlé in the renal tubule and are powerful diuretics.

- **CONTRA-INDICATIONS** Anuria · comatose and precomatose states associated with liver cirrhosis · renal failure due to nephrotoxic or hepatotoxic drugs · severe hypokalaemia · severe hyponatraemia

- **CAUTIONS** Can exacerbate diabetes (but hyperglycaemia less likely than with thiazides) · can exacerbate gout · hypotension should be corrected before initiation of treatment · hypovolaemia should be corrected before initiation of treatment · urinary retention can occur in prostatic hyperplasia

**CAUTIONS, FURTHER INFORMATION**

**Elderly** Lower initial doses of diuretics should be used in the elderly because they are particularly susceptible to the side-effects. The dose should then be adjusted according to renal function. Diuretics should not be used continuously on a long-term basis to treat simple gravitational oedema (which will usually respond to increased movement, raising the legs, and support stockings).

**Potassium loss** Hypokalaemia can occur with both thiazide and loop diuretics. The risk of hypokalaemia depends on the duration of action as well as the potency and is thus greater with thiazides than with an equipotent dose of a loop diuretic. Hypokalaemia is dangerous in severe cardiovascular disease and in patients also being treated with cardiac glycosides. Often the use of potassium-sparing diuretics avoids the need to take potassium supplements.

In hepatic failure, hypokalaemia caused by diuretics can precipitate encephalopathy, particularly in alcoholic cirrhosis.

**Urinary retention** If there is an enlarged prostate, urinary retention can occur, although this is less likely if small doses and less potent diuretics are used initially; an adequate urinary output should be established before initiating treatment.

- **INTERACTIONS** → Appendix 1 (diuretics).

- **SIDE-EFFECTS**
  - Very rare Hyperuricaemia
  - Frequency not known Acute urinary retention · blood disorders · bone-marrow depression · deafness (usually with high doses and rapid intravenous administration, and in renal impairment) · electrolyte disturbances · hepatic encephalopathy · hyperuricaemia (less common than with thiazides) · hypersensitivity reactions ·
Co-amilofruse

**INDICATIONS AND DOSE**

**Oedema**

**BY MOUTH**

- Adult: 2.5/20–10/80 mg daily, dose to be taken in the morning

**Co-amilofruse**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet

- **CO-AMILOFRUSE (Non-proprietary)**
  - Amiloride hydrochloride 2.5 mg, Furosemide 20 mg
  - Amiloride hydrochloride 5 mg, Furosemide 40 mg
  - Amiloride hydrochloride 10 mg, Furosemide 80 mg

- Frumil (Sanofi)
  - Amiloride hydrochloride 2.5 mg, Furosemide 20 mg
  - Amiloride hydrochloride 5 mg, Furosemide 40 mg

**Dose equivalence and conversion**

A mixture of amiloride hydrochloride and furosemide (frusemide) in the mass proportions of 1 part amiloride hydrochloride to 8 parts furosemide (frusemide).

- **CONTRA-INDICATIONS**
  - Addison’s disease
  - anuria
  - comatose or precomatose states associated with liver cirrhosis
  - dehydration
  - hyperkalaemia
  - hypovolaemia
  - renal failure
  - severe hypokalaemia
  - severe hyponatraemia

- **CAUTIONS**
  - Correct hypovolaemia before using in oliguria
  - diabetes mellitus
  - elderly
  - gout
  - hepatorenal syndrome
  - hypoproteinaemia
  - hypotension
  - impaired micturition
  - prostatic enlargement

- **INTERACTIONS**
  - Appendix 1 (diuretics).

- **SIDE-EFFECTS**
  - Agranulocytosis
  - anaphylaxis
  - aplastic anaemia
  - blood disorders
  - bone marrow depression
  - confusion
  - deafness
  - diabetes mellitus
  - eosinophilia
  - exfoliative dermatitis
  - gastro-intestinal disturbances
  - gout
  - haemolytic anaemia
  - hepatic encephalopathy
  - hyperglycaemia
  - hypersensitivity reactions
  - hyperuricaemia
  - hypocalcaemia
  - hypomagnesaemia
  - hypoproteinaemia
  - increased in serum cholesterol and triglyceride concentrations
  - tinnitus
  - toxic epidermal necrolysis

- **PREGNANCY**
  - Not used to treat hypertension in pregnancy.

- **BREAST FEEDING**
  - No information regarding amiloride component available.
  - Amount of furosemide in milk too small to be harmful.
  - Frusemide may inhibit lactation.

- **HEPATIC IMPAIRMENT**
  - Increased risk of hypomagnesaemia in alcoholic cirrhosis.

- **RENAL IMPAIRMENT**
  - Risk of hyperkalaemia in renal impairment but may need higher doses. Monitor plasma-potassium concentration. Avoid if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  - Monitor electrolytes.
Furosemide
(Frusemide)

INDICATIONS AND DOSE

**Oedema**

- **By mouth**
  - Adult: Initially 40 mg daily, dose to be taken in the morning, then maintenance 20–40 mg daily initially by intramuscular injection or by slow intravenous injection or by intravenous infusion

**Resistant oedema**

- **By mouth**
  - Adult: 80–120 mg daily initially by intramuscular injection or by slow intravenous injection or by intravenous infusion

**Resistant hypertension**

- **By mouth**
  - Adult: 40–80 mg daily initially by intramuscular injection or by slow intravenous injection or by intravenous infusion

- **By intramuscular injection or by intravenous infusion**
  - Adult: Initially 20–50 mg, then (by intramuscular injection or by intravenous injection or by intravenous infusion) increased in steps of 20 mg every 2 hours if required, doses greater than 50 mg given by intravenous infusion only; maximum 1.5 g per day

**CAUTIONS**

- Hepatorenal syndrome - hypoproteinaemia may reduce diuretic effect and increase risk of side-effects
- **SIDE-EFFECTS** Gout - intrahepatic cholestasis
- **PREGNANCY** Furosemide should not be used to treat gestational hypertension because of the maternal hypoproteinaemia associated with this condition.
- **BREAST FEEDING** Amount too small to be harmful. May inhibit lactation.
- **DIRECTIONS FOR ADMINISTRATION** Intravenous administration rate should not usually exceed 4 mg/minute however single doses of up to 80 mg may be administered more rapidly. A lower rate of infusion may be necessary in renal impairment. For intravenous infusion (Lasix®), give continuously in Sodium chloride 0.9%; infusion pH must be above 5.5 and rate should not exceed 4 mg/minute; glucose solutions are unsuitable.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, spray, oral solution

- **Tablet**
  - **Furosemide 20 mg** Furosemide 20mg tablets | 28 tablet | £1.13
  - **Furosemide 40 mg** Furosemide 40mg tablets | 28 tablet | £1.89

**Solution for injection**

- **Furosemide 50 mg** Furosemide 50mg/5ml oral solution sugar free (sugar-free) | 150 ml | £12.21
  - **Furosemide 80 mg** Furosemide 80mg/5ml oral solution sugar free (sugar-free) | 150 ml | £18.69
  - **Furosemide 100 mg** Furosemide 100mg/5ml oral solution sugar free (sugar-free) | 150 ml | £20.21

**Solution for injection**

- **Furosemide 20 mg** Furosemide 20mg/5ml oral solution sugar free (sugar-free) | 150 ml | £14.49

**Furosemide with potassium chloride**

The properties listed below are those particular to the combination only. For the properties of the components please consider, furosemide above, potassium chloride p. 863.

**INDICATIONS AND DOSE**

**Oedema**

- **By mouth**
  - Adult: consult product literature

**DIRECTIONS FOR ADMINISTRATION** Furosemide with modified-release potassium chloride tablets should be swallowed whole with plenty of fluid during meals while sitting or standing.

**PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer furosemide with potassium chloride tablets.

**LESS SUITABLE FOR PRESCRIBING** Furosemide with potassium chloride tablets are less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Modified-release tablet**
  - Lasilactone®
  - Furosemide 40 mg, Potassium chloride 600 mg
  - Diumide-K Continus tablets | 30 tablet | £3.00

**Furosemide with spironolactone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, furosemide above, spironolactone p. 168.

**INDICATIONS AND DOSE**

**Resistant oedema**

- **By mouth**
  - Adult: 20/50–80/200 mg daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - Lasilactone®

**Furosemide 20 mg, Spironolactone 50 mg** Lasilactone 20mg/50mg capsules | 28 capsule | £1.97

**Furosemide with triamterene**

The properties listed below are those particular to the combination only. For the properties of the components please consider, furosemide above, triamterene p. 203.

- **Tablet**
  - **Furosemide 4 mg** Furosemide 4mg/5ml oral solution sugar free (sugar-free) | 150 ml | £14.49
  - **Furosemide 50 mg** Furosemide 50mg/5ml oral solution sugar free (sugar-free) | 150 ml | £20.21
INDICATIONS AND DOSE

Oedema

BY MOUTH

Adult: 0.5–2 tablets daily, dose to be taken in the morning.

CONTRA-INDICATIONS

Anuria - comatose or precomatose states associated with liver cirrhosis - dehydration - hyperkalaemia - hypovolaemia - renal failure - severe hypoproteinaemia - severe hyponatraemia

CAUTIONS

Diabetes mellitus - elderly - gout - hepatorenal syndrome - hypotension - impaired micturition - may cause blue fluorescence of urine - prostatic enlargement

INTERACTIONS

Appendix 1 (diuretics).

SIDE-EFFECTS

Rare

Agranulocytosis - anaphylaxis - aplastic anaemia - blood disorders - bone marrow depression (withdrawal treatment) - deafness (usually in renal impairment or in hypoproteinaemia) - eosinophilia - exfoliative dermatitis - haemolytic anaemia - hypersensitivity reactions - intrahepatic cholestasis - leucopenia - pancreatitis - paraesthesia - photosensitivity - purpura - rash - thrombocytopenia - tinnitus (usually in renal impairment or in hypoproteinaemia)

Frequency not known

Dry mouth - electrolyte disturbances - gastro-intestinal disturbances - gout - hyperglycaemia (less common than with thiazides) - hyperkalaemia - hyperuricaemia - hypocalcaemia - hypokalaemia - hypomagnesaemia - hyponatraemia - hypotension - metabolic alkalosis - temporary increase in plasma cholesterol and triglyceride concentration - triamterene found in kidney stones

BREAST FEEDING

Triamterene present in milk—manufacturer advises avoid. Furosemide may inhibit lactation.

HEPATIC IMPAIRMENT

Increased risk of hypomagnesaemia in alcoholic cirrhosis. Hypokalaemia may precipitate coma.

RENAL IMPAIRMENT

May need high doses. Monitor plasma-potassium concentration in renal impairment (high risk of hyperkalaemia). Avoid in severe impairment.

MONITORING REQUIREMENTS

Monitor electrolytes.

PATIENT AND CARER ADVICE

Urine may look slightly blue in some lights.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

CAUTIONARY AND ADVISORY LABELS 14

Frusene (Orion Pharma (UK) Ltd)

Furosemide 40 mg, Triamterene 50 mg

Furosemide 50mg/40mg tablets | 56 tablet PD | £4.34 DT price | £4.34

Torasemide

INDICATIONS AND DOSE

Oedema

BY MOUTH

Adult: 5 mg once daily, to be taken preferably in the morning, then increased if necessary to 20 mg once daily; maximum 40 mg per day

Hypertension

BY MOUTH

Adult: 2.5 mg daily, then increased if necessary to 5 mg once daily

SIDE-EFFECTS

Rare

Limb paraesthesia

• Frequency not known

Dry mouth

PREGNANCY

Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING

Manufacturer advises avoid—no information available.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

TORASEMIDE (Non-proprietary)

Torasemide 5 mg

Torasemide 5 mg tablets | 28 tablet PD | £14.50 DT price | £14.49

Torasemide 10 mg

Torasemide 10 mg tablets | 28 tablet PD | £18.75 DT price | £18.67

Torem (Meda Pharmaceuticals Ltd)

Torasemide 2.5 mg

Torem 2.5 mg tablets | 28 tablet PD | £3.78 DT price | £3.78

Torem 5 mg

Torem 5 mg tablets | 28 tablet PD | £5.53 DT price | £5.49

Torem 10 mg

Torem 10 mg tablets | 28 tablet PD | £8.14 DT price | £8.07

OSMOTIC DIURETICS

Mannitol

INDICATIONS AND DOSE

Cerebral oedema

BY INTRAVENOUS INFUSION

Adult: 0.25–2 g/kg, repeated if necessary, to be administered over 30–60 minutes, dose may be repeated 1–2 times after 4–8 hours

Raised intra-ocular pressure

BY INTRAVENOUS INFUSION

Adult: 0.25–2 g/kg, repeated if necessary, to be administered over 30–60 minutes, dose may be repeated 1–2 times after 4–8 hours

CONTRA-INDICATIONS

Anuria - intracranial bleeding (except during craniotomy) - severe cardiac failure - severe dehydration - severe pulmonary oedema

CAUTIONS

Extravasation causes inflammation and thrombophlebitis

INTERACTIONS

Appendix 1 (mannitol).

SIDE-EFFECTS

Uncommon

Electrolyte imbalance - fluid imbalance - hypotension - thrombophlebitis

Rare


Very rare

Acute renal failure - congestive heart failure

PREGNANCY

Manufacturer advises avoid unless essential—no information available.

BREAST FEEDING

Manufacturer advises avoid unless essential—no information available.

RENAL IMPAIRMENT

Use with caution in severe impairment.

PRE-TREATMENT SCREENING

Assess cardiac function before treatment.

MONITORING REQUIREMENTS

Monitor fluid and electrolyte balance, serum osmolality, and cardiac, pulmonary and renal function.

DIRECTIONS FOR ADMINISTRATION

For mannitol 20%, an in-line filter is recommended (15-micron filters have been used).
**POTASSIUM-SPARING DIURETICS**

**Amiloride hydrochloride**

**INDICATIONS AND DOSE**

**Oedema (monotherapy)**

**BY MOUTH**

- Adult: Initially 10 mg daily, alternatively initially 5 mg twice daily, adjusted according to response; maximum 20 mg per day

Potassium conservation when used as an adjunct to thiazide or loop diuretics for hypertension or congestive heart failure

**BY MOUTH**

- Adult: Initially 5–10 mg daily

Potassium conservation when used as an adjunct to thiazide or loop diuretics for hepatic cirrhosis with ascites

**BY MOUTH**

- Adult: Initially 5 mg daily

**CONTRA-INDICATIONS**

- Addison’s disease - anuria - hyperkalaemia

**CAUTIONS**

- Diabetes mellitus - elderly

**INTERACTIONS**

→ Appendix 1 (diuretics).

**SIDE-EFFECTS**


**PREGNANCY**

Not to be used to treat gestational hypertension.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT**

Manufacturers advise avoid in severe impairment. Monitor plasma-potassium concentration (high risk of hyperkalaemia in renal impairment).

**MONITORING REQUIREMENTS**

Monitor electrolytes.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Amiloride hydrochloride 5 mg**

<table>
<thead>
<tr>
<th>Tablet</th>
<th>AMILORIDE HYDROCHLORIDE (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiloride hydrochloride 5 mg</td>
<td>28 tablet (£8.22)</td>
</tr>
</tbody>
</table>

**Oral solution**

**EXCIPIENTS:** May contain Propylene glycol

**AMILORIDE HYDROCHLORIDE (Non-proprietary)**

Amiloride hydrochloride 1 mg per 1 ml

Amiloride 1 mg/5ml oral solution sugar free (sugar-free) 150 ml (£39.73)

Brands may include Amiloram oral solution

**Amiloride with bumetanide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, amiloride hydrochloride above, bumetanide p. 200.

**INDICATIONS AND DOSE**

**Oedema**

**BY MOUTH**

- Adult: 1–2 tablets daily

**Triamterene**

**INDICATIONS AND DOSE**

**Oedema**

Potassium conservation with thiazide and loop diuretics

**BY MOUTH**

- Adult: Initially 150–250 mg daily in 2 divided doses, to be taken after breakfast and lunch, lower initial dose when given with other diuretics, then reduced to 150–250 mg once daily on alternate days in 2 divided doses, to be taken after breakfast and lunch, after one week of initial treatment

**CONTRA-INDICATIONS**

- Addison’s disease - anuria - hyperkalaemia

**CAUTIONS**

- Diabetes mellitus - elderly - gout - may cause blue fluorescence of urine

**INTERACTIONS**

→ Appendix 1 (triaterene).

**SIDE-EFFECTS**

- Common or very common Diarrhoea - hyperkalaemia - nausea - vomiting

- Uncommon Dry mouth - headache - hyperuricaemia - rash

- Rare Megaloblastic anaemia - pancytopenia - photosensitivity - serum sickness

- Very rare Renal failure (reversible on discontinuation) - triamterene found in kidney stones

- Frequency not known Jaundice - malaise - slight decrease in blood pressure

**PREGNANCY**

Not to be used to treat gestational hypertension.

Avoid unless essential.

**BREAST FEEDING** Present in milk—manufacturer advises avoid.

**HEPATIC IMPAIRMENT** Use with caution. Avoid in progressive impairment.

**RENAL IMPAIRMENT** Avoid in progressive impairment. Monitor plasma-potassium concentration (high risk of hyperkalaemia in renal impairment).

**MONITORING REQUIREMENTS** Monitor electrolytes.
Chlortalidone with triamterene

The properties listed below are those particular to the combination only. For the properties of the components please consider, triamterene p. 203, chlortalidone below.

INDICATIONS AND DOSE
Hypertension | Oedema
BY MOUTH
Adult: 1–2 tablets daily, dose to be taken in the morning

Co-triamterzide

The properties listed below are those particular to the combination only. For the properties of the components please consider, triamterene p. 203, hydrochlorothiazide p. 160.

INDICATIONS AND DOSE
Hypertension | Oedema
BY MOUTH
Adult: 1 tablet daily, increased if necessary up to 4 tablets daily, dose to be taken after breakfast

Oedema
BY MOUTH
Adult: 1 tablet twice daily, to be taken after breakfast and after midday meal, increased if necessary to 3 tablets daily, two tablets to be taken after breakfast and one tablet after midday meal; maintenance 1 tablet daily, alternatively maintenance 2 tablets once daily on alternate days; maximum 4 tablets per day

Cyclosporine

The properties listed below are those particular to the drug only. For properties common to the class, see thiazides and related diuretics, p. 159.

INDICATIONS AND DOSE
Heart failure
BY MOUTH
Adult: 250–500 micrograms daily, taken in the morning, then increased if necessary to 1 mg daily, reduce to lowest effective dose for maintenance

Hypertension
BY MOUTH
Adult: Initially 250 micrograms daily, taken in the morning, then increased if necessary to 500 micrograms daily

Oedema
BY MOUTH
Adult: Up to 500 micrograms daily for a short period

SIDE-EFFECTS
Rare Depression

BREAST FEEDING
The amount present in milk is too small to be harmful. Large doses may suppress lactation.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Tablet
EXCIPIENTS: May contain Gluten
Navidrex
Cyclosporine 500 microgram Navidrex 500 microgram tablets | 28 tablet (PAC) £1.27

THIAZIDES AND RELATED DIURETICS

Chlortalidone
(Chlorthalidone)
The properties listed below are those particular to the drug only. For properties common to the class, see thiazides and related diuretics, p. 159.
Regulating blood lipids, optimising glycaemic control in diabetes, taking aspirin p. 104 in a dose of 75 mg daily, and possibly weight reduction in obesity. Exercise training can improve symptoms of intermittent claudication; revascularisation procedures may be appropriate.

Nafidrofuryl oxalate p. 206 can alleviate symptoms of intermittent claudication and improve pain-free walking distance in moderate disease. Patients taking nafidrofuryl oxalate p. 206 should be assessed for improvement after 3–6 months.

Cilostazol p. 206 is licensed for use in intermittent claudication to improve walking distance in patients without peripheral tissue necrosis who do not have pain at rest; use is restricted to second-line treatment where lifestyle modifications and other appropriate interventions have failed to improve symptoms. Cilostazol should be initiated by those experienced in the management of intermittent claudication. Patients receiving cilostazol should be assessed for improvement after 3 months; consider discontinuation of treatment if there is no clinically relevant improvement in walking distance.

Inositol nicotinate p. 206 and pentoxifylline p. 207 are not established as being effective for the treatment of intermittent claudication. Management of Raynaud’s syndrome includes avoidance of exposure to cold and stopping smoking. More severe symptoms may require vasodilator treatment, which is most often successful in primary Raynaud’s syndrome. Nifedipine p. 154 is useful for reducing the frequency and severity of vasospastic attacks. Alternatively, nafidrofuryl oxalate p. 206 may produce symptomatic improvement; inositol nicotinate p. 206 (a nicotinic acid derivative) may also be considered. Pentoxifylline, prazosin p. 674, and moxisylyte below are not established as being effective for the treatment of Raynaud’s syndrome.

 Vasodilator therapy is not established as being effective for chilblains.

### ALPHA-ADRENOCEPTOR BLOCKERS

**Moxisylyte**

(Thymoxamine)

**INDICATIONS AND DOSE**

**Primary Raynaud’s syndrome (short-term treatment)**

**BY MOUTH**

Adult: Initially 40 mg 4 times a day, increased if necessary to 80 mg 4 times a day, increase dose if poor initial response, discontinue after 2 weeks if no response.

**CONTRA-INDICATIONS**

Active liver disease

**CAUTIONS**

Diabetes mellitus

**SIDE-EFFECTS**

Cholestatic jaundice · diarrhoea · dizziness · flushing · headache · hepatic reactions · hepatitis · nausea

**PREGNANCY**

Manufacturer advises avoid.

**LESS SUITABLE FOR PRESCRIBING**

Less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

Moxisylyte (as Moxisylyte hydrochloride) 40 mg Opilon 40mg tablets | 112 tablet [POM] £90.22 DT price = £90.22

---

**Peripheral vascular disease**

Peripheral vascular disease can be either occlusive (e.g. intermittent claudication) in which occlusion of the peripheral arteries is caused by atherosclerosis, or vasospastic (e.g. Raynaud’s syndrome). Peripheral arterial occlusive disease is associated with an increased risk of cardiovascular events; this risk is reduced by measures such as smoking cessation, effective control of blood pressure,
**FLAVONOIDS**

**Oxerutins**

**INDICATIONS AND DOSE**

Relief of symptoms of oedema associated with chronic venous insufficiency

**BY MOUTH**

- Adult: 500 mg twice daily

**SIDE-EFFECTS** Flushing, headache, mild gastro-intestinal disturbances, rash

**LESS SUITABLE FOR PRESCRIBING** Oxerutins (rutosides) are not vasodilators and are not generally regarded as effective preparations as capillary sealants or for the treatment of cramps; they are less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - Paroven (Novartis Consumer Health UK Ltd)
  - Oxerutins 250 mg Paroven 250mg capsules | 120 capsule £16.81 DT price + £16.81

**5HT₂ RECEPTOR ANTAGONISTS**

**Naftidrofuryl oxalate**

**INDICATIONS AND DOSE**

Peripheral vascular disease

**BY MOUTH**

- Adult: 100–200 mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3–6 months

Cerebral vascular disease

**BY MOUTH**

- Adult: 100 mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3–6 months

**SIDE-EFFECTS** Epigastric pain, hepatic failure, hepatitis, nausea, rash

**NATIONAL FUNDING/ACCESS DECISIONS**

- NICE technology appraisals (TAs)
  - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223
  - Inositol nicotinate is not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease; patients currently receiving treatment should have the option to continue until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA223

- Less suitable for prescribing

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

- **Tablet**
  - Hexopal (Genus Pharmaceuticals Ltd)
  - Inositol nicotinate 500 mg Hexopal 500mg tablets | 100 tablet £30.76 DT price + £30.76
  - Inositol nicotinate 750 mg Hexopal Forte 750mg tablets | 112 tablet £51.03 DT price + £51.03

**PHOSPHODIESTERASE TYPE-3 INHIBITORS**

**Cilostazol**

**INDICATIONS AND DOSE**

Intermittent claudication in patients without rest pain and no peripheral tissue necrosis

**BY MOUTH**

- Adult: 100 mg twice daily, to be taken 30 minutes before food, cilostazol should be initiated by those experienced in the management of intermittent claudication, patients receiving cilostazol should be assessed for improvement after 3 months; consider discontinuation of treatment if there is no clinically relevant improvement in walking distance

**Dose adjustments due to interactions**

Reduce dose to 50 mg twice daily with concomitant use of potent inhibitors of cytochrome P450 enzymes CYP3A4 (e.g. clarithromycin, itraconazole, ketoconazole, protease inhibitors) or CYP2C19, or with erythromycin or omeprazole.

**CONTRA-INDICATIONS** Active peptic ulcer, congestive heart failure, coronary intervention in previous 6 months, haemorrhagic stroke in previous 6 months, history of severe tachyarrhythmia, myocardial infarction in previous 6 months, poorly controlled hypertension, predisposition to bleeding, proliferative diabetic retinopathy.
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol

NATIONAL FUNDING/ACCESS DECISIONS

RENAL IMPAIRMENT

BREAST FEEDING

PREGNANCY

INTERACTIONS → Appendix 1 (cilostazol).

Caution with concomitant use of drugs that increase risk of bleeding. Contra-indicated with concomitant use of 2 or more antplatelets or antiagulants.

SIDE-EFFECTS

Common or very common Abdominal pain · angina · anorexia · arrhythmia · diarrhoea · dizziness · dyspepsia · ecchymosis · flatulence · headache · malaise · nausea · oedema · palpitation · pharyngitis · pruritus · rash · rhinitis · tachycardia · vomiting

Uncommon Abnormal dreams · anemia · anxiety · congestive heart failure · cough · diabetes mellitus · dyspnea · gastritis · haemorrhage · hyperglycaemia · insomnia · myalgia · myocardial infarction · pneumonia · postural hypotension

Rare Bleeding disorders · increased urinary frequency · renal impairment · thrombocythaemia

Frequency not known Agranulocytosis · aplastic anemia · conjunctivitis · hepatitis · hot flushes · hypertension · leucopenia · pancycopenia · pyrexia · Stevens-Johnson syndrome · thrombocytopenia · tinnitus · toxic epidermal necrolysis

SIDE-EFFECTS, FURTHER INFORMATION

Blood Disorders A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.

PREGNANCY Avoid—toxicity in animal studies.

BREAST FEEDING Present in milk in animal studies—manufacturer advises avoid.

HEPATIC IMPAIRMENT Avoid in moderate or severe liver disease.

RENAL IMPAIRMENT Avoid if eGFR less than 25 mL/minute/1.73 m².

PATIENT AND CARER ADVICE

Blood disorders Patients should be advised to report any unexplained bleeding, bruising, sore throat, or fever.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223 Cilostazol is not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease; patients currently receiving this treatment should have the option to continue until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA223

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2005) that cilostazol is not recommended for the treatment of intermittent claudication within NHS Scotland.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CILOSTAZOL (Non-proprietary) ▼

Cilostazol 50 mg Cilostazol 50mg tablets | 56 tablet £40.05 DT price = £39.91
Cilostazol 100 mg Cilostazol 100mg tablets | 56 tablet £31.70 DT price = £14.77

XANTHINES

Pentoxifylline

(Opentifylline)

INDICATIONS AND DOSE

Peripheral vascular disease | Venous leg ulcer (adjunct)

BY MOUTH

Adult: 400 mg 2–3 times a day

UNLICENSED USE Use of pentoxifylline as adjunct therapy for venous leg ulcers is an unlicensed indication.

CONTRA-INDICATIONS Acute myocardial infarction · cerebral haemorrhage · extensive retinal haemorrhage · severe cardiac arrhythmias

CAUTIONS Avoid in Acute porphyrias p. 864 · coronary artery disease · hypotension

INTERACTIONS → Appendix 1 (pentoxifylline).

SIDE-EFFECTS

Rare Angina · hypotension

Very rare Bleeding

Frequency not known Agitation · diarrhoea · dizziness · flushing · headache · intra-hepatic cholestasis · nausea · sleep disturbances · tachycardia · thrombocytopenia · vomiting

PREGNANCY Manufacturer advises avoid—no information available.

BREAST FEEDING Present in milk—manufacturer advises use only if potential benefit outweighs risk.

HEPATIC IMPAIRMENT Manufacturer advises reduce dose in severe impairment.

RENAL IMPAIRMENT Reduce dose by 30–50% if eGFR less than 30 mL/minute/1.73 m².

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223 Pentoxifylline is not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease; patients currently receiving this treatment should have the option to continue until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA223

LESS SUITABLE FOR PRESCRIBING Less suitable for prescribing.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 21, 25

Trental (Sanofi)

Pentoxifylline 400 mg Trental 400 modified-release tablets | 90 tablet £19.39 DT price = £19.39
9.1 Vein malformations

SCLEROSANTS

Sodium tetradecyl sulfate

INDICATIONS AND DOSE
Sclerotherapy of reticular veins and spider veins in legs and varicose veins
BY INTRAVENOUS INJECTION

- Adult: Test dose recommended before each treatment (consult product literature)

CONTRA-INDICATIONS
Acute infection - asthma - blood disorders - deep vein thrombosis - high risk of thromboembolism - hyperthyroidism - inability to walk - neoplasm - occlusive arterial disease - phlebitis - pulmonary embolism - recent acute superficial thrombophlebitis - recent surgery - respiratory disease - significant valvular incompetence in deep veins - skin disease - symptomatic patent foramen ovale (if administered as foam) - uncontrolled diabetes mellitus - varicose veins caused by tumours (unless tumour removed)

CAUTIONS
Arterial disease - asymptomatic patent foramen ovale (use smaller volumes and avoid Valsalva manoeuvre immediately after administration) - extravasation may cause necrosis of tissues - history of migraine (use smaller volumes)

SIDE-EFFECTS

Common or very common
- Local burning
- Local pain
- Phlebitis
- Skin discoloration
- Superficial thrombophlebitis
- Telangiectatic matting

Uncommon
- Deep vein thrombosis - scotoma

Rare
- Chest pain - cough - headache - migraine - paraesthesia - shortness of breath - vasovagal reactions

Very rare

PREGNANCY
Avoid unless benefits outweigh risks—no information available.

BREAST FEEDING
Use with caution—no information available.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
EXCIPIENTS: May contain Benzyl alcohol

- Fibro-Vein (STD Pharmaceutical Products Ltd)
  Sodium tetradecyl sulfate 2 mg per 1 ml Fibrovein 0.2% solution for injection 5ml vials | 10 vial £70.00
  Sodium tetradecyl sulfate 5 mg per 1 ml Fibrovein 0.5% solution for injection 2ml ampoules | 5 ampoule £18.00
  Sodium tetradecyl sulfate 10 mg per 1 ml Fibrovein 1% solution for injection 2ml ampoules | 5 ampoule £21.50
  Sodium tetradecyl sulfate 30 mg per 1 ml Fibrovein 3% solution for injection 2ml ampoules | 5 ampoule £32.00
  Fibrovein 3% solution for injection 5ml vials | 10 vial £158.50
Chapter 3
Respiratory system

Use and care of spacer devices

Patients should inhale from the spacer device as soon as possible after actuation because the drug aerosol is very short-lived; single-dose actuation is recommended. Tidal breathing is as effective as single breaths. The device should be cleaned once a month with mild detergent and then allowed to dry in air without rinsing; the mouthpiece should be wiped clean of detergent before use. Some manufacturers recommend more frequent cleaning, but this should be avoided since any electrostatic charge may affect drug delivery. Spacer devices should be replaced every 6–12 months.

Nebulisers

Solutions for nebulisation are available for use in severe acute asthma. They are administered over 5–10 minutes from a nebuliser usually driven by oxygen in hospital. Patients with a severe attack of asthma should preferably have oxygen during nebulisation since beta, agonists can increase arterial hypoxaemia. A nebuliser converts a solution of a drug into an aerosol for inhalation. It is used to deliver higher doses of drug to the airways than is usual with standard inhalers. The main indications for use of a nebuliser are to deliver:

- a beta, agonist or ipratropium bromide p. 217 to a patient with an acute exacerbation of asthma or of chronic obstructive pulmonary disease;
- a beta, agonist, corticosteroid, or ipratropium bromide on a regular basis to a patient with severe asthma or reversible airways obstruction when the patient is unable to use other inhalational devices;
- an antibiotic (such as colistimethate sodium p. 489) or a mucolytic to a patient with cystic fibrosis;
- budesonide p. 228 or adrenaline/epinephrine p. 196 to a child with severe croup;
- pentamidine isetionate p. 523 for the prophylaxis and treatment of pneumocystis pneumonia.

The use of nebulisers in chronic persistent asthma and chronic obstructive pulmonary disease should be considered only:

- after a review of the diagnosis;
- after review of therapy (see also Chronic Obstructive Pulmonary Disease p. 214) and the patient’s ability to use hand-held devices;
- after increased doses of inhaled therapy from hand-held inhalers (with a spacer if necessary) have been tried for 2 weeks;
- if the patient remains breathless, despite correctly using optimal therapy.

Before prescribing a nebuliser, a home trial should preferably be undertaken to monitor response for up to 2 weeks on standard treatment and up to 2 weeks on...
Respiratory system

of the lung. Droplets with a mass median diameter of
the droplet size, pattern of breath inhalation, and condition
solution is deposited in the airways or alveoli depends on
mouthpiece and tubing. The extent to which the nebulised
viscosity of the solution.
infection. The type of nebuliser is therefore chosen
nasal cannula.

oxygen is required, it should be given simultaneously by
dangerous and the nebuliser should be driven by air. If
compressor is required for domiciliary use.
provide an adequate flow rate therefore an electrical
driven by oxygen. Domiciliary oxygen cylinders do not
piped air or oxygen; in acute asthma the nebuliser should be
nebulised treatment. If prescribed, patients must:
• have clear instructions from a doctor, specialist nurse,
physiotherapist, or pharmacist on the use of the
nebuliser (including maintenance and cleaning) and on
peak-flow monitoring;
• be instructed not to treat acute attacks at home without
also seeking help;
• have regular follow up by a doctor, specialist nurse or
physiotherapist after about 1 month and annually
thereafter.
The proportion of a nebuliser solution that reaches the
lungs depends on the type of nebuliser and although it can be
as high as 30%, it is more frequently close to 10% and
sometimes below 10%. The remaining solution is left in the
nebuliser as residual volume or is deposited in the
mouthpiece and tubing. The extent to which the nebulised
solution is deposited in the airways or alveoli depends on
the droplet size, pattern of breath inhalation, and condition
of the lung. Droplets with a mass median diameter of
1–5 microns are deposited in the airways and are therefore
appropriate for asthma, whereas a particle size of
1–2 microns is needed for alveolar deposition of
pentamidine isetionate p. 523 to combat pneumocystis
infection. The type of nebuliser is therefore chosen
according to the deposition required and according to the
viscosity of the solution.

Jet nebulisers
Jet nebulisers are more widely used than ultrasonic
nebulisers. Most jet nebulisers require an optimum gas flow
rate of 6–8 litres/minute and in hospital can be driven by
piped air or oxygen; in acute asthma the nebuliser should be
driven by oxygen. Domiciliary oxygen cylinders do not
provide an adequate flow rate therefore an electrical
compressor is required for domiciliary use.
For patients at risk of hypercapnia, such as those with
chronic obstructive pulmonary disease, oxygen can be
dangerous and the nebuliser should be driven by air. If
oxygen is required, it should be given simultaneously by
nasal cannula.

Tubing
The Department of Health has reminded users of the need
to use the correct grade of tubing when connecting a
nebuliser to a medical gas supply or compressor.

Ultrasonic nebulisers
Ultrasonic nebulisers produce an aerosol by ultrasonic
vibration of the drug solution and therefore do not require a
gas flow; they are not suitable for the nebulisation of some
drugs, such as dornase alfa p. 256 and nebulised
suspensions.

Nebuliser diluent
Nebulisation may be carried out using an undiluted
nebuliser solution or it may require dilution beforehand.
The usual diluent is sterile sodium chloride 0.9%
(physiological saline).
In England and Wales nebulisers and compressors are not
available on the NHS (but they are free of VAT); some
nebulisers (but not compressors) are available on form
GP10A in Scotland (for details consult Scottish Drug Tariff).

Oral
The oral route is used when administration by inhalation is
not possible. Systemic side-effects occur more frequently
when a drug is given orally rather than by inhalation. Drugs
given by mouth for the treatment of asthma include beta,
agonists, corticosteroids, theophylline p. 238, and
leukotriene receptor antagonists.

Parenteral
Drugs such as beta, agonists, corticosteroids, and
aminophylline p. 237 can be given by injection in acute
severe asthma when administration by nebulisation is
inadequate or inappropriate. If the patient is being treated in
the community, urgent transfer to hospital should be
arranged.

NICE technology appraisals (TAs)

Inhaler devices for children under 5 years with chronic
asthma (August 2000) NICE TA10
A child’s needs and likelihood of good compliance should
govern the choice of inhaler and spacer device; only then
should cost be considered.
• corticosteroid and bronchodilator therapy should be
delivered by pressurised metered-dose inhaler and
spacer device, with a facemask if necessary;
• if this is not effective, and depending on the child’s
condition, nebulised therapy may be considered and, in
children over 3 years, a dry powder inhaler may also be
considered. www.nice.org.uk/TA10

Inhaler devices for children 5–15 years with chronic asthma
(March 2002) NICE TA38
A child’s needs, ability to develop and maintain effective
technique, and likelihood of good compliance should govern
the choice of inhaler and spacer device; only then should
cost be considered.
• corticosteroid therapy should be routinely delivered by
a pressurised metered-dose inhaler and spacer device;
• for other inhaled drugs, particularly bronchodilators, a
wider range of devices should be considered;
• children and their carers should be trained in the use of
the chosen device; suitability of the device should be
reviewed at least annually. Inhaler technique and
compliance should be monitored. www.nice.org.uk/TA38

1 Airways disease, obstructive

Asthma

Drugs used in the management of asthma include beta,agonists, antimuscarinic bronchodilators, theophylline p. 238, corticosteroids, sodium cromoglicate p. 234 and
decromomil sodium p. 234, leukotriene receptor antagonists,
and, in specialist centres, omalizumab p. 235.

Management of acute asthma

Important: Patients with severe or life-threatening acute
asthma may not be distressed and may not have all these
abnormalities; the presence of any should alert the doctor
Regard each emergency consultation as being for severe
acute asthma until shown otherwise.
See medical emergencies, for doses of drugs used for the
management of acute asthma.

Moderate acute asthma

• Able to talk
• Respiration (breaths/minute) < 25; child 2–5 years
≤ 40, 5–12 years ≤ 30
• Pulse (beats/minute) < 110; child 2–5 years ≤ 140,
5–12 years ≤ 125
• Arterial oxygen saturation ≥ 92%
• Peak flow > 50% of predicted or best; child 5–12 years
≥ 50%

Treat at home or in surgery and assess response to treatment

Treatment

• Inhaled short-acting beta, agonist via a large-volume
spacer or oxygen-driven nebuliser (if available); give
salbutamol 100 micrograms metered inhalation p. 222,
and repeat at 10–20 minute intervals if necessary or
give nebulised salbutamol or terbutaline sulphate p. 225,
and repeat at 20–30 minute intervals if necessary
• Prednisolone by mouth for at least 5 days; and for up to 3 days in children, or longer if necessary. If the child has been taking an oral corticosteroid for more than a few days, give prednisolone at the upper end of the dose range.

Monitor response for 15–30 minutes
If response is poor or a relapse occurs in 3–4 hours, send immediately to hospital for further assessment.

Severe acute asthma
• Cannot complete sentences in one breath; in children, too breathless to talk or feed
• Respiration (breaths/minute) ≥ 25; child 2–5 years > 40; 5–12 years > 30
• Pulse (beats/minute) ≥ 110; child 2–5 years > 140; 5–12 years > 125
• Arterial oxygen saturation ≥ 92%; child under 12 years < 92%
• Peak flow 33–50% of predicted or best; child 5–12 years 33–50%

Start treatment below and send immediately to hospital.

Treatment
• High-flow oxygen (if available)
• Inhaled short-acting beta, agonist via a large-volume spacer or oxygen-driven nebuliser (if available) as for moderate acute asthma
• Prednisolone p. 585 by mouth as for moderate acute asthma or intravenous hydrocortisone p. 583 (preferably as sodium succinate) every 4–6 hours until conversion to oral prednisolone is possible

Monitor response for 15–30 minutes
If response is poor:
• Inhaled ipratropium bromide p. 217 via oxygen-driven nebuliser (if available) every 4–6 hours in adults; or every 20–30 minutes for the first 2 hours, then every 4–6 hours as necessary in children.
• Refer those who fail to respond and require ventilatory support to an intensive care or high-dependency unit
• Consider intravenous beta, agonist, aminophylline p. 237, or magnesium sulfate p. 858 [unlicensed indication] only after consultation with senior medical staff.

Life-threatening acute asthma
• Silent chest, feeble respiratory effort, cyanosis
• Hypotension, bradycardia, arrhythmia, exhaustion, agitation (in children), or reduced level of consciousness
• Arterial oxygen saturation < 92%
• Peak flow < 33% of predicted or best; child 5–12 years < 33%

Start treatment below and send immediately to hospital; consult with senior medical staff and refer to intensive care

Treatment
• High-flow oxygen (if available)
• Short-acting beta, agonist via oxygen-driven nebuliser (if available); give salbutamol or terbutaline, and repeat at 20–30 minute intervals or as necessary; reserve intravenous beta, agonists for those in whom inhaled therapy cannot be used reliably
• Prednisolone by mouth as for moderate acute asthma or intravenous hydrocortisone p. 583 as for severe acute asthma
• Inhaled ipratropium bromide via oxygen-driven nebuliser (if available) as for severe acute asthma

Monitor response for 15–30 minutes
If response is poor:
• Consider intravenous aminophylline or magnesium sulfate [unlicensed indication] only after consultation with senior medical staff.

Management of severe acute asthma

Important
Regard each emergency consultation as being for severe acute asthma until shown otherwise. Failure to respond adequately at any time requires immediate transfer to hospital.

Severe acute asthma can be fatal and must be treated promptly. All patients with severe acute asthma should be given high-flow oxygen (if available) and an inhaled short-acting beta, agonist via a large-volume spacer or nebuliser; give salbutamol 100 micrograms/metered inhalation p. 222, each puff inhaled separately via a large volume spacer, and repeat at 10–20 minute intervals or as necessary. If there are life-threatening features, give salbutamol or terbutaline sulfate p. 225 via an oxygen-driven nebuliser every 20–30 minutes or as necessary. In all cases, a systemic corticosteroid should be given. For adults, give prednisolone by mouth for at least 5 days, or intravenous hydrocortisone (preferably as sodium succinate) every 6 hours until conversion to oral prednisolone is possible. For children, give prednisolone by mouth for up to 3 days, or longer if necessary, or intravenous hydrocortisone (preferably as sodium succinate) every 6 hours until conversion to oral prednisolone is possible. If the child has been taking an oral corticosteroid for more than a few days, then give prednisolone at the upper end of the dose range.

In severe or life-threatening asthma, also consider initial treatment with ipratropium bromide by nebuliser.

Most patients do not require and do not benefit from the addition of intravenous aminophylline or of intravenous beta, agonist; both cause more adverse effects than nebulised beta, agonists. Nevertheless, an occasional patient who has not been taking theophylline may benefit from aminophylline infusion. A single dose of magnesium sulfate [unlicensed indication] by intravenous infusion over 20 minutes can be used for patients with severe acute asthma, but evidence of benefit is limited.

Treatment of severe acute asthma is safer in hospital where resuscitation facilities are immediately available. Treatment should never be delayed for investigations, patients should never be sedated, and the possibility of a pneumothorax should be considered.

If the patient’s condition deteriorates despite pharmacological treatment, intermittent positive pressure ventilation may be needed.

Follow up in all cases
Episodes of acute asthma should be regarded as a failure of preventative therapy. A careful history should be taken to establish the reason for the exacerbation. Monitor symptoms and peak flow. Inhaler technique should be checked and regular treatment should be reviewed, see Management of chronic asthma below. Patients should be given a written asthma action plan aimed at preventing relapse, optimising treatment, and preventing delay in seeking assistance in future exacerbations. Follow-up within 48 hours should be arranged with the general practitioner or appropriate primary care health professional. Patients should also be reviewed by a respiratory specialist within one month of the exacerbation.

Advice on the management of acute asthma is based on the recommendations of the British Thoracic Society and Scottish Intercollegiate Guidelines Network (updated January 2012); updates available at www.brit-thoracic.org.uk.

Management of chronic asthma

Important: Start at step most appropriate to initial severity; before initiating a new drug consider whether diagnosis is correct, check compliance and inhaler technique, and eliminate trigger factors for acute exacerbations.
Advice on the management of chronic asthma is based on the recommendations of the British Thoracic Society and Scottish Intercollegiate Guidelines Network (updated January 2012); updates available at www.brit-thoracic.org.uk

Adult and child over 5 years

**Step 1: occasional relief bronchodilator**
- Inhaled short-acting beta₂ agonist as required (up to once daily).
- Move to step 2 if needed more than twice a week, or if night-time symptoms at least once a week, or if exacerbation in the last 2 years

**Step 2: regular inhaled preventer therapy**
- Inhaled short-acting beta₂ agonist as required
- Regular standard-dose inhaled corticosteroid (alternatives to inhaled corticosteroid are leukotriene receptor antagonists, theophylline, inhaled sodium cromoglicate, or inhaled nedocromil sodium, but are considerably less effective)

**Step 3: inhaled corticosteroid + long-acting inhaled beta₂ agonist**
- Inhaled short-acting beta₂ agonist as required
- Regular standard-dose inhaled corticosteroid
- Regular inhaled long-acting beta₂ agonist (salmeterol p. 222 or formoterol fumarate p. 220); if asthma not controlled increase dose of inhaled corticosteroid to upper end of standard dose range and
- Either stop long-acting beta₂ agonist if of no benefit or continue long-acting beta₂ agonist if of some benefit; if asthma still not controlled and long-acting beta₂ agonist stopped, add one of:
  - Leukotriene receptor antagonist
  - Modified-release oral theophylline
  - Modified-release oral beta₂ agonist (child under 12 years not recommended).

**Step 4: high-dose inhaled corticosteroid + regular bronchodilators**
- Inhaled short-acting beta₂ agonist as required
- Regular high-dose inhaled corticosteroid
- Inhaled long-acting beta₂ agonist
- In adults 6-week sequential therapeutic trial of one or more of:
  - Leukotriene receptor antagonist
  - Modified-release oral theophylline
  - Modified-release oral beta₂ agonist

**Step 5: regular corticosteroid tablets** (refer to a respiratory specialist)
- Inhaled short-acting beta₂ agonist as required
- Regular high-dose inhaled corticosteroid
- One or more long-acting bronchodilators (see step 4) plus
- Regular prednisolone p. 585 tablets (as single daily dose); in addition to regular prednisolone, continue high-dose inhaled corticosteroid in exceptional cases may exceed licensed doses; these patients should normally be referred to an asthma clinic

**Stepping down**
- Review treatment every 3 months; if control achieved, stepwise reduction may be possible; reduce dose of inhaled corticosteroid slowly (consider reduction every 3 months, decreasing dose by up to 50% each time)

**Child under 5 years**
Lung function measurements cannot be used to guide management of those under 5 years.

**Step 1: occasional relief bronchodilator**
- Short-acting beta₂ agonist as required (not more than once daily); preferably by inhalation (less effective and more side-effects when given by mouth)
- Move to step 2 if needed more than twice a week, or if night-time symptoms at least once a week, or if exacerbation in the last 2 years

**Step 2: regular preventer therapy**
- Inhaled short-acting beta₂ agonist as required plus
- Either regular standard-dose inhaled corticosteroid
- Or (if inhaled corticosteroid cannot be used) leukotriene receptor antagonist.

**Step 3: add-on therapy**
- Child under 2 years: Refer to respiratory paediatrician
- Child 2–5 years: Inhaled short-acting beta₂ agonist as required plus
- Regular inhaled corticosteroid in standard dose plus
- Leukotriene receptor antagonist

**Step 4: persistent poor control**
- Refer to respiratory paediatrician.

**Stepping down**
- Regularly review need for treatment.

**Standard-dose inhaled corticosteroids**

**Beclomethasone dipropionate or budesonide:**
- Adult and child over 12 years 100–400 micrograms twice daily
- Child under 12 years 100–200 micrograms twice daily

**Fluticasone propionate:**
- Adult and child over 12 years 50–200 micrograms twice daily
- Child 4–12 years 50–100 micrograms twice daily

**Mometasone furoate:**
- Adult and child over 12 years 400 micrograms as a single dose in the evening or in 2 divided doses
- Child under 12 years not recommended

Dose adjustments may be required for some inhaler devices, see individual preparations.

**High-dose inhaled corticosteroids**

**Beclomethasone dipropionate or budesonide:**
- Adult and child over 12 years 0.4–1 mg twice daily
- Child 5–12 years 200–400 micrograms twice daily

**Fluticasone propionate:**
- Adult and child over 12 years 200–500 micrograms twice daily
- Child 5–12 years 100–200 micrograms twice daily

**Mometasone furoate:**
- Adult and child over 12 years 400 micrograms twice daily
- Child under 12 years not recommended

Dose adjustments may be required for some inhaler devices, see individual preparations.

Failure to achieve control with these doses is unusual.

**Pregnancy and breast-feeding**
It is particularly important that asthma should be well controlled during pregnancy; when this is achieved asthma has no important effects on pregnancy, labour, or on the fetus. Drugs for asthma should preferably be administered by inhalation to minimise exposure of the fetus. Inhaled drugs, theophylline p. 238, and prednisolone can be taken as normal during pregnancy and breast-feeding. See individual leukotriene receptor antagonists for information on their use during pregnancy. Women planning to become pregnant should be counselled about the importance of taking their asthma medication regularly to maintain good control.

Severe acute exacerbations of asthma can have an adverse effect on pregnancy and should be treated promptly in hospital with conventional therapy, including nebulisation of a beta₂ agonist and oral or parenteral administration of a corticosteroid; prednisolone is the preferred corticosteroid for oral administration since very little of the drug reaches the fetus. Oxygen should be given immediately to maintain arterial oxygen saturation of 94–98% and prevent maternal and fetal hypoxia. An intravenous beta₂ agonist, aminophylline p. 237, or magnesium sulfate p. 858 can be used during pregnancy if necessary; parenteral beta₂ agonists can affect the myometrium.
Peak flow meters

When used in addition to symptom-based monitoring, peak flow monitoring has not been proven to improve asthma control in either adults or children, however measurement of peak flow may be of benefit in adult patients who are ‘poor perceivers’ and hence slow to detect deterioration in their asthma, and for those with more severe asthma.

When peak flow meters are used, patients must be given clear guidelines as to the action they should take if their peak flow falls below a certain level. Patients can be encouraged to adjust some of their own treatment (within specified limits) according to changes in peak flow rate.

Peak flow charts should be issued to patients where appropriate, and are available to purchase from:

- 3M Security Print and Systems Limited, Gorse Street, Chadderton, Oldham, OL9 9QH. Tel: 0845 610 1112
- GP practices can obtain supplies through their Area Team stores.
- NHS Hospitals can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com.
- In Scotland, peak flow charts can be obtained by emailing stockorders.dppas@apsgroup.co.uk.

Bronchodilators

Adrenoceptor agonists (sympathomimetics)

Selective beta₂ agonists produce bronchodilation. A short-acting beta₂ agonist is used for immediate relief of asthma symptoms while some long-acting beta₂ agonists are added to an inhaled corticosteroid in patients requiring prophylactic treatment.

The selective beta₂ agonists (selective beta₂-adrenoceptor agonists, selective beta₂ stimulants) such as salbutamol p. 222 or terbutaline sulfate p. 225 are the safest and most effective short-acting beta₂ agonists for asthma. Less selective beta₂ agonists such as ephedrine hydrochloride p. 226 is less suitable and less safe for use as a bronchodilator than the selective beta₂ agonists, because it is more likely to cause arrhythmias and other side-effects; it should be avoided whenever possible.

Adrenaline/epinephrine p. 196 (which has both alpha- and beta-adrenoceptor agonist properties) is used in the emergency management of acute allergic and anaphylactic reactions, in angioedema, in cardiopulmonary resuscitation, and in the management of severe croup.

Short-acting beta₂ agonists

Mild to moderate symptoms of asthma respond rapidly to the inhalation of a selective short-acting beta₂ agonist such as salbutamol or terbutaline sulfate. If beta₂ agonist inhalation is needed more often than twice a week, or if night-time symptoms occur at least once a week, or if the patient has suffered an exacerbation in the last 2 years, then prophylactic treatment should be considered using a stepped approach.

A short-acting beta₂ agonist inhaled immediately before exertion reduces exercise-induced asthma; however, frequent exercise-induced asthma probably reflects poor overall control and calls for reassessment of asthma treatment.

Long-acting beta₂ agonists

Formoterol fumarate p. 220 (eformoterol) and salmeterol p. 222 are longer-acting beta₂ agonists which are administered by inhalation. They should be used for asthma only in patients who regularly use an inhaled corticosteroid. They have a role in the long-term management of chronic asthma and can be useful in nocturnal asthma.

Salmeterol should not be used for the relief of an asthma attack; it has a slower onset of action than salbutamol or terbutaline sulfate. Formoterol fumarate is licensed for short-term symptom relief and for the prevention of exercise-induced bronchospasm; its speed of onset of action is similar to that of salbutamol.

Combination inhalers that contain a long-acting beta₂ agonist and a corticosteroid ensure that long-acting beta₂ agonists are not used without concomitant corticosteroids, but reduce the flexibility to adjust the dose of each component.

Indacaterol p. 221 and olodaterol p. 222 are long-acting beta₂ agonists licensed for chronic obstructive pulmonary disease in adults; they are not indicated for the relief of acute bronchospasm.

Vilanterol is a long-acting beta₂ agonist available only in a combination inhaler with fluticasone furoate or with umclidinium p. 219.

Oral

Oral preparations of beta₂ agonists may be used by patients who cannot manage the inhaled route. They are sometimes used for children and the elderly, but inhaled beta₂ agonists are more effective and have fewer side-effects. The longer-acting oral preparations, including bambuterol hydrochloride p. 220, may be of value in nocturnal asthma but they have a limited role and inhaled long-acting beta₂ agonists are usually preferred.

Parenteral

Salbutamol or terbutaline sulfate can be given intravenously for severe or life-threatening acute asthma; patients should be carefully monitored and the dose adjusted according to response and heart rate. The regular use of beta₂ agonists by the subcutaneous route is not recommended since the evidence of benefit is uncertain and it may be difficult to withdraw such treatment once started. In adults, beta₂ agonists may also be given by intramuscular injection.

Children

Selective beta₂ agonists are useful even in children under the age of 18 months. They are most effective by the inhaled route; a pressurised metered-dose inhaler should be used with a spacer device in children under 5 years. A beta₂ agonist may also be given by mouth but administration by inhalation is preferred; a long-acting inhaled beta₂ agonist may be used where appropriate. In severe attacks nebulisation using a selective beta₂ agonist or ipratropium bromide is advisable.

Antimuscarinic bronchodilators

Ipratropium bromide p. 217 can provide short-term relief in chronic asthma, but short-acting beta₂ agonists act more quickly and are preferred. Ipratropium bromide by nebulisation can be added to other standard treatment in life-threatening asthma or if acute asthma fails to improve with standard therapy.

The aerosol inhalation of ipratropium bromide can be used for short-term relief in mild chronic obstructive pulmonary disease in patients who are not using a long-acting antimuscarinic drug. Its maximal effect occurs 30–60 minutes after use; its duration of action is 3 to 6 hours and bronchodilation can usually be maintained with treatment 3 times a day.

Acclidinium bromide p. 217, glycopyrronium bromide p. 217, tiotropium p. 218, and umeclidinium p. 219 are licensed for the maintenance treatment of adults with chronic obstructive pulmonary disease. They are not suitable for the relief of acute bronchospasm. Tiotropium p. 218 (via Respimat® device) is also licensed as an adjunct to inhaled corticosteroids and long-acting beta₂ agonists for the maintenance treatment of patients with asthma who have suffered one or more severe exacerbations in the last year.

Theophylline

Theophylline p. 238 is a xanthine used as a bronchodilator in asthma and stable chronic obstructive pulmonary disease; it
is not generally effective in exacerbations of chronic obstructive pulmonary disease. Theophylline may have an additive effect when used in conjunction with small doses of beta; agonists; the combination may increase the risk of side-effects, including hypokalaemia.

Theophylline is given by injection as aminophylline p. 227, a mixture of theophylline with ethylenediamine, which is 20 times more soluble than theophylline alone. Aminophylline injection is needed rarely for severe acute asthma.

Compound bronchodilator preparations
In general, patients are best treated with single-ingredient preparations, such as a selective beta, agonist or ipratropium bromide p. 217, so that the dose of each drug can be adjusted. This flexibility is lost with compound bronchodilator preparations. However, a combination product may be appropriate for patients stabilised on individual components in the same proportion.

Chronic obstructive pulmonary disease
Smoking cessation reduces the progressive decline in lung function in chronic obstructive pulmonary disease (COPD, chronic bronchitis, or emphysema). Infection can complicate chronic obstructive pulmonary disease and may be prevented by vaccination (pneumococcal vaccine p. 1089 and influenza vaccine p. 1085). A trial of a high-dose inhaled corticosteroid or an oral corticosteroid is recommended for patients with moderate or severe airflow obstruction if the diagnosis is in doubt.

Symptoms of chronic obstructive pulmonary disease may be alleviated by an inhaled short-acting beta, agonist or a short-acting antimuscarinic bronchodilator used as required.

When the airways obstruction is more severe, regular inhaled therapy should be used. It is important to check compliance and inhaler technique before initiating a new drug.

If the Forced Expiratory Volume in 1 second (FEV), is 50% of predicted or more, either a long-acting antimuscarinic bronchodilator or a long-acting beta, agonist should be used. Short-acting antimuscarinic bronchodilators should be discontinued when a long-acting antimuscarinic bronchodilator is started. A long-acting beta, agonist with a corticosteroid in a combination inhaler can be used for patients who remain symptomatic despite regular treatment with a long-acting beta, agonist.

If FEV, is less than 50% of predicted, either a long-acting antimuscarinic bronchodilator or a long-acting beta, agonist with a corticosteroid in a combination inhaler should be used.

In any patient who remains breathless or continues to have exacerbations, triple therapy with a long-acting beta, agonist and a corticosteroid in a combination inhaler plus a long-acting antimuscarinic bronchodilator should be used.

If an inhaled corticosteroid is not appropriate, a long-acting antimuscarinic bronchodilator can be used with a long-acting beta, agonist (see Use of inhaled therapies in chronic obstructive pulmonary disease algorithm, p. 215).

If symptoms persist or if the patient is unable to use an inhaler, oral modified-release aminophylline p. 237 or theophylline p. 238 can be used.

Indacaterol p. 221 is a long-acting beta, agonist licensed for the maintenance treatment of chronic obstructive pulmonary disease.

In patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations, roflumilast p. 236 is licensed as an adjunct to existing bronchodilator treatment.

A mucolytic drug may be considered for a patient with a chronic productive cough.

Long-term oxygen therapy prolongs survival in patients with severe chronic obstructive pulmonary disease and hypoxaemia.

During an exacerbation of chronic obstructive pulmonary disease, bronchodilator therapy can be administered through a nebuliser if necessary and oxygen given if appropriate. Aminophylline can be given intravenously if response to nebulised bronchodilators is poor. A short course of oral corticosteroid, such as prednisolone for 7–14 days, should be given if increased breathlessness interferes with daily activities. Antibacterial treatment is required if sputum becomes more purulent than usual, or if there are other signs of infection.

Patients who have had an episode of hypercapnic respiratory failure should be given a 24% or 28% Venturi mask and an oxygen alert card endorsed with the oxygen saturations required during previous exacerbations. Patients and their carers should be instructed to show the card to emergency healthcare providers in the event of an exacerbation.

Oxygen alert card based on British Thoracic Society guideline for emergency oxygen use in adult patients (October 2008)

Oxygen alert card

Oxygen should be regarded as a drug. It is prescribed for hypoxaemic patients to increase alveolar oxygen tension and decrease the work of breathing. The concentration of oxygen required depends on the condition being treated; the administration of an inappropriate concentration of oxygen can have serious or even fatal consequences.

Oxygen is probably the most common drug used in medical emergencies. It should be prescribed initially to achieve a normal or near-normal oxygen saturation; in most acutely ill patients with a normal or low arterial carbon dioxide (PaCO₂), oxygen saturation should be 94–96% oxygen saturation. However, in some clinical situations such as cardiac arrest and carbon monoxide poisoning it is more appropriate to aim for the highest possible oxygen saturation until the patient is stable. A lower target of 88–92% oxygen saturation is indicated for patients at risk of hypercapnic respiratory failure.

High concentration oxygen therapy is safe in uncomplicated cases of conditions such as pneumonia, pulmonary thromboembolism, pulmonary fibrosis, shock, severe trauma, sepsis, or anaphylaxis. In such conditions low arterial oxygen (PaO₂) is usually associated with low or
normal arterial carbon dioxide ($P_{a}CO_2$), and therefore there is little risk of hypoventilation and carbon dioxide retention.

In acute severe asthma, the arterial carbon dioxide ($P_{a}CO_2$) is usually subnormal but as asthma deteriorates it may rise steeply (particularly in children). These patients usually require high concentrations of oxygen and if the arterial carbon dioxide ($P_{a}CO_2$) remains high despite other treatment, intermittent positive-pressure ventilation needs to be considered urgently.

Low concentration oxygen therapy (controlled oxygen therapy) is reserved for patients at risk of hypercapnic respiratory failure, which is more likely in those with:
- chronic obstructive pulmonary disease;
- advanced cystic fibrosis;
- severe non-cystic fibrosis bronchiectasis;
- severe kyphoscoliosis or severe ankylosing spondylitis;
- severe lung scarring caused by tuberculosis;
- musculoskeletal disorders with respiratory weakness, especially if on home ventilation;
- an overdose of opioids, benzodiazepines, or other drugs causing respiratory depression.

Until blood gases can be measured, initial oxygen should be given using a controlled concentration of 28% or less, titrated towards a target oxygen saturation of 88–92%. The aim is to provide the patient with enough oxygen to achieve an acceptable arterial oxygen tension without worsening carbon dioxide retention and respiratory acidosis. Patients may carry an oxygen alert card.

Domiciliary oxygen
Oxygen should only be prescribed for use in the home after careful evaluation in hospital by respiratory experts. Patients should be advised of the risks of continuing to smoke when receiving oxygen therapy, including the risk of fire. Smoking cessation therapy should be recommended before home oxygen prescription.

Air travel
Some patients with arterial hypoxaemia require supplementary oxygen for air travel. The patient’s requirement should be discussed with the airline before travel.
Long-term oxygen therapy

Long-term administration of oxygen (usually at least 15 hours daily) prolongs survival in some patients with chronic obstructive pulmonary disease. Assessment for long-term oxygen therapy requires measurement of arterial blood gas tensions. Measurements should be taken on 2 occasions at least 3 weeks apart to demonstrate clinical stability, and not sooner than 4 weeks after an acute exacerbation of the disease. Long-term oxygen therapy should be considered for patients with:

- chronic obstructive pulmonary disease with \( P_{O_2} < 7.3 \) kPa when breathing air during a period of clinical stability;
- chronic obstructive pulmonary disease with \( P_{O_2} \geq 7.3 \) kPa in the presence of secondary polycythæmia, nocturnal hypoxæmia, peripheral oedema, or evidence of pulmonary hypertension;
- severe chronic asthma with \( P_{O_2} < 7.3 \) kPa or persistent disabling breathlessness;
- interstitial lung disease with \( P_{O_2} < 8 \) kPa and in patients with \( P_{O_2} > 8 \) kPa with disabling dyspnoea;
- cystic fibrosis when \( P_{O_2} < 7.3 \) kPa or if \( P_{O_2} > 7.3 \) kPa in the presence of secondary polycythæmia, nocturnal hypoxæmia, pulmonary hypertension, or peripheral oedema;
- pulmonary hypertension, without parenchymal lung involvement when \( P_{O_2} < 8 \) kPa;
- neuromuscular or skeletal disorders, after specialist assessment;
- obstructive sleep apnoea despite continuous positive airways pressure therapy, after specialist assessment;
- pulmonary malignancy or other terminal disease with disabling dyspnoea;
- heart failure with daytime \( P_{O_2} < 7.3 \) kPa when breathing air or with nocturnal hypoxæmia;
- paediatric respiratory disease, after specialist assessment.

Increased respiratory depression is seldom a problem in patients with stable respiratory failure treated with low concentrations of oxygen although it may occur during exacerbations; patients and relatives should be warned to call for medical help if drowsiness or confusion occurs.

Short-burst oxygen therapy

Oxygen is occasionally prescribed for short-burst (intermittent) use for episodes of breathlessness not relieved by other treatment in patients with severe chronic obstructive pulmonary disease, interstitial lung disease, heart failure, and in palliative care. It is important, however, that the patient does not rely on oxygen instead of obtaining medical help or taking more specific treatment. Short-burst oxygen therapy can be used to improve exercise capacity and recovery; it should only be continued if there is proven improvement in breathlessness or exercise tolerance.

Ambulatory oxygen therapy

Ambulatory oxygen is prescribed for patients on long-term oxygen therapy who need to be away from home on a regular basis. Patients who are not on long-term oxygen therapy can be considered for ambulatory oxygen therapy if there is evidence of exercise-induced oxygen desaturation and of improvement in blood oxygen saturation and exercise capacity with oxygen. Ambulatory oxygen therapy is not recommended for patients with heart failure or those who smoke.

Oxygen therapy equipment

Under the NHS oxygen may be supplied as oxygen cylinders. Oxygen flow can be adjusted as the cylinders are equipped with an oxygen flow meter with ‘medium’ (2 litres/minute) and ‘high’ (4 litres/minute) settings.
ANTIMUSCARINICS

Glycopyrronium bromide

MEDICINAL FORMS
- Capsules with device
- Powder inhalation capsules
- Powder inhalation device

PATIENT AND CARER ADVICE
- Patients or carers should be given advice on how to administer glycopyrronium for inhalation.
- Manufacturer advises use only if potential benefit outweighs risk.

SIDE-EFFECTS
- Common or very common: Constipation, cough, diarrhoea, dry mouth, gastro-intestinal motility disorder, headache, rhinitis, sinusitis, nasopharyngitis, nausea, palpitation, paradoxical bronchospasm, pharyngitis, tachycardia, throat irritation, urinary retention
- Rare: Dental caries, dry skin
- Uncommon: Arrhythmia

INTERACTIONS
- Bladder outflow obstruction, prostatic hyperplasia, susceptibility to angle-closure glaucoma

CAUTIONS
- Hospitalisation with moderate or severe heart failure within last 12 months, myocardial infarction within last 6 months, newly diagnosed arrhythmia within last 3 months, unstable angina
- Use with caution if eGFR less than 30 mL/minute/1.73 m²
- Care needed to protect the patient’s eyes from nebulised drug or from drug powder.
- Severe or life-threatening acute asthma

INDICATIONS AND DOSE
- By inhalation of powder
- By nebulisation

IPRATROPNIUM BROMIDE

Glycopyrronium bromide (Glycopyrrrolate)

INDICATIONS AND DOSE
- Maintenance treatment of chronic obstructive pulmonary disease
- By inhalation of solution
- By inhalation of powder

CAUTIONS
- Cystic fibrosis

INTERACTIONS
- Beta-blockers, calcium channel blockers

INDICATIONS AND DOSE
- Reversible airways obstruction

PREGNANCY
- Manufacturer advises use only if potential benefit outweighs risk.

RENAI IMPAIRMENT
- Use with caution if eGFR less than 30 mL/minute/1.73 m²

PATIENT AND CARER ADVICE
- Patients or carers should be given advice on how to administer glycopyrronium for inhalation.
- There can be variation in the licensing of different medicines containing the same drug.

MEDICINAL FORMS
- Capsules with device
- Powder inhalation capsules
- Powder inhalation device

SIDE-EFFECTS
- Common or very common: Constipation, cough, diarrhoea, dry mouth, gastro-intestinal motility disorder, headache, rhinitis, sinusitis, nasopharyngitis, nausea, palpitation, paradoxical bronchospasm, pharyngitis, tachycardia, throat irritation, urinary retention
- Rare: Dental caries, dry skin
- Uncommon: Angina

CAUTIONS
- Hospitalisation with moderate or severe heart failure within last 12 months, myocardial infarction within last 6 months, newly diagnosed arrhythmia within last 3 months, unstable angina
- Use with caution if eGFR less than 30 mL/minute/1.73 m²
- Care needed to protect the patient’s eyes from nebulised drug or from drug powder.
- Severe or life-threatening acute asthma

INDICATIONS AND DOSE
- Reversible airways obstruction

PREGNANCY
- Manufacturer advises use only if potential benefit outweighs risk.

RENAI IMPAIRMENT
- Use with caution if eGFR less than 30 mL/minute/1.73 m²
218 Airways disease, obstructive

Ipratropium with salbutamol

The properties listed below are those particular to the combination only. For the properties of the components please consider, salbutamol p. 222, ipratropium bromide p. 217.

INDICATIONS AND DOSE
Bronchospasm in chronic obstructive pulmonary disease by inhalation of nebulised solution
- Adult: 0.5/2.5 mg 3–4 times a day

- CONTRAINDICATIONS
- Patients with known hypersensitivity to the components
- Do not use in patients with active oropharyngeal candidiasis

- PREGNANCY
- Breastfeeding

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Nebuliser liquid
- IPRATROPIUM BROMIDE (Non-proprietary) Ipratropium bromide 20 microgram per 1 ml, Salbutamol (as Salbutamol sulphate) 1 mg per 1 ml Ipratropium bromide 200 microgram per 1 ml, Salbutamol (as Salbutamol sulphate) 1 mg per 1 ml Ipratropium bromide 500 microgram per 1 ml, Salbutamol (as Salbutamol sulphate) 2.5 mg per 1 ml Ipratropium bromide 1 mg per 1 ml

- COMBIVENT (Boehringer Ingelheim Ltd) Ipratropium bromide 200 microgram per 1 ml, Salbutamol (as Salbutamol sulphate) 1 mg per 1 ml Combivent nebuliser liquid 2.5ml UDVs | 60 unit dose (POD) £24.10
- Brands may include Atrovent

- CAUTIONS
- Cardiac arrhythmia requiring intervention in the previous 12 months - hospitalisation for moderate to severe heart failure in the previous 12 months - life-threatening cardiac arrhythmia - myocardial infarction in the previous 6 months - unstable cardiac arrhythmia

- SIDE-EFFECTS
- Common or very common: Dizziness, epistaxis, oropharyngeal candidiasis, pruritus, taste disturbance
- Rare: Gingivitis, glossitis, insomnia, intestinal obstruction, paralytic ileus, sinusitis, stomatitis
- Frequency not known: Dehydration, joint swelling
- PREGNANCY
- Manufacturer advises use only if potential benefit outweighs risk

- BREAST FEEDING
- Manufacturer advises avoid—no information available.

- RENAL IMPAIRMENT
- Plasma-tiotropium concentration raised. Manufacturer advises use only if potential benefit outweighs risk if eGFR less than 50 mL/minute/1.73 m².

- PATIENT AND CARER ADVICE
- Counselling. Advise patients to report any worsening of cardiac symptoms during treatment.
- Patients or carers should be given advice on how to administer tiotropium powder inhalation and pressurised inhalation.

- NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2007) that Spiriva Respimat® is restricted for use in chronic obstructive pulmonary disease in patients who have poor manual dexterity and difficulty using the Handihaler™ device.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Pressurised inhalation
- SPIRIVA RESPIMAT® (Boehringer Ingelheim Ltd) Tiotropium bromide 25 microgram per 1 dose Tiotropium bromide 25 microgram per 1 dose solution for inhalation cartrige with device CFC free | 60 unit dose (POD) no price available DT price = £33.50

- SPIRIVA RESPIMAT® (Boehringer Ingelheim Ltd) Tiotropium bromide 25 microgram per 1 dose Tiotropium bromide 25 microgram per 1 dose solution for inhalation cartrige with device | 60 unit dose (POD) £33.50 DT price = £33.50
Inhalation powder

- Spiriva (Boehringer Ingelheim Ltd)
  Tiotropium (as Tiotropium bromide) 18 microgram Spiriva 18microgram inhalation powder capsules | 30 capsule [PMD] £33.50 DT price = £33.50
  Spiriva 18microgram inhalation powder capsules with HandiHaler | 30 capsule [PMD] £34.87 DT price = £34.87

Umeclidinium

INDICATIONS AND DOSE
Maintenance treatment of chronic obstructive pulmonary disease
BY INHALATION OF POWDER
- Adult: 55 micrograms once daily

Dose equivalence and conversion
Each 65 microgram inhalation of umeclidinium bromide delivers 55 micrograms of umeclidinium.

- CAUTIONS Cardiac disorders (particularly cardiac rhythm disorders)
- SIDE-EFFECTS
  Uncommon Arrhythmias - rash - sinusitis - urinary tract infection
  PREGNANCY Manufacturer advises use only if potential benefit outweighs risks.
  BREAST FEEDING Manufacturer advises avoid—no information available.
  HEPATIC IMPAIRMENT Use with caution in severe impairment.
  PATIENT AND CARER ADVICE Patient or carers should be given advice on how to administer umeclidinium inhalation powder.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  Inhalation powder
    Anoro Ellipta (GlaxoSmithKline UK Ltd)
    Umeclidinium bromide 65 microgram per 1 dose, Vilanterol (as Vilanterol trifenatate) 22 microgram per 1 dose Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler | 30 dose [PMD] £32.50

BETA₂ AGONISTS (LONG-ACTING)

Selective beta₂ agonists

- CONTRA-INDICATIONS Severe pre-eclampsia
- CAUTIONS Arrhythmias - cardiovascular disease - diabetes (risk of hyperglycaemia and ketoacidosis, especially with intravenous use) - hypertension - hyperthyroidism - hypokalaemia - susceptibility to QT-interval prolongation
- MEDICINAL FORMS
  Hypokalaemia Potentially serious hypokalaemia may result from beta₂ agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, diuretics, and by hypoxia.
  INTERACTIONS Appendix 1 (sympathomimetics, beta₂.). Hypokalaemia may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics.

- SIDE-EFFECTS Angioedema - arrhythmias - behavioural disturbances - collapse - fine tremor (particularly in the hands) - headache - hyperglycaemia (especially when given intravenously) - hypertension - ketoadidosis (especially when given intravenously) - muscle cramps - myocardial ischaemia - nervous tension - palpitation - paradoxical bronchospasm (occasionally severe) - peripheral vasodilation - rash - sleep disturbances - tachycardia - urticaria
- PREGNANCY Women planning to become pregnant should be counselled about the importance of taking their asthma medication regularly to maintain good control.

- MONITORING REQUIREMENTS
  In severe asthma, plasma-potassium concentration should be monitored (risk of hypokalaemia).
  In patients with diabetes, monitor blood glucose (risk of hyperglycaemia and ketoacidosis, especially when beta₂ agonist given intravenously).
  PATIENT AND CARER ADVICE When used by inhalation The dose, the frequency, and the maximum number of inhalations in 24 hours of the beta₂
Respiratory system

Formoterol fumarate

INDICATIONS AND DOSE
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy | Nocturnal asthma in patients requiring long-term regular bronchodilator therapy | Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy | Chronic asthma in patients who regularly use an inhaled corticosteroid

BY INHALATION OF POWDER
- Child 6-11 years: 12 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose
- Child 12-17 years: 24 micrograms twice daily, a daily dose of 48 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose

Formoterol fumarate

(Eformoterol fumarate)

INDICATIONS AND DOSE
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy | Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy | Chronic asthma in patients who regularly use an inhaled corticosteroid

BY INHALATION OF POWDER
- Child 6-11 years: 12 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose
- Child 12-17 years: 24 micrograms twice daily, a daily dose of 48 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose

BY INHALATION OF AEROSOL
- Child 12-17 years: 24 micrograms twice daily, a daily dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily

CHM ADVICE
To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting β₂ agonist (formoterol) should:
- be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately;
- not be initiated in patients with rapidly deteriorating asthma;
- be introduced at a low dose and the effect properly monitored before considering dose increase;
- be discontinued in the absence of benefit;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

仞

Bambuterol hydrochloride

仞

DRUG ACTION
Bambuterol is a pro-drug of terbutaline.

INDICATIONS AND DOSE
- Asthma (patients who have previously tolerated β₂-agonists)
- Other conditions associated with reversible airways obstruction (patients who have previously tolerated β₂-agonists)

BY MOUTH
- Adult: 20 mg once daily, dose to be taken at bedtime
- Child 6–12 years: 6 micrograms, dose to be taken before exercise
- Child 12–17 years: 12 micrograms, dose to be taken before exercise

PREGNANCY
Manufacturer advises avoid—no information available.

BREAST FEEDING
Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
Avoid in severe impairment.

RENAL IMPAIRMENT
Reduce initial dose by half if eGFR less than 50 mL/minute/1.73 m².

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Bambec (AstraZeneca UK Ltd)
  - Bambuterol hydrochloride 10 mg: Bambec 10mg tablets | 28 tablet blister pack £14.46 DT price = £14.46
  - Bambuterol hydrochloride 20 mg: Bambec 20mg tablets | 28 tablet blister pack £15.77 DT price = £15.77

Formoterol fumarate

Bambuterol hydrochloride

仞

ению
Beclometasone with formoterol

The properties listed below are those particular to the combination only. For the properties of the components please consider, beclometasone dipropionate p. 227, formoterol fumarate p. 220.

**INDICATIONS AND DOSE**

**Asthma maintenance therapy**

**BY INHALATION OF AEROSOL OR BY INHALATION OF POWDER**

- Adult: 100/6–200/12 micrograms twice daily; maximum 400/24 micrograms per day

**Asthma, maintenance and reliever therapy**

**BY INHALATION OF AEROSOL**

- Adult: Maintenance 100/6 micrograms twice daily; 100/6 micrograms as required for relief of symptoms; maximum 800/48 micrograms per day

**Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted**

**BY INHALATION OF AEROSOL**

- Adult: 200/12 micrograms twice daily

**Dose equivalence and conversion**

For inhalation of aerosol, when switching patients from other beclometasone dipropionate and formoterol fumarate inhalers, Fostair® 100/6 can be prescribed for patients already using beclometasone dipropionate 250 micrograms in another CFC-free inhaler; the dose of Fostair® should be adjusted according to response. For inhalation of powder, when switching patients from other beclometasone dipropionate formulations with non-extrafine particle size distribution, the dose should be adjusted according to response. 1 puff is equivalent to 100 micrograms beclometasone dipropionate and 6 micrograms formoterol fumarate.

**PATIENT AND CARER ADVICE**

With high doses, a steroid card should be supplied. Patients or carers should be given advice on how to administer beclometasone with formoterol inhalation.

**INDICATIONS AND DOSE**

**Maintenance treatment of chronic obstructive pulmonary disease**

**BY INHALATION OF POWDER**

- Adult: 150 micrograms once daily, then increased to 300 micrograms once daily

**INDICATIONS AND DOSE**

**Maintenance treatment of chronic obstructive pulmonary disease**

**BY INHALATION OF POWDER**

- Adult: 150 micrograms once daily, then increased to 300 micrograms once daily

**SIDE-EFFECTS**

- Very rare QT-interval prolongation
- Very rare hypokalaemia

**PREGNANCY**

Inhaled drugs for asthma can be taken as normal during pregnancy.

**BREAST FEEDING**

Inhaled drugs for asthma can be taken as normal during breast-feeding.

**PATIENT AND CARER ADVICE**

Advise patients not to exceed prescribed dose, and to follow manufacturer's directions; if a previously effective dose of inhaled formoterol fails to provide adequate relief, a doctor's advice should be obtained as soon as possible. Patients should be advised to report any deterioration in symptoms following initiation of treatment with a long-acting beta₂ agonist. Patient or carer should be given advice on how to administer formoterol fumarate inhalers.

**MACHINES AND DEVICES**

For inhalation of aerosol, when switching patients from other beclometasone dipropionate formulations with non-extrafine particle size distribution, the dose should be adjusted according to response. 1 puff is equivalent to 100 micrograms beclometasone dipropionate and 6 micrograms formoterol fumarate.

**PATIENT AND CARER ADVICE**

With high doses, a steroid card should be supplied. Patients or carers should be given advice on how to administer beclometasone with formoterol inhalation.

**INDICATIONS AND DOSE**

**Maintenance treatment of chronic obstructive pulmonary disease**

**BY INHALATION OF POWDER**

- Adult: 150 micrograms once daily, then increased to 300 micrograms once daily

**SIDE-EFFECTS**

- Common or very common Cough · dizziness · nasopharyngitis · oropharyngeal pain · peripheral oedema · rhinorrhoea · sinusitis
- Uncommon Atrial fibrillation · chest pain · paraesthesia · pruritus
- PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Use with caution in severe impairment—no information available.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer indacaterol inhalation powder.

**MACHINES AND DEVICES**

For inhalation of aerosol, when switching patients from other beclometasone dipropionate formulations with non-extrafine particle size distribution, the dose should be adjusted according to response. 1 puff is equivalent to 100 micrograms beclometasone dipropionate and 6 micrograms formoterol fumarate.

**PATIENT AND CARER ADVICE**

With high doses, a steroid card should be supplied. Patients or carers should be given advice on how to administer beclometasone with formoterol inhalation.

**INDICATIONS AND DOSE**

**Maintenance treatment of chronic obstructive pulmonary disease**

**BY INHALATION OF POWDER**

- Adult: 150 micrograms once daily, then increased to 300 micrograms once daily

**SIDE-EFFECTS**

- Common or very common Cough · dizziness · nasopharyngitis · oropharyngeal pain · peripheral oedema · rhinorrhoea · sinusitis
- Uncommon Atrial fibrillation · chest pain · paraesthesia · pruritus
- PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Use with caution in severe impairment—no information available.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer indacaterol inhalation powder.
Respiratory system

**Olodaterol**

**INDICATIONS AND DOSE**

Maintenance treatment of chronic obstructive pulmonary disease

- **BY INHALATION**
  - Adult: 5 micrograms once daily

**Dose equivalence and conversion**

2 puffs is equivalent to 5 micrograms.

- **CAUTIONS**
  - Anerysm • convulsive disorders

- **SIDE-EFFECTS**
  - Uncommon Dizziness • nasopharyngitis
  - Rare Arthralgia • hypertension

- **PREGNANCY** Manufacturer advises avoid—no information available.

- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Use with caution in severe hepatic impairment—no information available.

- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer olodaterol solution for inhalation.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Pressurised inhalation**
    - Serevent Respimat (Boehringer Ingelheim Ltd) ▼
    - Olodaterol (as Olodaterol hydrochloride) 2.5 microgram per 1 dose Serevent Respimat 2.5 micrograms/dose solution for inhalation cartridge with device | 60 dose [PO] £26.35 DT price = £26.35

**Salmeterol**

**INDICATIONS AND DOSE**

Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy | Nocturnal asthma in patients requiring long-term regular bronchodilator therapy | Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy | Chronic asthma only in patients who regularly use an inhaled corticosteroid (not for immediate relief of acute asthma)

- **BY INHALATION OF AEROSOL OR BY INHALATION OF POWDER**
  - Child 5–11 years: 50 micrograms twice daily
  - Child 12–17 years: 50 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 100 micrograms twice daily
  - Adult: 50 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 100 micrograms twice daily

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

- **BY INHALATION OF AEROSOL OR BY INHALATION OF POWDER**
  - Adult: 50 micrograms twice daily

**PHARMACOKINETICS**

At recommended inhaled doses, the duration of action of salmeterol is about 12 hours.

- **UNLICENSED USE** Neovent® not licensed for use in children under 12 years.

**Important safety information**

**CHM ADVICE**

- To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta₂ agonist (salmeterol) should: be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately; be not initiated in patients with rapidly deteriorating asthma; be introduced at a low dose and the effect properly monitored before considering dose increase; be discontinued in the absence of benefit; not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used; be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.

- **SIDE-EFFECTS**
  - Arthralgia • dizziness • nausea

- **PREGNANCY** Inhaled drugs for asthma can be taken as normal during pregnancy.

- **BREAST FEEDING** Inhaled drugs for asthma can be taken as normal during breast-feeding.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Salmeterol inhaler for asthma prevention (prophylaxis) [www.medicinesforchildren.org.uk/salmeterol-inhaler-for-asthma-prevention](http://www.medicinesforchildren.org.uk/salmeterol-inhaler-for-asthma-prevention)

Advise patients that salmeterol should not be used for relief of acute attacks, not to exceed prescribed dose, and to follow manufacturer’s directions; if a previously effective dose of inhaled salmeterol fails to provide adequate relief, a doctor’s advice should be obtained as soon as possible.

Patients should be advised to report any deterioration in symptoms following initiation of treatment with a long-acting beta, agonist.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Pressurised inhalation**
    - SALMETEROL (Non-proprietary)
      - Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose Salmeterol 25 micrograms/dose inhaler CFC free | 120 dose [PO] £29.26 DT price = £29.26
    - Serevent Evohaler (GlaxoSmithKline UK Ltd)
      - Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose Serevent 25 micrograms/dose Evohaler | 120 dose [PO] £29.26 DT price = £29.26
    - Brands may include Neovent; Vertine

**Inhalation powder**

- Serevent Accuhaler (GlaxoSmithKline UK Ltd)
  - Salmeterol (as Salmeterol xinafoate) 50 microgram per 1 dose Serevent 50 micrograms/dose Accuhaler | 60 dose [PO] £29.26 DT price = £29.26

**Salbutamol** (Albuterol)

**INDICATIONS AND DOSE**

Asthma | Other conditions associated with reversible airways obstruction

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 4 mg 3–4 times a day, maximum single dose 8 mg (but unlikely to provide much extra benefit or to be tolerated), inhalation route preferred over oral route, use elderly dose for sensitive patients
  - Elderly: Initially 2 mg 3–4 times a day, maximum single dose 6 mg (but unlikely to provide much extra benefit or to be tolerated), inhalation route preferred over oral route

- **BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
  - Adult: 500 micrograms every 4 hours if required
Uncomplicated premature labour (between 22 and 37 weeks of gestation) (specialist use only)

**BY INTRavenous INJECTION**
- Adult: Initially 10 micrograms/minute, rate increased gradually according to response at 10-minute intervals until contractions diminish then increase rate slowly until contractions cease (maximum rate 45 micrograms/minute), maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours, maximum duration 48 hours

**VENTOLIN ACCUHALER®**

**Acute bronchospasm**
- Adult: Initially 200 micrograms, up to 4 times daily for persistent symptoms

**Prophylaxis of allergen- or exercise-induced bronchospasm**
- **BY INHALATION OF POWDER**
  - Adult: 200 micrograms

**Moderate, severe, or life-threatening acute asthma**
- **BY INHALATION OF NEBULISED SOLUTION**
  - Child 1 month–4 years: 2.5 mg, then 2.5 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
  - Child 5–11 years: 2.5–5 mg, then 2.5–5 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
  - Child 12–17 years: 5 mg, then 5 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
  - Adult: 5 mg, then 5 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available

**Moderate and severe acute asthma**
- **BY INHALATION OF AEROSOL**
  - Child: 2–10 puffs, up to 4 times a day for persistent symptoms
  - Adult: 2–10 puffs, up to 4 times daily for persistent symptoms

**Exacerbation of reversible airways obstruction (including nocturnal asthma) Prophylaxis of allergen- or exercise-induced bronchospasm**
- **BY INHALATION OF AEROSOL**
  - Child: 100–200 micrograms, up to 4 times a day for persistent symptoms

**Chronic asthma**
- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 3–11 years: 4 mg twice daily
  - Child 12–17 years: 8 mg twice daily
  - Adult: 8 mg twice daily

**SALBUTAMOL**

**Acute bronchospasm**
- **BY INHALATION OF POWDER**
  - Adult: Initially 200 micrograms, up to 4 times daily for persistent symptoms

**Prophylaxis of allergen- or exercise-induced bronchospasm**
- **BY INHALATION OF POWDER**
  - Adult: 200 micrograms

**Respiratory system**
significant risk factors for myocardial ischaemia - threatened miscarriage

- **CAUTIONS**
  - With intravenous use mild to moderate pre-eclampsia (when used for uncomplicated premature labour) - suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour)

- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - Lactic acidosis (with high doses) - nausea
  - **SPECIFIC SIDE-EFFECTS**
    - When used for uncomplicated premature labour bronchospasm - muscle tension - pulmonary oedema - vomiting
  - **BREAST FEEDING**
    - Inhaled drugs for asthma can be taken as normal during breast-feeding.
  - **MONITORING REQUIREMENTS**
    - In uncomplicated premature labour it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient's fluid and electrolyte status (avoid over-hydration—discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).
  - **DIRECTIONS FOR ADMINISTRATION**
    - When used by inhalation For nebulisation, dilute nebuliser solution with a suitable volume of sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; salbutamol and ipratropium bromide solutions are compatible and can be mixed for nebulisation.
  - When used by continuous intravenous infusion For bronchodilatation, dilute to a concentration of 200 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%.
  - For premature labour, dilute with Glucose 5% to a concentration of 200 micrograms/mL for use in a syringe pump or for other infusion methods (preferably via controlled infusion device), dilute to a concentration of 20 micrograms/mL; close attention to patient's fluid and electrolyte status essential.

- **PATIENT AND CARER ADVICE**
  - For inhalation by aerosol or dry powder, advise patients and carers not to exceed prescribed dose and to follow manufacturer's directions; if a previously effective dose of inhaled salbutamol fails to provide at least 3 hours relief, a doctor's advice should be obtained as soon as possible.
  - For inhalation by nebuliser, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respiratory solution.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - *Salbutamol (as Salbutamol sulphate) 2 mg* Salbutamol 2mg tablets | 28 tablet [PST] £113.09 DT price = £104.95
    - *Salbutamol (as Salbutamol sulphate) 4 mg* Salbutamol 4mg tablets | 28 tablet [PST] £115.76 DT price = £107.43

  - **Modified-release capsule**
    - CAUTIONARY AND ADVISORY LABELS 25
    - Ventmax SR (Chiesi Ltd)
    - *Salbutamol (as Salbutamol sulphate) 4 mg* Ventmax SR 4mg capsules | 56 capsule [PST] £8.08 DT price = £8.08

- **Salbutamol (as Salbutamol sulphate) 8 mg** Ventmax SR 8mg capsules | 56 capsule [PST] £9.69 DT price = £9.69

- **Oral solution**
  - *Salbutamol (Non-proprietary)*
    - *Salbutamol (as Salbutamol sulphate) 400 microgram per 1 ml* Salbutamol 2mg/5ml oral solution sugar free (sugar-free) | 150 ml [PST] no price available DT price = £0.72
    - *Ventolin (GlaxoSmithKline UK Ltd)*
      - *Salbutamol (as Salbutamol sulphate) 400 microgram per 1 ml* Ventolin 2mg/5ml syrup (sugar-free) | 150 ml [PST] £0.72 DT price = £0.72

- **Solution for injection**
  - *Ventolin (GlaxoSmithKline UK Ltd)*
    - *Salbutamol (as Salbutamol sulphate) 500 microgram per 1 ml* Ventolin 500micrograms/1ml solution for injection ampoules | 5 ampoule [PST] £1.91

- **Solution for infusion**
  - *Ventolin (GlaxoSmithKline UK Ltd)*
    - *Salbutamol (as Salbutamol sulphate) 1 mg per 1 ml* Ventolin 5mg/5ml solution for infusion ampoules | 10 ampoule [PST] £24.81

- **Pressurised inhalation**
  - *Salbutamol (Non-proprietary)*
    - Salbutamol 100 microgram per 1 dose Easyhaler Salbutamol sulphate 100micrograms/dose dry powder inhaler | 200 dose [PST] £3.31 DT price = £3.31
    - Salbutamol 200 microgram per 1 dose Easyhaler Salbutamol sulphate 200micrograms/dose dry powder inhaler | 200 dose [PST] £6.63
    - *Asmasal Clickhaler (Focus Pharmaceuticals Ltd)*
      - *Salbutamol (as Salbutamol sulphate) 95 microgram per 1 dose* Asmasal 95micrograms/dose Clickhaler | 200 dose [PST] £5.65 DT price = £5.65
    - *Pulvinal (salbutamol) (Chiesi Ltd)*
      - Salbutamol 200 microgram per 1 dose Pulvinal Salbutamol 200micrograms/dose dry powder inhaler | 100 dose [PST] £4.85 DT price = £4.85
    - *Salbutin Novolizer (Meda Pharmaceuticals Ltd)*
      - *Salbutamol (as Salbutamol sulphate) 100 microgram per 1 dose* Salbutin Novolizer 100micrograms/dose inhalation powder refill | 200 dose [PST] £2.75
    - *Ventolin Accuhaler (GlaxoSmithKline UK Ltd)*
      - Salbutamol 200 microgram per 1 dose Ventolin 200micrograms/dose Accuhaler | 60 dose [PST] £3.00 DT price = £3.00

- **Nebuliser liquid**
  - *Salbutamol (Non-proprietary)*
    - *Salbutamol (as Salbutamol sulphate) 1 mg per 1 ml* Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose Steripoule vials | 20 unit dose [PST] £2.87 DT price = £1.91
    - *Salbutamol (as Salbutamol sulphate) 2 mg per 1 ml* Salbutamol 5mg/2.5ml nebuliser liquid unit dose vials | 20 unit dose [PST] £7.00 DT price = £1.91
    - *Ventolin (GlaxoSmithKline UK Ltd)*
      - *Salbutamol (as Salbutamol sulphate) 3 mg/7.5mg per 1 ml* Salbutamol 3mg/7.5mg nebuliser liquid unit dose vials | 20 unit dose [PST] £3.82
      - *Ventolin (GlaxoSmithKline UK Ltd)*
        - *Salbutamol (as Salbutamol sulphate) 5 mg per 1 ml* Ventolin 5mg/ml nebuliser liquid solution | 20 ml [PST] £2.18 DT price = £2.18
    - *Ventolin Nebules (GlaxoSmithKline UK Ltd)*
      - *Salbutamol (as Salbutamol sulphate) 1 mg per 1 ml* Ventolin 2.5mg Nebules | 20 unit dose [PST] £1.65 DT price = £1.91
      - *Salbutamol (as Salbutamol sulphate) 2 mg per 1 ml* Ventolin 5mg Nebules | 20 unit dose [PST] £2.78 DT price = £3.82
  - Brands may include *Salamol Steri-Neb*

Also available in combination with *ipratropium*, p. 218
Terbutaline sulfate

**INDICATIONS AND DOSE**

**Asthma**  | Other conditions associated with reversible airways obstruction

**BY MOUTH**
- Adult: Initially 2.5 mg 3 times a day for 1–2 weeks, then increased to up to 5 mg 3 times a day, use by inhalation preferred over by mouth

**BY SUBCUTANEOUS INJECTION OR BY SLOW INTRAVENOUS INJECTION**
- Adult: 250–500 micrograms up to 4 times a day, reserve intravenous beta, agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect

**BY CONTINUOUS INTRAVENOUS INFUSION**
- Adult: 90–300 micrograms/hour for 8–10 hours, to be administered as a solution containing 3–5 micrograms/mL, high doses require close monitoring, reserve intravenous beta, agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect

**BY INHALATION OF POWDER**
- Adult: 500 micrograms up to 4 times a day, for persistent symptoms

**BY INHALATION OF NEBULISED SOLUTION**
- Adult: 5–10 mg 2–4 times a day, additional doses may be necessary in severe acute asthma

**Acute asthma**

**BY SUBCUTANEOUS INJECTION OR BY SLOW INTRAVENOUS INJECTION**
- Child 2–14 years: 10 micrograms/kg up to 4 times a day (max. per dose 300 micrograms), reserve intravenous beta, agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect
- Child 15–17 years: 250–500 micrograms up to 4 times a day, reserve intravenous beta, agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect

**BY CONTINUOUS INTRAVENOUS INFUSION**
- Adult: Loading dose 2–4 micrograms/kg, then 1–10 micrograms/kg/hour, dose to be adjusted according to response and heart rate, close monitoring is required for doses above 10 micrograms/kg/hour, reserve intravenous beta, agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect

**Moderate, severe, or life-threatening acute asthma**

**BY INHALATION OF NEBULISED SOLUTION**
- Child 1 month–4 years: Initially 5 mg, then 5 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
- Child 5–11 years: Initially 5–10 mg, then 5–10 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
- Child 12–17 years: Initially 10 mg, then 10 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
- Adult: Initially 10 mg, then 10 mg every 20–30 minutes or when required, give via oxygen-driven nebuliser if available

**Exacerbation of reversible airways obstruction (including nocturnal asthma)**

**Prevention of exercise-induced bronchospasm**

**BY INHALATION OF POWDER**
- Child 5–17 years: 500 micrograms up to 4 times a day, for occasional use only

**BY MOUTH**
- Child 1 month–6 years: 75 micrograms/kg 3 times a day (max. per dose 2.5 mg)

**UNLICENSED USE**
- Tablets not licensed for use in children under 7 years. Injection not licensed for use in children under 2 years.

**CONTRA-INDICATIONS**
- When used for uncomplicated premature labour
  - abruptio placenta
  - antepartum haemorrhage
  - cord compression
  - eclampsia
  - history of cardiac disease
  - intra-uterine fetal death
  - intra-uterine infection
  - placenta praevia
  - pulmonary hypertension
  - severe pre-eclampsia
  - significant risk factors for myocardial ischaemia
  - threatened miscarriage

**CAUTIONS**
- Mild to moderate pre-eclampsia (when used for uncomplicated premature labour)
- Suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour)

**SIDE-EFFECTS**

- **GENERAL SIDE-EFFECTS**
  - Nausea

**SPECIFIC SIDE-EFFECTS**

**Pharmacokinetics**
- At recommended inhaled doses, the duration of action of terbutaline is about 3 to 5 hours.

**Respiratory system**

- Child 7–14 years: 2.5 mg 2–3 times a day
- Child 15–17 years: Initially 2.5 mg 3 times a day, then increased if necessary to 5 mg 3 times a day

**Uncomplicated premature labour (between 22 and 37 weeks of gestation)** (specialist supervision in hospital)

**BY INTRAVENOUS INFUSION**
- Adult: Initially 5 micrograms/minute for 20 minutes, then increased in steps of 2.5 micrograms/minute every 20 minutes until contractions have ceased (more than 10 micrograms/minute should seldom be given—20 micrograms/minute should not be exceeded), continue for 1 hour, then reduced in steps of 2.5 micrograms/minute every 20 minutes to lowest dose that maintains suppression (maximum total duration 48 hours)

**Pharmacokinetics**
- When used for uncomplicated premature labour
  - Suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour)

**DIRECTIONS FOR ADMINISTRATION**
- When used by inhalation
  - For nebulisation, dilute nebuliser solution with sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; terbutaline and ipratropium bromide solutions are compatible and may be mixed for nebulisation.

**With intravenous use in children**

- For continuous intravenous infusion, dilute to a concentration of 5 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%; if fluid-restricted, dilute to a concentration of 100 micrograms/mL.

- In uncomplicated premature labour
  - For bronchodilation by continuous intravenous infusion, dilute 1.5–2.5 mg with 500 mL glucose 5% or sodium chloride 0.9% and give over 8–10 hours. For premature labour by continuous intravenous infusion, dilute in glucose 5% and give via controlled infusion device preferably a syringe pump; if
Respiratory system

Asthma and irreversible airways disease.

Corticosteroids are used for the management of reversible airways disease (and hence reduce oedema and secretion of mucus into the airway).

**Patient and carer advice**

For inhalation by dry powder, advise patients and carers not to exceed prescribed dose and to follow manufacturer’s directions; if a previously effective dose of inhaled terbutaline fails to provide at least 3 hours relief, a doctor’s advice should be obtained as soon as possible.

For inhalation by nebuliser, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

- **Tablet**
  - Bricanyl (AstraZeneca UK Ltd)
  - Terbutaline sulfate 5 mg Bricanyl 5mg tablets | 100 tablet (PSM)
  - £4.91 DT price = £4.91

- **Oral solution**
  - Bricanyl (AstraZeneca UK Ltd)
  - Terbutaline sulfate 300 microgram per 1 ml Bricanyl 1.5mg/5ml syrup (sugar-free) | 100 ml (PSM) £2.80 DT price = £2.80

- **Solution for injection**
  - Bricanyl (AstraZeneca UK Ltd)
  - Terbutaline sulfate 500 microgram per 1 ml Bricanyl 2.5mg/5ml solution for injection ampoules | 10 ampoule (PSM) £16.74
  - Bricanyl 500micrograms/1ml solution for injection ampoules | 5 ampoule (PSM) £2.16

- **Inhalation powder**
  - Bricanyl Turbuhaler (AstraZeneca UK Ltd)
  - Terbutaline sulfate 500 microgram per 1 dose Bricanyl 500micrograms/dose Turbuhaler | 100 dose (PSM) £6.92 DT price = £6.92

- **Nebuliser liquid**
  - TERBUTALINE SULFATE (Non-proprietary)
  - Terbutaline sulfate 2.5 mg per 1 ml Terbutaline 5mg/2ml nebuliser liquid unit dose vials | 20 unit dose (PSM) £4.08 DT price = £4.08
  - Bricanyl Respules (AstraZeneca UK Ltd)
  - Terbutaline sulfate 2.5 mg per 1 ml Bricanyl 5mg/2ml Respules | 20 unit dose (PSM) £5.82 DT price = £5.82

**Corticosteroids**

Current and previous smoking reduces the effectiveness of inhaled corticosteroids and higher doses may be necessary. Corticosteroid inhalers must be used regularly for maximum benefit; alleviation of symptoms usually occurs 3 to 7 days after initiation. Beclometasone dipropionate p. 227, budesonide p. 228, fluticasone p. 230, and mometasone furoate p. 222 appear to be equally effective. Preparations that combine a corticosteroid with a long-acting beta₂ agonist may be helpful for patients stabilised on the individual components in the same proportion.

In adults using an inhaled corticosteroid and a long-acting beta₂ agonist for the prophylaxis of asthma, but who are poorly controlled, Symbicort® or Duo吸入Spiromax® (both containing budesonide with formoterol p. 229) can be used as relievers (instead of a short-acting beta₂ agonist), in addition to their regular use for the prophylaxis of asthma. Symbicort® can also be used in this way in adults using an inhaled corticosteroid with a dose greater than beclometasone dipropionate 400 micrograms daily, but who are poorly controlled (standard doses of other inhaled corticosteroids can be used). When starting this treatment, the total regular daily dose of inhaled corticosteroid should not be reduced. Patients must be carefully instructed on the appropriate dose and management of exacerbations before initiating this therapy. Patients using budesonide with formoterol as a reliever once a day or more should have their treatment reviewed regularly. The use of Symbicort® for both reliever and maintenance therapy is also used by some specialists in children 12–18 years [unlicensed].

Fostair® can also be used in adults as a reliever (instead of a short-acting beta₂ agonist) in addition to its regular use for the prophylaxis of asthma. It may be particularly useful for patients with poorly controlled asthma requiring reliever therapy, or for those who have had previous exacerbations of asthma which needed medical intervention. Patients requiring frequent daily use of Fostair® as a reliever should have their maintenance treatment reviewed. This approach has not been investigated with combination inhalers containing other corticosteroids and long-acting beta₂ agonists.

High doses of inhaled corticosteroid can be prescribed for patients who respond only partially to standard doses with a long-acting beta₂ agonist or another long-acting bronchodilator. High doses should be continued only if there is clear benefit over the lower dose. The recommended maximum dose of an inhaled corticosteroid should not generally be exceeded. However, if a higher dose is required, then it should be initiated and supervised by a specialist.

The use of high doses of inhaled corticosteroid can minimise the requirement for an oral corticosteroid.

**Oral corticosteroids**

Systemic corticosteroid therapy may be necessary during episodes of stress, such as severe infection, or if the asthma is worsening, when higher doses are needed and access of inhaled drug to small airways may be reduced; patients may need a reserve supply of corticosteroid tablets.

In chronic asthma, when the response to other drugs has been inadequate, longer term administration of an oral corticosteroid may be necessary; in such cases high doses of an inhaled corticosteroid should be continued to minimise oral corticosteroid requirements. Patients taking long-term oral corticosteroids for asthma can often be transferred to an inhaled corticosteroid but the transfer must be slow, with gradual reduction in the dose of the oral corticosteroid, and at a time when the asthma is well controlled.

An acute attack of asthma should be treated with a short course of an oral corticosteroid starting with a high dose. Patients whose asthma has deteriorated rapidly usually respond quickly to corticosteroids. The dose can usually be stopped abruptly; tapering is not needed provided that the patient receives an inhaled corticosteroid in an adequate dose (apart from those on maintenance oral corticosteroid

Airways disease, use of corticosteroids

Corticosteroids are used for the management of reversible and irreversible airways disease.

**Asthma**

**Inhaled corticosteroids**

An inhaled corticosteroid used for 3–4 weeks may help to distinguish asthma from chronic obstructive pulmonary disease; clear improvement over 3–4 weeks suggests asthma.

Corticosteroids are effective in asthma; they reduce airway inflammation (and hence reduce oedema and secretion of mucus into the airway).

An inhaled corticosteroid is used regularly for prophylaxis of asthma when patients require a beta₂ agonist more than twice a week, or if symptoms disturb sleep at least once a week, or if the patient has suffered an exacerbation in the last 2 years requiring a systemic corticosteroid. **Regular use** of inhaled corticosteroids reduces the risk of exacerbation of asthma.
treatment or where oral corticosteroids are required for 3 or more weeks). In patients who have needed several courses of oral corticosteroids and in whom the possibility of a period on maintenance corticosteroids is being considered, it may be useful to taper the corticosteroid dose gradually to identify a threshold dose for asthma control. This should only be done after other standard options for controlling asthma have been tried.

An oral corticosteroid should normally be taken as a single dose in the morning to reduce the disturbance to circadian cortisol secretion. Dosage should always be titrated to the lowest dose that controls symptoms. Regular peak-flow measurements help to optimise the dose.

Parenteral corticosteroids

Hydrocortisone p. 583 injection has a role in the emergency treatment of acute severe asthma.

Chronic obstructive pulmonary disease

Inhaled corticosteroids

In chronic obstructive pulmonary disease inhaled corticosteroid therapy may reduce exacerbations when given in combination with an inhaled long-acting beta<sub>2</sub> agonist.

Oral corticosteroids

During an acute exacerbation of chronic obstructive pulmonary disease, prednisolone p. 585 should be given; treatment can be stopped abruptly. Prolonged treatment with oral prednisolone p. 585 is of no benefit and maintenance treatment is not normally recommended.

Corticosteroids (inhaled)

- **INTERACTIONS**
  - Appendix 1 (corticosteroids).
  
  Interactions do not generally apply to corticosteroids used for inhalation unless specified.

- **SIDE-EFFECTS**
  - Very rare Paradoxical bronchospasm
  - Frequency not known Adrenal crisis (with prolonged high doses) - adrenal suppression (with prolonged high doses) - aggression (particularly in children) - anxiety - behavioural changes (particularly in children) - bruising - candidiasis of the mouth - candidiasis of the throat - cutaneous - coma (with prolonged high doses) - Cushing’s syndrome (with moon face, striae and acne) - depression - dysphonia - glaucoma (with prolonged high doses) - hoarseness - hyperactivity (particularly in children) - hyperglycaemia (usually only with high doses) - irritability (particularly in children) - lower respiratory tract infections in older patients with chronic obstructive pulmonary disease (with high doses) - pneumonia in older patients with chronic obstructive pulmonary disease (with high doses) - reduced mineral bone density (with long-term treatment of high doses) - side-effects applicable to systemic corticosteroids may also apply if absorption occurs following inhaled use - sleep disturbances - throat irritation

SIDE-EFFECTS, FURTHER INFORMATION

Candidiasis The risk of oral candidiasis can be reduced by using a spacer device with the corticosteroid inhaler; rinsing the mouth with water after inhalation of a dose may also be helpful. An anti-fungal oral suspension or oral gel can be used to treat oral candidiasis without discontinuing corticosteroid therapy.

Paradoxical bronchospasm The potential for paradoxical bronchospasm (calling for discontinuation and alternative therapy) should be borne in mind—mild bronchospasm may be prevented by inhalation of a short-acting beta<sub>2</sub> agonist beforehand (or by transfer from an aerosol inhalation to a dry powder inhalation).

- **PREGNANCY** Inhaled drugs for asthma can be taken as normal during pregnancy.

Beclometasone dipropionate

Beclometasone dipropionate

**INDICATIONS AND DOSE**

**Prophylaxis of asthma**

**By inhalation of powder**

- Child 5–11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary
- Child 12–17 years: 200–400 micrograms twice daily; increased if necessary up to 800 micrograms twice daily, dose to be adjusted as necessary
- Adult: 200–400 micrograms twice daily; increased if necessary up to 800 micrograms twice daily, dose to be adjusted as necessary

**Asmabec clickhaler<sup>®</sup>**

**Prophylaxis of asthma**

**By inhalation of powder**

- Child 6–11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary
- Child 12–17 years: 100–400 micrograms twice daily (max. 1 mg twice daily), dose to be adjusted as necessary
- Adult: 100–400 micrograms twice daily (max. 1 mg twice daily), dose to be adjusted as necessary

**Clenil modulite<sup>®</sup>**

**Prophylaxis of asthma**

**By inhalation of powder**

- Child 2–11 years: 100–200 micrograms twice daily
- Child 12–17 years: 200–400 micrograms twice daily, adjusted according to response; increased if necessary up to 1 mg twice daily
- Adult: 200–400 micrograms twice daily, adjusted according to response; increased if necessary up to 1 mg twice daily

**Qvar preparations<sup>®</sup>**

**Prophylaxis of asthma**

**By inhalation of powder**

- Child 12–17 years: 50–200 micrograms twice daily; increased if necessary up to 400 micrograms twice daily
- Adult: 50–200 micrograms twice daily; increased if necessary up to 400 micrograms twice daily

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Inhaled corticosteroids for the treatment of chronic asthma in adults and children over 12 years (March 2008) NICE TA138

For adults and children over 12 years with chronic asthma in whom treatment with an inhaled corticosteroid is considered appropriate, the least costly product that is suitable for an individual (taking into consideration NICE TAs 38 and 10), within its marketing authorisation is recommended.

For adults and children over 12 years with chronic asthma in whom treatment with an inhaled corticosteroid and a long-acting beta<sub>2</sub> agonist is considered appropriate, the following apply:

- the use of a combination inhaler within its marketing authorisation is recommended as an option;
- the decision to use a combination inhaler or two agents in separate inhalers should be made on an individual basis, taking into consideration therapeutic need, and the likelihood of treatment adherence;
- if a combination inhaler is chosen, then the least costly inhaler that is suitable for the individual is recommended. www.nice.org.uk/TA138

**SIDE-EFFECTS**

- Breast feeding Inhaled corticosteroids for asthma can be taken as normal during breast-feeding.

- **RESPIRATORY SYSTEM**
### Preparing and dispensing information

The MHRA has advised (July 2008) that beclomethasone dipropionate CFC-free inhalers should be prescribed by brand name.

**Qvar® preparations**

When switching a patient with well-controlled asthma from another corticosteroid inhaler, initially a 100-microgram metered-dose of Qvar® should be prescribed for 200–250 micrograms of beclomethasone dipropionate or budesonide and for 100 micrograms of fluticasone propionate.

When switching a patient with poorly controlled asthma from another corticosteroid inhaler, initially a 100-microgram metered-dose of Qvar® should be prescribed for 100 micrograms of beclomethasone dipropionate, budesonide, or fluticasone propionate; the dose of Qvar® should be adjusted according to response.

**Patient and carer advice**

Steroid card should be issued with high doses of inhaled beclomethasone dipropionate.

**Profession specific information**

Dental practitioners’ formulary

Clenil Modulite® 50 micrograms/metered inhalation may be prescribed.

### Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation powder**

- **BECLOMETHASONE DIPROPIONATE (Non-proprietary)**
  - Beclomethasone dipropionate 200 microgram per 1 dose Easyhaler Beclomethasone 200 micrograms/dose dry powder inhaler | 200 dose (PO) £14.93
  - Brands may include Asmabec Clickhaler; Pulvinal (beclomethasone)

### Budesonide

#### Indications and dose

**Prophylaxis of asthma**

- **By inhalation of powder**
  - Child 6–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary
  - Child 12–17 years: 100–800 micrograms twice daily, dose to be adjusted as necessary
  - Adult: 100–800 micrograms twice daily, dose to be adjusted as necessary

- **By inhalation of nebulised suspension**
  - Child 6 months–11 years: 125–500 micrograms twice daily, adjusted according to response; maximum 2 mg per day
  - Child 12–17 years: Initially 0.25–1 mg twice daily, adjusted according to response, doses higher than recommended max. may be used in severe disease; maximum 2 mg per day
  - Adult: Initially 0.25–1 mg twice daily, adjusted according to response, doses higher than recommended max. may be used in severe disease; maximum 2 mg per day

**Prophylaxis of mild to moderate asthma (in patients stabilised on twice daily dose)**

- **By inhalation of powder**
  - Child 6–11 years: 200–400 micrograms once daily, dose to be given in the evening
  - Child 12–17 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening
  - Adult: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening

### Pressurised inhalation

**Cautionary and advisory labels 5, 10**

- **BECLOMETHASONE DIPROPIONATE (Non-proprietary)**
  - Beclomethasone dipropionate 50 microgram per 1 dose Beclomethasone 50 micrograms/dose inhaler CFC free | 200 dose (PO) no price available
  - Beclomethasone dipropionate 100 microgram per 1 dose Beclomethasone 100 micrograms/dose inhaler CFC free | 200 dose (PO) £54.20
  - Beclomethasone dipropionate 200 microgram per 1 dose Beclomethasone 200 micrograms/dose inhaler CFC free | 200 dose (PO) no price available
  - Clenil Modulite (Chiesi Ltd)
    - Beclomethasone dipropionate 50 microgram per 1 dose Clenil Modulite 50 micrograms/dose inhaler | 200 dose (PO) £7.42
    - Beclomethasone dipropionate 100 microgram per 1 dose Clenil Modulite 100 micrograms/dose inhaler | 200 dose (PO) £16.17
    - Beclomethasone dipropionate 200 microgram per 1 dose Clenil Modulite 200 micrograms/dose inhaler | 200 dose (PO) £16.29
  - Qvar (Teva UK Ltd)
    - Beclomethasone dipropionate 50 microgram per 1 dose Qvar 50 inhaler | 200 dose (PO) £7.87
    - Beclomethasone dipropionate 100 microgram per 1 dose Qvar 100 inhaler | 200 dose (PO) £17.21
  - Qvar Autohaler (Teva UK Ltd)
    - Beclomethasone dipropionate 50 microgram per 1 dose Qvar 50 Autohaler | 200 dose (PO) £7.87 DT price = £7.87
    - Beclomethasone dipropionate 100 microgram per 1 dose Qvar 100 Autohaler | 200 dose (PO) £17.21 DT price = £17.21
  - Qvar Easi-Breathe (Teva UK Ltd)
    - Beclomethasone dipropionate 50 microgram per 1 dose Qvar 50 micrograms/dose Easi-Breathe inhaler | 200 dose (PO) £16.95 DT price = £17.21

Also available in combination with formoterol, p. 229
Budesonide with formoterol

The properties listed below are those particular to the combination only. For the properties of the components please consider, budesonide p. 228, formoterol fumarate p. 220.

INDICATIONS AND DOSE
SYMBICORT 100/6 TURBOHALER®
Asthma, maintenance therapy
BY INHALATION OF POWDER
- Child 6-17 years: Initially 1–2 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained
- Adult: Initially 1–2 puffs twice daily, increased if necessary up to 4 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained

Asthma, maintenance and reliever therapy
BY INHALATION OF POWDER
- Adult: Maintenance 2 puffs daily in 1–2 divided doses; 1 puff as required for relief of symptoms, increased if necessary up to 6 puffs as required; max. 8 per day; up to 12 puffs daily can be used for a limited time but medical assessment should be considered

SYMBICORT 200/6 TURBOHALER®
Asthma maintenance therapy
BY INHALATION OF POWDER
- Child 12-17 years: Initially 1–2 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained
- Adult: Initially 1–2 puffs twice daily, increased if necessary up to 4 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained

Asthma, maintenance and reliever therapy
BY INHALATION OF POWDER
- Adult: Maintenance 2 puffs daily in 1–2 divided doses, increased if necessary to 2 puffs twice daily; 1 puff as required for relief of symptoms, increased if necessary up to 6 puffs as required; max. 8 puffs per day; up to 12 puffs daily can be used for a limited time but medical assessment should be considered

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted
BY INHALATION OF POWDER
- Adult: 2 puffs twice daily

SYMBICORT 400/12 TURBOHALER®
Asthma, maintenance therapy
BY INHALATION OF POWDER
- Child 12-17 years: Initially 1 puff twice daily; reduced to 1 puff daily, dose reduced only if control is maintained
- Adult: Initially 1 puff twice daily, increased if necessary up to 2 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted
BY INHALATION OF POWDER
- Adult: 1 puff twice daily

Budesonide with formoterol (Meda Pharmaceuticals Ltd)
Budesonide 200 microgram per 1 dose Budesonide 200 micrograms/dose inhalation powder 100 dose (£8.86 DT price = £11.84
Budesonide Novolizer 200 micrograms/dose inhalation powder refill 100 dose (£9.50

• Pulmicort Respules (AstraZeneca UK Ltd)
Budesonide 100 microgram per 1 dose Pulmicort 0.5mg Respules 20 unit dose (£26.42 DT price = £40.00
Budesonide 500 microgram per 1 dose Pulmicort 1mg Respules 20 unit dose (£40.00 DT price = £63.00

• Pulmicort Turbohaler (AstraZeneca UK Ltd)
Budesonide 100 microgram per 1 dose Pulmicort 100 Turbohaler 200 dose (£11.84 DT price = £11.84
Budesonide 200 microgram per 1 dose Pulmicort 200 Turbohaler 100 dose (£11.84 DT price = £11.84
Budesonide 400 microgram per 1 dose Pulmicort 400 Turbohaler 50 dose (£13.86 DT price = £13.86

BNF 70
Airways disease, obstructive 229
Respiratory system

PULMICORT® RESPULES
Prophylaxis of asthma
BY INHALATION OF NEBULISED SUSPENSION
- Child 3 months-11 years: Initially 0.5–1 mg twice daily, reduced to 250–500 micrograms twice daily
- Child 12-17 years: Initially 1–2 mg twice daily, reduced to 0.5–1 mg twice daily
- Adult: Initially 1–2 mg twice daily, reduced to 0.5–1 mg twice daily

BUDELIN NOVOLIZER®
Prophylaxis of asthma
BY INHALATION OF POWDER
- Adult: 200–800 micrograms twice daily, dose is adjusted as necessary
Alternative in mild to moderate asthma, for patients previously stabilised on a twice daily dose
BY INHALATION OF POWDER
- Adult: 200–400 micrograms once daily (max. per dose 800 micrograms), to be taken in the evening

PULMICORT® TURBOHALER
Prophylaxis of asthma
BY INHALATION OF POWDER
- Adult: 100–800 micrograms twice daily, dose to be adjusted as necessary
Alternative in mild to moderate asthma, for patients previously stabilised on a twice daily dose
BY INHALATION OF POWDER
- Adult: 200–400 micrograms once daily (max. per dose 800 micrograms), to be taken in the evening

Potency
Dose adjustments may be required for some inhaler devices, see under individual preparations.

DIRECTIONS FOR ADMINISTRATION
Budesonide nebuliser suspension is not suitable for use in ultrasonic nebulisers.

PATIENT AND CARER ADVICE
With high doses, a steroid card should be supplied. Patients or carers should be given advice on how to administer budesonide dry powder inhaler and nebuliser suspension.

Medicines for Children leaflet: Budesonide inhaler for asthma prevention (prophylaxis)
www.medicinesforchildren.org.uk/budesonide-inhaler-asthma-prevention-prophylaxis

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Nebuliser liquid
CAUTIONARY AND ADVISORY LABELS 8, 10
Budesonide 250 microgram per 1 ml Budesonide 500 micrograms/2ml nebuliser liquid unit dose vials 20 unit dose (£57.00 DT price = £26.42
Budesonide 500 microgram per 1 ml Budesonide 1mg/2ml nebuliser liquid unit dose vials 20 unit dose (£63.00 DT price = £40.00

Pulmicort Respules (AstraZeneca UK Ltd)
Budesonide 250 microgram per 1 ml Pulmicort 0.5mg Respules 20 unit dose (£26.42 DT price = £26.42
Budesonide 500 microgram per 1 ml Pulmicort 1mg Respules 20 unit dose (£40.00 DT price = £40.00

Inhalation powder
CAUTIONARY AND ADVISORY LABELS 8, 10
BUDELIN NOVOLIZER (Non-proprietary)
Budesonide 100 microgram per 1 dose Easyhaler Budesonide 100micrograms/dose dry powder inhaler 200 dose (£8.86 DT price = £11.84
Budesonide 200 microgram per 1 dose Easyhaler Budesonide 200micrograms/dose dry powder inhaler 200 dose (£11.84
Budesonide 400 microgram per 1 dose Easyhaler Budesonide 400micrograms/dose dry powder inhaler 100 dose (£17.71
**Respiratory system**

**INDICATIONS AND DOSE**

**Fluticasone**

**INDICATIONS AND DOSE**

**Prophylaxis of asthma**

BY INHALATION OF POWDER

- Child 5-15 years: Initially 50–100 micrograms twice daily (max. per dose 200 micrograms twice daily), dose to be adjusted as necessary
- Child 16-17 years: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist
- Adult: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist

BY INHALATION OF AEROSOL

- Child 4-15 years: Initially 50–100 micrograms twice daily (max. per dose 200 micrograms twice daily), dose to be adjusted as necessary
- Child 16-17 years: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist
- Adult: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist

BY INHALATION OF NEBULISED SUSPENSION

- Child 4-15 years: 1 mg twice daily
- Child 16-17 years: 0.5–2 mg twice daily
- Adult: 0.5–2 mg twice daily

**SIDE-EFFECTS**

- athralgia
- dyspepsia

**DIRECTIONS FOR ADMINISTRATION**

Fluticasone nebuliser liquid may be diluted with sterile sodium chloride 0.9%. It is not suitable for use in ultrasonic nebulisers.

**PATIENT AND CARER ADVICE**

With high doses, a steroid card should be supplied. Fluticasone inhaler for asthma prevention (prophylaxis) www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention

Patients or carers should be given advice on how to administer all fluticasone inhalation preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Pressurised inhalation**

CAUTIONARY AND ADVISORY LABELS 8

- Alvesco (Takeda UK Ltd)
- Ciclesonide 80 microgram per 1 dose Alvesco 80 inhaler | 120 dose (£32.83 DT price = £32.83
- Ciclesonide 160 microgram per 1 dose Alvesco 160 inhaler | 60 dose (£13.31 DT price = £13.31 | 120 dose (£38.62 DT price = £38.62

**Ciclesonide**

**INDICATIONS AND DOSE**

**Prophylaxis of asthma**

BY INHALATION OF AEROSOL

- Child 12-17 years: 160 micrograms once daily; reduced to 80 micrograms daily, if control maintained
- Adult: Initially 160 micrograms once daily; reduced to 80 micrograms once daily, if control maintained; increased if necessary up to 320 micrograms twice daily, in severe asthma

**SIDE-EFFECTS**

- Nausea
- Taste disturbance

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer fluticasone inhaler.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Pressurised inhalation**

CAUTIONARY AND ADVISORY LABELS 8

- Flutide Evohaler (GlaxoSmithKline Ltd)
  - Fluticasone propionate 50 microgram per 1 dose Flutide 50micrograms/dose Evohaler | 120 dose (£5.44 DT price = £5.44

**DUORESP SPIROMAX® 160MICROGRAMS/4.5MICROGRAMS**

**Asthma maintenance therapy**

BY INHALATION OF POWDER

- Adult: 1–2 inhalations twice daily, increased if necessary up to 4 inhalations twice daily

**INDICATIONS AND DOSE**

**DuoResp Spiromax** containing the same drug.

- Adult: Asthma maintenance therapy DUORESP SPIROMAX® BY INHALATION OF POWDER

**CAUTIONARY AND ADVISORY LABELS 8**

- Alvesco (Takeda UK Ltd)
- Ciclesonide 80 microgram per 1 dose Alvesco 80 inhaler | 120 dose (£32.83 DT price = £32.83
- Ciclesonide 160 microgram per 1 dose Alvesco 160 inhaler | 60 dose (£13.31 DT price = £13.31 | 120 dose (£38.62 DT price = £38.62

**Patient and carer advice**

With high doses, a steroid card should be supplied. Patient counselling is advised for budesonide with formoterol dry powder inhalation (administration).
**Fluticasone with formoterol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, Fluticasone p. 230, formoterol p. 229.

**INDICATIONS AND DOSE**

**FLUTIFORM® 50 MICROGRAMS/5 MICROGRAMS**

Fluticasone propionate 50 microgram per 1 dose, Formoterol fumarate dihydrate 5 microgram per 1 dose

**Prophylaxis of asthma**

By Inhalation of Aerosol

- Child 12-17 years: 2 puffs twice daily
- Adult: 2 puffs twice daily

**Flutiform® 125 MICROGRAMS/5 MICROGRAMS**

**Prophylaxis of asthma**

By Inhalation of Aerosol

- Child 12-17 years: 2 puffs twice daily
- Adult: 2 puffs twice daily

**Flutiform® 250 MICROGRAMS/10 MICROGRAMS**

**Prophylaxis of asthma**

By Inhalation of Aerosol

- Adult: 2 puffs twice daily

**PAtIENT AND CARER ADVICE** With high doses, a steroid card should be provided. Patients or carers should be given advice on how to administer fluticasone with formoterol aerosol inhalation.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Pressurised Inhalation**

Contraindicated for use in children under 12 years of age.

**Flutiform®**

- **Flutiform 50 microgram per 1 dose Flutiform 50micrograms/dose Accuhaler | 60 dose £9.68**
- **Flutiform 125 microgram per 1 dose Flutiform 125micrograms/dose Accuhaler | 60 dose £14.92**
- **Flutiform 250 microgram per 1 dose Flutiform 250micrograms/dose Accuhaler | 60 dose £21.26**

**Fluticasone with salmeterol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluticasone p. 230, salmeterol p. 222.

**INDICATIONS AND DOSE**

**SERETIDE 50 EVOHALER®**

Fluticasone propionate 250 microgram per 1 dose, Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose

**Prophylaxis of asthma**

By Inhalation of Aerosol

- Child 12-17 years: 2 puffs twice daily
- Adult: 2 puffs twice daily

**SERETIDE 125 EVOHALER®**

Fluticasone propionate 250 microgram per 1 dose, Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose

**Prophylaxis of asthma**

By Inhalation of Aerosol

- Child 12-17 years: 2 puffs twice daily
- Adult: 2 puffs twice daily

**SERETIDE 250 ACCUHALER®**

Fluticasone propionate 500 microgram per 1 dose, Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose

**Prophylaxis of asthma**

By Inhalation of Powder

- Child 5-17 years: 1 inhalation twice daily, reduced to 1 inhalation daily, reduce dose if control maintained
- Adult: 1 inhalation twice daily, reduced to 1 inhalation daily, reduce dose if control maintained

**SERETIDE 500 ACCUHALER®**

Fluticasone propionate 1000 microgram per 1 dose, Salmeterol (as Salmeterol xinafoate) 50 microgram per 1 dose

**Prophylaxis of asthma**

By Inhalation of Powder

- Child 12-17 years: 1 inhalation twice daily
- Adult: 1 inhalation twice daily

**SERETIDE 750 ACCUHALER®**

Fluticasone propionate 1250 microgram per 1 dose, Salmeterol (as Salmeterol xinafoate) 50 microgram per 1 dose

**Prophylaxis of asthma**

By Inhalation of Powder

- Child 12-17 years: 1 inhalation twice daily
- Adult: 1 inhalation twice daily

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 60% of predicted

- Adult: 1 inhalation twice daily

**PATIENT AND CARER ADVICE** With preparations containing greater than 100 micrograms fluticasone, a steroid card should be provided. Patients or carers should be given advice on how to administer fluticasone with salmeterol dry powder inhalation and aerosol inhalation.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2008) that Salmeterol 50 microgram should not be recommended for use within NHS Scotland for chronic obstructive pulmonary disease in patients with a forced expiratory volume in 1 second (FEV1) less than 60% and greater than 50% of the predicted normal value, with significant symptoms despite regular bronchodilator therapy and a history of repeated exacerbations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Pressurised Inhalation**

Contraindicated for use in children under 12 years of age.

**Fluticasone with SALMETEROL (Non-proprietary)**

Fluticasone propionate 125 microgram per 1 dose, Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose

Sirdupa
Respiratory system

Fluticasone with vilanterol

Dose equivalence and conversion

Fluticasone with vilanterol

PROPHYLAXIS OF ASTHMA

Adult: 1 inhalation once daily

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 70% of predicted

Prophylaxis of asthma

BY INHALATION OF POWDER

Child 12-17 years: 1 inhalation once daily

Adult: 1 inhalation once daily

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 70% of predicted

Prophylaxis of asthma

BY INHALATION OF POWDER

Child 12-17 years: 1 inhalation once daily

Adult: 1 inhalation once daily

Dose equivalence and conversion

1 inhalation (delivered dose) of fluticasone furoate 92 micrograms once daily is approximately equivalent to fluticasone propionate 250 micrograms twice daily.

1 inhalation (delivered dose) of fluticasone furoate 184 micrograms once daily is approximately equivalent to fluticasone propionate 500 micrograms twice daily.

INDICATIONS AND DOSE

Fluticasone furoate 92 microgram per 1 dose, Vilanterol 22 microgram per 1 dose

Relvar Ellipta® 92 microgram / 22 microgram

Prophylaxis of asthma

BY INHALATION OF POWDER

Child 12-17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained

Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained

Prophylaxis of severe asthma

BY INHALATION OF POWDER

Child 12-17 years: Increased if necessary up to 400 micrograms twice daily

Adult: Increased if necessary up to 400 micrograms twice daily

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2014) that fluticasone furoate/vilanterol (Relvar Ellipta®) is accepted for restricted use within NHS Scotland in patients with severe chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV₁) less than 50% of the predicted normal value.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Inhalation powder

CAUTIONARY AND ADVISORY LABELS 8, 10

Mometasone furoate

INDICATIONS AND DOSE

Prophylaxis of asthma

BY INHALATION OF POWDER

Child 12-17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained

Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained

Prophylaxis of severe asthma

BY INHALATION OF POWDER

Child 12-17 years: Increased if necessary up to 400 micrograms twice daily

Adult: Increased if necessary up to 400 micrograms twice daily

SIDE-EFFECTS

Abdominal pain • back pain

PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING

Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT

Max. dose fluticasone furoate 92 micrograms, vilanterol 22 micrograms.

RELVAR ELLIPTA® 184 microgram / 22 microgram

Avoid in moderate to severe impairment.

PATIENT AND CARER ADVICE

A steroid card should be provided. Patients or carers should be given advice on how to administer fluticasone with vilanterol powder for inhalation.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (November 2003) that Asmanex® is restricted for use following failure of first-line inhaled corticosteroids.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Inhalation powder

CAUTIONARY AND ADVISORY LABELS 8, 10

Asmanex Twilighter® (Merck Sharpe & Dohme Ltd)

Mometasone furoate 200 microgram per 1 dose

Asmanex® 200 micrograms/dose twilighter 200 micrograms/dose Twilighter 30 dose £15.70 DT price = £15.70 60 dose £15.70 DT price = £31.40

Mometasone furoate 400 microgram per 1 dose

Asmanex® 400 micrograms/dose twilighter 30 dose £21.78 DT price = £21.78 60 dose £36.05 DT price = £36.05

Mometasone furoate 90 microgram / 18 microgram

Prophylaxis of asthma

BY INHALATION OF POWDER

Child 12-17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained

Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained

Prophylaxis of severe asthma

BY INHALATION OF POWDER

Child 12-17 years: Increased if necessary up to 400 micrograms twice daily

Adult: Increased if necessary up to 400 micrograms twice daily

SIDE-EFFECTS

Common or very common

Headache

Uncommon

Dyspepsia • palpitation • weight gain

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Mometasone furoate inhaler for asthma prevention (prophylaxis) www.medicinesforchildren.org.uk/mometasone-furoate-inhaler-for-asthma-prevention-prophylaxis

Patients or carers should be given advice on how to administer mometasone by inhaler. With high doses, a steroid card should be supplied.
LEUKOTRIENE RECEPTOR ANTAGONISTS

Leukotriene receptor antagonist

The leukotriene receptor antagonists, montelukast below and zafirlukast below, block the effects of cysteinyl leukotrienes in the airways. They are effective in asthma when used alone or with an inhaled corticosteroid.

Montelukast below has not been shown to be more effective than a standard dose of inhaled corticosteroid, but the two drugs appear to have an additive effect. The leukotriene receptor antagonists may be of benefit in exercise-induced asthma and in those with concomitant rhinitis, but they are less effective in those with severe asthma who are also receiving high doses of other drugs.

Montelukast

**INDICATIONS AND DOSE**

**Prophylaxis of asthma**

**BY MOUTH**

- Child 6 months–5 years: 4 mg once daily, dose to be taken in the evening
- Child 6–14 years: 5 mg once daily, dose to be taken in the evening
- Child 15–17 years: 10 mg once daily, dose to be taken in the evening
- Adult: 10 mg once daily, dose to be taken in the evening

**Symptomatic relief of seasonal allergic rhinitis in patients with asthma.**

**BY MOUTH**

- Child 15–17 years: 10 mg once daily, dose to be taken in the evening
- Adult: 10 mg once daily, dose to be taken in the evening

**INTERACTIONS**  → Appendix 1 (leukotriene receptor antagonists).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain • headache • hyperkinesia (in young children) • thirst
- **Uncommon** Abnormal dreams • aggressive behaviour • agitation • anxiety • arthralgia • bruising • depression • dizziness • drowsiness • dry mouth • dyspepsia • epistaxis • hostility • hypoaesthesia • irritability • malaise • muscle cramps • myalgia • oedema • paraesthesia • psychomotor hyperactivity • restlessness • seizures • sleep disturbances • sleep-walking
- **Rare** Disturbance in attention • increased bleeding tendency • memory impairment • palpitation • tremor
- **Very rare** Churg–Strauss syndrome • disorientation • erythema multiforme • erythema nodosum • hallucinations • hepatic disorders • hepatic eosinophilic infiltration • suicidal behaviour • suicidal thoughts

**SIDE-EFFECTS, FURTHER INFORMATION**

Churg–Strauss syndrome has occurred very rarely in association with the use of montelukast; in many of the reported cases the reaction followed the reduction or withdrawal of oral corticosteroid therapy. Prescribers should be alert to the development of eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, or peripheral neuropathy.

**PREGNANCY**

Manufacturer advises avoid unless essential.

**BREAST FEEDING**

Manufacturer advises avoid unless essential.

**DIRECTIONS FOR ADMINISTRATION**

Granules may be swallowed or mixed with cold, soft food (not liquid) and taken immediately.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of chewable tablet formulations may include cherry.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Montelukast for asthma www.medicinesforchildren.org.uk/montelukast-for-asthma Patients or carers should be given advice on how to administer montelukast granules.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2007) that Singulair® chewable tablets are restricted for use as an alternative to low-dose inhaled corticosteroids for children 2–14 years with mild persistent asthma who have not recently had serious asthma attacks that required oral corticosteroid use and who are not capable of using inhaled corticosteroids; Singulair® chewable tablets should be initiated by a specialist in paediatric asthma.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **MONTELUKAST (Non-proprietary)**
  - Montelukast (as Montelukast sodium) 10 mg Montelukast tablets | 28 tablet (P) £26.97 DT price = £2.20
  - Singulair (Merck Sharp & Dohme Ltd)
  - Montelukast (as Montelukast sodium) 10 mg Singulair 10 mg tablets | 28 tablet (P) £26.97 DT price = £2.20

**Chewable tablet**

CAUTIONARY AND ADVISORY LABELS 23, 24

**EXCIPIENTS:** May contain Aspartame

- **MONTELUKAST (Non-proprietary)**
  - Montelukast (as Montelukast sodium) 4 mg Montelukast 4 mg chewable tablets sugar free (sugar-free) | 28 tablet (P) £25.69 DT price = £1.18
  - Singulair (Merck Sharp & Dohme Ltd)
  - Montelukast (as Montelukast sodium) 4 mg Singulair Paediatric 4 mg chewable tablets (sugar-free) | 28 tablet (P) £25.69 DT price = £1.90
  - Montelukast (as Montelukast sodium) 5 mg Singulair Paediatric 5 mg chewable tablets (sugar-free) | 28 tablet (P) £25.69 DT price = £2.18

**Granules**

- **MONTELUKAST (Non-proprietary)**
  - Montelukast (as Montelukast sodium) 4 mg Montelukast 4 mg granules sachets sugar free (sugar-free) | 28 sachet (P) £4.25–£24.41 DT price = £4.25
  - Singulair (Merck Sharp & Dohme Ltd)
  - Montelukast (as Montelukast sodium) 4 mg Singulair Paediatric 4 mg granules sachets (sugar-free) | 28 sachet (P) £25.69 DT price = £4.25

Zafirlukast

**INDICATIONS AND DOSE**

**Prophylaxis of asthma**

**BY MOUTH**

- Child 12–17 years: 20 mg twice daily
- Adult: 20 mg twice daily

**CAUTIONS**

Elderly

**INTERACTIONS** → Appendix 1 (leukotriene receptor antagonists).
Respiratory system

usualy 3 could probably be given for in practice, it is difficult to predict who will benefit; they may be of value in asthma with an allergic basis, but, nedocromil sodium below is not completely understood.

The mode of action of sodium cromoglicate below and nedocromil sodium below is not completely understood.

Cromoglicate and related therapy

The mode of action of sodium cromoglicate below and nedocromil sodium below is not completely understood. They may be of value in asthma with an allergic basis, but, in practice, it is difficult to predict who will benefit; they could probably be given for 4 to 6 weeks to assess response. Dose frequency is adjusted according to response but is usually 3 to 4 times a day initially; this may subsequently be reduced.

In general, prophylaxis with sodium cromoglicate is less effective than prophylaxis with corticosteroid inhalations. There is evidence of efficacy of nedocromil sodium in children aged 5–12 years. Sodium cromoglicate and nedocromil sodium are of no value in the treatment of acute attacks of asthma.

Sodium cromoglicate can prevent exercise-induced asthma. However, exercise-induced asthma may reflect poor overall control and the patient should be reassessed.

Sodium cromoglicate below and nedocromil sodium below may also have a role in allergic conjunctivitis; sodium cromoglicate is used also in allergic rhinitis and allergy-related diarrhoea.

Nedocromil sodium

INDICATIONS AND DOSE

Prophylaxis of asthma

BY INHALATION OF AEROSOL

Child 5–17 years: Initially 4 mg 4 times a day, when control achieved may be possible to reduce to twice daily

Adult: Initially 4 mg 4 times a day, when control achieved may be possible to reduce to twice daily

Dose equivalence and conversion

2 puffs = 4 mg.
MONOCLONAL ANTIBODIES

Omalizumab

INDICATIONS AND DOSE

Prophylaxis of severe persistent allergic asthma

BY SUBCUTANEOUS INJECTION

• Adult: Dose according to immunoglobulin E concentration and body-weight (consult product literature)

Add-on therapy for chronic spontaneous urticaria in patients who have had an inadequate response to H1 antihistamine treatment

BY SUBCUTANEOUS INJECTION

• Adult: 300 mg every 4 weeks

● CAUTIONS

• Autoimmune disease - susceptibility to helminth infection—discontinue if infection does not respond to antihelmintic

● SIDE-EFFECTS

• Common or very common Abdominal pain - arthralgia - headache - injection-site reactions - pyrexia - sinusitis - upper respiratory tract infection


• Rare Angioedema - antibody formation - laryngoedema - parasitic infection

• Frequency not known Alopecia - arterial thromboembolic events - Churg-Strauss syndrome - joint swelling - myalgia - serum sickness (including fever and lymphadenopathy) - thrombocytopenia

SIDE-EFFECTS, FURTHER INFORMATION

Churg-Strauss syndrome Churg-Strauss syndrome has occurred rarely in patients given omalizumab; the reaction is usually associated with the reduction of oral corticosteroid therapy. Churg-Strauss syndrome can present as eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, or peripheral neuropathy. Hypersensitivity reactions Hypersensitivity reactions can also occur immediately following treatment with omalizumab or sometimes more than 24 hours after the first injection.

● PREGNANCY

Manufacturer advises avoid unless essential—crosses the placenta.

● BREAST FEEDING

Manufacturer advises avoid—present in milk in animal studies.

● HEPATIC IMPAIRMENT

Manufacturer advises caution—no information available.

● RENAL IMPAIRMENT

Manufacturer advises caution—no information available.

● NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

• Omalizumab for previously treated chronic spontaneous urticaria (June 2015) NICE TA339

Omalizumab is an option as add-on therapy for the treatment of severe chronic spontaneous urticaria in patients 12 years and over, only if:

• the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more,

• the patient’s condition has not responded to standard treatment with H1-antihistamines and leukotriene receptor antagonists,

• omalizumab is stopped at or before the fourth dose if the condition has not responded,
Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in patients aged 6 years and over:

- who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year), and
- only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme.

Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta agonists, leukotriene receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate.

Patients currently receiving omalizumab whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA278

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (December 2014) that omalizumab (Xolair®) is accepted for restricted use within NHS Scotland for the treatment of chronic spontaneous urticaria in patients aged 12 years and over, who have had an inadequate response to combination therapy with H1-antihistamines, leukotriene receptor antagonists and H2-antihistamines, used according to current treatment guidelines.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Xolair (Novartis Pharmaceuticals UK Ltd)
  - Omalizumab 150 mg per 1 ml Xolair 150mg/1ml solution for injection pre-filled syringes | 1 pre-filled disposable injection £256.15
  - Xolair 75mg/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection £128.07

**PHOSPHODIESTERASE TYPE-4 INHIBITORS**
Roflumilast

**DRUG ACTION**
Roflumilast is a phosphodiesterase type–4 inhibitor with anti-inflammatory properties.

**INDICATIONS AND DOSE**
Adjunct to bronchodilators for the maintenance treatment of patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations

**BY MOUTH**
- Adult: 500 micrograms once daily

**CONTRA-INDICATIONS**
Cancer (except basal cell carcinoma) • concomitant treatment with immunosuppressive drugs (except short-term systemic corticosteroids) • history of depression associated with suicidal ideation or behaviour • moderate to severe cardiac failure • severe acute infective disease • severe immunological disease

**CAUTIONS**
History of psychiatric illness (discontinue if new or worsening psychiatric symptoms occur) • latent infection (such as tuberculosis, viral hepatitis, herpes infection)

**INTERACTIONS**
Caution with concomitant use of drugs likely to cause psychiatric events (discontinue if new or worsening psychiatric symptoms occur).
Appendix 1 (roflumilast).

**SIDE-EFFECTS**
- Common or very common Abdominal pain • decreased appetite • diarrhoea • headache • insomnia • nausea • weight loss
- Uncommon Anxiety • back pain • dizziness • dyspepsia • gastritis • gastro-oesophageal reflux • malaise • muscle spasm • myalgia • palpitation • rash • tremor • vertigo • vomiting
- Rare Constipation • depression • gynaecomastia • haematochæzia • nervousness • raised creatine kinase • respiratory tract infections • suicidal behaviour • suicidal ideation • taste disturbances • urticaria

- **CONCEPTION AND CONTRACEPTION** Women of child-bearing age should use effective contraception.

- **PREGNANCY** Manufacturer advises avoidance — toxicity in animal studies.

- **BREAST FEEDING** Manufacturer advises avoidance — present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Caution in mild impairment. Avoid in moderate to severe impairment.

- **MONITORING REQUIREMENTS** Monitor body-weight.

- **PATIENT AND CARER ADVICE** Patients should be given a patient card before starting treatment and advised to record body-weight at regular intervals.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **NICE technology appraisals (TAs)**
  - Roflumilast for the management of severe chronic obstructive pulmonary disease (January 2012) NICE TA244
  Roflumilast is recommended only in the context of research as part of a clinical trial for adults with severe chronic obstructive pulmonary disease associated with chronic bronchitis with a history of frequent exacerbations as an add-on to bronchodilator treatment. Patients receiving roflumilast should have the option to continue treatment until they and their clinicians consider it appropriate to stop. www.nice.org.uk/TA244

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Daxas (Takeda UK Ltd)
  - Roflumilast 500 microgram Daxas 500microgram tablets | 30 tablet | £37.71
  - By mouth
  - Adult: 15–60 mg 3 times a day

**Ephedrine hydrochloride**

**INDICATIONS AND DOSE**
Reversible airflow obstruction

**BY MOUTH**
- Adult: 15–60 mg 3 times a day

**Neuropathic oedema**

**BY MOUTH**
- Adult: 30–60 mg 3 times a day
Ephedrine hydrochloride (Non-proprietary)  
Solution for injection

- **Ephedrine hydrochloride 3 mg per 1 ml**  
  Ephedrine 30mg/1ml solution for injection ampoules | 10 ampoules [£3.10]

- **Ephedrine hydrochloride 15 mg**  
  Ephedrine hydrochloride 15mg tablets | 28 tablet [£5.86-£6.38] DT price = £5.86

- **Ephedrine hydrochloride 30 mg**  
  Ephedrine hydrochloride 30mg tablets | 28 tablet [£4.87-£5.43] DT price = £4.87

**INDICATIONS AND DOSE**

**Severe acute asthma**

**By intravenous infusion**
- Child 1 month-11 years: 1 mg/kg/hour, adjusted according to plasma-theophylline concentration
- Child 12-17 years: 500–700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration
- Adult: 500–700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration

**By slow intravenous injection**
- Adult: 250–500 mg (max. per dose 5 mg/kg), to be followed by intravenous infusion

**Severe acute exacerbation of chronic obstructive pulmonary disease**

**By intravenous infusion**
- Adult: 500–700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration
- Elderly: 300 micrograms/kg/hour, adjusted according to plasma-theophylline concentration

**Severe acute exacerbation of chronic obstructive pulmonary disease in patients not previously treated with theophylline**

**By slow intravenous injection**
- Adult: 5 mg/kg (max. per dose 500 mg), to be followed by intravenous infusion

**Chronic asthma**

**By mouth using modified-release medicines**
- Child (body-weight 40 kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration

**By mouth using modified-release medicines**
- Adult (body-weight 40 kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration

**PHYLLOCONTIN CONTINUS® FORTE**

**Reversible airways obstruction**

**By mouth using modified-release medicines**
- Adult: Initially 350 mg twice daily for 1 week, then increased if necessary to 700 mg twice daily, increase dose according to plasma-theophylline concentration

**Dose adjustments due to interactions**

Dose adjustment may be necessary if smoking started or stopped during treatment.

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal weight for height.

**PHARMACOKINETICS**

Aminophylline is a stable mixture or combination of theophylline and ethylenediamine; the ethylenediamine confers greater solubility in water. Theophylline is metabolised in the liver. The plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. The plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in **continued**
If aminophylline is given intravenously, a blood sample should usually be taken 1123 hours after starting oral treatment. For specific details on the management of poisoning, see Appendix 1 (aminophylline).

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hypokalaemia** Potentially serious hypokalaemia may result from beta, agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.

**Overdose** Theophylline and related drugs are often prescribed as modified-release formulations and toxicity can therefore be delayed. They cause vomiting (which may be severe and intractable), agitation, restlessness, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemesis, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly. For specific details on the management of poisoning, see Theophylline, under Emergency treatment of poisoning p. 1123.

**ALLERGY AND CROSS-SENSITIVITY** Allergy to ethylenediamine can cause urticaria, erythema, and exfoliative dermatitis.

**PREGNANCY** Neonatal irritability and apnoea have been reported. Theophylline can be taken as normal during pregnancy as it is particularly important that asthma should be well controlled during pregnancy.

**BREAST FEEDING** Present in milk—irritability in infant reported; modified-release preparations preferable. Theophylline can be taken as normal during breast-feeding.

**HEPATIC IMPAIRMENT** Reduce dose.

**MONITORING REQUIREMENTS**

- Aminophylline is monitored therapeutically in terms of plasma-theophylline concentrations. Measurement of plasma-theophylline concentration may be helpful and is essential if a loading dose of intravenous aminophylline is to be given to children who are already taking theophylline, because serious side-effects such as convulsions and arrhythmias can occasionally precede other symptoms of toxicity. In most individuals, a plasma-theophylline concentration of 10–20 mg/litre (55–110 micromol/litre) is required for satisfactory bronchodilation, although a lower plasma-theophylline concentration of 5–15 mg/litre may be effective. Adverse effects can occur within the range 10–20 mg/litre and both the frequency and severity increase at concentrations above 20 mg/litre.
- If aminophylline is given intravenously, a blood sample should be taken 4–6 hours after starting treatment.
- Plasma-theophylline concentration is measured 5 days after starting oral treatment and at least 3 days after any dose adjustment. A blood sample should usually be taken 4–6 hours after an oral dose of a modified-release preparation (sampling times may vary—consult local guidelines).

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children For intravenous infusion, dilute to a concentration of 1 mg/mL with Glucose 5% or Sodium Chloride 0.9%.
- With intravenous use in adults For intravenous infusion, give continuously in Glucose 5% or Sodium Chloride 0.9%. For intravenous injection, give very slowly over at least 20 minutes (with close monitoring).
- With intramuscular use Aminophylline is too irritant for intramuscular use.

**PRESCRIBING AND DISPENSING INFORMATION**

Patients taking oral theophylline or aminophylline should not normally receive a loading dose of intravenous aminophylline. Consider intravenous aminophylline for treatment of severe and life-threatening acute asthma only after consultation with senior medical staff.

Modified release: The rate of absorption from modified-release preparations can vary between brands. If a prescription for a modified-release oral aminophylline preparation does not specify a brand name, the pharmacist should contact the prescriber and agree the brand to be dispensed. Additionally, it is essential that a patient discharged from hospital should be maintained on the brand on which that patient was stabilised as an in-patient. Phyllocontin Continus® Forte tablets are for smokers and other patients where theophylline half-life is shorter.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion, suppository.

Modified-release tablet

| CAUTIONARY AND ADVISORY LABELS 25 |
| AMINOPHYLLINE (Non-proprietary) |
| Aminophylline hydrate 225 mg | Aminophylline hydrate 225mg modified-release tablets | 56 tablet | no price available |
| Phyllocontin Continus (Napp Pharmaceuticals Ltd) |
| Aminophylline hydrate 225 mg | Phyllocontin Continus 225mg tablets | 56 tablet | £2.40 |
| Aminophylline hydrate 350 mg | Phyllocontin Forte Continus 350mg tablets | 56 tablet | £4.22 |

**Solution for injection**

| AMINOPHYLLINE (Non-proprietary) |
| Aminophylline 25 mg per 1 ml | Aminophylline 250mg/10ml solution for injection ampoules | 10 ampoule | £6.51 OT price = £6.51 |

## Theophylline

### INDICATIONS AND DOSE

**NUELIN SA® 175MG TABLETS**

**Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 6–11 years: 125–250 mg every 12 hours
  - Child 12–17 years: 250–500 mg every 12 hours

**Reversible airways obstruction | Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 250–500 mg every 12 hours
UNIPHPhyllIN Continus®

Chronic asthma

BY MOUTH USING MODIFIED-RELEASE MEDICINES

▶ Child 2–11 years: 9 mg/kg every 12 hours (max. per dose 200 mg), dose may be increased in some children with chronic asthma to 10–16 mg/kg every 12 hours (max. per dose 400 mg), may be appropriate to give larger evening or morning dose to achieve optimum therapeutic effect when symptoms most severe; in patients whose night or daytime symptoms persist despite other therapy, who are not currently receiving theophylline, total daily requirement may be added as single evening or morning dose

▶ Child 12–17 years: 200 mg every 12 hours, adjusted according to response to 400 mg every 12 hours, may be appropriate to give larger evening or morning dose to achieve optimum therapeutic effect when symptoms most severe; in patients whose night or daytime symptoms persist despite other therapy, who are not currently receiving theophylline, total daily requirement may be added as single evening or morning dose

Reversible airways obstruction | Chronic asthma

BY MOUTH USING MODIFIED-RELEASE MEDICINES

▶ Adult: 200 mg every 12 hours, adjusted according to response to 400 mg every 12 hours, may be appropriate to give larger evening or morning dose to achieve optimum therapeutic effect when symptoms most severe; in patients whose night or daytime symptoms persist despite other therapy, who are not currently receiving theophylline, total daily requirement may be added as single evening or morning dose

SLO-PHyllIN®

Chronic asthma

BY MOUTH USING MODIFIED-RELEASE MEDICINES

▶ Adult: 200–500 mg every 12 hours

PHARMACOKINETICS

Theophylline is metabolised in the liver. The plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. The plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in the half-life of theophylline are important because the toxic dose is close to the therapeutic dose.

• CAUTIONS Cardiac arrhythmias or other cardiac disease • elderly (increased plasma-theophylline concentration) • epilepsy • fever • hypertension • hyperthyroidism • peptic ulcer - risk of hypokalaemia

• INTERACTIONS → Appendix 1 (theophylline).

• SIDE-EFFECTS Arrhythmias • CNS stimulation • convulsions • diarrhoea • gastric irritation • headache • insomnia • nausea • palpitation • tachycardia • vomiting

• SIDE-EFFECTS, FURTHER INFORMATION

Hypokalaemia Potentially serious hypokalaemia may result from beta, agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.

• Overdose Theophylline in overdose can cause vomiting (which may be severe and intractable), agitation, restlessness, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemeses, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly. For details on the management of poisoning, see Theophylline, under Emergency treatment of poisoning p. 1123.

• PREGNANCY Neonatal irritability and apnoea have been reported. Theophylline can be taken as normal during pregnancy as it is particularly important that asthma should be well controlled during pregnancy.

• BREAST FEEDING Present in milk—irritability in infant reported; modified-release preparations preferable. Theophylline can be taken as normal during breast-feeding.

• HEPATIC IMPAIRMENT Reduce dose.

• MONITORING REQUIREMENTS

▶ In most individuals, a plasma-theophylline concentration of 10–20 mg/litre (55–110 micromol/litre) is required for satisfactory bronchodilatation, although a lower plasma-theophylline concentration of 5–15 mg/litre may be effective. Adverse effects can occur within the range 10–20 mg/litre and both the frequency and severity increase at concentrations above 20 mg/litre.

▶ Plasma-theophylline concentration is measured 5 days after starting oral treatment and at least 3 days after any dose adjustment. A blood sample should usually be taken 4–6 hours after an oral dose of a modified-release preparation (sampling times may vary—consult local guidelines).

• DIRECTIONS FOR ADMINISTRATION

SLO-PHYLLIN® Swallow whole with fluid or swallow enclosed granules with soft food (e.g. yoghurt). Contents of the capsule (enteric-coated granules) may be sprinkled on to a spoonful of soft food (e.g. yoghurt) and swallowed without chewing.

• PRESCRIBING AND DISPENSING INFORMATION The rate of absorption from modified-release preparations can vary between brands. If a prescription for a modified-release oral theophylline preparation does not specify a brand name, the pharmacist should contact the prescriber and agree the brand to be dispensed. Additionally, it is essential that a patient discharged from hospital should be maintained on the brand on which that patient was stabilised as an in-patient.

• PATIENT AND CARER ADVICE

SLO-PHyllIN® Patient or carer should be given advice on how to administer theophylline modified release capsules.

• MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 21, 25

▶ Nuélin SA (Meda Pharmaceuticals Ltd)

Theophylline 175 mg Nuélin SA175mg tablets | 60 tablet £6.38 DT price = £6.38

Theophylline 250 mg Nuélin SA 250 tablets | 60 tablet £8.92 DT price = £8.92

▶ Uniphyllin Continus (Napp Pharmaceuticals Ltd)

Theophylline 200 mg Uniphyllin Continus 200mg tablets | 56 tablet £2.96

Theophylline 300 mg Uniphyllin Continus 300mg tablets | 56 tablet £4.77

Theophylline 400 mg Uniphyllin Continus 400mg tablets | 56 tablet £5.65 DT price = £5.65

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 25

▶ Slo-Phyllin (Merck Serono Ltd)

Theophylline 60 mg Slo-Phyllin 60mg capsules | 56 capsule £2.76 DT price = £2.76
Nebuliser solutions
Also see sodium chloride p. 851

- **HYPERTONIC SODIUM CHLORIDE SOLUTIONS**

**INDICATIONS AND DOSE**

**MUCOCLEAR® 3%**
Mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis)

By Inhalation of Nebulised Solution

- Adult: 4 mL 2–4 times a day, temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction may occur; an inhaled bronchodilator can be used before treatment to reduce the risk of these adverse effects

- Mucoclear 3% inhalation solution 4ml ampoules (Pari Medical Ltd) | 20 ampoule • NHS indicative price = £12.98 • Drug Tariff (Part IXa) | 60 ampoule • NHS indicative price = £27.00 • Drug Tariff (Part IXa)

**INDICATIONS AND DOSE**

**MUCOCLEAR® 6%**
Mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis)

By Inhalation of Nebulised Solution

- Adult: 4 mL twice daily, temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction may occur; an inhaled bronchodilator can be used before treatment to reduce the risk of these adverse effects

- Mucoclear 6% inhalation solution 4ml ampoules (Pari Medical Ltd) | 20 ampoule • NHS indicative price = £12.98 • Drug Tariff (Part IXa) | 60 ampoule • NHS indicative price = £27.00 • Drug Tariff (Part IXa)

**INDICATIONS AND DOSE**

**NEBUSAL®**
Mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis)

By Inhalation of Nebulised Solution

- Adult: 4 mL up to twice daily, temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction may occur; an inhaled bronchodilator can be used before treatment to reduce the risk of these adverse effects

- Nebusal 7% inhalation solution 4ml vials (Forest Laboratories UK Ltd) | 60 vial • NHS indicative price = £27.00 • Drug Tariff (Part IXa)

**Peak flow meters**

- **LOW RANGE PEAK FLOW METERS**
  Compliant to standard EN ISO 23747:2007 except for scale range.

  **MEDI® LOW RANGE**
  Range 40–420 litres/minute.

  - Medi peak flow meter low range (Medicareplus International Ltd) | 1 device • NHS indicative price = £6.50 • Drug Tariff (Part IXa) price £6.50

  **MINI-WRIGHT® LOW RANGE**
  Range 30–400 litres/minute.

  - Medi peak flow meter low range (Medicareplus International Ltd) | 1 device • NHS indicative price = £6.50 • Drug Tariff (Part IXa) price £6.50

  **POCKETPEAK® LOW RANGE**
  Range 50–400 litres/minute.

  - nSpire Pocket Peak peak flow meter low range (nSpire Health Ltd) | 1 device • NHS indicative price = £6.53 • Drug Tariff (Part IXa) price £6.50

  **STANDARD RANGE PEAK FLOW METERS**

  **AIRZONE®**
  Range 60–720 litres/minute.

  - AirZone peak flow meter standard range (Clement Clarke International Ltd) | 1 device • NHS indicative price = £4.69 • Drug Tariff (Part IXa) price £4.50

  **MEDI® STANDARD RANGE**
  Range 60–800 litres/minute.

  - Medi peak flow meter standard range (Medicareplus International Ltd) | 1 device • NHS indicative price = £4.50 • Drug Tariff (Part IXa) price £4.50

  **MICROPEAK®**
  Range 60–900 litres/minute.

  - MicroPeak peak flow meter standard range (Micro Medical Ltd) | 1 device • NHS indicative price = £6.50 • Drug Tariff (Part IXa) price £6.50

  **MINI-WRIGHT® STANDARD RANGE**
  Range 60–800 litres/minute.

  - Mini-Wright peak flow meter standard range (Clement Clarke International Ltd) | 1 device • NHS indicative price = £7.08 • Drug Tariff (Part IXa) price £7.08

  **PIKO®**
  Range 15–999 litres/minute.

  - nSpire Pik-1 peak flow meter standard range (nSpire Health Ltd) | 1 device • NHS indicative price = £9.50 • Drug Tariff (Part IXa) price £9.50

  **PINNACLE®**
  Range 60–900 litres/minute.

  - Fyne Dynamics Pinnacle peak flow meter standard range (Fyne Dynamics Ltd) | 1 device • NHS indicative price = £6.50 • Drug Tariff (Part IXa) price £6.50

  **POCKETPEAK® STANDARD RANGE**
  Range 60–800 litres/minute.

  - nSpire Pocket Peak peak flow meter standard range (nSpire Health Ltd) | 1 device • NHS indicative price = £6.53 • Drug Tariff (Part IXa) price £6.50

  **VITALOGRAPH®**
  Range 50–800 litres/minute.

  - Vitalograph peak flow meter standard range (Vitalograph Ltd) | 1 device • NHS indicative price = £4.83 • Drug Tariff (Part IXa) price £4.83

**Spacers**

- **SPACERS**
  For use with all pressurised (aerosol) inhalers.

  - A2A Spacer (Clement Clarke International Ltd) | 1 device • NHS indicative price = £4.15 • Drug Tariff (Part IXa)

  - A2A Spacer with medium mask (Clement Clarke International Ltd) | 1 device • NHS indicative price = £6.68 • Drug Tariff (Part IXa)

  - A2A Spacer with small mask (Clement Clarke International Ltd) | 1 device • NHS indicative price = £6.68 • Drug Tariff (Part IXa)

  **ABLE SPACER®**
  Small-volume device. For use with all pressurised (aerosol) inhalers.

  - Able Spacer (Clement Clarke International Ltd) | 1 device • NHS indicative price = £4.39 • Drug Tariff (Part IXa)

  - Able Spacer with medium mask (Clement Clarke International Ltd) | 1 device • NHS indicative price = £7.16 • Drug Tariff (Part IXa)

  - Able Spacer with small mask (Clement Clarke International Ltd) | 1 device • NHS indicative price = £7.16 • Drug Tariff (Part IXa)

  **AEROCHAMBER PLUS®**
  Medium-volume device. For use with all pressurised (aerosol) inhalers.

  - AeroChamber Plus (GlaxoSmithKline UK Ltd) | 1 device • NHS indicative price = £4.79 • Drug Tariff (Part IXa)

  - AeroChamber Plus with adult mask (GlaxoSmithKline UK Ltd) | 1 device • NHS indicative price = £7.99 • Drug Tariff (Part IXa)

  - AeroChamber Plus with child mask (GlaxoSmithKline UK Ltd) | 1 device • NHS indicative price = £7.99 • Drug Tariff (Part IXa)
Allergic conditions 241

2 Allergic conditions

Antihistamines, allergen immunotherapy and allergic emergencies

Antihistamines

All antihistamines are of potential value in the treatment of nasal allergies, particularly seasonal allergic rhinitis (hayfever), and they may be of some value in vasomotor rhinitis. They reduce rhinorrhea and sneezing but are usually less effective for nasal congestion. Antihistamines are used topically in the eye, in the nose, and on the skin.

Oral antihistamines are also of some value in preventing urticaria and are used to treat urticarial rashes, pruritus, and insect bites and stings; they are also used in drug allergies. Injections of chlorphenamine maleate p. 245 or promethazine hydrochloride p. 251 are used as an adjunct to adrenaline/epinephrine p. 136 in the emergency treatment of anaphylaxis and angioedema. Antihistamines (including cinnarizine p. 342, cyclizine p. 343, and promethazine teoclolate p. 252) may also have a role in nausea and vomiting. Buclizine is included as an anti-emetic in a preparation for migraine. Antihistamines may also have a role in occasional insomnia.

All older antihistamines cause sedation but alimemazine tartrate p. 243 and promethazine may be more sedating whereas chlorphenamine maleate and cyclizine may be less so. This sedating activity is sometimes used to manage the pruritus associated with some allergies. There is little evidence that any one of the older, ‘sedating’ antihistamines is superior to another and patients vary widely in their response.

Non-sedating antihistamines such as acrivastine p. 243, bilastine p. 244, cetirizine hydrochloride p. 244, desloratadine p. 247 (an active metabolite of loratadine p. 250), fexofenadine hydrochloride p. 247 (an active metabolite of terfenadine), levocetirizine hydrochloride p. 249 (an isomer of cetirizine hydrochloride), loratadine, and mizolastine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

Allergic immunotherapy

Immunotherapy using allergen vaccines containing house dust mite, animal dander (cat or dog), or extracts of grass and tree pollen can reduce symptoms of asthma and allergic rhinoconjunctivitis. A vaccine containing extracts of wasp and bee venom is used to reduce the risk of severe anaphylaxis and systemic reactions in individuals with hypersensitivity to wasp and bee stings. An oral preparation of grass pollen extract (Grazax®) is also licensed for disease-modifying treatment of grass pollen-induced rhinitis and conjunctivitis. Those requiring immunotherapy must be referred to a hospital specialist for accurate diagnosis, assessment, and treatment.

Omalizumab p. 235 is a monoclonal antibody that binds to immunoglobulin E (IgE). It is used as additional therapy in individuals with proven IgE-mediated sensitivity to inhaled allergens, whose severe persistent allergic asthma cannot be controlled adequately with high dose inhaled corticosteroid together with a long-acting beta, agonist. Omalizumab should be initiated by physicians in specialist centres experienced in the treatment of severe persistent asthma. Omalizumab is also indicated as add-on therapy for the treatment of chronic spontaneous urticaria in patients who have had an inadequate response to H1 antihistamine treatment.
Allergic emergencies

Anaphylaxis

Anaphylaxis is a severe, life-threatening, generalised or systemic hypersensitivity reaction. It is characterised by the rapid onset of respiratory and/or circulatory problems and is usually associated with skin and mucosal changes; prompt treatment is required. Patients with pre-existing asthma, especially poorly controlled asthma, are at particular risk of life-threatening reactions. Insect stings are a recognised risk (in particular wasp and bee stings). Latex and certain foods, including eggs, fish, cow’s milk protein, peanuts, sesame, shellfish, soy, and tree nuts may also precipitate anaphylaxis. Medicinal products particularly associated with anaphylaxis include blood products, vaccines, hyposensitising (allergen) preparations, antibacterials, aspirin and other NSAIDs, and neuromuscular blocking drugs. In the case of drugs, anaphylaxis is more likely after parenteral administration; resuscitation facilities must always be available for injections associated with special risk. Anaphylactic reactions may also be associated with additives and excipients in foods and medicines. Refined arachis (peanut) oil, which may be present in some medicinal products, is unlikely to cause an allergic reaction—nevertheless it is wise to check the full formula of preparations which may contain allergens.

Treatment of anaphylaxis

Adrenaline/epinephrine p. 196 provides physiological reversal of the immediate symptoms associated with hypersensitivity reactions such as anaphylaxis and angioedema.

First-line treatment includes:

- securing the airway, restoration of blood pressure (laying the patient flat and raising the legs, or in the recovery position if unconscious or nauseous and at risk of vomiting);
- administering adrenaline/epinephrine (by intramuscular injection in a dose of 500 micrograms (a dose of 300 micrograms may be appropriate for immediate self-administration); the dose should be repeated if necessary at 5-minute intervals according to blood pressure, pulse, and respiratory function. Patients receiving beta-blockers require special consideration;
- administering high-flow oxygen and intravenous fluids is also of primary importance;
- administering an antihistamine, such as chlorphenamine maleate, by slow intravenous injection or intramuscular injection is a useful adjunctive treatment, given after adrenaline.
- Administering an intravenous corticosteroid such as hydrocortisone p. 583 (preferably as sodium succinate) is of secondary value in the initial management of anaphylaxis because the onset of action is delayed for several hours, but should be given to prevent further deterioration in severely affected patients.

Continuing respiratory deterioration requires further treatment with bronchodilators including inhaled or intravenous salbutamol p. 222, inhaled ipratropium bromide p. 217, intravenous aminophylline p. 237, or intravenous magnesium sulfate p. 858 [unlicensed indication] (as for acute severe asthma); in addition to oxygen, assisted respiration and possibly emergency tracheotomy may be necessary.

When a patient is so ill that there is doubt about the adequacy of the circulation, the initial injection of adrenaline/epinephrine may need to be given as a dilute solution by the intravenous route.

Cardiopulmonary arrest may follow an anaphylactic reaction; resuscitation should be started immediately.

On discharge, patients should be considered for further treatment with an oral antihistamine and an oral corticosteroid for up to 3 days to reduce the risk of further reaction. Patients should be instructed to return to hospital if symptoms recur and to contact their general practitioner for follow-up.

Patients who are suspected of having had an anaphylactic reaction should be referred to a specialist for specific allergy diagnosis. Avoidance of the allergen is the principal treatment; if appropriate, an adrenaline/epinephrine auto-injector should be given for self-administration or a replacement supplied.

Intramuscular adrenaline (epinephrine)

The intramuscular route is the first choice route for the administration of adrenaline/epinephrine in the management of anaphylaxis. Adrenaline/epinephrine is best given as an intramuscular injection into the anterolateral aspect of the middle third of the thigh; it has a rapid onset of action after intramuscular administration and in the shocked patient its absorption from the intramuscular site is faster and more reliable than from the subcutaneous site.

Patients with severe allergy should be instructed in the self-administration of adrenaline/epinephrine by intramuscular injection.

Prompt injection of adrenaline/epinephrine is of paramount importance. The adrenaline/epinephrine doses recommended for the emergency treatment of anaphylaxis by appropriately trained healthcare professionals are based on the revised recommendations of the Working Group of the Resuscitation Council (UK).

Dose of intramuscular injection of adrenaline (epinephrine) for the emergency treatment of anaphylaxis by healthcare professionals

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Volume of adrenaline 1 in 1000 (1 mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child under 6 years</td>
<td>150 micrograms</td>
<td>0.15 mL¹</td>
</tr>
<tr>
<td>Child 6-11 years</td>
<td>300 micrograms</td>
<td>0.3 mL</td>
</tr>
<tr>
<td>Child 12-17 years</td>
<td>500 micrograms</td>
<td>0.5 mL²</td>
</tr>
<tr>
<td>Adult</td>
<td>500 micrograms</td>
<td>0.5 mL</td>
</tr>
</tbody>
</table>

These doses may be repeated several times if necessary at 5-minute intervals according to blood pressure, pulse, and respiratory function.

1. Use suitable syringe for measuring small volume
2. 300 micrograms (0.3 mL) if child is small or prepubertal

Intravenous adrenaline (epinephrine)

Intravenous adrenaline/epinephrine p. 196 should be given only by those experienced in its use, in a setting where patients can be carefully monitored.

When the patient is severely ill and there is real doubt about the adequacy of the circulation and absorption after intramuscular injection, adrenaline/epinephrine can be given by slow intravenous injection repeated according to response; if multiple doses are required, adrenaline/epinephrine should be given as a slow intravenous infusion stopping when a response has been obtained.

It is important that, where intramuscular injection might still succeed, time should not be wasted seeking intravenous access.

The intravenous route is also used for cardiac resuscitation.

Angioedema

Angioedema is dangerous if laryngeal oedema is present. In this circumstance adrenaline/epinephrine injection and oxygen should be given as described under Anaphylaxis; antihistamines and corticosteroids should also be given. Tracheal intubation may be necessary.
Hereditary angioedema
The treatment of hereditary angioedema should be under specialist supervision. Unlike allergic angioedema, adrenaline/epinephrine, corticosteroids, and antihistamines should not be used for the treatment of acute attacks, including attacks involving laryngeal oedema, as they are ineffective and may delay appropriate treatment—intubation may be necessary. The administration of C1-esterase inhibitor p. 255, an endogenous complement blocker derived from human plasma, (in fresh frozen plasma or in partially purified form) can terminate acute attacks of hereditary angioedema; it can also be used for short-term prophylaxis before dental, medical or surgical procedures. Conestat alfa p. 255 and icatibant p. 255 are licensed for the treatment of acute attacks of hereditary angioedema in adults with C1-esterase inhibitor deficiency.

Tranexamic acid p. 95 and danazol p. 636 [unlicensed indication] are used for short-term and long-term prophylaxis of hereditary angioedema. Short-term prophylaxis with tranexamic acid or danazol is started several days before planned procedures (e.g. dental work) and continued for 2–5 days afterwards. Danazol should be avoided in children because of its androgenic effects.

**ANTIHISTAMINES**

Acrivastine

**INDICATIONS AND DOSE**

Symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria

**BY MOUTH**

- Child 12-17 years: 8 mg 3 times a day
- Adult: 8 mg 3 times a day

- CONTRA-INDICATIONS Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe) - elderly

- CAUTIONS Epilepsy

- INTERACTIONS → Appendix 1 (antihistamines). Sedative antihistamine interactions apply to a lesser extent to the non-sedating antihistamines.

- SIDE-EFFECTS

  - Uncommon Antimuscarinic effects - gastro-intestinal disturbances - headache - psychomotor impairment
  - Rare Anaphylaxis - angioedema - angle-closure glaucoma (in adults) - arrhythmias - blood disorders - bronchospasm - confusion - convulsions - depression - dizziness - extrapyramidal effects - hypersensitivity reactions - hypotension - liver dysfunction - palpitation - photosensitivity reactions - rashes - sleep disturbances - tremor
  - Frequency not known Blurred vision - drowsiness - dry mouth - urinary retention

**SIDE-EFFECTS, FURTHER INFORMATION**

Non-sedating antihistamines such as acrivastine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent. If drowsiness occurs, it may diminish after a few days of treatment. Children and the elderly are more susceptible to side-effects.

- ALLERGY AND CROSS-SENSITIVITY Contraindicated if history of hypersensitivity to triprolidine.

- PREGNANCY Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

- BREAST FEEDING Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- RENAL IMPAIRMENT Avoid in severe impairment.

- PATIENT AND CARER ADVICE Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); excess alcohol should be avoided.

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- Benadryl Allergy Relief (McNeil Products Ltd)
  - Acrivastine 8 mg Benadryl Allergy Relief 8mg capsules I
  - 12 capsule £2.91 DT price = £2.91 | 24 capsule P £4.95

Alimemazine tartrate

(Trimethazine tartrate)

**INDICATIONS AND DOSE**

Urticaria | Pruritus

**BY MOUTH**

- Child 2-4 years: 2.5 mg 3–4 times a day
- Child 5-11 years: 5 mg 3–4 times a day
- Child 12-17 years: 10 mg 2–3 times a day, in severe cases up to maximum daily dose has been used; maximum 100 mg per day
- Adult: 10 mg 2–3 times a day, in severe cases up to maximum daily dose has been used; maximum 100 mg per day
- Elderly: 10 mg 1–2 times a day

- CONTRA-INDICATIONS Epilepsy - hepatic dysfunction - history of narrow angle glaucoma - hypothyroidism - many antihistamines should be avoided in Acute porphyrias p. 864 but alimemazine is thought to be safe - myasthenia gravis - parkinson’s disease - phaeochromocytoma - prostatic hypertrophy - renal dysfunction

- CAUTIONS Cardiovascular diseases (due to tachycardia-inducing and hypotensive effects of phenothiazines) - elderly - exposure to sunlight should be avoided during treatment with high doses - pyloroduodenal obstruction - urinary retention - volume depleted patients who are more susceptible to orthostatic hypotension

- INTERACTIONS → Appendix 1 (antihistamines).

- SIDE-EFFECTS

  - Rare Anaphylaxis - angioedema - bronchospasm - hypersensitivity reactions
  - Frequency not known Acute dystonia - agitation - agranulocytosis - akathisia - akinesia - angle-closure glaucoma - anti-muscarinic effects - arrhythmias (may be predisposed by hypokalaemia and cardiac disease) - blurred vision - contact sensitisation - convulsions - drowsiness - dry mouth - dyskinesia - gastro-intestinal disturbances - headache - hyperprolactinaemia - hypotension - insomnia - jaundice - leukopenia (on prolonged high dose) - nasal stuffiness - neuroleptic malignant syndrome - ocular changes - pallor (in children) - paradoxical excitement - parkinsonism - photosensitivity - postural hypotension (in elderly) - postural hypotension (in volume depletion) - rashes - respiratory depression - rigidity - tardive dyskinesia (usually after prolonged high doses) - tremor - urinary retention

**SIDE-EFFECTS, FURTHER INFORMATION**

Patients on high dosage may develop photosensitivity and should avoid exposure to direct sunlight. Children and the elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days.
of treatment and is considerably less of a problem with the
newer antihistamines.

- **PREGNANCY** Most manufacturers of antihistamines advise
avoiding their use during pregnancy; however, there is no
evidence of teratogenicity. Use in the latter part of the
third trimester may cause adverse effects in neonates
such as irritability, paradoxical excitability, and tremor.

- **BREAST FEEDING** Most antihistamines are present in
breast milk in varying amounts; although not known to be
harmful, most manufacturers advise avoiding their use in
mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—
increased risk of coma.

- **RENAL IMPAIRMENT** Avoid.

- **PATIENT AND CARER ADVICE** Although drowsiness is rare,
nevertheless patients should be advised that it can occur
and may affect performance of skilled tasks (e.g. cycling
or driving); alcohol should be avoided.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral solution

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 2**
- **ALIMEMAZINE TARTRATE (Non-proprietary)**
  - **Alimemazine tartrate 10 mg** Alimemazine 10mg tablets | 25 tablet [P</n>]
  - **no price available** | 28 tablet [P</n>]
  - **£17.95 DT price = £6.27**

**Oral solution**

- **CAUTIONARY AND ADVISORY LABELS 2**
- **ALIMEMAZINE TARTRATE (Non-proprietary)**
  - **Alimemazine tartrate 1.5 mg per 1 ml** Alimemazine 7.5mg/5ml
  - **oral solution | 100 ml [P</n>]
  - **£28.00 DT price = £14.36**
  - **Alimemazine tartrate 6 mg per 1 ml** Alimemazine 30mg/5ml oral
  - **solution | 100 ml [P</n>]
  - **£72.75 DT price = £41.88**

**Bilastine**

**INDICATIONS AND DOSE**

Symptomatic relief of allergic rhinoconjunctivitis and
urticaria

**BY MOUTH**

- **Child 2-17 years**: 20 mg once daily
- **Adult**: 20 mg once daily

**CONTRA-INDICATIONS** Avoid in Acute porphyrias p. 864
(some antihistamines are thought to be safe)

**CAUTIONS** Epilepsy

**INTERACTIONS** → Appendix 1 (antihistamines).
Sedative antihistamine interactions apply to a lesser
extent to the non-sedating antihistamines.

**SIDE-EFFECTS**

- **Common or very common** Headache • malaise

- **Uncommon** Abdominal pain • anxiety • diarrhoea •
dizziness • dyspnoea • gastritis • increased appetite •
insomnia • oral herpes • prolongation of the QT interval •
pyrexia • thirst • tinnitus • vertigo • weight gain

**SIDE-EFFECTS, FURTHER INFORMATION**

Children and the elderly are more susceptible to side-
effects. Non-sedating antihistamines such as bilastine cause less
sedation and psychomotor impairment than the older
antihistamines because they penetrate the blood brain
barrier only to a slight extent.

- **PREGNANCY** Avoid—limited information available. Most
manufacturers of antihistamines advise avoiding their use
during pregnancy; however, there is no evidence of
teratogenicity.
Chlorphenamine maleate

**INDICATIONS AND DOSE**

Symptomatic relief of allergy such as hay fever, urticaria, food allergy, drug reactions. Relief of itch associated with chickenpox

**BY MOUTH**

- **Child 12-23 months:** 1 mg twice daily
- **Child 2-5 years:** 1 mg every 4–6 hours; maximum 6 mg per day
- **Child 6-11 years:** 2 mg every 4–6 hours; maximum 12 mg per day
- **Child 12-17 years:** 4 mg every 4–6 hours; maximum 24 mg per day
- **Adult:** 4 mg every 4–6 hours; maximum 24 mg per day
- **Elderly:** 4 mg every 4–6 hours; maximum 12 mg per day

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**

- **Child 1-5 months:** 250 micrograms/kg (max. per dose 2.5 mg), repeated if necessary; maximum 4 doses per day
- **Child 6 months-5 years:** 2.5 mg, repeated if necessary; maximum 4 doses per day
- **Child 6-11 years:** 5 mg, repeated if necessary; maximum 4 doses per day

**PROFESSION SPECIFIC INFORMATION**

**Dental practitioners’ formulary**

Cetirizine Tablets 10 mg may be prescribed. Cetirizine Oral Solution 5 mg/5 mL may be prescribed.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CETIRIZINE HYDROCHLORIDE (Non-proprietary)**
  - Cetirizine hydrochloride 10 mg Cetirizine 10mg tablets | 7 tablet blister strip [P] £1.40 | 30 tablet blister strip [P] £3.07 DT price + £1.07
  - 30 tablet [P] £8.29 DT price + £1.07
  - Brands may include Pollenshield; Zirtek

**Capsule**

- Benadryl Allergy (McNeil Products Ltd)
  - Cetirizine hydrochloride 10 mg Benadryl Allergy Liquid Release 10mg capsules | 7 capsule [P] £2.91 DT price + £1.91

**Oral solution**

**EXCIPIENTS:** May contain Propylene glycol

- **CETIRIZINE HYDROCHLORIDE (Non-proprietary)**
  - Cetirizine hydrochloride 1 mg per 1 ml Cetirizine 1mg/ml oral solution sugar free (sugar-free) | 200 ml [P] £0.79 (sugar-free) | 200 ml [P] £1.40 DT price + £1.79
  - Brands may include Benadryl Allergy; Zirtek

**SIDE-EFFECTS**

- Rare: Anaphylaxis - angioedema - angle-closure glaucoma in adults)
- Very common: arrhythmias - bronchospasm - confusion - convulsions - depression - dizziness - extrapyramidal effects - hypersensitivity reactions - hypotension - liver dysfunction - palpitation - photosensitivity reactions - sleep disturbances - tremor
- Frequency not known: Antimuscarinic effects - blood disorders - exfoliative dermatitis - rashes - tinnitus

**SPECIFIC SIDE-EFFECTS**

- **With intramuscular use:** CNS stimulation - irritant effects - transient hypotension
- **With intravenous use:** CNS stimulation - irritant effects - transient hypotension

**SIDE-EFFECTS, FURTHER INFORMATION**

Children and the elderly are more susceptible to side-effects.

Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

**PREGNANCY**

Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

**BREAST FEEDING**

Most antihistamines are present in breast milk in varying amounts; although not known to be

---

**RENAL IMPAIRMENT**

- **In adults** Use half normal dose if eGFR 30–50 mL/minute/1.73 m². Use half normal dose and reduce dose frequency to alternate days if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².
- **In children** Use half normal dose if estimated glomerular filtration rate 30–50 mL/minute/1.73 m². Use half normal dose and reduce dose frequency to alternate days if estimated glomerular filtration rate 10–30 mL/minute/1.73 m². Avoid if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**PATIENT AND CARER ADVICE**

Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

Medicines for Children leaflet: Cetirizine hydrochloride for hay fever www.medicinesforchildren.org.uk/cetirizine-hay-fever-0

**INTERACTIONS**

- Emergency treatment of anaphylactic reactions
  - By intramuscular injection or by intravenous injection
    - **Child 1-5 months:** 250 micrograms/kg (max. per dose 2.5 mg), repeated if necessary; maximum 4 doses per day
    - **Child 6 months-5 years:** 2.5 mg, repeated if necessary; maximum 4 doses per day
    - **Child 6-11 years:** 5 mg, repeated if necessary; maximum 4 doses per day
    - **Child 12-17 years:** 10 mg, repeated if necessary; maximum 4 doses per day
    - **Adult:** 10 mg, repeated if necessary; maximum 4 doses per day

**LICENSED USE**

- Tablets not licensed for use in children under 6 years.

**CONTRA-INDICATIONS**

Many antihistamines should be avoided in Acute porphyrias (p. 864) but chlorphenamine is thought to be safe

**CAUTIONS**

- Epilepsy - prostatic hypertrophy - pyloroduodenal obstruction - susceptibility to angle-closure glaucoma - urinary retention

**SIDE-EFFECTS**

- **GENERAL SIDE-EFFECTS**
  - Common or very common: Blurred vision - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - urinary retention
  - Rare: Anaphylaxis - angioedema - angle-closure glaucoma in adults)

**FURTHER INFORMATION**

Children under 6 years should not be given over-the-counter cough and cold medicines containing chlorphenamine.
harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

- **DIRECTIONS FOR ADMINISTRATION**
  - In children For intravenous injection, give over 1 minute; if small dose required, dilute with Sodium Chloride 0.9%.

- **PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g., cycling or driving); sedating effects enhanced by alcohol.

  - **CAUTIONS**
    - Medicines for Children leaflet: Chlorphenamine maleate for allergy symptoms www.medicinesforchildren.org.uk/
    - Chlorphenamine-maleate-allergy-symptoms-0

- **PROFESSION SPECIFIC INFORMATION**
  - Dental practitioners’ formulary Chlorphenamine tablets may be prescribed. Chlorphenamine oral solution may be prescribed.
  - **EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply to chlorphenamine injection where administration is for saving life in emergency.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution
  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 2
      - Chlorphenamine maleate 4 mg Chlorphenamine 4mg tablets | 28 tablet | £1.38 DT price = £0.96 | 30 tablet | no price available
      - Brands may include Hayleve; Piriton; Pollenase (chlorphenamine); Cyproheptadine hydrochloride
    - **Solution for injection**
      - CHLORPHENAMINE MALEATE (Non-proprietary)
        - Chlorphenamine maleate 400 microgram per 1 ml Chlorphenamine 2mg/5ml oral solution sugar free (sugar-free) | 150 ml | £2.85 DT price = £1.87
        - Brands may include Hayleve; Piriton
    - **Solution for injection**
      - CHLORPHENAMINE MALEATE (Non-proprietary)
        - Chlorphenamine maleate 10 mg per 1 ml Chlorphenamine 10mg/1ml solution for injection ampoules | 5 ampoule | no price available

- **Cyproheptadine hydrochloride**

  - **INDICATIONS AND DOSE**
    - Symptomatic relief of allergy such as hay fever, urticaria | Pruritus
    - **BY MOUTH**
      - Adult: 4 mg 3 times a day, usual dose 4–20 mg daily; maximum 32 mg per day

  - **CONTRA-INDICATIONS** Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe)

  - **CAUTIONS** Epilepsy | prostatic hypertrophy | pyloroduodenal obstruction | susceptibility to angle-closure glaucoma | urinary retention

  - **INTERACTIONS** → Appendix 1 (antihistamines).

  - **SIDE-EFFECTS**
    - Rare Anaphylaxis | angioedema | angle-closure glaucoma | arrhythmias | blood disorders | bronchospasm | confusion | convulsions | depression | diziness | extrapyramidal effects | hypersensitivity reactions | hypotension | liver dysfunction | palpitation | photosensitivity reactions | rashes | sleep disturbances | tremor
    - **FREQUENCY not known** Antimuscarinic effects | blurred vision | drowsiness | dry mouth | gastro-intestinal disturbances | headache | psychomotor impairment | urinary retention

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

  - **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

  - **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

  - **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

  - **PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving); sedating effects enhanced by alcohol.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 2
      - Tavegil (Novartis Consumer Health UK Ltd) Clemastine (as Clemastine hydrofumarate) 1 mg Tavegil 1mg tablets | 60 tablet | £5.00 DT price = £5.00

- **Clemastine**

  - **INDICATIONS AND DOSE**
    - Symptomatic relief of allergy such as hay fever, urticaria | Pruritus
    - **BY MOUTH**
      - Adult: 1 mg twice daily, increased if necessary up to 6 mg daily

  - **CONTRA-INDICATIONS** Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe)

  - **CAUTIONS** Epilepsy | prostatic hypertrophy | pyloroduodenal obstruction | susceptibility to angle-closure glaucoma | urinary retention

  - **INTERACTIONS** → Appendix 1 (antihistamines).

  - **SIDE-EFFECTS**
    - Rare Anaphylaxis | angioedema | angle-closure glaucoma | arrhythmias | blood disorders | bronchospasm | confusion | convulsions | depression | diziness | extrapyramidal effects | hypersensitivity reactions | hypotension | liver dysfunction | palpitation | photosensitivity reactions | rashes | sleep disturbances | tremor

  - **FREQUENCY not known** Antimuscarinic effects | blurred vision | drowsiness | dry mouth | gastro-intestinal disturbances | headache | psychomotor impairment | urinary retention

  - **SIDE-EFFECTS, FURTHER INFORMATION**
    - Elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

  - **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the
third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

- **PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving); sedating effects enhanced by alcohol.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

  **Tablet**

  CAUTIONARY AND ADVISORY LABELS

  Adult: 30 mg twice daily

  Child 6–11 years: 15 mg twice daily

  Child 12–17 years: 30 mg once daily

  Adult: 25 mg once daily

  **PHARMACOKINETICS**

  Desloratadine is a metabolite of loratadine.

- **CAUTIONS** Acute porphyrias p. 864; epilepsy

- **INTERACTIONS** → Appendix 1 (antihistamines). Sedative antihistamine interactions apply to a lesser extent to the non-sedating antihistamines.

- **SIDE-EFFECTS**

  - **Uncommon** Antimuscarinic effects - blurred vision - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - urinary retention

  - **Rare** Anaphylaxis - angioedema - angle-closure glaucoma (in adults) - arrhythmias - blood disorders - bronchospasm - confusion - convulsions - depression - dizziness - extrapyramidal effects - hypersensitivity reactions - hypotension - liver dysfunction - myalgia - palpitation - photosensitivity reactions - rashes - sleep disturbances - tremor

  - **Very rare** Hallucinations

  - **Frequency not known** Drowsiness

  **SIDE-EFFECTS, FURTHER INFORMATION**

  Children and the elderly are more susceptible to side-effects. Non-sedating antihistamines such as desloratadine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent. If drowsiness occurs, it may diminish after a few days of treatment.

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated if history of hypersensitivity to loratadine.

- **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **RENAL IMPAIRMENT** Use with caution in severe impairment.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include bubblegum.

- **PATIENT AND CARER ADVICE** Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. driving or cycling); excess alcohol should be avoided.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **DESLORATADINE (Non-proprietary)**
  - Desloratadine 5 mg Desloratadine 5mg tablets | 30 tablet £1.77
  - Neoclarityn (Merck Sharp & Dohme Ltd) Desloratadine 5 mg Neoclarityn 5mg tablets | 30 tablet £6.77
  - DT price = £1.77

- **Oral solution**
  - EXCIPIENTS: May contain Propylene glycol, sorbitol
  - DESLORATADINE (Non-proprietary)
  - Desloratadine 500 microgram per 1 ml Desloratadine 2.5mg/5ml oral solution sugar free (sugar-free) | 100 ml £6.77
  - Neoclarityn (Merck Sharp & Dohme Ltd) Desloratadine 500 microgram per 1 ml Neoclarityn 2.5mg/5ml oral solution (sugar-free) | 100 ml £6.77
  - DT price = £10.15

**Fexofenadine hydrochloride**

**INDICATIONS AND DOSE**

Symptomatic relief of seasonal allergic rhinitis

**BY MOUTH**

- Child 6–11 years: 30 mg twice daily
- Child 12–17 years: 120 mg once daily
- Adult: 120 mg once daily

Symptomatic relief of chronic idiopathic urticaria

**BY MOUTH**

- Child 12–17 years: 180 mg once daily
- Adult: 180 mg once daily

**PHARMACOKINETICS**

Fexofenadine is a metabolite of terfenadine.

- **CAUTIONS** Epilepsy

- **INTERACTIONS** → Appendix 1 (antihistamines). Sedative antihistamine interactions apply to a lesser extent to the non-sedating antihistamines.

- **SIDE-EFFECTS**

  - **Uncommon** Antimuscarinic effects - blurred vision - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - urinary retention

  - **Rare** Anaphylaxis - angioedema - angle-closure glaucoma (in adults) - arrhythmias - blood disorders - bronchospasm - confusion - convulsions - depression - dizziness - extrapyramidal effects - hypersensitivity reactions - hypotension - liver dysfunction - myalgia - palpitation - photosensitivity reactions - rashes - sleep disturbances - tremor

  - **Frequency not known** Drowsiness

  **SIDE-EFFECTS, FURTHER INFORMATION**

  Children and the elderly are more susceptible to side-effects. Non-sedating antihistamines such as fexofenadine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent. If drowsiness occurs, it may diminish after a few days of treatment.

- **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.
Hydroxyzine hydrochloride

INDICATIONS AND DOSE

Pruritus

**BY MOUTH**

- Child 1-5 years: Initially 5–15 mg once daily, dose to be taken at night, increased if necessary to 50 mg daily in 3–4 divided doses
- Child 6-11 years: Initially 15–25 mg once daily, dose to be taken at night, increased if necessary to 50–100 mg daily in 3–4 divided doses
- Child 12-17 years: Initially 25 mg once daily, dose to be taken at night, increased if necessary to 100 mg daily in 3–4 divided doses
- Adult: Initially 25 mg daily, dose to be taken at night; increased if necessary to 25 mg 3–4 times a day

**Important safety information**

**HYDROXYZINE: RISK OF QT-INTERVAL PROLONGATION AND TORSADE DE POINTES (APRIL 2015)**

Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.

To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:

- Hydroxyzine is contra-indicated in patients with prolonged QT-interval or who have risk factors for QT-interval prolongation;
- Avoid use in the elderly due to increased susceptibility to the side-effects of hydroxyzine;
- Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;
- In adults, the maximum daily dose is 100 mg;
- In the elderly, the maximum daily dose is 50 mg (if use of hydroxyzine cannot be avoided);
- In children with body-weight up to 40 kg, the maximum daily dose is 2 mg/kg;
- The lowest effective dose for the shortest period of time should be prescribed.

**CONTRA-INDICATIONS**

- Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe)

**CAUTIONS**

- Epilepsy • prostatic hypertrophy • pyloroduodenal obstruction • susceptibility to angle-closure glaucoma • susceptibility to QT interval prolongation • urinary retention

**INTERACTIONS**

- β-blockers and tricyclic antidepressants may increase the potential for cardiac toxicity
- Drowsiness may be enhanced by alcohol
- Alcohol should be avoided.

**SIDE-EFFECTS**

- Rare Anaphylaxis • angioedema • angle-closure glaucoma • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • palpitation • photosensitivity reactions • rashes • sleep disturbances - tremor
- Frequency not known Antimuscarinic effects - blurred vision - drowsiness - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - urinary retention

SIDE-EFFECTS, FURTHER INFORMATION

Children and the elderly are more susceptible to side-effects.

Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

**PREGNANCY**

- Most manufacturers of antihistamines advise avoiding their use during pregnancy; toxicity in animal studies with higher doses. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

**BREAST FEEDING**

- Manufacturer advises avoid. Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

**HEPATIC IMPAIRMENT**

- Reduce daily dose by one-third. Avoid in severe liver disease—increased risk of coma.

**RENAL IMPAIRMENT**

- Reduce daily dose by half.

**PATIENT AND CARER ADVICE**

- Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer</th>
<th>Form</th>
<th>Price</th>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 mg</td>
<td>Hydroxyzine hydrochloride 25 mg</td>
<td>tablet</td>
<td>£18</td>
<td>50 mg</td>
<td>daily</td>
</tr>
<tr>
<td>50 mg</td>
<td>Hydroxyzine hydrochloride 50 mg</td>
<td>tablet</td>
<td>£22</td>
<td>100 mg</td>
<td>daily</td>
</tr>
<tr>
<td>100 mg</td>
<td>Hydroxyzine hydrochloride 100 mg</td>
<td>tablet</td>
<td>£28</td>
<td>200 mg</td>
<td>daily</td>
</tr>
</tbody>
</table>

**Suspension**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer</th>
<th>Form</th>
<th>Price</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg/ml</td>
<td>Hydroxyzine hydrochloride 10 mg/ml</td>
<td>suspension</td>
<td>£14</td>
<td>100 ml</td>
</tr>
<tr>
<td>20 mg/ml</td>
<td>Hydroxyzine hydrochloride 20 mg/ml</td>
<td>suspension</td>
<td>£18</td>
<td>100 ml</td>
</tr>
</tbody>
</table>

**Oral solution**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer</th>
<th>Form</th>
<th>Price</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg/ml</td>
<td>Hydroxyzine hydrochloride 5 mg/ml</td>
<td>syrup</td>
<td>£15</td>
<td>200 ml</td>
</tr>
<tr>
<td>10 mg/ml</td>
<td>Hydroxyzine hydrochloride 10 mg/ml</td>
<td>syrup</td>
<td>£18</td>
<td>200 ml</td>
</tr>
</tbody>
</table>

**CONTRA-INDICATIONS**

- Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe)

**CAUTIONS**

- Epilepsy • prostatic hypertrophy • pyloroduodenal obstruction • susceptibility to angle-closure glaucoma • susceptibility to QT interval prolongation • urinary retention

**INTERACTIONS**

- β-blockers and tricyclic antidepressants may increase the potential for cardiac toxicity
- Drowsiness may be enhanced by alcohol
- Alcohol should be avoided.

**SIDE-EFFECTS**

- Rare Anaphylaxis • angioedema • angle-closure glaucoma • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • palpitation • photosensitivity reactions • rashes • sleep disturbances - tremor
- Frequency not known Antimuscarinic effects - blurred vision - drowsiness - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - urinary retention

SIDE-EFFECTS, FURTHER INFORMATION

Children and the elderly are more susceptible to side-effects.

Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

**PREGNANCY**

- Most manufacturers of antihistamines advise avoiding their use during pregnancy; toxicity in animal studies with higher doses. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

**BREAST FEEDING**

- Manufacturer advises avoid. Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

**HEPATIC IMPAIRMENT**

- Reduce daily dose by one-third. Avoid in severe liver disease—increased risk of coma.

**RENAL IMPAIRMENT**

- Reduce daily dose by half.

**PATIENT AND CARER ADVICE**

- Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer</th>
<th>Form</th>
<th>Price</th>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 mg</td>
<td>Hydroxyzine hydrochloride 25 mg</td>
<td>tablet</td>
<td>£18</td>
<td>50 mg</td>
<td>daily</td>
</tr>
<tr>
<td>50 mg</td>
<td>Hydroxyzine hydrochloride 50 mg</td>
<td>tablet</td>
<td>£22</td>
<td>100 mg</td>
<td>daily</td>
</tr>
<tr>
<td>100 mg</td>
<td>Hydroxyzine hydrochloride 100 mg</td>
<td>tablet</td>
<td>£28</td>
<td>200 mg</td>
<td>daily</td>
</tr>
</tbody>
</table>

**Suspension**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer</th>
<th>Form</th>
<th>Price</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg/ml</td>
<td>Hydroxyzine hydrochloride 10 mg/ml</td>
<td>suspension</td>
<td>£14</td>
<td>100 ml</td>
</tr>
<tr>
<td>20 mg/ml</td>
<td>Hydroxyzine hydrochloride 20 mg/ml</td>
<td>suspension</td>
<td>£18</td>
<td>100 ml</td>
</tr>
</tbody>
</table>

**Oral solution**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer</th>
<th>Form</th>
<th>Price</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg/ml</td>
<td>Hydroxyzine hydrochloride 5 mg/ml</td>
<td>syrup</td>
<td>£15</td>
<td>200 ml</td>
</tr>
<tr>
<td>10 mg/ml</td>
<td>Hydroxyzine hydrochloride 10 mg/ml</td>
<td>syrup</td>
<td>£18</td>
<td>200 ml</td>
</tr>
</tbody>
</table>
Ketotifen

INDICATIONS AND DOSE

Allergic rhinitis

BY MOUTH

- Child 3-17 years: 1 mg twice daily
- Adult: 1 mg twice daily, increased if necessary to 2 mg twice daily, to be taken with food

Allergic rhinitis in readily sedated patients

BY MOUTH

- Adult: Initially 0.5–1 mg once daily, dose to be taken at night

- CONTRA-INDICATIONS Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe).
- CAUTIONS Epilepsy - prostatic hypertrophy - pyloroduodenal obstruction - susceptibility to angle-closure glaucoma - urinary retention
- INTERACTIONS → Appendix 1 (antihistamines).

SIDE-EFFECTS

- Common or very common Excitation (in adults) - irritability - nervousness
- Uncommon Cystitis
- Rare Weight gain
- Very rare Stevens-Johnson syndrome

FREQUENCY NOT KNOWN


SIDE-EFFECTS, FURTHER INFORMATION

Children and the elderly are more susceptible to side effects.

Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

PREGNANCY

Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

BREAST FEEDING

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

HEPATIC IMPAIRMENT

Avoid in severe liver disease—increased risk of coma.

PATIENT AND CARER ADVICE

Drowsiness may affect performance of skilled tasks (e.g. driving or cycling); sedating effects enhanced by alcohol.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Zaditen** (CD Pharma AB)
  - Ketotifen (as Ketotifen fumarate) 1 mg Zaditen 1mg tablets | 60 tablet (cost £7.53)

Levocetirizine hydrochloride

INDICATIONS AND DOSE

Symptomatic relief of allergy such as hay fever, urticaria

BY MOUTH

- Child 6-17 years: 5 mg once daily
- Adult: 5 mg once daily

PHARMACOKINETICS

Levocetirizine is an isomer of cetirizine.

- CONTRA-INDICATIONS Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe).
- CAUTIONS Epilepsy

INTERACTIONS → Appendix 1 (antihistamines).

SIDE-EFFECTS

- Uncommon Antimuscarinic effects - blurred vision - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - urinary retention
- Rare Anaphylaxis - angioedema - angle-closure glaucoma (in adults) - arrhythmias - blood disorders - bronchospasm - confusion - convulsions - depression - dizziness - extrapyramidal effects - hypersensitivity reactions - hypotension - liver dysfunction - palpitation - photosensitivity reactions - rashes - sleep disturbances - tremor

- Very rare Weight gain

FREQUENCY NOT KNOWN

- Drowsiness

SIDE-EFFECTS, FURTHER INFORMATION

Children and the elderly are more susceptible to side effects. Non-sedating antihistamines such as levocetirizine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent. If drowsiness occurs, it may diminish after a few days of treatment.

PREGNANCY

Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

BREAST FEEDING

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

RENAI IMPAIRMENT

- In adults 5 mg on alternate days if eGFR 30–50 mL/minute/1.73 m². 5 mg every 3 days if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².
- In children Reduce dose frequency to alternate days if estimated glomerular filtration rate 30–50 mL/minute/1.73 m². Reduce dose frequency to every 3 days if estimated glomerular filtration rate 10–30 mL/minute/1.73 m². Avoid if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

PATIENT AND CARER ADVICE

Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.
### Tablet
- **LEVOCETIRIZINE HYDROCHLORIDE (Non-proprietary)**
  - Levocetirizine dihydrochloride 5 mg: 30 tablet (PO) £4.39 DT price = £3.95
  - Xyzal (UCB Pharma Ltd)
- Levocetirizine dihydrochloride 5 mg: 30 tablet (PO) £4.39 DT price = £3.95

### Oral solution
- Xyzal (UCB Pharma Ltd)
- Levocetirizine dihydrochloride 500 microgram per 1 ml: 100 ml (sugar-free) £6.00 DT price = £6.00

### Loratadine

#### INDICATIONS AND DOSE
Symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria

**BY MOUTH**
- Child 2-11 years (body-weight up to 30 kg): 5 mg once daily
- Child 2-11 years (body-weight 30 kg and above): 10 mg once daily
- Child 12-17 years: 10 mg once daily
- Adult: 10 mg once daily

#### CAUTIONS
- Acute porphyria p. 864
- Epilepsy

#### INTERACTIONS
- Appendix 1 (antihistamines).
- Sedative antihistamine interactions apply to a lesser extent to the non-sedating antihistamines.

#### SIDE-EFFECTS
- **Uncommon**
  - Antimuscarinic effects - blurred vision, dry mouth, gastrointestinal disturbances - Headache - psychomotor impairment - urinary retention
- **Rare**

#### Frequency not known
- Drowsiness

#### SIDE-EFFECTS, FURTHER INFORMATION
Children and elderly are more susceptible to side-effects. Non-sedating antihistamines such as loratadine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment.

#### PREGNANCY
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

#### BREAST FEEDING
Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

#### HEPATIC IMPAIRMENT
Reduce dose frequency to alternate days in severe impairment.

#### PATIENT AND CARER ADVICE
Although drowsiness is rare, nevertheless patients and their carers should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

#### PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulary Loratadine 10 mg tablets may be prescribed. Loratadine syrup 5 mg/5 ml may be prescribed.

### Medicinal Forms

#### Table
- **LORATADINE (Non-proprietary)**
  - Loratadine 10 mg: 7 tablet (OS) £1.75
  - 30 tablet (PO) £8.20 DT price = £1.11
  - Claritin (Loratadine) (Bayer Plc)
  - Loratadine 10 mg: 7 tablet (OS) £1.75
  - 30 tablet (OS) £4.97 DT price = £1.11
  - 60 tablet (PO) £8.85

#### Oral lyophilisate
- Claritin (Loratadine) (Bayer Plc)
- Loratadine 10 mg: 10 tablet (sugar-free) £3.24

### Mizolastine

#### INDICATIONS AND DOSE
Symptomatic relief of allergy such as hay fever, urticaria

**BY MOUTH**
- Child 12-17 years: 10 mg once daily
- Adult: 10 mg once daily

#### CONTRA-INDICATIONS
Avoid in Acute porphyria p. 864 (some antihistamines are thought to be safe).

- Cardiac disease - hypokalaemia - susceptibility to QT-interval prolongation

#### CAUTIONS
- Epilepsy

#### INTERACTIONS
- Appendix 1 (antihistamines).
- Sedative antihistamine interactions apply to a lesser extent to the non-sedating antihistamines.

#### SIDE-EFFECTS
- **Common or very common**
  - Anxiety - asthenia - weight gain
- **Uncommon**
  - Antimuscarinic effects - arthralgia - blurred vision - dry mouth - gastrointestinal disturbances - headache - myalgia - psychomotor impairment - urinary retention
- **Rare**

#### Frequency not known
- Drowsiness

#### SIDE-EFFECTS, FURTHER INFORMATION
Children and elderly are more susceptible to side-effects. Non-sedating antihistamines such as mizolastine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment.

#### PREGNANCY
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

#### BREAST FEEDING
Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

#### HEPATIC IMPAIRMENT
Manufacturer advises avoid in significant impairment.

#### PATIENT AND CARER ADVICE
Although drowsiness is rare, nevertheless patients and their carers should be advised...
that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

*Modified-release tablet*

**CAUTIONARY AND ADVISORY LABELS**

- Promethazine (Sanofi)
- Mizollen 10 mg (Mizollen 10mg modified-release tablets | 30 tablet [PO] £6.92 DT price + £6.92

**Promethazine hydrochloride**

**INDICATIONS AND DOSE**
Symptomatic relief of allergy such as hay fever and urticaria | Insomnia associated with urticaria and pruritus

**BY MOUTH**
- Child 2-4 years: 5 mg twice daily, alternatively 5–15 mg once daily, dose to be taken at night
- Child 5–9 years: 5–10 mg twice daily, alternatively 10–25 mg once daily, dose to be taken at night
- Child 10–17 years: 10–20 mg 2–3 times a day, alternatively 25 mg once daily, dose to be taken at night, increased if necessary to 25 mg twice daily
- Adult: 10–20 mg 2–3 times a day

**BY DEEP INTRAMUSCULAR INJECTION**
- Child 10–17 years: 20–50 mg (max. per dose 100 mg)

**Emergency treatment of anaphylactic reactions**

**BY SLOW INTRAVENOUS INJECTION**
- Adult: 25–50 mg to be administered as a solution containing 2.5 mg/mL in water for injections; maximum 100 mg per course

**Sedation (short-term use)**

**BY MOUTH**
- Child 2–4 years: 15–20 mg
- Child 5–9 years: 20–25 mg
- Child 10–17 years: 25–50 mg
- Adult: 25–50 mg

**BY DEEP INTRAMUSCULAR INJECTION**
- Adult: 25–50 mg

**Nausea | Vomiting | Vertigo | Labyrinthine disorders | Motion sickness**

**BY MOUTH**
- Child 2–4 years: 5 mg, to be taken at bedtime on night before travel, repeat following morning if necessary
- Child 5–9 years: 10 mg, to be taken at bedtime on night before travel, repeat following morning if necessary
- Child 10–17 years: 20–25 mg, to be taken at bedtime on night before travel, repeat following morning if necessary
- Adult: 20–25 mg, to be taken at bedtime on night before travel, repeat following morning if necessary

**SPECIFIC CAUTIONS**
- With intravenous use: avoid extravasation with intravenous injection

**INTERACTIONS**
- Appendix 1 (antihistamines).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Rare: Anaphylaxis | Angioedema | Angle-closure glaucoma | Arthralgias | Asthma | Blood disorders | Bronchospasm | Confusion | Convulsions | Depression | Dizziness | Extrapyramidal effects | Hypersensitivity reactions | Hypotension | Liver dysfunction | Palpitation | Photosensitivity reactions | Rash | Sleep disturbances | Tremor

- Frequency not known: Antimuscarinic effects | Blurred vision | Drowsiness | Dry mouth | Gastro-intestinal disturbances | Headache | Psychomotor impairment | Restlessness | Urinary retention

**SPECIFIC SIDE-EFFECTS**
- With intramuscular use: injection pain

**SIDE-EFFECTS, FURTHER INFORMATION**

Children and elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

**PREGNANCY**
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

**BREAST FEEDING**
Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

**HEPATIC IMPAIRMENT**
Avoid in severe liver disease—increased risk of coma.

**RENAL IMPAIRMENT**
Use with caution.

**PATIENT AND CARER ADVICE**
Drowsiness may affect the performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

**PROFESSION SPECIFIC INFORMATION**

**Dental practitioners’ formulary**
Promethazine Hydrochloride Tablets 10 mg or 25 mg may be prescribed. Promethazine Hydrochloride Oral Solution (elixir) 5 mg/5 mL may be prescribed.

**LESS SUITABLE FOR PRESCRIBING**
Promethazine is less suitable for prescribing for sedation.

**EXCEPTIONS TO LEGAL CATEGORY**
Prescription only medicine restriction does not apply to promethazine hydrochloride injection where administration is for saving life in emergency.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- Promethazine hydrochloride (Non-proprietary)
  - Promethazine hydrochloride 10 mg (Promethazine hydrochloride 10mg tablets | 56 tablet [PO] £2.96 DT price + £2.96

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS**

- Elixir: May contain Sulfites | ELECTROLYTES: May contain Sodium

- Phenergan (Sanofi)
  - Promethazine hydrochloride 1 mg per 1 mL (Phenergan 5mg/5ml elixir (sugar-free) | 100 mL [PO] £2.85 DT price + £2.85

**Important safety information**

MHRA/CHM ADVICE (MARCH 2008 AND FEBRUARY 2009)

**OVER-THE-COUNTER COUGH AND COLD MEDICINES FOR CHILDREN**

Children under 6 years should not be given over-the-counter cough and cold medicines containing promethazine.

**CONTRA-INDICATIONS**
Many antihistamines should be avoided in Acute porphyrias p. 864 but promethazine is thought to be safe.

**CAUTIONS**

**GENERAL CAUTIONS**
Epilepsy | Prostatic hypertrophy | Pyloroduodenal obstruction | Severe coronary artery disease | Susceptibility to angle-closure glaucoma | Urinary retention
Promethazine tocolate

INDICATIONS AND DOSE

<table>
<thead>
<tr>
<th>Nausea</th>
<th>Vertigo</th>
<th>Labyrinthine disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child 5-9 years: 12.5–37.5 mg daily</td>
<td>Child 10-17 years: 25–75 mg daily; maximum 100 mg per day</td>
<td>Adult: 25–75 mg daily; maximum 100 mg per day</td>
</tr>
</tbody>
</table>

Motion sickness prevention (acts longer than promethazine hydrochloride)

<table>
<thead>
<tr>
<th>BY MOUTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child 5-9 years: 12.5 mg once daily, dose to be taken at bedtime on night before travel, alternatively 12.5 mg once daily, dose to be taken 1–2 hours before travel</td>
</tr>
<tr>
<td>Child 10-17 years: 25 mg once daily, dose to be taken at bedtime on night before travel, alternatively 25 mg once daily, dose to be taken 1–2 hours before travel</td>
</tr>
<tr>
<td>Adult: 25 mg once daily, dose to be taken at bedtime on night before travel, alternatively 25 mg once daily, dose to be taken 1–2 hours before travel</td>
</tr>
</tbody>
</table>

Motion sickness treatment (acts longer than the hydrochloride)

<table>
<thead>
<tr>
<th>BY MOUTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child 5-9 years: 12.5 mg, dose to be taken at onset of motion sickness, then 12.5 mg daily for 2 days, dose to be taken at bedtime</td>
</tr>
<tr>
<td>Child 10-17 years: 25 mg, dose to be taken at onset of motion sickness, then 25 mg once daily for 2 days, dose to be taken at bedtime</td>
</tr>
<tr>
<td>Adult: 25 mg, dose to be taken at onset of motion sickness, then 25 mg once daily for 2 days, dose to be taken at bedtime</td>
</tr>
</tbody>
</table>

SIDE-EFFECTS, FURTHER INFORMATION

Children and the elderly patients are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitation, and tremor.

- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

- **RENAL IMPAIRMENT** Use with caution.

- **PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**

  CAUTIONARY AND ADVISORY LABELS 2

  - **Avomine** (Max Healthcare Ltd)
  - **Promethazine tocolate 25 mg** Avomine 25mg tablets | 10 tablet £1.13 | 28 tablet £3.13 DT price = £3.13

VACCINES (ALLERGEN-TYPE)

**Bee venom extract**

INDICATIONS AND DOSE

Hypersensitivity to bee venom

BY SUBCUTANEOUS INJECTION

- Adult: (consult product literature)

**Important safety information**

**DESENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- Seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs.

- Hypersensitivity to wasp and bee venoms. Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS**

Consult product literature

- **CAUTIONS**

- **INTERACTIONS** → Appendix 1 (antihistamines).

**SIDE-EFFECTS**

GENERAL SIDE-EFFECTS

- Rare Anaphylaxis, angioedema, angle-closure glaucoma, arrhythmias, blood disorders, bronchospasm, confusion, convulsions, depression, dizziness, extrapyramidal effects, hypersensitivity reactions, hypotension, liver dysfunction, palpitation, photosensitivity reactions, rashes, sleep disturbances, tremor

- Frequency not known Antimuscarinic effects, blurred vision, drowsiness, dry mouth, gastro-intestinal disturbances, headache, psychomotor impairment, restlessness, urinary retention

**SPECIFIC SIDE-EFFECTS**

- With intramuscular use injection pain

**Important safety information**

MHRA/CHM ADVICE (MARCH 2008 AND FEBRUARY 2009)

OVER-THE-COUNTER COUGH AND COLD MEDICINES FOR CHILDREN

Children under 6 years should not be given over-the-counter cough and cold medicines containing promethazine.

- **CAUTIONS** Acute porphyrias p. 864, asthma, bronchiectasis, bronchitis, epilepsy, prostatic hypertrophy, pyloroduodenal obstruction. Reye’s syndrome, severe coronary artery disease, susceptibility to angle-closure glaucoma, urinary retention

- **INTERACTIONS** → Appendix 1 (antihistamines).

**SIDE-EFFECTS**

- **Phenergan** (Sanofi) Promethazine hydrochloride 25 mg per 1 ml Phenergan 25mg/1ml solution for injection ampoules | 10 ampoule £6.74

- **Bee venom** extract

  - **Phenergan** (Sanofi) Promethazine hydrochloride 25 mg per 1 ml Phenergan 25mg/1ml solution for injection ampoules | 10 ampoule £6.74

  - **Avomine** (Max Healthcare Ltd) Promethazine tocolate 25 mg Avomine 25mg tablets | 10 tablet £1.13 | 28 tablet £3.13 DT price = £3.13

  - **Avomine** (Max Healthcare Ltd) Promethazine tocolate 25 mg Avomine 25mg tablets | 10 tablet £1.13 | 28 tablet £3.13 DT price = £3.13

  - **Avomine** (Max Healthcare Ltd) Promethazine tocolate 25 mg Avomine 25mg tablets | 10 tablet £1.13 | 28 tablet £3.13 DT price = £3.13
symptoms or signs of hypersensitivity develop (e.g. rash, urticaria, bronchospasm, faintness), even when mild, the patient should be observed until these have resolved completely.

- **PREGNANCY** Avoid.

- **PRESCRIBING AND DISPENSING INFORMATION** Each set of allergen extracts usually contains vials for the administration of graded amounts of allergen to patients undergoing hyposensitisation. Maintenance sets containing vials at the highest strength are also available. Product literature must be consulted for details of allergens, vial strengths, and administration.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**
    - Pharmalgen for bee and wasp venom allergy (February 2012)

  - **Pharmalgen**

    Pharmalgen® is an option for the treatment of IgE-mediated bee and wasp venom allergy in those who have had:
    - a severe systemic reaction to bee or wasp venom;
    - a moderate systemic reaction to bee or wasp venom and who have a raised baseline serum-tryptase concentration, a high risk of future stings, or anxiety about future stings.

  - Treatment with Pharmalgen® should be initiated and monitored in a specialist centre experienced in venom immunotherapy. [www.nice.org.uk/TA246](http://www.nice.org.uk/TA246)

- **MEDICATION FORMS**

  - There can be variation in the licensing of different medicines containing the same drug.

  - **Powder and solvent for solution for injection**

    - **BEE VENOM EXTRACT (Non-proprietary)**

      Bee venom 1.2 microgram Pharmalgen Bee Venom 1.2 microgram powder and solvent for solution for injection vials | 1 vial (PVT) no price available

      Bee venom 12 microgram Pharmalgen Bee Venom 12 microgram powder and solvent for solution for injection vials | 1 vial (PVT) no price available

      Bee venom 120 microgram Pharmalgen Bee Venom maintenance set 120 microgram powder and solvent for solution for injection vials | 1 vial (PVT) no price available | 4 vial (PVT) £150.00

      Bee venom 120 nanogram Pharmalgen Bee Venom 120 nanogram powder and solvent for solution for injection vials | 1 vial (PVT) no price available

  - **INDICATIONS AND DOSE**

    - **Grass pollen extract**

      Treatment of seasonal allergic hay fever due to grass pollen in patients who have failed to respond to anti-allergy drugs

      **BY SUBCUTANEOUS INJECTION**

        - Adult: (consult product literature)

      Treatment of seasonal allergic hay fever due to grass pollen in patients who have failed to respond to anti-allergy drugs (initiated under specialist supervision)

      **BY MOUTH**

        - Adult: 1 tablet daily, treatment to be started at least 4 months before start of pollen season and continue for up to 3 years

      **Important safety information**

      **DESENSITISING VACCINES**

      In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

      - seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
      - hypersensitivity to wasp and bee venoms.

      Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

  - **CONTRA-INDICATIONS** Consult product literature

  - **CAUTIONS** Consult product literature

  - **INTERACTIONS** Desensitising vaccines should be avoided in patients taking beta-blockers (adrenaline may be ineffective in case of a hypersensitivity reaction), or ACE inhibitors (risk of severe anaphylactoid reactions).

  - **SIDE-EFFECTS**

    **SIDE-EFFECTS, FURTHER INFORMATION** Consult product literature.

    **Hypersensitivity reactions** Hypersensitivity reactions to immunotherapy can be life-threatening; bronchospasm usually develops within 1 hour and anaphylaxis within 30 minutes of injection. Therefore, cardiopulmonary resuscitation must be immediately available and patients need to be monitored for at least 1 hour after injection. If symptoms or signs of hypersensitivity develop (e.g. rash, urticaria, bronchospasm, faintness), even when mild, the patient should be observed until these have resolved completely.

    - **PREGNANCY** Should be avoided in pregnant women—consult product literature.

    - **MONITORING REQUIREMENTS** The first dose of grass pollen extract should be (Grazax®) should be taken under medical supervision and the patient should be monitored for 20–30 minutes.

    - **DIRECTIONS FOR ADMINISTRATION** Oral lyophilisates should be placed under the tongue and allowed to disperse. Advise patient not to swallow for 1 minute, or eat or drink for 5 minutes after taking the tablet. The first should be taken under medical supervision and the patient should be monitored for 20–30 minutes.

    - **PRESCRIBING AND DISPENSING INFORMATION** Each set of allergen extracts usually contains vials for the administration of graded amounts of allergen to patients undergoing hyposensitisation. Maintenance sets containing vials at the highest strength are also available. Product literature must be consulted for details of allergens, vial strengths, and administration.

    - **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer oral lyophilisates.

  - **MEDICATION FORMS**

    - There can be variation in the licensing of different medicines containing the same drug.

    - **Oral lyophilisate**

      - Grazax (ALK-Abello Ltd)

      Phleum pratense 75000 SQ-T Grazax 75,000 SQ-T oral lyophilisates (sugar-free) | 30 tablet (PO) £80.12

      - **Injection**

        Pollinex Grasses + Rye (Allergy Therapeutics (UK) Ltd)

        Pollinex Grasses + Rye suspension for injection treatment and extension course vials | 4 vial (POM) £450.00

  - **Tree pollen extract**

    **INDICATIONS AND DOSE**

      Treatment of seasonal allergic hay fever due to tree pollen in patients who have failed to respond to anti-allergy drugs

      **BY SUBCUTANEOUS INJECTION**

        - Adult: (consult product literature)

      **Important safety information**

      **DESENSITISING VACCINES**

      In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:
Respiratory system

MEDICINAL FORMS

PRESCRIBING AND DISPENSING INFORMATION

PREGNANCY

SIDE-EFFECTS

SIDE-EFFECTS, FURTHER INFORMATION

Consult product literature.

Hypersensitivity reactions

Each set of desensitising vaccines usually contains vials for the administration of graded amounts of allergen to patients undergoing hyposensitisation. Maintenance sets containing vials at the highest strength are also available. Product literature must be consulted for details of allergens, vial strengths, and administration.

CAUTIONS

Consult product literature

INTERACTIONS

Medicines containing the same drug.

SPECIAL CONDITIONS

CONTRA-INDICATIONS

Consult product literature

CAUTIONS

Consult product literature

INTERACTIONS

Desensitising vaccines should be avoided in patients taking beta-blockers (adrenaline may be ineffective in case of a hypersensitivity reaction), or ACE inhibitors (risk of severe anaphylactoid reactions).

SIDE-EFFECTS

SIDE-EFFECTS, FURTHER INFORMATION

Consult product literature.

Hypersensitivity reactions

Hypersensitivity reactions to immunotherapy (especially to wasp and bee venom extracts) can be life-threatening; bronchospasm usually develops within 1 hour and anaphylaxis within 30 minutes of injection. Therefore, cardiopulmonary resuscitation must be immediately available and patients need to be monitored for at least 1 hour after injection. If symptoms or signs of hypersensitivity develop (e.g. rash, urticaria, bronchospasm, faintness), even when mild, the patient should be observed until these have resolved completely.

PREGNANCY

Avoid.

PRESCRIBING AND DISPENSING INFORMATION

Each set of allergen extracts usually contains vials for the administration of graded amounts of allergen to patients undergoing hyposensitisation. Maintenance sets containing vials at the highest strength are also available. Product literature must be consulted for details of allergens, vial strengths, and administration.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Pharmalgen for bee and wasp venom allergy (February 2012)

Pharmalgen is an option for the treatment of IgE-mediated bee and wasp venom allergy in those who have had:

- a severe systemic reaction to bee or wasp venom;
- a moderate systemic reaction to bee or wasp venom and who have a raised baseline serum-tryptase concentration, a high risk of future stings, or anxiety about future stings.

Treatment with Pharmalgen should be initiated and monitored in a specialist centre experienced in venom immunotherapy. [www.nice.org.uk/TA246](http://www.nice.org.uk/TA246)

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection

Pollinex Trees (Allergy Therapeutics (UK) Ltd)

Pollinex Trees No 3 suspension for injection 1ml vials | 1 vial (£30) no price available

Pollinex Trees No 2 suspension for injection 1ml vials | 1 vial (£30) no price available

Pollinex Trees No 1 suspension for injection 1ml vials | 1 vial (£30) no price available

Injection

Pollinex Trees (Allergy Therapeutics (UK) Ltd)

Pollinex Trees suspension for injection treatment and extension course vials | 4 vial (£10) £145.00

Wasp venom extract

INDICATIONS AND DOSE

Hypersensitivity to wasp venom

BY SUBCUTANEOUS INJECTION

Adult: (consult product literature)

Important safety information

DESENSITISING VACCINES

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti–allergic drugs;
- hypersensitivity to wasp and bee venom.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

CONTRA-INDICATIONS

Consult product literature

INTERACTIONS

Appendix 1 (wasp venom extracts). Contra-indicated in patients taking beta-blockers (adrenaline may be ineffective in case of a hypersensitivity reaction).

SIDE-EFFECTS

SIDE-EFFECTS, FURTHER INFORMATION

Consult product literature.

Hypersensitivity reactions

Hypersensitivity reactions to immunotherapy (especially to wasp and bee venom extracts) can be life-threatening; bronchospasm usually develops within 1 hour and anaphylaxis within 30 minutes of injection. Therefore, cardiopulmonary resuscitation must be immediately available and patients need to be monitored for at least 1 hour after injection. If symptoms or signs of hypersensitivity develop (e.g. rash, urticaria, bronchospasm, faintness), even when mild, the patient should be observed until these have resolved completely.

PRESCRIBING AND DISPENSING INFORMATION

Each set of allergen extracts usually contains vials for the administration of graded amounts of allergen to patients undergoing hyposensitisation. Maintenance sets containing vials at the highest strength are also available. Product literature must be consulted for details of allergens, vial strengths, and administration.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Pharmalgen for bee and wasp venom allergy (February 2012)

Pharmalgen is an option for the treatment of IgE-mediated bee and wasp venom allergy in those who have had:

- a severe systemic reaction to bee or wasp venom;
- a moderate systemic reaction to bee or wasp venom and who have a raised baseline serum-tryptase concentration, a high risk of future stings, or anxiety about future stings.

Treatment with Pharmalgen should be initiated and monitored in a specialist centre experienced in venom immunotherapy. [www.nice.org.uk/TA246](http://www.nice.org.uk/TA246)

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection

WASP VENOM EXTRACT (Non-proprietary)

Wasp venom 1.2 microgram Pharmalgen Wasp Venom 1.2microgram powder and solvent for solution for injection vials | 1 vial (£50) no price available

Wasp venom 12 microgram Pharmalgen Wasp Venom 12microgram powder and solvent for solution for injection vials | 1 vial (£50) no price available

Wasp venom 120 nanogram Pharmalgen Wasp Venom 120nanogram powder and solvent for solution for injection vials | 1 vial (£50) no price available

Wasp venom 120 microgram Pharmalgen Wasp Venom 120microgram powder and solvent for solution for injection vials | 1 vial (£50) no price available

4 vial (£20) £150.00

2.1 Angioedema

Drugs used for Angioedema not listed below;

Adrenaline/epinephrine, p. 196
COMPLEMENT BLOCKERS

C1-esterase inhibitor

**INDICATIONS AND DOSE**

**CINRYZE®**

Acute attacks of hereditary angioedema (under expert supervision)

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 1000 units for 1 dose, repeated if necessary
  - Short-term prophylaxis of hereditary angioedema before dental, medical, or surgical procedures (under expert supervision)

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 1000 units for 1 dose, to be administered up to 24 hours before procedure

Long-term prophylaxis of severe, recurrent attacks of hereditary angioedema where acute treatment is inadequate, or when oral prophylaxis is inadequate or not tolerated (under expert supervision)

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 1000 units every 3–4 days, interval between doses to be adjusted according to response

**BERINERT®**

Acute attacks of hereditary angioedema (under expert supervision)

- **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - Adult: 20 units/kg

Short-term prophylaxis of hereditary angioedema before dental, medical, or surgical procedures (under expert supervision)

- **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - Adult: 1000 units for 1 dose, to be administered less than 6 hours before procedure

**CAUTIONS** Vaccination against hepatitis A and hepatitis B may be required.

**SIDE-EFFECTS** Fever - headache - thrombosis (with high doses)

**PREGNANCY** Manufacturer advises avoid for use only if potential benefit outweighs risk.

**PRESCRIBING AND DISPENSING INFORMATION** C1-esterase inhibitor is prepared from human plasma.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Ruconest** (Swedish Orphan Biovitrum Ltd)
  - Conestat alfa 2100 unit — Ruconest 2.100 unit powder for solution for injection vials | 1 vial [PSt] £750.00

**SELECTIVE BRADYKININ B2 ANTAGONISTS**

Icatibant

**INDICATIONS AND DOSE**

Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 30 mg for 1 dose, then 30 mg after 6 hours if required, then 30 mg after 6 hours if required; maximum 3 doses per day

**CAUTIONS** Ischaemic heart disease - stroke

**SIDE-EFFECTS** Dizziness - erythema - headache - injection-site reactions - nausea - pruritus - pyrexia - rash

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid for 12 hours after administration.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Firazyr** (Shire Pharmaceuticals Ltd)
  - Icatibant (as Icatibant acetate) 10 mg per 1 ml — Firazyr 30mg/3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection [PSt] £1,395.00

Carbocisteine

**INDICATIONS AND DOSE**

Reduction of sputum viscosity

- **BY MOUTH**
  - Adult: Initially 2.25 g daily in divided doses, then reduced to 1.5 g daily in divided doses, as condition improves

**CONTRA-INDICATIONS** Active peptic ulceration
Respiratory system

HEPATIC IMPAIRMENT

PREGNANCY

▶ Very rare

Erdosteine

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CARBOCISTEINE (Non-proprietary)

Carbocisteine 375 mg Carbocisteine 375mg capsules | 120 capsule [Phar] £18.96 DT price = £17.11

Mucodyne (Sanofi)

Carbocisteine 375 mg Mucodyne 375mg capsules | 120 capsule [Phar] £18.96 DT price = £17.11

Oral solution

Mucodyne (Sanofi)

Carbocisteine 50 mg per 1 ml Mucodyne 250mg/5ml syrup | 300 ml [Phar] £6.99 DT price = £6.99

SIDE-EFFECTS

CAUTIONS

History of peptic ulceration (may disrupt the gastric mucosal barrier)

SIDE-EFFECTS

Rare

Gastro-intestinal bleeding

Frequency not known

Erythema multiforme · Stevens-Johnson syndrome

PREGNANCY

Manufacturer advises avoid in first trimester.

BREAST FEEDING

No information available.

PRESCRIBING AND DISPENSING INFORMATION

Flavours of oral liquid formulations may include cherry, raspberry, cinnamon, or rum.

FIRST AID

Emergency care should include emergency medical assistance.

CAUTIONS

History of peptic ulceration (may disrupt the gastric mucosal barrier)

SIDE-EFFECTS

Rare

Gastro-intestinal bleeding

Frequency not known

Erythema multiforme · Stevens-Johnson syndrome

PREGNANCY

Manufacturer advises avoid in first trimester.

BREAST FEEDING

No information available.

PRESCRIBING AND DISPENSING INFORMATION

Flavours of oral liquid formulations may include cherry, raspberry, cinnamon, or rum.

INDICATIONS AND DOSE

Symptomatic treatment of acute exacerbations of chronic bronchitis

BY MOUTH

Adult: 300 mg twice daily for up to 10 days

CAUTIONS

History of peptic ulceration (may disrupt the gastric mucosal barrier)

INDICATIONS AND DOSE

Management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted to improve pulmonary function

BY INHALATION OF NEBULISED SOLUTION

Adult: 2500 units once daily, administered by jet nebuliser, patients over 21 years may benefit from twice daily dosage

Dose equivalence and conversion

Dornase alfa 1000 units is equivalent to 1 mg

SIDE-EFFECTS

Rare

Chest pain · conjunctivitis · dyspepsia · dysphonia · dysphonia · laryngitis · pharyngitis · pyrexia · rash · rhinitis · urticaria

PREGNANCY

No evidence of teratogenicity; manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING

Amount probably too small to be harmful—manufacturer advises caution.

DIRECTIONS FOR ADMINISTRATION

Dornase alfa is administered by inhalation using a jet nebuliser, usually once daily at least 1 hour before physiotherapy; however, alternate-day therapy may be as effective as daily treatment. For use undiluted with jet nebulisers only; ultrasonic nebulisers are unsuitable.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

Erdotin (Galen Ltd)

Erdosteine 300 mg Erdotin 300mg capsules | 20 capsule [Phar] £4.25 DT price = £4.25

Erdotin (Galen Ltd)

Erdosteine 300 mg Erdotin 300mg capsules | 20 capsule [Phar] £4.25 DT price = £4.25

Erdotin (Galen Ltd)

Erdosteine 300 mg Erdotin 300mg capsules | 20 capsule [Phar] £4.25 DT price = £4.25

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Nebuliser liquid

Pulmozyme (Roche Products Ltd)

Dornase alfa 1 mg per 1 ml Pulmozyme 2.5mg nebuliser liquid 2.5ml ampoules | 30 ampoule [Phar] £496.43 DT price = £496.43

3.1 Cystic fibrosis

Mucolytics for cystic fibrosis

Mucolytics are prescribed to facilitate expectoration by reducing sputum viscosity. In some patients with chronic obstructive pulmonary disease and a chronic productive cough, mucolytics can reduce exacerbations; mucolytic therapy should be stopped if there is no benefit after a 4-week trial. Steam inhalation with postural drainage is effective in bronchiectasis and in some cases of chronic bronchitis.

Dornase alfa below is used to reduce sputum viscosity in patients with cystic fibrosis.

Nebulised hypertonic sodium chloride (3–7%) is used to mobilise lower respiratory tract secretions in mucus consolidation (e.g. cystic fibrosis). Nebulised hypertonic sodium chloride solution (3%) is used for mild to moderate acute viral bronchiolitis in infants.

Mannitol, administered by inhalation, improves mucus clearance and is licensed for the treatment of cystic fibrosis as an add-on therapy to standard care.

Dornase alfa

(Phosphorylated glycosylated recombinant human deoxyribonuclease 1 (rhDNase))

DRUG ACTION

Dornase alfa is a genetically engineered version of a naturally occurring human enzyme which cleaves extracellular deoxyribonucleic acid (DNA).

INDICATIONS AND DOSE

Management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted to improve pulmonary function

BY INHALATION OF NEBULISED SOLUTION

Adult: 2500 units once daily, administered by jet nebuliser, patients over 21 years may benefit from twice daily dosage

Dose equivalence and conversion

Dornase alfa 1000 units is equivalent to 1 mg

SIDE-EFFECTS

Rare

Chest pain · conjunctivitis · dyspepsia · dysphonia · dysphonia · laryngitis · pharyngitis · pyrexia · rash · rhinitis · urticaria

PREGNANCY

No evidence of teratogenicity; manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING

Amount probably too small to be harmful—manufacturer advises caution.

DIRECTIONS FOR ADMINISTRATION

Dornase alfa is administered by inhalation using a jet nebuliser, usually once daily at least 1 hour before physiotherapy; however, alternate-day therapy may be as effective as daily treatment. For use undiluted with jet nebulisers only; ultrasonic nebulisers are unsuitable.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Nebuliser liquid

Pulmozyme (Roche Products Ltd)

Dornase alfa 1 mg per 1 ml Pulmozyme 2.5mg nebuliser liquid 2.5ml ampoules | 30 ampoule [Phar] £496.43 DT price = £496.43

BNF Conditions affecting sputum viscosity

256

3

Respiratory system
**Ivacaftor**

**INDICATIONS AND DOSE**
Treatment of cystic fibrosis in patients who have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (under expert supervision)

**BY MOUTH**
- *Adults:* 150 mg every 12 hours

**Dose adjustments due to interactions**
Reduce dose to 150 mg twice a week with concomitant use of itraconazole, ketoconazole, posaconazole, voriconazole, telithromycin, and clarithromycin. Reduce dose to 150 mg once daily with concomitant use of fluconazole and erythromycin.

- **CONTRA-INDICATIONS** Organ transplantation (no information available)
- **INTERACTIONS** → Appendix 1 (ivacaftor). Avoid grapefruit and Seville oranges.
- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain, diarrhoea, dizziness, ear discomfort, headache, nasal congestion, nasopharyngitis, ophthalmic pain, pharyngolaryngeal pain, rash, rhinitis, tinnitus, upper respiratory tract infection
  - **Uncommon** Gynaecomastia, vestibular disorder
- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.
- **BREAST FEEDING** Manufacturer advises use only if potential benefit outweighs risk—no information available.
- **HEPATIC IMPAIRMENT** Max. 150 mg once daily in moderate impairment; in severe impairment, manufacturer recommends use only if potential benefit outweighs risk—starting dose 150 mg on alternate days, dosing interval adjusted according to clinical response and tolerability.
- **RENAL IMPAIRMENT** Caution in severe impairment.
- **PRE-TREATMENT SCREENING** If the patient’s genotype is unknown, a validated genotyping method should be performed to confirm the presence of the G551D mutation in at least one allele of the CFTR gene before starting treatment.
- **MONITORING REQUIREMENTS** Test liver function before treatment, every 3 months during the first year of treatment, then annually thereafter.
- **DIRECTIONS FOR ADMINISTRATION** Tablets should be taken with fat-containing food.
- **PRESCRIBING AND DISPENSING INFORMATION** Ivacaftor should be prescribed by a physician experienced in the treatment of cystic fibrosis.
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer ivacaftor tablets.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 5
    - **Ivacaftor 150 mg** Kalydeco 150mg tablets | 56 tablet (P58)
    - £14,000.00

---

**Mannitol**

**INDICATIONS AND DOSE**
Treatment of cystic fibrosis as an add-on therapy to standard care

**BY INHALATION OF POWDER**
- *Adult:* Maintenance 400 mg twice daily, an initiation dose assessment must be carried out under medical supervision, for details of the initiation dose regimen, consult product literature

- **CONTRA-INDICATIONS** Bronchial hyperresponsiveness to inhaled mannitol, impaired lung function (forced expiratory volume in 1 second < 50% of predicted), non-CF bronchiectasis
- **CAUTIONS** Asthma, haemoptysis
- **INTERACTIONS** → Appendix 1 (mannitol).
- **SIDE-EFFECTS**
  - **Common or very common** Cough, haemoptysis, headache, pharyngolaryngeal pain, throat irritation, vomiting, wheezing
  - **Uncommon** Acne, arthralgia, bronchospasm, dizziness, dysphonia, dysphonia, ear pain, eructation, flatulence, gastro-oesophageal reflux disease, glossodynia, hyperventilation, influenza-like illness, malaise, nausea, oral candidiasis, pharyngitis, pruritis, pyrexia, rash, rhinorrhoea, stomatitis, transient insomnia
- **PREGNANCY** Manufacturer advises avoid.
- **BREAST FEEDING** Manufacturer advises avoid.
- **PRE-TREATMENT SCREENING** Patients must be assessed for bronchial hyperresponsiveness to inhaled mannitol before starting the therapeutic dose regimen; an initiation dose assessment must be carried out under medical supervision—for details of the initiation dose regimen, consult product literature.
- **DIRECTIONS FOR ADMINISTRATION** The dose should be administered 5–15 minutes after a bronchodilator and before physiotherapy; the second daily dose should be taken 2–3 hours before bedtime.
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer mannitol inhalation powder.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Mannitol dry powder for inhalation for treating cystic fibrosis (November 2012) NICE TA266

Mannitol dry powder for inhalation is recommended as an option for treating cystic fibrosis in adults:
- who cannot use dornase alfa (rhDNase) because of inability, intolerance or inadequate response to dornase alfa (rhDNase), and
- whose lung function is rapidly declining (forced expiratory volume in 1 second decline greater than 2% annually), and
- for whom other osmotic agents are not considered appropriate. www.nice.org.uk/TA266

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium, has advised (November 2013) that mannitol (Bronchitol®) is accepted for restricted use within NHS Scotland for the treatment of cystic fibrosis in adults aged 18 years and over as an add-on therapy to best standard of care. Mannitol is restricted to patients who are not currently using dornase alfa due to lack of response, intolerance, or ineligibility and have rapidly declining lung function and in whom other osmotic agents are considered unsuitable.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order
respiratory system is particularly useful in children. being harmless and inexpensive; drowsiness which may reflect their main mode of action. preparations on sale to the public; all tend to cause suppressant component of many compound cough effects.

methadone hydrochloride linctus should be avoided because contraindicated because they induce sputum retention and pholcodine p. 259 are not generally recommended in children and should be avoided in children under 6 years.

mhra/chm advice (march 2008 and february 2009)
over-the-counter cough and cold medicines for children children under 6 years should not be given over-the-counter cough and cold medicines containing the following ingredients:
- brompheniramine, chlorphenamine maleate, diphenhydramine, doxylamine, promethazine, or tripolidine (antihistamines);
- dextromethorphan or pholcodine (cough suppressants);
- guaifenesin or ippecacuanha (expectorants);
- phenylephrine hydrochloride, pseudoephedrine hydrochloride, ephedrine hydrochloride, oxytetracycline, or xylometazoline hydrochloride (decongestants).

over-the-counter cough and cold medicines can be considered for children aged 6–12 years after basic principles of best care have been tried, but treatment should be restricted to five days or less. children should not be given more than 1 cough or cold preparation at a time because different brands may contain the same active ingredient; care should be taken to give the correct dose.

drugs used for cough and congestion not listed below; codeine phosphate, p. 360 · methadone hydrochloride, p. 436 · morphine hydrochloride, p. 367

4 cough and congestion

aromatic inhalations, cough preparations and systemic nasal decongestants

aromatic inhalations in adults
inhalations containing volatile substances such as eucalyptus oil are traditionally used and although the vapour may contain little of the additive it encourages deliberate inspiration of warm moist air which is often comforting in bronchitis; boiling water should not be used owing to the risk of scalding. inhalations are also used for the relief of nasal obstruction in acute rhinitis or sinusitis. eucalyptus with menthol p. 259 inhalation is used to relieve sinusitis affecting the maxillar antrum.

cough preparations in adults

cough suppressants

cough may be a symptom of an underlying disorder, such as asthma, gastro-oesophageal reflux disease, or rhinitis, which should be addressed before prescribing cough suppressants. cough may be a side-effect of another drug, such as an ace inhibitor, or it can be associated with smoking or environmental pollutants. cough can also have a significant habit component. when there is no identifiable cause, cough suppressants may be useful, for example if sleep is disturbed. they may cause sputum retention and this may be harmful in patients with chronic bronchitis and bronchiectasis. codeine phosphate p. 360 may be effective but it is constipating and can cause dependence;
dextromethorphan and pholcodine p. 259 have fewer side-effects.

sedating antihistamines are used as the cough suppressant component of many compound cough preparations on sale to the public; all tend to cause drowsiness which may reflect their main mode of action.

palliative care
diamorphine hydrochloride p. 361 and methadone hydrochloride p. 436 have been used to control distressing cough in terminal lung cancer although morphine p. 367 is now preferred. in other circumstances they are contraindicated because they induce sputum retention and ventilatory failure as well as causing opioid dependence. methadone hydrochloride linctus should be avoided because it has a long duration of action and tends to accumulate.

demulcent and expectorant cough preparations

demulcent cough preparations contain soothing substances such as syrup or glycerol and some patients believe that such preparations relieve a dry irritating cough. preparations such as simple linctus have the advantage of being harmless and inexpensive; paediatric simple linctus is particularly useful in children.

epectorants are claimed to promote expulsion of bronchial secretions, but there is no evidence that any drug can specifically facilitate expectoration.

compound preparations are on sale to the public for the treatment of cough and colds but should not be used in children under 6 years; the rationale for some is dubious. care should be taken to give the correct dose and to not use more than one preparation at a time.

systemic nasal decongestants

nasal decongestants for administration by mouth may not be as effective as preparations for local application but they do not give rise to rebound nasal congestion on withdrawal. pseudoephedrine hydrochloride p. 982 is available over the counter; it has few sympathomimetic effects.

aromatic inhalations in children

the use of strong aromatic decongestants (applied as rubs or to pillows) is not advised for infants under the age of 3 months. carers of young infants in whom nasal obstruction with mucus is a problem can readily be taught appropriate techniques of suction aspiration but sodium chloride 0.9% given as nasal drops is preferred; administration before feeds may ease feeding difficulties caused by nasal congestion.

cough preparations in children

the use of over-the-counter cough suppressants containing codeine phosphate p. 360 should be avoided in children under 12 years and in children of any age known to be cyp2d6 ultra-rapid metabolisers. cough suppressants containing similar opioid analgesics such as dextromethorphan and pholcodine p. 259 are not generally recommended in children and should be avoided in children under 6 years.

mhra/chm advice (march 2008 and february 2009)
over-the-counter cough and cold medicines for children children under 6 years should not be given over-the-counter cough and cold medicines containing the following ingredients:
- brompheniramine, chlorphenamine maleate, diphenhydramine, doxylamine, promethazine, or tripolidine (antihistamines);
- dextromethorphan or pholcodine (cough suppressants);
- guaifenesin or ippecacuanha (expectorants);
- phenylephrine hydrochloride, pseudoephedrine hydrochloride, ephedrine hydrochloride, oxytetracycline, or xylometazoline hydrochloride (decongestants).

over-the-counter cough and cold medicines can be considered for children aged 6–12 years after basic principles of best care have been tried, but treatment should be restricted to five days or less. children should not be given more than 1 cough or cold preparation at a time because different brands may contain the same active ingredient; care should be taken to give the correct dose.

drugs used for cough and congestion not listed below; codeine phosphate, p. 360 · methadone hydrochloride, p. 436 · morphine hydrochloride, p. 367

citric acid
(formulated as simple linctus)

indications and dose

cough
by mouth
- adult: 5 ml 3–4 times a day, this dose is for simple linctus, bp (2.5%)
\textbf{Prescribing and dispensing information} Flavours of oral liquid formulations may include anise. When prepared extemporaneously, the BP states Simple Linctus, BP consists of citric acid monohydrate 2.5%, in a suitable vehicle with an anise flavour.

\textbf{Medicinal forms}
There can be variation in the licensing of different medicines containing the same drug.

\textbf{Oral solution}
- **Citric acid (Non-proprietary)**
  - Citric acid monohydrate 6.25 mg per 1 ml Simple linctus
  - 200 ml GSK £0.93 DT price = £0.92
  - 2000 ml GSK £3.20

\section*{Menthol and Derivatives}

\textbf{Eucalyptus with menthol}

\textbf{Indications and dose}

\textit{Aromatic inhalation for relief of nasal congestion}

\textbf{By inhalation}
- Adult: Add one teaspoonful to a pint of hot, not boiling, water and inhale the vapour

\textbf{Prescribing and dispensing information}
When prepared extemporaneously, the BP states Benzoin Tincture, BP consists of benzoin tincture. There can be variation in the licensing of different medicines containing the same drug.

\textbf{Inhalation vapour}
- **Eucalyptus with menthol (Non-proprietary)**
  - Eucalyptus oil 100 microlitre per 1 ml, Menthol 20 mg per 1 ml
  - light 70 mg per 1 ml, Menthol 20 mg per 1 ml

\subsection*{Opioids}

\textbf{Pholcodine}

\textbf{Indications and dose}

\textit{Dry cough}

\textbf{By mouth using linctus}
- Child: 6-11 years: 2–5 mg 3–4 times a day
- Child: 12-17 years: 5–10 mg 3–4 times a day
- Adult: 5–10 mg 3–4 times a day

\textbf{Prescribing and dispensing information}
When prepared extemporaneously, the BP states Pholcodine Linctus, BP consists of pholcodine 400 microgram per 1 ml in a suitable flavoured vehicle, containing citric acid monohydrate 1% and Pholcodine Linctus, Strong, BP consists of pholcodine 10 mg/5 ml in a suitable flavoured vehicle, containing citric acid monohydrate 2%.

\textbf{Medicinal forms}
There can be variation in the licensing of different medicines containing the same drug.

\textbf{Oral solution}
- **Pholcodine (Non-proprietary)**
  - Pholcodine 1 mg per 1 ml Pholcodine 5mg/5ml linctus | 200 ml £1.28 DT price = £1.25 Schedule 5 (CD Inv)
  - Pholcodine Sng/5ml linctus sugar free (sugar-free) | 200 ml £2.75 DT price = £1.27 Schedule 5 (CD Inv) (sugar-free) | 2000 ml £11.70 Schedule 5 (CD Inv)
  - Pholcodine 2 mg per 1 ml Pholcodine 10mg/5ml linctus strong sugar free (sugar-free) | 2000 ml £10.19 DT price = £10.19 Schedule 5 (CD Inv)
  - Pholcodine 10mg/5ml linctus strong | 200 ml £1.61 Schedule 5 (CD Inv)
  - Galenphol (Thornton & Ross Ltd)
    - Pholcodine 400 microgram per 1 ml Galenphol Paediatric 2mg/5ml linctus (sugar-free) | 2000 ml £4.50 DT price = £4.50 Schedule 5 (CD Inv)
    - Pholcodine 1 mg per 1 ml Galenphol 5mg/5ml linctus (sugar-free) | 2000 ml £8.50 Schedule 5 (CD Inv)
    - Pholcodine 2 mg per 1 ml Galenphol Strong 10mg/5ml linctus (sugar-free) | 2000 ml £9.88 DT price = £9.19 Schedule 5 (CD Inv)
  - Brands may include Covonia Dry Cough, Pavacol-D

\section*{Resins}

\textbf{Benzoin tincture}

\textbf{(Friars’ Balsam)}

\textbf{Indications and dose}

\textit{Aromatic inhalation for relief of nasal congestion}

\textbf{By inhalation}
- Child: Add 5 mL to a pint of hot, not boiling, water and inhale the vapour; repeat after 4 hours if necessary
- Adult: Add 5 mL to a pint of hot, not boiling, water and inhale the vapour; repeat after 4 hours if necessary

\textbf{Side-effects}
Allergic contact dermatitis

\textbf{Prescribing and dispensing information}
Tincture, balsamic acids approx. 4.5%. When prepared extemporaneously, the BP states Benzoin Tincture, Compound, BP consists of balsamic acids approx. 4.5%. Not recommended (applied as a rub or to pillows) for infants under 3 months.
Idiopathic pulmonary fibrosis

ANTIFIBROTICS

Pirfenidone

- **DRUG ACTION** The exact mechanism of action of pirfenidone is not yet understood, but it is believed to slow down the progression of idiopathic pulmonary fibrosis by exerting both antifibrotic and anti-inflammatory properties.

**INDICATIONS AND DOSE**

Treatment of mild to moderate idiopathic pulmonary fibrosis (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: Initially 267 mg 3 times a day for 7 days, then increased to 534 mg 3 times a day for 7 days, then increased to 801 mg 3 times a day
  - **Dose adjustments due to interactions**
    - Caution with concomitant use with ciprofloxacin—reduce dose of pirfenidone to 534 mg three times daily with high-dose ciprofloxacin (750 mg twice daily).
    - Caution with concomitant use of drugs known to cause photosensitivity—if photosensitivity reaction or rash occurs, dose adjustment or treatment interruption may be required (consult product literature).

- **CONTRA-INDICATIONS** Cigarette smoking

- **CAUTIONS**
  - **CAUTIONS, FURTHER INFORMATION**
    - **Photosensitivity** Avoid exposure to direct sunlight—if photosensitivity reaction or rash occurs, dose adjustment or treatment interruption may be required (consult product literature).
  - **Treatment interruption** If treatment is interrupted for less than 14 consecutive days, the dose can be resumed at the previous daily dose without titration.
  - **INTERACTIONS** → Appendix 1 (pirfenidone).

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal discomfort - anorexia - arthralgia - constipation - diarrhoea - dizziness - dry skin - dysgeusia - dyspepsia - erythema - flatulence - gastritis - gastro-oesophageal reflux disease - headache - hot flush - insomnia - malaise - myalgia - nausea - non-cardiac chest pain - photosensitivity reaction - pruritus - raised hepatic enzymes - rash - somnolence - upper respiratory tract infection - urinary tract infection - vomiting - weight loss
  - **Rare** Raised bilirubin in combination with raised hepatic transaminases

**SIDE-EFFECTS, FURTHER INFORMATION**

Gastrointestinal side-effects may require dose reduction or treatment interruption—consult product literature.

- **PREGNANCY** Manufacturer advises avoid—no information available.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Use with caution in mild to moderate hepatic impairment, particularly if concomitant use of CYP1A2 inhibitors. Avoid use in severe hepatic impairment.

- **RENAL IMPAIRMENT** Avoid use if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  - Monitor for weight loss.
  - Test liver function before treatment, then at monthly intervals for the next 6 months, and then every 3 months thereafter; review if abnormal liver function tests—dose reduction, treatment interruption or discontinuation may be required (consult product literature).

- **PATIENT AND CARER ADVICE** Dizziness or malaise may affect performance of skilled tasks (e.g. driving).

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Pirfenidone for treating idiopathic pulmonary fibrosis (April 2013) NICE TA282
      - Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis only if:
        - the patient has a forced vital capacity (FVC) between 50% and 80% predicted, and
        - the manufacturer provides pirfenidone with the discount agreed in the patient access scheme.Treatment should be discontinued if there is evidence of disease progression, defined as a decline in predicted FVC of 10% or more within any 12 month period.
      - Patients currently receiving pirfenidone that is not within NHS Scotland for the treatment of mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is restricted for use in patients with a predicted forced vital capacity less than or equal to 80%, and only whilst pirfenidone is available at the price agreed in the patient access scheme.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Liquid**
  - **CAUTIONARY AND ADVISORY LABELS**
    - 15
      - BENZIIN TINCTURE (Non-proprietary)
        - Balsamic acids 16.5 mg per 1 ml Benzin tincture | 500 ml (£12.62–£22.78 DT price = £12.62)
  - **RENAL IMPAIRMENT**
    - **BREAST FEEDING**
      - Manufacturer advises avoid—no information available.

6 Respiratory depression, respiratory distress syndrome and apnoea

Respiratory stimulants

Respiratory stimulants (analeptic drugs) have a limited place in the treatment of ventilatory failure in patients with chronic obstructive pulmonary disease. They are effective only when given by intravenous injection or infusion and have a short duration of action. Their use has largely been replaced by ventilatory support including nasal intermittent positive pressure ventilation. However, occasionally when
ventilatory support is contra-indicated and in patients with hypercapnic respiratory failure who are becoming drowsy or comatose, respiratory stimulants in the short term may arouse patients sufficiently to co-operate and clear their secretions. Respiratory stimulants can also be harmful in respiratory failure since they stimulate non-respiratory as well as respiratory muscles. They should only be given under expert supervision in hospital and must be combined with active physiotherapy. There is at present no oral respiratory stimulant available for long-term use in chronic respiratory failure.

**RESPIRATORY STIMULANTS**

**Doxapram hydrochloride**

**INDICATIONS AND DOSE**

**Postoperative respiratory depression**

**INITIALLY BY INTRAVENOUS INJECTION**

▶ Adult: Initially 1–1.5 mg/kg, to be administered over at least 30 seconds, repeated if necessary after intervals of one hour, alternatively (by intravenous infusion) 2–3 mg/minute, adjusted according to response

**Acute respiratory failure**

**BY INTRAVENOUS INFUSION**

▶ Adult: 1.5–4 mg/minute, adjusted according to response, to be given concurrently with oxygen and whenever possible monitor with frequent measurement of blood gas tensions

**CONTRA-INDICATIONS** Cerebral oedema · cerebrovascular accident · coronary artery disease · epilepsy and other convulsive disorders · hyperthyroidism · physical obstruction of respiratory tract · severe hypertension · status asthmaticus

**CAUTIONS** Give with beta₂ agonist in bronchoconstriction · give with oxygen in severe irreversible airways obstruction or severely decreased lung compliance (because of increased work load of breathing) · hypertension · impaired cardiac reserve · phaeochromocytoma

**INTERACTIONS** → Appendix 1 (doxapram).

**SIDE-EFFECTS** Arrhythmias · bradycardia · bronchospasm · chest pain · confusion · convulsions · cough · dizziness · dyspnoea · extrasystoles · flushing · hallucination · headache · hyperactivity · hypertension · incontinence · laryngospasm · muscle spasms · nausea · perineal warmth · pyrexia · tachycardia · urinary retention · vomiting

**PREGNANCY** No evidence of harm, but manufacturer advises avoid unless benefit outweighs risk.

**HEPATIC IMPAIRMENT** Use with caution.

**MONITORING REQUIREMENTS** Frequent arterial blood gas and pH measurements are necessary during treatment to ensure correct dosage.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

▶ **DOXAPRAM HYDROCHLORIDE** (Non-proprietary)

Doxapram hydrochloride 20 mg per 1 ml Doxapram 100mg/5ml solution for injection ampoules | 5 ampoule [PMS] £30.00–£110.00

**Infusion**

▶ **DOXAPRAM HYDROCHLORIDE** (Non-proprietary)

Doxapram hydrochloride 2 mg per 1 ml Doxapram 1g/500ml infusion bags | 1 bag [PMS] no price available
Chapter 4

Nervous system

1 Dementia

Dementia

Acetylcholinesterase inhibiting drugs are used in the treatment of Alzheimer’s disease, specifically for mild to moderate disease. Rivastigmine p. 264 is also licensed for mild to moderate dementia associated with Parkinson’s disease. The evidence to support the use of these drugs relates to their cognitive enhancement.

Treatment with drugs for dementia should be initiated and supervised only by a specialist experienced in the management of dementia.

Benefit is assessed by repeating the cognitive assessment at around 3 months. Such assessment cannot demonstrate how the disease may have progressed in the absence of treatment but it can give a good guide to response. Up to half the patients given these drugs will show a slower rate of deterioration occurs during this short period, consideration should be given to restarting therapy.

ANTICHOLINESTERASES

Donepezil hydrochloride

- **DRUG ACTION** Donepezil is a reversible inhibitor of acetylcholinesterase.

- **INDICATIONS AND DOSE**
  - **Mild to moderate dementia in Alzheimer’s disease**
  - **BY MOUTH**
    - Adult: Initially 5 mg once daily for one month, then increased if necessary up to 10 mg daily, doses to be given at bedtime

- **CAUTIONS** Asthma · chronic obstructive pulmonary disease · sick sinus syndrome · supraventricular conduction abnormalities · susceptibility to peptic ulcers

- **INTERACTIONS** → Appendix 1 (parasympathomimetics). Caution with concomitant antipsychotic treatment—increased risk of neuroleptic malignant syndrome.

- **SIDE-EFFECTS**
  - Common or very common Abnormal dreams · aggression · agitation · anorexia · diarrhoea · dizziness · fatigue · hallucinations · headache · insomnia · muscle cramps · nausea · pruritus · rash · syncope · urinary incontinence · vomiting
  - Uncommon Bradycardia · duodenal ulcers · gastric ulcers · gastro-intestinal haemorrhage · seizures
  - Rare AV block · extrapyramidal symptoms · hepatitis · potential for bladder outflow obstruction · sino-atrial block
  - Very rare Neuroleptic malignant syndrome

- **SIDE-EFFECTS, FURTHER INFORMATION**
Acetylcholinesterase inhibitors can cause unwanted dose-related cholinergic effects and should be started at a low dose and the dose increased according to response and tolerability.

- **HEPATIC IMPAIRMENT** Caution in mild to moderate impairment. No information available for severe impairment.

- **DIRECTIONS FOR ADMINISTRATION** Donepezil orodispersible tablet should be placed on the tongue, allowed to disperse, and swallowed.

- **PATIENT AND CARER ADVICE** Patient or carers should be given advise on how to administer donepezil hydrochloride orodispersible tablets.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease (March 2011) NICE TA217
    - These drugs can be used for the treatment of mild to moderate Alzheimer’s disease. Treatment should only be prescribed under the following conditions:
      - Alzheimer’s disease must be diagnosed and treatment initiated by a specialist; treatment can be continued by general practitioners under a shared-care protocol;
      - the carer’s view of the condition should be sought before and during treatment;
● treatment should continue only if it is considered to have a worthwhile effect on cognitive, global, functional, or behavioural symptoms.
Healthcare professionals should not rely solely on assessment scales to determine the severity of Alzheimer’s disease when the patient has learning or other disabilities, or other communication difficulties. www.nice.org.uk/TA217

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet
▷ Donepezil hydrochloride (Non-proprietary)
Donepezil hydrochloride 5 mg | 28 tablet | £59.85 DT price = £1.31
Donepezil hydrochloride 10 mg | 28 tablet | £83.89 DT price = £1.65

Aricept
Donepezil hydrochloride 5 mg | 28 tablet | £59.85 DT price = £1.31
Donepezil hydrochloride 10 mg | 28 tablet | £83.89 DT price = £1.65

Orodispersible tablet
▷ Donepezil hydrochloride (Non-proprietary)
Donepezil hydrochloride 5 mg | 28 tablet | £59.85 DT price = £1.31
Donepezil hydrochloride 10 mg | 28 tablet | £83.89 DT price = £1.65

Aricept Evess
Donepezil hydrochloride 5 mg | 28 tablet | £83.89 DT price = £1.65

Donepezil hydrochloride 10 mg | 28 tablet | £83.89 DT price = £1.65

Oral solution
▷ Donepezil hydrochloride (Non-proprietary)
Donepezil hydrochloride 1 mg per 1 ml | 150 ml | £37.50 DT price = £1.57

Galantamine
● DRUG ACTION
Galantamine is a reversible inhibitor of acetylcholinesterase and it also has nicotinic receptor agonist properties.

INDICATIONS AND DOSE
Mild to moderate dementia in Alzheimer’s disease
By mouth using Immediate-release medicines
Adult: Initially 4 mg twice daily for 4 weeks, increased to 8 mg twice daily for 4 weeks; maintenance 8–12 mg twice daily
Mild to moderate dementia in Alzheimer’s disease
By mouth using Modified-release capsules
Adult: Initially 8 mg once daily for 4 weeks, increased to 16 mg once daily for 4 weeks; maintenance 16–24 mg daily

CAUTIONS
Asthma - avoid in gastrointestinal obstruction • avoid in urinary retention • avoid whilst recovering from bladder surgery • avoid whilst recovering from gastrointestinal surgery • cardiac disease • chronic obstructive pulmonary disease • congestive heart failure • electrolyte disturbances • history of seizures • pulmonary infection • sick sinus syndrome • supraventricular conduction abnormalities • susceptibility to peptic ulcers • unstable angina

INTERACTIONS
Appendix 1 (parasympathomimetics).

SIDE-EFFECTS
Common or very common Abdominal pain • anorexia • bradycardia • depression • diarrhoea • dizziness • drowsiness • dyspepsia • hallucination • headache • hypertension • malaise • muscle spasm • nausea • sweating • syncope • tremor • vomiting • weight loss
Uncommon Arrhythmias • blurring vision • dehydration • first-degree AV block • flushing • hypotension • muscular weakness • palpitation • paraesthesia • seizures • taste disturbance • tinnitus
Rare Exacerbation of Parkinson’s disease • hepatitis

NICE technology appraisals (TAs)
Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease (March 2011) NICE TA217
See Donepezil, p. 262. www.nice.org.uk/TA217

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

Tablet
CAUTIONARY AND ADVISORY LABELS
3, 21
Galantamine (Non-proprietary)
Galantamine (as Galantamine hydrobromide) 8 mg | 28 tablet | £61.09
Galantamine (as Galantamine hydrobromide) 12 mg | 28 tablet | £79.80

Reminyl
Shire Pharmaceuticals Ltd
Galantamine (as Galantamine hydrobromide) 8 mg | 28 tablet | £61.09
Galantamine (as Galantamine hydrobromide) 12 mg | 28 tablet | £79.80

Modified-release capsule
CAUTIONARY AND ADVISORY LABELS
3, 21
Reminyl XL (Shire Pharmaceuticals Ltd)
Galantamine (as Galantamine hydrobromide) 8 mg | 28 capsule | £64.90 DT price = £1.93
Galantamine (as Galantamine hydrobromide) 12 mg | 28 capsule | £79.80 DT price = £2.83

BRANDS MAY INCLUDE:
Acitor XL; Consion XL; Elmiron; Galantex XL; Galyxa XL; Gatalin XL; Galylan; Lotprosin XL; Luventa XL

Oral solution
CAUTIONARY AND ADVISORY LABELS
3, 21
Galantamine (Non-proprietary)
Galantamine (as Galantamine hydrobromide) 4 mg per 1 ml | 200 ml | £120.00

Galantamine (as Galantamine hydrobromide) 4 mg per 1 ml | 500 ml | £225.00

4
Nervous system
Dementia 263
Rivastigmine

● **DRUG ACTION** Rivastigmine is a reversible non-competitive inhibitor of acetylcholinesterases.

**INDICATIONS AND DOSE**

**Mild to moderate dementia in Alzheimer’s disease**

**BY MOUTH**

> Adult: Initially 1.5 mg twice daily, increased in steps of 1.5 mg twice daily; dose to be increased at intervals of at least 2 weeks according to response and tolerability; usual dose 3–6 mg twice daily (max. per dose 6 mg twice daily), if treatment interrupted for more than several days, titrate from 1.5 mg twice daily

**BY TRANSDERMAL APPLICATION USING PATCHES**

> Adult: Apply 4.6 mg/24 hours daily for at least 4 weeks, increased if tolerated to 9.5 mg/24 hours daily for a further 6 months, then increased if necessary to 13.3 mg/24 hours daily, increase to 13.3 mg/24 hours patch if well tolerated and cognitive deterioration or functional decline demonstrated; use caution in patients with body-weight less than 50 kg, if treatment interrupted for more than 3 days, titrate from 4.6 mg/24 hours patch

**Mild to moderate dementia in Parkinson’s disease**

**BY MOUTH**

> Adult: Initially 1.5 mg twice daily, increased in steps of 1.5 mg twice daily, dose to be increased at intervals of at least 2 weeks according to response and tolerability; usual dose 3–6 mg twice daily (max. per dose 6 mg twice daily), if treatment interrupted for more than several days, titrate from 1.5 mg twice daily.

**Dose equivalence and conversion**

When switching from oral to transdermal therapy, patients taking 3–6 mg by mouth daily should initially switch to 4.6 mg/24 hours patch, then titrate as above. Patients taking 9 mg by mouth daily should switch to 9.5 mg/24 hours patch if oral dose stable and well tolerated; if oral dose not stable or well tolerated, patients should switch to 4.6 mg/24 hours patch, then titrate as above. Patients taking 12 mg by mouth daily should switch to 9.5 mg/24 hours patch. The first patch should be applied on the day following the last oral dose.

**CAUTIONS** Bladder outflow obstruction - conduction abnormalities - duodenal ulcers - gastric ulcers - history of asthma - history of chronic obstructive pulmonary disease - history of seizures - risk of fatal overdose with patch administration errors - sick sinus syndrome - susceptibility to ulcers

**INTERACTIONS** → Appendix 1 (parasympathomimetics).

**SIDE-EFFECTS**

> **Common or very common** Abdominal pain - agitation - anorexia - anxiety - bradycardia - confusion - diarrhoea - dizziness - drowsiness - dyspepsia - extrapyramidal symptoms - headache - increased salivation - insomnia - malaise - nausea - sweating - tremor - urinary incontinence - vomiting - weight loss - worsening of Parkinson’s disease

> **Uncommon** Atrial fibrillation - AV block - depression - syncpe

> **Rare** Angina - duodenal ulceration - gastric ulceration - rash - seizures

> **Very rare** Gastro-intestinal haemorrhage - hallucinations - hypertension - pancreatitis - tachycardia

**SIDE-EFFECTS, FURTHER INFORMATION**

Transdermal administration less likely to cause gastro-intestinal disturbance.

Treatment should be interrupted if gastro-intestinal side-effects occur and withheld until their resolution—titrate dose if necessary. Acetylcholinesterase inhibitors can cause unwanted dose-related cholinergic effects and should be started at a low dose and the dose increased according to response and tolerability.

**Hepatic Impairment** Titrate according to individual tolerability in mild to moderate impairment. Use with caution in severe impairment—no information available.

**Renal Impairment** Titrate according to individual tolerability.

**Monitoring Requirements** Monitor body-weight.

**DIRECTIONS FOR ADMINISTRATION**

> With transdermal use Apply patches to clean, dry, non-hairy, non-irritated skin on back, upper arm, or chest, removing after 24 hours and sitting a replacement patch on a different area (avoid using the same area for 14 days).

**PATIENT AND CARER ADVICE**

**EXELON® TRANSDERMAL PATCHES.** Adhere patients and carers of patch administration instructions, particularly to remove the previous day’s patch before applying the new patch—consult product literature.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

> Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease (March 2011) NICE TA217

See Donepezil, p. 262. www.nice.org.uk/TA217

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (October 2007) that Exelon® patches should be restricted for use in patients with moderately severe Alzheimer’s disease under the conditions of the NICE guidance (September 2007) and when a transdermal patch is an appropriate choice of formulation.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 21, 25**

> **RIVASTIGMINE (Non-proprietary)**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Brand</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5 mg 1.5mg capsule</td>
<td>Exelon® (Novartis Pharmaceuticals UK Ltd)</td>
<td>£33.25 DT price + £3.25</td>
</tr>
<tr>
<td>3 mg 3mg capsule</td>
<td>Exelon® (Novartis Pharmaceuticals UK Ltd)</td>
<td>£33.25 DT price + £3.27</td>
</tr>
<tr>
<td>4.5 mg 4.5mg capsule</td>
<td>Exelon® (Novartis Pharmaceuticals UK Ltd)</td>
<td>£33.25 DT price + £15.82</td>
</tr>
<tr>
<td>6 mg 6mg capsule</td>
<td>Exelon® (Novartis Pharmaceuticals UK Ltd)</td>
<td>£33.25 DT price + £15.74</td>
</tr>
<tr>
<td>9 mg 9mg capsule</td>
<td>Exelon® (Novartis Pharmaceuticals UK Ltd)</td>
<td>£33.25 DT price + £15.74</td>
</tr>
</tbody>
</table>

**Brands may include Kerstipon; Nimvastid.**
### NMDA RECEPTOR ANTAGONISTS

#### Memantine hydrochloride

**DRUG ACTION** Memantine is a glutamate receptor antagonist.

### INDICATIONS AND DOSE

**Moderate to severe dementia in Alzheimer’s disease**

**BY MOUTH**

- Adult: Initially 5 mg once daily, increased in steps of 5 mg at weekly intervals; maximum 20 mg per day

### CAUTIONS

- History of convulsions
- INTERACTIONS → Appendix 1 (memantine).

### SIDE-EFFECTS

- Common or very common Constipation, dizziness, drowsiness, dyspnoea, headache, hypertension
- Uncommon Abnormal gait, confusion, fatigue, hallucinations, heart failure, thrombosis, vomiting
- Very rare Seizures
- Frequency not known Depression, pancreatitis, psychosis, suicidal ideation
- HEPATIC IMPAIRMENT Avoid in severe impairment—no information available.

### RENAL IMPAIRMENT

Reduce dose to 10 mg daily if eGFR 30–49 mL/minute/1.73 m²; if well tolerated after at least 7 days can be increased in steps to 20 mg daily; reduce dose to 10 mg daily if eGFR 5–29 mL/minute/1.73 m². Avoid if eGFR less than 5 mL/minute/1.73 m².

### DIRECTIONS FOR ADMINISTRATION

Oral solution should be dosed onto a spoon or into a glass of water.

### NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)


### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>MEMANTINE HYDROCHLORIDE (Non-proprietary)</th>
<th>Memantine hydrochloride 10 mg</th>
<th>Memantine 10mg tablets</th>
<th>7 tablet (PBM) £34.50 DT price = £1.86</th>
<th>56 tablet (PBM) £65.56</th>
<th>112 tablet (PBM) £100.10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memantine hydrochloride 20 mg</td>
<td>Memantine 20mg tablets</td>
<td>28 tablet (PBM) £69.01 DT price = £2.63</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Transdermal patch**

| RIVASTIGMINE (Non-proprietary) | Rivastigmine 4.6 mg per 24 hour | Transdermal patch | 30 patch (PBM) £77.97 DT price = £7.97 |
|--------------------------------|-------------------------------|-----------------|---------------------------------|-----------------|
| Rivastigmine 9.5 mg per 24 hour | Rivastigmine 9.5mg/24hours transdermal patches | 30 patch (PBM) £31.69 DT price = £3.16 |
| Exelon (Novartis Pharmaceuticals UK Ltd) | Rivastigmine 4.6 mg per 24 hour | Exelon 4.6mg/24hours transdermal patches | 30 patch (PBM) £31.69 DT price = £31.69 |
| Rivastigmine 9.5 mg per 24 hour | Exelon 9.5mg/24hours transdermal patches | 30 patch (PBM) £77.97 DT price = £7.97 |
| Rivastigmine 13.3 mg per 24 hour | Exelon 13.3mg/24hours transdermal patches | 30 patch (PBM) £77.97 DT price = £7.97 |

Brands may include Alzest, Eluden, Prometax, Rivatev, Somnition, Vokez,

**Ebixa** (Lundbeck Ltd)

- Memantine hydrochloride 5 mg | Ebixa 5mg tablets | 7 tablet (PBM) no price available
- Memantine hydrochloride 10 mg | Ebixa 10mg tablets | 7 tablet (PBM) no price available | 28 tablet (PBM) £34.50 DT price = £1.86 | 56 tablet (PBM) £69.01 | 112 tablet (PBM) £138.01
- Memantine hydrochloride 15 mg | Ebixa 15mg tablets | 7 tablet (PBM) no price available
- Memantine hydrochloride 20 mg | Ebixa 20mg tablets | 7 tablet (PBM) no price available | 28 tablet (PBM) £69.01 DT price = £2.63

- Ebixa (Lundbeck Ltd) Ebixa tablets treatment initiation pack | 28 tablet (PBM) £43.13 |

Brands may include Marixa, Nondatine

### Oral solution

**MEMANTINE HYDROCHLORIDE (Non-proprietary)**

- Memantine hydrochloride 10 mg/ml oral solution sugar free (sugar-free) | 50 ml (PBM) £55.00–£62.36 DT price = £62.24 (sugar-free) | 100 ml (PBM) £110.00–£124.72
- Ebixa (Lundbeck Ltd) Memantine hydrochloride 10 mg per 1 ml | Ebixa 5mg/0.5ml pump actuation oral solution (sugar-free) | 50 ml (PBM) £61.61 DT price = £62.24 (sugar-free) | 100 ml (PBM) £123.23

---

# 2 Mental health disorders

## 2.1 Anxiety

### Drugs used for Anxiety not listed below;

- Duloxetine, p. 288
- Escitalopram, p. 285
- Moclobemide, p. 283
- Oxprenolol hydrochloride, p. 145
- Paroxetine, p. 287
- Perixazine, p. 308
- Perphenazine, p. 308
- Pregabalin, p. 400
- Trazadone hydrochloride, p. 291
- Trifluoperazine, p. 310
- Venlafaxine, p. 289

---

### CARBAMATES

#### Meprobamate

**INDICATIONS AND DOSE**

Short-term use in anxiety—not recommended

**BY MOUTH**

- Adult: 400 mg 3–4 times a day
- Elderly: Up to 200 mg 3–4 times a day

### Important safety information

The European Medicines Agency has recommended (January 2012) the suspension of all marketing authorisations for meprobamate because the risks, particularly of serious CNS side-effects, outweigh the benefits.

### CONTRA-INDICATIONS

Acute porphyrias p. 864 - acute pulmonary insufficiency - respiratory depression

### CAUTIONS

Abrupt withdrawal (may precipitate convulsions) - avoid prolonged use - debilitated - elderly - epilepsy (may induce seizures) - history of alcohol abuse - history of drug abuse - marked personality disorder - muscle weakness - respiratory disease

### INTERACTIONS → Appendix 1 (anxiolytics and hypnotics).

### SIDE-EFFECTS

- Common or very common Amnesia - ataxia (especially in the elderly) - confusion (especially in the elderly) - dependence - drowsiness - lightheadedness - marked personality disorder - muscle weakness - paradoxical increase in aggression
- Uncommon Changes in libido - dizziness - dysarthria - gastro-intestinal disturbances - gynaecomastia - headache - hypotension - incontinence - salivation changes -
slurred speech, tremor, urinary retention, vertigo, visual disturbances

- **Rare** Agranulocytosis, apnoea, blood disorders, jaundice, rashes, respiratory depression, skin reactions
- **Frequency not known** CNS effects, paradoxical excitement, paraesthesia, weakness

- **PREGNANCY** Avoid if possible.
- **BREAST FEEDING** Avoid. Concentration in milk may exceed maternal plasma concentrations fourfold and may cause drowsiness in infant.
- **HEPATIC IMPAIRMENT** Can precipitate coma.
- **RENAL IMPAIRMENT** Increased cerebral sensitivity. Start with small doses in severe impairment.
- **PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.
- **LESS SUITABLE FOR PRESCRIBING** Meprobamate is less suitable for prescribing.

**HYPNOTICS AND SEDATIVES (BENZODIAZEPINE)**

### Benzodiazepines

- **CONTRA-INDICATIONS** Acute pulmonary insufficiency, marked neuromuscular respiratory weakness, sleep apnoea syndrome, unstable myasthenia gravis
- **CAUTIONS** Avoid prolonged use (and abrupt withdrawal thereafter), debilitated patients (reduce dose), elderly (reduce dose), history of alcohol dependence or abuse, history of drug dependence or abuse, myasthenia gravis, respiratory disease

**CAUTIONS, FURTHER INFORMATION**

- **Paradoxical effects** A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

- **INTERACTIONS** → Appendix 1 (anxiolytics and hypnotics).

**SIDE-EFFECTS**

- **Overdose** Benzodiazepines taken alone cause drowsiness, ataxia, dysarthria, nystagmus, and occasionally respiratory depression, and coma. For details on the management of poisoning, see Benzodiazepines, under Emergency treatment of poisoning p. 1123.
- **PREGNANCY** Risk of neonatal withdrawal symptoms when used during pregnancy. Avoid regular use and use only if there is a clear indication such as seizure control. High doses administered during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.
- **RENAL IMPAIRMENT** Increased cerebral sensitivity to benzodiazepines.
- **PATIENT AND CARER ADVICE** Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including benzodiazepines, see Drugs and driving under Guidance on prescribing p. 1.

### Alprazolam

**INDICATIONS AND DOSE**

**Short-term use in anxiety**

**BY MOUTH**

- **Adult** 250–500 micrograms 3 times a day, increased if necessary up to 3 mg daily, for debilitated patients, use elderly dose
- **Elderly** 250 micrograms 2–3 times a day, increased if necessary up to 3 mg daily

- **CONTRA-INDICATIONS** Chronic psychosis, hyperkinesia, not for use alone to treat depression (or anxiety associated with depression), obsessional states, phobic states, respiratory depression
- **CAUTIONS** Muscle weakness, organic brain changes, personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

- **SIDE-EFFECTS**
  - **Common or very common** Amnesia, ataxia (especially in the elderly), confusion (especially in the elderly), dependence, drowsiness the next day, lightheadedness the next day, muscle weakness, paradoxical increase in aggression
  - **Uncommon** Changes in libido, dizziness, dysarthria, gastro-intestinal disturbances, gynaecomastia, headache, hypotension, incontinence, salivation changes, slurred speech, tremor, urinary retention, vertigo, visual disturbances
  - **Rare** Apnoea, blood disorders, jaundice, respiratory depression, skin reactions
- **BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.
- **HEPATIC IMPAIRMENT** Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Start with smaller initial doses or reduce dose. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Start with small doses in severe impairment.
- **PATIENT AND CARER ADVICE** May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NHS restrictions** Alprazolam tablets are not prescribable under the NHS.

**MEDICINAL FORMS**

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS 2**
  - **Xanax (Pfizer Ltd)** Meprobamate 400 mg Meprobamate 400 mg tablets | 84 tablet | £197.63–£200.54 DT price | £200.54 Schedule 3 (CD No Register)

---

### Benzodiazepines

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS 2**
  - **MEPROBAMATE (Non-proprietary)**
    - Meprobamate 400 mg Meprobamate 400 mg tablets | 84 tablet | £197.63–£200.54 DT price | £200.54 Schedule 3 (CD No Register)

---

### Benzodiazepines

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS 2**
  - **MEPROBAMATE (Non-proprietary)**
    - Meprobamate 400 mg Meprobamate 400 mg tablets | 84 tablet | £197.63–£200.54 DT price | £200.54 Schedule 3 (CD No Register)
**Chlordiazepoxide hydrochloride**

**INDICATIONS AND DOSE**

**Short-term use in anxiety**

**BY MOUTH**
- Adult: 10 mg 3 times a day, increased if necessary to 60–100 mg daily in divided doses, for debilitated patients, use elderly dose
- Elderly: 5 mg 3 times a day, increased if necessary to 30–50 mg daily in divided doses

**Treatment of alcohol withdrawal in moderate dependence**

**BY MOUTH**
- Adult: 10–30 mg 4 times a day, dose to be gradually reduced over 5–7 days, consult local protocols for titration regimens

**Treatment of alcohol withdrawal in severe dependence**

**BY MOUTH**
- Adult: 10–50 mg 4 times a day and 10–40 mg as required for the first 2 days, dose to be gradually reduced over 7–10 days, consult local protocols for titration regimens; maximum 250 mg per day

**SIDE-EFFECTS**

- **Common or very common**
  - Amnesia
  - Ataxia
  - Confusion
  - Drowsiness
  - Impaired concentration
  - Impaired reaction time
  - Insomnia
  - Nervousness
  - Paradoxical increase in agitation
  - Respiratory depression
  - Sedation

- **Uncommon**
  - Sedative effects
  - Somnolence

- **Rare**
  - Blood disorders
  - Dizziness
  - Headache
  - Impaired sexual function
  - Tachycardia

- **Breastfeeding**

- **Contraindications**

- **Caution**

- **Hepatic impairment**

- **Renal impairment**

- **Special precautions**

- **Special warnings**

- **Funding/access decisions**

- **Medicinal forms**

- **Tablet**

**Capsule**

**Contraindications**

**Caution**

**Advisory labels**

**Price**

**NHS restrictions**

**Diazepam**

**INDICATIONS AND DOSE**

**Muscle spasm of varied aetiology**

**BY MOUTH**
- Adult: 2–15 mg daily in divided doses, then increased if necessary to 60 mg daily, adjusted according to response, dose only increased in spastic conditions

**Acute muscle spasm**

**BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION**
- Adult: 10 mg, then 10 mg after 4 hours if required, intravenous injection to be administered into a large vein at a rate of no more than 5 mg/minute

**Tetanus**

**BY INTRAVENOUS INJECTION**
- Child: 100–300 micrograms/kg every 1–4 hours
- Adult: 100–300 micrograms/kg every 1–4 hours

**BY INTRAVENOUS INFUSION OR BY NASODUODENAL TUBE**
- Child: 3–10 mg/kg, adjusted according to response, to be given over 24 hours
- Adult: 3–10 mg/kg, adjusted according to response, to be given over 24 hours

**Muscle spasm in cerebral spasticity or in postoperative skeletal muscle spasm**

**BY MOUTH**
- Child 1-11 months: Initially 250 micrograms/kg twice daily
- Child 1-4 years: Initially 2.5 mg twice daily
- Child 5-11 years: Initially 5 mg twice daily
- Child 12-17 years: Initially 10 mg twice daily; maximum 40 mg per day

**Anxiety**

**BY MOUTH**
- Adult: 2 mg 3 times a day, then increased if necessary to 15–30 mg daily in divided doses, for debilitated patients, use elderly dose
- Elderly: 1 mg 3 times a day, then increased if necessary to 7.5–15 mg daily in divided doses

**Insomnia associated with anxiety**

**BY MOUTH**
- Adult: 5–15 mg daily, to be taken at bedtime

**Severe acute anxiety / Control of acute panic attacks / Acute alcohol withdrawal**

**INITIALLY BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION**
- Adult: 10 mg, then (by intramuscular injection or by intravenous injection) 10 mg after at least 4 hours if required, intravenous injection to be administered into a large vein, at a rate of not more than 5 mg/minute

**continued**
Acute anxiety and agitation

**BY RECTUM**
- Adult: 500 micrograms/kg, then 500 micrograms/kg after 12 hours as required
- Elderly: 250 micrograms/kg, then 250 micrograms/kg after 12 hours as required

**Acute drug-induced dystonic reactions**

**BY INTRAVENOUS INJECTION**
- Adult: 5–10 mg, then 5–10 mg after at least 10 minutes as required, to be administered into a large vein, at a rate of not more than 5 mg/minute

**Premedication**

**BY MOUTH**
- Adult: 2.5–5 mg, to be given 1–2 hours before procedure

**BY INTRAVENOUS INJECTION**
- Adult: 100–200 micrograms/kg, to be administered into a large vein at a rate of not more than 5 mg/minute, immediately before procedure

**Status epilepticus**

**BY INTRAVENOUS INJECTION**
- Adult: 10–20 mg, to be administered into a large vein over 2–4 minutes, immediately before procedure

**Dyspnoea associated with anxiety in palliative care**

**BY MOUTH**
- Adult: 5–10 mg daily

**Pain of muscle spasm in palliative care**

**BY MOUTH**
- Adult: 5–10 mg daily

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Rare
  - Changes in libido (in adults), dizziness, dysarthria, gastro-intestinal disturbances, gynaecomastia
  - Muscle weakness, ataxia (especially in the elderly)
  - Muscle weakness, ataxia (especially in the elderly)
  - Changes in libido (in children), dizziness

**Specific side-effects**

- Changes in libido
- Dizziness
- Gynaecomastia
- Paradoxical increase in aggression
- Increased risk of seizures
- Increased risk of depression
- Increased risk of psychosis
- Increased risk of irritability

**Important safety information**

**ANAESTHESIA**

- Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

**CONTRA-INDICATIONS**

- Avoid injections containing benzyl alcohol in neonates
- Chronic psychosis (in adults)
- CNS depression
- Committed airway
- Hyperventilation
- Not for use alone to treat depression (or anxiety associated with depression) (in adults)
- Obsessional states
- Phobic states
- Respiratory depression

**CAUTIONS**

**GENERAL CAUTIONS**

- Muscle weakness
- Organic brain changes
- Parenteral administration (close observation required until full recovery from sedation)
- Personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

**SPECIFIC CAUTIONS**

- With intravenous use, high risk of venous thrombophlebitis with intravenous use (reduced by using an emulsion formulation)

**CAUTIONS, FURTHER INFORMATION**

- Special precautions for intravenous injection: When given intravenously for reversing respiratory depression with mechanical ventilation must be immediately available.

**SPECIFIC SIDE-EFFECTS**

- Life-threatening acute drug-induced dystonic reactions
- Intravenous injection
- Child: 100 micrograms/kg, repeated if necessary
- Child: 5–10 mg, repeated if necessary, to be given over 3–5 minutes
change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.

Epilepsy and Pregnancy Register All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1246).

- **BREAST FEEDING** Present in milk, and should be avoided if possible during breast-feeding.

- **HEPATIC IMPAIRMENT** Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half lives are safer, such as temazepam or oxazepam. Start with smaller initial doses or reduce dose. Avoid in severe impairment.

- **RENAL IMPAIRMENT** Start with small doses in severe impairment.

- **DIRECTIONS FOR ADMINISTRATION**
  - With intramuscular use Diazepam is absorbed by plasctics of infusion bags and giving sets.
  - With intravenous use Emulsion formulation preferred for intravenous injection.
  - With intravenous use in children For continuous intravenous infusion of diazepam emulsion, dilute to a concentration of max. 400 micrograms/mL with Glucose 5% or 10%; max. 6 hours between addition and completion of infusion. For continuous intravenous infusion of diazepam solution, dilute to a concentration of max. 50 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%.
  - With intravenous use in adults For intravenous infusion (solution) (Diazepam, Wockhardt), give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to a concentration of not more than 10 mg in 200 mL.
  - With intravenous use in adults For intravenous infusion (emulsion) (Diazemuls®), give continuously in Glucose 5% or 10%. May be diluted to a max. concentration of 200 mg in 500 mL; max. 6 hours between addition and completion of administration. May be given via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%.
  - With intramuscular use or intravenous use in adults Solution for injection should not be diluted, except for intravenous infusion.
  - With intramuscular use in adults Only use intramuscular route when oral and intravenous routes not possible.

- **PATIENT AND CARER ADVICE** May impair judgement and increase reaction time, and so affect ability to drive or perform skilled tasks; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair performance on the following day.

  Medicines for Children leaflet: Diazepam (rectal) for stopping seizures www.medicinesforchildren.org.uk/diazepam-rectal-stopping-seizures-0

  Medicines for Children leaflet: Diazepam for muscle spasm www.medicinesforchildren.org.uk/diazepam-for-muscle-spasm

  Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned of the risks of undertaking skilled tasks (e.g. driving) afterwards. For intravenous benzodiazepines the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home afterwards. The dangers of taking alcohol should be emphasised.

- **PROFESSION SPECIFIC INFORMATION**

  Dental practitioners’ formulary Diazepam Tablets may be prescribed. Diazepam Oral Solution 2 mg/5 mL may be prescribed.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, oral suspension, oral solution

---

### Tablet

**CAUTIONARY AND ADVISORY LABELS 2, 19**

- **DIAZEPAM (Non-proprietary)**
  - Diazepam 2 mg | 2 tablet | £3.80 DT price = £1.07 Schedule 4 (CD Benz) | 1000 tablet | £135.71 Schedule 4 (CD Benz)
  - Diazepam 5 mg | 2 tablet | £6.80 DT price = £1.09 Schedule 4 (CD Benz) | 1000 tablet | £242.85 Schedule 4 (CD Benz)
  - Diazepam 10 mg | 10 tablet | £9.80 DT price = £1.23 Schedule 4 (CD Benz) | 500 tablet | £175.00 Schedule 4 (CD Benz)

**Solution for injection**

**EXCIPENTS**: May contain Benzyl alcohol, ethanol, propylene glycol

- **DIAZEPAM (Non-proprietary)**
  - Diazepam 5 mg per 1 ml | Diazepam 10mg/2ml solution for injection ampoules | 10 ampoule | £4.00-£4.50 DT price = £4.50 Schedule 4 (CD Benz)

**Emulsion for injection**

- Diazemuls (Actavis UK Ltd)
  - Diazepam 5 mg per 1 ml | Diazemuls 10mg/2ml emulsion for injection ampoules | 10 ampoule | £9.05 Schedule 4 (CD Benz)

### Enema

**CAUTIONARY AND ADVISORY LABELS 2, 19**

- **DIAZEPAM (Non-proprietary)**
  - Diazepam 2 mg per 1 ml | Diazepam 5mg RecTubes | 5 tube | £5.85 DT price = £5.85 Schedule 4 (CD Benz)
  - Diazepam 2.5mg/1.25ml rectal solution tube | 5 tube | no price available Schedule 4 (CD Benz)
  - Diazepam 2.5mg RecTubes | 5 tube | £5.65 Schedule 4 (CD Benz)
  - Diazepam 5mg/2.5ml rectal solution tube | 5 tube | £6.30 DT price = £5.85 Schedule 4 (CD Benz)
  - Diazepam 4 mg per 1 ml | Diazepam 10mg RecTubes | 5 tube | £7.35 DT price = £7.35 Schedule 4 (CD Benz)
  - Diazepam 10mg/2.5ml rectal solution tube | 5 tube | £8.00 DT price = £7.35 Schedule 4 (CD Benz)
  - Stesolid (Actavis UK Ltd)
  - Diazepam 2 mg per 1 ml | Stesolid 5mg rectal tube | 5 tube | £6.89 DT price = £5.85 Schedule 4 (CD Benz)
  - Diazepam 4 mg per 1 ml | Stesolid 10mg rectal tube | 5 tube | £8.78 DT price = £7.35 Schedule 4 (CD Benz)

### SEROTONIN RECEPTOR AGONISTS

#### Buspirone hydrochloride

**INDICATIONS AND DOSE**

**Anxiety (short-term use)**

**BY MOUTH**

- Adult: 5 mg 2–3 times a day, increased if necessary up to 45 mg daily, dose to be increased at intervals of 2–3 days; usual dose 15–30 mg daily in divided doses

- **CONTRA-INDICATIONS** Acute porphyrias p. 864 - epilepsy

- **CAUTIONS** Does not alleviate symptoms of benzodiazepine withdrawal

**CAUTIONS, FURTHER INFORMATION**

A patient taking a benzodiazepine still needs to have the benzodiazepine withdrawn gradually; it is advisable to do this before starting buspirone.

- **INTERACTIONS** > Appendix 1 (anxiolytics and hypnotics).

- **SIDE-EFFECTS**
  - Common or very common Dizziness - excitement - headache - nausea - nervousness
  - Rare Chest pain - confusion - drowsiness - dry mouth - fatigue - palpitation - seizures - sweating - tachycardia

- **PREGNANCY** Avoid.

- **BREAST FEEDING** Avoid.
2.2 Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Central nervous system stimulants include the amphetamines (dexamphetamine sulfate below and lisdexamfetamine mesilate p. 271) and related drugs (e.g. methylphenidate hydrochloride p. 273). They have very few indications and in particular, should not be used to treat depression, obesity, senility, debility, or for relief of fatigue. CNS stimulants should be prescribed for children with severe and persistent symptoms of attention deficit hyperactivity disorder (ADHD), when the diagnosis has been confirmed by a specialist; children with moderate symptoms of ADHD can be treated with CNS stimulants when psychological interventions have been unsuccessful or are unavailable. Prescribing of CNS stimulants may be continued by general practitioners, under a shared-care arrangement. Treatment of ADHD often needs to be continued into adolescence, and may need to be continued into adulthood.

Drug treatment of ADHD should be part of a comprehensive treatment programme. The choice of medication should take into consideration co-morbid conditions (such as tic disorders, Tourette syndrome, and epilepsy), the adverse effect profile, potential for drug misuse, tolerance and dependance; and preferences of the patient and carers. Methylphenidate hydrochloride and atomoxetine are used for the management of ADHD; dexamphetamine sulfate and lisdexamfetamine mesilate are an alternative in children who do not respond to these drugs.

The need to continue drug treatment for ADHD should be reviewed at least annually. This may involve suspending treatment.

CNS STIMULANTS (AMPHETAMINE ISOMERS)

Dexamphetamine sulfate (Dexamphetamine sulfate)

INDICATIONS AND DOSE

Narcolepsy

BY MOUTH

• Adult: Initially 10 mg daily in divided doses, increased in steps of 10 mg every 1 week, maintenance dose to

be given in 2–4 divided doses; maximum 60 mg per day

• Elderly: Initially 5 mg daily in divided doses, increased in steps of 5 mg every 1 week, maintenance dose to be

given in 2–4 divided doses; maximum 60 mg per day

Refractory attention deficit hyperactivity disorder (initiated under specialist supervision)

BY MOUTH

• Child 6-17 years: Initially 2.5 mg 2–3 times a day, increased in steps of 5 mg daily if required, dose to be increased at weekly intervals, increased if necessary up to 1 mg/kg daily, maintenance dose to be given in 2–4 divided doses, up to 20 mg daily (40 mg daily has been required in some children)

• Adult: Initially 5 mg twice daily, dose is increased at weekly intervals according to response, maintenance dose to be given in 2–4 divided doses; maximum 60 mg per day
**Lisdexamfetamine mesilate**

**DRUG ACTION** Lisdexamfetamine is a prodrug of dexamfetamine.

**INDICATIONS AND DOSE**

**Attention deficit hyperactivity disorder refractory to methylphenidate (initiated by a specialist)**

**BY MOUTH**

- **Child 6-17 years:** Initially 30 mg once daily, increased in steps of 20 mg every week if required, dose to be taken in the morning, discontinue if response insufficient after 1 month; maximum 70 mg per day
- **Adult:** Initially 30 mg once daily, increased in steps of 20 mg every week if required, dose to be taken in the morning, discontinue if response insufficient after 1 month; maximum 70 mg per day

**UNLICENSED USE**

Not licensed for use in adults for attention deficit hyperactivity disorder.

**MONITORING REQUIREMENTS**

- Monitor growth in children.
- Monitor for aggressive behaviour or hostility during initial treatment.
- Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.

**TREATMENT CESSION** Avoid abrupt withdrawal.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use in children Tablets can be halved.

**PRESCRIBING AND DISPENSING INFORMATION**

Data on safety and efficacy of long-term use not complete.

**PATIENT AND CARER ADVICE**

- **Drugs and Driving** Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

- **Monitoring requirements** following each dose adjustment, and at least every 6 months thereafter.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Methylenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) (March 2006) NICE TA98

Dexamfetamine is recommended, within its licensed indications, as an option for the management of ADHD in children and adolescents. www.nice.org.uk/TA98

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, modified-release capsule

**Tablet**

- **DEXAMFETAMINE SULFATE (Non-proprietary)**
  - Dexamfetamine sulfate 5 mg Dexamfetamine 5mg tablets | 28 tablet | £24.75 GT price + £24.75 Schedule 2 (CD)

**Oral solution**

- **DEXAMFETAMINE SULFATE (Non-proprietary)**
  - Dexamfetamine sulfate 1 mg per 1 ml Dexamfetamine 5mg/5ml oral solution sugar free (sugar-free) | 500 ml | £109.04 Schedule 2 (CD)

**CONTRA-INDICATIONS** Advanced arteriosclerosis - agitated states - hyperexcitability - hyperthyroidism - moderate hypertension - severe hypertension - symptomatic cardiovascular disease

**CAUTIONS** Anorexia - bipolar disorder - history of alcohol abuse - history of cardiac abnormalities - history of cardiovascular disease - history of drug abuse - may lower seizure threshold (discontinue if seizures occur) - psychosis - susceptibility to angle-closure glaucoma - tics - Tourette syndrome

**CAUTIONS, FURTHER INFORMATION**

- **Tics and Tourette syndrome** Discontinue use if tics occur.

**Growth restriction in children** Monitor height and weight as growth restriction may occur during prolonged therapy (drug-free periods may allow catch-up in growth but withdraw slowly to avoid inducing depression or renewed hyperactivity).

**INTERACTIONS** → Appendix 1 (sympathomimetics).

**SIDE-EFFECTS**

- **Common or very common** Abdominal cramps - aggression - decreased appetite - diarrhea - dizziness - drowsiness - dry mouth - dysphoria - growth restriction in children - headache - lable mood - malaise - mydriasis - nausea - pyrexia - sleep disturbances - tics - vomiting - weight loss

- **Uncommon** Anorexia - anxiety - depression - dermatillomania - dysphoria - hallucination - hypertension - logorrhoea - mania - palpitation - paranoia - rash - restlessness - sexual dysfunction - sweating - tachycardia - tremor - visual disturbances

- **Very rare** Angle-closure glaucoma

- **Frequency not known** Cardiomyopathy - choreoathetoid movements (in predisposed individuals) - dyskinesia (in predisposed individuals) - euphoria - seizures - Tourette syndrome (in predisposed individuals)

**Overdose** Amphetamines cause wakefulness, excessive activity, paranoia, hallucinations, and hypertension followed by exhaustion, convulsions, hyperthermia, and coma. See Stimulants under Emergency treatment of poisoning, p. 1123.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid—present in human milk.

**RENAL IMPAIRMENT** Max. dose 50 mg daily in severe impairment.

**MONITORING REQUIREMENTS**

- Monitor for aggressive behaviour or hostility during initial treatment.

- **Monitor growth in children.**

- **Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.**

**TREATMENT CESSION** Avoid abrupt withdrawal.

**DIRECTIONS FOR ADMINISTRATION** Swallow whole or mix contents of capsule in yoghurt or a glass of water or orange juice; contents should be dispersed completely and consumed immediately.

**PATIENT AND CARER ADVICE**

Patients and carers should be counselled on the administration of capsules.

**Drugs and Driving** Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.
For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including amphetamines, see Drugs and driving under Guidance on prescribing p. 1.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 3, 25**

- **Lisdexamfetamine dimesylate (Non-proprietary)**

  - Lisdexamfetamine dimesylate 30 mg Elvanse Adult 30mg capsules | 28 capsule (P) £58.24 GT price + £58.24 Schedule 2 (CD)
  - Lisdexamfetamine dimesylate 50 mg Elvanse Adult 50mg capsules | 28 capsule (P) £68.60 GT price + £68.60 Schedule 2 (CD)
  - Lisdexamfetamine dimesylate 70 mg Elvanse Adult 70mg capsules | 28 capsule (P) £83.16 GT price + £83.16 Schedule 2 (CD)
  - Elvanse (Shire Pharmaceuticals Ltd) ▼

- Lisdexamfetamine dimesylate 30 mg Elvanse 30mg capsules | 28 capsule (P) £58.24 GT price + £58.24 Schedule 2 (CD)
- Lisdexamfetamine dimesylate 50 mg Elvanse 50mg capsules | 28 capsule (P) £68.60 GT price + £68.60 Schedule 2 (CD)
- Lisdexamfetamine dimesylate 70 mg Elvanse 70mg capsules | 28 capsule (P) £83.16 GT price + £83.16 Schedule 2 (CD)

**CNS STIMULANTS (NORADRENALINE REUPTAKE INHIBITORS)**

**Atomoxetine**

**INDICATIONS AND DOSE**

Attention deficit hyperactivity disorder (initiated by a specialist)

**BY MOUTH**

- Child 6-17 years (body-weight 70 kg and above): Initially 40 mg daily for 7 days, dose is increased according to response; maintenance 80 mg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening; high daily doses to be given under the direction of a specialist; maximum 120 mg per day
- Child 6-17 years (body-weight up to 70 kg): Initially 500 micrograms/kg daily for 7 days, dose is increased according to response; maintenance 1.2 mg/kg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening; high daily doses to be given under the direction of a specialist; maximum 1.8 mg/kg per day; maximum 120 mg per day
- Adult (body-weight up to 70 kg): Initially 500 micrograms/kg daily for 7 days, dose is increased according to response; maintenance 1.2 mg/kg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 1.8 mg/kg per day; maximum 120 mg per day
- Adult (body-weight 70 kg and above): Initially 40 mg daily for 7 days, dose is increased according to response; maintenance 80–100 mg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 120 mg per day

**UNLICENSED USE**

- In children Doses above 100 mg daily not licensed.
- In adults Dose maximum of 120 mg not licensed.

Atomoxetine doses in BNF may differ from those in product literature.

**CONTRA-INDICATIONS** Phaeochromocytoma - severe cardiovascular disease - severe cerebrovascular disease

**SIDE-EFFECTS**

- **Common or very common**: Abdominal pain - anorexia - anxiety - constipation - depression - dermatitis - dizziness - drowsiness - dry mouth - dyspepsia - flatulence - flushing - headache - chills - increased blood pressure - irritability - lethargy - malaise - mydriasis - nausea - palpitation - paraesthesia - prostatitis - rash - sexual dysfunction - sleep disturbances - sweating - tachycardia - taste disturbances - tremor - urinary dysfunction - vomiting
- **Uncommon**: Aggression - cold extremities - emotional lability - hostility - hypoaesthesia - menstrual disturbances - muscle spasms - pruritus - psychosis - QT-interval prolongation - suicidal ideation - syncope - tics
- **Rare**: Raynaud’s phenomenon - seizures
- **Very rare**: Angle-closure glaucoma - hepatic disorders

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk.

**BREAST FEEDING** Avoid-present in milk in animal studies.

**HEPATIC IMPAIRMENT** Halve dose in moderate impairment. Quarter dose in severe impairment.

**MONITORING REQUIREMENTS**

- Monitor for appearance or worsening of anxiety, depression or tics.
- Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Atomoxetine for attention deficit hyperactivity disorder (ADHD) www.medicinesforchildren.org.uk/atomoxetine-attention-deficit-hyperactivity-disorder-adhd

Suicidal ideation Following reports of suicidal thoughts and behaviour, patients and their carers should be informed about the risk and told to report clinical worsening, suicidal thoughts or behaviour, irritability, agitation, or depression. Hepatic impairment Following rare reports of hepatic disorders, patients and carers should be advised of the risk and be told how to recognise symptoms; prompt medical attention should be sought in case of abdominal pain, unexplained nausea, malaise, darkening of the urine, or jaundice.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Methylinide, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) (March 2006) NICE TA98

Atomoxetine is recommended, within its licensed indications, as an option for the management of ADHD in children and adolescents. www.nice.org.uk/TA98

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Capsule**

CAUTIONARY AND ADVISORY LABELS 3

- **Strattera** (Eli Lilly and Company Ltd)
  - Atomoxetine (as Atomoxetine hydrochloride) 10 mg Strattera 10mg capsules | 7 capsule (P) £15.62 | 28 capsule (P) £62.46 GT price = £62.46
  - Atomoxetine (as Atomoxetine hydrochloride) 18 mg Strattera 18mg capsules | 7 capsule (P) £15.62 | 28 capsule (P) £62.46 GT price = £62.46

**CONTRA-INDICATIONS** Phaeochromocytoma - severe cardiovascular disease - severe cerebrovascular disease

**INTERACTIONS** → Appendix 1 (atomoxetine).

Avoid concomitant use of drugs that prolong QT interval.

**CAUTIONS** QT-interval prolongation - aggressive behaviour - cardiovascular disease - cerebrovascular disease - emotional lability - history of seizures - hostility - hypertension - mania - psychosis - structural cardiac abnormalities - susceptibility to angle-closure glaucoma - tachycardia

**DRUG AND DRIVING**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension
Attention deficit hyperactivity disorder

**Methylenidate hydrochloride**

**INDICATIONS AND DOSE**

Attention deficit hyperactivity disorder (initiated under specialist supervision)

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 6–17 years: Initially 5 mg 1–2 times a day, increased in steps of 5–10 mg daily if required, at weekly intervals, increased if necessary up to 60 mg daily in 2–3 divided doses, increased if necessary up to 2.1 mg/kg daily in 2–3 divided doses, the licensed maximum dose is 60 mg daily in 2–3 doses, higher dose under the direction of a specialist, discontinue if no response after 1 month, if effect wears off in evening (with rebound hyperactivity) a dose at bedtime may be appropriate (establish need with trial bedtime dose). Treatment may be started using a modified-release preparation; maximum 90 mg per day.
  - Adult: Initially 5 mg 2–3 times a day, dose is increased if necessary at weekly intervals according to response, increased if necessary up to 100 mg daily in 2–3 divided doses, if effect wears off in evening (with rebound hyperactivity) a dose at bedtime may be appropriate (establish need with trial bedtime dose). Treatment may be started using a modified-release preparation.

**Narcolepsy**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 10–60 mg daily in divided doses; usual dose 20–30 mg daily in divided doses, dose to be taken before meals.

**CONCERTA® XL**

Attention deficit hyperactivity disorder

- **BY MOUTH**
  - Adult: Initially 18 mg once daily, dose to be taken in the morning; adjusted at weekly intervals according to response; maximum 108 mg per day.

Dose equivalence and conversion

Total daily dose of 15 mg of standard-release formulation is considered equivalent to Concerta® XL 18 mg once daily.

**MEDIKINET® XL**

Attention deficit hyperactivity disorder

- **BY MOUTH**
  - Child 6–17 years: Initially 10 mg once daily, dose to be taken in the morning with breakfast; adjusted at weekly intervals according to response; increased if necessary up to 2.1 mg/kg daily, licensed max. dose is 60 mg daily, to be increased to higher dose only under direction of specialist; discontinue if no response after 1 month; maximum 90 mg per day.
  - Adult: Initially 10 mg once daily, dose to be taken in the morning with breakfast; adjusted at weekly intervals according to response; maximum 100 mg per day.

**UNLICENSED USE**

Not licensed for use in children under 6 years; doses over 60 mg daily not licensed; doses of Concerta XL over 54 mg daily not licensed.

**CONTRA-INDICATIONS**

Anorexia nervosa, arrhythmias, cardiomyopathy, cardiovascular disease, cerebrovascular disorders, heart failure, hyperthyroidism, phaeochromocytoma, psychosis, severe depression, severe hypertension, structural cardiac abnormalities, suicidal ideation, uncontrolled bipolar disorder, vasculitis.

**CAUTIONS**

Agitation, alcohol dependence, anxiety, drug dependence, epilepsy (discontinue if increased seizure frequency), family history of Tourette syndrome, susceptibility to angle-closure glaucoma, tics.

**CONCERTA® XL** Dysphagia (dose form not appropriate) - restricted gastro-intestinal lumen (dose form not appropriate).

**INTERACTIONS**

- Appendix 1 (sympathomimetics).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, aggression, alopecia, anorexia, arrhythmias, arthralgia, asthenia, changes in blood pressure, cough, depression, diarrhoea, dizziness, drowsiness, dry mouth, dyspepsia, fever, growth restriction, headache, insomnia, irritability, movement disorders, nasopharyngitis, nausea, nervousness, palpititation, pruritus, rash, reduced weight gain, tachycardia, tics, vomiting.

- **Uncommon** Abnormal dreams, confusion, constipation, dysthymia, epistaxis, haematuria, muscle cramps, suicidal ideation, urinary frequency.

- **Rare** Angina, sweating, visual disturbances.

- **Very rare** Angle-closure glaucoma, blood disorders, cerebral arteritis, dependence, erythema multiforme, exfoliative dermatitis, hepatic dysfunction, leucopenia, myocardial infarction, neuroleptic malignant syndrome, psychosis, seizures, thrombocytopenia, tolerance, Tourette syndrome.

- **Frequency not known** Bradycardia, convulsions, supraventricular tachycardia.

**PREGNANCY**

Limited experience—avoid unless potential benefit outweighs risk.

**BREAST FEEDING**

Limited information available—avoid.

**MONITORING REQUIREMENTS**

- Monitor for psychiatric disorders.

- Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.

**TREATMENT CESSATION**

Avoid abrupt withdrawal.

**DIRECTIONS FOR ADMINISTRATION**

**MEDIKINET® XL**

Contents of capsule can be sprinkled on a tablespoon of apple sauce or yoghurt (then swallowed immediately without chewing).
274 Mental health disorders

EQUASYM® XL
Contents of capsule can be sprinkled on a tablespoon of apple sauce (then swallowed immediately without chewing).

- PRESCRIBING AND DISPENSING INFORMATION
  Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of methylphenidate, prescribers should specify the brand to be dispensed.

CONCERTA® XL
Consists of an immediate-release component (22% of the dose) and a modified-release component (78% of the dose).

EQUASYM® XL
Consists of an immediate-release component (30% of the dose) and a modified-release component (70% of the dose).

MEDIKINET® XL
Consists of an immediate-release component (50% of the dose) and a modified-release component (50% of the dose).

- PATIENT AND CARER ADVICE
  Drugs and Driving
  Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

2015 legislation regarding driving whilst taking certain drugs, may also apply to methylphenidate, see Drugs and driving under Guidance on prescribing p. 1.

CONCERTA® XL
Tablet membrane may pass through gastro-intestinal tract unchanged.

- NATIONAL FUNDING/ACCESS DECISIONS
  NICe technology appraisals (TAs)
  - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) (March 2006) NICE TA98
    Methylphenidate is recommended, within its licensed indications, as an option for the management of ADHD in children and adolescents. www.nice.org.uk/TA98

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, oral suspension, oral solution

Tablet
  - METHYLPHENIDATE HYDROCHLORIDE (Non-proprietary)
    Methylphenidate hydrochloride 5 mg Methylphenidate 5mg tablets | 30 tablet (P) £3.03 DT price + £3.03 Schedule 2 (CD)
    Methylphenidate hydrochloride 10 mg Methylphenidate 10mg tablets | 30 tablet (P) £5.49 DT price + £5.49 Schedule 2 (CD)
    Methylphenidate hydrochloride 20 mg Methylphenidate 20mg tablets | 30 tablet (P) £10.92 DT price + £10.92 Schedule 2 (CD)
  - Ritalin® (Novartis Pharmaceuticals UK Ltd)
    Methylphenidate hydrochloride 10 mg Ritalin® 10mg tablets | 30 tablet (P) £5.57 DT price + £5.49 Schedule 2 (CD)
  - Brands may include Medikinet; Tranquilyn

Modified-release tablet
  CAUTIONARY AND ADVISORY LABELS 25
  - Concerta® (Janssen-Cilag Ltd)
    Methylphenidate hydrochloride 18 mg Concerta XL 18mg tablets | 30 tablet (P) £31.19 DT price + £31.19 Schedule 2 (CD)
    Methylphenidate hydrochloride 27 mg Concerta XL 27mg tablets | 30 tablet (P) £36.81 DT price + £36.81 Schedule 2 (CD)
    Methylphenidate hydrochloride 36 mg Concerta XL 36mg tablets | 30 tablet (P) £42.45 DT price + £42.45 Schedule 2 (CD)

   - Brands may include Matoride XL; Xenidate XL

2.3 Bipolar disorder and mania

Drugs used for mania and hypomania

Antimanic drugs are used to control acute attacks and to prevent recurrence of episodes of mania or hypomania. Long-term treatment of bipolar disorder should continue for at least two years from the last manic episode and up to five years if the patient has risk factors for relapse.

An antidepressant drug may also be required for the treatment of co-existing depression, but should be avoided in patients with rapid-cycling bipolar disorder, a recent history of hypomania, or with rapid mood fluctuations.

Benzodiazepines

Use of benzodiazepines (such as lorazepam p. 412) may be helpful in the initial stages of treatment for behavioural disturbance or agitation; they should not be used for long periods because of the risk of dependence.

Antipsychotic drugs

Antipsychotic drugs (normally olanzapine p. 315, quetiapine p. 318, or risperidone p. 319) are useful in acute episodes of mania and hypomania; if the response to antipsychotic drugs is inadequate, lithium or valproate may be added. An antipsychotic drug may be used concomitantly with lithium or valproate in the initial treatment of severe acute mania.

Olanzapine p. 315 can be used for the long-term management of bipolar disorder in patients whose manic episode responded to olanzapine p. 315 therapy. It can be given either as monotherapy, or in combination with lithium or valproate if the patient has frequent relapses or continuing functional impairment.

Asenapine p. 276, a second-generation antipsychotic, is licensed for the treatment of moderate to severe manic episodes associated with bipolar disorder.

When discontinuing antipsychotics, the dose should be reduced gradually over at least 4 weeks if the patient is continuing with other antimanic drugs; if the patient is not continuing with other antimanic drugs or if there is a history of manic relapse, a withdrawal period of up to 3 months should be considered.
**Bipolar disorder and mania**

**Carbamazepine**

Carbamazepine p. 387 may be used under specialist supervision for the prophylaxis of bipolar disorder (manic-depressive disorder) in patients unresponsive to a combination of other prophylactic drugs; it is used in patients with rapid-cycling manic-depressive illness (4 or more affective episodes per year). The dose of carbamazepine p. 387 should not normally be increased if an acute episode of mania occurs.

**Valproate**

Valproic acid (as the semisodium salt) and sodium valproate p. 403 are used for the treatment of manic episodes associated with bipolar disorder. Valproate (valproic acid below and sodium valproate) is also used for the prophylaxis of bipolar disorder; however, it should not normally be prescribed for women of childbearing potential. In patients with frequent relapse or continuing functional impairment, consider switching therapy to lithium or olanzapine p. 394, or adding lithium or olanzapine to valproate. If a patient taking valproate experiences an acute episode of mania that is not ameliorated by increasing the valproate dose, consider concomitant therapy with olanzapine, quetiapine p. 318, or risperidone p. 319.

**Lithium**

Lithium salts are used in the prophylaxis and treatment of mania, hypomania and depression in bipolar disorder (manic-depressive disorder), and in the prophylaxis and treatment of recurrent unipolar depression. Lithium is also used as concomitant therapy with antidepressant medication in patients who have had an incomplete response to treatment for acute bipolar depression and to augment other antidepressants in patients with treatment-resistant depression [unlicensed indication]. It is also licensed for the treatment of aggressive or self-harming behaviour.

The decision to use prophylactic lithium requires specialist advice, and must be based on careful consideration of the likelihood of recurrence in the individual patient, and the benefit of treatment weighed against the risks. The full prophylactic effect of lithium may not occur for six to twelve months after the initiation of therapy. Olanzapine p. 315 or valproate (given alone or as adjunctive therapy with lithium) are alternative prophylactic treatments in patients who experience frequent relapses or continued functional impairment.

Drugs used for Bipolar disorder and mania not listed below: Carbamazepine, p. 387 · Chlorpromazine hydrochloride, p. 304 · Haloperidol, p. 306 · Lamotrigine, p. 394 · Olanzapine, p. 315 · Paliperidone, p. 317 · Perphenazine, p. 308 · Prochlorperazine, p. 309 · Quetiapine, p. 318 · Sodium valproate, p. 403 · Zuclopenthixol acetate, p. 311

**Valproic acid**

**INDICATIONS AND DOSE**

**Treatment of manic episodes associated with bipolar disorder**

**BY MOUTH**

- Adult: Initially 750 mg daily in 2–3 divided doses, then increased to 1–2 g daily, adjusted according to response, doses greater than 45 mg/kg daily require careful monitoring

**Migraine prophylaxis**

**BY MOUTH**

- Adult: Initially 250 mg twice daily, then increased if necessary to 1 g daily in divided doses

**CONVULEX®**

**Epilepsy**

**BY MOUTH**

- Child: Total daily dose to be given in 2–4 divided doses (consult product literature)
- Adult: Total daily dose to be given in 2–4 divided doses (consult product literature)

**Dose equivalence and conversion**

Semisodium valproate comprises equimolar amounts of sodium valproate and valproic acid. Convulex® has a 1:1 dose relationship with products containing sodium valproate, but nevertheless care is needed if switching or making changes.

---

**Unlicensed use** Not licensed for migraine prophylaxis.

**Contra-indications** Acute porphyrias p. 864 · family history of severe hepatic dysfunction

**Cautions** Systemic lupus erythematosus

**Caution, further information**

**Liver toxicity** Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (especially in children under 3 years and in those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in first 6 months and usually involving multiple antiepileptic therapy. Raised liver enzymes during valproate treatment are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal—discontinue if abnormally prolonged prothrombin time (particularly in association with other relevant abnormalities).

Consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

**Interactions** → Appendix 1 (valproic acid).

**Side-effects**

- **Common or very common** Diarrhoea · gastric irritation · hyperammonaemia · nausea · thrombocytopenia · transient hair loss (regrowth may be curly) · weight gain
- **Uncommon** Aggression · ataxia · behavioural disturbances · hyperactivity · increased alertness · tremor · vasculitis
- **Rare** Anaemia · blood disorders · confusion · drowsiness · hallucinations · hearing loss · hepatic dysfunction · lethargy · leucopenia · pancytopenia · rash · stupor
- **Very rare** Acne · coma · dementia · encephalopathy · enuresis · extrapyramidal symptoms · Fanconi’s syndrome · gynaecomastia · hirsutism · hyponatraemia · increase in bleeding time · pancreatitis · peripheral oedema · reduced bone mineral density · Stevens-Johnson syndrome · suicidal ideation · toxic epidermal necrolysis
- **Frequency not known** Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome · hypersensitivity reactions · male infertility · menstrual disturbances · syndrome of inappropriate secretion of antidiuretic hormone

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hepatic dysfunction** Withdraw treatment immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or loss of seizure control.

**Conception and contraception** Valproate is associated with teratogenic risks and should not be used in women of child-bearing potential unless there is no safer alternative—this should be fully considered and discussed before prescribing for women of child-bearing age.
276 Mental health disorders

Effective contraception advised in women of child-bearing potential.

**PREGNANCY** Valproate is associated with the highest risk of major and minor congenital malformations (in particular neural tube defects), and long-term neurodevelopmental effects. Valproate should not be used during pregnancy or in women of child-bearing potential unless there is no safer alternative and only after a careful discussion of the risks. If valproate is to be used during pregnancy, the lowest effective dose should be prescribed in divided doses to avoid peaks in plasma-valproate concentrations; doses greater than 1 g daily are associated with an increased risk of teratogenicity. Specialist prenatal monitoring should be instigated when valproate has been taken in pregnancy. Neonatal bleeding (related to hypofibrinogenemia) and neonatal hepatotoxicity also reported. The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**BREAST FEEDING** Amount too small to be harmful.

**HEPATIC IMPAIRMENT** Avoid if possible—hepatotoxicity and hepatic failure may occasionally occur (usually in first 6 months). Avoid in active liver disease.

**RENAL IMPAIRMENT** Reduce dose.

**MONITORING REQUIREMENTS**
- Monitor closely if dose greater than 45 mg/kg daily.
- Monitor liver function before therapy and during first 6 months especially in patients most at risk.
- Measure full blood count and ensure no undue potential for bleeding before starting and before surgery.

**EFFECT ON LABORATORY TESTS** False-positive urine tests for ketones.

**TREATMENT CESSATION** If treatment with valproate is stopped, reduce the dose gradually over at least 4 weeks.

**PRESCRIBING AND DISPENSING INFORMATION**
- Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic oral valproic acid product.
- **Pregnancy** Use only if potential benefit outweighs risk—risk to embryo/fetus.
- **Breast feeding** Avoid—no information available.
- **Hepatic impairment** Use with caution in moderate impairment. Avoid in severe impairment.
- **Renal impairment** Use with caution in moderate impairment. Avoid in severe impairment.
- **Pregnancy** Use only if potential benefit outweighs risk—risk to embryo/fetus.
- **Breast feeding** Avoid—no information available.
- **Hepatic impairment** Use with caution in moderate impairment. Avoid in severe impairment.
- **Renal impairment** Use with caution in moderate impairment. Avoid in severe impairment.

**SIDE EFFECTS**
- Convulsions, sedation, hyperreflexia, tremor, ataxia, dysgeusia, fatigue, headache, dizziness, constipation, diarrhoea, nausea and vomiting.
- Changes in body weight and carbohydrate intolerance.
- Increased appetite, anorexia, anovulation.
-Transaminase elevation, jaundice, hepatitis and pancreatitis.
- Increased uric acid, gout, hyperkalaemia.
- Hypocalcaemia, hypomagnesaemia.
- Photosensitivity.
- Hypothyroidism.

**CAUTIONS**
- Dementia with Lewy Bodies
- **Side effects** Anxiety, dysphagia, glossodynia, hyperkalaemia, rhabdomyolysis, speech disturbance, taste disturbance, tongue swelling, transient oral hypoesthesia, transient paraesthesia.
- **Pregnancy** Use only if potential benefit outweighs risk—risk to embryo/fetus.
- **Breast feeding** Avoid—no information available.
- **Hepatic impairment** Use with caution in moderate impairment. Avoid in severe impairment.
- **Renal impairment** Use with caution in moderate impairment. Avoid in severe impairment.
- **Pregnancy** Use only if potential benefit outweighs risk—risk to embryo/fetus.
- **Breast feeding** Avoid—no information available.
- **Hepatic impairment** Use with caution in moderate impairment. Avoid in severe impairment.
- **Renal impairment** Use with caution in moderate impairment. Avoid in severe impairment.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Sublingual tablet**
- Sycrest (Lundbeck Ltd)
  - Asenapine (as Asenapine maleate) 5 mg Sycrest 5mg sublingual tablets (sugar-free) | 60 tablet (DT price = £102.60 DT price = £102.60)
  - Asenapine (as Asenapine maleate) 10 mg Sycrest 10mg sublingual tablets (sugar-free) | 60 tablet (DT price = £102.60 DT price = £102.60)

**LITHIUM SALTS**

**Lithium salts**

**Contra-indications**
- Addison’s disease.
- Hypertension.
- Diuretic therapy.
- Depressed mood.
- Reduced renal function.
- Hepatic insufficiency.
- Acute dehydration.
- Hypothyroidism.
- Myasthenia gravis.
- Pseudocholinesterase deficiency.
- Hypokalaemia.

**Caution** Avoid abrupt withdrawal—cardiac disease—concurrent ECT (may lower seizure threshold)—diuretic treatment (risk of toxicity)—elderly (reduce dose).
The need for continued therapy should be assessed regularly and patients should be maintained on lithium after 3–5 years only if benefit persists.

- **INTERACTIONS** → Appendix 1 (lithium).
  - Caution with concomitant use of drugs and any therapy that may lower seizure threshold.
  - Caution with concomitant use of drugs that prolong the QT interval.
  - Lithium toxicity is made worse by sodium depletion, therefore concurrent use of diuretics (particularly thiazides) is hazardous and should be avoided.

- **SIDE-EFFECTS**
  - Very rare: Nystagmus
  - Frequency not known: Acneiform eruptions, alopecia, arthralgia, AV block, benign intracranial hypertension, bradycardia, cardiomyopathy, cognitive impairment, dry mouth, dysgeusia, ECG changes, electrolyte imbalance, encephalopathy, euthyroid goitre, extrapyramidal side-effects, fine tremor, gastritis, gastrointestinal disturbances, hallucinations, hyperparathyroidism, hypersalivation, hyperthyroidism, hypothyroidism, kidney changes, leucocytosis, malaise, memory loss, myalgia, myasthenia gravis, nephrogenic diabetes insipidus, nephrotic syndrome, oedema, other skin disorders, parathyroid adenoma, peripheral neuropathy, polydipsia, psoriasis, spina bifida, speech disorder, thyroid changes, vertigo, weight changes

- **Overdose** Signs of intoxication require withdrawal of treatment and include increasing gastro-intestinal disturbances (vomiting, diarrhoea), visual disturbances, polypigmentation, muscle weakness, fine tremor increasing to coarse tremor, CNS disturbances (confusion and drowsiness increasing to lack of coordination, restlessness, stupor); abnormal reflexes, myoclonus, incontinence, hypernatraemia. With severe overdosage (serum-lithium concentration above 2 mmol/litre) seizures, cardiac arrhythmias (including sino-atrial block, bradycardia and first-degree heart block), blood pressure changes, circulatory failure, renal failure, coma and sudden death reported.

For details on the management of poisoning, see Lithium, under Emergency treatment of poisoning p. 1123.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during treatment for women of child bearing potential.

- **PREGNANCY** Avoid if possible, particularly in the first trimester (risk of teratogenicity, including cardiac abnormalities).
  - Dose requirements increased during the second and third trimesters (but on delivery return abruptly to normal).
  - Close monitoring of serum-lithium concentration advised in pregnancy (risk of toxicity in neonate).

- **BREASTFEEDING** Present in milk and risk of toxicity in infant—avoid.

- **RENAL IMPAIRMENT** Caution in mild to moderate impairment. Avoid in severe impairment.
  - In renal impairment monitor serum-lithium concentration closely and adjust dose accordingly.

- **MONITORING REQUIREMENTS**
  - Serum concentrations: Lithium salts have a narrow therapeutic/toxic ratio and should therefore not be prescribed unless facilities for monitoring serum-lithium concentrations are available.
  - Samples should be taken 12 hours after the dose to achieve a serum-lithium concentration of 0.4–1 mmol/litre (lower end of the range for maintenance therapy and elderly patients).
  - A target serum-lithium concentration of 0.8–1 mmol/litre is recommended for acute episodes of mania, and for patients who have previously relapsed or have sub-syndromal symptoms. It is important to determine the optimum range for each individual patient.
  - Routine serum-lithium monitoring should be performed weekly after initiation and after each dose change until concentrations are stable, then every 3 months thereafter. Additional serum-lithium measurements should be made if a patient develops significant intercurrent disease or if there is a significant change in a patient’s sodium or fluid intake.
  - Renal function should be monitored at baseline and every 6 months thereafter (more often if there is evidence of deterioration or if the patient has other risk factors, such as starting ACE inhibitors, NSAIDs, or diuretics).
  - Assess cardiac and thyroid function before initiating, and thereafter every 6 months on stabilised regimens.

- **TREATMENT CESSATION** While there is no clear evidence of withdrawal or rebound psychosis, abrupt discontinuation of lithium increases the risk of relapse. If lithium is to be discontinued, the dose should be reduced gradually over a period of at least 4 weeks (preferably over a period of up to 3 months). Patients and their carers should be warned of the risk of relapse if lithium is discontinued abruptly. If lithium is stopped or is to be discontinued abruptly, consider changing therapy to an atypical antipsychotic or valproate.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks: May impair performance of skilled tasks (e.g. driving, operating machinery).
  - Lithium treatment packs: A lithium treatment pack should be given to patients on initiation of treatment with lithium.
  - The pack consists of a patient information booklet, lithium alert card, and a record book for tracking serum-lithium concentration. Packs may be purchased from 3M: 0845 610 1112 nhsforms@mmm.uk.com
  - Patients should be advised to report signs and symptoms of lithium toxicity, hypothyroidism, renal dysfunction (including polyuria and polydipsia), and benign intracranial hypertension (persistent headache and visual disturbance).
  - Maintain adequate fluid intake and avoid dietary changes which reduce or increase sodium intake.

### Lithium carbonate

#### INDICATIONS AND DOSE

<table>
<thead>
<tr>
<th>Treatment and prophylaxis of mania</th>
<th>Treatment and prophylaxis of bipolar disorder</th>
<th>Treatment and prophylaxis of recurrent depression</th>
<th>Treatment and prophylaxis of aggressive or self-harming behaviour</th>
</tr>
</thead>
</table>

- **BY MOUTH**
  - Adult: Dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

<table>
<thead>
<tr>
<th>CAMCOLIT TABLET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of mania</td>
</tr>
</tbody>
</table>

- **BY MOUTH**
  - Adult: Initially 1–1.5 g daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then continued →
every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

Prophylaxis of mania | Prophylaxis of bipolar disorder | Prophylaxis of recurrent depression | Prophylaxis of aggressive or self-harming behaviour

**BY MOUTH**

- Adult: Initially 300–400 mg daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**LISKONUM®**

**TREATMENT OF MANIA | TREATMENT OF BIPOLAR DISORDER | TREATMENT OF RECURRENT DEPRESSION | TREATMENT OF AGGRESSIVE OR SELF-HARMING BEHAVIOUR**

**BY MOUTH**

- Adult: Initially 450–675 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- Elderly: Initially 225 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

Prophylaxis of mania | Prophylaxis of bipolar disorder | Prophylaxis of recurrent depression | Prophylaxis of aggressive or self-harming behaviour

**CAMCOLT® MODIFIED-RELEASE TABLET**

**TREATMENT OF MANIA | TREATMENT OF BIPOLAR DISORDER | TREATMENT OF RECURRENT DEPRESSION | TREATMENT OF AGGRESSIVE OR SELF-HARMING BEHAVIOUR**

**BY MOUTH**

- Adult: Initially 1–1.5 g daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- Elderly: Reduce initial dose, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

Prophylaxis of mania | Prophylaxis of bipolar disorder | Prophylaxis of recurrent depression | Prophylaxis of aggressive or self-harming behaviour

**BY MOUTH**

- Adult: Initially 300–400 mg daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**PRIADEL® TABLETS**

**TREATMENT AND PROPHYLAXIS OF MANIA | TREATMENT AND PROPHYLAXIS OF BIPOLAR DISORDER | TREATMENT AND PROPHYLAXIS OF RECURRENT DEPRESSION | TREATMENT AND PROPHYLAXIS OF AGGRESSIVE OR SELF-HARMING BEHAVIOUR**

**BY MOUTH**

- Adult (body-weight up to 49 kg): Initially 200–400 mg daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- Adult (body-weight 50 kg and above): Initially 0.4–1.2 g once daily, alternatively initially 0.4–1.2 g daily in 2 divided doses, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

Dose equivalence and conversion

Preparations vary widely in bioavailability: changing the preparation requires the same precautions as initiation of treatment.
Lithium citrate

INDICATIONS AND DOSE
Treatment and prophylaxis of mania | Treatment and prophylaxis of bipolar disorder | Treatment and prophylaxis of recurrent depression | Treatment and prophylaxis of aggressive or self-harming behaviour

BY MOUTH

- Adult (body-weight up to 49 kg): Initially 509 mg twice daily; dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- Adult (body-weight 50 kg and above): Initially 1,018–3,054 g daily in 2 divided doses; dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- Elderly: Initially 509 mg twice daily; dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter.

2.4 Depression

Antidepressant drugs

Antidepressant drugs are effective for treating moderate to severe depression associated with psychomotor and physiological changes such as loss of appetite and sleep...
disturbance; improvement in sleep is usually the first benefit of therapy. Ideally, patients with moderate to severe depression should be treated with psychological therapy in addition to drug therapy. Antidepressant drugs are also effective for dysthymia (lower grade chronic depression (typically of at least 2 years duration)). Antidepressant drugs should not be used routinely in mild depression, and psychological therapy should be considered initially; however, a trial of antidepressant therapy may be considered in cases refractory to psychological treatments or in those associated with psychosocial or medical problems. Drug treatment of mild depression may also be considered in patients with a history of moderate or severe depression.

Choice
The major classes of antidepressant drugs include the tricyclic and related antidepressants, the selective serotonin re-uptake inhibitors (SSRIs), and the monoamine oxidase inhibitors (MAOIs). A number of antidepressant drugs cannot be accommodated easily into this classification. There is little to choose between the different classes of antidepressant drugs in terms of efficacy, so choice should be based on the individual patient’s requirements, including the presence of concomitant disease, existing therapy, suicide risk, and previous response to antidepressant therapy. Since there may be an interval of 2 weeks before the antidepressant action takes place, electroconvulsive treatment may be required in severe depression when delay is hazardous or intolerable. During the first few weeks of treatment, there is an increased potential for agitation, anxiety, and suicidal ideation.

SSRIs are better tolerated and are safer in overdose than other classes of antidepressants and should be considered first-line for treating depression. In patients with unstable angina or who have had a recent myocardial infarction, sertraline p. 288 has been shown to be safe. Tricyclic antidepressants have similar efficacy to SSRIs but are more likely to be discontinued because of side-effects; toxicity in overdose is also a problem. SSRIs are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. MAOIs have dangerous interactions with some foods and drugs, and should be reserved for use by specialists. Failure to respond to a second antidepressant may require the addition of another agent (such as lithium, aripiprazole p. 293, quetiapine p. 291, venlafaxine p. 289, or mirtazapine p. 283). Other second-line choices include lofepramine p. 297, moclobemide p. 282, and reboxetine p. 284. Other tricyclic antidepressants and venlafaxine p. 289 should be considered for more severe forms of depression; irreversible MAOIs should only be prescribed by specialists. Failure to respond to a second antidepressant may require the addition of another antidepressant of a different class, or use of an augmenting agent (such as lithium, aripiprazole p. 312 [unlicensed], olanzapine p. 315 [unlicensed], quetiapine p. 318, or risperidone p. 319 [unlicensed]), but such adjunctive treatment should be initiated only by doctors with special experience of these combinations. Electroconvulsive therapy may be initiated in severe refractory depression.

Management
Patients should be reviewed every 1–2 weeks at the start of antidepressant treatment. Treatment should be continued for at least 4 weeks (6 weeks in the elderly) before considering whether to switch antidepressant due to lack of efficacy. In cases of partial response, continue for a further 2–4 weeks (elderly patients may take longer to respond). Following remission, antidepressant treatment should be continued at the same dose for at least 6 months (about 12 months in the elderly), or for at least 12 months in patients receiving treatment for generalised anxiety disorder (as the likelihood of relapse is high). Patients with a history of recurrent depression should receive maintenance treatment for at least 2 years.

Hyponatraemia and Antidepressant Therapy
Hyponatraemia (usually in the elderly and possibly due to inappropriate secretion of antidiuretic hormone) has been associated with all types of antidepressants; however, it has been reported more frequently with SSRIs than with other antidepressants. Hyponatraemia should be considered in all patients who develop drowsiness, confusion, or convulsions while taking an antidepressant.

Suicidal Behaviour and Antidepressant Therapy
The use of antidepressants has been linked with suicidal thoughts and behaviour; children, young adults, and patients with a history of suicidal behaviour are particularly at risk. Where necessary patients should be monitored for suicidal behaviour, self-harm, or hostility, particularly at the beginning of treatment or if the dose is changed.

Serotonin syndrome
Serotonin syndrome or serotonin toxicity is a relatively uncommon adverse drug reaction caused by excessive central and peripheral serotonergic activity. Onset of symptoms, which range from mild to life-threatening, can occur within hours or days following the initiation, dose escalation, or overdose of a serotonergic drug, the addition of a new serotonergic drug, or the replacement of one serotonergic drug by another without allowing a long enough washout period in-between, particularly when the first drug is an irreversible MAOI or a drug with a long half-life. Severe toxicity, which is a medical emergency, usually occurs with a combination of serotonergic drugs, one of which is generally an MAOI. The characteristic symptoms of serotonin syndrome fall into 3 main areas, although features from each group may not be seen in all patients—neuromuscular hyperactivity (such as tremor, hyperreflexia, clonus, myoclonus, rigidity), autonomic dysfunction (tachycardia, blood pressure changes, hyperthermia, diaphoresis, shivering, diarrhoea), and altered mental state (agitation, confusion, mania).

Treatment consists of withdrawal of the serotonergic medication and supportive care; specialist advice should be sought.

Failure to respond
Failure to respond to initial treatment with an SSRI may require an increase in the dose, or switching to a different SSRI or mirtazapine p. 291. Other second-line choices include lofepramine p. 297, moclobemide p. 282, and reboxetine p. 284. Other tricyclic antidepressants and venlafaxine p. 289 should be considered for more severe forms of depression; irreversible MAOIs should only be prescribed by specialists. Failure to respond to a second antidepressant may require the addition of another antidepressant of a different class, or use of an augmenting agent (such as lithium, aripiprazole p. 312 [unlicensed], olanzapine p. 315 [unlicensed], quetiapine p. 318, or risperidone p. 319 [unlicensed]), but such adjunctive treatment should be initiated only by doctors with special experience of these combinations. Electroconvulsive therapy may be initiated in severe refractory depression.

Anxiety disorders and obsessive-compulsive disorder
Management of acute anxiety generally involves the use of a benzodiazepine or buspirone hydrochloride p. 269. For chronic anxiety (of longer than 4 weeks’ duration) it may be appropriate to use an antidepressant. Combined therapy with a benzodiazepine may be required until the antidepressant takes effect. Patients with generalised anxiety disorder, a form of chronic anxiety, should be offered...
psychological treatment before initiating an antidepressant. If drug treatment is needed, an SSRI such as escitalopram p. 285, paroxetine p. 287, or sertraline p. 288 [unlicensed], can be used. Duloxetine p. 288 and venlafaxine p. 289 (serotonin and noradrenaline reuptake inhibitors) are also recommended for the treatment of generalised anxiety disorder, if the patient cannot tolerate SSRIs or serotonin and noradrenaline reuptake inhibitors (or if treatment has failed to control symptoms), pregabalin p. 400 can be considered.

Panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and phobic states such as social anxiety disorder are treated with SSRIs. Clomipramine hydrochloride p. 294 or imipramine hydrochloride p. 296 can be used second-line in panic disorder [unlicensed]; clomipramine hydrochloride p. 294 can also be used second-line for obsessive-compulsive disorder. Moclobemide p. 283 is licensed for the treatment of social anxiety disorder.

Tricyclic and related antidepressant drugs

Choice
Tricyclic and related antidepressants block the re-uptake of both serotonin and noradrenaline, although to different extents. For example, clomipramine hydrochloride p. 294 is more selective for serotoninergic transmission, and imipramine hydrochloride p. 296 is more selective for noradrenergic transmission. Tricyclic and related antidepressant drugs can be roughly divided into those with additional sedative properties and those that are less sedating. Agitated and anxious patients tend to respond best to the sedative compounds, whereas withdrawn and apathetic patients will often obtain most benefit from the less sedating ones. Those with sedative properties include amitriptyline hydrochloride p. 292, clomipramine hydrochloride p. 294, dosulepin hydrochloride p. 295, doxepin p. 296, mianserin hydrochloride p. 290, trazodone hydrochloride p. 291, and trimipramine p. 299. Those with less sedative properties include imipramine hydrochloride p. 296, lofepramine p. 297, and nortriptyline p. 298.

Tricyclic and related antidepressants also have varying degrees of antimuscarinic side-effects and cardiotoxicity in overdose, which may be important in individual patients. Lofepramine has a lower incidence of side-effects and is less dangerous in overdose but is infrequently associated with hepatic toxicity. Imipramine hydrochloride is also well established, but has more marked antimuscarinic side-effects than other tricyclic and related antidepressants. Amitriptyline hydrochloride and dosulepin hydrochloride are effective but they are particularly dangerous in overdose and are not recommended for the treatment of depression; dosulepin hydrochloride should be initiated by a specialist.

Dosage
About 10 to 20% of patients fail to respond to tricyclic and related antidepressant drugs and inadequate dosage may account for some of these failures. It is important to use doses that are sufficiently high for effective treatment but not so high as to cause toxic effects. Low doses should be used for initial treatment in the elderly. In most patients the long half-life of tricyclic antidepressant drugs allows once-daily administration, usually at night; the use of modified-release preparations is therefore unnecessary. Some tricyclic antidepressants are used in the management of panic and other anxiety disorders. Some tricyclic antidepressants may also have a role in some forms of neuralgia and in nocturnal enuresis in children.

Children and adolescents
Studies have shown that tricyclic antidepressants are not effective for treating depression in children.

Monoamine-oxidase inhibitors

Monoamine-oxidase inhibitors are used much less frequently than tricyclic and related antidepressants, or SSRIs and related antidepressants because of the dangers of dietary and drug interactions and the fact that it is easier to prescribe MAOIs when tricyclic antidepressants have been unsuccessful than vice versa.

Tranylcypromine p. 283 has a greater stimulant action than phenelzine p. 283 or isocarboxazid p. 282 and is more likely to cause a hypertensive crisis. Isocarboxazid and phenelzine are more likely to cause hepatotoxicity than tranylcypromine.

Moclobemide p. 283 should be reserved as a second line treatment.

Phobic patients and depressed patients with atypical, hypochondriacal, or hysterical features are said to respond best to MAOIs. However, MAOIs should be tried in any patients who are refractory to treatment with other antidepressants as there is occasionally a dramatic response. Response to treatment may be delayed for 3 weeks or more and may take an additional 1 or 2 weeks to become maximal.

Other antidepressant drugs

The thioxanthene flupentixol p. 305 (Fluanxol®) has antidepressant properties when given by mouth in low doses. Flupentixol is also used for the treatment of psychoses.

MELATONIN RECEPTOR AGONISTS

Agomelatine

DRUG ACTION A melatonin receptor agonist and a selective serotonin-receptor antagonist; it does not affect the uptake of serotonin, noradrenaline, or dopamine.

INDICATIONS AND DOSE

Major depression
BY MOUTH
• Adult. 25 mg daily, dose to be taken at bedtime, dose to be increased if necessary after 2 weeks, increased if necessary to 50 mg daily, dose to be taken at bedtime

Dose adjustments due to interactions
Caution—dose adjustment may be necessary if smoking started or stopped during treatment.

CONTRA-INDICATIONS
Dementia • patients over 75 years of age

CAUTIONS
Bipolar disorder • diabetes • excessive alcohol consumption • hypomania • mania • non-alcoholic fatty liver disease • obesity

INTERACTIONS → Appendix 1 (agomelatine).
Caution with concomitant use of drugs associated with hepatic injury.

SIDE-EFFECTS
• Common or very common Abdominal pain • agitation • anxiety • back pain • constipation • diarrhea • dizziness • drowsiness • fatigue • headache • increased serum transaminases • nausea • sleep disturbances • sweating • vomiting
• Uncommon Blurred vision • eczema • paraesthesia • restless legs syndrome • tinnitus
• Rare Hepatic failure • hepatic injury • hepatitis • rash • weight changes
• Frequency not known Pruritus • suicidal behaviour

Drugs used for Depression not listed below; Flupentixol, p. 305 • Lithium carbonate, p. 277 • Lithium citrate, p. 279 • Quetiapine, p. 318
SIDE-EFFECTS, FURTHER INFORMATION

Suicidal behaviour The use of antidepressants has been linked with suicidal thoughts and behaviour; children, young adults, and patients with a history of suicidal behaviour are particularly at risk. Where necessary patients should be monitored for suicidal behaviour, self-harm, or hostility, particularly at the beginning of treatment or if the dose is changed.

PREGNANCY Manufacturer advises avoid.

BREAST FEEDING Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Avoid. Do not start if serum transaminases exceed 3 times the upper limit of reference range.

RENAL IMPAIRMENT Caution in moderate to severe impairment.

MONITORING REQUIREMENTS Test liver function before treatment and after 3, 6, 12 and 24 weeks of treatment, and then regularly thereafter when clinically indicated (restart monitoring schedule if dose increased); discontinue if serum transaminases exceed 3 times the upper limit of reference range or symptoms of liver disorder.

PATIENT AND CARER ADVICE Hepatotoxicity Patients should be told how to recognise signs of liver disorder, and advised to seek immediate medical attention if symptoms such as dark urine, light coloured stools, jaundice, bruising, fatigue, abdominal pain, or pruritus develop. Patients should be given a booklet with more information on the risk of hepatic side-effects.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Valdoxan (Servier Laboratories Ltd)
  Agomelatine 25 mg Valdoxan 25mg tablets | 28 tablet (POM) £30.00
  DT price = £30.00

MONOAMINE-OXIDASE A AND B INHIBITORS (IRREVERSIBLE)

Monoamine-oxidase inhibitors

DRUG ACTION MAOIs inhibit monoamine oxidase, thereby causing an accumulation of amine neurotransmitters.

CONTRA-INDICATIONS Cerebrovascular disease - not indicated in manic phase - phaeochromocytoma

CAUTIONS Acute porphyria - avoid in agitated patients - blood disorders - cardiovascular disease - concurrent electroconvulsive therapy - diabetes mellitus - elderly (great caution) - epilepsy - severe hypertensive reactions to certain drugs and foods - surgery

INTERACTIONS ▶ Appendix 1 (MAOIs). The metabolism of some amine drugs such as indirect-acting sympathomimetics (present in many cough and decongestant preparations) is inhibited and their pressor action may be potentiated; the pressor effect of tyramine (in some foods, such as mature cheese, pickled herring, broad bean pods, and Bovril®, Oxo®, Marmite® or any similar meat or yeast extract or fermented soya bean extract) may also be dangerously potentiated. These interactions may cause a dangerous rise in blood pressure. An early warning symptom may be a throbbing headache. The danger of interaction persists for up to 2 weeks after treatment with MAOIs is discontinued.

Some psychiatrists use selected tricyclics in conjunction with MAOIs but this is hazardous, indeed potentially lethal, except in experienced hands and there is no evidence that the combination is more effective than when either constituent is used alone.

SIDE-EFFECTS
- Common or very common Dizziness - postural hypotension (especially in elderly)
- Rare Fatal progressive hepatocellular necrosis
- Frequency not known jaundice - hypotoniemia - paraesthesia - peripheral neuritis - peripheral neuropathy (may be due to pyridoxine deficiency)

SIDE-EFFECTS, FURTHER INFORMATION

Risk of postural hypotension and hypertensive responses Discontinue use if palpitations or frequent headaches occur.

PREGNANCY Increased risk of neonatal malformations — manufacturer advises avoid unless there are compelling reasons.

HEPATIC IMPAIRMENT MAOIs may cause idiosyncratic hepatotoxicity if used in patients with hepatic impairment.

MONITORING REQUIREMENTS Monitor blood pressure (risk of postural hypotension and hypertensive responses).

TREATMENT CESSATION If possible avoid abrupt withdrawal. MAOIs are associated with withdrawal symptoms on cessation of therapy. Symptoms include agitation, irritability, ataxia, movement disorders, insomnia, drowsiness, vivid dreams, cognitive impairment, and slowed speech. Withdrawal symptoms occasionally experienced when discontinuing MAOIs include hallucinations and paranoid delusions. If possible MAOIs should be withdrawn slowly.

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment).

PATIENT AND CARER ADVICE Drowsiness may affect performance of skilled tasks (e.g. driving). Patients should be advised to eat only fresh foods and avoid food that is suspected of being stale or offal; game should be avoided. The danger of interaction persists for up to 2 weeks after treatment with MAOIs is discontinued. Patients should also be advised to avoid alcoholic drinks or de-alcoholised (low alcohol) drinks.

Isocarboxazid

INDICATIONS AND DOSE
Depressive illness
BY MOUTH
- Adult: Initially 30 mg daily until improvement occurs, initial dose may be given in single or divided doses, dose may be increased if necessary after 4 weeks up to 60 mg daily for 4–6 weeks, dose to be increased under
close supervision only, then reduced to 10–20 mg daily, usual maintenance dose, but up to 40 mg may be required  
- Elderly: 5–10 mg daily

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension  
Tablet  
CAUTIONARY AND ADVISORY LABELS 3, 10  
- ISOCARBOXAZID (Non-proprietary)  
Isocarboxazid 10 mg Isocarboxazid 10mg tablets | 56 tablet £39.95

**Phenelzine**

**INDICATIONS AND DOSE**  
Depressive illness  
BY MOUTH  
- Adult: Initially 15 mg 3 times a day; response is usually seen within first week; dose may be increased if necessary after 2 weeks if response is not evident, increased if necessary to 15 mg 4 times a day, doses up to 30 mg three times a day may be used in hospital patients, then reduced to 15 mg once daily on alternate days, response may not become apparent for up to 4 weeks, once satisfactory response has been achieved, reduce dose gradually to lowest suitable maintenance dose (15 mg on alternate days may be adequate)

**SIDE-EFFECTS**  
- Common or very common: Insomnia  
- Uncommon: Hyperpyrexia, lupus erythematosus-like syndrome, speech disturbances  
- Very rare: Angle-closure glaucoma, hypertensive crises with throbbing headache, liver damage (less frequent than with phenelzine)

**Benign hypertension**

- Frequency not known: Blood dyscrasias

**SIDE-EFFECTS, FURTHER INFORMATION**  
Hypertensive crisis and throbbing headache requiring discontinuation of treatment is more frequent than with other MAOIs.

**BREAST FEEDING**  
Present in milk in animal studies.

**HEPATIC IMPAIRMENT**  
Avoid if history of hepatic disease or if abnormal liver function tests.

**LEADING SUITABLE FOR PRESCRIBING**  
Less suitable for prescribing.

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug.  
Tablet  
CAUTIONARY AND ADVISORY LABELS 3, 10  
- TRANYLCYPROMINE (Non-proprietary)  
Tranylcypromine (as Tranylcypromine sulfate) 10 mg Tranylcypromine 10mg tablets | 28 tablet £243.98–£252.30 07 price = £248.14

**MONOAMINE-OXIDASE INHIBITORS**  
(Reversible)

**Moclobemide**

**DRUG ACTION**  
Moclobemide is reported to act by reversible inhibition of monoamine oxidase type A (it is therefore termed a RIMA).

**INDICATIONS AND DOSE**  
Depressive illness  
BY MOUTH  
- Adult: Initially 300 mg daily in divided doses, adjusted according to response; usual dose 150–600 mg daily, dose to be taken after food  
Social anxiety disorder  
BY MOUTH  
- Adult: Initially 300 mg daily for 3 days, then increased to 600 mg daily in 2 divided doses continued for 8–12 weeks to assess efficacy

**CONTRA-INDICATIONS**  
Acute confusional states  
- Phaeochromocytoma

**CAUTIONS**  
Avoid in agitated or excited patients (or give with sedative for up to 2–3 weeks)  
- May provoke manic episodes in bipolar disorders  
- Thyrotoxicosis

**INTERACTIONS**  
Appendix 1 (moclobemide).  
The risk of drug interactions is claimed to be less than with the traditional (irreversible) MAOIs, but patients still need to avoid sympathomimetics such as ephedrine and pseudoephedrine. In addition, moclobemide should not be given with another antidepressant. Owing to its short duration of action no treatment-free period is required after it has been stopped but it should not be started until at least a week after a tricyclic or related antidepressant or an SSRI or related antidepressant has been stopped (at least 5 weeks in the case of fluoxetine), or for at least a week after an MAOI has been stopped.

**SIDE-EFFECTS**  
- Rare: Galactorrhoea, hyponatraemia, raised liver enzymes  
- Frequency not known: Agitation, confusional states, dizziness, dry mouth, gastrointestinal disorders, headache, oedema, paraesthesia, restlessness, skin reactions, sleep disturbances, visual disturbances
Raynaud’s syndrome • suicidal behaviour • testicular pain • vomiting
• PREGNANCY Use only if potential benefit outweighs risk—limited information available.
• BREAST FEEDING Small amount present in milk—use only if potential benefit outweighs risk.
• HEPATIC IMPAIRMENT Initial dose 2 mg twice daily, increased according to tolerance.
• RENAL IMPAIRMENT Initial dose 2 mg twice daily, increased according to tolerance.
• TREATMENT CESSATION Caution—avoid abrupt withdrawal.
• PATIENT AND CARER ADVICE Counselling advised.

SELECTIVE SEROTONIN RE- UPTAKE INHIBITORS

Selective serotonin re-uptake inhibitors

• DRUG ACTION Selectively inhibit the re-uptake of serotonin (5-hydroxytryptamine, 5-HT).
• CONTRA-INDICATIONS Poorly controlled epilepsy • SSRIs should not be used if the patient enters a manic phase.
• CAUTIONS Cardiac disease • concurrent electroconvulsive therapy • diabetes mellitus • epilepsy (discontinue if convulsions develop) • history of bleeding disorders (especially gastro-intestinal bleeding) • history of mania • susceptibility to angle-closure glaucoma
• INTERACTIONS → Appendix 1 (antidepressants, SSRI).
Caution with other drugs that increase the risk of bleeding.

• SIDE-EFFECTS
• Common or very common Abdominal pain (dose-related) • constipation (dose-related) • diarrhea (dose-related) • dyspepsia (dose-related) • gastro-intestinal effects (dose-related) • nausea (dose-related) • vomiting (dose-related)
• Uncommon Serotonin syndrome
• Rare Angle-closure glaucoma
• Frequency not known Anaphylaxis • angioedema • anorexia with weight loss • anxiety • arthralgia • asthenia • bleeding disorders • convulsions • dizziness • drowsiness • dry mouth • dyskinesias • ecchymoses • galactorrhoea • hallucinations • headache • hypersensitivity reactions • hypomania • hyponatraemia • increased appetite • insomnia • mania • movement disorders • myalgia • nervousness • photosensitivity • purpura • rash • sexual dysfunction • suicidal behaviour • sweating • tremor • urinary retention • urticaria • visual disturbances • weight gain

SIDE-EFFECTS, FURTHER INFORMATION

Hypersensitivity reactions If hypersensitivity reactions (including rash) occur, consider discontinuation—may be sign of impending serious systemic reaction, possibly associated with vasculitis.

Overdose Symptoms of poisoning by selective serotonin re-uptake inhibitors include nausea, vomiting, agitation, tremor, nystagmus, drowsiness, and sinus tachycardia; convulsions may occur. Rarely, severe poisoning results in the serotonin syndrome, with marked neuropsychiatric effects, neuromuscular hyperactivity, and autonomic instability; hyperthermia, rhabdomyolysis, renal failure, and coagulopathies may develop.
For details on the management of poisoning, see Selective serotonin re-uptake inhibitors, under Emergency treatment of poisoning p. 1123.

- **PREGNANCY** Manufacturers advise avoid during pregnancy unless the potential benefit outweighs the risk. There is a small increased risk of congenital heart defects when taken during early pregnancy. If used during the third trimester there is a risk of neonatal withdrawal symptoms, and persistent pulmonary hypertension in the newborn has been reported.

- **TREATMENT CESSATION** Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, electric shock sensation in the head, neck, and spine, tinnitus, sleep disturbances, fatigue, influenza-like symptoms, and sweating are the most common features of abrupt withdrawal of an SSRI or marked reduction of the dose; palpitation and visual disturbances can occur less commonly. The dose should be tapered over at least a few weeks to avoid these effects. For some patients, it may be necessary to withdraw treatment over a longer period; consider obtaining specialist advice if symptoms persist. Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment).

- **PATIENT AND CARER ADVICE** May also impair performance of skilled tasks (e.g. driving, operating machinery).

### Citalopram

**INDICATIONS AND DOSE**

**Depressive illness**
- **BY MOUTH USING TABLETS**
  - Adult: 20 mg once daily, increased in steps of 20 mg daily if required, dose to be increased at intervals of 3–4 weeks; maximum 40 mg per day
  - Elderly: 10–20 mg once daily; maximum 20 mg per day
- **BY MOUTH USING ORAL DROPS**
  - Adult: 16 mg once daily, increased in steps of 16 mg daily if required, dose to be increased at intervals of 3–4 weeks; maximum 32 mg per day
  - Elderly: 8–16 mg daily; maximum 16 mg per day

**Panic disorder**
- **BY MOUTH USING TABLETS**
  - Adult: Initially 10 mg daily, increased in steps of 10 mg daily if required, dose to be increased gradually; usual dose 20–30 mg daily; maximum 40 mg per day
  - Elderly: Initially 10 mg daily, increased in steps of 10 mg daily if required, dose to be increased gradually; maximum 20 mg per day
- **BY MOUTH USING ORAL DROPS**
  - Adult: Initially 8 mg once daily, increased in steps of 8 mg if required, dose to be increased gradually; usual dose 16–24 mg daily; maximum 32 mg per day
  - Elderly: Initially 8 mg once daily, increased in steps of 8 mg if required, dose to be increased gradually; maximum 16 mg per day

**Dose equivalence and conversion**
- 4 oral drops (8 mg) is equivalent in therapeutic effect to 10 mg tablet.

**CONTRA-INDICATIONS** QT-interval prolongation

**CAUTIONS** Susceptibility to QT-interval prolongation

**INTERACTIONS** Avoid concomitant administration of drugs that prolong QT interval.

**SIDE-EFFECTS** abnormal dreams · aggression · amnesia · bradycardia · confusion · coughing · euphoria · haemorrhage · hepatitis · hypokalaemia · impaired concentration · increased salivation · malaise · micturition disorders · migraine · mydriasis · oedema · palpitation paradoxical increased anxiety during initial treatment of panic disorder (reduce dose) · paraesthesia · polyuria · postural hypotension · pruritus · QT-interval prolongation · rhinitis · tachycardia · tinnitus · taste disturbance · yawning

**BREAST FEEDING** Present in milk—use with caution.

**HEPATIC IMPAIRMENT** Use doses at lower end of range; for tablets up to maximum 20 mg; for oral solution up to maximum 16 mg.

**RENAL IMPAIRMENT** No information available for eGFR less than 20 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** Cipramil® oral drops should be mixed with water, orange juice, or apple juice before taking.

**PATIENT AND CARER ADVICE** Patients should be advised of the effects of citalopram on driving. Counselling on administration of oral drops is advised.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**
- **CITALOPRAM (Non-proprietary)**
  - Citalopram (as Citalopram hydrobromide) 10 mg
    - 10mg tablets | 28 tablet (P) £8.90 DT price = £1.05
    - Citalopram (as Citalopram hydrobromide) 20 mg
      - 20mg tablets | 28 tablet (P) £15.99 DT price = £1.09
  - Citalopram (as Citalopram hydrobromide) 40 mg
    - 40mg tablets | 28 tablet (P) £27.00 DT price = £1.28
- **Cipramil®** (Lundbeck Ltd)
  - Citalopram (as Citalopram hydrobromide) 20 mg
    - Cipramil 20mg tablets | 28 tablet (P) £8.95 DT price = £1.09

**Oral drops**
- **EXCipients:** May contain Alcohol
- **CITALOPRAM (Non-proprietary)**
  - Citalopram (as Citalopram hydrochloride) 40 mg per 1 ml
    - 40mg/ml oral drops sugar free (sugar-free) | 15 ml (P) £20.16 DT price = £1.56
  - Cipramil® (Lundbeck Ltd)
    - Citalopram (as Citalopram hydrochloride) 40 mg per 1 ml
      - Cipramil 40mg/ml drops (sugar-free) | 15 ml (P) £10.08 DT price = £0.56

### Escitalopram

- **DRUG ACTION** Escitalopram is the active enantiomer of citalopram.

**INDICATIONS AND DOSE**

**Depressive illness | Generalised anxiety disorder | Obsessive-compulsive disorder**
- **BY MOUTH**
  - Adult: 10 mg once daily; increased if necessary up to 20 mg daily
  - Elderly: Initially 5 mg once daily; maximum 10 mg per day

**Panic disorder**
- **BY MOUTH**
  - Adult: Initially 5 mg once daily for 7 days, then increased to 10 mg daily; maximum 20 mg per day
  - Elderly: Initially 2.5 mg once daily; maximum 10 mg per day

continued →
Fluoxetine

**INDICATIONS AND DOSE**

**Major depression**

- **BY MOUTH**
  - Adult: Initially 20 mg daily, dose is increased after 3–4 weeks if necessary, and at appropriate intervals thereafter, daily dose may be administered as a single or divided dose; maximum 60 mg per day
  - Elderly: Initially 20 mg daily, dose is increased after 3–4 weeks if necessary, and at appropriate intervals thereafter, daily dose may be administered as a single or divided dose, usual maximum dose is 40 mg but doses up to 60 mg can be used

**Bulimia nervosa**

- **BY MOUTH**
  - Adult: 60 mg daily, daily dose may be administered as a single or divided dose
  - Elderly: Up to 40 mg daily, daily dose may be administered as a single or divided dose, usual maximum dose is 40 mg but doses up to 60 mg can be used

**Obsessive compulsive disorder**

- **BY MOUTH**
  - Adult: 20 mg daily, increased if necessary up to 60 mg daily, daily dose may be administered as a single or divided dose, dose to be increased gradually, review treatment if inadequate response after 10 weeks; maximum 60 mg per day
  - Elderly: 20 mg daily, increased if necessary up to 40 mg daily, daily dose may be administered as a single or divided dose, dose to be increased gradually, review treatment if inadequate response after 10 weeks, usual maximum dose is 40 mg but doses up to 60 mg can be used

**PHARMACOKINETICS**

Consider the long half-life of fluoxetine when adjusting dosage (or in overdosage).

- **SIDE-EFFECTS**
  - Alopaeicia, changes in blood sugar, chills, confusion, diarrhoea, dysphagia, dyspnoea, euphoria, flushing, haemorrhage, hepatitis, hypotension, impaired concentration, malaise, neuroleptic malignant syndrome-like event, palpitation, pharyngitis, priapism, pulmonary fibrosis, pulmonary inflammation, sleep disturbances, taste disturbance, toxic epidermal necrolysis, urinary frequency, vasodilatation, yawning

- **BREAST FEEDING**
  - Present in milk—avoid.

- **HEPATIC IMPAIRMENT**
  - Reduction of dose required.

- **RENAL IMPAIRMENT**
  - Further reduction of dose required.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **ESCITALOPRAM (Non-proprietary)**
  - Escitalopram (as Escitalopram oxalate) 5 mg Escitalopram 5mg tablets | 28 tablet | £1.26–£8.97 DT price = £1.26
  - Escitalopram (as Escitalopram oxalate) 10 mg Escitalopram 10mg tablets | 28 tablet | £1.53–£14.16 DT price = £1.53
  - Escitalopram (as Escitalopram oxalate) 20 mg Escitalopram 20mg tablets | 28 tablet | £2.07–£23.94 DT price = £2.07
  - Cipralex (Lundbeck Ltd) Escitalopram (as Escitalopram oxalate) 5 mg Cipralex 5mg tablets | 28 tablet | £8.97 DT price = £1.26
  - Escitalopram (as Escitalopram oxalate) 10 mg Cipralex 10mg tablets | 28 tablet | £14.91 DT price = £1.53
  - Escitalopram (as Escitalopram oxalate) 20 mg Cipralex 20mg tablets | 28 tablet | £25.20 DT price = £2.07

**Oral drops**

- Cipralex (Lundbeck Ltd) Escitalopram (as Escitalopram oxalate) 20 mg per 1 ml Cipralex 20mg/ml oral drops (sugar-free) | 15 ml | £20.16

**Fluoxetine**

**INDICATIONS AND DOSE**

**Major depression**

- **BY MOUTH**
  - Adult: Initially 20 mg once daily for 2–4 weeks of treatment; usual dose 5–20 mg daily

- **CONTRA-INDICATIONS**
  - QT-interval prolongation

- **CAUTIONS**
  - Susceptibility to QT-interval prolongation

- **INTERACTIONS**
  - Avoid concomitant administration of drugs that prolong QT interval.

- **SIDE-EFFECTS**
  - **Common or very common**
    - Abnormal dreams, fatigue, paraesthesia, pyrexia, restlessness, sinusitis, yawning
  - **Uncommon**
    - Alopecia, bruxism, confusion, epistaxis, menstrual disturbances, mydriasis, oedema, pruritus, syncope, tachycardia, taste disturbance, tinnitus
  - **Rare**
    - Aggression, bradycardia, depersonalisation
  - **Frequency not known**
    - Hepatitis, paradoxical increased anxiety during initial treatment of panic disorder (reduce dose), postural hypotension, QT interval prolongation, thrombocytopenia

- **BREAST FEEDING**
  - Present in breast milk; avoid.

- **HEPATIC IMPAIRMENT**
  - Initial dose 5 mg daily for 2 weeks, thereafter increased to max. 10 mg daily according to response; particular caution in severe impairment.

- **RENAL IMPAIRMENT**
  - Caution if eGFR less than 30 mL/minute/1.73m².

- **DIRECTIONS FOR ADMINISTRATION**
  - Oral drops can be mixed with water, orange juice, or apple juice before swallowing.
  - Counselling on administration of oral drops advised.

- **SIDE-EFFECTS**
  - Alopecia, changes in blood sugar, chills, confusion, diarrhoea, dysphagia, dyspnoea, euphoria, flushing, haemorrhage, hepatitis, hypotension, impaired concentration, malaise, neuroleptic malignant syndrome-like event, palpitation, pharyngitis, priapism, pulmonary fibrosis, pulmonary inflammation, sleep disturbances, taste disturbance, toxic epidermal necrolysis, urinary frequency, vasodilatation, yawning

- **BREAST FEEDING**
  - Present in milk—avoid.

- **HEPATIC IMPAIRMENT**
  - Reduce dose or increase dose interval.

- **DIRECTIONS FOR ADMINISTRATION**
  - Dispersible tablets can be dispersed in water for administration or swallowed whole with plenty of water.

- **PATIENT AND CARER ADVICE**
  - Patients should be counselled about the effects on driving.
  - Patients and carers should be counselled on the administration of dispersible tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - **ESCITALOPRAM (Non-proprietary)**
    - Escitalopram (as Escitalopram oxalate) 5 mg Escitalopram 5mg tablets | 28 tablet | £1.26–£8.97 DT price = £1.26
    - Escitalopram (as Escitalopram oxalate) 10 mg Escitalopram 10mg tablets | 28 tablet | £1.53–£14.16 DT price = £1.53
    - Escitalopram (as Escitalopram oxalate) 20 mg Escitalopram 20mg tablets | 28 tablet | £2.07–£23.94 DT price = £2.07
  - Cipralex (Lundbeck Ltd) Escitalopram (as Escitalopram oxalate) 5 mg Cipralex 5mg tablets | 28 tablet | £8.97 DT price = £1.26
  - Escitalopram (as Escitalopram oxalate) 10 mg Cipralex 10mg tablets | 28 tablet | £14.91 DT price = £1.53
  - Escitalopram (as Escitalopram oxalate) 20 mg Cipralex 20mg tablets | 28 tablet | £25.20 DT price = £2.07

- **Oral drops**
  - Cipralex (Lundbeck Ltd) Escitalopram (as Escitalopram oxalate) 20 mg per 1 ml Cipralex 20mg/ml oral drops (sugar-free) | 15 ml | £20.16
Paroxetine (as Paroxetine hydrochloride) 4 mg per 1 ml  Prozac 20mg/5ml liquid | 70 ml [POM] £11.12 DT price = £3.69
Brands may include Prozep

Fluvoxamine maleate

INDICATIONS AND DOSE
Depressive illness
BY MOUTH
- Adult: Initially 50–100 mg daily, dose to be taken in the evening, dose to be increased gradually, then increased if necessary up to 300 mg daily, doses over 150 mg daily are given in divided doses; maintenance 100 mg daily

Obsessive-compulsive disorder
BY MOUTH
- Adult: Initially 50 mg daily, dose to be taken in the evening, dose is increased gradually if necessary after several weeks, doses over 150 mg daily are given in divided doses, then increased if necessary up to 300 mg daily; maintenance 100–300 mg daily, if no improvement in obsessive-compulsive disorder within 10 weeks, treatment should be reconsidered

SIDE-EFFECTS
- Common or very common Malaise · palpitation · tachycardia
- Uncommon Ataxia · confusion · postural hypotension
- Rare Abnormal liver function, usually symptomatic (discontinue treatment)
- Frequency not known Neuroleptic malignant syndrome-like event · paraesthesia · taste disturbance

BREAST FEEDING
Present in milk—avoid.

HEPATIC IMPAIRMENT
Reduce dose if eGFR less than 30 mL/minute/1.73 m².

PATIENT AND CARER ADVICE
Patients should be counselled about the effects on driving.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
Tablet
- FLUOXETINE MALEATE (Non-proprietary)
  - Fluvoxamine maleate 100 mg Fluvoxamine 100mg tablets | 30 tablet [POM] £24.95 DT price = £0.83
  - Faverin (BGP Products Ltd) Fluvoxamine maleate 50 mg Faverin 50mg tablets | 30 tablet [POM] £5.95 DT price = £0.19
  - Faverin (BGP Products Ltd) Fluvoxamine maleate 100 mg Faverin 100mg tablets | 30 tablet [POM] £11.95 DT price = £0.39

Paroxetine (as Paroxetine hydrochloride) 10 mg Paroxetine 10mg tablets | 28 tablet [POM] £14.21–£18.12 DT price = £1.747
Paroxetine (as Paroxetine hydrochloride) 20 mg Paroxetine 20mg tablets | 30 tablet [POM] £3.25 DT price = £0.11
Paroxetine (as Paroxetine hydrochloride) 30 mg Paroxetine 30mg tablets | 30 tablet [POM] £13.36 DT price = £0.45
Seroxat (GlaxoSmithKline UK Ltd) Paroxetine (as Paroxetine hydrochloride) 10 mg Seroxat 10mg tablets | 28 tablet [POM] £14.21 DT price = £0.1747
Seroxat (GlaxoSmithKline UK Ltd) Paroxetine (as Paroxetine hydrochloride) 20 mg Seroxat 20mg tablets | 30 tablet [POM] £15.23 DT price = £0.51
Seroxat (GlaxoSmithKline UK Ltd) Paroxetine (as Paroxetine hydrochloride) 30 mg Seroxat 30mg tablets | 30 tablet [POM] £26.74 DT price = £0.89

Obsessive-compulsive disorder
BY MOUTH
- Adult: Initially 20 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually, to 40 mg daily, no evidence of greater efficacy at higher doses; maximum 60 mg per day
- Elderly: Initially 20 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually; maximum 40 mg per day

Panic disorder
BY MOUTH
- Adult: Initially 10 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually, increased to 40 mg daily, no evidence of greater efficacy at higher doses; maximum 60 mg per day
- Elderly: Initially 10 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually; maximum 40 mg per day

CAUTIONS
Achlorhydria · high gastric pH

CAUTIONS, FURTHER INFORMATION
Achlorhydria or high gastric pH Causes reduced absorption of the oral suspension.

SIDE-EFFECTS
- Common or very common Abnormal dreams · raised cholesterol · yawning
- Uncommon Arrhythmias · confusion · urinary incontinence
- Rare Depersonalisation · neuroleptic malignant syndrome-like event · panic attacks · paradoxical increased anxiety during initial treatment of panic disorder (reduce dose) · restless legs syndrome
- Very rare Acute glaucoma · hepatic disorders · hepatitis · peripheral oedema · priapism
- Frequency not known Extrapyramidal reactions · orofacial dystonias · tinnitus · withdrawal reactions

PREGNANCY
Increased risk of congenital malformations, especially if used in the first trimester.

BREAST FEEDING
Present in milk but amount too small to be harmful.

HEPATIC IMPAIRMENT
Reduce dose.

PATIENT AND CARER ADVICE
Patients should be counselled about the effect on driving.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension
Tablet
CAUTIONARY AND ADVISORY LABELS 21
- PAROXETINE (Non-proprietary)
  - Paroxetine (as Paroxetine hydrochloride) 10 mg Paroxetine 10mg tablets | 28 tablet [POM] £14.21–£18.12 DT price = £1.747
  - Paroxetine (as Paroxetine hydrochloride) 20 mg Paroxetine 20mg tablets | 30 tablet [POM] £3.25 DT price = £0.11
  - Paroxetine (as Paroxetine hydrochloride) 30 mg Paroxetine 30mg tablets | 30 tablet [POM] £13.36 DT price = £0.45
  - Seroxat (GlaxoSmithKline UK Ltd) Paroxetine (as Paroxetine hydrochloride) 10 mg Seroxat 10mg tablets | 28 tablet [POM] £14.21 DT price = £0.1747
  - Seroxat (GlaxoSmithKline UK Ltd) Paroxetine (as Paroxetine hydrochloride) 20 mg Seroxat 20mg tablets | 30 tablet [POM] £15.23 DT price = £0.51
  - Seroxat (GlaxoSmithKline UK Ltd) Paroxetine (as Paroxetine hydrochloride) 30 mg Seroxat 30mg tablets | 30 tablet [POM] £26.74 DT price = £0.89

Nervous system
Sertraline

**INDICATIONS AND DOSE**

**Depressive illness**
- **BY MOUTH**
  - Adult: Initially 50 mg daily, then increased in steps of 50 mg at least every 1 week if required; maintenance 50 mg daily; maximum 200 mg per day

**Obsessive-compulsive disorder**
- **BY MOUTH**
  - Adult: Initially 50 mg daily, then increased in steps of 50 mg at least every 1 week if required; maximum 200 mg per day

**Panic disorder / Post-traumatic stress disorder / Social anxiety disorder**
- **BY MOUTH**
  - Adult: Initially 25 mg daily for 1 week, then increased to 50 mg daily, then increased in steps of 50 mg at least every 1 week if required, increase only if response is partial and if drug is tolerated; maximum 200 mg per day

**SIDE-EFFECTS**
- Aggression, anemia, bronchospasm, hepatitis, hypercholesterolaemia, hyperprolactinaemia, hypertension, hypoglycaemia, hypothyroidism, jaundice, leucopenia, liver failure, menstrual irregularities, palpitation, pancreatitis, parahypersensitivity, postural hypotension, stomatitis, tachycardia, tinnitus, urinary incontinence

**BREAST FEEDING**
- Not known to be harmful but consider discontinuing breast-feeding.

**HEPATIC IMPAIRMENT**
- Reduce dose or increase dose interval in mild or moderate impairment. Avoid in severe impairment.

**RENAI IMPAIRMENT**
- Use with caution.

**PATIENT AND CARER ADVICE**
- Patients should be counselled on the effects on driving.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**
- **SERTRALINE (Non-proprietary)**
  - Sertraline (as Sertraline hydrochloride) 50 mg Sertraline 50mg tablets | 28 tablet | £19.25 OT price = £1.46
  - Sertraline (as Sertraline hydrochloride) 100 mg Sertraline 100mg tablets | 28 tablet | £25.09 OT price = £1.66
- **Lustral (Pfizer Ltd)**
  - Sertraline (as Sertraline hydrochloride) 50 mg Lustral 50mg tablets | 28 tablet | £17.82 OT price = £1.46
  - Sertraline (as Sertraline hydrochloride) 100 mg Lustral 100mg tablets | 28 tablet | £29.16 OT price = £1.66

**SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS**

**Duloxetine**
- **DRUG ACTION**
  - Inhibits the re-uptake of serotonin and noradrenaline.

**INDICATIONS AND DOSE**

**Major depressive disorder**
- **BY MOUTH**
  - Adult: 60 mg once daily

**Generalised anxiety disorder**
- **BY MOUTH**
  - Adult: Initially 30 mg once daily, increased if necessary to 60 mg once daily; maximum 120 mg per day

**Diabetic neuropathy**
- **BY MOUTH**
  - Adult: 60 mg once daily, discontinue if inadequate response after 2 months; review treatment at least every 3 months, maximum dose to be given in divided doses; maximum 120 mg per day

**Moderate to severe stress urinary incontinence**
- **BY MOUTH**
  - Adult (female): 40 mg twice daily, patient should be assessed for benefit and tolerability after 2–4 weeks, alternatively initially 20 mg twice daily for 2 weeks, this can minimise side effects, then increased to 40 mg twice daily, the patient should be assessed for benefit and tolerability after 2–4 weeks.

**CAUTIONS**
- Bleeding disorders - cardiac disease - elderly - history of mania - history of seizures - hypertension (avoid if uncontrolled) - raised intra-ocular pressure - susceptibility to angle-closure glaucoma

**INTERACTIONS**
- Appendix 1 (duloxetine). Caution with concomitant use of drugs that increase risk of bleeding.

**SIDE-EFFECTS**
- **Common or very common**

- **Uncommon**

- **Rare**
  - Mania

- **Very rare**
  - Angle-closure glaucoma

- **Frequency not known**
  - Anaphylaxis - angioedema - chest pain - hallucinations - hypersensitivity reactions - hyponatraemia - rash - seizures - Stevens-Johnson syndrome - suicidal behaviour - supraventricular arrhythmia - urticaria

**PREGNANCY**
- Toxicity in animal studies—avoid in patients with stress urinary incontinence; in other conditions use only if potential benefit outweighs risk. Risk of neonatal withdrawal symptoms if used near term.

**BREAST FEEDING**
- Present in milk—manufacturer advises avoid.

**HEPATIC IMPAIRMENT**
- Manufacturer advises avoid.

**RENAI IMPAIRMENT**
- Avoid if eGFR less than 30 ml/minute/1.73 m².

**TREATMENT CESSATION**
- Nausea, vomiting, headache, anxiety, dizziness, paraesthesia, sleep disturbances, and tremor are the most common features of abrupt withdrawal or marked reduction of the dose; dose should be reduced over at least 1–2 weeks.
Venlafaxine

- **DRUG ACTION** A serotonin and noradrenaline re-uptake inhibitor.

**INDICATIONS AND DOSE**

**Major depression**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adults:** Initially 75 mg daily in 2 divided doses, then increased if necessary up to 375 mg daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- **Adults:** Initially 75 mg once daily, increased if necessary up to 375 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day

**Generalised anxiety disorder**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- **Adults:** 75 mg once daily, increased if necessary up to 225 mg once daily, dose to be increased at intervals of at least 2 weeks; maximum 225 mg per day

**Social anxiety disorder**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- **Adults:** 75 mg once daily, there is no evidence of greater efficacy at higher doses, increased if necessary up to 225 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks; maximum 225 mg per day

**CONTRA-INDICATIONS** Conditions associated with high risk of cardiac arrhythmia - uncontrolled hypertension

**CAUTIONS** Diabetes - heart disease (monitor blood pressure) - history of bleeding disorders - history of epilepsy - history or family history of mania - susceptibility to angle-closure glaucoma

**INTERACTIONS** Appendix 1 (venlafaxine). Concomitant use of drugs that increase risk of bleeding.

**SIDE-EFFECTS**

- **Common or very common** Abnormal dreams - anorexia - anxiety - anxiety (on withdrawal) - asthenia - changes in serum cholesterol - chills - confusion - constipation - difficulty with micturition - dizziness - dizziness (on withdrawal) - dry mouth - gastro-intestinal disturbances (on withdrawal) - headache - headache (on withdrawal) - hyperton - hypertension - hypotonia - insomnia - menstrual disturbances - mydriasis - nausea - nervousness - palpititation - paraesthesia (on withdrawal) - sensory disturbances - sexual dysfunction - sleep disturbances (on withdrawal) - sweating - sweating (on withdrawal) - tremor - tremor (on withdrawal) - vasodilatation - visual disturbances - vomiting - weight changes - yawning


- **Rare** Akathisia - extrapyramidal symptoms - hypomania - mania - seizures - urinary incontinence

- **Very rare** Angle-closure glaucoma

- **Frequency not known** Aggression - blood dyscrasias - delirium - hepatitis - hyperprolactinaemia - hypotension - neuroleptic malignant syndrome - pancreatitis - pruritus - QT interval prolongation - rhabdomyolysis - Stevens-Johnson syndrome - suicidal behaviour - syndrome of inappropriate anti-diuretic hormone secretion - urticaria - vertigo

**PREGNANCY** Avoid unless potential benefit outweighs risk—toxicity in animal studies. Risk of withdrawal effects in neonate.

**BREAST FEEDING** Present in milk—avoid.

**HEPATIC IMPAIRMENT** Consider reducing dose by 50% in mild or moderate impairment; use with caution and reduce dose by at least 50% in severe impairment.

**RENAL IMPAIRMENT** Use with caution. Use half normal dose (immediate-release tablets may be given once daily) if eGFR less than 30 mL/minute/1.73 m².

**TREATMENT CESSATION** Associated with a higher risk of withdrawal effects compared with other antidepressants. Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, tremor, sleep disturbances, and sweating are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks.

**PATIENT AND CARER ADVICE** May affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 3**

- **VENLAFAXINE (Non-proprietary)**
  - Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg
  - Venlafaxine 37.5 mg tablets | 56 tablet (P) £20.00 DT price + £2.37
  - Venlafaxine (as Venlafaxine hydrochloride) 75 mg
  - Venlafaxine 75 mg tablets | 56 tablet (P) £30.00 DT price + £2.66
  - Brands may include ViPax

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 3, 21, 25**

- **Venlafaxine (as Venlafaxine hydrochloride) 75 mg**
  - Venlafaxine XL 75 mg tablets | 30 tablet (P) £11.14 OT price + £11.20

- **Venlafaxine (as Venlafaxine hydrochloride) 150 mg**
  - Venlafaxine XL 150 mg tablets | 30 tablet (P) £18.64 DT price + £18.70

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (September 2006) that duloxetine (Cymbalta®) should be restricted for use by specialists when other treatments for diabetic peripheral neuropathic pain are unsuitable or inadequate.
**290 Mental health disorders**

**Mianserin hydrochloride**

- **Venlafaxine (as Venlafaxine hydrochloride) 75 mg**
  - Venlafaxine XL 75mg tablets | 28 tablet PDP £11.20
  - Venlafaxine (as Venlafaxine hydrochloride) 150 mg
  - Venlafaxine XL 150mg tablets | 28 tablet PDP £18.70
- **Venlalic XL (DB Ashbourne Ltd)**
  - Venlafaxine (as Venlafaxine hydrochloride) 75 mg
  - Venlalic XL 75mg tablets | 30 tablet PDP £23.75 DT price = £14.70
  - Venlafaxine (as Venlafaxine hydrochloride) 150 mg
  - Venlalic XL 150mg tablets | 30 tablet PDP £47.50 DT price = £29.00
- **ViePax XL (Dexcel-Pharma Ltd)**
  - Venlafaxine (as Venlafaxine hydrochloride) 75 mg ViePax XL 75mg tablets | 28 tablet PDP £10.44
  - Venlafaxine (as Venlafaxine hydrochloride) 150 mg ViePax XL 150mg tablets | 28 tablet PDP £17.44

**Modified-release capsule**

- **VENLAFAXINE (Non-proprietary)**
  - Venlafaxine (as Venlafaxine hydrochloride) 75 mg Venlafaxine 75mg modified-release capsules | 28 capsule PDP £22.50 DT price = £22.08
  - Venlafaxine (as Venlafaxine hydrochloride) 150 mg Venlafaxine 150mg modified-release capsules | 28 capsule PDP £37.50 DT price = £36.81
- **Efexor XL (Pfizer Ltd)**
  - Venlafaxine (as Venlafaxine hydrochloride) 75 mg Efexor XL 75mg capsules | 28 capsule PDP £22.08 DT price = £22.08
  - Venlafaxine (as Venlafaxine hydrochloride) 150 mg Efexor XL 150mg capsules | 28 capsule PDP £36.81 DT price = £36.81
- **Medications like Alventa XL; Amphero XL; Depefex XL; Foraven XL; ViePax XL; Venlalic XL; Venlafaxine; Venladex XL; Venlafaxine hydrochloride; Efexor XL; ViePax XL; Venlafaxine (as Venlafaxine hydrochloride); Efexor XL; Venlafaxine hydrochloride**

**TETRACYCLIC ANTIDEPRESSANTS**

**Mianserin hydrochloride**

**INDICATIONS AND DOSE**

Depressive illness (particularly where sedation is required)

- **By Mouth**
  - **Adult:** Initially 30–40 mg daily in divided doses, alternatively initially 30–40 mg once daily, dose to be taken at bedtime, increase dose gradually as necessary; usual dose 30–90 mg
  - **Elderly:** Initially 30 mg daily in divided doses, alternatively initially 30 mg once daily, dose to be taken at bedtime, increase dose gradually as necessary; usual dose 30–90 mg

- **CONTRA-INDICATIONS**
  - Acute porphyrias p. 864
  - arrhythmias - during the manic phase of bipolar disorder
  - heart block - immediate recovery period after myocardial infarction

- **CAUTIONS**
  - Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism - risk of arrhythmias - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

- **CAUTIONS, FURTHER INFORMATION**
  - Treatment should be stopped if the patient enters a manic phase.
  - Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with careful monitoring, particularly for psychiatric and cardiac side-effects.

- **INTERACTIONS**
  - Antidepressants, tricyclic (related).

- **SIDE-EFFECTS**
  - Common or very common: Agitation - anxiety - arrhythmia - blurred vision - confusion - dizziness - dry mouth - ECG changes - heart block - irritability - paraesthesia - postural hypotension - sleep disturbances - sudden death of patients with cardiac disease - tachycardia

- **Rare:** Dysarthria - extrapyramidal symptoms - paralytic ileus - tremor - urinary retention

- **Very rare:** Constipation - neuroleptic malignant syndrome - precipitation of angle-closure glaucoma

- **Frequency not known**
  - Alopecia - anorexia - arthralgia - arthritis - blood dyscrasias - breast enlargement - changes in blood sugar - chillis (on withdrawal) - convulsions - delusions - galactorrhoea - gynaecomastia - haematological reactions - hallucinations - headache (on withdrawal) - hepatic reactions - hypomania - hypotension - increased appetite - influenza-like symptoms (on withdrawal)
  - Insomnia (on withdrawal) - jaundice - mania - movement disorders (on withdrawal) - myalgia (on withdrawal)

**SIDE-EFFECTS, FURTHER INFORMATION**

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

**Overdose**

Emergency treatment of poisoning

The tricyclic-related antidepressant drugs may be associated with a lower risk of cardiotoxicity in overdosage. Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

- **PREGNANCY**
  - Avoid.

- **BREAST FEEDING**
  - The amount secreted into breast milk is too small to be harmful.

- **HEPATIC IMPAIRMENT**
  - Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

- **RENAI IMPAIRMENT**
  - Caution in renal impairment.

- **MONITORING REQUIREMENTS**
  - A full blood count is recommended every 4 weeks during the first 3 months of treatment; clinical monitoring should continue subsequently and treatment should be stopped and a full blood count obtained if fever, sore throat, stomatitis, or other signs of infection develop.

- **TREATMENT CESSATION**
  - Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

- **PATIENT AND CARER ADVICE**
  - Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.
Mirtazapine

**DRUG ACTION** Mirtazapine is a presynaptic alpha2-adrenoceptor antagonist which increases central noradrenergic and serotonergic neurotransmission.

**INDICATIONS AND DOSE**

**Major depression**

**BY MOUTH**

- Adult: Initially 15–30 mg daily for 2–4 weeks, dose to be taken at bedtime, then adjusted according to response to up to 45 mg once daily; increased if necessary up to 45 mg daily in 2 divided doses.

**CAUTIONS** Cardiac disorders - diabetes mellitus - elderly - history of bipolar depression - history of seizures - history of urinary retention - hypotension - psychoses (may aggravate psychotic symptoms) - susceptibility to angle-closure glaucoma

**INTERACTIONS** Appendix 1 (mirtazapine).

**SIDE-EFFECTS**

- **Common or very common** Abnormal dreams - agitation (on withdrawal) - anxiety - anxiety (on withdrawal) - arthralgia - confusion - dizziness - dizziness (on withdrawal) - drowsiness - dry mouth - fatigue - headache (on withdrawal) - increased appetite - insomnia - myalgia - nausea (on withdrawal) - oedema - postural hypotension - tremor - vomiting (on withdrawal) - weight gain

- **Uncommon** Hallucinations - mania - movement disorders - syncope

- **Rare** Aggression - myoclonus - pancreatitis

- **Frequency not known** Angle-closure glaucoma - blood disorders - convulsions - dysarthria - hypersalivation - hyponatraemia - inappropriate secretion of antidiuretic hormone - sedation during initial treatment - Stevens-Johnson syndrome - suicidal behaviour - toxic epidermal necrolysis

**PREGNANCY** Use with caution—limited experience; monitor neonate for withdrawal effects.

**BREAST FEEDING** Present in milk; use only if potential benefit outweighs risk.

**HEPATIC IMPAIRMENT** Use with caution. Discontinue if jaundice occurs.

**RENAL IMPAIRMENT** Clearance reduced by 30% if eGFR less than 40 mL/minute/1.73 m²; clearance reduced by 50% if eGFR less than 10 mL/minute/1.73 m².

**TREATMENT CESSATION** Nausea, vomiting, dizziness, agitation, anxiety, and headache are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks.

**DIRECTIONS FOR ADMINISTRATION** Orodispensible tablet (Zispin SolTab) should be placed on the tongue, allowed to disperse and swallowed.

**PATIENT AND CARER ADVICE** Counselling on administration of orodispensible tablet advised. Blood Disorders Patients should be advised to report any fever, sore throat, stomatitis or other signs of infection during treatment. Blood count should be performed and the drug stopped immediately if blood dyscrasia suspected.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, capsule, tablet.

**Tablet**

- **MANSERIN HYDROCHLORIDE (Non-proprietary)**
  - Mianserin hydrochloride 10 mg: 28 tablet £18.00 DT price = £8.25
  - Mianserin hydrochloride 30 mg: 28 tablet £25.00 DT price = £18.34

**INTERACTIONS**

- **Major depression**
  - **BY MOUTH**
    - Adult: Initially 15–30 mg daily for 2–4 weeks, dose to be taken at bedtime, then adjusted according to response to up to 45 mg once daily; increased if necessary up to 45 mg daily in 2 divided doses.

**INDICATIONS AND DOSE**

**Depression**

**BY MOUTH**

- **Adult:**
  - Initially 15 mg daily in divided doses, dose to be taken after food, alternatively initially 150 mg once daily, dose to be taken at bedtime, increased if necessary to 300 mg daily; increased if necessary to 600 mg daily in divided doses, higher dose for use in hospital patients only
  - Elderly: Initially 100 mg daily in divided doses, dose to be taken after food, alternatively initially 100 mg once daily, dose to be taken at bedtime, increased if necessary to 300 mg daily; increased if necessary to 600 mg daily in divided doses, higher dose for use in hospital patients only

**CAUTIONS**

- **Cardiovascular disease**
- **Diabetes mellitus**
- **History of seizures**
- **Psychosis** (may aggravate psychotic symptoms)

**SIDE-EFFECTS**

- **Frequency not known** Agitation, anxiety, and headache are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks.

**DIRECTIONS FOR ADMINISTRATION** Orodispensible tablet (Zispin SolTab) should be placed on the tongue, allowed to disperse and swallowed.

**CONTRA-INDICATIONS** Acute porphyrias p. 864 - arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

**CAUTIONS**

- **Cardiovascular disease**
- **Diabetes mellitus**
- **Epilepsy**
- **History of bipolar disorder**
- **History of psychosis**
- **Hypothyroidism (risk of arrhythmias)**
- **Increased intra-ocular pressure**
- **Patients with a significant risk of suicide**
- **Phaeochromocytoma (risk of arrhythmias)**
- **Prostatic hypertrophy**
- **Susceptibility to angle-closure glaucoma**
- **Urinary retention**

**TRIAZOLOPYRIDINES**

**Trazodone hydrochloride**

**INDICATIONS AND DOSE**

**Depressive illness (particularly where sedation is required)**

**BY MOUTH**

- Adult: Initially 150 mg daily in divided doses, dose to be taken after food, alternatively initially 150 mg once daily, dose to be taken at bedtime, increased if necessary to 300 mg daily; increased if necessary to 600 mg daily in divided doses, higher dose for use in hospital patients only

**CAUTIONS**

- **Cardiovascular disease**
- **Chronic constipation**
- **Diabetes mellitus**
- **Epilepsy**
- **History of bipolar disorder**
- **History of psychosis**
- **Hyperthyroidism** (risk of arrhythmias)
- **Increased intra-ocular pressure**
- **Patients with a significant risk of suicide**
- **Phaeochromocytoma (risk of arrhythmias)**
- **Prostatic hypertrophy**
- **Susceptibility to angle-closure glaucoma**
- **Urinary retention**
## Nervous system

### Treatment Cessation
- Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

### Interactions
- Antidepressants, tricyclic (related).

### Side-effects

- **Rare** Extrapyramidal symptoms - paralytic ileus
- **Very rare** precipitation of angle-closure glaucoma
- **Frequency not known** agitation - alopecia - anorexia - anxiety - arrhythmia - arthralgia - blurred vision - breast enlargement - changes in blood sugar - chills (on withdrawal) - confusion - constipation - convulsions - delusions - dizziness - drowsiness - dry mouth - dysarthria - dyspepsia - dyspnoea - ECG changes - galactorrhoea - gynaecomastia - haematological reactions - hallucinations - headache (on withdrawal) - heart block - hepatic reactions - hypersalivation - hypertension - hypomania - hypotension - increased appetite - influenza-like symptoms (on withdrawal) - insomnia (on withdrawal) - irritability - mania - movement disorders (on withdrawal) - myalgia - myalgia (on withdrawal) - nausea - nausea (on withdrawal) - palpitation - paraesthesia - photosensitivity - postural hypotension - priapism (discontinue immediately) - pruritus - rash - sexual dysfunction - sleep disturbances - sudden death of patients with cardiac disease - sweating - sweating (on withdrawal) - tachycardia - taste disturbance - tinnitus - tremor - urinary retention - urticaria - vivid dreams (on withdrawal) - vomiting - weight gain - weight loss

### Side-effects, Further Information

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

### Overdose

Emergency treatment of poisoning The tricyclic-related antidepressant drugs may be associated with a lower risk of cardiotoxicity in overdose. Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypoventilation, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

### Pregnancy

- Avoid during first trimester—limited information available. Monitor infant for signs of withdrawal if used until delivery.

### Breast Feeding

- The amount secreted into breast milk is too small to be harmful.

### Hepatic Impairment

- Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

### Renal Impairment

- Use with caution in severe impairment.

### Treatment Cessation

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

### Prescribing and Dispensing Information

Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose.

### Patient and Carer Advice

Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

### Table

**CAUTIONARY AND ADVISORY LABELS 2, 21**

<table>
<thead>
<tr>
<th>TRAZODONE HYDROCHLORIDE (Non-proprietary)</th>
<th>28 tablet [P] £30.00 DT price = £20.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moliapxin (Zentiva)</td>
<td>Trazodone hydrochloride 150 mg Moliapxin 150mg tablets</td>
</tr>
<tr>
<td>Capsule</td>
<td>28 tablet [P] £16.08 DT price = £20.05</td>
</tr>
</tbody>
</table>

### Capsule

**CAUTIONARY AND ADVISORY LABELS 2, 21**

<table>
<thead>
<tr>
<th>TRAZODONE HYDROCHLORIDE (Non-proprietary)</th>
<th>84 capsule [P] £31.00 DT price = £25.02</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trazodone hydrochloride 50 mg Trazodone 50mg capsules</td>
<td></td>
</tr>
<tr>
<td>Moliapxin (Zentiva)</td>
<td>Trazodone hydrochloride 100 mg Moliapxin 100mg capsules</td>
</tr>
<tr>
<td>Oral solution</td>
<td>84 capsule [P] £32.92 DT price = £25.02</td>
</tr>
<tr>
<td>Trazodone hydrochloride 50 mg Moliapxin 50mg capsules</td>
<td></td>
</tr>
<tr>
<td>Trazodone hydrochloride 100 mg Moliapxin 100mg capsules</td>
<td></td>
</tr>
</tbody>
</table>

### TRICYCLIC ANTIDEPRESSANTS

#### Amitriptyline hydrochloride

**Indications and Dose**

Abdominal pain or discomfort (in patients who have not responded to laxatives, loperamide, or antispasmodics)

**By Mouth**

- Adult: Initially 5–10 mg daily, to be taken at night; increased in steps of 10 mg at least every 2 weeks as required; maximum 50 mg per day.

Depressive illness (but not recommended)

**By Mouth**

- Adult: Initially 75 mg daily in divided doses, alternatively initially 75 mg once daily, dose to be taken at bedtime, increased if necessary to 150–200 mg daily, dose to be increased gradually.

Neuropathic pain

**By Mouth**

- Adult: Initially 30–75 mg daily in divided doses, alternatively initially 30–75 mg once daily, dose to be taken at bedtime, increased if necessary to 150–200 mg daily, dose to be increased gradually.

Migraine prophylaxis

**By Mouth**

- Adult: Initially 10 mg once daily, then increased if necessary to 75 mg once daily, dose to be taken at night, dose to be increased gradually, higher doses to be given on specialist advice.

**Unlicensed Use**

licensed for use in abdominal pain or discomfort in patients who have not responded to laxatives, loperamide, or antispasmodics.

- **CONTRA-INDICATIONS** Acute porphyrias p. 864 - arrhythmias - during manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

- **CAUTIONS** Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias) - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

**SIDE-EFFECTS, FURTHER INFORMATION**

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

- **INTERACTIONS** → Appendix 1 (Antidepressants, tricyclic).

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain - fatigue - hypertension - mydriasis - oedema - palpitation - restlessness - stomatitis
  - **Rare** Dysarthria - extrapyramidal symptoms - paralytic ileus - tremor
  - **Very rare** Neuroleptic malignant syndrome - precipitation of angle-closure glaucoma
  - **Frequency not known** Agitation - alopecia - anorexia - anxiety - arrhythmia - blurred vision - breast enlargement - changes in blood sugar - chills (on withdrawal) - confusion - constipation - convulsions - delusions - dizziness - drowsiness - dry mouth - ECG changes - galactorrhoea - gynaecomastia - haematological reactions - hallucinations - headache (on withdrawal) - heart block - hepatic reactions - hypomania - hypotension (on withdrawal) - increased appetite - increased intra-ocular pressure - influenza-like symptoms (on withdrawal) - Insomnia (on withdrawal) - irritability - mania - movement disorders (on withdrawal) - myalgia (on withdrawal) - nausea - nausea (on withdrawal) - paraesthesia - photosensitivity - postural hypotension - pruritus - rash - sexual dysfunction - sleep disturbances - sudden death of patients with cardiac disease - suicidal behaviour - sweating - sweating (on withdrawal) - tachycardia - taste disturbance - tinnitus - urinary retention - urticaria - vivid dreams (on withdrawal) - vomiting - weight gain - weight loss

**SIDE-EFFECTS, FURTHER INFORMATION**

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

**Overdose** Overdosage with amitriptyline is associated with a relatively high rate of fatality. Symptoms of overdosage may include dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning, see Tricyclic and related antidepressants, under Emergency treatment of poisoning p. 1123.

- **PREGNANCY** Use only if potential benefit outweighs risk.
- **BREAST FEEDING** The amount secreted into breast milk is too small to be harmful.

**HEPATIC IMPAIRMENT** Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

**TREATMENT CESSION** Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

- **PRESCRIBING AND DISPENSING INFORMATION** Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

**PATIENT AND CARER ADVICE** Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**

  - **AMITRIPTYLINE HYDROCHLORIDE (Non-proprietary)**
    - Amitriptyline hydrochloride 10 mg | 28 tablet | £1.12 DT price = £1.05
    - Amitriptyline hydrochloride 25 mg | 28 tablet | £1.40 DT price = £1.10
    - Amitriptyline hydrochloride 50 mg | 28 tablet | £1.26 DT price = £1.19

- **Oral solution**

  - **CAUTIONARY AND ADVISORY LABELS**

    - **AMITRIPTYLINE HYDROCHLORIDE (Non-proprietary)**
      - Amitriptyline hydrochloride 10mg/5ml oral solution sugar free (sugar-free) | 150 ml | £22.60 DT price = £22.60
      - Amitriptyline hydrochloride 5mg/1ml oral solution sugar free (sugar-free) | 150 ml | £18.00 DT price = £18.00
      - Amitriptyline hydrochloride 10mg/1ml oral solution sugar free (sugar-free) | 150 ml | £19.20 DT price = £19.20

**Amitriptyline with perphenazine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, amitriptyline hydrochloride p. 292, perphenazine p. 308.

**INDICATIONS AND DOSE**

**Depression with anxiety**

**BY MOUTH**

- Adult: 1 tablet 3 times a day, an additional tablet may be taken at bedtime when required

**LESS SUITABLE FOR PRESCRIBING** Less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**

  - **Triptafen (AMCo)**
    - Amitriptyline hydrochloride 25 mg, Perphenazine 2 mg | 100 tablet | £33.13
Clomipramine hydrochloride

INDICATIONS AND DOSE

Depressive illness

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 10 mg daily, then increased if necessary to 30–150 mg daily in divided doses; dose to be increased gradually, alternatively increased if necessary to 30–150 mg once daily, dose to be taken at bedtime; maximum 250 mg per day
- Elderly: Initially 10 mg daily, then increased to 30–75 mg daily, dose to be increased carefully over approximately 10 days

Phobic and obsessional states

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 25 mg daily, then increased to 100–150 mg daily, dose to be increased gradually over 2 weeks; maximum 250 mg per day
- Elderly: Initially 10 mg daily, then increased to 100–150 mg daily, dose to be increased gradually over 2 weeks; maximum 250 mg per day

Adjunctive treatment of cataplexy associated with narcolepsy

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 10 mg daily, dose to be gradually increased until satisfactory response; increased if necessary to 10–75 mg daily

ANAFRANIL SR®

Depressive illness

BY MOUTH
- Adult: Initially 10 mg once daily, then increased if necessary to 30–150 mg once daily, to be taken at bedtime, doses to be titrated using clomipramine capsules, dose to be increased gradually; maximum 250 mg per day
- Elderly: Initially 10 mg once daily, then increased to 30–75 mg once daily, dose to be increased carefully over approximately 10 days, doses to be titrated using clomipramine capsules

Phobic and obsessional states

BY MOUTH
- Adult: Initially 25 mg once daily, then increased to 100–150 mg once daily, dose to be increased gradually over 2 weeks, doses to be titrated using clomipramine capsules; maximum 250 mg per day
- Elderly: Initially 10 mg once daily, then increased to 100–150 mg once daily, dose to be increased gradually over 2 weeks, doses to be titrated using clomipramine capsules; maximum 250 mg per day

Adjunctive treatment of cataplexy associated with narcolepsy

BY MOUTH
- Adult: Initially 10 mg once daily, dose to be gradually increased until satisfactory response; usual dose 10–75 mg once daily, doses to be titrated using clomipramine capsules

CONTRA-INDICATIONS
- Acute porphyrias p. 864.
- arrhythmias during the manic phase of bipolar disorder
- heart block
- immediate recovery period after myocardial infarction

CAUTIONS
- Cardiovascular disease
- chronic constipation
- diabetes
- epilepsy
- history of bipolar disorder
- history of psychosis
- hyperthyroidism (risk of arrhythmias)
- increased intra-ocular pressure - patients with a significant risk of suicide
- phaeochromocytoma (risk of arrhythmias)
- prostatic hypertrophy
- susceptibility to angle-closure glaucoma
- urinary retention

INTERACTIONS
- Appendix 1 (antidepressants, tricyclic).

SIDE-EFFECTS
- Common or very common: Abdominal pain, diarrhea, fatigue, flushing, hypertension, impaired memory, muscle hypertonia, muscle weakness, mydriasis, myoclonus, restlessness, yawning.
- Rare: Dysarthria, extrapyramidal symptoms, paralytic ileus, tremor.
- Very rare: Allergic alveolitis, neuroleptic malignant syndrome, precipitation of angle-closure glaucoma.

FREQUENCY NOT KNOWN
- Agitation, alopecia, anorexia, anxiety, arrhythmias, blurred vision, breast enlargement, changes in blood sugar, chills (on withdrawal), confusion, constipation, convulsions, delusions, dizziness, dry mouth, ECG changes, galactorrhoea, gynaecomastia, haematological reactions, hallucinations, headache (on withdrawal), heart block, hepatic reactions, hypomania, hypotension, increased appetite, influenza-like symptoms (on withdrawal), insomnia (on withdrawal), irritability, mania, movement disorders (on withdrawal), myalgia (on withdrawal), nausea, numbness (on withdrawal), paraesthesia, photosensitivity, postural hypotension, pruritus, rash, sexual dysfunction, sleep disturbances, sudden death of patients with cardiac disease, suicidal behaviour, sweating, sweating (on withdrawal), tachycardia, taste disturbance, tinnitus, urinary retention, urticaria, vivid dreams (on withdrawal), vomiting, weight gain, weight loss.

SIDE-EFFECTS, FURTHER INFORMATION

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

OVERDOSE
- Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

PREGNANCY
- Neonatal withdrawal symptoms reported if used during third trimester.

HEPATIC IMPAIRMENT
- Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

TREATMENT CESSATION
- Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 6 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION
- Limited quantities of tricyclic antidepressants should be
prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

- **PATIENT AND CARER ADVICE** Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

- **LESS SUITABLE FOR PRESCRIBING** Anafranil SR® Anafranil SR® is less suitable for prescribing.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

<table>
<thead>
<tr>
<th>Modified-release tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anafranil SR (Novartis Pharmaceuticals UK Ltd)</td>
</tr>
<tr>
<td>Clomipramine hydrochloride 75 mg Anafranil SR 75mg tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clomipramine hydrochloride 10 mg Clomipramine 10mg capsules</td>
</tr>
<tr>
<td>Clomipramine hydrochloride 25 mg Clomipramine 25mg capsules</td>
</tr>
<tr>
<td>Clomipramine hydrochloride 50 mg Clomipramine 50mg capsules</td>
</tr>
</tbody>
</table>

**Dosulepin hydrochloride** (Dothiepin hydrochloride)

### INDICATIONS AND DOSE

**Depressive illness (particularly where sedation is required) (initiated by a specialist)**

**BY MOUTH**

- **Adult:** Initially 75 mg daily in divided doses, alternatively initially 75 mg once daily, dose to be taken at bedtime, increased if necessary to 150 mg daily, doses to be increased gradually; up to 225 mg daily in some circumstances (e.g. hospital use)
- **Elderly:** Initially 50–75 mg daily in divided doses, alternatively initially 50–75 mg once daily, dose to be taken at bedtime, increased if necessary to 75–150 mg daily, doses to be increased gradually; up to 225 mg daily in some circumstances (e.g. hospital use)

- **CONTRA-INDICATIONS** Acute porphyrias p. 864 - arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

- **CAUTIONS** Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias) - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

- **CAUTIONS, FURTHER INFORMATION**
  - Treatment should be stopped if the patient enters a manic phase.
  - Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.
  - **INTERACTIONS** → Appendix 1 (antidepressants, tricyclic).

- **SIDE-EFFECTS**
  - Rare: Dysarthria - extrapyramidal symptoms - paralytic ileus - tremor
  - Very rare: Neuroleptic malignant syndrome - precipitation of angle-closure glaucoma

- **Frequency not known** Agitation - alopecia - anorexia - anxiety - arrhythmias - dizziness - dry mouth - ECG changes - galactorrhea - gynaecomastia - haematological reactions - hallucinations - headache (on withdrawal) - heart block - hepatic reactions - hypomania - hypotension - increased appetite - increased intraocular pressure - influenza-like symptoms (on withdrawal) - insomnia (on withdrawal) - irritable mania - movement disorders (on withdrawal) - myalgia (on withdrawal) - nausea - nausea (on withdrawal) - paradoxism - photosensitivity - postural hypotension - pruritus - rash - sexual dysfunction - sleep disturbances - sudden death of patients with cardiac disease - suicidal behaviour - sweating - sweating (on withdrawal) - tachycardia - taste disturbance - tinnitus - urinary retention - urticaria - vivid dreams (on withdrawal) - vomiting - weight gain - weight loss

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

- **Overdose** Overdosage with dosulepin is associated with a relatively high rate of fatality. Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor planter responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

- **PREGNANCY** Use only if potential benefit outweighs risk.

- **BREAST FEEDING** The amount secreted into breast milk is too small to be harmful.

- **HEPATIC IMPAIRMENT** Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

- **TREATMENT CESSATION Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge. (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

- **PRESCRIBING AND DISPENSING INFORMATION** Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage. A maximum prescription equivalent to 2 weeks’ supply of 75 mg daily should be considered in patients with increased risk factors for suicide at initiation of treatment, during any dose adjustment, and until improvement occurs.

- **PATIENT AND CARER ADVICE** Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

- **LESS SUITABLE FOR PRESCRIBING** Dosulepin hydrochloride is less suitable for prescribing.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension
Doxepin (as Doxepin hydrochloride) 25 mg
Doxepin 25mg capsules | 28 capsule | £84.00 DT price = £84.00

Doxepin (as Doxepin hydrochloride) 50 mg
Doxepin 50mg capsules | 28 capsule | £84.00 DT price = £84.00

Imipramine hydrochloride

INDICATIONS AND DOSE
Depressive Illness

BY MOUTH

Adult: Initially up to 75 mg daily in divided doses, then increased to 150–200 mg daily, up to 150 mg may be given as a single dose at bedtime, dose to be increased gradually

Elderly: Initially 10 mg daily, increased to 30–50 mg daily, dose to be increased gradually

- suicidal behaviour
- sweating
- sweating (on withdrawal)
- tachycardia
- taste disturbance
- tinnitus
- urinary retention
- urticaria
- vivid dreams (on withdrawal)
- vomiting
- weight gain
- weight loss

SIDE-EFFECTS, FURTHER INFORMATION
The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Overdose Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

PREGNANCY Use with caution—limited information available.

BREAST FEEDING The amount secreted into breast milk is too small to be harmful. Accumulation of metabolite may cause sedation and respiratory depression in neonate.

HEPATIC IMPAIRMENT Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

RENAL IMPAIRMENT Use with caution.

TREATMENT CESSATION Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

PATIENT AND CARER ADVICE Drowsiness may affect performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, capsule
Depressive illness in hospital patients

BY MOUTH

▶ Adult: Initially up to 75 mg daily in divided doses, dose to be increased gradually, increased to up to 300 mg daily in divided doses

Nocturnal enuresis

BY MOUTH

▶ Child 6–7 years: 25 mg once daily, to be taken at bedtime, initial period of treatment (including gradual withdrawal) 3 months—full physical examination before further course

▶ Child 8–10 years: 25–50 mg once daily, to be taken at bedtime, initial period of treatment (including gradual withdrawal) 3 months—full physical examination before further course

▶ Child 11–17 years: 50–75 mg once daily, to be taken at bedtime, initial period of treatment (including gradual withdrawal) 3 months—full physical examination before further course

CONTRA-INDICATIONS immediate recovery period after myocardial infarction (in adults). Acute porphyrias p. 864. arrhythmia—during the manic phase of bipolar disorder—heart block

CAUTIONS Cardiovascular disease—chronic constipation—diabetes—epilepsy—history of bipolar disorder—history of psychosis—hyperthyroidism (risk of arrhythmias)—increased intra-ocular pressure (in adults)—patients with a significant risk of suicide—phaeochromocytoma (risk of arrhythmias)—prostatic hypertrophy (in adults)—susceptibility to angle-closure glaucoma—urinary retention

CAUTIONS, FURTHER INFORMATION

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

INTERACTIONS → Appendix 1 (antidepressants tricyclic).

SIDE-EFFECTS

▶ Common or very common Fatigue—flushing—headache—palpitation—restlessness

▶ Rare Extrapyramidal symptoms—paralytic ileus

▶ Very rare Abdominal pain—agression—allergic alveolitis—cardiac decompensation—diarrhoea (in children)—hypertension—mydriasis—myoclonus—neuroleptic malignant syndrome—oedema—peripheral vasospasm—precipitation of angle-closure glaucoma—stomatitis

Frequency not known Agitation—alopecia—anorexia—anxiety—arrhythmia—blurred vision—breast enlargement—changes in blood sugar—chills (on withdrawal)—confusion—constipation—convulsions—delusions—dizziness—drowsiness—dry mouth—dysarthria—ECG changes—galactorrhoea—gynaecomastia—haematological reactions—hallucinations—headache (on withdrawal)—heart block—hepatic reactions—hypomania—hypotenar paresthesia—increased appetite—flu—increased salivation—insomnia (on withdrawal)—irritability—mania—movement disorders (on withdrawal)—myalgia (on withdrawal)—nausea—nausea (on withdrawal)—paraesthesia—photosensitivity—postural hypotension—pruritus—rash—sexual dysfunction—sleep disturbances—sudden death of patients with cardiac disease—suicidal behaviour—swallowing—sweating (on withdrawal)—tachycardia—taste disturbance—tinnitus—tremor—urinary incontinence (on withdrawal)—urticaria—vivid dreams (on withdrawal)—vomiting—weight gain—weight loss

SIDE-EFFECTS, FURTHER INFORMATION

▶ In adults The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

OVERDOSE Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

PREGNANCY Colic, tachycardia, dyspnoea, irritability, muscle spasms, respiratory depression and withdrawal symptoms reported in neonates when used in the third trimester.

BREAST FEEDING The amount secreted into breast milk is too small to be harmful.

HEPATIC IMPAIRMENT Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

RENAL IMPAIRMENT Use with caution in severe impairment.

TREATMENT CESSATION Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

PATIENT AND CARER ADVICE Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

Medicines for Children leaflet: Imipramine www.medicinesforchildren.org.uk/imipramine

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet

CAUTIONARY AND ADVISORY LABELS 2

▶ IMPRIMAPINE HYDROCHLORIDE (Non-proprietary)

Imipramine hydrochloride 10 mg Imipramine 10mg tablets 1 28 tablet [P] £1.40 DT price + £1.40

Imipramine hydrochloride 25 mg Imipramine 25mg tablets 1 28 tablet [P] £1.35 DT price + £1.35

Oral solution

CAUTIONARY AND ADVISORY LABELS 2

▶ IMPRIMAPINE HYDROCHLORIDE (Non-proprietary)

Imipramine hydrochloride 5 mg per 1 ml Imipramine 25mg/5ml oral solution sugar free (sugar-free) 1 150 ml [P] £32.00

Lofepramine

INDICATIONS AND DOSE

Depressive illness

BY MOUTH

▶ Adult: 140–210 mg daily in divided doses

▶ Elderly: May respond to lower doses

CONTRA-INDICATIONS Acute porphyrias p. 864—arrhythmias—during the manic phase of bipolar disorder—
heart block - immediate recovery period after myocardial infarction

- **CAUTIONS** Cardiovascular disease · chronic constipation · diabetes · epilepsy · history of bipolar disorder · history of psychosis · hyperthyroidism (risk of arrhythmias) · increased intra-ocular pressure · patients with a significant risk of suicide · pheochromocytoma (risk of arrhythmias) · prostatic hypertrophy · susceptibility to angle-closure glaucoma · urinary retention

- **CAUTIONS, FURTHER INFORMATION**

Treatment should be stopped if the patient enters a manic phase.

Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

- **INTERACTIONS** → Appendix 1 (antidepressants, tricyclic).

- **SIDE-EFFECTS**
  - Common or very common Agitation · anxiety · confusion · dizziness · irritability · paraesthesia · postural hypotension · sleep disturbances
  - Rare Extrapyramidal symptoms · paralytic ileus
  - Very rare Neuroleptic malignant syndrome · precipitation of angle-closure glaucoma

- **Frequency not known** Alopecia · anorexia · arrhythmias · blurred vision · breast enlargement · changes in blood sugar · chills (on withdrawal) · constipation · convulsions · delusions · diaphoresis · drowsiness · dry mouth · dystarthritis · ECG changes · galactorrhoea · gynaecomastia · haematological reactions · hallucinations · headache · heart block · hepatic reactions · hypomania · hypotension · increased appetite · influenza-like symptoms (on withdrawal) · insomnia (on withdrawal) · mania · movement disorders (on withdrawal) · myalgia (on withdrawal) · nausea · nausea (on withdrawal) · oedema · photosensitivity · puritus · rash · sexual dysfunction · sudden death of patients with cardiac disease · suicidal behaviour · sweating · sweating (on withdrawal) · tachycardia · taste disturbance · tinnitus · tremor · urinary retention · urticaria · vivid dreams (on withdrawal) · vomiting · weight gain · weight loss

- **SIDE-EFFECTS, FURTHER INFORMATION**
The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

- **Overdose** Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

- **PREGNANCY** Neonatal withdrawal symptoms and respiratory depression reported if used during third trimester.

- **BREAST FEEDING** The amount secreted into breast milk is too small to be harmful.

- **HEPATIC IMPAIRMENT** Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

- **RENAL IMPAIRMENT** Avoid in severe impairment.

- **TREATMENT CESSATION** Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

- **PRESCRIBING AND DISPENSING INFORMATION** Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

- **PATIENT AND CARER ADVICE** Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

<table>
<thead>
<tr>
<th>Tablet</th>
<th>Lofepramine (Non-proprietary)</th>
<th>Lofepramine (as Lofepramine hydrochloride) 70mg tablets</th>
<th>56 tablet pack £21.03 70mg tablets £30.20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral suspension</td>
<td>Lofepramine (as Lofepramine hydrochloride) 14mg per 1ml Lofepramine 70mg oral suspension sugar free (sugar-free)</td>
<td>150ml pack £31.46</td>
<td></td>
</tr>
<tr>
<td>Oral suspension</td>
<td>Lofepramine (as Lofepramine hydrochloride) 14mg per 1ml Lofepramine 70mg oral suspension sugar free (sugar-free)</td>
<td>150ml pack £22.22</td>
<td></td>
</tr>
</tbody>
</table>

**Nortriptyline**

**INDICATIONS AND DOSE**

- **Depression**
  - **BY MOUTH**
    - Adult: To be initiated at a low dose, then increased if necessary to 75–100 mg daily in divided doses, alternatively increased if necessary to 75–100 mg once daily; maximum 150 mg per day
    - Elderly: To be initiated at a low dose, then increased if necessary to 30–50 mg daily in divided doses

- **Neuropathic pain**
  - **BY MOUTH**
    - Adult: Initially 10 mg once daily, to be taken at night, increased if necessary to 75 mg daily, dose to be increased gradually; higher doses to be given under specialist supervision

- **UNLICENSED USE** Not licensed for use in neuropathic pain.

- **CONTRA-INDICATIONS** Acute porphyrias p. 864 · arrhythmias · during the manic phase of bipolar disorder · heart block · immediate recovery period after myocardial infarction

- **CAUTIONS** Cardiovascular disease · chronic constipation · diabetes · epilepsy · history of bipolar disorder · history of psychosis · hyperthyroidism (risk of arrhythmias) · increased intra-ocular pressure · patients with a significant risk of suicide · pheochromocytoma (risk of arrhythmias) · prostatic hypertrophy · susceptibility to angle-closure glaucoma · urinary retention

- **CAUTIONS, FURTHER INFORMATION**

Treatment should be stopped if the patient enters a manic phase.

Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.
NORTRIPTYLINE (Non-proprietary)

Nortriptyline (as Nortriptyline hydrochloride)
10 mg Nortriptyline 10mg tablets | 100 tablet [Post] £72.02 DT price + £72.00
Nortriptyline (as Nortriptyline hydrochloride)
25 mg Nortriptyline 25mg tablets | 100 tablet [Post] £116.91 DT price + £116.88

Trimiptyline

INDICATIONS AND DOSE
Depressive illness (particularly where sedation required)
BY MOUTH
• Adult: Initially 50–75 mg daily in divided doses, alternatively initially 50–75 mg once daily, dose to be taken at bedtime, increased if necessary to 150–300 mg daily
• Elderly: Initially 10–25 mg 3 times a day, maintenance 75–150 mg daily

CONTRA-INDICATIONS
Acute porphyrias p. 864 • arrhythmias • during the manic phase of bipolar disorder • heart block • immediate recovery period after myocardial infarction

CAUTIONS
Cardiovascular disease • chronic constipation • diabetes • epilepsy • history of bipolar disorder • history of psychosis • hyperthyroidism (risk of arrhythmias) • increased intra-ocular pressure • patients with a significant risk of suicide • phaeochromocytoma (risk of arrhythmias) • prostatic hypertrophy • susceptibility to angle-closure glaucoma • urinary retention

CAUTIONS, FURTHER INFORMATION
Treatment should be stopped if the patient enters a manic phase.
Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

INTERACTIONS
• Appendix 1 (antidepressants, tricyclic).

SIDE-EFFECTS
• Rare Paralytic ileus
• Very rare Neuroleptic malignant syndrome • precipitation of angle-closure glaucoma
• Frequency not known Agitation • alopæcia • anorexia • anxiety • arrhythmia • blurred vision • breast enlargement • changes in blood sugar • chills (on withdrawal) • confusion • constipation • convulsions • delusions • diarrhoea • dizziness • dry mouth • dysarthria • ECG changes • flushing • galactorrhoea • gynaecomastia • haematological reactions • hallucinations • headache (on withdrawal) • heart block • hepatic reactions • hypomania • hypotension • increased appetite • influenza-like symptoms (on withdrawal) • insomnia (on withdrawal) • irritability • mania • movement disorders (on withdrawal) • myalgia (on withdrawal) • nausea • nausea (on withdrawal) • paraesthesia • photosensitivity • postural hypotension • pruritis • rash • sexual dysfunction • sleep disturbances • somnolence • sudden death of patients with cardiac disease • suicidal behaviour • sweating • sweating (on withdrawal) • tachycardia • taste disturbance • tinnitus • tremor • urinary retention • urticaria • vivid dreams (on withdrawal) • vomiting • weight gain • weight loss

SIDE-EFFECTS, FURTHER INFORMATION
The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

OVERDOSE
Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

PREGNANCY
Use only if potential benefit outweighs risk.

BREAST FEEDING
The amount secreted into breast milk is too small to be harmful.

HEPATIC IMPAIRMENT
Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

MONITORING REQUIREMENTS
Manufacturer advises plasma-nortriptyline concentration monitoring if dose above 100 mg daily, but evidence of practical value uncertain.

TREATMENT CESSATION
Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION
Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

PATIENT AND CARER ADVICE
Drowsiness may affect the performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.
to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

**Overdose** Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning, p. 1123.

- **PREGNANCY** Use only if potential benefit outweighs risk.
- **BREAST FEEDING** The amount secreted into breast milk is too small to be harmful.
- **HEPATIC IMPAIRMENT** Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.
- **TREATMENT CESSION** Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 6 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.
- **PRESCRIBING AND DISPENSING INFORMATION** Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose.
- **PATIENT AND CARER ADVICE** Drowsiness may affect the performance of skilled tasks (e.g., driving). Effects of alcohol enhanced.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- TRIMIPRAMINE (Non-proprietary) Trimipramine (as Trimipramine maleate) 10 mg Trimipramine 10mg tablets | 28 tablet £1.50 DT price = £31.30 | 84 tablet P no price available
- Trimipramine (as Trimipramine maleate) 25 mg Trimipramine 25mg tablets | 28 tablet £6.30 DT price = £36.34 | 84 tablet P no price available

**Capsule**

- TRIMIPRAMINE (Non-proprietary) Trimipramine (as Trimipramine maleate) 50 mg Trimipramine 50mg capsules | 28 capsule P £99.60 DT price = £39.00

### 2.5 Deviant antisocial sexual behaviour

#### ANTIPSYCHOTICS (FIRST-GENERATION)

**Benperidol**

The properties listed below are those particular to the drug only. For properties common to the class, see Antipsychotics, p. 303.

**INDICATIONS AND DOSE**

Control of deviant antisocial sexual behaviour

- **BY MOUTH**
  - Adult: 0.25–1.5 mg daily in divided doses, adjusted according to response, for debilitated patients, use elderly dose
  - Elderly: Initially 0.125–0.75 mg daily in divided doses, adjusted according to response

- **CONTRA-INDICATIONS** CNS depression - comatose states - phaeochromocytoma

- **CAUTIONS** Risk factors for stroke

- **PREGNANCY** Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy. Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremors, drowsiness, feeding problems, and respiratory distress.

- **BREAST FEEDING** There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.

- **HEPATIC IMPAIRMENT** Can precipitate coma.

- **RENAI IMPAIRMENT** Start with small doses in severe renal impairment because of increased cerebral sensitivity.

- **MONITORING REQUIREMENTS** Manufacturer advises regular blood counts and liver function tests during long-term treatment.

- **PRESCRIBING AND DISPENSING INFORMATION** The proprietary name Benquil® has been used for benperidol tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- BENPERIDOL (Non-proprietary) Benperidol 250 microgram Benperidol 250microgram tablets | 112 tablet £56.96 DT price = £117.31
- Anquil (Archimedes Pharma UK Ltd) Benperidol 250 microgram Anquil 250microgram tablets | 112 tablet £56.96 DT price = £117.31

### 2.6 Psychoses and schizophrenia

#### Psychoses and related disorders

Advice of Royal College of Psychiatrists on doses of antipsychotic drugs above BNF upper limit

Unless otherwise stated, doses in the BNF are licensed doses—any higher dose is therefore unlicensed

- Consider alternative approaches including adjuvant therapy and newer or second-generation antipsychotic drugs such as clozapine.

- Bear in mind risk factors, including obesity; particular caution is indicated in older patients, especially those over 70.

- Consider potential for drug interactions—see interactions: Appendix 1 (antipsychotics).

- Carry out ECG to exclude untoward abnormalities such as prolonged QT interval; repeat ECG periodically and
reduce dose if prolonged QT interval or other adverse cardiac abnormality develops.
- Increase dose slowly and not more often than once weekly.
- Carry out regular pulse, blood pressure, and temperature checks; ensure that patient maintains adequate fluid intake.
- Consider high-dose therapy to be for limited period and review regularly; abandon if no improvement after 3 months (return to standard dosage).

**Important:** When prescribing an antipsychotic for administration on an emergency basis, the intramuscular dose should be lower than the corresponding oral dose (owing to absence of first-pass effect), particularly if the patient is very active (increased blood flow to muscle considerably increases the rate of absorption). The prescription should specify the dose for each route and should not imply that the same dose can be given by mouth or by intramuscular injection. The dose of antipsychotic for emergency use should be reviewed at least daily.

### Antipsychotic drugs

Antipsychotic drugs are also known as 'neuroleptics' and (misleadingly) as 'major tranquillisers'. In the short term they are used to calm disturbed patients whatever the underlying psychopathology, which may be schizophrenia, brain damage, mania, toxic delirium, or agitated depression. Antipsychotic drugs are used to alleviate severe anxiety but this too should be a short-term measure.

### Schizophrenia

The aim of treatment is to alleviate the suffering of the patient (and carer) and to improve social and cognitive functioning. Many patients require life-long treatment with antipsychotic medication. Antipsychotic drugs relieve positive psychotic symptoms such as thought disorder, hallucinations, and delusions, and prevent relapse; they are usually less effective on negative symptoms such as apathy and social withdrawal. In many patients, negative symptoms persist between episodes of treated positive symptoms, but earlier treatment of psychotic illness may protect against the development of negative symptoms over time. Patients with acute schizophrenia generally respond better than those with chronic symptoms.

**Long-term treatment:**

Long-term treatment of a patient with a definitive diagnosis of schizophrenia is usually required after the first episode of illness in order to prevent relapses. Doses that are effective in acute episodes should generally be continued as prophylaxis.

### First-generation antipsychotic drugs

The first-generation antipsychotic drugs act predominantly by blocking dopamine D₂ receptors in the brain. First-generation antipsychotic drugs are not selective for any of the four dopamine pathways in the brain and so can cause a range of side-effects, particularly extrapyramidal symptoms and elevated prolactin. The phenothiazine derivatives can be divided into 3 main groups:

- **Group 1:** chlorpromazine hydrochloride p. 304, levomepromazine p. 345, and promazine hydrochloride p. 320, generally characterised by pronounced sedative effects and moderate antimuscarinic and extrapyramidal side-effects.
- **Group 2:** perazine p. 308 and pipotiazine palmitate, generally characterised by moderate sedative effects, but fewer extrapyramidal side-effects than groups 1 or 3.
- **Group 3:** fluphenazine decanoate p. 306, perphenazine p. 308, prochlorperazine p. 309, and trifluoperazine p. 310, generally characterised by fewer sedative and antimuscarinic effects, but more pronounced extrapyramidal side-effects than groups 1 and 2.

### Butyrophenones

(benperidol p. 300 and haloperidol p. 306) resemble the group 3 phenothiazines in their clinical properties. Thioxanthenes (flupentixol p. 305 and zuclopenthixol p. 311) have moderate sedative, antimuscarinic effects, and extrapyramidal effects. Diphenylbutytopiperidines (pimozide p. 306) and the substituted benzamides (sulpiride p. 310) have reduced sedative, antimuscarinic, and extrapyramidal effects.

### Second-generation antipsychotic drugs

The second-generation antipsychotic drugs (sometimes referred to as atypical antipsychotic drugs) act on a range of receptors in comparison to first-generation antipsychotic drugs and have more distinct clinical profiles, particularly with regard to side-effects.

### Prescribing for the elderly

**The balance of risks and benefit should be considered before prescribing antipsychotic drugs for elderly patients.** In elderly patients with dementia, antipsychotic drugs are associated with a small increased risk of mortality and an increased risk of stroke or transient ischaemic attack. Furthermore, elderly patients are particularly susceptible to postural hypotension and to hyper- and hypothermia in hot or cold weather.

It is recommended that:

- Antipsychotic drugs should not be used in elderly patients to treat mild to moderate psychotic symptoms.
- Initial doses of antipsychotic drugs in elderly patients should be reduced (to half the adult dose or less), taking into account factors such as the patient’s weight, co-morbidity, and concomitant medication.
- Treatment should be reviewed regularly.

### Side effects of antipsychotic drugs

**Side-effects** caused by antipsychotic drugs are common and contribute significantly to non-adherence to therapy.

**Extrapyramidal symptoms** occur most frequently with the piperazine phenothiazines (fluphenazine, perphenazine, prochlorperazine, and trifluoperazine), the butyrophenones (benperidol and haloperidol), and the first-generation depot preparations. They are easy to recognise but cannot be predicted accurately because they depend on the dose, the type of drug, and on individual susceptibility.

**Extrapyramidal symptoms consist of:**

- parkinsonian symptoms (including tremor), which may occur more commonly in adults or the elderly and may appear gradually;
- dystonia (abnormal face and body movements) and dyskinesia, which occur more commonly in children or young adults and after only a few doses;
- akathisia (restlessness), which characteristically occurs after large initial doses and may resemble an exacerbation of the condition being treated;
- tardive dyskinesia (rhythmic, involuntary movements of tongue, face, and jaw), which usually develops on long-term therapy or with high dosage, but it may develop on short-term treatment with low doses—short-lived tardive dyskinesia may occur after withdrawal of the drug.

**Parkinsonian symptoms** remit if the drug is withdrawn and may be suppressed by the administration of antimuscarinic drugs. However, routine administration of such drugs is not justified because not all patients are affected and they may unmask or worsen tardive dyskinesia.

**Tardive dyskinesia** is the most serious manifestation of extrapyramidal symptoms; it is of particular concern because it may be irreversible on withdrawing therapy and treatment is usually ineffective. In children, tardive dyskinesia is more likely to occur when the antipsychotic drug is withdrawn. However, some manufacturers suggest that drug withdrawal at the earliest signs of tardive dyskinesia (fine vermicular movements of the tongue) may halt its full development. Tardive dyskinesia occurs fairly...
frequently, especially in the elderly, and treatment must be carefully and regularly reviewed.

Most antipsychotic drugs, both first- and second-generation, increase prolactin concentration to some extent because dopamine inhibits prolactin release. Aripiprazole reduces prolactin because it is a dopamine-receptor partial agonist. Risperidone, amisulpride, and first-generation antipsychotic drugs are most likely to cause symptomatic hyperprolactinemia. The clinical symptoms of hyperprolactinemia include sexual dysfunction, reduced bone mineral density, menstrual disturbances, breast enlargement, and galactorrhea.

Sexual dysfunction is one of the main causes of non-adherence to antipsychotic medication; physical illness, psychiatric illness, and substance misuse are contributing factors. Antipsychotic-induced sexual dysfunction is caused by more than one mechanism. Reduced dopamine transmission and hyperprolactinemia decrease libido; antimuscarinic effects can cause disorders of arousal; and alpha- and adrenoreceptor antagonists are associated with erection and ejaculation problems in men. Risperidone and haloperidol commonly cause sexual dysfunction. If sexual dysfunction is thought to be antipsychotic-induced, dose reduction or switching medication should be considered.

Antipsychotic drugs have side-effects associated with cardiovascular side-effects such as tachycardia, arrhythmias, and hypotension. QT-interval prolongation is a particular concern with pimozide and haloperidol. There is also a higher probability of QT-interval prolongation in patients using any intravenous antipsychotic drug; or any antipsychotic drug or combination of antipsychotic drugs with doses exceeding the recommended maximum. Cases of sudden death have occurred.

Hyperglycaemia and sometimes diabetes can occur with antipsychotic drugs, particularly clozapine, olanzapine, quetiapine, and risperidone. All antipsychotic drugs may cause weight gain, but the risk and extent varies. Clozapine and olanzapine commonly cause weight gain.

**Hypotension and interference with temperature regulation**

Hypotension and interference with temperature regulation are dose-related side-effects that are liable to cause dangerous falls and hypothermia or hyperthermia in the elderly. Clozapine, chlorpromazine, lurasidone, and quetiapine can cause postural hypotension (especially during initial dose titration) which may be associated with syncope or reflex tachycardia in some patients. Neuroleptic malignant syndrome (hyperthermia, fluctuating level of consciousness, muscle rigidity, and autonomic dysfunction with pallor, tachycardia, labile blood pressure, sweating, and urinary incontinence) is a rare but potentially fatal side-effect of all antipsychotic drugs. Discontinuation of the antipsychotic drug is essential because there is no proven effective treatment, but bromocriptine and dantrolene have been used. The syndrome, which usually lasts for 5–7 days after drug discontinuation, may be unduly prolonged if depot preparations have been used.

**Blood dyscrasias**

Perform blood counts if unexplained infection or fever develops.

**Choice**

There is little meaningful difference in efficacy between each of the antipsychotic drugs (other than clozapine p. 313), and response and tolerability to each antipsychotic drug varies. There is no first-line antipsychotic drug which is suitable for all patients. Choice of antipsychotic medication is influenced by the patient’s medication history, the degree of sedation required (although tolerance to this usually develops), and consideration of individual patient factors such as risk of extrapyramidal side-effects, weight gain, impaired glucose tolerance, QT-interval prolongation, or the presence of negative symptoms.

Second-generation antipsychotic drugs may be better at treating the negative symptoms of schizophrenia.

Second-generation antipsychotic drugs should be prescribed if extrapyramidal side-effects are a particular concern. Of these, aripiprazole p. 312, clozapine p. 313, olanzapine p. 315, and quetiapine p. 318 are least likely to cause extrapyramidal side-effects. Although amisulpride p. 312 is a dopamine-receptor antagonist, extrapyramidal side-effects are less common than with the first-generation antipsychotic drugs because amisulpride selectively blocks mesolimbic dopamine receptors, and extrapyramidal symptoms are caused by blockade of the striatal dopamine pathway.


Schizophrenia is associated with insulin resistance and diabetes; the risk of diabetes is increased in patients with schizophrenia who take antipsychotic drugs. First-generation antipsychotic drugs are less likely to cause diabetes than second-generation antipsychotic drugs, and of the first-generation antipsychotic drugs, fluphenazine decanoate p. 306 and haloperidol p. 306 are lowest risk. Amisulpride p. 312 and aripiprazole p. 312 have the lowest risk of diabetes of the second-generation antipsychotic drugs. Aripiprazole, amisulpride, haloperidol, sulpiride p. 310, and trifluoperazine p. 310 are least likely to cause weight gain.

The antipsychotic drugs with the lowest risk of sexual dysfunction are aripiprazole p. 312 and quetiapine p. 318. Olanzapine p. 315 may be considered if sexual dysfunction is judged to be secondary to hyperprolactinemia. Hyperprolactinemia is usually not clinically significant with aripiprazole, clozapine p. 313, olanzapine, and quetiapine treatment. When changing from other antipsychotic drugs, a reduction in prolactin concentration may increase fertility.

Patients should receive an antipsychotic drug for 4–6 weeks before it is deemed ineffective. Prescribing more than one antipsychotic drug at a time should be avoided except in exceptional circumstances (e.g. clozapine augmentation or when changing medication during titration) because of the increased risk of adverse effects such as extrapyramidal symptoms, QT-interval prolongation, and sudden cardiac death.

Clozapine is licensed for the treatment of schizophrenia in patients unresponsive to, or intolerant of, other antipsychotic drugs. Clozapine should be introduced if schizophrenia is not controlled despite the sequential use of two or more antipsychotic drugs (one of which should be a second-generation antipsychotic drug), each for at least 6–8 weeks. If symptoms do not respond adequately to an optimised dose of clozapine, plasma-clozapine concentration should be checked before adding a second antipsychotic drug to augment clozapine; allow 8–10 weeks’ treatment to assess response. Patients must be registered with a clozapine patient monitoring service.

**Monitoring**

Full blood count, urea and electrolytes, and liver function test monitoring is required at the start of therapy with antipsychotic drugs, and then annually thereafter.

Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly.

Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly.
Before initiating antipsychotic drugs, an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, if there is a personal history of cardiovascular disease, or if the patient is being admitted as an inpatient.

Blood pressure monitoring is advised before starting therapy and frequently during dose titration of antipsychotic drugs.

**Other uses**

Some antipsychotic drugs can be used for the treatment of nausea and vomiting, choreas, and motor tic.

Chlorpromazine hydrochloride p. 304 and haloperidol p. 306 can be used for intractable hiccup. Benperidol p. 300 is used in deviant antisocial sexual behaviour but its value is not established.

Psychomotor agitation should be investigated for an underlying cause; it can be managed with low doses of chlorpromazine hydrochloride or haloperidol used for short periods. Antipsychotic drugs can be used with caution for the short-term treatment of severe agitation and restlessness in the elderly.

**Equivalent doses of oral antipsychotics**

These equivalences are intended only as an approximate guide; individual dosage instructions should also be checked; patients should be carefully monitored after any change in medication. Equivalent daily dose of antipsychotic drug:

- Chlorpromazine 100 mg
- Clozapine 50 mg
- Haloperidol 2–3 mg
- Pimozide 2 mg
- Risperidone 0.5–1 mg
- Sulpiride 200 mg
- Trifluoperazine 5 mg

**Important:** These equivalences must not be extrapolated beyond the maximum dose for the drug. Higher doses require careful titration in specialist units and the equivalences shown here may not be appropriate.

**Dosage**

After an initial period of stabilisation, in most patients, the total daily oral dose can be given as a single dose. The Royal College of Psychiatrists has published advice on doses of antipsychotic drugs above BNF upper limit.

**Antipsychotic depot injections**

Long-acting depot injections are used for maintenance therapy especially when compliance with oral treatment is unreliable. However, depot injections of conventional antipsychotics may give rise to a higher incidence of extrapyramidal reactions than oral preparations; extrapyramidal reactions occur less frequently with second-generation antipsychotic depot preparations, such as risperidone p. 319 and olanzapine embionate p. 316.

**Choice**

There is no clear-cut division in the use of the conventional antipsychotics, but zuclopenthixol p. 311 may be suitable for the treatment of agitation or aggressive patients whereas flupentixol decanoate p. 305 can cause over-excitement in such patients. Zuclopenthixol decanoate may be more effective in preventing relapses than other conventional antipsychotic depot preparations. The incidence of extrapyramidal reactions is similar for the conventional antipsychotics.

### Equivalent doses of depot antipsychotics

<table>
<thead>
<tr>
<th>Antipsychotic drug/interval</th>
<th>Dosage (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flupentixol decanoate / 2 weeks</td>
<td>40</td>
</tr>
<tr>
<td>Fluphenazine decanoate / 2 weeks</td>
<td>25</td>
</tr>
<tr>
<td>Haloperidol (as decanoate) / 4 weeks</td>
<td>100</td>
</tr>
<tr>
<td>Pipotiazine pimelinate / 4 weeks</td>
<td>50</td>
</tr>
<tr>
<td>Zuclopenthixol decanoate / 2 weeks</td>
<td>200</td>
</tr>
</tbody>
</table>

**Important:** These equivalences must not be extrapolated beyond the maximum dose for the drug.

These equivalences are intended only as an approximate guide; individual dosage instructions should also be checked; patients should be carefully monitored after any change in medication.

**Dosage**

Individual responses to neuroleptic drugs are variable and to achieve optimum effect, dosage and dosage interval must be titrated according to the patient’s response.

### Antipsychotics (First-generation)

#### Antipsychotic drugs

- **CAUTIONS**
  - Blood dyscrasias - cardiovascular disease - conditions predisposing to seizures - depression - epilepsy - history of jaundice - myasthenia gravis - Parkinson’s disease (may be exacerbated) - photosensitisation (may occur with higher dosages) - prostatic hypertrophy - severe respiratory disease - susceptibility to angle-closure glaucoma

- **CAUTIONS, FURTHER INFORMATION**
  - Cardiovascular disease

- **Antipsychotic drugs**

- **SIDE-EFFECTS**
  - Rare Neuroleptic malignant syndrome—discontinue (potentially fatal)
  - Very rare Precipitation of angle-closure glaucoma

- **Overdose**

Phenothiazines cause less depression of consciousness and respiration than other sedatives. Hypotension, hypothermia, sinus tachycardia, and arrhythmias may complicate poisoning. For details on the management of poisoning see Antipsychotics under Emergency treatment of poisoning, p. 1123.
**Nervous system**

**Chlorpromazine hydrochloride**

### **INDICATIONS AND DOSE**

Schizophrenia and other psychoses | Mania | Short-term adjunctive management of severe anxiety | Psychomotor agitation, excitement, and violent or dangerously impulsive behaviour

**By mouth**
- Adult: Initially 25 mg 3 times a day, adjusted according to response, alternatively initially 75 mg once daily, adjusted according to response, dose to be taken at night; maintenance 75–300 mg daily, increased if necessary up to 1 g daily, this dose may be required in psychoses, take a third to half adult dose in the elderly and debilitated patients

**By rectum**
- Adult: 100 mg every 6–8 hours, dose expressed as chlorpromazine base

Intractable hiccup

**By mouth**
- Adult: 25–50 mg 3–4 times a day

Relief of acute symptoms of psychoses (under expert supervision)

**By deep intramuscular injection**
- Adult: 25–50 mg every 6–8 hours

Nausea and vomiting of terminal illness (where other drugs have failed or are not available)

**By mouth**
- Child 1–5 years: 500 micrograms/kg every 4–6 hours; maximum 40 mg per day
- Child 6–11 years: 500 micrograms/kg every 4–6 hours; maximum 75 mg per day
- Child 12–17 years: 25 mg, then 25–50 mg every 3–4 hours until vomiting stops
- Adult: Initially 25 mg, then 25–50 mg every 3–4 hours until vomiting stops

**By rectum**
- Adult: 100 mg every 6–8 hours

Dose adjustments due to interactions

Dose adjustment may be necessary if smoking started or stopped during treatment.

Dose equivalence and conversion

For equivalent therapeutic effect 100 mg chlorpromazine base given rectally as a suppository \(\equiv\) 20–25 mg chlorpromazine hydrochloride by intramuscular injection \(\equiv\) 40–50 mg of chlorpromazine base or hydrochloride given by mouth.

**SIDE-EFFECTS**

- Acute dystonic reactions: Phenothiazines can induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.
- Hepatic impairment: Can precipitate coma; phenothiazines are hepatotoxic.
- Renal impairment: Start with small doses in severe renal impairment because of increased cerebral sensitivity.

**UNLICENSED USE** Rectal route is not licensed.

**CONTRA-INDICATIONS** CNS depression - comatose states - hypothyroidism - phaeochromocytoma

**CAUTIONS** Diabetes

**SIDE-EFFECTS, FURTHER INFORMATION**

**Unexplained anaphylaxis**

**Phenothiazines**

- Photosensitisation may occur with higher dosages, especially during heat, sunlight, and sweating.
- Exiting machinery, especially at start of treatment; effects of alcohol are enhanced.
- Hiccups may affect performance of skilled tasks (e.g. driving or operating machinery), especially at start of treatment; effects of alcohol are enhanced.
- As photosensitisation may occur with higher dosages, patients should avoid direct sunlight.

**HANDLING AND STORAGE**

- Products should be stored in a cool, dry place.
- Chlorpromazine hydrochloride 5 mg per 1 ml Chlorpromazine 5 mg, 10 ml. Chlorpromazine 5 mg, 15 ml. Chlorpromazine 5 mg, 100 ml. Chlorpromazine 100 mg, 31 ml. Chlorpromazine 100 mg, 150 ml. Chlorpromazine 200 mg, 6 ml. Chlorpromazine 25 mg, 300 ml. Chlorpromazine 25 mg, 500 ml. Chlorpromazine 50 mg, 500 ml.

**By mouth**

- Chlorpromazine hydrochloride 25 mg, 50 mg, 100 mg, 200 mg.

**By deep intramuscular injection**

- Child 1–5 years: 500 micrograms/kg every 4–6 hours; maximum 40 mg per day
- Child 6–11 years: 500 micrograms/kg every 4–6 hours; maximum 75 mg per day
- Child 12–17 years: Initially 25 mg, then 25–50 mg every 3–4 hours until vomiting stops
- Adult: Initially 25 mg, then 25–50 mg every 3–4 hours until vomiting stops

**By rectum**

- Adult: 100 mg every 6–8 hours

### **MONITORING REQUIREMENTS**

- It is advisable to monitor prolactin concentration at the start of therapy, at 6 months, and then yearly. Patients taking antipsychotic drugs not normally associated with symptomatic hyperprolactinaemia should be considered for prolactin monitoring if they show symptoms of hyperprolactinaemia (such as breast enlargement and galactorrhoea).
- Patients with schizophrenia should have physical health monitoring (including cardiovascular disease risk assessment) at least once per year.

**PATIENT AND CARER ADVICE**

Drowsiness may affect performance of skilled tasks (e.g. driving or operating machinery), especially at start of treatment; effects of alcohol are enhanced.

There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary. Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.

### **SIDE-EFFECTS, FURTHER INFORMATION**

**Extrapyramidal effects and withdrawal syndrome**

- Agitation, excitement, and violent or dangerously impulsive behaviour
- Psychomotor agitation, excitement, and violent or dangerously impulsive behaviour

**CNS depression**

**Hypothyroidism**

**Phenothiazine**

- Photosensitisation may occur with higher dosages, especially during heat, sunlight, and sweating.
- Exiting machinery, especially at start of treatment; effects of alcohol are enhanced.
- Hiccups may affect performance of skilled tasks (e.g. driving or operating machinery), especially at start of treatment; effects of alcohol are enhanced.
- As photosensitisation may occur with higher dosages, patients should avoid direct sunlight.
Flupentixol
(Flupenthixol)

INDICATIONS AND DOSE
Schizophrenia and other psychoses, particularly with apathy and withdrawal but not mania or psychomotor hyperactivity

BY MOUTH
- Adult: Initially 3–9 mg twice daily, adjusted according to response, for debilitated patients, use elderly dose; maximum 18 mg per day
- Elderly: Initially 0.75–4.5 mg twice daily, adjusted according to response

Depressive Illness

BY MOUTH
- Adult: Initially 1 mg once daily, dose to be taken in the morning, increased if necessary to 2 mg after 1 week, doses above 2 mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 3 mg per day
- Elderly: Initially 500 micrograms daily, dose to be taken in the morning, then increased if necessary to 1 mg after 1 week, doses above 1 mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 1.5 mg per day

CONTRA-INDICATIONS
- Circulatory collapse
- CNS depression
- Comatose states
- Excitable patients
- Overactive patients
- Impaired consciousness
- Overactive patients
- Phaeochromocytoma

CAUTIONS
- Acute porphyrias
- Cardiac disorders
- Cardiovascular disease
- Cerebral arteriosclerosis
- Diabetes
- Elderly
- Parkinsonism
- QT-interval prolongation
- Senile confusional states

INTERACTIONS
- Avoid concomitant administration of drugs that prolong QT interval.

SIDE-EFFECTS
- Asthenia
- Dysphoria
- Hypersalivation
- Myalgia
- Sudden death
- Torsade de pointes

SIDE-EFFECTS, FURTHER INFORMATION
- Less sedating but extrapyramidal symptoms frequent.
- PREGNANCY
- Avoid unless potential benefit outweighs risk.
- BREAST FEEDING
- Present in breast milk—avoid.
- HEPATIC IMPAIRMENT
- Can precipitate coma.
- Consider serum-flupentixol concentration monitoring in hepatic impairment.
- RENAL IMPAIRMENT
- Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity.
- Manufacturer advises caution in renal failure.
- PATIENT AND CARER ADVICE
- Although drowsiness may occur, can also have an alerting effect so should not be taken in the evening.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Largactil (Sanofi)
  Chlorpromazine hydrochloride 25 mg per 1 ml Largactil
  50mg/2ml solution for injection ampoules | 10 ampoules £7.51
- Depixol (Flupentixol decanoate) (Lundbeck Ltd)
  Flupentixol decanoate 100 mg per 1 ml Flupentixol Conc 100mg/1ml solution for injection ampoules | 10 ampoules £62.51
  Flupentixol 100 mg/1ml solution for injection ampoules | 200mg/1ml solution for injection ampoules | 5 ampoules £97.59
- Psytixol (Mylan Ltd)
  Flupentixol decanoate 20 mg per 1 ml Psytixol 20mg/1ml solution for injection ampoules | 10 ampoules £25.38
  Psytixol 20mg/1ml solution for injection ampoules | 5 ampoules £41.60
Fluphenazine decanoate

**INDICATIONS AND DOSE**

**Maintenance in schizophrenia and other psychoses**
- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: Test dose 12.5 mg, dose to be administered into the gluteal muscle, then 12.5–100 mg after 4–7 days, then 12.5–100 mg every 14–35 days, adjusted according to response
  - Elderly: Test dose 6.25 mg, dose to be administered into the gluteal muscle, then 12.5–100 mg after 4–7 days, then 12.5–100 mg every 14–35 days, adjusted according to response

**Dose adjustments due to interactions**
Dose adjustment may be necessary if smoking started or stopped during treatment.

- **CONTRA-INDICATIONS** Children - CNS depression - comatose states - marked cerebral atherosclerosis - phaeochromocytoma
- **CAUTIONS** QT-interval prolongation - when transferring from oral to depot therapy, the dose by mouth should be reduced gradually
- **INTERACTIONS** Avoid concomitant drugs that prolong QT interval.
- **SIDE-EFFECTS** Erythema - inappropriate anti-diuretic hormone secretion - nodules - oedema - pain at injection site - swelling - systemic lupus erythematosus
- **SIDE-EFFECTS, FURTHER INFORMATION** Less sedating and fewer antimuscarinic or hypotensive symptoms, but extrapyramidal symptoms, particularly dystonic reactions and akathisia, more frequent. Extrapyramidal symptoms usually appear a few hours after injection and continue for about 2 days but may be delayed.
  - If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.
- **HEPATIC IMPAIRMENT** Avoid in hepatic failure. Can precipitate coma; phenothiazines are hepatotoxic.
- **RENAL IMPAIRMENT** Manufacturer advises caution. Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity. Avoid in renal failure.
- **MONITORING REQUIREMENTS** Treatment requires careful monitoring for optimum effect.
- **DIRECTIONS FOR ADMINISTRATION** In general not more than 2–3 mL of oily injection should be administered at any one site. Correct injection technique (including use of z-track technique) and rotation of injection sites are essential. When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **EXCIPIENTS**: May contain Sesame oil
    - **Moderate** (Sanofi)
      - Fluphenazine decanoate 25 mg per 1 ml

- **Haloperidol**

**INDICATIONS AND DOSE**

**Schizophrenia | Psychoses | Mania and hypomania | Organic brain damage (depending on symptoms)**

- **BY MOUTH**
  - Adult: Initially 2–20 mg once daily, alternatively initially 2–20 mg daily in divided doses; maintenance 1–3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses, for debilitated patients, use elderly dose; maximum 20 mg per day
  - Elderly: Initially 1–10 mg once daily, alternatively initially 1–10 mg daily in divided doses; maintenance 1–3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses; maximum 20 mg per day

- **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 2–5 mg, repeated if necessary, repeated dose given according to response and tolerability, for debilitated patients, use elderly dose; maximum 12 mg per day
  - Elderly: Initially 1–2.5 mg, repeated if necessary, repeated dose given according to response and tolerability; maximum 12 mg per day

**Agitation and restlessness in the elderly**

- **BY MOUTH**
  - Elderly: Initially 0.75–1.5 mg 2–3 times a day, adjusted according to response

Management of mental or behavioural problems such as aggression, hyperactivity and self-mutilation in the mentally retarded and in patients with organic brain damage (depending on symptoms) | Gilles de la Tourette syndrome | Severe tics | Intractable hiccup | Adjunct to short-term management of moderate to severe psychomotor agitation, excitement and, violent or dangerously impulsive behaviour

- **BY MOUTH**
  - Adult: Initially 1.5–3 mg 2–3 times a day, alternatively initially 3–5 mg 2–3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5–1 mg 3 times a day, increased if necessary to 2–3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose, for debilitated patients, use elderly dose
  - Elderly: Initially 0.75–1.5 mg 2–3 times a day, alternatively initially 1.5–2.5 mg 2–3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5–1 mg 3 times a day, increased if necessary to 2–3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose

**Nausea and vomiting**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 1–2 mg

- **Nausea and vomiting in palliative care**
  - Adult: Initially 1.5 mg 1–2 times a day, increased if necessary to 5–10 mg daily in divided doses
Psychoses and schizophrenia 307

Capsule
CAUTIONARY AND ADVISORY LABELS 2
- Serenace (Teva UK Ltd)
  Haloperidol 500 microgram | 30 capsule (PO) £1.18 DT price = £1.18

Oral solution
CAUTIONARY AND ADVISORY LABELS 2
- HALOPERIDOL (Non-proprietary)
  Haloperidol 1 mg per 1 ml | 500 ml (PO) £3.05
  Haloperidol 5mg/5ml oral solution sugar free (sugar-free) | 100 ml (PO) £6.41
  Haloperidol 10mg/5ml oral solution sugar free (sugar-free) | 100 ml (PO) £6.75

Solution for injection
- HALOPERIDOL (Non-proprietary)
  Haloperidol 5 mg per 1 ml | 10 ampule (PO) £8.65

Haloperidol decanoate
INDICATIONS AND DOSE
Maintenance in schizophrenia and other psychoses
BY DEEP INTRAMUSCULAR INJECTION
- Adult: Initially 50 mg every 4 weeks, increased in steps of 50 mg if required, increased if necessary up to 300 mg every 4 weeks, higher doses may be needed in some patients, dose to be administered into gluteal muscle, if 2-weekly administration preferred, doses should be halved
- Elderly: Initially 12.5–25 mg every 4 weeks, if 2-weekly administration preferred, doses should be halved
Dose adjustments due to interactions
Dose adjustment may be necessary if smoking started or stopped during treatment.

Important safety information
When prescribing, dispensing or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.

- CONTRA-INDICATIONS Bradydysria - children - CNS depression - comatose states - lesions of the basal ganglia - Parkinson’s disease - phaeochromocytoma - QT-interval prolongation
- CAUTIONS Arteriosclerosis - hypokalaemia - hypoglycaemia - hypomagnesaemia - metabolic disturbances - subarachnoid haemorrhage - thyrotoxicosis
- INTERACTIONS Avoid concomitant administration of drugs that prolong QT interval.

SIDE-EFFECTS
- Common or very common Depression - weight loss
- Uncommon Dysphoria - oedema
- Rare Bronchospasm - hypoglycaemia - inappropriate antidiuretic hormone secretion - photosensitivity reactions - pigmentation
- Frequency not known Hypertension - Stevens-Johnson syndrome - sweating - toxic epidermal necrolysis

SIDE-EFFECTS, FURTHER INFORMATION
Less sedating and fewer antimuscarinic or hypotensive symptoms.

PREGNANCY
Avoid unless benefits outweigh risks.

HEPATIC IMPAIRMENT
Can precipitate coma.

RENAI IMPAIRMENT
Start with small doses in severe renal impairment because of increased cerebral sensitivity.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet
CAUTIONARY AND ADVISORY LABELS 2
- HALOPERIDOL (Non-proprietary)
  Haloperidol 500 microgram | 28 tablet (PO) £1.01
  Haloperidol 1.5 mg | 28 tablet (PO) £1.20
  Haloperidol 5 mg | 28 tablet (PO) £1.40
  Haloperidol 10 mg | 28 tablet (PO) £1.80
  Haloperidol 20 mg | 28 tablet (PO) £2.17

Important safety information
When prescribing, dispensing or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.
Pericyazine (Periciazine)

**INDICATIONS AND DOSE**

Schizophrenia | Psychoses
---|---
**BY MOUTH**
- Adult: Initially 75 mg daily in divided doses, then increased in steps of 25 mg every 1 week, adjusted according to response; maximum 300 mg per day
- Elderly: Initially 15–30 mg daily in divided doses, then increased in steps of 25 mg every 1 week, adjusted according to response; maximum 300 mg per day

Short-term adjunctive management of severe anxiety, psychomotor agitation, and violent or dangerously impulsive behaviour

**BY MOUTH**
- Adult: Initially 15–30 mg daily in 2 divided doses, adjusted according to response, larger dose to be taken at bedtime
- Elderly: Initially 5–10 mg daily in 2 divided doses, adjusted according to response, larger dose to be taken at bedtime

**SIDE-EFFECTS**
- Common or very common Hypotension (when treatment initiated)
- Frequency not known Respiratory depression

**HEPATIC IMPAIRMENT** Can precipitate coma; phenothiazines are hepatotoxic.

**RENAI IMPAIRMENT** Avoid in renal impairment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension

**Tablet**

- **Pericyazine** (Non-proprietary)
  - Pericyazine 2.5 mg 84 tablet £16.93
  - Pericyazine 10 mg 100 tablet no price available

Pericyazine 10 mg Pericyazine 10 mg tablets | 84 tablet £43.75 | 100 tablet (POM) no price available

**Oral solution**

- **Pericyazine** (Non-proprietary)
  - Pericyazine 2 mg per 1 ml 100 ml (POM) £46.00–£46.01

Pericyazine 10 mg/5 ml oral solution | 100 ml (POM) £46.01

**CONTRA-INDICATIONS** Agitation in the elderly | CNS depression | Comatose states | Phaeochromocytoma | Restlessness in the elderly

**CAUTIONS**
- With oral use hypothyroidism

**SIDE-EFFECTS**
- Rare Systemic lupus erythematosus
- Frequency not known Dystonic reactions

**SIDE-EFFECTS, FURTHER INFORMATION**

Less sedating.

Acute dystonic reactions Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.

**HEPATIC IMPAIRMENT** Can precipitate coma; phenothiazines are hepatotoxic.

**RENAI IMPAIRMENT** Start with small doses in severe renal impairment because of increased cerebral sensitivity.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension

**Pimozide**

**INDICATIONS AND DOSE**

**Schizophrenia**

**BY MOUTH**
- Adult: Initially 2 mg daily, adjusted according to response, then increased in steps of 2–4 mg at least every 1 week; usual dose 2–20 mg daily
- Elderly: Initially 1 mg daily, adjusted according to response, then increased in steps of 2–4 mg at least every 1 week; usual dose 2–20 mg daily

**Monosymptomatic hypochondriacal psychosis | Paranoid psychosis**

**BY MOUTH**
- Adult: Initially 4 mg daily, adjusted according to response, then increased in steps of 2–4 mg at least every 1 week; maximum 16 mg per day
- Elderly: Initially 2 mg daily, adjusted according to response, increased in steps of 2–4 mg at least every 1 week; maximum 16 mg per day

**MEDICATIONS**

- **Pericyazine** 2.5 mg, 10 mg tablets

**REFERENCE**

- Pericyazine 10 mg/5 ml oral solution | 100 ml (POM) £46.01
Prochlorperazine

INDICATIONS AND DOSE
Schizophrenia and other psychoses | Mania

By mouth
- Adult: 12.5 mg twice daily for 7 days, dose to be adjusted at intervals of 4–7 days according to response; usual dose 75–100 mg daily
- Adult: 12.5–25 mg 2–3 times a day

Short-term adjunctive management of severe anxiety

By mouth
- Adult: 15–20 mg daily in divided doses; maximum 40 mg per day

Nausea and vomiting, acute attack

By mouth
- Adult: Initially 20 mg, then 10 mg after 2 hours
- By deep intramuscular injection
- Adult: 12.5 mg as required, to be followed if necessary after 6 hours by an oral dose

Nausea and vomiting, prevention

By mouth
- Adult: 5–10 mg 2–3 times a day
- By deep intramuscular injection
- Adult: 12.5 mg as required, to be followed if necessary after 6 hours by an oral dose

Prevention and treatment of nausea

By mouth
- Child 1–11 years (body-weight 10 kg and above): 250 micrograms/kg 2–3 times a day
- Child 12-17 years: 5–10 mg up to 3 times a day if required
- By deep intramuscular injection
- Child 2–5 years: 1.25–2.5 mg up to 3 times a day if required
- Child 6–11 years: 5–6.25 mg up to 3 times a day if required
- Child 12–17 years: 12.5 mg up to 3 times a day if required

Labyrinthine disorders

Initially by mouth
- Adult: 5 mg 3 times a day, (by mouth) increased if necessary to 30 mg daily in divided doses, dose to be increased gradually, then reduced to 5–10 mg daily, dose is reduced after several weeks

Nausea and vomiting in previously diagnosed migraine

By mouth using buccal tablet
- Child 12–17 years: 3–6 mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve
- Adult: 3–6 mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve

Dose equivalence and conversion

Doses are expressed as prochlorperazine maleate or mesilate; 1 mg prochlorperazine maleate = 1 mg prochlorperazine mesilate.

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

### Table

<table>
<thead>
<tr>
<th>Medicines and Schizophrenia</th>
<th>309</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prochlorperazine</td>
<td></td>
</tr>
</tbody>
</table>
Solution for injection
» PROCHLORPERAZINE (Non-proprietary)
Prochlorperazine mesilate 12.5 mg per 1 ml Prochlorperazine 12.5mg/1ml solution for injection ampoules | 10 amoupe [P] no price available DT price = £5.23
» Stemetil (Sanofi)
Prochlorperazine mesilate 12.5 mg per 1 ml Stemetil 12.5mg/1ml solution for injection ampoules | 10 amoupe [P] £5.23 DT price = £5.23

Sulpiride
INDICATIONS AND DOSE
Schizophrenia with predominantly negative symptoms
BY MOUTH
» Adult: 200–400 mg twice daily; maximum 800 mg per day
» Elderly: Lower initial dose to be given, increased gradually according to response
Schizophrenia with mainly positive symptoms
BY MOUTH
» Adult: 200–400 mg twice daily; maximum 2.4 g per day
» Elderly: Lower initial dose to be given, increased gradually according to response

• CONTRA-INDICATIONS CNS depression • comatose states • phaeochromocytoma
• CAUTIONS Aggressive patients (even low doses may aggravate symptoms) • agitated patients (even low doses may aggravate symptoms) • excited patients (even low doses may aggravate symptoms)
• SIDE-EFFECTS Hepatitis
• HEPATIC IMPAIRMENT Can precipitate coma.
• RENAL IMPAIRMENT Start with small doses in severe renal impairment because of increased cerebral sensitivity.
• MONITORING REQUIREMENTS Sulpiride does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.
• PRESCRIBING AND DISPENSING INFORMATION Flavours of oral liquid formulations may include lemon and aniseed.

• MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet
CAUTIONARY AND ADVISORY LABELS 2
» Sulpiride (Non-proprietary)
Sulpiride 200 mg Sulpiride 200mg tablets | 30 tablet [P] £20.00 DT price = £4.63
Sulpiride 400 mg Sulpiride 400mg tablets | 30 tablet [P] £40.00 DT price = £18.80
» Dolmatil (Sanofi)
Sulpiride 200 mg Dolmatil 200mg tablets | 100 tablet [P] £6.00
Sulpiride 400 mg Dolmatil 400mg tablets | 100 tablet [P] £19.00

Oral solution
CAUTIONARY AND ADVISORY LABELS 2
» Sulpiride (Non-proprietary)
Sulpiride 40 mg per 1 ml Sulpiride 200mg/5ml oral solution sugar free [sugar-free] | 150 ml [P] no price available DT price = £25.38
Sulpiride (Rosemont Pharmaceuticals Ltd)
Sulpiride 40 mg per 1 ml Sulpor 200mg/5ml oral solution sugar free [sugar-free] | 150 ml [P] £25.38 DT price = £25.38

Trifluoperazine
INDICATIONS AND DOSE
Schizophrenia and other psychoses • Short-term adjunctive management of psychomotor agitation, excitement, and violent or dangerously impulsive behaviour
BY MOUTH
» Adults: Initially 5 mg twice daily for 1 week, then increased in steps of 5 mg daily, dose then to be increased at intervals of 3 days, according to response
» Elderly: Initially up to 2.5 mg twice daily for 1 week, then increased in steps of 5 mg daily, dose then to be increased at intervals of 3 days, according to response
Short-term adjunctive management of severe anxiety
BY MOUTH
» Adults: 2–4 mg daily in divided doses, increased if necessary to 6 mg daily
» Elderly: Up to 2 mg daily in divided doses, increased if necessary to 6 mg daily
Severe nausea and vomiting
BY MOUTH
» Adults: 2–4 mg daily in divided doses; maximum 6 mg per day

• CONTRA-INDICATIONS CNS depression • comatose states • phaeochromocytoma
• SIDE-EFFECTS Anorexia • dystonic reactions • muscle weakness
SIDE-EFFECTS, FURTHER INFORMATION
Extrapyramidal symptoms are more frequent, especially at doses exceeding 6 mg daily. Phenothiazines can also induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.
• HEPATIC IMPAIRMENT Can precipitate coma; phenothiazines are hepatotoxic.
• RENAL IMPAIRMENT Start with small doses in severe renal impairment because of increased cerebral sensitivity.
• MONITORING REQUIREMENTS Trifluoperazine does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.

• MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 2
» TRIFLUOPERAZINE (Non-proprietary)
Trifluoperazine (as Trifluoperazine hydrochloride) 1 mg Trifluoperazine 1mg tablets | 112 tablet [P] £54.00 DT price = £54.00
Trifluoperazine (as Trifluoperazine hydrochloride) 5 mg Trifluoperazine 5mg tablets | 112 tablet [P] £112.20 DT price = £77.00

Oral solution
CAUTIONARY AND ADVISORY LABELS 2
» TRIFLUOPERAZINE (Non-proprietary)
Trifluoperazine (as Trifluoperazine hydrochloride) 200 microgram per 1 ml Trifluoperazine 1mg/5ml oral solution sugar free [sugar-free] | 200 ml [P] £65.73 DT price = £65.73
Trifluoperazine (as Trifluoperazine hydrochloride) 1 mg per 1 ml Trifluoperazine 5mg/5ml oral solution sugar free [sugar-free] | 150 ml [P] £25.50 DT price = £25.50
**Zuclopenthixol**

**INDICATIONS AND DOSE**

**Schizophrenia and other psychoses**

**BY MOUTH**

- Adult: Initially 20–30 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20–50 mg daily (max. per dose 40 mg), for debilitated patients, use elderly dose.
- Elderly: Initially 5–15 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20–50 mg daily (max. per dose 40 mg).

- **CONTRA-INDICATIONS**
  - Apathetic states - CNS depression - comatose states - phaeochromocytoma - withdrawn states
- **CAUTIONS**
  - Avoid in Acute porphyrias p. 864
- **SIDE-EFFECTS**
  - Urinary frequency - urinary incontinence - weight loss (less common than weight gain)
- **HEPATIC IMPAIRMENT**
- **RENAI IMPAIRMENT**
  - Halve dose in renal failure; smaller starting doses used in severe renal impairment because of increased cerebral sensitivity.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- CAUTIONARY AND ADVISORY LABELS 2.
  - **Clopixol** (Zuclopenthixol) (Lundbeck Ltd)
  - Zuclopenthixol (as Zuclopenthixol dihydrochloride) 2 mg Clopixol 2mg tablets | 100 tablet £3.14 DT price = £3.14
  - Zuclopenthixol (as Zuclopenthixol dihydrochloride) 10 mg Clopixol 10mg tablets | 100 tablet £8.06 DT price = £8.06
  - Zuclopenthixol (as Zuclopenthixol dihydrochloride) 25 mg Clopixol 25mg tablets | 100 tablet £16.13 DT price = £16.13

**Zuclopenthixol acetate**

**INDICATIONS AND DOSE**

**Short-term management of acute psychosis | Short-term management of exacerbation of chronic psychosis**

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult: 50–150 mg, then 50–150 mg after 2–3 days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1–2 days after the first injection, maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2–3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.
- Elderly: 50–100 mg, then 50–100 mg after 2–3 days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1–2 days after the first injection, maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2–3 days after last injection, or to a longer acting antipsychotic depot injection given.

**Important safety information**

When prescribing, dispensing, or administering, check that this is the correct preparation—this preparation is usually used in hospital for an acute episode and should not be confused with depot preparations which are usually used in the community or clinics for maintenance treatment.

- **CONTRA-INDICATIONS**
  - CNS depression - comatose states - phaeochromocytoma
- **CAUTIONS**
  - Avoid in Acute porphyrias p. 864
- **HEPATIC IMPAIRMENT**
  - Can precipitate coma.
- **RENAI IMPAIRMENT**
  - Start with small doses in severe renal impairment because of increased cerebral sensitivity.

**Zuclopenthixol decanoate**

**INDICATIONS AND DOSE**

**Maintenance in schizophrenia and paranoid psychoses**

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult: Test dose 100 mg, dose to be administered into the upper outer buttck or lateral thigh, followed by 200–500 mg after at least 7 days, then 200–500 mg every 1–4 weeks, adjusted according to response, higher doses of more than 500mg can be used; do not exceed 600 mg weekly.
- Elderly: A quarter to half usual starting dose to be used when transferring from oral to depot therapy, the dose by mouth should be reduced gradually.

**Important safety information**

When prescribing, dispensing, or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the short-term management of an acute episode.

- **CONTRA-INDICATIONS**
  - Children - CNS depression - comatose states - phaeochromocytoma
- **CAUTIONS**
  - Avoid in Acute porphyrias p. 864 • QT interval prolongation • when transferring from oral to depot therapy, the dose by mouth should be reduced gradually
- **INTERACTIONS**
  - Avoid concomitant use of drugs that prolong QT interval.
- **SIDE-EFFECTS**
  - Erythema - nodules - pain at injection site - swelling

**SIDE-EFFECTS, FURTHER INFORMATION**

If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

- **HEPATIC IMPAIRMENT**
  - Can precipitate coma.
- **RENAI IMPAIRMENT**
  - Start with small doses in severe renal impairment because of increased cerebral sensitivity.

**MONITORING REQUIREMENTS**

Treatment requires careful monitoring for optimum effect.

- **DIRECTIONS FOR ADMINISTRATION**
  - In general not more than 2–3 mL of oily injection should be administered at
any one site. Correct injection technique (including use of z-track technique) and rotation of injection sites are essential. When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Clopixol** (Zuclopenthixol decanoate) (Lundbeck Ltd)
  - Zuclopenthixol decanoate 200 mg per 1 ml (Clopixol 200mg/1mL solution for injection ampoules) | 10 ampoule [POS] £31.51 DT price = £31.18
  - Zuclopenthixol decanoate 500 mg per 1 ml (Clopixol Conc 500mg/1mL solution for injection ampoules) | 5 ampoule [POS] £37.18 DT price = £37.18

**ANTIPSYCHOTICS (SECOND-GENERATION)**

**Amisulpride**

**DRUG ACTION**
Amisulpride is a selective dopamine receptor antagonist with high affinity for mesolimbic D₂ and D₃ receptors.

**INDICATIONS AND DOSE**

- **Acute psychotic episode in schizophrenia**
  - **BY MOUTH**
    - Adult: 400–800 mg daily in 2 divided doses, adjusted according to response; maximum 1.2 g per day
  - **Schizophrenia with predominantly negative symptoms**
    - Adult: 50–300 mg daily

**CONTRA-INDICATIONS**
CNS depression • comatose states • phaeochromocytoma • pre-pubertal children • prolactin-dependent tumours

**SIDE-EFFECTS**
- Common or very common Anxiety
- Uncommon Bradycardia
- **PREGNANCY** Avoid.
- **BREAST FEEDING** Avoid—no information available.
- **RENAL IMPAIRMENT** Halve dose if eGFR 30–60 mL/minute/1.73 m². Use one-third dose if eGFR 10–30 mL/minute/1.73 m². No information available if eGFR less than 10 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Amisulpride does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.

**PRESCRIBING AND DISPENSING INFORMATION**
Flavours of oral liquid formulations may include caramel.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMISULPRIDE</strong> (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Amisulpride 50 mg</td>
<td>Amisulpride 50mg tablets</td>
</tr>
<tr>
<td>Amisulpride 100 mg</td>
<td>Amisulpride 100mg tablets</td>
</tr>
<tr>
<td>Amisulpride 200 mg</td>
<td>Amisulpride 200mg tablets</td>
</tr>
<tr>
<td>Amisulpride 400 mg</td>
<td>Amisulpride 400mg tablets</td>
</tr>
<tr>
<td><strong>Solian</strong> (Sanofi)</td>
<td>Amisulpride 50 mg</td>
</tr>
</tbody>
</table>

**SIDE-EFFECTS**
- Common or very common Anxiety
- Uncommon Bradycardia
- **PREGNANCY** Avoid.
- **BREAST FEEDING** Avoid—no information available.
- **RENAL IMPAIRMENT** Halve dose if eGFR 30–60 mL/minute/1.73 m². Use one-third dose if eGFR 10–30 mL/minute/1.73 m². No information available if eGFR less than 10 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Amisulpride does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.
- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include caramel.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMISULPRIDE</strong> (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Amisulpride 50 mg</td>
<td>Amisulpride 50mg tablets</td>
</tr>
<tr>
<td>Amisulpride 100 mg</td>
<td>Amisulpride 100mg tablets</td>
</tr>
<tr>
<td>Amisulpride 200 mg</td>
<td>Amisulpride 200mg tablets</td>
</tr>
<tr>
<td>Amisulpride 400 mg</td>
<td>Amisulpride 400mg tablets</td>
</tr>
<tr>
<td><strong>Solian</strong> (Sanofi)</td>
<td>Amisulpride 50 mg</td>
</tr>
</tbody>
</table>

**SIDE-EFFECTS**
- Common or very common Anxiety
- Uncommon Bradycardia
- **PREGNANCY** Avoid.
- **BREAST FEEDING** Avoid—no information available.
- **RENAL IMPAIRMENT** Halve dose if eGFR 30–60 mL/minute/1.73 m². Use one-third dose if eGFR 10–30 mL/minute/1.73 m². No information available if eGFR less than 10 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Amisulpride does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.
- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include caramel.
## Psychoses and schizophrenia 313

### Aripiprazole 10 mg

- **Oral solution**
  - Aripiprazole 10 mg orodispersible tablets
  - Aripiprazole 15 mg orodispersible tablets

- **Powder and solvent for suspension for injection**
  - Aripiprazole 400 mg

### Clozapine

- **DRUG ACTION**
  - Clozapine is a dopamine D₂, dopamine D₃, 5-HT₄, α₁, adrenergic, and muscarinic-receptor antagonist.

### INDICTIONS AND DOSE

#### Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs

- **By mouth**
  - Adult 18–59 years: 12.5 mg 1–2 times a day for day 1, then 25–50 mg for day 2, then increased, if tolerated, in steps of 25–50 mg daily, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50–100 mg 1–2 times a week if required, it is preferable to increase once a week; usual dose 200–450 mg daily, restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)—extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900 mg per day
  - Adult 60 years and over: 12.5 mg once daily for day 1, then increased to 25–37.5 mg for day 2, then increased, if tolerated, in steps of up to 25 mg daily, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50–100 mg 1–2 times a week if required, it is preferable to increase once a week; usual dose 200–450 mg daily, restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)—extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900 mg per day

### Specific Contra-Indications:
- With intramuscular use do not use in children

### Cautions

#### General Cautions:
- Cerebrovascular disease - elderly (reduce initial dose)

#### Specific Cautions:
- With intramuscular use when transferring from oral to depot therapy, the dose by mouth should be reduced gradually

### Side-effects

#### General Side-effects
- Common or very common: Anxiety, hypersalivation, malaise
- Uncommon: Depression, dry mouth
- Frequency not known: Alopecia, anorexia, bradycardia, hepatitis, hyponatraemia, infection, laryngospasm, myalgia, oedema, oropharyngeal spasms, pancreatitis, pathological gambling, respiratory disorders, rhabdomyolysis, suicidal ideation, sweating, urinary disorders

### Specific Side-effects
- With intramuscular use: erythema, nodules, pain at injection site - swelling

### Cautions, Further Information
- With intramuscular use: If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose of the depot injection, it may be a month or longer before side-effects subside.

### Pregnancy
- Use only if potential benefit outweighs risk.

### Breast Feeding
- Manufacturer advises avoid—present in milk.

### Hepatic Impairment
- Use with caution in severe impairment (oral treatment preferred to intramuscular administration).

### Monitoring Requirements
- Aripiprazole does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.
- With intramuscular use: Treatment requires careful monitoring for optimum effect.

### Directions for Administration
- With oral use: Orodispersible tablets should be placed on the tongue and allowed to dissolve, or be dispersed in water and swallowed.
- With intramuscular use: Correct injection technique (including the use of z-track technique) and rotation of injection sites are essential.

### Patient and Carer Advice
- With oral use: Patients or carers should be given advice on how to administer aripiprazole orodispersible tablets.

### Medicinal Forms
- There can be variation in the licensing of different medicines containing the same drug.

#### Tablet

- **Aripiprazole 5 mg**
  - Aripiprazole 5 mg tablets | 28 tablet | £69.04
  - Aripiprazole 10 mg tablets | 28 tablet | £69.04

- **Aripiprazole 15 mg**
  - Aripiprazole 15 mg tablets | 28 tablet | £69.04

- **Aripiprazole 30 mg**
  - Aripiprazole 30 mg tablets | 28 tablet | £77.85

- **Aripiprazole 5 mg**
  - Aripiprazole 5 mg tablets | 28 tablet | £69.04

- **Aripiprazole 10 mg**
  - Aripiprazole 10 mg tablets | 28 tablet | £69.04

- **Aripiprazole 15 mg**
  - Aripiprazole 15 mg tablets | 28 tablet | £69.04

### Clozapine

- **Indications and Dose**
  - Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs
Psychosis in Parkinson's disease

BY MOUTH

- Adult: 12.5 mg once daily, dose to be taken at bedtime, then increased in steps of 12.5 mg up to twice weekly, adjusted according to response; usual dose 25–37.5 mg once daily, dose to be taken at bedtime; increased in steps of 12.5 mg once weekly, this applies only in exceptional cases, increased if necessary up to 100 mg daily in 1–2 divided doses; Usual maximum 50 mg/24 hours

Dose adjustments due to interactions

Dose adjustment may be necessary if smoking started or stopped during treatment.

- CONTRA-INDICATIONS Alcoholic and toxic psychoses - bone-marrow disorders - coma - drug intoxication - history of agranulocytosis - history of circulatory collapse - history of neutropenia - paralytic ileus - severe cardiac disorders (e.g. myocarditis) - severe CNS depression - uncontrolled epilepsy

- CAUTIONS Age over 60 years - prostatic hypertrophy - susceptibility to angle-closure glaucoma - taper off other antipsychotics before starting

CAUTIONS, FURTHER INFORMATION

Agranulocytosis Neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting; monitor counts every week for 18 weeks then at least every 2 weeks and if clozapine continued and blood count stable after 1 year at least every 4 weeks (and 4 weeks after discontinuation); if leucocyte count below 3000/mm³ or if absolute neutrophil count below 1500/mm³ discontinue permanently and refer to haematologist. Patients who have a low white blood cell count because of benign ethnic neutropenia may be started on clozapine with the agreement of a haematologist. Avoid drugs which depress leucopoiesis; patients should report immediately symptoms of infection, especially influenza-like illness.

Myocarditis and cardiomyopathy Fatal myocarditis (most commonly in first 2 months) and cardiomyopathy reported.

- Perform physical examination and take full medical history before starting
- Specialist examination required if cardiac abnormalities or history of heart disease found—clozapine initiated only in absence of severe heart disease and if benefit outweighs risk
- Persistent tachycardia especially in first 2 months should prompt observation for other indicators for myocarditis or cardiomyopathy
- If myocarditis or cardiomyopathy suspected clozapine should be stopped and patient evaluated urgently by cardiologist
- Discontinue permanently in clozapine-induced myocarditis or cardiomyopathy

Intestinal obstruction Impairment of intestinal peristalsis, including constipation, intestinal obstruction, faecal impaction, and paralytic ileus, (including fatal cases) reported. Clozapine should be used with caution in patients receiving drugs that may cause constipation (e.g. antimuscarinic drugs) or in those with a history of colonic disease or lower abdominal surgery. It is essential that constipation is recognised and actively treated.

- INTERACTIONS Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis.

- SIDE-EFFECTS

  Common or very common Anorexia - constipation - hypersalivation - malaise - speech disorders - urinary incontinence

  Uncommon Agranulocytosis

Rare Circulatory collapse - dysphagia - hepatitis - myocarditis - pancreatitis - pericarditis - pneumonia - pulmonary aspiration

Very rare Cardiomyopathy - hypercholesterolaemia - hypertriglyceridaemia - interstitial nephritis - intestinal obstruction (including fatal cases) - myocardial infarction - obsessive compulsive disorder - parotid gland enlargement - respiratory depression

Frequency not known Hepatic disorders - hepatic failure - muscle disorders - renal failure

SIDE-EFFECTS, FURTHER INFORMATION

Hypersalivation Hypersalivation associated with clozapine therapy can be treated with hyoscine hydrobromide (unlicensed indication), provided that the patient is not at particular risk from the additive antimuscarinic side-effects of hyoscine and clozapine.

- PREGNANCY Use with caution.

- BREAST FEEDING Avoid.


- RENAL IMPAIRMENT Avoid in severe impairment.

- MONITORING REQUIREMENTS

  - Monitor leucocyte and differential blood counts. Clozapine requires differential white blood cell monitoring weekly for 18 weeks, then fortnightly for up to one year, and then monthly as part of the clozapine patient monitoring service.
  - Close medical supervision during initiation (risk of collapse because of hypotension and convulsions).
  - Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotics. Patients taking clozapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.
  - Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly. Patients taking clozapine should have fasting blood glucose tested at baseline, after one months' treatment, then every 4–6 months.
  - Patient, prescriber, and supplying pharmacist must be registered with the appropriate Patient Monitoring Service—it takes several days to do this.

TREATMENT CESSATION On planned withdrawal reduce dose over 1–2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.

DIRECTIONS FOR ADMINISTRATION Shake oral suspension well for 90 seconds when dispensing or if visibly settled and stand for 24 hours before use; otherwise shake well for 10 seconds before use. May be diluted with water.

- PATIENT AND CARER ADVICE Patients or carers should be given advice on how to administer clozapine oral suspension.

- MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet

CAUTIONARY AND ADVISORY LABELS 3, 10

- Clozaril (Novartis Pharmaceuticals UK Ltd)
  - Clozapine 25 mg Clozaril 25mg tablets | 28 tablet (£58.82) £3.02
  - 84 tablet (£160.78) £9.06 (Hospital only)
  - 100 tablet (£10.78) £6.06 (Hospital only)

- Clozapine 100 mg Clozaril 100mg tablets | 28 tablet (£12.07) £7.22
  - 84 tablet (£36.22) £21.12 (Hospital only)
  - 100 tablet (£43.12) £25.67 (Hospital only)

- Denzapine (Britannia Pharmaceuticals Ltd)
  - Clozapine 25 mg Denzapine 25mg tablets | 84 tablet (£1.98) £16.64
  - 100 tablet (£19.80) £11.90

- Clozapine 100 mg Denzapine 100mg tablets | 84 tablet (£7.20) £66.53
  - 100 tablet (£7.92) £43.25
Lurasidone hydrochloride

- **DRUG ACTION** Lurasidone is a dopamine D₂, 5-HT₃, 5-HT₄, alpha₁A- and alpha₁C- adrenoceptor antagonist, and is a partial agonist at 5-HT₁A receptors.

**INDICATIONS AND DOSE**

**Schizophrenia**

- **BY MOUTH**
  - Adult: Initially 37 mg once daily, increased if necessary up to 148 mg once daily
  - Schizophrenia when given with concomitant moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole, and verapamil)

- **BY MOUTH**
  - Adult: Initially 18.5 mg once daily (max. per dose 74 mg once daily)

- **CAUTIONS** High doses in elderly. Susceptibility to QT-interval prolongation

- **INTERACTIONS** Contra-indicated with concomitant use of potent CYP3A4 inhibitors. Contra-indicated with concomitant use of potent CYP3A4 inducers. Caution with concomitant use of drugs that prolong the QT interval.

- **SIDE-EFFECTS**
  - Common or very common: Anxiety - musculoskeletal stiffness
  - Uncommon: Catatonia - decreased appetite - dysarthria - dysuria - hot flush - myalgia - nightmares
  - Frequency not known: Angina - AV block - bradycardia - dysphagia - panic attacks - pruritus - suicidal behaviour - vertigo
  - Pregnancy: Use only if potential benefit outweighs risk—limited information available.

- **HEPATIC IMPAIRMENT** Initially 18.5 mg once daily, up to max. 74 mg once daily in moderate impairment. Use with caution in severe impairment—initially 18.5 mg once daily, up to max. 37 mg once daily.

- **RENAL IMPAIRMENT** Initially 18.5 mg once daily, up to max. 74 mg once daily if eGFR less than 50 mL/minute/1.73 m². Manufacturer advises use only if potential benefit outweighs risk if eGFR less than 15 mL/minute/1.73 m².

- **DIRECTIONS FOR ADMINISTRATION** Patients on doses higher than 111 mg once daily whose treatment is interrupted for longer than 3 days should restart on 111 mg once daily and titrate to usual dose; for all other doses, restart on usual dose.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
  - Cautionary and advisory labels 2, 21, 25
  - Lurasidone (as Lurasidone hydrochloride) 18.3 mg | Latuda 18.3 mg tablets | 28 tablet (PO) £90.72
  - Lurasidone (as Lurasidone hydrochloride) 37 mg | Latuda 37 mg tablets | 28 tablet (PO) £90.72

**Contra-indications**

- With intramuscular use: acute myocardial infarction - bradycardia - recent heart surgery - severe hypotension - sick sinus syndrome - unstable angina

- **Caution** Bone-marrow depression - diabetes mellitus (risk of exacerbation or ketoadiabetic) - hypereosinophilic disorders - low leucocyte count - low neutrophil count - myeloproliferative disease - paralytic ileus

**Cautions, Further Information**

- CNS and respiratory depression: Blood pressure, pulse and respiratory rate should be monitored for at least 4 hours after intramuscular injection, particularly in those also
receiving a benzodiazepine or another antipsychotic (leave at least one hour between administration of olanzapine intramuscular injection and parenteral benzodiazepines).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Common or very common Arthralgia - hypercholesterolaemia - hypertriglyceridaemia - increased appetite - malaise - oedema
- Uncommon Alopecia - amnesia - bradycardia - epistaxis
- Rare Hepatitis - pancreatitis - rhabdomyolysis

**SPECIFIC SIDE-EFFECTS**

- With intramuscular use hyperventilation - sinus pause
- **PREGNANCY** Use only if potential benefit outweighs risk.
- **BREAST FEEDING** Avoid—present in milk.
- **HEPATIC IMPAIRMENT** Consider initial dose of 5 mg daily.
- **RENAL IMPAIRMENT** Consider initial dose of 5 mg daily.

**MONITORING REQUIREMENTS**

- Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs. Patients taking olanzapine require more frequent monitoring of these parameters: every 3 months from the first year, then yearly.
- Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly. Patients taking olanzapine should have fasting blood glucose tested at baseline, after one months’ treatment, then every 4–6 months.

**DIRECTIONS FOR ADMINISTRATION** Olanzapine orodispersible tablet may be placed on the tongue and allowed to dissolve, or dispersed in water, orange juice, apple juice, milk, or coffee.

**PRESCRIBING AND DISPENSING INFORMATION**

- With intramuscular use When prescribing, dispensing, or administering, check that this injection is the correct preparation—for this preparation is usually used in hospital for the rapid control of an acute episode and should not be confused with depot preparations which are usually used in the community or clinics for maintenance treatment.
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer orodispersible tablets.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

**Tablet**

<table>
<thead>
<tr>
<th>Product</th>
<th>Pack Size</th>
<th>Dosage</th>
<th>Price (per tablet)</th>
<th>Tariff Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine 5 mg</td>
<td>10 x 20</td>
<td>4 mg</td>
<td>£0.65</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 5 mg</td>
<td>10 x 20</td>
<td>5 mg</td>
<td>£0.75</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 10 mg</td>
<td>10 x 20</td>
<td>10 mg</td>
<td>£1.45</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 15 mg</td>
<td>10 x 20</td>
<td>15 mg</td>
<td>£2.15</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 20 mg</td>
<td>10 x 20</td>
<td>20 mg</td>
<td>£2.55</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 25 mg</td>
<td>10 x 20</td>
<td>25 mg</td>
<td>£3.15</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 30 mg</td>
<td>10 x 20</td>
<td>30 mg</td>
<td>£3.75</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 50 mg</td>
<td>10 x 20</td>
<td>50 mg</td>
<td>£6.50</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 75 mg</td>
<td>10 x 20</td>
<td>75 mg</td>
<td>£8.50</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>Olanzapine 100 mg</td>
<td>10 x 20</td>
<td>100 mg</td>
<td>£11.50</td>
<td>Tariff 2</td>
</tr>
</tbody>
</table>

**INDICATIONS AND DOSE**

Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 10 mg oral olanzapine daily)

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult 18-75 years: Initially 210 mg every 2 weeks, alternatively initially 405 mg every 4 weeks, then maintenance 150 mg every 2 weeks, alternatively maintenance 300 mg every 4 weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required

Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 15 mg oral olanzapine daily)

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult 18-75 years: Initially 300 mg every 2 weeks, then maintenance 210 mg every 2 weeks, alternatively maintenance 405 mg every 4 weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required

Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 20 mg oral olanzapine daily)

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult: Initially 300 mg every 2 weeks, then maintenance 300 mg every 2 weeks (max. per dose 300 mg every 2 weeks), adjusted according to response, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required

**Brands may include Zalasta;**

**Oloridispersible tablet**

<table>
<thead>
<tr>
<th>Price (per tablet)</th>
<th>Tariff Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>£0.65</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£0.75</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£1.45</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£2.15</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£2.55</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£3.15</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£3.75</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£6.50</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£8.50</td>
<td>Tariff 2</td>
</tr>
<tr>
<td>£11.50</td>
<td>Tariff 2</td>
</tr>
</tbody>
</table>

**Olanzapine embonate**

*(Olanzapine pamoate)*
**Dose adjustments due to interactions**
Dose adjustment may be necessary if smoking started or stopped during treatment.

**Important safety information**
When prescribing, dispensing or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.

- **CONTRA-INDICATIONS** Children
- **CAUTIONS** Bone-marrow depression • diabetes mellitus (risk of exacerbation or ketoacidosis) • hypereosinophilic disorders • low leucocyte count • low neutrophil count • myeloproliferative disease • paralytic ileus • when transferring from oral to depot therapy, the dose by mouth should be reduced gradually
- **SIDE-EFFECTS**
  - Common or very common Arthralgia • hypercholesterolaemia • hypertriglyceridaemia • increased appetite • malaise • oedema
  - Rare Alopecia • anemia • bradycardia • epistaxis
  - Frequency not known Erythema • nodules • pain at injection site • swelling

**SIDE-EFFECTS, FURTHER INFORMATION**
If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

**PREGNANCY** Post-injection reactions have been reported leading to signs and symptoms of overdose.

**BREAST FEEDING** Avoid—present in milk.

**HEPATIC IMPAIRMENT** Initially 150 mg every 4 weeks; increase with caution in moderate impairment.

**RENAI IMPAIRMENT** Initially 150 mg every 4 weeks.

**MONITORING REQUIREMENTS**
- Observe patient for at least 3 hours after injection.
- Treatment requires careful monitoring for optimum effect.
- Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs. Patients taking olanzapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.
- Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly. Patients taking olanzapine should have fasting blood glucose tested at baseline, after one months’ treatment, then every 4–6 months.

**DIRECTIONS FOR ADMINISTRATION** Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for suspension for injection**
- Zypadhera (Eli Lilly and Company Ltd)
  - Olanzapine (as Olanzapine embonate monohydrate) 210 mg Zypadhera 210mg powder and solvent for suspension for injection vials 1 vial (Pos) £14.76 (Hospital only)
  - Olanzapine (as Olanzapine embonate monohydrate) 300 mg Zypadhera 300mg powder and solvent for suspension for injection vials 1 vial (Pos) £22.64 (Hospital only)
  - Olanzapine (as Olanzapine embonate monohydrate) 405 mg Zypadhera 405mg powder and solvent for suspension for injection vials 1 vial (Pos) £28.52 (Hospital only)

**Paliperidone**

- **DRUG ACTION** Paliperidone is a metabolite of risperidone.

**INDICATIONS AND DOSE**
Maintenance in schizophrenia in patients previously responsive to paliperidone or risperidone

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 150 mg for 1 dose on day 1, then 100 mg for 1 dose on day 8, to be injected into the deltoid muscle, dose subsequently adjusted at monthly intervals according to response; maintenance 75 mg once a month, alternatively maintenance 25–150 mg once a month, following the second dose, monthly maintenance doses can be administered into either the deltoid or gluteal muscle, for missed doses see product literature

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Rotating injection sites are essential.
  - Inappropriate antidiuretic hormone secretion
  - When transferring from oral to depot therapy, the dose by mouth should be reduced gradually

- **CONTRA-INDICATIONS**
  - With intramuscular use children

- **CAUTIONS**
  - GENERAL CAUTIONS
    - Cataract surgery (risk of intraoperative floppy iris syndrome) • elderly patients with dementia • elderly patients with risk factors for stroke • predisposition to gastro-intestinal obstruction • prolactin-dependent tumours

  - SPECIFIC CAUTIONS
    - With intramuscular use when transferring from oral to depot therapy, the dose by mouth should be reduced gradually

- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - Common or very common Anxiety • appetite changes • arthralgia • depression • epistaxis • hypertension • infection • malaise • myalgia • oedema • respiratory disorders • sleep disorders • toothache • urinary disorders
    - Rare Inappropriate antidiuretic hormone secretion • intestinal obstruction • intra-operative floppy iris syndrome • pancreatitis • pulmonary embolism • rhabdomyolysis

  - **SPECIFIC SIDE-EFFECTS**
    - With intramuscular use erythema • nodules • pain at injection site • swelling

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - With intramuscular use if the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

- **PREGNANCY** Use only if potential benefit outweighs risk—toxicity in animal studies; if discontinuation during pregnancy is necessary, withdraw gradually.

- **BREAST FEEDING** Avoid—present in milk.

- **HEPATIC IMPAIRMENT** Caution in severe impairment—no information available.

- **RENAI IMPAIRMENT**
  - With oral use Initially 3 mg once daily if eGFR 50–80 mL/minute/1.73 m² (max. 6 mg once daily).
Nervous system

Quetiapine

▶ With intramuscular use

MONITORING REQUIREMENTS

▶ With intramuscular use

Elderly:

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Schizophrenia

Quetiapine is a dopamine D₂, dopamine D₃, 5-HT₂, alpha₁-adrenoceptor, and histamine-1 receptor antagonist.

INDICATIONS AND DOSE

Schizophrenia

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: 25 mg twice daily for day 1, then 50 mg twice daily for day 2, then 100 mg twice daily for day 3, then 150 mg twice daily for day 4, then, adjusted according to response, usual dose 300–450 mg daily in 2 divided doses, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 750 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 300 mg once daily for day 1, then 600 mg once daily for day 2, then, adjusted according to response, usual dose 600 mg once daily, maximum dose under specialist supervision; maximum 800 mg per day

Elderly: Initially 50 mg once daily, adjusted according to response. Adjusted in steps of 50 mg daily

Treatment of mania in bipolar disorder

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: 50 mg twice daily for day 1, then 100 mg twice daily for day 2, then, adjusted according to response, usual dose 200–240 mg daily in 2 divided doses, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 800 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 300 mg once daily for day 1, then 600 mg once daily for day 2, then, adjusted according to response, usual dose 400–800 mg once daily

Treatment of depression in bipolar disorder

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: 50 mg once daily for day 1, dose to be taken at bedtime, then 100 mg once daily for day 2, then 200 mg once daily for day 3, then 300 mg once daily for day 4, then, adjusted according to response; usual dose 300 mg once daily, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 600 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 50 mg once daily for day 1, dose to be taken at bedtime, then 100 mg once daily for day 2, then 200 mg once daily for day 3, then 300 mg once daily for day 4, then, adjusted according to response; usual dose 300 mg once daily; maximum 600 mg per day

Prevention of mania and depression in bipolar disorder

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300–800 mg daily in 2 divided doses

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300–800 mg once daily

Adjunctive treatment of major depression

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 50 mg once daily for 2 days, dose to be taken at bedtime, then 150 mg once daily for 2 days, then, adjusted according to response, usual dose 150–300 mg once daily

Elderly: Initially 50 mg once daily for 3 days, then increased if necessary to 100 mg once daily for 4 days, then adjusted in steps of 50 mg, adjusted according to response, usual dose 50–300 mg once daily, dose of 300 mg should not be reached before day 22 of treatment

Dose equivalence and conversion

Patients can be switched from immediate-release to modified-release tablets at the equivalent daily dose; to maintain clinical response, dose titration may be required.

• CAUTIONS

Cerebrovascular disease • elderly • patients at risk of aspiration pneumonia • treatment of depression in patients under 25 years (increased risk of suicide)

SIDE-EFFECTS

• Common or very common

Asthenia • dysarthria • dysphagia • elevated plasma-cholesterol concentrations • elevated plasma-triglyceride concentrations • increased appetite • irritability • peripheral oedema • sleep disorders

• Uncommon

Hyponatraemia • hypothyroidism • restless legs syndrome • rhinitis

• Rare

Hepatitis • pancreatitis

MEDICATION FORMS

There can be variation in the licensing of different medicines containing the same drug.

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 2, 25

• Invega (Janssen-Cilag Ltd)

Paliperidone 3 mg

28 tablet (P50) £97.28

Paliperidone 6 mg

28 tablet (P50) £97.28

Paliperidone 9 mg

28 tablet (P50) £145.92

Suspension for injection

• Xeplion (Janssen-Cilag Ltd)

Paliperidone palmitate 100 mg per 1 ml

Xeplion 150mg/1.5ml suspension for injection pre-filled syringes | 1 pre-filled disposable injection (P50) £392.59

Xeplion 75mg/0.75ml suspension for injection pre-filled syringes | 1 pre-filled disposable injection (P50) £244.90

Xeplion 100mg/1ml suspension for injection pre-filled syringes | 1 pre-filled disposable injection (P50) £314.07

Xeplion 50mg/0.5ml suspension for injection pre-filled syringes | 1 pre-filled disposable injection (P50) £183.92

Quetiapine

• DRUG ACTION

Quetiapine is a dopamine D₂, dopamine D₃, 5-HT₂, alpha₁-adrenoceptor, and histamine-1 receptor antagonist.

Treatment of mania in bipolar disorder

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: 50 mg twice daily for day 1, then 100 mg twice daily for day 2, then 150 mg twice daily for day 3, then 200 mg twice daily for day 4, then, adjusted in steps of up to 200 mg daily, adjusted according to response, usual dose 400–800 mg daily in 2 divided doses, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 800 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 300 mg once daily for day 1, then 600 mg once daily for day 2, then, adjusted according to response, usual dose 400–800 mg once daily

Treatment of depression in bipolar disorder

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: 50 mg once daily for day 1, dose to be taken at bedtime, then 100 mg once daily for day 2, then 200 mg once daily for day 3, then 300 mg once daily for day 4, then, adjusted according to response; usual dose 300 mg once daily, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 600 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 50 mg once daily for day 1, dose to be taken at bedtime, then 100 mg once daily for day 2, then 200 mg once daily for day 3, then 300 mg once daily for day 4, then, adjusted according to response; usual dose 300 mg once daily; maximum 600 mg per day

Prevention of mania and depression in bipolar disorder

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300–800 mg daily in 2 divided doses

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300–800 mg once daily

Adjunctive treatment of major depression

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 50 mg once daily for 2 days, dose to be taken at bedtime, then 150 mg once daily for 2 days, then, adjusted according to response, usual dose 150–300 mg once daily

Elderly: Initially 50 mg once daily for 3 days, then increased if necessary to 100 mg once daily for 4 days, then adjusted in steps of 50 mg, adjusted according to response, usual dose 50–300 mg once daily, dose of 300 mg should not be reached before day 22 of treatment

Dose equivalence and conversion

Patients can be switched from immediate-release to modified-release tablets at the equivalent daily dose; to maintain clinical response, dose titration may be required.

• CAUTIONS

Cerebrovascular disease • elderly • patients at risk of aspiration pneumonia • treatment of depression in patients under 25 years (increased risk of suicide)

SIDE-EFFECTS

• Common or very common

Asthenia • dysarthria • dysphagia • elevated plasma-cholesterol concentrations • elevated plasma-triglyceride concentrations • increased appetite • irritability • peripheral oedema • sleep disorders

• Uncommon

Hyponatraemia • hypothyroidism • restless legs syndrome • rhinitis

• Rare

Hepatitis • pancreatitis

318 Mental health disorders

BNF 70
**Risperidone**

**DRUG ACTION** Risperidone is a dopamine D2, 5-HT2a, alpha-, adrenoceptor, and histamine-1 receptor antagonist.

**INDICATIONS AND DOSE**

Schizophrenia and other psychoses in patients tolerant to risperidone by mouth and taking oral risperidone up to 4 mg daily

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult: Initially 25 mg every 2 weeks, to be administered into the deltoid or gluteal muscle, adjusted in steps of 12.5 mg at least every 4 weeks.
SPECIFIC SIDE-EFFECTS
> With intramuscular use erythema · nodules · pain at injection site · swelling

SIDE-EFFECTS, FURTHER INFORMATION
> With intramuscular use If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

PREGNANCY Use only if potential benefit outweighs risk.
BREAST FEEDING Use only if potential benefit outweighs risk—small amount present in milk.

HEPATIC IMPAIRMENT
> With intramuscular use If an oral dose of at least 2 mg daily tolerated, 25 mg as a depot injection can be given every 2 weeks.
> With oral use Initial and subsequent oral doses should be halved.

RENAL IMPAIRMENT Initial and subsequent oral doses should be halved.

MONITORING REQUIREMENTS
> With intramuscular use Treatment requires careful monitoring for optimum effect.

DIRECTIONS FOR ADMINISTRATION
> With oral use Orodispersible tablets should be placed on the tongue, allowed to dissolve and swallowed. Oral liquid should be halved.

PATIENT AND CARER ADVICE
> With oral use Patients or carers should be given advice on how to administer risperidone orodispersible tablets. Patients or carers should be given advice on how to administer risperidone oral liquid; counselling on use of dose syringe advised.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet
CAUTIONARY AND ADVISORY LABELS 2
> RISPERIDONE (Non-proprietary)
Risperidone 500 microgram Risperidone 500microgram tablets | 20 tablet [PROM] £6.18 DT price = £1.07
Risperidone 1 mg Risperidone 1mg tablets | 20 tablet [PROM] £1.03 DT price = £1.03 | 60 tablet [PROM] £25.07
Risperidone 2 mg Risperidone 2mg tablets | 60 tablet [PROM] £16.10 DT price = £1.68
Risperidone 3 mg Risperidone 3mg tablets | 60 tablet [PROM] £88.38 DT price = £2.12
Risperidone 4 mg Risperidone 4mg tablets | 60 tablet [PROM] £116.67 DT price = £2.48
Risperidone 6 mg Risperidone 6mg tablets | 28 tablet [PROM] £82.50 DT price = £4.36 | 60 tablet [PROM] no price available
Risperdal (Janssen-Cilag Ltd)
Risperidone 500 microgram Risperidone 500microgram tablets | 20 tablet [PROM] £5.08 DT price = £1.07
Risperidone 1 mg Risperidone 1mg tablets | 20 tablet [PROM] £8.36 DT price = £1.03 | 60 tablet [PROM] £17.56
Risperidone 2 mg Risperidone 2mg tablets | 60 tablet [PROM] £34.62 DT price = £1.68
Risperidone 3 mg Risperidone 3mg tablets | 60 tablet [PROM] £50.91 DT price = £2.12
Risperidone 4 mg Risperidone 4mg tablets | 60 tablet [PROM] £67.20 DT price = £2.48
Risperidone 6 mg Risperdal 6mg tablets | 28 tablet [PROM] £67.88 DT price = £4.36

Orodispensible tablet
CAUTIONARY AND ADVISORY LABELS 2
EXCIPIENTS: May contain Aspartame
> RISPERIDONE (Non-proprietary)
Risperidone 500 microgram Risperidone 500microgram orodispersable tablets sugar free (sugar-free) | 28 tablet [PROM] £23.88 DT price = £23.81
Risperidone 1 mg Risperidone 1mg orodispersible tablets sugar free (sugar-free) | 28 tablet [PROM] £21.09 DT price = £21.03
Risperidone 2 mg Risperidone 2mg orodispersible tablets sugar free (sugar-free) | 28 tablet [PROM] £38.79 DT price = £38.65
Risperidone 3 mg Risperidone 3mg orodispersible tablets sugar free (sugar-free) | 28 tablet [PROM] £33.50 DT price = £33.50
Risperidone 4 mg Risperidone 4mg orodispersible tablets sugar free (sugar-free) | 28 tablet [PROM] £37.95 DT price = £37.95
Risperdal Quicklet (Janssen-Cilag Ltd)
Risperidone 500 microgram Risperidone 500microgram orodispersible tablets (sugar-free) | 28 tablet [PROM] £8.23 DT price = £8.23
Risperidone 1 mg Risperidone 1mg orodispersible tablets (sugar-free) | 28 tablet [PROM] £13.66 DT price = £13.65
Risperidone 2 mg Risperidone 2mg orodispersible tablets (sugar-free) | 28 tablet [PROM] £26.12 DT price = £26.12
Risperidone 3 mg Risperidone 3mg orodispersible tablets (sugar-free) | 28 tablet [PROM] £28.99 DT price = £28.99
Risperidone 4 mg Risperidone 4mg orodispersible tablets (sugar-free) | 28 tablet [PROM] £37.34 DT price = £37.34

Oral solution
CAUTIONARY AND ADVISORY LABELS 2
> RISPERIDONE (Non-proprietary)
Risperidone 1 mg per 1 ml Risperidone 1mg/ml oral solution sugar free (sugar-free) | 100 ml [PROM] £61.15 DT price = £61.15
Risperdal (Janssen-Cilag Ltd)
Risperidone 1 mg per 1 ml Risperidone 1mg/ml liquid (sugar-free) | 100 ml [PROM] £37.01 DT price = £37.01

Powder and solvent for suspension for injection
> Risperdal Consta (Janssen-Cilag Ltd)
Risperidone 25 mg Risperidone Consta 25mg powder and solvent for suspension for injection vials | 1 vial [PROM] £175.69
Risperidone 37.5 mg Risperidone Consta 37.5mg powder and solvent for suspension for injection vials | 1 vial [PROM] £111.32
Risperidone 50 mg Risperidone Consta 50mg powder and solvent for suspension for injection vials | 1 vial [PROM] £142.76

3 Movement disorders

3.1 Dystonias and other involuntary movements

Drugs used for Dystonias and other involuntary movements not listed below: Chlorpromazine hydrochloride, p. 304 · Clozapine hydrochloride, p. 137 · Clonazepam, p. 313 · Diazepam, p. 267 · Haloperidol, p. 306 · Orphenadrine hydrochloride, p. 325 · Perhexiline, p. 308 · Pramipexole, p. 336 · Prochelorperazine, p. 309 · Procyclidine hydrochloride, p. 326 · Roclopride, p. 338 · Rotigotine, p. 339 · Trifluoperazine, p. 310 · Trihexyphenidyl, p. 326

ANTIPSYCHOTICS (FIRST-GENERATION)
Promazine hydrochloride

The properties listed below are those particular to the drug only. For properties common to the class, see Antipsychotics, p. 303.

INDICATIONS AND DOSE
Short-term adjunctive management of psychomotor agitation
BY MOUTH
> Adult: 100–200 mg 4 times a day
Dystonias and other involuntary movements

Agitation and restlessness in elderly
BY MOUTH
▶ Elderly: 25–50 mg 4 times a day

- CONTRA-INDICATIONS CNS depression - comatose states - phaeochromocytoma
- CAUTIONS Cerebral arteriosclerosis
- SIDE-EFFECTS Haemolytic anaemia
- HEPATIC IMPAIRMENT Can precipitate coma; phenothiazines are hepatotoxic.
- RENAL IMPAIRMENT Start with small doses in severe renal impairment because of increased cerebral sensitivity.
- LESS SUITABLE FOR PRESCRIBING Promazine hydrochloride is less suitable for prescribing.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet
CAUTIONARY AND ADVISORY LABELS 2
▶ PROMAZINE HYDROCHLORIDE (Non-proprietary)
Promazine hydrochloride 25 mg Promazine 25mg tablets | 100 tablet (P) £39.50
Promazine hydrochloride 50 mg Promazine 50mg tablets | 100 tablet (P) £76.49

Oral solution
CAUTIONARY AND ADVISORY LABELS 2
▶ PROMAZINE HYDROCHLORIDE (Non-proprietary)
Promazine hydrochloride 5 mg per 1 ml Promazine 5mg/5ml syrup | 150 ml (P) £11.50 DT price = £11.87
Promazine 25mg/5ml oral solution | 150 ml (P) £11.87 DT price = £11.87
Promazine hydrochloride 10 mg per 1 ml Promazine 10mg/5ml syrup | 150 ml (P) £13.50 DT price = £13.93
Promazine 50mg/5ml oral solution | 150 ml (P) £13.93 DT price = £13.93

CNS STIMULANTS

Piracetam

INDICATIONS AND DOSE
Adjunctive treatment of cortical myoclonus
BY MOUTH
▶ Adult: Initially 7.2 g daily in 2–3 divided doses, then increased in steps of 4.8 g every 3–4 days, adjusted according to response, subsequently, attempts should be made to reduce dose of concurrent therapy; maximum 24 g per day

- CONTRA-INDICATIONS Cerebral haemorrhage - Huntington’s chorea
- CAUTIONS Gastric ulcer - history of haemorrhagic stroke - increased risk of bleeding - major surgery - underlying disorders of haemostasis
- INTERACTIONS Caution with concomitant drugs that increase bleeding.
- SIDE-EFFECTS
  - Common or very common Hyperkinesia - nervousness - weight gain
- PREGNANCY Avoid.
- BREAST FEEDING Avoid.
- HEPATIC IMPAIRMENT Adjust dose if both hepatic and renal impairment.
- RENAL IMPAIRMENT Use two-thirds of normal dose if eGFR 50–80 mL/minute/1.73 m²; use one-third of normal dose in 2 divided doses if eGFR 30–50 mL/
minute/1.73 m²; use one-sixth of normal dose as a single dose if eGFR 20–30 mL/minute/1.73 m². Avoid if eGFR less than 20 mL/minute/1.73 m².
- TREATMENT CESSATION Avoid abrupt withdrawal.
- PRESCRIBING AND DISPENSING INFORMATION Piracetam has been used in children 16 years and over as adjunctive treatment for cortical myoclonus.
- DIRECTIONS FOR ADMINISTRATION Follow the oral solution with a glass of water (or soft drink) to reduce bitter taste.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 3
▶ Nootropil (UCB Pharma Ltd)
Piracetam 800 mg Nootropil 800mg tablets | 90 tablet (P) £11.75
Piracetam 1.2 gram Nootropil 1.2g tablets | 60 tablet (P) £10.97

Oral solution
CAUTIONARY AND ADVISORY LABELS 3
▶ Nootropil (UCB Pharma Ltd)
Piracetam 33.3 mg per 1 ml Nootropil 33% oral solution (sugar-free) | 300 ml (P) £16.31

MONOAMINE DEPLETING DRUGS

Tetrabenazine

INDICATIONS AND DOSE
Movement disorders due to Huntington’s chorea, hemiballismus, senile chorea, and related neurological conditions
BY MOUTH
▶ Adult: Initially 25 mg 3 times a day, then increased, if tolerated, in steps of 25 mg every 3–4 days; maximum 200 mg per day
▶ Elderly: Lower initial dose may be necessary
Moderate to severe tardive dyskinesia
BY MOUTH
▶ Adult: Initially 12.5 mg daily, dose to be gradually increased according to response

- CONTRA-INDICATIONS Depression - parkinsonism - phaeochromocytoma - prolactin-dependent tumours
- CAUTIONS Susceptibility to QT-interval prolongation
- INTERACTIONS Appendix 1 (tetrabenazine).
Caution with concomitant use of drugs that prolong QT interval.

- SIDE-EFFECTS
  - Common or very common Anxiety - confusion - constipation - depression - diarrhoea - drowsiness - dysphagia - hypotension - insomnia - nausea - parkinsonism - vomiting
  - Uncommon Altered consciousness level - extrapyramidal disorders - hyperthermia
  - Rare Neuroleptic malignant syndrome
  - Very rare Rhabdomyolysis
  - Frequency not known Agitation - amnesia - ataxia - bradycardia - disorientation - dizziness - dry mouth - dyspepsia
- PREGNANCY Avoid unless essential—toxicity in animal studies.
- BREAST FEEDING Avoid.
- HEPATIC IMPAIRMENT Use half initial dose and slower dose titration in mild to moderate impairment. Use with caution in severe impairment.
- RENAL IMPAIRMENT Use with caution.
- TREATMENT CESSATION Avoid abrupt withdrawal.
PATIENT AND CARER ADVICE  May affect performance of skilled tasks (e.g. driving).

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, powder preparation.

Tablet
- RILUZOLE (Non-proprietary)
  Riluzole 50 mg Riluzole 50mg tablets | 56 tablet POM £320.00 DT price = £29.61
  Rilutek (Sanofi)
  Riluzole 50 mg Rilutek 50mg tablets | 56 tablet POM £320.33 DT price = £29.61

Riluzole

CONTRA-INDICATIONS  Acute porphyria

CAUTIONS  History of abnormal hepatic function (consult product literature for details) - interstitial lung disease

CAUTIONS, FURTHER INFORMATION
Interstitial lung disease Perform chest radiography if symptoms such as dry cough or dyspnoea develop; discontinue if interstitial lung disease is diagnosed.

SIDE-EFFECTS
- Common or very common Abdominal pain · asthenia · diarrhoea · dizziness · drowsiness · headache · nausea · oral paraesthesia · tachycardia · vomiting
- Uncommon Anaemia · angioedema · interstitial lung disease · pancreatitis
- Rare Neutropenia
- Very rare Hepatitis

SIDE-EFFECTS, FURTHER INFORMATION
Neutropenia White blood cell counts should be determined in febrile illness; neutropenia requires discontinuation of riluzole.

PREGNANCY  Avoid—no information available.

BREAST FEEDING  Avoid—no information available.

HEPATIC IMPAIRMENT  Avoid.

RENAI IMPAIRMENT  Avoid—no information available.

PATIENT AND CARER ADVICE  Dizziness or vertigo may affect performance of skilled tasks (e.g. driving). Blood disorders Patients or their carers should be told how to recognise signs of neutropenia and advised to seek immediate medical attention if symptoms such as fever occur.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Riluzole for motor neurone disease (January 2001) NICE TA20 Riluzole is recommended for treating the amyotrophic lateral sclerosis (ALS) form of motor neurone disease (MND). Treatment should be initiated by a specialist in MND but it can then be supervised under a shared-care arrangement involving the general practitioner.

www.nice.org.uk/TA20

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, powder preparation.

Tablet
- RILUZOLE (Non-proprietary)
  Riluzole 50 mg Riluzole 50mg tablets | 56 tablet POM £320.00 DT price = £29.61
  Rilutek (Sanofi)
  Riluzole 50 mg Rilutek 50mg tablets | 56 tablet POM £320.33 DT price = £29.61

Tafamidis

INDICATIONS AND DOSE
Treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment (initiated under specialist supervision)

BY MOUTH
- Adult: 20 mg once daily

SIDE-EFFECTS  Abdominal pain · diarrhoea · urinary tract infection · vaginal infection

CONCEPTION AND CONTRACEPTION  Exclude pregnancy before treatment and ensure effective contraception during and for one month after stopping treatment.

PREGNANCY  Avoid (toxicity in animal studies).

BREAST FEEDING  Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT  Caution in severe impairment—no information available.

PRESCRIBING AND DISPENSING INFORMATION  Tafamidis should be prescribed in addition to standard treatment, but before liver transplantation; it should be discontinued in patients who undergo liver transplantation.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule
- CAUTIONARY AND ADVISORY LABELS 25
  Tafamidis 20 mg Vyndaqel 20mg capsules | 30 capsule POM £10.685.00

NEUROTOXINS (BOTULINUM TOXINS)

Botulinum toxin type A

INDICATIONS AND DOSE
Treatment of focal spasticity (including hand and wrist disability associated with stroke) (specialist use only) · Blepharospasm (specialist use only) · Hemifacial spasm (specialist use only) · Spasmodic torticollis (specialist use only) · Severe hyperhidrosis of the axillae (specialist use only) · Prophylaxis of headaches in adults with chronic migraine (specialist use only) · Temporary improvement of moderate to severe wrinkles between the eyebrows in adults under 65 years (specialist use only) · Ankle disability due to lower limb spasticity associated with stroke (specialist use only) · Management of bladder dysfunctions (specialist use only) · Temporary improvement of moderate to severe crow’s feet (specialist use only)· BY SUBCUTANEOUS INJECTION OR BY INTRADERMAL INJECTION OR BY INTRAMUSCULAR INJECTION
- Adult: (consult product literature)

Dose equivalence and conversion
Important: information is specific to each individual preparation.
CONTRA-INDICATIONS  Acute urinary retention (specific to use in bladder disorders only) • catheterisation difficulties (specific to use in bladder disorders only) • generalised disorders of muscle activity • infection at injection site • myasthenia gravis • presence of bladder calculi (specific to use in bladder disorders only) • urinary tract infection (specific to use in bladder disorders only)

CAUTIONS

GENERAL CAUTIONS:
Atrophy in target muscle • chronic respiratory disorder • elderly • excessive weakness in target muscle • history of aspiration • history of dysphagia • inflammation in target muscle • neurological disorders • neuromuscular disorders • off-label use (fatal adverse events reported)

SPECIFIC CAUTIONS:
When used for blepharospasm or hemifacial spasm • risk of angle-closure glaucoma

CAUTIONS, FURTHER INFORMATION
When used for blepharospasm and hemifacial spasm, reduced blinking can lead to corneal exposure, persistent epithelial defect and corneal ulceration (especially in those with VIIth nerve disorders)—careful testing of corneal sensation in previously operated eyes, avoidance of injection in lower lid area to avoid ectropion, and vigorous treatment of epithelial defect needed. Neuromuscular or neurological disorders can lead to increased sensitivity and exaggerated muscle weakness including dysphagia and respiratory compromise.

SIDE-EFFECTS

GENERAL SIDE-EFFECTS
• Common or very common Excessive doses may paralyse distant muscles • increased electrophysiologic jitter in some distant muscles • influenza-like symptoms • misplaced injections may paralyse nearby muscle groups

• Rare Antibody formation (substantial deterioration in response) • arthralgia or myalgia • fever • generalized weakness or malaise • seizures

• Very rare Aspiration • dysphagia • dysphonia • exaggerated muscle weakness • respiratory disorders

SPECIFIC SIDE-EFFECTS
• Common or very common
• When used for focal upper-limb spasticity associated with stroke dysphagia • hypertension • purpura
• When used for axillary hyperhidrosis pain in extremities
• When used for spasmodic torticollis back pain • dizziness • drowsiness • dry mouth • dysphagia and pooling of saliva (occurs most frequently after injection into sternomastoid muscle) • headache • hypertension • malaise • nausea • numbness • rhinitis • stiffness • weakness

• When used for hemifacial spasm dry eye • ecchymosis • facial oedema • irritation • keratitis • lacrimation • lagophthalmos • pharyngitis • ptosis

• When used for temporary improvement of moderate to severe wrinkles between the eyebrows facial oedema • headache • ptosis

• When used for blepharospasm dry eye • ecchymosis • facial oedema • irritation • keratitis • lacrimation • lagophthalmos • pharyngitis • ptosis

• When used for axillary hyperhidrosis abnormal skin odour • alopecia • hot flushes • non-axillary sweating • paraesthesia • pruritus • subcutaneous nodule

• Uncommon
• When used for focal upper-limb spasticity associated with stroke amnesia • arthralgia • bursitis • cough • depression • dry mouth • dysaesthesia • haematoma • headache • insomnia • malaise • pain in extremities • paraesthesia • peripheral oedema • vertigo

• When used for blepharospasm conjunctivitis • dermatitis • diplopia • dizziness • drooping • dry mouth • ectropion • entropion • facial weakness • headache • paraesthesia • tiredness • visual disturbances

• When used for axillary hyperhidrosis joint pain • myalgia

When used for hemifacial spasm conjunctivitis • dermatitis • diplopia • dizziness • drooping • dry mouth • ectropion • entropion • facial weakness • headache • paraesthesia • tiredness • visual disturbances

When used for spasmodic torticollis colitis • diarrhoea • diplopia • dysphagia • eye pain • myalgia • ptosis • skeletal pain • sweating • tremor • voice alteration • vomiting

When used for focal upper-limb specificity associated with stroke nausea

When used for temporary improvement of moderate to severe wrinkles between the eyebrows anxiety • asthenia • blepharitis • dizziness • dry mouth • dry skin • muscle cramp • nausea • paraesthesia • photosensitivity reactions • tinnitus • visual disturbances

Rare

When used for blepharospasm eyelid bruising and swelling (minimised by applying gentle pressure at injection site immediately after injection)

When used for hemifacial spasm eyelid bruising and swelling (minimised by applying gentle pressure at injection site immediately after injection)

Very rare

When used for blepharospasm angle-closure glaucoma • corneal epithelial defect • corneal perforation • corneal ulceration

When used for hemifacial spasm angle-closure glaucoma • corneal epithelial defect • corneal perforation • corneal ulceration

Frequency not known

When used for focal lower-limb spasticity associated with stroke arthralgia • peripheral oedema • rash

CONCEPTION AND CONTRACEPTION Avoid in women of child-bearing age unless using effective contraception.

PREGNANCY Avoid unless essential—toxicity in animal studies (manufacturer of Botox® advise avoid).

BREAST FEEDING Low risk of systemic absorption but avoid unless essential.

PRESCRIBING AND DISPENSING INFORMATION Preparations are not interchangeable.

PATIENT AND CARER ADVICE Patients and carers should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties; they should be advised to seek immediate medical attention if swallowing, speech or breathing difficulties occur.

NATIONAL FUNDING / ACCESS DECISIONS

NICE technology appraisals (TAs)
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (June 2012) NICE TA260 Botulinum toxin type A is recommended as an option for the prophylaxis of headaches in adults with chronic migraine, (defined as headaches on at least 15 days per month, of which at least 8 days are with migraine), that has not responded to at least three prior pharmacological prophylaxis therapies and whose condition is appropriately managed for medication overuse.

www.nice.org.uk/TA260

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (March 2011 and March 2013) that Botox® is not recommended for use within NHS Scotland for prophylaxis of headaches in adults with chronic migraine. The Scottish Medicines Consortium has advised that Azzalure® and Vistabel® (December 2010), and Bocouture® (February 2011) are not recommended for use within NHS Scotland.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
### Nervous system

**MEDICINAL FORMS**

- **PRESCRIBING AND DISPENSING INFORMATION**
- **PREGNANCY**
- **SIDE-EFFECTS**
- **CONTRA-INDICATIONS**
- **CAUTIONS**
- **CONTRA-INDICATIONS**
- **SIDE-EFFECTS**
- **CONTRA-INDICATIONS**
- **SIDE-EFFECTS**
- **CONTRA-INDICATIONS**
- **SIDE-EFFECTS**
- **CONTRA-INDICATIONS**
- **SIDE-EFFECTS**

**Botulinum toxin type B**

**INDICATIONS AND DOSE**

- **Spasmodic torticollis (cervical dystonia) (specialist use only)**
  - **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 5000–10 000 units, adjusted according to response, dose to be divided between 2–4 most affected muscles.
  
  **Dose equivalence and conversion**
  
  **Important**: information specific to each individual preparation.

  - **CONTRA-INDICATIONS** Neurumuscular disorders, neuromuscular junctional disorders.
  - **CAUTIONS** History of dysphagia or aspiration, off-label use (risk of toxin spread), tolerance may occur.
  - **SIDE-EFFECTS**
    - **Common or very common** Dry mouth, dyspepsia, dysphagia, dysphonia, headache, increased electrophysiologic jitter in some distant muscles, influenza-like symptoms, myasthenia, neck pain, taste disturbances, visual disturbances, worsening torticollis.
    - **Frequency not known** Aspiration pneumonia, constipation, exaggerated muscle weakness, malaise, ptosis, respiratory disorders, vomiting.
  - **PREGNANCY** Low risk of systemic absorption but avoid unless essential.
  - **BREAST FEEDING** Low risk of systemic absorption but avoid unless essential.
  - **DIRECTIONS FOR ADMINISTRATION** Injection may be diluted with sodium chloride 0.9%.
  - **PRESCRIBING AND DISPENSING INFORMATION** Important: not interchangeable with other botulinum toxin preparations.
  - **PATIENT AND CARER ADVICE** Patients should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties; they should be advised to seek immediate medical attention if swallowing, speech or breathing difficulties occur.

  - **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

---

<table>
<thead>
<tr>
<th>Powder for solution for injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botulinum toxin type A 125 unit Azzalure 125 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Botulinum toxin type A 50 unit Bocouture 50 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Botulinum toxin type A 50 unit Botox 50 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Botulinum toxin type A 100 unit Botox 100 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Botulinum toxin type A 200 unit Botox 200 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Dysport (Ipsen Ltd)</td>
</tr>
<tr>
<td>Botulinum toxin type A 300 unit Dysport 300 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Botulinum toxin type A 500 unit Dysport 500 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Xeomin (Merz Pharma UK Ltd)</td>
</tr>
<tr>
<td>Botulinum toxin type A 50 unit Xeomin 50 unit powder for solution for injection vials</td>
</tr>
<tr>
<td>Botulinum toxin type A 100 unit Xeomin 100 unit powder for solution for injection vials</td>
</tr>
</tbody>
</table>

**Solution for injection**

- NeuroBloc (Eisai Ltd)
  - Botulinum toxin type B 5000 unit per 1 ml NeuroBloc 5000 units/1ml solution for injection vials | 1 vial £148.27 |
  - Botulinum toxin type B 10,000 units/2ml solution for injection vials | 1 vial £197.69 |
  - Botulinum toxin type B 25,000 units/0.5ml solution for injection vials | 1 vial £111.20 |

---

### 3.2 Parkinson’s disease

#### Parkinson’s disease and related disorders

**Parkinson’s disease**

In idiopathic Parkinson’s disease, the progressive degeneration of pigmented neurones in the substantia nigra leads to a deficiency of the neurotransmitter dopamine. The resulting neurochemical imbalance in the basal ganglia causes the characteristic signs and symptoms of the illness. Drug therapy does not prevent disease progression, but it improves most patients’ quality of life.

With suspected Parkinson’s disease should be referred to a specialist to confirm the diagnosis; the diagnosis should be reviewed every 6–12 months.

Features resembling those of Parkinson’s disease can occur in diseases such as progressive supranuclear palsy and multiple system atrophy, but they do not normally show a sustained response to the drugs used in the treatment of idiopathic Parkinson’s disease.

When initiating treatment, patients should be advised about its limitations and possible side-effects. About 5–10% of patients with Parkinson’s disease respond poorly to treatment.

Treatment is usually not started until symptoms cause significant disruption of daily activities. Levodopa, non-ergot-derived dopamine-receptor agonists, or monoamine-oxidase-B inhibitors can be prescribed for initial treatment in early Parkinson’s disease. Therapy with two or more antiparkinsonian drugs may be necessary as the disease progresses. Most patients eventually require levodopa and subsequently develop motor complications.

**Elderly**

Antiparkinsonian drugs can cause confusion in the elderly. It is particularly important to initiate treatment with low doses and to increase the dose gradually.

**Dopaminergic drugs used in Parkinson’s disease**

- **Dopamine-receptor agonists**
  - The dopamine-receptor agonists have a direct action on dopamine receptors. Initial treatment of Parkinson’s disease is often with the dopamine-receptor agonists pramipexole p. 336, ropinirole p. 338, and rotigotine p. 339. The ergot-derived dopamine-receptor agonists bromocriptine p. 333, cabergoline p. 334, and pergolide p. 336 are rarely used because of the risk of fibrotic reactions.
  - When used alone, dopamine-receptor agonists cause fewer motor complications in long-term treatment compared with levodopa treatment but the overall motor performance improves slightly less. The dopamine-receptor agonists are associated with more psychiatric side-effects than levodopa.
  - Dopamine-receptor agonists are also used with levodopa in more advanced disease. If a dopamine-receptor agonist is added to levodopa therapy, the dose of levodopa needs to be reduced.
  - Apomorphine hydrochloride p. 332 is a potent dopamine-receptor agonist that is sometimes helpful in advanced
disease for patients experiencing unpredictable ‘off’ periods with levodopa treatment. Apomorphine hydrochloride should be initiated in a specialist clinic. After an overnight withdrawal of oral antiparkinsonian medication to induce an ‘off’ episode, the threshold dose of apomorphine hydrochloride is determined. Oral antiparkinsonian medication is then restarted. The patient must be taught to self-administer apomorphine hydrochloride by subcutaneous injection into the lower abdomen or outer thigh at the first sign of an ‘off’ episode. Once treatment has been established it may be possible to gradually reduce other antiparkinsonian medications.

**Levodopa**

Levodopa, the amino-acid precursor of dopamine, acts by replenishing depleted striatal dopamine. It is given with an extracerebral dopa-decarboxylase inhibitor, which reduces the peripheral conversion of levodopa to dopamine, thereby limiting side-effects such as nausea, vomiting, and cardiovascular effects; additionally, effective brain-dopamine concentrations are achieved with lower doses of levodopa. The extracerebral dopa-decarboxylase inhibitors used with levodopa are benserazide (in co-beneldopa p. 328) and carbidopa (in co-careldopa p. 329).

Levodopa, in combination with a dopa-decarboxylase inhibitor, is useful in the elderly or frail, in patients with other significant illnesses, and in those with more severe symptoms. It is effective and well tolerated in the majority of patients.

Levodopa therapy should be initiated at a low dose and increased in small steps; the final dose should be as low as possible. Intervals between doses should be chosen to suit the needs of the individual patient.

Nausea and vomiting with co-beneldopa or co-careldopa are rarely dose-limiting and domperidone p. 346 can be useful in controlling these effects.

Levodopa treatment is associated with potentially troublesome motor complications including response fluctuations and dyskinesias. Response fluctuations are characterised by large variations in motor performance, with normal function during the ‘on’ period, and weakness and restricted mobility during the ‘off’ period. ‘End-of-dose’ deterioration with progressively shorter duration of benefit also occurs. Modified-release preparations may help with ‘end-of-dose’ deterioration or nocturnal immobility and rigidity. Motor complications are particularly problematic in young patients treated with levodopa.

**Monoamine-oxidase-B inhibitors**

Rasagiline p. 340 and selegiline hydrochloride p. 340 are monoamine-oxidase-B inhibitors used in Parkinson’s disease. Early treatment with selegiline hydrochloride alone can delay the need for levodopa therapy.

**Antimuscarinic drugs used in parkinsonism**

Antimuscarinic drugs can be useful in drug-induced parkinsonism, but they are generally not used in idiopathic Parkinson’s disease because they are less effective than dopaminergic drugs and they are associated with cognitive impairment.

The antimuscarinic drugs orphenadrine hydrochloride below, procyclidine hydrochloride p. 326, and trihexyphenidyl hydrochloride p. 326 reduce the symptoms of parkinsonism induced by antipsychotic drugs, but there is no justification for giving them routinely in the absence of parkinsonian side-effects. Tardive dyskinesia is not improved by antimuscarinic drugs and may be made worse.

In idiopathic Parkinson’s disease, antimuscarinic drugs reduce tremor and rigidity but they have little effect on bradykinesia. They may be useful in reducing sialorrhoea.

There are no important differences between the antimuscarinic drugs, but some patients tolerate one better than another.

Procyclidine hydrochloride can be given parenterally and is effective emergency treatment for acute drug-induced dystonic reactions.

If treatment with an antimuscarinic is ineffective, intravenous diazepam p. 267 can be given for life-threatening acute drug-induced dystonic reactions.

**Drugs used in essential tremor, chorea, tics, and related disorders**

Tetrahydrobenzidine p. 321 is mainly used to control movement disorders in Huntington’s chorea and related disorders. Tetrahydrobenzidine can also be prescribed for the treatment of tardive dyskinesia if switching or withdrawing the causative antipsychotic drug is not effective. It acts by depleting nerve endings of dopamine. It is effective in only a proportion of patients and its use may be limited by the development of depression.

Haloperidol p. 306 [unlicensed indication], olanzapine p. 315 [unlicensed indication], risperidone p. 319 [unlicensed indication], and quetiapine p. 318 [unlicensed indication] can also be used to suppress chorea in Huntington’s disease.

Haloperidol can also improve motor tics and symptoms of Tourette syndrome and related choreas. Other treatments for Tourette syndrome include pimozide p. 308 [unlicensed indication] (important: ECG monitoring required), clonidine hydrochloride p. 137 [unlicensed indication], and sulpiride p. 310 [unlicensed indication]. Trihexyphenidyl hydrochloride p. 326 in high dosage can also improve some movement disorders; it is sometimes necessary to build the dose up over many weeks. Chlorpromazine hydrochloride p. 304 and haloperidol p. 306 are used to relieve intractable hiccup.

Propranolol hydrochloride p. 146 or another beta-adrenoceptor blocking drug may be useful in treating essential tremor or tremors associated with anxiety or thyrotoxicosis.

Primaldine p. 401 in some cases provides relief from benign essential tremor; the dose is increased slowly to reduce side-effects.

Piracetam p. 321 is used as an adjunctive treatment for myoclonus of cortical myoclonus of cortical origin. After an acute episode, attempts should be made every 6 months to decrease or discontinue treatment.

Riluzole p. 322 is used to extend life in patients with motor neurone disease who have amyotrophic lateral sclerosis.

**Torsion dystonia and other involuntary movements**

Treatment with botulinum toxin type A p. 322 can be considered after an acquired non-progressive brain injury if rapid-onset spasticity causes postural or functional difficulties.

**ANTIMUSCARINICS**

**Orphenadrine hydrochloride**

- **Drug action** Orphenadrine exerts its antiparkinsonian action by reducing the effects of the relative central cholinergic excess that occurs as a result of dopamine deficiency.

**INDICATIONS AND DOSE**

**Parkinsonism** | Drug-induced extrapyramidal symptoms (but not tardive dyskinesia)

**By mouth**

- **Adult:** Initially 150 mg daily in divided doses, then increased in steps of 50 mg every 2–3 days, adjusted according to response; usual dose 150–300 mg daily in divided doses; maximum 400 mg per day
- **Elderly:** Preferably dose at lower end of range
**Procyclidine hydrochloride**

**INDICATIONS AND DOSE**

**Parkinsonism | Extrapyramidal symptoms (but not tardive dyskinesia)**

**BY MOUTH**

- Adult: 2.5 mg 3 times a day, then increased in steps of 2.5–5 mg daily if required; increased if necessary up to 30 mg daily in 2–4 divided doses, to be increased at 2–3 day intervals. Maximum daily dose only to be used in exceptional circumstances; maximum 60 mg per day.
- Elderly: Lower end of range preferable

---

**Acute dystonia**

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**

- Adult: 5–10 mg, occasionally, more than 10 mg, dose usually effective in 5–10 minutes but may need 30 minutes for relief
- Elderly: Lower end of range preferable

---

**Trihexyphenidyl hydrochloride** *(Benzhexol hydrochloride)*

**INDICATIONS AND DOSE**

Parkinson’s disease (if used in combination with carbidopa or co-beneldopa)

- Adult: Maintenance 2–6 mg daily in divided doses, use not recommended because of toxicity in the elderly and the risk of aggravating dementia
Parkeinson's disease 327

**CATECHOL-O-METHYLMUTRANSFERASE INHIBITORS**

**Entacapone**

**DRUG ACTION** Entacapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-O-methyltransferase, allowing more levodopa to reach the brain.

**INDICATIONS AND DOSE**

Adjunct to co-beneldopa or co-careldopa in Parkinson's disease with 'end-of-dose' motor fluctuations (under expert supervision)

**BY MOUTH**

- Adult: 200 mg, dose to be given with each dose of levodopa with dopa-decarboxylase inhibitor; maximum 2 g per day

**CONTRA-INDICATIONS** History of neuroleptic malignant syndrome, history of non-traumatic rhabdomyolysis, phaeochromocytoma

**CAUTIONS** Concurrent levodopa dose may need to be reduced by about 10–30% ischaemic heart disease

**INTERACTIONS** Appendix 1 (entacapone). Avoid iron-containing products at the same time of day.

**SIDE-EFFECTS**

- Common or very common Abdominal pain, abnormal dreams, confusion, constipation, diarrhea, dizziness, dry mouth, dyskinesia, dystonia, fatigue, hallucinations, insomnia, ischaemic heart disease, nausea, sweating, urinary incontinence, urinary retention, vomiting
- Uncommon Myocardial infarction, Rash
- Rare Agitation, anorexia, urticaria, weight loss
- Frequency not known Colitis, hepatitis, neuroleptic malignant syndrome, rhabdomyolysis, skin, hair, and nail discoloration

**PREGNANCY** Avoid—no information available.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Avoid.

**TREATMENT CESSATION** Avoid abrupt withdrawal.

**PATIENT AND CARER ADVICE** Patient counselling is advised (may colour urine reddish-brown, concomitant iron containing products).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- **ENTACAPONE (Non-proprietary)**
  - Entacapone 200 mg Entacapone 200mg tablets | 30 tablet [POM] £6.38 DT price = £6.12 | 100 tablet [POM] £5.45
  - Comtess (Orion Pharma (UK) Ltd) Entacapone 200 mg Comtess 200mg tablets | 30 tablet [POM] £17.24 DT price = £6.12 | 100 tablet [POM] £5.74

Also available in combination with carbidopa with entacapone and levodopa, p. 331

**Tolcapone**

**DRUG ACTION** Tolcapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-O-methyltransferase, allowing more levodopa to reach the brain.

**INDICATIONS AND DOSE**

Adjunct to co-beneldopa or co-careldopa in Parkinson's disease with 'end-of-dose' motor fluctuations if another inhibitor of peripheral catechol-O-methyltransferase inappropriate (under expert supervision)

**BY MOUTH**

- Adult: 100 mg 3 times a day (max. per dose 200 mg 3 times a day) continuing beyond 3 weeks only if substantial improvement, leave 6 hours between each dose; first daily dose should be taken at the same time as levodopa with dopa-decarboxylase inhibitor, dose maximum only in exceptional circumstances
CONTRA-INDICATIONS Phaeochromocytoma - previous history of hyperthermia - previous history of neuroleptic malignant syndrome - previous history of rhabdomyolysis - severe dyskinesia

CAUTIONS Most patients receiving more than 600 mg levodopa daily require reduction of levodopa dose by about 30%

CAUTIONS, FURTHER INFORMATION Hepatotoxicity Potentially life-threatening hepatotoxicity including fulminant hepatitis reported rarely, usually in women and during the first 6 months, but late-onset liver injury also reported; discontinue if abnormal liver function tests or symptoms of liver disorder; do not reintroduce tolcapone once discontinued.

INTERACTIONS → Appendix 1 (tolcapone).

SIDE-EFFECTS
- Common or very common Abdominal pain - anorexia - chest pain - confusion - constipation - diarrhoea - dizziness - drowsiness - dyskinesia - dyspepsia - dystonia - excessive dreaming - hallucinations - headache - hepatotoxicity - nausea - sleep disturbances - sweating - syncpe - urine discoloration - vomiting - xerostomia
- Frequency not known Neuroleptic malignant syndrome reported on dose reduction or withdrawal - rhabdomyolysis reported on dose reduction or withdrawal

PREGNANCY Toxicity in animal studies—use only if potential benefit outweighs risk.

BREAST FEEDING Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Avoid.

RENAL IMPAIRMENT Caution if eGFR less than 30 mL/minute/1.73 m².

MONITORING REQUIREMENTS Test liver function before treatment, and monitor every 2 weeks for first year, every 4 weeks for next 6 months and then every 8 weeks thereafter (restart monitoring schedule if dose increased).

TREATMENT CESSION Avoid abrupt withdrawal.

PATIENT AND CARER ADVICE Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop.

MEDICINAL FORMS

TREATMENT CESSATION

1. BY MOUTH USING MODIFIED-RELEASE MEDICINES
   - Adult: Initially 1 capsule 3 times a day; maximum 6 capsules per day

PARKINSON’S DISEASE (PATIENTS TRANSFERRING FROM IMMEDIATE-RELEASE LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR PREPARATIONS)

BY MOUTH USING MODIFIED-RELEASE MEDICINES
- Adult: Initially 1 capsule substituted for every 100 mg of levodopa and given at same dosage frequency, increased every 2–3 days according to response; average increase 50% needed over previous levodopa dose and titration may take up to 4 weeks, supplementary dose of immediate-release Madopar® may be needed with first morning dose; if response still poor to total daily dose of Madopar® CR plus Madopar® corresponding to 1.2 g levodopa—consider alternative therapy.

Dose equivalence and conversion
Dose is expressed as levodopa.

IMPULSIVE CONTROL DISORDERS
Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.

CAUTIONS
- Cushing’s syndrome - diabetes mellitus - endocrine disorders - history of convulsions - history of myocardial infarction with residual arrhythmia - history of peptic ulcer - hyperthyroidism - osteomalacia - phaeochromocytoma - psychiatric illness (avoid if severe and discontinue if deterioration) - severe cardiovascular disease - severe pulmonary disease - susceptibility to angle-closure glaucoma

INTERACTIONS → Appendix 1 (co-beneldopa, levodopa).

SIDE-EFFECTS
- Common or very common Abnormal dreams - anorexia - anxiety - arrhythmias - chorea - confusion - depression - dizziness - drowsiness - dry mouth - dyskinesia - dystonia - euphoria - fatigue - insomnia - nausea - palpitations - postural hypotension - psychosis - syncpe - taste disturbances - vomiting
- Uncommon Ataxia - chest pain - constipation - diaphoresis - dysphagia - flatulence - hand tremor - hoarseness - hypersalivation - hypertension - malaise - muscle cramps - oedema - reddish discoloration of the urine and other body fluids - weakness - weight changes
- Very rare Angle-closure glaucoma - suicidal ideation
- Frequency not known Compulsive behaviour

Important safety information

Co-beneldopa

INDICATIONS AND DOSE

PARKINSON’S DISEASE

INITIALLY BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 50 mg 3–4 times a day, then (by mouth) increased in steps of 100 mg daily, dose to be increased once or twice weekly according to response; maintenance 400–800 mg daily in divided doses

PARKINSON’S DISEASE (IN ADVANCED DISEASE)

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 100 mg 3 times a day, then increased in steps of 100 mg daily, dose to be increased once or twice weekly according to response; maintenance 400–800 mg daily in divided doses

Important safety information

IMPULSIVE CONTROL DISORDERS
Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.

CAUTIONS
- Cushing’s syndrome - diabetes mellitus - endocrine disorders - history of convulsions - history of myocardial infarction with residual arrhythmia - history of peptic ulcer - hyperthyroidism - osteomalacia - phaeochromocytoma - psychiatric illness (avoid if severe and discontinue if deterioration) - severe cardiovascular disease - severe pulmonary disease - susceptibility to angle-closure glaucoma

INTERACTIONS → Appendix 1 (co-beneldopa, levodopa).

SIDE-EFFECTS
- Common or very common Abnormal dreams - anorexia - anxiety - arrhythmias - chorea - confusion - depression - dizziness - drowsiness - dry mouth - dyskinesia - dystonia - euphoria - fatigue - insomnia - nausea - palpitations - postural hypotension - psychosis - syncpe - taste disturbances - vomiting
- Uncommon Ataxia - chest pain - constipation - diaphoresis - dysphagia - flatulence - hand tremor - hoarseness - hypersalivation - hypertension - malaise - muscle cramps - oedema - reddish discoloration of the urine and other body fluids - weakness - weight changes
- Very rare Angle-closure glaucoma - suicidal ideation
- Frequency not known Compulsive behaviour

Important safety information

IMPULSIVE CONTROL DISORDERS
Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.

CAUTIONS
- Cushing’s syndrome - diabetes mellitus - endocrine disorders - history of convulsions - history of myocardial infarction with residual arrhythmia - history of peptic ulcer - hyperthyroidism - osteomalacia - phaeochromocytoma - psychiatric illness (avoid if severe and discontinue if deterioration) - severe cardiovascular disease - severe pulmonary disease - susceptibility to angle-closure glaucoma

INTERACTIONS → Appendix 1 (co-beneldopa, levodopa).

SIDE-EFFECTS
- Common or very common Abnormal dreams - anorexia - anxiety - arrhythmias - chorea - confusion - depression - dizziness - drowsiness - dry mouth - dyskinesia - dystonia - euphoria - fatigue - insomnia - nausea - palpitations - postural hypotension - psychosis - syncpe - taste disturbances - vomiting
- Uncommon Ataxia - chest pain - constipation - diaphoresis - dysphagia - flatulence - hand tremor - hoarseness - hypersalivation - hypertension - malaise - muscle cramps - oedema - reddish discoloration of the urine and other body fluids - weakness - weight changes
- Very rare Angle-closure glaucoma - suicidal ideation
- Frequency not known Compulsive behaviour
Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg

Madopar 100mg/25mg capsules | 100 capsule £6.91
DT price = £6.91

Benserazide (as Benserazide hydrochloride) 50 mg, Levodopa 200 mg
Madopar 200mg/50mg capsules | 100 capsule £11.78
DT price = £11.78

Co-careldopa

INDICATIONS AND DOSE
Parkinson’s disease
BY MOUTH
Adult: Initially 25/100 mg 3 times a day, then increased in steps of 12.5/50 mg once daily or on alternate days, adjusted according to response, alternatively increased in steps of 25/100 mg once daily or on alternate days, adjusted according to response; dose increased until 800 mg levodopa (with 200 mg carbidopa) daily in divided doses is reached, then maintenance up to 200/2000 mg daily in divided doses, adjusted according to response, when co-careldopa is used, the total daily dose of carbidopa should be at least 70 mg. A lower dose may not achieve full inhibition of extracerebral dopa-decarboxylase, with a resultant increase in side-effects.

Parkinson’s disease—alternative regimen
BY MOUTH
Adult: Initially 12.5/50 mg 3–4 times a day, alternatively initially 10/100 mg 3–4 times a day, then increased in steps of 12.5/50 mg once daily or on alternate days, adjusted according to response, alternatively increased in steps of 10/100 mg once daily or on alternate days, adjusted according to response; dose increased until 500 mg levodopa (with up to 200 mg carbidopa) daily in divided doses is reached, then maintenance up to 200/2000 mg daily in divided doses, adjusted according to response, when co-careldopa is used, the total daily dose of carbidopa should be at least 70 mg. A lower dose may not achieve full inhibition of extracerebral dopa-decarboxylase, with a resultant increase in side-effects.

Dose equivalence and conversion
The proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively.

CARAMET® CR
Parkinson’s disease (patients not receiving levodopa/dopa-decarboxylase inhibitor preparations, expressed as levodopa)

BY MOUTH USING MODIFIED-RELEASE TABLETS
Adult: Initially 100–200 mg twice daily, dose to be given at least 6 hours apart; dose adjusted according to response at intervals of at least 2 days

Parkinson’s disease (patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations)

BY MOUTH USING MODIFIED-RELEASE TABLETS
Adult: Discontinue previous preparation at least 12 hours before first dose of Caramet® CR; substitute Caramet® CR to provide a similar amount of levodopa daily and extend dosing interval by 30–50%; dose then adjusted according to response at intervals of at least 2 days. continued

Benserazide (as Benserazide hydrochloride) 12.5 mg, Levodopa 50 mg
Madopar 50mg/12.5mg capsules | 100 capsule £4.96
DT price = £4.96

Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg
Madopar 100mg/25mg capsules | 100 capsule £6.91
DT price = £6.91

Benserazide (as Benserazide hydrochloride) 50 mg, Levodopa 200 mg
Madopar 200mg/50mg capsules | 100 capsule £11.78
DT price = £11.78

Modified-release capsule
CAUTIONARY AND ADVISORY LABELS 5, 10, 14, 25

Madopar CR (Roche Products Ltd)

Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg
Madopar CR capsules | 100 capsule £12.77 DT price = £12.77

Nervous system

PATIENT AND CARER ADVICE
Sudden onset of sleep Excessive daytime sleepiness and sudden onset of sleep can occur with co-beneldopa. Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour. Patients or carers should be given advice on how to administer co-beneldopa dispersible tablets.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution and dispersible tablet.

Dispersible tablet
CAUTIONARY AND ADVISORY LABELS 10, 14, 21

Madopar (Roche Products Ltd)

Benserazide (as Benserazide hydrochloride) 12.5 mg, Levodopa 50 mg
Madopar 50mg/12.5mg dispersible tablets (sugar-free) | 100 tablet £5.90 DT price = £5.90

Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg
Madopar 100mg/25mg dispersible tablets (sugar-free) | 100 tablet £10.45 DT price = £10.45

Capsule
CAUTIONARY AND ADVISORY LABELS 10, 14, 21

CO-BENELDOPA (Non-proprietary)

Benserazide (as Benserazide hydrochloride) 12.5 mg, Levodopa 50 mg
Co-beneldopa 12.5mg/50mg capsules | 100 capsule £4.71–£4.96 DT price = £4.96

Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg
Co-beneldopa 25mg/100mg capsules | 100 capsule £5.56–£5.91 DT price = £5.91

Benserazide (as Benserazide hydrochloride) 50 mg, Levodopa 200 mg
Co-beneldopa 50mg/200mg capsules | 100 capsule £11.19–£11.78 DT price = £11.78

Madopar (Roche Products Ltd)

Benserazide (as Benserazide hydrochloride) 12.5 mg, Levodopa 50 mg
Madopar 50mg/12.5mg capsules | 100 capsule £4.96 DT price = £4.96

Co-careldopa
**SINEMET® CR**

Parkinson's disease (patients not receiving levodopa/dopa-decarboxylase inhibitor therapy)

**BY MOUTH**
- **Adult:** Initially 1 tablet twice daily, both dose and interval then adjusted according to response at intervals of not less than 3 days

Parkinson's disease (patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations)

**BY MOUTH**
- **Adult:** 1 tablet twice daily, dose can be substituted for a daily dose of levodopa 300–400 mg in immediate-release Sinemet® tablets (substitute Sinemet® CR to provide approximately 10% more levodopa per day and extend dosing interval by 30–50%); dose and interval then adjusted according to response at intervals of not less than 3 days.

**HALF SINEMET® CR**

Parkinson's disease (for fine adjustment of Sinemet® CR dose)

**BY MOUTH**
- **Adult:** (consult product literature)

**DUPODA®**

Severe Parkinson's disease inadequately controlled by other preparations

- **Adult:** Administered as intestinal gel, for use with enteral tube (consult product literature)

---

**Important safety information**

**IMPULSE CONTROL DISORDERS**

Treatment with levodopa is associated with impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.

- **CAUTIONS** Cushing's syndrome · diabetes mellitus · endocrine disorders · history of convulsions · history of myocardial infarction with residual arrhythmia · history of peptic ulcer · hyperthyroidism · osteomalacia · phaeochromocytoma · psychiatric illness (avoid if severe and discontinue if deterioration) · severe cardiovascular disease · severe pulmonary disease · susceptibility to angle-closure glaucoma

- **INTERACTIONS** → Appendix 1 (co-careldopa, levodopa).

- **SIDE-EFFECTS**
  
  - **Common or very common** Abnormal dreams · anorexia · anxiety · arthralgia · chorea · confusion · dementia · depression · dizziness · drowsiness · dry mouth · dyskinesia · dystonia · euphoria · fatigue · insomnia · nausea · palpitations · postural hypotension · psychosis · syncope · taste disturbances · vomiting
  
  - **Uncommon** Ataxia · chest pain · constipation · diarrhoea · dysphagia · flatulence · hand tremor · hoarseness · hypersalivation · hypertension · malaise · muscle cramps · oedema · reddish discoloration of the urine and other body fluids · weakness · weight changes
  
  - **Rare** Abdominal pain · activation of Horner's syndrome · activation of malignant melanoma · agitation · agranulocytosis · alopecia · blepharospasm · blurred vision · bruxism · convulsions · diplopia · disorientation · duodenal ulcer · dyspepsia · dyspnoea · exanthema · flushing · gastro-intestinal bleeding · haemolytic anaemia · headache · Henoch-Schönlein purpura · hiccups · leucopenia · neurological malignant syndrome (associated with abrupt withdrawal) · non-haemolytic anaemia · ocular crisis · paraesthesia · phlebitis · priapism · pupil dilatation · reduced mental acuity · sweating · thrombocytopenia · trismus · urinary incontinence · urinary retention
  
  - **Very rare** Angle-closure glaucoma · suicidal ideation
  
  - **Frequency not known** Compulsive behaviour
  
  - **PREGNANCY** Use with caution—toxicity has occurred in animal studies.
  
  - **BREAST FEEDING** May suppress lactation; present in milk—avoid
  
  - **HEPATIC IMPAIRMENT** Use with caution.
  
  - **RENAL IMPAIRMENT** Use with caution.
  
  - **EFFECT ON LABORATORY TESTS** False positive tests for urinary ketones have been reported.

- **TREATMENT CESSATION** Avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis).

- **PREscribing and dispensing information** Co-careldopa is a mixture of carbidopa and levodopa; the proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively. When transferring patients from another levodopa/dopa-decarboxylase inhibitor preparation, the previous preparation should be discontinued at least 12 hours before.

  Co-careldopa 25/100 provides an adequate dose of carbidopa when low doses of levodopa are needed. 2 tablets Sinemet® 12.5 mg/50 mg → 1 tablet Sinemet® Plus 25 mg/100 mg.

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 10, 14**

- **CO-CARELDOPA (Non-proprietary)**
  
  - Carbidopa (as Carbidopa monohydrate) 10 mg, Levodopa 100 mg Co-careldopa 10mg/100mg tablets | 100 tablet [P] | £10.25 DT price = £7.30
  
  - Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 100 mg Co-careldopa 25mg/100mg tablets | 100 tablet [P] | £26.99 DT price = £15.83
  
  - Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 250 mg Co-careldopa 25mg/250mg tablets | 100 tablet [P] | £35.00 DT price = £34.91
  
  - Sinemet (Merrick Sharp & Dohme Ltd)
  
  - Carbidopa (as Carbidopa monohydrate) 12.5 mg, Levodopa 50 mg Sinemet 12.5mg/50mg tablets | 90 tablet [P] | £6.28 DT price = £6.28
  
  - Carbidopa (as Carbidopa monohydrate) 10 mg, Levodopa 100 mg Sinemet 10mg/100mg tablets | 100 tablet [P] | £7.30 DT price = £7.30
  
  - Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 250 mg Sinemet 25mg/250mg tablets | 100 tablet [P] | £18.29 DT price = £14.91
  
  - Sinemet Plus (Merrick Sharp & Dohme Ltd)
  
  - Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 100 mg Sinemet Plus 25mg/100mg tablets | 100 tablet [P] | £12.88 DT price = £15.83

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 10, 14, 25**

- **CO-CARELDOPA (Non-proprietary)**
  
  - Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 100 mg Co-careldopa 25mg/100mg modified-release tablets | 50 tablet [P] | no price available | 60 tablet [P] no price available
  
  - Carbidopa (as Carbidopa monohydrate) 50 mg, Levodopa 200 mg Co-careldopa 50mg/200mg modified-release tablets | 60 tablet [P] | no price available
  
  - Caramet CR (Teva UK Ltd)
  
  - Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 100 mg Caramet 25mg/100mg CR tablets | 60 tablet [P] | £11.47
  
  - Carbidopa (as Carbidopa monohydrate) 50 mg, Levodopa 200 mg Caramet 50mg/200mg CR tablets | 60 tablet [P] | £11.47

Carbidopa with entacapone and levodopa

The properties listed below are those particular to the combination only. For the properties of the components please consider, entacapone p. 327, co-careldopa p. 329.

**INDICATIONS AND DOSE**

**STALEVO® 75/18.75/200**
Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**BY MOUTH**

- Adult: 1 tablet for each dose; maximum 10 tablets per day

**STALEVO® 50/12.5/200**
Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**BY MOUTH**

- Adult: 1 tablet for each dose; maximum 10 tablets per day

**STALEVO® 150/37.5/200**
Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**BY MOUTH**

- Adult: 1 tablet for each dose; maximum 10 tablets per day

**STALEVO® 200/50/200**
Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**BY MOUTH**

- Adult: 1 tablet for each dose; maximum 7 tablets per day

**STALEVO® 125/31.25/200**
Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**BY MOUTH**

- Adult: 1 tablet for each dose; maximum 10 tablets per day

**STALEVO® 175/43.75/200**
Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**BY MOUTH**

- Adult: 1 tablet for each dose; maximum 8 tablets per day

**STALEVO® 100/25/200**
Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**BY MOUTH**

- Adult: 1 tablet for each dose; maximum 10 tablets per day

**PRESCRIBING AND DISPENSING INFORMATION**

Patients receiving standard-release co-careldopa or co-beneldopa alone, initiate Stalevo® at a dose that provides similar (or slightly lower) amount of levodopa. Patients with dyskinesia or receiving more than 800 mg levodopa daily, introduce entacapone before transferring to Stalevo® (levodopa dose may need to be reduced by 10–30% initially). Patients receiving entacapone and standard-release co-careldopa or co-beneldopa, initiate Stalevo® at a dose that provides similar (or slightly higher) amount of levodopa.

**PATIENT AND CARER ADVICE**

**Sudden onset of sleep**
Excessive daytime sleepiness and sudden onset of sleep can occur with Stalevo®.

Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- 10, 14
- 1/4

**Stalevo®**
(Orion Pharma (UK) Ltd)

- Carbidopa 37.5 mg, Entacapone 200 mg, Levodopa 150 mg

  - Tablet for each dose; maximum 30 tablets per day

- Carbidopa 175 mg, Entacapone 200 mg, Levodopa 75 mg

  - Tablet for each dose; maximum 30 tablets per day

- Carbidopa 50 mg, Entacapone 200 mg, Levodopa 200 mg

  - Tablet for each dose; maximum 100 tablets per day

- Carbidopa 175 mg, Entacapone 200 mg, Levodopa 175 mg

  - Tablet for each dose; maximum 100 tablets per day

- Carbidopa 31.25 mg, Entacapone 200 mg, Levodopa 125 mg

  - Tablet for each dose; maximum 100 tablets per day

- Carbidopa 12.5 mg, Entacapone 200 mg, Levodopa 50 mg

  - Tablet for each dose; maximum 100 tablets per day

- Carbidopa 25 mg, Entacapone 200 mg, Levodopa 100 mg

  - Tablet for each dose; maximum 100 tablets per day

**DOPAMINE RECEPTOR AGONISTS**

**Amantadine hydrochloride**

**DRUG ACTION**
Amantadine is a weak dopamine agonist with modest antiparkinsonian effects.
 Oral solution
- AMANTADINE HYDROCHLORIDE (Non-proprietary)
  Amantadine hydrochloride 10 mg per 1 ml
  Oral solution sugar free (sugar-free) 150 ml
  Pod: £89.30–£117.20
  DT price = £101.25

Apomorphine hydrochloride

INDICATIONS AND DOSE
Refractory motor fluctuations in Parkinson’s disease (‘off’ episodes) inadequately controlled by co-beneldopa or co-carbidopa or other dopaminergics (in patients requiring division into more than 10 injections daily) (under expert supervision)

BY CONTINUOUS SUBCUTANEOUS INFUSION
- Adult: Initially 1 mg/hour, adjusted according to response, then increased in steps of up to 500 micrograms/hour, dose to be increased at intervals not more often than every 4 hours; usual dose 1–4 mg/hour, alternatively usual dose 15–60 micrograms/kg/hour, change infusion site every 12 hours and give during waking hours only (tolerance may occur unless there is a 4-hour treatment-free period at night—24-hour infusions not recommended unless severe night time symptoms); intermittent bolus doses may be needed; maximum 100 mg per day

Important safety information
IMPULSE CONTROL DISORDERS
Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.

CONTRA-INDICATIONS
Avoid if ‘on’ response to levodopa marred by severe dyskinesia or dystonia • dementia • psychosis • respiratory depression

CAUTIONS
Cardiovascular disease • history of postural hypotension (special care on initiation) • neuropsychiatric conditions • pulmonary disease • susceptibility to QT-interval prolongation

INTERACTIONS
- Appendix 1 (apomorphine).

SIDE-EFFECTS
- Common or very common Confusion • drowsiness • hallucinations • nausea • sudden onset of sleep • vomiting • yawning
Solution for infusion

CAUTIONARY AND ADVISORY LABELS 10

EXCIPIENTS: May contain Sulphites

APO-go PF5 (Britannia Pharmaceuticals Ltd)

Apomorphine hydrochloride 5 mg per 1 ml
APO-go PF5
50mg/10ml solution for infusion pre-filled syringes | 5 pre-filled disposable injection £73.11

Bromocriptine

• DRUG ACTION Bromocriptine is a stimulant of dopamine receptors in the brain; it also inhibits release of prolactin by the pituitary.

INDICATIONS AND DOSE

Prevention of lactation
BY MOUTH
• Adult: Initially 2.5 mg daily for 1 day, then 2.5 mg twice daily for 14 days

Suppression of lactation
BY MOUTH
• Adult: Initially 2.5 mg daily for 2–3 days, then 2.5 mg twice daily for 14 days

Hypogonadism | Galactorrhoea | Infertility
BY MOUTH
• Adult: Initially 1–1.25 mg daily, dose to be taken at bedtime, increase dose gradually; usual dose 7.5 mg daily in divided doses, increased if necessary up to 30 mg daily, usual dose in infertility without hyperprolactinaemia is 2.5 mg twice daily

Acromegaly
BY MOUTH
• Adult: Initially 1–1.25 mg daily, dose to be taken at bedtime, then increased to 5 mg every 6 hours, increase dose gradually

Prolactinoma
BY MOUTH
• Adult: Initially 1–1.25 mg daily, dose to be taken at bedtime, then increased to 5 mg every 6 hours, increase dose gradually. Occasionally patients may require up to 30 mg daily

Parkinson's disease
BY MOUTH
• Adult: Initially 1–1.25 mg daily for 1 week, dose to be taken at night, then 2–2.5 mg daily for 1 week, dose to be taken at night, then 2.5 mg twice daily for 1 week, then 2.5 mg 3 times a day for 1 week, then increased in steps of 2.5 mg every 3–14 days, adjusted according to response; maintenance 10–30 mg daily

Important safety information

FIBROTIC REACTIONS
Bromocriptine has been associated with pulmonary, retropertitoneal, and pericardial fibrotic reactions. Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for Parkinson's disease or chronic endocrine disorders (excludes suppression of lactation); it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful.

IMPULSE CONTROL DISORDERS
Treatment with dopamine-receptor agonists are associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders.
There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

- **CONTRA-INDICATIONS** Avoid in pre-eclampsia, cardiac valvulopathy (exclude before treatment), hypertension in postpartum women, or in puерperium.

**CONTRA-INDICATIONS, FURTHER INFORMATION**

Postpartum or puërperium: Should not be used postpartum or in puërperium in women with high blood pressure, coronary artery disease, or symptoms (or history) of serious mental disorder; monitor blood pressure carefully (especially during first few days) in postpartum women. Very rarely hypertension, myocardial infarction, seizures or stroke (both sometimes preceded by severe headache or visual disturbances), and mental disorders have been reported in postpartum women given bromocriptine for lactation suppression—caution with antihypertensive therapy and avoid other ergot alkaloids. Discontinue immediately if hypertension, unrelenting headache, or oedema.

- **CAUTIONS** Acute porphyrias p. 864; cardiovascular disease; history of peptic ulcer (particularly in acromegalic patients); history of serious mental disorders (especially psychotic disorders) - Raynaud’s syndrome.

**CAUTIONS, FURTHER INFORMATION**

Hyperprolactinemic patients: In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment).

- **INTERACTIONS** Appendix 1 (bromocriptine).

Tolerance may be reduced by alcohol.

- **SIDE-EFFECTS**
  - Common or very common: Constipation, headache, nasal congestion, nausea.
  - Uncommon: Confusion (particularly with high doses), dizziness, dry mouth, fatigue, hallucinations (particularly with high doses), postural hypotension, psychomotor excitation (particularly with high doses), vomiting.
  - Rare: Abdominal pain, arrhythmia, bradycardia, diarrhoea, gastric ulcer, gastrointestinal bleeding, insomnia, paraesthesia, psychosis, tachycardia, tinnitus, visual disturbances.
  - Very rare: Neuroleptic malignant syndrome on withdrawal, vasospasm of fingers and toes (particularly in patients with Raynaud’s syndrome).

- **Frequency not known**
  - Allergic skin reactions, alopecia, cardiomyopathy, constriuctive pericarditis, drowsiness, dyskinesia, dyspnoea, hypotension, increased libido, leg cramps, leucopenia, pathological gambling, pericardial effusion, peripheral oedema, pleural effusion, pleural fibrosis, pleuritis, pulmonary fibrosis, retroperitoneal fibrosis, reversible hearing loss, thrombocytopenia, urinary incontinence.

- **SIDE-EFFECTS, FURTHER INFORMATION**

**Gastro-intestinal bleeding** Treatment should be withdrawn if gastro-intestinal bleeding occurs.

- **ALLERGY AND CROSS-SENSITIVITY** Bromocriptine should not be used in patients with hypersensitivity to ergot alkaloids.

- **CONCEPTION AND CONTRACEPTION** Caution—provide contraceptive advice if appropriate (oral contraceptives may increase prolactin concentration).

- **BREAST FEEDING** Suppresses lactation; avoid breast feeding for about 5 days if lactation prevention fails.

- **HEPATIC IMPAIRMENT** Dose reduction may be necessary.

- **MONITORING REQUIREMENTS**
  - Specialist evaluation—monitor for pituitary enlargement, particularly during pregnancy; monitor visual field to detect secondary field loss in macroprolactinoma.
  - Monitor for fibrotic disease.
  - Monitor blood pressure for a few days after starting treatment and following dosage increase.

- **TREATMENT CESSATION** Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

- **PATIENT AND CARER ADVICE**

**Sudden onset of sleep** Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.

Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions** Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 10, 21</th>
<th>BROMOCRIPTINE (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bromocriptine (as Bromocriptine mesilate) 1 mg</td>
<td>Bromocriptine 1mg tablets</td>
</tr>
<tr>
<td>Bromocriptine (as Bromocriptine mesilate) 2.5 mg</td>
<td>Bromocriptine 2.5mg tablets</td>
</tr>
<tr>
<td>Bromocriptine (as Bromocriptine mesilate) 5 mg</td>
<td>Bromocriptine 5mg capsules</td>
</tr>
<tr>
<td>Parlodol (Meda Pharmaceuticals Ltd)</td>
<td>Parlodol 5mg</td>
</tr>
<tr>
<td>Parlodol (Meda Pharmaceuticals Ltd)</td>
<td>Parlodol 10mg</td>
</tr>
</tbody>
</table>

**Cabergoline**

- **DRUG ACTION** Cabergoline is a stimulant of dopamine receptors in the brain and it also inhibits release of prolactin by the pituitary.

**INDICATIONS AND DOSE**

**Prevention of lactation**

- Adult: 1 mg, to be taken as a single dose on the first day postpartum.

**Suppression of established lactation**

- Adult: 250 micrograms every 12 hours for 2 days.

**Hyperprolactinaemic disorders**

- Adult: Initially 500 micrograms once weekly, dose may be taken as a single dose or as 2 divided doses on
Cabergoline has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions. Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for Parkinson’s disease or chronic endocrine disorders (excludes suppression of lactation); it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking cabergoline should be regularly monitored for cardiac fibrosis by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).

**IMPALE CONTROL DISORDERS**

Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

**CONTRA-INDICATIONS**

Avoid in pre-eclampsia - cardiac valvulopathy (excludes before treatment) - history of periarterial fibrotic disorders - history of puerperal disease - history of serious mental disorders - operating machinery.

**INTERACTIONS**

Appendix 1 (cabergoline). Tolerance may be reduced by alcohol.

**SIDE-EFFECTS**

Abdominal pain - angina - breast pain - confusion - constipation - depression - dyspepsia - epigastric pain - gastritis - hallucinations - headache - nausea - syncope

**Caution**

- Digital vasospasm.
- Epistaxis.
- Hot flushes.
- Muscle weakness.
- Palpitation.
- Paraesthesia.
- Transient hemianopia.
- Vomiting.

**Frequency not known**

- Allergic skin reactions.
- Alopecia.
- Angioedema.
- Cardiac valvulopathy.
- Constrictive pericarditis.
- Drowsiness.
- Dyskinesia.
- Erythromelalgia.
- Hypersexuality.
- Hypertension.
- Increased libido.
- Leg cramps.
- Pathological gambling.
- Pericardial effusion.
- Peripheral oedema.
- Pleural effusion.
- Pleural fibrosis.
- Pleuritis.
- Pulmonary fibrosis.
- Retropertitoneal fibrosis.

**Gastro-intestinal bleeding**

Treatment should be withdrawn if gastro-intestinal bleeding occurs.

**ALLERGY AND CROSS-SENSITIVITY**

Cabergoline should not be used in patients with hypersensitivity to ergot alkaloids.

**CONCEPTION AND CONTRACEPTION**

Exclude pregnancy before starting and perform monthly pregnancy tests during the amenorrhoeic period. Caution—advise non-hormonal contraception if pregnancy not desired. Discontinue 1 month before intended conception (ovulatory cycles persist for 6 months).

**PREGNANCY**

Discontinue if pregnancy occurs during treatment (specialist advice needed).

**BREAST FEEDING**

Suppresses lactation; avoid breast-feeding if lactation prevention fails.

**HEPATIC IMPAIRMENT**

Reduce dose in severe hepatic impairment.

**MONITORING REQUIREMENTS**

- Monitor for fibrotic disease.
- Monitor blood pressure for a few days after starting treatment and following dosage increase.

**TREATMENT CESSATION**

Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

**PRESCRIBING AND DISPENSING INFORMATION**

Dispense in original container (contains desiccant).

**PATIENT AND CARER ADVICE**

Sudden onset of sleep

Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists. Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring. Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions**

Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CABERGOLINE (Non-proprietary)</th>
<th>Cabergoline 500 microgram</th>
<th>Cabergoline 500microgram tablets</th>
<th>8 tablet</th>
<th>P49</th>
<th>£34.99</th>
<th>DT price = £34.89</th>
</tr>
</thead>
<tbody>
<tr>
<td>CABERGOLINE (Non-proprietary)</td>
<td>Cabergoline 1 mg</td>
<td>Cabergoline 1mg tablets</td>
<td>20 tablet</td>
<td>P45</td>
<td>£66.00</td>
<td>DT price = £66.25</td>
</tr>
<tr>
<td>CABERGOLINE (Non-proprietary)</td>
<td>Cabergoline 2 mg</td>
<td>Cabergoline 2mg tablets</td>
<td>20 tablet</td>
<td>P45</td>
<td>£73.14</td>
<td>DT price = £72.94</td>
</tr>
</tbody>
</table>
Nervous system

CONTRA-INDICATIONS
Other than ergot derivative not appropriate

Adult:
BY MOUTH

★ Cabaser (Pfizer Ltd)
Cabergoline 1 mg Cabaser 1mg tablets | 20 tablet [PA] £83.00 DT price = £64.25
Cabergoline 2 mg Cabaser 2mg tablets | 20 tablet [PA] £83.00 DT price = £72.94
★ Dostinex (Pfizer Ltd)
Cabergoline 500 microgram Dostinex 500microgram tablets | 8 tablet [PA] £30.04 DT price = £34.89

Pergolide

INDICATIONS AND DOSE
Monotherapy in Parkinson’s disease where dopamine-receptor agonists other than ergot derivative not appropriate
BY MOUTH
Adult: Initially 50 micrograms once daily for day 1, dose to be taken at bedtime, then 50 micrograms twice daily for days 2–4, then increased in steps of 100–250 micrograms daily, dose to be increased at intervals of 3–4 days, increased to 1.5 mg daily in 3 divided doses at day 28, then increased in steps of up to 250 micrograms every 3–4 days, this increase to be started after day 30; maintenance 2.1–2.5 mg daily; maximum 3 mg per day

Adjunctive therapy with co-beneldopa or co-careldopa in Parkinson’s disease where dopamine-receptor agonists other than ergot derivative not appropriate
BY MOUTH
Adult: Initially 50 micrograms daily for 2 days, then increased in steps of 100–150 micrograms every 3 days, dose to be adjusted over next 12 days following initial dose and usually given in 3 divided doses, then increased in steps of 250 micrograms every 3 days, during pergolide titration, levodopa dose may be reduced cautiously; maximum 3 mg per day

Important safety information
FIBROTIC REACTIONS
Pergolide has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions. Exclude cardiac valvulopathy with echocardiography before starting treatment with pergolide; it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking pergolide should be regularly monitored for cardiac fibrosis by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).

UNCONTROLLED HYPERPLASIA
Treatment with dopamine-receptor agonists is associated with uncontrolled hyperplasia, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of uncontrolled hyperplasia. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause uncontrolled hyperplasia, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an uncontrolled hyperplasia, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.

CONTRA-INDICATIONS
Cardiac valvulopathy (exclude before treatment) - history of fibrotic disorders

★ CAUTIONS
Acute porphyrias p. 864 - arrhythmias - dyskinesia (may exacerbate) - hallucinations - history of confusion - psychosis - underlying cardiac disease

★ INTERACTIONS
→ Appendix 1 (pergolide).

★ SIDE-EFFECTS

★ PREGNANCY
Use only if potential benefit outweighs risk.

★ BREAST FEEDING
May suppress lactation.

★ TREATMENT CESSATION
Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

★ PATIENT AND CARER ADVICE
Sudden onset of sleep
Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists. Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

Hypotensive reactions
Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

★ MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 10

★ PERGOLIDE (Non-proprietary)
Pergolide (as Pergolide mesilate) 50 microgram Pergolide 50microgram tablets | 100 tablet [PA] £35.00 DT price = £32.66
Pergolide (as Pergolide mesilate) 250 microgram Pergolide 250microgram tablets | 100 tablet [PA] £35.00–£36.00 DT price = £35.92
Pergolide (as Pergolide mesilate) 1 mg Pergolide 1mg tablets | 100 tablet [PA] £125.00–£140.00 DT price = £131.66

Pramipexole

INDICATIONS AND DOSE
Parkinson’s disease, used alone or as an adjunct to co-beneldopa or co-careldopa
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
Adult: Initially 88 micrograms 3 times a day, increased if tolerated to 350 micrograms 3 times a day, dose to be increased by doubling dose every 5–7 days, then increased in steps of 180 micrograms 3 times a day if required, dose to be increased at weekly intervals, during dose titration and maintenance, levodopa dose may be reduced, maximum daily dose to be given in 3 divided doses; maximum 3.3 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES
Adult: Initially 260 micrograms once daily, increased to 1.05 mg once daily, dose to be increased by doubling dose every 5–7 days, then increased in steps of 520 micrograms every 1 week if required, during dose titration and maintenance, levodopa dose may be reduced according to response; maximum 3.15 mg per day
Restless legs syndrome

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: Initially 88 micrograms once daily, dose to be taken 2–3 hours before bedtime, dose to be increased by doubling dose every 4–7 days, repeat dose titration if restarting treatment after an interval of more than a few days; maximum 540 micrograms per day

Dose equivalence and conversion

Doses and strengths are stated in terms of pramipexole (base).

Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for immediate-release preparations are as follows:

- 88 micrograms base = 125 micrograms salt;
- 180 micrograms base = 250 micrograms salt;
- 350 micrograms base = 500 micrograms salt;
- 700 micrograms base = 1 mg salt.

Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for modified-release preparations are as follows:

- 260 micrograms base = 375 micrograms salt;
- 520 micrograms base = 750 micrograms salt;
- 1.05 mg base = 1.5 mg salt;
- 1.57 mg base = 2.25 mg salt;
- 2.1 mg base = 3 mg salt;
- 2.62 mg base = 3.75 mg salt;
- 3.15 mg base = 4.5 mg salt.

Important safety information

IMPULSE CONTROL DISORDERS

Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

- CAUTIONS Psychotic disorders • risk of visual disorders (ophthalmological testing recommended) • severe cardiovascular disease
- INTERACTIONS Appendix 1 (pramipexole).
- SIDE-EFFECTS
  - Common or very common Confusion • constipation • decreased appetite • dizziness • drowsiness • dyskinesia • hallucinations • headache • hyperkinesia • hypotension • nausea • peripheral oedema • postural hypotension • restlessness • sleep disturbances • sudden onset of sleep • visual disturbances • vomiting • weight changes
  - Uncommon Anorexia • binge eating • cardiac failure • compulsive behaviour • delusion • dysphoria • hiccup • paranoia • pneumonia • pruritus • rash • syncope
  - Frequency not known Paradoxical worsening of restless legs syndrome
- PREGNANCY Use only if potential benefit outweighs risk—no information available.
- BREAST FEEDING May suppress lactation; avoid—present in milk in animal studies.
- RENAL IMPAIRMENT For immediate-release tablets in Parkinson’s disease, initially 88 micrograms twice daily (max. 1.57 mg daily in 2 divided doses) if eGFR 20–50 mL/minute/1.73 m²; initially 88 micrograms once daily (max. 1.1 mg once daily) if eGFR less than 20 mL/minute/1.73 m². If renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR. For immediate-release tablets, reduce dose if eGFR less than 20 mL/minute/1.73 m². For modified-release tablets, initially 260 micrograms on alternate days if eGFR 30–50 mL/minute/1.73 m², increased to 250 micrograms once daily after 1 week, further increased if necessary by 260 micrograms daily at weekly intervals to max. 1.57 mg daily. For modified-release tablets, avoid if eGFR less than 30 mL/minute/1.73 m².

MONITORING REQUIREMENTS Risk of postural hypotension (especially on initiation)—monitor blood pressure.

TREATMENT CESSATION Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

PATIENT AND CARER ADVICE

- Sudden onset of sleep Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists. Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

- Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

Hypotensive reactions Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 10

- PRAMIPEXOLE (Non-proprietary)
  - Pramipexole (as Pramipexole dihydrochloride monohydrate) 88 microgram Pramipexole 88microgram tablets | 30 tablet | £9.54 DT price = £2.28
  - Pramipexole (as Pramipexole dihydrochloride monohydrate) 180 microgram Pramipexole 180microgram tablets | 30 tablet | £17.19 DT price = £1.77 | 100 tablet | £19.09
  - Pramipexole (as Pramipexole dihydrochloride monohydrate) 350 microgram Pramipexole 350microgram tablets | 30 tablet | £38.20 DT price = £3.46 | 100 tablet | £45.53
  - Pramipexole (as Pramipexole dihydrochloride monohydrate) 700 microgram Pramipexole 700microgram tablets | 30 tablet | £76.40 DT price = £2.75 | 100 tablet | £254.69
  - Mirapexin (Boehringer Ingelheim Ltd)
    - Pramipexole (as Pramipexole dihydrochloride monohydrate) 88 microgram Mirapexin 0.088mg tablets | 30 tablet | £11.24 DT price = £2.28
    - Pramipexole (as Pramipexole dihydrochloride monohydrate) 180 microgram Mirapexin 0.18mg tablets | 30 tablet | £22.49 DT price = £1.77 | 100 tablet | £74.95
    - Pramipexole (as Pramipexole dihydrochloride monohydrate) 350 microgram Mirapexin 0.35mg tablets | 30 tablet | £44.97 DT price = £13.46 | 100 tablet | £149.30
    - Pramipexole (as Pramipexole dihydrochloride monohydrate) 700 microgram Mirapexin 0.7mg tablets | 30 tablet | £89.94 DT price = £2.75 | 100 tablet | £299.82

- Brands may include Opryme

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 10, 25

- PRAMIPEXOLE (Non-proprietary)
  - Pramipexole (as Pramipexole dihydrochloride monohydrate) 260 microgram Pramipexole 260microgram modified-release tablets | 30 tablet | £30.87–£32.49 DT price = £32.49
Pramipexole (as Pramipexole dihydrochloride monohydrate) 520 microgram Pramipexole 520microgram modified-release tablets | 30 tablet | £61.73–£64.98 DT price = £64.98
Pramipexole (as Pramipexole dihydrochloride monohydrate) 1.05 mg Pramipexole 1.05mg modified-release tablets | 30 tablet | £123.46–£129.96 DT price = £129.96
Pramipexole (as Pramipexole dihydrochloride monohydrate) 1.57 mg Pramipexole 1.57mg modified-release tablets | 30 tablet | £123.46–£129.96 DT price = £129.96
Pramipexole (as Pramipexole dihydrochloride monohydrate) 2.1 mg Pramipexole 2.1mg modified-release tablets | 30 tablet | £129.96 DT price = £129.96
Pramipexole (as Pramipexole dihydrochloride monohydrate) 2.62 mg Pramipexole 2.62mg modified-release tablets | 30 tablet | £137.27 DT price = £137.27
Pramipexole (as Pramipexole dihydrochloride monohydrate) 3.15 mg Pramipexole 3.15mg modified-release tablets | 30 tablet | £137.27–£389.87 DT price = £389.87
- Mirapexin (Boehringer Ingelheim Ltd)
Pramipexole (as Pramipexole dihydrochloride monohydrate) 260 microgram Mirapexin 0.26mg modified-release tablets | 30 tablet | £32.49 DT price = £32.49
Pramipexole (as Pramipexole dihydrochloride monohydrate) 520 microgram Mirapexin 0.52mg modified-release tablets | 30 tablet | £64.98 DT price = £64.98
Pramipexole (as Pramipexole dihydrochloride monohydrate) 1.05 mg Mirapexin 1.05mg modified-release tablets | 30 tablet | £129.96 DT price = £129.96
Pramipexole (as Pramipexole dihydrochloride monohydrate) 1.57 mg Mirapexin 1.57mg modified-release tablets | 30 tablet | £202.36 DT price = £202.36
Pramipexole (as Pramipexole dihydrochloride monohydrate) 2.1 mg Mirapexin 2.1mg modified-release tablets | 30 tablet | £202.36 DT price = £202.36
Pramipexole (as Pramipexole dihydrochloride monohydrate) 2.62 mg Mirapexin 2.62mg modified-release tablets | 30 tablet | £237.27 DT price = £237.27
Pramipexole (as Pramipexole dihydrochloride monohydrate) 3.15 mg Mirapexin 3.15mg modified-release tablets | 30 tablet | £389.87 DT price = £389.87
- Brands may include Opyrme

in patients over 75 years, when administered as adjunct to levodopa, concurrent dose of levodopa may gradually be reduced by approx. 30%, if treatment interrupted for 1 day or more, consider re-initiation with immediate-release tablets

Moderate to severe restless legs syndrome
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 250 micrograms once daily for 2 days, increased if tolerated to 500 micrograms once daily for 5 days, then increased if tolerated to 1 mg once daily for 7 days, then increased in steps of 500 micrograms daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 2 mg once daily, doses to be taken at night, repeat dose titration if restarting after interval of more than a few days; maximum 4 mg per day

Dose adjustments due to interactions
Dose adjustment may be necessary if smoking started or stopped during treatment.

UNLICENSED USE Doses in the BNF may differ from those in product literature.

Important safety information
IMPULSE CONTROL DISORDERS
Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

CAUTIONS Elderly - major psychiatric disorders - severe cardiovascular disease (risk of hypotension—monitor blood pressure)

INTERACTIONS Appendix 1 (ropinirole).

SIDE-EFFECTS
- Common or very common Abdominal pain, confusion, constipation, dizziness, drowsiness, dyskinesia, dyspepsia, fatigue, gastro-esophageal reflux disease, hallucinations, hypotension, nausea, nervousness, peripheral oedema, sudden onset of sleep - syncope - vomiting
- Uncommon Compulsive behaviour - psychosis
- Very rare Hepatic disorders
- Frequency not known Paradoxical worsening of restless legs syndrome

PREGNANCY Avoid unless potential benefit outweighs risk—toxicity in animal studies.

BREAST FEEDING May suppress lactation—avoid.

HEPATIC IMPAIRMENT Avoid—no information available.

RENAL IMPAIRMENT Avoid if eGFR less than 30 mL/minute/1.73 m².

TREATMENT CESSATION Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

PATIENT AND CARER ADVICE

Sudden onset of sleep Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists. Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep...
sleep should refrain from driving or operating machines until these effects have stopped occurring. Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

Hypotensive reactions Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

- NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2006) that Ropinirole should be restricted for use in patients with a baseline score of 24 points or more on the International Restless Legs Scale.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder Tableta

Tablet

CAUTIONARY AND ADVISORY LABELS 10, 21

ROPINIROLE (Non-proprietary)

Ropinirole (as Ropinirole hydrochloride) 250 microgram 250microgram tablets | 12 tablet (PO) £4.13 DT price = £1.69

Ropinirole (as Ropinirole hydrochloride) 500 microgram 500microgram tablets | 28 tablet (PO) £15.34 DT price = £2.12

Ropinirole (as Ropinirole hydrochloride) 1 mg 1mg tablets | 84 tablet (PO) £49.01 DT price = £3.03

Ropinirole (as Ropinirole hydrochloride) 2 mg 2mg tablets | 28 tablet (PO) £22.31–26.97 DT price = £2.31

Ropinirole (as Ropinirole hydrochloride) 5 mg 5mg tablets | 84 tablet (PO) £175.60 DT price = £6.65

Adartrel (GlaxoSmithKline UK Ltd)

Ropinirole (as Ropinirole hydrochloride) 250 microgram Adartrel 250microgram tablets | 12 tablet (PO) £3.94 DT price = £1.89

Ropinirole (as Ropinirole hydrochloride) 500 microgram Adartrel 500microgram tablets | 28 tablet (PO) £15.75 DT price = £2.12

Ropinirole (as Ropinirole hydrochloride) 2 mg Adartrel 2mg tablets | 28 tablet (PO) £15.75 DT price = £2.12

ReQuip (GlaxoSmithKline UK Ltd)

Ropinirole (as Ropinirole hydrochloride) 250 microgram ReQuip 250microgram tablets | 21 tablet (PO) £5.70 | 42 tablet (PO) no price available

Ropinirole (as Ropinirole hydrochloride) 500 microgram ReQuip 500microgram tablets | 42 tablet (PO) no price available

Ropinirole (as Ropinirole hydrochloride) 1 mg ReQuip 1mg tablets | 21 tablet (PO) no price available | 42 tablet (PO) no price available | 84 tablet (PO) £6.71 DT price = £3.03

Ropinirole (as Ropinirole hydrochloride) 2 mg ReQuip 2mg tablets | 63 tablet (PO) no price available | 84 tablet (PO) £113.44

Ropinirole (as Ropinirole hydrochloride) 5 mg ReQuip 5mg tablets | 84 tablet (PO) £195.92 DT price = £5.65

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 10, 25

ReQuip XL (GlaxoSmithKline UK Ltd)

Ropinirole (as Ropinirole hydrochloride) 2 mg ReQuip XL 2mg tablets | 28 tablet (PO) £12.34 DT price = £1.21

Ropinirole (as Ropinirole hydrochloride) 4 mg ReQuip XL 4mg tablets | 28 tablet (PO) £24.69 DT price = £2.26

Ropinirole (as Ropinirole hydrochloride) 8 mg ReQuip XL 8mg tablets | 28 tablet (PO) £32.11 DT price = £2.61

Brands may include Aimpact XL; Epinix XL; Ralnea XL; Raponer XL; Repiner XL; Spiroco XL

Rotigotine

INDICATIONS AND DOSE

Monotherapy in Parkinson’s disease

BY TRANSDERMAL APPLICATION USING PATCHES

- Adult: Initially 2 mg/24 hours, then increased in steps of 2 mg/24 hours every 1 week if required; maximum 8 mg/24 hours per day

Adjunctive therapy with co-beneldopa or co-careldopa in Parkinson’s disease

BY TRANSDERMAL APPLICATION USING PATCHES

- Adult: Initially 4 mg/24 hours, then increased in steps of 2 mg/24 hours every 1 week if required; maximum 16 mg/24 hours per day

Moderate to severe restless legs syndrome

BY TRANSDERMAL APPLICATION USING PATCHES

- Adult: Initially 1 mg/24 hours, then increased in steps of 1 mg/24 hours every 1 week if required; maximum 3 mg/24 hours per day

Important safety information

IMPULSE CONTROL DISORDERS

Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

- CAUTIONS Avoid exposure of patch to heat - remove patch (aluminium-containing) before magnetic resonance imaging or cardioversion

- INTERACTIONS Appendix 1 (rotigotine).

SIDE-EFFECTS

- Common or very common Abnormal behaviour - abnormal thinking - aggression - application site reactions - confusion - constipation - dizziness - drowsiness - dry mouth - dyskinesia - dyspepsia - hallucinations - headache - hiccups - hypertension - malaise - nausea - palpitations - paranoia - peripheral oedema - postural hypotension - pruritus - psychosis - rash - sleep disturbances - sudden onset of sleep - sweating - syncope - vomiting - weight changes

- Uncommon Abdominal pain - atrial fibrillation - erectile dysfunction - hypotension - impulse control disorders - visual disturbances

- Rare Irritability - obsessive compulsive disorder - seizures - tachycardia

PREGNANCY Avoid—no information available.

BREAST FEEDING May suppress lactation—avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Caution in severe impairment—no information available.

MONITORING REQUIREMENTS Ophthalmic testing recommended.

TREATMENT CESSATION Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

DIRECTIONS FOR ADMINISTRATION Apply patch to dry, non-irritated skin on torso, thigh, or upper arm, removing after 24 hours and siting replacement patch on a different area (avoid using the same area for 14 days).
PATIENT AND CARER ADVICE

Sudden onset of sleep  Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists. Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

Hypotensive reactions  Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised that Neupro® is accepted for restricted use for the treatment of advanced Parkinson’s disease in combination with levodopa where the transdermal route would facilitate treatment (July 2007).

The Scottish Medicines Consortium has advised that Neupro® is accepted as monotherapy for the treatment of early-stage idiopathic Parkinson’s disease (June 2007).

The Scottish Medicines Consortium has advised (April 2009) that rotigotine (Neupro®) is accepted for restricted use within NHS Scotland for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults with a baseline score of 15 points or more on the International Restless Legs Scale.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Transdermal patch

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rotigotine 1 mg per 24 hour Neupro 1mg/24hours transdermal patches</td>
<td>28 patch</td>
</tr>
<tr>
<td>Rotigotine 2 mg per 24 hour Neupro 2mg/24hours transdermal patches</td>
<td>7 patch</td>
</tr>
<tr>
<td>Rotigotine 3 mg per 24 hour Neupro 3mg/24hours transdermal patches</td>
<td>28 patch</td>
</tr>
<tr>
<td>Rotigotine 4 mg per 24 hour Neupro 4mg/24hours transdermal patches</td>
<td>7 patch</td>
</tr>
<tr>
<td>Rotigotine 6 mg per 24 hour Neupro 6mg/24hours transdermal patches</td>
<td>7 patch</td>
</tr>
<tr>
<td>Rotigotine 8 mg per 24 hour Neupro 8mg/24hours transdermal patches</td>
<td>7 patch</td>
</tr>
</tbody>
</table>

MONOAmine-OxIdase B inhibItors

Rasagiline

DRUG ACTION  Rasagiline is a monoamine-oxidase B inhibitor.

INDICATIONS AND DOSE  Parkinson’s disease, used alone or as adjunct to co-beneldopa or co-careldopa for ‘end-of-dose’ fluctuations

BY MOUTH

Adult: 1 mg daily

INTERACTIONS  Appendix 1 (rasagiline).

SIDE-EFFECTS

Common or very common  Abnormal dreams - angina - anorexia - arthralgia - conjunctivitis - constipation - depression - dry mouth - dryness - hallucinations - headache - hypotension - incontinence - fatigue - fever - influenza-like symptoms - leucopenia - rash - rhinitis - skin carcinoma - urinary urgency - vertigo - weight loss

Uncommon  Cerebrovascular accident - myocardial infarction

PREGNANCY  Use with caution.

BREAST FEEDING  Use with caution—may suppress lactation.

HEPATIC IMPAIRMENT  Use with caution in mild impairment. Avoid in moderate to severe impairment.

TREATMENT CESSATION  Avoid abrupt withdrawal.

MEdICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet

Azilect (Teva UK Ltd)

Rasagiline (as Rasagiline mesilate) 1 mg  Azilect 1mg tablets | 28 tablet | £70.72 DT price = £70.72

Selegiline hydrochloride

DRUG ACTION  Selegiline is a monoamine-oxidase-B inhibitor.

INDICATIONS AND DOSE  Parkinson’s disease, used alone or as adjunct to co-beneldopa or co-careldopa to reduce ‘end of dose’ deterioration | Symptomatic parkinsonism

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: Initially 5 mg once daily for 2–4 weeks, then increased if tolerated to 10 mg daily, dose to be taken in the morning

BY MOUTH USING ORAL LYOPHILISATE

Adult: 1.25 mg once daily, dose to be taken before breakfast

Dose equivalence and conversion

1.25–mg oral lyophilisate is equivalent to 10–mg tablet.

Patients receiving 10 mg conventional selegiline hydrochloride tablets can be switched to oral lyophilisates (Zelapar®) 1.25 mg.

CONTRA-INDICATIONS  Active duodenal ulceration - active gastric ulceration - avoid or use with great caution in postural hypotension (when used in combination with levodopa)

CAUTIONS  Angina - arrhythmias - avoid in Acute porphyrias p. 864 - duodenal ulceration - gastric ulceration - history of hepatic dysfunction - patients predisposed to confusion and psychosis - psychosis - uncontrolled hypertension

INTERACTIONS  Appendix 1 (selegiline).

Avoid with drugs that increase blood pressure.

SIDE-EFFECTS


Frequency not known  Hypersexuality
Nausea and labyrinth disorders

Nausea and labyrinth disorders

Antiemetics should be prescribed only when the cause of vomiting is known because otherwise they may delay diagnosis, particularly in children. Antiemetics are unnecessary and sometimes harmful when the cause can be treated, such as in diabetic ketoacidosis, or in digoxin p. 94 or antiepileptic overdose.

If antiemetic drug treatment is indicated, the drug is chosen according to the aetiology of vomiting.

Antihistamines are effective against nausea and vomiting resulting from many underlying conditions. There is no evidence that any one antihistamine is superior to another but their duration of action and incidence of adverse effects (drowsiness and antimuscarinic effects) differ.

The phenothiazines are dopamine antagonists and act centrally by blocking the chemoreceptor trigger zone. They are of considerable value for the prophylaxis and treatment of nausea and vomiting associated with diffuse neoplastic disease, radiation sickness, and the emesis caused by drugs such as opioids, general anaesthetics, and cytotoxics. Prochlorperazine p. 309, perphenazine p. 308, and trifluoperazine p. 310 are less sedating than chlorpromazine hydrochloride p. 304; severe dystonic reactions sometimes occur with phenothiazines, especially in children. Some phenothiazines are available as rectal suppositories, which can be useful in patients with persistent vomiting or with severe nausea; prochlorperazine p. 309 can also be administered as a buccal tablet which is placed between the upper lip and the gum.

Other antipsychotic drugs including haloperidol p. 306 and levomepromazine p. 345 are used for the relief of nausea and vomiting in terminal illness. Metoclopramide hydrochloride p. 347 is an effective antiemetic and its activity closely resembles that of the phenothiazines. Metoclopramide hydrochloride also acts directly on the gastro-intestinal tract and it may be superior to the phenothiazines for emesis associated with gastroduodenal, hepatic, and biliary disease. Domperidone p. 346 acts at the chemoreceptor trigger zone; it is licensed only for the relief of nausea and vomiting. It has the advantage over metoclopramide hydrochloride and the phenothiazines of being less likely to cause central effects such as sedation and dystonic reactions because it does not readily cross the blood-brain barrier. In Parkinson’s disease, it can be used to treat nausea caused by dopaminergic drugs.

Granisetron p. 348 and ondansetron p. 349 are of value in the management of nausea and vomiting in patients receiving cytotoxics and in postoperative nausea and vomiting. Palonosetron p. 350 is licensed for prevention of nausea and vomiting associated with moderately or highly emetogenic cytotoxic chemotherapy.

Dexamethasone p. 581 has antiemetic effects and it is used in vomiting associated with cancer chemotherapy. It can be used alone or with metoclopramide hydrochloride, prochlorperazine p. 309, lorazepam p. 412, or a 5HT,- receptor antagonist.

Aprepitant p. 351 and fosaprepitant p. 351 are neurokinin 1-receptor antagonists licensed for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based cytotoxic chemotherapy; they are given with dexamethasone p. 581 and a 5HT,- receptor antagonist.

Nabilone p. 346 is a synthetic cannabinoid with antiemetic properties. It may be used for nausea and vomiting caused by cytotoxic chemotherapy that is unresponsive to conventional antiemetics.

Vomiting during pregnancy

Nausea in the first trimester of pregnancy is generally mild and does not require drug therapy. On rare occasions if vomiting is severe, short-term treatment with an antihistamine, such as promethazine, may be required. Prochlorperazine p. 309 or metoclopramide hydrochloride p. 347 are alternatives. If symptoms do not settle in 24 to 48 hours then specialist opinion should be sought.

Hyperemesis gravidarum is a more serious condition, which requires regular antiemetic therapy, intravenous fluid and electrolyte replacement and sometimes nutritional support. Supplementation with thiamine p. 882 must be considered in order to reduce the risk of Wernicke’s encephalopathy.

Postoperative nausea and vomiting

The incidence of postoperative nausea and vomiting depends on many factors including the anaesthetic used,
and the type and duration of surgery. Other risk factors include female sex, non-smokers, a history of postoperative nausea and vomiting or motion sickness, and intraoperative and postoperative use of opioids. Therapy to prevent postoperative nausea and vomiting should be based on the assessed risk of postoperative nausea and vomiting in each patient. Drugs used include 5HT3-receptor antagonists, droperidol p. 345, dexamethasone p. 581, some phenothiazines (e.g. prochlorperazine p. 309), and antihistamines (e.g. cyclizine p. 343). A combination of two or more antiemetic drugs that have different mechanisms of action is often indicated in those at high risk of postoperative nausea and vomiting or where postoperative vomiting presents a particular danger (e.g. in some types of surgery). When a prophylactic antiemetic drug has failed, postoperative nausea and vomiting should be treated with one or more drugs from a different class.

Motion sickness
Antiemetics should be given to prevent motion sickness rather than after nausea or vomiting develop. The most effective drug for the prevention of motion sickness is hyoscine. If a sedative effect is desired promethazine is useful, but generally a slightly sedating antihistamine such as cyclizine p. 343 or cinnarizine below is preferred. Domperidone p. 346, metoclopramide hydrochloride p. 347, 5HT3-receptor antagonists, and the phenothiazines (except the antihistamine promethazine p. 343) are ineffective in motion sickness.

Other vestibular disorders
Management of vestibular diseases is aimed at treating the underlying cause as well as treating symptoms of the balance disturbance and associated nausea and vomiting. Vertigo and nausea associated with Ménière’s disease and middle-ear surgery can be difficult to treat. Betahistine dihydrochloride p. 352 is an analogue of histamine and is claimed to reduce endolymphatic pressure by improving the microcirculation. Betahistine dihydrochloride is licensed for vertigo, tinnitus, and hearing loss associated with Ménière’s disease.

A diuretic alone or combined with salt restriction may provide some benefit in vertigo associated with Ménière’s disease; antihistamines (such as cinnarizine below), and anticholecterol agents (such as prochlorperazine p. 309) are also used. Where possible, prochlorperazine should be reserved for the treatment of acute symptoms.

Cytotoxic chemotherapy, palliative care, and migraine
Antiemetics have a role in the management of nausea and vomiting induced by cytotoxic chemotherapy, in palliative care, and associated with migraine.

**Drugs used for Nausea and labyrinth disorders not listed below; Chlorpromazine hydrochloride, p. 304 - Haloperidol, p. 306 - Lorazepam, p. 412 - Perphenazine, p. 308 - Prochlorperazine, p. 309 - Promethazine hydrochloride, p. 251 - Promazine teoclote, p. 252 - Trifluoperazine, p. 310**

**ANTIHISTAMINES**

### Cinnarizine

#### INDICATIONS AND DOSE

Relief of symptoms of vestibular disorders, such as vertigo, tinnitus, nausea, and vomiting in Ménière’s disease

**BY MOUTH**
- Child 5-11 years: 15 mg 3 times a day
- Child 12-17 years: 30 mg 3 times a day
- Adult: 30 mg 3 times a day

#### Motion sickness

**BY MOUTH**
- Child 5-11 years: Initially 15 mg, dose to be taken 2 hours before travel, then 7.5 mg every 8 hours if required, dose to be taken during journey
- Child 12-17 years: Initially 30 mg, dose to be taken 2 hours before travel, then 15 mg every 8 hours if required, dose to be taken during journey
- Adult: Initially 30 mg, dose to be taken 2 hours before travel, then 15 mg every 8 hours if required, dose to be taken during journey

#### SIDE-EFFECTS

- **Common or very common** Drowsiness
- **Rare** Anaphylaxis - angioedema - angle-closure glaucoma - arrhythmias - blood disorders - bronchospasm - confusion - convulsions - depression - dizziness - extrapyramidal effects - hypersensitivity reactions - hypotension - lichen planus - liver dysfunction - lupus-like skin reactions - palpitation - paradoxical stimulation (especially with high doses in children) (in children) - paradoxical stimulation (especially with high doses in the elderly) (in adults) - photosensitivity reactions - rashes - sleep disturbances - sweating - tremor - weight gain
- **Frequency not known** Antimuscarinic effects - blurred vision - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - urinary retention

**SIDE-EFFECTS, FURTHER INFORMATION**

Children and the elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **PREGNANCY** Manufacturer advises avoid; however, there is no evidence of teratogenicity. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.
- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.
- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.
- **RENAL IMPAIRMENT** Use with caution—no information available.
- **PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); sedating effects enhanced by alcohol.
Cinnarizine with dimenhydrinate

The properties listed below are those particular to the combination only. For the properties of the components please consider, cinnarizine.

**INDICATIONS AND DOSE**

**Vertigo**

**BY MOUTH**

- Adult: 1 tablet 3 times a day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- CINNARIZINE (Non-proprietary)

  - Cinnarizine 15 mg: Cinnarizine 15mg tablets | 84 tablet | £42.00
  - Stugeron: 15 mg tablets | 15 tablet | £1.84
  - Cinnarizine 15 mg: Stugeron 15mg tablets | 100 tablet | £4.18
  - Brands may include Mylan

---

Cyclizine

**INDICATIONS AND DOSE**

**Nausea** | **Vomiting** | **Vertigo** | **Motion sickness** | **Labyrinthine disorders**

**BY MOUTH OR BY INTRAVENOUS INJECTION**

- Adult: 50 mg up to 3 times a day (max. per dose 25 mg), intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure

- Child 6-11 years: 25 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure

- Child 12-17 years: 50 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure

**BY RECTUM**

- Child 2-5 years: 12.5 mg up to 3 times a day

- Child 6-11 years: 25 mg up to 3 times a day

- Child 12-17 years: 50 mg up to 3 times a day

**BY CONTINUOUS INTRAVENOUS INFUSION OR BY SUBCUTANEOUS INFUSION**

- Child 1 month-1 year: 3 mg/kg, dose to be given over 24 hours

- Child 2-4 years: 50 mg, dose to be given over 24 hours

- Child 6-11 years: 75 mg, dose to be given over 24 hours

- Child 12-17 years: 150 mg, dose to be given over 24 hours

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- **Rare** Anaphylaxis - angioedema - angle-closure glaucoma - arrhythmias - blood disorders - bronchospasm - confusion - convulsions - depression - dizziness - extrapyramidal effects - hypersensitivity reactions - hypotension - liver dysfunction - palpitation - paradoxical stimulation (especially with high doses in children) - paradoxical stimulation (especially with high doses in the elderly) (in adults) - photosensitivity reactions - rashes - sleep disturbances - tremor

- **Frequency not known** Antimuscarinic effects - blurred vision - dry mouth - gastrointestinal disturbances - hallucinations - headache - hypertension - movement disorders - ocular emergencies - paraesthesia - psychromotor impairment - tachycardia - transient speech disorders - twitching - urinary retention

**SPECIFIC SIDE-EFFECTS**

- **Nausea and vomiting associated with palliative care**

  **BY SUBCUTANEOUS INFUSION**

  - Adult: 150 mg, dose to be given over 24 hours

  **BY MOUTH**

  - Adult: 50 mg up to 3 times a day

**UNLICENSED USE**


**CONTRA-INDICATIONS**

- Avoid in Acute porphyrias p. 864 (some antihistamines are thought to be safe) - neonate (due to significant antimuscarinic activity) (in neonates)

**CAUTIONS**

- Epilepsy - glaucoma - may counteract haemodynamic benefits of opioids - neuromuscular disorders - increased risk of transient paralysis with intravenous use - prostatic hypertrophy (in adults) - pyloroduodenal obstruction - severe heart failure - may cause fall in cardiac output and associated increase in heart rate, mean arterial pressure and pulmonary wedge pressure - susceptibility to angle-closure glaucoma - urinary retention

**INTERACTIONS**

- See Appendix 1 (antihistamines).

**PREGNANCY**

- Manufacturer advises avoid; however, there is no evidence of teratogenicity. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitation, and tremor.

**BREAST FEEDING**

- No information available. Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

**HEPATIC IMPAIRMENT**

- Avoid in severe liver disease - increased risk of coma

**DIRECTIONS FOR ADMINISTRATION**

- For administration by mouth, tablets may be crushed. Mixing and compatibility for the use of syringe drivers in palliative care Cyclizine may precipitate at concentrations above 10 mg/mL or in the presence of sodium chloride 0.9%
PATIENT AND CARER ADVICE
Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); effects of alcohol enhanced.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, oral suspension, oral solution.

- CYCLIZINE (Non-proprietary)
  - Cyclizine hydrochloride 50 mg: Cyclizine 50mg tablets | 100 tablet: £13.64 DT price = £10.97

Solution for injection
- CYCLIZINE (Non-proprietary)
  - Cyclizine lactate 50 mg per 1 ml: Cyclizine 50mg/1ml solution for injection ampoules | 5 ampoule: £6.65 DT price = £8.65

ANTIMUSCARINICS
Hyoscine hydrobromide (Scopolamine hydrobromide)
The properties listed below are those particular to the drug only. For properties common to the class, see Antimuscarinics, Systemic, p. 668.

INDICATIONS AND DOSE
Motion sickness
BY MOUTH
- Child 4–9 years: 75–150 micrograms, dose to be taken up to 30 minutes before the start of journey, then 75–150 micrograms every 6 hours if required; maximum 450 micrograms per day.
- Child 10–17 years: 150–300 micrograms, dose to be taken up to 30 minutes before the start of journey, then 150–300 micrograms every 6 hours if required; maximum 900 micrograms per day.
- Adult: 150–300 micrograms, dose to be taken up to 30 minutes before the start of journey, then 150–300 micrograms every 6 hours if required; maximum 900 micrograms per day.

BY TRANSDERMAL APPLICATION
- Child 10–17 years: Apply 1 patch, apply behind ear 5–6 hours before journey, then apply 1 patch after 72 hours if required, remove old patch and site replacement patch behind the other ear.
- Adult: Apply 1 patch, apply behind ear 5–6 hours before journey, then apply 1 patch after 72 hours if required, remove old patch and site replacement patch behind the other ear.

Hyper-salivation associated with clozapine therapy
BY MOUTH
- Adult: 300 micrograms up to 3 times a day; maximum 900 micrograms per day.

Excessive respiratory secretion (in palliative care)
BY SUBCUTANEOUS INJECTION
- Adult: 400 micrograms every 4 hours as required, hourly use is occasionally necessary

Bowel colic in palliative care
BY SUBCUTANEOUS INJECTION
- Adult: 400 micrograms every 4 hours as required, hourly use is occasionally necessary

UNLICENSED USE
- In children Not licensed for use in excessive respiratory secretions or hyper-salivation associated with clozapine therapy.

Important safety information
Antimuscarinic drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.

CAUTIONS
Epilepsy
CAUTIONS, FURTHER INFORMATION
Anticholinergic syndrome
In some patients, especially children and the elderly, hyoscine may cause the central anticholinergic syndrome (excitement, ataxia, hallucinations, behavioural abnormalities, and drowsiness).

PREGNANCY
Use only if potential benefit outweighs risk.
Injection may depress neonatal respiration.

BREAST FEEDING
Amount too small to be harmful.

HEPATIC IMPAIRMENT
Use with caution.

RENAL IMPAIRMENT
Use with caution.

DIRECTIONS FOR ADMINISTRATION
- With topical use Patch applied to hairless area of skin behind ear; if less than whole patch required either cut with scissors along full thickness ensuring membrane is not peeled away or cover portion to prevent contact with skin.
- With oral use in children For administration by mouth, injection solution may be given orally.

PRESCRIBING AND DISPENSING INFORMATION
Flavours of chewable tablet formulations may include raspberry.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, oral suspension, oral solution.

- HYOSCINE HYDROBROMIDE (Non-proprietary)
  - Hyoscine hydrobromide 300 microgram: Hyoscine hydrobromide 300microgram tablets | 12 tablet: £1.67
  - Kwells (Bayer Plc)
  - Hyoscine hydrobromide 150 microgram: Kwells Kids 150microgram tablets | 12 tablet: £1.67

- Brands may include Travel Calm
**Droperidol**

The properties listed below are those particular to the drug only. For properties common to the class, see Antipsychotics, p. 303.

- **DRUG ACTION** Droperidol is a butyrophenone, structurally related to haloperidol, which blocks dopamine receptors in the chemoreceptor trigger zone.

### INDICATIONS AND DOSE

**Prevention and treatment of postoperative nausea and vomiting**

- **BY INTRAVENOUS INJECTION**
  - Adult: 0.625–1.25 mg, dose to be given 30 minutes before end of surgery, then 0.625–1.25 mg every 6 hours as required
  - Elderly: 625 micrograms, dose to be given 30 minutes before end of surgery, then 625 micrograms every 6 hours as required

**Prevention of nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia (PCA)**

- **BY INTRAVENOUS INJECTION**
  - Adult: 15–50 micrograms of droperidol for every 1 mg of morphine in PCA, reduce dose in elderly; maximum 5 mg per day

- **CONTRA-INDICATIONS** Bradycardia · CNS depression · comatose states · hypokalaemia · hypomagnesaemia · phaeochromocytoma · QT-interval prolongation
- **CAUTIONS** Chronic obstructive pulmonary disease · electrolyte disturbances · history of alcohol abuse · respiratory failure
- **INTERACTIONS** → Appendix 1 (droperidol). Avoid concomitant administration of drugs that prolong QT interval.
- **SIDE-EFFECTS** Anxiety · cardiac arrest · hallucinations · inappropriate antidiuretic hormone secretion
- **PREGNANCY** Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy. Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.
- **BREAST FEEDING** Limited information available—avoid repeated administration.
- **HEPATIC IMPAIRMENT** In postoperative nausea and vomiting, max. 625 micrograms repeated every 6 hours as required. For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.
- **RENA L IMPAIRMENT** In postoperative nausea and vomiting, max. 625 micrograms repeated every 6 hours as required. For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.
- **MONITORING REQUIREMENTS** Continuous pulse oximetry required if risk of ventricular arrhythmia—continue for 30 minutes following administration.
- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, capsule

### Solution for injection

- **HYOSCINE HYDROBROMIDE (Non-proprietary)**
  - Hyoscine hydrobromide 400 microgram per 1 ml Hyoscine hydrobromide 400microgram/1ml solution for injection ampoules | 10 ampoule [P] £31.29

- **HYOSCINE HYDROBROMIDE 600 microgram per 1 ml** Hyoscine hydrobromide 600microgram/1ml solution for injection ampoules | 10 ampoule [P] £33.50

### Transdermal patch

- **CAUTIONARY AND ADVISORY LABELS**
  - Scopoderm (Novartis Consumer Health UK Ltd)
  - Hyoscine 1 mg per 72 hour Scopoderm 1.5mg patches | 2 patch [P] £4.52 DT price = £4.52

### Chewable tablet

- **Joy-Rides** (Forest Laboratories UK Ltd)

### HYOSCINE HYDROBROMIDE (Non-proprietary)

- **Joy-rides 150microgram chewable tablets (sugar-free) | 12 tablet [P] £1.55**

### Levomepromazine

(Methotrimeprazine)

The properties listed below are those particular to the drug only. For properties common to the class, see Antipsychotics, p. 303.

### INDICATIONS AND DOSE

**Pain in palliative care (reserved for distressed patients with severe pain unresponsive to other measures)**

- **BY CONTINUOUS SUBCUTANEOUS INFUSION OR BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**
  - Adult: Seek specialist advice

**Restlessness and confusion in palliative care**

- **BY CONTINUOUS SUBCUTANEOUS INFUSION**
  - Child 1-11 years: 0.35–3 mg/kg, to be administered over 24 hours
  - Child 12-17 years: 12.5–200 mg, to be administered over 24 hours

- **BY MOUTH**
  - Adult: 6 mg every 2 hours as required
  - **BY SUBCUTANEOUS INJECTION**
    - Adult: 6.25 mg every 2 hours as required
  - **BY SUBCUTANEOUS INFUSION**
    - Adult: Initially 12.5–50 mg/24 hours, titrated according to response (doses greater than 100 mg/24 hours should be given under specialist supervision)

**Nausea and vomiting in palliative care**

- **BY CONTINUOUS INTRAVENOUS INFUSION OR BY SUBCUTANEOUS INFUSION**
  - Child 1 month-11 years: 100–400 micrograms/kg, to be administered over 24 hours
  - Child 12-17 years: 5–25 mg, to be administered over 24 hours

- **BY MOUTH**
  - Adult: 6 mg once daily, dose to be taken at bedtime, increased if necessary to 12.5–25 mg twice daily
  - **BY SUBCUTANEOUS INJECTION**
    - Adult: 6.25 mg once daily, dose to be given at bedtime, increased if necessary to 12.5–25 mg twice daily
  - **BY SUBCUTANEOUS INFUSION**
    - Adult: 5–25 mg/24 hours, sedation can limit the dose

**Schizophrenia**

- **BY MOUTH**
  - Adult: Initially 25–50 mg daily in divided doses, dose can be increased as necessary

**Schizophrenia (bed patients)**

- **BY MOUTH**
  - Adult: Initially 100–200 mg daily in 3 divided doses, increased if necessary to 1 g daily
Nabilone

**INDICATIONS AND DOSE**

Nausea and vomiting caused by cytotoxic chemotherapy, unresponsive to conventional antiemetics (preferably in hospital setting) (under close medical supervision) **BY MOUTH**

- Adult: Initially 1 mg twice daily, increased if necessary to 2 mg twice daily throughout each cycle of cytotoxic therapy and, if necessary, for 48 hours after the last dose of each cycle, the first dose should be taken the night before initiation of cytotoxic treatment and the second dose 1–3 hours before the first dose of cytotoxic drug, daily dose maximum should be given in 3 divided doses; maximum 6 mg per day

**CAUTIONS**

- Adverse effects on mental state can persist for 48–72 hours after stopping; elderly – heart disease; history of psychiatric disorder – hypertension

**SIDE-EFFECTS**


**SIDE-EFFECTS, FURTHER INFORMATION**

Drowsiness and dizziness occur frequently with standard doses.

**PREGNANCY**

- Avoid unless essential.

**BREAST FEEDING**

- Avoid—no information available.

**HEPATIC IMPAIRMENT**

- Avoid in severe impairment.

**PATIENT AND CARER ADVICE**

Drowsiness may affect performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including nabilone, see Drugs and driving under Guidance on prescribing p. 1. Behavioural effects: Patients should be made aware of possible changes of mood and other adverse behavioural effects.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral solution, oral suspension

**Tablet**

- CAUTIONARY AND ADVISORY LABELS 2

  - **Levomepromazine maleate** 6 mg
  - 28 tablet (P) no price available

- **Noziman (Sanofi)**

  - Levomepromazine maleate 25 mg
  - 84 tablet (P) £20.26 DT price = £20.26

**Solution for injection**

- **LEVOMEPROMAZINE (Non-proprietary)**

  - Levomepromazine hydrochloride 25 mg per 1 ml
  - 10 ampoule (P) £20.13 DT price = £20.13

- **Noziman (Sanofi)**

  - Levomepromazine hydrochloride 25 mg per 1 ml
  - 10 ampoule (P) £20.13 DT price = £20.13

**CANNABINOIDS**

**Nabilone**

**INDICATIONS AND DOSE**

Nausea and vomiting caused by cytotoxic chemotherapy, unresponsive to conventional antiemetics (preferably in hospital setting) (under close medical supervision) **BY MOUTH**

- Adult: Initially 1 mg twice daily, increased if necessary to 2 mg twice daily throughout each cycle of cytotoxic therapy and, if necessary, for 48 hours after the last dose of each cycle, the first dose should be taken the night before initiation of cytotoxic treatment and the second dose 1–3 hours before the first dose of cytotoxic drug, daily dose maximum should be given in 3 divided doses; maximum 6 mg per day

**CAUTIONS**

- Risk of postural hypotension; not recommended for ambulant patients over 50 years unless risk of hypotensive reaction assessed.

**SIDE-EFFECTS**

- Raised erythrocyte sedimentation rate

**PREGNANCY**

- There is limited information available

**SIDE-EFFECTS, FURTHER INFORMATION**

- Frequency not known: Drowsiness – dizziness – hypotension – nausea – sleep disturbance – vertigo – visual disturbance

**SIDE-EFFECTS, FURTHER INFORMATION**

Drowsiness and dizziness occur frequently with standard doses.

**PREGNANCY**

- Avoid unless essential.

**BREAST FEEDING**

- Avoid—no information available.

**HEPATIC IMPAIRMENT**

- Avoid in severe impairment.

**PATIENT AND CARER ADVICE**

Drowsiness may affect performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including nabilone, see Drugs and driving under Guidance on prescribing p. 1. Behavioural effects: Patients should be made aware of possible changes of mood and other adverse behavioural effects.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule

**Capsule**

- CAUTIONARY AND ADVISORY LABELS 2

  - **NABILONE (Non-proprietary)**

    - Nabilone 250 microgram Nabilone 250microgram capsules | 20 capsule (P) £96.11 Schedule 2 (CD)

    - Nabilone 1 mg Nabilone 1mg capsules | 20 capsule (P) £125.84 Schedule 2 (CD)

**DOPAMINE RECEPTOR ANTAGONISTS**

**Domperidone**

**INDICATIONS AND DOSE**

Relief of nausea and vomiting **BY MOUTH**

- Child (body-weight up to 35 kg): 250 micrograms/kg up to 3 times a day; maximum 750 micrograms/kg per day

- Child 12-17 years (body-weight 35 kg and above): 10 mg up to 3 times a day; maximum 30 mg per day

- Adult (body-weight 35 kg and above): 10 mg up to 3 times a day; maximum 30 mg per day

**Gastro-intestinal pain in palliative care** **BY MOUTH**

- Adult: 10 mg 3 times a day, before meals

**UNLICENSED USE**

- Not licensed for use in children for gastro-oesophageal reflux disease.

**Important safety information**

MHRA/CHM ADVICE—DOMPERIDONE: RISK OF CARDIAC SIDE-EFFECTS—RESTRICTED INDICATION, NEW CONTRA-INDICATIONS, REDUCED DOSE AND DURATION OF USE

The benefits and risks of domperidone have been reviewed. As domperidone is associated with a small increased risk of serious cardiac side-effects, the following restrictions to indication, dose and
duration of treatment have been made, and new contra-
indications added:

- Domperidone should only be used for the relief of the
  symptoms of nausea and vomiting;
- Domperidone should be used at the lowest effective
dose for the shortest possible duration (max.
treatment duration should not normally exceed 1
week);
- Domperidone is contra-indicated for use in conditions
where cardiac conduction is, or could be impaired, or
where there is underlying cardiac disease, when
administered concomitantly with drugs that prolong
the QT interval or potent CYP3A4 inhibitors, and in
severe hepatic impairment;
- The recommended dose in adults and adolescents
over 12 years and over 35 kg is 10 mg up to 3 times
daily;
- The recommended dose in children under 35 kg is
250 micrograms/kg up to 3 times daily;
- Oral liquid formulations should be given via an
appropriately designed, graduated oral syringe to
ensure dose accuracy.
This advice does not apply to unlicensed uses of
domperidone (e.g. palliative care).

- CONTRA-INDICATIONS Cardiac disease - conditions where
cardiac conduction is, or could be, impaired (in adults) -
gastro-intestinal haemorrhage (in children) - if increased
gastrointestinal motility harmful (in adults) - mechanical
obstruction (in children) - mechanical perforation (in
children) - predisposition to cardiac conduction disorders
(in children) - prolactinoma
- CAUTIONS Children - if there are cardiac concerns, obtain
ECG before and during treatment (in children) - patients
over 60 years - increased risk of ventricular arrhythmia (in
adults)
- INTERACTIONS → Appendix 1 (domperidone).
Contra-indicated with concomitant use of drugs that
prolong the QT interval.
Contra-indicated with concomitant use of potent CYP3A4
inhibitors.
- SIDE-EFFECTS
  - Common or very common Drowsiness - dry mouth - malaise
  - Uncommon Anxiety - breast pain - decreased libido -
diarrhoea - galactorrhoea - headache - pruritus - rash
  - Frequency not known Agitation - amenorrhea -
convulsions - extrapyramidal disorders - gynaecomastia -
nervousness - oculogyric crisis - QT-interval prolongation -
sudden cardiac death - urinary retention - ventricular
arrhythmias
- PREGNANCY Use only if potential benefit outweighs risk.
- BREAST FEEDING Amount too small to be harmful.
- HEPATIC IMPAIRMENT Avoid in moderate or severe
impairment.

- RENAL IMPAIRMENT Reduce frequency.

- PATIENT AND CARER ADVICE
  Arrhythmia Patients and their carers should be told how to
recognise signs of arrhythmia and advised to seek medical
attention if symptoms such as palpitation or syncope
develop.
Medicines for Children leaflet: Domperidone for gastro-
oesophageal reflux www.medicinesforchildren.org.uk/
domperidone-for-gastro-oesophageal-reflux

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: solution for injection, oral suspension,
suppository

Nausea and labyrinth disorders

Tablet

CAUTIONARY AND ADVISORY LABELS 22

- DOMPERIDONE (Non-proprietary)
  - Domperidone (as Domperidone maleate) 10 mg
    Domperidone 10mg tablets | 30 tablet (P) £1.75 | 100 tablet (P) £9.04 DT price = £5.83
  - Motilium (Zentiva)
    - Domperidone (as Domperidone maleate) 10 mg
      Motilium 10mg tablets | 30 tablet (P) £2.71 DT price = £1.75 | 100 tablet (P) £9.04 DT price = £5.83

Oral suspension

CAUTIONARY AND ADVISORY LABELS 22

- DOMPERIDONE (Non-proprietary)
  - Domperidone 1 mg per 1 ml
    Domperidone 5mg/5ml oral suspension sugar free (sugar-free) | 200 ml (P) £13.43 DT price = £13.43

Metoclopramide hydrochloride

INDICATIONS AND DOSE

Symptomatic treatment of nausea and vomiting including
that associated with acute migraine | Delayed (but not
acute) chemotherapy-induced nausea and vomiting | Radiotherapy-induced nausea and vomiting | Prevention of
postoperative nausea and vomiting

BY MOUTH OR BY INTRAMUSCULAR INJECTION OR BY SLOW
INTRAVENOUS INJECTION

- Adult (body-weight up to 60 kg): Up to 500 micrograms/kg
daily in 3 divided doses, when administered by slow
intravenous injection, to be given over at least 3
minutes
- Adult (body-weight 60 kg and above): 10 mg up to 3 times
a day, when administered by slow intravenous
injection, to be given over at least 3 minutes

Hiccup in palliative care

BY MOUTH OR BY INTRAMUSCULAR INJECTION OR BY
SUBCUTANEOUS INJECTION

- Adult: 10 mg every 6–8 hours

Nausea and vomiting in palliative care

BY MOUTH

- Adult: 10 mg 3 times a day

BY SUBCUTANEOUS INFUSION

- Adult: 30–100 mg/24 hours

Important safety information

MHRA/CHM ADVICE—METOCLOPRAMIDE: RISK OF
NEUROLOGICAL ADVERSE EFFECTS—RESTRICTED DOSE AND
DURATION OF USE (AUGUST 2013)
The benefits and risks of metoclopramide have been
reviewed by the European Medicines Agency’s
Committee on Medicinal Products for Human Use,
which concluded that the risk of neurological effects
such as extrapyramidal disorders and tardive dyskinesia
outweigh the benefits in long-term or high-dose
 treatment. To help minimise the risk of potentially
serious neurological adverse effects, the following
restrictions to indications, dose, and duration of use
have been made:

- In adults over 18 years, metoclopramide should only
  be used for prevention of postoperative nausea and
  vomiting, radiotherapy-induced nausea and vomiting,
delayed (but not acute) chemotherapy-induced
  nausea and vomiting, and symptomatic treatment of
  nausea and vomiting, including that associated with
  acute migraine (where it may also be used to improve
  absorption of oral analgesics);
- Metoclopramide should only be prescribed for short-
term use (up to 5 days);
- Usual dose is 10 mg, repeated up to 3 times daily;
  max. daily dose is 500 micrograms/kg;
PATIENT AND CARER ADVICE

DIRECTIONS FOR ADMINISTRATION

- With intravenous use
  - Frequency not known

SIDE-EFFECTS

- Common or very common Extrapyramidal effects
  - galactorrhoea
  - gynaecomastia
  - hyperprolactinaemia
  - menstrual changes
- Very rare Depression
  - methaemoglobinæmia (more severe in G6PD deficiency)
  - neuroleptic malignant syndrome
- Frequency not known Anxiety
  - confusion
  - diarrhoea
  - dizziness
  - drowsiness
  - dyspnoea
  - hypotension
  - oedema
  - pruritis
  - rash
  - restlessness
  - tardive dyskinesia on prolonged administration
  - tremor
  - urticaria
  - visual disturbances

SPECIFIC SIDE-EFFECTS

- Very rare
- With intravenous use cardiac conduction abnormalities

SIDE-EFFECTS, FURTHER INFORMATION

Metoclopramide can induce acute dystonic reactions involving facial and skeletal muscle spasms and oculogryric crises. These dystonic effects are more common in the young (especially girls and young women) and the very old; they usually occur shortly after starting treatment with metoclopramide and subside within 24 hours of stopping it. Injection of an antiparkinsonian drug such as procyclidine will abort dystonic attacks.

PREGNANCY

Not known to be harmful.

BREAST FEEDING

Small amount present in milk; avoid.

HEPATIC IMPAIRMENT

Reduce dose.

RENAL IMPAIRMENT

Avoid or use small dose in severe impairment; increased risk of extrapyramidal reactions.

DIRECTIONS FOR ADMINISTRATION

Oral liquid preparation to be given via a graduated oral dosing syringe.

PATIENT AND CARER ADVICE

Counselling on use of pipette advised with oral solution.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

- METOCLOPRAMIDE HYDROCHLORIDE (Non-proprietary)
  - Metoclopramide hydrochloride 10 mg Metoclopramide 10mg tablets | 28 tablet £1.23 DT price = £0.97
  - Maxolon (AMCo)

- Metoclopramide hydrochloride 10 mg Maxolon 10mg tablets | 84 tablet £5.24

Oral solution

- METOCLOPRAMIDE HYDROCHLORIDE (Non-proprietary)
  - Metoclopramide hydrochloride 1 mg per 1 ml Metoclopramide 5mg/5ml oral solution sugar free (sugar-free) | 150 ml £19.77 DT price = £13.77

Solution for injection

- METOCLOPRAMIDE HYDROCHLORIDE (Non-proprietary)
  - Metoclopramide hydrochloride 5 mg per 1 ml Metoclopramide 10mg/2ml solution for injection ampoules | 5 ampoule £1.31-£1.82 | 10 ampoule £3.50 DT price = £3.23
  - Maxolon (AMCo)

- Metoclopramide hydrochloride 5 mg per 1 ml Maxolon 10mg/2ml solution for injection ampoules | 12 ampoule £3.21
  - Maxolon High Dose 100mg/20ml solution for injection ampoules | 10 ampoule £26.68

5HT3 RECEPTOR ANTAGONISTS

Granisetron

- DRUG ACTION
  - Granisetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastrointestinal tract and in the CNS.

INDICATIONS AND DOSE

Nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3–5 days where oral antiemetics cannot be used

BY TRANSDERMAL APPLICATION USING PATCHES

- Adult: Apply 3.1 mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24–48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy

Prevention of postoperative nausea and vomiting

BY INTRAVENOUS INJECTION

- Adult: 1 mg, to be administered before induction of anaesthesia, dose to be diluted to 5 mL and given over 30 seconds

Treatment of postoperative nausea and vomiting

BY INTRAVENOUS INJECTION

- Adult: 1 mg, dose to be diluted to 5 mL and given over 30 seconds; maximum 3 mg per day

Management of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy

BY MOUTH

- Adult: 1–2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1–2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9 mg in 24 hours

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

- Adult: 10–40 micrograms/kg (max. per dose 3 mg), to be given 5 minutes before start of treatment, dose may be repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day

CAUTIONS

Subacute intestinal obstruction • susceptibility to QT-interval prolongation (including electrolyte disturbances)

INTERACTIONS

Appendix 1 (5HT3-receptor Antagonists).

Caution with concomitant use of drugs that prolong QT interval.

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

- Common or very common Constipation • diarrhoea • headache • insomnia
Severely emetogenic chemotherapy (consult product literature for dose of concomitant corticosteroid)

**INITIALLY BY MOUTH**

- Adult: 24 mg, dose to be taken 1–2 hours before treatment, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days

**INITIALLY BY RECTUM**

- Adult: 16 mg, dose to be administered 1–2 hours before treatment, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days

**INITIALLY BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION**

- Adult 18–65 years: Initially 8 mg, dose to be administered immediately before treatment, followed by (by intramuscular injection or by slow intravenous injection) 8 mg every 4 hours if required for 2 doses, alternatively followed by (by continuous intravenous infusion) 1 mg/hour for up to 24 hours, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days

**INDICATIONS AND DOSE**

Moderately emetogenic chemotherapy or radiotherapy

**INITIALLY BY MOUTH**

- Adult: Initially 8 mg, dose to be taken 1–2 hours before treatment, alternatively (by rectum) initially 16 mg, dose to be administered 1–2 hours before treatment, alternatively (by intramuscular injection or by slow intravenous injection) initially 8 mg, dose to be administered immediately before treatment, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days

- Elderly: Initially 8 mg, dose to be taken 1–2 hours before treatment, alternatively (by rectum) initially 16 mg, dose to be administered 1–2 hours before treatment, alternatively (by intramuscular injection or by intravenous infusion) initially 8 mg, dose to be administered immediately before treatment, intravenous infusion dose to be administered over at least 15 minutes, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days

**PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING**

**INITIALLY BY MOUTH**

- Adult: 16 mg, dose to be taken 1 hour before anaesthesia, alternatively (by intramuscular injection or by slow intravenous injection) 4 mg, dose to be administered at induction of anaesthesia

**TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING**

**BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION**

- Adult: 4 mg for 1 dose

**CONTRA-INDICATIONS**

- Congenital long QT syndrome

**CAUTIONS**

- Adenotonsillar surgery - subacute intestinal obstruction - susceptibility to QT-interval prolongation (including electrolyte disturbances)

**INTERACTIONS**

- Appendix 1 (5HT3-receptor Antagonists).
Caution with concomitant use of drugs that prolong QT interval.

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Common or very common: Constipation, flushing, headache, injection site-reactions
- Uncommon: Arrhythmias, bradycardia, chest pain, hiccups, hypotension, movement disorders, seizures

**SPECIFIC SIDE-EFFECTS**
- Rare
- With intravenous use: dizziness, transient visual disturbances
- Very rare
- With intravenous use: transient blindness
- Frequency not known
- With rectal use: rectal irritation

**PREGNANCY**
- No information available; avoid unless potential benefit outweighs risks.

**BREAST FEEDING**
- Present in milk in animal studies—avoid.

**HEPATIC IMPAIRMENT**
- Maximum 8 mg daily in moderate or severe impairment.

**DIRECTIONS FOR ADMINISTRATION**
- With intravenous use: For intravenous infusion (Zofran®), give continuously or intermittently in Glucose 5% or Glucose 5% with Potassium chloride 0.3% or Sodium chloride 0.9% or Sodium chloride 0.9% with Potassium chloride 0.3% or Mannitol 10% or Ringsers solution; for intermittent infusion, dilute the required dose in 50–100 mL of infusion fluid and give over at least 15 minutes.
- With oral use: Orodispersible films and lyophilisates should be placed on the tongue, allowed to disperse and swallowed.

**PRESCRIBING AND DISPENSING INFORMATION**
- Flavours of oral liquid formulations may include strawberry.

**PATIENT AND CARER ADVICE**
- Patients or carers should be given advice on how to administer orodispersible films and lyophilisates.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Table**
- **ONDANSETRON (Non-proprietary)**
  - Ondansetron (as Ondansetron hydrochloride) 4 mg
    - 4mg tablets | 10 tablet (PO) £25.46 DT price = £1.88 | 30 tablet (PO) £76.38
    - Ondansetron 8 mg tablets | 10 tablet (PO) £47.99 DT price = £6.94
  - Ondansetron (as Ondansetron hydrochloride) 8 mg
    - Zofran 4mg tablets | 30 tablet (PO) £10.79
  - Ondansetron (as Ondansetron hydrochloride) 8 mg
    - Ondansetron 8mg tablets | 10 tablet (PO) £11.94 DT price = £1.64
  - Brands may include Ondemet

**Orodispersible tablet**
- **ONDANSETRON (Non-proprietary)**
  - Ondansetron 4 mg
    - Ondansetron 4mg orodispersible tablets | 10 tablet (PO) £40.46 DT price = £4.04
  - Ondansetron 8 mg
    - Ondansetron 4mg orodispersible tablets | 10 tablet (PO) £80.93 DT price = £8.09

**Orodispersible film**
- Setofilm (Norgine Pharmaceuticals Ltd)
  - Ondansetron 4 mg
    - Setofilm 4mg orodispersible films (sugar-free) | 10 film (PO) £28.50
  - Ondansetron 8 mg
    - Setofilm 8mg orodispersible films (sugar-free) | 10 film (PO) £57.00

**Oral solution**
- **ONDANSETRON (Non-proprietary)**
  - Ondansetron (as Ondansetron hydrochloride) 800 microgram per 1 ml
    - Ondansetron 4mg/5ml oral solution sugar free (sugar-free) | 50 ml (PO) £38.08 DT price = £3.74

**Solution for injection**
- **ONDANSETRON (Non-proprietary)**
  - Ondansetron (as Ondansetron hydrochloride) 2 mg per 1 ml
    - Ondansetron 8mg/4ml solution for injection ampoules | 5 ampoule (PO) £58.45
    - Ondansetron 4mg/2ml solution for injection ampoules | 5 ampoule (PO) £29.20 | 10 ampoule (PO) £75.00

**Zofran Flexi-amp (Novartis Pharmaceuticals UK Ltd)**
- Ondansetron (as Ondansetron hydrochloride) 2 mg per 1 ml
  - Zofran Flexi-amp 8mg/4ml solution for injection | 5 ampoule (PO) £59.95
  - Zofran Flexi-amp 4mg/2ml solution for injection | 5 ampoule (PO) £29.97

**Suppository**
- **Zofran (Novartis Pharmaceuticals UK Ltd)**
  - Ondansetron 16 mg
    - Zofran 16mg suppositories | 1 suppository (PO) £14.39

**Palonosetron**

**DRUG ACTION**
- Palonosetron is a specific 5HT3 receptor antagonist which blocks 5HT3 receptors in the gastrointestinal tract and in the CNS.

**INDICATIONS AND DOSE**
- Moderately emetogenic chemotherapy
  - Initially by mouth
    - Adult: 500 micrograms, dose to be taken 1 hour before treatment, alternatively by (intravenous injection), 250 micrograms for 1 dose, dose to be administered over 30 seconds, 30 minutes before treatment
  - Severely emetogenic chemotherapy
    - By intravenous injection
      - Adult: 250 micrograms for 1 dose, dose to be administered over 30 seconds, 30 minutes before treatment

**CAUTIONS**
- History of constipation, intestinal obstruction, susceptibility to QT-interval prolongation (including electrolyte disturbances)

**INTERACTIONS**
- Caution with concomitant use of drugs that prolong QT interval.

**SIDE-EFFECTS**
- Common or very common: Constipation, diarrhoea, dizziness, headache
- Uncommon: Abdominal pain, amebolgia, anorexia, anxiety, arrhythmia, arthralgia, asthena, atrioventricular block, bradycardia, changes in blood pressure, dry mouth, dyspnea, electrolyte disturbance, euphoria, extrasystoles, eye irritation, eye swelling, flatulence, glycosuria, hiccups, hyperglycaemia, influenza-like symptoms, insomnia, motion sickness, myalgia, myocardial ischaemia, peripheral neuropathy, rash, tachycardia, tinnitus, urinary retention

**PREGNANCY**
- Avoid—no information available.

**BREAST FEEDING**
- Avoid—no information available.

**PATIENT AND CARER ADVICE**
- Dizziness or drowsiness may affect performance of skilled tasks (e.g. driving).
Fosaprepitant

- **DRUG ACTION** Fosaprepitant is a prodrug of aprepitant.

**INDICATIONS AND DOSE**

Adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy

**BY INTRAVENOUS INFUSION**

- Adult: 150 mg, dose to be administered over 20–30 minutes and given 30 minutes before chemotherapy on day 1 of cycle only; consult product literature for dose of concomitant corticosteroid and 5HT3-receptor antagonist

**CONTRA-INDICATIONS** Acute porphyrias p. 864

**INTERACTIONS** → Appendix 1 (aprepitant).

**SIDE-EFFECTS**

- Common or very common Anorexia · asthenia · constipation · diarrhoea · dizziness · dyspepsia · headache · hiccups
- Uncommon Abdominal pain · abnormal dreams · acne · anaemia · anxiety · bradycardia · chills · colitis · confusion · conjunctivitis · cough · drowsiness · dry mouth · duodenal ulcer · dysuria · euphoria · flatulence · flushing · haematuria · hyperglycaemia · hypernatraemia · myalgia · neutropenia · oedema · palpitations · pharyngitis · photosensitivity · polyuria · pruritus · rash · sneezing · stomatitis · sweating · taste disturbance · thirst · tinnitus · weight changes
- Frequency not known Dysarthria · dyspnoea · insomnia · Stevens-Johnson syndrome · urticaria · visual disturbances

**CONCEPTION AND CONTRACEPTION** Efficacy of hormonal contraceptives reduced—effective non-hormonal methods of contraception necessary during treatment and for 2 months after stopping fosaprepitant.

**PREGNANCY** Avoid unless potential benefit outweighs risk—no information available.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Caution in moderate to severe impairment.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Ivemend®), give intermittently in Sodium chloride 0.9%; reconstitute each 150 mg vial with 5 mL sodium chloride 0.9% gently without shaking to avoid foaming, then dilute in 145 mL infusion fluid; give over 20–30 minutes.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2011) that fosaprepitant (Ivemend®) is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- Ivemend (Merck Sharp & Dohme Ltd) Fosaprepitant (as Fosaprepitant dimeglumine) 150 mg I vial 150 mg powder for solution for infusion vials | 1 vial £47.42

---

**NEUROKININ RECEPTOR ANTAGONISTS**

Aprepitant

**INDICATIONS AND DOSE**

Adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy

**BY MOUTH**

- Adult: Initially 125 mg, dose to be taken 1 hour before chemotherapy, then 80 mg once daily for 2 days; consult product literature for dose of concomitant corticosteroid and 5HT3-receptor antagonist

**CONTRA-INDICATIONS** Acute porphyrias p. 864

**INTERACTIONS** → Appendix 1 (aprepitant).

**SIDE-EFFECTS**

- Common or very common Anorexia · asthenia · constipation · diarrhoea · dizziness · dyspepsia · headache · hiccups
- Uncommon Abdominal pain · abnormal dreams · acne · anaemia · anxiety · bradycardia · chills · colitis · confusion · conjunctivitis · cough · drowsiness · dry mouth · duodenal ulcer · dysuria · euphoria · flatulence · flushing · haematuria · hyperglycaemia · hypernatraemia · myalgia · neutropenia · oedema · palpitations · pharyngitis · photosensitivity · polyuria · pruritus · rash · sneezing · stomatitis · sweating · taste disturbance · thirst · tinnitus · weight changes
- Frequency not known Dysarthria · dyspnoea · insomnia · Stevens-Johnson syndrome · urticaria · visual disturbances

**CONCEPTION AND CONTRACEPTION** Efficacy of hormonal contraceptives reduced—effective non-hormonal methods of contraception necessary during treatment and for 2 months after stopping aprepitant.

**PREGNANCY** Avoid unless potential benefit outweighs risk—no information available.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Caution in moderate to severe impairment.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Emend®), give intermittently in Sodium chloride 0.9%; reconstitute each 150-mg vial with 5 mL sodium chloride 0.9% gently without shaking to avoid foaming, then dilute in 145 mL infusion fluid; give over 20–30 minutes.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2011) that aprepitant (Emend®) is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- Alox® (Sinclair IS Pharma Plc) Palonosetron (as Palonosetron hydrochloride) 500 microgram Alox® 500 microgram capsules | 1 capsule £55.89

**Solution for injection**

- Alox® (Sinclair IS Pharma Plc) Palonosetron (as Palonosetron hydrochloride) 50 microgram per 1 mL Alox® 250 microgram/2 mL solution for injection vials | 1 vial £55.89

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- Alox® (Sinclair IS Pharma Plc) Palonosetron (as Palonosetron hydrochloride) 500 microgram Alox® 500 microgram capsules | 1 capsule £55.89

**Solution for injection**

- Alox® (Sinclair IS Pharma Plc) Palonosetron (as Palonosetron hydrochloride) 50 microgram per 1 mL Alox® 250 microgram/2 mL solution for injection vials | 1 vial £55.89

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- Alox® (Sinclair IS Pharma Plc) Palonosetron (as Palonosetron hydrochloride) 500 microgram Alox® 500 microgram capsules | 1 capsule £55.89

**Solution for injection**

- Alox® (Sinclair IS Pharma Plc) Palonosetron (as Palonosetron hydrochloride) 50 microgram per 1 mL Alox® 250 microgram/2 mL solution for injection vials | 1 vial £55.89
4.1 Meniere’s disease

HISTAMINE ANALOGUES

**Beta-histidine dihydrochloride**

**INDICATIONS AND DOSE**

Vertigo, tinnitus and hearing loss associated with Ménière’s disease

**BY MOUTH**

- **Adult:** Initially 16 mg 3 times a day, dose preferably
taken with food; maintenance 24–48 mg daily

- **CONTRA-INDICATIONS** Phaeochromocytoma

- **CAUTIONS** Asthma - history of peptic ulcer

- **INTERACTIONS** → Appendix 1 (betahistine).

- **SIDE-EFFECTS** Gastro-intestinal disturbances - headache -
pruritus - rashes

- **PREGNANCY** Avoid unless clearly necessary — no
information available.

- **BREAST FEEDING** Use only if potential benefit outweighs
risk — no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral solution, oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 21**

- **BETAHISTINE DIHYDROCHLORIDE (Non-proprietary)**
  - Betahistine dihydrochloride 8 mg Betahistine 8 mg tablets | 84 tablet (P) £17.05 DT price = £2.00
  - Betahistine dihydrochloride 16 mg Betahistine 16 mg tablets | 84 tablet (P) £17.19 DT price = £2.00
  - Serc (BGP Products Ltd) £9.04
  - Betahistine dihydrochloride 8 mg Serc 8 mg tablets | 120 tablet (P) £12.65 DT price = £2.00
  - Betahistine dihydrochloride 16 mg Serc 16 mg tablets | 84 tablet (P) £12.65 DT price = £2.00

5 Pain

**Analgesics**

The non-opioid drugs, paracetamol p. 354 and aspirin p. 104
(and other NSAIDs), are particularly suitable for pain in
musculoskeletal conditions, whereas the opioid analgesics
are more suitable for moderate to severe pain, particularly
of visceral origin.

**Pain in sickle-cell disease**

The pain of mild sickle-cell crises is managed with
paracetamol p. 354, a NSAID, codeine phosphate p. 360, or
dihydrocodeine tartrate p. 362. Severe crises may require
the use of morphine p. 367 or diamorphine hydrochloride
p. 361; concomitant use of a NSAID may potentiate
analgesia and allow lower doses of the opioid to be used.
Pethidine hydrochloride p. 372 should be avoided if possible
because accumulation of a neurotoxic metabolite can
precipitate seizures; the relatively short half-life of
pethidine hydrochloride necessitates frequent injections.

**Dental and orofacial pain**

Analgesics should be used judiciously in dental care as a
temporary measure until the cause of the pain has been dealt with.

Dental pain of inflammatory origin, such as that
associated with pulpitis, apical infection, localised osteitis
or pericoronitis is usually best managed by treating the
infection, providing drainage, restorative procedures, and
other local measures. Analgesics provide temporary relief of
pain (usually for about 1 to 7 days) until the causative
factors have been brought under control. In the case of
pulpitis, intra-osseous infection or abscess, reliance on
analgesics alone is usually inappropriate.

Similarly the pain and discomfort associated with acute
problems of the oral mucosa (e.g. acute herpetic
gingivostomatitis, erythema multiforme) may be relieved by
benzylamine hydrochloride p. 993 mouthwash or spray
until the cause of the mucosal disorder has been dealt with.
However, where a patient is febrile, the antipyretic action of
paracetamol p. 354 or ibuprofen p. 927 is often helpful.

The choice of an analgesic for dental purposes should be
based on its suitability for the patient. Most dental pain is
relieved effectively by non-steroidal anti-inflammatory
( NSAIDS). NSAIDs that are used for dental pain
include ibuprofen p. 927, diclofenac sodium p. 921, and
aspirin p. 104. Paracetamol p. 354 has analgesic and
antipyretic effects but no anti-inflammatory effect.

Opioid analgesics such as dihydrocodeine tartrate p. 362
act on the central nervous system and are traditionally used for moderate to severe pain. However, opioid analgesics are
relatively ineffective in dental pain and their side-effects
may be unpleasant. Paracetamol, ibuprofen, or aspirin are
adequate for most cases of dental pain and an opioid is
rarely required.

Combining a non-opioid with an opioid analgesic can
provide greater relief of pain than either analgesic given
alone. However, this applies only when an adequate dose of
each analgesic is used. Most combination analgesic
preparations have not been shown to provide greater relief
of pain than an adequate dose of the non-opioid component
given alone. Moreover, combination preparations have the
disadvantage of an increased number of side-effects.

Any analgesic given before a dental procedure should
have a low risk of increasing postoperative bleeding. In the
case of pain after the dental procedure, taking an analgesic
before the effect of the local anaesthetic has worn off can
improve control. Postoperative analgesia with ibuprofen or
aspirin is usually continued for about 24 to 72 hours.

**Temporomandibular dysfunction** can be related to anxiety
in some patients who may clench or grind their teeth
(bruxism) during the day or night. The muscle spasm (which
appears to be the main source of pain) may be treated
empirically with an oral appliance which provides a free
sliding occlusion and may also interfere with grinding. In
addition, diazepam p. 267, which has muscle relaxant as
well as anti-inflammatory properties, may be helpful but it
should only be prescribed on a short-term basis during the
acute phase. Analgesics such as aspirin or ibuprofen may also
be required.

**Dysmenorrhoea**

Use of an oral contraceptive prevents the pain of
dysmenorrhoea which is generally associated with ovulatory
cycles. If treatment is necessary paracetamol p. 354 or a
NSAID will generally provide adequate relief of pain. The
vomiting and severe pain associated with dysmenorrhoea in
women with endometriosis may call for an antiemetic (in
addition to an analgesic). Antispasmodics (such as alverine
citrate p. 74) have been advocated for dysmenorrhoea but
the antispasmodic action does not generally provide
significant relief.

**Non-opioid analgesics and compound analgesic
preparations**

Aspirin p. 104 is indicated for headache, transient
musculoskeletal pain, dysmenorrhoea, and pyrexia. In
inflammatory conditions, most physicians prefer anti-
inflammatory treatment with another NSAID which may be
better tolerated and more convenient for the patient.
Aspirin is used increasingly for its antiplatelet properties.
Aspirin tablets or dispersible aspirin tablets are adequate for most purposes as they act rapidly. Gastric irritation may be a problem; it is minimised by taking the dose after food. Enteric-coated preparations are available, but have a slow onset of action and are therefore unsuitable for single-dose analgesic use (though their prolonged action may be useful for night pain).

Aspirin interacts significantly with a number of other drugs and its interaction with warfarin sodium is a special hazard.

Paracetamol p. 354 is similar in efficacy to aspirin, but has no demonstrable anti-inflammatory activity; it is less irritant to the stomach and for that reason is now generally preferred to aspirin, particularly in the elderly. Overdosage with paracetamol is particularly dangerous as it may cause hepatic damage which is sometimes not apparent for 4 to 6 days. Nefopam hydrochloride p. 356 may have a place in the relief of persistent pain unresponsive to other non-opioid analgesics. It causes little or no respiratory depression, but sympathomimetic and antimuscarinic side-effects may be troublesome.

Non-steroidal anti-inflammatory analgesics (NSAIDs) are particularly useful for the treatment of patients with chronic disease accompanied by pain and inflammation. Some of them are also used in the short-term treatment of mild to moderate pain including transient musculoskeletal pain but paracetamol is now often preferred, particularly in the elderly. They are also suitable for the relief of pain in dysmenorrhoea and to treat pain caused by secondary bone tumours, many of which produce lysis of bone and release prostaglandins. Selective inhibitors of cyclo-oxygenase-2 may be used in preference to non-selective NSAIDs for patients at high risk of developing serious gastro-intestinal side-effects. Several NSAIDs are also used for postoperative analgesia.

A non-opioid analgesic administered by intrathecal infusion (ziconotide (Prialt®), available from Eisai) is licensed for the treatment of chronic severe pain; ziconotide can be used by a hospital specialist as an adjunct to opioid analgesics.

Compound analgesic preparations

Compound analgesic preparations that contain a simple analgesic (such as aspirin p. 104 or paracetamol p. 354) with an opioid component reduce the need for effective titration of the individual components in the management of pain of varying intensity. Compound analgesic preparations containing paracetamol p. 354 or aspirin p. 104 with a low dose of an opioid analgesic (e.g. 8 mg of codeine phosphate per compound tablet) are commonly used, but the advantages have not been substantiated. The low dose of the opioid may be enough to cause opioid side-effects (in particular, constipation) and can complicate the treatment of overdosage yet may not provide significant additional relief of pain.

A full dose of the opioid component (e.g. 60 mg codeine phosphate) in compound analgesic preparations effectively augments the analgesic activity but is associated with the full range of opioid side-effects (including nausea, vomiting, severe constipation, drowsiness, respiratory depression, and risk of dependence on long-term administration). Important: the elderly are particularly susceptible to opioid side-effects and should receive lower doses.

In general, when assessing pain, it is necessary to weigh up carefully whether there is a need for a non-opioid and an opioid analgesic to be taken simultaneously.

Caffeine is a weak stimulant that is often included, in small doses, in analgesic preparations. It is claimed that the addition of caffeine may enhance the analgesic effect, but the alerting effect, mild habit-forming effect and possible provocation of headache may not always be desirable.

Moreover, in excessive dosage or on withdrawal caffeine may itself induce headache.

Co-proxamol tablets (dextropropoxyphene in combination with paracetamol) are no longer licensed because of safety concerns, particularly toxicity in overdose. Co-proxamol tablets (unlicensed) may still be prescribed for patients who find it difficult to change, because alternatives are not effective or suitable.

Opioid analgesics

Opioid analgesics are usually used to relieve moderate to severe pain particularly of visceral origin. Repeated administration may cause dependence and tolerance, but this is no deterrent in the control of pain in terminal illness. Regular use of a potent opioid may be appropriate for certain cases of chronic non-malignant pain; treatment should be supervised by a specialist and the patient should be assessed at regular intervals.

Strong opioids

Morphine p. 367 remains the most valuable opioid analgesic for severe pain although it frequently causes nausea and vomiting. It is the standard against which other opioid analgesics are compared. In addition to relief of pain, morphine also confers a state of euphoria and mental detachment.

Methadone hydrochloride p. 436 has both opioid agonist and antagonist properties and may precipitate withdrawal symptoms, including pain, in patients dependent on other opioids. It has abuse potential and may itself cause dependence. It has a much longer duration of action than morphine and sublingually is an effective analgesic for 6 to 8 hours. Unlike most opioid analgesics, the effects of buprenorphine are only partially reversed by naloxone hydrochloride p. 113.

Dipipanone hydrochloride used alone is less sedating than morphine but the only preparation available contains an antiemetic and is therefore not suitable for regular regimens in palliative care. Diamorphine hydrochloride p. 361 (heroin) is a powerful opioid analgesic. It may cause less nausea and hypotension than morphine. In palliative care the greater solubility of diamorphine hydrochloride allows effective doses to be injected in smaller volumes and this is important in the emaciated patient.

Alfentanil p. 357, fentanyl p. 362 and remifentanil p. 1108 are used by injection for intra-operative analgesia; fentanyl is available in a transdermal drug delivery system as a self-adhesive patch which is changed every 72 hours.

Methadone hydrochloride p. 436 is less sedating than morphine and acts for longer periods. In prolonged use, methadone hydrochloride should not be administered more often than twice daily to avoid the risk of accumulation and opioid over dosage. Methadone hydrochloride may be used instead of morphine in the occasional patient who experiences excitation (or exacerbation of pain) with morphine.

Oxycodone hydrochloride p. 369 has an efficacy and side-effect profile similar to that of morphine. It is used primarily for control of pain in palliative care.

Papaveretum p. 371 is rarely used; morphine is easier to prescribe and less prone to error with regard to the strength and dose.

Pentazocine p. 371 has both agonist and antagonist properties and precipitates withdrawal symptoms, including pain in patients dependent on opioids. By injection it is more potent than dihydrocodeine tartrate or codeine phosphate, but hallucinations and thought disturbances may occur. It is not recommended and, in particular, should
be avoided after myocardial infarction as it may increase pulmonary and aortic blood pressure as well as cardiac work.

Pethidine hydrochloride p. 372 produces prompt but short-lasting anaesthesia; it is less constipating than morphine, but even in high doses is a less potent analgesic. It is not suitable for severe continuing pain. It is used for analgesia in labour; however, other opioids, such as morphine or diamorphine hydrochloride p. 361, are often preferred for obstetric pain.

Tapentadol p. 372 produces analgesia by two mechanisms. It is an opioid-receptor agonist and it also inhibits noradrenaline reuptake. Nausea, vomiting, and constipation are less likely to occur with tapentadol than with other strong opioid analgesics.

Tramadol hydrochloride p. 373 produces analgesia by two mechanisms: an opioid effect and an enhancement of serotonergic and adrenergic pathways. It has fewer of the typical opioid side-effects (notably, less respiratory depression, less constipation and less addiction potential); psychiatric reactions have been reported.

Weak opioids
Codeine phosphate p. 360 can be used for the relief of mild to moderate pain where other painkillers such as paracetamol or ibuprofen have proved ineffective. Dihydrocodeine tartrate p. 362 has an analgesic efficacy similar to that of codeine phosphate. Higher doses may provide some additional pain relief but this may be at the cost of more nausea and vomiting.

Meptazinol p. 367 is claimed to have a low incidence of respiratory depression. It has a reported length of action of 2 to 7 hours with onset within 15 minutes.

Postoperative analgesia
A combination of opioid and non-opioid analgesics is used to treat postoperative pain. The use of intra-operative opioids affects the prescribing of postoperative analgesics. A postoperative opioid analgesic should be given with care since it may potentiate any residual respiratory depression.

Morphine p. 367 is used most widely. Tramadol hydrochloride p. 373 is not as effective in severe pain as other opioid analgesics. Buprenorphine p. 434 may antagonise the analgesic effect of previously administered opioids and is generally not recommended. Pethidine hydrochloride p. 372 is generally not recommended for postoperative pain because it is metabolised to norpethidine which may accumulate, particularly in renal impairment; norpethidine stimulates the central nervous system and may cause convulsions.

Opioids are also given epidurally [unlicensed route] in the postoperative period but are associated with side-effects such as pruritus, urinary retention, nausea and vomiting; respiratory depression can be delayed, particularly with morphine.

Patient-controlled analgesia (PCA) can be used to relieve postoperative pain—consult individual hospital protocols.

Pain management and opioid dependence
Although caution is necessary, patients who are dependent on opioids or have a history of drug dependence may be treated with opioid analgesics when there is a clinical need. Treatment with opioid analgesics in this patient group should normally be carried out with the advice of specialists. However, doctors do not require a special licence to prescribe opioid analgesics to patients with opioid dependence for relief of pain due to organic disease or injury.

ANALGESICS

Aspirin with codeine
The properties listed below are those particular to the combination only. For the properties of the components please consider, aspirin p. 104, codeine phosphate p. 360.

INDICATIONS AND DOSE
Mild to moderate pain | Pyrexia

BY MOUTH
▶ Adult: 1–2 tablets every 4–6 hours as required, dose to be dispersed in water; maximum 8 tablets per day

PRESCRIBING AND DISPENSING INFORMATION When co-codaprin tablets or dispersible tablets are prescribed and no strength is stated, tablets or dispersible tablets, respectively, containing codeine phosphate 8 mg and aspirin 400 mg should be dispensed.

LESS SUITABLE FOR PRESCRIBING Aspirin with codeine is less suitable for prescribing.

EXCEPTIONS TO LEGAL CATEGORY Aspirin with codeine can be sold to the public provided packs contain no more than 32 capsules or tablets; pharmacists can sell multiple packs up to a total quantity of 100 capsules or tablets in justifiable circumstances.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Dispersible tablet

CODIS (Reckitt Benckiser Healthcare (UK) Ltd)
Aspirin 500 mg, Codeine phosphate 8 mg Codis 500 dispersible tablets (sugar-free) | 32 tablet | £3.23 Schedule 5 (CD Inv)
Co-codaprin (Non-proprietary)
Aspirin 400 mg, Codeine 8 mg Co-codaprin 8 mg/400 mg dispersible tablets | 100 tablet | £3.75 Schedule 5 (CD Inv)

Paracetamol
(Acetaminophen)

INDICATIONS AND DOSE
Mild to moderate pain | Pyrexia

BY MOUTH
▶ Adult: 0.5–1 g every 4–6 hours; maximum 4 g per day

BY INTRAVENOUS INFUSION
▶ Adult (body-weight 10–50 kg): 15 mg/kg every 4–6 hours, dose to be administered over 15 minutes; maximum 60 mg/kg per day
▶ Adult (body-weight 50 kg and above): 1 g every 4–6 hours, dose to be administered over 15 minutes; maximum 4 g per day

BY RECTUM
▶ Adult: 0.5–1 g every 4–6 hours; maximum 4 g per day
Pain

**Pain**

**PYREXIA**

- **By mouth**
  - Child 3-5 months: 60 mg every 4–6 hours; maximum 4 doses per day
  - Child 6 months-1 year: 120 mg every 4–6 hours; maximum 4 doses per day
  - Child 2-3 years: 180 mg every 4–6 hours; maximum 4 doses per day
  - Child 4-5 years: 240 mg every 4–6 hours; maximum 4 doses per day
  - Child 6-7 years: 240–250 mg every 4–6 hours; maximum 4 doses per day
  - Child 8-9 years: 360–375 mg every 4–6 hours; maximum 4 doses per day
  - Child 10-11 years: 480–500 mg every 4–6 hours; maximum 4 doses per day
  - Child 12-15 years: 480–750 mg every 4–6 hours; maximum 4 doses per day
  - Child 16-17 years: 0.5–1 g every 4–6 hours; maximum 4 doses per day

- **By rectum**
  - Child 3-11 months: 60–125 mg every 4–6 hours as required; maximum 4 doses per day
  - Child 1-4 years: 125–250 mg every 4–6 hours as required; maximum 4 doses per day
  - Child 5-11 years: 250–500 mg every 4–6 hours as required; maximum 4 doses per day
  - Child 12-17 years: 500 mg every 4–6 hours

**Post-immunisation pyrexia in infants**

- **By mouth**
  - Child 2 months: 60 mg for 1 dose, then 60 mg after 4–6 hours if required

**PANADOL ON**

**Mild to moderate pain**

- **By mouth**
  - Adult: 1 g up to 4 times a day, dose not to be taken more often than every 4 hours

**UNLICENSED USE**

- Paracetamol oral suspension 500 mg/5 mL not licensed for use in children under 16 years. Not licensed for use in children under 2 months by mouth; under 3 months by rectum. Intra muscular infusion not licensed in pre-term neonates, or children and neonates with body-weight under 10 kg.

**CAUTIONS**

- Alcohol dependence - before administering, check when paracetamol last administered and cumulative paracetamol dose over previous 24 hours - chronic alcoholism - chronic dehydration - chronic malnutrition - hepatocellular insufficiency

**INTERACTIONS** → Appendix 1 (paracetamol).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Rare: Acute generalised exanthematous pustulosis - malaise - skin reactions - Stevens-Johnson syndrome - toxic epidermal necrolysis

- Frequency not known: Blood disorders - leucopenia - neutropenia - thrombocytopenia

**SPECIFIC SIDE-EFFECTS**

- Rare
  - With intravenous use: flushing - tachycardia
  - Frequency not known
  - With intravenous use: hypotension

**OVERDOSE**

**Important**:

Liver damage and less frequently renal damage may occur following overdose.

Nausea and vomiting, the only early features of poisoning, usually settle within 24 hours. Persistence beyond this time, often associated with the onset of right subcostal pain and tenderness, usually indicates development of hepatic necrosis.

For specific details on the management of poisoning, see Paracetamol, under Emergency treatment of poisoning, p. 1123

- **PREGNANCY** Not known to be harmful.
- **BREAST FEEDING** Amount too small to be harmful.
- **HEPATIC IMPAIRMENT** Dose-related toxicity—avoid large doses.

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (Perfalgan®), give in Glucose 5% or Sodium Chloride 0.9%; dilute to a concentration of not less than 1 mg/mL and use within an hour; may also be given undiluted. For children under 33 kg, use 50 mL-vial.

**PRESCRIBING AND DISPENSING INFORMATION**

BP directs that when Paediatric Paracetamol Oral Suspension or Paediatric Paracetamol Mixture is prescribed Paracetamol Oral Suspension 120 mg/5 mL should be dispensed.

**PATIENT AND CARER ADVICE**

- In children: Medicines for Children leaflet: Paracetamol for mild-to-moderate pain www.medicinesforchildren.org.uk/paracetamol-for-mildtomoderate-pain

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulary

Paracetamol Tablets may be prescribed. Paracetamol Soluble Tablets 500 mg may be prescribed. Paracetamol Oral Suspension may be prescribed.

**EXCEPTIONS TO LEGAL CATEGORY**

Paracetamol capsules or tablets can be sold to the public provided packs contain no more than 32 capsules or tablets; pharmacists can sell multiple packs up to a total quantity of 100 capsules or tablets in justifiable circumstances.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, oral suspension, oral solution

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

29, 30

- **PARACETAMOL (Non-proprietary)**
  - Paracetamol 500 mg
    - 16 tablet [GS] £0.43 | 32 tablet [P] £2.11 DT price = £0.96 | 100 tablet [PS] £3.18 DT price = £3.00
  - Paracetamol 500 mg tablets
    - 16 tablet [GS] £0.48 | 30 tablet [P] £1.24 DT price = £0.96 | 100 tablet [PS] £3.18 DT price = £3.00 | 1000 tablet [PS] £31.25 | 5000 tablet [PS] no price available
    - Panadol (GlaxoSmithKline Consumer Healthcare)
  - Paracetamol 500 mg
    - 16 tablet [GS] £0.07 | 32 tablet [P] £1.74 DT price = £0.96
  - Brands may include Mandinal

**Effervescent tablet**

- **PARACETAMOL (Non-proprietary)**
  - Paracetamol 500 mg
## Paracetamol (Non-proprietary)

### Solution for infusion
- **Paracetamol 120 mg** Disprol Paracetamol 120mg solution tablets (sugar-free) 16 tablet (GSL) £0.97
- **Oral solution**
  - **Capol Fastmelts** McNeil Products Ltd
  - **Paracetamol 250 mg** Capol Six Plus Fastmelts 250mg tablets (sugar-free) 12 tablet (P) £2.28 (sugar-free) 24 tablet (P) £3.59

### Capsule
- **Paracetamol 500 mg** Numark Paracetamol 500mg capsules | 12 capsule (P) £0.54 DT price = £1.33
- **Paracetamol 500mg capsules** | 16 capsule (P) £0.55
- **Paracetamol 500mg capsules** | 16 capsule (GSL) no price available

### Oral suspension
- **Paracetamol 24 mg per 1 ml** Paracetamol 120mg/5ml oral suspension paediatric | 100 ml (P) £0.72 | 500 ml (P) £3.10 DT price = £1.10
- **Paracetamol 120mg/5ml oral suspension paediatric sugar-free** (sugar-free) | 100 ml (P) £2.40 DT price = £1.39 (sugar-free) | 200 ml (P) £2.78 (sugar-free) | 500 ml (P) £6.95 (sugar-free) | 1000 ml (P) £13.90

### Paracetamol with tramadol

The properties listed below are those particular to the combination only. For the properties of the components please consider, paracetamol p.354, tramadol hydrochloride p.373.

### INDICATIONS AND DOSE

**Moderate to severe pain**

**By mouth**
- **Child:** 12-17 years: 2 tablets up to every 6 hours; maximum 8 tablets per day
- **Adult:** 2 tablets up to every 6 hours; maximum 8 tablets per day

### MEDICINAL FORMS

There may be variation in the licensing of different medicines containing the same drug.

### Tablet

- **Paracetamol 325 mg, Tramadol hydrochloride 37.5 mg** Tramadol 37.5mg / Paracetamol 325mg tablets | 60 tablet (GSL) £9.20-£9.68 DT price = £9.22 Schedule 3 (CD No Register Exempt Safe Custody)
- **Tramact (Grunenthal Ltd)**
  - **Paracetamol 325 mg, Tramadol hydrochloride 37.5 mg** Tramact 37.5mg/325mg effervescent tablets (sugar-free) | 60 tablet (P) £9.68 DT price = £9.22 Schedule 3 (CD No Register Exempt Safe Custody)

### Effervescent tablet

- **Paracetamol with tramadol**
  - **By mouth**
    - **Adult:** Initially 60 mg 3 times a day, adjusted according to response; usual dose 30–90 mg 3 times a day

### Nefopam hydrochloride

### INDICATIONS AND DOSE

**Moderate pain**

**By mouth**
- **Adult:** Initially 60 mg 3 times a day, adjusted according to response; usual dose 30–90 mg 3 times a day
Opioids

CONTRA-INDICATIONS Acute respiratory depression • comatose patients • head injury (opioid analgesics interfere with pupillary responses vital for neurological assessment) • raised intracranial pressure (opioid analgesics interfere with pupillary responses vital for neurological assessment) • risk of paralytic ileus

CAUTIONS Adrenocortical insufficiency (reduced dose is recommended) • asthma (avoid during an acute attack) • convulsive disorders • debilitated patients (reduced dose is recommended) • diseases of the biliary tract • elderly (reduced dose is recommended) • hypotension • hypothyroidism (reduced dose is recommended) • impaired respiratory function (avoid in chronic obstructive pulmonary disease) • inflammatory bowel disorders • myasthenia gravis • obstructive bowel disorders • prostatic hypertrophy • shock • urethral stenosis

CAUTIONS, FURTHER INFORMATION Dependence Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence.

Palliative care In the control of pain in terminal illness, the cautions listed should not necessarily be a deterrent to the use of opioid analgesics.

INTERACTIONS → Appendix 1 (opioid analgesics).

SIDE-EFFECTS

Common or very common Biliary spasm • bradycardia • confusion • constipation • dependence • difficulty with micturition • dizziness • drowsiness • dry mouth • dysphoria • euphoria • flushing • hallucinations • headache • hypotension (larger doses) • miosis • mood changes • muscle rigidity (larger doses) • nausea (particularly in initial stages) • oedema • palpitation • postural hypotension • pruritus • rash • respiratory depression (larger doses) • sexual dysfunction • sleep disturbances • sweating • tachycardia • ureteric spasm • urinary retention • urticaria • vertigo • visual disturbances • vomiting (particularly in initial stages)

Frequency not known Adrenal insufficiency (long-term use) • hyperalgesia (long-term use) • hypogonadism (long-term use)

SIDE-EFFECTS, FURTHER INFORMATION

Hypogonadism and adrenal insufficiency Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both males and females. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction.

Hyperalgesia Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.

Respiratory depression Respiratory depression is a major concern with opioid analgesics and it may be treated by artificial ventilation or be reversed by naloxone.

Dependence and withdrawal Psychological dependence rarely occurs when opioids are used therapeutically (e.g. for pain relief) but tolerance can develop during long-term treatment.

Overdose Opioids (narcotic analgesics) cause coma, respiratory depression, and pinpoint pupils. For details on the management of poisoning, see Opioids, under Emergency treatment of poisoning p. 1123 and consider the specific antidote, naloxone hydrochloride p. 1133.

Pregnancy Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour.

Hepatic impairment Avoid use or reduce dose; may precipitate coma in patients with hepatic impairment.

Renal impairment Avoid use or reduce dose; may precipitate coma in patients with renal impairment.

Drug and driving legislation regarding driving whilst taking certain controlled drugs, including opioids, see Drugs and driving under Guidance on prescribing p. 1.

Alfentanil

INDICATIONS AND DOSE

Spontaneous respiration: analgesia and enhancement of anaesthesia for short procedures

BY INTRAVENOUS INJECTION

Adult: Initially up to 500 micrograms, dose to be administered over 30 seconds; supplemental doses 250 micrograms

Assisted ventilation: analgesia and enhancement of anaesthesia for short procedures

BY INTRAVENOUS INJECTION

Adult: Initially 30–50 micrograms/kg, supplemental doses 15 micrograms/kg
Assisted ventilation: analgesia and enhancement of anaesthesia during maintenance of anaesthesia for longer procedures

**BY INTRAVENOUS INFUSION**
- Adult: Initially 50–100 micrograms/kg, dose to be administered over 10 minutes or as a bolus, followed by maintenance 30–60 micrograms/kg/hour

**Assisted ventilation: analgesia and suppression of respiratory activity during intensive care**

**BY INTRAVENOUS INFUSION**
- Adult: Initially 2 mg/hour, adjusted according to response; usual dose 0.5–10 mg/hour, alternatively initially 5 mg in divided doses, to be administered over 10 minutes; dose used for more rapid initial control, reduce rate of administration if hypotension or bradycardia occur; additional doses of 0.5–1 mg may be given by intravenous injection during short painful procedures

**Doses at extremes of body-weight**
To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal bodyweight.

**PHARMACOKINETICS**
Half-life is prolonged in neonates and accumulation is likely with prolonged use. Clearance may be increased in children 1 month–12 years and higher infusion doses might be needed.

**CAUTIONS**

**CAUTIONS, FURTHER INFORMATION**
Repeated intra-operative doses Repeated intra-operative doses of alfentanil should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive.

**SIDE-EFFECTS**
- **Common or very common** Hypertension - myoclonic movements
- **Uncommon** Arrhythmias - hiccup - laryngospasm
- **Rare** Epistaxis
- **Frequency not known** Cardiac arrest - convulsions - cough - muscle rigidity - pyrexia

**SIDE-EFFECTS, FURTHER INFORMATION**
Muscle rigidity Alfentanil can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.

**BREAST FEEDING**
Present in milk— withhold breastfeeding for 24 hours.

**RENAL IMPAIRMENT**
Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**DIRECTIONS FOR ADMINISTRATION**
5 mg/mL injection to be diluted before use. For continuous or intermittent intravenous infusion dilute in Glucose 5% or Sodium Chloride 0.9%.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, spray

**Solution for injection**
- **ALFENTANIL** (Non-proprietary) Alfentanil (as Alfentanil hydrochloride) 500 microgram per 1 ml Alfentanil 1mg/2ml solution for injection ampoules | 10 ampoule (Pom) £7.00 Schedule 2 (CD)
Alfentanil 5mg/1ml solution for injection ampoules | 5 ampoule (Pom) £16.00 Schedule 2 (CD)
Alfentanil (as Alfentanil hydrochloride) 5 mg per 1 ml Alfentanil 5mg/1ml solution for injection ampoules | 10 ampoule (Pom) £25.00 Schedule 2 (CD)

**Co-codamol**

**INDICATIONS AND DOSE**
Mild to moderate pain (using co-codamol 8/500 preparations only)

**BY MOUTH**
- Adult: 8/500–16/1000 mg every 4–6 hours as required; maximum 64/4000 mg per day

Mild to moderate pain (using co-codamol 15/500 preparations only)

**BY MOUTH**
- Adult: 15/500–30/1000 mg every 4–6 hours as required; maximum 120/4000 mg per day

Severe pain (using co-codamol 30/500 preparations only)

**BY MOUTH**
- Adult: 30/500–60/1000 mg every 4–6 hours as required; maximum 240/4000 mg per day

**SOLPADOIL® CAPLETS**
Severe pain

**BY MOUTH**
- Adult: 2 tablets every 4–6 hours as required; maximum 8 tablets per day

**KAPACE® 15/500**
Mild to moderate pain

**BY MOUTH**
- Adult: 2 tablets every 4–6 hours as required; maximum 8 tablets per day

**SOLPADOIL® EFFERVESCENT TABLETS**
Severe pain

**BY MOUTH USING EFFERVESCENT TABLETS**
- Adult: 2 tablets every 4–6 hours as required, tablets to be dispersed in water; maximum 8 tablets per day

**SOLPADOIL® CAPSULES**
Severe pain

**BY MOUTH**
- Adult: 2 capsules every 4–6 hours as required; maximum 8 capsules per day

**Important safety information**
See codeine phosphate p. 360 for MHRA/CHM advice for restrictions on the use of codeine as an analgesic in children.

**CONTRA-INDICATIONS**
Acute ulcerative colitis - antibiotic-associated colitis - children under 18 years who undergo the removal of tonsils or adenoids for the treatment of obstructive sleep apnoea - conditions where abdominal distention develops - conditions where inhibition of peristalsis should be avoided - known ultra-rapid codeine metabolisers

**CAUTIONS**
Acute abdomen - alcohol dependence - avoid abrupt withdrawal after long-term treatment - cardiac arrhythmias - chronic alcoholism - chronic dehydration - chronic malnutrition - convulsive disorders - gallstones - hepatocellular insufficiency

**CAUTIONS, FURTHER INFORMATION**
Variation in metabolism The capacity to metabolise codeine to morphine can vary considerably between

**Rapifen (Janssen-Cilag Ltd)**
Alfentanil (as Alfentanil hydrochloride) 500 microgram per 1 ml Rapifen 5mg/10ml solution for injection ampoules | 5 ampoule (Pom) £14.50 Schedule 2 (CD)
Alfentanil 1mg/2ml solution for injection ampoules | 10 ampoule (Pom) £6.34 Schedule 2 (CD)
Alfentanil (as Alfentanil hydrochloride) 5 mg per 1 ml Rapifen Intensive Care 5mg/1ml solution for injection ampoules | 10 ampoule (Pom) £23.19 (Hospital only) Schedule 2 (CD)
individuals; there is a marked increase in morphine toxicity in patients who are ultra-rapid codeine metabolisers (CYP2D6 ultra-rapid metabolisers) and a reduced therapeutic effect in poor codeine metabolisers.

**INTERACTIONS**  Appendix 1 (paracetamol).

**SIDE-EFFECTS** Abdominal pain, anorexia, blood disorders, depression (with larger doses), hypothermia, leucopenia, malaise, muscle fasciculation, neutropenia, pancreatitis, seizures, thrombocytopenia.

**Overdose Important:** liver damage (and less frequently renal damage) following overdosage with paracetamol.

**BREAST FEEDING** Avoid—although amount of codeine usually too small to be harmful, mothers vary considerably in their capacity to metabolise codeine—risk of morphine overdose in infant.

**HEPATIC IMPAIRMENT** Dose-related toxicity with paracetamol—avoid large doses.

**RENAI IMPAIRMENT** Reduce dose or avoid codeine; increased and prolonged effect; increased cerebral sensitivity.

**PRESCRIBING AND DISPENSING INFORMATION** Co-codamol is a mixture of codeine phosphate and paracetamol; the proportions are expressed in the form x/y, where x and y are the strengths in milligrams of codeine phosphate and paracetamol respectively.

When co-codamol tablets, dispersible (or effervescent) tablets, or capsules are prescribed and no strength is stated, tablets, dispersible (or effervescent) tablets, or capsules, respectively, containing codeine phosphate 8 mg and paracetamol 500 mg should be dispensed. The Drug Tariff allows tablets of co-codamol labelled "dispersible" to be dispensed against an order for "effervescent" and vice versa.

**LESS SUITABLE FOR PRESCRIBING** Co-codamol is less suitable for prescribing.

**EXCEPTIONS TO LEGAL CATEGORY** Co-codamol 8/500 can be sold to the public in certain circumstances; for exemptions see Medicines, Ethics and Practice. London, Pharmaceutical Press (always consult latest edition).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

**Tablet**

**CO-CODAMOL (Non-proprietary)**

Codeine phosphate 8 mg, Paracetamol 500 mg. Co-codamol 8mg/500mg tablets 30 tablet (£1.19 DT price = £1.19 Schedule 5 (CD Inv) 32 tablet (£1.42 Schedule 5 (CD Inv) 100 tablet (£5.98 Schedule 5 (CD Inv) 1000 tablet (£39.70 Schedule 5 (CD Inv) Co-codamol 8mg/500mg tablets 32 tablet (£0.69 Schedule 5 (CD Inv)

Codeine phosphate 15 mg, Paracetamol 500 mg. Co-codamol 15mg/500mg tablets 100 tablet (£5.00 DT price = £5.58 Schedule 5 (CD Inv)

Codeine phosphate 30 mg, Paracetamol 500 mg. Co-codamol 30mg/500mg tablets 100 tablet (£9.00 DT price = £5.80 Schedule 5 (CD Inv) Co-codamol 30mg/500mg tablets 30 tablet (£2.45 DT price = £1.74 Schedule 5 (CD Inv) 100 tablet (£11.00 DT price = £5.80 Schedule 5 (CD Inv)

Kapake (Galen Ltd)

Codeine phosphate 15 mg, Paracetamol 500 mg Kapake 15mg/500mg tablets 100 tablet (£7.01 DT price = £5.98 Schedule 5 (CD Inv)

Codeine phosphate 30 mg, Paracetamol 500 mg Kapake 30mg/500mg tablets 100 tablet (£6.04 DT price = £5.80 Schedule 5 (CD Inv)

Solpadol (Sanofi)

Codeine phosphate 30 mg, Paracetamol 500 mg Solpadol 30mg/500mg tablets 30 tablet (£2.23 DT price = £1.74

Schedule 5 (CD Inv) 100 tablet (£5.80 Schedule 5 (CD Inv)

Brands may include Codipar, Migraleve Yellow, Panadol Ultra, Solpadine Max, Zapain

**Effervescent tablet**

CAUTIONARY AND ADVISORY LABELS 2, 13, 29, 30

**EXCipients:** May contain Aspartame

**ELECTROLYTES:** May contain Sodium

**CO-CODAMOL (Non-proprietary)**

Codeine phosphate 8 mg, Paracetamol 500 mg Co-codamol 8mg/500mg effervescent tablets 32 tablet (£4.51 DT price = £2.52 Schedule 5 (CD Inv) 60 tablet (£6.40 no price available Schedule 5 (CD Inv) 100 tablet (£12.97 DT price = £8.88 Schedule 5 (CD Inv)

Codeine phosphate 30 mg, Paracetamol 500 mg Co-codamol 30mg/500mg effervescent tablets 32 tablet (£5.40 DT price = £2.80 Schedule 5 (CD Inv) 100 tablet (£9.20 DT price = £8.75 Schedule 5 (CD Inv)

Tylex (UEB Pharma Ltd)

Codeine phosphate 30 mg, Paracetamol 500 mg Tylex 30mg/500mg effervescent tablets 100 tablet (£9.06 DT price = £8.75 Schedule 5 (CD Inv)

Brands may include Codipar, Paracodol; Solpadol

**Capsule**

CAUTIONARY AND ADVISORY LABELS 2, 29, 30

**EXCipients:** May contain Sulphites

**CO-CODAMOL (Non-proprietary)**

Codeine phosphate 8 mg, Paracetamol 500 mg Co-codamol 8mg/500mg capsules 32 capsule (£3.68 DT price = £3.68 Schedule 5 (CD Inv) 100 capsule (£11.50 DT price = £11.50 Schedule 5 (CD Inv)

Codeine phosphate 30 mg, Paracetamol 500 mg Co-codamol 30mg/500mg capsules 100 capsule (£15.00 DT price = £14.10 Schedule 5 (CD Inv)

Codipar (AMCO)

Codeine phosphate 15 mg, Paracetamol 500 mg Codipar 15mg/500mg capsules 100 capsule (£7.25 Schedule 5 (CD Inv)

Kapake (Galen Ltd)

Codeine phosphate 30 mg, Paracetamol 500 mg Kapake 30mg/500mg capsules 100 capsule (£6.04 DT price = £6.10 Schedule 5 (CD Inv)

Solpadol (Sanofi)

Codeine phosphate 30 mg, Paracetamol 500 mg Solpadol 30mg/500mg capsules 100 capsule (£6.74 Schedule 5 (CD Inv)

Tylex (UEB Pharma Ltd)

Codeine phosphate 30 mg, Paracetamol 500 mg Tylex 30mg/500mg capsules 100 capsule (£0.61 Schedule 5 (CD Inv) 24 capsule (£1.78 Schedule 5 (CD Inv) 100 capsule (£7.93 DT price = £4.10 Schedule 5 (CD Inv)

Zapain (AMCO)

Codeine phosphate 30 mg, Paracetamol 500 mg Zapain 30mg/500mg capsules 100 capsule (£3.85 DT price = £4.10 Schedule 5 (CD Inv)

**Co-dydramol**

**INDICATIONS AND DOSE**

Mild to moderate pain (using co-dydramol 10/500 preparations only)

**BY MOUTH**

Adult: 10/500 – 20/1000 mg every 4 – 6 hours as required; maximum 80/4000 mg per day

Severe pain (using co-dydramol 20/500 preparations only)

**BY MOUTH**

Adult: 20/500 – 40/1000 mg every 4 – 6 hours as required; maximum 160/4000 mg per day

Severe pain (using co-dydramol 30/500 preparations only)

**BY MOUTH**

Adult: 30/500 – 60/1000 mg every 4 – 6 hours as required; maximum 240/4000 mg per day

**Dose equivalence and conversion**

A mixture of dihydrocodeine tartrate and paracetamol; the proportions are expressed in the form x/y,
Nervous system

Codeine phosphate

**PRESCRIBING AND DISPENSING INFORMATION**

**RENAL IMPAIRMENT**
Reduce dose or avoid.

**SIDE-EFFECTS**
- Abdominal pain
- Acute diarrhoea
- Constipation
- Reversible liver damage (and less frequently renal damage) following overdose with paracetamol.
- **OVERDOSAGE**
  - **Important:** liver damage (and less frequently renal damage) following overdose with paracetamol.

**INTERACTIONS**
- **Appendix 1 (paracetamol).**
- **CO-DYDRAMOL (Non-proprietary)**
  - Dihydrocodeine tartrate 10 mg, Paracetamol 500 mg
  - **Tablet**
    - Containing the same drug. Forms available from special-order
    - There can be variation in the licensing of different medicines.

**CONTRADICTION**
- Codeine is contra-indicated in all children (under 18 years) who undergo the removal of tonsils or adenoids for the treatment of obstructive sleep apnoea.
- **Cautions and Advisory Labels**
  - Co-dyramol tablets are prescribed and no strength is stated, tablets containing dihydrocodeine tartrate 10 mg and paracetamol 500 mg should be dispensed.
  - Co-dyramol is less suitable for prescribing.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, powder.

**Important safety information**

**MHRA/CHM ADVICE (JULY 2013) CODEINE FOR ANALGESIA:**
- RESTRICTED USE IN CHILDREN DUE TO REPORTS OF MORPHINE TOXICITY
- Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone.

**Codeine phosphate**

**INDICATIONS AND DOSE**

**Acute diarrhoea**

**BY MOUTH**
- Child: 30 mg 3–4 times a day; usual dose 15–60 mg 3–4 times a day.
- Adult: 30 mg 3–4 times a day; usual dose 15–60 mg 3–4 times a day.

**Mild to moderate pain**

**BY MOUTH**
- Adult: 30–60 mg every 4 hours if required; maximum 240 mg per day.
- **BY INTRAMUSCULAR INJECTION**
- Adult: 30–60 mg every 4 hours if required.

**Short-term treatment of acute moderate pain**

**BY MOUTH OR BY INTRAMUSCULAR INJECTION**
- Child 12-17 years: 30–60 mg every 6 hours if required for maximum 3 days; maximum 240 mg per day.

**CONTRA-INDICATIONS**
- Acute ulcerative colitis - antibiotic-associated colitis - children under 18 years who undergo the removal of tonsils or adenoids for the treatment of obstructive sleep apnoea - conditions where abdominal distension develops - conditions where inhibition of peristalsis should be avoided - known ultrarapid codeine metabolisers

**CAUTIONS**
- Acute abdominal - cardiac arrhythmias - gallstones - not recommended for adolescents aged 12–18 years with breathing problems

**CAUTIONS, FURTHER INFORMATION**

**Variation in metabolism**
- The capacity to metabolise codeine to morphine can vary considerably between individuals; there is a marked increase in morphine toxicity in patients who are ultrarapid codeine.

---

**HYDROCODEINE TARTRATE 10 mg, PARACETAMOL 500 mg**

**Tablet**

**Schedule**

**P**

**DT price = £1.17 Schedule 5 (CD Inv)**

**100 tablet (P) £11.00**

**Schedule 5 (CD Inv)**

**500 tablet (P) £13.50 Schedule 5 (CD Inv)**

---

**MEDICATION SYSTEM OF CLASSIFICATION**

- N02C Codeine
- N02CA09 Dihydrocodeine
- N02B20 Paracetamol

---

**DRY OR PAINFUL COUGH**

**BY MOUTH USING LINCTUS**

- Adult: 15–30 mg 3–4 times a day.
metabolisers (CYP2D6 ultra-rapid metabolisers) and a reduced therapeutic effect in poor codeine metabolisers.

- **SIDE-EFFECTS** Abdominal pain · anorexia · antidiuretic effect · hypothermia · malaise · muscle fasciculation · pancreatitis · seizures
- **BREAST FEEDING** Avoid—although amount usually too small to be harmful, mothers vary considerably in their capacity to metabolise codeine—risk of morphine overdose in infant.
- **RENAL IMPAIRMENT** Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.
- **PRESCRIBING AND DISPENSING INFORMATION** BP directs that when Diabetic Codeine Linctus is prescribed, Codeine Linctus formulated with a vehicle appropriate for administration to diabetics, whether or not labelled 'Diabetic Codeine Linctus', shall be dispensed or supplied.
- **PATIENT AND CARER ADVICE** Medicines for Children leaflet: Codeine phosphate for pain www.medicinesforchildren.org.uk/codeine-phosphate-pain-0

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, solution for injection, oral suspension, oral solution

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2**

- **CODEINE PHOSPHATE (Non-proprietary)**
  - Codeine phosphate 15 mg Codeine 15mg tablets | 28 tablet (PBM) £1.90 DT price = £1.26 Schedule 5 (CD Inv) | 30 tablet (PBM) no price available Schedule 5 (CD Inv) | 100 tablet (PBM) £6.60 DT price = £4.46 Schedule 5 (CD Inv) | 500 tablet (PBM) no price available Schedule 5 (CD Inv)
  - Codeine phosphate 30 mg Codeine 30mg tablets | 28 tablet (PBM) £2.50 DT price = £1.52 Schedule 5 (CD Inv) | 30 tablet (PBM) no price available Schedule 5 (CD Inv) | 100 tablet (PBM) £5.68 DT price = £3.43 Schedule 5 (CD Inv) | 500 tablet (PBM) £44.00 Schedule 5 (CD Inv)
  - Codeine phosphate 60 mg Codeine 60mg tablets | 28 tablet (PBM) £5.95 DT price = £2.70 Schedule 5 (CD Inv)

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS 2**

- **CODEINE PHOSPHATE (Non-proprietary)**
  - Codeine phosphate 3 mg per 1 ml Codeine 15mg/5ml linctus sugar free (sugar-free) | 200 ml (PBM) £3.06 DT price = £1.69 Schedule 5 (CD Inv) (sugar-free) | 2000 ml (PBM) £16.90 Schedule 5 (CD Inv)
  - Codeine 15mg/5ml linctus | 200 ml (PBM) £1.79 DT price = £1.79 Schedule 5 (CD Inv) | 2000 ml (PBM) no price available Schedule 5 (CD Inv)
  - Codeine phosphate 5 mg per 1 ml Codeine 25mg/5ml oral solution | 500 ml (PBM) £6.53 DT price = £6.53 Schedule 5 (CD Inv)
  - Galcodine (Thornton & Ross Ltd)
    - Codeine phosphate 3 mg per 1 ml Galcodine 15mg/5ml linctus sugar free (sugar-free) | 2000 ml (PBM) £3.90 Schedule 5 (CD Inv)

**Solution for injection**

- **CODEINE PHOSPHATE (Non-proprietary)**
  - Codeine phosphate 60 mg per 1 ml Codeine 60mg/1ml solution for injection ampoules | 10 ampoule (PBM) £23.70–£25.00 Schedule 2 (CD)

---

**Diamorphine hydrochloride**

*Heroin hydrochloride*

**INDICATIONS AND DOSE**

**Acute pain**

- **BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION**
  - Adult: 5 mg every 4 hours if required
  - By SLOW INTRAVENOUS INJECTION
  - Adult: 1.25–2.5 mg every 4 hours if required

**Acute pain (heavier, well-muscled patients)**

- **BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION**
  - Adult: Up to 10 mg every 4 hours if required
  - By SLOW INTRAVENOUS INJECTION
  - Adult: 2.5–5 mg every 4 hours if required

**Chronic pain not currently treated with a strong opioid analgesic**

- **BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 2.5–5 mg every 4 hours, adjusted according to response
  - By SUBCUTANEOUS INFUSION
  - Adult: Initially 5–10 mg, adjusted according to response, dose to be administered over 24 hours

**Acute pulmonary oedema**

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 2.5–5 mg, dose to be administered at a rate of 1 mg/minute

**Myocardial infarction**

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 5 mg, followed by 2.5–5 mg if required, dose to be administered at a rate of 1–2 mg/minute
  - Elderly: 2.5 mg, followed by 1.25–2.5 mg if required, dose to be administered at a rate of 1–2 mg/minute

**Myocardial infarction (frail patients)**

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 2.5 mg, followed by 1.25–2.5 mg if required, dose to be administered at a rate of 1–2 mg/minute

- **CONTRA-INDICATIONS** Delayed gastric emptying · phaeochromocytoma

- **CAUTIONS** CNS depression · severe cor pulmonale · severe diarrhoea · toxic psychosis

- **SIDE-EFFECTS** Anorexia · asthenia · myocardial infarction · raised intracranial pressure · syncope · taste disturbance

- **BREAST FEEDING** Therapeutic doses unlikely to affect infant; withdrawal symptoms in infants of dependent mothers; breast-feeding not best method of treating dependence in offspring.

- **RENAL IMPAIRMENT** Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: powder for solution for injection, suppository, solution for injection, oral solution, capsule, impregnated cigarette

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2**

- **DIAMORPHINE HYDROCHLORIDE (Non-proprietary)**
  - Diamorphine hydrochloride 10 mg Diamorphine 10mg tablets | 100 tablet (PBM) £24.09 DT price = £28.09 Schedule 2 (CD)
  - Diamorphine 5mg powder for solution for injection ampoules | 5 vial (PBM) £11.89–£15.00 Schedule 2 (CD)
  - Diamorphine hydrochloride 5 mg Diamorphine 5mg powder for solution for injection ampoules | 5 vial (PBM) £11.36 DT price = £11.36 Schedule 2 (CD)
  - Diamorphine hydrochloride 10 mg Diamorphine 10mg powder for solution for injection ampoules | 5 vial (PBM) £15.00 DT price = £15.00 Schedule 2 (CD)
  - Diamorphine hydrochloride 30 mg Diamorphine 30mg powder for solution for injection ampoules | 5 vial (PBM) £16.99–£21.00 Schedule 2 (CD)
  - Diamorphine hydrochloride 50 mg Diamorphine 50mg powder for solution for injection ampoules | 5 vial (PBM) £14.02 DT price = £14.02 Schedule 2 (CD)
  - Diamorphine hydrochloride 100 mg Diamorphine 100mg powder for solution for injection ampoules | 5 vial (PBM) £42.99–£54.00 Schedule 2 (CD)
Dihydrocodeine tartrate

INDICATIONS AND DOSE
Moderate to severe pain
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Child 4–11 years: 0.5–1 mg/kg every 4–6 hours (max. per dose 30 mg)
- Child 12–17 years: 30 mg every 4–6 hours
- Adult: 30 mg every 4–6 hours as required
BY DEEP SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION
- Adult: Up to 50 mg every 4–6 hours if required
Chronic severe pain
BY MOUTH USING MODIFIED-RELEASE MEDICINES
- Child 12–17 years: 60–120 mg every 12 hours
- Adult: 60–120 mg every 12 hours

DF118 FORTE

Severe pain
BY MOUTH
- Child 12–17 years: 40–80 mg 3 times a day; maximum 240 mg per day
- Adult: 40–80 mg 3 times a day; maximum 240 mg per day

- UNLICENSED USE Most preparations not licensed for use in children under 4 years.
- CAUTIONS Pancreatitis, severe corticosteroids, paralytic ileus.
- SIDE-EFFECTS Abdominal pain, diarrhoea, paraesthesia, raised intracranial pressure.
- BREAST FEEDING Use only if potential benefit outweighs risk.
- RENAL IMPAIRMENT Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.
- PROFESSIONAL SPECIFIC INFORMATION
- Dental practitioners’ formulary Dihydrocodeine tablets 30 mg may be prescribed.
- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Table
CAUTIONARY AND ADVISORY LABELS 2
- DIHYDROCODEINE TARTRATE (Non-proprietary)
  - Dihydrocodeine tartrate 30 mg
  - Dihydrocodeine 30mg tablets
  - 28 tablet PO £1.75 DT price = £3.35 Schedule 5 (CD Inv)
  - 30 tablet PO £1.56 Schedule 5 (CD Inv)
  - 100 tablet PO £6.81 DT price = £8.82 Schedule 5 (CD Inv)
  - 500 tablet PO £24.11 Schedule 5 (CD Inv)
  - DF 118 (Martenstal Pharmaceuticals Ltd)
  - Dihydrocodeine tartrate 40 mg
  - DF 118 Forte 40mg tablets
  - 100 tablet PO £11.51 DT price = £15.11 Schedule 5 (CD Inv)

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 2, 25
- DHC Continus (Napp Pharmaceuticals Ltd)
  - Dihydrocodeine tartrate 60 mg
  - DHC Continus 60mg tablets
  - 56 tablet PO £5.20 DT price = £7.20 Schedule 5 (CD Inv)
  - Dihydrocodeine tartrate 90 mg
  - DHC Continus 90mg tablets
  - 56 tablet PO £8.66 DT price = £10.66 Schedule 5 (CD Inv)
  - Dihydrocodeine tartrate 120 mg
  - DHC Continus 120mg tablets
  - 56 tablet PO £10.95 DT price = £13.95 Schedule 5 (CD Inv)

Oral solution
CAUTIONARY AND ADVISORY LABELS 2
- DIHYDROCODEINE TARTRATE (Non-proprietary)
  - Dihydrocodeine tartrate 2 mg per 1 ml
  - Dihydrocodeine 10mg/5ml
  - Oral solution
  - 150 ml PO £6.20 Schedule 5 (CD Inv)

Solution for injection
- DIHYDROCODEINE TARTRATE (Non-proprietary)
  - Dihydrocodeine tartrate 50 mg per 1 ml
  - Dihydrocodeine 50mg/2ml solution for injection ampoules
  - 10 ampoule PO £78.90

Dipipanone hydrochloride with cyclizine

INDICATIONS AND DOSE
Acute pain
BY MOUTH
- Adult: Initially 1 tablet every 6 hours, then increased if necessary up to 3 tablets every 6 hours, dose to be increased gradually

- CAUTIONS Diabetes mellitus, palliative care (not recommended), phaeochromocytoma.
- SIDE-EFFECTS Psychosis, raised intracranial pressure, restlessness.
- BREAST FEEDING No information available.
- RENAL IMPAIRMENT Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Table
- DIPANNONE HYDROCHLORIDE WITH CYCLIZINE (Non-proprietary)
  - Cyclizine hydrochloride 30 mg, Dipipanone hydrochloride
  - 10 mg
  - Dipipanone 10mg / Cyclizine 30mg tablets
  - 50 tablet PO £181.67 DT price = £181.67 Schedule 2 (CD)

Fentanyl

INDICATIONS AND DOSE
Chronic intractable pain not currently treated with a strong opioid analgesic
BY TRANSDERMAL APPLICATION
- Child 16–17 years: Initially 12 micrograms/hour every 72 hours, alternatively initially 25 micrograms/hour every 72 hours, when starting, evaluation of the analgesic effect should not be made before the system has been worn for 24 hours (to allow for the gradual increase in plasma-fentanyl concentration)—previous analgesic therapy should be phased out gradually from time of first patch application, dose should be adjusted at 48–72 hour intervals in steps of 12–25 micrograms/hour if necessary, more than one patch may be used at a time (but applied at the same time to avoid confusion)—consider additional or alternative analgesic therapy if dose required exceeds 300 micrograms/hour (important: it takes 17 hours or more for the plasma-fentanyl concentration to decrease by 50%—replacement opioid therapy should be initiated at a low dose and increased gradually)
- Adult: Initially 12 micrograms/hour every 72 hours, alternatively initially 25 micrograms/hour every 72 hours, when starting, evaluation of the analgesic effect should not be made before the system has been worn for 24 hours (to allow for the gradual increase in plasma-fentanyl concentration)—previous analgesic
therapy should be phased out gradually from time of first patch application, dose should be adjusted at 48–72 hour intervals in steps of 12–25 micrograms/hour if necessary, more than one patch may be used at a time (but applied at the same time to avoid confusion)—consider additional or alternative analgesic therapy if dose required exceeds 300 micrograms/hour (important: it takes 17 hours or more for the plasma-fentanyl concentration to decrease by 50%—replacement opioid therapy should be initiated at a low dose and increased gradually).

**Chronic intractable pain currently treated with a strong opioid analgesic**

**By Transdermal Application**

- Child 2-17 years: Initial dose based on previous 24-hour opioid requirement (consult product literature), for evaluating analgesic efficacy and dose increments, see under Chronic intractable pain not currently treated with a strong opioid analgesic, for conversion from long-term oral morphine to transdermal fentanyl, see Pain management with opioids under p. 20.
- Adult: Initial dose based on previous 24-hour opioid requirement (consult product literature), for evaluating analgesic efficacy and dose increments, see under Chronic intractable pain not currently treated with a strong opioid analgesic, for conversion from long-term oral morphine to transdermal fentanyl, see Pain management with opioids under p. 20.

**Spontaneous respiration: analgesia and enhancement of anaesthesia, during operation**

**By Slow Intravenous Injection**

- Adult: Initially 50–100 micrograms (max. per dose 200 micrograms); dose maximum on specialist advice, then 25–50 micrograms as required

**By Intravenous Infusion**

- Adult: 3–4.8 micrograms/kg/hour, adjusted according to response

**Assisted ventilation: analgesia and enhancement of anaesthesia during operation**

**By Slow Intravenous Injection**

- Adult: Initially 10 micrograms/kg, dose to be given over 10 minutes, then 6 micrograms/kg/hour, adjusted according to response, may require up to 180 micrograms/kg/hour during cardiac surgery

**By Intravenous Infusion**

- Adult: Initially 10 micrograms/kg, dose to be given over 10 minutes, then 6 micrograms/kg/hour, adjusted according to response, may require up to 180 micrograms/kg/hour during cardiac surgery

**Breakthrough pain in patients receiving opioid therapy for chronic cancer pain**

**INITIALLY BY BUCCAL ADMINISTRATION USING LOZENGES**

- Child 16-17 years: Initially 200 micrograms, dose to be given over 15 minutes, then (by buccal administration) 200 micrograms after 15 minutes if required, no more than 2 dose units for each pain episode; if adequate pain relief not achieved with 1 dose unit for consecutive breakthrough pain episodes, increase the strength of the dose unit until adequate pain relief achieved with 4 lozenges or less daily, if more than 4 episodes of breakthrough pain each day, adjust background analgesia

- Adult: Initially 200 micrograms, dose to be given over 15 minutes, then (by buccal administration) 200 micrograms after 15 minutes if required, no more than 2 dose units for each pain episode; if adequate pain relief not achieved with 1 dose unit for consecutive breakthrough pain episodes, increase the strength of the dose unit until adequate pain relief achieved with 4 lozenges or less daily, if more than 4 episodes of breakthrough pain each day, adjust background analgesia

**By Buccal Administration Using Buccal Films**

- Adult: Initially 200 micrograms, adjusted according to response, consult product literature for information on dose adjustments, maximum 1.2 mg per episode of breakthrough pain; leave at least 4 hours between treatment of episodes of breakthrough pain, if more than 4 episodes of breakthrough pain each day occur on more than 4 consecutive days, adjust background analgesia

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal bodyweight.

**Dose equivalence and conversion**

Fentanyl films are not bioequivalent to other fentanyl preparations. Fentanyl preparations for the treatment of breakthrough pain are not interchangeable; if patients are switched from another fentanyl-containing preparation, a new dose titration is required.

**ABSTRAL®**

**Breakthrough pain in patients receiving opioid therapy for chronic cancer pain**

**By Mouth Using SUBLINGUAL TABLETS**

- Adult: Initially 100 micrograms, then 100 micrograms after 15–30 minutes if required, dose to be adjusted according to response—consult product literature, no more than 2 dose units 15–30 minutes apart, for each pain episode; max. 800 micrograms per episode of breakthrough pain; leave at least 2 hours between treatment of episodes of breakthrough pain, if more than 4 episodes of breakthrough pain each day occur on more than 4 consecutive days, adjust background analgesia

**RECIVIT® SUBLINGUAL TABLETS**

**Breakthrough pain in patients receiving opioid therapy for chronic cancer pain**

**By Mouth**

- Adult: Initially 133 micrograms, then 133 micrograms after 15–30 minutes (max. per dose 800 micrograms), dose to be repeated only if necessary. Consult product literature for dose adjustments, no more than 2 dose units 15–30 minutes apart, for each pain episode, maximum of 800 micrograms per episode of breakthrough pain, if more than 4 episodes of breakthrough pain each day occur on more than 4 consecutive days, adjust background analgesia; maximum 4 doses per day

**EFFENTORA®**

**Breakthrough pain in patients receiving opioid therapy for chronic cancer pain**

**By Mouth Using SUBLINGUAL TABLETS**

- Adult: Initially 100 micrograms, then 100 micrograms after 30 minutes if required, dose to be adjusted according to response—consult product literature, no more than 2 dose units for each pain episode; max. 800 micrograms per episode of breakthrough pain; leave at least 4 hours between treatment of episodes of breakthrough pain during titration

Continued →
PECFENT®
Breakthrough pain in patients receiving opioid therapy for chronic cancer pain
BY INTRanasAL ADMINISTRATION
- Adult: Initially 100 micrograms, adjusted according to response, dose to be administered into one nostril only, maximum 2 sprays for each pain episode and minimum 4 hours between treatment of each pain episode, if more than 4 breakthrough pain episodes daily, adjust background analgesia

INSTANyL®
Breakthrough pain in patients receiving opioid therapy for chronic cancer pain
BY INTRanasAL ADMINISTRATION
- Adult: Initially 50 micrograms, dose to be administered into one nostril, then 50 micrograms after 10 minutes if required, dose to be adjusted according to response, maximum 2 sprays for each pain episode and minimum 4 hours between treatment of each pain episode, if more than 4 breakthrough pain episodes daily, adjust background analgesia

UNLICENSED USE
- Not licensed for use in children under 2 years; infusion not licensed for use in children under 12 years.

CAUTIONS
- GENERAL CAUTIONS: Cerebral tumour, diabetes mellitus (with Actiq® lozenges), impaired consciousness
- SPECIFIC CAUTIONS
  - With buccal use: mucositis—absorption from oral preparations may be increased, caution during dose titration (in adults)
  - Transdermal preparations
    - Transdermal fentanyl patches are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patients.
    - Repeated intra-operative doses
      - Repeated intra-operative doses should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive.

SIDE-EFFECTS
- COMMON SIDE-EFFECTS
  - Uncommon: amnesia, arthralgia, blood disorders, chills, depressed level of consciousness, dysgeusia, flatulence, hypoventilation, ileus, impaired coordination, impaired vasodilation
  - Rare: hiccups
  - Very rare: Apnoea, arrhythmia, ataxia, bladder pain, delusions, haemoptysis

SPECIFIC SIDE-EFFECTS
- Common or very common
  - With intravenous use: myoclonic movements
  - Uncommon
  - With intravenous use: laryngospasm
  - Rare
    - With intravenous use: astyole, insomnia

SIDE-EFFECTS, FURTHER INFORMATION
- Fever or external heat: Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption).
- Muscle rigidity: Intravenous fentanyl can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.

BREAST FEEDING
- Monitor infant for opioid-induced side-effects.

RENAL IMPAIRMENT
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

DIRECTIONS FOR ADMINISTRATION
- With transdermal use: For patches, apply to dry, non-irritated, non-irradiated, non-hairy skin on torso or upper arm, removing after 72 hours and siting replacement patch on a different area (avoid using the same area for several days).
- With intravenous use in children: For intravenous infusion, injection solution may be diluted in Glucose 5% or Sodium Chloride 0.9%.
- With intravenous use in adults: For intravenous infusion (Sublimaze), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%.
- With buccal use: For buccal films, moisten mouth, place film on inner lining of cheek (pink side to cheek), hold for at least 5 seconds until it sticks, and leave to dissolve (15–30 minutes); if more than 1 film required do not overlap, but use another area of the mouth. Avoid liquids for 5 minutes after application; avoid food until the film has dissolved.
  - With buccal use: Patients should be advised to place the lozenge in the mouth against the cheek and move it around the mouth using the applicator; each lozenge should be sucked over a 15 minute period. In patients with a dry mouth, water may be used to moisten the buccal mucosa. Patients with diabetes should be advised each lozenge contains approximately 2 g glucose.

EFFENTORA®
- Place tablet between cheek and gum and leave to dissolve; if more than 1 tablet required, place second tablet on the other side of the mouth; tablet may alternatively be placed under the tongue (sublingually).

INSTANyL®
- Patient should sit or stand during administration.

PRESCRIBING AND DISPENSING INFORMATION
- Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write ‘Fentanyl 25 patches’ to prescribe patches that release fentanyl 25 micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. ‘one patch to be applied every 72 hours’. The total quantity of patches to be supplied should be written in words and figures.

PATIENT AND CARER ADVICE
- Medicines for Children leaflet: Fentanyl lozenges for pain
  - www.medicinesforchildren.org.uk/fentanyl-lozenges-for-pain
- Medicines for Children leaflet: Fentanyl patches for pain
  - www.medicinesforchildren.org.uk/fentanyl-patches-for-pain
- With transdermal use: Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdose. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or
impaired speech, and patients and carers should seek prompt medical attention.

- With buccal use Patients or carers should be given advice on how to administer fentanyl buccal films or fentanyl lozenges.
- With intranasal use Patients or carers should be given advice on how to administer fentanyl nasal spray.

**ABSTRAL®**

Patients should be advised not to eat or drink until the tablet is completely dissolved. In patients with a dry mouth, the buccal mucosa may be moistened with water before administration of tablet.

**RECVIT® SUBLINGUAL TABLETS**

Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed. In patients with a dry mouth, the buccal mucosa may be moistened with water before administration of tablet.

**EFFENTORA®**

Patients or carers should be given advice on how to administer Effentora® buccal tablets. Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed with a glass of water. Patients with a dry mouth should be advised to drink water to moisten the buccal mucosa before administration of the tablets; if appropriate effervescence does not occur, a switch of therapy may be advised.

**PECFENT® INSTANYL®**

Avoid concomitant use of other nasal preparations. Patients or carers should be given advice on how to administer the spray.

### NATIONAL FUNDING/ACCESS DECISIONS

**ABSTRAL®**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (January 2005) that Abstral® sublingual tablets should be restricted for use within NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

**EFFENTORA®**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised that Effentora® buccal tablets should be restricted for use within NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

**PECFENT®**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised PecFent® nasal spray should be restricted for use within NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

**INSTANYL®**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised that Instanyl® nasal spray should be restricted for use within NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for infusion, infusion.
Lozenge
CAUTIONARY AND ADVISORY LABELS 2
EXCIPIENTS: May contain Propylene glycol
- Actiq (Teva UK Ltd)
- Fentanyl (as Fentanyl citrate) 200 microgram Actiq 200 microgram lozenges with integral oromucosal applicator | 3 lozenge (P) £21.05 Schedule 2 (CD) | 30 lozenge (P) £210.41 Schedule 2 (CD)
- Fentanyl (as Fentanyl citrate) 400 microgram Actiq 400 microgram lozenges with integral oromucosal applicator | 3 lozenge (P) £21.05 Schedule 2 (CD) | 30 lozenge (P) £210.41 Schedule 2 (CD)
- Fentanyl (as Fentanyl citrate) 600 microgram Actiq 600 microgram lozenges with integral oromucosal applicator | 3 lozenge (P) £21.05 Schedule 2 (CD) | 30 lozenge (P) £210.41 Schedule 2 (CD)
- Fentanyl (as Fentanyl citrate) 800 microgram Actiq 800 microgram lozenges with integral oromucosal applicator | 3 lozenge (P) £21.05 Schedule 2 (CD) | 30 lozenge (P) £210.41 Schedule 2 (CD)
- Fentanyl (as Fentanyl citrate) 1.2 mg Actiq 1.2 mg lozenges with integral oromucosal applicator | 3 lozenge (P) £21.05 Schedule 2 (CD) | 30 lozenge (P) £210.41 Schedule 2 (CD)
- Fentanyl (as Fentanyl citrate) 1.6 mg Actiq 1.6 mg lozenges with integral oromucosal applicator | 3 lozenge (P) £21.05 Schedule 2 (CD) | 30 lozenge (P) £210.41 Schedule 2 (CD)

Solution for injection
- FENTANYL (Non-proprietary)
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 ml Fentanyl 100 micrograms/2 ml solution for injection ampoules | 10 ampoule (P) £7.50 Schedule 2 (CD)
  - Fentanyl 50 micrograms/10 ml solution for injection ampoules | 10 ampoule (P) £12.50 Schedule 2 (CD)
- Sublimaze (Janssen-Cilag Ltd)
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 ml Sublimaze 500 micrograms/10 ml solution for injection ampoules | 5 ampoule (P) £6.53 Schedule 2 (CD)

Solution for infusion
- FENTANYL (Non-proprietary)
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 ml Fentanyl 2.5 mg/50 ml solution for infusion vials | 1 vial (P) £5.00 Schedule 2 (CD)

Transdermal patch
CAUTIONARY AND ADVISORY LABELS 2
- FENTANYL (Non-proprietary)
  - Fentanyl 12 microgram per 1 hour Fentanyl 12 micrograms/hour transdermal patches | 5 patch (P) £12.59 DT price = £12.59 Schedule 2 (CD)
  - Fentanyl 25 microgram per 1 hour Fentanyl 25 micrograms/hour transdermal patches | 5 patch (P) £17.99 DT price = £17.99 Schedule 2 (CD)
  - Fentanyl 50 microgram per 1 hour Fentanyl 50 micrograms/hour transdermal patches | 5 patch (P) £33.66 DT price = £33.66 Schedule 2 (CD)
  - Fentanyl 75 microgram per 1 hour Fentanyl 75 micrograms/hour transdermal patches | 5 patch (P) £46.99 DT price = £46.99 Schedule 2 (CD)
  - Fentanyl 100 microgram per 1 hour Fentanyl 100 micrograms/hour transdermal patches | 5 patch (P) £57.86 DT price = £57.86 Schedule 2 (CD)
  - Durogesic DTrans (Janssen-Cilag Ltd)
  - Fentanyl 12 microgram per 1 hour Durogesic DTrans 12 micrograms transdermal patches | 5 patch (P) £12.59 DT price = £12.59 Schedule 2 (CD)
  - Fentanyl 25 microgram per 1 hour Durogesic DTrans 25 micrograms transdermal patches | 5 patch (P) £17.99 DT price = £17.99 Schedule 2 (CD)
  - Fentanyl 50 microgram per 1 hour Durogesic DTrans 50 micrograms transdermal patches | 5 patch (P) £33.66 DT price = £33.66 Schedule 2 (CD)
  - Fentanyl 75 microgram per 1 hour Durogesic DTrans 75 micrograms transdermal patches | 5 patch (P) £46.99 DT price = £46.99 Schedule 2 (CD)
  - Fentanyl 100 microgram per 1 hour Durogesic DTrans 100 micrograms transdermal patches | 5 patch (P) £57.86 DT price = £57.86 Schedule 2 (CD)

Spray
CAUTIONARY AND ADVISORY LABELS 2
- Instanyl (Takeda UK Ltd)
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 dose Instanyl 50 micrograms/dose nasal spray | 6 dose (P) £35.70 Schedule 2 (CD) | 10 dose (P) £59.50 Schedule 2 (CD) | 20 dose (P) £119.00 Schedule 2 (CD)
  - Fentanyl (as Fentanyl citrate) 100 microgram per 1 dose Instanyl 100 micrograms/dose nasal spray | 6 dose (P) £35.70 Schedule 2 (CD) | 10 dose (P) £59.50 Schedule 2 (CD) | 20 dose (P) £119.00 Schedule 2 (CD)
- PecFent (Archimedes Pharma UK Ltd)
  - Fentanyl (as Fentanyl citrate) 100 microgram per 1 dose PecFent 100 micrograms/dose nasal spray | 8 dose (P) £36.48 Schedule 2 (CD) | 32 dose (P) £145.92 Schedule 2 (CD)
  - Fentanyl (as Fentanyl citrate) 400 microgram per 1 dose PecFent 400 micrograms/dose nasal spray | 8 dose (P) £36.48 Schedule 2 (CD) | 32 dose (P) £145.92 Schedule 2 (CD)

Hydromorphone hydrochloride

INDICATIONS AND DOSE
Severe pain in cancer
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Child 12-17 years: 1.3 mg every 4 hours, dose to be increased if necessary according to severity of pain
- Adult: 1.3 mg every 4 hours, dose to be increased if necessary according to severity of pain

BY MOUTH USING MODIFIED-RELEASE MEDICINES
- Child 12-17 years: 4 mg every 12 hours, dose to be increased if necessary according to severity of pain
- Adult: 4 mg every 12 hours, dose to be increased if necessary according to severity of pain

CONTRA-INDICATIONS
- Acute abdomen

CAUTIONS
- Pancreatitis - toxic psychosis

SIDE-EFFECTS
- Common or very common Abdominal pain - anorexia - anxiety
- Uncommon Agitation - diarrhoea - dysgeusia - dyskinesia - myoclonus - paraesthesia - paralytic ileus - peripheral oedema - seizures - tremor
- BREAST FEEDING
- Avoid—no information available.

RENAL IMPAIRMENT
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

DIRECTIONS FOR ADMINISTRATION
For immediate-release capsules, swallow whole capsule or sprinkle contents on soft food. For modified-release capsules, swallow whole or open capsule and sprinkle contents on soft cold food (swallow the pellets within the capsule whole; do not crush or chew).

PATIENT AND CARER ADVICE
- Patients or carers should be given advice on how to administer hydromorphone hydrochloride capsules and modified-release capsules.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral solution

Capsule
CAUTIONARY AND ADVISORY LABELS 2
- Palladone (Napp Pharmaceuticals Ltd)
  - Hydromorphone hydrochloride 1.3 mg Palladone 1.3 mg capsules | 56 capsule (P) £8.82 Schedule 2 (CD)
  - Hydromorphone hydrochloride 2.6 mg Palladone 2.6 mg capsules | 56 capsule (P) £17.64 Schedule 2 (CD)
**Meptazinol**

**INDICATIONS AND DOSE**

Moderate to severe pain, including post-operative and obstetric pain and renal colic

**BY MOUTH**

- **Adult:** 200 mg every 3–6 hours as required
- **BY INTRAMUSCULAR INJECTION**
  - **Adult:** 75–100 mg every 2–4 hours if required
  - **BY SLOW INTRAVENOUS INJECTION**
  - **Adult:** 50–100 mg every 2–4 hours if required

**Obstetric analgesia**

- **BY INTRAMUSCULAR INJECTION**
- **Adult:** 2 mg/kg, usual dose 100–150 mg

**CONTRA-INDICATIONS**

- **Myocardial infarction - phaeochromocytoma**

**SIDE-EFFECTS**

- **Abdominal pain** - can induce withdrawal symptoms in patients dependent on opioids - diarrhoea - dyspepsia - hypothermia

**Overdose**

- Effects only partially reversed by naloxone.

**BREAST FEEDING**

- Use only if potential benefit outweighs risk.

**RENAL IMPAIRMENT**

- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 2**
- **Meptid (Almirall Ltd)**
  - Meptazinol (as Meptazinol hydrochloride) 200 mg Meptid 200mg tablets | 112 tablet | £22.11 DT price = £22.11

**Solution for injection**

- **Meptid (Almirall Ltd)**
  - Meptazinol (as Meptazinol hydrochloride) 100 mg per 1 ml Meptid 100mg/ml solution for injection ampoules | 10 ampoule | £19.21

**Morphine**

**INDICATIONS AND DOSE**

**Pain**

**BY SUBCUTANEOUS INJECTION**

- **Child 1-5 months:** Initially 100–200 micrograms/kg every 6 hours, adjusted according to response
- **Child 6 months-1 year:** Initially 100–200 micrograms/kg every 4 hours, adjusted according to response
- **Child 2-11 years:** Initially 200 micrograms/kg every 4 hours, adjusted according to response
- **Child 12-17 years:** Initially 2.5–10 mg every 4 hours, adjusted according to response

**BY INTRAMUSCULAR INJECTION**

- **Child 1-5 months:** 100 micrograms/kg every 6 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 100 micrograms/kg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 10–30 micrograms/kg/hour, adjusted according to response
- **Child 6 months-11 years:** 100 micrograms/kg every 4 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 100 micrograms/kg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 20–30 micrograms/kg/hour, adjusted according to response
- **Child 12-17 years:** 5 mg every 4 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 5 mg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 20–30 micrograms/kg/hour, adjusted according to response
- **Child 1-2 years:** Initially 50–100 micrograms/kg every 4 hours, adjusted according to response
- **Child 3-5 years:** 100–150 micrograms/kg every 4 hours, adjusted according to response
- **Child 6-11 years:** 200 micrograms/kg every 4 hours, adjusted according to response
- **Child 1 year:** Initially 200–300 micrograms/kg every 4 hours, adjusted according to response
- **Child 2-3 years:** Initially 200–300 micrograms/kg every 4 hours (max. per dose 10 mg), adjusted according to response
- **Child 12-17 years:** Initially 5–10 mg every 4 hours, adjusted according to response

**Acute pain**

**BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**

- **Adult:** Initially 10 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be given more frequently during titration, use dose for elderly in frail patients
- **Elderly:** Initially 5 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be given more frequently during titration

**BY SLOW INTRAVENOUS INJECTION**

- **Adult:** Initially 5 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be adjusted more frequently during titration, reduced dose recommended in frail and elderly patients

**Chronic pain**

**BY MOUTH OR BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**

- **Adult:** Initially 5–10 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients
- **Child:** Initially 0.15 mg/kg every 4 hours, increased according to response
- **Child 2-11 years:** 200 micrograms/kg every 4 hours, adjusted according to response
- **Child 12-17 years:** 2.5–10 mg every 4 hours, adjusted according to response

**Pain (with modified-release 12-hourly preparations)**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- **Adult:** Every 12 hours, dose adjusted according to daily morphine requirements, dosage requirements should be reviewed if the brand is altered
Pain with modified-release 24-hourly preparations

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- Adult: Every 24 hours, dose adjusted according to daily morphine requirements, dosage requirements should be reviewed if the brand is altered.

Pain in palliative care

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: Usual dose 30–200 mg every 4 hours, for management of breakthrough pain and other general advice, see Pain management with opioids under p. 20.
- By Mouth using modified-release medicines
  - Adult: Usual dose 100–600 mg every 12 hours, for management of breakthrough pain and other general advice, see Pain management with opioids under p. 20.

Pain management in palliative care (starting dose for opioid-naive patients)

**BY MOUTH**
- Adult: 20–30 mg daily in divided doses, dose for either immediate-release or a 12-hour modified-release preparation, for management of breakthrough pain and other general advice, see Pain management with opioids under p. 20.

Pain management in palliative care (starting dose for patients being switched from a regular weak opioid)

**BY MOUTH**
- Adult: 40–60 mg daily in divided doses, for management of breakthrough pain and other general advice, see Pain management with opioids under p. 20.

Cough in terminal disease

**BY MOUTH**
- Adult: Initially 5 mg every 4 hours

Prenicitation

**BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
- Adult: Up to 10 mg, dose to be administered 60–90 minutes before operation

Patient controlled analgesia (PCA)

**BY INTRAVENOUS INFUSION**
- Adult: (consult local protocol)

Myocardial infarction

**BY SLOW INTRAVENOUS INJECTION**
- Adult: 5–10 mg, followed by 5–10 mg if required, dose to be administered at a rate of 1–2 mg/minute, use dose for elderly in frail patients
- Elderly: 2.5–5 mg, followed by 2.5–5 mg if required, dose to be administered at a rate of 1–2 mg/minute

Acute pulmonary oedema

**BY SLOW INTRAVENOUS INJECTION**
- Adult: 5–10 mg, dose to be administered at a rate of 2 mg/minute, use dose for elderly in frail patients
- Elderly: 2.5–5 mg, dose to be administered at a rate of 2 mg/minute

Persistent cyanosis in congenital heart disease when blood glucose less than 3 mmol/litre (following glucose)

**BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
- Child: 100 micrograms/kg

Dyspnoea in palliative care

**BY MOUTH**
- Adult: Initially 5 mg every 4 hours, to be given in carefully titrated doses

Dose equivalence and conversion

The doses stated refer equally to morphine hydrochloride and sulfate.

**UNLICENSED USE**

Oramorph® solution and MX® capsules not licensed for use in children under 1 year. Sevedrol® tablets not licensed for use in children under 3 years.

Oramorph® unit dose vials and Filmarine® SR tablets not licensed for use in children under 6 years. MST Continus® preparations licensed to treat children with cancer pain (age-range not specified by manufacturer). Suppositories are not licensed for use in children.

**CONTRA-INDICATIONS**
- Acute abdomen
- delayed gastric emptying
- heart failure secondary to chronic lung disease
- phaeochromocytoma

**CAUTIONS**
- Cardiac arrhythmias
- pancreatitis
- severe cor pulmonale

**SIDE-EFFECTS**
- Abdominal pain
- agitation
- amenorrhoea
- anorexia
- asthenia
- bronchospasm
- delirium
- disorientation
- dyspepsia
- exacerbation of pancreatitis
- excitement
- hypertension
- hypothermia
- inhibition of cough reflex
- malaise
- muscle fasciculation
- myoclonus
- nystagmus
- paraesthesia
- paralytic ileus
- raised intracranial pressure
- restlessless
- rhabdomyolysis
- seizures
- syncope
- taste disturbance

**BREAST FEEDING**

Therapeutic doses unlikely to affect infant.

**RENAL IMPAIRMENT**

Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**DIRECTIONS FOR ADMINISTRATION**
- With intravenous use in children For continuous intravenous infusion, dilute with Glucose 5% or 10% or Sodium Chloride 0.9%.
- With intravenous use in neonates Neonatal intensive care, dilute 2.5 mg/kg body-weight to a final volume of 50 mL with infusion fluid; an intravenous infusion rate of 0.1 mL/hour provides a dose of 5 micrograms/kg/hour.
- With oral use For modified release capsules—swallow whole or open capsule and sprinkle contents on soft food.

**PRESCRIBING AND DISPENSING INFORMATION**

Prescriptions must also specify the ‘form’.

With rectal use Both the strength of the suppositories and the morphine salt contained in them must be specified by the prescriber.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Morphine for pain www.medicinesforchildren.org.uk/morphine-for-pain

Patients or carers should be given advice on how to administer morphine modified-release capsules.

**EXCEPTIONS TO LEGAL CATEGORY**

Morphine Oral Solutions Prescription-only medicines or schedule 2 controlled drug. The proportion of morphine hydrochloride may be altered when specified by the prescriber; if above 13 mg per 5 mL the solution becomes a schedule 2 controlled drug. It is usual to adjust the strength so that the dose volume is 5 or 10 mL.

Oral solutions of morphine can be prescribed by writing the formula:

Morphine hydrochloride 5 mg
Chloroform water to 5 mL

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, solution for injection, solution for infusion, oral solution, gel, capsule, nebuliser liquid, infusion

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2**

- Sevedrol® (Napp Pharmaceuticals Ltd)
  - Morphine sulfate 10 mg Sevedrol 10mg tablets | 56 tablet
  - £5.31 DT price = £5.31 Schedule 2 (CD)
  - Morphine sulfate 20 mg Sevedrol 20mg tablets | 56 tablet
  - £10.61 DT price = £10.61 Schedule 2 (CD)
  - Morphine sulfate 50 mg Sevedrol 50mg tablets | 56 tablet
  - £28.02 DT price = £28.02 Schedule 2 (CD)
Morphine (Non-proprietary)
Solution for injection
- MORPHINE (Non-proprietary)
  Morphine sulfate 1 mg per 1 ml
  Morphine sulfate 50mg/50ml
  solution for infusion via 1 | vial (POM) £3.29 Schedule 2 (CD)
  10 mg per 1 ml (POM) no price available Schedule 2 (CD)

Morphine sulfate 2 mg per 1 ml
  Morphine sulfate 100mg/50ml
  solution for infusion via 1 | vial (POM) £5.89 Schedule 2 (CD)

**Suppository**

Morphine sulfate 10 mg
  Morphine sulfate 10mg suppositories |
  12 suppository (POM) £18.34 Schedule 2 (CD)

Morphine sulfate 15 mg
  Morphine sulfate 15mg suppositories |
  12 suppository (POM) £16.48 Schedule 2 (CD)

**Solution for infusion**

- MORPHINE (Non-proprietary)
  Morphine sulfate 1 mg per 1 ml
  Morphine sulfate 50mg/50ml
  solution for infusion via 1 | vial (POM) £3.29 Schedule 2 (CD)
  10 mg per 1 ml (POM) no price available Schedule 2 (CD)

Morphine sulfate 2 mg per 1 ml
  Morphine sulfate 100mg/50ml
  solution for infusion via 1 | vial (POM) £5.89 Schedule 2 (CD)

**Cautionary and Advisory Labels**

Modified-release capsule
- MST Continus (Napp Pharmaceuticals Ltd)
  Morphine sulfate 20 mg
  Morphine sulfate 20mg granules (sugar-free) |
  30 sachets (POM) £3.59 Schedule 2 (CD)

Modified-release granules
- MST Continus (Napp Pharmaceuticals Ltd)
  Morphine sulfate 20 mg
  Morphine sulfate 20mg granules sachets (sugar-free) |
  30 sachets (POM) £3.59 Schedule 2 (CD)

Morphine sulfate 30 mg
  Morphine sulfate 30mg granules (sugar-free) |
  30 sachets (POM) £4.95 Schedule 2 (CD)

Morphine sulfate 50 mg
  Morphine sulfate 50mg granules (sugar-free) |
  30 sachets (POM) £8.50 Schedule 5 (CD Inv)

**Morphine sulfate 10 mg per 1 ml**
  Morphine sulfate 10mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £3.96 Schedule 2 (CD)

**Morphine sulfate 15 mg per 1 ml**
  Morphine sulfate 15mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £3.96 Schedule 2 (CD)

**Morphine sulfate 20 mg per 1 ml**
  Morphine sulfate 20mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £4.73 Schedule 2 (CD)

**Morphine sulfate 30 mg per 1 ml**
  Morphine sulfate 30mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £4.04 Schedule 2 (CD)

**Morphine sulfate 50 mg per 1 ml**
  Morphine sulfate 50mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £6.84 Schedule 2 (CD)

**Morphine sulfate 100 mg per 1 ml**
  Morphine sulfate 100mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £9.36 Schedule 2 (CD)

**Morphine sulfate 150 mg per 1 ml**
  Morphine sulfate 150mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £11.82 Schedule 2 (CD)

**Morphine sulfate 200 mg per 1 ml**
  Morphine sulfate 200mg/1ml
  solution for injection ampoules |
  10 ampoule (POM) £15.36 Schedule 2 (CD)
### BY INTRAVENOUS INFUSION
- **Adult:** Initially 2 mg/hour, adjusted according to response
- **BY SUBCUTANEOUS INJECTION**
- **Adult:** Initially 5 mg every 4 hours as required
- **BY SUBCUTANEOUS INFUSION**
- **Adult:** Initially 7.5 mg/24 hours, adjusted according to response

### Patient controlled analgesia (PCA)
- **BY INTRAVENOUS INFUSION**
- **Adult:** (consult local protocol)

### Dose equivalence and conversion
2 mg oral oxycodone is approximately equivalent to 1 mg parenteral oxycodone.

#### CONTRA-INDICATIONS
- Acute abdomen - chronic constipation - cor pulmonale - delayed gastric emptying

#### CAUTIONS
- Pancreatitis - toxic psychosis

#### SIDE-EFFECTS
- **Common or very common** Abdominal pain - anorexia - anxiety - asthenia - bronchospasm - chills - diarrhoea - dyspepsia - dyspnoea - impaired cough reflex

#### BREAST FEEDING
- Present in milk—avoid.

#### HEPATIC IMPAIRMENT
- Max. initial dose 2.5 mg every 6 hours in patients not currently treated with an opioid with mild impairment. Avoid in moderate to severe impairment.

#### RENAL IMPAIRMENT
- Max. initial dose 2.5 mg every 6 hours in patients not currently with an opioid with mild to moderate impairment. Avoid if eGFR less than 10 mL/minute/1.73 m².

#### DIRECTIONS FOR ADMINISTRATION
- For intravenous infusion (Oxynorm®), give continuously or intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to a concentration of 1 mg/mL.

#### NATIONAL FUNDING/ACCESS DECISIONS

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (October 2004 and November 2010) that Oxynorm® injection is restricted for use within NHS Scotland for patients with cancer who have difficulty in tolerating morphine or diamorphine.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, solution for infusion, oral solution

<table>
<thead>
<tr>
<th>Modified-release tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OXYCODONE HYDROCHLORIDE (Non-proprietary)</strong></td>
</tr>
<tr>
<td>Oxycodone hydrochloride 5 mg</td>
</tr>
<tr>
<td>Oxycodone hydrochloride 10 mg</td>
</tr>
<tr>
<td>Oxycodone hydrochloride 20 mg</td>
</tr>
<tr>
<td>Oxycodone hydrochloride 40 mg</td>
</tr>
</tbody>
</table>

Oxycodone hydrochloride 80 mg Oxycodone 80mg modified-release tablets 56 tablet (£200) no price available DT price = £200.39 Schedule 2 (CD)

- **Oxycodone (Napp Pharmaceuticals Ltd)**
- **Oxycodone Hydrochloride 5 mg** Oxycodone 5mg modified-release tablets | 28 tablet (£90) £12.52 DT price = £12.52 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 10 mg** Oxycodone 10mg modified-release tablets | 56 tablet (£150) £25.04 DT price = £25.04 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 15 mg** Oxycodone 15mg modified-release tablets | 56 tablet (£180) £38.12 DT price = £38.12 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 20 mg** Oxycodone 20mg modified-release tablets | 56 tablet (£310) £50.08 DT price = £50.08 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 30 mg** Oxycodone 30mg modified-release tablets | 56 tablet (£420) £76.23 DT price = £76.23 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 40 mg** Oxycodone 40mg modified-release tablets | 56 tablet (£630) £100.19 DT price = £100.19 Schedule 2 (CD) |

- **Oxycodone Hydrochloride 60 mg** Oxycodone 60mg modified-release tablets | 56 tablet (£840) £152.49 DT price = £152.49 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 80 mg** Oxycodone 80mg modified-release tablets | 56 tablet (£1050) £200.39 DT price = £200.39 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 120 mg** Oxycodone 120mg modified-release tablets | 56 tablet (£1500) £305.02 DT price = £305.02 Schedule 2 (CD) |

- **Brands may include Oxtex; Oxylan; Reitebion**

#### Capsule

**CAUTIONARY AND ADVISORY LABELS 2**

- **OxyNorm (Napp Pharmaceuticals Ltd)**
- **Oxycodone Hydrochloride 5 mg** Oxycodone 5mg capsules | 56 capsule (£3.43 DT price = £3.43 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 10 mg** Oxycodone 10mg capsules | 56 capsule (£4.86 DT price = £4.86 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 20 mg** Oxycodone 20mg capsules | 56 capsule (£6.39 DT price = £6.39 Schedule 2 (CD) |

- **Brands may include Lynlor; Shortec**

#### Oral solution

**CAUTIONARY AND ADVISORY LABELS 2**

- **OXYCODONE HYDROCHLORIDE (Non-proprietary)**
- **Oxycodone Hydrochloride 1 mg per ml** Oxycodone 5mg/5ml oral solution sugar free (sugar-free) | 250 ml (£30) £9.71 DT price = £9.71 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 10 mg per ml** Oxycodone 10mg/ml oral solution sugar free (sugar-free) | 120 ml (£30) £4.63 DT price = £4.63 Schedule 2 (CD) |
- **Oxynorm (Napp Pharmaceuticals Ltd)**
- **Oxycodone Hydrochloride 1 mg per ml** Oxycodone 5mg/5ml oral solution sugar-free | 250 ml (£90) £30.00 DT price = £30.00 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 10 mg per ml** Oxycodone 10mg/ml oral solution sugar-free | 120 ml (£100) £36.00 DT price = £36.00 Schedule 2 (CD) |

#### Solution for injection

**OXYCODONE HYDROCHLORIDE (Non-proprietary)**

- **Oxycodone Hydrochloride 10 mg per ml** Oxycodone 10mg/2ml solution for injection ampoules | 5 ampoule (£60) £16.00 DT price = £16.00 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 1 mg per ml** Oxycodone 1mg/1ml solution for injection ampoules | 5 ampoule (£200) £8.00 DT price = £8.00 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 0.5 mg per ml** Oxycodone 0.5mg/1ml solution for injection ampoules | 5 ampoule (£300) £7.00 DT price = £7.00 Schedule 2 (CD) |
- **Oxynorm (Napp Pharmaceuticals Ltd)**
- **Oxycodone Hydrochloride 1 mg per ml** Oxycodone 1mg/1ml solution for injection ampoules | 5 ampoule (£60) £16.00 DT price = £16.00 Schedule 2 (CD) |
- **Oxycodone Hydrochloride 0.5 mg per ml** Oxycodone 0.5mg/1ml solution for injection ampoules | 5 ampoule (£100) £7.00 DT price = £7.00 Schedule 2 (CD) |

---

**Oxycodone with naloxone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, naloxone hydrochloride p. 1133, oxycodone hydrochloride p. 369.
Pentazocine

**INDICATIONS AND DOSE**

Moderate to severe pain

**BY MOUTH**
- Adult: 50 mg every 3–4 hours, dose to be taken preferably after food, usual dose 25–100 mg every 3–4 hours; maximum 600 mg per day

**Severe pain**
- Adult: 45–60 mg every 3–4 hours as required; maximum 360 mg per day

**CONTRA-INDICATIONS**
- Acute porphyrias p. 864 - heart failure secondary to chronic lung disease - patients dependent on opioids (can precipitate withdrawal)
- **CAUTIONS**
  - Arterial hypertension - cardiac arrhythmias - myocardial infarction - pancreatitis - phaeochromocytoma - pulmonary hypertension
- **SIDE-EFFECTS**
  - Abdominal pain - blood disorders - chills - disorientation - hypertension - hypothermia - myalgia - paraesthesia - raised intracranial pressure - seizures - syncope - toxic epidermal necrolysis - tremor
- **Overdose**
  - Effects only partially reversed by naloxone.
- **BREAST FEEDING**
  - Use with caution—limited information available.
- **RENAL IMPAIRMENT**
  - Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.
- **LESS SUITABLE FOR PRESCRIBING**
  - Pentazocine is less suitable for prescribing.

**MEDICATION FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**
- **PAPAVERETUM (Non-proprietary)**
  - Papaveretum 15.4 mg per 1 ml Papaveretum 15.4mg/1ml solution for injection ampoules | 10 ampoule | £48.96 Schedule 2 (CD)

---

**Papaveretum**

**INDICATIONS AND DOSE**

Postoperative analgesia | Severe chronic pain

**BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
- Adult: 7.7–15.4 mg every 4 hours if required
- Elderly: Initially 7.7 mg every 4 hours if required

**BY INTRAVENOUS INJECTION**
- Adult: Use 25 to 50% of the corresponding subcutaneous/intramuscular dose

**PREMEDICATION**

**BY INTRAVENOUS INJECTION**
- Adult: Use 25 to 50% of the corresponding subcutaneous/intramuscular dose

**Important safety information**

Do not confuse with papaverine.

**CONTRA-INDICATIONS**
- Heart failure secondary to chronic lung disease - phaeochromocytoma

**CAUTIONS**
- Supraventricular tachycardia

**SIDE-EFFECTS**
- Hypothermia

**BREAST FEEDING**
- Therapeutic doses unlikely to affect infant.

**RENAL IMPAIRMENT**
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**PRESCRIBING AND DISPENSING INFORMATION**

The name Omnopon® was formerly used for papaveretum preparations. Papaveretum is a mixture of 253 parts of morphine hydrochloride, 23 parts of papaverine hydrochloride and 20 parts of codeine hydrochloride.

**LESS SUITABLE FOR PRESCRIBING**
- Papaveretum is less suitable for prescribing.
### Pethidine hydrochloride (Meperidine)

**INDICATIONS AND DOSE**

**Acute pain**
- **By mouth**
  - Adult: 50–150 mg every 4 hours
  - By subcutaneous injection or by intramuscular injection
  - Adult: 25–100 mg, then 25–100 mg after 4 hours, for debilitated patients use dose described for elderly patients.
  - Elderly: Initially 25 mg, then 25–100 mg after 4 hours
- By slow intravenous injection
  - Adult: 25–50 mg, then 25–50 mg after 4 hours, for debilitated patients use dose described for elderly patients.
  - Elderly: Initially 25 mg, then 25–50 mg after 4 hours

**Obstetric analgesia**
- By subcutaneous injection or by intramuscular injection
  - Adult: 50–100 mg, then 50–100 mg after 1–3 hours if required; maximum 400 mg per day

**Premedication**
- By intramuscular injection
  - Adult: 25–100 mg, dose to be given 1 hour before operation, for debilitated patients use dose described for elderly patients.
  - Elderly: 25 mg, dose to be given 1 hour before operation

**Postoperative pain**
- By subcutaneous injection or by intramuscular injection
  - Adult: 25–100 mg every 2–3 hours if required, for debilitated patients use dose described for elderly patients.
  - Elderly: Initially 25 mg every 2–3 hours if required

**SIDE-EFFECTS**
- Phaeochromocytoma
- Accumulation of metabolites may result in neurotoxicity - cardiac arrhythmias - not suitable for severe continuing pain - severe cor pulmonale
- Hypothermia - restlessless - tremor
- Convulsions reported in overdosage.

**RENAI IMPAIRMENT**
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (May 2011) that tapentadol (Palexia® SR) is accepted for restricted use within NHS Scotland for the management of severe chronic pain in adult patients, which can be adequately managed only with opioid analgesics, when morphine sulphate modified-release has failed to provide adequate pain control or is not tolerated.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, solution for injection, oral solution, capsule

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pethidine hydrochloride (Non-proprietary)</td>
</tr>
<tr>
<td>Pethidine hydrochloride 50 mg: Pethidine 50mg tablets</td>
</tr>
<tr>
<td>Solution for injection</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Pethidine hydrochloride (Non-proprietary)</td>
</tr>
<tr>
<td>Pethidine hydrochloride 10 mg per 1 ml: Pethidine 50mg/5ml solution for injection ampoules</td>
</tr>
<tr>
<td>Pethidine hydrochloride 50 mg per 1 ml: Pethidine 50mg/1ml solution for injection ampoules</td>
</tr>
<tr>
<td>Pethidine 100mg/2ml solution for injection ampoules</td>
</tr>
</tbody>
</table>

---

### Tapentadol

**INDICATIONS AND DOSE**

Moderate to severe acute pain which can be managed only with opioid analgesics

**By mouth using immediate-release medicines**
- Adult: Initially 50 mg every 4–6 hours, adjusted according to response, maximum 700 mg in the first 24 hours, during the first 24 hours of treatment, an additional dose of 50 mg may be taken 1 hour after the initial dose, if pain control not achieved; maximum 600 mg per day

**Severe chronic pain**
- Adult: Initially 50 mg every 12 hours, adjusted according to response; maximum 500 mg per day

**SIDE-EFFECTS**

**BREAST FEEDING**
- Avoid — no information available.

**HEPATIC IMPAIRMENT**
- For immediate-release tablets, initial max. daily dose 150 mg; for modified-release tablets, initial max. daily dose 50 mg.

**RENAI IMPAIRMENT**
- Manufacturer advises no dose adjustment needed in mild or moderate impairment.
- Avoid in severe impairment. Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (May 2011) that tapentadol (Palexia® SR) is accepted for restricted use within NHS Scotland for the management of severe chronic pain in adult patients, which can be adequately managed only with opioid analgesics, when morphine sulphate modified-release has failed to provide adequate pain control or is not tolerated.
Tramadol hydrochloride

**INDICATIONS AND DOSE**

Moderate to severe pain

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**

- Adult: 50–100 mg every 4–6 hours, intravenous injection to be given over 2–3 minutes

Moderate to severe acute pain

**BY MOUTH**

- Child 12-17 years: Initially 100 mg, then 50–100 mg every 4–6 hours; maximum 400 mg per day
- Adult: Initially 100 mg, then 50–100 mg every 4–6 hours; maximum 400 mg per day

Moderate to severe chronic pain

**BY MOUTH**

- Child 12-17 years: Initially 50 mg, then adjusted according to response to; maximum 400 mg per day
- Adult: Initially 50 mg, then adjusted according to response to; maximum 400 mg per day

Postoperative pain

**BY INTRAVENOUS INJECTION**

- Adult: Initially 100 mg, then 50 mg every 10–20 minutes if required to a total maximum of 250 mg (including initial dose) in first hour, then 50–100 mg every 4–6 hours; intravenous injection to be given over 2–3 minutes; maximum 600 mg per day

Moderate to severe pain (with modified-release 12-hourly preparations)

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Child 12-17 years: 50–100 mg twice daily, increased if necessary to 150–200 mg twice daily; maximum daily dose not usually required; maximum 400 mg per day
- Adult: 50–100 mg twice daily, increased if necessary to up to 150–200 mg twice daily; maximum daily dose not usually required; maximum 400 mg per day

Moderate to severe pain (with modified-release 24-hourly preparations)

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Child 12-17 years: Initially 100–150 mg once daily, increased if necessary up to 400 mg once daily
- Adult: Initially 100–150 mg once daily, increased if necessary up to 400 mg once daily

**SYMPTOMATICALLY**

- Child 12-17 years: Initially 150 mg once daily, increased if necessary up to 400 mg once daily
- Adult: Initially 150 mg once daily, increased if necessary up to 400 mg once daily

**CONTRAINDICATIONS**

- Acute intoxication with alcohol - acute intoxication with analgesics - acute intoxication with hypnotics - acute intoxication with opioids - not suitable for narcotic withdrawal treatment - uncontrolled epilepsy

**CAUTIONS**

- Excessive bronchial secretions - history of epilepsy - use tramadol only if compelling reasons - impaired consciousness - not suitable as a substitute in opioid-dependent patients - not suitable in some types of general anaesthesia - susceptibility to seizures - use tramadol only if compelling reasons

**CAUTIONS, FURTHER INFORMATION**

**General anaesthesia**

Not recommended for analgesia during potentially light planes of general anaesthesia (possibly increased intra-operative recall reported).

**SIDE-EFFECTS**

- Common or very common Malaise
- Uncommon Diarrhoea - flatulence - gastritis - retching
- Rare Abnormal coordination - anorexia - anxiety - bronchospasm - changes in appetite - delirium - dysphonia - hypertension - muscle weakness - nightmares - paraesthesia - seizures - syncope - tremor - wheezing

**OCEANIC**

- Frequency not known Blood disorders - hypoglycaemia - speech disorders

**PREGNANCY**

Embryotoxic in animal studies - manufacturers advise avoid.

**BREAST FEEDING**

Amount probably too small to be harmful, but manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

Caution (avoid for oral drops) in severe impairment.

**RENAL IMPAIRMENT**

Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs. Caution (avoid for oral drops) in severe impairment.

**DIRECTIONS FOR ADMINISTRATION**

Tramadol hydrochloride orodispersible tablets should be sucked and then swallowed. May also be dispersed in water. Some tramadol hydrochloride modified-release capsule preparations may be opened and the content swallowed immediately without chewing - check individual preparations. For intravenous infusion, dilute in glucose 5% or Sodium Chloride 0.9%

**PRESCRIBING AND DISPENSING INFORMATION**

Do not confuse modified-release 12-hourly preparations with 24-hourly preparations.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Tramadol for pain

www.medicinesforchildren.org.uk/tramadol-for-pain

Patients or carers should be given advice on how to administer tramadol hydrochloride orodispersible tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Soluble tablet**

**CAUTIONARY AND ADVISORY LABELS** 2, 13

- Zydol (Grunenthal Ltd)
  - tramadol hydrochloride 50 mg Zydol 50mg soluble tablets (sugar-free) | 20 tablet [POT] £2.79 Schedule 3 (CD No Register Exempt Safe Custody) (sugar-free) | 100 tablet [POT] £13.33 DT price + £13.33 Schedule 3 (CD No Register Exempt Safe Custody)

**Orodispersible tablet**

**CAUTIONARY AND ADVISORY LABELS** 2

- **TRAMADOL HYDROCHLORIDE (Non-proprietary)**
  - Tramadol hydrochloride 50 mg Tramadol 50mg orodispersible tablets sugar free (sugar-free) | 60 tablet [POT] £8.40 Schedule 3 (CD No Register Exempt Safe Custody)
  - Zamadol Melt (Meda Pharmaceuticals Ltd)
    - tramadol hydrochloride 50 mg Zamadol Melt 50mg tablets (sugar-free) | 60 tablet [POT] £7.12 Schedule 3 (CD No Register Exempt Safe Custody)

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS** 2, 25

- **TRAMADOL HYDROCHLORIDE (Non-proprietary)**
  - Tramadol hydrochloride 50 mg Tramadol 50mg modified-release tablets | 60 tablet [POT] no price available Schedule 3 (CD No Register Exempt Safe Custody)
  - Tramadol hydrochloride 100 mg Tramadol 100mg modified-release tablets | 60 tablet [POT] £4.80 Schedule 3 (CD No Register Exempt Safe Custody)
Tramadol hydrochloride 150 mg
Tramadol 150mg modified-release tablets | 60 tablet | £57.85 Schedule 3 (CD No Register Exempt Safe Custody)

Tramadol hydrochloride 200 mg
Tramadol 200mg modified-release tablets | 30 tablet | £27.39 Schedule 3 (CD No Register Exempt Safe Custody)

Tramadol hydrochloride 300 mg
Tramadol 300mg modified-release tablets | 30 tablet | £36.52 Schedule 3 (CD No Register Exempt Safe Custody)

Tramadol hydrochloride 400 mg
Tramadol 400mg modified-release tablets | 28 tablet | £36.52 Schedule 3 (CD No Register Exempt Safe Custody)

Zydol SR
Zydol SR 50mg tablets | 60 tablet | £4.60 Schedule 3 (CD No Register Exempt Safe Custody)

Zydol hydrochloride 100 mg
Zydol SR 100mg tablets | 60 tablet | £13.28 Schedule 3 (CD No Register Exempt Safe Custody)

Zydol hydrochloride 150 mg
Zydol SR 150mg tablets | 60 tablet | £27.39 Schedule 3 (CD No Register Exempt Safe Custody)

Zydol hydrochloride 200 mg
Zydol SR 200mg tablets | 60 tablet | £36.52 Schedule 3 (CD No Register Exempt Safe Custody)

Zydol hydrochloride 300 mg
Zydol SR 300mg tablets | 30 tablet | £49.86 Schedule 3 (CD No Register Exempt Safe Custody)

Zydol hydrochloride 400 mg
Zydol SR 400mg tablets | 30 tablet | £52.47 Schedule 3 (CD No Register Exempt Safe Custody)

Brands may include Maxidol SR; Madron; Maneo; Marol; Oldaram; Tildol SR; Tradorec XL; Traumil SC; Zamadol 24hr; Zeridame SR

CAUTIONARY AND ADVISORY LABELS 2

Tramadol hydrochloride (Non-proprietary)

Tramadol hydrochloride 50 mg
Tramadol 50mg capsules | 30 capsule | £4.71 DT price = £1.20 Schedule 3 (CD No Register Exempt Safe Custody)

Zydol (Grunenthal Ltd)
Zydol hydrochloride 50 mg
Zydol 50mg capsules | 30 capsule | £2.29 DT price = £1.20 Schedule 3 (CD No Register Exempt Safe Custody)

Brands may include Zamadol

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 2, 25

Tramadol hydrochloride 50 mg
Tramadol 50mg modified-release capsules | 60 capsule | £7.64 Schedule 3 (CD No Register Exempt Safe Custody)

Tramadol hydrochloride 100 mg
Tramadol 100mg modified-release capsules | 60 capsule | £15.28 Schedule 3 (CD No Register Exempt Safe Custody)

Tramadol hydrochloride 150 mg
Tramadol 150mg modified-release capsules | 60 capsule | £22.92 Schedule 3 (CD No Register Exempt Safe Custody)

Tramadol hydrochloride 200 mg
Tramadol 200mg modified-release capsules | 60 capsule | £30.55 Schedule 3 (CD No Register Exempt Safe Custody)

Brands may include Maxidol SR; Tramquel SR; Zamadol SR

Oral drops

CAUTIONARY AND ADVISORY LABELS 2, 13

Tramadol hydrochloride (Non-proprietary)

Tramadol (as Tramadol hydrochloride) 100 mg per 1 ml
Tramadol 100mg/ml oral drops | 10 ml | £3.90 DT price = £3.50 Schedule 3 (CD No Register Exempt Safe Custody)

Solution for injection

Tramadol hydrochloride 50 mg per 1 ml
Tramadol 100mg/2ml solution for injection ampoules | 5 ampoule | £4.90-£4.92 Schedule 3 (CD No Register Exempt Safe Custody)

Brands may include Zamadol; Zydol

5.1 Migraine

Migraine

Treatment of acute migraine

Treatment of a migraine attack should be guided by response to previous treatment and the severity of the attacks. A simple analgesic such as aspirin p. 104, paracetamol p. 354 (preferably in a soluble or dispersible form) or a NSAID is often effective; concomitant antiemetic treatment may be required. If treatment with an analgesic is inadequate, an attack may be treated with a specific antimigraine compound such as a 5HT1-receptor agonist ('triptan'). Ergot alkaloids are rarely required now; oral preparations are associated with many side-effects and should be avoided in cerebrovascular or cardiovascular disease.

Excessive use of acute treatments for migraine (opioid and non-opioid analgesics, 5HT1-receptor agonists, and ergotamine) is associated with medication-overuse headache (analgesic-induced headache); therefore, increasing consumption of these medicines needs careful management.

Analgesics

Most migraine headaches respond to analgesics such as aspirin p. 104 or paracetamol p. 354 but because peristalsis is often reduced during migraine attacks the medication may not be sufficiently well absorbed to be effective; dispersible or effervescent preparations are therefore preferred. Compound preparations containing analgesics and antiemetics are available.

The NSAID tolfenamic acid p. 381 is licensed specifically for the treatment of an acute attack of migraine; diclofenac potassium p. 920, flurbiprofen p. 927, and ibuprofen p. 927 are also licensed for use in migraine.

5HT1-receptor agonists

A 5HT1-receptor agonist is of considerable value in the treatment of an acute migraine attack. The 5HT1-receptor agonists (‘tripts’) act on the 5HT (serotonin) 1B/1D receptors and they are therefore sometimes referred to as 5HT1B/D-receptor agonists. A 5HT1-receptor agonist may be used during the established headache phase of an attack and is the preferred treatment in those who fail to respond to conventional analgesics.

The 5HT1-receptor agonists available for treating migraine are almotriptan p. 377, eletriptan p. 377, frovatriptan p. 378, naratriptan p. 378, rizatriptan p. 379, sumatriptan p. 379, and zolmitriptan p. 380. If a patient does not respond to one 5HT1-receptor agonist, an alternative 5HT1-receptor agonist should be tried. For patients who have prolonged attacks that frequently recur despite treatment with a 5HT1-receptor agonist, combination therapy with a NSAID such as naproxen can be considered. Sumatriptan or zolmitriptan are also used to treat cluster headache.

Ergot Alkaloids

The value of ergotamine tartrate p. 376 for migraine is limited by difficulties in absorption and by its side-effects, particularly nausea, vomiting, abdominal pain, and...
muscular cramps; it is best avoided. The recommended doses of ergotamine tartrate preparations should not be exceeded and treatment should not be repeated at intervals of less than 4 days. To avoid habituation the frequency of administration of ergotamine tartrate should be limited to no more than twice a month. It should never be prescribed prophylactically but in the management of cluster headache a low dose is occasionally given for 1 to 2 weeks [unlicensed indication].

**Antiemetics**

Antiemetics, such as metoclopramide hydrochloride p. 347 or domperidone p. 346, or phenothiazine and antihistamine antiemetics, relieve the nausea associated with migraine attacks. Antiemetics may be given by intramuscular injection or rectally if vomiting is a problem. Metoclopramide hydrochloride and domperidone have the added advantage of promoting gastric emptying and normal peristalsis; a single dose should be given at the onset of symptoms. Oral analgesic preparations containing metoclopramide hydrochloride are a convenient alternative.

**Prophylaxis of migraine**

Where migraine attacks are frequent, possible provoking factors such as stress, irregular lifestyle (e.g. lack of sleep), or chemical triggers (e.g. alcohol and nitrates) should be sought; combined oral contraceptives may also provoke migraine.

Preventive treatment for migraine should be considered for patients who:

- suffer at least two attacks a month;
- suffer an increasing frequency of headaches;
- suffer significant disability despite suitable treatment for migraine attacks;
- cannot take suitable treatment for migraine attacks.

Prophylaxis is also necessary in some rare migraine subtypes and those at risk of migrainous infarction. The beta-blockers propranolol hydrochloride p. 146, atenolol p. 141, metoprolol tartrate p. 144, nadolol p. 145, and timolol maleate p. 147 are all effective. Propranolol hydrochloride p. 146 is the most commonly used.

Tricyclic antidepressants [unlicensed indication], topiramate p. 406, sodium valproate p. 403 [unlicensed indication], valproic acid p. 275 [unlicensed indication], and gabapentin p. 392 [unlicensed indication] are also effective for preventing migraine.

Pizotifen p. 376 is an antihistamine and a serotonin-receptor antagonist, structurally related to the tricyclic antidepressants. It is of limited value and may cause weight gain.

Botulinum toxin type A is licensed for the prophylaxis of headaches in adults with chronic migraine.

**Cluster headache and the trigeminal autonomic cephalalgias**

Cluster headache rarely responds to standard analgesics. Sumatriptan p. 379 given by subcutaneous injection is the drug of choice for the treatment of cluster headache. If an injection is unsuitable, sumatriptan nasal spray or zolmitriptan p. 380 nasal spray [both unlicensed use] may be used. Alternatively, 100% oxygen at a rate of 10–15 litres/minute for 10–20 minutes is useful in aborting an attack.

Prophylaxis of cluster headache is considered if the attacks are frequent, last over 3 weeks, or if they cannot be treated effectively. Verapamil hydrochloride p. 156 or lithium [both unlicensed use] are used for prophylaxis.

Prednisolone p. 585 can be used for short-term prophylaxis of episodic cluster headache [unlicensed use] either as monotherapy, or in combination with verapamil hydrochloride p. 156 during verapamil titration.

Ergotamine tartrate p. 376, used on an intermittent basis is an alternative for patients with short bouts, but it should not be used for prolonged periods.

The other trigeminal autonomic cephalalgias, paroxysmal hemihemiania (sensitive to indometacin p. 929), and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, are seen rarely and are best managed by a specialist.

**Drugs used for Migraine not listed below:** Amitriptyline hydrochloride, p. 290 · Atenolol, p. 141 · Botulinum toxin type A, p. 322 · Clonidine hydrochloride, p. 137 · Diclofenac potassium, p. 920 · Gabapentin, p. 392 · Metoprolol tartrate, p. 144 · Nadolol, p. 145 · Sodium valproate, p. 403 · Timolol maleate, p. 147 · Topiramate, p. 406 · Trifluoperazine, p. 310 · Valproic acid, p. 275

### ANALGESICS

**Buclizine hydrochloride with codeine phosphate and paracetamol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, codeine phosphate p. 360, paracetamol p. 354.

#### INDICATIONS AND DOSE

**MIGRALEVE®**

**Acute migraine**

**BY MOUTH**

- **Child 12-14 years:** Initially 1 pink tablet to be taken at onset of attack, or if it is imminent, followed by 1 yellow tablet every 4 hours if required; maximum 1 pink and 3 yellow tablets in 24 hours
- **Child 15-17 years:** Initially 2 pink tablets to be taken at onset of attack, or if it is imminent, followed by 2 yellow tablets every 4 hours if required; maximum 2 pink and 6 yellow tablets in 24 hours
- **Adult:** Initially 2 pink tablets to be taken at onset of attack, or if it is imminent, followed by 2 yellow tablets every 4 hours if required; maximum 2 pink and 6 yellow tablets in 24 hours

#### LESS SUITABLE FOR PRESCRIBING

Migraleve® is less suitable for prescribing.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2, 17, 30**

- **Migraleve Pink** (McNeil Products Ltd)
  - Buclizine hydrochloride 6.25 mg, Codeine phosphate 8 mg, Paracetamol 500 mg Migraleve Pink tablets | 8 tablet | £no price available Schedule 5 (CD Inv) | 12 tablet | £3.21 Schedule 5 (CD Inv) | 16 tablet | £3.16 Schedule 5 (CD Inv) | 32 tablet | £no price available Schedule 5 (CD Inv) | 48 tablet | £3.97 Schedule 5 (CD Inv)

- **Migraleve** (McNeil Products Ltd)
  - Migraleve tablets | 12 tablet | £3.45 Schedule 5 (CD Inv) | 24 tablet | £5.45 Schedule 5 (CD Inv) | 48 tablet | £3.64 Schedule 5 (CD Inv)

**Metoclopramide with paracetamol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, metoclopramide hydrochloride p. 347, paracetamol p. 354.
INDICATIONS AND DOSE

Acute migraine
INITIALLY BY MOUTH USING TABLETS
- Adult: 2 tablets, to be taken at the onset of attack, followed by (by mouth) 2 tablets every 4 hours if required; maximum 6 tablets per day

INITIALLY BY MOUTH USING EFFERVESCENT POWDER SACHETS
- Adult: 2 sachets, to be taken at the onset of attack, then (by mouth) 2 sachets every 4 hours if required, sachets to be dissolved in a quarter tumblerful of water; maximum 6 sachets per day

SIDE-EFFECTS

- BREAST FEEDING Amount probably too small to be harmful, but manufacturer advises avoid.
- HEPATIC IMPAIRMENT Use with caution.
- RENAL IMPAIRMENT Use with caution.
- PATIENT AND CARER ADVICE Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

Medicines for Children leaflet: Pizotifen to prevent migraine headaches www.medicinesforchildren.org.uk/pizotifen-to-prevent-migraine-headaches

INTERACTIONS

- MUSCARINIC ANTAGONISTS Increased risk of antimuscarinic effects
- MAO INHIBITORS Increased risk of hypertensive crisis
- CYCLOSPORINE Increased risk of hypercalcemia
- LITHIUM Increased risk of hypercalcaemia
- ORAL ANTICOAGULANTS Increased risk of anticoagulant effects
- CARBAMAZEPINE Increased risk of carbamazepine toxicity
- PROTON PUMP INHIBITORS Increased risk of paroxysmal hypertension

Mediterranean lynx

- CONTRA-INDICATIONS
  - Known hypersensitivity to pizotifen, ergot alkaloids, or any component of the product
  - Hypertension (including severe hypertension)
  - Cardiac disease (including severe cardiac disease)
  - Hypothyroidism
  - Renal artery spasm

- PATIENTS WITH A HISTORY OF:
  - Familiar or personal cardiovascular disease
  - Cardiac arrhythmias
  - Renal disease
  - Hypotension
  - Seizures (including epilepsy)
  - Urinary retention (including prostatic hypertrophy)
  - Myasthenia gravis
  - Myocardial ischaemia
  - Severe anaemia

- PATIENTS TREATED WITH:
  - Ergot alkaloids
  - Monamine oxidase inhibitors
  - Lithium
  - Tricyclic antidepressants
  - Antihypertensive agents
  - Digitalis
  - Intravenous vasopressors

- PRECAUTIONS
  - Pregnancy
  - Breastfeeding
  - Renal impairment
  - Hepatic impairment

- Use with caution in:
  - Hypertension
  - Hyperthyroidism
  - Thyrotoxicosis
  - Hypotension
  - Cardiac disease
  - Renal disease
  - Seizures
  - Intestinal ischaemia
  - Severe renal artery spasm

- Avoid; risk of renal vasoconstriction.

- Avoid in severe impairment

- Avoid; oxytocic effect on the uterus.

- Avoid; risk of renal vasoconstriction.

ANTIHISTAMINES

Pizotifen

INDICATIONS AND DOSE

Prevention of vascular headache | Prevention of classical migraine | Prevention of common migraine | Prevention of cluster headache

BY MOUTH
- Adult: Initially 500 micrograms at night, increased gradually up to 1.5 mg at night, alternatively increased gradually to 1.5 mg daily in 3 divided doses; further increased if necessary up to 4.5 mg daily (but rarely necessary); max. single dose 3 mg

Prophylaxis of migraine

BY MOUTH
- Child 5-17 years: Initially 500 micrograms at night, then increased gradually up to 1.5 mg daily in divided doses, max. single dose (at night) 1 mg

- UNLICENSED USE 1.5–mg tablets not licensed for use in children.
- CAUTIONS Avoid abrupt withdrawal; history of epilepsy; susceptibility to angle-closure glaucoma; urinary retention
- INTERACTIONS → Appendix 1 (pizotifen).
- SIDE-EFFECTS
  - Common or very common Dizziness; drowsiness; dry mouth; increased appetite; nausea; weight gain
  - Uncommon Constipation
  - Rare Aggression; anxiety; arthralgia; depression; hallucination; insomnia; myalgia; paraesthesia
  - Very rare Rash (in adults); seizures; urticaria (in adults)
  - Frequency not known Hepatitis; jaundice; muscle cramps
- PREGNANCY Avoid unless potential benefit outweighs risk.

- MEDICINAL FORMS
  - Tablet
  - Effervescent powder
  - CAUTIONARY AND ADVISORY LABELS

ERGOT ALKALOIDS

Ergotamine tartrate

INDICATIONS AND DOSE

Management of cluster headache

BY MOUTH USING TABLETS
- Adult: 1 mg once daily for 6 nights in 7; occasionally given for 1–2 weeks, dose to be taken at night

- UNLICENSED USE Not licensed for the management of cluster headache.

- CONTRA-INDICATIONS
  - Acute porphyrias p. 864
  - Coronary heart disease
  - Hyperthyroidism
  - Inadequately controlled hypertension
  - Obliterative vascular disease
  - Peripheral vascular disease
  - Raynaud’s syndrome
  - Sepsis
  - Severe hypertension
  - Temporal arteritis

- CAUTIONS
  - Anaemia
  - Cardiac disease
  - Dependence
  - Elderly
  - Risk of peripheral vasospasm

- INTERACTIONS → Appendix 1 (ergot alkaloids).

- SIDE-EFFECTS
  - Common or very common Abdominal pain; dizziness; nausea; vomiting
  - Uncommon Cyanosis; diarrhoea; hypoaesthesia; pain in extremities; paraesthesia; peripheral vasoconstriction; weakness in extremities
  - Rare Arrhythmias; bradycardia; dysphoae; ergotism (including absence of pulse and numbness in extremities); increased blood pressure; intestinal ischaemia; myalgia; rash; tachycardia; urticaria
  - Very rare Gangrene; heart-valve fibrosis; myocardial infarction; myocardial ischaemia

- Frequency not known Anxiety; arthralgia; blood disorders; blurred vision; cerebral ischaemia; confusion; constipation; depression; drowsiness; dry mouth; extrapyramidal effects; hallucinations; renal artery spasm; seizures; sleep disturbances; thrombosis; tremor; urinary retention

- PREGNANCY Avoid; oxytocic effect on the uterus.

- BREAST FEEDING Avoid; ergotism may occur in infant; repeated doses may inhibit lactation.

- HEPATIC IMPAIRMENT Avoid in severe impairment—risk of toxicity increased.

- RENAL IMPAIRMENT Avoid; risk of renal vasoconstriction.

Important safety information

Metoclopramide can cause severe extrapyramidal effects, particularly in young adults.

- CAUTIONS Treatment should not exceed 3 months due to risk of tardive dyskinesia.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  Tablet
  - CAUTIONARY AND ADVISORY LABELS 17, 30
    - Paramax (Zentiva)
      - Metoclopramide hydrochloride 5 mg, Paracetamol 500 mg Paramax tablets | 42 tablet [R] £0.64 DT price = £3.64
  - Effervescent powder
    - CAUTIONARY AND ADVISORY LABELS 13, 17, 30
      - Paramax (Zentiva)
        - Metoclopramide hydrochloride 5 mg, Paracetamol 500 mg Paramax sachets (sugar-free) | 42 sachet [R] £12.52 DT price = £12.52

- PATIENT AND CARER ADVICE

- CONTRA-INDICATIONS
  - History of epilepsy
  - History of renal impairment
  - History of cardiac disease
  - History of Raynaud’s syndrome
  - History of peripheral vascular disease

- PATIENTS TREATED WITH:
  - Ergot alkaloids
  - Monoamine oxidase inhibitors
  - Lithium
  - Tricyclic antidepressants

- PRECAUTIONS
  - Pregnancy
  - Breastfeeding
  - Renal impairment
  - Hepatic impairment

- Use with caution in:
  - Hypertension
  - Hyperthyroidism
  - Thyrotoxicosis
  - Hypotension
  - Cardiac disease
  - Renal disease
  - Seizures
  - Intestinal ischaemia
  - Severe renal artery spasm

- Avoid; risk of renal vasoconstriction.

- Avoid in severe impairment

- Avoid; oxytocic effect on the uterus.

- Avoid; risk of renal vasoconstriction.
Ergotamine tartrate with caffeine hydrate and cyclizine hydrochloride

The properties listed below are those particular to the combination only. For the properties of the components please consider, cyclizine p. 343, ergotamine tartrate p. 376.

**INDICATIONS AND DOSE**

**Treatment of acute migraine and migraine variants unresponsive to analgesics**

**BY MOUTH**

- **Adult**: 1 tablet, to be taken at onset, followed by 0.5–1 tablet after 30 minutes, then 0.5–1 tablet every 30 minutes if required, max. 3 tablets in 24 hours, max. 4 tablets per attack, max. 6 tablets in one week

**SIDE-EFFECTS, FURTHER INFORMATION**

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasoconstriction or to anaphylaxis).

**INTERACTIONS**

- **Sensitivities**
  - Sulfonamides: cross-sensitivity may occur.
  - Cimetidine: increased levels of ergotamine may occur.

**CONTRA-INDICATIONS**

- Recent ischaemic stroke
- Severe hypertension
- Severe peripheral vascular disease
- Severe ischaemic heart disease
- Severe heart failure
- Severe depression
- Severe tinnitus
- Severe photophobia
- Severe anaphylaxis

**PRECAUTIONS**

- Discontinue if intense, may be due to coronary vasoconstriction or to anaphylaxis.

**PATIENT AND CARER ADVICE**

Patient counselling is advised.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

3

- **ALMOTRIPTAN (Non-proprietary)**
  - Almotriptan (as Almotriptan hydrogen malate) 12.5 mg, Almotriptan 12.5 mg tablets | 3 tablet (PO) £9.07 | 6 tablet (PO) £18.14 DT price + £18.14 | 9 tablet (PO) £27.21
  - Almogran (Almirall Ltd)
    - Almotriptan (as Almotriptan hydrogen malate) 12.5 mg, Almogran 12.5 mg tablets | 3 tablet (PO) £9.07 | 6 tablet (PO) £18.14 DT price + £18.14 | 9 tablet (PO) £27.20

**Eléctriptan**

**INDICATIONS AND DOSE**

**Treatment of acute migraine**

**BY MOUTH**

- **Adult**: 40 mg, followed by 40 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding should not take second dose for same attack); increased if necessary to 80 mg, dose to be taken for subsequent attacks if 40 mg dose inadequate; maximum 80 mg per day

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, diarrhoea, dry mouth, dyspepsia, headache, myalgia, myastenia, palpitation, pharyngitis, rhinitis, sweating, tachycardia
- **Uncommon** Agitation, anorexia, arthralgia, confusion, depersonalisation, depression, diarrhoea, dysarthria, dysphonia, euphoria, glossitis, hypertonia, insomnia, movement disorders, oedema, photophobia, pruritus, rash, stupor, taste disturbance, thirst, tinnitus, tremor, urinary frequency, visual disturbances, yawning

**INTERACTIONS**

- **Appendix 1 (5HT_1 agonists).**

**UNLICENSED USE**

Not licensed for use in elderly.

**CONTRA-INDICATIONS**

Arrhythmias, coronary vasospasm, heart failure, ischaemic heart disease, peripheral vascular disease, previous cerebrovascular accident, previous myocardial infarction, previous transient ischaemic attack, Prinzmetal’s angina, severe hypertension, uncontrolled hypertension

**CAUTIONS**

Conditions which predispose to coronary artery disease—elderly

**INTERACTIONS**

- Appendix 1 (5HT_1 agonists)

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, diarrhoea, dry mouth, dyspepsia, headache, myalgia, myastenia, palpitation, pharyngitis, rhinitis, sweating, tachycardia
- **Uncommon** Agitation, anorexia, arthralgia, confusion, depersonalisation, depression, diarrhoea, dysarthria, dysphonia, euphoria, glossitis, hypertonia, insomnia, movement disorders, oedema, photophobia, pruritus, rash, stupor, taste disturbance, thirst, tinnitus, tremor, urinary frequency, visual disturbances, yawning
- **Rare** Asthma, bradycardia, constipation, lymphadenopathy, menorrhagia, oesophagitis, syncope
- **Frequency not known** Dizziness, fatigue, feeling of weakness, flushing, hypotension, ischaemic colitis, nausea, vomiting

**Ergotamine tartrate with caffeine hydrate and cyclizine hydrochloride**

**PATIENT AND CARER ADVICE**

Peripheral vasospasm: Warn patient to stop treatment immediately if numbness or tingling of extremities develops and to contact doctor.

**LESS SUITABLE FOR PRESCRIBING**

Ergotamine tartrate is less suitable for prescribing.

**INDICATIONS AND DOSE**

**Treatment of acute migraine and migraine variants unresponsive to analgesics**

**BY MOUTH**

- **Adult**: 12.5 mg, dose to be taken as soon as possible after onset, followed by 12.5 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding should not take second dose for same attack); maximum 25 mg per day

**SIDE-EFFECTS**

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasoconstriction or to anaphylaxis).

**ALLERGY AND CROSS-SENSITIVITY**

Caution in patients with sensitivity to sulfonamides.

**PREGNANCY**

There is limited experience of using 5HT_1 receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

**BREAST FEEDING**

Present in milk in animal studies—hold breast-feeding for 24 hours.

**HEPATIC IMPAIRMENT**

Caution in mild to moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT**

Max. 12.5 mg in 24 hours if eGFR less than 30 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

3

- **ALMOTRIPTAN (Non-proprietary)**
  - Almotriptan (as Almotriptan hydrogen malate) 12.5 mg, Almotriptan 12.5 mg tablets | 3 tablet (PO) £9.07 | 6 tablet (PO) £18.14 DT price + £18.14 | 9 tablet (PO) £27.21
  - Almogran (Almirall Ltd)
    - Almotriptan (as Almotriptan hydrogen malate) 12.5 mg, Almogran 12.5 mg tablets | 3 tablet (PO) £9.07 | 6 tablet (PO) £18.14 DT price + £18.14 | 9 tablet (PO) £27.20

**Almotriptan**

**INDICATIONS AND DOSE**

**Treatment of acute migraine**

**BY MOUTH**

- **Adult**: 12.5 mg, dose to be taken as soon as possible after onset, followed by 12.5 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding should not take second dose for same attack); maximum 25 mg per day
### Naratriptan

**INDICATIONS AND DOSE**

**Treatment of acute migraine**

**BY MOUTH**

- Adult: 2.5 mg, dose to be taken as soon as possible after onset, followed by 2.5 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 5 mg per day

- **UNLICENSED USE** Not licensed for use in elderly.
- **CONTRA-INDICATIONS**
  - Coronary vasospasm - ischaemic heart disease - moderate or severe hypertension - peripheral vascular disease - previous cerebrovascular accident - previous myocardial infarction - previous transient ischaemic attack - Prinzmetal’s angina - severe hypertension - uncontrolled hypertension

- **CAUTIONS** Conditions which predispose to coronary artery disease - elderly

- **INTERACTIONS** → Appendix 1 (5HT, agonists).

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain - drowsiness - dry mouth - dyspepsia - headache - paraesthesia - sweating - visual disturbances
  - Rare Abnormal dreams - anemia - bilirubinaemia - bradycardia - breast tenderness - constipation - epistaxis - gastro-oesophageal reflux - hiccup - hyperventilation - hypocalcaemia - hypoglycaemia - hypotonia - irritable bowel syndrome - peptic ulcer - purpura - pyrexia - stomatitis - urticaria
  - Frequency not known Dizziness - fatigue - feeling of weakness - flushing - nausea - vomiting

---

**SIDE-EFFECTS, FURTHER INFORMATION**

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasoconstriction or to anaphylaxis).

- **PREGNANCY** There is limited experience of using 5HT1-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

- **BREAST FEEDING** Present in milk in animal studies— withhold breast-feeding for 24 hours.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

---

**TABLET**

**CAUTIONARY AND ADVISORY LABELS 3**

- Migard (A. Menarini Farmaceutica Internazionale SRL)
  - Naratriptan (as Naratriptan succinate monohydrate) 2.5 mg Migard 2.5 mg tablets | 6 tablet | £16.60

---

**Frovatriptan**

**INDICATIONS AND DOSE**

**Treatment of acute migraine**

**BY MOUTH**

- Adult: 2.5 mg, dose to be taken as soon as possible after onset, followed by 2.5 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 5 mg per day

- **UNLICENSED USE** Not licensed for use in elderly.
- **CONTRA-INDICATIONS**
  - Coronary vasospasm - ischaemic heart disease - moderate or severe hypertension - peripheral vascular disease - previous cerebrovascular accident - previous myocardial infarction - previous transient ischaemic attack - Prinzmetal’s angina - severe hypertension - uncontrolled hypertension

- **CAUTIONS** Conditions which predispose to coronary artery disease - elderly

- **INTERACTIONS** → Appendix 1 (5HT, agonists).

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain - drowsiness - dry mouth - dyspepsia - headache - paraesthesia - sweating - visual disturbances
  - Rare Abnormal dreams - anemia - bilirubinaemia - bradycardia - breast tenderness - constipation - epistaxis - gastro-oesophageal reflux - hiccup - hyperventilation - hypocalcaemia - hypoglycaemia - hypotonia - irritable bowel syndrome - peptic ulcer - purpura - pyrexia - stomatitis - urticaria
  - Frequency not known Dizziness - fatigue - feeling of weakness - flushing - nausea - vomiting

---

**SIDE-EFFECTS, FURTHER INFORMATION**

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasoconstriction or to anaphylaxis).

- **PREGNANCY** There is limited experience of using 5HT1-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

- **BREAST FEEDING** Present in milk in animal studies— withhold breast-feeding for 24 hours.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
**PATIENT AND CARER ADVICE**

**DIRECTIONS FOR ADMINISTRATION**

**HEPATIC IMPAIRMENT**

**BREAST FEEDING**

**PREGNANCY**

**INTERACTIONS**

**CONTRA-INDICATIONS**

**UNLICENSED USE**

**SIDE-EFFECTS**

**COMMON OR VERY COMMON** Decreased alertness · diarrhoea · drowsiness · dry mouth · dysphagia · headache · palpitation · paraesthesia · pharyngeal discomfort · sweating · tachycardia · tremor

**UNCOMMON** Arrhythmias · ataxia · blurred vision · confusion · dyspepsia · hypertension · insomnia · muscle weakness · myalgia · nervousness · pruritus · taste disturbances · thirst · urticaria · vertigo

**RARE** Bradycardia · syncope

**FREQUENCY NOT KNOWN** Dizziness · fatigue · feeling of weakness · flushing · nausea · seizures · toxic epidermal necrolysis · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—continue if intense, may be due to coronary vasospastic prong or coronary spasm which may cause coronary vasospasm and angina; maximum 12 mg per day

**PREGNANCY** There is limited experience of using 5HT₁-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

**BREAST FEEDING** Present in milk in animal studies— withhold breast-feeding for 24 hours.

**HEPATIC IMPAIRMENT** Reduce dose to 5 mg in mild to moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT** Reduce dose to 5 mg in mild to moderate impairment. Avoid in severe impairment.

**DIRECTIONS FOR ADMINISTRATION** Rizatriptan orodispersible tablets should be placed on the tongue, allowed to disperse and swallowed. Rizatriptan oral lyophilisates should be placed on the tongue and allowed to dissolve.

**PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving). Patients or carers should be given advice on how to administer rizatriptan orodispersible tablets and oral lyophilisates.

---

**Rizatriptan**

**INDICATIONS AND DOSE**

**Treatment of acute migraine**

**BY MOUTH**

- Adult: 10 mg, dose to be taken as soon as possible after onset, followed by 10 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 20 mg per day

**SIDE-EFFECTS**

**COMMON OR VERY COMMON** Decreased alertness · diarrhoea · drowsiness · dry mouth · dysphagia · headache · palpitation · paraesthesia · pharyngeal discomfort · sweating · tachycardia · tremor

**UNCOMMON** Arrhythmias · ataxia · blurred vision · confusion · dyspepsia · hypertension · insomnia · muscle weakness · myalgia · nervousness · pruritus · taste disturbances · thirst · urticaria · vertigo

**RARE** Bradycardia · syncope

**FREQUENCY NOT KNOWN** Dizziness · fatigue · feeling of weakness · flushing · nausea · seizures · toxic epidermal necrolysis · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—continue if intense, may be due to coronary vasospastic prong or coronary spasm which may cause coronary vasospasm and angina; maximum 12 mg per day

**PREGNANCY** There is limited experience of using 5HT₁-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

**BREAST FEEDING** Present in milk in animal studies— withhold breast-feeding for 24 hours.

**HEPATIC IMPAIRMENT** Reduce dose to 5 mg in mild to moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT** Reduce dose to 5 mg in mild to moderate impairment. Avoid in severe impairment.

**DIRECTIONS FOR ADMINISTRATION** Rizatriptan orodispersible tablets should be placed on the tongue, allowed to disperse and swallowed. Rizatriptan oral lyophilisates should be placed on the tongue and allowed to dissolve.

**PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving). Patients or carers should be given advice on how to administer rizatriptan orodispersible tablets and oral lyophilisates.

---

**Migraine**

**INDICATIONS AND DOSE**

**Treatment of acute migraine**

**BY MOUTH**

- Adult: Initially 50–100 mg for 1 dose, followed by 50–100 mg after at least 2 hours if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 300 mg per day

**BY SUBCUTANEOUS INJECTION**

- Adult: Initially 6 mg for 1 dose, followed by 6 mg after at least 1 hour if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack), dose to be administered using an auto-injector; not for intravenous injection which may cause coronary vasospasm and angina; maximum 12 mg per day

**Treatment of acute cluster headache**

**BY SUBCUTANEOUS INJECTION**

- Adult: Initially 6 mg for 1 dose, followed by 6 mg after at least 1 hour if required, to be taken only if headache recurs (patient not responding to initial dose should not take second dose for same attack), dose to be administered using an auto-injector; not for intravenous injection which may cause coronary vasospasm and angina; maximum 12 mg per day

**BY INTRanasAL ADMINISTRATION**

- Adult 18–65 years: Initially 10–20 mg, to be administered into one nostril, followed by 10–20 mg after at least 2 hours if required, to be taken...
only if headache recurs (patient not responding to initial dose should not take second dose for same attack); maximum 40 mg per day

- **UNLICENSED USE** Not licensed for use in elderly.
- **CONTRA-INDICATIONS** Coronary vasospasm - ischaemic heart disease - mild uncontrolled hypertension - moderate and severe hypertension - peripheral vascular disease - previous cerebrovascular accident - previous myocardial infarction - previous transient ischaemic attack - Prinzmetal's angina
- **CAUTIONS** Conditions which predispose to coronary artery disease - elderly - history of seizures - mild, controlled hypertension - pre-existing cardiac disease - risk factors for seizures
- **INTERACTIONS** ➔ Appendix 1 (5HT, agonists).

**SIDE-EFFECTS**

- **GENERAL SIDE-EFFECTS**
  - Common or very common: Dizziness - drowsiness - dysphoena - fatigue - flushing - myalgia - nausea - sensory disturbances - transient increase in blood pressure - vomiting - weakness

**SPECIFIC SIDE-EFFECTS**

- Common or very common: With intranasal use dysgeusia - epistaxis

**SIDE-EFFECTS, FURTHER INFORMATION**
Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasoconstriction or anaphylaxis).

**ALLERGY AND CROSS-SENSITIVITY** Caution in patients with sensitivity to sulfonamides.

**PREGNANCY** There is limited experience of using 5HT₁-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

**BREAST FEEDING** Present in milk but amount probably too small to be harmful; withhold breast-feeding for 12 hours after treatment.

**HEPATIC IMPAIRMENT** Reduce oral dose to 25–50 mg. Avoid in severe impairment.

**RENAL IMPAIRMENT** Use with caution.

**PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving).

**EXCEPTIONS TO LEGAL CATEGORY** Sumatriptan 50 mg tablets can be sold to the public to treat previously diagnosed migraine; max. daily dose 100 mg.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **SUMATRIPTAN (Non-proprietary)**
  - **Sumatriptan (as Sumatriptan succinate) 50 mg** Sumatriptan 50mg tablets | 6 tablet (PPh) £24.85 DT price = £1.75
  - **Sumatriptan (as Sumatriptan succinate) 100 mg** Sumatriptan 100mg tablets | 6 tablet (PPh) £40.18 DT price = £1.83
  - **Imigran (GlaxoSmithKline UK Ltd, Forest Laboratories UK Ltd)**
  - **Sumatriptan (as Sumatriptan succinate) 50 mg** Imigran Radis 50mg tablets | 6 tablet (PPh) £23.90 DT price = £1.75
  - **Imigran 50mg tablets** | 6 tablet (PPh) £31.85 DT price = £1.75
  - **Imigran Recovery 50mg tablets** | 2 tablet (P) £4.76

**Solution for injection**

- **SUMATRIPTAN (Non-proprietary)**
  - **Sumatriptan (as Sumatriptan succinate) 12 mg per 1 ml** Sumatriptan 6mg/0.5ml solution for injection pre-filled pen | 2 pre-filled disposable injection (PPh) £39.50 DT price = £39.50
  - **Imigran Subject (GlaxoSmithKline UK Ltd)**
  - **Sumatriptan (as Sumatriptan succinate) 12 mg per 1 ml** Imigran Subject 6mg/0.5ml solution for injection syringe refill pack | 2 pre-filled disposable injection (PPh) £40.41 DT price = £40.41

**Spray**

- **Imigran (GlaxoSmithKline UK Ltd)**
  - **Sumatriptan 100 mg per 1 ml** Imigran 10mg nasal spray | 2 unit dose (PPh) £11.80 DT price = £1.18
  - **Sumatriptan 200 mg per 1 ml** Imigran 20mg nasal spray | 2 unit dose (PPh) £14.16 | 6 unit dose (PPh) £35.39 DT price = £3.35

**Zolmitriptan**

**INDICATIONS AND DOSE**

**Treatment of acute migraine**

**BY MOUTH**

- **Adult**: 2.5 mg, followed by 2.5 mg after at least 2 hours if required, dose to be taken only if migraine recurs, then increased if necessary to 5 mg, dose to be taken only for subsequent attacks in patients not achieving satisfactory relief with 2.5 mg dose; maximum 10 mg per day

**BY INTRanasal ADMINISTRATION**

- **Adult**: 5 mg, dose to be administered as soon as possible after onset into one nostril only, followed by 5 mg after at least 2 hours if required, dose to be administered only if migraine recurs; maximum 10 mg per day

**Treatment of acute cluster headache**

**BY INTRanasal ADMINISTRATION**

- **Adult**: 5 mg, dose to be administered as soon as possible after onset into one nostril only, followed by 5 mg after at least 2 hours if required, dose to be administered only if migraine recurs; maximum 10 mg per day

**Dose adjustments due to interactions**
Max. 5 mg in 24 hours with concomitant cimetidine, fluvoxamine, moclobemide, or quinolone antibiotics.

**Dose equivalence and conversion**
1 spray of Zomig® nasal spray = 5 mg zolmitriptan.
INDICATIONS AND DOSE
Acute migraine
BY MOUTH
• Adult: 1 sachet, sachet to be mixed in water, and dose to be taken at the start of the attack, then 1 sachet after 2 hours if required; maximum 3 sachets per day.

Important safety information
Metoclopramide can cause severe extrapyramidal effects, particularly in children and young adults.

CAUTIONS
• Treatment should not exceed 3 months due to risk of tardive dyskinesia.
• PRESCRIBING AND DISPENSING INFORMATION Flavours of oral powder formulations may include lemon.

MEDICINAL FORMS
• There can be variation in the licensing of different medicines containing the same drug.
• Powder CAUTIONARY AND ADVISORY LABELS 13, 21, 32 EXCIPIENTS: May contain Aspartame
  • MigraMax (Zentiva)
  Aspirin DL-Lysine 900 mg, Metoclopramide hydrochloride
  10 mg MigraMax oral powder sachets (sugar-free) | 6 sachet DT price = £6.61
  17 mg MigraMax oral powder sachets (sugar-free) | 6 sachet DT price = £6.61

Toltenamic acid

INDICATIONS AND DOSE
Treatment of acute migraine
BY MOUTH
• Adult: 200 mg, dose to be taken at onset, then 200 mg after 1–2 hours if required.

CONTRA-INDICATIONS
• Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal haemorrhage (two or more distinct episodes) - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure.

CAUTIONS
• Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension.

INTERACTIONS
• Appendix I (NSAIDs).

SIDE-EFFECTS
• Rare Alveolitis - aspetic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis.

Frequency not known
• Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - confusion - Crohn’s disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - dysuria (most commonly in men) - euphoria - fluid retention (rarely precipitating congestive heart failure) - gastrointestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - hallucination - headache -
5.2 Neuropathic pain

Neuropathic pain, which occurs as a result of damage to neural tissue, includes phantom limb pain, compression neuropathies, peripheral neuropathies (e.g. due to Diabetes p. 588, chronic excessive alcohol intake, HIV infection p. 555, chemotherapy, idiopathic neuropathy), trauma, central pain (e.g. pain following stroke, spinal cord injury, and syringomyelia), and postherpetic neuralgia (peripheral nerve damage following acute herpes zoster infection (shingles)). The pain may occur in an area of sensory deficit and is sometimes accompanied by pain that is evoked by a non-noxious stimulus (allodynia).

Trigeminal neuralgia is also caused by dysfunction of neural tissue, but its management is distinct from other forms of neuropathic pain.

Neuropathic pain is generally managed with a tricyclic antidepressant or with certain antiepileptic drugs.

Amitriptyline hydrochloride p. 292 [unlicensed indication] and pregabalin p. 400 are effective treatments for neuropathic pain. Amitriptyline hydrochloride p. 292 and pregabalin can be used in combination if the patient has an inadequate response to either drug at the maximum tolerated dose.

Nortriptyline p. 298 [unlicensed indication] may be better tolerated than amitriptyline hydrochloride.

Gabapentin p. 392 is also effective for the treatment of neuropathic pain.

Neuropathic pain may respond to opioid analgesics. There is evidence of efficacy for tramadol hydrochloride p. 373, morphine p. 367, and oxycodone hydrochloride p. 369; however, treatment with morphine or oxycodone hydrochloride should be initiated only under specialist supervision. Tramadol hydrochloride p. 373 can be prescribed when other treatments have been unsuccessful, while the patient is waiting for assessment by a specialist.

Patients with localised pain who are unable to take oral medicines may benefit from topical local anaesthetic preparations, such as lidocaine hydrochloride p. 1116 medicated plasters, while awaiting specialist review.

Capsaicin p. 383 is licensed for neuropathic pain (but the intense burning sensation during initial treatment may limit use). Capsaicin p. 383 0.075% cream is licensed for the symptomatic relief of postherpetic neuralgia. A self-adhesive patch containing capsaicin p. 383 8% is licensed for the treatment of peripheral neuropathic pain in non-diabetic patients. It should be used under specialist supervision.

A corticosteroid may help to relieve pressure in compression neuropathy and thereby reduce pain.

Neurmodulation by spinal cord stimulation may be of benefit in some patients. Many patients with chronic neuropathic pain require multidisciplinary management, including physiotherapy and psychological support.

Trigeminal neuralgia

Surgery may be the treatment of choice in many patients; a neurological assessment will identify those who stand to benefit. Carbamazepine p. 387 taken during the acute stages of trigeminal neuralgia, reduces the frequency and severity of attacks. It is very effective for the severe pain associated with trigeminal neuralgia and (less commonly) glossopharyngeal neuralgia. Blood counts and electrolytes should be monitored when high doses are given. Small doses should be used initially to reduce the incidence of side-effects e.g. dizziness. Some cases respond to phenytoin p. 398; the drug may be given by intravenous infusion (possibly as fosphenytoin sodium p. 391) in a crisis (specialist use only).

Chronic facial pain

Chronic oral and facial pain including persistent idiopathic facial pain (also termed ‘atypical facial pain’) and temporomandibular dysfunction (previously termed temporomandibular joint pain dysfunction syndrome) may call for prolonged use of analgesics or for other drugs. Tricyclic antidepressants may be useful for facial pain [unlicensed indication], but are not on the Dental Practitioners’ List. Disorders of this type require specialist referral and psychological support to accompany drug treatment. Patients on long-term therapy need to be monitored both for progress and for side-effects.

Drugs used for Neuropathic pain not listed below; Amantadine hydrochloride, p. 331 - Amitriptyline hydrochloride, p. 292 - Capsaicin, p. 383 - Carbamazepine, p. 387 - Nortriptyline, p. 298 - Oxycodone hydrochloride, p. 369 - Phenytoin, p. 398 - Pregabalin, p. 400
ALKALOID ANALGESICS

Capsaicin

INDICATIONS AND DOSE

AXSAIN®

Post-herpetic neuralgia
 TO THE SKIN
 ▶ Adult: Apply 3–4 times a day, dose to be applied sparingly; important; after lesions have healed, not more often than every 4 hours

Painful diabetic neuropathy (under expert supervision)
 TO THE SKIN
 ▶ Adult: Apply 3–4 times a day for 8 weeks then review, dose to be applied sparingly, not more often than every 4 hours

ZACIN®

Symptomatic relief in osteoarthritis
 TO THE SKIN
 ▶ Adult: Apply 4 times a day, dose to be applied sparingly, not more often than every 4 hours

QUTENZA®

Peripheral neuropathic pain in non-diabetic patients (under the supervision of a physician)
 TO THE SKIN
 ▶ Adult: (consult product literature)

CAUTIONS

GENERAL CAUTIONS
Avoid contact with broken skin - avoid contact with inflamed skin

SPECIFIC CAUTIONS:
▷ With topical use avoid contact with eyes - avoid hot shower or bath just before or after application (burning sensation enhanced) - avoid inhalation of vapours - not to be used under tight bandages
▷ With transdermal use avoid contact with the face, scalp or in proximity to mucous membranes - avoid holding near eyes or mucous membranes - recent cardiovascular events - uncontrolled hypertension

SIDE-EFFECTS
▷ Common or very common
 ▶ With topical use transient burning sensation during initial treatment (particularly if too much used or if administered less than 3–4 times daily)
 ▶ With transdermal use application site reactions - erythema - pruritus - transient burning
 ▶ Uncommon
 ▶ With transdermal use burning sensation - cough - dysgeusia - eye irritation - first degree AV block - hypertension - hypoesthesia - muscle spasm - nausea - pain in extremities - palpitations - peripheral oedema - pruritus - tachycardia - throat irritation
 ▶ Rare
 ▶ With topical use cough - eye irritation - sneezing
 ▶ Frequency not known
 ▶ With topical use dyspnoea - exacerbation of asthma

MONITORING REQUIREMENTS
▷ With transdermal use Monitor blood pressure during treatment procedure.

HANDLING AND STORAGE
▷ With topical use Wash hands immediately after use (or wash hands 30 minutes after application if hands treated).
▷ With transdermal use Nitrile gloves to be worn while handling patches and cleaning treatment areas (latex gloves do not provide adequate protection).

NATIONAL FUNDING/ACCESS DECISIONS

QUTENZA®
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (January 2011) that capsaicin 179 mg (8%) patch (Qutenza®) is accepted for restricted use within NHS Scotland for the treatment of postherpetic neuralgia in patients who have not achieved adequate pain relief from, or who have not tolerated conventional first and second line treatments. Treatment should be under the supervision of a specialist in pain management.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream

Cream
EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol)
▷ Axsain (Teva UK Ltd)
Capsaicin 750 microgram per 1 gram Axsain 0.075% cream | 45 gram (P) £14.58 DT price = £14.58
▷ Zacin (Teva UK Ltd)
Capsaicin 250 microgram per 1 gram Zacin 0.025% cream | 45 gram (P) £17.71 DT price = £17.71

Cutaneous patch
EXCIPIENTS: May contain Butylated hydroxyanisole
▷ Qutenza (Astellas Pharma Ltd)
Capsaicin 179 mg (Qutenza 179mg cutaneous patches | 1 patch (P) £210.00

6 Seizures

6.1 Epilepsy

Epilepsy

Control of the epilepsies
The object of treatment is to prevent the occurrence of seizures by maintaining an effective dose of one or more antiepileptic drugs. Careful adjustment of doses is necessary, starting with low doses and increasing gradually until seizures are controlled or there are significant adverse effects.

When choosing an antiepileptic drug, the presenting epilepsy syndrome should first be considered. If the syndrome is not clear, the seizure type should determine the choice of treatment. Concomitant medication, co-morbidity, age, and sex should also be taken into account.

The dosage frequency is often determined by the plasma-drug half-life, and should be kept as low as possible to encourage adherence with the prescribed regimen. Most antiepileptics, when used in the usual dosage, can be given twice daily. Lamotrigine p. 394, perampanel p. 398, phenobarbital p. 409, and phenytoin p. 398, which have long half-lives, can be given once daily at bedtime.

However, with large doses, some antiepileptics may need to be given more frequently to avoid adverse effects associated with high peak plasma-drug concentration.

Management
When monotherapy with a first-line antiepileptic drug has failed, monotherapy with a second drug should be tried; the diagnosis should be checked before starting an alternative drug if the first drug showed lack of efficacy. The change from one antiepileptic drug to another should be cautious, slowly withdrawing the first drug only when the new regimen has been established. Combination therapy with two or more antiepileptic drugs may be necessary, but the concurrent use of antiepileptic drugs increases the risk of adverse effects and drug interactions. If combination
therapy does not bring about worthwhile benefits, revert to the regimen (monotherapy or combination therapy) that provided the best balance between tolerability and efficacy. A single antiepileptic drug should be prescribed wherever possible.

MHRA/CHM advice: Antiepileptic drugs: new advice on switching between different manufacturers’ products for a particular drug (November 2013)

The CHM has reviewed spontaneous adverse reactions received by the MHRA and publications that reported potential harm arising from switching of antiepileptic drugs in patients previously stabilised on a branded product to a generic. The CHM concluded that reports of loss of seizure control and/or worsening of side-effects around the time of switching between products could be explained as chance associations, but that a causal role of switching could not be ruled out in all cases. The following guidance has been issued to help minimise risk:

- Different antiepileptic drugs vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers’ products of a particular drug may cause adverse effects or loss of seizure control;
- Antiepileptic drugs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer’s product. These categories are listed below;
- If it is felt desirable for a patient to be maintained on a specific manufacturer’s product this should be prescribed either by specifying a brand name, or by using the generic name and name of the manufacturer (otherwise known as the Marketing Authorisation Holder);
- This advice relates only to antiepileptic drug use for treatment of epilepsy; it does not apply to their use in other indications (e.g. mood stabilisation, neuropathic pain);
- Please report on a Yellow Card any suspected adverse reactions to antiepileptic drugs;
- Dispensing pharmacists should ensure the continuity of supply of a particular product when the prescription specifies it. If the prescribed product is unavailable, it may be necessary to dispense a product from a different manufacturer to maintain continuity of treatment of that antiepileptic drug. Such cases should be discussed and agreed with both the prescriber and patient (or carer);
- Usual dispensing practice can be followed when a specific product is not stated.

**Category 1**
Phenytoin p. 398, carbamazepine p. 387, phenobarbital p. 405, primidone p. 401. For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product.

**Category 2**
Valproate, lamotrigine p. 394, perampanel p. 398, retigabine p. 402, rufinamide p. 402, clobazam p. 410, clonazepam p. 411, oxcarbazepine p. 397, eslicarbazepine acetate p. 390, zonisamide p. 408, topiramate p. 406. For these drugs, the need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient and/or carer taking into account factors such as seizure frequency and treatment history.

**Category 3**
Levetiracetam p. 396, lacosamide p. 393, tiagabine p. 406, gabapentin p. 292, pregabalin p. 400, ethosuximide p. 390, vigabatrin p. 407. For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific concerns such as patient anxiety, and risk of confusion or dosing errors Interactions.

**Antiepileptic hypersensitivity syndrome**
Antiepileptic hypersensitivity syndrome is a rare but potentially fatal syndrome associated with some antiepileptic drugs (carbamazepine, lacosamide, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, primidone, and rufinamide); rarely cross-sensitivity occurs between some of these antiepileptic drugs. Some other antiepileptics (eslicarbazepine, stiripentol, and zonisamide) have a theoretical risk. The symptoms usually start between 1 and 8 weeks of exposure; fever, rash, and lymphadenopathy are most commonly seen. Other systemic signs include liver dysfunction, haematological, renal, and pulmonary abnormalities, vasculitis, and multi-organ failure. If signs or symptoms of hypersensitivity syndrome occur, the drug should be withdrawn immediately, the patient must not be re-exposed, and expert advice should be sought.

**Interactions**
Interactions between antiepileptics are complex and may increase toxicity without a corresponding increase in antiepileptic effect. Interactions are usually caused by hepatic enzyme induction or inhibition; displacement from protein binding sites is not usually a problem. These interactions are highly variable and unpredictable.

**Withdrawal**
Antiepileptic drugs should be withdrawn under specialist supervision. Avoid abrupt withdrawal, particularly of barbiturates and benzodiazepines, because this can precipitate severe rebound seizures. Reduction in dosage should be gradual and, in the case of barbiturates, withdrawal of the drug may take months.

The decision to withdraw antiepileptic drugs from a seizure-free patient, and its timing, is often difficult and depends on individual circumstances. Even in patients who have been seizure-free for several years, there is a significant risk of seizure recurrence on drug withdrawal. In patients receiving several antiepileptic drugs, only one drug should be withdrawn at a time.

**Driving**
Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.

Guidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards.

Patients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.

**Pregnancy**
Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy.

There is an increased risk of teratogenicity associated with the use of antiepileptic drugs (especially if used during the first trimester and particularly if the patient takes two or more antiepileptic drugs). Valproate is associated with the highest risk of major and minor congenital malformations (in particular neural tube defects), and long-term neurodevelopmental effects. There is also an increased risk of teratogenicity with phenytoin, primidone, phenobarbital,
Lamotrigine, and carbamazepine. Topiramate carries an increased risk of cleft palate if taken in the first trimester of pregnancy. There is not enough evidence to establish the risk of teratogenicity with other antiepileptic drugs. Prescribers should also consider carefully the choice of antiepileptic therapy in pre-pubescent girls who may later become pregnant. Women of child-bearing potential who take antiepileptic drugs should be given contraceptive advice. Some antiepileptic drugs can reduce the efficacy of hormonal contraceptives, and the efficacy of some antiepileptics may be affected by hormonal contraceptives.

Women who want to become pregnant should be referred to a specialist for advice in advance of conception. For some women, the severity of seizure or the seizure type may not pose a serious threat, and drug withdrawal may be considered; therapy may be resumed after the first trimester. If treatment with antiepileptic drugs must continue throughout pregnancy, then monotherapy is preferable at the lowest effective dose. Once an unplanned pregnancy is discovered it is usually too late for changes to be made to the treatment regimen; the risk of harm to the mother and fetus from convulsive seizures outweighs the risk of continued therapy. The likelihood of a woman who is taking antiepileptic drugs having a baby with no malformations is at least 90%, and it is important that women do not stop taking essential treatment because of concern over harm to the fetus. To reduce the risk of neural tube defects, folate supplementation is advised before conception and throughout the first trimester.

The concentration of antiepileptic drugs in the plasma can change during pregnancy. Doses of phenytoin, carbamazepine, and lamotrigine should be adjusted on the basis of plasma-drug concentration monitoring; the dose of other antiepileptic drugs should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis. Plasma-drug concentration monitoring during pregnancy is also useful to check compliance. Additionally, in patients taking topiramate or levetiracetam, it is recommended that fetal growth should be monitored. Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.

Routine injection of vitamin K at birth minimises the risk of neonatal haemorrhage associated with antiepileptics. Withdrawal effects in the newborn may occur with some antiepileptic drugs, in particular benzodiazepines and phenobarbital.

Epilepsy and Pregnancy Register

All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).

Breast-feeding

Women taking antiepileptic monotherapy should generally be encouraged to breast-feed; if a woman is on combination therapy or if there are other risk factors, such as premature birth, specialist advice should be sought. All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones. Infants should also be monitored for adverse effects associated with the antiepileptic drug particularly with newer antiepileptics, if the antiepileptic is readily transferred into breast-milk causing high infant serum-drug concentrations (e.g. ethosuximide, lamotrigine, primidone, and zonisamide), or if slower metabolism in the infant causes drugs to accumulate (e.g. phenobarbital and lamotrigine). Serum-drug concentration monitoring should be undertaken in breast-fed infants if suspected adverse reactions develop; if toxicity develops it may be necessary to introduce formula feeds to limit the infant’s drug exposure, or to wean the infant off breast-milk altogether.

Primidone, phenobarbital, and the benzodiazepines are associated with an established risk of drowsiness in breast-fed babies and caution is required.

Withdrawal effects may occur in infants if a mother suddenly stops breast-feeding, particularly if she is taking phenobarbital, primidone, or lamotrigine.

Focal seizures with or without secondary generalisation

Carbamazepine p. 387 and lamotrigine p. 394 are first-line options for treating newly diagnosed focal seizures; oxcarbazepine p. 397, sodium valproate p. 403 and levetiracetam p. 396 may be used if carbamazepine or lamotrigine are unsuitable or not tolerated. If monotherapy is unsuccessful with two of these first-line antiepileptic drugs, adjunctive treatment may be considered. Options for adjunctive treatment include carbamazepine, clobazam p. 410, gabapentin p. 392, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, or topiramate p. 406. If adjunctive treatment is ineffective or not tolerated, a tertiary epilepsy specialist should be consulted who may consider eslicarbazepine acetate p. 390, lacosamide p. 393, phenobarbital p. 409, phenytoin p. 398, pregabalin p. 400, tiagabine p. 406, vigabatrin p. 407 and zonisamide p. 408.

Generalised seizures

Tonic-clonic seizures

Sodium valproate p. 403 is the first-line treatment for newly diagnosed generalised tonic-clonic seizures. Lamotrigine p. 394 is the alternative choice if sodium valproate is not suitable, but may exacerbate myoclonic seizures. In those with established epilepsy with generalised tonic-clonic seizures only, lamotrigine or sodium valproate may be prescribed as the first-line treatment. Carbamazepine p. 387 and oxcarbazepine p. 397 may also be considered in newly diagnosed and established tonic-clonic seizures, but may exacerbate myoclonic and absence seizures. Clobazam p. 410, lamotrigine p. 394, levetiracetam p. 396, sodium valproate or topiramate p. 406 may be used as adjunctive treatment if monotherapy is ineffective or not tolerated.

Absence seizures

Ethosuximide p. 390 or sodium valproate p. 403 are the drugs of choice in absence seizures and syndromes; lamotrigine p. 394 is a suitable alternative when ethosuximide and sodium valproate are unsuitable, ineffective or not tolerated. Sodium valproate should be used as the first choice if there is a high risk of generalised tonic-clonic seizures. A combination of any two of these drugs may be used if monotherapy is ineffective. Clobazam p. 410, clonazepam p. 411, levetiracetam p. 396, topiramate p. 406 or zonisamide p. 408 may be considered by a tertiary epilepsy specialist if adjunctive treatment fails. Carbamazepine p. 387, gabapentin p. 392, oxcarbazepine p. 397, phenytoin p. 398, pregabalin p. 400, tiagabine p. 406 and vigabatrin p. 407 are not recommended in absence seizures or syndromes.

Myoclonic seizures

Myoclonic seizures (myoclonic jerks) occur in a variety of syndromes, and response to treatment varies considerably. Sodium valproate p. 403 is the drug of choice in newly diagnosed myoclonic seizures; topiramate p. 406 and levetiracetam p. 396 are alternative options if sodium valproate is unsuitable but consideration should be given to the less favourable side-effect profile of topiramate. A combination of two of these drugs may be used if monotherapy is ineffective or not tolerated. If adjunctive treatment fails, a tertiary epilepsy specialist should be consulted and may consider clobazam p. 410, clonazepam p. 411, zonisamide p. 408 or piracetam p. 321.

and vigabatrin p. 407 are not recommended for the treatment of myoclonic seizures. Sodium valproate and levetiracetam are effective in treating the generalised tonic-clonic seizures that coexist with myoclonic seizures in idiopathic generalised epilepsy.

**Atonic and tonic seizures**

Atonic and tonic seizures are usually seen in childhood, in specific epilepsy syndromes, or associated with cerebral damage or mental retardation. They may respond poorly to the traditional drugs. Sodium valproate p. 403 is the drug of choice; lamotrigine p. 394 can be added as adjunctive treatment. If adjunctive treatment is ineffective or not tolerated, a tertiary epilepsy specialist should be consulted, and may consider rufinamide p. 402 or topiramate p. 406. Carbamazepine p. 387, gabapentin p. 392, oxcarbazepine p. 397, pregabalin p. 400, tiagabine p. 406 or vigabatrin p. 407 are not recommended in atonic and tonic seizures.

**Epilepsy syndromes**

Some drugs are licensed for use in particular epilepsy syndromes, such as lamotrigine p. 394 and rufinamide p. 402 in Lennox-Gastaut syndrome. The epilepsy syndromes are specific types of epilepsy that are characterised according to a number of features including seizure type, age of onset, and EEG characteristics.

**Antiepileptic drugs**

**Carbamazepine and related antiepileptics**

Carbamazepine p. 387 is a drug of choice for simple and complex focal seizures and is a first-line treatment option for generalised tonic-clonic seizures. It can be used as adjunctive treatment for focal seizures when monotherapy has been ineffective. It is essential to initiate carbamazepine therapy at a low dose and build this up slowly. Carbamazepine may exacerbate tonic, atonic, myoclonic and absence seizures and is therefore not recommended if these seizures are present.

Oxcarbazepine p. 397 is licensed as monotherapy or adjunctive therapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures. It can also be considered for the treatment of primary generalised tonic-clonic seizures [unlicensed]. Oxcarbazepine is not recommended in tonic, atonic, absence or myoclonic seizures due to the risk of seizure exacerbation. Eslicarbazepine acetate p. 390 is licensed for adjunctive treatment in adults with focal seizures with or without secondary generalisation.

**Ethosuximide**

Ethosuximide p. 390 is a first-line treatment option for absence seizures. It may also be prescribed as adjunctive treatment for absence seizures when monotherapy is ineffective. Ethosuximide is also licensed for myoclonic seizures.

Gabapentin and pregabalin

Gabapentin p. 392 and pregabalin p. 400 are used for the treatment of focal seizures with or without secondary generalisation. They are not recommended if tonic, atonic, absence or myoclonic seizures are present. Both are also licensed for the treatment of neuropathic pain. Pregabalin is licensed for the treatment of generalised anxiety disorder. Gabapentin is an effective treatment for migraine prophylaxis [unlicensed].

**Lamotrigine**

Lamotrigine p. 394 is an antiepileptic drug recommended as a first-line treatment for focal seizures and primary and secondary generalised tonic-clonic seizures. It is also licensed for typical absence seizures in children (but efficacy may not be maintained in all children) and is an unlicensed treatment option in adults if first-line treatments have been unsuccessful. Lamotrigine can also be used as adjunctive treatment in atonic or tonic seizures if first-line treatment has failed [unlicensed]. Myoclonic seizures may be exacerbated by lamotrigine and it can cause serious rashes especially in children; dose recommendations should be adhered to closely.

Lamotrigine is used either as sole treatment or as an adjunct to treatment with other antiepileptic drugs. Valproate increases plasma-lamotrigine concentration, whereas the enzyme-inducing antiepileptics reduce it; care is therefore required in choosing the appropriate initial dose and subsequent titration. When the potential for interaction is not known, treatment should be initiated with lower doses, such as those used with valproate.

**Levetiracetam**

Levetiracetam p. 396 is used for monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation, and for adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy and primary generalised tonic-clonic seizures. Levetiracetam may be prescribed alone and in combination for the treatment of myoclonic seizures, and under specialist supervision for absence seizures [both unlicensed].

**Phenobarbital and primidone**

Phenobarbital p. 409 is effective for tonic-clonic and focal seizures but may be sedative in adults. It may be tried for atypical absence, atonic, and tonic seizures. Rebound seizures may be a problem on withdrawal. Primidone p. 401 is largely converted to phenobarbital and this is probably responsible for its antiepileptic action. A low initial dose of primidone is essential.

**Phenytoin**

Phenytoin p. 398 is licensed for tonic-clonic and focal seizures but may exacerbate absence or myoclonic seizures and should be avoided if these seizures are present. It has a narrow therapeutic index and the relationship between dose and plasma-drug concentration is non-linear; small dosage increases in some patients may produce large increases in plasma concentration with acute toxic side-effects. Similarly, a few missed doses or a small change in drug absorption may result in a marked change in plasma-drug concentration. Monitoring of plasma-drug concentration improves dosage adjustment.

When only parenteral administration is possible, fosphenytoin sodium p. 391, a pro-drug of phenytoin, may be convenient to give. Unlike phenytoin (which should only be given intravenously), fosphenytoin sodium may also be given by intramuscular injection.

**Rufinamide**

Rufinamide p. 402 is licensed for the adjunctive treatment of seizures in Lennox-Gastaut syndrome. It may be considered by a tertiary specialist for the treatment of refractory tonic or atonic seizures [unlicensed].

**Topiramate**

Topiramate p. 406 can be given alone or as adjunctive treatment in generalised tonic-clonic seizures or focal seizures with or without secondary generalisation. It can be used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome and for absence, tonic and atonic seizures under specialist supervision [unlicensed]. It can also be considered as an option in myoclonic seizures [unlicensed]. Topiramate is also licensed for prophylaxis of migraine.

**Valproate**

Sodium valproate p. 403 is effective in controlling tonic-clonic seizures, particularly in primary generalised epilepsy. It is a drug of choice in a primary generalised tonic-clonic seizures, focal seizures, generalised absences and myoclonic seizures, and can be tried in atypical absence seizures. It is recommended as a first-line option in atonic and tonic seizures.
seizures. Sodium valproate has widespread metabolic effects and monitoring of liver function tests and full blood count is essential.

Valproic acid p. 275 (as semisodium valproate) is licensed for acute mania associated with bipolar disorder.

Zonisamide
Zonisamide p. 408 can be used alone for the treatment of focal seizures with or without secondary generalisation in adults with newly diagnosed epilepsy, and as adjunctive treatment for refractory focal seizures with or without secondary generalisation in adults and children aged 6 years and above. It can also be used under the supervision of a specialist for refractory absence and myoclonic seizures [unlicensed indications].

Benzodiazepines
Clobazam p. 410 may be used as adjunctive therapy in the treatment of generalised tonic-clonic and refractory focal seizures. It may be prescribed under the care of a specialist for refractory absence and myoclonic seizures. Clonazepam p. 411 may be prescribed by a specialist for refractory absence and myoclonic seizures, but its sedative side-effects may be prominent.

Other drugs
Acetazolamide p. 965, a carbonic anhydrase inhibitor, has a specific role in treating epilepsy associated with menstruation. Piracetam p. 321 is used as adjunctive treatment for cortical myoclonus.

Status epilepticus
Convulsive status epilepticus
Immediate measures to manage status epilepticus include positioning the patient to avoid injury, supporting respiration including the provision of oxygen, maintaining blood pressure, and the correction of any hypoglycaemia. Parenteral thiamine p. 882 should be considered if alcohol abuse is suspected; pyridoxine hydrochloride p. 882 should be given if the status epilepticus is caused by pyridoxine hydrochloride deficiency.

Seizures lasting longer than 5 minutes should be treated urgently with intravenous lorazepam p. 412 (repeated once after 10 minutes if seizures recur or fail to respond). Intravenous diazepam p. 267 is effective but it carries a high risk of thrombophlebitis (reduced by using an emulsion formulation). Absorption of diazepam p. 267 from intramuscular injection or from suppositories is too slow for refractory absence and myoclonic seizures. Diazepam can be administered as a rectal solution (formulation). Absorption of diazepam p. 4.24 may be prescribed under the care of a specialist for refractory absence and myoclonic seizures, but its sedative side-effects may be prominent.

Other drugs
Acetazolamide p. 965, a carbonic anhydrase inhibitor, has a specific role in treating epilepsy associated with menstruation. Piracetam p. 321 is used as adjunctive treatment for cortical myoclonus.

Status epilepticus
Convulsive status epilepticus
Immediate measures to manage status epilepticus include positioning the patient to avoid injury, supporting respiration including the provision of oxygen, maintaining blood pressure, and the correction of any hypoglycaemia. Parenteral thiamine p. 882 should be considered if alcohol abuse is suspected; pyridoxine hydrochloride p. 882 should be given if the status epilepticus is caused by pyridoxine hydrochloride deficiency.

Seizures lasting longer than 5 minutes should be treated urgently with intravenous lorazepam p. 412 (repeated once after 10 minutes if seizures recur or fail to respond). Intravenous diazepam p. 267 is effective but it carries a high risk of thrombophlebitis (reduced by using an emulsion formulation). Absorption of diazepam p. 267 from intramuscular injection or from suppositories is too slow for treatment of status epilepticus. Patients should be monitored for respiratory depression and hypotension.

Where facilities for resuscitation are not immediately available, diazepam can be administered as a rectal solution or midazolam p. 414 oromucosal solution can be given into the buccal cavity.

Important
If, after initial treatment with benzodiazepines, seizures recur or fail to respond 25 minutes after onset, phenytoin sodium, fosphenytoin sodium p. 391, or phenobarbital sodium should be used; contact intensive care unit if seizures continue. If these measures fail to control seizures 45 minutes after onset, anaesthesia with thiopental sodium p. 412, midazolam p. 414, or a non-barbiturate anaesthetic such as propofol p. 1095 [unlicensed indication], should be instituted with full intensive care support.

Phenytoin sodium can be given by slow intravenous injection, followed by the maintenance dosage if appropriate.

Alternatively, fosphenytoin sodium p. 391 (a pro-drug of phenytoin), can be given more rapidly and when given intravenously causes fewer injection-site reactions than phenytoin sodium. Although it can also be given intramuscularly, absorption is too slow by this route for treatment of status epilepticus. Doses of fosphenytoin sodium p. 391 should be expressed in terms of phenytoin sodium.

Non-convulsive status epilepticus
The urgency to treat non-convulsive status epilepticus depends on the severity of the patient’s condition. If there is incomplete loss of awareness, usual oral antiepileptic therapy should be continued or restarted. Patients who fail to respond to oral antiepileptic therapy or have complete lack of awareness can be treated in the same way as for convulsive status epilepticus, although anaesthesia is rarely needed.

Febrile convulsions
Brief febrile convulsions need no specific treatment; antipyretic medication (e.g. paracetamol p. 354), is commonly used to reduce fever and prevent further convulsions but evidence to support this practice is lacking. Prolonged febrile convulsions (those lasting 5 minutes or longer), or recurrent febrile convulsions without recovery must be treated actively (as for convulsive status epilepticus). Long-term anticonvulsant prophylaxis for febrile convulsions is rarely indicated.

Drugs used for Seizures not listed below: Acetazolamide, p. 965 - Lidocaine hydrochloride, p. 1116 - Magnesium sulfate, p. 858

ANTIEPILEPTICS
Carbamazepine

**INDICATIONS AND DOSE**

**Focal and secondary generalised tonic-clonic seizures | Primary generalised tonic-clonic seizures**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adult:** Initially 100–200 mg 1–2 times a day, increased in steps of 100–200 mg every 2 weeks; usual dose 0.8–1.2 g daily in divided doses; increased if necessary up to 1.6–2 g daily in divided doses
- **Elderly:** Reduce initial dose
- **BY RECTUM**
- **Adult:** Up to 1 g daily in 4 divided doses for up to 7 days, for short-term use when oral therapy temporarily not possible

**Trigeminal neuralgia**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adult:** Initially 100 mg 1–2 times a day, some patients may require higher initial dose, increased in steps of 100–200 mg every 2 weeks, adjusted according to response, usual dose 200 mg 3–4 times a day; increased if necessary up to 1.6 g daily

**Prophylaxis of bipolar disorder unresponsive to lithium**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adult:** Initially 400 mg daily in divided doses, increased in steps of 100–200 mg every 2 weeks until symptoms controlled; usual dose 400–600 mg daily; maximum 1.6 g per day

**Treatment of alcohol withdrawal**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adult:** Initially 800 mg daily in divided doses, then reduced to 200 mg daily usual treatment duration 7–10 days, dose to be reduced gradually over 5 days

**Diabetic neuropathy**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adult:** Initially 100 mg 1–2 times a day, increased in steps of 100–200 mg every 2 weeks, adjusted according to response, usual dose 200 mg 3–4 times a day; increased if necessary up to 1.6 g daily

---

**BNF 70**

**Epilepsy 387**

**Nervous system**
Focal and generalised tonic-clonic seizures

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 1 month–11 years: Initially 5 mg/kg once daily, dose to be taken at night, alternatively initially 2.5 mg/kg twice daily, then increased in steps of 2.5–5 mg/kg every 3–7 days as required; maintenance 5 mg/kg 2–3 times a day, increased if necessary up to 20 mg/kg daily
- Child 12–17 years: Initially 100–200 mg 1–2 times a day, then increased to 200–400 mg 2–3 times a day, increased if necessary up to 1.8 g daily, dose should be increased slowly

Dose equivalence and conversion

Suppositories of 125 mg may be considered to be approximately equivalent in therapeutic effect to tablets of 100 mg but final adjustment should always depend on clinical response (plasma concentration monitoring recommended).

CARBAGEN® SR

Focal and secondary generalised tonic-clonic seizures

Primary generalised tonic-clonic seizures

BY MOUTH

- Adult: Initially 100–400 mg daily in 1–2 divided doses, increased in steps of 100–200 mg every 2 weeks, usual dose 8.1–12.2 g daily in 1–2 divided doses; increased if necessary up to 1.6–2 g daily in 1–2 divided doses
- Elderly: Reduce initial dose

Trigeminal neuralgia

BY MOUTH

- Adult: Initially 100–200 mg daily in 1–2 divided doses, some patients may require higher initial dose, increased in steps of 100–200 mg every 2 weeks, adjusted according to response, usual dose 600–800 mg daily in 2 divided doses; increased if necessary up to 1.6 g daily in 2 divided doses, dose should be increased slowly

Prophylaxis of bipolar disorder unresponsive to lithium

BY MOUTH

- Adult: Initially 400 mg daily in 2 divided doses, increased in steps of 100–200 mg every 2 weeks until symptoms controlled; usual dose 400–600 mg daily in 2 divided doses; maximum 1.6 g per day

Focal and generalised tonic-clonic seizures | Prophylaxis of bipolar disorder

BY MOUTH

- Child 5–11 years: Initially 5 mg/kg daily in 1–2 divided doses, then increased in steps of 2.5–5 mg/kg every 3–7 days as required; maintenance 10–15 mg/kg daily in 1–2 divided doses, increased if necessary up to 20 mg/kg daily in 1–2 divided doses
- Child 12–17 years: Initially 100–400 mg daily in 1–2 divided doses, then increased to 400–1200 mg daily in 1–2 divided doses, increased if necessary up to 1.8 g daily in 1–2 divided doses, dose should be increased slowly

TEGRETOL® PROLONGED RELEASE

Focal and secondary generalised tonic-clonic seizures

Primary generalised tonic-clonic seizures

BY MOUTH

- Adult: Initially 100–400 mg daily in 2 divided doses, increased in steps of 100–200 mg every 2 weeks, usual dose 0.8–1.2 g daily in 2 divided doses; increased if necessary up to 1.6–2 g daily in 2 divided doses
- Elderly: Reduce initial dose

Focal and generalised tonic-clonic seizures | Prophylaxis of bipolar disorder

BY MOUTH

- Child 5–11 years: Initially 5 mg/kg daily in 2 divided doses, then increased in steps of 2.5–5 mg/kg every 3–7 days as required; maintenance 10–15 mg/kg daily in 2 divided doses, increased if necessary up to 20 mg/kg daily in 2 divided doses
- Child 12–17 years: Initially 100–400 mg daily in 2 divided doses, then increased to 400–1200 mg daily in 2 divided doses, increased if necessary up to 1.6 g daily in 2 divided doses, dose should be increased slowly

Trigeminal neuralgia

BY MOUTH

- Adult: Initially 100–200 mg daily in 2 divided doses, some patients may require higher initial dose, increased in steps of 100–200 mg every 2 weeks, adjusted according to response, usual dose 600–800 mg daily in 2 divided doses; increased if necessary up to 1.6 g daily in 2 divided doses, dose should be increased slowly

Prophylaxis of bipolar disorder unresponsive to lithium

BY MOUTH

- Adult: Initially 400 mg daily in 2 divided doses, increased in steps of 100–200 mg every 2 weeks until symptoms controlled; usual dose 400–600 mg daily in 2 divided doses; maximum 1.6 g per day

- UNLICENSED USE

  - In children Suppositories not licensed for use in trigeminal neuralgia or prophylaxis of bipolar disorder.
  - In adults Use in the treatment of alcohol withdrawal is an unlicensed indication. Use in diabetic neuropathy is an unlicensed indication.

- CONTRA-INDICATIONS

  - Acute porphyrias p. 864. AV conduction abnormalities (unless paced). History of bone-marrow depression

- CAUTIONS

  - Cardiac disease. History of haematological reactions to other drugs. May exacerbate absence and myoclonic seizures. Skin reactions. Susceptibility to angle-closure glaucoma

- CAUTIONS, FURTHER INFORMATION

  - Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

Blood, hepatic, or skin disorders

Carbamazepine should be withdrawn immediately in cases of aggravated liver dysfunction or acute liver disease. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).

- INTERACTIONS

  - Appendix 1 (carbamazepine).

- SIDE-EFFECTS

  - Common or very common


  - Uncommon


  - Rare


  - Very rare

interstitial nephritis • muscle pain • neuroleptic malignant syndrome • osteomalacia • osteoporosis • pancreatitis • photosensitivity • pneumonia • pneumonitis • psychosis • pulmonary hypersensitivity • purpura • renal failure • sexual dysfunction • Stevens-Johnson syndrome • stomatitis • sweating • taste disturbance • thromboembolism • thrombophlebitis • toxic epidermal necrolysis • urinary frequency • urinary retention

- Frequency not known Suicidal ideation

SIDE-EFFECTS, FURTHER INFORMATION
Some side-effects (such as headache, ataxia, drowsiness, nausea, vomiting, blurring of vision, dizziness, unsteadiness, and allergic skin reactions) are dose-related, and may be dose-limiting. These side-effects are more common at the start of treatment and in the elderly. Patients should be offered a modified-release preparation to reduce the risk of side-effects; altering the timing of medication may also be beneficial.

Overdose
For details on the management of poisoning, see Active elimination techniques, under Emergency treatment of poisoning p. 1123.

- ALLERGY AND CROSS-SENSITIVITY Antiepileptic hypersensitivity syndrome associated with carbamazepine. See under Epilepsy p. 383 for more information. Caution—cross-sensitivity reported with oxcarbazepine and with phenytoin.

- PREGNANCY Doses should be adjusted on the basis of plasma-drug concentration monitoring.

- BREAST FEEDING Amount probably too small to be harmful. Monitor infant for possible adverse reactions.

- HEPATIC IMPAIRMENT Metabolism impaired in advanced liver disease.

- RENAL IMPAIRMENT Use with caution.

- PRE-TREATMENT SCREENING Test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative—risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).

- MONITORING REQUIREMENTS
  - Plasma concentration for optimum response 4–12 mg/litre (20–50 micromol/litre) measured after 1–2 weeks.
  - Manufacturer recommends blood counts and hepatic and renal function tests (but evidence of practical value uncertain).

- TREATMENT CESSATION When stopping treatment with carbamazepine for bipolar disorder, reduce the dose gradually over a period of at least 4 weeks.

- DIRECTIONS FOR ADMINISTRATION
  - In children Oral liquid has been used rectally—should be retained for at least 2 hours (but may have laxative effect).
  - Tegretol® Prolonged Release tablets can be halved but should not be chewed.

- PRESCRIBING AND DISPENSING INFORMATION
  - Switching between formulations Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer’s product.

- PATIENT AND CARER ADVICE
  - Medicines for Childrenleaflet: Carbamazepine (oral) for preventing seizures www.medicinesforchildren.org.uk/carbamazepine-oral-preventing-seizures-0

Blood, hepatic, or skin disorders Patients or their carers should be told how to recognise signs of blood, liver, or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop.

PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulation Carbamazepine Tablets may be prescribed.

MÉDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 3, 8

- CARBAMAZEPINE (Non-proprietary)
  - Carbamazepine 100 mg Carbamazepine 100mg tablets | 28 tablet (P) €5.95 DT price = £4.81 | 84 tablet (P) €6.63
  - Carbamazepine 200 mg Carbamazepine 200mg tablets | 28 tablet (P) €12.35 DT price = £5.11 | 84 tablet (P) €6.47
  - Carbamazepine 400 mg Carbamazepine 400mg tablets | 28 tablet (P) £15.73 | 56 tablet (P) £18.30 DT price = £5.02

- Carbagen (Mylan Ltd)
  - Carbamazepine 100 mg Carbagen 100mg tablets | 28 tablet (P) £5.74 DT price = €4.81 | 56 tablet (P) no price available (Hospital only) | 84 tablet (P) no price available (Hospital only)
  - Carbamazepine 200 mg Carbagen 200mg tablets | 28 tablet (P) €4.99 DT price = £5.11 | 56 tablet (P) no price available (Hospital only) | 84 tablet (P) no price available (Hospital only)
  - Carbamazepine 400 mg Carbagen 400mg tablets | 28 tablet (P) €4.27 | 56 tablet (P) no price available DT price = £5.02 (Hospital only)

- Tegretol (Novartis Pharmaceuticals UK Ltd)
  - Carbamazepine 100 mg Tegretol 100mg tablets | 84 tablet (P) £2.07
  - Carbamazepine 200 mg Tegretol 200mg tablets | 84 tablet (P) £3.83
  - Carbamazepine 400 mg Tegretol 400mg tablets | 56 tablet (P) £5.02 DT price = £5.02

Chewable tablet

CAUTIONARY AND ADVISORY LABELS 3, 8, 21, 24

- Tegretol Chewtabs (Novartis Pharmaceuticals UK Ltd)
  - Carbamazepine 100 mg Tegretol 100mg Chewtabs (sugar-free) | 56 tablet (P) £3.16 DT price = £3.16

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 3, 8, 25

- CARBAMAZEPINE (Non-proprietary)
  - Carbamazepine 200 mg Carbamazepine 200mg modified-release tablets | 56 tablet (P) £12.00 DT price = £5.20
  - Carbamazepine 400 mg Carbamazepine 400mg modified-release tablets | 56 tablet (P) £24.00 DT price = £10.24

- Carbagen SR (Mylan Ltd)
  - Carbamazepine 200 mg Carbagen SR 200mg tablets | 56 tablet (P) £4.16 DT price = £5.20
  - Carbamazepine 400 mg Carbagen SR 400mg tablets | 56 tablet (P) £8.20 DT price = £10.24

- Tegretol Retard (Novartis Pharmaceuticals UK Ltd)
  - Carbamazepine 200 mg Tegretol Prolonged Release 200mg tablets | 56 tablet (P) £5.20 DT price = £5.20
  - Carbamazepine 400 mg Tegretol Prolonged Release 400mg tablets | 56 tablet (P) £10.24 DT price = £10.24

Oral suspension

CAUTIONARY AND ADVISORY LABELS 3, 8

- CARBAMAZEPINE (Non-proprietary)
  - Carbamazepine 20 mg per 1 ml Carbamazepine 100mg/5ml oral suspension sugar-free (sugar-free) | 300 ml (P) £6.12 DT price = £6.12

- Tegretol (Novartis Pharmaceuticals UK Ltd)
  - Carbamazepine 20 mg per 1 ml Tegretol 100mg/5ml liquid (sugar-free) | 300 ml (P) £6.12 DT price = £6.12

Suppository

CAUTIONARY AND ADVISORY LABELS 3, 8

- Tegretol (Novartis Pharmaceuticals UK Ltd)
  - Carbamazepine 125 mg Tegretol 125mg suppositories | 5 suppository (P) £0.93
  - Carbamazepine 250 mg Tegretol 250mg suppositories | 5 suppository (P) £10.71
Eslicarbazepine acetate

INDICATIONS AND DOSE

Adjunctive treatment in adults with focal seizures with or without secondary generalisation

BY MOUTH

- Adult: Initially 400 mg once daily for 1–2 weeks, then increased to 800 mg once daily (max. per dose 1.2 g)

CONTRA-INDICATIONS
Second- or third-degree AV block

CAUTIONS
- Elderly - hyponatraemia - PR-interval prolongation

INTERACTIONS → Appendix 1 (eslicarbazepine). Caution—avoid concomitant administration of drugs that prolong PR interval.

SIDE-EFFECTS

- Common or very common Dizziness - drowsiness - fatigue - gastrointestinal disturbances - headache - impaired coordination - rash - tremor - visual disturbances


- Very rare Leucopenia - pancreatitis - thrombocytopenia

- Frequency not known PR-interval prolongation - suicidal ideation

ALLERGY AND CROSS-SENSITIVITY

Antiepileptic hypersensitivity syndrome theoretically associated with eslicarbazepine. See under Epilepsy p. 383 for more information.

PREGNANCY

The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

HEPATIC IMPAIRMENT

Avoid in severe impairment—no information available.

RENAL IMPAIRMENT

Reduce initial dose to 400 mg every other day for 2 weeks then 400 mg once daily if eGFR 30–60 mL/minute/1.73 m², adjusted according to response. Avoid if eGFR less than 30 mL/minute/1.73 m².

PRE-TREATMENT SCREENING

Test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative—risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).

MONITORING REQUIREMENTS

Monitor plasma-sodium concentration in patients at risk of hyponatraemia and discontinue treatment if hyponatraemia occurs.

PRESCRIBING AND DISPENSING INFORMATION

Switching between formulations Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2010) that eslicarbazepine acetate (Zebinix®) is accepted for restricted use within NHS Scotland as adjunctive therapy in adults with focal seizures with or without secondary generalisation. It is restricted for use in refractory epilepsy.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 8
- Zebinix (Eisai Ltd)

- Eslicarbazepine acetate 800 mg Zebinix 800mg tablets | 30 tablet(s) £13.60

Ethosuximide

INDICATIONS AND DOSE

Absence seizures | Atypical absence seizures | Myoclonic seizures

BY MOUTH

- Child 1 month-5 years: Initially 5 mg/kg twice daily (max. per dose 125 mg), dose to be increased every 5–7 days; maintenance 10–20 mg/kg twice daily (max. per dose 500 mg), total daily dose may rarely be given in 3 divided doses

- Child 6–17 years: Initially 250 mg twice daily, then increased in steps of 250 mg every 5–7 days; usual dose 500–750 mg twice daily, increased if necessary up to 1 g twice daily

- Adult: Initially 500 mg daily in 2 divided doses, then increased in steps of 250 mg every 5–7 days; usual dose 1–1.5 g daily in 2 divided doses, increased if necessary up to 2 g daily

CAUTIONS
- Avoid in Acute porphyrias p. 864

INTERACTIONS → Appendix 1 ( ethosuximide).

SIDE-EFFECTS

- Common or very common anorexia - abdominal pain - diarrhoea - gastro-intestinal disturbances - nausea - vomiting - weight loss

- Uncommon Agitation - ataxia - dizziness - drowsiness - euphoria - fatigue - headache - hiccups - impaired concentration - irritability

- Rare Depression - dyskinesia - gingival hypertrophy - increased libido - myopia - photophobia - psychosis - rash - sleep disturbances - tongue swelling - vaginal bleeding

- Frequency not known Agranulocytosis - aplastic anaemia - blood disorders - hyperactivity - increase in seizure frequency - leucopenia - pancytopenia - Stevens-Johnson syndrome - suicidal ideation - systemic lupus erythematosus

SIDE-EFFECTS, FURTHER INFORMATION

Blood disorders Blood counts required if features of infection.

PREGNANCY

The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

BRIDDEN FREE

Present in milk. Hyperexcitability and sedation reported.

HEPATIC IMPAIRMENT

Use with caution.

RENAL IMPAIRMENT

Use with caution.

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Ethosuximide for preventing seizures www.medicinesforchildren.org.uk/ ethosuximide-for-preventing-seizures

Blood disorders Patients or their carers should be told how to recognise signs of blood disorders, and advised to seek immediate medical attention if symptoms such as fever, mouth ulcers, bruising, or bleeding develop.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.
Fosphenytoin sodium

**DRUG ACTION**
Fosphenytoin is a pro-drug of phenytoin.

**INDICATIONS AND DOSE**

**Status epilepticus**

**BY INTRAVENOUS INFUSION**

- **Adult:** Initially 20 mg(PE)/kg, dose to be administered at a rate of 100–150 mg(PE)/minute, then 4–5 mg (PE)/kg daily in 1–2 divided doses, dose to be administered at a rate of 50–100 mg(PE)/minute, dose to be adjusted according to response and trough plasma-phenytoin concentration
- **Elderly:** Consider 10–25% reduction in dose or infusion rate

**Prophylaxis or treatment of seizures associated with neurosurgery or head injury**

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INFUSION**

- **Adult:** Initially 10–15 mg(PE)/kg, intravenous infusion to be administered at a rate of 50–100 mg(PE)/minute, then 4–5 mg(PE)/kg daily in 1–2 divided doses. Intravenous infusion to be administered at a rate of 50–100 mg(PE)/minute, dose to be adjusted according to response and trough plasma-phenytoin concentration
- **Elderly:** Consider 10–25% reduction in dose or infusion rate

**Temporary substitution for oral phenytoin**

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INFUSION**

- **Adult:** Intravenous infusion to be administered at a rate of 50–100 mg(PE)/minute, same dose and same dosing frequency as oral phenytoin therapy
- **Elderly:** Consider 10–25% reduction in dose or infusion rate

**Dose equivalence and conversion**

Doses are expressed as phenytoin sodium equivalent (PE); fosphenytoin sodium 1.5 mg = phenytoin sodium 1 mg.

**UNLICENSED USE**

Fosphenytoin sodium doses in BNF may differ from those in product literature.

**CONTRA-INDICATIONS**

- Acute porphyrias p. 864
- Second-degree heart block
- Sino-atrial block
- Sinus bradycardia
- Stokes-Adams syndrome
- Third-degree heart block

**CAUTIONS**

- Heart failure
- Hypotension
- Injection solutions alkaline (irritant to tissues)
- Respiratory depression
- Resuscitation facilities must be available

**INTERACTIONS**

- Appendix 1 (fosphenytoin).

**SIDE-EFFECTS**

**COMMON OR VERY COMMON**

- Alterations in respiratory function
- Arrhythmias
- Asthenia
- Cardiovascular collapse
- Cardiovascular depression (particularly if injection too rapid)
- Chills
- CNS depression (particularly if injection too rapid)
- Dry mouth
- Dysarthria
- Ecchymosis
- Euphoria
- Hypotension
- Incoordination
- Pruritus
- Respiratory arrest
- Taste disturbance

**UNCOMMON**

- Decreased reflexes
- Hypoacusis
- Hypoesthesia
- Increased reflexes
- Muscle spasm
- Muscle weakness
- Pain
- Stupor

**FREQUENCY NOT KNOWN**

- Bradycardia
- Confusion
- Extrapyramidal disorder
- Heart block
- Hyperglycaemia
- Purple glove syndrome
- Tonic seizures
- Twitching

**SIDE-EFFECTS, FURTHER INFORMATION**

**Important**

Intravenous infusion of fosphenytoin has been associated with severe cardiovascular reactions including asystole, ventricular fibrillation, and cardiac arrest. Hypotension, bradycardia, and heart block have also been reported. The following are recommended:

- Monitor heart rate, blood pressure, and respiratory function for duration of infusion;
- Observe patient for at least 30 minutes after infusion;
- If hypotension occurs, reduce infusion rate or discontinue;

**ALLERGY AND CROSS-SENSITIVITY**

Cross-sensitivity reported with carbamazepine.

**PREGNANCY**

Changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult—monitor unbound fraction. The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**BREAST FEEDING**

Small amounts present in milk, but not known to be harmful.

**HEPATIC IMPAIRMENT**

Consider 10–25% reduction in dose or infusion rate (except initial dose for status epilepticus).

**RENAL IMPAIRMENT**

Consider 10–25% reduction in dose or infusion rate (except initial dose for status epilepticus).

**PRE-TREATMENT SCREENING**

HLA-B*1502 allele in individuals of Han Chinese or Thai origin—avoid unless essential (increased risk of Stevens-Johnson syndrome).

**MONITORING REQUIREMENTS**

- Manufacturer recommends blood counts (but evidence of practical value uncertain).
- ECG monitoring required.
- Monitor heart rate, blood pressure, and respiratory function for duration of infusion.

**DIRECTIONS FOR ADMINISTRATION**

For intermittent intravenous infusion (Pro-Epanutin®), give in Glucose 5% or Sodium chloride 0.9%; dilute to a concentration of 1.5–25 mg (phenytoin sodium equivalent (PE))/mL.

**PRESCRIBING AND DISPENSING INFORMATION**

Prescriptions for fosphenytoin sodium should state the dose in terms of phenytoin sodium equivalent (PE); fosphenytoin sodium 1.5 mg = phenytoin sodium 1 mg.

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**ELECTROLYTES**

May contain Phosphate

- **Pro-Epanutin** (Pfizer Ltd)
  - Fosphenytoin sodium 75 mg per 1 ml
  - Pro-Epanutin 750mg/10ml concentrate for solution for injection vials | 10 vial (£400.00 (Hospital only))
Gabapentin

INDICATIONS AND DOSE

Adjunctive treatment of focal seizures with or without secondary generalisation

**BY MOUTH**
- **Child 6–11 years**: Initially 300 mg once daily; then 10 mg/kg twice daily; then 300 mg 3 times a day; maximum 2–3 days in 3 divided doses, adjusted according to response; usual dose 6 mg/kg 3 times a day; some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate
- **Child 12–17 years**: Initially 300 mg once daily; then 300 mg twice daily; then 300 mg 3 times a day; maximum 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day); some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate
- **Adult**: Initially 300 mg once daily; then 300 mg twice daily; then 300 mg 3 times a day; maximum 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day); some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate

**Monotherapy for focal seizures with or without secondary generalisation**

**BY MOUTH**
- **Child 12–17 years**: Initially 300 mg once daily; then 300 mg twice daily; then 300 mg 3 times a day; maximum 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day); some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate
- **Adult**: Initially 300 mg once daily; then 300 mg twice daily; then 300 mg 3 times a day; maximum 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day); some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate

**Neuropathic pain**

**BY MOUTH**
- **Adult**: Initially 300 mg once daily; then 300 mg twice daily; then 300 mg 3 times a day; maximum 2–3 days in 3 divided doses, adjusted according to response; maximum 3.6 g per day

**Migraine prophylaxis**

**BY MOUTH**
- **Adult**: Initially 300 mg daily; then increased to up to 2.4 g daily in divided doses, adjusted according to response

**UNLICENSED USE**
- In children Not licensed for use in children under 6 years. Not licensed at doses over 50 mg/kg daily in children under 12 years.
- In adults Not licensed for migraine prophylaxis.

**Important safety information**

The levels of propylene glycol, acesulfame K and saccharin sodium may exceed the recommended WHO daily intake limits if high doses of gabapentin oral solution (Rosemont brand) are given to adolescents or adults with low body-weight (35–50 kg)—consult product literature.

**CAUTIONS**

- Diabetes mellitus - elderly - high doses of oral solution in adolescents and adults with low body-weight - history of psychotic illness - mixed seizures (including absences)

**INTERACTIONS**


- **Uncommon** Palpitations

- **Frequency not known** Acute renal failure - alopecia - blood glucose fluctuations in patients with diabetes - breast hypertrophy - gynaecomastia - hallucinations - hepatitis - hypersensitivity syndrome - incontinence - pancreatitis - Stevens-Johnson syndrome - suicidal ideation - thrombocytopenia - tinnitus

**PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**BREAST FEEDING** Present in milk—manufacturer advises use only if potential benefit outweighs risk.

**RENAL IMPAIRMENT**
- In adults Reduce dose to 0.6–1.8 g daily in 3 divided doses if eGFR 50–80 mL/minute/1.73 m². Reduce dose to 300–900 mg daily in 3 divided doses if eGFR 30–50 mL/minute/1.73 m². Reduce dose to 300 mg on alternate days (up to max. 600 mg daily) in 3 divided doses if eGFR 15–30 mL/minute/1.73 m². Reduce dose to 300 mg on alternate days (up to max. 300 mg daily) in 3 divided doses if eGFR less than 15 mL/minute/1.73 m²—consult product literature.
- In children Reduce dose if estimated glomerular filtration rate less than 80 mL/minute/1.73 m²; consult product literature.

**EFFECT ON LABORATORY TESTS** False positive readings with some urinary protein tests.

**DIRECTIONS FOR ADMINISTRATION** Capsules can be opened but the bitter taste is difficult to mask.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Gabapentin for neuropathic pain www.medicinesforchildren.org.uk/gabapentin-for-neuropathic-pain

Medicines for Children leaflet: Gabapentin for preventing seizures www.medicinesforchildren.org.uk/gabapentin-for-preventing-seizures
LACOSAMIDE

**INDICATIONS AND DOSE**

Adjuvant treatment of focal seizures with or without secondary generalisation

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Child 16-17 years: Initially 50 mg twice daily, infusion to be administered over 15–60 minutes (for up to 5 days), then increased, if tolerated, in steps of 50 mg twice daily, adjusted according to response, dose to be increased in weekly intervals; maintenance 100 mg twice daily (max. per dose 200 mg twice daily)

- Adult: Initially 50 mg twice daily, infusion to be administered over 15–60 minutes (for up to 5 days), then increased, if tolerated, in steps of 50 mg twice daily, adjusted according to response, dose to be increased in weekly intervals; maintenance 100 mg twice daily (max. per dose 200 mg twice daily)

Adjuvant treatment of focal seizures with or without secondary generalisation (alternative loading dose regimen when it is necessary to rapidly attain therapeutic plasma concentrations) (under close medical supervision)

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Child 16-17 years: Loading dose 200 mg, infusion to be administered over 15–60 minutes (for up to 5 days), followed by maintenance 100 mg twice daily, to be given 12 hours after initial dose, then increased, if tolerated, in steps of 50 mg twice daily (max. per dose 200 mg twice daily), adjusted according to response, dose to be increased in weekly intervals

- Adult: Loading dose 200 mg, infusion to be administered over 15–60 minutes (for up to 5 days), followed by maintenance 100 mg twice daily, to be

given 12 hours after initial dose, then increased, if tolerated, in steps of 50 mg twice daily (max. per dose 200 mg twice daily), adjusted according to response, dose to be increased in weekly intervals

**CONTRA-INDICATIONS**

- Second- or third-degree AV block

**CAUTIONS**

- Conduction problems - elderly (in adults) - risk of PR-interval prolongation - severe cardiac disease

**INTERACTIONS**

- → Appendix 1 (Lacosamide). Caution with concomitant use of drugs that prolong PR interval.

**SIDE-EFFECTS**

- Common or very common Abnormal gait - blurred vision - cognitive disorder - constipation - depression - dizziness - drowsiness - fatigue - flatulence - headache - impaired coordination - nausea -ystagmus - pruritus - tremor - vomiting

- Rare Multi-organ hypersensitivity reaction


**ALLERGY AND CROSS-SENSITIVITY**

- Antiepileptic hypersensitivity syndrome associated with lacosamide. See under Epilepsy p. 383 for more information.

**PREGNANCY**

The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Titrated with caution in mild to moderate impairment if co-existing renal impairment. Caution in severe impairment—no information available.

**RENAL IMPAIRMENT**

Loading dose regimen can be considered in mild to moderate impairment—titrate above 200 mg with caution. Titrated with caution in severe impairment, max. 250 mg daily.

- In adults Consult product literature for loading dose if eGFR less than 30 mL/minute/1.73 m².

- In children Consult product literature for loading dose if estimated glomerular filtration rate is less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

- In children For intravenous infusion, give undiluted or dilute with Glucose 5% or Sodium Chloride 0.9%.

- In adults For intravenous infusion (Vimpat®), give intermittently in Glucose 5% or Sodium Chloride 0.9%. May be administered undiluted.

**PRESCRIBING AND DISPENSING INFORMATION**

- Flavours of syrup may include strawberry.

**PATIENT AND CARER ADVICE**

- Medicines for Children leaflet: Lacosamide for preventing seizures www.medicinesforchildren.org.uk/lacosamide-for-preventing-seizures

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2009) that lacosamide (Vimpat®) is accepted for restricted use within NHS Scotland as adjunctive treatment for focal seizures with or without secondary generalisation in patients from 16 years. It is restricted for specialist use in refractory epilepsy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Lamotrigine

**INDICATIONS AND DOSE**

**Monotherapy of focal seizures | Monotherapy of primary and secondary generalised tonic-clonic seizures | Monotherapy of seizures associated with Lennox-Gastaut syndrome**

**BY MOUTH**

- **Child 12-17 years:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses; increased if necessary up to 500 mg daily, dose titration should be repeated if restarting after interval of more than 5 days

- **Adult:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses; increased if necessary up to 500 mg daily, dose titration should be repeated if restarting after interval of more than 5 days

**Adjunctive therapy of focal seizures with valproate | Adjunctive therapy of primary and secondary generalised tonic-clonic seizures with valproate | Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome with valproate**

**BY MOUTH**

- **Child 2–11 years (body-weight up to 13 kg):** Initially 2 mg once daily on alternate days for first 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to 300 micrograms/kg every 7–14 days; maintenance 1–5 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day

- **Child 2–11 years (body-weight above 13 kg):** Initially 150 micrograms/kg once daily for 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to 300 micrograms/kg every 7–14 days; maintenance 1–5 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day

- **Child 12–17 years:** Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

- **Adult:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**Adjunctive therapy of focal seizures (with enzyme inducing drugs) without valproate | Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (with enzyme inducing drugs) without valproate | Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (with enzyme inducing drugs) without valproate**

**BY MOUTH**

- **Child 2–11 years:** Initially 300 micrograms/kg twice daily for 14 days, then 600 micrograms/kg twice daily for further 14 days, then increased in steps of up to 1.2 mg/kg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

- **Child 12–17 years:** Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased in steps of up to 50 mg every 7–14 days; maintenance 200–400 mg daily in 2 divided doses, increased if necessary up to 700 mg daily, dose titration should be repeated if restarting after interval of more than 5 days

**By MOUTH**

- **1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days**

- **Adult:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**By MOUTH**

- **Child 2–11 years:** Initially 300 micrograms/kg daily in 1–2 divided doses for 14 days, then 600 micrograms/kg daily in 1–2 divided doses for further 14 days, then increased in steps of up to 600 micrograms/kg every 7–14 days; maintenance 1–10 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**By MOUTH**

- **Child 12–17 years:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**By MOUTH**

- **Adult:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**By MOUTH**

- **Child 2–11 years:** Initially 300 micrograms/kg daily in 1–2 divided doses for 14 days, then 600 micrograms/kg daily in 1–2 divided doses for further 14 days, then increased in steps of up to 600 micrograms/kg every 7–14 days; maintenance 1–10 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**By MOUTH**

- **Child 12–17 years:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**By MOUTH**

- **Adult:** Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**Monotherapy or adjunctive therapy of bipolar disorder (without enzyme inducing drugs) without valproate**

**By MOUTH**

- **Child 2–11 years:** Initially 25 mg once daily for 14 days, then 50 mg daily in 1–2 divided doses for further 14 days, then 100 mg daily in 1–2 divided doses for further 14 days.
7 days; maintenance 200 mg daily in 1–2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens—consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400 mg per day

**Adjuvant therapy of bipolar disorder with valproate**

**BY MOUTH**

- Adult: Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then 50 mg daily in 1–2 divided doses for further 7 days; maintenance 100 mg daily in 1–2 divided doses; patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens—consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day

**Adjuvant therapy of bipolar disorder (with enzyme inducing drugs) without valproate**

**BY MOUTH**

- Adult: Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased to 100 mg twice daily for further 7 days, then increased to 150 mg twice daily for further 7 days; maintenance 200 mg twice daily, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens—consult product literature, dose titration should be repeated if restarting after interval of more than 5 days

**SIDE-EFFECTS, FURTHER INFORMATION**

**Skin reactions** Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.

**ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under Epilepsy p. 383 for more information.

**PRECAUTIONS** Myoclonic seizures (may be exacerbated). Parkinson’s disease (may be exacerbated) (in adults)

**INTERACTIONS** → Appendix 1 (lamotrigine)

**SIDE-EFFECTS**

- Common or very common: blurred vision, aggression, agitation, ataxia, back pain, diarrhea, diplopia, dizziness, drowsiness, dry mouth, headache, insomnia, nausea, nystagmus, rash, tremor, vomiting

- Rare: Conjunctivitis

- Very rare: Anaemia, blood disorders, confusion, exacerbation of Parkinson’s disease (in adults), hallucination, hepatic failure, hypersensitivity syndrome, increase in seizure frequency, leucopenia, lupus erythematosus-like reactions, movement disorders, pancytopenia, thrombocytopenia, unsteadiness

- Frequency not known: Aseptic meningitis, suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Skin reactions** Aseptic meningitis

**PRECAUTIONS** Myoclonic seizures (may be exacerbated). Parkinson’s disease (may be exacerbated) (in adults)

**INTERACTIONS** → Appendix 1 (lamotrigine)

**SIDE-EFFECTS**

- Common or very common: blurred vision, aggression, agitation, ataxia, back pain, diarrhea, diplopia, dizziness, drowsiness, dry mouth, headache, insomnia, nausea, nystagmus, rash, tremor, vomiting

- Rare: Conjunctivitis

- Very rare: Anaemia, blood disorders, confusion, exacerbation of Parkinson’s disease (in adults), hallucination, hepatic failure, hypersensitivity syndrome, increase in seizure frequency, leucopenia, lupus erythematosus-like reactions, movement disorders, pancytopenia, thrombocytopenia, unsteadiness

- Frequency not known: Aseptic meningitis, suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Skin reactions** Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.

**ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under Epilepsy p. 383 for more information.

**PRECAUTIONS** Myoclonic seizures (may be exacerbated). Parkinson’s disease (may be exacerbated) (in adults)

**INTERACTIONS** → Appendix 1 (lamotrigine)

**SIDE-EFFECTS**

- Common or very common: blurred vision, aggression, agitation, ataxia, back pain, diarrhea, diplopia, dizziness, drowsiness, dry mouth, headache, insomnia, nausea, nystagmus, rash, tremor, vomiting

- Rare: Conjunctivitis

- Very rare: Anaemia, blood disorders, confusion, exacerbation of Parkinson’s disease (in adults), hallucination, hepatic failure, hypersensitivity syndrome, increase in seizure frequency, leucopenia, lupus erythematosus-like reactions, movement disorders, pancytopenia, thrombocytopenia, unsteadiness

- Frequency not known: Aseptic meningitis, suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Skin reactions** Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.

**ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under Epilepsy p. 383 for more information.

**PRECAUTIONS** Myoclonic seizures (may be exacerbated). Parkinson’s disease (may be exacerbated) (in adults)

**INTERACTIONS** → Appendix 1 (lamotrigine)

**SIDE-EFFECTS**

- Common or very common: blurred vision, aggression, agitation, ataxia, back pain, diarrhea, diplopia, dizziness, drowsiness, dry mouth, headache, insomnia, nausea, nystagmus, rash, tremor, vomiting

- Rare: Conjunctivitis

- Very rare: Anaemia, blood disorders, confusion, exacerbation of Parkinson’s disease (in adults), hallucination, hepatic failure, hypersensitivity syndrome, increase in seizure frequency, leucopenia, lupus erythematosus-like reactions, movement disorders, pancytopenia, thrombocytopenia, unsteadiness

- Frequency not known: Aseptic meningitis, suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Skin reactions** Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.

**ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under Epilepsy p. 383 for more information.

**PRECAUTIONS** Myoclonic seizures (may be exacerbated). Parkinson’s disease (may be exacerbated) (in adults)

**INTERACTIONS** → Appendix 1 (lamotrigine)

**SIDE-EFFECTS**

- Common or very common: blurred vision, aggression, agitation, ataxia, back pain, diarrhea, diplopia, dizziness, drowsiness, dry mouth, headache, insomnia, nausea, nystagmus, rash, tremor, vomiting

- Rare: Conjunctivitis

- Very rare: Anaemia, blood disorders, confusion, exacerbation of Parkinson’s disease (in adults), hallucination, hepatic failure, hypersensitivity syndrome, increase in seizure frequency, leucopenia, lupus erythematosus-like reactions, movement disorders, pancytopenia, thrombocytopenia, unsteadiness

- Frequency not known: Aseptic meningitis, suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Skin reactions** Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.

**ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under Epilepsy p. 383 for more information.
Levetiracetam

**INDICATIONS AND DOSE**

**Monotherapy of focal seizures with or without secondary generalisation**

- **By mouth or by intravenous infusion**
  - **Child 16-17 years:** Initially 250 mg once daily for 1 week, then increased to 250 mg twice daily, then increased in steps of 250 mg twice daily (max. per dose 1.5 g twice daily), adjusted according to response, dose to be increased every 2 weeks
  - **Adult:** Initially 250 mg once daily for 1–2 weeks, then increased to 250 mg twice daily, then increased in steps of 250 mg twice daily (max. per dose 1.5 g twice daily), adjusted according to response, dose to be increased every 2 weeks

**Adjunctive therapy of focal seizures with or without secondary generalisation**

- **By mouth**
  - **Child 1-5 months:** Initially 7 mg/kg once daily, then increased in steps of up to 7 mg/kg twice daily (max. per dose 21 mg/kg twice daily), dose to be increased every 2 weeks
  - **Child 6 months–17 years (body-weight up to 50 kg):** Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks
  - **Child 12-17 years (body-weight 50 kg and above):** Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks
  - **Adult:** Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks

- **By intravenous infusion**
  - **Child 4-17 years (body-weight up to 50 kg):** Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks
  - **Child 12-17 years (body-weight 50 kg and above):** Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2 weeks
  - **Adult:** Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks

**Adjunctive therapy of myoclonic seizures and tonic-clonic seizures**

- **By mouth or by intravenous infusion**
  - **Child 12-17 years (body-weight up to 50 kg):** Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks
  - **Child 12-17 years (body-weight 50 kg and above):** Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2 weeks
  - **Adult:** Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks

**UNLICENSED USE**

- **In children** Granules not licensed for use in children under 6 years, for initial treatment in children with body-weight less than 25 kg, or for the administration of doses below 250 mg.

**In adults** Levetiracetam doses in BNF may differ from those in product literature.

**INTERACTIONS** → Appendix 1 (levetiracetam).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, agitation, anxiety, ataxia, convulsion, cough, depression, diarrhea, dizziness, drowsiness, dyspepsia, headache, insomnia, irritability, malaise, nasopharyngitis, nausea, rash, tremor, vertigo, vomiting

- **Uncommon** Agitation, alopecia, anemia, blurred vision, confusion, diplopia, eczema, impaired attention, leucopenia, myalgia, paraesthesia, pruritus, psychosis, suicidal ideation, thrombocytopenia, weight changes

- **Rare** Agranulocytosis, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hyponatraemia, neutropenia, pancreatitis, pancytopenia, Stevens-Johnson syndrome, toxic epidermal necrolysis

**Frequency not known** Completed suicide, pancytopenia

**PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis. It is recommended that the fetal growth should be monitored.

**BREAST FEEDING** Present in milk—manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

- In adults Halve dose in severe hepatic impairment if eGFR less than 60 mL/minute/1.73 m².

- In children Halve dose in severe hepatic impairment if estimated glomerular filtration rate less than 60 mL/minute/1.73 m².

**RENAL IMPAIRMENT**

- In children Reduce dose if estimated glomerular filtration rate less than 80 mL/minute/1.73 m² (consult product literature).

- In adults Maximum 2 g daily if eGFR 50–80 mL/minute/1.73 m². Maximum 1.5 g daily if eGFR 30–50 mL/minute/1.73 m². Maximum 1 g daily if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For intravenous infusion, dilute requisite dose with at least 100 mL Glucose 5% or Sodium Chloride 0.9% give over 15 minutes.

- With oral use For administration of oral solution, requisite dose may be diluted in a glass of water.

**PRESCRIBING AND DISPENSING INFORMATION** If switching between oral therapy and intravenous therapy (for those temporarily unable to take oral medication), the intravenous dose should be the same as the established oral dose.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Levetiracetam for preventing seizures www.medicinesforchildren.org.uk/levantiracetam-for-preventing-seizures

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** B

**LEVRITIRACETAM (Non-proprietary)**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Pack Size</th>
<th>BNF Code</th>
<th>Unit Price</th>
<th>Volume Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam 250 mg</td>
<td>60 tablets</td>
<td>£28.01 DT price = £0.47</td>
<td>£1.68</td>
<td></td>
</tr>
<tr>
<td>Levetiracetam 500 mg</td>
<td>60 tablets</td>
<td>£49.32 DT price = £0.82</td>
<td>£2.96</td>
<td></td>
</tr>
<tr>
<td>Levetiracetam 750 mg</td>
<td>60 tablets</td>
<td>£64.02 DT price = £1.07</td>
<td>£3.84</td>
<td></td>
</tr>
<tr>
<td>Levetiracetam 1 gram</td>
<td>60 tablets</td>
<td>£95.34 DT price = £1.62</td>
<td>£5.57</td>
<td></td>
</tr>
</tbody>
</table>
Epilepsy 397

Oxcarbazepine

INDICATIONS AND DOSE

Monotherapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures

BY MOUTH

- Child 6-17 years: Initially 4–5 mg/kg twice daily (max. per dose 300 mg), then increased in steps of up to 5 mg/kg twice daily, adjusted according to response, dose to be adjusted at weekly intervals; maximum 46 mg/kg per day
- Adult: Initially 300 mg twice daily, then increased in steps of up to 600 mg daily, adjusted according to response, dose to be adjusted at weekly intervals; usual dose 0.6–2.4 g daily in divided doses

Adjunctive therapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures

BY MOUTH

- Child 6-17 years: Initially 4–5 mg/kg twice daily (max. per dose 300 mg), then increased in steps of up to 5 mg/kg twice daily, adjusted according to response, dose to be adjusted at weekly intervals; maintenance 15 mg/kg twice daily; maximum 46 mg/kg per day
- Adult: Initially 300 mg twice daily, then increased in steps of up to 600 mg daily, adjusted according to response, dose to be adjusted at weekly intervals; usual dose 0.6–2.4 g daily in divided doses

Treatment of primary generalised tonic-clonic seizures

BY MOUTH

- Adult: Initially 300 mg twice daily, then increased in steps of up to 600 mg daily, adjusted according to response, dose to be adjusted at weekly intervals; usual dose 0.6–2.4 g daily in divided doses

Dose adjustments due to interactions

In adjunctive therapy, the dose of concomitant antiepileptics may need to be reduced when using high doses of oxcarbazepine.

• UNLICENSED USE

- In adults: Not licensed for the treatment of primary generalised tonic-clonic seizures.

• CAUTIONS

- Avoid in Acute porphyrias p. 864 - cardiac conduction disorders - heart failure - hyponatraemia

• INTERACTIONS → Appendix 1 (oxcarbazepine).

• SIDE-EFFECTS

- Common or very common Abdominal pain - acne - agitation - alopeica - amnesia - asthenia - ataxia - confusion - constipation - depression - diarrhoea - diplopia - dizziness - drowsiness - headache - hyponatraemia - impaired concentration - nausea - nyctagmus - rash - tremor - visual disorders - vomiting
- Uncommon Leucopenia - urticaria
- Frequency not known Aplastic anaemia - bone marrow depression - hypertension - hypothyroidism - neutropenia - osteoporotic bone disorders - pancytopenia - suicidal ideation

• ALLERGY AND CROSS-SENSITIVITY

Caution in patients with hypersensitivity to carbamazepine. Antiepileptic hypersensitivity syndrome associated with oxcarbazepine. See under Epilepsy p. 383 for more information.

• PREGNANCY

The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

• BREAST FEEDING

Amount probably too small to be harmful but manufacturer advises avoid.

• HEPATIC IMPAIRMENT

Caution in severe impairment—no information available.

• RENAL IMPAIRMENT

- In adults: Halve initial dose if eGFR less than 30 mL/minute/1.73 m²; increase according to response at intervals of at least 1 week.
- In children: Halve initial dose if estimated glomerular filtration rate less than 30 mL/minute/1.73 m²; increase according to response at intervals of at least 1 week.

• PRE-TREATMENT SCREENING

Test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative—risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).

• MONITORING REQUIREMENTS

- Monitor plasma-sodium concentration in patients at risk of hyponatraemia.
- Monitor body-weight in patients with heart failure.

• PRESCRIBING AND DISPENSING INFORMATION

Patients may need to be maintained on a specific manufacturer’s branded or generic oxcarbazepine product. Switching between formulations Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with...
the patient or their carer, taking into account factors such as seizure frequency and treatment history.

**PATIENT AND CARER ADVICE**
Medicines for Children: Oxcarbazepine for preventing seizures www.medicinesforchildren.org.uk/oxcarbazepine-for-preventing-seizures

Blood, hepatic, or skin disorders Patients or their carers should be told how to recognise signs of blood, liver, or skin disorders, and advised to seek immediate medical attention if symptoms such as lethargy, confusion, muscular twitching, fever, rash, blistering, mouth ulcers, bruising, or bleeding develop.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

### Tablet
**CAUTIONARY AND ADVISORY LABELS 3, 8**
- Oxcarbazepine (non-proprietary)
  - Oxcarbazepine 150 mg Oxcarbazepine 150mg tablets | 50 tablet [P] £11.14 DT price = £9.81
  - Oxcarbazepine 300 mg Oxcarbazepine 300mg tablets | 50 tablet [P] £22.61 DT price = £19.48
  - Oxcarbazepine 600 mg Oxcarbazepine 600mg tablets | 50 tablet [P] £45.19 DT price = £40.23
- Trileptal (Novartis Pharmaceuticals UK Ltd)
  - Oxcarbazepine 150 mg Trileptal 150mg tablets | 50 tablet [P] £10.20 DT price = £8.81
  - Oxcarbazepine 300 mg Trileptal 300mg tablets | 50 tablet [P] £20.40 DT price = £19.48
  - Oxcarbazepine 600 mg Trileptal 600mg tablets | 50 tablet [P] £40.80 DT price = £40.23

**Oral suspension**
**CAUTIONARY AND ADVISORY LABELS 3, 8**
- Excipients: May contain Propylene glycol
  - Trileptal (Novartis Pharmaceuticals UK Ltd)
  - Oxcarbazepine 60 mg per 1 ml Trileptal 60mg/ml oral suspension (sugar-free) | 250 ml [P] £40.80

**Perampanel**

### INDICATIONS AND DOSE
**Adjunctive treatment of focal seizures with or without secondary generalised seizures**

**BY MOUTH**
- **Child 12-17 years:** Initially 2 mg once daily, dose to be taken before bedtime, then increased, if tolerated, in steps of 2 mg at least every 2 weeks, adjusted according to response; maintenance 4–8 mg once daily; maximum 12 mg per day
- **Adult:** Initially 2 mg once daily, dose to be taken before bedtime, then increased, if tolerated, in steps of 2 mg at least every 2 weeks, adjusted according to response; maintenance 4–8 mg once daily; maximum 12 mg per day

**Dose adjustments due to interactions**
Titrates at intervals of at least 1 week with concomitant carbamazepine, fosphenytoin, oxcarbazepine, or phenytoin.

**INTERACTIONS**
- Appendix 1 (perampanel).

**SIDE-EFFECTS**
- Aggression · anxiety · ataxia · back pain · blurred vision · changes in appetite · confusion · diplopia · dizziness · drowsiness · dysarthria · gait disturbance · irritability · malaise · nausea · suicidal behaviour · suicidal ideation · vertigo · weight increase

**PREGNANCY**
Manufacturer advises avoid.
The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**BREAST FEEDING**
Avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Increase at intervals of at least 2 weeks, up to max. 8 mg daily in mild or moderate impairment. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Avoid in moderate or severe impairment.
- **PRESCRIBING AND DISPENSING INFORMATION**
  Switching between formulations Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history. Patients may need to be maintained on a specific manufacturer’s branded or generic perampanel product.

**Phenytoin**

### INDICATIONS AND DOSE
**Tonic-clonic seizures | Focal seizures**

**BY MOUTH**
- **Child 1 month-11 years:** Initially 1.5–2.5 mg/kg twice daily, then adjusted according to response to 2.5–5 mg/kg twice daily (max. per dose 7.5 mg/kg twice daily), dose also adjusted according to plasma-phenytoin concentration; maximum 300 mg per day
- **Child 12-17 years:** Initially 75–150 mg twice daily, then adjusted according to response to 150–200 mg twice daily (max. per dose 300 mg twice daily), dose also adjusted according to plasma-phenytoin concentration
- **Adult:** Initially 3–4 mg/kg daily, alternatively 150–300 mg once daily, alternatively 150–300 mg daily in 2 divided doses, then increased to 200–500 mg daily to be taken preferably with or after food, dose to be increased gradually as necessary (with plasma-phenytoin concentration monitoring), exceptionally, higher doses may be used

**Status epilepticus | Acute symptomatic seizures associated with head trauma or neurosurgery**

**INITIALLY BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- **Adult:** Loading dose 20 mg/kg (max. per dose 2 g), to be given at a rate not exceeding 1 mg/kg/minute (max. 50 mg per minute), to be given with blood pressure and ECG monitoring, then (by intravenous infusion or by slow intravenous injection or by mouth) maintenance 100 mg every 6–8 hours adjusted according to plasma-concentration monitoring, to be given with blood pressure and ECG monitoring, adjusted according to plasma-phenytoin concentration
Status epilepticus | Acute symptomatic seizures associated with trauma or neurosurgery

**BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- **Child 1 month–11 years:** Loading dose 20 mg/kg, then 2.5–5 mg/kg twice daily, to be given with blood pressure and ECG monitoring.
- **Child 12–17 years:** Loading dose 20 mg/kg, then up to 100 mg 3–4 times a day, to be given with blood pressure and ECG monitoring.

**Dose equivalence and conversion**

Preparations containing phenytoin sodium are not bioequivalent to those containing phenytoin base (such as Epanutin Infatabs® and Epanutin® suspension); 100 mg of phenytoin sodium is approximately equivalent in therapeutic effect to 92 mg phenytoin base. The dose is the same for all phenytoin products when initiating therapy, however, if switching between these products the difference in phenytoin content may be clinically significant. Care is needed when making changes between formulations and plasma-phenytoin concentration monitoring is recommended.

- **UNLICENSED USE**
  - With oral use Licensed for use in children (age range not specified by manufacturer).
  - With intravenous use Phenytoin doses in BNF publications may differ from those in product literature.
- **CONTRA-INDICATIONS**
  - **GENERAL CONTRA-INDICATIONS**
    - Acute porphyrias p. 864
  - **SPECIFIC CONTRA-INDICATIONS**
    - With intravenous use second- and third-degree heart block.
    - sino-atrial block.
    - sinus bradycardia.
    - Stokes-Adam syndrome.
- **CAUTIONS**
  - **GENERAL CAUTIONS**
    - Enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary)
  - **SPECIFIC CAUTIONS**
    - With intravenous use heart failure.
    - Hypotension.
    - Injection solutions alkaline (irritant to tissues).
    - Respiratory depression.
    - Resuscitation facilities must be available.

**CAUTIONS, FURTHER INFORMATION**

Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium. Intramuscular phenytoin should not be used (absorption is slow and erratic).

**INTERACTIONS**

- Appendix 1 (phenytoin).
- **SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- **Common or very common**
  - Acne.
  - Anorexia.
  - Coarsening of facial appearance.
  - Constipation.
  - Dizziness.
  - Drowsiness.
  - Gingival hypertrophy and tenderness.
  - Maintain good oral hygiene.
  - Headache.
  - Hirsutism.
  - Insomnia.
  - Nausea.
  - Parasthesia.
  - Rash.
  - Transient nervousness.
  - Tremor.
  - Vomiting.

- **Rare**
  - Leucopenia.
  - Aplastic anaemia.
  - Blood disorders.
  - Dyskinesia.
  - Hepatotoxicity.
  - Lupus erythematosus.
  - Lymphadenopathy.
  - Megaloblastic anaemia.
  - Osteomalacia.
  - Peripheral neuropathy.
  - Polyanuritis nodosa.
  - Stevens-Johnson syndrome.
  - Thrombocytopenia.
  - Toxic epidermal necrolysis.

- **Frequency not known**
  - Hypersensitivity syndrome.
  - Interstitial nephritis.
  - Pneumonitis.
  - Polyarthropathy.
  - Suicidal ideation.

**SPECIFIC SIDE-EFFECTS**

- **Common or very common**
  - With intravenous use Alterations in respiratory function.
  - Arrhythmias.
  - Cardiovascular collapse.
  - Cardiovascular depression (particularly if injection too rapid).
  - CNS depression (particularly if injection too rapid).

- **Frequency not known**
  - With intravenous use Purple glove syndrome.

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Rash**
  - Discontinue; if mild re-introduce cautiously but discontinue immediately if recurrence.

- **Hepatotoxicity**
  - Discontinue immediately and do not re-administer.

- **With intravenous use**
  - Reduce rate of administration if bradycardia or hypotension occurs.
  - Phenytoin may cause coarsening of the facial appearance, acne, hirsutism, and gingival hyperplasia and so may be particularly undesirable in adolescent patients.

- **Overdose**
  - Symptoms of phenytoin toxicity include nyctagmus, diplopia, slurred speech, ataxia, confusion, and hyperglycaemia.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Cross-sensitivity reported with carbamazepine.
  - Antiepileptic hypersensitivity syndrome associated with phenytoin. See under Epilepsy p. 383 for more information.

- **PREGNANCY**
  - Changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult—monitor unbound fraction. Doses should be adjusted on the basis of plasma-drug concentration monitoring.

- **BREAST FEEDING**
  - Small amounts present in milk, but not known to be harmful.

- **HEPATIC IMPAIRMENT**
  - Reduce dose to avoid toxicity.

- **PRE-TREATMENT SCREENING**
  - HLA® 1502 allele in individuals of Han Chinese or Thai origin—avoid unless essential (increased risk of Stevens-Johnson syndrome).

- **MONITORING REQUIREMENTS**

  - In adults The usual total plasma-phenytoin concentration for optimum response is 10–20 mg/litre (or 40–80 micromol/litre). In pregnancy, the elderly, and certain disease states where protein binding may be reduced, careful interpretation of total plasma-phenytoin concentration is necessary; it may be more appropriate to measure free plasma-phenytoin concentration.

  - In children Therapeutic plasma-phenytoin concentrations reduced in first 3 months of life because of reduced protein binding. Trough plasma concentration for optimum response: neonate—3 months, 6–15 mg/litre (25–60 micromol/litre); child 3 months–18 years, 10–20 mg/litre (40–80 micromol/litre).

  - Manufacturer recommends blood counts (but evidence of practical value uncertain).

  - Monitor ECG and blood pressure with intravenous use.

- **DIRECTIONS FOR ADMINISTRATION**

  - With intravenous use in children Before and after administration flush intravenous line with Sodium Chloride 0.9%. For intravenous injection, give into a large vein at rate not exceeding 1 mg/kg/minute (max. 50 mg/minute). For intravenous infusion, dilute to a concentration not exceeding 10 mg/mL with Sodium Chloride 0.9% and give into a large vein through an inline filter (0.22–0.50 micron) at a rate not exceeding 1 mg/kg/minute (max. 50 mg/minute); complete administration within 1 hour of preparation.

  - With intravenous use in adults For intravenous infusion (Epanutin®), give intermittently in Sodium chloride 0.9%. Flush intravenous line with Sodium chloride 0.9% before and after infusion; dilute in 50–100 mL infusion fluid (final concentration not to exceed 10 mg/mL) and give
Pregabalin

**INDICATIONS AND DOSE**

**Peripheral and central neuropathic pain**

**BY MOUTH**

- **Adult:** Initially 150 mg daily in 2–3 divided doses, then increased if necessary to 300 mg daily in 2–3 divided doses, dose to be increased after 3–7 days, then increased if necessary up to 600 mg daily in 2–3 divided doses, dose to be increased after 7 days

**Adjunctive therapy for focal seizures with or without secondary generalisation**

**BY MOUTH**

- **Adult:** Initially 25 mg twice daily, then increased in steps of 50 mg daily, dose to be increased at 7 day intervals, increased to 300 mg daily in 2–3 divided doses for 7 days, then increased if necessary up to 600 mg daily in 2–3 divided doses

**Generalised anxiety disorder**

**BY MOUTH**

- **Adult:** Initially 150 mg daily in 2–3 divided doses, then increased in steps of 150 mg daily if required, dose to be increased at 7 day intervals, increased if necessary up to 600 mg daily in 2–3 divided doses

**UNLICENSED USE** Pregabalin doses in BNF may differ from those in product literature.

**CAUTIONS** Conditions that may precipitate encephalopathy: severe congestive heart failure

**INTERACTIONS** → Appendix 1 (pregabalin).

**SIDE-EFFECTS**

- **Common or very common** Appetite changes • blurred vision • confusion • constipation • diplopia • disturbances in muscle control and movement • dizziness • drowsiness • dry mouth • euphoria • flatulence • impaired attention • impaired memory • insomnia • irritability • malaise • oedema • paraesthesia • sexual dysfunction • speech disorder • visual disturbances • visual field defects • vomiting • weight gain

- **Uncommon** Abdominal distension • abnormal dreams • agitation • arthralgia • chills • cognitive impairment • depersonalisation • depression • dry eye • dysphonia • dysuria • first-degree AV block • flushing • gastroesophageal reflux disease • hallucinations • hyperacusis • hypersalivation • hypertension • hypoglycaemia • hypotension • hyponatremia • lacrimation • myalgia • nasal dryness • nasopharyngitis • panic attacks • rash • stupor • sweating • syncope • tachycardia • taste disturbance • thirst • thrombocytopenia • urinary incontinence

- **Rare** Arrhythmia • asictes • bradycardia • breast discharge • breast hypertrophy • breast pain • cold extremities • cough • dysphagia • epistaxis • hyperglycaemia • hypokalaemia • leucopenia • menstrual disturbances • neutropenia • oliguria • pancreatitis • parosmia • renal failure • rhabdomyolysis • rhinitis • urticaria • weight loss

- **Frequency not known** Agitation • congestive heart failure • convulsions • diarrhoea • encephalopathy • headache • keratitis • nausea • puritus • QT-interval prolongation • Stevens-Johnson syndrome • suicidal ideation • urinary retention

**RENAL IMPAIRMENT** Initially 75 mg daily and maximum 300 mg daily if eGFR 30–60 mL/minute/1.73 m². Initially 25–50 mg daily and maximum 150 mg daily in 1–2 divided doses if eGFR 15–30 mL/minute/1.73 m². Initially 25 mg once daily and maximum 75 mg once daily if eGFR less than 15 mL/minute/1.73 m².

**TREATMENT CESSATION** Avoid abrupt withdrawal (taper over at least 1 week).

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include strawberry.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (July 2007) that pregabalin (Lyrica®) is not recommended for the treatment of central neuropathic pain. The Scottish Medicines Consortium has advised (April 2009) that pregabalin (Lyrica®) is accepted for restricted use within NHS Scotland for the treatment of peripheral neuropathic pain.

<table>
<thead>
<tr>
<th>Formulations</th>
<th>PHARMACOPOEIA</th>
<th>BNF 70</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BY MOUTH</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epanutin (Phenytoin)</strong> (Pfizer Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin sodium 50 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin sodium 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epanutin Infatabs 50 mg chewable tablets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epanutin (Phenytoin sodium)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin sodium 25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin sodium 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin sodium 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ORAL SUSPENSION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epanutin (Phenytoin)</strong> (Pfizer Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin 6 mg per 1 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>500 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SOLUTION FOR INJECTION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epanutin (Phenytoin)</strong> (Pfizer Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin sodium 25 mg per 1 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 ampoules</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 ampoules no price available</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epanutin (Phenytoin sodium)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin sodium 50 mg per 1 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 ampoules</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PREGABALIN**

BY MOUTH

- **Adult:** Initially 150 mg daily in 2–3 divided doses, then increased if necessary to 300 mg daily in 2–3 divided doses, dose to be increased after 3–7 days, then increased if necessary up to 600 mg daily in 2–3 divided doses, dose to be increased after 7 days

**Adjunctive therapy for focal seizures with or without secondary generalisation**

**BY MOUTH**

- **Adult:** Initially 25 mg twice daily, then increased in steps of 50 mg daily, dose to be increased at day intervals, increased to 300 mg daily in 2–3 divided doses for 7 days, then increased if necessary up to 600 mg daily in 2–3 divided doses

**Generalised anxiety disorder**

**BY MOUTH**

- **Adult:** Initially 150 mg daily in 2–3 divided doses, then increased in steps of 150 mg daily if required, dose to be increased at 7 day intervals, increased if necessary up to 600 mg daily in 2–3 divided doses

**UNLICENSED USE** Pregabalin doses in BNF may differ from those in product literature.

**CAUTIONS** Conditions that may precipitate encephalopathy: severe congestive heart failure

**INTERACTIONS** → Appendix 1 (pregabalin).

**SIDE-EFFECTS**

- **Common or very common** Appetite changes • blurred vision • confusion • constipation • diplopia • disturbances in muscle control and movement • dizziness • drowsiness • dry mouth • euphoria • flatulence • impaired attention • impaired memory • insomnia • irritability • malaise • oedema • paraesthesia • sexual dysfunction • speech disorder • visual disturbances • visual field defects • vomiting • weight gain

- **Uncommon** Abdominal distension • abnormal dreams • agitation • arthralgia • chills • cognitive impairment • depersonalisation • depression • dry eye • dysphonia • dysuria • first-degree AV block • flushing • gastroesophageal reflux disease • hallucinations • hyperacusis • hypersalivation • hypertension • hypoglycaemia • hypotension • hyponatremia • lacrimation • myalgia • nasal dryness • nasopharyngitis • panic attacks • rash • stupor • sweating • syncope • tachycardia • taste disturbance • thirst • thrombocytopenia • urinary incontinence

- **Rare** Arrhythmia • asictes • bradycardia • breast discharge • breast hypertrophy • breast pain • cold extremities • cough • dysphagia • epistaxis • hyperglycaemia • hypokalaemia • leucopenia • menstrual disturbances • neutropenia • oliguria • pancreatitis • parosmia • renal failure • rhabdomyolysis • rhinitis • urticaria • weight loss

- **Frequency not known** Agression • congestive heart failure • convulsions • diarrhoea • encephalopathy • headache • keratitis • nausea • puritus • QT-interval prolongation • Stevens-Johnson syndrome • suicidal ideation • urinary retention

**RENAL IMPAIRMENT** Initially 75 mg daily and maximum 300 mg daily if eGFR 30–60 mL/minute/1.73 m². Initially 25–50 mg daily and maximum 150 mg daily in 1–2 divided doses if eGFR 15–30 mL/minute/1.73 m². Initially 25 mg once daily and maximum 75 mg once daily if eGFR less than 15 mL/minute/1.73 m².

**TREATMENT CESSATION** Avoid abrupt withdrawal (taper over at least 1 week).

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include strawberry.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (July 2007) that pregabalin (Lyrica®) is not recommended for the treatment of central neuropathic pain. The Scottish Medicines Consortium has advised (April 2009) that pregabalin (Lyrica®) is accepted for restricted use within NHS Scotland for the treatment of peripheral neuropathic pain.
neuropathic pain in adults who have not achieved adequate pain relief with, or have not tolerated, first- or second-line treatments; discontinue treatment if sufficient benefit is not achieved within 8 weeks of reaching the maximum tolerated dose.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, powder, capsule.

- **INDICATIONS AND DOSE**

  **Capsule**

  **CAUTIONARY AND ADVISORY LABELS 3, 8**

  - **PREGABALIN (Non-proprietary)**
    - Pregabalin 25 mg: Pregabalin 25mg capsules | 56 capsule [PO] £64.40 DT price = £64.40 | 84 capsule [PO] £96.60
    - Pregabalin 50 mg: Pregabalin 50mg capsules | 84 capsule [PO] £96.60 DT price = £96.60
    - Pregabalin 75 mg: Pregabalin 75mg capsules | 56 capsule [PO] £64.40 DT price = £64.40 | 84 capsule [PO] £96.60
    - Pregabalin 100 mg: Pregabalin 100mg capsules | 84 capsule [PO] £96.60 DT price = £96.60
    - Pregabalin 150 mg: Pregabalin 150mg capsules | 56 capsule [PO] £64.40 DT price = £64.40 | 84 capsule [PO] £96.60
    - Pregabalin 225 mg: Pregabalin 225mg capsules | 56 capsule [PO] £64.40 DT price = £64.40 | 84 capsule [PO] £96.60
    - Pregabalin 300 mg: Pregabalin 300mg capsules | 56 capsule [PO] £64.40 DT price = £64.40
    - Lyrica (Pfizer Ltd)
      - Pregabalin 25 mg: Lyrica 25mg capsules | 56 capsule [PO] £64.40 DT price = £64.40 | 84 capsule [PO] £96.60
      - Pregabalin 50 mg: Lyrica 50mg capsules | 84 capsule [PO] £96.60 DT price = £96.60
      - Pregabalin 75 mg: Lyrica 75mg capsules | 56 capsule [PO] £64.40 DT price = £64.40 | 84 capsule [PO] £96.60
      - Pregabalin 100 mg: Lyrica 100mg capsules | 84 capsule [PO] £96.60 DT price = £96.60
      - Pregabalin 150 mg: Lyrica 150mg capsules | 56 capsule [PO] £64.40 DT price = £64.40 | 84 capsule [PO] £96.60
      - Pregabalin 200 mg: Lyrica 200mg capsules | 84 capsule [PO] £96.60 DT price = £96.60
      - Pregabalin 250 mg: Lyrica 225mg capsules | 56 capsule [PO] £64.40 DT price = £64.40
      - Pregabalin 300 mg: Lyrica 300mg capsules | 56 capsule [PO] £64.40
      - Brands may include Alzain; Lecaent; Rewica
  
  **Oral solution**

  **CAUTIONARY AND ADVISORY LABELS 3, 8**

  - Lyrica (Pfizer Ltd)
    - Pregabalin 20 mg per 1 ml: Lyrica 20mg/ml oral solution (sugar-free) | 473 ml [PO] £99.48
  
**Primidone**

**INDICATIONS AND DOSE**

- **All forms of epilepsy except typical absence seizures**
  
  - **BY MOUTH**
    - Child 1 month-1 year: Initially 125 mg daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, adjusted according to response; maintenance 125–250 mg twice daily.
    - Child 2-4 years: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, adjusted according to response; maintenance 250–375 mg twice daily.
    - Child 5-8 years: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, adjusted according to response; maintenance 375–500 mg twice daily.
    - Child 9-17 years: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, increased to 250 mg twice daily, then increased in steps of 250 mg every 3 days (max. per dose 750 mg twice daily), adjusted according to response.
      - Adult: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, increased to 500 mg daily in 2 divided doses, then increased in steps of 250 mg every 3 days, adjusted according to response; maintenance 0.75–1.5 g daily in 2 divided doses.

**Essential tremor**

- **BY MOUTH**
  - Adult: Initially 50 mg daily, then adjusted according to response to up to 750 mg daily, dose to be increased over 2–3 weeks.

- **CAUTIONS** Avoid in acute porphyria; children; debilitated; elderly; history of alcohol abuse; history of drug abuse; respiratory depression (avoid if severe).

- **CAUTIONS, FURTHER INFORMATION**

  - **SIDE-EFFECTS**
    - **Common or very common** Agranulocytosis; allergic skin reactions; ataxia; behavioural disturbances; cholestasis; depression; drowsiness; hallucinations; hepatitis; hyperactivity (in children); hyperactivity particularly in the elderly; hypotension; impaired cognition; impaired memory; irritability; lethargy; megaloblastic anaemia (may be treated with folic acid); nausea; nystagmus; osteomalacia; paradoxical excitement (in adults); respiratory depression; thrombocytopenia; visual disturbances.
    - **Uncommon** Dizziness; headache; vomiting.
    - **Rare** Arthralgia; lupus erythematosus; psychosis.
    - **Very rare** Antiepileptic hypersensitivity syndrome; Stevens-Johnson syndrome; suicidal ideation; toxic epidermal necrolysis.
    - **Frequency not known** Dupuytren’s contracture.

- **ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with primidone. See under Epilepsy p. 383 for more information.

- **PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

- **HEPATIC IMPAIRMENT** Reduce dose. May precipitate coma.

- **RENAL IMPAIRMENT** Use with caution.

- **MONITORING REQUIREMENTS** Monitor plasma concentrations of derived phenobarbital; plasma concentration for optimum response is 15–40 mg/litre (60–180 micromol/litre).

- **TREATMENT CESSATION** Avoid abrupt withdrawal (dependence with prolonged use).

- **PRESCRIBING AND DISPENSING INFORMATION** Switching between formulations. Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer’s product.

**MEDICINAL FORMS**

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS 2, 8**
  - **PRIMIDONE (Non-proprietary)**
    - Primidone 50 mg: Primidone 50mg tablets | 100 tablet [POA] £70.00–£75.00 DT price = £74.88
    - Primidone 250 mg: Primidone 250mg tablets | 90 tablet [POA] no price available | 100 tablet [POA] £77.50–£82.50 DT price = £82.43
**Retigabine**

**INDICATIONS AND DOSE**

Adjunctive treatment of drug-resistant focal seizures with or without secondary generalisation when other appropriate drug combinations have proved inadequate or have not been tolerated

**BY MOUTH**
- **Adult:** Initially up to 300 mg daily in 3 divided doses, then increased in steps of up to 150 mg every 1 week, adjusted according to response; maintenance 0.6–1.2 g daily
- **Elderly:** Initially 150 mg daily in 3 divided doses, then increased in steps of up to 150 mg every 1 week, adjusted according to response; maximum 900 mg per day

**CAUTIONS**
- Known QT-interval prolongation - risk of urinary retention

**SIDE-EFFECTS**
- **Common or very common** Amnesia • anxiety • blurred vision • confusion • constipation • diplopia • discolouration of lips • discolouration of nails • discolouration of ocular tissue • discolouration of skin • dizziness • drowsiness • dry mouth • dysuria • haematuria • impaired attention • impaired coordination • impaired speech • increased appetite • malaise • myoclonus • nausea • parasthesia • peripheral oedema • psychosis • tremor • vertigo • visual impairment • weight gain
- **Uncommon** Dyspepsia • dysphagia • hypokinesia • nephrolithiasis • rash • suicidal ideation • sweating • urinary retention

**PREGNANCY**
- The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**HEPATIC IMPAIRMENT**
- Reduce dose by 50% in moderate to severe impairment; increase by 50 mg every week according to response up to maximum 600 mg daily (450 mg in elderly).

**RENAL IMPAIRMENT**
- Reduce dose by 50% if eGFR less than 50 mL/minute/1.73 m²; increase by 50 mg every week according to response up to maximum 600 mg daily (450 mg in elderly).

**MONITORING REQUIREMENTS**
- Ophthalmological monitoring A comprehensive ophthalmological examination (including visual acuity test, slit-lamp examination, and dilated fundoscopy) should be performed at initiation of treatment and at least every 6 months thereafter during treatment. Changes in vision or retinal pigment should lead to re-assessment of the benefits and risks of continuing treatment—discontinue unless no other treatment options are available. Monitoring should be increased if treatment is continued.
- Monitor for discolouration of ocular tissue and visual impairment.
- Monitor for blue-grey discolouration of nails, lips and skin—continue treatment only if potential benefit outweighs risk.

**PRESCRIBING AND DISPENSING INFORMATION**

Switching between formulations Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (July 2011) NICE TA232
- Retigabine is recommended as an option for the adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and older with epilepsy, only when previous treatment with carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, and topiramate has not provided an adequate response, or has not been tolerated. [www.nice.org.uk/TA232](http://www.nice.org.uk/TA232)

**Scottish Medicines Consortium (SMC) Decisions**
- The Scottish Medicines Consortium has advised (June 2011) that retigabine (Trobalt®) is accepted for restricted use within NHS Scotland as adjunctive therapy in adults with focal seizures with or without secondary generalisation. It is restricted use for refractory epilepsy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

| Retigabine 50 mg | Trobalt 50mg tablets | 21 tablet [P] £4.87 | 84 tablet [P] £19.46 |
| Retigabine 100 mg | Trobalt 100mg tablets | 21 tablet [P] £3.73 | 42 tablet [P] no price available | 84 tablet [P] £7.89 |
| Retigabine 200 mg | Trobalt 200mg tablets | 84 tablet [P] £77.86 |
| Retigabine 300 mg | Trobalt 300mg tablets | 84 tablet [P] £116.78 |
| Retigabine 400 mg | Trobalt 400mg tablets | 84 tablet [P] £127.68 |

**Rufinamide**

**INDICATIONS AND DOSE**

Adjunctive treatment of seizures in Lennox-Gastaut syndrome

**BY MOUTH**
- **Child 4–17 years (body-weight up to 30 kg):** Initially 100 mg twice daily, then increased in steps of 100 mg twice daily (max. per dose 500 mg twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days.
- **Child 4–17 years (body-weight 30–50 kg):** Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 900 mg twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days.
- **Adult (body-weight 30–50 kg):** Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 1.2 g twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days.
Sodium valproate

INDICATIONS AND DOSE
All forms of epilepsy

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Child 1 month–11 years: Initially 10–15 mg/kg daily in 1–2 divided doses (max. per dose 600 mg); maintenance 25–30 mg/kg daily in 2 divided doses, doses up to 60 mg/kg daily in 2 divided doses may be used in infantile spasms; monitor clinical chemistry and haematological parameters if dose exceeds 40 mg/kg daily
- Child 12–17 years: Initially 600 mg daily in 1–2 divided doses, increased in steps of 150–300 mg every 3 days; maintenance 1–2 g daily in 2 divided doses; maximum 2.5 g per day
- Adult: Initially 600 mg daily in 1–2 divided doses, then increased in steps of 150–300 mg every 3 days; maintenance 1–2 g daily, alternatively maintenance 20–30 mg/kg daily; maximum 2.5 g per day

Initiation of valproate treatment
INITIALLY BY INTRAVENOUS INJECTION
- Adult: Initially 10 mg/kg, (usually 400–800 mg), followed by (by intravenous infusion or by intravenous injection) up to 2.5 g daily in 2–4 divided doses, alternatively (by continuous intravenous infusion) up to 2.5 g daily; usual dose 1–2 g daily, (20–30 mg/kg daily), intravenous injection to be administered over 3–5 minutes

Continuation of valproate treatment
BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION OR BY CONTINUOUS INTRAVENOUS INFUSION
- Adult: If switching from oral therapy to intravenous therapy give current oral daily dose, give over 3–5 minutes by intravenous injection or in 2–4 divided doses by intravenous infusion

EPILIM CHRONO®
All forms of epilepsy
BY MOUTH
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

EPIVAL®
All forms of epilepsy
BY MOUTH
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

EPISENTA® CAPSULES
All forms of epilepsy
BY MOUTH
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

Mania
BY MOUTH
- Adult: Initially 750 mg daily in 1–2 divided doses, adjusted according to response, usual dose 1–2 g daily in 1–2 divided doses, doses greater than 45 mg/kg daily require careful monitoring.
**EPISENTA® GRANULES**

All forms of epilepsy

**BY MOUTH**

- **Adult:** Total daily dose to be given in 1–2 divided doses (consult product literature)

**Mania**

**BY MOUTH**

- **Adult:** Initially 750 mg daily in 1–2 divided doses, adjusted according to response; usual dose 1–2 g daily in 1–2 divided doses, doses greater than 45 mg/kg daily require careful monitoring

**EPILIM CHRONOSPHERE®**

All forms of epilepsy

**BY MOUTH**

- **Adult:** Total daily dose to be given in 1–2 divided doses (consult product literature)

**Migraine prophylaxis**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adult:** Initially 200 mg twice daily, then increased if necessary to 1.2–1.5 g daily in divided doses

### Side-effects, Further Information

**Liver toxicity**

Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (especially in children under 3 years and in those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in first 6 months and usually involving multiple antiepileptic therapy. Raised liver enzymes during valproate treatment are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal—discontinue if abnormally prolonged prothrombin time (particularly in association with other relevant abnormalities). Consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

### Interactions

→ Appendix I (sodium valproate)

###UNLICENSED USE

- In adults Not licensed for migraine prophylaxis.

### Contra-Indications

Family history of severe hepatic dysfunction - knon mitochondrial disorders (higher rate of acute liver failure and liver-related deaths) - personal or family history of severe hepatic dysfunction - porphyria - suspected mitochondrial disorders (higher rate of acute liver failure and liver-related deaths)

### CAUTIONS

Systemic lupus erythematosus

### CAUTIONS, FURTHER INFORMATION

Liver toxicity

Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (especially in children under 3 years and in those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in first 6 months and usually involving multiple antiepileptic therapy. Raised liver enzymes during valproate treatment are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal—discontinue if abnormally prolonged prothrombin time (particularly in association with other relevant abnormalities). Consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

### Side-Effects

- **Very rare** Acne - gynaecomastia - hepatic dysfunction - hirsutism - increase in bleeding time - pancreatitis

- **Frequency not known** Hypersensitivity reactions - suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hepatic dysfunction**

Withdraw treatment immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or loss of seizure control.

**Conception and Contraception**

Valproate is associated with teratogenic risks and should not be used in women of child-bearing potential unless there is no safer alternative—this should be fully considered and discussed before prescribing for women of child-bearing age. Effective contraception advised in women of child-bearing potential.

**Pregnancy**

Valproate is associated with the highest risk of major and minor congenital malformations (in particular neural tube defects), and long-term neurodevelopmental effects. Valproate should not be used during pregnancy or in women of child-bearing potential unless there is no safer alternative and only after a careful discussion of the risks. If valproate is to be used during pregnancy, the lowest effective dose should be prescribed in divided doses or as modified-release tablets to avoid peaks in plasma-valproate concentrations; doses greater than 1 g daily are associated with an increased risk of teratogenicity. Avoid use in the treatment of epilepsy and bipolar disorder unless there is no safer alternative and only after a careful discussion of the risks—effective contraception advised in women of child-bearing potential. Avoid use for the prophylaxis of migraine [unlicensed]—exclude pregnancy before treatment and ensure effective contraception is used during treatment. Neonatal bleeding (related to hypofibrinemia) reported. Neonatal hepatotoxicity also reported. Specialist prenatal monitoring should be instigated when valproate has been taken in pregnancy. The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**Breast feeding**

Present in milk—risk of haematological disorders in breast-fed newborns and infants.

**Hepatic Impairment**

Avoid if possible—hepatotoxicity and hepatic failure may occasionally occur (usually in first 6 months). Avoid in active liver disease.

**Renal Impairment**

Reduce dose.

**Monitoring Requirements**

- Plasma-valproate concentrations are not a useful index of efficacy, therefore routine monitoring is unhelpful.
- Monitor liver function before therapy and during first 6 months especially in patients most at risk.
- Measure full blood count and ensure no undue potential for bleeding before starting and before surgery.

**Effect on Laboratory Tests**

False-positive urine tests for ketones.

**Directions for Administration**

- With rectal use in children For rectal administration, sodium valproate oral solution may be given rectally and retained for 15 minutes (may require dilution with water to prevent rapid expulsion).
- With intravenous use in children For intravenous injection, may be diluted in Glucose 5% or Sodium Chloride 0.5% and given over 3–5 minutes. For intravenous infusion, dilute injection solution with Glucose 5% or Sodium Chloride 0.9%.
- With intravenous use in adults For intravenous infusion (Epilim®[a], Episenta®[b]), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstitute Epilim® with solvent provided then dilute with infusion fluid.
EPIVAL® Tablets may be halved but not crushed or chewed.

EPISENTA® CAPSULES Contents of capsule may be mixed with cold soft food or drink and swallowed immediately without chewing.

EPISENTA® GRANULES Granules may be mixed with cold soft food or drink and swallowed immediately without chewing. 

EPILIM® ORAL SOLUTION May be diluted, preferably in Syrup BP; use within 14 days.

PRESCRIBING AND DISPENSING INFORMATION Switching between formulations Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic oral sodium valproate product.

EPILIM CHRONOSPHERE® Prescribe dose to nearest whole 50 mg sachet.

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Sodium valproate for preventing seizures 

Blood or hepatic disorders Patients or their carers should be told how to recognise signs and symptoms of blood or liver disorders and advised to seek immediate medical attention if symptoms develop.

Pancreatitis Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek immediate medical attention if symptoms such as abdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed.

Counselling advised on pregnancy.

Administration advice should be given for Epival®, Episenta®, capsules and granules, and Epilim® Chronosphere and Epilim® oral Solution

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 8, 10, 21

Epival CR (Chanelle Medical UK Ltd) ▼

Sodium valproate 300 mg Epival CR 300mg tablets | 100 tablet (£5.12) 12.13

Sodium valproate 500 mg Epival CR 500mg tablets | 100 tablet (£5.20) 20.21

Gastro-resistant tablet

CAUTIONARY AND ADVISORY LABELS 5, 8, 10, 25

SODIUM VALPROATE (Non-proprietary) ▼

Sodium valproate 200 mg Sodium valproate 200mg gastro-resistant tablets | 100 tablet (£5.00) 10.00 DT price = £4.49

Sodium valproate 500 mg Sodium valproate 500mg gastro-resistant tablets | 100 tablet (£9.99) 19.98 DT price = £8.56

Epilim (Sanofi)▼

Sodium valproate 200 mg Epilim 200 gastro-resistant tablets | 100 tablet (£7.70) 15.40 DT price = £4.49

Sodium valproate 500 mg Epilim 500 gastro-resistant tablets | 100 tablet (£12.25) 24.50 DT price = £8.56

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 8, 10, 21, 25

SODIUM VALPROATE (Non-proprietary) ▼

Sodium valproate 300 mg Sodium valproate 300mg modified-release capsules | 100 capsule (£2.90) no price available

Episenta (Destin Pharma Ltd)▼

Sodium valproate 150 mg Episenta 150mg modified-release capsules | 100 capsule (£7.00) 14.00

Sodium valproate 300 mg Episenta 300mg modified-release capsules | 100 capsule (£13.00) 26.00

Modified-release granules

CAUTIONARY AND ADVISORY LABELS 8, 10, 21, 25

Epilim Chronosphere MR (Sanofi)▼

Sodium valproate 50 mg Epilim Chronosphere MR 50mg granules sachets (sugar-free) | 30 sachet (£5.00) 15.00

Sodium valproate 100 mg Epilim Chronosphere MR 100mg granules sachets (sugar-free) | 30 sachet (£2.90) 8.70

Sodium valproate 250 mg Epilim Chronosphere MR 250mg granules sachets (sugar-free) | 30 sachet (£3.00) 9.00

Sodium valproate 500 mg Epilim Chronosphere MR 500mg granules sachets (sugar-free) | 30 sachet (£3.00) 9.00

Sodium valproate 750 mg Epilim Chronosphere MR 750mg granules sachets (sugar-free) | 30 sachet (£3.00) 9.00

Sodium valproate 1 gram Epilim Chronosphere MR 1000mg granules sachets (sugar-free) | 30 sachet (£3.00) 9.00

Episenta (Destin Pharma Ltd)▼

Sodium valproate 500 mg Episenta 500mg modified-release granules sachets (sugar-free) | 100 sachet (£2.10) 21.00

Sodium valproate 1 gram Episenta 1000mg modified-release granules sachets (sugar-free) | 100 sachet (£4.10) 41.00

Oral solution

CAUTIONARY AND ADVISORY LABELS 8, 10, 21

SODIUM VALPROATE (Non-proprietary) ▼

Sodium valproate 40 mg per 1 ml Sodium valproate 200mg/5ml oral solution sugar free (sugar-free) | 300 ml (£7.99) 33.95 DT price = £5.07

Epilim (Sanofi)▼

Sodium valproate 40 mg per 1 ml Epilim 200mg/5ml liquid (sugar-free) | 300 ml (£7.78) 23.34 DT price = £5.07

Epilim 200mg/5ml syrup | 300 ml (£3.33) 9.99 DT price = £3.33

Solution for injection

SODIUM VALPROATE (Non-proprietary) ▼

Sodium valproate 100 mg per 1 ml Sodium valproate 400mg/4ml solution for injection ampoules | 5 ampoule (£3.75) 18.75

Episenta (Destin Pharma Ltd)▼

Sodium valproate 100 mg per 1 ml Episenta 300mg/3ml solution for injection ampoules | 5 ampoule (£3.50) 17.50

Powder and solvent for solution for injection

Epilim (Sanofi)▼

Sodium valproate 400 mg Epilim Intravenous 400mg powder and solvent for solution for injection vials | 1 vial (£13.32)
Tiagabine

**INDICATIONS AND DOSE**
Adjunctive treatment for focal seizures with or without secondary generalisation that are not satisfactorily controlled by other antiepileptics (with enzyme-inducing drugs)

**BY MOUTH**
- Child 12-17 years: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours every 1 week; maintenance 30–45 mg daily in 2–3 divided doses
- Adult: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours every 1 week; maintenance 30–45 mg daily in 2–3 divided doses

Adjunctive treatment for focal seizures with or without secondary generalisation that are not satisfactorily controlled by other antiepileptics (without enzyme-inducing drugs)

**BY MOUTH**
- Child 12-17 years: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours every 1 week; maintenance 15–30 mg daily in 2–3 divided doses
- Adult: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours every 1 week; maintenance 15–30 mg daily in 2–3 divided doses

**SIDE-EFFECTS**
- Common or very common Diarrhoea; dizziness; emotional lability; impaired concentration; nervousness; speech impairment; tiredness; tremor
- Rare Bruising; confusion; depression; drowsiness; non-convulsive status epilepticus; psychosis; suicidal ideation; visual disturbances
- Frequency not known Leucopenia

**PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**HEPATIC IMPAIRMENT** In mild to moderate impairment reduce dose, prolong the dose interval, or both. Avoid in severe impairment.

**PATIENT AND CARER ADVICE** May impair performance of skilled tasks (e.g. driving).

**CAUTIONS** Avoid in Acute porphyrias p. 864

**CAUTIONS, FURTHER INFORMATION**
Tiagabine should be avoided in absence, myoclonic, tonic and atonic seizures due to risk of seizure exacerbation.

**INTERACTIONS** → Appendix 1 (tiagabine).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Quantity</th>
<th>Retail Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg</td>
<td>100 tablet</td>
<td>£0.75</td>
</tr>
<tr>
<td>10 mg</td>
<td>100 tablet</td>
<td>£1.00</td>
</tr>
<tr>
<td>15 mg</td>
<td>100 tablet</td>
<td>£1.25</td>
</tr>
</tbody>
</table>

**Topiramate**

**INDICATIONS AND DOSE**
Monotherapy of generalised tonic-clonic seizures or focal seizures with or without secondary generalisation

**BY MOUTH**
- Child 6–17 years: Initially 0.5–1 mg/kg once daily (max. per dose 25 mg) for 1 week, dose to be taken at night, then increased in steps of 250–500 micrograms/kg twice daily, dose to be increased by a maximum of 25 mg twice daily at intervals of 1–2 weeks; usual dose 50 mg twice daily (max. per dose 7.5 mg/kg twice daily), if child cannot tolerate titration regimens recommended above then smaller steps or longer interval between steps may be used; maximum 500 mg per day
- Adult: Initially 25 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25–50 mg every 1–2 weeks, dose to be taken in 2 divided doses; usual dose 100–200 mg daily in 2 divided doses, adjusted according to response, doses of 1 g daily have been used in refractory epilepsy; maximum 500 mg per day

Adjunctive treatment of generalised tonic-clonic seizures or focal seizures with or without secondary generalisation | Adjunctive treatment for seizures associated with Lennox-Gastaut syndrome

**BY MOUTH**
- Child 2–17 years: Initially 1–3 mg/kg once daily (max. per dose 25 mg) for 1 week, dose to be taken at night, then increased in steps of 0.5–1.5 mg/kg twice daily, dose to be increased by a maximum of 25 mg twice daily at intervals of 1–2 weeks; usual dose 2.5–4.5 mg/kg twice daily (max. per dose 7.5 mg/kg twice daily), if child cannot tolerate recommended titration regimen then smaller steps or longer interval between steps may be used; maximum 400 mg per day
- Adult: Initially 25–50 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25–50 mg every 1–2 weeks, dose to be taken in 2 divided doses; usual dose 200–400 mg daily in 2 divided doses; maximum 400 mg per day

**Migraine prophylaxis**

**BY MOUTH**
- Adult: Initially 25 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25 mg every 1 week; usual dose 50–100 mg daily in 2 divided doses; maximum 200 mg per day

**UNLICENSED USE** Not licensed for use in children for migraine prophylaxis.

**CAUTIONS** Avoid in Acute porphyrias p. 864 · risk of metabolic acidosis · risk of nephrolithiasis—ensure adequate hydration (especially in strenuous activity or warm environment)

**INTERACTIONS** → Appendix 1 (topiramate).

**SIDE-EFFECTS**
- Common or very common Abdominal pain; aggression; agitation; alopecia; anaemia; anxiety; appetite changes; arthralgia; cognitive impairment; confusion; constipation; depression; diarrhoea; dizziness; drowsiness; dry mouth; dyspepsia; dyspnoea; epistaxis; gastritis; impaired attention; impaired coordination; irritability; malaise; mood changes; movement disorders; muscle spasm; muscular weakness; myalgia; nausea; nephrolithiasis; nystagnus; paraesthesia; pruritus; rash; seizures; sleep disturbance; speech disorder; taste disturbance; tinnitus; tremor; urinary disorders; visual disturbances; vomiting
- Uncommon Abdominal distension; altered sense of smell; blepharospasm; blood disorders; bradycardia; dry eye;
Epilepsy 407

**INDICATIONS AND DOSE**

Adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics (under expert supervision)

**BY MOUTH**

- **Child 1 month-2 years:** Initially 15–20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 75 mg/kg twice daily)
- **Child 2-11 years:** Initially 15–20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 1.5 g twice daily)
- **Child 12-17 years:** Initially 250 mg twice daily, to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 1–1.5 g twice daily
- **Adult:** Initially 1 g once daily, alternatively initially 1 g daily in 2 divided doses, then increased in steps of 500 mg every 1 week, adjusted according to response; usual dose 2–3 g daily; maximum 3 g per day

**BY RECTUM**

- **Child 1 month-1 year:** Initially 15–20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 75 mg/kg twice daily)
408 Seizures

- Child 2-11 years: Initially 15–20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 1.5 g twice daily).
- Child 12–17 years: Initially 250 mg twice daily, to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 1–1.5 g twice daily.

- UNLICENSED USE Granules not licensed for rectal use. Tablets not licensed to be crushed and dispersed in liquid. Vigabatrin doses in BNF publications may differ from those in product literature.
- CONTRA-INDICATIONS Visual field defects
- CAUTIONS Elderly - history of behavioural problems - history of depression - history of psychosis

CAUTIONS, FURTHER INFORMATION
Vigabatrin may worsen absence, myoclonic, tonic and atonic seizures.

Visual field defects Vigabatrin is associated with visual field defects. The onset of symptoms varies from 1 month to several years after starting. In most cases, visual field defects have persisted despite discontinuation, and further deterioration after discontinuation cannot be excluded. Product literature advises visual field testing before treatment and at 6-month intervals. Patients and their carers should be warned to report any new visual symptoms that develop and those with symptoms should be referred for an urgent ophthalmological opinion. Gradual withdrawal of vigabatrin should be considered.

- INTERACTIONS → Appendix 1 (vigabatrin).
- SIDE-EFFECTS
  - Common or very common Abdominal pain - aggression - agitation - blurred vision - depression - diplopia - dizziness - drowsiness - excitement (in children) - fatigue - headache - impaired concentration - impaired memory - irritability - nausea - nervousness -ystagmus - oedema - paraesthesia - paraesthesia - paraparesis - speech disorder - tremor - visual field defects - vomiting - weight gain
  - Uncommon Ataxia - mania - occasional increase in seizure frequency (especially if myoclonic) - psychosis - rash
  - Rare Peripheral retinal neuropathy - retinal disorders - suicidal ideation
  - Very rare Hepatitis - optic atrophy - optic neuritis
  - Frequency not known Movement disorders in infantile spasms

SIDE-EFFECTS, FURTHER INFORMATION
Visual field defects About one-third of patients treated with vigabatrin have suffered visual field defects; counselling and careful monitoring for this side-effect are required. Encephalopathic symptoms including marked sedation, stupor, and confusion with non-specific slow wave EEG can occur rarely—reduce dose or withdraw.

- PREGNANCY The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.
- BREAST FEEDING Present in milk—manufacturer advises avoid.

- RENAL IMPAIRMENT
  - In adults Consider reduced dose or increased dose interval if eGFR less than 60 mL/minute/1.73 m².
  - In children Consider reduced dose or increased dose interval if estimated glomerular filtration rate less than 60 mL/minute/1.73 m².

- MONITORING REQUIREMENTS Closely monitor neurological function.
- DIRECTIONS FOR ADMINISTRATION
  - With rectal use Dissolve contents of sachet in small amount of water and administer rectally [unlicensed use].

The contents of a sachet should be dissolved in water or a soft drink immediately before taking. Tablets may be crushed and dispersed in liquid.

- PATIENT AND CARER ADVICE
  - Medicines for Children leaflet: Vigabatrin for preventing seizures www.medicinesforchildren.org.uk/vigabatrin-for-preventing-seizures
  - Patients and their carers should be warned to report any new visual symptoms that develop.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution
  - Tablet CAUTIONARY AND ADVISORY LABELS 3, 8
    - Vigabatrin 500 mg Sabril 500mg tablets | 100 tablet £37.01 DT price = £37.01
  - Powder CAUTIONARY AND ADVISORY LABELS 3, 8, 13
    - Vigabatrin 500 mg Sabril 500mg oral powder sachets (sugar-free) | 50 sachet £20.50 DT price = £20.50

Zonisamide

INDICATIONS AND DOSE
Monotherapy for treatment of focal seizures with or without secondary generalisation in adults with newly diagnosed epilepsy

BY MOUTH
- Adult: Initially 100 mg once daily for 2 weeks, then increased in steps of 100 mg every 2 weeks, usual maintenance dose 300 mg once daily; maximum 500 mg per day

Adjunctive treatment for refractory focal seizures with or without secondary generalisation

BY MOUTH
- Child 6–17 years (body-weight 20–54 kg): Initially 1 mg/kg once daily for 7 days, then increased in steps of 1 mg/kg every 7 days (max. per dose 500 mg once daily), usual maintenance 6–8 mg/kg once daily, dose to be increased at 2-week intervals in patients who are not receiving concomitant carbamazepine, phenytoin, phenobarbital or other potent inducers of cytochrome P450 enzyme CYP3A4.
- Child 6–17 years (body-weight 55 kg and above): Initially 1 mg/kg once daily for 7 days, then increased in steps of 1 mg/kg every 7 days, usual maintenance 300–500 mg once daily, dose to be increased at 2-week intervals in patients who are not receiving concomitant carbamazepine, phenytoin, phenobarbital or other potent inducers of cytochrome P450 enzyme CYP3A4.
- Adult: Initially 50 mg daily in 2 divided doses for 7 days, then increased to 100 mg daily in 2 divided doses, then increased in steps of 100 mg every 7 days, usual maintenance 300–500 mg daily in 1–2 divided doses, dose to be increased at 2-week intervals in patients who are not receiving concomitant carbamazepine, phenytoin, phenobarbital or other potent inducers of cytochrome P450 enzyme CYP3A4.

- CAUTIONS Elderly - low body-weight or poor appetite—monitor weight throughout treatment (fatal cases of weight loss reported in children) - metabolic acidosis—monitor serum bicarbonate concentration in children and those with other risk factors (consider dose reduction or discontinuation if metabolic acidosis develops) - risk factors for renal stone formation (particularly predisposition to nephrolithiasis)
CAUTIONS, FURTHER INFORMATION
Avoid overheating and ensure adequate hydration especially in children, during strenuous activity or if in a warm environment (fatal cases of heat stroke reported in children).

- INTERACTIONS → Appendix 1 (zonisamide).
- In adults Caution with concomitant use of drugs that increase risk of hyperthermia, metabolic acidosis, or nephrolithiasis.
- In children Caution with concomitant use of drugs that increase risk of nephrolithiasis. Contraindicated with use of drugs that increase risk of hyperthermia or metabolic acidosis.

- SIDE-EFFECTS
  - Uncommon Aggression - cholecystitis - cholelithiasis - dyspepsia - hypokalaemia - pneumonia - seizures - suicidal ideation - urinary calculus - urinary tract infection - vomiting

- ALLERGY AND CROSS-SENSITIVITY

- CONCEPTION AND CONTRACEPTION
  Manufacturer advises women of childbearing potential should use adequate contraception during treatment and for 4 weeks after last dose.

- PREGNANCY
  The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

- BREAST FEEDING
  Manufacturer advises avoid for 4 weeks after last dose.

- HEPATIC IMPAIRMENT
  Initially increase dose at 2-week intervals if mild or moderate impairment. Avoid in severe impairment.

- RENAL IMPAIRMENT
  Initially increase dose at 2-week intervals; discontinue if renal function deteriorates.

- TREATMENT CESSATION
  Avoid abrupt withdrawal (consult product literature for recommended withdrawal regimens in children).

- PRESCRIBING AND DISPENSING INFORMATION
  Switching between formulations. Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.
  Patients may need to be maintained on a specific manufacturer’s branded or generic zonisamide product.

- PATIENT AND CARER ADVICE
  Medicines for Children leaflet: Zonisamide for preventing seizures www.medicinesforchildren.org.uk/zonisamide-for-preventing-seizures
  Children and their carers should be made aware of how to prevent and recognise overheating and dehydration.

- NATIONAL FUNDING/ACCESS DECISIONS
  Scottish Medicines Consortium (SMC) Decisions
  The Scottish Medicines Consortium has advised (February 2014) that zonisamide (Zonegran®) is accepted for restricted use within NHS Scotland as adjunctive treatment of focal seizures, with or without secondary generalisation, in adolescents and children aged 6 years and above. It is restricted to use on advice from specialists in paediatric neurology or epilepsy.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

  **Capsule**

  CAUTIONARY AND ADVISORY LABELS 3, 8, 10

  Zonisamide 25 mg Zonegran 25mg capsules | 14 capsule Pсте £8.82 DT price = £8.82
  Zonisamide 50 mg Zonegran 50mg capsules | 56 capsule Pсте £47.04 DT price = £47.04
  Zonisamide 100 mg Zonegran 100mg capsules | 56 capsule Pсте £62.72 DT price = £62.72

- BARBITURATES
  Phenobarbital (Phenobarbitalone)

  **INDICATIONS AND DOSE**

  All forms of epilepsy except typical absence seizures

  **BY MOUTH**

  - Child 1 month-11 years: Initially 1–1.5 mg/kg twice daily, then increased in steps of 2 mg/kg daily as required; maintenance 2.5–4 mg/kg 1–2 times a day
  - Child 12-17 years: 60–180 mg once daily, dose to be taken at night
  - Adult: 60–180 mg once daily, dose to be taken at night

  **Status epilepticus**

  **BY INTRAVENOUS INJECTION**

  - Adult: 10 mg/kg (max. per dose 1 g), dose to be administered at a rate not more than 100 mg/minute, injection to be diluted 1 in 10 with water for injections

  **BY SLOW INTRAVENOUS INJECTION**

  - Neonate: Initially 20 mg/kg, dose to be administered at a rate not faster than 1 mg/kg/minute, then 2.5–5 mg/kg 1–2 times a day
  - Child 1 month-11 years: Initially 20 mg/kg, dose to be administered at a rate not faster than 1 mg/kg/minute, then 2.5–5 mg/kg 1–2 times a day
  - Child 12-17 years: Initially 20 mg/kg (max. per dose 1 g), dose to be administered at a rate no faster than 1 mg/kg/minute, then 300 mg twice daily

  **Dose equivalence and conversion**

  For therapeutic purposes phenobarbital and phenobarbital sodium may be considered equivalent in effect.

- **CAUTIONS**
  Avoid in Acute porphyrias p. 654 - children - debilitated - elderly - history of alcohol abuse - history of drug abuse - respiratory depression (avoid if severe)

- **CAUTIONS, FURTHER INFORMATION**
  Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

- **INTERACTIONS → Appendix 1 (phenobarbital).**

- **SIDE-EFFECTS**
  - Common or very common Agranulocytosis - allergic skin reactions - ataxia - behavioural disturbances - cholestasis - depression - drowsiness - hallucinations - hepatitis - hyperactivity particularly in the elderly and in children - hypotension - impaired cognition - impaired memory -
irritability · lethargy · megaloblastic anaemia (may be treated with folic acid) · myasthenia · osteomalacia · paradoxical excitement (in adults) · respiratory depression · thrombocytopenia

▶ Very rare Antiepileptic Hypersensitivity Syndrome · Stevens-Johnson syndrome · suicidal ideation · toxic epidermal necrolysis

▶ Frequency not known Hyperkinesia (in children)

Οverdose For details on the management of poisoning, see Active elimination techniques, under Emergency treatment of poisoning p. 1123.

● ALLERGY AND CROSS-SENSITIVITY Antiepileptic hypersensitivity syndrome associated with phenobarbital. See under Epilepsy p. 383 for more information.

● PREGNANCY The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

● BREAST FEEDING Avoid if possible; drowsiness may occur.

● HEPATIC IMPAIRMENT May precipitate coma. Avoid in severe impairment.

● RENAL IMPAIRMENT Use with caution.

● MONITORING REQUIREMENTS

▶ Plasma–phenobarbital concentration for optimum response is 15–40 mg/litre (60–180 micrograms/ml); however, monitoring the plasma–drug concentration is less useful than with other drugs because tolerance occurs.

● TREATMENT CESSION Avoid abrupt withdrawal (dependence with prolonged use).

● DIRECTIONS FOR ADMINISTRATION Solution for injection must be diluted before intravenous administration.

▶ With intravenous use in children. For intravenous injection, dilute to a concentration of 20 mg/ml with Water for Injections; give over 20 minutes (no faster than 1 mg/kg/minute).

▶ With oral use in children. For administration by mouth, tablets may be crushed.

● PRESCRIBING AND DISPENSING INFORMATION

Switching between formulations. Different formulations of oral preparations may vary in bioavailability. Patients should be maintained on a specific manufacturer’s product. Some hospitals supply alcohol-free formulations of varying phenobarbital strengths.

● PATIENT AND CARER ADVICE

Medicines for Children leaflet: Phenobarbital for preventing seizures www.medicinesforchildren.org.uk/phenobarbital-for-preventing-seizures

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, tablet, capsule

Table

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 2, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PHENOBARBITAL (Non-proprietary)</td>
</tr>
<tr>
<td>Phenobarbital 15 mg Phenobarbital 15mg tablets</td>
<td>28 tablet (PO) £24.95 DT price + £24.61 Schedule 3 (CD No Register Phenobarbital)</td>
</tr>
<tr>
<td>Phenobarbital 30 mg Phenobarbital 30mg tablets</td>
<td>28 tablet (PO) £5.99 DT price + £0.97 Schedule 3 (CD No Register Phenobarbital)</td>
</tr>
<tr>
<td>Phenobarbital 60 mg Phenobarbital 60mg tablets</td>
<td>28 tablet (PO) £7.99 DT price + £6.58 Schedule 3 (CD No Register Phenobarbital)</td>
</tr>
</tbody>
</table>

Oral solution

| CAUTIONARY AND ADVISORY LABELS 2, 8 |
| PHENOBARBITAL (Non-proprietary) |
| Phenobarbital 3 mg per 1 ml Phenobarbital 15mg/5ml elixir | 500 ml (PO) £83.00 DT price + £83.00 Schedule 3 (CD No Register Phenobarbital) |

BENZODIAZEPINES

Clobazam

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

INDICATIONS AND DOSE

Adjunct in epilepsy

BY MOUTH

▶ Child 6–17 years: Initially 5 mg daily, dose to be increased if necessary at intervals of 5 days, maintenance 0.3–1 mg/kg daily, daily doses of up to 30 mg may be given as a single dose at bedtime; higher doses should be divided; maximum 60 mg per day

▶ Adult: 20–30 mg daily, then increased if necessary up to 60 mg daily

Anxiety (short-term use)

BY MOUTH

▶ Adult: 20–30 mg daily in divided doses, alternatively 20–30 mg once daily, dose to be taken at bedtime; increased if necessary up to 60 mg daily in divided doses, dose only increased in severe anxiety (in hospital patients), for debilitated patients, use elderly dose

▶ Elderly: 10–20 mg daily

● UNLICENSED USE Not licensed for use in children under 6 years. Not licensed as monotherapy.

● CONTRA-INDICATIONS Chronic psychosis (in adults) · hyperkinesia · not for use alone to treat anxiety associated with depression (in adults) · obsessive states · phobic states · respiratory depression

● CAUTIONS Muscle weakness · organic brain changes · personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

CAUTIONS, FURTHER INFORMATION

The effectiveness of clobazam may decrease significantly after weeks or months of continuous therapy.

● SIDE-EFFECTS

▶ Common or very common Amnesia · ataxia (especially in the elderly) · confusion (especially in the elderly) · dependence · drowsiness the next day · lightheadedness the next day · muscle weakness · paradoxical increase in aggression

▶ Uncommon Changes in libido (in adults) · dizziness · dystarthisia · gastro-intestinal disturbances · gynaecomastia · headache (in adults) · hypotension (in adults) · incontinence · salivation changes · slurred speech (in adults) · tremor · urinary retention (in adults) · vertigo (in adults) · visual disturbances

▶ Rare Apnoea · blood disorders · changes in libido (in children) · headache (in children) · hypotension (in children) · jaundice · respiratory depression · skin reactions · urinary retention (in children) · vertigo (in children)

▶ Frequency not known Delusions (in children) · excitement (in children) · hallucinations (in children) · irritability (in children) · psychosis (in children) · restlessness (in children)

● BREAST FEEDING Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding. All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.

● HEPATIC IMPAIRMENT Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.
■ RENAL IMPAIRMENT Start with small doses in severe impairment.

■ MONITORING REQUIREMENTS
>
• In children Routine measurement of plasma concentrations of antiepileptic drugs is not usually justified, because the target concentration ranges are arbitrary and often vary between individuals. However, plasma drug concentrations may be measured in children with worsening seizures, status epilepticus, suspected noncompliance, or suspected toxicity. Similarly, haematological and biochemical monitoring should not be undertaken unless clinically indicated.

■ TREATMENT CESSION
Antiepileptic drugs should be withdrawn under specialist supervision. Avoid abrupt withdrawal because this can precipitate severe rebound seizures. Reduction in dosage should be gradual.

The decision to withdraw antiepileptic drugs from a seizure-free patient, and its timing, is often difficult and depends on individual circumstances. Even in patients who have been seizure-free for several years, there is a significant risk of seizure recurrence on drug withdrawal. In patients receiving several antiepileptic drugs, only one drug should be withdrawn at a time.

• In children Drugs should be gradually withdrawn over at least 2–3 months by reducing the daily dose by 10–25% at intervals of 1–2 weeks. Benzodiazepines may need to be withdrawn over 6 months or longer.

■ PRESCRIBING AND DISPENSING INFORMATION
Switching between formulations Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic clobazam product.

■ PATIENT AND CARER ADVICE
Medicines for Children leaflet: Clobazam for preventing seizures www.medicinesforchildren.org.uk/ clobazam-preventing-seizures-0

■ NATIONAL FUNDING/ACCESS DECISIONS
NHS restrictions Clobazam is not prescribable under the NHS except for epilepsy and endorsed ‘SLS’.

■ MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, capsule

- Tablet
  CAUTIONARY AND ADVISORY LABELS 2, 19, 8
  • Clobazam (Non-proprietary)
    Clobazam 10 mg Clobazam 10mg tablets | 30 tablet [PO] £3.75 DT price = £2.99 Schedule 4 (CD Benz)
  ▶ Brands may include Frisium

- Oral suspension
  CAUTIONARY AND ADVISORY LABELS 2, 19, 8
  • Clobazam (Non-proprietary)
    Clobazam 1 mg per 1 ml Periarm 5mg/5ml oral suspension (sugar-free) | 150 ml [PO] £9.00 DT price = £128.61 Schedule 4 (CD Benz)
    Clobazam 2 mg per 1 ml Periarm 2mg/ml oral suspension (sugar-free) | 150 ml [PO] £9.50 DT price = £134.25 Schedule 4 (CD Benz)
  ▶ Brands may include Tapclob

Clonazepam

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

INDICATIONS AND DOSE
All forms of epilepsy

BY MOUTH
- Child 1-11 months: Initially 250 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 0.5–1 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary
- Child 1-4 years: Initially 250 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 1–3 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary
- Child 5-11 years: Initially 500 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary
- Child 12-17 years: Initially 1 mg once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary
- Adult: Initially 1 mg once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary
- Elderly: Initially 500 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary

■ UNLICENSED USE
- In children Clonazepam doses in BNFC may differ from those in product literature.
- In adults Clonazepam doses in BNF may differ from those in product literature.

■ CONTRA-INDICATIONS
Coma · current alcohol abuse · current drug abuse · respiratory depression

■ CAUTIONS
Acute porphyrias p. 864 · airways obstruction · brain damage · cerebellar ataxia · depression · spinal ataxia · suicidal ideation

CAUTIONS, FURTHER INFORMATION
The effectiveness of clonazepam may decrease significantly after weeks or months of continuous therapy.

■ SIDE-EFFECTS
- Common or very common Amnesia · bronchial hypersecretion in infants and small children · co-ordination disturbances · confusion · dependence · dizziness · drowsiness · fatigue · muscle hypotonia · nystagmus · poor concentration · restlessness · salivary hypersecretion in infants and small children · withdrawal symptoms (in children)
- Rare Aggression · anxiety · blood disorders · dysarthria · gastro-intestinal symptoms · headache · paradoxical effects · pruritus · respiratory depression · reversible hair loss · sexual dysfunction · skin pigmentation changes · suicidal ideation (in adults) · urinary incontinence · urticaria · visual disturbances on long-term treatment
- Very rare Increase in seizure frequency

■ BREAST FEEDING
Present in milk, and should be avoided if possible during breast-feeding. All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.

■ HEPATIC IMPAIRMENT
Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

■ RENAL IMPAIRMENT
Start with small doses in severe impairment.

■ MONITORING REQUIREMENTS
Routine measurement of plasma concentrations of antiepileptic drugs is not
6.2 Status epilepticus

**Drugs used for Status epilepticus not listed below:**
- *Diazepam*, p. 267
- *Phenobarbital*, p. 409
- *Phenytoin*, p. 398

### BARBITURATES

<table>
<thead>
<tr>
<th>Thiopental sodium (Thiopentone sodium)</th>
</tr>
</thead>
</table>

#### INDICATIONS AND DOSE

**Status epilepticus** (only if other measures fail)

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Status epilepticus</td>
<td>2.5% (25 mg/mL) solution</td>
</tr>
</tbody>
</table>

**Induction of anaesthesia**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial dose</td>
<td>75–125 mg for 1 dose, to be administered as a 2.5% (25 mg/mL) solution</td>
</tr>
<tr>
<td>Follow-up dose</td>
<td>100–150 mg after 0.5–1 minute if required, dose to be given in fit and premedicated adults; debilitated patients or adults over 65 years may require a lower dose or increased administration time, alternatively initially up to 4 mg/kg (max. per dose 500 mg)</td>
</tr>
</tbody>
</table>

#### Important safety information

Thiopental sodium should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- **CONTRA-INDICATIONS** Acute porphyrias p. 864 • myotonic dystrophy
- **CAUTIONS** Acute circulatory failure (shock) • avoid intra-arterial injection • cardiovascular disease • elderly • fixed cardiac output • hypovolaemia • reconstituted solution is highly alkaline (extravasation causes tissue necrosis and severe pain)
- **INTERACTIONS** → Appendix 1 (anaesthetics, general).
- **SIDE-EFFECTS** Arrhythmias • cough • headache • hypersensitivity reactions • hypotension • laryngeal spasm • myocardial depression • rash • sneezing
- **PREGNANCY** May depress neonatal respiration when used during delivery.
- **BREAST FEEDING** Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.
- **HEPATIC IMPAIRMENT** Use with caution—reduce dose.
- **RENAL IMPAIRMENT** Caution in severe impairment.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

- **MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral drops, oral solution, orodispersible tablet

**Powder for solution for injection**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiopental sodium 500 mg</td>
<td>Thiopental 500 mg powder for solution for injection vials</td>
</tr>
</tbody>
</table>

**MEDIATEA**

**Lorazepam**

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.
INDICATIONS AND DOSE

Status epilepticus | Febrile convulsions | Convulsions caused by poisoning

- **BY SLOW INTRAVENOUS INJECTION INTO LARGE VEIN**
  - Child 1 month-11 years: 100 micrograms/kg (max. per dose 4 mg) for 1 dose, then 100 micrograms/kg after 10 minutes (max. per dose 4 mg) if required for 1 dose
  - Child 12-17 years: 4 mg for 1 dose, then 4 mg after 10 minutes if required for 1 dose
  - Adult: 4 mg for 1 dose, then 4 mg after 10 minutes if required for 1 dose

- **Short-term use in anxiety**
  - BY MOUTH
    - Adult: 1–4 mg daily in divided doses, for debilitated patients, use elderly dose
    - Elderly: 0.5–2 mg daily in divided doses

- **Short-term use in insomnia associated with anxiety**
  - BY MOUTH
    - Adult: 1–2 mg daily, to be taken at bedtime

- **Acute panic attacks**
  - BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION
    - Adult: 25–30 micrograms/kg every 6 hours if required; usual dose 1.5–2.5 mg every 6 hours if required, intravenous injection to be administered into a large vein, only use intramuscular route when oral and intravenous routes not possible

- **Conscious sedation for procedures**
  - BY MOUTH
    - Adult: 2–3 mg, to be taken the night before operation; 2–4 mg, to be taken 1–2 hours before operation
  - BY SLOW INTRAVENOUS INJECTION
    - Adult: 50 micrograms/kg, to be administered 30–45 minutes before operation
  - BY INTRAMUSCULAR INJECTION
    - Adult: 50 micrograms/kg, to be administered 60–90 minutes before operation

- **Premedication**
  - BY MOUTH
    - Adult: 2–3 mg, to be taken the night before operation; 2–4 mg, to be taken 1–2 hours before operation
  - BY SLOW INTRAVENOUS INJECTION
    - Adult: 50 micrograms/kg, to be administered 30–45 minutes before operation
  - BY INTRAMUSCULAR INJECTION
    - Adult: 50 micrograms/kg, to be administered 60–90 minutes before operation

- **UNLICENSED USE**

- **FURTHER INFORMATION**
  - **ANAESTHESIA**
    - Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

- **CONTRA-INDICATIONS**
  - Avoid injections containing benzyl alcohol in neonates; chronic psychosis (in adults); CNS depression; compromised airway; hyperkinesia; not for use alone to treat depression (or anxiety associated with depression) (in adults); obsessional states; phobic states; respiratory depression

- **CAUTIONS**
  - Muscle weakness; organic brain changes; parenteral administration; personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

- **SIDE-EFFECTS**
  - Common or very common Amnesia - ataxia (in children) - ataxia (especially in the elderly) (in adults) - confusion (in children) - confusion (especially in the elderly) (in adults) - dependence - drowsiness the next day - lightheadedness - tremor - urinary retention (in adults) - vertigo (in adults) - visual disturbances
  - Rare - Apnoea - blood disorders - changes in libido (in children) - jaundice - marked respiratory depression, particularly with high dose and intravenous use (facilities for its treatment are essential) - pain (on intravenous injection) - psychosis (in children) - restlessness (in children) - thrombophlebitis (on intravenous injection)

- **PREGNANCY**
  - Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol. All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).

- **BREAST FEEDING**
  - Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Can precipitate coma. Start with smaller initial doses or reduce dose. If treatment is necessary, benzodiazepines with shorter half-lives are safer. Avoid in severe impairment.

- **RENAL IMPAIRMENT**
  - Start with small doses in severe impairment.

- **DIRECTIONS FOR ADMINISTRATION**
  - In children For intravenous injection, dilute with an equal volume of Sodium Chloride 0.9% (for neonates, dilute injection solution to a concentration of 100 micrograms/ml). Give over 3–5 minutes; max. rate 50 micrograms/kg over 3 minutes.
  - In adults For intramuscular injection, solution for injection should be diluted with an equal volume of water for injections or sodium chloride 0.9% (but only use when oral and intravenous routes not possible). For slow intravenous injection, solution for injection should preferably be diluted with an equal volume of water for injections or sodium chloride 0.9%.
Midazolam

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

**INDICATIONS AND DOSE**

**Status epilepticus | Febrile convulsions**

**BY BUCAL ADMINISTRATION**
- Child 1-2 months: 300 micrograms/kg (max. per dose 2.5 mg), then 300 micrograms/kg after 10 minutes (max. per dose 2.5 mg) if required
- Child 3-11 months: 2.5 mg, then 2.5 mg after 10 minutes if required
- Child 1-4 years: 5 mg, then 5 mg after 10 minutes if required
- Child 5-9 years: 7.5 mg, then 7.5 mg after 10 minutes if required
- Adult: 10 mg, then 10 mg after 10 minutes if required

**Conscious sedation for procedures**

**BY SLOW INTRAVENOUS INJECTION**
- Adult: Initially 2–2.5 mg, to be administered 5–10 minutes before procedure at a rate of approximately 2 mg/minute, increased in steps of 1 mg if required, usual total dose is 3.5–5 mg; maximum 7.5 mg per course
- Elderly: Initially 0.5–1 mg, to be administered 5–10 minutes before procedure at a rate of approximately 2 mg/minute, increased in steps of 0.5–1 mg if required; maximum 3.5 mg per course

**Sedative in combined anaesthesia**

**INITIALLY BY INTRAVENOUS INJECTION**
- Adult: 30–100 micrograms/kg, repeated if necessary, alternatively (by continuous intravenous infusion) 30–100 micrograms/kg/hour
- Elderly: Lower doses needed

**Premedication**

**BY DEEP INTRAVASCULAR INJECTION**
- Adult: 70–100 micrograms/kg, to be administered 20–60 minutes before induction, for debilitated patients, use elderly dose
- Elderly: 25–50 micrograms/kg, to be administered 20–60 minutes before induction

**BY INTRAVENOUS INJECTION**
- Adult: 1–2 mg, repeated if necessary, to be administered 5–30 minutes before procedure, for debilitated patients, use elderly dose
- Elderly: 0.5 mg, repeated if necessary, to be administered 5–30 minutes before procedure, repeat dose slowly as required

**Induction of anaesthesia (but rarely used)**

**BY SLOW INTRAVENOUS INJECTION**
- Adult: 150–200 micrograms/kg daily in divided doses (max. per dose 5 mg), dose to be given at intervals of 2 minutes, maximum total dose 600 micrograms/kg, for debilitated patients, use elderly dose
- Elderly: 50–150 micrograms/kg daily in divided doses (max. per dose 5 mg), dose to be given at intervals of 2 minutes, maximum total dose 600 micrograms/kg

**Sedation of patient receiving intensive care**

**INITIALLY BY SLOW INTRAVENOUS INJECTION**
- Adult: Initially 30–300 micrograms/kg, dose to be given in steps of 1–2.5 mg every 2 minutes, then (by slow intravenous injection or by continuous intravenous infusion) 30–200 micrograms/kg/hour, reduce dose (or reduce or omit initial dose) in hypovolaemia, vasoconstriction, or hypothermia, lower doses may be adequate if opioid analgesic also used

**Confusion and restlessness in palliative care**

**BY SUBCUTANEOUS INFUSION**
- Adult: Initially 10–20 mg/24 hours, adjusted according to response; usual dose 20–60 mg/24 hours

**Convolusions in palliative care**

**BY CONTINUOUS SUBCUTANEOUS INFUSION**
- Adult: Initially 20–40 mg/24 hours

**UNLICENSED USE** Oromucosal solution not licensed for use in children under 3 months. Oromucosal solution not licensed for use in adults over 18 years. Unlicensed oromucosal formulations are also available and may have different doses—refer to product literature. Injection not licensed for use in status epilepticus or febrile convulsions.


**Important safety information**

**ANAESTHESIA**

Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

**PRESCRIBING OF MIDAZOLAM IN PALLIATIVE CARE**

The use of high-strength midazolam (5 mg/mL in 2 mL and 10 mL ampoules, or 2 mg/mL in 5 mL ampoules) should be considered in palliative care and other situations where a higher strength may be more appropriate to administer the prescribed dose, and where the risk of overdosage has been assessed. It is advised that flumazenil is available when midazolam is used, to reverse the effects if necessary.

**CONTRA-INDICATIONS** CNS depression · compromised airway · severe respiratory depression
- **CAUTIONS** Cardiac disease - children (particularly if cardiovascular impairment) - concentration of midazolam in children under 15 kg not to exceed 1 mg/mL - debilitated patients (reduce dose) - hypothermia - hypovolaemia (risk of severe hypotension) - neonates - risk of airways obstruction and hypoventilation in children under 6 months (monitor respiratory rate and oxygen saturation) - vasoconstriction

**CAUTIONS, FURTHER INFORMATION**

**Recovery when used for sedation** Midazolam has a fast onset of action, recovery is faster than for other benzodiazepines such as diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing.

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Amnesia
- Anaphylaxis
- Ataxia
- Blood disorders
- Bronchospasm
- Cardiac arrest
- Changes in libido (in adults)
- Confusion
- Convulsions (more common in neonates)
- Depression of consciousness
- Dizziness
- Drowsiness
- Dry mouth
- Dysarthria
- Euphoria
- Fatigue (in children)
- Gastro-intestinal disturbances
- Hallucinations
- Headache
- Heart rate changes
- Hiccups
- Hypotension
- Incontinence
- Increased appetite
- Injection-site reactions
- Involuntary movements
- Jaundice
- Laryngospasm
- Muscle weakness
- Paradoxical aggression (especially in children and elderly)
- Paradoxical excitement (especially in children and elderly)
- Respiratory arrest (particularly with high doses or on rapid injection)
- Respiratory depression (may be severe with sedative and peri-operative use - facilities for its treatment are essential)
- Respiratory depression (particularly with high doses or on rapid injection)
- Restlessness (with sedative and peri-operative use) in children
- Salivation changes
- Sedation
- Seizures (afterwards).
- Side-effects of benzodiazepines such as diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing.
- **CAUTIONARY AND ADVISORY LABELS**

**SIDE-EFFECTS, FURTHER INFORMATION**

**Sedation** Midazolam is associated with profound sedation when high doses are given or when it is used with certain other drugs. Midazolam is not recommended for prolonged sedation in neonates; drug accumulation is likely to occur.

**Overdose** There have been reports of overdosage when high strength midazolam has been used for conscious sedation. The use of high-strength midazolam (5 mg/mL in 2 mL and 10 mL ampoules, or 2 mg/mL in 5 mL ampoules) should be restricted to general anaesthesia, intensive care, palliative care, or other situations where the risk has been assessed. It is advised that ifumazenil is available when midazolam is used, to reverse the effects if necessary.

**PREGNANCY** Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol. All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).

**BREAST FEEDING** Small amount present in milk—avoid breast-feeding for 24 hours after administration (although amount probably too small to be harmful after single doses).

**HEPATIC IMPAIRMENT** Use with caution particularly in sedative doses; can precipitate coma. For status epileptics and febrile convulsions: use with caution in mild to moderate impairment; avoid in severe impairment.

**RENAL IMPAIRMENT** Use with caution in chronic renal failure.

**DIRECTIONS FOR ADMINISTRATION**

**For intravenous infusion (Hynovel®)**, give continuously in Glucose 5% or Sodium Chloride 0.9%.

**For neonate and children under 15 kg** dilute to a concentration of 1 mg/mL.

**With intravenous use in children** For **intravenous injection** in status epilepticus and febrile convulsions, dilute with Glucose 5% or Sodium Chloride 0.9%; rapid intravenous injection (less than 2 minutes) may cause seizure-like myoclonus in preterm neonates.

**With intravenous use in neonates** Neonatal intensive care, dilute 15 mg/kg body-weight to a final volume of 50 mL with infusion fluid; an intravenous infusion rate of 0.1 mL/hour provides a dose of 30 micrograms/kg/hour.

**With oral use in children** For administration by mouth for sedation and premedication, injection solution may be diluted with apple or black currant juice, chocolate sauce, or cola.

**With rectal use in children** For **rectal administration** of the injection solution for sedation and premedication, attach a plastic applicator onto the end of a syringe; if the volume to be given rectally is too small, dilute with Water for Injections.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Midazolam for stopping seizures www.medicinesforchildren.org.uk/midazolam-for-stopping-seizures

Patients or carers should be given advice on how to administer midazolam oromucosal solution.

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of undertaking skilled tasks (e.g. driving) afterwards. For intravenous benzodiazepines the risk extends to at least 24 hours after administration.

Responsible persons should be available to take patients home afterwards. The dangers of taking alcohol should be emphasised.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, solution for injection, oral suspension, solution for infusion, oral solution, oromucosal solution, infusion

**Oromucosal solution**

**CAUTIONARY AND ADVISORY LABELS**

- **Buccolam (VistPharma Ltd)**
  - Midazolam (as Midazolam hydrochloride) 2 mg per 1 mL
  - Midazolam (as Midazolam hydrochloride) 5 mg per 1 mL
  - Midazolam (as Midazolam hydrochloride) 10 mg per 1 mL

**Solution for injection**

**MIDAZOLAM (Non-proprietary)**

- Midazolam (as Midazolam hydrochloride) 1 mg per 1 mL
- Midazolam (as Midazolam hydrochloride) 5 mg per 1 mL
- Midazolam (as Midazolam hydrochloride) 10 mg per 1 mL
7 Sleep disorders

7.1 Insomnia

Hypnotics and anxiolytics

Most hypnotics (‘sedatives’) will induce sleep when given at night and most hypnotics will sedate when given during the day. Prescribing of these drugs is widespread but dependence (both physical and psychological) and tolerance occur. This may lead to difficulty in withdrawing the drug after the patient has been taking it regularly for more than a week. Hypnotics and anxiolytics should therefore be reserved for short courses to alleviate acute conditions after causative factors have been established.

Benzodiazepines are the most commonly used anxiolytics and hypnotics; they act at benzodiazepine receptors which are associated with gamma-aminobutyric acid (GABA) receptors. Older drugs such as meprobamate and hypnotics; they act at benzodiazepine receptors which occur. This may lead to difficulty in withdrawing the drug dependence (both physical and psychological) and tolerance may vary from several months to a year or more.

Withdrawal of a benzodiazepine should be gradual because abrupt withdrawal may produce confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens.

The benzodiazepine withdrawal syndrome may develop at any time up to 3 weeks after stopping a long-acting benzodiazepine, but may occur within a day in the case of a short-acting one. It is characterised by insomnia, anxiety, loss of appetite and of body-weight, tremor, perspiration, tinnitus, and perceptual disturbances. Some symptoms may be similar to the original complaint and encourage further prescribing; some symptoms may continue for weeks or months after stopping benzodiazepines.

Benzodiazepine withdrawal should be flexible and carried out at a reduction rate that is tolerable for the patient. The rate should depend on the initial dose of benzodiazepine, duration of use, and the patient’s clinical response. Short-term users of benzodiazepines (2–4 weeks only) can usually taper off within 2–4 weeks. However, long-term users should be withdrawn over a much longer period of several months or more.

A suggested protocol for withdrawal for prescribed long-term benzodiazepine patients is as follows:

- Transfer patient stepwise, one dose at a time over about a week, to an equivalent daily dose of diazepam preferably taken at night.
- Reduce diazepam dose, usually by 1–2 mg every 2–4 weeks (in patients taking high doses of benzodiazepines, initially it may be appropriate to reduce the dose by up to one-tenth every 1–2 weeks). If uncomfortable withdrawal symptoms occur, maintain this dose until symptoms lessen.
- Reduce diazepam dose further, if necessary in smaller steps; steps of 500 micrograms may be appropriate towards the end of withdrawal. Then stop completely.
- For long-term patients, the period needed for complete withdrawal may vary from several months to a year or more.

Approximate equivalent doses, diazepam 5 mg
- alprazolam 250 micrograms
- clobazam 10 mg
- clonazepam 250 micrograms
- flurazepam 7.5–15 mg
- chlordiazepoxide 12.5 mg
- loprazolam 0.5–1 mg
- lorazepam 500 micrograms
- lormetazepam 0.5–1 mg
- nitrazepam 5 mg
- oxazepam 10 mg
- temazepam 10 mg

Withdrawal symptoms for long-term users usually resolve within 6–18 months of the last dose. Some patients will recover more quickly, others may take longer. The addition of beta-blockers, antidepressants and antipsychotics should be avoided where possible.

Counselling can be of considerable help both during and after the taper.

Hypnotics

Before a hypnotic is prescribed the cause of the insomnia should be established and, where possible, underlying factors should be treated. However, it should be noted that some patients have unrealistic sleep expectations, and others underestimate their alcohol consumption which is often the cause of the insomnia. Short-acting hypnotics are preferable in patients with sleep onset insomnia, when sedation the following day is undesirable, or when prescribing for elderly patients. Long-acting hypnotics are indicated in patients with poor sleep maintenance (e.g. early morning waking) that causes daytime effects, when an anxiolytic effect is needed during the day, or when sedation the following day is acceptable.

Transient insomnia may occur in those who normally sleep well and may be due to extraneous factors such as noise, shift work, and jet lag. If a hypnotic is indicated one that is rapidly eliminated should be chosen, and only one or two doses should be given.

Short-term insomnia is usually related to an emotional problem or serious medical illness. It may last for a few weeks and may recur; a hypnotic can be useful but should not be given for more than three weeks (preferably only one week). Intermittent use is desirable with omission of some doses. A short-acting drug is usually appropriate.
**Chronic insomnia** is rarely benefited by hypnotics and is sometimes due to mild dependence caused by injudicious prescribing of hypnotics. Psychiatric disorders such as anxiety, depression, and abuse of drugs and alcohol are common causes. Sleep disturbance is very common in depressive illness and early wakening is often a useful pointer. The underlying psychiatric complaint should be treated, adapting the drug regimen to alleviate insomnia. For example, clomipramine hydrochloride p. 294 or mirtazapine p. 291 prescribed for depression will also help to promote sleep if taken at night. Other causes of insomnia include daytime cat-napping and physical causes such as pain, pruritus, and dyspnoea.

Hypnotics should not be prescribed indiscriminately and routine prescribing is undesirable. They should be reserved for short courses in the acutely distressed. Tolerance to routine prescribing is undesirable. They should be reserved for patients because of its freedom from hangover but, as with drowsiness the following day. The sedative effect of their prolonged duration of action can often cause rebound insomnia and a withdrawal syndrome.

Where prolonged administration is unavoidable hypnotics should be discontinued as soon as feasible and the patient warned that sleep may be disturbed for a few days before normal rhythm is re-established; broken sleep with vivid dreams may persist for several weeks.

**Elderly**

Benzodiazepines and the Z drugs should be avoided in the elderly, because the elderly are at greater risk of becoming ataxic and confused, leading to falls and injury.

**Dental patients**

Some anxious patients may benefit from the use of hypnotics during dental procedures such as temazepam p. 420 or diazepam p. 267. Temazepam p. 420 is preferred when it is important to minimise any residual effect the following day.

**Benzodiazepines**

Benzodiazepines used as hypnotics include nitrazepam p. 419 and flurazepam p. 418 which have a prolonged action and may give rise to residual effects on the following day; repeated doses tend to be cumulative.

Lorazepam p. 418, lormetazepam p. 419, and temazepam p. 420 act for a shorter time and they have little or no hangover effect. Withdrawal phenomena are more common with the short-acting benzodiazepines.

If insomnia is associated with daytime anxiety then the use of a long-acting benzodiazepine anxiolytic such as diazepam p. 267 given as a single dose at night may effectively treat both symptoms.

**Zaleplon, zolpidem, and zopiclone**

Zaleplon p. 422, zolpidem tartrate p. 423 and zopiclone p. 423 are non-benzodiazepine hypnotics (sometimes referred to as Z drugs), but they act at the benzodiazepine receptor. They are not licensed for long-term use; dependence has been reported in a small number of patients. Zolpidem tartrate and zopiclone have a short duration of action; zaleplon is very short acting.

**Chloral and derivatives**

There is no convincing evidence that they are particularly useful in the elderly and their role as hypnotics is now very limited.

**Clomethiazole**

Clomethiazole p. 421 may be a useful hypnotic for elderly patients because of its freedom from hangover but, as with all hypnotics, routine administration is undesirable and dependence occurs.

**Antihistamines**

Some antihistamines such as promethazine hydrochloride p. 251 are on sale to the public for transient insomnia; their prolonged duration of action can often cause drowsiness the following day. The sedative effect of antihistamines may diminish after a few days of continued treatment; antihistamines are associated with headache, psychomotor impairment and antimuscarinic effects.

**Alcohol**

Alcohol is a poor hypnotic because the diuretic action interferes with sleep during the latter part of the night. Alcohol also disturbs sleep patterns, and so can worsen sleep disorders.

**Melatonin**

Melatonin p. 422 is a pineal hormone; it is licensed for the short-term treatment of insomnia in adults over 55 years.

**Anxiolytics**

Benzodiazepine anxiolytics can be effective in alleviating anxiety states. Although these drugs are sometimes prescribed for stress-related symptoms, unhappiness, or minor physical disease, their use in such conditions is inappropriate. Benzodiazepine anxiolytics should not be used as sole treatment for chronic anxiety, and they are not appropriate for treating depression or chronic psychosis. In bereavement, psychological adjustment may be inhibited by benzodiazepines.

Anxiolytic benzodiazepine treatment should be limited to the lowest possible dose for the shortest possible time. Dependence is particularly likely in patients with a history of alcohol or drug abuse and in patients with marked personality disorders.

Some antidepressant drugs are licensed for use in anxiety and related disorders. Some antipsychotic drugs, in low doses, are also sometimes used in severe anxiety for their sedative action, but long-term use should be avoided because of the risk of adverse effects. The use of antihistamines (e.g. hydroxyzine hydrochloride p. 248) for their sedative effect in anxiety is not appropriate.

**Beta-adrenoceptor blocking drugs**

These do not affect psychological symptoms of anxiety, such as worry, tension, and fear, but they do reduce autonomic symptoms, such as palpitation and tremor; they do not reduce non-autonomic symptoms, such as muscle tension. Beta-blockers are therefore indicated for patients with predominantly somatic symptoms; this, in turn, may prevent the onset of worry and fear.

**Benzodiazepines**

Benzodiazepines are indicated for the short-term relief of severe anxiety; long-term use should be avoided. Diazepam p. 267, alprazolam p. 266, clorazepate hydrochloride p. 267, and clobazam p. 410 have a sustained action. Shorter-acting compounds such as lorazepam p. 412 and oxazepam p. 420 may be preferred in patients with hepatic impairment but they carry a greater risk of withdrawal symptoms.

In panic disorders (with or without agoraphobia) resistant to antidepressant therapy, a benzodiazepine may be used; alternatively, a benzodiazepine may be used as short-term adjunctive therapy at the start of antidepressant treatment to prevent the initial worsening of symptoms.

Diazepam p. 267 or lorazepam p. 412 are very occasionally administered intravenously for the control of panic attacks. This route is the most rapid but the procedure is not without risk and should be used only when alternative measures have failed. The intramuscular route has no advantage over the oral route.

**Buspirone**

Buspirone hydrochloride p. 269 is thought to act at specific serotonin (5HT1A) receptors. Response to treatment may take up to 2 weeks. It does not alleviate the symptoms of benzodiazepine withdrawal. Therefore a patient taking a benzodiazepine still needs to have the benzodiazepine withdrawn gradually; it is advisable to do this before starting buspirone hydrochloride. The dependence and abuse potential of buspirone hydrochloride is low; it is,
however, licensed for short-term use only (but specialists occasionally use it for several months).

**Meprobamate**
Meprobamate p. 265 is less effective than the benzodiazepines, more hazardous in overdosage, and can also induce dependence. It is not recommended.

**Barbiturates**
The intermediate-acting barbiturates have a place only in the treatment of severe intractable insomnia in patients already taking barbiturates; they should be avoided in the elderly. Intermediate-acting barbiturate preparations containing amobarbital sodium, butobarbital, and secobarbital sodium are available on a named patient basis. The long-acting barbiturate phenobarbital is still sometimes of value in epilepsy but its use as a sedative is unjustified.

The very short-acting barbiturate thiopental sodium p. 412 is used in anaesthesia. Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.

**SIDE-EFFECTS**
- Common or very common: Amnesia, ataxia (especially in the elderly), confusion (especially in the elderly), drowsiness, headache, hypotension, incontinence, lightheadedness, sleep disturbance, tremor, urinary retention, vertigo, visual disturbances
- Uncommon: Changes in libido, dizziness, dysarthria, gastro-intestinal disturbances, gynaecomastia, headache, hyponatraemia, incontinence, salivation changes, slurred speech, tremor, urinary retention, vertigo, visual disturbances
- Rare: Anorexia, blood disorders, jaundice, respiratory depression, skin reactions
- **BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.
- **HEPATIC IMPAIRMENT** Avoid in severe impairment. Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer.
- **RENAL IMPAIRMENT** Start with small doses in severe impairment.
- **PATIENT AND CARER ADVICE** May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.
- **NATIONAL FUNDING/ACCESS DECISIONS** Flurazepam capsules are not prescribable under the NHS.
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Drugs used for Insomnia not listed below; Diazepam, p. 267 · Promethazine hydrochloride, p. 251**

### BENZODIAZEPINES

#### Flurazepam

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

**BY MOUTH**
- **Adult:** 15–30 mg once daily, dose to be taken at bedtime, for debilitated patients, use elderly dose
- **Elderly:** 15 mg once daily, dose to be taken at bedtime

**CONTRA-INDICATIONS**
- Not for use alone to treat chronic psychosis, not for use alone to treat depression (or anxiety associated with depression) · respiratory depression

**CAUTIONS**
- Acute porphyrias p. 864 · hypoaalbuminaemia · marked personality disorder · muscle weakness

**CAUTIONS, FURTHER INFORMATION**

**Paradoxical effects**

A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

**SIDE-EFFECTS**
- Common or very common: Amnesia, ataxia (especially in the elderly), confusion (especially in the elderly), drowsiness the next day, lightheadedness the next day, muscle weakness, paradoxical increase in aggression
- Uncommon: Changes in libido, dizziness, dysarthria, gastro-intestinal disturbances, gynaecomastia, headache, hypotension, incontinence, salivation changes, slurred speech, tremor, urinary retention, vertigo, visual disturbances
- Rare: Anorexia, blood disorders, jaundice, respiratory depression, skin reactions

**BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

**HEPATIC IMPAIRMENT**

If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Start with smaller...
initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

- **RENAL IMPAIRMENT** Start with small doses in severe impairment.

- **PATIENT AND CARER ADVICE** May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

- **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  
  CAUTIONARY AND ADVISORY LABELS 19
  
  - **Loprazolam (Non-proprietary)**
  
  Loprazolam (as Loprazolam mesilate) 1 mg Loprazolam 1mg tablets | 28 tablet [PO] £18.00 DT price = £18.00 Schedule 4 (CD Benz)


**Lormetazepam**

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

**BY MOUTH**

- Adult: 0.5–1.5 mg once daily, dose to be taken at bedtime, for debilitated patients, use elderly dose
- Elderly: 500 micrograms once daily, dose to be taken at bedtime

- **CONTRA-INDICATIONS** Not for use alone to treat chronic psychosis - not for use alone to treat depression (or anxiety associated with depression) - respiratory depression

- **CAUTIONS** Acute porphyrias p. 864 - hypoalbuminaemia - marked personality disorder - muscle weakness

**CAUTIONS, FURTHER INFORMATION**

**Paradoxical effects** A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

- **SIDE-EFFECTS**
  
  - **Common or very common** Amnesia - ataxia (especially in the elderly) - confusion (especially in the elderly) - dependence - drowsiness the next day - lightheadedness the next day - muscle weakness - paradoxical increase in aggression
  
  - **Uncommon** Changes in libido - dizziness - dysarthria - gastro-intestinal disturbances - gynaecomastia - headache - hypotension - incontinence - salivation changes - slurred speech - tremor - urinary retention - vertigo - visual disturbances
  
  - **Rare** Apnoea - blood disorders - jaundice - respiratory depression - skin reactions

- **BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

- **HEPATIC IMPAIRMENT** If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

- **RENAL IMPAIRMENT** Start with small doses in severe impairment.

- **PATIENT AND CARER ADVICE** May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol.

**Nitrazepam**

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

**BY MOUTH**

- Adult: 5–10 mg daily, dose to be taken at bedtime, for debilitated patients, use elderly dose
- Elderly: 2.5–5 mg daily, dose to be taken at bedtime

- **CONTRA-INDICATIONS** Not for use alone to treat depression (or anxiety associated with depression) - respiratory depression

- **CAUTIONS** Acute porphyrias p. 864 - hypoalbuminaemia - marked personality disorder - muscle weakness

- **CAUTIONS, FURTHER INFORMATION**

  **Paradoxical effects** A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

- **SIDE-EFFECTS**
  
  - **Common or very common** Amnesia - ataxia (especially in the elderly) - confusion (especially in the elderly) - dependence - drowsiness the next day - lightheadedness the next day - muscle weakness - paradoxical increase in aggression
  
  - **Uncommon** Changes in libido - dizziness - dysarthria - gastro-intestinal disturbances - gynaecomastia - headache - hypotension - incontinence - salivation changes - slurred speech - tremor - urinary retention - vertigo - visual disturbances
  
  - **Rare** Apnoea - blood disorders - jaundice - respiratory depression - skin reactions

- **BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

- **HEPATIC IMPAIRMENT** If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

- **RENAL IMPAIRMENT** Start with small doses in severe impairment.

- **PATIENT AND CARER ADVICE** May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol.
Moreover the hangover effects of a night dose may impair driving on the following day.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 19**

- NITRAZEPAM (Non-proprietary)
  - Nitrazepam 5 mg Nitrazepam 5mg tablets | 28 tablet (PSt) £10.55
    - Schedule 4 (CD Benz)
  - Brains may include Mogadon

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 19**

- NITRAZEPAM (Non-proprietary)
  - Nitrazepam 500 microgram per 1 ml Nitrazepam 2.5mg/5ml oral suspension | 150 ml (PSt) £10.60

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2**

- OXAZEPAM (Non-proprietary)
  - Oxazepam 10 mg Oxazepam 10mg tablets | 28 tablet (PSt) £13.00
    - Schedule 4 (CD Benz)
  - Oxazepam 15 mg Oxazepam 15mg tablets | 28 tablet (PSt) £14.50
    - Schedule 4 (CD Benz)

Oxazepam

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

**INDICATIONS AND DOSE**

***Anxiety (short-term use)***

**BY MOUTH**

- Adult: 15–30 mg 3–4 times a day, for debilitated patients, use elderly dose
- Elderly: 10–20 mg 3–4 times a day

***Insomnia associated with anxiety***

**BY MOUTH**

- Adult: 15–25 mg once daily (max. per dose 50 mg), dose to be taken at bedtime

**CONTRA-INDICATIONS**

Chronic psychosis · hyperkinesia · not for use alone to treat depression (or anxiety associated with depression) · obsessional states · phobic states · respiratory depression

**CAUTIONS**

Muscle weakness · organic brain changes · personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

**CAUTIONS, FURTHER INFORMATION**

Paradoxical effects A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

**SIDE-EFFECTS**

- Common or very common Amnesia · ataxia (especially in the elderly) · confusion (especially in the elderly) · dependence · drowsiness the next day · lightheadedness the next day · muscle weakness · paradoxical increase in aggression
- Uncommon Changes in libido · dizziness · dysarthria · gastro-intestinal disturbances · gynaecomastia · headache · hypotension · incontinence · salivation changes · slurred speech · tremor · urinary retention · vertigo · visual disturbances
- Rare Apnoea · blood disorders · jaundice · respiratory depression · skin reactions

**BREAST FEEDING**

Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

**HEPATIC IMPAIRMENT**

If treatment is necessary, benzodiazepines with shorter half-lives are safer. Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

**RENAL IMPAIRMENT**

Start with small doses in severe impairment.

**PATIENT AND CARER ADVICE**

May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 19**

- TEMAZEPAM (Non-proprietary)
  - Temazepam 15 mg Temazepam 15mg tablets | 28 tablet (PSt) £13.00
    - Schedule 4 (CD Benz)
  - Temazepam 20 mg Temazepam 20mg tablets | 28 tablet (PSt) £14.50
    - Schedule 4 (CD Benz)

Temazepam

The properties listed below are those particular to the drug only. For properties common to the class, see Benzodiazepines, p. 266.

**INDICATIONS AND DOSE**

***Insomnia (short-term use)***

**BY MOUTH**

- Adult: 10–20 mg once daily, alternatively 30–40 mg once daily, higher dose range only to be administered in exceptional circumstances, dose to be taken at bedtime, for debilitated patients, use elderly dose
- Elderly: 10 mg once daily, alternatively 20 mg once daily, higher dose only to be administered in exceptional circumstances, dose to be taken at bedtime

**Conscious sedation for dental procedures**

**BY MOUTH**

- Adult: 15–30 mg, to be administered 30–60 minutes before procedure

**Premedication before surgery or investigatory procedures**

**BY MOUTH**

- Adult: 10–20 mg, to be taken 1–2 hours before procedure, alternatively 30 mg, to be taken 1–2 hours before procedure, higher alternate dose only administered in exceptional circumstances
- Elderly: 10 mg, to be taken 1–2 hours before procedure, alternatively 20 mg, to be taken 1–2 hours before procedure, higher alternate dose only administered in exceptional circumstances

**UNLICENSED USE**

Temazepam doses in BNF may differ from those in product literature. Not licensed for conscious sedation for dental procedures.

**CONTRA-INDICATIONS**

CNS depression · compromised airway · hyperkinesia · not for use alone to treat chronic psychosis · not for use alone to treat depression (or anxiety associated with depression) · obsessional state · phobic state · respiratory depression

**CAUTIONS**

Hypoaalbuminaemia · muscle weakness · organic brain changes · personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive)—may increase risk of dependence

**CAUTIONS, FURTHER INFORMATION**

Paradoxical effects A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.
Medicinal forms

Common or very common
- Amnesia • ataxia (especially in the elderly) • confusion (especially in the elderly) • dependence • drowsiness the next day • lightheadedness the next day • muscle weakness • paradoxical increase in aggression

Uncommon
- Changes in libido • diziness • dysarthria • gastro-intestinal disturbances • gynaecomastia • headache • hypotension • incontinence • salivation changes • slurred speech • tremor • urinary retention • vertigo • visual disturbances

Rare
- Apnoea • blood disorders • jaundice • skin reactions

Frequency not known
- Respiratory depression (may be marked when used for sedation; facilities for its treatment are essential)

Breast feeding
- Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

Hepatic impairment
- If treatment is necessary, benzodiazepines with shorter half-lives are safer. Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

Renal impairment
- Start with small doses in severe impairment.

Patient and carer advice
- May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair functioning on the following day.
- Patients given sedatives and analgesics during minor procedures should be emphasised.
- Avoid contact with mucous membranes.
- Avoid prolonged use (and abrupt withdrawal thereafter).

Cautionary and advisory labels
- There can be variation in the licensing of different medicines manufactured by different companies. Forms available from special-order manufacturers include: oral solution, oral suspension, elixir.

Contra-indications
- Acute porphyrias
- Gastritis
- Severe cardiac disease

Caution
- Avoid contact with mucous membranes.
- Avoid contact with skin.
- Avoid prolonged use (and abrupt withdrawal thereafter).
- Reduce dose in debilitated/reduce dose in elderly

Interactions
- Appendix 1 (anxiolytics and hypnotics).

Side-effects
- Abdominal distention • delirium (especially on abrupt withdrawal) • dependence • excitement • flatulence • gastric irritation • headache • ketonuria • nausea • rash • tolerance • vomiting

Pregnancy
- Avoid.

Breast feeding
- Risk of sedation in infant—avoid.

Hepatic impairment
- Reduce dose in mild to moderate impairment.
- Can precipitate coma. Avoid in severe impairment.

Renal impairment
- Avoid in severe impairment.

Directions for administration
- With oral use for administration by mouth dilute liquid with plenty of water or juice to mask unpleasant taste.

Prescribing and dispensing information
- Flavours of oral liquid formulations may include blackcurrant. When prepared extemporaneously, the BP states Chloral Mixture, BP 2000 consists of chloral hydrate 500 mg/5 ml in a suitable vehicle.

Patient and carer advice
- Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

Less suitable for prescribing
- Chloral hydrate is less suitable for prescribing in insomnia.

Medicinal forms
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, oral suspension, oral solution, enema.

Tablet
- CAUTIONARY AND ADVISORY LABELS 19
  - TEMAZEPAM (Non-proprietary)
    - Temazepam 10 mg: 28 tablets
      - E5.05 (100) Schedule 3 (CD No Register)
    - 500 tablet: £6.24 (28) Schedule 3 (CD No Register)
    - Temazepam 20 mg: 28 tablets
      - E5.35 (100) Schedule 3 (CD No Register)
      - 250 tablet: £3.07 (150) Schedule 3 (CD No Register)

Oral solution
- CAUTIONARY AND ADVISORY LABELS 19
  - TEMAZEPAM (Non-proprietary)
    - Temazepam 2 mg per 5 ml: 300 ml sugar-free (sugar-free)
      - E8.45 (300) Schedule 3 (CD No Register)

CNS depressants

Chloral hydrate

Indications and dose
- Insomnia (short-term use)
  - BY MOUTH USING ORAL SOLUTION
    - Adult: 0.5–2 g daily, dose to be taken at bedtime
  - WELLDOM® ELIXIR
  - Insomnia (short-term use)
  - BY MOUTH
    - Adult: 15–45 ml, alternatively 0.4–1.3 g, dose to be taken with water or milk at bedtime; maximum 70 ml per day; maximum 2 g per day

Contra-indications
- Severe insomnia
- Approach the elderly with caution

Caution
- Avoid contact with mucous membranes
- Avoid contact with skin
- Avoid prolonged use (and abrupt withdrawal thereafter)
- Reduce dose in debilitated/reduce dose in elderly

Interactions
- Appendix 1 (anxiolytics and hypnotics)

Side-effects
- Abdominal distention • delirium (especially on abrupt withdrawal) • dependence • excitement • flatulence • gastric irritation • headache • ketonuria • nausea • rash • tolerance • vomiting

Pregnancy
- Avoid

Breast feeding
- Risk of sedation in infant—avoid

Hepatic impairment
- Reduce dose in mild to moderate impairment
- Can precipitate coma. Avoid in severe impairment

Renal impairment
- Avoid in severe impairment

Directions for administration
- With oral use for administration by mouth dilute liquid with plenty of water or juice to mask unpleasant taste

Prescribing and dispensing information
- Flavours of oral liquid formulations may include blackcurrant. When prepared extemporaneously, the BP states Chloral Mixture, BP 2000 consists of chloral hydrate 500 mg/5 ml in a suitable vehicle

Patient and carer advice
- Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

Less suitable for prescribing
- Chloral hydrate is less suitable for prescribing in insomnia

Medicinal forms
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, oral suspension, oral solution, enema

Tablet
- CAUTIONARY AND ADVISORY LABELS 19
  - CHLORAL HYDRATE (Non-proprietary)
    - Chloral betaine 707 mg: 30 tablets £68.00–£123.03 DT price = £110.06

Oral solution
- CAUTIONARY AND ADVISORY LABELS 19
  - CHLORAL HYDRATE (Non-proprietary)
    - Chloral hydrate 28.66 mg per 1 ml: 150 ml £120.00–£126.74 DT price = £194.06

Crystals
- CHLORAL HYDRATE (Non-proprietary)
  - Chloral hydrate 1 mg per 1 mg: 100 gram £11.14 DT price = £11.14

Clomethiazole (Chloromethiazole)

Indications and dose
- Severe insomnia (short-term use)
  - BY MOUTH USING CAPSULES
    - Elderly: 192–384 mg daily, dose to be taken at bedtime
  - BY MOUTH USING ORAL SOLUTION
    - Elderly: 5–10 mL daily, dose to be taken at bedtime

Restlessness and agitation
- BY MOUTH USING CAPSULES
  - Elderly: 192 mg 3 times a day
  - BY MOUTH USING ORAL SOLUTION
  - Elderly: 5 mL 3 times a day

Alcohol withdrawal
- Initially by mouth using capsules
  - Adult: Initially 2–4 capsules, to be repeated if necessary after some hours, then by mouth continued →
422 Sleep disorders

9–12 capsules daily in 3–4 divided doses for day 1 (first 24 hours), then (by mouth) 6–8 capsules daily in 3–4 divided doses for day 2, then (by mouth) 4–6 capsules daily in 3–4 divided doses for day 3, dose then to be gradually reduced over days 4–6, total treatment for not more than 9 days

BY MOUTH USING ORAL SOLUTION
- Adult: Initially 10–20 mL, to be repeated if necessary after some hours, then 45–60 mL daily in 3–4 divided doses for day 1 (first 24 hours), then 30–40 mL daily in 3–4 divided doses for day 2, then 20–30 mL daily in 3–4 divided doses for day 3, dose then to be gradually reduced over days 4–6, total treatment for not more than 9 days

Dose equivalence and conversion
1 capsule contains 192 mg of clomethiazole base.

- CONTRA-INDICATIONS Acute pulmonary insufficiency - alcohol-dependent patients who continue to drink
- CAUTIONS Avoid prolonged use (and abrupt withdrawal therapy) - cardiac disease (confusional state may indicate hypoxia) - chronic pulmonary insufficiency - elderly - excessive sedation may occur (particularly with higher doses) - history of drug abuse - marked personality disorder - respiratory disease (confusional state may indicate hypoxia) - sleep apnoea syndrome
- INTERACTIONS ➔ Appendix 1 (anxiolytics and hypnotics).
- SIDE-EFFECTS
  - Common or very common Conjunctival irritation - headache - increased bronchial secretions - increased nasopharyngeal secretions - nasal congestion - nasal irritation
  - Rare Alterations in liver enzymes - anaphylaxis - bullous eruption - confusion - dependence - gastro-intestinal disturbances - paradoxical excitement - rash - urticaria
- PREGNANCY Avoid if possible—especially during the first and third trimesters.
- BREAST FEEDING Use only if benefit outweighs risk—present in breast milk but effects unknown.
- HEPATIC IMPAIRMENT Reduce dose. Can precipitate coma.
- RENAL IMPAIRMENT Increased cerebral sensitivity. Start with small doses in severe impairment.
- PATIENT AND CARER ADVICE Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  Capsule
  CAUTIONARY AND ADVISORY LABELS 19
  - CLOMETHIAZOLE (Non-proprietary)
    Clomethiazole 192 mg Clomethiazole 192mg capsules | 60 capsule [PO] £23.00 DT price = £20.00
  Oral solution
  CAUTIONARY AND ADVISORY LABELS 19
  EXCIPIENTS: May contain Alcohol
  - CLOMETHIAZOLE (Non-proprietary)
    Clomethiazole (as Clomethiazole edisilate) 50 mg per 1 ml Clomethiazole 31.5mg/ml oral solution sugar free (sugar-free) | 300 ml [PO] £20.00–£22.00

Melatonin

INDICATIONS AND DOSE
Insomnia (short-term use)

BY MOUTH USING MODIFIED-RELEASE TABLETS
- Adult 55 years and over: 2 mg once daily for up to 13 weeks, dose to be taken 1–2 hours before bedtime

- CAUTIONS Autoimmune disease (manufacturer advises avoid—no information available)
- INTERACTIONS ➔ Appendix 1 (melatonin).
- SIDE-EFFECTS
- Frequency not known Galactorrhoea - mouth oedema - tongue oedema
- PREGNANCY No information available—avoid.
- BREAST FEEDING Present in milk—avoid.
- HEPATIC IMPAIRMENT Clearance reduced—avoid.
- RENAL IMPAIRMENT No information available—use with caution.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, modified-release capsule, oral solution, capsule, orodispersible tablet

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 2, 21, 25
- Circadin (Flynn Pharma Ltd)
  Melatonin 2 mg Circadin 2mg modified-release tablets | 30 tablet [PO] £15.39 DT price = £15.39

Zaleplon

INDICATIONS AND DOSE
Insomnia (short-term use)

BY MOUTH
- Adult: 10 mg daily for up to 2 weeks, dose to be taken at bedtime or after going to bed if difficulty falling asleep
- Elderly: 5 mg daily for up to 2 weeks, dose to be taken at bedtime or after going to bed if difficulty falling asleep

- CONTRA-INDICATIONS Marked neuromuscular respiratory weakness - sleep apnoea syndrome - unstable myasthenia gravis
- CAUTIONS Avoid prolonged use (risk of tolerance and withdrawal symptoms) - depression (risk of suicidal ideation) - history of alcohol abuse - history of drug abuse - muscle weakness - myasthenia gravis - respiratory insufficiency (avoid if severe)
- INTERACTIONS ➔ Appendix 1 (anxiolytics and hypnotics).
- SIDE-EFFECTS
  - Common or very common Annesia - drowsiness - dysmenorrhea - paraesthesia
  - Uncommon Anorexia - asthenia - confusion - depersonalisation - depression - disturbances of hearing - disturbances of smell - disturbances of speech - disturbances of vision - dizziness - hallucinations - impaired concentration - incoordination - nausea - photosensitivity
- Frequency not known Paradoxical effects - sleep-walking

SIDE-EFFECTS, FURTHER INFORMATION
Paradoxical effects A paradoxical increase in hostility and aggression may be reported. The effects range from...
talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects. Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.

- **PREGNANCY** Use only if necessary and restrict to occasional short-term use. Risk of withdrawal symptoms in neonate if used in late pregnancy.
- **BREAST FEEDING** Present in milk but amount probably too small to be harmful.
- **HEPATIC IMPAIRMENT** Reduce dose to 5 mg. Can precipitate coma. Avoid if severe impairment.
- **RENAI IMPAIRMENT** Avoid in severe impairment.
- **PATIENT AND CARER ADVICE** Patients should be advised not to take a second dose during a single night.

### NATIONAL FUNDING/ACCESS DECISIONS

- **NICE technology appraisals (TAs)**
  - Zaleplon, zolpidem, and zopiclone for the short-term management of insomnia (April 2004) NICE TA77

Zaleplon is recommended for the short-term management of severe insomnia that interferes with normal daily life, and should be prescribed for short periods of time only. [www.nice.org.uk/TA77](http://www.nice.org.uk/TA77)

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- CAUTIONARY AND ADVISORY LABELS 2
  - Sonata (Meda Pharmaceuticals Ltd)
    - Zaleplon 5 mg: Sonata 5 mg capsules | 14 capsule £3.12 DT price = £3.12 Schedule 4 (CD Benz)
    - Zaleplon 10 mg: Sonata 10 mg capsules | 14 capsule £3.76 DT price = £3.76 Schedule 4 (CD Benz)

### Zolpidem tartrate

#### INDICATIONS AND DOSE

**Insomnia (short-term use)**

**BY MOUTH**

- Adult: 10 mg daily for up to 4 weeks, dose to be taken at bedtime, for debilitated patients, use elderly dose
- Elderly: 5 mg daily for up to 4 weeks, dose to be taken at bedtime

- **CONTRA-INDICATIONS** Acute respiratory depression - marked neuromuscular respiratory weakness - obstructive sleep apnoea - psychotic illness - severe respiratory depression - unstable myasthenia gravis
- **CAUTIONS** Avoid prolonged use (and abrupt withdrawal thereafter) - depression - elderly - history of alcohol abuse - history of drug abuse - muscle weakness - myasthenia gravis
- **INTERACTIONS** → Appendix 1 (anxiolytics and hypnotics).

**SIDE-EFFECTS, FURTHER INFORMATION**

**Paradoxical effects** A paradoxical increase in hostility and aggression may be reported. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects. Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.

- **PREGNANCY** Avoid regular use (risk of neonatal withdrawal symptoms); high doses during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.
- **BREAST FEEDING** Small amounts present in milk—avoid.
- **HEPATIC IMPAIRMENT** Reduce dose to 5 mg. Can precipitate coma. Avoid if severe impairment.
- **RENAI IMPAIRMENT** Use with caution.
- **PATIENT AND CARER ADVICE** Drowsiness may persist the next day—leave at least 8 hours between taking zolpidem and performing skilled tasks (e.g. driving, or operating machinery); effects of alcohol and other CNS depressants enhanced.

### NATIONAl FUNDING/ACCESS DECISIONS

- **NICE technology appraisals (TAs)**
  - Zaleplon, zolpidem, and zopiclone for the short-term management of insomnia (April 2004) NICE TA77

Zopiclone is recommended for the short-term management of severe insomnia that interferes with normal daily life, and should be prescribed for short periods of time only. [www.nice.org.uk/TA77](http://www.nice.org.uk/TA77)

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: powder

**Tablet**

- CAUTIONARY AND ADVISORY LABELS 19
  - ZOLPIDEM TARTRATE (Non-proprietary)
    - Zolpidem tartrate 5 mg: Zolpidem 5 mg tablets | 28 tablet £3.08 DT price = £3.75 Schedule 4 (CD Benz)
    - Zolpidem tartrate 10 mg: Zolpidem 10 mg tablets | 28 tablet £4.48 DT price = £1.57 Schedule 4 (CD Benz)
    - Stilnoct (Sanofi)
      - Zolpidem tartrate 5 mg: Stilnoct 5 mg tablets | 28 tablet £1.10 DT price = £1.75 Schedule 4 (CD Benz)
      - Zolpidem tartrate 10 mg: Stilnoct 10 mg tablets | 28 tablet £1.00 DT price = £1.57 Schedule 4 (CD Benz)

### Zopiclone

#### INDICATIONS AND DOSE

**Insomnia (short-term use)**

**BY MOUTH**

- Adult: 7.5 mg once daily for up to 4 weeks, dose to be taken at bedtime
- Elderly: Initially 3.75 mg once daily for up to 4 weeks, dose to be taken at bedtime, increased if necessary to 7.5 mg daily

**Insomnia (short-term use) in patients with chronic pulmonary insufficiency**

**BY MOUTH**

- Adult: Initially 3.75 mg once daily for up to 4 weeks, dose to be taken at bedtime, increased if necessary to 7.5 mg daily

- **CONTRA-INDICATIONS** Marked neuromuscular respiratory weakness - respiratory failure - severe sleep apnoea syndrome - unstable myasthenia gravis
- **CAUTIONS** Avoid prolonged use (risk of tolerance and withdrawal symptoms) - chronic pulmonary insufficiency (increased risk of respiratory depression) - elderly - history of drug abuse - muscle weakness - myasthenia gravis (avoid if unstable) - psychiatric illness
- **INTERACTIONS** → Appendix 1 (anxiolytics and hypnotics).
- **SIDE-EFFECTS**
  - **Common or very common** Taste disturbance
424 Sleep disorders

- Uncommon Dizziness · drowsiness · dry mouth · headache · nausea · vomiting
- Rare Amnesia · confusion · depression · hallucinations · nightmares
- Very rare Incoordination · light headedness
- Frequency not known Paradoxical effects · sleep-walking

SIDE-EFFECTS, FURTHER INFORMATION
Paradoxical effects A paradoxical increase in hostility and aggression may be reported. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects. Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.

- PREGNANCY Not recommended (risk of neonatal withdrawal symptoms). Use during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.
- BREAST FEEDING Present in milk—avoid.
- HEPATIC IMPAIRMENT Reduce dose to 3.75 mg in mild to moderate impairment, dose can be increased with caution if necessary. Avoid in severe impairment—can precipitate encephalopathy.
- RENAL IMPAIRMENT Start with reduced dose of 3.75 mg. Increased cerebral sensitivity.
- PATIENT AND CARER ADVICE Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.
- NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Zaleplon, zolpidem and zopiclone for the short-term management of insomnia (April 2004) NICE TA77

Zopiclone is recommended for the short-term management of severe insomnia that interferes with normal daily life, and should be prescribed for short periods of time only. www.nice.org.uk/TA77

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Table

<table>
<thead>
<tr>
<th>Zopiclone (Non-proprietary)</th>
<th>DT price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zopiclone 3.75 mg</td>
<td>£1.60</td>
</tr>
<tr>
<td>Zopiclone 7.5 mg</td>
<td>£1.67</td>
</tr>
<tr>
<td>Zimovane 3.75 mg</td>
<td>£2.24</td>
</tr>
<tr>
<td>Zimovane 7.5 mg</td>
<td>£3.26</td>
</tr>
</tbody>
</table>

7.2 Narcolepsy

Drugs used for Narcolepsy not listed below:
- Dexamfetamine sulphate, p. 270 · Methylphenidate hydrochloride, p. 273

CNS STIMULANTS

Modafinil

INDICATIONS AND DOSE
Excessive sleepiness associated with narcolepsy with or without cataplexy

BY MOUTH
- Adult: Initially 200 mg daily in 2 divided doses, dose to be taken in the morning and at noon, alternatively initially 200 mg once daily, dose to be taken in the morning, adjusted according to response to 200–400 mg daily in 2 divided doses, alternatively adjusted according to response to 200–400 mg once daily
- Elderly: Initially 100 mg daily

- CONTRA-INDICATIONS Arrhythmia · history of clinically significant signs of CNS stimulant-induced mitral valve prolapse (including ischaemic ECG changes, chest pain and arrhythmias) · history of cor pulmonale · history of left ventricular hypertrophy · moderate uncontrolled hypertension · severe uncontrolled hypertension
- CAUTIONS History of alcohol abuse · history of depression · history of drug abuse · history of mania · history of psychosis · possibility of dependence
- INTERACTIONS → Appendix 1 (modafinil).
- SIDE-EFFECTS
  - Common or very common Abdominal pain · anxiety · appetite changes · asthenia · chest pain · confusion · constipation · depression · diarrhea · dizziness · drowsiness · dry mouth · dyspepsia · gastrointestinal disturbances · headache · nausea · palpititation · paraesthesia · sleep disturbances · tachycardia · vasodilatation · visual disturbances
  - Uncommon Abnormal dreams · acne · aggression · agitation · amnesia · arrhythmia · arthralgia · bradycardia · decreased libido · dry eye · dyskinesia · dysphagia · dysphoria · emotional lability · eosinophilia · epistaxis · flatulence · glossitis · hypercholesterolaemia · hyperglycaemia · hypertension · hypertonia · hypotension · leucopenia · menstrual disturbances · migraine · mouth ulcers · muscle cramps · myalgia · myasthenia · peripheral oedema · pruritus · rash · reflux · rhabdomyolysis · somnolence · suicidal ideation · sweating · tachycardia · tremor · urinary frequency · vomiting · weight changes
  - Rare Hallucinations · mania · psychosis
  - Frequency not known Multi-organ hypersensitivity reaction · psychiatric symptoms · Stevens-Johnson syndrome · toxic epidermal necrolysis

SIDE-EFFECTS, FURTHER INFORMATION
Rash Discontinue treatment if rash develops. Psychiatric symptoms Discontinue treatment if psychiatric symptoms develop.
- PREGNANCY Avoid.
- BREAST FEEDING Avoid—present in milk in animal studies.
- HEPATIC IMPAIRMENT Halve dose in severe impairment.
- RENAL IMPAIRMENT Use with caution—limited information available.
- PRE-TREATMENT SCREENING ECG required before initiation.
- MONITORING REQUIREMENTS Monitor blood pressure and heart rate in hypertensive patients.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension
CNS DEPRESSANTS

Sodium oxybate

**INDICATIONS AND DOSE**

**Narcolepsy with cataplexy (under expert supervision)**

*BY MOUTH*

- **Adult:** Initially 2.25 g daily, dose to be taken on retiring and 2.25 g after 2.5–4 hours, then increased in steps of 1.5 g daily in 2 divided doses, dose adjusted according to response at intervals of 1–2 weeks; dose titration should be repeated if restarting after interval of more than 14 days, maximum 9 g daily in 2 divided doses

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain - anorexia - anxiety - arthralgia - asthma - back pain - blurred vision - confusion - depression - diarrhoea - disorientation - dizziness - drowsiness - dysphonia - headache - hypertension - hypoaesthesia - impaired attention - muscle spasm - nasal congestion - nausea - nocturnal enuresis - palpitation - paraesthesia - peripheral oedema - rash - sleep disorders - sleep paralysis - sleep walking - sweating - taste disturbance - tremor - urinary incontinence - vertigo - vomiting
- **Uncommon** Agitation - amnesia - faecal incontinence - hallucination - myoclonus - paranoia - psychosis - restless legs syndrome - suicidal behaviour
- **Frequency not known** Dependence - euphoria - respiratory depression - seizures - sleep apnoea - suicidal ideation - urticaria

**PREGNANCY** Avoid.

**HEPATIC IMPAIRMENT** Halve initial dose.

**RENAL IMPAIRMENT** Caution—contains 3.96 mmol Na⁺ per mL.

**DIRECTIONS FOR ADMINISTRATION** Dilute each dose with 60 mL water; prepare both doses before retiring. Observe the same time interval (2–3 hours) each night between the last meal and the first dose.

**PATIENT AND CARER ADVICE** Leave at least 6 hours between taking sodium oxybate and performing skilled tasks (e.g. driving or operating machinery); effects of alcohol and other CNS depressants enhanced.

Patients or carers should be given advice on how to administer sodium oxybate oral solution.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

*CAUTIONARY AND ADVISORY LABELS 13, 19 ELECROLYTES: May contain Sodium*

- **Xyrem (UCB Pharma Ltd)**
  - Sodium oxybate 500 mg per 1 ml Xyrem 500mg/ml oral solution (sugar-free) | 180 ml (PO) £360.00 Schedule 2 (CD)

**8 Substance dependence**

**Substance dependence**


**Alcohol dependence**

Excessive drinking of alcoholic beverages over a prolonged period of time can result in an alcohol withdrawal syndrome on abrupt cessation of, or marked reduction in, drinking. The presence and severity of alcohol dependence can be assessed by *The Severity of Alcohol Dependence Questionnaire (SADQ)*; other assessment questionnaires are also available.

**Acute alcohol withdrawal**

People with moderate dependence can generally be treated in a community setting unless they are under 18 years of age, or are at high-risk of severe reactions or treatment failure. People with severe dependence should undergo withdrawal in an inpatient setting; withdrawal in severely dependent patients without medical support may lead to seizures, delirium tremens, and death. Long-acting benzodiazepines, usually clonazepam hydrochloride p. 267, are used to attenuate alcohol withdrawal symptoms. In primary care, fixed-dose reducing regimens are usually used, whilst a symptom-triggered flexible regimen is used in hospital or other settings where continued assessment and monitoring is carried out for 24–48 hours, usually followed by a fixed 5-day reducing dose schedule (sometimes it may be necessary to continue treatment for up to 10 days). Patients with compensated liver disease should be treated under specialist supervision.

Carbamazepine p. 387 [unlicensed indication] is sometimes used as an alternative treatment in acute alcohol withdrawal when benzodiazepines are contra-indicated or not tolerated. Clomethiazole p. 421 is licensed for use in acute alcohol withdrawal, but benzodiazepines are preferred. It should only be used in an inpatient setting and should not be prescribed if the patient is liable to continue drinking alcohol.

Patients with marked agitation or hallucinations and those at risk of delirium tremens (characterised by delirium, hallucinations, tremor, and disorientation) may be prescribed antipsychotic drugs, such as haloperidol p. 306 or olanzapine p. 315 [unlicensed indication], as adjunctive therapy to benzodiazepines; antipsychotics should not be used alone because they do not treat alcohol withdrawal and may lower the seizure threshold. Delirium tremens is a medical emergency that requires specialist inpatient care.

If a patient taking a benzodiazepine as part of a withdrawal regimen develops alcohol withdrawal seizures, a fast-acting benzodiazepine (such as intravenous lorazepam p. 412 [unlicensed indication] or rectal diazepam p. 267) should be prescribed; thereafter an increase in the dose of...
oral benzodiazepine should be considered to prevent further seizures from occurring.

Alcohol dependence

Acamprosate calcium p. 429 and naltrexone hydrochloride p. 430 are effective treatments for relapse prevention in patients with alcohol dependence; disulfiram p. 428 is an alternative. Disulfiram should only be used in patients in whom acamprosate calcium and naltrexone hydrochloride are not suitable, or if the patient prefers disulfiram. Nalmefene p. 429 is licensed for the reduction of alcohol consumption in patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms, and who do not require immediate detoxification.

Patients with alcohol dependence are at risk of developing Wernicke’s encephalopathy; patients at high-risk are those who are malnourished, at risk of malnourishment, or have decompensated liver disease. Parenteral thiamine p. 882 (as Pabrinex®) should be prescribed for treatment of suspected or confirmed Wernicke’s encephalopathy, and for prophylaxis in alcohol dependent patients attending hospital for acute treatment (including treatment unrelated to alcohol dependence); parenteral prophylaxis may also be considered for high-risk patients being treated in primary care. High-dose oral thiamine p. 882 should be prescribed following parenteral treatment until cognitive function is maximised. In primary care, prophylactic high-dose oral thiamine should be prescribed during acute withdrawal of alcohol, before planned withdrawal, and for patients not undergoing withdrawal but who are at high-risk of developing Wernicke’s encephalopathy.

Patients with chronic alcohol-related pancreatitis who have symptoms of steatorrhoea or who have poor nutritional status due to exocrine pancreatic insufficiency should be prescribed pancreatic enzyme supplements; supplements are not indicated when pain is the only symptom.

Corticosteroids are used in patients with severe acute alcohol-related hepatitis.

Drugs used in alcohol dependence

Acamprosate

Acamprosate calcium p. 429, in combination with counselling, may be helpful for maintaining abstinence in alcohol-dependent patients. It is useful for patients who are concerned that strong cravings will result in relapse. It should be initiated as soon as possible after abstinence has been achieved and continued for 1 year. Treatment should be maintained if the patient has a temporary relapse but stopped if the patient returns to regular or excessive drinking that persists 4–6 weeks after starting treatment. Acamprosate calcium p. 429 is not effective in all patients, so efficacy should be regularly assessed.

Disulfiram

Disulfiram p. 428 gives rise to an extremely unpleasant systemic reaction after the ingestion of even a small amount of alcohol because it causes accumulation of acetaldehyde in the body; it is only effective if taken daily. Symptoms can occur within 10 minutes of ingesting alcohol and include flushing of the face, throbbing headache, palpitation, tachycardia, nausea, vomiting, and, with large doses of alcohol, arrhythmias, hypotension, and collapse; these reactions can last several hours. Small amounts of alcohol such as those included in many oral medicines may be sufficient to precipitate a reaction—even toiletries and mouthwashes that contain alcohol should be avoided.

Nalmefene

Nalmefene p. 429 should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene p. 429 is not recommended for patients aiming to achieve immediate abstinence.

Naltrexone

Naltrexone hydrochloride p. 430 is an opioid-receptor antagonist, but is useful as an adjunct in the treatment of alcohol dependence after a successful withdrawal. Treatment should be initiated by a specialist and continued under specialist supervision. Naltrexone hydrochloride p. 430 should be stopped if drinking continues for 4–6 weeks after starting treatment.

Nicotine dependence

Smoking cessation interventions are a cost-effective way of reducing ill health and prolonging life. Smokers should be advised to stop and offered help with follow-up when appropriate. If possible, smokers should have access to smoking cessation services for behavioural support.

Therapy to aid smoking cessation is chosen according to the smoker’s likely adherence, availability of counselling and support, previous experience of smoking-cessation aids, contra-indications and adverse effects of the preparations, and the smoker’s preferences. Nicotine replacement therapy, bupropion hydrochloride p. 433, and varenicline p. 432 are effective aids to smoking cessation. The use of nicotine replacement therapy in an individual who is already accustomed to nicotine introduces few new risks and it is widely accepted that there are no circumstances in which it is safer to smoke than to use nicotine replacement therapy.

Some patients benefit from having more than one type of nicotine replacement therapy prescribed, such as a combination of transdermal and oral preparations. The combination of nicotine replacement therapy with varenicline or bupropion hydrochloride is not recommended.

Concomitant medication

Cigarette smoking increases the metabolism of some medicines by stimulating the hepatic enzyme CYP1A2. When smoking is discontinued, the dose of these drugs, in particular theophylline, cinacalcet, ropinirole, and some antidepressants (including clozapine, olanzapine, chlorpromazine hydrochloride, and haloperidol), may need to be reduced. Regular monitoring for adverse effects is advised.

Bupropion hydrochloride p. 433 has been used as an antidepressant. Its mode of action in smoking cessation is not clear and may involve an effect on noradrenaline and dopamine neurotransmission.

Nicotine replacement therapy

Nicotine replacement therapy can be used in place of cigarettes after abrupt cessation of smoking, or alternatively to reduce the amount of cigarettes used in advance of making a quit attempt. Nicotine replacement therapy can also be used to minimise passive smoking, and to treat cravings and reduce compensatory smoking after enforced abstinence in smoke-free environments. Smokers who find it difficult to achieve abstinence should consult a healthcare professional for advice.

Choice

Nicotine patches are a prolonged-release formulation and are applied for 16 hours (with the patch removed overnight) or for 24 hours. If patients experience strong cravings for cigarettes on waking, a 24-hour patch may be more suitable. Immediate-release nicotine preparations (gum, lozenges, sublingual tablets, inhalator, nasal spray, and oral spray) are used whenever the urge to smoke occurs or to prevent cravings.

The choice of nicotine replacement preparation depends largely on patient preference, and should take into account what preparations, if any, have been tried before. Patients with a high level of nicotine dependence, or who have failed with nicotine replacement therapy previously, may benefit...
from using a combination of an immediate-release preparation and patches to achieve abstinence. **Side-effects of specific nicotine preparations** Mild local reactions at the beginning of treatment are common because of the irritant effect of nicotine. Oral preparations and **inhalation cartridges** can cause irritation of the throat, **gum, lozenges**, and **oral spray** can cause increased salivation, and **patches** can cause minor skin irritation. The nasal spray commonly causes coughing, nasal irritation, epistaxis, sneezing, and watery eyes; the **oral spray** can cause watery eyes and blurred vision. Gastro-intestinal disturbances are common and may be caused by swallowed nicotine. Nausea, vomiting, dyspepsia, and hiccup occur most frequently. Ulcerative stomatitis has also been reported. Dry mouth is a common side-effect of **lozenges, patches, oral spray, and sublingual tablets**. Lozenges cause diarrhoea, constipation, dysphagia, oesophagitis, gastritis, mouth ulcers, bloating, flatulence, and less commonly, taste disturbance, thirst, gingival bleeding, and halitosis. The **oral spray** may also cause abdominal pain, flatulence, and taste disturbance. Palpitations may occur with nicotine replacement therapy, and rarely **patches** and **oral spray** can cause arrhythmia. **Patches, lozenges**, and **oral spray** can cause chest pain. The **inhalator** can very rarely cause reversible atrial fibrillation. Parasthesia is a common side-effect of **oral spray**. Abnormal dreams can occur with **patches**; removal of the patch before bed may help. **Lozenges** and **oral spray** may cause rash and hot flushes. Sweating and myalgia can occur with **patches** and **oral spray**; the patches can also cause arthralgia.

**Opioid dependence**

The management of opioid dependence requires medical, social, and psychological treatment; access to a multidisciplinary team is recommended. Treatment for opioid dependence should be initiated under the supervision of an appropriately qualified prescriber. **Untreated heroin dependence shows early withdrawal symptoms within 8 hours, with peak symptoms at 36–72 hours; symptoms subside substantially after 5 days.** Methadone hydrochloride p. 436 or buprenorphine p. 434 withdrawal occurs later, with longer-lasting symptoms.

**Opioid substitution therapy**

Methadone hydrochloride and buprenorphine are used as substitution therapy in opioid dependence. Substitute medication should be commenced with a short period of stabilisation, followed by either a withdrawal regimen or by maintenance treatment. Maintenance treatment enables patients to achieve stability, reduces drug use and crime, and improves health; it should be regularly reviewed to ensure the patient continues to derive benefit. The prescriber should monitor for signs of toxicity, and the patient should be told to be aware of warning signs of toxicity on initiation and during titration. A withdrawal regimen after stabilisation with methadone hydrochloride or buprenorphine should be attempted only after careful consideration. Enforced withdrawal is ineffective for sustained abstinence, and it increases the risk of patients relapsing and subsequently overdosing because of loss of tolerance. Complete withdrawal from opioids usually takes up to 4 weeks in an inpatient or residential setting, and up to 12 weeks in a community setting. If abstinence is not achieved, illicit drug use is resumed, or the patient cannot tolerate withdrawal, the withdrawal regimen should be stopped and maintenance therapy should be resumed at the optimal dose. Following successful withdrawal treatment, further support and monitoring to maintain abstinence should be provided for a period of at least 6 months.

**Missed doses**

Patients who miss 3 days or more of their regular prescribed dose of opioid maintenance therapy are at risk of overdose because of loss of tolerance. Consider reducing the dose in these patients. If the patient misses 5 or more days of treatment, an assessment of illicit drug use is also recommended before restarting substitution therapy; this is particularly important for patients taking buprenorphine p. 434 because of the risk of precipitated withdrawal.

**Buprenorphine**

Buprenorphine p. 434 is preferred by some patients because it is less sedating than methadone hydrochloride p. 436; for this reason it may be more suitable for employed patients or those undertaking other skilled tasks such as driving. Buprenorphine is safer than methadone hydrochloride when used in conjunction with other sedating drugs, and has fewer drug interactions. Dose reductions may be easier than with methadone hydrochloride because the withdrawal symptoms are milder, and patients generally require fewer adjunctive medications; there is also a lower risk of overdose. Buprenorphine can be given on alternate days in higher doses and it requires a shorter drug-free period than methadone hydrochloride before induction with naltrexone hydrochloride p. 430 for prevention of relapse.

Patients dependent on high doses of opioids may be at increased risk of precipitated withdrawal. Precipitated withdrawal can occur in any patient if buprenorphine is administered when other opioid agonist drugs are in circulation. Precipitated opioid withdrawal, if it occurs, starts within 1–3 hours of the first buprenorphine dose and peaks at around 6 hours. Non-opioid adjunctive therapy, such as lofexidine hydrochloride, may be required if symptoms are severe.

To reduce the risk of precipitated withdrawal, the first dose of buprenorphine should be given when the patient is exhibiting signs of withdrawal, or 6–12 hours after the last use of heroin (or other short-acting opioid), or 24–48 hours after the last dose of methadone hydrochloride. It is possible to titrate the dose of buprenorphine within one week—more rapidly than with methadone hydrochloride therapy—but care is still needed to avoid toxicity or precipitated withdrawal; dividing the dose on the first day may be useful.

A combination preparation containing buprenorphine with naloxone p. 436 (Suboxone®) can be prescribed for patients when there is a risk of dose diversion for parenteral administration; the naloxone hydrochloride p. 1133 component precipitates withdrawal if the preparation is injected, but it has little effect when the preparation is taken sublingually.

**Methadone**

Methadone hydrochloride p. 436, a long-acting opioid agonist, is usually administered in a single daily dose as methadone hydrochloride oral solution 1 mg/mL. Patients with a long history of opioid misuse, those who typically abuse a variety of sedative drugs and alcohol, and those who experience increased anxiety during withdrawal of opioids may prefer methadone hydrochloride to buprenorphine because it has a more pronounced sedative effect.

Methadone hydrochloride is initiated at least 8 hours after the last heroin dose, provided that there is objective evidence of withdrawal symptoms. A supplementary dose on the first day may be considered if there is evidence of persistent opioid withdrawal symptoms. Because of the long half-life, plasma concentrations progressively rise during initial treatment even if the patient remains on the same daily dose (it takes 3–10 days for plasma concentrations to reach steady-state in patients on a stable dose); a dose tolerated on the first day of treatment may become a toxic dose on the third day as cumulative toxicity develops. Thus,
tivation to the optimal dose in methadone hydrochloride maintenance treatment may take several weeks.

**Opioid substitution during pregnancy**

Acute withdrawal of opioids should be avoided in pregnancy because it can cause fetal death. Opioid substitution therapy is recommended during pregnancy because it carries a lower risk to the fetus than continued use of illicit drugs. If a woman who is stabilised on methadone hydrochloride or buprenorphine for treatment of opioid dependence becomes pregnant, therapy should be continued (buprenorphine is not licensed for use in pregnancy). Many pregnant patients choose a withdrawal regimen, but withdrawal during the first trimester should be avoided because it is associated with an increased risk of spontaneous miscarriage. Withdrawal of methadone hydrochloride or buprenorphine should be undertaken gradually during the second trimester, with dose reductions made every 3–5 days. If illicit drug use occurs, the patient should be re-stabilised at the optimal maintenance dose and consideration should be given to stopping the withdrawal regimen.

Further withdrawal of methadone hydrochloride or buprenorphine in the third trimester is not recommended because maternal withdrawal, even if mild, is associated with fetal distress, stillbirth, and the risk of neonatal mortality. Drug metabolism can be increased in the third trimester; it may be necessary to either increase the dose of methadone hydrochloride or change to twice-daily consumption (or a combination of both strategies) to prevent withdrawal symptoms from developing.

The neonate should be monitored for respiratory depression and signs of withdrawal if the mother is prescribed high doses of opioid substitute.

Signs of neonatal withdrawal from opioids usually develop 24–72 hours after delivery but symptoms may be delayed for up to 14 days, so monitoring may be required for several weeks. Symptoms include a high-pitched cry, rapid breathing, hungry but ineffective suckling, and excessive wakefulness; severe, but rare symptoms include hypertonicity and convulsions.

**Opioid substitution during breastfeeding**

Doses of methadone and buprenorphine should be kept as low as possible in breast-feeding mothers. Increased sleepiness, breathing difficulties, or limpness in breast-fed babies of mothers taking opioid substitutes should be reported urgently to a healthcare professional.

**Adjunctive therapy and symptomatic treatment**

Adjunctive therapy may be required for the management of opioid withdrawal symptoms. Loperamide hydrochloride p. 56 may be used for the control of diarrhoea; mebeverine hydrochloride p. 75 for controlling stomach cramps; paracetamol p. 354 and non-steroidal anti-inflammatory drugs for musculoskeletal pain and headaches; metoclopramide hydrochloride p. 347 or prochlorperazine p. 309 may be useful for nausea or vomiting. Topical rufecainals can be helpful for relieving muscle pain associated with methadone hydrochloride p. 436 withdrawal. If a patient is suffering from insomnia, short-acting benzodiazepines or zopiclone p. 423 may be prescribed, but because of the potential for abuse, prescriptions should be limited to a short course of a few days only. If anxiety or agitation is severe, specialist advice should be sought.

**Lorazepam**

Lorazepam hydrochloride p. 434 may alleviate some of the physical symptoms of opioid withdrawal by attenuating the increase in adrenergic neurotransmission that occurs during opioid withdrawal. Lorazepam hydrochloride can be prescribed as an adjuvant to opioid substitution therapy, initiated either at the same time as the opioid substitute or during withdrawal of the opioid substitute. Alternatively, lofexidine hydrochloride may be prescribed instead of an opioid substitute in patients who have mild or uncertain dependence (including young people), and those with a short history of illicit drug use.

**Opioid-receptor antagonists**

Patients dependant on opioids can be given a supply of naloxone hydrochloride p. 1133 to be used in case of accidental overdose.

Naltrexone hydrochloride p. 430 precipitates withdrawal symptoms in opioid-dependent subjects. Because the effects of opioid-receptor agonists are blocked by naltrexone hydrochloride, it is prescribed as an aid to prevent relapse in formerly opioid-dependent patients.

**Opioid dependence in children**

In younger patients (under 18 years), the harmful effects of drug misuse are more often related to acute intoxication than to dependence, so substitution therapy is usually inappropriate. Maintenance treatment with opioid substitution therapy is therefore controversial in young people; however, it may be useful for the older adolescent who has a history of opioid use to undergo a period of stabilisation with buprenorphine or methadone hydrochloride before starting a withdrawal regimen.

### 8.1 Alcohol dependence

**ALDEHYDE DEHYDROGENASE INHIBITORS**

**Disulfiram**

**INDICATIONS AND DOSE**

Adjunct in the treatment of alcohol dependence (under expert supervision)

BY MOUTH

- Adult: 200 mg daily, increased if necessary up to max. 500 mg daily

- **UNLICENSED USE** Disulfiram doses in BNF may differ from those in product literature.

- **CONTRA-INDICATIONS** Cardiac failure - coronary artery disease - history of cerebrovascular accident - hypertension - psychosis - severe personality disorder - suicide risk

- **CAUTIONS** Alcohol challenge not recommended on routine basis (if considered essential—specialist units only with resuscitation facilities) - avoid in Acute porphyrias p. 864 - diabetes mellitus - epilepsy - respiratory disease

- **INTERACTIONS** → Appendix 1 (disulfiram).

Disulfiram gives rise to an extremely unpleasant systemic reaction after the ingestion of even a small amount of alcohol. Ensure that alcohol is not consumed for at least 24 hours before initiating treatment and should be avoided for at least 1 week after stopping treatment.

- **SIDE-EFFECTS**
  - **Common or very common** Drowsiness - fatigue - halitosis - nausea - reduced libido - vomiting
  - **Rare** Allergic dermatitis - depression - hepatic cell damage - mania - paranoia - peripheral neuritis - psychotic reactions - schizophrenia

- **PREGNANCY** High concentrations of acetaldehyde which occur in presence of alcohol may be teratogenic; avoid in first trimester.

- **BREAST FEEDING** Avoid—no information available.

- **HEPATIC IMPAIRMENT** Use with caution.

- **RENAI IMPAIRMENT** Use with caution.
PRE-TREATMENT SCREENING  Before initiating disulfiram, prescribers should evaluate the patient’s suitability for treatment, because some patient factors, for example memory impairment or social circumstances, make compliance to treatment or abstinence from alcohol difficult.

MONITORING REQUIREMENTS  During treatment with disulfiram, patients should be monitored at least every 2 weeks for the first 2 months, then each month for the following 4 months, and at least every 6 months thereafter.

PATIENT AND CARER ADVICE  Patient counselling is advised (alcohol reaction).

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Table

CAUTIONARY AND ADVISORY LABELS

▶ Antabuse (Actavis UK Ltd)
Disulfiram 200 mg  Antabuse 200mg tablets | 50 tablet pack | £31.00 DT price = £31.00

GAMMA-AMINOBUTYRIC ACID ANALOGUES AND DERIVATIVES

Acamprosate calcium

INDICATIONS AND DOSE

Maintenance of abstinence in alcohol-dependent patients

BY MOUTH
▶ Adult 18-65 years (body-weight up to 60 kg): 666 mg once daily, dose to be taken with breakfast and 333 mg twice daily, dose to be taken at midday and at night
▶ Adult 18-65 years (body-weight 60 kg and above): 666 mg 3 times a day

CAUTIONS  Continued alcohol abuse (risk of treatment failure)

SIDE-EFFECTS
▶ Common or very common  Abdominal pain · diarrhoea · fluctuation in libido · maculopapular rash · nausea · pruritus · vomiting
▶ Rare  Bullous skin reactions

PREGNANCY  Avoid.

BREAST FEEDING  Avoid.

HEPATIC IMPAIRMENT  Avoid if severe.

RENAL IMPAIRMENT  Avoid if serum-creatinine greater than 120 micromol/litre.

PRESCRIBING AND DISPENSING INFORMATION

Acamprosate sodium has been used for the maintenance of abstinence in alcohol-dependent patients aged 18 years and over (unlicensed).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

CAUTIONARY AND ADVISORY LABELS 21, 25

ELECTROLYTES: May contain Calcium
▶ Campral EC (Merck Serono Ltd)
Acamprosate calcium 333 mg  Campral EC 333mg tablets | 168 tablet pack | £28.80 DT price = £28.80

OPIOID RECEPTOR ANTAGONISTS

Nalmefene

INDICATIONS AND DOSE

Reduction of alcohol consumption in patients with alcohol dependence who have a high drinking risk level without physical withdrawal symptoms, and who do not require immediate detoxification

BY MOUTH
▶ Adult: 18 mg daily if required, taken on each day there is a risk of drinking alcohol, preferably taken 1–2 hours before the anticipated time of drinking, if a dose has not been taken before drinking alcohol, 1 dose should be taken as soon as possible; maximum 18 mg per day

CONTRA-INDICATIONS  Recent history of acute alcohol withdrawal syndrome · recent or current opioid use

CAUTIONS  Continued treatment for more than 1 year · history of seizure disorders (including alcohol withdrawal seizures) · psychiatric illness

INTERACTIONS  → Appendix 1 (nalmefene). Avoid concomitant use of opioids—discontinue treatment 1 week before anticipated use of opioids; if emergency analgesia is required during treatment, an increased dose of opioid analgesic may be necessary (monitor for opioid intoxication).

SIDE-EFFECTS
▶ Common or very common  Confusion · decreased appetite · decreased libido · disturbance in attention · dizziness · dry mouth · headache · hyperhidrosis · hypoaesthesia · malaise · muscle spasms · nausea · palpitation · paraesthesia · restlessness · sleep disorders · somnolence · tachycardia · tremor · vomiting · weight loss
▶ Frequency not known  Dissociation · hallucinations

PREGNANCY  Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING  Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT  Use with caution—avoid in severe impairment.

RENAL IMPAIRMENT  Use with caution—avoid in severe impairment.

PRE-TREATMENT SCREENING  Before initiating treatment, prescribers should evaluate the patient’s clinical status, alcohol dependence, and level of alcohol consumption. Nalmefene should only be prescribed for patients who continue to have a high drinking risk level two weeks after the initial assessment.

MONITORING REQUIREMENTS  During treatment, patients should be monitored regularly and the need for continued treatment assessed.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

▶ Nalmefene for reducing alcohol consumption in people with alcohol dependence (November 2014) NICE TA325

Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for patients with alcohol dependence:
▶ who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization’s drinking risk levels) without physical withdrawal symptoms, and
▶ who do not require immediate detoxification.

The marketing authorisation states that nalmefene should:
Naltrexone hydrochloride

**Drug action**

Naltrexone is an opioid-receptor antagonist.

**Indications and dose**

Adjunct to prevent relapse in formerly opioid-dependent patients (who have remained opioid-free for at least 7-10 days) (initiated under specialist supervision)

**By mouth**

- Adult: Initially 25 mg daily, then increased to 50 mg daily, total weekly dose may be divided and given on 3 days of the week for improved compliance (e.g. 100 mg on Monday and Wednesday, and 150 mg on Friday); maximum 350 mg per week

Adjunct to prevent relapse in formerly alcohol-dependent patients (initiated under specialist supervision)

**By mouth**

- Adult: 25 mg once daily on the first day, then increased if tolerated to 50 mg daily

**Unlicensed use**

Unlicensed for use in children under 18 years. 25 mg dose for adjunct to prevent relapse in formerly alcohol-dependent patients is an unlicensed dose.

**Contra-indications**

Patients currently dependent on opioids

**Interactions**

Avoid concomitant use of opioids but increased dose of opioid analgesic may be required for pain (monitor for opioid intoxication).

**Side-effects**

- Common or very common: joint and muscle pain, abdominal pain, anxiety, chest pain, chills, constipation, decreased potency, delayed ejaculation, diarrhoea, dizziness, headache, increased energy, increased lacrimation, increased sweating, increased thirst, irritability, mood swings, nausea, rash, reduced appetite, sleep disorders, urinary retention, vomiting

- Rare: Depression, hepatic dysfunction, speech disorders, suicidal ideation, tinnitus

- Very rare: Exanthema, hallucinations, idiopathic thrombocytopenia, tremor

**Pregnancy**

Use only if benefit outweighs risk.

**Breast feeding**

Avoid—potential toxicity.

**Hepatic impairment**

Avoid in acute hepatitis, hepatic failure, or severe impairment.

**Renal impairment**

Avoid in severe impairment.

**Pre-treatment screening**

Test for opioid dependence with naloxone before treatment.

**Monitoring requirements**

Liver function tests needed before and during treatment.

**Patient and carer advice**

Patients should be warned that an attempt to overcome the blockade of opioid receptors by overdosing could result in acute opioid intoxication.

**National funding/access decisions**

NICE technology appraisals (TAs)

- Naltrexone for the management of opioid dependence (January 2007) NICE TA115

Naltrexone is recommended for the prevention of relapse in formerly opioid-dependent patients who are motivated to remain in a supportive care abstinence programme. Naltrexone should be administered under supervision and its effectiveness in preventing opioid misuse reviewed regularly. www.nice.org.uk/TA115

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- CAUTIONARY AND ADVISORY LABELS 25

  ▶ Selincro (Lundbeck Ltd)

  Nalmefene (as Nalmefene hydrochloride) 18 mg Selincro 18 mg tablets | 14 tablet box £42.42 DT price = £42.42 | 28 tablet box £84.84

---

### 8.2 Nicotine dependence

**Nicotine**

**Indications and dose**

Nicotine replacement therapy in individuals who smoke fewer than 20 cigarettes each day

**By mouth using chewing gum**

- Adult: 2 mg as required, chew 1 piece of gum when the urge to smoke occurs or to prevent cravings, if attempting smoking cessation, treatment should continue for up to 3 months before reducing the dose

**By sublingual administration using sublingual tablets**

- Adult: 1 tablet every 1 hour, increased to 2 tablets every 1 hour if required, if attempting smoking cessation, treatment should continue for up to 3 months before reducing the dose; maximum 40 tablets per day

Nicotine replacement therapy in individuals who smoke more than 20 cigarettes each day or who require more than 15 pieces of 2-mg strength gum each day

**By mouth using chewing gum**

- Adult: 4 mg as required, chew 1 piece of gum when the urge to smoke occurs or to prevent cravings, if attempting smoking cessation, treatment should not exceed 15 pieces of 4-mg strength gum daily, if attempting smoking cessation, treatment should continue for 3 months before reducing the dose

Nicotine replacement therapy in individuals who smoke more than 20 cigarettes each day

**By sublingual administration using sublingual tablets**

- Adult: 2 tablets every 1 hour, if attempting smoking cessation, treatment should continue for up to 3 months before reducing the dose; maximum 40 tablets per day

Nicotine replacement therapy

**By inhalation using inhalator**

- Adult: As required, the cartridges can be used when the urge to smoke occurs or to prevent cravings, patients should not exceed 12 cartridges of the 10-mg
strength daily, or 6 cartridges of the 15-mg strength daily.

BY MOUTH USING LOZENGES

- Adult: 1 lozenge every 1–2 hours as required, one lozenge should be used when the urge to smoke occurs, individuals who smoke less than 20 cigarettes each day should usually use the lower-strength lozenges; individuals who smoke more than 20 cigarettes each day and those who fail to stop smoking with the low-strength lozenges should use the higher-strength lozenges; if attempting smoking cessation, treatment should continue for 6–12 weeks before attempting a reduction in dose; maximum 15 lozenges per day.

BY MOUTH USING OROMUCOSAL SPRAY

- Adult: 1–2 sprays as required, patients can spray in the mouth when the urge to smoke occurs or to prevent cravings, individuals should not exceed 2 sprays per episode (up to 4 sprays every hour); maximum 64 sprays per day.

BY INTRANASAL ADMINISTRATION USING NASAL SPRAY

- Adult: 1 spray as required, patients can spray into each nostril when the urge to smoke occurs, up to twice every hour for 16 hours daily, if attempting smoking cessation, treatment should continue for 8 weeks before reducing the dose; maximum 64 sprays per day.

BY TRANSDERMAL APPLICATION USING PATCHES

- Adult: Individuals who smoke more than 10 cigarettes daily should apply a high-strength patch daily for 6–8 weeks, followed by the medium-strength patch for 2 weeks, and then the low-strength patch for the final 2 weeks; individuals who smoke fewer than 10 cigarettes daily can usually start with the medium-strength patch for 6–8 weeks, followed by the low-strength patch for 2–4 weeks; a slower titration schedule can be used in patients who are not ready to quit but want to reduce cigarette consumption before a quit attempt; if abstinence is not achieved, if withdrawal symptoms are experienced, the strength of the patch used should be maintained or increased until the patient is stabilised; patients using the high-strength patch who experience excessive side-effects, that do not resolve within a few days, should change to a medium-strength patch for the remainder of the initial period and then use the low-strength patch for 2–4 weeks.

• UNLICENSED USE All preparations are licensed for adults and children over 12 years (with the exception of Nicotinell™ lozenges which are licensed for children under 18 years only when recommended by a doctor).

• CAUTIONS

GENERAL CAUTIONS

Diabetes mellitus—blood-glucose concentration should be monitored closely when initiating treatment - haemodynamically unstable patients hospitalised with cerebrovascular accident - haemodynamically unstable patients hospitalised with myocardial infarction - haemodynamically unstable patients hospitalised with severe arrhythmias - phaeochromocytoma - uncontrolled hyperthyroidism

SPECIFIC CAUTIONS

- With oral (topical) use gum may also stick to and damage dentures.
- With intranasal use bronchial asthma (may exacerbate).
- With oral use gastritis (can be aggravated by swallowed nicotine) - oesophagitis (can be aggravated by swallowed nicotine) - peptic ulcers (can be aggravated by swallowed nicotine).
- With transdermal use patches should not be placed on broken skin - patients with skin disorders.

• When used by inhalation bronchospastic disease - chronic throat disease - obstructive lung disease.

CAUTIONS, FURTHER INFORMATION

Most warnings for nicotine replacement therapy also apply to continued cigarette smoking, but the risk of continued smoking outweighs any risks of using nicotine preparations.

Specific cautions for individual preparations are usually related to the local effect of nicotine.

• INTERACTIONS → Appendix 1 (nicotine).

• SIDE-EFFECTS

- Common or very common Bloating - blurred vision - constipation - coughing - diarrhoea - dry mouth - dyspepsia - dysphagia - epistaxis - flatulence - gastritis - gastro-intestinal disturbances (may be caused by swallowed nicotine) - hiccup - increased salivation - irritation of the throat - mild local reactions at the beginning of treatment are common because of the irritant effect of nicotine - minor skin irritation - mouth ulcers - nasal irritation - nausea - oesophagitis - paraesthesia - sneezing - vomiting - watery eyes

- Uncommon Gingival bleeding - halitosis - thirst

- Rare Arrhythmia

- Very rare Reversible atrial fibrillation

- Frequency not known Abdominal pain - abnormal dreams (may occur with patches, removal of the patch before bed may help) - arthralgia - chest pain - flatulence - hot flushes - myalgia - palpitations - rash - sweating - taste disturbance - ulcerative stomatitis

SIDE-EFFECTS, FURTHER INFORMATION

Side-effects listed have been reported with use of various nicotine replacement therapy preparations. See Substances dependence p. 425, Nicotine replacement therapy for specific side-effects of individual preparations.

Nicotine withdrawal: Some systemic effects occur on initiation of therapy, particularly if the patient is using high-strength preparations; however, the patient may confuse side-effects of the nicotine-replacement preparation with nicotine withdrawal symptoms. Common symptoms of nicotine withdrawal include malaise, headache, dizziness, sleep disturbance, coughing, influenza–like symptoms, depression, irritability, increased appetite, weight gain, restless-ness, anxiety, drowsiness, aphantus ulcers, decreased heart rate, and impaired concentration.

• PREGNANCY

The use of nicotine replacement therapy in pregnancy is preferable to the continuation of smoking, but should be used only if smoking cessation without nicotine replacement fails. Intermittent therapy is preferable to patches but avoid liquorice–flavoured nicotine products. Patches are useful, however, if the patient is experiencing pregnancy-related nausea and vomiting. If patches are used, they should be removed before bed.

• BREAST FEEDING

Nicotine is present in milk; however, the amount to which the infant is exposed is small and less hazardous than second-hand smoke. Intermittent therapy is preferred.

• HEPATIC IMPAIRMENT

Use with caution in moderate to severe hepatic impairment.

• RENAL IMPAIRMENT

Use with caution in severe renal impairment.

• DIRECTIONS FOR ADMINISTRATION

Acidic beverages, such as coffee or fruit juice, may decrease the absorption of nicotine through the buccal mucosa and should be avoided for 15 minutes before the use of oral nicotine replacement therapy. Administration by transdermal patch: Patches should be applied on waking to dry, non-hairy skin on the hip, trunk, or upper arm and held in position for 10–20 seconds to ensure...
adhesion; place next patch on a different area and avoid using the same site for several days.

Administration by nasal spray. Initially 1 spray should be used in both nostrils but when withdrawing from therapy, the dose can be gradually reduced to 1 spray in 1 nostril.

Administration by oral spray. The oral spray should be released into the mouth, holding the spray as close to the mouth as possible and avoiding the lips. The patient should not inhale while spraying and avoid swallowing for a few seconds after use. If using the oral spray for the first time, or if unit not used for 2 or more days, prime the unit before administration.

Administration by sublingual tablet. Each tablet should be placed under the tongue and allowed to dissolve. Administration by lozenge. Slowly allow each lozenge to dissolve in the mouth; periodically move the lozenge from one side of the mouth to the other. Lozenges last for 10–30 minutes, depending on their size.

Administration by inhalation. Insert the cartridge into the device and draw in air through the mouthpiece; each session can last for approximately 5 minutes. The amount of nicotine from 1 puff of the cartridge is less than that from a cigarette, therefore it is necessary to inhale more often than when smoking a cigarette. A single 10 mg cartridge lasts for approximately 20 minutes of intense use; a single 15 mg cartridge lasts for approximately 40 minutes of intense use. Administration by medicated chewing gum. Chew the gum until the taste becomes strong, then rest it between the cheek and gum; when the taste starts to fade, repeat this process. One piece of gum lasts for approximately 30 minutes.

PRESCRIBING AND DISPENSING INFORMATION

- Flavours of chewing gum and lozenges may include mint, freshfruit, freshmint, icy white, or cherry.
- Patient or carers should be given advice on how to administer nicotine chewing gum, inhalators, lozenges, sublingual tablets, oral spray, nasal spray and patches.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Sublingual tablet

CAUTIONARY AND ADVISORY LABELS 26

- Nicorette Microtab (McNeil Products Ltd)

Nicotine (as Nicotine cycloexdrin complex) 2 mg Nicorette Microtab 2 mg sublingual tablets (sugar-free) | 100 tablet(s) GSK £13.12 DT price = £13.12

Orodispersible film

- NiQuitin (GlaxoSmithKline Consumer Healthcare)

Nicotine 2.5 mg NiQuitin Strips Mint 2.5mg oral films (sugar-free) | 15 film(s) GSK £3.51 (sugar-free) | 60 film(s) GSK £10.85

Lozenges

EXCIPIENTS: May contain Aspartame

ELECTROLYTES: May contain Sodium

- NiQuitin (GlaxoSmithKline Consumer Healthcare)

Nicotine 1.5 mg NiQuitin Mintis Mint 1.5mg lozenges (sugar-free) | 20 lozenge(s) GSK £3.50 (sugar-free) | 60 lozenge(s) GSK £9.56 DT price = £8.93
Nicotine Minis Cherry 1.5mg lozenges (sugar-free) | 20 lozenge(s) GSK £3.18 (sugar-free) | 60 lozenge(s) GSK £8.93 DT price = £8.93
Nicotine Minis Orange 1.5mg lozenges (sugar-free) | 20 lozenge(s) GSK £3.18 (sugar-free) | 60 lozenge(s) GSK £8.93 DT price = £8.93

Nicotine 2 mg NiQuitin Mint 2mg lozenges (sugar-free) | 36 lozenge(s) GSK £5.12 (sugar-free) | 72 lozenge(s) GSK £9.97 DT price = £9.97
Nicotine 2 mg Nicorette Cools 2mg lozenges (sugar-free) | 36 lozenge(s) GSK £5.12 (sugar-free) | 72 lozenge(s) GSK £9.97 DT price = £9.97

Nicotine 4 mg NiQuitin Mint 4mg lozenges (sugar-free) | 36 lozenge(s) GSK £5.12 (sugar-free) | 72 lozenge(s) GSK £9.97 DT price = £9.97
Nicotine 4 mg Nicorette Cools 4mg lozenges (sugar-free) | 36 lozenge(s) GSK £5.12 (sugar-free) | 72 lozenge(s) GSK £9.97 DT price = £9.97
Nicotine Pre-Quit Mint 4mg lozenges (sugar-free) | 36 lozenge(s) GSK £5.12 (sugar-free) | 72 lozenge(s) GSK £9.97 DT price = £9.97

NiQuitin 4mg lozenges original menthol mint (sugar-free) | 36 lozenge(s) GSK £5.12 (sugar-free) | 72 lozenge(s) GSK £9.97 DT price = £9.97

- Nicorette (McNeil Products Ltd)

Nicotine 2 mg Nicorette Cools 2mg lozenges (sugar-free) | 20 lozenge(s) GSK £3.18 (sugar-free) | 80 lozenge(s) GSK £11.48
Nicotine 4 mg Nicorette Cools 4mg lozenges (sugar-free) | 20 lozenge(s) GSK £3.50 (sugar-free) | 80 lozenge(s) GSK £11.48

- Nicotinell (Novartis Consumer Health UK Ltd)

Nicotine (as Nicotine bitartrate) 1 mg Nicotinell 1mg lozenges (sugar-free) | 12 lozenge(s) GSK £1.59 (sugar-free) | 36 lozenge(s) GSK £4.27 (sugar-free) | 72 lozenge(s) GSK £8.03 (sugar-free) | 96 lozenge(s) GSK £12.12 DT price = £12.12 (sugar-free) | 144 lozenge(s) GSK £13.59
Nicotine (as Nicotine bitartrate) 2 mg Nicotinell 2mg lozenges (sugar-free) | 36 lozenge(s) GSK £4.95 (sugar-free) | 72 lozenge(s) GSK £9.31 (sugar-free) | 96 lozenge(s) GSK £10.60 (sugar-free) | 144 lozenge(s) GSK £15.88

Medicated chewing-gum

- NICOTINE (Non-proprietary)

Nicotine 2 mg Boots NicAssist Minty Fresh 2mg medicated chewing gum (sugar-free) | 30 piece(s) GSK no price available (sugar-free) | 105 piece(s) GSK no price available (sugar-free)

Nicotine 4 mg Boots NicAssist Minty Fresh 4mg medicated chewing gum (sugar-free) | 105 piece(s) GSK no price available (sugar-free)

- Brands may include NiQuitin, Nicorette, Nicotex Icy White, Nicotinell

Inhalation vapour

- Nicorette (McNeil Products Ltd)

Nicotine 15 mg Nicorette 15mg inhalator | 4 cartridge(s) GSK £4.27 DT price = £4.27 | 20 cartridge(s) GSK £15.11 DT price = £15.11 | 36 cartridge(s) GSK £24.03 DT price = £24.03

Transdermal patch

- NICOTINE (Non-proprietary)

Nicotine 5 mg per 16 hour Boots NicAssist 5mg patches | 7 patch(s) GSK no price available

Nicotine 7 mg per 24 hour Nicotine 7mg/24hours transdermal patches | 7 patch(s) GSK no price available

Nicotine 10 mg per 16 hour Boots NicAssist 10mg patches | 7 patch(s) GSK no price available DT price = £10.37

Nicotine 15 mg per 16 hour Boots NicAssist 15mg patches | 7 patch(s) GSK no price available DT price = £10.37

- Brands may include NiQuitin, Nicorette Clear, Nicorette Invisi, Nicotinell TTS

Spray

EXCIPIENTS: May contain Ethanol

- Nicorette (McNeil Products Ltd)

Nicotine 500 microgram per 1 actuation Nicorette 500micrograms/dose nasal spray | 10 ml GSK £11.80 DT price = £11.80

- Nicorette QuickMist (McNeil Products Ltd)

Nicotine 1 mg per 1 actuation Nicorette QuickMist 1mg/dose mouthspray (sugar-free) | 12.3 ml GSK £12.12 DT price = £12.12 (sugar-free) | 26.4 ml GSK £13.14

Varenicline

DRUG ACTION Varenicline is a selective nicotine-receptor partial agonist.

INDICATIONS AND DOSE

To aid smoking cessation

BY MOUTH

Adult: Initially 500 micrograms once daily for 3 days, increased to 500 micrograms twice daily for 4 days, then 1 mg twice daily for 11 weeks; reduced if not tolerated to 500 micrograms twice daily, usually to be started 1–2 weeks before target stop date but can be started up to a maximum of 5 weeks before target stop date, 12-week course can be repeated in abstinent individuals to reduce risk of relapse

Important safety information

MRHA/CHM ADVICE: SUICIDAL BEHAVIOUR AND VARENICLINE

Patients should be advised to discontinue treatment and seek prompt medical advice if they develop agitatio,
depressed mood, or suicidal thoughts. Patients with a history of psychiatric illness should be monitored closely while taking varenicline.

- **CAUTIONS** Conditions that may lower seizure threshold - history of cardiovascular disease - history of psychiatric illness (may exacerbate underlying illness including depression) - predisposition to seizures

- **SIDE-EFFECTS**
  - **Common or very common** taste disturbance - abnormal dreams - appetite changes - dizziness - drowsiness - dry mouth - gastro-intestinal disturbances - headache - sleep disorders
  - **Rare** Cerebrovascular accident
  - **Frequency not known** Aggression - diabetes mellitus - hyperglycaemia - irrational behaviour - myocardial infarction - psychosis - sleep-walking - Stevens-Johnson syndrome - suicidal ideation

- **PREGNANCY** Avoid - toxicity in animal studies.

- **BREAST FEEDING** Avoid - present in milk in animal studies.

- **RENAI L IMPAIRMENT** If eGFR less than 30 mL/minute/1.73 m², initial dose 500 micrograms once daily, increased after 3 days to 1 mg once daily.

- **TREATMENT CESSATION** Risk of relapse, irritability, depression, and insomnia on discontinuation; consider dose tapering on completion of 12-week course.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - **Varenicline for smoking cessation (July 2007)** NICE TA123 Varenicline is recommended, within its licensed indications, as an option for smokers who have expressed a desire to quit smoking; it should normally be prescribed only as part of a programme of behavioural support.
    - www.nice.org.uk/TA123

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 3
      - **Varenicline (as Varenicline tartrate) 500 microgram** Champix 0.5mg tablets | 11 tablet | no price available | 56 tablet | £54.60 DT price = £54.60
      - **Varenicline (as Varenicline tartrate) 1 mg** Champix 1mg tablets | 14 tablet | no price available | 28 tablet | £27.30 DT price = £27.30 | 56 tablet | £54.60
      - **Champix (Pfizer Ltd)**▼ Champix titration pack | 25 tablet | £27.30

- **SEROTONIN AND NORADRENA LINE RE-UPTAKE INHIBITORS**
  - **Bupropion hydrochloride**
    - (Amfebutamone hydrochloride)

- **INDICATIONS AND DOSE**
  - To aid smoking cessation in combination with motivational support in nicotine-dependent patients
  - **BY MOUTH**
    - **Adult:** Initially 150 mg daily for 6 days, then 150 mg twice daily (max. per dose 150 mg), minimum 8 hours between doses; period of treatment 7–9 weeks, start treatment 1–2 weeks before target stop date, discontinue if abstinence not achieved at 7 weeks, consider maximum 150 mg daily in patients with risk factors for seizures; maximum 300 mg per day
    - **Elderly:** 150 mg daily for 7–9 weeks, start treatment 1–2 weeks before target stop date, discontinue if abstinence not achieved at 7 weeks; maximum 150 mg per day

- **CONTRA-INDICATIONS** Acute alcohol withdrawal - acute benzodiazepine withdrawal - bipolar disorder - CNS tumour - eating disorders - history of seizures - severe hepatic cirrhosis

- **CAUTIONS** Alcohol abuse - diabetes - elderly - history of head trauma - predisposition to seizures (prescribe only if benefit clearly outweighs risk)

- **INTERACTIONS** ▶ Appendix 1 (bupropion).

  Contraindication with concomitant use of drugs that lower seizure threshold.

- **SIDE-EFFECTS**
  - **Common or very common** Agitation - anxiety - depression - dizziness - dry mouth - fever - gastro-intestinal disturbances - headache - impaired concentration - insomnia (reduced by avoiding dose at bedtime) - pruritus - rash - swelling - taste disturbance - tremor
  - **Uncommon** Anorexia - asthenia - chest pain - confusion - flushing - hypertension - tachycardia - tinnitus - visual disturbances
  - **Very rare** Aggression - delusions - paranoid ideation - restlessness
  - **Frequency not known** Suicidal ideation
  - **PREGNANCY** Avoid - no information available.
  - **BREAST FEEDING** Present in milk - avoid.
  - **HEPATIC IMPAIRMENT** Reduce dose to 150 mg daily. Avoid in severe hepatic cirrhosis.
  - **RENAI L IMPAIRMENT** Reduce dose to 150 mg daily.
  - **MONITORING REQUIREMENTS** Measure blood pressure before and during treatment.
  - **PATIENT AND CARER ADVICE** May impair performance of skilled tasks (e.g. driving).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Modified-release tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 25
      - **Zyban** (GlaxoSmithKline UK Ltd)
        - **Bupropion hydrochloride 150 mg** Zyban 150mg modified-release tablets | 60 tablet | £41.76 DT price = £41.76
8.3 Opioid dependence

**ALPHA₂ ADRENOCEPTOR AGONISTS**

**Lofexidine hydrochloride**

*DRUG ACTION* Lofexidine is an alpha₂-adrenergic agonist.

**INDICATIONS AND DOSE**

Management of symptoms of opioid withdrawal

**BY MOUTH**

- **Adult:** Initially 800 micrograms daily in divided doses, increased in steps of 400–800 micrograms daily (max. per dose 800 micrograms) as required for 7–10 days if no opioid use (but longer may be required); maximum 2.4 mg per day

**CAUTIONS** Bradycardia, cerebrovascular disease, depression, history of QT prolongation, hypotension (monitor pulse rate and blood pressure), metabolic disturbances, recent myocardial infarction, severe coronary insufficiency

**INTERACTIONS** Appendix 1 (lofexidine).

Caution with concomitant administration of drugs that prolong QT interval.

**SIDE-EFFECTS** Bradycardia, dizziness, drowsiness, dry mucous membranes, hypotension, QT-interval prolongation

**PREGNANCY** Use only if benefit outweighs risk—no information available.

**BREAST FEEDING** Use only if benefit outweighs risk—no information available.

**RENAI IMPAIRMENT** Caution in chronic impairment.

**MONITORING REQUIREMENTS** Monitoring of blood pressure and pulse rate is recommended on initiation, for at least 72 hours or until a stable dose is achieved, and on discontinuation.

**PRESCRIBING AND DISPENSING INFORMATION** Lofexidine has been used in children over 12 years for the management of symptoms of opioid withdrawal

**TREATMENT CESSATION** Treatment should be withdrawn gradually over 2–4 days (or longer) to reduce the risk of rebound hypertension and associated symptoms.

**PATIENT AND CARER ADVICE** The patient should take part of the dose at bedtime to offset insomnia associated with opioid withdrawal.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

| CAUTIONARY AND ADVISORY LABELS | 2 |
|BritLofex (Britainia Pharmaceuticals Ltd) | 300 micrograms tablets | 6 tablet | £1.79 |

**OPIOIDS**

**Buprenorphine**

The properties listed below are those particular to the drug only. For properties common to the class, see opioids, p. 357.

*DRUG ACTION* Buprenorphine is an opioid-receptor partial agonist (it has opioid agonist and antagonist properties).

**INDICATIONS AND DOSE**

Moderate to severe pain

**BY SUBLINGUAL ADMINISTRATION**

- **Child (body-weight 16–25 kg):** 100 micrograms every 6–8 hours
- **Child (body-weight 25–37.5 kg):** 100–200 micrograms every 6–8 hours
- **Adult:** 800 micrograms every 6–8 hours

**BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION**

- **Child 6 months–11 years:** 3–6 micrograms/kg every 6–8 hours (max. per dose 9 micrograms/kg)
- **Child 12–17 years:** 300–600 micrograms every 6–8 hours
- **Adult:** 300–600 micrograms every 6–8 hours

**PREMEDICATION**

**BY SUBLINGUAL ADMINISTRATION**

- **Adult:** 400 micrograms

**Intra-operative analgesia**

**BY SUBLINGUAL ADMINISTRATION**

- **Adult:** Initially 0.8–4 mg for 1 dose on the first day, adjusted in steps of 2–4 mg daily if required; usual dose 12–24 mg daily; maximum 32 mg per day

**Dose equivalence and conversion**

For opioid substitution therapy, in patients taking methadone who want to switch to buprenorphine, the dose of methadone should be reduced to a maximum of 20 mg daily before starting buprenorphine treatment. If the dose of methadone is over 10 mg daily, buprenorphine can be started at a dose of 4 mg daily and titrated according to requirements; if the methadone dose is below 10 mg daily, Buprenorphine can be started at a dose of 2 mg daily.

**HAPOCTASIN**

Moderate to severe chronic cancer pain | Severe pain unresponsive to non-opioid analgesics

**BY TRANSDERMAL APPLICATION USING PATCHES**

- **Adult:** Patients who have not previously received strong opioid analgesics initially 35 micrograms/hour up to every 72 hours; patients who have received strong opioid analgesic, initial dose based on previous 24-hour opioid requirement, consult product literature, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 72 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200–400 micrograms buprenorphine sublingually

**PHARMACOKINETICS**

It may take approximately 25 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

**TRANSTEC**

Moderate to severe chronic cancer pain | Severe pain unresponsive to non-opioid analgesics

**BY TRANSDERMAL APPLICATION USING PATCHES**

- **Adult:** Patients who have not previously received strong opioid analgesics, initially 35 micrograms/hour up to every 96 hours; patients who have received strong opioid analgesic, initial dose based on previous 24-hour opioid requirement, consult product literature, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase
in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 96 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200—400 micrograms buprenorphine sublingually.

**PHARMACOKINETICS**

It may take approximately 30 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

**BUTRANS®**

Moderate, non-malignant pain unresponsive to non-opioid analgesics

**BY TRANSDERMAL APPLICATION USING PATCHES**

- Adult: Initially 5 micrograms/hour up to every 7 days, dose adjustments—when starting, analgesic effect should not be evaluated until the system has been worn for 72 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of at least 3 days using a patch of the next strength or a combination of 2 patches applied in different places (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time.

- **UNLICENSED USE** Sublingual tablets not licensed for use in children under 6 years. Injection not licensed for use in children under 6 months.

- **CAUTIONS**
  - **GENERAL CAUTIONS**
    - Impaired consciousness
  - **SPECIFIC CAUTIONS**
    - With transdermal use other opioids should not be administered within 24 hours of patch removal (long duration of action) (in adults)
    - When used for adjunct in the treatment of opioid dependence hepatitis B infection (in adults) · hepatitis C infection (in adults) · pre-existing liver enzyme abnormalities (in adults)
  - **INTERACTIONS**
    - Caution with concomitant use of hepatotoxic drugs.
  - **SIDE-EFFECTS**
    - **Common or very common** Abdominal pain · agitation · anorexia · anxiety · asthenia · diarrhoea · dyspepsia · dry skin · fatigue · mild withdrawal symptoms in patients dependent on opioids · paraesthesia · vasodilatation
    - **Uncommon** Angina (in adults) · cough · depersonalisation · dry eye · dry skin · dysarthria · flatulence · hypertension · hypoaesthesia · hypoxia · impaired memory · influenza-like symptoms · muscle cramp · myalgia · pyrexia · restlessness · rhinitis · rigors · syncope · taste disturbance · tinnitus · tremor · wheezing
    - **Rare** Diureticulitis (in children) · dysphagia · impaired concentration · paralytic ileus · psychosis
    - **Very rare** Hiccups · hyperventilation · muscle fasciculation · retching
    - **Frequency not known** Hepatic necrosis · hepatitis

  - **SIDE-EFFECTS, FURTHER INFORMATION**
    - Fever or external heat
      - Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat (may also increase absorption).
    - **Overdose**
      - The effects of buprenorphine are only partially reversed by naloxone.
  - **HAPOCATASIN®**
    - In view of the long duration of action, patients who have severe side-effects should be monitored for up to 25 hours after removing patch.

**TRANSTECA®**

In view of the long duration of action, patients who have severe side-effects should be monitored for up to 30 hours after removing patch.

- **BREAST FEEDING** Present in low levels in breast milk. Neonates should be monitored for drowsiness, adequate weight gain, and developmental milestones.
- **RENAL IMPAIRMENT** Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.
- **PRE-TREATMENT SCREENING** Documentation of viral hepatitis status is recommended before commencing therapy for opioid dependence.
- **MONITORING REQUIREMENTS** Monitor liver function; when used in opioid dependence baseline liver function test is recommended before commencing therapy, and regular liver function tests should be performed throughout treatment.
- **DIRECTIONS FOR ADMINISTRATION**
  - With sublingual use in children For administration by mouth, tablets may be halved.
  - **HAPOCATASIN®**
    - Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 72 hours and siting replacement patch on a different area (avoid same area for at least 7 days).
  - **TRANSTECA®**
    - Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 96 hours and siting replacement patch on a different area (avoid same area for at least 6 days).
  - **BUTRANS®**
    - Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after 7 days and siting replacement patch on a different area (avoid same area for at least 3 weeks).
  - **PRESCRIBING AND DISPENSING INFORMATION**
    - Transdermal buprenorphine patches are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose.
  - **PATIENT AND CARER ADVICE**
    - **HAPOCATASIN® TRANSTECA® BUTRANS®**
      - Patients or carers should be given advice on how to administer buprenorphine transdermal patches.
  - **NATIONAL FUNDING/ACCESS DECISIONS**
    - **NICE technology appraisals (TAs)**
      - Methadone and buprenorphine for the management of opioid dependence (January 2007) NICE TA114
      - Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable. www.nice.org.uk/TA114
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
    - **Sublingual tablet**
      - **CAUTIONARY AND ADVISORY LABELS 2, 26**
      - **BUPRENORPHINE (Non-proprietary)**
        - Buprenorphine (as Buprenorphine hydrochloride) 200 microgram Buprenorphine 200microgram sublingual tablets sugar free (sugar-free) | 50 tablet (PDR) £5.04 DT price = £5.04 Schedule 3 (CD No Register)
        - Buprenorphine (as Buprenorphine hydrochloride) 400 microgram Buprenorphine 400microgram sublingual tablets sugar free (sugar-free) | 7 tablet (PDR) £5.00 DT price = £1.60 Schedule 3 (CD No Register) (sugar-free) | 50 tablet (PDR) £10.07 DT price = £10.07 Schedule 3 (CD No Register)
Nervous system

Buprenorphine (as Buprenorphine hydrochloride)
2 mg Buprenorphine 2mg sublingual tablets sugar free (sugar-free) | 7 tablet (P) £11.50 DT price = £2.14 Schedule 3 (CD No Register)
Buprenorphine (as Buprenorphine hydrochloride)
8 mg Buprenorphine 8mg sublingual tablets sugar free (sugar-free) | 7 tablet (P) £52.00 DT price = £3.85 Schedule 3 (CD No Register)

▶ Gabup (Martindale Pharmaceuticals Ltd)
Buprenorphine (as Buprenorphine hydrochloride) 400 microgram Gabup 0.4mg sublingual tablets (sugar-free) | 7 tablet (P) £1.60 DT price = £1.60 Schedule 3 (CD No Register)
Buprenorphine (as Buprenorphine hydrochloride) 1 mg Gabup 1mg sublingual tablets (sugar-free) | 7 tablet (P) £2.00 Schedule 3 (CD No Register)
Buprenorphine (as Buprenorphine hydrochloride) 2 mg Gabup 2mg sublingual tablets (sugar-free) | 7 tablet (P) £2.14 DT price = £2.14 Schedule 3 (CD No Register)
Buprenorphine (as Buprenorphine hydrochloride) 4 mg Gabup 4mg sublingual tablets (sugar-free) | 7 tablet (P) £3.90 Schedule 3 (CD No Register)
Buprenorphine (as Buprenorphine hydrochloride) 6 mg Gabup 6mg sublingual tablets (sugar-free) | 7 tablet (P) £4.10 Schedule 3 (CD No Register)
Buprenorphine (as Buprenorphine hydrochloride) 8 mg Gabup 8mg sublingual tablets (sugar-free) | 7 tablet (P) £3.85 DT price = £3.85 Schedule 3 (CD No Register)

▶ Temgesic (RB Pharmaceuticals Ltd)
Buprenorphine (as Buprenorphine hydrochloride) 200 microgram Temgesic 200microgram sublingual tablets (sugar-free) | 50 tablet (P) £5.04 DT price = £5.04 Schedule 3 (CD No Register)
Buprenorphine (as Buprenorphine hydrochloride) 400 microgram Temgesic 400microgram sublingual tablets (sugar-free) | 50 tablet (P) £10.07 DT price = £10.07 Schedule 3 (CD No Register)

▶ Brands may include Natzon; Prefibin; Subutex; Tephine

Solution for injection

▶ Temgesic (RB Pharmaceuticals Ltd)
Buprenorphine (as Buprenorphine hydrochloride) 300 microgram per 1 ml Temgesic 300micrograms/1ml solution for injection ampoules | 5 ampoule (P) £2.46 Schedule 3 (CD No Register)

Transdermal patch

▶ CAUTIONARY AND ADVISORY LABELS 2

BUPRENORPHINE (Non-proprietary)
Buprenorphine 35 microgram per 1 hour Buprenorphine 35micrograms/hour transdermal patches | 4 patch (P) £15.80 DT price = £15.80 Schedule 3 (CD No Register)
Buprenorphine 52.5 microgram per 1 hour Buprenorphine 52.5micrograms/hour transdermal patches | 4 patch (P) £23.71 DT price = £23.71 Schedule 3 (CD No Register)
Buprenorphine 70 microgram per 1 hour Buprenorphine 70micrograms/hour transdermal patches | 4 patch (P) £31.60 DT price = £31.60 Schedule 3 (CD No Register)

▶ BuTrans (Napp Pharmaceuticals Ltd)
Buprenorphine 5 microgram per 1 hour BuTrans 5micrograms/hour transdermal patches | 4 patch (P) £17.60 DT price = £17.60 Schedule 3 (CD No Register)
Buprenorphine 10 microgram per 1 hour BuTrans 10micrograms/hour transdermal patches | 4 patch (P) £31.55 DT price = £31.55 Schedule 3 (CD No Register)
Buprenorphine 20 microgram per 1 hour BuTrans 20micrograms/hour transdermal patches | 4 patch (P) £57.46DT price = £57.46 Schedule 3 (CD No Register)

▶ Hapocasin (Actavis UK Ltd)
Buprenorphine 35 microgram per 1 hour Hapocasin 35micrograms/hour transdermal patches | 4 patch (P) £9.48 DT price = £9.48 Schedule 3 (CD No Register)
Buprenorphine 52.5 microgram per 1 hour Hapocasin 52.5micrograms/hour transdermal patches | 4 patch (P) £14.23 DT price = £14.23 Schedule 3 (CD No Register)

▶ Transnec (Napp Pharmaceuticals Ltd)
Buprenorphine 35 microgram per 1 hour Transnec 35micrograms/hour transdermal patches | 4 patch (P) £11.80 DT price = £11.80 Schedule 3 (CD No Register)

Buprenorphine 52.5 microgram per 1 hour Transnec 52.5micrograms/hour transdermal patches | 4 patch (P) £23.71 DT price = £23.71 Schedule 3 (CD No Register)

Buprenorphine 70 microgram per 1 hour Transnec 70micrograms/hour transdermal patches | 4 patch (P) £31.60 DT price = £31.60 Schedule 3 (CD No Register)

Buprenorphine with naxalone

The properties listed below are those particular to the combination only. For the properties of the components please consider, buprenorphine p. 434, naloxone hydrochloride p. 1133.

INDICATIONS AND DOSE

Adjunct in the treatment of opioid dependence (dose expressed as buprenorphine)

BY SUBLINGUAL ADMINISTRATION

▶ Adult: Initially 2–4 mg once daily, an additional dose of 2–4 mg may be administered on day 1 depending on the individual patient’s requirement, increased in steps of 2–8 mg, adjusted according to response, total weekly dose may be divided and given on alternate days or 3 times weekly; maximum 24 mg per day

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2007) that Suboxone® should be restricted for use in patients in whom methadone is not suitable.

SUBLINGUAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Methadone hydrochloride

The properties listed below are those particular to the drug only. For properties common to the class, see opioids, p. 357.

INDICATIONS AND DOSE

Severe pain

BY MOUTH OR BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION

▶ Adult: 5–10 mg every 6–8 hours, adjusted according to response, on prolonged use not to be given more frequently than every 12 hours

Adjunct in treatment of opioid dependence

BY MOUTH USING ORAL SOLUTION

▶ Adult: Initially 10–30 mg daily, increased in steps of 5–10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60–120 mg daily

Adjunct in treatment of opioid dependence if tolerance low or not known

BY MOUTH USING ORAL SOLUTION

▶ Adult: Initially 10–20 mg daily, increased in steps of 5–10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in
**Opioid dependence**

The first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60–120 mg daily

Adjunct in treatment of opioid dependence if tolerance high (under expert supervision)

**DIRECTIONS FOR ADMINISTRATION**

**TREATMENT CESSATION**

Avoid abrupt withdrawal.

**DIRECTIONS FOR ADMINISTRATION**

Syrup preserved with hydroxybenzoate (parabens) esters may be incompatible with methadone hydrochloride.

**SIDE-EFFECTS**

- **Dry eyes**
- **Hyperprolactinaemia**
- **Hypothermia**
- **Restlessness**
- **Dysmenorrhoea**
- **Cough in terminal disease**

**UNLICENSED USE**

Methadone hydrochloride doses for opioid dependence in the BNF may differ from those in the product literature.

**CONTRA-INDICATIONS**

Phaeochromocytoma

**CAUTIONS**

Family history of sudden death (ECG monitoring recommended) - history of cardiac conduction abnormalities

**CAUTIONS, FURTHER INFORMATION**

QT-interval prolongation Patients with the following risk factors for QT-interval prolongation should be carefully monitored while taking methadone: heart or liver disease, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval; patients requiring more than 100 mg daily should also be monitored.

**SIDE-EFFECTS**

Dry eyes - dysmenorrhea - hyperprolactinaemia - hypothermia - QT-interval prolongation - raised intracranial pressure - restlessness - torsade de pointes

**SIDE-EFFECTS, FURTHER INFORMATION**

Methadone is a long-acting opioid therefore effects may be cumulative. Methadone, even in low doses is a special hazard for children; non-dependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction.

**Overdose** Methadone has a very long duration of action; patients may need to be monitored for long periods following large overdoses.

**BREAST FEEDING** Withdrawal symptoms in infant; breast-feeding permissible during maintenance but dose should be as low as possible and infant monitored to avoid sedation (high doses of methadone can carry an increased risk of sedation and respiratory depression in the neonate).

**RENAL IMPAIRMENT**

Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**TREATMENT CESSATION**

Avoid abrupt withdrawal.

**DIRECTIONS FOR ADMINISTRATION**

Syrup preserved with hydroxybenzoate (parabens) esters may be incompatible with methadone hydrochloride.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral liquid formulations may include tolu.

**METHADOSE® ORAL SOLUTION**

The final strength of the methadone mixture to be dispensed to the patient must be specified on the prescription.

**Important**—care is required in prescribing and dispensing the correct strength since any confusion could lead to an overdose; this preparation should be dispensed only after dilution as appropriate with Methadose® Diluent (life of diluted solution 3 months) and is for drug dependent persons.

**NICE TECHNOLOGY APPRAISALS (TAs)**

Methadone and buprenorphine for the management of opioid dependence (January 2007) NICE TA114

Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable. www.nice.org.uk/TA114

**LESS SUITABLE FOR PRESCRIBING** Methadone linctus is less suitable for prescribing for cough in terminal disease (has a tendency to accumulate).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, suppository, solution for injection, oral suspension, oral solution, capsule, impregnated cigarette

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Physeptone** (Martindale Pharmaceuticals Ltd)
  - Methadone hydrochloride 5 mg
  - Physeptone 5mg tablets
  - 50 tablet
  - £3.39
  - Schedule 2 (CD)

**METHADONE HYDROCHLORIDE (Non-proprietary)**

Methadone hydrochloride 1 mg per 1 ml

- Methadone 1mg/ml oral solution 100 ml
  - £11.26
  - £1.38
  - Schedule 2 (CD)
  - 500 ml
  - £6.90
  - Schedule 2 (CD)

- Methadone 1mg/ml oral solution sugar free (sugar-free)
  - 50 ml
  - £1.04
  - Schedule 2 (CD) (sugar-free)
  - 100 ml
  - £2.08
  - Schedule 2 (CD) (sugar-free)
  - 500 ml
  - £6.30
  - Schedule 2 (CD) (sugar-free)

- Methadose® Diluent (life of diluted solution 3 months) and is for drug dependent persons.

**METHADONE HYDROCHLORIDE (Non-proprietary)**

Methadone hydrochloride 10 mg per 1 ml

- Methadone 10mg/ml oral solution concentrate (sugar-free)
  - 150 ml
  - £12.01
  - Schedule 2 (CD)

- Methadone hydrochloride 20 mg per 1 ml
  - Methadose 20mg/ml oral solution concentrate (sugar-free)
  - 150 ml
  - £24.02
  - Schedule 2 (CD)

- Brands may include Methadose; Physeptone

**Solution for injection**

- **METHADONE HYDROCHLORIDE (Non-proprietary)**
  - Methadone hydrochloride 10 mg per 1 ml
    - Methadone 50mg/5ml solution for injection ampoules
      - 10 ampoule
      - £18.94
      - Schedule 2 (CD)
  - Methadone 35mg/3.5ml solution for injection ampoules
    - 10 ampoule
    - £13.92
    - Schedule 2 (CD)
  - Methadone hydrochloride 25 mg per 1 ml
    - Methadone 50mg/2ml solution for injection ampoules
      - 10 ampoule
      - £15.14
      - Schedule 2 (CD)

- Brands may include Physeptone; Synastone

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**
  - Methadone and buprenorphine for the management of opioid dependence (January 2007) NICE TA114
  - Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable. www.nice.org.uk/TA114

- **LESS SUITABLE FOR PRESCRIBING** Methadone linctus is less suitable for prescribing for cough in terminal disease (has a tendency to accumulate).
Chapter 5
Infection

CONTENTS
1 Amoebic infection 438
2 Bacterial infection 438
2.1 Anthrax 499
2.2 Leprosy 499
2.3 Lyme disease 500
2.4 Methicillin-resistant staphylococcus aureus 501
2.5 Tuberculosis 501
2.6 Urinary tract infections 510
3 Fungal infection 512
3.1 Pneumocystis pneumonia 522
4 Helminth infection 524
5 Protozoal infection 526
5.1 Leishmaniasis 527
5.2 Malaria 527
6 Viral infection 541
6.1 Hepatitis 541
6.2 Hepatitis B, chronic 542
6.3 Hepatitis C, chronic 544
6.4 Herpesvirus infections 549
6.5 Herpesvirus infections, cytomegalovirus 553
6.6 HIV infection 555
6.7 Influenza 571

1 Amoebic infection

Drugs used for Amoebic infection not listed below: Metronidazole, p. 475; Tinidazole, p. 476

Diloxanide furoate

INDICATIONS AND DOSE
Chronic amoebiasis | Acute amoebiasis as adjunct to metronidazole or tinidazole
BY MOUTH
- Child 12-17 years: 500 mg 3 times a day for 10 days
- Adult: 500 mg 3 times a day for 10 days

SIDE-EFFECTS Flatulence, pruritus, urticaria, vomiting

PREGNANCY Manufacturer advises avoid—no information available.

BREAST FEEDING Manufacturer advises avoid.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet
CAUTIONARY AND ADVISORY LABELS 9
- DILOXANIDE FUROATE (Non-proprietary)
- Diloxanide furoate 500 mg Diloxanide 500mg tablets | 30 tablet £93.50

Mepacrine hydrochloride

INDICATIONS AND DOSE
Giardiasis
BY MOUTH
- Adult: 100 mg every 8 hours for 5–7 days

UNLICENSED USE Not licensed for use in giardiasis.

CAUTIONS Avoid in psoriasis, elderly, history of psychosis

INTERACTIONS → Appendix 1 (mepacrine).

SIDE-EFFECTS Aplastic anaemia (on prolonged treatment) - blue/black discoloration of nails - blue/black discoloration of palate - chronic dermatoses (on prolonged treatment) - CNS stimulation (with large doses) - corneal deposits with visual disturbances - dizziness - gastrointestinal disturbances - headache - hepatitis (on prolonged treatment) - nausea (with large doses) - severe exfoliative dermatitis (on prolonged treatment) - transient acute toxic psychosis (with large doses) - vomiting (with large doses) - yellow discoloration of skin (on prolonged treatment) - yellow discoloration of urine (on prolonged treatment)

- HEPATIC IMPAIRMENT Use with caution.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

2 Bacterial infection

Antibacterials, principles of therapy

Choice of a suitable drug

Before selecting an antibacterial the clinician must first consider two factors—the patient and the known or likely causative organism. Factors related to the patient which must be considered include history of allergy, renal and hepatic function, susceptibility to infection (i.e. whether immunocompromised), ability to tolerate drugs by mouth, severity of illness, ethnic origin, age, whether taking other medication and, if female, whether pregnant, breast-feeding or taking an oral contraceptive.

The known or likely organism and its antibacterial sensitivity, in association with the above factors, will suggest one or more antibacterials, the final choice depending on the microbiological, pharmacological, and toxicological properties.

An example of a rational approach to the selection of an antibacterial is treatment of a urinary-tract infection in a patient complaining of nausea and symptoms of a urinary-tract infection in early pregnancy. The organism is reported as being resistant to ampicillin p. 483 but sensitive to
nitrofurantoin p. 512 (can cause nausea), gentamicin p. 450 (can be given only by injection and best avoided in pregnancy), tetracycline p. 498 (causes dental discoloration) and trimethoprim p. 462 (folate antagonist therefore theoretical teratogenic risk), and cefalexin p. 456. The safest antibiotics in pregnancy are the penicillins and cephalosporins; therefore, cefalexin p. 456 would be indicated for this patient.

The principles involved in selection of an antibacterial must allow for a number of variables including changing renal and hepatic function, increasing bacterial resistance, and information on side-effects. Duration of therapy, dosage, and route of administration depend on site, type and severity of infection and response.

**Antibacterial policies**

Local policies often limit the antibacterials that may be used to achieve reasonable economy consistent with adequate cover, and to reduce the development of resistant organisms. A policy may indicate a range of drugs for general use, and permit other drugs only on the advice of the microbiologist or physician responsible for the control of infectious diseases.

**Before starting therapy**

The following precepts should be considered before starting:

- **Viral infections should not be treated with antibacterials.** However, antibacterials may be used to treat secondary bacterial infection (e.g. bacterial pneumonia secondary to influenza);
- **Samples should be taken for culture and sensitivity testing;** 'blind' antibacterial prescribing for unexplained pyrexia usually leads to further difficulty in establishing the diagnosis;
- **Knowledge of prevalent organisms** and their current sensitivity is of great help in choosing an antibacterial before bacteriological confirmation is available. Generally, narrow-spectrum antibacterials are preferred to broad-spectrum antibacterials unless there is a clear clinical indication (e.g. life-threatening sepsis);
- **The dose of an antibacterial varies according to a number of factors including age, weight, hepatic function, renal function, and severity of infection.** The prescribing of the so-called 'standard' dose in serious infections may result in failure of treatment or even death of the patient; therefore it is important to prescribe a dose appropriate to the condition. An inadequate dose may also increase the likelihood of antibacterial resistance. On the other hand, for an antibacterial with a narrow margin between the toxic and therapeutic dose (e.g. an aminoglycoside) it is also important to avoid an excessive dose and the concentration of the drug in the plasma may need to be monitored;
- **The route of administration of an antibacterial often depends on the severity of the infection.** Life-threatening infections require intravenous therapy. Antibacterials that are well absorbed may be given by mouth even for some serious infections. Parenteral administration is also appropriate when the oral route cannot be used (e.g. because of vomiting) or if absorption is inadequate. Whenever possible, painful intramuscular injections should be avoided in children;
- **Duration of therapy depends on the nature of the infection and the response to treatment.** Courses should not be unduly prolonged because they encourage resistance, they may lead to side-effects and they are costly. However, in certain infections such as tuberculosis or osteomyelitis it may be necessary to treat for prolonged periods. Conversely a single dose of an antibacterial may cure uncomplicated urinary-tract infections. The prescription for an antibacterial should specify the duration of treatment or the date when treatment is to be reviewed.

**Superinfection**

In general, broad-spectrum antibacterial drugs such as the cephalosporins are more likely to be associated with adverse reactions related to the selection of resistant organisms e.g. *fungal infections* or antibiotic-associated colitis (pseudomembranous colitis); other problems associated with superinfection include vaginitis and pruritus ani.

**Therapy**

When the pathogen has been isolated treatment may be changed to a more appropriate antibacterial if necessary. If no bacterium is cultured the antibacterial can be continued or stopped on clinical grounds.

**Notifiable diseases**

Doctors must notify the Proper Officer of the local authority (usually the consultant in communicable disease control) when attending a patient suspected of suffering from any of the diseases listed below; a form is available from the Proper Officer.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td>Mumps</td>
</tr>
<tr>
<td>Botulism</td>
<td>Paratyphoid fever</td>
</tr>
<tr>
<td>Brucellosis</td>
<td>Plague</td>
</tr>
<tr>
<td>Cholera</td>
<td>Poliomyelitis, acute</td>
</tr>
<tr>
<td>Diarrhoea (infectious bloody)</td>
<td>Rabies</td>
</tr>
<tr>
<td>Diphtheria</td>
<td>Rubella</td>
</tr>
<tr>
<td>Encephalitis, acute</td>
<td>SARS</td>
</tr>
<tr>
<td>Food poisoning</td>
<td>Scarlet fever</td>
</tr>
<tr>
<td>Haemolytic uraemic syndrome</td>
<td>Smallpox</td>
</tr>
<tr>
<td>Haemorrhagic fever (viral)</td>
<td>Streptococcal disease (Group A, invasive)</td>
</tr>
<tr>
<td>Hepatitis, viral</td>
<td></td>
</tr>
<tr>
<td>Legionnaires’ disease</td>
<td></td>
</tr>
<tr>
<td>Leprosy</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td></td>
</tr>
<tr>
<td>Meningococcal septicaemia</td>
<td></td>
</tr>
</tbody>
</table>

It is good practice for doctors to also inform the consultant in communicable disease control of instances of other infections (e.g. psittacosis) where there could be a public health risk.

**Antibacterials, use for prophylaxis**

**Prevention of recurrence of rheumatic fever**

Phenoxyphthenilpenicillin p. 481 or sulfadiazine p. 495.

**Prevention of secondary case of invasive group A streptococcal infection**

Phenoxyphthenilpenicillin p. 481.

Patients who are penicillin allergic, *either* erythromycin p. 471 or azithromycin p. 469 [unlicensed indication].

For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Public Health England Laboratory).

**Prevention of secondary case of meningococcal meningitis**

Ciprofloxacin p. 490 *or* rifampicin p. 508 *or* i/m ceftriaxone p. 459 [unlicensed indication].

For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Public Health England Laboratory).
Infection

Infection

Infection

Prevention of secondary case of Haemophilus influenzae type b disease
Rifampicin p. 508 or (if rifampicin cannot be used) i/m or i/v ceftriaxone p. 459 [unlicensed indication].

For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Public Health England laboratory). Unless there has been direct exposure of the mouth or nose to infectious droplets from a patient with meningococcal disease who has received less than 24 hours of antibacterial treatment, healthcare workers do not generally require chemoprophylaxis.

Prevention of secondary case of Haemophilus influenzae type b disease

Within 4 weeks of illness onset in the index case with confirmed or suspected invasive *Haemophilus influenzae* type b disease, give antibacterial prophylaxis to all household contacts if there is a vulnerable individual in the household. Also, give antibacterial prophylaxis to the index case if they are in contact with vulnerable household contacts or if they are under 10 years of age. Vulnerable individuals include the immunocompromised, those with HIV, or if the infant is less than 3 months of age. Give rifampicin or azithromycin or (if the infant is over 3 months of age) i/v cefuroxime or amoxiclav. If there is a vulnerable individual in the household, give antibacterial prophylaxis to the index case if they are in contact with vulnerable household contacts or if they are under 10 years of age. Vulnerable individuals include the immunocompromised, those with meningococcal disease or with asplenia, or children under 10 years of age. If there are 2 or more cases of invasive *Haemophilus influenzae* type b disease within 120 days in a pre-school or primary school, antibacterial prophylaxis should also be given to all room contacts (including staff).

Prevention of secondary case of diphtheria in non-immune patient
Erythromycin p. 471 (or azithromycin p. 469 or clarithromycin p. 470).

Treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment.

Prevention of pertussis
Claritromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471).

Within 3 weeks of onset of cough in the index case, give antibacterial prophylaxis to all close contacts if amongst them there is at least one unimmunised or partially immunised child under 1 year of age, or if there is at least one individual who has not received a pertussis-containing vaccine more than 1 week and less than 5 years ago (so long as that individual lives or works with children under 4 months of age, is pregnant at over 20 weeks gestation, or is a healthcare worker who works with children under 1 year of age or with pregnant women).

Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease
Phenoxymethylpenicillin p. 481.

If penicillin-allergic, erythromycin p. 471.

Antibacterial prophylaxis is not fully reliable. Antibacterial prophylaxis may be discontinued in children over 5 years of age with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection.

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive
Isoniazid p. 506 or isoniazid + rifampicin p. 508 or (if isoniazid-resistant tuberculosis in patients under 35 years) rifampicin.

For details of those who should receive chemoprophylaxis contact the lead clinician for local tuberculosis services (or a consultant in communicable disease control).

Prevention of infection from animal and human bites

Co-amoxiclav p. 484 alone (or doxycycline p. 496 + metronidazole p. 475 if penicillin-allergic). Cleanse wound thoroughly. For tetanus-prone wound, give human tetanus immunoglobulin p. 1065 (with a tetanus-containing vaccine if necessary, according to immunisation history and risk of infection).

Consider rabies prophylaxis for bites from animals in endemic countries. Assess risk of blood-borne viruses (including HIV, hepatitis B and C) and give appropriate prophylaxis to prevent viral spread.

Antibacterial prophylaxis recommended for wounds less than 48–72 hours old when the risk of infection is high (e.g. bites from humans or cats; bites to the hand, foot, face, or genitai area; bites involving oedema, crush or puncture injury, or other moderate to severe injury; wounds that cannot be debrided adequately; patients with diabetes mellitus, cirrhosis, asplenia, prosthetic joints or valves, or those who are immunocompromised). Give antibacterial prophylaxis for up to 5 days.

Prevention of early-onset neonatal infection
i/v benzylpenicillin sodium p. 480 (or i/v clindamycin p. 467 if history of allergy to penicillins).

Give intrapartum prophylaxis to women with group B streptococcal colonisation, bacteriuria, or infection in the current pregnancy, or to women who had a previous baby with an invasive group B streptococcal infection. Consider prophylaxis for women in preterm labour if there is prelabour rupture of membranes or if intrapartum rupture of membranes lasting more than 18 hours is suspected.

Prevention of infection in gastro-intestinal procedures
Operations on stomach or oesophagus
Single dose of i/v gentamicin p. 450 or i/v cefuroxime p. 460 or i/v co-amoxiclav p. 484 (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Add i/v teicoplanin p. 464 (or vancomycin p. 465) if high risk of meticillin-resistant *Staphylococcus aureus*.

Open biliary surgery
Single dose of i/v cefuroxime p. 460 + i/v metronidazole p. 475 or i/v gentamicin p. 450 + i/v metronidazole or i/v co-amoxiclav p. 484 alone (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

Add i/v teicoplanin p. 464 (or vancomycin p. 465) if high risk of meticillin-resistant *Staphylococcus aureus*.

Resections of colon and rectum for carcinoma, and resections in inflammatory bowel disease, and appendicectomy
Single dose of i/v gentamicin p. 450 + i/v metronidazole p. 475 or i/v cefuroxime p. 460 + i/v metronidazole or i/v co-amoxiclav p. 484 alone (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.
Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

Add i/v teicoplanin p. 464 (or vancomycin p. 465) if high risk of meticillin-resistant *Staphylococcus aureus*.

**Endoscopic retrograde cholangiopancreatography**

Single dose of i/v gentamicin p. 450 or oral or i/v ciprofloxacin p. 490.

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Prophylaxis recommended if pancreatic pseudocyst, immunocompromised, history of liver transplantation, or risk of incomplete biliary drainage. For biliary complications following liver transplantation, add i/v amoxicillin p. 482 or i/v teicoplanin p. 464 (or vancomycin p. 465).

**Percutaneous endoscopic gastrostomy or jejunostomy**

Single dose of i/v co-amoxiclav p. 484 or i/v cefuroxime p. 460.

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v teicoplanin p. 464 (or vancomycin p. 465) if history of allergy to penicillins or cephalosporins, or if high risk of meticillin-resistant *Staphylococcus aureus*.

**Prevention of infection in orthopaedic surgery**

**Joint replacement including hip and knee**

Single dose of i/v cefuroxime p. 460 alone or i/v flucloxacillin p. 486 + i/v gentamicin p. 450 (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

If history of allergy to penicillins or to cephalosporins or if high risk of meticillin-resistant *Staphylococcus aureus*, use single dose of i/v teicoplanin p. 464 (or vancomycin p. 465) + i/v gentamicin (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Closed fractures**

Single dose of i/v cefuroxime p. 460 or i/v flucloxacillin p. 486 (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

If history of allergy to penicillins or to cephalosporins or if high risk of meticillin-resistant *Staphylococcus aureus*, use single dose of i/v teicoplanin p. 464 (or vancomycin p. 465) + i/v gentamicin (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Open fractures**

Use i/v co-amoxiclav p. 484 alone or i/v cefuroxime p. 460 + i/v metronidazole p. 475 (or i/v clindamycin p. 467 alone if history of allergy to penicillins or to cephalosporins).

Add i/v teicoplanin p. 464 (or vancomycin p. 465) if high risk of meticillin-resistant *Staphylococcus aureus*. Start prophylaxis within 3 hours of injury and continue until soft tissue closure (max. 72 hours).

At first debridement also use a single dose of i/v cefuroxime + i/v metronidazole + i/v gentamicin or i/v co-amoxiclav + i/v gentamicin (or i/v clindamycin + i/v gentamicin if history of allergy to penicillins or to cephalosporins).

At time of skeletal stabilisation and definitive soft tissue closure use a single dose of i/v gentamicin + i/v teicoplanin (or vancomycin) (intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure).

**High lower-limb amputation**

Use i/v co-amoxiclav p. 484 alone or i/v cefuroxime p. 460 + i/v metronidazole p. 475.

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Continue antibacterial prophylaxis for at least 2 doses after procedure (max. duration of prophylaxis 5 days). If history of allergy to penicillins or to cephalosporins, or if high risk of meticillin-resistant *Staphylococcus aureus*, use i/v teicoplanin p. 464 (or vancomycin p. 465) + i/v gentamicin p. 450 + i/v metronidazole.

Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

**Prevention of infection in urological procedures**

**Transrectal prostate biopsy**

Single dose of oral ciprofloxacin p. 490 or oral metronidazole p. 475 or i/v gentamicin p. 450 + i/v metronidazole (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v gentamicin + i/v metronidazole if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra-operative or postoperative doses of antibacterial may be given for prolonged procedures or if there is major blood loss).

Where i/v metronidazole p. 475 is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

**Transurethral resection of prostate**

Single dose of oral ciprofloxacin p. 490 or i/v gentamicin p. 450 or i/v cefuroxime p. 460 (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v gentamicin p. 450 if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Prevention of infection in obstetric and gynaecological surgery**

**Caesarean section**

Single dose of i/v cefuroxime p. 460 (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Substitute i/v clindamycin p. 467 if history of allergy to penicillins or cephalosporins. Add i/v teicoplanin p. 464 (or vancomycin p. 465) if high risk of meticillin-resistant *Staphylococcus aureus*.

**Hysterectomy**

Single dose of i/v cefuroxime p. 460 + i/v metronidazole p. 475 or i/v gentamicin p. 450 + i/v metronidazole or i/v co-amoxiclav p. 484 alone (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v gentamicin + i/v metronidazole or add i/v teicoplanin p. 464 (or vancomycin p. 465) to other regimens if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).
Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

**Termination of pregnancy**

Single dose of oral metronidazole p. 475 (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

If genital chlamydial infection cannot be ruled out, give doxycycline p. 496 postoperatively.

**Prevention of infection in cardiologic procedures**

**Cardiac pacemaker insertion**

Single dose of i/v cefuroxime p. 460 alone or i/v flucloxacinil p. 466 + i/v gentamicin p. 450 or i/v teicoplanin p. 464 (or vancomycin p. 465) + i/v gentamicin (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v teicoplanin (or vancomycin) + i/v cefuroxime or i/v teicoplanin (or vancomycin) + i/v gentamicin if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Prevention of infection in vascular surgery**

**Reconstructive arterial surgery of abdomen, pelvis or legs**

Single dose of i/v cefuroxime p. 460 alone or i/v flucloxacinil p. 466 + i/v gentamicin p. 450 (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Add i/v metronidazole p. 475 for patients at risk from anaerobic infections including those with diabetes, gangrene, or undergoing amputation. Use single dose of i/v teicoplanin (or vancomycin) + i/v cefuroxime or i/v teicoplanin (or vancomycin) + i/v gentamicin if history of allergy to penicillins or cephalosporins, or if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Prevention of endocarditis**

NICE guidance: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures (March 2008)

Antibacterial prophylaxis and chlorhexidine mouthwash are **not** recommended for the prevention of endocarditis in patients undergoing dental procedures.

Antibacterial prophylaxis is **not** recommended for the prevention of endocarditis in patients undergoing procedures of the:

- upper and lower respiratory tract (including ear, nose, and throat procedures and bronchoscopy);
- genito-urinary tract (including urological, gynaecological, and obstetric procedures);
- upper and lower gastro-intestinal tract.

Whilst these procedures can cause bacteraemia, there is no clear association with the development of infective endocarditis. Prophylaxis may expose patients to the adverse effects of antimicrobials when the evidence of benefit has not been proven.

Any infection in patients at risk of endocarditis should be investigated promptly and treated appropriately to reduce the risk of endocarditis.

If patients at risk of endocarditis are undergoing a gastro-intestinal or genito-urinary tract procedure at a site where infection is suspected, they should receive appropriate antibacterial therapy that includes cover against organisms that cause endocarditis.

Patients at risk of endocarditis should be:

- advised to maintain good oral hygiene;
- told how to recognise signs of infective endocarditis, and advised when to seek expert advice.

Patients at risk of endocarditis include those with valve replacement, acquired valvular heart disease with stenosis or regurgitation, structural congenital heart disease (including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices considered to be endotheallised), hypertrophic cardiomyopathy, or a previous episode of infective endocarditis.

**Dermatological procedures**

Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who undergo dermatological procedures do not require antibacterial prophylaxis against endocarditis.

The British Association of Dermatologists Therapy Guidelines and Audit Subcommittee advise that such dermatological procedures include skin biopsies and excision of moles or of malignant lesions.

**Joint prostheses and dental treatment**

Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients with prosthetic joint implants (including total hip replacements) do not require antibiotic prophylaxis for dental treatment. The Working Party considers that it is unacceptable to expose patients to the adverse effects of antibiotics when there is no evidence that such prophylaxis is of any benefit, but that those who develop any intercurrent infection require prompt treatment with antibiotics to which the infecting organisms are sensitive.

The Working Party has commented that joint infections have rarely been shown to follow dental procedures and are even more rarely caused by oral streptococci.

**Immunosuppression and indwelling intraperitoneal catheters**

Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who are immunosuppressed (including transplant patients) and patients with indwelling intraperitoneal catheters do not require antibiotic prophylaxis for dental treatment provided there is no other indication for prophylaxis.

The Working Party has commented that there is little evidence that dental treatment is followed by infection in immunosuppressed and immunodeficient patients nor is there evidence that dental treatment is followed by infection in patients with indwelling intraperitoneal catheters.

**Blood infections, bacterial**

**Antibacterial therapy for septicaemia: community-acquired**

- A broad-spectrum antipseudomonal penicillin (e.g. piperacillin with tazobactam p. 479, ticarcillin with clavulanic acid p. 480) or a broad-spectrum cephalosporin (e.g. cefuroxime p. 460)

  - If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin p. 465 (or teicoplanin p. 464).

  - If anaerobic infection suspected, add metronidazole p. 475 to broad-spectrum cephalosporin.

  - If other resistant micro-organisms suspected, use a more broad-spectrum beta-lactam antibiotic (e.g. meropenem p. 454).
Antibacterial therapy for septicaemia: hospital-acquired

- A broad-spectrum antipseudomonal beta-lactam antibiotic (e.g. piperacillin with tazobactam p. 479, ticarcillin with clavulanic acid p. 480, ceftazidime p. 458, imipenem with cilastatin p. 454, or meropenem p. 454)
  - If meticillin-resistant \textit{Staphylococcus aureus} suspected, add vancomycin p. 465 (or teicoplanin p. 464).
  - If anaerobic infection suspected, add metronidazole p. 475 to broad-spectrum cephalosporin

Septicaemia related to vascular catheter

- Vancomycin p. 465 (or teicoplanin p. 464)
  - If Gram-negative sepsis suspected, especially in the immunocompromised, add a broad-spectrum antipseudomonal beta-lactam.
  - Consider removing vascular catheter, particularly if infection caused by \textit{Staphylococcus aureus}, pseudomonas, or \textit{Candida} species.

Meningococcal septicaemia

If meningococcal disease suspected, a single dose of benzylpenicillin sodium p. 480 should be given before urgent transfer to hospital, so long as this does not delay the transfer; cefotaxime p. 457 may be an alternative in penicillin allergy; chloramphenicol p. 452 may be used if history of immediate hypersensitivity reaction to penicillin or to cephalosporins.

- Benzylpenicillin sodium or cefotaxime (or ceftriaxone p. 459)
- If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol

To eliminate nasopharyngeal carriage, ciprofloxacin p. 490, or rifampicin p. 508, or ceftriaxone may be used.

**Cardiovascular system infections, bacterial**

Antibacterial therapy for endocarditis: initial ‘blind’ therapy

- Native valve endocarditis, amoxicillin p. 482 (or ampicillin p. 483)
  - Consider adding low-dose gentamicin p. 450
  - If penicillin-allergic, or if meticillin-resistant \textit{Staphylococcus aureus} suspected, or if severe sepsis, use vancomycin p. 465 + low-dose gentamicin
  - If severe sepsis with risk factors for Gram-negative infection, use vancomycin + meropenem p. 454
- If prosthetic valve endocarditis, vancomycin + rifampicin p. 508 + low-dose gentamicin

Antibacterial therapy for native-valve endocarditis caused by staphylococci

- Flucloxacillin p. 486
  - \textit{Suggested duration of treatment} 4 weeks (at least 6 weeks if secondary lung abscess or osteomyelitis also present)
- If \textit{penicillin-allergic} or \textit{if meticillin-resistant Staphylococcus aureus}, vancomycin p. 465 + rifampicin
  - \textit{Suggested duration of treatment} 4 weeks (at least 6 weeks if secondary lung abscess or osteomyelitis also present)

Antibacterial therapy for prosthetic valve endocarditis caused by \textit{staphylococci}

- Flucloxacillin p. 486 + rifampicin p. 508 + low-dose gentamicin
  - \textit{Suggested duration of treatment} at least 6 weeks; review need to continue gentamicin p. 450 at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks
- If \textit{penicillin-allergic} or if \textit{meticillin-resistant Staphylococcus aureus}, vancomycin p. 465 + rifampicin + low-dose gentamicin
  - \textit{Suggested duration of treatment} at least 6 weeks; review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks

Antibacterial therapy for endocarditis caused by fully-sensitive \textit{streptococci}

- Benzylpenicillin sodium p. 480
  - \textit{Suggested duration of treatment} 4–6 weeks (6 weeks for prosthetic valve endocarditis)
- If \textit{penicillin-allergic}, vancomycin p. 465 (or teicoplanin p. 464) + low-dose gentamicin
  - \textit{Suggested duration of treatment} 4–6 weeks (stop gentamicin p. 450 after 2 weeks)

Antibacterial therapy for endocarditis caused by less-sensitive \textit{streptococci}

- Benzylpenicillin sodium p. 480 + low-dose gentamicin
  - \textit{Suggested duration of treatment} 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin p. 450 at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks; stop gentamicin at 2 weeks if micro-organisms moderately sensitive to penicillin
- If \textit{penicillin-allergic} or \textit{highly penicillin-resistant}, vancomycin p. 465 (or teicoplanin p. 464) + low-dose gentamicin
  - \textit{Suggested duration of treatment} 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks; stop gentamicin at 2 weeks if micro-organisms moderately sensitive to penicillin

Antibacterial therapy for endocarditis caused by \textit{enterococci}

- Amoxicillin p. 482 (or ampicillin p. 483) + low dose gentamicin p. 450 or benzylpenicillin sodium p. 480 + low-dose gentamicin
  - \textit{Suggested duration of treatment} 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks
- If \textit{penicillin-allergic} or \textit{penicillin-resistant}, vancomycin p. 465 (or teicoplanin p. 464) + low-dose gentamicin
  - \textit{Suggested duration of treatment} 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks
- If gentamicin resistant, amoxicillin (or ampicillin)
  - Add streptomycin p. 451 (if susceptible) for 2 weeks
  - \textit{Suggested duration of treatment} at least 6 weeks
Antibacterial therapy for endocarditis caused by Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella species (‘HACEK’ micro-organisms)

- Amoxicillin p. 482 (or ampicillin p. 483) + low-dose gentamicin
  
  Suggested duration of treatment 4 weeks (6 weeks for prosthetic valve endocarditis); stop gentamicin p. 450 after 2 weeks
- If amoxicillin-resistant, ceftriaxone p. 459 (or cefotaxime p. 457) + low-dose gentamicin
  
  Suggested duration of treatment 4 weeks (6 weeks for prosthetic valve endocarditis); stop gentamicin after 2 weeks

Central nervous system infections, bacterial

Antibacterial therapy for meningitis: initial empirical therapy

- Transfer patient to hospital urgently.
- If meningococcal disease (meningitis with non-blanching rash or meningococcal septicemia) suspected, benzylpenicillin sodium p. 480 should be given before transfer to hospital, so long as this does not delay the transfer. If a patient with suspected bacterial meningitis without non-blanching rash cannot be transferred to hospital urgently, benzylpenicillin sodium should be given before the transfer. Cefotaxime p. 457 may be an alternative in penicillin allergy; chloramphenicol p. 452 may be used if history of immediate hypersensitivity reaction to penicillin or cephalosporins.
- In hospital, consider adjunctive treatment with dexamethasone p. 581 (particularly if pneumococcal meningitis suspected in adults), preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial; avoid dexamethasone in septic shock, meningococcal septicemia, or if immunocompromised, or in meningitis following surgery.
- Adult and child: 3 months–50 years, cefotaxime (or ceftriaxone p. 459)
  
  Consider adding vancomycin p. 465 if prolonged or multiple use of other antibacterials in the last 3 months, or if travelled, in the last 3 months, to areas outside the UK with highly penicillin- and cephalosporin-resistant pneumococci.
  
  Suggested duration of treatment at least 10 days
- Adult over 50 years: cefotaxime (or ceftriaxone) + amoxicillin p. 482 (or ampicillin p. 483)
  
  Consider adding vancomycin if prolonged or multiple use of other antibacterials in the last 3 months, or if travelled, in the last 3 months, to areas outside the UK with highly penicillin- and cephalosporin-resistant pneumococci.
  
  Suggested duration of treatment at least 10 days

Antibacterial therapy for meningitis caused by meningococci

- Benzylpenicillin sodium p. 480 or cefotaxime p. 457 (or ceftriaxone p. 459)
  
  Suggested duration of treatment 7 days.
- If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol
  
  Suggested duration of treatment 7 days.

Antibacterial therapy for meningitis caused by pneumococci

- Cefotaxime p. 457 (or ceftriaxone p. 459)
  
  Consider adjunctive treatment with dexamethasone p. 581, preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial (may reduce penetration of vancomycin p. 465 into cerebrospinal fluid).
  
  If micro-organism penicillin-sensitive, replace cefotaxime with benzylpenicillin sodium p. 480. If micro-organism highly penicillin- and cephalosporin-resistant, add vancomycin and if necessary rifampicin p. 508.
  
  Suggested duration of antibacterial treatment 14 days

Antibacterial therapy for meningitis caused by Haemophilus influenzae

- Cefotaxime p. 457 (or ceftriaxone p. 459)
  
  Consider adjunctive treatment with dexamethasone p. 581, preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial.
  
  Suggested duration of antibacterial treatment 10 days.
  
  For H. influenzae type b give rifampicin for 4 days before hospital discharge to those under 10 years of age or to those in contact with vulnerable household contacts
- If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, or if micro-organism resistant to cefotaxime, chloramphenicol
  
  Consider adjunctive treatment with dexamethasone, preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial.
  
  Suggested duration of antibacterial treatment 10 days.
  
  For H. influenzae type b give rifampicin p. 508 for 4 days before hospital discharge to those under 10 years of age or to those in contact with vulnerable household contacts

Antibacterial therapy for meningitis caused by Listeria

- Amoxicillin p. 482 (or ampicillin p. 483) + gentamicin
  
  Suggested duration of treatment 21 days.
  
  Consider stopping gentamicin p. 450 after 7 days.
- If history of immediate hypersensitivity reaction to penicillin, co-trimoxazole
  
  Suggested duration of treatment 21 days.

Ear infections, bacterial

Antibacterial therapy for otitis externa

For topical treatments, consider Otitis externa, under Ear p. 976.

Consider systemic antibacterial if spreading cellulitis or patient systemically unwell.

- Flucloxacillin
  
  If penicillin-allergic, clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
  
  If pseudomonas suspected, ciprofloxacin p. 490 (or an aminoglycoside)

Antibacterial therapy for otitis media

Many infections caused by viruses. Most uncomplicated cases resolve without antibacterial treatment. In children without systemic features, antibacterial treatment may be started after 72 hours if no improvement. Consider earlier treatment if deterioration, if systemically unwell, if at high risk of serious complications (e.g. in immunosuppression,
cystic fibrosis), if mastoiditis present, or in children under 2 years of age with bilateral otitis media.

- Amoxicillin p. 482 (or ampicillin p. 483)
  Consider co-amoxiclav p. 484 if no improvement after 48 hours.
  In severe infection, initial parenteral therapy with co-amoxiclav or cefuroxime p. 460.
  Suggested duration of treatment 5 days (longer if severely ill).
- If penicillin-allergic, clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
  Suggested duration of treatment 5 days (longer if severely ill)

**Eye infections, bacterial**

**Antibacterial therapy for purulent conjunctivitis**
- Chloramphenicol eye drops p. 955.

**Gastro-intestinal system infections, bacterial**

**Antibacterial therapy for gastro-enteritis**
Frequently self-limiting and may not be bacterial.
- Antibacterial not usually indicated

**Antibacterial therapy for campylobacter enteritis**
Frequently self-limiting; treat if immunocompromised or if severe infection.
- Clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
- Alternative, ciprofloxacin
  Strains with decreased sensitivity to ciprofloxacin p. 490 isolated frequently

**Antibacterial therapy for salmonella (non-typhoid)**
Treat invasive or severe infection. Do not treat less severe infection unless there is a risk of developing invasive infection (e.g., immunocompromised patients, those with haemoglobinopathy, or children under 6 months of age).
- Ciprofloxacin p. 490 or cefotaxime p. 457

**Antibacterial therapy for shigellosis**
Antibacterial not indicated for mild cases.
- Ciprofloxacin p. 490 or azithromycin p. 469
- Alternatives if micro-organism sensitive, amoxicillin p. 482 or trimethoprim p. 462

**Antibacterial therapy for typhoid fever**
Infections from Middle-East, South Asia, and South-East Asia may be multiple-antibacterial-resistant and sensitivity should be tested.
- Cefotaxime p. 457 (or ceftriaxone p. 459)
  Azithromycin p. 469 may be an alternative in mild or moderate disease caused by multiple-antibacterial-resistant organisms.
- Alternative if micro-organism sensitive, ciprofloxacin p. 490

**Antibacterial therapy for Clostridium difficile infection**
- For first episode of mild to moderate infection, oral metronidazole
  Suggested duration of treatment 10–14 days
- For second or subsequent episode of infection, for severe infection, for infection not responding to metronidazole p.
  475, or in patients intolerant of metronidazole, oral vancomycin
  For severe infection in patients with multiple co-morbidities who are receiving treatment with other antibacterials, or for second or subsequent episode of infection, fidaxomicin p. 468 can replace vancomycin p. 465
  Suggested duration of treatment 10–14 days
- For infection not responding to vancomycin or fidaxomicin, for life-threatening infection, or in patients with ileus, oral vancomycin + i/v metronidazole
  For infection not responding to vancomycin in patients without life-threatening infection or ileus, fidaxomicin can be used instead of vancomycin + metronidazole
  Suggested duration of treatment 10–14 days

**Antibacterial therapy for biliary-tract infection**
- Ciprofloxacin p. 490 or gentamicin p. 450 or a cephalosporin

**Antibacterial therapy for perforitis**
- A cephalosporin + metronidazole p. 1008 or gentamicin p. 450 + metronidazole or gentamicin + clindamycin p. 467 or piperacillin with tazobactam p. 479 alone

**Antibacterial therapy for perforitis: peritoneal dialysis-associated**
- Vancomycin p. 465 (or teicoplanin p. 464) + ceftazidime p. 458 added to dialysis fluid or vancomycin added to dialysis fluid + ciprofloxacin p. 490 by mouth
  Suggested duration of treatment 14 days or longer

**Genital system infections, bacterial**

**Antibacterial therapy for bacterial vaginosis**
- Oral metronidazole
  Suggested duration of treatment 5–7 days (or high-dose metronidazole p. 475 as a single dose)
- Alternatively, topical metronidazole for 5 days or topical clindamycin p. 467 for 7 days

**Antibacterial therapy for uncomplicated genital chlamydial infection, non-gonococcal urethritis, and non-specific genital infection**
Contact tracing recommended.
- Azithromycin or doxycycline
  Suggested duration of treatment azithromycin p. 469 as a single dose or doxycycline p. 496 for 7 days
- Alternatively, erythromycin p. 471.
  Suggested duration of treatment 14 days

**Antibacterial therapy for gonorrhoea: uncomplicated**
Contact tracing recommended. Consider chlamydia co-infection. Choice of alternative antibacterial regimen depends on locality where infection acquired.
- Azithromycin p. 469 + i.m ceftriaxone
  Suggested duration of treatment is a single-dose of each antibacterial
- Alternatively, when parenteral administration is not possible, cefixime p. 457 + azithromycin
  Suggested duration of treatment is a single-dose of each antibacterial
- Alternatively, if micro-organism is sensitive to a quinolone, ciprofloxacin p. 490 + azithromycin
  Suggested duration of treatment is a single-dose of each antibacterial
Antibacterial therapy for pelvic inflammatory disease

Contact tracing recommended.
- Doxycycline p. 496 + metronidazole p. 475 + single-dose of i/m ceftriaxone p. 459 or oloxacan p. 494 + metronidazole
  *Suggested duration of treatment* 14 days (except i/m ceftriaxone p. 459).
- In severely ill patients, initial treatment with doxycycline p. 496 + i/v ceftriaxone p. 459 + i/v metronidazole p. 475, then switch to oral treatment with doxycycline + metronidazole to complete 14 days’ treatment

Antibacterial therapy for early syphilis (infection of less than 2 years)

Contact tracing recommended.
- Benzathine benzylpenicillin [unlicensed]
  *Suggested duration of treatment* single-dose (repeat dose after 7 days for women in the third trimester of pregnancy).
- Alternatively, doxycycline p. 496 or erythromycin
  *Suggested duration of treatment* 14 days

Antibacterial therapy for late latent syphilis (asymptomatic infection of more than 2 years)

Contact tracing recommended.
- Benzathine benzylpenicillin [unlicensed]
  *Suggested duration of treatment* once weekly for 2 weeks
- Alternatively, doxycycline p. 496
  *Suggested duration of treatment* 28 days

Asymptomatic contacts of patients with infectious syphilis
- Doxycycline p. 496
  *Suggested duration of treatment* 14 days

Musculoskeletal system infections, bacterial

Antibacterial therapy for osteomyelitis

Seek specialist advice if chronic infection or prostheses present.
- Flucloxacillin p. 486
  Consider adding fusidic acid p. 463 or rifampicin p. 508 for initial 2 weeks.
  *Suggested duration of treatment* 6 weeks for acute infection
- If penicillin-allergic, clindamycin p. 467
  Consider adding fusidic acid or rifampicin for initial 2 weeks.
  *Suggested duration of treatment* 6 weeks for acute infection
- If meticillin-resistant Staphylococcus aureus suspected, vancomycin p. 465 (or teicoplanin p. 464)
  Consider adding fusidic acid or rifampicin for initial 2 weeks.
  *Suggested duration of treatment* 6 weeks for acute infection

Antibacterial therapy for septic arthritis

Seek specialist advice if prostheses present.
- Flucloxacillin p. 486
  *Suggested duration of treatment* 4–6 weeks (longer if infection complicated).
- If penicillin-allergic, clindamycin p. 467
  *Suggested duration of treatment* 4–6 weeks (longer if infection complicated).
- If meticillin-resistant Staphylococcus aureus suspected, vancomycin p. 465 (or teicoplanin p. 464)
  *Suggested duration of treatment* 4–6 weeks (longer if infection complicated).
- If gonococcal arthritis or Gram-negative infection suspected, cefotaxime p. 457 (or ceftriaxone p. 459)
  *Suggested duration of treatment* 4–6 weeks (longer if infection complicated; treat gonococcal infection for 2 weeks).

Nose infections, bacterial

Antibacterial therapy for sinusitis

Antibacterial should usually be used only for persistent symptoms and purulent discharge lasting at least 7 days or if severe symptoms. Also, consider antibacterial for those at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis).
- Amoxicillin p. 482 (or ampicillin p. 483) or doxycycline p. 496 or clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
  *Suggested duration of treatment* 7 days.
- Consider oral co-amoxiclav p. 484 if no improvement after 48 hours.
- In severe infection, initial parenteral therapy with co-amoxiclav or cefuroxime p. 460 may be required.

Oral bacterial infections

Antibacterial drugs should only be prescribed for the treatment of oral infections on the basis of defined need. They may be used in conjunction with (but not as an alternative to) other appropriate measures, such as providing drainage or extracting a tooth. The ‘blind’ prescribing of an antibacterial for unexplained pyrexia, cervical lymphadenopathy, or facial swelling can lead to difficulty in establishing the diagnosis. In severe oral infections, a sample should always be taken for bacteriology.

Oral infections which may require antibacterial treatment include acute periapical or periodontal abscess, cellulitis, acutely created oral-antral communication, and acute necrotising ulcerative gingivitis, and destructive forms of chronic periodontal disease. Most of these infections are readily resolved by the early establishment of drainage and removal of the cause (typically an infected necrotic pulp). Antibacterials may be required if treatment has to be delayed, in immunocompromised patients, or in those with conditions such as diabetes or Paget’s disease. Certain rarer infections including bacterial sialadenitis, osteomyelitis, actinomycosis, and infections involving fascial spaces such as Ludwig’s angina, require antibiotics and specialist hospital care.

Antibacterial drugs may also be useful after dental surgery in some cases of spreading infection. Infection may spread to involve local lymph nodes, to fascial spaces (where it can cause airway obstruction), or into the bloodstream (where it can lead to cavernous sinus thrombosis and other serious complications). Extension of an infection can also lead to...
maxillary sinusitis; osteomyelitis is a complication, which usually arises when host resistance is reduced.

If the oral infection fails to respond to antibacterial treatment within 48 hours the antibacterial should be changed, preferably on the basis of bacteriological investigation. Failure to respond may also suggest an incorrect diagnosis, lack of essential additional measures (such as drainage), poor host resistance, or poor patient compliance.

Combination of a penicillin (or a macrolide) with metronidazole p. 475 may sometimes be helpful for the treatment of severe oral infections or oral infections that have not responded to initial antibacterial treatment.

**Penicillins**

Phenoxymethylpenicillin p. 481 is effective for dentoalveolar abscess.

**Broad-spectrum penicillins**

Amoxicillin p. 482 is as effective as phenoxymethylpenicillin p. 481 but is better absorbed; however, it may encourage emergence of resistant organisms.

Like phenoxymethylpenicillin, amoxicillin is ineffective against bacteria that produce beta-lactamases.

Amoxicillin may be useful for short course oral regimens. Co-amoxiclav p. 484 is active against beta-lactamase-producing bacteria that are resistant to amoxicillin. Co-amoxiclav may be used for severe dental infection with spreading cellulitis or dental infection not responding to first-line antibacterial treatment.

**Cephalosporins**

The cephalosporins offer little advantage over the penicillins in dental infections, often being less active against anaerobes. Infections due to oral streptococci (often termed viridans streptococci) which become resistant to penicillin are usually also resistant to cephalosporins. This is of importance in the case of patients who have had rheumatic fever and are on long-term penicillin therapy. Cefalexin p. 456 and cefradine p. 458 have been used in the treatment of oral infections.

**Tetracyclines**

In adults, tetracyclines can be effective against oral anaerobes but the development of resistance (especially by oral streptococci) has reduced their usefulness for the treatment of acute oral infections; they may still have a role in the treatment of destructive (refractory) forms of periodontal disease. Doxycycline p. 498 has a longer duration of action than tetracycline p. 498 or oxytetracycline p. 498 and need only be given once daily; it is reported to be more active against anaerobes than some other tetracyclines.

Doxycycline may have a role in the treatment of recurrent aphthous ulceration, or as an adjunct to gingival scaling and root planing for periodontitis.

**Macrolides**

The macrolides are an alternative for oral infections in penicillin-allergic patients or where a beta-lactamase producing organism is involved. However, many organisms are now resistant to macrolides or rapidly develop resistance; their use should therefore be limited to short courses.

**Clindamycin**

Clindamycin p. 467 should not be used routinely for the treatment of oral infections because it may be no more effective than penicillins against anaerobes and there may be cross-resistance with erythromycin-resistant bacteria. Clindamycin can be used for the treatment of dentoalveolar abscess that has not responded to penicillin or to metronidazole p. 475.

**Metronidazole and tinidazole**

Metronidazole p. 475 is an alternative to a penicillin for the treatment of many oral infections where the patient is allergic to penicillin or the infection is due to beta-lactamase-producing anaerobes. It is the drug of first choice for the treatment of acute necrotising ulcerative gingivitis (Vincent’s infection) and pericoronitis; amoxicillin p. 482 is a suitable alternative. For these purposes metronidazole for 3 days is sufficient, but the duration of treatment may need to be longer in pericoronitis. Tinidazole p. 476 is licensed for the treatment of acute ulcerative gingivitis.

**Respiratory system infections, bacterial**

**Antibacterial therapy for haemophilus influenzae epiglottitis**

- Cefotaxime p. 457 (or ceftriaxone p. 459)
- If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol p. 452

**Antibacterial therapy for chronic bronchitis: acute exacerbations**

Treat if increase in sputum purulence accompanied by an increase in sputum volume or increase in dyspnoea.

- Amoxicillin p. 482 (or ampicillin p. 483) or a tetracycline p. 496
  - Some pneumococci and Haemophilus influenzae strains tetracycline-resistant; approx. 20% H. influenzae strains amoxicillin-resistant
  - Suggested duration of treatment 5 days; longer treatment may be necessary in severely ill patients
- Alternative, clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
  - Suggested duration of treatment 5 days; longer treatment may be necessary in severely ill patients

**Antibacterial therapy for pneumonia: low-severity community-acquired**

- Amoxicillin p. 482 (or ampicillin p. 483)
  - Pneumococci with decreased penicillin sensitivity being isolated, but not yet common in UK.
  - If atypical pathogens suspected, add clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471). If staphylococci suspected (e.g. in influenza or measles), add flucloxacillin p. 486. 
  - Suggested duration of treatment 7 days (14–21 days for infections caused by staphylococci)
- Alternatives, doxycycline p. 496 or clarithromycin (or azithromycin or erythromycin)
  - Suggested duration of treatment 7 days (14–21 days for infections caused by staphylococci)

**Antibacterial therapy for pneumonia: moderate-severity community-acquired**

- Amoxicillin p. 482 (or ampicillin p. 483) + clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471) or doxycycline p. 496 alone
  - Pneumococci with decreased penicillin sensitivity being isolated, but not yet common in UK.
  - If meticillin-resistant Staphylococcus aureus suspected, add vancomycin p. 465 (or teicoplanin p. 464).
  - Suggested duration of treatment 7 days (14–21 days for infections caused by staphylococci)
Antibacterial therapy for pneumonia: high-severity community-acquired
- Benzylpenicillin sodium p. 480 + clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471) or benzylpenicillin sodium + doxycycline
  If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin p. 465 (or teicoplanin p. 464).
  *Suggested duration of treatment* 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci suspected)
- If life-threatening infection, or if Gram-negative infection suspected, or if co-morbidities present, or if living in long-term residential or nursing home
  *Suggested duration of treatment* 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci or Gram-negative enteric bacilli suspected)
- Alternatives if life-threatening infection, or if Gram-negative infection suspected, or if co-morbidities present, or if living in long-term residential or nursing home, cefuroxime p. 460 + clarithromycin (or azithromycin or erythromycin) or cefotaxime (or ceftriaxone p. 459) + clarithromycin (or azithromycin or erythromycin)
  If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin (or teicoplanin).
  *Suggested duration of treatment* 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci or Gram-negative enteric bacilli suspected)
- Alternatives if life-threatening infection, or if Gram-negative infection suspected, or if co-morbidities present, or if living in long-term residential or nursing home, co-amoxiclav p. 484 + clarithromycin (or azithromycin or erythromycin) or benzylpenicillin sodium + doxycycline
  If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin p. 465 (or teicoplanin).
  *Suggested duration of treatment* 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci suspected)
  - Clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
    - If high-severity Legionella infection, add rifampicin p. 508 for the first few days.
    - *Suggested duration of treatment* 14 days (usually 7–10 days for Legionella)
  - *Alternative if Legionella infection suspected*, a quinolone
    - If high-severity Legionella infection, add clarithromycin (or azithromycin or erythromycin) or rifampicin for the first few days.
    - *Suggested duration of treatment usually* 7–10 days
  - *Alternative for chlamydial or mycoplasma infections*, doxycycline p. 496
    - *Suggested duration of treatment* 14 days

Antibacterial therapy for pneumonia: hospital-acquired
- Early-onset infection less than 5 days after admission to hospital, co-amoxiclav p. 484 or cefuroxime
  If life-threatening infection, or if history of antibacterial treatment in the last 3 months, or if resistant micro-organisms suspected, treat as for late-onset hospital-acquired pneumonia.
  *Suggested duration of treatment* 7 days
- Late-onset infection (more than 5 days after admission to hospital), an antipseudomonal penicillin (e.g. piperacillin with tazobactam p. 479) or a broad-spectrum cephalosporin (e.g. ceftazidime p. 458) or another antipseudomonal beta-lactam or a quinolone (e.g. ciprofloxacin p. 490)
  If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin p. 465.
  For severe illness caused by *Pseudomonas aeruginosa*, consider adding an aminoglycoside.
  *Suggested duration of treatment* 7 days (longer if *Pseudomonas aeruginosa* confirmed)

Skin infections, bacterial

Antibacterial therapy for impetigo: small areas of skin infected
Seek local microbiology advice before using topical treatment in hospital.
- Topical fusidic acid p. 1008
  - *Suggested duration of treatment* 7 days is usually adequate (max. 10 days).
- Alternatively, if meticillin-resistant *Staphylococcus aureus*, topical mupirocin p. 1009
  - *Suggested duration of treatment* 7 days is usually adequate (max. 10 days).

Impetigo: widespread infection
- Oral flucloxacillin p. 486
  - If streptococci suspected in severe infection, add phenoxymethylpenicillin p. 481.
  - *Suggested duration of treatment* 7 days.
- If penicillin-allergic, oral clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
  - *Suggested duration of treatment* 7 days.

Antibacterial therapy for erysipelas
- Phenoxymethylpenicillin p. 481 or benzylpenicillin sodium
  - If severe infection, replace phenoxymethylpenicillin or benzylpenicillin sodium with high-dose flucloxacillin p. 486
  - *Suggested duration of treatment* at least 7 days.
- If penicillin-allergic, clindamycin p. 467 or clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471)
  - *Suggested duration of treatment* at least 7 days

Antibacterial therapy for cellulitis
- Flucloxacillin p. 486 (high-dose)
  - If streptococcal infection confirmed, replace flucloxacillin with phenoxymethylpenicillin p. 481 or benzylpenicillin sodium p. 480
  - If Gram-negative bacteria or anaerobes suspected, use broad-spectrum antibacterials.
- If penicillin-allergic, clindamycin p. 467 or clarithromycin p. 470 (or azithromycin p. 469 or erythromycin p. 471) or vancomycin p. 465 (or teicoplanin p. 464)
  - If Gram-negative bacteria suspected, use broad-spectrum antibacterials.

Antibacterial therapy for animal and human bites
Cleanse wound thoroughly. For tetanus-prone wound, give human tetanus immunoglobulin p. 1065 (with a tetanus-containing vaccine if necessary, according to immunisation history and risk of infection). Consider rabies prophylaxis for bites from animals in endemic countries. Assess risk of blood-borne viruses (including HIV, hepatitis B and C) and give appropriate prophylaxis to prevent viral spread.
Co-amoxiclav p. 484.
- If penicillin-allergic, doxycycline p. 496 + metronidazole p. 475


Antibacterial therapy for mastitis during breast-feeding
Treat if severe, if systemically unwell, if nipple fissure present, if symptoms do not improve after 12–24 hours of effective milk removal, or if culture indicates infection.

- Flucloxacillin p. 486, if *penicillin-allergic*, erythromycin

Continue breast-feeding or expressing milk during treatment.

Suggested duration of treatment 10–14 days.

AMINOGLYCOSIDES

Aminoglycosides
These include amikacin p. 450, gentamicin p. 450, neomycin sulfate p. 451, streptomycin p. 451, and tobramycin p. 452. All are bactericidal and active against some Gram-positive and many Gram-negative organisms. Amikacin, gentamicin, and tobramycin are also active against *Pseudomonas aeruginosa*; streptomycin is active against *Mycobacterium tuberculosis* and is now almost entirely reserved for tuberculosis.

The aminoglycosides are not absorbed from the gut (although there is a risk of absorption in inflammatory bowel disease and liver failure) and must therefore be given by injection for systemic infections.

Gentamicin is the aminoglycoside of choice in the UK and is used widely for the treatment of serious infections. It has a broad spectrum but is inactive against anaerobes and has poor activity against haemolytic streptococci and pneumococci. When used for the ‘blind’ therapy of undiagnosed serious infections it is usually given in conjunction with a penicillin or metronidazole p. 475 (or both). Gentamicin is used together with another antibiotic for the treatment of endocarditis. Streptomycin may be used as an alternative in gentamicin-resistant enterococcal endocarditis.

Loading and maintenance doses of gentamicin may be calculated on the basis of the patient’s weight and renal function (e.g. using a nomogram); adjustments are then made according to serum-gentamicin concentrations. High doses are occasionally indicated for serious infections, especially in the neonate, in the patient with cystic fibrosis, or in the immunocompromised patient. Whenever possible treatment should not exceed 7 days.

Amikacin is more stable than gentamicin to enzyme inactivation. Amikacin is used in the treatment of serious infections caused by gentamicin-resistant Gram-negative bacilli.

Tobramycin has similar activity to gentamicin. It is slightly more active against *Ps. aeruginosa* but shows less activity against certain other Gram-negative bacteria. Tobramycin can be administered by nebuliser or by inhalation of powder on a cyclical basis (28 days of tobramycin followed by a 28-day tobramycin-free interval) for the treatment of chronic pulmonary *Ps. aeruginosa* infection in cystic fibrosis; however, resistance may develop and some patients do not respond to treatment.

Neomycin sulfate is too toxic for parenteral administration and can only be used for infections of the skin or mucous membranes or to reduce the bacterial population of the colon prior to bowel surgery or in hepatic failure. Oral administration may lead to malabsorption. Small amounts of neomycin sulfate may be absorbed from the gut in patients with hepatic failure and, as these patients may also be uremic, cumulation may occur with resultant ototoxicity.

Once daily dosage
Once daily administration of aminoglycosides is more convenient, provides adequate serum concentrations, and in many cases has largely superseded *multiple daily dose regimens* (given in 2–3 divided doses during the 24 hours). Local guidelines on dosage and serum concentrations should be consulted. A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with endocarditis due to Gram-positive bacteria, HACEK endocarditis, burns of more than 20% of the total body surface area, or creatinine clearance less than 20 mL/minute. There is insufficient evidence to recommend a once daily, high-dose regimen of an aminoglycoside in pregnancy.

Serum concentrations
Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy. Serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides and must be determined in the elderly, in obesity, and in cystic fibrosis, or if high doses are being given, or if there is renal impairment.

Aminoglycosides (by injection)

CONTRA-INDICATIONS
Myasthenia gravis
(aminoglycosides may impair neuromuscular transmission)

CAUTIONS
GENERAL CAUTIONS
Care must be taken with dosage (the main side-effects of the aminoglycosides are dose-related) - conditions characterised by muscular weakness (aminoglycosides may impair neuromuscular transmission) - if possible, dehydration should be corrected before starting an aminoglycoside

SPECIFIC CAUTIONS
Whenever possible, parenteral treatment should not exceed 7 days

INTERACTIONS → Appendix 1 (aminoglycosides).
If possible, aminoglycosides should not be given with potentially ototoxic drugs (e.g. cisplatin). Administration of an aminoglycoside and of an ototoxic diuretic (e.g. furosemide) should be separated by as long a period as practicable.

SIDE-EFFECTS

- Rare Antibiotic-associated colitis - electrolyte disturbances - hypocalcaemia - hypokalaemia - hypomagnesaemia on prolonged therapy - nausea - peripheral neuropathy - stomatitis - vomiting
- Very rare Blood disorders - CNS effects - convulsions - encephalopathy - headache
- Frequency not known Auditory damage - impaired neuromuscular transmission - irreversible ototoxicity - nephrotoxicity - transient myasthenic syndrome in patients with normal neuromuscular function with large doses given during surgery - vestibular damage

SIDE-EFFECTS, FURTHER INFORMATION

Nephrotoxicity Occurs most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.

PREGNANCY
There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin. The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential.
If given during pregnancy, serum-aminoglycoside concentration monitoring is essential.

- **RENAL IMPAIRMENT** If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well. Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment. Otoxicity and nephrotoxicity occur commonly in patients with renal failure. A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20 mL/minute.

  Serum-aminoglycoside concentrations must be monitored in patients with renal impairment; earlier and more frequent measurement of aminoglycoside concentration may be required.

- **MONITORING REQUIREMENTS**
  - Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy.
  - Serum-aminoglycoside concentrations should be measured in all patients receiving parenteral aminoglycosides and must be determined in the elderly, obesity, if high doses are being given and in cystic fibrosis.
  - In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen and after a dose change. For multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (‘peak’ concentration) and also just before the next dose (‘trough’ concentration). If the pre-dose (‘trough’) concentration is high, the interval between doses must be increased. If the post-dose (‘peak’) concentration is high, the dose must be decreased. For once daily dose regimens, consult local guidelines on serum concentration monitoring.
  - Renal function should be assessed before starting an aminoglycoside and during treatment.
  - Auditory and vestibular function should also be monitored during treatment.

- **SIDE-EFFECTS**
  - Uncommon Rash

- **MONITORING REQUIREMENTS**
  - **Multiple daily dose regimen:** one-hour (‘peak’) serum concentration should not exceed 30 mg/litre; pre-dose (‘trough’) concentration should be less than 10 mg/litre.
  - **Once daily dose regimen:** pre-dose (‘trough’) concentration should be less than 5 mg/litre.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Amikin®); intermittent in Glucose 5% or Sodium chloride 0.9%. To be given over 30 minutes.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Once daily dose regime not to be used for endocarditis, febrile neutropenia, or meningitis. Consult local guidelines.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **AMIKACIN (Non-proprietary)**
  - Amikacin (as Amikacin sulfate) 250 mg per 1 ml
  - Amikacin 500mg/2ml solution for injection vials | 5 vial | £60.00
  - Amikin (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Amikacin (as Amikacin sulfate) 50 mg per 1 ml
  - Amikin 100mg/2ml solution for injection vials | 5 vial | £10.33

---

**Gentamicin**

**INDICATIONS AND DOSE**

Gram-positive bacterial endocarditis or HACEK endocarditis (in combination with other antibacterials)

- **BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - Adult: 1 mg/kg every 12 hours, intravenous injection to be administered over at least 3 minutes, to be given in a multiple daily dose regimen

- **Septicaemia | Meningitis and other CNS infections | Biliary-tract infection | Acute pyelonephritis | Endocarditis | Pneumonia in hospital patients | Adjunct in listerial meningitis | Prostatitis**
  - **BY INTRAVENOUS INFUSION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
  - Adult: 3–5 mg/kg daily in 3 divided doses, to be given in a multiple daily dose regimen, divided doses to be given every 8 hours, intravenous injection to be administered over at least 3 minutes
  - **BY INTRAVENOUS INFUSION**
  - Adult: Initially 5–7 mg/kg, subsequent doses adjusted according to serum-gentamicin concentration, to be given in a once daily dose regimen

- **CNS infections (administered on expert advice)**
  - **BY INTRATHECAL INJECTION**
  - Adult: 1 mg daily, increased if necessary to 5 mg daily, seek specialist advice

- **Surgical prophylaxis (including joint replacement surgery)**
  - **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 1.5 mg/kg, intravenous injection to be administered over at least 3 minutes, administer dose up to 30 minutes before the procedure, dose may be repeated every 8 hours for high-risk procedures and joint replacement surgery; up to 3 further doses may be given
  - **BY INTRAVENOUS INFUSION**
  - Adult: 5 mg/kg for 1 dose, administer dose up to 30 minutes before the procedure

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, use ideal weight for height to calculate dose and monitor serum-gentamicin concentration closely.

- **SIDE-EFFECTS**
  - Uncommon Rash

- **MONITORING REQUIREMENTS**
  - For multiple daily dose regimen, one-hour (‘peak’) serum concentration should be 5–10 mg/litre; pre-dose (‘trough’) concentration...
should be less than 2 mg/litre. For multiple daily dose regimens in endocarditis, one-hour (‘peak’) serum concentration should be 3–5 mg/litre; pre-dose (‘trough’) concentration should be less than 1 mg/litre. Serum-gentamicin concentration should be measured after 3 or 4 doses, then at least every 3 days and after a dose change (more frequently in renal impairment). For once-daily dose regimen, consult local guidelines on monitoring serum-gentamicin concentration.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Cidomycin®); Gentamicin paediatric injection, Beacon; Gentamicin injection Hospira), give intermittently or via drip tubing in Glucose 5% or Sodium Chloride 0.9%. Suggested volume for intermittent infusion 50–100 ml given over 20–30 minutes (given over 60 minutes for once daily dose regimen).

**PRESCRIBING AND DISPENSING INFORMATION** Local guidelines may vary in the dosing advice provided for once daily administration.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, oral suspension, oral solution, cream, injection.

**Solution for injection**

- **GENTAMICIN (Non-proprietary)**
  - Gentamicin (as Gentamicin sulfate) 5 mg per 1 ml Gentamicin Intrathecal 5mg/1ml solution for injection ampoules | 5 ampoule (£50) £22.50 (Hospital only)
  - Gentamicin (as Gentamicin sulfate) 10 mg per 1 ml Gentamicin Paediatric 20mg/2ml solution for injection vials | 5 vial (£50) £11.25
  - Gentamicin (as Gentamicin sulfate) 40 mg per 1 ml Gentamicin 80mg/2ml solution for injection vials | 5 vial (£50) £20.00
  - Gentamicin 80mg/2ml solution for injection ampoules | 10 ampoule (£50) £30.00
- **Cidomycin**
  - Gentamicin (as Gentamicin sulfate) 40 mg per 1 ml Cidomycin Adult injectable 80mg/2ml solution for injection vials | 5 vial (£50) £6.88
  - Cidomycin Adult Injectable 80mg/2ml solution for injection ampoules | 5 ampoule (£50) £6.88

**Neomycin sulfate**

**INDICATIONS AND DOSE**

- **Bowel sterilisation before surgery**
  - **BY MOUTH**
    - Adult: 1 g every 1 hour for 4 hours, then 1 g every 4 hours for 2–3 days
  - **Hepatic coma**
    - Adult: Up to 4 g daily in divided doses usually for 5–7 days

- **CONTRA-INDICATIONS** Intestinal obstruction - myasthenia gravis (aminoglycosides may impair neuromuscular transmission).

- **CAUTIONS** Avoid prolonged use

**CAUTIONS, FURTHER INFORMATION**

Although neomycin is associated with the same cautions as other aminoglycosides it is generally considered too toxic for systemic use.

**INTERACTIONS**

- **Appendix 1 (aminoglycosides).**

**SIDE-EFFECTS**

- **Common or very common** Rash
- **Frequency not known** Impaired intestinal absorption with steatorrhea and diarrhoea - increased salivation

**SIDE-EFFECTS, FURTHER INFORMATION**

Although neomycin is associated with the same side effects as other aminoglycosides it is generally considered too toxic for systemic use and is poorly absorbed after oral administration.

**PREGNANCY**

There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy.

**HEPATIC IMPAIRMENT** Absorbed from gastro-intestinal tract in liver disease—increased risk of ototoxicity.

**RENAI IMPAIRMENT** Adjust dose according to individual patient monitoring. Increased potential for systemic side effects, notably ototoxicity and nephrotoxicity in renal impairment.

**MONITORING REQUIREMENTS**

- Renal function should be assessed before starting an aminoglycoside and during treatment.
- Auditory and vestibular function should also be monitored during treatment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, cream, injection.

**Tablet**

- **NEOMYCIN SULFATE (Non-proprietary)**
  - Neomycin sulfate 500 mg Neomycin 500mg tablets | 100 tablet (£50) £34.69

**Streptomycin**

**INDICATIONS AND DOSE**

Tuberculosis, resistant to other treatment, in combination with other drugs

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult: 15 mg/kg daily (max. per dose 1 g), reduce dose in those under 50 kg and those over 40 years

**Adjunct to doxycycline in brucellosis (administered on expert advice)**

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult: (consult local protocol)

**Enterococcal endocarditis**

- Adult: (consult local protocol)

**UNLICENSED USE**

Use in tuberculosis is an unlicensed indication.

**Important safety information**

Side-effects increase after a cumulative dose of 100 g, which should only be exceeded in exceptional circumstances.

**SIDE-EFFECTS**

- **Common or very common** Rash
- **Frequency not known** Hypersensitivity reactions - paraesthesia of mouth

**RENAI IMPAIRMENT** Should preferably be avoided. If essential, use with great care and consider dose reduction.

**MONITORING REQUIREMENTS**

- One-hour (‘peak’) concentration should be 15–40 mg/litre; pre-dose (‘trough’) concentration should be less than 5 mg/litre (less than 1 mg/litre in renal impairment or in those over 50 years).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: powder for solution for injection.
Tobramycin

**INDICATIONS AND DOSE**

- Septicaemia | Meningitis and other CNS infections | Biliary tract infection | Acute pyelonephritis or prostatitis | Pneumonia in hospital patients
  - BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION
    - Adult: 3 mg/kg daily in 3 divided doses; increased if necessary up to 5 mg/kg daily in 3–4 divided doses, increased dose used in severe infection; dose to be reduced back to 3 mg/kg as soon as clinically indicated

- Urinary-tract infection
  - BY INTRAMUSCULAR INJECTION
  - Adult: 112 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution

  - BY INHALATION OF POWDER
  - Adult: 112 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin inhalation powder

**CAUTIONS**

- When used by inhalation | Severe haemoptysis—risk of further haemorrhage
- **SIDE-EFFECTS**
  - Uncommon
  - With intramuscular use | Rash
  - With intravenous use | Rash
  - Frequency not known
  - When used by inhalation | Bronchospasm | cough (more frequent by inhalation of powder) | dysphonia | epistaxis | haemoptysis | laryngitis | mouth ulcers | pharyngitis | salivary hypersecretion | taste disturbances

**MONITORING REQUIREMENTS**

- With intramuscular use or intravenous use | One-hour (‘peak’) serum concentration should not exceed 10 mg/litre; pre-dose (‘trough’) concentration should be less than 2 mg/litre.
- When used by inhalation | Measure lung function before and after initial dose of tobramycin and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using bronchodilator. Monitor renal function before treatment and then annually.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use | For intravenous infusion (Nebcin®); intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%. For adult intermittent infusion suggested volume 50–100 mL given over 20–60 minutes.
- When used by inhalation | Other inhaled drugs should be administered before tobramycin.

**PATIENT AND CARER ADVICE**

Patient counselling is advised for Tobramycin dry powder for inhalation (administration).

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**
  - Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013) NICE TA276
  - Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by *Pseudomonas aeruginosa* in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contra-indications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA276

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Solution for injection**

- **TOBRAMYCIN (Non-proprietary)**
  - Tobramycin (as Tobramycin sulfate) 40 mg per 1 ml Tobramycin 40mg/1ml solution for injection vials | 10 vial (PMS) £37.00 | 10 vial (PMS) £37.00 (Hospital only)
  - Tobramycin 80mg/2ml solution for injection vials | 5 vial (PMS) £20.80 | 10 vial (PMS) £37.72 | 10 vial (PMS) £47.00 (Hospital only)
  - Tobramycin 240mg/6ml solution for injection vials | 1 vial (PMS) £19.20

- **Brands** may include Nebcin

**Inhalation powder**

- **Tobi Podhaler** (Novartis Pharmaceuticals UK Ltd)

**Nebuliser liquid**

- **Bramitob** (Chiesi Ltd)
  - Tobramycin 75 mg per 1 ml Bramitob 300mg/4ml nebuliser solution 4ml ampoules | 56 ampoule (PMS) £1.187.00

- **TOBI** (Novartis Pharmaceuticals UK Ltd)
  - Tobramycin 60 mg per 1 ml Tobi 300mg/5ml nebuliser solution 5ml ampoules | 56 ampoule (PMS) £1.187.20 DT price + £1.187.20

**Brands** may include Tymbrel

**BACTERIAL TRANSEPITIDATION INHIBITORS**

**Chloramphenicol**

**INDICATIONS AND DOSE**

- Life threatening infections particularly those caused by *Haemophilus influenzae* | Typhoid fever
  - BY MOUTH OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION
  - Adult: 12.5 mg/kg every 6 hours, in exceptional cases dose can be doubled for severe infections such as sepsicaemia and meningitis, providing high doses reduced as soon as clinically indicated

**DRUG ACTION**

Chloramphenicol is a potent broad-spectrum antibiotic.

**CONTRA-INDICATIONS**

Acute porphyrias p. 864

**CAUTIONS**

Avoid repeated courses and prolonged treatment

**INTERACTIONS** → Appendix 1 (chloramphenicol).

**SIDE-EFFECTS**

- Blood disorders - depression - diarrhoea - dry mouth - erythema multiforme - glossitis - headache - nausea - nocturnal haemoglobinuria - optic neuritis - peripheral neuritis - reversible and irreversible aplastic anaemia (with reports of resulting leukaemia) - stomatitis - urticaaria - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Associated with serious haematological side-effects when given systemically and should therefore be reserved for the treatment of life-threatening infections.

**PREGNANCY**

Manufacturer advises avoid; neonatal ‘grey-baby syndrome’ if used in third trimester.

**BREAST FEEDING**

Manufacturer advises avoid; use another antibiotic; may cause bone-marrow toxicity in infant;
Concentration in milk usually insufficient to cause ‘grey syndrome’.

- **HEPATIC IMPAIRMENT**
  Avoid if possible—increased risk of bone-marrow depression. Reduce dose and monitor plasma-chloramphenicol concentration in hepatic impairment.

- **RENAL IMPAIRMENT**
  Avoid in severe renal impairment unless no alternative; dose-related depression of haematopoiesis.

- **MONITORING REQUIREMENTS**
  Plasma concentration monitoring preferred in the elderly.

- **Recommended peak plasma concentration** (approx. 2 hours after administration by mouth, intravenous injection or infusion) 10–25 mg/litre; pre-dose (‘trough’) concentration should not exceed 15 mg/litre.

- **Blood counts required** before and periodically during treatment.

- **DIRECTIONS FOR ADMINISTRATION**
  For *intravenous infusion* *(Kemicetine®)*, give intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  - **Chloramphenicol (Non-proprietary)**
    - Chloramphenicol 250 mg
    - 60 capsule (Pfizer) £37.00

  **Powder for solution for injection**
  - **Electrolytes: May contain Sodium**
  - **Kemicetine (Pfizer Ltd)**
    - Chloramphenicol (as Chloramphenicol sodium succinate) 1 gram
    - 1 vial (Pfizer) £1.39

### CARBAPENEMES

#### Carbapenems

The carbapenems are beta-lactam antibacterials with a broad-spectrum of activity which includes many Gram-positive and Gram-negative bacteria, and anaerobes; *imipenem* *(imipenem with cilastatin p. 454)* and meropenem p. 454 have good activity against *Pseudomonas aeruginosa*. The carbapenems are not active against meticillin-resistant *Staphylococcus aureus* and *Enterococcus faecium*.

Imipenem (imipenem with cilastatin) and meropenem are used for the treatment of severe hospital-acquired infections and polymicrobial infections including septicaemia, hospital-acquired pneumonia, intra-abdominal infections, skin and soft-tissue infections, and complicated urinary-tract infections.

Ertapenem below is licensed for treating abdominal and gynaecological infections and for community-acquired pneumonia, but it is not active against atypical respiratory pathogens and it has limited activity against penicillin-resistant pneumococci. It is also licensed for treating foot infections of the skin and soft tissue in patients with diabetes. Unlike the other carbapenems, ertapenem is not active against *Pseudomonas* or against *Acinetobacter spp*.

Imipenem is partially inactivated in the kidney by enzymatic activity and is therefore administered in combination with cilastatin (imipenem with cilastatin), a specific enzyme inhibitor, which blocks its renal metabolism. Meropenem and ertapenem are stable to the renal enzyme which inactivates imipenem and therefore can be given without cilastatin.

Side-effects of imipenem with cilastatin are similar to those of other beta-lactam antibiotics. Meropenem has less seizure-inducing potential and can be used to treat central nervous system infection.

### Ertapenem

#### INDICATIONS AND DOSE

<table>
<thead>
<tr>
<th>Abdominal infections</th>
<th>Acute gynaecological infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community-acquired pneumonia</td>
<td></td>
</tr>
</tbody>
</table>

- **BY INTRAVENOUS INFUSION**
  - Adult: 1 g once daily

- **Diabetic foot infections of the skin and soft tissue**
  - **BY INTRAVENOUS INFUSION**
  - Adult: 1 g once daily

- **Surgical prophylaxis, colorectal surgery**
  - **BY INTRAVENOUS INFUSION**
  - Adult: 1 g for 1 dose; dose to be completed within 1 hour before surgery

- **CAUTIONS**
  - CNS disorders—risk of seizures • elderly

- **INTERACTIONS**
  - → Appendix 1 (ertapenem).

- **SIDE-EFFECTS**
  - **Common or very common**
    - Diarrhoea • headache • injection-site reactions • nausea • pruritus • raised platelet count • rash (also reported with eosinophilia and systemic symptoms) • vomiting
  - **Uncommon**
    - Abdominal pain • anorexia • antibiotic-associated colitis • asthenia • bradycardia • chest pain • confusion • constipation • dizziness • dry mouth • dyspepsia • dysphoria • hypotension • melaena • oedema • petechiae • pharyngeal discomfort • raised glucose • seizures • sleep disturbances • taste disturbances
  - **Rare**
    - Agitation • anxiety • arrhythmia • blood disorders • cholecystitis • cough • depression • dysphagia • electrolyte disturbances • haemorrhage • hypoglycaemia • increase in blood pressure • jaundice • liver disorder • muscle cramp • nasal congestion • neutropenia • pelvic peritonitis • renal impairment • scleral disorder • syncope • thrombocytopenia • tremor • wheezing

- **Frequency not known**
  - Dyskinesia • hallucinations

- **ALLERGY AND CROSS-SENSITIVITY**
  - Avoid if history of immediate hypersensitivity reaction to beta-lactam antibacterials. Use with caution in patients with sensitivity to beta-lactam antibacterials.

- **PREGNANCY**
  - Manufacturer advises avoid unless potential benefit outweighs risk.

- **BREAST FEEDING**
  - Present in milk—manufacturer advises avoid.

- **RENAL IMPAIRMENT**
  - Risk of seizures; max. 500 mg daily if eGFR less than 30 mL/minute/1.73 m².

- **DIRECTIONS FOR ADMINISTRATION**
  - **FOR INTRAVENOUS INFUSION** *(Invanz®)*, give intermittently in Sodium chloride 0.9%. Reconstitute 1 g with 10 mL Water for injections or Sodium chloride 0.9%; dilute requisite dose in infusion fluid to a final concentration not exceeding 20 mg/mL; give over 30 minutes; incompatible with glucose solutions.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Powder for solution for infusion**
  - **Electrolytes: May contain Sodium**
  - **Invanz** *(Merck Sharp & Dohme Ltd)*
    - Ertapenem (as Ertapenem sodium) 1 gram Invanz 1g powder for solution for infusion vials | 1 vial (Pfizer) £31.65
Imipenem with cilastatin

INDICATIONS AND DOSE
Aerobic and anaerobic Gram-positive and Gram-negative infections (not indicated for CNS infections) | Hospital-acquired septicemia

BY INTRAVENOUS INFUSION
- Adult: 500 mg every 6 hours, alternatively 1 g every 8 hours
Infection caused by Pseudomonas or other less sensitive organisms
Empirical treatment of infection in febrile patients with neutropenia | Life-threatening infection
BY INTRAVENOUS INFUSION
- Adult: 1 g every 6 hours

- CAUTIONS CNS disorders - epilepsy
- INTERACTIONS → Appendix 1 (imipenem with cilastatin).
- SIDE-EFFECTS
  - Common or very common Diarrhoea - eosinophilia - nausea (may reduce rate of infusion) - rash - vomiting
  - Rare Acute renal failure - anaphylactic reactions - antibiotic-associated colitis - encephalopathy - hearing loss - hepatitis - paraesthesia - polyuria - Stevens-Johnson syndrome - taste disturbances - tooth, tongue or urine discoloration - toxic epidermal necrolysis - tremor
  - Frequency not known Neurotoxicity (at high dose, renal failure, CNS disease)
- ALLERGY AND CROSS-SENSITIVITY Avoid if history of immediate hypersensitivity reaction to beta-lactam antibacterials. Use with caution in patients with sensitivity to beta-lactam antibacterials.
- PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk (toxicity in animal studies).
- BREAST FEEDING Present in milk but unlikely to be absorbed.
- RENAL IMPAIRMENT Risk of CNS side-effects; reduce dose if eGFR less than 70 mL/minute/1.73 m² – consult product literature.
- EFFECT ON LABORATORY TESTS Positive Coombs’ test.
- DIRECTIONS FOR ADMINISTRATION For intravenous infusion dilute to a concentration of 5 mg (as imipenem) in Sodium chloride 0.9%: give up to 500 mg of imipenem over 20–30 minutes, give dose greater than 500 mg (as imipenem) over 40–60 minutes.
- PRESCRIBING AND DISPENSING INFORMATION Dose expressed in terms of imipenem.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  - Powder for solution for infusion
    ELECTROLYTES: May contain Sodium
    - IMIPENEM WITH CILASTATIN (Non-proprietary)
      Cilastatin (as Cilastatin sodium) 500 mg, Imipenem (as Imipenem monohydrate) 500 mg | Cilastatin 500mg powder for solution for infusion vials | 1 vial (P05) £10.00
      - 5 vial (P05) £60.00 (Hospital only) | 10 vial (P05) £55.45–65.45
      - Primaxin IV (Merk Sharp & Dohme Ltd) Cilastatin (as Cilastatin sodium) 500 mg, Imipenem (as Imipenem monohydrate) 500 mg | Primaxin IV 500mg powder for solution for infusion vials | 1 vial (P05) £12.00

Meropenem

INDICATIONS AND DOSE
Aerobic and anaerobic Gram-positive and Gram-negative infections | Hospital acquired septicemia

BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION
- Adult: 0.5–1 g every 8 hours
Exacerbations of chronic lower respiratory-tract infection in cystic fibrosis
BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION
- Adult: 2 g every 8 hours
Meningitis
BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION
- Adult: 2 g every 8 hours
Endocarditis (in combination with another antibacterial)
BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION
- Adult: 2 g every 8 hours

- UNLICENSED USE Not licensed for use in endocarditis.
- INTERACTIONS → Appendix 1 (meropenem).
- SIDE-EFFECTS
  - Common or very common Abdominal pain - diarrhoea - disturbances in liver function tests - headache - nausea - pruritus - rash - thrombocytopenia - vomiting
  - Uncommon Eosinophilia - leucopenia - paraesthesia - thrombocytopenia
  - Rare Convulsions
  - Frequency not known Antibiotic-associated colitis - haemolytic anaemia - Stevens-Johnson syndrome - toxic epidermal necrolysis
- ALLERGY AND CROSS-SENSITIVITY Avoid if history of immediate hypersensitivity reaction to beta-lactam antibacterials. Use with caution in patients with sensitivity to beta-lactam antibacterials.
- PREGNANCY Use only if potential benefit outweighs risk – no information available.
- BREAST FEEDING Unlikely to be absorbed (however, manufacturer advises avoid).
- HEPATIC IMPAIRMENT Monitor liver function in hepatic impairment.
- RENAL IMPAIRMENT Use normal dose every 12 hours if eGFR 26–50 mL/minute/1.73 m². Use half normal dose every 12 hours if eGFR 10–25 mL/minute/1.73 m². Use half normal dose every 24 hours if eGFR less than 10 mL/minute/1.73 m².
- EFFECT ON LABORATORY TESTS Positive Coombs’ test.
- DIRECTIONS FOR ADMINISTRATION Intravenous injection to be administered over 5 minutes. For intravenous infusion (Meropenem®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Dilute dose in infusion fluid to a final concentration of 1–20 mg/mL; give over 15–30 minutes.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  - Powder for solution for injection
    ELECTROLYTES: May contain Sodium
    - MEROPENEM (Non-proprietary)
      Meropenem (as Meropenem trihydrate) 500 mg | Meropenem 500mg powder for solution for injection vials | 10 vial (P06) £92.70–88.00
      - Meropenem (as Meropenem trihydrate) 1 gram | Meropenem 1g powder for solution for injection vials | 10 vial (P06) £139.20–171.90 | 10 vial (P06) £171.90 (Hospital only)
      - Meronem (AstraZeneca UK Ltd) Meropenem (as Meropenem trihydrate) 500 mg | Meropenem 500mg powder for solution for injection vials | 10 vial (P06) £103.14
      - Meropenem (as Meropenem trihydrate) 1 gram | Meropenem 1g powder for solution for injection vials | 10 vial (P06) £206.28
CEPHALOSPORINS

Cephalosporins

The cephalosporins are broad-spectrum antibiotics which are used for the treatment of septicema, pneumonia, meningitis, biliary-tract infections, peritonitis, and urinary-tract infections. The pharmacology of the cephalosporins is similar to that of the penicillins, excretion being principally renal. Cephalosporins penetrate the cerebrospinal fluid poorly unless the meninges are inflamed; cefotaxime p. 457 and ceftriaxone p. 459 are suitable cephalosporins for infections of the CNS (e.g. meningitis).

The principal side-effect of the cephalosporins is hypersensitivity and about 0.5–6.5% of penicillin-sensitive patients will also be allergic to the cephalosporins. If a cephalosporin is essential in patients with a history of alternative antibacterial is not available, then cefixime p. 457, cefotaxime, ceftazidime p. 458, ceftriaxone, or cefuroxime p. 450 can be used with caution; cefaclor below, cefadroxil p. 456, cefalexin p. 456, cefradine p. 458, and cefotaxime fosamil p. 458 should be avoided.

The orally active 'first generation' cephalosporins, cefalexin, cefadroxil, and cefuroxime and the 'second generation' cephalosporin, cefaclor below, have a similar antimicrobial spectrum. They are useful for urinary-tract infections which do not respond to other drugs or which occur in pregnancy, respiratory-tract infections, otitis media, sinusitis, and skin and soft-tissue infections. Cefaclor below has good activity against *H. influenzae*.

Cefadroxil has a long duration of action and can be given twice daily; it has poor activity against *H. influenzae*.

Cefuroxime axetil, an ester of the 'second generation' cephalosporin cefuroxime, has the same antibacterial spectrum as the parent compound; it is poorly absorbed and needs to be given with food to maximise absorption.

Cefixime is an orally active 'third generation' cephalosporin. It has a longer duration of action than the other cephalosporins that are active by mouth. It is only licensed for acute infections.

Cefuroxime is a 'second generation' cephalosporin that is less susceptible than the earlier cephalosporins to inactivation by beta-lactamases. It is, therefore, active against certain bacteria which are resistant to the other drugs and has greater activity against *Haemophilus influenzae*.

Cefotaxime, ceftazidime and ceftriaxone are 'third generation' cephalosporins with greater activity than the 'second generation' cephalosporins against certain Gram-negative bacteria. However, they are less active than cefuroxime against Gram-positive bacteria, most notably *Staphylococcus aureus*. Their broad antibacterial spectrum may encourage superinfection with resistant bacteria or fungi.

Ceftazidime has good activity against pseudomonas. It is also active against other Gram-negative bacteria.

Ceftriaxone has a longer half-life and therefore needs to be given only once daily. Indications include serious infections such as septicema, pneumonia, and meningitis. The calcium salt of ceftriaxone forms a precipitate in the gall bladder which may rarely cause symptoms but these usually resolve when the antibiotic is stopped.

Cefadroxil fosamil is a 'fifth generation' cephalosporin with bactericidal activity similar to cefotaxime; however, cefadroxil fosamil has an extended spectrum of activity against Gram-positive bacteria that includes meticillin-resistant *Staphylococcus aureus* and multi-drug resistant *Streptococcus pneumoniae*. Cefadroxil fosamil is licensed for the treatment of community-acquired pneumonia and complicated skin and soft-tissue infections, but there is no experience of its use in pneumonia caused by meticillin-resistant *S. aureus*.

Cephalosporins

- **INTERACTIONS** → Appendix 1 (cephalosporins).
- **SIDE-EFFECTS**
  - Rare Antibiotic-associated colitis
  - **Frequency not known** Abdominal discomfort, agranulocytosis, allergic reactions, anaphylaxis, aplastic anaemia, blood disorders, confusion, diarrhoea, disturbances in liver enzymes, dizziness, eosinophilia, haemolytic anaemia, hallucinations, headache, hyperactivity, hypertension, leucopenia, nausea, nervousness, pruritus, rashes, reversible interstitial nephritis, serum sickness-like reactions with rashes, fever and arthralgia, sleep disturbances, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, transient cholestatic jaundice, transient hepatitis, urticaria, vomiting
- **SIDE-EFFECTS, FURTHER INFORMATION** Antibiotic-associated colitis Antibiotic-associated colitis may occur more commonly with second- and third-generation cephalosporins.
- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with cephalosporin hypersensitivity. Cross-sensitivity with other beta-lactam antibacterials About 0.5–6.5% of penicillin-sensitive patients will also be allergic to the cephalosporins. Patients with a history of immediate hypersensitivity to penicillin and other beta-lactams should not receive a cephalosporin. Cephalosporins should be used with caution in patients with sensitivity to penicillin and other beta-lactams.
- **EFFECT ON LABORATORY TESTS** False positive urinary glucose (if tested for reducing substances). False positive Coombs’ test.

Cefaclor

**INDICATIONS AND DOSE**

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria

**INITIALLY BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Child 1-11 months:** 20 mg/kg daily in 3 divided doses, alternatively (by mouth) 62.5 mg 3 times a day
- **Child 1-4 years:** 20 mg/kg daily in 3 divided doses, alternatively (by mouth) 125 mg 3 times a day
- **Child 5-11 years:** 20 mg/kg daily in 3 divided doses, usual max. 1 g daily, alternatively (by mouth) 250 mg 3 times a day
- **Child 12-17 years:** 250 mg 3 times a day; maximum 4 g per day
- **Adult:** 250 mg 3 times a day; maximum 4 g per day

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- **Child 12-17 years:** 375 mg every 12 hours, dose to be taken with food
- **Adult:** 375 mg every 12 hours, dose to be taken with food

Severe susceptible infections due to sensitive Gram-positive and Gram-negative bacteria

**BY MOUTH**

- **Child 1-11 months:** 40 mg/kg daily in 3 divided doses, usual max. 1 g daily, alternatively 125 mg 3 times a day
- **Child 1-4 years:** 40 mg/kg daily in 3 divided doses, usual max. 1 g daily, alternatively 250 mg 3 times a day

---

**BNF 70**

Bacterial infection **455**
### Cefadroxil

#### INDICATIONS AND DOSE

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria

- **BY MOUTH**
  - Child 6-17 years (body-weight up to 40 kg): 0.5 g twice daily
  - Child 6-17 years (body-weight 40 kg and above): 0.5–1 g twice daily
  - Adult: 0.5–1 g twice daily

#### Skin infections | Soft-tissue infections | Uncomplicated urinary-tract infections

- **BY MOUTH**
  - Child 6-17 years (body-weight 40 kg and above): 1 g once daily
  - Adult: 1 g daily

#### CONTRAINDICATIONS

- Not known to be harmful.

#### BREAST FEEDING

Present in milk in low concentration, but appropriate to use.

#### RENAL IMPAIRMENT

- In adults: 1 g initially, then 500 mg every 12 hours if eGFR 26–50 mL/minute/1.73 m². 1 g initially, then 500 mg every 24 hours if eGFR 11–26 mL/minute/1.73 m². 1 g initially, then 500 mg every 36 hours if eGFR less than 11 mL/minute/1.73 m².
- In children: Reduce dose if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - **CAUTIONARY AND ADVISORY LABELS 9**
  - **CEFADROXIL (Non-proprietary)**
    - Cefadroxil (as Cefadroxil monohydrate) 500 mg
      - Cefadroxil 500mg capsules | 20 capsule [PoD] £22.36 DT price = £22.36 | 100 capsule [PoD] £111.90

### Cefalexin

(Cephalexin)

#### INDICATIONS AND DOSE

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria

- **BY MOUTH**
  - Child 1-11 years: 12.5 mg/kg twice daily, alternatively 125 mg twice daily
  - Child 1-4 years: 12.5 mg/kg twice daily, alternatively 125 mg 3 times a day
  - Child 5-11 years: 12.5 mg/kg twice daily, alternatively 250 mg 3 times a day
  - Child 12-17 years: 500 mg 2–3 times a day
  - Adult: 250 mg every 6 hours, alternatively 500 mg every 8–12 hours; increased to 1–1.5 g every 6–8 hours, increased dose to be used for severe infections

#### Serious susceptible infections due to sensitive Gram-positive and Gram-negative bacteria

- **BY MOUTH**
  - Child 1 month-11 years: 25 mg/kg 2–4 times a day (max. per dose 1 g 4 times a day)
  - Child 12-17 years: 1–1.5 g 3–4 times a day

#### Prophylaxis of recurrent urinary-tract infection

- **BY MOUTH**
  - Child: 12.5 mg/kg once daily (max. per dose 125 mg), dose to be taken at night
  - Adult: 125 mg once daily, dose to be taken at night
PATIENT AND CARER ADVICE

In children

▶ Reducing dose in moderate impairment.

In adults

▶ Reduce dose in moderate impairment.

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Cefalexin for bacterial infections www.medicinesforchildren.org.uk/cefalexin-bacterial-infections-0

PROFESSION SPECIFIC INFORMATION

Dental practitioners' Formulary Cefalexin Capsules may be prescribed. Cefalexin Oral Suspension may be prescribed.

MEDIcINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 9

▶ CEFALEXIN (Non-proprietary)

Cefalexin 250 mg Cefalexin 250mg tablets | 28 tablet [POM] £5.02 DT price = £2.12 | 100 tablet [POM] £4.93

Cefalexin 500 mg Cefalexin 500mg tablets | 21 tablet [POM] £5.88 DT price = £2.38

▶ Ceporex (Co-Pharma Ltd)

Cefalexin 250 mg Ceporex 250mg tablets | 28 tablet [POM] £4.02 DT price = £2.12 | 100 tablet [POM] £13.74

Cefalexin 500 mg Ceporex 500mg tablets | 28 tablet [POM] £7.85 | 100 tablet [POM] £26.90

▶ Keflex (Flynn Pharma Ltd)

Cefalexin 250 mg Keflex 250mg tablets | 28 tablet [POM] £1.60 DT price = £2.12

Cefalexin 500 mg Keflex 500mg tablets | 21 tablet [POM] £2.08 DT price = £2.38

Capsule

CAUTIONARY AND ADVISORY LABELS 9

▶ CEFALEXIN (Non-proprietary)

Cefalexin 250 mg Cefalexin 250mg capsules | 28 capsule [POM] £4.01 DT price = £1.59 | 100 capsule [POM] £5.01-£7.50

Cefalexin 500 mg Cefalexin 500mg capsules | 21 capsule [POM] £5.88 DT price = £1.71 | 100 capsule [POM] £9.43

▶ Ceporex (Co-Pharma Ltd)

Cefalexin 250 mg Ceporex 250mg capsules | 28 capsule [POM] £4.02 DT price = £1.59 | 100 capsule [POM] £13.74

Cefalexin 500 mg Ceporex 500mg capsules | 28 capsule [POM] £7.85 | 100 capsule [POM] £26.90

▶ Keflex (Flynn Pharma Ltd)

Cefalexin 250 mg Keflex 250mg capsules | 28 capsule [POM] £1.46 DT price = £1.59

Cefalexin 500 mg Keflex 500mg capsules | 21 capsule [POM] £1.98 DT price = £1.71

Oral suspension

CAUTIONARY AND ADVISORY LABELS 9

▶ CEFALEXIN (Non-proprietary)

Cefalexin 25 mg per 1 ml Cefalexin 125mg/5ml oral suspension sugar free [sugar-free] | 100 ml [POM] no price available

Cefalexin 125mg/5ml oral suspension | 100 ml [POM] £4.90 DT price = £1.40

Cefalexin 50 mg per 1 ml Cefalexin 250mg/5ml oral suspension sugar free [sugar-free] | 100 ml [POM] no price available

Cefalexin 250mg/5ml oral suspension | 100 ml [POM] £5.25 DT price = £1.81

Cefalexin 100 mg per 1 ml Cefalexin 500mg/5ml oral suspension | 100 ml [POM] no price available

▶ Ceporex (Co-Pharma Ltd)

Cefalexin 25 mg per 1 ml Ceporex 125mg/5ml syrup | 100 ml [POM] £1.43 DT price = £1.40

Cefalexin 50 mg per 1 ml Ceporex 250mg/5ml syrup | 100 ml [POM] £2.87 DT price = £1.81

▶ Keflex (Flynn Pharma Ltd)

Cefalexin 25 mg per 1 ml Keflex 125mg/5ml oral suspension | 100 ml [POM] £0.84 DT price = £1.40

Cefalexin 50 mg per 1 ml Keflex 250mg/5ml oral suspension | 100 ml [POM] £1.40 DT price = £1.81

Cefixime

INDICATIONS AND DOSE

Acute infections due to sensitive Gram-positive and Gram-negative bacteria

BY MOUTH

▶ Child 6-11 months: 75 mg daily

▶ Child 1-4 years: 100 mg daily

▶ Child 4-10 years: 200 mg daily

▶ Child 10-17 years: 200–400 mg daily, alternatively 100–200 mg twice daily

▶ Adult: 200–400 mg daily in 1–2 divided doses

Uncomplicated gonorrhoea

BY MOUTH

▶ Adult: 400 mg for 1 dose

UNLICENSED USE

Use of cefixime for uncomplicated gonorrhoea is an unlicensed indication.

PREGNANCY

Not known to be harmful.

BREAST FEEDING

Manufacturer advises avoid unless essential—no information available.

RENAL IMPAIRMENT

▶ In adults Reduce dose if eGFR less than 20 mL/minute/1.73 m² (max. 200 mg once daily).

▶ In children Reduce dose if estimated glomerular filtration rate less than 20 mL/minute/1.73 m².

MEDIcINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 9

▶ Suprax (Sanofi)

Cefixime 200 mg Suprax 200mg tablets | 7 tablet [POM] £13.23 DT price = £13.23

Cefotaxime

INDICATIONS AND DOSE

Uncomplicated gonorrhoea

BY INTRAMUSCULAR INJECTION

▶ Adult: 500 mg for 1 dose

Infections due to sensitive Gram-positive and Gram-negative bacteria | Surgical prophylaxis | Haemophilus epiglottitis

BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

▶ Adult: 1 g every 12 hours

Severe susceptible infections due to sensitive Gram-positive and Gram-negative bacteria | Meningitis

BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

▶ Adult: 8 g daily in 4 divided doses, increased if necessary to 12 g daily in 3–4 divided doses, intramuscular doses over 1 g should be divided between more than one site

Emergency treatment of suspected bacterial meningitis or meningococcal disease, before urgent transfer to hospital, in patients who cannot be given benzylpenicillin (e.g. because of an allergy)

BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION

▶ Child 1 month-11 years: 50 mg/kg for 1 dose

▶ Child 12-17 years: 1 g for 1 dose

▶ Adult: 1 g for 1 dose
**INDICATIONS AND DOSE**

**Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria | Surgical prophylaxis**

**BY MOUTH**

- Child 7-11 years: 25–50 mg/kg daily in 2–4 divided doses
- Child 12-17 years: 250–500 mg 4 times a day, alternatively 0.5–1 g twice daily; increased if necessary up to 1 g 4 times a day, increased dose may be used in severe infections
- Adult: 250–500 mg 4 times a day, alternatively 0.5–1 g twice daily; increased if necessary up to 1 g 4 times a day, increased dose may be used in severe infections

**Powder for solution for injection**

- Cefotaxime (as Cefotaxime sodium) 500 mg: £1.50
- Cefotaxime (as Cefotaxime sodium) 1 gram: £3.00
- Cefotaxime (as Cefotaxime sodium) 2 gram: £8.00

**Cefradine (Cephradine)**

**INDICATIONS AND DOSE**

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria | Surgical prophylaxis

**BY MOUTH**

- Child 7-11 years: 25–50 mg/kg daily in 2–4 divided doses
- Child 12-17 years: 250–500 mg 4 times a day, alternatively 0.5–1 g twice daily; increased if necessary up to 1 g 4 times a day, increased dose may be used in severe infections
- Adult: 250–500 mg 4 times a day, alternatively 0.5–1 g twice daily; increased if necessary up to 1 g 4 times a day, increased dose may be used in severe infections

**CAUTIONS**

- Seizure disorders
- **PREGNANCY** Manufacturer advises avoid unless essential—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAL IMPAIRMENT** 400 mg every 12 hours if eGFR 30–50 mL/minute/1.73 m². Manufacturer advises avoid if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

For intravenous injection, give intermittently in Glucose 5% or Sodium chloride 0.9%. Suggested volume 40–100 mL given over 20–60 minutes; incompatible with alkaline solutions.

**CEFOTAXIME (Non-proprietary)**

- Cefotaxime 250 mg: £6.00 DT price = £2.25
- Cefotaxime 500 mg: £12.00 DT price = £3.41
- Brands may include Nicef

**Ceftaroline fosamil**

**INDICATIONS AND DOSE**

Community-acquired pneumonia

**BY INTRAVENOUS INFUSION**

- Adult: 600 mg every 12 hours for 5–7 days

Complicated skin and soft-tissue infections

**BY INTRAVENOUS INFUSION**

- Adult: 600 mg every 12 hours for 5–14 days

**CAUTIONS**

- Seizure disorders
- **PREGNANCY** Manufacturer advises avoid unless essential—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAL IMPAIRMENT** 400 mg every 12 hours if eGFR 30–50 mL/minute/1.73 m². Manufacturer advises avoid if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstitute 600 mg with 20 mL water for injections, then dilute with 250 mL infusion fluid (in fluid restriction, may be diluted with 50–100 mL infusion fluid); give over 60 minutes.

**SCOTTISH MEDICINES CONSORTIUM (SMC) DECISIONS**

The Scottish Medicines Consortium, has advised (Dec 2012) that ceftaroline fosamil (Zinforo®) is accepted for restricted use within NHS Scotland when meticillin-resistant S. aureus is suspected in complicated skin and soft-tissue infection and vancomycin cannot be used.

**UNLICENSED USE**

Not licensed for use in children for prevention of Staphylococcus aureus lung infection in cystic fibrosis.

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Present in milk in low concentration, but appropriate to use.

**RENAL IMPAIRMENT**

- In adults Use half normal dose if eGFR 5–20 mL/minute/1.73 m². Use one-quarter normal dose if eGFR less than 5 mL/minute/1.73 m².
- In children Reduce dose if estimated glomerular filtration rate less than 20 mL/minute/1.73 m².

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulary Cefradine Capsules may be prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **CEFTRADINE (Non-proprietary)**
  - Cefradine 500 mg: £6.00 DT price = £2.25
  - Cefradine 1000 mg: £12.00 DT price = £3.41
  - Brands may include Nicef

**Ceftaroline fosamil**

**INDICATIONS AND DOSE**

Community-acquired pneumonia

**BY INTRAVENOUS INFUSION**

- Adult: 600 mg every 12 hours for 5–7 days

Complicated skin and soft-tissue infections

**BY INTRAVENOUS INFUSION**

- Adult: 600 mg every 12 hours for 5–14 days

**CAUTIONS**

- Seizure disorders
- **PREGNANCY** Manufacturer advises avoid unless essential—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAL IMPAIRMENT** 400 mg every 12 hours if eGFR 30–50 mL/minute/1.73 m². Manufacturer advises avoid if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstitute 600 mg with 20 mL water for injections, then dilute with 250 mL infusion fluid (in fluid restriction, may be diluted with 50–100 mL infusion fluid); give over 60 minutes.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium, has advised (Dec 2012) that ceftaroline fosamil (Zinforo®) is accepted for restricted use within NHS Scotland when meticillin-resistant S. aureus is suspected in complicated skin and soft-tissue infection and vancomycin cannot be used.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- Zinforo (AstraZeneca UK Ltd)

**Ceftaroline fosamil (as Ceftaroline fosamil acetic acid solvate monohydrate) 600 mg**: £375.00
Pseudomonal lung infection in cystic fibrosis
By intravenous infusion or by intravenous injection or by deep intramuscular injection
- Adult: 100–150 mg/kg daily in 3 divided doses; maximum 9 g per day

Septicaemia | Hospital-acquired pneumonia
By intravenous infusion or by intravenous injection or by deep intramuscular injection
- Adult 18–79 years: 2 g every 8 hours
- Adult 80 years and over: 2 g every 8 hours; usual maximum 3 g per day

Febrile neutropenia
By intravenous infusion or by intravenous injection or by deep intramuscular injection
- Adult 18–79 years: 2 g every 8 hours
- Adult 80 years and over: 2 g every 8 hours; usual maximum 3 g per day

Meningitis
By intravenous infusion or by intravenous injection or by deep intramuscular injection
- Adult 18–79 years: 2 g every 8 hours
- Adult 80 years and over: 2 g every 8 hours; usual maximum 3 g per day

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria
By intravenous infusion or by intravenous injection or by deep intramuscular injection
- Adult 18–79 years: 1–2 g every 8 hours
- Adult 80 years and over: 1–2 g every 8 hours; usual maximum 3 g per day

SIDE-EFFECTS
Paraesthesia - taste disturbances
Pregnancy
Not known to be harmful.
Breast feeding
Present in milk in low concentration, but appropriate to use.
Hepatic impairment
Manufacturer advises caution in severe impairment.
Renal impairment
Reduce dose if eGFR less than 50 mL/minute/1.73 m²—consult product literature.

DIRECTIONS FOR ADMINISTRATION
Intramuscular administration used when intravenous administration not possible; single doses over 1 g by intravenous route only. For intravenous infusion give intermittently or via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%. Dissolve 2 g initially in 10 mL (3 g in 15 mL) infusion fluid. For Fortum® dilute further to a concentration of 40 mg/mL. For Kefadim® dilute further to a concentration of 20 mg/mL. Give over up to 30 minutes.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion, eye drops

Powder for solution for injection
Electrolytes: May contain Sodium

Ceftazidime (Non-proprietary)
Ceftazidime (as Ceftazidime pentahydrate) 500 mg Ceftazidime 500mg powder for solution for injection vials | 1 vial (PMP) £4.33–£4.70
Ceftazidime (as Ceftazidime pentahydrate) 1 gram Ceftazidime 1g powder for solution for injection vials | 1 vial (PMP) £7.90–£11.80 | 5 vial (PMP) £39.55 | 10 vial (PMP) £13.90
Ceftazidime (as Ceftazidime pentahydrate) 2 gram Ceftazidime 2g powder for solution for injection vials | 1 vial (PMP) £17.75–£22.10 | 5 vial (PMP) £79.15 | 10 vial (PMP) £21.90
Fortum (GlaxoSmithKline UK Ltd)
Ceftazidime (as Ceftazidime pentahydrate) 3 gram Fortum 500mg powder for solution for injection vials | 1 vial (PMP) £4.40 (Hospital only)
Ceftazidime (as Ceftazidime pentahydrate) 1 gram Fortum 1g powder for solution for injection vials | 1 vial (PMP) £8.79 (Hospital only)

Ceftriaxone

INDICATIONS AND DOSE
Surgical prophylaxis
By deep intramuscular injection or by intravenous injection
- Adult: 1 g for 1 dose, to be administered up to 30 minutes before procedure

Prophylaxis before colorectal surgery
By deep intramuscular injection or by intravenous infusion
- Adult: 2 g for 1 dose, to be administered up to 30 minutes before procedure, intramuscular doses over 1 g divided between more than one site

Uncomplicated gonorrhoea | Pelvic inflammatory disease
By deep intramuscular injection
- Adult: 500 mg for 1 dose

Early syphilis
By deep intramuscular injection
- Adult: 500 mg daily for 10 days

Endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial)
By intravenous infusion
- Adult: 2–4 g daily

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria
By deep intramuscular injection or by intravenous injection or by intravenous infusion
- Adult: 1 g daily; increased to 2–4 g daily, increased dose to be used for severe infections, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only

Meningitis
By intravenous infusion
- Child 1 month–11 years (body-weight up to 50 kg): 50–80 mg/kg daily, doses of 50 mg/kg and over to be administered by intravenous infusion only
- Deep intramuscular injection or by intravenous infusion
- Child 1 month–11 years (body-weight 50 kg and above): 2–4 g daily, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only
- Child 12–17 years: 2–4 g daily, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only

Prevention of secondary case of meningococcal meningitis
By intramuscular injection
- Adult: 250 mg for 1 dose

Prevention of secondary case of Haemophilus influenzae type b disease
By intramuscular injection or by intravenous injection
- Adult: 1 g daily for 2 days

UNLICENSED USE
Not licensed for prophylaxis of meningococcal meningitis or Haemophilus influenzae type b disease.
In adults Not licensed for early syphilis. Not licensed for endocarditis caused by haemophilus, actinobacillus, cardio bacterium, eikenella, and kingella species (HACEK organisms) (in combination with another antibacterial). Dose not licensed for treatment of uncomplicated gonorrhea or pelvic inflammatory disease.

**CONTRA-INDICATIONS** Concomitant treatment with intravenous calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks corrected gestational age—risk of precipitation in urine and lungs—neonates less than 41 weeks corrected gestational age—neonates over 41 weeks corrected gestational age with jaundice, hyperalbuminaemia, acidosis, unconjugated hyperbilirubinaemia, or impaired bilirubin binding

**CAUTIONS** Dehydration (risk of ceftriaxone precipitation in gall bladder) - may displace bilirubin from serum albumin, administer over 60 minutes in neonates - treatment longer than 14 days - use with caution in neonates

**SIDE-EFFECTS**
- **Common or very common** Calcium ceftriaxone precipitates in gall bladder—consider discontinuation if symptomatic - calcium ceftriaxone precipitates in urine (particularly in very young, dehydrated or those who are immobilised)—consider discontinuation if symptomatic
- **Rare** Pancreatitis - prolongation of prothrombin time
- **PREGNANCY** Not known to be harmful.
- **BREAST FEEDING** Present in milk in low concentration, but appropriate to use.
- **HEPATIC IMPAIRMENT** Reduce dose if both hepatic and severe renal impairment. Monitor plasma concentration if both hepatic and severe renal impairment.
- **RENAL IMPAIRMENT** Use with caution in renal failure. Monitor plasma concentration if both hepatic and severe renal impairment.
- **In adults** Reduce dose if eGFR less than 10 mL/minute/1.73 m² (max. 2 g daily).
- **In children** Max. 50 mg/kg/day (max. 2 g daily) in severe renal impairment.

**DIRECTIONS FOR ADMINISTRATION** For intravenous injection, give over at least 2–4 minutes.
- With intravenous use in children For intravenous infusion, dilute reconstituted solution with Glucose 5% or 10% or Sodium Chloride 0.9%; give over at least 30 minutes (60 minutes in neonates). Not to be given simultaneously with parenteral nutrition or infusion fluids containing calcium, even by different infusion lines; may be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites. Displacement value may be significant, consult local guidelines.
- With intramuscular use in children For intramuscular injection ceftriaxone may be mixed with 1% Lidocaine Hydrochloride Injection to reduce pain at intramuscular injection site; final concentration 250–350 mg/mL. Displacement value may be significant, consult local guidelines.
- With intravenous use in adults For intravenous infusion (Rocephin®; Ceftriaxone Injection, Genus), give intermittently or via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%. Reconstitute 2-g vial with 40 mL infusion fluid. Give by intermittent infusion over at least 30 minutes (60 minutes in neonates). Not to be given simultaneously with total parenteral nutrition or infusion fluids containing calcium, even by different infusion lines. May be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

**Powder for solution for injection**
- **ELECTROLYTES:** May contain Sodium

| Ceftriaxone (as Ceftriaxone sodium) 250 mg | Ceftriaxone 250 mg powder for solution for injection vials | 1 vial (POM) £1.80–£2.30 DT price = £2.40 |
| Ceftriaxone (as Ceftriaxone sodium) 1 gram | Ceftriaxone 1 g powder for solution for injection vials | 1 vial (POM) £3.58 DT price = £3.58 | 5 vial (POM) £45.75 | 10 vial (POM) £110.00 |
| Ceftriaxone (as Ceftriaxone sodium) 2 gram | Ceftriaxone 2 g powder for solution for injection vials | 1 vial (POM) £18.39 DT price = £19.18 | 10 vial (POM) £130.00 |
| Ceftriaxone 2 g powder for solution for infusion vials | 1 vial (POM) £15.10 DT price = £19.18 |
- **Rocephin (Roche Products Ltd)**

| Ceftriaxone (as Ceftriaxone sodium) 250 mg | Rocephin 250 mg powder for solution for injection vials | 1 vial (POM) £2.40 DT price = £2.40 |
| Ceftriaxone (as Ceftriaxone sodium) 1 gram | Rocephin 1 g powder for solution for injection vials | 1 vial (POM) £3.58 DT price = £3.58 |
| Ceftriaxone (as Ceftriaxone sodium) 2 gram | Rocephin 2 g powder for solution for injection vials | 1 vial (POM) £13.18 DT price = £19.18 |

**Cefuroxime**

**INDICATIONS AND DOSE**

Susceptible infections due to Gram-positive and Gram-negative bacteria

**BY MOUTH**
- Child 3 months–1 year: 10 mg/kg twice daily (max. per dose 125 mg)
- Child 2–11 years: 15 mg/kg twice daily (max. per dose 250 mg)
- Child 12–17 years: 250 mg twice daily, dose may be doubled in severe lower respiratory-tract infections or if pneumonia is suspected
- Adult: 250 mg twice daily, dose may be doubled in severe lower respiratory-tract infections or if pneumonia is suspected

**BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
- Child: 20 mg/kg every 8 hours (max. per dose 750 mg); increased to 50–60 mg/kg every 6–8 hours (max. per dose 1.5 g), increased dose used for severe infection and cystic fibrosis
- Adult: 750 mg every 6–8 hours; increased if necessary up to 1.5 g every 6–8 hours, increased dose used for severe infections

**Lyme disease**

**BY MOUTH**
- Adult: 500 mg twice daily for 14–21 days (for 28 days in Lyme arthritis)

**LOWER URINARY-TRACT INFECTION**

**BY MOUTH**
- Child 12–17 years: 125 mg twice daily
- Adult: 125 mg twice daily

**Pyelonephritis**

**BY MOUTH**
- Adult: 250 mg twice daily

**Surgical prophylaxis**

**INITIALLY BY INTRAVENOUS INJECTION**
- Adult: 1.5 g, to be administered up to 30 minutes before the procedure, then (by intravenous injection or by intramuscular injection) 750 mg every 8 hours if required for up to 3 doses (in high risk procedures)
Co-trimoxazole is the drug of choice in the prophylaxis and treatment of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia; it is also indicated for nocardiosis, Stenotrophomonas maltophilia infection [unlicensed indication], and toxoplasmosis. It should only be considered for use in acute exacerbations of chronic bronchitis and infections of the urinary tract when there is bacteriological evidence of sensitivity to co-trimoxazole and good reason to prefer this combination to a single antibacterial; similarly it should only be used in acute otitis media in children when there is good reason to prefer it. Co-trimoxazole is also used for the treatment of infections caused by Burkholderia cepacia in cystic fibrosis [unlicensed indication].

**CONTRA-INDICATIONS**

Acute porphyrias p. 864

**CAUTIONS**

Asthma - avoid in blood disorders (unless under specialist supervision) - avoid in infants under 6 weeks (except for treatment or prophylaxis of pneumocystis pneumonia) because of the risk of kernicterus - elderly (increased risk of serious side-effects) (in adults) - G6PD deficiency (risk of haemolytic anaemia) - maintain adequate fluid intake - predisposition to folate deficiency - predisposition to hyperkalaemia (in adults)

**INTERACTIONS** → Appendix 1 (trimethoprim, sulfamethoxazole).
■ SIDE-EFFECTS
  ▶ Common or very common Diarrhoea · headache · hyperkalaemia · nausea · rash
  ▶ Uncommon Vomiting
  ▶ Rare Agranulocytosis · bone marrow depression
  ▶ Very rare Anorexia · antibiotic-associated colitis · arthralgia · aseptic meningitis · ataxia · blood disorders · convulsions · cough · depression · eosinophilia · glossitis · hallucinations · hepatic necrosis · hypoglycaemia · hyponatraemia · interstitial nephritis · jaundice · leucopenia · liver damage · megaloblastic anaemia · myalgia · myocarditis · pancreatitis · peripheral neuropathy · photosensitivity · pulmonary infiltrates · renal disorders · shortness of breath · Stevens-Johnson syndrome · stomatitis · systemic lupus erythematosus · thrombocytopenia · tinnitus · toxic epidermal necrolysis · uveitis · vasculitis · vertigo
  ▶ Frequency not known Rhabdomyolysis reported in HIV-infected patients

■ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Septrin Adult 120mg/400mg/5ml oral suspension (sugar-free)</td>
<td>£2.45</td>
</tr>
<tr>
<td>Septrin Adult 60mg/400mg/5ml oral suspension</td>
<td>£1.52</td>
</tr>
<tr>
<td>Septrin Adult 160mg/800mg/5ml oral suspension</td>
<td>£3.46</td>
</tr>
</tbody>
</table>

Solution for infusion

EXCIPIENTS: May contain Alcohol, propylene glycol, sulphites
ELECTROLYTES: May contain Sodium

■ Trimethoprim

INDICATIONS AND DOSE

Urinary-tract infections | Respiratory tract infections

BY MOUTH

▶ Child 4–5 weeks: 4 mg/kg twice daily (max. per dose 200 mg)
▶ Child 6–11 years: 4 mg/kg twice daily (max. per dose 200 mg), alternatively 25 mg twice daily
▶ Child 11–17 years: 800 mg twice daily
▶ Adult: 200 mg twice daily

Prophylaxis of urinary-tract infection (considered for recurrent infection, significant urinary-tract anomalies, or significant kidney damage)

BY MOUTH

▶ Child 4–5 weeks: 2 mg/kg once daily (max. per dose 100 mg), dose to be taken at night
▶ Child 6–11 years: 2 mg/kg once daily (max. per dose 100 mg), dose to be taken at night, alternatively 12.5 mg once daily, dose to be taken at night
▶ Child 6–11 years: 2 mg/kg once daily (max. per dose 100 mg), dose to be taken at night, alternatively 50 mg once daily, dose to be taken at night
▶ Child 12–17 years: 100 mg once daily, dose to be taken at night
▶ Adult: 100 mg once daily, dose to be taken at night

Flavours of oral liquid formulations may include banana, or vanilla.

Co-trimoxazole is a mixture of trimethoprim and sulfamethoxazole (sulfamethoxazole) in the proportions of 1 part to 5 parts.
Treatment of mild to moderate *Pneumocystis jirovecii* (Pneumocystis carinii) pneumonia in patients who cannot tolerate co-trimoxazole (in combination with dapsone)

**BY MOUTH**
- Child: 5 mg/kg every 6–8 hours
- Adult: 5 mg/kg every 6–8 hours

Acne resistant to other antibacterials

**BY MOUTH**
- Adult: 300 mg twice daily

**Prostatitis**

**BY MOUTH**
- Adult: (consult product literature)

**Shigellosis | Invasive salmonella infection**

**BY MOUTH**
- Adult: (consult product literature)


- **CONTRA-INDICATIONS** Blood dyscrasias

- **CAUTIONS** Elderly · acute porphyrias p. 864 · neonates (specialist supervision required) · predisposition to folate deficiency

- **INTERACTIONS** → Appendix 1 (trimethoprim).

- **SIDE-EFFECTS**
  - Rare: Allergic reactions · anaphylaxis · angioedema · erythema multiforme · photosensitivity · toxic epidermal necrolysis
  - Frequency not known: Aseptic meningitis · depression of haematopoiesis · gastrointestinal disturbances · hyperkalaemia · nausea · pruritus · rashes · uveitis (in adults) · vomiting

- **INDICATIONS AND DOSE**

  **Tablet**
  - CAUTIONARY AND ADVISORY LABELS 9
  - **TRIMETHOPRIM (Non-proprietary)**
    - Trimethoprim 100 mg Trimethoprim 100 mg tablets | 28 tablet (POST) £9.99 DT price = £1.00
    - Trimethoprim 200 mg Trimethoprim 200 mg tablets | 6 tablet (POST) £3.60 DT price = £0.56 | 14 tablet (POST) £9.99 DT price = £1.31
  - **Oral suspension**
    - CAUTIONARY AND ADVISORY LABELS 9
    - **TRIMETHOPRIM (Non-proprietary)**
      - Trimethoprim 10 mg per 1 ml Trimethoprim 50 mg/5 ml oral suspension sugar free (sugar-free) | 100 ml (POST) £15.00 DT price = £2.11
    - Brands may include Monotrim

- **FUSIDATES**

  **Fusidic acid**

  - **DRUG ACTION** Fusidic acid and its salts are narrow-spectrum antibiotics used for staphylococcal infections.

  - **INDICATIONS AND DOSE**
    - Staphylococcal skin infection
      - **BY MOUTH USING TABLETS**
        - Child 12–17 years: 250 mg every 12 hours for 5–10 days
        - Adult: 250 mg every 12 hours for 5–10 days
    - Penicillin-resistant staphylococcal infection including osteomyelitis | Staphylococcal endocarditis in combination with other antibiotics
      - **BY MOUTH USING ORAL SUSPENSION**
        - Child 1–11 months: 15 mg/kg 3 times a day
        - Child 1–4 years: 250 mg 3 times a day
        - Child 5–11 years: 500 mg 3 times a day
        - Child 12–17 years: 750 mg 3 times a day
        - Adult: 750 mg 3 times a day
      - **BY MOUTH USING TABLETS**
        - Child 12–17 years: 500 mg every 8 hours, increased to 1 g every 8 hours, increased dose can be used for severe infections
        - Adult: 500 mg every 8 hours, increased to 1 g every 8 hours, increased dose can be used for severe infections

  - **Dose equivalence and conversion**
    - Fusidic acid is incompletely absorbed and doses recommended for suspension are proportionately higher than those for sodium fusidate tablets.

  - **INTERACTIONS** → Appendix 1 (fusidic acid).

  - **SIDE-EFFECTS**
    - Common or very common: Abdominal pain · diarrhoea · dizziness · drowsiness · dyspepsia · nausea · vomiting
    - Uncommon: Anorexia · headache · malaise · pruritus · rash
    - Frequency not known: Acute renal failure (usually with jaundice) · blood disorders · reversible jaundice especially after high dosage (withdraw therapy if persistent)

  - **PREGNANCY** Not known to be harmful; manufacturer advises use only if potential benefit outweighs risk.

  - **BREAST FEEDING** Present in milk—manufacturer advises caution.

  - **HEPATIC IMPAIRMENT** Impaired biliary excretion; possibly increased risk of hepatotoxicity; avoid or reduce dose; monitor liver function in hepatic impairment.

  - **MONITORING REQUIREMENTS** Monitor liver function with caution.

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

  - **MEDICATIONS**
    - There can be variation in the licensing of different medicines containing the same drug.
Teicoplanin

**DRUG ACTION** The glycopeptide antibiotic teicoplanin has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of *Staphylococcus aureus* with reduced susceptibility to glycopeptides and increasing reports of glycopeptide-resistant enterococci. Teicoplanin is similar to vancomycin, but has a significantly longer duration of action, allowing once daily administration after the loading dose.

**INDICATIONS AND DOSE**

**Clostridium difficile infection**

**BY MOUTH**

- Adult: 100–200 mg twice daily for 10–14 days

**Serious infections caused by Gram-positive bacteria (e.g. complicated skin and soft tissue infections, pneumonia)**

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION OR BY INTRAMUSCULAR INJECTION**

- Adult (body-weight up to 70 kg): Initially 400 mg every 12 hours for 3 doses, followed by 400 mg once daily
- Adult (body-weight 70 kg and above): Initially 6 mg/kg every 12 hours for 3 doses, then 6 mg/kg once daily

**Streptococcal or enterococcal endocarditis (in combination with another antibacterial)**

- Adult: Initially 10 mg/kg every 12 hours for 3–5 doses, then 10 mg/kg once daily, subsequent doses can be given by intramuscular injection

**Bone and joint infections**

**BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION**

- Adult: Initially 12 mg/kg every 12 hours for 3–5 doses, then 12 mg/kg once daily subsequent doses can be given by intramuscular injection, increased risk of fever and rash with doses of 12 mg/kg

**Surgical prophylaxis**

**BY INTRAVENOUS INJECTION**

- Adult: 400 mg, to be administered up to 30 minutes before the procedure

**Surgical prophylaxis in open fractures**

**BY INTRAVENOUS INFUSION**

- Adult: 800 mg, to be administered up to 30 minutes before skeletal stabilisation and definitive soft-tissue closure

**Peritonitis associated with peritoneal dialysis (added to dialysis fluid)**

**BY INTRAPERITONEAL INFUSION**

- Adult: (consult local protocol)

**PHARMACOKINETICS**

Teicoplanin should not be given by mouth for systemic infections because it is not absorbed significantly.

---

**UNLICENSED USE** Teicoplanin doses in BNF may differ from those in product literature. Not licensed for surgical prophylaxis.

**INTERACTIONS** → Appendix 1 (teicoplanin).

If other nephrotoxic or neurotoxic drugs given, monitor renal and auditory function on prolonged administration.

**SIDE-EFFECTS**

- **Common or very common** Pruritus - rash

**Frequency not known** Exfoliative dermatitis - nephrotoxicity - renal failure - Stevens-Johnson syndrome - toxic epidermal necrolysis

**SIDE-EFFECTS, FURTHER INFORMATION**

**Nephrotoxicity** Teicoplanin is associated with a lower incidence of nephrotoxicity than vancomycin.

**ALLERGY AND CROSS-SENSITIVITY** Caution if history of vancomycin sensitivity.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** No information available.

**RENAL IMPAIRMENT** Use normal dose regimen on days 1–4, then use normal maintenance dose every 48 hours if eGFR 30–80 ml/minute/1.73 m² and use normal maintenance dose every 72 hours if eGFR less than 30 ml/minute/1.73 m². Plasma-teicoplanin concentration should be monitored during parenteral maintenance treatment. Also monitor renal and auditory function during prolonged treatment in renal impairment.

**MONITORING REQUIREMENTS**

- Blood counts and liver and kidney function tests required.
- With intramuscular use or intravenous use Plasma-teicoplanin concentration is not measured routinely because a relationship between plasma concentration and toxicity has not been established. However, the plasma-teicoplanin concentration can be used to optimise parenteral treatment in severe sepsis or burns, deep-seated staphylococcal infection (including bone and joint infection), endocarditis and in intravenous drug abusers. Pre-dose (‘trough’) concentrations should be greater than 15 mg/litre (greater than 20 mg/litre in endocarditis or deep-seated infection such as bone and joint infection), but less than 60 mg/litre. Plasma-teicoplanin concentration should be measured in elderly patients.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For intravenous infusion (Targocid®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute initially with water for injections provided; infuse over 30 minutes. Continuous infusion not usually recommended.
- With oral use Injection can be used to prepare solution for oral administration.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Powder and solvent for solution for injection**

**ELECTROLYTES:** May contain Sodium

- Targocid (Sanofi) ▼
  - Teicoplanin 200 mg Targocid 200mg powder and solvent for solution for injection vials | 1 vial (£3.93)
  - Teicoplanin 400 mg Targocid 400mg powder and solvent for solution for injection vials | 1 vial (£7.32)

---

**Telavancin**

**DRUG ACTION** Telavancin is a glycopeptide antibacterial; it has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of *Staphylococcus aureus* with reduced susceptibility to...
Vancomycin

**DRUG ACTION** The glycopeptide antibiotic vancomycin has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of *Staphylococcus aureus* with reduced susceptibility to glycopeptides. There are increasing reports of glycopeptide-resistant enterococci. Penetration into cerebrospinal fluid is poor.

**INDICATIONS AND DOSE**

**Clostridium difficile infection**

**BY MOUTH**

- Adult: 125 mg 4 times a day for 10–14 days, dose may be increased if infection fails to respond or is life-threatening, increased if necessary up to 500 mg 4 times a day

**Infections due to Gram-positive bacteria including endocarditis, osteomyelitis, septicaemia and soft-tissue infections**

**BY INTRAVENOUS INFUSION**

- Adult: 1–1.5 g every 12 hours
- Elderly: 500 mg every 12 hours, alternatively 1 g once daily

**Surgical prophylaxis (when high risk of MRSA)**

**BY INTRAVENOUS INFUSION**

- Adult: 1 g

**Peritonitis associated with peritoneal dialysis**

**BY INTRAPERITONEAL ADMINISTRATION**

- Adult: (consult local protocol)

**PHARMACOKINETICS**

Vancomycin should not be given by mouth for systemic infections because it is not absorbed significantly.

**UNLICENSED USE** Vancomycin doses in BNF publications may differ from those in product literature. Use of vancomycin (added to dialysis fluid) for the treatment of peritonitis associated with peritoneal dialysis is an unlicensed route.

**CAUTIONS**

**GENERAL CAUTIONS**

Avoid if history of deafness • elderly

**SPECIFIC CAUTIONS**

- With oral use: Systemic absorption may follow oral administration especially in inflammatory bowel disorders or following multiple doses

**INTERACTIONS**

- Appendix 1 (vancomycin).

**SIDE-EFFECTS**

- Common or very common
- With intravenous use: Blood disorders, including neutropenia (usually after 1 week or cumulative dose of 25 g); interstitial nephritis • nephrotoxicity • ototoxicity (discontinue if tinnitus occurs) • renal failure
- Rare
- With intravenous use: Agranulocytosis • thrombocytopenia
- Frequency not known
- With intravenous use: Anaphylaxis • cardiac arrest on rapid infusion • chills • dyspnoea • eosinophilia • exfoliative
dermatitis · fever · flushing of the upper body (‘red man’ syndrome) · nausea · pain and muscle spasm of back and chest · plebitis (irritant to tissue) · pruritus · rash · severe hypotension on rapid infusion · shock on rapid infusion · Stevens-Johnson syndrome · toxic epidermal necrolysis · urticaria · vasculitis · wheezing

SIDE-EFFECTS, FURTHER INFORMATION

Nephrotoxicity Vancomycin is associated with a higher incidence of nephrotoxicity than teicoplanin.

- ALLERGY AND CROSS-SENSITIVITY  Caution if teicoplanin sensitivity.

- PREGNANCY  Manufacturer advises use only if potential benefit outweighs risk. Plasma-vancomycin concentration monitoring essential to reduce risk of fetal toxicity.

- BREAST FEEDING  Present in milk—significant absorption following oral administration unlikely.

- RENAL IMPAIRMENT  Reduce dose. In renal impairment monitor plasma-vancomycin concentration and renal function regularly. Also monitor auditory function regularly.

- MONITORING REQUIREMENTS
  - All patients require plasma-vancomycin measurement (after 3 or 4 doses if renal function normal, earlier if renal impairment).
  - Pre-dose (‘trough’) concentration should be 10–15 mg/litre (15–20 mg/litre for endocarditis or less sensitive strains of meticillin-resistant Staphylococcus aureus or for complicated infections caused by S. aureus). An initial loading dose, by intravenous infusion, may be considered—consult local guidelines.
  - All patients require blood counts, urinalysis, and renal function tests.
  - Monitor auditory function in elderly.

- DIRECTIONS FOR ADMINISTRATION
  - With intravenous use Avoid rapid infusion (risk of anaphylactoid reactions and reactions) and rotate infusion sites.
    For intravenous infusion (Vancomycin®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute each 500 mg with 10 mL water for injections and dilute with infusion fluid to a concentration of up to 5 mg/mL (10 mg/mL in fluid restriction but increased risk of infusion-related effects); give over at least 60 minutes (rate not to exceed 10 mg/minute for doses over 500 mg); use continuous infusion only if intermittent not feasible.
  - With oral use Injection can be used to prepare solution for oral administration; flavouring syrups may be added to the solution at the time of administration.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, solution for injection, oral suspension, oral solution, pastille, infusion

Capsule

CAUTIONARY AND ADVISORY LABELS 9

- VANCOMYCIN (Non-proprietary)
  - Vancomycin (as Vancomycin hydrochloride) 125 mg Vancomycin 125mg capsules | 28 capsule [PPh] £132.47 DT price = £132.47
  - Vancomycin (as Vancomycin hydrochloride) 250 mg Vancomycin 250mg capsules | 28 capsule [PPh] £140.08 DT price = £140.08
  - Brands may include Vancocin Matrigel

- POWDER FOR SOLUTION FOR INJECTION

- VANCOMYCIN (Non-proprietary)
  - Vancomycin (as Vancomycin hydrochloride) 500 mg Vancomycin 500mg powder for solution for infusion vials | 1 vial [PPh] £6.25–£7.25 (Hospital only) | 1 vial [PPh] £6.50–£6.50
  - Vancomycin 250mg powder for concentrate for solution for infusion vials | 1 vial [PPh] £17.75–£18.75

- Vancomycin (as Vancomycin hydrochloride) 1 gram Vancomycin 1g powder for solution for infusion vials | 1 vial [PPh] £13.50–£14.50 (Hospital only) | 1 vial [PPh] £17.25

- Vancomycin 1g powder for concentrate for solution for infusion vials | 1 vial [PPh] £17.25

GLYCICYLCYCLINE ANTIMICROBIALS

Tigecycline

- DRUG ACTION  Tigecycline is a glycyclcline antibacterial structurally related to the tetracyclines. Tigecycline is active against Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms, and some anaerobes. It is also active against meticillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, but Pseudomonas aeruginosa and many strains of Proteus spp are resistant to tigecycline.

- INDICATIONS AND DOSE  Treatment of complicated skin and soft-tissue infections and complicated abdominal infections caused by multiple-antibacterial resistant organisms when other antibacterials cannot be used

- BY INTRAVENOUS INFUSION
  - Adult: Initially 100 mg, then 50 mg every 12 hours for 5–14 days, not recommended for the treatment of foot infections in patients with diabetes

- CAUTIONS  Cholestasis

- INTERACTIONS  → Appendix 1 (tigecycline).

- SIDE-EFFECTS
  - Common or very common  Abdominal pain · anorexia · bilirubinaemia · diarrhoea · dizziness · dyspepsia · headache · hypoglycaemia · injection-site reactions · nausea · prolonged activated partial thromboplastin time · prolonged prothrombin time · pruritus · rash · vomiting
  - Uncommon  Cholestasis jaundice · hypoproteinaemia · pancreatitis
  - Frequency not known  Antibiotic-associated colitis · hepatic failure · Stevens-Johnson syndrome · thrombocytopenia

- SIDE-EFFECTS, FURTHER INFORMATION

SIDE-effects similar to those of the tetracyclines can potentially occur.

- ALLERGY AND CROSS-SENSITIVITY  Contra-indicated in patients hypersensitive to tetracyclines.

- PREGNANCY  Tetracyclines should not be given to pregnant women; effects on skeletal development have been documented in the first trimester in animal studies. Administration during the second or third trimester may cause discoloration of the child’s teeth, and maternal hepatotoxicity has been reported with large parental doses.

- BREAST FEEDING  Manufacturer advises caution—present in milk in animal studies.

- HEPATIC IMPAIRMENT  Initially 100 mg then 25 mg every 12 hours in severe hepatic impairment.

- DIRECTIONS FOR ADMINISTRATION  For intravenous infusion (Tygacil®), give intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstitute each vial with 5.3 mL infusion fluid to produce a 10 mg/mL solution; dilute requisite dose in 100 mL infusion fluid; give over 30–60 minutes.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.
**LINCOksamide Antibacterials**

**Clindamycin**

- **Drug Action** Clindamycin is active against Gram-positive cocci, including streptococci and penicillin-resistant staphylococci, and also against many anaerobes, especially *Bacteroides fragilis*. It is well concentrated in bone and excreted in bile and urine.

- **Indications and Dose**
  - **Staphyloccocal bone and joint infections such as osteomyelitis** | **Peritonitis** | **Intra-abdominal sepsis** | **Metastatic-Resistant Staphylococcus Aureus (MRSA)** in bronchiectasis, bone and joint infections, and skin and soft-tissue infections
  - **Erysipelas or Cellulitis in Penicillin-Allergic Patients** (alternative to macrolides)

- **Contraindications**
  - **Diarrhoeal states**
  - **Children** | **Polyarthritis**

- **Side-Effects**
  - **General Side-Effects**
  - **Specific Side-Effects**
    - With intramuscular use Induration (after intramuscular injection) · abscess (after intramuscular injection) · pain (after intramuscular injection)
    - With intravenous use Thrombophlebitis (after intravenous injection)

- **Antibiotic-Associated Colitis** Clindamycin has been associated with antibiotic-associated colitis, which may be fatal. Although antibiotic-associated colitis can occur with most antibacterials, it occurs more frequently with clindamycin. Patients should therefore discontinue treatment immediately if diarrhoea develops.

- **Pregnancy** Not known to be harmful.

- **Breastfeeding** Amount probably too small to be harmful but bloody diarrhoea reported in 1 infant.

- **Monitoring Requirements**
  - Monitor liver and renal function if treatment exceeds 10 days.
  - In children Monitor liver and renal function in infants.

- **Directions for Administration** Avoid rapid intravenous administration.

- **With intravenous use** in children For **intravenous infusion**, dilute to a concentration of not more than 18 mg/mL with Glucose 5% or Sodium Chloride 0.9%; give over 10–60 minutes at a max. rate of 20 mg/kg/hour.

- **With intravenous use** in adults For **intravenous infusion** (Dalacin® C Phosphate), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute to not more than 18 mg/mL and give over 10–60 minutes at a rate not exceeding 30 mg/minute (1.2 g over at least 60 minutes; higher doses by continuous infusion).

- **Patient and Carer Advice** Patients and their carers should be advised to discontinue immediately and contact doctor if diarrhoea develops. Capsules should be swallowed with a glass of water.

- **Profession Specific Information** Dental practitioners’ formulary Clindamycin Capsules may be prescribed.

- **Medicinal Forms** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

- **Capsule**
  - **Cautionary and Advisory Labels** 9, 27
  - **Clindamycin (Non-proprietary)**
    - Clindamycin (as Clindamycin hydrochloride) 150 mg Clindamycin 150 mg capsules | 24 capsule (P) £48.00 DT price = £3.38 | 100 capsule (P) £55.08
    - Clindamycin (as Clindamycin hydrochloride) 300 mg Clindamycin 300 mg capsules | 30 capsule (P) £31.20 DT price = £31.19
  - **Dalacin C (Pfizer Ltd)**
    - Clindamycin (as Clindamycin hydrochloride) 75 mg Dalacin C 75 mg capsules | 24 capsule (P) £7.45 DT price = £7.45
    - Clindamycin (as Clindamycin hydrochloride) 150 mg Dalacin C 150 mg capsules | 24 capsule (P) £11.72 DT price = £3.38 | 100 capsule (P) £55.08

- **Solution for Injection**
  - **Excipients**: May contain Benzyl alcohol
  - **Clindamycin (Non-proprietary)**
    - Clindamycin (as Clindamycin phosphate) 150 mg per 1 ml Clindamycin 600 mg/mL for injection ampoules | 5 ampoule (P) £5.75-£61.75
    - Clindamycin 300 mg/mL solution for injection ampoules | 5 ampoule (P) £28.50-£31.01
  - **Dalacin C (Pfizer Ltd)**
    - Clindamycin (as Clindamycin phosphate) 150 mg per 1 ml Dalacin C Phosphate 300 mg/mL solution for injection ampoules | 5 ampoule (P) £31.01
    - Dalacin C Phosphate 600 mg/mL solution for injection ampoules | 5 ampoule (P) £61.75

- **Liquid**
  - **Excipients**: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), propylene glycol
Daptomycin

**DRUG ACTION** Daptomycin is a lipopeptide antibacterial with a spectrum of activity similar to vancomycin but its efficacy against enterococci has not been established. It needs to be given with other antibacterials for mixed infections involving Gram-negative bacteria and some anaerobes.

**INDICATIONS AND DOSE**
Complicated skin and soft-tissue infections caused by Gram-positive bacteria, including meticillin-resistant *Staphylococcus aureus* (MRSA) by slow intravenous injection or by intravenous infusion
- Adult: 4 mg/kg once daily; increased to 6 mg/kg once daily, increase dose only if associated with *Staphylococcus aureus* bacteraemia

Staphylococcal endocarditis caused by organisms resistant to vancomycin or in patients intolerant of vancomycin (in combination with other antibacterials) by slow intravenous injection or by intravenous infusion
- Adult: 6 mg/kg once daily

- **UNLICENSED USE** Not licensed for use in left-sided endocarditis.
- **INTERACTIONS** → Appendix 1 (daptomycin).
  Monitor creatine kinase more frequently than weekly during treatment if receiving another drug known to cause myopathy (preferably avoid concomitant use).
- **SIDE-EFFECTS**
  - Common or very common Abdominal pain - anaemia - anxiety - arthralgia - asthenia - constipation - diarrhoea - dizziness - flatulence - headache - hypertension - hypotension - injection-site reactions - insomnia - nausea - pruritus - rash - vomiting
  - Rare Jaundice - rhabdomyolysis
  - Frequency not known Antibiotic-associated colitis - elevated creatine kinase - esoinophilic pneumonia - peripheral neuropathy - syncope - wheezing

**SIDE-EFFECTS, FURTHER INFORMATION**
Muscle effects If unexplained muscle pain, tenderness, weakness, or cramps develop during treatment, measure creatine kinase every 2 days; discontinue if unexplained muscular symptoms and creatine elevated markedly.

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING** Present in milk in small amounts, but absorption from gastrointestinal tract negligible.

- **HEPATIC IMPAIRMENT**Manufacturer advises caution in severe hepatic impairment—no information available.

- **RENAL IMPAIRMENT** Use normal dose every 48 hours if eGFR less than 30 mL/minute/1.73 m². If eGFR less than 80 mL/minute/1.73 m², monitor renal function, and monitor creatine kinase before treatment and then at least weekly during treatment.

- **MONITORING REQUIREMENTS** Monitor creatine kinase before treatment and then weekly during treatment (more frequently if creatine kinase elevated more than 5 times upper limit of normal before treatment).
- **EFFECT ON LABORATORY TESTS** Interference with assay for prothrombin time and INR—take blood sample immediately before daptomycin dose.
- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Cubicin®), give intermittently in Sodium chloride 0.9%; reconstitute with sodium chloride 0.9% (350 mg in 7 mL, 500 mg in 10 mL); gently rotate vial without shaking; allow to stand for at least 10 minutes then rotate gently to dissolve; dilute requisite dose in 50 mL infusion fluid and give over 30 minutes. For intravenous injection, give over 2 minutes.
- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions The Scottish Medicines Consortium has advised (February 2008) that daptomycin (Cubicin®) is accepted for restricted use within NHS Scotland for the treatment of MRSA bacteraemia associated with right-sided endocarditis or with complicated skin and soft-tissue infections.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**
- Cubicin (Novartis Pharmaceuticals UK Ltd)
  Daptomycin 350 mg (Cubicin 350 mg powder for concentrate for solution for infusion vials | 1 vial [Posm] £62.00)
  Daptomycin 500 mg (Cubicin 500 mg powder for concentrate for solution for infusion vials | 1 vial [Posm] £88.57 (Hospital only)

MACROCYCLIC ANTIBACTERIALS

Fidaxomicin

**DRUG ACTION** Fidaxomicin is a macrocyclic antibacterial that is poorly absorbed from the gastro-intestinal tract, and, therefore, it should not be used to treat systemic infections.

**INDICATIONS AND DOSE**
*Clostridium difficile* infection
**BY MOUTH**
- Adult: 200 mg every 12 hours for 10 days, limited clinical data is available on the use of fidaxomicin in severe or life-threatening *Clostridium difficile* infection

**CAUTIONS** Inflammatory bowel disease - severe or life-threatening *C. difficile* infection
**INTERACTIONS** → Appendix 1 (fidaxomicin).

**SIDE-EFFECTS**
- Common or very common Constipation - nausea - vomiting
- Uncommon Abdominal distension - decreased appetite - dizziness - dry mouth - flatulence - headache - taste disturbance

**ALLERGY AND CROSS-SENSITIVITY** Use with caution in macrolide hypersensitivity.

- **PREGNANCY** Manufacturer advises avoid—no information available.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment—no information available.

- **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available.
MACROLIDES AND RELATED DRUGS

### Macrolides

The macrolides have an antibacterial spectrum that is similar but not identical to that of penicillin; they are thus an alternative in penicillin-allergic patients. They are active against many penicillin-resistant staphylococci, but some are now also resistant to the macrolides. Indications for the macrolides include campylobacter enteritis, respiratory infections (including pneumonia, whooping cough, Legionella, chlamydia, and mycoplasma infection), and skin infections.

Erythromycin p. 471 is also used in the treatment of early syphilis, uncomplicated genital chlamydia infection, and non-gonococcal urethritis. Erythromycin has poor activity against *Haemophilus influenzae*. Erythromycin causes nausea, vomiting, and diarrhoea in some patients; in mild to moderate infections this can be avoided by giving a lower dose, but if a more serious infection, such as Legionella pneumonia, is suspected higher doses are needed.

Azithromycin below is a macrolide with slightly less activity than erythromycin against Gram-positive bacteria, but enhanced activity against some Gram-negative organisms including *H. influenzae*. Plasma concentrations are very low, but tissue concentrations are much higher. It has a long tissue half-life and once daily dosage is recommended. Azithromycin is also used in the treatment of uncomplicated genital chlamydia infection, non-gonococcal urethritis, uncomplicated gonorrhoea, typhoid [unlicensed indication], and trachoma [unlicensed indication].

Clarithromycin p. 470 is an erythromycin derivative with slightly greater activity than the parent compound. Tissue concentrations are higher than with erythromycin. It is given twice daily. Clarithromycin is also used in regimens for *Helicobacter pylori* eradication.

Telithromycin p. 473 is a ketolide derivative of erythromycin with an antibacterial spectrum similar to that of other macrolides and it is also active against penicillin- and erythromycin-resistant *Streptococcus pneumoniae*.

Erythromycin, azithromycin, and clarithromycin have a role in the treatment of Lyme disease p. 500. Spiramycin is also a macrolide which is used for the treatment of toxoplasmosis.

#### Cautions

- Electrolyte disturbances (predisposition to QT interval prolongation) - may aggravate myasthenia gravis - predisposition to QT interval prolongation

### Azithromycin

**Indications and dose**

Prevention of secondary case of invasive group A streptococcal infection in patients who are allergic to penicillin

**By mouth**

- Child 6 months–11 years: 12 mg/kg once daily (max. per dose 500 mg) for 5 days
- Child 12–17 years: 500 mg once daily for 5 days
- Adult: 500 mg once daily for 5 days

**Respiratory-tract infections, otitis media, skin and soft-tissue infections**

**By mouth**

- Child 6 months–17 years: 10 mg/kg once daily (max. per dose 500 mg) for 3 days
- Child 6 months–17 years (body-weight 15–25 kg): 200 mg once daily for 3 days
- Child 6 months–17 years (body-weight 26–35 kg): 300 mg once daily for 3 days
- Child 6 months–17 years (body-weight 36–45 kg): 400 mg once daily for 3 days
- Child 6 months–17 years (body-weight 46 kg and above): 500 mg once daily for 3 days
- Adult: 500 mg once daily for 3 days, alternatively initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days

**Uncomplicated genital chlamydial infections**

**By non-gonococcal urethritis**

**By mouth**

- Child 12–17 years: 1 g for 1 dose
- Adult: 1 g for 1 dose

**Lyme disease**

**By mouth**

- Adult: 500 mg daily for 7–10 days

**Mild to moderate typhoid due to multiple-antibacterial resistant organisms**

**By mouth**

- Adult: 500 mg daily for 7 days

**Community-acquired pneumonia, low to moderate severity**

**By mouth**

- Adult: 500 mg once daily for 3 days, alternatively initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days
Community-acquired pneumonia, high severity
INITIALLY BY INTRavenous INFUSION
▶ Adult: Initially 500 mg once daily for at least 2 days, then (by mouth) 500 mg once daily for a total duration of 7–10 days
Antibacterial prophylaxis for insertion of intra-uterine device
BY MOUTH
▶ Adult: 1 g for 1 dose

● UNLICENSED USE Not licensed for uncomplicated gonorrhoea, mild or moderate typhoid due to multiple-antibacterial-resistant organisms, Lyme disease, or prophylaxis of group A streptococcal infection. Not licensed for community-acquired pneumonia (high severity) when oral treatment continues for more than 3 days.

● INTERACTIONS → Appendix 1 (macrolides).
Caution with concomitant use of drugs that prolong the QT interval.

● SIDE-EFFECTS
▶ Common or very common Anorexia · arthralgia · arthralgia · disturbances in taste · disturbances in vision · dizziness · dyspepsia · flatulence · headache · malaise · paraesthesia · reversible hearing loss (sometimes with tinnitus) after long-term therapy ·
▶ Uncommon Anxiety · chest pain · constipation · gastritis · hypoaesthesia · leucopenia · oedema · photosensitivity · sleep disturbances
▶ Rare Agitation
▶ Frequency not known Acute renal failure · convulsions · haemolytic anaemia · interstitial nephritis · smell disturbances · syncope · thrombocytopenia · tongue discoloration

● PREGNANCY Manufacturers advise use only if adequate alternatives not available.

● BREAST FEEDING Present in milk; use only if no suitable alternatives.

● HEPATIC IMPAIRMENT Manufacturers advise avoid in severe liver disease—no information available.

● RENAL IMPAIRMENT
▶ In adults Use with caution if eGFR less than 10 mL/minute/1.73 m².
▶ In children Use with caution if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

● DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Zedbac®), give intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstitute 500 mg with 4.8 mL water for injections to produce a 100 mg/mL solution, then dilute 5 mL of solution with infusion fluid to a final concentration of 1 or 2 mg/mL; give the 1 mg/mL solution over 3 hours or give the 2 mg/mL solution over 1 hour.

● PRESCRIBING AND DISPENSING INFORMATION Flavours of oral liquid formulations may include cherry or banana.

● PATIENT AND CARER ADVICE
Medicines for Children leaflet: Azithromycin for bacterial infections www.medicinesforchildren.org.uk/aizithromycin-bacterial-infections-0

● PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulary Azithromycin Capsules may be prescribed. Azithromycin Tablets may be prescribed. Azithromycin Oral Suspension 200 mg/5 mL may be prescribed.

● EXCEPTIONS TO LEGAL CATEGORY Azithromycin tablets can be sold to the public for the treatment of confirmed, asymptomatic Chlamydia trachomatis genital infection in those over 16 years of age, and for the epidemiological treatment of their sexual partners, subject to maximum single dose of 1 g, maximum daily dose 1 g, and a pack size of 1 g.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
Tablet
CAUTIONARY AND ADVISORY LABELS 5, 9
▶ AZITHROMYCIN (Non-proprietary)
Azithromycin 250 mg Azithromycin 250mg tablets | 4 tablet (Pkt) £10.11 DT price = £1.83 | 6 tablet (Pkt) £14.46
Azithromycin 500 mg Azithromycin 500mg tablets | 3 tablet (Pkt) £9.80 DT price = £1.77
Brands may include Clamelle
Capsule
CAUTIONARY AND ADVISORY LABELS 5, 9, 23
▶ AZITHROMYCIN (Non-proprietary)
Azithromycin (as Azithromycin dihydrate) 250 mg Azithromycin 250mg capsules | 4 capsule (Pkt) £10.10 | 6 capsule (Pkt) £15.15 DT price = £11.11
Zithromax (Pfizer Ltd)
Azithromycin (as Azithromycin dihydrate) 250 mg Zithromax 250mg capsules | 4 capsule (Pkt) £7.16 | 6 capsule (Pkt) £10.74 DT price = £11.11
Oral suspension
CAUTIONARY AND ADVISORY LABELS 5, 9
▶ AZITHROMYCIN (Non-proprietary)
Azithromycin 40 mg per 1 ml Azithromycin 200mg/5ml oral suspension | 15 ml (Pkt) £6.18 DT price = £0.46 | 30 ml (Pkt) £11.04 DT price = £11.04
Zithromax (Pfizer Ltd)
Azithromycin 40 mg per 1 ml Zithromax 200mg/5ml oral suspension | 15 ml (Pkt) £4.06 DT price = £0.46 | 22.5 ml (Pkt) £6.10 DT price = £11.04Defacto price = £11.04
Powder for solution for infusion
ELECTROLYTES: May contain Sodium
Zedbac (Aspire Pharma Ltd)
Azithromycin (as Azithromycin dihydrate) 500 mg Zedbac 500mg powder for solution for infusion vials | 1 vial (Pkt) £9.50 (Hospital only)

Indications and dose
Respiratory-tract infections | Mild to moderate skin and soft-tissue infections | Otitis media
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
▶ Child 1 month–11 years (body-weight up to 8 kg): 7.5 mg/kg twice daily
▶ Child 1 month–11 years (body-weight 8–11 kg): 6.25 mg twice daily
▶ Child 1 month–11 years (body-weight 12–19 kg): 125 mg twice daily
▶ Child 1 month–11 years (body-weight 20–29 kg): 187.5 mg twice daily
▶ Child 1 month–11 years (body-weight 30–40 kg): 250 mg twice daily
▶ Child 12–17 years: 250 mg twice daily usually for 7–14 days, increased to 500 mg twice daily, if required in severe infections (e.g. pneumonia)
▶ Adult: 250 mg twice daily usually for 7–14 days, increased to 500 mg twice daily, if required in severe infections (e.g. pneumonia)
BY MOUTH USING MODIFIED-RELEASE MEDICINES
▶ Child 12–17 years: 500 mg once daily usually for 7–14 days, increased to 1 g once daily, if required in severe infections (e.g. pneumonia)
▶ Adult: 500 mg once daily usually for 7–14 days, increased to 1 g once daily, if required in severe infections (e.g. pneumonia)
BY INTRAVENOUS INFUSION
Adult: 500 mg every 12 hours maximum duration 5 days, switch to oral route when appropriate, to be administered into a large proximal vein
 Lyme disease

BY MOUTH
- Child 12-17 years: 500 mg twice daily for 14–21 days
- Adult: 500 mg twice daily for 14–21 days

Prevention of pertussis

BY MOUTH
- Child 1 month–11 years (body-weight up to 8 kg): 7.5 mg/kg twice daily for 7 days
- Child 1 month–11 years (body-weight 8-11 kg): 62.5 mg twice daily for 7 days
- Child 1 month–11 years (body-weight 12-19 kg): 125 mg twice daily for 7 days
- Child 1 month–11 years (body-weight 20-29 kg): 187.5 mg twice daily for 7 days
- Child 1 month–11 years (body-weight 30-40 kg): 250 mg twice daily for 7 days
- Child 12-17 years: 500 mg twice daily for 7 days
- Adult: 500 mg twice daily for 7 days

Helicobacter pylori eradication in combination with a proton pump inhibitor and amoxicillin

BY MOUTH
- Adult: 500 mg twice daily

Helicobacter pylori eradication in combination with a proton pump inhibitor and metronidazole

BY MOUTH
- Adult: 250 mg twice daily

- **UNLICENSED USE** Tablets not licensed for use in children under 12 years; oral suspension not licensed for use in infants under 6 months. Intravenous infusion not licensed for use in children under 12 years.

- **INTERACTIONS** → Appendix 1 (macrolides).
  Caution with concomitant use of drugs that prolong the QT interval.

- **SIDE-EFFECTS**
  - **Common or very common** Dyspepsia · headache · hyperhidrosis · insomnia · taste disturbances
  - **Uncommon** Anorexia · anxiety · blood disorders · chest pain · constipation · dizziness · dry mouth · flatulence · gastritis · glossitis · hepatic dysfunction including jaundice · leucopenia · malaise · myalgia · stomatitis · tinnitus · tremor
  - **Frequency not known** Abnormal dreams · confusion · convulsions · depression · hypoglycaemia · interstitial nephritis · myopathy · paraesthesia · psychotic disorders · renal failure · smell disturbances · tongue discolouration · tooth discoloration

- **PREGNANCY** Manufacturer advises avoid, particularly in the first trimester, unless potential benefit outweighs risk.

- ** BREAST FEEDING** Manufacturer advises avoid unless potential benefit outweighs risks—present in milk.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment if renal impairment also present.

- **RENAL IMPAIRMENT** Avoid if severe hepatic impairment also present.
  - In adults Use half normal dose if eGFR less than 30 mL/minute/1.73 m², max. duration 14 days. Avoid Klaricid XL® or clarithromycin m/t preparations if eGFR less than 30 mL/minute/1.73 m².
  - In children Use half normal dose if estimated glomerular filtration rate less than 30 mL/minute/1.73 m², max. duration 14 days. Avoid Klaricid XL® or clarithromycin m/t preparations if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².

- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use in children. For intermittent intravenous infusion dilute reconstituted solution further in Glucose 5% or Sodium chloride 0.9% to a concentration of 2 mg/mL; give into large proximal vein over 60 minutes.

- **With intravenous use in adults** For intravenous infusion (Klaricid® i.v.), give intermittently in Glucose 5% or Sodium Chloride 0.9%; dissolve initially in water for injections (500 mg in 10 mL) then dilute to a concentration of 2 mg/mL; give over 60 minutes.

- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: Clarithromycin for bacterial infections www.medicinesforchildren.org.uk/
    clarithromycin-bacterial-infections

- **PROFESSION SPECIFIC INFORMATION**
  - Dental practitioners’ formulary Clarithromycin Tablets may be prescribed. Clarithromycin Oral Suspension may be prescribed.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

**Tablet**

| CAUTIONARY AND ADVISORY LABELS | 9 |
| CLARITHROMYCIN (Non-proprietary) |  |
| Clarithromycin 250 mg | Clarithromycin 250 mg tablets | 14 tablet (P) £10.50 DT price = £1.63 |
| Clarithromycin 500 mg | Clarithromycin 500 mg tablets | 14 tablet (P) £21.50 DT price = £2.94 |

**Modified-release tablet**

| CAUTIONARY AND ADVISORY LABELS | 9, 21, 25 |
| CLARITHROMYCIN (Non-proprietary) |  |
| Clarithromycin 500 mg | Clarithromycin XL 500 mg tablets | 7 tablet (P) £6.72 DT price = £6.72 | 14 tablet (P) £13.23 |
| Brands may include Claire XL; Febzin XL; Mycifor XL |

**Granules**

| CAUTIONARY AND ADVISORY LABELS | 9, 13 |
| Klaricid | Klaricid Adult 250 mg granules | 14 sachet (P) £11.68 |

**Oral suspension**

| CAUTIONARY AND ADVISORY LABELS | 9 |
| CLARITHROMYCIN (Non-proprietary) |  |
| Clarithromycin 25 mg per 1 ml | Clarithromycin 125 mg/5 ml oral suspension | 70 ml (P) £11.99 DT price = £4.22 |
| Clarithromycin 50 mg per 1 ml | Clarithromycin 250 mg/5 ml oral suspension | 70 ml (P) £21.75 DT price = £6.17 |
| Klaricid (BGP Products Ltd) | Clarithromycin 25 mg per 1 ml Klaricid Paediatric 125 mg/5 ml oral suspension | 70 ml (P) £5.26 DT price = £4.22 | 100 ml (P) £9.04 |
| Clarithromycin 50 mg per 1 ml | Clarithromycin 250 mg/5 ml oral suspension | 70 ml (P) £10.51 DT price = £6.17 |

**Powder for solution for infusion**

**ELECTROLYTES** May contain Sodium

| CLARITHROMYCIN (Non-proprietary) |  |
| Clarithromycin 500 mg | Clarithromycin 500 mg powder for solution for infusion vials | 1 vial (P) £9.45 DT price = £9.45 |
| Klaricid (BGP Products Ltd) | Clarithromycin 500 mg powder for solution for infusion vials | 1 vial (P) £9.45 DT price = £9.45 |

**Erythromycin**

**INDICATIONS AND DOSE**

Susceptible infections in patients with penicillin hypersensitivity (e.g. respiratory–tract infections (including Legionella infection), skin and oral infections, and campylobacter enteritis)

**BY MOUTH**
- Child 1 month–1 year: 125 mg 4 times a day, total daily dose may alternatively be given in two divided doses. Increased to 250 mg 4 times a day in severe infections
- Child 2–7 years: 250 mg 4 times a day, total daily dose may alternatively be given in two divided doses. Increased to 500 mg 4 times a day in severe infections continued→
**472 Bacterial infection**

**Chronic prostatitis**
- **Child 2**
- **Child 1 month**

**Uncomplicated genital chlamydia | Non-gonococcal urethritis**
- **BY MOUTH**
  - **Adult:** 500 mg 4 times a day for 14–21 days

**Prevention and treatment of pertussis**
- **BY MOUTH**
  - **Child 1 month-1 year:** 125 mg 4 times a day, total daily dose may alternatively be given in two divided doses. Increased to 250 mg 4 times a day in severe infections
  - **Child 1 year:** 125 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment
  - **Child 2-7 years:** 250 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment
  - **Child 8-17 years:** 500 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment

**Prevention of secondary case of diphtheria in non-immune patient**
- **BY MOUTH**
  - **Child 1 month-1 year:** 125 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment
  - **Child 2-7 years:** 250 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment
  - **Child 8-17 years:** 500 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment

**Prevention of secondary case of invasive group A streptococcal infection in penicillin allergic patients**
- **BY MOUTH**
  - **Child 1 month-1 year:** 125 mg every 6 hours for 10 days
  - **Child 2-7 years:** 250 mg every 6 hours for 10 days
  - **Child 8-17 years:** 500 mg every 6 hours for 10 days
  - **Adult:** 500–1000 mg 4 times a day in severe infections

**Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease, and who are penicillin allergic**
- **BY MOUTH**
  - **Child 1 month-1 year:** 125 mg twice daily, antibiotic prophylaxis is not fully reliable
  - **Child 2-7 years:** 125 mg twice daily, antibiotic prophylaxis is not fully reliable. It may be discontinued in those over 5 years of age with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection
  - **Child 8-17 years:** 500 mg twice daily, antibiotic prophylaxis is not fully reliable. It may be discontinued in those over 5 years of age with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection
  - **Adult:** 500 mg twice daily, antibiotic prophylaxis is not fully reliable. It may be discontinued in those over 5 years of age with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection

**Prevention of recurrence of rheumatic fever**
- **BY MOUTH**
  - **Child 1 month-1 year:** 125 mg twice daily
  - **Child 2-17 years:** 250 mg twice daily

**Rosacea**
- **BY MOUTH**
  - **Adult:** 500 mg twice daily courses usually last 6–12 weeks and are repeated intermittently

**Acne**
- **BY MOUTH**
  - **Adult:** 500 mg twice daily

---

**UNLICENSED USE**
- With intravenous use or oral use in children. Not licensed for use in gastro-intestinal stasis.

**CAUTIONS**
- Avoid in Acute porphyrias p. 864. Neonate under 2 weeks (risk of hypertrophic pyloric stenosis) (in neonates)

**STIEMYCIN®**
- Some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide

**INTERACTIONS** → See Appendix 1 (macrolides). Caution with concomitant use of drugs that prolong the QT interval.

**PREGNANCY**
- Not known to be harmful.

**BREAST FEEDING**
- Only small amounts in milk—not known to be harmful.

**HEPATIC IMPAIRMENT**
- May cause idiosyncratic hepatotoxicity.

**RENAL IMPAIRMENT**
- In adults Max. 1.5 g daily in severe renal impairment (ototoxicity).
- In children Reduce dose in severe renal impairment (ototoxicity).

**DIRECTIONS FOR ADMINISTRATION**
- With intravenous use in children. Dilute reconstituted solution further in glucose 5% (neutralised with Sodium bicarbonate) or sodium chloride 0.9% to a concentration of 1–5 mg/mL; give over 20–60 minutes. Concentration of up to 10 mg/mL may be used in fluid-restriction if administered via a central venous catheter.
- With intravenous use in adults. For intravenous infusion (as lactobionate), give intermittently in Glucose 5% (neutralised with sodium bicarbonate) or Sodium chloride 0.9%; dissolve initially in water for injections (1 g in 20 mL) then dilute to a concentration of 1–5 mg/mL; give over 20–60 minutes.
### Prescribing and Dispensing Information
Flavours of oral liquid formulations may include banana.

### Patient and Carer Advice
Medicines for Children leaflet: Erythromycin for bacterial infections www.medicinesforchildren.org.uk/erythromycin-for-bacterial-infections

### Profession Specific Information
Dental practitioners’ formulary Erythromycin tablets e/c may be prescribed. Erythromycin ethyl succinate oral suspension may be prescribed. Erythromycin stearate tablets may be prescribed. Erythromycin ethyl succinate tablets may be prescribed.

### Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug.

#### Tablet
**Cautionary and Advisory Labels**
- **ERYTHROMYCIN (Non-proprietary)**
  - Erythromycin 250 mg Erythromycin 250mg gastro-resistant tablets | 28 tablet | £3.00 DT price £1.88 | 500 tablet | £3.37

#### Gastro-resistant capsule
**Cautionary and Advisory Labels**
- **ERYTHROMYCIN (Non-proprietary)**
  - Erythromycin 250 mg Erythromycin 250mg gastro-resistant capsules | 28 capsule | £23.53 DT price £5.61 | 30 capsule no price available

#### Oral suspension
**Cautionary and Advisory Labels**
- **ERYTHROMYCIN (Non-proprietary)**
  - Erythromycin (as Erythromycin ethyl succinate) 100 mg per 1 ml Erythromycin ethyl succinate 100mg/5ml oral suspension | 100 ml | £5.54 DT price £5.53
  - Erythromycin ethyl succinate 250mg/5ml oral suspension sugar free (sugar-free) | 100 ml | £4.00 DT price £3.21
  - Erythromycin ethyl succinate 50 mg | 1 ml Erythromycin ethyl succinate 50mg/5ml oral suspension sugar free (sugar-free) | 100 ml | £0.63 DT price £0.63

#### Powder for solution for infusion
- **ERYTHROMYCIN (Non-proprietary)**
  - Erythromycin lactobionate 1g powder for solution for infusion vials | 1 vial | £0.90

### Interactions
- **ERYTHROMYCIN**
  - Treatment is contra-indicated if conventional treatment is contra-indicated

### Contra-indications
- **ERYTHROMYCIN**
  - Erythromycin 250 mg Erythromycin 250mg gastro-resistant tablets | 28 tablet | £3.00 DT price £1.88 | 500 tablet | £3.37

### Medication History
- **ERYTHROMYCIN**
  - Erythromycin ethyl succinate 250mg/5ml oral suspension sugar free (sugar-free) | 100 ml | £7.99 DT price £4.48

### Contra-indications
- **ERYTHROMYCIN**
  - Erythromycin ethyl succinate 100mg/5ml oral suspension | 100 mg | £12.99 DT price £12.99

### Drug Action
The ketolide telithromycin is a derivative of erythromycin. The antibacterial spectrum of telithromycin is similar to that of macrolides and it is also active against penicillin- and erythromycin-resistant Streptococcus pneumoniae.

### Indications and Dose
**Treatment of sinusitis or exacerbations of chronic bronchitis if caused by organisms resistant to beta-lactam antibacterials and other macrolides, or if conventional treatment is contra-indicated**
- **By Mouth**
  - Adult: 800 mg once daily for 5 days

**Treatment of community-acquired pneumonia if caused by organisms resistant to beta-lactam antibacterials and other macrolides, or if conventional treatment is contra-indicated**
- **By Mouth**
  - Adult: 800 mg once daily for 7–10 days

**Treatment of beta-haemolytic streptococcal pharyngitis if caused by organisms resistant to beta-lactam antibacterials and other macrolides, or if conventional treatment is contra-indicated**
- **By Mouth**
  - Child 12–17 years: 800 mg once daily for 5 days
  - Adult: 800 mg once daily for 5 days

### CONTRA-INDICATIONS
- **ERYTHROMYCIN**
  - Congenital history of QT interval prolongation (if not excluded by ECG) • Family history of QT interval prolongation (if not excluded by ECG) • History of telithromycin-associated hepatitis • History of telithromycin-associated jaundice • Hypersensitivity • Prolongation of QT interval

### Caution
- **erythromycin**
  - Avoid in Acute porphyrias p. 864 • Bradycardia—risk of QT interval prolongation • Coronary heart disease—risk of QT interval prolongation • Hypokalaemia—risk of QT interval prolongation • Hypomagnesaemia—risk of QT interval prolongation • Ventricular arrhythmias—risk of QT interval prolongation

### Interactions
  - **ERYTHROMYCIN**
    - Appendix 1 (telithromycin)

### Side-effects
- **ERYTHROMYCIN**
  - Common or very common: Abdominal pain • Diarrhoea • Dizziness • Flatulence • Headache • Nausea • Taste disturbances • Vomiting

### Pregnancy
- **ERYTHROMYCIN**
  - Toxicity in animal studies—manufacturer advises use only if potential benefit outweighs risk.

### Breast Feeding
- **ERYTHROMYCIN**
  - Manufacturer advises avoid—present in milk in animal studies

### Hepatic Impairment
- **ERYTHROMYCIN**
  - Manufacturer advises caution.

### Renal Impairment
- **ERYTHROMYCIN**
  - Manufacturer advises avoid if possible if eGFR less than 30 mL/minute/1.73 m²—If no
alternative, use alternating daily doses of 800 mg and 400 mg, starting with 800 mg dose.

**PATIENT AND CARER ADVICE** Visual disturbances or transient loss of consciousness may affect performance of skilled tasks (e.g. driving); effects may occur after the first dose. Administration at bedtime may reduce these side-effects. Patients should be advised not to drive or operate machinery if affected. Hepatic disorders Counselling on hepatic disorders is advised. Patients should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, abdominal pain, jaundice, or dark urine develop.

**MEDICINAL FORMS** Medicines not identified.

### MONOCYCLIC BETA-LACTAM ANTIBACTERIALS

**Aztreonam**

- **DRUG ACTION** Aztreonam is a monocular beta-lactam (‘monobactam’) antibiotic with an antibacterial spectrum limited to Gram-negative aerobic bacteria including *Pseudomonas aeruginosa*, *Neisseria meningitidis*, and *Haemophilus influenzae*; it should not be used alone for ‘blind’ treatment since it is not active against Gram-positive organisms. Aztreonam is also effective against *Neisseria gonorrhoeae* (but not against concurrent chlamydial infection).

#### INDICATIONS AND DOSE

Gram-negative infections including *Pseudomonas aeruginosa, Haemophilus influenzae*, and *Neisseria meningitidis*

BY DEEP INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION

- Adult: 1 g every 8 hours, alternatively 2 g every 12 hours, single doses over 1 g by intravenous route only
- Severe gram-negative infections including *Pseudomonas aeruginosa, Haemophilus influenzae*, *Neisseria meningitidis*, and lung infections in cystic fibrosis

BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION

- Adult: 2 g every 6–8 hours
- Gonorrhoea / Cystitis
  - BY INTRAMUSCULAR INJECTION
    - Adult: 1 g for 1 single dose
- Urinary-tract infections

BY DEEP INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION

- Adult: 0.5–1 g every 8–12 hours
- Chronic pulmonary *Pseudomonas aeruginosa* infection in patients with cystic fibrosis

BY INHALATION OF NEBULISED SOLUTION

- Adult: 75 mg 3 times a day for 28 days, doses to be administered at least 4 hours apart, subsequent courses repeated after 28-day interval without aztreonam nebuliser solution

**CAUTIONS**

- When used by inhalation Haemoptysis—risk of further haemorrhage

**INTERACTIONS** → Appendix 1 (aztreonam).

**SIDE-EFFECTS**

- **SPECIFIC SIDE-EFFECTS**
  - Rare
  - With systemic use Antibiotic-associated colitis · asthenia · blood disorders · breast tenderness · chest pain · confusion · diplopia · dizziness · dysphonia · gastro-intestinal bleeding · halitosis · headache · hepatitis · hypotension · insomnia · jaundice · myalgia · neutropenia · paraesthesia · seizures · thrombocytopenia · tinnitus
  - Frequency not known Bronchospasm · rash
  - When used by inhalation Arthralgia · cough · haemoptysis · pharyngolaryngeal pain · pyrexia · rhinorrhea · wheezing
  - With systemic use Abdominal pain · diarrhoea · erythema multiforme · flushing · mouth ulcers · nausea · taste disturbances · toxic epidermal necrolysis · vomiting

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in aztreonam hypersensitivity. Use with caution in patients with hypersensitivity to other beta-lactam antibiotics (although aztreonam may be less likely than other beta-lactams to cause hypersensitivity in penicillin-sensitive patients).

**PREGNANCY**

- With systemic use No information available; manufacturer of injection advises avoid.

- When used by inhalation No information available; manufacturer of powder for nebuliser solution advises avoid unless essential.

**BREAST FEEDING** Amount in milk probably too small to be harmful.

**HEPATIC IMPAIRMENT**

- With systemic use Use injection with caution. Monitor liver function.

**RENAL IMPAIRMENT**

- With systemic use If eGFR 10–30 mL/minute/1.73 m², usual initial dose of injection, then half normal dose. If eGFR less than 10 mL/minute/1.73 m², usual initial dose of injection, then one-quarter normal dose.

**MONITORING REQUIREMENTS**

- When used by inhalation Measure lung function before and after initial dose of aztreonam and monitor for bronchospasm.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For intravenous injection, give over 3–5 minutes. For intravenous infusion (Azactam®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Dissolve initially in water for injections (1 g per 3 mL) then dilute to a concentration of less than 20 mg/mL; to be given over 20–60 minutes.

- When used by inhalation Other inhaled drugs should be administered before aztreonam; a bronchodilator should be administered before each dose.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2014) that aztreonam powder for nebuliser solution (Cayston®) is accepted for restricted use within NHS Scotland when inhaled colistimethate sodium and inhaled tobramycin are not tolerated or are not providing satisfactory therapeutic benefit (measured as >2% decline in forced expiratory volume in 1 second).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Azactam** (Bristol-Myers Squibb Pharmaceuticals Ltd)
- **Aztreonam**
  - **1 gram** Azactam 1g powder for solution for injection vials | 1 vial £0.90 (Hospital only)
  - **2 gram** Azactam 2g powder for solution for injection vials | 1 vial £13.82 (Hospital only)

**Powder and solvent for nebuliser solution**

- **Cayston** (Gilead Sciences International Ltd)
- **Aztreonam (as Aztreonam lysine)** 75 mg Cayston 75mg powder and solvent for nebuliser solution vials with Altera Nebuliser Handset | 84 vial £2,181.53
5-NITROIMIDAZOLE DERIVATIVES

Metronidazole

**DRUG ACTION** Metronidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa.

**INDICATIONS AND DOSE**

- **Anaerobic infections**
  - **BY MOUTH**
    - Child 1 month: 7.5 mg/kg every 12 hours usually treated for 7 days (for 10–14 days in *Clostridium difficile* infection)
    - Child 2 months–11 years: 7.5 mg/kg every 8 hours (max. per dose 400 mg) usually treated for 7 days (for 10–14 days in *Clostridium difficile* infection)
    - Child 12–17 years: 400 mg every 8 hours
    - Adult: 400 mg every 8 hours, alternatively 500 mg every 8 hours usually treated for 7 days (for 10–14 days in *Clostridium difficile* infection)

- **BY RECTUM**
  - Child 1–11 months: 125 mg 3 times a day for 3 days, then 125 mg twice daily, for usual total treatment duration of 7 days
  - Child 1–4 years: 250 mg 3 times a day for 3 days, then 250 mg twice daily, for usual total treatment duration of 7 days
  - Child 5–9 years: 500 mg 3 times a day for 3 days, then 500 mg twice daily, for usual total treatment duration of 7 days
  - Child 10–17 years: 1 g 3 times a day for 3 days, then 1 g twice daily, for usual total treatment duration of 7 days
  - Adult: 1 g 3 times a day for 3 days, then 1 g twice daily, for usual total treatment duration of 7 days

- **BY INTRAVENOUS INFUSION**
  - Adult: 500 mg every 8 hours usually treated for 7 days (for 10–14 days in *Clostridium difficile* infection), to be given over 20 minutes

**Helicobacter pylori eradication; in combination with clarithromycin and esomeprazole; or in combination with amoxicillin and lansoprazole; or in combination with clarithromycin and omeprazole; or in combination with clarithromycin and pantoprazole; or in combination with clarithromycin and rabeprazole**

- **BY MOUTH**
  - Adult: 400 mg twice daily

- **Helicobacter pylori eradication; in combination with amoxicillin and omeprazole**

- **BY MOUTH**
  - Adult: 400 mg 3 times a day

**Helicobacter pylori eradication failure (two-week regimen comprising a proton pump inhibitor plus tripotassium dichromatobisulfate plus tetracycline)**

- **BY MOUTH**
  - Adult: 400–500 mg 3 times a day for 2 weeks

**Fistulating Crohn’s disease**

- **BY MOUTH**
  - Adult: 10–20 mg/kg daily in divided doses, usual dose 400–500 mg 3 times a day usually given for 1 month but no longer than 3 months because of concerns about peripheral neuropathy

**Leg ulcers and pressure sores**

- **BY MOUTH**
  - Adult: 400 mg every 8 hours for 7 days

**Bacterial vaginosis (notably *Gardnerella vaginalis* infection)**

- **BY MOUTH**
  - Adult: 400–500 mg twice daily for 5–7 days, alternatively 2 g for 1 dose

**Bacterial vaginosis**

- **BY VAGINA USING VAGINAL GEL**
  - Adult: 1 applicatorful daily for 5 days, dose to be administered at night

**Pelvic inflammatory disease**

- **BY MOUTH**
  - Adult: 400 mg twice daily for 14 days

**Acute ulcerative gingivitis**

- **BY MOUTH**
  - Child 1–2 years: 50 mg every 8 hours for 3–7 days
  - Child 3–6 years: 100 mg every 12 hours for 3–7 days
  - Child 7–9 years: 100 mg every 8 hours for 3–7 days
  - Child 10–17 years: 200–250 mg every 8 hours for 3 days
  - Adult: 200–250 mg every 8 hours for 3 days

**Acute oral infections**

- **BY MOUTH**
  - Child 1–2 years: 50 mg every 8 hours for 3–7 days
  - Child 3–6 years: 100 mg every 12 hours for 3–7 days
  - Child 7–9 years: 100 mg every 8 hours for 3–7 days
  - Adult: 200 mg every 8 hours for 3–7 days

**Surgical prophylaxis**

- **BY MOUTH**
  - Adult: 400–500 mg, to be administered 2 hours before surgery, then 400–500 mg every 8 hours if required for up to 3 doses (in high-risk procedures)

- **BY RECTUM**
  - Adult: 1 g, to be administered 2 hours before surgery, then 1 g every 8 hours if required for up to 3 doses (in high-risk procedures)

- **BY INTRAVENOUS INFUSION**
  - Adult: 500 mg, to be administered up to 30 minutes before the procedure (if rectal administration inappropriate), then 500 mg every 8 hours if required for up to 3 doses (in high-risk procedures)

**Invasive intestinal amoebiasis / Extra-intestinal amoebiasis (including liver abscess)**

- **BY MOUTH**
  - Child 1–2 years: 200 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Child 3–6 years: 200 mg 4 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Child 7–9 years: 400 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Child 10–17 years: 800 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Adult: 800 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)

**Urogenital trichomoniasis**

- **BY MOUTH**
  - Child 1–2 years: 50 mg 3 times a day for 7 days
  - Child 3–6 years: 100 mg twice daily for 7 days
  - Child 7–9 years: 100 mg 3 times a day for 7 days
  - Child 10–17 years: 200 mg 3 times a day for 7 days, alternatively 400–500 mg twice daily for 5–7 days, alternatively 2 g for 1 dose
  - Adult: 200 mg 3 times a day for 7 days, alternatively 400–500 mg twice daily for 5–7 days, alternatively 2 g for 1 dose

**Giardiasis**

- **BY MOUTH**
  - Child 1–2 years: 500 mg once daily for 3 days

**continued**
**Child 3–6 years:** 600–800 mg once daily for 3 days  
**Child 7–9 years:** 1 g once daily for 3 days  
**Child 10–17 years:** 2 g once daily for 3 days, alternatively 400 mg 3 times a day for 5 days, alternatively 500 mg twice daily for 7–10 days  
**Adult:** 2 g once daily for 3 days, alternatively 400 mg 3 times a day for 5 days, alternatively 500 mg twice daily for 7–10 days  
**Established case of tetanus**  
**By intravenous infusion**  
**Adult:** (consult product literature)  

**UNLICENSED USE** Metronidazole doses in the BNF may differ from those in product literature.  

**CAUTIONS**  
With vaginal use Not recommended during menstruation, some systemic absorption may occur with vaginal gel  

**INTERACTIONS**  
With systemic use → Appendix 1 (metronidazole). Caution—disulfiram-like reaction with alcohol.  

**SIDE-EFFECTS**  
Very rare  
**With systemic use** Arthralgia - ataxia - darkening of urine - dizziness - drowsiness - erythema multiforme - headache - hepatitis - jaundice - leucopenia (on prolonged or intensive therapy) - myalgia - pancreatitis - pancytopenia - peripheral neuropathy (on prolonged or intensive therapy) - pruritus - psychotic disorders - rash - thrombocytopenia - transient epileptiform seizures (on prolonged or intensive therapy) - visual disturbances  
**Frequency not known**  
**With systemic use** Anorexia - aseptic meningitis - furred tongue - gastro-intestinal disturbances - nausea - optic neuropathy - oral mucositis - taste disturbances - vomiting  
**With vaginal use** Abnormal vaginal discharge - local irritation - pelvic discomfort - vaginal candidiasis  

**PREGNANCY**  
With systemic use Manufacturer advises avoidance of high-dose regimens; use only if potential benefit outweighs risk.  

**BREAST FEEDING**  
With systemic use Significant amount in milk; manufacturer advises avoid large single doses though otherwise compatible; may give milk a bitter taste.  

**HEPATIC IMPAIRMENT**  
With systemic use In severe liver disease reduce total daily dose to one-third, and give once daily. Use with caution in hepatic encephalopathy.  

**MONITORING REQUIREMENTS**  
With systemic use Clinical and laboratory monitoring advised if treatment exceeds 10 days.  

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion, give over 20–30 minutes.  

**PRESCRIBING AND DISPENSING INFORMATION**  
With systemic use Metronidazole is well absorbed orally and the intravenous route is normally reserved for severe infections. Metronidazole by the rectal route is an effective alternative to the intravenous route when oral administration is not possible.  

**PATIENT AND CARER ADVICE**  
Medicines for Children leaflet: Metronidazole for bacterial infections www.medicinesforchildren.org.uk/metronidazole-for-bacterial-infections  

**PROFESSION SPECIFIC INFORMATION**  
Dental practitioners’ formulary Metronidazole Tablets may be prescribed. Metronidazole Oral Suspension may be prescribed.  

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, gel, cream.  

**Tablet**  
**CAUTIONARY AND ADVISORY LABELS 4, 9, 21, 25, 27**  
**METRONIDAZOLE (Non-proprietary)**  
Metronidazole 200 mg Metronidazole 200mg tablets | 21 tablet (PO) £10.73 DT price = £6.46 | 250 tablet (PO) £19.69  
Metronidazole 400 mg Metronidazole 400mg tablets | 21 tablet (PO) £7.95 DT price = £1.70  
Metronidazole 500 mg Metronidazole 500mg tablets | 21 tablet (PO) £37.82 DT price = £3.82  
**Flagyl (Zentiva)**  
Metronidazole 200 mg Flagyl 200mg tablets | 21 tablet (PO) £4.49 DT price = £6.46  
Metronidazole 400 mg Flagyl 400mg tablets | 14 tablet (PO) £6.34  

**Oral suspension**  
**CAUTIONARY AND ADVISORY LABELS 4, 9**  
**METRONIDAZOLE (Non-proprietary)**  
Metronidazole (as Metronidazole benzoate) 40 mg per 1 ml Metronidazole 200mg/5ml oral suspension | 100 ml (PO) £32.93 DT price = £32.93  

**Infusion**  
**ELECTROLYTES:** May contain Sodium  
**METRONIDAZOLE (Non-proprietary)**  
Metronidazole 5 mg per 1 ml Metronidazole 500mg/100ml infusion 100ml bags | 20 bag (PO) £62.00  
Metronidazole 500mg/100ml infusion 100ml Macoflex bags | 1 bag (PO) no price available | 60 bag (PO) no price available  

**Suppository**  
**CAUTIONARY AND ADVISORY LABELS 4, 9**  
**Flagyl (Zentiva)**  
Metronidazole 500 mg Flagyl 500mg suppositories | 10 suppository (PO) £15.18  
Metronidazole 1 gram Flagyl 1g suppositories | 10 suppository (PO) £23.06  

**Vaginal gel**  
**EXCIPIENTS:** May contain Disodium edetate, hydroxybenzoates (parabens), propylene glycol  
**METRONIDAZOLE (Non-proprietary)**  
Metronidazole 7.5 mg per 1 g Metronidazole 0.75% vaginal gel | 40g (PO) no price available  
**Zidoval (Meda Pharmaceuticals Ltd)**  
Metronidazole 7.5 mg per 1 g Zidoval 0.75% vaginal gel | 40g (PO) £4.31  

**Tinidazole**  
**DRUG ACTION** Tinidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa; it has a longer duration of action than metronidazole.  

**INDICATIONS AND DOSE**  
**Anaerobic infections**  
**By mouth**  
**Adult:** Initially 2 g, followed by 1 g daily usually for 5–6 days, alternatively 500 mg twice daily usually for 5–6 days  

**Bacterial vaginosis | Acute ulcerative gingivitis**  
**By mouth**  
**Adult:** 2 g for 1 single dose  

**Abdominal surgery prophylaxis**  
**By mouth**  
**Adult:** 2 g for 1 single dose, to be administered approximately 12 hours before surgery  

**Intestinal amoebiasis**  
**By mouth**  
**Child 1 month–11 years:** 50–60 mg/kg once daily (max. per dose 2 g) for 3 days  
**Child 12–17 years:** 2 g once daily for 2–3 days  
**Adult:** 2 g once daily for 2–3 days
Amoebic involvement of liver

**BY MOUTH**
- Child 1 month–11 years: 50–60 mg/kg once daily (max. per dose 2 g) for 5 days
- Child 12–17 years: 1.5–2 g once daily for 3–6 days
- Adult: 1.5–2 g once daily for 3–6 days

Urogenital trichomoniasis | Giardiasis

**BY MOUTH**
- Child 1 month–11 years: 50–75 mg/kg (max. per dose 2 g) for 1 single dose, dose may be repeated once if necessary
- Child 12–17 years: 2 g for 1 single dose, dose may be repeated once if necessary
- Adult: 2 g for 1 single dose

**HELICOBACTER PYLORI ERADICATION**

**BY MOUTH**
- Adult: (consult local protocol)

### DRUG ACTION
Linezolid, an oxazolidinone antibacterial, is active against Gram-positive bacteria including meticillin-resistant *Staphylococcus aureus* (MRSA), and glycopeptide-resistant enterococci. Resistance to linezolid can develop with prolonged treatment or if the dose is less than that recommended. Linezolid is not active against common Gram-negative organisms; it must be given in combination with other antibacterials for mixed infections that also involve Gram-negative organisms.

### INDICATIONS AND DOSE

**Pneumonia (when other antibacterials e.g. a glycopetide, such as vancomycin, cannot be used) (initiated under specialist supervision)** | Complicated skin and soft-tissue infections caused by Gram-positive bacteria, when other antibacterials cannot be used (initiated under specialist supervision)

**BY MOUTH**
- Adult: 600 mg every 12 hours usually for 10–14 days (maximum duration of treatment 28 days)

**BY INTRAVENOUS INFUSION**
- Adult: 600 mg every 12 hours

### CAUTIONS

- **Avoid in Acute porphyrias**. p. 864
- **INTERACTIONS** → Appendix 1 (tinidazole).
- **SIDE-EFFECTS**
  - **Common or very common** Anorexia - furred tongue - gastro-intestinal disturbances - nausea - oral mucositis - taste disturbances - vomiting
  - **Very rare** Arthralgia - ataxia - darkening of urine - dizziness - drowsiness - erythema multiforme - headache - hepatitis - jaundice - leukopenia (on prolonged or intensive therapy) - myalgia - pancreatitis - pancytopenia - peripheral neuropathy (on prolonged or intensive therapy) - pruritus - psychotic disorders - rash - thrombocytopenia - transient epileptiform seizures (on prolonged or intensive therapy) - visual disturbances
- **Frequency not known** Aseptic meningitis - optic neuropathy
- **PREGNANCY** Manufacturer advises avoid in first trimester.
- **BREAST FEEDING** Present in milk—manufacturer advises avoid breast-feeding during and for 3 days after stopping treatment.
- **MONITORING REQUIREMENTS** Clinical and laboratory monitoring advised if treatment exceeds 10 days.
- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>4, 9, 21, 25</th>
</tr>
</thead>
</table>
| Tinidazole 500 mg               | Fasigyn 500mg tablets | 16 tablet | £11.04
| DT price = £11.04              |              |

### OXAZOLIDINONE ANTIBACTERIALS

**Linezolid**

- **DRUG ACTION** Linezolid, an oxazolidinone antibacterial, is active against Gram-positive bacteria including meticillin-resistant *Staphylococcus aureus* (MRSA), and glycopeptide-resistant enterococci. Resistance to linezolid can develop with prolonged treatment or if the dose is less than that recommended. Linezolid is not active against common Gram-negative organisms; it must be given in combination with other antibacterials for mixed infections that also involve Gram-negative organisms.

**INDICATIONS AND DOSE**

**Pneumonia (when other antibacterials e.g. a glycopetide, such as vancomycin, cannot be used) (initiated under specialist supervision)** | Complicated skin and soft-tissue infections caused by Gram-positive bacteria, when other antibacterials cannot be used (initiated under specialist supervision)

**BY MOUTH**
- Adult: 600 mg every 12 hours usually for 10–14 days (maximum duration of treatment 28 days)

**BY INTRAVENOUS INFUSION**
- Adult: 600 mg every 12 hours

### CAUTIONS

- **Acute confusional states** | **bipolar depression** | **carcinoid tumour** | **elderly (increased risk of blood disorders)** | **history of seizures** | **phaeochromocytoma** | **schizophrenia** | **thyrotoxicosis** | **uncontrolled hypertension**

### CAUTIONS, FURTHER INFORMATION

**Close observation** Unless close observation and blood pressure monitoring possible, linezolid should be avoided in uncontrolled hypertension, phaeochromocytoma, carcinoid tumour, thyrotoxicosis, bipolar depression, schizophrenia, or acute confusional states.

### INTERACTIONS

- **→ Appendix 1 (linezolid, MAOIs).**
  - **Monoamine oxidase inhibition** Linezolid is a reversible, non-selective monoamine oxidase inhibitor (MAOI). Patients should avoid consuming large amounts of tyramine-rich foods (such as mature cheese, yeast extracts, undistilled alcoholic beverages, and fermented soybean products). In addition, linezolid should not be given with another MAOI or within 2 weeks of stopping another MAOI. Unless close observation and blood pressure monitoring is possible, avoid in those receiving SSRI s, 5HT, agonists (‘triptans’), tricyclic antidepressants, sympathomimetics, dopaminergics, buspirone, pethidine and possibly other opioid analgesics.
Penicillins

**Benzylpenicillin and phenoxyethylpenicillin**

Benzylpenicillin sodium p. 480 (Penicillin G) remains an important and useful antibiotic but is inactivated by bacterial beta-lactamases. It is effective for many streptococcal (including pneumococcal), gonococcal, and meningococcal infections and also for anthrax, diphtheria, gas-gangrene, leptospirosis, and treatment of Lyme disease.

Pneumococci, meningococci, and gonococci which have decreased sensitivity to penicillin have been isolated; benzylpenicillin sodium is no longer the drug of first choice for pneumococcal meningitis. Although benzylpenicillin sodium is effective in the treatment of tetanus, metronidazole p. 1008 is preferred. Benzylpenicillin is inactivated by gastric acid and absorption from the gastrointestinal tract is low; therefore it must be given by injection.

**Benzathine benzylpenicillin** is used for the treatment of early syphils and late latent syphilis; it is given by intramuscular injection.

Phenoxyethylpenicillin p. 481 (Penicillin V) has a similar antibacterial spectrum to benzylpenicillin sodium, but is less active. It is gastric acid-stable, so is suitable for oral administration. It should not be used for serious infections because absorption can be unpredictable and plasma concentrations variable. It is indicated principally for respiratory-tract infections in children, for streptococcal tonsillitis, and for continuing treatment after one or more injections of benzylpenicillin sodium when clinical response has begun. It should not be used for meningococcal or gonococcal infections. Phenoxyethylpenicillin is used for prophylaxis against streptococcal infections following rheumatic fever and against pneumococcal infections following splenectomy or in sickle-cell disease.

**Penicillin-resistant penicillins**

Most staphylococci are now resistant to benzylpenicillin because they produce penicillinases. Flucloxacillin p. 486, however, is not inactivated by these enzymes and is thus effective in infections caused by penicillin-resistant staphylococci, which is the sole indication for its use. Flucloxacillin is acid-stable and can, therefore, be given by mouth as well as by injection. Flucloxacillin is well absorbed from the gut.

Temocillin p. 487 is active against Gram-negative bacteria and is stable against a wide range of beta-lactamases. It should be reserved for the treatment of infections caused by beta-lactamase-producing strains of Gram-negative bacteria, including those resistant to third-generation cephalosporins. Temocillin is not active against *Pseudomonas aeruginosa* or *Acinetobacter spp*.

**Broad-spectrum penicillins**

Ampicillin p. 483 is active against certain Gram-positive and Gram-negative organisms but is inactivated by penicillinases including those produced by *Staphylococcus aureus* and by common Gram-negative bacilli such as *Escherichia coli*. Almost all staphylococci, approx. 60% of *E. coli* strains and approx. 20% of *Haemophilus influenzae* strains are now resistant. The likelihood of resistance should therefore be considered before using ampicillin for the ‘blind’ treatment of infections; in particular, it should not be used for hospital patients without checking sensitivity.

Ampicillin is well excreted in the bile and urine. It is principally indicated for the treatment of exacerbations of chronic bronchitis and middle ear infections, both of which may be due to *Streptococcus pneumoniae* and *H. influenzae*, and for urinary-tract infections.

Ampicillin can be given by mouth but less than half the dose is absorbed, and absorption is further decreased by the presence of food in the gut.

Maculopapular rashes commonly occur with ampicillin (and amoxicillin p. 482) but are not usually related to true penicillin allergy. They almost always occur in patients with glandular fever; broad-spectrum penicillins should not therefore be used for ‘blind’ treatment of a sore throat. The risk of rash is also increased in patients with acute or chronic lymphocytic leukaemia or in cytomegalovirus infection.
Amoxicillin is a derivative of ampicillin and has a similar antibacterial spectrum. It is better absorbed than ampicillin when given by mouth, producing higher plasma and tissue concentrations; unlike ampicillin, absorption is not affected by the presence of food in the stomach. Amoxicillin may also be used for the treatment of Lyme disease [not licensed].

Co-amoxiclav p. 484 consists of amoxicillin with the betalactamase inhibitor clavulanic acid. Clavulanic acid itself has no significant antibacterial activity but, by inactivating beta-lactamases, it makes the combination active against beta-lactamase-producing bacteria that are resistant to amoxicillin. These include resistant strains of *Staph. aureus*, *E. coli*, and *H. influenzae*, as well as many *Bacteroides* and *Klebsiella* spp. Co-amoxiclav should be reserved for infections likely, or known, to be caused by amoxicillin-resistant beta-lactamase-producing strains. A combination of ampicillin with flucloxacillin p. 486 (as co-fluampicil) p. 485 is available to treat infections involving either streptococci or staphylococci (e.g. cellulitis).

**Antipseudomonal penicillins**

**Piperacillin**, a ureidopenicillin, is only available in combination with the beta-lactamase inhibitor tazobactam. **Ticarcillin**, a carboxypenicillin, is only available in combination with the beta-lactamase inhibitor clavulanic acid. Both preparations have a broad spectrum of activity against a range of Gram-positive and Gram-negative bacteria, and anaerobes. Piperacillin with tazobactam below has activity against a wider range of Gram-negative organisms than ticarcillin with clavulanic acid p. 480 and it is more active against *Pseudomonas aeruginosa*. These antibacterials are not active against MRSA. They are used in the treatment of septicaemia, hospital-acquired pneumonia, and complicated infections involving the urinary tract, skin and soft tissues, or intra-abdomen. For severe pseudomonas infections these antipseudomonal penicillins can be given with an aminoglycoside (e.g. gentamicin p. 450) since they have a synergistic effect.

**Mecillinams**

Pivmecillinam hydrochloride p. 486 has significant activity against many Gram-negative bacteria including *Escherichia coli*, *klebsiella*, enterobacter, and salmonellae. It is not active against *Pseudomonas aeruginosa* or enterococci. Pivmecillinam hydrochloride p. 486 is hydrolysed to mecillinam, which is the active drug.

**Penicillins**

**DRUG ACTION** The penicillins are bactericidal and act by interfering with bacterial cell wall synthesis. They diffuse well into body tissues and fluids, but penetration into the cerebrospinal fluid is poor except when the meninges are inflamed. They are excreted in the urine in therapeutic concentrations.

**CAUTIONS** History of allergy

**INTERACTIONS** Appendix 1 (penicillins).

**SIDE-EFFECTS**

- **Common or very common** Anaphylaxis - angioedema - diarrhoea - fever - hypersensitivity reactions - joint pains - rashes - serum sickness-like reaction - urticaria
- **Rare** Cerebral irritation - CNS toxicity (including convulsions) - coagulase disorders - encephalopathy - haemolytic anaemia - interstitial nephritis - leucopenia - thrombocytopenia
- **Frequency not known** Antibiotic-associated colitis

**SIDE-EFFECTS, FURTHER INFORMATION**

- **CNS toxicity** A rare but serious toxic effect of the penicillins is encephalopathy due to cerebral irritation. This may result from excessively high doses or in patients with severe renal failure. The penicillins should **not** be given by intrathecal injection because they can cause encephalopathy which may be fatal.
- **Diarrhoea** Diarrhoea frequently occurs during oral penicillin therapy. It is most common with broad-spectrum penicillins, which can also cause antibiotic-associated colitis.

- **ALLERGY AND CROSS-SENSITIVITY** The most important side-effect of the penicillins is hypersensitivity which causes rashes and anaphylaxis and can be fatal. Allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactic reactions occur in fewer than 0.05% of treated patients. Patients with a history of atopic allergy (e.g. asthma, eczema, hay fever) are at a higher risk of anaphylactic reactions to penicillins. Individuals with a history of anaphylaxis, urticaria, or rash immediately after penicillin administration are at risk of immediate hypersensitivity to a penicillin; these individuals should not receive a penicillin. Individuals with a history of a minor rash (i.e. non-confluent, non-pruritic rash restricted to a small area of the body) or a rash that occurs more than 72 hours after penicillin administration are probably not allergic to penicillin and in these individuals a penicillin should not be withheld unnecessarily for serious infections; the possibility of an allergic reaction should, however, be borne in mind. Other beta-lactam antibiotics (including cephalosporins) can be used in these patients.

Patients who are allergic to one penicillin will be allergic to all because the hypersensitivity is related to the basic penicillin structure. Patients with a history of immediate hypersensitivity to penicillins may also react to the cephalosporins and other beta-lactam antibiotics, they should not receive these antibiotics. If a penicillin (or another beta-lactam antibiotic) is essential in an individual with immediate hypersensitivity to penicillin then specialist advice should be sought on hypersensitivity testing or using a beta-lactam antibiotic with a different structure to the penicillin that caused the hypersensitivity.

- **Penicillins (antipseudomonal)**
  - **Piperacillin with tazobactam**

**INDICATIONS AND DOSE**

**Hospital-acquired pneumonia** | **Septicaemia** | **Complicated infections involving the urinary-tract or skin and soft tissues**
---|---|---
**BY INTRAVENOUS INFUSION**
- Adult: 4.5 g every 8 hours; increased if necessary to 4.5 g every 6 hours, increased frequency may be used for severe infections
- **Complicated intra-abdominal infections**
  - **BY INTRAVENOUS INFUSION**
    - Adult 18 years: 4.5 g every 8 hours; increased if necessary to 4.5 g every 6 hours, increased frequency may be used for severe infections
  - **Infections in neutropenic patients**
    - **BY INTRAVENOUS INFUSION**
      - Adult: 4.5 g every 6 hours

**CAUTIONS** High doses may lead to hypernatraemia (owing to sodium content of preparations)

**SIDE-EFFECTS**
- **Common or very common** Nausea - vomiting
- **Uncommon** Constipation - dyspepsia - headache - hypotension - injection-site reactions - insomnia - jaundice - stomatitis
- **Rare** Abdominal pain - eosinophilia - hepatitis
Ticarcillin with clavulanic acid

**INDICATIONS AND DOSE**

Infections due to Pseudomonas and Proteus spp

**BY INTRAVENOUS INFUSION**

- **Adult:** 3.2 g every 6–8 hours; increased if necessary to 3.2 g every 4 hours, increased frequency used for more severe infections

**CAUTIONS**

High doses may lead to hypernatraemia (owing to sodium content of preparations)

**CAUTIONS, FURTHER INFORMATION**

**Cholestatic jaundice**

Cholestatic jaundice is possibly associated with clavulanic acid. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav (amoxicillin, clavulanic acid) than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.

**SIDE-EFFECTS**

Eosinophilia; haemorrhagic cystitis (more frequent in children); hypokalaemia; injection-site reactions; nausea; Stevens-Johnson syndrome; toxic epidermal necrolysis; vomiting

**PREGNANCY**

Not known to be harmful.

**BREAST FEEDING**

Trace amounts in milk, but appropriate to use.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution in severe impairment.

**RENAL IMPAIRMENT**

Reduce dose to 3.2 g every eight hours if eGFR 30–60 mL/minute/1.73 m²; 1.6 g every eight hours if eGFR 10–30 mL/minute/1.73 m²; 1.6 g every twelve hours if eGFR less than 10 mL/minute/1.73 m². Accumulation of electrolytes contained in preparation can occur in patients with renal failure.

**EFFECT ON LABORATORY TESTS**

False-positive urinary glucose (if tested for reducing substances).

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstitute initially (2.25 g in 10 mL, 4.5 g in 20 mL) with water for injections, or glucose 5% (Tazocin® brand only), or sodium chloride 0.9%, then dilute to 50–150 mL with infusion fluid; give over 30 minutes.

**PRESCRIBING AND DISPENSING INFORMATION**

Dose expressed as a combination of ticarcillin and tazobactam (both as sodium salts).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

**Powder for solution for injection**

**ELECTROLYTES:** May contain Sodium, Potassium.

**Tazocin (Pfizer Ltd)**

- Ticarcillin (as Ticarcillin sodium) 2 gram, Tazobactam (as Tazobactam sodium) 250 mg Ticarcillin 2g / Tazobactam 250mg powder for solution for injection vials | 1 vial (PO) £7.91; 5 vials £39.55; 10 vials £79.10

**Tazocin (Timentin GlaxoSmithKline UK Ltd)**

- Ticarcillin (as Ticarcillin sodium) 3 gram Timentin 3.2g powder for solution for infusion vials | 4 vial (PO) £21.32

**BENZYL Penicillin sodium (Penicillin G)**

**INDICATIONS AND DOSE**

Mild to moderate susceptible infections | Throat infections | Otitis media | Cellulitis | Pneumonia

- **BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - **Adult:** 0.6–1.2 g every 6 hours, dose may be increased if necessary in more serious infections (consult product literature), single doses over 1.2 g to be given by intravenous route only

**Endocarditis (in combination with other antibacterial if necessary)**

- **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - **Adult:** 1.2 g every 4 hours, increased if necessary to 2.4 g every 4 hours, dose may be increased in infections such as enterococcal endocarditis

**Anthrax (in combination with other antibacterials)**

- **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - **Adult:** 2.4 g every 4 hours

**Intrapartum prophylaxis against group B streptococcal infection**

- **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - **Adult:** Initially 3 g for 1 dose, then 1.5 g every 8 hours until delivery

**Meningitis | Meningococcal disease**

- **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - **Adult:** 2.4 g every 4 hours

**BY INTRAVENOUS INFUSION**

- **Neonate up to 6 days:** 50 mg/kg every 12 hours.
  - **Neonate 7-28 days:** 50 mg/kg every 8 hours.
Phenoxymethylpenicillin (Penicillin V)

**INDICATIONS AND DOSE**

<table>
<thead>
<tr>
<th>Oral infections</th>
<th>Tonsillitis</th>
<th>Otitis media</th>
<th>Erysipelas</th>
<th>Cellulitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Powder for solution for injection**

**ELECTROLYTES:** May contain Sodium

- **BENZYPENICILLIN SODIUM (Non-proprietary)**
  - Benzylpenicillin sodium 600 mg Benzylpenicillin 600mg powder for solution for injection vials | 2 vial PD £4.67 DT price + £4.67 | 25 vial PD £58.37-£58.38
  - Benzylpenicillin sodium 1.2 gram Benzylpenicillin 1.2g powder for solution for injection vials | 25 vial PD £78.64 DT price + £78.64

**Phenoxymethylpenicillin**

**UNLICENSED USE** Phenoxymethylpenicillin doses in the BNF may differ from product literature.

**Important safety information**

Intrathecal injection of benzylpenicillin is **not** recommended.

**CAUTIONS** Accumulation of sodium from injection can occur with high doses.

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Trace amounts in milk, but inappropriate to use.

**RENAL IMPAIRMENT** Accumulation of sodium from injection can occur in renal failure. High doses may cause neurotoxicity, including cerebral irritation, convulsions, or coma.

- **In adults** Reduce dose—consult product literature.
- **In children** Estimated glomerular filtration rate 10–50 mL/minute/1.73 m², use normal dose every 8–12 hours. Estimated glomerular filtration rate less than 10 mL/minute/1.73 m² use normal dose every 12 hours.

**EFFECT ON LABORATORY TESTS** False-positive urinary glucose (if tested for reducing substances).

**DIRECTIONS FOR ADMINISTRATION**

- **With intravenous use in children** Intravenous route recommended in neonates and infants. For **intravenous infusion**, dilute with Glucose 5% or Sodium Chloride 0.9%; give over 15–30 minutes. Longer administration time is particularly important when using doses of 50 mg/kg (or greater) to avoid CNS toxicity.
- **With intravenous use in adults** For **intravenous infusion** (Crystapen®), give intermittently in Glucose 5% or Sodium chloride 0.9%; suggested volume 100 mL given over 30–60 minutes. Continuous infusion not usually recommended.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, eye drops.
Infection

Amoxicillin

**INDICATIONS AND DOSE**

Susceptible infections (including urinary-tract infections, otitis media, sinusitis, uncomplicated community acquired pneumonia, salmonellosis, oral infections)

**BY MOUTH**

- Child 1-11 months: 125 mg 3 times a day; increased if necessary up to 30 mg/kg 3 times a day
- Child 1-4 years: 250 mg 3 times a day; increased if necessary up to 30 mg/kg 3 times a day
- Child 5-11 years: 500 mg 3 times a day; increased if necessary up to 30 mg/kg 3 times a day (max. per dose 1 g)
- Child 12-17 years: 500 mg 3 times a day; increased if necessary up to 1 g 3 times a day, use increased dose in severe infections
- Adult: 500 mg every 8 hours, increased if necessary to 1 g every 8 hours, increased dose used in severe infections

**BY INTRAMUSCULAR INJECTION**

- Adult: 500 mg every 8 hours

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: 500 mg every 8 hours, increased to 1 g every 6 hours, use increased dose in severe infections

**Lyme disease (under expert supervision)**

- Child 5-17 years: 500 mg 3 times a day for 14–21 days (for 28 days in Lyme arthritis)
- Adult: 500 mg 3 times a day for 14–21 days (for 28 days in Lyme arthritis)

**Anthrax (treatment and post-exposure prophylaxis)**

- Child (body-weight up to 20 kg): 80 mg/kg daily in 3 divided doses
- Child (body-weight 20 kg and above): 500 mg 3 times a day
- Adult: 500 mg 3 times a day

**Dental abscess (short course)**

- Adult: 3 g, then 3 g after 8 hours

**Urinary-tract infections (short course)**

- Adult: 3 g, then 3 g after 10–12 hours

**Listerial meningitis (in combination with another antibiotic)**

**BY INTRAVENOUS INFUSION**

- Adult: 2 g every 4 hours

**Endocarditis (in combination with another antibiotic if necessary)**

**BY INTRAVENOUS INFUSION**

- Adult: 2 g every 4 hours

Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease— if cover also needed for Haemophilus influenzae

- **BY MOUTH**
  - Child 1 month–4 years: 125 mg twice daily
  - Child 5–11 years: 250 mg twice daily
  - Child 12–17 years: 500 mg twice daily

**Helicobacter pylori eradication in combination with metronidazole and omeprazole**

- **BY MOUTH**
  - Adult: 500 mg 3 times a day

**Helicobacter pylori eradication; in combination with clarithromycin and esomeprazole; or in combination with clarithromycin and lansoprazole; or in combination with metronidazole and lansoprazole; or in combination with clarithromycin and omeprazole; or in combination with clarithromycin and pantoprazole; or in combination with clarithromycin and rabeprazole**

**BY MOUTH**

- Adult: 1 g twice daily

**SIDE-EFFECTS**

- With intravenous use Accumulation of sodium can occur with high parenteral doses

**GENERAL CAUTIONS**

- Acute lymphocytic leukaemia (increased risk of erythematous rashes) · chronic lymphocytic leukaemia (increased risk of erythematous rashes) · cytomegalovirus infection (increased risk of erythematous rashes) · glandular fever (erythematous rashes common) · maintain adequate hydration with high doses (particularly during parenteral therapy)

**SPECIFIC CAUTIONS**

- With intravenous use Amoxicillin doses in BNF Publications may differ from those in product literature. Amoxicillin is not licensed for use for treatment of Lyme disease.

**CAUTIONS**

- Unlikely to cause diarrhoea

**SIDE-EFFECTS, FURTHER INFORMATION**

If rash occurs, discontinue treatment.

**PREGNANCY**

- Not known to be harmful.

**MILK**

- Trace amount in milk, but appropriate to use.

**RENAL IMPAIRMENT**

- Reduce dose in severe impairment; rashes more common. Risk of crystalluria with high doses (particularly during parenteral therapy). Accumulation of sodium from injection can occur in patients with renal failure.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children Displacement value may be significant when reconstituting injection, consult local guidelines. Dilute intravenous injection to a concentration of 50 mg/mL (100 mg/mL for neonates). May be further diluted with Glucose 5% or Glucose 10% or Sodium chloride 0.9% or 0.45% for intravenous infusion. Give intravenous infusion over 30 minutes when using doses over 30 mg/kg.

- With intravenous use in adults For intravenous infusion (Amoxicillin®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstituted solutions diluted and given without delay; suggested volume 100 mL given over 30–60 minutes or give via drip tubing in Glucose 5% or Sodium chloride 0.9%; continuous infusion not usually recommended.
PATIENT AND CARER ADVICE

Patient counselling is advised for Amoxicillin (Amoxil®) paediatric suspension (use of pipette).

Medicines for Children leaflet: Amoxicillin for bacterial infections www.medicinesforchildren.org.uk/amoxicillin-bacterial-infections-0

PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulation Amoxicillin capsules may be prescribed. Amoxicillin sachets may be prescribed as Amoxicillin Oral Powder. Amoxicillin Oral Suspension may be prescribed.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 9

AMOXICILLIN (Non-proprietary)

Amoxicillin (as Amoxicillin trihydrate) 250 mg Amoxicillin 250mg capsules | 15 capsule (PO) £5.00 DT price = £0.33 | 21 capsule (PO) £5.00 DT price = £1.37 | 500 capsule (PO) £120.00

Amoxicillin (as Amoxicillin trihydrate) 500 mg Amoxicillin 500mg capsules | 15 capsule (PO) £7.50 DT price = £1.16 | 21 capsule (PO) £15.00 DT price = £1.62 | 100 capsule (PO) £75.00

Amoxil (GlaxoSmithKline UK Ltd)

Amoxicillin (as Amoxicillin trihydrate) 250 mg Amoxicillin capsules | 21 capsule (PO) £3.38 DT price = £1.37

Amoxicillin (as Amoxicillin trihydrate) 500 mg Amoxicillin capsules | 21 capsule (PO) £6.77 DT price = £1.62

Oral suspension

CAUTIONARY AND ADVISORY LABELS 9

EXCIPIENTS: May contain Sucrose

AMOXICILLIN (Non-proprietary)

Amoxicillin (as Amoxicillin trihydrate) 25 mg per 1 ml Amoxicillin 125mg/5ml oral suspension sugar-free (sugar-free) | 100 ml (PO) £25.00 DT price = £1.27

Amoxicillin 125mg/5ml oral suspension | 100 ml (PO) £1.68 DT price = £1.21

Amoxicillin (as Amoxicillin trihydrate) 50 mg per 1 ml Amoxicillin 250mg/5ml oral suspension sugar-free (sugar-free) | 100 ml (PO) £35.00 DT price = £1.41

Amoxicillin 250mg/5ml oral suspension | 100 ml (PO) £1.99 DT price = £1.34

Amoxil (GlaxoSmithKline UK Ltd)

Amoxicillin (as Amoxicillin trihydrate) 100 mg per 1 ml Amoxicillin 125mg/1.25ml paediatric oral suspension | 20 ml (PO) £3.18 DT price = £1.58

Powder for solution for injection

ELECTROLYTES: May contain Sodium

AMOXICILLIN (Non-proprietary)

Amoxicillin (as Amoxicillin sodium) 250 mg Amoxicillin 250mg powder for solution for injection vials | 10 vial (PO) £4.65–£4.80

Amoxicillin (as Amoxicillin sodium) 500 mg Amoxicillin 500mg powder for solution for injection vials | 10 vial (PO) £8.85–£9.60 DT price = £5.48

Amoxicillin (as Amoxicillin sodium) 1 gram Amoxicillin 1g powder for solution for injection vials | 1 vial (PO) £1.92 | 10 vial (PO) £16.50 DT price = £10.96

Amoxil (GlaxoSmithKline UK Ltd)

Amoxicillin (as Amoxicillin sodium) 500 mg Amoxicillin 500mg powder for solution for injection vials | 10 vial (PO) £15.48 DT price = £5.48

Amoxicillin (as Amoxicillin sodium) 1 gram Amoxicillin 1g powder for solution for injection vials | 10 vial (PO) £10.96 DT price = £10.96

Powder

CAUTIONARY AND ADVISORY LABELS 9, 13

AMOXICILLIN (Non-proprietary)

Amoxicillin (as Amoxicillin trihydrate) 3 gram Amoxicillin 3g oral powder sachets sugar-free (sugar-free) | 2 sachet (PO) £15.00 DT price = £3.97

Amoxil (GlaxoSmithKline UK Ltd)

Amoxicillin (as Amoxicillin trihydrate) 3 gram Amoxicillin 3g oral powder sachets sucrose free (sugar-free) | 2 sachet (PO) £2.99 DT price = £3.97

INDICATIONS AND DOSE

SUSCEPTIBLE INFECTIONS (INCLUDING URINARY-TRACT INFECTIONS, OTITIS MEDIA, SINUSITIS, UNCOMPLICATED COMMUNITY-ACQUIRED PNEUMONIA, SALMONELLOSIS)

BY MOUTH

• Child 1-11 months: 125 mg 4 times a day; increased if necessary up to 30 mg/kg 4 times a day
• Child 1-4 years: 250 mg 4 times a day; increased if necessary up to 30 mg/kg 4 times a day
• Child 5-11 years: 500 mg 4 times a day; increased if necessary up to 30 mg/kg 4 times a day (max. per dose 1 g)
• Child 12-17 years: 500 mg 4 times a day; increased if necessary up to 1 g 4 times a day, use increased dose in severe infection

• Adult: 0.5–1 g every 6 hours

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

• Adult: 500 mg every 4–6 hours

BY INTRAMUSCULAR INJECTION

• Adult: 500 mg every 4–6 hours

ENDOTRANCID (IN COMBINATION WITH ANOTHER ANTIBIOTIC IF NECESSARY) | LISTERIAL MENINGITIS (IN COMBINATION WITH ANOTHER ANTIBIOTIC) | By intravenous infusion

• Adult: 2 g every 4 hours

UNLICENSED USE Amoxicillin doses in BNF may differ from those in product literature.

CAUTIONS

GENERAL CAUTIONS

Acute lymphocytic leukaemia (increased risk of erythematous rashes) • Chronic lymphocytic leukaemia (increased risk of erythematous rashes) • Cytomegalovirus infection (increased risk of erythematous rashes) • Glandular fever (erythematous rashes common)

SPECIFIC CAUTIONS

• With intravenous use Accumulation of electrolytes contained in parenteral preparations can occur with high doses

SIDE-EFFECTS

• Common or very common: Nausea, vomiting

SIDE-EFFECTS, FURTHER INFORMATION

If rash occurs, discontinue treatment.

PREGNANCY

Not known to be harmful.

BREAST FEEDING

Trace amounts in milk, but inappropriate to use.

RENAI IMPAIRMENT

Accumulation of electrolytes contained in parenteral preparations can occur in patients with renal failure.

• In adults Reduce dose if eGFR less than 10 mL/minute/1.73 m²; rashes more common.

• In children If estimated glomerular filtration rate less than 10 mL/minute/1.73 m² reduce dose or frequency; rashes more common.

DIRECTIONS FOR ADMINISTRATION

• With oral use Administer at least 30 minutes before food.

• With intravenous use in children Displacement value may be significant when reconstituting injection, consult local guidelines. Dilute intravenous injection to a concentration of 50–100 mg/mL. May be further diluted with glucose 5% or 10% or sodium chloride 0.9% or 0.45% for infusion. Give over 30 minutes when using doses of greater than 50 mg/kg to avoid CNS toxicity including convulsions.

• With intravenous use in adults For intravenous infusion (Penbritin®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstituted solutions diluted and given without delay; suggested volume 100 mL given over 30–60 minutes via drip tubing in Glucose 5% or Sodium.
Infection

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Ampicillin for bacterial infection www.medicinesforchildren.org.uk/ampicillin-bacterial-infection

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 9, 23

AMPCILLIN (Non-proprietary)

Ampicillin 250 mg Ampicillin 250mg capsules | 28 capsule £25.00 DT price = £4.75
Ampicillin 500 mg Ampicillin 500mg capsules | 28 capsule £35.00 DT price = £21.37
Penbritin (Chemirex Pharma Ltd)
Ampicillin 250 mg Penbritin 250mg capsules | 28 capsule £2.10 DT price = £4.75
Ampicillin 500 mg Penbritin 500mg capsules | 28 capsule £5.28 DT price = £21.37

Oral suspension

CAUTIONARY AND ADVISORY LABELS 9, 23

AMPCILLIN (Non-proprietary)

Ampicillin 25 mg per 1 ml Ampicillin 125mg/5ml oral suspension | 100 ml (PO) £29.86 DT price = £29.86
Ampicillin 50 mg per 1 ml Ampicillin 250mg/5ml oral suspension | 100 ml (PO) £38.86 DT price = £38.86

Powder for solution for injection

AMPCILLIN (Non-proprietary)

Ampicillin (as Ampicillin sodium) 500 mg Ampicillin 500mg powder for solution for injection vials | 10 vial £76.30

Co-amoxiclav

INDICATIONS AND DOSE

Infections due to beta-lactamase-producing strains (where amoxicillin alone not appropriate), including respiratory tract infections, bone and joint infections, genito-urinary and abdominal infections, cellulitis and animal bites

INITIALLY BY MOUTH USING TABLETS

• Child 12-17 years: 250/125 mg every 8 hours; (by mouth) increased to 500/125 mg every 8 hours, increased dose used for severe infection
• Adult: 250/125 mg every 8 hours; (by mouth) increased to 500/125 mg every 8 hours, increased dose used for severe infection

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

• Adult: 1.2 g every 8 hours, intravenous injection to be administered over 3–4 minutes

Severe dental infection with spreading cellulitis | Dental infection not responding to first-line bacterial

BY MOUTH USING TABLETS

• Child 12-17 years: 250/125 mg every 8 hours for 5 days
• Adult: 250/125 mg every 8 hours for 5 days

Surgical prophylaxis

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

• Adult: 1.2 g, to be administered up to 30 minutes before the procedure, then 1.2 g every 8 hours for up to 2–3 further doses in high risk procedures

Dose equivalence and conversion

Doses are expressed as co-amoxiclav.

A mixture of amoxicillin (as the trihydrate or as the sodium salt) and clavulanic acid (as potassium clavulanate); the proportions are expressed in the form x/y where x and y are the strengths in milligrams of amoxicillin and clavulanic acid respectively.

CONTRA-INDICATIONS

History of co-amoxiclav-associated jaundice or hepatic dysfunction - history of penicillin-associated jaundice or hepatic dysfunction

CAUTIONS

GENERAL CAUTIONS

Acute lymphocytic leukaemia (increased risk of erythematous rashes) · chronic lymphocytic leukaemia (increased risk of erythematous rashes) · cytomegalovirus infection (increased risk of erythematous rashes) · glandular fever (erythematous rashes common) - maintain adequate hydration with high doses (particularly during parental therapy)

SPECIFIC CAUTIONS

• With intravenous use Accumulation of electrolytes contained in parenteral preparations can occur with high doses

CAUTIONS, FURTHER INFORMATION

Cholestatic jaundice Cholestatic jaundice can occur either during or shortly after the use of co-amoxiclav. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

• Common or very common Cholestatic jaundice - hepatitis - nausea - vomiting
• Rare Dizziness - headache - prolongation of bleeding time
• Frequency not known Exfoliative dermatitis - Steven-Johnson syndrome - toxic epidermal necrolysis - vasculitis

SPECIFIC SIDE-EFFECTS

• Rare
• With intravenous use phlebitis at injection site
• With oral use superficial staining of teeth with suspension

SIDE-EFFECTS, FURTHER INFORMATION

Rash If rash occurs, discontinue treatment.

PREGNANCY

Not known to be harmful.

BREAST FEEDING

Trace amount in milk, but appropriate to use.

HEPATIC IMPAIRMENT

Monitor liver function in liver disease.

RENAL IMPAIRMENT

Risk of crystalluria with high doses (particularly during parenteral therapy).

• With oral use in adults Co-amoxiclav 250/125 tablets or 500/125 tablets: if eGFR 10–30 mL/minute/1.73 m², one 250/125 strength tablet every 12 hours or one 500/125 strength tablet every 12 hours; if eGFR less than 10 mL/minute/1.73 m², one 250/125 strength tablet every 24 hours or one 500/125 strength tablet every 24 hours.

Co-amoxiclav 400/57 suspension: avoid if eGFR less than 30 mL/minute/1.73 m².

• With intravenous use in adults Co-amoxiclav injection (expressed as co-amoxiclav): if eGFR 10–30 mL/minute/1.73 m², 1.2 g initially, then 600 mg every 12 hours; if eGFR less than 10 mL/minute/1.73 m², 1.2 g initially, then 600 mg every 24 hours. Accumulation of electrolytes contained in parenteral preparations can occur in patients with renal failure.

• With oral use in children Co-amoxiclav 125/31 suspension, 250/62 suspension, 250/125 suspension, or 500/125 tablets: use normal dose every 12 hours if estimated glomerular filtration rate 10–30 mL/minute/1.73 m². Use the normal dose recommended for mild or moderate infections every 12 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m². Co-amoxiclav 400/57 suspension: avoid if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².
Bacterial infection 485

Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (sugar-free) | 100 ml (PDP) £35.00 DT price = £1.89
Amoxicillin (as Amoxicillin trihydrate) 80 mg per 1 ml, Clavulanic acid (as Potassium clavulanate) 1.4 mg per 1 ml Co-amoxiclav 400mg/57mg/5ml oral suspension sugar free (sugar-free) | 35 ml (PDP) £4.13 DT price = £4.13 (sugar-free) | 70 ml (PDP) £5.79 DT price = £5.79
Augmentin (GlaxoSmithKline UK Ltd)
Amoxicillin (as Amoxicillin trihydrate) 25 mg per 1 ml, Clavulanic acid (as Potassium clavulanate) 0.6 mg per 1 ml Augmentin 125/31.5F oral suspension (sugar-free) | 100 ml (PDP) £3.54 DT price = £1.81
Amoxicillin (as Amoxicillin trihydrate) 50 mg per 1 ml, Clavulanic acid (as Potassium clavulanate) 1.25 mg per 1 ml Augmentin 250/62.5F oral suspension (sugar-free) | 100 ml (PDP) £3.60 DT price = £1.89
Augmentin-Duo (GlaxoSmithKline UK Ltd)
Amoxicillin (as Amoxicillin trihydrate) 80 mg per 1 ml, Clavulanic acid (as Potassium clavulanate) 1.4 mg per 1 ml Augmentin-Duo 400/57F oral suspension (sugar-free) | 35 ml (PDP) £4.13 DT price = £4.13 (sugar-free) | 70 ml (PDP) £5.79 DT price = £5.79
Powder for solution for injection
ELECTROLYTES: May contain Potassium, sodium
- CO-AMOXICLAV (Non-proprietary)
  Amoxicillin (as Amoxicillin sodium) 500 mg, Clavulanic acid (as Potassium clavulanate) 100 mg Co-amoxiclav 500mg/100mg powder for solution for injection vials | 10 vial (PDP) £4.90
  Amoxicillin (as Amoxicillin sodium) 1000 mg, Clavulanic acid (as Potassium clavulanate) 200 mg Co-amoxiclav 1000mg/200mg powder for solution for injection vials | 10 vial (PDP) £29.70
- Augmentin Intravenous (GlaxoSmithKline UK Ltd)
  Amoxicillin (as Amoxicillin sodium) 500 mg, Clavulanic acid (as Potassium clavulanate) 100 mg Augmentin Intravenous 600mg powder for solution for injection vials | 10 vial (PDP) £10.60
  Amoxicillin (as Amoxicillin sodium) 1000 mg, Clavulanic acid (as Potassium clavulanate) 200 mg Augmentin Intravenous 1.2g powder for solution for injection vials | 10 vial (PDP) £10.60

Co-fluampicil

INDICATIONS AND DOSE
Mixed infections involving beta-lactamase-producing staphylococci
BY MOUTH
- Child 1 month-9 years: 125/125 mg every 6 hours
- Child 10-17 years: 250/250 mg every 6 hours
- Adult: 250/250 mg every 6 hours
BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION
- Adult: 250/250 mg every 6 hours
Severe mixed infections involving beta-lactamase-producing staphylococci
BY MOUTH
- Child 1 month-9 years: 250/250 mg every 6 hours
- Child 10-17 years: 500/500 mg every 6 hours
- Adult: 500/500 mg every 6 hours
BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION
- Adult: 500/500 mg every 6 hours

Important safety information
HEPATIC DISORDERS
Cholestatic jaundice and hepatitis may occur very rarely, up to two months after treatment with fluclouxacin has been stopped. Administration for more than 2 weeks and increasing age are risk factors.
Healthcare professionals are reminded that:
- fluclouxacin should not be used in patients with a history of hepatic dysfunction associated with fluclouxacin;
- fluclouxacin should be used with caution in patients with hepatic impairment;
PENICILLINS (MECILLINAM-TYPE)

Pivmecillinam hydrochloride

**INDICATIONS AND DOSE**
Acute uncomplicated cystitis

**BY MOUTH**
- Child (body-weight 40 kg and above): Initially 400 mg for 1 dose, then 200 mg every 8 hours for 3 days
- Adult (body-weight 40 kg and above): Initially 400 mg for 1 dose, then 200 mg every 8 hours for 3 days

**Chronic or recurrent bacteriuria**

**BY MOUTH**
- Child (body-weight 40 kg and above): 400 mg every 6–8 hours
- Adult (body-weight 40 kg and above): 400 mg every 6–8 hours

**Urinary-tract infections**

**BY MOUTH**
- Child (body-weight up to 40 kg): 5–10 mg/kg every 6 hours, alternatively 20–40 mg/kg daily in 3 divided doses

**UNLICENSED USE**
Not licensed for use in children under 3 months.

**CONTRA-INDICATIONS**
Carnitine deficiency · gastro-intestinal obstruction · infants under 3 months · oesophageal strictures

**CAUTIONS**
Avoid in Acute porphyrias p. 864

**SIDE-EFFECTS**
- Common or very common Abdominal pain · dizziness · headache · nausea · vomiting
- Frequency not known Mouth ulcers · oesophagitis · reduced serum and total body carnitine (especially with long-term or repeated use)

**PREGNANCY**
Not known to be harmful, but manufacturer advises avoid.

**BREAST FEEDING**
Trace amount in milk, but appropriate to use.

**MONITORING REQUIREMENTS**
Liver and renal function tests required in long-term use.

**EFFECT ON LABORATORY TESTS**
False-positive urinary glucose (if tested for reducing substances).

**DIRECTIONS FOR ADMINISTRATION**
Tablets should be swallowed whole with plenty of fluid during meals while sitting or standing.

**PATIENT AND CARER ADVICE**
Patient counselling is advised on administration of pivmecillinam hydrochloride tablets (posture).

**MEDI C I N A L F O R M S**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Pivmecillinam hydrochloride 200 mg | 10 tablet | £4.50
- Selexid 200mg tablets | 10 tablet | £4.50

**PENICILLINS (PENICILLINASE-RESISTANT)**

Flucloxacillin

**INDICATIONS AND DOSE**
Infections due to beta-lactamase-producing staphylococci including otitis externa | Adjunct in pneumonia | Adjunct in impetigo | Adjunct in cellulitis

**BY MOUTH**
- Child 1 month–1 year: 62.5–125 mg 4 times a day
- Child 2–9 years: 125–250 mg 4 times a day
Flucloxacillin (as Flucloxacillin sodium) 50 mg per capsule £0.17; 25 mg per capsule £0.08; 250 mg powder for solution for injection vials 10 vial £17.80; capsules £0.50; 500 mg capsules £0.65.

Flucloxacillin-for-bacterial-infections www.medicinesforchildren.org.uk/ flucloxacillin-for-bacterial-infections

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

<table>
<thead>
<tr>
<th>Capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAUTIONARY AND ADVISORY LABELS 9, 23</strong></td>
</tr>
<tr>
<td><strong>FLUCLOXACILLIN (Non-proprietary)</strong></td>
</tr>
<tr>
<td>Flucloxacillin (as Flucloxacillin sodium) 250 mg capsules</td>
</tr>
<tr>
<td>Flucloxacillin (as Flucloxacillin sodium) 500 mg capsules</td>
</tr>
<tr>
<td>DT price = £2.60</td>
</tr>
<tr>
<td>Brands may include Floxapen</td>
</tr>
</tbody>
</table>

**ORAL solution**

**CAUTIONARY AND ADVISORY LABELS 9, 23**

**Flucloxacillin (as Flucloxacillin sodium) 25 mg per ml Flucloxacillin (as Flucloxacillin sodium) 25mg capsules | 20 capsule £3.56 | 28 capsule £11.64 | 100 capsule £17.80 | 500 capsule £52.14 |
| Flucloxacillin (as Flucloxacillin sodium) 50 mg capsules | 20 capsule £7.50 | 28 capsule £10.50 |
| DT price = £2.60 | 100 capsule £37.50 |
| **Flucloxacillin-for-bacterial-infections** www.medicinesforchildren.org.uk/ flucloxacillin-for-bacterial-infections

**Powder for solution for injection**

**Flucloxacillin (as Flucloxacillin sodium) 250 mg capsules | 20 capsule £3.56 | 28 capsule £11.64 | 100 capsule £17.80 | 500 capsule £52.14 |
| Flucloxacillin (as Flucloxacillin sodium) 500 mg capsules | 20 capsule £7.50 | 28 capsule £10.50 |
| DT price = £2.60 | 100 capsule £37.50 |
| **Flucloxacillin-for-bacterial-infections** www.medicinesforchildren.org.uk/ flucloxacillin-for-bacterial-infections

**Temocillin**

**INDICATIONS AND DOSE**

Septicaemia | Urinary-tract infections | Lower respiratory-tract infections caused by susceptible Gram-negative bacteria

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

| Adult | Adult: 1–2 g every 12 hours, give over 3–4 minutes when administered by intravenous injection |

**HEPATIC IMPAIRMENT** Use with caution.

**RENAL IMPAIRMENT**

| In adults | Reduce dose if eGFR less than 10 mL/minute/1.73 m². Accumulation of electrolytes can occur in patients with renal failure. |
| In children | Use normal dose every 8 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m². |

**EFFECT ON LABORATORY TESTS** False-positive urinary glucose (if tested for reducing substances).

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (Fluxapen®), give intermittently in Glucose 5% or Sodium chloride 0.9%; suggested volume 100 mL given over 30–60 minutes, via drip tubing in Glucose 5% or Sodium chloride 0.9%; continuous infusion not usually recommended.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Flucloxacillin for bacterial infections www.medicinesforchildren.org.uk/ flucloxacillin-for-bacterial-infections

**UNLICENSED USE** Flucloxacillin doses in the BNF may differ from those in product literature.

**Important safety information**

**HEPATIC DISORDERS**

Cholestatic jaundice and hepatitis may occur very rarely, up to two months after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. Healthcare professionals are reminded that:

- **flucloxacillin should not be used in patients with a history of hepatic dysfunction associated with flucloxacillin**
- **flucloxacillin should be used with caution in patients with hepatic impairment**
- **careful enquiry should be made about hypersensitivity reactions to beta-lactam antibacterials**

**CAUTIONS**

- With intravenous use Accumulation of electrolytes can occur with high doses
- **SIDE-EFFECTS**
  - **Common or very common** Gastrointestinal disturbances
  - **Very rare** Cholestatic jaundice, hepatitis
- **PREGNANCY** Not known to be harmful.
- **BREAST FEEDING** Trace amounts in milk, but appropriate to use.
PHOSPHONIC ACID ANTIBACTERIALS

Fosfomycin

**DRUG ACTION** Fosfomycin, a phosphonic acid antibacterial, is active against a range of Gram-positive and Gram-negative bacteria including *Staphylococcus aureus* and Enterobacteriaceae.

**INDICATIONS AND DOSE** Uncomplicated lower urinary-tract infections caused by multiple-antibacterial resistant organisms when other antibacterials cannot be used

**BY MOUTH**
- Adult (female): 3 g for 1 dose.
- Adult (male): 3 g for 1 dose, then 3 g after 3 days.

Osteomyelitis when first-line treatments are inappropriate or ineffective
- Hospital-acquired lower respiratory-tract infections when first-line treatments are inappropriate or ineffective

**BY INTRAVENOUS INFUSION**
- Adult: 12–24 g once daily in 2–3 divided doses (max. per dose 8 g), use the high-dose regimen in severe infection suspected or known to be caused by less sensitive organisms

Complicated urinary-tract infections when first-line treatment ineffective or inappropriate

**BY INTRAVENOUS INFUSION**
- Adult: 12–16 g daily in 2–3 divided doses (max. per dose 8 g)

Bacterial meningitis when first-line treatment ineffective or inappropriate

**BY INTRAVENOUS INFUSION**
- Adult: 16–24 g daily in 3–4 divided doses (max. per dose 8 g), use the high-dose regimen in severe infection suspected or known to be caused by less sensitive organisms

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Common or very common Gastro-intestinal disturbances • rash
- Uncommon Diarrhoea • nausea • vomiting
- Frequency not known Abdominal pain

**SPECIFIC SIDE-EFFECTS**
- With intravenous use Decreased appetite • dyspnoea • fatigue • headache • hypernatraemia • hypokalaemia • taste disturbances • vertigo
- Rare
  - With intravenous use Aplastic anaemia • blood disorders • eosinophilia
  - Very rare
  - With intravenous use Fatty liver • visual impairment
  - Frequency not known
  - With intravenous use Antibiotic-associated colitis • bronchospasm • confusion • hepatitis • jaundice • tachycardia

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises use only if potential benefit outweighs risk—present in milk.

**RENAI IMPAIRMENT**
- With oral use Avoid if eGFR less than 10 mL/minute/1.73 m².
- With intravenous use Use with caution if eGFR 40–80 mL/minute/1.73 m² and consult product literature for dose if eGFR less than 40 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- With intravenous use Monitor electrolytes and fluid balance.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion
- Give intermittently in Glucose 5% or 10% or Sodium chloride 0.9%. Reconstitute 1 g with 10 mL water for injections then dilute with 50–150 mL infusion fluid; give over 30–40 minutes.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- **ELECTROLYTES: May contain Sodium**
  - **Negaban** (Eumedica Pharmaceuticals)
    - **Temocillin (as Temocillin sodium)** 1 gram
      - **Negaban 1g powder for solution for injection vials** 1 vial (PSt) no price available

**Granules**
- **FOSFOMYCIN (Non-proprietary)**
  - Fosfomycin (as Fosfomycin trometamol) 3 gram
    - Monuril 3g granules sachets | 1 sachet (PSt) £54.45

**Powder for solution for infusion**
- **ELECTROLYTES: May contain Sodium**
  - **Fomicixt (Nordic Pharma Ltd)**
    - Fosfomycin (as Fosfomycin sodium) 2 gram
      - Fomicixt 2g powder for solution for infusion vials | 10 vial (PSt) £150.00
    - Fosfomycin (as Fosfomycin sodium) 4 gram
      - Fomicixt 4g powder for solution for infusion vials | 10 vial (PSt) £300.00

**UNLICENSED USE** Oral preparations containing fosfomycin are not marketed in the UK and use of these preparations is unlicensed.

**CAUTIONS**
- With intravenous use Cardiac insufficiency • elderly (high doses) • hyperaldosteronism • hypernatraemia • hypertension • pulmonary oedema

**INTERACTIONS** ➔ Appendix 1 (fosfomycin).
POLYMYXIN ANTIBACTERIALS

Colistimethate sodium (Colistin sulphomethate sodium)

- **DRUG ACTION** The polymyxin antibiotic, colistimethate sodium (colistin sulphomethate sodium), is active against Gram-negative organisms including *Pseudomonas aeruginosa*, *Acinetobacter baumanii*, and *Klebsiella pneumoniae*. It is not absorbed by mouth and thus needs to be given by injection for a systemic effect.

**INDICATIONS AND DOSE**

Gram-negative infections resistant to other antibacterials, including those caused by *Pseudomonas aeruginosa*, *Acinetobacter baumanii* and *Klebsiella pneumoniae*

**BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENTOUS INFUSION**

- Adult (body-weight up to 59 kg): 50 000–75 000 units/kg daily in 3 divided doses, to be administered into a totally implantable venous access device when giving via slow intravenous injection
- Adult (body-weight 60 kg and above): 1–2 million units every 8 hours, to be administered into a totally implantable venous access device when giving via slow intravenous injection

**Adjunct to standard antibacterial therapy for *Pseudomonas aeruginosa* infection in cystic fibrosis**

**BY INHALATION OF NEBULISED SOLUTION**

- Adult: 1–2 million units twice daily; increased to 2 million units 3 times a day, dose only to be increased for subsequent respiratory isolates of *Pseudomonas aeruginosa*

**BY INHALATION OF POWDER**

- Adult: 1.66 million units twice daily

- **CONTRA-INDICATIONS** Myasthenia gravis
- **CAUTIONS**
- **GENERAL CAUTIONS** Acute porphyrias p. 864
- **SPECIFIC CAUTIONS**
- When used by inhalation: Severe haemoptysis — risk of further haemorrhage
- **INTERACTIONS** Appendix 1 (polymyxins)
- **SIDE-EFFECTS**
- Common or very common
  - When used by inhalation: Bronchospasm · cough · dysphonia · nausea · sore mouth · sore throat · taste disturbances · vomiting
  - Uncommon
  - When used by inhalation: Hypersalivation · thirst
  - Rare
  - With intravenous use: Vasomotor instability
  - Frequency not known
  - With intravenous use: Apnoea · confusion · headache · muscle weakness · nephrotoxicity · neurotoxicity reported especially with excessive doses · perioral paraesthesia · peripheral paraesthesia · psychosis · rash · slurred speech · vertigo · visual disturbances
- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Dose-related side effects: The major adverse effects are dose-related neurotoxicity and nephrotoxicity.
  - **PREGNANCY**
  - When used by inhalation: Clinical use suggests probably safe.
  - With intravenous use: Use only if potential benefit outweighs risk.
  - **BREAST FEEDING** Present in milk but poorly absorbed from gut; manufacturers advise avoid (or use only if potential benefit outweighs risk).

- **RENAL IMPAIRMENT**
  - With intravenous use: Reduce dose. In renal impairment, monitor plasma colistimethate sodium concentration during parenteral treatment — consult product literature.
  - Recommended ‘peak’ plasma colistimethate sodium concentration (approx. 1 hour after intravenous injection or infusion) 5–12 mg/litre; pre-dose (‘trough’) concentration 2–6 mg/litre.
  - **MONITORING REQUIREMENTS**
    - With intravenous use: Monitor renal function.
    - When used by inhalation: Measure lung function before and after initial dose of colistimethate sodium and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using a bronchodilator before the dose of colistimethate sodium.

- **DIRECTIONS FOR ADMINISTRATION**
  - When used by inhalation: Other inhaled drugs should be administered before colistimethate sodium. For nebulisation: administer required dose in 2–4 mL of sodium chloride 0.9% (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection.
  - With intravenous use: For intravenous infusion (*Colomycin*, *Promixin*®), give intermittently in sodium chloride 0.9% (or Glucose 5% for *Promixin*® brand only); dilute with 50 mL infusion fluid and give over 30 minutes.

**COLOMYCIN® POWDER FOR SOLUTION FOR INJECTION**

*Colomycin*® Injection may be used for nebulisation; administer required dose in 2–4 mL of sodium chloride 0.9%, (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Colistimethate sodium is included in some preparations for topical application.
- **PATIENT AND CARER ADVICE**
  - Patient should be advised to rinse mouth with water after each dose of dry powder inhalation.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - Colistimethate sodium by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)

  **NICE TA276**

  Colistimethate sodium dry powder for inhalation is recommended for nebulized pulmonary infection caused by *Pseudomonas aeruginosa* in patients with cystic fibrosis who would benefit from continued treatment, but do not tolerate the drug in its nebulised form. The manufacturer must provide colistimethate sodium dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving colistimethate sodium dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA276

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ear drops, oral solution

**Tablet**

- *Colomycin* (Forest Laboratories UK Ltd)
  - Colistin sulphate 1500000 unit Colomycin 1.5 million unit tablets | 50 tablet pack £55.00

**Powder for solution for injection**

**ELECTROLYTES:** May contain Sodium

- *COLISTIMETHATE SODIUM* (Non-proprietary)
  - Colistimethate sodium 1000000 unit Colistimethate 1 million unit powder for solution for injection vials | 10 vial pack £18.00
  - 10 vial pack £19.75 (Hospital only)

- *Colomycin* (Forest Laboratories UK Ltd)
  - Colistimethate sodium 1000000 unit Colomycin 1 million unit powder for solution for injection vials | 10 vial pack £18.00

- Colistimethate sodium 2000000 unit Colomycin 2 million unit powder for solution for injection vials | 10 vial pack £32.40
Bacterial infection

Quinolones

Nalidixic acid p. 493 and norfloxacin p. 493 are effective in uncomplicated urinary-tract infections.

Ciprofloxacin below is active against both Gram-positive and Gram-negative bacteria. It is particularly active against Gram-negative bacteria, including salmonella, shigella, campylobacter, neisseria, and pseudomonas. Ciprofloxacin has only moderate activity against Gram-positive bacteria such as Streptococcus pneumoniae and Enterococcus faecalis; it should not be used for pneumococcal pneumonia. It is active against chlamydia and some mycobacteria. Most anaerobic organisms are not susceptible. Ciprofloxacin can be used for respiratory tract infections (but not for pneumococcal pneumonia). It is particularly active against Gram-negative bacteria, including salmonella, shigella, and Gram-negative bacteria. It has only moderate activity against Gram-positive bacteria, including salmonella, shigella, and pseudomonas. Ciprofloxacin has only moderate activity against Gram-positive bacteria such as Streptococcus pneumoniae and Enterococcus faecalis; it should not be used for pneumococcal pneumonia. It is active against chlamydia and some mycobacteria. Most anaerobic organisms are not susceptible. Ciprofloxacin can be used for respiratory tract infections (but not for pneumococcal pneumonia), urinary-tract infections, infections of the gastro-intestinal system (including typhoid fever), bone and joint infections, gonorrhoea and septicemia caused by sensitive organisms.

Ifloxacin p. 494 is used for urinary-tract infections, lower respiratory-tract infections, gonorrhoea, and non-gonococcal urethritis and cervicitis.

Levofloxacin p. 492 is active against Gram-negative and Gram-negative organisms. It has greater activity against pneumococci than ciprofloxacin below. Levofloxacin is licensed for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia, but it should only be considered for these infections when first-line treatment cannot be used or is ineffective. Levofloxacin is also licensed for the treatment of urinary-tract infections.

Although ciprofloxacin, levofloxacin, moxifloxacin p. 492, and ofloxacin are licensed for skin and soft-tissue infections, many staphylococci are resistant to the quinolones and their use should be avoided in MRSA infections.

Moxifloxacin should be reserved for the treatment of sinusitis, community-acquired pneumonia, exacerbations of chronic bronchitis, mild to moderate pelvic inflammatory disease, or complicated skin and soft-tissue infections which have failed to respond to other antibacterials or for patients who cannot be treated with other antibacterials. It has been associated with QT interval prolongation and life-threatening hepatotoxicity. Moxifloxacin is active against Gram-positive and Gram-negative organisms. It has greater activity against Gram-positive organisms, including pneumococci, than ciprofloxacin. Moxifloxacin is not active against Pseudomonas aeruginosa or meticillin-resistant Staphylococcus aureus (MRSA).

Convulsions; taking NSAIDs at the same time may also induce them.

Tendon damage

Tendon damage (including rupture) has been reported rarely in patients receiving quinolones. Tendon rupture may occur within 48 hours of starting treatment; cases have also been reported several months after stopping a quinolone. Healthcare professionals are reminded that:

- quinolones are contra-indicated in patients with a history of tendon disorders related to quinolone use;
- patients over 60 years of age are more prone to tendon damage;
- the risk of tendon damage is increased by the concomitant use of corticosteroids;
- if tendinitis is suspected, the quinolone should be discontinued immediately.

Quinolones

Important safety information

The CSM has warned that quinolones may induce convulsions in patients with or without a history of convulsions; taking NSAIDs at the same time may also induce them.

Tendon damage

Tendon damage (including rupture) has been reported rarely in patients receiving quinolones. Tendon rupture may occur within 48 hours of starting treatment; cases have also been reported several months after stopping a quinolone. Healthcare professionals are reminded that:

- quinolones are contra-indicated in patients with a history of tendon disorders related to quinolone use;
- patients over 60 years of age are more prone to tendon damage;
- the risk of tendon damage is increased by the concomitant use of corticosteroids;
- if tendinitis is suspected, the quinolone should be discontinued immediately.

Quinolones

CONTRA-INDICATIONS

History of tendon disorders related to quinolone use.

CAUTIONS

Can prolong the QT interval - conditions that predispose to seizures - exposure to excessive sunlight should be avoided (discontinue if photosensitivity occurs).

- G6PD deficiency - history of epilepsy - myasthenia gravis (risk of exacerbation).

INTERACTIONS

Appendix 1 (quinolones).

SIDE-EFFECTS

Very rare - Stevens-Johnson syndrome - toxic epidermal necrolysis.

SIDE-EFFECTS, FURTHER INFORMATION

The drug should be discontinued if psychiatric, neurological, or hypersensitivity reactions (including severe rash) occur.

ALLERGY AND CROSS-SENSITIVITY

Use of quinolones contraindicated in quinolone hypersensitivity.

PREGNANCY

Avoid in pregnancy—shown to cause arthropathy in animal studies; safer alternatives are available.

Ciprofloxacin

INDICATIONS AND DOSE

Fistulating Crohn’s disease

BY MOUTH

- Adult: 500 mg twice daily

Respiratory-tract infections

BY MOUTH

- Adult: 500–750 mg twice daily

BY INTRAVENOUS INFUSION

- Adult: 400 mg every 8–12 hours, dose to be administered over 60 minutes
Pseudomonal lower respiratory-tract infection in cystic fibrosis

BY MOUTH
- Adult: 750 mg twice daily

Urinary-tract infections

BY MOUTH
- Adult: 250–750 mg twice daily

BY INTRAVENOUS INFUSION
- Adult: 400 mg every 8–12 hours, dose to be administered over 60 minutes

Acute uncomplicated cystitis in women

BY MOUTH
- Adult: 250 mg twice daily for 3 days

Acute or chronic prostatitis

BY MOUTH
- Adult: 500 mg twice daily for 28 days

BY INTRAVENOUS INFUSION
- Adult: 400 mg every 8–12 hours, dose to be administered over 60 minutes

Gonorrhoea

BY MOUTH
- Adult: 500 mg for 1 dose

Most other infections

BY MOUTH
- Adult: Initially 500 mg twice daily; increased to 750 mg twice daily, in severe or deep-seated infection

BY INTRAVENOUS INFUSION
- Adult: 400 mg every 8–12 hours, dose to be administered over 60 minutes

Surgical prophylaxis

BY MOUTH
- Adult: 750 mg, to be taken 60 minutes before procedure

Anthrax (treatment and post-exposure prophylaxis)

BY MOUTH
- Adult: 500 mg twice daily

BY INTRAVENOUS INFUSION
- Adult: 400 mg every 12 hours, to be given over 60 minutes

Prevention of secondary case of meningococcal meningitis

BY MOUTH
- Child 1 month–4 years: 30 mg/kg (max. per dose 125 mg) for 1 dose
- Child 5-11 years: 250 mg for 1 dose
- Child 12-17 years: 500 mg for 1 dose
- Adult: 500 mg for 1 dose

**UNLICENSED USE** Not licensed for use in children under 1 year of age. Not licensed for use in children for prophylaxis of meningococcal meningitis

**CAUTIONS** Acute myocardial infarction (risk factor for QT interval prolongation) - avoid excessive alkalinity of urine (risk of crystalluria) - bradycardia (risk factor for QT interval prolongation) - congenital long QT syndrome (risk factor for QT interval prolongation) - electrolyte disturbances (risk factor for QT interval prolongation) - ensure adequate fluid intake (risk of crystalluria) - heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) - history of symptomatic arrhythmias (risk factor for QT interval prolongation)

**INTERACTIONS** Caution if concomitant use with other drugs known to prolong the QT interval.

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Rare Abnormal dreams - chest pain - dysphagia - dyspnoea - erythema nodosum - hot flushes - hyperglycaemia - hypoglycaemia - oedema - pancreatitis - sweating - syncope - tachycardia
- Very rare Intracranial hypertension - movement disorders - tenosynovitis - tinnitus - vasculitis (in children)
- Frequency not known Peripheral neuropathy - polyneuropathy

**SPECIFIC SIDE-EFFECTS**

- Common or very common With intravenous use Flattulence - pain at injection site - phlebitis at injection site
- With oral use Flattulence

**PREGNANCY** A single dose of ciprofloxacin may be used for the prevention of a secondary case of meningococcal meningitis.

**BREAST FEEDING** Amount too small to be harmful but manufacturer advises avoid.

**RENAL IMPAIRMENT**
- With oral use in adults Give 250–500 mg every 12 hours if eGFR 30–60 mL/minute/1.73 m² (every 24 hours if eGFR less than 30 mL/minute/1.73 m²).
- With intravenous use in adults Give (200 mg over 30 minutes), 200–400 mg every 12 hours if eGFR 30–60 mL/minute/1.73 m² (every 24 hours if eGFR less than 30 mL/minute/1.73 m²).
- With intravenous use or oral use in children Reduce dose if estimated glomerular filtration rate less than 30 mL/minute/1.73 m²—consult product literature.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include strawberry.

**PATIENT AND CARER ADVICE** May impair performance of skilled tasks (e.g. driving); effects enhanced by alcohol. Medicines for Children leaflet: Ciprofloxacin for bacterial infections www.medicinesforchildren.org.uk/ciprofloxacin-bacterial-infections-0

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, oral suspension, ear drops

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>7, 9, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CIPROFLOXACIN (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin (as Ciprofloxacin hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>100 mg</td>
<td>Ciprofloxacin 100mg tablets</td>
</tr>
<tr>
<td>10 mg</td>
<td>Ciprofloxacin 100mg tablets</td>
</tr>
<tr>
<td>500 mg</td>
<td>Ciprofloxacin 500mg tablets</td>
</tr>
<tr>
<td>100 mg</td>
<td>Ciprofloxacin 500mg tablets</td>
</tr>
<tr>
<td>250 mg</td>
<td>Ciprofloxacin 250mg tablets</td>
</tr>
<tr>
<td>400 mg</td>
<td>Ciprofloxacin 400mg tablets</td>
</tr>
<tr>
<td>750 mg</td>
<td>Ciprofloxacin 750mg tablets</td>
</tr>
</tbody>
</table>

**Oral suspension**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>7, 9, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ciprofloxacin (as Ciprofloxacin hydrochloride)</strong></td>
<td></td>
</tr>
<tr>
<td>750 mg</td>
<td>Ciprofloxacin 750mg tablets</td>
</tr>
<tr>
<td>250 mg</td>
<td>Ciprofloxacin 250mg tablets</td>
</tr>
<tr>
<td>500 mg</td>
<td>Ciprofloxacin 500mg tablets</td>
</tr>
<tr>
<td>10 mg</td>
<td>Ciprofloxacin 10mg tablets</td>
</tr>
<tr>
<td>20 mg</td>
<td>Ciprofloxacin 20mg tablets</td>
</tr>
<tr>
<td>30 mg</td>
<td>Ciprofloxacin 30mg tablets</td>
</tr>
</tbody>
</table>

**Infusion**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>7, 9, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CIPROFLOXACIN (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin (as Ciprofloxacin lactate)</td>
<td></td>
</tr>
<tr>
<td>2 mg per 1 ml</td>
<td>Ciproxin 250mg/5ml oral infusion</td>
</tr>
<tr>
<td>1 ml</td>
<td>Ciproxin 200mg/100ml infusion bags</td>
</tr>
<tr>
<td>1 ml</td>
<td>Ciproxin 400mg/200ml infusion bags</td>
</tr>
</tbody>
</table>

**BNF 70**

**Bacterial infection 491**
Levofoxacin

INDICATIONS AND DOSE

Acute sinusitis
BY MOUTH
- Adult: 500 mg once daily for 10–14 days

Acute exacerbation of chronic bronchitis
BY MOUTH
- Adult: 500 mg once daily for 7–10 days

Community-acquired pneumonia
BY MOUTH
- Adult: 500 mg 1–2 times a day for 7–14 days
- Adult: 500 mg 1–2 times a day, to be given over at least 60 minutes

Urinary-tract infections
BY MOUTH
- Adult: 500 mg once daily for 7–14 days

Urinary-tract infections ( uncomplicated infection)
BY MOUTH
- Adult: 250 mg once daily for 3 days

Complicated urinary-tract infections
BY INTRAVENOUS INFUSION
- Adult: 500 mg once daily, to be given over at least 60 minutes

Chronic prostatitis
BY MOUTH
- Adult: 500 mg once daily for 28 days

Complicated skin and soft tissue infections
BY MOUTH
- Adult: 500 mg 1–2 times a day for 7–14 days
- Adult: 500 mg 1–2 times a day, to be given over at least 60 minutes

Inhalation of anthrax (treatment and post-exposure prophylaxis)
BY MOUTH
- Adult: 500 mg once daily for 8 weeks

INTERACTIONS
- Caution if concomitant use with other drugs known to prolong the QT interval.

SIDE-EFFECTS
- Frequency not known
- Benign intracranial hypertension - extrapyramidal symptoms
- Local reactions - peripheral neuropathy - pneumonitis
- Potentially life-threatening hepatic failure - rhabdomyolysis - stomatitis - syncope - transient hypotension

Moxifloxacin

INDICATIONS AND DOSE

Sinusitis
BY MOUTH
- Adult: 400 mg once daily for 7 days
**Community-acquired pneumonia**

**BY MOUTH**
- Adult: 400 mg once daily for 7–14 days

**BY INTRAVENOUS INFUSION**
- Adult: 400 mg once daily for 7–14 days, to be given over 60 minutes

**Exacerbations of chronic bronchitis**

**BY MOUTH**
- Adult: 400 mg once daily for 5–10 days

**Mild to moderate pelvic inflammatory disease**

**BY MOUTH**
- Adult: 400 mg once daily for 7–21 days

**Complicated skin and soft-tissue infections which have failed to respond to other antibacterials or for patients who cannot be treated with other antibacterials**

**BY MOUTH**
- Adult: 400 mg once daily for 7–21 days, to be given over 60 minutes

**CONTRA-INDICATIONS** Acute myocardial infarction (risk factor for QT interval prolongation) - bradycardia (risk factor for QT interval prolongation) - congenital long QT syndrome (risk factor for QT interval prolongation) - electrolyte disturbances (risk factor for QT interval prolongation) - heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) - history of symptomatic arrhythmias (risk factor for QT interval prolongation)

**INTERACTIONS** + Appendix 1 (quinolones).

Avoid concomitant use with other drugs known to prolong the QT interval.

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Common or very common: Angina - arrhythmias - constipation - flatulence - gastritis - hyperlipidaemia - palpitation - sweating - vasodilatation
- Uncommon: Dyspnoea
- Rare: Abnormal dreams - amnesia - dysphagia - hyperglycaemia - hypertension - hyperuricaemia - incoordination - myopathy - oedema - peripheral neuropathy - stomatitis - syncope
- Very rare: Potentially life-threatening hepatic failure - rhabdomyolysis

**SPECIFIC SIDE-EFFECTS**
- With intravenous use: Pain at injection site - phlebitis at injection site

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises avoid in severe impairment.

**PATIENT AND CARER ADVICE** May impair performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 6, 9
- **MOXIFLOXACIN (Non-proprietary)**
- **Moxifloxacin (as Moxifloxacin hydrochloride)**
  - **400 mg** Moxifloxacin 400mg tablets | 5 tablet | **POM** £8.05–£11.81 DT price = £10.85
  - **Avelox** (Bayer Plc)
  - **Moxifloxacin (as Moxifloxacin hydrochloride)**
  - **400 mg** Avelox 400mg tablets | 5 tablet | **POM** £12.43 DT price = £10.85

**Solution for infusion**

**ELECTROLYTES:** May contain Sodium

- **MOXIFLOXACIN (Non-proprietary)**
  - Moxifloxacin (as Moxifloxacin hydrochloride) 1.6 mg per 1 ml Moxifloxacin 400mg/250ml solution for infusion bottles | 1 bottle | **POM** £39.95
  - **Avelox** (Bayer Plc)
  - Moxifloxacin (as Moxifloxacin hydrochloride) 1.6 mg per 1 ml Avelox 400mg/250ml solution for infusion bottles | 1 bottle | **POM** £39.95 (Hospital only) | 5 bottle | **POM** £199.75 (Hospital only)

**Nalidixic acid**

**INDICATIONS AND DOSE**

**Urinary-tract infections**

**BY MOUTH**
- Adult: 900 mg every 6 hours for 7 days, then reduced to 600 mg every 6 hours for prolonged therapy in chronic infections

**CAUTIONS** Acute myocardial infarction (risk factor for QT interval prolongation) - avoid in Acute porphyrias p. 864 - bradycardia (risk factor for QT interval prolongation) - congenital long QT syndrome (risk factor for QT interval prolongation) - electrolyte disturbances (risk factor for QT interval prolongation) - heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) - history of symptomatic arrhythmias (risk factor for QT interval prolongation)

**INTERACTIONS** Caution if concomitant use with other drugs known to prolong the QT interval.

**SIDE-EFFECTS** Cranial nerve palsy - increased intracranial pressure - metabolic acidosis - peripheral neuropathy - toxic psychosis

**BREAST FEEDING** Risk to infant very small but one case of haemolytic anaemia reported.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in liver disease.

**RENAL IMPAIRMENT** Use with caution; avoid if eGFR less than 20 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor blood counts, renal and liver function if treatment exceeds 2 weeks.

**EFFECT ON LABORATORY TESTS** False positive urinary glucose (if tested for reducing substances).

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include raspberry and strawberry.

**MEDICINAL FORMS**

Medicines not identified.

**Norfloxacin**

**INDICATIONS AND DOSE**

**‘Lower’ urinary-tract infections**

**BY MOUTH**
- Adult: 400 mg twice daily for 7–10 days (for 3 days for uncomplicated infections in women)

**Chronic relapsing ‘lower’ urinary-tract infections**

**BY MOUTH**
- Adult: 400 mg twice daily for up to 12 weeks; reduced to 400 mg once daily, if adequate suppression within first 4 weeks

**Chronic prostatitis**

**BY MOUTH**
- Adult: 400 mg twice daily for 28 days
Infection

MEDICINAL FORMS

BREAST FEEDING

▶ Very rare

▶ Rare

Common or very common

INTERACTIONS Caution if concomitant use with other drugs known to prolong the QT interval.

SIDE-EFFECTS

▶ Common or very common Epiphora • tinnitus

▶ Rare Pancreatitis

▶ Very rare Arthralgia

Frequency not known Exfoliative dermatitis • polyneuropathy

INTERACTIONS Caution if concomitant use with other drugs known to prolong the QT interval.

SIDE-EFFECTS

▶ Common or very common Cough • eye irritation • nasopharyngitis

▶ Rare ▶ With intravenous use Abnormal dreams • arrhythmias • bronchospasm • dyspnoea • hot flushes • hyperhidrosis

▶ Very rare Extrapyramidal symptoms • neuropathy • tinnitus

▶ Frequency not known Changes in blood sugar • pneumonitis • rhabdomyolysis

PATIENT AND CARER ADVICE May impair performance of skilled tasks (e.g. driving).

CAUTIONS Acute myocardial infarction (risk factor for QT interval prolongation) • bradycardia (risk factor for QT interval prolongation) • congenital long QT syndrome (risk factor for QT interval prolongation) • heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) • history of symptomatic arrhythmias (risk factor for QT interval prolongation)

INTERACTIONS Caution if concomitant use with other drugs known to prolong the QT interval.

SIDE-EFFECTS

▶ Common or very common Epiphora • tinnitus

▶ Rare Pancreatitis

▶ Very rare Arthralgia

Frequency not known Exfoliative dermatitis • polyneuropathy

RENAI IMPAIRMENT Use No information available—manufacturer advises avoid.

PATIENT AND CARER ADVICE May impair performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet CAUTIONARY AND ADVISORY LABELS 7, 9, 23 ▶ NORFLOXACIN (Non-proprietary)

Norfloxacin 400 mg Norfloxacin 400mg tablets | 6 tablet [PMS] £5.40 | 14 tablet [PMS] £8.90

Norfloxacin (Non-proprietary) 400 mg TABLET (Sanofi)

INDICATIONS AND DOSE

Urinary-tract infections

BY MOUTH

▶ Adult: 200–400 mg daily, preferably taken in the morning; increased if necessary to 400 mg twice daily, in upper urinary tract infections

Complicated urinary-tract infection

BY INTRAVENOUS INFUSION

▶ Adult: 200 mg daily Increased to 400 mg twice daily, for severe or complicated infections, to be given over at least 30 minutes for each 200 mg

Acute or chronic prostatitis

BY MOUTH

▶ Adult: 200 mg twice daily for 28 days

Lower respiratory-tract infections

BY MOUTH

▶ Adult: 400 mg daily, dose preferably taken in the morning, then increased if necessary to 400 mg twice daily

BY INTRAVENOUS INFUSION

▶ Adult: 200 mg twice daily, increased to 400 mg twice daily, for severe or complicated infections, to be given over at least 30 minutes for each 200 mg

Skin and soft-tissue infections

BY MOUTH

▶ Adult: 400 mg twice daily

BY INTRAVENOUS INFUSION

▶ Adult: 400 mg twice daily, to be given over at least 30 minutes for each 200 mg

Uncomplicated gonorrhoea

BY MOUTH

▶ Adult: 400 mg once daily as a single dose

Uncomplicated genital chlamydial infection | Non-gonococcal urethritis

BY MOUTH

▶ Adult: 400 mg daily for 7 days, dose may be taken as a single daily dose or in divided doses

Pelvic inflammatory disease

BY MOUTH

▶ Adult: 400 mg twice daily for 14 days

Septicaemia

BY INTRAVENOUS INFUSION

▶ Adult: 200 mg twice daily, increased to 400 mg twice daily, for severe or complicated infections. To be given over at least 30 minutes for each 200 mg

CAUTIONS Acute myocardial infarction (risk factor for QT interval prolongation) • bradycardia (risk factor for QT interval prolongation) • congenital long QT syndrome (risk factor for QT interval prolongation) • heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) • history of symptomatic arrhythmias (risk factor for QT interval prolongation)

INTERACTIONS Caution if concomitant use with other drugs known to prolong the QT interval.

SIDE-EFFECTS

▶ Common or very common Cough • eye irritation • nasopharyngitis

▶ Rare ▶ With intravenous use Abnormal dreams • arrhythmias • bronchospasm • dyspnoea • hot flushes • hyperhidrosis

▶ Very rare Extrapyramidal symptoms • neuropathy • tinnitus

▶ Frequency not known Changes in blood sugar • pneumonitis • rhabdomyolysis

PATIENT AND CARER ADVICE May impair performance of skilled tasks (e.g. driving); effects enhanced by alcohol.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet CAUTIONARY AND ADVISORY LABELS 6, 9, 11 ▶ OFLOXACIN (Non-proprietary)

Ofloxacin 200 mg Ofloxacin 200mg tablets | 10 tablet [PMS] £5.97

Ofloxacin 400 mg Ofloxacin 400mg tablets | 5 tablet [PMS] £12.80

Tarivid (Sanofi)

Ofloxacin 200 mg Tarivid 200mg tablets | 10 tablet [PMS] £7.53 DT price = £5.97 | 20 tablet [DS] £15.05

Ofloxacin 400 mg Tarivid 400mg tablets | 5 tablet [PMS] £7.52 DT price = £10.82 | 10 tablet [PMS] £14.99

Solution for infusion

Tarivid (Sanofi)

Ofloxacin (as Ofloxacin hydrochloride) 2 mg per 1 ml Tarivid 200mg/100ml solution for infusion bottles | 1 bottle [PMS] £16.16
Rifaximin

- **DRUG ACTION** Rifaximin is a rifamycin that is poorly absorbed from the gastro-intestinal tract, and, therefore, should not be used to treat systemic infections.

**INDICATIONS AND DOSE**

Travellers’ diarrhoea that is not associated with fever, bloody diarrhoea, blood or leucocytes in the stool, or 8 or more unformed stools in the previous 24 hours

**BY MOUTH**

- Adult: 200 mg every 8 hours for 3 days
- **Reduction in recurrence of hepatic encephalopathy**
  - **BY MOUTH**
  - Adult: 550 mg twice daily

- **CONTRA-INDICATIONS** Intestinal obstruction
- **INTERACTIONS** Rifaximins interactions in Appendix 1 do not apply to rifaximin.
- **SIDE-EFFECTS** Rifaximins interactions in Appendix 1 do not apply to rifaximin.
  - **Uncommon** Anorexia, antibiotic-associated colitis, diarrhoea, dizziness, dyspnoea, flatulence, headache, muscle spasm, nausea, pruritus, rash, vomiting
  - **Uncommon** Anorexia, antibiotic-associated colitis, diarrhoea, dizziness, dyspnoea, flatulence, headache, muscle spasm, nausea, pruritus, rash, vomiting
  - **Rare** Blood pressure changes, constipation
  - **Frequency not known** Syncpe

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated if history of rifamycin hypersensitivity.
- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.
- **BREAST FEEDING** Unlikely to be present in milk in significant amounts, but manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution when used for hepatic encephalopathy in patients with severe hepatic impairment.
- **PRESCRIBING AND DISPENSING INFORMATION** Not recommended for diarrhoea associated with invasive organisms such as Campylobacter and Shigella.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
  - **Rifaximin for preventing episodes of overt hepatic encephalopathy** (March 2015) NICE TA337
  - Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in adults.
  - www.nice.org.uk/TA337

**SULFONAMIDES**

**Sulfadiazine** (Sulphadiazine)

- **DRUG ACTION** Sulfadiazine is a short-acting sulphonamide with bacteriostatic activity against a broad spectrum of organisms. The importance of the sulfonamides has decreased as a result of increasing bacterial resistance and their replacement by antibacterials which are generally more active and less toxic.

**INDICATIONS AND DOSE**

Prevention of rheumatic fever recurrence

**BY MOUTH**

- Adult (body-weight up to 30 kg): 500 mg daily
- Adult (body-weight 30 kg and above): 1 g daily

- **UNLICENSED USE** Not licensed for use in toxoplasmosis.
- **CONTRA-INDICATIONS** Acute porphyrias p. 864
- **CAUTIONS** Asthma • avoid in blood disorders (unless under specialist supervision) • avoid in infants under 6 weeks (except for treatment or prophylaxis of pneumocystis pneumonia) because of the risk of kernicterus • elderly • G6PD deficiency (risk of haemolytic anaemia) • maintain adequate fluid intake • predisposition to folate deficiency • predisposition to hyperkalaemia

- **INTERACTIONS** → Appendix 1 (sulfonamides).

- **SIDE-EFFECTS**
  - **Common or very common** Diarrhoea, headache, hyperkalaemia, nausea, rash
  - **Uncommon** Vomiting
  - **Rare** Agranulocytosis • bone marrow depression
  - **Very rare** Anorexia, antibiotic-associated colitis, arthralgia, aseptic meningitis, ataxia, blood disorders, convulsions, cough, depression, eosinophilia, glositis, hallucinations, hepatic necrosis, hypoglycaemia, hypoponeraemia, interstitial nephritis, jaundice, leucopenia, liver damage, megaloblastic anaemia, myalgia, myocardiitis, pancreatitis, peripheral neuropathy, photosensitivity, pulmonary infiltrates, renal disorders, shortness of breath, Stevens-Johnson syndrome, stomatitis, systemic lupus erythematous, thrombocytopenia, tinnitus, toxic epidermal necrosis, uveitis, vasculitis, vertigo
  - **Frequency not known** Benign intracranial hypertension, photosensitivity, optic neuropathy, rhabdomyolysis reported in HIV-infected patients

**SIDE-EFFECTS, FURTHER INFORMATION**

Blood disorders or rash Discontinue immediately if blood disorders (including leucopenia, thrombocytopenia, megaloblastic anaemia, eosinophilia) or rash (including Stevens-Johnson syndrome, toxic epidermal necrosis, photosensitivity) develop.

- **PREGNANCY** Risk of neonatal haemolysis and methaemoglobinemia in third trimester; fear of increased risk of kernicterus in neonates appears to be unfounded

- **BREAST FEEDING** Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants.

- **HEPATIC IMPAIRMENT** Use with caution in mild to moderate impairment; avoid in severe impairment.

- **RENAI IMPAIRMENT** Use with caution in mild to moderate impairment; avoid in severe impairment; high risk of crystalluria.

- **MONITORING REQUIREMENTS** Monitor blood counts on prolonged treatment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>14, 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targaxan (Norgine Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Rifaximin 550 mg Targaxan 550mg tablets</td>
<td>56 tablet [POM] £259.23 DT price = £259.23</td>
</tr>
<tr>
<td>Xifaxanta (Norgine Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Rifaximin 200 mg Xifaxanta 200mg tablets</td>
<td>9 tablet [POM] £15.15 DT price = £15.15</td>
</tr>
</tbody>
</table>

**SULFONAMIDES**

**Bacterial infection** 495
TETRACYCLINES AND RELATED DRUGS

Tetracyclines

The tetracyclines are broad-spectrum antibiotics whose value has decreased owing to increasing bacterial resistance. They remain, however, the treatment of choice for infections caused by chlamydia (trachoma, psittacosis, salpingitis, urethritis, and lymphogranuloma venereum), rickettsia (including Q-fever), brucella (doxycycline below with either streptomycin p. 451 or rifampicin p. 508), and the spirochaete, Borrelia burgdorferi (See Lyme disease). They are also used in respiratory and genital mycoplasma infections, in acne, in destructive (refractory) periodontal disease, in exacerbations of chronic bronchitis (because of their activity against Haemophilus influenzae), and for leptospirosis in penicillin hypersensitivity (as an alternative to erythromycin p. 471).

Tetracyclines have a role in the management of metcillin-resistant Staphylococcus aureus (MRSA) infection. Microbiologically, there is little to choose between the various tetracyclines, the only exception being minocycline p. 498 which has a broader spectrum; it is active against Neisseria meningitidis and has been used for meningococcal prophylaxis but is no longer recommended because of side-effects including dizziness and vertigo. Compared to other tetracyclines, minocycline is associated with a greater risk of lupus-erythematosus-like syndrome. Minocycline sometimes causes irreversible pigmentation.

Tetracyclines

- **CONTRA-INDICATIONS** Children under 12 years (deposition in growing bone and teeth, by binding to calcium, causes staining and occasionally dental hypoplasia)
- **CAUTIONS** Myasthenia gravis (muscle weakness may be increased) - systemic lupus erythematosus (may be exacerbated)
- **INTERACTIONS** ➔ Appendix 1 (tetracyclines). Antacids, and aluminium, calcium, iron, magnesium and zinc salts decrease the absorption of tetracyclines. Use with caution in those receiving potentially hepatotoxic drugs.
- **SIDE-EFFECTS**
  - Rare Anaphylaxis - angioedema - blood disorders - exfoliative dermatitis - hepatotoxicity - hypersensitivity reactions - pancreatitis - pericarditis - photosensitivity (particularly with demeclocycline) - rash - Stevens-Johnson syndrome - urticaria
  - Frequency not known Antibiotic-associated colitis - benign intracranial hypertension - diarrhoea - dysphagia - headache - nausea - oesophageal irritation - visual disturbances - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Benign intracranial hypertension Headache and visual disturbances may indicate benign intracranial hypertension (discontinue treatment).

- **PREGNANCY** Should not be given to pregnant women; effects on skeletal development have been documented in the first trimester in animal studies. Administration during the second or third trimester may cause discoloration of the child’s teeth, and maternal hepatotoxicity has been reported with large parenteral doses.

- **BREAST FEEDING** Should not be given to women who are breast-feeding (although absorption and therefore discoloration of teeth in the infant is probably usually prevented by chelation with calcium in milk).

- **HEPATIC IMPAIRMENT** Should be avoided or used with caution in patients with hepatic impairment.

Demeclocycline hydrochloride

**INDICATIONS AND DOSE**

Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)

- **BY MOUTH**
- Adult: 150 mg 4 times a day, alternatively 300 mg twice daily

Treatment of hypotension resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable

- **BY MOUTH**
- Adult: Initially 0.9–1.2 g daily in divided doses, maintenance 600–900 mg daily

- **CAUTIONS** Photosensitivity more common than with other tetracyclines

- **INTERACTIONS** Milk reduces absorption.

- **SIDE-EFFECTS** Acute renal failure - reversible nephrogenic diabetes insipidus

- **HEPATIC IMPAIRMENT** Max. 1 g daily in divided doses.

- **RENAL IMPAIRMENT** May exacerbate renal failure and should not be given to patients with renal impairment.

**PATIENT AND CARER ADVICE**

Patients should be advised to avoid exposure to sunlight or sun lamps.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Capsule

CAUTIONARY AND ADVISORY LABELS 7, 9, 11, 23

**DEMECLOCYCLINE HYDROCHLORIDE (Non-proprietary)**

Demeclocycline hydrochloride 150 mg Demeclocycline 150mg capsules | 28 capsule [Pack] £81.49 DT price = £81.49

Doxycycline

**INDICATIONS AND DOSE**

Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)

- **BY MOUTH**
  - Child 12-17 years: Initially 200 mg daily for 1 dose, then 100 mg daily; 200 mg daily, increased dose used for severe infections including refractory urinary-tract infections
  - Adult: Initially 200 mg daily for 1 dose, then 100 mg daily; 200 mg daily, increased dose used for severe infections including refractory urinary-tract infections

**Acne**

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 100 mg daily
- Adult: 100 mg daily

**Rosacea**

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: 100 mg daily

**Papulopustular facial rosacea (without ocular involvement)**

BY MOUTH USING MODIFIED-RELEASE MEDICINES

- Adult: 40 mg once daily for 16 weeks, dose to be taken in the morning, consider discontinuing treatment if no response after 6 weeks

**Early syphilis**

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 100 mg twice daily for 14 days
- Adult: 100 mg twice daily for 14 days
RENAL IMPAIRMENT

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 100 mg twice daily for 28 days
- Adult: 100 mg twice daily for 28 days

Neurosyphilis

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: 200 mg twice daily for 28 days

Uncomplicated genital chlamydia / Non-gonococcal urethritis

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 100 mg twice daily for 7 days
- Adult: 100 mg twice daily for 7 days

Pelvic inflammatory disease

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 100 mg twice daily for 14 days
- Adult: 100 mg twice daily for 14 days

Lyme disease

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: 200 mg twice daily for 28 days in Lyme arthritis
- Adult: 100 mg twice daily for 10–14 days (for 28 days in Lyme arthritis)

Anthrax (treatment or post-exposure prophylaxis)

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 100 mg twice daily
- Adult: 100 mg twice daily

Prophylaxis of malaria

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 100 mg once daily, to be started 1–2 days before entering endemic area and continued for 4 weeks after leaving, can be used for up to 2 years
- Adult: 100 mg once daily, to be started 1–2 days before entering endemic area and continued for 4 weeks after leaving

Adjunct to quinine in treatment of Plasmodium falciparum malaria

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 200 mg daily for 7 days
- Adult: 200 mg daily for 7 days

Periodontitis (as an adjunct to gingival scaling and root planing)

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Child 12-17 years: 20 mg twice daily for 3 months
- Adult: 20 mg twice daily for 3 months

UNLICENSED USE


CAUTIONS

Alcohol dependence

INTERACTIONS

The metabolism of doxycycline may be influenced by antiepileptics.

SIDE-EFFECTS

Anorexia - anxiety - dry mouth - flushing - fungal superinfection (when used for periodontitis) - tinnitus

PREGNANCY

When travel to malarious areas is unavoidable during pregnancy, doxycycline can be used for malaria prophylaxis if other regimens are unsuitable, and if the entire course of doxycycline can be completed before 15 weeks’ gestation.

RENAL IMPAIRMENT

Use with caution (avoid excessive doses).

MONITORING REQUIREMENTS

When used for periodontitis, monitor for superficial fungal infection, particularly if predisposition to oral candidiasis.

DIRECTIONS FOR ADMINISTRATION

Capsules and tablets should be swallowed whole with plenty of fluid, while sitting or standing. Capsules should be taken during meals.

PATIENT AND CARER ADVICE

Counselling on administration advised (posture). Photosensitivity Patients should be advised to avoid exposure to sunlight or sun lamps.

PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulary

Doxycycline Capsules 100 mg may be prescribed. Dispersible tablets may be prescribed as Dispersible Doxycycline Tablets. Tablets may be prescribed as Doxycycline Tablets 20 mg.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Dispersible tablet

CAUTIONARY AND ADVISORY LABELS 6, 9, 11, 13

- Vibramycin-D (Pfizer Ltd)
  - Doxycycline (as Doxycycline monohydrate) 100 mg 100 mg dispersible tablets (sugar-free) | 8 tablet £4.91 DT price - £4.91

Capsule

CAUTIONARY AND ADVISORY LABELS 6, 9, 11, 27

- DOXYCYCLINE (Non-proprietary)
  - Doxycycline (as Doxycycline hyclate) 50 mg Doxycycline 50 mg capsules | 28 capsule £4.00 DT price + £1.67
  - Doxycycline (as Doxycycline hyclate) 100 mg Doxycycline 100 mg capsules | 8 capsule  £3.00 DT price + £1.13 | 50 capsule £7.06

- Brands may include Vibrox

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 6, 11, 27

- Efraacea (Galderma (UK) Ltd)
  - Doxycycline (as Doxycycline monohydrate) 40 mg Efraacea 40 mg modified-release capsules | 14 capsule £7.99 DT price + £7.99 | 56 capsule £21.71

Lymecycline

INDICATIONS AND DOSE

Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)

BY MOUTH

- Child 12-17 years: 408 mg twice daily, increased to 1.224–1.632 g daily, (in severe infection)
- Adult: 408 mg twice daily, increased to 1.224–1.632 g daily, (in severe infection)

Acne

BY MOUTH

- Child 12-17 years: 408 mg daily for at least 8 weeks
- Adult: 408 mg daily for at least 8 weeks

RENAL IMPAIRMENT

May exacerbate renal failure and should not be given to patients with renal impairment.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 6, 9

- LYMECTYLE (Non-proprietary)
  - Lymecycline 408 mg Lymecycline 408 mg capsules | 28 capsule £9.18 DT price + £9.05 | 56 capsule £18.36
  - Tetraysal (Galderma (UK) Ltd)

- Lymecycline 408 mg Tetraysal 300 capsules | 28 capsule £3.95 DT price + £3.95 | 56 capsule £11.53
Minocycline

**INDICATIONS AND DOSE**

**Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Child 12-17 years:** 100 mg twice daily
- **Adult:** 100 mg twice daily

**Acne vulgaris**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Child 12-17 years:** 100 mg once daily, alternatively 50 mg twice daily
- **Adult:** 100 mg once daily, alternatively 50 mg twice daily

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- **Child 12-17 years:** 100 mg daily
- **Adult:** 100 mg daily

**Prophylaxis of asymptomatic meningococcal carrier state**

(but no longer recommended)

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- **Adult:** 100 mg twice daily for 5 days, minocycline treatment is usually followed by administration of rifampicin

**MEDICINAL FORMS**

**Capsule**

- Minocycline (as Minocycline hydrochloride) 100 mg

**Tablet**

- Minocycline (as Minocycline hydrochloride) 100 mg

**CAUTIONARY AND ADVISORY LABELS**

- **Systemic lupus erythematosus**
- **Frequency not known**
- **Vertigo**
- **Use with caution**

**SIDE-EFFECTS**

- **Rare** Acute renal failure - alopecia - anorexia - hyperaesthesia - impaired hearing - paraesthesia - pigmentation (sometimes irreversible) - tinnitus
- **Very rare** Discoloration of conjunctiva - discoloration of sweat - discoloration of tears - systemic lupus erythematosus

**INTERACTIONS**

- **Milk reduces absorption.**

**REMEDIAL MEASURES**

- **If severe side effects develop or if the condition worsens.**

**MALIGNANT PROGRESSION**

- **Discontinue and consult medical practitioner.**

**MEDICINAL FORMS**

- **Tablet**

**CAPSULE**

- **Minocycline (as Minocycline hydrochloride) 50 mg**

**INDICATIONS AND DOSE**

**Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)**

**BY MOUTH**

- **Child 12-17 years:** 250–500 mg 4 times a day
- **Adult:** 250–500 mg 4 times a day

**Rosacea**

**BY MOUTH**

- **Adult:** 500 mg twice daily usually for 6–12 weeks (course may be repeated intermittently)

**MEDICINAL FORMS**

**Capsule**

- **Minocycline (as Minocycline hydrochloride) 50 mg**

**Tablet**

- **Minocycline (as Minocycline hydrochloride) 100 mg**

**DIABETES**

- **Increased risk of hyperglycaemia.**

**IMMUNE SYSTEM**

- **Risk of systemic lupus erythematosus.**

**INTERACTIONS**

- **Increased risk of systemic lupus erythematosus.**

**MALIGNANT PROGRESSION**

- **Discontinue and consult medical practitioner.**

**MALIGNANT PROGRESSION**

- **Discontinue and consult medical practitioner.**

**MEDICINAL FORMS**

**Capsule**

- **Minocycline (as Minocycline hydrochloride) 50 mg**

**Tablet**

- **Minocycline (as Minocycline hydrochloride) 100 mg**

**SIDE-EFFECTS**

- **Menstrual disturbance**
- **Diabetes**
- **Diabetes**
- **Diabetes**
- **Diabetes**

**INTERACTIONS**

- **Increased risk of hyperglycaemia.**

**MALIGNANT PROGRESSION**

- **Discontinue and consult medical practitioner.**

**MEDICINAL FORMS**

**Capsule**

- **Minocycline (as Minocycline hydrochloride) 50 mg**

**Tablet**

- **Minocycline (as Minocycline hydrochloride) 100 mg**

**DIABETES**

- **Increased risk of hyperglycaemia.**

**IMMUNE SYSTEM**

- **Risk of systemic lupus erythematosus.**

**INTERACTIONS**

- **Increased risk of systemic lupus erythematosus.**

**MALIGNANT PROGRESSION**

- **Discontinue and consult medical practitioner.**

**MEDICINAL FORMS**

**Capsule**

- **Minocycline (as Minocycline hydrochloride) 50 mg**

**Tablet**

- **Minocycline (as Minocycline hydrochloride) 100 mg**

**SIDE-EFFECTS**

- **Menstrual disturbance**
- **Diabetes**
- **Diabetes**
- **Diabetes**
- **Diabetes**

**INTERACTIONS**

- **Increased risk of hyperglycaemia.**

**MALIGNANT PROGRESSION**

- **Discontinue and consult medical practitioner.**

**MEDICINAL FORMS**

**Capsule**

- **Minocycline (as Minocycline hydrochloride) 50 mg**

**Tablet**

- **Minocycline (as Minocycline hydrochloride) 100 mg**
Acne

BY MOUTH
- Child 12-17 years: 500 mg twice daily for at least 3 months, if there is no improvement for the first 3 months another oral antibacterial should be used, maximum improvement usually occurs after 4 to 6 months but in more severe cases treatment may need to be continued for 2 years or longer
- Adult: 500 mg twice daily for at least 3 months, if there is no improvement after the first 3 months another oral antibacterial should be used, maximum improvement usually occurs after 4 to 6 months but in more severe cases treatment may need to be continued for 2 years or longer

Diabetic diarrhoea in autonomic neuropathy

BY MOUTH
- Adult: 250 mg for 2 or 3 doses

Non-gonococcal urethritis

BY MOUTH
- Child 12-17 years: 500 mg 4 times a day for 7–14 days (21 days if failure or relapse after first course)
- Adult: 500 mg 4 times a day for 7–14 days (21 days if failure or relapse after first course)

Helicobacter pylori eradication failure in combination with a proton pump inhibitor, tripotassium dicitratobismuthate, and metronidazole

BY MOUTH
- Adult: 500 mg 4 times a day for 2 weeks

- UNLICENSED USE Not licensed for treatment of diabetic diarrhoea in autonomic neuropathy.
- INTERACTIONS Milk reduces absorption.
- SIDE-EFFECTS Acute renal failure, skin discoloration
- HEPATIC IMPAIRMENT Max. 1 g daily in divided doses.
- RENAL IMPAIRMENT May exacerbate renal failure and should not be given to patients with renal impairment.
- DIRECTIONS FOR ADMINISTRATION Tablets should be swallowed whole with plenty of fluid while sitting or standing.
- PATIENT AND CARER ADVICE Counselling on administration advised.
- PROFESSION SPECIFIC INFORMATION Dental practitioners’ formulary Tetracycline Tablets may be prescribed.

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, capsule

Tablet

| CAUTIONARY AND ADVISORY LABELS | 7, 9, 23 |
| TETRACYCLINE (Non-proprietary) |
| Tetracycline hydrochloride 250 mg | Tetracycline 250mg tablets | 28 tablet pack | £25.65 DT price = £2.44 |

2.1 Anthrax

Anthrax

Inhalation or gastro-intestinal anthrax should be treated initially with either ciprofloxacin [unlicensed indication] or doxycycline [unlicensed indication] for 7 days. Treatment may be switched to amoxicillin if the infecting strain is susceptible. Treatment may need to be extended to 60 days if exposure is due to aerosol. A combination of antibacterials for 14 days is recommended for cutaneous anthrax with systemic features, extensive oedema, or lesions of the head or neck.

Ciprofloxacin or doxycycline may be given for post-exposure prophylaxis. If exposure is confirmed, antibacterial prophylaxis should continue for 60 days. Antibacterial prophylaxis may be switched to amoxicillin after 10–14 days if the strain of *B. anthracis* is susceptible. Vaccination against anthrax may allow the duration of antibacterial prophylaxis to be shortened.

2.2 Leprosy

Leprosy

Advice from a member of the Panel of Leprosy Opinion is essential for the treatment of leprosy (Hansen’s disease). Details can be obtained from the Hospital for Tropical Diseases, London (telephone (020) 3456 7890). The World Health Organization has made recommendations to overcome the problem of dapsone p. 500 resistance and to prevent the emergence of resistance to other antileproptic drugs. Drugs recommended are dapsone, rifampicin p. 508, and clofazimine p. 500. Other drugs with significant activity against *Mycobacterium leprae* include ofloxacin p. 494, minocycline p. 498 and clarithromycin p. 470, but none of these are as active as rifampicin; at present they should be reserved as second-line drugs for leprosy.

A three-drug regimen is recommended for *multibacillary leprosy* (lepromatous, borderline-lepromatous, and borderline leprosy) and a two-drug regimen for *paucibacillary leprosy* (borderline-tuberculoid, tuberculoid, and indeterminate).

Multibacillary leprosy should be treated with a combination of rifampicin, dapsone and clofazimine p. 500 for at least 2 years. Treatment should be continued unchanged during both type I (reversal) or type II (erythema nodosum lepromatous) reactions. During reversal reactions neuritic pain or weakness can herald the rapid onset of permanent nerve damage. Treatment with prednisolone p. 585 should be instituted at once. Mild type II reactions may respond to aspirin. Severe type II reactions may require corticosteroids; thalidomide p. 798 [unlicensed] is also useful in patients who have become corticosteroid dependent, but it should be used only under specialist supervision. Thalidomide is teratogenic and, therefore, contra-indicated in pregnancy; it must not be given to women of child-bearing potential unless they comply with a pregnancy prevention programme. Increased doses of clofazimine are also useful.

Paucibacillary leprosy should be treated with rifampicin and dapsone for 6 months. If treatment is interrupted the regimen should be recommenced where it was left off to complete the full course.

Neither the multibacillary nor the paucibacillary antileprosy regimen is sufficient to treat tuberculosis.
Dapsone

**INDICATIONS AND DOSE**
Multibacillary leprosy in combination with rifampicin and dapsone (3-drug regimen) | Paucibacillary leprosy in combination with rifampicin (2-drug regimen)

**BY MOUTH**
- **Adult** (body-weight up to 35 kg): 50 mg daily, alternatively 1–2 mg/kg daily, may be self-administered
- **Adult** (body-weight 35 kg and above): 100 mg daily, may be self-administered

**Dermatitis herpetiformis**
- **BY MOUTH**
  - **Adult**: (consult product literature or local protocols)

**Treatment of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia** (in combination with trimethoprim)

**BY MOUTH**
- **Adult**: 100 mg once daily

**Prophylaxis of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia**
- **BY MOUTH**
  - **Adult**: 100 mg daily

### 2.3 Lyme disease

**Lyme disease**

Lyme disease should generally be treated by those experienced in its management. Doxycycline p. 496, amoxicillin p. 482 [unlicensed indication] or cefuroxime p. 460 (as cefuroxime axetil) are the antibacterials of choice for early Lyme disease or Lyme arthritis. If these antibacterials are contra-indicated, a **macrolide** (e.g. clarithromycin p. 470) can be used for early Lyme disease. Intravenous administration of ceftriaxone p. 459, cefotaxime p. 457, or benzylpenicillin sodium p. 480 is recommended for Lyme disease associated with cardiac or neurological complications. The duration of treatment is usually 2–4 weeks; Lyme arthritis may require further treatment.
2.4 Methicillin-resistant staphylococcus aureus

MRSA

Infection from Staphylococcus aureus strains resistant to meticillin (now discontinued) (methicillin-resistant Staph. aureus, MRSA) and to flucloxacillin p. 486 can be difficult to manage. Treatment is guided by the sensitivity of the infecting strain.

Rifampicin p. 508 or fusidic acid p. 463 should not be used alone because resistance may develop rapidly. A tetracycline alone or a combination of rifampicin and fusidic acid can be used for skin and soft-tissue infections caused by MRSA; clindamycin p. 467 alone is an alternative.

A glycopeptide (e.g. vancomycin p. 465) can be used for severe skin and soft-tissue infections associated with MRSA; if a glycopeptide is unsuitable, linezolid p. 477 can be used on expert advice. As linezolid is not active against gram-negative organisms, it can be used for mixed skin and soft-tissue infections only when other treatments are not available; linezolid must be given with other antibacterials if the infection also involves Gram-negative organisms. A combination of a glycopeptide and fusidic acid or a glycopeptide and rifampicin can be considered for skin and soft-tissue infections that have failed to respond to a single antibiotic.

Tigecycline p. 466 and daptomycin p. 468 are licensed for the treatment of complicated skin and soft-tissue infections involving MRSA.

A tetracycline or clindamycin can be used for bronchiectasis caused by MRSA. A glycopeptide can be used for pneumonia associated with MRSA; if a glycopeptide is unsuitable, linezolid can be used on expert advice. Linezolid must be given with other antibacterials if the infection also involves Gram-negative organisms.

A tetracycline can be used for urinary-tract infections caused by MRSA; trimethoprim p. 462 or nitrofurantoin p. 512 are alternatives. A glycopeptide can be used for urinary-tract infections that are severe or resistant to other antibacterials.

A glycopeptide can be used for septicaemia associated with MRSA.

See the management of endocarditis, osteomyelitis, or septic arthritis associated with MRSA.

Prophylaxis with vancomycin p. 465 or teicoplanin p. 464 (alone or in combination with another antibacterial active against other pathogens) is appropriate for patients undergoing surgery if:

- there is a history of MRSA colonisation or infection without documented eradication;
- there is a risk that the patient’s MRSA carriage has recurred;
- the patient comes from an area with a high prevalence of MRSA.

See eradication of nasal carriage of MRSA in Nose p. 980.

2.5 Tuberculosis

Tuberculosis is treated in two phases—an initial phase using 4 drugs and a continuation phase using 2 drugs in fully sensitive cases. Treatment requires specialised knowledge and supervision, particularly where the disease involves resistant organisms or non-respiratory organs.

There are two regimens recommended for the treatment of tuberculosis in the UK; variations occur in other countries. Either the unsupervised regimen or the supervised regimen should be used; the two regimens should not be used concurrently. Compliance with therapy is a major determinant of its success.

Initial phase

The concurrent use of 4 drugs during the initial phase is designed to reduce the bacterial population as rapidly as possible and to prevent the emergence of drug-resistant bacteria. The drugs are best given as combination preparations unless one of the components cannot be given because of resistance or intolerance. The treatment of choice for the initial phase is the daily use of isoniazid p. 506, rifampicin p. 508, pyrazinamide p. 506 and ethambutol hydrochloride p. 505. Treatment should be started without waiting for culture results if clinical features or histology results are consistent with tuberculosis; treatment should be continued even if initial culture results are negative. The initial phase drugs should be continued for 2 months. Where a positive culture for M. tuberculosis has been obtained, but susceptibility results are not available after 2 months, treatment with rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride should be continued until full susceptibility is confirmed, even if this is for longer than 2 months.

Streptomycin p. 451 is rarely used in the UK but it may be used in the initial phase of treatment if resistance to isoniazid has been established before therapy is commenced.

Continuation phase

After the initial phase, treatment is continued for a further 4 months with isoniazid with rifampicin p. 510 (preferably given as a combination preparation). Longer treatment is necessary for meningitis, direct spinal cord involvement, and for resistant organisms which may also require modification of the regimen.

Unsupervised treatment

The unsupervised treatment regimen should be used for patients who are likely to take antituberculous drugs reliably without supervision. Patients who are unlikely to comply with daily administration of antituberculous drugs should be treated with the regimen described under Supervised Treatment.

Pregnancy and breast-feeding

The standard unsupervised 6-month treatment regimen may be used during pregnancy. Streptomycin should not be given in pregnancy.

The standard unsupervised 6-month treatment regimen may be used during breast-feeding.

Supervised treatment

Drug administration needs to be fully supervised (directly observed therapy, DOT) in patients who cannot comply reliably with the treatment regimen. These patients are given isoniazid, rifampicin, pyrazinamide and ethambutol hydrochloride (or streptomycin) 3 times a week under supervision for the first 2 months followed by isoniazid and rifampicin 3 times a week for a further 4 months.

Immunocompromised patients

Multi-resistant Mycobacterium tuberculosis may be present in immunocompromised patients. The organism should always be cultured to confirm its type and drug sensitivity. Confirmed M. tuberculosis infection sensitive to first-line drugs should be treated with a standard 6-month regimen; after completing treatment, patients should be closely monitored. The regimen may need to be modified if
**Recommended dosage for standard unsupervised 6-month treatment**

### 2-month initial phase

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage Details</th>
</tr>
</thead>
</table>
| Rifater® [isoniazid, pyrazinamide and rifampicin] | - Adult body-weight up to 40 kg: 3 tablets daily  
- Adult body-weight 40-49 kg: 4 tablets daily  
- Adult body-weight 50-64 kg: 5 tablets daily  
- Adult body-weight 65 kg and above: 6 tablets daily |
| Ethambutol hydrochloride      | - Adult: 15 mg/kg once daily                                                  |

### 4-month continuation phase following initial treatment with Rifater® and ethambutol

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage Details</th>
</tr>
</thead>
</table>
| Isoniazid with rifampicin    | - Adult body-weight up to 50 kg: 450/300 mg daily, use Rifinah® 150/100 Tablets  
- Adult body-weight 50 kg and above: 600/300 mg daily, use Rifinah® 300/150 Tablets |

**or (if combination preparations not appropriate):**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage Details</th>
</tr>
</thead>
</table>
| Isoniazid (for 6 months)     | - Child: 10 mg/kg once daily (max. 300 mg)  
- Adult: 300 mg daily                                    |
| Rifampicin (for 6 months)    | - Child body-weight up to 50 kg: 15 mg/kg once daily (max. 450 mg)  
- Child body-weight 50 kg and above: 15 mg/kg daily (max. 600 mg)  
- Adult body-weight up to 50 kg: 450 mg daily  
- Adult body-weight 50 kg and above: 600 mg daily |
| Pyrazinamide (for 2-month initial phase only) | - Child body-weight up to 50 kg: 35 mg/kg once daily (max. 1.5 g)  
- Child body-weight 50 kg and above: 35 mg/kg once daily (max. 2 g)  
- Adult body-weight up to 50 kg: 1.5 g once daily  
- Adult body-weight 50 kg and above: 2 g once daily |
| Ethambutol hydrochloride (for 2-month initial phase only) | - Child: 20 mg/kg once daily  
- Adult: 15 mg/kg once daily |

**Recommended dosage for intermittent supervised 6-month treatment**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage Details</th>
</tr>
</thead>
</table>
| Isoniazid (for 6 months)     | - Child: 15 mg/kg (max. 900 mg) 3 times a week  
- Adult: 15 mg/kg (max. 900 mg) 3 times a week |
| Rifampicin (for 6 months)    | - Child: 15 mg/kg (max. 900 mg) 3 times a week  
- Adult: 600-900 mg 3 times a week |
| Pyrazinamide (for 2-month initial phase only) | - Child body-weight up to 50 kg: 50 mg/kg 3 times a week (max. 2 g 3 times a week)  
- Child body-weight 50 kg and above: 50 mg/kg 3 times a week (max. 2.5 g 3 times a week)  
- Adult body-weight up to 50 kg: 2 g 3 times a week  
- Adult body-weight 50 kg and above: 2.5 g 3 times a week |
| Ethambutol hydrochloride (for 2-month initial phase only) | - Child: 30 mg/kg 3 times a week  
- Adult: 30 mg/kg 3 times a week |

Infection is caused by resistant organisms, and specialist advice is needed. Specialist advice should be sought about tuberculosis treatment or chemoprophylaxis in a HIV-positive individual; care is required in choosing the regimen and in avoiding potentially serious interactions. Starting antiretroviral treatment in the first 2 months of antituberculosis treatment increases the risk of immune reconstitution syndrome. Infection may also be caused by other mycobacteria e.g. M. avium complex in which case specialist advice on management is needed.

**Corticosteroids**

In meningeal or pericardial tuberculosis, a corticosteroid should be started at the same time as antituberculosis therapy.

**Prevention of tuberculosis**

Some individuals may develop tuberculosis owing to reactivation of previously latent disease. Chemoprophylaxis may be required in those who have evidence of latent tuberculosis and are receiving treatment with immunosuppressants (including cytotoxics and possibly long-term treatment with systemic corticosteroids). In these cases, chemoprophylaxis involves use of either isoniazid alone for 6 months or of isoniazid and rifampicin for 3 months; longer chemoprophylaxis is not recommended.

See prevention of tuberculosis in susceptible close contacts or those who have become tuberculin-positive. See advice on immunisation against tuberculosis.

**Treatment failure**

Major causes of treatment failure are incorrect prescribing by the physician and inadequate compliance by the patient. Monthly tablet counts and urine examination (rifampicin imparts an orange-red coloration) may be useful indicators of compliance with treatment. Avoid both excessive and inadequate dosage. Treatment should be supervised by a specialist physician.

**Antituberculosis drugs**

Isoniazid is cheap and highly effective. Like rifampicin it should always be included in any antituberculous regimen unless there is a specific contra-indication. Rifampicin, a rifamycin, is a key component of any antituberculous regimen. Like isoniazid it should always be included unless there is a specific contra-indication.

During the first two months (‘initial phase’) of rifampicin administration transient disturbance of liver function with elevated serum transaminases is common but generally does not require interruption of treatment. Occasionally more serious liver toxicity requires a change of treatment particularly in those with pre-existing liver disease.

On intermittent treatment six toxicity syndromes have been recognised—influenza-like, abdominal, and respiratory symptoms, shock, renal failure, and thrombocytopenic purpura—and can occur in 20 to 30% of patients.
Rifabutin, another rifamycin, is indicated for prophylaxis against M. avium complex infections in patients with a low CD4 count; it is also licensed for the treatment of non-tuberculous mycobacterial disease and pulmonary tuberculosis.

Pyrazinamide is a bactericidal drug only active against intracellular dividing forms of Mycobacterium tuberculosis; it exerts its main effect only in the first two or three months. It is particularly useful in tuberculous meningitis because of good meningeal penetration. It is not active against M. bovis.

Ethambutol hydrochloride is included in a treatment regimen if isoniazid resistance is suspected; it can be omitted if the risk of resistance is low.

Drugs resistant tuberculosis should be treated by a specialist physician with experience in such cases, and where appropriate facilities for infection-control exist. Second-line drugs available for infections caused by resistant organisms, or when first-line drugs cause unacceptable side-effects, include aminosalicylic acid below, amikacin p. 450, capreomycin p. 504, cycloserine p. 594, newer macrolides (e.g. azithromycin p. 469 and clarithromycin p. 470), moxifloxacin p. 492 and prothionamide (prothionamide; no longer on UK market).

Bedaquiline below and delamanid p. 504 are licensed for the treatment of multiple-drug resistant pulmonary tuberculosis. Bedaquiline has a long half-life.

Management of tuberculosis in children

Children are given isoniazid, rifampicin, pyrazinamide, and ethambutol hydrochloride for the first 2 months followed by isoniazid and rifampicin during the next 4 months. However, care is needed in young children receiving ethambutol hydrochloride because of the difficulty in testing eyesight and in obtaining reports of visual symptoms.

Drugs used for Tuberculosis not listed below; Streptomycin, p. 451

ANTIMYCOBACTERIALS

Aminosalicylic acid

INDICATIONS AND DOSE

Multiple-drug resistant tuberculosis, in combination with other drugs

BY MOUTH

Adult: 4 g every 8 hours for a usual treatment duration of 24 months; maximum 12 g per day

Desensitisation regimen

BY MOUTH

Adult: (consult product literature)

CAUTIONS

Peptic ulcer

SIDE-EFFECTS

Common or very common Abdominal pain - bloating - diarrhoea - nausea - rash - vestibular syndrome - vomiting

Uncommon Anorexia

Rare Gastrointestinal bleeding - hypothyroidism - jaundice - malabsorption syndrome - metallic taste - peptic ulcer - urticaria

Very rare Agranulocytosis - anaemia - crystalluria - dizziness - headache - hypoglycaemia - leucopenia - methemoglobinemia - peripheral neuropathy - purpura - tendon pain - thrombocytopenia - visual abnormalities - weight loss

Frequency not known Hepatitis - hypersensitivity

Bedaquiline

INDICATIONS AND DOSE

Multiple-drug resistant pulmonary tuberculosis, in combination with other drugs

BY MOUTH

Adult: Initially 400 mg once daily for 2 weeks, then 200 mg 3 times a week for 22 weeks, intervals of at least 48 hours between each dose, continue appropriate combination therapy after bedaquiline

CONTRA-INDICATIONS QTc interval more than 500 milliseconds (derived using Fridericia’s formula) - ventricular arrhythmia

CAUTIONS Hypothyroidism - QTc interval (derived using Fridericia’s formula) 450–500 milliseconds—discontinue if QTc interval more than 500 milliseconds - risk factors for QT interval prolongation (e.g. electrolyte disturbances, heart failure with reduced left ventricular ejection fraction, history of symptomatic arrhythmias (avoid if ventricular arrhythmia present), bradycardia, congenital long QT syndrome)

INTERACTIONS Appendix 1 (bedaquiline). Caution with concomitant use of hepatotoxic drugs.

SIDE-EFFECTS Arthralgia - diarrhoea - dizziness - headache - myalgia - nausea - QT interval prolongation - vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Syncope If syncope occurs, obtain ECG.

PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk.

BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Manufacturer advises caution in moderate impairment; avoid in severe impairment—no

Infection
information available. Avoid concomitant use of hepatotoxic drugs unless essential.

- **RENAL IMPAIRMENT** Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  - Determine serum potassium, calcium, and magnesium before starting treatment (correct if abnormal)—remeasure if QT prolongation occurs during treatment.
  - Obtain ECG before starting treatment, and then at least monthly during treatment or more frequently if concomitant use with other drugs known to prolong the QT interval.
  - Monitor liver function before starting treatment and then at least monthly during treatment—discontinue treatment if severe abnormalities in liver function tests.

- **PATIENT AND CARER ADVICE**
  - Dizziness may affect performance of skilled tasks (e.g. driving)
  - **Missed doses** If a dose is missed during the first two weeks of treatment, the missed dose should not be taken and the next dose should be taken at the usual time; if a dose is missed during weeks 3–24 of treatment, the missed dose should be taken as soon as possible and then the usual regimen resumed.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**:
    - CAUTIONARY AND ADVISORY LABELS 4, 8, 21
      - Sirturo (Janssen-Cilag Ltd) ▼
      - Bedaquiline (as Bedaquiline fumarate) 100 mg Sirturo 100mg tablets | 188 tablet [PO] £18,700.00

### Capreomycin

#### INDICATIONS AND DOSE

Tuberculosis resistant to first-line drugs in combination with other drugs

**BY DEEP INTRAMUSCULAR INJECTION**

- Adult: 1 g daily (max. per dose 20 mg/kg) for 2–4 months, then reduced to 1 g 2–3 times a week

#### CAUTIONS

- Auditory impairment

#### INTERACTIONS

- Appendix 1 (capreomycin).

#### SIDE-EFFECTS

- Induration at injection site
- Changes in liver function tests
- Electrolyte disturbances
- Hearing loss with tinnitus and vertigo
- Hypersensitivity reactions
- Leucocytosis
- Nephrotoxicity
- Neuromuscular block after large doses
- Pain at injection site
- Rash
- Thrombocytopenia
- Urticaria

#### PREGNANCY

- Manufacturer advises use only if potential benefit outweighs risk—teratogenic in animal studies.

#### BREAST FEEDING

- Manufacturer advises caution—no information available.

#### HEPATIC IMPAIRMENT

- Use with caution.

#### RENAL IMPAIRMENT

- Reduce dose—consult product literature. Nephrotoxic; ototoxic.

#### MONITORING REQUIREMENTS

- Monitor renal, hepatic, auditory, and vestibular function and electrolytes.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for injection**
    - CAPREOMYCIN (Non-proprietary)
      - Capreomycin (as Capreomycin sulfate) 1 gram Capreomycin 1g powder for solution for injection vials | 1 vial [PO] £28.61

### Cycloserine

#### INDICATIONS AND DOSE

Tuberculosis resistant to first-line drugs, in combination with other drugs

**BY MOUTH**

- Adult: Initially 250 mg every 12 hours for 2 weeks, then increased if necessary up to 500 mg every 12 hours, dose to be increased according to blood concentration and response

#### PHARMACOKINETICS

- Cycloserine penetrates the CNS.

#### CONTRA-INDICATIONS

- Alcohol dependence · depression · epilepsy · psychotic states · severe anxiety

#### INTERACTIONS

- Appendix 1 (cycloserine).

#### SIDE-EFFECTS

- Allergic dermatitis · changes in liver function tests · confusion · convulsions · depression · dizziness · drowsiness · headache · heart failure at high doses · megaloblastic anaemia · psychosis · rashes · tremor · vertigo

#### SIDE-EFFECTS, FURTHER INFORMATION

- CNS toxicity
  - Discontinue or reduce dose if symptoms of CNS toxicity occur.
  - Rashes or allergic dermatitis
  - Discontinue or reduce dose if rashes or allergic dermatitis develops.

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk—crosses the placenta.

- **BREAST FEEDING**
  - Present in milk—amount too small to be harmful.

- **RENAL IMPAIRMENT**
  - Increase interval between doses if creatinine clearance less than 50 mL/minute. Monitor blood-cycloserine concentration if creatinine clearance less than 50 mL/minute.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.
  - **Capsule**:
    - CAUTIONARY AND ADVISORY LABELS 2, 8
      - CYCLOSERINE (Non-proprietary)
        - Cycloserine 250 mg Cycloserine 250mg capsules | 100 capsule [PO] £402.63 DT price = £402.63

### Delamanid

#### INDICATIONS AND DOSE

Multiple-drug resistant pulmonary tuberculosis, in combination with other drugs

**BY MOUTH**

- Adult: 100 mg twice daily for 24 weeks, continue appropriate combination therapy after delamanid

#### CONTRA-INDICATIONS

- QTC interval more than 500 milliseconds (derived using Fridericia’s formula) · serum albumin less than 28 g/litre

#### CAUTIONS

- Risk factors for QT interval prolongation (e.g. electrolyte disturbances, acute myocardial infarction, heart failure with reduced left ventricular ejection fraction, severe hypertension, left ventricular hypertrophy, bradycardia, congenital long QT syndrome, history of symptomatic arrhythmias).

#### INTERACTIONS

- Appendix 1 (delamanid).
CAUTIONS

CONTRA-INDICATIONS

ETHAMBUTOL HYDROCHLORIDE (Non-proprietary)

Ethambutol hydrochloride 100 mg Ethambutol 100mg tablets | 56 tablet [P38] £11.52 DT price = £11.52
Ethambutol hydrochloride 400 mg Ethambutol 400mg tablets | 56 tablet [P38] £42.74 DT price = £42.74

Also available in combination with isoniazid, pyrazinamide and rifampicin, p. 509
Isoniazid

INDICATIONS AND DOSE
Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)

BY MOUTH OR BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION

- Child: 10 mg/kg once daily (max. per dose 300 mg) for 6 months (initial and continuation phases)
- Adult: 300 mg daily for 6 months (initial and continuation phases)

Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)

BY MOUTH OR BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION

- Child: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)
- Adult: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive

BY MOUTH OR BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION

- Child 1 month-11 years: 10 mg/kg daily (max. per dose 300 mg) for 6 months, alternatively 10 mg/kg daily (max. per dose 300 mg) for 3 months, to be taken in combination with rifampicin
- Child 12-17 years: 300 mg daily for 6 months, alternatively 300 mg daily for 3 months, to be taken in combination with rifampicin
- Adult: 300 mg daily for 6 months, alternatively 300 mg daily for 3 months, to be taken in combination with rifampicin

CONTRA-INDICATIONS Drug-induced liver disease

CAUTIONS Acute porphyrias p. 864 - alcohol dependence - diabetes mellitus - epilepsy - history of psychosis - HIV infection - malnutrition - slow acetylator status (increased risk of side-effects)

CAUTIONS, FURTHER INFORMATION
Peripheral neuropathy Peripheral neuropathy is more likely to occur where there are pre-existing risk factors such as diabetes, alcohol dependence, chronic renal failure, pregnancy, malnutrition and HIV infection. In patients at increased risk of peripheral neuropathy, pyridoxine hydrochloride p. 882 should be given prophylactically from the start of treatment.

INTERACTIONS Appendix 1 (isoniazid).

When used with tyramine or histamine rich foods, tachycardia, palpitation, hypotension, flushing, headache, dizziness, and sweating reported.

SIDE-EFFECTS

- Common or very common Peripheral neuropathy
- Rare Hepatitis - psychotic episodes

SIDE-EFFECTS, FURTHER INFORMATION

Hepatitis Hepatitis more common in those aged over 35 years.

PREGNANCY Not known to be harmful; prophylactic pyridoxine recommended.

BREAST FEEDING Theoretical risk of convulsions and neuropathy; prophylactic pyridoxine advisable in mother. In breast-feeding, monitor infant for possible toxicity.

HEPATIC IMPAIRMENT Use with caution. In patients with pre-existing liver disease or hepatic impairment monitor liver function regularly and particularly frequently in the first 2 months.

RENAL IMPAIRMENT Risk of ototoxicity and peripheral neuropathy; prophylactic pyridoxine hydrochloride p. 882 recommended.

MONITORING REQUIREMENTS
- Renal function should be checked before treatment.
- Hepatic function should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment.
- Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months.

PRESCRIBING AND DISPENSING INFORMATION
- In children in general, doses should be rounded up to facilitate administration of suitable volumes of liquid or an appropriate strength of tablet. Doses may need to be recalculated to allow for weight gain in younger children.

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Isoniazid for latent tuberculosis www.medicinesforchildren.org.uk/isoniazid-for-latent-tuberculosis


Hepatic disorders Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet

Isoniazid (Non-proprietary) Isoniazid 50 mg Isoniazid 5mg tablets | 56 tablet £19.24 DT price = £19.24
Isoniazid 100 mg Isoniazid 10 mg tablets | 28 tablet £19.24 DT price = £19.24

Solution for injection

Isoniazid (Non-proprietary) Isoniazid 25 mg per ml Isoniazid 50mg/2ml solution for injection ampoules | 10 ampoule £277.00

Also available in combination with pyrazinamide and rifampicin, p. 510 - rifampicin, p. 510

Pyrazinamide

INDICATIONS AND DOSE
Tuberculosis in combination with other drugs (standard unsupervised 6-month treatment)

BY MOUTH

- Child (body-weight up to 50 kg): 35 mg/kg once daily for 2 months (initial phase); maximum 1.5 g per day
- Child (body-weight 50 kg and above): 35 mg/kg once daily for 2 months (initial phase); maximum 2 g per day
- Adult (body-weight up to 50 kg): 1.5 g once daily for 2 months (initial phase)
- Adult (body-weight 50 kg and above): 2 g once daily for 2 months (initial phase)
**Tuberculosis in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)**

**BY MOUTH**
- **Child** (body-weight up to 50 kg): 50 mg/kg 3 times a week (max. per dose 2 g 3 times a week) for 2 months (initial phase)
- **Child** (body-weight 50 kg and above): 50 mg/kg 3 times a week (max. per dose 2.5 g 3 times a week) for 2 months (initial phase)
- **Adult** (body-weight up to 50 kg): 2 g 3 times a week for 2 months (initial phase)
- **Adult** (body-weight 50 kg and above): 2.5 g 3 times a week for 2 months (initial phase)

**MONITORING REQUIREMENTS**
- **In children**
- Hepatic function should be checked before treatment. If there is no evidence of liver disease (and pre-treatment checks of hepatic function, particularly in the first 30 months) further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment.
- **Those with alcohol dependence** should have frequent checks of hepatic function, particularly in the first 3 months; blood counts should also be monitored in these patients.

**CAUTIONS**
- Diabetes • gout

**INTERACTIONS**
- Appendix 1 (pyrazinamide).

**SIDE-EFFECTS**
- Anorexia • arthralgia • dysuria • fever • flushing • hepatomegaly • hepatotoxicity • jaundice • liver failure • nausea • photosensitivity • rash • sideroblastic anaemia • splenomegaly • thrombocytopenia • vomiting

**PREGNANCY**
- Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**
- Amount too small to be harmful.

**HEPATIC IMPAIRMENT**
- Idiosyncratic hepatotoxicity more common; avoid in severe hepatic impairment. In patients with pre-existing liver disease or hepatic impairment monitor liver function regularly and particularly frequently in the first 2 months.

**RENAI IMPAIRMENT**
- Monitor for gout in renal impairment.
- **In adults** 25–30 mg/kg 3 times a week if eGFR less than 30 mL/minute/1.73 m².
- **In children** If estimated glomerular filtration rate less than 30 mL/minute/1.73 m², use 25–30 mg/kg 3 times a week.

**MONITORING REQUIREMENTS**
- Renal function should be checked before treatment.
- Hepatic function should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment.
- Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months.

**PRESCRIBING AND DISPENSING INFORMATION**
- In children In general, doses should be rounded up to facilitate administration of suitable volumes of liquid or an appropriate strength of tablet. Doses may also need to be recalculated to allow for weight gain in younger children.

**PATIENT AND CARER ADVICE**
- Hepatic disorders Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

**MEDICINAL FORMS**

- **Tablet**
- **Pyrazinamide (Non-proprietary)**
  - Pyrazinamide 500 mg Pyrazinamide 500mg tablets | 30 tablet [P] £38.34 | 50 tablet [P] £52.25

- **Zinamide** (Thornton & Ross Ltd)
  - Pyrazinamide 500 mg Zinamide 500mg tablets | 30 tablet [P] £31.35

Also available in combination with ethambutol with isoniazid and rifampicin, p. 509 - isoniazid and rifampicin, p. 510

**INDICATIONS AND DOSE**

**PROPHYLAXIS OF Mycobacterium avium complex infections in immunosuppressed patients with low CD4 count**

**BY MOUTH**
- **Adult**: 300 mg once daily, also consult product literature

**TREATMENT OF non-tuberculous mycobacterial disease, in combination with other drugs**

**BY MOUTH**
- **Adult**: 450–600 mg once daily for up to 6 months after cultures negative

**TREATMENT OF pulmonary tuberculosis, in combination with other drugs**

**BY MOUTH**
- **Adult**: 150–450 mg once daily for at least 6 months

**CAUTIONS**
- Acute porphyrias p. 864 • discoulors soft contact lenses

**INTERACTIONS**
- Appendix 1 (rifamycins).

**SIDE-EFFECTS**
- **Common or very common** Anaemia • blood disorders • leucopenia • myalgia • nausea • pyrexia • rash • thrombocytopenia
- **Uncommon** Arthralgia • body secretions coloured orange-red • bronchospasm • corneal deposits • eosinophilia • hypersensitivity reactions • jaundice • raised liver enzymes • saliva coloured orange-red • skin coloured orange-red • urine coloured orange-red • uvetitis (especially following high doses or concomitant use with drugs that increase plasma concentration) • vomiting
- **Rare** Haemolysis
- **Frequency not known** Chest pain • dyspnoea • hepatitis • influenza-like symptoms

**SIDE-EFFECTS, FURTHER INFORMATION**

Discontinue permanently if serious side-effects develop.

**ALLERGY AND CROSS-SENSITIVITY**
Contra-indicated in patients with rifamycin hypersensitivity.

**CONCEPTION AND CONTRACEPTION**
- Important Rifabutin induces hepatic enzymes and the effectiveness of hormonal contraceptives is reduced; alternative family planning advice should be offered.

**PREGNANCY**
- Manufacturer advises avoid — no information available.

**BREAST FEEDING**
- Manufacturer advises avoid — no information available.

**HEPATIC IMPAIRMENT**
- Reduce dose in severe impairment.

In patients with pre-existing liver disease or hepatic impairment monitor liver function regularly and particularly frequently in the first 2 months; blood counts should also be monitored in these patients.

**RENAI IMPAIRMENT**
- Use half normal dose if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months. Blood counts should also be monitored in these patients.
Renal function should be checked before treatment.

Hepatic function should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment. However, hepatic function should be monitored on prolonged therapy.

Blood counts should be monitored on prolonged therapy.

**PRESCRIBING AND DISPENSING INFORMATION** If treatment interruption occurs, re-introduce with low dosage and increase gradually.

**PATIENT AND CARER ADVICE**

Soft contact lenses Patients or their carers should be advised to replace them if there is any risk of transmission. Soft contact lenses should be discarded if a patient becomes tuberculin positive. In those who have become tuberculin positive, who are under expert supervision, those who have become tuberculin positive, in combination with other drugs (standard 3-drug regimen)

**MENICAl FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Capsule**

CAUTIONARY AND ADVISORY LABELS 8, 14

- Mycobutin (Pfizer Ltd)
- rifabutin 150 mg Mycobutin 150mg capsules | 30 capsule £30.38

**Rifampicin**

**INDICATIONS AND DOSE**

Brucellosis in combination with other antibacterials | Legionnaires disease in combination with other antibacterials | Serious staphylococcal infections in combination with other antibacterials

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Child 1–11 months: 5–10 mg/kg; twice daily
- Child 1–7 years: 10 mg/kg; twice daily (max. per dose 600 mg)
- Adult: 0.6–1.2 g daily in 2–4 divided doses

Endocarditis in combination with other drugs

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Adult: 0.6–1.2 g daily in 2–4 divided doses

Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)

**BY MOUTH**

- Child: 15 mg/kg; 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)
- Adult: 600–900 mg; 3 times a week for 6 months (initial and continuation phases)

Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)

**BY MOUTH**

- Child (body-weight up to 50 kg): 15 mg/kg; once daily for 6 months (initial and continuation phases); maximum 450 mg per day
- Child (body-weight 50 kg and above): 15 mg/kg; once daily for 6 months (initial and continuation phases); maximum 600 mg per day
- Adult (body-weight up to 50 kg): 450 mg daily for 6 months (initial and continuation phases)
- Adult (body-weight 50 kg and above): 600 mg daily for 6 months (initial and continuation phases)

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, in combination with isoniazid

**BY MOUTH**

- Child 1 month–11 years (body-weight up to 50 kg): 15 mg/kg; daily for 3 months; maximum 450 mg per day
- Child 1 month–11 years (body-weight 50 kg and above): 15 mg/kg; daily for 3 months; maximum 600 mg per day
- Child 12–17 years (body-weight up to 50 kg): 450 mg daily for 3 months
- Adult (body-weight up to 50 kg): 450 mg daily for 3 months
- Child 12–17 years (body-weight 50 kg and above): 600 mg daily for 3 months
- Adult (body-weight 50 kg and above): 600 mg daily for 3 months

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, who are isoniazid-resistant

**BY MOUTH**

- Child 1 month–11 years (body-weight up to 50 kg): 15 mg/kg; daily for 6 months; maximum 450 mg per day
- Child 1 month–11 years (body-weight 50 kg and above): 15 mg/kg; daily for 6 months; maximum 600 mg per day
- Child 12–17 years (body-weight up to 50 kg): 450 mg daily for 6 months
- Child 12–17 years (body-weight 50 kg and above): 600 mg daily for 6 months

Prevention of secondary case of Haemophilus influenzae type b disease

**BY MOUTH**

- Adult 18–34 years (body-weight up to 50 kg): 450 mg daily for 6 months
- Adult 18–34 years (body-weight 50 kg and above): 600 mg daily for 6 months

Prevention of secondary case of meningococcal meningitis

**BY MOUTH**

- Child 1–11 months: 10 mg/kg; once daily for 4 days
- Child 3 months–11 years: 20 mg/kg; once daily (max. per dose 600 mg) for 4 days
- Child 12–17 years: 600 mg; once daily for 4 days
- Adult: 600 mg once daily for 4 days

Multibacillary leprosy in combination with dapson and clofazimine (3-drug regimen) | Paucibacillary leprosy in combination with dapson (2-drug regimen)

**BY MOUTH**

- Adult (body-weight up to 35 kg): 450 mg once a month, supervised administration
- Adult (body-weight 35 kg and above): 600 mg once a month, supervised administration

**CONTRA-INDICATIONS** Acute porphyrias p. 864; jaundice

**CAUTIONS** Discolours soft contact lenses

**INTERACTIONS** Appendix 1 (rifamycins). Rifampicin induces hepatic enzymes which accelerate the metabolism of several drugs including oestrogens,
corticosteroids, phenytoin, sulfonylureas, and anticoagulants.

- **SIDE-EFFECTS**
  
  **GENERAL SIDE-EFFECTS**
  Acute renal failure · adrenal insufficiency · alterations of liver function · anorexia · antibiotic-associated colitis · body secretions coloured orange-red · collapse and shock · diarrhoea · disseminated intravascular coagulation · drowsiness · eosinophilia · exfoliative dermatitis · flushing · gastro-intestinal symptoms · haemolytic anaemia · headache · influenza-like symptoms (with chills, fever, dizziness, bone pain) · jaundice · leucopenia · menstrual disturbances · muscular weakness · myopathy · nausea · oedema · pemphigoid reactions · psychoses · rashes · respiratory symptoms · saliva coloured orange-red · shortness of breath · Stevens-Johnson syndrome · thrombocytopenic purpura · toxic epidermal necrolysis · urine coloured orange-red · urticaria · vomiting

  **SPECIFIC SIDE-EFFECTS**
  - With intravenous use Thrombophlebitis reported if infusion used for prolonged period
  - **SIDE-EFFECTS, FURTHER INFORMATION**
  Discontinue permanently if serious side-effects develop.
  - **Intermittent therapy** Side-effects that mainly occur with intermittent therapy include influenza-like symptoms (with chills, fever, dizziness, bone pain), respiratory symptoms (including shortness of breath), collapse and shock, haemolytic anaemia, thrombocytopenic purpura, disseminated intravascular coagulation, and acute renal failure
  - **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with rifampicyn hypersensitivity.
  - **CONCEPTION AND CONTRACEPTION** Important Effectiveness of hormonal contraceptives is reduced and alternative family planning advice should be offered.
  - **PREGNANCY** Manufacturers advise very high doses teratogenic in animal studies in first trimester; risk of neonatal bleeding may be increased in third trimester.
  - **BREAST FEEDING** Amount too small to be harmful.
  - **HEPATIC IMPAIRMENT** Impaired elimination. Avoid or do not exceed 8 mg/kg daily. In patients with pre-existing liver disease or hepatic impairment, monitor liver function regularly and particularly frequently in the first 2 months; blood counts should also be monitored in these patients.
  - **RENAL IMPAIRMENT**
    - In children Use with caution if doses above 10 mg/kg daily.
    - In adults Use with caution if dose above 600 mg daily.
  - **MONITORING REQUIREMENTS**
    - Renal function should be checked before treatment.
    - Hepatic function should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment. However, liver function should be monitored on prolonged therapy.
    - Blood counts should be monitored in patients on prolonged therapy.
    - Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months. Blood counts should also be monitored in these patients.
  - **DIRECTIONS FOR ADMINISTRATION**
    - With intravenous use in adults. For intravenous infusion (Rifadin®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute with solvent provided then dilute with 500 mL infusion fluid; give over 2–3 hours.
    - With intravenous use in children Displacement value may be significant, consult local reconstitution guidelines; reconstitute with solvent provided. May be further diluted with Glucose 5% or Sodium chloride 0.9% to a final concentration of 1.2 mg/mL. Infuse over 2–3 hours.

  **PRESCRIBING AND DISPENSING INFORMATION**
  If treatment interruption occurs, re-introduce with low dosage and increase gradually.

  - **With oral use in children** In general, doses should be rounded up to facilitate administration of suitable volumes of liquid or an appropriate strength of tablet. Doses may also need to be recalculated to allow for weight gain in younger children. Flavours of syrup may include raspberry.

  **PATIENT AND CARER ADVICE**
  Medicines for Children leaflet: Rifampicin for meningococcal prophylaxis www.medicinesforchildren.org.uk/rifampicin-for-meningococcal-prophylaxis

  **SIDE-EFFECTS**
  Soft contact lenses Patients or their carers should be advised that rifampicin discolours soft contact lenses. Hepatic disorders Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

  **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution
  - **Capsule**
    - **CAUTIONARY AND ADVISORY LABELS** 8, 14, 23
    - **RIFAMPICIN (Non-proprietary)**
      - Rifampicin 150 mg Rifampicin 150mg capsules | 100 capsule £47.10 DT price = £15.75
      - Rifampicin 300 mg Rifampicin 300mg capsules | 100 capsule £47.39-£48.00 DT price = £48.00
      - Rifadin (Sanofi)
      - Rifampicin 150 mg Rifampicin 150mg capsules | 100 capsule £18.32 DT price = £15.75
      - Rifampicin 300 mg Rifampicin 300mg capsules | 100 capsule £36.63 DT price = £48.00
      - Rimactane (Sandoz Ltd)
      - Rifampicin 300 mg Rimactane 300mg capsules | 60 capsule £25.92
  - **Oral suspension**
    - **CAUTIONARY AND ADVISORY LABELS** 8, 14, 23
    - **EXCIPIENTS:** May contain Sucrose
      - Rifadin (Sanofi)
      - Rifampicin 20 mg per 1 ml Rifampicin 100mg/5ml syrup | 120 ml £3.56
  - **Powder and solvent for solution for infusion**
    - **ELECTROLYTES:** May contain Sodium
      - Rifadin (Sanofi)
      - Rifampicin 600 mg Rifadin 600mg powder and solvent for solution for infusion vials | 1 vial £7.67

---

**Ethambutol with isoniazid, pyrazinamide and rifampicin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ethambutol hydrochloride p. 505, isoniazid p. 506, pyrazinamide p. 506, rifampicin p. 506.
Isoniazid with rifampicin and pyrazinamide

The properties listed below are those particular to the combination only. For the properties of the components please consider, isoniazid p. 506, rifampicin p. 508.

INDICATIONS AND DOSE

Treatment of tuberculosis (continuation phase)

BY MOUTH
- Adult (body-weight 50 kg and above): 4 tablets daily for 3 months (continuation phase after 2-month initial phase), use Rifater 150/100 Tablets, preferably taken before breakfast.
- Adult (body-weight 50 kg and above): 6 tablets daily for 4 months (continuation phase after 2-month initial phase), use Rifinah 300/150 Tablets, preferably taken before breakfast.

Dose equivalence and conversion
Rifinah Tablets contain rifampicin and isoniazid; the proportions are expressed in the form x/y where x and y are the strengths in milligrams of rifampicin and isoniazid respectively. Each Rifinah 150/100 Tablet contains rifampicin 150 mg and isoniazid 100 mg. Each Rifinah 300/150 Tablet contains rifampicin 300 mg and isoniazid 150 mg.

2.6 Urinary tract infections

Urinary-tract infections

Urinary-tract infection is more common in women than in men; when it occurs in men there is frequently an underlying abnormality of the renal tract. Recurrent episodes of infection are an indication for radiological investigation especially in children in whom untreated pyelonephritis may lead to permanent kidney damage.

Escherichia coli is the most common cause of urinary-tract infection; Staphylococcus saprophyticus is also common in sexually active young women. Less common causes include Proteus and Klebsiella spp. Pseudomonas aeruginosa infections usually occur in the hospital setting and may be associated with functional or anatomical abnormalities of the renal tract. Staphylococcus epidermidis and Enterococcus faecalis infection may complicate catheterisation or instrumentation.

A specimen of urine should be collected for culture and sensitivity testing before starting antibacterial therapy;
- in men;
- in pregnant women;
- in children under 3 years of age;
- in patients with suspected upper urinary-tract infection;
- complicated infection, or recurrent infection;
- if resistant organisms are suspected;
- if urine dipstick testing gives a single positive result for leucocyte esterase or nitrite;
- if clinical symptoms are not consistent with results of dipstick testing.
Treatment should not be delayed while waiting for results. The antibacterial chosen should reflect current local bacterial sensitivity to antibacterials.

**Antibacterial therapy for lower urinary-tract infections**

Uncomplicated lower urinary-tract infections often respond to trimethoprim p. 462 or nitrofurantoin p. 512, or alternatively, amoxicillin p. 482, ampicillin p. 483 or oral cephalosporin.

_Suggested duration of treatment_ is 7 days, but a short course (e.g. 3 days) is usually adequate for uncomplicated urinary-tract infections in women.

Infections caused by fully sensitive bacteria respond to amoxicillin.

Widespread bacterial resistance to ampicillin, amoxicillin, and trimethoprim has been reported. Alternatives for resistant organisms include co-amoxiclav p. 484 (amoxicillin with clavulanic acid), an oral cephalosporin, nitrofurantoin, pimecillinam hydrochloride p. 486, or a quinolone.

Fosfomycin [unlicensed] can be used, on the advice of a microbiologist, for the treatment of uncomplicated lower urinary-tract infections caused by multiple-antibacterial resistant organisms when other antibacterials cannot be used.

Long-term low dose therapy may be required in selected patients to prevent _recurrence of infection_; indications include frequent relapses and significant kidney damage. Trimethoprim, nitrofurantoin and cefalexin p. 456 have been recommended for long-term therapy.

Methenamine hippurate below (hexamine hippurate) should not generally be used because it requires an acidic urine for its antimicrobial activity and it is ineffective for upper urinary-tract infections; it may, however, have a role in the prophylaxis and treatment of chronic or recurrent uncomplicated lower urinary-tract infections.

**Antibacterial therapy for upper urinary-tract infections**

Acute pyelonephritis can lead to septicemia and is treated initially by injection of a broad-spectrum antibacterial such as a cephalosporin (e.g. cefuroxime p. 460) or a quinolone if the patient is severely ill; gentamicin p. 450 can also be used.

_Suggested duration of treatment_ is 10–14 days (longer treatment may be necessary in complicated pyelonephritis). Prostatitis can be difficult to cure and requires treatment for several weeks with an antibacterial which penetrates prostatic tissue such as some of the quinolones (ciprofloxacin p. 490 or ofloxacin p. 494), or alternatively, trimethoprim.

_Suggested duration of treatment_ is 28 days. Where infection is localised and associated with an indwelling catheter, a bladder instillation is often effective.

**Pregnancy**

Urinary-tract infection in pregnancy may be asymptomatic and requires prompt treatment to prevent progression to acute pyelonephritis. Penicillins and cephalosporins are suitable for treating urinary-tract infection during pregnancy. Nitrofurantoin may also be used but it should be avoided at term. Sulfonamides and quinolones should be avoided during pregnancy; trimethoprim should also preferably be avoided particularly in the first trimester.

**Renal impairment**

In renal failure antibacterials normally excreted by the kidney accumulate with resultant toxicity unless the dose is reduced. This applies especially to the aminopenicillins which should be used with great caution; tetracyclines, methenamine hippurate, and nitrofurantoin should be avoided altogether.

**Urinary-tract infections in children**

Urinary-tract infections in children require prompt antibacterial treatment to minimise the risk of renal scarring. Uncomplicated ‘lower’ urinary-tract infections in _children over 3 months of age_ can be treated with trimethoprim, nitrofurantoin, a first generation cephalosporin (e.g. cefalexin), or amoxicillin for 3 days; children should be reassessed if they continue to be unwell 24–48 hours after the initial assessment. Amoxicillin should only be used if the organism causing the infection is sensitive to it.

Acute pyelonephritis in children over 3 months of age can be treated with a first generation cephalosporin or co-amoxiclav for 7–10 days. If the patient is severely ill, then the infection is best treated initially by injection of a broad-spectrum antibacterial such as cefotaxime or co-amoxiclav; gentamicin is an alternative.

_Children under 3 months of age_ should be transferred to hospital and treated initially with intravenous antibacterial drugs such as ampicillin with gentamicin, or cefotaxime alone, until the infection responds; full doses of oral antibacterials are then given for a further period.

Recurrent episodes of infection are an indication for imaging tests. _Antibacterial prophylaxis_ with low doses of trimethoprim or nitrofurantoin may be considered for children with recurrent infection, significant urinary-tract anomalies, or significant kidney damage.

---

**Methenamine hippurate**

*(Hexamine hippurate)*

**INDICATIONS AND DOSE**

**Prophylaxis and long-term treatment of chronic or recurrent uncomplicated lower urinary-tract infections**

**BY MOUTH**

- **Adult:** 1 g every 12 hours

**Prophylaxis and long-term treatment of chronic or recurrent uncomplicated lower urinary-tract infections in patients with catheters**

**BY MOUTH**

- **Adult:** 1 g every 8–12 hours

- **CONTRA-INDICATIONS** Gout - metabolic acidosis - severe dehydration

- **INTERACTIONS** → Appendix 1 (methenamine). Caution—avoid concurrent administration with sulfonamides (risk of crystalluria) or urinary alkalising agents.

- **SIDE-EFFECTS** Bladder irritation - gastro-intestinal disturbances - rash

- **PREGNANCY** Use with caution.

- **BREAST FEEDING** Amount too small to be harmful.

- **HEPATIC IMPAIRMENT** Avoid.

- **RENAL IMPAIRMENT** Avoid if eGFR less than 10 mL/minute/1.73 m² — risk of hippurate crystalluria.

- **LESS SUITABLE FOR PRESCRIBING** Methenamine (hexamine) hippurate should not generally be used because it requires an acidic urine for its antimicrobial activity and it is ineffective for upper urinary-tract infections; it may, however, have a role in the prophylaxis and treatment of chronic or recurrent uncomplicated lower urinary-tract infections. It is considered less suitable for prescribing.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

---
Nitrofurantoin

INDICATIONS AND DOSE
Acute uncomplicated urinary-tract infections
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Child 3 months-11 years: 750 micrograms/kg 4 times a day for 3–7 days
- Child 12-17 years: 50 mg 4 times a day for 3–7 days
- Adult: 50 mg 4 times a day for 3–7 days

BY MOUTH USING MODIFIED-RELEASE MEDICINES
- Child 12-17 years: 100 mg twice daily, dose to be taken with food
- Adult: 100 mg twice daily, dose to be taken with food

Severe chronic recurrent urinary-tract infections
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Child 12-17 years: 100 mg 4 times a day for 3–7 days
- Adult: 100 mg 4 times a day for 7 days, dose to be taken with food, reduce dose or discontinue treatment if severe nausea occurs

Prophylaxis of urinary-tract infection (considered for recurrent infection, significant urinary-tract anomalies, or significant kidney damage)
BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Child 3 months-11 years: 1 mg/kg once daily, dose to be taken at night
- Child 12-17 years: 50–100 mg once daily, dose to be taken at night
- Adult: 50–100 mg once daily, dose to be taken at night

Genito-urinary surgical prophylaxis
BY MOUTH USING MODIFIED-RELEASE MEDICINES
- Adult: 100 mg twice daily on day of operation and for 3 days after surgery

CONTRA-INDICATIONS
Acute porphyrias p. 864. G6PD deficiency. Infants less than 3 months old

CAUTIONS
Anemia. Diabetes mellitus. Electrolyte imbalance. Folate deficiency. Pulmonary fibrosis. Susceptibility to peripheral neuropathy. Urine may be coloured yellow or brown. Vitamin B deficiency

INTERACTIONS
Side-effects of nitrofurantoin

RARE
- Agranulocytosis
- Aplastic anemia
- Arthralgia
- Benign intracranial hypertension
- Blood disorders
- Cholestatic jaundice
- Erythema multiforme
- Exfoliative dermatitis
- Hepatitis
- Pancreatitis
- Thrombocytopenia
- Transient alopecia

FREQUENCY NOT KNOWN
- Acute pulmonary reactions
- Anaphylaxis
- Angioedema
- Anorexia
- Chronic pulmonary reactions (pulmonary fibrosis reported; possible association with lupus erythematosus-like syndrome)
- Diarrhoea
- Hypersensitivity reactions
- Nausea
- Peripheral neuropathy
- Pruritus
- Rash
- Sialadenitis
- Urticaria
- Vomiting

PREGNANCY
Avoid at term—may produce neonatal haemolysis.

BREAST FEEDING
Avoid; only small amounts in milk but enough to produce haemolysis in G6PD-deficient infants.

HEPATIC IMPAIRMENT
Use with caution; cholestatic jaundice and chronic active hepatitis reported.

RENAL IMPAIRED
Risk of peripheral neuropathy; antibacterial efficacy depends on renal secretion of the drug into urinary tract.

In adults Avoid if eGFR less than 45 mL/minute/1.73 m²; may be used with caution if eGFR 30–44 mL/minute/1.73 m² as a short-course only (3 to 7 days), to treat uncomplicated lower urinary-tract infection caused by suspected or proven multidrug resistant bacteria and only if potential benefit outweighs risk.

In children Avoid if estimated glomerular filtration rate less than 45 mL/minute/1.73 m²; may be used with caution if estimated glomerular filtration rate 30–44 mL/minute/1.73 m² as a short-course only (3 to 7 days), to treat uncomplicated lower urinary-tract infection caused by suspected or proven multidrug resistant bacteria and only if potential benefit outweighs risk.

MONITORING REQUIREMENTS
On long-term therapy, monitor liver function and monitor for pulmonary symptoms, especially in the elderly (discontinue if deterioration in lung function).

EFFECT ON LABORATORY TESTS
False positive urinary glucose (if tested for reducing substances).

PATIENT AND CARER ADVICE
Medicines for Children leaflet: Nitrofurantoin for urinary tract infections www.medicinesforchildren.org.uk/nitrofurantoin-for-urinary-tract-infections

MEDICAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet
CAUTIONARY AND ADVISORY LABELS 9, 14, 21
- NITROFURANTOIN (Non-proprietary)

Nitrofurantoin 50 mg
- Nitrofurantoin 50 mg tablets | 28 tablet (£5.00 DT price = £13.93)
- 100 tablet (£6.00 DT price = £12.99)

Nitrofurantoin 100 mg
- Nitrofurantoin 100 mg tablets | 28 tablet (£6.00 DT price = £12.99)

Nitrofurantoin 150 mg
- Nitrofurantoin 150 mg tablets | 28 tablet (£4.62 DT price = £11.89)

Modified-release capsule
CAUTIONARY AND ADVISORY LABELS 9, 14, 21
- NITROFURANTOIN (Non-proprietary)

Nitrofurantoin 50 mg
- Nitrofurantoin 50 mg capsules | 30 capsule (£0.52 DT price = £1.12)

Nitrofurantoin 100 mg
- Nitrofurantoin 100 mg capsules | 30 capsule (£0.52 DT price = £1.12)

Macrobid

Oral suspension
CAUTIONARY AND ADVISORY LABELS 9, 14, 21
- NITROFURANTOIN (Non-proprietary)

Nitrofurantoin 5 mg per 1 ml
- Nitrofurantoin 5 mg/1 ml oral suspension (sugar-free) | 300 ml (£15.42 DT price = £46.46)

3 Fungal infection

Antifungals, systemic use

The systemic treatment of common fungal infections is outlined below; specialist treatment is required in most forms of systemic or disseminated fungal infections. Local treatment is suitable for a number of fungal infections (genital, bladder, eye, ear, oropharynx, and skin).

Aspergillosis
Aspergillosis most commonly affects the respiratory tract but in severely immunocompromised patients, invasive forms can affect the heart, brain, and skin. Voriconazole p. 521 is the treatment of choice for aspergillosis; liposomal amphotericin p. 517 is an alternative first-line treatment...
Fungal infection

513

Immunocompromised patients

514

Fungal infection

515

Immunocompromised patients are at particular risk of fungal infections and may receive antifungal drugs prophylactically; oral triazole antifungals are the drugs of choice for prophylaxis. Fluconazole is more reliably absorbed than itraconazole p. 519, but fluconazole is not effective against Aspergillus spp. Itraconazole is preferred in patients at risk of invasive aspergillosis. Posaconazole p. 521 can be used for prophylaxis in patients who are undergoing haematopoietic stem cell transplantation or receiving chemotherapy for acute myeloid leukaemia and myelodysplastic syndrome, if they are intolerant of fluconazole or itraconazole. Micafungin p. 516 can be used for prophylaxis of candidiasis in patients undergoing haematopoietic stem cell transplantation when fluconazole, itraconazole or posaconazole cannot be used.

Amphotericin p. 517 by intravenous infusion or caspofungin p. 515 is used for the empirical treatment of serious fungal infections; caspofungin is not effective against fungal infections of the CNS.

Triazole antifungals

516

Triazole antifungal drugs have a role in the prevention and systemic treatment of fungal infections.

Fluconazole is very well absorbed after oral administration. It also achieves good penetration into the cerebrospinal fluid to treat fungal meningitis. Fluconazole is excreted largely unchanged in the urine and can be used to treat candiduria.

Itraconazole is active against a wide range of dermatophytes. Itraconazole capsules require an acid environment in the stomach for optimal absorption. Itraconazole has been associated with liver damage and should be avoided or used with caution in patients with liver disease; fluconazole is less frequently associated with hepatotoxicity.

Posaconazole is licensed for the treatment of invasive fungal infections unresponsive to conventional treatment. Voriconazole p. 521 is a broad-spectrum antifungal drug which is licensed for use in life-threatening infections.

Imidazole antifungals

517

The imidazole antifungals include clotrimazole p. 712, econazole nitrate p. 712, ketoconazole p. 713, and tioconazole p. 1012. They are used for the local treatment of vaginal candidiasis and for dermatophyte infections. Miconazole p. 997 can be used locally for oral infections; it is also effective in intestinal infections. Systemic absorption may follow use of miconazole oral gel and may result in significant drug interactions.
Polyene antifungals

The polyene antifungals include amphotericin p. 517 and nystatin p. 997; neither drug is absorbed when given by mouth. Nystatin is used for oral, oropharyngeal, and perioral infections by local application in the mouth. Nystatin is also used for Candida albicans infection of the skin.

Amphotericin by intravenous infusion is used for the treatment of systemic fungal infections and is active against most fungi and yeasts. It is highly protein bound and penetrates poorly into body fluids and tissues. When given parenterally amphotericin is toxic and side-effects are common. Lipid formulations of amphotericin (Abelcet® and AmBisome®) are significantly less toxic and are recommended when the conventional formulation of amphotericin is contra-indicated because of toxicity, especially nephrotoxicity or when response to conventional amphotericin is inadequate; lipid formulations are more expensive.

Echinocandin antifungals

The echinocandin antifungals include anidulafungin p. 515, caspofungin p. 515 and micafungin p. 516. They are only active against Aspergillus spp. and Candida spp.; however, anidulafungin and micafungin are not used for the treatment of aspergillosis. Echinocandins are not effective against fungal infections of the CNS.

Other antifungals

Flucytosine p. 516 is used with amphotericin in a synergistic combination. Bone marrow depression can occur which limits its use, particularly in HIV-positive patients; weekly blood counts are necessary during prolonged therapy. Resistance to flucytosine can develop during treatment and sensitivity testing is essential before and during treatment. Resistance to flucytosine can develop during therapy and sensitivity testing is essential before and during treatment. Flucytosine has a role in the treatment of systemic candidiasis and cryptococcal meningitis.

Griseofulvin below is effective for widespread or intractable dermatophyte infections but has been superseded by newer antifungals, particularly for nail infections. It is the drug of choice for widespread or intractable dermatophyte infections but has been superseded by newer antifungals, particularly for nail infections. It is the drug of choice for trichophyton infections and is also used for ringworm infections where oral treatment is considered appropriate.

Antifungals

Griseofulvin

**INDICATIONS AND DOSE**

Dermatophyte infections where topical therapy has failed or is inappropriate

**BY MOUTH**

- Child 1 month-11 years: Usual dose 10 mg/kg daily (max. per dose 500 mg), alternatively 20 mg/kg daily, higher dose for severe infections; reduce dose when response occurs, daily dose may be taken once daily or in divided doses
- Child 12-17 years: 500 mg daily, alternatively 1 g daily, higher dose for severe infections; reduce dose when response occurs, daily dose may be taken once daily or in divided doses
- Adult: 500 mg daily, alternatively 1 g daily, higher dose for severe infections; reduce dose when response occurs, daily dose may be taken once daily or in divided doses

Tinea capitis caused by Trichophyton tonsurans

**BY MOUTH**

- Child 1 month-11 years: 15–20 mg/kg once daily (max. per dose 1 g), alternatively 15–20 mg/kg daily in divided doses
- Child 12-17 years: 1 g once daily, alternatively 1 g daily in divided doses
- Adult: 1 g once daily, alternatively 1 g daily in divided doses

- **UNLICENSED USE** Griseofulvin doses in BNF may differ from those in product literature.
- **CONTRA-INDICATIONS** Acute porphyrias p. 864 · systemic lupus erythematosus (risk of exacerbation)
- **INTERACTIONS** → Appendix 1 (griseofulvin).
- **SIDE-EFFECTS**
  - Rare Erythema multiforme · toxic epidermal necrolysis
  - Very rare Headache
- **Frequency not known** Abdominal pain · agitation · confusion · depression · diarrhoea · dizziness · dyspepsia · fatigue · glossitis · hepatotoxicity · impaired coordination · impaired hearing · leucopenia · menstrual disturbances · nausea · peripheral neuropathy · photosensitivity · rash · renal failure · sleep disturbances · systemic lupus erythematosus · taste disturbances · vomiting

**CONCEPTION AND CONTRACEPTION** Effective contraception required during and for at least 1 month after administration to women (important: effectiveness of oral contraceptives may be reduced, additional contraceptive precautions e.g. barrier method, required). Men should avoid fathering a child during and for at least 6 months after administration

**PREGNANCY** Avoid (fetotoxicity and teratogenicity in animals).

**BREAST FEEDING** Avoid — no information available.

**HEPATIC IMPAIRMENT** Avoid in severe liver disease.

**PATIENT AND CARER ADVICE** May impair performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

**M EDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 9, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GRISEOFULVIN (Non-proprietary)</strong></td>
</tr>
<tr>
<td>Griseofulvin 125 mg Griseofulvin 125mg tablets</td>
</tr>
<tr>
<td>Griseofulvin 500 mg Griseofulvin 500mg tablets</td>
</tr>
</tbody>
</table>

Terbinafine

**INDICATIONS AND DOSE**

Tinea pedis

**BY MOUTH**

- Adult: 250 mg daily for 2–6 weeks

Tinea corporis

**BY MOUTH**

- Adult: 250 mg once daily for 4 weeks

Tinea cruris

**BY MOUTH**

- Adult: 250 mg once daily for 2–4 weeks
Echinocandin antifungals

Anidulafungin

**INDICATIONS AND DOSE**

**Invasive candidiasis**

**BY INTRAVENOUS INFUSION**

- Adult: Initially 200 mg once daily for 1 day, then 100 mg once daily

**SIDE-EFFECTS**

- **Common or very common** Gagging; convulsion; diarrhea; flushing; headache; hypokalaemia; nausea; pruritus; raised serum creatinine; rash; vomiting

- **Uncommon** Abdominal pain; cholestasis; hyperglycaemia; hypertension; injection-site pain; urticaria

**FREQUENCY NOT KNOWN** Bronchospasm; dyspnoea; hepatitis; hypotension

**PREGNANCY** Manufacturer advises avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid unless potential benefit outweighs risk—present in milk in animal studies.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Ecalta®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstitute each 100 mg with 30 mL water for injections and allow up to 5 minutes for reconstitution; dilute dose in infusion fluid to a concentration of 770 micrograms/mL; give at a rate not exceeding 1.1 mg/minute. Follow product information if using stock supplied with ethanol solvent.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- Ecalta (Pfizer Ltd) Anidulafungin 100 mg Ecalta 100mg powder for concentrate for solution for infusion vials | 1 vial (P) £295.99

**Caspofungin**

**INDICATIONS AND DOSE**

Invasive aspergillosis | Invasive candidiasis | Empirical treatment of systemic fungal infections in patients with neutropenia

**BY INTRAVENOUS INFUSION**

- Adult (body-weight up to 81 kg): 70 mg once daily for 1 day, then 50 mg once daily

- Adult (body-weight 81 kg and above): 70 mg once daily

**INTERACTIONS** → Appendix 1 (caspofungin).

**SIDE-EFFECTS**

- **Common or very common** Arthralgia; diarrhoea; dyspnoea; headache; hypokalaemia; injection-site reactions; nausea; pruritus; rash; sweating; vomiting

- **Uncommon** Abdominal pain; anaemia; anorexia; anxiety; arthrythmia; ascites; blurred vision; bronchospasm; chest pain; cholestasis; constipation; cough; disorientation; dizziness; dry mouth; dyspnoea; dysphagia; erythema multiforme; fatigue; flatulence; flushing; heart failure; hepatic dysfunction; hyperglycaemia; hypertension; hypoaesthesia; hypocalcaemia; hypomagnesaemia; hypotension; leukopenia; metabolic acidosis; muscular weakness; myalgia; palpitation; paraesthesia; renal failure; sleep disturbances; taste disturbances; thrombocytopenia; thrombophlebitis; tremor

- **FREQUENCY NOT KNOWN** Adult respiratory distress syndrome | anaphylaxis

**PREGNANCY** Manufacturer advises avoid unless essential—toxicity in animal studies.

**BREAST FEEDING** Present in milk in animal studies—manufacturer advises avoid.

**HEPATIC IMPAIRMENT** 70 mg on first day then 35 mg once daily in moderate impairment. No information available for severe impairment.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Cancidas®), give intermittently in Sodium chloride 0.9%. Allow vial to reach room temperature; initially reconstitute each vial with 10.5 mL water for injections, mixing gently to dissolve then dilute requisite dose in 250 mL infusion fluid (35- or 50-mg doses may be diluted in 100 mL infusion fluid if necessary); give over 60 minutes; incompatible with glucose solutions.
Micafungin

**INDICATIONS AND DOSE**

Invasive candidiasis

**BY INTRAVENOUS INFUSION**

- Adult (body-weight up to 40 kg): 2 mg/kg once daily for at least 14 days; increased if necessary to 4 mg/kg once daily, increase dose if response inadequate
- Adult (body-weight 40 kg and above): 100 mg once daily for at least 14 days; increased if necessary to 200 mg once daily, increase dose if response inadequate

**Oesophageal candidiasis**

**BY INTRAVENOUS INFUSION**

- Adult (body-weight up to 40 kg): 3 mg/kg once daily
- Adult (body-weight 40 kg and above): 150 mg once daily

**Prophylaxis of candidiasis in patients undergoing bone-marrow transplantation or who are expected to become neutropenic for over 10 days**

**BY INTRAVENOUS INFUSION**

- Adult (body-weight up to 40 kg): 1 mg/kg once daily continue for at least 7 days after neutrophil count is desirable range
- Adult (body-weight 40 kg and above): 50 mg once daily continue for at least 7 days after neutrophil count is desirable range

**INTERACTIONS**

Appendix 1 (micafungin).

Caution with concomitant use of other hepatotoxic drugs.

**SIDE-EFFECTS**

- **Common or very common**
  - Abdominal pain
  - anaemia
  - diarrhoea
  - fever
  - headache
  - hypokalaemia
  - hypoglycaemia
  - leucopenia
  - nausea
  - phlebitis
  - rash
  - vomiting
- **Uncommon**
  - Anorexia
  - anxiety
  - blood pressure changes
  - bradycardia
  - cholestasis
  - confusion
  - constipation
  - dizziness
  - dyspepsia
  - dysphonia
  - eosinophilia
  - flushing
  - hepatitis
  - hepatomegaly
  - hyperhidrosis
  - hyperkalaemia
  - hypotension
  - hypophosphataemia
  - myalgia
  - neuralgia
  - pruritus
  - rashes
  - tremor
- **Rare**
  - Haemolytic anaemia
- **Frequency not known**
  - Disseminated intravascular coagulation
  - hepatotoxicity (potentially life-threatening)
  - renal failure
  - Stevens-Johnson syndrome
  - toxic epidermal necrolysis
- **PREGNANCY**
  - Manufacturer advises avoid unless essential—toxicity in animal studies.
- **BREAST FEEDING**
  - Manufacturer advises use only if potential benefit outweighs risk—present in milk in animal studies.
- **HEPATIC IMPAIRMENT**
  - Use with caution in mild to moderate impairment. Avoid in severe impairment.
- **RENAL IMPAIRMENT**
  - Use with caution; renal function may deteriorate.
- **MONITORING REQUIREMENTS**
  - Monitor renal function.
  - Monitor liver function—discontinue if significant and persistent abnormalities in liver function tests develop.
- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Micafungin®), give intravenously in Glucose 5% or Sodium chloride 0.9%. Reconstitute each vial with 5 mL infusion fluid; gently rotate vial, without shaking, to dissolve; dilute requisite dose with infusion fluid to 100 mL (final concentration of 0.5–2 mg/mL); protect infusion from light; give over 60 minutes.

**MEDIINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- **Cancidas** (Merck Sharp & Dohme Ltd)
  - Caspofungin (as Caspofungin acetate) 50 mg
  - Cancidas 50mg powder for solution for infusion vials | 1 vial (PMD) £327.67
  - Caspofungin (as Caspofungin acetate) 70 mg
  - Cancids 70mg powder for solution for infusion vials | 1 vial (PMD) £416.78

**FLUORONATED PYRIMIDINE ANTIFUNGALS**

**Flucytosine**

**INDICATIONS AND DOSE**

Systemic yeast and fungal infections

**ADJUNCT TO AMPHOTERICIN IN SEVERE SYSTEMIC CANDIDIASIS AND IN OTHER SEVERE OR LONG-LASTING INFECTIONS**

**BY INTRAVENOUS INFUSION**

- Adult: Usual dose 200 mg/kg daily in 4 divided doses usually for not more than 7 days, alternatively 100–150 mg/kg daily in 4 divided doses, lower dose may be sufficient for sensitive organisms

**CRYPTOCOCCAL MENINGITIS (ADJUNCT TO AMPHOTERICIN)**

**BY INTRAVENOUS INFUSION**

- Adult: 100 mg/kg daily in 4 divided doses for 2 weeks

**INTERACTIONS**

Appendix 1 (flucytosine).

- **SIDE-EFFECTS**
  - Diarrhoea
  - nausea
  - rashes
  - vomiting
  - Hair loss
  - Alopecia
  - Anaphylaxis
  - Tachycardia
  - Vomiting
  - Bradycardia

**UNLICENSED USE**

Use in cryptococcal meningitis for 2 weeks is an unlicensed duration.

**CAUTIONS**

Blood disorders - elderly

**INTERACTIONS**

Appendix 1 (flucytosine).

**MEDIINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- **Mycame** (Astellas Pharma Ltd)
  - Micafungin (as Micafungin sodium) 50 mg
  - Mycame 50mg powder for solution for infusion vials | 1 vial (PMD) £196.09
  - Micafungin (as Micafungin sodium) 100 mg
  - Mycame 100mg powder for solution for infusion vials | 1 vial (PMD) £341.00
POLYENE ANTIFUNGALS

Amphotericin (Amphotericin B)

**INDICATIONS AND DOSE**

**AMBISOME®**

Severe systemic or deep mycoses where toxicity (particularly nephrotoxicity) precludes use of conventional amphotericin | Suspected or proven infection in febrile neutropenic patients unresponsive to broad-spectrum antibacterials

**BY INTRAVENOUS INFUSION**

- Adult: Test dose 1 mg, to be given over 10 minutes, then 3 mg/kg once daily; maximum 5 mg/kg per day

**Aspergillosis**

**BY INTRAVENOUS INFUSION**

- Adult: Test dose 1 mg, to be given over 10 minutes, then 3 mg/kg once daily; maximum 5 mg/kg per day

**Visceral leishmaniasis (unresponsive to the antimonal alone)**

**BY INTRAVENOUS INFUSION**

- Adult: 1–3 mg/kg daily for 10–21 days to a cumulative dose of 21–30 mg/kg, alternatively 3 mg/kg for 5 consecutive days, followed by 3 mg/kg after 6 days for 1 dose

**FUNGIZONE®**

Systemic fungal infections

**BY INTRAVENOUS INFUSION**

- Adult: Test dose 1 mg, to be given over 20–30 minutes, then 250 micrograms/kg daily, gradually increased over 2–4 days, increased if tolerated to 1 mg/kg daily, max. (severe infection) 1.5 mg/kg daily or on alternate days. Prolonged treatment usually necessary; if interrupted for longer than 7 days recommence at 250 micrograms/kg daily and increase gradually

**ABELCET®**

Severe invasive candidiasis | Severe systemic fungal infections in patients not responding to conventional amphotericin or to other antifungal drugs or where toxicity or renal impairment precludes conventional amphotericin, including invasive aspergillosis, cryptococcal meningoitits and disseminated cryptococcosis in HIV patients

**BY INTRAVENOUS INFUSION**

- Adult: Test dose 1 mg, to be given over 15 minutes, then 5 mg/kg once daily for at least 14 days

**INTERACTIONS**

- Appendix 1 (amphotericin).
- Caution—corticosteroids (avoid except to control reactions).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain | abnormal liver function (discontinue treatment) | anaemia | arrhythmias | blood disorders | blood pressure changes | cardiovascular effects | chest pain | diarrhoea | disturbances in renal function | dyspnoea | electrolyte disturbances | febrile reactions | headache | hypokalaemia | hypomagnesaemia | nausea | rash | renal tubular acidosis | thrombocytopenia | vomiting

- **Uncommon** Anaphylactic reactions | bronchospasm | convulsions | diplopia | encephalopathy | hearing loss | neurological disorders | peripheral neuropathy | tremor

- **Frequency not known** Anorexia | arthralgia | myalgia | Stevens-Johnson syndrome | toxic epidermal necrolysis

**PREGNANCY** Not known to be harmful but manufacturers advise avoid unless potential benefit outweighs risk

**BREAST FEEDING** No information available.

**RENAL IMPAIRMENT** Use only if no alternative; nephrotoxicity may be reduced with use of lipid formulation

**MONITORING REQUIREMENTS** Hepatic and renal function tests, blood counts, and plasma electrolyte (including plasma-potassium and magnesium concentration) monitoring required.

**DIRECTIONS FOR ADMINISTRATION**

**AMBISOME®**

Amphotericin (liposomal)

For intravenous infusion (AmBisome®), give intermittently in Glucose 5% or 10%. Reconstitute each vial with 12 mL water for injections and shake vigorously to produce a preparation containing 4 mg/mL; withdraw requisite dose from vial and introduce into infusion fluid through the 5 micron filter provided to produce a final concentration of 0.2–2 mg/mL; infuse over 30–60 minutes, or if non-anaphylactic infusion-related reactions occur infuse over 2 hours (initial test dose of 1 mg over 10 minutes); an in-line filter (pore size no less than 1 micron) may be used; incompatible with sodium chloride solutions, flush existing intravenous line with glucose 5% or 10%, or use separate line.

**FUNGIZONE®**

Amphotericin (as sodium deoxycholate complex)

For intravenous infusion (Fungizone®), give intermittently in Glucose 5%. Reconstitute each vial with 10 mL water of injections and shake immediately to produce a 5 mg/mL colloidal solution; dilute further in infusion fluid to a concentration of 100 micrograms/mL: pH of the glucose must not be below 4.2 (check each container—consult product literature for details of the buffer); infuse over 2–4 hours, or longer if not tolerated (initial test dose of 1 mg over 20–30 minutes); begin infusion immediately after dilution; protect from light; incompatible with sodium chloride solutions, flush existing intravenous line with glucose 5% or use separate line; an in-line filter (pore size no less than 1 micron) may be used.

**ABELCET®**

Amphotericin (lipid complex)

For intravenous infusion, give intermittently in Glucose 5%. Allow suspension to reach room temperature, shake gently to ensure no yellow settlement, withdraw requisite dose (using 17–19 gauge needle) into one or more 20–mL syringes; replace needle on syringe with a 5-micron filter needle provided (fresh needle for each syringe) and dilute to a concentration of 1 mg/mL (2 mg/mL can be used if fluid restriction and in children); preferably give via an infusion pump at a rate of 2.5 mg/kg/hour (initial test dose of 1 mg over 15 minutes); an in-line filter (pore size no less than 15 micron) may be used; do not use sodium
Fluconazole

TRIAZOLE ANTIFUNGALS

**Fluconazole**

**INDICATIONS AND DOSE**

**Candidal balanitis**
- **BY MOUTH**
  - Child 16–17 years: 150 mg for 1 dose
  - Adult: 150 mg for 1 dose

**Vaginal candidiasis**
- **BY MOUTH**
  - Child 16–17 years: 150 mg for 1 dose
  - Adult: 150 mg for 1 dose

**Vulvovaginal candidiasis (recurrent)**
- **BY MOUTH**
  - Adult: Initially 150 mg every 72 hours for 3 doses, then 150 mg once weekly for 6 months

**Mucosal candidiasis (except genital)**
- **BY MOUTH OR BY INTRAVENOUS INFUSION**
  - Child 1 month–11 years: 3–6 mg/kg, dose to be given on first day, then 3 mg/kg daily (max. per dose 100 mg) for 7–14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14–30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections)
  - Child 12–17 years: 50 mg for 7–14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14–30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100 mg daily, increased dose only for unusually difficult infections

**BY MOUTH**
- Adult: 50 mg daily given for 7–14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14 days in atrophic oral candidiasis associated with dentures; for 14–30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100 mg daily, increased dose only for unusually difficult infections

**SIDE-EFFECTS**

- **Common or very common** Abdominal discomfort, diarrhoea, flatulence, headache, nausea, rash
- **Uncommon** Alopecia, anaemia, angioedema (in children), dizziness, dyspepsia, hepatic disorders, hyperlipidaemia, hypersensitivity reactions (in adults), pruritus, seizures, Stevens-Johnson syndrome, taste disturbance, toxic epidermal necrolysis, vomiting
- **Frequency not known** Hypokalaemia, leucopenia, thrombocytopenia

**SIDE-EFFECTS, FURTHER INFORMATION**

- If rash occurs, discontinue treatment (or monitor closely if infection invasive or systemic); severe cutaneous reactions are more likely in patients with AIDS

**PREGNANCY**
- Manufacturer advises avoid—multiple congenital abnormalities reported with long-term high doses

**BREAST FEEDING**
- Present in milk but amount probably too small to be harmful

**HEPATIC IMPAIRMENT**
- Toxicity with related drugs

**PRESCRIBING AND DISPENSING INFORMATION**

Different preparations of intravenous amphotericin vary in their pharmacodynamics, pharmacokinetics, dosage, and administration; these preparations should not be considered interchangeable. To avoid confusion, prescribers should specify the brand to be dispensed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, oral solution, lozenge

**Powder for solution for infusion**
- **EXCIPIENTS:** May contain Sucrose
- **ELECTROLYTES:** May contain Sodium
- **AmBisome** (Gilead Sciences International Ltd)
  - Amphotericin B liposomal 50 mg AmBisome 50mg powder for solution for infusion vials |10 vial £212.97
- **Fungizone** (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Amphotericin B 50 mg Fungizone intravenous 50mg powder for solution for infusion vials |1 vial £3.88

**Suspension for infusion**
- **EXCIPIENTS:** May contain Sodium
- **Abelcet** (Teva UK Ltd)
  - Amphotericin B (as Amphotericin B phospholipid complex) 5 mg per 1 ml Abelcet 100mg/20ml concentrate for suspension for infusion vials |10 vial £775.04 (Hospital only)

**Interactions**

- Susceptibility to QT interval prolongation
- Acute porphyrias
- Hepatic impairment

**Contraindications**

- Acute porphyrias

**Caution**

- Susceptibility to QT interval prolongation

**Further information**

- More information can be found in the Appendix of Antifungals and Triazole.

**Fungal infection**

- Tinea pedis, corporis, cruris, pityriasis versicolor
- Dermal candidiasis

**BY MOUTH**

- Adult: 50 mg daily for 2–4 weeks (for up to 6 weeks in tinea pedis); max. duration of treatment 6 weeks

**Invasive candidal infections (including candidaemia and disseminated candidiasis) and cryptococcal infections (including meningitis)**

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Child: 6–12 mg/kg daily (max. per dose 800 mg) treatment continued according to response (at least 8 weeks for cryptococcal meningitis)
- Adult: 400 mg, dose to be given on first day, then 200–400 mg daily (max. per dose 800 mg daily) treatment continued according to response (at least 8 weeks for cryptococcal meningitis), maximum dose for use in severe infections

**Prevention of fungal infections in immunocompromised patients**

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Child: 3–12 mg/kg daily (max. per dose 400 mg), commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose given according to extent and duration of neutropenia
- Adult: 50–400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose adjusted according to risk

**Prevention of fungal infections in immunocompromised patients (for patients with high risk of systemic infections e.g. following bone-marrow transplantation)**

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Adult: 400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range

**Prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy**

**BY MOUTH OR BY INTRAVENOUS INFUSION**

- Adult: 200 mg daily

**CONTRA-INDICATIONS**

- Acute porphyrias p. 864

**CAUTIONS**

- Susceptibility to QT interval prolongation

**INTERACTIONS**

- Appendix 1 (antifungals, triazole); in general, fluconazole interactions in Appendix 1 relate to multiple-dose treatment. Caution with concomitant use of hepatotoxic drugs.
Itraconazole

INDICATIONS AND DOSE

Vulvovaginal candidiasis

BY MOUTH

▸ Adult: 200 mg twice daily for 1 day

Vulvovaginal candidiasis (recurrent)

BY MOUTH

▸ Adult: 50–100 mg daily for 6 months

Oral or oesophageal candidiasis that has not responded to fluconazole

BY MOUTH USING ORAL SOLUTION

▸ Adult: 100–200 mg twice daily for 2 weeks (continue for another 2 weeks if no response; the higher dose should not be used for longer than 2 weeks if no signs of improvement)

Oral or oesophageal candidiasis in HIV-positive or other immunocompromised patients

BY MOUTH USING ORAL SOLUTION

▸ Adult: 200 mg daily in 1–2 divided doses for 1 week (continue for another week if no response)

Systemic candidiasis where other antifungal drugs inappropriate or ineffective

BY MOUTH

▸ Adult: 100–200 mg once daily

BY INTRAVENOUS INFUSION

▸ Adult: 200 mg every 12 hours for 2 days, then 200 mg once daily for max. 12 days

Pityriasis versicolor

BY MOUTH

▸ Adult: 200 mg once daily for 7 days

Tinea pedis | Tinea manuum

BY MOUTH

▸ Adult: 100 mg once daily for 30 days, alternatively 200 mg twice daily for 7 days

Tinea corporis | Tinea cruris

BY MOUTH

▸ Adult: 100 mg once daily for 15 days, alternatively 200 mg once daily for 7 days

Onychomycosis

BY MOUTH

▸ Adult: 200 mg once daily for 3 months, alternatively 200 mg twice daily for 7 days, subsequent courses repeated after 21-day intervals; fingernails 2 courses, toenails 3 courses

Aspergillosis

BY MOUTH

▸ Adult: 200 mg twice daily

Systemic aspergillosis where other antifungal drugs inappropriate or ineffective

BY INTRAVENOUS INFUSION

▸ Adult: 200 mg every 12 hours for 2 days, then 200 mg once daily for max. 12 days

Histoplasmosis

BY MOUTH

▸ Adult: 200 mg 3 times a day for 3 days, then 200 mg 1–2 times a day

BY INTRAVENOUS INFUSION

▸ Adult: 200 mg every 12 hours for 2 days, then 200 mg once daily for max. 12 days

Systemic cryptococcosis including cryptococcal meningitis where other antifungal drugs inappropriate or ineffective

BY MOUTH

▸ Adult: 200 mg once daily, dose increased in invasive or disseminated disease and in cryptococcal meningitis, increased to 200 mg twice daily

continued

MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 9

▸ FLUCONAZOLE (Non-proprietary)

Fluconazole 50 mg Fluconazole 50 mg capsules | 7 capsule (£0.02)

Fluconazole 150 mg Fluconazole 150 mg capsules | 1 capsule (£1.03)

Fluconazole 200 mg Fluconazole 200 mg capsules | 7 capsule (£1.31)

▸ Diflucan (Pfizer Ltd)

Fluconazole 50 mg Diflucan 50 mg capsules | 7 capsule (£0.02)

Fluconazole 150 mg Diflucan 150 mg capsules | 1 capsule (£1.03)

Fluconazole 200 mg Diflucan 200 mg capsules | 7 capsule (£1.31)

▸ Brands may include Canesten (fluconazole)

Oral suspension

CAUTIONARY AND ADVISORY LABELS 9

▸ FLUCONAZOLE (Non-proprietary)

Fluconazole 10 mg per 1 ml Fluconazole 50 mg/5 ml oral suspension | 35 ml (£0.51)

▸ Diflucan (Pfizer Ltd)

Fluconazole 10 mg per 1 ml Diflucan 50 mg/5 ml oral suspension | 35 ml (£0.51)

Infusion

▸ FLUCONAZOLE (Non-proprietary)

Fluconazole 2 mg per 1 ml Fluconazole 200 mg/100 ml infusion bags | 5 bag (£18.45)

Solution for infusion

ELECTROLYTES: May contain Sodium

▸ FLUCONAZOLE (Non-proprietary)

Fluconazole 2 mg per 1 ml Fluconazole 100 mg/50 ml solution for infusion bottles | 5 bottle (£0.02)

Fluconazole 2 mg per 1 ml Fluconazole 200 mg/100 ml solution for infusion vials | 1 vial (£0.02)

Fluconazole 2 mg per 1 ml Fluconazole 50 mg/25 ml solution for infusion vials | 1 vial (£0.02)

▸ Diflucan (Pfizer Ltd)

Fluconazole 2 mg per 1 ml Diflucan 200 mg/100 ml solution for infusion vials | 1 vial (£0.02)
**BY INTRAVENOUS INFUSION**
- Adult: 200 mg every 12 hours for 2 days, then 200 mg once daily for max. 12 days

**Maintenance in HIV-infected patients to prevent relapse of underlying fungal infection and prophylaxis in neutropenia when standard therapy inappropriate***
- Adult: 200 mg once daily, then increased to 200 mg twice daily, dose increased only if low plasma-itraconazole concentration

Prophylaxis of deep fungal infections (when standard therapy inappropriate) in patients with haematological malignancy or undergoing bone-marrow transplantation who are expected to become neutropenic
- Adult: 5 mg/kg daily in 2 divided doses, to be started before transplantation or before chemotherapy (taking care to avoid interaction with cytotoxic drugs) and continued until neutrophil count recovers, safety and efficacy not established in elderly patients

### Important safety information
- **HEART FAILURE**
  Following reports of heart failure, caution is advised when prescribing itraconazole to patients at high risk of heart failure. Those at risk include:
  - patients receiving high doses and longer treatment courses;
  - older adults and those with cardiac disease;
  - patients with chronic lung disease (including chronic obstructive pulmonary disease) associated with pulmonary hypertension;
  - patients receiving treatment with negative inotropic drugs, e.g. calcium channel blockers.
  Itraconazole should be avoided in patients with ventricular dysfunction or a history of heart failure unless the infection is serious.

### CONTRA-INDICATIONS
- Acute porphyrias p. 864

### CAUTIONS
- Active liver disease - history of hepatotoxicity with other drugs - susceptibility to congestive heart failure

### INTERACTIONS
- Appendix 1 (antifungals, triazole).

### SIDE-EFFECTS
- **GENERAL SIDE-EFFECTS**
  - Abdominal pain - diarrhea - dyspepsia - headache - hepatitis - hypokalaemia - nausea - rash - taste disturbances - vomiting
  - Constipation - dizziness - dyspepsia - flatulence - menstrual disorder - myalgia - oedema - peripheral neuropathy (discontinue treatment)
  - Frequency not known - Arthralgia - blood pressure changes - confusion - drowsiness - hepatotoxicity - renal impairment - thrombocytopenia - tremor

### SPECIFIC SIDE-EFFECTS
- With intravenous use - Hyperglycaemia

**SIDE-EFFECTS, FURTHER INFORMATION**
- **Hepatotoxicity** Potentially life-threatening hepatotoxicity reported very rarely—discontinue if signs of hepatitis develop.

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment and until the next menstrual period following end of treatment.

**PREGNANCY** Manufacturer advises use only in life-threatening situations (toxicity at high doses in animal studies).

**BREAST FEEDING** Small amounts present in milk—may accumulate; manufacturer advises avoid.

**HEPATIC IMPAIRMENT** Dose reduction may be necessary. Use only if potential benefit outweighs risk of hepatotoxicity.

**RENAI IMPAIRMENT** Risk of congestive heart failure.
- With oral use Bioavailability of oral formulations possibly reduced.
- With intravenous use Use intravenous infusion with caution if eGFR less than 30 mL/minute/1.73 m²; avoid intravenous infusion if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- Absorption reduced in AIDS and neutropenia (monitor plasma-itraconazole concentration and increase dose if necessary).
- Monitor liver function if treatment continues for longer than one month, if receiving other hepatotoxic drugs, if history of hepatotoxicity with other drugs, or in hepatic impairment.

**DIRECTIONS FOR ADMINISTRATION**
- With intravenous use For intravenous infusion (Sporanox®), give intermittently in Sodium Chloride 0.9%; dilute 250 mg in 50 mL infusion fluid and infuse only 60 mL through an in-line filter (0.2 micron) over 60 minutes.
- With oral use For oral liquid, do not take with food; swish around mouth and swallow, do not rinse afterwards.

**PRESCRIBING AND DISPENSING INFORMATION**
- Flavours of oral liquid formulations may include cherry.

**PATIENT AND CARER ADVICE**
- Patients should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine develop. Patients or carers should be given advice on how to administer itraconazole oral liquid.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Capsule**
- **CAUTIONARY AND ADVISORY LABELS** 5, 9, 21, 25
- **ITRACONAZOLE (Non-proprietary)**
  - Itraconazole 100 mg Itraconazole 100mg capsules | 4 capsule | £3.75  | 15 capsule | £21.50  | DT price | £4.57  | 60 capsule | £11.74  | £56.21
  - Sporanox (Janssen-Cilag Ltd)
  - Itraconazole 100 mg Sporanox-Pulse 100mg capsules | 28 capsule | £25.72  
  - Sporanox 100mg capsules | 4 capsule | £3.67  | 15 capsule | £13.77  | DT price | £4.57  | 60 capsule | £55.10

**Oral solution**
- **CAUTIONARY AND ADVISORY LABELS** 9, 23
- **ITRACONAZOLE (Non-proprietary)**
  - Itraconazole 10 mg per 1 ml Itraconazole 50mg/5ml oral solution | sugar free | 150 ml | £58.34  | DT price | £58.34
  - Sporanox (Janssen-Cilag Ltd)
  - Itraconazole 10 mg per 1 ml Sporanox 50mg/5ml oral solution (sugar-free) | 150 ml | £58.34  | DT price | £58.34

**Solution for infusion**
- **EXCipients:** May contain Propylene glycol
- **Sporanox** (Janssen-Cilag Ltd)
  - Itraconazole 10 mg per 1 ml Sporanox I.V. 250mg/25ml solution for infusion ampoules and diluent | 1 ampoule | £79.71
**Posaconazole**

**INDICATIONS AND DOSE**

Invasive aspergillosis in patients who are refractory to, or intolerant of voriconazole and liposomal amphotericin | Fusariosis either unresponsive to, or in patients intolerant of, amphotericin | Chromoblastomycosis and mycetoma either unresponsive to, or in patients intolerant of, itraconazole | Coccidioidomycosis either unresponsive to, or in patients intolerant of, amphotericin, itraconazole, or fluconazole

**BY MOUTH USING ORAL SUSPENSION**
- Adult: 400 mg twice daily, to be taken with food, alternatively 200 mg 4 times a day, dose if food not tolerated

**BY MOUTH USING TABLETS**
- Adult: 300 mg twice daily on first day, then 300 mg once daily

Oropharyngeal candidiasis (severe infection or in immunocompromised patients only)

**BY MOUTH USING ORAL SUSPENSION**
- Adult: 200 mg on first day, then 100 mg once daily for 13 days, dose to be taken with food

Prophylaxis of invasive fungal infections in patients undergoing bone-marrow transplantation or receiving chemotherapy for acute myeloid leukaemia and myelodysplastic syndrome who are expected to become neutropenic, and who are intolerant of fluconazole or itraconazole

**BY MOUTH USING ORAL SUSPENSION**
- Adult: 200 mg 3 times a day start before transplantation or before chemotherapy and continued until neutrophil count recovers, dose to be taken with food

**BY MOUTH USING TABLETS**
- Adult: 300 mg twice daily on first day, then 300 mg once daily start before transplantation or before chemotherapy and continued until neutrophil count recovers

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain | anaemia | anorexia | blood disorders | constipation | diarrhoea | dizziness | drowsiness | dry mouth | dyspepsia | electrolyte disturbances | fatigue | fever | flatulence | gastro-intestinal disturbances | headache | nausea | neutropenia | paraesthesia | pruritus | rash | thrombocytopenia | vomiting
- **Uncommon** Alopecia | aphasia | arrhythmias | bradycardia | changes in blood pressure | convulsions | cough | gastro-oesophageal reflux | hepatic disorders | hiccups | hyperglycaemia | insomnia | menstrual disorders | mouth ulcers | muscular skeletal pain | neuropathy | oedema | palpitation | pancreatitis | renal failure | tachycardia | tremor | vasculitis | visual disturbances
- **Rare** Adrenal insufficiency | breast pain | cardiac failure | depression | encephalopathy | hearing impairment | ileus | myocardial infarction | pneumonitis | psychosis | Stevens-Johnson syndrome | stroke | syncope | thrombosis

**CONCEPTION AND CONTRACEPTION** Manufacturer recommends effective contraception during treatment.

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk; toxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises caution. Monitor liver function in hepatic impairment.

**MONITORING REQUIREMENTS**
- Monitor electrolytes (including potassium, magnesium, and calcium) before and during therapy.
- Monitor liver function before and during therapy.

**PRESCRIBING AND DISPENSING INFORMATION** Where possible, Noxfail® tablets should be used in preference to the suspension because the tablets have a higher bioavailability; the suspension is not interchangeable with the tablets on a milligram-for-milligram basis. Flavours of oral liquid formulations may include cherry.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant tablet**

**CAUTIONARY AND ADVISORY LABELS 3, 9, 25**

- Noxfail (Merck Sharp & Dohme Ltd)

  Posaconazole 100 mg Noxfail 100mg gastro-resistant tablets | 24 tablet (P37) £596.96 | 96 tablet (P37) £2,387.85

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 3, 9, 21**

- Noxfail (Merck Sharp & Dohme Ltd)

  Posaconazole 40 mg per 1 ml Noxfail 40mg/ml oral suspension | 105 ml (P37) £491.20 (Hospital only)

**Voriconazole**

**INDICATIONS AND DOSE**

Invasive aspergillosis | Serious infections caused by Scedosporium spp., Fusarium spp., or invasive fluconazole-resistant Candida spp. (including C. krusei)

**BY MOUTH**

- Adult (body-weight up to 40 kg): 200 mg every 12 hours for 2 doses, then 100 mg every 12 hours, (by mouth) increased if necessary to 150 mg every 12 hours
- Adult (body-weight 40 kg and above): 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours, increased if necessary to 300 mg every 12 hours

**BY INTRAVENOUS INFUSION**

- Adult: Initially 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours for max. 6 months, reduced if not tolerated to 3 mg/kg every 12 hours

**CONTRA-INDICATIONS** Acute porphyrias p. 864

**CAUTIONS** Avoid exposure to sunlight - bradycardia - cardiomyopathy - electrolyte disturbances - history of QT interval prolongation - patients at risk of pancreatitis - symptomatic arrhythmias

**INTERACTIONS** → Appendix 1 (antifungals, triazole). Caution with comitant use with other drugs known to cause QT-interval prolongation.

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain | acute renal failure | agitation | alopecia | altered perception | anaemia | anxiety | asthenia | blood disorders | blurred vision | chest pain | confusion | depression | diarrhea | diziness | encephalopathy | hearing impairment | ileus | myocardial infarction | nausea | oedema | pancytopenia | paraesthesia | photosensitivity | pruritus | rash | respiratory distress

- **Unlicensed Use** Tablets not licensed for oropharyngeal candidiasis.

- **Contra-Indications** Acute porphyrias p. 864

- **Caution** Avoid exposure to sunlight - bradycardia - cardiomyopathy - electrolyte disturbances - history of QT interval prolongation - patients at risk of pancreatitis - symptomatic arrhythmias

- **Interactions** → Appendix 1 (antifungals, triazole). Caution with comitant use with other drugs that prolong QT interval.

- **Side-Effects**

**General Side-Effects**

- **Common or very common** Abdominal pain | acute renal failure | agitation | alopecia | altered perception | anaemia | anxiety | asthenia | blood disorders | blurred vision | chest pain | confusion | depression | diarrhea | diziness | encephalopathy | hearing impairment | ileus | myocardial infarction | nausea | oedema | pancytopenia | paraesthesia | photosensitivity | pruritus | rash | respiratory distress
Patients and their carers should be advised that patients should avoid intense or prolonged exposure to direct sunlight, and to avoid the use of sunbeds. In sunlight, patients should cover sun-exposed areas of skin and use a sunscreen with a high sun protection factor. Patients should seek medical attention if they experience sunburn or a severe skin reaction following exposure to light or sun.

### Medicinal Forms

- **Tablet**
  - Cautionary and Advisory Labels 9, 11, 23
  - Vfenonazole 50 mg VFEND 50mg tablets | 28 tablet £27.68
  - Vfenonazole 200 mg VFEND 200mg tablets | 28 tablet £1.102.74

- **Oral Suspension**
  - Cautionary and Advisory Labels 9, 11, 23
  - VFEND (Pfizer Ltd)
  - Vfenonazole 40 mg per 1 ml VFEND 40mg/ml oral suspension | 75 ml [Post] £551.37

- **Powder for Solution for Infusion**
  - Exipients: May contain Sulphobutyl ether beta cyclodextrin sodium
  - ElectrOlytes: May contain Sodium
  - VFEND (Pfizer Ltd)
  - Vfenonazole 200 mg VFEND 200mg powder for solution for infusion vials | 1 vial [Post] £77.14

- **Powder and Solvent for Solution for Infusion**
  - Exipients: May contain Sulphobutyl ether beta cyclodextrin sodium
  - ElectrOlytes: May contain Sodium
  - VFEND (Pfizer Ltd)
  - Vfenonazole 200 mg VFEND 200mg powder and solvent for solution for infusion vials | 1 vial [Post] £77.14

### Pneumocystis pneumonia

**Pneumocystis pneumonia**

Pneumonia caused by *Pneumocystis jirovecii* (*Pneumocystis carinii*) occurs in immunosuppressed patients; it is a common cause of pneumonia in AIDS. Pneumocystis pneumonia should generally be treated by those experienced in its management. Blood gas measurement is used to assess disease severity.

**Treatment**

- **Mild to moderate disease**
  - Co-trimoxazole p. 461 in high dosage is the drug of choice for the treatment of mild to moderate pneumocystis pneumonia.
  - Atovaquone p. 523 is licensed for the treatment of mild to moderate pneumocystis infection in patients who cannot tolerate co-trimoxazole. A combination of dapsone p. 500 with trimethoprim p. 462 is given by mouth for the treatment of mild to moderate disease [unlicensed indication].
  - A combination of clindamycin p. 467 and primaquine p. 538 by mouth is used in the treatment of mild to moderate disease [unlicensed indication]; this combination is associated with considerable toxicity.

- **Severe disease**
  - Co-trimoxazole in high dosage, given by mouth or by intravenous infusion, is the drug of choice for the treatment of severe pneumocystis pneumonia. Pentamidine isetionate p. 523 given by intravenous infusion is an alternative for patients who cannot tolerate co-trimoxazole, or who have not responded to it. Pentamidine isetionate is a potentially toxic drug that can cause severe hypotension during or immediately after infusion.
Corticosteroid treatment can be lifesaving in those with severe pneumocystis pneumonia. 

**Adjuvant therapy**
In moderate to severe infections associated with HIV infection, prednisolone p. 585 is given by mouth for 5 days (alternatively, hydrocortisone p. 583 may be given parenterally); the dose is then reduced to complete 21 days of treatment. Corticosteroid treatment should ideally be started at the same time as the anti-pneumocystis therapy and certainly no later than 24–72 hours afterwards. The corticosteroid should be withdrawn before anti-pneumocystis treatment is complete.

**Prophylaxis**
Prophylaxis against pneumocystis pneumonia should be given to all patients with a history of the infection. Prophylaxis against pneumocystis pneumonia should also be considered for severely immunocompromised patients. Prophylaxis should continue until immunity recovers sufficiently. It should not be discontinued if the patient has oral candidiasis, continues to lose weight, or is receiving cytotoxic therapy or long-term immunosuppressant therapy.

Co-trimoxazole p. 461 by mouth is the drug of choice for prophylaxis against pneumocystis pneumonia. It is given daily or on alternate days (3 times a week); the dose may be reduced to improve tolerance. Inhaled pentamidine isetionate is better tolerated than parental pentamidine isetionate. Intermittent inhalation of pentamidine isetionate is used for prophylaxis against pneumocystis pneumonia in patients unable to tolerate co-trimoxazole. It is effective but patients may be prone to extrapulmonary infection. Alternatively, dapsone p. 500 can be used. Atovaquone below has also been used for prophylaxis [unlicensed indication].

**Atovaquone**

**INDICATIONS AND DOSE**

**Treatment of mild to moderate** Pneumocystis jirovecii (Pneumocystis carinii) pneumonia in patients intolerant of co-trimoxazole

**BY MOUTH**
- Adult: 750 mg twice daily for 21 days, dose to be taken with food, particularly high fat food

**Prophylaxis against pneumocystis pneumonia**

**BY MOUTH**
- Adult: 750 mg twice daily

**SIDE-EFFECTS**

- Abnormal liver-function tests
- Anaemia
- Chills
- Diarrhoea
- Headache
- Rash
- Stevens–Johnson syndrome
- Vomiting

**CAUTIONS**
- Other causes of pulmonary disease should be sought and treated
- Elderly: initial diarrhoea and difficulty in taking with food may reduce absorption (and require alternative therapy)
- Elderly: high fat content may reduce absorption

**UNLICENSED USE**
Not licensed for primary prevention of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia by inhalation of nebulised solution.

**CAUTIONS**
- Anaemia
- Bradycardia
- Coronary heart disease
- History of ventricular arrhythmia
- Hyperglycaemia
- Hypertension
- Hypoglycaemia
- Hypokalaemia
- Hypomagnesaemia
- Hypotension
- Leucopenia
- Risk of severe hypotension following administration
- Thrombocytopenia

**INTERACTIONS**
- Appendix 1 (pentamidine isetionate)
- Caution with concomitant use of other drugs that prolong the QT interval

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Abnormal liver-function tests
- Acute renal failure
- Anaemia
- Arrhythmias (can be severe and sometimes fatal)
- Azotaemia
- Dizziness
- Flushing
- Hyperglycaemia
- Hyperkalaemia
- Hypocalcaemia
- Hypoglycaemia (can be severe and sometimes fatal)
- Hypotension (can be severe and sometimes fatal)
- Leucopenia
- Nausea
- Pancreatitis (can be severe and sometimes fatal)
- Rash
- Stevens–Johnson syndrome
- Syncope
- Taste disturbances
- Thrombocytopenia
- Vomiting

**SPECIFIC SIDE-EFFECTS**
- When used by inhalation
- Bronchoconstriction (may be prevented by prior use of bronchodilators)
- Cough
- Shortness of breath
- With intramuscular use
- Injection site reactions (muscle necrosis, discomfort, pain, induration, abscess formation)
- With intravenous use
- Injection site reactions (muscle necrosis, discomfort, pain, induration, abscess formation)

**PREGNANCY**
Manufacturer advises avoid unless essential.
Infection

hands and scrubbing nails before each meal and after each mouth, often via food eaten with unwashed hands. Washing take place in the large bowel. Adult female worms lay ova intestinal tract. Direct multiplication of worms does not and exposed to the action of digestive juices in the upper and for development of fresh worms, ova must be swallowed and for threadworm (pinworms, Drugs for threadworms

Advice on prophylaxis and treatment of helminth infections is available from the following specialist centres:

| Birmingham | (0121) 424 0357 |
| Scotland | Contact local Infectious Diseases Unit |
| Liverpool | (0151) 705 3100 |
| London | 0845 155 5000 (treatment) |

Drugs for hookworms

Hookworms (ancylostomiasis, necatoriasis) live in the upper small intestine and draw blood from the point of their attachment to their host. An iron-deficiency anaemia may occur and, if present, effective treatment of the infection requires not only expulsion of the worms but treatment of the anaemia.

Mebendazole p. 526 has a useful broad-spectrum activity, and is effective against hookworms. Albendazole p. 525 [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is an alternative. Levamisole p. 525 is also effective in children.

Schistosomicides (bilharziasis)

Adult Schistosoma haematobium worms live in the genito-urinary veins and adult S. mansoni in those of the colon and mesentery. S. japonicum is more widely distributed in veins of the alimentary tract and portal system. Praziquantel p. 526 [unlicensed] is available from Merck Serono (Cysticide®) and is effective against all human schistosomes. No serious adverse effects have been reported. Of all the available schistosomicides, it has the most attractive combination of effectiveness, broad-spectrum activity, and low toxicity.

Filaricides

Diethylcarbamazine [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is
effective against microfilareia and adults of *Loa loa*, *Wuchereria bancrofti*, and *Brugia malayi*. To minimise reactions, treatment in adults and children over 1 month, is commenced with a dose of diethylcarbamazine citrate on the first day and increased gradually over 3 days. Length of treatment varies according to infection type, and usually gives a radical cure for these infections. Close medical supervision is necessary particularly in the early phase of treatment.

In heavy infections there may be a febrile reaction, and in heavy *Loa loa* infection there is a small risk of encephalopathy. In such cases specialist advice should be sought, and treatment must be given under careful in-patient supervision and stopped at the first sign of cerebral involvement.

Ivermectin below [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is the treatment of choice for chronic Strongyloides infection in adults and children over 5 years. Albendazole [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is an alternative given to adults and children over 2 years.

**Drugs for cutaneous larva migrans (creeping eruption)**

Dog and cat hookworm larvae may enter human skin where they produce slowly extending itching tracks usually on the foot. Single tracks can be treated with topical thiabendazole (no commercial preparation available). Multiple infections respond to ivermectin, albendazole or thiabendazole (thiabendazole) by mouth [all unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies).

**Drugs for strongyloidiasis**

Adult *Strongyloides stercoralis* live in the gut and produce larvae which penetrate the gut wall and invade the tissues, setting up a cycle of auto-infection. Ivermectin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is the treatment of choice for chronic *Strongyloides* infection in adults and children over 5 years. Albendazole [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is an alternative given to adults and children over 2 years.

**ANTHELMINTICS**

**Albendazole**

**INDICATIONS AND DOSE**

**Chronic *Strongyloides* infection**

**BY MOUTH**

- Adult: 400 mg twice daily for 3 days, dose may be repeated after 3 weeks if necessary

**Hydatid disease, in conjunction with surgery to reduce the risk of recurrence or as primary treatment in inoperable cases**

**BY MOUTH**

- Adult: (consult product literature)

**Hookworm infections**

**BY MOUTH**

- Adult: 400 mg for 1 dose

- **UNLICENSED USE** Albendazole is an unlicensed drug.

- **INTERACTIONS** ➔ Appendix 1 (albendazole).

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, chewable tablet

**Diethylcarbamazine**

**INDICATIONS AND DOSE**

*Wuchereria bancrofti* infections | *Brugia malayi* infections

**BY MOUTH**

- Adult: Initially 1 mg/kg daily in divided doses on the first day, then increased to 6 mg/kg daily in divided doses, dose to be increased gradually over 3 days

*Loa loa* infections

**BY MOUTH**

- Adult: Initially 1 mg/kg daily in divided doses on the first day, then increased to 6 mg/kg daily in divided doses, dose to be increased gradually over 3 days; maximum 9 mg/kg per day

- **INTERACTIONS** ➔ Appendix 1 (diethylcarbamazine).

- **MEDICINAL FORMS**

  Medicines are available from importing manufacturers.

**Ivermectin**

**INDICATIONS AND DOSE**

*Chronic *Strongyloides* infection*

**BY MOUTH**

- Adult: 200 micrograms/kg daily for 2 days

*Onchoderciasis*

**BY MOUTH**

- Adult: 150 micrograms/kg for 1 dose, retreatment at intervals of 6 to 12 months may be required depending on symptoms

**Scabies, in combination with topical drugs, for the treatment of hyperkeratotic (crusted or ‘Norwegian’) scabies that does not respond to topical treatment alone**

**BY MOUTH**

- Adult: 200 micrograms/kg for 1 dose, further doses of 200 micrograms/kg may be required

- **UNLICENSED USE** Ivermectin is an unlicensed drug.

- **INTERACTIONS** ➔ Appendix 1 (ivermectin).

- **SIDE-EFFECTS**

  Aggravation of itching - aggravation of rash

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

**Levamisole**

**INDICATIONS AND DOSE**

*Roundworm infections*

**BY MOUTH**

- Adult: 120–150 mg for 1 dose

- **UNLICENSED USE** Not licensed.

- **CONTRA-INDICATIONS**

  Blood disorders

- **CAUTIONS**

  Epilepsy - Sjögren’s syndrome

- **INTERACTIONS** ➔ Appendix 1 (levamisole).

- **SIDE-EFFECTS**

  Arthralgia (on prolonged treatment) - blood disorders (on prolonged treatment) - convulsions (on prolonged treatment) - diarrhoea - dizziness - headache - influenza-like syndrome (on prolonged treatment) - insomniia (on prolonged treatment) - myalgia (on prolonged treatment) - nausea - rash (on prolonged treatment) - taste disturbances (on prolonged treatment) - vasculitis (on prolonged treatment) - vomiting

- **PREGNANCY**

  Embryotoxic in animal studies, avoid if possible.
Mebendazole

INDICATIONS AND DOSE

Threadworm infections

BY MOUTH
- Child 6 months–1 year: 100 mg for 1 dose, if reinfection occurs, second dose may be needed after 2 weeks
- Adult: 100 mg for 1 dose, if reinfection occurs, second dose may be needed after 2 weeks

Whipworm infections | Hookworm infections

BY MOUTH
- Child 1–7 years: 100 mg twice daily for 3 days
- Adult: 100 mg twice daily for 3 days

Roundworm infections

BY MOUTH
- Child 1 year: 100 mg twice daily for 3 days
- Child 2–7 years: 100 mg twice daily for 3 days, alternatively 500 mg for 1 dose
- Adult: 100 mg twice daily for 3 days, alternatively 500 mg for 1 dose

UNLICENSED USE Not licensed for use in children under 2 years.

Treatment of roundworm infections with mebendazole 500 mg as a single dose is an unlicensed dose.

INTERACTIONS → Appendix 1 (mebendazole).

SIDE-EFFECTS
- Common or very common Abdominal pain
- Uncommon Diarrhoea, flatulence
- Rare Alopecia, convulsions, dizziness, hepatitis, neutropenia, rash, Stevens–Johnson syndrome, toxic epidermal necrolysis, urticaria
- PREGNANCY Manufacturer advises avoid—toxicity in animal studies.
- BREAST FEEDING Amount present in milk too small to be harmful but manufacturer advises avoid.
- PRESCRIBING AND DISPENSING INFORMATION Flavours of oral liquid formulations may include banana.
- PATIENT AND CARER ADVICE Medicines for Children leaflet: Mebendazole for worm infections www.medicinesforchildren.org.uk/mebendazole-for-worm-infections
- EXCEPTIONS TO LEGAL CATEGORY Mebendazole tablets can be sold to the public if supplied for oral use in the treatment of enterobiasis in adults and children over 2 years provided its container or package is labelled to show a max. single dose of 100 mg and it is supplied in a container or package containing not more than 800 mg.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Chewable tablet
- MEBENDAZOLE (Non-proprietary)
  - Mebendazole 100 mg
  - Vermox (Janssen-Cilag Ltd)
  - Mebendazole 100 mg Vermox 100 mg chewable tablets (sugar-free) | 6 tablet | £1.36 OT price = £1.36
- Brands may include Ovex

Praziquantel

INDICATIONS AND DOSE

Tapeworm infections (Taenia solium)

BY MOUTH
- Adult: 5–10 mg/kg for 1 dose, to be taken after a light breakfast

Tapeworm infections (Hymenolepis nana)

BY MOUTH
- Adult: 25 mg/kg for 1 dose, to be taken after a light breakfast

Schistosoma haematobium worm infections | Schistosoma mansoni worm infections

BY MOUTH
- Adult: 20 mg/kg, followed by 20 mg/kg after 4–6 hours

Schistosoma japonicum worm infections

BY MOUTH
- Adult: 20 mg/kg 3 times a day for 1 day

UNLICENSED USE Praziquantel is an unlicensed drug.

INTERACTIONS → Appendix 1 (praziquantel).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

5 Protozoal infection

Antiprotozoal drugs

Amoebicides

Metronidazole p. 475 is the drug of choice for acute invasive amoebic dysentery since it is very effective against vegetative forms of Entamoeba histolytica in ulcers. Tinidazole p. 476 is also effective. Metronidazole and tinidazole p. 476 are also active against amoebae which may have migrated to the liver. Treatment with metronidazole or tinidazole is followed by a 10-day course of diloxanide furoate p. 438.

Diloxanide furoate is the drug of choice for asymptomatic patients with E. histolytica cysts in the faeces; metronidazole and tinidazole are relatively ineffective. Diloxanide furoate is relatively free from toxic effects and the usual course is of 10 days, given alone for chronic infections or following metronidazole or tinidazole treatment.

For amoebic abscesses of the liver metronidazole is effective; tinidazole is an alternative. Aspiration of the abscess is indicated where it is suspected that it may rupture or where there is no improvement after 72 hours of metronidazole; the aspiration may need to be repeated. Aspiration aids penetration of metronidazole and, for abscesses with more than 100 mL of pus, if carried out in conjunction with drug therapy, may reduce the period of disability.

Diloxanide furoate p. 438 is not effective against hepatic amoebiasis, but a 10-day course should be given at the completion of metronidazole or tinidazole treatment to destroy any amoebae in the gut.
Trichomonacides
Metronidazole is the treatment of choice for *Trichomonas vaginalis* infection. Contact tracing is recommended and sexual contacts should be treated simultaneously. If metronidazole is ineffective, tinidazole may be tried.

Antigiardial drugs
Metronidazole is the treatment of choice for *Giardia lamblia* infections. Alternative treatments are tinidazole or mepacrine hydrochloride p. 438.

Leishmaniacides
Cutaneous leishmaniasis frequently heals spontaneously but if skin lesions are extensive or unsightly, treatment is indicated, as it is in visceral leishmaniasis (kala-azar). Leishmaniasis should be treated under specialist supervision.

Sodium stibogluconate below, an organic pentavalent antimony compound, is used for visceral leishmaniasis. The dosage varies with different geographical regions and expert advice should be obtained. Some early non-inflamed lesions of cutaneous leishmaniasis can be treated with intralesional injections of sodium stibogluconate below under specialist supervision.

Amphotericin p. 517 is used with or after an antimony compound for visceral leishmaniasis unresponsive to the antimonial alone; side-effects may be reduced by using liposomal amphotericin (AmBisome®) Abelet® a lipid formulation of amphotericin is also likely to be effective but less information is available.

Pentamidine isetionate p. 523 has been used in antimony-resistant visceral leishmaniasis, but although the initial response is often good, the relapse rate is high; it is associated with serious side-effects. Other treatments include paromomycin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies).

Trypanocides
The prophylaxis and treatment of trypanosomiasis is difficult and differs according to the strain of organism. Expert advice should therefore be obtained.

Drugs for toxoplasmosis
Most infections caused by *Toxoplasma gondii* are self-limiting, and treatment is not necessary. Exceptions are patients with eye involvement (toxoplasma chorioretinitis), and those who are immunosuppressed. Toxoplastic encephalitis is a common complication of AIDS. The treatment of choice is a combination of pyrimethamine p. 539 and sulfadiazine p. 495, given for several weeks (expert advice essential). Pyrimethamine is a folate antagonist, and adverse reactions to this combination are relatively common (folinic acid supplements and weekly blood counts needed). Alternative regimens use combinations of pyrimethamine p. 539 with clindamycin p. 467 or clariithromycin p. 470 or azithromycin p. 469. Long-term secondary prophylaxis is required after treatment of toxoplasmosis in immunocompromised patients; prophylaxis should continue until immunity recovers.

If toxoplasmosis is acquired in pregnancy, transplacental infection may lead to severe disease in the fetus; specialist advice should be sought on management. Spiramycin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) may reduce the risk of transmission of maternal infection to the fetus.

5.1 Leishmaniasis

Sodium stibogluconate

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visceral leishmaniasis (specialist use only)</td>
</tr>
<tr>
<td>BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION</td>
</tr>
<tr>
<td>Adult: 20 mg/kg daily for 28 days</td>
</tr>
<tr>
<td>Cutaneous leishmaniasis (specialist use only)</td>
</tr>
<tr>
<td>BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION</td>
</tr>
<tr>
<td>Adult: 20 mg/kg daily for 20 days</td>
</tr>
</tbody>
</table>

- **CAUTIONS** Heart disease (withdraw if conduction disturbances occur) - mucocutaneous disease - predisposition to QT interval prolongation - treat intercurrent infection (e.g. pneumonia)

**CAUTIONS, FURTHER INFORMATION**
Mucocutaneous disease Successful treatment of mucocutaneous leishmaniasis may induce severe inflammation around the lesions (may be life-threatening if pharyngeal or tracheal involvement)—may require corticosteroid.

**INTERACTIONS** -> Appendix 1 (sodium stibogluconate). Caution with concomitant use of drugs that prolong QT interval.

**SIDE-EFFECTS**
- Rare: Bleeding from gums, bleeding from nose, fever, flushing, jaundice, rash, substernal pain, sweating, vertigo
- **Frequency not known** Abdominal pain, anaphylaxis, anorexia, arthralgia, coughing, diarrhoea, ECG changes, headache, lethargy, myalgia, nausea, pain on intramuscular injection, pain on intravenous administration, pancreatitis, thrombosis on intravenous administration, vomiting

**PREGNANCY**
Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**
Amount probably too small to be harmful.

**HEPATIC IMPAIRMENT**
Use with caution.

**RENAL IMPAIRMENT**
Avoid in significant impairment.

**MONITORING REQUIREMENTS**
Monitor ECG before and during treatment.

**DIRECTIONS FOR ADMINISTRATION**
Intravenous injections must be given slowly over 5 minutes (to reduce risk of local thrombosis) and stopped if coughing or substernal pain occur. Injection should be filtered immediately before administration using a filter of 5 microns or less.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Pentostam (GlaxoSmithKline UK Ltd)
  - Antimony pentavalent (as Sodium stibogluconate) 100 mg per 1 ml Pentostam 10g/100ml solution for injection vials | 1 vial £66.43

5.2 Malaria

**Antimalarials**

Artemether with lumefantrine p. 534 is licensed for the treatment of acute non-complicated *falciparum* malaria.
Chloroquine
Chloroquine p. 536 is used for the prophylaxis of malaria in areas of the world where the risk of chloroquine-resistant falciparum malaria is still low. It is also used with proguanil hydrochloride p. 539 when chloroquine-resistant falciparum malaria is present but this regimen may not give optimal protection (see recommended regimens for prophylaxis against malaria in Malaria, prophylaxis below).

Chloroquine is no longer recommended for the treatment of falciparum malaria owing to widespread resistance, nor is it recommended if the infective species is not known or if the infection is mixed; in these cases treatment should be with quinine p. 540, Malarone®, or Riamet®. It is still recommended for the treatment of non-falciparum malaria.

Mefloquine
Mefloquine p. 537 is used for the prophylaxis of malaria in areas of the world where there is a high risk of chloroquine-resistant falciparum malaria (for details, see recommended regimens for prophylaxis against malaria in Malaria, prophylaxis below).

Mefloquine is now rarely used for the treatment of falciparum malaria because of increased resistance. It is rarely used for the treatment of non-falciparum malaria because better tolerated alternatives are available.

Mefloquine should not be used for treatment if it has been used for prophylaxis.

Piperaquine with artenimol
Artenimol with piperquaine phosphate p. 535 is not recommended for the first-line treatment of acute uncomplicated falciparum malaria because of its widespread use in travellers who usually reside in areas where malaria is not endemic. Piperaquine has a long half-life.

Primaquine
Primaquine p. 536 is used to eliminate the liver stages of P. vivax or P. ovale following chloroquine treatment.

Proguanil
Proguanil hydrochloride p. 539 is used (usually with chloroquine, but occasionally alone) for the prophylaxis of malaria, (for details, see Recommended regimens for prophylaxis against malaria p. 530).

Proguanil hydrochloride used alone is not suitable for the treatment of malaria; however, Malarone® (a combination of atovaquone with proguanil hydrochloride p. 536) is licensed for the treatment of acute uncomplicated falciparum malaria. Malarone® is also used for the prophylaxis of falciparum malaria in areas of widespread mefloquine or chloroquine resistance. Malarone® is also used as an alternative to mefloquine or doxycycline p. 496. Malarone® is particularly suitable for short trips to highly chloroquine-resistant areas because it needs to be taken only for 7 days after leaving an endemic area.

Pyrimethamine
Pyrimethamine p. 539 should not be used alone, but is used with sulfadoxine.

Pyrimethamine with sulfadoxine is not recommended for the prophylaxis of malaria, but can be used in the treatment of falciparum malaria with (or following) quinine.

Quinine
Quinine is not suitable for the prophylaxis of malaria.

Quinine is used for the treatment of falciparum malaria or if the infective species is not known or if the infection is mixed (for details see Malaria, treatment p. 529).

Tetracyclines
Doxycycline p. 496 is used in adults and children over 12 years for the prophylaxis of malaria in areas of widespread mefloquine or chloroquine resistance. Doxycycline is also used as an alternative to mefloquine or Malarone® (for details, see Recommended regimens for prophylaxis against malaria p. 530).

Malaria, prophylaxis

Prophylaxis
The recommendations on prophylaxis reflect guidelines agreed by UK malaria specialists; the advice is aimed at residents of the UK who travel to endemic areas. The choice of drug for a particular individual should take into account:

- risk of exposure to malaria
- extent of drug resistance
- efficacy of the recommended drugs
- side-effects of the drugs
- patient-related factors (e.g. age, pregnancy, renal or hepatic impairment, compliance with prophylactic regimen)

Protection against bites

Prophylaxis is not absolute, and breakthrough infection can occur with any of the drugs recommended. Personal protection against being bitten is very important. Mosquito nets impregnated with permethrin p. 1015 provide the most effective barrier protection against insects; mats and vapourised insecticides are also useful. Diethyltoluamide (DEET) 20–50% in lotions, sprays, or roll-on formulations is safe and effective when applied to the skin of adults and children over 2 months of age. It can also be used during pregnancy and breast-feeding. The duration of protection varies according to the concentration of DEET and is longest for DEET 50%. When sunscreen is also required, DEET should be applied after the sunscreen. Long sleeves and trousers worn after dusk also provide protection against bites.

Length of prophylaxis

In order to determine tolerance and to establish habit, prophylaxis should generally be started one week (2–3 weeks in the case of mefloquine p. 537) before travel into an endemic area; Malarone® or doxycycline p. 496 prophylaxis should be started 1–2 days before travel. Prophylaxis should be continued for 4 weeks after leaving (except for Malarone® prophylaxis which should be stopped 1 week after leaving).

In those requiring long-term prophylaxis, chloroquine p. 536 and proguanil hydrochloride p. 539 may be used for periods of over 5 years. Mefloquine is licensed for up to 1 year (although, if it is tolerated in the short term, there is no evidence of harm when it is used for up to 3 years). Doxycycline can be used for up to 2 years. Malarone® can be used for up to 1 year. Prophylaxis with mefloquine, doxycycline, or Malarone® may be considered for longer durations if it is justified by the risk of exposure to malaria. Specialist advice should be sought for long-term prophylaxis.

Return from malarial region

It is important to be aware that any illness that occurs within 1 year and especially within 3 months of return might be malaria even if all recommended precautions against malaria were taken. Travellers should be warned of this and told that if they develop any illness particularly within 3 months of their return they should go immediately to a doctor and specifically mention their exposure to malaria.

Epilepsy

Both chloroquine p. 536 and mefloquine are unsuitable for malaria prophylaxis in individuals with a history of epilepsy. In areas without chloroquine resistance proguanil alone is recommended; in areas with chloroquine resistance, doxycycline or Malarone® may be considered.
Asplenia
Asplenic individuals (or those with severe splenic dysfunction) are at particular risk of severe malaria. If travel to malarious areas is unavoidable, rigorous precautions are required against contracting the disease.

Renal impairment
Avoidance (or dosage reduction) of proguanil hydrochloride p. 539 is recommended since it is excreted by the kidneys. Malarone® should not be used for prophylaxis in patients with estimated glomerular filtration rate less than 30 mL/minute/1.73m². Chloroquine p. 536 is only partially excreted by the kidneys and reduction of the dose for prophylaxis is not required except in severe impairment. Mefloquine is considered to be appropriate to use in renal impairment and does not require dosage reduction. Doxycycline is also considered to be appropriate.

Pregnancy
Travel to malarious areas should be avoided during pregnancy; if travel is unavoidable, effective prophylaxis must be used. Chloroquine and proguanil hydrochloride can be given in the usual doses during pregnancy, but these drugs are not appropriate for most areas because their effectiveness has declined, particularly in Sub-Saharan Africa; in the case of proguanil hydrochloride, folic acid p. 836 (dosed as a pregnancy at ‘high-risk’ of neural tube defects) should be given for at least the first trimester. The centres listed (see Malaria, treatment below) should be consulted for advice on prophylaxis in chloroquine-resistant areas. Although the manufacturer advises that mefloquine should not be used during pregnancy, particularly in the first trimester, unless the potential benefit outweighs the risk, studies of mefloquine in pregnancy (including use in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas. Doxycycline p. 496 is contra-indicated during pregnancy; however, it can be used for malaria prophylaxis if other regimens are unsuitable, and if the entire course of doxycycline can be completed before 15 weeks’ gestation [unlicensed]. Malarone® should be avoided during pregnancy, however, it can be considered during the second and third trimesters if there is no suitable alternative.

Breast-feeding
Prophylaxis is required in breast-fed infants; although antimalarials are present in milk, the amounts are too variable to give reliable protection.

Anticoagulants
Travellers taking warfarin sodium p. 121 should begin chemoprophyaxis 2–3 weeks before departure. The INR should be stable before departure. It should be measured before starting chemoprophyaxis, 7 days after starting, and after completing the course. For prolonged stays, the INR should be checked at regular intervals.

Standby treatment
Travellers visiting remote, malarious areas for prolonged periods should carry standby treatment if they are likely to be more than 24 hours away from medical care. Self-medication should be avoided if medical help is accessible. In order to avoid excessive self-medication, the traveller should be provided with written instructions that urgent medical attention should be sought if fever (38°C or more) develops 7 days (or more) after arriving in a malarious area and that self-treatment is indicated if medical help is not available within 24 hours of fever onset. In view of the continuing emergence of resistant strains and of the different regimens required for different areas expert advice should be sought on the best treatment course for an individual traveller. A drug used for chemoprophyaxis should not be considered for standby treatment for the same traveller.

Specific recommendations
Where a journey requires two regimens, the regimen for the higher risk area should be used for the whole journey. Those travelling to remote or little-visited areas may require expert advice. See also Recommended regimens for prophylaxis against malaria p. 530

Important
Settled immigrants (or long-term visitors) to the UK may be unaware that any immunity they may have acquired while living in malarious areas is lost rapidly after migration to the UK, or that any non-malarious areas where they lived previously may now be malarious.

Malaria, treatment
A number of specialist centres are able to provide advice on specific problems.

Advice for healthcare professionals
PHE (Public Health England) Malaria Reference Laboratory (020) 7637 0248 (fax) (prophylaxis only) www.malaria-reference.co.uk

National Travel Health Network and Centre 0845 602 6712
Travel Medicine Team, Health Protection Scotland (registered users of Travax only) www.travax.nhs.uk (for registered users of the NHS Travax website only) (0141) 300 1100 (weekdays 2–4 p.m. only)
Birmingham (0121) 424 03587
Liverpool (0151) 705 3100
London 0845 155 5000 (treatment)
Oxford (01865) 225 430

Advice for travellers
Hospital for Tropical Diseases Travel Healthline (020) 7950 7799 www.fitfortravel.nhs.uk
WHO advice on international travel and health www.who.int/ith
National Travel Health Network and Centre (NaTHNaC) www.nathnac.org/travel/index.htm

Treatment of malaria
Recommendations on the treatment of malaria reflect guidelines agreed by UK malaria specialists.
If the infective species is not known, or if the infection is mixed, initial treatment should be as for falciparum malaria with quinine p. 540, Malarone® (atovaquone with proguanil hydrochloride p. 536), or Riamet® (artemether with lumefantrine p. 534). Falciparum malaria can progress rapidly in unprotected individuals and antimalarial treatment should be considered in those with features of severe malaria and possible exposure, even if the initial blood tests for the organism are negative.

Falciparum malaria (treatment)
Falciparum malaria (malignant malaria) is caused by Plasmodium falciparum. In most parts of the world P. falciparum is now resistant to chloroquine p. 536 which should not therefore be given for treatment.
Quinine, Malarone® (atovaquone with proguanil hydrochloride p. 536), or Riamet® (artemether with lumefantrine) can be given by mouth if the patient can swallow and retain tablets and there are no serious manifestations (e.g. impaired consciousness); quinine should be given by intravenous infusion if the patient is seriously ill or unable to take tablets. Mefloquine p. 537 is now rarely used for treatment because of concerns about resistance.
Oral quinine is given by mouth for 5–7 days, together with or followed by either doxycycline p. 496 for 7 days or
**Key to recommended regimens for prophylaxis against malaria**

<table>
<thead>
<tr>
<th>Codes for regimens</th>
<th>Details of regimens for prophylaxis against malaria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chemoprophylaxis not recommended, but avoid mosquito bites and consider malaria if fever presents</td>
</tr>
<tr>
<td>2</td>
<td>Chloroquine only</td>
</tr>
<tr>
<td>3</td>
<td>Chloroquine with proguanil</td>
</tr>
<tr>
<td>4</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline or mefloquine</td>
</tr>
<tr>
<td>5</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline</td>
</tr>
</tbody>
</table>

**Specific recommendations**

<table>
<thead>
<tr>
<th>Country</th>
<th>Comments on risk of malaria and regional or seasonal variation</th>
<th>Codes for regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>Risk below 2000 m from May–November</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low risk below 2000 m from December–April</td>
<td>1</td>
</tr>
<tr>
<td>Algeria</td>
<td>Very low risk in Illizi department only</td>
<td>1</td>
</tr>
<tr>
<td>Andaman and Nicobar Islands (India)</td>
<td>Risk present</td>
<td>1</td>
</tr>
<tr>
<td>Angola</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Argentina</td>
<td>Low risk in low altitude areas of Salta provinces bordering Bolivia and in Chaco, Corrientes, and Misiones provinces close to border with Paraguay and Brazil</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in Iguazu Falls and areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Armenia</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>Low to no risk</td>
<td>1</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>High risk in Chittagong Hill Tract districts (but not Chittagong city)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in Chittagong city and other areas, except Chittagong Hill Tract districts</td>
<td>1</td>
</tr>
<tr>
<td>Belize</td>
<td>Low risk in rural areas</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in Belize district (including Belize city and islands)</td>
<td>1</td>
</tr>
<tr>
<td>Benin</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Bhutan</td>
<td>Risk in southern belt districts, along border with India: Chukha, Geyleg-phug, Samchi, Samdrup Jonkar, and Shemgang</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Bolivia</td>
<td>High risk in Amazon basin</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Risk in rural areas below 2500 m (other than above)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk above 2500 m</td>
<td>1</td>
</tr>
<tr>
<td>Botswana</td>
<td>High risk from November–June in northern half, including Okavango Delta area</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low risk from July–October in northern half; low to no risk all year in southern half</td>
<td>1</td>
</tr>
<tr>
<td>Brazil</td>
<td>Risk in Amazon basin, including city of Manaus</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above, and no risk in Iguazu Falls</td>
<td>1</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>Very low risk</td>
<td>1</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Burundi</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Cambodia</td>
<td>High risk, with widespread chloroquine and mefloquine resistance, in western provinces bordering Thailand</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>High risk in areas other than those above and below</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Angkor Wat and Lake Tonle Sap, including Siem Reap; no risk in Phnom Penh</td>
<td>1</td>
</tr>
<tr>
<td>Cameroon</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>Very low risk on island of Santiago (Sao Tiago) and Boa Vista</td>
<td>1</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Chad</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>China</td>
<td>High risk in Yunnan and Hainan provinces</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above and below</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>No risk in Hong Kong</td>
<td>1</td>
</tr>
<tr>
<td>Colombia</td>
<td>High risk in rural areas below 1600 m</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low to no risk above 1600 m and in Cartagena</td>
<td>1</td>
</tr>
<tr>
<td>Country</td>
<td>Comments on risk of malaria and regional or seasonal variation</td>
<td>Codes for regimens</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Comoros</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Congo</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>Risk in Limon province (but not city of Limon)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Cote d’Ivoire (Ivory Coast)</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Djibouti</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>Risk in all areas except cities of Santiago and Santo Domingo</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Cities of Santiago and Santo Domingo</td>
<td>1</td>
</tr>
<tr>
<td>East Timor (Timor-Leste)</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Ecuador</td>
<td>Risk in areas below 1500 m including coastal provinces and Amazon basin (no risk in Galapagos islands or city of Guayaquil)</td>
<td>4</td>
</tr>
<tr>
<td>Egypt</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>El Salvador</td>
<td>Low risk in rural areas of Santa Ana, Ahuachapán, and La Unión provinces in western part of country; low to no risk in other areas</td>
<td>1</td>
</tr>
<tr>
<td>Equatorial Guinea</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Eritrea</td>
<td>High risk below 2200 m</td>
<td>4</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>High risk below 2000 m</td>
<td>4</td>
</tr>
<tr>
<td>French Guiana</td>
<td>High risk (particularly in border areas) except city of Cayenne or Devil’s Island (Ile du Diable)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>No risk in city of Cayenne or Devil’s Island (Ile du Diable)</td>
<td>1</td>
</tr>
<tr>
<td>Gabon</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Gambia</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Georgia</td>
<td>Very low risk in rural south east from June–October</td>
<td>1</td>
</tr>
<tr>
<td>Ghana</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Guatemala</td>
<td>Low risk below 1500 m</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in Guatemala City, Antigua, or Lake Atitlan</td>
<td>–</td>
</tr>
<tr>
<td>Guinea</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Guyana</td>
<td>High risk in all interior regions</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Georgetown and coastal region</td>
<td>1</td>
</tr>
<tr>
<td>Haiti</td>
<td>Risk present</td>
<td>2</td>
</tr>
<tr>
<td>Honduras</td>
<td>Risk below 1000 m and in Roatán and other Bay Islands (no risk in San Pedro Sula or Tegucigalpa)</td>
<td>2</td>
</tr>
<tr>
<td>India</td>
<td>High risk in states of Assam and Orissa, districts of East Godavari, Srikakulam, Vishakhapatnam, and Vizianagaram in the state of Andhra Pradesh, and districts of Balaghat, Dindori, Mandla, and Seoni in the state of Madhya Pradesh</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Risk in areas other than those above or below (including Goa, Andaman and Nicobar islands)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>No risk in Lakshadweep islands</td>
<td>–</td>
</tr>
<tr>
<td>Indonesia</td>
<td>High risk in Lombok and Irian Jaya (Papua)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Risk in areas other than those above or below</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Bali, and cities on islands of Java and Sumatra</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>No risk in city of Jakarta</td>
<td>–</td>
</tr>
<tr>
<td>Indonesia (Borneo)</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Iran</td>
<td>Risk from March–November in rural south eastern provinces and in north, along Azerbaijain border in Ardabil, and near Turkmenistan border in North Khorasan</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Iraq</td>
<td>Very low risk from May–November in rural northern area below 1500 m</td>
<td>1</td>
</tr>
<tr>
<td>Kenya</td>
<td>High risk below 2500 m (except city of Nairobi)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in the highlands above 2500 m and in city of Nairobi</td>
<td>1</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>Very low risk from June–October in southwest areas bordering Tajikistan and Uzbekistan</td>
<td>1</td>
</tr>
</tbody>
</table>
## Key to recommended regimens for prophylaxis against malaria

<table>
<thead>
<tr>
<th>Codes for regimens</th>
<th>Details of regimens for prophylaxis against malaria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chemoprophylaxis not recommended, but avoid mosquito bites and consider malaria if fever presents</td>
</tr>
<tr>
<td>2</td>
<td>Chloroquine only</td>
</tr>
<tr>
<td>3</td>
<td>Chloroquine with proguanil</td>
</tr>
<tr>
<td>4</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline or mefloquine</td>
</tr>
<tr>
<td>5</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline</td>
</tr>
</tbody>
</table>

## Specific recommendations

<table>
<thead>
<tr>
<th>Country</th>
<th>Comments on risk of malaria and regional or seasonal variation</th>
<th>Codes for regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laos</td>
<td>High risk along the border with Myanmar in the provinces of Bokeo and Louang Namtha, and along the border with Thailand in the province of Champasak and Saravan</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>High risk in areas other than those above or below</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in city of Vientiane</td>
<td>1</td>
</tr>
<tr>
<td>Liberia</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Libya</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>Madagascar</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Malawi</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Malaysia</td>
<td>Risk in inland forested areas of peninsular Malaysia</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in rest of peninsular Malaysia, including Cameron Highlands and city of Kuala Lumpur</td>
<td>1</td>
</tr>
<tr>
<td>Malaysia (Borneo)</td>
<td>High risk in inland areas of eastern Sabah and in inland, forested areas of Sarawak</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above, including coastal areas of Sabah and Sarawak</td>
<td>1</td>
</tr>
<tr>
<td>Mali</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Mauritania</td>
<td>High risk all year in southern provinces, and from July-October in the north</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low risk from November-June in north</td>
<td>1</td>
</tr>
<tr>
<td>Mauritius</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>Mayotte</td>
<td>Risk present</td>
<td>4</td>
</tr>
<tr>
<td>Mexico</td>
<td>Low risk in Oaxaca and Chiapas</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Mozambique</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Myanmar</td>
<td>High risk (but not in cities of Mandalay and Yangon)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>No risk in cities of Mandalay and Yangon</td>
<td>1</td>
</tr>
<tr>
<td>Namibia</td>
<td>High risk all year in regions of Caprivi Strip, Kavango, and Kunene river, and from November-June in northern third of country</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in areas other than those above; low risk from July-October in northern third of country</td>
<td>1</td>
</tr>
<tr>
<td>Nepal</td>
<td>Risk below 1500 m, particularly in Terai district</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>No risk in city of Kathmandu and on typical Himalayan treks</td>
<td>1</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>Low risk (except Managua)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Managua</td>
<td>1</td>
</tr>
<tr>
<td>Niger</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Nigeria</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>North Korea</td>
<td>Very low risk in some southern areas</td>
<td>1</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Risk below 2000 m</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low to no risk above 2000 m</td>
<td>1</td>
</tr>
<tr>
<td>Panama</td>
<td>Risk east of Canal Zone</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low risk west of Canal Zone</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in Panama City or Canal Zone itself</td>
<td>1</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>High risk below 1800 m</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low to no risk above 1800 m</td>
<td>1</td>
</tr>
<tr>
<td>Paraguay</td>
<td>Low risk in departments of Alto Paranà and Caaguazu</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Country</td>
<td>Comments on risk of malaria and regional or seasonal variation</td>
<td>Codes for regimens</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Peru</td>
<td>High risk in Amazon basin along border with Brazil, particularly in Loreto province. Risk in rural areas below 2000 m (other than those above and below) and in part of the Amazon basin that borders Bolivia. No risk in city of Lima and coastal region south of Chiclayo.</td>
<td>4</td>
</tr>
<tr>
<td>Philippines</td>
<td>Risk in rural areas below 600 m and on islands of Luzon, Mindanao, Mindoro, and Palawan. No risk in cities or on islands of Boracay, Bohol, Catanduanes, Cebu, or Leyte.</td>
<td>3</td>
</tr>
<tr>
<td>Rwanda</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>São Tomé and Príncipe</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>Risk in south-western provinces along border with Yemen, including below 2000 m in Asir province. No risk in cities of Jeddah, Makkah (Mecca), Medina, Riyadh, or Ta‘il, or above 2000 m in Asir province.</td>
<td>3</td>
</tr>
<tr>
<td>Senegal</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Somalia</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>South Africa</td>
<td>Moderate risk from September–May in low altitude areas of Mpumalanga and Limpopo, which border Mozambique and Zimbabwe (including Kruger National Park). Low risk in north-east KwaZulu-Natal. Low risk in areas bordering those above.</td>
<td>4</td>
</tr>
<tr>
<td>South Korea</td>
<td>Very low risk in northern areas, in Gangwon-do and Gyeonggi-do provinces, and Incheon city (towards Demilitarized Zone).</td>
<td>1</td>
</tr>
<tr>
<td>South Sudan</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>Low risk north of Vavuniya. Very low risk in areas other than those above and below. No risk in Colombo or Kandy.</td>
<td>1</td>
</tr>
<tr>
<td>Sudan</td>
<td>High risk in central and southern areas; risk also present in rest of country (except Khartoum). Very low risk in Khartoum.</td>
<td>4</td>
</tr>
<tr>
<td>Suriname</td>
<td>High risk (except coastal districts or city of Paramaribo). Very low risk in coastal districts; no risk in city of Paramaribo.</td>
<td>4</td>
</tr>
<tr>
<td>Swaziland</td>
<td>High risk in northern and eastern regions bordering Mozambique and South Africa, including all of Lubombo district and Big Bend, Mhlupe, Simunye, and Tshaneni regions. Very low risk in the areas other than those above.</td>
<td>4</td>
</tr>
<tr>
<td>Syria</td>
<td>Very low risk in small, remote foci of El Hasakah.</td>
<td>1</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>Risk below 2000 m from June–October. Low risk below 2000 m from November–May.</td>
<td>3</td>
</tr>
<tr>
<td>Tanzania</td>
<td>High risk below 1800 m; risk also in Zanzibar.</td>
<td>4</td>
</tr>
<tr>
<td>Thailand</td>
<td>High risk, with chloroquine and mefloquine resistance, in rural forested borders with Cambodia, Laos, and Myanmar. Very low risk in areas other than those above, including Kanchanaburi (Kwai Bridge); no risk in cities of Bangkok, Chiang Mai, Chiang Rai, Koh Phang, Koh Samui, and Pattaya.</td>
<td>5</td>
</tr>
<tr>
<td>Togo</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Turkey</td>
<td>Low risk from May–October along the border plain with Syria, around Adana and east of Adana. Very low risk from November–April along the border plain with Syria, around Adana and east of Adana; very low risk all year in rest of country.</td>
<td>2</td>
</tr>
<tr>
<td>Uganda</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>Very low risk in extreme south-east.</td>
<td>1</td>
</tr>
<tr>
<td>Vanuatu</td>
<td>Risk present</td>
<td>4</td>
</tr>
<tr>
<td>Venezuela</td>
<td>High risk in all areas south of, and including, the Orinoco river and Angel Falls. Risk in rural areas of Apure, Monagas, Sucre, and Zulia states.</td>
<td>4</td>
</tr>
<tr>
<td>No risk in city of Caracas or on Margarita Island</td>
<td></td>
<td>3</td>
</tr>
</tbody>
</table>
Infection

clindamycin p. 467 for 7 days [unlicensed].

If the parasite is likely to be sensitive, pyrimethamine with sulfadoxine p. 540 as a single dose [unlicensed] may be given (instead of either clindamycin p. 467 or doxycycline p. 496) together with, or after, a course of quinine. Alternatively, Malarone® or Riamet® may be given instead of quinine. It is not necessary to give clindamycin, doxycycline, or pyrimethamine with sulfadoxine after Malarone® or Riamet® treatment.

If the patient is seriously ill or unable to take tablets, or if more than 2% of red blood cell are parasitized, quinine should be given by intravenous infusion [unlicensed] (until patient can swallow tablets to complete the 7-day course together with or followed by either doxycycline p. 496 or clindamycin p. 467).

Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine p. 540, infection acquired in quinine-resistant areas of south east Asia) because intravenous artesunate may be available for ‘named-patient’ use.

Pregnancy

Falciparum malaria is particularly dangerous in pregnancy, especially in the last trimester. The adult treatment doses or oral and intravenous quinine (including the loading dose) can safely be given to pregnant women. Clindamycin should be given after quinine [unlicensed indication]. Doxycycline should be avoided in pregnancy (affects teeth and skeletal development); pyrimethamine with sulfadoxine, Malarone®, and Riamet® are also best avoided until more information is available. Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine, infection acquired in quinine-resistant areas of south east Asia) because intravenous artesunate may be available for ‘named patient’ use.

Non-falciparum malaria (treatment)

Non-falciparum malaria is usually caused by Plasmodium vivax and less commonly by P. ovale and P. malariae. P. knowlesi is also present in the Asia-Pacific region. Chloroquine p. 536 is the drug of choice for the treatment of non-falciparum malaria but chloroquine-resistant P. vivax has been reported in the Indonesian archipelago, the Malay Peninsula, including Myanmar, and eastward to Southern Vietnam). For the treatment of chloroquine-resistant non-falciparum malaria, Malarone® [unlicensed indication], quinine, or Riamet® [unlicensed indication] can be used; as with chloroquine p. 536, primaquine p. 538 should be given for radical cure.

Chloroquine p. 536 alone is adequate for P. malariae and P. knowlesi infections but in the case of P. vivax and P. ovale, a radical cure (to destroy parasites in the liver and thus prevent relapses) is required. This is achieved with primaquine p. 538 [unlicensed] given after chloroquine, with the dose dependent on the infecting organism. For a radical cure, primaquine [unlicensed] is then given for 14 days, with the dose also dependent on the infecting organism.

Parenteral

Parenteral If the patient is unable to take oral therapy, quinine p. 540 can be given by intravenous infusion [unlicensed], changed to oral chloroquine p. 536 as soon as the patient’s condition permits.

Pregnancy

The adult treatment doses of chloroquine p. 536 can be given for non-falciparum malaria. In the case of P. vivax or P. ovale, however, the radical cure with primaquine p. 538 should be postponed until the pregnancy is over; instead chloroquine p. 536 should be continued, given weekly during the pregnancy.

Artemether with lumefantrine

INDICATIONS AND DOSE

Treatment of acute uncomplicated falciparum malaria | Treatment of chloroquine-resistant non-falciparum malaria

BY MOUTH

Adult (body-weight 35 kg and above): Initially 4 tablets, followed by 4 tablets for 5 doses each given at 8, 24, 36, 48, and 60 hours (total 24 tablets over 60 hours)
Artemether with piperaquine phosphate (Piperquine tetraphosphate with dihydroartemisinin)

**INDICATIONS AND DOSE**

Treatment of uncomplicated falciparum malaria

**BY MOUTH**

- Child 6 months-17 years (body-weight 7-12 kg): 0.5 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course
- Child 6 months-17 years (body-weight 13-23 kg): 1 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course
- Child 6 months-17 years (body-weight 24-35 kg): 2 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course
- Child 6 months-17 years (body-weight 36-74 kg): 3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course
- Adult (body-weight 36-74 kg): 3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course
- Adult (body-weight 75 kg and over): 4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain - anorexia - arthralgia - asthma - cough - diarrhea - dizziness - headache - myalgia - nausea - palpitation - paraesthesia - prolonged QT interval - pruritus - rash - sleep disturbances - vomiting
- **Uncommon** Ataxia - clonus - hypoaesthesia

**PREGNANCY** Toxicity in animal studies with artemether. Manufacturer advises use only if potential benefit outweighs risk.

**CONTRA-INDICATIONS**

- Acute myocardial infarction - bradycardia - congenital long QT syndrome - electrolyte disturbances - family history of sudden death - heart failure with reduced left ventricular ejection fraction - history of symptomatic arrhythmias - left ventricular hypertrophy - risk factors for QT interval prolongation - severe hypertension

**INTERACTIONS**

- Avoid in Acute porphyrias p. 864 - electrolyte disturbances
- Monitor patients unable to take food (greater risk of recrudescence).
- Manufacturer advises caution in breastfeeding for at least 3 week after last dose. Present in milk in animal studies.
- Manufacturer advises use only if potential benefit outweighs risk.
- Manufacturer advises monitor ECG and plasma-potassium concentration.
- Monitor patients unable to take food (greater risk of recrudescence).
- Tablets may be crushed just before administration.
- Dizziness may affect performance of skilled tasks (e.g. driving).
- There is no information available in moderate to severe impairment.
- Thrombocytopenia (in children) - vomiting (in children)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- Riamet (Novartis Pharmaceuticals UK Ltd)
- Artemether 20 mg, Lumefantrine 120 mg
- Riamet tablets | 24 tablet £22.50

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain - anorexia - arthralgia - asthma - cough - diarrhea - dizziness - headache - myalgia - nausea - palpitation - paraesthesia - prolonged QT interval - pruritus - rash - sleep disturbances - vomiting
- **Uncommon** Ataxia - clonus - hypoaesthesia

**MEDICATIONS**

- No information available in moderate to severe impairment.
- Manufacturer advises monitor ECG and plasma-potassium concentration in moderate to severe hepatic impairment.

**MONITORING REQUIREMENTS**

- Obtain ECG as soon as possible after starting treatment then continue monitoring in those taking medicines that increase plasma-piperaquine concentration, in children who are vomiting, in females, or in the elderly.
- Consider obtaining ECG in all patients before third dose and 4–6 hours after third dose.
- If QTc interval more than 500 milliseconds, discontinue treatment and monitor ECG for a further 24–48 hours.

**DIRECTIONS FOR ADMINISTRATION**

- Tablets to be taken at least 3 hours before and at least 3 hours after food.
- Tablets may be crushed and mixed with water immediately before administration.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer tablets containing piperaquine phosphate with arteminol.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
**Indications and Dose**

**Malarone®**

Prophylaxis of falciparum malaria, particularly where resistance to other antimalarial drugs suspected

**By mouth**

- Adult (body-weight 40 kg and above): 1 tablet daily, to be started 1–2 days before entering endemic area and continued for 1 week after leaving

**Treatment of acute uncomplicated falciparum malaria**

**By mouth**

- Adult (body-weight 11–20 kg): 1 tablet once daily for 3 days
- Adult (body-weight 21–30 kg): 2 tablets once daily for 3 days
- Adult (body-weight 31–40 kg): 3 tablets once daily for 3 days
- Adult (body-weight 41 kg and above): 4 tablets once daily for 3 days

**Atovaquone with proguanil hydrochloride**

**Tablet**

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atovaquone 250 mg, Proguanil hydrochloride 100 mg</td>
</tr>
<tr>
<td>Malarone (GlaxoSmithKline UK Ltd)</td>
</tr>
<tr>
<td>Atovaquone 250 mg, Proguanil hydrochloride 100 mg</td>
</tr>
<tr>
<td>Brands may include Reprapog</td>
</tr>
</tbody>
</table>

**Side-effects**

- **Common or very common** Abdominal pain, abnormal dreams, anorexia, cough, depression, diarrhea, dizziness, fever, headache, insomnia, nausea, pruritus, rash, vomiting
- **Uncommon** Anxiety, blood disorders, hair loss, hypotension, palpitation, stomatitis
- **Frequency not known** Cholestasis, hallucinations, hepatitis, mouth ulcers, photosensitivity, seizures, Stevens-Johnson syndrome, tachycardia, vasculitis

**Pregnancy**

Manufacturer advises avoid unless essential.

**Breast-feeding**

Use only if no suitable alternative available.

**Renal Impairment**

Avoid for malaria prophylaxis (and if possible for malaria treatment) if eGFR less than 30 mL/minute/1.73m².

**Patient and Carer Advice**

Warn travellers about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return.

**National Funding/Access Decisions**

NHS restrictions Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials prescribed.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Chloroquine**

**Indications and Dose**

Active rheumatoid arthritis (administered on expert advice) | Systemic and discoid lupus erythematosus (administered on expert advice)

**By mouth**

- Adult: 150 mg daily; maximum 2.5 mg/kg per day

**Prophylaxis of Malaria**

**Initially by mouth using syrup**

- Child 6 weeks–5 months (body-weight 4.5–8 kg): 50 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
- Child 6–11 months (body-weight 8–11 kg): 75 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
- Child 1–2 years (body-weight 11–15 kg): 100 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
- Child 3–4 years (body-weight 15–16.5 kg): 125 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
- Child 4–7 years (body-weight 16.5–25 kg): 150 mg once weekly, alternatively (by mouth using tablets) 155 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
- Child 8–12 years (body-weight 25–45 kg): 225 mg once weekly, alternatively (by mouth using tablets) 232.5 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
- Child 13–17 years (body-weight 45 kg and above): 310 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
- Adult (body-weight 45 kg and above): 310 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving

**Treatment of non-falciparum malaria**

**By mouth**

- Child: Initially 10 mg/kg (max. per dose 620 mg), then 5 mg/kg after 6–8 hours (max. per dose 310 mg), then 5 mg/kg daily (max. per dose 310 mg) for 2 days
- Adult: Initially 620 mg, then 310 mg after 6–8 hours, then 310 mg daily for 2 days, approximate total cumulative dose of 25 mg/kg of base

**P. vivax or P. ovale infection during pregnancy while radical cure is postponed**

**By mouth**

- Adult: 310 mg once weekly

**Doses at extremes of body-weight**

In active rheumatoid arthritis and systemic and discoid lupus erythematosus, to avoid excessive dosage in obese patients, the daily maximum dose should be calculated on the basis of ideal body weight.

**Dose equivalence and conversion**

Doses expressed as chloroquine base. Chloroquine base 150 mg = chloroquine sulfate 200 mg = chloroquine phosphate 250 mg (approx).
**UNLICENSED USE** Chloroquine doses for the treatment and prophylaxis of malaria in BNF publications may differ from those in product literature.

**Important safety information**

Ocular toxicity is unlikely if the adult dose of chloroquine phosphate does not exceed 4 mg/kg daily (equivalent to chloroquine base approx. 2.5 mg/kg daily).

**CAUTIONS** Acute porphyrias p. 864 - elderly - G6PD deficiency - long-term therapy (regular ophthalmic examination recommended by manufacturers) - may aggravate myasthenia gravis - may exacerbate psoriasis - neurological disorders, especially epilepsy (avoid for prophylaxis of malaria if history of epilepsy) - severe gastro-intestinal disorders

**CAUTIONS, FURTHER INFORMATION**

Screening for ocular toxicity A review group convened by the Royal College of Ophthalmologists has updated guidelines for screening adults to prevent ocular toxicity on long-term treatment with chloroquine and hydroxychloroquine (Hydroxychloroquine and Ocular Toxicity: Recommendations on Screening 2009).

Chloroquine should be considered (for treating chronic inflammatory conditions) only if other drugs have failed. All patients taking chloroquine should receive oculcar examination according to a protocol arranged locally between the prescriber and the ophthalmologist.

**INTERACTIONS** → Appendix 1 (chloroquine, hydroxychloroquine).

Avoid concurrent therapy with hepatotoxic drugs.

**SIDE-EFFECTS**

- **Common or very common** Gastro-intestinal disturbances • headache • pruritus • rashes • skin reactions
- **Uncommon** Convulsions • discoloration of mucous membranes • discoloration of nails • discoloration of skin • ECG changes • hyperpigmentation • hair loss • keratopathy • otoxicity • retinal damage • visual changes
- **Rare** Acute generalised exanthematous pustulosis • agranulocytosis • angioedema • aplastic anaemia • blood disorders • bone marrow suppression • cardiomyopathy • emotional disturbances • exfoliative dermatitis • hepatic damage • hypersensitivity reactions • mental changes • myopathy • neuromyopathy • photosensitivity • psychosis • Stevens-Johnson syndrome • thrombocytopenia • urticaria
- **Frequency not known** Diffuse parenchymal lung disease • drug rash with eosinophilia and systemic symptoms • extrapyramidal symptoms (associated with use in malaria) • hypotension • visual disturbances • bronchospasm (in children)

**SIDE-EFFECTS, FURTHER INFORMATION**

**Malaria prophylaxis and treatment** Serious skin reactions, ECG changes, visual effects, otoxicity, blood disorders, mental changes, myopathies and hepatic damage are not usually associated with malaria prophylaxis or treatment.

**Overdose** Chloroquine is very toxic in overdosage; overdosage is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).

**PREGNANCY** Benefit of use in prophylaxis and treatment in malaria outweighs risk. For rheumatoid disease, it is not necessary to withdraw an antimalarial drug during pregnancy if the disease is well controlled.

**BREAST FEEDING** Present in breast milk and breast-feeding should be avoided when used to treat rheumatic disease. Amount in milk probably too small to be harmful when used for malaria.

**HEPATIC IMPAIRMENT** Use with caution in moderate to severe impairment.

**RENAL IMPAIRMENT** Only partially excreted by the kidneys and reduction of the dose is not required for prophylaxis of malaria except in severe impairment. For rheumatoid arthritis and lupus erythematosus, reduce dose. Manufacturers advise caution.

**MONITORING REQUIREMENTS**

- in adults Manufacturers recommend regular ophthalmological examination but the evidence of practical value is unsatisfactory.
- in children Ophthalmic examination with long-term therapy.

**PATIENT AND CARER ADVICE** Warn travellers going to malarious areas about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NHS restrictions** Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials are prescribed.

**EXCEPTIONS TO LEGAL CATEGORY** Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 5

- **Avloclor** (Alliance Pharmaceuticals Ltd)
  - Chloroquine phosphate 250 mg Avloclor 250mg tablets | 20 tablet (50) £4.90 DT price = £4.90

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS** 5

- **Malarivon** (Wallace Manufacturing Chemists Ltd)
  - Chloroquine phosphate 16 mg per 1 ml Malarivon 80mg/5ml syrup | 75 ml (50) £10.85

**Chloroquine with proguanil**

The properties listed below are those particular to the combination only. For the properties of the components please consider, proguanil hydrochloride p. 539, chloroquine p. 536.

**INDICATIONS AND DOSE**

**Prophylaxis of malaria**

**BY MOUTH**

- **Adult:** (consult product literature)

**EXCEPTIONS TO LEGAL CATEGORY** Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablets**

**CAUTIONARY AND ADVISORY LABELS** 5, 21

- **CHLOROQUINE WITH PROGUANIL** (Non-proprietary)
  - Paludrine/Avloclor tablets anti-malarial travel pack | 112 tablet (50) £11.75

**Mefloquine**

**INDICATIONS AND DOSE**

**Treatment of malaria**

**BY MOUTH**

- **Adult:** (consult product literature) continued →
Protozoal infection

Prophylaxis of malaria

BY MOUTH

- Child (body-weight 5-15 kg): 62.5 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving.
- Child (body-weight 16–24 kg): 125 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving.
- Child (body-weight 25–44 kg): 187.5 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving.
- Child 1–17 years (body-weight 45 kg and above): 250 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving.
- Adult (body-weight 45 kg and above): 250 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving.

**UNLICENSED USE** Melquine doses in BNF Publications may differ from those in product literature. Not licensed for use in children under 5 kg body-weight and under 3 months.

**CONTRA-INDICATIONS** Avoid for prophylaxis if history of psychiatric disorders (including depression) or convulsions. Avoid for standby treatment if history of convulsions - history of blackwater fever.

**CAUTIONS** Cardiac conduction disorders - epilepsy (avoid for prophylaxis) - not recommended in infants under 3 months (5 kg) - traumatic brain injury.

**CAUTIONS, FURTHER INFORMATION**

**Neuropsychiatric reactions** Melquine is associated with potentially serious neuropsychiatric reactions. Abnormal dreams, insomnia, anxiety, and depression occur commonly. Psychosis, suicidal ideation, and suicide have also been reported. Psychiatric symptoms such as nightmares, acute anxiety, depression, restlessness, or confusion should be regarded as potentially prodromal for a more serious event. If neuropsychiatric symptoms occur, patients should be advised to discontinue melquine and to seek immediate medical attention so that melquine can be replaced with an alternative antimalarial. Adverse reactions may occur and persist up to several months after discontinuation because melquine has a long half-life. Melquine is contraindicated for malaria prophylaxis in those with a history of psychiatric disorders or convulsions.

**INTERACTIONS** → Appendix 1 (melquine).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain - diarrhea - dizziness - headache - nausea - neuropsychiatric reactions - pruritus - visual disturbances - vomiting.
- **Very rare** Optic neuropathy.

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with hypersensitivity to quinine.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during prophylaxis and for 4 months after stopping (teratogenicity in animal studies).

**PREGNANCY** Manufacturer advises avoid (particularly in the first trimester) unless the potential benefit outweighs the risk; however, studies of melquine in pregnancy (including use in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas.

**BREAST FEEDING** Present in milk but risk to infant minimal.

**HEPATIC IMPAIRMENT** Elimination may be prolonged; avoid in severe impairment.

**RENNAL IMPAIRMENT** Manufacturer advises caution.

**DIRECTIONS FOR ADMINISTRATION** Tablet may be crushed and mixed with food such as jam or honey just before administration.

**PATIENT AND CARER ADVICE** Inform travellers about adverse reactions of melquine and, if they occur, to seek medical advice on alternative antimalarials before the next dose is due. Also warn travellers about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return. Dizziness or a disturbed sense of balance may affect performance of skilled tasks (e.g. driving); effects may occur and persist up to several months after stopping melquine.

**NATIONAL FUNDING/ACCESS DECISIONS** NHS restrictions Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>Lariam (Roche Products Ltd)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melquine (as Melquine hydrochloride) 250 mg</td>
<td>Lariam 250 mg tablets</td>
</tr>
</tbody>
</table>

**Primquine**

**INDICATIONS AND DOSE**

Adjunct in the treatment of non-falciparum malaria caused by *P. vivax* infection

**BY MOUTH**

- Adult: 30 mg daily for 14 days

Adjunct in the treatment of non-falciparum malaria caused by *P. ovale* infection

**BY MOUTH**

- Adult: 15 mg daily for 14 days

Adjunct in the treatment of non-falciparum malaria caused by *P. vivax* infection in patients with mild G6PD deficiency (administered on expert advice)

Adjunct in the treatment of non-falciparum malaria caused by *P. ovale* infection in patients with mild G6PD deficiency (administered on expert advice)

**BY MOUTH**

- Adult: 45 mg once weekly for 8 weeks

Treatment of mild to moderate pneumocystis infection (in combination with clindamycin)

**BY MOUTH**

- Adult: 30 mg daily, this combination is associated with considerable toxicity

**UNLICENSED USE** Not licensed.

**CAUTIONS** G6PD deficiency - systemic diseases associated with granulocytopenia (e.g. juvenile idiopathic arthritis, rheumatoid arthritis, lupus erythematosus)

**INTERACTIONS** → Appendix 1 (primquine).
Primaquine (as Primaquine phosphate) 7.5 mg tablets | 100 tablet no price available

Pyrimethamine

INDICATIONS AND DOSE
Toxoplasmosis in pregnancy (in combination with sulfadiazine and folic acid)

BY MOUTH
Adult: 50 mg once daily until delivery

Congenital toxoplasmosis (in combination with sulfadiazine and folic acid)

BY MOUTH
Adult 18-28 years: 1 mg/kg twice daily for 2 days, then 1 mg/kg once daily for 5 months, then 1 mg/kg 3 times a week for 6 months

Malaria
Adult: No dose stated because not recommended alone

SIDE-EFFECTS
Common or very common Anaemia (with high doses) - blood disorders (with high doses) - diarrhoea - dizziness - headache - leucopenia (with high doses) - nausea - rash - thrombocytopenia (with high doses) - vomiting

UNLICENSED USE
Proguanil doses in BNF Publications may differ from those in product literature.

INTERACTIONS
Appendix 1 (pyrimethamine).

References:
...
540 Protozoal infection

**MONITORING REQUIREMENTS** Blood counts required with prolonged treatment.

**LESS SUITABLE FOR PRESCRIBING** Pyrimethamine should not be used alone for malaria, but is used with sulfadoxine.

**INTERACTIONS**

**CONTRA-INDICATIONS**

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- **Daraprim (GlaxoSmithKline UK Ltd)**
  - Pyrimethamine 25 mg Daraprim 25mg tablets | 30 tablet £13.00

**CONTRASTIVE USE**

**SIDE-EFFECTS**

**Dose equivalence and conversion**

Dose quantities are expressed in the form x/y where x and y are the strengths in milligrams of pyrimethamine and sulfadoxine respectively.

**SIDE-EFFECTS, FURTHER INFORMATION**

Discontinue immediately if blood disorders or rash occur. Discontinue if cough or shortness of breath occur.

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with sulfonamide allergy.

**PREGNANCY** Possible teratogenic risk in first trimester (pyrimethamine a folate antagonist); in third trimester—risk of neonatal haemolysis and methaemoglobinemia. Fear of increased risk of kernicterus in neonates appears to be unfounded.

**BREAST FEEDING** Small risk of kernicterus in jaundiced infants; risk of haemolysis in G6PD-deficient infants (due to sulfadoxine).

**MONITORING REQUIREMENTS** Monitor blood counts on prolonged treatment.

**PATIENT AND CARER ADVICE** Patients should be advised to maintain adequate fluid intake.

**QUININE**

**INDICATIONS AND DOSE**

Nocturnal leg cramps

**BY MOUTH**

- Adult: 200–300 mg once daily, to be taken at bedtime

**Non-falciparum malaria**

**BY INTRAVENOUS INFUSION**

- Adult: 10 mg/kg every 8 hours (max. per dose 700 mg), infused over 4 hours, given if patient is unable to take oral therapy. Changed to oral chloroquine as soon as the patient’s condition permits

**Falciparum malaria**

**BY MOUTH**

- Child: 10 mg/kg every 8 hours (max. per dose 600 mg) for 7 days together with or followed by either clindamycin or, in children over 12 years, doxycycline
- Adult: 600 mg every 8 hours for 5–7 days, the quinine should be given together with or followed by either doxycycline or clindamycin

**Falciparum malaria (in intensive care unit)**

**BY INTRAVENOUS INFUSION**

- Adult: Loading dose 20 mg/kg (max. per dose 1.4 g), infused over 4 hours, the loading dose of 20 mg/kg should not be used if the patient has received quinine or mefloquine during the previous 12 hours, then maintenance 10 mg/kg every 8 hours (max. per dose 700 mg) until patient can swallow tablets to complete the 7-day course, to be given 8 hours after the start of the loading dose and infused over 4 hours, the quinine should be given together with or followed by either doxycycline or clindamycin

**Dose equivalence and conversion**

When using quinine for malaria, doses are valid for quinine hydrochloride, dihydrochloride, and sulfate; they are not valid for quinine bisulfate which contains a correspondingly smaller amount of quinine.

Quinine (anhydrous base) 100 mg = quinine bisulfate 169 mg; quinine dihydrochloride 122 mg; quinine hydrochloride 122 mg; and quinine sulfate 121 mg. Quinine bisulfate 300 mg tablets are available but provide less quinine than 300 mg of the dihydrochloride, hydrochloride, or sulfate.
6 Viral infection

6.1 Hepatitis

Hepatitis

Treatment for viral hepatitis should be initiated by a specialist. The management of uncomplicated acute viral hepatitis is largely symptomatic. Early treatment of acute hepatitis C with interferon alfa p. 794 [unlicensed indication] may reduce the risk of chronic infection. Hepatitis B and hepatitis C viruses are major causes of chronic hepatitis. Active or passive immunisation against hepatitis A and B infections can be given.

Hepatitis B, chronic

Peginterferon alfa p. 542 is an option for the initial treatment of chronic hepatitis B and may be preferable to interferon alfa. The use of peginterferon alfa and interferon alfa is limited by a response rate of 30–40% and relapse is frequent. Treatment should be discontinued if no improvement occurs after 4 months. The manufacturers of peginterferon alfa-2a and interferon alfa contraindicate use in decompensated liver disease, but low doses can be used with great caution in these patients. Although interferon alfa is contra-indicated in patients receiving immunosuppressant treatment (or who have received it recently), cautious use of peginterferon alfa-2a may be justified in some cases.

Entecavir p. 543 or tenofovir disoproxil p. 564 are options for the initial treatment of chronic hepatitis B. If the response is inadequate after 6–9 months of treatment, a change in treatment should be considered. Other drugs that are licensed for the treatment of chronic hepatitis B include adefovir dipivoxil p. 544, lamivudine p. 563, or telbivudine p. 544.

Entecavir p. 543 alone, tenofovir disoproxil p. 564 alone, or a combination of lamivudine with either adefovir dipivoxil or tenofovir disoproxil can be used in patients with decompensated liver disease.

If drug-resistant hepatitis B virus emerges during treatment, another antiviral drug to which the virus is sensitive should be added. Hepatitis B viruses with reduced susceptibility to lamivudine have emerged following extended therapy. Adefovir dipivoxil or tenofovir disoproxil can be given with lamivudine in lamivudine-resistant chronic hepatitis B; telbivudine p. 544 or entecavir p. 543 should not be used because cross-resistance can occur. If there is no toxicity or loss in efficacy, treatment with adefovir dipivoxil, entecavir, lamivudine, telbivudine, or tenofovir disoproxil is usually continued until 6 months after adequate seroconversion has occurred. Treatment is usually continued long-term in patients with decompensated liver disease.

Tenofovir disoproxil, or a combination of tenofovir disoproxil with either emtricitabine p. 563 or lamivudine may be used with other antiretrovirals, as part of ‘highly active antiretroviral therapy’ in patients who require treatment for both HIV and chronic hepatitis B. If patients infected with both HIV and chronic hepatitis B only require treatment for chronic hepatitis B, they should receive antivirals that are not active against HIV, such as peginterferon alfa p. 542 or adefovir dipivoxil. Treatment may be continued long-term, even if adequate seroconversion occurs. Management of these patients should be coordinated between HIV and hepatology specialists.

Hepatitis C, chronic

Before starting treatment, the genotype of the infecting hepatitis C virus should be determined and the viral load
measured as this may affect the choice and duration of treatment. A combination of ribavirin p. 545 and peginterferon alfa below is used for the treatment of chronic hepatitis C. The combination of ribavirin and interferon alfa is less effective than the combination of peginterferon alfa and ribavirin. Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Ribavirin monotherapy is ineffective.

Boceprevir p. 547 and telaprevir p. 548 are protease inhibitors that inhibit the replication of hepatitis C virus genotype 1, but they are less effective against other genotypes of the virus. Monotherapy is not recommended because there is a high likelihood of resistance developing. Either boceprevir or telaprevir is licensed for use in combination with ribavirin and peginterferon alfa for the treatment of chronic hepatitis C infection of genotype 1 in patients with compensated liver disease; these combinations are more effective than dual therapy with ribavirin and peginterferon alfa. However, triple therapy is associated with a higher incidence and greater severity of anaemia than dual therapy. Neutropenia seems to be more frequent during treatment with regimens containing boceprevir than with those containing telaprevir. Rash is a particular concern with telaprevir, and to a lesser extent with boceprevir.

Daclatasvir p. 544 is licensed for use in combination with sofosbuvir p. 546 for the treatment of chronic hepatitis C infection of genotypes 1 or 4, with or without compensated cirrhosis; the addition of ribavirin should be considered for patients with advanced liver disease or with other negative prognostic factors, such as prior treatment experience. It is also licensed in combination with sofosbuvir and ribavirin for the treatment of chronic hepatitis C infection of genotype 3 in patients who are treatment experienced, with or without compensated cirrhosis, and in combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C infection of genotype 4. Daclatasvir p. 544 must not be given as monotherapy. Sofosbuvir is a pro-drug of a nucleoside inhibitor that is effective against hepatitis C virus polymerase NS5B. It is licensed for use in combination with ribavirin, with or without peginterferon alfa, for the treatment of chronic hepatitis C infection of genotypes 1, 2, 3, 4, 5, or 6 in patients with compensated liver disease. Sofosbuvir monotherapy is not recommended because it is less effective than combination therapy.

Simeprevir p. 548 is licensed for use in combination with ribavirin and peginterferon alfa for the treatment of chronic hepatitis C infection of genotype 1 or 4; regimens containing peginterferon alfa-2b are less effective than those containing peginterferon alfa-2a. Simeprevir may also be used in combination with sofosbuvir, with or without ribavirin p. 545, for the urgent treatment of chronic hepatitis C infection of genotypes 1 or 4 only when peginterferon alfa cannot be used because of intolerance or contra-indications. Simeprevir monotherapy is not recommended.

6.2 Hepatitis B, chronic

INTERFERONS

Peginterferon alfa

- **Drug Action** Polyethylene glycol-conjugated (‘pegylated’) derivatives of interferon alfa (peginterferon alfa-2a and peginterferon alfa-2b) are available; pegylation increases the persistence of the interferon in the blood.

**INDICATIONS AND DOSE**

PEGASYS®

Combined with ribavirin for chronic hepatitis C | Monotherapy for chronic hepatitis C if ribavirin not tolerated or contra-indicated | Monotherapy for chronic hepatitis B

BY SUBCUTANEOUS INJECTION

- Adults: (consult product literature)

VIRAFERON peg®

Combined with ribavirin for chronic hepatitis C | Combined with ribavirin and boceprevir for chronic hepatitis C infection of genotype 1 in patients with compensated liver disease | Monotherapy for chronic hepatitis C if ribavirin not tolerated or contra-indicated

BY SUBCUTANEOUS INJECTION

- Adults: (consult product literature)

- **CONTRA-INDICATIONS** For contra-indications consult product literature.
- **CAUTIONS** For cautions consult product literature.
- **INTERACTIONS** → Appendix 1 (interferons).
- **SIDE-EFFECTS**
  - **Common or very common** Anorexia, diarrhoea, influenza-like symptoms, lethargy, nausea.
  - **Frequency not known** Alopecia, arthralgia, cardiovascular problems, coma (usually with high doses in the elderly), confusion, depression, hepatotoxicity, hyperglycaemia, hypertension, hypertriglyceridaemia (sometimes severe), hypotension, myelosuppression (particularly affecting granulocyte counts), nephrotoxicity, ocular side-effects, palpitation, psoriasiform rash, seizures (usually with high doses in the elderly), suicidal behaviour, thyroid abnormalities

**SIDE-EFFECTS, FURTHER INFORMATION**

For information on side effects consult product literature.

**CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment—consult product literature.

**PREGNANCY** Manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in animal studies).

**BREAST FEEDING** Manufacturers advise avoid—no information available.

**HEPATIC IMPAIRMENT** Avoid in severe impairment. Close monitoring required in mild to moderate hepatic impairment.

**RENAL IMPAIRMENT** Reduce dose in moderate to severe impairment. For information on peginterferon alfa use in renal impairment consult product literature. Close monitoring required in renal impairment.

**MONITORING REQUIREMENTS** Monitoring of lipid concentration is recommended.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

- Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010) NICE TA200
  - The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (‘watchful waiting’). Peginterferon alfa alone can be used if ribavirin is contra-indicated or not tolerated. www.nice.org.uk/TA200
- Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010) NICE TA200
  - The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years:
  - not previously treated with interferon alfa or peginterferon alfa;
Entecavir

**INDICATIONS AND DOSE**

Chronic hepatitis B in patients with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis) not previously treated with nucleoside analogues

**BY MOUTH**

- Adult: 500 micrograms once daily

**SIDE-EFFECTS**

- Alopecia
- Diarrhoea
- Fatigue
- Headache
- Nausea
- Raised serum amylase
- Raised serum lipase
- Sleep disturbances
- Vomiting

**CAUTIONS, FURTHER INFORMATION**

Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.

**NATIONAL FUNDING/ACCESS DECISIONS**

Entecavir is an option for the treatment of chronic hepatitis B. www.nice.org.uk/TA153

Entecavir is an option for the treatment of chronic hepatitis B (August 2008) NICE TA153

Entecavir is an option for the treatment of chronic hepatitis B. www.nice.org.uk/TA153

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**EXCIPIENTS:** May contain Benzyl alcohol

- Peginterferon alfa.2a 180 microgram per 1 ml Pegasis 90 micrograms/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSD) £76.51
- Peginterferon alfa.2a 270 microgram per 1 ml Pegasis 135 micrograms/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSD) £107.76
- Peginterferon alfa.2a 360 microgram per 1 ml Pegasis 180 micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (PSD) £497.60
- Pegasis 180 micrograms/0.5ml solution for injection pre-filled pen | 4 pre-filled disposable injection (PSD) £497.60

- Peginterferon Peg.2b 50 microgram Viraferon Peg 50 microgram powder and solvent for solution for injection pre-filled disposable devices | 1 least pre-filled disposable injection (PLS) £66.46
- Viraferon Peg 50 microgram powder and solvent for solution for injection pre-filled disposable devices CLEARCLICK | 1 pre-filled disposable injection (PSD) £106.34
- Viraferon Peg 80 microgram powder and solvent for solution for injection pre-filled disposable devices CLEARCLICK | 1 pre-filled disposable injection (PSD) £106.34
- Viraferon Peg 100 microgram powder and solvent for solution for injection pre-filled disposable devices CLEARCLICK | 1 pre-filled disposable injection (PSD) £132.92
- Viraferon Peg 120 microgram powder and solvent for solution for injection pre-filled disposable devices CLEARCLICK | 1 pre-filled disposable injection (PSD) £139.38
- Viraferon Peg 150 microgram powder and solvent for solution for injection pre-filled disposable devices CLEARCLICK | 1 pre-filled disposable injection (PSD) £199.38

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Baraclude (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Entecavir (as Entecavir monohydrate) 0.5 microgram Baraclude 0.5mg tablets | 30 tablet (PT) £63.26
  - Entecavir (as Entecavir monohydrate) 1 mg Baraclude 1mg tablets | 30 table (PT) £63.26

**Oral solution**

- Baraclude (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Entecavir (as Entecavir monohydrate) 50 microgram per 1 ml Baraclude 0.05mg/ml oral solution (sugar-free) | 210 ml (PSO) £423.80

**NUCLEOSIDE ANALOGUES**

Entecavir

**INDICATIONS AND DOSE**

Chronic hepatitis B in patients with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis) not previously treated with nucleoside analogues

**BY MOUTH**

- Adult: 1 mg once daily, consider other treatment if inadequate response after 6 months

Chronic hepatitis B in patients with decompensated liver disease

**BY MOUTH**

- Adult: 1 mg once daily
Telbivudine

**INDICATIONS AND DOSE**
Chronic hepatitis B infection with compensated liver disease, evidence of viral replication, and histologically documented active liver inflammation or fibrosis, when other treatment is not appropriate

**BY MOUTH**
- Adult: 600 mg once daily

- **CAUTIONS**
  - Lamivudine-resistant chronic hepatitis B—risk of telbivudine resistance

- **CAUTIONS, FURTHER INFORMATION**
  - Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.

- **INTERACTIONS**
  - Appendix 1 (telbivudine).

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · cough · diarrhea · dizziness · fatigue · headache · nausea · raised serum amylase · raised serum lipase · rash
  - **Uncommon** Arthralgia · myalgia · myopathy (discontinue treatment) · peripheral neuropathy · taste disturbance
  - **Rare** Lactic acidosis · rhabdomyolysis

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING**
  - Manufacturer advises avoid—present in milk in animal studies.

- **RENAL IMPAIRMENT**
  - 600 mg every 48 hours if eGFR 30–49 mL/minute/1.73 m²; 600 mg every 72 hours if eGFR less than 30 mL/minute/1.73 m²

- **MONITORING REQUIREMENTS**
  - Monitor liver function tests every 3 months and viral markers of hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

- **PATIENT AND CARER ADVICE**
  - Muscle effects and peripheral neuropathy
  - Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, or numbness, tingling or burning sensations.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - NICE technology appraisals (TAs)
    - Telbivudine for chronic hepatitis B (August 2008) NICE TA154
    - Telbivudine is not recommended for the treatment of chronic hepatitis B. Patients currently receiving telbivudine can continue treatment until they and their clinician consider it appropriate to stop. [www.nice.org.uk/TA154](http://www.nice.org.uk/TA154)

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - Hepsera (Gilead Sciences International Ltd)
    - Telbivudine 600 mg Hepsera 600mg tablets | 28 tablet [Pres] £290.33

Nucleotide Analogue

**Adefovir dipivoxil**

**INDICATIONS AND DOSE**
Chronic hepatitis B infection with either compensated liver disease with evidence of viral replication, and histologically documented active liver inflammation and fibrosis, when other treatment not appropriate or decompensated liver disease in combination with another antiviral for chronic hepatitis B that has no cross-resistance to adefovir

**BY MOUTH**
- Adult: 10 mg once daily

- **CAUTIONS**
  - Elderly
  - Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.

  - **SIDE-EFFECTS**
    - Abdominal pain · asthenia · diarrhea · dyspepsia · flatulence · headache · hypophosphataemia · nausea · pancreatitis · pruritus · rash · renal failure · vomiting

  - **CONCEPTION AND CONTRACEPTION**
    - Effective contraception required during treatment.

  - **PREGNANCY**
    - Toxicity in animal studies—manufacturer advises use only if potential benefit outweighs risk.

  - **BREAST FEEDING**
    - Manufacturer advises avoid—no information available.

  - **RENAL IMPAIRMENT**
    - 10 mg every 48 hours if eGFR 30–50 mL/minute/1.73 m²; 10 mg every 72 hours if eGFR 10–30 mL/minute/1.73 m²

  - **MONITORING REQUIREMENTS**
    - Monitor liver function tests every 3 months, and viral markers for hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

    - Monitor renal function before treatment then every 3 months during treatment and discontinuation.

    - **MONITORING REQUIREMENTS**
      - Monitor liver function tests every 3 months, and viral markers for hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

    - **MONITORING REQUIREMENTS**
      - Monitor renal function before treatment then every 3 months, more frequently in patients receiving nephrotoxic drugs.

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

  - **Tablet**
    - Hepsera (Gilead Sciences International Ltd)
      - Adefovir dipivoxil 10 mg Hepsera 10mg tablets | 30 tablet [Pres] £252.22

6.3 Hepatitis C, chronic

**Non-structural protein 5a inhibitors**

**Daclatasvir**

- **DRUG ACTION**
  - Daclatasvir is an inhibitor of the multifunctional protein NS5A, which is an essential component of the hepatitis C virus replication process.

- **INDICATIONS AND DOSE**
  - In combination with sofosbuvir for the treatment of chronic hepatitis C infection of genotypes 1 or 4, with or without compensated cirrhosis
  - In combination with sofosbuvir and ribavirin for the treatment of chronic hepatitis C infection of genotype 3 in patients who are treatment experienced, with or without compensated cirrhosis
  - In combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C infection of genotype 4

- **BY MOUTH**
  - Adult: Usual dose 60 mg once daily (for duration of treatment consult product literature)

  - **Dose adjustments due to interactions**
    - Reduce dose to 30 mg once daily with concomitant use of potent CYP3A4 inhibitors (e.g. atazanavir boosted with ritonavir, boceprevir, clarithromycin, cobicistat, itraconazole, ketoconazole, posaconazole, telaprevir, telithromycin, and voriconazole).
    - Increase dose to 90 mg once daily with concomitant use of moderate CYP3A4 inducers (e.g. efavirenz).
**Ribavirin (Tribavirin)**

**INDICATIONS AND DOSE**

**COPEGUS® TABLETS**

Chronic hepatitis C (in combination with direct acting antivirals, or interferon alfa 2a, or peginterferon alfa 2a with or without direct acting antivirals)

**BY MOUTH**

- Adult (body-weight up to 74 kg): 400 mg, dose to be taken in the morning and 600 mg, dose to be taken in the evening
- Adult (body-weight 75 kg and above): 600 mg twice daily

Chronic hepatitis C (in combination with peginterferon alfa 2b with or without direct acting antivirals)

**BY MOUTH**

- Adult (body-weight up to 64 kg): 400 mg twice daily
- Adult (body-weight 65-80 kg): 400 mg, to be taken in the morning and 600 mg, to be taken in the evening
- Adult (body-weight 81-105 kg): 600 mg twice daily
- Adult (body-weight 106 kg and above): 600 mg, to be taken in the morning and 800 mg, to be taken in the evening

**SIDE-EFFECTS**

**Common or very common** Abdominal pain, alopecia, anaemia, anxiety, arthralgia, blurred vision, constipation, cough, decreased appetite, depression, diarrhoea, disturbance in attention, dizziness, dry mouth, dry skin, dyspnoea, flatulence, gastro-oesophageal reflux, headache, hot flush, insomnia, irritability, lymphopenia, malaise, migraine, myalgia, nasal congestion, nausea, neutropenia, pruritus, pyrexia, rash, reduced visual acuity, vomiting.

**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects listed are reported when daclatasvir is used in combination with sofosbuvir with or without ribavirin or with ribavirin and peginterferon alfa.

**CONCEPTION AND CONTRACEPTION**

Highly effective contraception required during and for 5 weeks after treatment.

**PREGNANCY**

Manufacturer advises avoid (toxicity in animal studies).

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**PATIENT AND CARER ADVICE**

Missed doses: If a dose is more than 2 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. May affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 25

- Daklinza (Bristol-Myers Squibb Pharmaceuticals Ltd)
- Daclatasvir (as Daclatasvir dihydrochloride) 30 mg Daklinza 30mg tablets | 28 tablet (P08) £8.172.61
- Daclatasvir (as Daclatasvir dihydrochloride) 60 mg Daklinza 60mg tablets | 28 tablet (P08) £8.172.61

**NUCLEOSIDE ANALOGUES**

**Ribavirin**

**INDICATIONS AND DOSE**

**COPEGUS® TABLETS**

Chronic hepatitis C genotype 2 or 3 (not previously treated), or patients infected with HIV and hepatitis C (in combination with peginterferon alfa)

**BY MOUTH**

- Adult: Usual dose 400 mg twice daily

**REBETOL® CAPSULES**

Chronic hepatitis C (in combination with interferon alfa 2b, or peginterferon alfa 2b with or without boceprevir)

**BY MOUTH**

- Adult (body-weight up to 64 kg): 400 mg twice daily
- Adult (body-weight 65-80 kg): 400 mg, dose to be given in the morning and 600 mg, dose to be given in the evening
- Adult (body-weight 81-104 kg): 600 mg twice daily
- Adult (body-weight 105 kg and above): 600 mg, dose to be given in the morning and 800 mg, dose to be given in the evening

**REBETOL® ORAL SOLUTION**

Chronic hepatitis C (in combination with interferon alfa or peginterferon alfa)

**BY MOUTH**

- Adult (body-weight up to 64 kg): 400 mg twice daily
- Adult (body-weight 65-80 kg): 400 mg daily, dose to be given in the morning and 600 mg daily, dose to be given in the evening
- Adult (body-weight 81-104 kg): 600 mg twice daily
- Adult (body-weight 105 kg and above): 600 mg daily, dose to be given in the morning and 800 mg daily, dose to be given in the evening

**CONTRA-INDICATIONS**

Consult product literature for specific contra-indications when ribavirin used in combination with other medicinal products.

**CAUTIONS**

Anaemia (haemoglobin concentration should be monitored during the treatment and corrective action taken) - cardiac disease (assessment including ECG recommended before and during treatment—discontinue if deterioration) - consult product literature for specific cautions when ribavirin used in combination with other medicinal products - gout - haemolysis (haemoglobin concentration should be monitored during the treatment and corrective action taken) - patients with a transplant—risk of rejection - severe dental disorders - severe ocular disorders - severe periodontal disorders - severe psychiatric effects.

**INTERACTIONS**

Appendix 1 (ribavirin).

**SIDE-EFFECTS**

Abdominal pain, abnormal dreams, acne, alopecia, angina, anorexia, anxiety, aplastic anaemia, arthralgias, ataxia, bacterial disorders, breast pain, cardiomyopathy, cerebral haemorrhage, cerebral ischaemia, changes in blood pressure, cholelithiasis, chest pain, colitis, constipation, cough, dehydration, diabetes, diarrhoea, dizziness, dry eyes, dry mouth, dry skin, dyspepsia, dysphagia, dysphonia, earache, endocarditis, eye pain, flatulence, flushing, gastro-intestinal bleeding, gingival bleeding, gingivitis, glossitis, haemolytic anaemia (anaemia may be improved by epoprostenol), headache, hearing impairment, hearing loss, hyperaesthesia, hyperglycaemia, hyperkinesia, hyperventilation, hypertonia, hypertriglyceridaemia, hyperuricaemia, hypoaesthesia, hypocalcaemia, impaired concentration and memory, increased sweating, influenza-like symptoms, interstitial pneumonitis, leucopenia, lymphadenopathy, malaise, mania, menstrual disturbance, micturition disorders, mouth ulcers, musculoskeletal pain, myalgia, myocardial infarction, myositis, nasal congestion, nausea, neutropenia, optic neuropathy, oral candidiasis, palpititation, pancreatitis, —
paraesthesia • peptic ulcer • pericarditis • peripheral neuropathy • peripheral oedema • photosensitivity • prostatitis • pruritus • psoriasis • psychotic disorders • pulmonary embolism • rash • renal failure • respiratory infections • retinal detachment • retinal haemorrhage • rhombomylia • rheumatoid arthritis • sarcoidosis • seizures • sexual dysfunction • sinus congestion • skin discoloration • sleep disturbances • sore throat • Stevens-Johnson syndrome • stomatitis • suicidal ideation (more frequent in children) • syncope • systemic lupus erythematosus • tachycardia • taste disturbance • thrombocytopenia • thrombocytopenia purpura • thyroid disorders • tinnitus • tongue pigmentation • toxic epidermal necrolysis • tremor • urinary tract infections • vacuities • vision loss • visual disturbances • vomiting • weight loss • wheezing

SIDE-EFFECTS, FURTHER INFORMATION

Side-effects listed are reported when oral ribavirin is used in combination with peginterferon alfa or interferon alfa, consult product literature for details.

- CONCEPTION AND CONTRACEPTION
  Exclude pregnancy before treatment in females of childbearing age. Effective contraception essential during treatment and for 4 months after treatment in females and for 7 months after treatment in males of childbearing age. Routine monthly pregnancy tests recommended. Condoms must be used if partner of male patient is pregnant (ribavirin excreted in semen).

- PREGNANCY
  Avoid; teratogenicity in animal studies.

- BREAST FEEDING
  Avoid—no information available.

- HEPATIC IMPAIRMENT
  No dosage adjustment required. Avoid oral ribavirin in severe hepatic dysfunction or decompensated cirrhosis.

- RENAL IMPAIRMENT
  Plasma-ribavirin concentration increased.

  Manufacturer advises avoid oral ribavirin unless essential if eGFR less than 50 ml/minute/1.73 m²—monitor haemoglobin concentration closely.

- MONITORING REQUIREMENTS
  Determine full blood count, platelets, electrolytes, glucose, serum creatinine, liver function tests and uric acid before starting treatment and then on weeks 2 and 4 of treatment, then as indicated clinically—adjust dose if adverse reactions or laboratory abnormalities develop (consult product literature).

- PRESCRIBING AND DISPENSING INFORMATION
  Flavours of oral liquid formulations may include bubble-gum.

- NATIONAL FUNDING/ACCESS DECISIONS

  NICE technology appraisals (Tas)
  - Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa. www.nice.org.uk/TA200

  - MEDICINAL FORMS
    There can be variation in the licensing of different medicines containing the same drug.

    **Tablet**
    **CAUTIONARY AND ADVISORY LABELS 21**
    - RIBAVIRIN (Non-proprietary)
      Ribavirin 200 mg Ribavirin 200mg tablets | 42 tablet Pk £92.50 | 112 tablet Pk £246.65-£246.65 | 168 tablet Pk £369.98
      Ribavirin 400 mg Copegus 400mg tablets | 56 tablet Pk £246.65

    **Capsule**
    **CAUTIONARY AND ADVISORY LABELS 21**
    - RIBAVIRIN (Non-proprietary)
      Ribavirin 200 mg Ribavirin 200mg capsules | 84 capsule Pk £160.69 | 140 capsule Pk £267.81 | 168 capsule Pk £321.38
      Ribavirin 400 mg Copegus 400mg capsules | 56 capsule Pk £246.65

    **Oral solution**
    **CAUTIONARY AND ADVISORY LABELS 21**
    - RiboCprep (Merck Sharp & Dohme Ltd)
      Ribavirin 40 mg per 1 ml RiboCprep 40mg/ml oral solution | 100 ml Pk £57.08

  NUCLEOTIDE ANALOGUES

  **Sofosbuvir**

  **INDICATIONS AND DOSE**
  In combination with ribavirin (Copegus®), with or without peginterferon alfa, for chronic hepatitis C infection of genotypes 1, 3, 4, 5, or 6 in patients with compensated liver disease | In combination with ribavirin (Copegus®) for chronic hepatitis C infection of genotype 2 in patients with compensated liver disease | In combination with daclatasvir for chronic hepatitis C infection of genotype 1, 3, or 4

  **BY MOUTH**

  - Adult: 400 mg once daily, for duration of treatment consult product literature

  **CAUTIONS, FURTHER INFORMATION**
  In chronic hepatitis C of genotype 1, 4, 5, or 6, only use sofosbuvir with ribavirin in those with intolerance or contra-indications to peginterferon alfa who require urgent treatment.

  **INTERACTIONS** → Appendix 1 (sofosbuvir).

  **SIDE-EFFECTS** Abdominal discomfort • agitation • alopecia • anaemia • anxiety • arthralgia • asthma • blurred vision • chest pain • constipation • cough • decreased appetite • depression • diarrhoea • disturbance in attention • dizziness • dry mouth • dyspnoea • gastro-oesophageal reflux • headache • influenza-like symptoms • insomnia • irritability • memory impairment • migraine • myalgia • nausea • neutropenia • rash • vomiting • weight loss

  **SIDE-EFFECTS, FURTHER INFORMATION**
  Side-effects listed are reported when sofosbuvir is used in combination with ribavirin or with ribavirin and peginterferon alfa

  **PREGNANCY** Manufacturer advises avoid.

  **BREAST FEEDING** Manufacturer advises avoid—metabolites present in milk in animal studies.
Hepatitis C, chronic

547

RENAL IMPAIRMENT Safety and efficacy not established if eGFR less than 30 mL/minute/1.73 m²—accumulation may occur.

PRESCRIBING AND DISPENSING INFORMATION Dispense in original container (contains desiccant).

PATIENT AND CARER ADVICE Missed doses If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Sofosbuvir for treating chronic hepatitis C (February 2015) NICE TA330

Sofosbuvir in combination with peginterferon alfa and ribavirin is an option for treating adults with chronic hepatitis C infection:
- of genotype 1
- of genotype 3 with cirrhosis (treatment naive patients)
- of genotype 3 that has not adequately responded to interferon-based treatment
- of genotype 4, 5, or 6 with cirrhosis

Sofosbuvir in combination with ribavirin is an option for treating adults with chronic hepatitis C infection:
- of genotype 2 who are intolerant to or ineligible for interferon (treatment naive patients)
- of genotype 2 that has not adequately responded to interferon-based treatment
- of genotype 3 with cirrhosis who are intolerant to or ineligible for interferon (treatment naive patients)
- of genotype 3 that has not adequately responded to interferon-based treatment

Sofosbuvir in combination with ribavirin is not recommended for the treatment of adults with chronic hepatitis C infection of genotypes 1, 4, 5, or 6. www.nice.org.uk/TA330

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2014) that sofosbuvir (Sovaldi®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis C infection of genotypes 1 to 6; its use in combination with ribavirin as dual therapy for chronic hepatitis C infection of either genotype 2 (in treatment naive patients) or genotype 3 is restricted to those who cannot use peginterferon alfa because of intolerance or contra-indications.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Table CAUTIONARY AND ADVISORY LABELS 21, 25

Sofosbuvir 400 mg Sovaldi 400mg tablets | 28 tablet £11.660.98

PROTEASE INHIBITORS (HEPATITIS)

Boceprevir

INDICATIONS AND DOSE Chronic hepatitis C infection of genotype 1 in patients with compensated liver disease

BY MOUTH
- Adult: 800 mg 3 times a day, for duration of treatment consult product literature

CONTRA-INDICATIONS Autoimmune hepatitis
CAUTIONS Coagulopathy hypoalbuminaemia low platelets predisposition to QT interval prolongation

CAUTIONS, FURTHER INFORMATION

Low platelets, hypoalbuminaemia, or coagulopathy Not recommended in patients with low platelets, hypoalbuminaemia, or coagulopathy—if initiated in these patients monitor closely for signs of infection, worsening liver impairment and anaemia (increased risk of severe morbidity and mortality).

INTERACTIONS Appendix 1 (boceprevir). Caution with concomitant use of other drugs known to prolong QT interval.

SIDE-EFFECTS

Common or very common Abdominal pain agitation alopecia amnesia anaemia anxiety arthralgia asthenia blood pressure changes changes in libido constipation cough decreased appetite depression diarrhoea disturbances in smell disturbances in taste dizziness dry eyes dry mouth dysphagia erectile dysfunction flatulence gastro-oesophageal reflux haemorrhoids headache hyperglycaemia hyperhidrosis hyperglycaemia hyperuricaemia hyperkalaemia hypothyroidism influenza-like symptoms insomnia leucopenia mouth ulcers muscle spasms myalgia nausea palpitation pancytopenia paraesthesia peripheral oedema polyuria pruritus psoriasis rash stomatitis syncope thrombocytopenia tinnitus tooth disorder tremor visual disturbances vomiting weight loss

Uncommon Amenorrhoea arrhythmias colitis conjunctival haemorrhage dysphagia dysphonia dysuria eye pain flushing gingivitis gout hearing impairment homicidal ideation hyperaesthesia hyperbilirubinaemia hypercalcaemia hypercalciuria hypokalaemia increased lacrimation menorrhagia pallor pancreatitis photophobia photosensitivity retinal ischaemia retinopathy skin ulceration suicidal ideation tongue discoloration venous thromboembolism

Rare Acute myocardial infarction aspergillosis bipolar disorder cholecytitis coronary artery disease encephalopathy hallucinations pericarditis pleural effusion respiratory failure sarcoidosis thyroid neoplasms

Frequency not known Rash with eosinophilia and systemic symptoms Stevens-Johnson syndrome}

SIDE-EFFECTS, FURTHER INFORMATION Side-effects listed are reported when boceprevir is used in combination with ribavirin and peginterferon alfa

PREGNANCY Manufacturer advises avoid.

BREAST FEEDING Manufacturer advises avoid; present in milk in animal studies.

MONITORING REQUIREMENTS Monitor full blood count before starting treatment and then on weeks 2, 4, 8, and 12 of treatment, then as indicated clinically.

PATIENT AND CARER ADVICE Missed doses If a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Boceprevir for chronic hepatitis C infection of genotype 1 (April 2012) NICE TA253

Boceprevir in combination with ribavirin and peginterferon alfa is an option for the treatment of chronic hepatitis C infection of genotype 1 in adults with compensated liver disease:
- who have not been treated previously;
- in whom previous treatment (e.g. with peginterferon alfa in combination with ribavirin) has failed. www.nice.org.uk/TA253
Simeprevir

**INDICATIONS AND DOSE**

In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 or 4. In combination with sofosbuvir (with or without ribavirin) for urgent treatment of chronic hepatitis C infection of genotype 1 or 4 when peginterferon alfa cannot be used because of intolerance or contra-indications.

**BY MOUTH**

- Adult: 150 mg once daily (for duration of treatment consult product literature).

**CAUTIONS**

Consider alternative treatment in presence of NS3 Q80K polymorphism—efficacy of simeprevir is reduced. Patients of East Asian origin.

**INTERACTIONS**

Appendix 1 (simeprevir).

**SIDE-EFFECTS**

Contipation, dyspnoea, fatigue (in combination with sofosbuvir), headache (in combination with sofosbuvir), insomnia (in combination with sofosbuvir), nausea, photoaenstivity, pruritus, raised bilirubin concentration. Rash

**SIDE-EFFECTS, FURTHER INFORMATION**

Rash. Monitor for deterioration if mild or moderate; discontinue if severe.

**CONCEPTION AND CONTRACEPTION**

Effective contraception essential during treatment.

**PREGNANCY**

Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid—present in plasma of breast-fed animals.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution in moderate to severe impairment—elimination reduced in severe impairment. Manufacturer advises caution in decompensated cirrhosis—elimination reduced in severe impairment.

**RENAL IMPAIRMENT**

Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m²—elimination may be reduced.

**PRE-TREATMENT SCREENING**

Test for NS3 Q80K polymorphism before combination treatment with ribavirin and peginterferon alfa in patients with chronic hepatitis C infection of genotype 1a. Consider testing for NS3 Q80K polymorphism before combination treatment with sofosbuvir (with or without ribavirin) in patients with chronic hepatitis C infection of genotype 1a.

**PATIENT AND CARER ADVICE**

Missed doses. If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (February 2015) NICE TA331

Simeprevir in combination with peginterferon alfa and ribavirin, is recommended within its marketing authorisation, as an option for the treatment of chronic hepatitis C infection of genotype 1 and 4 in adults. www.nice.org.uk/TA331

Telaprevir

**INDICATIONS AND DOSE**

In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 in patients with compensated liver disease.

BY MOUTH

- Adult: 1.125 g every 12 hours, alternatively 750 mg every 8 hours, for duration of treatment consult product literature.

**CAUTIONS**


**INTERACTIONS**

Appendix 1 (telaprevir). Caution in concomitant use with other drugs known to prolong QT interval.

**SIDE-EFFECTS**


- Rare. Stevens-Johnson syndrome. Toxic epidermal necrosis.

**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects listed are reported when telaprevir is used in combination with ribavirin and peginterferon alfa.

**SIDE-EFFECTS, FURTHER INFORMATION**

Rash. Rash occurs very commonly. If rash mild or moderate, may continue without interruption, but monitor for deterioration. If moderate rash deteriorates, consider permanent discontinuation of telaprevir; if rash does not improve within 7 days of discontinuation, suspend ribavirin. If severe rash or if rash accompanied by blistering or mucosal ulceration, discontinue telaprevir permanently; if rash does not improve within 7 days of discontinuation, consider discontinuation of ribavirin and peginterferon alfa. If serious rash, or if severe rash deteriorates, or if rash accompanied by systemic symptoms, discontinue telaprevir, ribavirin, and peginterferon alfa permanently.

**CONCEPTION AND CONTRACEPTION**

Effectiveness of hormonal contraceptives reduced during treatment and for 2 months after stopping telaprevir—effective non-hormonal methods of contraception necessary during this time.

**PREGNANCY**

Manufacturer advises avoid.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.
Herpesvirus infections

Herpes simplex infections

The two most important herpesvirus pathogens are herpes simplex virus (herpesvirus hominis) and varicella–zoster virus.

Herpes simplex infections

Herpes infection of the mouth and lips and in the eye is generally associated with herpes simplex virus serotype 1 (HSV-1); other areas of the skin may also be infected, especially in immunodeficiency. Genital infection is most often associated with HSV-2 and also HSV-1. Treatment of herpes simplex infection should start as early as possible and usually within 5 days of the appearance of the infection. In individuals with good immune function, mild infection of the eye (ocular herpes) and of the lips (herpes labialis or cold sores) is treated with a topical antiviral drug. Primary herpetic gingivostomatitis is managed by changes to diet and with analgesics. Severe infection, neonatal herpes infection or infection in immunocompromised individuals requires treatment with a systemic antiviral drug. Primary or recurrent genital herpes simplex infection is treated with an antiviral drug given by mouth. Persistence of a lesion or recurrence in an immunocompromised patient may signal the development of resistance.

Specialist advice should be sought for systemic treatment of herpes simplex infection in pregnancy.

Varicella-zoster infections

Regardless of immune function and the use of any immunoglobulins, neonates with chickenpox should be treated with a parenteral antiviral to reduce the risk of severe disease. Oral therapy in children is not recommended as absorption is variable. Chickenpox in otherwise healthy children between 1 month and 12 years is usually mild and antiviral treatment is not usually required.

Chickenpox is more severe in adolescents and adults than in children; antiviral treatment started within 24 hours of the onset of rash may reduce the duration and severity of symptoms in otherwise healthy adults and adolescents. Antiviral treatment is generally recommended in immunocompromised patients and those at special risk (e.g. because of severe cardiovascular or respiratory disease or chronic skin disorder); in such cases, an antiviral is given for 10 days with at least 7 days of parenteral treatment.

Pregnant women who develop severe chickenpox may be at risk of complications, especially varicella pneumonia. Specialist advice should be sought for the treatment of chickenpox during pregnancy.

Those who have been exposed to chickenpox and are at special risk of complications may require prophylaxis with varicella-zoster immunoglobulin (see under Disease Specific Immunoglobulins).

In herpes zoster (shingles) systemic antiviral treatment can reduce the severity and duration of pain, reduce complications, and reduce viral shedding. Treatment with the antiviral should be started within 72 hours of the onset of rash and is usually continued for 7–10 days. Immunocompromised patients at high risk of disseminated or severe infection should be treated with a parenteral antiviral drug.

Chronic pain which persists after the rash has healed (postherpetic neuralgia) requires specific management.

Choice

Aciclovir p. 550 is active against herpesviruses but does not eradicate them. Uses of aciclovir include systemic treatment of varicella–zoster and the systemic and topical treatment of herpes simplex infections of the skin and mucous membranes. It is used by mouth for severe herpetic stomatitis. Aciclovir eye ointment is used for herpes simplex infections of the eye; it is combined with systemic treatment for ophthalmic zoster.

Famciclovir p. 552, a prodrug of penciclovir, is similar to aciclovir and is licensed for use in herpes zoster and genital herpes.

Valaciclovir p. 552 is an ester of aciclovir, licensed for herpes zoster and herpes simplex infections of the skin and mucous membranes (including genital herpes); it is also licensed for preventing cytomegalovirus disease following solid organ transplantation. Famciclovir or valaciclovir are suitable alternatives to aciclovir for oral lesions associated with herpes zoster. Valaciclovir once daily may reduce the risk of transmitting genital herpes to heterosexual partners—specialist advice should be sought.

Foscarnet sodium p. 553 is used for mucocutaneous herpes simplex virus infection unresponsive to aciclovir in immunocompromised patients; it is toxic and can cause renal impairment.

Inosine pranobex p. 550 has been used by mouth for herpes simplex infections; its effectiveness remains unproven.

Cytomegalovirus infection

Ganciclovir p. 554 is related to aciclovir but it is more active against cytomegalovirus (CMV); it is also much more toxic than aciclovir and should therefore be prescribed only when the potential benefit outweighs the risks. Ganciclovir is administered by intravenous infusion for the initial treatment of CMV infection. Ganciclovir causes profound myelosuppression when given with zidovudine p. 566; the
two should not normally be given together particularly during initial ganciclovir therapy. The likelihood of ganciclovir resistance increases in patients with a high viral load or in those who receive the drug over a long duration. Valganciclovir is an ester of ganciclovir which is licensed for the initial treatment and maintenance treatment of CMV retinitis in AIDS patients. Valganciclovir is also licensed for preventing CMV disease following solid organ transplantation from a cytomegalovirus-positive donor. Foscarnet sodium is also active against cytomegalovirus; it is toxic and can cause renal impairment. See local treatment of CMV retinitis.

**INOSINE COMPLEXES**

**Inosine pranobex** *(Inosine acedoben dimepranol)*

**INDICATIONS AND DOSE**

**Mucocutaneous herpes simplex**

*BY MOUTH*

- Adult: 1 g 4 times a day for 7–14 days

**Adjuvant treatment of genital warts**

*BY MOUTH*

- Adult: 1 g 3 times a day for 14–28 days

**Subacute sclerosing panencephalitis**

*BY MOUTH*

- Adult: 50–100 mg/kg daily in 6 divided doses

**CAUTIONS**

- History of gout - history of hyperuricaemia

**SIDE-EFFECTS**

- Common or very common Reversible increase in serum uric acid - reversible increase in urinary uric acid

- Uncommon Arthralgia - epigastric discomfort - fatigue - headache - itching - nausea - rashes - vertigo - vomiting

- Rare Anxiety - constipation - diarrhoea - polyuria - sleep disturbances

**PREGNANCY**

Manufacturer advises avoid.

**RENAL IMPAIRMENT**

Manufacturer advises caution;

metabolised to uric acid.

**LESS SUITABLE FOR PRESCRIBING**

Inosine pranobex is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

*Imunovir* *(KoRa Healthcare)*

- Inosine acedoben dimepranol 500 mg Imunovir 500mg tablets £39.50

**NUCLEOSIDE ANALOGUES**

**Aciclovir** *(Acyclovir)*

**INDICATIONS AND DOSE**

**Herpes simplex, suppression**

*BY MOUTH*

- Child 12-17 years: 400 mg twice daily, alternatively 200 mg 4 times a day; increased to 400 mg 3 times a day, dose may be increased if recurrences occur on standard suppressive therapy or for suppression of genital herpes during late pregnancy (from 36 weeks gestation), therapy interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

- Adult: 400 mg twice daily, alternatively 200 mg 4 times a day; increased to 400 mg 3 times a day, dose may be increased if recurrences occur on standard suppressive therapy or for suppression of genital herpes during late pregnancy (from 36 weeks gestation), therapy interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

**Herpes simplex, prophylaxis in the immunocompromised**

*BY MOUTH*

- Child 1 month-1 year: 100–200 mg 4 times a day

- Child 2-17 years: 200–400 mg 4 times a day

- Adult: 200–400 mg 4 times a day

**Herpes simplex, treatment (non-genital)**

*BY MOUTH*

- Child 1 month-1 year: 100 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

- Child 2-17 years: 200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

- Adult: 200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

**Herpes simplex, treatment (non-genital) in simplex encephalitis, immunocompromised patients or if absorption impaired**

*BY MOUTH*

- Child 1 month-1 year: 200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

- Child 2-17 years: 400 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

- Adult: 400 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

**Genital herpes simplex, treatment of first episode**

*BY MOUTH*

- Adult: 200 mg 5 times a day, alternatively 400 mg 3 times a day both courses usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

**Genital herpes simplex, treatment of severe, initial infection**

*BY INTRAVENOUS INFUSION*

- Adult: Initially 5 mg/kg every 8 hours usually for 5 days; increased to 10 mg/kg every 8 hours for at least 14 days in encephalitis (at least 21 days if also immunocompromised)—confirm cerebrospinal fluid negative for herpes simplex virus before stopping treatment, to be increased only if resistant organisms suspected or in simplex encephalitis

**Genital herpes simplex, treatment of first episode in immunocompromised or HIV-positive patients**

*BY MOUTH*

- Adult: 400 mg 5 times a day for 7–10 days

**Herpes simplex, treatment of recurrent infection**

*BY MOUTH*

- Adult: 800 mg 3 times a day for 2 days, alternatively 200 mg 5 times a day for 5 days, alternatively 400 mg 3 times a day for 3–5 days

**Genital herpes simplex, treatment of recurrent infection in immunocompromised or HIV-positive patients**

*BY MOUTH*

- Adult: 400 mg 3 times a day for 5–10 days
<table>
<thead>
<tr>
<th>Side-effects</th>
<th>Doses at extremes of body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk of neurological reactions</strong></td>
<td>To avoid excessive dosage in obese patients parenteral dose should be calculated on the basis of ideal weight for height.</td>
</tr>
</tbody>
</table>

**Unlicensed use**

Attenuation of chickenpox is an unlicensed indication. Tablets and suspension not licensed for suppression of herpes simplex or for treatment of herpes zoster in children (age range not specified by manufacturer).

**Caution**

Elderly (risk of neurological reactions) (in adults) - maintain adequate hydration (especially with infusion or high doses).

**Interactions**

Appendix 1 (aciclovir).

**Side-effects**

**General side-effects**

Abdominal pain, diarrhoea, fatigue, headache, nausea, photosensitivity, pruritus, rash, urticaria, vomiting.

**Very rare**

Acute renal failure, anaemia, ataxia, confusion, convulsions, dizziness, drowsiness, dysarthria, dyspnoea, hallucinations, hepatitis, jaundice, leucopenia, neurological reactions, thrombocytopenia.

**Specific side-effects**

**Very rare**

With intravenous use — agitation, fever, psychosis, severe local inflammation (sometimes leading to ulceration) — tremors.

**Pregnancy**

Not known to be harmful—manufacturers advise use only when potential benefit outweighs risk.

**Breast feeding**

Significant amount in milk after systemic administration—not known to be harmful but manufacturer advises caution.

**Renal impairment**

Risk of neurological reactions increased. Maintain adequate hydration (especially during renal impairment).

With intravenous use in adults

Use normal intravenous dose every 12 hours if eGFR 25–50 mL/minute/1.73 m² (every 24 hours if eGFR 10–25 mL/minute/1.73 m²). Consult product literature for intravenous dose if eGFR less than 10 mL/minute/1.73 m².

With oral use in adults

For herpes zoster, use normal oral dose every 8 hours if eGFR 10–25 mL/minute/1.73 m² (every 12 hours if eGFR less than 10 mL/minute/1.73 m²). For herpes simplex, use normal oral dose every 12 hours if eGFR less than 10 mL/minute/1.73 m².

With oral use in children

For herpes zoster, use normal oral dose every 8 hours if estimated glomerular filtration rate 10–25 mL/minute/1.73 m² (every 12 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m²). For herpes simplex, use normal dose every 12 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**Directions for administration**

For intravenous infusion

Zovirax IV®, Aciclovir IV® (Genus), give intermittently in Sodium chloride 0.9% or Sodium chloride and glucose; initially reconstitute to 25 mg/mL in water for injection or sodium chloride 0.9% then dilute to not more than 5 mg/mL with the infusion fluid; to be given over 1 hour; alternatively, may be administered in a concentration of 25 mg/mL using a suitable infusion pump and given over 1 hour; for Aciclovir IV® (Hospira) dilute to not more than 5 mg/mL with infusion fluid; give over 1 hour.

**Prescribing and dispensing information**

Flavours of oral liquid preparations may include banana, or orange.

**Patient and carer advice**

Medicines for Children leaflet: Aciclovir (oral) for viral infections www.medicinesforchildren.org.uk/aciclovir-for-viral-infections

**Professor specific information**

Dental practitioners' formulary: Aciclovir Tablets 200 mg or 800 mg may be prescribed. Aciclovir Oral Suspension 200 mg/5mL may be prescribed. Aciclovir Cream may be prescribed.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

Tablet

<table>
<thead>
<tr>
<th>BNF 70</th>
<th>Herpesvirus infections 551</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cautionary and advisory labels</strong></td>
<td>9</td>
</tr>
<tr>
<td><strong>Aciclovir (non-proprietary)</strong></td>
<td>200 mg Aciclovir 200 mg tablets</td>
</tr>
<tr>
<td>Aciclovir 400 mg</td>
<td>400 mg tablets</td>
</tr>
<tr>
<td>Aciclovir 800 mg</td>
<td>800 mg tablets</td>
</tr>
</tbody>
</table>

**Dispersible tablet**

Tablet

<table>
<thead>
<tr>
<th>BNF 70</th>
<th>Herpesvirus infections 551</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cautionary and advisory labels</strong></td>
<td>9</td>
</tr>
<tr>
<td><strong>Aciclovir (non-proprietary)</strong></td>
<td>200 mg Aciclovir 200 mg dispersible tablets</td>
</tr>
<tr>
<td>Aciclovir 400 mg</td>
<td>400 mg dispersible tablets</td>
</tr>
<tr>
<td>Aciclovir 800 mg</td>
<td>800 mg dispersible tablets</td>
</tr>
<tr>
<td>Zovirax (GlaxoSmithKline UK Ltd)</td>
<td>200 mg Zovirax</td>
</tr>
<tr>
<td>Aciclovir 800 mg</td>
<td>800 mg dispersible tablets</td>
</tr>
<tr>
<td>Oral suspension</td>
<td>Aciclovir 40 mg per 1 ml</td>
</tr>
<tr>
<td>Aciclovir 80 mg per 1 ml</td>
<td>400 mg oral suspension</td>
</tr>
</tbody>
</table>
Famciclovir

**INDICATIONS AND DOSE**

**Herpes zoster infection, treatment**

BY MOUTH

- Adult: 500 mg 3 times a day for 7 days, alternatively 750 mg 1–2 times a day for 7 days

**Herpes zoster infection, treatment in immunocompromised patients**

BY MOUTH

- Adult: 500 mg 3 times a day for 10 days, continue for 2 days after crusting of lesions

**Genital herpes, suppression**

BY MOUTH

- Adult: 250 mg twice daily, therapy to be interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

**Genital herpes, suppression in immunocompromised or HIV-positive patients**

BY MOUTH

- Adult: 500 mg twice daily, therapy to be interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

**Herpes simplex infection, treatment of first episode**

BY MOUTH

- Adult: 250 mg 3 times a day for 5 days or longer if new lesions appear during treatment or if healing incomplete

**Herpes simplex infection, treatment of first episode in immunocompromised or HIV-positive patients**

BY MOUTH

- Adult: 500 mg twice daily for 10 days

**Genital herpes infection, treatment of recurrent infection**

BY MOUTH

- Adult: 125 mg twice daily for 5 days, alternatively 1 g twice daily for 1 day

**Genital herpes infection, treatment of recurrent infections in immunocompromised or HIV-positive patients**

BY MOUTH

- Adult: 500 mg twice daily for 5–10 days

**Herpes simplex infection (non-genital), treatment in immunocompromised patients**

BY MOUTH

- Adult: 500 mg twice daily for 5–10 days

**UNLICENSED USE** Famciclovir doses in BNF may differ from those in product literature.

Valaciclovir

**INDICATIONS AND DOSE**

**Herpes zoster infection, treatment**

BY MOUTH

- Adult: 1 g 3 times a day for 7 days

**Herpes zoster infection, treatment in immunocompromised patients**

BY MOUTH

- Adult: 1 g 3 times a day for at least 7 days and continued for 2 days after crusting of lesions

**Herpes simplex, treatment of first infective episode**

BY MOUTH

- Adult: 500 mg twice daily for 5 days (longer if new lesions appear during treatment or healing is incomplete)

**Herpes simplex infections treatment of first episode in immunocompromised or HIV-positive patients**

BY MOUTH

- Adult: 1 g twice daily for 10 days

**Herpes simplex, treatment of recurrent infections**

BY MOUTH

- Adult: 500 mg twice daily for 3–5 days

**Treatment of recurrent herpes simplex infections in immunocompromised or HIV-positive patients**

BY MOUTH

- Adult: 1 g twice daily for 5–10 days

**INTERACTIONS** → Appendix 1 (famciclovir).

**SIDE-EFFECTS**

- Common or very common: Headache, nausea, vomiting
- Rare: Confusion
- Very rare: Dizziness, drowsiness, hallucinations, jaundice, rash, Stevens-Johnson syndrome, thrombocytopenia

**PREGNANCY** Manufacturers advise avoid unless potential benefit outweighs risk.

**BREAST FEEDING** No information available—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Usual dose in well compensated liver disease (information not available on decompensated).

**RENAL IMPAIRMENT** Reduce dose; consult product literature.

**PRESCRIBING AND DISPENSING INFORMATION** Famciclovir is a pro-drug of penciclovir.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **FAMCICLOVIR** (Non-proprietary)
  - Famciclovir 125 mg, Famciclovir 125mg tablets | 10 tablet | £33.22
  - Famciclovir 250 mg, Famciclovir 250mg tablets | 15 tablet | £44.54
  - Famciclovir 500 mg, Famciclovir 500mg tablets | 14 tablet | £154.04
  - Famciclovir (Novartis Pharmaceuticals UK Ltd) 125 mg, Famciclovir 125mg tablets | 10 tablet | £44.54
  - Famciclovir 250 mg, Famciclovir 250mg tablets | 15 tablet | £154.04
  - Famciclovir 500 mg, Famciclovir 500mg tablets | 14 tablet | £154.04

**Valaciclovir**

**INDICATIONS AND DOSE**

**Herpes zoster infection, treatment**

BY MOUTH

- Adult: 1 g 3 times a day for 7 days

**Herpes zoster infection, treatment in immunocompromised patients**

BY MOUTH

- Adult: 1 g 3 times a day for at least 7 days and continued for 2 days after crusting of lesions

**Herpes simplex, treatment of first infective episode**

BY MOUTH

- Adult: 500 mg twice daily for 5 days (longer if new lesions appear during treatment or healing is incomplete)

**Herpes simplex infections treatment of first episode in immunocompromised or HIV-positive patients**

BY MOUTH

- Adult: 1 g twice daily for 10 days

**Herpes simplex, treatment of recurrent infections**

BY MOUTH

- Adult: 500 mg twice daily for 3–5 days

**Treatment of recurrent herpes simplex infections in immunocompromised or HIV-positive patients**

BY MOUTH

- Adult: 1 g twice daily for 5–10 days
Herpes simplex, suppression of infections

**BY MOUTH**

- Adult: 500 mg daily in 1–2 divided doses, therapy to be interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences.
- Adult: 500 mg twice daily, therapy to be interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences.

**Genital herpes, reduction of transmission**

Administer on herpes simplex virus infections every 10 hours after initial dose; if eGFR less than 10 mL/minute/1.73 m²; 500 mg every 24 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**For treatment of herpes simplex**, 500 mg (1 g in immunocompromised or HIV-positive children) every 24 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**For treatment of herpes labialis**, if estimated glomerular filtration rate 30–50 mL/minute/1.73 m², initially 1 g, then 1 g 12 hours after initial dose if estimated glomerular filtration rate 10–30 mL/minute/1.73 m², initially 500 mg, then 500 mg every 12 hours after initial dose; if estimated glomerular filtration rate less than 10 mL/minute/1.73 m², 500 mg as a single dose.

For suppression of herpes simplex, 250 mg (500 mg in immunocompromised or HIV-positive patients) every 24 hours if eGFR less than 30 mL/minute/1.73 m².

For reduction of genital herpes transmission, 250 mg every 24 hours if eGFR less than 15 mL/minute/1.73 m². Reduce dose according to eGFR for *cytomegalovirus prophylaxis* following solid organ transplantation (consult product literature).

**In children**

For herpes zoster, 1 g every 12 hours if estimated glomerular filtration rate 30–50 mL/minute/1.73 m², 1 g every 24 hours if estimated glomerular filtration rate 10–30 mL/minute/1.73 m²; 500 mg every 24 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**For treatment of herpes simplex**, 500 mg (1 g in immunocompromised or HIV-positive children) every 24 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**For treatment of herpes labialis**, if estimated glomerular filtration rate 30–50 mL/minute/1.73 m², initially 1 g, then 1 g 12 hours after initial dose (if estimated glomerular filtration rate 10–30 mL/minute/1.73 m², initially 500 mg, then 500 mg every 12 hours after initial dose; if estimated glomerular filtration rate less than 10 mL/minute/1.73 m², 500 mg as a single dose). For suppression of herpes simplex, 250 mg (500 mg in immunocompromised or HIV-positive children) every 24 hours if estimated glomerular filtration rate less than 30 mL/minute/1.73 m². Reduce dose according to estimated glomerular filtration rate for *cytomegalovirus prophylaxis* following solid organ transplantation (consult product literature).

**PRESCRIBING AND DISPENSING INFORMATION**

Valaciclovir is a pro-drug of aciclovir.
Ganciclovir

INDICATIONS AND DOSE
Prevention of cytomegalovirus disease during immunosuppressive therapy following organ transplantation

BY INTRAVENOUS INFUSION
- Adult: 5 mg/kg every 12 hours for 7–14 days

Treatment of life-threatening or sight-threatening cytomegalovirus infections in immunocompromised patients only

BY INTRAVENOUS INFUSION
- Adult: 5 mg/kg every 12 hours for 14–21 days, followed by maintenance 6 mg/kg daily on 5 days of the week, alternatively 5 mg/kg daily until adequate recovery of immunity, maintenance only for patients at risk of relapse of retinitis, if retinitis progresses initial induction treatment may be repeated

CONTRA-INDICATIONS
- Abnormally low haemoglobin count (consult product literature)
- Abnormally low neutrophil count (consult product literature)
- Abnormally low platelet count (consult product literature)

CAUTIONS
- Children (possible risk of long-term carcinogenic or reproductive toxicity) ensure adequate hydration, history of cytopenia, potential carcinogen, potential teratogen, radiotherapy, vesicant

INTERACTIONS
- Appendix 1 (ganciclovir).
- Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature.

SIDE-EFFECTS
- Common or very common Abdominal pain, acute renal failure, aggression, agitation, anaemia, anorexia, anxiety, changes in blood pressure, changes in ECG, confusion, constipation, convulsions, depression, diarrhoea, dizziness, dyspepsia, dysuria, electrolyte disturbances, genital irritation and ulceration (due to high concentrations excreted in urine), granulocytopenia, headache, hepatic dysfunction, hypocalcaemia, hypokalaemia, hypomagnesaemia, leucopenia, malaise, myalgia, nausea (reduce infusion rate), neurological disorders, oedema, palpitation, pancreatitis, paraesthesia (reduce infusion rate), polyuria, pruritus, rash, renal impairment, thrombocytopenia, thrombophlebitis if given undiluted by peripheral vein, tremor, vomiting
- Uncommon Acidity
- Frequency not known Diabetes insipidus, myasthenia, myositis, oesophageal ulceration, rhabdomyolysis, ventricular arrhythmias

CONCEPTION AND CONTRACEPTION
- Men should avoid fathering a child during and for 6 months after treatment.

PREGNANCY
- Manufacturer advises avoid.

BREAST FEEDING
- Avoid—present in milk in animal studies.

RENAHAL IMPAIRMENT
- Reduce dose; consult product literature.

MONITORING REQUIREMENTS
- Monitor electrolytes, particularly calcium and magnesium.
- Monitor serum creatinine every second day during induction and every week during maintenance.

DIRECTIONS FOR ADMINISTRATION
- Avoid rapid infusion.
- For intravenous infusion (Foscavir®), give intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute to a concentration of 12 mg/mL for infusion into peripheral vein (undiluted solution via central venous line only); infuse over at least 1 hour (infuse doses greater than 60 mg/kg over 2 hours).

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.
- Solution for infusion ELECTROLYTES: May contain Sodium
  - Foscavir (Clinigen Healthcare Ltd)
  - Foscarnet sodium 24 mg per 1 ml Foscavir 6g/250ml solution for infusion bottles | 1 bottle £119.85 (Hospital only)

NUCLEOSIDE ANALOGUES

Ganciclovir
Valganciclovir

**INDICATIONS AND DOSE**

**Cytomegalovirus retinitis, induction**

**BY MOUTH**
- Adult: Initially 900 mg twice daily for 21 days, then 900 mg daily, induction regimen may be repeated if retinitis progresses.

**Prevention of cytomegalovirus disease following solid organ transplantation**

**BY MOUTH**
- Adult: 900 mg daily for 100 days (for 100–200 days following kidney transplantation), to be started within 10 days of transplantation.

**Dose equivalence and conversion**

Oral valganciclovir 900 mg twice daily is equivalent to intravenous ganciclovir 5 mg/kg twice daily.

- **CONTRA-INDICATIONS** Abnormally low haemoglobin count (consult product literature) - abnormally low neutrophil count (consult product literature) - abnormally low platelet count (consult product literature).
- **CAUTIONS** Children (possible risk of long-term carcinogenic or reproductive toxicity) - history of cytopenia - potential carcinogen - potential teratogen - radiotherapy.
- **INTERACTIONS** → Appendix 1 (valganciclovir).
- **SIDE-EFFECTS**
- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients hypersensitive to ganciclovir, aciclovir, or valaciclovir.
- **CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment and barrier contraception for men during and for at least 90 days after treatment.
- **PREGNANCY** Avoid - teratogenic risk.
- **BREAST FEEDING** Avoid - no information available.
- **RENAL IMPAIRMENT** Reduce dose, consult product literature.
- **MONITORING REQUIREMENTS** Monitor full blood count closely (severe deterioration may require correction and possibly treatment interruption).
- **PRESCRIBING AND DISPENSING INFORMATION**
  - Valganciclovir is a pro-drug of ganciclovir. Flavours of oral liquid formulations may include tutti-frutti.
- **HANDLING AND STORAGE**
  - Caution in handling Valganciclovir is a potential teratogen and carcinogen and caution is advised when handling the powder, reconstituted solution, or broken tablets; if these come into contact with skin or mucosa, wash off immediately with water; avoid inhalation of powder.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 21**
  - **Valcyte** (Roche Products Ltd)
    - Valganciclovir (as Valganciclovir hydrochloride) 450 mg Valcyte 450 mg tablets | 60 tablet £1.081.46
- **Oral solution**
  - **CAUTIONARY AND ADVISORY LABELS 21**
    - **Valcyte** (Roche Products Ltd)
      - Valganciclovir (as Valganciclovir hydrochloride) 50 mg per 1 ml Valcyte 50 mg/ml oral solution (sugar-free) | 100 ml £220.32

### 6.6 HIV infection

**HIV infection**

There is no cure for infection caused by the human immunodeficiency virus (HIV) but a number of drugs slow or halt disease progression. Drugs for HIV infection (antiretrovirals) may be associated with serious side-effects. Although antiretrovirals increase life expectancy considerably and decrease the risk of complications associated with premature ageing, mortality and morbidity remain slightly higher than in uninfected individuals. Treatment should be undertaken only by those experienced in their use.

**Principles of treatment**

Treatment aims to prevent the mortality and morbidity associated with chronic HIV infection whilst minimising drug toxicity. Although it should be started before the immune system is irreversibly damaged, the need for early drug treatment should be balanced against the risk of toxicity. Commitment to treatment and strict adherence over many years are required; the regimen chosen should take into account convenience and patient tolerance. The development of drug resistance is reduced by using a combination of drugs; such combinations should have synergistic or additive activity while ensuring that their toxicity is not additive. It is recommended that viral sensitivity to antiretroviral drugs is established before starting treatment or before switching drugs if the infection is not responding.

Treatment also reduces the risk of HIV transmission to sexual partners, but the risk is not eliminated completely; this risk and strategies to reduce HIV transmission should be discussed with patients and their sexual partners.

**Initiation of treatment**

The optimum time for initiating antiretroviral treatment depends primarily on the CD4 cell count. The timing and choice of treatment should also take account of clinical symptoms, comorbidities, and the possible effect of antiretroviral drugs on factors such as the risk of cardiovascular events. Treatment includes a combination of drugs known as ‘highly active antiretroviral therapy’.

Treatment of HIV-1 infection is initiated with 2 nucleoside reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor, or a boosted protease inhibitor, or an integrase inhibitor; the regimens of choice contain tenofovir disoproxil and emtricitabine with either efavirenz or ritonavir-boosted atazanavir, or ritonavir-boosted darunavir, or raltegravir. Alternative regimens contain abacavir and lamivudine with either lopinavir or ritonavir, or ritonavir-boosted fosamprenavir, or nevirapine, or rilpivirine. Patients who require treatment for both HIV
and chronic hepatitis B should be treated with antivirals active against both diseases.

**Switching therapy**

Deterioration of the condition (including clinical and virological changes) may require a change in therapy. The choice of an alternative regimen depends on factors such as the response to previous treatment, tolerance and the possibility of cross-resistance.

**Pregnancy**

Treatment of HIV infection in pregnancy aims to reduce the risk of toxicity to the fetus (although information on the teratogenic potential of most antiretroviral drugs is limited), to minimise the viral load and disease progression in the mother, and to prevent transmission of infection to the neonate. All treatment options require careful assessment by a specialist. Combination antiretroviral therapy maximises the chance of preventing transmission and represents optimal therapy for the mother. However, it may be associated with a greater risk of preterm delivery. Pregnancies in HIV-positive women and babies born to them should be reported prospectively to the National Study of HIV in Pregnancy and Childhood at www.ucl.ac.uk/ nshpc/ and to the Antiretroviral Pregnancy Registry at www.apregistry.com.

**Breast-feeding**

Breast-feeding by HIV-positive mothers may cause HIV infection in the infant and should be avoided.

**Post-exposure prophylaxis**

Prophylaxis with antiretroviral drugs [unlicensed indication] may be appropriate following exposure to HIV-contaminated material. Immediate expert advice should be sought in such cases; national guidelines on post-exposure prophylaxis for healthcare workers have been developed (by the Chief Medical Officer’s Expert Advisory Group on AIDS), www.gov.uk/dh and local ones may also be available. Antiretrovirals for prophylaxis are chosen on the basis of efficacy and potential for toxicity. Prompt prophylaxis with antiretroviral drugs [unlicensed indication] is also appropriate following potential sexual exposure to HIV; recommendations have been developed by the British Association for Sexual Health and HIV, www.bashh.org.

**Drugs for HIV infection**

Zidovudine p. 566, a nucleoside reverse transcriptase inhibitor (or ‘nucleoside analogue’), was the first anti-HIV drug to be introduced. Other nucleoside reverse transcriptase inhibitors include abacavir p. 561, didanosine p. 562, emtricitabine p. 563, lamivudine p. 563, stavudine p. 564, and tenofovir disoproxil p. 564.

The protease inhibitors include atazanavir p. 567, darunavir p. 568, fosamprenavir p. 568 (a pro-drug of amprenavir), indinavir p. 569, lopinavir (available as lopinavir with ritonavir), ritonavir p. 570, saquinavir p. 570, and tipranavir p. 571. Indinavir is rarely used in the treatment of HIV-infection because it is associated with nephrolithiasis. Ritonavir in low doses boosts the activity of atazanavir, darunavir, fosamprenavir, indinavir, lopinavir (available as lopinavir with ritonavir), saquinavir, and tipranavir increasing the persistence of plasma concentrations of these drugs; at such a low dose, ritonavir has no intrinsic antiviral activity. The protease inhibitors are metabolised by cytochrome P450 enzyme systems and therefore have a significant potential for drug interactions. Protease inhibitors are associated with lipodystrophy and metabolic effects.

The non-nucleoside reverse transcriptase inhibitors efavirenz p. 558, etravirine p. 559, nevirapine p. 560, and rilpivirine p. 561 are used in the treatment of HIV-1 infection, but not against the subtype HIV-2, a subtype that is rare in the UK. Nevirapine is associated with a high incidence of rash (including Stevens-Johnson syndrome) and occasionally fatal hepatitis. Rash is also associated with efavirenz and etravirine but it is usually milder. Psychiatric or CNS disturbances are common with efavirenz, CNS disturbances are often self-limiting and can be reduced by taking the dose at bedtime (especially in the first 2–4 weeks of treatment). Efavirenz has also been associated with an increased plasma–cholesterol concentration. Etravirine is used in regimens containing a boosted protease inhibitor for HIV infection resistant to other non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Efavirenz p. 557, which inhibits the fusion of HIV to the host cell, is licensed for managing infection that has failed to respond to a regimen of other antiretroviral drugs; enfuvirtide should be combined with other potentially active antiretroviral drugs.

Maraviroc p. 557 is an antagonist of the CCR5 chemokine receptor. It is licensed for patients exclusively infected with CCR5-tropic HIV.

Dolutegravir p. 557 and raltegravir p. 558 are inhibitors of HIV integrase. They are licensed for the treatment of HIV infection in combination with other antiretroviral drugs.

Elvitegravir is also an inhibitor of HIV integrase that is only available as a component of a fixed-dose combination product (cobicistat with elvitegravir, emtricitabine and tenofovir). Cobicistat p. 567 is a pharmacokinetic enhancer that boosts the concentrations of other antiretrovirals, but it has no antiretroviral activity itself.

**Immune reconstitution syndrome**

Improvement in immune function as a result of antiretroviral treatment may provoke a marked inflammatory reaction against residual opportunistic organisms; these reactions may occur within the first few weeks or months of initiating treatment. Autoimmune disorders (such as Graves’ disease) have also been reported many months after initiation of treatment.

**Lipodystrophy syndrome**

Metabolic effects associated with antiretroviral treatment include fat redistribution, insulin resistance, and dyslipidaemia; collectively these have been termed lipodystrophy syndrome. The usual risk factors for cardiovascular disease should be taken into account before starting antiretroviral therapy and patients should be advised about lifestyle changes to reduce their cardiovascular risk. Plasma lipids and blood glucose should be measured before starting antiretroviral therapy, after 3–6 months of treatment, and then annually.

Fat redistribution (with loss of subcutaneous fat, increased abdominal fat, ‘buffalo hump’ and breast enlargement) is associated with regimens containing protease inhibitors and nucleoside reverse transcriptase inhibitors. Stavudine (especially in combination with didanosine), and to a lesser extent zidovudine, are associated with a higher risk of lipodystrophy and should be used only if alternative regimens are not suitable.

Dyslipidaemia is associated with antiretroviral treatment, particularly with protease inhibitors. Protease inhibitors and some nucleoside reverse transcriptase inhibitors are associated with insulin resistance and hyperglycaemia. Of the protease inhibitors, atazanavir and darunavir may be less likely to cause dyslipidaemia, while saquinavir and atazanavir may be less likely to impair glucose tolerance.

**Osteonecrosis**

Osteonecrosis has been reported in patients with advanced HIV disease or following long-term exposure to combination antiretroviral therapy.
HIV infection in children

HIV disease in children has a different natural progression to adults. Children infected with HIV should be managed within a formal paediatric HIV clinical network by specialists with access to guidelines and information on antiretroviral drugs for children.

CCR5 CHEMOKINE RECEPTOR ANTAGONISTS

Maraviroc

**DRUG ACTION** Maraviroc is an antagonist of the CCR5 chemokine receptor.

**INDICATIONS AND DOSE**

CCR5-tropic HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretrovirals

**BY MOUTH**

- Adult: 300 mg twice daily

**CAUTIONS** Cardiovascular disease

**INTERACTIONS** → Appendix 1 (maraviroc).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, anaemia, anorexia, depression, diarrhoea, flatulence, headache, insomnia, malaise, nausea, rash

- **Uncommon** Myositis, proteinuria, renal failure, seizures

- **Rare** Angina, granulocytopenia, hepatitis, pancreatopathy, Stevens-Johnson syndrome, toxic epidermal necrolysis

**FREQUENCY NOT KNOWN** Eosinophilia, fever, hepatic reactions, hypersensitivity reactions, osteonecrosis, rash

**SIDE-EFFECTS, FURTHER INFORMATION**

Osteonecrosis

For further information see HIV infection p. 555.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risks.

**HEPATIC IMPAIRMENT** Manufacturer advises caution—no information available; chronic hepatitis B or C (possibly greater risk of hepatic side-effects).

**DIRECTIONS FOR ADMINISTRATION**

For **SUBCUTANEOUS INJECTION**, reconstitute with 1.1 mL Water for Injections and allow to stand (for up to 45 minutes) to dissolve; do not shake or invert vial.

**PATIENT AND CARER ADVICE**

Hypersensitivity reactions. Patients or carers should be told how to recognise signs of hypersensitivity, and advised to discontinue treatment and seek immediate medical attention if symptoms develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Celsentri** (ViiV Healthcare UK Ltd)
  - Maraviroc 150 mg Celsentri 150mg tablets | 60 tablet | £441.27
  - Maraviroc 300 mg Celsentri 300mg tablets | 60 tablet | £812.54

**HIV-FUSION INHIBITORS**

Enfuvirtide

**DRUG ACTION** Enfuvirtide inhibits the fusion of HIV to the host cell.

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs for resistant infection or for patients intolerant to other antiretroviral regimens

**BY SUBCUTANEOUS INJECTION**

- Adult: 90 mg twice daily

**INTERACTIONS** → Appendix 1 (enfuvirtide).

**SIDE-EFFECTS**

- **Common or very common** Acne, anorexia, anxiety, asthenia, conjunctivitis, diabetes mellitus, dry skin, erythema, gastro-oesophageal reflux disease, haematuria, hypertriglyceridaemia, impaired concentration, influenza-like illness, injection-site reactions, irritability, lymphenadonopathy, myalgia, nightmares, pancreatitis, peripheral neuropathy, pneumonia, renal calculi, sinusitis, skin papilloma, tremor, vertigo, weight loss

- **Uncommon** Hypersensitivity reactions

**FREQUENCY NOT KNOWN** Osteonecrosis

**SIDE-EFFECTS, FURTHER INFORMATION**

Hypersensitivity reactions

Hypersensitivity reactions including rash, fever, nausea, vomiting, chills, rigors, low blood pressure, respiratory distress, glomerulonephritis, and raised liver enzymes reported; discontinue immediately if any signs or symptoms of systemic hypersensitivity develop and do not rechallenge.

Osteonecrosis

For further information see HIV infection p. 555.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risks.

**HEPATIC IMPAIRMENT** Manufacturer advises caution—no information available; chronic hepatitis B or C (possibly greater risk of hepatic side-effects).

**DIRECTIONS FOR ADMINISTRATION**

For **SUBCUTANEOUS INJECTION**, reconstitute with 1.1 mL Water for Injections and allow to stand (for up to 45 minutes) to dissolve; do not shake or invert vial.

**PATIENT AND CARER ADVICE**

Hypersensitivity reactions. Patients or carers should be told how to recognise signs of hypersensitivity, and advised to discontinue treatment and seek immediate medical attention if symptoms develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

**ELECTROLYTES** May contain Sodium

- Fusenze (Roche Products Ltd)
  - Enfuvirtide 108 mg Fusenze 108mg powder and solvent for solution for injection vials | 60 vial (enfuvirtide)

**HIV-INTEGRASE INHIBITORS**

Dolutegravir

**DRUG ACTION** Dolutegravir is an inhibitor of HIV integrase.

**INDICATIONS AND DOSE**

HIV infection without resistance to other inhibitors of HIV integrase, in combination with other antiretroviral drugs

**BY MOUTH**

- Adult: 50 mg once daily

**HIV infection in patients where resistance to other inhibitors of HIV integrase suspected, in combination with other antiretroviral drugs**

**BY MOUTH**

- Adult: 50 mg twice daily, dose to be taken with food

**HIV infection in combination with other antiretroviral drugs (with concomitant efavirenz, nevirapine, tipranavir, or rifampicin)**

**BY MOUTH**

- Adult: 50 mg twice daily, avoid concomitant use with these drugs if resistance to other inhibitors of HIV integrase suspected

**INTERACTIONS** → Appendix 1 (dolutegravir).
Caution—avoid concomitant use with etravirine, unless used in combination with atazanavir, darunavir, or lopinavir.

### SIDE-EFFECTS

- **Common or very common** Abdominal pain · abnormal dreams · diarrhoea · dizziness · fatigue · flatulence · headache · insomnia · nausea · pruritus · raised creatine kinase · rash · vomiting
- **Uncommon** Hepatitis · hypersensitivity reactions
- **Frequency not known** Osteonecrosis

#### SIDE-EFFECTS, FURTHER INFORMATION

**Hypersensitivity reactions** Hypersensitivity reactions (including severe rash, or rash accompanied by fever, malaise, arthralgia, myalgia, blistering, oral lesions, conjunctivitis, angioedema, eosinophilia, or raised liver enzymes) reported uncommonly. Discontinue immediately if any sign or symptoms of hypersensitivity reactions develop.

**Osteonecrosis** For further information see HIV infection p. 555.

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available.
- **DIRECTIONS FOR ADMINISTRATION** Avoid antacids 6 hours before or 2 hours after taking raltegravir.
- **PATIENT AND CARER ADVICE**

- **Missed doses** If a dose is more than 2 hours late on the once daily regimen (or more than 8 hours late on the twice daily regimen), the missed dose should not be taken and the next dose should be taken at the normal time. Patients or carers should be given advice on how to administer raltegravir tablets.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - Tivicay (ViiV Healthcare UK Ltd) ▼
    - Raltegravir (as Raltegravir sodium) 50 mg Tivicay 50mg tablets | 30 tablet [P] £49.87
  - Also available in combination with abacavir and lamivudine, p. 562

#### Raltegravir

**DRUG ACTION** Raltegravir is an inhibitor of HIV integrase.

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs

- **BY MOUTH USING TABLETS**
  - Adult: 400 mg twice daily
  - Dose equivalence and conversion
    - The bioavailability of Isentress® chewable tablets is higher than that of the 'standard' 400 mg tablets; the chewable tablets are not interchangeable with the 'standard' tablets on a milligram-for-milligram basis.

- **CAUTIONS** Psychiatric illness (may exacerbate underlying illness including depression) · risk factors for myopathy · risk factors for rhabdomyolysis
- **INTERACTIONS** Appendix 1 (raltegravir).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain · abnormal dreams · anxiety · arthritis · depression · diarrhoea · dizziness · dyspepsia · flatulence · headache · hyperactivity · hypertriglyceridaemia · insomnia · nausea · rash · vomiting
- **Uncommon** Acne · alopecia · anaemia · anxiety · appetite changes · arthralgia · bradycardia · carpal tunnel syndrome · chest pain · chills · confusion · constipation · drowsiness · dry mouth · dry skin · dysphonia · epistaxis · erectile dysfunction · flushing · gastritis · gingivitis · glossitis · gynaecomastia · hepatitis · hyperhidrosis · hypertension · impaired memory and attention · lipodystrophy · Lipodystrophy Syndrome · menopausal symptoms · myalgia · nasal congestion · neutropenia · nocturia · oedema · osteopenia · pain on swallowing · palpitation · pancreatitis · peptic ulcer · peripheral neuropathy · polyphasia · pruritus · pyrexia · rash with eosinophilia and systemic symptoms · rectal bleeding · renal failure · rhabdomyolysis · skin papilloma · Stevens-Johnson syndrome · suicidal ideation · taste disturbances · thrombocytopenia · tinnitus · tremor · ventricular extrasystoles · visual disturbances
- **Frequency not known** Osteonecrosis

**SIDE-EFFECTS, FURTHER INFORMATION**

**Rash** Rash occurs commonly. Discontinue if severe rash or rash accompanied by fever, malaise, arthralgia, myalgia, blisters, mouth ulceration, conjunctivitis, angioedema, hepatitis, or eosinophilia.

**Lipodystrophy syndrome** For further information see HIV infection p. 555.

**Osteonecrosis** For further information see HIV infection p. 555.

- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available. Use with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side-effects).
- **PRESCRIBING AND DISPENSING INFORMATION** Dispense raltegravir chewable tablets in original container (contains desiccant).

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

- The Scottish Medicines Consortium has advised (April 2010) that raltegravir (Isentress®) is accepted for restricted use within NHS Scotland for the treatment of HIV infection when non-nucleoside reverse transcriptase inhibitors or protease inhibitors cannot be used because of intolerance, drug interactions, or resistance.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - Isentress (Merck Sharp & Dohme Ltd)
    - Raltegravir 400 mg Isentress 400mg tablets | 60 tablet [P] £471.41
  - Isentress 25 mg Isentress 25mg chewable tablets | 60 tablet [P] £29.46
  - Isentress 100 mg Isentress 100mg chewable tablets | 60 tablet [P] £117.85
  - Also available in granules
    - Isentress (Merck Sharp & Dohme Ltd)
      - Raltegravir 25 mg Isentress 25mg chewable tablets | 60 tablet [P] £29.46
      - Isentress 100 mg Isentress 100mg chewable tablets | 60 tablet [P] £117.85
      - Granules
        - Isentress 100 mg Isentress 100mg granules sachets | 60 satch [P] £231.02

**NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS**

**Efavirenz**

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs

- **BY MOUTH USING CAPSULES**
  - Adult: 600 mg once daily
Etravirine

INDICATIONS AND DOSE
HIV infection resistant to other non-nucleoside reverse transcriptase inhibitor and protease inhibitors in combination with other antiretroviral drugs (including a boosted protease inhibitor)

BY MOUTH

Adult: 200 mg twice daily, to be taken after food

CONTRA-INDICATIONS
Acute porphyrias p. 864

SIDE-EFFECTS
- Common or very common Abdominal pain · abnormal dreams · anxiety · depression · diarrhoea · dizziness · fatigue · headache · impaired concentration · nausea · pruritus · rash · sleep disturbances · Stevens-Johnson syndrome · vomiting
- Uncommon Amnesia · ataxia · blurred vision · convulsions · flushing · gynaecomastia · hepatitis · mania · pancreatitis · psychosis · suicidal ideation · tinnitus · tremor
- Rare Hepatic failure · photosensitivity · suicide
- Frequency not known Lipodystrophy Syndrome · osteonecrosis · raised serum cholesterol

SIDE-EFFECTS, FURTHER INFORMATION
- Rash Rash, usually in the first 2 weeks, is the most common side-effect; discontinue if severe rash with blistering, desquamation, mucosal involvement or fever; if rash mild or moderate, may continue without interruption—usually resolves within 1 month.
- CNS effects Administration at bedtime especially in first 2–4 weeks reduces CNS effects.
- Lipodystrophy Syndrome For further information see HIV infection p. 555.
- Osteonecrosis For further information see HIV infection p. 555.

PREGNANCY
Reports of neural tube defects when used in first trimester.

HEPATIC IMPAIRMENT Greater risk of hepatic side-effects in chronic hepatitis B or C. Avoid in moderate to severe impairment. In mild liver disease, monitor for dose related side-effects (e.g. CNS effects) and monitor liver function.

RENAL IMPAIRMENT Manufacturer advises caution in severe renal failure—no information available.

MONITORING REQUIREMENTS Monitor liver function if receiving other hepatotoxic drugs.

DIRECTIONS FOR ADMINISTRATION Capsules may be opened and contents added to food (contents have a peppery taste).

PRESCRIBING AND DISPENSING INFORMATION Flavours of oral liquid formulations may include strawberry and mint.

PATIENT AND CARER ADVICE
Psychiatric disorders Patients or their carers should be advised to seek immediate medical attention if symptoms such as severe depression, psychosis or suicidal ideation occur.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 23

ETRAVIRINE (Non-proprietary)
Etravirine 600 mg Etravirine 600 mg tablets | 30 tablet £102.79 (Hospital only)
PATIENT AND CARER ADVICE

Missed doses If a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Hypersensitivity reactions Patients or carers should be told how to recognise hypersensitivity reactions and advised to seek immediate medical attention if hypersensitivity reaction or severe rash develop.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Nevirapine

INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs (initial dose)

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: Initially 200 mg once daily for first 14 days, initial dose titration using 'immediate-release' preparation should not exceed 28 days; if rash occurs and is not resolved within 28 days, alternative treatment should be sought. If treatment interrupted for more than 7 days, restart using the lower dose of the 'immediate-release' preparation for the first 14 days as for new treatment

HIV infection in combination with other antiretroviral drugs (maintenance dose following initial dose titration if no rash present)

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
- Adult: 400 mg once daily

CONTRA-INDICATIONS

Acute porphyrias p. 864; post-exposure prophylaxis

CAUTIONS

Females (at greater risk of hepatic side effects)
- high CD4 cell count (at greater risk of hepatic side effects)

CAUTIONS, FURTHER INFORMATION

Hepatic effects Patients with chronic hepatitis B or C, high CD4 cell count, and women are at increased risk of hepatic side effects— if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250 cells/mm³ or in men with CD4 cell count greater than 400 cells/mm³ unless potential benefit outweighs risk.

INTERACTIONS

→ Appendix 1 (nevirapine).

SIDE-EFFECTS

Common or very common
- Abdominal pain, diarrhea, headache, fatigue, fever, granulocytopenia, myalgia, nausea, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, vomiting

Uncommon
- Anaemia, arthralgia, myalgia

Frequency not known
- Osteonecrosis

SIDE-EFFECTS, FURTHER INFORMATION

Hepatic effects Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 5 weeks; discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction—discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction.

Rash Rash, usually in first 5 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased gradually (after 14 days); discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, facial oedema, general malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose should not be increased until rash resolves.

Osteonecrosis For more information see HIV infection p. 555.

HEPATIC IMPAIRMENT

Manufacturer advises avoid modified-release preparation—no information available; use 'immediate-release' preparation with caution in moderate impairment and avoid in severe impairment.

Use with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side effects).

RENAI IMPAIRMENT

Manufacturer advises avoid modified-release preparation—no information available.

MONITORING REQUIREMENTS

- Hepatic disease Close monitoring of liver function required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly.
- Rash Monitor closely for skin reactions during first 18 weeks.

PATIENT AND CARER ADVICE

Missed doses If a dose is more than 8 hours late with the 'immediate-release' preparation or more than 12 hours late with the modified-release preparation, the missed dose should not be taken and the next dose should be taken at the usual time.

Hypersensitivity reactions Patients or carers should be told how to recognise hypersensitivity reactions and advised to discontinue treatment and seek immediate medical attention if severe skin reaction, hypersensitivity reactions, or symptoms of hepatitis develop.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 21</th>
</tr>
</thead>
</table>
| Nevirapine 200 mg | Nevirapine 200mg tablets | 120 tablet PVP £75.32
| Etravirine 100 mg | Etravirine 100mg tablets | 120 tablet PVP £301.27
| Etravirine 200 mg | Etravirine 200mg tablets | 60 tablet PVP £301.27 |

Nevirapine

NEVIRAPINE (Non-proprietary)

- Nevirapine 200 mg Nevirapine 200mg tablets | 60 tablet PVP £170.00
- Viramune (Boehringer Ingelheim Ltd)
  - Nevirapine 200 mg Viramune 200mg tablets | 14 tablet PVP £39.67 | 60 tablet PVP £170.00
  - Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

- Viramune (Boehringer Ingelheim Ltd)
  - Nevirapine 50 mg Viramune 50mg modified-release tablets | 180 tablet PVP £127.50 (Hospital only)
  - Nevirapine 100 mg Viramune 100mg modified-release tablets | 90 tablet PVP £127.50 (Hospital only)
  - Nevirapine 400 mg Viramune 400mg modified-release tablets | 30 tablet PVP £170.00 (Hospital only)

Oral suspension

- Viramune (Boehringer Ingelheim Ltd)
  - Nevirapine (as Nevirapine hemihydrate) 10 mg per 1 ml Viramune 50mg/5ml oral suspension | 240 ml PVP £50.40

- Envirapine (Janssen-Cilag Ltd)
  - Etravirine 100 mg Etravirine 100mg modified-release tablets | 180 tablet PVP £127.50 (Hospital only)
  - Etravirine 200 mg Etravirine 200mg modified-release tablets | 60 tablet PVP £127.50 (Hospital only)
  - Etravirine 500 mg Etravirine 500mg modified-release tablets | 30 tablet PVP £170.00 (Hospital only)
Rilpivirine

INDICATIONS AND DOSE
HIV infection in combination with other antiretroviral drugs in patients not previously treated with antiretroviral therapy and if plasma HIV-1 RNA concentration less than 100,000 copies/mL

BY MOUTH

Adult: 25 mg once daily

INTERACTIONS

> Appendix 1 (rilpivirine).

SIDE-EFFECTS

Abnormal dreams - anorexia - depression - dizziness - dry mouth - headache - hyperlipidaemia - Lipodystrophy Syndrome - malaise - nausea - osteonecrosis - raised serum amylase - raised serum lipase - rash - sleep disturbances - vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Lipodystrophy

For further information see HIV infection p. 555.

Osteonecrosis

For further information see HIV infection p. 555.

PREGNANCY

Manufacturer advises caution in moderate impairment; avoid in severe impairment — no information available; greater risk of hepatic side-effects in chronic hepatitis B or C.

HEPATIC IMPAIRMENT

Manufacturer advises caution in severe impairment.

DIRECTIONS FOR ADMINISTRATION

Avoid antacids 2 hours before or 4 hours after taking rilpivirine.

PATIENT AND CARER ADVICE

Missed doses

If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. Patients or carers should be given advice on how to administer rilpivirine tablets.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS

Edurant (Janssen-Cilag Ltd).

Rilpivirine (as Rilpivirine hydrochloride) 25 mg

Edurant 25 mg tablets | 30 tablet blister pack £20.27

Also available in combination with emtricitabine and tenofovir, p. 565

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Nucleoside reverse transcriptase inhibitors

> Appendix 1 (abacavir).

SIDE-EFFECTS


SIDE-EFFECTS, FURTHER INFORMATION

Lipodystrophy Syndrome

For further information see HIV infection p. 555.

Osteonecrosis

For further information see HIV infection p. 555.

PREGNANCY

Mitochondrial dysfunction has been reported in infants exposed to nucleoside reverse transcriptase inhibitors in utero; the main effects include haematological, metabolic, and neurological disorders; all infants whose mothers received nucleoside reverse transcriptase inhibitors during pregnancy should be monitored for relevant signs or symptoms.

HEPATIC IMPAIRMENT

Use with caution in patients with chronic hepatitis B or C (greater risk of hepatic side-effects).

Abacavir

INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs

BY MOUTH

Adult: 600 mg daily in 1–2 divided doses

CAUTIONS

HIV load greater than 100,000 copies/mL - patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)

INTERACTIONS

> Appendix 1 (abacavir).

SIDE-EFFECTS

Very rare - Stevens-Johnson syndrome - toxic epidermal necrolysis

Frequency not known - Hypersensitivity reactions

Hypersensitivity reactions

Life-threatening hypersensitivity reactions reported—characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis; laboratory abnormalities may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time. Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out, even when other diagnoses possible—if rechallenge necessary it must be carried out in hospital setting; if abacavir is stopped for any reason other than hypersensitivity, exclude hypersensitivity reaction as the cause and rechallenge only if medical assistance is readily available; care needed with concomitant use of drugs which cause skin toxicity.

Gastro-intestinal disturbances

More common in children.

Rash

More common in children.
Abacavir with lamivudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 561, lamivudine p. 563.

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretrovirals by mouth
- Adult (body-weight 40 kg and above): 1 tablet once daily

**RENALE IMPAIRMENT** Avoid Kivexa® if eGFR less than 50 mL/minute/1.73 m² (consult product literature).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Kivexa (ViiV Healthcare UK Ltd)
  Abacavir (as Abacavir sulfate) 600 mg, Lamivudine 300 mg
  Kivexa 600mg/300mg tablets | 30 tablet £299.41

Abacavir with lamivudine and zidovudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 561, lamivudine p. 563, zidovudine p. 566.

**INDICATIONS AND DOSE**

HIV infection (use only if patient is stabilised for 6–8 weeks on the individual components in the same proportions) by mouth
- Adult: 1 tablet twice daily

**RENALE IMPAIRMENT** Avoid Trizivir® if eGFR less than 50 mL/minute/1.73 m² (consult product literature). Avoid Trizivir® if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Trizivir (ViiV Healthcare UK Ltd)
  Abacavir (as Abacavir sulfate) 300 mg, Lamivudine 150 mg, Zidovudine 300 mg
  Trizivir tablets | 60 tablet £142.70

Didanosine (ddi; DDI)

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretrovirals by mouth
- Adult (body-weight up to 60 kg): 250 mg daily in 1–2 divided doses
- Adult (body-weight 60 kg and above): 400 mg daily in 1–2 divided doses

**CAUTIONS** History of pancreatitis (preferably avoid, otherwise extreme caution) • hyperuricaemia • peripheral neuropathy

**INTERACTIONS** Appendix 1 (didanosine).

Antacids in tablet formulation might affect absorption of other drugs—give at least 2 hours apart.

**SIDE-EFFECTS** Acute renal failure • alopecia • anaphylactic reactions • diabetes mellitus • dry eyes • dry mouth • hyperuricaemia (suspend if raised significantly) • hypoglycaemia • liver failure • non-cirrhotic portal hypertension • optic nerve changes • pancreatitis (less
common in children - parotid gland enlargement - peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops) - retinal changes - rhabdomyolysis - siadalenitis

**SIDE-EFFECTS, FURTHER INFORMATION**

**Pancreatitis** Suspend treatment if serum lipase raised (even if asymptomatic) or if symptoms of pancreatitis develop; discontinue if pancreatitis confirmed. Whenever possible avoid concomitant treatment with other drugs known to cause pancreatic toxicity (e.g. intravenous pentamidine isetionate); monitor closely if concomitant therapy unavoidable. Since significant elevations of triglycerides cause pancreatitis monitor closely if elevated.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**HEPATIC IMPAIRMENT** Insufficient information. In hepatic impairment, monitor for toxicity.

**RENAL IMPAIRMENT** Reduce dose if eGFR less than 60 mL/minute/1.73 m²; consult product literature.

**MONITORING REQUIREMENTS** Ophthalmological examination (including visual acuity, colour vision, and dilated fundus examination) recommended annually or if visual changes occur.

**DIRECTIONS FOR ADMINISTRATION** With chewable tablets, to ensure sufficient antacid, each dose to be taken as at least 2 tablets (child under 1 year 1 tablet) chewed thoroughly, crushed or dispersed in water; clear apple juice may be added for flavouring; tablets to be taken 2 hours after food; capsules should be swallowed whole and taken at least 2 hours before or 2 hours after food.

**PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer didanosine capsules and chewable tablets.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Chewable tablet**

- **Gastro-resistant capsule**
  - **Videx (Bristol-Myers Squibb Pharmaceuticals Ltd)**
    - Didanosine 25 mg: Videx 25mg chewable dispersible tablets (sugar-free) | 60 tablet (POM) £25.06 (Hospital only)
  - **Videx EC (Bristol-Myers Squibb Pharmaceuticals Ltd)**
    - Didanosine 25 mg: Videx EC 125mg capsules | 30 capsule (POM) £46.18 (Hospital only)
    - Didanosine 200 mg: Videx EC 200mg capsules | 30 capsule (POM) £17.09 (Hospital only)
    - Didanosine 250 mg: Videx EC 250mg capsules | 30 capsule (POM) £96.37 (Hospital only)
    - Didanosine 400 mg: Videx EC 400mg capsules | 30 capsule (POM) £154.19 (Hospital only)

**Emtricitabine**

**(FTC)**

**INDICATIONS AND DOSE**

**HIV infection in combination with other antiretroviral drugs**

- **BY MOUTH USING CAPSULES**
  - Adult: 200 mg once daily
- **BY MOUTH USING ORAL SOLUTION**
  - Adult: 240 mg once daily

Dose equivalence and conversion

240 mg oral solution ≡ 200 mg capsule; where appropriate the capsule may be used instead of the oral solution.

**INTERACTIONS** → Appendix 1 (emtricitabine).

**SIDE-EFFECTS** Abnormal dreams - hyperpigmentation - pruritus

**HEPATIC IMPAIRMENT** On discontinuation, monitor patients with hepatitis B (risk of exacerbation of hepatitis).

**RENAL IMPAIRMENT** Reduce dose if eGFR less than 50 mL/minute/1.73 m²; consult product literature.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include candy.

**PATIENT AND CARER ADVICE** Missed doses. If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **Emtriva (Gilead Sciences International Ltd)**
  - Emtricitabine 200 mg: Emtriva 200mg capsules | 30 capsule (POM) £138.98

**Oral solution**

ELECTROLYTES: May contain Sodium

- **Emtriva (Gilead Sciences International Ltd)**
  - Emtricitabine 10 mg per 1 ml: Emtriva 10mg/ml oral solution (sugar-free) | 170 ml (POM) £39.53

Also available in combination with cobicistat with elvitegravir, tenofovir, p. 565 · efavirenz with tenofovir, p. 565 · rilpivirine and tenofovir, p. 565 · tenofovir, p. 566

**Lamivudine**

**(3TC)**

**INDICATIONS AND DOSE**

**ZEFFIX®**

Chronic hepatitis B infection either with compensated liver disease (with evidence of viral replication and histology of active liver inflammation or fibrosis) when first-line treatments cannot be used, or (in combination with another antiviral drug without cross-resistance to lamivudine) with decompensated liver disease

**BY MOUTH**

- Adult: 100 mg once daily, patients receiving lamivudine for concomitant HIV infection should continue to receive lamivudine in a dose appropriate for HIV infection

**EPIVIR® TABLETS**

HIV infection in combination with other antiretroviral drugs

**BY MOUTH**

- Adult: 150 mg every 12 hours, alternatively 300 mg once daily

**EPIVIR® ORAL SOLUTION**

HIV infection in combination with other antiretroviral drugs

**BY MOUTH**

- Adult: 150 mg every 12 hours, alternatively 300 mg once daily

**CAUTIONS** Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine.

**INTERACTIONS** → Appendix 1 (lamivudine).

**SIDE-EFFECTS** Alopecia - muscle disorders - nasal symptoms - peripheral neuropathy - rhabdomyolysis

**BREAST FEEDING** Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.

**RENAL IMPAIRMENT** Reduce dose if eGFR less than 50 mL/minute/1.73 m²; consult product literature.
Stavudine (d4T)

**INDICATIONS AND DOSE**
HIV infection in combination with other antiretroviral drugs when no suitable alternative available and when prescribed for shortest period possible

**BY MOUTH**
- Adult (body-weight up to 60 kg): 30 mg every 12 hours, to be taken preferably at least 1 hour before food
- Adult (body-weight 60 kg and above): 40 mg every 12 hours, to be taken preferably at least 1 hour before food

**CAUTIONS**
Excessive alcohol intake · higher risk of lactic acidosis than other nucleoside reverse transcriptase inhibitors (especially when used in combination with didanosine)—use only if alternative regimens are not suitable · history of pancreatitis · history of peripheral neuropathy

**INTERACTIONS**
Appendix 1 (stavudine). Caution with concomitant use of isoniazid—risk of peripheral neuropathy. Caution with concomitant use with other drugs associated with pancreatitis.

**SIDE-EFFECTS**
- Common or very common · Abnormal dreams · cognitive dysfunction · depression · drowsiness · peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops) · pruritus
- Uncommon · Anxiety · gynaecomastia
- PREGNANCY
- Manufacturer advises use only if potential benefit outweighs risk.
- RENAL IMPAIRMENT
- Use half normal dose every 12 hours if eGFR 25–50 mL/minute/1.73 m². Use half normal dose every 24 hours if eGFR less than 25 mL/minute/1.73 m².

Risk of peripheral neuropathy.

**PRESCRIBING AND DISPENSING INFORMATION**
Flavours of oral liquid formulations may include cherry.

**LESS SUITABLE FOR PRESCRIBING**
Stavudine (especially in combination with didanosine) is associated with a higher risk of lipodystrophy and should be used only if alternative regimens are not suitable; it is considered to be less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- LAMIVUDINE (Non proprietary)
  - Lamivudine 100 mg Lamivudine 100mg tablets | 28 tablet £74.19-£78.09 DT price = £74.55
  - Lamivudine 150 mg Lamivudine 150mg tablets | 60 tablet £85.80–£136.15
  - Lamivudine 300 mg Lamivudine 300mg tablets | 30 tablet £54.98–£149.63
- Epivir (ViiV Healthcare UK Ltd)
  - Lamivudine 150 mg Epivir 150mg tablets | 60 tablet £121.82
  - Lamivudine 300 mg Epivir 300mg tablets | 30 tablet £133.89
- Zeffix (GlaxoSmithKline Ltd)
  - Lamivudine 100 mg Zeffix 100mg tablets | 28 tablet £78.09

**Oral solution**
- EXCipients: May contain Sucrose
  - Epivir (ViiV Healthcare UK Ltd)
  - Lamivudine 10 mg per 1 ml Epivir 50mg/5ml oral solution | 240 ml £33.16

Also available in combination with abacavir and dolutegravir, p. 562 · abacavir, p. 562 · abacavir and zidovudine, p. 562 · zidovudine, p. 567

**Tenofovir disoproxil**

**INDICATIONS AND DOSE**
HIV infection in combination with other antiretroviral drugs (Chronic hepatitis B infection with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis)) | Chronic hepatitis B infection with decompensated liver disease

**BY MOUTH**
- Adult: 245 mg once daily

**Dose equivalence and conversion**
7.5 scoops of granules contains approx. 245 mg tenofovir disoproxil (as fumarate).

**INTERACTIONS**
Appendix 1 (tenofovir). Use with caution if concomitant or recent use of nephrotoxic drugs.

**SIDE-EFFECTS**
- Rare · Nephrogenic diabetes insipidus · proximal renal tubulopathy · renal failure
- Frequency not known · Hypophosphataemia · reduced bone density

**RENA L IMPAIRMENT**
- Granules: 132 mg once daily if eGFR 30–50 mL/minute/1.73 m²; 66 mg once daily if eGFR 20–30 mL/minute/1.73 m²; 33 mg once daily if eGFR 10–20 mL/minute/1.73 m². Tablets: 245 mg every 2 days if eGFR 30–50 mL/minute/1.73 m²; 245 mg every 3–4 days if eGFR 10–30 mL/minute/1.73 m². Monitor renal function—interrupt treatment if further deterioration.

**MONITORING REQUIREMENTS**
- Test renal function and serum phosphate before treatment, then every 4 weeks (more frequently if at increased risk of renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate decreases.
- When treating chronic hepatitis B with tenofovir, monitor liver function tests every 3 months and viral markers for hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

**DIRECTIONS FOR ADMINISTRATION**
- Granules: mix 1 scoop of granules with 1 tablespoon of soft food (e.g. yoghurt, apple sauce) and take immediately without chewing. Do not mix granules with liquids.
Cobicistat with elvitegravir, emtricitabine and tenofovir

The properties listed below are those particular to the combination only. For the properties of the components please consider, emtricitabine p. 563, tenofovir disoproxil p. 564, cobicistat p. 567.

INDICATIONS AND DOSE
HIV infection
BY MOUTH
Adult: 1 tablet once daily

INTERACTIONS → Appendix 1 (cobicistat, elvitegravir, emtricitabine, tenofovir).

SIDE-EFFECTS
Uncommon Depression and suicidal ideation (in patients with a history of psychiatric illness)

CONCEPTION AND CONTRACEPTION Women of childbearing potential should use effective contraception during treatment (if using a hormonal contraceptive, it must contain norgestimate as the progestogen and at least 30 micrograms ethinylestradiol).

PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.

HEPATIC IMPAIRMENT Avoid Strivid® in severe impairment.

RENAL IMPAIRMENT If eGFR less than 90 mL/minute/1.73 m², only initiate Strivid® if other treatments cannot be used (avoid initiating Strivid® if eGFR less than 70 mL/minute/1.73 m²); if eGFR less than 70 mL/minute/1.73 m², only continue Strivid® if potential benefit outweighs risk (discontinue Strivid® if eGFR less than 50 mL/minute/1.73 m²).

MONITORING REQUIREMENTS Test urine glucose before treatment, then every 4 weeks for 1 year and then every 3 months.

DIRECTIONS FOR ADMINISTRATION Avoid antacids 4 hours before or 4 hours after taking Strivid®.

PRESCRIBING AND DISPENSING INFORMATION Dispense in original container (contains desiccant).

PATIENT AND CARER ADVICE
Missed doses
If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Efavirenz with emtricitabine and tenofovir

The properties listed below are those particular to the combination only. For the properties of the components please consider, efavirenz p. 558, emtricitabine p. 563, tenofovir disoproxil p. 564.

INDICATIONS AND DOSE
HIV infection stabilised on antiretroviral therapy for more than 3 months
BY MOUTH
Adult: 1 tablet once daily

HEPATIC IMPAIRMENT Manufacturer of Atripla® advises caution in mild impairment; avoid Atripla® in moderate to severe impairment.

RENAL IMPAIRMENT Avoid Atripla® if eGFR less than 50 mL/minute/1.73 m².

PATIENT AND CARER ADVICE
Missed doses If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Emtricitabine with rilpivirine and tenofovir

The properties listed below are those particular to the combination only. For the properties of the components please consider, emtricitabine p. 563, rilpivirine p. 561, tenofovir disoproxil p. 564.

INDICATIONS AND DOSE
HIV infection in patients with plasma HIV-1 RNA concentration less than 100 000 copies/mL
BY MOUTH
Adult: 1 tablet once daily
HIV infection in combination with other antiretroviral drugs in patients temporarily unable to take zidovudine by mouth

BY INTRAVENOUS INFUSION

▶ Adult: 0.8–1 mg/kg every 4 hours usually for not more than 2 weeks, dose approximating to 1.2–1.5 mg/kg every 4 hours by mouth

CONTRA-INDICATIONS

Acute porphyrias p. 864 • abnormally low haemoglobin concentration (consult product literature) • abnormally low neutrophil counts (consult product literature)

CAUTIONS

Elderly • risk of haematological toxicity particularly with high dose and advanced disease • vitamin B12 deficiency (increased risk of neutropenia)

INTERACTIONS

▶ Appendix 1 (zidovudine). Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature.

SIDE-EFFECTS

Anaemia (may require transfusion) • anxiety • chest pain • convulsions • depression • dizziness • drowsiness • gynaecomastia • influenza-like symptoms • loss of mental acuity • myopathy • neuropathy • paraesthesia • pigmentation of nails • pigmentation of oral mucosa • pigmentation of skin • pruritus • sweating • taste disturbance • urinary frequency

SIDE-EFFECTS, FURTHER INFORMATION

Anaemia and myelosuppression If anaemia or myelosuppression occur, reduce dose or interrupt treatment according to product literature, or consider other treatment

Lipoatrophy Zidovudine is associated with a higher risk of lipoatrophy than other antiretrovirals and should be used only if alternative regimens are not suitable.

HEPATIC IMPAIRMENT

Accumulation may occur.

RENAL IMPAIRMENT

Reduce oral dose to 300–400 mg daily in divided doses or intravenous dose to 1 mg/kg 3–4 times daily if eGFR is less than 10 mL/minute/1.73 m².

MONITORING REQUIREMENTS

Monitor full blood count after 4 weeks of treatment, then every 3 months.

DIRECTIONS FOR ADMINISTRATION

For intermittent intravenous infusion, dilute to a concentration of 2 mg/mL or 4 mg/mL with Glucose 5% and give over 1 hour.

PRESCRIBING AND DISPENSING INFORMATION

The abbreviation AZT which is sometimes used for zidovudine has also been used for another drug.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

▶ ZIDOVUDINE (Non-proprietary)

Zidovudine 100 mg Zidovudine 100mg capsules | 60 capsule £40.41

Zidovudine 250 mg Zidovudine 250mg capsules | 60 capsule £96.36

▶ Retrovir (ViiV Healthcare UK Ltd)

Zidovudine 100 mg Retrovir 100mg capsules | 100 capsule £68.86

Zidovudine 250 mg Retrovir 250mg capsules | 40 capsule £88.86

Oral solution

▶ Retrovir (ViiV Healthcare UK Ltd)

Zidovudine 10 mg per 1 ml Retrovir 50mg/5ml oral solution (sugar-free) | 200 ml £17.78

Solution for infusion

▶ Retrovir (ViiV Healthcare UK Ltd)

Zidovudine 10 mg per 1 ml Retrovir IV 200mg/20ml concentrate for solution for infusion vials | 5 vial £44.61

Emtricitabine with tenofovir

The properties listed below are those particular to the combination only. For the properties of the components please consider, emtricitabine p. 563, tenofovir disoproxil p. 564.

INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs

BY MOUTH

▶ Adult: 1 tablet once daily

RENAL IMPAIRMENT

Use normal dose of Truvada® every 2 days if eGFR 30–50 mL/minute/1.73 m².

Avoid Truvada® if eGFR less than 30 mL/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION

Patients with swallowing difficulties may disperse tablet in half a glass of water, orange juice, or grape juice (but bitter taste).

PATIENT AND CARER ADVICE

Missed doses

If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Patients or carers should be given advice on how to administer Emtriva®.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21, 25

► Emtriva (Gilead Sciences International Ltd)

Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg Truvada tablets | 30 tablet £55.95

Zidovudine (Azidothymidine; AZT)

INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs

BY MOUTH

▶ Adult: 250–300 mg twice daily

Prevention of maternal-fetal HIV transmission

BY MOUTH OR BY INTRAVENOUS INFUSION

▶ Adult: Seek specialist advice (combination therapy preferred) (consult local protocol)
Abacavir with lamivudine and zidovudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 561, lamivudine p. 563, zidovudine p. 566.

**INDICATIONS AND DOSE**

HIV infection (use only if patient is stabilised for 6–8 weeks on the individual components in the same proportions)

**BY MOUTH**

- **Adult:** 1 tablet twice daily

**RENAL IMPAIRMENT**

Avoid *Trizivir*® if eGFR less than 50 mL/minute/1.73 m² (consult product literature). Avoid *Trizivir*® if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - *Trizivir* (ViiV Healthcare UK Ltd)
  - Abacavir (as Abacavir sulfate) 300 mg, Lamivudine 150 mg, Zidovudine 300 mg *Trizivir* tablets | 60 tablet [POD] £432.70

Lamivudine with zidovudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, lamivudine p. 563, zidovudine p. 566.

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretrovirals

**BY MOUTH**

- **Adult:** 1 tablet twice daily

**RENAL IMPAIRMENT**

Avoid if eGFR less than 50 mL/minute/1.73 m² (consult product literature).

**DIRECTIONS FOR ADMINISTRATION**

**COMBIVIR® TABLETS**

Tablets may be crushed and mixed with semi-solid food or liquid just before administration.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - **LAMIVUDINE WITH ZIDOVUDINE (Non-proprietary)**
    - Lamivudine 150 mg, Zidovudine 300 mg | Zidovudine 300mg tablets | 60 tablet [POD] £70.61–£80.12
  - **Combivir** (ViiV Healthcare UK Ltd)
    - Lamivudine 150 mg, Zidovudine 300 mg | Combivir 150mg/300mg tablets | 60 tablet [POD] £255.10

**PHARMACOKINETIC ENHANCERS**

**Cobicistat**

**INDICATIONS AND DOSE**

Pharmacokinetic enhancer used to increase the effect of atazanavir or darunavir

**BY MOUTH**

- **Adult:** 150 mg once daily

**INTERACTIONS**

† Appendix 1 (cobicistat).

**PREGNANCY**

Manufacturer advises avoid unless essential.

**HEPATIC IMPAIRMENT**

Manufacturer advises avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**

No dose adjustment required; inhibits tubular secretion of creatinine; when any co-administered drug requires dose adjustment based on renal function, avoid initiating cobicistat if eGFR less than 70 mL/minute/1.73 m².

**PRESCRIBING AND DISPENSING INFORMATION**

Dispense in original container (contains desiccant).

**PATIENT AND CARER ADVICE**

**Missed doses**

If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS** 21
    - *Tybost* (Gilead Sciences International Ltd) ▼
      - Cobicistat 150 mg Tybost 150mg tablets | 30 tablet [POD] £21.38
  - Also available in combination with *elvitegravir, emtricitabine and tenofovir*, p. 565

**PROTEASE INHIBITORS (HIV)**

**Protease inhibitors**

**CONTRA-INDICATIONS**

Acute porphyrias p. 864

**CAUTIONS**

Diabetes - haemophilia (increased risk of bleeding)

**SIDE-EFFECTS**


**SIDE-EFFECTS, FURTHER INFORMATION**

Lipodystrophy Syndrome For further information see HIV infection p. 555.

**OSTEONECROSIS**

For further information see HIV infection p. 555.

**HEPATIC IMPAIRMENT**

Use with caution in patients with chronic hepatitis B or C (increased risk of hepatic side-effects).

**Atazanavir**

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs—*with low-dose ritonavir*

**BY MOUTH**

- **Adult:** 300 mg once daily

**HIV infection in combination with other antiretroviral drugs—*with cobicistat***

**BY MOUTH**

- **Adult:** 300 mg daily

**CAUTIONS**

Cardiac conduction disorders - electrolyte disturbances - predisposition to QT interval prolongation

**INTERACTIONS**

† Appendix 1 (atazanavir).

Caution if concomitant use with drugs that prolong PR interval. Caution with concomitant use of drugs that prolong QT interval.

**SIDE-EFFECTS**

- **Uncommon** Abnormal dreams - alopecia - amnesia - anxiety - arthralgia - chest pain - cholelithiasis - depression - disorientation - dry mouth - dyspnoea - gynaecomastia - haematuria - hypertension - increased appetite - mouth
ulcers · nephrolithiasis · peripheral neuropathy · proteinuria · syncope · torsiade de pointes · urinary frequency · weight changes

- **Rare** Abnormal gait · cholecystitis · hepatosplenomegaly · oedema · palpititation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Rash** Mild to moderate rash occurs commonly, usually within the first 3 weeks of therapy. Severe rash occurs less frequently and may be accompanied by systemic symptoms. Discontinue if severe rash develops.

- **PREGNANCY** Theoretical risk of hyperbilirubinemia in neonate if used at term. In pregnancy, monitor viral load and plasma-atazanavir concentration during third trimester.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild impairment; avoid in moderate to severe impairment.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**

  **CAUTIONARY AND ADVISORY LABELS 5, 21**

  - Reyataz (Bristol-Myers Squibb Pharmaceuticals Ltd)
    - Darunavir (as Darunavir ethanolate) 150 mg Reyataz 150mg capsules | 60 capsule (£90.38 (Hospital only))
    - Darunavir (as Darunavir ethanolate) 200 mg Reyataz 200mg capsules | 60 capsule (£90.38 (Hospital only))
    - Darunavir (as Daranavir ethanolate) 300 mg Reyataz 300mg capsules | 30 capsule (£90.38 (Hospital only))

**Darunavir**

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretroviral therapy—with low-dose ritonavir

**BY MOUTH**

- Adult: 600 mg twice daily, alternatively 800 mg once daily if no resistance to darunavir, if plasma HIV-RNA concentration less than 100 000 copies/mL, and if CD4 cell count greater than 100 cells × 10⁹/litre

HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretroviral therapy—with cobicistat

**BY MOUTH**

- Adult: 800 mg once daily, if no resistance to darunavir, if plasma HIV-RNA concentration less than 100 000 copies/mL, and if CD4 cell count greater than 100 cells × 10⁹/litre

HIV infection in combination with other antiretroviral drugs in patients not previously treated with antiretroviral therapy—with low-dose ritonavir

**BY MOUTH**

- Adult: 800 mg once daily

**INTERACTIONS** → Appendix 1 (darunavir).

**SIDE-EFFECTS**

- **Common or very common** Peripheral neuropathy · rash

- **Uncommon** Abnormal dreams · acne · alopecia · angina · anxiety · arthralgia · conjunctival hyperaemia · cough · depression · dry eyes · dry mouth · dysphagia · dysuria · eczema · erectile dysfunction · flushing · gynaecomastia · hypertension · hypothyroidism · increased appetite · increased sweating · memory impairment · myocardial infarction · nail discolouration · nephrolithiasis · osteoporosis · peripheral oedema · polyuria · pyrexia · QT interval prolongation · reduced libido · renal failure · severe skin rash · Stevens-Johnson syndrome · stomatitis · tachycardia · throat irritation · toxic epidermal necrolysis · weight changes

- **Rare** Bradycardia · confusion · convulsions · haematemesis · palpititation · rhinorrhea · seborrhoeic dermatitis · syncope · visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

**Rash** Mild to moderate rash occurs commonly, usually within the first 4 weeks of therapy and resolves without stopping treatment. Severe skin rash (including Stevens-Johnson syndrome and toxic epidermal necrolysis) occurs less frequently and may be accompanied by fever, malaise, arthralgia, myalgia, oral lesions, conjunctivitis, hepatitis, or eosinophilia; treatment should be stopped if severe rash develops.

- **ALLERGY AND CROSS-SENSITIVITY** Use with caution in patients with sulphonamide sensitivity.

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk; if required, use the twice daily dose regimen.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment—no information available.

- **MONITORING REQUIREMENTS** Monitor liver function before and during treatment.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include strawberry.

- **PATIENT AND CARER ADVICE**

  **Missed doses** If a dose is more than 6 hours late on the twice daily regimen (or more than 12 hours late on the once daily regimen), the missed dose should not be taken and the next dose should be taken at the normal time.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**

  **CAUTIONARY AND ADVISORY LABELS 21**

  - Prezista (Janssen-Cilag Ltd)
    - Darunavir (as Darunavir ethanolate) 75 mg Prezista 75mg tablets | 480 tablet (£446.70)
    - Darunavir (as Darunavir ethanolate) 150 mg Prezista 150mg tablets | 240 tablet (£446.70)
    - Darunavir (as Darunavir ethanolate) 400 mg Prezista 400mg tablets | 60 tablet (£297.80)
    - Darunavir (as Darunavir ethanolate) 600 mg Prezista 600mg tablets | 60 tablet (£446.70)
    - Darunavir (as Darunavir ethanolate) 800 mg Prezista 800mg tablets | 30 tablet (£297.80)

  **Oral suspension**

  **CAUTIONARY AND ADVISORY LABELS 21**

  - Prezista (Janssen-Cilag Ltd)
    - Darunavir (as Darunavir ethanolate) 100 mg per 1 ml Prezista 100mg/ml oral suspension (sugar-free) | 200 ml (£248.17)

**Fosamprenavir**

- **DRUG ACTION** Fosamprenavir is a pro-drug of ampranavir.

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs—with low-dose ritonavir

**BY MOUTH**

- Adult: 700 mg twice daily

**Dose equivalence and conversion**

700 mg fosamprenavir is equivalent to approximately 600 mg ampranavir.

**INTERACTIONS** → Appendix 1 (fosamprenavir).
a low-fat light meal; in combination with didanosine tablets, allow 1 hour between each drug (antacids in didanosine tablets reduce absorption of indinavir); in combination with low-dose ritonavir, give with food.

**SIDE-EFFECTS, FURTHER INFORMATION**

- Rash Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption—usually resolves within 2 weeks and may respond to antihistamines.
- **PREGNANCY** Toxicity in animal studies; manufacturer advises use only if potential benefit outweighs risks.
- **HEPATIC IMPAIRMENT** Reduce dose to 450 mg twice daily in moderate impairment; reduce dose to 300 mg twice daily in severe impairment. Manufacturer advises caution in mild impairment.
- **DIRECTIONS FOR ADMINISTRATION** Oral suspension should be taken on an empty stomach.

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs

- **BY MOUTH USING TABLETS**
  - Adult: 400/100 mg twice daily, alternatively (by mouth) 800/200 mg once daily in adults with a HIV strain that has less than 3 mutations to protease inhibitors.
  - **INTERACTIONS** → Appendix 1 (lopinavir, ritonavir).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **Crixivan** (ViiV Healthcare UK Ltd) Indinavir (as Indinavir sulfate) 200 mg Crixivan 200mg capsules | 360 capsule pack £81.02
- Indinavir (as Indinavir sulfate) 400 mg Crixivan 400mg capsules | 180 capsule pack £161.02

**Dose equivalence and conversion**

The proportions are expressed in the form x/y where x and y are the strengths in milligrams of lopinavir and ritonavir respectively.

**CAUTIONS** Cardiac conduction disorders · pancreatitis · patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%) · structural heart disease

**SIDE-EFFECTS**

- Common or very common Amenorrhoea · anxiety · arthralgia · colitis · hypertension · menorrhagia · neuropathy · night sweats · sexual dysfunction · weight changes
- Uncommon Abnormal dreams · alopecia · AV block · cerebrovascular accident · convulsions · deep vein thrombosis · dry mouth · gastro-intestinal ulcer · haematuria · myocardial infarction · nephritis · rectal bleeding · stomatitis · tinnitus · tremor · visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- **PREGNANCY** Avoid oral solution due to high propylene glycol content; use tablets only if potential benefit outweighs risk (toxicity in animal studies).
- **HEPATIC IMPAIRMENT** Avoid oral solution due to propylene glycol content; manufacturer advises avoid tablets in severe impairment.
RENAL IMPAIRMENT  Avoid oral solution due to high propylene glycol content. Use tablets with caution in severe impairment.

MONITORING REQUIREMENTS  Monitor liver function before and during treatment.

PATIENT AND CARER ADVICE  Oral solution tastes bitter.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS  21, 25

Norvir 100 mg  Norvir 100mg tablets  30 tablet  £19.44

Oral solution

CAUTIONARY AND ADVISORY LABELS  21

EXCIPIENTS: May contain Alcohol, propylene glycol

Ritonavir 80 mg per 1 ml  Norvir 80mg/ml oral solution (sugar-free)  450 ml  £403.20

INDICATIONS AND DOSE

HIV infection in combination with other antiretrovirals in patients previously treated with antiretroviral therapy— with low-dose ritonavir

BY MOUTH

Adult:  1 g every 12 hours

HIV infection in combination with other antiretrovirals in patients not previously treated with antiretroviral therapy—with low-dose ritonavir

BY MOUTH

Adult:  500 mg every 12 hours for 7 days, then increased to 1 g every 12 hours

CONTRA-INDICATIONS  Bradycardia · congenital QT prolongation · electrolyte disturbances · heart failure with reduced left ventricular ejection fraction · history of symptomatic arrhythmias · predisposition to cardiac arrhythmias

INTERACTIONS  → Appendix 1 (saquinavir). Caution with concomitant use of garlic (avoid garlic capsules—reduces plasma-saquinavir concentration). Contra-indicated if concomitant use of drugs that prolong QT or PR interval. Contra-indicated if concomitant use of drugs that increase plasma-saquinavir concentration (avoid unless no alternative treatment available).

SIDE-EFFECTS  Common or very common  Alopecia · changes in libido · dry mouth · dysphonia · increased appetite · peripheral neuropathy

Rare

SIDE-EFFECTS, FURTHER INFORMATION

Pancreatitis  Signs and symptoms suggestive of pancreatitis (including raised serum lipase) should be evaluated—discontinue if pancreatitis diagnosed.

PREGNANCY  Only use low-dose booster to increase the effect of other protease inhibitors.

HEPATIC IMPAIRMENT  Avoid in decompensated liver disease; in severe impairment without decompensation, use 'booster' doses with caution (avoid treatment doses).

DIRECTIONS FOR ADMINISTRATION  Bitter taste of oral solution can be masked by mixing with chocolate milk; do not mix with water, measuring cup must be dry.

PATIENT AND CARER ADVICE  Patients or carers should be given advice on how to administer ritonavir oral solution.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet

Kaletra

EXCIPIENTS: May contain Alcohol, propylene glycol

Ritonavir 80 mg per 1 ml  Kaletra 80mg/ml oral solution (sugar-free)  1500 ml  £737.25

Saquinavir

INDICATIONS AND DOSE

HIV infection in combination with other antiretrovirals in patients previously treated with antiretroviral therapy— with low-dose ritonavir

BY MOUTH

Adult:  1 g every 12 hours

HIV infection in combination with other antiretrovirals in patients not previously treated with antiretroviral therapy—with low-dose ritonavir

BY MOUTH

Adult:  500 mg every 12 hours for 7 days, then increased to 1 g every 12 hours

CONTRA-INDICATIONS  Bradycardia · congenital QT prolongation · electrolyte disturbances · heart failure with reduced left ventricular ejection fraction · history of symptomatic arrhythmias · predisposition to cardiac arrhythmias

INTERACTIONS  → Appendix 1 (saquinavir). Caution with concomitant use of garlic (avoid garlic capsules—reduces plasma-saquinavir concentration). Contra-indicated if concomitant use of drugs that prolong QT or PR interval. Contra-indicated if concomitant use of drugs that increase plasma-saquinavir concentration (avoid unless no alternative treatment available).

SIDE-EFFECTS  Common or very common  Alopecia · changes in libido · dry mouth · dysphonia · increased appetite · peripheral neuropathy

Rare

SIDE-EFFECTS, FURTHER INFORMATION

Pancreatitis  Signs and symptoms suggestive of pancreatitis (including raised serum lipase) should be evaluated—discontinue if pancreatitis diagnosed.

PREGNANCY  Only use low-dose booster to increase the effect of other protease inhibitors.

HEPATIC IMPAIRMENT  Avoid in decompensated liver disease; in severe impairment without decompensation, use 'booster' doses with caution (avoid treatment doses).

DIRECTIONS FOR ADMINISTRATION  Bitter taste of oral solution can be masked by mixing with chocolate milk; do not mix with water, measuring cup must be dry.

PATIENT AND CARER ADVICE  Patients or carers should be given advice on how to administer ritonavir oral solution.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet

Kaletra

EXCIPIENTS: May contain Alcohol, propylene glycol

Ritonavir 80 mg per 1 ml  Kaletra 80mg/ml oral solution (sugar-free)  1500 ml  £737.25

Saquinavir

INDICATIONS AND DOSE

HIV infection in combination with other antiretrovirals in patients previously treated with antiretroviral therapy— with low-dose ritonavir

BY MOUTH

Adult:  1 g every 12 hours

HIV infection in combination with other antiretrovirals in patients not previously treated with antiretroviral therapy—with low-dose ritonavir

BY MOUTH

Adult:  500 mg every 12 hours for 7 days, then increased to 1 g every 12 hours

CONTRA-INDICATIONS  Bradycardia · congenital QT prolongation · electrolyte disturbances · heart failure with reduced left ventricular ejection fraction · history of symptomatic arrhythmias · predisposition to cardiac arrhythmias

INTERACTIONS  → Appendix 1 (saquinavir). Caution with concomitant use of garlic (avoid garlic capsules—reduces plasma-saquinavir concentration). Contra-indicated if concomitant use of drugs that prolong QT or PR interval. Contra-indicated if concomitant use of drugs that increase plasma-saquinavir concentration (avoid unless no alternative treatment available).

SIDE-EFFECTS  Common or very common  Alopecia · changes in libido · dry mouth · dysphonia · increased appetite · peripheral neuropathy

Rare

SIDE-EFFECTS, FURTHER INFORMATION

Pancreatitis  Signs and symptoms suggestive of pancreatitis (including raised serum lipase) should be evaluated—discontinue if pancreatitis diagnosed.

PREGNANCY  Only use low-dose booster to increase the effect of other protease inhibitors.

HEPATIC IMPAIRMENT  Avoid in decompensated liver disease; in severe impairment without decompensation, use 'booster' doses with caution (avoid treatment doses).

DIRECTIONS FOR ADMINISTRATION  Bitter taste of oral solution can be masked by mixing with chocolate milk; do not mix with water, measuring cup must be dry.

PATIENT AND CARER ADVICE  Patients or carers should be given advice on how to administer ritonavir oral solution.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet

Kaletra

EXCIPIENTS: May contain Alcohol, propylene glycol

Ritonavir 80 mg per 1 ml  Kaletra 80mg/ml oral solution (sugar-free)  1500 ml  £737.25

Saquinavir

INDICATIONS AND DOSE

HIV infection in combination with other antiretrovirals in patients previously treated with antiretroviral therapy— with low-dose ritonavir

BY MOUTH

Adult:  1 g every 12 hours

HIV infection in combination with other antiretrovirals in patients not previously treated with antiretroviral therapy—with low-dose ritonavir

BY MOUTH

Adult:  500 mg every 12 hours for 7 days, then increased to 1 g every 12 hours

CONTRA-INDICATIONS  Bradycardia · congenital QT prolongation · electrolyte disturbances · heart failure with reduced left ventricular ejection fraction · history of symptomatic arrhythmias · predisposition to cardiac arrhythmias

INTERACTIONS  → Appendix 1 (saquinavir). Caution with concomitant use of garlic (avoid garlic capsules—reduces plasma-saquinavir concentration). Contra-indicated if concomitant use of drugs that prolong QT or PR interval. Contra-indicated if concomitant use of drugs that increase plasma-saquinavir concentration (avoid unless no alternative treatment available).

SIDE-EFFECTS  Common or very common  Alopecia · changes in libido · dry mouth · dysphonia · increased appetite · peripheral neuropathy

Rare

SIDE-EFFECTS, FURTHER INFORMATION

Pancreatitis  Signs and symptoms suggestive of pancreatitis (including raised serum lipase) should be evaluated—discontinue if pancreatitis diagnosed.

PREGNANCY  Only use low-dose booster to increase the effect of other protease inhibitors.

HEPATIC IMPAIRMENT  Avoid in decompensated liver disease; in severe impairment without decompensation, use 'booster' doses with caution (avoid treatment doses).

DIRECTIONS FOR ADMINISTRATION  Bitter taste of oral solution can be masked by mixing with chocolate milk; do not mix with water, measuring cup must be dry.

PATIENT AND CARER ADVICE  Patients or carers should be given advice on how to administer ritonavir oral solution.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.
6.7 Influenza

### Oseltamivir

**INDICATIONS AND DOSE**

Prevention of influenza

**BY MOUTH**

- **Child 1-2 months:** 2.5 mg/kg once daily for 10 days for post-exposure prophylaxis
- **Child 3-11 months:** 3 mg/kg once daily for 10 days for post-exposure prophylaxis

**Dose equivalence and conversion**

- **Oseltamivir capsules**
  - Adult: 75 mg twice daily
  - Child <2 months: 140 mg/kg once daily
  - Child 2-11 months: 75 mg once daily
  - Child >11 months and <12 years: 150 mg twice daily

**Oseltamivir oral solution**

- Child: 10 mg/kg once daily

**Rare**

- Development of resistance to oseltamivir in influenza A virus may occur, typically in people who are severely immunocompromised or who received the drug very late after symptom onset.

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Digestive system**: Nausea, vomiting, abdominal discomfort, diarrhoea
- **Central nervous system**: Confusion, agitation, abnormally elevated body temperature (fever)
- **Skin and subcutaneous tissue**: Rash, itching, photosensitivity
- **Other adverse reactions**
  - Blood and blood-forming organ disorders: Anaemia, leucopenia, lymphopenia
  - Clinical, laboratory, and functional findings: Liver function test abnormalities, renal impairment

**Contraindications**

- Pneumonia cases where oseltamivir is unlikely to be effective
- Patients with severe heart or kidney disease
- Patients with severe liver disease
- Patients with severe neuromuscular disorders
- Patients with severe psychiatric disorders
- Patients with severe renal impairment

**Cautions**

- Patients with cardiac, renal, or psychiatric disorders
- Patients with cardiovascular disease
- Patients with diabetes mellitus
- Patients with seizures

**Drug interactions**

- Omeprazole, atazanavir, ritonavir, saquinavir

**Neurominidase inhibitors**

- **Neurominidase inhibitors**
  - **Oseltamivir**
  - **Zanamivir**

**Oseltamivir**

- **Drug action**: Reduces replication of influenza A and B viruses by inhibiting viral neuraminidase.

- **Indications and dose**
  - **Prevention of influenza**
    - **Child 1-2 months:** 2.5 mg/kg once daily for 10 days for post-exposure prophylaxis
    - **Child 3-11 months:** 3 mg/kg once daily for 10 days for post-exposure prophylaxis

- **Oseltamivir capsules**
  - Adult: 75 mg twice daily
  - Child <2 months: 140 mg/kg once daily
  - Child 2-11 months: 75 mg once daily
  - Child >11 months and <12 years: 150 mg twice daily

- **Oseltamivir oral solution**
  - Child: 10 mg/kg once daily
Infection

▶ Child 1-12 years (body-weight 10-15 kg): 30 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
▶ Child 1-12 years (body-weight 15-23 kg): 45 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
▶ Child 1-12 years (body-weight 23-40 kg): 60 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
▶ Child 1-12 years (body-weight 40 kg and above): 75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
▶ Adult: 75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic

Treatment of influenza

BY MOUTH
▶ Child 1-2 months: 2.5 mg/kg twice daily for 5 days
▶ Child 3-11 months: 3 mg/kg twice daily for 5 days
▶ Child 1-12 years (body-weight 10-15 kg): 30 mg twice daily for 5 days
▶ Child 1-12 years (body-weight 15-23 kg): 45 mg twice daily for 5 days
▶ Child 1-12 years (body-weight 23-40 kg): 60 mg twice daily for 5 days
▶ Child 1-12 years (body-weight 40 kg and above): 75 mg twice daily for 5 days
▶ Child 13-17 years: 75 mg twice daily for 5 days
▶ Adult: 75 mg twice daily for 5 days

UNLICENSED USE
Not licensed for use in children under 1 year of age unless there is a pandemic.

SIDE-EFFECTS
▶ Common or very common Abdominal pain · dyspepsia · headache · nausea · vomiting
▶ Uncommon Altered consciousness (usually in children and adolescents) · arrhythmias · convulsions · eczema · rash
▶ Rare Gastro-intestinal bleeding · hepatitis · neuropsychiatric disorders (usually in children and adolescents) · Stevens-Johnson syndrome · thrombocytopenia · toxic epidermal necrolysis · visual disturbances

PREGNANCY
Although safety data are limited, oseltamivir can be used in women who are pregnant when the potential benefit outweighs the risk (e.g. during a pandemic). Use only if potential benefit outweighs risk (e.g. during a pandemic).

BREAST FEEDING
Although safety data are limited, oseltamivir can be used in women who are breast-feeding when the potential benefit outweighs the risk (e.g. during a pandemic). Oseltamivir is the preferred drug in women who are breast-feeding. Amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic).

RENAL IMPAIRMENT
▶ In adults For treatment, use 30 mg twice daily if eGFR 30–60 mL/minute/1.73 m² (30 mg once daily if eGFR 10–30 mL/minute/1.73 m²). For prevention, use 30 mg once daily if eGFR 30–60 mL/minute/1.73 m² (30 mg every 48 hours if eGFR 10–30 mL/minute/1.73 m²). Avoid for treatment and prevention if eGFR less than 10 mL/minute/1.73 m².
▶ In children For treatment, use 40% of normal dose twice daily if estimated glomerular filtration rate 30–60 mL/minute/1.73 m² (40% of normal dose once daily if estimated glomerular filtration rate 10–30 mL/minute/1.73 m²). For prevention, use 40% of normal dose once daily if estimated glomerular filtration rate 30–60 mL/minute/1.73 m² (40% of normal dose every 48 hours if estimated glomerular filtration rate 10–30 mL/minute/1.73 m²). Avoid for treatment and prevention if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION
If suspension not available, capsules can be opened and the contents mixed with a small amount of sweetened food, such as sugar water or chocolate syrup, just before administration.

PRESCRIBING AND DISPENSING INFORMATION
Flavours of oral liquid formulations may include tutti-frutti.

PATIENT AND CARER ADVICE
Medicines for Children leaflet: Oseltamivir for influenza (flu) www.medicinesforchildren.org.uk/oseltamivir-for-influenza

NATIONAL FUNDING/ACCESS DECISIONS

Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008) [NICE TA158]
The drugs described here are not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.

Amantadine is not recommended for prophylaxis of influenza.

Oseltamivir is not recommended for seasonal prophylaxis against influenza.

When influenza is circulating in the community, either oseltamivir or zanamivir is recommended (in accordance with UK licensing) for post-exposure prophylaxis in at-risk patients who are not effectively protected by influenza vaccine, and who have been in close contact with someone suffering from influenza-like illness in the same household or residential setting. Oseltamivir should be given within 48 hours of exposure to influenza while zanamivir should be given within 36 hours of exposure to influenza. National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.

During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, either oseltamivir or zanamivir may be used for post-exposure prophylaxis in at-risk patients (regardless of influenza vaccination) living in long-term residential or nursing homes.

At risk patients include those aged over 65 years or those who have one or more of the following conditions:
chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);
chronic heart disease;
chronic renal disease;
chronic liver disease;
chronic neurological disease;
immunosuppression;
diabetes mellitus.
The Department of Health in England has advised (November 2010 and April 2011) that ‘at risk patients’ also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.

This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community. www.nice.org.uk/TA158

Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (February 2009) [NICE TA168]
The drugs described here are not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.

Amantadine is not recommended for prophylaxis of influenza.
When influenza is circulating in the community, either oseltamivir or zanamivir is recommended (in accordance with UK licensing) for the treatment of influenza in at-risk patients who can start treatment within 48 hours of the onset of symptoms. National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.

During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, either oseltamivir or zanamivir may be used for treatment at-risk patients living in long-term residential or nursing homes. At risk patients include those aged over 65 years or those who have one or more of the following conditions:

- chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);
- chronic heart disease;
- chronic renal disease;
- chronic liver disease;
- chronic neurological disease;
- immunosuppression;
- diabetes mellitus.

The Department of Health in England has advised (November 2010 and April 2011) that ‘at risk patients’ also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant. This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community. www.nice.org.uk/TA168

NHS restrictions Except for the treatment and prophylaxis of influenza as indicated in the NICE guidance; endorse prescription ‘SLS’.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Capsule**

- **Tamiflu** (Roche Products Ltd)
  - Oseltamivir (as Oseltamivir phosphate) 30 mg Tamiflu 30mg capsules | 10 capsule [PDL] £7.71
  - Oseltamivir (as Oseltamivir phosphate) 45 mg Tamiflu 45mg capsules | 10 capsule [PDL] £15.41
  - Oseltamivir (as Oseltamivir phosphate) 75 mg Tamiflu 75mg capsules | 10 capsule [PDL] £15.41

**Oral suspension**

- **Tamiflu** (Roche Products Ltd)
  - Oseltamivir (as Oseltamivir phosphate) 6 mg per 1 ml Tamiflu 6mg/ml oral suspension (sugar-free) | 65 ml [PDL] £10.27

**Oral solution**

- **Oseltamivir (Non-proprietary)**
  - Oseltamivir (as Oseltamivir phosphate) 15 mg per 1 ml Oseltamivir 15mg/ml oral solution sugar free (sugar-free) | 20 ml [PDL] £10.00

**Zanamivir**

**DRUG ACTION** Reduces replication of influenza A and B viruses by inhibiting viral neuraminidase.

**INDICATIONS AND DOSE**

**Post-exposure prophylaxis of influenza**

- **BY INHALATION OF POWDER**
  - Child 5-17 years: 10 mg once daily for up to 28 days
  - Adult: 10 mg once daily for up to 28 days

**Prevention of influenza during an epidemic**

- **BY INHALATION OF POWDER**
  - Child 5-17 years: 10 mg twice daily for 5 days (for up to 10 days if resistance to oseltamivir suspected)
  - Adult: 10 mg twice daily for 5 days (for up to 10 days if resistance to oseltamivir suspected)

**UNLICENSED USE** Use of zanamivir for up to 10 days if resistance to oseltamivir suspected is an unlicensed duration.

**CAUTIONS**

- Asthma - chronic pulmonary disease - uncontrolled chronic illness

**CAUTIONS, FURTHER INFORMATION**

- **Asthma and chronic pulmonary disease** Risk of bronchospasm—short-acting bronchodilator should be available. Avoid in severe asthma unless close monitoring possible and appropriate facilities available to treat bronchospasm.

**SIDE-EFFECTS**

- Common or very common Rash
- Uncommon Angioedema - bronchospasm - dyspnoea - urticaria
- Rare Neuropsychiatric disorders (in children) - neuropsychiatric disorders (especially in children and adolescents) (in adults) - Stevens-Johnson syndrome - toxic epidermal necrolysis

**PREGNANCY** Although safety data are limited, zanamivir can be used in women who are pregnant when the potential benefit outweighs the risk (e.g. during a pandemic). Amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic). Amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic). Use only if potential benefit outweighs risk (e.g. during a pandemic). Amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic). Amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic).

**DIRECTIONS FOR ADMINISTRATION** Other inhaled drugs should be administered before zanamivir.

**PRESCRIBING AND DISPENSING INFORMATION** Except for the treatment and prophylaxis of influenza as indicated in the NICE guidance; endorse prescription ‘SLS’.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009) [NICE TA168], see p. 572
- Oseltamivir, zanamivir, and amantadine for treatment of influenza (September 2008) [NICE TA158], see p. 572

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation powder**

- **Relenza** (GlaxoSmithKline UK Ltd)
  - Zanamivir 5 mg Relenza 5mg inhalation powder blisters with Diskhaler | 20 blister [PDL] £16.36
Chapter 6
Endocrine system

1 Antidiuretic hormone disorders

Posterior pituitary hormones and antagonists

Posterior pituitary hormones

Diabetes insipidus
Vasopressin p. 576 (antidiuretic hormone, ADH) is used in the treatment of pituitary (cranial) diabetes insipidus as is its analogue desmopressin. Dosage is tailored to produce a slight diuresis every 24 hours to avoid water intoxication. Treatment may be required for a limited period only in diabetes insipidus following trauma or pituitary surgery.

Desmopressin is more potent and has a longer duration of action than vasopressin; unlike vasopressin it has no vasoconstrictor effect. It is given by mouth or intranasally for maintenance therapy, and by injection in the postoperative period or in unconscious patients. Desmopressin is also used in the differential diagnosis of diabetes insipidus. Following a dose intramuscularly or intranasally, restoration of the ability to concentrate urine after water deprivation confirms a diagnosis of cranial diabetes insipidus. Failure to respond occurs in nephrogenic diabetes insipidus.

In nephrogenic and partial pituitary diabetes insipidus benefit may be gained from the paradoxical antidiuretic effect of thiazides.

Carbamazepine p. 387 is sometimes useful in partial pituitary diabetes insipidus [unlicensed]; it may act by sensitising the renal tubules to the action of remaining endogenous vasopressin.

Other uses
Desmopressin is also used to boost factor VIII concentration in mild to moderate haemophilia and in von Willebrand’s disease; it is also used to test fibrinolytic response. Desmopressin may also have a role in nocturnal enuresis.

 Vasopressin infusion is used to control variceal bleeding in portal hypertension, prior to more definitive treatment and with variable results. Terlipressin acetate p. 77, a derivative of vasopressin with reportedly less pressor and antidiuretic activity, is used similarly.

Oxytocin p. 705, another posterior pituitary hormone, is indicated in obstetrics.

Antidiuretic hormone antagonists
Demeclocycline hydrochloride p. 496 can be used in the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable. Demeclocycline hydrochloride is thought to act by directly blocking the renal tubular effect of antidiuretic hormone.

Tolvaptan p. 577 is a vasopressin V2-receptor antagonist licensed for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion; treatment duration with tolvaptan is determined by the underlying disease and its treatment.

Rapid correction of hyponatraemia during tolvaptan therapy can cause osmotic demyelination, leading to serious neurological events; close monitoring of serum sodium concentration and fluid balance is essential.

1.1 Diabetes insipidus

Drugs used for Diabetes insipidus not listed below; Chlortalidone, p. 204

VASOPRESSIN AND ANALOGUES

Desmopressin

• DRUG ACTION Desmopressin is an analogue of vasopressin.
INDICATIONS AND DOSE

Diabetes insipidus, diagnosis (water deprivation test)

BY INTRANASAL ADMINISTRATION

Adult: 20 micrograms, limit fluid intake to 500 mL from 1 hour before to 8 hours after administration

BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION

Adult: 2 micrograms for 1 dose, limit fluid intake to 500 mL from 1 hour before to 8 hours after administration

Diabetes insipidus, treatment

BY MOUTH

Child 1 month–1 year: Initially 10 micrograms 2–3 times a day, adjusted according to response; usual dose 30–150 micrograms daily

Child 2–11 years: Initially 50 micrograms 2–3 times a day, adjusted according to response; usual dose 100–800 micrograms daily

Child 12–17 years: Initially 100 micrograms 2–3 times a day, adjusted according to response; usual dose 0.2–1.2 mg daily

Adult: Initially 60 micrograms 3 times a day, adjusted according to response; usual dose 40–240 micrograms 3 times a day

BY INTRANASAL ADMINISTRATION

Child 2–17 years: Initially 60 micrograms 3 times a day, adjusted according to response; usual dose 40–240 micrograms 3 times a day

Adult: Initially 60 micrograms 3 times a day, adjusted according to response; usual dose 40–240 micrograms 3 times a day

BY INTRAVENOUS INFUSION OR BY SUBCUTANEOUS INJECTION

Adult: 1–2 micrograms, blood to be sampled after 8 hours after administration to avoid fluid overload

Primary nocturnal enuresis

BY MOUTH

Child 5–17 years: 200 micrograms once daily, only increased to 400 micrograms if dose not effective; withdraw for at least 1 week for reassessment after 3 months, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration

Adult 18–65 years: 200 micrograms once daily, only increased to 400 micrograms if dose not effective; withdraw for at least 1 week for reassessment after 3 months, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration

BY SUBLINGUAL ADMINISTRATION

Child 5–17 years: 120 micrograms once daily, increased if necessary to 240 micrograms once daily, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration, dose to be increased only if lower dose not effective, reassess after 3 months by withdrawing treatment for at least 1 week

Adult 18–65 years: 120 micrograms once daily, increased if necessary to 240 micrograms once daily, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration, dose to be increased only if lower dose not effective, reassess after 3 months by withdrawing treatment for at least 1 week

Postoperative polyuria or polydipsia

BY MOUTH

Adult: Dose to be adjusted according to urine osmolality

Polyuria or polydipsia after hypophysectomy

BY SUBLINGUAL ADMINISTRATION

Adult: Dose to be adjusted according to urine osmolality

Nocturia associated with multiple sclerosis (when other treatments have failed)

BY INTRANASAL ADMINISTRATION

Adult 18–65 years: 10–20 micrograms once daily, to be taken at bedtime, dose not to be repeated within 24 hours, limit fluid intake from 1 hour before to 8 hours after administration

Renal function testing

BY INTRANASAL ADMINISTRATION

Adult: 40 micrograms, empty bladder at time of administration and limit fluid intake to 500 mL from 1 hour before until 8 hours after administration to avoid fluid overload

BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION

Adult: 2 micrograms, empty bladder at time of administration and restrict fluid intake to 500 mL from 1 hour before until 8 hours after administration to avoid fluid overload

Mild to moderate haemophilia and von Willebrand’s disease

BY INTRANASAL ADMINISTRATION

Adult: 300 micrograms every 12 hours if required, one 150 microgram spray into each nostril, 30 minutes before surgery or when bleeding, dose may be alternatively repeated at intervals of at least 3 days, if self-administered

BY INTRAVENOUS INFUSION OR BY SUBCUTANEOUS INJECTION

Adult: 300 nanograms/kg for 1 dose, to be administered immediately before surgery or after trauma; may be repeated at intervals of 12 hours if no tachycardia

Fibrinolytic response testing

BY INTRANASAL ADMINISTRATION

Adult: 300 micrograms, blood to be sampled after 1 hour for fibrinolytic activity, one 150 microgram spray to be administered into each nostril

BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INJECTION

Adult: 300 nanograms/kg for 1 dose, blood to be sampled after 20 minutes for fibrinolytic activity

Lumbar-puncture-associated headache

BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION

Adult: (consult product literature)

**CONTRA-INDICATIONS**

Cardiac insufficiency - conditions treated with diuretics - polydipsia in alcohol dependence - psychogenic polydipsia

**CAUTIONS**

GENERAL CAUTIONS

Asthma - avoid fluid overload - cardiovascular disease (not indicated for nocturnal enuresis or nocturia) - conditions which might be aggravated by water retention - cystic fibrosis - elderly (avoid for nocturnal enuresis and nocturia in those over 65 years) epilepsy - heart failure - hypertension (not indicated for nocturnal enuresis or nocturia) - migraine - nocturia—limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards - nocturnal enuresis—limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards

SPECIFIC CAUTIONS

With intranasal use should not be given intranasally for nocturnal enuresis due to an increased incidence of side-effects
In adults

**SIDE-EFFECTS**

- Allergic reactions - emotional disturbance in children - epistaxis - fluid retention - headache - hyponatraemia (in more serious cases with convulsions) on administration without restricting fluid intake - nasal congestion - nausea - stomach pain - vomiting

**SPECIFIC SIDE-EFFECTS**

- With intranasal use Rhinitis

**SIDE-EFFECTS, FURTHER INFORMATION**

- Hyponatraemic convulsions The risk of hyponatraemic convulsions can be minimised by keeping to the recommended starting doses and by avoiding concomitant use of drugs which increase secretion of vasopressin (e.g. tricyclic antidepressants).

- PREGNANCY Small oxytocic effect in third trimester; increased risk of pre-eclampsia.

- BREAST FEEDING Amount too small to be harmful.

- RENAL IMPAIRMENT Use with caution; antidiuretic effect may be reduced.

**INTERACTIONS**

- Monitor blood pressure and weight checks are needed to monitor for fluid retention (especially disease of coronary arteries) unless extreme caution.

- Antidiuretic hormone disorders

- Osmotic diarrhoea

- Emotional disturbance in children

- Myocardial ischaemia

- Asthma - avoid fluid overload - conditions which might be aggravated by water retention - epilepsy - heart failure - hypertension - migraine

- CONTRA-INDICATIONS Chronic nephritis (until reasonable blood nitrogen concentrations attained) - vascular disease (especially disease of coronary arteries) unless extreme caution

- CAUTIONS Pituitary diabetes insipidus

**MEDICATIONS**

- Pituitary diabetes insipidus

- Osmotic diarrhoea

- Emotional disturbance in children

- Myocardial ischaemia

- Asthma - avoid fluid overload - conditions which might be aggravated by water retention - epilepsy - heart failure - hypertension - migraine

- CONTRA-INDICATIONS Chronic nephritis (until reasonable blood nitrogen concentrations attained) - vascular disease (especially disease of coronary arteries) unless extreme caution

- CAUTIONS Pituitary diabetes insipidus

**SIDE-EFFECTS**

- Abdominal cramps

- Nausea

- Vomiting

- Headache

- Pallor

- Sweating

- Vertigo

- Pallor - peripheral ischaemia - sweating - tremor - vertigo - vomiting

- PREGNANCY Oxytocic effect in third trimester.

**Vasopressin**

**INDICATIONS AND DOSE**

**Pituitary diabetes insipidus**

- By intramuscular injection or by subcutaneous injection

- Adult: ≥ 20 units every 4 hours

- Initial control of oesophageal variceal bleeding

- By intravenous infusion

- Adult: 20 units, dose to be administered over 15 minutes

**Oral lypophilate**

**CAUTIONARY AND ADVISORY LABELS**

**DESMOPRESSIN (Non-proprietary)**

- Desmopressin (as Desmopressin acetate) 60 microgram DDAVP Melt 60 microgram oral lypophilates (sugar-free) | 100 tablet DT price = £50.53

- Desmopressin (as Desmopressin acetate) 120 microgram DDAVP Melt 120 microgram oral lypophilates sugar-free (sugar-free) | 100 tablet DT price = £101.07

- Desmopressin (as Desmopressin acetate) 240 microgram DDAVP Melt 240 microgram oral lypophilates (sugar-free) | 100 tablet DT price = £202.14

- Desmopressin (as Desmopressin acetate) 240 microgram Desmocollin 240 microgram oral lypophilates (sugar-free) | 30 tablet DT price = £60.68

**Solution for Injection**

**DESMOPRESSIN (Non-proprietary)**

- Desmopressin acetate 4 microgram per 1 ml DDAVP 4 microgram/1ml solution for injection ampoules | 10 ampoule DT price = £13.16

- Octim (Ferring Pharmaceuticals Ltd) Desmopressin acetate 15 microgram per 1 ml Octim 15 micrograms/1ml solution for injection ampoules | 10 ampoule DT price = £192.20

**Spray**

**DESMOPRESSIN (Non-proprietary)**

- Desmopressin acetate 10 microgram per 1 dose Desmocollin 10 micrograms/dose nasal spray | 60 dose DT price = £23.04 DT price = £8.18

- Desmospray (Ferring Pharmaceuticals Ltd) Desmopressin acetate 2.5 microgram per 1 dose Desmospray 2 micrograms/dose nasal spray | 50 dose no price available

- Desmopressin acetate 10 microgram per 1 dose Desmospray 10 micrograms/dose nasal spray | 60 dose DT price = £25.02 DT price = £8.18

- Octim (Ferring Pharmaceuticals Ltd) Desmopressin acetate 150 microgram per 1 dose Octim 150 micrograms/dose nasal spray | 25 dose DT price = £57.60

**Oral solution**

**DESMOPRESSIN (Non-proprietary)**

- Desmopressin (as Desmopressin acetate) 360 microgram per 1 ml Desmopressin 360 micrograms/ml oral solution | 15 ml DT price = £30.00

**Tablet**

**DESMOPRESSIN (Non-proprietary)**

- Desmopressin acetate 100 microgram Desmopressin 100 microgram tablets | 90 tablet (P) 61.43 DT price = £61.43

- Desmopressin acetate 200 microgram DDAVP 0.2 mg tablets | 90 tablet (P) 88.23

- Desmopressin 200 microgram tablets | 30 tablet (P) 35.23 DT price = £9.26

- Desmospray (Ferring Pharmaceuticals Ltd) Desmopressin acetate 200 microgram Desmospray 200 micrograms/ml oral solution | 15 ml (P) 23.43 DT price = £9.26

- Desmopressin (as Desmopressin acetate) 360 microgram per 1 ml Desmopressin 360 micrograms/ml oral solution | 15 ml (P) 30.00

**Table**

**DESMOPRESSIN (Non-proprietary)**

- Desmopressin acetate 100 microgram Desmopressin 100 microgram tablets | 90 tablet (P) 61.43 DT price = £61.43

- Desmopressin acetate 200 microgram DDAVP 0.2 mg tablets | 90 tablet (P) 88.23

- Desmopressin 200 microgram tablets | 30 tablet (P) 35.23 DT price = £9.26

- Desmospray (Ferring Pharmaceuticals Ltd) Desmopressin acetate 200 microgram Desmospray 200 micrograms/ml oral solution | 15 ml (P) 23.43 DT price = £9.26

**Oral solution**

**DESMOPRESSIN (Non-proprietary)**

- Desmopressin (as Desmopressin acetate) 360 microgram per 1 ml Desmopressin 360 micrograms/ml oral solution | 15 ml (P) 30.00
1.2 Syndrome of inappropriate antidiuretic hormone secretion

Drugs used for Syndrome of inappropriate antidiuretic hormone secretion not listed below; Demeclocycline hydrochloride, p. 496

SELECTIVE VASOPRESSIN V2-RECEPTOR ANTAGONISTS

Tolvaptan

- **DRUG ACTION** Tolvaptan is a vasopressin V₂-receptor antagonist.

- **INDICATIONS AND DOSE**
  Treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion
  **BY MOUTH**
  - Adult: 15 mg once daily, increased if necessary up to 60 mg daily treatment duration is determined by the underlying disease and its treatment

- **CONTRA-INDICATIONS** Anuria · hyponaatraemia · hypovolaemic hyponatraemia · impaired perception of thirst · volume depletion

- **CAUTIONS**
  Alcoholism (increased risk of demyelination syndrome if rapid correction of hyponatraemia) · diabetes mellitus · ensure adequate fluid intake · hypoxia (increased risk of demyelination syndrome if rapid correction of hyponatraemia) · malnutrition (increased risk of demyelination syndrome if rapid correction of hyponatraemia) · pseudohyponatraemia associated with diabetes mellitus (exclude before treatment)

- **INTERACTIONS** → Appendix 1 (tolvaptan).
  Avoid concomitant drugs that increase serum-sodium concentration.

- **SIDE-EFFECTS**
  - **Common or very common** Constipation · decreased appetite · dehydration · dry mouth · ecchymosis · fever · hyperglycaemia · hyperkalaemia · increased blood creatinine · malaise · nausea · neurological disturbance (following rapid correction of hyponatraemia) · postural hypotension · pruritus · thirst · urinary frequency
  - **Uncommon** Renal impairment · taste disturbance
  - **Frequency not known** Dizziness · hepatic impairment (discontinue) · hyponatraemia · hyperuricaemia · hypoglycaemia · syncope

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - **Hepatic impairment** Discontinue and perform liver-function tests promptly if symptoms of hepatic impairment (anorexia, nausea, vomiting, fatigue, abdominal pain, jaundice, dark urine, pruritus).

## 2 Corticosteroid responsive conditions

### CORTICOSTEROIDS

**Corticosteroids, general use**

Dosages of corticosteroids vary widely in different diseases and in different patients. If the use of a corticosteroid can save or prolong life, as in exfoliative dermatitis, pemphigus, acute leukaemia or acute transplant rejection, high doses may need to be given, because the complications of therapy are likely to be less serious than the effects of the disease itself.

When long-term corticosteroid therapy is used in some chronic diseases, the adverse effects of treatment may become greater than the disabilities caused by the disease. To minimise side-effects the maintenance dose should be kept as low as possible.

When potentially less harmful measures are ineffective corticosteroids are used topically for the treatment of inflammatory conditions of the skin. Corticosteroids should be avoided or used only under specialist supervision in psoriasis.

Corticosteroids are used both topically (by rectum) and systematically (by mouth or intravenously) in the management of ulcerative colitis and Crohn’s disease. They are also included in locally applied creams for haemorrhoids.

Use can be made of the mineralocorticoid activity of fludrocortisone acetate p. 582 to treat postural hypotension in autonomic neuropathy.

High-dose corticosteroids should be avoided for the management of septic shock. However, there is evidence that administration of lower doses of hydrocortisone p. 583 and fludrocortisone acetate is of benefit in adrenocortical insufficiency resulting from septic shock.

Dexamethasone p. 581 and betamethasone p. 581 have little if any mineralocorticoid action and their long duration of action makes them particularly suitable for suppressing corticotropin secretion in congenital adrenal hyperplasia where the dose should be tailored to clinical response and

**PREGNANCY** Avoid—toxicity in animal studies.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Use with caution in severe impairment—no information available.

**RENAL IMPAIRMENT** No information available in severe impairment.

**MONITORING REQUIREMENTS**
- Monitor for dehydration in patients who are fluid-restricted.
- Monitor serum-sodium concentration and fluid balance no later than 6 hours after initiating treatment and every 6 hours during the first 1–2 days of treatment and until dose stabilised. Discontinue if rapid rise in serum-sodium concentration (greater than 12 mmol/litre in 24 hours or 18 mmol/litre in 48 hours).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Samsca** (Otsuka Pharmaceuticals (UK) Ltd) Tolvaptan 15 mg Samsca 15mg tablets | 10 tablet £74.60
- **Samsca** 30 mg Samsca 30mg tablets | 10 tablet £74.60

**BREAST FEEDING** Not known to be harmful.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (argipressin), give intermittently in Glucose 5%; suggested concentration 20 units/100mL given over 15 minutes.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **VASOPRESSIN (Non-proprietary)** Argipressin 20 unit per 1 ml Argipressin 20units/1ml solution for injection ampoules | 10 ampoule £800.00 (Hospital only)
Corticosteroid therapy is also weakly linked with peptic ulceration and perforation.

Psychiatric reactions may also occur.

**Managing side-effects**

Side-effects can be minimised by using lowest effective dose for minimum period possible. The suppressive action of a corticosteroid on cortisol secretion is least when it is given as a single dose in the morning. In an attempt to reduce pituitary-adrenal suppression further, the usual dose for two days can sometimes be taken as a single dose on alternate days; alternate-day administration has not been very successful in the management of asthma. Pituitary-adrenal suppression can also be reduced by means of intermittent therapy with short courses. In some conditions it may be possible to reduce the dose of corticosteroid by adding a small dose of an immunosuppressive drug.

Whenever possible local treatment with creams, intra-articular injections, inhalations, eye-drops, or enemas should be used in preference to systemic treatment.

Inhaled corticosteroids have considerably fewer systemic effects than oral corticosteroids, but adverse effects including adrenal suppression have been reported. Use of other corticosteroid therapy (including topical) or concurrent use of drugs which inhibit corticosteroid metabolism should be taken into account when assessing systemic risk. In children, growth restriction is associated with systemic corticosteroid therapy does not seem to occur with recommended doses of inhaled therapy; although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height. Large-volume spacer devices should be used for administering inhaled corticosteroids in children under 15 years; they are also useful in older children and adults, particularly if high doses are required. Spacer devices increase airway deposition and reduce oropharyngeal deposition.

**Corticosteroids, replacement therapy**

The adrenal cortex normally secretes hydrocortisone p. 583 (cortisol) which has glucocorticoid activity and weak mineralocorticoid activity. It also secretes the mineralocorticoid aldosterone.

In deficiency states, physiological replacement is best achieved with a combination of hydrocortisone and the mineralocorticoid fludrocortisone acetate p. 582; hydrocortisone alone does not usually provide sufficient mineralocorticoid activity for complete replacement.

In Addison's disease or following adrenalectomy, hydrocortisone by mouth is usually required. This is given in 2 doses, the larger in the morning and the smaller in the evening, mimicking the normal diurnal rhythm of cortisol secretion. The optimum daily dose is determined on the basis of clinical response. Glucocorticoid therapy is supplemented by fludrocortisone acetate.

In acute adrenocortical insufficiency, hydrocortisone is given intravenously (preferably as sodium succinate) every 6 to 8 hours in sodium chloride p. 953 intravenous infusion 0.9%.

In hypopituitarism, glucocorticoids should be given as in adrenocortical insufficiency, but since production of aldosterone is also regulated by the renin-angiotensin system a mineralocorticoid is not usually required. Additional replacement therapy with levothyroxine sodium p. 665 and sex hormones should be given as indicated by the pattern of hormone deficiency.
**Glucocorticoid therapy**

In comparing the relative potencies of corticosteroids in terms of their anti-inflammatory (glucocorticoid) effects it should be borne in mind that high glucocorticoid activity in itself is of no advantage unless it is accompanied by relatively low mineralocorticoid activity (see Disadvantages of Corticosteroids). The mineralocorticoid activity of fluorocortisone acetate p. 582 is so high that its anti-inflammatory activity is of no clinical relevance.

**Equivalent anti-inflammatory doses of corticosteroids**

This table takes no account of mineralocorticoid effects, nor does it take account of variations in duration of action

<table>
<thead>
<tr>
<th>Corticosteroids</th>
<th>Equivalent Anti-Inflammatory Doses (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone 5 mg</td>
<td>Betamethasone 750 micrograms</td>
</tr>
<tr>
<td></td>
<td>Dexamethasone 750 micrograms</td>
</tr>
<tr>
<td></td>
<td>Hydrocortisone 20 mg</td>
</tr>
<tr>
<td></td>
<td>Methylprednisolone 4 mg</td>
</tr>
<tr>
<td></td>
<td>Prednisone 5 mg</td>
</tr>
<tr>
<td></td>
<td>Triamcinolone 4 mg</td>
</tr>
</tbody>
</table>

The relatively high mineralocorticoid activity of hydrocortisone p. 583, and the resulting fluid retention, makes it unsuitable for disease suppression on a long-term basis. However, hydrocortisone can be used for adrenal replacement therapy. Hydrocortisone is used on a short-term basis by intravenous injection for the emergency management of some conditions. The relatively moderate anti-inflammatory potency of hydrocortisone also makes it a useful topical corticosteroid for the management of inflammatory skin conditions because side-effects (both topical and systemic) are less marked.

Prednisolone p. 585 and prednisone p. 586 have predominantly glucocorticoid activity. Prednisolone is the corticosteroid most commonly used by mouth for long-term disease suppression.

Betamethasone p. 581 and dexamethasone p. 581 have very high glucocorticoid activity in conjunction with insignificant mineralocorticoid activity. This makes them particularly suitable for high-dose therapy in conditions where fluid retention would be a disadvantage.

Betamethasone and dexamethasone also have a long duration of action and this, coupled with their lack of mineralocorticoid action makes them particularly suitable for conditions which require suppression of corticotropin (corticotrophin) secretion (e.g. congenital adrenal hyperplasia).

Some esters of betamethasone and of beclometasone dipropionate p. 38 (beclometasone) exert a considerably more marked topical effect (e.g. on the skin or the lungs) than when given by mouth; use is made of this to obtain topical effects whilst minimising systemic side-effects (e.g. for skin applications and asthma inhalations).

Deflazacort p. 581 has a high glucocorticoid activity; it is derived from prednisolone.

**Corticosteroids (systemic)**

**CONTRA-INDICATIONS** Avoid live virus vaccines in those receiving immunosuppressive doses (serum antibody response diminished) - systemic infection (unless specific therapy given)

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**


**SPECIFIC SIDE-EFFECTS**

- **With intra-articular use** Flushing - may affect the hyaline cartilage

**SIDE-EFFECTS, FURTHER INFORMATION**

For further information on side-effects associated with intra-articular, intradermal and intralesional preparations, consult product literature.

**CAUTIONS** Congestive heart failure - diabetes mellitus (including a family history of) - diverticulitis - epilepsy - glaucoma (including a family history of or susceptibility to) - history of steroid myopathy - history of tuberculosis or X-ray changes (frequent monitoring required) - hypertension - hypothroidism - infection (particularly untreated) - myasthenia gravis - ocular herpes simplex (risk of corneal perforation) - osteoporosis (postmenopausal women and the elderly at special risk) - peptic ulcer - psychiatric reactions - posterior subcapsular cataracts - recent myocardial infarction (rupture reported) - severe affective disorders (particularly if history of steroid-induced psychosis) - should not be used long-term - thromboembolic disorders - ulcerative colitis

**CONTRA-INDICATIONS, FURTHER INFORMATION**

For further information on contra-indications associated with intra-articular, intradermal and intralesional preparations, consult product literature.

**INTERACTIONS** → Appendix 1 (corticosteroids).
suitable regimen for corticosteroid replacement, in patients who have taken more than 10 mg prednisolone daily (or equivalent) within 3 months of surgery, is:

- Minor surgery under general anaesthesia—usual oral corticosteroid dose on the morning of surgery or hydrocortisone (usually the sodium succinate) intravenously at induction; the usual oral corticosteroid dose is recommenced after surgery.
- Moderate or major surgery—usual oral corticosteroid dose on the morning of surgery and hydrocortisone intravenously at induction, followed by hydrocortisone 3 times a day by intravenous injection for 24 hours after moderate surgery or for 48–72 hours after major surgery; the usual pre-operative oral corticosteroid dose is recommenced on stopping hydrocortisone injections.

Patients on long-term corticosteroid treatment should carry a steroid treatment card which gives guidance on minimising risk and provides details of prescriber, drug, dosage and duration of treatment.

**Infections** Prolonged courses of corticosteroids increase susceptibility to infections and severity of infections; clinical presentation of infections may also be atypical. Serious infections e.g. *septicaemia* and *tuberculosis* may reach an advanced stage before being recognised, and *amoebiasis* or *strongyloidiasis* may be activated or exacerbated (exlude before initiating a corticosteroid in those at risk or with suggestive symptoms). Fungal or viral *ocular infections* may also be exacerbated.

**Chickenpox** Unless they have had chickenpox, patients receiving oral or parenteral corticosteroids for purposes other than replacement should be regarded as being at risk of severe chickenpox (see Steroid Treatment Card). Manifestations of fulminant illness include pneumonia, hepatitis and disseminated intravascular coagulation; rash is not necessarily a prominent feature. Passive immunisation with varicella–zoster immunoglobulin is needed for exposed non–immune patients receiving systemic corticosteroids or for those who have used them within the previous 3 months. Confirmed chickenpox warrants specialist care and urgent treatment. Corticosteroids should not be stopped and dosage may need to be increased.

**Measles** Patients taking corticosteroids should be advised to take particular care to avoid exposure to measles and to seek immediate medical advice if exposure occurs. Prophylaxis with intramuscular normal immunoglobulin may be needed.

**Psychiatric reactions** Systemic corticosteroids, particularly in high doses, are linked to psychiatric reactions including euphoria, nightmares, insomnia, irritability, mood lability, suicidal thoughts, psychotic reactions, and behavioural disturbances. A serious paranoid state or depression with risk of suicide can be induced, particularly in patients with a history of mental disorder. These reactions frequently subside on reducing the dose or discontinuing the corticosteroid but they may also require specific management. Patients should be advised to seek medical advice if psychiatric symptoms (especially depression and suicidal thoughts) occur and they should also be alert to the rare possibility of such reactions during withdrawal of corticosteroid treatment.

Systemic corticosteroids should be prescribed with care in those predisposed to psychiatric reactions, including those who have previously suffered corticosteroid-induced psychosis, or who have a personal or family history of psychiatric disorders.

**Pregnancy** The benefit of treatment with corticosteroids during pregnancy outweighs the risk. Corticosteroid cover is required during labour. Following a review of the data on the safety of systemic corticosteroids used in pregnancy and breast-feeding the CSM (May 1998) concluded that corticosteroids vary in their ability to cross the placenta but there is no convincing evidence that systemic corticosteroids increase the incidence of congenital abnormalities such as cleft palate or lip. When administration is prolonged or repeated during pregnancy, systemic corticosteroids increase the risk of intra-uterine growth restriction; there is no evidence of intra-uterine growth restriction following short-term treatment (e.g. prophylactic treatment for neonatal respiratory distress syndrome). Any adrenal suppression in the neonate following prenatal exposure usually resolves spontaneously after birth and is rarely clinically important. Pregnant women with fluid retention should be monitored closely when given systemic corticosteroids.

- **BREAST FEEDING** The benefit of treatment with corticosteroids during breast-feeding outweighs the risk.
- **HEPATIC IMPAIRMENT** The plasma–drug concentration may be increased (particularly on systemic use). Oral and parenteral use should be undertaken with caution.
- **RENAL IMPAIRMENT** Use by oral and injectable routes should be undertaken with caution.
- **EFFECT ON LABORATORY TESTS** Suppression of skin test reactions.
- **TREATMENT CESSATION** Abrupt withdrawal after a prolonged period can lead to acute adrenal insufficiency, hypotension or death. Withdrawal can also be associated with fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and weight loss. The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case–by–case basis, taking into consideration the underlying condition that is being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have:
  - received more than 40 mg prednisolone (or equivalent) daily for more than 1 week;
  - been given repeat doses in the evening;
  - received more than 3 weeks’ treatment;
  - recently received repeated courses (particularly if taken for longer than 3 weeks); taken a short course within 1 year of stopping long-term therapy;
  - other possible causes of adrenal suppression.

Systemic corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse and who are not included in the patient groups described above. During corticosteroid withdrawal the dose may be reduced rapidly down to physiological doses (equivalent to prednisolone 7.5 mg daily) and then reduced more slowly. Assessment of the disease may be needed during withdrawal to ensure that relapse does not occur.

- **PATIENT AND CARER ADVICE** Advice for patients. Patients on long-term corticosteroid treatment should carry a Steroid Treatment Card which gives guidance on minimising risk and provides details of prescriber, drug, dosage and duration of treatment. A patient information leaflet is supplied to every patient when a systemic corticosteroid is prescribed. Patients should especially be advised of the following:
  - **Immunosuppression** Prolonged courses of corticosteroids can increase susceptibility to infection and serious infections can go unrecognised. Unless already immune, patients are at risk of severe chickenpox and should avoid close contact with people who have chickenpox or shingles. Similarly,
Betamethasone soluble tablets (steroid card). Patient counselling is advised for these products. Steroid treatment cards should be issued where appropriate. Consider giving a ‘steroid card’ to support communication of the risks associated with treatment, and specific written advice to consider corticosteroid replacement during an episode of stress, such as severe intercurrent illness or an operation, to patients using greater than maximum licensed doses of inhaled corticosteroids. Steroid treatment cards are available for purchase from 3M Security Print and Systems Limited, Gorse Street, Chadderton, Oldham OL9 9QH Tel: 0845 510 1112 GP practices can obtain supplies through their Local Area Team Stores. NHS Trusts can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com.

In Scotland, steroid treatment cards can be obtained from APS Group Scotland by emailing stockorders.dppas@theapsgroup.com or by fax on 0131 629 9967.

Betamethasone

INDICATIONS AND DOSE

Suppression of inflammatory and allergic disorders

BY MOUTH
▼ Adult: Usual dose 0.5–5 mg daily
▼ By intramuscular injection or by slow intravenous infusion
▼ Adult: 4–20 mg, repeated up to 4 times in 24 hours

PREGNANCY Readily crosses the placenta. Transient effect on fetal movements and heart rate.

DIRECTIONS FOR ADMINISTRATION For intravenous infusion (as sodium phosphate) (Betnesol®), give continuously or intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%.

PATIENT AND CARER ADVICE
▼ With oral use Patient counselling is advised for betamethasone soluble tablets (steroid card).

MEDICINAL FORMS
▼ There can be variation in the licensing of different medicines containing the same drug.

Soluble tablet

CAUTIONARY AND ADVISORY LABELS 10, 13, 21
▼ BETAMETHASONE (Non-proprietary)
Betamethasone (as Betamethasone sodium phosphate) 500 microgram Betamethasone 500 microgram soluble tablets sugar free (sugar-free) | 100 tablet [P] £29.85 DT price + £29.70

Corticosteroid responsive conditions

Deflazacort

INDICATIONS AND DOSE

Suppression of inflammatory and allergic disorders

BY MOUTH
▼ Adult: Maintenance 3–18 mg daily
▼ Suppression of inflammatory and allergic disorders (acute disorders)
▼ Adult: Initially up to 120 mg daily

Inflammatory and allergic disorders

BY MOUTH
▼ Child 1 month–11 years: Maintenance 0.25–1.5 mg/kg daily or on alternate days; increased if necessary up to 2.4 mg/kg daily (max. per dose 120 mg), in emergency situations
▼ Child 12–17 years: Initially 3–18 mg daily or on alternate days; increased if necessary up to 2.4 mg/kg daily (max. per dose 120 mg), in emergency situations

RENAL IMPAIRMENT Use with caution.

PATIENT AND CARER ADVICE Patient counselling is advised for deflazacort tablets (steroid card).

MEDICINAL FORMS
▼ There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

Tablet

CAUTIONARY AND ADVISORY LABELS 5, 10
▼ Calcort (Sanofi)
Deflazacort 6 mg Calcort 6mg tablets | 60 tablet [P] £15.82

Dexamethasone

INDICATIONS AND DOSE

Diagnosis of Cushing’s disease | Congenital adrenal hyperplasia

BY MOUTH
▼ Adult: 0.5–10 mg daily
▼ By intramuscular injection or by slow intravenous infusion
▼ Adult: 0.4–20 mg

Overnight dexamethasone supression test

BY MOUTH
▼ Adult: 1 mg for 1 dose, to be given at night

Suppression of inflammatory and allergic disorders

BY MOUTH
▼ Adult: 0.5–10 mg daily

Mild croup

BY MOUTH
▼ Child: 150 micrograms/kg for 1 dose
▼ Adult: 150 micrograms/kg for 1 dose

Severe croup (or mild croup that might cause complications)

INITIALLY BY MOUTH
▼ Child: Initially 150 micrograms/kg for 1 dose, to be given before transfer to hospital, then (by mouth or by intravenous injection) 150 micrograms/kg, then (by mouth or by intravenous injection) 150 micrograms/kg after 12 hours if required
### Corticosteroid responsive conditions

- **DIRECTIONS FOR ADMINISTRATION**
  - With oral use in children For administration by mouth tablets may be dispersed in water or injection solution given by mouth.
  - With intravenous use in children For intravenous infusion dilute with Glucose 5% or Sodium Chloride 0.9%; give over 15–20 minutes.
  - With intravenous use in adults For intravenous infusion (Dexamethasone, Hospira) give continuously or intermittently or via drip tubing in Glucose 5% or Sodium Chloride 0.9%.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Dexamethasone 3.8 mg/mL Injection has replaced Dexamethasone 4 mg/mL Injection.
  - **PATIENT AND CARER ADVICE**
    - Medicines for Children leaflet: Dexamethasone for croup [www.medicinesforchildren.org.uk/dexamethasone-croup-0](http://www.medicinesforchildren.org.uk/dexamethasone-croup-0)
    - With systemic use Patient counselling is advised for dexamethasone tablet, oral solution and injection (steroid card).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, capsule Table.

#### MEDICATIONS

<table>
<thead>
<tr>
<th>Name</th>
<th>Form</th>
<th>Price</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>Tablet</td>
<td>£0.10</td>
<td>60 mg daily</td>
</tr>
<tr>
<td></td>
<td>Suspension</td>
<td>£0.10</td>
<td>3 mg every 6 hours as required for 2–4 days, subsequently, reduce dose gradually and stop over 5–7 days</td>
</tr>
<tr>
<td></td>
<td>Injection</td>
<td>£0.20</td>
<td>4 mg/mL injection</td>
</tr>
</tbody>
</table>

#### CAUTIONARY AND ADVISORY LABELS

- **UNLICENSED USE** Consult product literature; not licensed for use in bacterial meningitis.
- **SIDE-EFFECTS**
  - With intravenous use Perineal irritation may follow intravenous administration of the phosphate ester

---

**Fludrocortisone acetate**

**INDICATIONS AND DOSE**

- **Mineralocorticoid replacement in adrenocortical insufficiency**
  - **BY MOUTH**
    - Adult: 50–300 micrograms daily
  - Adrenocortical insufficiency resulting from septic shock (in combination with hydrocortisone)
    - **BY MOUTH**
      - Adult: 50 micrograms daily
Neuropathic postural hypotension

**BY MOUTH**
- Adult: 100–400 micrograms daily

- **UNLICENSED USE** Not licensed for use in neuropathic postural hypotension.
- **HEPATIC IMPAIRMENT** Monitor patient closely in hepatic impairment.
- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, capsule

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Florinef (Aspen Pharma Trading Ltd)</td>
<td>Florinef 100 microgram tablets</td>
</tr>
</tbody>
</table>

Hydrocortisone

**INDICATIONS AND DOSE**

**Thyrotoxic crisis (thyroid storm)**

- **BY INTRAVENOUS INJECTION**
  - Adult: 100 mg every 6 hours, to be administered as sodium succinate

**Adrenocortical insufficiency in Addison’s disease or following adrenalectomy**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 20–30 mg daily in 2 divided doses, the larger dose to be given in the morning and the smaller in the evening, mimicking the normal diurnal rhythm of cortisol secretion, the optimum daily dose is determined on the basis of clinical response

**Adrenocortical insufficiency**

- **BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INFUSION**
  - Adult: 100–500 mg 3–4 times a day or when required

**Replacement in adrenocortical insufficiency**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 20–30 mg once daily, adjusted according to response, dose to be taken in the morning

**Adrenocortical insufficiency resulting from septic shock**

- **BY INTRAVENOUS INJECTION**
  - Adult: 50 mg every 6 hours, given in combination with fludrocortisone

**Acute hypersensitivity reactions such as angioedema of the upper respiratory tract and anaphylaxis (adjunct to adrenaline)**

- **BY INTRAVENOUS INJECTION**
  - Adult: 100–300 mg, to be administered as sodium succinate

Corticosteroid replacement, in patients who have taken more than 10 mg prednisolone daily (or equivalent) within 3 months of minor surgery under general anaesthesia

- **BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - Adult: Initially 25–50 mg, to be administered at induction of surgery, the patient’s usual oral corticosteroid dose is recommenced after surgery

Corticosteroid replacement, in patients who have taken more than 10 mg prednisolone daily (or equivalent) within 3 months of moderate or major surgery

- **BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - Adult: Initially 25–50 mg, to be administered at induction of surgery (following usual oral corticosteroid dose on the morning of surgery), followed by 25–50 mg 3 times a day for 24 hours after moderate surgery and for 48–72 hours after major surgery

**Severe inflammatory bowel disease**

- **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - Adult: 100–500 mg 3–4 times a day or when required

**Ulcerative colitis | Proctitis | Proctosigmoiditis**

- **BY RECTUM USING RECTAL FOAM**
  - Adult: Initially 1 metered application 1–2 times a day for 2–3 weeks, then reduced to 1 metered application once daily on alternate days, to be inserted into the rectum

**Acute hypersensitivity reactions | Angioedema**

- **BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**
  - Child 1–5 months: Initially 25 mg 3 times a day, adjusted according to response
  - Child 6 months–5 years: Initially 50 mg 3 times a day, adjusted according to response
  - Child 6–11 years: Initially 100 mg 3 times a day, adjusted according to response
  - Child 12–17 years: Initially 200 mg 3 times a day, adjusted according to response

**Severe acute asthma | Life-threatening acute asthma**

- **BY INTRAVENOUS INJECTION**
  - Child 1 month–1 year: 4 mg/kg every 6 hours (max. per dose 100 mg), alternatively 25 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate
  - Child 2–4 years: 4 mg/kg every 6 hours (max. per dose 100 mg), alternatively 50 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate
  - Child 5–11 years: 4 mg/kg every 6 hours (max. per dose 100 mg), alternatively 100 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate
  - Adult: 100 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate

**HYDROCORTISTAB®**

**Local inflammation of joints and soft tissues**

- **BY INTRA-ARTICULAR INJECTION**
  - Adult: 5–50 mg, select dose according to size of patient and joint; where appropriate dose may be repeated at intervals of 21 days. Not more than 3 joints should be treated on any one day, for details consult product literature

**Dose equivalence and conversion**

When switching from immediate-release hydrocortisone tablets to modified release Plenadren® use same total daily dose. Bioavailability of Plenadren® lower than immediate release tablets—monitor clinical response.

- **CONTRA-INDICATIONS**
  - With rectal use Bowel perforation | extensive fistulas | intestinal obstruction | recent intestinal anastomoses

- **CAUTIONS**
  - With rectal use Systemic absorption may occur

- **SIDE-EFFECTS**
  - **SPECIFIC SIDE-EFFECTS**
    - With intravenous use Phosphate ester associated with pain and paraesthesia (particularly in the perineal region)
  - With rectal use Local irritation

- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use in children For intravenous administration, dilute with Glucose 5% or Sodium Chloride 0.9%. For intermittent infusion give over 20–30 minutes.
  - With intravenous use in adults For intravenous infusion (SoluCortef® or Efocortes®), give continuously or
intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%.

- **PATIENT AND CARER ADVICE** Patient counselling is advised for hydrocortisone tablets and injections (steroid card).

- **LESS SUITABLE FOR PRESCRIBING** Hydrocortisone as the sodium phosphate is less suitable for prescribing as paraesthesia and pain (particularly in the perineal region) may follow intravenous injection. Efcorstol™ is less suitable for prescribing.

- **EXCEPTIONS TO LEGAL CATEGORY**
  - With intramuscular use or intravenous use
  - Prescription only medicine restriction does not apply where administration is for saving life in emergency.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: suppository, oral suspension, oral solution, capsule, liquid

**Table**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Form</th>
<th>Manufacturer</th>
<th>Strength</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efcortesol</td>
<td>tablet</td>
<td>Pfizer Ltd</td>
<td>10 mg</td>
<td>£0.33</td>
</tr>
<tr>
<td>Plenadren</td>
<td>vial</td>
<td>ViroPharma Ltd</td>
<td>500 mg</td>
<td>£50.00</td>
</tr>
<tr>
<td>Solu-Medrone</td>
<td>vial</td>
<td>Pfizer Ltd</td>
<td>40 mg</td>
<td>£16.68</td>
</tr>
<tr>
<td>Solu-Medrone</td>
<td>vial</td>
<td>Pfizer Ltd</td>
<td>100 mg</td>
<td>£33.33</td>
</tr>
</tbody>
</table>

**Solution for injection**

- **CAUTIONARY AND ADVISORY LABELS 10, 21**
  - Efcorstol (AMCo)
  - Hydrocortisone (as Hydrocortisone sodium phosphate) 100 mg per 1 ml Efcorstol 100mg/1ml solution for injection ampoules | 5 ampoule (Pf) £5.38
  - Efcorstol 500mg/5ml solution for injection ampoules | 5 ampoule (Pf) £24.45

**Powder for solution for injection**

- **Solu-Cortef** (Pfizer Ltd)
  - Hydrocortisone (as Hydrocortisone sodium succinate) 100 mg Solu-Cortef 100mg powder for solution for injection vials | 10 vial (Pf) £9.17

**Powder and solvent for solution for injection**

- **Solu-Cortef** (Pfizer Ltd)
  - Hydrocortisone (as Hydrocortisone sodium succinate) 100 mg Solu-Cortef 100mg powder and solvent for solution for injection vials | 1 vial (Pf) £1.16 DT price = £1.16

**Suspension for injection**

- **Hydrocortistab** (AMCo)
  - Hydrocortisone acetate 25 mg per 1 ml Hydrocortistab 25mg/1ml suspension for injection ampoules | 10 ampoule (Pf) £68.72 DT price = £68.72

**Foam**

- **Exipients:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), propylene glycol
- **Colifoam** (Meda Pharmaceuticals Ltd)
  - Hydrocortisone acetate 100 mg per 1 gram Colifoam 10% aerosol | 14 dose (Pf) £9.33 DT price = £9.33

**Methylprednisolone**

**INDICATIONS AND DOSE**

- Suppression of inflammatory and allergic disorders
- Cerebral oedema associated with malignancy

**BY MOUTH**

- **Adult:** Usual dose 2–40 mg daily

**BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- **Adult:** Initially 10–500 mg

**Treatment of graft rejection reactions**

**BY INTRAVENOUS INFUSION**

- **Adult:** Up to 1 g daily for up to 3 days

**DEPO-MEDRONETM**

- Local inflammation of joints and soft tissues

**BY INTRA-ARTICULAR INJECTION**

- **Adult:** 4–80 mg, select dose according to size; where appropriate dose may be repeated at intervals of 7–35 days, for details consult product literature

**Suppression of inflammatory and allergic disorders**

**BY DEEP INTRAMUSCULAR INJECTION**

- **Adult:** 40–120 mg, then 40–120 mg after 2–3 weeks if required, to be injected into the gluteal muscle

- **CAUTIONS**
  - With intravenous use Rapid intravenous administration of large doses associated with cardiovascular collapse

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (as sodium succinate) (Solu-Medrone®), give continuously or intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%. Reconstitute initially with water for injections; doses up to 250 mg should be given over at least 5 minutes, high doses over at least 30 minutes.

- **PATIENT AND CARER ADVICE** Patient counselling is advised for methylprednisolone tablets and injections (steroid card).

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Table**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Form</th>
<th>Manufacturer</th>
<th>Strength</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylprednisolone 2 mg</td>
<td>Tablet</td>
<td>Medrone</td>
<td>2mg tablets</td>
<td>30 tablet (Pf) £13.88</td>
</tr>
<tr>
<td>Methylprednisolone 4 mg</td>
<td>Tablet</td>
<td>Medrone</td>
<td>4mg tablets</td>
<td>30 tablet (Pf) £6.19</td>
</tr>
<tr>
<td>Methylprednisolone 16 mg</td>
<td>Tablet</td>
<td>Medrone 16mg tablets</td>
<td>30 tablet (Pf) £17.17</td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone 100 mg</td>
<td>Tablet</td>
<td>Medrone 100mg tablets</td>
<td>20 tablet (Pf) £48.32</td>
<td></td>
</tr>
</tbody>
</table>

**Powder and solvent for solution for injection**

- **CAUTIONARY AND ADVISORY LABELS 10, 21**
  - Methylprednisolone (as Methylprednisolone sodium succinate) 500 mg Methylprednisolone sodium succinate 500mg powder and solvent for solution for injection vials | 1 vial (Pf) £9.60
  - Methylprednisolone (as Methylprednisolone sodium succinate) 1 gram Methylprednisolone sodium succinate 1g powder and solvent for solution for injection vials | 1 vial (Pf) £17.30
  - Methylprednisolone (as Methylprednisolone sodium succinate) 40 mg Methylprednisolone sodium succinate 40mg powder and solvent for solution for injection vials | 1 vial (Pf) £1.58

**BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- **Adult:** Initially 10–500 mg

**Treatment of graft rejection reactions**

**BY INTRAVENOUS INFUSION**

- **Adult:** Up to 1 g daily for up to 3 days
Prednisolone

INDICATIONS AND DOSE

Exacerbation of chronic obstructive pulmonary disease (if increased breathlessness interferes with daily activities)

BY MOUTH

» Adult: 30 mg daily for 7–14 days

Severe cough (before transfer to hospital) | Mild cough that might cause complications (before transfer to hospital)

BY MOUTH

» Child: 1–2 mg/kg

Mild to moderate acute asthma (when oral corticosteroid taken for more than a few days) | Severe or life-threatening acute asthma (when oral corticosteroid taken for more than a few days)

BY MOUTH

» Child 1 month–11 years: 2 mg/kg once daily (max. per dose 60 mg) for up to 3 days, longer if necessary

» Child 12–17 years: 40–50 mg daily for at least 5 days

Mild to moderate acute asthma | Severe or life-threatening acute asthma

BY MOUTH

» Child 1 month–11 years: 1–2 mg/kg once daily (max. per dose 40 mg) for up to 3 days, longer if necessary

» Child 12–17 years: 40–50 mg daily for at least 5 days

Suppressive treatment of inflammatory and allergic disorders

BY MOUTH

» Adult: Initially 10–20 mg daily, dose preferably taken in the morning after breakfast, can often be reduced within a few days but may need to be continued for several weeks or months; maintenance 2.5–15 mg daily, higher doses may be needed; cushingoid side-effects increasingly likely with doses above 7.5 mg daily

BY INTRAMUSCULAR INJECTION

» Adult: 25–100 mg 1–2 times a week, as prednisolone acetate

Suspension for injection

CAUTIONARY AND ADVISORY LABELS 10

Methylprednisolone acetate 40 mg per 1 ml

Depo-Medrone (Pfizer Ltd)

40mg/1ml suspension for injection vials | 1 vial £3.44 10 vial pack £34.04

Depo-Medrone 80mg/2ml suspension for injection vials | 1 vial £6.18 10 vial pack £61.39

Depo-Medrone 120mg/3ml suspension for injection vials | 1 vial £8.96 10 vial pack £88.81

Response, to be inserted into the rectum, 1 metered application contains 20 mg prednisolone

Rectal complications of Crohn’s disease

BY RECTUM USING SUPPOSITORIES

» Adult: 5 mg twice daily, to be inserted into the rectum morning and night, after a bowel movement

Rectal and rectosigmoidal ulcerative colitis | Rectal and rectosigmoidal Crohn’s disease

BY RECTUM USING ENEMA

» Adult: 20 mg daily for 2–4 weeks, continued if response good, to be used at bedtime

Proctitis

BY RECTUM USING RECTAL FOAM

» Adult: 1 metered application 1–2 times a day for 2 weeks, continued for further 2 weeks if good response, to be inserted into the rectum, 1 metered application contains 20 mg prednisolone

Rectal and rectosigmoidal ulcerative colitis

BY RECTUM USING SUPPOSITORIES

» Adult: 5 mg twice daily, to be inserted in to the rectum morning and night, after a bowel movement

Neuritic pain or weakness heralding rapid onset of permanent nerve damage (during reversal reactions multidisciplinary leprosy)

BY MOUTH

» Adult: Initially 40–60 mg daily, dose to be instituted at once

Generalised myasthenia gravis (when given on alternate days)

INITIALLY BY MOUTH

» Adult: Initially 10 mg once daily on alternate days, then increased in steps of 10 mg once daily on alternate days, increased to 1–1.5 mg/kg once daily on alternate days (max. per dose 100 mg)

Generalised myasthenia gravis in ventilated patients (when given on alternate days)

BY MOUTH

» Adult: Initially 1.5 mg/kg once daily on alternate days (max. per dose 100 mg)

Generalised myasthenia gravis (when giving daily)

BY MOUTH

» Adult: Initially 5 mg daily, increased in steps of 5 mg daily. maintenance 60–80 mg daily, alternatively maintenance 0.75–1 mg/kg daily, ventilated patients may be started on 1.5 mg/kg (max. 100 mg) on alternate days

Ocular myasthenia

BY MOUTH

» Adult: Usual dose 10–40 mg daily on alternate days, reduce to minimum effective dose

Reduction in rate of joint destruction in moderate to severe rheumatoid arthritis of less than 2 years’ duration

BY MOUTH

» Adult: 7.5 mg daily

Polymyalgia rheumatica

BY MOUTH

» Adult: 10–15 mg daily until remission of disease activity; maintenance 7.5–10 mg daily, reduce gradually to maintenance dose. Many patients require treatment for at least 2 years and in some patients it may be necessary to continue long term low-dose corticosteroid treatment

Giant cell (temporal) arteritis

BY MOUTH

» Adult: 40–60 mg daily until remission of disease activity, the higher dose being used if visual symptoms occur; maintenance 7.5–10 mg daily, reduce gradually to maintenance dose. Many patients require treatment for at least 2 years and in continued
some patients it may be necessary to continue long-term low-dose corticosteroid treatment

**Polyarteritis nodosa** | **Polyomylitis** | Systemic lupus erythematosus
---|---|---

**BY MOUTH**
- Adult: Initially 60 mg daily, then maintenance 10–15 mg daily

**Pneumocystis pneumonia in moderate to severe infections associated with HIV infection**

**BY MOUTH**
- Adult: 50–80 mg daily for 5 days, the dose is then reduced to complete 21 days of treatment, corticosteroid treatment should ideally be started at the same time as the anti-pneumocystis therapy and certainly no later than 24–72 hours afterwards. The corticosteroid should be withdrawn before anti-pneumocystis treatment is complete

**Short-term prophylaxis of episodic cluster headache as monotherapy or in combination with verapamil during verapamil titration**

**BY MOUTH**
- Adult: 60–100 mg once daily for 2–5 days, then reduced in steps of 10 mg every 2–3 days until prednisolone is discontinued

**Anorexia (symptom control in palliative care)**

**BY MOUTH**
- Adult: 15–30 mg daily

**Deltastab®**

**Local inflammation of joints**

**BY INTRA-ARTICULAR INJECTION**
- Adult: 5–25 mg, dose according to size; not more than 3 joints should be treated on any one day; where appropriate may be repeated when relapse occurs, for details consult product literature

**CONTRA-INDICATIONS**
- With rectal use Bowel perforation - extensive fistulas - intestinal obstruction - recent intestinal anastomoses

**CAUTIONS**
- With rectal use Systemic absorption may occur with rectal preparations
- With systemic use Duchenne’s muscular dystrophy (possible transient rhabdomyolysis and myoglobinuria following strenuous physical activity)

**PREGNANCY**
- As it crosses the placenta 88% of prednisolone is inactivated.
- With systemic use Pregnant women with fluid retention should be monitored closely.

**BREAST FEEDING**
- Prednisolone appears in small amounts in breast milk but maternal doses of up to 40 mg daily are unlikely to cause systemic effects in the infant.
- With systemic use Infant should be monitored for adrenal suppression if mother is taking a dose higher than 40 mg.

**PATIENT AND CARER ADVICE**
- Medicines for Children leaflet: Prednisolone for asthma www.medicinesforchildren.org.uk/prednisolone-for-asthma and Prednisolone (oral) for nephrotic syndrome www.medicinesforchildren.org.uk/prednisolone-oral-for-nephrotic-syndrome
- Patient counselling is advised for prednisolone tablets (steroid card).

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, enema

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS 10, 21**
- **Prednisolone (Non-proprietary)**
  - Prednisolone 1 mg Prednisolone 1mg tablets | 28 tablet (PO) £4.00 DT price = £1.08 | 100 tablet (PO) no price available

**Prednisolone 5 mg**
- Prednisolone 5mg tablets | 28 tablet (PO) £11.00 DT price = £1.29 | 100 tablet (PO) no price available
- Prednisolone 25 mg Prednisolone 25mg tablets | 56 tablet (PO) £75.00 DT price = £5.00
- **Brands may include Pevanti**

**Soluble tablet**
- **CAUTIONARY AND ADVISORY LABELS 10, 13, 21**
- **Prednisolone (Non-proprietary)**
  - Prednisolone (as Prednisolone sodium phosphate) 5 mg Prednisolone 5mg soluble tablets | 30 tablet (PO) £53.48 DT price = £53.48

**Gastro-resistant tablet**
- **CAUTIONARY AND ADVISORY LABELS 5, 10, 25**
- **Prednisolone (Non-proprietary)**
  - Prednisolone 2.5 mg Prednisolone 2.5mg gastro-resistant tablets | 28 tablet (PO) £15.45 DT price = £1.59 | 30 tablet (PO) £13.36 | 100 tablet (PO) £13.43
  - Prednisolone 5 mg Prednisolone 5mg gastro-resistant tablets | 28 tablet (PO) £13.50 DT price = £1.65 | 30 tablet (PO) £6.29 | 100 tablet (PO) £13.54
  - **Deltacortril Enteric** (Alliance Pharmaceuticals Ltd)
    - Prednisolone 2.5 mg Deltacortril 2.5mg gastro-resistant tablets | 30 tablet (PO) £1.16
    - Prednisolone 5 mg Deltacortril 5mg gastro-resistant tablets | 30 tablet (PO) £1.19
  - **Brands may include Dilacort**

**Oral solution**
- **Prednisolone (Non-proprietary)**
  - Prednisolone 1 mg per 1 ml Prednisolone 5mg/5ml oral solution unit dose | 10 unit dose (PO) £11.41

**Suspension for injection**
- **Deltastab** (AMCo)
  - Prednisolone acetate 25 mg per 1 ml Deltastab 25mg/1ml suspension for injection ampoules | 10 ampoule (PO) £18.72

**Foam**
- **Prednisolone (Non-proprietary)**
  - Prednisolone (as Prednisolone sodium metasulphobenzoate) 20 mg per 1 application Prednisolone 20mg/application foam enema | 14 dose (PO) £68.00 DT price = £68.00

**Suppository**
- **Prednisolone (Non-proprietary)**
  - Prednisolone (as Prednisolone sodium phosphate) 5 mg Prednisolone sodium phosphate 5mg suppositories | 10 suppository (PO) £27.50 DT price = £27.36

**Enema**
- **Predsol** (Focus Pharmaceuticals Ltd)
  - Prednisolone sodium phosphate 200 microgram per 1 ml Predsol 20mg/100ml retention enema | 7 enema (PO) £7.50

**Prednisone**

**INDICATIONS AND DOSE**
- Moderate to severe rheumatoid arthritis

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- Adult: 10–20 mg daily, adjusted according to response, dose to be taken at bedtime

**HEPATIC IMPAIRMENT**
- Monitor patient closely in hepatic impairment.

**PATIENT AND CARER ADVICE**
- Patient counselling is advised for prednisone tablets (steroid card).

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**
- **CAUTIONARY AND ADVISORY LABELS 10, 21, 25**
- **Lodotra** (Napp Pharmaceuticals Ltd)
  - Prednisone 1 mg Lodotra 1mg modified-release tablets | 30 tablet (PO) £26.70
  - Prednisone 2 mg Lodotra 2mg modified-release tablets | 30 tablet (PO) £26.70 | 100 tablet (PO) £89.00
  - Prednisone 5 mg Lodotra 5mg modified-release tablets | 30 tablet (PO) £26.70 | 100 tablet (PO) £89.00
Cushing’s syndrome and disease

2.1 Cushing’s syndrome and disease

Cushing’s Syndrome

Most types of Cushing’s syndrome are treated surgically, that which occasionally accompanies carcinoma of the bronchus is not usually amenable to surgery. Metyrapone p. 588 has been found helpful in controlling the symptoms of the disease; it is also used in other forms of Cushing’s syndrome to prepare the patient for surgery.

The dosages of metyrapone used are either low, and tailored to cortisol production, or high, in which case corticosteroid replacement therapy is also needed.

IMIDAZOLE ANTIFUNGALS

Ketoconazole

- **DRUG ACTION** An imidazole derivative which acts as a potent inhibitor of cortisol and aldosterone synthesis by inhibiting the activity of 17α-hydroxylase, 11-hydroxylation steps and at higher doses the cholesterol side-chain cleavage enzyme. It also inhibits the activity of adrenal C17-20 lyase enzymes resulting in androgen synthesis inhibition, and may have a direct effect on corticotrophic tumour cells in patients with Cushing’s disease.

**INDICATIONS AND DOSE**

**Endogenous Cushing’s syndrome (specialist use only)**

**BY MOUTH**

- Adult: Initially 400–600 mg daily in 2–3 divided doses, increased to 800–1200 mg daily; maintenance 400–800 mg daily in 2–3 divided doses, for dose titrations in patients with established dose, adjustments in adrenal insufficiency, or concomitant corticosteroid replacement therapy, consult product literature; maximum 1200 mg per day

**Important safety information**

**CHMP ADVICE: KETOCONAZOLE (JULY 2013)**

The CHMP has recommended that the marketing authorisation for oral ketoconazole to treat fungal infections should be suspended. The CHMP concluded that the risk of hepatotoxicity associated with oral ketoconazole is greater than the benefit in treating fungal infections. Doctors should review patients who are being treated with oral ketoconazole for fungal infections, with a view to stopping treatment or choosing an alternative treatment. Patients with a prescription of oral ketoconazole for fungal infections should be referred back to their doctors.

Oral ketoconazole for Cushing’s syndrome and topical products containing ketoconazole are not affected by this advice.

**contra-indications** Acquired QTc prolongation - avoid concomitant use of hepatotoxic drugs - congenital QTc prolongation

**cautions** Risk of adrenal insufficiency

**interactions** → Appendix 1 (antifungals, imidazole).

**side-effects**

- Common or very common Abdominal pain - adrenal insufficiency - diarrhoea - hepatic enzymes increased - nausea - pruritus - rash - vomiting

- Uncommon Alopecia - dizziness - headache - malaise - somnolence - thrombocytopenia - urticaria

- Rare Hepatic failure - hepatitis - jaundice - liver damage

- Very rare Pyrexia


**side-effects, further information**

**Hepatotoxicity** Potentially life-threatening hepatotoxicity reported rarely.
CONCEPTION AND CONTRACEPTION Effective contraception must be used in women of child-bearing potential.

PREGNANCY Manufacturer advises avoid—teratogenic in animal studies.

BREAST FEEDING Manufacturer advises avoid—present in breast milk.

HEPATIC IMPAIRMENT Avoid in acute or chronic impairment. Do not initiate treatment if liver enzymes greater than 2 times the normal upper limit.

MONITORING REQUIREMENTS Monitor ECG before and one week after initiation, and then as clinically indicated thereafter.

Adrenal insufficiency Monitor adrenal function within one week of initiation, then regularly thereafter. When cortisol levels are normalised or close to target and effective dose established, monitor every 3–6 months as there is a risk of autoimmune disease development or exacerbation after normalisation of cortisol levels. If symptoms suggestive of adrenal insufficiency such as fatigue, anorexia, nausea, vomiting, hypotension, hyponatraemia, hyperkalaemia, and/or hypoglycaemia occur, measure cortisol levels and discontinue treatment temporarily (can be resumed thereafter at lower dose) or reduce dose and if necessary, initiate corticosteroid substitution.

Hepatotoxicity Monitor liver function before initiation of treatment, then weekly for 1 month after initiation, then monthly for 6 months—more frequently if dose adjusted or abnormal liver function detected. Reduce dose if liver enzymes increase less than 3 times the normal upper limit—consult product literature; if liver enzymes are raised to times the normal upper limit, discontinue dose and if necessary, initiate corticosteroid substitution.

PATIENT AND CARER ADVICE Dizziness and somnolence may affect the performance of skilled tasks (e.g. driving). Patients or their carers should also be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, jaundice, abdominal pain, or dark urine develop. Patients or their carers should also be told how to recognise signs of adrenal insufficiency.

PATIENT AND CARER ADVICE Resistance to Cushing syndrome (specialist supervision in hospital)

BY MOUTH

Adult: Usual dose 0.25–6 g daily, dose to be tailored to cortisol production, dose is either low, and tailored to cortisol production, or high, in which case corticosteroid replacement therapy is also needed.

Resistant oedema due to increased aldosterone secretion in cirrhosis, nephrotic syndrome, and congestive heart failure (with glucocorticoid replacement therapy) (specialist supervision in hospital)

BY MOUTH

Adult: 3 g daily in divided doses

CONTRA-INDICATIONS Adrenocortical insufficiency

CAUTIONS Avoid in acute porphyrias p. 864 • gross hypopituitarism (risk of precipitating acute adrenal failure) • hypertension on long-term administration • hypothyroidism (delayed response)

INTERACTIONS Many drugs interfere with diagnostic estimation of steroids.

SIDE-EFFECTS

Rare Abdominal pain • allergic skin reactions • hirsutism • hypoadrenalism

Frequency not known Dizziness • headache • hypotension • nausea • sedation • vomiting

PREGNANCY Avoid (may impair biosynthesis of fetal-placental steroids).

BREAST FEEDING Avoid—no information available.

HEPATIC IMPAIRMENT Use with caution in hepatic impairment (delayed response).

PATIENT AND CARER ADVICE Drowsiness may affect the performance of skilled tasks (e.g. driving).

MEDIcINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS. 21

Ketoconazole (HRA Pharma UK Ltd)

Metyrapone 250 mg Metopirone 250 mg capsules 100 capsule £36.66

11/β-HYDROXYLASE INHIBITORS

Metyrapone

DRUG ACTION Metyrapone is a competitive inhibitor of 11β-hydroxylation in the adrenal cortex; the resulting inhibition of cortisol (and to a lesser extent aldosterone) production leads to an increase in ACTH production which, in turn, leads to increased synthesis and release of cortisol precursors. Metyrapone may be used as a test of anterior pituitary function.

INDICATIONS AND DOSE

Differential diagnosis of ACTH-dependent Cushing’s syndrome (specialist supervision in hospital)

BY MOUTH

Adult: 750 mg every 4 hours for 6 doses

MANAGEMENT OF CUSHING’S SYNDROME

Type 1 diabetes, (formerly referred to as insulin-dependent diabetes mellitus (IDDM)), occurs as a result of a deficiency of insulin following autoimmune destruction of pancreatic beta cells. Patients with type 1 diabetes require administration of insulin.

Type 2 diabetes, (formerly referred to as non-insulin-dependent diabetes (NIDDM)), is due to reduced secretion of insulin or to peripheral resistance to the action of insulin or to a combination of both. Although patients may be controlled on diet alone, many also require oral antidiabetic

3 Diabetes mellitus and hypoglycaemia

3.1 Diabetes mellitus

Diabetes

Diabetes mellitus occurs because of a lack of insulin or resistance to its action. It is diagnosed by measuring fasting or random blood-glucose concentration (and occasionally by oral glucose tolerance test). Although there are many subtypes, the two principal classes of diabetes are type 1 diabetes and type 2 diabetes.

Type 1 diabetes, (formerly referred to as insulin-dependent diabetes mellitus (IDDM)), occurs as a result of a deficiency of insulin following autoimmune destruction of pancreatic beta cells. Patients with type 1 diabetes require administration of insulin.

Type 2 diabetes, (formerly referred to as non-insulin-dependent diabetes (NIDDM)), is due to reduced secretion of insulin or to peripheral resistance to the action of insulin or to a combination of both. Although patients may be controlled on diet alone, many also require oral antidiabetic
drugs or insulin (or both) to maintain satisfactory control. In overweight individuals, type 2 diabetes may be prevented by losing weight and increasing physical activity; use of the anti-obesity drug orlistat p. 78 may be considered in obese patients.

**Treatment of diabetes**

Treatment of all forms of diabetes should be aimed at alleviating symptoms and minimising the risk of long-term complications; tight control of diabetes is essential.

Diabetes is a strong risk factor for cardiovascular disease. Other risk factors for cardiovascular disease such as smoking, hypertension, obesity, and hyperlipidaemia should be addressed. Cardiovascular risk in patients with diabetes can be further reduced by the use of an ACE inhibitor, low-dose aspirin p. 104 and a lipid-regulating drug.

**Prevention of diabetic complications**

Optimal glycaemic control in both type 1 diabetes and type 2 diabetes reduces, in the long term, the risk of microvascular complications including retinopathy, development of proteinuria and to some extent neuropathy. However, a temporary deterioration in established diabetic retinopathy may occur when normalising blood-glucose concentration. ACE inhibitors and angiotensin-II receptor antagonists may also have a role in the management of diabetic nephropathy. A measure of the total glycosylated (or glycated) haemoglobin (HbA1c) or a specific fraction (HbA1c) provides a good indication of glycaemic control over the previous 2–3 months. Overall it is ideal to aim for an HbA1c (glycosylated haemoglobin) concentration of 48–59 mmol/mol or less (reference range 20–42 mmol/mol) but this cannot always be achieved and for those using insulin there is a significantly increased risk of disabling hypoglycaemia; in those at risk of arterial disease, the aim should be to maintain the HbA1c concentration at 48 mmol/mol or less. HbA1c should be measured every 3–6 months.

**Measurement of HbA1c**

HbA1c values are expressed in mmol of glycosylated haemoglobin per mol of haemoglobin (mmol/mol), a standardised unit specific for HbA1c, created by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). HbA1c values were previously aligned to the assay used in the Diabetes Control and Complications Trial (DCCT) and expressed as a percentage.

<table>
<thead>
<tr>
<th>Equivalent values IFCC-HbA1c (mmol/mol)</th>
<th>DCCT-HbA1c (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>42</td>
<td>6.0</td>
</tr>
<tr>
<td>48</td>
<td>6.5</td>
</tr>
<tr>
<td>53</td>
<td>7.0</td>
</tr>
<tr>
<td>59</td>
<td>7.5</td>
</tr>
<tr>
<td>64</td>
<td>8.0</td>
</tr>
<tr>
<td>75</td>
<td>9.0</td>
</tr>
</tbody>
</table>

Laboratory measurement of serum-fructosamine concentration is technically simpler and cheaper than the measurement of HbA1c, and can be used to assess control over short periods of time, particularly when HbA1c monitoring is invalid (e.g. disturbed erythrocyte turnover or abnormal haemoglobin type).

Tight control of blood pressure in hypertensive patients with type 2 diabetes reduces mortality and protects visual acuity (by reducing considerably the risks of maculopathy and retinal photocoagulation).

**Driving**

Drivers with diabetes may be required to notify the Driver and Vehicle Licensing Agency (DVLA) of their condition depending on their treatment, the type of licence, and whether they have diabetic complications. Detailed guidance on eligibility to drive, and precautions required, is available from the DVLA (www.gov.uk/government/publications/at-a-glance).

Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems. Drivers treated with insulin should normally check their blood-glucose concentration before driving and, on long journeys, at 2-hour intervals as specified by DVLA guidance; depending on the type of licence, monitoring may also be necessary for drivers taking oral antidiabetic drugs which carry a risk of hypoglycaemia (e.g. sulfonylureas, nateglinide p. 507, repaglinide p. 608). Drivers treated with insulin should ensure that a supply of sugar is always available in the vehicle and they should avoid driving if their meal is delayed. If hypoglycaemia occurs, or warning signs develop, the driver should:

- stop the vehicle in a safe place;
- switch off the ignition and move from the driver’s seat;
- eat or drink a suitable source of sugar;
- wait until 45 minutes after blood glucose has returned to normal, before continuing journey.

**Diabetic nephropathy**

Regular review of diabetic patients should include an annual test for urinary protein (using Albustix®) and serum creatinine measurement. If the urinary protein test is negative, the urine should be tested for microalbuminuria (the earliest sign of nephropathy). If reagent strip tests (Microtest II® or Microbumintest®) are used and prove positive, the result should be confirmed by laboratory analysis of a urine sample. Provided there are no contra-indications, all diabetic patients with nephropathy causing proteinuria or with established microalbuminuria (at least 3 positive tests) should be treated with an ACE inhibitor or an angiotensin-II receptor antagonist even if the blood pressure is normal; in any case, to minimise the risk of renal deterioration, blood pressure should be carefully controlled. Patients with diabetic nephropathy are particularly susceptible to developing hyperkalaemia and should not be given an ACE inhibitor together with an angiotensin-II receptor antagonist.

ACE inhibitors can potentiate the hypoglycaemic effect of insulin and oral antidiabetic drugs; this effect is more likely during the first weeks of combined treatment and in patients with renal impairment. See also treatment of hypertension in diabetes.

**Diabetic neuropathy**

Optimal diabetic control is beneficial for the management of painful neuropathy in patients with type 1 diabetes. Paracetamol p. 354 or a non-steroidal anti-inflammatory drug such as ibuprofen p. 927 may relieve mild to moderate pain.

Duloxetine p. 288 is effective for the treatment of painful diabetic neuropathy; amitriptyline hydrochloride p. 292 [unlicensed use] can be used if duloxetine is ineffective or unsuitable. Nortriptyline p. 298 [unlicensed use] may be better tolerated than amitriptyline hydrochloride. If treatment with amitriptyline hydrochloride or duloxetine is inadequate, treatment with pregabalin p. 400 should be tried. Combination therapy of duloxetine or amitriptyline hydrochloride with pregabalin can be used if monotherapy at the maximum tolerated dose does not control symptoms. Neuropathic pain may respond to opioid analgesics. There is evidence of efficacy for tramadol hydrochloride p. 373, morphine p. 367, and oxycodone hydrochloride p. 369; however treatment with morphine or oxycodone hydrochloride should be initiated only under specialist supervision. Tramadol hydrochloride can be prescribed while the patient is waiting for assessment by a specialist if other treatments have been unsuccessful.
Diabetic ketoacidosis, management


- To restore circulating volume if systolic blood pressure is below 90 mmHg (adjusted for age, sex, and medication as appropriate), give 500 mL sodium chloride 0.9% by intravenous infusion over 10–15 minutes; repeat if blood pressure remains below 90 mmHg and seek senior medical advice.
- When blood pressure is over 90 mmHg, sodium chloride 0.5% should be given by intravenous infusion at a rate that replaces deficit and provides maintenance; see guideline or suggested regimen.
- Include potassium chloride in the fluids unless anuria is suspected; adjust according to plasma-potassium concentration (measure at 60 minutes, 2 hours, and 2 hourly thereafter; measure hourly if outside the normal range).
- Start an intravenous insulin infusion: soluble insulin should be diluted (and mixed thoroughly) with sodium chloride 0.5% intravenous infusion to a concentration of 1 unit/mL; infuse at a fixed rate of 0.1 units/kg/hour.
- Established subcutaneous therapy with long-acting insulin analogues (insulin detemir or insulin glargine) should be continued during treatment of diabetic ketoacidosis.
- Monitor blood-ketone and blood-glucose concentrations hourly and adjust the insulin infusion rate accordingly. Blood-ketone concentration should fall by at least 0.5 mmol/litre/hour and blood-glucose concentration should fall by at least 3 mmol/litre/hour.
- Once blood-glucose concentration falls below 14 mmol/litre, glucose 10% should be given by intravenous infusion (into a large vein through a large-gauge needle) at a rate of 125 mL/hour, in addition to the sodium chloride 0.9% infusion.
  - Continue insulin infusion until blood-ketone concentration is below 0.3 mmol/litre, blood pH is above 7.3 and the patient is able to eat and drink; ideally give subcutaneous fast-acting insulin and a meal, and stop the insulin infusion 1 hour later.

The management of hyperosmolar hyperglycaemic state or hyperosmolar hyperglycaemic nonketotic coma is similar to that of diabetic ketoacidosis, although lower rates of insulin infusion are usually necessary and slower rehydration may be required.

Insulins and anti-diabetic drugs

Insulins

Insulin plays a key role in the regulation of carbohydrate, fat, and protein metabolism. It is a polypeptide hormone of complex structure. There are differences in the amino-acid sequence of animal insulins, human insulins and the human insulin analogues. Insulin may be extracted from pork pancreas and purified by crystallisation; it may also be extracted from beef pancreas, but beef insulins are now rarely used. Human sequence insulin may be produced semisynthetically by enzymatic modification of porcine insulin (emp) or biosynthetically by recombinant DNA technology using bacteria (crb, prb) or yeast (pyr).

All insulin preparations are to a greater or lesser extent immunogenic in man but immunological resistance to insulin action is uncommon. Preparations of human sequence insulin should theoretically be less immunogenic, but no real advantage has been shown in trials.

Insulin is inactivated by gastro-intestinal enzymes, and must therefore be given by injection; the subcutaneous route is ideal in most circumstances. Insulin is usually injected into the upper arms, thighs, buttocks, or abdomen; absorption from a limb site may be increased if the limb is used in strenuous exercise after the injection. Generally subcutaneous insulin injections cause few problems; lipodystrophy may occur but can be minimised by using different injection sites in rotation. Local allergic reactions are rare.

Insulin is needed by all patients with ketoacidosis, and it is likely to be needed by most patients with:
- rapid onset of symptoms;
- substantial loss of weight;
- weakness;
- ketonuria;
- a first-degree relative who has type 1 diabetes.

Insulin is also needed for type 2 diabetes when other methods have failed to achieve good control, and temporally in the presence of intercurrent illness or peri-operatively. Pregnant women with type 2 diabetes may be treated with insulin when diet alone fails. Antidiabetic drugs have a role in the management of diabetes in pregnancy.

Safe and Effective Use of Insulin in Hospitalised Patients (March 2010)


Management of diabetes with insulin

The aim of treatment is to achieve the best possible control of blood-glucose concentration without making the patient obsessional and to avoid disabling hypoglycaemia; close cooperation is needed between the patient and the medical team because good control reduces the risk of complications.

Insulin preparations can be divided into 3 types:
- those of short duration which have a relatively rapid onset of action, namely soluble insulin and the rapid-
hypopituitarism), or in coeliac disease.

Infections, stress, accidental or surgical trauma, and during puberty. Requirements may be increased by infection, stress, accidental or surgical trauma, and during puberty.

Mixtures of insulin preparations may be required and appropriate combinations have to be determined for the individual patient. Treatment should be started with a short-acting insulin (e.g. soluble insulin) or a rapid-acting insulin analogue (e.g. insulin aspart) given before meals with intermediate-acting or long-acting insulin once or twice daily. Alternatively, for those who have difficulty with, or prefer not to use, multiple injection regimens, a mixture of premixed short-acting insulin or rapid-acting insulin analogue with an intermediate-acting or long-acting insulin (most commonly in a proportion of 30% soluble insulin and 70% isophane insulin) can be given once or twice daily. The dose of short-acting or rapid-acting insulin (or the proportion of the short-acting soluble insulin component in premixed insulin) can be increased in those with excessive postprandial hyperglycaemia. The dose of insulin is increased gradually according to the patient’s individual requirements, taking care to avoid troublesome hypoglycaemic reactions.

Insulin requirements may be increased by infection, stress, accidental or surgical trauma, and during puberty. Requirements may be decreased in those with certain endocrine disorders (e.g. Addison’s disease, hypopituitarism), or in coeliac disease.

Examples of recommended insulin regimens

- Multiple injection regimen: short-acting insulin or rapid-acting insulin analogue, before meals. With intermediate-acting or long-acting insulin, once or twice daily;
- Short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting or long-acting insulin, once or twice daily (before meals);
- Intermediate-acting or long-acting insulin, once or twice daily. With or without short-acting insulin or rapid-acting insulin analogue, before meals;
- Continuous subcutaneous insulin infusion.

Hypoglycaemia

Loss of warning of hypoglycaemia among insulin-treated patients can be a serious hazard, especially for drivers and those in dangerous occupations. Very tight control of diabetes lowers the blood-glucose concentration needed to trigger hypoglycaemic symptoms; an increase in the frequency of hypoglycaemic episodes may reduce the warning symptoms experienced by the patient. Beta-blockers can also blunt hypoglycaemic awareness (and also delay recovery).

To restore the warning signs, episodes of hypoglycaemia must be minimised; this involves appropriate adjustment of insulin type, dose and frequency together with suitable timing and quantity of meals and snacks.

Some patients have reported loss of hypoglycaemia warning after transfer to human insulin. Clinical studies do not confirm that human insulin decreases hypoglycaemia awareness. If a patient believes that human insulin is responsible for the loss of warning it is reasonable to revert to animal insulin and essential to educate the patient about avoiding hypoglycaemia. Great care should be taken to specify whether a human or an animal preparation is required.

Few patients are now treated with beef insulin; when undertaking conversion from beef to human insulin, the total dose should be reduced by about 10% with careful monitoring for the first few days. When changing between pork and human-sequence insulins, a dose change is not usually needed, but careful monitoring is still advised.

Diabetes and surgery

Perioperative control of blood-glucose concentrations in patients with type 1 diabetes is achieved via an adjustable, continuous, intravenous infusion of insulin. Detailed local protocols should be available to all healthcare professionals involved in the treatment of these patients; in general, the following steps should be followed:

- give an injection of the patient’s usual insulin on the night before the operation;
- early on the day of the operation, start an intravenous infusion of glucose containing potassium chloride (provided that the patient is not hyperkalaemic) and infuse at a constant rate appropriate to the patient’s fluid requirements (usually 125 mL per hour); make up a solution of soluble insulin in sodium chloride 0.9% and infuse intravenously using a syringe pump piggybacked to the intravenous infusion. Glucose and potassium infusions, and insulin infusions should be made up according to locally agreed protocols;
- the rate of the insulin infusion should be adjusted according to blood-glucose concentration (frequent monitoring necessary) in line with locally agreed protocols. Other factors affecting the rate of infusion include the patient’s volume depletion, cardiac function, and age.

Protocols should include specific instructions on how to manage resistant cases (such as patients who are in shock or severely ill or those receiving corticosteroids or sympathomimetics) and those with hypoglycaemia.

If a syringe pump is not available, soluble insulin should be added to the intravenous infusion of glucose and potassium chloride (provided the patient is not hyperkalaemic), and the infusion run at the rate appropriate to the patient’s fluid requirements (usually 125 mL per hour) with the insulin dose adjusted according to blood-glucose concentration in line with locally agreed protocols.

Once the patient starts to eat and drink, give subcutaneous insulin before breakfast and stop intravenous insulin 30 minutes later; the dose may need to be 10–20% more than usual if the patient is still in bed or unwell. If the patient was not previously receiving insulin, an appropriate initial dose is 20–40 units daily in four divided doses using soluble insulin before meals and intermediate-acting insulin at bedtime and the dose adjusted from day to day. Patients with hyperglycaemia often relapse after conversion back to subcutaneous insulin calling for one of the following approaches:

- additional doses of soluble insulin at any of the four injection times (before meals or bedtime) or
- temporary addition of intravenous insulin infusion (while continuing the subcutaneous regimen) until blood-glucose concentration is satisfactory or
- complete reversion to the intravenous regimen (especially if the patient is unwell).

Short-acting insulins

Soluble insulin is a short-acting form of insulin. For maintenance regimens it is usual to inject it 15 to 30 minutes before meals.

Soluble insulin is the most appropriate form of insulin for use in diabetic emergencies e.g. diabetic ketoacidosis (see Diabetic ketoacidosis, management p. 590) and at the time of surgery. It can be given intravenously and intramuscularly, as well as subcutaneously.

When injected subcutaneously, soluble insulin has a rapid onset of action (30 to 60 minutes), a peak action between 2 and 4 hours, and a duration of action of up to 8 hours.

When injected intravenously, soluble insulin has a very short half-life of only about 5 minutes and its effect disappears within 30 minutes.
The rapid-acting human insulin analogues, insulin aspart, insulin glulisine, and insulin lispro have a faster onset and shorter duration of action than soluble insulin; as a result, compared to soluble insulin, fasting and preprandial blood-glucose concentrations are a little higher, postprandial blood-glucose concentration is a little lower, and hypoglycaemia occurs slightly less frequently. Subcutaneous injection of insulin analogues may be convenient for those who wish to inject shortly before or, when necessary, shortly after a meal. They can also help those susceptible to hypoglycaemia before lunch and those who eat late in the evening and are prone to nocturnal hypoglycaemia. They can also be administered by subcutaneous infusion. Insulin aspart and insulin lispro can be administered intravenously and can be used as alternatives to soluble insulin for diabetic emergencies and at the time of surgery.

Intermediate- and long-acting insulins

When given by subcutaneous injection, intermediate- and long-acting insulins have an onset of action of approximately 1–2 hours, a maximal effect at 4–12 hours, and a duration of 16–42 hours. Some are given twice daily in conjunction with short-acting (soluble) insulin, and others are given once daily, particularly in elderly patients. Soluble insulin can be mixed with intermediate and long-acting insulins (except insulin detemir, insulin glargine, and insulin degludec) in the syringe, essentially retaining the properties of the two components, although there may be some blunting of the initial effect of the soluble insulin component (especially on mixing with protamine zinc insulin).

Isophane insulin is a suspension of insulin with protamine; it is of particular value for initiation of twice-daily insulin regimens. Patients usually mix isophane with soluble insulin but ready-mixed preparations may be appropriate (biphasic isophane insulin, biphasic insulin aspart, or biphasic insulin lispro).

Insulin zinc suspension (30% amorphous, 70% crystalline) has a more prolonged duration of action.

Protamine zinc insulin is usually given once daily with short-acting (soluble) insulin. It has the drawback of binding with the soluble insulin when mixed in the same syringe and is now rarely used.

Insulin glargine and insulin detemir are both long-acting human insulin analogues with a prolonged duration of action; insulin glargine is given once daily and insulin detemir is given once or twice daily. NICE (December 2002) has recommended that insulin glargine should be available as an option for patients with type 1 diabetes.

NICE (May 2009) has recommended that, if insulin is required in patients with type 2 diabetes, insulin detemir or insulin glargine may be considered for those:

- who require assistance with injecting insulin or
- whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemia or
- who would otherwise need twice–daily basal insulin injections in combination with oral antidiabetic drugs or
- who cannot use the device needed to inject isophane insulin.

Insulin detemir is also licensed as add-on therapy in patients receiving treatment with lixisenatide.

Insulin degludec is a long-acting human insulin analogue for once daily subcutaneous administration.

Hypodermic equipment

Patients should be advised on the safe disposal of lancets, single-use syringes, and needles. Suitable arrangements for the safe disposal of contaminated waste must be made before these products are prescribed for patients who are carriers of infectious diseases.

Lancets, needles, syringes, and accessories are listed under Hypodermic Equipment in Part IXA of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 3 of the Scottish Drug Tariff). The drug Tariffs can be accessed online at:

- National Health Service Drug Tariff for England and Wales: www.ppa.org.uk/ppa/edt_intro.htm
- Health and Personal Social Services for Northern Ireland Drug Tariff: www.dhsspsni.gov.uk/ps-tariff
- Scottish Drug Tariff: www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/

Antidiabetic drugs

Oral antidiabetic drugs are used for the treatment of type 2 diabetes mellitus. They should be prescribed only if the patient fails to respond adequately to at least 3 months’ restriction of energy and carbohydrate intake and an increase in physical activity. They should be used to augment the effect of diet and exercise, and not to replace them.

For patients not adequately controlled by diet and oral hypoglycaemic drugs, insulin may be added to the treatment regimen or substituted for oral therapy. When insulin is added to oral therapy, it is generally given at bedtime as isophane or long-acting insulin, and when insulin replaces an oral regimen it may be given as twice-daily injections of a biphasic insulin (or isophane insulin p. 607 mixed with soluble insulin), or a multiple injection regimen. Weight gain and hypoglycaemia may be complications of insulin therapy but weight gain may be reduced if the insulin is given in combination with metformin hydrochloride p. 594.

Pregnancy and breast-feeding

During pregnancy, women with pre-existing diabetes can be treated with metformin hydrochloride [unlicensed use], either alone or in combination with insulin. Metformin hydrochloride can be continued, or glibenclamide p. 611 resumed, during breast-feeding for those with pre-existing diabetes. Women with gestational diabetes may be treated, with or without concomitant insulin, with glibenclamide from 11 weeks gestation (after organogenesis) [unlicensed use] or with metformin [unlicensed use]. Women with gestational diabetes should discontinue hypoglycaemic treatment after giving birth.

Sulfonylureas

The sulfonylureas act mainly by augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present; during long-term administration they also have an extrapancreatic action. All may cause hypoglycaemia but this is uncommon and usually indicates excessive dosage. Sulfonylurea-induced hypoglycaemia may persist for many hours and must always be treated in hospital.

Sulfonylureas are considered for patients who are not overweight, or in whom metformin hydrochloride is contraindicated or not tolerated. Several sulfonylureas are available and choice is determined by side-effects and the duration of action as well as the patient’s age and renal function. Glibenclamide, a long-acting sulfonylurea, is associated with a greater risk of hypoglycaemia; for this reason it should be avoided in the elderly, and shorter-acting alternatives, such as gliclazide p. 611 or tolbutamide p. 613, should be used instead.

When the combination of strict diet and sulfonylurea treatment fails, other options include:

- combining with metformin;
- combining with pioglitazone;
- combining with alogliptin, lixisenatide, saxagliptin, sitagliptin, or vildagliptin;
- combining with canagliflozin, dapagliflozin or empagliflozin;
- combining with exenatide, lixisenatide, or liraglutide;
- combining with acarbose, which may have a small beneficial effect, but flatulence can be a problem;
• combining with bedtime isophane insulin but weight gain and hypoglycaemia can occur.
Insulin therapy should be instituted temporarily during intercurrent illness (such as myocardial infarction, coma, infection, and trauma). Sulfonylureas should be omitted on the morning of surgery; insulin is required because of the ensuing hyperglycaemia in these circumstances.

**Biguanides**

Metformin hydrochloride, the only available biguanide, has a different mode of action from the sulfonylureas, and is not interchangeable with them.
Metformin hydrochloride is the drug of first choice in overweight patients in whom strict dieting has failed to control diabetes, if appropriate it may also be considered as an option in patients who are not overweight. It is also used when diabetes is inadequately controlled with sulfonylurea treatment. When the combination of strict diet and metformin hydrochloride treatment fails, other options include:
- combining with a sulfonylurea;
- combining with pioglitazone;
- combining with repaglinide or nateglinide;
- combining with alogliptin, linagliptin, saxagliptin, sitagliptin, or vildagliptin;
- combining with canagliflozin, dapagliflozin or empagliflozin;
- combining with exenatide, liraglutide, or lixisenatide;
- combining with acarbose, which may have a small beneficial effect, but flatulence can be a problem;
- combining with insulin but weight gain and hypoglycaemia can be problems (weight gain minimised if insulin given at night).
Insulin treatment is almost always required in medical and surgical emergencies; insulin should also be substituted before elective surgery (omit metformin hydrochloride on the morning of surgery and give insulin if required).

Hypoglycaemia does not usually occur with metformin hydrochloride; other advantages are the lower incidence of weight gain and lower plasma-insulin concentration. It does not exert a hypoglycaemic action in non-diabetic subjects unless given in overdose.
Metformin hydrochloride is used for the symptomatic management of polycystic ovary syndrome [unlicensed indication]; however, treatment should be initiated by a specialist. Metformin hydrochloride improves insulin sensitivity, may aid weight reduction, helps to normalise menstrual cycle (increasing the rate of spontaneous ovulation), and may improve hirsutism.

**Other antidiabetic drugs**

Use of acarbose p. 594 is usually reserved for when other oral hypoglycaemics are not tolerated or are contra-indicated. Postprandial hyperglycaemia in type 1 diabetes can be reduced by acarbose, but it has been little used for this purpose. Flatulence deters some from using acarbose although this side-effect tends to decrease with time.

Nateglinide p. 607 and repaglinide p. 608 stimulate insulin secretion. Both drugs have a rapid onset of action and short duration of activity, and should be administered shortly before each main meal. Repaglinide may be given as monotherapy for patients who are not overweight or for those in whom metformin hydrochloride is contra-indicated or not tolerated, or it may be given in combination with metformin hydrochloride. Nateglinide is licensed only for use with metformin hydrochloride.

Pioglitazone p. 613 can be used alone or in combination with metformin hydrochloride or with a sulfonylurea (if metformin hydrochloride inappropriate), or with both; the combination of pioglitazone plus metformin hydrochloride is preferred to pioglitazone plus sulfonylurea, particularly for obese patients. Inadequate response to a combination of metformin hydrochloride and sulfonylurea may indicate failing insulin release; the introduction of pioglitazone has a limited role in these circumstances and the initiation of insulin is often more appropriate. Pioglitazone is also licensed in combination with insulin, in patients who have not achieved adequate glycaemic control with insulin alone, when metformin hydrochloride is inappropriate. Blood-glucose control may deteriorate temporarily when pioglitazone is substituted for an oral antidiabetic drug that is being used in combination with another. Long-term benefits of pioglitazone have not yet been demonstrated. NICE (May 2009) has recommended that, when glycaemic control is inadequate with existing treatment, pioglitazone can be added to:
- a sulfonylurea, if metformin hydrochloride is contra-indicated or not tolerated;
- metformin, if risks of hypoglycaemia with sulfonylurea are unacceptable or a sulfonylurea is contra-indicated or not tolerated;
- a combination of metformin hydrochloride and a sulfonylurea, if insulin is unacceptable because of lifestyle or other personal issues, or because the patient is obese.
NICE has recommended that treatment with pioglitazone is continued only if HbA1c concentration is reduced by at least 0.5 percentage points within 6 months of starting treatment.

Linagliptin p. 596 is licensed for use in type 2 diabetes as monotherapy (if metformin hydrochloride inappropriate), or in combination with metformin hydrochloride (when treatment with metformin hydrochloride alone fails to achieve adequate glycaemic control), or both metformin hydrochloride and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control). Linagliptin may also be used in combination with insulin (with or without metformin hydrochloride p. 594) when a stable dose of insulin has not provided adequate glycaemic control.

Saxagliptin p. 597 and vildagliptin p. 598 are licensed for use in type 2 diabetes as monotherapy (if metformin hydrochloride inappropriate), or in combination with metformin hydrochloride or a sulfonylurea (if metformin hydrochloride inappropriate), or pioglitazone (when treatment with metformin hydrochloride alone fails to achieve adequate glycaemic control), and also in combination with both metformin hydrochloride and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control). The combination of either saxagliptin or vildagliptin, and insulin (with or without metformin hydrochloride) is also licensed for use when a stable dose of insulin has not provided adequate glycaemic control.

Alogliptin p. 596 is also licensed for use as triple therapy in combination with metformin hydrochloride and either pioglitazone or insulin.

NICE (May 2009) has recommended that, when glycaemic control is inadequate with existing treatment:
- sitagliptin or vildagliptin (instead of a sulfonylurea) can be added to metformin, if there is a significant risk of hypoglycaemia or if a sulfonylurea is contra-indicated or not tolerated;
- sitagliptin or vildagliptin can be added to a sulfonylurea, if metformin is contra-indicated or not tolerated;
- sitagliptin can be added to both metformin and a sulfonylurea, if insulin is unacceptable because of lifestyle or other personal issues, or because the patient is obese.
NICE has recommended that treatment with sitagliptin or vildagliptin is continued only if HbA1c concentration is reduced by at least 0.5 percentage points within 6 months of starting treatment.

Treatment with exenatide p. 599, liraglutide p. 600, and lixisenatide p. 601 is associated with the prevention of
weight gain and possible promotion of weight loss which can be beneficial in overweight patients. They are given by subcutaneous injection for the treatment of type 2 diabetes mellitus.

Exenatide is licensed in combination with metformin hydrochloride or a sulfonylurea, or both, or with pioglitazone, or with both metformin hydrochloride and pioglitazone, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination; standard-release exenatide is also licensed in combination with basal insulin alone or with metformin hydrochloride or pioglitazone (or both).

NICE (May 2009) has recommended that, when glycaemic control is inadequate with metformin hydrochloride and sulfonylurea treatment, the addition of standard-release exenatide may be considered if the patient has:

- a body mass index of 35 kg/m² or over and is of European descent (with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems or
- a body mass index less than 35 kg/m², and insulin would be unacceptable for occupational reasons or weight loss would benefit other significant obesity-related comorbidities.

NICE has recommended that treatment with standard release exenatide is continued only if HbA₁c concentration is reduced by at least 1 percentage point and a weight loss of at least 3% is achieved within 6 months of starting treatment.

Liraglutide is licensed for the treatment of type 2 diabetes mellitus in combination with metformin hydrochloride or a sulfonylurea, or both, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination. Liraglutide is also licensed for use in combination with basal insulin or both metformin hydrochloride and pioglitazone when dual therapy with these drugs fails to achieve adequate glycaemic control. Lixisenatide is licensed for the treatment of type 2 diabetes mellitus in combination with oral antidiabetic drugs (e.g. metformin hydrochloride, pioglitazone, or a sulfonylurea) or basal insulin, or both, when adequate glycaemic control has not been achieved with these drugs;lixisenatide should not be used in combination with both basal insulin and a sulfonylurea because of an increased risk of hypoglycaemia. Canagliflozin p. 608 and dapagliflozin p. 609, and empagliflozin p. 610 are licensed for use in type 2 diabetes as monotherapy (if metformin hydrochloride inappropriate), or in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control). Dapagliflozin is not recommended in combination with pioglitazone.

### ALPHA GLUCOSIDASE INHIBITORS

**Acarbose**

- **DRUG ACTION** Acarbose, an inhibitor of intestinal alpha glucosidases, delays the digestion and absorption of starch and sucrose; it has a small but significant effect in lowering blood glucose.

**INDICATIONS AND DOSE**

**Diabetes mellitus inadequately controlled by diet or by diet with oral antidiabetic drugs**

**BY MOUTH**

- Adult: Initially 50 mg daily, then increased to 50 mg 3 times a day for 6–8 weeks, then increased if necessary to 100 mg 3 times a day (max. per dose 200 mg 3 times a day)

**SIDE-EFFECTS**

- Common or very common Abdominal distention and pain • diarrhea (may need to reduce dose or withdraw) • flatulence • soft stools

- Rare Abnormal liver function tests • nausea • skin reactions

**SIDE-EFFECTS, FURTHER INFORMATION**

**Antacids** Antacids unlikely to be beneficial for treating side effects.

**PREGNANCY** Avoid.

**BREAST FEEDING** Avoid.

**HEPATIC IMPAIRMENT** Avoid.

**RENAL IMPAIRMENT** Avoid if eGFR less than 25 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor liver function.

**DIRECTIONS FOR ADMINISTRATION** Tablets should be chewed with first mouthful of food or swallowed whole with a little liquid immediately before food.

**PATIENT AND CARER ADVICE** Antacids unlikely to be beneficial for treating side-effects. To counteract possible hypoglycaemia, patients receiving insulin or a sulfonylurea as well as acarbose need to carry glucose (not sucrose—acarbose interferes with sucrose absorption). Patients should be given advice on how to administer acarbose tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **ACARBOSE (Non-proprietary)**
  - Acarbose 50 mg | 90 tablet "price £9.65 DT price £9.65
  - Acarbose 100 mg | 90 tablet "price £16.42 DT price £16.42

- **Glucobay (Bayer Plc)**
  - Acarbose 50 mg | 90 tablet "price £7.35 DT price £7.35
  - Acarbose 100 mg | 90 tablet "price £13.50 DT price £13.50

**BIGUANIDES**

**Metformin hydrochloride**

- **DRUG ACTION** Metformin exerts its effect mainly by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose; since it acts only in the presence of endogenous insulin it is effective only if there are some residual functioning pancreatic islet cells.

**INDICATIONS AND DOSE**

**Diabetes mellitus**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: Initially 500 mg once daily for at least 1 week, dose to be taken with breakfast, then 500 mg twice daily for at least 1 week, dose to be taken with breakfast and evening meal, then 500 mg 3 times a day, dose to be taken with breakfast, lunch and evening meal; maximum 2 g per day

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adult: Initially 500 mg once daily, then increased if necessary up to 2 g once daily, dose increased...
gradually, every 10–15 days, dose to be taken with evening meal, alternatively increased to 1 g twice daily, dose to be taken with meals, alternative dose only to be used if control not achieved with once daily dose regimen. If control still not achieved then change to standard release tablets

**Polycystic ovary syndrome**

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- **Adult:** Initially 500 mg once daily for 1 week, dose to be taken with breakfast, then 500 mg twice daily for 1 week, dose to be taken with breakfast and evening meal, then 1.5–1.7 g daily in 2–3 divided doses

- **UNLICENSED USE** Doses in the BNF may differ from those in the product literature. Not licensed for polycystic ovary syndrome.

- **CONTRA-INDICATIONS** Ketoacidosis - use of general anaesthesia (suspend metformin on the morning of surgery and restart when renal function returns to baseline)

**CONTRA-INDICATIONS, FURTHER INFORMATION**

- **Iodine-containing X-ray contrast media** Intravenous administration of iodinated contrast agents can cause renal failure, which can increase the risk of lactic acidosis with metformin. Suspend metformin prior to the test; restart no earlier than 48 hours after the test if renal function has returned to baseline.

- **CAUTIONS** Can provoke lactic acidosis

- **INTERACTIONS** Appendix 1 (antidiabetics).

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain - anorexia - diarrhoea (usually transient) - nausea - taste disturbance - vomiting
  - Rare Decreased vitamin-B₁₂ absorption - erythema - lactic acidosis (withdraw treatment) - pruritus - urticaria
  - Frequency not known Hepatitis

**Gastro-intestinal effects** Gastro-intestinal side-effects are initially common with metformin, and may persist in some patients, particularly when very high doses are given. A slow increase in dose may improve tolerability.

- **PREGNANCY** Can be used in pregnancy for both pre-existing and gestational diabetes. Women with gestational diabetes should discontinue treatment after giving birth.

- **BREAST FEEDING** May be used during breast-feeding in women with pre-existing diabetes.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (September 2009) that Glucophage® SR is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in adult patients who are intolerant of standard-release metformin, and in whom the prolonged-release tablet allows the use of a dose of metformin not previously tolerated, or in patients for whom a once daily preparation offers a clinically significant benefit.

- **HEPATIC IMPAIRMENT** Withdraw if tissue hypoxia likely.

- **RENAI IMPAIRMENT** Use with caution in renal impairment— increased risk of lactic acidosis.

Lactic acidosis Withdraw or interrupt treatment in those at risk of tissue hypoxia or sudden deterioration in renal function, such as those with dehydration, severe infection, shock, sepsis, acute heart failure, respiratory failure or hepatic impairment, or those who have recently had a myocardial infarction.

**NICE (clinical guideline 87 (May 2009): Type 2 diabetes:** The management of type 2 diabetes) recommends that the dose should be reviewed if eGFR less than 45 mL/minute/1.73 m² and to avoid if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS** Determine renal function before treatment and at least annually (at least twice a year in patients with additional risk factors for renal impairment, or if deterioration suspected).

**PRESCRIBING AND DISPENSING INFORMATION** Patients taking up to 2 g daily of the standard-release metformin may start with the same daily dose of metformin modified release; not suitable if dose of standard-release tablets more than 2 g daily.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, capsule

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 21**

- **METFORMIN HYDROCHLORIDE (Non-proprietary)**
  - Metformin hydrochloride 500 mg Metformin 500mg tablets | 28 tablet (P) £1.55 DT price = £1.47 | 84 tablet (P) £4.41 | 500 tablet (P) £2.25
  - Metformin hydrochloride 850 mg Metformin 850mg tablets | 56 tablet (P) £2.48 DT price = £1.86 | 60 tablet (P) no price available | 300 tablet (P) £10.12
  - Glucophage (Merck Serono Ltd)
  - Metformin hydrochloride 500 mg Glucophage 500mg tablets | 84 tablet (P) £2.88
  - Metformin hydrochloride 850 mg Glucophage 850mg tablets | 56 tablet (P) £3.20 DT price = £1.86

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 21, 25**

- **METFORMIN HYDROCHLORIDE (Non-proprietary)**
  - Metformin hydrochloride 500 mg Metformin 500mg modified-release tablets | 28 tablet (P) £1.89 | 56 tablet (P) £3.25 DT price = £3.32
  - Metformin hydrochloride 1 gram Metformin 1g modified-release tablets | 28 tablet (P) £4.26 | 56 tablet (P) £8.52 DT price = £8.52
  - Glucophage SR (Merck Serono Ltd)
  - Metformin hydrochloride 500 mg Glucophage SR 500mg tablets | 28 tablet (P) £2.66 | 56 tablet (P) £5.32 DT price = £5.32
  - Metformin hydrochloride 750 mg Glucophage SR 750mg tablets | 28 tablet (P) £3.20 | 56 tablet (P) £6.40 DT price = £6.40
  - Metformin hydrochloride 1 gram Glucophage SR 1000mg tablets | 28 tablet (P) £4.26 | 56 tablet (P) £8.52 DT price = £8.52
  - Brands may include Bolamyn SR; Diagemet XL; Glucient SR; Metabeta SR; Sukkato SR

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS 21**

- **METFORMIN HYDROCHLORIDE (Non-proprietary)**
  - Metformin hydrochloride 100 mg per 1 ml Metformin 500mg/5ml oral solution sugar free (sugar-free) | 100 ml (P) £47.52 (sugar-free) | 150 ml (P) £63.80 DT price = £63.80

**Powder**

- **METFORMIN HYDROCHLORIDE (Non-proprietary)**
  - Metformin hydrochloride 1 gram Metformin 1g oral powder sachets sugar free (sugar-free) | 30 sachet (P) no price available

Also available in combination with alogliptin, p. 596; canagliflozin, p. 609; dapagliflozin, p. 610; linagliptin, p. 597; pioglitazone, p. 614; saxagliptin, p. 597; sitagliptin, p. 598; vildagliptin, p. 599
Alogliptin

**INDICATIONS AND DOSE**
Type 2 diabetes as dual therapy in combination with either metformin, pioglitazone, a sulfonylurea, or insulin (when treatment with these drugs alone fails to achieve adequate glycaemic control), or as triple therapy in combination with metformin and either pioglitazone or insulin.

**BY MOUTH**
- **Adult:** 25 mg once daily

**Dose adjustments due to interactions**
Dose of concomitant sulfonylurea or insulin may need to be reduced. Caution with use in combination with both metformin and pioglitazone—risk of hypoglycaemia (dose of metformin or pioglitazone may need to be reduced).

**SIDE-EFFECTS**
- **Common or very common**
  - Abdominal pain
  - Nasopharyngitis
  - Pruritus
  - Upper respiratory tract infection

**SIDE-EFFECTS, FURTHER INFORMATION**
- **Pancreatitis** Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

**CONTRA-INDICATIONS**
- Ketoacidosis

**CAUTIONS**
- History of pancreatitis: Avoid use.

**INTERACTIONS**
- Avoid in combination with metformin when addition of a sulfonylurea is inappropriate (January 2013, and in combination with metformin when addition of a sulfonylurea is inappropriate (December 2011).

**MEDICATION FORMS**
- Available in different presentations.

**Linagliptin**

**INDICATIONS AND DOSE**
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with metformin (when treatment with metformin alone fails to achieve adequate glycaemic control), or both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control). Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control.

**BY MOUTH**
- **Adult:** 5 mg once daily

**Dose adjustments due to interactions**
Dose of concomitant sulfonylurea or insulin may need to be reduced.

**SIDE-EFFECTS**
- **Uncommon** Cough, nasopharyngitis

**SIDE-EFFECTS, FURTHER INFORMATION**
- **Pancreatitis** Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

**PRECAUTIONARY AND ADVISORY LABELS**
- **Avoid**—present in milk in animal studies.

**MEDICATION FORMS**
- Available in different presentations.

**Linagliptin with metformin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, alogliptin above, metformin hydrochloride p. 594.
Linagliptin with metformin

The properties listed below are those particular to the combination only. For the properties of the components please consider, linagliptin p. 596, metformin hydrochloride p. 594.

**INDICATIONS AND DOSE**
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin

**BY MOUTH**
- Adult: 1 tablet twice daily, based on patient’s current metformin dose

**INTERACTIONS**
Dose of concomitant sulfonylurea or insulin may need to be reduced.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jentadueto (Boehringer Ingelheim Ltd)</td>
<td></td>
</tr>
<tr>
<td>Linagliptin 2.5 mg, Metformin hydrochloride 850 mg</td>
<td>Jentadueto 2.5mg/850mg tablets</td>
</tr>
<tr>
<td>Linagliptin 2.5 mg, Metformin hydrochloride 1000 mg</td>
<td>Jentadueto 2.5mg/1000mg tablets</td>
</tr>
</tbody>
</table>

Saxagliptin

**DRUG ACTION**
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.

**INDICATIONS AND DOSE**
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with metformin or a sulfonylurea (if metformin inappropriate), or pioglitazone (when treatment with either metformin or a sulfonylurea or pioglitazone fails to achieve adequate glycaemic control), and also in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control) | Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control

**BY MOUTH**
- Adult: 5 mg once daily

**Dose adjustments due to interactions**
Dose of concomitant sulfonylurea or insulin may need to be reduced.

**CAUTIONS**
Elderly

**INTERACTIONS**
Appendix 1 (antidiabetics).

**SIDE-EFFECTS**
- Common or very common: Dizziness, dyspepsia, fatigue, gastritis, gastroenteritis, headache, hypoglycaemia, myalgia, nasopharyngitis, peripheral oedema, sinusitis, upper respiratory tract infection, urinary tract infection, vomiting
- Uncommon: Anaphylaxis, arthralgia, dyslipidaemia, erectile dysfunction, hypersensitivity reactions, hypertriglyceridaemia, pancreatitis
- Frequency not known: Rash

**SIDE-EFFECTS, FURTHER INFORMATION**
pancreatitis: Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

**ALLERGY AND CROSS-SENSITIVITY**
Contraindicated if patient has a history of serious hypersensitivity to dipeptidylpeptidase-4 inhibitors.

**PREGNANCY**
Avoid unless essential—toxicity in animal studies.

Metformin with saxagliptin

The properties listed below are those particular to the combination only. For the properties of the components please consider, metformin hydrochloride p. 594, saxagliptin above.

**INDICATIONS AND DOSE**
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin

**BY MOUTH**
- Adult: 1 tablet twice daily, based on patient’s current metformin dose

**INTERACTIONS**
Dose of concomitant sulfonylurea or insulin may need to be reduced.

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised that saxagliptin (Onglyza®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onglyza (AstraZeneca UK Ltd)</td>
<td></td>
</tr>
<tr>
<td>Saxagliptin (as Saxagliptin hydrochloride) 2.5 mg</td>
<td>Onglyza 2.5mg tablets</td>
</tr>
<tr>
<td>Saxagliptin (as Saxagliptin hydrochloride) 5 mg</td>
<td>Onglyza 5mg tablets</td>
</tr>
</tbody>
</table>

**BREAST FEEDING**
Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**
Use with caution in moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT**
Reduce dose to 2.5 mg once daily in moderate to severe impairment. Use with caution in severe impairment.

**MONITORING REQUIREMENTS**
Determine renal function before treatment and periodically thereafter.

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised that saxagliptin (Onglyza®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Komboglyze (Boehringer Ingelheim Ltd)</td>
<td></td>
</tr>
<tr>
<td>Metformin hydrochloride 850 mg, Saxagliptin (as Saxagliptin hydrochloride) 2.5 mg</td>
<td>Komboglyze 2.5mg/850mg tablets</td>
</tr>
<tr>
<td>Metformin hydrochloride 1 gram, Saxagliptin (as Saxagliptin hydrochloride) 2.5 mg</td>
<td>Komboglyze 2.5mg/1000mg tablets</td>
</tr>
</tbody>
</table>
Sitagliptin

**DRUG ACTION** Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.

**INDICATIONS AND DOSE**
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with metformin or a sulfonylurea (if metformin inappropriate), or pioglitazone (when treatment with either metformin or a sulfonylurea or pioglitazone fails to achieve adequate glycaemic control), and also in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control) | Type 2 diabetes mellitus in combination with both metformin and pioglitazone when dual therapy with these drugs fails to achieve adequate glycaemic control, and may also be used in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control

**BY MOUTH**
- Adult: 100 mg once daily
- Dose adjustments due to interactions
- Dose of concomitant sulfonylurea or insulin may need to be reduced.

**CONTRA-INDICATIONS** KETOACIDOSIS

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**
- Common or very common  
  - Gastro-intestinal disturbances - nasopharyngitis - pain - peripheral oedema - upper respiratory tract infection
- Uncommon  
  - Anorexia - dizziness - drowsiness - dry mouth - headache - hypoglycaemia - osteoarthritis
- Frequency not known  
  - Cutaneous vasculitis - pancreatitis - rash - Stevens-Johnson syndrome

**SIDE-EFFECTS, FURTHER INFORMATION**
Pancreatitis Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

**PREGNANCY** Avoid—toxicity in animal studies.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**RENAL IMPAIRMENT** Reduce dose to 50 mg once daily if eGFR 30–50 mL/minute/1.73 m². Reduce dose to 25 mg once daily if eGFR less than 30 mL/minute/1.73 m².

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (July 2008) that Janumet® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus when the addition of a sulfonylurea to metformin is not appropriate; it is also accepted for use in NHS Scotland in combination with a sulfonylurea in patients inadequately controlled on maximum tolerated doses of metformin and a sulfonylurea.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Januvia (Merck Sharp & Dohme Ltd) 25 mg Januvia 25mg tablets | 28 tablet (£33.26 DT price = £33.26)  
- Sitagliptin (as Sitagliptin phosphate) 50 mg Januvia 50mg tablets | 28 tablet (£33.26 DT price = £33.26)  
- Sitagliptin (as Sitagliptin phosphate) 100 mg Januvia 100mg tablets | 28 tablet (£33.26 DT price = £33.26)

**Vildagliptin**

**DRUG ACTION** Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.

**INDICATIONS AND DOSE**
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or pioglitazone or insulin

**BY MOUTH**
- Adult: 1 tablet twice daily

**INTERACTIONS** Dose of concomitant sulfonylurea or insulin may need to be reduced.

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (July 2008) that Janumet® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus when the addition of a sulfonylurea to metformin is not appropriate; it is also accepted for use in NHS Scotland in combination with a sulfonylurea in patients inadequately controlled on maximum tolerated doses of metformin and a sulfonylurea.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- CAUTIONARY AND ADVISORY LABELS 21  
  - Janumet (Merck Sharp & Dohme Ltd)  
    - Metformin hydrochloride 1 gram, Sitagliptin (as Sitagliptin phosphate) 50 mg Janumet 50mg/1000mg tablets | 56 tablet (£33.26 DT price = £33.26)

**CONTRA-INDICATIONS** KETOACIDOSIS

**CAUTIONS** Manufacturer advises avoid in severe heart failure—no information available

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**
- Common or very common  
  - Asthenia - dizziness - headache - nausea - peripheral oedema - tremor
- Uncommon  
  - Arthralgia - constipation - hypoglycaemia
- Rare  
  - Hepatic dysfunction
- Very rare  
  - Nasopharyngitis - upper respiratory tract infection
- Frequency not known  
  - Bullous skin reactions - exfoliative skin reactions - pancreatitis

**Metformin with sitagliptin**
The properties listed below are those particular to the combination only. For the properties of the components please consider, metformin hydrochloride p. 594, sitagliptin above.
Metformin with vildagliptin

The properties listed below are those particular to the combination only. For the properties of the components please consider, metformin hydrochloride p. 594, vildagliptin p. 598.

INDICATIONS AND DOSE
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin

Adult: 1 tablet twice daily, based on patient’s current metformin dose

INTERACTIONS Dose of concomitant sulfonylurea or insulin may need to be reduced.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium (SMC) has advised (June 2008) that Eucreas® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in patients unable to achieve adequate glycaemic control with metformin alone or those already treated with vildagliptin and metformin as separate tablets.
SIDE-EFFECTS, FURTHER INFORMATION

Pancreatitis Severe pancreatitis (sometimes fatal), including haemorrhagic or necrotising pancreatitis, has been reported rarely;discontinue permanently if pancreatitis is diagnosed.

- CONCEPTION AND CONTRACEPTION Women of childbearing age should use effective contraception during treatment with modified-release exenatide and for 12 weeks after discontinuation.

- PREGNANCY Avoid—toxicity in animal studies.

- BREAST FEEDING Avoid—no information available.

- RENAL IMPAIRMENT For standard-release injection, use with caution if eGFR 30–50 mL/minute/1.73 m². For standard-release injection, avoid if eGFR less than 30 mL/minute/1.73 m². For modified-release injection, avoid if eGFR less than 50 mL, only when glycaemic control is inadequate and the patient has:
  - a body mass index (BMI) 35 kg/m² (in those of European descent, with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems, or
  - a BMI 35 kg/m², and insulin would be unacceptable for occupational reasons, or weight loss would benefit other significant obesity-related comorbidities.

Treatment with modified-release exenatide in a triple therapy regimen should be continued only if Hba1c concentration is reduced by at least 1 percentage point and a weight loss of at least 3% is achieved within 6 months of starting treatment.

Modified-release exenatide in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended only if:

- treatment with metformin or a sulphonylurea is contra-indicated or not tolerated, and
- treatment with thiazolidinediones and dipeptidylpeptidase-4 inhibitors is contra-indicated or not tolerated.

Modified-release exenatide in dual therapy regimens should be continued only if Hba1c concentration is reduced by at least 1 percentage point within 6 months of starting treatment. www.nice.org.uk/TA248

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2007) that standard-release exenatide (Byetta) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin or sulphonylurea (or both), as an alternative to treatment with insulin in patients where treatment with metformin or sulphonylurea (or both) at maximally tolerated doses has been inadequate, and treatment with insulin would be the next option.

The Scottish Medicines Consortium has also advised (February 2011) that standard-release exenatide (Byetta) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin and pioglitazone as a third-line pre-insulin treatment option.

The Scottish Medicines Consortium has advised (December 2011) that modified-release exenatide (Bydureon) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes as a third-line treatment option.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

**CAUTIONARY AND ADVISORY LABELS 1D**

- Byetta (AstraZeneca UK Ltd)
  - Exenatide 250 microgram per 1 ml Byetta 10micrograms/0.04ml solution for injection 2.4ml pre-filled disposable devices | 1 prefilled disposable injection \( \text{PDr} \) £68.24 DT price = £68.24
  - Byetta 5micrograms/0.02ml solution for injection 1.2ml pre-filled disposable devices | 1 prefilled disposable injection \( \text{PDr} \) £68.24 DT price = £68.24

**Powder and solvent for suspension for injection**

**CAUTIONARY AND ADVISORY LABELS 1D**

- Bydureon (AstraZeneca UK Ltd)
  - Exenatide 2 mg Bydureon 2mg powder and solvent for suspension for injection vials | 4 vial \( \text{PDr} \) £73.36
  - Bydureon 2mg powder and solvent for suspension for injection pre-filled pen | 4 pre-filled disposable injection \( \text{PDr} \) £73.36

**Liraglutide**

- **DRUG ACTION**
  - Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus in combination with metformin or a sulphonylurea, or both, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination | Type 2 diabetes mellitus in combination with basal insulin or both metformin and pioglitazone when dual therapy with these drugs fails to achieve adequate glycaemic control | By subcutaneous injection

- Adult: Initially 0.6 mg once daily for at least 1 week, then increased to 1.2 mg once daily for at least 1 week, then increased if necessary up to 1.8 mg once daily

**Dose adjustments due to interactions**

Dose of concomitant insulin or sulphonylurea may need to be reduced.

- **CONTRA-INDICATIONS**
  - Diabetic gastroparesis
  - Inflammatory bowel disease
  - Ketoacidosis
  - Moderate to severe congestive heart failure—no information available

- **CAUTIONS**
  - Asymptomatic left ventricular dysfunction
  - History of pancreatitis
  - Mild congestive heart failure—limited experience
  - Thyroid disease

- **INTERACTIONS**
  - Appendix 1 (antidiabetics).

- **SIDE-EFFECTS**
  - Common or very common
    - Abdominal pain and distension
    - Brunchitis
    - Constipation
    - Decreased appetite
    - Diarrhoea
    - Dizziness
    - Dyspepsia
    - Flatulence
    - Gastritis
    - Gastrointestinal disturbances
    - Gastro-oesophageal reflux disease
    - Headache
    - Hypoglycaemia
    - Injection site reactions
    - Nasal congestion
    - Nausea
    - Tachycardia
    - Vomiting

- Uncommon
  - Acute renal failure
  - Dehydration
  - Renal impairment
Liraglutide for the treatment of type 2 diabetes mellitus in combination with oral antidiabetic drugs (e.g. metformin, pioglitazone, or a sulfonylurea) or basal insulin, or both, when adequate glycaemic control has not been achieved with these drugs by subcutaneous injection

- **CONTRA-INDICATIONS** Ketoacidosis • severe gastro-intestinal disease

- **INTERACTIONS** Appendix 1 (antidiabetics). Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after lixisenatide injection, or taken with a meal when lixisenatide is not administered, to minimise possible interference with absorption.

- **SIDE-EFFECTS**
  - Common or very common
    - Diarrhoea • dizziness • drowsiness • dyspepsia • headache • hypoglycaemia • injection-site reactions • nausea • palpitation • vomiting
  - Uncommon
    - Tachycardia • urticaria

**SIDE-EFFECTS, FURTHER INFORMATION**

**PANCREATITIS** Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

**RENAL IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².

**HEPATIC IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².

**BREAST FEEDING** Avoid—no information available.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

- Liraglutide for the treatment of type 2 diabetes mellitus (October 2010) NICE TA203
- Liraglutide in triple therapy regimens (in combination with metformin and a sulfonylurea, or metformin and a thiazolidinedione) is recommended for the treatment of type 2 diabetes, only when glycaemic control is inadequate, and the patient has:
  - a body mass index of 35 kg/m² or over and is of European descent (with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems, or
  - a body mass index of less than 35 kg/m², and insulin would be unacceptable for occupational reasons or weight loss would benefit other significant obesity-related comorbidities.

Treatment with liraglutide in a triple therapy regimen should be continued only if HbA1c concentration is reduced by at least 1 percentage point and a weight loss of at least 3% is achieved within 6 months of starting treatment.

Liraglutide in dual therapy regimens (in combination with metformin or a sulfonylurea) is recommended only if:

- treatment with metformin or a sulfonylurea is contraindicated or not tolerated, and
- treatment with thiazolidinediones and dipeptidylpeptidase-4 inhibitors is contra-indicated or not tolerated.

Liraglutide, in combination with metformin or a sulfonylurea should be continued only if HbA1c concentration is reduced by at least 1 percentage point within 6 months of starting treatment. Liraglutide 1.8 mg daily is not recommended.

www.nice.org.uk/TA203

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **LIRAGLU TIDE (Non-proprietary)**
  - Liraglutide 6 mg per 1 ml: Liraglutide 6 mg/ml solution for injection 3 ml pre-filled disposable devices | 2 pre-filled disposable injection no price available | 3 pre-filled disposable injection no price available
  - Victoza (Novo Nordisk Ltd)
    - Liraglutide 6 mg per 1 ml: Victoza 6 mg/ml solution for injection 3 ml pre-filled pen | 2 pre-filled disposable injection | £78.48 | 3 pre-filled disposable injection | £117.72

**Lixisenatide**

**DRUG ACTION**

Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus in combination with oral antidiabetic drugs (e.g. metformin, pioglitazone, or a sulfonylurea) or basal insulin, or both, when adequate glycaemic control has not been achieved with these drugs by subcutaneous injection

- **Adult** Initially 10 micrograms once daily for 14 days, then increased to 20 micrograms once daily, dose to be taken within 1 hour before the first meal of the day or the evening meal

**Dose adjustments due to interactions**

Dose of concomitant sulfonylurea or insulin may need to be reduced.

**CONTRA-INDICATIONS**

Ketoacidosis • severe gastro-intestinal disease

**INTERACTIONS**

Appendix 1 (antidiabetics). Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after lixisenatide injection, or taken with a meal when lixisenatide is not administered, to minimise possible interference with absorption.

**SIDE-EFFECTS**

- Common or very common
  - Diarrhoea • dizziness • drowsiness • dyspepsia • headache • hypoglycaemia • injection-site reactions • nausea • palpitation • vomiting
- Uncommon
  - Tachycardia • urticaria

**SIDE-EFFECTS, FURTHER INFORMATION**

**PANCREATITIS** Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

**RENAL IMPAIRMENT** Use with caution if eGFR less than 30 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m²—no information available.

**BREAST FEEDING** Avoid—no information available.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (August 2013) that lixisenatide (Lyxumia®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with oral antidiabetic drugs or basal insulin (or both), when adequate glycaemic control has not been achieved with these drugs; use is restricted to patients in whom a GLP-1 agonist is appropriate, as an alternative to an existing GLP-1 agonist (exenatide or liraglutide).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **LYXUMIA (Sanofi)**
  - Lixisenatide 50 microgram per 1 ml: Lyxumia 10 micrograms/0.2 ml solution for injection 3 ml pre-filled pen | 1 pre-filled disposable injection no price available | 47707 DT price = £27.07
  - Lixisenatide 20 microgram/0.2 ml solution for injection 3 ml pre-filled pen | 1 pre-filled disposable injection no price available | 1 pre-filled disposable injection £5.44

**CAUTIONARY AND ADVISORY LABELS**

10
INSULINS

Insulins

- **SIDE-EFFECTS**
  - **Common or very common** Fat hypertrophy at injection site · local reactions at injection site · transient oedema
  - **Rare** Hypersensitivity reactions · rash · urticaria
  - **Overdose** Overdose causes hypoglycaemia.

- **PREGNANCY** During pregnancy, insulin requirements may alter and doses should be assessed frequently by an experienced diabetes physician. The dose of insulin generally needs to be increased in the second and third trimesters of pregnancy.

- **BREAST FEEDING** During breast-feeding, insulin requirements may alter and doses should be assessed frequently by an experienced diabetes physician.

- **HEPATIC IMPAIRMENT** Insulin requirements may be decreased in patients with hepatic impairment.

- **RENAL IMPAIRMENT** Insulin requirements may decrease in patients with renal impairment and therefore dose reduction may be necessary. The compensatory response to hypoglycaemia is impaired in renal impairment.

- **MONITORING REQUIREMENTS**
  - Many patients now monitor their own blood-glucose concentrations; all carers and children need to be trained to do this.
  - Since blood-glucose concentration varies substantially throughout the day, ‘normoglycaemia’ cannot always be achieved throughout a 24-hour period without causing damaging hypoglycaemia.
  - It is therefore best to recommend that patients should maintain a blood-glucose concentration of between 4 and 9 mmol/litre for most of the time (4–7 mmol/litre before meals and less than 9 mmol/litre after meals).
  - While accepting that on occasions, for brief periods, the blood-glucose concentration will be above these values; strenuous efforts should be made to prevent it from falling below 4 mmol/litre. Patients using multiple injection regimens should understand how to adjust their insulin dose according to their carbohydrate intake. With fixed-dose insulin regimens, the carbohydrate intake needs to be regulated, and should be distributed throughout the day to match the insulin regimen. The intake of energy and of simple and complex carbohydrates should be adequate to allow normal growth and development but obesity must be avoided.

- **DIRECTIONS FOR ADMINISTRATION** Insulin is generally given by subcutaneous injection; the injection site should be rotated to prevent lipodystrophy. Injection devices (‘pens’), which hold the insulin in a cartridge and meter the required dose, are convenient to use. Insulin syringes (for use with needles) are required for insulins not available in cartridge form, but are less popular with children and carers. For intensive insulin regimens multiple subcutaneous injections (3 or more times daily) are usually recommended.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Units The word ‘unit’ should not be abbreviated.
  - Show container to patient or carer and confirm the expected version is dispensed.

- **PATIENT AND CARER ADVICE** Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems.

- **Insulin Passport** Insulin Passports and patient information booklets should be offered to patients receiving insulin. The Insulin Passport provides a record of the patient’s current insulin preparations and contains a section for emergency information. The patient information booklet provides advice on the safe use of insulin. They are available for purchase from:
  - 3M Security Print and Systems Limited
    - Gorse Street, Chadderton
    - Oldham OL9 9QH
    - 0845 610 1112
  - GP practices can obtain supplies through their Local Area Team stores.
  - NHS Trusts can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com. Further information is available at www.npsa.nhs.uk.

**Hypoglycaemia**

Hypoglycaemia is a potential problem with insulin therapy. All patients must be carefully instructed on how to avoid it; this involves appropriate adjustment of insulin type, dose and frequency together with suitable timing and quantity of meals and snacks.

### Biphasic insulin aspart
**(Intermediate-acting insulin)**

**INDICATIONS AND DOSE**

**Diabetes mellitus**

**BY SUBCUTANEOUS INJECTION**

- **Child:** Administer dose up to 10 minutes before or soon after a meal, according to requirements
- **Adult:** Administer dose up to 10 minutes before or soon after a meal, according to requirements

- **INTERACTIONS** → Appendix 1 (antidiabetics).

- **SIDE-EFFECTS** Protamine may cause allergic reactions

**PRESCRIBING AND DISPENSING INFORMATION** Check product container—the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries).

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **NovoMix 30 FlexPen** (Novo Nordisk Ltd)
  - Insulin aspart 30 unit per 1 ml, Insulin aspart (as Insulin aspart protamine) 70 unit per 1 ml NovoMix 30 FlexPen 100 units/ml suspension for injection 3 ml pre-filled pen | 5 pre-filled disposable injection £29.89
- **NovoMix 30 Penfill** (Novo Nordisk Ltd)
  - Insulin aspart 30 unit per 1 ml, Insulin aspart (as Insulin aspart protamine) 70 unit per 1 ml NovoMix 30 Penfill 100 units/ml suspension for injection 3 ml cartridges | 5 cartridge £28.79

### Biphasic insulin lispro
**(Intermediate-acting insulin)**

**INDICATIONS AND DOSE**

**Diabetes mellitus**

**BY SUBCUTANEOUS INJECTION**

- **Child:** Administer up to 15 minutes before or soon after a meal, according to requirements
- **Adult:** Administer up to 15 minutes before or soon after a meal, according to requirements

- **CAUTIONS** Children under 12 years (use only if benefit likely compared to soluble insulin)

- **INTERACTIONS** → Appendix 1 (antidiabetics).

- **SIDE-EFFECTS** Protamine may cause allergic reactions

**PRESCRIBING AND DISPENSING INFORMATION** Check product container—the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries).
which the proportions are stated may not be the same in other countries).

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection

► Humalog Mix25 (Eli Lilly and Company Ltd)
Insulin lispro 25 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 75 unit per 1 ml Humalog Mix25 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £16.61
Humalog Mix25 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £29.46
► Humalog Mix25 KwikPen (Eli Lilly and Company Ltd)
Insulin lispro 25 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 75 unit per 1 ml Humalog Mix25 KwikPen 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Pos) £30.98
► Humalog Mix50 (Eli Lilly and Company Ltd)
Insulin lispro 50 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 50 unit per 1 ml Humalog Mix50 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £20.46
► Humalog Mix50 KwikPen (Eli Lilly and Company Ltd)
Insulin lispro 50 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 50 unit per 1 ml Humalog Mix50 KwikPen 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Pos) £30.98

Biphasic isophane insulin
(Biphasic Isophane Insulin injection—intermediate acting)

INDICATIONS AND DOSE

Diabetes mellitus

BY SUBCUTANEOUS INJECTION

► Child: According to requirements
► Adult: According to requirements

● INTERACTIONS → Appendix 1 (antidiabetics).

● SIDE-EFFECTS

Protamine may cause allergic reactions

● PRESCRIBING AND DISPENSING INFORMATION

A sterile buffered suspension of either porcine or human insulin complexed with protamine sulfate (or another suitable protamine) in a solution of insulin of the same species.

Check product container—the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries).

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection

► Humulin M3 (Eli Lilly and Company Ltd)
Insulin human (as Insulin soluble human) 70 unit per 1 ml, Insulin human (as insulin soluble human) 30 unit per 1 ml Humulin M3 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £19.08
Humulin M3 100units/ml suspension for injection 10ml vials | 1 vial (Pos) £15.68
► Humulin M3 KwikPen (Eli Lilly and Company Ltd)
Insulin human (as Insulin soluble human) 70 unit per 1 ml, Insulin human (as insulin soluble human) 30 unit per 1 ml Humulin M3 KwikPen 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Pos) £21.70
► Hypurin Porcine 30/70 Mix (Wockhardt UK Ltd)
Insulin porcine (as Insulin isophane porcine) 70 unit per 1 ml, Insulin porcine (as insulin soluble porcine) 30 unit per 1 ml Hypurin Porcine 30/70 Mix 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £37.80
Hypurin Porcine 30/70 Mix 100units/ml suspension for injection 10ml vials | 1 vial (Pos) £23.20
► Insulan Comb 15 (Sanofi)
Insulin human (as Insulin isophane human) 85 unit per 1 ml, Insulin human (as insulin soluble human) 15 unit per 1 ml Insulan Comb 15 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £17.50
► Insulan Comb 25 (Sanofi)
Insulin human (as insulin isophane human) 75 unit per 1 ml, Insulin human (as insulin soluble human) 25 unit per 1 ml Insulan Comb 25 100units/ml suspension for injection 5ml vials | 1 vial (Pos) £5.61
Insulan Comb 25 100units/ml suspension for injection 3ml pre-filled SoloStar pen | 5 pre-filled disposable injection (Pos) £13.80
Insulan Comb 25 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £17.50
► Insulan Comb 50 (Sanofi)
Insulin human (as insulin isophane human) 50 unit per 1 ml, Insulin human (as insulin soluble human) 50 unit per 1 ml Insulan Comb 50 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Pos) £17.50

Insulin
(Insulin Injection; Neutral Insulin; Soluble Insulin)

INDICATIONS AND DOSE

Diabetes mellitus

BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION

OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

► Adult: According to requirements

Diabetic ketoacidosis | Diabetes during surgery

► INTRAVENOUS INFUSION

► Adult: (consult local protocol)

● INTERACTIONS → Appendix 1 (antidiabetics).

● DIRECTIONS FOR ADMINISTRATION

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team. Some insulin preparations are not recommended for use in subcutaneous insulin infusion pumps—may precipitate in catheter or needle—consult product literature.

For intravenous infusion give continuously in Sodium chloride 0.9%. Adsorbed to some extent by plastic infusion set; ensure insulin is not injected into ‘dead space’ of injection port of the infusion bag.

● PRESCRIBING AND DISPENSING INFORMATION

A sterile solution of insulin (i.e. bovine or porcine) or of human insulin; pH 6.6–8.0.

● NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

► Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151
Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:

● who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or

● whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate.

Children on insulin pumps should undergo a trial of
multiple-injection therapy between the ages of 12 and 18 years. www.nice.org.uk/TA151

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- Actrapid (Novo Nordisk Ltd)
  - Insulin human (as insulin soluble human) 100 unit per 1 ml
    - Actrapid 100units/ml solution for injection 10ml vials | 1 vial £7.48
  - Humulin S (Eli Lilly and Company Ltd)
    - Insulin human (as insulin soluble human) 100 unit per 1 ml
      - Humulin S 100units/ml solution for injection 10ml vials | 1 vial £15.68
      - Humulin S 100units/ml solution for injection 3ml cartridges | 5 cartridge £19.08
  - Hypurin Bovine Neutral (Wockhardt UK Ltd)
    - Insulin bovine (as Insulin soluble bovine) 100 unit per 1 ml
      - Hypurin Bovine Neutral 100units/ml solution for injection 10ml vials | 1 vial £27.72
  - Hypurin Porcine Neutral (Wockhardt UK Ltd)
    - Hypurin Porcine Neutral 100units/ml solution for injection 10ml vials | 1 vial £25.20
  - Hypurin Porcine Neutral 100units/ml solution for injection 3ml cartridges | 5 cartridge £37.80
  - Insulan Rapid (Sanofi)
    - Insulin human (as insulin soluble human) 100 unit per 1 ml
      - Insulan Rapid 100unit/ml solution for injection 3ml cartridges | 5 cartridge £17.50

**Insulin aspart**

*(Recombinant human insulin analogue)*

**INDICATIONS AND DOSE**

**Diabetes mellitus**

**BY SUBCUTANEOUS INJECTION**

- Adult: Administer immediately before meals or when necessary shortly after meals, according to requirements

**BY SUBCUTANEOUS INFUSION OR BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION**

- Child 2-17 years: According to requirements

- Adult: According to requirements

**INTERACTIONS** → Appendix 1 (antidiabetics).

**PREGNANCY** Not known to be harmful—may be used during pregnancy.

**BREAST FEEDING** Not known to be harmful—may be used during lactation.

**DIRECTIONS FOR ADMINISTRATION** Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.

- In adults For *intravenous infusion*, give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to 0.05-1 unit/ml with infusion fluid; adsorbed to some extent by plastics of infusion set.

- In children For *intravenous infusion*, dilute to a concentration of 0.05–1 unit/ml with Glucose 5% or Sodium Chloride 0.9% and mix thoroughly; insulin may be adsorbed by plastics, flush giving set with 5 mL of infusion fluid containing insulin.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151

Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:

- who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or

- whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years. www.nice.org.uk/TA151

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- NovoRapid (Novo Nordisk Ltd)
  - Insulin aspart 100 unit per 1 ml
    - NovoRapid 100units/ml solution for injection 10ml vials | 1 vial £14.08
  - NovoRapid FlexPen (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml
      - NovoRapid FlexPen 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £30.60
  - NovoRapid FlexTouch (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml
      - NovoRapid FlexTouch 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £32.13
  - NovoRapid Penfill (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml
      - NovoRapid Penfill 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £28.31
  - NovoRapid PumpCart (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml
      - NovoRapid PumpCart 100units/ml solution for injection 1.6ml cartridges | 5 cartridge £15.10

**Insulin degludec**

*(Recombinant human insulin analogue—long acting)*

**INDICATIONS AND DOSE**

**Diabetes mellitus**

**BY SUBCUTANEOUS INJECTION**

- Adult: Dose to be given according to requirements

**INTERACTIONS** → Appendix 1 (antidiabetics).

**PREGNANCY** Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin is recommended where longer-acting insulins are needed; insulin detemir may also be considered.

**PRESCRIBING AND DISPENSING INFORMATION** Insulin degludec (*Tresiba®*) is available in strengths of 100 units/mL (allows 1-unit dose adjustment) and 200 units/mL (allows 2-unit dose adjustment)—ensure correct strength prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Tresiba FlexTouch (Novo Nordisk Ltd)
  - Insulin human (as Insulin degludec) 100 unit per 1 ml Tresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £72.00
Insulin degludec with liraglutide

The properties listed below are those particular to the combination only. For the properties of the components please consider, insulin degludec p. 604, liraglutide p. 600.

INDICATIONS AND DOSE

As add-on to oral antidiabetics in type 2 diabetes mellitus not controlled by oral antidiabetics alone or by oral antidiabetics in combination with basal insulin

BY SUBCUTANEOUS INJECTION

- Adult: Initially 10 dose-steps once daily, adjusted according to response; maximum 50 dose-steps per day

When transferring from basal insulin in type 2 diabetes mellitus not controlled by oral antidiabetics alone or by oral antidiabetics in combination with basal insulin

BY SUBCUTANEOUS INJECTION

- Adult: Initially 16 dose-steps once daily, adjusted according to response; maximum 50 dose-steps per day

- INTERACTIONS Dose of concomitant sulfonylurea may need to be reduced.
- PATIENT AND CARER ADVICE Counselling advised on administration. Show container to patient and confirm that patient is expecting the version dispensed.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Xultophy (Novo Nordisk Ltd)

Insulin human (as insulin degludec) 100 unit per 1 ml
Liraglutide 3.6 mg per 1 ml Xultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £159.22

Insulin degludec

(Recombinant human insulin analogue—long acting)

INDICATIONS AND DOSE

Diabetes mellitus

BY SUBCUTANEOUS INJECTION

- Child 2-17 years: According to requirements
- Adult: According to requirements

- INTERACTIONS → Appendix 1 (antidiabetics).
- PREGNANCY Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin is recommended where longer-acting insulins are needed; insulin detemir may also be considered.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Lantus (Sanofi)

Insulin human (as insulin glargine) 100 unit per 1 ml Lantus 100units/ml solution for injection 3ml cartridges | 5 cartridge £41.50 | Lantus 100units/ml solution for injection 3ml pre-filled SoloStar pen | 5 pre-filled disposable injection £41.50 | Lantus 100units/ml solution for injection 10ml vials | 1 vial £30.68

Insulin glulisine

(Recombinant human insulin analogue)

INDICATIONS AND DOSE

Diabetes mellitus

BY SUBCUTANEOUS INJECTION

- Child 6-17 years: According to requirements
- Adult: According to requirements

- INTERACTIONS → Appendix 1 (antidiabetics).
- DIRECTIONS FOR ADMINISTRATION Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device
Endocrine system

606 Diabetes mellitus and hypoglycaemia

In adults For intravenous infusion (Apidra®), give continuously in Sodium chloride 0.9%; dilute to 1 unit/mL with infusion fluid; use a co-extruded polysyntelin/polymide plastic infusion bag with a dedicated infusion line.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151 Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:

- who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or
- whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years. www.nice.org.uk/TA151

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2008) that Apidra® is accepted for restricted use within NHS Scotland for the treatment of adults and children over 6 years with diabetes mellitus in whom the use of a short-acting insulin analogue is appropriate.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Apidra (Sanofi)
  - Insulin glulisine 100 unit per 1 ml Apidra 100 units/ml solution for injection 10ml vials | 1 vial £16.00
  - Apidra 100 units/ml solution for injection 3ml cartridges | 5 cartridge £28.30
- Apida SoloStar (Sanofi)
  - Insulin glulisine 100 unit per 1 ml Apidra 100 units/ml solution for injection 3ml pre-filled SoloStar pen | 5 pre-filled disposable injection £26.30

Insulin lispro

(Recombinant human insulin analogue)

INDICATIONS AND DOSE

Diabetes mellitus

BY SUBCUTANEOUS INJECTION

- Child 2-17 years: Administer shortly before meals or when necessary shortly after meals, according to requirements
- Adult: Administer shortly before meals or when necessary shortly after meals, according to requirements

BY SUBCUTANEOUS INFUSION OR BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION

- Child 2-17 years: According to requirements

CAUTIONS

Children (use only if benefit likely compared to soluble insulin)

INTERACTIONS

Appendix 1 (antidiabetics).

PREGNANCY

Not known to be harmful—may be used during pregnancy.

BREAST FEEDING

Not known to be harmful—may be used during lactation.

DIRECTIONS FOR ADMINISTRATION

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens (see also NICE guidance, below). Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.

Continuous subcutaneous insulin infusion is also recommended as an option in adults and children over 12 years with type 1 diabetes:

- who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or
- whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years. www.nice.org.uk/TA151

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Humalog (Eli Lilly and Company Ltd)
  - Insulin lispro 100 unit per 1 ml Humalog 100 units/ml solution for injection 10ml vials | 1 vial £16.61
  - Humalog 100 units/ml solution for injection 3ml cartridges | 5 cartridge £28.31
- Humalog KwikPen (Eli Lilly and Company Ltd)
  - Insulin lispro 100 unit per 1 ml Humalog KwikPen 100 units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £58.92
  - Insulin lispro 200 unit per 1 ml Humalog KwikPen 200 units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £58.92
Insulin zinc suspension
(Insulin Zinc Suspension (Mixed)—long acting)

INDICATIONS AND DOSE
Diabetes mellitus
BY SUBCUTANEOUS INJECTION
Child: According to requirements
Adult: According to requirements

INTERACTIONS ➔ Appendix 1 (antidiabetics).

PREGNANCY Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin below is recommended where longer-acting insulins are needed; insulin detemir p. 605 may also be considered.

PRESCRIBING AND DISPENSING INFORMATION A sterile neutral suspension of bovine or porcine insulin or of human insulin in the form of a complex obtained by the addition of a suitable zinc salt; consists of rhombohedral crystals (10–40 microns) and of particles of no uniform shape (not exceeding 2 microns).

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection
- Hypurin Bovine Lente (Workdhart UK Ltd)
  Insulin bovine (as Insulin zinc suspension mixed bovine) 100 unit per 1 ml Hypurin Bovine Lente 100units/ml suspension for injection 10ml vials | 1 vial (£) £27.72

Isophane insulin
(Isophane Insulin Injection; Isophane Protamine Insulin Injection; Isophane Insulin (NPH)—intermediate acting)

INDICATIONS AND DOSE
Diabetes mellitus
BY SUBCUTANEOUS INJECTION
Child: According to requirements
Adult: According to requirements

INTERACTIONS ➔ Appendix 1 (antidiabetics).

SIDE-EFFECTS Protamine may cause allergic reactions

PREGNANCY Recommended where longer-acting insulins are needed.

PRESCRIBING AND DISPENSING INFORMATION A sterile suspension of bovine or porcine insulin or of human insulin in the form of a complex obtained by the addition of protamine sulfate or another suitable protein.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection
- Humulin I (Eli Lilly and Company Ltd)
  Insulin human (as Insulin isophane human) 100 unit per 1 ml Humulin I 100units/ml suspension for injection 10ml vials | 1 vial (£) £15.68
  Humulin I 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£) £19.08
- Humulin I KwikPen (Eli Lilly and Company Ltd)
  Insulin human (as Insulin isophane human) 100 unit per 1 ml Humulin I KwikPen 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (£) £21.70
- Humyrin Bovine Isophane (Workdhart UK Ltd)
  Insulin bovine (as Insulin isophane bovine) 100 unit per 1 ml Humyrin Bovine Isophane 100units/ml suspension for injection 10ml vials | 1 vial (£) £27.72
  Humyrin Bovine Isophane 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£) £41.58

- Hypurin Porcine Isophane (Wockhardt UK Ltd)
  Insulin porcine (as Insulin isophane porcine) 100 unit per 1 ml Hypurin Porcine Isophane 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£) £37.80
  Hypurin Porcine Isophane Porcine 100units/ml suspension for injection 10ml vials | 1 vial (£) £25.20
- Insulatard (Novo Nordisk Ltd)
  Insulin human (as Insulin isophane human) 100 unit per 1 ml Insulatard 100units/ml suspension for injection 10ml vials | 1 vial (£) £7.48
- Insulatard InnoLet (Novo Nordisk Ltd)
  Insulin human (as Insulin isophane human) 100 unit per 1 ml Insulatard Penfill (Novo Nordisk Ltd)
  Insulin human (as Insulin isophane human) 100 unit per 1 ml Insulatard Penfill 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£) £22.90
- Insuman Basal (Sanofi)
  Insulin human (as Insulin isophane human) 100 unit per 1 ml Insuman Basal 100units/ml suspension for injection 3ml pre-filled Solostar pen | 5 pre-filled disposable injection (£) £19.80
  Insuman Basal 100units/ml suspension for injection 10ml vials | 1 vial (£) £5.61
  Insuman Basal 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£) £17.50

Protamine zinc insulin
(Protamine Zinc Insulin Injection—long acting)

INDICATIONS AND DOSE
Diabetes mellitus
BY SUBCUTANEOUS INJECTION
Child: According to requirements
Adult: According to requirements

INTERACTIONS ➔ Appendix 1 (antidiabetics).

SIDE-EFFECTS Protamine may cause allergic reactions

PREGNANCY Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin above is recommended where longer-acting insulins are needed; insulin detemir p. 605 may also be considered.

PRESCRIBING AND DISPENSING INFORMATION A sterile suspension of insulin in the form of a complex obtained by the addition of a suitable protamine and zinc chloride; this preparation was included in BP 1980 but is not included in BP 1988.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection
- Hypurin Bovine Protamine Zinc (Wockhardt UK Ltd)
  Insulin bovine (as Insulin protamine zinc bovine) 100 unit per 1 ml Hypurin Bovine Protamine Zinc 100units/ml suspension for injection 10ml vials | 1 vial (£) £27.72

MEGGLITINIDES

Nateglinide

DRUG ACTION Nateglinide stimulates insulin secretion.

INDICATIONS AND DOSE
Type 2 diabetes mellitus in combination with metformin when metformin alone inadequate
BY MOUTH
Adult: Initially 60 mg 3 times a day (max. per dose 180 mg), adjusted according to response, to be taken within 30 minutes before main meals

CONTRA-INDICATIONS Ketoacidosis
Repaglinide

**DRUG ACTION** Repaglinide stimulates insulin secretion.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate)

**BY MOUTH**

- Adult 18–74 years: Initially 500 micrograms (max. per dose 4 mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1–2 weeks; maximum 16 mg per day
- Adult 75 years and over: Not recommended

Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate), if transferring from another oral hypoglycaemic drug

**BY MOUTH**

- Adult 18–74 years: Initially 1 mg (max. per dose 4 mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1–2 weeks; maximum 16 mg per day
- Adult 75 years and over: Not recommended

**CONTRA-INDICATIONS** Ketoacidosis

**CAUTIONS** Debilitated patients, elderly, malnourished patients

**CAUTIONS, FURTHER INFORMATION**

Substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection, and trauma) and during surgery (omit repaglinide on morning of surgery and recommence when eating and drinking normally).

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**

- Common or very common Abdominal pain, constipation, diarrhoea, nausea, vomiting
- Rare Hypersensitivity reactions, hypoglycaemia, pruritus, rashes, urticaria, vasculitis, visual disturbances
- **PREGNANCY** Avoid.

**BREAST FEEDING** Avoid—poison in milk in animal studies.

**HEPATIC IMPAIRMENT** Avoid in severe liver disease.

**RENAL IMPAIRMENT** Use with caution.

**PATIENT AND CARER ADVICE** Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Starlix** (Novartis Pharmaceuticals UK Ltd)
  - Nateglinide 60 mg Starlix 60 mg tablets | 84 tablet DT price = £22.71
  - Nateglinide 120 mg Starlix 120 mg tablets | 84 tablet DT price = £25.88
  - Nateglinide 180 mg Starlix 180 mg tablets | 84 tablet DT price = £25.88

**SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS**

Canagliflozin

**DRUG ACTION** Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus as monotherapy if metformin inappropriate | Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)

**BY MOUTH**

- Adult: 100 mg once daily; increased if tolerated to 300 mg once daily if required, dose to be taken preferably before breakfast

**Dose adjustments due to interactions**

Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**CONTRA-INDICATIONS** Ketoacidosis

**CAUTIONS** Cardiovascular disease (risk of hypotension) | elderly (risk of hypotension) | elevated haematocrit | history of hypotension

**CAUTIONS, FURTHER INFORMATION**

**Volume depletion** Correct hypovolaemia before starting treatment.

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**

- Common or very common Constipation, dyslipidaemia, genital infection, hypoglycaemia (in combination with insulin or sulfonylurea), nausea, polyuria, raised haematocrit, thirst, urinary frequency, urinary-tract infection
- Uncommon Dehydration, dizziness, hypovolaemia, postural hypotension, raised serum creatinine, raised serum urea, rash, syncope

**SIDE-EFFECTS, FURTHER INFORMATION**

**Volume depletion** Consider interrupting treatment if volume depletion occurs.

**PREGNANCY** Avoid—poison in milk in animal studies.
Canagliflozin with metformin

The properties listed below are those particular to the combination only. For the properties of the components please consider, canagliflozin p. 608, metformin hydrochloride p. 594.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with insulin or other antidiabetic drugs

**BY MOUTH**

- Adult: 1 tablet twice daily, dose based on patient’s current metformin dose, daily dose of metformin should not exceed 2 g

Dose adjustments due to interactions

Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**RENAI IMPAIRMENT** Avoid if eGFR less than 50 mL/minute/1.73 m².

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2014) that Vokanamet® is accepted for restricted use within NHS Scotland in patients with type 2 diabetes mellitus for whom a combination of canagliflozin and metformin is an appropriate choice of therapy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - CAUTIONARY AND ADVISORY LABELS 21
    - Vokanamet (Janssen-Cilag Ltd)
    - Canagliflozin (as Canagliflozin hemihydrate) 50 mg, Metformin hydrochloride 850 mg Vokanamet 50mg/850mg tablets | 60 tablet (POM) £39.20 DT price = £39.20
    - Canagliflozin (as Canagliflozin hemihydrate) 50 mg, Metformin hydrochloride 1 gram Vokanamet 50mg/1000mg tablets | 60 tablet (POM) £39.20 DT price = £39.20

Dapagliflozin

- **DRUG ACTION** Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus as monotherapy if metformin is not appropriate | Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)

**BY MOUTH**

- Adult 18-74 years: 10 mg once daily
- Adult 75 years and over: Initiation not recommended

Dose adjustments due to interactions

Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**CONTRA-INDICATIONS** Ketoacidosis

**CAUTIONS** Cardiovascular disease (risk of hypotension) - elderly (risk of hypotension) - electrolyte disturbances - hypotension - raised haematocrit

**CAUTIONS, FURTHER INFORMATION**

Volume depletion Correct hypovolaemia before starting treatment.

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**

- Common or very common Back pain - constipation - dyslipidaemia - dysuria - genital infection - hypoglycaemia (in combination with insulin or sulphonylurea) - polyuria - sweating - thirst - urinary-tract infection
- Uncommon Dehydration - dizziness - hypotension - hypovolaemia - nausea - nocturia - raised serum creatinine - raised serum urea - rash
Diabetes mellitus and hypoglycaemia

**SIDE-EFFECTS, FURTHER INFORMATION**

**Volume depletion** Consider interrupting treatment if volume depletion occurs.

**PREGNANCY** Avoid—toxicity in animal studies.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Initial dose 5 mg daily in severe impairment, increased according to response.

**RENAL IMPAIRMENT** Avoid if eGFR less than 60 mL/minute/1.73 m² (ineffective).

**MONITORING REQUIREMENTS** Determine renal function before treatment and at least annually thereafter.

**NATIONAL FUNDING/ACCESS DECISIONS**

* NICE technology appraisals (TAs)
  - Dapagliflozin in combination therapy for treating type 2 diabetes (June 2013) NICE TA288
  - Dapagliflozin in a dual therapy regimen in combination with metformin is recommended for the treatment of type 2 diabetes, only if glycaemic control is inadequate, and the patient has a significant risk of hypoglycaemia or if a sulfonylurea is contra-indicated or not tolerated. Dapagliflozin in combination with insulin (alone or with other antidiabetic drugs) is an option for the treatment of type 2 diabetes. Dapagliflozin in combination with metformin and a sulfonylurea as triple therapy is not recommended for the treatment of type 2 diabetes except as part of a clinical trial. Patients currently receiving dapagliflozin in a dual or triple therapy regimen that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA288

* Scottish Medicines Consortium (SMC) Decisions
  - The Scottish Medicines Consortium has advised that dapagliflozin (Forxiga®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin, when treatment with metformin alone is inadequate and a sulfonylurea is inappropriate (December 2012), or in combination with insulin when treatment with insulin alone is inadequate (February 2014).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

* Tablet
  - Forxiga (AstraZeneca UK Ltd)
    - Dapagliflozin 5 mg: Forxiga 5mg tablets | 28 tablet (POM) £36.59 OT price = £36.59
    - Dapagliflozin 10 mg: Forxiga 10mg tablets | 28 tablet (POM) £36.59 OT price = £36.59

**NATIONAL FUNDING/ACCESS DECISIONS**

* Scottish Medicines Consortium (SMC) Decisions
  - The Scottish Medicines Consortium has advised (July 2014) that dapagliflozin plus metformin (Xigduo®) is accepted for restricted use within NHS Scotland in patients for whom a combination of dapagliflozin and metformin is an appropriate choice of therapy i.e when metformin alone does not provide adequate glycemic control and a sulfonylurea is inappropriate, or in combination with insulin, when insulin and metformin does not provide adequate control, or in combination with a sulphonylurea, when a sulfonylurea and metformin does not provide adequate control.

Empagliflozin

**DRUG ACTION** Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

**INDICATIONS AND DOSE**

Type II diabetes as monotherapy (if metformin inappropriate) / Type II diabetes in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycemic control)

**BY MOUTH**
  - Adult 18-84 years: 10 mg once daily, increased to 25 mg once daily if necessary and if tolerated
  - Adult 85 years and over: Initiation not recommended

**Dose adjustments due to interactions**

Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**CONTRA-INDICATIONS** Diabetic ketoacidosis

**CAUTIONS** Cardiovascular disease (increased risk of volume depletion) - complicated urinary tract infections—consider temporarily interrupting treatment - concomitant antihypertensive therapy (increased risk of volume depletion) - elderly patients aged over 75 years (increased risk of volume depletion) - heart failure - history of hypotension (increased risk of volume depletion) - patients at increased risk of volume depletion - predisposition to fluid disturbances e.g. gastro-intestinal illness, concomitant use of diuretics (increased risk of volume depletion)

**CAUTIONS, FURTHER INFORMATION**

**Volume depletion** Correct hypovolaemia before starting treatment. Consider interrupting treatment if volume depletion occurs.

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**
  - Common or very common Genital infection - hypoglycaemia (in combination with insulin or sulfonylurea) - polyuria - pruritus - urinary tract infection
  - Uncommon Dysuria - volume depletion

**PREGNANCY** Manufacturer advises avoid—severe hypoglycaemia may occur.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**Dapagliflozin with metformin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dapagliflozin p. 609, metformin hydrochloride p. 594.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with insulin or other antidiabetic drugs

**BY MOUTH**
  - Adult 18-74 years: 1 tablet twice daily, based on patient’s current metformin dose
  - Adult 75 years and over: Initiation not recommended

**INTERACTIONS** Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**HEPATIC IMPAIRMENT** Avoid.

**CONTRA-INDICATIONS** Diabetic ketoacidosis

**CAUTIONS** Cardiovascular disease (increased risk of volume depletion) - complicated urinary tract infections—consider temporarily interrupting treatment - concomitant antihypertensive therapy (increased risk of volume depletion) - elderly patients aged over 75 years (increased risk of volume depletion) - heart failure - history of hypotension (increased risk of volume depletion) - patients at increased risk of volume depletion - predisposition to fluid disturbances e.g. gastro-intestinal illness, concomitant use of diuretics (increased risk of volume depletion)

**CAUTIONS, FURTHER INFORMATION**

**Volume depletion** Correct hypovolaemia before starting treatment. Consider interrupting treatment if volume depletion occurs.

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**
  - Common or very common Genital infection - hypoglycaemia (in combination with insulin or sulfonylurea) - polyuria - pruritus - urinary tract infection
  - Uncommon Dysuria - volume depletion

**PREGNANCY** Manufacturer advises avoid—severe hypoglycaemia may occur.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
● **HEPATIC IMPAIRMENT** Manufacturer advises avoid in severe impairment—no information available.

● **RENAL IMPAIRMENT** Reduce dose to 10 mg once daily if eGFR falls persistently below 60 mL/minute/1.73 m². Avoid initiation if eGFR below 60 mL/minute/1.73 m². Avoid if eGFR is persistently below 45 mL/minute/1.73 m².

● **MONITORING REQUIREMENTS** Determine renal function before treatment and before initiation of concomitant drugs that may reduce renal function, then at least annually thereafter.

● **NATIONAL FUNDING/ACCESS DECISIONS**

  NICE technology appraisals (TAs)
  - Empagliflozin in combination therapy for treating type 2 diabetes (March 2015) NICE TA336
  - Empagliflozin in a dual therapy regimen in combination with metformin is an option for the treatment of type 2 diabetes, only if:
    - a sulfonylurea is contraindicated or not tolerated, or
    - the patient is at significant risk of hypoglycaemia or its consequences.
  - Empagliflozin in a triple therapy regimen is an option for the treatment of type 2 diabetes in combination with:
    - metformin and a sulfonylurea or
    - metformin and a thiazolidinedione.
  - Empagliflozin in combination with insulin with or without other antidiabetic drugs is an option for the treatment of type 2 diabetes.
  - Patients currently receiving empagliflozin whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA336

● **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - Jardiance (Boehringer Ingelheim Ltd)
  - Empagliflozin 10 mg Jardiance 10mg tablets | 28 tablet (POM) £36.59 DT price = £36.59
  - Empagliflozin 25 mg Jardiance 25mg tablets | 28 tablet (POM) £36.59 DT price = £36.59

**SULFONYLUREAS**

**Sulfonylureas**

- **DRUG ACTION** The sulfonylureas act mainly by augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present; during long-term administration they also have an extrapancreatic action.

- **CONTRA-INDICATIONS** Presence of ketoacidosis

- **CAUTIONS** Can encourage weight gain (should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting) • elderly • G6PD deficiency

- **SIDE-EFFECTS**
  - Uncommon Hypoglycaemia
  - Rare Agranulocytosis • aplastic anaemia • Blood disorders • cholestatic jaundice • haemolytic anaemia • hepatic failure • hepatitis • leucopenia • pancytopenia • thrombocytopenia • Frequency not known Allergic skin reactions (usually in the first 6–8 weeks of therapy) • constipation • diarrhoea • disturbance in liver function • erythema multiforme (usually in the first 6–8 weeks of therapy) • exfoliative dermatitis (usually in the first 6–8 weeks of therapy) • fever (usually in the first 6–8 weeks of therapy) • gastrointestinal disturbances • Hypersensitivity reactions (usually in the first 6–8 weeks of therapy) • jaundice (usually in the first 6–8 weeks of therapy) • nausea • vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hypoglycaemia** This is uncommon and usually indicates excessive dosage. Sulfonylurea-induced hypoglycaemia may persist for many hours and must always be treated in hospital.

- **HEPATIC IMPAIRMENT** Sulfonylureas should be avoided or a reduced dose should be used in severe hepatic impairment, because there is an increased risk of hypoglycaemia. Jaundice may occur.

- **RENAL IMPAIRMENT** Sulfonylureas should be used with care in those with mild to moderate renal impairment, because of the hazard of hypoglycaemia. Care is required to use the lowest dose that adequately controls blood glucose. Avoid where possible in severe renal impairment.

- **PATIENT AND CARER ADVICE** Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems. The risk of hypoglycaemia associated with sulfonylureas should be discussed with the patient, especially when concomitant glucose-lowering drugs are prescribed.

**Glibenclamide**

**INDICATIONS AND DOSE**

**Type 2 diabetes mellitus**

- **BY MOUTH**
  - Adult: Initially 5 mg daily, adjusted according to response, dose to be taken with or immediately after breakfast; maximum 15 mg per day


- **CONTRA-INDICATIONS** Avoid where possible in Acute porphyrias p. 864

- **INTERACTIONS** → Appendix 1 (antidiabetics).

- **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes.

- **BREAST FEEDING** Glibenclamide can be used during breast-feeding in women with pre-existing diabetes.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Tablet**

- Glibenclamide (Non-proprietary)
  - Glibenclamide 2.5 mg Glibenclamide 2.5mg tablets | 28 tablet (POM) £15.48 DT price = £9.22
  - Glibenclamide 5 mg Glibenclamide 5mg tablets | 28 tablet (POM) £19.99 DT price = £11.09

**Gliclazide**

**INDICATIONS AND DOSE**

**Type 2 diabetes mellitus**

- **INITIALLY BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 40–80 mg daily, adjusted according to response, (by mouth) increased if necessary up to 160 mg once daily, dose to be taken with breakfast, doses higher than 160 mg to be given in divided doses; maximum 320 mg per day

continued →
Glimepiride

Indications and Dose
Type 2 diabetes mellitus

By Mouth
- Adult: Initially 1 mg daily, adjusted according to response, then increased in steps of 1 mg every 1–2 weeks, increased to 4 mg daily, dose to be taken shortly before or with first main meal, the daily dose may be increased further, in exceptional circumstances; maximum 20 mg per day

Caution, Further Information
Porphyria Sulfonylureas should be avoided where possible in Acute porphyrias p. 864 but glimepiride is thought to be safe.

Interactions
- Appendix 1 (antidiabetics).

Side-effects
- Hyponatraemia

Pregnancy
The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.

Breast Feeding
Avoid—theoretical possibility of hypoglycaemia in the infant.

Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet
- Glimepiride (Non-proprietary)
  - Glimepiride 1 mg Glimepiride 1mg tablets | 30 tablet [POD] £2.00 DT price = £1.13
  - Glimepiride 2 mg Glimepiride 2mg tablets | 30 tablet [POD] £2.75 DT price = £1.23
  - Glimepiride 3 mg Glimepiride 3mg tablets | 30 tablet [POD] £9.67 DT price = £9.16
  - Glimepiride 4 mg Glimepiride 4mg tablets | 30 tablet [POD] £5.25 DT price = £1.52
- Amaryl (Zentiva)
  - Glimepiride 1 mg Amaryl 1mg tablets | 30 tablet [POD] £4.33 DT price = £1.13
  - Glimepiride 2 mg Amaryl 2mg tablets | 30 tablet [POD] £7.13 DT price = £1.23
  - Glimepiride 3 mg Amaryl 3mg tablets | 30 tablet [POD] £10.75 DT price = £9.16
  - Glimepiride 4 mg Amaryl 4mg tablets | 30 tablet [POD] £14.24 DT price = £1.52

Glipizide

Indications and Dose
Type 2 diabetes mellitus

By Mouth
- Adult: Initially 2.5–5 mg daily, adjusted according to response, dose to be taken shortly before breakfast or lunch, doses up to 15 mg may be given as a single dose, higher doses to be given in divided doses; maximum 20 mg per day

Caution, Further Information
Porphyria Sulfonylureas should be avoided where possible in Acute porphyrias p. 864 but glipizide is thought to be safe.

Interactions
- Appendix 1 (antidiabetics).

Side-effects
- Rare Photosensitivity
- Frequency not known Dizziness - drowsiness - hyponatraemia

Pregnancy
The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.

Breast Feeding
Avoid— the theoretical possibility of hypoglycaemia in the infant.

Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

Tablet
- Glipizide (Non-proprietary)
  - Glipizide 5 mg Glipizide 5mg tablets | 28 tablet [POD] £3.23 DT price = £3.23 | 56 tablet [POD] £13.44
- Minodiol (Pfizer Ltd)
  - Glipizide 5 mg Minodiol 5mg tablets | 28 tablet [POD] £1.26 DT price = £1.23
**Tolbutamide**

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus

**BY MOUTH**

- Adult: 0.5–1.5 g daily in divided doses (max. per dose 2 g), dose to be taken with or immediately after meals, alternatively 0.5–1.5 g once daily (max. per dose 2 g), dose to be taken with or immediately after breakfast.

- **CONTRA-INDICATIONS** Avoid where possible in Acute porphyrias p. 864
- **INTERACTIONS** → Appendix 1 (antidiabetics).
- **SIDE-EFFECTS** Headache · tinnitus
- **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
- **BREAST FEEDING** The use of sulfonylureas in breastfeeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.
- **RENAI IMPAIRMENT** If necessary, the short-acting drug tolbutamide can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
- **Tablet**
  - TOLBUTAMIDE (Non-proprietary)
    - Tolbutamide 500 mg Tolbutamide 500mg tablets \[28 tablet \(\text{P}35\) £42.50 DT price × £20.50 | 112 tablet \(\text{P}6\) £82.00–£94.48

**THIIZOLIDINEDIONES**

**Pioglitazone**

- **DRUG ACTION** The thiazolidinedione, pioglitazone, reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus (alone or combined with metformin or a sulfonylurea, or with both, or with insulin)

**BY MOUTH**

- Adult: Initially 15–30 mg once daily, adjusted according to response to 45 mg once daily, in elderly patients, initiate with lowest possible dose and increase gradually; review treatment after 3–6 months and regularly thereafter.

**Dose adjustments due to interactions**

Dose of concomitant sulfonylurea or insulin may need to be reduced.

**Important safety information**

MHRA/CHM ADVICE: PIOGLITAZONE CARDIOVASCULAR SAFETY (DECEMBER 2007 AND JANUARY 2011)

Incidence of heart failure is increased when pioglitazone is combined with insulin especially in patients with predisposing factors e.g. previous myocardial infarction. Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs.

Pioglitazone should not be used in patients with heart failure or a history of heart failure.

PIOGLITAZONE: RISK OF BLADDER CANCER (JULY 2011)

The European Medicines Agency has advised that there is a small increased risk of bladder cancer associated with pioglitazone use. However, in patients who respond adequately to treatment, the benefits of pioglitazone continue to outweigh the risks.

Pioglitazone should not be used in patients with active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Pioglitazone should be used with caution in elderly patients as the risk of bladder cancer increases with age.

Before initiating treatment with pioglitazone, patients should be assessed for risk factors of bladder cancer (including age, smoking status, exposure to certain occupational or chemotherapy agents, or previous radiation therapy to the pelvic region) and any macroscopic haematuria should be investigated. The safety and efficacy of pioglitazone should be reviewed after 3–6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment.

Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3–6 months, as above.

Patients should be advised to report promptly any haematuria, dysuria, or urinary urgency during treatment.

- **CONTRA-INDICATIONS** History of heart failure · previous or active bladder cancer · uninvestigated macroscopic haematuria
- **CAUTIONS** Avoid in Acute porphyrias p. 864 · cardiovascular disease or in combination with insulin (risk of heart failure) · elderly (increased risk of heart failure, fractures, and bladder cancer) · increased risk of bone fractures, particularly in women · risk factors for bladder cancer

**CAUTIONS, FURTHER INFORMATION**

Substitute insulin during peri-operative period (omit pioglitazone on morning of surgery and recommence treatment).

**INTERACTIONS** → Appendix 1 (antidiabetics).

**SIDE-EFFECTS**

- **Common or very common** Anaemia · arthralgia · dizziness · gastro-intestinal disturbances · haematuria · headache · hypoaesthesia · impotence · oedema · vertigo · visual disturbances · weight gain
- **Uncommon** Altered blood lipids · bladder cancer · fatigue · hypoglycaemia · insomnia · proteinuria · sweating
- **Rare** Liver dysfunction

**SIDE-EFFECTS, FURTHER INFORMATION**

Liver toxicity Rare reports of liver dysfunction; discontinue if jaundice occurs.

- **PREGNANCY** Avoid—toxicity in animal studies.
- **BREAST FEEDING** Avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Avoid.
- **MONITORING REQUIREMENTS** Monitor liver function before treatment and periodically thereafter.
- **PATIENT AND CARER ADVICE**

Liver toxicity Patients should be advised to seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue and dark urine develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium accepts use of pioglitazone (February 2007) with metformin and a sulfonylurea, for patients (especially if overweight) whose glycaemic control is inadequate despite the use of 2 oral hypoglycaemic drugs and who are unable or unwilling to take insulin; treatment should be initiated and monitored by an experienced diabetes physician.
Endocrine system

Inappropriate action. Normal fluctuations in blood glucose can lead to confusion on the results obtained. Inadequate understanding of the glucose monitoring systems and to take appropriate action measure of the glucose concentration at the time of the test.

Blood glucose monitoring using a meter gives a direct measurement of the blood-glucose concentration during activities, including driving.

In the UK blood-glucose concentration is expressed in mmol/litre and Diabetes UK advises that these units should be used for self-monitoring of blood glucose. In other European countries units of mg/100 mL (or mg/dL) are commonly used.

It is advisable to check that the meter is pre-set in the correct units.

If the patient is unwell and diabetic ketoacidos is suspected, blood ketones should be measured according to local guidelines. Patients and their carers should be trained in the use of blood ketone monitoring systems and to take appropriate action on the results obtained, including when to seek medical attention.

**Metformin with pioglitazone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, metformin hydrochloride p. 594, pioglitazone p. 613.

**INDICATIONS AND DOSE**

Type 2 diabetes not controlled by metformin alone

**BY MOUTH**

► Adult: 1 tablet twice daily, titration with the individual components (pioglitazone and metformin) desirable before initiation.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CoWEX†

Pioglitazone (as Pioglitazone hydrochloride) 15 mg Diabom 15mg tablets | 28 tablet (PO) £26.00 DT price = £1.23

Pioglitazone 15mg tablets | 28 tablet (PO) £25.83 DT price = £1.23

Pioglitazone (as Pioglitazone hydrochloride) 30 mg Diabom 30mg tablets | 28 tablet (PO) £36.00 DT price = £1.46

Pioglitazone 30mg tablets | 28 tablet (PO) £35.89 DT price = £1.46

Pioglitazone (as Pioglitazone hydrochloride) 45 mg Diabom 45mg tablets | 28 tablet (PO) £40.00 DT price = £1.68

Pioglitazone 45mg tablets | 28 tablet (PO) £39.55 DT price = £1.68

► Actos (Takeda UK Ltd)

Pioglitazone (as Pioglitazone hydrochloride) 15 mg Actos 15mg tablets | 28 tablet (PO) £25.83 DT price = £1.23

Pioglitazone (as Pioglitazone hydrochloride) 30 mg Actos 30mg tablets | 28 tablet (PO) £35.89 DT price = £1.46

Pioglitazone (as Pioglitazone hydrochloride) 45 mg Actos 45mg tablets | 28 tablet (PO) £39.55 DT price = £1.68

Brands may include Glidion

**3.2 Diabetes mellitus, diagnosis and monitoring**

**Diabetes mellitus, diagnostic and monitoring devices**

**Urinalysis**

Reagent strips are available for measuring for glucose in the urine. Tests for ketones by patients are rarely required unless they become unwell—see Blood Monitoring. Microalbuminuria can be detected with *Micral-Test II* but this should be followed by confirmation in the laboratory, since false positive results are common.

**Blood monitoring**

Blood glucose monitoring using a meter gives a direct measure of the glucose concentration at the time of the test and can detect hypoglycaemia as well as hyperglycaemia. Patients should be properly trained in the use of blood glucose monitoring systems and to take appropriate action on the results obtained. Inadequate understanding of the normal fluctuations in blood glucose can lead to confusion and inappropriate action.

Patients using multiple injection regimens should understand how to adjust their insulin dose according to their carbohydrate intake. With fixed-dose insulin regimens, the carbohydrate intake needs to be regulated, and should be distributed throughout the day to match the insulin regimen.

Self-monitoring of blood-glucose concentration is appropriate for patients with type 2 diabetes:

► who are treated with insulin;

► who are treated with oral hypoglycaemic drugs e.g. sulfonylureas, to provide information on hypoglycaemia;

► to monitor changes in blood-glucose concentration resulting from changes in lifestyle or medication, and during intercurrent illness;

► to ensure safe blood-glucose concentration during activities, including driving.

In the UK blood-glucose concentration is expressed in mmol/litre and Diabetes UK advises that these units should be used for self-monitoring of blood glucose. In other European countries units of mg/100 mL (or mg/dL) are commonly used.

It is advisable to check that the meter is pre-set in the correct units.

If the patient is unwell and diabetic ketoacidosis is suspected, blood ketones should be measured according to local guidelines. Patients and their carers should be trained in the use of blood ketone monitoring systems and to take appropriate action on the results obtained, including when to seek medical attention.

**Oral glucose tolerance test**

The oral glucose p. 852 tolerance test is used mainly for diagnosis of impaired glucose p. 852 tolerance; it is not recommended or necessary for routine diabetic use when severe symptoms of hyperglycaemia are present. In patients who have less severe symptoms and blood glucose levels that do not establish or exclude diabetes (e.g. impaired fasting glycaemia), an oral glucose p. 852 tolerance test may be required. It is also used to establish the presence of gestational diabetes. The oral glucose p. 852 tolerance test generally involves giving anhydrous glucose p. 852 by mouth to the fasting patient, and measuring blood-glucose concentrations at intervals.

The appropriate amount of glucose p. 852 should be given with 200–300 mL fluid. Anhydrous glucose p. 852 may alternatively be given as 113 mL *Polycal*® with extra fluid to administer a total volume of 200–300 mL, or as *Rapilose*® *OGTT* oral solution.

**Blood monitoring test strips**

**BLOOD GLUCOSE TESTING STRIPS**

► Diastix testing strips (Bayer Diagnostics Manufacturing Ltd)

50 strip · NHS indicative price = £2.89 · Drug Tariff (Part IXr)

► Element testing strips (Neon Diagnostics Ltd)

50 strip · NHS indicative price = £3.89 · Drug Tariff (Part IXr)

► FreeStyle Lite testing strips (Abbott Laboratories Ltd)

50 strip · NHS indicative price = £15.73 · Drug Tariff (Part IXr)

► FreeStyle Optium testing strips (Abbott Laboratories Ltd)

50 strip · NHS indicative price = £15.64 · Drug Tariff (Part IXr)

► GluNEO testing strips (Abbott Laboratories Ltd)

50 strip · NHS indicative price = £15.74 · Drug Tariff (Part IXr)

► GluNEO testing strips (Neon Diagnostics Ltd)

50 strip · NHS indicative price = £3.89 · Drug Tariff (Part IXr)

► GlucoDock testing strips (Medisana Healthcare (UK) Ltd)

50 strip · NHS indicative price = £14.90 · Drug Tariff (Part IXr)

► Glucomen GM testing strips (A Menarini Diagnostics Ltd)

50 strip · NHS indicative price = £3.95 · Drug Tariff (Part IXr)

► Glucomen LX Sensor testing strips (A Menarini Diagnostics Ltd)

50 strip · NHS indicative price = £15.52 · Drug Tariff (Part IXr)
## Meters and test strips

<table>
<thead>
<tr>
<th>Meter (all ®)</th>
<th>Type of monitoring</th>
<th>Compatible test strips</th>
<th>Test strip net price</th>
<th>Sensitivity range (mmol/litre)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accu-Chek® Active Meter no longer available</td>
<td>Blood glucose</td>
<td>Active®</td>
<td>50 strip = £9.95</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Advantage Meter no longer available</td>
<td>Blood glucose</td>
<td>Advantage Plus®</td>
<td>50 strip = £16.02</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Aviva</td>
<td>Blood glucose</td>
<td>Aviva®</td>
<td>50 strip = £15.72</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Aviva Expert</td>
<td>Blood glucose</td>
<td>Aviva®</td>
<td>50 strip = £15.72</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Compact Plus Meter no longer available</td>
<td>Blood glucose</td>
<td>Compact®</td>
<td>3 x 17 strips = £16.15</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Mobile</td>
<td>Blood glucose</td>
<td>Mobile®</td>
<td>100 device = £32.18</td>
<td>0.3-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Aviva Nano</td>
<td>Blood glucose</td>
<td>Aviva®</td>
<td>50 strip = £15.72</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>BGStar® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>BGStar®</td>
<td>50 strip = £14.73</td>
<td>1.1-33.3 mmol/litre</td>
<td>Sanofi</td>
</tr>
<tr>
<td>Breeze 2®</td>
<td>Blood glucose</td>
<td>Breeze 2®</td>
<td>50 strip = £15.00</td>
<td>0.6-33.3 mmol/litre</td>
<td>Bayer Plc</td>
</tr>
<tr>
<td>CareSens N® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>CareSens N®</td>
<td>50 strip = £12.75</td>
<td>1.1-33.3 mmol/litre</td>
<td>Spirit Healthcare Ltd</td>
</tr>
<tr>
<td>Contour®</td>
<td>Blood glucose</td>
<td>Contour®</td>
<td>50 strip = £15.23</td>
<td>0.6-33.3 mmol/litre</td>
<td>Bayer Diagnostics Manufacturing Ltd</td>
</tr>
<tr>
<td>Contour® XT</td>
<td>Blood glucose</td>
<td>Contour® Next</td>
<td>50 strip = £15.04</td>
<td>0.6-33.3 mmol/litre</td>
<td>Bayer Diagnostics Manufacturing Ltd</td>
</tr>
<tr>
<td>Element®</td>
<td>Blood glucose</td>
<td>Element®</td>
<td>50 strip = £9.89</td>
<td>0.55-33.3 mmol/litre</td>
<td>Neon Diagnostics Ltd</td>
</tr>
<tr>
<td>FreeStyle® Meter no longer available</td>
<td>Blood glucose</td>
<td>FreeStyle®</td>
<td>50 strip = £15.74</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Freedom® Meter no longer available</td>
<td>Blood glucose</td>
<td>FreeStyle®</td>
<td>50 strip = £15.74</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Freedom Lite®</td>
<td>Blood glucose</td>
<td>FreeStyle Lite®</td>
<td>50 strip = £15.73</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle InsuLinx®</td>
<td>Blood glucose</td>
<td>FreeStyle Lite®</td>
<td>50 strip = £15.73</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Lite®</td>
<td>Blood glucose</td>
<td>FreeStyle Lite®</td>
<td>50 strip = £15.73</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Mini® Meter no longer available</td>
<td>Blood glucose</td>
<td>FreeStyle®</td>
<td>50 strip = £15.74</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Optium®</td>
<td>Blood glucose</td>
<td>FreeStyle Optium®</td>
<td>50 strip = £15.64</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Optium® Blood ketones</td>
<td>FreeStyle Optium® /-ketone</td>
<td>10 strip = £21.04</td>
<td>0-8.0 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
<td></td>
</tr>
<tr>
<td>FreeStyle Optium Neo® Blood glucose</td>
<td>FreeStyle Optium®</td>
<td>50 strip = £15.64</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
<td></td>
</tr>
<tr>
<td>FreeStyle Optium Neo® Blood ketones</td>
<td>FreeStyle Optium® /-ketone</td>
<td>10 strip = £21.04</td>
<td>0-8.0 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
<td></td>
</tr>
<tr>
<td>GlucoDock® module For use with iPhone®, iPod touch®, and iPad®</td>
<td>Blood glucose</td>
<td>GlucoDock®</td>
<td>50 strip = £14.90</td>
<td>1.1-33.3 mmol/litre</td>
<td>Medisana Healthcare (UK) Ltd</td>
</tr>
</tbody>
</table>
### 616 Diabetes mellitus and hypoglycaemia

<table>
<thead>
<tr>
<th>Meter (all)</th>
<th>Type of monitoring</th>
<th>Compatible test strips</th>
<th>Test strip net price</th>
<th>Sensitivity range (mmol/litre)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlucoLab®</td>
<td>Blood glucose</td>
<td>GlucoLab®</td>
<td>50 strip = £9.89</td>
<td>0.55-33.3 mmol/litre</td>
<td>Neon Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® GM</td>
<td>Blood glucose</td>
<td>GlucoMen® GM</td>
<td>50 strip = £9.95</td>
<td>0.6-33.3 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® LX</td>
<td>Blood glucose</td>
<td>GlucoMen® LX Sensor</td>
<td>50 strip = £15.52</td>
<td>1.1-33.3 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® LX Plus</td>
<td>Blood glucose</td>
<td>GlucoMen® LX Sensor</td>
<td>50 strip = £15.52</td>
<td>1.1-33.3 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® LX Plus</td>
<td>Blood ketones</td>
<td>GlucoMen® LX Ketone</td>
<td>10 strip = £20.75</td>
<td>0-0.8 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® Visio</td>
<td>Blood glucose</td>
<td>GlucoMen® Visio Sensor</td>
<td>50 strip = £15.60</td>
<td>1.1-33.3 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoRx® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>GlucoRx®</td>
<td>50 strip = £9.45</td>
<td>1.1-33.3 mmol/litre</td>
<td>Disposable Medical Equipment Ltd</td>
</tr>
<tr>
<td>GlucoRx Nexus® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>GlucoRx Nexus®</td>
<td>50 strip = £9.95</td>
<td>1.1-33.3 mmol/litre</td>
<td>Disposable Medical Equipment Ltd</td>
</tr>
<tr>
<td>Glucotrend® Meter no longer available</td>
<td>Blood glucose</td>
<td>Active®</td>
<td>50 strip = £9.95</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>iBGStar®</td>
<td>Blood glucose</td>
<td>iBGStar®</td>
<td>50 strip = £14.73</td>
<td>1.1-33.3 mmol/litre</td>
<td>Sanofi</td>
</tr>
<tr>
<td>IME-DC®</td>
<td>Blood glucose</td>
<td>IME-DC®</td>
<td>50 strip = £14.10</td>
<td>1.1-33.3 mmol/litre</td>
<td>Arctic Medical Ltd</td>
</tr>
<tr>
<td>Mendor Discreet®</td>
<td>Blood glucose</td>
<td>Mendor Discreet®</td>
<td>50 strip = £14.75</td>
<td>1.1-33.3 mmol/litre</td>
<td>Merck Serono Ltd</td>
</tr>
<tr>
<td>Microlot® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>Microlot®</td>
<td>50 strip = £9.99</td>
<td>1.1-29.2 mmol/litre</td>
<td>Cambridge Sensors Ltd</td>
</tr>
<tr>
<td>MyGlucoHealth®</td>
<td>Blood glucose</td>
<td>MyGlucoHealth®</td>
<td>50 strip = £15.50</td>
<td>0.6-33.3 mmol/litre</td>
<td>Entra Health Systems Ltd</td>
</tr>
<tr>
<td>Omnitest® 3</td>
<td>Blood glucose</td>
<td>Omnitest® 3</td>
<td>50 strip = £9.89</td>
<td>0.6-33.3 mmol/litre</td>
<td>B.Braun Medical Ltd</td>
</tr>
<tr>
<td>One Touch Ultra® Meter no longer available</td>
<td>Blood glucose</td>
<td>One Touch Ultra®</td>
<td>50 strip = £11.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch Ultra 2® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>One Touch Ultra®</td>
<td>50 strip = £11.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch UltraEasy® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>One Touch Ultra®</td>
<td>50 strip = £11.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch UltraSmart® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>One Touch Ultra®</td>
<td>50 strip = £11.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch® VerioPro Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>One Touch® Verio</td>
<td>50 strip = £15.12</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch® Vita Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>One Touch® Vita</td>
<td>50 strip = £15.07</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>SD CodeFree®</td>
<td>Blood glucose</td>
<td>SD CodeFree®</td>
<td>50 strip = £6.99</td>
<td>0.6-33.3 mmol/litre</td>
<td>SD Biosensor Inc</td>
</tr>
<tr>
<td>Sensocard Plus® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>Sensocard®</td>
<td>50 strip = £16.30</td>
<td>1.1-33.3 mmol/litre</td>
<td>BBI Healthcare Ltd</td>
</tr>
<tr>
<td>Meter (all ▶)</td>
<td>Type of monitoring</td>
<td>Compatible test strips</td>
<td>Test strip net price</td>
<td>Sensitivity range (mmol/litre)</td>
<td>Manufacturer</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>----------------------</td>
<td>-------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>SuperCheck®</td>
<td>Blood glucose</td>
<td>SuperCheck®</td>
<td>50 strip = £8.49</td>
<td>1.1-33.3 mmol/litre</td>
<td>Apollo Medical Technologies Ltd</td>
</tr>
<tr>
<td>TRUEone®</td>
<td>Blood glucose</td>
<td>TRUEone®</td>
<td>50 strip = £14.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEresult®</td>
<td>Blood glucose</td>
<td>TRUEresult®</td>
<td>50 strip = £14.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEresult twist®</td>
<td>Blood glucose</td>
<td>TRUEresult®</td>
<td>50 strip = £14.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEtrack®</td>
<td>Blood glucose</td>
<td>TRUEtrack®</td>
<td>50 strip = £14.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEyou mini®</td>
<td>Blood glucose</td>
<td>TRUEyou®</td>
<td>50 strip = £9.92</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>WaveSense JAZZ®</td>
<td>Blood glucose</td>
<td>WaveSense JAZZ®</td>
<td>50 strip = £9.87</td>
<td>1.1-33.3 mmol/litre</td>
<td>AgaMatrix Europe Ltd</td>
</tr>
</tbody>
</table>

**BLOOD KETONES TESTING STRIPS**

- **FreeStyle Optum beta-ketone testing strips (Abbott Laboratories Ltd)**
  10 strip - NHS indicative price = £21.04 - Drug Tariff (Part IX)
- **GlucoMen LX beta-ketone testing strips (A Menarini Diagnostics Ltd)**
  10 strip - NHS indicative price = £20.75 - Drug Tariff (Part IX)

**Hypodermic insulin injection pens**

- **AUTOPEN® 24**
  For use with Sanofi-Aventis 3-ml insulin cartridges, allowing 1-unit dosage adjustment, max. 21 units (single-unit version) or 2-unit dosage adjustment, max. 42 units (2-unit version).
- **Automatic hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-21 units (Owen Mumford Ltd)**
  1 device - NHS indicative price = £16.47 - Drug Tariff (Part IXa)
- **Autopen Classic (for use with Lilly and Wockhardt 3-ml insulin cartridges)**, allowing 1-unit dosage adjustment, max. 21 units (single-unit version) or 2-unit dosage adjustment, max. 42 units (2-unit version).
- **Automatic hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-21 units (Owen Mumford Ltd)**
  1 device - NHS indicative price = £16.72 - Drug Tariff (Part IXa)

**Needle free Insulin delivery systems**

- **NEEDLE FREE INSULIN DELIVERY SYSTEMS INSUJECT®**
  For use with any 10-ml vial or 3-ml cartridge of insulin, allowing 1-unit dosage adjustment, max. 40 units. Available as **starter set (Insuject® device, nozzle cap, nozzle and piston, 1 x 10-ml adapter, 1 x 3-ml adapter, 1 cartridge cap removal key), nozzle pack (15 nozzles), cartridge adaptor pack (15 adaptors), or vial adaptor pack (15 adaptors)**.
  - **Insuject 10ml vial adaptor pack (Spirit Healthcare Ltd)**
    1 pack - NHS indicative price = £21.70 - Drug Tariff (Part IXa)
  - **Insuject 3ml cartridge adaptor pack (Spirit Healthcare Ltd)**
    1 pack - NHS indicative price = £21.70 - Drug Tariff (Part IXa)
  - **Insuject needle pack (Spirit Healthcare Ltd)**
    1 pack - NHS indicative price = £28.40 - Drug Tariff (Part IXa)
  - **Insuject starter set (Spirit Healthcare Ltd)**
    1 pack - NHS indicative price = £43.80 - Drug Tariff (Part IXa)
3.3 Hypoglycaemia

Hypoglycaemia

Treatment of hypoglycaemia

Initially glucose p. 852 10–20 g is given by mouth either in liquid form or as granulated sugar or sugar lumps. Approximately 10 g of glucose is available from non-diet versions of Lucozade® Energy Original 55 mL, Coca-Cola® 100 mL, Ribena® Blackcurrant 19 mL (to be diluted), 2 teaspoons of sugar, and also from 3 sugar lumps. Proprietary products of quick-acting carbohydrate (e.g. GlucoJet®, Dextrogel®, GSF-Syrup®, Rapilose® gel) are available on prescription for the patient to keep to hand in case of hypoglycaemia. If necessary this may be repeated in 10–15 minutes. After initial treatment, a snack providing sustained availability of carbohydrate (e.g. a sandwich, fruit, milk, or biscuits) or the next meal, if it is due, can prevent blood-glucose concentration from falling again.

Hypoglycaemia which causes unconsciousness is an emergency. Glucagon, a polypeptide hormone produced by the alpha cells of the islets of Langerhans, increases plasma-glucose concentration by mobilising glycogen stored in the liver. In hypoglycaemia, if sugar cannot be given by mouth, glucagon can be given by injection. Carbohydrates should be given as soon as possible to restore liver glycogen; glucagon is not appropriate for chronic hypoglycaemia. Glucagon may be issued to close relatives of insulin-treated patients for emergency use in hypoglycaemic attacks. It is often advisable to prescribe on an ‘if necessary’ basis to hospitalised insulin-treated patients, so that it may be given rapidly by the nurses during an hypoglycaemic emergency. If not effective in 10 minutes intravenous glucose should be given.

Alternatively, glucose intravenous infusion 20% may be given intravenously into a large vein through a large-gauge needle; care is required since this concentration is irritant especially if extravasation occurs. Glucose intravenous infusion 10% may also be used but larger volumes are needed. Glucose intravenous infusion 5% is not recommended because of the higher risk of extravasation injury and because administration is difficult. Close monitoring is necessary in the case of an overdose with a long-acting insulin because further administration of glucose may be required. Patients whose hypoglycaemia is caused by an oral antidiabetic drug should be transferred to hospital because the hypoglycaemic effects of these drugs may persist for many hours.

See also emergency management of hypoglycaemia in dental practice for further advice.

Chronic hypoglycaemia

Diazoxide p. 619, administered by mouth, is useful in the management of patients with chronic hypoglycaemia from excess endogenous insulin secretion, either from an islet cell tumour or islet cell hyperplasia. It has no place in the management of acute hypoglycaemia.

GLYCOGENOLYTIC HORMONES

Glucagon

INDICATIONS AND DOSE

Insulin-induced hypoglycaemia

By subcutaneous injection or by intramuscular injection

- Child 1 month–1 year: 500 micrograms
- Child 2–17 years (body-weight up to 25 kg): 500 micrograms, if no response within 10 minutes intravenous glucose must be given
- Child 2–17 years (body-weight 25 kg and above): 1 mg, if no response within 10 minutes intravenous glucose must be given
- Adult: 1 mg, if no response within 10 minutes intravenous glucose must be given

Beta-blocker poisoning (cardiogenic shock unresponsive to atropine)

Initially by intravenous injection

- Child: 50–150 micrograms/kg (max. per dose 10 mg), to be administered in glucose 5% (with precautions to protect the airway in case of vomiting), followed by (by intravenous infusion) 50 micrograms/kg/hour
- Adult: 2–10 mg, to be administered in glucose 5% (with precautions to protect the airway in case of vomiting), followed by (by intravenous infusion) 50 micrograms/kg/hour

Dose equivalence and conversion

1 unit of glucagon = 1 mg of glucagon.

UNLICENSED USE

Dose and indication for cardiogenic shock unresponsive to atropine in beta-blocker overdose not licensed.

- In children Unlicensed for growth hormone test and hyperinsulinism.

CONTRA-INDICATIONS

Phaeochromocytoma

CAUTIONS

Glucagonoma - ineffective in chronic hypoglycaemia, starvation, and adrenal insufficiency · insulinoma - when used in the diagnosis of growth hormone secretion, delayed hypoglycaemia may result — deaths reported (ensure a meal is eaten before discharge)

SIDE-EFFECTS

- Rare Hypersensitivity reactions
**Disorders of bone metabolism**

### 4 Disorders of bone metabolism

#### Bone metabolism

##### Osteoporosis

Osteoporosis occurs most commonly in postmenopausal women and in those taking long-term oral corticosteroids (glucocorticosteroids). Other risk factors for osteoporosis include low body weight, cigarette smoking, excess alcohol intake, lack of physical activity, family history of osteoporosis, and early menopause.

Those at risk of osteoporosis should maintain an adequate intake of calcium and vitamin D and any deficiency should be corrected by increasing dietary intake or taking supplements.

Elderly patients, especially those who are housebound or live in residential or nursing homes, are at increased risk of calcium and vitamin D deficiency and may benefit from supplements. Reversible secondary causes of osteoporosis such as hyperthyroidism, hyperparathyroidism, osteomalacia or hypogonadism should be excluded, in both men and women, before treatment for osteoporosis is initiated.

**Postmenopausal osteoporosis**

The **bisphosphonates** (such as alendronate and risedronate) are effective for preventing postmenopausal osteoporosis.

**Hormone replacement therapy (HRT)** is an option where other therapies are contra-indicated, cannot be tolerated, or if there is a lack of response. The CSM has advised that HRT should **not** be considered for women at higher risk of osteoporosis. HRT is of most benefit for the prophylaxis of postmenopausal osteoporosis if started early in menopause and continued for up to 5 years, but bone loss resumes (possibly at an accelerated rate) on stopping HRT. Women of Afro-Caribbean origin appear to be less susceptible to osteoporosis than those who are white or of Asian origin.

Postmenopausal osteoporosis may be **treated with a bisphosphonate**. The bisphosphonates (such as alendronate or risedronate) decrease the risk of vertebral fracture; alendronate and risedronate have also been shown to reduce non-vertebral fractures. If bisphosphonates are unsuitable, calcitriol, p. 885 or **strontium ranelate** may be considered. Calcitriol (salmon)/salcatonin [unlicensed indication] has been used for pain relief for up to 3 months after a vertebral fracture when other analgesics were ineffective, but the benefits of treatment should be balanced against the risks.

**Parathyroid hormone, and teriparatide** have been introduced for the treatment of postmenopausal osteoporosis.

**Raloxifene** is licensed for the prophylaxis and treatment of vertebral fractures in postmenopausal women.

#### Corticosteroid-induced osteoporosis

To reduce the risk of osteoporosis doses of oral corticosteroids should be as low as possible and courses of treatment as short as possible. The risk of osteoporosis may be related to cumulative dose of corticosteroids; even

---

**BNF 70**

**Tablet**

- **Eudeme** (Focus Pharmaceuticals Ltd)
  - **Diazoxide 50 mg** Eudeme 50mg tablets | 100 tablet **£46.45**

---

### 3.4 Hypoglycaemia, chronic

#### THIAZIDES AND RELATED DIURETICS

**Diazoxide**

**INDICATIONS AND DOSE**

**Chronic intractable hypoglycaemia**

**BY MOUTH**

- Adult: Initially 5 mg/kg daily in 2–3 divided doses, adjusted according to response; maintenance 3–8 mg/kg daily in 2–3 divided doses

**CAUTIONS**

- Aortic coarctation • aortic stenosis • arteriovenous shunt • heart failure • hyperuricaemia • impaired cardiac circulation • impaired cerebral circulation

**INTERACTIONS**

- Appendix 1 (diazoxide).

**SIDE-EFFECTS**

- Abdominal pain • anaemia • anorexia (prolonged use) • bleeding • constipation • decreased libido • dermatitis • diarrhoea • dizziness • dyspnoea • eosinophilia • extrapyramidal effects • galactorrhoea • headache • heart failure • hyperglycaemia • hyperosmolar non-ketotic coma • hypertrichosis • hyperuricaemia • hyperuricaemia (prolonged use) • hypotension • ileus • lacrimation • leucopenia • lichenoid eruption • musculoskeletal pain • nausea • pancreatitis • pruritus • pulmonary hypertension • raised serum creatinine • raised serum urea • reversible nephritic syndrome • sodium and fluid retention • taste disturbance • thrombocytopenia • tinnitus • transient cataracts • visual disturbances • vomiting

**PREGNANCY**

Use only if essential; alopecia and hypertrichosis reported in neonates with prolonged use; may inhibit uterine activity during labour.

**BREAST FEEDING**

Manufacturer advises avoid — no information available.

**RENAL IMPAIRMENT**

Dose reduction may be required.

**MONITORING REQUIREMENTS**

- Monitor blood pressure.
- Monitor white cell and platelet count during prolonged use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, capsule
intermittent courses can therefore increase the risk. The greatest rate of bone loss occurs during the first 6–12 months of corticosteroid use and so early steps to prevent the development of osteoporosis are important. Long-term use of high-dose inhaled corticosteroids may also contribute to corticosteroid-induced osteoporosis. Patients taking (or who are likely to take) an oral corticosteroid for 3 months or longer should be assessed and where necessary given prophylactic treatment; those aged over 65 years are at greater risk. Patients taking oral corticosteroids who have sustained a low trauma fracture should receive treatment for osteoporosis. The therapeutic options for prophylaxis and treatment of corticosteroid-induced osteoporosis are the same:

- a bisphosphonate;
- calcitriol [unlicensed indication];
- hormone replacement (HRT in women, testosterone in men [unlicensed indication]).

Calcitonin and parathyroid hormone

Calcitonin is involved with parathyroid hormone in the regulation of bone turnover and hence in the maintenance of calcium balance and homeostasis. Calcitonin (salmon)/salcatonin (synthetic or recombinant salmon calcitonin) is used to lower the plasma-calcium concentration in patients with hypercalcaemia associated with malignancy. Calcitonin (salmon)/salcatonin is also licensed for treatment of Paget’s disease of bone when other treatments are ineffective or inappropriate; it is also licensed for the prevention of acute bone loss due to sudden immobility. Calcitonin (salmon)/salcatonin is no longer recommended for the prevention or treatment of postmenopausal osteoporosis because the benefits are outweighed by the risk of malignancy associated with long-term use.

Recombinant parathyroid hormone is used for the treatment of postmenopausal osteoporosis. Teriparatide p. 629 (a recombinant fragment of parathyroid hormone) is used for the treatment of postmenopausal osteoporosis, osteoporosis in men at increased risk of fracture, and corticosteroid-induced osteoporosis. Cinacalcet p. 855 is licensed for the treatment of hypercalcaemia in parathyroid carcinoma.

Bisphosphonates

Bisphosphonates have an important role in the prophylaxis and treatment of osteoporosis and corticosteroid-induced osteoporosis; alendronic acid p. 621 or risedronate sodium p. 624 are considered the drugs of choice for these conditions. Bisphosphonates are also used in the treatment of Paget’s disease, hypercalcaemia of malignancy, and in bone metastases in breast cancer.

Strontium ranelate

Strontium ranelate treatment has been associated with an increased risk of serious cardiovascular disease, including myocardial infarction, and the risk should be assessed before treatment and regularly during treatment. Strontium ranelate should be initiated only by specialists for the treatment of severe osteoporosis in postmenopausal women or men at high risk of fracture for whom other treatments are contra-indicated or not tolerated.

See also calcium, phosphorus, vitamin D and oestrogens in postmenopausal osteoporosis.

Drugs used for Disorders of bone metabolism not listed below: Calcitriol, p. 885

ANABOLIC STEROIDS

Nandrolone

INDICATIONS AND DOSE

Osteoporosis in postmenopausal women (but not recommended)

BY DEEP INTRAMUSCULAR INJECTION

> Adult: 50 mg every 3 weeks.

- CONTRA-INDICATIONS Acute porphyrias p. 864, male breast cancer, prostate cancer
- CAUTIONS Cardiac impairment, diabetes mellitus, epilepsy, hypertension, migraine, skeletal metastases (risk of hypercalcaemia)
- INTERACTIONS → Appendix 1 (anabolic steroids).
- SIDE-EFFECTS Abnormal liver-function tests (with high doses), acne, amenorrhoea, inhibition of spermatogenesis, liver tumours (with prolonged treatment with anabolic steroids), premature epiphyseal closure, sodium retention with oedema, virilisation (with high doses including voice changes—sometimes irreversible)
- HEPATIC IMPAIRMENT Use in severe hepatic impairment only if benefit outweighs risk.
- RENAL IMPAIRMENT Use with caution—may cause sodium and water retention.
- MONITORING REQUIREMENTS Monitor skeletal maturation in young patients.
- LESS SUITABLE FOR PRESCRIBING Nandrolone injection is less suitable for prescribing.

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXPICIENTS: May contain Arachis (peanut) oil, benzyl alcohol

Deca-Durabolin (Aspen Pharma Trading Ltd)

Nandrolone decanoate 50 mg per 1 ml Deca-Durabolin 50mg/1ml solution for injection ampoules | 1 ampoule £17 Schedule 4 (CD Anab)

BISPHOSPHONATES

Bisphosphonates

> DRUG ACTION Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth and dissolution, and therefore reducing the rate of bone turnover.

Important safety information

MHRA/CHM ADVICE: BISPHOSPHONATES: ATYPICAL FEMORAL FRACTURES (JUNE 2011)

Atypical femoral fractures have been reported rarely with bisphosphonate treatment, mainly in patients receiving long-term treatment for osteoporosis. The need to continue bisphosphonate treatment for osteoporosis should be re-evaluated periodically based on an assessment of the benefits and risks of treatment for individual patients, particularly after 5 or more years of use.

Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate. Discontinuation of bisphosphonate treatment in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.

BISPHOSPHONATES: OSTEONECROSIS OF THEjaw

The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous...
bisdiphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget’s disease.

Risk factors for developing osteonecrosis of the jaw that should be considered are: potency of bisphosphonate (highest for zoledronate), route of administration, cumulative dose, duration and type of malignant disease, concomitant treatment, smoking, comorbid conditions, and history of dental disease.

All patients should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. During bisphosphonate treatment patients should maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms.


PATIENT AND CARER ADVICE
Atypical femoral fractures Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate. Osteonecrosis of the jaw During bisphosphonate treatment patients should maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms.

Alendronic acid (Alendronate)

INDICATIONS AND DOSE
Treatment of postmenopausal osteoporosis
BY MOUTH
- Adult: 10 mg daily, alternatively 70 mg once weekly.

Treatment of osteoporosis in men
BY MOUTH
- Adult: 10 mg daily.

Prevention and treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving hormone replacement therapy
BY MOUTH
- Adult: 10 mg daily.

CONTRA-INDICATIONS Abnormalities of oesophagus - hypocalcaemia - other factors which delay emptying (e.g. stricture or achalasia)

CAUTIONS Active gastro-intestinal bleeding - atypical femoral fractures - duodenitis - dysphagia - exclude other causes of osteoporosis - gastritis - history (within 1 year) of ulcers - surgery of the upper gastro-intestinal tract - symptomatic oesophageal disease - ulcers - upper gastrointestinal disorders

INTERACTIONS • Appendix 1 (bisphosphonates).

SIDE-EFFECTS
- Common or very common Abdominal distension - abdominal pain - alopecia - asthenia - constipation - diarrhea - dizziness - dyspepsia - flatulence - headache - joint swelling - musculoskeletal pain - oesophageal reactions - peripheral oedema - pruritus - regurgitation - vertigo
- Uncommon Dysgeusia - episceratitis - erythema - gastritis - malaise (on initiation) - melena - myalgia (on initiation) - nausea - rash - scleritis - uveitis - vomiting
- Rare Atypical femoral fractures with long-term use - fever (on initiation) - hypocalcaemia - osteonecrosis of the jaw - photosensitivity - severe skin reactions - Stevens-Johnson syndrome - toxic epidermal necrolysis

SIDE-EFFECTS, FURTHER INFORMATION
Oesophageal reactions Severe oesophageal reactions (oesophagitis, oesophageal ulcers, oesophageal stricture and oesophageal erosions) have been reported; patients should be advised to stop taking the tablets and to seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, new or worsening heartburn, pain on swallowing or retrosternal pain.

PREGNANCY Avoid.

BREAST FEEDING Manufacturer advises avoid—no information available.

RENAL IMPAIRMENT Avoid if eGFR less than 35 mL/minute/1.73 m².

MONITORING REQUIREMENTS Correct disturbances of calcium and mineral metabolism (e.g. vitamin-D deficiency, hypocalcaemia) before starting treatment. Monitor serum-calcium concentration during treatment.

DIRECTIONS FOR ADMINISTRATION Tablets should be swallowed whole and oral solution should be swallowed as a single 100 mL dose. Doses should be taken with plenty of water while sitting or standing, on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after administration.

PATIENT AND CARER ADVICE Patients or their carers should be given advice on how to administer alendronic acid tablets and oral solution. Oesophageal reactions Patients (or their carers) should be advised to stop taking alendronic acid and to seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, new or worsening heartburn, pain on swallowing or retrosternal pain.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA160

Alendronate is recommended as a treatment option for the primary prevention of osteoporotic fractures in the following susceptible postmenopausal women:
- Women over 70 years who have an independent risk factor for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis) or an indicator of low bone mineral density (body mass index under 22 kg/m², ankylosing spondylitis, Cohn’s disease, prolonged immobility, untreated premature menopause, or rheumatoid arthritis) and confirmed osteoporosis.
- Women aged 65–69 years who have an independent risk factor for fracture and confirmed osteoporosis.
- Women under 65 years who have an independent risk factor for fracture and at least one additional indicator of low bone mineral density and confirmed osteoporosis. www.nice.org.uk/TA160
- Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA161

This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.

Alendronate is recommended as a treatment option for the secondary prevention of osteoporotic fractures in susceptible postmenopausal women. www.nice.org.uk/TA161
622 Disorders of bone metabolism

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet
- ALENDRONIC ACID (Non-proprietary)
  Alendronic acid (as Alendronate sodium) 10 mg 10mg tablets | 28 tablet [P] £3.75 DT price = £1.64
  Alendronic acid (as Alendronate sodium) 70 mg 70mg tablets | 4 tablet [P] £22.80 DT price = £1.03
  Fosamax (Merck Sharp & Dohme Ltd)
  Alendronic acid (as Alendronate sodium) 10 mg Fosamax 10mg tablets | 28 tablet [P] £23.12 DT price = £1.64
  Alendronic acid (as Alendronate sodium) 70 mg Fosamax Once Weekly 70mg tablets | 4 tablet [P] £22.80 DT price = £1.03

Oral solution
- ALENDRONIC ACID (Non-proprietary)
  Alendronic acid 700 microgram per 1 ml 10 mg tablets 70mg/100ml oral solution unit dose sugar free (sugar-free) | 4 unit dose [P] £22.80 DT price = £22.80

Alendronic acid with calciferol
The properties listed below are those particular to the combination only. For the properties of the components please consider, alendronic acid p. 621, calciferol p. 886.

INDICATIONS AND DOSE
Treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency
BY MOUTH
- Adult: 1 tablet once weekly.

DIRECTIONS FOR ADMINISTRATION
Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet.

PATIENT AND CARER ADVICE
Patients or carers should be given advice on how to administer alendronic acid with calciferol tablets.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Fosavance (Merck Sharp & Dohme Ltd)
  Alendronic acid (as Alendronate sodium) 70 mg, Calciferol 70 microgram Fosavance tablets | 4 tablet [P] £22.80 DT price = £22.80

Ibandronic acid

INDICATIONS AND DOSE
Reduction in bone damage in bone metastases in breast cancer
INITIALLY BY MOUTH
- Adult: 50 mg daily, alternatively (by intravenous infusion) 6 mg every 3–4 weeks

HYPERCALCAEMIA OF MALIGNANCY
BY INTRAVENOUS INFUSION
- Adult: 2–4 mg as a single infusion, dose to be adjusted according to serum calcium concentration

TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
INITIALLY BY MOUTH
- Adult: 150 mg once a month, alternatively (by intravenous injection) 3 mg every 3 months, to be administered over 15–30 seconds.

CONTRA-INDICATIONS

GENERAL CONTRA-INDICATIONS:
Hypocalcaemia

SPECIFIC CONTRA-INDICATIONS:
- With oral use Abnormalities of the oesophagus - other factors which delay emptying (e.g. stricture or achalasia)
- CAUTIONS Atypical femoral fractures - cardiac disease (avoid fluid overload)
- INTERACTIONS → Appendix 1 (bisphosphonates).

SIDE-EFFECTS

GENERAL SIDE-EFFECTS
- Common or very common Abdominal pain - asthenia - bone pain - chills - diarrhoea - dyspepsia - fever - gastritis - headache - hypocalcaemia - hypophosphataemia - influenza-like symptoms - muscle pain - nausea - pharyngitis - rash - vomiting
- Rare Anaemia - angioedema - atypical femoral fractures - bronchospasm - hypersensitivity reactions - injection-site reactions - pruritus - urticaria
- Very rare Osteonecrosis of the jaw

SPECIFIC SIDE-EFFECTS
- Common or very common
- With oral use Severe oesophageal reactions (discontinue)
- PREGNANCY Avoid.

BREAST FEEDING
Avoid—present in milk in animal studies.

RENAI IMPAIRMENT
- With intravenous use When used for bone metastases, if eGFR 30–50 mL/minute/1.73 m² reduce dose to 4 mg and infuse over 1 hour; if eGFR less than 30 mL/minute/1.73 m² reduce dose to 2 mg and infuse over 1 hour.
- With oral use When used for bone metastases, if eGFR 30–50 mL/minute/1.73 m² reduce dose to 50 mg on alternative days; if eGFR less than 30 mL/minute/1.73 m² reduce dose to 50 mg once weekly. When used for postmenopausal osteoporosis, avoid if eGFR less than 30 mL/minute/1.73 m².

MONITORING REQUIREMENTS
Monitor renal function and serum calcium, phosphate and magnesium.

DIRECTIONS FOR ADMINISTRATION
Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet.

For intravenous infusion (Bonviva®), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute requisite dose in 500 mL infusion fluid and give over 1–2 hours.

PATIENT AND CARER ADVICE
Patients or carers should be given advice on how to administer ibandronic acid tablets. Oesophageal reactions Patients and carers should be advised to stop tablets and seek medical attention for symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- IBANDRONIC ACID (Non-proprietary)
  Ibandronic acid (as Ibandronic sodium monohydrate) 50 mg Ibandronic acid 50mg tablets | 28 tablet [P] £174.51 DT price = £10.76
  Ibandronic acid (as Ibandronic sodium monohydrate) 150 mg Ibandronic acid 150mg tablets | 1 tablet [P] £18.40 DT price = £1.68 | 3 tablet [P] £55.21
Disorders of bone metabolism 623

Pamidronate disodium
(Formerly called aminohydroxypropylidenediphosphonate disodium (APD))

INDICATIONS AND DOSE

Hypercalcaemia of malignancy

BY INTRAVENOUS INFUSION

Adult: 15–60 mg, to be given (via cannula in a relatively large vein) as a single infusion or in divided doses over 2–4 days, dose adjusted according to serum calcium concentration; maximum 90 mg per course

Osteolytic lesions and bone pain in bone metastases associated with breast cancer or multiple myeloma

BY INTRAVENOUS INFUSION

Adult: 90 mg every 4 weeks, to be administered via cannula in a relatively large vein, dose may alternatively be administered every 3 weeks, to coincide with chemotherapy in breast cancer

Paget’s disease of bone

BY INTRAVENOUS INFUSION

Adult: 30 mg every 1 week for a 6 week course (total dose 180 mg), alternatively initially 30 mg once weekly for 1 week, then increased to 60 mg every 2 weeks (max. per dose 60 mg) for a 6 week course (total dose 210 mg), to be administered via cannula in a relatively large vein, course may be repeated every 6 months; maximum 360 mg per course

CAUTIONS

Atypical femoral fractures - cardiac disease (especially in elderly) - ensure adequate hydration - previous thyroid surgery (risk of hypocalcaemia)

INTERACTIONS  Appendix 1 (bisphosphonates).

Avoid concurrent use with other bisphosphonates.

SIDE-EFFECTS

Common or very common - Abdominal pain - anaemia - anorexia - arthralgia - bone pain - constipation - diarrhea - drowsiness - fever - headache - hypertension - hypomagnesaemia - hypophosphataemia - influenza - like symptoms (sometimes accompanied by malaise, rigors, fatigue and flushed) - insomnia - lymphocytopenia - myalgia - nausea - paraesthesia - rash - symptomatic hypocalcaemia - tetany - thrombocytopenia - vomiting


Frequency not known - Atrial fibrillation - injection-site reactions - reactivation of herpes simplex - reactivation of herpes zoster

SIDE-EFFECTS, FURTHER INFORMATION

Calcium and vitamin D supplements Oral supplements are advised to minimise potential risk of hypocalcaemia for those with mainly lytic bone metastases or multiple myeloma at risk of calcium or vitamin D deficiency (e.g. through malabsorption or lack of exposure to sunlight) and in those with Paget’s disease.

PREGNANCY Avoid—toxicity in animal studies.

BREAST FEEDING Avoid.

HEPATIC IMPAIRMENT Caution in severe hepatic impairment—no information available.

RENAL IMPAIRMENT Max. infusion rate 20 mg/hour. Avoid if eGFR less than 30 mL/minute/1.73 m², except in life-threatening hypercalcaemia if benefit outweighs risk. If renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value.

MONITORING REQUIREMENTS

- Monitor serum electrolytes, calcium and phosphate—possibility of convulsions due to electrolyte changes.
- Assess renal function before each dose.

DIRECTIONS FOR ADMINISTRATION

- With intravenous use For slow intravenous infusion (Aredia®, Pamidronate disodium, Hospira, Medac, Wockhardt), give intermittently in Glucose 5% or Sodium chloride 0.9%; give at a rate not exceeding 1 mg/minute; not to be given with infusion fluids containing calcium. For Aredia®, reconstitute initially with water for injections (15 mg in 5 mL, 30 mg or 90 mg in 10 mL), then dilute with infusion fluid to a concentration of not more than 90 mg in 250 mL. For Pamidronate disodium (Wockhardt), dilute with infusion fluid to a concentration of not more than 60 mg in 250 mL or for Pamidronate disodium (Medac, Hospira) dilute with infusion fluid to a concentration of not more than 90 mg in 250 mL.

PATIENT AND CARER ADVICE Patients should be warned against performing skilled tasks (e.g. cycling, driving or operating machinery) immediately after treatment (somnolence or dizziness may occur).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

PAMIDRONATE DISODIUM (Non-proprietary)

Pamidronate disodium 3 mg per 1 ml Pamidronate disodium 15mg/5ml solution for infusion vials | 1 vial (Roche Products Ltd) £18.40
Pamidronate disodium 6 mg per 1 ml Pamidronate disodium 6mg/2ml solution for infusion vials | 1 vial (Roche Products Ltd) £29.36 (Hospital only)
Pamidronate disodium 9 mg per 1 ml Pamidronate disodium 9mg/3ml solution for infusion vials | 1 vial (Roche Products Ltd) £48.64

Solution for infusion

Pamidronate disodium 3 mg per 1 ml Pamidronate disodium 3mg/3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (Roche Products Ltd) £18.60
Pamidronate disodium 6 mg per 1 ml Pamidronate disodium 6mg/3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (Roche Products Ltd) £36.40

BY INTRAVENOUS INFUSION

Pamidronate disodium (as Ibandronic sodium monohydrate) 1 mg per 1 ml Ibandronic acid 1 mg per 1 ml solution for infusion pre-filled vials | 1 vial (Roche Products Ltd) £65.20
Pamidronate disodium (as Ibandronic sodium monohydrate) 1 mg per 1 ml Ibandronic acid 1 mg per 1 ml solution for infusion pre-filled vials | 1 vial (Roche Products Ltd) £69.50

† Bondronat (Roche Products Ltd)
Ibandronic acid (as Ibandronic sodium monohydrate)
50 mg Bondronat 50mg tablets | 28 tablet (Roche Products Ltd) £183.69 DT price = £10.76
Bonviva (Roche Products Ltd)
Ibandronic acid (as Ibandronic sodium monohydrate)
150 mg Bondviva 150mg tablets | 1 tablet (Roche Products Ltd) £18.40 DT price = £1.68

† Brands may include latisbon; Quodiorx

Solution for injection

Ibandronic acid (as Ibandronic sodium monohydrate) 1 mg per 1 ml Ibandronic acid 1 mg/ml solution for injection pre-filled vials | 1 vial (Roche Products Ltd) £183.69
Pamidronate disodium (as Ibandronic sodium monohydrate) 1 mg per 1 ml Pamidronate disodium 1 mg/ml solution for injection pre-filled vials | 1 vial (Roche Products Ltd) £183.69

Monitrol.

Cautions

Ensure adequate hydration with infusion fluids containing calcium. For Aredia®, give at a rate not exceeding 1 mg/minute; not to be given with infusion fluids containing calcium. For Aredia®, reconstitute initially with water for injections (15 mg in 5 mL, 30 mg or 90 mg in 10 mL), then dilute with infusion fluid to a concentration of not more than 90 mg in 250 mL. For Pamidronate disodium (Wockhardt), dilute with infusion fluid to a concentration of not more than 60 mg in 250 mL or for Pamidronate disodium (Medac, Hospira) dilute with infusion fluid to a concentration of not more than 90 mg in 250 mL.
**Indications and Dose**

**Paget’s disease of bone**

**By mouth**

- **Adult**: 30 mg daily for 2 months, course may be repeated if necessary after at least 2 months.

**Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures**

**By mouth**

- **Adult**: 5 mg daily, alternatively 35 mg once weekly.

**Prevention of osteoporosis (including corticosteroid-induced osteoporosis) in postmenopausal women**

**By mouth**

- **Adult**: 5 mg daily.

**Treatment of osteoporosis in men at high risk of fractures**

**By mouth**

- **Adult**: 35 mg once weekly.

**Contra-indications**

- Hypocalcaemia

**Caution**

- Atypical femoral fractures - oesophageal abnormalities - other factors which delay transit or emptying (e.g. stricture or achalasia)

**Interactions**

- **Common or very common**: Abdominal pain - constipation - diarrhoea - dyspepsia - headache - musculoskeletal pain - nausea

- **Uncommon**: Duodenitis - dysphagia - gastritis - oesophageal ulcer - oesophagitis - uveitis

- **Rare**: Atypical femoral fractures - glossoitis - oesophageal stricture

- **Frequency not known**: Cutaneous vasculitis - gastroduodenal ulceration - hair loss - hepatic disorders - osteonecrosis of the jaw - Stevens-Johnson syndrome - toxic epidermal necrolysis

**Pregnancy**

Avoid.

**Breast feeding**

Avoid.

**Renal Impairment**

Avoid if eGFR less than 30 mL/minute/1.73 m².

**Monitoring Requirements**

- Correct hypocalcaemia before starting.

- Correct other disturbances of bone and mineral metabolism (e.g. vitamin D deficiency) at onset of treatment.

**Directions for Administration**

Swallow tablets whole with full glass of water; on rising, take on an empty stomach at least 30 minutes before first food or drink of the day or, if taking at any other time of the day, avoid food and drink for at least 2 hours before or after risedronate (particularly avoid calcium-containing products e.g. milk; also avoid iron and mineral supplements and antacids); stand or sit upright for at least 30 minutes; do not take tablets at bedtime or before rising.

**Patient and carer advice**

Patients or carers should be given advice on how to administer risedronate sodium tablets.

Oesophageal reactions: Patients should be advised to stop taking the tablets and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn.

**National Funding/Access Decisions**

**NICE technology appraisals (TAs)**

- Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA160

Risedronate is recommended as an alternative for women:

- in whom alendronate is contra-indicated or not tolerated and

- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance. [www.nice.org.uk/TA160](http://www.nice.org.uk/TA160)

- Alendronate, etidronate, risedronate, raloxifene, and strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA161

This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.

Risedronate is recommended as an alternative for women:

- in whom alendronate is contra-indicated or not tolerated and

- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis, as indicated in the full NICE guidance. [www.nice.org.uk/TA161](http://www.nice.org.uk/TA161)

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include oral solution, oral suspension.

**Tablet**

- **Risedronate Sodium (Non-proprietary)**
  - **Risedronate sodium 5 mg**
    - Risedronate sodium 5 mg tablets | 28 tablet [BNF] £16.52 DT price = £14.95
  - **Risedronate sodium 30 mg**
    - Risedronate sodium 30 mg tablets | 28 tablet [BNF] £132.17 DT price = £112.48
  - **Risedronate sodium 35 mg**
    - Risedronate sodium 35 mg tablets | 4 tablet [BNF] £19.12 DT price = £1.27
  - **Actonel (Warner Chilcott UK Ltd)**
    - **Risedronate sodium 5 mg**
      - Risedronate sodium 5 mg tablets | 28 tablet [BNF] £17.99 DT price = £14.95
    - **Risedronate sodium 30 mg**
      - Actonel 30 mg tablets | 28 tablet [BNF] £143.95 DT price = £112.48
    - **Risedronate sodium 35 mg**
      - Actonel Once a Week 35 mg tablets | 4 tablet [BNF] £19.12 DT price = £1.27
      - Actonel 35 mg tablets | 4 tablet [BNF] no price available DT price = £1.27

**Risedronate with calcium carbonate and colecalciferol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, calcium carbonate p. 856, colecalciferol p. 886, risedronate sodium above.
INDICATIONS AND DOSE

Sodium clodronate

Treat Osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma

Adult: 1.6 g daily in 1–2 divided doses, then increased if necessary up to 3.2 g daily in 2 divided doses

LORON 520®

Osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma

Adult: Initially 2 tablets daily in 1–2 divided doses, increased if necessary up to 4 tablets daily

CONTRA-INDICATIONS
Acute gastrointestinal inflammatory conditions

CAUTIONS
Atypical femoral fractures • maintain adequate fluid intake during treatment

INTERACTIONS → Appendix 1 (bisphosphonates).
Renal dysfunction reported in patients receiving concomitant NSAIDs.

SIDE-EFFECTS
Common or very common Bronchospasm • diarrhoea • nausea • skin reactions • vomiting
Rare Atypical femoral fractures
Very rare Osteonecrosis of the jaw
Frequency not known Renal impairment • uveitis
PREGNANCY Avoid.

BREAST FEEDING
Manufacturer advises avoid—no information available.

RENAL IMPAIRMENT
Max. initial dose 1200 mg daily if eGFR 30–50 mL/minute/1.73 m². Use half normal dose if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².

MONITORING REQUIREMENTS
Monitor renal function, serum calcium and serum phosphate before and during treatment.

Zoledronic acid

INDICATIONS AND DOSE

ZOMETA® INFUSION

Reduction of bone damage in advanced malignancies involving bone

BY INTRAVENOUS INFUSION

Adult: 4 mg every 3–4 weeks, to be administered over at least 15 minutes, calcium 500 mg daily and vitamin D 400 units daily should also be taken

Hypercalcaemia of malignancy

BY INTRAVENOUS INFUSION

Adult: 4 mg for 1 dose, to be administered over at least 15 minutes

ACLASTA®

Treatment of Paget’s disease of bone

BY INTRAVENOUS INFUSION

Adult: 5 mg 1 times yearly, to be administered over at least 15 minutes, at least 500 mg elemental calcium twice daily (with vitamin D) for at least 10 days is recommended following infusion

Treatment of postmenopausal osteoporosis and osteoporosis in men (including corticosteroid-induced osteoporosis)

BY INTRAVENOUS INFUSION

Adult: 5 mg 1 times yearly, to be administered over at least 15 minutes, in patients with a recent low-trauma hip fracture, the dose should be given 2 or more weeks following hip fracture repair; before first infusion give 50000–125000 units of vitamin D

CAUTIONS
Atypical femoral fractures • cardiac disease (avoid fluid overload) • concomitant medicines that affect renal function

INTERACTIONS → Appendix 1 (bisphosphonates).

SIDE-EFFECTS

Common or very common Anaemia • arthralgia • atrial fibrillation • bone pain • conjunctivitis • dizziness • fever • gastrointestinal disturbances • headache •
hypophosphataemia · influenza · like symptoms · myalgia · renal impairment · rigors

- **Uncommon** Angioedema · anorexia · anxiety · asthenia · blurred vision · chest pain · cough · dry mouth · dyspnoea · haematuria · hypersensitivity reactions · hypertension · hypokalaemia · hypomagnesaemia · hypotension · injection-site reactions · lethargy · leucopenia · muscle cramps · paraesthesia · peripheral oedema · proteinuria · pruritus · rash · sleep disturbance · stomatitis · sweating · taste disturbance · thrombocytopenia · tremor · urinary frequency · weight gain

- **Rare** Acute renal failure · atypical femoral fractures · bradycardia · confusion · hyperkalaemia · hypokalaemia · hypophosphataemia · osteonecrosis of the jaw · pancytopenia

- **Very rare** Episcleritis · uveitis

### SIDE-EFFECTS, FURTHER INFORMATION

**Renal function** Renal impairment and renal failure have been reported; ensure patient is hydrated before each dose and assess renal function.

- **CONCEPTION AND CONTRA-IndICATIONS** Contra-indicated in women of child-bearing potential.

- **PREGNANCY** Avoid—toxicity in animal studies.

- **BREAST FEEDING** Avoid—no information available.

- **HEPATIC IMPAIRMENT** Caution in severe hepatic impairment—limited information available.

- **RENAL IMPAIRMENT** In advanced malignancies involving bone, if eGFR 50–60 mL/minute/1.73 m² reduce dose to 3.5 mg every 3–4 weeks; if eGFR 40–50 mL/minute/1.73 m² reduce dose to 3.3 mg every 3–4 weeks; if eGFR 30–40 mL/minute/1.73 m² reduce dose to 3 mg every 3–4 weeks; if renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value. Avoid in tumour-induced hypercalcaemia if serum creatinine above 265 micromol/litre.

- **MONITORING REQUIREMENTS** Correct disturbances of calcium metabolism (e.g. vitamin D deficiency, hypocalcaemia) before starting. Monitor serum electrolytes, calcium, phosphate and magnesium.

- **Monitor renal function in patients at risk, such as those with pre-existing renal impairment, those of advanced age, those taking concomitant nephrotoxic drugs or diuretics, or those who are dehydrated.**

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Zometa®), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute requisite dose according to product literature; infuse over at least 15 minutes; administer as a single intravenous solution in a separate infusion line.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **Scottish Medicines Consortium (SMC) Decisions** The Scottish Medicines Consortium has advised (May 2002) that for the prevention of skeletal related events Zometa® is accepted for restricted use within NHS Scotland for the treatment of patients with breast cancer and multiple myeloma if prescribed by an oncologist.

  - **Scottish Medicines Consortium (SMC) Decisions** The Scottish Medicines Consortium has advised (February 2008) that in postmenopausal women Aclasta® is accepted for restricted use within the NHS Scotland for the treatment of osteoporosis in those for whom oral treatment options for osteoporosis are inappropriate and when initiated by a specialist.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Infusion

- **ZOLEDRONIC ACID (Non-proprietary)**
  - Zoledronic acid (as Zoledronic acid monohydrate) 40 microgram per 1 mL Zoledronic acid 4mg/100ml infusion bags | 1 bag (Pax) £174.14 (Hospital only) | 1 bag (Pax) £150.00
  - Zoledronic acid 4mg/100ml infusion bottles | 1 bottle (Pax) £165.00
  - Zoledronic acid (as Zoledronic acid monohydrate) 50 microgram per 1 mL Zoledronic acid 5mg/100ml infusion bags | 1 bag (Pax) £217.68
  - Aclasta (Novartis Pharmaceuticals UK Ltd) Zoledronic acid (as Zoledronic acid monohydrate) 50 microgram per 1 mL Aclasta 5mg/100ml infusion bottles | 1 bottle (Pax) £235.38
  - Zometa (Novartis Pharmaceuticals UK Ltd) Zoledronic acid (as Zoledronic acid monohydrate) 40 microgram per 1 mL Zometa 4mg/100ml infusion bottles | 1 bottle (Pax) £174.14

- **Brands may include Zerlinga**

#### Solution for infusion

- **ZOLEDRONIC ACID (Non-proprietary)**
  - Zoledronic acid (as Zoledronic acid monohydrate) 40 microgram per 1 mL Zoledronic acid 4mg/100ml solution for infusion vials | 1 vial (Pax) £174.14
  - Zoledronic acid (as Zoledronic acid monohydrate) 50 microgram per 1 mL Zoledronic acid 5mg/100ml solution for infusion vials | 1 vial (Pax) £215.37–£266.72
  - Zoledronic acid (as Zoledronic acid monohydrate) 800 microgram per 1 mL Zoledronic acid 4mg/5ml concentrate for solution for infusion vials | 1 vial (Pax) £174.14 (Hospital only) | 1 vial (Pax) £122.50–£174.17
  - Zoledronic acid 4mg/5ml solution for infusion vials | 1 vial (Pax) £85.63–£180.00
  - Zometa (Novartis Pharmaceuticals UK Ltd) Zoledronic acid (as Zoledronic acid monohydrate) 800 microgram per 1 mL Zometa 4mg/5ml solution for infusion vials | 1 vial (Pax) £174.17

### BONE FORMATION STIMULANTS

#### Strontium ranelate

- **DRUG ACTION** Stimulates bone formation and reduces bone resorption.

#### INDICATIONS AND DOSE

Treatment of severe osteoporosis in postmenopausal women or men at high risk of fracture for whom other treatments are contra-indicated or not tolerated (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: 2 g once daily, dose to be taken in water, preferably at bedtime

- **CONTRA-INDICATIONS** Cerebrovascular disease · current or previous venous thromboembolic event · ischaemic heart disease · peripheral arterial disease · temporary or prolonged immobilisation · uncontrolled hypertension

- **CAUTIONS** Predisposition to cardiovascular disease—assess risk before and every 6–12 months during treatment

- **INTERACTIONS** Appendix 1 (strontium ranelate).

#### SIDE-EFFECTS

- **Common or very common** Dermatitis · diarrhoea · eczema · headache · myocardial infarction · nausea · venous thromboembolism

- **Very rare** Angioedema · hypersensitivity reactions · pruritus · rash · urticaria

- **Frequency not known** Abdominal pain · alopecia · bone marrow suppression · constipation · dyspepsia · flatulence · gastro-oesophageal reflux · peripheral oedema · stomatitis · vomiting
SIDE-EFFECTS, FURTHER INFORMATION

Severe allergic reactions
Severe allergic reactions, including drug rash with eosinophilia and systemic symptoms (DRESS), have been reported in patients taking strontium ranelate. DRESS starts with rash, fever, swollen glands, and increased white cell count, and it can affect the liver, kidneys and lungs; DRESS can also be fatal. Treatment with strontium ranelate should not be restarted.

- **RENAIМ IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².
- **EFFECT ON LABORATORY TESTS** Interferes with colorimetric measurements of calcium in blood and urine.
- **DIRECTIONS FOR ADMINISTRATION** Avoid for 2 hours before and after taking granules, particularly calcium-containing products e.g. milk; also preferably avoid concomitant antacids containing aluminium and magnesium hydroxides for 2 hours after taking granules.
- **PATIENT AND CARER ADVICE** Severe allergic reactions Patients should be advised to stop taking strontium ranelate and consult their doctor immediately if skin rash develops. Patients or carers should be given advice on how to administer strontium ranelate granules.
- **NATIONAL FUNDING/ACCESS DECISIONS** NICE technology appraisals (TAs)
  - Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA160

**Strontium ranelate** is recommended as an alternative for women:
- in whom alendronate and risedronate are contra-indicated or not tolerated and
- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance. www.nice.org.uk/TA160

- Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA161

This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.

**Strontium ranelate** is recommended as an alternative for women:
- in whom alendronate and risedronate are contra-indicated or not tolerated and
- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance. www.nice.org.uk/TA161

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Granules**

| CAUTIONARY AND ADVISORY LABELS | 5, 13 |
| EXCipients: May contain Aspartame |

- Protelos (Servier Laboratories Ltd)
  - Strontium ranelate 2 gram Protelos 2g granules sachets (sugar-free) | 28 sachet [POT] £27.08 DT price = £27.08

**CALCITONINS**

**Calcitonin salmon** (Salcatonin)

**INDICATIONS AND DOSE**

- Hypercalcaemia of malignancy
  - **BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
    - Adult: 100 units every 6–8 hours (max. per dose 400 units every 6–8 hours), adjusted according to response
  - **BY INTRAVENOUS INFUSION**
    - Adult: Up to 10 units/kg, in severe or emergency cases, to be administered by slow intravenous infusion over at least 6 hours

- Paget’s disease of bone
  - **BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
    - Adult: Initially 100 units daily in 1–2 divided doses, then reduced to 50 units daily at the start of mobilisation, usual duration of treatment is 2 weeks; maximum 4 weeks

- **CONTRA-INDICATIONS** Hypocalcaemia
- **CAUTIONS** Heart failure - history of allergy (skin test advised) - risk of malignancy—avoid prolonged use (use lowest effective dose for shortest possible time)

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain - diarrhoea - dizziness - fatigue - flushing - headache - malignancy (with long-term use) - muscle-skeletal pain - nausea - taste disturbances - vomiting
- **Uncommon** Cough - hypersensitivity reactions - hypertension - injection-site reactions - oedema - polyuria - pruritus - rash - visual disturbances
- **Frequency not known** Tremor

- **PREGNANCY** Avoid unless potential benefit outweighs risk (toxicity in animal studies).
- **BREAST FEEDING** Avoid; inhibits lactation in animals.
- **RENAIМ IMPAIRMENT** Use with caution.

**DIRECTIONS FOR ADMINISTRATION**

- **For intravenous infusion** (Micalcic), give intermittently in Sodium chloride 0.9%. Diluted solution given without delay. Dilute in 500 mL, give over at least 6 hours; glass or hard plastic containers should not be used; some loss of potency on dilution and administration.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Micalcic (Novartis Pharmaceuticals UK Ltd)
  - Calcitonin (salmon) 50 unit per 1 ml Micalcic 50units/1ml solution for injection ampoules | 5 ampoule [POT] £17.10
  - Calcitonin (salmon) 100 unit per 1 ml Micalcic 100units/1ml solution for injection ampoules | 5 ampoule [POT] £34.21

- Calcitonin (salmon) 200 unit per 1 ml Micalcic 400units/2ml multidose solution for injection vials | 1 vial [POT] £24.60
**MONOCLONAL ANTIBODIES**

**Denosumab**

**DRUG ACTION** Denosumab is a human monoclonal antibody that inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption.

**INDICATIONS AND DOSE**

**XGEVA®**

Prevention of skeletal related events in patients with bone metastases from solid tumours

BY SUBCUTANEOUS INJECTION

- **Adult:** 120 mg every 4 weeks, supplementation of at least Calcium 500 mg and vitamin D 400 units daily should also be taken unless hypercalcaemia is present

Treatment of giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity in adults and skeletally mature adolescent

BY SUBCUTANEOUS INJECTION

- **Adult:** 120 mg every 4 weeks, give additional dose on days 8 and 15 of the first month of treatment only, supplementation of at least Calcium 500 mg and vitamin D 400 units daily should also be taken unless hypercalcaemia is present

**PROLIA®**

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures | Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures

BY SUBCUTANEOUS INJECTION

- **Adult:** 60 mg every 6 months, supplement with calcium and vitamin D

---

**Important safety information**

**MHRA/CHM ADVICE: DENOSUMAB: ATYPICAL FEMORAL FRACTURES (FEBRUARY 2013)**

Atypical femoral fractures have been reported rarely in patients receiving denosumab for the long-term treatment (2.5 or more years) of postmenopausal osteoporosis.

Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.

Discontinuation of denosumab in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.

**MHRA/CHM ADVICE: DENOSUMAB: MINIMISING THE RISK OF OSTEONECROSIS OF THE JAW; MONITORING FOR HYPOCALCAEMIA—UPDATED RECOMMENDATIONS (SEPTEMBER 2014)**

Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia.

**Osteonecrosis of the jaw**

Osteonecrosis of the jaw is a well-known and common side-effect in patients receiving denosumab 120 mg for cancer. Risk factors include smoking, old age, poor oral hygiene, invasive dental procedures (including tooth extractions, dental implants, oral surgery), comorbidity (including dental disease, anaemia, coagulopathy, infection), advanced cancer, previous treatment with bisphosphonates, and concomitant treatments (including chemotherapy, anti-angiogenic biologics, corticosteroids, and radiotherapy to head and neck).

The following precautions are now recommended to reduce the risk of ONJ:

- Denosumab 120 mg (cancer indication)
  - A dental examination and appropriate preventative dentistry before starting treatment are now recommended for all patients

- Do not start denosumab in patients with a dental or jaw condition requiring surgery, or in patients who have not recovered following oral surgery
- Check for ONJ risk factors before starting treatment. A dental examination and appropriate preventative dentistry are now recommended for patients with risk factors
- All patients should be informed to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.

**Hypocalcaemia**

Denosumab is associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment.

Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later in treatment.

Plasma-calcium concentration monitoring is recommended for denosumab 120 mg (cancer indication):

- before the first dose
- within two weeks after the initial dose
- if suspected symptoms of hypocalcaemia occur
- consider monitoring more frequently in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30 mL/minute)

Plasma-calcium concentration monitoring is recommended for denosumab 60 mg (osteoporosis indication):

- before each dose
- within two weeks after the initial dose in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30 mL/minute)
- if suspected symptoms of hypocalcaemia occur

All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).

**CONTRA-INDICATIONS** Hypocalcaemia

**CAUTIONS** Atypical femoral fractures • hypocalcaemia • osteonecrosis of the jaw—consider temporary interruption of treatment if occurs

**SIDE-EFFECTS**

- **Common or very common** Abdominal discomfort • constipation • diarrhoea • dysphoena • eczema
- hypocalcaemia (fatal cases reported) • hypophosphataemia • musculoskeletal pain • osteonecrosis of the jaw • pain in extremity • rash • sciatica • sweating • upper respiratory tract infection • urinary tract infection
- **Uncommon** Cellulitis (seek prompt medical attention) • diverticulitis • ear infection • skin infections (seek prompt medical attention)

**Rare** Atypical femoral fractures • osteonecrosis of the jaw

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception in women of child-bearing potential, during treatment and for at least 5 months after stopping treatment.

**PREGNANCY** Avoid—toxicity in animal studies; risk of toxicity increases with each trimester—advise women who become pregnant during treatment to enrol in the manufacturer’s Pregnancy Surveillance Programme (consult product literature).

**BREAST FEEDING** Avoid (if women do decide to breastfeed during treatment, they should enrol in the manufacturer’s Lactation Surveillance Programme—consult product literature).
PARATHYROID HORMONES AND ANALOGUES

Parathyroid hormone
(Human recombinant parathyroid hormone)

INDICATIONS AND DOSE
Treatment of osteoporosis in postmenopausal women at high risk of fractures (to reduce the risk of vertebral fractures)

BY SUBCUTANEOUS INJECTION

- Adult: 100 micrograms daily for maximum duration of treatment 24 months

CONTRA-INDICATIONS
- Hyperparathyroidism - metabolic bone disease - Paget’s disease - pre-existing hypercalcemia - previous radiation therapy to skeleton - unexplained raised levels of alkaline phosphatase
- CAUTIONS
  - Active urolithiasis - previous urolithiasis
- INTERACTIONS
  - Use with caution with concomitant cardiac glycosides.

SIDE-EFFECTS
- Common or very common
  - Asthenia - back pain - constipation - diarrhoea - dizziness - dyspepsia - fatigue - headache - hypercalcemia - injection-site reactions - muscle cramp - nausea - pain in extremities - palpitation - transient hypercalcemia - vomiting
- Uncommon
  - Abdominal pain - altered sense of smell - anorexia - hyperuricaemia - influenza - taste disturbance
- PREGNANCY
  - Avoid.
- BREAST FEEDING
  - Avoid.
- HEPATIC IMPAIRMENT
  - Avoid.
- RENAL IMPAIRMENT
  - Avoid if eGFR less than 30 mL/minute/1.73 m².
- MONITORING REQUIREMENTS
  - Monitor serum or urinary calcium concentration at 1, 3 and 6 months after initiation of treatment (consult product literature for guidance if serum-calcium concentration raised).
- PRESCRIBING AND DISPENSING INFORMATION
  - Preotact® cartridges are for use with Preotact® pen device.
- NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium, has advised (February 2007) that parathyroid hormone (Preotact®) should be initiated by specialists experienced in the treatment of osteoporosis.

MEDICINAL FORMS
Medicines not identified.

Teriparatide

INDICATIONS AND DOSE
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures | Treatment of corticosteroid-induced osteoporosis

BY SUBCUTANEOUS INJECTION

- Adult: 20 micrograms daily for maximum duration of treatment 24 months (course not to be repeated)

CONTRA-INDICATIONS
- Bone metastases
- hyperparathyroidism - metabolic bone diseases - Paget’s
Dopamine-responsive conditions

DOPAMINE RECEPTOR AGONISTS

Dopamine-receptor agonists

Bromocriptine p. 333 is used for the treatment of galactorrhoea, and for the treatment of prolactinomas (when it reduces both plasma prolactin concentration and tumour size). Bromocriptine also inhibits the release of growth hormone and is sometimes used in the treatment of acromegaly, but somatostatin analogues (such as octreotide p. 789) are more effective.

Cabergoline p. 334 has similar side-effects to bromocriptine, however patients intolerant of bromocriptine may be able to tolerate cabergoline (and vice versa).

Quinagolide has actions and uses similar to those of ergot-derived dopamine agonists, but its side-effects differ slightly.

Suppression of lactation

Although bromocriptine and cabergoline are licensed to suppress lactation, they are not recommended for routine suppression (or for the relief of symptoms of postpartum pain and engorgement) that can be adequately treated with simple analgesics and breast support. If a dopamine-receptor agonist is required, cabergoline is preferred. Quinagolide is not licensed for the suppression of lactation.

Drugs used for Dopamine responsive conditions not listed below: Bromocriptine, p. 333 - Cabergoline, p. 334

Quinagolide

- **DRUG ACTION** Quinagolide is a non-ergot dopamine D₂ agonist.

**INDICATIONS AND DOSE**

Hyperprolactinaemia

**BY MOUTH**

- Adult: Initially 25 micrograms daily for 3 days, dose to be taken at bedtime, increased in steps of 25 micrograms every 3 days; usual dose 75–150 micrograms daily, for doses higher than 300 micrograms daily increase in steps of 75–150 micrograms at intervals of not less than 4 weeks

- **UNLICENSED USE** Not licensed for the suppression of lactation.

- **CAUTIONS** Acute porphyrias.

- **CAUTIONS, FURTHER INFORMATION**

Hyperprolactinaemic patients In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment).

- **INTERACTIONS** Appendix 1 (quinagolide).

- **SIDE-EFFECTS**

  - **Common or very common** Abdominal pain - anorexia - constipation or diarrhoea - dizziness - fatigue - flushing - headache - hypotension - insomnia - nasal congestion - nausea - oedema - syncope - vomiting

  - **Very rare** Psychosis

  - **SIDE-EFFECTS, FURTHER INFORMATION**

Gastro-intestinal bleeding Treatment should be withdrawn if gastro-intestinal bleeding occurs.

- **ALLERGY AND CROSS-SENSITIVITY** Quinagolide should not be used in patients with hypersensitivity to quinagolide (does not apply to hypersensitivity to ergot alkaloids).

- **CONCEPTION AND CONTRACEPTION** Advise non-hormonal contraception if pregnancy not desired.

- **PREGNANCY** Discontinue when pregnancy confirmed unless medical reason for continuing (specialist advice needed).

- **BREAST FEEDING** Supresses lactation.

- **HEPATIC IMPAIRMENT** Avoid—no information available.
**6 Gonadotrophin responsive conditions**

**Gonadotrophins**

**Drugs affecting gonadotrophins**

Danazol p. 636 is licensed for the treatment of endometriosis and for the relief of severe pain and tenderness in benign fibrocystic breast disease where other measures have proved unsatisfactory. It may also be effective in the long-term management of hereditary angioedema [unlicensed indication].

Cetrorelix p. 636 and ganirelix p. 636 are luteinisin hormone releasing hormone antagonists, which inhibit the release of gonadotrophins (luteinizin hormone and follicle stimulating hormone). They are used in the treatment of infertility by assisted reproductive techniques.

**Gonadorelin analogues**

Gonadorelin analogues are used in the treatment of endometriosis, precocious puberty, infertility, male hyposexualitly with severe sexual deviation, anaemia due to endometriosis, precocious puberty, infertility, male

**MONITORING REQUIREMENTS**

Monitor blood pressure for a few days after starting treatment and following dosage increase.

**PATIENT AND CARER ADVICE**

Sudden onset of sleep Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.

Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or comitant medication. Patients should be counselled on improving sleep behavour.

**Hypotensive reactions** Hypotensive reactions can be disturbing in some patients during the first few days of treatment with dopamine-receptor agonists, particular care should be exercised when driving or operating machinery.

**RENAL IMPAIRMENT** Avoid—no information available.

**DRUG ACTION**

Administration of gonadorelin analogues produces a initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which ultimately lead to inhibition of androgen and oestrogen production.

**INDICATIONS AND DOSE**

**Endometriosis**

**BY INTRANASAL ADMINISTRATION**

- Adult: 300 micrograms 3 times a day maximum duration of treatment 6 months (do not repeat), to be started on days 1 or 2 of menstruation; administer one 150 microgram spray into each nostril

**Pituitary desensitisation before induction of ovulation by gonadotrophins for in vitro fertilisation (under expert supervision)**

**BY SUBCUTANEOUS INJECTION**

- Adult: 200–500 micrograms once daily, increased if necessary up to 500 micrograms twice daily, starting in early follicular phase (day 1) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down-regulation achieved (usually 1–3 weeks) then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of chorionic gonadotrophin at appropriate stage of follicular development)

**BY INTRANASAL ADMINISTRATION**

- Adult: 150–300 micrograms 4 times a day, (150 micrograms equivalent to one spray), to be administered during waking hours. Start in early follicular phase (day 1) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down-regulation achieved (usually about 2–3 weeks) then maintained during gonadotrophin administration (stopping continued
gonadotrophin responsive conditions

Advanced prostate cancer

INITIALLY BY SUBCUTANEOUS INJECTION

- Adult: 500 micrograms every 8 hours for 7 days, then (by intranasal administration) 200 micrograms 6 times a day, (a single 100 microgram spray to be administered into each nostril)

CONTRA-INDICATIONS

- When used for endometriosis Hormone dependent tumours - undiagnosed vaginal bleeding - use longer than 6 months (do not repeat)
- When used for pituitary desensitisation Hormone dependent tumours - undiagnosed vaginal bleeding

CAUTIONS

Depression - diabetes - hypertension - patients with metabolic bone disease (decrease in bone mineral density can occur) - polycystic ovarian disease

SIDE-EFFECTS

GENERAL SIDE-EFFECTS


SPECIFIC SIDE-EFFECTS

With intranasal use Altered sense of taste and smell - nasal irritation - nose bleeds

SIDE-EFFECTS, FURTHER INFORMATION

When used for Advanced prostate Cancer

Tumour flare During the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain. When such problems are anticipated, alternative treatments (e.g. orchidectomy) or concomitant use of an anti-androgen such as cyprotorexin acetate or flutamide are recommended; anti-androgen treatment should be started before the gonadorelin analogue.

CONCEPTION AND CONTRACEPTION

Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

PREGNANCY

Avoid.

BREAST FEEDING

Avoid.

DIRECTIONS FOR ADMINISTRATION

With intranasal use Avoid use of nasal decongestants before and for at least 30 minutes after treatment.

With subcutaneous use Rotate injection site to prevent atrophy and nodule formation.

PATIENT AND CARER ADVICE

Patients or carers should be given advice on how to administer buserelin nasal spray.

MATERIAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Suprecur (Sanofi) Buserelin (as Buserelin acetate) 1 mg per 1 ml Suprecur 5.5mg/5.5ml solution for injection vials | 2 vial £27.52
- Suprefact (Sanofi) Buserelin (as Buserelin acetate) 1 mg per 1 ml Suprefact 5.5mg/5.5ml solution for injection vials | 2 vial £28.64
- Spray

- Suprecur (Sanofi) Buserelin (as Buserelin acetate) 150 microgram per 1 dose Suprecur 150micrograms/dose nasal spray | 168 dose £87.63
- Suprefact (Sanofi) Buserelin (as Buserelin acetate) 100 microgram per 1 dose Suprefact 100micrograms/dose nasal spray | 336 dose £101.87

Goserelin

DRUG ACTION

Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

INDICATIONS AND DOSE

ZOLADEX®

Locally advanced prostate cancer as an alternative to surgical castration | Adjutant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Metastatic prostate cancer | Advanced breast cancer | Oestrogen-receptor-positive early breast cancer

BY SUBCUTANEOUS INJECTION

- Adult: 3.6 mg every 28 days, to be administered into the anterior abdominal wall

Endometriosis

BY SUBCUTANEOUS INJECTION

- Adult: 3.6 mg every 28 days maximum duration of treatment 6 months (do not repeat), to be administered into the anterior abdominal wall

Endometrial thinning before intra-uterine surgery

BY SUBCUTANEOUS INJECTION

- Adult: 3.6 mg, dose may be repeated after 28 days if uterus is large or to allow flexible surgical timing, to be administered into the anterior abdominal wall

Before surgery in women who have anaemia due to uterine fibroids

BY SUBCUTANEOUS INJECTION

- Adult: 3.6 mg every 28 days maximum duration of treatment 3 months, to be given with supplementary iron, to be administered into the anterior abdominal wall

Pituitary desensitisation before induction of ovulation by gonadotrophins for in vitro fertilisation (after exclusion of pregnancy) (under expert supervision)

BY SUBCUTANEOUS INJECTION

- Adult: 3.6 mg, dose given to achieve pituitary down-regulation (usually 1–3 weeks) then gonadotrophin is administered (stopping gonadotrophin on
Gonadotrophin responsive conditions

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Implant**

- Zoladex (AstraZeneca UK Ltd) 3.6 mg
- Zoladex 3.6 mg implant Safesystem pre-filled syringes | 1 pre-filled disposable injection (£55.00 DT price = £55.00)
- Zoladex LA (AstraZeneca UK Ltd) 10.8 mg
- Zoladex LA 10.8 mg implant Safesystem pre-filled syringes | 1 pre-filled disposable injection (£235.00 DT price = £235.00)

**Leuprolin acetate**

**DRUG ACTION** Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

**INDICATIONS AND DOSE**

**PROSTAP 3 DCS**

**Endometriosis**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 11.25 mg for 1 dose, dose to be given as a single dose in first 5 days of menstrual cycle, then 11.25 mg every 3 months for maximum 6 months (course not to be repeated)

**Locally advanced prostate cancer as an alternative to surgical castration**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 10.8 mg every 12 weeks, to be administered into the anterior abdominal wall

**INDICATIONS AND DOSE**

**PROSTAP SR DCS**

**Endometriosis**

- **BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 3.75 mg for 1 dose, dose to be given as a single dose in first 5 days of menstrual cycle, then 3.75 mg every 1 month for maximum 6 months (course not to be repeated)

**Locally advanced prostate cancer as an alternative to surgical castration**

- **BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 3.75 mg every 1 month usually for 3–4 months (maximum 6 months)

**Locally advanced prostate cancer as an alternative to surgical castration**

- **BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
  - Adult: 3.75 mg every 1 month

**CONTRA-INDICATIONS**

**GENERAL CONTRA-INDICATIONS**

- Undiagnosed vaginal bleeding

**SPECIFIC CONTRA-INDICATIONS**

- When used for endometriosis Use longer than 6 months (do not repeat)
DIRECTIONS FOR ADMINISTRATION

Men at risk of tumour

BREAST FEEDING

When used for prostate cancer

Tumour flare In prostate cancer, during the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain. When such problems are anticipated, alternative treatments (e.g. orchidectomy) or concomitant use of an anti-androgen such as cyproterone acetate or flutamide are recommended; anti-androgen treatment should be started before the gonadorelin analogue.

CONCEPTION AND CONTRACEPTION Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

PREGNANCY Avoid—teratogenic in animal studies.

BREAST FEEDING Avoid.

MONITORING REQUIREMENTS

Monitor liver function.

Men at risk of tumour ‘flare’ should be monitored closely during the first month of therapy.

DIRECTIONS FOR ADMINISTRATION Rotate injection site to prevent atrophy and nodule formation.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for suspension for injection

Prostap 3 DCS (Takeda UK Ltd)

Leuprorelin acetate 11.25 mg Prostap 3 DCS 11.25mg powder and solvent for suspension for injection pre-filled syringes | 1 pre-filled disposable injection £225.72 DT price = £225.72

Prostap SR DCS (Takeda UK Ltd)

Leuprorelin acetate 3.75 mg Prostap SR DCS 3.75mg powder and solvent for suspension for injection pre-filled syringes | 1 pre-filled disposable injection £75.24 DT price = £75.24

Nafarelin

DRUG ACTION Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

INDICATIONS AND DOSE

Endometriosis

BY INTRANASAL ADMINISTRATION

Adult: 200 micrograms twice daily for maximum 6 months (do not repeat), one spray in one nostril in the morning, and one spray in the other nostril in the evening (starting on days 2–4 of menstruation).

Pituitary desensitisation before induction of ovulation by gonadotrophins for in vitro fertilisation (under expert supervision)

BY INTRANASAL ADMINISTRATION

Adult: 400 micrograms twice daily, one spray in each nostril, to be started in early follicular phase (day 2) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down regulation achieved (usually within 4 weeks) then maintained (usually for 8–12 days) during gonadotrophin administration (stopping gonadotrophin and nafarelin on administration of choric gonadotropin at follicular maturity), discontinue if down-regulation not achieved within 12 weeks

CONTRA-INDICATIONS Undiagnosed vaginal bleeding - use longer than 6 months in the treatment of endometriosis (do not repeat)

CAUTIONS Patients with metabolic bone disease (decrease in bone mineral density can occur)


SIDE-EFFECTS, FURTHER INFORMATION

- When used for prostate cancer

Tumour flare In prostate cancer, during the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain. When such problems are anticipated, alternative treatments (e.g. orchidectomy) or concomitant use of an anti-androgen such as cyproterone acetate or flutamide are recommended; anti-androgen treatment should be started before the gonadorelin analogue.

CONCESSION AND CONTRACEPTION Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

PREGNANCY Avoid—teratogenic in animal studies.

BREAST FEEDING Avoid.

MONITORING REQUIREMENTS

Monitor liver function.

Men at risk of tumour ‘flare’ should be monitored closely during the first month of therapy.

DIRECTIONS FOR ADMINISTRATION Rotate injection site to prevent atrophy and nodule formation.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for suspension for injection

Leuprorelin acetate 11.25 mg Prostap 3 DCS 11.25mg powder and solvent for suspension for injection pre-filled syringes | 1 pre-filled disposable injection £225.72 DT price = £225.72

Leuprorelin acetate 3.75 mg Prostap SR DCS 3.75mg powder and solvent for suspension for injection pre-filled syringes | 1 pre-filled disposable injection £75.24 DT price = £75.24

Spray

CAUTIONARY AND ADVISORY LABELS

Synarel (Pfizer Ltd)

Nafarelin (as Nafarelin acetate) 200 microgram per 1 dose Synarel 200micrograms/dose nasal spray | 60 dose £52.43

Spray

CAUTIONARY AND ADVISORY LABELS

10

Synarel (Pfizer Ltd)

Nafarelin (as Nafarelin acetate) 200 microgram per 1 dose Synarel 200micrograms/dose nasal spray | 60 dose £52.43
Triptorelin

**DRUG ACTION** Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

**INDICATIONS AND DOSE**

### DECAPEPTYL® SR 3MG

**Endometriosis**

**BY INTRAMUSCULAR INJECTION**

- Adult: 3 mg every 4 weeks for at least 3 months, maximum duration of treatment 6 months (not to be repeated), to be started during first 5 days of menstrual cycle

**Reduction in size of fibroids**

**BY INTRAMUSCULAR INJECTION**

- Adult: 3 mg every 4 weeks for at least 3 months, maximum duration of treatment 6 months (not to be repeated), to be started during first 5 days of menstrual cycle

**Locally advanced non-metastatic prostate cancer as an alternative to surgical castration** | **Metastatic prostate cancer** | **Adjuvant treatment to radiotherapy in high-risk localised or locally advanced prostate cancer** | **Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer** | **Adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression**

**BY INTRAMUSCULAR INJECTION**

- Adult: 3 mg every 4 weeks

### DECAPEPTYL® SR 11.25MG

**Endometriosis**

**BY INTRAMUSCULAR INJECTION**

- Adult: 11.25 mg every 3 months for maximum 6 months (not to be repeated), to be started during first 5 days of menstrual cycle

**Locally advanced non-metastatic prostate cancer as an alternative to surgical castration** | **Metastatic prostate cancer** | **Adjuvant treatment to radiotherapy in high-risk localised or locally advanced prostate cancer** | **Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer** | **Adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression**

**BY INTRAMUSCULAR INJECTION**

- Adult: 11.25 mg every 3 months

### DECAPEPTYL® SR 22.5MG

**Locally advanced non-metastatic prostate cancer as an alternative to surgical castration** | **Metastatic prostate cancer** | **Adjuvant treatment to radiotherapy in high-risk localised or locally advanced prostate cancer** | **Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer** | **Adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression**

**BY INTRAMUSCULAR INJECTION**

- Adult: 22.5 mg every 6 months

**SALVACYL®**

**Male hypersexuality with severe sexual deviation**

**BY INTRAMUSCULAR INJECTION**

- Adult: 11.25 mg every 12 weeks

---

**GONAPEPTYL DEPOT®**

**Endometriosis | Reduction in size of fibroids**

**BY SUBCUTANEOUS INJECTION OR BY DEEP INTRAMUSCULAR INJECTION**

- Adult: 3.75 mg every 4 weeks maximum duration of 6 months (not to be repeated), to be started during first 5 days of menstrual cycle

**Advanced prostate cancer**

**BY SUBCUTANEOUS INJECTION OR BY DEEP INTRAMUSCULAR INJECTION**

- Adult: 3.75 mg every 4 weeks

**CONTRA-INDICATIONS** In endometriosis do not use for longer than 6 months (do not repeat) - undiagnosed vaginal bleeding

**SALVACYL®** Severe osteoporosis

**CAUTIONS**

**GENERAL CAUTIONS**

Patients with metabolic bone disease (decrease in bone mineral density can occur)

**SPECIFIC CAUTIONS**

- When used for prostate cancer risk factors for osteoporosis - risk of spinal cord compression in men - risk of ureteric obstruction in men

**SALVACYL®** Increased risk of sensitivity to restored testosterone if treatment interrupted—consider administration of an antiandrogen before stopping treatment - transient increase in serum testosterone occurs on initiation—consider administration of an antiandrogen

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

Anaphylaxis - arthralgia - asthenia - asthma - breast tenderness (males and females) - changes in blood pressure - changes in breast size - changes in scalp and body hair - depression - gastro-intestinal disturbances - headache - hot flushes - hypersensitivity reactions - increased sweating - local reactions at injection site - mood changes - ovarian cysts (may require withdrawal) - paraesthesia - pruritus - rash - urticaria - visual disturbances - weight changes

**SPECIFIC SIDE-EFFECTS**

- When used for prostate cancer Dizziness - dry mouth - hair loss - increased dysuria - myalgia - peripheral oedema - sexual dysfunction - sleep disorders

- When used for reduction in size of uterine fibroids Bleeding associated with fibroid degeneration - decrease in trabecular bone density - dyspareunia - loss of libido - menopausal-like symptoms - migraine - musculoskeletal pain - musculoskeletal weakness - oedema of the face and extremities - palpitation - vaginal dryness - withdrawal bleeding (may occur in the first month of treatment)

- When used for endometriosis Decrease in trabecular bone density - dyspareunia - loss of libido - menopausal-like symptoms - migraine - musculoskeletal pain - musculoskeletal weakness - oedema of the face and extremities - palpitation - vaginal dryness - withdrawal bleeding (may occur in the first month of treatment)

- When used for endometriosis Décrease in trabecular bone density - dyspareunia - loss of libido - menopausal-like symptoms - migraine - musculoskeletal pain - musculoskeletal weakness - oedema of the face and extremities - palpitation

- When used for gonadotrophin-dependent precocious puberty Decrease in trabecular bone density - dyspareunia - loss of libido - menopausal-like symptoms - migraine - musculoskeletal pain - musculoskeletal weakness - oedema of the face and extremities - palpitation - vaginal dryness - withdrawal bleeding (may occur in the first month of treatment)
**Cetrorelix**

- **INDICATIONS AND DOSE**
  - Adjuvant in the treatment of female infertility (under expert supervision)

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 250 micrograms daily, dose to be injected preferably into the upper leg (rotate injection sites to prevent lipoatrophy), dose to be administered in the morning (or each afternoon) starting on day 5 or day 6 of ovarian stimulation with gonadotrophins, continue throughout administration of gonadotrophins including day of ovulation induction (if administering in afternoon, give last dose in afternoon before ovulation induction)

- **SIDE-EFFECTS**
  - Very rare: Facial oedema, hypersensitivity reactions, rash
  - Frequency not known: Dyspnoea, headache, injection-site reactions, malaise, nausea

- **PREGNANCY**
  - Avoid in confirmed pregnancy—tocicity in animal studies.

- **BREAST FEEDING**
  - Avoid—no information available.

- **HEPATIC IMPAIRMENT**
  - Avoid in moderate or severe hepatic impairment.

- **RENAI IMPAIRMENT**
  - Avoid in moderate to severe renal impairment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug

- **Powder and solvent for solution for injection**
  - Cetrorelix (as Cetrorelix acetate) 250 microgram

- **Solution for injection**
  - Ganirelix 500 microgram per 1 ml

**Gonadotrophin-responsive conditions**

**SIDE-EFFECTS, FURTHER INFORMATION**

- When used for prostate cancer
  - Tumour flare in prostate cancer: During the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain. When such problems are anticipated, alternative treatments (e.g. orchidectomy) or concomitant use of an anti-androgen such as cyproterone acetate or flutamide are recommended; anti-androgen should be started before the gonadorelin analogue.

- **CONCEPTION AND CONTRACEPTION**
  - Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

- **PREGNANCY**
  - Avoid.

- **BREAST FEEDING**
  - Avoid.

- **MONITORING REQUIREMENTS**
  - When used for prostate cancer: Men at risk of tumour ‘flare’ should be monitored closely during the first month of therapy.

- **DIRECTIONS FOR ADMINISTRATION**
  - Rotate injection site to prevent atrophy and nodule formation.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - **DECAPTEYL® PREPARATIONS**
    - Each strength of vial includes an overage to allow accurate administration of the required dose.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Powder and solvent for suspension for injection**
  - Decapeptyl SR
    - Triptorelin (as Triptorelin acetate) 3 mg
      - Decapeptyl SR 3mg powder and solvent for suspension for injection vials | 1 vial (£22.61)
      - £69.00
    - Triptorelin (as Triptorelin acetate) 11.25 mg
      - Decapeptyl SR 11.25mg powder and solvent for suspension for injection vials | 1 vial (£22.61)
      - £207.00
    - Triptorelin (as Triptorelin embonate) 22.5 mg
      - Decapeptyl SR 22.5mg powder and solvent for suspension for injection vials | 1 vial (£22.61)
      - £414.00
    - Gonapeteryl Depot
      - Triptorelin (as Triptorelin acetate) 3.75 mg
        - Gonapeteryl Depot 3.75mg powder and solvent for suspension for injection pre-filled disposable devices | 1 pre-filled disposable injection (£22.61)
        - £81.69
    - Salvacyl
      - Triptorelin (as Triptorelin embonate) 11.25 mg
        - Salvacyl 11.25mg powder and solvent for suspension for injection vials | 1 vial (£22.61)
        - £248.00

**GONADOTROPHIN-RELEASING HORMONE ANTAGONISTS**

**Cetrorelix**

- **INDICATIONS AND DOSE**
  - Adjuvant in the treatment of female infertility (initiated under specialist supervision)

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 250 micrograms once daily, dose to be administered in the morning, starting on day 5 or 6 of ovarian stimulation with gonadotrophins (or each evening starting on day 5 of ovarian stimulation), continue throughout administration of gonadotrophin including day of ovulation induction (or evening before ovulation induction), dose to be injected into the lower abdominal wall.

  **SIDE-EFFECTS**
  - Common or very common: Headache, injection site reactions, nausea
  - Rare: Hypersensitivity reactions

  **PREGNANCY**
  - Avoid in confirmed pregnancy.

  **BREAST FEEDING**
  - Avoid.

  **HEPATIC IMPAIRMENT**
  - Avoid in moderate or severe liver impairment.

  **RENAI IMPAIRMENT**
  - Avoid in moderate or severe renal impairment.

**Medicinal forms**

- There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- Cetrorelix (as Cetrorelix acetate) 250 microgram
  - Cetrotide (Merck Serono Ltd)
  - 250 microgram powder and solvent for solution for injection vials | 1 vial (£22.61) | 7 vial (£158.26)

**Ganirelix**

- **INDICATIONS AND DOSE**
  - Adjunct in the treatment of female infertility (under expert supervision)

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 250 micrograms daily, to be injected preferably into the upper leg (rotate injection sites to prevent lipoatrophy, dose to be administered in the morning (or each afternoon) starting on day 5 or day 6 of ovarian stimulation with gonadotrophins, continue throughout administration of gonadotrophins including day of ovulation induction (if administering in afternoon, give last dose in afternoon before ovulation induction)

  **SIDE-EFFECTS**
  - Very rare: Facial oedema, hypersensitivity reactions, rash
  - Frequency not known: Dyspnoea, headache, injection-site reactions, malaise, nausea

  **PREGNANCY**
  - Avoid in confirmed pregnancy—tocicity in animal studies.

  **BREAST FEEDING**
  - Avoid—no information available.

  **HEPATIC IMPAIRMENT**
  - Avoid in moderate or severe hepatic impairment.

  **RENAI IMPAIRMENT**
  - Avoid in moderate to severe renal impairment.

**Medicinal forms**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Orgalutran (Merck Sharp & Dohme Ltd)
  - Ganirelix 500 microgram per 1 ml
  - Orgalutran 250 micrograms/0.5 ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (£22.61)
  - £21.48

**6.1 Hereditary angioedema**

**GONADOTROPHIN-RELEASING HORMONE ANTAGONISTS**

**Danazol**

- **DRUG ACTION**
  - Danazol inhibits pituitary gonadotrophins; it combines androgenic activity with antiestrogenic and antiprogesteronic activity.
**INDICATIONS AND DOSE**

**Endometriosis**

**BY MOUTH**

- Adult: 200–800 mg daily in up to 4 divided doses usually for 3–6 months, dose to be adjusted to achieve amenorrhoea, in women of child-bearing potential, treatment should start during menstruation, preferably on day 1.

Severe pain and tenderness in benign fibrocystic breast disease not responding to other treatment

**BY MOUTH**

- Adult: 300 mg daily in divided doses usually for 3–6 months, in women of child-bearing potential, treatment should start during menstruation, preferably on day 1.

**Hereditary angiodema**

**BY MOUTH**

- Adult: Initially 100–200 mg daily, dose to be reduced according to response, in women of child-bearing potential, treatment should start during menstruation, preferably on day 1.

**SIDE-EFFECTS**

- Rare Benign hepatic adenomata · cholestatic jaundice · clitoral hypertrophy · pancreatitis · polycystic ovaries

**Frequency not known**

- Acne · androgenic effects · anxiety · backache · changes in libido · dizziness · eosinophilia · epigastric pain · exfoliative dermatitis · fatigue · fever · flushing and reduction in breast size · hair loss · headache · headache (may indicate benign intracranial hypertension) · hirsutism · insulin resistance · joint pain · joint swelling · leucopenia · menstrual disturbances · mood changes · musculo-skeletal spasm · nausea · nervousness · oedema · oily skin · pleuritic pain · rashes · reversible erythrocytosis · reversible polycythaemia · skin reactions · temporary alteration in lipoproteins and other metabolic changes · thrombocytopenia · thrombotic events · vaginal dryness · vaginal irritation · vertigo · visual disturbances (may indicate benign intracranial hypertension) · voice changes · weight gain

**SIDE-EFFECTS, FURTHER INFORMATION**

**Viralisation** Withdraw if viralisation effects occur—may be irreversible on continued use.

**CONCEPTION AND CONTRACEPTION** Ensure patients with amenorrhoea are not pregnant. Non-hormonal contraceptive methods should be used, if appropriate.

**PREGNANCY** Avoid; has weak androgenic effects and virilisation of female fetus reported.

**BREAST FEEDING** No data available but avoid because of possible androgenic effects in infant.

**HEPATIC IMPAIRMENT** Caution in hepatic impairment (avoid if severe).

**RENAL IMPAIRMENT** Caution in renal impairment (avoid if severe).

**UNLICENSED USE** Not licensed for use in hereditary angioedema.

**CONTRA-INDICATIONS** Acute porphyrias p. 864 · androgen-dependent tumours · thromboembolic disease · undiagnosed genital bleeding

**CAUTIONS** Cardiac impairment (avoid if severe) · diabetes mellitus · elderly · epilepsy · history of thrombosis or thromboembolic disease · hypertension · lipoprotein disorder · migraine · polycythaemia

**INTERACTIONS** → Appendix 1 (danazol).

**7 Hypothalamic and anterior pituitary hormone related disorders**

**Hypothalamic and anterior pituitary hormones**

**Anterior pituitary hormones**

Tetracosactide (tetracosactrin), an analogue of corticotropin (ACTH), is used to test adrenocortical function; failure of the plasma cortisol concentration to rise after administration of tetracosactide indicates adrenocortical insufficiency.

Both corticotropin and tetracosactide were formerly used as alternatives to corticosteroids in conditions such as Crohn’s disease or rheumatoid arthritis; their value was limited by the variable and unpredictable therapeutic response and by the waning of their effect with time.

**Gonadotrophins**

Follicle-stimulating hormone (FSH) and luteinising hormone (LH) together, follicle-stimulating hormone alone (as in follicitropin), or chorionic gonadotrophin p. 639, are used in the treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene citrate p. 659, or in superovulation treatment for assisted conception (such as in vitro fertilisation).

The gonadotrophins are also occasionally used in the treatment of hypogonadotropic hypogonadism and associated oligospernia. There is no justification for their use in primary gonadal failure.

Chorionic gonadotrophin has also been used in delayed puberty in the male to stimulate endogenous testosterone production, but has little advantage over testosterone.

**Growth hormone**

Growth hormone is used to treat deficiency of the hormone in children and in adults. In children it is used in Prader-Willi syndrome, Turner syndrome, chronic renal insufficiency, short children considered small for gestational age at birth, and short stature homeobox-containing gene (SHOX) deficiency.

Growth hormone of human origin (HGH; somatotrophin) has been replaced by a growth hormone of human DNA sequence, somatropin p. 642, produced using recombinant DNA technology.

Mecasermin, a human insulin-like growth factor-1 (rhIGF-I), is licensed to treat growth failure in children and adolescents with severe primary insulin-like growth factor-I deficiency.

**Hypothalamic hormones**

Gonadorelin p. 639 when injected intravenously in normal subjects leads to a rapid rise in plasma concentrations of both luteinising hormone (LH) and follicle-stimulating...
hormone (FSH). It has not proved to be very helpful, however, in distinguishing hypothalamic pituitary lesions. Gonadorelin analogues are indicated in endometriosis and infertility and in breast and prostate cancer.

## 7.1 Adrenocortical function testing

### CORTICOTROPHINS

#### Tetracosactide

*(Tetracosactrin)*

**INDICATIONS AND DOSE**

- **Diagnosis of adrenocortical insufficiency (diagnostic 30-minute test)**
  - By intravenous injection or by intramuscular injection
    - Adult: 250 micrograms for 1 dose
  - Diagnosis of adrenocortical insufficiency (diagnostic 5-hour test)
    - By intramuscular injection using depot injection
      - Adult: 1 mg for 1 dose

#### Alternative to corticosteroids in conditions such as Crohn's disease or rheumatoid arthritis (formerly used but value was limited by the variable and unpredictable therapeutic response and by the waning of effect with time)

- **INITIALLY BY INTRAMUSCULAR INJECTION USING DEPOT INJECTION**
  - Adult: Initially 1 mg daily, alternatively (by intramuscular injection) initially 1 mg every 12 hours, (in acute cases), then (by intramuscular injection) reduced to 1 mg every 2–3 days, followed by (by intramuscular injection) 1 mg once weekly, alternatively (by intramuscular injection) 500 micrograms every 2–3 days

#### SIDE-EFFECTS

- Abdominal distention • abscess • acne • anaphylactic shock • angioneurotic oedema • aseptic necrosis of femoral and humeral heads • benign intracranial pressure increased with papilloedema • calcium deficiency • cardiac disorders • convulsions • Cushing's syndrome • decreased carbohydrate tolerance • dizziness • dyspepsia • ecchymosis • erythema • euphoria • fluid retention • flushing • glaucoma • growth retardation • headache • hirsutism • hyperglycaemia • hyperhidrosis • hypersensitivity reactions (tend to be more severe in patients susceptible to allergies, especially asthma) • hypertension • hypokalaemia • hypokalaemic alkalosis • impaired healing • increased appetite • increased intraocular pressure • infection susceptibility increased • insomnia • irregular menstruation • leukocytosis • malaise • manifestations of latent diabetes mellitus • mood swings • muscle atrophy • muscular weakness • myopathy • nausea • necrotising vasculitis • negative nitrogen balance • osteoporosis • pancreatitis • pathological fracture of long bones • peptic ulcer • personality changes • petechiae • posterior subcapsular cataracts • pruritis • psychotic manifestations • Quincke’s oedema • secondary adrenocortical unresponsiveness • secondary pituitary unresponsiveness • severe depression • skin atrophy • skin hyperpigmentation • skin reactions at injection site • sodium retention • spinal compression fractures • tendon rupture • thromboembolism • ulcerative oesophagitis • uticaria • vertigo • vomiting • weight increase

#### ALLERGY AND CROSS-SENSITIVITY

- Contraindicated in patients with history of hypersensitivity to tetracosactide/corticotrophins or excipients.
- **PREGNANCY** Avoid (but may be used diagnostically if essential).
- **BREAST FEEDING** Avoid (but may be used diagnostically if essential).
- **HEPATIC IMPAIRMENT** An enhanced effect of tetracosactide therapy may occur in patients with cirrhosis of the liver. Use with caution in hepatic impairment. Monitor hepatic function closely during treatment.
- **RENAL IMPAIRMENT** Use with caution in patients with renal impairment.
- **EFFECT ON LABORATORY TESTS** May suppress skin test reactions. Post administration total plasma cortisol levels during 30-minute test for diagnosis of adrenocortical insufficiency might be misleading due to altered cortisol binding globulin levels in some special clinical situations including, patients on oral contraceptives, post-operative patients, critical illness, severe liver disease and nephrotic syndrome.
- **MEDICINAL FORMS**

- **Tetracosactide acetate 1 mg per 1 ml** Synacthen 250 micrograms/1ml solution for injection ampoules | 5 ampoule £30.00
- **Tetracosactide acetate 1 mg per 1 ml** Synacthen Depot 1mg/1ml suspension for injection ampoules | 10 ampoule £41.83

### Contra-Indications

- Acute psychosis • adrenogenital syndrome • allergic disorders • asthma • avoid injections containing benzy alcohol in neonates • Cushing's syndrome • infectious diseases • peptic ulcer • primary adrenocortical insufficiency • refractory heart failure

### Caution

- Active infectious diseases (should not be used unless adequate disease-specific therapy is being given) • active systemic diseases (should not be used unless adequate disease-specific therapy is being given) • diabetes mellitus • diverticulitis • history of asthma • history of atopic allergy • history of eczema • history of hayfever • history of hypersensitivity • hypertension • latent amoebiasis (may become activated) • latent tuberculosis (may become activated) • myasthenia gravis • ocular herpes simplex • osteoporosis • predisposition to thromboembolic • psychological disturbances may be triggered • recent intestinal anastomosis • reduced immune response (should not be used unless adequate disease-specific therapy is being given) • ulcerative colitis

### Risk of anaphylaxis

- Should only be administered under medical supervision. Consult product literature.

### Hypertension

- Patients already receiving medication for moderate to severe hypertension must have their dosage adjusted if treatment started.

### Diabetes mellitus

- Patients already receiving medication for diabetes mellitus must have their dosage adjusted if treatment started.

### Interactions

- Appendix 1 (corticosteroids).
7.2 Assessment of pituitary function

GONADOTROPHIN-RELEASING HORMONE ANALOGUES

Gonadorelin
(Gonadotrophin-releasing hormone; GnRH; LH-RH)

INDICATIONS AND DOSE
Assessment of pituitary function
BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INJECTION
▶ Adult: 100 micrograms for 1 dose

● CAUTIONS Pituitary adenoma
● SIDE-EFFECTS Abdominal pain, headache, hypersensitivity reaction on repeated administration of large doses, increased menstrual bleeding, irritation at injection site, nausea
● PREGNANCY Avoid.
● BREAST FEEDING Avoid.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
EXCIPIENTS: May contain Benzyl alcohol
▶ GONADORELIN (Non-proprietary)
Gonadorelin (as Gonadorelin hydrochloride) 100 microgram
Gonadorelin 100 microgram powder and solvent for solution for injection vials | 1 vial (£31.38 Schedule 4 (CD Aban)

7.3 Gonadotrophin replacement therapy

GONADOTROPHINS

Chorionic gonadotrophin alfa
(Human chorionic gonadotrophin)

INDICATIONS AND DOSE
Treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene
Supervoluation treatment for assisted conception (such as in vitro fertilisation)
BY SUBCUTANEOUS INJECTION
▶ Adult: Adjusted according to response.

● CONTRA-INDICATIONS Active thromboembolic disorders - ectopic pregnancy in previous 3 months - hypothalamic malignancy - mammary malignancy - ovarian enlargement or cyst (unless caused by polycystic ovarian disease) - ovarian malignancy - pituitary malignancy - uterine malignancy
● CAUTIONS Acute porphyrias p. 864
● SIDE-EFFECTS Abdominal pain, breast pain, depression, diarrhoea, ectopic pregnancy, headache, injection-site reactions, irritability, nausea, ovarian hyperstimulation syndrome, ovarian torsion, tiredness, vomiting

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Chorionic gonadotrophin
(Human Chorionic Gonadotrophin; HCG)

DRUG ACTION A preparation of a glycoprotein fraction secreted by the placenta and obtained from the urine of pregnant women having the action of the pituitary luteinising hormone.

INDICATIONS AND DOSE
Treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene
Supervoluation treatment for assisted conception (such as in vitro fertilisation)
BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION
▶ Adult: Adjusted according to response.

● CONTRA-INDICATIONS Androgen-dependent tumours
● CAUTIONS Asthma, cardiac impairment, epilepsy, migraine, prepubertal boys (risk of premature epiphyseal closure or precocious puberty)
● SIDE-EFFECTS Gynaecomastia, headache, local reactions, may aggravate ovarian hyperstimulation syndrome (particularly in males—reduce dose) - tiredness
● RENAL IMPAIRMENT Use with caution.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection
▶ Choragon (Ferring Pharmaceuticals Ltd)
Chorionic gonadotrophin human 5000 unit Choragon 5,000 unit powder and solvent for solution for injection ampoules | 3 ampoules (£31.38 Schedule 4 (CD Aban)
Chorionic gonadotrophin human 1500 unit Pregnyl 1,500 unit powder and solvent for solution for injection ampoules | 1 ampoule (£31.38 Schedule 4 (CD Aban)
Chorionic gonadotrophin human 5000 unit Pregnyl 5,000 unit powder and solvent for solution for injection ampoules | 1 ampoule (£31.38 Schedule 4 (CD Aban)

Corifollitropin alfa

INDICATIONS AND DOSE
Controlled ovarian stimulation in combination with a gonadotrophin-releasing hormone antagonist
BY SUBCUTANEOUS INJECTION
▶ Adult (body-weight up to 60 kg): 100 micrograms
▶ Adult (body-weight 60 kg and above): 150 micrograms

● CONTRA-INDICATIONS History of ovarian hyperstimulation syndrome - ovarian enlargement or cyst - polycystic ovarian syndrome - tumours of breast - tumours of hypothalamus - tumours of ovaries - tumours of pituitary - tumours of uterus - vaginal bleeding of unknown cause
● CAUTIONS Acute porphyrias p. 864 - risk factors for thromboembolism - risk of ovarian hyperstimulation syndrome
● SIDE-EFFECTS
▶ Common or very common Breast pain, fatigue, headache, nausea, ovarian hyperstimulation, pelvic pain
**Follitropin alfa** (Recombinant human follicle stimulating hormone)

**INDICATIONS AND DOSE**
Infertility in women with proven hypopituitarism or who have not responded to clomifene | Superovulation treatment for assisted conception (such as in vitro fertilisation)

BY SUBCUTANEOUS INJECTION
- Adult: Adjusted according to response.

**CONTRA-INDICATIONS**
- Ovarian cysts (not caused by polycystic ovarian syndrome) - tumours of breast - tumours of hypothalamus - tumours of ovaries - tumours of pituitary - tumours of prostate - tumours of testes - tumours of uterus - vaginal bleeding of unknown cause

**CAUTIONS**
- Acute porphyrias p. 864

**SIDE-EFFECTS**
- Fever - gastro-intestinal disturbances - headache - hypersensitivity reactions - injection site reactions - joint pain - ovarian hyperstimulation
- Very rare: Thromboembolism
- Frequency not known: Acne - gynaecomastia - increased risk of miscarriage - increased risk of multiple pregnancy - weight gain

**PREGNANCY**
- Avoid.

**BREAST FEEDING**
- Avoid.

**PATIENT AND CARER ADVICE**
Patients planning to conceive should be warned that there is a risk of multiple pregnancy.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Follitropin alfa (Non-proprietary)**
- Follitropin alfa 600 unit per 1 ml
  - Bemfola 225units/0.375ml solution for injection pre-filled pen | 1 pre-filled disposable injection (PSN) £70.50
  - Bemfola 300units/0.5ml solution for injection pre-filled pen | 1 pre-filled disposable injection (PSN) £94.00
  - Bemfola 150units/0.25ml solution for injection pre-filled pen | 1 pre-filled disposable injection (PSN) £47.00
  - Bemfola 75units/0.125ml solution for injection pre-filled pen | 1 pre-filled disposable injection (PSN) £23.50
  - Bemfola 450units/0.75ml solution for injection pre-filled pen | 1 pre-filled disposable injection (PSN) £141.00

- Gonal-f (Merck Serono Ltd)
  - Follitropin alfa 600 unit per 1 ml
    - Gonal-f 450units/0.75ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSN) £141.00
    - Gonal-f 900units/1.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSN) £282.00
    - Gonal-f 300units/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PSN) £94.00

**Powder and solvent for solution for injection**
- Gonal-f (Merck Serono Ltd)
- Follitropin alfa 75 unit
  - Gonal-f 75unit powder and solvent for solution for injection vials | 1 vial (PSN) £21.02 | 5 vial (PSN) £107.20
- Follitropin alfa 450 unit
  - Gonal-f 450unit powder and solvent for solution for injection vials | 1 vial (PSN) £126.10
- Follitropin alfa 1050 unit
  - Gonal-f 1,050unit powder and solvent for solution for injection vials | 1 vial (PSN) £294.22

**Follitropin beta** (Recombinant human follicle stimulating hormone)

**INDICATIONS AND DOSE**
Infertility in women with proven hypopituitarism or who have not responded to clomifene | Superovulation treatment for assisted conception (such as in vitro fertilisation)

BY SUBCUTANEOUS INJECTION
- Adult: Adjusted according to response.

**CONTRA-INDICATIONS**
- Ovarian cysts (not caused by polycystic ovarian syndrome) - tumours of breast - tumours of hypothalamus - tumours of ovaries - tumours of pituitary - tumours of prostate - tumours of testes - tumours of uterus - vaginal bleeding of unknown cause

**CAUTIONS**
- Acute porphyrias p. 864

**SIDE-EFFECTS**
- Fever - gastro-intestinal disturbances - headache - hypersensitivity reactions - injection site reactions - joint pain - ovarian hyperstimulation
- Very rare: Thromboembolism
- Frequency not known: Acne - gynaecomastia - increased risk of miscarriage - increased risk of multiple pregnancy - weight gain

**PREGNANCY**
- Avoid.
Menotrophin

**INDICATIONS AND DOSE**

Infertility in women with proven hypopituitarism or who have not responded to clomifene | Suproovulation treatment for assisted conception (such as in vitro fertilisation)

**BY SUBCUTANEOUS INJECTION OR BY DEEP INTRAMUSCULAR INJECTION**

**Adult:** Adjusted according to response.

Menotrophin

**INDICATIONS AND DOSE**

Infertility in women with proven hypopituitarism or who have not responded to clomifene | Suproovulation treatment for assisted conception (such as in vitro fertilisation)

**BY SUBCUTANEOUS INJECTION OR BY DEEP INTRAMUSCULAR INJECTION**

**Adult:** Adjusted according to response.

**EDUCATION AND FEEDING**

Avoid.

**DIRECTIONS FOR ADMINISTRATION**

Cartridges and vials are used for subcutaneous administration; vials are used for intramuscular injection.

**PATIENT AND CARER ADVICE**

Patients planning to conceive should be warned that there is a risk of multiple pregnancy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

EXCIPIENTS: May contain Neomycin, streptomycin

- Puregon (Merck Sharp & Dohme Ltd)
  - Follitropin beta 100 unit per 1 ml Puregon 500units/0.5ml solution for injection vials | 1 vial | £18.03
  - Follitropin beta 200 unit per 1 ml Puregon 1000units/0.5ml solution for injection vials | 1 vial | £36.06
  - Follitropin beta 833 unit per 1 ml Puregon 900units/1.08ml solution for injection vials | 1 vial | £292.23
  - Puregon 600units/0.72ml solution for injection vials | 1 vial | £194.82 | | P33 10 | £97.41

**SIDE-EFFECTS**

Abdominal pain, adnexal torsion, breast pain, ecotopic pregnancy, haemoperitoneum, headache, injection-site reactions, nausea, ovarian cyst, ovarian hyperstimulation syndrome, pelvic pain, somnolence, thromboembolism, vomiting

**CONTRA-INDICATIONS**

Acute porphyrias p. 684

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Puregon (Merck Sharp & Dohme Ltd)
  - Menotrophin 150 unit Menotrophin 150unit powder and solvent for solution for injection vials | 1 vial | £163.80
  - Menotrophin 150 unit Menotrophin 150unit powder and solvent for solution for injection vials | 5 vial | £163.80 | | P33 10 | £327.60
  - Menotrophin 600 unit Menotrophin 600unit powder and solvent for solution for injection vials | 1 vial | £131.04
  - Menotrophin 1200 unit Menotrophin 1200unit powder and solvent for solution for injection vials | 1 vial | £262.08
  - Merional (IBSA Farmaceutici Italia Srl)
    - Menotrophin 75 unit Merional 75unit powder and solvent for solution for injection vials | 1 vial | £279.00
  - Menotrophin 150 unit Merional 150unit powder and solvent for solution for injection vials | 1 vial | £558.00

**Urofollitropin**

**INDICATIONS AND DOSE**

Infertility in women with proven hypopituitarism or who have not responded to clomifene | Suproovulation treatment for assisted conception (such as in vitro fertilisation)

**BY SUBCUTANEOUS INJECTION OR BY DEEP INTRAMUSCULAR INJECTION**

**Adult:** Adjusted according to response.

**CONTRA-INDICATIONS**

Ovarian cysts (not caused by polycystic ovarian syndrome) - tumours of breast - tumours of hypothalamus - tumours of ovaries - tumours of pituitary - tumours of prostate - tumours of testes - tumours of uterus - vaginal bleeding of unknown cause

**CAUTIONS**

Acute porphyrias p. 684

**SIDE-EFFECTS**

Very rare Thromboembolism

**Frequency not known**

Fever, gastro-intestinal disturbances, headache, hypersensitivity reactions, increased risk of miscarriage, increased risk of multiple

**Urofollitropin**

**INDICATIONS AND DOSE**

Infertility in women with proven hypopituitarism or who have not responded to clomifene | Suproovulation treatment for assisted conception (such as in vitro fertilisation)

**BY SUBCUTANEOUS INJECTION OR BY DEEP INTRAMUSCULAR INJECTION**

**Adult:** (consult product literature).
Hypothalamic and anterior pituitary hormone related disorders

7.4 Growth hormone disorders

GROWTH HORMONE RECEPTOR ANTAGONISTS

Pegvisomant

**DRUG ACTION** Pegvisomant is a genetically modified analogue of human growth hormone and is a highly selective growth hormone receptor antagonist.

**INDICATIONS AND DOSE**
Treatment of acromegaly in patients with inadequate response to surgery, radiation, or both, and to treatment with somatostatin analogues (initiated by a specialist)

**BY SUBCUTANEOUS INJECTION**
- Adult: Initially 80 mg for 1 dose, followed by 10 mg daily, then increased in steps of 5 mg daily, adjusted according to response; maximum 30 mg per day

**CAUTIONS**
- Diabetes mellitus (adjustment of antidiabetic therapy may be necessary) - liver disease
- **SIDE-EFFECTS**
  - **Uncommon** Bleeding tendency - leucocytosis - leucopenia - thrombocytopenia
  - **Frequency not known** Abdominal distension - arthralgia - asthenia - constipation - diarrhea - dizziness - drowsiness - dyspepsia - elevated liver enzymes - fatigue - flatulence - headache - hypercholesterolaemia - hyperglycaemia - hypertension - hypoglycaemia - influenza-like syndrome - injection-site reactions - myalgia - nausea - pruritus - rash - sleep disturbances - sweating - tremor - vomiting - weight gain

**SIDE-EFFECTS, FURTHER INFORMATION**

**Injection-site reactions** Rotate injection sites to avoid lipohypertrophy.

**CONCEPTION AND CONTRACEPTION** Possible increase in female fertility.

**PREGNANCY** Avoid.

**BREAST FEEDING** Avoid.

**MONITORING REQUIREMENTS** Monitor liver enzymes every 4–6 weeks for 6 months or if symptoms of hepatitis develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- Somavert (Pfizer Ltd)
  - Pegvisomant 10 mg Somavert 10 mg powder and solvent for solution for injection vials | 30 vial £1.500.00
  - Pegvisomant 15 mg Somavert 15 mg powder and solvent for solution for injection vials | 30 vial £2.250.00
  - Pegvisomant 20 mg Somavert 20 mg powder and solvent for solution for injection vials | 1 vial £100.00 | 30 vial £3.000.00

**HUMAN GROWTH HORMONES**

Somatropin

(Recombinant Human Growth Hormone)

**INDICATIONS AND DOSE**

_Gonadal dysgenesis (Turner syndrome)_

**BY SUBCUTANEOUS INJECTION**
- Adult: 1.4 mg/m² daily, alternatively
  - 45–50 micrograms/kg daily

_Deficiency of growth hormone_ **BY SUBCUTANEOUS INJECTION**
- Adult: Initially 150–300 micrograms daily, then increased if necessary up to 1 mg daily, dose to be increased gradually, use minimum effective dose (requirements may decrease with age)

Dose equivalence and conversion
Dose formerly expressed in units; somatropin 1 mg equivalent to 3 units.

**CONTRA-INDICATIONS**
Evidence of tumour activity (complete antitumour therapy and ensure intracranial lesions inactive before starting) - not to be used after renal transplantation - not to be used for growth promotion in children with closed epiphyses (or near closure in Prader-Willi syndrome) - severe obesity in Prader-Willi syndrome - severe respiratory impairment in Prader-Willi syndrome

**CAUTIONS**
Diabetes mellitus (adjustment of antidiabetic therapy may be necessary) - disorders of the epiphysis of the hip (monitor for limping) - history of malignant disease - hypothyroidism - manufacturers recommend periodic thyroid function tests but limited evidence of clinical value - initiation of treatment close to puberty not recommended in child born small for corrected gestational age - papilloedema - relative deficiencies of other pituitary hormones - resolved intracranial hypertension (monitor closely) - Silver-Russell syndrome

**INTERACTIONS**
- Appendix 1 (somatropin).

**SIDE-EFFECTS**
Antibody formation - arthralgia - benign intracranial hypertension - carpal tunnel syndrome - fluid retention (peripheral oedema) - headache - hyperglycaemia - hypoglycaemia - hypothyroidism - insulin resistance - leukaemia in children with growth hormone deficiency - myalgia - nausea - papilloedema - paraesthesia - reactions at injection site - visual problems - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Papilloedema
Funduscopic for papilloedema recommended if severe or recurrent headache, visual problems, nausea and vomiting occur—if papilloedema confirmed consider benign intracranial hypertension (rare cases reported).

**PREGNANCY** Discontinue if pregnancy occurs—no information available.

**BREAST FEEDING** No information available. Absorption from milk unlikely.

**DIRECTIONS FOR ADMINISTRATION** Rotate subcutaneous injection sites to prevent lipohypertrophy.
Genotropin®, Humatrope cartridges, Norditropin®, NutropinAQ®, Omnitrope®, Saizen® and Zomacton® preparations
For use by subcutaneous injection.

**HUMATROPE® POWDER FOR RECONSTITUTION**
For use by subcutaneous or intramuscular injection.

- **PRESCRIBING AND DISPENSING INFORMATION**
  Medicinal products containing somatropin are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.

**GENOTROPIN® PREPARATIONS**
Cartridges are for use with Genotropin® Pen device (non-NHS but available free of charge from clinics).

**NORDITROPIN® PREPARATIONS**
Cartridges are for use with appropriate NordiPen® device (non-NHS but available free of charge from clinics). Multidose disposable prefilled pens for use with Novofine® or NovoTwist® needles.

**NUTRUPINAQ®**
For use with NutropinAQ® Pen device (non-NHS but available free of charge from clinics).

**OMNITROPE®**
For use with Omnitrope Pen 5° and Omnitrope Pen 10° devices (non-NHS but available free of charge from clinics).

**SAIZEN® POWDER AND SOLVENT FOR SOLUTION FOR INJECTION**
For use with one.click® autoinjector device or cool.click® needle-free autoinjector device or easypod® autoinjector device (non-NHS but available free of charge from clinics).

**SAIZEN® SOLUTION FOR INJECTION**
For use with cool.click® needle-free autoinjector device or easypod® autoinjector device (non-NHS but available free of charge from clinics).

**ZOMACTON®**
4mg vial for use with ZomaJet 2° Vision needle-free device (non-NHS but available free of charge from clinics) or with needles and syringes. 10mg vial for use with ZomaJet Vision X® needle-free device (non-NHS but available free of charge from clinics) or with needles and syringes.

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**
  - Somatropin for adults with growth hormone deficiency (August 2003) NICE TA64
    Somatropin is recommended in adults only if the following 3 criteria are fulfilled:
    - Severe growth hormone deficiency, established by an appropriate method,
    - Impaired quality of life, measured by means of a specific questionnaire,
    - Already receiving treatment for another pituitary hormone deficiency.
    Somatropin treatment should be discontinued if the quality of life has not improved sufficiently by 9 months. Severe growth hormone deficiency developing after linear growth is complete but before the age of 25 years should be treated with growth hormone; treatment should continue until adult peak bone mass has been achieved. Treatment for adult-onset growth hormone deficiency should be stopped only when the patient and the patient’s physician consider it appropriate.
    Treatment with somatropin should be initiated and managed by a physician with expertise in growth hormone disorders; maintenance treatment can be prescribed in the community under a shared-care protocol. www.nice.org.uk/TA64

- Somatropin for the treatment of growth failure in children (May 2010) NICE TA188
  Somatropin is recommended for children with growth failure who:
  - have growth-hormone deficiency
  - have Turner syndrome
  - have Prader-Willi syndrome
  - have chronic renal insufficiency
  - are born small for gestational age with subsequent growth failure at 4 years of age or later
  - have short stature homeobox-containing gene (SHOX) deficiency.
  Treatment should be discontinued if growth velocity increases by less than 50% from baseline in the first year of treatment. www.nice.org.uk/TA188

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **EXCIPIENTS**: May contain Benzyl alcohol
  - Norditropin NordiFlex (Novo Nordisk Ltd)
    Somatropin (epr) 5 mg per 1 ml
    Norditropin NordiFlex
    15mg/1.5ml solution for injection pre-filled ink | 1 pre-filled disposable injection (PFS) £347.70 Schedule 4 (CD Anab)
  - Norditropin Simplexx (Novo Nordisk Ltd)
    Somatropin (epr) 3.3 mg per 1 ml
    Norditropin Simplexx
    5mg/1.5ml solution for injection cartridges | 1 cartridge (PFS) £106.35 Schedule 4 (CD Anab)
  - Somatropin (epr) 6.7 mg per 1 ml
    Norditropin Simplexx
    10mg/1.5ml solution for injection cartridges | 1 cartridge (PFS) £212.70 Schedule 4 (CD Anab)
  - Somatropin (epr) 10 mg per 1 ml
    Norditropin Simplexx
    15mg/1.5ml solution for injection cartridges | 1 cartridge (PFS) £319.05 Schedule 4 (CD Anab)
  - Saizen® (Otsuka)
    Somatropin (rbe) 2 mg per 1 ml
    Saizen
    10mg/2ml solution for injection cartridges | 1 cartridge (PFS) £203.20 Schedule 4 (CD Anab)
    Saizen
    4mg/4ml solution for injection cartridges | 5 cartridge (PFS) £368.74 Schedule 4 (CD Anab)
  - Omnitrope Pen (Sandoz Ltd)
    Somatropin (rbe) 3.33 mg per 1 ml
    Omnitrope Pen 5
    5mg/1.5ml solution for injection cartridges | 5 cartridge (PFS) £368.74 Schedule 4 (CD Anab)
  - Omnitrope SurePal (Sandoz Ltd)
    Somatropin (rbe) 3.33 mg per 1 ml
    Omnitrope SurePal 5
    5mg/1.5ml solution for injection cartridges | 5 cartridge (PFS) £368.74 Schedule 4 (CD Anab)
    Somatropin (rbe) 6.67 mg per 1 ml
    Omnitrope Pen 10
    10mg/1.5ml solution for injection cartridges | 5 cartridge (PFS) £737.49 Schedule 4 (CD Anab)
  - Saizen (Merck Serono Ltd)
    Somatropin (rbe) 5 mg per 1 ml
    Saizen 3mg/1ml solution for injection cartridges | 1 cartridge (PFS) £139.08 Schedule 4 (CD Anab)
    Somatropin (rbe) 8 mg per 1 ml
    Saizen 5mg/1ml solution for injection cartridges | 1 cartridge (PFS) £278.16 Schedule 4 (CD Anab)
  - Saizen (Merck Serono Ltd)
    Somatropin (rbe) 10 mg per 1 ml
    Saizen 5mg/1ml solution for injection cartridges | 1 cartridge (PFS) £463.60 Schedule 4 (CD Anab)

- **Powder and solvent for solution for injection**
  **EXCIPIENTS**: May contain Benzyl alcohol
  - Genotropin (Pfizer Ltd)
    Somatropin (rbe) 5 mg
    Genotropin 5.3mg powder and solvent for solution for injection cartridges | 1 cartridge (PFS) £92.15 Schedule 4 (CD Anab)
  - Genotropin (Pfizer Ltd)
    Somatropin (rbe) 12 mg
    Genotropin 12mg powder and solvent for solution for injection cartridges | 1 cartridge (PFS) £208.65 Schedule 4 (CD Anab)
  - Genotropin (Pfizer Ltd)
    Somatropin (rbe) 5 mg
    Genotropin 5.3mg powder and solvent for solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (PFS) £92.15 Schedule 4 (CD Anab)
Sex hormone responsive conditions

8 Sex hormone responsive conditions

Sex hormones

Oestrogens and HRT

Oestrogens are necessary for the development of female secondary sexual characteristics; they also stimulate myometrial hypertrophy with endometrial hyperplasia. In terms of oestrogenic activity natural oestrogens (estradiol p. 649, estrone, and estriol p. 713) have a more appropriate profile for hormone replacement therapy (HRT) than synthetic oestrogens (ethinylestradiol p. 655 and mestranol). Tibolone p. 646 has oestrogenic, progestogenic and weak androgenic activity.

Oestrogen therapy is given cyclically or continuously for a number of gynaecological conditions. If long-term therapy is required in women with a uterus, a progestogen should normally be added to reduce the risk of cystic hyperplasia of the endometrium (or of endometriotic foci in women who have had a hysterectomy) and possible transformation to cancer.

Oestrogens are no longer used to suppress lactation because of their association with thromboembolism.

Hormone replacement therapy

Hormone replacement therapy (HRT) with small doses of an oestrogen (together with a progestogen in women with a uterus) is appropriate for alleviating menopausal symptoms such as vaginal atrophy or vasomotor instability. Oestrogen given systematically in the perimenopausal and postmenopausal period or tibolone given in the postmenopausal period also diminish postmenopausal osteoporosis but other drugs are preferred. Menopausal atrophic vaginitis may respond to a short course of a topical vaginal oestrogen preparation used for a few weeks and repeated if necessary.

Systemic therapy with an oestrogen or drugs with oestrogenic properties alleviates the symptoms of oestrogen deficiency such as vasomotor symptoms. Tibolone combines oestrogenic and progestogenic activity with weak androgenic activity; it is given continuously, without cyclical progestogen.

HRT may be used in women with early natural or surgical menopause (before age 45 years), since they are at high risk of osteoporosis. For early menopause, HRT can be given until the approximate age of natural menopause (i.e. until age 50 years). Alternatives to HRT should be considered if osteoporosis is the main concern.

Clonidine hydrochloride p. 137 may be used to reduce vasomotor symptoms in women who cannot take an oestrogen, but clonidine hydrochloride may cause unacceptable side-effects.

HRT increases the risk of venous thromboembolism, stroke, endometrial cancer (reduced by a progestogen), breast cancer, and ovarian cancer; there is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. For details of these risks see HRT Risk table.

The minimum effective dose of HRT should be used for the shortest duration. Treatment should be reviewed at least annually and for osteoporosis alternative treatments considered. HRT does not prevent coronary heart disease or protect against a decline in cognitive function and it should not be prescribed for these purposes. Experience of treating women over 65 years with HRT is limited.

For the treatment of menopausal symptoms the benefits of short-term HRT outweigh the risks in the majority of women, especially in those aged under 60 years.

Risk of breast cancer

It is estimated that using all types of HRT, including tibolone, increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping. Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use; tibolone has only a limited effect on mammographic density.

Risk of endometrial cancer

The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT. In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a...
Tibolone increases the risk of breast cancer but to a lesser extent than with combined HRT. Evidence suggests an increased risk of endometrial cancer with tibolone. After 2.7 years of use (in women of average age 68 years), 1 extra case of endometrial hyperplasia and 4 extra cases of endometrial cancer were diagnosed compared with placebo users. The risk of endometrial cancer cannot be reliably estimated in those using combined HRT because the addition of progestogen for at least 10 days per 28-day cycle greatly reduces the additional risk, and addition of a daily progestogen eliminates the additional risk. The risk of endometrial cancer in women who have not used HRT increases with body mass index (BMI); the increased risk of endometrial-only HRT or tibolone is more apparent in women who are not overweight. Limited data does not suggest an increased risk of thromboembolism with tibolone compared with combined HRT or women not taking HRT. Although the level of risk of thromboembolism associated with non-oral routes of administration of HRT has not been established, it may be lower for the transdermal route. Tibolone increases the risk of stroke about 2.2 times from the first year of treatment; risk of stroke is age-dependent and therefore the absolute risk of stroke with tibolone increases with age. There is insufficient data to draw a conclusion on the risk of coronary heart disease with tibolone.

### Risk of ovarian cancer
Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer; this excess risk disappears within a few years of stopping.

### Risk of venous thromboembolism
Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use. In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits. Travel involving prolonged immobility further increases the risk of deep vein thrombosis.

### Risk of stroke
Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke. Tibolone increases the risk of stroke about 2.2 times from the first year of treatment.

### Risk of coronary heart disease
HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

### Choice
The choice of HRT for an individual depends on an overall balance of indication, risk, and convenience. A woman with a uterus normally requires oestrogen with cyclical progestogen for the last 12 to 14 days of the cycle or a preparation which involves continuous administration of an oestrogen and a progestogen (or one which provides both oestrogenic and progestogenic activity in a single preparation). Continuous combined preparations or tibolone are not suitable for use in the perimenopause or within 12 months of the last menstrual period; women who use such preparations may bleed irregularly in the early stages of treatment— if bleeding continues endometrial abnormality should be ruled out and consideration given to changing to cyclical HRT.

An oestrogen alone is suitable for use in women without a uterus. However, in endometriosis, endometrial foci may remain despite hysterectomy and the addition of a progestogen should be considered in these circumstances.

An oestrogen may be given by mouth or by transdermal administration, which avoids first-pass metabolism.

### Surgery
Major surgery under general anaesthesia, including orthopaedic and vascular leg surgery, is a predisposing factor for venous thromboembolism and it may be prudent to stop HRT 4–6 weeks before surgery; it should be restarted only after full mobilisation. If HRT is continued or if discontinuation is not possible (e.g. in non-elective
surgery), prophylaxis with unfractionated or low molecular weight heparin and graduated compression hosiery is advised.

Reasons to stop HRT
Hormone replacement therapy should be stopped (pending investigation and treatment), if any of the following occur:
- sudden severe chest pain (even if not radiating to left arm);
- sudden breathlessness (or cough with blood-stained sputum);
- unexplained swelling or severe pain in calf of one leg;
- severe stomach pain;
- serious neurological effects including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perceptual disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body;
- hepatitis, jaundice, liver enlargement;
- blood pressure above systolic 160 mmHg or diastolic 95 mmHg;
- prolonged immobility after surgery or leg injury;
- detection of a risk factor which contra-indicates treatment

Ethinylestradiol
Ethinylestradiol p. 655 (ethinylestrodiol) is licensed for short-term treatment of symptoms of oestrogen deficiency, for osteoporosis prophylaxis if other drugs cannot be used and for the treatment of female hypogonadism and menstrual disorders. Ethinylestradiol is occasionally used under specialist supervision for the management of hereditary haemorrhagic telangiectasia (but evidence of benefit is limited). It is also used licensed for the palliative treatment of prostate cancer.

Raloxifene
Raloxifene hydrochloride p. 659 is licensed for the treatment of postmenopausal osteoporosis; unlike hormone replacement therapy, raloxifene hydrochloride does not reduce menopausal vasomotor symptoms.

Raloxifene hydrochloride may reduce the incidence of oestrogen-receptor-positive breast cancer but its role in established breast cancer is not yet clear. The manufacturer advises avoiding its use during treatment for breast cancer.

Progestogens and progesterone receptor modulators
There are two main groups of progestogen, progesterone and its analogues (dydrogesterone and medroxyprogesterone acetate p. 695) and testosterone analogues (norethisterone p. 656 and norgestrel). The newer progestogens (desogestrel p. 691, norgestimate, and gestodene) are all derivatives of norgestrel; levonorgestrel p. 692 is the active isomer of norgestrel and has twice its potency. Progestogen p. 658 and its analogues are less androgenic than the testosterone derivatives and neither progestogen nor dydrogesterone causes virilisation.

Where endometriosis requires drug treatment, it may respond to a progestogen, e.g. norethisterone, administered on a continuous basis. Danazol p. 626 and gonadorelin analogues are also available.

Although oral progestogens have been used widely for menorrhagia they are relatively ineffective compared with tranexamic acid p. 95 or, particularly where dysmenorrhoea is also a factor, mefenamic acid p. 932; the levonorgestrel-releasing intra-uterine system may be particularly useful for women also requiring contraception. Oral progestogens have also been used for severe dysmenorrhoea, but where contraception is also required in younger women the best choice is a combined oral contraceptive.

Progestogens have also been advocated for the alleviation of premenstrual symptoms, but no convincing physiological basis for such treatment has been shown.

Progestogens have been used for the prevention of miscarriage in women with a history of recurrent miscarriage but there is no evidence of benefit and they are not recommended for this purpose. In pregnant women with antiphospholipid antibody syndrome who have suffered recurrent miscarriage, administration of low-dose aspirin p. 104 and a prophylactic dose of a low molecular weight heparin may decrease the risk of fetal loss (use under specialist supervision only).

Hormone replacement therapy
In women with a uterus a progestogen needs to be added to long-term oestrogen therapy for hormone replacement, to prevent cystic hyperplasia of the endometrium and possible transformation to cancer; it can be added on a cyclical or a continuous basis. Combined packs incorporating suitable progestogen tablets are available.

Oral contraception
Desogestrel, gestodene, levonorgestrel, norethisterone, and norgestimate are used in combined oral contraceptives and in progestogen-only contraceptives.

Cancer
Progestogens also have a role in neoplastic disease.

Progesterone receptor modulators
Ulipristal acetate p. 691 is a progesterone receptor modulator with a partial progesterone antagonist effect. Ulipristal acetate is used in the pre-operative treatment of moderate to severe symptoms of uterine fibroids; it is also used as an hormonal emergency contraceptive.

8.1 Female sex hormone responsive conditions

Drugs used for Female sex hormones responsive conditions not listed below; Medroxyprogesterone acetate, p. 695; Clonidine hydrochloride, p. 137

NORETYNODREL DERIVATIVES

Tibolone

INDICATIONS AND DOSE
Short-term treatment of symptoms of oestrogen deficiency (including women being treated with gonadotrophin releasing hormone analogues) | Osteoporosis prophylaxis in women at high risk of fractures when other prophylaxis contra-indicated or not tolerated

BY MOUTH
- Adult: 2.5 mg daily

CONTRA-INDICATIONS
Acute porphyrias p. 864 | acute or recent arterial thromboembolic disease (e.g. angina or myocardial infarction) | active thrombophlebitis | Dubin-Johnson and Rotor syndrome (or monitor closely) | history of breast cancer | history of cardiovascular disease | history of cerebrovascular disease | history of recurrent venous thromboembolism (unless already on anticoagulant treatment) | history of thromboembolism | history of thrombophlebitis | hormone-dependent tumours | liver disease (where liver function tests have failed to return to normal) | oestrogen-dependent cancer | thrombophilic disorder | uninvestigated or undiagnosed
vaginal bleeding • untreated endometrial hyperplasia • venous thromboembolism

- CAUTIONS Acute porphyrias p. 864 • diabetes (increased risk of heart disease) • epilepsy • factors predisposing to thromboembolism • history of breast nodules—closely monitor breast status (risk of breast cancer) • history of endometrial hyperplasia • history of fibrocystic disease—closely monitor breast status (risk of breast cancer) • history of liver disease • hypertriglyceridaemia • hypophysial tumours • migraine (or migraine-like headaches) • presence of antiphospholipid antibodies (increased risk of thrombotic events) • prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer • risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) • risk of stroke

CAUTIONS, FURTHER INFORMATION

Other conditions The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

- INTERACTIONS Appendix 1 (tibolone).

- SIDE-EFFECTS

  - Common or very common Abdominal pain • facial hair • leucorrhoea • vaginal bleeding • weight changes
  - Rare Amnesia
  - Frequency not known Arthralgia • breast cancer • depression • dizziness • gastro-intestinal disturbances • headache • increased risk of gall-bladder disease • migraine • myalgia • oedema • pruritus • rash • seborrhoeic dermatitis • symptoms of endometriosis may be exacerbated • uterine fibroids may increase in size • visual disturbances

SIDE-EFFECTS, FURTHER INFORMATION

Vaginal bleeding Investigate for endometrial cancer if bleeding continues beyond 6 months or after stopping treatment.

Reasons to withdraw treatment Withdraw treatment if signs of thromboembolic disease, abnormal liver function tests, or signs of cholestatic jaundice.

- PREGNANCY Avoid; toxicity in animal studies.

- BREAST FEEDING Avoid.

- HEPATIC IMPAIRMENT Avoid in acute liver disease or if history of liver disease and liver function tests not returned to normal.

- RENAL IMPAIRMENT Patients with renal impairment should be closely monitored (risk of fluid retention).

- PRESCRIBING AND DISPENSING INFORMATION Unsuitable for use in the premenopause (unless being treated with gonadotrophin-releasing hormone analogue) and as (or with) an oral contraceptive. Also unsuitable for use within 12 months of last menstrual period (may cause irregular bleeding). If transferring from cyclical HRT, start at end of regimen; if transferring from continuous-combined HRT, start at any time.

- MEDICINAL FORMS

  There can be variation in the licensing of different medicines containing the same drug.

Tablet

- TIBOLONE (Non-proprietary)

  Tibolone 2.5 mg | tablet 28 | price £10.36 DF
  Tibolone 2.5 mg | tablet 84 | price £31.08

- Lidal (Merck Sharp & Dohme Ltd)

  Livial 2.5 mg | tablet 28 | price £10.36 DF
  Livial 2.5 mg | tablet 84 | price £31.08

OESTROGENS

Conjugated oestrogens (equine)

INDICATIONS AND DOSE

PREMARIN® TABLETS

Menopausal symptoms

BY MOUTH

- Adult: 0.3–1.25 mg daily continuously; with cyclical progestogen for 12–14 days of each cycle in women with a uterus

Osteoporosis prophylaxis

BY MOUTH

- Adult: 0.625–1.25 mg daily continuously; with cyclical progestogen for 12–14 days of each cycle in women with a uterus

- CONTRA-INDICATIONS Active arterial thromboembolic disease (e.g. angina or myocardial infarction) • active thrombophlebitis • Dubin-Johnson syndromes (or monitor closely) • history of breast cancer • history of recurrent venous thromboembolism (unless already on anticoagulant treatment) • liver disease (where liver function tests have failed to return to normal) • oestrogen-dependent cancer • recent arterial thromboembolic disease (e.g. angina or myocardial infarction) • Rotor syndromes (or monitor closely) • thrombophilic disorder • undiagnosed vaginal bleeding • untreated endometrial hyperplasia • venous thromboembolism

- CAUTIONS Acute porphyrias p. 864 • diabetes (increased risk of heart disease) • factors predisposing to thromboembolism • history of breast nodules (closely monitor breast status—risk of breast cancer) • history of endometrial hyperplasia • history of fibrocystic disease (closely monitor breast status—risk of breast cancer) • hypophysial tumours • increased risk of gall-bladder disease reported • migraine • migraine-like headaches • presence of antiphospholipid antibodies (increased risk of thrombotic events) • risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) • risk of breast cancer

CAUTIONS, FURTHER INFORMATION

Risk of breast cancer It is estimated that using all types of HRT, including tibolone, increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping. Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use.

Risk of endometrial cancer The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT. In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

Risk of ovarian cancer Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.

Risk of venous thromboembolism Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use. In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is
prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits. Travel involving prolonged immobility further increases the risk of deep vein thrombosis.

Risk of stroke Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.

Risk of coronary heart disease HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

Other conditions The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

INTERACTIONS ➔ Appendix 1 (oestrogens).

SIDE-EFFECTS Abdominal bloating - abdominal cramps - altered blood lipids (may lead to pancreatitis, rashes and chloasma) - breast enlargement - breast tenderness - changes in libido - cholestatic jaundice - contact lenses may irritate - depression - dizziness - fluid retention - glucose intolerance - headache - headache (on vigorous exercise) - leg cramps (rule out venous thrombosis) - migraine - mood changes - nausea - premenstrual-like syndrome - prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer - sodium retention - symptoms of endometriosis may be exacerbated - uterine fibroids may increase in size - vaginal candidiasis - vomiting - weight changes

SIDE-EFFECTS, FURTHER INFORMATION Withdrawal bleeding Cyclical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

CONCEPTION AND CONTRACEPTION HRT does not provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary. Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone (particularly in women aged under 50 years) do not necessarily preclude the possibility of becoming pregnant.

PREGNANCY Not known to be harmful.

BREAST FEEDING Avoid until weaning or for 6 months after birth (adverse effects on lactation).

HEPATIC IMPAIRMENT Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin–Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Tablet

- CONJUGATED OESTROGENS (EQUINE) (Non-proprietary)
  - Conjugated oestrogens 625 microgram Conjugated oestrogens 625 microgram tablets | 42 tablet (Pfizer) no price available | 84 tablet (Pfizer) no price available DT price = £4.02
  - Conjugated oestrogens 1.25 mg Conjugated oestrogens 1.25 mg tablets | 84 tablet (Pfizer) no price available DT price = £3.58

- Premarin (Pfizer Ltd)
  - Conjugated oestrogens 300 microgram Premarin 0.3 mg tablets | 84 tablet (Pfizer) £6.07 DT price = £6.07
  - Conjugated oestrogens 625 microgram Premarin 0.625 mg tablets | 84 tablet (Pfizer) £4.02 DT price = £4.02
  - Conjugated oestrogens 1.25 mg Premarin 1.25 mg tablets | 84 tablet (Pfizer) £3.58 DT price = £3.58

Conjugated oestrogens with medroxyprogesterone

The properties listed below are those particular to the combination only. For the properties of the components please consider, medroxyprogesterone acetate p. 695, conjugated oestrogens (equine) p. 647.

INDICATIONS AND DOSE

PREMIQUE®

- Menopausal symptoms in women with a uterus
- Osteoporosis prophylaxis in women with a uterus

BY MOUTH

- Adult: 1 tablet daily continuously

PREMIQUE® LOW DOSE TABLETS

- Menopausal symptoms in women with a uterus

BY MOUTH

- Adult: 1 tablet daily continuously

INTERACTIONS ➔ Appendix 1 (oestrogens, progestogens).

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Premique (Pfizer Ltd)
  - Conjugated oestrogens 625 microgram, Medroxyprogesterone acetate 5 mg Premique 0.625 mg/5 mg tablets | 84 tablet (Pfizer) £10.61 DT price = £10.61

Modified-release tablet

- Premique (Pfizer Ltd)
  - Conjugated oestrogens 300 microgram, Medroxyprogesterone acetate 1.5 mg Premique Low Dose 0.3 mg/1.5 mg modified-release tablets | 84 tablet (Pfizer) £6.52 DT price = £6.52

Conjugated oestrogens with norgestrel

The properties listed below are those particular to the combination only. For the properties of the components please consider, conjugated oestrogens (equine) p. 647.

INDICATIONS AND DOSE

PREMPAK C® 0.625

- Menopausal symptoms in women with a uterus
- Osteoporosis prophylaxis in women with a uterus

BY MOUTH

- Adult: 1 tablet daily continuously, maroon tablet to be taken and started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) and...
**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Prempak-C (Pfizer Ltd)**  
  Prempak-C: 1.25mg/0.15mg tablets | 120 tablet [PDR] £7.40 DT price = £74.00  
  Prempak-C: 0.625mg/0.15mg tablets | 120 tablet [PDR] £6.25 DT price = £62.50

**Prempak-C**

**Menopausal symptoms in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**Osteoporosis prophylaxis in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**BY MOUTH**

- **Menopausal symptoms**  
  Adult: 1 tablet daily continuously, (yellow tablet) to be taken and started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) and 1 tablet daily, (brown tablet) to be taken and started on days 17–28 of each 28-day treatment cycle, subsequent courses are repeated without interval  

**Prempak-C**

**Menopausal symptoms in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**Osteoporosis prophylaxis in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**BY MOUTH**

- **Menopausal symptoms**  
  Adult: 1 tablet daily continuously, (yellow tablet) to be taken and started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) and 1 tablet daily, (brown tablet) to be taken and started on days 17–28 of each 28-day treatment cycle, subsequent courses are repeated without interval  

**Prempak-C**

**Menopausal symptoms in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**Osteoporosis prophylaxis in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**BY MOUTH**

- **Menopausal symptoms**  
  Adult: 1 tablet daily continuously, (yellow tablet) to be taken and started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) and 1 tablet daily, (brown tablet) to be taken and started on days 17–28 of each 28-day treatment cycle, subsequent courses are repeated without interval  

**Progestogen**

**Menopausal symptoms in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**Osteoporosis prophylaxis in women with a uterus (if symptoms not fully controlled with lower strength pack)**  
**BY MOUTH**

- **Menopausal symptoms**  
  Adult: 1 tablet daily continuously, (yellow tablet) to be taken and started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) and 1 tablet daily, (brown tablet) to be taken and started on days 17–28 of each 28-day treatment cycle, subsequent courses are repeated without interval

---

**Endocrine system**
to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, therapy should be initiated with Evorel 50 patch; subsequently adjust according to response; dose may be reduced to Evorel 25 patch after first month if necessary for menopausal symptoms only

FEMSEVEN®

Menopausal symptoms | Osteoporosis prophylaxis
BY TRANSDERMAL APPLICATION
- Adult: Apply 1 patch once weekly continuously, to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with FemSeven 50 patches for the first few months, subsequently adjust according to response

PROGYNOVA® TS

Menopausal symptoms | Osteoporosis prophylaxis
BY TRANSDERMAL APPLICATION
- Adult: Apply 1 patch once weekly continuously, alternatively apply 1 patch once weekly for 3 weeks, followed by a 7-day patch-free interval (cyclical), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with Progynova TS 50, subsequently adjust according to response; women receiving Progynova TS 100 patches for menopausal symptoms may continue with this strength for osteoporosis prophylaxis

OESTROGEL®

Menopausal symptoms
TO THE SKIN
- Adult: Apply 1.5 mg once daily continuously, increased if necessary up to 3 mg after 1 month continuously, to be applied over an area twice that of the template provided, starting within 5 days of menstruation (or anytime if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus

Osteoporosis prophylaxis
TO THE SKIN
- Adult: Apply 1.5 mg once daily continuously, to be applied over an area twice that of the template provided, starting within 5 days of menstruation (or anytime if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus

Dose equivalence and conversion
2 measures is equivalent to estradiol 1.5 mg

SANDRENA®

Menopausal symptoms
TO THE SKIN
- Adult: Apply 1 mg once daily, to be applied over area 1–2 sizes of hand; with cyclical progestogen for 12–14 days of each cycle in women with a uterus, dose may be adjusted after 2–3 cycles to lowest effective dose; usual dose 0.5–1.5 mg daily

ESTRING®

Postmenopausal urogenital conditions (not suitable for vasomotor symptoms or osteoporosis prophylaxis)
BY VAGINA
- Adult: To be inserted into upper third of vagina and worn continuously; replace after 3 months; max. duration of continuous treatment 2 years

VAGIFEM®

Improve the vaginal epithelium in menopausal atrophic vaginitis
BY VAGINA
- Adult: 1 tablet daily for 2 weeks, then reduced to 1 tablet twice weekly

● CONTRA-INDICATIONS
- Active arterial thromboembolic disease (e.g. angina or myocardial infarction) - active thrombophlebitis - Dubin-Johnson syndrome (or monitor closely) - history of breast cancer - history of recurrent venous thromboembolism (unless already on anticoagulant treatment) - oestrogen-dependent cancer - recent arterial thromboembolic disease (e.g. angina or myocardial infarction) - Rotor syndrome (or monitor closely) - thrombophilic disorder - undiagnosed vaginal bleeding - untreated endometrial hyperplasia - venous thromboembolism

● CAUTIONS

GENERAL CAUTIONS
- Acute porphyrias p. 864 - diabetes (increased risk of heart disease) - history of breast nodules—closely monitor breast status (risk of breast cancer) - history of endometrial hyperplasia; factors predisposing to thromboembolism - history of fibrocystic disease—closely monitor breast status (risk of breast cancer) - hypophyseal tumours - increased risk of gall-bladder disease - migraine (or migraine-like headaches) - presence of anti-phospholipid antibodies (increased risk of thrombotic events) - prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer - risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) - symptoms of endometriosis may be exacerbated - uterine fibroids may increase in size

SPECIFIC CAUTIONS
- With vaginal use Interrupt treatment periodically to assess need for continued treatment

CAUTIONS, FURTHER INFORMATION

Risk of breast cancer
- It is estimated that using all types of HRT increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping. Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use.

Risk of endometrial cancer
- The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT. In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

Risk of ovarian cancer
- Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.

Risk of venous thromboembolism
- Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use. In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits. Travel involving prolonged immobility further increases the risk of deep vein thrombosis.

Risk of stroke
- Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.

Risk of coronary heart disease
- HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little
information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women. 

**Other conditions** The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

**INTERACTIONS** → Appendix 1 (oestrogens).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

Abdominal bloating - abdominal cramps - altered blood lipids (may lead to pancreatitis, rashes and chloasma) - breast enlargement - breast tenderness - changes in libido - cholestatic jaundice - contact lenses may irritate - depression - dizziness - fluid retention - glucose intolerance - headache - headache (on vigorous exercise) - leg cramps (rule out venous thrombosis) - migraine - mood changes - nausea - premenstrual-like syndrome - sodium retention - vaginal candidiasis - vomiting - weight changes

**SPECIFIC SIDE-EFFECTS**

- **With transdermal use** Cause contact sensitisation (possible severe hypersensitivity reaction on continued exposure)
- **With vaginal use** Local irritation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Withdrawal bleeding** Cylindrical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

**CONCEPTION AND CONTRACEPTION** HRT does not provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary. Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone (particularly in women aged under 50 years) do not necessarily preclude the possibility of becoming pregnant.

**VAGIFEM®** No evidence of damage to latex condoms and diaphragms.

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Avoid; adverse effects on lactation.

**HEPATIC IMPAIRMENT** Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin–Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

**MONITORING REQUIREMENTS**

- History of breast nodules or fibrocystic disease—closely monitor breast status (risk of breast cancer).
- The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

**DIRECTIONS FOR ADMINISTRATION**

- **With transdermal use** Patch should be removed after 3–4 days (or once a week in case of 7-day patch) and replaced with fresh patch on slightly different site; recommended sites: clean, dry, unbroken areas of skin on trunk below waistline; not to be applied on or near breasts or under waistband. If patch falls off in bath allow skin to cool before applying new patch.

**PATIENT AND CARER ADVICE**

- **With transdermal use** Patient counselling is advised for estradiol patches (administration).
- **With topical use** Patient counselling is advised for estradiol gels (administration).

**OSTROGEL®** Apply gel to clean, dry, intact skin such as arms, shoulders or inner thighs and allow to dry for 5 minutes before covering with clothing. Not to be applied on or near breasts or on vulval region. Avoid skin contact with another person (particularly male) and avoid other skin products or washing the area for at least 1 hour after application.

**SANDRENA®** Apply gel to intact areas of skin such as lower trunk or thighs, using right and left sides on alternate days. Wash hands after application. Not to be applied on the breasts or face and avoid contact with eyes. Allow area of application to dry for 5 minutes and do not wash area for at least 1 hour.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: implant

**Tablet**

- **ESTRADIOL (Non-proprietary)**
  - Estradiol 1 mg Estradiol 1mg tablets | 18 tablet [P] no price available | 42 tablet [P] no price available | 48 tablet [P] no price available
  - Estradiol 2 mg Estradiol 2mg tablets | 16 tablet [P] no price available | 36 tablet [P] no price available | 48 tablet [P] no price available
  - Estradiol valerate 2 mg Estradiol valerate 2mg tablets | 11 tablet [P] no price available | 16 tablet [P] no price available | 48 tablet [P] no price available
  - Estradiol 3 mg Estradiol 3mg tablets | 6 tablet [P] no price available
  - Estradiol 4 mg Estradiol 4mg tablets | 36 tablet [P] no price available

- **Bedol (ReSource Medical UK Ltd)**
  - Estradiol 2 mg Bedol 2mg tablets | 84 tablet [P] £0.07
  - Climaval (Novartis Pharmaceuticals UK Ltd)
    - Estradiol valerate 1 mg Climaval 1mg tablets | 28 tablet [P] £2.94 | 84 tablet [P] £8.82
    - Estradiol valerate 2 mg Climaval 2mg tablets | 28 tablet [P] £2.94 | 84 tablet [P] £8.82
  - Elleste Solo (Meda Pharmaceuticals Ltd)
    - Estradiol 1 mg Elleste Solo 1mg tablets | 84 tablet [P] £0.90
    - Estradiol 2 mg Elleste Solo 2mg tablets | 84 tablet [P] £3.05
  - Progynova (Bayer Plc)
    - Estradiol valerate 1 mg Progynova 1mg tablets | 84 tablet [P] £3.30
    - Estradiol valerate 2 mg Progynova 2mg tablets | 84 tablet [P] £7.30
  - Zumenon (BGP Products Ltd)
    - Estradiol 1 mg Zumenon 1mg tablets | 84 tablet [P] £6.89
    - Estradiol 2 mg Zumenon 2mg tablets | 84 tablet [P] £6.89

**Pessary**

- Vagifem (Novo Nordisk Ltd)
  - Estradiol 10 microgram Vagifem 10microgram vaginal tablets | 24 pessary [P] £16.72 DT price = £16.72

**Endocrine system**
### Vaginal delivery system

**CAUTIONARY AND ADVISORY LABELS**

- **EXCIPIENTS:** May contain Propylene glycol Gel
- **Progynova TS**
- **Estraderm MX**
- **Elleste Solo MX**
- **Transdermal patch**
- **Estring**

**CAUTIONARY AND ADVISORY LABELS**

- **Vaginal delivery system**
- **Estradiol (as Estradiol hemihydrate) 1 mg 500 (Orion Pharma (UK) Ltd)**
- **Estradiol 100 microgram per 24 hour patch 4 (Teva UK Ltd)**
- **Estradiol 100 microgram per 24 hour patch 8 (Teva UK Ltd)**
- **Estradiol 80 microgram per 24 hour patch 8 (Teva UK Ltd)**
- **Estradiol 75 microgram per 24 hour patch 6 (Pfizer Ltd)**
- **Estradiol 75 microgram per 24 hour patch 8 (Pfizer Ltd)**
- **Estradiol 75 microgram per 24 hour patch 31 (Novartis Pharmaceuticals UK Ltd)**
- **Estradiol 50 microgram per 24 hour patch 8 (Pfizer Ltd)**
- **Estradiol 25 microgram per 24 hour patch 8 (Pfizer Ltd)**
- **Estradiol 25 microgram per 24 hour patch 6 (OptraPharmaceuticals Ltd)**
- **Estradiol 10 microgram per 24 hour patch 6 (OptraPharmaceuticals Ltd)**
- **Estradiol 10 microgram per 24 hour patch 8 (OptraPharmaceuticals Ltd)**
- **Estradiol 4 microgram per 24 hour patch 6 (OptraPharmaceuticals Ltd)**
- **Estradiol 2 microgram per 24 hour patch 6 (OptraPharmaceuticals Ltd)**

**INDICATIONS AND DOSE**

**Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously**

- **Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 12 months previously**
  - **BY MOUTH**
  - **Adult:** 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase

**CAUTIONS**

- **Use with care if an increased concentration of potassium might be hazardous**

**RENAI IMPAIRMENT**

- **Avoid if eGFR less than 30 mL/minute/1.73 m².**

**MEDICINAL FORMS**

- **There can be variation in the licensing of different medicines containing the same drug.**

**Tablet**

- **Angeliq (Bayer Plc)**
  - **Drospirenone 2 mg, Estradiol (as Estradiol hemihydrate) 1 mg**
  - **Angeliq tablets 84 tablet (Pf) £29.00**

**Drospirenone with estradiol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 649.

**INDICATIONS AND DOSE**

**FEMOSTON®-CONTI 0.5 MG/2.5 MG**

- **Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously**

  - **BY MOUTH**
  - **Adult:** 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase

**FEMOSTON®-CONTI 1 MG/5 MG**

- **Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously**

  - **BY MOUTH**
  - **Adult:** 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase

**FEMOSTON® 1 MG/10 MG**

- **Menopausal symptoms in women with a uterus**

  - **BY MOUTH**
  - **Adult:** 1 tablet daily for 14 days, white tablet to be taken and started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), then 1 tablet daily for 14 days, grey tablet to be taken, subsequent courses repeated without interval, Femoston® 1 mg/10 mg given initially and Femoston® 2 mg/10 mg substituted if symptoms not controlled

**Osteoporosis prophylaxis in women with a uterus**

**BY MOUTH**

- **Adult:** 1 tablet daily for 14 days, white tablet to be taken and started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), then 1 tablet daily for 14 days, grey tablet to be taken, subsequent courses repeated without interval

**Dydrogesterone with estradiol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 649.

**INDICATIONS AND DOSE**

**FEMOSTON®-CONTI Protection**

- **Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously**

  - **BY MOUTH**
  - **Adult:** 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase

**FEMOSTON®-CONTI Protection 1 MG/5 MG**

- **Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously**

  - **BY MOUTH**
  - **Adult:** 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase
 Estradiol with estriol and estrone

**BY MOUTH**

- Adult: 1 tablet daily for 14 days, red tablet to be taken and started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), then 1 tablet daily for 14 days, yellow tablet to be taken, subsequent courses repeated without interval.

**INTERACTIONS**

- **CONTRA-INDICATIONS** Acute porphyrias p. 864, genital or breast cancer - history during pregnancy of idiopathic jaundice, severe pruritus, or pemphigoid gestationis, history of liver tumours, severe arterial disease, undiagnosed vaginal bleeding.
- **CAUTIONS** Conditions that may worsen with fluid retention e.g. epilepsy, hypertension, migraine, asthma, or cardiac dysfunction - diabetes (progestogens can decrease glucose tolerance), history of depression - in those susceptible to thromboembolism (particular caution with high dose).
- **SIDE-EFFECTS** Acne, alopecia, anaphylactoid reactions, bloating, breast tenderness, change in libido, depression, dizziness, drowsiness, fluid retention, headache, hirsutism, insomnia, jaundice, menstrual disturbances, nausea, premenstrual-like syndrome, pruritus, rash, skin reactions, utricaria, weight change.
- **HEPATIC IMPAIRMENT** Avoid.
- **RENAL IMPAIRMENT** Use with caution.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **DYDROGESTERONE WITH ESTRADIOL (Non-proprietary)**
  - Dydrogesterone 10 mg, Estradiol 2 mg
  - Dydrogesterone 10 mg tablets / 42 tablet (POM) no price available
  - Dydrogesterone 10 mg, Estradiol 1 mg
  - Estradiol 2 mg / Dydrogesterone 10mg tablets / 42 tablet (POM) no price available
  - Femoston-conti (BGP Products Ltd)
    - Dydrogesterone 2.5 microgram, Estradiol 500 microgram
    - Femoston-conti 0.5mg/2.5mg tablets / 84 tablet (POM) £24.43
    - Dydrogesterone 5 mg, Estradiol 1 mg
    - Femoston-conti 1mg/5mg tablets / 84 tablet (POM) £24.43
    - Femoston 1/10 (BGP Products Ltd)
      - Femoston 1/10 tablets / 84 tablet (POM) £16.16
    - Femoston 2/10 (BGP Products Ltd)
      - Femoston 2/10 tablets / 84 tablet (POM) £16.16

**Medically responsive conditions**

**Estradiol with levonorgestrel**

**INDICATIONS AND DOSE**

**FEMSEVEN CONTI**

Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously.

**BY TRANSDERMAL APPLICATION**

- Adult: Apply 1 patch once weekly continuously.

**FEMSEVEN SEQUI**

Menopausal symptoms in women with a uterus whose last menstrual period occurred over 3 years previously.

**BY TRANSDERMAL APPLICATION**

- Adult: Apply 1 phase 1 patch once weekly for 2 weeks, then apply 1 phase 2 patch once weekly for 2 weeks, subsequent courses are repeated without interval.

**PATIENT AND CARER ADVICE**

Patient counselling is advised for estradiol with levonorgestrel patches (application).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Transdermal patch**

- FemSeven Conti (Teva UK Ltd)
  - Estradiol 50 microgram per 24 hour, Levonorgestrel 7 microgram per 24 hour FemSeven Conti patches / 4 patch (POM) £15.48 / 12 patch (POM) £44.12
- FemSeven Sequi (Teva UK Ltd)
  - Estradiol 50 microgram per 24 hour, Levonorgestrel 7 microgram per 24 hour FemSeven Sequi patches / 4 patch (POM) £13.18 / 12 patch (POM) £37.54

**Estradiol with medroxyprogesterone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, medroxyprogesterone acetate p. 695, estradiol p. 649.

**INDICATIONS AND DOSE**

**INDIVINA**

Menopausal symptoms in women with a uterus whose last menstrual period occurred over 3 years previously. Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 3 years previously.

**BY MOUTH**

- Adult: Initially 1/2.5 mg daily taken continuously, adjusted according to response, to be started at end of scheduled bleed if changing from cyclical HRT.

**TRIDESTRA**

Menopausal symptoms in women with a uterus. Osteoporosis prophylaxis in women with a uterus.

**BY MOUTH**

- Adult: 1 white tablet daily for 70 days, then 1 blue tablet daily for 14 days, then 1 yellow tablet daily for 7 days, subsequent courses are repeated without interval.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
### Estradiol with norethisterone

The properties listed below are those particular to the combination only. For the properties of the components please consider, norethisterone p. 656, estradiol p. 649.

#### INDICATIONS AND DOSE

**CLIMAGEST® 1-MG**

**Menopausal symptoms**

**BY MOUTH**

- Adult: 1 grey tablet daily for 16 days, started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 white tablet daily for 12 days, subsequent courses are repeated without interval.

**CLIMAGEST® 2-MG**

**Menopausal symptoms (if symptoms not controlled with lower strength)**

**BY MOUTH**

- Adult: 1 blue tablet daily for 16 days, started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 white tablet daily for 12 days, subsequent courses are repeated without interval.

**CLIMESSE®**

**Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously**

**Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 12 months previously**

**BY MOUTH**

- Adult: 1 tablet daily continuously.

**CLINOCETTE®**

**Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus**

**BY MOUTH**

- Adult: 1 white tablet daily for 16 days, starting on day 5 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 pink tablet daily for 12 days, subsequent courses repeated without interval.

**ELLESTE-DUET® CONTI**

**Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously | Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 12 months previously**

**BY MOUTH**

- Adult: 1 tablet daily continuous basis, if changing from cyclical HRT begin treatment at the end of scheduled bleed.

**ELLESTE-DUET® 1-MG**

**Menopausal symptoms**

**BY MOUTH**

- Adult: 1 white tablet daily for 16 days, started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 green tablet daily for 12 days, subsequent courses are repeated without interval.
PATIENT AND CARER ADVICE

EVOREL® SEQUI

Patients and carers should be advised on the application of Evorel® Sequi patches.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Climesse (Novartis Pharmaceuticals UK Ltd)
  Estradiol valerate 2 mg, Norethisterone 700 microgram Climesse tablets | 28 tablet (POD) £9.92
  84 tablet (POD) £29.78 DT price = £29.78
- Climadest (Novartis Pharmaceuticals UK Ltd)
  Climadest 1mg tablets | 28 tablet (POD) £5.51
  Climadest 2mg tablets | 28 tablet (POD) £16.02
  Climadest 2mg tablets | 28 tablet (POD) £5.51
- Cliniorette (Resource Medical UK Ltd)
  Cliniorette tablets | 84 tablet (POD) £9.23
- Elleste Duet (Media Pharmaceuticals Ltd)
  Elleste Duet 1mg tablets | 84 tablet (POD) £9.20
  Elleste Duet 2mg tablets | 84 tablet (POD) £9.20
- Novofem (Novo Nordisk Ltd)
  Novofem tablets | 84 tablet (POD) £11.43
- Trisequens (Novo Nordisk Ltd)
  Trisequens tablets | 84 tablet (POD) £11.10
- Kliofem (Novo Nordisk Ltd)
  Estradiol 2mg, Norethisterone acetate 1 mg Kliofem tablets | 84 tablets (POD) £11.43
- Kliovance (Novo Nordisk Ltd)
  Estradiol 1 mg, Norethisterone acetate 500 micrograms Kliovance tablets | 84 tablet (POD) £11.20
- Nuvelle Continuous (Bayer Plc)
  Estradiol 2mg, Norethisterone acetate 1 mg Nuvelle Continuous tablets | 84 tablets (POD) £19.00

Transdermal patch

- Estragest (Novartis Pharmaceuticals UK Ltd)
  Estradiol 50 microgram per 24 hour, Norethisterone acetate 250 microgram per 24 hour Estragest TTS patches | 4 patch (POD) no price available
  12 patch (POD) no price available
- Evorel Conti (Janssen-Cilag Ltd)
  Estradiol 50 microgram per 24 hour
  Evorel Conti patches | 4 patch (POD) no price available
  8 patch (POD) £13.00
  24 patch (POD) £37.22 DT price = £37.22
- Evorel Sequi (Janssen-Cilag Ltd)
  Evorel Sequi patches | 8 patch (POD) £11.09

Estradiol with norgestrel

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 649.

INDICATIONS AND DOSE

Cyclo-Progynova® 2MG TABLETS

Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus

BY MOUTH

- Adult: 1 white tablet daily for 11 days; started on day 5 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 brown tablet daily for 10 days, followed by a 7-day tablet free interval

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Cyclo-Progynova (Meda Pharmaceuticals Ltd)
  Cyclo-Progynova 2mg tablets | 21 tablet (POD) £3.11

Ethinylestradiol

(Ethinyleoestradiol)

INDICATIONS AND DOSE

Short-term treatment of symptoms of oestrogen deficiency | Osteoporosis prophylaxis if other drugs cannot be used

BY MOUTH

- Adult: 10–50 micrograms daily for 21 days, repeated after 7-day tablet-free period, to be given with progestogen for 12–14 days per cycle in women with intact uterus.

Female hypogonadism

BY MOUTH

- Adult: 10–50 micrograms daily usually on cyclical basis, initial oestrogen therapy should be followed by combined oestrogen and progestogen therapy.

Menstrual disorders

BY MOUTH

- Adult: 20–50 micrograms daily from day 5 to 25 of each cycle, to be given with progestogen, added either throughout the cycle or from day 15 to 25.

Palliative treatment of prostate cancer

BY MOUTH

- Adult: 0.15–1.5 mg daily.

CONTRA-INDICATIONS

Acute porphyrias p. 864 - active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction) - active thrombophlebitis - Dubin-Johnson and Rotor syndromes (or monitor closely) - gallstones - heart disease associated with pulmonary hypertension - heart disease associated with risk of embolus - history during pregnancy of cholestatic jaundice - history during pregnancy of oestrogen-dependent cancer - history during pregnancy of phegmphoid gastropathies - history during pregnancy of pruritus - history of breast cancer - history of haemolytic uraemic syndrome - liver disease (where liver function tests have failed to return to normal) - migraine with aura - oestrogen-dependent cancer - sclerosing treatment for varicose veins - severe or multiple risk factors for arterial disease - severe or multiple risk factors for venous thromboembolism - systemic lupus erythematosus with (or unknown) antiphospholipid antibodies - thrombophilic disorder - transient cerebral ischaemic attacks without headaches - undiagnosed vaginal bleeding - untreated endometrial hyperplasia - venous thromboembolism, or history of recurrent venous thromboembolism (unless already on anticoagulant treatment)

CAUTIONS

Active trophoblastic disease (until return to normal of urine - and plasma-gonadotrophin concentration) - seek specialist advice - cardiovascular disease (sodium retention with oedema, thromboembolism) - Crohn’s disease - diabetes (increased risk of heart disease) - gene mutations associated with breast cancer (e.g. BRCA 1) - history of breast nodules or fibrocystic disease - history of severe depression especially if induced by hormonal contraception - hyperprolactinaemia (seek specialist advice) - hypophysial tumours - increased risk of gall-bladder disease - inflammatory bowel disease - migraine (migraine-like headaches) - personal or family history of hypertriglyceridaemia (increased risk of pancreatitis) - presence of antiphospholipid antibodies (increased risk of thrombotic events) - prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer - risk factors for arterial disease - risk factors for migraine - risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) - risk factors for venous thromboembolism - sickle-cell disease - undiagnosed breast mass
CAUTIONS, FURTHER INFORMATION

Other conditions

The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present, see above). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

Risk of venous thromboembolism

Use with caution if any of following factors present but avoid if two or more factors present:

- family history of venous thromboembolism in first-degree relative aged under 45 years (avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies including lupus anticoagulant);
- obesity—body mass index ≥30 kg/m² (avoid if body mass index ≥35 kg/m² unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
- long-term immobilisation e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);
- history of superficial thrombophlebitis;
- age over 35 years (avoid if over 50 years);
- smoking.

Risk factors for arterial disease

Use with caution if any one of following factors present but avoid if two or more factors present:

- family history of arterial disease in first degree relative aged under 45 years (avoid if atherogenic lipid profile);
- diabetes mellitus (avoid if diabetes complications present);
- hypertension—blood pressure above systolic 140 mmHg or diastolic 90 mmHg (avoid if blood pressure above systolic 160 mmHg or diastolic 95 mmHg); (In adolescents, caution if blood pressure very high);
- smoking (avoid if smoking 40 or more cigarettes daily);
- age over 35 years (avoid if over 50 years);
- obesity (avoid if body mass index ≥35 kg/m² unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
- migraine without aura (avoid if migraine with aura (focal symptoms), or severe migraine frequently lasting over 72 hours despite treatment, or migraine treated with ergot derivatives).

Migraine

Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour).

INTERACTIONS

Appendix 1 (oestrogens).

SIDE-EFFECTS

- Rare
- Gallstones • systemic lupus erythematosus
- Frequency not known
- Abdominal bloating • abdominal cramps • absence of withdrawal bleeding • altered blood lipids (may lead to pancreatitis) • amenorrhoea after discontinuation • breast enlargement • breast secretion • breast tenderness • cervical erosion • changes in libido • changes in lipid metabolism • changes in vaginal discharge • chloasma • cholestatic jaundice • chorea • contact lenses may irritate • depression • dizziness • feminising effects • fluid retention • glucose intolerance • headache • hepatic tumours • hypertension • irritability • leg cramps (rule out venous thrombosis) • liver impairment • migraine • mood changes • nausea • nervousness • photosensitivity • premenstrual-like syndrome • rash • reduced menstrual loss • skin reactions • sodium retention • symptoms of endometriosis may be exacerbated • thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB) • uterine fibroids may increase in size • vaginal candidiasis • visual disturbances • vomiting • weight changes • ‘spotting’ in early cycles

SIDE-EFFECTS, FURTHER INFORMATION

Withdrawal bleeding

Cyclical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

- PREGNANCY
- Not known to be harmful.
- BREAST FEEDING
- Avoid until weaning or for 6 months after birth (adverse effects on lactation).
- HEPATIC IMPAIRMENT
- Avoid.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, capsule

Tablet

- ETHINYLESTRADIOL (Non-proprietary)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol 2 microgram</td>
<td>£200.00</td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 10 microgram</td>
<td>£200.00</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol 1 mg</td>
<td>£200.00</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol 50 mg</td>
<td>£200.00</td>
<td></td>
</tr>
</tbody>
</table>

DIFFERENTIATED PROGESTOGENS

Norethisterone

INDICATIONS AND DOSE

Endometriosis

BY MOUTH

- Adult: 10–15 mg daily for 4–6 months or longer, to be started on day 5 of cycle; increased to 20–25 mg daily if required, dose only increased if spotting occurs and reduced once bleeding has stopped

Dysfunctional uterine bleeding (to arrest bleeding)

BY MOUTH

- Adult: 5 mg 3 times a day 10 days

Dysfunctional uterine bleeding (to prevent bleeding)

BY MOUTH

- Adult: 5 mg twice daily, to be taken from day 19 to day 26 of cycle

Dysmenorrhoea

BY MOUTH

- Adult: 5 mg 3 times a day for 3–4 cycles, to be taken from day 5–24 of cycle

Premenstrual syndrome (but not recommended)

BY MOUTH

- Adult: 5 mg 2–3 times a day for several cycles, to be taken from day 19–26 of cycle

Postponement of menstruation

BY MOUTH

- Females of childbearing potential: 5 mg 3 times a day, to be started 3 days before expected onset (menstruation occurs 2–3 days after stopping)
Breast cancer
BY MOUTH
▶ Adult: 40 mg daily, increased if necessary to 60 mg daily

Short-term contraception
BY DEEP INTRAMUSCULAR INJECTION
▶ Females of childbearing potential: 200 mg, to be administered within first 5 days of cycle or immediately after parturition (duration 8 weeks), then 200 mg after 8 weeks if required

Contraception
BY MOUTH
▶ Females of childbearing potential: 350 micrograms daily, dose to be taken at same time each day, starting on day 1 of cycle then continuously, if administration delayed for 3 hours or more it should be regarded as a ‘missed pill’

CONTRA-INDICATIONS

GENERAL CONTRA-INDICATIONS
Avoid in patients with a history of liver tumours - breast cancer (unless progestogens are being used in the management of this condition) - genital cancer (unless progestogens are being used in the management of this condition) - history during pregnancy of idiopathic jaundice - history during pregnancy of phephigoid gestationis (non-contraceptive indications) - history during pregnancy of severe pruritus (non-contraceptive indications) - when used as a contraceptive, history of breast cancer (can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable)

SPECIFIC CONTRA-INDICATIONS
▶ With oral use Acute porphyrias p. 864 - severe arterial disease - undiagnosed vaginal bleeding

CAUTIONS

GENERAL CAUTIONS
Asthma - cardiac dysfunction - conditions that may worsen with fluid retention - diabetes (progestogens can decrease glucose tolerance—monitor patient closely) - epilepsy - history of depression - hypertension - migraine - susceptibility to thromboembolism (particular caution with high dose)

SPECIFIC CAUTIONS
▶ When used for contraception Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice - arterial disease - functional ovarian cysts - history of jaundice in pregnancy - malabsorption syndromes - past ectopic pregnancy - sex-steroid dependent cancer - systemic lupus erythematosus with positive (or unknown) anti-phospholipid antibodies with intramuscular use for contraception disturbances of lipid metabolism - history during pregnancy of deterioration of otosclerosis - history during pregnancy of pruritus - possible risk of breast cancer

CAUTIONS, FURTHER INFORMATION
Use as a contraceptive in co-morbidities The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes mellitus and migraine; evidence for caution in these conditions is unsatisfactory.

Breast cancer risk with contraceptive use There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

INTERACTIONS
▶ Appendix 1 (progestogens).

With intramuscular use Effectiveness of parenteral progestogen-only contraceptives is not affected by antibacterials that do not induce liver enzymes. The effectiveness of norethisterone intramuscular injection is not affected by enzyme-inducing drugs and may be continued as normal during courses of these drugs.

SIDE-EFFECTS

GENERAL SIDE-EFFECTS
Acne - alopecia - anaphylactoid reactions - breast tenderness - change in libido - depression - disturbance of appetite - dizziness - fluid retention - headache - hirsutism - insomnia (non-contraceptive indications) - jaundice - menstrual disturbances - nausea - premenstrual-like syndrome - pruritus - rash - skin reactions - urticaria - vomiting - weight change

SPECIFIC SIDE-EFFECTS
▶ With intramuscular use Injection-site reactions

SIDE-EFFECTS, FURTHER INFORMATION
Cervical cancer Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives (use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years). The risk of cervical cancer with other progestogen-only contraceptives is not yet known.

PREGNANCY Masculinisation of female fetuses and other defects reported with non-contraceptive use.

BREAST FEEDING Progestogen-only contraceptives do not affect lactation. Higher doses (used in malignant conditions) may suppress lactation and alter milk composition—use lowest effective dose.

With intramuscular use Withhold breast-feeding for neonates with severe or persistent jaundice requiring medical treatment.

HEPATIC IMPAIRMENT When used as a contraceptive; caution in severe liver disease and recurrent cholestatic jaundice, avoid in liver tumour. Avoid in non-contraceptive indications.

RENAL IMPAIRMENT Use with caution in non-contraceptive indications.

PATIENT AND CARER ADVICE
Missed oral contraceptive pill The following advice is recommended: ‘If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days.’

The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.

Diarrhoea and vomiting with oral contraceptives Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.
Starting routine for oral contraceptives. One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not necessary when initiating treatment.

Changing from a combined oral contraceptive: start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).

After childbirth: oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days. Contraceptives by injection: Full counselling backed by patient information leaflet required before administration—likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

#### Tablet

- **NORETHISTERONE (Non-proprietary)**
  - Norethisterone 350 microgram tablets | 84 tablet | no price available DT price | £1.80
  - Norethisterone 5 mg tablets | 30 tablet | £0.50 DT price | £2.35
- **Micronor** (Janssen-Cilag Ltd)
  - Micronor 35 microgram tablets | 84 tablet | £1.00 DT price | £1.80
  - Noriday (Pfizer Ltd)
  - Noriday 350 microgram tablets | 84 tablet | £2.10 DT price | £1.80

- **Primolut N (Bayer Plc)**
  - Primolut N 5 mg tablets | 30 tablet | £0.50 DT price | £2.35
  - Ulotvlan (Pfizer Ltd)
  - Norethisterone 5 mg tablets | 30 tablet | £0.50 DT price | £2.35

#### Solution for injection

- **Noristerat** (Bayer Plc)
  - Norethisterone enantate 200 mg per 1 ml injection ampoules | 1 ampoule | £0.55

Also available in combination with estradiol, p. 654

### SIDE-EFFECTS

- Acne
- Alopecia
- Anaphylactoid reactions
- Gastro-intestinal disturbances
- Headache
- Hirsutism
- Insomnia
- Jaundice
- Menstrual disturbances
- Nausea
- Premenstrual-like syndrome
- Pruritus
- Rash
- Skin reactions
- Urticaria
- Weight change

### CONTRA-INDICATIONS

- Acute porphyrias p. 864
- Av avoidance in patients with a history of liver tumours—breast cancer (unless progestogens are being used in the management of this condition)—genital cancer (unless progestogens are being used in the management of this condition)—history during pregnancy of idiopathic jaundice—history during pregnancy of pemphigoid gestationis—history during pregnancy of severe pruritus—Incomplete miscarriage—missed miscarriage—severe arterial disease—undiagnosed vaginal bleeding

### CAUTIONS

- Asthma
- Cardiac dysfunction—conditions that may worsen with fluid retention—diabetes (progestogens can decrease glucose tolerance—monitor patient closely)
- Epilepsy
- History of depression
- Hypertension
- Migraine
- Susceptibility to thromboembolism (particular caution with high dose)

### INTERACTIONS

- 

### ESTRADIOL

#### INSTRUCTIONS

- 

### DIRECTIONS FOR ADMINISTRATION

Capsules should be taken at bedtime on an empty stomach.

### PATIENT AND CARER ADVICE

Patient counselling is advised for progesterone capsules (administration).
Anti-oestrogens 659

### 8.2 Anti-oestrogens

#### Clomifene citrate (Clomiphene citrate)

- **Drug action** Anti-oestrogen which induces gonadotrophin release by occupying oestrogen receptors in the hypothalamus, thereby interfering with feedback mechanisms; choriionic gonadotrophin is sometimes used as an adjunct.

#### Indications and dose

**Treatment of female infertility due to oligomenorrhoea or secondary amenorrhoea (e.g. associated with polycystic ovarian disease)**

- **By mouth**
  - Adult: 50 mg daily for 5 days, to be started within about 5 days of onset of menstruation (preferably on 2nd day) or at any time (normally preceded by a progesterone induced withdrawal bleed) if cycles have ceased, followed by 100 mg daily if required for a further 5 days, this second course may be given in absence of ovulation; most patients who are going to respond will do so to first course, 2 courses should constitute adequate therapeutic trial; long-term cyclical therapy not recommended.

#### Important safety information

The CSM has recommended that clomifene should not normally be used for longer than 6 cycles (possibly increased risk of ovarian cancer).
CONTRA-INDICATIONS Abnormal uterine bleeding of undetermined cause • hormone-dependent tumours • ovarian cysts

CAUTIONS Ectopic pregnancy • incidence of multiple births increased (consider ultrasound monitoring) • ovarian hyperstimulation syndrome • polycystic ovary syndrome (cysts may enlarge during treatment, also risk of exaggerated response to usual doses) • uterine fibroids

SIDE-EFFECTS Abdominal discomfort • breast tenderness • convulsions • depression • diziness • endometriosis • hair loss • headache • hot flushes • insomnia • intermenstrual spotting • menorrhagia • nausea • ovarian hyperstimulation (withdraw) • rashes • visual disturbances (withdraw and initiate ophthalmological examination) • vomiting • weight gain

CONCEPTION AND CONTRACEPTION Exclude pregnancy before treatment.

PREGNANCY Possible effects on fetal development.

BREAST FEEDING May inhibit lactation.

HEPATIC IMPAIRMENT Avoid in severe liver disease.

PATIENT AND CARER ADVICE Patients planning to conceive should be warned that there is a risk of multiple pregnancy (rarely more than twins).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Clomifene citrate (Non-proprietary)
  Clomifene citrate 50 mg (Clomifene 50mg tablets | 30 tablet [PAR])
  £21.74 DT price = £21.74
- Clomid (Sanofi)
  Clomifene citrate 50 mg Clomid 50mg tablets | 30 tablet [PAR]
  £8.46 DT price = £21.74

8.3 Male sex hormone responsive conditions

Androgens, anti-androgens and anabolic steroids

Androgens

Androgens cause masculinisation; they may be used as replacement therapy in castrated adults and in those who are hypogonadal due to either pituitary or testicular disease. In the normal male they inhibit pituitary gonadotrophin secretion and depress spermatogenesis. Androgens also have an anabolic action which led to the development of anabolic steroids.

Androgens are useless as a treatment of impotence and impaired spermatogenesis unless there is associated hypogonadism; they should not be given until the hypogonadism has been properly investigated. Treatment should be under expert supervision.

When given to patients with hypopituitarism they can lead to normal sexual development and potency but not to fertility. If fertility is desired, the usual treatment is with gonadotrophins or pulsatile gonadotrophin-releasing hormone which will stimulate spermatogenesis as well as androgen production.

Intramuscular depot preparations of testosterone esters are preferred for replacement therapy. Testosterone enantate, propionate or undecanoate, or alternatively Sustanon® — which consists of a mixture of testosterone esters and has a longer duration of action, may be used.

Anti-androgens

Cyproterone acetate

Cyproterone acetate p. 662 is an anti-androgen used in the treatment of severe hypersexuality and sexual deviation in the male. It inhibits spermatogenesis and produces reversible infertility (but is not a male contraceptive); abnormal sperm forms are produced. Fully informed consent is recommended and an initial spermatogram. As hepatic tumours have been produced in animal studies, careful consideration should be given to the risk/benefit ratio before treatment. Cyproterone acetate is also licensed for use alone in patients with metastatic prostate cancer refractory to gonadorelin analogue therapy and has been used as an adjunct in prostatic cancer and in the treatment of acne and hirsutism in women.

Dutasteride and finasteride

Dutasteride p. 676 and finasteride p. 676 are alternatives to alpha-blockers particularly in men with a significantly enlarged prostate. Finasteride is also licensed for use with doxazosin in the management of benign prostatic hyperplasia.

A low strength of finasteride is licensed for treating male-pattern baldness in men.

Anabolic steroids

Anabolic steroids have some androgenic activity but they cause less virilisation than androgens in women. They are used in the treatment of some aplastic anaemias. Anabolic steroids have been given for osteoporosis in women but they are no longer advocated for this purpose.

The protein-building properties of anabolic steroids have not proved beneficial in the clinical setting. Their use as body builders or tonics is unjustified; some athletes abuse them.

ANDROGENS

Androgens

CONTRA-INDICATIONS Breast cancer in males • history of liver tumours • hypercalcaemia • prostate cancer

CAUTIONS Cardiac impairment • diabetes mellitus • elderly • epilepsy • hypertension • ischaemic heart disease • migraine • pre-pubertal boys (fusion of epiphyses is hastened and may result in short stature)—statural growth and sexual development should be monitored • skeletal metastases—risk of hypercalcaemia or hypercalciuria (if this occurs, treat appropriately and restart treatment once normal serum calcium concentration restored) • sleep apnoea • stop treatment or reduce dose if severe polycythaemia occurs • tumours—risk of hypercalcaemia or hypercalciuria (if this occurs, treat appropriately and restart treatment once normal serum calcium concentration restored)

INTERACTIONS → Appendix 1 (testosterone).

SIDE-EFFECTS

Common or very common Acne • androgenic effects (to be assessed regularly in women) • anxiety • arthralgia • asthenia • changes in libido • cholestasis • jaundice • depression • electrolyte disturbances • excessive duration of penile erection • excessive frequency of penile erection • gastro-intestinal bleeding • gynaecomastia • headache • hirsutism • hypercalcaemia • hypertension • increased bone growth • irritability • male-pattern baldness • muscle cramps • nausea • nervousness • oedema • paraesthesia • polycystaemia • precocious sexual development in pre-pubertal males • premature closure of epiphyses in pre-pubertal males • prostate abnormalities • prostate cancer • pruritus • seborrhoea • sodium retention • suppression of virilism in women • vomiting • weight gain
**Testosterone**

**INDICATIONS AND DOSE**

- **TESTIM®**
  - **Hypogonadism due to testosterone deficiency in men**
  - **BY TRANSDERMAL APPLICATION**
    - Adult: Apply 50 mg once daily, subsequent application adjusted according to response; maximum 100 mg per day
  
  **Dose equivalence and conversion**
  - One tube of 5 g contains 50 mg testosterone.

- **TESTOGEL®**
  - **Hypogonadism due to androgen deficiency in men**
  - **BY TRANSDERMAL APPLICATION**
    - Adult: Apply 50 mg once daily; increased in steps of 25 mg, adjusted according to response; maximum 100 mg per day
  
  **Dose equivalence and conversion**
  - One sachet of 5 g contains 50 mg of testosterone.

- **TOSTRAN®**
  - **Hypogonadism due to testosterone deficiency in men**
  - **BY TRANSDERMAL APPLICATION**
    - Adult: Apply 60 mg once daily, subsequent application adjusted according to response; maximum 80 mg per day
  
  **Dose equivalence and conversion**
  - 1 g of gel contains 20 mg testosterone.

**SIDE-EFFECTS**

- Suppression of spermatogenesis - allergic reactions - local irritation

**DIRECTIONS FOR ADMINISTRATION**

- With topical use: Avoid skin contact with gel application sites to prevent testosterone transfer to other people, especially pregnant women and children—consult product literature.

- **TESTIM®**
  - Squeeze entire content of tube on to one palm and apply as a thin layer on clean, dry, healthy skin of shoulder or upper arm, preferably in the morning after washing or bathing (if 2 tubes required use 1 per shoulder or upper arm); rub in and allow to dry before putting on clothing to cover site; wash hands with soap after application; avoid washing application site for at least 6 hours.

- **TESTOGEL®**
  - Apply thin layer of gel on clean, dry, healthy skin such as shoulders, arms or abdomen, immediately after sachet is opened. Not to be applied on genital area as high alcohol content may cause local irritation. Allow to dry for 3–5 minutes before dressing. Wash hands with soap and water after applying gel; avoid washing application site for at least 2 hours. Not to be applied on genital area.

- **TOSTRAN®**
  - Apply gel on clean, dry, intact skin of abdomen or both inner thighs, preferably in the morning. Gently rub in with a finger until dry before dressing. Wash hands with soap and water after applying gel; avoid washing application site for at least 2 hours. Not to be applied on genital area.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Testosterone enanate**

**INDICATIONS AND DOSE**

- **Hypogonadism**
  - **BY INTRAMUSCULAR INJECTION**
    - Adult: Initially 250 mg every 2–3 weeks; maintenance 250 mg every 3–6 weeks
  - Breast cancer
    - **BY INTRAMUSCULAR INJECTION**
      - Adult: 250 mg every 2–3 weeks

- **SIDE-EFFECTS**
  - Suppression of spermatogenesis

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **TESTOSTERONE ENANTATE (Non-proprietary)**
  - Testosterone enanate 250 mg per 1 ml
  - Testosterone enanate 250 mg/1 ml solution for injection ampoules | 3 ampoule
  - £68.00 Dose price + £68.00 Schedule 4 (CD Anab)
Testosterone propionate

**INDICATIONS AND DOSE**

**Androgen deficiency**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 50 mg 2–3 times a week

- **Delayed puberty in males**
  - **BY INTRAMUSCULAR INJECTION**
    - Adult: 50 mg once weekly

- **Breast cancer in women**
  - **BY INTRAMUSCULAR INJECTION**
    - Adult: 100 mg 2–3 times a week

**SIDE-EFFECTS** Suppression of spermatogenesis

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, cream.

Testosterone decanoate, isocaproate, phenylpropionate and propionate

The properties listed below are those particular to the combination only. For the properties of the components please consider, testosterone propionate above.

**INDICATIONS AND DOSE**

**Androgen deficiency**

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 1 ml every 3 weeks

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Capsule containing the same drug.** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, cream.

Testosterone undecanoate

**INDICATIONS AND DOSE**

**Androgen deficiency**

- **BY MOUTH**
  - Adult: 120–160 mg daily for 2–3 weeks; maintenance 40–120 mg daily

**Hypogonadism**

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 1 g every 10–14 weeks, to be given over 2 minutes, if necessary, second dose may be given after 6 weeks to achieve rapid steady state plasma testosterone levels and then every 10–14 weeks.

**SIDE-EFFECTS** Suppression of spermatogenesis

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- CAUTIONARY AND ADVISORY LABELS 21, 25
  - Restandol (Merck Sharp & Dohme Ltd)

- **Testosterone undecanoate 40 mg**
  - Restandol 40mg Testocaps | 30 capsule [POM] £8.55 Schedule 4 (CD Anab) | 60 capsule [POM] £17.10 DT price = £17.10 Schedule 4 (CD Anab)

Solution for injection

- **Nebido** (Bayer Plc)
  - Testosterone undecanoate 250 mg per 1 ml Nebido 1000mg/4ml solution for injection ampoules | 1 ampoule [POM] £80.00 DT price = £80.00 Schedule 4 (CD Anab)

- **Nebido** 1000mg/4ml solution for injection vials | 1 vial [POM] £80.00 Schedule 4 (CD Anab)

8.4 Male sex hormone antagonism

**ANTIOANDROGENS**

Cyproterone acetate

**INDICATIONS AND DOSE**

**Hypersexuality | Sexual deviation**

- **BY MOUTH**
  - Adult: 50 mg twice daily, to be taken after food.

- **Prevention of tumour flare with initial gonadorelin analogue therapy**

- **BY MOUTH**
  - Adult: 200 mg daily in 2–3 divided doses for 5–7 days before initiation of gonadorelin analogue, followed by 200 mg daily in 2–3 divided doses for 3–4 weeks after initiation of gonadorelin analogue; maximum 300 mg per day.

- **Long-term palliative therapy where gonadorelin analogues or orchiectomy contra-indicated, not tolerated, or where oral therapy preferred**

- **BY MOUTH**
  - Adult: 200–300 mg daily in 2–3 divided doses.

- **Hot flushes with gonadorelin analogue therapy or after orchiectomy**

- **BY MOUTH**
  - Adult: Initially 50 mg daily, then adjusted according to response to 50–150 mg daily in 1–3 divided doses.

**CONTRA-INDICATIONS** In hypersexuality, Dubin-Johnson syndrome - in hypersexuality, history of thromboembolic disorders - in hypersexuality, liver disease - in hypersexuality, malignant diseases - in hypersexuality, previous or existing liver tumours - in hypersexuality, Rotor syndrome - in hypersexuality, severe depression - in hypersexuality, severe diabetes (with vascular changes) - in hypersexuality, sickle-cell anaemia - in hypersexuality, wasting diseases - meningioma or history of meningioma - youths under 18 years (may arrest bone maturation and testicular development)

**CAUTIONS** Diabetes mellitus - in prostate cancer, severe depression - in prostate cancer, sickle-cell anaemia - ineffective for male hypersexuality in chronic alcoholism (relevance to prostate cancer not known)

**SIDE-EFFECTS**

- Rare Hypersensitivity reactions - osteoporosis - rash

- **Frequency not known** Breathlessness - changes in hair pattern - fatigue - gynaecomastia (rarely leading to galactorrhoea and benign breast nodules) - hepatic failure - hepatitis - hepatotoxicity - inhibition of spermatogenesis - jaundice - lassitude - reduced sebum production (may clear acne) - risk of recurrence of thromboembolic disease - weight changes

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hepatotoxicity** Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported (fatalities reported, usually after several months, at dosages of 100 mg and above). If hepatotoxicity is confirmed, cyproterone should normally be withdrawn unless the hepatotoxicity can be explained by another cause such as
metastatic disease (in which case cyproterone should be continued only if the perceived benefit exceeds the risk).

- **HEPATIC IMPAIRMENT** Avoid (unless used for prostate cancer)—dose-related toxicity.

- **MONITORING REQUIREMENTS**
  - Monitor blood counts initially and throughout treatment.
  - Monitor adrenocortical function regularly.
  - Monitor hepatic function regularly—liver function tests should be performed before and regularly during treatment and whenever symptoms suggestive of hepatotoxicity occur.

- **PATIENT AND CARER ADVICE** Fatigue and lassitude may impair performance of skilled tasks (e.g. driving).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, tablet, capsule.
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS**
    - **21**
      - **Cyproterone Acetate (Non-proprietary)**
      - **Cyproterone acetate 50 mg** Cyproterone 50mg tablets | 56 tablet £48.95 | 168 tablet £87.00 DT price = £87.00
      - **Cyproterone acetate 100 mg** Cyproterone 100mg tablets | 84 tablet £132.57 DT price = £55.19
      - **Androcur (Bayer Plc)**
        - Cyproterone acetate 50 mg Androcur 50mg tablets | 56 tablet £29.25
      - **Cyprostat (Bayer Plc)**
        - Cyproterone acetate 50 mg Cyprostat 50mg tablets | 168 tablet £87.00 DT price = £87.00
        - **Cyproterone acetate 100 mg** Cyprostat 100mg tablets | 84 tablet £132.57 DT price = £55.19

9 Thyroid disorders

**THYROID STIMULATING HORMONES**

**Thyrotropin alfa**
(Recombinant human thyroid stimulating hormone; rhTSH)

- **DRUG ACTION** Thyrotropin alfa is a recombinant form of thyrotrophin (thyroid stimulating hormone).

- **INDICATIONS AND DOSE**
  - Detection of thyroid remnants and thyroid cancer in post-thyroidectomy patients, together with serum thyroglobulin testing (with or without radioiodine imaging) to increase radio-iodine uptake for the ablation of thyroid remnant tissue in suitable post-thyroidectomy patients

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 900 micrograms every 24 hours for 2 doses, dose to be administered into the gluteal muscle, consult product literature for further information on indications and dose

- **CAUTIONS** Presence of thyroglobulin autoantibodies may give false negative results

- **SIDE-EFFECTS**
  - **Common or very common** Dizziness, fatigue, headache, nausea, vomiting
  - **Uncommon** Asthenia, back pain, influenza-like symptoms, paraesthesia, rash, urticaria
  - **Rare** Diarrhoea
  - **Very rare** Arthralgia, dyspnnea, flushing, hyperhidrosis, injection-site pain, injection-site pruritus, injection-site rash, injection-site reactions, myalgia, pain at site of metastases, palpitation, tremor

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated if previous hypersensitivity to bovine or human thyrotrophin.

- **PREGNANCY** Avoid.

- **BREAST FEEDING** Avoid.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for injection**
    - **Thyrogen** (Genzyme Therapeutics Ltd)
      - Thyrotropin alfa 900 microgram Thyrogen 900microgram powder for solution for injection vials | 2 vial £583.04

9.1 Hyperthyroidism

**Antithyroid drugs**

Antithyroid drugs are used for hyperthyroidism either to prepare patients for thyroidectomy or for long-term management. In the UK carbimazole is the most commonly used drug. Propylthiouracil p. 664 should be reserved for patients who are intolerant of carbimazole or for those who experience sensitivity reactions to carbimazole (sensitivity is not necessarily displayed to both drugs), and for whom other treatments are inappropriate. Both drugs act primarily by interfering with the synthesis of thyroid hormones.

Over-treatment with antithyroid drugs can result in the rapid development of hypothyroidism and should be avoided particularly during pregnancy because it can cause fetal goitre.

A combination of carbimazole with levothyroxine sodium daily p. 665, may be used in a blocking-replacement regimen; therapy is usually given for 18 months. The blocking-replacement regimen is not suitable during pregnancy.

**Iodine** has been used as an adjunct to antithyroid drugs for 10 to 14 days before partial thyroidectomy; however, there is little evidence of a beneficial effect. Iodine should not be used for long-term treatment because its antithyroid action tends to diminish.

Radioactive sodium iodide ($^{131}$I) solution is used increasingly for the treatment of thyrotoxicosis at all ages, particularly where medical therapy or compliance is a problem, in patients with cardiac disease, and in patients who relapse after thyroidectomy.

Propranolol hydrochloride p. 146 is useful for rapid relief of thyrotoxic symptoms and may be used in conjunction with antithyroid drugs or as an adjunct to radioactive iodine. Beta-blockers are also useful in neonatal thyrotoxicosis and in supraventricular arrhythmias due to hyperthyroidism. Propranolol hydrochloride p. 146 has been used in conjunction with iodine to prepare mildly thyrotoxic patients for surgery but it is preferable to make the patient euthyroid with carbimazole. Laboratory tests of thyroid function are not altered by beta-blockers. Most experience in treating thyrotoxicosis has been gained with propranolol hydrochloride but nadolol p. 145 is also used.

**Thyrotoxic crisis** (‘thyroid storm’) requires emergency treatment with intravenous administration of fluids, propranolol hydrochloride and hydrocortisone p. 583 (as sodium succinate), as well as oral iodine solution and carbimazole or propylthiouracil which may need to be administered by nasogastric tube.

**Pregnancy**

Radioactive iodine therapy is contra-indicated during pregnancy. Propylthiouracil and carbimazole can be given but the blocking-replacement regimen is not suitable. Rarely, carbimazole has been associated with congenital defects, including aplasia cutis of the neonate, therefore
propylthiouracil remains the drug of choice during the first trimester of pregnancy. In the second trimester, consider switching to carbimazole because of the potential risk of hepatotoxicity with propylthiouracil. Both propylthiouracil and carbimazole cross the placenta and in high doses may cause fetal goitre and hypothyroidism—the lowest dose that will control the hyperthyroid state should be used (requirements in Graves’ disease tend to fall during pregnancy).

Drugs used for Hyperthyroidism not listed below; Metoprolol tartrate, p. 144; Nadolol, p. 145; Propranolol hydrochloride, p. 146

Antithyroids
Carbamazole

Indications and dose
Hyperthyroidism

- Adult: 15–40 mg daily continue until the patient becomes euthyroid, usually after 4 to 8 weeks, higher doses should be prescribed under specialist supervision only, then reduced to 5–15 mg daily, reduce dose gradually, therapy usually given for 12 to 18 months

Hyperthyroidism (blocking-replacement regimen) in combination with levothyroxine

- Adult: 40–60 mg daily, therapy usually given for 18 months

Dose equivalence and conversion
When substituting, carbimazole 1 mg is considered equivalent to propylthiouracil 10 mg but the dose may need adjusting according to response.

Important safety information
Neutropenia and agranulocytosis
Doctors are reminded of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.
- Patient should be asked to report symptoms and signs suggestive of infection, especially sore throat.
- A white blood cell count should be performed if there is any clinical evidence of infection.
- Carbimazole should be stopped promptly if there is clinical or laboratory evidence of neutropenia.

- Contra-indications
  - Severe blood disorders

- Side-effects
  - Common or very common: Arthralgia, fever, headache, jaundice, malaise, mild gastrointestinal disturbances, nausea, pruritus, rash, taste disturbance
  - Rare: Agranulocytosis, alopecia, bone marrow suppression, jaundice, myopathy, pancytopenia

- Side-effects, further information
Rashes and pruritus are common with carbimazole but they can be treated with antihistamines without discontinuing therapy; alternatively propylthiouracil can be substituted.

- Pregnancy
  - Carbimazole can be given but the blocking-replacement regimen is not suitable. Rarely, carbimazole has been associated with congenital defects, including aplasia cutis of the neonate. Carbimazole crosses the placenta and in high doses may cause fetal goitre and hypothyroidism—the lowest dose that will control the hyperthyroid state should be used (requirements in Graves’ disease tend to fall during pregnancy).

- Breast feeding
  - Present in breast milk but this does not preclude breast-feeding as long as neonatal development is closely monitored and the lowest effective dose is used. Amount in milk may be sufficient to affect neonatal thyroid function therefore lowest effective dose should be used.

- Hepatic impairment
  - Use with caution in mild to moderate impairment. Avoid in severe impairment.

- Patient and carer advice
  - Warn patient or carers to tell doctor immediately if sore throat, mouth ulcers, bruising, fever, malaise, or non-specific illness develops.

- Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, capsule

Tablet
- Carbimazole (Non-proprietary)
  - Carbimazole 5 mg Carbimazole 5mg tablets | 100 tablet
    - DT price = £93.84
  - Carbimazole 20 mg Carbimazole 20mg tablets | 100 tablet
    - DT price = £208.17

Propylthiouracil

Indications and dose
Hyperthyroidism

- Adult: Initially 200–400 mg daily in divided doses until the patient becomes euthyroid, then reduced to 50–150 mg daily in divided doses, initial dose should be gradually reduced to the maintenance dose

Dose equivalence and conversion
When substituting, carbimazole 1 mg is considered equivalent to propylthiouracil 10 mg but the dose may need adjusting according to response.

- Side-effects
  - Common or very common: Arthralgia, fever, headache, jaundice, leucopenia, malaise, mild gastro-intestinal disturbances, nausea, pruritus, rash, taste disturbance
  - Rare: Agranulocytosis, alopecia, aplastic anaemia, bone marrow suppression, cutaneous vasculitis, encephalopathy, hepatic disorders, hepatic failure, hepatic necrosis, hepatitis, hypeprothrombinaemia, jaundice, lupus erythematos-like syndromes, myopathy, nephritis, pancytopenia, thrombocytopenia

- Side-effects, further information
Hepatotoxicity
Severe hepatic reactions have been reported, including fatal cases and cases requiring liver transplant—discontinue if significant liver-enzyme abnormalities develop.

- Pregnancy
  - Propylthiouracil can be given but the blocking-replacement regimen is not suitable. Propylthiouracil crosses the placenta and in high doses may cause fetal goitre and hypothyroidism—the lowest dose that will control the hyperthyroid state should be used (requirements in Graves’ disease tend to fall during pregnancy).

- Breast feeding
  - Present in breast milk but this does not preclude breast-feeding as long as neonatal development is closely monitored and the lowest effective dose is used. Amount in milk may be sufficient to affect neonatal thyroid function therefore lowest effective dose should be used.

- Hepatic impairment
  - Reduce dose.

- Renal impairment
  - Use three-quarters normal dose if eGFR 10–50 mL/minute/1.73 m². Use half normal dose if eGFR less than 10 mL/minute/1.73 m².

- Monitoring requirements
  - Monitor for hepatotoxicity.
Hypothyroidism 665

Liothyronine sodium by intravenous injection is the treatment of choice in hypothyroid coma. Adjunctive therapy includes intravenous fluids, hydrocortisone p. 583, and treatment of infection; assisted ventilation is often required.

THYROID HORMONES

Levothyroxine sodium (Thyroxine sodium)

INDICATIONS AND DOSE
Hypothyroidism
BY MOUTH
- Adult 18–49 years: Initially 50–100 micrograms once daily; adjusted in steps of 25–50 micrograms every 3–4 weeks, adjusted according to response; maintenance 100–200 micrograms once daily, dose to be taken preferably at least 30 minutes before breakfast, caffeine-containing liquids (e.g. coffee, tea), or other medication
- Adult 50 years and over: Initially 25 micrograms once daily; adjusted in steps of 25 micrograms every 4 weeks, adjusted according to response; maintenance 50–200 micrograms once daily, dose to be taken preferably at least 30 minutes before breakfast, caffeine-containing liquids (e.g. coffee, tea), or other medication

Hypothyroidism in patients with cardiac disease | Severe hypothyroidism
BY MOUTH
- Adult: Initially 25 micrograms once daily; adjusted in steps of 25 micrograms every 4 weeks, adjusted according to response; maintenance 50–200 micrograms once daily, dose to be taken preferably at least 30 minutes before breakfast, caffeine-containing liquids (e.g. coffee, tea), or other medication

Hyperthyroidism (blocking-replacement regimen) in combination with carbimazole
BY MOUTH
- Adult: 50–150 micrograms daily therapy usually given for 18 months

CONTRA-INDICATIONS
Thyrotoxicosis

CAUTIONS
Cardiovascular disorders · diabetes insipidus · diabetes mellitus (dose of antidiabetic drugs including insulin may need to be increased) · elderly · hypertension · long-standing hypothyroidism · myocardial infarction · myocardial insufficiency · panhypopituitarism (initiate corticosteroid therapy before starting levothyroxine) · predisposition to adrenal insufficiency (initiate corticosteroid therapy before starting levothyroxine)

CAUTIONS, FURTHER INFORMATION
Cardiovascular disorders Baseline ECG is valuable because changes induced by hypothyroidism can be confused with ischaemia.

INTERACTIONS
- Appendix 1 (thyroid hormones).

SIDE-EFFECTS
Anginal pain (usually at excessive dosage) · arrhythmias (usually at excessive dosage) · diarrhoea (usually at excessive dosage) · excitability (usually at excessive dosage) · fever · flushing · headache · heat intolerance · hypersensitivity reactions · insomnia (usually at excessive dosage) · muscle cramp · muscular weakness · oedema · palpitation (usually at excessive dosage) · pruritus · rash · restlessness (usually at excessive dosage) · sweating · tachycardia (usually at excessive dosage) · transient hair loss in children · tremor (usually at excessive dosage) · vomiting (usually at excessive dosage) · weight-loss

9.2 Hypothyroidism

Thyroid hormones

Thyroid hormones are used in hypothyroidism (myxoedema), and also in diffuse non-toxic goitre, Hashimoto’s thyroiditis (lymphadenoid goitre), and thyroid carcinoma. Neonatal hypothyroidism requires prompt treatment for normal development. Liothyronine sodium below (thyroxine sodium) below is the treatment of choice for maintenance therapy.

In infants and children with congenital hypothyroidism and juvenile myxoedema, the dose of levothyroxine sodium should be titrated according to clinical response, growth assessment, and measurements of plasma thyroxine and thyroid-stimulating hormone.

Liothyronine sodium p. 666 has a similar action to levothyroxine sodium but is more rapidly metabolised and has a more rapid effect. Its effects develop after a few hours and disappear within 24 to 48 hours of discontinuing treatment. It may be used in severe hypothyroid states when a rapid response is desired.
666  Thyroid disorders

**SIDE-EFFECTS, FURTHER INFORMATION**

Initial dosage in patients with cardiovascular disorders  If metabolism increases too rapidly (causing diarrhoea, nervousness, rapid pulse, insomnia, tremors and sometimes anginal pain where there is latent myocardial ischaemia), reduce dose or withhold for 1–2 days and start again at a lower dose.

- **PREGNANCY**  Levotyroxine requirement may increase during pregnancy. Levotyroxine may cross the placenta. Excessive or insufficient maternal thyroid hormones can be detrimental to fetus. Assess maternal thyroid function before conception (if possible), at diagnosis of pregnancy, at antenatal booking, during both the second and third trimesters, and after delivery (more frequent monitoring required on initiation or adjustment of levotyroxine).

- **BREAST FEEDING**  Amount too small to affect tests for neonatal hypothyroidism.

- **MEDICINAL FORMS**  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: powder for solution for injection, oral suspension, oral solution, powder, capsule

  **Tablet**
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 12.5 microgram per 1 tablet  | 28 tablet  | £4.00 DT price = £2.95 | 500 tablet  | £42.32-52.68
    - Levothyroxine sodium anhydrous 25 microgram per 1 tablet  | 28 tablet  | £5.00 DT price = £3.80 | 1000 tablet  | £93.40
    - Levothyroxine sodium anhydrous 50 microgram per 1 tablet  | 28 tablet  | £7.00 DT price = £5.40 | 1000 tablet  | £130.51
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 40 microgram per 1 tablet  | 28 tablet  | £12.00 DT price = £9.20 | 1000 tablet  | £222.51
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 50 microgram per 1 tablet  | 28 tablet  | £13.00 DT price = £10.20 | 1000 tablet  | £223.51
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 62.5 microgram per 1 tablet  | 28 tablet  | £16.00 DT price = £12.40 | 1000 tablet  | £224.51
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 75 microgram per 1 tablet  | 28 tablet  | £20.00 DT price = £15.80 | 1000 tablet  | £225.51
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 100 microgram per 1 tablet  | 28 tablet  | £25.00 DT price = £19.80 | 1000 tablet  | £226.51
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 125 microgram per 1 tablet  | 28 tablet  | £30.00 DT price = £23.80 | 1000 tablet  | £227.51
  - **LEVOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium anhydrous 150 microgram per 1 tablet  | 28 tablet  | £35.00 DT price = £27.80 | 1000 tablet  | £228.51

**Oral solution**

- **LEVOTHYROXINE SODIUM (Non-proprietary)**
  - Levothyroxine sodium anhydrous 5 microgram per 1 ml  | 100 ml  | £10.00 DT price = £7.65
  - Levothyroxine sodium anhydrous 2.5 microgram per 1 ml  | 100 ml  | £5.00 DT price = £3.20
  - Levothyroxine sodium anhydrous 2 microgram per 1 ml  | 100 ml  | £4.00 DT price = £2.90
  - Levothyroxine sodium anhydrous 1 microgram per 1 ml  | 100 ml  | £3.00 DT price = £2.20

**Dose equivalence and conversion**

- 20–25 micrograms of liothyronine sodium is equivalent to approximately 100 micrograms of levothyroxine sodium.

- Branded drugs may not be bioequivalent. Performance of some medications may be better in certain patients. If symptoms recur, try other preparations.

**RECOMMENDATIONS TO THE PATIENT**

- Avoid taking other medications with levotyroxine (e.g. synthetic thyroid hormones) unless approval is given by the prescribing doctor.

- 

**CONTRA-INDICATIONS**  Thyrotoxicosis

**INDICATIONS AND DOSE**

**Hypothyroidism**

- Adult: Initially 10–20 micrograms daily; increased to 60 micrograms daily in 2–3 divided doses, dose should be increased gradually, smaller initial doses given for the elderly

**Hypothyroid coma**

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 5–20 micrograms every 12 hours, increased to 5–20 micrograms every 4 hours if required, alternatively initially 50 micrograms for 1 dose, then 25 micrograms every 8 hours, reduced to 25 micrograms twice daily

- **Dose equivalence and conversion**
  - 20–25 micrograms of liothyronine sodium is equivalent to approximately 100 micrograms of levotyroxine sodium.

- Brands without a UK licence may not be bioequivalent and dose adjustment may be necessary.

- **CONTRA-INDICATIONS**  Thyrotoxicosis

- **CAUTIONS**  Cardiovascular disorders - diabetes insipidus - diabetes mellitus (dose of antidiabetic drugs including insulin may need to be increased) - elderly - hypertension - long-standing hypothyroidism - myocardial infarction - myocardial insufficiency - pancytopenia (initiate corticosteroid therapy before starting levotyroxine) - prediabetes to adrenal insufficiency (initiate corticosteroid therapy before starting levotyroxine)

- **INTERACTIONS**  → Appendix 1 (thyroid hormones).

- **SIDE-EFFECTS**  Anginal pain (usually at excessive dosage) - arrhythmias (usually at excessive dosage) - diarrhoea (usually at excessive dosage) - excitability (usually at excessive dosage) - fever - flushing - headache - heat intolerance - hypersensitivity reactions - insomnia (usually at excessive dosage) - muscle cramp - muscular weakness - oedema - palpitation (usually at excessive dosage) - pruritus - rash - restlessness (usually at excessive dosage) - sweating - tachycardia (usually at excessive dosage) - tremor (usually at excessive dosage) - vomiting (usually at excessive dosage) - weight-loss

**SIDE-EFFECTS, FURTHER INFORMATION**

Initial dosage in patients with cardiovascular disorders  If metabolism increases too rapidly (causing diarrhoea, nervousness, rapid pulse, insomnia, tremors and sometimes anginal pain where there is latent myocardial ischaemia), reduce dose or withhold for 1–2 days and start again at a lower dose.

- **PREGNANCY**  Liothyronine requirement may increase during pregnancy. Does not cross the placenta in significant amounts. Excessive or insufficient maternal thyroid hormones can be detrimental to fetus. Assess maternal thyroid function before conception (if possible), at diagnosis of pregnancy, at antenatal booking, during both the second and third trimesters, and after delivery (more frequent monitoring required on initiation or adjustment of liothyronine).

- **BREAST FEEDING**  Amount too small to affect tests for neonatal hypothyroidism.

- **PRESCRIBING AND DISPENSING INFORMATION**  Switching to a different brand  Patients switched to a different brand should be monitored (particularly if pregnant or if heart disease present) as brands without a UK licence may not be bioequivalent. Pregnant women or those with heart disease should undergo an early review of thyroid status, and other patients should have thyroid function assessed if experiencing a significant change in symptoms. If liothyronine is continued long-term, thyroid function tests should be repeated 1–2 months after any change in brand.

- **MEDIcINAL FORMS**  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, solution for injection, oral suspension, oral solution, capsule

  **Tablet**
  - **LIOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium 20 microgram per 1 tablet  | 28 tablet  | £12.18 DT price = £10.51
  - **LIOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium 10 microgram per 1 tablet  | 28 tablet  | £6.18 DT price = £5.35

  **Powder for solution for injection**
  - **LIOTHYROXINE SODIUM (Non-proprietary)**
    - Levothyroxine sodium 20 microgram per 1 vial  | 5 vial  | £1.425.00
The need for continuing antimuscarinic drug therapy should be licensed for urinary frequency, urgency, and incontinence.

Trospium chloride p.

Oxybutynin hydrochloride p.

Urgency and increase bladder capacity. Effective when used as an adjunct to pelvic floor exercises.

It may be more effective for severe stress incontinence in women; it may be more generally managed by non-drug methods. Duloxetine p.

Floor exercises and bladder training; stress incontinence is managed by non-drug methods. Flavoxate hydrochloride p.

Urge incontinence and increase bladder capacity.

To severe stress incontinence in women; it may be more generally managed by non-drug methods. Duloxetine p.

Urinary frequency, enuresis, and incontinence

Chapter 7
Genito-urinary system

CONTENTS

1 Bladder and urinary disorders

1.1 Urinary frequency, enuresis, and incontinence

2 Bladder instillations and urological surgery

3 Contraception

3.1 Contraception, combined

3.2 Contraception, devices

3.3 Contraception, oral progestogen-only

3.4 Contraception, parenteral progestogen-only

3.5 Contraception, spermicidal

4 Erectile and ejaculatory conditions

1 Bladder and urinary disorders

1.1 Urinary frequency, enuresis, and incontinence

Urinary frequency, enuresis and incontinence

Urinary frequency and incontinence

Incontinence in adults which arises from detrusor instability is managed by combining drug therapy with conservative methods for managing urge incontinence such as pelvic floor exercises and bladder training; stress incontinence is generally managed by non-drug methods. Duloxetine p. 288 can be added and is licensed for the treatment of moderate to severe stress incontinence in women; it may be more effective when used as an adjunct to pelvic floor exercises.

Antimuscarinic drugs reduce symptoms of urgency and urge incontinence and increase bladder capacity. Oxybutynin hydrochloride p. 669 also has a direct relaxant effect on urinary smooth muscle. Side-effects limit the use of oxybutynin hydrochloride, but they may be reduced by starting at a lower dose. A modified-release preparation of oxybutynin hydrochloride is effective and has fewer side-effects; a transdermal patch is also available. The efficacy and side-effects of tolterodine tartrate p. 671 are comparable to those of modified-release oxybutynin hydrochloride. Flavoxate hydrochloride p. 669 has less marked side-effects but it is also less effective. Darifenacin p. 668, fesoterodine fumarate p. 668, propiverine hydrochloride p. 670, solifenacin succinate p. 670, and trospium chloride p. 671 are newer antimuscarinic drugs licensed for urinary frequency, urgency, and incontinence. The need for continuing antimuscarinic drug therapy should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

Propantheline bromide p. 74 and tricyclic antidepressants were used for urge incontinence but they are little used now because of their side-effects. The use of imipramine hydrochloride p. 296 is limited by its potential to cause cardiac side-effects.

Mirabegron p. 671, a selective beta, agonist, is licensed for the treatment of urinary frequency, urgency, and urge incontinence associated with overactive bladder syndrome.

Purified bovine collagen implant (Contigen®, Bard) is indicated for urinary incontinence caused by intrinsic sphincter deficiency (poor or non-functioning bladder outlet mechanism). The implant should be inserted only by surgeons or physicians trained in the technique for injection of the implant.

Nocturnal enuresis in children

Nocturnal enuresis is common in young children, but persists in a small proportion by 10 years of age. For children under 5 years, reassurance and advice on the management of nocturnal enuresis can be useful for some families. Treatment may be considered in children over 5 years depending on their maturity and motivation, the frequency of nocturnal enuresis, and the needs of the child and their family.

Initially, advice should be given on fluid intake, diet, toileting behaviour, and reward systems; for children who do not respond to this advice, further treatment may be necessary. An enuresis alarm should be first line treatment for motivated, well-supported children; alarms have a lower relapse rate than drug treatment when discontinued.

Treatment should be reviewed after 4 weeks, and, if there are early signs of response, continued until a minimum of 2 weeks’ uninterrupted dry nights have been achieved. If complete dryness is not achieved after 3 months, only continue if the condition is still improving and the child remains motivated to use the alarm. If initial alarm treatment is unsuccessful, consider combination treatment with desmopressin p. 574, or desmopressin alone if the alarm is no longer appropriate or desirable.

Desmopressin is given by oral or by sublingual administration. Desmopressin alone can be offered to children over 5 years of age if an alarm is inappropriate or undesirable, or when rapid or short-term results are the priority (for example to cover periods away from home); desmopressin alone can also be used if there has been a partial response to a combination of desmopressin and an alarm following initial treatment with an alarm. Treatment should be assessed after 4 weeks and continued for
Treatment should not normally exceed 3 months unless a physical examination is made and the child is fully reassessed; toxicity following overdosage with tricyclics is of particular concern.

**Antimuscarinics (systemic)**

- **CONTRA-INDICATIONS** Gastro-intestinal obstruction - intestinal atony - myasthenia gravis (but some antimuscarinics may be used to decrease muscarinic side-effects of anticholinesterases) - paralytic ileus - prostatic enlargement - pyloric stenosis - severe ulcerative colitis - significant bladder outflow obstruction - toxic megacolon - urinary retention

- **CAUTIONS** Acute myocardial infarction - arrhythmias (may be worsened) - autonomic neuropathy - cardiac insufficiency (due to association with tachycardia) - cardiac surgery (due to association with tachycardia) - conditions characterised by tachycardia - congestive heart failure (may be worsened) - coronary artery disease (may be worsened) - diarrhoea - elderly (especially if frail) - gastro-oesophageal reflux disease - hiatus hernia with reflux oesophagitis - hypertension - hypotension (due to association with tachycardia) - individuals susceptible to angle-closure glaucoma - prostatic hyperplasia - pyrexia - ulcereative colitis

- **INTERACTIONS** Appendix I (antimuscarinics).

Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation. Concomitant use of other drugs with antimuscarinic effects can also lead to confusion in the elderly.

- **SIDE-EFFECTS**
  - **Common or very common** Constipation - dilation of pupils with loss of accommodation - dry mouth - photophobia - reduced bronchial secretions - skin dryness - skin flushing - transient bradycardia (followed by tachycardia, palpitation and arrhythmias) - urinary retention - urinary urgency
  - **Uncommon** Confusion (particularly in the elderly) - giddiness - nausea - vomiting
  - **Very rare** Angle-closure glaucoma
  - **Frequency not known** Angioedema - blurred vision - blurred vision - central nervous system stimulation - convulsion - diarrhoea - difficulty in micturition - disorientation - dizziness - drowsiness - dry eyes - euphoria - fatigue - flatulence - hallucinations - headache - impaired memory - palpitation - photosensitivity - rash - reduced sweating (may lead to heat sensations and fainting in hot environments or patients with fever) - restlessness - taste disturbances

- **PATIENT AND CARER ADVICE** Antimuscarinics can affect the performance of skilled tasks (e.g. driving).

### Darifenacin

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Incontinence

- **BY MOUTH**

  - **Adult:** Initially 7.5 mg once daily, increased if necessary to 15 mg after 2 weeks

- **SIDE-EFFECTS**
  - **Uncommon** Cough - dyspnoea - hypertension - impotence - insomnia - oedema - rhinitis - ulcerative stomatitis - vaginitis - weakness

- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.

- **BREAST FEEDING** Present in milk in animal studies—manufacturer advises caution.

- **HEPATIC IMPAIRMENT** Max. 7.5 mg daily in moderate impairment. Avoid in severe impairment.

- **PRESCRIBING AND DISPENSING INFORMATION** The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Modified-release tablet**

  *Emselex (Merus Labs Luxco S.a R.L.)*

  **Darifenacin** (as Darifenacin hydrobromide) 7.5 mg

  *Emselex* 7.5 mg modified-release tablets | 28 tablet (P35) £25.48 DT price = £25.48

  **Darifenacin** (as Darifenacin hydrobromide) 15 mg

  *Emselex* 15 mg modified-release tablets | 28 tablet (P35) £25.48

### Fesoterodine fumarate

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urge incontinence

- **BY MOUTH**

  - **Adult:** 4 mg once daily, increased if necessary up to 8 mg once daily

- **Dose adjustments due to interactions**

  Max. 4 mg daily with concomitant atazanavir, clarithromycin, indinavir, laranconazole, ritonavir, saquinavir, or telithromycin

  In patients with hepatic or renal impairment, consult product literature before concomitant use with amprenavir, aripiprant, atazanavir, clarithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, indinavir, laranconazole, ritonavir, saquinavir, telithromycin, verapamil, or grapefruit juice

- **SIDE-EFFECTS**

  - **Common or very common** Insomnia
  - **Uncommon** Cough - nasal dryness - pharyngolaryngeal pain - vertigo

- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Manufacturer advises increase dose cautiously; max. 4 mg daily in moderate impairment. Avoid in severe impairment. Consult product literature before concomitant use of cytochrome P450 enzyme inhibitors.

- **RENAL IMPAIRMENT** Increase dose cautiously if eGFR 30–80 mL/minute/1.73m²; max. 4 mg daily if eGFR less than 30 mL/minute/1.73m². Consult product literature before concomitant use of cytochrome P450 enzyme inhibitors.
Flavoxate hydrochloride

**INDICATIONS AND DOSE**

Urinary frequency | Urinary incontinence | Dysuria | Urinary urgency | Bladder spasm due to catheterisation, cystoscopy, or surgery

**BY MOUTH**

- Adult: 200 mg 3 times a day

**CONTRA-INDICATIONS**

Gastro-intestinal haemorrhage

**SIDE-EFFECTS**

- Eosinophilia • erythema • leucopenia • pruritus • urticaria • vertigo

**PREGNANCY**

Manufacturer advises avoid unless no safer alternative.

**BREAST FEEDING**

Manufacturer advises caution—no information available.

**PRESCRIBING AND DISPENSING INFORMATION**

The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS**

3, 25

- Toviaz (Pfizer Ltd)
  - Fesoterodine fumarate 4 mg Toviaz 4 mg modified-release tablets | 28 tablet [PO] £25.78 DT price = £25.78
  - Fesoterodine fumarate 8 mg Toviaz 8 mg modified-release tablets | 28 tablet [PO] £25.78 DT price = £25.78

**Oxybutynin hydrochloride**

**INDICATIONS AND DOSE**

Urinary frequency | Urinary incontinence | Dysuria | Urinary urgency | Neurogenic bladder instability

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Child 5-11 years: Initially 5 mg once daily, adjusted in steps of 5 mg every 1 week, adjusted according to response; maximum 15 mg per day
  - Adult: Initially 5 mg once daily, increased in steps of 5 mg every 1 week, adjusted according to response; maximum 20 mg per day

**BY TRANSDERMAL APPLICATION USING PATCHES**

- Adult: Apply 1 patch twice weekly, patch to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3–4 days and site replacement patch on a different area. The same area should be avoided for 7 days

**Nocturnal enuresis associated with overactive bladder**

**BY MOUTH USING MODIFIED-RELEASE TABLETS**

- Child 5-17 years: Initially 5 mg once daily, adjusted in steps of 5 mg every 1 week, adjusted according to response; maximum 15 mg per day

**Dose equivalence and conversion**

Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of **Lyrinel® XL**

**UNLICENSED USE**


**CAUTIONS**

Acute porphyrias p. 864

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Uncommon Anorexia • facial flushing
  - Rare Night terrors
  - Frequency not known Cognitive impairment

**SPECIFIC SIDE-EFFECTS**

- Rare
  - With transdermal use Application site reactions with patches

**PREGNANCY**

Manufacturers advise avoid unless essential—toxicity in animal studies.

**BREAST FEEDING**

Manufacturers advise avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution.

**RENAL IMPAIRMENT**

Manufacturer advises caution.

**DIRECTIONS FOR ADMINISTRATION**

- With transdermal use Apply patches to clean, dry, unbroken skin on abdomen, hip or buttock, remove after every 3–4 days and site replacement patch on a different area (avoid using same area for 7 days).

**PRESCRIBING AND DISPENSING INFORMATION**

- In adults The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.
  - In children The need for therapy for urinary indications should be reviewed soon after it has been commenced and then at regular intervals; a response usually occurs within 6 months but may take longer.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Oxybutynin for daytime urinary symptoms www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms

Patients or carers should be given advice on how to administer oxybutynin transdermal patches.

**NATIONAL FUNDING/ACCESS DECISIONS**

The Scottish Medicines Consortium (SMC) has advised (July 2005) that **Kentera®** should be restricted for use in adults who...
Genito-urinary system

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, modified-release tablets, transdermal patches, and oral solutions.

**OXYBUTYNIN HYDROCHLORIDE (Non-proprietary)**

- **Transdermal patch**
  - Propiverine hydrochloride 30 mg: Lyrinel XL 30mg capsules | 28 capsule (EMA) £24.45 DT price = £24.45
  - Propiverine hydrochloride 45 mg: Lyrinel XL 45mg capsules | 28 capsule (EMA) £27.00 DT price = £27.00

**Propiverine hydrochloride**

**INDICATIONS AND DOSE**

Urinary frequency, urgency and incontinence associated with overactive bladder

- **Initially by mouth using immediate-release medicines**
  - Adult: 15 mg 1–2 times a day, increased if necessary up to 15 mg 3 times a day

- **By mouth using modified-release capsules**
  - Adult: 30 mg once daily

Urinary frequency, urgency and incontinence associated with neurogenic bladder instability

- **By mouth using immediate-release medicines**
  - Adult: 15 mg 3 times a day

**PRECAUTIONS AND ADVISORY LABELS**

- **Cautions** Neurogenic bladder disorder - susceptibility to QT-interval prolongation
- **Side-effects**
  - Uncommon: Gastro-oesophageal reflux - oedema
  - Frequency not known: Dysphonia - hepatic impairment - hyperkalaemia - muscle weakness - reduced appetite - torsade de pointes
- **Pregnancy** Manufacturer advises caution—no information available.
- **Breastfeeding** Manufacturer advises avoid—present in milk in animal studies.
- **Hepatic impairment** Max. 5 mg daily in moderate impairment, avoid in moderate impairment in those already taking potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole, ketoconazole, or ritonavir).
- **Renal impairment** Max. 5 mg daily if eGFR less than 30 ml/minute/1.73 m²; avoid if eGFR less than 30 ml/minute/1.73 m² in those already taking potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole or ritonavir).
- **Prescribing and dispensing information**}

**Solifenacin succinate**

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urinary incontinence

- **By mouth**
  - Adult: 5 mg once daily, increased, if necessary to 10 mg once daily

**Dose adjustments due to interactions**

Max. 5 mg daily with concomitant potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole, ketoconazole, or ritonavir).

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Solifenacin succinate**

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urinary incontinence

- **By mouth**
  - Adult: 5 mg once daily, increased, if necessary to 10 mg once daily

**Dose adjustments due to interactions**

Max. 5 mg daily with concomitant potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole, ketoconazole, or ritonavir).

**Precautions and advisory labels**

- **Cautions** Neurogenic bladder disorder - susceptibility to QT-interval prolongation
- **Side-effects**
  - Uncommon: Gastro-oesophageal reflux - oedema
  - Frequency not known: Dysphonia - hepatic impairment - hyperkalaemia - muscle weakness - reduced appetite - torsade de pointes
- **Pregnancy** Manufacturer advises caution—no information available.
- **Breastfeeding** Manufacturer advises avoid—present in milk in animal studies.
- **Hepatic impairment** Max. 5 mg daily in moderate impairment, avoid in moderate impairment in those already taking potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole or ritonavir).
- **Renal impairment** Max. 5 mg daily if eGFR less than 30 ml/minute/1.73 m²; avoid if eGFR less than 30 ml/minute/1.73 m² in those already taking potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole or ritonavir).
- **Prescribing and dispensing information** The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.
**Tolterodine tartrate**

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urinary incontinence

**INITIALLY BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adults: 2 mg twice daily, reduced if not tolerated to 1 mg twice daily

**INITIALLY BY MOUTH USING MODIFIED-RELEASE CAPSULES**

- Adults: 4 mg once daily

**CAUTIONS**

- History of QT-interval prolongation
- Caution with concomitant use with other drugs known to prolong QT interval.

**INTERACTIONS**

- Caution with concomitant use with other drugs known to prolong QT interval.

**SIDE-EFFECTS**

- Uncommon
- Common or very common

- Bronchitis · chest pain · fatigue · paraesthesia · peripheral oedema · sinusitis · vertigo · weight gain

- Memory impairment
- Frequency not known
- Flushing
- Manufacturer advises avoid—toxicity in animal studies.

**PREGNANCY**

- Manufacturer advises caution.

**RENAL IMPAIRMENT**

- Reduce dose to 20 mg once daily or 20 mg on alternate days if eGFR 10–30 mL/minute/1.73 m². Use with caution. Avoid Regurin® XL.

**PRESCRIBING AND DISPENSING INFORMATION**

- The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder.

**Tablet**

- TOLTERODINE TARTRATE (Non-proprietary)
- Tolterodine tartrate 4 mg | 20 tablet (Pfizer) £24.79 DT price = £24.78
- Tolterodine tartrate 1 mg | 28 tablet (Pfizer) £29.03 DT price = £2.61
- Tolterodine tartrate 2 mg | 56 tablet (Pfizer) £31.56 DT price = £2.78

**Modified-release capsule**

- TOLTERODINE TARTRATE (Non-proprietary)
- Tolterodine tartrate 4 mg | 14 capsule (Pfizer) £25.78 DT price = £2.78
- Tolterodine tartrate 2 mg | 28 capsule (Pfizer) £25.78 DT price = £2.78

**BETA₂-ADRENOCEPTOR AGONISTS**

**Mirabegron**

**INDICATIONS AND DOSE**

Urinary frequency, urgency, and urge incontinence

**BY MOUTH**

- Adults: 50 mg once daily

**SIDE-EFFECTS**

- Rare
  - Asthenia · chest pain · dyspnoea
- Very rare
  - Arthralgia · myalgia

**PREGNANCY**

- Manufacturer advises caution.

**RENAL IMPAIRMENT**

- With concomitant use of strong cytochrome P450 inhibitors such as itraconazole, ketoconazole, ritonavir, or clarithromycin reduce dose to 25 mg once daily in mild impairment, and avoid in moderate impairment.

- With concomitant use of strong cytochrome P450 inhibitors such as itraconazole, ketoconazole, ritonavir, or clarithromycin reduce dose to 25 mg once daily if eGFR less than 30–89 mL/minute/1.73 m², and avoid if eGFR less than 30 mL/minute/1.73 m².

**SIDE-EFFECTS**

- Common or very common
  - Tachycardia · urinary-tract infection
- Atrial fibrillation · dyspepsia · gastritis · hypertension · joint swelling · palpititation · pruritus · rash · vulvovaginal infection · vulvovaginal pruritus

**Trospium chloride**

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urinary incontinence

**INITIALLY BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adults: 20 mg twice daily, to be taken before food

**INITIALLY BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adults: 60 mg once daily
1.2 Urinary retention

Drugs for urinary retention

Acute retention is painful and is treated by catheterisation. Chronic retention is painless and often long-standing. Catheterisation is unnecessary unless there is deterioration of renal function. After the cause has initially been established and treated, drugs may be required to increase detrusor muscle tone.

Benign prostatic hyperplasia is treated either surgically or medically with alpha-blockers. Dutasteride p. 676 and finasteride p. 676 are alternatives to alpha-blockers, particularly in men with a significantly enlarged prostate. Tadalafil p. 700, a phosphodiesterase type-5 inhibitor, may also be used in the management of benign prostatic hyperplasia.

Alpha-blockers


Parasympathomimetics

The parasympathomimetic bethanechol chloride p. 676 increases detrusor muscle contraction. However, it has only a limited role in the relief of urinary retention; its use has been superseded by catheterisation.
Doxazosin

INDICATIONS AND DOSE

Hypertension

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: Initially 1 mg once daily for 1–2 weeks, then increased to 2 mg once daily, then increased if necessary to 4 mg once daily; maximum 16 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

- Adult: Initially 4 mg once daily, dose can be adjusted after 4 weeks, then increased if necessary to 8 mg once daily

Benign prostatic hyperplasia

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: Initially 1 mg daily, dose may be doubled at intervals of 1–2 weeks according to response; usual maintenance 2–4 mg daily; maximum 8 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

- Adult: Initially 4 mg once daily, dose can be adjusted after 4 weeks, then increased if necessary to 8 mg once daily

Dose adjustments due to interactions

Caution with concomitant antihypertensives in benign prostatic hyperplasia—reduced dosage and specialist supervision may be required

- CONTRA-INDICATIONS History of micturition syncope (in patients with benign prostatic hypertrophy) - history of postural hypotension - monotherapy in patients with overfull bladder or anuria

- CAUTIONS Care with initial dose (postural hypotension) - cataract surgery (risk of intra-operative floppy iris syndrome) - elderly - heart failure - pulmonary oedema due to aortic or mitral stenosis

- INTERACTIONS → Appendix 1 (alpha-blockers).

- SIDE-EFFECTS

  - Common or very common Anxiety, back pain, coughing, dyspnoea, fatigue, influenza-like symptoms, myalgia - paraesthesia - sleep disturbance - vertigo

  - Uncommon Agitation, angina, arthralgia, epistaxis, gout, hypoaesthesia, micturition disturbance, myocardial infarction, tinnitus, tremor, weight changes

  - Very rare Abnormal ejaculation, alopecia, arrhythmias, bradycardia, bronchospasm, cholestasis, gynaecomastia, hepatitis, hot flashes, jaundice, leucopenia, thrombocytopenia

  - Frequency not known Angioedema, asthenia, blurred vision, depression, dizziness, drowsiness, dry mouth, erectile disorders, gastro-intestinal disturbances, headache, hypersensitivity, hypotension, intra-operative floppy iris syndrome, oedema, palpitations, postural hypotension, priapism, pruritus, rash, rhinitis, syncope, tachycardia

  - PREGNANCY No evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk.

  - BREAST FEEDING Accumulates in milk in animal studies—manufacturer advises avoid.

  - HEPATIC IMPAIRMENT Use with caution. Manufacturer advises avoid in severe impairment—no information available.

- PATIENT AND CARER ADVICE May affect performance of skilled tasks e.g. driving. Patient counselling is advised for doxazosin tablets (initial dose).

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, capsule

Tablet

- DOXAZOSIN (Non-proprietary)
  - Ofdoxazosin (as Doxazosin mesilate) 1 mg | 28 tablet (Pfizer Ltd) DT price = £0.92
  - Ofdoxazosin (as Doxazosin mesilate) 2 mg | 28 tablet (Pfizer Ltd) DT price = £0.95
  - Ofdoxazosin (as Doxazosin mesilate) 4 mg | 28 tablet (Pfizer Ltd) DT price = £1.12
  - Cardura (Pfizer Ltd)
    - Ofdoxazosin (as Doxazosin mesilate) 1 mg | Cardura 1 mg tablets | 28 tablet (Pfizer Ltd) DT price = £0.92
    - Ofdoxazosin (as Doxazosin mesilate) 2 mg | Cardura 2 mg tablets | 28 tablet (Pfizer Ltd) DT price = £0.95

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

- Cardura XL (Pfizer Ltd)
  - Ofdoxazosin (as Doxazosin mesilate) 4 mg | Cardura XL 4 mg tablets | 28 tablet (Pfizer Ltd) DT price = £0.92
  - Ofdoxazosin (as Doxazosin mesilate) 8 mg | Cardura XL 8 mg tablets | 28 tablet (Pfizer Ltd) DT price = £0.98

- Brands may include Doxadura

Indoramin

INDICATIONS AND DOSE

Hypertension

BY MOUTH

- Adult: Initially 25 mg twice daily, increased in steps of 25–50 mg every 2 weeks, maximum daily dose should be given in divided doses; maximum 200 mg per day

Benign prostatic hyperplasia

BY MOUTH

- Adult: 20 mg twice daily, increased in steps of 20 mg every 2 weeks if required, increased if necessary up to 100 mg daily in divided doses
- Elderly: 20 mg daily, dose to be taken at night

Dose adjustments due to interactions

Caution with concomitant antihypertensives in benign prostatic hyperplasia—reduced dosage and specialist supervision may be required

- CONTRA-INDICATIONS Established heart failure - history micturition syncope (when used for benign prostatic hyperplasia) - history of postural hypotension (when used for benign prostatic hyperplasia)

- CAUTIONS Cataract surgery (risk of intra-operative floppy iris syndrome) - control incipient heart failure before initiating indoramin - elderly - epilepsy (convulsions in animal studies) - history of depression - Parkinson’s disease (extrapyramidal disorders reported)

- INTERACTIONS → Appendix 1 (alpha-blockers).

Avoid alcohol (enhances rate and extent of absorption).

- SIDE-EFFECTS

  - Common or very common Sedation

  - Uncommon Failure of ejaculation, fatigue, weight gain

  - Frequency not known Angioedema, asthenia, blurred vision, depression, dizziness, drowsiness, dry mouth, erectile disorders, extrapyramidal disorders, gastro-intestinal disturbances, headache, hypersensitivity reactions, hypotension, incontinence, intra-operative floppy iris syndrome, oedema, palpitations, postural hypotension, priapism, pruritus, rash, rhinitis, syncope, tachycardia, urinary frequency
Prazosin

**INDICATIONS AND DOSE**

**Hypertension**

**BY MOUTH**
- **Adult**: Initially 500 micrograms 2–3 times a day for 3–7 days, the initial dose should be taken on retiring to bed at night to avoid collapse, increased to 1 mg 2–3 times a day for a further 3–7 days, then increased if necessary up to 20 mg daily in divided doses

**Congestive heart failure (rarely used)**

**BY MOUTH**
- **Adult**: 500 micrograms 2–4 times a day, initial dose to be taken at bedtime, then increased to 4 mg daily in divided doses; maintenance 4–20 mg daily in divided doses

Raynaud’s syndrome (but efficacy not established)

**BY MOUTH**
- **Adult**: Initially 500 micrograms twice daily, initial dose to be taken at bedtime, dose may be increased after 3–7 days, then increased if necessary up to 1–2 mg twice daily

**Benign prostatic hyperplasia**

**BY MOUTH**
- **Adult**: Initially 500 micrograms twice daily for 3–7 days, subsequent doses should be adjusted according to response, maintenance 2 mg twice daily, initiate with lowest possible dose in elderly patients

**Dose adjustments due to interactions**

Caution with concomitant antihypertensives in benign prostatic hyperplasia—reduced dosage and specialist supervision may be required

Tamsulosin hydrochloride

**INDICATIONS AND DOSE**

**Benign prostatic hyperplasia**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- **Adult**: 400 micrograms once daily

**CONTRA-INDICATIONS**

History of micturition syncope - history of postural hypotension

**CAUTIONS**

Cataract surgery (risk of intra-operative floppy iris syndrome) - concomitant antihypertensives (reduced dosage and specialist supervision may be required) - elderly

**INTERACTIONS**

Appendix 1 (alpha-blockers).

**SIDE-EFFECTS**

Angioedema - asthma - blurred vision - depression - dizziness - dry mouth - dyspnoea - gastro-intestinal disturbances - headache - nasal congestion - nervousness - oedema - palpitations - syncope - urinary frequency - vertigo - weakness

- **Uncommon** Arthralgia - epistaxis - eye disorders - insomnia - paraesthesia - pruritus - rash - sweating - tachycardia - tinnitus - urticaria
- **Rare** Alopecia - bradycardia - flushing - gynaecostasia - hallucinations - pancreatitis - priapism - urinary incontinence - vasculitis - worsening of narcolepsy

**FREQUENCY NOT KNOWN**

Angioedema - asthenia - erectile disorders - hypersensitivity reactions - hypotension - intra-operative floppy iris syndrome - postural hypotension - rhinitis

**SIDE-EFFECTS, FURTHER INFORMATION**

First dose effect

First dose may cause collapse due to hypotensive effect (therefore should be taken on retiring to bed). Patients should be warned to lie down if symptoms such as dizziness, fatigue or sweating develop, and to remain lying down until they abate completely.

**PREGNANCY**

No evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk.

**BREAST FEEDING**

Present in milk, amount probably too small to be harmful; manufacturer advises use with caution.

**HEPATIC IMPAIRMENT**

Initially 500 micrograms daily; increased with caution.

**RENAL IMPAIRMENT**

Initially 500 micrograms daily in moderate to severe impairment; increased with caution.

**PATIENT AND CARER ADVICE**

May affect performance of skilled tasks e.g. driving.

First dose effect

First dose may cause collapse due to hypotensive effect (therefore should be taken on retiring to bed). Patients should be warned to lie down if symptoms such as dizziness, fatigue or sweating develop, and to remain lying down until they abate completely.
**HEPATIC IMPAIRMENT**

Tamsulosin hydrochloride 400 microgram capsules can be sold to the public for the treatment of functional symptoms of benign prostatic hyperplasia in men aged 45–75 years to be taken for up to 6 weeks before clinical assessment by a doctor.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, powder

**Modified-release tablet**

CAUTIONARY AND ADVISORY LABELS 25

Tamsulosin hydrochloride 400 microgram: Tamsulosin 400 microgram modified-release tablets | 30 tablet (£10.47 DT price = £10.47

Flomaxtra XL: Flomaxtra XL 400 microgram | tablet (£10.47 DT price = £10.47

Brands may include Costam XL; Faramsil; Flectone XL

**Modified-release capsule**

CAUTIONARY AND ADVISORY LABELS 25

Dutasteride hydrochloride 400 microgram: Dutasteride 400 microgram modified-release capsules | 30 capsule (£6.15 DT price = £4.52

Brands may include Contiflo XL; Diffundox XL; Flomax MR; Galebon; Losinate MR; Pamsvax XL; Pemtye MR; Pintexel PR; Prosurin XL; Talamfex; Tamurex

---

**Dutasteride with tamsulosin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dutasteride p. 670, tamsulosin hydrochloride p. 674.

**INDICATIONS AND DOSE**

Benign prostatic hyperplasia

BY MOUTH

Adult (male): 1 capsule daily.

**PATIENT AND CARER ADVICE**

May affect performance of skilled tasks e.g. driving.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

CAUTIONARY AND ADVISORY LABELS 25

Combodart (GlaxoSmithKline UK Ltd)

Dutasteride 500 microgram, Tamsulosin hydrochloride 400 microgram: Combodart 0.5mg/0.4mg capsules | 30 capsule (£19.80 DT price = £19.80

**Solifenacin with tamsulosin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, solifenacin succinate p. 670, tamsulosin hydrochloride p. 674.

**INDICATIONS AND DOSE**

Moderate to severe urinary frequency, urgency, and obstructive symptoms associated with benign prostatic hyperplasia when monotherapy ineffective

BY MOUTH

Adult (male): 1 tablet daily.

Dose adjustments due to interactions

Max. 1 Vesomni® tablet daily with concomitant potent inhibitors of cytochrome P450 enzyme CYP3A4 (such as itraconazole or ritonavir).

**HEPATIC IMPAIRMENT**

Max. 1 Vesomni® tablet daily in moderate impairment.

---

**Terazosin**

**INDICATIONS AND DOSE**

Mild to moderate hypertension

BY MOUTH

Adult: 1 mg daily for 7 days, then increased if necessary to 2 mg daily, dose should be taken at bedtime; maintenance 2–10 mg once daily, doses above 20 mg rarely improve efficacy

**Benign prostatic hyperplasia**

BY MOUTH

Adult: Initially 1 mg daily, dose should be taken at bedtime, if necessary dose may be doubled at intervals of 1–2 weeks according to response; maintenance 5–10 mg daily; maximum 10 mg per day

**CONTRA-INDICATIONS**

History of micturition syncope (in benign prostatic hyperplasia) - history of postural hypotension (in benign prostatic hyperplasia)

**CAUTIONS**

Cataract surgery (risk of intra-operative floppy iris syndrome) - elderly - first dose

**CAUTIONS, FURTHER INFORMATION**

First dose may cause collapse due to hypotension within 30–90 minutes, therefore should be taken on retiring to bed; may also occur with rapid dose increase.

**INTERACTIONS**

→ Appendix 1 (alpha-blockers).

**SIDE-EFFECTS**


**PREGNANCY**

No evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk.

**BREAST FEEDING**

No information available.

**PATIENT AND CARER ADVICE**

May affect performance of skilled tasks e.g. driving. Patient counselling is advised for terazosin tablets (initial dose).

First dose effect First dose may cause collapse due to hypotensive effect (therefore should be taken on retiring to bed). Patient should be warned to lie down if symptoms such as dizziness, fatigue or sweating develop, and to remain lying down until they abate completely.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

TERAZOSIN (Non-proprietary)

Terazosin (as Terazosin hydrochloride) 2 mg Terazosin 2mg tablets | 28 tablet (£4.50 DT price = £2.45

Terazosin (as Terazosin hydrochloride) 5 mg Terazosin 5mg tablets | 28 tablet (£6.57 DT price = £2.80
Dutasteride

- **Medicinal forms**: Tablets 500 microgram daily, review treatment at 3–6 months and then every 6–12 months (may require several months treatment before benefit is obtained).

  - **Interactions**: Appendix 1 (dutasteride).
  - **Side-effects**: Breast enlargement, decreased libido, ejaculation disorders. Impotence.

- **Conception and contraception**: Dutasteride is excreted in semen and use of a condom is recommended if sexual partner is pregnant or likely to become pregnant.

- **Hepatic impairment**: Avoid in severe impairment—no information available.

- **Effect on laboratory tests**: May decrease serum concentration of prostate cancer markers such as prostate-specific antigen; reference values may need adjustment.

- **Handling and storage**: Women of childbearing potential should avoid handling leaking capsules of dutasteride.

- **Patient and carer advice**: Cases of male breast cancer have been reported. Patients or their carers should be told to promptly report to their doctor any changes in breast tissue such as lumps, pain, or nipple discharge.

- **Medicinal forms**: There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution.

  - **Capsule**: Bethanechol chloride 10 mg (Cheplapharm Arzneimittel GmbH) | 80 tablet | £2.60 DT price = £0.10

  - **Tablet**: Bethanechol chloride 10 mg (Cheplapharm Arzneimittel GmbH) | 30 tablet | £2.50 DT price = £0.08

  - **Tablet**: Bethanechol chloride 25 mg (Cheplapharm Arzneimittel GmbH) | 30 tablet | £2.50 DT price = £0.08

- **Drug action**: A specific inhibitor of the enzyme 5α-reductase, which metabolises testosterone into the more potent androgen, dihydrotestosterone.

- **Indications and dose**: Benign prostatic hyperplasia.

  - **By mouth**

    - **Adult**: 500 micrograms daily, review treatment at 3–6 months and then every 6–12 months (may require several months treatment before benefit is obtained).

- **Contraindications**: Bradycardia, heart block. There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution.

  - **Capsule**: Myotonine (Cheplapharm Arzneimittel GmbH) | 30 tablet | £2.60 DT price = £0.08

  - **Tablet**: Myotonine (Cheplapharm Arzneimittel GmbH) | 30 tablet | £2.60 DT price = £0.08

  - **Tablet**: Myotonine (Cheplapharm Arzneimittel GmbH) | 30 tablet | £2.60 DT price = £0.08

- **Drug action**: A specific inhibitor of the enzyme 5α-reductase, which metabolises testosterone into the more potent androgen, dihydrotestosterone.

- **Indications and dose**: Benign prostatic hyperplasia.

  - **By mouth**

    - **Adult**: 5 mg daily, review treatment at 3–6 months and then every 6–12 months (may require several months treatment before benefit is obtained).
PATIENT AND CARER ADVICE  Cases of male breast cancer have been reported. Patients or their carers should be told to promptly report to their doctor any changes in breast tissue such as lumps, pain, or nipple discharge.

NATIONAL FUNDING/ACCESS DECISIONS  NHS restrictions  Finasteride is not prescribable under the NHS for the treatment of androgenetic alopecia in men.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, powder, tablet.

Tablet  
- FINASTERIDE (Non-proprietary)  
  Finasteride 5 mg  Finasteride 5mg tablets | 28 tablet  [PO] £12.20 DT price = £1.65
  - Aindeem (Actavis UK Ltd)  
    Finasteride 1 mg  Aindeem 1mg tablet | 28 tablet  [PO] £33.68 | 84 tablet  [PO] £88.40
  - Propecia (Merck Sharp & Dohme Ltd)  
    Finasteride 1 mg  Propecia 1mg tablets | 28 tablet  [PO] £29.99
  - Proscar (Merck Sharp & Dohme Ltd)  
    Finasteride 5 mg  Proscar 5mg tablets | 28 tablet  [PO] £13.94 DT price = £1.65

1.3 Urological pain

Urological pain  The acute pain of ureteric colic may be relieved with pethidine hydrochloride p. 372. Diclofenac by injection or as suppositories is also effective and compares favourably with pethidine hydrochloride; other non-steroidal anti-inflammatory drugs are occasionally given by injection.

Lidocaine hydrochloride gel p. 1116 is a useful topical application in urethral pain or to relieve the discomfort of catheterisation.

Alkalisation of urine  Alkalisation of urine can be undertaken with potassium citrate. The alkalisation action may relieve the discomfort of cystitis caused by lower urinary tract infections. Sodium bicarbonate p. 848 is used as a urinary alkalising agent in some metabolic and renal disorders.

Drugs used for Urological pain not listed below; Sodium bicarbonate, p. 848

ALKALINISING DRUGS

Citric acid with potassium citrate

INDICATIONS AND DOSE  
- Relief of discomfort in mild urinary-tract infections  
- Alkalisation of urine

BY MOUTH USING ORAL SOLUTION  
- Adult: 10 mL 3 times a day, diluted well with water

CAUTIONS  
- Cardiac disease  
- Elderly

INTERACTIONS  
- Appendix 1 (potassium salts).

SIDE-EFFECTS  
- Hyperkalaemia on prolonged high dosage  
- Mild diuresis

RENAL IMPAIRMENT  
- Avoid in severe impairment. Close monitoring required in renal impairment—high risk of hyperkalaemia.

PRESCRIBING AND DISPENSING INFORMATION  
- When prepared extemporaneously, the BP states Potassium Citrate Mixture BP consists of potassium citrate 30%,
Bladder instillations and urological surgery

Anethol with borneol, camphene, cineole, fenchone and pinene

**TERPENES**

**INDICATIONS AND DOSE**

Urolithiasis for the expulsion of calculi

**By mouth**

- Adult: 1–2 capsules 3–4 times a day, to be taken before food

**LESS SUITABLE FOR PRESCRIBING**

Preparation is less suitable for prescribing.

**PERCUSSION MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **CAUTIONARY AND ADVISORY LABELS 25**
  - *Rowatinex* (Meadow Laboratories Ltd)
    - Anethol 4 mg, Borneol 10 mg, Camphene 15 mg, Cineole 3 mg, Fenchone 4 mg, Pinene 31 mg *Rowatinex* capsules | 50 capsule *Rowatinex* £7.35

**PRESCRIBING AND DISPENSING INFORMATION**

Sodium citrate 300 mmol/litre (88.2 mg/mL) oral solution is licensed for use before general anaesthesia for caesarean section (available from Viridian).

**EXCEPTIONS TO LEGAL CATEGORY**

Proprietary brands of sodium citrate are on sale to the public for the relief of discomfort in mild urinary-tract infections.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include:

- **Granules**
  - **SODIUM CITRATE (Non-proprietary)**
    - Sodium citrate 4 gram Cystitis Relief 4g oral granules sachets | 6 sachet *GSK* £1.33
    - Lloydspharmacy Cystitis Relief 4g oral granules sachets | 6 sachet *GSK* no price available
  - **Brands may include Canesten Oasis, Cymalon (sodium citrate), Cystocolm**

- **Oral solution**
  - **SODIUM CITRATE (Non-proprietary)**
    - Sodium citrate 88.23 mg per 1 ml Sodium citrate 0.3M oral solution | 30 ml *Posa* £39.60
    - Sodium citrate 441.17mg/5ml oral solution | 30 ml *Posa* no price available

- **Enema**
  - **SODIUM CITRATE (Non-proprietary)**
    - Sodium citrate 90 mg per 1 ml Sodium citrate compound 5ml enema | 12 enema *P* no price available
  - **Micolette Micro-enema** (Wockhardt UK Ltd)
    - Sodium citrate 90 mg per 1 ml Micolette Micro-enema 5ml | 12 enema *P* £4.95
  - **Micralax Micro-enema** (Focus Pharmaceuticals Ltd)
    - Sodium citrate 90 mg per 1 ml Micralax Micro-enema 5ml | 12 enema *P* £4.87
  - **Relaxit** (Supra Enterprises Ltd)
    - Sodium citrate 90 mg per 1 ml Relaxit Micro-enema 5ml | 12 enema £3.21

**Irrigation solution**

- **SODIUM CITRATE (Non-proprietary)**
  - Sodium citrate 3% irrigation solution 1litre bags | 1 bag no price available

- **Powder**
  - **SODIUM CITRATE (Non-proprietary)**
    - Sodium citrate 4 gram Numark cystitis treatment 4g oral powder sachets | 6 sachet *GSK* £1.55
  - **SODIUM CITRATE (Non-proprietary)**
    - Sodium citrate 1 mg per 1 mg Sodium citrate powder | 500 gram *GSK* £5.28 0T price = £5.28

**2 Bladder instillations and urological surgery**

**Bladder instillations and urological surgery**

**Bladder infection**

Various solutions are available as irrigations or washouts. Aqueous chlorhexidine p. 1051 can be used in the management of common infections of the bladder but it is ineffective against most *Pseudomonas spp*. Solutions containing chlorhexidine 1 in 5000 (0.02%) are used but they may irritate the mucosa and cause burning and haematuria (in which case they should be discontinued); sterile sodium chloride solution 0.9% p. 851 (physiological saline) is usually adequate and is preferred as a mechanical irrigant.

Continuous bladder irrigation with amphotericin 50 micrograms/ml. p. 517 may be of value in mycotic infections in adults.

**Dissolution of blood clots**

Clot retention is usually treated by irrigation with sterile sodium chloride solution 0.9% but sterile sodium citrate solution for bladder irrigation 3% may also be helpful.

**Bladder cancer**

Bladder instillations of doxorubicin hydrochloride p. 754 and mitomycin p. 767 are used for recurrent superficial bladder tumours. Such instillations reduce systemic side-effects; adverse effects on the bladder (e.g. micturition disorders and reduction in bladder capacity) may occur.

Instillation of epirubicin hydrochloride p. 756 is used for treatment and prophylaxis of certain forms of superficial bladder cancer; instillation of doxorubicin hydrochloride p. 754 is also used for some papillary tumours.

Instillation of *BCG* (bacillus calmette-guérin p. 794), a live attenuated strain derived from *Mycobacterium bovis* is licensed for the treatment of primary or recurrent bladder carcinoma in-situ and for the prevention of recurrence following transurethral resection.

**Urological surgery**

Glycine irrigation solution 1.5% p. 679 is the irrigant of choice for transurethral resection of the prostate gland and bladder tumours; sterile sodium chloride solution 0.9% (physiological saline) is used for percutaneous renal surgery.

**Maintenance of indwelling urinary catheters**

The deposition which occurs in catheterised patients is usually chiefly composed of phosphate and to minimise this the irrigant of choice (if latex) should be changed at least as often as every 6 weeks. If the catheter is to be left for longer periods a silicone catheter should be used together with the appropriate use of catheter maintenance solutions. Repeated blockage usually indicates that the catheter needs to be changed.

**Chlorhexidine with lidocaine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine p. 1051, lidocaine hydrochloride p. 1161.
**CONTRAINDICATIONS**

- Hypersensitivity to any component.
- Glaucoma.
- Pregnancy.
- Known or suspected breast cancer.
- Renal or hepatic impairment.
- Acute infection.

**MEDICINAL FORMS**

- **Gel**: May contain parabens (preservatives).
- **Instillagel**: Contains hydrochloric acid 20 mg per ml, Lidocaine hydrochloride 20 mg per ml, Chlorhexidine gluconate 500 microgram per ml.

**SIDE-EFFECTS**

- Hypersensitivity, including angio-oedema and anaphylaxis.
- Hypervolaemia.
- Renal failure.

**INTERACTIONS**

- **Cæsarean section**: Risk of uterine rupture.
- **Breast feeding**: Caution advised.
- **Contraception**: Does not contain a spermicide.
- **Combined oral contraceptives containing a progestogen** (e.g., Femidom, Femilon, Ovral, Ortho-Cycline, Ortho-Novum) are effective preparations for general use. Advantages of combined oral contraceptives include:
  - Reliable and reversible.
  - Reduced dysmenorrhoea and menorrhagia.
  - Reduced incidence of premenstrual tension.
  - Less symptomatic fibroids and functional ovarian cysts.
  - Less benign breast disease.
  - Reduced risk of ovarian and endometrial cancer.
  - Reduced risk of pelvic inflammatory disease.

**SIDE-EFFECTS**

- The risk of pelvic inflammatory disease is reduced.
- A transdermal patch and tablet are highly effective and can be reliable for well-motivated couples if used in conjunction with a spermicide.

**MONITORING REQUIREMENTS**

- Ophthalmic, renal and hepatic assessments at intervals of 6 months are required in long-term treatment.

**PRECAUTIONS**

- Avoid exposure to sunlight or ultraviolet light.
- The risk of pelvic inflammatory disease is reduced.

**PATIENT INFORMATION**

- A transdermal patch and tablet are highly effective and can be reliable for well-motivated couples if used in conjunction with a spermicide.

**CONTRAINDICATIONS**

- Pregnancy.

**MEDICINAL FORMS**

- **Gel**:
  - Contains parabens (preservatives).
- **Instillagel**:
  - Contains hydrochloric acid 20 mg per ml, Lidocaine hydrochloride 20 mg per ml, Chlorhexidine gluconate 500 microgram per ml.

**SIDE-EFFECTS**

- Hypersensitivity, including angio-oedema and anaphylaxis.
- Hypervolaemia.
- Renal failure.

**INTERACTIONS**

- **Cæsarean section**: Risk of uterine rupture.
- **Breast feeding**: Caution advised.
- **Contraception**: Does not contain a spermicide.
- **Combined oral contraceptives containing a progestogen** (e.g., Femidom, Femilon, Ovral, Ortho-Cycline, Ortho-Novum) are effective preparations for general use. Advantages of combined oral contraceptives include:
  - Reliable and reversible.
  - Reduced dysmenorrhoea and menorrhagia.
  - Reduced incidence of premenstrual tension.
  - Less symptomatic fibroids and functional ovarian cysts.
  - Less benign breast disease.
  - Reduced risk of ovarian and endometrial cancer.
  - Reduced risk of pelvic inflammatory disease.

**SIDE-EFFECTS**

- The risk of pelvic inflammatory disease is reduced.
- A transdermal patch and tablet are highly effective and can be reliable for well-motivated couples if used in conjunction with a spermicide.

**MONITORING REQUIREMENTS**

- Ophthalmic, renal and hepatic assessments at intervals of 6 months are required in long-term treatment.

**PRECAUTIONS**

- Avoid exposure to sunlight or ultraviolet light.
- The risk of pelvic inflammatory disease is reduced.

**PATIENT INFORMATION**

- A transdermal patch and tablet are highly effective and can be reliable for well-motivated couples if used in conjunction with a spermicide.
Combined Oral Contraceptives

Monophasic 21-day preparations

<table>
<thead>
<tr>
<th>Oestrogen content</th>
<th>Progestogen content</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol</td>
<td>Desogestrel 150 micrograms</td>
<td>Gedarel 20/150</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Desogestrel 150 micrograms</td>
<td>Mercilon</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Gestodene 75 micrograms</td>
<td>Femidette</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Gestodene 75 micrograms</td>
<td>Millinette 20/75</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Norethisterone acetate 1 mg</td>
<td>Loestrin 20</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Desogestrel 150 micrograms</td>
<td>Marvelon</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Drospirenone 3 mg</td>
<td>Yasmin</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Gestodene 75 micrograms</td>
<td>Femodene</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Gestodene 75 micrograms</td>
<td>Katya 30/75</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Gestodene 75 micrograms</td>
<td>Millinette 30/75</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Levonorgestrel 150 micrograms</td>
<td>Levest</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Levonorgestrel 150 micrograms</td>
<td>Microgynon 30</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Levonorgestrel 150 micrograms</td>
<td>Ovanette</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Levonorgestrel 150 micrograms</td>
<td>Rigevidon</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Norethisterone acetate 1.5 mg</td>
<td>Loestrin 30</td>
</tr>
<tr>
<td>30 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Norgestimate 250 micrograms</td>
<td>Cilest</td>
</tr>
<tr>
<td>35 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Norethisterone 500 micrograms</td>
<td>Brevinor</td>
</tr>
<tr>
<td>35 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Norethisterone 500 micrograms</td>
<td>Ovysmen</td>
</tr>
<tr>
<td>35 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Norethisterone 1 mg</td>
<td>Norimin</td>
</tr>
<tr>
<td>35 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mestranol 50 micrograms</td>
<td>Norethisterone 1 mg</td>
<td>Zoely</td>
</tr>
</tbody>
</table>

Combined Oral Contraceptives Phasic 21-day preparations

<table>
<thead>
<tr>
<th>Oestrogen content</th>
<th>Progestogen content</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol</td>
<td>Gestrone 3 mg</td>
<td>Logynon</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Gestrone 7 mg</td>
<td>Logynon</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Gestrone 10 mg</td>
<td>Logynon</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Micronor 1 mg</td>
<td>Logynon</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Micronor 2 mg</td>
<td>Logynon</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Micronor 3 mg</td>
<td>Logynon</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate</td>
<td>1 mg</td>
<td>Qlaira</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate</td>
<td>2 mg</td>
<td>Qlaira</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate</td>
<td>3 mg</td>
<td>Qlaira</td>
</tr>
<tr>
<td>20 micrograms</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Choice
The majority of combined oral contraceptives contain ethinylestradiol p. 655 as the oestrogen component; mestranol and estradiol are also used. The ethinylestradiol content of combined oral contraceptives ranges from 20 to 40 micrograms. Generally a preparation with the lowest oestrogen and progestogen content which gives good cycle control and minimal side-effects in the individual woman is chosen. It is recommended that combined hormonal contraceptives are not continued beyond 50 years of age since more suitable alternatives exist.
**Low strength preparations** (containing ethinylestradiol 20 micrograms) are particularly appropriate for women with risk factors for circulatory disease, provided a combined oral contraceptive is otherwise suitable.

**Standard strength preparations** (containing ethinylestradiol 30 or 35 micrograms or in 30–40 microgram phased preparations) are appropriate for standard use. Phased preparations are generally reserved for women who either do not have withdrawal bleeding or who have breakthrough bleeding with monophasic products.

The progestogens desogestrel with ethinylestradiol p. 685, drospirenone with ethinylestradiol p. 686, and ethinylestradiol with gestodene p. 687 may be considered for women who have side-effects (such as acne, headache, depression, breast symptoms, and breakthrough bleeding) with other progestogens. Drospirenone, a derivative of spironolactone, has anti-androgenic and anti-mineralocorticoid activity; it should be used with care if an increased plasma-potassium concentration might be hazardous.

Dienogest with estradiol valerate p. 685 is in the combined oral contraceptive Qlaira®. Nomegestrol is the progestogen contained in the combined oral contraceptive Zoely®, in combination with estradiol.

The progestogen norelgestromin is combined with ethinylestradiol in a transdermal patch (Evra®). The vaginal contraceptive ring contains the progestogen etonogestrel combined with ethinylestradiol (NuvaRing®).

**Surgery**

Oestrogen-containing contraceptives should preferably be discontinued (and adequate alternative contraceptive arrangements made) 4 weeks before major elective surgery and all surgery to the legs or surgery which involves prolonged immobilisation of a lower limb; they should normally be recommenced at the first menses occurring at least 2 weeks after full mobilisation. A progestogen-only contraceptive may be offered as an alternative and the oestrogen-containing contraceptive restarted after mobilisation. When discontinuation of an oestrogen-containing contraceptive is not possible, e.g. after trauma or if a patient admitted for an elective procedure is still on an oestrogen-containing contraceptive, thromboprophylaxis (with unfractionated or low molecular weight heparin and graduated compression hose) is advised. These recommendations do not apply to minor surgery with short duration of anaesthesia, e.g. laparoscopic sterilisation or tooth extraction, or to women using oestrogen-free hormonal contraceptives.

**Reason to stop immediately**

Combined hormonal contraceptives or hormone replacement therapy (HRT) should be stopped pending investigation and treatment, if any of the following occur:

- sudden severe chest pain (even if not radiating to left arm);
- sudden breathlessness (or cough with blood-stained sputum);
- unexplained swelling or severe pain in calf of one leg;
- severe stomach pain;
- serious neurological effects including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perception disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body;
- hepatitis, jaundice, liver enlargement;
- blood pressure above systolic 160 mmHg or diastolic 95 mmHg; (in adolescents stop if blood pressure very high);
- prolonged immobility after surgery or leg injury;

- detection of a risk factor which contra-indicates treatment.

**Progestogen-only contraceptives**

**Oral progestogen-only contraceptives**

Oral progestogen-only preparations alter cervical mucus to prevent sperm penetration and may inhibit ovulation in some women; oral desogestrel-only preparations consistently inhibit ovulation and this is their primary mechanism of action. There is insufficient clinical trial evidence to compare the efficacy of oral progestogen-only contraceptives with each other or with combined hormonal contraceptives. Progestogen-only contraceptives offer a suitable alternative to combined hormonal contraceptives when oestrogens are contra-indicated (including those with venous thrombosis or a past history or predisposition to venous thrombosis, heavy smokers, those with hypertension above systolic 160 mmHg or diastolic 95 mmHg, valvular heart disease, diabetes mellitus with complications, and migraine with aura).

**Parenteral progestogen-only contraceptives**

Medroxyprogesterone acetate (Depo-Provera®, SAYANA PRESS®) p. 695 is a long-acting progestogen given by injection; it is at least as effective as the combined oral preparations but because of its prolonged action it should never be given without full counselling backed by the patient information leaflet. It may be used as a short-term or long-term contraceptive for women who have been counselled about the likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility. Troublesome bleeding has been reported in patients given medroxyprogesterone acetate in the immediate puerperium; delaying the first injection until 6 weeks after birth may minimise bleeding problems. If the woman is not breast-feeding, the first injection may be given within 5 days postpartum (she should be warned that the risk of troublesome bleeding may be increased).

In adolescents, medroxyprogesterone acetate (Depo-Provera®, SAYANA PRESS®) should be used only when other methods of contraception are inappropriate;

- in all women, the benefits of using medroxyprogesterone acetate beyond 2 years should be evaluated against the risks;

- in women with risk factors for osteoporosis, a method of contraception other than medroxyprogesterone acetate should be considered.

**Norethisterone enantate** (Noristerat®) is a long-acting progestogen given as an oily injection which provides contraception for 8 weeks; it is used as short-term interim contraception e.g. before vasectomy becomes effective. An etonogestrel-releasing implant (Nexplanon®) is also available. It is a highly effective long-acting contraceptive, consisting of a single flexible rod that is inserted subdermally into the lower surface of the upper arm and provides contraception for up to 3 years. The manufacturer advises that in heavier women, blood-etonogestrel concentrations are lower and therefore the implant may not provide effective contraception during the third year; they advise that earlier replacement may be considered in such patients—however, evidence to support this recommendation is lacking. Local reactions such as bruising and itching can occur at the insertion site. The contraceptive effect of etonogestrel is rapidly reversed on removal of the implant.

**Intra-uterine progestogen-only device**

The progestogen-only intra-uterine systems, Mirena® and Jaydess®, releases levonorgestrel p. 692 directly into the uterine cavity. Mirena® is licensed for use as a contraceptive, for the treatment of primary menorrhagia, and for the prevention of endometrial hyperplasia during
of oestrogen replacement therapy. Jaydess® is licensed for contraception. These may therefore be a contraceptive method of choice for women who have excessively heavy menses.

The effects of the progestogen-only intra-uterine system are mainly local and hormonal including prevention of endometrial proliferation, thickening of cervical mucous, and suppression of ovulation in some women (in some cycles). In addition to the progestogenic activity, the intra-uterine system itself may contribute slightly to the contraceptive effect. Return of fertility after removal is rapid and appears to be complete.

Advantages of the progestogen-only intra-uterine system over copper intra-uterine devices are that there may be an improvement in any dysmenorrhoea and a reduction in blood loss; there is also evidence that the frequency of pelvic inflammatory disease may be reduced (particularly in the youngest age groups who are most at risk).

In primary menorrhagia, menstrual bleeding is reduced significantly within 3–6 months of inserting the progestogen-only intra-uterine system, probably because it prevents endometrial proliferation. Another treatment should be considered if menorrhagia does not improve within this time.

**Surgery**

All progestogen-only contraceptives (including those given by injection) are suitable for use as an alternative to combined hormonal contraceptives before major elective surgery, before all surgery to the legs, or before surgery which involves prolonged immobilisation of a lower limb.

**Emergency contraception**

**Hormonal methods**

Hormonal emergency contraceptives include levonorgestrel p. 692 and ulipristal acetate p. 691; either drug should be taken as soon as possible after unprotected intercourse to increase efficacy.

Levonorgestrel is effective if taken within 72 hours (3 days) of unprotected intercourse and may also be used between 72 and 96 hours after unprotected intercourse [unlicensed use], but efficacy decreases with time. Ulipristal acetate, a progestrone receptor modulator, is effective if taken within 120 hours (5 days) of unprotected intercourse.

Levonorgestrel is less effective than insertion of an intra-uterine device. Ulipristal acetate is as effective as levonorgestrel, but its efficacy compared to an intra-uterine device is not yet known.

**Intra-uterine device**

Insertion of an intra-uterine device is more effective than oral levonorgestrel p. 692 for emergency contraception. A copper intra-uterine contraceptive device can be inserted up to 120 hours (5 days) after unprotected intercourse; sexually transmitted infections should be tested for and insertion of the device should usually be covered by antibacterial prophylaxis (e.g. azithromycin p. 469). If intercourse has occurred more than 5 days previously, the device can still be inserted up to 5 days after the earliest likely calculated ovulation (i.e. within the minimum period before implantation), regardless of the number of episodes of unprotected intercourse earlier in the cycle.

**Contraceptives, interactions**

**Combined hormonal contraceptives interactions**

The effectiveness of combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, and vaginal rings can be considerably reduced by interaction with drugs that induce hepatic enzyme activity (e.g. carbamazepine p. 387, eslicarbazepine acetate p. 390, nevirapine p. 560, oxcarbazepine p. 397, phenytoin p. 398, phenobarbital p. 409, primidone p. 401, ritonavir p. 570, St John’s Wort, topiramate p. 406 and, above all, rifabutin p. 507 and rifampicin p. 508). A condom together with a long-acting method, such as an injectable contraceptive, may be more suitable for patients with HIV infection or at risk of HIV infection; advice on the possibility of interaction with antiretroviral drugs should be sought from HIV specialists.

Women taking combined hormonal contraceptives who require enzyme-inducing drugs should be advised to change to a contraceptive method that is unaffected by enzyme-inducers (e.g. some parenteral progestogen-only contraceptives, intra-uterine devices) for the duration of treatment and for 4 weeks after stopping. If a change in contraceptive method is undesirable or inappropriate the following options should be discussed:

- For a short course (2 months or less) of an enzyme-inducing drug, continue with a combined oral contraceptive providing ethinylestradiol 30 micrograms or more daily and use a ‘tricycling’ regimen (i.e. taking 3 packets of monophasic tablets without a break followed by a shortened tablet-free interval of 4 days [unlicensed use]). Additional contraceptive precautions should also be used whilst taking the enzyme-inducing drug and for 4 weeks after stopping. Another option (except for rifampicin or rifabutin) is to follow the advice for long-term courses.

  - For women using combined hormonal contraceptive patches or vaginal rings, additional contraceptive precautions are also required whilst taking the enzyme-inducing drug and for 4 weeks after stopping. If concomitant administration runs beyond the 3 weeks of patch or vaginal ring use, a new treatment cycle should be started immediately, without a patch-free or ring-free break.

  - For a long-term course (over 2 months) of an enzyme-inducing drug (except rifampicin or rifabutin), adjust the dose of combined oral contraceptive to provide ethinylestradiol 50 micrograms or more daily [unlicensed use] and use a ‘tricycling’ regimen; continue for the duration of treatment with the enzyme-inducing drug and for 4 weeks after stopping. If breakthrough bleeding occurs (and all other causes are ruled out) it is recommended that the dose of ethinylestradiol is increased by increments of 10 micrograms up to a maximum of 70 micrograms daily [unlicensed use], or to use additional precautions, or to change to a method unaffected by enzyme-inducing drugs.

  - Contraceptive patches and vaginal rings are not recommended for women taking enzyme-inducing drugs over a long period.

- For a long-term course (over 2 months) of rifampicin or rifabutin, an alternative method of contraception (such as an IUD) is always recommended because they are such potent enzyme-inducing drugs; the alternative method of contraception should be continued for 4 weeks after stopping the enzyme-inducing drug.

**Antibacterials that do not induce liver enzymes**

Latest recommendations are that no additional contraceptive precautions are required when combined oral contraceptives are used with antibacterials that do not induce liver enzymes, unless diarrhoea or vomiting occur. These recommendations should be discussed with the woman, who should also be advised that guidance in patient information leaflets may differ.

It is also currently recommended that no additional contraceptive precautions are required when contraceptive patches or vaginal rings are used with antibacterials that do not induce liver enzymes. There have been concerns that some antibacterials that do not induce liver enzymes (e.g. ampicillin p. 483, doxycycline p. 496) reduce the efficacy of combined oral contraceptives by impairing the bacterial flora
lesions, which may increase the risk of acquiring these infections.

Products such as petroleum jelly (Vaseline®), baby oil and oil-based vaginal and rectal preparations are likely to damage condoms and contraceptive diaphragms made from latex rubber, and may render them less effective as a barrier method of contraception and as a protection from sexually transmitted infections (including HIV).

**Contraceptive devices**

The intra-uterine device (IUD) is a suitable contraceptive for women of all ages irrespective of parity; however, it is less appropriate for those with an increased risk of pelvic inflammatory disease e.g. women under 25 years.

The most effective intra-uterine devices have at least 380 mm² of copper and have bonded copper on the arms. Smaller devices have been introduced to minimise side-effects; these consist of a plastic carrier wound with copper wire or fitted with copper bands; some also have a central core of silver to prevent fragmentation of the copper.

Fertility declines with age and therefore a copper intra-uterine device which is fitted in a woman over the age of 40, may remain in the uterus until menopause.

A frameless, copper-bearing intra-uterine device (Gyne Fix®) is also available. It consists of a knotted, polypropylene thread with 6 copper sleeves; the device is anchored in the uterus by inserting the knot into the uterine fundus.

---

**3.1 Contraception, combined**

**OESTROGENS**

**Combined hormonal contraceptives**

- **CONTRA-INDICATIONS** Acute porphyrias p. 864; gallstones — heart disease associated with pulmonary hypertension or risk of embolus — history during pregnancy of cholestatic jaundice — history during pregnancy of chorea — history during pregnancy of pemphigoid gestationis — history during pregnancy of pruritus — history of breast cancer (but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable) — history of haemolytic uraemic syndrome — migraine with aura — personal history of venous or arterial thrombosis — sclerosing treatment for varicose veins — severe or multiple risk factors for arterial disease. Severe or multiple risk factors for venous thromboembolism — systemic lupus erythematosus with (or unknown) antiphospholipid antibodies — transient cerebral ischaemic attacks without headaches — undiagnosed vaginal bleeding

- **CAUTIONS** Active trophoblastic disease (until return to normal of urine- and plasma- gonadotrophin concentration)— seek specialist advice — Crohn’s disease — genetic mutations associated with breast cancer (e.g. BRCA 1) — history of severe depression especially if induced by hormonal contraceptive — hyperprolactinaemia (seek specialist advice) — inflammatory bowel disease — migraine with aura — personal or family history of hypertriglyceridaemia (increased risk of pancreatitis) — risk factors for arterial disease — risk factors for venous thromboembolism — sickle cell disease — undiagnosed breast mass

**CAUTIONS. FURTHER INFORMATION**

Risk of venous thromboembolism. There is an increased risk of venous thromboembolic disease in users of combined hormonal contraceptives particularly during the first year and possibly after restarting combined hormonal
contraceptives following a break of four weeks or more. This risk is considerably smaller than that associated with pregnancy (about 60 cases of venous thromboembolic disease per 100 000 pregnancies). In all cases the risk of venous thromboembolism increases with age and in the presence of other risk factors, such as obesity. The risk also varies depending on the type of progestogen. Provided that women are informed of the relative risks of venous thromboembolism and accept them, the choice of oral contraceptive is for the woman together with the prescriber jointly to make in light of her individual medical history and any contra-indications.

Combined hormonal contraceptives also slightly increase the risk of arterial thromboembolism; however, there is no evidence to suggest that this risk varies between different preparations.

**Risk factors for venous thromboembolism** Use with caution if any of following factors present but avoid if two or more factors present:
- family history of venous thromboembolism in first-degree relative aged under 45 years (avoid contraceptive containing desogestrel or gestodene, or avoid if known prothrombin coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));
- obesity; body mass index ≥ 30 kg/m² (avoid if body mass index ≥ 35 kg/m² unless no suitable alternative); (in adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
- long-term immobilisation e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);
- history of superficial thrombophlebitis;
- age over 35 years (avoid if over 50 years);
- smoking.

### Combined Hormonal Contraception and Risk of Venous Thromboembolism

<table>
<thead>
<tr>
<th>Progestogen in Combined Hormonal Contraceptive</th>
<th>Estimated incidence per 10 000 women per year of use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-pregnant, not using combined hormonal contraception</td>
<td>2</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>5-7</td>
</tr>
<tr>
<td>Norgestimate</td>
<td>5-7</td>
</tr>
<tr>
<td>Norethisterone</td>
<td>5-7</td>
</tr>
<tr>
<td>Etonogestrel</td>
<td>6-12</td>
</tr>
<tr>
<td>Norelgestromin</td>
<td>6-12</td>
</tr>
<tr>
<td>Gestodene</td>
<td>9-12</td>
</tr>
<tr>
<td>Desogestrel</td>
<td>9-12</td>
</tr>
<tr>
<td>Dronrospirenone</td>
<td>Not known–insufficient data</td>
</tr>
<tr>
<td>Nomegestrol</td>
<td>Not known–insufficient data</td>
</tr>
</tbody>
</table>

"Combined with ethinylestradiol" "Combined with estradiol"

**Risk factors for arterial disease** Use with caution if any one of following factors present but avoid if two or more factors present:
- family history of arterial disease in first degree relative aged under 45 years (avoid if atherogenic lipid profile);
- diabetes mellitus (avoid if diabetes complications present);
- hypertension; blood pressure above systolic 140 mmHg or diastolic 90 mmHg (avoid if blood pressure above systolic 160 mmHg or diastolic 95 mmHg); (in adolescents, avoid if blood pressure very high);
- smoking (avoid if smoking 40 or more cigarettes daily);
- age over 35 years (avoid if over 50 years);
- obesity (avoid if body mass index ≥ 35 kg/m² unless no suitable alternative); (in adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
- migraine without aura (avoid if migraine with aura (focal symptoms), or severe migraine frequently lasting over 72 hours despite treatment, or migraine treated with ergot derivatives).

**Migraine** Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour). Combined hormonal contraceptives should be stopped (pending investigation and treatment), if serious neurological effects occur, including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perceptual disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body.

**INTERACTIONS** → Appendix 1 (oestrogens, progestogens).

**SIDE-EFFECTS**
- Rare: Gallstones • systemic lupus erythematosus
- Frequency not known: Abdominal cramps • absence of withdrawal bleeding • amenorrhoea after discontinuation • breast enlargement • breast secretion • breast tenderness • cervical erosion • changes in libido • changes in lipid metabolism • changes in vaginal discharge • chloasma • chorea • contact lenses may irritate • depression • fluid retention • headache • hepatic tumours • hypertension • irritability • leg cramps • liver impairment • nausea • nervousness • photosensitivity • reduced menstrual loss • skin reactions • thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB) • visual disturbances • vomiting • ‘spotting’ in early cycles

**SIDE-EFFECTS, FURTHER INFORMATION**

**Breast cancer** There is a small increase in the risk of having breast cancer diagnosed in women taking the combined oral contraceptive pill; this relative risk may be due to an earlier diagnosis. In users of combined oral contraceptive pills the cancers are more likely to be localised to the breast. The most important factor for diagnosing breast cancer appears to be the age at which the contraceptive is stopped rather than the duration of use; any increase in the rate of diagnosis diminishes gradually during the 10 years after stopping and disappears by 10 years.

**Cervical cancer** Use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years. The possible small increase in the risk of breast cancer and cervical cancer should be weighed against the protective effect against cancers of the ovary and endometrium.

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Avoid until weaning or for 6 months after birth (adverse effects on lactation).

**HEPATIC IMPAIRMENT** Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), liver tumours.

**DIRECTIONS FOR ADMINISTRATION**
- With oral use Each tablet should be taken at approximately same time each day; if delayed, contraceptive protection may be lost. 21-day combined preparations, 1 tablet daily for 21 days; subsequent courses repeated after a 7-day
PATIENT AND CARER ADVICE

Missed pill

The critical time for loss of contraceptive protection is when a pill is omitted at the beginning or end of a cycle (which lengthens the pill-free interval).

If a woman forgets to take a pill, it should be taken as soon as she remembers, and the next one taken at the normal time (even if this means taking 2 pills together). A missed pill is one that is 24 or more hours late. If a woman misses only one pill, she should take an active pill as soon as she remembers and then resume normal pill-taking. No additional precautions are necessary. If a woman misses 2 or more pills (especially from the first 7 in a packet), she may not be protected. She should take an active pill as soon as she remembers and then resume normal pill-taking. In addition, she must either abstain from sex or use an additional method of contraception such as a condom for the next 7 days. If these 7 days run beyond the end of the packet, the next packet should be started at once, omitting the pill-free interval (or, in the case of everyday (ED) pills, omitting the 7 inactive tablets). Emergency contraception is recommended if 2 or more combined oral contraceptive tablets are missed from the first 7 tablets in a packet and unprotected intercourse has occurred since finishing the last packet.

Travel

Women taking oral contraceptives are at an increased risk of deep vein thrombosis during travel involving long periods of immobility (over 3 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery. Diarrhoea and vomiting

Vomiting and persistent, severe diarrhoea can interfere with the absorption of combined oral contraceptives. If vomiting occurs within 2 hours of taking a combined oral contraceptive another pill should be taken as soon as possible. In cases of persistent vomiting or severe diarrhoea lasting more than 24 hours, additional precautions should be used during and for 7 days after recovery. If the vomiting and diarrhoea occur during the last 7 tablets, the next pill-free interval should be omitted (in the case of ED tablets the inactive ones should be omitted).
precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Gedarel** (Consilient Health Ltd)
  - Desogestrel 150 microgram, Ethinylestradiol 20 microgram Gedarel 20microgram/150microgram tablets | £3 tablet (P St) £5.98
  - Desogestrel 150 microgram, Ethinylestradiol 30 microgram Gedarel 30microgram/150microgram tablets | £3 tablet (P St) £4.19
- **Marvelon** (Merck Sharp & Dohme Ltd)
  - Desogestrel 150 microgram, Ethinylestradiol 30 microgram Marvelon tablets | £3 tablet (P St) £7.10
- **Mercilon** (Merck Sharp & Dohme Ltd)
  - Desogestrel 150 microgram, Ethinylestradiol 20 microgram Mercilon 150microgram/20microgram tablets | £3 tablet (P St) £8.44
- **Brands may include Alenini; Cimitz; Lestramy; Munalea**

Drospericone with ethinylestradiol

The properties listed below are those particular to the combination only. For the properties of the components please consider, ethinylestradiol p. 655.

**INDICATIONS AND DOSE**

- **Contraception with 21-day combined preparations**
- **Menstrual symptoms with 21-day combined preparations**
  - **BY MOUTH**
    - Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Yasmin** (Bayer Plc)
  - Drospericone 3 mg, Ethinylestradiol 30 microgram Yasmin tablets | £3 tablet (P St) £14.70
  - **Brands may include Acondro; Cloosena; Dreline; Lucette**

Estradiol with nomegestrol

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 649.

**INDICATIONS AND DOSE**

- **Contraception**
  - **BY MOUTH**
    - Females of childbearing potential: 1 active tablet daily for 24 days, followed by 1 inactive tablet daily for 4 days, to be started on day 1 of cycle with first active tablet (withdrawal bleeding occurs when inactive tablets being taken); subsequent courses repeated without interval

**DIRECTIONS FOR ADMINISTRATION**

**Zoely® (every day (ED) combined (monophasic) preparation)**, 1 active tablet daily for 24 days, followed by 1 inactive tablet daily for 4 days, starting on day 1 of cycle with first active tablet; subsequent courses repeated without interval (withdrawal bleeding occurs when inactive tablets being taken). Changing to combined preparation containing different progestogen If previous contraceptive used correctly, or pregnancy can reasonably be excluded, start the first active tablet of new brand immediately.

- Changing to Zoely®: start the first active Zoely® tablet on the day after taking the last active tablet of the previous brand or, at the latest, the day after the tablet-free or inactive tablet interval of the previous brand

**PATIENT AND CARER ADVICE**

- **Missed dose** A missed pill for a patient taking Zoely® is one that is 12 hours or more late; for information on how to manage missed pills in women taking Zoely®, refer to product literature. Diarrhoea and vomiting In cases of persistent vomiting or severe diarrhoea lasting more than 12 hours in women taking Zoely®, refer to product literature.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Zoely** (Merck Sharp & Dohme Ltd)
  - Estradiol (as Estradiol hemihydrate) 1.5 mg, Nomegestrol 2.5 mg Zoely 2.5mg/1.5mg tablets | 84 tablet (P St) £19.60 DT price + £13.80

Ethinylestradiol with etonogestrel

The properties listed below are those particular to the combination only. For the properties of the components please consider, ethinylestradiol p. 655, etonogestrol p. 695.

**INDICATIONS AND DOSE**

- **Contraception | Menstrual symptoms**
  - **BY VAGINA**
  - Females of childbearing potential: 1 unit, insert the ring into the vagina on day 1 of cycle and leave in for 3 weeks; remove ring on day 22; subsequent courses repeated after 7-day ring free interval (during which withdrawal bleeding occurs)

**DIRECTIONS FOR ADMINISTRATION**

Changing method of contraception to vaginal ring Insert ring at the latest on the day after the usual tablet-free, patch-free, or inactive-tablet interval. If previous contraceptive used correctly, or pregnancy can reasonably be excluded, can switch to ring on any day of cycle. Changing from progestogen-only method From an implant or intra-uterine progestogen-only device, insert ring on the day implanta or intra-uterine progestogen-only device removed; from an injection, insert ring when next injection due; from oral preparation, first ring may be inserted on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days. After first trimester abortion Start immediately. After childbirth (not breast-feeding) or second trimester abortion Start 4 weeks after birth or abortion; if started later than 4 weeks after birth or abortion, additional precautions (barrier methods) should be used for first 7 days.

**PATIENT AND CARER ADVICE**

- **Expulsion, delayed insertion or removal, or broken vaginal ring** If the vaginal ring is expelled for less than 3 hours, rinse the ring with cool water and reinsert immediately; no additional contraception is needed. If the ring remains outside the vagina for more than 3 hours or if the user does not know when the ring was expelled, contraceptive protection may be reduced:
  - If ring expelled during week 1 or 2 of cycle, rinse ring with cool water and reinsert; use additional precautions (barrier methods) for next 7 days;
  - If ring expelled during week 3 of cycle, either insert a new ring to start a new cycle or allow a withdrawal bleed and insert a new ring no later than 7 days after ring was expelled; latter option only available if ring was used continuously for at least 7 days before expulsion.
If insertion of a new ring at the start of a new cycle is delayed, contraceptive protection is lost. A new ring should be inserted as soon as possible; additional precautions (barrier methods) should be used for the first 7 days of the new cycle. If intercourse occurred during the extended ring-free interval, pregnancy should be considered. No additional contraception is required if removal of the ring is delayed by up to 1 week (4 weeks of continuous use). The 7-day ring-free interval should be observed and subsequently a new ring should be inserted. Contraceptive protection may be reduced with continuous use of the ring for more than 4 weeks—pregnancy should be ruled out before inserting a new ring. If the ring breaks during use, remove it and insert a new ring immediately; additional precautions (barrier methods) should be used for the first 7 days of the new cycle.

Patients or carers should be given advice on how to administer vaginal ring.

Counselling The presence of the ring should be checked regularly.

Travel Women using the vaginal ring are at an increased risk of deep vein thrombosis during travel involving long periods of immobility (over 3 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Vaginal delivery system**

- **NuvaRing** (Merck Sharp & Dohme Ltd)
  - Ethinylestradiol 2.7 mg, Etonogestrel 11.7 mg NuvaRing 0.12mg/0.15mg per day vaginal delivery system | 3 system (POA) £29.70

---

**Ethinylestradiol with levonorgestrel**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ethinylestradiol p. 655, levonorgestrel p. 692.

**INDICATIONS AND DOSE**

Contraception with 21-day combined preparations | Menstrual symptoms with 21-day combined preparations

**BY MOUTH**

- **Females of childbearing potential:** 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding occurs during the 7-day interval, if reasonably certain woman is not pregnant, first course can be started on any day of cycle— if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day

Contraception with 28-day combined preparations | Menstrual symptoms with 28-day combined preparations

**BY MOUTH**

- **Females of childbearing potential:** 1 active tablet once daily for 21 days, followed by 1 inactive tablet daily for 7 days; subsequent courses repeated without interval, withdrawal bleeding occurs during the 7-day interval of inactive tablets being taken, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Femodone** (Bayer Plc)
  - Ethinylestradiol 30 microgram, Gestodene 75 microgram Femodone tablets | 63 tablet (POA) £6.73
- **Femodette** (Bayer Plc)
  - Ethinylestradiol 20 microgram, Gestodene 75 microgram Femodette tablets | 63 tablet (POA) £8.85
- **Katya** (Stragen UK Ltd)
  - Ethinylestradiol 30 microgram, Gestodene 75 microgram Katya 30/75 tablets | 63 tablet (POA) £5.01
- **Millenette** (Consilent Health Ltd)
  - Ethinylestradiol 20 microgram, Gestodene 75 microgram Millenette 20microgram/7.5microgram tablets | 63 tablet (POA) £5.41
- **Sunya** (Stragen UK Ltd)
  - Ethinylestradiol 20 microgram, Gestodene 75 microgram Sunya 20/75 tablets | 63 tablet (POA) £6.62

**Brands may include Aidilana**

---

**Ethinylestradiol with gestodene**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ethinylestradiol p. 655, gestodene p. 692.
Ethinylestradiol with norethisterone

The properties listed below are those particular to the combination only. For the properties of the components please consider, ethinylestradiol p. 655, norethisterone p. 656.

INDICATIONS AND DOSE
Contraception with 21-day combined preparations | Menstrual symptoms with 21-day combined preparations
BY MOUTH
- Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding occurs during the 7-day interval, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Cilest (Janssen-Cilag Ltd)
  Ethinylestradiol 35 microgram, Norgestimate 250 microgram
  Tablet £1.16
- Rigevidon (Consilient Health Ltd)
  Ethinylestradiol 30 microgram, Levonorgestrel 150 microgram
  Tablet $2.82
- Brands may include Elevin; Erilibelle; Maexeni

Ethinylestradiol with norgestimate

The properties listed below are those particular to the combination only. For the properties of the components please consider, ethinylestradiol p. 655.

INDICATIONS AND DOSE
Contraception | Menstrual symptoms
BY TRANSDERMAL APPLICATION
- Females of childbearing potential. Apply 1 patch once weekly for 3 weeks, apply first patch on day 1 of cycle, change patch on days 8 and 15; remove third patch on day 22 and apply new patch after 7-day patch-free interval to start subsequent contraceptive cycle, subsequent courses repeated after a 7-day patch-free interval (during which withdrawal bleeding occurs)

DIRECTIONS FOR ADMINISTRATION
Adhesives or bandages should not be used to hold patch in place. If no longer sticky do not reapply but use a new patch.
Changing to a transdermal combined hormonal contraceptive
Changing from combined oral contraception
Apply patch on the first day of withdrawal bleeding; if no withdrawal bleeding within 5 days of taking last active tablet, rule out pregnancy before applying first patch. Unless patch is applied on first day of withdrawal bleeding, additional precautions (barrier methods) should be used concurrently for first 7 days.
Changing from progestogen-only method
- from an implant, apply first patch on the day implant removed
- from an injection, apply first patch when next injection due
- from oral progestogen, first patch may be applied on any day after stopping pill
For all methods additional precautions (barrier methods) should be used concurrently for first 7 days.

After childbirth (not breast-feeding)
Start 4 weeks after birth; if started later than 4 weeks after birth additional precautions (barrier methods) should be used for first 7 days.

After abortion or miscarriage
Before 20 weeks’ gestation start immediately; no additional contraception required if started immediately. After 20 weeks’ gestation start on day 21 after abortion or on the first day of first spontaneous menstruation; additional precautions (barrier methods) should be used for first 7 days after applying the patch.

PATIENT AND CARER ADVICE
Delayed application or detached patch
If a patch is partly detached for less than 24 hours, reapply to the same site or replace with a new patch immediately; no additional contraception is needed and the next patch should be applied on the usual ‘change day’. If a patch remains detached for more than 24 hours or if the user is not aware when the patch became detached, then stop the current contraceptive cycle and start a new cycle by applying a new patch, giving a new ‘Day 1’; an additional non-hormonal contraceptive must be used concurrently for the first 7 days of the new cycle.
If application of a new patch at the start of a new cycle is delayed, contraceptive protection is lost. A new patch should be applied as soon as remembered giving a new ‘Day 1’; additional non-hormonal methods of contraception should be used for the first 7 days of the
new cycle. If application of a patch in the middle of the cycle is delayed (i.e. the patch is not changed on day 8 or day 15):

- for up to 48 hours, apply a new patch immediately; next patch ‘change day’ remains the same and no additional contraception is required;
- for more than 48 hours, contraceptive protection may have been lost. Stop the current cycle and start a new 4-week cycle immediately by applying a new patch giving a new ‘Day 1’; additional non-hormonal contraception should be used for the first 7 days of the new cycle.

If the patch is not removed at the end of the cycle (day 22), remove it as soon as possible and start the next cycle on the usual ‘change day’, the day after day 28; no additional contraception is required.

Patients and carers should be given advice on how to administer patches.

- **Travel**
  - Women using patches are at an increased risk of deep vein thrombosis during travel involving long periods of immobility (over 3 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **Scottish Medicines Consortium (SMC) Decisions**
  The Scottish Medicines Consortium has advised (September 2003) that Evra® patches should be restricted for use in women who are likely to comply poorly with combined oral contraceptives.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Transdermal patch**
    - Evra® (Janssen-Cilag Ltd)
    - Ethinylestradiol 33.9 microgram per 24 hour, Norelgestromin 203 microgram per 24 hour
    - 9 patch pack £13.51
    - DT price = £13.51

**Mestranol with norethisterone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, norethisterone p. 656.

- **INDICATIONS AND DOSE**
  - Contraception | Menstrual symptoms
  - **BY MOUTH**
    - Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding can occur during the 7-day interval, if reasonably certain woman is not pregnant, first course can be started on any day of cycle— if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at the same time each day

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - Norinyl®-1 (Pfizer Ltd)
    - Mestranol 50 microgram, Norethisterone 1 mg
    - Norinyl®-1 tablets | 63 tablet pack £2.19
    - DT price = £2.19

### 3.2 Contraception, devices

| Drugs used for Contraception, devices not listed below: | Levonorgestrel, p. 652 |

### CONTRACEPTIVE DEVICES

#### Intra-uterine contraceptive devices (copper)

- **INDICATIONS AND DOSE**
  - Contraception
  - **BY INTRA-UTERINE ADMINISTRATION**
  - Females of childbearing potential: (consult product literature)

- **CONTRA-INDICATIONS**
  - Active trophoblastic disease (until return to normal of urine and plasma-gonadotrophin concentration).
  - Distorted uterine cavity—established or marked immunosuppression.
  - Medical diathesis—pelvic inflammatory disease.
  - Recent sexually transmitted infection (if not fully investigated and treated).
  - Severe anaemia—small uterine cavity.
  - Unexplained uterine bleeding.

- **CAUTIONS**
  - Anaemia—anticoagulant therapy (avoid if possible).
  - Diabetes—disease-induced immunosuppression.
  - Drug-induced immunosuppression (risk of infection—avoid if marked immunosuppression).
  - Endometritis—epilepsy (risk of seizure at time of insertion).
  - Fertility problems—history of pelvic inflammatory disease.
  - Increased risk of expulsion if inserted before uterine involution.
  - Menorrhagia—progestogen intra-uterine system might be preferable.
  - Nulliparity—severe cervical stenosis.
  - Severe primary dysmenorrhoea.
  - Severely scarred uterus (including after endometrial resection).
  - Young age.

- **SIDE-EFFECTS**
  - Allergy—bleeding (on insertion).
  - Cervical perforation.
  - Displacement.
  - Dysmenorrhoea.
  - Expulsion.
  - Menorrhagia—occasionally epileptic seizure (on insertion).
  - Pain (on insertion, alleviated by NSAID such as ibuprofen 30 minutes before insertion).
  - Pelvic infection may be exacerbated.

- **PREGNANCY**
  - If an intra-uterine device fails and the patient has a copper allergy.
  - If an intra-uterine device fails and the woman wishes to continue to full-term the device should be removed in the first trimester if possible. Remove
device; if pregnancy occurs, increased likelihood that it may be ectopic.

- **BREAST FEEDING** Not known to be harmful.
- **MONITORING REQUIREMENTS** Gynaecological examination before insertion, 6–8 weeks after insertion, then annually.
- **DIRECTIONS FOR ADMINISTRATION** The timing and technique of fitting an intra-uterine device are critical for its subsequent performance. The healthcare professional installing (or removing) the device should be fully trained in the technique and should provide full counselling backed, where available, by the patient information leaflet. Devices should not be fitted during the heavy days of the period; they are best fitted after the end of menstruation and before the calculated time of implantation.

- **PRESCRIBING AND DISPENSING INFORMATION**

  **ANCORA® 375 CU PRODUCTS**
  For uterine length over 6.5 cm; replacement every 5 years.
  **COPPER T380® PRODUCTS**
  For uterine length 6.5–9 cm; replacement every 10 years.
  **FLEXI-T® 300 PRODUCTS**
  For uterine length over 5 cm; replacement every 5 years.
  **FLEXI-T®+ 380 PRODUCTS**
  For uterine length over 6 cm; replacement every 5 years.
  **GYNEFLEX® PRODUCTS**
  Suitable for all uterine sizes; replacement every 5 years.
  **LOAD® 375 PRODUCTS**
  For uterine length over 7 cm; replacement every 5 years.
  **MINI T380® SLIMLINE**
  For minimum uterine length 5 cm; replacement every 5 years.
  **MULTILoad® CU375**
  For uterine length 6–9 cm; replacement every 5 years.
  **MULTI-SAFE® 375 PRODUCTS**
  For uterine length over 6–9 cm; replacement every 5 years.
  **NEO-SAFE® T380 PRODUCTS**
  For uterine length 6.5–9 cm; replacement every 5 years.
  **NOVALPLUS T 380® AG**
  ‘Mini’ size for minimum uterine length 5 cm; ‘Normal’ size for uterine length 6.5–9 cm; replacement every 5 years.
  **NOVALPLUS T 380® CU**
  ‘Mini’ size for minimum uterine length 5 cm; ‘Normal’ size for uterine length 6.5–9 cm; replacement every 5 years.
  **NOVA-T® 380 PRODUCTS**
  For uterine length 6.5–9 cm; replacement every 5 years.
  **T-SAFE® 380A QL PRODUCTS**
  For uterine length 6.5–9 cm; replacement every 10 years.
  **TT380® SLIMLINE PRODUCTS**
  For uterine length 6.5–9 cm; replacement every 10 years.
  **UT380 SHORT® PRODUCTS**
  For uterine length 5–7 cm; replacement every 5 years.
  **UT380 STANDARD® PRODUCTS**
  For uterine length 6.5–9 cm; replacement every 5 years.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Contraceptive devices**
  - **INTRA-UTERINE CONTRACEPTIVE DEVICES (COPPER) (Non-proprietary)**
    - Copper T380 A intra-uterine contraceptive device | 1 device £8.95
    - Steriload intra-uterine contraceptive device | 1 device £9.65
    - Load 375 intra-uterine contraceptive device | 1 device £8.52
    - Novaplu T 380 Ag intra-uterine contraceptive device mini | 1 device £12.50
    - T-Safe 380A QL intra-uterine contraceptive device | 1 device £10.47
    - UT380 Standard intra-uterine contraceptive device | 1 device £11.22
    - Nova-T 380 intra-uterine contraceptive device | 1 device £11.20
  - **FlexiT+ 380 intra-uterine contraceptive device** | 1 device £10.06
  - **Mini TT380 Slimline intra-uterine contraceptive device** | 1 device £12.46
  - **Flexi T 300 intra-uterine contraceptive device** | 1 device £9.47
  - Multi-Safe 375 intra-uterine contraceptive device | 1 device £8.96
  - Multiload Cu375 intra-uterine contraceptive device | 1 device £9.24
  - Optima Tco 380A intra-uterine contraceptive device | 1 device £9.65
  - Novaplu T 380 Ag intra-uterine contraceptive device normal | 1 device £12.50
  - GyneFix intra-uterine contraceptive device | 1 device £27.11
  - Novaplu T 380 Cu intra-uterine contraceptive device mini | 1 device £10.95
  - TT380 Slimline intra-uterine contraceptive device | 1 device £12.46
  - Ancora 375 Cu intra-uterine contraceptive device | 1 device £7.95
  - Novaplu T 380 Cu intra-uterine contraceptive device normal | 1 device £10.95
  - Neo-Safe T380 intra-uterine contraceptive device | 1 device £13.31
  - UT380 Short intra-uterine contraceptive device | 1 device £11.22

  **Vaginal contraceptives**
  - **SILICONE CONTRACEPTIVE DIAPHRAGMS**
    - Milex arcing spring silicone diaphragm 60mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex arcing spring silicone diaphragm 65mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex arcing spring silicone diaphragm 70mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex arcing spring silicone diaphragm 75mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex arcing spring silicone diaphragm 80mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex arcing spring silicone diaphragm 85mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex omniflex coil spring silicone diaphragm 60mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex omniflex coil spring silicone diaphragm 65mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex omniflex coil spring silicone diaphragm 70mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex omniflex coil spring silicone diaphragm 75mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex omniflex coil spring silicone diaphragm 80mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex omniflex coil spring silicone diaphragm 85mm (Durbin Plc)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex arcing spring silicone diaphragm 60mm (Janssen-Cilag Ltd)
      - 1 device | NHS indicative price = £9.31 - Drug Tariff (Part Ixa)
    - Milex arcing spring silicone diaphragm 65mm (Janssen-Cilag Ltd)
      - 1 device | NHS indicative price = £8.35 - Drug Tariff (Part Ixa)
    - Ortho All-Flex arcing spring silicone diaphragm 60mm (Janssen-Cilag Ltd)
      - 1 device | NHS indicative price = £8.35 - Drug Tariff (Part Ixa)
    - Ortho All-Flex arcing spring silicone diaphragm 65mm (Janssen-Cilag Ltd)
      - 1 device | NHS indicative price = £8.35 - Drug Tariff (Part Ixa)
    - Ortho All-Flex arcing spring silicone diaphragm 80mm (Janssen-Cilag Ltd)
      - 1 device | NHS indicative price = £8.35 - Drug Tariff (Part Ixa)
    - Ortho All-Flex arcing spring silicone diaphragm 85mm (Janssen-Cilag Ltd)
      - 1 device | NHS indicative price = £8.35 - Drug Tariff (Part Ixa)

  - **SILICONE CONTRACEPTIVE PESSARIES**
    - FemCap 22mm (Durbin Plc)
      - 1 device | NHS indicative price = £15.29 - Drug Tariff (Part Ixa)
    - FemCap 26mm (Durbin Plc)
      - 1 device | NHS indicative price = £15.29 - Drug Tariff (Part Ixa)
    - FemCap 30mm (Durbin Plc)
      - 1 device | NHS indicative price = £15.29 - Drug Tariff (Part Ixa)
3.3 Contraception, oral progestogen-only

| Drugs used for Contraception, oral progestogen-only not listed below; Norethisterone, p. 656 |

Ulipristal acetate

- **DRUG ACTION** Ulipristal acetate is a progestosterone receptor modulator with a partial progestosterone antagonist effect.

**INDICATIONS AND DOSE**

**Emergency contraception**

- Females of childbearing potential: 30 mg for 1 dose, to be taken as soon as possible after coitus, but no later than within 120 hours
- Pre-operative treatment of moderate to severe symptoms of uterine fibroids

**BY MOUTH**

- Adults: 5 mg daily for up to 3 months starting during the first week of menstruation, course may be repeated once if necessary, starting during the second menstruation after the first course completed, maximum 2 courses of 3 months

- **CONTRA-INDICATIONS**
  - **GENERAL CONTRA-INDICATIONS**
    - Repeated use as an emergency contraceptive within a menstrual cycle
  - **SPECIFIC CONTRA-INDICATIONS**
    - When used for uterine fibroids: Breast cancer, cervical cancer, ovarian cancer, undiagnosed vaginal bleeding, uterine cancer, vaginal bleeding not caused by uterine fibroids
  - **CAUTIONS**
    - Uncontrolled severe asthma
  - **INTERACTIONS** → Appendix 1 (ulipristal).
    - The effectiveness of ulipristal as an emergency contraceptive is possibly reduced in women taking enzyme-inducing drugs (and possibly for 4 weeks after stopping); a copper intra-uterine device can be offered instead. There is no need to increase the dose for emergency contraception if the patient is taking antibacterials that are not enzyme inducers.

- **SIDE-EFFECTS**
  - Common or very common
  - When used for emergency contraception: Abdominal pain, back pain, diarrhoea, dizziness, fatigue, gastrointestinal disturbances, headache, menstrual irregularities, muscle spasms, nausea, vomiting
  - When used for uterine fibroids: Abdominal pain, acne, breast pain, dizziness, endometrial thickening, headache, hot flushes, hyperhidrosis, malaise, menstrual disturbances, myalgia, nausea, oedema, ovarian cyst (including rupture), pelvic pain, uterine haemorrhage
  - Uncommon
    - When used for emergency contraception: Blurred vision, breast tenderness, dry mouth, hot flushes, pruritus, rash, tremor, uterine spasm
  - When used for uterine fibroids: Anxiety, constipation, dry mouth, dyspepsia, epistaxis, flatulence, urinary incontinence

- **CONCEPTION AND CONTRACEPTION**
  - When ulipristal is given as an emergency contraceptive the effectiveness of combined hormonal and progestogen-only contraceptives may be reduced—additional precautions (barrier methods) required for 14 days for combined and parenteral progestogen-only hormonal contraceptives (16 days for Qlaira™) and 9 days for oral progestogen-only contraceptives. When ulipristal is given for uterine fibroids non-hormonal contraceptive methods (barrier methods or intra-uterine device) should be used both during treatment and for 12 days after stopping, if required.
  - **PREGNANCY**
    - Manufacturer advises avoid for uterine fibroids—no information available. Limited information available when used as an emergency contraceptive.
  - **BREASTFEEDING**
    - When used for uterine fibroids, manufacturer advises avoid—no information available. In emergency contraception manufacturer advises avoid for 1 week after administration—present in milk.
  - **HEPATIC IMPAIRMENT**
    - Caution with use in uterine fibroids in moderate to severe hepatic impairment—no information available. Manufacturer advises avoiding use as an emergency contraceptive in severe hepatic impairment—no information available.
  - **RENAL IMPAIRMENT**
    - Caution in severe renal impairment when used for uterine fibroids—no information available.
  - **PATIENT AND CARER ADVICE**
    - When ulipristal is given as an emergency contraceptive, if vomiting occurs within 3 hours of taking a dose, a replacement dose should be given. When prescribing or supplying hormonal emergency contraception, women should be advised:
      - that their next period may be early or late;
      - that a barrier method of contraception needs to be used until the next period;
      - to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;
      - to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy, or absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).

- **MEDICAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - Ellane (HRA Pharma UK Ltd)
    - Ulipristal acetate 30 mg Ellane 30mg tablets | 1 tablet £14.05
    - Esmya (Gedeon Richter UK Ltd)
    - Ulipristal acetate 5 mg Esmya 5mg tablets | 28 tablet pack £114.13

**PROGESTOGENS**

Desogestrel

**INDICATIONS AND DOSE**

**Contraception**

**BY MOUTH**

- Females of childbearing potential: 75 micrograms daily, dose to be taken at same time each day, starting on day 1 of cycle then continuously, if administration delayed for 12 hours or more it should be regarded as a ‘missed pill’

- **CONTRA-INDICATIONS**
  - Acute porphyrias p. 864 - history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable - severe arterial disease - undiagnosed vaginal bleeding

- **CAUTIONS**
  - Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice - arterial disease - functional ovarian cysts - history of jaundice in pregnancy - malabsorption syndromes - past ectopic pregnancy - sex-steroid dependent cancer - systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies
Genito-urinary system

PATIENT AND CARER ADVICE

BREAST FEEDING

PREGNANCY

SIDE-EFFECTS

BREAST DISCOMFORT

DEPRESSION

DISTURBANCE OF APPETITE

DIZZINESS

HEADACHE

MENTRAL IRREGULARITIES

NAUSEA

SKIN DISORDERS

SIDE-EFFECTS, FURTHER INFORMATION

BREAST CANCER

There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

PREGNANCY

Not known to be harmful.

BREAST FEEDING

Progestogen-only contraceptives do not affect lactation.

HEPATIC IMPAIRMENT

Caution in severe liver disease and recurrent cholestatic jaundice. Avoid in liver tumour.

PATIENT AND CARER ADVICE

Missed pill

The following advice is recommended: 'If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 4 hours (12 hours for desogestrel) overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days. The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours (12 hours for desogestrel) late and unprotected intercourse has occurred before 2 further tablets have been correctly taken. Surgery

All progestogen-only contraceptives (including those given by injection) are suitable for use as an alternative to combined hormonal contraceptives before major elective surgery, before all surgery to the legs, or before surgery which involves prolonged immobilisation of a lower limb. Starting routine

One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours for desogestrel) contraceptive protection may be lost).

Additional contraceptive precautions are not necessary when initiating treatment. Changing from a combined oral contraceptive

Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).

After childbirth

Intra-uterine contraception

Conditions

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (September 2003) that Cerazette® should be restricted for use in women who cannot tolerate oestrogen-containing contraceptives or in whom such preparations are contra-indicated.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

Brands may include Aizea; Cerelle; Desomono; Desorex; Feanolla; Narrez; Zelleta

Levonorgestrel

INDICATIONS AND DOSE

Emergency contraception

BY MOUTH

Females of childbearing potential: 1.5 mg for 1 dose, taken as soon as possible after coitus, preferably within 12 hours but no later than after 72 hours

Contraception

BY MOUTH

Females of childbearing potential: 1 tablet daily starting on day 1 of the cycle then continuously, dose is to be taken at the same time each day, if administration delayed for 3 hours or more it should be regarded as a ‘missed pill’

JAYDESS® 13.5MG INTRA-UTERINE DEVICE

Contraception

BY VAGINA

Females of childbearing potential: Insert into uterine cavity within 7 days of onset of menstruation, or any time if replacement, or immediately after first-trimester termination; postpartum insertions should be delayed until at least 6 weeks after delivery (12 weeks if uterus involution is substantially delayed); effective for 3 years

MIRENA®20MICROGRAMS/24HOURS INTRA-UTERINE DEVICE

Contraception | Menorrhagia

BY INTRA-UTERINE ADMINISTRATION

Females of childbearing potential: Insert into uterine cavity within 7 days of onset of menstruation, or any time if replacement, or any time if reasonably certain woman is not pregnant and there is no risk of conception (additional precautions (e.g. barrier methods) necessary for next 7 days), or immediately after first-trimester termination by curettage; postpartum insertions should be delayed until at least 4 weeks after delivery; effective for 5 years

Prevention of endometrial hyperplasia during oestrogen replacement therapy

BY INTRA-UTERINE ADMINISTRATION

Females of childbearing potential: Insert during last days of menstruation or withdrawal bleeding or at any time if amenorrhoic; effective for 4 years

CONTRA-INDICATIONS

With intra-uterine use: Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration; acute cervicitis; acute vaginitis; distorted uterine cavity; established immunosuppression; genital
Contraception, oral progestogen-only 693

When used orally as an emergency contraceptive, the effectiveness of levonorgestrel is reduced in women taking enzyme-inducing drugs (and possibly for 4 weeks after stopping); a copper intra-uterine device can be offered instead. If the copper intra-uterine device is undesirable or inappropriate, the dose of levonorgestrel should be increased to a total of 3 mg taken as a single dose [unlicensed dose—advise women accordingly]. There is no need to increase the dose for emergency contraception if the patient is taking antibiotics that are not enzyme inducers. With the progestogen-only intra-uterine device, levonorgestrel is released close to the site of the main contraceptive action (on cervical mucous and endometrium) and therefore progestogenic side-effects and interactions are less likely; in particular, enzyme-inducing drugs are unlikely to significantly reduce the progestational effect of the progestogen-only intra-uterine system and additional contraceptive precautions are not required.

### SIDE-EFFECTS

#### GENERAL SIDE-EFFECTS

- **Common or very common** Depression (sometimes severe) - headache - nausea
- **Frequency not known** Vomiting

#### SPECIFIC SIDE-EFFECTS

- **Common or very common**
  - With intra-uterine use Abdominal pain - acne - alopecia - back pain - breast pain - changes in the pattern and duration of menstrual bleeding (spotting or prolonged bleeding) - expulsion - hirsutism - migraine - nervousness - pelvic pain - peripheral oedema - salpingitis
  - **Uncommon**
  - With intra-uterine use Abdominal distension - cervicitis - eczema - pelvic inflammatory disease - pruritus - skin hyperpigmentation
- **Rare**
  - With intra-uterine use Rash - uterine perforation
- **Frequency not known**
  - With intra-uterine use Allergy - bleeding (on insertion) - cervical perforation - displacement - dysmenorrhoea - epileptic seizures (on insertion) - functional ovarian cysts - genitourinary system and additional contraceptive precautions are not required.
- **With oral use** Breast discomfort - breast tenderness - changes in libido - disturbances of appetite - dizziness - fatigue - menstrual irregularities - skin disorders
- **SIDE-EFFECTS, FURTHER INFORMATION**

Endometrial disorders should be ruled out before insertion and the patient should be fully counselled (and provided with a patient information leaflet). Improvement in progestogenic side-effects, such as mastalgia and in the bleeding pattern may often become very light or absent.

### Breast cancer

There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

Although the progestogen-only intra-uterine system produces little systemic progestogenic activity, it is usually avoided for 5 years after any evidence of breast cancer. However, the system can be considered for a

#### MIRENA® 30MICROGRAMS/24HOURS INTRA-UTERINE DEVICE

Advanced uterine atrophy

#### INTERACTIONS

- Appendix 1 (progestogens).

---

**INTERACTIONS**

- With oral use Acute porphyrias p. 864
- With oral use for contraception History of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable - severe arterial disease - undiagnosed vaginal bleeding
- **CAUTIONS**
  - With intra-uterine use Anaemia - anticoagulant therapy (avoid if possible) - diabetes - disease-induced immunosuppression (risk of infection—avoid if marked immunosuppression) - drug-induced immunosuppression (risk of infection—avoid if marked immunosuppression) - endometriosis - epilepsy (risk of seizure at time of insertion) - fertility problems - history of pelvic inflammatory disease - increased risk of expulsion if inserted before uterine involution - menorrhagia (progestogen intra-uterine system might be preferable) - multiple cysts - severe cervical stenosis - severe primary dysmenorrhoea - severely scarred uterus (including after endometrial resection) - young age
  - With oral use for contraception Active trophoblastic disease (until return to normal of urine- and plasma-gondotrophin concentration)—seek specialist advice - arterial disease - functional ovarian cysts - history of jaundice in pregnancy - malabsorption syndromes - past ectopic pregnancy - sex-steroi dependent cancer - systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies
  - When used for emergency contraception Active trophoblastic disease (until return to normal of urine- and plasma-gondotrophin concentration)—seek specialist advice - past ectopic pregnancy - severe malabsorption syndromes

#### CAUTIONS, FURTHER INFORMATION

**Risk of infection with intra-uterine devices** The main excess risk of infection occurs in the first 20 days after insertion and is believed to be related to existing carriage of a sexually transmitted infection. Women are considered to be at a higher risk of sexually transmitted infections if:
- they are under 25 years old or
- they are over 25 years old and have a new partner or
- have had more than one partner in the past year or
- their regular partner has other partners.

In these women, pre-insertion screening (for chlamydia and, depending on sexual history and local prevalence of disease, Neisseria gonorrhoeae) should be performed. If results are unavailable at the time of fitting a intra-uterine device for emergency contraception, appropriate prophylactic antibacterial cover should be given. The woman should be advised to attend as an emergency if she experiences sustained pain during the next 20 days. An intra-uterine device should not be removed in mid-cycle unless an additional contraceptive was used for the previous 7 days. If removal is essential post-coital contraception should be considered.

**With oral use** Use as a contraceptive in co-morbidities The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes mellitus and migraine; evidence for caution in these conditions is unsatisfactory.

**MIRENA® 30MICROGRAMS/24HOURS INTRA-UTERINE DEVICE**

Advanced uterine atrophy

**INTERACTIONS**

- Appendix 1 (progestogens).
woman in long-term remission from breast cancer who has menorrhagia and requires effective contraception. Removal of the intra-uterine system should be considered if the patient experiences migraine or severe headache, jaundice, marked increase of blood pressure, or severe arterial disease.

- **PREGNANCY**
  - With oral use Not known to be harmful.
  - With vaginal use If an intra-uterine device fails and the woman wishes to continue to full-term the device should be removed in the first trimester if possible. Avoid; if pregnancy occurs remove intra-uterine system.

- **BREAST FEEDING** Progestogen-only contraceptives do not affect lactation.

- **HEPATIC IMPAIRMENT** Caution in severe liver disease and recurrent cholestatic jaundice. Avoid in liver tumour.

- **MONITORING REQUIREMENTS** Gynaecological examination before insertion, 4–6 weeks after insertion, then annually.

- **DIRECTIONS FOR ADMINISTRATION**
  - With intra-uterine use The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.

- **PRESCRIBING AND DISPENSING INFORMATION**

  - **JAYDESS® 13.5MG INTRA-UTERINE DEVICE**
    When system is removed (and not replaced immediately) and pregnancy is not desired, remove within 7 days of the onset of menstruation; additional precautions (e.g. barrier methods) should be used if the system is removed at some other time during the cycle and there is intercourse within 7 days.

  - **MIRENA® 20MICROGRAMS/24HOURS INTRA-UTERINE DEVICE**
    When system is removed (and not immediately replaced) and pregnancy is not desired, remove during first few days of menstruation, otherwise additional precautions (e.g. barrier methods) should be used for at least 7 days before removal.

- **PATIENT AND CARER ADVICE**
  - Missed doses When used as an oral contraceptive, the following advice is recommended: if you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days. The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken. Diarrhoea and vomiting Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.
  - With oral use for Contraception starting routine One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not necessary when initiating treatment. Changing from a combined oral contraceptive Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones). After childbirth Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days.
  - With oral use for Emergency contraception If vomiting occurs within 2 hours of taking levonorgestrel, a replacement dose should be given. When prescribing or supplying hormonal emergency contraception, women should be advised:
    - that their next period may be early or late;
    - that a barrier method of contraception needs to be used until the next period;
    - to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;
    - to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or heavy, or is absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).
  - With intra-uterine use Counsel women to seek medical attention promptly in case of significant symptoms, especially pain. Patient counselling advised. Patient information leaflet to be provided.

- **EXCEPTIONS TO LEGAL CATEGORY** Levonelle® One Step can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

| Tablet | Levonorgestrel (Non-proprietary) | Levonorgestrel 1.5 mg Levonorgestrel 1.5mg tablets | 1 tablet (£5.20–£13.83) DT price = £5.20 | 1 tablet (£5.20) DT price = £5.20
|        | Levonorgestrel 1.5 mg | § Isteranda (Sandoz Ltd)
|        | Levonorgestrel 1.5 mg | § Isteranda 1.5mg tablets | 1 tablet (£5.20) DT price = £5.20
|        | Levonelle (Bayer Plc) | Levonelle 1.5 mg Levonelle 1500microgram tablets | 1 tablet (£5.20) DT price = £5.20
|        | Levonelle (Bayer Plc) | Levonelle One Step 1.5mg tablets | 1 tablet (£11.33) DT price = £5.20
|        | Norgeston (Bayer Plc) | Norgeston 30 microgram tablets | 35 tablet (£0.92) DT price = £0.92
|        | Upostelle (Consilient Health Ltd) | Levonorgestrel 1.5 mg Upostelle 1500microgram tablets | 1 tablet (£3.75) DT price = £5.20
|        | Intratu-terine device | Jaydess (Bayer Plc) | §
|        | Intratu-terine device | Levonorgestrel 13.5 mg Jaydess 13.5mg intra-uterine device | 1 device (£69.22)
|        | Intratu-terine device | Levovest (Actavis UK Ltd) | § Levovest 20 micrograms/24hours intra-uterine device | 1 device (£66.00)
|        | Intratu-terine device | Mirena (Bayer Plc) | § Mirena 20micrograms/24hours intra-uterine device | 1 device (£88.00)

3.4 Contraception, parenteral progestogen-only

Drugs used for Contraception, parenteral progestogen-only not listed below; Norethisterone, p. 655
Medroxyprogesterone acetate

**INDICATIONS AND DOSE**

**Dysfunctional uterine bleeding**
- Adult: 2.5–10 mg daily for 5–10 days, repeated for 2 cycles, begin treatment on day 16–21 of cycle

**Secondary amenorrhoea**
- Adult: 2.5–10 mg daily for 5–10 days, repeated for 3 cycles, begin treatment on day 16–21 of cycle

**Mild to moderate endometriosis**
- Adult: 10 mg 3 times a day for 90 consecutive days, begin treatment on day 1 of cycle

**Progestogenic opposition of oestrogen HRT**
- Adult: 10 mg daily for the last 14 days of each 28-day oestrogen HRT cycle

**Endometrial cancer | Renal cell cancer**
- Adult: 200–600 mg daily

**Breast cancer**
- Adult: 0.4–1.5 g daily
Contraception

BY DEEP INTRAMUSCULAR INJECTION
- Females of childbearing potential: 150 mg, to be administered within the first 5 days of cycle or within first 5 days after parturition (delay until 6 weeks after parturition if breast-feeding)

BY SUBCUTANEOUS INJECTION
- Females of childbearing potential: 104 mg, to be administered within first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding), injected into anterior thigh or abdomen, dose only suitable if no hormonal contraceptive use in previous month

Contraception (when patient changing from other hormonal contraception)
BY SUBCUTANEOUS INJECTION
- Females of childbearing potential: (consult product literature)

- CONTRA-INDICATIONS
  - GENERAL CONTRA-INDICATIONS
    - Acute porphyrias p. 864 - severe arterial disease - undiagnosed vaginal bleeding
  - SPECIFIC CONTRA-INDICATIONS
    - With intramuscular or subcutaneous use: History of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable
    - With oral use: Breast cancer (unless progestogens are being used in the management of this condition) - genital cancer (unless progestogens are being used in the management of this condition) - history of liver tumours

- CAUTIONS
  - GENERAL CAUTIONS:
    - Possible risk of breast cancer
  - SPECIFIC CAUTIONS:
    - With intramuscular or subcutaneous use: History during pregnancy in disturbances of lipid metabolism - history during pregnancy of pruritus
    - With oral use: Asthma - cardiac dysfunction - conditions that may worsen with fluid retention - diabetes (progestogens can decrease glucose tolerance—monitor patient closely) - epilepsy - history of depression - hypertension - migraine - susceptibility to thromboembolism (particular caution with high dose)

- INTERACTIONS → Appendix 1 (progestogens).
  - Effectiveness of parenteral progestogen-only contraceptives is not affected by antibacterials that do not induce liver enzymes. The effectiveness of medroxyprogesterone acetate intramuscular and subcutaneous injections is not affected by enzyme-inducing drugs and they may be continued as normal during courses of these drugs.

- SIDE-EFFECTS
  - GENERAL SIDE-EFFECTS: Breast discomfort - changes in libido - depression - dizziness - headache - indigestion - loss of vision during treatment (discontinue treatment if papilloedema or retinal vascular lesions) - menstrual irregularities - nausea - pruritus - vomiting - weight gain

  - SPECIFIC SIDE-EFFECTS
    - Rare
    - With intramuscular or subcutaneous use: Osteoporosis - osteoporotic fractures
    - Frequency not known
      - With intramuscular or subcutaneous use: Disturbance of appetite - injection site-reactions - reduced bone mineral density - skin disorders
    - With oral use: Acne - adrenergic-like effects (when used for malignant disease) - alopecia - anaphylactoid reactions - bloating - breast tenderness - cervical erosions (when used for malignant disease) - confusion (when used for malignant disease) - congestive heart failure (when used for malignant disease) - constipation (when used for malignant disease) - diarrhoea (when used for malignant disease) - drowsiness - dry mouth (when used for malignant disease) - euphoria (when used for malignant disease) - fluid retention - galactorrhoea (when used for malignant disease) - glucocorticoid effects may lead to a cushingoid syndrome (with high doses for malignant disease) - hirsutism - hypercalcaemia (when used for malignant disease) - hyperpyrexia (when used for malignant disease) - hypertension (when used for malignant disease) - insomnia - jaundice - loss of concentration (when used for malignant disease) - nervousness (when used for malignant disease) - palpitation (when used for malignant disease) - premenstrual-like syndrome - raised platelet count (when used for malignant disease) - raised white blood cell count (when used for malignant disease) - rash - retinal thrombosis (when used for malignant disease) - skin reactions - tachycardia (when used for malignant disease) - urticaria - vision disorders (when used for malignant disease)

  - SIDE-EFFECTS, FURTHER INFORMATION
    - Cervical cancer: Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives. The risk of cervical cancer with other progestogen-only contraceptives is not yet known. Reduction in bone mineral density occurs in the first 2–3 years of use then stabilises.

  - CONCEPTION AND CONTRACEPTION
    - With intramuscular use: If interval between dose is greater than 12 weeks and 5 days (in long-term contraception), rule out pregnancy before next injection and advise patient to use additional contraceptive measures (e.g. barrier) for 14 days after the injection.
    - With subcutaneous use: If interval between dose is greater than 13 weeks and 7 days (in long-term contraception), rule out pregnancy before next injection.

  - PREGNANCY
    - With oral use: Avoid—genital malformations and cardiac defects reported.
    - With intramuscular use or subcutaneous use: Not known to be harmful.

  - BREAST FEEDING
    - Present in milk—no adverse effects reported. Progesterone-only contraceptives do not affect lactation.
    - With intramuscular use or subcutaneous use: The manufacturers advise that in women who are breast-feeding, the first dose should be delayed until 6 weeks after birth; however, evidence suggests no harmful effect to infant if given earlier. The benefits of using medroxyprogesterone acetate in breast-feeding women outweigh any risks.

  - HEPATIC IMPAIRMENT
    - With oral use: Avoid in hepatic impairment.
Erectile dysfunction


table or subcutaneous use. Caution in severe liver disease and recurrent cholestatic jaundice. Avoid in liver tumour.

- **RENAL IMPAIRMENT** Use with caution.
- **PREGNANCY**

- **SIDE-EFFECTS** Genital lesions
- **SIDE-EFFECTS, FURTHER INFORMATION** High frequency use of the spermicide nonoxinol-9 '9' has been associated with genital lesions, which may increase the risk of acquiring these infections.
- **CONCEPTION AND CONTRACEPTION** No evidence of harm to latex condoms and diaphragms.
- **PREGNANCY** Toxicity in *animal* studies.
- **BREAST FEEDING** Present in milk in *animal* studies.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - Forms available from special-order manufacturers include: oral suspension, oral solution.

**Tablet**
- **Climanor** (Resource Medical UK Ltd)
  - Medroxyprogesterone acetate 5 mg Climanor 5mg tablets | 28 tablet | £3.27
- **Provera** (Pfizer Ltd)
  - Medroxyprogesterone acetate 2.5 mg Provera 2.5mg tablets | 30 tablet | £1.84 DT price + £1.84
  - Medroxyprogesterone acetate 5 mg Provera 5mg tablets | 10 tablet | £1.23 DT price + £1.23 | 100 tablet | £12.32
  - Medroxyprogesterone acetate 10 mg Provera 10mg tablets | 10 tablet | £2.47 | 90 tablet | £22.16 DT price + £22.16 | 100 tablet | £24.73
- **Gygel** (Marbleborough Pharmaceuticals Ltd)
  - Nonoxinol-9 20 mg per 1 ml Gygel 2% contraceptive jelly | 30 gram | £4.25 | 81 gram | £11.00

**Suspension for injection**
- **Depo-Provera** (Pfizer Ltd)
  - Medroxyprogesterone acetate 150 mg per 1 ml Depo-Provera 150mg/1ml suspension for injection pre-filled syringes | 1 pre-filled disposable injection | £6.01 DT price + £6.01
  
- **Sayana Press** (Pfizer Ltd)
  - Medroxyprogesterone acetate 160 mg per 1 ml Sayana Press 160mg/0.65 ml suspension for injection pre-filled disposable devices | 1 pre-filled disposable injection | £6.90

3.5 Contraception, spermicidal

**SPERMICIDALS**

**Nonoxinol**

**INDICATIONS AND DOSE**
Spermicidal contraceptive in conjunction with barrier methods of contraception such as diaphragms or caps

**BY VAGINA**
- Females of childbearing potential: consult product literature
  
**SIDE-EFFECTS** Genital lesions

**SIDE-EFFECTS, FURTHER INFORMATION**
High frequency use of the spermicide nonoxinol-9 '9' has been associated with genital lesions, which may increase the risk of acquiring these infections.

**CONCEPTION AND CONTRACEPTION**
No evidence of harm to latex condoms and diaphragms.

**PREGNANCY**
Toxicity in *animal* studies.

**BREAST FEEDING**
Present in milk in *animal* studies.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

4 Erectile and ejaculatory conditions

4.1 Erectile dysfunction

**Erectile dysfunction**

Reasons for failure to produce a satisfactory erection include psychogenic, vascular, neurogenic, and endocrine abnormalities; impotence can also be drug-induced.

Intracavernosal, urethral or topical application of vasoactive drugs under careful medical supervision are used for the management of erectile dysfunction. Intracavernosal or intrurethral preparations can also be used in the diagnosis of erectile dysfunction.

Erectile disorders may also be treated with drugs given by mouth which increase the blood flow to the penis. Drugs should be used with caution if the penis is deformed (e.g. in angulation, cavernosal fibrosis, and Peyronie's disease).

**Priapism**
If priapism occurs with alprostadil p. 701, treatment should not be delayed more than 6 hours and is as follows:

- Initial therapy by penile aspiration; using aseptic technique a 19-21 gauge butterfly needle inserted into the corpus cavernosum and 20–50 ml of blood aspirated; if necessary the procedure may be repeated on the opposite side.
- If initial aspiration is unsuccessful a second 19–21 gauge butterfly needle can be inserted into the opposite corpus cavernosum and sterile physiological saline introduced through the first needle and drained through the second.
- If aspiration and lavage of corpora are unsuccessful, cautious intracavernosal injection of a sympathomimetic with action on alpha-adrenergic receptors, continuously monitoring blood pressure and pulse (extreme caution: coronary heart disease, hypertension, cerebral ischaemia or if taking antidepressant) can be given.
- If necessary the sympathomimetic injections can be followed by further aspiration of blood through the same butterfly needle.
- If sympathomimets unsuccessful, urgent surgical referral for management (possibly including shunt procedure).

**Prescribing on the NHS**
Some drug treatments for erectile dysfunction may only be prescribed on the NHS under certain circumstances; for details see the criteria listed in part XVIII of the Drug Tariff (Part XII of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The Drug Tariffs can be accessed online at: National Health Service Drug Tariff for England and Wales: www.jspa.org.uk/pja/edt_intro.htm

Health and Personal Social Services for Northern Ireland Drug Tariff: www.dhsspsni.gov.uk/pas-tariff

Scottish Drug Tariff: www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/
Erectile and ejaculatory conditions

**Avanafil**

**INDICATIONS AND DOSE**

**Erectile dysfunction**

- Adult: Initially 100 mg, to be taken approximately 30 minutes before sexual activity, then adjusted according to response to 50–200 mg (max. per dose 200 mg), to be taken as a single dose as needed; maximum 1 dose per day

**Erectile dysfunction in patients on alpha-blocker therapy**

- Adult: Initially 50 mg, to be taken approximately 30 minutes before sexual activity, then adjusted according to response to 50–200 mg (max. per dose 200 mg), to be taken as a single dose as needed; maximum 1 dose per day

**Dose adjustments due to interactions**

Max. 100 mg once every 48 hours with concomitant moderate inhibitors of cytochrome P450 enzyme CYP3A4 e.g. aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, or verapamil.

Concomitant treatment with a phosphodiesterase type-5 inhibitor and an alpha-blocker can increase the risk of postural hypotension—initiate treatment with a phosphodiesterase type-5 inhibitor (at a low dose) only once the patient is stable on the alpha-blocker.

**CONTRA-INDICATIONS**

- Avoid if systolic blood pressure below 90 mmHg (no information available) - blood pressure > 170/100 mmHg - hereditary degenerative retinal disorders - history of non-articentric anterior ischaemic optic neuropathy - life-threatening arrhythmia in previous 6 months - mild to severe heart failure - patients in whom vasodilation or sexual activity are disadvantageous - recent history of myocardial infarction - recent history of stroke - recent unstable angina

**CAUTIONS**

- Active peptic ulceration - anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) - bleeding disorders - cardiovascular disease - left ventricular outflow obstruction - predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia)

**SIDE-EFFECTS**

- Common or very common Back pain - dizziness - dyspepsia - flushing - headache - migraine - myalgia - nasal congestion - nausea - visual disturbances - vomiting

- Uncommon Drowsiness - epistaxis - hypertension - hypotension - malaise - painful red eyes - palpitation - tachycardia

- Rare Abdominal pain - diarrhoea - dry mouth - facial oedema - gastritis - genital irritation - gout - haematuria - hyperactivity - hyperbilirubinaemia - hypersensitivity - peripheral oedema - polymorphism - priapism - rash - Stevens-Johnson syndrome - syncope - weight gain

- Frequency not known Arrhythmia - myocardial infarction - non-articentric anterior ischaemic optic neuropathy (stop drug if sudden visual impairment occurs) - retinal vascular occlusion - seizures - serious cardiovascular events - sudden hearing loss (discontinue drug and seek medical advice) - unstable angina

**HEPATIC IMPAIRMENT**

Use lowest effective initial dose in mild to moderate impairment, adjusted according to response. Manufacturer advises avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**

Avoid if eGFR less than 30 mL/minute/1.73 m².

**PATIENT AND CARER ADVICE**

Onset of effect may be delayed if taken with food.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NHS restrictions** Spedra® is not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff (Part XII of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed 'SLS'.


**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Spedra (A. Menarini Farmaceutica Internazionale SRL) ▼
  - Avanafil 50 mg Spedra 50mg tablets | 4 tablet (PST) £10.94 | 8 tablet (PST) £19.70
  - Avanafil 100 mg Spedra 100mg tablets | 4 tablet (PST) £14.08 | 8 tablet (PST) £26.26
  - Avanafil 200 mg Spedra 200mg tablets | 4 tablet (PST) £21.90 | 8 tablet (PST) £39.40

**Sildenafil**

**INDICATIONS AND DOSE**

**Pulmonary arterial hypertension**

- Adult: 20 mg 3 times a day

**BY INTRAVENOUS INJECTION**

- Adult: 10 mg 3 times a day, use intravenous route when the oral route is not appropriate
Erectile dysfunction

BY MOUTH

► Adult: Initially 50 mg, to be taken approximately 1 hour before sexual activity, adjusted according to response to 25–100 mg (max. per dose 100 mg) as required, to be taken as a single dose; maximum 1 dose per day

► CONTRA-INDICATIONS

GENERAL CONTRA-INDICATIONS
Hereditary degenerative retinal disorders - history of non-articent anterior ischaemic optic neuropathy - recent history of myocardial infarction - recent history of stroke

SPECIFIC CONTRA-INDICATIONS
► When used for erectile dysfunction Avoid if systolic blood pressure below 90 mmHg (no information available) - patients in whom vasodilatation or sexual activity are inadvisable - recent unstable angina
► When used for pulmonary arterial hypertension Sickle-cell anemia

► CAUTIONS

GENERAL CAUTIONS
Active peptic ulceration - bleeding disorders - cardiovascular disease - left ventricular outflow obstruction

SPECIFIC CAUTIONS
► When used for erectile dysfunction Anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) - predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia)
► When used for pulmonary arterial hypertension Anatomical deformation of the penis - autonomic dysfunction
► Hypotension (avoid if systolic blood pressure below 90 mmHg) - intravenous volume depletion - predisposition to priapism - pulmonary veno-occlusive disease

► INTERACTIONS → Appendix 1 (sildenafil).

► SIDE-EFFECTS

GENERAL SIDE-EFFECTS
Back pain - dyspepsia - flushing - migraine - myalgia - nasal congestion - visual disturbances

► Frequency not known Non-articent anterior ischaemic optic neuropathy (discontinue if sudden visual impairment occurs) - sudden hearing loss (advise patient to seek medical help)

SPECIFIC SIDE-EFFECTS
► Common or very common
► When used for erectile dysfunction Nausea - dizziness - vomiting

► Uncommon
► When used for erectile dysfunction Chest pain - drowsiness - dry mouth - epistaxis - fatigue - hypertension - hypoaesthesia - hypotension - painful red eyes - palpitation - tachycardia - tinnitus - vertigo
► When used for pulmonary arterial hypertension Gynaecomastia - haematuria - penile haemorrhage - priapism

► Rare
► When used for erectile dysfunction Atrial fibrillation - cerebrovascular accident - facial oedema - hypersensitivity reactions - priapism - rash - Stevens-Johnson syndrome - syncope

► Frequency not known
► When used for erectile dysfunction Arrhythmia - myocardial infarction - seizures - unstable angina
► When used for pulmonary arterial hypertension Rash - retinal vascular occlusion

► PREGNANCY Use only if potential benefit outweighs risk—no evidence of harm in animal studies.

► BREAST FEEDING Manufacturer advises avoid—no information available.

► HEPATIC IMPAIRMENT In pulmonary arterial hypertension, if usual dose not tolerated, reduce oral dose to 20 mg twice daily and intravenous dose to 10 mg twice daily. For erectile dysfunction, use initial dose of 25 mg. Manufacturer advises avoid in severe impairment.

► RENAL IMPAIRMENT Use initial dose of 25 mg in erectile dysfunction if eGFR less than 30 mL/minute/1.73 m². In pulmonary hypertension, if usual dose not tolerated, reduce oral dose to 20 mg twice daily and intravenous dose to 10 mg twice daily.

► TREATMENT CESSATION
► When used for Pulmonary arterial hypertension Consider gradual withdrawal.

► PATIENT AND CARER ADVICE
► When used for Erectile dysfunction Onset of effect may be delayed if taken with food.

► NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (January 2010 and February 2011) that sildenafil tablets (Revatio®) should be initiated for patients with pulmonary arterial hypertension only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists and that sildenafil injection (Revatio®) should be prescribed only on the advice of specialists in the Scottish Pulmonary Vascular Unit or the Scottish Adult Congenital Cardiac Service.

NHS restrictions Viagra® is not prescribable under NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff (Part XIB of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’. For more information see Prices in the BNF, under How to use BNF publications p. xi.

► MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: pessary, oral suspension, oral solution

Tablet
► SILDENAFIL (Non-proprietary)
Sildenafil (as Sildenafil citrate) 25 mg Sildenafil 25mg tablets | 4 tablet (Pfizer) £16.59 DT price = £1.09 | 8 tablet (Pfizer) £33.19
Sildenafil (as Sildenafil citrate) 50 mg Sildenafil 50mg tablets | 4 tablet (Pfizer) £21.27 DT price = £1.15 | 8 tablet (Pfizer) £42.54
Sildenafil (as Sildenafil citrate) 100 mg Sildenafil 100mg tablets | 4 tablet (Pfizer) £33.50 DT price = £1.23 | 8 tablet (Pfizer) £64.99 | 12 tablet (Pfizer) £7.85
► Revatio (Pfizer Ltd)
Sildenafil (as Sildenafil citrate) 20 mg Revatio 20mg tablets | 90 tablet (Pfizer) £46.33
Viagra (Pfizer Ltd)
Sildenafil (as Sildenafil citrate) 25 mg Viagra 25mg tablets | 4 tablet (Pfizer) £16.59 DT price = £1.09 | 8 tablet (Pfizer) £33.19
Sildenafil (as Sildenafil citrate) 50 mg Viagra 50mg tablets | 4 tablet (Pfizer) £21.27 DT price = £1.15 | 8 tablet (Pfizer) £42.54
Sildenafil (as Sildenafil citrate) 100 mg Viagra 100mg tablets | 4 tablet (Pfizer) £23.50 DT price = £1.23 | 8 tablet (Pfizer) £64.99
Brands may include Vizarsin
Tadalafil

**INDICATIONS AND DOSE**

**Pulmonary arterial hypertension**
- **BY MOUTH**
  - Adult: 40 mg once daily

**Erectile dysfunction**
- **BY MOUTH**
  - Adult: Initially 10 mg once daily (max. per dose 20 mg), to be taken at least 30 minutes before sexual activity, subsequent doses adjusted according to response, the effect of intermittent dosing may persist for longer than 24 hours, daily dose of 10–20 mg not recommended; maximum 1 dose per day
  - **Erectile dysfunction; for patients who anticipate sexual activity at least twice a week**
    - **BY MOUTH**
      - Adult: 5 mg once daily, reduced to 2.5 mg once daily, adjusted according to response, the effect of intermittent dosing may persist for longer than 24 hours
  - **Benign prostatic hyperplasia**
    - **BY MOUTH**
      - Adult: 5 mg once daily

**CONTRA-INDICATIONS**

**GENERAL CONTRA-INDICATIONS**
- History of non-arteritic anterior ischaemic optic neuropathy

**SPECIFIC CONTRA-INDICATIONS**
- When used for benign prostatic hyperplasia or erectile dysfunction
  - Hypotension (avoid if systolic blood pressure below 90 mmHg) - mild to severe heart failure - myocardial infarction - patients in whom vasodilation or sexual activity are inadvisable - recent stroke - uncontrolled arrhythmias - uncontrolled hypertension - unstable angina
- When used for pulmonary arterial hypertension
  - Acute myocardial infarction in past 90 days

**CAUTIONS**
- When used for benign prostatic hyperplasia or erectile dysfunction
  - Anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) - cardiovascular disease - left ventricular outflow obstruction - predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia)
- When used for pulmonary arterial hypertension
  - Anatomical deformation of the penis - aortic and mitral valve disease - congestive cardiomyopathy - coronary artery disease - hereditary degenerative retinal disorders - hypertension (avoid if systolic blood pressure below 90 mmHg) - left ventricular dysfunction - life-threatening arrhythmias - pericardial constriction - predisposition to priapism - pulmonary veno-occlusive disease - uncontrolled hypertension

**INTERACTIONS**
- → Appendix 1 (tadalafil)

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Common or very common
  - Back pain - dyspepsia - flushing - headache - myalgia - nausea - vomiting
- Uncommon
  - Hypertension - tachycardia
- Frequency not known
  - Arrhythmia - myocardial infarction - non-arteritic anterior ischaemic optic neuropathy (stop drug if sudden visual impairment occurs) - retinal vascular occlusion - sudden hearing loss (discontinue drug and seek medical advice) - unstable angina

**SPECIFIC SIDE-EFFECTS**
- Common or very common
  - When used for benign prostatic hyperplasia or erectile dysfunction
    - Dizziness - migraine - nasal congestion - visual disturbances
- When used for pulmonary arterial hypertension
  - Blurred vision - chest pain - epistaxis - facial oedema - gastro-esophageal reflux - hypotension - increased uterine bleeding - limb pain - nasopharyngitis - palpitation - rash
- Uncommon
  - When used for benign prostatic hyperplasia or erectile dysfunction
    - Epistaxis - hypotension - painful red eyes - palpitation
  - When used for pulmonary arterial hypertension or erectile dysfunction
    - Amnesia - hyperhidrosis - priapism - seizures
  - Rare
  - When used for benign prostatic hyperplasia or erectile dysfunction
    - Facial oedema - hypersensitivity reactions - priapism - rash - Stevens-Johnson syndrome - syncope
  - Frequency not known
  - When used for benign prostatic hyperplasia or erectile dysfunction
    - Abdominal pain - increased sweating - seizures - serious cardiovascular events - transient amnesia
  - When used for pulmonary arterial hypertension
    - Stevens-Johnson syndrome - stroke - visual field defect

**PREGNANCY**
- Manufacturer advises avoid.

**BREAST FEEDING**
- Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**
- When used for pulmonary arterial hypertension use initial dose of 20 mg once daily in mild to moderate impairment and avoid in severe impairment. Use maximum dose of 10 mg in erectile dysfunction and benign prostatic hyperplasia. Manufacturer advises caution in severe impairment and for regular once-daily dosing in erectile dysfunction and benign prostatic hyperplasia—no information available.

**RENAL IMPAIRMENT**
- In pulmonary arterial hypertension for patients with mild to moderate impairment, initially use 20 mg once daily, increased to 40 mg once daily if tolerated; avoid in severe impairment. For erectile dysfunction and benign prostatic hyperplasia, maximum dose 10 mg if eGFR less than 30 mL/minute/1.73 m² (avoid regular once-daily dosing).

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions
- The Scottish Medicines Consortium has advised (June 2012) that tadalafil (Adcirca®) should be initiated only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.

NHS restrictions
- Cialis® is not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIII of the Drug Tariff (Part XII of the Northern Ireland Drug Tariff, Part 12 of...
**Erectile dysfunction**

**701**

- **Uncommon** Drowsiness - dyspnoea - epistaxis - hypertension - hypotension - increased lacrimation - painful red eyes - palpitation - photosensitivity - tachycardia
- **Rare** Anxiety - facial oedema - hypersensitivity reactions - hypertonia - priapism - raised intra-ocular pressure - rash - Stevens-Johnson syndrome - syncope - transient amnesia
- **Frequency not known** Arrhythmia - myocardial infarction - non-arteritic anterior ischaemic optic neuropathy (stop drug if sudden visual impairment occurs) - retinal vascular occlusion - seizures - serious cardiovascular events - sudden hearing loss (discontinue drug and seek medical advice) - unstable angina

**Hepatic impairment** Initial dose 5 mg in mild to moderate impairment, increased subsequently according to response (max. 10 mg in moderate impairment). Manufacturer advises avoid in severe impairment. Orodispersible tablets not suitable for patients with moderate hepatic impairment.

**Renal impairment** Initial dose 5 mg if eGFR less than 30 mL/minute/1.73 m². Orodispersible tablets not suitable if eGFR less than 30 mL/minute/1.73 m².

**Prescribing and dispensing information** Orodispersible tablets not suitable for initiation of therapy in patients taking alpha-blockers.

**National funding/access decisions**

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (September 2011) that vardenafil orodispersible tablets (Levitra®) are accepted for restricted use within NHS Scotland for men for whom an orodispersible tablet is an appropriate formulation.

NHS restrictions Levitra® is not prescribable under the NHS for the treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff (Part Xib of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’. For more information see Prices in the BNF, under How to use BNF publications p. xi.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Adcirca** (Eli Lilly and Company Ltd)
- **Tadalafil 20 mg** Adcirca 20mg tablets | 56 tablet [PO] £491.22
- **Cialis** (Eli Lilly and Company Ltd)
- **Tadalafil 2.5 mg** Cialis 2.5mg tablets | 28 tablet [PO] £4.99 DT price = £4.99
- **Tadalafil 5 mg** Cialis 5mg tablets | 28 tablet [PO] £54.99 DT price = £54.99
- **Tadalafil 10 mg** Cialis 10mg tablets | 4 tablet [PO] £26.99 DT price = £26.99
- **Tadalafil 20 mg** Cialis 20mg tablets | 4 tablet [PO] £53.98

**Vardenafil**

**INDICATIONS AND DOSE**

**Erectile dysfunction**

**BY MOUTH USING TABLETS**

- **Adult**: Initially 10 mg (max. per dose 20 mg), to be taken approximately 25–60 minutes before sexual activity, subsequent doses adjusted according to response, onset of effect may be delayed if taken with high-fat meal; maximum 1 dose per day

**BY MOUTH USING ORODISPERISIBLE TABLET**

- **Adult**: 10 mg, to be taken approximately 25–60 minutes before sexual activity; maximum 10 mg per day

**Erectile dysfunction (patients on alpha-blocker therapy)**

**BY MOUTH USING TABLETS**

- **Adult**: Initially 5 mg (max. per dose 20 mg), to be taken approximately 25–60 minutes before sexual activity, subsequent doses adjusted according to response, onset of effect may be delayed if taken with high-fat meal; maximum 1 dose per day

**Dose adjustments due to interactions**

Concomitant treatment with phosphodiesterase type-5 inhibitor and an alpha-blocker can increase the risk of postural hypotension—initiate treatment with a phosphodiesterase type-5 inhibitor (at a low dose) only once the patient is stable on the alpha-blocker.

**Dose equivalence and conversion**

Levitra® 10 mg orodispersible tablets and Levitra® 10 mg film coated tablets are **not** bioequivalent.

**CONTRA-INDICATIONS** Avoid if systolic blood pressure below 90 mmHg · hereditary degenerative retinal disorders · myocardial infarction · patients in whom vasodilatation or sexual activity are inadvisable · previous history of non-arteritic anterior ischaemic optic neuropathy · recent stroke · unstable angina

**CAUTIONS** Active peptic ulceration · anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) · bleeding disorders · cardiovascular disease · elderly · left ventricular outflow obstruction · predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia) · susceptibility to prolongation of QT interval

**INTERACTIONS** → Appendix 1 (vardenafil)
Caution with concomitant use of drugs which prolong QT interval. Avoid concomitant use of nitrates.

**SIDE-EFFECTS**

- **Common or very common** Back pain · dizziness · dyspepsia · flushing · headache · migraine · myalgia · nasal congestion · nausea · visual disturbances · vomiting

**Genito-urinary system**

- **Vardenafil**
- **Alprostadil**
- **Prostaglandins (Erectile Dysfunction)**
Aid to diagnosis of erectile dysfunction

**BY URETHRAL APPLICATION**

- Adult: 500 micrograms for 1 dose

**Erectile dysfunction**

**TO THE SKIN**

- Adult: Apply 300 micrograms, to the tip of the penis, 5–30 minutes before sexual activity; max 1 dose in 24 hours not more than 2–3 times per week

**VIRIDAL DUO STARTER PACK**

**Neurogenic erectile dysfunction**

**BY INTRACAVERNOSAL INJECTION**

- Adult: Initially 2.5 micrograms, increased in steps of 2.5–5 micrograms, to obtain dose suitable for producing erection not lasting more than 1 hour; usual dose 10–20 micrograms (max. per dose 40 micrograms), maximum frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

**Erectile dysfunction**

**BY INTRACAVERNOSAL INJECTION**

- Adult: Initially 5 micrograms, increased in steps of 2.5–5 micrograms, to obtain dose suitable for producing erection not lasting more than 1 hour; usual dose 10–20 micrograms (max. per dose 40 micrograms), maximum frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

**CAVERJECT DUAL CHAMBER**

**Erectile dysfunction**

**BY INTRACAVERNOSAL INJECTION**

- Adult: Initially 2.5 micrograms for 1 dose (first dose), followed by 5 micrograms for 1 dose (second dose), to be given if some response to first dose, alternatively 7.5 micrograms for 1 dose (second dose), to be given if no response to first dose, then increased in steps of 5–10 micrograms, to obtain a dose suitable for producing erection lasting not more than 1 hour; if no response to dose then next higher dose can be given within 1 hour, if there is a response the next dose should not be given for at least 24 hours; usual dose 5–20 micrograms (max. per dose 60 micrograms), maximum frequency of injection not more than 3 times per week with at least 24 hour interval between injections

**Erectile dysfunction associated with neurological dysfunction**

**BY INTRACAVERNOSAL INJECTION**

- Adult: Initially 1.25 micrograms for 1 dose (first dose), then 2.5 micrograms for 1 dose (second dose), then 5 micrograms for 1 dose (third dose), increased in steps of 5–10 micrograms, to obtain a dose suitable for producing erection lasting not more than 1 hour; if no response to dose then next higher dose can be given within 1 hour, if there is a response the next dose should not be given for at least 24 hours; usual dose 5–20 micrograms (max. per dose 60 micrograms), maximum frequency of injection not more than 3 times per week with at least 24 hour interval between injections

**Aid to diagnosis**

**BY INTRACAVERNOSAL INJECTION**

- Adult: 10–20 micrograms for 1 dose (consult product literature)

**Aid to diagnosis where evidence of neurological dysfunction**

**BY INTRACAVERNOSAL INJECTION**

- Adult: Initially 5 micrograms (max. per dose 10 micrograms) for 1 dose (consult product literature)

**VIRIDAL DUO CONTINUATION PACK**

**Erectile dysfunction**

**BY INTRACAVERNOSAL INJECTION**

- Adult: Initially 5 micrograms, increased in steps of 2.5–5 micrograms, to obtain dose suitable for producing erection not lasting more than 1 hour; usual dose 10–20 micrograms (max. per dose 40 micrograms), maximum frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

**Neurogenic erectile dysfunction**

**BY INTRACAVERNOSAL INJECTION**

- Adult: Initially 2.5 micrograms, increased in steps of 2.5–5 micrograms, to obtain dose suitable for producing erection not lasting more than 1 hour; usual dose 10–20 micrograms (max. per dose 40 micrograms), maximum frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

**CONTRA-INDICATIONS**

**GENERAL CONTRA-INDICATIONS**

Not for use in patients with penile implants or when sexual activity medically inadvisable (e.g. orthostatic hypotension, myocardial infarction, and syncope) • not for use with other agents for erectile dysfunction - predisposition to prolonged erection (as in thrombocytopenia, polycythemia, sickle cell anaemia,
multiple myeloma or leukaemia) • urethral application contra-indicated in balanitis • urethral application contra-indicated in severe curvature • urethral application contra-indicated in severe hypospadias • urethral application contra-indicated in urethritis

SPECIFIC CONTRA-INDICATIONS

• With topical use Balanitis • severe curvature • severe hypospadias • urethral stricture • urethritis

• CAUTIONS Anatomical deformations of penis (painful erection more likely)—follow up regularly to detect signs of penile fibrosis (consider discontinuation if angulation, cavernosal fibrosis or Peyronie’s disease develop) • priapism (patients should be instructed to report any erection lasting 4 hours or longer)

• INTERACTIONS → Appendix 1 (alprostadil).

• SIDE-EFFECTS

• Common or very common Dizziness • haematoma • haemosiderin deposits • headache • hypertension • hypotension • influenza-like syndrome • injection site reactions • other localised pain (buttocks, leg, testicular, abdominal) • penile fibrosis • penile oedema • penile pain • penile rash • urethral bleeding • urethral burning

• Uncommon Abnormal ejaculation • asthenia • balanitis • dry mouth • haematuria • irritation • leg cramps • local reactions • micturation difficulties • mydriasis • nausea • pelvic pain • penile numbness or sensitivity • penile warmth • phimosis • priapism • pruritus • rapid pulse • scrotal erythema • scrotal oedema • scrotal pain • supraventricular extrasystole • sweating • syncope • testicular oedema • testicular thickening • urethral stenosis • vasodilatation

• Rare Anaphylaxis • erythema • hypersensitivity reactions • rash • urinary-tract infection • urticaria • vertigo

• CONCEPTION AND CONTRACEPTION

• With urethral use If partner is pregnant, barrier contraception should be used. No evidence of harm to latex condoms and diaphragms.

• With topical use Condoms should be used to avoid exposure to women of child-bearing age, pregnant or lactating women. No evidence of harm to latex condoms.

• DIRECTIONS FOR ADMINISTRATION

• With intracavernosal use The first dose of the intracavernosal injection must be given by medically trained personnel; self-administration may only be undertaken after proper training.

• With urethral use During initiation of treatment the urethral application should be used under medical supervision; self-administration may only be undertaken after proper training.

• PATIENT AND CARER ADVICE Patients should be instructed to report any erection lasting 4 hours or longer.

• With topical use Counsel patients that condoms should be used to avoid local reactions and exposure of alprostadil to women of childbearing age, pregnant, or lactating women.

• NATIONAL FUNDING/ACCESS DECISIONS

NHS restrictions Caverject®, Viridal® Duo, Vitaros® and MUSE® are not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIII of the Drug Tariff (Part Xib of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’ For more information see Prices in the BNF, under How to use BNF publications p. xi

• MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection

• Caverject (Pfizer Ltd)

Alprostadil 5 microgram Caverject 5 microgram powder and solvent for solution for injection vials | 1 vial (£79.73 DT price = £7.73

Alprostadil 10 microgram Caverject 10 microgram powder and solvent for solution for injection vials | 1 vial (£92.24 DT price = £9.24

Caverject Dual Chamber 10 microgram powder and solvent for solution for injection | 2 pre-filled disposable injection (£44.70

Alprostadil 20 microgram Caverject Dual Chamber 20 microgram powder and solvent for solution for injection | 2 pre-filled disposable injection (£19.00

Caverject 20 microgram powder and solvent for solution for injection vials | 1 vial (£11.94 DT price = £11.94

Alprostadil 40 microgram Caverject 40 microgram powder and solvent for solution for injection vials | 1 vial (£21.58 DT price = £21.58

• Viridal (UCB Pharma Ltd)

Alprostadil 10 microgram Viridal Duo Starter Pack 10 microgram powder and solvent for solution for injection cartridges with device | 2 cartridge (£20.13 (Hospital only)

Viridal Duo Continuation Pack 10 microgram powder and solvent for solution for injection cartridges | 2 cartridge (£16.55

Alprostadil 20 microgram Viridal Duo Starter Pack 20 microgram powder and solvent for solution for injection cartridges with device | 2 cartridge (£24.54 (Hospital only)

Viridal Duo Continuation Pack 20 microgram powder and solvent for solution for injection cartridges | 2 cartridge (£21.39

Alprostadil 40 microgram Viridal Duo Starter Pack 40 microgram powder and solvent for solution for injection cartridges with device | 2 cartridge (£29.83 (Hospital only)

Viridal Duo Continuation Pack 40 microgram powder and solvent for solution for injection cartridges | 2 cartridge (£27.22

Cream

• Vitaros (Takeda UK Ltd)

Alprostadil 3 mg per 1 gram Vitaros 3mg/g cream | 1 applicator (£40.00

Urethral application

• Muse (Meda Pharmaceuticals Ltd)

Alprostadil 250 microgram Muse 250 microgram urethral sticks | 1 applicator (£11.30 DT price = £11.30 | 6 applicator (£67.79

Alprostadil 500 microgram Muse 500 microgram urethral sticks | 1 applicator (£11.30 DT price = £11.30 | 6 applicator (£67.79

Alprostadil 1 mg Muse 1000 microgram urethral sticks | 1 applicator (£11.56 DT price = £11.56 | 6 applicator (£65.67

4.2 Premature ejaculation

SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS

Dapoxetine

• DRUG ACTION Dapoxetine is a short-acting selective serotonin re-uptake inhibitor.

INDICATIONS AND DOSE

Premature ejaculation in men who meet all the following criteria: poor control over ejaculation, a history of premature ejaculation over the past 6 months, marked distress or interpersonal difficulty as a consequence of premature ejaculation, and an intravaginal ejaculatory latency time of less than two minutes.

BY MOUTH

• Adult: Initially 30 mg, to be taken approximately 1–3 hours before sexual activity, subsequent doses adjusted according to response; review treatment after 4 weeks (or 6 doses) and at least every 6 months thereafter, not recommended for adults 65 years and over; maximum 1 dose per day; maximum 60 mg per day continued →
Premature ejaculation in men who meet all the following criteria: poor control over ejaculation, a history of premature ejaculation over the past 6 months, marked distress or interpersonal difficulty as a consequence of premature ejaculation, and an intravaginal ejaculatory latency time of less than two minutes (with concomitant apreptitant, clarithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, and verapamil).

BY MOUTH
- Adult: Up to 30 mg, to be taken approximately 1–3 hours before sexual activity; review treatment after 4 weeks (or 6 doses) and at least every 6 months thereafter, not recommended for adults 65 years and over; maximum 1 dose per day.

Dose adjustments due to interactions
Max. single dose 30 mg with concomitant apreptitant, clarithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, and verapamil.

Use 60-mg dose with caution with concomitant potent inhibitors of cytochrome P450 enzyme CYP2D6.

- **CONTRA-INDICATIONS** History of bipolar disorder - history of mania - history of severe depression - history of syncope - significant cardiac disease - uncontrolled epilepsy
- **CAUTIONS** Bleeding disorders - epilepsy (discontinue if convulsions develop) - susceptibility to angle-closure glaucoma
- **INTERACTIONS** ▶ Appendix 1 (dapoxetine).
Caution with concomitant use of drugs that increase risk of bleeding.

- **SIDE-EFFECTS**
- **Common or very common** Abdominal distension - abdominal pain - abnormal dreams - agitation - anxiety - constipation - diarrhoea - dizziness - dry mouth - dyspepsia - flushing - headache - hypertension - impaired attention - irritability - malaise - nausea - paraesthesia - sexual dysfunction - sleep disturbances - sweating - tinnitus - tremor - visual disturbances - vomiting
- **Uncommon** Abnormal thoughts - bradycardia - bruxism - confusion - depression - eye pain - hypotension - mood disturbances - mydriasis - postural hypotension - pruritus - restlessness - sinus arrest - syncope - tachycardia - taste disturbances - vertigo
- **Rare** Defaecation urgency - sudden onset of sleep

SIDE-EFFECTS, FURTHER INFORMATION
Discontinue if psychiatric disorder develops. Avoid if postural hypotension occurs during test dose.

- **HEPATIC IMPAIRMENT** Use with caution if eGFR 30–80 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m².

- **PRE-TREATMENT SCREENING** Test for postural hypotension before starting treatment.

- **PATIENT AND CARER ADVICE**
Postural hypotension and syncope Patients should be advised to maintain hydration and to sit or lie down until prodromal symptoms such as nausea, dizziness, and sweating abate.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Table

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priligy (A. Menarini Farmaceutica Internazionale SRL)</td>
<td></td>
</tr>
<tr>
<td><strong>Dapoxetine 30 mg</strong> Priligy 30mg tablets</td>
<td>3 tablet £14.71</td>
</tr>
<tr>
<td>6 tablet £26.48</td>
<td></td>
</tr>
<tr>
<td><strong>Dapoxetine 60 mg</strong> Priligy 60mg tablets</td>
<td>3 tablet £19.12</td>
</tr>
<tr>
<td>6 tablet £34.42</td>
<td></td>
</tr>
</tbody>
</table>

5 Obstetrics

**Obstetrics**

**Prostaglandins and oxytocics**

Prostaglandins and oxytocics are used to induce abortion or induce or augment labour and to minimise blood loss from the placental site. They include oxytocin p. 705, carboprin p. 706, ergometrine maleate p. 707, and the prostaglandins. All induce uterine contractions with varying degrees of pain according to the strength of contractions induced.

**Induction of abortion**

Gemeprost p. 709, a prostaglandin administered vaginally as pessaries, is suitable for the medical induction of late therapeutic abortion; gemeprost is also used to ripen the cervix before surgical abortion, particularly in primigravida. The prostaglandin misoprostol p. 709 is given by mouth, buccally, sublingually, or vaginally, to induce medical abortion [unlicensed indication]. Intravaginal use ripens the cervix before surgical abortion [unlicensed indication]. Extra-amniotic dinoprostone p. 706 is rarely used nowadays.

Pre-treatment with mifepristone p. 708 can facilitate the process of medical abortion. It sensitises the uterus to subsequent administration of a prostaglandin and, therefore, abortion occurs in a shorter time and with a lower dose of prostaglandin.

**Induction and augmentation of labour**

Dinoprostone p. 706 is available as vaginal tablets, pessaries and vaginal gels for the induction of labour. The intravenous solution is rarely used; it is associated with more side-effects.

Oxytocin p. 705 ([Syntocinon]®) is administered by slow intravenous infusion, using an infusion pump, to induce or augment labour, usually in conjunction with amniotomy. Uterine activity must be monitored carefully and hyperstimulation avoided. Large doses of oxytocin may result in excessive fluid retention.

Misoprostol p. 709 is given orally or vaginally for the induction of labour [unlicensed indication].


**Prevention and treatment of haemorrhage**

Bleeding due to incomplete miscarriage or abortion can be controlled with ergometrine maleate and oxytocin ([Syntometrine]®) given intramuscularly. The dose is adjusted according to the patient’s condition and blood loss. This is commonly used before surgical evacuation of the uterus, particularly when surgery is delayed. Oxytocin and ergometrine maleate combined are more effective in early pregnancy than either drug alone.

Active management of the third stage of labour reduces the risk of postpartum haemorrhage; oxytocin is given by intramuscular injection [unlicensed] on delivery of the anterior shoulder or, at the latest, immediately after the baby is delivered. Alternatively, ergometrine maleate with oxytocin ([Syntometrine]®) can be given by intramuscular injection in the absence of hypertension; oxytocin alone causes less nausea, vomiting, and hypertension than when given with ergometrine maleate p. 707.

In excessive uterine bleeding, any placental products remaining in the uterus should be removed. Oxytocic drugs are used to treat postpartum haemorrhage caused by uterine atony; treatment options are as follows:

- oxytocin by slow intravenous injection, followed in severe cases by intravenous infusion of oxytocin at a rate that controls uterine atony or
- ergometrine by intramuscular injection or
ergometrine by slow intravenous injection (use with caution—risk of hypertension) or
- ergometrine with oxytocin (Syntometrine®) by intramuscular injection

Carboprost p. 706 has an important role in severe postpartum haemorrhage unresponsive to ergometrine maleate and oxytocin.

Misoprostol p. 709 [unlicensed] can be used in postpartum haemorrhage when oxytocin, ergometrine maleate, and carboprost are not available or are inappropriate.

**Mifepristone**

For termination of pregnancy, a single dose of mifepristone p. 708 is followed by administration of a prostaglandin (gemeprost p. 709 or misoprostol p. 709 [unlicensed]).

Guidelines of the Royal College of Obstetricians and Gynaecologists (November 2011) include [unlicensed] regimens for inducing medical abortion.

**Myometrial relaxants**

Tocolytic drugs postpone premature labour and they are used with the aim of reducing harm to the child. However, there is no satisfactory evidence that the use of these drugs reduces mortality. The greatest benefit is gained by using the delay to administer corticosteroid therapy or to implement other measures which improve perinatal health (including transfer to a unit with neonatal intensive care facility).

The oxytocin receptor antagonist, atosiban p. 708, is licensed for the inhibition of uncomplicated premature labour between 24 and 33 weeks of gestation. Atosiban may be preferable to a beta, agonist because it has fewer side effects. The dihydropyridine calcium-channel blocker nifedipine p. 154 also has fewer side-effects than a beta, agonist.

The beta, agonists salbutamol p. 222 and terbutaline sulfate p. 225 are licensed for inhibiting uncomplicated premature labour between 22 and 37 weeks of gestation to permit a delay in delivery of up to 48 hours. Use of high-dose short acting beta, agonists in obstetric indications has been associated with serious, sometimes fatal cardiovascular events in the mother and fetus, particularly when used for a prolonged period of time. Oral therapy is no longer recommended and parenteral therapy should be restricted to a maximum duration of 48 hours, given under the supervision of a specialist, and with close monitoring.

Indometacin p. 929, a cyclo-oxygenase inhibitor, also inhibits labour [unlicensed indication] and it can be useful in situations where a beta, agonist is not appropriate; however, there are concerns about neonatal complications such as transient impairment of renal function and premature closure of ductus arteriosus.

### Induction of labour

**PROSTAGLANDINS AND OXYTOCICS**

**Oxytocin**

**INDICATIONS AND DOSE**

Induction of labour for medical reasons | Stimulation of labour in hypotonic uterine inertia

**BY INTRAVENOUS INFUSION**

- Adult: Initially 0.001–0.004 units/minute, not to be started for at least 6 hours after administration of vaginal prostaglandin, dose increased at intervals of at least 30 minutes until a maximum of 3–4 contractions occur every 10 minutes (0.01 units/minute is often adequate) up to max. 0.02 units/minute, if regular contractions not established after a total of 5 units, stop induction attempt (may be repeated next day starting again at 0.001–0.004 units/minute)

**Caesarean section**

**BY SLOW INTRAVENOUS INJECTION**

- Adult: 5 units immediately after delivery

**Prevention of postpartum haemorrhage after delivery of placenta**

**BY INTRAVENOUS INFUSION**

- Adult: 5 units, if infusion previously used for induction or enhancement of labour, increase rate during third stage and for next few hours

**BY INTRAMUSCULAR INJECTION**

- Adult: 10 units, can be used instead of oxytocin with ergometrine (Syntometrine®)

**Treatment of postpartum haemorrhage**

**BY SLOW INTRAVENOUS INJECTION**

- Adult: 5 units, repeated if necessary

**Treatment of severe cases of postpartum haemorrhage (following intravenous injection)**

**BY INTRAVENOUS INFUSION**

- Adult: 40 units in 500 mL infusion fluid given at a rate sufficient to control uterine atony

**Incomplete, inevitable, or missed miscarriage**

**INITIALLY BY SLOW INTRAVENOUS INJECTION**

- Adult: 5 units, followed by (by intravenous infusion) 0.02–0.04 units/minute if required, the rate of infusion can be faster if necessary

**Important safety information**

Prolonged intravenous administration at high doses with large volume of fluid (which is possible in inevitable or missed miscarriage or postpartum haemorrhage) may cause water intoxication with hyponatraemia. To avoid: use electrolyte-containing diluent (i.e. not glucose), increase oxytocin concentration to reduce fluid, restrict fluid intake by mouth; monitor fluid and electrolytes.

**CONTRA-INDICATIONS** Any condition where spontaneous labour inadvisable - any condition where vaginal delivery inadvisable - avoid intravenous injection during labour - avoid prolonged administration in oxytocin-resistant uterine inertia - avoid rapid intravenous injection (may transiently reduce blood pressure) - fetal distress (discontinue immediately if this occurs) - hypertonic uterine contractions (discontinue immediately if this occurs) - severe cardiovascular disease - severe pre-eclamptic toxaemia

**CAUTIONS** Avoid large infusion volumes and restrict fluid intake by mouth (risk of hyponatraemia and water-intoxication) - enhancement of labour—presence of borderline cephalopelvic disproportion (avoid if significant) - history of lower-uterine segment caesarean section - induction of labour—presence of borderline cephalopelvic disproportion (avoid if significant) - mild pregnancy-induced cardiac disease - mild pregnancy-induced hypertension - moderate pregnancy-induced cardiac disease - moderate pregnancy-induced hypertension - risk factors for disseminated intravascular coagulation - secondary uterine inertia - women over 35 years

**INTERACTIONS** → Appendix 1 (oxytocin).

Effects enhanced by concomitant prostaglandins (very careful monitoring of uterine activity). Caudal block anaesthesia (may enhance hypertensive effects of sympathomimetic vasopressors).
706 Obstetrics

Genito-urinary system

- **SIDE-EFFECTS**
- **HEPATIC IMPAIRMENT** Manufacturer advises avoid.
- **RENAL IMPAIRMENT** Manufacturer advises avoid.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Pain (Ferring Pharmaceuticals Ltd)
  - Carbetocin 100 microgram per 1 ml Pain 100micrograms/ml solution for injection ampoules | 5 ampoule [Pain] £88.20 (Hospital only)

Carboprost

**INDICATIONS AND DOSE**
Postpartum haemorrhage due to uterine atony in patients unresponsive to ergometrine and oxytocin

- By deep intramuscular injection
  - Adult: 250 micrograms at least every 15 minutes, repeated if necessary, total dose should not exceed 2 mg (8 doses)

- **CONTRA-INDICATIONS** Cardiac disease - pulmonary disease - untreated pelvic infection
- **CAUTIONS** Excessive dosage may cause uterine rupture - history of anaemia - history of asthma - history of diabetes - history of epilepsy - history of glaucoma - history of hypertension - history of hypotension - history of jaundice - history of raised intra-ocular pressure - uterine scars

- **INTERACTIONS** Appendix 1 (prostaglandins)
- **SIDE-EFFECTS** Bronchospasm - cardiovascular collapse - chills - diaphoresis - diarrhoea - dizziness - dyspnoea - erythema at injection site - flushing - headache - hyperthermia - nausea - pain at injection site - pulmonary oedema - raised blood pressure - vomiting
- **HEPATIC IMPAIRMENT** Manufacturer advises avoid.
- **RENAL IMPAIRMENT** Manufacturer advises avoid.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Pain (Pfizer Ltd)
  - Carboprost (as Carboprost trometamol) 250 microgram per 1 ml Pain 250micrograms/ml solution for injection ampoules | 10 ampoule [Pain] £182.01 (Hospital only)

Dinoprostone

**INDICATIONS AND DOSE**
Prostaglandins and oxytocics

**Carbetocin**

**INDICATIONS AND DOSE**
Prevention of uterine atony after caesarean section

- By slow intravenous injection
  - Adult: 100 micrograms for 1 dose, to be given over 1 minute, administer as soon as possible after delivery, preferably before removal of placenta

- **CONTRA-INDICATIONS** Eclampsia - epilepsy - pre-eclampsia
- **CAUTIONS** Asthma - cardiovascular disease (avoid if severe) - hyponatraemia - migraine

5.2 Postpartum haemorrhage

- **SIDE-EFFECTS**
  - Common or very common Arrhythmia - headache - nausea - vomiting
  - Rare Anaphylactoid reactions (with dyspnoea, hypotension, or shock) - disseminated intravascular coagulation - hyponatraemia associated with high doses with large infusion volumes of electrolyte-free fluid - rash - uterine hyperstimulation (usually with excessive doses—may cause fetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture) - uterine spasm (may occur at low doses) - water intoxication associated with high doses with large infusion volumes of electrolyte-free fluid

- **MEDICATIONS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Pain (Hospital)
  - Carbetocin 100 microgram per 1 ml Pain 100micrograms/ml solution for injection ampoules | 5 ampoule [Pain] £88.20 (Hospital only)
PROSTIN E2® VAGINAL TABLETS
Induction of labour
BY VAGINA
- Adult: 3 mg, inserted high into the posterior fornix, followed by 3 mg after 6–8 hours (max. per dose 6 mg), to be given if labour not established

Dose equivalence and conversion
Prostin E2 Vaginal tablets and Vaginal Gel are not bioequivalent.

PROPESES®
Cervical ripening and induction of labour at term
BY VAGINA
- Adult: 1 pessary, insert pessary (in retrieval device) high into posterior fornix and remove when cervical ripening adequate; if oxytocin necessary, remove 30 minutes before oxytocin infusion; remove if cervical ripening inadequate after 24 hours (dose not to be repeated).

- CONTRA-INDICATIONS Active cardiac disease • active pulmonary disease • avoid extra-amniotic route in cervicitis or vaginitis • fetal distress • fetal malpresentation • grand multiparas • history of caesarean section • history of difficult or traumatic delivery • history of major uterine surgery • major cephalopelvic disproportion • multiple pregnancy • placenta praevia or unexplained vaginal bleeding during pregnancy • ruptured membranes • untreated pelvic infection

- CAUTIONS Effect of oxytocin enhanced • history of asthma • history of epilepsy • history of glaucoma and raised intraocular pressure • hypertension • risk factors for disseminated intravascular coagulation • uterine rupture • uterine scarring

- INTERACTIONS → Appendix 1 (prostaglandins).

- SIDE-EFFECTS Abruptio placenta • amniotic fluid embolism • backache • bronchospasm • cardiac arrest • diarrhoea • disseminated intravascular coagulation • fetal distress • fever • low Apgar scores • maternal hypertension • nausea • pulmonary embolism • rapid cervical dilation • severe uterine contractions • stillbirth or neonatal death • uterine hypercontractility with or without fetal bradycardia • uterine hypertonus • uterine rupture • vaginal symptoms (warmth, irritation, pain) • vomiting

- HEPATIC IMPAIRMENT Manufacturers advise avoid.

- RENAL IMPAIRMENT Manufacturers advise avoid.

- MONITORING REQUIREMENTS
  - Monitor for disseminated intravascular coagulation after parturition.
  - Monitor uterine activity and fetal status (particular care if history of uterine hypertony)
  - Care needed in monitoring uterine activity when used in sequence following oxytocin.

- DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Prostin E2®) give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%.

- PRESCRIBING AND DISPENSING INFORMATION
  Important: Do not confuse dose of Prostin E2® vaginal gel with that of Prostin E2® vaginal tablets—not bioequivalent.

- LESS SUITABLE FOR PRESCRIBING
  Intravenous solution rarely used and is considered less suitable for prescribing. Extra-amniotic solution less commonly used and is considered less suitable for prescribing.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

- Solution for infusion
  → Prostin E2 (Pfizer Ltd)
  Dinoprostone 1 mg per 1 ml Prostin E2 750micrograms/0.75ml solution for infusion ampoules | 1 ampoule £8.52 (Hospital only)
  Dinoprostone 10 mg per 1 ml Prostin E2 5mg/0.5ml solution for infusion ampoules | 1 ampoule £18.40 (Hospital only)

- Pessary
  → Prostin E2 (Pfizer Ltd)
  Dinoprostone 3 mg Prostin E2 3mg vaginal tablets | 8 pessary £106.23 (Hospital only)

- Vaginal gel
  → Prostin E2 (Pfizer Ltd)
  Dinoprostone 1 mg Prostin E2 1mg vaginal gel | 1mg/2.5ml £13.28 (Hospital only)
  Dinoprostone 2 mg Prostin E2 2mg vaginal gel | 2mg/2.5ml £13.28 (Hospital only)

- Vaginal device
  → Propess (Ferring Pharmaceuticals Ltd)
  Dinoprostone 10 mg Propess 10mg vaginal delivery system | 5 device £150.00

- Vaginal gel
  → Prostin E2 (Pfizer Ltd)
  Dinoprostone 1 mg Prostin E2 1mg vaginal gel | 2.5 mL £13.28 (Hospital only)
  Dinoprostone 2 mg Prostin E2 2mg vaginal gel | 2.5 mL £13.28 (Hospital only)

- Liquid
  → Prostin E2 (Pfizer Ltd)
  Dinoprostone 10 mg per 1 ml Prostin E2 5mg/0.5ml extraamniotic solution ampoules | 1 ampoule £18.40 (Hospital only)

Ergometrine maleate

INDICATIONS AND DOSE
Postpartum haemorrhage caused by uterine atony
BY INTRAMUSCULAR INJECTION OR BY SLOW INTRAVENOUS INJECTION
- Adult: 250–500 micrograms

- CONTRA-INDICATIONS Eclampsia • first stage of labour • induction of labour • second stage of labour • sepsis • severe cardiac disease • severe hypertension • vascular disease

- CAUTIONS Acute porphyrias p. 864 • cardiac disease • hypertension • multiple pregnancy • risk of hypertension associated with intravenous administration

- INTERACTIONS → Appendix 1 (ergot alkaloids).

- SIDE-EFFECTS
  - Common or very common Abdominal pain • arrhythmias • bradycardia • chest pain • dizziness • dyspnoea • headache • hypertension • nausea • palpitation • pulmonary oedema • rash • tinnitus • vasoconstriction • vomiting
  - Very rare Myocardial infarction

- HEPATIC IMPAIRMENT Manufacturer advises caution in mild or moderate impairment. Manufacturer advises avoid in severe impairment.

- RENAL IMPAIRMENT Manufacturer advises caution in mild or moderate impairment. Manufacturer advises avoid in severe impairment.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

- Solution for injection
  → ERGOMETRINE MALEATE (Non-proprietary)
  Ergometrine maleate 500 microgram per 1 ml Ergometrine 500micrograms/2ml solution for injection ampoules | 10 ampoule £15.00

- Intravenous solution rarely used and is considered less suitable for prescribing.
Ergometrine with oxytocin

The properties listed below are those particular to the combination only. For the properties of the components please consider, ergometrine maleate p. 707, oxytocin p. 705.

**INDICATIONS AND DOSE**

Active management of the third stage of labour | Postpartum haemorrhage caused by uterine atony

**BY INTRAVENOUS INJECTION**

- Adult: 1 ml for one dose.

**BY INTRAMUSCULAR INJECTION**

- Adult: No longer recommended.

**BLEEDING DUE TO INCOMPLETE MISCARRIAGE OR ABORTION**

**BY INTRAMUSCULAR INJECTION**

- Adult: Adjusted according to response to, the patient’s condition and blood loss.

**SIDE-EFFECTS**

- **Common or very common** Dizziness · headache · hot flushes · hyperglycaemia · hypotension · injection-site reaction · nausea · tachycardia · vomiting

- **Uncommon** Fever · insomnia · pruritus · rash

- **HEPATIC IMPAIRMENT** No information available.

- **RENAL IMPAIRMENT** No information available.

- **MONITORING REQUIREMENTS** Monitor blood loss after delivery.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Tractocile® concentrate for intravenous infusion), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 10 ml infusion fluid from 100-ml bag and replace with 10 ml atosiban concentrate (7.5 mg/ml) to produce a final concentration of 750 micrograms/ml.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **ATOSIBAN (Non-proprietary)**

  Atosiban (as Atosiban acetate) 7.5 mg per 1 ml Atosiban 6.75mg/0.9ml solution for injection vials | 1 vial [POD] £18.41 (Hospital only)

  Tractocile (Ferring Pharmaceuticals Ltd)

  Atosiban (as Atosiban acetate) 7.5 mg per 1 ml Tractocile 6.75mg/0.9ml solution for injection vials | 1 vial [POD] £18.41 (Hospital only)

**Solution for infusion**

- **ATOSIBAN (Non-proprietary)**

  Atosiban (as Atosiban acetate) 7.5 mg per 1 ml Atosiban 37.5mg/ml concentrate for solution for infusion vials | 1 vial [POD] £52.82 (Hospital only)

  Tractocile (Ferring Pharmaceuticals Ltd)

  Atosiban (as Atosiban acetate) 7.5 mg per 1 ml Tractocile 37.5mg/ml solution for infusion vials | 1 vial [POD] £52.82 (Hospital only)

**5.4 Termination of pregnancy**

**PROGESTERONE RECEPTOR MODULATORS**

**Mifepristone**

- **DRUG ACTION** Mifepristone, an antiprogestogenic steroid, sensitises the myometrium to prostaglandin-induced contractions and ripens the cervix.

**INDICATIONS AND DOSE**

Cervical ripening before mechanical cervical dilatation for termination of pregnancy of up to 64 days gestation (under close medical supervision)

**BY MOUTH**

- Adult: 200 mg for 1 dose, to be taken 36-48 hours before procedure

Labour induction in fetal death in utero where prostaglandin or oxytocin inappropriate (under close medical supervision)

**BY MOUTH**

- Adult: 600 mg once daily for 2 days, if labour not started within 72 hours of first dose, another method should be used

Medical termination of intra-uterine pregnancy of up to 49 days gestation (under close medical supervision)

**BY MOUTH**

- Adult: 600 mg for 1 dose, dose followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina or misoprostol 400 micrograms by mouth, alternatively 200 mg for 1 dose, dose followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina; observe for at least 3 hours (or until bleeding or pain at acceptable level); follow-up visit within 2 weeks to verify complete expulsion and to assess vaginal bleeding

Medical termination of intra-uterine pregnancy of 50–63 days gestation (under close medical supervision)

**BY MOUTH**

- Adult: 600 mg for 1 dose, alternatively 200 mg for 1 dose, dose followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina; observe for at least 3 hours (or until bleeding or pain at acceptable level); follow-up visit within 2 weeks to verify complete expulsion and to assess vaginal bleeding
Termination of pregnancy of 13–24 weeks gestation (in combination with a prostaglandin) (under close medical supervision)

**BY MOUTH**

- **Adult:** 600 mg for 1 dose, alternatively 200 mg for 1 dose, dose followed 36–48 hours later by gemeprost 1 mg by vagina every 3 hours up to max. 5 mg or misoprostol; if abortion does not occur, 24 hours after start of treatment repeat course of gemeprost 1 mg by vagina up to max. 5 mg; follow-up visit after appropriate interval to assess vaginal bleeding recommended

- **SIDE-EFFECTS**
  - **Common or very common** Gastro-intestinal cramps - uterine contractions - vaginal bleeding (sometimes severe) may occur between administration of mifepristone and surgery (and rarely abortion may occur before surgery)
  - **Uncommon** Hypersensitivity reactions - rash - urticaria
  - **Rare** Chills - dizziness - fever - headache - hot flushes - hypotension - malaise
  - **Frequency not known** Infections - toxic shock syndrome

- **INTERACTIONS** → Appendix 1 (mifepristone).

- **CONTRA-INDICATIONS** Placenta praevia - unexplained vaginal bleeding - uterine scarring

- **CAUTIONS** Cardiovascular insufficiency - cervicitis - obstructive airways disease - raised intra-ocular pressure - vaginitis

**INDICATIONS AND DOSE**

- **BY VAGINA**
  - **Adult:** 1 mg every 3 hours for maximum 5 administrations, to be inserted into posterior fornix, second course may begin 24 hours after start of treatment (if treatment fails, pregnancy should be terminated by another method)

**Second trimester intra-uterine death**

- **BY VAGINA**
  - **Adult:** 1 mg every 3 hours for maximum 5 administrations only, to be inserted into posterior fornix

**Medical termination of intra-uterine pregnancy of up to 49 days gestation following mifepristone**

- **BY VAGINA**
  - **Adult:** 1 mg

**Termination of pregnancy of 13–24 weeks gestation (in combination with a prostaglandin) following mifepristone**

- **BY VAGINA**
  - **Adult:** 1 mg every 3 hours (max. per dose 5 mg), if abortion does not occur, 24 hours after start of treatment repeat course of gemeprost 1 mg by vagina up to max. 5 mg; follow-up visit after appropriate interval to assess vaginal bleeding recommended, careful monitoring of blood pressure and pulse essential for 3 hours after administration of gemeprost pessary (risk of profound hypotension)

**CONTRA-INDICATIONS** Acute porphyrias p. 864 - chronic adrenal failure - suspected ectopic pregnancy (use other specific means of termination) - uncontrolled severe asthma

<table>
<thead>
<tr>
<th>Medicines</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misoprostol</td>
<td>Drug Action: Misoprostol is a synthetic prostaglandin analogue that has antisecretory and protective properties, promoting healing of gastric and duodenal ulcers. It also acts as a potent uterine stimulant.</td>
</tr>
<tr>
<td>Misoprostol</td>
<td><strong>INDICATIONS AND DOSE</strong> Termination of pregnancy following mifepristone (gestation up to 49 days) <strong>BY MOUTH</strong></td>
</tr>
<tr>
<td>Misoprostol</td>
<td>Adult: 400 micrograms for 1 dose, dose to be given 24–48 hours after mifepristone</td>
</tr>
</tbody>
</table>
**Vaginal and vulval conditions**

**Termination of pregnancy following mifepristone (gestation 50 to 63 days)**
- **INITIALLY BY VAGINA OR BY BUCAL ADMINISTRATION OR BY SUBLINGUAL ADMINISTRATION**
  - Adult: 800 micrograms for 1 dose, dose to be given 24–48 hours after mifepristone, if abortion has not occurred 4 hours after first misoprostol dose a further dose may be given, (by mouth or by vagina) 400 micrograms for 1 dose
- **Termination of pregnancy following mifepristone (gestation of 9 to 13 weeks)**
  - **INITIALLY BY VAGINA**
    - Adult: 800 micrograms for 1 dose, dose to be given 36–48 hours after mifepristone, followed by (by vagina or by mouth) 400 micrograms every 3 hours if required for a maximum of 4 doses
- **Termination of pregnancy following mifepristone (gestation of 13 to 24 weeks)**
  - **INITIALLY BY VAGINA**
    - Adult: 800 micrograms for 1 dose, dose to be given 36–48 hours after mifepristone, followed by (by vagina or by mouth) 400 micrograms every 3 hours if required for a maximum of 4 doses, if abortion has not occurred 3 hours after the last dose of misoprostol, a further dose of mifepristone may be given, and misoprostol may be recommenced 12 hours later

**Benign gastric ulceration | Benign duodenal ulceration | NSAID-associated ulceration**

**BY MOUTH**
- Adult: 800 micrograms daily in 2–4 divided doses continued for at least 4 weeks or may be continued for up to 8 weeks if required, dose to be taken with breakfast (or main meals) and at bedtime

**Prophylaxis of NSAID-induced gastric ulcer | Prophylaxis of duodenal ulcer**

**BY MOUTH**
- Adult: 200 micrograms 4 times a day, reduced if not tolerated to 200 micrograms 2–3 times a day, use lower dose is less effective

**UNLICENSED USE** Use of misoprostol for termination of pregnancy is an unlicensed use.

**CAUTIONS** Conditions where hypotension might precipitate severe complications (e.g. cerebrovascular disease, cardiovascular disease) - inflammatory bowel disease

**SIDE-EFFECTS**
- **Common or very common** Diarrhoea
- **Frequency not known** Abdominal pain - abnormal vaginal bleeding - dizziness - dyspepsia - flatulence - intermenstrual bleeding - menorrhagia - nausea - postmenopausal bleeding - rashes - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

**Diarrhoea** May occasionally be severe and require withdrawal, reduced by giving single doses not exceeding 200 micrograms and by avoiding magnesium-containing antacids.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises that misoprostol should not be used in women of childbearing age unless pregnancy has been excluded. In such patients it is advised that misoprostol should only be used if the patient takes effective contraceptive measures and has been advised of the risks of taking misoprostol if pregnant.

**PREGNANCY** Avoid—potent uterine stimulant (has been used to induce abortion). Teratogenic risk in first trimester.

**BREAST FEEDING** Present in milk, but amount probably too small to be harmful.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 21**

- **MISOPROSTOL (Non-proprietary)**
  - Misoprostol 200 microgram Misoprostol 200microgram vaginal tablets | 4 tablet (£0.00 no price available (Hospital only))
  - Cytotec (Pfizer Ltd)
    - Misoprostol 200 microgram Cytotec 200microgram tablets | 56 tablet (£0.00 no price available | 60 tablet (£0.10 DT price = £0.10)
  - Topogyn (Nordic Pharma Ltd)
    - Misoprostol 400 microgram Topogyn 400microgram tablets | 16 tablet (£0.00 £128.00 (Hospital only))

**Vaginal delivery system**

- Mysodelle (Ferring Pharmaceuticals Ltd)
  - Misoprostol 7 microgram per 1 hour Mysodelle 200micrograms vaginal delivery system | 5 unit (£0.00 £463.00

---

**6 Vaginal and vulval conditions**

**Vaginal and vulval conditions**

Symptoms are often restricted to the vulva, but infections almost invariably involve the vagina which should also be treated. Applications to the vulva alone are likely to give only symptomatic relief without cure.

*Aqueous medicated douches* may disturb normal vaginal acidity and bacterial flora.

*Topical anaesthetic agents* give only symptomatic relief and may cause sensitivity reactions. They are indicated only in cases of pruritus where specific local causes have been excluded.

*Systemic drugs* are required in the treatment of infections such as gonorrhoea and syphilis.

**Preparations for vaginal and vulval changes**

A cream containing an oestrogen may be applied on a short-term basis to improve the vaginal epithelium in *menopausal atrophic vaginitis*. It is important to bear in mind that topical oestrogens should be used in the *smallest effective* amount to minimise systemic effects. Modified-release vaginal tablets and an impregnated vaginal ring are now also available.

The risk of endometrial hyperplasia and carcinoma is increased when *systemic* oestrogens are administered alone for prolonged periods. The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

Topical oestrogens are also used in postmenopausal women before vaginal surgery for prolapse when there is epithelial atrophy.

**Non-hormonal preparations for vaginal atrophy**

Several non-hormonal vaginal moisturisers are available and some are prescribable on the NHS (consult Drug Tariff).

**Vaginal and vulval infections**

Effective specific treatments are available for the common vaginal infections.

**Fungal infections**

*Candidal vulvitis* can be treated locally with cream, but is almost invariably associated with vaginal infection which should also be treated. *Vaginal candidiasis* is treated primarily with antifungal pessaries or cream inserted high into the vagina (including during menstruation). Single-
dose preparations offer an advantage when compliance is a problem. Local irritation may occur on application of vaginal antifungal products.

**Imidazole** drugs ( clotrimazole p. 712, econazole nitrate p. 712, fencosonate nitrate p. 713, and miconazole p. 713) are effective against candida in short courses of 1 to 14 days according to the preparation used; treatment can be repeated if initial course fails to control symptoms or if symptoms recur. Vaginal applications may be supplemented with antifungal cream for vulvitis and to treat other superficial sites of infection.

Oral treatment of vaginal infection with fluconazole p. 518 or itraconazole p. 519 is also effective.

**Vulvovaginal candidiasis in pregnancy**

Vulvovaginal candidiasis is common during pregnancy and can be treated with vaginal application of an imidazole (such as clotrimazole p. 712), and a topical imidazole cream for vulvitis. Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection. Oral antifungal treatment should be avoided during pregnancy.

**Recurrent vulvovaginal candidiasis**

Recurrence of vulvovaginal candidiasis is particularly likely if there are predisposing factors, such as antibacterial therapy, pregnancy, diabetes mellitus, or possibly oral contraceptive use. Reservoirs of infection may also lead to recontamination and should be treated; these include other skin sites such as the digits, nail beds, and umbilicus as well as the gastro-intestinal tract and the bladder. The partner may also be the source of reinfection and, if symptomatic, should be treated with a topical imidazole cream at the same time.

Treatment against candida may need to be extended for 6 months in recurrent vulvovaginal candidiasis.

**Other infections**

*Trichomonal infections* commonly involve the lower urinary tract as well as the genital system and need systemic treatment with metronidazole p. 475 or tinidazole p. 476.

*Bacterial infections* with Gram-negative organisms are particularly common in association with gynaecological operations and trauma. Metronidazole is effective against certain Gram-negative organisms, especially *Bacteroides* spp. and can be used prophylactically in gynaecological surgery.

Clindamycin cream below and metronidazole gel are indicated for bacterial vaginosis.

Vaginal preparations intended to restore normal acidity may prevent recurrence of vaginal infections and permit the re-establishment of the normal vaginal flora.

The antiviral drugs aciclovir p. 552, famciclovir p. 552, and valaciclovir p. 552 can be used in the treatment of genital infection due to *herpes simplex virus*, the HSV type 2 being a major cause of genital ulceration; they have a beneficial effect on virus shedding and healing, generally giving relief from pain and other symptoms.
Metronidazole

- **Drug Action** Metronidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa.

**Indications and Dose**

- Bacterial vaginosis
  - **by Vagina Using Vaginal Gel**
    - Adult: 1 applicatorful daily for 5 days, dose to be administered at night

- **Caution** Not recommended during menstruation - some systemic absorption may occur with vaginal gel

- **Side-Effects** Abnormal vaginal discharge - local irritation - pelvic discomfort - vaginal candidiasis

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

- **Vaginal Gel**
  - **Clotrimazole (Non-proprietary)**
    - Metronidazole 75 mg per 1 gram
    - Metronidazole 0.75% vaginal gel | 40 gram (£0.50) no price available
  - **Zidovar (Meda Pharmaceuticals Ltd)**
    - Metronidazole 75 mg per 1 gram | 40 gram (£0.80) £4.31

- **Cream**
  - **Canesten (clotrimazole)**
    - Metronidazole 20 mg per 1 gram
    - Metronidazole 100 mg pessaries | 1 pessary (£4.00 DT price = £3.47)
    - Canesten 100mg Soft Gel pessaries | 1 pessary (£6.23 DT price = £3.47)
  - **Canesten (clotrimazole)** (Bayer Plc)
    - Metronidazole 20 mg per 1 gram
    - Canesten 100 mg pessaries | 6 pessary (£3.50 DT price = £3.50)
    - Canesten 200 mg pessaries | 3 pessary (£3.10 DT price = £3.10)

- **Econazole Nitrate 150 mg**
  - **Gyno-Pevaryl**
    - Econazole nitrate 150 mg vaginal pessaries | 1 pessary (£6.23 DT price = £6.23)

**Side-effects**

- Abnormal vaginal discharge
- Local irritation
- Pelvic discomfort
- Vaginal candidiasis

6.2 Vaginal and vulval infections, fungal

**Imidazole Antifungals**

Clotrimazole

- **Indications and Dose**
  - **Superficial sites of infection in vaginal and vulval candidiasis (dose for 1% or 2% cream)**
    - **by Vagina Using Cream**
      - Adult: Apply 2–3 times a day, to be applied to anogenital area
  - **Vaginal candidiasis (dose for 10% intravaginal cream)**
    - **by Vagina Using Vaginal Cream**
      - Adult: 5 g for 1 dose, one applicatorful to be inserted into the vagina at night, dose can be repeated once if necessary
  - **Vaginal candidiasis**
    - **by Vagina Using Pessaries**
      - Adult: 200 mg for 3 nights, course can be repeated once if necessary, alternatively 100 mg for 6 nights, course can be repeated once if necessary, alternatively 500 mg for 1 night, dose can be repeated once if necessary
  - **Recurrent vulvovaginal candidiasis**
    - **by Vagina Using Pessaries**
      - Adult: 500 mg every 1 week for 6 months, dose to be administered following topical imidazole for 10–14 days

- **Unlicensed Use** Consult product literature for individual preparations.

- **Side-effects** Occasional local irritation

- **Conception and Contraception** Cream and pessaries may damage latex condoms and diaphragms.

- **Pregnancy** Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection.

**Econazole Nitrates**

- **Indications and Dose**
  - **Gyno-Pevaryl® Cream**
    - Vaginal and vulval candidiasis
    - **Initially by Vagina Using Vaginal Cream**
      - Adult: 1 applicatorful daily for at least 14 days, dose to be inserted vaginally at night and (to the skin) apply daily for at least 14 days, to be applied to vulva at night, course can be repeated once if necessary
  - **Gyno-Pevaryl® Once**
    - Vaginal and vulval candidiasis
    - **by Vagina**
      - Adult: 1 pessary for 1 dose, pessary to be inserted at night, dose to be repeated once if necessary

- **Pregnancy**
  - Econazole nitrate 150 mg | Gyno-Pevaryl Once 150mg vaginal pessary | 1 pessary (£3.69)
  - Econazole Nitrate 150 mg vaginal pessaries | 3 pessary (£4.17)

- **Exceptions to Legal Category** Brands for sale to the public include Canesten® Internal Cream.

- **Medicinal Forms**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Pessary**
    - **Clotrimazole (Non-proprietary)**
      - Clotrimazole 500 mg Clotrimazole 500mg pessaries | 1 pessary (£4.00 DT price = £3.47)
      - Canesten (clotrimazole) (Bayer Plc) Clotrimazole 100 mg Canesten 100mg pessaries | 6 pessary (£3.50 DT price = £3.50)
      - Clotrimazole 200 mg Canesten 200mg pessaries | 3 pessary (£3.10 DT price = £3.10)
      - Clotrimazole 500 mg Canesten 500mg Soft Gel pessaries | 1 pessary (£6.23 DT price = £3.47)
    - Canesten 500mg pessaries | 1 pessary (£0.50) £2.00 DT price = £1.47
    - Canesten Vaginal 500mg pessaries | 1 pessary (£0.50) £2.00 DT price = £1.47

- **Cream**
  - **Canesten (clotrimazole)** (Bayer Plc)
    - Clotrimazole 20 mg per 1 gram
    - Canesten 1% thrush cream | 10 gram (no price available) £4.46 DT price = £4.46
    - Clotrimazole 100 mg per 1 gram
      - Canesten Internal 10% cream | 5 gram (£6.23 DT price = £6.23)
      - Canesten 10% VC cream | 5 gram (£0.40) £4.50 DT price = £6.23
Fenticonazole nitrate

**INDICATIONS AND DOSE**

**Vaginal and vulval candidiasis**

- **Cream**
  - Adult: Apply 1–2 times a day, to be applied to the anogenital area

- **Cream**
  - Child: 1 capsule daily, ovule to be inserted at night as a single dose, dose can be repeated once if necessary

- **Side-effects**
  - Local irritation

- **Conception and contraception**
  - Effect on latex and vaginal capsules damage latex condoms and diaphragms.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - **Excipients:** May contain Butylated hydroxyanisole, fragrances

- **Cream**
  - **Excipients:** May contain Butylated hydroxyanisole, fragrances

**6.3 Vaginal atrophy**

**OESTROGENS**

**Estriol**

**INDICATIONS AND DOSE**

**Gynest**

- Improve the vaginal epithelium in menopausal atrophic vaginitis
  - **by Vagina**
  - Adult: Apply 1 applicatorful daily until improvement occurs, dose to be applied preferably in the evening, reduced to 1 applicatorful twice weekly, attempts to discontinue should be made at 3–6 month intervals with re-examination

- **Ovestin**
  - Improve the vaginal epithelium in menopausal atrophic vaginitis
  - **by Vagina**
  - Adult: Apply 1 applicatorful daily for 2–3 weeks, then reduced to 1 applicatorful twice weekly, discontinued every 2–3 months for 4 weeks to assess need for further treatment

**Vaginal surgery for prolapse when there is epithelial atrophy in postmenopausal women (before surgery)**

- **by Vagina**
  - Adult: Apply 1 applicatorful daily for 2 weeks before surgery, resume 2 weeks after surgery

**Contra-indications**

- Active arterial thromboembolic disease (e.g. angina or myocardial infarction) - active thrombophlebitis - Dubin-Johnson syndrome (or monitor closely) - history of breast cancer - history of recurrent venous thromboembolism (unless already on anticoagulant treatment) - oestrogen-dependent cancer - recent arterial thromboembolic disease (e.g. angina or myocardial infarction).

**CAUTIONS**


**CAUTIONS, FURTHER INFORMATION**

### Risk of breast cancer

It is estimated that using all types of HRT increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping. Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use.

### Risk of endometrial cancer

The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT. In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

### Risk of ovarian cancer

Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.

### Risk of venous thromboembolism

Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use. Women who have predisposing factors (such as a personal or family history of deep-vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits. Travel involving prolonged immobility further increases the risk of deep vein thrombosis.

### Risk of stroke

Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.

### Risk of coronary heart disease

HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

### Other conditions

The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

### INTERACTIONS

- Appendix 1 (oestrogens).

### SIDE-EFFECTS


### SIDE-EFFECTS, FURTHER INFORMATION

**Leg Cramps** Venous thrombosis should be ruled out.

**Withdrawal Bleeding** Cyclic HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

### CONCEPTION AND CONTRACEPTION

Intravaginal cream may damage latex condoms and diaphragms.

**Gynest**

May damage latex condoms and diaphragms.

**Ovestin**

Effect on latex condoms and diaphragms not yet known.

### PREGNANCY

Not known to be harmful.

### BREAST FEDDING

Avoid; adverse effects on lactation.

### HEPATIC IMPAIRMENT

Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin–Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

### RENAL IMPAIRMENT

Manufacturer advises caution in renal disease. Evidence for caution is unsatisfactory and many women with these conditions may stand to benefit from HRT.

### MONITORING REQUIREMENTS

- Closely monitor breast status if history of breast nodules or fibrocystic disease (risk of breast cancer).
- The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**EXCIPIENTS:** May contain Arachis (peanut) oil, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates.

- **Estriol (Non-proprietary)**
  - Estranol 100 microgram per 1 gram Estranol 0.01% cream | 80 gram (PMD) no price available
  - **Ovestin** (Aspen Pharma Trading Ltd)
  - Ovestin 1mg per gram | 15 gram (PMD) £4.15
  - **Gynest** (Marlborough Pharmaceuticals Ltd)
  - Gynest 100 micrograms per 1 gram Gynest 0.01% cream | 80 gram (PMD) £4.15
Chapter 8
Malignant disease

CONTENTS

1 Immune system 715
  1.1 Immune system disorders and transplantation 715
  1.2 Multiple sclerosis 726

2 Malignant disease 734
  2.1 Antibody responsive malignancy 734
  2.2 Cytotoxic responsive malignancy 744
  2.3 Cytotoxic drug-induced side effects 781

2.4 Hyperuricaemia associated with cytotoxic drugs 783

2.5 Hormone responsive malignancy 784

2.6 Hormone responsive breast cancer 790

2.7 Immunotherapy responsive malignancy 793

2.8 Photodynamic therapy responsive malignancy 799

2.9 Targeted therapy responsive malignancy 800

1 Immune system

1.1 Immune system disorders and transplantation

Immune response

Azathioprine p. 716, ciclosporin p. 717, mercaptopurine p. 762, and methotrexate p. 762 have a role in the treatment of inflammatory bowel disease.

Folic acid p. 836 should be given to reduce the possibility of methotrexate toxicity [unlicensed indication]. Folic acid is usually given weekly on a different day to the methotrexate; alternative regimens may be used in some settings.

Immunosuppressant therapy

Immunosuppressants are used to suppress rejection in organ transplant recipients and to treat a variety of chronic inflammatory and autoimmune diseases. Solid organ transplant patients are maintained on drug regimens, which may include antiproliferative drugs (azathioprine or mycophenolate mofetil p. 725), calcineurin inhibitors (ciclosporin p. 717 or tacrolimus p. 720), corticosteroids, or sirolimus p. 719. Choice is dependent on the type of organ, time after transplantation, and clinical condition of the patient. Specialist management is required and other immunomodulators may be used to initiate treatment or to treat rejection.

Impaired immune responsiveness

Modification of tissue reactions caused by corticosteroids and other immunosuppressants may result in the rapid spread of infection. Corticosteroids may suppress clinical signs of infection and allow diseases such as septicaemia or tuberculosis to reach an advanced stage before being recognised—important: normal immunoglobulin administration should be considered as soon as possible after measles exposure, and varicella–zoster immunoglobulin (VZIG) is recommended for individuals who have significant chickenpox (varicella) exposure. Specialist advice should be sought on the use of live vaccines for those being treated with immunosuppressive drugs.

Antiproliferative immunosuppressants

Azathioprine is widely used for transplant recipients and it is also used to treat a number of auto-immune conditions, usually when corticosteroid therapy alone provides inadequate control. It is metabolised to mercaptopurine, and doses should be reduced when allopurinol p. 909 is given concurrently.

Mycophenolate mofetil p. 725 is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine.

There is evidence that compared with similar regimens incorporating azathioprine, mycophenolate mofetil reduces the risk of acute rejection episodes; the risk of opportunistic infections (particularly due to tissue-invasive cytomegalovirus) and the occurrence of blood disorders such as leucopenia may be higher. Cyclophosphamide p. 750 is less commonly prescribed as an immunosuppressant.

Corticosteroids and other immunosuppressants

Prednisolone p. 585 is widely used in oncology. It has a marked antitumour effect in acute lymphoblastic leukaemia, Hodgkin’s disease, and the non-Hodgkin lymphomas. It has a role in the palliation of symptomatic end-stage malignant disease when it may enhance appetite and produce a sense of well-being.

The corticosteroids are also powerful immunosuppressants. They are used to prevent organ transplant rejection, and in high dose to treat rejection episodes.

Ciclosporin p. 717 a calcineurin inhibitor, is a potent immunosuppressant which is virtually non-myelotoxic but markedly nephrotoxic. It has an important role in organ and tissue transplantation, for prevention of graft rejection following bone marrow, kidney, liver, pancreas, heart, lung, and heart-lung transplantation, and for prophylaxis and treatment of graft-versus-host disease.

Tacrolimus p. 720 is also a calcineurin inhibitor. Although not chemically related to ciclosporin it has a similar mode of action and side-effects, but the incidence of neurotoxicity appears to be greater; cardiomyopathy has also been reported. Disturbance of glucose metabolism also appears to be significant.

Sirolimus p. 719 is a non-calcineurin inhibiting immunosuppressant licensed for renal transplantation. Basiliximab p. 724 is used for prophylaxis of acute rejection in allogeneic renal transplantation. It is given with ciclosporin and corticosteroid immunosuppression regimes; its use should be confined to specialist centres.

Belatacept p. 726 is a fusion protein and co-stimulation blocker that prevents T-cell activation; it is licensed for prophylaxis of graft rejection in adults undergoing renal transplantation who are seropositive for the Epstein-Barr virus. It is used with interleukin-2 receptor antagonist...
Malignant disease

**INDICATIONS AND DOSE**

Severe acute Crohn's disease | Maintenance of remission of Crohn's disease | Maintenance of remission of acute ulcerative colitis

**BY MOUTH**
- Adult: 2–2.5 mg/kg daily, some patients may respond to lower doses

Rheumatoid arthritis that has not responded to other disease-modifying drugs | Severe systemic lupus erythematosus and other connective tissue disorders | Polymyositis in cases of corticosteroid resistance

**BY MOUTH**
- Adult: Initially up to 2.5 mg/kg daily in divided doses, adjusted according to response, rarely more than 3 mg/kg daily; maintenance 1–3 mg/kg daily, consider withdrawal if no improvement within 3 months

Autoimmune conditions

**BY MOUTH OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- Adult: 1–3 mg/kg daily, adjusted according to response, consider withdrawal if no improvement within 3 months, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion

**Suppression of transplant rejection**

**BY MOUTH OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- Adult: 1–2.5 mg/kg daily, adjusted according to response, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion

**Severe refractory eczema, normal or high TPMT activity**

**BY MOUTH**
- Adult: 1–3 mg/kg daily

**Severe refractory eczema, intermediate TPMT activity**

**BY MOUTH**
- Adult: 0.5–1.5 mg/kg daily

**Generalised myasthenia gravis**

**INITIALLY BY MOUTH OR BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- Adult: Initially 0.5–1 mg/kg daily, then increased to 2–2.5 mg/kg daily, dose is increased over 3–4 weeks, azathioprine is usually started at the same time as the corticosteroid and allows a lower maintenance dose of the corticosteroid to be used, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion

**Unlicensed use**

Azathioprine doses given in BNF for suppression of transplant rejection and autoimmune conditions may differ from those in product literature. Use for severe refractory eczema is unlicensed.

**Contra-indications**

- When used for severe refractory eczema absent thiopurine methyltransferase (TPMT) activity · very low thiopurine methyltransferase (TPMT) activity

**Caution**

Reduce dose in elderly · reduced thiopurine methyltransferase activity

**Interactions** → Appendix 1 (azathioprine).

**Side-effects**

- Rare: Hepatic veno-occlusive disease · lymphoma · pancreatitis · pneumonia · red cell aplasia
- Frequency not known: Arthralgia · cholestatic jaundice · colitis in patients also receiving corticosteroids · diarrhoea · dizziness · dose-related bone marrow suppression · fever · hair loss · herpes zoster infection · hypersensitivity reactions · hypotension · increased susceptibility to
Infections in patients also receiving corticosteroids - interstitial nephritis - liver impairment - malaise - myalgia - nausea - neutropenia - rash - rigors - thrombocytopenia - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

**Red cell aplasia** Cases of pure red cell aplasia have been reported with azathioprine; dose reduction or discontinuation should be considered under specialist supervision.

**Neutropenia and thrombocytopenia** Usually resolved by reducing the dose.

**Nausea, vomiting and diarrhoea** Nausea, vomiting and diarrhoea may occur, usually starting early during the course of treatment, and in rheumatoid arthritis it may be appropriate to withdraw the drug.

**Hypersensitivity reactions** Hypersensitivity reactions (including malaise, dizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia, rash, hypotension and interstitial nephritis) call for immediate withdrawal.

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in hypersensitivity to mercaptopurine.

**Pregnancy** Transplant patients immunosuppressed with azathioprine should not discontinue it on becoming pregnant. However, there have been reports of premature birth and low birth-weight following exposure to azathioprine, particularly in combination with corticosteroids. Spontaneous abortion has been reported following maternal or paternal exposure. Azathioprine is teratogenic in animal studies. The use of azathioprine during pregnancy needs to be supervised in specialist units. Treatment should not generally be initiated during pregnancy.

**Breast feeding** Present in milk in low concentration. No evidence of harm in small studies — use if potential benefit outweighs risk.

**Hepatic impairment** Reduce dose. Monitor liver function.

**Renal impairment** Reduce dose.

**Pre-treatment screening** Thiopurine methyltransferase The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.

**Monitoring requirements**

- Monitor for toxicity throughout treatment.
- Monitor full blood count weekly (more frequently with higher doses or if severe hepatic or renal impairment) for first 4 weeks (manufacturer advises weekly monitoring for 8 weeks but evidence of practical value unsatisfactory), thereafter reduce frequency of monitoring to at least every 3 months.
- Blood tests and monitoring for signs of myelosuppression are essential in long-term treatment.

**Directions for administration** For intravenous injection, give over at least 1 minute (followed by 50 mL sodium chloride intravenous infusion). For intravenous infusion (Imuran®), give intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstitute 50 mg with 5–15 mL Water for Injections; dilute requisite dose to a volume of 20–200 mL with infusion fluid. Intravenous injection is alkaline and very irritant, intravenous route should therefore be used only if oral route not feasible.

**Patient and carer advice** Bone marrow suppression Patients and their carers should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. inexplicable bruising or bleeding, infection.

**Medicinal forms** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, capsule

### Table

**CAUTIONARY AND ADVISORY LABELS 21**

- **AZATHIOPRINE (Non-proprietary)**
  - Azathioprine 25 mg Azathioprine 25mg tablets | 28 tablet | £23.00
  - Azathioprine 50 mg Azathioprine 50mg tablets | 56 tablet | £15.85

- **Imuran (Aspen Pharma Trading Ltd)**
  - Azathioprine 25 mg Imuran 25mg tablets | 100 tablet | £8.00
  - Azathioprine 50 mg Imuran 50mg tablets | 100 tablet | £10.99
  - Brands may include Azaferon

**Powder for solution for injection**

- Imuran (Aspen Pharma Trading Ltd)
  - Azathioprine 50 mg Imuran 50mg powder for solution for injection vials | 1 vial | £15.38

### Calcineurin inhibitors and related drugs

**Ciclosporin**

**Drug action** Ciclosporin is a calcineurin inhibitor.

**indications and dose**

**Severe acute ulcerative colitis refractory to corticosteroid treatment**

- **By continuous intravenous infusion**
  - Adult: 2 mg/kg, to be given over 24 hours, dose adjusted according to blood-ciclosporin concentration and response

**Severe active rheumatoid arthritis where conventional second-line therapy inappropriate or ineffective (administered on expert advice)**

- **By mouth**
  - Adult: Initially 2.5 mg/kg daily in 2 divided doses, then increased if necessary up to 4 mg/kg after 6 weeks, dose increase, if required should be gradual, continue if response insufficient after 3 months, dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks)

**Short-term treatment of severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)**

- **By mouth**
  - Adult: Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily) usually maximum 8 weeks but may be used for longer, if good initial response not achieved within 2 weeks, increase dose rapidly up to maximum

**Short-term treatment of very severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)**

- **By mouth**
  - Adult: Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily), increased gradually to maximum if no improvement within 2 weeks but evidence of practical value unsatisfactory), thereafter reduce frequency of monitoring to at least every 3 months.

- Adult: Initially 2.5 mg/kg daily in 2 divided doses, then increased if necessary up to 4 mg/kg after 6 weeks, dose increase, if required should be gradual, continue if response insufficient after 3 months, dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks)

- Short-term treatment of severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)

- By mouth

  - Adult: Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily) usually maximum 8 weeks but may be used for longer

- Severe psoriasis where conventional therapy ineffective or inappropriate (administered on expert advice)

  - By mouth

    - Adult: Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily), increased gradually to maximum if no improvement within continued
1 month, initial dose of 2.5 mg/kg twice daily justified if condition requires rapid improvement; discontinue if inadequate response after 3 months at the optimum dose; max. duration of treatment usually 1 year unless other treatments cannot be used

Organ transplantation (used alone)

BY MOUTH
- Adult: 10–15 mg/kg, to be administered 4–12 hours before transplantation, followed by 10–15 mg/kg daily for 1–2 weeks postoperatively, then maintenance 2–6 mg/kg daily, reduce dose gradually to maintenance. Dose should be adjusted according to blood-ciclosporin concentration and renal function; dose is lower if given concomitantly with other immunosuppressants (e.g. corticosteroids); if necessary one-third corresponding oral dose can be given by intravenous infusion over 2–6 hours

Bone-marrow transplantation | Prevention and treatment of graft-versus-host disease

INITIALLY BY INTRAVENOUS INFUSION
- Adult: 5–10 mg/kg/day, to be administered over 2–6 hours from day before transplantation to 2 weeks postoperatively, alternatively (by mouth) 12.5–15 mg/kg daily, then (by mouth) 12.5 mg/kg daily for 3–6 months and then tailed off (may take up to a year after transplantation)

Nephrotic syndrome

BY MOUTH
- Adult: 5 mg/kg daily in 2 divided doses, for maintenance reduce to lowest effective dose according to proteinuria and serum creatinine measurements; discontinue after 3 months if no improvement in glomerulonephritis or glomerulosclerosis (after 6 months in membranous glomerulonephritis)

- UNLICENSED USE Not licensed for use in severe acute ulcerative colitis refractory to corticosteroid treatment

Important safety information

Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration.

- CONTRA-INDICATIONS Abnormal renal function (in non-transplant indications) - malignancy (in non-transplant indications) - uncontrolled hypertension (in non-transplant indications) - uncontrolled infections (in non-transplant indications) - use with tacrolimus specifically contraindicated

- CAUTIONS Hyperuricaemia - in atopic dermatitis Staphylococcus aureus skin infections - not absolute contra-indication providing controlled (but avoid erythromycin unless no other alternative) - in atopic dermatitis allow herpes simplex infections to clear before starting (if they occur during treatment withdraw if severe) - in atopic dermatitis and psoriasis discontinue if lymphoproliferative disorder develops - in psoriasis treat patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option)

- INTERACTIONS Appendix 1 (ciclosporin).

For patients other than transplant recipients, preferably avoid other immunosuppressants (increased risk of infection and malignancies, including lymphoma and skin cancer).

- SIDE-EFFECTS GENERAL SIDE-EFFECTS

- Common or very common Abdominal pain - anorexia - diarrhoea - fatigue - gingival hyperplasia - headache - hepatic dysfunction - hypercholesterolaemia - hyperkaeemia - hyperlipidaemia - hypertension - hypertrichosis - hyperuricaemia - hypomagnesaemia - muscle cramps - myalgia - myasthenia - paraesthesia - renal dysfunction (renal structural changes on long-term administration) - tremor - vomiting

- Uncommon Anaemia - oedema - signs of encephalopathy - thrombocytopenia - weight gain

- Rare Gynaecomastia - haemolytic uraemic syndrome - hyperglycaemia - menstrual disturbances - microangiopathic haemolytic anaemia - motor polyneuropathy - muscle weakness - myopathy - pancreatitis - visual disturbances secondary to benign intracranial hypertension

SPECIFIC SIDE-EFFECTS

- With intravenous use anaphylaxis

SIDE-EFFECTS, FURTHER INFORMATION

Visual disturbances Discontinue if visual disturbances secondary to benign intracranial hypertension occur.

- PREGNANCY Crosses placenta. There is less experience of ciclosporin in pregnancy but it does not appear to be any more harmful than azathioprine. The use of ciclosporin during pregnancy needs to be supervised in specialist units.

- BREAST FEEDING Present in milk - manufacturer advises avoid.

- HEPATIC IMPAIRMENT Dosage adjustment based on bilirubin and liver enzymes may be needed.

- RENAL IMPAIRMENT In patients with nephrotic syndrome and renal impairment initially 2.5 mg/kg daily. Reduce dose by 25–50% if serum creatinine more than 30% above baseline on more than one measurement. In rheumatoid arthritis, reduce dose if serum creatinine increases more than 30% above baseline in more than 1 measurement; if above 50%, reduce dose by 50% (even if within normal range) and discontinue if reduction not successful within 1 month.

In psoriasis and atopic dermatitis, reduce dose by 25–50% if serum creatinine increases more than 30% above baseline (even if within normal range) and discontinue if reduction not successful within 1 month.

- PRE-TREATMENT SCREENING In psoriasis, exclude malignancies (including those of skin and cervix) before starting (biopsy any lesions not typical of psoriasis).

- MONITORING REQUIREMENTS

Dermatological and physical examination, including blood pressure and renal function measurements required at least twice before starting treatment for psoriasis or atopic dermatitis.

Monitor liver function.

Monitor serum potassium especially in renal dysfunction (risk of hyperkalaemia).

Monitor serum magnesium.

Measure blood lipids before treatment and after the first month of treatment.

In psoriasis and atopic dermatitis monitor serum creatinine every 2 weeks for first 3 months then every month.

Investigate lymphadenopathy that persists despite improvement in atopic dermatitis.

Monitor kidney function - dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction in transplant patients (exclude rejection if kidney transplant) or discontinuation in non-transplant patients.

Monitor blood pressure - discontinue if hypertension develops that cannot be controlled by antihypertensives.

In long-term management of nephrotic syndrome, perform renal biopsies at yearly intervals.

In rheumatoid arthritis measure serum creatinine at least twice before treatment. During treatment, monitor serum
creatinine every 2 weeks for first 3 months, then every month for a further 3 months, then every 4–8 weeks depending on the stability of the disease, concomitant medication, and concomitant diseases (or more frequently if dose increased or concomitant NSAIDs introduced or increased).

- Monitor hepatic function if concomitant NSAIDs given.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use Mix solution with orange juice (or squash) or apple juice (to improve taste) or with water immediately before taking (and rinse with more to ensure total dose). Do not mix with grapefruit juice. With capsules and oral solution, total daily dose should be taken in 2 divided doses.
- With intravenous use For intravenous infusion (Sandimmun®), give intermittently or continuously in Glucose 5% or Sodium Chloride 0.9%; dilute to a concentration of 50 mg in 20–100 ml, give intermittent infusion over 2–6 hours; not to be used with PVC equipment. Observe patient for signs of anaphylaxis for at least 30 minutes after starting infusion and at frequent intervals thereafter.

**PRESCRIBING AND DISPENSING INFORMATION**

Brand name prescribing. Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient to a different ciclosporin, the patient should be monitored closely for changes in blood-ciclosporin concentration, serum creatinine, blood pressure, and transplant function. Sandimmun® capsules and oral solution are available direct from Novartis for patients who cannot be transferred to a different oral preparation.

**HANDLING AND STORAGE**

Keep medicine measure away from other liquids (including water).

**PATIENT AND CARER ADVICE**

Patients and carers should be counselled on the administration of ciclosporin capsules and oral solution. Avoid excessive exposure to UV light, including sunlight. In psoriasis and atopic dermatitis, avoid use of UVB or PUVA.

**MEDICINAL FORMS**

There can be variations in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, eye ointment.

- **Capsule**
  - Excipients: May contain Ethanol, ethyl lactate, propylene glycol
  - *Capsules (Non-proprietary)*
    - Ciclosporin 25 mg | 30 capsule [POD] no price available
    - Ciclosporin 50 mg | 30 capsule [POD] no price available
    - Ciclosporin 100 mg | 30 capsule [POD] no price available
  - *Capsules (Mylan Ltd)*
    - Ciclosporin 25 mg | 30 capsule [POD] £25.50
    - Ciclosporin 50 mg | 30 capsule [POD] £48.50
  - *Capsules (Morningside Healthcare Ltd)*
    - Ciclosporin 25 mg | 30 capsule [POD] £13.05
    - Ciclosporin 50 mg | 30 capsule [POD] £25.50
    - Ciclosporin 100 mg | 30 capsule [POD] £48.50
  - *Capsules (Dexcel-Pharma Ltd)*
    - Ciclosporin 25 mg | 30 capsule [POD] £13.06
    - Ciclosporin 50 mg | 30 capsule [POD] £25.60
    - Ciclosporin 100 mg | 30 capsule [POD] £48.90

- **Solution for infusion**
  - Excipients: May contain Ethanol, propylene glycol
  - *Sandimmun (Novartis Pharmaceuticals UK Ltd)*
    - Ciclosporin 100 mg per 1 ml | 30 capsule [POD] £59.16
  - *Sandimmun (Teva UK Ltd)*
    - Ciclosporin 50 mg per 1 ml | 30 capsule [POD] £25.59
    - Ciclosporin 100 mg per 1 ml | 30 capsule [POD] £48.89

**INTRA-VENOUS INJECTION**

- Solution for injection 500 mg/ml concentrate for infusion ampoules | 10 ampoule [POD] £9.71
  - Sandimmun 500 mg/ml concentrate for injection ampoules | 10 ampoule [POD] £19.36
- Solution for injection 250 mg/ml concentrate for infusion ampoules | 10 ampoule [POD] £19.36

- *Neoral (Novartis Pharmaceuticals UK Ltd)*
  - Ciclosporin 10 mg | 60 capsule [POD] £16.68
  - Ciclosporin 25 mg | 30 capsule [POD] £16.79
  - Ciclosporin 50 mg | 30 capsule [POD] £32.88
  - Ciclosporin 100 mg | 30 capsule [POD] £62.41
- *Sandimmun (Novartis Pharmaceuticals UK Ltd)*
  - Ciclosporin 25 mg | 30 capsule [POD] £24.65
  - Ciclosporin 50 mg | 30 capsule [POD] £48.27
  - Ciclosporin 100 mg | 30 capsule [POD] £91.61
  - *Vanquoral (Teva UK Ltd)*
  - Ciclosporin 25 mg | 30 capsule [POD] £13.05
  - Ciclosporin 50 mg | 30 capsule [POD] £25.59
  - Ciclosporin 100 mg | 30 capsule [POD] £48.89

**Capsules**

- *Capsules (Mylan Ltd)*
  - Ciclosporin 25 mg | 30 capsule [POD] £6.15
  - Ciclosporin 50 mg | 30 capsule [POD] £12.30
  - Ciclosporin 100 mg | 30 capsule [POD] £24.60

**Solution for Oral Suspension**

- Climipine (Mylan Ltd)
  - Ciclosporin 25 mg | 30 capsule [POD] £6.15
  - Ciclosporin 50 mg | 30 capsule [POD] £12.30
  - Ciclosporin 100 mg | 30 capsule [POD] £24.60

**Solution for Oral Suspension (sugar-free)**

- Climipine (Mylan Ltd)
  - Ciclosporin 25 mg | 30 capsule [POD] £6.15
  - Ciclosporin 50 mg | 30 capsule [POD] £12.30
  - Ciclosporin 100 mg | 30 capsule [POD] £24.60

**Sirolimus**

**DRUG ACTION**

Sirolimus is a non-calcineurin inhibiting immunosuppressant.

**INDICATIONS AND DOSE**

**Prophylaxis of organ rejection in kidney allograft recipients**

- **By mouth**
  - Adult: Initially 6 mg for 1 dose, to be given after surgery once wound has healed, then 2 mg once daily for 2–3 months (in combination with ciclosporin and corticosteroid); sirolimus dose should be given after ciclosporin), followed by maintenance 2 mg once daily, ciclosporin should then be withdrawn over 4–8 weeks (if not possible, sirolimus should be discontinued and an alternate immunosuppressive regimen used), dose to be adjusted according to whole blood-sirolimus trough concentration.

**Dose equivalence and conversion**

The 500 microgram tablet is not bioequivalent to the 1 mg and 2 mg tablets. Multiples of 500 microgram tablets should not be used as a substitute for other tablet strengths.

**CAUTIONS**

- Hyperlipidaemia - increased susceptibility to infection (especially urinary-tract infection) - increased susceptibility to lymphoma and other malignancies, particularly of the skin (limit exposure to UV light)

**INTERACTIONS**

- Appendix 1 (sirolimus).

**SIDE-EFFECTS**

- Common or very common Abdominal pain - acne - anaemia - arthralgia - ascites - constipation - diarrhoea - epistaxis - haemolytic uraemic syndrome - headache - hypercholesterolaemia - hyperglycaemia - hypertension - hypertriglyceridaemia - hypokalaemia - hypophosphataemia - impaired healing - leucopenia - lymphocele - nausea - neutropenia - oedema - osteonecrosis - pleural effusion - pneumonitis - proteinuria -
Malignant disease

- pyrexia · rash · stomatitis · tachycardia · thrombocytopenia · thrombotic thrombocytopenic purpura · venous thromboembolism
- Uncommon Nephrotic syndrome · pancreatitis · pancytopenia · pericardial effusion · pulmonary embolism · pulmonary haemorrhage
- Rare Alveolar proteinosis · anaphylactic reactions · angioedema · exfoliative dermatitis · hepatic necrosis · hypersensitivity reactions · hypersensitivity vasculitis · interstitial lung disease · lymphoedema
- Frequency not known Focal segmental glomerulosclerosis · reversible impairment of male fertility
- CONCEPTION AND CONTRACEPTION Effective contraception must be used during treatment and for 12 weeks after stopping.
- PREGNANCY Avoid unless essential—toxicity in animal studies.
- BREAST FEEDING Discontinue breast-feeding.
- HEPATIC IMPAIRMENT In severe impairment decrease dose by 50% and monitor whole blood-sirolimus trough concentration every 5–7 days until 3 consecutive measurements have shown stable blood-sirolimus concentration. Clearance reduced in mild to moderate impairment. Monitor whole blood-sirolimus level closely and consult local treatment protocol in hepatic impairment.
- MONITORING REQUIREMENTS
  - Monitor whole blood-sirolimus trough concentration (Afro-Caribbean patients may require higher doses).
  - Manufacturer advises pre-dose (‘trough’) whole blood-sirolimus concentration (using chromatographic assay) when used with ciclosporin should be 4–12 micrograms/litre (local treatment protocols may differ); after withdrawal of ciclosporin pre-dose whole blood-sirolimus concentration should be 12–20 micrograms/litre (local treatment protocols may differ).
  - Close monitoring of whole blood-sirolimus concentration required if concomitant treatment with potent inducers or inhibitors of metabolism and after discontinuing them, or if ciclosporin dose reduced significantly or stopped.
  - When changing between oral solution and tablets, measurement of whole blood ‘trough’ sirolimus concentration after 1–2 weeks is recommended.
  - Sirolimus whole-blood concentration is measured using either high performance liquid chromatography (HPLC) or immunoassay. Switching between different immunoassays or between an immunoassay and HPLC can lead to clinically significant differences in results and therefore incorrect dose adjustments. Adjustment to the target therapeutic dose range should be made with knowledge of the assay used and corresponding reference range.
  - Monitor kidney function when given with ciclosporin; monitor lipids; monitor urine proteins.
- DIRECTIONS FOR ADMINISTRATION Food may affect absorption (take at the same time with respect to food). Sirolimus oral solution should be mixed with at least 60 mL water or orange juice in a glass or plastic container immediately before taking; refill container with at least 120 mL of water or orange juice and drink immediately (to ensure total dose). Do not mix with any other liquids.
- PATIENT AND CARER ADVICE Patient or carers should be given advice on how to administer sirolimus. Patients should be advised to avoid excessive exposure to UV light.

● MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.
  - Tablet
    - Rapamune (Pfizer Ltd)
    - Sirolimus 1 mg Rapamune 1mg tablets | 30 tablet £86.49 DT price = £86.49
    - Sirolimus 2 mg Rapamune 2mg tablets | 30 tablet £172.98 DT price = £172.98
  - Oral solution
    - EXCIPIENTS: May contain Ethanol
    - Rapamune (Pfizer Ltd)
    - Sirolimus 1 mg per 1 ml Rapamune 1mg/ml oral solution (sugar-free) | 60 ml £162.41

Tacrolimus

- DRUG ACTION Tacrolimus is a calcineurin inhibitor.

INDICATIONS AND DOSE

ADOPORT®

Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation
BY MOUTH
- Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
BY MOUTH
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation
BY MOUTH
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation
BY MOUTH
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

Allograft rejection resistant to conventional immunosuppressive therapy
BY MOUTH
- Adult: Seek specialist advice

ADVAGRAF®

Prophylaxis of graft rejection following liver transplantation, starting 12–18 hours after transplantation
BY MOUTH
- Adult: 100–200 micrograms/kg once daily, to be taken in the morning

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
BY MOUTH
- Adult: 200–300 micrograms/kg once daily, to be taken in the morning

Allograft rejection resistant to conventional immunosuppressive therapy
BY MOUTH
- Adult: Seek specialist advice

CAPEXION®

Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation
BY MOUTH
- Adult: Initially 100–200 micrograms/kg daily in 2 divided doses
### Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation

**BY MOUTH**
- Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

### Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation

**BY MOUTH**
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

### Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation

**BY MOUTH**
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

### Allograft rejection resistant to conventional immunosuppressive therapy

**BY MOUTH**
- Adult: Seek specialist advice

### ENvarsus®

**BY MOUTH**
- Adult: 110–130 micrograms/kg once daily, to be taken in the morning

### Rejection therapy

**BY MOUTH**
- Adult: Seek specialist advice

### Prograf® Capsules

**Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation**

**BY MOUTH**
- Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

**Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation**

**BY MOUTH**
- Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

**Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation**

**BY MOUTH**
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

**Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation**

**BY MOUTH**
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

### Allograft rejection resistant to conventional immunosuppressive therapy

**BY MOUTH**
- Adult: Seek specialist advice

### Prograf® Infusion

**Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation when oral route not appropriate**

**BY INTRAVENOUS INFUSION**
- Adult: Initially 10–50 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

**Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation when oral route not appropriate**

**BY INTRAVENOUS INFUSION**
- Adult: Initially 50–100 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

**Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation**

**BY INTRAVENOUS INFUSION**
- Adult: Initially 10–20 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

**Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation**

**BY INTRAVENOUS INFUSION**
- Adult: Initially 10–20 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

**Allograft rejection resistant to conventional immunosuppressive therapy**

**BY CONTINUOUS INTRAVENOUS INFUSION**
- Adult: Seek specialist advice (consult local protocol)

### Tacni®

**Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation**

**BY MOUTH**
- Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

### Seek specialist advice

- Initially divided doses
- Initially divided doses
- Initially divided doses
- Initial days (then transfer to oral therapy), dose to be continued
Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
BY MOUTH
- Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation
BY MOUTH
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation, starting within 12 hours of transplantation
BY MOUTH
- Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
BY MOUTH
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

Allograft rejection resistant to conventional immunosuppressive therapy
BY MOUTH
- Adult: Seek specialist advice

VIVAX®

Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation
BY MOUTH
- Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
BY MOUTH
- Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 12 hours of transplantation
BY MOUTH
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

Allograft rejection resistant to conventional immunosuppressive therapy
BY MOUTH
- Adult: Seek specialist advice

Important safety information
MHRA/CHM advice: Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection. To ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, oral tacrolimus products should be prescribed and dispensed by brand name only.
- Advagraf® is a prolonged-release capsule that is taken once daily in the morning.
- Advagraf® is not interchangeable with other oral tacrolimus containing products; the MHRA has advised (June 2012) that oral tacrolimus products should be prescribed and dispensed by brand only.

CAUTIONS
- UV light (avoid excessive exposure to sunlight and sunlamps), increased risk of infections, lymphoproliferative disorders, malignancies, neurotoxicity, QT-interval prolongation

INTERACTIONS
- Appendix 1 (tacrolimus).

Contra-indication — avoid concurrent administration with ciclosporin (care if patient has previously received ciclosporin).

SIDE-EFFECTS
- Common or very common acne, alopecia, anaemia, anorexia, anxiety, arthralgia, ascites, bile-duct abnormalities, bloating, blood disorders, cholestasis, confusion, constipation, depression, diarrhoea, dizziness, dyspepsia, dyspnoea, electrolyte disturbances, flatulence, gastro-intestinal inflammation, gastrointestinal perforation, gastro-intestinal ulceration, haemorrhage, headache, hepatic dysfunction, hyperglycaemia, hyperkalaemia, hypertension, hyperuricaemia, hypokalaemia, impaired hearing, ischaemic events, jaundice, leukopenia, mood changes, muscle cramp, nausea, oedema, pancytopenia, paraesthesia, parenchymal lung disorders, peripheral neuropathy, photophobia, pleural effusion, psychosis, renal failure, renal impairment, renal tubular necrosis, seizures, sleep disturbances, sweating, tachycardia, thrombocytopenia, thromboembolic events, tinnitus, tremor, urinary abnormalities, visual disturbances, vomiting, weight changes
- Uncommon amnesia, arrhythmia, cardiac arrest, cardiomyopathy, cataract, cerebrovascular accident, coagulation disorders, coma, dermatitis, dysmennorrhoea, encephalopathy, gastro-intestinal reflux disease, heart failure, hypertonia, hypoglycaemia, influenza-like symptoms, palpitation, pancreatitis, paralysis, paralytic ileus, peritonitis, photosensitivity, respiratory failure, speech disorder
- Rare blindness, dehydrogenase, hirsutism, pericardial effusion, posterior reversible encephalopathy syndrome, respiratory distress syndrome, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis
- Very rare haemorrhagic cystitis, myasthenia, Stevens-Johnson syndrome
- Frequency not known agranulocytosis, haemolytic anaemia, pure red cell aplasia

CARDIOMYOPATHY
Cardiomyopathy has been reported in children. Patients should be monitored by echocardiography for hypertrophic changes — consider dose reduction or discontinuation if these occur.

ALLERGY AND CROSS-SENSITIVITY
Contraindicated if history of hypersensitivity to macrolides.

CONCEPTION AND CONTRACEPTION
Exclude pregnancy before treatment.

PREGNANCY
Avoid unless potential benefit outweighs risk — crosses the placenta and risk of premature delivery, intra-uterine growth restriction, and hyperkalaemia.

BREAST FEEDING
Avoid — present in breast milk.

HEPATIC IMPAIRMENT
Dose reduction may be necessary in severe impairment.
**MEDICINAL FORMS**

**NATIONAL FUNDING/ACCESS DECISIONS**

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Prograf®), give continuously in Glucose 5% or Sodium Chloride 0.9%. Dilute concentrate in infusion fluid to a final concentration of 4–100 micrograms/mL; give over 24 hours. Tacrolimus is incompatible with PVC.

**PATIENT AND CARER ADVICE** May affect performance of skilled tasks (e.g. driving). Avoid excessive exposure to UV light including sunlight.

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (November 2010) that tacrolimus granules for oral suspension (Modigraf®) are accepted for restricted use within NHS Scotland in patients for whom tacrolimus is an appropriate choice of immunosuppressive therapy and where small changes (less than 500 micrograms) in dosing increments are required (such as, in paediatric patients) or in seriously ill patients who are unable to swallow tacrolimus capsules.

**IMMUNOGLOBULINS**

**Antithymocyte immunoglobulin (rabbit)**

**INDICATIONS AND DOSE**

Prophylaxis of organ rejection in heart allograft recipients

- **By intravenous infusion**
  - Adult: 1–2.5 mg/kg daily for 3–5 days, to be given over at least 6 hours

Prophylaxis of organ rejection in renal allograft recipients

- **By intravenous infusion**
  - Adult: 1–1.5 mg/kg daily for 3–9 days, to be given over at least 6 hours

Treatment of corticosteroid-resistant allograft rejection in renal transplantation

- **By intravenous infusion**
  - Adult: 1.5 mg/kg daily for 7–14 days, to be given over at least 6 hours

Doses at extremes of body-weight

To avoid excessive dosage in obese patients, calculate dose on the basis of ideal body weight.

**CONTRA-INDICATIONS** Infection

**SIDE-EFFECTS** Anaphylaxis - cytokine release syndrome - diarrhoea - dysphagia - fever - hypotension - increased susceptibility to infection - increased susceptibility to malignancy - infusion-related reactions - lymphopenia - myalgia - nausea - neutropenia - pruritus - rash - serum sickness - shivering - thrombocytopenia - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Tolerability is increased by pretreatment with an intravenous corticosteroid and antithistamine; an antipyretic drug such as paracetamol may also be beneficial.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk – no information available.

**BREAST FEEDING** Manufacturer advises avoid — no information available.

**MONITORING REQUIREMENTS** Monitor blood count.
Canakinumab

**Drug Action** Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 receptor binding.

**Indications and Dose**

- **Acute gout** in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or who are intolerant of them.
  - **By Subcutaneous Injection**
    - **Adult:** 150 mg for 1 dose, may be repeated at least 12 weeks after initial response if symptoms recur, patients who do not respond to initial dose should not be retreated.
  - Treatment of cryopyrin-associated periodic syndromes, including severe forms of familial cold auto-inflammatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological cutaneous and articular syndrome).
  - **By Subcutaneous Injection**
    - **Adult:** (consult product literature)

**Contraindications**

- Active infection, leucopenia, neutropenia.

**Precautions, Further Information**

- **Vaccinations** Patients should receive all recommended vaccinations (including pneumococcal and inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs risk—consult product literature for further information.

**Interactions**

- **Appendix 1** (canakinumab).
- Contra-indicated with concomitant use with tumour necrosis factor inhibitors (possible increased risk of infections).

**Side-effects**

- Common or very common: Back pain, increased susceptibility to infection (including serious infection), injection-site reactions, malaise, neutropenia, vertigo.
- Uncommon: Gastro-oesophageal reflux.
- Frequency not known: Malignancy, vomiting.

**Conception and Contraception**

- Effective contraception required during treatment and for up to 3 months after last dose.

**Pregnancy**

- Manufacturer advises avoid unless potential benefit outweighs risk.

**Breast feeding**

- Consider if benefit outweighs risk—not known if present in human milk.

**Hepatic Impairment** No information available.

**Renal Impairment** Limited information available but manufacturer advises no dose adjustment required.

**Pre-treatment Screening**

- Patients should be evaluated for latent and active tuberculosis before starting treatment.

**Monitoring Requirements**

- **Monitor full blood count including neutrophil count before starting treatment, 1–2 months after starting treatment, and periodically thereafter.**
- **Monitor for signs and symptoms of tuberculosis during and after treatment.**

**Medicinal Forms**

- There can be variation in the licensing of different medicines containing the same drug.

**Powder for Solution for Injection**

- **Ilaris** (Novartis Pharmaceuticals UK Ltd)

**Canakinumab 150 mg** Ilaris 150mg powder for solution for injection vials | 1 vial £9.927.80

**Monoclonal Antibodies (Anti-lymphocyte)**

Basiliximab

**Drug Action** Basiliximab is a monoclonal antibody that acts as an interleukin-2 receptor antagonist and prevents T-lymphocyte proliferation.

**Indications and Dose**

- **Prophylaxis of acute rejection in allogeneic renal transplantation used in combination with ciclosporin and corticosteroid-containing immunosuppression regimes (specialist use only)**

**By Intravenous Injection or By Intravenous Infusion**

- **Adult:** Initially 20 mg, administered within 2 days before transplant surgery, followed by 20 mg after 4 days, dose to be administered after surgery, withhold second dose if severe hypersensitivity or graft loss occurs.

**Caution**

- Off-label use in cardiac transplantation—increased risk of serious cardiac side-effects.

**Interactions**

- **Appendix 1** (basiliximab).

**Side-effects**

- Atrial flutter, cardiac arrest, cytokine release syndrome, palpitations, severe hypersensitivity reactions.

**Conception and Contraception**

- Adequate contraception must be used during treatment and for 16 weeks after last dose.

**Pregnancy**

- Manufacturer advises avoid—no information available.

**Breast feeding**

- Manufacturer advises avoid—no information available.

**Directions for Administration**

- **For intravenous infusion (Simulect®** give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute 10 mg with 2.5 mL water for injections then dilute to at least 25 mL with infusion fluid; reconstitute 20 mg with 5 mL water for injections then dilute to at least 50 mL with infusion fluid; give over 20–30 minutes.

**Medicinal Forms**

- There can be variation in the licensing of different medicines containing the same drug.

**Powder and Solvent for Solution for Injection**

- **Simulect** (Novartis Pharmaceuticals UK Ltd)

**Basiliximab 10 mg** Simulect 10mg powder and solvent for solution for injection vials | 1 vial £758.63 (Hospital only)

**Basiliximab 20 mg** Simulect 20mg powder and solvent for solution for injection vials | 1 vial £842.38 (Hospital only)
Belimumab

**INDICATIONS AND DOSE**

Adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy

**BY INTRAVENOUS INFUSION**
- Adult: 10 mg/kg every 2 weeks for 3 doses, then 10 mg/kg every 4 weeks, review treatment if no response within 6 months

- **CAUTIONS** Do not initiate until active infections controlled - history or development of malignancy - predisposition to infection
- **INTERACTIONS** → Appendix 1 (belimumab).
- **SIDE-EFFECTS**
  - Common or very common Infusion-related reactions
  - Frequency not known Depression - diarrhoea - hypersensitivity reactions - infections - insomnia - myalgia - nausea - pain in extremities - pyrexia - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related side-effects are reported commonly, including severe or life-threatening hypersensitivity and infusion reactions. Premedication with an antihistamine, with or without an antipyretic may be considered.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during treatment and for at least 4 months after last dose.
- **PREGNANCY** Avoid unless essential.
- **BREAST FEEDING** Avoid—present in milk in animal studies.
- **RENAL IMPAIRMENT** Caution in severe impairment—no information available.
- **MONITORING REQUIREMENTS** Delay in the onset of acute hypersensitivity reactions has been observed; patients should remain under clinical supervision for several hours following at least the first 2 infusions.
- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Benlysta®), give intermittently in Sodium chloride 0.9%; reconstitute with water for injections (420 mg in 1.5 mL, 400 mg in 4.8 mL) to produce a solution containing 80 mg/mL; gently swirl vial for 60 seconds, then allow to stand; swirl vial (without shaking) for 60 seconds every 5 minutes until dissolved; dilute requisite dose with infusion fluid to a final volume of 250 mL and give over 1 hour.

- **MEDIACION FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for infusion**
    - Benlysta® (GlaxoSmithKline UK Ltd.)
      - Belimumab 120 mg: Reconstitute with water for injection (1 vial) £121.50 (Hospital only)
      - Belimumab 400 mg: Reconstitute with water for injection (1 vial) £405.00 (Hospital only)

**PURINE SYNTHESIS INHIBITORS**

Mycophenolate mofetil

**INDICATIONS AND DOSE**

Prophylaxis of acute rejection in renal transplantation (in combination with a corticosteroid and ciclosporin) (under expert supervision)

**BY MOUTH**
- Adult: 1 g twice daily to be started within 72 hours of transplantation

- **CAUTIONS** Active serious gastro-intestinal disease (risk of haemorrhage, ulceration and perforation) - children (higher incidence of side-effects may call for temporary reduction of dose or interruption) - delayed graft function - elderly (increased risk of infection, gastro-intestinal haemorrhage and pulmonary oedema) - increased susceptibility to skin cancer (avoid exposure to strong sunlight) - risk of hypogammaglobulinaemia or bronchiectasis when used in combination with other immunosuppressants

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Hypogammaglobulinaemia or bronchiectasis Measure serum immunoglobulin levels if recurrent infections develop, and consider bronchiectasis or pulmonary fibrosis if persistent respiratory symptoms such as cough and dyspnoea develop.

- **INTERACTIONS** → Appendix 1 (mycophenolate).
- **Live vaccines** Specialist advice should be sought for those being treated with immunosuppressive drugs.

**SIDE-EFFECTS**
- Frequency not known Interstitial lung disease - intestinal villous atrophy - progressive multifocal leucoencephalopathy - pulmonary fibrosis

**SIDE-EFFECTS, FURTHER INFORMATION**

Cases of pure red cell aplasia has been reported with mycophenolate mofetil; dose reduction or
discontinuation should be considered under specialist supervision.

- **CONCEPTION AND CONTRACEPTION** Exclude pregnancy before starting treatment. Effective contraception required before treatment, during treatment, and for 6 weeks after discontinuation of treatment.

**MYFORTIC®** Manufacturer advises that men should use condoms during treatment and for 13 weeks after last dose.

- **PREGNANCY** Manufacturer advises avoid—congenital malformations reported.

- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

- **RENAL IMPAIRMENT** No data available in cardiac or hepatic transplant patients with renal impairment.

- **MONITORING REQUIREMENTS** Monitor full blood count every week for 4 weeks then twice a month for 2 months then every month in the first year (consider interrupting treatment if neutropenia develops).

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (CellCept®), give intermittently in Glucose 5%; reconstitute each 500–mg vial with 14 ml glucose 5% and dilute the contents of 2 vials in 140 ml infusion fluid; give over 2 hours.

- **PATIENT AND CARER ADVICE**
  - Bone marrow suppression Patients should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. infection or inexcusable bruising or bleeding.

**MEDICINAL FORMS**

<table>
<thead>
<tr>
<th>Form</th>
<th>Brand Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for solution for infusion</td>
<td>Belatacept, Myfortic, CellCept</td>
</tr>
<tr>
<td>Capsule</td>
<td>Belatacept, Myfortic, CellCept</td>
</tr>
<tr>
<td>Oral suspension</td>
<td>Belatacept, Myfortic, CellCept</td>
</tr>
</tbody>
</table>

**T-CELL ACTIVATION INHIBITORS**

**Belatacept**

**INDICATIONS AND DOSE**

Prophylaxis of graft rejection in adults undergoing renal transplantation who are seropositive for the Epstein-Barr virus

**BY INTRAVENOUS INFUSION**

- Adult: (consult product literature)

- **CAUTIONS** Increased risk of acute graft rejection—with tapering of corticosteroid, particularly in patients with high immunologic risk, increased risk of infection, latent and active tuberculosis, risk factors for post-transplant lymphoproliferative disorder

- **SIDE-EFFECTS**
  - Common or very common Anaemia, constipation, cough, dehydration, diarrhoea, headache, hypertension, hypophosphataemia, infection, leucopenia, malignancy, nausea, peripheral oedema, pyrexia, vomiting
  - Uncommon Infusion related reactions, progressive multifocal leucoencephalopathy

**ACETYLCHOLINE-RELEASE ENHANCERS**

**Fampridine**

**INDICATIONS AND DOSE**

Improvement of walking disability in multiple sclerosis (specialist use only)

**BY MOUTH**

- Adult. 10 mg every 12 hours, discontinue treatment if no improvement within 2 weeks

- **CONTRA-INDICATIONS** History of seizures (discontinue treatment if seizures occur)

- **CAUTIONS**
  - Atrioventricular conduction disorders - predisposition to seizures - sinoatrial conduction disorders - symptomatic cardiac rhythm disorders

- **INTERACTIONS**
  - Appendix 1 (fampridine). Caution in concomitant use of drugs that lower seizure threshold.
Multiple sclerosis 727

- **SIDE-EFFECTS**
  - Common or very common: Anxiety, back pain, constipation, dizziness, dyspepsia, dysphagia, headache, insomnia, malaise, nausea, paraesthesia, pharyngolaryngeal pain, tremor, urinary tract infection, vomiting
  - Uncommon: Seizures
  - **PREGNANCY** Avoid—toxicity in animal studies.
  - **BREAST FEEDING** Avoid—no information available.
  - **RENAL IMPAIRMENT** Avoid if eGFR less than 80 mL/minute/1.73 m².
  - **PRESCRIBING AND DISPENSING INFORMATION** Dispense in original container (pack contains a desiccant) and discard any tablets remaining 7 days after opening.

- **MEDIcular FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule
  - **Modified-release tablet**
    - CAUTIONARY AND ADVISORY LABELS 23, 25
    - Fampyra (Biogen Idec Ltd) ▼
  - **FAMPRIDINE 10 mg** Fampyra 10mg modified-release tablets | 28 tablet | £181.00 | 56 tablet | £362.00

**FUMARIC ACIDS**

### Dimethyl fumarate

- **DRUG ACTION** Dimethyl fumarate has immunomodulatory and anti-inflammatory properties.

#### INDICATIONS AND DOSE

Treatment of adults with relapsing-remitting multiple sclerosis (initiated by a specialist) by mouth

- **Adult:** 120 mg twice daily for 7 days, then increased to 240 mg twice daily, for dose adjustment due to side effects—consult product literature

#### CAUTIONS

- Reduced lymphocyte count • risk of serious infections (do not start treatment until resolved and consider suspending treatment if infection develops during treatment) • severe active gastrointestinal disease

#### SIDE-EFFECTS

- Abdominal pain • burning sensation • diarrhoea • dyspepsia • erythema • flushing (may be severe and indicate hypersensitivity) • gastritis • gastroenteritis • leucopenia • lymphopenia • nausea • proteinuria • pruritus • rash • vomiting

#### SIDE-EFFECTS, FURTHER INFORMATION

Progressive multifocal leukoencephalopathy (PML) Severe prolonged lymphopenia reported, and patients are exposed to a potential risk of PML. Treatment should be stopped immediately if PML is suspected.

- **CONCEPTION AND CONTRACEPTION** Contraception required in women of child-bearing potential (consider non-hormonal methods).

- **PREGNANCY** Manufacturer advises avoid unless essential and potential benefit outweighs risk—toxicity in animal studies.

- **BREAST FEEDING** Manufacturer advises avoid.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment.

- **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment.

- **MONITORING REQUIREMENTS**
  - Monitor full blood count (including lymphocytes) before treatment (within 6 months before initiation), then every 6 to 12 months thereafter, and as clinically indicated.
  - Monitor patient closely for features of progressive multifocal leukoencephalopathy (PML) (e.g. signs and symptoms of neurological dysfunction) and other opportunistic infections.
  - Monitor renal and hepatic function before treatment, after 3 and 6 months of treatment, then every 6 to 12 months thereafter, and as clinically indicated.

- **PATIENT AND CARER ADVICE** Patient information leaflet should be provided. Counselling is advised on progressive multifocal leukoencephalopathy.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (August 2014) NICE TA320
    - Dimethyl fumarate is recommended for the treatment of active relapsing-remitting multiple sclerosis, only if:
      - the patient does not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis and
      - the manufacturer provides dimethyl fumarate with the discount agreed in the patient access scheme
    - Patients currently receiving dimethyl fumarate whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA320

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Gastro-resistant capsule**
    - CAUTIONARY AND ADVISORY LABELS 21, 25
    - Tecfidera (Biogen Idec Ltd)
    - Dimethyl fumarate 120 mg Tecfidera 120mg gastro-resistant capsules | 14 capsule | £343.00
    - Dimethyl fumarate 240 mg Tecfidera 240mg gastro-resistant capsules | 56 capsule | £1,373.00

**IMMUNOMODULATING DRUGS**

### Fingolimid

- **DRUG ACTION** Fingolimid is an immunomodulating drug.

#### INDICATIONS AND DOSE

Treatment of highly active relapsing-remitting multiple sclerosis in patients who have high disease activity despite treatment with at least one disease modifying therapy or in those with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)

- **BY MOUTH**
  - **Adult:** 500 micrograms once daily

**Important safety information**

MHRA/CHM ADVICE: FINGOLIMOD—NOT RECOMMENDED FOR PATIENTS AT KNOWN RISK OF CARDIOVASCULAR EVENTS. ADVICE FOR EXTENDED MONITORING FOR THOSE WITH SIGNIFICANT BRADYCARDIA OR HEART BLOCK AFTER THE FIRST DOSE AND FOLLOWING TREATMENT INTERRUPTION (JANUARY 2013)

Fingolimid is known to cause transient bradycardias and heart block after the first dose. Fingolimid is not recommended in the following patient groups who are at high risk of cardiovascular events unless the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought before initiation:

**Patients with the following medical conditions:**

- 2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sinoatrial heart block
- Significant QT prolongation (QT-interval greater than 470 milliseconds in women, or greater than 450 milliseconds in men)
- History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial
Malignant disease

CONCEPTION AND CONTRACEPTION

▶ Frequency not known

Uncommon

SIDE-EFFECTS

malignancies (except cutaneous basal cell carcinoma) • macular oedema • paraesthesia • influenza • depression • diarrhea • dizziness • dizziness • eosinophilia • eye pain • gastroenteritis • headache • herpes • hypertension • influenza • leucopoenia • lymphopenia • malaise • migraine • paraesthesia • pruritus • sinusitis • tinea • weight loss

▶ Uncommon Macular oedema • neutropenia • pneumonia

▶ Frequency not known Haemophagocytic syndrome • lymphoma

CONCEPTION AND CONTRACEPTION Exclude pregnancy before treatment. Ensure effective contraception during and for at least 2 months after treatment.

PREGNANCY Avoid (toxicity in animal studies).

BREAST FEEDING Avoid.

HEPATIC IMPAIRMENT Use with caution in mild to moderate impairment. Avoid in severe impairment.

MONITORING REQUIREMENTS

▶ Eye examination recommended 3–4 months after initiation of treatment (and before initiation of treatment in patients with diabetes or history of uveitis).

Monitor hepatic transaminases before treatment, then every 3 months for 1 year, then periodically thereafter.

Monitor full blood count before treatment, at 3 months, then at least yearly thereafter and if signs of infection—interrupt treatment if lymphocyte count reduced—consult product literature.

Monitor for signs and symptoms of haemophagocytic syndrome (including pyrexia, asthenia, hepatitis, splenomegaly and adenopathy)—may be associated with hepatic failure and respiratory distress; also progressive cytopenia, elevated serum-ferritin concentrations, hypertriglyceridaemia, hypofibrinogenaemia, coagulopathy, hepatic cytolysis, hyponatraemia)—initiate treatment immediately.

NATIONAL FUNDING/ACCESS DECISIONS

NIC technology appraisals (TAs)

Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (April 2012) NICE TA254

Fingolimod is recommended as an option for the treatment of highly active relapsing-remitting multiple sclerosis in adults, only if:

▶ they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta, and

▶ the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme

Patients currently receiving fingolimod whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA254

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (August 2012) that fingolimod (Gilenya®) is accepted for restricted use within NHS Scotland as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta, with an unchanged or increased relapse rate or ongoing severe relapses, as compared to the previous year.

CONTRA-INDICATIONS Active infection • active malignancies (except cutaneous basal cell carcinoma) • immunosuppression

CAUTIONS Check varicella zoster virus status—consult product literature for further information • chronic obstructive pulmonary disease • pulmonary fibrosis • risk of macular oedema • severe respiratory disease • susceptibility to QT-interval prolongation (including electrolyte disturbances)

INTERACTIONS → Appendix 1 (fingolimod).

Caution with concomitant use of drugs that prolong QT interval.

SIDE-EFFECTS

Common or very common Alopecia • AV block • back pain • blurred vision • bradycardia • bronchitis • cough • depression • diarrhea • dizziness • dyspnoea • eczema • eye pain • gastroenteritis • headache • herpes • hypertension • influenza • leucopoenia • lymphopenia • malaise • migraine • paraesthesia • pruritus • sinusitis • tinea • weight loss

Glatiramer acetate

DRUG ACTION Glatiramer is an immunomodulating drug comprising synthetic polypeptides.

INDICATIONS AND DOSE

Treatment of initial symptoms in patients at high risk of developing multiple sclerosis (initiated under specialist supervision) / Reducing frequency of relapses in ambulatory patients with relapsing-remitting multiple sclerosis who have had at least 2 clinical relapses in the past 2 years (initiated under specialist supervision) by subcutaneous injection

Adult: 20 mg daily
INTERFERONS

**Interferon beta**

### INDICATIONS AND DOSE

**REBIF® PRE-FILLED PEN AND SYRINGE**

For relapsing, remitting multiple sclerosis (characterised by at least two attacks of neurological dysfunction over the previous 2 or 3 years, followed by complete or incomplete recovery) who are able to walk unaided | For a single demyelinating event with an active inflammatory process (if severe enough to require intravenous corticosteroid and patient at high risk of developing multiple sclerosis)

**BY SUBCUTANEOUS INJECTION**

- Adult: (consult product literature)

**EXTAVIA®**

For relapsing, remitting multiple sclerosis (characterised by at least two attacks of neurological dysfunction over the previous 2 or 3 years, followed by complete or incomplete recovery) who are able to walk unaided | For secondary progressive multiple sclerosis with active disease | For a single demyelinating event with an active inflammatory process (if severe enough to require intravenous corticosteroid and patient at high risk of developing multiple sclerosis)

**BY INTRAMUSCULAR INJECTION**

- Adult: (consult product literature)

**AVONEX® VIAL**

For relapsing, remitting multiple sclerosis (characterised by at least two attacks of neurological dysfunction over the previous 2 or 3 years, followed by complete or incomplete recovery) who are able to walk unaided | For a single demyelinating event with an active inflammatory process (if severe enough to require intravenous corticosteroid and patient at high risk of developing multiple sclerosis)

**BY INTRAMUSCULAR INJECTION**

- Adult: (consult product literature)

### MEDICINAL FORMS

**Copaxone (Teva UK Ltd)**

- Glatiramer acetate 20 mg per 1 ml Copaxone 20mg/1ml solution for injection pre-filled syringes | 28 pre-filled disposable injection [REB] £21.95 (Hospital only)
- Glatiramer acetate 40 mg per 1 ml Copaxone 40mg/1ml solution for injection pre-filled syringes | 12 pre-filled disposable injection [REB] £31.95 (Hospital only)

**NHS restrictions**

- Provision of disease-modifying therapies for multiple sclerosis
  - The Department of Health, the National Assembly for Wales, the Scottish Executive, the Northern Ireland Department of Health, Social Services & Public Safety, and the manufacturers have reached agreement on a risk-sharing scheme for the NHS supply of interferon beta and glatiramer acetate for multiple sclerosis. Health Service Circular (HSC 2002/004) explains how patients can participate in the scheme. It is available on the Department of Health website (www.dh.gov.uk).

### CAUTIONS, FURTHER INFORMATION

- **CONTRA-INDICATIONS**
  - Decompensated liver disease - severe depressive illness

- **CAUTIONS**
  - History of cardiac disorders - history of depressive disorders (avoid in severe depression or in those with suicidal ideation) - history of seizures - history of severe myelosupression

Consult product literature for further information on contra-indications.
SID-EFFECTS Alopecia · anaphylaxis · blood disorders · chills · confusion · convulsions · fever · hepatitis · hypersensitivity reactions · influenza-like symptoms (decreasing over time) · irritation at injection site (including inflammation, hypersensitivity, necrosis) · malaise · menstrual disorders · mood and personality changes · myalgia · nausea · nephrotic syndrome · suicide attempts · thrombotic microangiopathy · thyroid dysfunction · urticaria · vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Also consult product literature for all side effects.

CONCEPTION AND CONTRACEPTION Effective contraception required during treatment—consult product literature.

PREGNANCY Avoid unless potential benefit outweighs risk (toxicity in animal studies).

BREAST FEEDING Avoid—no information available.

HEPATIC IMPAIRMENT Caution in severe hepatic impairment.

RENAL IMPAIRMENT Caution in severe renal impairment.

MONITORING REQUIREMENTS
- Monitor for signs of hepatic injury—hepatic failure has been reported rarely.
- Patients should be monitored for clinical features of thrombotic microangiopathy (TMA), including thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion and paresis), and impaired renal function. Any signs of TMA should be investigated fully and, if diagnosed, interferon beta should be stopped immediately and treatment for TMA promptly initiated (consult product literature for details).
- Patients should also be monitored for signs and symptoms of nephrotic syndrome, including oedema, proteinuria, and impaired renal function—monitor renal function periodically. If nephrotic syndrome develops, treat promptly and consider stopping interferon beta treatment.

PRESCRIBING AND DISPENSING INFORMATION
BETAFERON® INJECTION
An auto-injector device is available from Bayer Schering.

EXTAVIA®
An auto-injector device (ExtaviPro® 30g) is supplied as part of the ExtaviPro® 30g kit.

REBIF®
Cartridges for use with RebiSmart® auto-injector device.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
Interferon beta and glatiramer acetate are not recommended for the treatment of multiple sclerosis in the NHS in England and Wales. Patients who are currently receiving interferon beta or glatiramer acetate for multiple sclerosis, whether as routine therapy or as part of a clinical trial, should have the option to continue treatment until they and their consultant consider it appropriate to stop, having regard to the established criteria for withdrawal from treatment. www.nice.org.uk/TA32

NHS restrictions
- Provision of disease-modifying therapies for multiple sclerosis
The Department of Health, the National Assembly for Wales, the Scottish Executive, the Northern Ireland Department of Health, Social Services & Public Safety, and the manufacturers have reached agreement on a risk-sharing scheme for the NHS supply of interferon beta and glatiramer acetate for multiple sclerosis. Health Service Circular (HSC 2002/004) explains how patients can participate in the scheme. It is available on the Department of Health website (www.dh.gov.uk).

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
EXCIPIENTS: May contain Benzyl alcohol
- Avonex (Biogen Idec Ltd)
  Interferon beta-1a 12 mega u per 1 ml Avonex 30micrograms/0.5ml (6millilions units) solution for injection pre-filled syringes | 4 pre-filled disposable injection £654.00 | 12 pre-filled disposable injection £1,962.00
  Avonex 30micrograms/0.5ml (6millilions units) solution for injection pre-filled pen | 4 pre-filled disposable injection £654.00 | 12 pre-filled disposable injection £1,962.00
- Rebif (Merck Serono Ltd)
  Interferon beta-1a 12 mega u per 1 ml Rebif 22micrograms/0.5ml (6millilions units) solution for injection 1.5ml cartridges | 4 cartridge £613.52
  Rebif 8.8micrograms/0.2ml (2.4millions units) solution for injection pre-filled syringes | 6 pre-filled disposable injection £no price available
  Rebif 8.8micrograms/0.2ml (2.4millions units) solution for injection pre-filled pen | 6 pre-filled disposable injection £no price available
  Rebif 22micrograms/0.5ml (6millilions units) solution for injection pre-filled pen | 6 pre-filled disposable injection £no price available
  Rebif 22micrograms/0.5ml (6millilions units) solution for injection pre-filled syringes | 6 pre-filled disposable injection £no price available
  Rebif 22micrograms/0.5ml (6millilions units) solution for injection pre-filled syringes | 12 pre-filled disposable injection £613.52
  Rebif 22micrograms/0.5ml (6millilions units) solution for injection pre-filled pen | 12 pre-filled disposable injection £613.52
  Rebif 44micrograms/0.5ml (12millilions units) solution for injection pre-filled pen | 12 pre-filled disposable injection £813.21
  Rebif 44micrograms/0.5ml (12millilions units) solution for injection pre-filled syringes | 12 pre-filled disposable injection £813.21
  Rebif 44micrograms/0.5ml (12millilions units) solution for injection pre-filled syringes | 12 pre-filled disposable injection £813.21

Powder and solvent for solution for injection
- Avonex (Biogen Idec Ltd)
  Interferon beta-1a 30 microgram Avonex 30microgram powder and solvent for solution for injection vials | 4 vial £654.00
- Betaseron (Bayer Plc)
  Interferon beta-1b 300 microgram Betaseron 300microgram powder and solvent for solution for injection vials | 15 vial £596.63
- Extavia (Novartis Pharmaceuticals UK Ltd)
  Interferon beta-1b 300 microgram Extavia 300microgram powder and solvent for solution for injection vials | 15 vial £596.63

Peginterferon beta-1a

DRUG ACTION Peginterferon beta-1a is a polyethylene glycol-conjugated (‘pegylated’) derivative of interferon beta; pegylation increases the persistence of interferon in the blood.

INDICATIONS AND DOSE
Treatment of relapsing, remitting multiple sclerosis
BY SUBCUTANEOUS INJECTION
- Adults: (consult product literature)

CONTRA-INDICATIONS
Severe depression · suicidal ideation

CAUTIONS
History of cardiac disorders · history of depressive disorders (avoid in severe depression or in those with suicidal ideation) · history of seizures · history of severe myelosuppression

CAUTIONS, FURTHER INFORMATION
Consult product literature for further information about cautions.

SIDE-EFFECTS
Consult product literature for information about side effects.
CONCEPTION AND CONTRACEPTION Effective contraception required during treatment—consult product literature.

PREGNANCY Do not initiate during pregnancy. Avoid unless potential benefit outweighs risk.

BREAST FEEDING Avoid—no information available.

HEPATIC IMPAIRMENT Caution in severe hepatic impairment.

RENAL IMPAIRMENT Caution in severe renal impairment.

MONITORING REQUIREMENTS
- Monitor for signs of hepatic injury—hepatic failure has been reported rarely.
- Thrombotic microangiopathy Patients should be monitored for clinical features of thrombotic microangiopathy (TMA), including thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion and paresis), and impaired renal function. Any signs of TMA should be investigated fully and, if diagnosed, interferon beta should be stopped immediately and treatment for TMA promptly initiated (consult product literature for details).
- Nephrotic syndrome Patients should also be monitored for signs and symptoms of nephrotic syndrome, including oedema, proteinuria, and impaired renal function—monitor renal function periodically. If nephrotic syndrome develops, treat promptly and consider stopping interferon beta treatment.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Plegridy (Biogen Idec Ltd)
  - Peginterferon beta-1a 126 microgram per 1 ml Plegridy 63micrograms/0.5ml solution for injection pre-filled pen | 1 pre-filled disposable injection £0.00
  - Peginterferon beta-1a 188 microgram per 1 ml Plegridy 94micrograms/0.5ml solution for injection pre-filled pen | 1 pre-filled disposable injection £0.00
  - Peginterferon beta-1a 250 microgram per 1 ml Plegridy 125micrograms/0.5ml solution for injection pre-filled pen | 2 pre-filled disposable injection £0.00 | 6 pre-filled disposable injection £1,962.00

MONOCLONAL ANTIBODIES (ANTI-LYMPHOCYTE)

Anti-lymphocyte monoclonal antibodies

DRUG ACTION The anti-lymphocyte monoclonal antibodies cause lysis of B lymphocytes.

SIDE-EFFECTS
- Common or very common Allergic reactions - angioedema - bronchospasm - chills - cytokine release syndrome - dyspnoea - fever - flushing - nausea - pruritus - rash - tumour pain - vomiting
- Frequency not known Cardiac events

INFORMATION
- Infusion-related side-effects In rare cases infusion reactions may be fatal. Infusion-related side-effects occur predominantly during the first infusion. Patients should receive premedication before administration of anti-lymphocyte monoclonal antibodies to reduce these effects—consult product literature for details of individual regimens. The infusion may have to be stopped temporarily and the infusion-related effects treated—consult product literature for appropriate management. Evidence of pulmonary infiltration and features of tumour lysis syndrome should be sought if infusion-related effects occur.
- Cytokine release syndrome Fatalities following severe cytokine release syndrome (characterised by severe dyspnoea) and associated with features of tumour lysis syndrome have occurred after infusions of anti-lymphocyte monoclonal antibodies. Patients with a high tumour burden as well as those with pulmonary insufficiency or infiltration are at increased risk and should be monitored very closely (and a slower rate of infusion considered).

PRE-TREATMENT SCREENING All patients should be screened for hepatitis B before treatment.

MONITORING REQUIREMENTS Patients should also be monitored for cytopenias—consult product literature for specific recommendations.

Alemtuzumab

INDICATIONS AND DOSE
Treatment of adults with relapsing-remitting multiple sclerosis with active disease defined by clinical or imaging features

BY INTRAVENOUS INFUSION
- Adult: (consult product literature)

UNLICENSED USE Although no longer licensed for oncological and transplant indications, alemtuzumab is also available through a patient access programme for these indications.

CONTRA-INDICATIONS Human immunodeficiency virus

CAUTIONS Hepatitis B carriers - hepatitis C carriers - in patients with active infection, a delay in initiation of alemtuzumab treatment should be considered until the infection is fully controlled - not recommended for inactive disease - not recommended for stable disease - patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course - patients with previous autoimmune conditions other than multiple sclerosis - pretreatment before administration is required (consult product literature)

CAUTIONS, FURTHER INFORMATION
Autoimmune mediated conditions The risk of autoimmune mediated conditions may increase during treatment, including immune thrombocytopenic purpura, thyroid disorders, nephropathies, and cytopenias, and should be monitored for throughout the course of treatment (consult product literature).

For full details of cautions, consult product literature.

INTERACTIONS Appendix 1 (alemtuzumab).

SIDE-EFFECTS For full side effects details (including monitoring and management) consult product literature.

CONCEPTION AND CONTRACEPTION Women of childbearing potential should use effective contraception during and for 4 months after treatment.

PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. Autoimmune thyroid disease during treatment may affect fetus (consult product literature).
Natalizumab

**DRUG ACTION** Natalizumab is a monoclonal antibody that inhibits the migration of leucocytes into the central nervous system, hence reducing inflammation and demyelination.

**INDICATIONS AND DOSE**

Highly active relapsing-remitting multiple sclerosis (initiated under specialist supervision).

**BY INTRAVENOUS INFUSION**

- Adult: 300 mg every 4 weeks, treatment should be discontinued if no response after 6 months

**CONTRA-INDICATIONS** Active infection • active malignancies (except cutaneous basal cell carcinoma) • immunosuppression • progressive multifocal leucoencephalopathy

**CAUTIONS, FURTHER INFORMATION**

Progressive Multifocal Leucoencephalopathy Natalizumab is associated with an increased risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML) caused by JC virus. The risk of developing PML increases with the presence of anti-JCV antibodies, previous use of immunosuppressant therapy, and treatment duration (especially beyond 2 years of treatment); the risk beyond 4 years of treatment is not known. Patients with all three risk factors should only be treated with natalizumab if the benefits of treatment outweigh the risks. Treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued. For information on cautions consult product literature.

**INTERACTIONS** → Appendix 1 (natalizumab).

Concurrent use of interferon beta or glatiramer acetate contra-indicated.

**SIDE-EFFECTS**

- **Common or very common** Arthralgia • autoantibodies • nasopharyngitis • urinary-tract infection
- **Uncommon** Hypersensitivity reactions (discontinue permanently)
- **Frequency not known** Arthralgia (during infusion) • dizziness (during infusion) • fatigue (during infusion) • flushing (during infusion) • headache (during infusion) • increased risk of opportunistic infection • liver toxicity • nausea (during infusion) • pruritus (during infusion) • pyrexia (during infusion) • rigors (during infusion) • urticaria (during infusion) • vomiting (during infusion)

**SIDE-EFFECTS, FURTHER INFORMATION**

Progressive Multifocal Leucoencephalopathy If Progressive Multifocal Leucoencephalopathy (PML) is suspected, treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.

Liver toxicity Discontinue treatment if significant liver injury occurs.

**PREGNANCY** Avoid unless essential—toxicity in animal studies.

**BREAST FEEDING** Present in milk in animal studies—avoid.

**PRE-TREATMENT SCREENING** Progressive Multifocal Leucoencephalopathy A magnetic resonance image (MRI) scan is recommended before starting treatment with natalizumab. Testing for serum anti-JCV antibodies before starting treatment or in those with unknown antibody status already receiving natalizumab is recommended and should be repeated every 6 months (consult product literature for full details).

**MONITORING REQUIREMENTS**

- Monitor liver function.
- Progressive Multifocal Leucoencephalopathy A magnetic resonance image (MRI) scan is recommended annually. Patients should be monitored for new or worsening neurological symptoms, and for cognitive and psychiatric signs of PML. All patients should continue to be monitored for signs and symptoms that may be suggestive of PML for approximately 6 months following discontinuation of treatment.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Tysabri®), give intermittently in Sodium chloride 0.9%; dilute 300 mg in 100 mL infusion fluid; gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour.

**PATIENT AND CARER ADVICE** A patient alert card should be provided.

Hypersensitivity reactions Patients should be told the importance of uninterrupted dosing, particularly in the early months of treatment (intermittent therapy may increase risk of sensitisation).

Progressive Multifocal Leucoencephalopathy Patients should be informed about the risks of PML before starting treatment with natalizumab and again after 2 years; they should be given an alert card which includes information about the symptoms of PML.

Liver toxicity Advise patients to seek immediate medical attention if symptoms such as jaundice or dark urine develop.
NATIONAL FUNDING/ACCESS DECISIONS

**NICE technology appraisals (TAs)**

- **Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (August 2007)**

  NICE TA127  
  Natalizumab is an option for the treatment only of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). RES is defined by 2 or more disabling relapses in 1 year, and 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.  
  www.nice.org.uk/TA127

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (August 2007) that natalizumab is accepted for restricted use as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis only in patients with rapidly evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year and with 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

  **Solution for infusion**
  
  **ELECTROLYTES:** May contain Sodium
  
  Tysabri (Biogen Idec Ltd) ▼
  
  Natalizumab 20 mg per 1 ml Tysabri 300mg/15ml concentrate for solution for infusion vials | 1 vial (£97) no price available (Hospital only)

PYRIMIDINE SYNTHESIS INHIBITORS

**Teriflunomide**

- **DRUG ACTION** Teriflunomide is a metabolite of leflunomide which has immunomodulating and anti-inflammatory properties.

INDICATIONS AND DOSE

Treatment of relapsing-remitting multiple sclerosis (initiated under specialist supervision)

BY MOUTH

- **DOSAGE**
  - **Adult:** 14 mg once daily

CONTRA-INDICATIONS

- Anaemia; leucopenia; neutropenia; serious infection; severe hypoproteinaemia; severe immunodeficiency; significantly impaired bone-marrow function; thrombocytopenia

CAUTIONS

- Adult over 65 years; anaemia; dyspnoea—assess for interstitial lung disease and consider suspending treatment; hypoproteinaemia (avoid if severe); impaired bone-marrow function (avoid if severe); latent tuberculosis; leucopenia; persistent cough—assess for interstitial lung disease and consider suspending treatment; severe infection—delay or suspend treatment until resolved; significant alcohol consumption—signs or symptoms of serious skin reactions (including ulcerative stomatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis)—discontinue treatment—switching between other immunomodulating drugs—thrombocytopenia

INTERACTIONS

- Appendix 1 (teriflunomide).

SIDE-EFFECTS

- Common or very common Acne; alopecia; anxiety; carpal tunnel syndrome; cystitis; diarrhoea; elevated liver enzymes; gastroenteritis; hyperaesthesia; hypertension; laryngitis; leucopenia; menorrhagia; musculoskeletal pain; myalgia; nausea; neuralgia; neutropenia; oral infection; paraesthesia; peripheral neuropathy; pollakiuria; rash; respiratory tract infection; sciatica; tinea pedis; urinary tract infection; vomiting; weight loss

Uncommon

- Anaemia; thrombocytopenia

Very rare

- Intestinal lung disease; pancreatitis

SIDE-EFFECTS, FURTHER INFORMATION

**Accelerated elimination procedure Important:** accelerated elimination procedure recommended following discontinuation due to serious adverse effects (consult product literature).

**Hepatic injury** Discontinue treatment if signs or symptoms of hepatic injury, or if liver enzymes exceed 3 times the upper limit of reference range.

CONCEPTION AND CONTRACEPTION

Effective contraception essential for women of child-bearing potential during treatment and for up to 2 years after treatment. In patients undergoing treatment with teriflunomide that are planning to conceive, the accelerated elimination procedure should be used prior to conception. Use of non-oral contraception is recommended during the accelerated elimination procedure—consult product literature.

PREGNANCY

- Avoid—toxicity in animal studies.

BREAST FEEDING

Present in milk in animal studies—manufacturer advises avoid.

HEPATIC IMPAIRMENT

- Avoid in severe impairment.

MONITORING REQUIREMENTS

- Monitor full blood count (including differential white cell count and platelet count) before treatment and as clinically indicated during treatment.

- Monitor blood pressure before treatment and periodically thereafter.

- Hepatic monitoring Monitor liver function before treatment and every 2 weeks for first 6 months then every 8 weeks thereafter or as clinically indicated (pre-existing liver disease may increase risk). Increase to weekly monitoring if alanine aminotransferase (ALT) is 2–3 times the upper limit of reference range: discontinue treatment if signs or symptoms of hepatic injury, or if liver enzymes exceed 3 times the upper limit of reference range.

TREATMENT CESSATION

Accelerated elimination procedures. To aid drug elimination in case of serious adverse effect or before conception, stop treatment and give either colestyramine p. 173 or charcoal, activated p. 1130. After the accelerated elimination procedure a plasma concentration of less than 20 micrograms/litre (measured on 2 occasions at least 14 days apart) and a waiting period of one and a half months are necessary before conception.

NATIONAL FUNDING/ACCESS DECISIONS

**NICE technology appraisals (TAs)**

- **Teriflunomide for treating relapsing-remitting multiple sclerosis (January 2014)**

  NICE TA303  
  Teriflunomide is recommended for the treatment of adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), in adults who:
  - do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis and
  - the manufacturer provides teriflunomide with the discount agreed in the patient access scheme.

  www.nice.org.uk/TA303

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (February 2014) that the use of teriflunomide (Aubagio)® in NHS Scotland is restricted to use in patients with relapsing-remitting multiple sclerosis who do not have highly active disease, and only as an alternative to treatment with interferon beta or glatiramer acetate.
2 Malignant disease

2.1 Antibody responsive malignancy

MONOClonAL Antibodies (anTI-LymphocyTE)

Rituximab

The properties listed below are those particular to the drug only. For properties common to the class, see Anti-lymphocyte monoclonal antibodies, p. 731.

INDICATIONS AND DOSE

Treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them (in combination with methotrexate)

BY INTRAVENOUS INFUSION

- Adult: 1 g, then 1 g after 2 weeks, patients should receive premedication before each infusion (consult product literature for details)
- Treatment of previously untreated stage III–IV follicular lymphoma (in combination with other chemotherapy) | Maintenance therapy in patients with follicular non-Hodgkin’s lymphoma that has responded to induction therapy (in combination with other chemotherapy)
- Treatment of diffuse large B-cell non-Hodgkin’s lymphoma (in combination with other chemotherapy)
- Treatment of chemotherapy-resistant or relapsed stage III–IV follicular non-Hodgkin’s lymphoma | Previously untreated or relapsed chronic lymphocytic leukaemia | Induction of remission in patients with severe, active granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis (in combination with glucocorticoids)

BY INTRAVENOUS INFUSION

- Adult: Patients should receive premedication before each dose (consult product literature for details) (consult product literature or local protocols)

CONTRA-INDICATIONS

Severe heart failure (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis) | Severe infection | Severe, uncontrolled heart disease (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)

CONTRA-INDICATIONS, FURTHER INFORMATION

For full details on contra-indications, consult product literature.

CAUTIONS

GENERAL CAUTIONS

History of cardiovascular disease; in adults exacerbation of angina, arrhythmia, and heart failure have been reported | patients receiving cardiotoxic chemotherapy; in adults exacerbation of angina, arrhythmia, and heart failure have been reported | transient hypotension occurs frequently during infusion (anti-hypertensives may need to be withheld for 12 hours before infusion)

SPECIFIC CAUTIONS

- When used for rheumatoid arthritis predisposition to infection

CAUTIONS, FURTHER INFORMATION

Hepatitis B infection and reactivation

Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking rituximab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).

For full details on cautions, consult product literature or local treatment protocol.

INTERACTIONS

- Appendix 1 (rituximab)

SIDE-EFFECTS

Abdominal pain | anaemia | antibody formation | aplastic anaemia | arthralgia | asthenia | blood disorders | depression | dyspepsia | headache | hypertension | hypotension | injection-site reactions | leucopenia | lupus erythematosus-like syndrome | migraine | muscle spasm | pancytopenia | paraesthesia | progressive multifocal leucoencephalopathy | pruritus | rhinitis | severe fatal skin reactions | severe skin reactions (permanently discontinue treatment if occurs) | sore throat | Stevens-Johnson syndrome (permanently discontinue treatment if occurs) | thrombocytopenia | toxic epidermal necrolysis (permanently discontinue treatment if occurs) | urticaria | worsening heart failure

SIDE-EFFECTS, FURTHER INFORMATION

Associated with infections, sometimes severe, including tuberculosis, sepsicaemia, and hepatitis B reactivation.

Progressive multifocal leucoencephalopathy

Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.

For full details, including management of side-effects, consult product literature.

CONCEPTION AND CONTRACEPTION

Effective contraception (in both sexes) required during and for 12 months after treatment.

PREGNANCY

Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletion in fetus.

BREAST FEEDING

Avoid breast-feeding during and for 12 months after treatment.

MONITORING REQUIREMENTS

For full details on monitoring requirements consult product literature.

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (MabThera®), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to 1-4 mg/mL and gently invert bag to avoid foaming.

PATIENT AND CARER ADVICE

Alert card | Patients treated for granulomatosis with polyangiitis and microscopic polyangiitis or rheumatoid arthritis should be provided with a patient alert card with each infusion.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Rituximab for aggressive non-Hodgkin’s lymphoma

This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of...
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2009) NICE TA174
This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia. www.nice.org.uk/TA174

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010) NICE TA193
This NICE guidance was issued for rituximab by intravenous infusion. Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition:
• is refractory to fludarabine (that is, it has not responded to fludarabine, or has relapsed within 6 months of treatment), or
• has previously been treated with rituximab, unless it was in the context of a clinical trial, or a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or with chemotherapy other than fludarabine and cyclophosphamide. Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for patients with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with rituximab, unless rituximab has been given as specified above. www.nice.org.uk/TA193

Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) NICE TA195
Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained. www.nice.org.uk/TA195

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma (June 2011) NICE TA226
This NICE guidance was issued for rituximab by intravenous infusion. Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy. www.nice.org.uk/TA226

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012) NICE TA243
This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with:
• cyclophosphamide, vincristine and prednisolone (CVP);
• cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP);
• mitoxantrone, chlorambucil and prednisolone (MCP);
• cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alpha (CHVPi); or
• chlorambucil is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients. www.nice.org.uk/TA243

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014) NICE TA308
This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener’s] and microscopic polyangiitis), only if:
• further cyclophosphamide-based treatment would exceed the maximum cumulative cyclophosphamide dose, or
• cyclophosphamide is contraindicated or not tolerated, or
• the patient has not completed their family, and treatment with cyclophosphamide may materially affect their fertility, or
• the disease has remained active or progressed despite a course of cyclophosphamide lasting 3–6 months or
• the patient has had uroepithelial malignancy. www.nice.org.uk/TA308

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (August 2013) that Rituximab (MabThera®) is accepted for restricted use within NHS Scotland, in combination with glucocorticoids for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. It is restricted to use in patients who have relapsed following treatment with cyclophosphamide or who are intolerant to or unable to receive cyclophosphamide.
The Scottish Medicines Consortium has advised (June 2014) that subcutaneous rituximab (MabThera®) is accepted for restricted use within NHS Scotland, in accordance with UK licensing, except in the maintenance setting, where use is restricted to patients who have responded to induction therapy with rituximab plus chemotherapy.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
• MabThera (Roche Products Ltd)
Rituximab 119.66 mg per 1 ml MabThera 1400mg/11.7ml solution for injection vials | 1 vial (P) £1,344.65 (Hospital only)

Solution for infusion
• MabThera (Roche Products Ltd)
Rituximab 10 mg per 1 ml MabThera 100mg/10ml concentrate for solution for infusion vials | 2 vial (P) £340.25
MabThera 500mg/50ml concentrate for solution for infusion vials | 1 vial (P) £873.15
MONOCLONAL ANTIBODIES (ANTINEOPLASTIC)

Bevacizumab

**DRUG ACTION** Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor.

**INDICATIONS AND DOSE**
Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy / First-line treatment of metastatic breast cancer in combination with paclitaxel when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate | First-line treatment of metastatic breast cancer in combination with capcitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate | Patients who have received adjuvant taxane or anthracycline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capcitabine | Advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a | First-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology (in combination with platinum-based chemotherapy) | First-line treatment of advanced (FIGO stages IIIIB, IIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel) | First recurrence of platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have not been treated previously with bevacizumab or other drugs that target vascular endothelial growth factor (in combination with carboplatin and gemcitabine)

**ADMINISTRATION**
BY INTRAVENOUS INFUSION

**INDICATIONS**
- **Malignant disease**
  - First-line treatment of metastatic colorectal cancer (December 2010) NICE TA202
  - Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer
- **Advanced or metastatic renal cell carcinoma** (August 2009) NICE TA118
  - Bevacizumab (first-line), sorafenib (first-and second-line), and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.
- **Breast cancer**
  - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine for the treatment of metastatic colorectal cancer (December 2010) NICE TA212
  - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine is not recommended for the treatment of metastatic colorectal cancer.
- **Non-small cell lung cancer**
  - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) NICE TA214
  - Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic breast cancer.

**SIDE-EFFECTS**
- Abdominal pain • alopecia • anaemia • anorexia • arterial thromboembolism • asthma • bone marrow suppression • chest pain • congestive heart failure • constipation • dehydration • diarrhoea • drowsiness • dry skin • dysarthria • dyspnoea • exfoliative dermatitis • extravasation • eye disorders • fistulas • flushing • gall bladder perforation • gastro-intestinal perforation • haemorrhage • hand-foot syndrome • headache • hypersensitivity reactions • hypertension • hyperuricaemia • hypotension • hypoxia • impaired wound healing • infection • intestinal obstruction • lethargy • mucocutaneous bleeding • nausea • necrotising fasciitis (discontinue and initiate treatment promptly) • neutropenia • oral mucositis • osteonecrosis of the jaw • peripheral neuropathy • posterior reversible encephalopathy syndrome • proteinuria • pulmonary hypertension • pyrexia • rash • rhinitis • rashes • skin discoloration • supraventricular tachycardia • syncope • taste disturbances • thrombocytopenia • thromboembolism • tumour lysis syndrome • vomiting

**CONCEPTION AND CONTRACEPTION**
Effective contraception required during and for at least 6 months after treatment in women

**PREGNANCY**
Avoid toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**
Manufacturer advises avoid breast-feeding during and for at least 6 months after treatment.

**MONITORING REQUIREMENTS**
- Monitor for necrotising fasciitis (usually secondary to wound healing complications, gastro-intestinal perforation or fistula formation) — discontinue and initiate treatment promptly.
- Monitor blood pressure.
- Monitor for congestive heart failure.
- Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, headache, altered mental status, visual disturbance or cortical blindness, with or without hypertension).
- Consider dental check-up before initiating treatment (risk of osteonecrosis of the jaw).

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE TECHNOLOGY APPRAISALS (TAS)**
- Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007) NICE TA118
- Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy. www.nice.org.uk/TA118
- Bevacizumab (first-line), sorafenib (second-line), sunitinib (second-line), and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) NICE TA178
- Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.
- Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine for the treatment of metastatic colorectal cancer (December 2010) NICE TA212
- Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine is not recommended for the treatment of metastatic colorectal cancer.
- Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) NICE TA214
- Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic breast cancer.

**IMPORTANT SAFETY INFORMATION**
- Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw. Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.
- Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.
- If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.

**CAUTIONS**
Elective surgery (withhold treatment and avoid for at least 28 days after major surgery or until wound fully healed) • history of arterial thromboembolism • history of cardiovascular disease (increased risk of cardiovascular events, especially in the elderly) • history of hypertension (increased risk of proteinuria—discontinue if nephrotic syndrome) • increased risk of fistulas (discontinue permanently if tracheo-oesophageal or grade 4 fistula develops) • increased risk of haemorrhage • increased risk of tumour-associated haemorrhage • intra-abdominal inflammation (risk of gastro-intestinal perforation and gall bladder perforation) • uncontrolled hypertension • untreated CNS metastases

**INTERACTIONS**
- Appendix 1 (bevacizumab).

**SIDE-EFFECTS**
- Abdominal pain • alopecia • anaemia • anorexia • arterial thromboembolism • asthma • bone marrow suppression • chest pain • congestive heart failure • constipation • dehydration • diarrhoea • drowsiness • dry skin • dysarthria • dyspnoea • exfoliative dermatitis • extravasation • eye disorders • fistulas • flushing • gall bladder perforation • gastro-intestinal perforation • haemorrhage • hand-foot syndrome • headache • hypersensitivity reactions • hypertension • hyperuricaemia • hypotension • hypoxia • impaired wound healing • infection • intestinal obstruction • lethargy • mucocutaneous bleeding • nausea • necrotising fasciitis (discontinue and initiate treatment promptly) • neutropenia • oral mucositis • osteonecrosis of the jaw • peripheral neuropathy • posterior reversible encephalopathy syndrome • proteinuria • pulmonary hypertension • pyrexia • rash • rhinitis • rashes • skin discoloration • supraventricular tachycardia • syncope • taste disturbances • thrombocytopenia • thromboembolism • tumour lysis syndrome • vomiting
**Brentuximab vedotin and panitumumab** for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE TA242

Brentuximab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is not recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy; see also NICE guidance on Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007). www.nice.org.uk/TA242

- **Bevacizumab in combination with capecitabine** for the first-line treatment of metastatic breast cancer (August 2012) NICE TA263

Bevacizumab in combinations with capecitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months. www.nice.org.uk/TA263

- **Bevacizumab in combination with paclitaxel and carboplatin** for the first-line treatment of advanced ovarian cancer (May 2013) NICE TA284

Bevacizumab in combination with paclitaxel and carboplatin is not recommended for the first-line treatment of advanced ovarian cancer (including fallopian tube and primary peritoneal cancer). www.nice.org.uk/TA284

- **Bevacizumab in combination with gemcitabine and carboplatin** for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013) NICE TA285

Bevacizumab in combination with gemcitabine and carboplatin is not recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents. www.nice.org.uk/TA285

### Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (April 2012) that bevacizumab (Avastin®) is not recommended for use within NHS Scotland for the first line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.

## MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for infusion**

- **Avastin** (Roche Products Ltd)

  Bevacizumab 25 mg per 1 ml Avastin 400mg/16ml solution for infusion vials | 1 vial (P50) £324.40 (Hospital only)

  Avastin 100mg/4ml solution for infusion vials | 1 vial (P50) £242.66 (Hospital only)

- **Brentuximab vedotin**

**Medications related to Brentuximab vedotin**

- **Adcetris** (Takeda UK Ltd)

  Brentuximab vedotin 50 mg Adcetris 50mg powder for concentrate for solution for infusion vials | 1 vial (P50) £2,500.00

### Catumaxomab

**INDICATIONS AND DOSE**

Treatment of malignant ascites in patients with epithelial cell adhesion molecule (EpCAM) positive carcinomas, where standard therapy is not available or no longer feasible

**By intraperitoneal infusion**

- **Adult:** (consult product literature)

### CAUTIONS

- Elevated BMI—risk of hyperglycaemia · high tumour burden—risk of tumour lysis syndrome · rapidly proliferating tumours—risk of tumour lysis syndrome

### INTERACTIONS

- **Appendix 1** (brentuximab vedotin).

### SIDE-EFFECTS

- **Common or very common**
  - Anaphylaxis · arthralgia · back pain · constipation · cough · demyelinating polyneuropathy · diarrhoea · dizziness · dyspnoea · fatigue · hyperglycaemia · infusion-related reactions · myalgia · peripheral neuropathy · pruritus · rash

- **Uncommon**
  - Stevens-Johnson syndrome

- **Frequency not known**
  - Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · nausea · oral mucositis · progressive multifocal leucoencephalopathy · thromboembolism · tumour lysis syndrome · vomiting

### CONCEPTION AND CONTRACEPTION

Effective contraception required during treatment and for 6 months after treatment in men and women.

**PREGNANCY**

Avoid unless potential benefit outweighs risk (toxicity in animal studies).

**BREAST FEEDING**

Avoid—no information available.

**MONITORING REQUIREMENTS**

- Monitor for symptoms of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological, cognitive or behavioural signs or symptoms).
- Monitor for new or worsening abdominal pain—investigate and withhold treatment if acute pancreatitis suspected and discontinue if confirmed (fatal cases reported).
- Monitor for pulmonary toxicity—treat symptoms promptly.
- Routinely monitor hepatic function.
- Monitor for infusion-related (including anaphylactic) reactions.
- Monitor for signs of peripheral neuropathy—consult product literature for treatment adjustment.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

**ELECTROLYTES:** May contain Sodium

- **Adcetris** (Takeda UK Ltd)

  Brentuximab vedotin 50 mg Adcetris 50mg powder for concentrate for solution for infusion vials | 1 vial (P50) £2,500.00
Malignant disease

Uncommon

- Acute renal failure • gastro-intestinal haemorrhage • intestinal obstruction • seizures
- Frequency not known
  - Allopurinol • bone-marrow suppression • extravasation • hyperuricaemia • infusion related side-effects • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

<table>
<thead>
<tr>
<th>Indication and Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of wild-type RAS metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated.</td>
</tr>
</tbody>
</table>

Important safety information

MHRA/CHM advice: epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)

Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative keratitis is diagnosed.

Patients must receive an antihistamine and a corticosteroid at least one hour before infusion. Resuscitation facilities should be available and treatment should be initiated by a specialist.

- Contra-indications: RAS mutated colorectal tumours (or if RAS tumour status unknown) • combination of cetuximab with oxaliplatin-containing chemotherapy is contra-indicated in patients with metastatic colorectal cancer who have mutant or unknown RAS status
- Caution: Cardiopulmonary disease • cardiovascular disease • history of keratitis • pulmonary disease—discontinue if interstitial lung disease • risk factors for keratitis • severe dry eye • ulcerative keratitis (including contact lens use)
- Interactions: Appendix 1 (cetuximab).
- Side-effects:
  - Common or very common
    - Acne • aseptic meningitis • blepharitis • bronchospasm • chills • conjunctivitis • desquamation • diarrhoea • dizziness • dry skin • dyspnoea • fever • headache • hypertension • hypertrichosis • hypocalcaemia • hypomagnesaemia • hypotension • infusion-related reactions • keratitis • nail disorders • nausea • pruritus • rash • severe (sometimes fatal) hypersensitivity reactions (possibly delayed onset) • shock • skin reactions • urticaria • vomiting
  - Very rare
    - Stevens-Johnson syndrome • toxic epidermal necrolysis
- Pregnancy: Use only if potential benefit outweighs risk—no information available. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- Breast feeding: Avoid breast-feeding during and for 2 months after treatment—no information available.
- Pre-treatment screening:
  - Evidence of non-mutated (wild-type) RAS status (at exons 2, 3 and 4 of KRAS and NRAS) is required before cetuximab is initiated for the treatment of metastatic colorectal cancer, and should be determined by an experienced laboratory using a validated test method.
- Directions for administration: Resuscitation facilities should be available.

National funding/access decisions

NICE technology appraisals (TAs)

- Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) NICE TA145
- Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated. www.nice.org.uk/TA145
- Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009) NICE TA172
- Cetuximab in combination with platinum-based chemotherapy is not recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck. www.nice.org.uk/TA172
- Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009) NICE TA176
- Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances:
  - the primary tumour has been resected or is potentially operable;
  - the metastatic disease is confined to the liver and is unresectable; and
  - the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.
- In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative.
- In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin.
- Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be...
assessed for resection of liver metastases. www.nice.org.uk/TA176

- Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE TA242

Cetuximab monotherapy or combination chemotherapy is not recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy. www.nice.org.uk/TA242

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2014) that cetuximab (Erbitux®) is accepted for restricted use within NHS Scotland, in combination with irinotecan or oxaliplatin-based chemotherapy, for the treatment of RAS wild-type metastatic colorectal cancer in patients who have not previously received chemotherapy for their metastatic disease (first-line treatment).

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

- Erbitux (Merck Serono Ltd)

Cetuximab 5 mg per 1 ml Erbitux 100mg/20ml solution for infusion vials | 1 vial £178.10 (Hospital only)

Erbitux 500mg/100ml solution for infusion vials | 1 vial £880.50 (Hospital only)

Solution for infusion

- Yervoy (Bristol-Myers Squibb Pharmaceuticals Ltd)

Ipilimumab 5 mg per 1 ml Yervoy 50mg/10ml concentrate for solution for infusion vials | 1 vial £3,750.00 (Hospital only)

Yervoy 200mg/40ml concentrate for solution for infusion vials | 1 vial £15,000.00 (Hospital only)

Ipilimumab

- DRUG ACTION

Ipilimumab causes T-cell activation.

INDICATIONS AND DOSE

Treatment of unresectable or metastatic advanced melanoma

BY INTRAVENOUS INFUSION

- Adult: (consult product literature)

- CAUTIONS

For full details consult product literature.

- INTERACTIONS

Appendix 1 (ipilimumab).

SIDE-EFFECTS, FURTHER INFORMATION

Immune-related reactions A corticosteroid can be used after starting ipilimumab, to treat immune-related reactions.

For further information on side-effects, (including monitoring and management of side effects) consult product literature.

- CONCEPTION AND CONTRACEPTION

Use effective contraception.

- PREGNANCY

Avoid unless potential benefit outweighs risk (toxicity in animal studies).

- BREAST FEEDING

Discontinue breast-feeding—no information available.

- HEPATIC IMPAIRMENT

Use with caution if plasma-bilirubin concentration greater than 3 times upper limit of normal range or if plasma-transaminase concentration 5 times or greater than the upper limit of normal range.

- MONITORING REQUIREMENTS

For information on monitoring of side effects, consult product literature.

- PRESCRIBING AND DISPENSING INFORMATION

Infusion-related side-effects have been reported; premedication with paracetamol and an antihistamine is recommended.

- NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (December 2012) NICE TA268

Ipilimumab is recommended as an option for the treatment of advanced (unresectable or metastatic) melanoma in patients who have received prior therapy, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme. www.nice.org.uk/TA268

- Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (July 2014) NICE TA319

Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme. www.nice.org.uk/TA319

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2013) that ipilimumab (Yervoy®) is accepted for restricted use within NHS Scotland for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy, only whilst ipilimumab is available at the price agreed in the patient access scheme.

Obinutuzumab

The properties listed below are those particular to the drug only. For properties common to the class, see Anti-lymphocyte monoclonal antibodies, p. 731.

INDICATIONS AND DOSE

Treatment of previously untreated chronic lymphocytic leukaemia in patients for whom full-dose fludarabine-based therapy is unsuitable due to co-morbidities

BY INTRAVENOUS INFUSION

- Adult: (consult product literature or local protocols)

CONTRA-INDICATIONS

For obinutuzumab contraindications, consult product literature.

CAUTIONS

CAUTIONS, FURTHER INFORMATION

Hepatitis B infection and reactivation

Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking obinutuzumab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).

For full details on the cautions of obinutuzumab, consult product literature.

- INTERACTIONS

Appendix 1 (obinutuzumab).

SIDE-EFFECTS

For full side effect details for obinutuzumab (including monitoring and management), consult product literature.

CONCEPTION AND CONTRACEPTION

Use effective contraception during and for 18 months after treatment.

PREGNANCY

Avoid unless potential benefit outweighs risk of B-lymphocyte depletion in fetus.
**Malignant disease**

- **BREAST FEEDING** Avoid breast-feeding during and for 18 months after treatment—present in milk in animal studies.
- **MONITORING REQUIREMENTS** Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Ofatumumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015) NICE TA343
    - Gazyvaro in combination with chlorambucil (Hospital only)
    - Ofatumumab 25 mg per 1 ml Gazyvaro 1000mg/40ml concentrate for solution for infusion vials | 1 vial (Ex) £3,312.00 (Hospital only)

**Ofatumumab**

The properties listed below are those particular to the drug only. For properties common to the class, see Anti-lymphocyte monoclonal antibodies, p. 731.

**INDICATIONS AND DOSE**

**Treatment of chronic lymphocytic leukaemia (CLL) in patients refractory to fludarabine and alemtuzumab**

**Treatment of CLL in patients who have not received prior therapy and who are not eligible for fludarabine based therapy (in combination with chlorambucil or bendamustine)**

**BY INTRAVENOUS INFUSION**

- **Adult:** Premedication must be given 30 minutes to 2 hours before each dose—consult product literature for details (consult local protocol)

**CONTRA-INDICATIONS** For full details on the contra-indications for ofatumumab, consult product literature.

**CAUTIONS** History of cardiac disease—monitor closely and discontinue treatment if cardiac arrhythmias occur

**CAUTIONS, FURTHER INFORMATION**

**Hepatitis B infection and reactivation** Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking ofatumumab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature). For full details about the cautions for ofatumumab, consult product literature

**INTERACTIONS** → Appendix 1 (ofatumumab).

**SIDE-EFFECTS**

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related side-effects (including cytokine release syndrome) have been reported with ofatumumab; premedication with paracetamol, an antihistamine, and a corticosteroid must be given—consult product literature. For full details (including monitoring and management of side-effects) consult product literature.

**CONCEPTION AND CONTRACEPTION** Use effective contraception during and for 12 months after treatment.

**PREGNANCY** Avoid unless potential benefit outweighs risk.

**BREAST FEEDING** Discontinue breast-feeding during and for 12 months after treatment—no information available.

**RENAL IMPAIRMENT** No information available for creatinine clearance less than 30 mL/minute.

**MONITORING REQUIREMENTS**

- Monitor electrolytes (including potassium and magnesium) before and during administration and correct if abnormal.
- Patients must be monitored closely during each infusion for the onset of infusion reactions.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (October 2010) NICE TA202
  - Ofatumumab is not recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab.
  - Patients currently receiving ofatumumab for this condition should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA202
  - Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015) NICE TA344
  - Ofatumumab in combination with chlorambucil is an option for untreated chronic lymphocytic leukaemia only if: the person is ineligible for fludarabine-based therapy and the manufacturer provides ofatumumab with the discount agreed in the patient access scheme. Patients currently receiving ofatumumab that is not and the person is ineligible for fludarabine-based therapy and the manufacturer provides ofatumumab with the discount agreed in the patient access scheme. Patients currently receiving ofatumumab that is not

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- Gazyvaro (Roche Products Ltd) ▼
  - Obinutuzumab 25 mg per 1 ml Gazyvaro 1000mg/40ml concentrate for solution for infusion vials | 1 vial (Ex) £3,312.00 (Hospital only)

**Ofatumumab**

- **Solution for infusion**
  - Ofatumumab 20 mg per 1 ml Arzerra 100mg/5ml concentrate for solution for infusion vials | 3 vial (Ex) no price available (Hospital only)
  - Arzerra 1000mg/50ml concentrate for solution for infusion vials | 1 vial (Ex) £1,820.00 (Hospital only)
Panitumumab

**DRUG ACTION** Panitumumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).

**INDICATIONS AND DOSE**
Treatment of non-mutated RAS metastatic colorectal cancer (combination therapy) / Treatment of non-mutated RAS metastatic colorectal cancer (monotherapy after failure of fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens) BY INTRAVENOUS INFUSION

‡ Adult: (consult product literature)

**INTERACTIONS**

**CONTRA-INDICATIONS** Intestinal pulmonary disease - the combination of panitumumab with oxaliplatin-containing chemotherapy is contra-indicated in patients with mutant RAS metastatic colorectal cancer or for whom RAS status is unknown

**CAUTIONS** History of keratitis - history of severe dry eye - history of ulcerative keratitis - pulmonary disease—discontinue if interstitial lung disease develops - risk factors for keratitis - risk factors for severe dry eye - risk factors for ulcerative keratitis (including contact lens use)

**INTERACTIONS** → Appendix 1 (panitumumab).

**SIDE-EFFECTS**


‡ Uncommon Bronchospasm - cyanosis - hirsutism - infusion-related reactions - nasal dryness

‡ Rare Keratitis - skin necrosis - Stevens-Johnson syndrome - toxic epidermal necrolysis


‡ CONCEPTION AND CONTRACEPTION Manufacturer advises effective contraception during and for at least 6 months after treatment in women

‡ PREGNANCY Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

‡ BREAST FEEDING Manufacturer advises avoid breastfeeding during and for 2 months after treatment.

‡ PRE-TREATMENT SCREENING Evidence of non-mutated RAS status (at exons 2, 3 and 4 of KRAS and NRAS) is required before panitumumab treatment is initiated, and should be determined by an experienced laboratory using a validated test method.

‡ MONITORING REQUIREMENTS

‡ ‡ Monitor for hypomagnesaemia.

‡ Monitor for hypocalcaemia.

‡ Monitor for dermatological reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (consult product literature).

‡ NATIONAL FUNDING/ACCESS DECISIONS

‡ NICE technology appraisals (TAs)

‡ Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE TA242

‡ Panitumumab monotherapy is not recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy. www.nice.org.uk/TA242

‡ MEDICINAL FORMS

‡ There can be variation in the licensing of different medicines containing the same drug.

‡ Solution for infusion

‡ ELECTROLYTES: May contain Sodium

‡ Vectorix (Amgen Ltd)

‡ Panitumumab 20 mg per 1 ml Vectorix 400mg/20ml concentrate for solution for infusion vials [1 vial (P2D) £1.517.16 (Hospital only) Vectorix 100mg/5ml concentrate for solution for infusion vials [1 vial (P2D) £379.29 (Hospital only)]

Pertuzumab

**DRUG ACTION** Pertuzumab is a recombinant humanised monoclonal antibody, and acts by inhibiting human epidermal growth factor receptor 2 protein (HER2) dimerisation.

**INDICATIONS AND DOSE**

‡ Treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel, in patients who have not received previous anti-HER2 therapy or chemotherapy (initiated by a specialist)

‡ BY INTRAVENOUS INFUSION

‡ Adult: (consult product literature)

‡ CAUTIONS

‡ Conditions that could impair left ventricular function - history of congestive heart failure - impaired left ventricular function - prior anthracycline exposure - radiotherapy to the chest area - recent myocardial infarction - serious cardiac arrhythmia - uncontrolled hypertension

‡ INTERACTIONS → Appendix 1 (pertuzumab).
SIDE-EFFECTS
- Common or very common When used in combination with trastuzumab and docetaxel: anaemia, arthralgia, chills, constipation, cough, decreased appetite, diarrhoea, dizziness, dry skin, dyspepsia, dysphoeca, febrile neutropenia, headache, increased lacrimation, infusion-related reactions, insomnia, left ventricular dysfunction, leucopenia, malaise, myalgia, nail disorder, nasopharyngitis, neutropenia, oedema, pain, paronychia, peripheral neuropathy, pleural effusion, pruritis, pyrexia, rash, severe hypersensitivity reactions, taste disturbance, upper respiratory tract infection
- Uncommon Interstitial lung disease (when used in combination with trastuzumab and docetaxel)
- Frequency not known Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

CONCEPTION AND CONTRACEPTION
Ensure effective contraception during and for at least six months after treatment in women of childbearing potential

PREGNANCY
Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

BREAST FEEDING
Avoid—no information available.

HEPATIC IMPAIRMENT
Caution—no information available.

RENAL IMPAIRMENT
Caution in severe impairment—no information available.

MONITORING REQUIREMENTS
- Assess for signs and symptoms of congestive heart failure (including left ventricular ejection fraction) before and during treatment—consult product literature, and withhold treatment if necessary.
- Monitor for febrile neutropenia.

DIRECTIONS FOR ADMINISTRATION
Resuscitation facilities should be available.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
- Perjeta (Roche Products Ltd) ▼
  Pertuzumab 30 mg per 1 ml Perjeta 420mg/14ml concentrate for solution for infusion vials | 1 vial (P) £2,395.00 (Hospital only)

Siltuximab

DRUG ACTION
Siltuximab is a monoclonal antibody that inhibits interleukin-6 receptor binding.

INDICATIONS AND DOSE
Treatment of multicentric Castleman’s disease (MCD) in patients who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative
- By intravenous infusion
  • Adult: 11 mg/kg every 3 weeks

CAUTIONS
Patients at increased risk of gastrointestinal perforation—promptly investigate those presenting with symptoms suggestive of gastrointestinal perforation—severe infection— withhold treatment until resolved-treat infection prior to treatment

CAUTIONS, FURTHER INFORMATION
Hypersensitivity reactions Infusion-related side-effects are reported commonly with siltuximab; resuscitation facilities should be available during treatment. Consult product literature for further information about siltuximab cautions.

INTERACTIONS
- Appendix 1 (siltuximab).
  Live vaccines should not be given concurrently or within 4 weeks before starting siltuximab treatment.

SIDE-EFFECTS, FURTHER INFORMATION
Infusion-related side effects Siltuximab therapy should be discontinued permanently in the event of a severe infusion-related reaction, anaphylaxis, a severe allergic reaction, or the occurrence of cytokine-release syndrome. Mild to moderate infusion-related reactions may improve by temporarily reducing the rate or stopping the infusion. When restarting treatment, a reduced infusion rate and the administration of antihistamines, paracetamol, and corticosteroids should be considered. Consider discontinuation of siltuximab if more than 2 doses are delayed due to treatment-related toxicities during the first 48 weeks—for full details consult product literature.

CONCEPTION AND CONTRACEPTION
Women of childbearing potential should use effective contraception during and for 3 months after treatment.

PREGNANCY
Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
Use with caution in hepatic impairment.

MONITORING REQUIREMENTS
- Monitor neutrophil and platelet count, and haemoglobin levels prior to each dose of siltuximab treatment for the first 12 months and thereafter prior to every third dosing cycle. Consider delaying treatment if required neutrophil, platelet, and haemoglobin levels not achieved—consult product literature for details.
- Monitor for infection during treatment.

DIRECTIONS FOR ADMINISTRATION
For intravenous infusion (Sylvant®), give intermittently in Glucose 5%. Allow vials to reach room temperature over approximately 30 minutes, then reconstitute each 100 mg vial with 5.2 mL of water for injection, and each 400 mg vial with 20 mL of water for injection, to produce a 20 mg/mL solution. Gently swirl without shaking to dissolve. Further dilute to 250 mL with glucose 5% and gently mix. Use within 6 hours of dilution and give over 60 minutes using an administration set lined with polyvinyl chloride or polyurethane, through a low-protein binding in-line 0.2 micron filter.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion
- Sylvant (Janssen-Cilag Ltd) ▼
  Siltuximab 100 mg Sylvant 100mg powder for concentrate for solution for infusion vials | 1 vial (P) £415.00 (Hospital only)
  Siltuximab 400 mg Sylvant 400mg powder for concentrate for solution for infusion vials | 1 vial (P) £1,661.00 (Hospital only)
Trastuzumab

INDICATIONS AND DOSE
Treatment of early breast cancer which overexpresses human epidermal growth factor receptor-2 (HER2) (initiated by a specialist)

Treatment of metastatic breast cancer in patients with HER2-positive tumours who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate (in combination with paclitaxel or docetaxel) (initiated by a specialist)

Treatment of metastatic gastric cancer in patients with tumours that overexpress HER2 who have received at least 2 chemotherapy regimens including, where appropriate, an anthracycline and a taxane (initiated by a specialist)

BY INTRAVENOUS INFUSION OR BY SUBCUTANEOUS INJECTION

Adult: (consult product literature or local protocols)

Monotherapy for metastatic breast cancer in postmenopausal patients with hormone-receptor positive HER2-positive tumours not previously treated with trastuzumab (in combination with an aromatase inhibitor) (initiated by a specialist)

BY INTRAVENOUS INFUSION OR BY SUBCUTANEOUS INJECTION

Adult: Women with oestrogen-receptor-positive breast cancer should also have received hormonal therapy (consult product literature or local protocols)

Treatment of metastatic gastric cancer in patients with HER2-positive tumours who have not received treatment for metastatic gastric cancer (in combination with capecitabine or fluorouracil and cisplatin) (initiated by a specialist)

BY INTRAVENOUS INFUSION

Adult: (consult product literature or local protocols)

复习

CONTRA-INDICATIONS
Severe dyspnoea at rest

CAUTIONS
Coronary artery disease • history of hypertension • symptomatic heart failure • uncontrolled arrhythmias

INTERACTIONS
Use with anthracyclines

Concomitant use of trastuzumab with anthracyclines is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If an anthracycline needs to be used, cardiac function should be monitored closely.

SIDE-EFFECTS
Acne • alopecia • alopecia • anaphylaxis • angioedema • anxiety • arthralgia • arthritis • asthenia • bone pain • bone-marrow suppression • cardiotoxicity • chest pain • chills • depression • dizziness • drowsiness • dry eye • dry skin • ecchymosis • extravasation • fever • gastro-intestinal symptoms • headache • hepatitis • hypersensitivity reactions • hypertension • hypertonia • hyperuricaemia • hypotension • increased lacrimation • infection • infusion-related side-effects (possibly delayed onset) • insomnia • leg cramps • malaise • mastitis • myalgia • nail disorders • nausea • oedema • oral mucositis • paraesthesia • paresis • peripheral neuropathy • pruritus • pulmonary events (possibly delayed onset) • rash • sweating • taste disturbance • thrombocytopenia • tremor • tumour lysis syndrome • urticaria • vomiting • weight loss

PREGNANCY
Manufacturer advises avoid—oligohydramnios reported. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

BREAST FEEDING
Avoid breast-feeding during treatment and for 7 months afterwards.

MONITORING REQUIREMENTS
Cardiotoxicity Monitor cardiac function before and during treatment—for details of monitoring and managing cardiotoxicity, consult product literature.

DIRECTIONS FOR ADMINISTRATION
Resuscitation facilities should be available during administration of trastuzumab.

PRESCRIBING AND DISPENSING INFORMATION
When prescribing, dispensing or administering, check that this is the correct preparation—trastuzumab is not interchangeable with trastuzumab emtansine.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002) NICE TA34

Trastuzumab in combination with paclitaxel is recommended as an option for patients with tumours expressing human epidermal growth factor receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer, and in whom anthracycline treatment is inappropriate.

Trastuzumab monotherapy is recommended as an option for patients with tumours expressing HER2 scored at levels of 3+ who have received at least two chemotherapy regimens for metastatic breast cancer. Prior chemotherapy must have included at least an anthracycline and a taxane where these treatments are appropriate. It should also have included hormonal therapy in suitable oestrogen-receptor-positive patients. www.nice.org.uk/TA34

Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (August 2006) NICE TA107

Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as an option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). www.nice.org.uk/TA107

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010) NICE TA208

Trastuzumab in combination with cisplatin and capecitabine or fluorouracil is recommended for human epidermal growth factor receptor-2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who:

• have not received treatment for metastatic disease and
• have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3.

www.nice.org.uk/TA208

Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012) NICE TA257

Lapatinib or trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).

Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA257

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2013) that subcutaneous trastuzumab injection (Herceptin®) is accepted for restricted use within NHS Scotland for the treatment of adults with HER2 positive metastatic breast cancer and early breast cancer, when used within licensed indications excluding use in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with trastuzumab.
Trastuzumab emtansine

**DRUG ACTION** Trastuzumab emtansine is an antibody-conjugate that contains trastuzumab covalently linked to DM1, a cytotoxic microtubule inhibitor.

**INDICATIONS AND DOSE**
Monotherapy for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have previously received trastuzumab and a taxane separately or in combination (initiated by a specialist) / Monotherapy for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have developed disease recurrence during or within 6 months of completing adjuvant therapy (initiated by a specialist) by intravenous infusion

Adult: (consult product literature or local protocols)

**CAUTIONS**
Dyspnoea at rest—increased risk of pulmonary events / history of congestive heart failure / patients over 75 years / peripheral neuropathy (temporarily discontinue treatment—consult product literature) / recent history of myocardial infarction / recent history of unstable angina / risk of left ventricular dysfunction—consult product literature for specific risks with trastuzumab treatment—serious arrhythmias

**INTERACTIONS** → Appendix 1 (trastuzumab). Caution with concomitant anticoagulant medication—increased risk of thrombocytopenia with haemorrhagic events.

**SIDE-EFFECTS**
Common or very common / Abdominal pain / arthralgia / blurred vision / chills / conjunctivitis / constipation / cough / diarrhea / dizziness / dry eye / dry mouth / dysgeusia / dyspepsia / dysphonia / epistaxis / gingival bleeding / haemorrhage / hand-foot syndrome / headache / hypertension / hypokalaemia / increased lactation / infusion-related reactions / insomina / left ventricular dysfunction / malaise / memory impairment / myalgia / nail disorder / periphereral neuropathy / peripheral oedema / pruritus / pyrexia / rash / thrombocytopenia / urinary tract infection / urticaria

Uncommon / Hepatic failure / hepatic toxicity / interstitial lung disease / nodular regenerative hyperplasia / pneumonitis / portal hypertension

Frequency not known / Alopecia / bone-marrow suppression / extravasation / hyperuricaemia / nausea / oral mucositis / thromboembolism / tumour lysis syndrome / vomiting

**CONCEPTION AND CONTRACEPTION**
Effective contraception must be used during and for 6 months after stopping treatment in women and men.

**PREGNANCY**
Manufacturer advises avoid—oligohydramnios reported with trastuzumab. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**
Manufacturer advises avoid breast-feeding during and for 6 months after treatment.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Herceptin (Roche Products Ltd)**
  - Trastuzumab 120 mg per 1 ml
  - Herceptin 600mg/5ml solution for injection vials | 1 vial (£222.20, Hospital only)

**Powder for solution for infusion**
- **Herceptin (Roche Products Ltd)**
  - Trastuzumab 150 mg
  - Herceptin 150mg powder for solution for infusion vials | 1 vial (£407.40)

**Trastuzumab emtansine**

**HEPATIC IMPAIRMENT** Consult product literature for dose modification in cases of abnormal liver function tests. Consult product literature for initiating treatment and discontinuation in cases of abnormal liver function tests.

**RENAL IMPAIRMENT** No information available—manufacturer advises caution in severe impairment.

**MONITORING REQUIREMENTS**
- Monitor hepatic function before each dose.
- Monitor for signs and symptoms of neurotoxicity.
- Monitor closely for infusion-related and hypersensitivity reactions.
- Monitor platelet count before each dose and as clinically indicated (consult product literature for treatment modification in thrombocytopenia).
- Test cardiac function before treatment and regularly during treatment—delay or discontinue treatment in cases of left ventricular dysfunction.
- Monitor for dyspnoea, cough, fatigue and pulmonary infiltrates—discontinue if interstitial lung disease or pneumonitis confirmed (fatal cases reported).

**DIRECTIONS FOR ADMINISTRATION**
Resuscitation facilities should be available during administration of trastuzumab emtansine.

**PRESCRIBING AND DISPENSING INFORMATION**
When prescribing, dispensing or administering, check that this is the correct preparation—trastuzumab emtansine and trastuzumab are not interchangeable.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**
- **Kadcyla (Roche Products Ltd)**
  - Trastuzumab emtansine 100 mg
  - Kadcyla 100mg powder for concentrate for solution for infusion vials | 1 vial (£641.01)
  - Trastuzumab emtansine 160 mg
  - Kadcyla 160mg powder for concentrate for solution for infusion vials | 1 vial (£2,625.62)

2.2 Cytotoxic responsive malignancy

**Cytotoxic drugs**
The chemotherapy of cancer is complex and should be confined to specialists in oncology. Cytotoxic drugs have both anti-cancer activity and the potential to damage normal tissue; most cytotoxic drugs are teratogenic. Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms. In an increasing number of cases chemotherapy may be combined with radiotherapy or surgery or both as either neoadjuvant treatment (initial chemotherapy aimed at shrinking the primary tumour, thereby rendering local therapy less destructive or more effective) or as adjuvant treatment (which follows definitive treatment of the primary disease, when the risk of subclinical metastatic disease is known to be high). All cytotoxic drugs cause side-effects and a balance has to be struck between likely benefit and acceptable toxicity.

Combinations of cytotoxic drugs, as continuous or pulsed cycles of treatment, are frequently more toxic than single drugs but have the advantage in certain tumours of enhanced response, reduced development of drug resistance and increased survival. However for some tumours, single-agent chemotherapy remains the treatment of choice. Cytotoxic drugs fall into a number of classes, each with characteristic antitumour activity, sites of action, and toxicity. A knowledge of sites of metabolism and excretion...
is important because impaired drug handling as a result of disease is not uncommon and may result in enhanced toxicity.

**Guidelines for handling cytotoxic drugs**
- Trained personnel should reconstitute cytotoxics
- Reconstitution should be carried out in designated pharmacy areas
- Protective clothing (including gloves, gowns, and masks) should be worn
- The eyes should be protected and means of first aid should be specified
- Pregnant staff should avoid exposure to cytotoxic drugs (all females of child-bearing age should be informed of the reproductive hazard)
- Use local procedures for dealing with spillages and safe disposal of waste material, including syringes, containers, and absorbent material
- Staff exposure to cytotoxic drugs should be monitored

**Intrathecal chemotherapy**
A Health Service Circular (HSC 2008/001) provides guidance on the introduction of safe practice in NHS Trusts where intrathecal chemotherapy is administered; written local guidance covering all aspects of national guidance should be available. Support for training programmes is also available.

Copies, and further information may be obtained from: Department of Health
PO Box 777
London
SE1 6XH
Fax: 01623 724524
It is also available from the Department of Health website (www.dh.gov.uk).

**Safe systems for cytotoxic medicines**
NHS cancer networks have been established across the UK to bring together all stakeholders in all sectors of care, to work collaboratively to plan and deliver high quality cancer services for a given population. NHS cancer networks have websites containing information on local chemotherapy services and treatment (see www.cancer.nhs.uk/networks.htm).

Safe system requirements:
- cytotoxic drugs for the treatment of cancer should be given as part of a wider pathway of care coordinated by a multidisciplinary team
- cytotoxic drugs should be prescribed, dispensed, and administered only in the context of a written protocol or treatment plan
- injectable cytotoxic drugs should only be dispensed if they are prepared for administration
- oral cytotoxic medicines should be dispensed with clear directions for use

**Important safety information**
**Risks of incorrect dosing of oral anti-cancer medicines**
The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.

Standards to be followed to achieve this include:
- non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;
- staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.

**Doses**
Doses of cytotoxic drugs are determined using a variety of different methods including body-surface area or body-weight. Alternatively, doses may be fixed. Doses may be further adjusted following consideration of a patient’s neutrophil count, renal and hepatic function, and history of previous adverse effects to the cytotoxic drug. Doses may also differ depending on whether a drug is used alone or in combination.

Because of the complexity of dosage regimens in the treatment of malignant disease, dose statements have been omitted from some of the drug entries in this chapter. However, even where dose statements have been provided, detailed specialist literature, individual hospital chemotherapy protocols, or local cancer networks (www.cancer.nhs.uk/networks.htm) should be consulted before prescribing, dispensing, or administering cytotoxic drugs.

Prescriptions should not be repeated except on the instructions of a specialist.

**Side-effects of cytotoxic drugs**
Side-effects common to most cytotoxic drugs are discussed below whilst side-effects characteristic of a particular drug or class of drugs (e.g. neurotoxicity with vinca alkaloids) are mentioned in the appropriate sections. Manufacturers’ product literature, hospital-trust protocols, and cancer-network protocols should be consulted for full details of side-effects associated with individual drugs and specific chemotherapy regimes.

Many side-effects of cytotoxic drugs often do not occur at the time of administration, but days or weeks later. It is therefore important that patients and healthcare professionals can identify symptoms that cause concern and can contact an expert for advice. Toxicities should be accurately recorded using a recognised scoring system such as the Common Toxicity Criteria for Adverse Events (CTCAE) developed by the National Cancer Institute.

**Extravasation of intravenous drugs**
A number of cytotoxic drugs will cause severe local tissue necrosis if leakage into the extravascular compartment occurs. To reduce the risk of extravasation injury it is recommended that cytotoxic drugs are administered by appropriately trained staff. See information on the prevention and management of extravasation injury.

**Oral mucositis**
A sore mouth is a common complication of cancer chemotherapy; it is most often associated with fluorouracil p. 761, methotrexate p. 762, and the anthracyclines. It is best to prevent the complication. Good oral hygiene (rinsing the mouth frequently and effective brushing of the teeth with a soft brush 2–3 times daily) is probably beneficial. For fluorouracil, sucking ice chips during short infusions of the drug is also helpful.

Once a sore mouth has developed, treatment is much less effective. Saline mouthwashes should be used but there is no good evidence to support the use of antiseptic or anti-inflammatory mouthwashes. In general, mucositis is self-limiting but with poor oral hygiene it can be a focus for bone-borne infection.

**Tumour lysis syndrome**
Tumour lysis syndrome occurs secondary to spontaneous or treatment-related rapid destruction of malignant cells. Patients at risk of tumour lysis syndrome include those with non-Hodgkin’s lymphoma (especially if high grade and
bulky disease), Burkitt’s lymphoma, acute lymphoblastic leukaemia and acute myeloid leukaemia (particularly if high white blood cell counts or bulky disease), and occasionally those with solid tumours. Pre-existing hyperuricaemia, dehydration, and renal impairment are also predisposing factors. Features include hyperkalaemia, hyperuricaemia (see below), and hyperphosphataemia with hypocalcaemia; renal damage and arrhythmias can follow. Early identification of patients at risk, and initiation of prophylaxis or therapy for tumour lysis syndrome, is essential.

Hyperuricaemia
Hyperuricaemia, which may be present in high-grade lymphoma and leukaemia, can be markedly worsened by chemotherapy and is associated with acute renal failure. Allopurinol p. 909 should be started 24 hours before treating such tumours and patients should be adequately hydrated. The dose of mercaptopurine p. 762 or azathioprine p. 716 should be reduced if allopurinol needs to be given concomitantly.

Rasburicase p. 784, a recombinant urate oxidase, is licensed for hyperuricaemia in patients with haematological malignancy. It rapidly reduces plasma-urate acid concentration and may be of particular value in preventing complications following treatment of leukaemias or bulky lymphomas.

Bone-marrow suppression
All cytotoxic drugs except vincristine sulfate p. 773 and bleomycin p. 756 cause bone-marrow suppression. This commonly occurs 7 to 10 days after administration, but is delayed for certain drugs, such as Carmustine p. 749, lomustine p. 752, and melphalan p. 752. Peripheral blood counts must be checked before each treatment, and doses should be reduced or therapy delayed if bone-marrow has not recovered.

Cytotoxic drugs may be contra-indicated in patients with acute infection; any infection should be treated before, or when starting, cytotoxic drugs.

Fever in a neutropenic patient (neutrophil count less than 1.0 x 10^9/litre) requires immediate broad-spectrum antibacterial therapy. Appropriate bacteriological investigations should be conducted as soon as possible.

Patients taking cytotoxic drugs who have signs or symptoms of infection should be advised to seek prompt medical attention. All patients should initially be investigated and treated under the supervision of the appropriate oncology or haematology specialist.

In selected patients, the duration and the severity of neutropenia can be reduced by the use of recombinant human granulocyte-colony stimulating factors.

Symptomatic anaemia is usually treated with red blood cell transfusions. For guidance on the use of erythropoietins in patients with cancer, see MHRA/CHM advice and NICE guidance.

See advice on the use of live vaccines in individuals with impaired immune response.

Alopecia
Reversible hair loss is a common complication, although it varies in degree between drugs and individual patients. No pharmacological methods of preventing this are available.

Thromboembolism
Venous thromboembolism can be a complication of cancer itself, but chemotherapy increases the risk.

Pregnancy and reproductive function
Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.

Exclude pregnancy before treatment with cytotoxic drugs. Contraceptive advice should be given before cytotoxic therapy begins—women of childbearing age should use effective contraception during and after treatment. Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.

Alkylation drugs often severely affect gametogenesis and carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.

Nausea and vomiting
Nausea and vomiting cause considerable distress to many patients who receive chemotherapy and to a lesser extent abdominal radiotherapy, and may lead to refusal of further treatment; prophylaxis of nausea and vomiting is therefore extremely important. Symptoms may be acute (occurring within 24 hours of treatment), delayed (first occurring more than 24 hours after treatment), or anticipatory (occurring prior to subsequent doses). Delayed and anticipatory symptoms are more difficult to control than acute symptoms and require different management.

Patients vary in their susceptibility to drug-induced nausea and vomiting; those affected more often include women, patients under 50 years of age, anxious patients, and those who experience motion sickness. Susceptibility also increases with repeated exposure to the cytotoxic drug.

Drugs may be divided according to their emetogenic potential and some examples are given below, but the symptoms vary according to the dose, to other drugs administered and to the individual’s susceptibility to emetogenic stimuli.

Mildly emetogenic treatment—fluorouracil, etoposide, methotrexate (less than 100 mg/m², low dose in children), the vinca alkaloids, and abdominal radiotherapy.

Moderately emetogenic treatment—the taxanes, doxorubicin hydrochloride, intermediate and low doses of cyclophosphamide, mitoxantrone, and high doses of methotrexate (0.1–1.2 g/m²).

Highly emetogenic treatment—cisplatin p. 768, dacarbazine p. 751, and high doses of cyclophosphamide.

Prevention of acute symptoms
For patients at low risk of emesis, pretreatment with dexamethasone p. 581 or lorazepam p. 412 may be used.

For patients at high risk of emesis, a 5HT3-receptor antagonist, usually given by mouth in combination with dexamethasone p. 581 and the neurokinin receptor antagonist aprepitant p. 351 is effective.

Prevention of delayed symptoms
For delayed symptoms associated with moderately emetogenic chemotherapy, a combination of dexamethasone and 5HT3-receptor antagonist is effective; for highly emetogenic chemotherapy, a combination of dexamethasone and aprepitant is effective. Metoclopramide hydrochloride p. 347 is also licensed for delayed chemotherapy-induced nausea and vomiting.
Prevention of anticipatory symptoms
---
Good symptom control is the best way to prevent anticipatory symptoms. Lorazepam can be helpful for its amnesic, sedative, and anxiolytic effects.

Treatment for cytotoxic-induced side effects
---

**Anthracycline side-effects**

Anthracycline-induced cardiotoxicity

The anthracycline cytotoxic drugs are associated with dose-related, cumulative, and potentially life-threatening cardiotoxic side-effects.

**Anthracycline extravasation**

Local guidelines for the management of extravasation should be followed or specialist advice sought.

See further information on the prevention and management of extravasation injury.

Chemotherapy-induced mucositis and myelosuppression

Folinic acid p. 781 (given as calcium folinate) is used to counteract the folate-antagonist action of methotrexate p. 762 and thus speed recovery from methotrexate-induced mucositis or myelosuppression (‘folinic acid rescue’).

Folinic acid is also used in the management of methotrexate overdose, together with other measures to maintain fluid and electrolyte balance, and to manage possible renal failure.

Folinic acid does not counteract the antibacterial activity of folate antagonists such as trimethoprim p. 462. When folinic acid and fluorouracil p. 761 are used together in metastatic colorectal cancer the response-rate improves compared to that with fluorouracil alone.

The calcium salt of levofolinic acid p. 782, a single isomer of folinic acid, is also used for rescue therapy following methotrexate administration, for cases of methotrexate overdose, and for use with fluorouracil for colorectal cancer.

The dose of calcium levofolinate is generally half that of calcium folinate.

The disodium salts of folinic acid and levofolic acid are also used for rescue therapy following methotrexate therapy, and for use with fluorouracil for colorectal cancer.

**Urothelial toxicity**

Haemorrhagic cystitis is a common manifestation of urothelial toxicity which occurs with the oxazaphosphorines, cyclophosphamide p. 750 and ifosfamide p. 751; it is caused by the metabolite acrolein. Mesna p. 783 reacts specifically with this metabolite in the urinary tract, preventing toxicity. Mesna is used routinely (preferably by mouth) in patients receiving ifosfamide, and in patients receiving cyclophosphamide p. 750 by the intravenous route at a high dose (e.g. more than 2 g) or in those who experienced urothelial toxicity when given cyclophosphamide previously.

**Anthracyclines and other cytotoxic antibiotics**

Drugs in this group are widely used. Many cytotoxic antibiotics act as radiomimetics and simultaneous use of radiotherapy should be avoided because it may markedly increase toxicity. Daunorubicin p. 754, doxorubicin hydrochloride p. 754, epirubicin hydrochloride p. 756 and idarubicin hydrochloride p. 756 are anthracycline antibiotics. Mitoxantrone p. 778 is an anthracycline derivative.

Doxorubicin hydrochloride is available as both conventional and liposomal formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable. Conventional doxorubicin hydrochloride is used to treat the acute leukaemias, Hodgkin’s and non-Hodgkin’s lymphomas, paediatric malignancies, and some solid tumours including breast cancer.

Epirubicin hydrochloride is structurally related to doxorubicin hydrochloride and clinical trials suggest that it is as effective in the treatment of breast cancer. Idarubicin hydrochloride has general properties similar to those of doxorubicin hydrochloride; it is mostly used in the treatment of haematological malignancies.

Daunorubicin also has general properties similar to those of doxorubicin hydrochloride.

Mitoxantrone is structurally related to doxorubicin hydrochloride.

Pixantrone p. 779 is licensed as monotherapy for the treatment of refractory or multiply relapsed aggressive non-Hodgkin B-cell lymphomas, although the benefits of using it as a fifth-line or greater chemotherapy in refractory patients has not been established.

Bleomycin p. 766 is given intravenously or intramuscularly to treat metastatic germ cell cancer and, in some regimens, non-Hodgkin’s lymphoma.

Dactinomycin is principally used to treat paediatric cancers. Its side-effects are similar to those of doxorubicin, except that cardiac toxicity is not a problem.

Mitomycin p. 767 is given intravenously to treat upper gastrointestinal and breast cancers and by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals.

**Vincal alkaloids**

The vincal alkaloids, vinblastine sulfate p. 773, vincristine sulfate p. 773, and vindesine sulfate p. 774, are used to treat a variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer). Vinorelbine p. 775 is a semi-synthetic vincal alkaloid. See also, role of vinorelbine in the treatment of breast cancer.

**Antimetabolites**

Antimetabolites are incorporated into new nuclear material or combine irreversibly with cellular enzymes, preventing normal cellular division.

**Alkylation drugs**

Extensive experience is available with these drugs, which are among the most widely used in cancer chemotherapy. They act by damaging DNA, thus interfering with cell replication.

Cyclophosphamide p. 750 is used mainly in combination with other agents for treating a wide range of malignancies, including some leukaemias, lymphomas, and solid tumours. It is given by mouth or intravenously; it is inactive until metabolised by the liver.

Ifosfamide p. 751 is related to cyclophosphamide and is given intravenously.

Melphalan p. 752 is licensed for the treatment of multiple myeloma, polycythaemia vera, childhood neuroblastoma, advanced ovarian adenocarcinoma, and advanced breast cancer. However, in practice, melphalan is rarely used for ovarian adenocarcinoma; it is no longer used for advanced breast cancer. Melphalan is also licensed for regional arterial perfusion in localised malignant melanoma of the extremities and localised soft-tissue sarcoma of the extremities.

Lomustine p. 752 is a lipid-soluble nitrosourea and the drug is given at intervals of 4 to 6 weeks.

Carmustine p. 749 has similar activity to lomustine; it is given to patients with multiple myeloma, non-Hodgkin’s lymphomas, and brain tumours. Carmustine implants are licensed for intracranial use in adults for the treatment of recurrent glioblastoma multiforme as an adjunct to surgery. Carmustine implants are also licensed for high-grade malignant glioma as adjunctive treatment to surgery and radiotherapy.
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia; it is available on a named-patient basis from specialist importing companies.

ALKYLATING AGENTS

Bendamustine hydrochloride

INDICATIONS AND DOSE
Treatment of chronic lymphocytic leukaemia | Treatment of non-Hodgkin’s lymphoma | Treatment of multiple myeloma
BY INTRAVENOUS INFUSION
Adult: (consult local protocol)

CONTRA-INDICATIONS
Jaundice · low leucocyte count · low platelet count · major surgery less than 30 days before start of treatment · severe bone marrow suppression

CAUTIONS
Avoid in Acute porphyrias p. 864 · cardiac disorders—monitor serum potassium and ECG

INTERACTIONS
→ Appendix 1 (bendamustine).

SIDE-EFFECTS
▶ Common or very common Amenorrhoea · angina · anorexia · arthralgias · chill· constipation · dehydration · diarrhoea · electrolyte disturbances · haemorrhage · hypertension · hypokalaemia · hypotension · infection · insomnia · malaise · pain · palpitation · pyrexia · respiratory dysfunction
▶ Uncommon Pericardial effusion
▶ Rare Acute circulatory failure · drowsiness · sweating · voice changes
▶ Very rare Anticholinergic syndrome · ataxia · cardiac failure · encephalitis · haemolysis · multiple organ failure · myocardial infarction · neurological disorders · paraesthesia · peripheral neuropathy · phlebitis · pulmonary fibrosis · tachycardia · taste disturbance
▶ Frequency not known Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · male sterility · nausea · oral mucositis · premature menopause · secondary malignancy · Stevens-Johnson syndrome · thromboembolism · toxic epidermal necrolysis · tumour lysis syndrome · vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

CONCEPTION AND CONTRACEPTION
Effective contraception is required during treatment in men or women, and for 6 months after treatment in men.

PREGNANCY
Avoid (teratogenic and mutagenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

BREAST FEEDING
Discontinue breast-feeding.

HEPATIC IMPAIRMENT
Consider a 30% dose reduction in moderate impairment. Avoid in severe impairment.

RENAL IMPAIRMENT
No information available on use in patients with creatinine clearance less than 10 ml/minute.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011) NICE TA216
Bendamustine is recommended as an option for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate. www.nice.org.uk/TA216

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (March 2011) that bendamustine (Levact®) is accepted for restricted use within NHS Scotland for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion
▶ Levact (Napp Pharmaceuticals Ltd)
Bendamustine hydrochloride 25 mg Levact 25mg powder for concentrate for solution for infusion vials | 5 vial £347.26 (Hospital only)
Bendamustine hydrochloride 100 mg Levact 100mg powder for concentrate for solution for infusion vials | 5 vial £1,379.04 (Hospital only)

Busulfan
(Busulphan)

INDICATIONS AND DOSE
Chronic myeloid leukaemia, induction of remission
BY MOUTH
Adult: 60 micrograms/kg daily (max. per dose 4 mg); maintenance 0.5–2 mg daily
Conditioning treatment before haematopoietic stem-cell transplantation
BY MOUTH OR BY INTRAVENOUS INFUSION
Adult: (consult local protocol)
Doses at extremes of body-weight
Dose may need to be calculated based on body surface area or adjusted ideal body weight in obese patients—consult product literature.

Caution
Avoid in Acute porphyrias p. 864 · high dose (antiepileptic prophylaxis required) · history of seizures (antiepileptic prophylaxis required) · ineffective once in blast crisis phase · previous progenitor cell transplant (increased risk of hepatic veno-occlusive disease) · previous radiation therapy (increased risk of hepatic veno-occlusive disease) · risk of second malignancy · three or more cycles of chemotherapy (increased risk of hepatic veno-occlusive disease)

INTERACTIONS
→ Appendix 1 (busulfan).

SIDE-EFFECTS
GENERAL SIDE-EFFECTS
▶ Common or very common Cardiac tamponade in thalassaemia · hepatic fibrosis · hepatic veno-occlusive disease · hepatotoxicity · hyperbilirubininaemia · jaundice · pneumonia · skin hyperpigmentation
▶ Rare Aplastic anaemia · seizures · visual disturbances
▶ Very rare Gyanaeomastia · myasthenia gravis
▶ Frequency not known Alopecia · bone-marrow suppression · hyperuricaemia · irreversible bone-marrow aplasia · lung toxicity · male sterility · nausea · oral mucositis · premature menopause · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

SPECIFIC SIDE-EFFECTS
▶ With intravenous use extravasation

SIDE-EFFECTS, FURTHER INFORMATION
Lung toxicity Discontinue if lung toxicity develops.
Carmustine

**INDICATIONS AND DOSE**

**Multiple myeloma** | **Non-Hodgkin’s lymphomas** | **Brain tumours**
---|---|---
**BY INTRAVENOUS INFUSION**
- Adult: (consult product literature)
- Recurrent glioblastoma multiforme as an adjunct to surgery | High-grade malignant glioma as adjunctive treatment to surgery and radiotherapy
- BY INTRALESIONAL IMPLANTATION
- Adult: (consult product literature)

**CAUTIONS** Avoid in Acute porphyrias p. 864
**INTERACTIONS** → Appendix 1 (carmustine).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Alopecia - bone-marrow suppression (delayed) - hyperuricaemia - irritant to tissues - male sterility - nausea - oral mucositis - premature menopause - secondary malignancy - thromboembolism - tumour lysis syndrome - vomiting

**SPECIFIC SIDE-EFFECTS**
- With intravenous use pulmonary fibrosis (delayed) - renal damage (cumulative)

**SIDE-EFFECTS, FURTHER INFORMATION**

Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during treatment in men or women.

**PREGNANCY** Avoid (teratogenic in animals). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (June 2007) NICE TA121
- Carmustine implants are an option for the treatment of newly diagnosed high-grade (Grade 3 or 4) glioma for patients in whom at least 90% of the tumour has been resected. Carmustine implants should only be used within specialist centres. www.nice.org.uk/TA121

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Implant**
- Gliadel (Eisai Ltd)
  - Carmustine 7.7 mg Gliadel 7.7 mg implant | 8 device (£5,203.00 (Hospital only))

Chlorambucil

**INDICATIONS AND DOSE**

Some lymphomas and chronic leukaemias (used either alone or in combination therapy)

**BY MOUTH**
- Adult: (consult local protocol)

**CAUTIONS** Avoid in Acute porphyrias p. 864 · children with nephrotic syndrome (increased seizure risk) · history of epilepsy (increased seizure risk)

**SIDE-EFFECTS**

- Uncommon Skin rash
- Very rare Male sterility (in prepubertal and pubertal males)
- Frequency not known Alopecia · bone-marrow suppression · hyperuricaemia · nausea · oral mucositis · premature menopause · secondary malignancy · Stevens-Johnson syndrome · thromboembolism · toxic epidermal necrolysis · tumour lysis syndrome · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia. Skin reactions If a rash occurs further chlorambucil is contra-indicated and cyclophosphamide is substituted.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during treatment in men or women.

**PREGNANCY** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Manufacturer advises consider dose reduction in severe impairment—limited information available.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015) NICE TA343
- Obinutuzumab, in combination with chlorambucil, is an option for untreated chronic lymphocytic leukaemia in
patients who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if:
- bendamustine-based therapy is not suitable and
- the manufacturer provides obinutuzumab with the discount agreed in the patient access scheme.
Patients currently receiving obinutuzumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA344

Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015) NICE TA344
Ofatumumab in combination with chlorambucil is an option for untreated chronic lymphocytic leukaemia only if:
- the person is ineligible for fludarabine-based therapy and
- bendamustine is not suitable and
- the manufacturer provides ofatumumab with the discount agreed in the patient access scheme.
Patients currently receiving ofatumumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA344

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- CHLORAMBUCIL (Non-proprietary) Chlorambucil 2 mg Chlorambucil 2mg tablets | 25 tablet [PMR] £40.51 DT price = £40.51

**Cyclophosphamide**

**INDICATIONS AND DOSE**
Rheumatoid arthritis with severe systemic manifestations

**BY MOUTH**
- Adult: 1–1.5 mg/kg daily

Severe systemic rheumatoid arthritis | Other connective tissue diseases (especially with active vasculitis)

**BY INTRAVENOUS INJECTION**
- Adult: 0.5–1 g every 2 weeks, then reduced to 0.5–1 g every 1 month, frequency adjusted according to clinical response and haematological monitoring. To be given with prophyactic mesna

Used, mainly in combination with other agents for treating a wide range of malignancies, including some leukaemias, lymphomas, and solid tumours

**BY MOUTH OR BY INTRAVENOUS INFUSION**
- Adult: (consult local protocol)

**UNLICENSED USE**
Not licensed for rheumatoid arthritis with severe systemic manifestations.

**Important safety information**
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

**CONTRA-INDICATIONS**
Haemorrhagic cystitis

**CAUTIONS**
Avoid in Acute porphyrias p. 864 · diabetes mellitus · previous or concurrent mediastinal irradiation—risk of cardiotoxicity

**INTERACTIONS**
Appendix 1 (cyclophosphamide).

**SIDE-EFFECTS**
- **GENERAL SIDE-EFFECTS**
  - Common or very common Anorexia · cardiotoxicity at high doses · disturbances of carbohydrate metabolism · inappropriate secretion of anti-diuretic hormone · interstitial pulmonary fibrosis · pancreatitis · pigmentation of nails · pigmentation of palms · pigmentation of soles · urothelial toxicity
  - Rare Hepatotoxicity · renal dysfunction
  - Frequency not known Alopecia · bone-marrow suppression · haemorrhagic cystitis · hyperuricaemia · male sterility · nausea · oral mucositis · premature menopause · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

**SPECIFIC SIDE-EFFECTS**
- With intravenous use extravasation

SIDE-EFFECTS, FURTHER INFORMATION
Haemorrhagic cystitis A urinary metabolite of cyclophosphamide, acrolein, can cause haemorrhagic cystitis; this is a rare but serious complication; increased fluid intake for 24–48 hours after intravenous injection, can prevent this complication. When high-dose therapy (e.g. more than 2 g intravenously) is used or when the patient is considered to be at high risk of cystitis (e.g. because of pelvic irradiation), mesna (given initially intravenously then by mouth) can also help prevent cystitis.

Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for at least 3 months after treatment in men or women.

**PREGNANCY**
Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**
Discontinue breast-feeding during and for 36 hours after stopping treatment.

**HEPATIC IMPAIRMENT**
Reduce dose—consult local treatment protocol for details.

**RENAL IMPAIRMENT**
Reduce dose if serum creatinine concentration greater than 120 micromol/litre.

**DIRECTIONS FOR ADMINISTRATION**
For intravenous infusion (cyclophosphamide injection; Baxter) give via drip tubing in Glucose 5% or Sodium chloride 0.9%; reconstitute 500 mg with 25 mL sodium chloride 0.9%; reconstitute 1 g with 50 mL sodium chloride 0.9%.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, solution for injection, oral suspension, solution for infusion, oral solution

**Tablet**
CAUTIONARY AND ADVISORY LABELS 25, 27
- CYCLOPHOSPHAMIDE (Non-proprietary) Cyclophosphamide (as Cyclophosphamide monohydrate) 50 mg Cyclophosphamide 50mg tablets | 100 tablet [POM] £139.00 DT price = £139.00

**Powder for solution for injection**
- CYCLOPHOSPHAMIDE (Non-proprietary) Cyclophosphamide (as Cyclophosphamide monohydrate) 500 mg Cyclophosphamide 500mg powder for solution for injection vials | 1 vial [POM] £9.66–£9.95
  - Cyclophosphamide (as Cyclophosphamide monohydrate) 1 gram Cyclophosphamide 1g powder for solution for injection vials | 1 vial [POM] £10.66–£11.47

**Powder for solution for injection**
- Cyclophosphamide (as Cyclophosphamide monohydrate) 2 gram Cyclophosphamide 2g powder for solution for injection vials | 1 vial [POM] no price available
Cytotoxic responsive malignancy 751

Dacarbazine

**INDICATIONS AND DOSE**
Metastatic melanoma | Soft tissue sarcomas (combination therapy) | Hodgkin’s disease (combination therapy)

**BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION**

- **Adult:** (consult local protocol)

- **CAUTIONS**
  - Caution in handling—irritant to tissues
  - Interactions → Appendix 1 (dacarbazine).

- **SIDE-EFFECTS**
  - **Rare** Irritant to skin · irritant to tissues · liver necrosis due to hepatic vein thrombosis
  - **Frequency not known** Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · myelosuppression · oral mucositis · severe nausea · severe vomiting · tumour lysis syndrome · vomiting

- **CONCEPTION AND CONTRACEPTION**
  - Ensure effective contraception during and for at least 6 months after treatment in men or women.

- **PREGNANCY**
  - Avoid (carcinogenic and teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING**
  - Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Dose reduction may be required in combined renal and hepatic impairment. Avoid in severe impairment.

- **RENAL IMPAIRMENT**
  - Dose reduction may be required in combined renal and hepatic impairment. Avoid in severe impairment.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Dacarbazine is a component of a commonly used combination for Hodgkin’s disease (ABVD—doxorubicin [previously Adriamycin®], bleomycin, vinblastine, and dacarbazine).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Powder for solution for injection**
  - **Dacarbazine (as Dacarbazine citrate) 100 mg** Dacarbazine 100mg powder for solution for injection vials | 10 vial [PSI] £30.00
  - **Dacarbazine (as Dacarbazine citrate) 200 mg** Dacarbazine 200mg powder for solution for injection vials | 10 vial [PSI] £160.00

- **Powder for solution for infusion**
  - **Dacarbazine (as Dacarbazine citrate) 500 mg** Dacarbazine 500mg powder for solution for infusion vials | 1 vial [PSI] £37.50
  - **Dacarbazine (as Dacarbazine citrate) 1 gram** Dacarbazine 1g powder for solution for infusion vials | 1 vial [PSI] £70.00

Ifosfamide

**INDICATIONS AND DOSE**
Malignant disease

**BY INTRAVENOUS INFUSION**

- **Adult:** (consult local protocol)

- **CONTRA-INDICATIONS**
  - Acute infection · urinary-tract infection · urinary-tract obstruction · urothelial damage

- **CAUTIONS**
  - Avoid in Acute porphyrias p. 864 · diabetes mellitus

- **INTERACTIONS** → Appendix 1 (ifosfamide).

- **SIDE-EFFECTS**
  - **Common or very common** Confusion · disorientation · drowsiness · psychosis · renal toxicity (may lead to tubular dysfunction, Fanconi’s syndrome, or diabetes insipidus) · restlessness · uraemia
  - **Uncommon** Severe encephalopathy
  - **Rare** Anorexia · constipation · convulsions · diarrhoea
  - **Very rare** Jaundice · syndrome of inappropriate antidiuretic hormone secretion · thrombophlebitis · arrhythmias · bone-marrow suppression · extravasation · heart failure · hyperuricaemia · male sterility · nausea · oral mucositis · premature menopause · secondary malignancy · thrombopoemobolism · tumour lysis syndrome · vomiting

Estramustine phosphate

**INDICATIONS AND DOSE**
Prostate cancer

**BY MOUTH**

- **Adult:** Initially 560–840 mg daily in divided doses; maintenance 140–1400 mg daily in divided doses

- **CONTRA-INDICATIONS**
  - Peptic ulceration · severe cardiovascular disease · thromboembolic disorders

- **CAUTIONS**
  - Avoid in Acute porphyrias p. 864 · cardiovascular disease · cerebrovascular disease · conditions which might be aggravated by fluid retention (such as epilepsy or migraine) · congestive heart failure · diabetes · hypercalcaemia · hypertension

- **INTERACTIONS** → Appendix 1 (estramustine).

- **SIDE-EFFECTS**
  - **Rare** Angioedema
  - **Frequency not known** Alopecia · altered endocrine function · altered liver function · bone-marrow suppression · congestive heart failure · diarrhoea · gynaecomastia · hyperuricaemia · impotence · ischaemic heart disease · male sterility · myocardial infarction · nausea · oedema · oral mucositis · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
Secondary malignancy
  - Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

- **CONCEPTION AND CONTRACEPTION**
  - Men should use effective contraceptive methods during treatment.

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises caution.

- **RENAL IMPAIRMENT**
  - Manufacturer advises caution.

- **DIRECTIONS FOR ADMINISTRATION**
  - Each dose should be taken no less than 1 hour before or 2 hours after meals and should not be taken with products containing calcium, magnesium or aluminium, including dairy products and antacid medication.

- **PATIENT AND CARER ADVICE**
  - Patients should be given advice on how to administer estramustine capsules.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - **CAUTIONARY AND ADVISORY LABELS 5, 23**
  - Estracyt (Pfizer Ltd)

  Estramustine phosphate (as Estramustine sodium phosphate) 140 mg Estracyt 140mg capsules | 100 capsule [PSI] £171.28
Malignant disease

SIDE-EFFECTS, FURTHER INFORMATION

**Urethral toxicity** Mesna is routinely given with ifosfamide to reduce urethral toxicity.

**Secondary malignancy** Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during and for at least 6 months after treatment in men or women.

**PREGNANCY** Avoid (teratogenic and carcinogenic in animals). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Avoid.

**RENAL IMPAIRMENT** Avoid if serum creatinine concentration greater than 120 micromol/litre.

**MONITORING REQUIREMENTS** Ensure satisfactory electrolyte balance and renal function before each course (risk of tubular dysfunction, Fanconi’s syndrome or diabetes insipidus if renal toxicity not treated promptly).

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Ifosfamide (Non-proprietary)**
  - Ifosfamide 1 gram Ifosfamide 1g powder for concentrate for solution for injection vials | 1 vial £59.52
  - Ifosfamide 2 gram Ifosfamide 2g powder for concentrate for solution for injection vials | 1 vial £174.32

**Melphanal**

**INDICATIONS AND DOSE**
Multiple myeloma

**BY MOUTH**
- Adult: 150 micrograms/kg daily for 4 days, dose to be repeated every 5 weeks, dose may vary according to regimen

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
- Adult: (consult product literature)

**Polycythaemia vera**

**BY MOUTH**
- Adult: Initially 6–10 mg daily for 5–7 days, then reduced to 2–4 mg daily until satisfactory response, then reduced to 2–6 mg once weekly

Localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities

**BY REGIONAL ARTERIAL PERFUSION**
- Adult: (consult local protocol)

**Important safety information**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745**

**CAUTIONS** Avoid in Acute porphyrias p. 864

**INTERACTIONS** → Appendix 1 (melphanal).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Rare Interstitial pneumonitis, life threatening pulmonary fibrosis

- Frequency not known Alopecia, bone-marrow suppression (delayed), hyperuricaemia, male sterility, nausea, oral mucositis, permanent bone marrow damage (with prolonged use), premature menopause, secondary malignancy, thromboembolism, tumour lysis syndrome, vomiting

**SPECIFIC SIDE-EFFECTS**

- With intravenous use extravasation

**SIDE-EFFECTS, FURTHER INFORMATION**
Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during treatment in men or women.

**PREGNANCY** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**RENAL IMPAIRMENT** Reduce dose initially (consult product literature).

**MONITORING REQUIREMENTS** Monitor full blood count before and throughout treatment.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**SIDE-EFFECTS, FURTHER INFORMATION**

**MEDICINES, see p. 745**

**Important safety information**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745**

**CAUTIONS** Avoid in Acute porphyrias p. 864

**INTERACTIONS** → Appendix 1 (melphanal).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Rare Interstitial pneumonitis, life threatening pulmonary fibrosis

- Frequency not known Alopecia, bone-marrow suppression (delayed), hyperuricaemia, male sterility, nausea, oral mucositis, permanent bone marrow damage (with prolonged use), premature menopause, secondary malignancy, thromboembolism, tumour lysis syndrome, vomiting

**SPECIFIC SIDE-EFFECTS**

- With intravenous use extravasation

**SIDE-EFFECTS, FURTHER INFORMATION**
Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during treatment in men or women.

**PREGNANCY** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**RENAL IMPAIRMENT** Reduce dose initially (consult product literature).

**MONITORING REQUIREMENTS** Monitor full blood count before and throughout treatment.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.
Temozolomide may be considered for the treatment of recurrent malignant glioma, which has not responded to first-line chemotherapy. www.nice.org.uk/TA23
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (June 2007) NICE TA121
Temozolomide is an option for the treatment of newly diagnosed glioblastoma multiforme in patients with a WHO performance status of 0 or 1. www.nice.org.uk/TA121
RENAL IMPAIRMENT
BREAST FEEDING

Thiotepa
INDICATIONS AND DOSE
Conditioning treatment before haematopoietic stem cell transplantation in the treatment of haematological disease or solid tumours, in combination with other chemotherapy
BY INTRAVENOUS INFUSION
Adult: (consult local protocol)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
Capsule
CAUTIONARY AND ADVISORY LABELS 23, 25
TEMZOLOMIDE (Non-proprietary)
Temozolomide 5 mg Temozolomide 5mg capsules | 5 capsule £10.58–£11.30
Temozolomide 20 mg Temozolomide 20mg capsules | 5 capsule £65.20
Temozolomide 100 mg Temozolomide 100mg capsules | 5 capsule £346.00
Temozolomide 140 mg Temozolomide 140mg capsules | 5 capsule £296.47–£484.40
Temozolomide 180 mg Temozolomide 180mg capsules | 5 capsule £381.18–£622.80
Temozolomide 250 mg Temozolomide 250mg capsules | 5 capsule £529.42–£865.00
Temodal (Merck Sharp & Dohme Ltd)
Temozolomide 5 mg Temodal 5mg capsules | 5 capsule £10.59 (Hospital only)
Temozolomide 20 mg Temodal 20mg capsules | 5 capsule £42.35 (Hospital only)
Temozolomide 100 mg Temodal 100mg capsules | 5 capsule £221.77 (Hospital only)
Temozolomide 140 mg Temodal 140mg capsules | 5 capsule £296.48 (Hospital only)
Temozolomide 180 mg Temodal 180mg capsules | 5 capsule £381.19 (Hospital only)
Temozolomide 250 mg Temodal 250mg capsules | 5 capsule £529.43 (Hospital only)
Brands may include Temodar
Malignant disease

Powder for solution for infusion

- **Tepadina** (Adienne Pharma & Biotech)
  - Thiopeta 15 mg Tepadina 15mg powder for concentrate for solution for infusion vials | 1 vial $P39 no price available
  - Thiopeta 100 mg Tepadina 100mg powder for concentrate for solution for infusion vials | 1 vial $P39 no price available

**Treosulfan**

**INDICATIONS AND DOSE**

- **Ovarian cancer**
  - **BY MOUTH OR BY INTRAVENOUS INJECTION OR BY INTRAPERITONEAL INSTILLATION**
  - **Adult:** (consult product literature)

**Important safety information**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**, see p. 745

- **CAUTIONS** Avoid in Acute porphyrias, p. 864
- **SIDE-EFFECTS**
  - **Common or very common** Skin pigmentation
  - **Rare** Allergic alveolitis, haemorrhagic cystitis, pulmonary fibrosis
  - **Frequency not known** Alopecia, bone-marrow suppression, extravasation of intravenous drugs, hyperuricaemia, nausea, oral mucositis, pulmonary fibrosis, Premature menopause, secondary malignancy, thromboembolism, tumour lysis syndrome, vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Secondary malignancy: Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukemia.
- **PREGNANCY** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

*CAUTIONARY AND ADVISORY LABELS 25*

- **TREOSULFAN (Non-proprietary)**
  - **Treosulfan 250 mg** Treosulfan 250mg capsules | 100 capsule $P39 £622.10

**Powder for solution for injection**

- **TREOSULFAN (Non-proprietary)**
  - **Treosulfan 1 gram** Treosulfan 1g powder for solution for injection vials | 5 vial $P39 £256.35
  - **Treosulfan 5 gram** Treosulfan 5g powder for solution for injection vials | 5 vial $P39 £990.64

**ANTHRACYCLINES**

**Daunorubicin**

**INDICATIONS AND DOSE**

- **Acute myelogenous leukaemia** | **Acute lymphocytic leukaemia**
  - **BY INTRAVENOUS INFUSION**
    - **Adult:** (consult local protocol)
    - **Advanced AIDS-related Kaposi’s sarcoma (liposomal formulation only)**
     - **BY INTRAVENOUS INFUSION**
     - **Adult:** (consult product literature)

- **CONTRA-INDICATIONS** Myocardial insufficiency, previous treatment with maximum cumulative doses of daunorubicin or other anthracycline, recent myocardial infarction, severe arrhythmia

- **CAUTIONS** Caution in handling—irritant to tissues
- **INTERACTIONS** Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility. Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.
- **SIDE-EFFECTS** Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Cardiotoxicity** All anthracycline antibiotics have been associated with varying degrees of cardiac toxicity—this may be idiosyncratic and reversible, but is commonly related to total cumulative dose and is irreversible
- **PREGNANCY** Avoid (teratogenic and carcinogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Reduce dose according to serum bilirubin concentration—consult local protocol for details.
- **Avoid in severe impairment.
- **RENAL IMPAIRMENT** Reduce dose by 25% if serum creatinine 105–265 micromol/litre. Reduce dose by 50% if serum creatinine greater than 265 micromol/litre. Avoid in severe impairment.
- **MONITORING REQUIREMENTS** Cardiac monitoring essential.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- **DAUNORUBICIN (Non-proprietary)**
  - Daunorubicin (as Daunorubicin hydrochloride) 20 mg Daunorubicin 20mg powder for solution for infusion vials | 10 vial $P39 £550.00 (Hospital only)

**Emulsion for infusion**

- **DaunoXome (Galen Ltd)**
  - Daunorubicin (as Daunorubicin hydrochloride citrate) 50 mg DaunoXome 50mg emulsion for infusion vials | 1 vial $P39 £131.75

**Doxorubicin hydrochloride**

**INDICATIONS AND DOSE**

- **Acute leukaemias** | **Hodgkin’s lymphoma** | **Non-Hodgkin’s lymphoma** | **Some solid tumours including breast cancer**

- **BY INTRAVENOUS INJECTION**
  - Adult: (consult product literature)
  - Some papillary bladder tumours (bladder instillation)
  - Recurrent superficial bladder tumours (bladder instillation)
  - Transitional cell carcinoma (bladder instillation)
  - Carcinoma in situ (bladder instillation)

- **BY INTRAVESICAL INSTILLATION**
  - Adult: (consult product literature)
Caelyx®
For AIDS-related Kaposis’s sarcoma in patients with low CD4 count and extensive mucocutaneous or visceral disease | Advanced ovarian cancer when platinum-based chemotherapy has failed | Progressive multiple myeloma (in combination with bortezomib) in patients who have received at least one prior therapy and who have undergone or are unsuitable for bone-marrow transplantation | Monotherapy for metastatic breast cancer in patients with increased cardiac risk

By intravenous infusion
- Adult: (consult product literature)

MYOCET®
For use with cyclophosphamide for metastatic breast cancer
- Adult: (consult product literature)

- CONTRA-INDICATIONS Consult product literature
- CAUTIONS Cardiac disease · caution in handling—irritant to tissues · consult product literature · elderly · hypotension · previous myocardial infarction
- INTERACTIONS → Appendix 1 (doxorubicin).
  Caution is necessary with concomitant use of cardiotonic drugs, or drugs that reduce cardiac contractility. Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.

- SIDE-EFFECTS
  - Common or very common Dehydration · diarrhoea · red colouration of the urine
  - Uncommon Supraventricular tachycardia (related to drug administration)
  - Frequency not known Alopecia · bone-marrow suppression · cardiomyopathy (with higher cumulative doses) · consult product literature · extravasation · heart failure (potentially fatal) · hyperuricaemia · nausea · oral mucositis · renal damage · thromboembolism · tumour lysis syndrome · vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Extravasation Extravasation can cause severe tissue necrosis.
Cardiomyopathy Higher cumulative doses are associated with cardiomyopathy and it is usual to limit total cumulative doses to 450 mg/m² because symptomatic and potentially fatal heart failure is common above this dose.
Cardiotoxic Some evidence suggests that weekly low-dose administration may be less cardiotoxic.

Liposomal formulations Liposomal formulations of doxorubicin may reduce the incidence of cardiotoxicity and lower the potential for local necrosis, but infusion reactions, sometimes severe, may occur. Hand-foot syndrome (painful, macular reddening skin eruptions) occurs commonly with liposomal doxorubicin and may be dose limiting. It can occur after 2–3 treatment cycles and may be prevented by cooling hands and feet and avoiding socks, gloves, or tight-fitting footwear for 4–7 days after treatment.

Elevated bilirubin concentration Doxorubicin is largely excreted in the bile and an elevated bilirubin concentration is an indication for reducing the dose.

- CONCEPTION AND CONTRACEPTION Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.

- PREGNANCY Avoid (teratogenic and toxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- BREAST FEEDING Discontinue breast-feeding.

- HEPATIC IMPAIRMENT Reduce dose according to bilirubin concentration—consult product literature or local treatment protocol for details. Avoid in severe impairment.

- RENAL IMPAIRMENT Consult product literature in severe impairment.

- MONITORING REQUIREMENTS Patients should be assessed before treatment, by echocardiography. Cardiac monitoring during treatment may assist in determining safe dosage.

- DIRECTIONS FOR ADMINISTRATION Conventional doxorubicin is given by injection into a fast-running infusion, commonly at 21-day intervals.

- PRESCRIBING AND DISPENSING INFORMATION Doxorubicin is available as both conventional and liposomal formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.

- NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005) NICE TA91
  Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy. Paclitaxel alone is an option for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy.

Pegylated liposomal doxorubicin is an option for advanced ovarian cancer that does not respond to, or relapses within 12 months of completing initial platinum-based chemotherapy. Pegylated liposomal doxorubicin are options for advanced ovarian cancer in patients who are allergic to platinum compounds. Topotecan alone is an option only for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy or in those allergic to platinum compounds and for whom paclitaxel alone or pegylated liposomal doxorubicin are inappropriate.

www.nice.org.uk/TA91

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

Solution for injection
- DOXORUBICIN HYDROCHLORIDE (Non-proprietary)
  Doxorubicin hydrochloride 2 mg per 1 ml Doxorubicin 10mg/5ml solution for injection vials | 1 vial (£95) £18.54 (Hospital only) Doxorubicin 50mg/25ml solution for injection Cytosafe vials | 1 vial (£95) £50.00 Doxorubicin 50mg/25ml solution for infusion vials | 1 vial (£95) £103.00 (Hospital only) Doxorubicin 10mg/5ml solution for injection Cytosafe vials | 1 vial (£95) £20.60 Doxorubicin 10mg/5ml concentrate for solution for infusion vials | 1 vial (£95) no price available Doxorubicin 10mg/5ml solution for infusion vials | 1 vial (£95) £20.60 (Hospital only) Doxorubicin 50mg/25ml solution for injection vials | 1 vial (£95) £92.70 (Hospital only) Doxorubicin 50mg/25ml concentrate for solution for infusion vials | 1 vial (£95) no price available

- Powder for solution for injection
  - Doxorubicin (medac UK)
    Doxorubicin hydrochloride 10 mg Doxorubicin 10mg powder for solution for injection vials | 10 vial (£92) £182.80
    Doxorubicin hydrochloride 50 mg Doxorubicin 50mg powder for solution for injection vials | 10 vial (£92) £914.00

Solution for infusion
- DOXORUBICIN HYDROCHLORIDE (Non-proprietary)
  Doxorubicin hydrochloride 2 mg per 1 ml Doxorubicin 200mg/100ml solution for injection Cytosafe vials | 1 vial (£70) £412.00
Epirubicin hydrochloride

INDICATIONS AND DOSE
Treatment of breast cancer | Treatment and prophylaxis of certain forms of superficial bladder cancer
BY INTRAVENOUS INFUSION OR BY INTRAVESICAL INSTILLATION
→ Adult: (consult product literature or local protocols)

• CONTRA-INDICATIONS Bladder inflammation or contraction (when used as a bladder instillation) - catheterisation difficulties (when used as a bladder instillation) - haematuria (when used as a bladder instillation) - invasive tumours penetrating the bladder (when used as a bladder instillation) - myocardialopathy - previous treatment with maximum cumulative doses of epirubicin or other anthracycline - recent myocardial infarction - severe arrhythmia - severe myocardial insufficiency - unstable angina - urinary tract infections (when used as a bladder instillation)

• CAUTIONS Caution in handling—irritant to tissues

• INTERACTIONS → Appendix 1 (epirubicin). Caution is necessary with concomitant use of cardio toxic drugs, or drugs that reduce cardiac contractility. Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.

• SIDE-EFFECTS Alopecia - bone-marrow suppression - cardiotoxicity - extravasation - hyperpigmentation of nails - hyperpigmentation of oral mucosa - hyperpigmentation of skin - hyperuricaemia - nausea - oral mucositis - red colouration of the urine - thromboembolism - tumour lysis syndrome - vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Cardiotoxicity A maximum cumulative dose of 0.9–1 g/m² is recommended to help avoid cardiotoxicity.

• PREGNANCY Avoid (carcinogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

• BREAST FEEDING Discontinue breast-feeding.

• HEPATIC IMPAIRMENT Reduce dose according to bilirubin concentration—consult local treatment protocol for details. Avoid in severe impairment.

• RENAL IMPAIRMENT Dose reduction may be necessary in severe impairment.

• MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for infusion

Solution for injection
→ EPIRUBICIN HYDROCHLORIDE (Non-proprietary)
Epirubicin hydrochloride 2 mg per 1 ml Epirubicin 10mg/5ml solution for injection vials | 1 vial (POM) £12.24 Epirubicin 50mg/25ml solution for injection vials | 1 vial (POM) £10.88

Pharmonubicin (Pfizer Ltd)
Epirubicin hydrochloride 2 mg per 1 ml Pharmonubicin 50mg/25ml solution for injection Cytosafe vials | 1 vial (POM) £110.19 Pharmonubicin 10mg/5ml solution for injection Cytosafe vials | 1 vial (POM) £21.24

Solution for infusion
→ EPIRUBICIN HYDROCHLORIDE (Non-proprietary)
Epirubicin hydrochloride 2 mg per 1 ml Epirubicin 200mg/100ml solution for infusion vials | 1 vial (POM) £386.16 Epirubicin 100mg/50ml solution for infusion vials | 1 vial (POM) £169.92

Pharmonubicin (Pfizer Ltd)
Epirubicin hydrochloride 2 mg per 1 ml Pharmonubicin 200mg/100ml solution for infusion Cytosafe vials | 1 vial (POM) £386.16

Idarubicin hydrochloride

INDICATIONS AND DOSE
Acute non-lymphocytic leukaemias monotherapy
BY MOUTH
→ Adult: 30 mg/m² daily for 3 days; maximum 400 mg/m² per course

Acute non-lymphocytic leukaemia in combination therapy
BY MOUTH
→ Adult: 15–30 mg/m² daily for 3 days; maximum 400 mg/m² per course

Advanced breast cancer after failure of first-line chemotherapy (not including anthracyclines)–monotherapy
BY MOUTH
→ Adult: 45 mg/m² for 1 dose, repeat treatment every 3–4 weeks, alternatively 15 mg/m² daily for 3 consecutive days, repeat treatment every 3–4 weeks; maximum 400 mg/m² per course

Acute leukaemias | Advanced breast cancer after failure of first-line chemotherapy (not including anthracyclines)
BY INTRAVENOUS INJECTION
→ Adult: (consult product literature)

Important safety information
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

• CONTRA-INDICATIONS Previous treatment with maximum cumulative dose of idarubicin or other anthracycline - recent myocardial infarction - severe arrhythmias - severe myocardial insufficiency

• CAUTIONS Caution in handling—irritant to tissues

• INTERACTIONS → Appendix 1 (idarubicin). Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.

• SIDE-EFFECTS

GENERAL SIDE-EFFECTS
→ Common or very common Abdominal pain - cardiac disorders - diarrhoea - haemorrhage - rash - red pigmentation of the urine
→ Uncommon Nail hyperpigmentation - skin hyperpigmentation
Azacitidine

**DRUG ACTION** Azacitidine is a pyrimidine analogue.

**INDICATIONS AND DOSE**

Treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia, in adults who are not eligible for haematoopoietic stem cell transplantation

**BY SUBCUTANEOUS INJECTION**

Adult: (consult local protocol)

**CONTRA-INDICATIONS** Advanced malignant hepatic tumour

**CAUTIONS** History of severe congestive heart failure - unstable cardiac disease (consider cardiopulmonary assessment before and during treatment) - unstable pulmonary disease (consider cardiopulmonary assessment before and during treatment)

**SIDE-EFFECTS**

- Uncommon Anaphylactic reactions - hypersensitivity reactions
- Frequency not known Alopecia - bone-marrow suppression - extravasation - hepatic coma - hepatic failure - hyperuricaemia - nausea - oral mucositis - renal failure - thromboembolism - tumour lysis syndrome - vomiting

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for 3 months after treatment in men or women.

**PREGNANCY** Avoid (teratogenic and toxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746:

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Caution in severe impairment.

**RENAL IMPAIRMENT** Delay next treatment cycle if serum-creatinine or blood urea nitrogen greater than twice baseline value and above the upper level of normal until values return to normal or baseline, and then reduce dose by 50% on the next treatment cycle. Reduce dose by 50% on the next treatment cycle if serum-bicarbonate concentration less than 20 mmol/litre.

**MONITORING REQUIREMENTS**

- Monitor liver function tests, serum creatinine, and serum bicarbonate before initiation of treatment and before each treatment cycle.
- Monitor full blood count before initiation of treatment, before each treatment cycle, and as clinically indicated.
- Monitor for bleeding.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

- Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (March 2011) NICE TA218

Azacitidine is recommended in adults who are not eligible for haematoopoietic stem cell transplantation as an option for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia, or acute myeloid leukaemia. www.nice.org.uk/TA218

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

CAUTIONARY AND ADVISORY LABELS 25

- Zavedos (Pfizer Ltd)
  - Idarubicin hydrochloride 5 mg Zavedos 5mg capsules | 1 capsule £41.47
  - Idarubicin hydrochloride 10 mg Zavedos 10mg capsules | 1 capsule £66.12

**Solution for injection**

- IDARUBICIN HYDROCHLORIDE (Non-proprietary)
  - Idarubicin hydrochloride 1 mg per 1 ml Idarubicin 1mg/1ml solution for injection vials | 1 vial £165.98
  - Idarubicin 5mg/5ml solution for injection vials | 1 vial £82.99–£87.36

**Powder for solution for injection**

- Zavedos (Pfizer Ltd)
  - Idarubicin hydrochloride 5 mg Zavedos 5mg powder for solution for injection vials | 1 vial £174.72
  - Idarubicin hydrochloride 10 mg Zavedos 10mg powder for solution for injection vials | 1 vial £360.00

Capecitabine

**DRUG ACTION** Capecitabine is metabolised to fluorouracil.

**INDICATIONS AND DOSE**

Stage III colon cancer, adjuvant following surgery (monotherapy)

**BY MOUTH**

- Adult: 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability—consult product literature

Stage III colon cancer, adjuvant following surgery (combination therapy)

**BY MOUTH**

- Adult: 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability—consult product literature

Metastatic colorectal cancer (monotherapy)

**BY MOUTH**

- Adult: 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature
### Metastatic colorectal cancer (combination therapy)

**BY MOUTH**
- Adult: 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature

**Advanced gastric cancer (first-line treatment in combination with a platinum based regimen)**
- Adult: 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, alternatively 625 mg/m² twice daily given continuously, adjust dose according to tolerability—consult product literature

**Locally advanced or metastatic breast cancer (second-line treatment as monotherapy after failure of a taxane and anthracycline regimen or where further anthracycline treatment as monotherapy after failure of a taxane and anthracycline regimen is not indicated)** Locally advanced or metastatic breast cancer (second-line treatment, in combination with docetaxel, where previous therapy included an anthracycline)
- Adult: 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature

#### CONTRA-INDICATIONS
Diaphyromyridine dehydrogenase deficiency

#### CAUTIONS
- Diabetes mellitus, diarrhoea or dehydration—consult product literature for guidance on dose modification and treatment interruption—electrolyte disturbances—history of angina pectoris—history of arrhythmias—history of significant cardiovascular disease—nervous system disease

#### INTERACTIONS
Appendix 1 (capecitabine).

#### SIDE-EFFECTS
- Alopecia—bone-marrow suppression—hyperuricaemia—nausea—oral mucositis—thrombocytopenia—tumour lysis syndrome—vomiting

#### SIDE-EFFECTS, FURTHER INFORMATION
For further information on side-effects, consult product literature

#### PREGNANCY
Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

#### BREAST FEEDING
Discontinue breast-feeding.

#### HEPATIC IMPAIRMENT
Manufacturer advises monitor liver function in mild to moderate impairment—consult product literature for guidance on treatment interruption; avoid in severe impairment.

#### RENAL IMPAIRMENT
Reduce starting dose of 1.25 g/m² to 75% if creatinine clearance 30–50 mL/minute. Avoid if creatinine clearance less than 30 mL/minute.

#### MONITORING REQUIREMENTS
- Severe skin reactions Monitor for symptoms of severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis)—permanently discontinue treatment immediately if symptoms occur.
- Hand-foot syndrome Monitor for symptoms of hand-foot syndrome—interrupt treatment if significant syndrome occurs and refer to product literature.
- Monitor plasma–calcium concentration.
- Monitor for eye disorders (including keratitis and corneal disorders).

#### NATIONAL FUNDING/ACCESS DECISIONS
**NICE technology appraisals (TAs)**
- Capecitabine and tegafur for uracil for metastatic colorectal cancer (May 2003) NICE TA61
- Capecitabine or tegafur with uracil (now discontinued) in combination with folinic acid is an option for the first-line treatment of metastatic colorectal cancer. www.nice.org.uk/TA61

- Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006) NICE TA100
- Capecitabine alone or oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes’ C) colon cancer. www.nice.org.uk/TA100

- Capecitabine for the treatment of advanced gastric cancer (July 2010) NICE TA191
- Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer. www.nice.org.uk/TA191

- Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010) NICE TA212
- Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is not recommended for the treatment of metastatic colorectal cancer. www.nice.org.uk/TA212

- Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) NICE TA263
- Bevacizumab in combinations with capecitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months. www.nice.org.uk/TA263

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **CAPECITABINE (Non-proprietary)**
  - Capecitabine 150 mg | 60 tablet [PPh £46.02 (Hospital only)] | 60 tablet [PPh £39.99]
  - Capecitabine 300 mg | 300 tablet [PPh £39.99 | 60 tablet [PPh £54.00]
  - Capecitabine 500 mg | 500 tablet [PPh £265.55 (Hospital only)] | 120 tablet [PPh £265.00]

- **Xeloda (Roche Products Ltd)**
  - Capecitabine 150 mg | 150mg tablets | 60 tablet [PPh £40.02]
  - Capecitabine 500 mg | 500mg tablets | 120 tablet [PPh £265.55]

#### Cladribine

**INDICATIONS AND DOSE**

**LITAK®**

**Hairy cell leukaemia**

**BY SUBCUTANEOUS INJECTION**

- Adult: (consult product literature or local protocols)

**LEUSTAT®**

**B-cell chronic lymphocytic leukaemia in patients who have failed to respond to standard regimens containing an alkylating agent** Hairy cell leukaemia

**BY INTRAVENOUS INFUSION**

- Adult: (consult product literature or local protocols)

#### CAUTIONS
Use irradiated blood only

**CAUTIONS, FURTHER INFORMATION**

Immunosuppressive effect of cladribine Cladribine has a potent and prolonged immunosuppressive effect. Patients treated with cladribine are more prone to serious bacterial, opportunistic fungal, and viral infections, and prophylactic therapy is recommended in those at risk. To prevent potentially fatal transfusion-related graft-versus-host reaction, only irradiated blood products should be
administered. Prescribers should consult specialist literature when using highly immunosuppressive drugs.

- **INTERACTIONS** → Appendix 1 (cladribine).
- **SIDE-EFFECTS** Abdominal pain, acute renal failure (with high doses) - alopecia - anxiety - arthralgia - asthma - bone-marrow suppression - chills - constipation - cough - diarrhoea - dizziness - dyspnoea - extravasation - flatulence - haemolytic anaemia - headache - hyperuricaemia - insomnia - malaise - myalgia - nausea - oedema - oral mucositis - pruritus - purpura - rash - severe myelosuppression (with neutropenia, anaemia and thrombocytopenia) - severe neurotoxicity (with high doses) - sweating - tachycardia - thromboembolism - tumour lysis syndrome - vomiting

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises that men should not father children during and for 6 months after treatment.
- **PREGNANCY** Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Regular monitoring recommended in hepatic impairment.
- **RENAL IMPAIRMENT** Regular monitoring recommended in renal impairment.
- **DIRECTIONS FOR ADMINISTRATION** Litak® for subcutaneous use only — no dilution required.

### Cytarabine

#### INDICATIONS AND DOSE

**Induction of remission of acute myeloblastic leukaemia**

- **BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION**
  - Adult: (consult local protocol)
  - Lymphomatous meningitis
    - **BY INTRATHECAL INJECTION**
    - Adult: (consult local protocol)

#### Important safety information

Not all cytarabine preparations can be given by intrathecal injection — consult product literature.

#### INTERACTIONS → Appendix 1 (cytarabine).

#### SIDE-EFFECTS

- Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting
- **PREGNANCY** Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Reduce dose — consult product literature.
- **MONITORING REQUIREMENTS** Cytarabine is a potent myelosuppressant and requires careful haematological monitoring.

#### NATIONAL FUNDING/ACCESS DECISIONS

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (July 2007) that liposomal cytarabine suspension (DepoCyt®) is not recommended for use within NHS Scotland for the intrathecal treatment of lymphomatous meningitis.

### Clofarabine

#### INDICATIONS AND DOSE

**Relapsed or refractory acute lymphoblastic leukaemia in patients who have received at least two previous regimes by INTRAVENOUS INFUSION**

- Adult 18-20 years: (consult local protocol)

#### IMPORTANT SAFETY INFORMATION

- **CAUTIONS** Cardiac disease
- **PREGNANCY** Manufacturer advises avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **ELECTROLYTES:** May contain Sodium
- **DepoCyt®**
  - Cytarabine 1 mg per 1 ml Evoltra 20mg/20ml concentrate for solution for infusion vials | 4 vial (£93) £3,304.72 (Hospital only)

**Solution for injection**

- **CYTARABINE (Non-proprietary)**
  - Cytarabine 200 mg per 1 ml Evoltra 500mg/25ml solution for injection vials | 1 vial (£39) £135.00
  - Cytarabine 100 mg per 1 ml Evoltra 250mg/12.5ml solution for injection vials | 5 vial (£32) £60.98–£30.00
  - Cytarabine 20 mg per 1 ml Evoltra 200mg/10ml solution for injection vials | 5 vial (£10) £78.00–£40.00
  - Cytarabine 10 mg per 1 ml Evoltra 100mg/5ml suspension for injection vials | 1 vial (£40) no price available (Hospital only)
Decitabine

- **DRUG ACTION** Decitabine is a pyrimidine analogue.

**INDICATIONS AND DOSE**

Treatment of newly diagnosed acute myeloid leukaemia in patients over 65 years of age who are not candidates for standard induction chemotherapy

- **BY INTRAVENOUS INFUSION**
  - Elderly: (consult local protocol)

- **CAUTIONS**
  - History of severe congestive heart failure
  - History of unstable cardiac disease

- **INTERACTIONS** → Appendix 1 (decitabine).

**SIDE-EFFECTS**

- Common or very common Diarrhoea · epistaxis · headache
- Uncommon Acute febrile neutrophilic dermatosis
- Frequency not known Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

**PREGNANCY** Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution—no information available.

**RENAL IMPAIRMENT**

Manufacturer advises caution if creatinine clearance less than 30 mL/minute—no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Powder for solution for infusion**
  - **ELECTROLYTES:** May contain Potassium, sodium
  - **Dacogen** (Janssen-Cilag Ltd)
    - Decitabine 50 mg Dacogen 50mg powder for concentrate for solution for infusion vials (1 vial PIP 1970.86)

---

Fludarabine phosphate

**INDICATIONS AND DOSE**

Initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL) or after first line treatment in patients with sufficient bone marrow reserves

- **BY MOUTH**
  - Adult: 40 mg/m² for 5 days every 28 days, usually given for 6 cycles

- **BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

**SIDE-EFFECTS**

- Common or very common Acute myeloid leukaemia · anorexia · chills · cough · diarrhoea · fever · immunosupression · malaise · myelodysplastic syndrome · myelosuppression (may be cumulative) · oedema · peripheral neuropathy · pneumonia · rash · visual disturbances · weakness

- Uncommon Autoimmune disorder · confusion · fibrosis · haemorrhage · immune-mediated haemolytic anaemia · neutropenia · pneumonitis · pulmonary toxicity · thrombocytopenia

- Rare Agitation · arthralgia · blindness · coma · heart failure · optic neuropathy · seizures · skin cancer · Stevens–Johnson syndrome · toxic epidermal necrolysis

- Frequency not known Alopecia · bone-marrow suppression · extravasation · haemorrhagic cystitis · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.

**PREGNANCY**

Avoid (embryotoxic and teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**

Discontinue breast-feeding.

**RENAL IMPAIRMENT**

Reduce dose by up to 50% if creatinine clearance 30–70 mL/minute. Avoid if creatinine clearance less than 30 mL/minute.

**MONITORING REQUIREMENTS**

- Monitor for signs of haemolysis.
- Monitor for neurological toxicity.
- Assess creatinine clearance in patients over 65 years before treatment initiation.

**DIRECTIONS FOR ADMINISTRATION** Concentrate for intravenous injection or infusion must be diluted before administration (consult product literature).

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**
  - Fludarabine for the treatment of B-cell chronic lymphocytic leukaemia (September 2001) NICE TA29
    - Oral fludarabine is recommended for the second-line treatment of B-cell chronic lymphocytic leukaemia in patients who have either failed, or are intolerant of, first line chemotherapy, and who would otherwise have received combination chemotherapy of either:
      - cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
      - cyclophosphamide, doxorubicin and prednisolone (CAP)
    - In patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) when the patient has disease-related symptoms or evidence of progressive disease.

- Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (February 2007) NICE TA119
  - Fludarabine monotherapy is not recommended for the first-line treatment of chronic lymphocytic leukaemia.

- [Scottish Medicines Consortium (SMC) Decisions](www.nice.org.uk/TA29)

  - The Scottish Medicines Consortium has advised (October 2006) that fludarabine is accepted for restricted use for the treatment of B-cell chronic lymphocytic leukaemia (CLL) in patients with sufficient bone marrow reserves.
  - First-line treatment should only be initiated in patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease-related symptoms or evidence of progressive disease.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
### Florouracil

**INDICATIONS AND DOSE**

Treatment of some solid tumours including gastro-intestinal tract cancers and breast cancer in combination with folic acid in advanced colorectal cancer.

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION OR BY INTRA-ARTERIAL INFUSION**

- **Adult:** (consult product literature)
- **INTERACTIONS** → Appendix 1 (fluorouracil).
- **SIDE-EFFECTS**
  - **Rare** Cerebellar syndrome
  - **Frequency not known** Alopecia, bone-marrow suppression, desquamative hand-foot syndrome (on prolonged infusion), extravasation, hyperuricaemia, mucositis, myelosuppression, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting
- **PREGNANCY**
  - Avoid (teratogenic). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution.
- **HANDLING AND STORAGE** Caution in handling—irritant to tissues.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **FLUOROURACIL (Non-proprietary)**
  - Fluorouracil (as Fluorouracil sodium) 25 mg per 1 ml
  - Fluorouracil 500mg/20ml solution for injection vials | 1 vial (£3) £64.00
  - Fluorouracil 25mg/2ml solution for injection vials | 1 vial (£3) £110.42
  - Fluorouracil 50mg/2ml concentrate for solution for injection vials | 1 vial (£3) £156.00

**Solution for infusion**

- **FLUOROURACIL (Non-proprietary)**
  - Fluorouracil (as Fluorouracil sodium) 25 mg per 1 ml
  - Fluorouracil 5g/100ml solution for infusion vials | 1 vial (£3) £64.00
  - Fluorouracil (as Fluorouracil sodium) 50 mg per 1 ml
  - Fluorouracil 2.5g/50ml solution for infusion vials | 1 vial (£3) £32.00

---

### Gemcitabine

**INDICATIONS AND DOSE**

First-line treatment for locally advanced or metastatic non-small cell lung cancer (as monotherapy in elderly patients and in palliative treatment; otherwise in combination with cisplatin). Treatment of locally advanced or metastatic pancreatic cancer. Treatment of advanced or metastatic bladder cancer (in combination with cisplatin).

**Treatment of locally advanced or metastatic epithelial ovarian cancer** which has relapsed after a recurrence-free interval of at least 6 months following previous platinum-based therapy (in combination with carboplatin).

**Treatment of metastatic breast cancer** which has relapsed after previous chemotherapy including an anthracycline (in combination with paclitaxel).

**BY INTRAVENOUS INFUSION**

- **Adult:** (consult local protocol)

- **INTERACTIONS** → Appendix 1 (gemcitabine).
- **SIDE-EFFECTS**
  - **Rare** Haemolytic uraemic syndrome
  - **Frequency not known** Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, influenza-like symptoms, microangiopathic haemolytic anaemia, mild gastrointestinal side-effects, musculoskeletal pain, nausea, oral mucositis, pulmonary toxicity, rash, renal impairment, thromboembolism, tumour lysis syndrome, vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Microangiopathic haemolytic anaemia. Gemcitabine should be discontinued if signs of microangiopathic haemolytic anaemia occur.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.

**PREGNANCY** Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Manufacturer advises caution.

**RENAL IMPAIRMENT** Manufacturer advises caution.

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**
  - Gemcitabine is an option for first-line chemotherapy for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky score of at least 50 [Karnofsky score is a measure of the ability to perform ordinary tasks].
  - Gemcitabine is not recommended for patients who can have potentially curative surgery. There is insufficient evidence about its use for second-line treatment of pancreatic adenocarcinoma. www.nice.org.uk/TA25

- **Gemcitabine for the treatment of metastatic breast cancer (January 2007) NICE TA116**
  - Gemcitabine, in combination with paclitaxel, is an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capcitabine are also considered appropriate. www.nice.org.uk/TA116

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (November 2006) that gemcitabine is accepted for restricted use for the treatment of metastatic breast cancer, which has relapsed following previous chemotherapy including an anthracycline (unless contra-indicated).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Solution for infusion

▶ GEMCITABINE (Non-proprietary)
Gemcitabine (as Gemcitabine hydrochloride)
200 mg Gemcitabine 200mg/5.3ml concentrate for solution for infusion vials | 1 vial £32.00
Gemcitabine 200mg/2ml concentrate for solution for infusion vials | 1 vial £32.00
Gemcitabine (as Gemcitabine hydrochloride) 1 gram Gemcitabine 1g/26.3ml concentrate for solution for infusion vials | 1 vial £162.00

Powder for solution for infusion

▶ GEMCITABINE (Non-proprietary)
Gemcitabine (as Gemcitabine hydrochloride)
200 mg Gemcitabine 200mg powder for solution for infusion vials | 1 vial £32.00
Gemcitabine (as Gemcitabine hydrochloride) 1 gram Gemcitabine 1g powder for solution for infusion vials | 1 vial £162.00
Gemcitabine (as Gemcitabine hydrochloride) 1.5 gram Gemcitabine 1.5g powder for solution for infusion vials | 1 vial £233.93
Gemcitabine (as Gemcitabine hydrochloride) 2 gram Gemcitabine 2g powder for solution for infusion vials | 1 vial £324.00
Gemzar (Eli Lilly and Company Ltd)
Gemcitabine (as Gemcitabine hydrochloride) 200 mg Gemzar 200mg powder for solution for infusion vials | 1 vial £32.55
Gemcitabine (as Gemcitabine hydrochloride) 1 gram Gemzar 1g powder for solution for infusion vials | 1 vial £162.76

Mercaptopurine

(6-Mercaptopurine)

INDICATIONS AND DOSE
Severe acute Crohn’s disease | Maintenance of remission of Crohn’s disease | Ulcerative colitis
BY MOUTH
> Adult: 1–1.5 mg/kg daily, some patients may respond to lower doses
Acute leukaemias | Chronic myeloid leukaemia
BY MOUTH USING TABLETS
> Adult: Initially 2.5 mg/kg daily, adjusted according to response, alternatively initially 50–75 mg/m² daily, adjusted according to response
> BY MOUTH USING ORAL SUSPENSION
> Adult: Initially 25–75 mg/m² daily, adjusted according to response

Dose equivalence and conversion
Mercaptopurine tablets and Xaluprine® oral suspension are not bioequivalent, haematological monitoring is advised when switching formulations.

UNLICENSED USE
Not licensed for use in severe ulcerative colitis and Crohn’s disease.

Important safety information
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

CONTRA-INDICATIONS
Absence thiopurine methyltransferase activity

CAUTIONS
Reduced thiopurine methyltransferase activity

Thiopurine methyltransferase
The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.

INTERACTIONS
> Appendix 1 (mercaptopurine).

SIDE-EFFECTS
> Rare Pancreatitis · transient oligospermia
> Very rare Intestinal ulceration · lymphoma
> Frequency not known Alopecia · anorexia · bone-marrow suppression · hepatotoxicity · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Gastro-intestinal side-effects
Tgiouanine has a lower incidence of gastrointestinal side-effects than mercaptopurine.

PREGNANCY
Avoid (teratogenic). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

BREAST FEEDING
Discontinue breast-feeding.

HEPATIC IMPAIRMENT
May need dose reduction.

RENAL IMPAIRMENT
Reduce dose.

PRE-TREATMENT SCREENING
Consider measuring thiopurine methyltransferase (TPMT) activity before starting mercaptopurine therapy.

MONITORING REQUIREMENTS
Monitor liver function.

PRESCRIBING AND DISPENSING INFORMATION
Flavours of oral liquid formulations may include raspberry.

METHOTREXATE

DRUG ACTION
Methotrexate inhibits the enzyme dihydrofolate reductase, essential for the synthesis of purines and pyrimidines.

INDICATIONS AND DOSE
Severe Crohn’s disease
BY INTRAMUSCULAR INJECTION
> Adult: Initially 25 mg once weekly until remission induced; maintenance 15 mg once weekly
Maintenance of remission of severe Crohn’s disease
BY MOUTH
> Adult: 10–25 mg once weekly
Moderate to severe active rheumatoid arthritis
BY MOUTH
> Adult: 7.5 mg once weekly, adjusted according to response; maximum 20 mg per week
Severe active rheumatoid arthritis
BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION
▶ Adult: Initially 7.5 mg once weekly, then increased in steps of 2.5 mg once weekly, adjusted according to response; maximum 25 mg per week

Neoplastic diseases
BY INTRAVENOUS INJECTION OR BY INTRATHecal INJECTION OR BY INTRA-ARTERIAL INFUSION OR BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INFUSION OR BY MOUTH
▶ Adult: (consult product literature)
Severe psoriasis unresponsive to conventional therapy (specialist use only)
BY MOUTH OR BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION
▶ Adult: Initially 2.5–10 mg depending on response, then increased in steps of 2.5–5 mg, adjusted according to response, dose to be adjusted at intervals of at least 1 week; usual dose 7.5–15 mg once weekly, stop treatment if inadequate response after 3 months at the optimum dose; maximum 30 mg per week

UNLICENSED USE Not licensed for use in severe Crohn’s disease.

Gastro-intestinal toxicity Withdraw treatment if stomatitis develops—may be first sign of gastro-intestinal toxicity.

INTERACTIONS ⇒ Appendix L (methotrexate).
If aspirin or other NSAIDs are given concurrently the dose of methotrexate should be carefully monitored.

SIDE-EFFECTS
▶ Rare Pneumonitis
▶ Frequency not known Abdominal discomfort • acne • alopecia • anaphylactic reactions • anorexia • arthralgia • blood disorders • changes in nail pigmentation • changes in skin pigmentation • chills • chronic pulmonary fibrosis • confusion • conjunctivitis • cystitis • diarrhoea • dizziness • drowsiness • dyspepsia • dysuria • ecchymosis • fever • furunculosis • gastro-intestinal bleeding • gastro-intestinal ulceration • haematuria • headache • hepatotoxicity • hypotension • impotence • injection-site reactions • insomnia • interstitial pneumonitis • malaise • menstrual disturbances • mood changes • mucositis • myalgia • myelosuppression • nausea • neurotoxicity • osteoporosis • paraesthesia • pericardial tamponade • pericarditis • photosensitivity • pleuritic pain • precipitation of diabetes • pruritus • pulmonary fibrosis • pulmonary oedema • rash • reduced libido • renal failure • Stevens-Johnson syndrome • telangiectasia • thrombosis • toxic epidermal necrolysis • toxic megacolon • urticaria • vaginitis • vasculitis • visual disturbance • vomiting

SIDE-EFFECTS, FURTHER INFORMATION
In patients taking methotrexate for non-malignant conditions who experience side-effects, folic acid given on a different day from the methotrexate, may help to reduce the frequency of such side-effects. Withdraw treatment if stomatitis develops—may be first sign of gastro-intestinal toxicity. Treatment with folic acid (as calcium folinate) may be required in acute toxicity.

CONCEPTION AND CONTRACEPTION Effective contraception required during and for at least 3 months after treatment in men or women.

PREGNANCY Avoid (teratogenic; fertility may be reduced during therapy but this may be reversible).

BREAST FEEDING Discontinue breast-feeding—present in milk.

HEPATIC IMPAIRMENT When used for malignancy, avoid in severe hepatic impairment—consult local treatment protocol for details. Avoid with hepatic impairment in non-malignant conditions—dose-related toxicity.

RENAL IMPAIRMENT Reduce dose. Risk of nephrotoxicity at high doses. Avoid in severe impairment.

PRE-TREATMENT SCREENING Exclude pregnancy before treatment. Patients should have full blood count and renal and liver function tests before starting treatment.

MONITORING REQUIREMENTS
▶ In view of reports of blood dyscrasias (including fatalities) and liver cirrhosis with low-dose methotrexate patients should:
• have full blood count and renal and liver function tests repeated every 1–2 weeks until therapy stabilised, thereafter patients should be monitored every 2–3 months
• be advised to report all symptoms and signs suggestive of infection, especially sore throat
▶ Local protocols for frequency of monitoring may vary.
▶ Treatment with folic acid (as calcium folinate) may be required in acute toxicity.

PRESCRIBING AND DISPENSING INFORMATION
Folic acid following methotrexate administration helps to prevent methotrexate-induced mucositis and myelosuppression.

PATIENT AND CARER ADVICE
Methotrexate treatment booklets Methotrexate treatment booklets should be issued where appropriate.
In England, Wales, and Northern Ireland, they are available for purchase from: 3M Security Print and Systems Limited Gorse Street, Chadderton Oldham OL9 9QH Tel: 0845 610 1112 GPs can obtain supplies through their Local Area Team stores. NHS Hospitals can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com. In Scotland, treatment booklets can be obtained by emailing stockorders.dpps@theagroup.com or by fax on 0131 629 9967.

These booklets include advice for adults taking oral methotrexate for inflammatory conditions, and a section for recording results of blood tests and dosage information.

Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen. Patients should be counselled on the dose, treatment booklet, and the use of NSAIDs. Patients and their carers should be warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort and dark urine), and respiratory effects (e.g. shortness of breath).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral suspension, oral solution.

Tablet

- METHOTREXATE (Non-proprietary)
  - Methotrexate 2.5 mg: Methotrexate 2.5mg tablets | 24 tablet POM £3.75 | 28 tablet POM £3.82 DT price = £2.80 | 100 tablet POM £14.19
  - Methotrexate 10 mg: Methotrexate 10mg tablets | 100 tablet POM £57.21 DT price = £35.15
  - Mavtex (Pfizer Ltd)
    - Methotrexate 2.5 mg: Mavtex 2.5mg tablets | 24 tablet POM £2.29 | 100 tablet POM £9.96
    - Methotrexate 10 mg: Mavtex 10mg tablets | 100 tablet POM £45.16 DT price = £35.15

Solution for injection

- METHOTREXATE (Non-proprietary)
  - Methotrexate (as Methotrexate sodium) 2.5 mg per 1 ml
    - Methotrexate 5mg/2ml solution for injection vials | 5 vial POM £30.00-£36.00
  - Methotrexate (as Methotrexate sodium) 25 mg per 1 ml
    - Methotrexate 1g/40ml solution for injection vials | 1 vial POM £43.68 (Hospital only) | 1 vial POM £44.57-£67.50
    - Methotrexate 500mg/20ml solution for injection vials | 1 vial POM £6.89 can be variatio | 1 vial POM £25.07-£48.00
    - Methotrexate 50mg/2ml solution for injection vials | 1 vial POM £4.49 (Hospital only) | 1 vial POM £3.00 | 5 vial POM £35.00
    - Methotrexate 200mg/8ml solution for injection vials | 1 vial POM £10.02
  - Methotrexate (as Methotrexate sodium) 100 mg per 1 ml
    - Methotrexate 1g/10ml solution for injection vials | 1 vial POM £85.00
  - Metotrex PEN (medac UK)
    - Methotrexate 50 mg per 1 ml
      - Metotrex PEN 30mg/0.6ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £18.95 Metotrex PEN 22.5mg/0.45ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £18.45 Metotrex PEN 12.5mg/0.25ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £16.50 Metotrex PEN 20mg/0.4ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £17.84 Metotrex PEN 17.5mg/0.35ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £17.50 Metotrex PEN 7.5mg/0.15ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £14.85 Metotrex PEN 10mg/0.2ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £15.29 Metotrex PEN 7.5mg/0.15ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £14.85 Metotrex PEN 10mg/0.2ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £18.89 Metotrex PEN 25mg/0.5ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £18.48 Metotrex PEN 15mg/0.3ml solution for injection pre-filled pen | 1 pre-filled disposable injection POM £16.57

Solution for infusion

- METHOTREXATE (Non-proprietary)
  - Methotrexate (as Methotrexate sodium) 25 mg per 1 ml
    - Methotrexate 5g/200ml solution for infusion vials | 1 vial POM £200.57
  - Methotrexate (as Methotrexate sodium) 100 mg per 1 ml
    - Methotrexate 5g/50ml solution for infusion vials | 1 vial POM £400.00

Nelarabine

INDICATIONS AND DOSE

T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma in patients who have relapsed or who are refractory after receiving at least two previous regimens

BY INTRAVENOUS INFUSION

- Adults: (consult local protocol)

- CAUTIONS
  - Previous or concurrent craniospinal irradiation (increased risk of neurotoxicity), previous or concurrent intrathecal chemotherapy (increased risk of neurotoxicity)

- SIDE-EFFECTS
  - Common or very common Neurotoxicity (discontinue)

- CONCEPTION AND CONCEPTION

- Manufacturer advises effective contraception during and for at least 3 months after treatment in men and women.

- PREGNANCY
  - Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- BREAST FEEDING
  - Discontinue breast-feeding.

- MONITORING REQUIREMENTS
  - Neurotoxicity Close monitoring for neurological events is strongly recommended—discontinue if neurotoxicity occurs.

- PATIENT AND CARER ADVICE
  - Drowsiness may affect performance of skilled tasks (e.g. cycling or driving).

- NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2008) that the use of nelarabine (Atriance®) within NHS Scotland is restricted to bridging treatment before stem cell transplantation.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

ELECTROLYTES: May contain Sodium

- Atriance (Novartis Pharmaceuticals UK Ltd) ▼

Nelarabine 5 mg per 1 ml

- Atriance 250mg/50ml solution for infusion vials | 6 vial POM £1,332.00
Pemetrexed

**DRUG ACTION** Pemetrexed inhibits thymidylate transferase and other folate-dependent enzymes.

**INDICATIONS AND DOSE**
Treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (in combination with cisplatin) | First-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (in combination with cisplatin) | Second-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (monotherapy) | Maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy (monotherapy)

**SIDE-EFFECTS**
Common or very common: Conjunctivitis, dehydration, gastro-intestinal disturbances, increased lacrimation, neuropathy, oedema, skin disorders
Uncommon: Arrhythmias, colitis, interstitial pneumonitis
Rare: Acute renal failure, hepatitis, peripheral ischaemia
Frequency not known: Alopecia, bone marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, Stevens–Johnson syndrome, thromboembolism, toxic epidermal necrolysis, tumour lysis syndrome, vomiting

**CAUTIONS**
- Diabetes - history of cardiovascular disease - prophylactic folic acid supplementation required (consult product literature)
- Cautions with concomitant nephrotoxic drugs including non-steroidal anti-inflammatory drugs (consult product literature)

**INTERACTIONS**
- Appendix 1 (pemetrexed). Caution with concomitant nephrotoxic drugs including non-steroidal anti-inflammatory drugs (consult product literature).

**CONCEPTION AND CONTRACEPTION**
Manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.

**PREGNANCY**
Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**
Discontinue breast-feeding.

**RENAL IMPAIRMENT**
Manufacturer advises avoid if creatinine clearance less than 45 mL/minute—no information available.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Pemetrexed for the treatment of non-small cell lung cancer (August 2007) NICE TA124
  Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy. www.nice.org.uk/TA124
- Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008) NICE TA135
  Pemetrexed is an option for the treatment of malignant pleural mesothelioma only in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate. www.nice.org.uk/TA135
- Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009) NICE TA181
  Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma. www.nice.org.uk/TA181

- Pemetrexed for the treatment of non-small cell lung cancer (June 2010) NICE TA190
  Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel. www.nice.org.uk/TA190

- Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (April 2014) NICE TA309
  Pemetrexed is not recommended for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer in patients whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin. www.nice.org.uk/TA309

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (August 2008) that pemetrexed (Alimta®) is accepted for restricted use within NHS Scotland as monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer without predominantly squamous cell histology; it is restricted for use in patients with good performance status who would otherwise be eligible for docetaxel treatment.

The Scottish Medicines Consortium has advised (January 2010) that pemetrexed (Alimta®) is accepted for restricted use within NHS Scotland in combination with cisplatin for the first-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology; it is restricted to patients in whom the histology of the tumour has been confirmed as adenocarcinoma or large cell carcinoma.

The Scottish Medicines Consortium has advised (July 2005) that pemetrexed (Alimta®) in combination with cisplatin is accepted for restricted use within NHS Scotland for previously untreated patients with stage III/IV unresectable malignant pleural mesothelioma.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

<table>
<thead>
<tr>
<th>ELECTROLYTES: May contain Sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alimta (Eli Lilly and Company Ltd)</td>
</tr>
<tr>
<td>Pemetrexed (as Pemetrexed disodium) 100 mg Alimta 100mg powder for concentrate for solution for infusion vials</td>
</tr>
<tr>
<td>Pemetrexed (as Pemetrexed disodium) 500 mg Alimta 500mg powder for concentrate for solution for infusion vials</td>
</tr>
</tbody>
</table>

**Tegafur with gimeracil and oteracil**

**DRUG ACTION** Tegafur is a prodrug of fluorouracil. Gimeracil inhibits the degradation of fluorouracil and oteracil decreases the activity of fluorouracil in normal gastrointestinal mucosa.
Indications and Dose
Tretment of advanced gastric cancer when used in combination with cisplatin

By Mouth
- Adult: (consult local protocol)

Important Safety Information
Risks of incorrect dosing of oral anti-cancer medicines, see p. 745

- Contra-Indications
  Dihydropyrimidine dehydrogenase deficiency

- Interactions
  → Appendix 1 (tegafur).

- Side-Effects
  Alopecia - bone-marrow suppression - hyperuricaemia - nausea - neuropathy - ocular toxicity - oral mucositis - thrombocytopenia - tumour lysis syndrome - vomiting

- Conception and Contraception
  Manufacturer advises effective contraception during and for up to 6 months after treatment.

- Pregnancy
  Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- Breast Feeding
  Discontinue breast-feeding.

- Renal Impairment
  Reduce dose if creatinine clearance 30–50 mL/minute—consult product literature. Manufacturer advises avoid if creatinine clearance less than 30 mL/minute.

- National Funding/Access Decisions
  Scottish Medicines Consortium (SMC) Decisions
  The Scottish Medicines Consortium has advised (August 2012) that tegafur with gimeracil and oteracil (Teysuno®) is accepted for restricted use within NHS Scotland for the treatment of advanced gastric cancer, when given in combination with cisplatin, in patients who are unsuitable for an anthracycline, fluorouracil and platinum triplet first-line regimen.

Medical Forms
There can be variation in the licensing of different medicines containing the same drug.

Capsule
  Cautionary and Advisory Labels 23
- Teysuno (Nordic Pharma Ltd)
  Gimeracil 4.35 mg, Oteracil (as Oteracil potassium) 11.8 mg,
  Tegafur 15 mg
  126 capsule (£38) £279.72
  Gimeracil 5.8 mg, Oteracil (as Oteracil potassium) 15.8 mg,
  Tegafur 20 mg
  84 capsule (£38) £248.40

Tioguanine
(Thioguanine)

Indications and Dose
Acute leukaemia | Chronic myeloid leukaemia

By Mouth
- Adult: 100–200 mg/m² daily, can be given at various stages of treatment in short-term cycles

Important Safety Information
Risks of incorrect dosing of oral anti-cancer medicines, see p. 745

- Contra-Indications
  Absent thiopurine methyltransferase activity

- Caution
  Thiopurine methyltransferase status

Cautions, Further Information
Thiopurine methyltransferase
  The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.

Long-Term Therapy
  Long-term therapy is no longer recommended because of the high risk of liver toxicity.

- Interactions
  → Appendix 1 (tioguanine).

- Side-Effects
  Rare Intestinal necrosis - intestinal perforation
  Frequency not known Alopecia - bone-marrow suppression - hepatotoxicity (discontinue) - hyperuricaemia - nausea - oral mucositis - stomatitis - thrombocytopenia - tumour lysis syndrome - vomiting - vomiting

Side-Effects, Further Information
Gastro-intestinal side-effects
  Tioguanine has a lower incidence of gastrointestinal side-effects than mercaptopurine.

- Conception and Contraception
  Ensure effective contraception during treatment in men or women.

- Pregnancy
  Avoid (teratogenicity reported when men receiving tioguanine have fathered children). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- Breast Feeding
  Discontinue breast-feeding.

- Hepatic Impairment
  Reduce dose.

- Renal Impairment
  Reduce dose.

- Pre-Treatment Screening
  Consider measuring thiopurine methyltransferase (TPMT) activity before starting tioguanine therapy.

- Monitoring Requirements
  Monitor liver function weekly—discontinue if liver toxicity develops.

Medical Forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule

Tablet
- Tioguanine (Non-proprietary)
  Tioguanine 40 mg
  Tioguanine 40 mg tablets | 25 tablet (£38)
  £103.54

Antineoplastic Antibiotics

Bleomycin

Indications and Dose
Squamous cell carcinoma | Metastatic germ cell cancer | Non-Hodgkin’s lymphoma

By Intravenous injection or by local infiltration or by intra-arterial infusion or by intramuscular injection or by intravenous infusion
- Adult: (consult product literature or local protocols)

- Caution
  Caution in handling—irritant to tissues

- Interactions
  → Appendix 1 (bleomycin).

- Side-Effects
  Common or Very Common Dermatological toxicity - mucositis
  Frequency not known Alopecia - chills (after drug administration) - extravasation - fever (after drug administration) - hypersensitivity reactions - hyperuricaemia - increased pigmentation particularly affecting the flexures and subcutaneous sclerotic plaques - less bone marrow suppression - nausea - oral mucositis - progressive pulmonary fibrosis (dose-related) - pulmonary
toxicity - Raynaud’s phenomenon - thromboembolism - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hypersensitivity reactions** Hypersensitivity reactions manifest by chills and fever commonly occur a few hours after drug administration and may be prevented by simultaneous administration of a corticosteroid, for example hydrocortisone intravenously.

**Progressive pulmonary fibrosis** This is dose-related, occurring more commonly at cumulative doses greater than 300 000 units and in the elderly. Basal lung crepitations or suspicious chest X-ray changes are an indication to stop therapy with this drug.

**Respiratory failure** Patients who have received extensive treatment with bleomycin (e.g. cumulative dose more than 100 000 units) may be at risk of developing respiratory failure if a general anaesthetic is given with high inspired oxygen concentrations. Anaesthetists should be warned of this.

**Pregnancy** Avoid (teratogenic and carcinogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**Breast feeding** Discontinue breast-feeding.

**Renal impairment** Reduce dose by half if serum creatinine 177–354 μmol/litre; reduce dose further if serum-creatinine greater than 354 μmol/litre.

**Prescribing and dispensing information** To conform to the European Pharmacopoeia vials previously labelled as containing ‘15 units’ of bleomycin are now labelled as containing 15 000 units. The amount of bleomycin in the vial has not changed.

**Medicinal forms** There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Bleo-Kyowa** (ProStrakan Ltd)
  - Bleomycin (as Bleomycin sulfate) 15000 unit Bleo-Kyowa 15,000unit powder for solution for injection vials | 10 vial £10.00

**Mitomycin**

**Indications and dose**

Recurrent superficial bladder tumours (bladder instillation)

**By intravesical instillation**

- Adult: (consult product literature or local protocols)

Upper gastro-intestinal cancers | Breast cancers

**By intravenous injection**

- Adult: (consult product literature or local protocols)

**Cautions** Caution in handling—irritant to tissues

**Side-effects**

**General Side-effects**

Alopecia - bone marrow damage - bone-marrow suppression - hyperuricaemia - lung fibrosis - nausea - oral mucositis - renal damage - thromboembolism - tumour lysis syndrome - vomiting

**Specific Side-effects**

- With intravenous use extravasation

**Side-effects, further information**

Bone-marrow toxicity Mitomycin is usually administered at 6-weekly intervals because it causes delayed bone-marrow toxicity. Prolonged use may result in a permanent effect.

**Pregnancy** Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**Breast-feeding** Discontinue breast-feeding.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Mitomycin (non-proprietary)**
  - Mitomycin 2 mg Mitomycin-C Kyowa 2mg powder for solution for injection vials | 10 vial £58.83

  - Mitomycin 10 mg Mitomycin-C Kyowa 10mg powder for solution for injection vials | 1 vial £21.37

  - Mitomycin 20 mg Mitomycin-C Kyowa 20mg powder for solution for injection vials | 1 vial £39.94

  - Mitomycin 40 mg Mitomycin-C Kyowa 40mg powder for solution for injection vials | 1 vial £78.88

**Platinum compounds**

**Carboplatin**

**Indications and dose**

Treatment of advanced ovarian cancer and lung cancer (particularly the small cell type)

**By intravenous infusion**

- Adult: The dose of carboplatin is determined according to renal function rather than body surface area (consult product literature)

**Interactions** → Appendix 1 (platinum compounds).

**Side-effects**

Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - myelosuppression - nausea - nausée - nephrotoxicity - neurotoxicity - oral mucositis - ototoxicity - thromboembolism - tumour lysis syndrome - vomiting - vomiting

**Side-effects, further information**

Carboplatin is better tolerated than cisplatin; nausea and vomiting are reduced in severity and nephrotoxicity, neurotoxicity, and ototoxicity are much less of a problem than with cisplatin. It is, however, more myelosuppressive than cisplatin.

**Pregnancy** Avoid (teratogenic and embryotoxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**Breast-feeding** Discontinue breast-feeding.

**Renal impairment** Reduce dose. Avoid if creatinine clearance less than 20 ml/minute. Monitor haematomatological parameters in renal impairment. Monitor renal function in renal impairment.

**Prescribing and dispensing information**

Carboplatin can be given in an outpatient setting.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **Carboplatin (non-proprietary)**
  - Carboplatin 10 mg per 1 ml Carboplatin 50mg/5ml concentrate for solution for infusion vials | 1 vial £22.04 (Hospital only) | 1 vial £20.00 Carboplatin 150mg/15ml concentrate for solution for infusion vials | 1 vial £56.92 (Hospital only) | 1 vial £50.00 Carboplatin 600mg/60ml concentrate for solution for infusion vials | 1 vial £126.00 Carboplatin 600mg/60ml solution for infusion vials | 1 vial £120.00 Carboplatin 450mg/45ml concentrate for solution for infusion vials | 1 vial £116.85 (Hospital only) | 1 vial £150.00 Carboplatin 450mg/45ml solution for infusion vials | 1 vial £117.48 Carboplatin 150mg/15ml solution for infusion vials | 1 vial £85.83 Carboplatin 50mg/5ml solution for infusion vials | 1 vial £22.86
Cisplatin

INDICATIONS AND DOSE
Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer (alone or in combination)
BY INTRAVENOUS INFUSION
- Adult: (consult product literature)

- CAUTIONS
CAUTIONS, FURTHER INFORMATION
Hydration Cisplatin requires intensive intravenous hydration and treatment may be complicated by severe nausea and vomiting.

- INTERACTIONS → Appendix 1 (platinum compounds).

- SIDE-EFFECTS
Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · hypomagnesaemia · myelosuppression · nephrotoxicity · oral mucositis · ototoxicity · peripheral neuropathy · severe nausea · severe vomiting · thromboembolism · tumour lysis syndrome

- CONTRA-INDICATIONS
Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.

- PREGNANCY
Avoid (teratogenic and toxic in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- BREAST FEEDING
Discontinue breast-feeding.

- NICE technology appraisals (TAs)
- irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005) NICE TA93
A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer. Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently. www.nice.org.uk/TA93

- Capetibamine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006) NICE TA100
Capetibamine alone or oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes’ C) colon cancer. www.nice.org.uk/TA100

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
- Cisplatin 1 mg per 1 ml
- Cisplatin 50mg/50ml concentrate for solution for infusion vials | 1 vial | price not available
- Cisplatin 100mg/100ml solution for infusion vials | 1 vial | price not available
- Cisplatin 50mg/50ml solution for infusion vials | 1 vial | price not available
- Cisplatin 100mg/100ml solution for infusion vials | 1 vial | price not available
- Cisplatin 100mg/200ml solution for infusion vials | 1 vial | price not available
- Cisplatin 100mg/100ml solution for infusion vials | 1 vial | price not available
- Cisplatin 100mg/500mg solution for infusion vials | 1 vial | price not available
- Cisplatin 100mg/1000mg solution for infusion vials | 1 vial | price not available
- Cisplatin 100mg/2000mg solution for infusion vials | 1 vial | price not available

- OXALIPLATIN (Non-proprietary)
- Oxaliplatin 100 mg | 1 vial | price not available
- Oxaliplatin 200 mg | 1 vial | price not available
- Oxaliplatin 500 mg | 1 vial | price not available
- Oxaliplatin 1000 mg | 1 vial | price not available

- OXALIPLATIN (Proprietary)
- Oxaliplatin 150 mg | 1 vial | price not available
- Oxaliplatin 100 mg | 1 vial | price not available

Oxaliplatin

INDICATIONS AND DOSE
Treatment of metastatic colorectal cancer (in combination with fluorouracil and folinic acid) | Treatment of colon cancer after resection of the primary tumour (adjuvant treatment)
BY INTRAVENOUS INFUSION
- Adult: (consult product literature)

- CONTRA-INDICATIONS
Peripheral neuropathy with functional impairment

- INTERACTIONS → Appendix 1 (platinum compounds).

- SIDE-EFFECTS
Alopecia · bone-marrow suppression · extravasation · gastro-intestinal disturbances · hyperuricaemia · myelosuppression · nausea · neurotoxicity (dose limiting) · ototoxicity · posterior reversible encephalopathy syndrome (associated with oxaliplatin combination chemotherapy) · sensory peripheral neuropathy (dose limiting) · thromboembolism · transient vision loss (reversible on discontinuation) · tumour lysis syndrome · vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Respiratory symptoms If unexplained respiratory symptoms occur, oxaliplatin should be discontinued until investigations exclude interstitial lung disease and pulmonary fibrosis.

- CONCEPTION AND CONTRACEPTION
Effective contraception required during and for 4 months after treatment in women and 6 months after treatment in men.

- PREGNANCY
Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- BREAST FEEDING
Discontinue breast-feeding.

- NICE technology appraisals (TAs)
- Oxaliplatin, irinotecan, and capecitabine for advanced colorectal cancer (August 2005) NICE TA100
A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer. Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently. www.nice.org.uk/TA100

- Capetibamine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006) NICE TA100
Capetibamine alone or oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes’ C) colon cancer. www.nice.org.uk/TA100

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
- Oxaliplatin 100 mg | 1 vial | price not available
- Oxaliplatin 200 mg | 1 vial | price not available
- Oxaliplatin 500 mg | 1 vial | price not available
- Oxaliplatin 1000 mg | 1 vial | price not available

- OXALIPLATIN (Non-proprietary)
- Oxaliplatin 100 mg | 1 vial | price not available
- Oxaliplatin 200 mg | 1 vial | price not available
- Oxaliplatin 500 mg | 1 vial | price not available
- Oxaliplatin 1000 mg | 1 vial | price not available

- OXALIPLATIN (Proprietary)
- Oxaliplatin 150 mg | 1 vial | price not available
- Oxaliplatin 100 mg | 1 vial | price not available

RETINOIDS AND RELATED DRUGS

Bexarotene

- DRUG ACTION
Bexarotene is an agonist at the retinoid X receptor, which is involved in the regulation of cell differentiation and proliferation. Bexarotene can cause regression of cutaneous T-cell lymphoma.
Tretinoin

**INDICATIONS AND DOSE**
Induction of remission in acute promyelocytic leukaemia (used in previously untreated patients as well as in those who have relapsed after standard chemotherapy or who are refractory to it)

**BY MOUTH**
- Adult: 45 mg/m² daily in 2 divided doses maximum duration of treatment is 90 days, consult product literature for details of concomitant chemotherapy

**CAUTIONS**
Increased risk of thromboembolism during first month of treatment

**INTERACTIONS**
- Appendix 1 (retinoids).

**SIDE-EFFECTS**

**SIDE-EFFECTS, FURTHER INFORMATION**

**Retinoic acid syndrome**
Fever, dyspnoea, acute respiratory distress, pulmonary infiltrates, pleural effusion, hyperleucocytosis, hypotension, oedema, weight gain, hepatic, renal and multi-organ failure requires immediate treatment—consult product literature.

**CONCEPTION AND CONTRACEPTION**
Exclude pregnancy before starting treatment. Effective contraception must be used for at least 1 month before oral treatment, during treatment and for at least 1 month after stopping (oral progesterone-only contraceptives not considered effective).

**PREGNANCY**
Teratogenic. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**
Avoid (discontinue breast-feeding).

**HEPATIC IMPAIRMENT**
Reduce dose to 25 mg/m².

**RENAL IMPAIRMENT**
Reduce dose to 25 mg/m².

**MONITORING REQUIREMENTS**
Monitor haematological and coagulation profile, liver function, serum calcium and plasma lipids before and during treatment.

**PRESCRIBING AND DISPENSING INFORMATION**
Tretinoin is the acid form of vitamin A.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 21, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tretinoin (Non-proprietary)</td>
</tr>
</tbody>
</table>

| Tretinoin 10 mg | Tretinoin 10mg capsules | 100 capsule | £23.30 |

**TAXANES**
Cabazitaxel

**INDICATIONS AND DOSE**
Treatment of hormone refractory metastatic prostate cancer in patients who have previously been treated with a docetaxel-containing regimen (in combination with prednisone or prednisolone)

**BY INTRAVENOUS INFUSION**
- Adult: (consult product literature or local protocols)

**CAUTIONS**
Avoid in Acute porphyrias p. 864

**INTERACTIONS**
- Appendix 1 (cabazitaxel).

**SIDE-EFFECTS**
- Common or very common
  - Hypersensitivity reactions
  - Frequency not known


**SIDE-EFFECTS, FURTHER INFORMATION**

**Hypersensitivity reactions**
Routine premedication with a corticosteroid, an antihistamine, and a histamine H₂-receptor antagonist is recommended to prevent severe hypersensitivity reactions.
Docetaxel

INDICATIONS AND DOSE
Adjuvant treatment of operable node-positive and operable node-negative breast cancer (in combination with doxorubicin and cyclophosphamide) | Initial chemotherapy of locally advanced or metastatic breast cancer (with doxorubicin) | Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline or an alkylating drug has failed (monotherapy) | Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline has failed (with capcitabine) | Initial chemotherapy of metastatic breast cancer which overexpresses human epidermal growth factor-2 (with trastuzumab) | Locally advanced or metastatic non-small-cell lung cancer (with cisplatin) | Hormone-resistant metastatic prostate cancer (in combination with prednisone or prednisolone) | Initial treatment of metastatic gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction (with cisplatin and fluorouracil) | Induction treatment of locally advanced squamous cell carcinoma of the head and neck (with cisplatin and fluorouracil) | BY INTRAVENOUS INFUSION | Adult: (consult product literature or local protocols)
Paclitaxel

- **DRUG ACTION** Paclitaxel is a member of the taxane group of drugs.

**INDICATIONS AND DOSE**

Treatment of ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin (conventional paclitaxel only) / Treatment of metastatic ovarian cancer where platinum-containing therapy has failed (conventional paclitaxel only) / Treatment of locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate) (conventional paclitaxel only) / Adjuvant treatment of node-positive breast cancer following treatment with anthracycline and cyclophosphamide (conventional paclitaxel only) / Treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate (conventional paclitaxel only) / Treatment of advanced AIDS-related Kaposi's sarcoma where liposomal anthracycline therapy has failed (conventional paclitaxel only) / First-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine) (conventional paclitaxel only) / Monotherapy of metastatic breast cancer when first-line treatment has failed and standard, anthracycline-containing therapy is not indicated (albumin-bound paclitaxel only) / In combination with gemcitabine for the first-line treatment of metastatic adenocarcinoma of the pancreas (albumin-bound paclitaxel only)

- **BY INTRAVENOUS INFUSION**

- **ADULTS** (consult product literature or local protocols)

- **CAUTIONS** Avoid in Acute porphyrias p. 864 - consult product literature - patients aged over 75 years with metastatic adenocarcinoma of the pancreas

- **INTERACTIONS** Appendix 1 (paclitaxel).

- **SIDE-EFFECTS**

  - Common or very common Arrhythmia - arthralgia - febrile neutropenia - gastro-intestinal disorders - myalgia - peripheral neuropathy - sensory neuropathy - tachycardia

  - Rare Bradycardia - cardiac arrest - congestive heart failure - left ventricular dysfunction

  - Frequency not known Alopecia - arrhythmias (nearly always asymptomatic) - asymptomatic hypotension - bone-marrow suppression - bradycardia - cardiac conduction defects - extravasation - hypersensitivity reactions - hyperuricaemia - muscle pain - myelosuppression - nausea - neutropenia - oral mucositis - pneumonitis - Stevens-Johnson syndrome - thromboembolism - toxic epidermal necrolysis - tumour lysis syndrome - vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**

  - Hypersensitivity reactions Routine premedication with a corticosteroid, an antihistamine and a histamine H$_2$-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication.

- **CONCEPTION AND CONTRACEPTION** Ensure effective contraception during and for at least 6 months after treatment in men or women.

- **PREGNANCY** Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING** Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment.

- **MONITORING REQUIREMENTS**

  - Cardiac monitoring should be undertaken, particularly if patients have underlying cardiac disease or previous exposure to anthracyclines.

  - Patients should be monitored for signs and symptoms of pneumonitis and sepsis.

- **PRESCRIBING AND DISPENSING INFORMATION** Paclitaxel is available as both conventional and albumin-bound formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable. Prescribers should specify the brand to be dispensed.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)** Paclitaxel for ovarian cancer (January 2003) NICE TA05

    - Either paclitaxel in combination with a platinum compound (cisplatin or carboplatin) or a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).

    - www.nice.org.uk/TA05

  - Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005) NICE TA91

    - Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy. Paclitaxel alone is an option for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy.

    - Paclitaxel alone is an option for advanced ovarian cancer in patients who are allergic to platinum compounds. www.nice.org.uk/TA91

    - Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006) NICE TA108

    - Paclitaxel, within its licensed indication, is not recommended for the adjuvant treatment of women with early node-positive breast cancer. www.nice.org.uk/TA108

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

  - **Solution for infusion**

    - EXCIPIENTS: May contain Polyoxyl castor oils

    - **PACLITAXEL (Non-proprietary)** Paclitaxel 6 mg per 1 ml Paclitaxel 150mg/25ml concentrate for solution for infusion vials | 1 vial (PPh) £300.52 - £561.00 (Hospital only) | 1 vial (PPh) £300.52 Paclitaxel 30mg/5ml concentrate for solution for infusion vials | 1 vial (PPh) £91.45 - £116.05 (Hospital only) | 1 vial (PPh) £105.84

    - Paclitaxel 100mg/16.7ml concentrate for solution for infusion vials | 1 vial (PPh) £303.65 - £374.00 (Hospital only) | 1 vial (PPh) £317.21

    - Paclitaxel 300mg/50ml concentrate for solution for infusion vials | 1 vial (PPh) £861.52 - £1.122.00 (Hospital only) | 1 vial (PPh) £951.63

- **Powder for suspension for infusion**

  - ELECTROLYTES: May contain Sodium

    - **Abrasaxe** (Celgene Ltd)

    - Paclitaxel albumin 100 mg Abraxane 100mg powder for suspension for infusion vials | 1 vial (PPh) £246.00 (Hospital only)
TOPOISOMERASE I INHIBITORS

Irinotecan hydrochloride

**DRUG ACTION** Irinotecan inhibits topoisomerase I, an enzyme involved in DNA replication.

**INDICATIONS AND DOSE**
Metastatic colorectal cancer in combination with fluorouracil and folinic acid or as monotherapy when treatment containing fluorouracil has failed: First-line treatment of metastatic colorectal carcinoma of the colon or rectum (in combination with fluorouracil, folinic acid and bevacizumab) in metastatic colorectal cancer (incombination with capecitabine with or without bevacizumab).

**CONTRA-INDICATIONS** Bowel obstruction · chronic inflammatory bowel disease

**CAUTIONS** Raised plasma-bilirubin concentration · risk factors for cardiac disease

**INTERACTIONS** → Appendix 1 (irinotecan).

**SIDE-EFFECTS**
- Uncommon Interstitial pulmonary disease
- Frequency not known Acute cholinergic syndrome (with early diarrhoea) and delayed diarrhoea (consult product literature) · alopecia · anorexia · asthenia · bone-marrow suppression · extravasation · gastrointestinal effects (delayed diarrhoea requiring prompt treatment may follow irinotecan treatment) · hyperuricaemia · myelosuppression (dose limiting) · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for up to 3 months after treatment in men.

**PREGNANCY** Avoid (teratogenic and toxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Avoid if plasma-bilirubin concentration greater than 3 times upper limit of normal range. Monitor closely for neutropenia if plasma-bilirubin concentration 1.5–3 times upper limit of normal range (consult product literature).

**RENAL IMPAIRMENT** Manufacturer advises avoid—no information available.

**MONITORING REQUIREMENTS** Monitor respiratory function.

**NATIONAL FUNDING/ACCESS DECISIONS**

**BNF**

**Solution for infusion**

<table>
<thead>
<tr>
<th>IRINOTECAN HYDROCHLORIDE (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irinotecan hydrochloride trihydrate 20 mg per 1 ml</td>
</tr>
<tr>
<td>(Hospital only)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>(Hospital only)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Topotecan**

**DRUG ACTION** Topotecan inhibits topoisomerase I, an enzyme involved in DNA replication.

**INDICATIONS AND DOSE**
Metastatic ovarian cancer when first-line or subsequent treatment has failed: Treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB cervical cancer (October 2005) NICE TA183.

**CONTRA-INDICATIONS** Bowel obstruction · chronic inflammatory bowel disease

**CAUTIONS** Raised plasma-bilirubin concentration · risk factors for cardiac disease

**INTERACTIONS** → Appendix 1 (topotecan).

**SIDE-EFFECTS**
- Alopecia · anorexia · asthenia · bone-marrow suppression · extravasation · gastrointestinal effects · hyperuricaemia · myelosuppression (dose limiting) · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

**PREGNANCY** Avoid (teratogenicity and fetal loss in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Avoid in severe impairment.

**RENAI IMPAIRMENT** Reduce dose. Avoid infusion if creatinine clearance less than 20 mL/minute. Avoid oral route if creatinine clearance less than 60 mL/minute.

**NATIONAL FUNDING/ACCESS DECISIONS**

**BNF**

**Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005) NICE TA91**

Topotecan alone is an option only for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing platinum-based chemotherapy or in those allergic to platinum compounds and for whom paclitaxel alone or pegylated liposomal doxorubicin are inappropriate. www.nice.org.uk/TA91

**Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009) NICE TA183**

Topotecan in combination with cisplatin is recommended as a treatment option for recurrent or stage IVB cervical cancer in patients who have not previously received cisplatin. www.nice.org.uk/TA183
Topotecan (as Topotecan hydrochloride) 1 mg
| Topotecan (as Topotecan hydrochloride) 4 mg
| Topotecan (as Topotecan hydrochloride) 1 mg
| Topotecan (as Topotecan hydrochloride) 250 microgram

Solution for infusion

Solution for infusion

Powder for solution for infusion

Powder for solution for infusion

Topotecan (as Topotecan hydrochloride) 1 mg

Vincristine injections are for intravenous administration only. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal.

The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.

CONTRA-INDICATIONS

CONTRA-INDICATIONS, FURTHER INFORMATION

Intrathecal injection contra-indicated.

CAUTIONS

Caution in handling—irritant to tissues

INTERACTIONS

Appendix 1 (vinblastine).

SIDE-EFFECTS, FURTHER INFORMATION

Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids; it occurs less often with vinblastine than with vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur and dose reduction or discontinuation of therapy may be appropriate if motor weakness increases. Recovery from neurotoxic effects is usually slow but complete.

PREGNANCY

Avoid (limited experience suggests fetal harm; teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

BREAST FEEDING

Discontinue breast-feeding.

HEPATIC IMPAIRMENT

Dose reduction may be necessary—consult local treatment protocol for details.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS

5

Hycamtin (Novartis Pharmaceuticals UK Ltd)

Topotecan (as Topotecan hydrochloride) 1 mg
Topotecan (as Topotecan hydrochloride) 4 mg

Solution for infusion

Solution for infusion

Topotecan (as Topotecan hydrochloride) 4 mg

Vinblastine sulfate

INDICATIONS AND DOSE

Variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer)

Adult: (consult product literature)

Important safety information

Vinblastine is for intravenous administration only. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal.

The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.

CONTRA-INDICATIONS

CONTRA-INDICATIONS, FURTHER INFORMATION

Intrathecal injection contra-indicated.

CAUTIONS

Caution in handling—irritant to tissues

neuromuscular disease

Appendix 1 (vincristine).
**SIDE-EFFECTS**

- **Rare** Diarrhoea - inappropriate secretion of antidiuretic hormone - intestinal necrosis - paralytic ileus - seizures - urinary retention
- **Frequency not known** Abdominal pain - alopecia - autonomic neuropathy - constipation - extravasation - eye disorders - hyperuricaemia - loss of deep tendon reflexes - motor weakness - muscle wasting - myelosuppression (negligible) - nausea - neurotoxicity - oral mucositis - otorrhexis - peripheral neuropathy - peripheral paraesthesia - severe bronchospasm following administration (more commonly when used in combination with mitomycin-C) - severe local irritation (care must be taken to avoid extravasation) - thromboembolism - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Neurotoxicity**
  - Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids and is a limiting side-effect of vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur and dose reduction or discontinuation of therapy may be appropriate if motor weakness increases. Recovery from neurotoxic effects is usually slow but complete.

- **PREGNANCY**
  - Avoid (teratogenicity and fetal loss in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING**
  - Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Dose reduction may be necessary—consult local treatment protocol for details.

**MEDICINAL FORMS**

- **Vincristine Sulfate (Non-proprietary)**
  - Vincristine sulfate 1 mg per 1 ml
    - Vincristine 1mg/1ml solution for injection vials | 1 vial £11.47 | 5 vial £58.75
    - Vincristine 2mg/2ml solution for injection vials | 1 vial £30.07 | 5 vial £157.37
  - Vincristine 5mg/5ml solution for injection vials | 5 vial £133.30

**Vinflunine**

**INDICATIONS AND DOSE**

Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen (monotherapy)

- **Adult:** (consult local protocol)

**Vinflunine sulfate**

**INDICATIONS AND DOSE**

Variety of cancers including leukemias, lymphomas, and some solid tumours (e.g. breast and lung cancer)

- **Adult:** (consult product literature)

**Important safety information**

Vinflunine injections are for **intravenous administration only**. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal.

The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.

**SIDE-EFFECTS**

- Alopecia - autonomic neuropathy - bone-marrow suppression - extravasation - hyperuricaemia - irritant to tissues - myelosuppression (dose-limiting) - nausea - neurotoxicity - oral mucositis - peripheral neuropathy - severe bronchospasm following administration (more commonly when used in combination with mitomycin-C) - severe local irritation (if extravasated) - thromboembolism - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Neurotoxicity**
  - Neurotoxicity, usually as peripheral or autonomic neuropathy; it occurs less often with vindesine than with vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur, and increasing motor weakness calls for dose reduction or discontinuation. Recovery from neurotoxic effects is usually slow but complete.

- **PREGNANCY**
  - Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING**
  - Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Dose reduction may be necessary.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- Eldisine (Genus Pharmaceuticals Ltd)
  - Vindesine sulfate 5 mg. Eldisine 5mg powder for solution for injection vials | 1 vial £78.30 (Hospital only)
**INDICATIONS AND DOSE**

**Advanced breast cancer** | **Advanced non-small cell lung cancer**
---|---
**BREAST FEEDING** | **HEPATIC IMPAIRMENT**
Reduce dose unless essential (teratogenicity, and fetal loss in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746. | Reduce dose if creatinine clearance is less than 50 mL/min—consult product literature.

**SIDE-EFFECTS, FURTHER INFORMATION**

**Neurotoxicity**

Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids and is a limiting side-effect of vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; otoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur and dose reduction or discontinuation of therapy may be appropriate if motor weakness increases. Recovery from neurotoxic effects is usually slow but complete.

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises effective contraception during and for up to 3 months after treatment.

**PREGNANCY**

Avoid unless essential—teratogenicity and embryotoxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**

Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

Reduce dose—consult product literature.

**RENAI IMPAIRMENT**

Reduce dose if creatinine clearance is less than 60 mL/min—consult product literature.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (January 2013) NICE TA272

Vinflunine is not recommended for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract that has progressed after treatment with platinum-based chemotherapy. [www.nice.org.uk/Ta272](http://www.nice.org.uk/Ta272)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- [Javlor](http://www.nice.org.uk/Ta272) (Pierre Fabre Ltd) 250mg/10ml concentrate for solution for infusion | 1 vial [POD] £11.062.50
- [Javlor](http://www.nice.org.uk/Ta272) 50mg/2ml concentrate for solution for infusion | 1 vial [POD] £212.50

**Vinorelbine**

**DRUG ACTION**

Vinorelbine is a semi-synthetic vincaalkoid.

**INDICATIONS AND DOSE**

**Advanced breast cancer** | **Advanced non-small cell lung cancer**
---|---
**BREAST FEEDING** | **HEPATIC IMPAIRMENT**
Reduce dose unless essential (teratogenicity, and fetal loss in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746. | Reduce oral dose in moderate impairment. Avoid oral use in severe impairment. Reduce intravenous dose in severe impairment.

**SIDE-EFFECTS, FURTHER INFORMATION**

**Neurotoxicity**

Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids and is a limiting side-effect of vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; otoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur and dose reduction or discontinuation of therapy may be appropriate if motor weakness increases. Recovery from neurotoxic effects is usually slow but complete.

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises effective contraception during and for up to 3 months after treatment; men must avoid fathering a child during and for at least 3 months after treatment.

**PREGNANCY**

Avoid unless essential—teratogenicity and embryotoxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**

Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

Reduce oral dose in moderate impairment. Avoid oral use in severe impairment. Reduce intravenous dose in severe impairment.
776 Malignant disease

**Vinorelbine (as Vinorelbine tartrate)** 30 mg Navelbine 30mg capsules | 1 capsule (P) £65.98 (Hospital only)
Vinorelbine (as Vinorelbine tartrate) 80 mg Navelbine 80mg capsules | 1 capsule (P) £175.92 (Hospital only)

**Solution for infusion**
- **VINORELBINE (Non-proprietary)**
  - Vinorelbine (as Vinorelbine tartrate) 10 mg per 1 ml Navelbine 10mg/1ml concentrate for solution for infusion vials | 1 vial (P) £139.00 | 10 vial (P) £1,539.80 Vinorelbine 10mg/1ml concentrate for solution for infusion vials | 1 vial (P) £29.00 | 10 vial (P) £292.50
  - Navelbine (Pierre Fabre Ltd) Vinorelbine (as Vinorelbine tartrate) 10 mg per 1 ml Navelbine 10mg/1ml concentrate for solution for infusion vials | 1 vial (P) £297.45 (Hospital only) Navelbine 50mg/5ml concentrate for solution for infusion vials | 10 vial (P) £1,395.79 (Hospital only)

**OTHER CYTOTOXIC DRUGS**

**Arsenic trioxide**

**INDICATIONS AND DOSE**
Acute promyelocytic leukaemia in patients who have relapsed or failed to respond to previous treatment with a retinoid and chemotherapy

**BY INTRAVENOUS INFUSION**
- Adult: (consult local protocol)

- **CAUTIONS** Hypokalaemia (correct before treatment) - hypomagnesaemia (correct before treatment) - previous treatment with anthracyclines (increased risk of QT interval prolongation)

- **INTERACTIONS** → Appendix 1 (arsenic trioxide).
  Avoid concomitant administration with drugs causing QT interval prolongation.

- **SIDE-EFFECTS**
  - **Common or very common** Atrial fibrillation - atrial flutter - diarrhoea - fatigue - haemorrhage - hyperglycaemia - hypokalaemia - leucocyte activation syndrome - musculoskeletal pain - paraesthesia - pleuritic pain - QT interval prolongation
  - **Uncommon** Abdominal pain - blurred vision - hypotension - oedema - pneumonitis - rash - renal failure - seizures - tachycardia - vasculitis
  - **Frequency not known** Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
Leucocyte activation syndrome: Signs and symptoms of leucocyte activation syndrome include unexplained fever, dysphagia, weight gain, pulmonary infiltrates, pleural or pericardial effusions, with or without leucocytosis—treat with high dose corticosteroids, consult product literature.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during treatment in men and women.

- **PREGNANCY** Avoid (teratogenic and embryotoxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING** Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution—limited information available.

- **RENAL IMPAIRMENT** Manufacturer advises caution—limited information available.

- **MONITORING REQUIREMENTS** ECG required before and during treatment—consult product literature.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
- Trisenox (Teva UK Ltd)
  - Arsenic trioxide 1 mg per 1 ml Trisenox 10mg/10ml concentrate for solution for infusion ampoules | 1 ampoule (P) £2,920.00 (Hospital only)

**Crisantaspase**

- **DRUG ACTION** Crisantaspase is the enzyme asparaginase produced by Erwinia chrysanthemi.

**INDICATIONS AND DOSE**
Acute lymphoblastic leukaemia

BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INJECTION
- Adult: (consult product literature)

- **CONTRA-INDICATIONS** History of pancreatitis related to asparaginase therapy

- **SIDE-EFFECTS**
  - **Common or very common** Coagulation disorders - confusion - convulsions - diarrhoea - dizziness - drowsiness - headache - lethargy - liver dysfunction - neurotoxicity - pancreatitis
  - **Uncommon** Anaphylaxis - changes in blood lipids - hyperglycaemia
  - **Rare** CNS depression
  - **Very rare** Abdominal pain - hypertension - myalgia
  - **Frequency not known** Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

- **PREGNANCY** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING** Discontinue breast-feeding.

- **DIRECTIONS FOR ADMINISTRATION** Facilities for the management of anaphylaxis should be available.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- Erwinase (EUSA Pharma Ltd)
  - Crisantaspase 10000 unit Erwinase 10,000unit powder for solution for injection vials | 5 vial (P) £3,065.00

**Eribulin**

**INDICATIONS AND DOSE**
Treatment of locally advanced or metastatic breast cancer when the disease has progressed after treatment with at least 1 chemotherapy regimen for advanced disease

**BY INTRAVENOUS INJECTION**
- Adult: Give on day 1 and day 8 of a 21-day cycle, previous therapy should have included an anthracycline and a taxane in either the adjuvant or previous therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless the patient is unsuitable for these treatments (consult local protocol)

- **CONTRA-INDICATIONS** Congenital long QT syndrome

- **CAUTIONS** Bradycardia - bradycardia - increased susceptibility to QT-interval prolongation - congestive heart failure (increased susceptibility to QT-interval prolongation) - electrolyte disturbances (increased susceptibility to QT-interval prolongation) - susceptibility to QT-interval prolongation

- **INTERACTIONS** → Appendix 1 (eribulin).
  Caution with concomitant use of drugs that prolong QT-interval.

- **SIDE-EFFECTS** Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - myelosuppression -
Etoposide

**INDICATIONS AND DOSE**

Small cell carcinoma of the bronchus, the lymphomas and testicular cancer

**BY MOUTH**

- Adult: 120–240 mg/m² daily for 5 days

**BY INTRAVENOUS INFUSION**

- Adult: (consult product literature)

**SIDE-EFFECTS**

- Alopecia
- Bone-marrow suppression
- Hyperuricaemia
- Irritant to tissues
- Nausea
- Oral mucositis
- Peripheral neuropathy
- QT-interval prolongation
- Thromboembolism
- Tumour lysis syndrome
- Vomiting

**PREGNANCY**

- Avoid (teratogenic in animal studies)
- See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**

- Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

- Avoid in severe impairment.

**MEDICAL FORMS**

- Etoposide (as Etoposide phosphate) 100 mg capsules (Bristol-Myers Squibb Pharmaceuticals Ltd)
- Etoposide 50 mg capsules (Bristol-Myers Squibb Pharmaceuticals Ltd)

**DIRECTIONS FOR ADMINISTRATION**

- Etoposide may be given orally or by slow intravenous infusion, the oral dose being double the intravenous dose. A preparation containing etoposide phosphate can be given by intravenous injection or infusion. Etoposide is usually given daily for 3–5 days and courses should not be repeated more frequently than at intervals of 21 days.

**REMEDIAL/SOURCES OF FURTHER INFORMATION**

- Etoposide (as Etoposide phosphate) "Etopophos" (Hospital only)
- Etoposide 50 mg capsules (Hospital only)
- Etoposide 100 mg capsules (Hospital only)

**SIDE-EFFECTS**

- Bone-marrow suppression
- Dizziness
- Drowsiness
- Hypomagnesaemia
- Hypotension
- Nausea and vomiting
- Peripheral neuropathy
- QT-interval prolongation
- Thromboembolism
- Tumour lysis syndrome
- Vomiting

**CAUTIONS**

- Leg ulcers (review treatment if cutaneous vasculitic ulcerations develop)

**INTERACTIONS**

- Appendix 1 (hydroxyurea)

**SIDE-EFFECTS**

- Alopecia
- Bleeding (in sickle-cell disease)
- Bone-marrow suppression
- Dizziness
- Hyperuricaemia
- Hypomagnesaemia
- Nausea
- Oral mucositis
- Rash
- Reduced sperm count
- Skin cancers
- Thromboembolism
- Tumour lysis syndrome
- Vomiting

**CONCEPTION AND CONTRACEPTION**

- Manufacturer advises effective contraception before and during treatment.

**Hydroxyurea**

**INDICATIONS AND DOSE**

- Treatment of chronic myeloid leukaemia
- Treatment of cancer of the cervix in conjunction with radiotherapy
- Polycythaemia

**BY MOUTH**

- Adult: 20–30 mg/kg daily, alternatively 80 mg/kg every 3 days

**SICKLE-CELL DISEASE**

- Consult with a specialist centre

**BY MOUTH**

- Adult: Initially 15 mg/kg daily, increased in steps of 2.5–5 mg/kg daily every 12 weeks according to response; usual dose 15–30 mg/kg daily; maximum 35 mg/kg per day
Malignant disease

8

Mitotane

Mitotane selectively inhibits the activity of the adrenal cortex, necessitating corticosteroid replacement therapy.

INDICATIONS AND DOSE
Symptomatic treatment of advanced or inoperable adrenocortical carcinoma

BY MOUTH
- Adult: Initially 2–3 g daily in 2–3 divided doses adjusted according to plasma-concentration monitoring. In severe illness initial dose can be increased up to 6 g daily, reduce dose or interrupt treatment if signs of toxicity, discontinue if inadequate response after 3 months

Important safety information
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

CAUTIONS
- Avoid in Acute porphyrias p. 864 • risk of accumulation in overweight patients

INTERACTIONS
- Appendix 1 (mitotane).

SIDE-EFFECTS
- Common or very common Anaemia • anorexia • asthenia • ataxia • cognitive impairment • confusion • diarrhoea • dizziness • drowsiness • endocrine side effects • epigastric discomfort • gastro-intestinal disturbances • gynaecomastia • headache • hypercholesterolaemia • hypertiglyceridaemia • hypogonadism • leucopenia • liver disorders • movement disorder • myasthenia • nausea • neuropathy • neurotoxicity • paraesthesia • prolonged bleeding time • rash • thrombocytopenia • thyroid disorders • vomiting
- Rare Flushing • haematuria • haemorrhagic cystitis • hypersalivation • hypertension • hypouricaemia • ocular disorders • postural hypotension • proteinuria • pyrexia • visual disturbances
- Frequency not known Alopecia • bone-marrow suppression • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

PREGNANCY
- Manufacturer advises avoid. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

BREAST FEEDING
- Discontinue breast-feeding.

HEPATIC IMPAIRMENT
- Manufacturer advises caution in mild to moderate hepatic impairment. Avoid in severe impairment. In mild to moderate hepatic impairment, monitoring of plasma-mitotane concentration is recommended.

RENAL IMPAIRMENT
- Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment. In mild to moderate renal impairment, monitoring of plasma-mitotane concentration is recommended.

MONITORING REQUIREMENTS
- Plasma-mitotane concentration for optimum response

MEDICATIONS
- Monitor plasma-mitotane concentration—consult product literature.

PRESCRIBING AND DISPENSING INFORMATION
- Corticosteroid replacement therapy Corticosteroid replacement therapy is necessary with treatment with mitotane. The dose of glucocorticoid should be increased in case of shock, trauma, or infection.

PATIENT AND CARER ADVICE
- Central nervous system toxicity may affect performance of skilled tasks (e.g. driving). Patients should be warned to contact doctor immediately if injury, infection, or illness occurs (because of risk of acute adrenal insufficiency).

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, capsule Table
- Siklos (Nordic Pharma Ltd)
  - Hydroxycarbamide 100 mg Siklos 100mg tablets | 60 tablet £100.00
  - Hydroxycarbamide 1 gram Siklos 1000mg tablets | 30 tablet £50.00

- Hydroxycarbamide (Non-proprietary)
  - Hydroxycarbamide 500 mg Hydroxycarbamide 500mg capsules | 100 capsule £86.00 DT price = £11.25
  - Hydrea (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Hydroxycarbamide 500 mg Hydroxycarbamide 500mg capsules | 100 capsule £10.47 DT price = £11.25

Mitoxantrone

Mitoxantrone (Mitoxantrone)

INDICATIONS AND DOSE
Metastatic breast cancer | Non-Hodgkin’s lymphoma | Adult acute non-lymphocytic leukaemia | Non-resectable primary hepatocellular carcinoma
- Intravenous infusion
  - Adult: (consult local protocol)

CAUTIONS
- Intrathecal administration not recommended

INTERACTIONS
- Appendix 1 (mitoxantrone).

Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility. Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to
MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

- Nipent ( Hospira UK Ltd)
  Pentostatin 10 mg Nipent 10mg powder for solution for injection vials | 1 vial (PZN) 8663.78 (Hospital only)

Pixintrone

INDICATIONS AND DOSE

Treatment of refractory or multiply relapsed aggressive non-Hodgkin B-cell lymphomas (monotherapy)

BY INTRAVENOUS INFUSION

- Adult: (consult product literature)

CONTRA-INDICATIONS

Active severe infection • risk factors for severe infection

CAUTIONS

Active cardiovascular disease • cardiac risk factors • caution in handling—irritant to tissues • concurrent radiotherapy to the mediastinal area • previous radiotherapy to the mediastinal area • previous therapy with anthracyclines • previous therapy with anthracenidines • non-Hodgkin B-cell lymphomas (monotherapy) • cardiac risk factors • increased risk of cardiac toxicity • Contra-indicated with concurrent immunisation with live virus vaccines.

SIDE-EFFECTS

- Common or very common Abdominal pain • abnormal liver function tests • biochemical disturbances • bone pain • cardiac disorders • cardiac toxicity (during or following treatment) • chromaturia • conjunctivitis • constipation • cough • diarrhoea • drowsiness • dry mouth • dyspepsia • dyspnoea • electrolyte disturbances • haematuria • headache • hypotension • infection • loss of appetite • malaise • nail disorder • oedema • pallor • paraesthesia • pruritus • pyrexia • severe myelosuppression • skin discolouration • tachycardia • taste disturbances • vein discolouration • weight loss
  - Uncommon Anxiety • arrhythmia • arthralgia • arthritis • dizziness • dry eye • keratitis • musculoskeletal pain • musculoskeletal weakness • night sweats • oesophagitis • oliguria • petechiae • pleural effusion • pneumonitis • rash • rectal haemorrhage • rhinorrhea • skin ulcer • sleep disorder • spontaneous erection • tumour progression • vein disorder • vertigo
  - Frequency not known Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • nausea • oral mucositis • photosensitivity • thromboembolism • tumour lysis syndrome • vomiting

CONCEPTION AND CONTRACEPTION

Ensure effective contraception during and for at least 6 months after treatment in men or women.

PREGNANCY

Manufacturer advises avoid—tumour lysis syndrome • vomiting

BREAST FEEDING

Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT

No information available—manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.

RENA L IMPAIRMENT

No information available—manufacturer advises caution.

MONITORING REQUIREMENTS

Baseline investigations should include a full blood count, assessment of cardiac function measured by left ventricular ejection fraction, and measurement of serum concentrations of total bilirubin and total creatinine.

Pentostatin

INDICATIONS AND DOSE

Hairy cell leukaemia (initiated in specialist centres)

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

- Adult: To be given on alternate weeks (consult product literature)

INTERACTIONS

- Appendix 1 (pentostatin).

SIDE-EFFECTS

- Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • immunosuppression • myelosuppression • nausea • neurotoxicity (withhold or discontinue) • oral mucositis • severe rash (withhold treatment) • thromboembolism • tumour lysis syndrome • vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Pentostatin can cause myelosuppression, immunosuppression, and a number of other side effects that may be severe. Treatment should be withheld in patients who develop a severe rash, and withheld or discontinued in patients showing signs of neurotoxicity.

CONCEPTION AND CONTRACEPTION

Manufacturer advises that men should not father children during and for 6 months after treatment.

PREGNANCY

Avoid (teratogenic in animal studies).

See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

BREAST FEEDING

Discontinue breast-feeding.

HEPATIC IMPAIRMENT

Manufacturer advises caution—limited information available.

RENA L IMPAIRMENT

Avoid if creatinine clearance less than 60 ml/minute.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

- Nipent ( Hospira UK Ltd)
  Pentostatin 10 mg Nipent 10mg powder for solution for injection vials | 1 vial (PZN) 8663.78 (Hospital only)

INFORMATION AND DOSE

Treatment of refractory or multiply relapsed aggressive non-Hodgkin B-cell lymphomas (monotherapy)

BY INTRAVENOUS INFUSION

- Adult: (consult product literature)
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma (February 2014) NICE TA306
Pixantrone monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma in patients:
- who have previously been treated with rituximab and
d who are receiving third- or fourth-line treatment and
- if the manufacturer provides pixantrone with the discount agreed in the patient access scheme. www.nice.org.uk/TA306

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**
ELECTROLYTES: May contain Sodium
- Pixuvri (CTI Life Sciences Ltd) ▼
- Pixantrone (as Pixantrone dimaleate) 29 mg Pixuvri 29mg powder for concentrate for solution for infusion vials | 1 vial £295 no price available

**Procarbazine**
- **DRUG ACTION** Procarbazine is a mild monoamine-oxidase inhibitor.

**INDICATIONS AND DOSE**
Hodgkin’s lymphoma
- **Adult:** (consult local protocol)

**Important safety information**
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

**CONTRA-INDICATIONS**
Pre-existing severe leucopenia - pre-existing severe thrombocytopenia

**CAUTIONS**
Cardiovascular disease - cerebrovascular disease - epilepsy - phaeochromocytoma - procarbazine is a mild monoamineoxidase inhibitor (dietary restriction is rarely considered necessary)

**INTERACTIONS** ▶ Appendix 1 (procarbazine).
Alcohol ingestion may cause a disulfiram-like reaction.

**SIDE-EFFECTS**
- Common or very common Loss of appetite
- Frequency not known Alopecia - bone-marrow suppression - hypersensitivity rash (discontinue treatment) - hyperuricaemia - jaundice - myelosuppression - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting
- **PREGNANCY** Avoid (teratogenic in animal studies and isolated reports in humans). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Caution in mild to moderate impairment. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Caution in mild to moderate impairment. Avoid in severe impairment.

**Raltitrexed**
- **DRUG ACTION** Raltitrexed is a thymidylate synthase inhibitor.

**INDICATIONS AND DOSE**
 Palliation of advanced colorectal cancer when fluorouracil and folinic acid cannot be used
BY INTRAVENOUS INFUSION
 ▶ Adult: (consult local protocol)

**INTERACTIONS** ▶ Appendix 1 (raltitrexed).
- **SIDE-EFFECTS** Alopecia - bone-marrow suppression - extravasation - gastro-intestinal effects - hyperuricaemia - myelosuppression - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting
- **CONCEPTION AND CONTRACEPTION** Ensure effective contraception during and for at least 6 months after treatment in men or women.
- **PREGNANCY** See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Caution in mild to moderate impairment. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Reduce dose and increase dosing interval if creatinine clearance less than 65 mL/minute (consult product literature). Avoid if creatinine clearance less than 25 mL/minute.

**NATIONAL FUNDING/ACCESS DECISIONS**
NICE technology appraisals (TAs)
- Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005) NICE TA93
Raltitrexed is **not** recommended for the treatment of advanced colorectal cancer. Its use should be confined to clinical studies. www.nice.org.uk/TA93

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**
- Tomudex (Hospira UK Ltd) Raltitrexed 2 mg Tomudex 2mg powder for solution for infusion vials | 1 vial £175.00

**Trabectedin**
- **INDICATIONS AND DOSE**
  Treatment of advanced soft tissue sarcoma when treatment with anthracyclines and ifosfamide has failed or is contra-indicated | Treatment of relapsed platinum-sensitive ovarian cancer (in combination with pegylated liposomal doxorubicin)
  BY INTRAVENOUS INFUSION
  ▶ Adult: (consult product literature or local protocols)

**CONTRA-INDICATIONS**
Elevated creatine phosphokinase (consult product literature).

**INTERACTIONS** Caution in concomitant use with hepatotoxic drugs (avoid alcohol).
2.3 Cytotoxic drug-induced side effects

FOLATES

Folinic acid

**INDICATIONS AND DOSE**

Prevention of methotrexate-induced adverse effects

BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION

- Adult: 15 mg every 6 hours for 24 hours, to be started usually 12–24 hours after start of methotrexate infusion, dose may be continued by mouth, consult local treatment protocol for further information

Suspected methotrexate overdosage

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

- Adult: Initial dose equal to or exceeding dose of methotrexate, to be given at a maximum rate of 160 mg/minute, consult poisons information centres for advice on continuing management

Adjunct to fluorouracil in colorectal cancer

BY SLOW INTRAVENOUS INJECTION

- Adult: (consult product literature)

**SODIOFOLIN®**

As an antidote to methotrexate

BY INTRAVENOUS INFUSION OR BY INTRAVENOUS INFUSION

- Adult: (consult product literature)

Adjunct to fluorouracil in colorectal cancer

BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

- Adult: (consult product literature)

**CONTRA-INDICATIONS**

Intrathecal injection

**CAUTIONS**

Not indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B12 deficiency • avoid simultaneous administration of methotrexate

**INTERACTIONS**

→ Appendix 1 (folicates).

**SIDE-EFFECTS**

- Rare • Agitation (after high doses) • depression (after high doses) • insomnia (after high doses) • pyrexia (after parenteral use)

**PREGNANCY**

Not known to be harmful; benefit outweighs risk.

**BREAST FEEDING**

Presence in milk unknown but benefit outweighs risk.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

- Trabectedin for the treatment of advanced soft tissue sarcoma (February 2010) NICE TA185
- Trabectedin for the treatment of relapsed ovarian cancer (April 2011) NICE TA222

Trabectedin in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010) NICE TA212

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is not recommended for the treatment of metastatic colorectal cancer. www.nice.org.uk/TA212

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- FOLINIC ACID (Non-proprietary)
  
  Folinic acid (as Calcium folinate) 3 mg per 1 ml Calcium folinate 3mg/1ml solution for injection ampoules | 5 ampoule [PSt] £30.00–£36.00
  
  Folinic acid (as Calcium folinate) 7.5 mg per 1 ml Calcium folinate 15mg/2ml solution for injection ampoules | 5 ampoule [PSt] £38.99–£39.00
  
  Folinic acid (as Calcium folinate) 10 mg per 1 ml Calcium folinate 50mg/5ml solution for injection ampoules | 1 vial [PSt] £18.44 (Hospital
Levofolic acid

**DRUG ACTION** Levofolic acid is an isomer of folinic acid.

**INDICATIONS AND DOSE**

**Prevention of methotrexate-induced adverse effects**
- **BY INTRAMUSCULAR INJECTION** OR **BY INTRAVENOUS INJECTION**
  - Adult: Usual dose 7.5 mg every 6 hours for 10 doses, usually started 12–24 hours after beginning of methotrexate infusion

**Suspected methotrexate overdosage**
- **BY INTRAVENOUS INFUSION** OR **BY INTRAVENOUS INJECTION**
  - Adult: Initial dose at least 50% of the dose of methotrexate, intravenous infusion to be administered at a maximum rate of 150 mg/minute, consult poisons information centres for advice on continuing management

**Adjunct to fluorouracil in colorectal cancer**
- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: (consult product literature)

**CONTRA-INDICATIONS** Intrathecal injection

**CAUTIONS** Not indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B<sub>12</sub> deficiency; avoid simultaneous administration of methotrexate

**INTERACTIONS** → Appendix 1 (folates).

**SIDE-EFFECTS**
- Rare Agitation (after high doses) - depression (after high doses) - insomnia (after high doses) - pyrexia (after parenteral use)
- PREGNANCY Not known to be harmful; benefit outweighs risk.
- BREAST FEEDING Presence in milk unknown but benefit outweighs risk.

**MEDICINAL FORMS**

<table>
<thead>
<tr>
<th>Dosage Form</th>
<th>Dosage Details</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodiofolin</td>
<td>50 mg per 1 ml</td>
<td>Pfizer Ltd</td>
</tr>
<tr>
<td>Refolinon</td>
<td>300 mg/10 ml</td>
<td>Sodiofolin</td>
</tr>
<tr>
<td>Disodium folinate</td>
<td>1000 mg/10 ml</td>
<td>Pfizer Ltd</td>
</tr>
</tbody>
</table>

*Note: Dosages and manufacturers may vary.*

**Iron Chelators**

**Dexrazoxane**

**INDICATIONS AND DOSE**

**CARDIOXANE®**

Prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin treatment in advanced or metastatic breast cancer patients who have received a prior cumulative dose of 300 mg/m<sup>2</sup> of doxorubicin or a prior cumulative dose of 540 mg/m<sup>2</sup> of epirubicin when further anthracycline treatment is required

**BY INTRAVENOUS INFUSION**
- Adult: Administer 10 times the doxorubicin-equivalent dose or 10 times the epirubicin-equivalent dose, dose to be given 30 minutes before anthracycline administration

**SAVENE®**

Anthracycline extravasation

**BY INTRAVENOUS INFUSION**
- Adult: Initially 1 g/m<sup>2</sup>; daily (max. per dose 2 g) for 2 days, then 500 mg/m<sup>2</sup> for 1 day, first dose to be given as soon as possible and within 6 hours after injury

**CONTRA-INDICATIONS** Children

**CAUTIONS** Myelosuppression (effects may be additive to those of chemotherapy)

**CARDIOXANE®**

Manufacturer advises caution in patients with heart failure—no information available • manufacturer advises caution in patients with myocardial infarction in previous 12 months—no information available • manufacturer advises caution in patients with symptomatic valvular heart disease—no information available • manufacturer advises caution in patients with uncontrolled angina—no information available

**INTERACTIONS** → Appendix 1 (dexrazoxane).

**SIDE-EFFECTS**

**CARDIOXANE®**
- Common or very common Anorexia - asthenia - diarrhoea - dizziness - dry mouth - dyspnoea - erythema - infection - malaise - nausea - oedema - paraesthesia - peripheral neuropathy - stomatitis - syncope - vomiting
- Uncommon Abdominal pain - acute myeloid leukaemia - constipation - cough - dyspepsia - headache - lymphoedema - nail disorder - reduced ejection fraction - tachycardia - thromboembolism (when given with cytotoxic drugs)

**Frequency not known** Alopecia - anaemia - blood disorders - fatigue - injection-site reactions - leucopenia - phlebitis - pruritis - pyrexia - thrombocytopenia

**SAVENE®**
- Uncommon Drowsiness - myalgia - thromboembolism (when given with cytotoxic drugs) - weight loss

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during and for at least 3 months after treatment in men and women.

**PREGNANCY** Avoid unless essential (toxicity in animal studies).

**BREAST FEEDING** Discontinue breast-feeding.
PREGNANCY

Manufacturer advises that if anthracycline dose is reduced, reduce the Cardioxane® dose by a similar ratio.

SAVENE®

Manufacturer advises avoid—no information available.

RENEWAL IMPAIRMENT

Cardioxane®

Manufacturer advises reduce dose by 50% if creatinine clearance less than 40 mL/minute.

SAVENE®

Manufacturer advises avoid—risk of accumulation.

MONITORING REQUIREMENTS

◆ Monitor full blood count.
◆ Monitor serum creatinine levels.
◆ Monitor for cardiac toxicity.
◆ Monitor liver function.

DIRECTIONS FOR ADMINISTRATION

Local coolants such as ice packs should be removed at least 15 minutes before administration.

Cardioxane®

For intravenous infusion, give intermittently in compound sodium lactate; reconstitute each vial with 25 mL water for injections and dilute each vial with 25–100 mL infusion fluid; give requisite dose over 15 minutes.

SAVENE®

For intravenous infusion, reconstitute each 500–mg vial with 25 mL of diluent; dilute requisite dose further in remaining diluent and give over 1–2 hours into a large vein in an area other than the one affected.

MEDITICL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

◆ Cardioxane (Clinigen Healthcare Ltd)
  Dextrazoxane 500 mg Cardioxane 500 mg powder for solution for infusion vials | 1 vial [POD] £156.57

Powder and solvent for solution for infusion

Electrolytes: May contain potassium, sodium

Dextrazoxane 500 mg Saven 1000 mg powder for concentrate and solvent for solution for infusion vials | 10 vial [POD] no price available

RECOMBINANT HUMAN KERATINOCYTE GROWTH FACTORS

Palifermin

◆ Drug Action Palifermin is a human keratinocyte growth factor.

INDICATIONS AND DOSE

Management of oral mucositis in patients with haematological malignancies receiving myeloblastic radiochemotherapy with autologous haematopoietic stem-cell support

By intravenous injection

◆ Adult: 60 micrograms/kg once daily for 3 doses (third dose given 24–48 hours before myeloblastic therapy) then 3 further doses at least 24 hours after myeloblastic therapy, and more than 4 days after most recent palifermin injection, starting on the same day as (but after) stem-cell infusion

SIDE-EFFECTS

◆ Arthralgia - discoloration of the tongue - erythema - fever - oedema - oral paraesthesia - pruritus - rash - skin hyperpigmentation - taste disturbance - thickening of the tongue

PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

◆ Kepivance (Swedish Orphan Biovitrum Ltd)
  Palifermin 6.25 mg Kepivance 6.25 mg powder for solution for injection vials | 6 vial [POD] £265.44

UROPROTECTIVE DRUGS

Mesna

INDICATIONS AND DOSE

Cytotoxic induced urothelial toxicity

BY MOUTH OR BY INTRAVENOUS INJECTION

◆ Adult: Dose to be calculated according to oxazaphosphorine (cyclophosphamide or ifosfamide) treatment (consult product literature)

SIDE-EFFECTS

◆ Common or very common: Colic - depression - diarrhoea - fatigue - headache - hypotension - irritability - joint pains - limb pains - nausea - rash - tachycardia - vomiting

◆ Rare: Hypersensitivity reactions (more common in patients with auto-immune disorders)

ALLERGY AND CROSS-SENSITIVITY

Contraindicated if history of hypersensitivity to thiol-containing compounds.

PREGNANCY

Not known to be harmful.

See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

EFFECT ON LABORATORY TESTS

False positive urinary ketones. False positive or false negative urinary erythrocytes.

DIRECTIONS FOR ADMINISTRATION

For oral administration of the injection, contents of ampoule are taken in a flavoured drink such as orange juice or cola which may be stored in a refrigerator for up to 24 hours in a sealed container.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

◆ Mesna (Non-proprietary)
  Mesna 400 mg Mesna 400 mg tablets | 10 tablet [POD] £134.30-£134.40
  Mesna 600 mg Mesna 600 mg tablets | 10 tablet [POD] £190.60

Solution for injection

◆ Mesna (Non-proprietary)
  Mesna 100 mg per 1 ml Mesna 1g/10ml solution for injection ampoules | 15 ampoule [POD] £64.1 15 Mesna 400mg/4ml solution for injection ampoules | 15 ampoule [POD] £201.15

2.4 Hyperuricaemia associated with cytotoxic drugs

Drugs used for Hyperuricaemia associated with cytotoxic drugs not listed below; Allopurinol, p. 905
Malignant disease

URATE OXIDASES

**Rasburicase**

**INDICATIONS AND DOSE**

Prophylaxis and treatment of acute hyperuricaemia, before and during initiation of chemotherapy, in patients with haematological malignancy and high tumour burden at risk of rapid lysis

**BY INTRAVENOUS INFUSION**

- Adult: 200 micrograms/kg once daily for up to 7 days according to plasma-urate concentration

- Precautions: Monitor closely for reactions.

**SIDE-EFFECTS**

- Fever
- Headache
- Rash
- Vomiting

**CONTRA-INDICATIONS**

- G6PD deficiency

**CAUTIONS**

- Atopic allergies

**MEDICINAL FORMS**

- Powder and solvent for solution for infusion

**Powder and solvent for solution for infusion**

- Rasburicase 1.5 mg (Fasturtec 1.5mg powder and solvent for solution for infusion vials $1 3 3$ 2 0 8 $1 3$ Hospital only)

- Rasburicase 7.5 mg (Fasturtec 7.5mg powder and solvent for solution for infusion vials $1 1 2 8 9 4 4$ Hospital only)

- Medicinal forms

- There can be variation in the licensing of different medicines containing the same drug.

**Hormones, malignant disease**

Hormonal manipulation has an important role in the treatment of breast, prostate, and endometrial cancer, and a more marginal role in the treatment of hypernephroma. These treatments are not curative, but may provide excellent palliation of symptoms in selected patients, sometimes for a period of years. Tumour response, and treatment toxicity should be carefully monitored and treatment changed if progression occurs or side-effects exceed benefit.

**Oestrogens**

Diethylstilbestrol p. 788 is sometimes used to treat prostate cancer, but it is not usually used first-line because of its side-effects. It is occasionally used in postmenopausal women with breast cancer. Ethinylestradiol p. 655 is the most potent oestrogen available; unlike other oestrogens it is only slowly metabolised in the liver.

**Progestogens**

Progestogens have a role in the treatment of endometrial cancer; their use in breast cancer and renal cell cancer has declined. Progestogens are now rarely used to treat prostate cancer. Medroxyprogesterone acetate p. 695 or megestrol acetate p. 788 are usually chosen and can be given orally; high-dose or parenteral treatment cannot be recommended.

**Androgens**

Testosterone esters have largely been superseded by other drugs for breast cancer.

**Hormone Antagonists**

**Breast Cancer**

The management of patients with breast cancer involves surgery, radiotherapy, drug therapy, or a combination of these. For operable breast cancer, treatment before surgery (neoadjuvant therapy) reduces the size of the tumour and facilitates breast-conserving surgery; hormone antagonist therapy (e.g. letrozole) is chosen for steroid hormone-receptor-positive breast cancer and chemotherapy for steroid hormone-receptor-negative tumours or for younger women.

**Early breast cancer**

All women should be considered for adjuvant therapy following surgical removal of the tumour. Adjuvant therapy is used to eradicate the micrometastases that cause relapses. Choice of adjuvant treatment is determined by the risk of recurrence, steroid hormone-receptor status of the primary tumour, and menopausal status.

Adjuvant therapy comprises cytotoxic chemotherapy and hormone-antagonist therapy. Women with steroid hormone-receptor-positive breast cancer are considered for hormone-antagonist therapy (preceded by cytotoxic chemotherapy if necessary) whilst women with steroid hormone-receptor-negative breast cancer should be considered for cytotoxic chemotherapy.

Aromatase inhibitors act predominantly by blocking the conversion of androgens to oestrogens in the peripheral tissues. They do not inhibit ovarian oestrogen synthesis and should not be used in premenopausal women. Anastrozole p. 792 and letrozole p. 793 are non-steroidal aromatase inhibitors; exemestane p. 792 is a steroidal aromatase inhibitor. Aromatase inhibitors are usually prescribed as initial adjuvant therapy in postmenopausal women with oestrogen-receptor-positive tumours; tamoxifen p. 791, an oestrogen-receptor antagonist, is used if an aromatase inhibitor is not appropriate. Adjuvant hormone antagonist therapy should generally be continued for 5 years following removal of the tumour. In postmenopausal women considered for extended adjuvant therapy, 5 years of tamoxifen is followed by letrozole for a further 2–3 years.

**Advanced breast cancer**

Treatment of advanced breast cancer depends on the patient’s drug history and an assessment of disease severity. Aromatase inhibitors, such as anastrozole or letrozole, are the preferred treatment in postmenopausal women with oestrogen-receptor-positive advanced breast cancer, a long disease-free interval following treatment for early breast cancer, and disease limited to bone or soft tissues; tamoxifen can be used if aromatase inhibitors are not suitable. Progestogens, such as medroxyprogesterone acetate p. 695, may be used after aromatase inhibitors and tamoxifen in postmenopausal women.
Widespread, with strontium ranelate p.

Bone disease can often be palliated with irradiation or, if to other hormone manipulation e.g. with an anti-androgen.

Occasional patients respond disease progression despite this treatment (hormone-refractory prostate cancer), but occasional patients respond to other hormone manipulation e.g. with an anti-androgen.

Cytotoxic chemotherapy is indicated for advanced steroid hormone-receptor-negative tumours and for aggressive disease, particularly when metastases involve visceral sites (e.g. the liver) or if the disease-free interval following treatment for early breast cancer is short.

Cytotoxic drugs used in breast cancer

An anthracycline combined with fluorouracil p. 761 and cyclophosphamide p. 750, and sometimes also with methotrexate p. 762 is effective. Cyclophosphamide, methotrexate, and fluorouracil can be useful if an anthracycline is inappropriate (e.g. in cardiac disease).

Metastatic disease

The choice of chemotherapeutic regimen will be influenced by whether the patient has previously received adjuvant treatment and the presence of any co-morbidity.

For women who have not previously received chemotherapy, an anthracycline (such as doxorubicin hydrochloride p. 754 or epirubicin hydrochloride p. 756) alone or in combination with another cytotoxic drug is the standard initial therapy for metastatic breast disease.

Patients with anthracycline-refractory or resistant disease should be considered for treatment with a taxane either alone or in combination with trastuzumab p. 743 if they have tumours that overexpress HER2. Other cytotoxic drugs with activity against breast cancer include capcitabine p. 757, mitoxantrone p. 778, mitomycin p. 767, and vinorelbine p. 775. Trastuzumab p. 743 alone is an option for chemotherapy-resistant cancers that overexpress HER2.

Trastuzumab emtansine can be used as monotherapy in HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, or when there is a disease recurrence during or following adjuvant therapy.

The use of bisphosphonates in patients with metastatic breast cancer may reduce pain and prevent skeletal complications of bone metastases.

Gonadorelin analogues and gonadotrophin-releasing hormone antagonists

Metastatic cancer of the prostate usually responds to hormonal treatment aimed at androgen depletion. Standard treatments include bilateral subcapsular orchidectomy or use of a gonadorelin analogue (buserelin p. 631, goserelin p. 632, leuprolrelate acetate p. 633, or triptorelin p. 635). The gonadotrophin-releasing hormone antagonist, degarelix p. 787, is also available. Response in most patients lasts for 12 to 18 months. No entirely satisfactory therapy exists for disease progression despite this treatment (hormone-refractory prostate cancer), but occasional patients respond to other hormone manipulation e.g. with an anti-androgen.

Bone disease can often be palliated with irradiation or, if widespread, with strontium ranelate p. 626 or prednisolone p. 585.

Gonadorelin analogues

Gonadorelin analogues are as effective as orchidectomy or diethylstilbestrol p. 788 but are expensive and require parenteral administration, at least initially. They cause initial stimulation then depression of luteinising hormone release by the pituitary.

Gonadorelin analogues are also used in women for breast cancer and other indications. The gonadorelin analogues cause side-effects similar to the menopause in women and orchidectomy in men.

Anti-androgens

Cyproterone acetate p. 662, flutamide p. 787 and bicalutamide p. 786 are anti-androgens that inhibit the tumour ‘flare’ which may occur after commencing gonadorelin analogue administration. Cyproterone acetate and flutamide are also licensed for use alone in patients with metastatic prostate cancer refractory to gonadorelin analogue therapy. Bicalutamide is used for prostate cancer either alone or as an adjunct to other therapy, according to the clinical circumstances.

Abiraterone acetate p. 786 (in combination with prednisone p. 586 or prednisolone p. 585) and enzalutamide p. 787 are licensed for metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with a docetaxel-containing chemotherapy regimen. Abiraterone acetate p. 786 and enzalutamide p. 787 are also licensed to treat metastatic castration-resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. Medical castration with a luteinising hormone-releasing hormone analogue should be continued during treatment in patients not surgically castrated.

Gonadotrophin-releasing hormone antagonists

Degarelix p. 787 is a gonadotrophin-releasing hormone antagonist used to treat advanced hormone-dependent prostate cancer. It does not induce a testosterone surge or tumour ‘flare’, therefore anti-androgen therapy is not required.

Somatostatin analogues

Lanreotide p. 789, octreotide p. 789 and pasireotide p. 790 are analogous of the hypothalamic release-inhibiting hormone somatostatin. Lanreotide and octreotide are indicated for the relief of symptoms associated with neuroendocrine (particularly carcinoid) tumours and acromegaly. Additionally, lanreotide is licensed for the treatment of thyroid tumours and octreotide is also licensed for the prevention of complications following pancreatic surgery. Lanreotide (Somatuline Autogel®) is also licensed for the treatment of unresectable locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded. Octreotide long-acting depot injection is licensed for treatment of advanced neuroendocrine tumours of the midgut, or treatment where primary origin is not known but non-midgut sites of origin have been excluded. Octreotide may also be valuable in reducing vomiting in palliative care and in stopping variceal bleeding [unlicensed indication]—see also vasopressin p. 576 and terlipressin acetate p. 77. Pasireotide is licensed for the treatment of Cushing’s disease when surgery has failed or is inappropriate.
Abiraterone acetate

**INDICATIONS AND DOSE**

Metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with a docetaxel-containing chemotherapy regimen (in combination with prednisone or prednisolone) | Metastatic castration-resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (in combination with prednisone or prednisolone)

**BY MOUTH**
- Adult: 1 g once daily, for dose of concurrent prednisone or prednisolone—consult product literature

**CAUTIONS**
- Diabetes (increased risk of hyperglycaemia—monitor blood sugar frequently) | history of cardiovascular disease
- Hypokalaemia before treatment (if significant risk of congestive heart failure, such as history of cardiac failure, uncontrolled hypertension or cardiac events, consult product literature for management and increased monitoring).

**INTERACTIONS** → Appendix 1 (abiraterone). Caution with concurrent chemotherapy—safety and efficacy not established. Caution with concomitant use of drugs known to be associated with myopathy or rhabdomyolysis.

**SIDE-EFFECTS**
- **Common or very common** Angina | arhythmia | atrial fibrillation | diarrhoea | dyspepsia | fractures | haematuria | heart failure | hepatotoxicity | hypertension | hypertriglyceridaemia | hypokalaemia | peripheral oedema | rash | sepsis | tachycardia | urinary tract infection

- **Uncommon** Adrenal insufficiency | myopathy | rhabdomyolysis

- **Rare** Allergic alveolitis

**CONCEPTION AND CONTRACEPTION**

Men should use condoms if their partner is pregnant, and use condoms in combination with another effective contraceptive method if their partner is of child-bearing potential—toxicity in animal studies.

**HEPATIC IMPAIRMENT**

Use with caution in moderate impairment and only if benefit clearly outweighs risk. Avoid in severe impairment.

**RENAL IMPAIRMENT**

Use with caution in severe impairment—no information available.

**MONITORING REQUIREMENTS**

- Monitor blood pressure, serum potassium concentration, and fluid balance before treatment, and at least monthly during treatment—consult product literature for management of hypertension, hypokalaemia and oedema.
- Monitor liver function before treatment, then every 2 weeks for the first 3 months of treatment, then monthly thereafter—interrupt treatment if serum alanine aminotransferase or aspartate aminotransferase greater than 5 times the upper limit (consult product literature for details of restarting treatment at a lower dose) and discontinue permanently if 20 times the upper limit.

**NATIONAL FUNDING/ACCESS DECISIONS**

- Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (June 2012) NICE TA259

Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration-resistant metastatic prostate cancer only if:
- their disease has progressed on or after one docetaxel-containing chemotherapy regimen, and
- the manufacturer provides abiraterone with the discount agreed in the patient access scheme. Patients currently receiving abiraterone in combination with prednisone or prednisolone whose disease does not meet the first criteria should be able to continue therapy until they and their clinician consider it appropriate to stop. [www.nice.org.uk/TA259](www.nice.org.uk/TA259)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (July 2012) that abiraterone (Zytiga®), in combination with prednisone or prednisolone, is accepted for restricted use within NHS Scotland for the treatment of metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with docetaxel-containing chemotherapy regimen, and have received only one prior chemotherapy regimen.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 23**
  - Zytiga (Janssen-Cilag Ltd)
    - Abiraterone acetate 250 mg Zytiga 250mg tablets | 120 tablet pack £2,930.00

**Bicalutamide**

**INDICATIONS AND DOSE**

Locally advanced prostate cancer at high risk of disease progression either alone or as adjuvant treatment to prostatectomy or radiotherapy | Locally advanced, non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate

**BY MOUTH**
- Adult: 150 mg once daily

**Advanced prostate cancer, in combination with gonadorelin analogue or surgical castration**

**BY MOUTH**
- Adult: 50 mg once daily, to be started at the same time as surgical castration or at least 3 days before gonadorelin therapy

**CAUTIONS**

- Risk of photosensitivity—avoid excessive exposure to UV light and sunlight

**INTERACTIONS** → Appendix 1 (bicalutamide).

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain | alopecia | anaemia | arthralgia | asthenia | breast tenderness | chest pain | cholestasis | constipation | decreased appetite | decreased libido | depression | dizziness | dry skin | dyspepsia | fatigue | gynaecomastia | haematuria | hepatotoxicity | hirsutism | hot flushes | impotence | jaundice | nausea | oedema | pruritus | rash | somnolence | weight gain

- **Uncommon** Angioedema | hypersensitivity reactions | interstitial lung disease | urticaria

- **Rare** Hepatic failure | photosensitivity reactions

**HEPATIC IMPAIRMENT**

Increased accumulation possible in moderate to severe impairment—manufacturer advises caution.

**MONITORING REQUIREMENTS**

Consider periodic liver function tests.
Enzalutamide

INDICATIONS AND DOSE
Metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after docetaxel therapy

BY MOUTH
- Adult: 160 mg once daily, for dose adjustments due to side-effects, consult product literature

- CAUTIONS
  - Alcoholism - bradycardia - brain injury - brain metastases - brain tumours - history of QT-interval prolongation - history or risk of seizure - recent cardiovascular disease - risk factors for QT-interval prolongation - stroke - uncontrolled hypertension
  - INTERACTIONS → Appendix 1 (enzalutamide).
  - Caution with concurrent use of medication which may lower seizure threshold. Caution with concurrent chemotherapy—safety and efficacy not established. Caution with concomitant use of drugs that prolong QT interval.

- SIDE-EFFECTS
  - Common or very common Anxiety - cognitive disorder - dry skin - falls - fractures - headache - hot flush - hypertension - memory impairment - neutropenia - pruritus - visual hallucinations
  - Uncommon Leucopenia - seizure

- CONCEPTION AND CONTRACEPTION
  - Men should use condoms during treatment and for 3 months after stopping treatment if their partner is pregnant, and use condoms in combination with another effective contraceptive method if their partner is of child-bearing potential—toxicity in animal studies.

- HEPATIC IMPAIRMENT
  - Manufacturer advises caution in moderate impairment. Avoid in severe impairment.

- RENAL IMPAIRMENT
  - Caution in severe impairment—no information available.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  - CAUTIONARY AND ADVISORY LABELS 25
  - Enzalutamide 40 mg
    - Xtandi (Astellas Pharma Ltd) ▼
    - Enzalutamide 40 mg capsules | 112 capsule £2,734.67

Flutamide

INDICATIONS AND DOSE
Advanced prostate cancer

BY MOUTH
- Adult: 250 mg 3 times a day

- CAUTIONS
  - Avoid excessive alcohol consumption - avoid in Acute porphyrias p. 864 - cardiac disease (oedema reported)

- INTERACTIONS → Appendix 1 (flutamide).

- SIDE-EFFECTS

- HEPATIC IMPAIRMENT
  - Use with caution (hepatotoxic).

- MONITORING REQUIREMENTS
  - Liver function tests, monthly for first 4 months, periodically thereafter and at the first sign or symptom of liver disorder (e.g. pruritus, dark urine, persistent anorexia, jaundice, abdominal pain, unexplained influenza-like symptoms).

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - FLUTAMIDE (Non-proprietary)
    - Flutamide 250 mg
      - Flutamide 250mg tablets | 84 tablet £98.58 DT price = £74.84

Degarelix

INDICATIONS AND DOSE
Advanced hormone-dependent prostate cancer

BY SUBCUTANEOUS INJECTION
- Adult: Initially 240 mg, to be administered as 2 injections of 120 mg, then 80 mg every 28 days, dose to be administered into the abdominal region

- CAUTIONS
  - Diabetes - susceptibility to QT-interval prolongation

- INTERACTIONS
  - Avoid concomitant use of drugs that prolong QT interval.

- SIDE-EFFECTS
  - Common or very common
    - Asthenia - dizziness - drowsiness - headache - hot flushes - influenza-like symptoms - injection-site reactions - insomnia - nausea - night sweats - sweating - weight gain
  - Uncommon

- HEPATIC IMPAIRMENT
  - Manufacturer advises caution in severe impairment—no information available.

- RENAL IMPAIRMENT
  - Manufacturer advises caution in severe impairment—no information available.

- MONITORING REQUIREMENTS
  - Monitor bone density.
**OESTROGENS**

**Diethylstilbestrol**

*(Stilboestrol)*

**INDICATIONS AND DOSE**

- Breast cancer in postmenopausal women
  - By mouth
    - Adult: 10–20 mg daily
- Prostate cancer
  - By mouth
    - Adult: 1–3 mg daily

**CAUTIONS**

- Cardiovascular disease
- **SIDE-EFFECTS**
  - Arterial thrombosis
  - Bone pain
  - Bronchitis
  - Cataracts
  - Central nervous system changes
  - Coughing
  - Dizziness
  - Dryness
  - Fluid retention
  - Headache
  - Hirsutism
  - Indigestion
  - Insomnia
  - Jaundice
  - Loss of vision during treatment
  - Pancreatitis (shortly after administration)
  - Pancreatitis (after long-term treatment)
  - Pruritus
  - Rash
  - Skin reactions
  - Tumour flare
  - Urinary frequency
  - Urticaria
  - Vomiting
  - Weight change
  - Weight gain

**PREGNANCY**

Avoid. Reversible feminisation of male fetuses reported in animal studies. Risk of hypospadias in male fetuses and masculinisation of female fetuses.

**BREAST FEEDING**

Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

Avoid. Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **DIETHYLSILBESTROL (Non-proprietary)**
  - Diethylstilbestrol 1 mg
    - Diethylstilbestrol 1mg tablets | 28 tablet [P] £120.00 DT price = £112.47
  - Diethylstilbestrol 5 mg
    - Diethylstilbestrol 5mg tablets | 28 tablet [P] £208.00 DT price = £208.00

**PROGESTOGENS**

**Megestrol acetate**

**INDICATIONS AND DOSE**

- Treatment of breast cancer
  - By mouth
    - Adult: 160 mg once daily

**CONTRA-INDICATIONS**

- Acute porphyrias p. 864
- Breast cancer (unless progestogens are being used in the management of this condition)
- Genital cancer (unless progestogens are being used in the management of this condition)
- History during pregnancy of idiopathic jaundice
- History during pregnancy of pheochromocytoma
- History during pregnancy of severe pruritus
- History of liver tumours
- Severe arterial disease
- Undiagnosed vaginal bleeding

**CAUTIONS**

- Asthma
- Cardiac dysfunction
- Conditions that may worsen with fluid retention
- Diabetes (progestogens can decrease glucose tolerance—monitor patient closely)
- Epilepsy
- History of depression
- Hypertension
- Migraine
- Susceptibility to thromboembolism (particular caution with high dose)

**INTERACTIONS**

- Appendix 1 (progestogens)

**SIDE-EFFECTS**

- Acne
- Adrenal insufficiency
- Alopexia
- Anaphylactoid reactions
- Asthenia
- Bloating
- Breast tenderness
- Cardial tunnel syndrome
- Change in libido
- Constipation
- Cushings syndrome
- Depression
- Diarrhoea
- Dizziness
- Drowsiness
- Fluid retention
- Headache
- Hirsutism
- Indigestion
- Insomnia
- Jaundice
- Loss of vision during treatment
- Pancreatitis (shortly after administration)
- Pancreatitis (after long-term treatment)
- Pruritus
- Rash
- Skin reactions
- Tumour flare
- Urinary frequency
- Urticaria
- Vomiting
- Weight change
- Weight gain

**PREGNANCY**

Avoid. Reversible feminisation of male fetuses reported in animal studies. Risk of hypospadias in male fetuses and masculinisation of female fetuses.

**BREAST FEEDING**

Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

Avoid. Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Megace**
  - Megace (Bristol-Myers Squibb Pharmaceuticals Ltd)
    - Megace acetate 160 mg Megace 160mg tablets | 30 tablet [P] £19.52 DT price = £19.52

**SOMATOSTATIN ANALOGUES**

**Somatostatin analogues**

- **CAUTIONS**
  - Diabetes mellitus (antidiabetic requirements may be reduced)
  - Insulinoma (increased depth and duration of hypoglycaemia may occur—observe patients and monitor blood glucose levels when initiating treatment and changing doses)
  - May cause growth hormone-secreting pituitary tumour expansion during treatment (causing serious complications)

- **SIDE-EFFECTS**
  - Rare: Pancreatitis (shortly after administration)
  - Frequency not known: Abdominal pain, anorexia, bloating, diarrhoea, flatulence, gallstones (after long-term treatment), gastro-intestinal disturbances, hyperglycaemia (with chronic administration), hyperglycaemia (with chronic administration) - irritation at the injection site
  - Nausea
  - Pain at the injection site
  - Steatorrhoea
  - Vomiting

**MONITORING REQUIREMENTS**

- Monitor for signs of tumour expansion (e.g. visual field defects)
- Ultrasound examination of the gallbladder is recommended before treatment and at intervals of 6–12 months during treatment.

**DIRECTIONS FOR ADMINISTRATION**

- Injection sites should be rotated.
Lanreotide

**INDICATIONS AND DOSE**

**Somatuline Autogel**

- **Acromegaly (if somatostatin analogue not given previously)**
  - Adult: Initially 60 mg every 28 days, adjusted according to response, (consult product literature), for patients treated previously with somatostatin analogue, consult product literature for initial dose, dose to be given in the gluteal region

- **Neuroendocrine (particularly carcinoid) tumours**
  - Adult: Initially 60–120 mg every 28 days, adjusted according to response, dose to be given in the gluteal region

**NEED FEEDING**

- Rare
- Uncommon

**SIDE-EFFECTS**

- Monitor for hypothyroidism
- Manufacturer advises use only if potential benefit outweighs risk.

**INTERACTIONS**

- Adult: (consult product literature)

**CAUTIONS**

- Cardiac disorders (including bradycardia) - patients with carcinoid tumours—exclude the presence of an obstructive intestinal tumour before treatment

**SIDE-EFFECTS**

- Common or very common: Alopecia - biliary dilatation - bradycardia - constipation - dizziness - dyspepsia - headache - lethargy - malaise - muscularkeletal pain - myalgia - raised bilirubin
- Uncommon: Hot flushes - insomnia
- Rare: Hypothyroidism

**PREGNANCY**

- Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**

- Manufacturer advises caution—no information available.

**MONITORING REQUIREMENTS**

- Monitor for hypothyroidism when clinically indicated.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Somatuline Autogel (Ipsen Ltd)
  
  **Lanreotide** (as Lanreotide acetate) 120 mg per 1 ml Somatuline Autogel 60mg/0.5ml solution for injection pre-filled syringes with safety system | 1 pre-filled disposable injection (£31.50)

  **Lanreotide** (as Lanreotide acetate) 180 mg per 1 ml Somatuline Autogel 90mg/0.5ml solution for injection pre-filled syringes with safety system | 1 pre-filled disposable injection (£36.00)

- Somatuline Autogel (Ipsen Ltd)
  
  **Lanreotide** (as Lanreotide acetate) 240 mg per 1 ml Somatuline Autogel 120mg/0.5ml solution for injection pre-filled syringes with safety system | 1 pre-filled disposable injection (£37.00)

**Powder and solvent for suspension for injection**

- Somatuline LA (Ipsen Ltd)
  
  **Lanreotide** (as Lanreotide acetate) 30 mg Somatuline LA 30mg powder and solvent for suspension for injection vials | 1 vial (£3.23)

Octreotide

**INDICATIONS AND DOSE**

**Symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas**

**BY SUBCUTANEOUS INJECTION**

- Adult: Initially 50 micrograms 1–2 times a day, adjusted according to response to 200 micrograms 3 times a day, higher doses may be required exceptionally; maintenance doses are variable; in carcinoid tumours, discontinue after 1 week if no effect; if rapid response required, initial dose may be given by intravenous injection (with ECG monitoring)

  **Acromegaly, short-term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or until radiotherapy becomes fully effective**

**PREVENTION OF COMPLICATIONS FOLLOWING PANCREATIC SURGERY**

**BY SUBCUTANEOUS INJECTION**

- Adult: (consult product literature)

**Test dose before use of depot preparation**

**BY SUBCUTANEOUS INJECTION**

- Adult: Test dose 50–100 micrograms for 1 dose, test dose should be given if subcutaneous octreotide not previously given

**Acromegaly | Neuroendocrine (particularly carcinoid) tumour adequately controlled by subcutaneous octreotide**

**BY DEEP INTRAMUSCULAR INJECTION USING DEPOT INJECTION**

- Adult: Initially 20 mg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30 mg every 4 weeks, to be administered into the gluteal muscle, for acromegaly, start depot 1 day after the last dose of subcutaneous octreotide, for neuroendocrine tumours, continue subcutaneous octreotide for 2 weeks after first dose of depot octreotide

**Advanced neuroendocrine tumours of the midgut, or tumours of unknown primary origin where non-midgut sites of origin have been excluded**

**BY DEEP INTRAMUSCULAR INJECTION USING DEPOT INJECTION**

- Adult: 30 mg every 4 weeks

**Reduce intestinal secretions in palliative care**

**BY CONTINUOUS SUBCUTANEOUS INFUSION**

- Adult: 0.25–0.5 mg/24 hours (max. per dose 0.75 mg/24 hours), occasionally doses higher than the maximum are sometimes required

**INTERACTIONS**

**SIDE-EFFECTS**

- Alopecia - arthralgias - biliary colic (associated with abrupt withdrawal of subcutaneous octreotide) - bradycardia - dehydration - dizziness - dyspepsia - headache - hepatotoxicity - pancreatitis (associated with abrupt withdrawal of subcutaneous octreotide) - rash

**SIDE-EFFECTS, FURTHER INFORMATION**

- Gastro-intestinal side-effects: Administering non-depot injections of octreotide between meals and at bedtime may reduce gastro-intestinal side-effects.

**CONCEPTION AND CONTRACEPTION**

- Effective contraception required during treatment.

**PREGNANCY**

- Possible effect on fetal growth; manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**

- Manufacturer advises avoid—present in milk in animal studies.
DIRECTIONS FOR ADMINISTRATION

Monitor liver function.

With intravenous use

MONITORING REQUIREMENTS

acting subcutaneous octreotide (associated with biliary colic and pancreatitis).

TREATMENT CESSATION

Avoid abrupt withdrawal of short-acting subcutaneous octreotide (associated with biliary colic and pancreatitis).

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion, dilute with Sodium Chloride 0.9% to a concentration of 10–50%.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

Octreotide (as Octreotide acetate) 50 microgram per 1 ml
Octreotide 50 micrograms/1ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (Pasireotide) £15.85
Octreotide 50 micrograms/1ml solution for injection ampoules | 5 ampoule (Pasireotide) £9.74–£18.60 Octreotide 50 micrograms/1ml solution for injection vials | 5 vial (Pasireotide) £14.87–£22.00
Octreotide (as Octreotide acetate) 100 microgram per 1 ml
Octreotide 100 micrograms/1ml solution for injection ampoules | 5 ampoule (Pasireotide) £18.61–£32.65 Octreotide 100 micrograms/1ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (Pasireotide) £28.90 Octreotide 100 micrograms/1ml solution for injection vials | 5 vial (Pasireotide) £27.97–£32.65
Octreotide (as Octreotide acetate) 200 microgram per 1 ml
Octreotide 1 mg/5ml solution for injection vials | 1 vial (Pasireotide) £65.00–£69.66
Octreotide (as Octreotide acetate) 500 microgram per 1 ml
Octreotide 500 micrograms/1ml solution for injection vials | 5 vial (Pasireotide) £115.47–£158.25 Octreotide 500 micrograms/1ml solution for injection ampoules | 5 ampoule (Pasireotide) £74.80–£169.35 DT price = £135.47 Octreotide 500 micrograms/1ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (Pasireotide) £135.47–£149.00
Sandostatin (Novartis Pharmaceuticals UK Ltd)

Octreotide (as Octreotide acetate) 50 microgram per 1 ml
Sandostatin 50 micrograms/1ml solution for injection ampoules | 5 ampoule (Pasireotide) £14.87
Octreotide (as Octreotide acetate) 100 microgram per 1 ml
Sandostatin 100 micrograms/1ml solution for injection ampoules | 5 ampoule (Pasireotide) £27.97
Octreotide (as Octreotide acetate) 200 microgram per 1 ml
Sandostatin 1 mg/5ml solution for injection vials | 1 vial (Pasireotide) £55.73
Octreotide (as Octreotide acetate) 500 microgram per 1 ml
Sandostatin 500 micrograms/1ml solution for injection ampoules | 5 ampoule (Pasireotide) £135.47–£149.00

Powder and solvent for suspension for injection

Sandostatin LAR (Novartis Pharmaceuticals UK Ltd)

Octreotide (as Octreotide acetate) 10 mg
Sandostatin LAR 10mg powder and solvent for suspension for injection vials | 1 vial (Pasireotide) £469.84
Octreotide (as Octreotide acetate) 20 mg
Sandostatin LAR 20mg powder and solvent for suspension for injection vials | 1 vial (Pasireotide) £717.05
Octreotide (as Octreotide acetate) 30 mg
Sandostatin LAR 30mg powder and solvent for suspension for injection vials | 1 vial (Pasireotide) £993.44

Pasireotide

INDICATIONS AND DOSE

Cushing’s disease when surgery has failed or is inappropriate

BY SUBCUTANEOUS INJECTION

Adult: Initially 600 micrograms twice daily for 2 months, then increased if necessary to 900 micrograms twice daily, consider discontinuation if no response within 2 months, for dose adjustment due to side effects—consult product literature

CAUTIONS

Cardiac disorders (including bradycardia) - susceptibility to QT-interval prolongation (including electrolyte disturbances)

INTERACTIONS

Appendix 1 (pasireotide).

Caution with concomitant use of drugs that prolong QT interval.

SIDE-EFFECTS

Adrenal insufficiency - alopecia - anaemia - arthralgia - bradyarrhythmia - decreased appetite - fatigue - headache - hyperglycaemia - hypotension - myalgia - pruritus - QT-interval prolongation

PREGNANCY

Avoid—toxicity in animal studies.

BREAST FEEDING

Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT

Reduce initial dose to 300 micrograms twice daily (increased if necessary after 2 months to max. 600 micrograms twice daily) in moderate impairment. Avoid in severe impairment.

MONITORING REQUIREMENTS

Monitor liver function before treatment, weekly for the first 1–2 months of treatment, periodically thereafter, and 3 months after treatment is complete.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

Pasireotide (as Pasireotide disaspartate) 300 microgram per 1 ml
Pasireotide 0.3mg/1ml solution for injection ampoules | 60 ampoule (Pasireotide) £2,800.00
Pasireotide (as Pasireotide disaspartate) 600 microgram per 1 ml
Pasireotide 0.6mg/1ml solution for injection ampoules | 60 ampoule (Pasireotide) £3,240.00
Pasireotide (as Pasireotide disaspartate) 900 microgram per 1 ml
Pasireotide 0.9mg/1ml solution for injection ampoules | 60 ampoule (Pasireotide) £3,240.00

2.6 Hormone responsive breast cancer

ANTI-OESTROGENS

Fulvestrant

INDICATIONS AND DOSE

Treatment of oestrogen-receptor-positive metastatic or locally advanced breast cancer in postmenopausal women in whom disease progresses or relapses while on, or after, other anti-oestrogen therapy

BY DEEP INTRAMUSCULAR INJECTION

Adult: 500 mg every 2 weeks for the first 3 doses, then 500 mg every 1 month, to be administered into the buttock

SIDE-EFFECTS

Common or very common Anorexia - asthenia - back pain - diarrhoea - headache - hot flushes - hypersensitivity reactions - injection-site reactions - nausea - rash - urinary tract infections - venous thromboembolism - vomiting
Tamoxifen

**DRUG ACTION** An anti-oestrogen which induces gonadotrophin release by occupying oestrogen receptors in the hypothalamus, thereby interfering with feedback mechanisms; chorionic gonadotrophin is sometimes used in the hypothalamus, thereby interfering with feedback mechanisms; chorionic gonadotrophin is sometimes used as an adjunct in the treatment of female infertility.

**INDICATIONS AND DOSE**

Pre- and perimenopausal women with oestrogen-receptor-positive breast cancer not previously treated with tamoxifen

**BY MOUTH**

- Adult: 20 mg daily

**Anovulatory infertility**

- Adult: Initially 20 mg daily on days 2, 3, 4 and 5 of cycle, if necessary the daily dose may be increased to 40 mg then 80 mg for subsequent courses; if cycles irregular, start initial course on any day, with subsequent course starting 45 days later or on day 2 of cycle if menstruation occurs

**CONTRA-INDICATIONS** Treatment of infertility contra-indicated if personal or family history of idiopathic venous thromboembolism or genetic predisposition to thromboembolism

**CAUTIONS** Porphyria

**INTERACTIONS** → Appendix 1 (tamoxifen).

**SIDE-EFFECTS**

- Rare Angioedema - bullous pemphigoid - cholestasis - fatty liver - hepatitis - hypersensitivity reactions - hypertriglyceridaemia - interstitial pneumonitis - neutropenia - Stevens-Johnson syndrome

- Frequency not known Alopecia - anemia - catacacts - corneal changes - decreased platelet counts - endometrial changes - gastrointestinal disturbances - headache - hot flushes - hypercalcaemia if bony metastases - increased risk of thromboembolic events, especially when used with cytotoxics - leucopenia - light-headedness - liver enzyme changes - occasional cystic ovarian swellings in premenopausal women - occasionally oedema - pancreatitis - pruritus vulvae - rashes - retinopathy - suppression of menstruation in some premenopausal women - thrombocytopenia - thromboembolic events - tumour flare - uterine fibroids - vaginal bleeding - vaginal discharge - visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

**Endometrial changes** Increased endometrial changes, including hyperplasia, polyps, cancer, and uterine sarcoma reported; prompt investigation required if abnormal vaginal bleeding including menstrual irregularities, vaginal discharge, and pelvic pain or pressure in those receiving (or who have received) tamoxifen.

**Risk of thromboembolism** Tamoxifen can increase the risk of thromboembolism particularly during and immediately after major surgery or periods of immobility (consider interrupting treatment to initiate anticoagulant measures).

**CONCEPTION AND CONTRACEPTION** Unless being used in the treatment of female infertility, effective contraception must be used during treatment and for 2 months after stopping. Patients being treated for infertility should be warned that there is a risk of multiple pregnancy (rarely more than twins).

**PREGNANCY** Avoid—possible effects on fetal development.

**BREAST FEEDING** Suppresses lactation. Avoid unless potential benefit outweighs risk.

**PATIENT AND CARER ADVICE**

Endometrial changes Patients should be informed of the risk of endometrial cancer and told to report relevant symptoms promptly. Thromboembolism Patients should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness and any pain in the calf of one leg.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Fulvestrant (AstraZeneca UK Ltd)
  - Fulvestrant 50 mg per 1 ml
    - Fulvestrant 250mg/5ml solution for injection pre-filled syringes | 2 pre-filled disposable injection
    - Price available

**Tamoxifen**

- Adult: 20 mg daily
- Adult: 40 mg for subsequent courses
- Adult: 80 mg for subsequent courses
- Adult: 160 mg for subsequent courses

**INDICATIONS AND DOSE**

Hormone-dependent metastatic breast cancer in postmenopausal women

**BY MOUTH**

- Adult: 60 mg daily

**CONTRA-INDICATIONS** Bradycardia - electrolyte disturbances (particularly uncorrected hypokalaemia) - endometrial hyperplasia - heart failure with reduced left-ventricular ejection fraction - history of arrhythmias - QT prolongation

**CAUTIONS** Avoid in Acute porphyrias p. 864 - history of severe thromboembolic disease

**INTERACTIONS** → Appendix 1 (toremifene).
Avoid concomitant administration of drugs that prolong QT interval.

**SIDE-EFFECTS**
- **Common or very common** Depression • dizziness • fatigue • hot flushes • nausea • oedema • rash • sweating • vaginal bleeding • vaginal discharge • vomiting
- **Uncommon** Anorexia • constipation • dyspnoea • endometrial hypertrophy • headache • increased weight • insomnia • thromboembolic events
- **Very rare** Alopecia • jaundice • transient corneal opacity
- **Frequency not known** Hypercalcaemia (especially if bone metastases and usually at beginning of treatment)

**SIDE-EFFECTS, FURTHER INFORMATION**
- **Endometrial changes** Increased endometrial changes, including hyperplasia, polyps and cancer reported. Abnormal vaginal bleeding including menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.

**PREGNANCY** Avoid.
**BREAST FEEDING** Avoid.
**HEPATIC IMPAIRMENT** Elimination decreased in hepatic impairment—avoid if severe.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **ANASTROZOLE (Non-proprietary)**
  - Anastrozole 1 mg [Fareston 1mg tablets | 30 tablet](®) £29.08
- **Arimidex** (AstraZeneca UK Ltd)
  - Anastrozole 1 mg [Arimidex 1mg tablets | 28 tablet](®) £68.56 DT price = £1.98

**Exemestane**

**INDICATIONS AND DOSE**
Adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenopausal women following 2–3 years of tamoxifen therapy

**Advanced breast cancer in postmenopausal women in whom anti-oestrogen therapy has failed**

**BY MOUTH**
- Adult: 25 mg daily

**CONTRA-INDICATIONS** Not indicated for premenopausal women
**INTERACTIONS** → Appendix 1 (exemestane).

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain • alopecia • anorexia • constipation • depression • dizziness • dyspepsia • fatigue • headache • hot flushes • insomnia • nausea • rash • sweating • vomiting
- **Uncommon** Asthenia • drowsiness • peripheral oedema
- **Rare** Leucopenia • thrombocytopenia
**PREGNANCY** Avoid.
**BREAST FEEDING** Avoid.
**HEPATIC IMPAIRMENT** Manufacturer advises caution.
**RENAL IMPAIRMENT** Manufacturer advises caution.

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (October 2005) that exemestane (Aromasin®) is accepted for restricted use within NHS Scotland as an adjuvant treatment in postmenopausal women with oestrogen-receptor-positive invasive early breast cancer, following 2–3 years of initial adjuvant tamoxifen therapy.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS** 21
  - **EXEMESTANE (Non-proprietary)**
    - Exemestane 25 mg [Exemestane 25mg tablets | 30 tablet](®) £88.80 DT price = £22.48
    - 90 tablet (®) no price available
  - **Aromasin** (Pfizer Ltd)
    - Exemestane 25 mg [Aromasin 25mg tablets | 30 tablet](®) £88.80 DT price = £22.48
Letrozole

**INDICATIONS AND DOSE**

First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. Adjunct treatment of oestrogen-receptor-positive invasive early breast cancer in postmenopausal women. Advanced breast cancer in postmenopausal women (naturally or artificially induced menopause) in whom other anti-oestrogen therapy has failed. Extended adjunct treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years. Neo-adjuvant treatment in postmenopausal women with localised hormone-receptor-positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated.

**BY MOUTH**

- Adult: 2.5 mg daily

- **CONTRA-INDICATIONS**
  Not indicated for premenopausal women

- **CAUTIONS**
  Susceptibility to osteoporosis

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain - alopecia - anorexia - appetite increase - arthralgia - bone fracture - constipation - depression - diarrhoea - dizziness - dry skin - dyspepsia - fatigue - headache - hot flushes - hypercholesterolaemia - hypertension - increased sweating - musculoskeletal pain - nausea - osteoporosis - peripheral oedema - rash - vaginal bleeding - vomiting - weight changes
  - **Rare** Arterial thrombosis - pulmonary embolism
  - **Frequency not known** Hepatitis - toxic epidermal necrolysis

- **CONCEPTION AND CONTRACEPTION**
  Manufacturer advises effective contraception required until postmenopausal status fully established (return of ovarian function reported in postmenopausal women).

- **PREGNANCY**
  Avoid (isolated cases of birth defects reported).

- **BREAST FEEDING**
  Manufacturer advises avoid.

- **HEPATIC IMPAIRMENT**
  Manufacturer advises caution in severe impairment.

- **RENAL IMPAIRMENT**
  Manufacturer advises caution if creatinine clearance less than 10 mL/minute.

- **MONITORING REQUIREMENTS**
  Osteoporosis Assess bone mineral density before treatment and at regular intervals.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Letrozole (Non-proprietary)**
  Letrozole 2.5 mg tablets | 14 tablet (PO) £49.90
  DT price = £2.26 | 28 tablet (PO) £84.86
  Femara (Novartis Pharmaceuticals UK Ltd)

- **Letrozole 2.5 mg** Femara 2.5mg tablets | 30 tablet (PO) £90.92

2.7 Immunotherapy responsive malignancy

**IMMUNOMODULATING DRUGS**

**Mifamurtide**

**INDICATIONS AND DOSE**

Treatment of high-grade, resectable, non-metastatic osteosarcoma after complete surgical resection (in combination with chemotherapy).

**BY INTRAVENOUS INFUSION**

- Adult: Infusion to be given over 1 hour (consult product literature or local protocols)

- **UNLICENSED USE**
  Not licensed for use in patients over 30 years of age at initial diagnosis.

- **CAUTIONS**

- **INTERACTIONS**
  - Appendix 1 (mifamurtide).

- **SIDE-EFFECTS**

- **CONCEPTION AND CONTRACEPTION**
  Effective contraception required.

- **PREGNANCY**
  Avoid.

- **BREAST FEEDING**
  Avoid—no information available.

- **HEPATIC IMPAIRMENT**
  Use with caution—no information available.

- **RENAL IMPAIRMENT**
  Use with caution—no information available.

- **MONITORING REQUIREMENTS**
  - Monitor renal function, hepatic function and clotting parameters.
  - Monitor patients with history of venous thrombosis, vasculitis, or unstable cardiovascular disorders for persistent or worsening symptoms during administration—consult product literature.

- **NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Mifamurtide for the treatment of osteosarcoma (October 2011) NICE TA235

Mifamurtide in combination with postoperative multi-agent chemotherapy is recommended (within its licensed indication), as an option for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection in children, adolescents and young adults and when mifamurtide is made available at a reduced cost to the NHS under the patient access scheme. www.nice.org.uk/TA235

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
IMMUNOSTIMULANTS

Histamine dihydrochloride

INDICATIONS AND DOSE
Maintenance therapy, in combination with aldesleukin, in patients with acute myeloid leukaemia in first remission
BY SUBCUTANEOUS INJECTION
Adult: (consult local protocol)

CONTRA-INDICATIONS Consult product literature for information about histamine dihydrochloride contra-indications.

CAUTIONS Consult product literature for information about histamine dihydrochloride cautions.

INTERACTIONS → Appendix 1 (histamine).

SIDE-EFFECTS Consult product literature for side effects.

CONCEPTION AND CONTRACEPTION Ensure effective contraception during treatment in men and women.

PREGNANCY Manufacturer advises avoid—no information available.

BREAST FEEDING Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT Increased risk of tachycardia and hypotension in moderate to severe impairment.

RENAL IMPAIRMENT Increased risk of hypotension in severe impairment.

NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (December 2010) that histamine dihydrochloride (Ceplene®) is not recommended for use within NHS Scotland.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
Ceplene (Meda Pharmaceuticals Ltd) ▼ Histamine dihydrochloride 1 mg per 1 ml Ceplene 0.5mg/0.5ml solution for injection vials | 14 vial £1,181.32

IMMUNOTHERAPIES

Bacillus calmette-guérin

DRUG ACTION Bacillus Calmette-Guérin is a live attenuated strain derived from Mycobacterium bovis.

INDICATIONS AND DOSE
Bladder instillation for the treatment of primary or recurrent bladder carcinoma and for the prevention of recurrence following transurethral resection
BY INTRAVESICAL INSTILLATION
Adult: (consult product literature)

CONTRA-INDICATIONS Fever of unknown origin · HIV infection · impaired immune response · severe haematoma · tuberculosis · urinary-tract infection

CAUTIONS Bladder injury (delay administration until mucosal damage healed) · traumatic catheterisation (delay administration until mucosal damage healed) · urethral injury (delay administration until mucosal damage healed)

SIDE-EFFECTS
Rare Arthralgia · bladder contracture · hypersensitivity reactions · orchitis · rash · renal abscess · transient urethral obstruction

Frequency not known Cystitis · dysuria · fever · haematuria · influenza-like syndrome · malaise · ocular symptoms · systemic BCG infection (with fatalities)—consult product literature · urinary frequency

PREGNANCY Avoid.

BREAST FEEDING Avoid.

PRE-TREATMENT SCREENING Screen for active tuberculosis (contra-indicated if tuberculosis confirmed).

MEDICINAL FORMS
Powder for reconstitution for installation
ImmuCyst (Alliance Pharmaceuticals Ltd) Connaught strain Bacillus of Calmette-Guerin 81 mg ImmuCyst 81mg powder for reconstitution for installation vials | 1 vial £79.23 (Hospital only)
Oncotec (Merck Sharp & Dohme Ltd) TICE strain Bacillus of Calmette-Guerin 12.5 mg Oncotec 12.5mg powder for reconstitution for installation vials | 1 vial £71.61 (Hospital only)

INTERFERONS

Interferon alfa

DRUG ACTION Interferon alfa has shown some antitumour effect in certain lymphomas and solid tumours.

INDICATIONS AND DOSE
INTRONA® PEN
Chronic myelogenous leukaemia (as monotherapy or in combination with cytarabine) | Hairy cell leukaemia | Follicular lymphoma | Lymph or liver metastases of carcinoid tumour | Chronic hepatitis B | Chronic hepatitis C | Adjunct to surgery in malignant melanoma | Maintenance of remission in multiple myeloma
BY SUBCUTANEOUS INJECTION
Adult: (consult local protocol)

INTRONA® VIALS
Chronic myelogenous leukaemia (as monotherapy or in combination with cytarabine) | Hairy cell leukaemia | Follicular lymphoma | Lymph or liver metastases of carcinoid tumour | Chronic hepatitis B | Chronic hepatitis C | Adjunct to surgery in malignant melanoma | Maintenance of remission in multiple myeloma
BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INFUSION
Adult: (consult local protocol)

ROFERON-A®
Chronic myelogenous leukaemia | Hairy cell leukaemia | Chronic hepatitis B | Chronic hepatitis C | Adjunct to surgery in malignant melanoma | AIDS-related Kaposi’s sarcoma | Advanced renal cell carcinoma | Progressive cutaneous T-cell lymphoma | Follicular non-Hodgkin’s lymphoma
BY SUBCUTANEOUS INJECTION
Adult: (consult local protocol)

CONTRA-INDICATIONS Avoid injections containing benzyl alcohol in neonates

CONTRA-INDICATIONS, FURTHER INFORMATION
For contra-indications consult product literature and local treatment protocol.

CAUTIONS For cautions consult product literature and local treatment protocol.

INTERACTIONS → Appendix 1 (interferons).
### Interferon gamma-1b (Immune interferon)

#### INDICATIONS AND DOSE

**To reduce the frequency of serious infection in chronic granulomatous disease**

**BY SUBCUTANEOUS INJECTION**
- Adult: 50 micrograms/m² 3 times a week

**To reduce the frequency of serious infection in severe malignant osteoporosis**
- Adult: 50 micrograms/m² 3 times a week

#### CAUTIONS
- Arrhythmias, cardiac disease, congestive heart failure, ischaemia, seizure disorders (including seizures associated with fever)

#### INTERACTIONS
- Appendix 1 (interferons).
- Avoid simultaneous administration of foreign proteins including immunological products (risk of exaggerated immune response).

#### SIDE-EFFECTS
- Common or very common Abdominal pain, arthralgia, chills, depression, diarrhoea, fatigue, fever, headache, injection-site reactions, myalgia, nausea, rash, vomiting
- Rare Confusion, systemic lupus erythematosus
- Frequency not known Neutropenia, proteinuria, raised liver enzymes, thrombocytopenia

#### CONCEPTION AND CONTRACEPTION
- Effective contraception required during treatment—consult product literature.

#### NATIONAL FUNDING/ACCESS DECISIONS
- NICE technology appraisals (TAs)
- Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010) NICE TA200
- Interferon alfa may be switched to peginterferon alfa.
  - www.nice.org.uk/TA200

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Solution for injection

**EXCIPIENTS:** May contain Benzyl alcohol

- **IntronA** (Merck Sharp & Dohme Ltd)
  - Interferon alfa-2b 10 mega u per 1 ml IntronA 10millon units/1ml solution for injection vials | 1 vial (PST) | £37.21
  - Interferon alfa-2b 15 mega u per 1 ml IntronA 18million units/1.2ml solution for injection multidose pens | 1 pre-filled disposable injection (PST) | £74.83
  - Interferon alfa-2b 25 mega u per 1 ml IntronA 30million units/1.2ml solution for injection multidose pens | 1 pre-filled disposable injection (PST) | £124.72
  - Interferon alfa-2b 50 mega u per 1 ml IntronA 60million units/1.2ml solution for injection multidose pens | 1 pre-filled disposable injection (PST) | £249.45

- **Roferon-A** (Roche Products Ltd)
  - Interferon alfa-2a 6 mega u per 1 ml Roferon-A 3million units/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PST) | £14.20
  - Interferon alfa-2a 9 mega u per 1 ml Roferon-A 4.5million units/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PST) | £21.29
  - Interferon alfa-2a 12 mega u per 1 ml Roferon-A 6million units/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PST) | £28.37
  - Interferon alfa-2a 18 mega u per 1 ml Roferon-A 9million units/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PST) | £42.57

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Solution for injection

- **Imimkin** (Boehringer Ingelheim Ltd)
  - Interferon gamma-1b (recombinant human) 200 microgram per 1 ml Immunkin 100micrograms/0.5ml solution for injection vials | 6 vial (PST) | £450.00
INTERLEUKINS

Aldesleukin

**DRUG ACTION** Aldesleukin produces tumour shrinkage in a small proportion of patients, but it has not been shown to increase survival.

**INDICATIONS AND DOSE**

- Metastatic renal cell carcinoma (specialist use only)
- BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INFUSION
  - Adult: (consult product literature)

**SIDE-EFFECTS**

- Common or very common Bone-marrow toxicity · CNS toxicity · hepatic toxicity · renal toxicity · thyroid toxicity
- Rare or very rare Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting
- Also consult product literature.

**CONTRA-INDICATIONS** Consult product literature for information about aldesleukin contra-indications.

**CAUTIONS** Consult product literature for information about aldesleukin cautions.

**INTERACTIONS** → Appendix 1 (aldesleukin).

**SIDE-EFFECTS**

- Common or very common Bone-marrow toxicity · CNS toxicity · hepatic toxicity · renal toxicity · thyroid toxicity
- Frequency not known Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting
- Also consult product literature.

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment in men and women.

**PREGNANCY** Use only if potential benefit outweighs risk (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING** Discontinue breast-feeding.

**DIRECTIONS FOR ADMINISTRATION** Aldesleukin is now rarely given by intravenous infusion because of an increased risk of capillary leak syndrome, which can cause pulmonary oedema and hypotension.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- Proleukin (Novartis Pharmaceuticals UK Ltd)
  - Aldesleukin 18 mega u Proleukin 18 million unit powder for solution for injection vials | 1 vial £112.00 | 10 vial £1,036.00

THALIDOMIDE AND RELATED ANOLOGUES

Lenalidomide

**DRUG ACTION** Lenalidomide is an immunomodulating drug with anti-neoplastic, anti-angiogenic, and pro-erythropoietic properties.

**INDICATIONS AND DOSE**

- Multiple myeloma (newly diagnosed) in patients not eligible for transplant, given in combination with dexamethasone
- Until disease progression
- BY MOUTH
  - Adult: 25 mg once daily for 21 consecutive days of repeated 28-day cycles, for doses of dexamethasone, and dose adjustments due to side-effects, consult product literature

Multiple myeloma in patients who have received at least one prior therapy, given in combination with dexamethasone

BY MOUTH

- Adult: 10 mg once daily for 21 consecutive days of repeated 28-day cycles for up to 9 cycles, for doses of melphalan and prednisone, and dose adjustments due to side-effects; consult product literature

Multiple myeloma in patients not eligible for transplant, given in combination with melphalan and prednisone followed by maintenance monotherapy

BY MOUTH

- Adult: 10 mg once daily for 21 consecutive days of repeated 28-day cycles for up to 9 cycles, for doses of melphalan and prednisone, and dose adjustments due to side-effects, consult product literature

Treatment of transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other treatment options are insufficient or inadequate

BY MOUTH

- Adult: 10 mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustments due to side-effects; consult product literature

**CAUTIONS** High tumour burden—risk of tumour lysis syndrome · patients with risk factors for myocardial infarction

**CAUTIONS, FURTHER INFORMATION**

**Thromboembolism** Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised and thromboprophylaxis should be considered in patients with multiple risk factors.

**Second primary malignancy** Patients should be carefully evaluated before and during treatment with lenalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.

**INTERACTIONS** → Appendix 1 (lenalidomide).

Use caution with concomitant drugs that increase the risk of thromboembolism.

**SIDE-EFFECTS**

- Common or very common Abdominal pain · anaemia · arhythmias · arthralgia · ataxia · atrial fibrillation · bacterial infections · bradycardia · cardiac failure · cataract · cerebrovascular events · chest pain · cholestasis · constipation · decreased appetite · deep vein thrombosis · dehydration · depression · diarrhoea · diziness · dry mouth · dyspepsia · dysphagia · dyspnoea · electrolyte disturbances · falls · flu-like illness · fungal infections · haematoma · haematuria · haemorrhagic disorders · headache · hearing disturbances · hyperglycaemia · hyperviscosity · hypertension · hypothyroidism · insomnia · iron-overload · lethargy · leucopenia · malaise · mood changes · musculoskeletal disorders · myalgia · myocardial infarction · nausea · oedema · peripheral neuropathy · pneumonia · pruritus · pulmonary embolism · pyrexia · rash · renal failure · respiratory distress · respiratory tract infections · sepsis · severe neutropenia · sexual dysfunction · sinusitis · skin disorders · stomatitis · syncope · tachycardia · taste disturbance · thrombocytopenia · tremor · urinary incontinence · urinary retention · vasculitis · viral infections · visual disturbances · vomiting

- Uncommon Acquired Fanconi syndrome · angioedema · blindness · cecitis · clotting disorders · colitis · haemolysis · hepatic failure · ischaemia · secondary malignancies

- Rare Stevens-Johnson syndrome · toxic epidermal necrolysis · tumour lysis syndrome
PATIENT AND CARER ADVICE

- **Frequency not known** Cholestatic hepatitis - cytolytic hepatitis - interstitial pneumonitis - leukocytoclastic vasculitis - pancreatitis - toxic hepatitis

**SIDE-EFFECTS, FURTHER INFORMATION**

**Monitor visual ability regularly (risk of cataract).**

**Monitor full blood count (including differential white cell count) impaired liver function.**

**Interrupt treatment if neutropenia, thrombocytopenia or hepatitis develop.**

**Abnormal liver function**

**Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.**

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Lenalidomide for the treatment of multiple myeloma (June 2009) NICE TA171**
  Lenalidomide in combination with dexamethasone is an option for the treatment of multiple myeloma in patients who have received two or more prior therapies. The drug cost of lenalidomide will be met by the manufacturer for patients who remain on treatment for more than 26 cycles. www.nice.org.uk/TA171

- **Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014) NICE TA322**
  Lenalidomide is recommended as an option, within its marketing authorisation, for treating transfusion-dependent anaemia caused by low or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, with the following condition:
  - the drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the company. www.nice.org.uk/TA322

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (April 2010) that lenalidomide, in combination with dexamethasone, is accepted for restricted use within NHS Scotland for patients with multiple myeloma who have received at least two prior therapies (and (March 2014) for those who have received prior treatment with bortezomib and for whom thalidomide has not been tolerated or is contraindicated.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **CAUTIONARY AND ADVISORY LABELS 25**
  - **Revlimid (Celgene Ltd)**
  - **Lenalidomide 2.5 mg** Revlimid 2.5mg capsules | 21 capsule | £3,426.00
  - **Lenalidomide 5 mg** Revlimid 5mg capsules | 21 capsule | £3,570.00
  - **Lenalidomide 10 mg** Revlimid 10mg capsules | 21 capsule | £3,780.00
  - **Lenalidomide 15 mg** Revlimid 15mg capsules | 21 capsule | £3,969.00
  - **Lenalidomide 25 mg** Revlimid 25mg capsules | 21 capsule | £4,368.00

**Pomalidomide**

- **DRUG ACTION** Pomalidomide is structurally related to thalidomide and has immunomodulatory properties and direct anti-myeloma tumoricidal activity.

**INDICATIONS AND DOSE**

Treatment of relapsed and refractory multiple myeloma in patients who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and who have had disease progression during the last treatment (in combination with dexamethasone)

**B y mouth**

- Adult: 4 mg once daily for 21 consecutive days of repeated 28-day cycles, for doses of dexamethasone and dose adjustment due to side effects—consult product literature
CAUTIONS
Cardiac disease • cardiac risk factors • high tumour burden—risk of tumour lysis syndrome • interstitial lung disease—discontinue if suspected • peripheral neuropathy

CAUTIONS, FURTHER INFORMATION
Thromboembolism Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised. Thromboprophylaxis should be considered, particularly in patients with additional risk factors.

Second primary malignancy Patients should be carefully evaluated before and during treatment with pomalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.

INTERACTIONS
Appendix 1 (pomalidomide).

SIDE-EFFECTS
Common or very common Anaemia • bone pain • cardiac failure • confusion • constipation • cough • decreased appetite • diarrhoea • dizziness • dyspnoea • febrile neutropenia • hypertension • hyperkalaemia • hypertension • impaired consciousness • interstitial lung disease • leucopenia • malaise • muscle spasms • nausea • neutropenia • neutropenic sepsis • pelvic pain • peripheral neuropathy • peripheral oedema • pneumonia • pruritus • pyrexia • rash • renal failure • respiratory tract infection • thrombocytopaenia • thromboembolic events • tremor • urinary retention • vertigo • vomiting

Uncommon Hepatitis

Frequency not known Atrial fibrillation • pulmonary oedema

CONCEPTION AND CONTRACEPTION
For women of childbearing potential, pregnancy must be excluded before starting treatment with pomalidomide (perform pregnancy test on initiation or within 3 days prior to initiation). Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intra-uterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer’s Pregnancy Prevention Programme.

PREGNANCY
Important: teratogenic risk.

BREAST FEEDING
Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
Manufacturer advises caution—no information available.

RENAL IMPAIRMENT
Manufacturer advises caution—no information available.

MONITORING REQUIREMENTS
Monitor full blood count before treatment, then every week for the first 8 weeks, then monthly thereafter (reduce dose or interrupt treatment if neutropenia or thrombocytopaenia develop—consult product literature).

Monitor for arterial or venous thromboembolism.

Monitor for signs and symptoms of cardiac failure.

Monitor for acute onset or unexplained worsening of respiratory symptoms.

Monitor liver function for 6 months after initiation, then as clinically indicated.

PRESCRIBING AND DISPENSING INFORMATION
Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.

PATIENT AND CARER ADVICE
Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb. Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopaenia (such as bleeding) develop. Patient counselling is advised for pomalidomide capsules (pregnancy and contraception).

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (March 2015) NICE TA338 Pomalidomide, in combination with dexamethasone, is not recommended for the treatment of relapsed and refractory multiple myeloma in adults who have had at least 2 previous treatments, including lenalidomide and bortezomib, and whose disease has progressed on the last therapy. www.nice.org.uk/TA338

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule
CAUTIONARY AND ADVISORY LABELS
3, 25 EXCIPIENTS: May contain Propylene glycol

N N N
Pomalidomide 1 mg
Imnovid (Celgene Ltd) ▼ 1 capsule
Pomalidomide 2 mg
1 capsule
Pomalidomide 3 mg
1 capsule
Pomalidomide 4 mg
1 capsule

Thalidomide

DRUG ACTION
Thalidomide has immunomodulatory and anti-inflammatory activity.

INDICATIONS AND DOSE
First-line treatment for untreated multiple myeloma, in patients aged 65 years and over, or for those not eligible for high-dose chemotherapy (for example, patients with significant co-morbidity such as cardiac risk factors) in combination with melphalan and prednisolone

BY MOUTH
Adult: 200 mg once daily for 6–week cycle for a maximum of 12 cycles, dose to be taken at bedtime

CAUTIONS
High tumour burden—risk of tumour lysis syndrome

CAUTIONS, FURTHER INFORMATION
Thromboembolism Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised. Thromboprophylaxis is recommended for at least the first 5 months of treatment, especially in patients with additional thrombotic risk factors.

Second primary malignancy Patients should be carefully evaluated before and during treatment with thalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.

Peripheral neuropathy Patients with pre-existing peripheral neuropathy should not be treated with thalidomide unless the potential clinical benefits outweigh the risk.
2.8 Photodynamic therapy responsive malignancy

**PHOTOSENSITISERS**

**Porfimer sodium**

- **DRUG ACTION** Porfimer sodium accumulates in malignant tissue and is activated by laser light to produce a cytotoxic effect.

- **INDICATIONS AND DOSE** Photodynamic therapy of non-small cell lung cancer and obstructing oesophageal cancer
  
  **BY SLOW INTRAVENOUS INJECTION**
  
  **Adult:** (consult product literature)

- **CONTRA-INDICATIONS** Acute porphyrias p. 864  
  - broncho-oesophageal fistula  
  - tracheo-oesophageal fistula

- **SIDE-EFFECTS** Alopecia  
  - bone-marrow suppression  
  - constipation  
  - extravasation  
  - hyperuricaemia  
  - nausea  
  - oral mucositis  
  - photosensitivity (sunscreens offer no protection)  
  - thromboembolism  
  - tumour lysis syndrome  
  - vomiting

- **PREGNANCY** Manufacturer advises avoid unless essential.

- **BREAST FEEDING** No information available—manufacturer advises avoid.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment.

- **PATIENT AND CARER ADVICE** Patients and their carers should be advised of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb.

- **PATIENT AND CARER ADVICE** Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.

- **PATIENT AND CARER ADVICE** Patients and their carers should be advised to seek medical advice if symptoms of peripheral neuropathy such as paraesthesia, abnormal coordination, or weakness develop.

- **PATIENT AND CARER ADVICE** Patient counselling advised for thalidomide capsules (pregnancy and contraception).

- **NATIONAL FUNDING/ACCESS DECISIONS** NICE technology appraisals (TAs)
  
  **Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011) NICE TA228**

  Thalidomide in combination with an alkylating drug and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate. [www.nice.org.uk/TA228](http://www.nice.org.uk/TA228)

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, tablet

  - **Tablet**
    - Talidex (Alan Pharmaceuticals)
      - Thalidomide 25 mg Talidex tablets | 30 tablet £485.00
  
  - **Capsule**
    - Thalidomide (Non-proprietary)
      - Thalidomide 50 mg Thalidomide Celgene 50mg capsules | 28 capsule (£) £298.48

---

**SIDE-EFFECTS, FURTHER INFORMATION**

**SIDE-EFFECTS**

- Common or very common
  - Anaemia  
  - asthenia  
  - bradycardia  
  - cardiac failure  
  - confusion  
  - constipation  
  - deep vein thrombosis  
  - depression  
  - dizziness  
  - drowsiness  
  - dry mouth  
  - dysaesthesia  
  - dyspepsia  
  - dyspnoea  
  - interstitial lung disease  
  - leucopenia  
  - lymphopenia  
  - neutropenia  
  - paraesthesia  
  - peripheral neuropathy  
  - peripheral oedema  
  - pneumonia  
  - pulmonary embolism  
  - pyrexia  
  - skin reactions  
  - Stevens-Johnson syndrome  
  - syncope  
  - thrombocytopenia  
  - tremor  
  - vomiting

- Frequency not known
  - Atrial fibrillation  
  - atrioventricular block  
  - cerebrovascular events  
  - convulsions  
  - gastro-intestinal haemorrhage  
  - gastro-intestinal perforation  
  - hearing loss  
  - hepatic disorders  
  - hypothyroidism  
  - intestinal obstruction  
  - menstrual disorders  
  - myocardial infarction  
  - renal failure  
  - second primary malignancy  
  - sexual dysfunction  
  - toxic epidermal necrolysis  
  - worsening of Parkinson’s disease symptoms

- **CONCEPTION AND CONTRACEPTION** For women of childbearing potential, pregnancy must be excluded before starting treatment with thalidomide (perform pregnancy test on initiation or within 3 days prior to initiation). Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intra-uterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer’s Pregnancy Prevention Programme.

- **PREGNANCY** Important: teratogenic risk.

- **BREAST FEEDING** Avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Caution in severe impairment—no information available.

- **RENAL IMPAIRMENT** Caution in severe impairment—no information available.

- **MONITORING REQUIREMENTS**
  
  - Monitor white blood cell count (including differential count) and platelet count (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develop—consult product literature).
  
  - Monitor for arterial or venous thromboembolism.
  
  - Monitor patients for signs and symptoms of peripheral neuropathy.
  
  - Hepatic disorder Liver function should be monitored, particularly when there is history of, or concurrent viral liver infection, or when thalidomide is combined with drugs known to be associated with liver dysfunction (e.g. paracetamol).

- **PRESCRIBING AND DISPENSING INFORMATION** Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a complete Prescription Authorisation Form.

---

**BREAST FEEDING**

- Avoid—present in milk in animal studies.
2.9 Targeted therapy responsive malignancy

HEDGEHOG PATHWAY INHIBITORS

Vismodegib

- **DRUG ACTION** Vismodegib is a hedgehog pathway inhibitor.

**INDICATIONS AND DOSE**
Symptomatic metastatic basal cell carcinoma | Locally advanced basal cell carcinoma not appropriate for surgery or radiotherapy

**BY MOUTH**
- Adult: 150 mg once daily

**Important safety information**
Risks of incorrect dosing of oral anti-cancer medicines, see p. 745

- **INTERACTIONS** → Appendix 1 (vismodegib).
- **SIDE-EFFECTS**
  - Common or very common Abdominal pain | abnormal hair growth | alopecia | amenorrhea | arthralgia | constipation | decreased appetite | dehydration | diarrhoea | dyspepsia | hypoponataemia | malaise | muscle spasms | musculoskeletal pain | nausea | pruritus | rash | taste disturbances | vomiting | weight loss
- **CONCEPTION AND CONTRACEPTION**
  For women of child-bearing potential, pregnancy must be excluded before initiation of treatment, and monthly during treatment. Women must use two contraceptive methods (including one highly effective method and one barrier method) during treatment and for 24 months after the final dose of vismodegib. Men must use a condom during treatment and for 2 months after the final dose.
- **PREGNANCY** Important: teratogenic risk — may cause severe birth defects and embryo-foetal death.
- **BREAST FEEDING** Avoid during treatment and for 24 months after final dose.
- **HEPATIC IMPAIRMENT**
  No information available — manufacturer advises caution in moderate to severe impairment.
- **RENAL IMPAIRMENT**
  No information available — manufacturer advises caution in severe impairment.
- **PRESCRIBING AND DISPENSING INFORMATION**
  Prescribers and pharmacists must comply with prescribing and dispensing restrictions as specified in the manufacturer’s Pregnancy Prevention Programme, and ensure that the patient fully acknowledges the programme’s pregnancy prevention measures — consult product literature for further information.
- **PATIENT AND CARER ADVICE**
  Counselling on pregnancy and contraception advised. Patients must comply with the manufacturer’s pregnancy prevention programme.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**
CAUTIONARY AND ADVISORY LABELS 25
- **Erivedge** (Roche Products Ltd)
  - Vismodegib 150 mg | Erivedge 150 mg capsules | 28 capsule Pack £6,285.00 (Hospital only)

**Temoporfin**

- **DRUG ACTION** Temoporfin accumulates in malignant tissue and is activated by laser light to produce a cytotoxic effect.

**INDICATIONS AND DOSE**
Photodynamic therapy of advanced head and neck squamous cell carcinoma refractory to, or unsuitable for, other treatments

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: (consult product literature)
**PROTEASOME INHIBITORS**

**Bortezomib**

- **DRUG ACTION** Bortezomib is a proteasome inhibitor.

### INDICATIONS AND DOSE

Treatment of multiple myeloma that has progressed despite the use of at least one therapy, and where the patient has already had, or is unable to have, haematopoietic stem cell transplantation (either as monotherapy, or in combination with pegylated liposomal doxorubicin or dexamethasone). Treatment of previously untreated multiple myeloma in patients who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation (in combination with melphalan and prednisolone). Induction treatment of previously untreated multiple myeloma in patients who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation (in combination with dexamethasone, or with dexamethasone and thalidomide).

**BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION**
- **Adult:** (consult local protocol)

**Important safety information**

Bortezomib injection is for **intravenous or subcutaneous administration** only. Inadvertent intrathecal administration with fatal outcome has been reported.

- **CONTRA-INDICATIONS** Acute diffuse infiltrative pulmonary disease - pericardial disease
- **CAUTIONS** Amyloidosis - cardiovascular disease - consider antiviral prophylaxis for herpes zoster infection - dehydration - history of syncope - pulmonary disease (discontinue if interstitial lung disease develops) - risk factors for seizures - risk of neuropathy - consult product literature
- **INTERACTIONS** → Appendix 1 (bortezomib). Caution with concurrent use of medication which may cause hypotension.

### SIDE-EFFECTS

- **Common or very common** Constipation (cases of ileus reported) - decreased appetite - diarrhoea - dyspnoea - fatigue - headache - herpes zoster - hypotension - myalgia - paraesthesia - peripheral neuropathy - pyrexia - rash - reactivation of herpes zoster - sensory neuropathy

- **Uncommon** Acute diffuse infiltrative pulmonary disorders - heart failure - posterior reversible encephalopathy syndrome (discontinue treatment) - pulmonary hypertension - seizures

- **Rare** Autonomic neuropathy

- **Very rare** Progressive multifocal leucoencephalopathy

- **Frequency not known** Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

### SIDE-EFFECTS, FURTHER INFORMATION

For further information on side-effects, consult product literature.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for 3 months after treatment in men or women.

- **PREGNANCY** Toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING** Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT** Reduce dose in moderate to severe impairment — consult product literature.

- **RENAL IMPAIRMENT** No information available for creatinine clearance less than 20 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- **Monitor** blood-glucose concentration in patients on oral antidiabetics.

- **Monitor for symptoms** of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological signs or symptoms) — discontinue treatment if diagnosed.

- **Chest x-ray** recommended before treatment to monitor for pulmonary disease — discontinue if interstitial lung disease develops.

### NATIONAL FUNDING/ACCESS DECISIONS

**NICE technology appraisals (TAs)**

- **Bortezomib monotherapy for relapsed multiple myeloma** (October 2007) NICE TA129

Bortezomib monotherapy is an option for the treatment of progressive multiple myeloma in patients who are at first relapse having received one prior therapy and who have undergone, or are unsuitable for, bone-marrow transplantation, under the following circumstances:

- the response to bortezomib is measured using serum M protein after a maximum of four cycles of treatment, and treatment is continued only in patients who have a reduction in serum M protein of 50% or more (where serum M protein is not measurable, an appropriate alternative biochemical measure of response should be used) and

- the manufacturer rebates the full cost of bortezomib if there is an inadequate response (as defined above) after four cycles of treatment. [www.nice.org.uk/TA129](http://www.nice.org.uk/TA129)

- **Bortezomib and thalidomide for the first-line treatment of multiple myeloma** (July 2011) NICE TA228

Bortezomib in combination with an alkylating drug and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if:

- high-dose chemotherapy with stem cell transplantation is considered inappropriate and

- the person is unable to tolerate or has contra-indications to thalidomide. [www.nice.org.uk/TA228](http://www.nice.org.uk/TA228)

- **Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation** (April 2014) NICE TA311

Bortezomib is recommended as an option within its marketing authorisation, in combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. [www.nice.org.uk/TA311](http://www.nice.org.uk/TA311)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium, has advised (December 2013) that bortezomib (Velcade®) is accepted for restricted use within NHS Scotland in combination with dexamethasone and thalidomide for the induction treatment of adults with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Powder for solution for injection**
  - **Velcade** (Janssen-Cilag Ltd)
  - **Bortezomib 3.5 mg** Velcade 3.5mg powder for solution for injection vials | 1 vial (PoS) £762.38 (Hospital only)
PROTEIN KINASE INHIBITORS

Afatinib

**DRUG ACTION** Afatinib is a protein kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations, in patients who have not previously been treated with EGFR tyrosine kinase inhibitor

**BY MOUTH**
- Adult: 40 mg once daily for 3 weeks, then increased if tolerated to 50 mg once daily, consult product literature for details on dosing and dose adjustment due to side effects

**SIDE-EFFECTS**

Common or very common Acne - conjunctivitis - cystitis - decreased appetite - dehydration - diarrhoea - dry eyes - dry skin - dysgeusia - dyspepsia - epistaxis - hand-foot syndrome - hyperkalaemia - muscle spasms - paronychia - pruritus - pyrexia - rash (see Cautions) - renal failure - rhinorrhoea - weight loss

**INTERACTIONS** → Appendix 1 (afatinib).

**CONTRAINDICATIONS** See Appendix 1 (afatinib).

**MEXICAN FORMS**

- **Afatinib 50 mg**
- **Afatinib 30 mg**
- **Afatinib 20 mg**

**USEFUL INFORMATION**

- **Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014) NICE TA310**

Afatinib is recommended as an option, within its marketing authorisation, for treating locally advanced or metastatic non-small-cell lung cancer in adults:

- whose tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation, and
- who have not previously had an EGFR-TK inhibitor, and
- if the manufacturer provides afatinib with the discount agreed in the patient access scheme. www.nice.org.uk/TA310

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Afatinib 50 mg**

**Afatinib 20 mg**

**Afatinib 30 mg**

**Afatinib 20 mg**

**Afatinib 30 mg**

**Afatinib 50 mg**

**Afatinib 50 mg**

---

Axitinib

**DRUG ACTION** Axitinib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of advanced renal cell carcinoma following failure of previous treatment with sunitinib or a cytokine (aldesleukin or interferon alfa)

**BY MOUTH**
- Adult: (consult product literature)

**SIDE-EFFECTS**


**INTERACTIONS** → Appendix 1 (axitinib).
Targeted therapy responsive malignancy 803

**BNF 70**

- **Uncommon** Hypertensive crisis • polycythaemia • posterior reversible encephalopathy syndrome
- **Frequency not known** Alopecia • bone-marrow suppression • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting
- **CONCEPTION AND CONTRACEPTION** Effective contraception required during and for up to 1 week after treatment.
- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **HEPATIC IMPAIRMENT** Reduce starting dose in moderate impairment. Avoid in severe impairment—no information available.
- **MONITORING REQUIREMENTS**
  - Monitor for symptoms of fistula.
  - Monitor for symptoms of gastro-intestinal perforation.
  - Monitor for signs and symptoms of fluid retention.
  - Monitor liver function before treatment initiation, then monthly for the first 3 months and thereafter as clinically indicated.
  - Monitor hepatic function.
  - Monitor for thyroid dysfunction.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - **Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (February 2015)**
      - **NICE TA333**
      - Axitinib is recommended as an option for treating adults with advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor or a cytokine, only if the company provides axitinib with the discount agreed in the patient access scheme. [www.nice.org.uk/TA333](http://www.nice.org.uk/TA333)
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS 25**
      - Inlyta (Pfizer Ltd) ▼
        - Axitinib 1 mg Inlyta 1mg tablets | 56 tablet [PDR] £703.40 (Hospital only)
        - Axitinib 3 mg Inlyta 3mg tablets | 56 tablet [PDR] £2,110.20 (Hospital only)
        - Axitinib 5 mg Inlyta 5mg tablets | 56 tablet [PDR] £3,517.00 (Hospital only)
        - Axitinib 7 mg Inlyta 7mg tablets | 56 tablet [PDR] £4,923.80 (Hospital only)

**Bosutinib**

**INDICATIONS AND DOSE**

Treatment of chronic, accelerated and blast phase Philadelphia chromosome-positive chronic myeloid leukaemia, in those previously treated with one or more tyrosine kinase inhibitor, and for whom imatinib, nilotinib and dasatinib are not clinically appropriate

- Adult: 500 mg once daily, consult product literature for dose adjustment due to side effects, or incomplete haematologic response by week 8, or incomplete cytogenetic response by week 12

- **CAUTIONS** Cardiac disease • history of pancreatitis— withhold treatment if lipase elevated and abdominal symptoms occur • history of QT prolongation—monitor ECG and correct hypokalaemia and hypomagnesaemia before and during treatment • significant gastrointestinal disorder

- **INTERACTIONS** → Appendix 1 (bosutinib).

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain • abnormal liver function • acne • arthralgia • biochemical disturbances • cough • decreased appetite • dehydration • diarrhoea • dizziness • dysgeusia • dysphonia • electrolyte disturbances • gastritis • headache • hepatotoxicity • infection • malaise • myalgia • oedema • pericardial effusion • pleural effusion • pruritus • pyrexia • QT prolongation • rash • renal failure • renal impairment • urticaria
  - **Uncommon** Gastric haemorrhage • pancreatitis • pericarditis • pulmonary hypertension • pulmonary oedema • respiratory failure • tinnitus
  - **Frequency not known** Alopecia • bone-marrow suppression • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

- **CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment in women.
- **PREGNANCY** Avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Avoid—no information available.
- **MONITORING REQUIREMENTS**
  - Monitor liver function before treatment initiation, then monthly for the first 3 months and thereafter as clinically indicated—consult product literature for management of raised transaminases.
  - Monitor full blood count weekly for the first month and then monthly thereafter or as clinically indicated.
  - Monitor for signs and symptoms of fluid retention (including pericardial effusion, pleural effusion and pulmonary oedema).

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - **Bosutinib for previously treated chronic myeloid leukaemia (November 2013)**
      - **NICE TA299**
      - Bosutinib is not recommended within its marketing authorisation for treating Philadelphia-chromosompositive chronic myeloid leukaemia. [www.nice.org.uk/TA299](http://www.nice.org.uk/TA299)

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS 21**
      - Bosulif (Pfizer Ltd) ▼
        - Bosutinib 100 mg Bosulif 100mg tablets | 28 tablet [PDR] £859.17 (Hospital only)
        - Bosutinib 500 mg Bosulif 500mg tablets | 28 tablet [PDR] £3,436.67 (Hospital only)
**804 Malignant disease**

**Cabozaatnib**

- **Drug Action** Cabozantinib is an inhibitor of several protein kinases.

**Indications and Dose**

Treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma

**By Mouth**

- Adult: 140 mg once daily, for dose adjustment or treatment interruption due to side effects, consult product literature (closely monitor for first 8 weeks of therapy).

**Important Safety Information**

**Risks of Incorrect Dosing of Oral Anti-Cancer Medicines**, see p. 745

**Contra-Indications** Reversible Posterior Leukoencephalopathy Syndrome

**Caution** Hypertension—discontinue treatment if uncontrolled despite medical intervention—palmar-planter erythrodysaesthesia syndrome—consider treatment interruption if severe and restart at a lower dose when resolved to grade 1—patients at increased risk of fistulas—consult product literature—patients at increased risk of gastro-intestinal perforation—consult product literature—patients at increased risk of intra-abdominal abscess—consult product literature—patients at risk of haemorrhage (including tumour involvement of the trachea or bronchi)—discontinue if symptoms develop—patients at risk of thromboembolic events including myocardial infarction—discontinue if symptoms develop—risk of osteonecrosis of the jaw—susceptibility to QT-interval prolongation (e.g. cardiac disease, electrolyte disturbances, bradycardia, concomitant use of drugs that prolong the QT interval)—monitor ECG and electrolytes periodically

**Caution, Further Information**

**Elective Surgery** Withhold treatment for at least 28 days before elective surgery and restart only if adequate wound healing—discontinue in patients with wound healing complications requiring medical intervention.

**Risk of Osteonecrosis of the Jaw** Discontinue treatment at least 28 days before elective invasive dental procedures—monitor for symptoms before and during treatment and discontinue if osteonecrosis develops.

**Interactions**

- Appendix 1 (cabozantinib).

Caution with concomitant use of drugs which increase the risk of osteonecrosis of the jaw e.g. bisphosphonates. Caution with concomitant use of drugs that prolong the QT interval.

**Side-Effects**

- Common or very common: Abdominal pain, abnormal hair growth, abscess, acne, alopecia, anal fissure, anxiety, arthralgia, aspiration, atrial fibrillation, blurred vision, chelitis, chills, cholelithiasis, constipation, decreased appetite, dehydration, depression, diarrhoea, dizziness, dry skin, dysgeusia, dyspepsia, dysphagia, dysphonia, dysuria, erythema, face oedema, folliculitis, fungal infection, gastro-intestinal perforation, gastrointestinal haemorrhage, glossodynia, haematuria, haemorrhoids, hair colour changes, headache, hyperbilirubinaemia, hyperkeratosis, hypertension, hypoalbuninaemia, hypocalcaemia, hypokalaemia, hypophosphataemia, hypotension, hypothyroidism, impaired wound healing, lymphopenia, mucosal inflammation, muscle spasms, musculoskeletal chest pain, nausea, neutropenia, non-gastro-intestinal fistula, oropharyngeal pain, osteonecrosis of jaw, pallor, palmar-planter erythrodysaesthesia syndrome, pancreatitis, paraesthesia, peripheral coldness, peripheral neuropathy, platelet disorders, pneumonia, proteinuria, pulmonary embolism, rash, respiratory tract haemorrhage, skin exfoliation, skin hypopigmentation, stomatitis, tinnitus, tremor, venous thrombosis, vomiting.

**Uncommon**

- Acute renal failure, amnorrhoaea, angina, arterial thrombosis, aspergillosis, ataxia, atelectasis, cataract, conjunctivitis, cyst, delirium, facial pain, gastro-intestinal fistula, hepatic encephalopathy, hypocalcaemia, loss of consciousness, oesophagitis, pharyngeal oedema, pneumonitis, posterior reversible encephalopathy syndrome, rhabdomyolysis, skin ulcer, speech disorder, supraventricular tachycardia, telangiectasia, transient ischaemic attack, vaginal haemorrhage.

**Frequency Not Known**

- Bone-marrow suppression, hyperuricaemia, oral mucositis, thromboembolism, tumour lysis syndrome.

**Conception and Contraception**

Patients and their sexual partners must use effective contraception (in addition to barrier method) during treatment and for at least 4 months after the last dose.

**Pregnancy**

Manufacturer advises avoid unless potential benefit outweighs risk—tobacco use in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**Breast Feeding**

Manufacturer advises discontinue breast-feeding during treatment and for at least 4 months after the last dose.

**Renal Impairment**

Manufacturer advises avoid.

**Hepatic Impairment**

Manufacturer advises avoid.

**Monitoring Requirements**

Monitor liver function regularly and discontinue if nephrotic syndrome develops.

**Patient and Carer Advice**

Fatigue and weakness may affect performance of skilled tasks e.g. driving. Food should not be consumed for at least 2 hours before and at least 1 hour after each dose.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**Cautionary and Advisory Labels** 25

- **Cometriq** (Swedish Orphan Biovitrum Ltd). ▼
  - Cabozantinib (as Cabozantinib s-malate) 20 mg Cometriq 20 mg capsules | 7 capsule (PSt) no price available | 21 capsule (PSt) no price available | 84 capsule (PSt) £4,800.00
  - Cabozantinib (as Cabozantinib s-malate) 80 mg Cometriq 80 mg capsules | 7 capsule (PSt) no price available | ▼
  - Cometriq (Swedish Orphan Biovitrum Ltd). ▼
  - Cometriq 20 mg capsules and Cometriq 80 mg capsules | 56 capsule (PSt) £4,800.00 | 112 capsule (PSt) £4,800.00

**Crizotinib**

- **Drug Action** Crizotinib is a tyrosine kinase inhibitor.

**Indications and Dose**

Treatment of previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

**By Mouth**

- Adult: 250 mg twice daily, for dose adjustments due to side-effect, consult product literature

**Important Safety Information**

**Risks of Incorrect Dosing of Oral Anti-Cancer Medicines**, see p. 745

**Caution** History of diverticulitis (risk of gastrointestinal perforation—discontinue treatment if
Targeted therapy responsive malignancy

Dabrafenib

**INDICATIONS AND DOSE**
Monotherapy for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation

**BY MOUTH**
- Adult: 150 mg every 12 hours, for dose adjustments due to side effects consult product literature

**SIDE-EFFECTS**
- **Common or very common** Bradycardia, constipation, decreased appetite, diarrhoea, dizziness, dyspepsia, fatigue, hyperuricaemia, interstitial lung disease, oedema, pneumonia, QT-interval prolongation, rash, syncope, taste disturbance
- **Uncommon** Gastrointestinal perforation, hepatotoxicity
- **Frequency not known** Alopecia, bone-marrow suppression, hyperkalaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome

**CONCESSION AND CONTRA-INDICATIONS**
Ensure effective contraception during and for at least 90 days after treatment.

**PREGNANCY**
Avoid (toxicity in animal studies).

**BREAST FEEDING**
Avoid—no information available.

**HEPATIC IMPAIRMENT**
Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT**
Reduce dose to 250 mg once daily in severe impairment not requiring peritoneal dialysis or hemodialysis. May be increased to 200 mg twice daily after at least 4 weeks, based on individual assessment of safety and tolerability.

**MONITORING REQUIREMENTS**
- Monitor liver function once a week during the first 2 months of treatment, then at least monthly thereafter and as clinically indicated.
- Monitor ECG and electrolytes (correct if abnormal) in all patients before starting treatment, then periodically and as clinically indicated thereafter.
- Monitor for signs and symptoms of treatment emergent bradycardia (including syncope, dizziness and hypotension)—monitor blood pressure and heart rate regularly.

**PATIENT AND CARER ADVICE**
Counsel all patients on the early signs and symptoms of gastrointestinal perforation—advice to seek immediate medical attention.

**Driving and skilled tasks**
Symptomatic bradycardia (including syncope, dizziness and hypotension), vision disorder and fatigue may affect performance of skilled tasks (e.g. driving or operating machinery).

**CONTRA-INDICATIONS**
BRAF wild-type melanoma, long QT syndrome, uncorrectable electrolyte abnormalities (including magnesium)

**CAUTIONS**
Pyrexia (interrupt treatment if $>38.5^\circ\text{C}$ and assess for signs and symptoms of infection—consult product literature)

**INTERACTIONS**
Appendix 1 (dabrafenib).

**SIDE-EFFECTS, FURTHER INFORMATION**
Important safety information

**BNF 70**
8
Malignant disease
Malignant disease

806 Malignant disease

- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- **BREAST FEEDING** Manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment. Additional monitoring of ECG and electrolytes required in hepatic impairment—consult product literature.
- **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available.

- **MONITORING REQUIREMENTS**
  - Assess for cutaneous squamous cell carcinoma and new primary melanoma before treatment, monthly during treatment, and for 6 months after discontinuation or until initiation of alternative treatment.
  - Assess and monitor for non-cutaneous secondary or recurrent malignancy before, during, and for 6 months after discontinuation or until initiation of alternative treatment—consult product literature.
  - Monitor serum creatinine and other signs of renal failure—consult product literature and interrupt dose as appropriate.
  - Monitor for ophthalmologic reactions including uveitis and iritis.
  - Monitor ECG and electrolytes (including magnesium) before and one month after treatment initiation and after each dose modification—consult product literature if abnormalities occur.

- **PATIENT AND CARER ADVICE** Ocular adverse reactions and fatigue may affect performance of skilled tasks e.g. driving.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - NICE technology appraisals (TAs)
    - Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (October 2014) NICE TA321 Dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma only if the manufacturer provides dabrafenib with the discount agreed in the patient access scheme. [www.nice.org.uk/TA321](http://www.nice.org.uk/TA321)
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium has advised (February 2015) that dabrafenib (Tafinlar®) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic BRAFV600 mutation-positive melanoma in patients who have received no prior therapy.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Capsule**
    - CAUTIONARY AND ADVISORY LABELS 23, 25
    - Tafinlar (Novartis Pharmaceuticals UK Ltd) ▼
    - Dabrafenib (as Dabrafenib mesilate) 50 mg Tafinlar 50mg capsules | 28 capsule (PST) £93.33 (Hospital only)
    - Dabrafenib (as Dabrafenib mesilate) 75 mg Tafinlar 75mg capsules | 28 capsule (PST) £1.400.00 (Hospital only)

Dasatinib

- **DRUG ACTION** Dasatinib is a tyrosine kinase inhibitor.

### INDICATIONS AND DOSE

#### Chronic phase chronic myeloid leukaemia (consult product literature for details)

**BY MOUTH**

- Adult: 100 mg once daily, then increased if necessary up to 140 mg once daily

### Important safety information

- **CAUTIONS** Risk of cardiac dysfunction (monitor closely) - susceptibility to QT-interval prolongation (correct hypokalaemia or hypomagnesaemia before starting treatment)

### CAUTIONS, FURTHER INFORMATION

- **Pulmonary arterial hypertension** Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease before starting treatment; echocardiography should be performed at the start of treatment in patients with symptoms of cardiac disease and considered for patients with risk factors for cardiac or pulmonary disease. Treatment should be interrupted or the dose reduced in patients who develop dyspnoea or fatigue, while they are evaluated for common aetiologies (e.g. pleural effusion, pulmonary oedema, anaemia or lung infiltration); pulmonary arterial hypertension should be considered in the absence of these conditions, and if there is no improvement following dose reduction or interruption. If pulmonary arterial hypertension is confirmed, dasatinib should be permanently discontinued.

### INTERACTIONS

- Appendix 1 (dasatinib).

### SIDE-EFFECTS

- **Common or very common** Abdominal pain · acne · anorexia · arrhythmias · chest pain · CNS haemorrhage · colitis · congestive heart failure · constipation · cough · depression · dermatitis · diarrhoea · dizziness · dry skin · dyspepsia · dysphagia · flushing · gastritis · gastro-intestinal haemorrhage · haemorrhage · headache · hypertension · influenza-like symptoms · insomnia · musculoskeletal pain · neuropathy · oedema (more common in patients over 65 years old) · palpitation · pleural effusion · pruritus · pulmonary hypertension · sweating · taste disturbance · tinnitus · urticaria · visual disturbances · weight changes
- **Uncommon** Anemia · asthma · cholecystitis · cholestasis · drowsiness · erythema nodosum · gynaecomastia · hepatitis · hypersensitivity reactions · hypocalcaemia · hypotension · irregular menstruation · nail disorders · oesophagitis · pancreatitis · photosensitivity · pigmentation · proteinuria · rhabdomyolysis · seizures · syncope · thrombophlebitis · transient ischaemic attack · tremor · urinary frequency
- **Rare** Cor pulmonale · Frequency not known Alopecia · bone-marrow suppression · hyperuricaemia · interstitial lung disease · nausea · oral mucositis · thromboembolism · thrombosis · tumour lysis syndrome · vomiting

### CONCEPTION AND CONTRACEPTION

- Effective contraception required during treatment.

### PREGNANCY

- Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

### BREAST FEEDING

- Discontinue breast-feeding.

### HEPATIC IMPAIRMENT

- Manufacturer advises caution in hepatic impairment.

### Monitor for ophthalmologic reactions including uveitis

- Monitor serum creatinine and other signs of renal failure—consult product literature and interrupt dose as appropriate.
- Monitor for ophthalmologic reactions including uveitis and iritis.
- Monitor ECG and electrolytes (including magnesium) before and one month after treatment initiation and after each dose modification—consult product literature if abnormalities occur.

### Frequency not known

- **Common or very common** Abdominal pain · acne · anorexia · arrhythmias · chest pain · CNS haemorrhage · colitis · congestive heart failure · constipation · cough · depression · dermatitis · diarrhoea · dizziness · dry skin · dyspepsia · dysphagia · flushing · gastritis · gastro-intestinal haemorrhage · haemorrhage · headache · hypertension · influenza-like symptoms · insomnia · musculoskeletal pain · neuropathy · oedema (more common in patients over 65 years old) · palpitation · pleural effusion · pruritus · pulmonary hypertension · sweating · taste disturbance · tinnitus · urticaria · visual disturbances · weight changes
- **Uncommon** Anemia · asthma · cholecystitis · cholestasis · drowsiness · erythema nodosum · gynaecomastia · hepatitis · hypersensitivity reactions · hypocalcaemia · hypotension · irregular menstruation · nail disorders · oesophagitis · pancreatitis · photosensitivity · pigmentation · proteinuria · rhabdomyolysis · seizures · syncope · thrombophlebitis · transient ischaemic attack · tremor · urinary frequency
- **Rare** Cor pulmonale · Frequency not known Alopecia · bone-marrow suppression · hyperuricaemia · interstitial lung disease · nausea · oral mucositis · thromboembolism · thrombosis · tumour lysis syndrome · vomiting

### CONCEPTION AND CONTRACEPTION

- Effective contraception required during treatment.

### PREGNANCY

- Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

### BREAST FEEDING

- Discontinue breast-feeding.

### HEPATIC IMPAIRMENT

- Manufacturer advises caution in hepatic impairment.
**Erlotinib**

**DRUG ACTION** Erlotinib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**

- **Treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy**
- **Monotherapy for maintenance treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of platinum-based chemotherapy**

**BY MOUTH**

- **Adult:** 150 mg once daily

**Treatment of metastatic pancreatic cancer (in combination with gemcitabine)**

**BY MOUTH**

- **Adult:** 100 mg once daily

---

**Important safety information**

**EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS: SERIOUS CASES OF KERATITIS AND ULCERATIVE KERATITIS (MAY 2012)**

Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness.

Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative keratitis is diagnosed.

---

**ERLOTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC EGFR-TK MUTATION-POSITIVE NON- small-cell LUNG CANCER (JUNE 2012) NICE TA227**

Erlotinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if:

- they test positive for the epidermal growth factor tyrosine kinase (EGFR-TK) mutation
- the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).

---

**ERLOTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC EGFR-TK MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (JUNE 2012) NICE TA258**

Erlotinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if:

- they test positive for the epidermal growth factor tyrosine kinase (EGFR-TK) mutation
- the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).
Everolimus

**Drug Action**

Everolimus is a protein kinase inhibitor.

**Indications and Dose**

**Votubia®**

Subependymal giant cell astrocytoma associated with tuberous sclerosis complex

By mouth

- Adult: (consult product literature)

Renal angiomyolipoma associated with tuberous sclerosis complex

By mouth

- Adult: (consult product literature)

**Afinitor®**

Treatment of advanced renal cell carcinoma when the disease has progressed despite treatment with vascular endothelial growth factor-targeted therapy | Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin | Treatment of hormone-receptor-positive, human epidermal growth factor-2 (HER-2) negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-stereoidal aromatase inhibitor

By mouth

- Adult: 10 mg once daily

**Important safety information**

**Risks of incorrect dosing of oral anti-cancer medicines**, see p. 745

**Caution**

- History of bleeding disorders

**Interactions** → Appendix 1 (everolimus).

Caution with concomitant use of drugs that increase risk of bleeding.

**Side-effects**

- **Common or very common** Abdominal pain | anorexia | arthralgia | asthenia | chest pain | convulsions | dehydration | diarrhoea | dry mouth | dysphagia | electrolyte disturbance | epistaxis | eyelid oedema | fatigue | hand-foot syndrome | headache | hypercholesterolaemia | hyperglycaemia | hyperlipidaemia | hypertension | hypoglycaemia | increased susceptibility to aspergillosis | increased susceptibility to candidiasis | increased susceptibility to infections | increased susceptibility to pneumonia | insomnia | interstitial lung disease | irritability | nail disorders | peripheral oedema | pneumonitis | renal failure | skin disorders | taste disturbance

- **Uncommon** Aggression | agitation | congestive heart failure | flushing | impaired wound healing | rhabdomyolysis

- **Frequency not known** Alopecia | bone-marrow suppression | haemorrhage | hepatitis B reactivation | hyperuricaemia | nausea | oral mucositis | thromboembolism | tumour lysis syndrome | vomiting

**Side-effects, Further Information**

Reduce dose or discontinue if severe side-effects occur—consult product literature.

**Conception and Contraception**

Effective contraception must be used during and for up to 8 weeks after treatment.

**Pregnancy**

Manufacturer advises avoid.

**Hepatic Impairment**

Consult product literature.

**Monitoring Requirements**

- Monitor blood-glucose concentration, serum-triglycerides and serum-cholesterol before treatment and periodically thereafter.

- Monitor renal function before treatment and periodically thereafter.

**Directions for Administration**

**Votubia®** Tablets may be dispersed in approximately 30 mL of water by gently stirring, immediately before drinking. After solution has been swallowed, any residue must be re-dispersed in the same volume of water and swallowed.

**Patient and Carer Advice**

Pneumonitis Non-infectious pneumonitis reported. Patients should be advised to seek urgent medical advice if new or worsening respiratory symptoms occur.

**National Funding/Access Decisions**

**NICE Technology Appraisals (TAs)**

- Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) **NICE TA219**
  
  Everolimus is not recommended for the second-line treatment of advanced renal cell carcinoma. [www.nice.org.uk/TA219](http://www.nice.org.uk/TA219)

- Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (August 2013) **NICE TA295**
  
  Everolimus, in combination with exemestane, is not recommended within its marketing authorisation for treating postmenopausal women with advanced human epidermal growth factor receptor 2 (HER2) negative hormone-receptor-positive breast cancer that has recurred or progressed following treatment with a non-stereoidal aromatase inhibitor. [www.nice.org.uk/TA295](http://www.nice.org.uk/TA295)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (April 2012) that everolimus (Afinitor®) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin (pNET) in adults with progressive disease.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.
Targeted therapy responsive malignancy 809

Gefitinib

**DRUG ACTION** Gefitinib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of epidermal growth factor receptor

*BY MOUTH*

- Adult: 250 mg once daily

**INTERACTIONS** → Appendix 1 (gefitinib).

**SIDE-EFFECTS**

- Common or very common Acne, anorexia, asthenia, blepharitis, conjunctivitis, diarrhoea, dry eye, dry mouth, dry skin, epistaxis, haematuria, interstitial lung disease—discontinue if confirmed, nail disorder, proteinuria, pruritus, pyrexia, rash, skin reactions
- Uncommon Cornal erosion, pancreatitis
- Rare Hepatitis, toxic epidermal necrolysis
- Frequency not known Alopecia, bone-marrow suppression, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome—vomiting

**PREGNANCY**

- Manufacturer advises avoid unless essential—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

**BREAST FEEDING**

- Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

- Manufacturer advises caution in moderate to severe impairment due to cirrhosis.

**RENAL IMPAIRMENT**

- Manufacturer advises caution if creatinine clearance less than 20 mL/minute.

**MONITORING REQUIREMENTS**

- Monitor for worsening of dyspnoea, cough and fever—discontinue if interstitial lung disease confirmed.
- Monitor liver function—consider discontinuing if severe changes in liver function occur.

**NICE technology appraisals (TAs)**

- Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010) NICE TA192

**Medicinal forms**

- Gefitinib 250 mg Iressa 250 mg tablets | 30 tablet | £2,167.71

Ibrutinib

**DRUG ACTION** Ibrutinib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of relapsed or refractory mantle cell lymphoma

*BY MOUTH*

- Adult: 560 mg once daily, for dose adjustments due to side effects consult product literature

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

- Adult: 420 mg once daily, for dose adjustments due to side effects consult product literature

**TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA**

- Treatment of chronic lymphocytic leukaemia, in patients who have received at least one prior therapy, or as first-line treatment in patients with 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy

**MEDICATION FORMS**

- Iressa (AstraZeneca UK Ltd)

**Important safety information**

- Avoid concomitant use of drugs that increase risk of bleeding.

**CAUTIONS**

- Family history of congenital short QT syndrome—increased risk of leuokastosis, consider withholding treatment temporarily and monitor closely. Patients at risk from further shortening of QTC interval—personal history of congenital short QT syndrome—risk of haemorrhagic events—withdraw ibrutinib treatment for at least 5 to 7 days before and after surgery depending on risk of bleeding.

**INTERACTIONS** → Appendix 1 (ibrutinib).

- Avoid concomitant use of drugs that increase risk of bleeding.
810 Malignant disease

- **SIDE-EFFECTS**
  - Common or very common: Arthralgia, atrial fibrillation, blurred vision, bruising, constipation, dehydration, diarrhoea, dizziness, dry mouth, epistaxis, haemorrhage, headache, musculoskeletal pain, peripheral oedema, petechiae, pyrexia, rash, respiratory tract infection, sepsis, sinusitis, skin infection, subdural haematoma, urinary tract infection
  - Uncommon: Leukostasis
  - Frequency not known: Alopecia, bone-marrow suppression, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

- **CONCESSION AND CONTRACEPTION**
  - Highly effective contraception (must include a non-hormonal method) required during and for 3 months after stopping treatment.

- **PREGNANCY**
  - Manufacturer advises avoid—毒性 in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING**
  - Manufacturer advises discontinue breastfeeding—no information available.

- **HEPATIC IMPAIRMENT**
  - Reduce dose to 140 mg daily in moderate impairment—monitor for toxicity and adjust dose if necessary (consult product literature).

- **RENAL IMPAIRMENT**
  - Use in severe impairment only if benefit outweighs risk and with close monitoring for toxicity. Maintain hydration and monitor serum creatinine periodically in mild to moderate renal impairment.

- **MONITORING REQUIREMENTS**
  - Monitor full blood count once a month.
  - Monitor for atrial fibrillation (increased risk in cardiac risk factors, acute infections and history of atrial fibrillation), monitor all patients periodically and complete ECG if arrhythmic symptoms or dyspnoea develop—consult product literature in severe impairment.

- **MEDICATION FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **CAPSULE**
  - CAUTIONARY AND ADVISORY LABELS 25
  - Imbruvica (Janssen-Cilag Ltd) ▼
  - Idelalisib 140 mg Imbruvica 140 mg capsules | 90 capsule £4,599.00 | 120 capsule £6,132.00

### Idelalisib

- **DRUG ACTION**
  - Idelalisib is a protein kinase inhibitor.

#### INDICATIONS AND DOSE

- Treatment of chronic lymphocytic leukaemia in patients who have received at least one previous therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemoinmunotherapy (in combination with rituximab). Treatment of follicular lymphoma refractory to two lines of treatment (monotherapy)

  BY MOUTH
  - Adult: 150 mg twice daily, for dose adjustment due to side effects, consult product literature

#### Important safety information

- **RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**, see p. 745

- **CAUTIONS**
  - Active hepatitis, diarrhoea—symptomatic management recommended (consult product literature)
  - Pneumonitis— withhold treatment (consult product literature)

#### INTERACTIONS

- ▶ Appendix 1 (idelalisib)

#### SIDE-EFFECTS

- Alopecia, bone-marrow suppression, diarrhoea, hyperuricaemia, infections, nausea, neutropenia, oral mucositis, pneumonitis, pyrexia, rash, thromboembolism, tumour lysis syndrome, vomiting

#### CONCESSION AND CONTRACEPTION

- Highly effective contraception (in addition to barrier method) required during and for one month after treatment.

#### PREGNANCY

- Manufacturer advises avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING**
  - Manufacturer advises avoid—no information available.

#### HEPACTIC IMPAIRMENT

- Manufacturer advises caution in hepatic impairment.

#### MONITORING REQUIREMENTS

- Monitor liver function—consult product literature.

#### NATIONAL FUNDING/ACCESS DECISIONS

- Scottish Medicines Consortium (SMC) Decisions
  - The Scottish Medicines Consortium has advised (March 2015) that idelalisib (Zydelig®) is accepted for restricted use within NHS Scotland for the treatment of relapsed chronic lymphocytic leukaemia in patients who are unsuitable for chemotherapy and treatment naive patients with 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy.

#### MEDICATION FORMS

- There can be variation in the licensing of different medicines containing the same drug.

#### Tablet

- CAUTIONARY AND ADVISORY LABELS 25
  - ▼ Zydelig (Gilead Sciences International Ltd)
  - Idelalisib 100 mg Zydelig 100 mg tablets | 60 tablet £3,114.75 (Hospital only)
  - Idelalisib 150 mg Zydelig 150 mg tablets | 60 tablet £3,114.75 (Hospital only)

### Imatinib

- **DRUG ACTION**
  - Imatinib is a tyrosine kinase inhibitor.

#### INDICATIONS AND DOSE

- Treatment of chronic myeloid leukaemia in chronic phase after failure with interferon alfa

  BY MOUTH
  - Adult: 400 mg once daily, increased if necessary up to 800 mg daily in 2 divided doses

- Treatment of chronic myeloid leukaemia in accelerated phase, or in blast crisis

  BY MOUTH
  - Adult: 600 mg once daily, then increased if necessary up to 800 mg daily in 2 divided doses

- Treatment of newly diagnosed acute lymphoblastic leukaemia (in combination with other chemotherapy) | Monotherapy for relapsed or refractory acute lymphoblastic leukaemia

  BY MOUTH
  - Adult: 600 mg once daily
Targeted therapy responsive malignancy 811

Treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST) | Adjuvant treatment following resection of c-kit (CD117)-positive GIST, in patients at significant risk of relapse | Treatment of myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement | BY MOUTH

- Adult: 400 mg once daily

Treatment of unresectable dermatofibrosarcoma protuberans | Recurrent or metastatic dermatofibrosarcoma protuberans, in patients who cannot have surgery | BY MOUTH

- Adult: 800 mg daily in 2 divided doses

Treatment of advanced hyper eosinophilic syndrome and chronic eosinophilic leukaemia

- Adult: 100–400 mg once daily

Important safety information

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

- CAUTIONS Cardiac disease · history of renal failure · risk factors for heart failure
- INTERACTIONS Common or very common Abdominal pain · appetite changes · arthralgia · ascert · conjunctivitis · constipation · cough · cramps · diarrhoea · dizziness · dry eyes · dry mouth · dry skin · dyspnoea · epistaxis · fatigue · flatulence · flushing · gastro-oesophageal reflex · haemorrhage · headache · hypoaesthesia · increased lacrimation · influenza-like symptoms · insomnia · oedema · paraesthesia · photosensitivity · pleural effusion · pruritus · pulmonary oedema · rash · sweating · taste disturbance · visual disturbances · weight changes
- SIDE-EFFECTS Uncommon Acute respiratory failure · anxiety · cold extremities · cough · depression · drowsiness · dysphagia · electrolyte disturbances · gastric ulceration · gout · gynaecomastia · haematoma · hearing loss · heart failure · hepatic dysfunction · hypertension · hypotension · impaired memory · irregular menstruation · menorrhagia · migraine · palpitation · pancreatitis · peripheral neuropathy · renal failure · sexual dysfunction · skin hyperpigmentation · syncope · tachycardia · tinnitus · tremor · urinary frequency · vertigo
- Rare Angina · angioedema · arrhythmia · aseptic necrosis of bone · atrial fibrillation · catarrh · confusion · convulsions · exfoliative dermatitis · gastro-intestinal perforation · glaucoma · haemolytic anaemia · hepatic failure · hepatic necrosis · increased intracranial pressure · inflammatory bowel disease · intestinal obstruction · myocardial infarction · myopathy · pulmonary fibrosis · pulmonary hypertension · rhabdomyolysis · Stevens-Johnson syndrome
- Frequency not known Alopecia · bone-marrow suppression · drug rash with eosinophilia and systemic symptoms (DRESS) · growth retardation in children · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting
- CONCEPTION AND CONTRACEPTION Effective contraception required during treatment.
- PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.
- BREAST FEEDING Discontinue breast-feeding.
- HEPATIC IMPAIRMENT Max. 400 mg daily; reduce dose further if not tolerated.

- RENAL IMPAIRMENT Maximum starting dose 400 mg daily if creatinine clearance less than 60 mL/minute; reduce dose further if not tolerated.

- MONITORING REQUIREMENTS
  - Monitor for gastrointestinal haemorrhage.
  - Monitor complete blood counts regularly.
  - Monitor for fluid retention.
  - Monitor liver function.
  - Monitor growth in children (may cause growth retardation).

- DIRECTIONS FOR ADMINISTRATION Tablets may be dispersed in water or apple juice.

- PATIENT AND CARER ADVICE Patients or carers should be given advice on how to administer imatinib tablets.

- NATIONAL FUNDING/ACCESS DECISIONS

  NICE technology appraisals (TAs) NICE TA70
  - Imatinib for chronic myeloid leukaemia (October 2003)
  - Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase and as an option for patients presenting in the accelerated phase or with blast crisis, provided that imatinib has not been used previously: www.nice.org.uk/TA70
  - Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004) NICE TA86
  - Imatinib 400 mg daily is recommended as first-line management of KIT (CD117)-positive unresectable or metastatic, or both, gastro-intestinal stromal tumours. Continued therapy is recommended only if a response to initial treatment (as defined by Southwest Oncology Group criteria available at www.nice.org.uk/TA86) is achieved within 12 weeks. Patients who have responded should be assessed at 12-week intervals. Discontinue if tumour ceases to respond. www.nice.org.uk/TA86
  - Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010) NICE TA209
  - Imatinib 600 mg daily or 800 mg daily is not recommended for unresectable or metastatic, or both, gastro-intestinal stromal tumours whose disease has progressed after treatment with imatinib 400 mg daily. www.nice.org.uk/TA209
  - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012) NICE TA241
  - High-dose imatinib is not recommended for the treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib. www.nice.org.uk/TA241
  - Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012) NICE TA251
  - Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML). www.nice.org.uk/TA251
  - Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (November 2014) NICE TA326
  - Imatinib is recommended as an option for adjuvant treatment of adult patients who are at high risk of relapse after surgery for KIT (CD117)-positive gastro-intestinal stromal tumours, as defined by the Miettinen 2006 criteria (based on tumour size, location, and mitotic rate), for up to 3 years. Patients currently receiving treatment initiated within the NHS with imatinib that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/TA326
Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2002) that imatinib (Glivec®) should be used for chronic myeloid leukaemia only under specialist supervision in accordance with British Society of Haematology guidelines (November 2001).

The Scottish Medicines Consortium has also advised (February 2012) that imatinib (Glivec®) is accepted for restricted use within NHS Scotland for the treatment of adult patients who are at significant risk of relapse following resection of a KIT (CD117) positive gastrointestinal stromal tumour (GIST) and who are at high risk of recurrence following complete resection (according to the Armed Forces Institute of Pathology (AFIP) risk criteria).

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21, 27

- Glivec (Novartis Pharmaceuticals UK Ltd)

  Imatinib (as imatinib mesilate) 100 mg Glivec 100mg tablets | 60 tablet (P) £19.18.23
  Imatinib (as imatinib mesilate) 400 mg Glivec 400mg tablets | 30 tablet (P) £1,836.48

Lapatinib

● DRUG ACTION
Lapatinib is a tyrosine kinase inhibitor.

INDICATIONS AND DOSE

Treatment of advanced or metastatic breast cancer in patients with tumours that overexpress human epidermal growth factor receptor-2 (HER2) with hormone-receptor-negative disease who have had previous treatment with trastuzumab in combination with chemotherapy (in combination with trastuzumab)

BY MOUTH

- Adult: 1 g once daily

Treatment of advanced or metastatic breast cancer in patients with tumours that overexpress human epidermal growth factor receptor-2 (HER2), for patients who have had previous treatment with an anthracycline, a taxane, and trastuzumab (in combination with capecitabine)

BY MOUTH

- Adult: 1.25 g once daily

Treatment of advanced or metastatic breast cancer with tumours that overexpress human epidermal growth factor receptor-2 (HER2), for postmenopausal women with hormone-receptor-positive disease (in combination with an aromatase inhibitor)

BY MOUTH

- Adult: 1.5 g once daily

Important safety information

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

● CAUTIONS
Diarrhoea—withdraw treatment if severe (consult product literature) - low gastric pH (reduced absorption) - susceptibility to QT-interval prolongation (including electrolyte disturbances)

● INTERACTIONS
Appendix 2 (lapatinib).
Caution with concomitant use of drugs that prolong QT-interval.

● SIDE-EFFECTS

- Common or very common
  Anorexia • cardiac failure (fatal cases reported) • decreased left ventricular ejection fraction • diarrhoea (treat promptly) • hepatotoxicity

(National Institute for Health and Care Excellence) recommend (January 2016) lapatinib/trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (NICE TA257).

Lapatinib or trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).

Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA257

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

Tyverb (Novartis Pharmaceuticals UK Ltd)

Lapatinib ditosylate monohydrate 250 mg Tyverb 250mg tablets | 84 tablet (P) £96.16 | 105 tablet (P) £1,206.45

Nilotinib

● DRUG ACTION
Nilotinib is a tyrosine kinase inhibitor.

INDICATIONS AND DOSE

Treatment of newly diagnosed chronic myeloid leukaemia in the chronic phase

BY MOUTH

- Adult: 300 mg twice daily
Targeted therapy responsive malignancy

Treatment of chronic and accelerated phase chronic myeloid leukaemia in patients who have resistance to or intolerance of previous therapy, including imatinib

BY MOUTH
- Adult: 400 mg twice daily

Important safety information
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

- **CAUTIONS** History of pancreatitis - susceptibility to QT-interval prolongation (including electrolyte disturbances)
- **INTERACTIONS** Appendix 1 (nilotinib).
  - Caution with concomitant use of drugs that prolong QT interval.
- **SIDE-EFFECTS**
  - **Frequency not known** Alopecia - bone-marrow suppression - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting
- **CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment.
- **PREGNANCY** Manufacturer advises caution.
  - **INTERACTIONS** Appendix 1 (nilotinib).
  - Caution with concomitant use of drugs that prolong QT interval.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012) NICE TA241
      - Nilotinib is recommended for the treatment of chronic or accelerated phase Philadelphia-chromosone-positive chronic myeloid leukaemia (CML) in adults:
        - whose CML is resistant to treatment with standard dose imatinib, or
        - who have imatinib intolerance, and
      - if the manufacturer makes nilotinib available with the discount agreed as part of the patient access scheme. www.nice.org.uk/TA241
    - Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012) NICE TA251
      - Nilotinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-
chromosome-positive CML if the manufacturer makes nilotinib available with the discount agreed as part of the patient access scheme. www.nice.org.uk/TA251
- **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (February 2008) that nilotinib (Tasigna®) is accepted for restricted use within NHS Scotland for the treatment of chronic phase chronic myeloid leukaemia in adults resistant to or intolerant of at least one previous therapy, including imatinib, and (July 2011) for the treatment of adults with newly diagnosed chronic myeloid leukaemia in the chronic phase.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Capsule** CAUTIONARY AND ADVISORY LABELS 23, 25, 27
    - Tasigna (Novartis Pharmaceuticals UK Ltd)
      - Nilotinib (as Nilotinib hydrochloride monohydrate)
        - 150 mg Tasigna 150mg capsules | 112 capsule pack £2,432.85
        - 200 mg Tasigna 200mg capsules | 112 capsule pack £2,432.85

**Pazopanib**

- **DRUG ACTION** Pazopanib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**
- First-line treatment of advanced renal cell carcinoma
- Treatment of advanced renal cell carcinoma in patients who have had previous treatment with cytokine therapy

BY MOUTH
- Adult: 800 mg daily, adjust dose in steps of 200 mg according to tolerability; maximum 800 mg per day

**Treatment of selective subtypes of advanced soft tissue sarcoma**

BY MOUTH
- Adult: (consult product literature)

Important safety information
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745

- **CONTRA-INDICATIONS** Cerebral haemorrhage - clinically significant gastro-intestinal haemorrhage - haemoptysis in the past 6 months
- **CAUTIONS** Cardiac disease - increased risk of gastro-intestinal fistulas - increased risk of gastro-intestinal perforation - increased risk of haemorrhage - increased risk of thrombotic microangiopathy—permanently discontinue if symptoms develop - ischaemic stroke - myocardial infarction - risk of thrombotic events - susceptibility to QT-interval prolongation (including electrolyte disturbances) - transient ischaemic attack

**ELECTIVE SURGERY**
- Discontinue treatment 7 days before elective surgery and restart only if adequate wound healing.

**Blood pressure**
- Blood pressure must be controlled before initiating treatment.

- **INTERACTIONS** Appendix 1 (pazopanib).
  - Caution with concomitant use of drugs that prolong QT-interval.

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal distension - abdominal pain - anorexia - blood disorders - blurred vision - chest pain - cough - dehydration - diarrhoea - dizziness - dry mouth - dry skin - dyspepsia - dyspnnea - epistaxis - flatulence - flushing - hair discoloration - headache - hepatic dysfunction - hiccups - hyperalbuminaemia -
hyperhilitrubinaemia • hypertension • hypothyroidism • increased amylase • insomnia • malaise • muscle spasm • myalgia • nail disorders • oedema • paraesthesia • pneumothorax • proteinuria (discontinue if grade 4) • skin discoloration • skin reactions • sweating • taste disturbance • thrombocytopenia • venous thromboembolic events • voice changes • weight loss

Malignant disease

Pazopanib for the first-line treatment of advanced renal cell carcinoma (updated August 2013) NICE TA215

Pazopanib is recommended as a first-line treatment option for people with advanced renal cell carcinoma:

• who have not received prior cytokine therapy and have an Eastern Cooperative Oncology Group performance status of 0 or 1

• if the manufacturer provides pazopanib at the discounted price agreed under the patient access scheme. www.nice.org.uk/TA215

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2011) that pazopanib (Votrient®) is accepted for restricted use within NHS Scotland for the first-line treatment of advanced renal cell carcinoma and (December 2012) is not recommended for use within NHS Scotland for the treatment of selective subtypes of advanced soft tissue sarcoma in patients who have received prior chemotherapy for metastatic disease, or who have progressed within 12 months after neoadjuvant therapy.

Malignant disease

Pazopanib

INDICATIONS AND DOSE

Treatment of chronic, accelerated, or blast phase chronic myeloid leukaemia in patients who have the T315I mutation or who have resistance to or intolerance of dasatinib or nilotinib, and for whom subsequent treatment with imatinib is not clinically appropriate.

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in patients who have the T315I mutation or who have resistance to or intolerance of dasatinib, and for whom subsequent treatment with imatinib is not clinically appropriate.

BY MOUTH

Adult: 45 mg once daily, for dose adjustment due side effects—consult product literature.

Dose adjustments due to interactions

Consider reducing the initial dose to 30 mg once daily with concomitant use of potent inhibitors of cytochrome P450 enzyme CYP3A4 (e.g. clarithromycin, indinavir, ritonavir, saquinavir, telithromycin or voriconazole).

Important safety information

MHRA/CHM ADVICE: PONATINIB: RISK OF VASCULAR OCCLUSIVE EVENTS (NOVEMBER 2014)

The benefits and risks of ponatinib have been reviewed by the European Medicines Agency’s Committee on Medicinal Products for Human Use, which has recommended that strengthened warnings should be added to the product information aimed at minimising the risk of blood clots and blockages in the arteries. The review concluded that available evidence shows that the risk of blood vessel blockage with ponatinib is likely to be dose-dependent. However, the data is insufficient to recommend reducing the dose of ponatinib, and there is a risk that a lower dose might not be as effective as the current dose in all patients and in long-term treatment. Therefore, no change has been made to the recommended starting dose.

Prescribers may wish to consider reducing the dose in patients with chronic phase chronic myeloid leukaemia who are responding well to treatment, and who might be at high risk of blood vessel blockage. Stop ponatinib if a complete response has not occurred within 3 months of treatment, and monitor patients for high blood pressure or signs of heart problems.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 23, 25

Votrient (Novartis Pharmaceuticals UK Ltd)
P pazopanib (as Pazopanib hydrochloride) 200 mg
Votrient 200 mg tablets | 30 tablet (Pack) £56.50
P pazopanib (as Pazopanib hydrochloride) 400 mg
Votrient 400 mg tablets | 30 tablet (Pack) £1,121.00

Ponatinib
**TABLET**

**CAUTIONARY AND ADVISORY LABELS 3, 25**

- **Iclusig (Ariad Pharma (UK) Ltd)**
  - **Ponatinib (as Ponatinib hydrochloride) 15 mg** Iclusig 15mg tablets | 60 tablet | £5.050.00
  - **Ponatinib (as Ponatinib hydrochloride) 45 mg** Iclusig 45mg tablets | 30 tablet | £5.050.00

**Regorafenib**

- **DRUG ACTION** Regorafenib is an inhibitor of several protein kinases.

**INDICATIONS AND DOSE**

Treatment of metastatic colorectal cancer in patients who have previously been treated, or who are unsuitable for standard treatment including fluoropyrimidine-based chemotherapy, a vascular endothelial growth factor inhibitor, and an epidermal growth factor receptor inhibitor

**BY MOUTH**

- **Adult:** 160 mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustment due to side effects—consult product literature

**Important Safety Information**

- **CAUTIONS** Ensure measures to prevent hand-foot skin reaction - Gilbert’s syndrome—risk of hyperbilirubinaemia - history of ischaemic heart disease—monitor for signs and symptoms of myocardial ischaemia and interrupt treatment if signs of ischaemia or infarction develop - hypertension—control blood pressure before treatment initiation and monitor as clinically indicated during treatment (review dose and consider treatment interruption if severe or persistent hypertension develops; discontinue treatment if hypertensive crisis occurs) - may impair wound healing—withdraw treatment for major surgical procedures - predisposition to bleeding

- **INTERACTIONS** → Appendix 1 (regorafenib).

Caution in concomitant treatment with drugs that may increase the risk of bleeding (increased risk of haemorrhagic events).

- **SIDE-EFFECTS**
  - **Common or very common** Abnormal international normalised ratio - biochemical disturbances - decreased appetite - diarrhoea - dry mouth - dry skin - dysphoria - electrolyte disturbances - epistaxis - erectile dysfunction - exfoliative dermatitis - flushing - gastrointestinal reflux disease - headache - hypertension - infection - insomnia - intermittent claudication - malaise - muscle spasms - musculoskeletal pain - oedema - pancreatitis - pericardial effusion - peripheral neuropathy - pleural effusion - pruritus - pyrexia - rash - thromboembolic events - vascular occlusion - weight loss
  - **Uncommon** Atrial flutter - cerebral artery stenosis - cerebral infarction - gastric haemorrhage - hepatotoxicity - jaundice - retinal vein occlusion - retinal vein thrombosis - visual impairment
  - **Frequency not known** Alopecia - bone-marrow suppression - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment in men and women; effectiveness of hormonal contraception unknown—alternative or additional methods of contraception should be used.

- **PREGNANCY** Avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING** Manufacturer advises discontinue breastfeeding—no information available.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment.

- **RENAL IMPAIRMENT** No information available—manufacturer advises caution if creatinine clearance less than 50 mL/minute.

- **MONITORING REQUIREMENTS**
  - **Monitor serum lipase every 2 weeks for the first 2 months and periodically thereafter for all patients— withhold treatment if lipase elevated and abdominal symptoms occur.**
  - **Monitor full blood count every 2 weeks for the first 3 months and then monthly thereafter or as clinically indicated.**
  - **Monitor liver function periodically.**
  - **Monitor for vascular occlusion or thromboembolism—interrupt treatment immediately if this occurs.**

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

---

**BNF 70**

**Targeted therapy responsive malignancy** 815

**Malignant disease**
contraindicated during treatment and up to 8 weeks after last dose.

- **Pregnancy** Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **Breast Feeding** Avoid—present in milk in animal studies.

- **Hepatic Impairment** Manufacturer advises caution in moderate impairment. Avoid in severe impairment.

- **Renal Impairment** Caution in severe impairment—no information available.

- **Monitoring Requirements**
  - Monitor blood count and coagulation parameters and consider permanent discontinuation in event of severe bleeding.
  - Monitor hepatic function before treatment, then at least every two weeks for the first 2 months, then at least monthly thereafter and as clinically indicated—consult product literature if changes in liver function observed.
  - Monitor for signs and symptoms of posterior reversible encephalopathy syndrome (including seizure, headache, altered mental status, visual disturbances or cortical blindness, with or without hypertension)—discontinue treatment if symptoms occur.
  - Monitor biochemical, electrolyte and metabolic parameters during treatment; ensure measures to prevent hand-foot skin reaction—consult product literature if signs or symptoms develop.

- **Directions for Administration** Tablets should be taken at the same time each day, swallowed whole with water after a light meal that contains less than 30% fat.

- **Patient and Carer Advice** Counselling advised (administration).

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 21
- **Electrolytes:** May contain Sodium
  - Stivarga (Bayer Plc) ▼
    - Regorafenib 40 mg Stivarga 40mg tablets | 84 tablet (£3,744.00 Hospital only)

### Ruxolitinib

- **Drug Action** Ruxolitinib is a selective inhibitor of the Janus-associated tyrosine kinases JAK1 and JAK2.

#### Indications and Dose

Treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis

**By Mouth**

- **Adult:** (consult product literature or local protocols)

#### Important Safety Information

**Risks of Incorrect Dosing of Oral Anti-Cancer Medicines**, see p. 745

**Cautions** Assess risk of developing infection before treatment—do not initiate until active serious infections are resolved

**Cautionary and Advisory Labels**

**Tuberculosis** Patients should be evaluated for latent and active tuberculosis before starting treatment and monitored for signs and symptoms of tuberculosis during treatment.

### Interactions

Appendix 1 (ruxolitinib).

### Side-Effects

- **Common or very common** Dizziness · flattulence · headache · hypercholesterolaemia · weight gain
- **Uncommon** Tuberculosis
- **Frequency not known** Alopecia · bone-marrow suppression · hyperuricaemia · nausea · oral mucositis · progressive multifocal leucoencephalopathy · thrombocytopenia · tumour lysis syndrome · vomiting
- **Pregnancy** Avoid—toxicity in animal studies.

### Monitoring Requirements

- Monitor full blood count (including differential white cell count) before treatment, then every 2–4 weeks until dose stabilised, then as clinically indicated.
- Monitor for infection during treatment.
- Monitor for symptoms of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological, cognitive or psychiatric signs or symptoms)—withhold treatment if suspected.

### Renal Impairment

Reduce dose (consult product literature).

### Hepatic Impairment

- Reduce dose (consult product literature).

### Monitoring Requirements

- Monitor for infection during treatment.
- Monitor for symptoms of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological, cognitive or psychiatric signs or symptoms)—withhold treatment if suspected.

### National Funding/Access Decisions

**NICE Technology Appraisals (TAs)**

- **Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (June 2013) NICE TA289**
  - Ruxolitinib is not recommended for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. www.nice.org.uk/TA289

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Jakavi (Novartis Pharmaceuticals UK Ltd) ▼
  - Jakavi 5 mg tablets 56 tablet (£1,680.00) £1,680.00
  - Jakavi 10 mg tablets 56 tablet (£3,600.00) £3,600.00
  - Jakavi 15 mg tablets 56 tablet (£3,600.00) £3,600.00

### Sorafenib

- **Drug Action** Sorafenib is an inhibitor of multiple kinases.

#### Indications and Dose

Treatment of advanced renal cell carcinoma when treatment with interferon alfa or interleukin-2 has failed or is unsuitable | Treatment of progressive, locally advanced, or metastatic, differentiated thyroid carcinoma that is refractory to radioactive iodine | Treatment of hepatocellular carcinoma

**By Mouth**

- **Adult:** 400 mg twice daily, for dose adjustments due to side effects, consult product literature

#### Important Safety Information

**Risks of Incorrect Dosing of Oral Anti-Cancer Medicines**, see p. 745
Sorafenib for the treatment of advanced hepatocellular carcinoma (DTC) and consider permanent withdrawal of sorafenib in any patient that requires medical intervention for bleeding - susceptibility to QT-interval prolongation

> Interactions → Appendix 1 (sorafenib).

> Side-effects

  > Common or very common Acne, anorexia, arthralgia, asthenia, congestive heart failure, constipation, depression, dermatitis, desquamation, diarrhoea, dry skin, dysgeusia, dyspepsia, dysphagia, dysphonia, electrolyte disturbances, erectile dysfunction, exanthema, fatigue, fever, flushing, gastro-oesophageal reflux disease, haemorrhage, hand-foot skin reaction, hoarseness, hyperkeratosis, hypertension, hypophosphataemia, hypophosphataemia, keratoacanthoma, malaise, muscle spasms, myalgia, myocardial infarction, myocardial ischaemia, peripheral neuropathy, proteinuria, pruritus, rash, renal failure, rhinorrhoea, thyroid dysfunction, tinnitus

  > Uncommon Altered INR, altered prothrombin time, cholangitis, cholecytitis, dehydration, eczema, erythema multiforme, gastritis, gastrointestinal perforations, gynaecomastia, hypertensive crisis, interstitial lung disease-like events, pancreatitis, posterior reversible encephalopathy syndrome

  > Rare Hepatitis, leucocytoclastic vasculitis, nephrotic syndrome, QT-interval prolongation, rhabdomyolysis, Stevens-Johnson syndrome, toxic epidermal necrolysis

  > Frequency not known Alopecia, bone-marrow suppression, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

> Pregnancy

Manufacturer advises avoid unless essential — toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

> Breast feeding Discontinue breast-feeding.

> Hepatic impairment Manufacturer advises caution in severe impairment — no information available.

> Monitoring requirements

Consider periodic monitoring of ECG and electrolytes in patients susceptible to QT-interval prolongation.

Monitor blood pressure regularly and consider permanent discontinuation of sorafenib if resistant to antihypertensive therapy.

Monitor plasma-calcium concentration (increased risk of hypocalcaemia if history of hypoparathyroidism).

Monitor thyroid stimulating hormone in patients with differentiated thyroid carcinoma.

> National funding/access decisions

NICE technology appraisals (TAs)

  > Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) NICE TA178

  > Bevacizumab, sorafenib, and temsirolimus are recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma.

Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma. www.nice.org.uk/TA178

  > Sorafenib for the treatment of advanced hepatocellular carcinoma (May 2010) NICE TA189

Sorafenib is not recommended for the treatment of advanced hepatocellular carcinoma in patients for whom surgical or locoregional therapies have failed or are unsuitable. www.nice.org.uk/TA189

> Conception and contraception Effective contraception required during treatment.

> Pregnancy

Manufacturer advises avoid unless potential benefit outweighs risk — toxicity in animal studies. See

### Suniatinib

> Drug action

Sunitinib is a tyrosine kinase inhibitor.

#### Indications and dose

- Treatment of unresectable or metastatic malignant gastrointestinal stromal tumours, after failure of imatinib
- Treatment of advanced or metastatic renal cell carcinoma

  > By mouth

    > Adult: 50 mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle, adjusted in steps of 12.5 mg, doses adjusted according to tolerability; usual dose 25–75 mg daily

- Treatment of unresectable or metastatic pancreatic neuroendocrine tumours

  > By mouth

    > Adult: 37.5 mg once daily without treatment-free period; adjusted in steps of 12.5 mg, doses adjusted according to tolerability; maximum 50 mg per day

**Important safety information**

**Risk of osteonecrosis of the jaw (January 2011)**

Treatment with sunitinib may be a risk factor for the development of osteonecrosis of the jaw.

Patients treated with sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.

Dental examination and appropriate preventive dentistry should be considered before treatment with sunitinib.

If possible, invasive dental procedures should be avoided in patients treated with sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.

**Risks of incorrect dosing of oral anti-cancer medicines, see p. 745**

> Conception and contraception Effective contraception required during treatment.

> Pregnancy

Manufacturer advises avoid unless potential benefit outweighs risk — toxicity in animal studies. See

### MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**Cautionary and advisory labels**

- Nexavar (Bayer Plc)

  > Sorafenib (as Sorafenib tosylate) 200 mg Nexavar 200mg tablets | 112 tablet pack £2,980.47

### Sunitinib

> Drug action

Sunitinib is a tyrosine kinase inhibitor.

> Indications and dose

- Treatment of unresectable or metastatic malignant gastrointestinal stromal tumours, after failure of imatinib
- Treatment of advanced or metastatic renal cell carcinoma

  > By mouth

    > Adult: 50 mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle, adjusted in steps of 12.5 mg, doses adjusted according to tolerability; usual dose 25–75 mg daily

- Treatment of unresectable or metastatic pancreatic neuroendocrine tumours

  > By mouth

    > Adult: 37.5 mg once daily without treatment-free period; adjusted in steps of 12.5 mg, doses adjusted according to tolerability; maximum 50 mg per day

**Important safety information**

**Risk of osteonecrosis of the jaw (January 2011)**

Treatment with sunitinib may be a risk factor for the development of osteonecrosis of the jaw.

Patients treated with sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.

Dental examination and appropriate preventive dentistry should be considered before treatment with sunitinib.

If possible, invasive dental procedures should be avoided in patients treated with sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.

**Risks of incorrect dosing of oral anti-cancer medicines, see p. 745**

> Conception and contraception Effective contraception required during treatment.

> Pregnancy

Manufacturer advises avoid unless potential benefit outweighs risk — toxicity in animal studies. See

### MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**Cautionary and advisory labels**

- Nexavar (Bayer Plc)

  > Sorafenib (as Sorafenib tosylate) 200 mg Nexavar 200mg tablets | 112 tablet pack £2,980.47

### Sunitinib

> Drug action

Sunitinib is a tyrosine kinase inhibitor.

> Indications and dose

- Treatment of unresectable or metastatic malignant gastrointestinal stromal tumours, after failure of imatinib
- Treatment of advanced or metastatic renal cell carcinoma

  > By mouth

    > Adult: 50 mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle, adjusted in steps of 12.5 mg, doses adjusted according to tolerability; usual dose 25–75 mg daily

- Treatment of unresectable or metastatic pancreatic neuroendocrine tumours

  > By mouth

    > Adult: 37.5 mg once daily without treatment-free period; adjusted in steps of 12.5 mg, doses adjusted according to tolerability; maximum 50 mg per day

**Important safety information**

**Risk of osteonecrosis of the jaw (January 2011)**

Treatment with sunitinib may be a risk factor for the development of osteonecrosis of the jaw.

Patients treated with sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.

Dental examination and appropriate preventive dentistry should be considered before treatment with sunitinib.

If possible, invasive dental procedures should be avoided in patients treated with sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.

**Risks of incorrect dosing of oral anti-cancer medicines, see p. 745**

> Conception and contraception Effective contraception required during treatment.

> Pregnancy

Manufacturer advises avoid unless potential benefit outweighs risk — toxicity in animal studies. See
818 Malignant disease

also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- BREAST FEEDING Discontinue breast-feeding.
- MONITORING REQUIREMENTS Monitor for thyroid dysfunction.

- NATIONAL FUNDING/ACCESS DECISIONS
  **NICE technology appraisals (TAs)**
  - Sunitinib for advanced or metastatic renal cell carcinoma (March 2009) NICE TA169
    Sunitinib is recommended as first-line treatment for advanced or metastatic renal cell carcinoma in patients who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group performance status of 0 or 1. www.nice.org.uk/TA169
  - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) NICE TA178
    Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma. www.nice.org.uk/TA178
  - Sunitinib for the treatment of gastrointestinal stromal tumours (September 2009) NICE TA179
    Sunitinib is recommended as an option for treatment in patients with unresectable or metastatic gastrointestinal stromal tumours if imatinib treatment has failed because of resistance or intolerance, and the cost of sunitinib for the first treatment cycle is met by the manufacturer.
    Scottish Medicines Consortium (SMC) Decisions
    The Scottish Medicines Consortium (SMC) has advised (October 2009 and April 2011) that sunitinib (Sutent®) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours after failure of imatinib and for unresectable or metastatic pancreatic neuroendocrine tumours.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  CAUTIONARY AND ADVISORY LABELS 14
  - Sutent (Pfizer Ltd)
    - Sunitinib (as Sunitinib maleate) 12.5 mg Sutent 12.5mg capsules | 28 capsule £784.70
    - Sunitinib (as Sunitinib maleate) 25 mg Sutent 25mg capsules | 28 capsule £1569.40
    - Sunitinib (as Sunitinib maleate) 50 mg Sutent 50mg capsules | 28 capsule £3,138.80

Temsnirolimus

- DRUG ACTION Temsirolimus is a protein kinase inhibitor.

- INDICATIONS AND DOSE
  - First-line treatment of advanced renal cell carcinoma | Treatment of relapsed or refractory mantle cell lymphoma
  - BY INTRAVENOUS INFUSION
    - Adult: (consult product literature or local protocols)

- INTERACTIONS → Appendix 1 (temsirolimus).
  The main active metabolite of temsirolimus is sirolimus—see also interactions of sirolimus and consult product literature.

- SIDE-EFFECTS
  - Uncommon  Intracerebral bleeding
  - Frequency not known  Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

- HYPERSENSIBILITY REACTIONS
  Hypersensitivity reactions, including some life-threatening and rare fatal reactions, are associated with temsirolimus therapy, usually during administration of the first dose. Symptoms include flushing, chest pain, dyspnoea, apnoea, hypotension, loss of consciousness, and anaphylaxis. Where possible, patients should receive an intravenous dose of antihistamine 30 minutes before starting the temsirolimus infusion. The infusion may have to be stopped temporarily for the treatment of infusion-related effects—consult product literature for appropriate management. If adverse reactions are not managed with dose delays, a dose reduction should be considered—consult product literature.

- CONCEPTION AND CONTRACEPTION
  Ensure effective contraception during treatment in men and women.

- PREGNANCY
  Manufacturer advises avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- BREAST FEEDING
  Manufacturer advises discontinue breast-feeding.

- HEPATIC IMPAIRMENT
  In renal cell carcinoma, reduce dose in severe impairment (consult product literature). Use with caution. In mantle cell lymphoma, avoid in moderate or severe impairment.

- RENAL IMPAIRMENT
  Manufacturer advises caution in severe impairment—no information available.

- MONITORING REQUIREMENTS
  - Monitor respiratory function.
  - Monitor blood lipids.

- NATIONAL FUNDING/ACCESS DECISIONS
  **NICE technology appraisals (TAs)**
  - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsiroliusm (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) NICE TA178
    Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma. www.nice.org.uk/TA178

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
EXCIPIENTS: May contain Ethanol, propylene glycol
- Torisel (Pfizer Ltd)
  Temsirolimus 25 mg per 1 ml Torisel 30mg/1.2ml concentrate for solution for infusion vials and diluent | 1 vial £620.00 (Hospital only)
Targeted therapy responsive malignancy 819

**Vandetanib**

**DRUG ACTION** Vandetanib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease

**BY MOUTH**

- Adult: 300 mg once daily, for dose adjustment due to side effects—consult product literature

**CONTRA-INDICATIONS** Congenital long QT syndrome • QT interval greater than 480 milliseconds

**CAUTIONS** Brain metastases (intracranial haemorrhage reported) • electrolyte disturbances • history of torsades de pointes • hypertension • photoxicity reactions reported (wear protective clothing and/or sunscreen) • susceptibility to QT-prolongation

**INTERACTIONS** → Appendix 1 (vandetanib). Caution with concomitant use of drugs that prolong QT interval.

**SIDE-EFFECTS**

- Common or very common Abdominal pain • alopecia • anxiety • asthenia • balance disorders • blurred vision • cholelithiasis • colitis • conjunctivitis • constipation • corneal changes (including opacity) • corneal deposits • decreased appetite • dehydration • depression • diarrhoea • dizziness • dry eye • dry mouth • dysaesthesia • dyspepsia • dysphagia • dysuria • electrolyte disturbances • epistaxis • gastritis • gastrointestinal haemorrhage • glaucoma • haematuria • haemoptysis • halo vision • hand-foot syndrome • headache • hyperglycaemia • hypertension • hypothyroidism • insomina • ischaemic cerebrovascular conditions • keratopathy • lethargy • loss of consciousness • micturition urgency • nephrolithiasis • oedema • pain • paraesthesia • photopsia • photosexsitivety reactions • pneumonitis • polymiopathy • proteinuria • pyrexia • QT-interval prolongation • taste disturbance • tremor

- Uncommon Accommodation disorders • anuria • aspiration pneumonia • brain oedema • bullous dermatitis • cardiac arrest • cardiac conduction disorders • cardiac rate disorders • cardiac rhythm disorders • cataract • chromaturia • clonus • conulsions • erythema multiforme • faecal incontinence • heart failure • ileus • impaired healing • increased haemoglobin • interstitial lung disease (sometimes fatal) • intestinal perforation • pancreatitis • peritonitis • posterior reversible encephalopathy syndrome • respiratory failure • Stevens-Johnson syndrome • ventricular arrhythmia

- Frequency not known Alopecia • bone-marrow suppression • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

- CONCEPTION AND CONTRACEPTION Effective contraception required during and for at least 4 months after treatment.

- PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- BREAST FEEDING Avoid—no information available.

- HEPATIC IMPAIRMENT Manufacturer advises avoid in severe impairment (serum bilirubin greater than 1.5 times the upper limit of normal).

- RENAL IMPAIRMENT Reduce dose to 200 mg if creatinine clearance 30–49 mL/minute. Avoid if creatinine clearance less than 30 mL/minute.

**Important safety information**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745**

- Contraindicated in patients with uncorrected QT-interval greater than 480 milliseconds

- Monitor ECG, serum potassium, calcium, magnesium and thyroid stimulating hormone before treatment, then 1, 3, 6 and 12 weeks after starting treatment and following dose adjustment or interruption, then every 3 months for at least 1 year.

**DIRECTIONS FOR ADMINISTRATION** Tablets may be dispersed in half a glass of water by stirring until dispersed (approximately 10 minutes), immediately before drinking (do not crush). After solution has been swallowed, any residue must be re-dispersed in the same volume of water and swallowed. The solution can also be administered via nasogastric or gastrostomy tubes.

**PATIENT AND CARER ADVICE** Alert card should be provided. Patients or carers should be given advice on how to administer vandetanib tablets.

**Phototoxicity reactions Patients should be advised to wear protective clothing and/or sunscreen.**

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- (AstraZeneca UK Ltd) ▼
  - Vandetanib 100 mg Caprelsa 100mg tablets | 30 tablet [POD] £2,500.00
  - Vandetanib 300 mg Caprelsa 300mg tablets | 30 tablet [POD] £5,000.00

**Vemurafenib**

**DRUG ACTION** Vemurafenib is a BRAF kinase inhibitor.

**INDICATIONS AND DOSE**

Monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma

**BY MOUTH**

- Adult: 960 mg twice daily, for dose adjustment due to side effects—consult product literature

**Important safety information**

**DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS SYNDROME)**

DRESS syndrome has been reported in patients taking vemurafenib. DRESS syndrome starts with rash, fever, swollen glands, and increased white cell count, and it can affect the liver, kidneys and lungs; DRESS can also be fatal. Patients should be advised to stop taking vemurafenib and consult their doctor immediately if skin rash develops. Treatment with vemurafenib should not be restarted.

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES, see p. 745**

- Wild-type BRAF malignant melanoma

- Contraindicated in patients with uncorrected QT-interval greater than 480 milliseconds

- Monitor ECG, serum potassium, calcium, magnesium and thyroid stimulating hormone before treatment, then 1, 3, 6 and 12 weeks after starting treatment and following dose adjustment or interruption, then every 3 months for at least 1 year.

- Electrolyte disturbances • prior or concurrent cancer associated with RAS mutation—increased risk of tumour progression • susceptibility to QT-prolongation

- → Appendix 1 (vemurafenib). Caution with concomitant use of drugs that prolong QT interval.

**SIDE-EFFECTS**

- Common or very common Actinic keratosis • alopecia • arthralgia • arthritis • asthenia • basal cell carcinoma • Bell’s palsy • constipation • cough • cutaneous squamous cell carcinoma • decreased appetite • diarrhoea • dizziness • dry skin • erythema • erythema nodosum • fatigue • folliculitis • hand-foot syndrome • headache • hyperkeratosis • keratosis pilaris • musculoskeletal pain • myalgia • new primary melanoma • pain in extremities •
Malignant disease

VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS

**Afiblercept**

- **DRUG ACTION** Afiblercept is a recombinant fusion protein that acts as a soluble decoy receptor and binds to vascular endothelial growth factors A and B (VEGF-A, VEGF-B) and placental growth factor (PIGF). Afiblercept inhibits the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

**INDICATIONS AND DOSE** In combination with irinotecan, fluorouracil and folinic acid (FOLFIRI) chemotherapy, in metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing regimen.

**BY INTRAVENOUS INFUSION**

- Adult: (consult local protocol)

- **CONTRA-INDICATIONS** Moderate or severe congestive heart failure - uncontrolled hypertension

- **CAUTIONS** Febrile neutropenia - history of cardiovascular disease (may be exacerbated by hypertension) - increased risk of haemorrhage (including fatal events) - increased risk of hypertension - increased risk of thromboembolic events (consult product literature if event occurs) - may impair wound healing—withhold treatment for at least 4 weeks before elective surgery and for at least 4 weeks after major surgery, or until wound fully healed - neutropenic infection - risk of fistula formation (discontinue if fistula develops) - risk of neutropenia - risk of thrombocytopenia

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain - aphthous stomatitis - decreased appetite - dehydration - diarrhoea - dysphonia - dysphagia - erythema - fistula - haemorrhage (including nasal, rectal and gastro-intestinal) - haemorrhoids - hand-foot syndrome - headache - hypertension - infection - leucopenia - malaise - nasopharyngitis - neutropenia (including febrile neutropenia) - ophthalmic pain - proctalgia - proteinuria - rhinorrhoea - sepsis - skin hyperpigmentation - stomatitis - thrombocytopenia - thromboembolic events (arterial and venous) - toothache - urinary tract infection - weight loss
  - **Uncommon** Gastro-intestinal perforation - impaired wound healing - nephrotic syndrome - posterior reversible encephalopathy syndrome - thrombotic microangiopathy

**CONCEPTION AND CONTRACEPTION** Exclude pregnancy before treatment. Effective contraception required during and for at least 6 months after treatment in men and women. Contraceptive advice should be given to men and women before therapy begins (and should cover the duration of contraception required after therapy has ended).

- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs, p. 746.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Caution in severe impairment—no information available.

- **RENAL IMPAIRMENT** Caution in severe impairment—no information available.

- **MONITORING REQUIREMENTS**

  - Monitor blood pressure at initiation and at least fortnightly during treatment (do not initiate treatment if pre-existing hypertension is uncontrolled)
product literature if hypertension develops during treatment.

- Monitor for signs of gastro-intestinal perforation (discontinue if perforation develops).
- Monitor full blood count, including differential count and platelets at baseline and before each treatment cycle.
- Monitor for proteinuria before each treatment administration (consult product literature if symptoms develop).
- Monitor for signs and symptoms of diarrhoea and dehydration, particularly in elderly—consult product literature if severe diarrhoea occurs.
- Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, altered mental status, nausea, vomiting, headache, or visual disturbance).

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014) NICE TA307
  
  Aflibercept in combination with irinotecan and fluorouracil-based therapy is **not** recommended within its marketing authorisation for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. [www.nice.org.uk/TA307](http://www.nice.org.uk/TA307)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **Zaltrap** (Sanofi)

  Aflibercept 25 mg per 1 ml Zaltrap 200mg/8ml concentrate for solution for infusion vials | 1 vial [PON] £591.30 (Hospital only)
  
  Zaltrap 100mg/4ml concentrate for solution for infusion vials | 1 vial [PON] £295.65 (Hospital only)
Chapter 9
Blood and nutrition

1 Blood and blood-forming organs

1.1 Anaemias

Anaemias
Before initiating treatment for anaemia it is essential to determine which type is present. Iron salts may be harmful and result in iron overload if given alone to patients with anaemias other than those due to iron deficiency.

Sickle-cell disease
Sickle-cell disease is caused by a structural abnormality of haemoglobin resulting in deformed, less flexible red blood cells. Acute complications in the more severe forms include sickle-cell crisis, where infarction of the microvasculature and blood supply to organs results in severe pain. Sickle-cell crisis requires hospitalisation, intravenous fluids, analgesia and treatment of any concurrent infection. Chronic complications include skin ulceration, renal failure, and increased susceptibility to infection. Pneumococcal vaccine, haemophilus influenzae type b vaccine, an annual influenza vaccine and prophylactic penicillin reduce the risk of infection. Hepatitis B vaccine should be considered if the patient is not immune.

In most forms of sickle-cell disease, varying degrees of haemolytic anaemia are present accompanied by increased erythropoiesis; this may increase folate requirements and folate supplementation may be necessary.

Hydroxycarbamide p. 777 can reduce the frequency of crises and the need for blood transfusions in sickle-cell disease. The beneficial effects of hydroxycarbamide may not become evident for several months.

1.2 Anaemias, G6PD deficiency

G6PD deficiency
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is highly prevalent in individuals originating from most parts of Africa, from most parts of Asia, from Oceania, and from Southern Europe; it can also occur, rarely, in any other individuals. G6PD deficiency is more common in males than it is in females.

Individuals with G6PD deficiency are susceptible to developing acute haemolytic anaemia when they take a number of common drugs. They are also susceptible to developing acute haemolytic anaemia when they eat fava beans (broad beans, Vicia faba); this is termed favism and can be more severe in children or when the fresh fava beans are eaten raw.

When prescribing drugs for patients with G6PD deficiency, the following three points should be kept in mind:

- G6PD deficiency is genetically heterogeneous;
- susceptibility to the haemolytic risk from drugs varies;
Anaemias, hypoplastic, haemolytic, and renal

1.3 Anaemias, hypoplastic, haemolytic, and renal

Anaemias, hypoplastic, haemolytic, and renal

Anabolic steroids, pyridoxine hydrochloride p. 882, antilymphocyte immunoglobulin, and various corticosteroids are used in hypoplastic and haemolytic anaemias.

Antilymphocyte immunoglobulin given intravenously through a central line over 12–18 hours each day for 5 days produces a response in about 50% of cases of acquired aplastic anaemia; the response rate may be increased when ciclosporin p. 717 is given as well. Severe reactions are common in the first 2 days and profound immunosuppression can occur; antilymphocyte immunoglobulin should be given under specialist supervision with appropriate resuscitation facilities. Alternatively, oxymetholone tablets (available from ‘special order’ manufacturers or specialist importing companies) can be used in aplastic anaemia for 3 to 6 months.

It is unlikely that dietary deprivation of pyridoxine hydrochloride produces clinically relevant haematological effects. However, certain forms of sideroblastic anaemia respond to pharmacological doses, possibly reflecting its role as a co-enzyme during haemoglobin synthesis. Pyridoxine hydrochloride is indicated in both idiopathic acquired and hereditary sideroblastic anaemias. Although complete cures have not been reported, some increase in haemoglobin can occur; the dose required is usually high. Reversible sideroblastic anaemias respond to treatment of the underlying cause but in pregnancy, haemolytic anaemias, and alcohol dependence, or during isoniazid treatment, pyridoxine hydrochloride is also indicated.

Corticosteroids have an important place in the management of haematological disorders. They include conditions with an autoimmune haemolytic anaemia, immune thrombocytopenias and neutropenias, and major transfusion reactions. They are also used in chemotherapy schedules for many types of lymphoma, lymphoid leukaemias, and paraproteinaemias, including multiple myeloma.

Erythropoietins (recombinant human erythropoietins) are used to treat the anaemia associated with erythropoietin deficiency in chronic renal failure, to increase the yield of autologous blood in normal individuals and to shorten the period of symptomatic anaemia in patients receiving cytotoxic chemotherapy.

Epoetin beta p. 828 is also used for the prevention of anaemia in perterm neonates of low birth-weight; only unpreserved formulations should be used in neonates because other preparations may contain benzyl alcohol. Darbepoetin alfa p. 825 is a hyperglycosylated derivative of epoetin; it has a longer half life and can be administered less frequently than epoetin.

Methoxy polyethylene glycol-epoetin beta p. 824 is a continuous erythropoietin receptor activator that is licensed for the treatment of symptomatic anaemia associated with chronic kidney disease. It has a longer duration of action than epoetin.

ANDROSTAN DERIVATIVES

Oxymetholone

**INDICATIONS AND DOSE**

Aplastic anaemia

**BY MOUTH**

- Adult: 1–5 mg/kg daily for 3 to 6 months

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Capsule**

- **OXYMETHOLONE (Non-proprietary)**
  - Oxymetholone 50 mg (Oxymetholone 50mg capsules) 50 capsule blister pack £395.00 Schedule 4 (CD Anab)
CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATORS

Methoxy polyethylene glycol-epoetin beta

INDICATIONS AND DOSE
Symptomatic anaemia associated with chronic kidney disease in patients on dialysis and not currently treated with erythropoietins

BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INJECTION

Adult: Initially 600 nanograms/kg every 2 weeks, dose to be adjusted according to response at intervals of at least 4 weeks, maintenance dose of double the previous fortnightly dose may be given every 4 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia associated with chronic kidney disease in patients not on dialysis and not currently treated with erythropoietins

INITIALLY BY SUBCUTANEOUS INJECTION

Adult: Initially 1.2 micrograms/kg every 4 weeks, alternatively (by subcutaneous injection or by intravenous injection) initially 600 nanograms/kg every 2 weeks, dose to be adjusted according to response at intervals of at least 4 weeks, patients treated once every 2 weeks may be given a maintenance dose of double the previous fortnightly dose every 4 weeks, subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks; or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia associated with chronic kidney disease in patients currently treated with erythropoietins

BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INJECTION

Adult: (consult product literature)

SIDE-EFFECTS
Hot flushes

PREGNANCY
No evidence of harm in animal studies—manufacturer advises caution.

BREAST FEEDING
Manufacturer advises use only if potential benefit outweighs risk—present in milk in animal studies.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

Mircea (Roche Products Ltd)
Methoxy polyethylene glycol-epoetin beta 100 microgram per 1 ml Mircea 30micrograms/0.3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection £146.81
Methoxy polyethylene glycol-epoetin beta 166.667 microgram per 1 ml Mircea 50micrograms/0.3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection £73.41
Methoxy polyethylene glycol-epoetin beta 250 microgram per 1 ml Mircea 75micrograms/0.3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection £110.11

EPOETINS

Important safety information
MHRA/CHM ADVICE (DECEMBER 2007) ERYTHROPOIETINS—HAEMOGLOBIN CONCENTRATION
Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:

• patients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy unless symptoms of anaemia are present

• the haemoglobin concentration should be maintained within the range 10–12 g/100 mL

• haemoglobin concentrations higher than 12 g/100 mL should be avoided

• the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range)

MHRA/CHM ADVICE (DECEMBER 2007 AND JULY 2008) ERYTHROPOIETINS—TUMOUR PROGRESSION AND SURVIVAL IN PATIENTS WITH CANCER

Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins outside of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have not received chemotherapy):

• erythropoietins licensed for the treatment of symptomatic anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy

• the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis

CONTRA-INDICATIONS
Patients unable to receive thromboprophylaxis, pure red cell aplasia following erythropoietin therapy, uncontrolled hypertension
Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure, such as iron or folate deficiency, before treatment. During dialysis (increase in unfractuated or low molecular weight heparin dose may be needed) - epilepsy - inadequately treated or poorly controlled blood pressure - interrupt treatment if blood pressure uncontrolled - ischaemic vascular disease - malignant disease - other inflammatory disease (can impair the response to erythropoietin) - risk of thrombosis may be increased when used for anaemia before orthopaedic surgery - avoid in cardiovascular disease including recent myocardial infarction or cerebrovascular accident - risk of thrombosis may be increased when used for anaemia in adults receiving cancer chemotherapy - sickle-cell disease (lower target haemoglobin concentration may be appropriate) - sudden stabbing migraine-like pain (warning of a hypertensive crisis) - thrombocytosis (monitor platelet count for first 8 weeks)

**SIDE-EFFECTS**

- **Common or very common** Aggravation of hypertension (dose-dependent) - cardiovascular events - diarrhoea - dose-dependent increase in platelet count regressing during treatment (but thrombocytosis rare) - headache - hypertensive crisis (in isolated patients with normal or low blood pressure) - increase in blood pressure (dose-dependent) - influenza-like symptoms (may be reduced if intravenous injection given over 5 minutes) - nausea - shunt thrombosis especially if tendency to hypotension or arteriovenous shunt complications - vomiting
- **Very rare** Sudden loss of efficacy because of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure
- **Frequency not known** Anaaphylaxis - angioedema - hyperkalaemia - hypersensitivity reactions - injection-site reactions - peripheral oedema - skin reactions

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hypertensive crisis** In isolated patients with normal or low blood pressure, hypertensive crisis with encephalopathy-like symptoms and generalised tonic-clonic seizures requiring immediate medical attention has occurred with epoetin.

**Pure red cell aplasia** There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should not be switched to another form of erythropoietin.

**MONITORING REQUIREMENTS**

- Monitor closely blood pressure, reticulocyte counts, haemoglobin, and electrolytes - interrupt treatment if blood pressure uncontrolled.
- Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients.

---

**Darbepoetin alfa**

**INDICATIONS AND DOSE**

Symptomatic anaemia associated with chronic renal failure in patients on dialysis

**BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INJECTION**

- **Adult:** Initially 450 nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose to be given once weekly or once every 2 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment

Symptomatic anaemia associated with chronic renal failure in patients not on dialysis

**BY SUBCUTANEOUS INJECTION**

- **Adult:** Initially 450 nanograms/kg once weekly, alternatively initially 750 nanograms/kg every 2 weeks, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose can be given once weekly, every 2 weeks, or once a month, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment

**BY INTRAVENOUS INJECTION**

- **Adult:** Initially 450 nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose given once weekly, subcutaneous route preferred in patients not on haemodialysis, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment

Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy

**BY SUBCUTANEOUS INJECTION**

- **Adult:** Initially 6.75 micrograms/kg every 3 weeks, alternatively initially 2.25 micrograms/kg once weekly, if response inadequate after 9 weeks further treatment may not be effective; if adequate response obtained then reduce dose by 25–50%, reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy

**SIDE-EFFECTS** Injection-site pain - oedema

**PREGNANCY** No evidence of harm in animal studies - manufacturer advises caution.
Epoetin alfa

INDICATIONS AND DOSE

EPREX® PRE-FILLED SYRINGES

Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis

- Adult: Initially 50 units/kg twice weekly, adjusted in steps of 25 units/kg 3 times a week, according to response. Dose to be increased at intervals of at least 4 weeks; if haemoglobin concentration exceeds 12 g/100 mL, dose to be reduced by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration increases 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis

- Adult: Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, increased according to response. Dose to be increased at intervals of at least 4 weeks; maintenance 17–33 units/kg 3 times a week (max. per dose 200 units/kg 3 times a week), intravenous route preferred, intravenous injection to be given over 1–5 minutes, subcutaneous injection, maximum 1 mL per injection site, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration increases 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia in adults receiving cancer chemotherapy

- Adult: Initially 150 units/kg 3 times a week, alternatively initially 450 units/kg once weekly, increased to 300 units/kg 3 times a week, increased if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, subcutaneous injection maximum 1 mL per injection site, reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration increases 12 g/100 mL; if haemoglobin concentration continues

Solution for injection

- **Aranesp (Amgen Ltd)**
  - Darbepoetin alfa 25 microgram per 1 mL Aranesp 10micrograms/0.4ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £58.72
  - Darbepoetin alfa 40 microgram per 1 mL Aranesp 20micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £231.62
  - Darbepoetin alfa 100 microgram per 1 mL Aranesp 50micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £234.30
  - Darbepoetin alfa 200 microgram per 1 mL Aranesp 100micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £763.42
  - Darbepoetin alfa 500 microgram per 1 mL Aranesp 300micrograms/0.6ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £880.86
  - **Aranesp SureClick (Amgen Ltd)**
    - Darbepoetin alfa 40 microgram per 1 mL Aranesp SureClick 20micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £29.36
    - Darbepoetin alfa 100 microgram per 1 mL Aranesp SureClick 40micrograms/0.4ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £58.72
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp SureClick 150micrograms/0.3ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £146.81
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp SureClick 500micrograms/1ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £134.05

- **Medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Solution for injection**
  - **Aranesp (Amgen Ltd)**
    - Darbepoetin alfa 25 microgram per 1 mL Aranesp 10micrograms/0.4ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £58.72
    - Darbepoetin alfa 40 microgram per 1 mL Aranesp 20micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £231.62
    - Darbepoetin alfa 100 microgram per 1 mL Aranesp 50micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £234.30
    - Darbepoetin alfa 200 microgram per 1 mL Aranesp 100micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £763.42
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp 300micrograms/0.6ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £880.86
  - **Aranesp SureClick (Amgen Ltd)**
    - Darbepoetin alfa 40 microgram per 1 mL Aranesp SureClick 20micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £29.36
    - Darbepoetin alfa 100 microgram per 1 mL Aranesp SureClick 40micrograms/0.4ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £58.72
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp SureClick 150micrograms/0.3ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £146.81
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp SureClick 500micrograms/1ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £134.05

- **NICE technology appraisals (TAs)**
  - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) NICE TA323
    - Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.
    - If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used. www.nice.org.uk/TA323

- **Filling disposable devices**
  - **Aranesp SureClick**
    - Darbepoetin alfa 200 microgram per 1 mL Aranesp 100micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £763.42
  - **Darbepoetin alfa 200 microgram per 1 mL Aranesp**
    - 100micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £763.42

- **Use**
  - **Injection**
    - BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION
      - **Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis**
      - **Eprex®**
      - **Aranesp (Amgen Ltd)**
    - Darbepoetin alfa 25 microgram per 1 mL Aranesp 10micrograms/0.4ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £58.72
    - Darbepoetin alfa 40 microgram per 1 mL Aranesp 20micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £231.62
    - Darbepoetin alfa 100 microgram per 1 mL Aranesp 50micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £234.30
    - Darbepoetin alfa 200 microgram per 1 mL Aranesp 100micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £763.42
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp 300micrograms/0.6ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £880.86
  - **Aranesp SureClick (Amgen Ltd)**
    - Darbepoetin alfa 40 microgram per 1 mL Aranesp SureClick 20micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £29.36
    - Darbepoetin alfa 100 microgram per 1 mL Aranesp SureClick 40micrograms/0.4ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £58.72
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp SureClick 150micrograms/0.3ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £146.81
    - Darbepoetin alfa 500 microgram per 1 mL Aranesp SureClick 500micrograms/1ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £134.05
to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.

To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery

BY INTRAVENOUS INJECTION

- Adult: 600 units/kg twice weekly for 3 weeks before surgery, consult product literature for details and advice on ensuring high iron stores, intravenous injection to be given over 1–5 minutes

Moderate anaemia (haemoglobin concentration 10–13 g/100 mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable

BY SUBCUTANEOUS INJECTION

- Adult: 600 units/kg once weekly for 3 weeks before surgery and on day of surgery, alternatively 300 units/kg daily for 15 days starting 10 days before surgery, consult product literature for details, subcutaneous injection maximum 1 mL per injection site

BINOCRIT® PRE-FILLED SYRINGES

Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis

BY INTRAVENOUS INJECTION

- Adult: Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 25–100 units/kg 3 times a week, intravenous injection to be given over 1–5 minutes, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis

BY INTRAVENOUS INJECTION

- Adult: Initially 50 units/kg twice weekly; maintenance 25–50 units/kg twice weekly, intravenous injection to be given over 1–5 minutes, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis

BY INTRAVENOUS INJECTION

- Adult: Initially 50 units/kg 3 times a week, increased in steps of 25 units/kg 3 times a week, adjusted according to response, dose to be increased at intervals of at least 4 weeks; maintenance 17–33 units/kg 3 times a week (max. per dose 200 units/kg 3 times a week), intravenous injection to be given over 1–5 minutes, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia in adults receiving cancer chemotherapy

BY SUBCUTANEOUS INJECTION

- Adult: Initially 150 units/kg 3 times a week, alternatively initially 450 units/kg once weekly, increased to 300 units/kg 3 times a week, increase if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, subcutaneous injection maximum 1 mL per injection site, reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy.

To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery

BY INTRAVENOUS INJECTION

- Adult: 600 units/kg twice weekly for 3 weeks before surgery, consult product literature for details and advice on ensuring high iron stores, intravenous injection to be given over 1–5 minutes

Moderate anaemia (haemoglobin concentration 10–13 g/100 mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable

BY SUBCUTANEOUS INJECTION

- Adult: 600 units/kg once weekly for 3 weeks before surgery and on day of surgery, alternatively 300 units/kg daily for 15 days starting 10 days before surgery, consult product literature for details, subcutaneous injection maximum 1 mL per injection site

PREGNANCY

No evidence of harm. Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.

BREAST FEEDING

Unlikely to be present in milk. Minimal effect on infant.

HEPATIC IMPAIRMENT

Manufacturers advise caution in chronic hepatic failure.

PRESCRIBING AND DISPENSING INFORMATION

Products containing epoetin alfa are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) NICE TA323

Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.

If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used. www.nice.org.uk/TA323
BY SUBCUTANEOUS INJECTION

Adult: Initially 40 units/kg 3 times a week for 4 weeks, then increased to 80 units/kg 3 times a week, then increased in steps of 20 units/kg 3 times a week if required, dose to be increased at intervals of 4 weeks; maintenance, initially reduce dose by half, subsequent dose adjusted according to response at intervals of 1–2 weeks, intravenous injection to be administered over 2 minutes, subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720 units/kg per week.

Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy

BY SUBCUTANEOUS INJECTION

Adult: Initially 450 units/kg once weekly for 4 weeks, dose to be given weekly as a single dose or in 3–7 divided doses, increase dose after 4 weeks (if a rise in haemoglobin of at least 1 g/100 mL not achieved), increased to 900 units/kg once weekly, dose to be given weekly as a single dose or in 3–7 divided doses, if adequate response obtained reduce dose by 25–50%, discontinue treatment if haemoglobin concentration does not increase by at least 1 g/100 mL after 8 weeks of therapy (response unlikely). Reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy; maximum 60 000 units per week.

To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia when blood-conserving procedures are insufficient or unavailable

BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION

Adult: (consult product literature)

Pregnancy

No evidence of harm. Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.

Breast feeding

Unlikely to be present in milk. Minimal effect on infant.

Hepatic impairment

Manufacturers advise caution in chronic hepatic failure.

National funding/access decisions

NICE technology appraisals (TAs)

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) NICE TA323

Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used. www.nice.org.uk/TA323

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.
Epoetin zeta

INDICATIONS AND DOSE

Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis

BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION

Adult: Initially 50 units/kg 3 times a week, adjusted according to response, adjusted in steps of 25 units/kg 3 times a week, dose to be adjusted at intervals of at least 4 weeks; maintenance 25–100 units/kg 3 times a week, intravenous injection to be given over 1–5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks

Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis

BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION

Adult: Initially 50 units/kg twice weekly; maintenance 25–50 units/kg twice weekly, intravenous injection to be given over 1–5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks

Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis

BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION

Adult: Initially 50 units/kg 3 times a week, adjusted according to response, adjusted in steps of 25 units/kg 3 times a week, dose to be increased at intervals of at least 4 weeks; maintenance 17–33 units/kg 3 times a week (max. per dose 200 units/kg 3 times a week), intravenous injection to be given over 1–5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks

Symptomatic anaemia in adults receiving cancer chemotherapy

BY SUBCUTANEOUS INJECTION

Adult: Initially 150 units/kg 3 times a week, alternatively initially 450 units/kg once weekly,

increased to 300 units/kg 3 times a week, only increase dose if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, maximum 1 mL per injection site, reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy

To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery

BY INTRAVENOUS INJECTION

Adult: 600 units/kg twice weekly for 3 weeks before surgery, intravenous injection to be given over 1–5 minutes, consult product literature for details and advice on ensuring high iron stores

Moderate anaemia (haemoglobin concentration 10–13 g/100 mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable

BY SUBCUTANEOUS INJECTION

Adult: 600 units/kg every 1 week for 3 weeks before surgery and on day of surgery, alternatively 300 units/kg daily for 15 days starting 10 days before surgery, maximum 1 mL per injection site, consult product literature for details

PREGNANCY
No evidence of harm. Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.

BREAST FEEDING
Unlikely to be present in milk. Minimal effect on infant.

HEPATIC IMPAIRMENT
Manufacturers advise caution in chronic hepatic failure.

PRESCRIBING AND DISPENSING INFORMATION

Products containing epoetin zeta are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) NICE TA323

Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used. www.nice.org.uk/TA323

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Phenylalanine

> Retacrit (Hospira UK Ltd)

Epoetin zeta 3333 unit per 1 mL Retacrit 2,000 units/0.6 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection (POD) £67.88 (Hospital only)
MONOCLONAL ANTIBODIES

Eculizumab

- **DRUG ACTION** Eculizumab, a recombinant monoclonal antibody, inhibits terminal complement activation at the C5 protein and thereby reduces haemolysis and thrombotic microangiopathy.

**INDICATIONS AND DOSE**

Reduce haemolysis in paroxysmal nocturnal haemoglobinuria (PNH), in those with a history of bone transfusions (under expert supervision)

**BY INTRAVENOUS infusion**

- Adult: Initially 600 mg once weekly for 4 weeks, then increased to 900 mg once weekly for 1 week; maintenance 900 mg every 12–16 days

Reduce thrombotic microangiopathy in atypical haemolytic uraemic syndrome (aHUS) (specialist use only)

**BY INTRAVENOUS infusion**

- Adult: Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week; maintenance 1.2 g every 12–16 days

**CONTRA-INDICATIONS** Patients unvaccinated against *Neisseria meningitidis* - unresolved *Neisseria meningitidis* infection

**CAUTIONS** Active systemic infection

**CAUTIONS, FURTHER INFORMATION**

Meningococcal infection Vaccine against *Neisseria meningitidis* at least 2 weeks before treatment (tetravalent vaccine against serotypes A, C, W135 and Y recommended); revaccinate according to current medical guidelines. Patients receiving eculizumab less than 2 weeks after receiving meningococcal vaccine must be given prophylactic antibiotics until 2 weeks after vaccination. Advise patient to report promptly any signs of meningococcal infection. Other immunisations should also be up to date.

**SIDE-EFFECTS**

- **Common or very common** Alopecia · arthralgia · blood disorders · cough · dizziness · dysgeusia · dysuria · fatigue · gastro-intestinal disturbances · headache · infection (including meningococcal infection) · influenza-like symptoms · infusion-related reactions · leucopenia · myalgia · nasopharyngitis · oedema · paraesthesia · pruritus · rash · spontaneous erection · thrombocytopenia · vertigo

- **Uncommon** Anorexia · anxiety · chest pain · depression · epistaxis · gingival pain · Graves’ disease · haematemesis · hot flushing · hyperhidrosis · hypotension · jaundice · malignant melanoma · menstrual disorders · mood changes · muscle spasms · myelodysplastic syndrome · palpitation · petechiae · renal impairment · skin depigmentation · sleep disturbances · syncope · tinnitus · tremor · visual disturbances

- **CONCEPTION AND CONCEPTION** Manufacturer advises effective contraception during and for 5 months after treatment.

- **PREGNANCY** No information available—use only if potential benefit outweighs risk. Human IgG antibodies known to cross placenta.

- **BREAST FEEDING** No information available—manufacturer advises avoid breast-feeding during and for 5 months after treatment.

- **MONITORING REQUIREMENTS**

  - Monitor for 1 hour after infusion.

  - For paroxysmal nocturnal haemoglobinuria, monitor for intravascular haemolysis (including serum-lactate dehydrogenase concentration) during treatment and for at least 8 weeks after discontinuation.

  - For atypical haemolytic uraemic syndrome, monitor for thrombotic microangiopathy (measure platelet count, serum-lactate dehydrogenase concentration, and serum creatinine) during treatment and for at least 12 weeks after discontinuation.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Soliris®), give intravenously in Glucose 5% or Sodium chloride 0.9%. Dilute requisite dose to a concentration of 5 mg/ml and mix gently; give over 25–45 minutes (infusion time may be increased to 2 hours if infusion-related reactions occur).

- **PRESCRIBING AND DISPENSING INFORMATION** Consult product literature for details of supplemental doses with concomitant plasmapheresis, plasma exchange, or plasma infusion.

- **PATIENT AND CARER ADVICE** A patient information card should be provided. Patient or carers should be advised to report promptly any signs of meningococcal infection.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

**ELECTROLYTES**: May contain Sodium

- **Soliris** (Alexion Pharma UK Ltd)

  - Eculizumab 10 mg per 1 ml

    - Soliris 300mg/30ml concentrate for solution for infusion vials | 1 vial (BNF) £135.00 (Hospital only)

### 1.4 Anaemias, iron deficiency

**Anaemias, iron-deficiency**

*Treatment* with an iron preparation is justified only in the presence of a demonstrable iron-deficiency state. Before starting treatment, it is important to exclude any serious underlying cause of the anaemia (e.g. gastric erosion, gastro-intestinal cancer).

Prophylaxis with an iron preparation may be appropriate in malabsorption, menstruation, pregnancy, after subtotal or total gastrectomy, in haemodialysis patients, and in the management of low birth-weight infants such as preterm neonates.

**Oral iron**

Iron salts should be given by mouth unless there are good reasons for using another route.

Ferrous salts show only marginal differences between one another in efficiency of absorption of iron. Haemoglobin regeneration rate is little affected by the type of salt used provided sufficient iron is given, and in most patients the
speed of response is not critical. Choice of preparation is thus usually decided by the incidence of side-effects and cost.

The oral dose of elemental iron for iron-deficiency anaemia should be 100 to 200 mg daily. It is customary to give this as dried ferrous sulfate; for prophylaxis of iron-deficiency anaemia, ferrous sulfate may be effective.

### Iron salt/amount

<table>
<thead>
<tr>
<th>Iron salt/amount</th>
<th>Content of ferrous iron</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrous fumarate 200 mg</td>
<td>65 mg</td>
</tr>
<tr>
<td>Ferrous gluconate 300 mg</td>
<td>35 mg</td>
</tr>
<tr>
<td>Ferrous sulfate 300 mg</td>
<td>60 mg</td>
</tr>
<tr>
<td>Ferrous sulfate, dried 200 mg</td>
<td>65 mg</td>
</tr>
</tbody>
</table>

#### Compound preparations

Preparations containing iron and folic acid p. 836 are used during pregnancy in women who are at high risk of developing iron and folic acid deficiency; they should be distinguished from those used for the prevention of neural tube defects in women planning a pregnancy.

It is important to note that the small doses of folic acid p. 836 contained in these preparations are inadequate for the treatment of megaloblastic anaemias.

Some oral preparations contain ascorbic acid p. 884 to aid absorption of the iron but the therapeutic advantage of such preparations is minimal and cost may be increased.

There is no justification for the inclusion of other ingredients, such as the B group of vitamins (except folic acid for pregnant women).

#### Modified-release preparations

Modified-release preparations of iron are licensed for once-daily dosage, but have no therapeutic advantage and should not be used. These preparations are formulated to release iron gradually; the low incidence of side-effects may reflect the small amounts of iron available for absorption as the iron is carried past the first part of the duodenum into an area of the gut where absorption may be poor.

#### Parenteral iron

Iron can be administered parenterally as iron dextran p. 832, iron sucrose p. 832, ferric carboxymaltose below, or iron isomaltoside 1000 p. 832. Parenteral iron is generally reserved for use when oral therapy is unsuccessful because the patient cannot tolerate oral iron, or does not take it reliably, or if there is continuing blood loss, or in malabsorption. Parenteral iron may also have a role in the management of chemotherapy-induced anaemia, when given with erythropoietins, in specific patient groups (see NICE guidance).

Many patients with chronic renal failure who are receiving haemodialysis (and some who are receiving peritoneal dialysis) also require iron by the intravenous route on a regular basis.

With the exception of patients with severe renal failure receiving haemodialysis, parenteral iron does not produce a faster haemoglobin response than oral iron provided that the oral iron preparation is taken reliably and is absorbed adequately. If parenteral iron is necessary, the dose should be calculated according to the patient’s body-weight and total iron deficit. Depending on the preparation used, parenteral iron is given as a total dose or in divided doses. Further treatment should be guided by monitoring haemoglobin and serum iron concentrations.

## Anaemias, iron deficiency

### Iron (injectable)

#### Important safety information

MHRA/CHM Advice: Serious hypersensitivity reactions

**Reactions with intravenous iron (August 2013)**

Serious hypersensitivity reactions, including life-threatening and fatal anaphylactic reactions, have been reported in patients receiving intravenous iron. These reactions can occur even when a previous administration has been tolerated (including a negative test dose). Test doses are no longer recommended and caution is needed with every dose of intravenous iron. Intravenous iron products should only be administered when appropriately trained staff and resuscitation facilities are immediately available; patients should be closely monitored for signs of hypersensitivity during and for at least 30 minutes after every administration. In the event of a hypersensitivity reaction, treatment should be stopped immediately and appropriate management initiated.

The risk of hypersensitivity is increased in patients with known allergies, immune or inflammatory conditions, or those with a history of severe asthma, eczema, or other atopic allergy; in these patients, intravenous iron should only be used if the benefits outweigh the risks. Intravenous iron should be avoided in the first trimester of pregnancy and used in the second or third trimesters only if the benefit outweighs the potential risks for both mother and fetus.

#### Side-effects

- **Hypersensitivity reactions**

#### Side-effects, Further information

**Anaphylactic reactions** Anaphylactic reactions can occur with parenteral administration of iron complexes and facilities for cardiopulmonary resuscitation must be available.

**Overdose** For details on the management of poisoning, see Iron salts, under Emergency treatment of poisoning p. 1123.

### Ferric carboxymaltose

#### Indications and dose

**Iron-deficiency anaemia**

**By slow intravenous injection or by intravenous infusion**

- Adult: Dose calculated according to body-weight and iron deficit (consult product literature)

#### Caution

- **Allergic disorders • asthma • eczema • hypersensitivity** can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available.

#### Side-effects

- **Common or very common** Dizziness • gastro-intestinal disturbances • headache • injection-site reactions • rash

- **Uncommon** Anaphylaxis • arthralgia • back pain • chest pain • fatigue • flushing • hypertension • hypotension • malaise • myalgia • paraesthesia • peripheral oedema • pruritus • pyrexia • rigors • urticaria

- **Rare** Dyspnoea

#### Pregnancy

Avoid in first trimester; crosses the placenta in animal studies. May influence skeletal development.

#### Hepatic impairment

Use with caution. Avoid in conditions where iron overload increases risk of impairment.
Iron dextran

**INDICATIONS AND DOSE**

- **Iron-deficiency anaemia**
  
  **BY DEEP INTRAMUSCULAR INJECTION**
  
  - Adult: Intramuscular injection to be administered into the gluteal muscle, doses calculated according to body-weight and iron deficit (consult product literature).

  **BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**
  
  - Adult: Doses calculated according to body-weight and iron deficit (consult product literature).

- **CONTRA-INDICATIONS** Active rheumatoid arthritis - asthma - eczema - history of allergic disorders

- **CAUTIONS** Hypersensitivity can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available - infection (discontinue if ongoing bacteraemia) - oral iron should not be given until 5 days after last injection

- **SIDE-EFFECTS**
  
  - **Uncommon** Abdominal pain - anaphylaxis - blurred vision - cramps - dyspnoea - flushing - nausea - numbness - pruritus - rash - vomiting
  
  - **Rare** Angioedema - arthralgia - chest pain - diarrhoea - dizziness - fatigue - hypotension - impaired consciousness - injection-site reactions - malaise - myalgia - numbness - seizures - sweating - tachycardia - tremor
  
  - **Very rare** Bradycardia - delirium - flushing - haemolysis - headache - hypothermia - palpitation - paraesthesia - transient deafness

- **PREGNANCY** Avoid in first trimester.

- **HEPATIC IMPAIRMENT** Avoid in decompensated liver disease and hepatitis.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Ferinject®), give intermittently in Sodium chloride 0.9%, dilute 200–500 mg in up to 100 mL infusion fluid and give over at least 6 minutes; dilute 0.5–1 g in up to 250 mL infusion fluid and give over at least 15 minutes.

- **PRESCRIBING AND DISPENSING INFORMATION** A ferric carboxymaltose complex containing 5% (50 mg/mL) of iron.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

---

**Iron isomaltoside 1000**

**INDICATIONS AND DOSE**

**Iron-deficiency anaemia**

**BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: Doses calculated according to body-weight and iron deficit (consult product literature)

- **CONTRA-INDICATIONS** Active rheumatoid arthritis - asthma - eczema - history of allergic disorders

- **CAUTIONS** Hypersensitivity can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available - infection (discontinue if ongoing bacteraemia) - oral iron should not be given until 5 days after last injection

**SIDE-EFFECTS**

- **Uncommon** Abdominal pain - anaphylaxis - blurred vision - constipation - cramps - dyspnoea - fever - flushing - injection-site reactions - nausea - numbness - pruritus - rash - vomiting

- **Rare** Altered mental status - angioedema - arthralgia - chest pain - diarrhoea - dizziness - hypotension - loss of consciousness - malaise - myalgia - restless - seizures - sweating - tachycardia - tremor

- **Very rare** Foetal bradycardia - haemolysis - headache - hypertension - palpitation - paraesthesia - transient deafness

**PREGNANCY** Avoid in first trimester.

**HEPATIC IMPAIRMENT** Avoid in decompensated liver disease and hepatitis.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Monofer®), give intermittently in Sodium chloride 0.9%. For details consult product literature.

**PRESCRIBING AND DISPENSING INFORMATION** A complex of ferric iron and isomaltosides containing 10% (100 mg/mL) of iron.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Cosmofer** (Pharmacosmos UK Ltd)
  
  Iron (as iron dextran) 50 mg per 1 mL

  - Solution for injection ampoules | 2 ampoule [P] £79.70
  
  Cosmofer 100 mg/2 mL solution for injection ampoules | 5 ampoule [P] £38.85

---

**Iron sucrose**

**INDICATIONS AND DOSE**

**Iron-deficiency anaemia**

**BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: Doses calculated according to body-weight and iron deficit (consult product literature)

- **CONTRA-INDICATIONS** Anaphylaxis - asthma - eczema - history of allergic disorders
Iron (oral)

- **SIDE-EFFECTS** Constipation, diarrhoea, epigastric pain (dose related), faecal impaction, gastro-intestinal irritation, nausea (dose related)

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Managing side-effects** If side-effects occur, the dose may be reduced; alternatively, another iron salt may be used, but an improvement in tolerance may simply be a result of a lower content of elemental iron. The incidence of side-effects due to ferrous sulfate is no greater than with other iron salts when compared on the basis of equivalent amounts of elemental iron.

- **Altered bowel habit** Iron preparations taken orally can be constipating and occasionally lead to faecal impaction. Oral iron, particularly modified-release preparations, can exacerbate diarrhoea in patients with inflammatory bowel disease; care is also needed in patients with intestinal strictures and diverticular disease. The relationship between dose and altered bowel habit (constipation or diarrhoea) is less clear than for nausea and epigastric pain.

- **Overdose** For details on the management of poisoning, see iron salts, under Emergency treatment of poisoning p. 1123.

- **MONITORING REQUIREMENTS** The haemoglobin concentration should rise by about 100–200 mg/100 mL (1–2 g/litre) per day or 2 g/100 mL (20 g/litre) over 3–4 weeks. When the haemoglobin is in the normal range, treatment should be continued for a further 3 months to replenish the iron stores. Epithelial tissue changes such as atrophic glossitis and koilonychia are usually improved, but the response is often slow.

- **CAUTIONS** Hypersensitivity reactions can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available. Infection (discontinue if ongoing bacteraemia) or oral iron should not be given until 5 days after last injection.

**HEPATIC IMPAIRMENT** Use with caution. Avoid in conditions where iron overload increases risk of impairment.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Venofer®), give intermittently in Sodium chloride 0.9%, dilute 100 mg in up to 100 mL infusion fluid; give 25 mg over 15 minutes initially, then give at a rate not exceeding 3.33 mg/minute.

**PRESCRIBING AND DISPENSING INFORMATION** A complex of ferric hydroxide with sucrose containing 2% (20 mg/mL) of iron.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Venofer® (Vifor Pharma UK Ltd®)
  - Iron (as iron sucrose) 20 mg per 1 mL Venofer 100mg/5ml solution for injection vials | 5 vial pack £43.52

Iron-deficiency anaemia (prophylactic)

**INDICATIONS AND DOSE**

**BY MOUTH USING TABLETS**
- Child 12–17 years: 210 mg 1–2 times a day
- Adult: 210 mg 1–2 times a day

**BY MOUTH USING SYRUP**
- Child 12–17 years: 140 mg twice daily
- Adult: 140 mg twice daily

Iron-deficiency anaemia (therapeutic)

**BY MOUTH USING TABLETS**
- Child 12–17 years: 210 mg 2–3 times a day
- Adult: 210 mg 2–3 times a day

**BY MOUTH USING SYRUP**
- Child 12–17 years: 280 mg twice daily
- Adult: 280 mg twice daily

FERSADAY®

- **Iron-deficiency anaemia (prophylactic)**
  - BY MOUTH
    - Adult: 322 mg daily
  - **Iron-deficiency anaemia (therapeutic)**
    - BY MOUTH
      - Adult: 322 mg twice daily

GALFER® CAPSULES

- **Iron-deficiency anaemia (prophylactic)**
  - BY MOUTH
    - Child 12–17 years: 305 mg daily
    - Adult: 305 mg daily
  - **Iron-deficiency anaemia (therapeutic)**
    - BY MOUTH
      - Child 12–17 years: 305 mg twice daily
      - Adult: 305 mg twice daily

GALFER® SYRUP

- **Iron-deficiency anaemia (prophylaxis)**
  - BY MOUTH
    - Child 1 month–11 years: 0.25 mL/kilogram twice daily, the total daily dose may alternatively be given in 3 divided doses, prophylactic iron supplementation may be required in babies of low birth-weight who are solely breast-fed; supplementation is started 4–6 weeks after birth and continued until mixed feeding is established; maximum 20 mL per day
    - Child 12–17 years: 10 mL once daily
    - Adult: 10 mL once daily

- **Iron-deficiency anaemia (therapeutic)**
  - BY MOUTH
    - Child 1 month–11 years: 0.25 mL/kilogram twice daily, the total daily dose may alternatively be given in 3 divided doses; maximum 20 mL per day
    - Child 12–17 years: 10 mL 1–2 times a day
    - Adult: 10 mL 1–2 times a day

**INTERACTIONS** → Appendix 1 (iron salts).

**PATIENT AND CARER ADVICE**

Although iron preparations are best absorbed on an empty stomach they can be taken after food to reduce gastro-intestinal side-effects. May discolor stools.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Blood and blood-forming organs

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Tablet**

- **FERROUS GLUCONATE (Non-proprietary)**
  - Ferrous gluconate 210 mg Ferrous gluconate 210mg tablets | 84 tablet £2.30 DT price = £2.30
  - Fersaday (AMCo) Ferrous gluconate 322 mg Fersaday 322mg tablets | 28 tablet £0.95 DT price = £0.95

**Capsule**

- Galfer (Thorton & Ross Ltd) Ferrous fumarate 305 mg Galfer 305mg capsules | 100 capsule £2.00 DT price = £2.00 | 250 capsule £5.00

**Oral solution**

- **FERROUS GLUCONATE (Non-proprietary)**
  - Ferrous gluconate 300 mg Ferrous gluconate 300mg tablets | 28 tablet £3.35 DT price = £1.95 | 1000 tablet £119.64

**Fersaday**

- Sideromal (Pfertec Ltd) Ferrous gluconate 130 mg Sideromal 130mg capsules | 28 capsule £25.00

---

**Ferrous fumarate with folic acid**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ferrous fumarate p. 833, folic acid p. 836.

**INDICATIONS AND DOSE**

Iron deficiency anaemia

**BY MOUTH USING CAPSULES**

- Adult: 1 capsule daily, to be taken before food
- Adult: 1 tablet daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Pregraday (Focus Pharmaceuticals Ltd) Ferrous fumarate 322 mg, Folic acid 350 microgram Pregraday 322mg/350microgramtablets | 28 tablet £1.25 DT price = £1.25

**Capsule**

- Galfer FA (Thorton & Ross Ltd) Ferrous fumarate 305 mg, Folic acid 350 microgram Galfer FA capsules | 100 capsule £3.25 DT price = £3.25

---

**Ferrous gluconate**

**INDICATIONS AND DOSE**

Prophylaxis of iron-deficiency anaemia

**BY MOUTH USING TABLETS**

- Child 6–11 years: 300–900 mg daily, dose to be taken before food
- Child 12–17 years: 600 mg daily, dose to be taken before food
- Adult: 600 mg daily, dose to be taken before food

Treatment of iron-deficiency anaemia

**BY MOUTH**

- Child 6–11 years: 300–900 mg daily, dose to be taken before food
- Child 12–17 years: 1.2–1.8 g daily in divided doses, dose to be taken before food
- Adult: 1.2–1.8 g daily in divided doses, dose to be taken before food

**INTERACTIONS** → Appendix 1 (iron salts).

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Ferrous gluconate for iron-deficiency anaemia www.medicinesforchildren.org.uk/ferrous-gluconate-for-iron-deficiency-anaemia

---

**Ferrous sulfate**

**INDICATIONS AND DOSE**

Iron-deficiency anaemia (prophylactic and therapeutic)

**BY MOUTH**

- Child 12–17 years: 1 tablet daily, dose to be taken before food
- Adult: 1 tablet daily, dose to be taken before food

**FEOSPAN**

Iron-deficiency anaemia

**BY MOUTH**

- Child 1–2 years: 1 capsule daily, capsule can be opened and sprinkled on food
- Adult: 1–2 capsules daily, capsule can be opened and sprinkled on food

**IRONORM DROPS**

Iron-deficiency anaemia, prophylactic

**BY MOUTH**

- Adult: 2.4–4.8 mL daily

Iron deficiency anaemia, therapeutic

**BY MOUTH**

- Adult: 4 mL 1–2 times a day

**INTERACTIONS** → Appendix 1 (iron salts).

**PRESCRIBING AND DISPENSING INFORMATION**

Modified-release preparations of iron are licensed for once-daily dosage, but have no therapeutic advantage and should not be used. These preparations are formulated to release iron gradually; the low incidence of side-effects may reflect the small amounts of iron available for absorption as the iron is carried past the first part of the duodenum into an area of the gut where absorption may be poor.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Ferrous sulfate for iron-deficiency anaemia www.medicinesforchildren.org.uk/ferrous-sulfate-iron-deficiency-anaemia

**NATIONAL FUNDING/ACCESS DECISIONS**

NHS restrictions Feospan® is not prescribable under the National Health Service.

**LESST SUITABLE FOR PRESCRIBING**

Feospan® and Ferrograd® are less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.
**Anaemias, iron deficiency 835**

**Ferrous sulfate with ascorbic acid**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ascorbic acid p. 884, ferrous sulfate p. 834.

**INDICATIONS AND DOSE**

Iron deficiency anaemia

BY MOUTH USING MODIFIED-RELEASE TABLETS

- Adult: 1 tablet daily, dose to be taken before food

**NATIONAL FUNDING/ACCESS DECISIONS**

NHS restrictions Ferrograd C® is not prescribable on the National Health Service.

**LESS SUITABLE FOR PRESCRIBING**

Ferrograd C® is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

CAUTIONARY AND ADVISORY LABELS 25

- Ferrograd (Teofarma)
  - Ferrous sulfate dried 325 mg, Ascorbic acid (as Sodium ascorbate) 500 mg Ferrograd C (Teofarma) | 20 tablet £4.60 | 100 tablet £4.60 | 1000 tablet £15.00

**INDICATIONS AND DOSE**

Iron-deficiency anaemia (therapeutic)

BY MOUTH

- Child 1-2 years: 2.5 mL daily
- Adult: 2.5 mL daily

**Iron-deficiency anaemia (prophylactic)**

BY MOUTH

- Child 1-month-1 year: 1 drop (approximately 500 micrograms iron) per 450 g body-weight to be given 3 times a daily, dose to be administered from dropper bottle, prophylactic iron supplementation may be required in babies of low birth-weight who are solely breast-fed; supplementation is started 4–6 weeks after birth and continued until mixed feeding is established
- Child 12-17 years: 2.5 mL daily

**Iron-deficiency anaemia (therapeutic) if required during second and third trimester of pregnancy**

BY MOUTH

- Child 12-17 years: 5 mL once daily
- Adult: 5 mL once daily

- INTERACTIONS → Appendix 1 (iron salts).

- PATIENT AND CARER ADVICE Counselling on the use of the dropper advised.

- NATIONAL FUNDING/ACCESS DECISIONS

NHS restrictions Niferex® is not available on prescription under NHS, except 30-mL paediatric dropper bottle for prophylaxis and treatment of iron deficiency in infants born prematurely; endorse prescription ’SLS’.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- Niferex (Tillomed Laboratories Ltd)
  - Iron (as Polysaccharide-iron complex) 100 mg Niferex 100mg/5mL elixir (sugar-free) | 30 mL £2.16 (sugar-free) | 240 mL £6.06

**Sodium feredetate**

(Sodium ironedetate)

**INDICATIONS AND DOSE**

Iron-deficiency anaemia (therapeutic)

BY MOUTH USING ORAL SOLUTION

- Child 1-11 months: Up to 2.5 mL twice daily, smaller doses to be used initially
- Child 1-4 years: 2.5 mL 3 times a day
- Child 5-11 years: 5 mL 3 times a day
- Child 12-17 years: 5 mL 3 times a day, increased to 10 mL 3 times a day, dose to be increased gradually continued →
Blood and nutrition

malabsorption of vitamin B12 resulting from an autoimmune gastritis causes pernicious anaemia not be instituted until the results of tests are available. Sometimes necessary to administer both substances after injection. In emergencies, when delay might be dangerous, it is usually advisable to administer vitamin B12 first. Once the deficiency is known, maintenance treatment, which is usually for life, can be instituted with frequent administration of intramuscular injections to replenish the depleted body stores. Thereafter, maintenance treatment, which is usually for life, can be instituted. There is no evidence that doses larger than those recommended provide any additional benefit in vitamin B12 neuropathy.

Folic acid below has few indications for long-term therapy since most causes of folate deficiency are self-limiting or will yield to a short course of treatment. It should not be used in undiagnosed megaloblastic anaemia unless vitamin B12 is administered concurrently otherwise neuropathy may be precipitated.

1.5 Anaemias, megaloblastic

Anaemias, megaloblastic

Most megaloblastic anaemias result from a lack of either vitamin B12 or folate, and it is essential to establish in every case which deficiency is present and the underlying cause. In emergencies, when delay might be dangerous, it is sometimes necessary to administer both substances after the bone marrow test while plasma assay results are awaited. Normally, however, appropriate treatment should not be instituted until the results of tests are available.

One cause of megaloblastic anaemia in the UK is pernicious anaemia in which lack of gastric intrinsic factor resulting from an autoimmune gastritis causes malabsorption of vitamin B12. Vitamin B12 is also needed in the treatment of megaloblastosis caused by prolonged nitrous oxide anaesthesia, which inactivates the vitamin, and in the rare syndrome of congenital transcobalamin II deficiency.

Vitamin B12 should be given prophylactically after total gastrectomy or total ileal resection (or partial gastrectomy if a vitamin B12 absorption test shows vitamin B12 malabsorption).

Apart from dietary deficiency, all other causes of vitamin B12 deficiency are attributable to malabsorption. There is little place for the use of low-dose vitamin B12 orally and none for vitamin B12 intrinsic factor complexes given by mouth. Vitamin B12 in larger oral doses [unlicensed] may be effective.

Hydroxocobalamin p. 837 has completely replaced cyanocobalamin p. 837 as the form of vitamin B12 of choice for therapy; it is retained in the body longer than cyanocobalamin and thus for maintenance therapy can be given at intervals of up to 3 months. Treatment is generally initiated with frequent administration of intramuscular injections to replenish the depleted body stores. Thereafter, maintenance treatment, which is usually for life, can be instituted. There is no evidence that doses larger than those recommended provide any additional benefit in vitamin B12 neuropathy.

Folic acid below has few indications for long-term therapy since most causes of folate deficiency are self-limiting or will yield to a short course of treatment. It should not be used in undiagnosed megaloblastic anaemia unless vitamin B12 is administered concurrently otherwise neuropathy may be precipitated.

In folate-deficient megaloblastic anaemia (e.g. because of poor nutrition, pregnancy, or antiepileptic drugs), daily folic acid supplementation for 4 months brings about haematological remission and replenishes body stores. For prophylaxis in chronic haemolytic states, malabsorption, or in renal dialysis, folic acid is given daily or sometimes weekly, depending on the diet and the rate of haemolysis.

Folic acid is also used for the prevention of methotrexate-induced side-effects in severe Crohn’s disease, rheumatic disease, and severe psoriasis.

Folic acid p. 781 is also effective in the treatment of folate deficient megaloblastic anaemia but it is generally used in association with cytotoxic drugs; it is given as calcium folinate.

There is no justification for prescribing multiple ingredient vitamin preparations containing vitamin B12 or folic acid.

FOLATES

Folic acid

INDICATIONS AND DOSE

Folate-deficient megaloblastic anaemia

BY MOUTH

Child 1-11 months: Initially 500 micrograms/kg once daily (max. per dose 5 mg) for up to 4 months, in malabsorption states, doses up to 10 mg daily may be required

Child 1-17 years: 5 mg daily for 4 months (until term in pregnant women), in malabsorption states, doses up to 15 mg daily may be required

Adult: 5 mg daily for 4 months (until term in pregnant women), in malabsorption states, doses up to 15 mg daily may be required

Prevention of neural tube defects (women at a low risk of conceiving a child with a neural tube defect)

BY MOUTH

Adult: 400 micrograms daily, to be taken before conception and until week 12 of pregnancy

Prevention of neural tube defects (women at low risk who have not been taking folic acid and who suspect they are pregnant)

BY MOUTH

Adult: 400 micrograms daily, to be taken at once and continued until week 12 of pregnancy

Prevention of neural tube defects (women in the high-risk group who wish to become pregnant or who are at risk of becoming pregnant)

BY MOUTH

Adult: 5 mg daily until week 12 of pregnancy

Prevention of neural tube defects (women with sickle-cell disease)

BY MOUTH

Adult: 5 mg daily, patient should continue taking their normal dose of folic acid 5 mg daily (or to increase the dose to 5 mg daily) and continue this throughout pregnancy

Prevention of methotrexate-induced side-effects in rheumatic disease

BY MOUTH

Adult: 5 mg once weekly, dose to be taken on a different day to methotrexate dose

Prevention of methotrexate side-effects in severe Crohn’s disease

BY MOUTH

Adult: 5 mg once weekly, dose to be taken on a different day to methotrexate dose
Anaemias, megaloblastic 837

Hydroxocobalamin

INDICATIONS AND DOSE
Prophylaxis of macrocytic anaemias associated with vitamin B12 deficiency
BY INTRAMUSCULAR INJECTION
- Adult: 1 mg every 2–3 months
Pernicious anaemia and other macrocytic anaemias without neurological involvement
BY INTRAMUSCULAR INJECTION
- Adult: Initially 1 mg 3 times a week for 2 weeks, then 1 mg every 3 months
Pernicious anaemia and other macrocytic anaemias with neurological involvement
BY INTRAMUSCULAR INJECTION
- Adult: Initially 1 mg once daily on alternate days until no further improvement, then 1 mg every 2 months
Tobacco amblyopia
BY INTRAMUSCULAR INJECTION
- Adult: Initially 1 mg daily for 2 weeks, then 1 mg twice weekly until no further improvement, then 1 mg every 1–3 months
Leber’s optic atrophy
BY INTRAMUSCULAR INJECTION
- Adult: Initially 1 mg daily for 2 weeks, then 1 mg twice weekly until no further improvement, then 1 mg every 1–3 months

Cyanocobalamin

INDICATIONS AND DOSE
Vitamin B12 deficiency of dietary origin
BY MOUTH
- Adult: 50–150 micrograms daily, dose to be taken between meals.
- Adult: Initially 1 mg every 2–3 days for 10 doses; maintenance 1 mg every 1 month

PRESCRIBING AND DISPENSING INFORMATION
- The British Association of Pharmacists directs that when vitamin B12 injection is prescribed or demanded hydroxocobalamin injection shall be dispensed or supplied. Currently available brands of the tablet may not be suitable for vegans.

NATIONAL FUNDING/ACCESS DECISIONS
- NHS restrictions: Cyanocobalamin liquid, Cytacon® tablets and Cytacon® injection not available on prescription under the NHS.

LESS SUITABLE FOR PRESCRIBING
- Cyanocobalamin is less suitable for prescribing.

MEDIcular FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, tablet solution for injection

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 50 microgram
  - Tablet £2.00 DT price £2.00
  - Tablet £2.00 DT price £2.00

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 35 microgram/5ml oral solution
  - 200 ml £8.75

Solution for injection
- Cytacon (Focus Pharmaceuticals Ltd)
- Cyanocobalamin 1 mg per 1 ml
- Cytacon 1000 micrograms/1ml solution for injection ampoules | 5 ampoule (Pfizer) £14.50 DT price £14.50

VITAMIN B GROUP

Cyanocobalamin

PRESCRIBING AND DISPENSING INFORMATION
- The BP directs that when vitamin B12 injection is prescribed or demanded hydroxocobalamin injection shall be dispensed or supplied. Currently available brands of the tablet may not be suitable for vegans.

NATIONAL FUNDING/ACCESS DECISIONS
- NHS restrictions: Cyanocobalamin liquid, Cytacon® tablets and Cytacon® injection not available on prescription under the NHS.

LESS SUITABLE FOR PRESCRIBING
- Cyanocobalamin is less suitable for prescribing.

MEDIcular FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, tablet solution for injection

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 50 microgram
  - Tablet £2.00 DT price £2.00
  - Tablet £2.00 DT price £2.00

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 35 microgram/5ml oral solution
  - 200 ml £8.75

Solution for injection
- Cytacon (Focus Pharmaceuticals Ltd)
- Cyanocobalamin 1 mg per 1 ml
- Cytacon 1000 micrograms/1ml solution for injection ampoules | 5 ampoule (Pfizer) £14.50 DT price £14.50

VITAMIN B GROUP

Cyanocobalamin

PRESCRIBING AND DISPENSING INFORMATION
- The BP directs that when vitamin B12 injection is prescribed or demanded hydroxocobalamin injection shall be dispensed or supplied. Currently available brands of the tablet may not be suitable for vegans.

NATIONAL FUNDING/ACCESS DECISIONS
- NHS restrictions: Cyanocobalamin liquid, Cytacon® tablets and Cytacon® injection not available on prescription under the NHS.

LESS SUITABLE FOR PRESCRIBING
- Cyanocobalamin is less suitable for prescribing.

MEDIcular FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, tablet solution for injection

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 50 microgram
  - Tablet £2.00 DT price £2.00
  - Tablet £2.00 DT price £2.00

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 35 microgram/5ml oral solution
  - 200 ml £8.75

Solution for injection
- Cytacon (Focus Pharmaceuticals Ltd)
- Cyanocobalamin 1 mg per 1 ml
- Cytacon 1000 micrograms/1ml solution for injection ampoules | 5 ampoule (Pfizer) £14.50 DT price £14.50

VITAMIN B GROUP

Cyanocobalamin

PRESCRIBING AND DISPENSING INFORMATION
- The BP directs that when vitamin B12 injection is prescribed or demanded hydroxocobalamin injection shall be dispensed or supplied. Currently available brands of the tablet may not be suitable for vegans.

NATIONAL FUNDING/ACCESS DECISIONS
- NHS restrictions: Cyanocobalamin liquid, Cytacon® tablets and Cytacon® injection not available on prescription under the NHS.

LESS SUITABLE FOR PRESCRIBING
- Cyanocobalamin is less suitable for prescribing.

MEDIcular FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, tablet solution for injection

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 50 microgram
  - Tablet £2.00 DT price £2.00
  - Tablet £2.00 DT price £2.00

- CYANOCOBALAMIN (Non-proprietary)
  - Cyanocobalamin 35 microgram/5ml oral solution
  - 200 ml £8.75

Solution for injection
- Cytacon (Focus Pharmaceuticals Ltd)
- Cyanocobalamin 1 mg per 1 ml
- Cytacon 1000 micrograms/1ml solution for injection ampoules | 5 ampoule (Pfizer) £14.50 DT price £14.50

VITAMIN B GROUP

Cyanocobalamin

PRESCRIBING AND DISPENSING INFORMATION
- The BP directs that when vitamin B12 injection is prescribed or demanded hydroxocobalamin injection shall be dispensed or supplied. Currently available brands of the tablet may not be suitable for vegans.

NATIONAL FUNDING/ACCESS DECISIONS
- NHS restrictions: Cyanocobalamin liquid, Cytacon® tablets and Cytacon® injection not available on prescription under the NHS.

LESS SUITABLE FOR PRESCRIBING
- Cyanocobalamin is less suitable for prescribing.

MEDIcular FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, tablet solution for injection
Blood and nutrition

Iron overload

Severe tissue iron overload can occur in aplastic and other refractory anaemias, mainly as the result of repeated blood transfusions. It is a particular problem in refractory anaemias with hyperplastic bone marrow, especially thalassaemia major, where excessive iron absorption from the gut and inappropriate iron therapy can add to the tissue siderosis.

Iron overload associated with haemochromatosis can be treated with repeated venesection. Venesection may also be used for patients who have received multiple transfusions and whose bone marrow has recovered. Where venesection is contra-indicated, the long-term administration of the iron chelating compound desferrioxamine mesilate p. 839 is useful. Desferrioxamine mesilate (up to 2 g per unit of blood) may also be given at the time of blood transfusion, provided that the desferrioxamine mesilate is not given through the same line as the blood (but the two may be given through the same cannula).

Iron excretion induced by desferrioxamine mesilate is enhanced by administration of ascorbic acid p. 884 (vitamin C) daily by mouth; it should be given separately from food since it also enhances iron absorption. Ascorbic acid should not be given to patients with cardiac dysfunction; in patients with normal cardiac function ascorbic acid should be introduced 1 month after starting desferrioxamine mesilate.

Desferrioxamine mesilate infusion can be used to treat aluminium overload in dialysis patients; theoretically 100 mg of desferrioxamine binds with 4.1 mg of aluminium.

IRON CHELATORS

Deferasirox

DRUG ACTION Deferasirox, is an oral iron chelator.

INDICATIONS AND DOSE

Transfusion-related chronic iron overload when desferrioxamine is contra-indicated or inadequate in children aged 2–5 years with thalassaemia major who receive frequent blood transfusions. Transfusion-related chronic iron overload when desferrioxamine is contra-indicated or inadequate in patients with thalassaemia major who receive infrequent blood transfusions (less than 7 ml/kg/month of packed red blood cells).

Transfusion-related chronic iron overload when desferrioxamine is contra-indicated or inadequate in patients with other anaemias. Treatment of chronic iron overload in patients with thalassaemia major who receive frequent blood transfusions (more than 7 ml/kg/month of packed red blood cells).

BY MOUTH

Adult: Initially 10–30 mg/kg once daily, dose adjusted according to serum-ferritin concentration and amount of transfused blood—consult product literature; adjusted in steps of 5–10 mg/kg every 3–6 months, dose adjusted for maintenance according to serum-ferritin concentration; usual dose up to 30 mg/kg daily, increased if necessary up to 40 mg/kg daily and reduced in steps of 5–10 mg/kg, dose to be reduced once control achieved.

Treatment of chronic iron overload when desferrioxamine is contra-indicated or inadequate (with non-transfusion-dependent thalassaemia syndromes)

BY MOUTH

Adult: Initially 10 mg/kg once daily; adjusted in steps of 5–10 mg/kg every 3–6 months, dose adjusted for maintenance according to serum-ferritin concentration and liver-iron concentration (consult product literature); maximum 20 mg/kg per day.
Iron overload 839

**INDICATIONS AND DOSE**
Treatment of iron overload in patients with thalassaemia major in whom desferrioxamine is contraindicated or is inadequate

**BY MOUTH**
- Adult: 25 mg/kg 3 times a day; maximum 100 mg/kg per day

**CONTRA-INDICATIONS** History of agranulocytosis or recurrent neutropenia

**SIDE-EFFECTS** Agranulocytosis - arthropathy - blood dyscrasias - gastro-intestinal disturbances (reducing dose and increasing gradually may improve tolerance) - headache - increased appetite - neutropenia - red-brown urine discoloration - zinc deficiency

**CONCEPTION AND CONTRACEPTION** Manufacturer advises avoid before intended conception—teratogenic and embryotoxic in animal studies. Contraception advised in females of child-bearing potential.

**PREGNANCY** Manufacturer advises avoid during pregnancy—teratogenic and embryotoxic in animal studies.

**BREAST FEEDING** Manufacturer advises avoid unless information available.

**HEPATIC IMPAIRMENT** Use with caution in moderate impairment, reduce dose considerably then gradually increase to max. 50% of normal dose. Avoid if severe impairment.

**RENAL IMPAIRMENT** Reduce dose by 10 mg/kg if eGFR 60–90 mL/minute/1.73 m² and if serum creatinine increased by more than 33% of baseline measurement on 2 consecutive occasions—interrupt treatment if deterioration in renal function persists after dose reduction. Avoid if eGFR less than 60 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- Eye and ear examinations required before treatment and annually during treatment.
- Monitor body-weight, height, and sexual development in children annually.
- Monitor serum-ferritin concentration monthly.
- Test liver function before treatment, then every 2
- Test liver function after treatment, then every 2 weeks during the first month, and then monthly.
- Measure baseline serum creatinine and monitor renal function weekly during the first month of treatment and monthly thereafter.
- Test for proteinuria monthly.

**DIRECTIONS FOR ADMINISTRATION** Tablets should be dispersed in water, orange juice, or apple juice; if necessary resuspend residue.

**PATIENT AND CARER ADVICE** Patient or carers should be given advice on how to administer deferasirox dispersible tablets.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium (SMC) has advised (January 2007) that deferasirox is accepted for restricted use within NHS Scotland for the treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions. It is not recommended for patients with myelodysplastic syndromes.

**MEDICAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, capsule

**Tablet**

| Deferiprone 500 mg per 1 ml | £152.39 |

**Deferiprone**

**DRUG ACTION** Deferiprone, is an oral iron chelator.

**INDICATIONS AND DOSE**
Iron poisoning

**BY CONTINUOUS INTRAVENOUS INFUSION**
- Adult: Initially up to 15 mg/kg/hour, dose to be reduced after 4–6 hours, in severe cases, higher doses may be given on advice from the National Poisons Information Service; maximum 80 mg/kg per day

**Aluminium overload in dialysis patients**

**BY INTRAVENOUS INFUSION**
- Adult: (consult product literature or local protocols)

**Chronic iron overload (low iron overload)**

**BY SUBCUTANEOUS INFUSION**
- Adult: The dose should reflect the degree of iron overload

**Chronic iron overload (established overload)**

**BY SUBCUTANEOUS INFUSION**
- Adult: 20–50 mg/kg daily
1.7 Neutropenia and stem cell mobilisation

Neutropenia

Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropenia and thereby reduce the incidence of associated sepsis; there is as yet no evidence that it improves overall survival. Filgrastim (glycosylated rhG-CSF) and lenograstim p. 842 (glycosylated rhG-CSF) have similar effects; both have been used in a variety of clinical settings, but they do not have any clear-cut routine indications. In congenital neutropenia filgrastim p. 841 usually increases the neutrophil count with an appropriate clinical response. Pegfilgrastim p. 842 is a polyethylene glycol-conjugated (‘pegylated’) derivative of filgrastim; pegylation increases the duration of filgrastim activity. Lipegfilgrastim p. 842 is a polyethylene glycol-conjugated via a glycine linker derivative of filgrastim. Granulocyte-colony stimulating factors should only be prescribed by those experienced in their use.

CHEMOKINE RECEPTOR ANTAGONISTS

Plerixafor

**DRUG ACTION** Plerixafor is a chemokine receptor antagonist.

**INDICATIONS AND DOSE**

Mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or multiple myeloma (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- Adult: 240 micrograms/kg daily usually for 2–4 days (max 7 days), to be administered 6–11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor

**SIDE-EFFECTS**

- **Common or very common** Arthralgia · dizziness · dry mouth · erythema · fatigue · gastrointestinal disturbances · headache · injection-site reactions · insomnia · musculoskeletal pain · oral hypoaesthesia · sweating
- **Uncommon** Dyspnoea · hypersensitivity reactions · periorbital swelling
- **Rare** Anaphylaxis · pyrexia · rash · retinopathy · thrombocytopenia · visual disturbances · Yersinia and mucormycosis infections
- **Very rare** Acute respiratory distress syndrome · bone disorders · disturbance of coagulation · disturbances of immunity · infections · thromboembolism · visual disturbances · Yersinia and mucormycosis infections
- **Frequency not known** Muscle spasms
- **RENAL IMPAIRMENT** Use with caution.

**MONITORING REQUIREMENTS**

- Eye and ear examinations before treatment and at 3-month intervals during treatment.
- Monitor body-weight and height in children at 3-month intervals—risk of growth retardation with excessive doses.
- For full details and warnings relating to administration, consult product literature.
- For intravenous infusion (Desferal®), give continuously or intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstitute with water for injections to a concentration of 100 mg/mL; dilute with infusion fluid.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **DESFERROXAMINE MESILATE (Non-proprietary)**
  - Desferrioxamine mesilate 500 mg Desferrioxamine 500mg powder for solution for injection vials | 10 vial [Post] £39.90–£50.00
  - Desferrioxamine mesilate 2 gram Desferrioxamine 2g powder for solution for injection vials | 1 vial [Post] £17.65–£20.00
- **Desferal** (Novartis Pharmaceuticals UK Ltd)
  - Desferrioxamine mesilate 500 mg Desferal 500mg powder for solution for injection vials | 10 vial [Post] £46.63
  - Desferrioxamine mesilate 2 gram Desferal 2g powder for solution for injection vials | 1 vial [Post] £18.66

**GRANULOCYTE-COLONY STIMULATING FACTORS**

**Granulocyte-colony stimulating factors**

**DRUG ACTION** Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils.

**CAUTIONS** Malignant myeloid conditions · pre-malignant myeloid conditions · risk of splenomegaly and rupture—spleen size should be monitored · sickle-cell disease

**CAUTIONS, FURTHER INFORMATION**

Acute respiratory distress syndrome There have been reports of pulmonary infiltrates leading to acute respiratory distress syndrome—patients with a recent
history of pulmonary infiltrates or pneumonia may be at higher risk.

**SIDE-EFFECTS**

- **Common or very common** Alopecia, anorexia, asthenia, bone pain, chest pain, fever, gastrointestinal disturbances, headache, injection-site reactions, leukocytosis, musculoskeletal pain, rash, thrombocytopenia
- **Rare** Acute febrile neutrophilic dermatosis, cutaneous vasculitis, pulmonary side-effects (particularly interstitial pneumonia)

**SIDE-EFFECTS, FURTHER INFORMATION** Treatment should be withdrawn in patients who develop signs of pulmonary infiltration.

**PREGNANCY** There have been reports of toxicity in animal studies and manufacturers advise not to use granulocyte-colony stimulating factors during pregnancy unless the potential benefit outweighs the risk.

**BREAST FEEDING** There is no evidence for the use of granulocyte-colony stimulating factors during breast-feeding and manufacturers advise avoiding their use.

**MONITORING REQUIREMENTS**

- Full blood counts including differential white cell and platelet counts should be monitored.
- Spleen size should be monitored during treatment—risk of splenomegaly and rupture.

---

**INDICATIONS AND DOSE**

Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)

**BY SUBCUTANEOUS INJECTION OR BY INTRAVENOUS INFUSION**

- **Adult**: 5 micrograms/kg daily until neutrophil count in normal range, to be started the day after completing chemotherapy, for timing of leucopheresis, consult product literature
- **BY SUBCUTANEOUS INJECTION**
  - **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

**MOBILISATION OF PERIPHERAL BLOOD PROGENITOR CELLS (SPECIALIST USE ONLY)**

Reduction in duration of neutropenia and mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

Mobilisation of peripheral blood progenitor cells for autologous transplantation (specialist use only)

**BY INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION**

- **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

Mobilisation of peripheral blood progenitor cells for autologous transplantation, following adjunctive myelosuppressive chemotherapy—to improve yield (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- **Adult**: 5 micrograms/kg daily until neutrophil count in normal range, to be started the day after completing chemotherapy, for timing of leucopheresis, consult product literature

Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)

**BY SUBCUTANEOUS INJECTION**

- **Adult**: 10 micrograms/kg/day for 5–7 days, to be administered by subcutaneous infusion over 24 hours if given

---

**CONTRA-INDICATIONS** Severe congenital neutropenia (Kostmann’s syndrome) with abnormal cytogenetics

**CAUTIONS** Osteoporotic bone disease (monitor bone density if given for more than 6 months) · secondary acute myeloid leukaemia

**INTERACTIONS** 

- **Appendix 1 (filgrastim).**

**SIDE-EFFECTS**

- **Common or very common** Anaemia, dysuria, epistaxis, exacerbation of rheumatoid arthritis, haematuria, hepatomegaly, mucositis, osteoporosis, proteinuria, pseudogout, raised uric acid, splenic enlargement, transient decrease in blood glucose, transient hypotension, urinary abnormalities
- **Uncommon** Capillary leak syndrome (including fatal cases)
- **Rare** Splenic rupture

**MONITORING REQUIREMENTS**

- Regular morphological and cytogenetic bone-marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia).

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Neupogen®; Nivestim®; Ratiogran®; Zarzio®) give continuously or intermittently in Glucose 5% for a filgrastim concentration of less than 1 500 000 units/mL (15 micrograms/mL) albumin solution (human albumin solution) is added to produce a final albumin concentration of 2 mg/mL; should not be diluted to a filgrastim concentration of less than 200 000 units/mL (2 micrograms/mL) and should not be diluted with sodium chloride solution.

**PRESCRIBING AND DISPENSING INFORMATION**

Products containing filgrastim are not identical and although theoretically there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Blood and blood-forming organs

Solution for injection

- **Accofil** (Accord Healthcare Ltd)
  - Filgrastim 60 mega u per 1 ml Accofil 30 million units/0.5 ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (£) £284.20
  - Filgrastim 96 mega u per 1 ml Accofil 48 million units/0.5 ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (£) £384.40

- **Neupogen** (Amgen Ltd)
  - Filgrastim 30 mega u per 1 ml Neupogen 30 million units/1 ml solution for injection vials | 5 vial (£) £263.52

- **Nivestim** (Hospira UK Ltd)
  - Filgrastim 60 mega u per 1 ml Nivestim 30 million units/0.5 ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (£) £429.00
  - Filgrastim 96 mega u per 1 ml Nivestim 48 million units/0.5 ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (£) £676.40

- **Zarzio** (Sanofz Ltd)
  - Filgrastim 60 mega u per 1 ml Zarzio 30 million units/0.5 ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (£) £465.00
  - Filgrastim 96 mega u per 1 ml Zarzio 48 million units/0.5 ml solution for injection pre-filled syringes | 5 pre-filled disposable injection (£) £702.75

- **Lonquex** (Teva UK Ltd)
  - Lonquex 6 mg for each chemotherapy cycle, to be given approximately 24 hours after chemotherapy, dose expressed as filgrastim

Lenograstim
(Recombinant human granulocyte-colony stimulating factor, rHuG-CSF)

**INDICATIONS AND DOSE**

Reduction in the duration of neutropenia and associated complications following bone-marrow transplantation for non-myeloid malignancy (specialist use only). Reduction in the duration of neutropenia and associated complications following peripheral stem cells transplantation for non-myeloid malignancy (specialist use only) by intravenous infusion or by subcutaneous injection.

- Adult: 150 micrograms/m² daily until neutrophil count stable in acceptable range (max. 28 days), to be started the day after transplantation. Intravenous infusion to be given over 30 minutes.

Reduction in the duration of neutropenia and associated complications following treatment with cytokine-induced neutropenia associated with a significant incidence of febrile neutropenia (specialist use only)

- By subcutaneous injection.
  - Adult: 150 micrograms/m² daily until neutrophil count stable in acceptable range (max. 28 days), to be started on the day after completion of chemotherapy.

Mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion, used alone (specialist use only)

- By subcutaneous injection.
  - Adult: 10 micrograms/kg daily for 4–6 days (5–6 days in healthy donors).

Mobilisation of peripheral blood progenitor cells, used following adjunctive myelosuppressive chemotherapy (to improve yield) (specialist use only)

- By subcutaneous injection.
  - Adult: 150 micrograms/m² daily until neutrophil count stable in acceptable range, to be started 1–5 days after completion of chemotherapy. For timing of leucopheresis, consult product literature.

**SIDE-EFFECTS**

- Mucositis, splenic rupture, toxic epidermal necrolysis

**DIRECTIONS FOR ADMINISTRATION**

- For intravenous infusion (Granocyte-34), give intermittently in Sodium chloride 0.9%; initially reconstitute with 1 ml water for injection provided (do not shake vigorously) then dilute with up to 50 ml infusion fluid for each vial of Granocyte-13 or up to 100 ml infusion fluid for Granocyte-34; give over 30 minutes.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- Powder and solvent for solution for injection: May contain Phenylalanine

- Granocyte (Chugai Pharma UK Ltd)
  - Lenograstim 6.4 mega u Granocyte-13 powder and solvent for solution for injection vials | 1 vial (£) £60.11 | 5 vial (£) £200.55

- Lenograstim 3.6 mega u Granocyte-34 powder and solvent for solution for injection vials | 1 vial (£) £62.54 | 5 vial (£) £312.69

**Lipegfilgrastim**
(Glycopegylated recombinant methionyl human granulocyte-colony stimulating factor)

**INDICATIONS AND DOSE**

Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes)

- By subcutaneous injection.
  - Adult: 5 mg, for each chemotherapy cycle, given approximately 24 hours after chemotherapy, dose expressed as filgrastim.

**SIDE-EFFECTS**

- Hypokalaemia

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**SOLUTION FOR INJECTION**

- Lonquex (Teva UK Ltd)
  - Lipegfilgrastim 10 mg per 1 ml Lonquex 6 mg/0.6 ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (£) £652.06

**Pegfilgrastim**
(Pegylated recombinant methionyl human granulocyte-colony stimulating factor)

**INDICATIONS AND DOSE**

Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)

- By subcutaneous injection.
  - Adult: 6 mg for each chemotherapy cycle, to be given at least 24 hours after chemotherapy, dose is expressed as filgrastim.

**SIDE-EFFECTS**

- Acute leukaemia, myelosuppressive chemotherapy

- Rare: Capillary leak syndrome (including fatal cases)
1.8 Platelet disorders, essential thrombocythaemia

Essential thrombocythaemia

Anagrelide below inhibits platelet formation. It is licensed for essential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugs. At risk patient is defined by one or more of the following features: over 60 years of age, or a platelet count greater than 1000 x 10^9/L or a history of thrombo-haemorrhagic events. Anagrelide should be initiated under specialist supervision.

Cyclic AMP Phosphodiesterase III Inhibitors

Anagrelide

**INDICATIONS AND DOSE**

Essential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugs (initiated under specialist supervision)

**BY MOUTH**

- Adult: Initially 500 micrograms twice daily, dose to be adjusted at weekly intervals according to response, increased in steps of 500 micrograms daily; usual dose 1–3 mg daily in divided doses (max. per dose 2.5 mg); maximum 10 mg per day

**CAUTIONS**

Cardiovascular disease—assess cardiac function before and regularly during treatment—concomitant use of drugs that prolong QT-interval—assess cardiac function before and regularly during treatment—risk factors for QT-interval prolongation—assess cardiac function before and regularly during treatment

**INTERACTIONS**

Appendix 1 (anagrelide). Caution with concomitant aspirin in patients at risk of haemorrhage.

**SIDE-EFFECTS**

- **Common or very common** Anaemia · dizziness · fatigue · fluid retention · gastro-intestinal disturbances · headache · palpitation · rash · tachycardia
- **Uncommon** Alopecia · amnesia · anorexia · arthralgias · arthralgia · back pain · blood disorders · chest pain · confusion · congestive heart failure · depression · dry mouth · dyspnoea · ecchymosis · epistaxis · fever · gastro-intestinal haemorrhage · haemorrhage · hypertension · hypoaesthesia · impotence · malaise · myalgia · nervousness · oedema · pancreatitis · paraesthesia · pneumonia pleural effusion · pruritus · skin discoloration · sleep disturbances · syncope · weight changes
- **Rare** Angina · asthenia · cardiomegaly · cardiomyopathy · colitis · dry skin · dysarthria · gastritis · gingival bleeding · impaired coordination · migraine · myocardial infarction · nocturia · pericardial effusion · postural hypotension · pulmonary hypertension · pulmonary infiltrates · renal failure · somnolence · tinnitus · vasodilatation · visual disturbances

**Frequency not known** Hepatitis · interstitial lung disease · Torsade de pointes · tubulointerstitial nephritis

**CONCEPTION AND CONTRACEPTION**

Effective contraception required during treatment.

**PREGNANCY**

Manufacturer advises avoid (toxicity in animal studies).

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution in mild impairment. Avoid in moderate to severe impairment.

**RENAI IMPAIRMENT**

Manufacturer advises avoid if eGFR less than 50 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- Monitor full blood count (monitor platelet count every 2 days for 1 week, then weekly until maintenance dose established).
- Monitor liver function.
- Monitor serum creatinine.
- Monitor ura.
- Monitor ura and electrolytes (including potassium, magnesium and calcium) before and during treatment.

**PATIENT AND CARER ADVICE**

Dizziness may affect performance of skilled tasks (e.g. cycling, driving).

1.9 Platelet disorders, idiopathic thrombocytopenic purpura

Idiopathic thrombocytopenic purpura

Acute idiopathic thrombocytopenic purpura is usually self-limiting in children. In adults, idiopathic thrombocytopenic purpura can be treated with a corticosteroid, e.g. prednisolone p. 585, gradually reducing the dose over several weeks. Splenectomy is considered if a satisfactory platelet count is not achieved or if there is a relapse on reducing the dose of corticosteroid or withdrawing it. Immunoglobulin preparations, are also used in idiopathic thrombocytopenic purpura or where a temporary rapid rise in platelets is needed, as in pregnancy or pre-operatively; they are also used for children often in preference to a corticosteroid. Anti-D (rh) immunoglobulin p. 1061 is effective in raising the platelet count in about 80% of unsplenectomised rhesus-positive individuals; its effects may last longer than normal immunoglobulin p. 1063 for intravenous use, but further doses are usually required.

Other therapy that has been tried in refractory idiopathic thrombocytopenic purpura includes azathioprine p. 716, cyclophosphamide p. 750, vincristine sulfate p. 773, ciclosporin p. 717, and danazol p. 636. Rituuximab p. 734 may also be effective and in some cases induces prolonged remission. For patients with chronic severe
thrombocytopenia refractory to other therapy, tranexamic acid p. 95 may be given to reduce the severity of haemorrhage.

Eltrombopag below and romiplostim p. 845 are thrombopoietin receptor agonists licensed for the treatment of chronic idiopathic thrombocytopenic purpura in splenectomised patients refractory to other treatments, such as corticosteroids or immunoglobulins, or as a second-line treatment in non-splenectomised patients when surgery is contra-indicated (see also NICE guidance).

Eltrombopag is an oral preparation and romiplostim is an injection which is made biosynthetically by recombinant DNA technology; they should both be used under the supervision of a specialist.

THROMBOPOIETIN RECEPTOR AGONISTS

Eltrombopag

INDICATIONS AND DOSE

Treatment of chronic idiopathic thrombocytopenic purpura in splenectomised patients refractory to other treatments (such as corticosteroids or immunoglobulins) (under expert supervision) | Second-line treatment of chronic idiopathic thrombocytopenic purpura in non-splenectomised patients when surgery is contra-indicated (under expert supervision)

BY MOUTH

- Adult: Initially 50 mg once daily, dose to be adjusted to achieve a platelet count of 50 × 10^9/litre or more—consult product literature for dose adjustments, discontinue if inadequate response after 4 weeks treatment at maximum dose; maximum 75 mg per day
- Adult (patients of East Asian origin): Initially 25 mg once daily, dose to be adjusted to achieve a platelet count of 50 × 10^9/litre or more—consult product literature for dose adjustments, discontinue if inadequate response after 4 weeks treatment at maximum dose; maximum 75 mg per day.

Treatment of thrombocytopenia associated with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (under expert supervision)

BY MOUTH

- Adult: Initially 25 mg once daily, dose to be adjusted to achieve a platelet count sufficient to initiate antiviral therapy then a platelet count of 50–75 × 10^9/litre during antiviral therapy—consult product literature for dose adjustments, discontinue if inadequate response after 2 weeks treatment at maximum dose; maximum 100 mg per day.

CAUTIONS

- Patients of East Asian origin—risk factors for thromboembolism
- INTERACTIONS — Appendix 1 (eltrombopag)
- SIDE-EFFECTS
  - Common or very common Abdominal pain · alopecia · arthralgia · bone pain · cataract · constipation · diarrhoea · dry eye · fatigue · gastro-intestinal disturbances · headache · insomnia · myalgia · nausea · paraesthesia · peripheral oedema · pruritus · rash
  - Uncommon Acute myocardial infarction · anaemia · anorexia · anxiety · bone disorders · changes in appetite · cholestasis · cough · deep vein thrombosis · depression · dizziness · dry mouth · ecchymosis · eosinophilia · epistaxis · eye disorders · flushing · gingival bleeding · gout · haemolysis · haemorrhoids · hemiparesis · hepatitis · hypertension · migraine · mood changes · myelocytosis · nocturia · palpititation · peripheral neuropathy · pulmonary embolism · QT-interval prolongation · rectosigmoid cancer · renal failure · respiratory infections · skin reactions · sleep disorders · sweating · tachycardia · taste disturbances · thromboembolic events · tremor · urinary tract infections · vertigo · weight gain

CONCEPTION AND CONTRACEPTION

Ensure effective contraception during treatment.

PREGNANCY

Avoid—toxicity in animal studies.

BREAST FEEDING

Manufacturer advises avoid.

HEPATIC IMPAIRMENT

For idiopathic thrombocytopenic purpura, avoid unless potential benefit outweighs risk—reduce initial dose to 25 mg once daily. For thrombocytopenia associated with chronic hepatitis C infection, in severe hepatic impairment use only if potential benefit outweighs risk and monitor closely—increased risk of hepatic decompensation and thromboembolic events

- RENAL IMPAIRMENT
- Use with caution.

MONITORING REQUIREMENTS

- Monitor liver function before treatment, every two weeks when adjusting the dose, and monthly thereafter.
- Regular ophthalmological examinations for cataract formation recommended.
- For idiopathic thrombocytopenic purpura, monitor full blood count including platelet count and peripheral blood smears every week during treatment until a stable platelet count is reached (50 × 10^9/litre or more for at least 4 weeks), then monthly thereafter.
- For thrombocytopenia associated with chronic hepatitis C infection, monitor platelet count every week before and during antiviral treatment until a stable platelet count is reached (50–75 × 10^9/litre), then monitor full blood count including platelet count and peripheral blood smears monthly thereafter.

DIRECTIONS FOR ADMINISTRATION

Each dose should be taken at least 4 hours before or after any dairy products (or foods containing calcium), indigestion remedies, or medicines containing aluminium, calcium, iron, magnesium, zinc, or selenium to reduce possible interference with absorption.

PATIENT AND CARER ADVICE

Patient counselling is advised on how to administer eltrombopag tablets.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (July 2013) NICE TA293

Eltrombopag is recommended for the treatment of chronic immune (idiopathic) thrombocytopenic purpura in splenectomised adults refractory to other treatments, or as a second-line treatment in non-splenectomised adults when surgery is contraindicated, only if:

- the manufacturer provides eltrombopag at the agreed discount as part of the patient access scheme and
- their condition is refractory to standard active treatments and rescue therapies or
- they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies.

Patients currently receiving eltrombopag whose disease does not meet these criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA293

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (July 2010) that eltrombopag (Revolade®) is accepted for restricted use within NHS Scotland for the treatment of both splenectomised and non-splenectomised patients with severe symptomatic immune (idiopathic) thrombocytopenic purpura or a high risk of bleeding.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.
Romiplostim

INDICATIONS AND DOSE
Treatment of chronic idiopathic thrombocytopenic purpura in splenectomised patients refractory to other treatments (such as corticosteroids or immunoglobulins) (under expert supervision) – Second-line treatment of chronic idiopathic thrombocytopenic purpura in non-splenectomised patients when surgery is contra-indicated (under expert supervision)

BY SUBCUTANEOUS INJECTION

Adult: Initially 1 microgram/kg once weekly, adjusted in steps of 1 microgram/kg once weekly (max. per dose 10 micrograms/kg once weekly) until a stable platelet count of 50 x 10^9/litre or more is reached, discontinue treatment if inadequate response after 4 weeks at maximum dose, consult product literature for dose adjustments.

SIDE-EFFECTS
- Arthralgia
- Asthenia
- Bone pain
- Dizziness
- Ecchymosis
- Fatigue
- Flushing
- Gastro-intestinal disturbances
- Increased bone marrow reticulin
- Influenza-like symptoms
- Injection site reactions
- Insomnia
- Migraine
- Muscle spasm
- Myalgia
- Oedema
- Parasthesia
- Rash

PREGNANCY
Manufacturer advises use only if essential – toxicity in animal studies.

BREAST FEEDING
Manufacturer advises avoid – no information available.

HEPATIC IMPAIRMENT
Avoid in moderate or severe impairment unless potential benefit outweighs risk (e.g. of portal vein thrombosis).

RENAL IMPAIRMENT
Manufacturer advises caution – no information available.

MONITORING REQUIREMENTS
- Monitor full blood count and peripheral blood smears for morphological abnormalities before and during treatment.
- Monitor platelet count weekly until platelet count reaches
  50 x 10^9 /litre or more for at least 4 weeks without dose adjustment, then monthly thereafter.

PATIENT AND CARER ADVICE
- Dizziness may affect performance of skilled tasks (e.g. driving).

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (April 2011)

NICE TA221
Romiplostim is recommended for the treatment of chronic immune (idiopathic) thrombocytopenic purpura in adults:
- if the manufacturer provides romiplostim at the agreed discount as part of the patient access scheme and
- whose condition is refractory to standard active treatments and rescue therapies or
- who have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies.

www.nice.org.uk/TA221

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (September 2009) that romiplostim (Nplate®) is accepted for restricted use within NHS Scotland for patients with severe symptomatic idiopathic thrombocytopenic purpura or those at high risk of bleeding.

2 Fluid and electrolyte imbalances

Fluids and electrolytes

The electrolyte concentrations (intravenous fluid) table and the electrolyte content (gastro-intestinal secretions) table may be helpful in planning replacement electrolyte therapy; faeces, vomit, or aspiration should be saved and analysed where possible if abnormal losses are suspected.

Oral preparations for fluid and electrolyte imbalance
Sodium and potassium salts, may be given by mouth to prevent deficiencies or to treat established deficiencies of mild or moderate degree.

Oral potassium
Compensation for potassium loss is especially necessary:
- in those taking digoxin or anti-arrhythmic drugs, where potassium depletion may induce arrhythmias;
- in patients in whom secondary hyperaldosteronism occurs, e.g. renal artery stenosis, cirrhosis of the liver, the nephrotic syndrome, and severe heart failure;
- in patients with excessive losses of potassium in the faeces, e.g. chronic diarrhoea associated with intestinal malabsorption or laxative abuse.

Measures to compensate for potassium loss may also be required in the elderly since they frequently take inadequate amounts of potassium in the diet (but see warning on renal insufficiency). Measures may also be required during long-term administration of drugs known to induce potassium loss (e.g. corticosteroids). Potassium supplements are seldom required with the small doses of diuretics given to treat hypertension; potassium-sparing diuretics (rather than potassium supplements) are recommended for prevention of hypokalaemia due to diuretics such as furosemide p. 201 or the thiazides when these are given to eliminate oedema.

If potassium salts are used for the prevention of hypokalaemia, then doses of potassium chloride daily (in divided doses) by mouth are suitable in patients taking a normal diet. Smaller doses must be used if there is renal insufficiency (common in the elderly) to reduce the risk of hyperkalaemia.

Potassium salts cause nausea and vomiting and poor compliance is a major limitation to their effectiveness; when appropriate, potassium-sparing diuretics are preferable.

When there is established potassium depletion larger doses may be necessary, the quantity depending on the severity of any continuing potassium loss (monitoring of plasma-potassium concentration and specialist advice would be required). Potassium depletion is frequently associated with chloride depletion and with metabolic alkalosis, and these disorders require correction.

Management of hypokalaemia
Acute severe hypokalaemia (plasma-potassium concentration above 6.5 mmol/litre or in the presence of ECG changes) calls for urgent treatment with calcium...
glucose 10% p. 587 by slow intravenous injection, titrated and adjusted to ECG improvement, to temporarily protect against myocardial excitability. An intravenous injection of soluble insulin (5–10 units) with 50 mL glucose 50% p. 852, reduces serum-potassium concentration; this is repeated if necessary or a continuous infusion instituted. Salbutamol p. 222 [unlicensed indication], by nebulisation or slow intravenous injection may also reduce plasma-potassium concentration; it should be used with caution in patients with cardiovascular disease. The correction of causal or compounding acidosis with sodium bicarbonate p. 848 infusion should be considered (important: preparations of sodium bicarbonate and calcium salts should not be administered in the same line—risk of precipitation). Drugs exacerbating hyperkalaemia should be reviewed and stopped as appropriate; occasionally haemodialysis is needed. Ion-exchange resins may be used to remove excess potassium in mild hyperkalaemia or in moderate hyperkalaemia when there are no ECG changes.

**Oral sodium and water**

Sodium chloride p. 851 is indicated in states of sodium depletion and usually needs to be given intravenously. In chronic conditions associated with mild or moderate degrees of sodium depletion, e.g. in salt-losing bowel or renal disease, oral supplements of sodium chloride or sodium bicarbonate, according to the acid-base status of the patient, may be sufficient.

**Oral rehydration therapy (ORT)**

As a worldwide problem diarrhoea is by far the most important indication for fluid and electrolyte replacement. Intestinal absorption of sodium and water is enhanced by glucose (and other carbohydrates). Replacement of fluid and electrolytes lost through diarrhoea can therefore be achieved by oral solutions containing sodium, potassium, and glucose or another carbohydrate such as rice starch. Oral rehydration solutions should:

- enhance the absorption of water and electrolytes;
- replace the electrolyte deficit adequately and safely;
- contain an alkalinising agent to counter acidosis;
- be slightly hypo-osmolar (about 250 mmol/litre) to prevent the possible induction of osmotic diarrhoea;
- be simple to use in hospital and at home;
- be palatable and acceptable, especially to children;
- be readily available.

It is the policy of the World Health Organization (WHO) to promote a single oral rehydration solution but to use it flexibly (e.g. by giving extra water between drinks of oral rehydration solution to moderately dehydrated infants).

The WHO oral rehydration salts formulation contains sodium chloride 2.6 g, potassium chloride 1.5 g, sodium citrate 2.9 g, anhydrous glucose 13.5 g. Its is dissolved in sufficient water to produce 1 litre (providing Na⁺ 75 mmol, K⁺ 20 mmol, Cl⁻ 65 mmol, citrate 10 mmol, glucose 75 mmol/litre). This formulation is recommended by the WHO and the United Nations Children’s fund, but it is not commonly used in the UK. Oral rehydration solutions used in the UK are lower in sodium (50–60 mmol/litre) than the WHO formulation since, in general, patients suffer less severe sodium loss.

Rehydration should be rapid over 3 to 4 hours (except in hypernatraemic dehydration in which case rehydration should occur more slowly over 12 hours). The patient should be reassessed after initial rehydration and if still dehydrated rapid fluid replacement should continue.

Once rehydration is complete further dehydration is prevented by encouraging the patient to drink normal volumes of an appropriate fluid and by replacing continuing losses with an oral rehydration solution; in infants, breast-feeding or formula feeds should be offered between oral rehydration drinks.

---

**Fluid and electrolyte imbalances**

**Oral bicarbonate**

Sodium bicarbonate p. 848 is given by mouth for **chronic acidotic states** such as uremic acidosis or renal tubular acidosis. The dose for correction of metabolic acidosis is not predictable and the response must be assessed. For severe metabolic acidosis, sodium bicarbonate can be given intravenously.

Sodium bicarbonate may also be used to increase the pH of the urine; it is also used in dyspepsia.

Sodium supplements may increase blood pressure or cause fluid retention and pulmonary oedema in those at risk; hypokalaemia may be exacerbated.

Where **hyperchloremic acidosis** is associated with potassium deficiency, as in some renal tubular and gastrointestinal disorders it may be appropriate to give oral **potassium bicarbonate**, although acute or severe deficiency should be managed by intravenous therapy.

**Parenteral preparations for fluid and electrolyte imbalance**

**Electrolytes and water**

Solutions of electrolytes are given intravenously, to meet normal fluid and electrolyte requirements or to replenish major deficits or continuing losses, when the patient is nauseated or vomiting and is unable to take adequate amounts by mouth. When intravenous administration is not possible, fluid (as sodium chloride 0.9% p. 851 or glucose 5% p. 852) can also be given by subcutaneous infusion (hypodermoclysis).

The nature and severity of the electrolyte imbalance must be assessed from the history and clinical and biochemical investigations. Sodium, potassium, chloride, magnesium, phosphate, and water depletion can occur singly and in combination with or without disturbances of acid-base balance.

Isotonic solutions may be infused safely into a peripheral vein. Solutions more concentrated than plasma, e.g. 20% glucose p. 852, are best given through an indwelling catheter positioned in a large vein.

**Intravenous sodium**

Sodium chloride in isotonic solution provides the most important extracellular ions in near physiological concentrations and is indicated in **sodium depletion**, which can arise from such conditions as gastro-enteritis, diabetic ketoacidosis, ileus, and ascites. In a severe deficit of 4 to 8 litres, 2 to 3 litres of isotonic sodium chloride may be given over 2 to 3 hours; thereafter the infusion can usually be at a slower rate.

**Chronic hyponatraemia** arising from inappropriate secretion of antidiuretic hormone should ideally be corrected by fluid restriction. However, if sodium chloride is required for acute or chronic hyponatraemia, regardless of the cause, the deficit should be corrected slowly to avoid the risk of osmotic demyelination syndrome and the rise in plasma-sodium concentration should not exceed 10 mmol/litre in 24 hours. In severe hyponatraemia, sodium chloride 1.8% may be used cautiously.

**Compound sodium lactate** (Hartmann’s solution) can be used instead of isotonic sodium chloride solution during or after surgery, or in the initial management of the injured or wounded; it may reduce the risk of hyperchloremic acidosis.

Glucose with sodium chloride solutions are indicated when there is combined **water and sodium depletion**. A 1:1 mixture of isotonic sodium chloride and 5% glucose allows some of the water (free of sodium) to enter body cells which suffer most from dehydration while the sodium salt with a volume of water determined by the normal plasma Na⁺ remains extracellular.

Combined sodium, potassium, chloride, and water depletion may occur, for example, with severe diarrhoea or persistent vomiting; replacement is carried out with sodium...
Electrolyte concentrations—intravenous fluids

<table>
<thead>
<tr>
<th>Intravenous infusion</th>
<th>Na⁺</th>
<th>K⁺</th>
<th>HCO₃⁻</th>
<th>Cl⁻</th>
<th>Ca²⁺</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal plasma values</td>
<td>142</td>
<td>4.5</td>
<td>26</td>
<td>103</td>
<td>2.5</td>
</tr>
<tr>
<td>Sodium Chloride 0.9%</td>
<td>150</td>
<td>-</td>
<td>-</td>
<td>150</td>
<td>-</td>
</tr>
<tr>
<td>Compound Sodium Lactate (Hartmann’s)</td>
<td>131</td>
<td>5</td>
<td>29</td>
<td>111</td>
<td>2</td>
</tr>
<tr>
<td>Sodium Chloride 0.18% and Glucose 4% (Adults only)</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>30</td>
<td>-</td>
</tr>
<tr>
<td>Potassium Chloride 0.3% and Glucose 5%</td>
<td>-</td>
<td>40</td>
<td>-</td>
<td>40</td>
<td>-</td>
</tr>
<tr>
<td>Potassium Chloride 0.3% and Sodium Chloride 0.9%</td>
<td>150</td>
<td>40</td>
<td>-</td>
<td>190</td>
<td>-</td>
</tr>
</tbody>
</table>

To correct metabolic acidosis
- Sodium Bicarbonate 1.26%: 150 - 150 - - -
- Sodium Bicarbonate 8.4% for cardiac arrest: 1000 - 1000 - - -
- Sodium Lactate (m/6): 167 - 167 - - -

Electrolyte content—gastro-intestinal secretions

<table>
<thead>
<tr>
<th>Type of fluid</th>
<th>H⁺</th>
<th>Na⁺</th>
<th>K⁺</th>
<th>HCO₃⁻</th>
<th>Cl⁻</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric</td>
<td>40-60</td>
<td>20-80</td>
<td>5-20</td>
<td>-</td>
<td>100-150</td>
</tr>
<tr>
<td>Biliary</td>
<td>-</td>
<td>120-140</td>
<td>5-15</td>
<td>30-50</td>
<td>80-120</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>-</td>
<td>120-140</td>
<td>5-15</td>
<td>70-110</td>
<td>40-80</td>
</tr>
<tr>
<td>Small bowel</td>
<td>-</td>
<td>120-140</td>
<td>5-15</td>
<td>20-40</td>
<td>90-130</td>
</tr>
</tbody>
</table>

chloride p. 851 intravenous infusion 0.9% and glucose p. 852 intravenous infusion 5% with potassium as appropriate.

**Intravenous glucose**
Glucose solutions (5%) are used mainly to replace water deficit. Average water requirements in a healthy adult are 1.5 to 2.5 litres daily and this is needed to balance unavoidable losses of water through the skin and lungs and to provide sufficient for urinary excretion. Water depletion (dehydration) tends to occur when these losses are not matched by a comparable intake, as may occur in coma or dysphagia or in the elderly or apathetic who may not drink enough water on their own initiative.

Excessive loss of water without loss of electrolytes is uncommon, occurring in fevers, hyperthyroidism, and in uncommon water-losing renal states such as diabetes insipidus or hypercalcaemia. The volume of glucose p. 852 solution needed to replace deficits varies with the severity of the disorder, but usually lies within the range of 2 to 6 litres.

Glucose solutions are also used to correct and prevent hypoglycaemia and to provide a source of energy in those too ill to be fed adequately by mouth; glucose solutions are a key component of parenteral nutrition.

Glucose solutions are given in regimens with calcium and insulin for the emergency management of hyperkalaemia. They are also given, after correction of hyperglycaemia, during treatment of diabetic ketoacidosis, when they must be accompanied by continuing insulin infusion.

**Intravenous potassium**
Potassium chloride with sodium chloride intravenous infusion is the initial treatment for the correction of severe hypokalaemia and when sufficient potassium cannot be taken by mouth.

Repeated measurement of plasma-potassium concentration is necessary to determine whether further infusions are required and to avoid the development of hyperkalaemia, which is especially likely in renal impairment.

Initial potassium replacement therapy should not involve glucose infusions, because glucose may cause a further decrease in the plasma-potassium concentration.

**Bicarbonate and lactate**
Sodium bicarbonate p. 848 is used to control severe metabolic acidosis (pH<7.1) particularly that caused by loss of bicarbonate (as in renal tubular acidosis or from excessive gastro-intestinal losses). Mild metabolic acidosis associated with volume depletion should first be managed by appropriate fluid replacement because acidosis usually resolves as tissue and renal perfusion are restored. In more severe metabolic acidosis or when the acidosis remains unresponsive to correction of anoxia or hypovolaemia, sodium bicarbonate (1.26%) can be infused over 3–4 hours with plasma-pH and electrolyte monitoring. In severe shock, for example in cardiac arrest, metabolic acidosis can develop without sodium or volume depletion; in these circumstances sodium bicarbonate is best given as a small volume of hypertonic solution, such as 50 mL of 8.4% solution intravenously.

Sodium lactate intravenous infusion is no longer used in metabolic acidosis because of the risk of producing lactic acidosis, particularly in seriously ill patients with poor tissue perfusion or impaired hepatic function.

For chronic acidotic states, sodium bicarbonate can be given by mouth.

**Plasma and plasma substitutes**
Plasma and plasma substitutes (‘colloids’) contain large molecules that do not readily leave the intravascular space where they exert osmotic pressure to maintain circulatory volume. Compared to fluids containing electrolytes such as sodium chloride p. 851 and glucose p. 852 (‘crystalloids’), a smaller volume of colloid is required to produce the same expansion of blood volume, thereby shifting salt and water from the extravascular space. If resuscitation requires a volume of fluid that exceeds the maximum dose of the colloid then crystalloids can be given; packed red cells may also be required.

Albumin solution p. 853, prepared from whole blood, contains soluble proteins and electrolytes but no clotting factors, blood group antibodies, or plasma cholinesterases; they may be given without regard to the recipient’s blood group.

Albumin is usually used after the acute phase of illness, to correct a plasma-volume deficit; hypoalbuminaemia itself is
not an appropriate indication. The use of albumin solution in acute plasma or blood loss may be wasteful; plasma substitutes are more appropriate. Concentrated albumin solution (20%) can be used under specialist supervision in patients with an intravascular fluid deficit and oedema because of interstitial fluid overload, to restore intravascular plasma volume with less exacerbation of the salt and water overload than isotonic solutions. Concentrated albumin solution may also be used to obtain a diuresis in hypoalbuminaemic patients (e.g. in hepatic cirrhosis).

Recent evidence does not support the previous view that the use of albumin increases mortality.

**Plasma substitutes**

Dextran, gelatin p. 854, and the hydroxyethyl starch, tetrasarach, are macromolecular substances which are metabolised slowly. Dextran and gelatin may be used at the outset to expand and maintain blood volume in shock arising from conditions such as burns or septicemia; they may also be used as an immediate short-term measure to treat haemorrhage until blood is available. Dextran and gelatin are rarely needed when shock is due to sodium and water depletion because, in these circumstances, the shock responds to water and electrolyte repletion.

Hydroxyethyl starches should only be used for the treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient; they should be used at the lowest effective dose for the first 24 hours of fluid resuscitation.

Plasma substitutes should not be used to maintain plasma volume in conditions such as burns or peritonitis where there is loss of plasma protein, water, and electrolytes over periods of several days or weeks. In these situations, plasma or plasma protein fractions containing large amounts of albumin should be given.

Large volumes of some plasma substitutes can increase the risk of bleeding through depletion of coagulation factors.

### BICARBONATE

**Sodium bicarbonate**

**INDICATIONS AND DOSE**

**Chronic acidotic states such as uraemic acidosis or renal tubular acidosis**

**BY MOUTH**

- Adult: 4.8 g daily, (57 mmol each of Na⁺ and HCO₃⁻), higher doses may be required and should be adjusted according to response

**Severe metabolic acidosis**

**BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- Adult: Administer an amount appropriate to the body base deficit, to be given by slow intravenous injection of a strong solution (up to 8.4%), or by continuous intravenous infusion of a weaker solution (usually 1.26%)

**Alkalisation of urine | Relief of discomfort in mild urinary-tract infections**

**BY MOUTH**

- Adult: 3 g every 2 hours until urinary pH exceeds 7, to be dissolved in water

**Maintenance of alkaline urine**

**BY MOUTH**

- Adult: 5–10 g daily, to be dissolved in water

**CONTRA-INDICATIONS** Salt restricted diet

**CAUTIONS** Avoid prolonged use in urinary conditions - cardiac disease - elderly - patients on sodium-restricted diet - respiratory acidosis

**INTERACTIONS** → Appendix 1 (antacids).

**SIDE-EFFECTS**

- When used for chronic acidotic states such as uraemic acidosis or renal tubular acidosis, and for maintenance of alkaline urine fluid retention (in those at risk) - hypokalaemia may be exacerbated - increase blood pressure - pulmonary oedema (in those at risk)

- When used for alkalisation of urine, and for relief of discomfort in mild urinary-tract infections alkalosis on prolonged use - eruption

**PREGNANCY** Use with caution in urinary conditions.

**HEPATIC IMPAIRMENT** In patients with fluid retention, avoid large amounts of sodium.

**RENAL IMPAIRMENT** Avoid (except for specialised role in some forms of renal disease).

**MONITORING REQUIREMENTS**

- With intravenous use Plasma pH and electrolytes should be monitored.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For slow intravenous injection use a small volume of hypertonic solution (such as 50 mL of 8.4%). For continuous intravenous infusion a weaker solution of 1.26% can be infused over 3–4 hours.

- With oral use Sodium bicarbonate may affect the stability or absorption of other drugs if administered at the same time. If possible, allow 1–2 hours before administering other drugs orally.

**PRESCRIBING AND DISPENSING INFORMATION** Oral solutions of sodium bicarbonate are required occasionally; these are available from ‘special-order’ manufacturers or specialist importing companies; the strength of sodium bicarbonate should be stated on the prescription.

**PATIENT AND CARER ADVICE** Patients or carers should be given advice on the administration of sodium bicarbonate oral medicines.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral suspension, oral solution, powder, capsule, liquid, mouthwash

**Tablet**

- SODIUM BICARBONATE (Non-proprietary) Sodium bicarbonate 600 mg Sodium bicarbonate 600mg tablets

**Capsule**

- SODIUM BICARBONATE (Non-proprietary) Sodium bicarbonate 500 mg Sodium bicarbonate 500mg capsules 56 capsule (no price available DT price = £2.88) 100 capsule (no price available)

**Solution for injection**

- SODIUM BICARBONATE (Non-proprietary) Sodium bicarbonate 84 mg per 1 ml Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 10ml ampoules 10 ampoule £67.01 Sodium bicarbonate 8.4% solution for injection 10ml Minijet pre-filled syringes 11 pre-filled disposable inject (no price available) £9.71 Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 250ml bottles 10 bottle £105.34 Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 100ml bottles 10 bottle £62.04

**Infusion**

- SODIUM BICARBONATE (Non-proprietary) Sodium bicarbonate 12.6 mg per 1 ml Polyfusor BC sodium bicarbonate 1.26% infusion 500ml bottles 1 bottle £8.94 12 bottle (no price available) Sodium bicarbonate 14 mg per 1 ml Polyfusor BD sodium bicarbonate 1.4% infusion 500ml bottles 1 bottle £9.54 12 bottle (no price available) Sodium bicarbonate 27.4 mg per 1 ml Polyfusor V sodium bicarbonate 2.74% infusion 500ml bottles 1 bottle £15.94 12 bottle (no price available) Sodium bicarbonate 42 mg per 1 ml Polyfusor E sodium bicarbonate 4.2% infusion 500ml bottles 1 bottle £19.94 12 bottle (no price available)
**ORAL REHYDRATION SALTS**

**Disodium hydrogen citrate with glucose, potassium chloride and sodium chloride**

**INDICATIONS AND DOSE**

**Fluid and electrolyte loss in diarrhoea**

- **BY MOUTH**
  - Adult: 200–400 mL, to be given after every loose motion, dose according to fluid loss

- **INDICATIONS AND DOSE**
  - Fluid and electrolyte loss in diarrhoea

**DIRECTIONS FOR ADMINISTRATION**

Reconstitute 1 sachet with 200 mL of water (freshly boiled and cooled for infants); 5 sachets reconstituted with 1 litre of water provide Na⁺ 60 mmol, K⁺ 20 mmol, Cl⁻ 60 mmol, citrate 10 mmol, and glucose 90 mmol.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral powder formulations may include black currant, citrus, or natural.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Oral rehydration salts www.medicinesforchildren.org.uk/oral-rehydration-salts

After reconstitution any unused solution should be discarded no later than 1 hour after preparation unless stored in a refrigerator when it may be kept for up to 24 hours.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder**

- **Dioralyte** (Sanofi)
  - Potassium chloride 300 mg, Rice powder pre-cooked 6 gram, Sodium chloride 350 mg, Sodium citrate 580 mg Dioralyte relief oral powder sachets blackcurrant (sugar-free) | 20 sachet £7.13

**Potassium chloride with glucose, sodium bicarbonate and sodium chloride**

**INDICATIONS AND DOSE**

**Fluid and electrolyte loss in diarrhoea**

- **BY MOUTH**
  - Adult: 200–400 mL, to be given after every loose motion, dose according to fluid loss

**DIRECTIONS FOR ADMINISTRATION**

Reconstitute 1 sachet with 200 mL of water (freshly boiled and cooled for infants); 5 sachets when reconstituted with 1 litre of water provide Na⁺ 50 mmol, K⁺ 20 mmol, Cl⁻ 40 mmol, HCO₃⁻ 30 mmol, and glucose 111 mmol.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral powder formulations may include banana, orange, black current, lemon and lime, plain, or multi-flavoured.

**PATIENT AND CARER ADVICE**

Patients and carers should be advised how to reconstitute *Electrolyte*® oral powder.

After reconstitution any unused solution should be discarded no later than 1 hour after preparation unless stored in a refrigerator when it may be kept for up to 24 hours.

**Potassium chloride with calcium chloride dihydrate, and sodium chloride**

(Ringer’s solution)

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 863, sodium chloride p. 851.

**INDICATIONS AND DOSE**

**Electrolyte imbalance**

- **BY INTRAVENOUS INFUSION**
  - Adult: Dosed according to the deficit or daily maintenance requirements (consult product literature)

**DIRECTIONS FOR ADMINISTRATION**

Reconstitute 1 sachet with 200 mL of water (freshly boiled and cooled for infants); 5 sachets when reconstituted with 1 litre of water provide Na⁺ 60 mmol, K⁺ 20 mmol, Cl⁻ 50 mmol and citrate 10 mmol.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral powder formulations may include apricot, black currant, or raspberry.

**PATIENT AND CARER ADVICE**

Patients and carers should be advised how to reconstitute Dioralyte® Relief oral powder.

After reconstitution any unused solution should be discarded no later than 1 hour after preparation unless stored in a refrigerator when it may be kept for up to 24 hours.
### Potassium chloride with calcium chloride, sodium chloride and sodium lactate

(Sodium Lactate Intravenous Infusion, Compound; Hartmann’s Solution for Injection; Ringer-Lactate Solution for Injection)

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 863, sodium chloride p. 851, calcium chloride p. 857.

#### Indications and Dose

For prophylaxis, and replacement therapy, requiring the use of sodium chloride and lactate, with minimal amounts of calcium and potassium.

**By Intravenous Infusion**
- Adult: (consult product literature)

#### Prescribing and Dispensing Information

Compound sodium lactate intravenous infusion contains Na+ 131 mmol, K+ 5 mmol, Ca2+ 2 mmol, HCO3− (as lactate) 29 mmol, Cl− 111 mmol/litre.

#### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Infusion**
- **Calcium Chloride with Potassium Chloride and Sodium Chloride and Sodium Lactate** (Non-proprietary)
  - Calcium chloride 270 microgram per 1 ml, Potassium chloride 400 microgram per 1 ml, Sodium chloride 6 mg per 1 ml, Sodium lactate 3.17 mg per 1 ml
- Sodium lactate compound infusion 1 litre (1 bag £0.67 / 10 bag £6.70 no price available)

### Potassium chloride with glucose

The properties listed below are those particular to the combination only. For the properties of the components please consider, glucose p. 852, potassium chloride p. 863.

#### Indications and Dose

Electrolyte imbalance.

**By Intravenous Infusion**
- Adult: Dosed according to the deficit or daily maintenance requirements

#### Prescribing and Dispensing Information

Concentration of potassium chloride to be specified by the prescriber (usually K+ 10–40 mmol/litre).

#### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

<table>
<thead>
<tr>
<th>Infusion</th>
<th>£1.67</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose anhydrous 40 mg per 1 ml, Potassium chloride 3 mg per 1 ml</td>
<td>1 bag</td>
</tr>
<tr>
<td>Potassium chloride 0.2% (potassium 13.3mmol/500ml) / glucose 5% infusion 500ml bags</td>
<td></td>
</tr>
</tbody>
</table>

### Potassium chloride with potassium bicarbonate

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 863.

#### Indications and Dose

Potassium depletion.

**By Mouth**
- Adult: Dosed according to the deficit or daily maintenance requirements (consult product literature)

#### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Effervescent tablet</th>
<th>£7.65</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sando-K (HK Pharma Ltd) Potassium bicarbonate 400 mg, Potassium chloride 600 mg</td>
<td>100 tablet</td>
</tr>
</tbody>
</table>
Potassium chloride with sodium chloride

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 863, sodium chloride below.

**INDICATIONS AND DOSE**

**Electrolyte imbalance**

**BY INTRAVENOUS INFUSION**

- Adult: Depending on the deficit or the daily maintenance requirements (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion, infusion

**INFUSION**

- POTASSIUM CHLORIDE WITH SODIUM CHLORIDE (Non-proprietary)

Potassium chloride 3 mg per 1 ml, Sodium chloride 9 mg per 1 ml Potassium chloride 0.3% (potassium 20mmol/500ml) / sodium chloride 0.9% infusion 500ml bags | 1 bag (POM) £1.42

Potassium chloride 3% (potassium 40mmol/1litre) / Sodium chloride 0.9% infusion 1 litre bags | 1 bag (POM) £1.79

Potassium chloride 1.5 mg per 1 ml, Sodium chloride 9 mg per 1 ml Potassium chloride 0.19% (potassium 10mmol/500ml) / sodium chloride 0.9% infusion 500ml bags | 1 bag (POM) £1.67

Potassium chloride 0.15% (potassium 20mmol/1litre) / sodium chloride 0.9% infusion 1litre bags | 1 bag (POM) £2.20 | 10 bag (POM) £22.00

Potassium chloride 2 mg per 1 ml, Sodium chloride 9 mg per 1 ml Potassium chloride 0.2% (potassium 13.3mmol/500ml) / sodium chloride 0.9% infusion 500ml bags | 1 bag (POM) £1.67

Potassium chloride 0.2% (potassium 27mmol/1litre) / sodium chloride 0.9% infusion 1litre bags | 1 bag (POM) £2.20

**SIDE-EFFECTS**

With intravenous use administration of large doses may give rise to sodium accumulation, hyperchloremic acidosis, oedema

**MONITORING REQUIREMENTS**

- Adult: Management of diabetic ketoacidosis (if systolic blood pressure is below 90 mmHg and adjusted for age, sex, and medication as appropriate)

**BY INTRAVENOUS INFUSION**

- Adult: 500 ml, sodium chloride 0.9% to be given over 10–15 minutes, repeat if blood pressure remains below 90 mmHg and seek senior medical advice, when blood pressure is over 90 mmHg, sodium chloride 0.9% should be given by intravenous infusion at a rate that replaces deficit and provides maintenance, management regimen also includes administration of potassium chloride, soluble insulin, long acting insulin analogues and glucose 10% solution

**Diluent for instillation of drugs to the bladder**

**BY INTRAVESICAL INSTILLATION**

- Adult: (consult product literature)

**CAUTIONS**

**GENERAL CAUTIONS:**

- Dilutional hyponatraemia especially in children and the elderly

**SPECIFIC CAUTIONS:**

- With intravenous use avoid excessive administration, cardiac failure, hypertension, peripheral oedema, pulmonary oedema, restrict intake in impaired renal function, toxaemia of pregnancy

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, solution for injection, irrigation, solution for infusion, oral solution, capsule, eye ointment, nebuliser liquid, infusion

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 25**

- Slow Sodium (Hikpharma Ltd)

Sodium chloride 600 mg Slow Sodium 600mg tablets | 100 tablet (GEL) £6.05 DT price + £6.05

**Solution for injection**

- SODIUM CHLORIDE (Non-proprietary)

Sodium chloride 9 mg per 1 ml Sodium chloride 0.9% solution for injection 2ml ampoules | 10 ampoule (POM) £1.80–£2.57 DT price + £2.07

Sodium chloride 0.9% solution for injection 5ml ampoules | 10 ampoule (POM) £2.00–£2.12 DT price + £2.12 | 50 ampoule (POM) £10.50–£13.50

Sodium chloride 0.9% solution for injection 10ml ampoules | 10 ampoule (POM) £2.30–£2.97 DT price + £2.96 | 50 ampoule (POM) £14.75–£16.75

Sodium chloride 0.9% solution for injection 20ml ampoules | 20 ampoule (POM) £15.75–£16.75

Sodium chloride 0.9% solution for injection 50ml vials | 1 vial (POM) £3.41 | 25 vial (POM) £75.00–£85.00

Sodium chloride 300 mg per 1 ml Sodium chloride 30% solution for injection 10ml ampoules | 10 ampoule (POM) £64.25

Sodium chloride 30% solution for injection 50ml vials | 1 vial (POM) £10.67

**Infusion**

- SODIUM CHLORIDE (Non-proprietary)

Sodium chloride 1.8 mg per 1 ml Sodium chloride 0.18% infusion 500ml bottles | 1 bottle (POM) £3.28

Sodium chloride 4.5 mg per 1 ml Sodium chloride 0.45% infusion 500ml bottles | 1 bottle (POM) £3.28

Sodium chloride 0.45% infusion 500ml bags | 1 bag (POM) £1.38

Sodium chloride 9 mg per 1 ml Sodium chloride 0.9% infusion 50ml bags | 1 bag (POM) £1.49

Sodium chloride 0.9% infusion 100ml bags | 1 bag (POM) £1.27

Sodium chloride 0.9% infusion 250ml bags | 1 bag (POM) £1.61

Sodium chloride 0.9% infusion 500ml bags | 1 bag (POM) £1.61

Sodium chloride 0.9% infusion 1litre bags | 1 bag (POM) no price available

Sodium chloride 0.9% infusion 2litre bags | 1 bag (POM) £3.01

Sodium chloride 0.9% infusion 100ml polyethylene bottles | 1 bottle (POM) £0.55 | 20 bottle (POM) £11.00

Sodium chloride 18 mg per 1 ml Sodium chloride 1.8% infusion 500ml bottles | 1 bottle (POM) £3.28

Sodium chloride 27 mg per 1 ml Sodium chloride 2.7% infusion 500ml bottles | 1 bottle (POM) £3.28

Sodium chloride 50 mg per 1 ml Sodium chloride 5% infusion 500ml bottles | 1 bottle (POM) £3.28

**SIDE-EFFECTS**

- Adult: The jugular venous pressure should be assessed, the bases of the lungs should be examined for crepitations, and in elderly or seriously ill patients it is often helpful to monitor the right atrial (central) venous pressure.

**PRESCRIBING AND DISPENSING INFORMATION**

- Adult: With intravenous use The term ‘normal saline’ should not be used to describe sodium chloride intravenous infusion 0.9%; the term ‘physiological saline’ is acceptable but it is preferable to give the composition (i.e. sodium chloride intravenous infusion 0.9%).

**SODIUM**

Sodium chloride

**INDICATIONS AND DOSE**

**Prophylaxis of sodium chloride deficiency**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adult: 4–8 tablets daily, to be taken with water, up to maximum 20 tablets daily in severe depletion

**Chronic renal salt wasting**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Adult: Up to 20 tablets daily, to be taken with appropriate fluid intake

**Management of diabetic ketoacidosis (if systolic blood pressure is below 90 mmHg and adjusted for age, sex, and medication as appropriate)**

**BY INTRAVENOUS INFUSION**

- Adult: 500 ml, sodium chloride 0.9% to be given over 10–15 minutes, repeat if blood pressure remains below 90 mmHg and seek senior medical advice, when blood pressure is over 90 mmHg, sodium chloride 0.9% should be given by intravenous infusion at a rate that replaces deficit and provides maintenance, management regimen also includes administration of potassium chloride, soluble insulin, long acting insulin analogues and glucose 10% solution

**Blood and nutrition**
Intravesical solution
▶ SODIUM CHLORIDE (Non-proprietary)
Sodium chloride 9 mg per 1 ml Sodium chloride 0.9% intravesical solution 50ml bags | 1 bag £0.66

Sodium chloride with glucose
The properties listed below are those particular to the combination only. For the properties of the components please consider, glucose below, sodium chloride p. 851.

INDICATIONS AND DOSE
Combined water and sodium depletion
BY INTRAVENOUS INFUSION
▶ Adult: (consult product literature)

Monitoring requirements
Maintenance fluid should accurately reflect daily requirements and close monitoring is required to avoid fluid and electrolyte imbalance.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

Infusion
▶ GLUCOSE WITH SODIUM CHLORIDE (Non-proprietary)
Glucose anhydrous 25 mg per 1 ml, Sodium chloride 4.5 mg per 1 ml Sodium chloride 0.45% / glucose 2.5% infusion 500ml bags | 1 bag no price available
Sodium chloride 0.45% / glucose 2.5% infusion 500ml bags | 1 bag no price available
Glucose anhydrous 40 mg per 1 ml, Sodium chloride 1.8 mg per 1 ml Sodium chloride 0.18% / glucose 4% infusion 1litre bags | 1 bag no price available
Glucose anhydrous 50 mg per 1 ml, Sodium chloride 0.9% glucose BP 9% / sodium chloride 0.9% infusion 50ml bags | 1 bag £0.92
Glucose 50 mg per 1 ml, Sodium chloride 9 mg per 1 ml Sodium chloride 0.9% / glucose 5% infusion 500ml bags | 1 bag £0.27
Glucose 5% / sodium chloride 0.9% infusion 1litre bags | 1 bag £2.10 | 10 bag £21.00
Glucose anhydrous 50 mg per 1 ml, Sodium chloride 4.5 mg per 1 ml Sodium chloride 0.18% / glucose 4% infusion 500ml bags | 1 bag £1.10
Glucose anhydrous 100 mg per 1 ml, Sodium chloride 1.8 mg per 1 ml Sodium chloride 0.18% / glucose anhydrous 500ml bags | 1 bag £0.67

SUGARS
Glucose
(Dextrose Monohydrate)

INDICATIONS AND DOSE
Energy source
BY INTRAVENOUS INFUSION
▶ Adult: 1–3 litres daily, solution concentration of 20–50% to be administered

Water replacement
BY INTRAVENOUS INFUSION
▶ Adult: The volume of glucose solution needed to replace deficits may vary (consult product literature)

Hypoglycaemia
BY INTRAVENOUS INFUSION
▶ Child: 500 mg/kg, to be administered as Glucose 10% intravenous infusion into a large vein through a large-gauge needle; care is required since this concentration is irritant especially if extravasation occurs
▶ Adult: 10 g, to be administered as Glucose 20% intravenous infusion into a large vein through a large-gauge needle; care is required since this concentration is irritant especially if extravasation occurs

Management of diabetic ketoacidosis
BY INTRAVENOUS INFUSION
▶ Child: Glucose 5% or 10% should be added to replacement fluid once blood-glucose concentration falls below 14 mmol/litre
▶ Adult: Glucose 10% should be given once blood-glucose concentration falls below 14 mmol/litre, to be administered into a large vein through a large-gauge needle at a rate of 125 mL/hour, in addition to the sodium chloride 0.9% infusion

Oral glucose tolerance test
BY MOUTH
▶ Adult: Test dose 75 g, anhydrous glucose to be given to the fasting patient and blood-glucose concentrations measured at intervals, to be given with 200–300 mL fluid

Establish presence of gestational diabetes
BY MOUTH
▶ Adult: Test dose 75 g, anhydrous glucose to be given to the fasting patient and blood-glucose concentrations measured at intervals, to be given with 200–300 mL fluid

Persistent cyanosis (in combination with propranolol) when blood glucose less than 3 mmol/litre (followed by morphine)
BY INTRAVENOUS INFUSION
▶ Child: 200 mg/kg, to be administered as Glucose 10% intravenous infusion over 10 minutes

Dose equivalence and conversion
75 g anhydrous glucose is equivalent to Glucose BP 82.5 g.

CAUTIONS
Do not give alone except when there is no significant loss of electrolytes - prolonged administration of glucose solutions without electrolytes can lead to hyponatraemia and other electrolyte disturbances

CAUTIONS, FURTHER INFORMATION
▶ With intravenous use in children Glucose 4% intravenous infusion fluid should not be used for fluid replacement in children aged 16 years or less because of the risk of hyponatraemia; availability of this infusion should be restricted to high dependency and intensive care units, and specialist wards, such as renal, liver, and cardiac units. Local guidelines on intravenous fluids should be consulted.

SIDE-EFFECTS
Glucose injections especially if hypertonic may have a low pH and may cause venous irritation and thrombophlebitis

DIRECTIONS FOR ADMINISTRATION
▶ With intravenous use in children Injections containing more than 10% glucose can be irritant and should be given into a central venous line; however, solutions containing up to 12.5% can be administered for a short period into a peripheral line.

PRESCRIBING AND DISPENSING INFORMATION
Glucose BP is the monohydrate but Glucose Intravenous Infusion BP is a sterile solution of anhydrous glucose or glucose monohydrate, potency being expressed in terms of anhydrous glucose.

EXCEPTIONS TO LEGAL CATEGORY
▶ With intravenous use Prescription only medicine restriction does not apply to 50% solution where administration is for saving life in emergency.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for infusion
**Oral solution**

- **Rapilose OGTT** (Aspire Pharma Ltd)

**Glucose 250 mg per 1 ml** Rapilose OGTT solution | 300 ml £3.48

**Infusion**

- **GLUCOSE (Non-proprietary)**

  Glucose anhydrous 50 mg per 1 ml Glucose 5% infusion 50ml bags | 1 bag | no price available
  Glucose 5% infusion 100ml bags | 1 bag | £1.27
  Glucose 5% infusion 250ml bags | 1 bag | no price available
  Glucose 5% infusion 500ml bags | 1 bag | £1.27
  Glucose 5% infusion 1 litre bags | 1 bag | no price available
  Glucose 5% infusion 500ml bottles | 1 bottle | £2.14
  Glucose 5% infusion 1 litre bottles | 1 bottle | £2.88
  Glucose anhydrous 100 mg per 1 ml Glucose 10% infusion 500ml bags | 1 bag | £1.76
  Glucose 10% infusion 1 litre bags | 1 bag | £2.42
  Glucose anhydrous 200 mg per 1 ml Glucose 20% infusion 500ml bags | 1 bag | £2.31
  Glucose anhydrous 400 mg per 1 ml Glucose 40% infusion 500ml bags | 1 bag | £2.81
  Glucose anhydrous 500 mg per 1 ml Glucose 50% infusion 500ml bags | 1 bag | £3.10
  Glucose 50% infusion 500ml polyethylene bottles | 1 bottle | £2.94

**Solution for infusion**

- **GLUCOSE (Non-proprietary)**

  Glucose anhydrous 200 mg per 1 ml Glucose 20% solution for infusion 100ml vials | 1 vial | £3.50
  Glucose anhydrous 500 mg per 1 ml Glucose 50% solution for infusion 20ml ampoules | 10 ampoules | £10.00-£12.50
  Glucose 50% solution for infusion 50ml vials | 1 vial | £2.01 DT price = £2.01 | 25 vial | £45.00-£50.00

Also available in combination with potassium chloride, p. 850
- potassium chloride and sodium chloride, p. 850

## 2.1 Low blood volume

### COLLOIDS

#### Albumin solution

*Human albumin solution*

**INDICATIONS AND DOSE**

Acute or sub-acute loss of plasma volume e.g. in burns, pancreatitis, trauma, and complications of surgery (with isotonic solutions) | Plasma exchange (with isotonic solutions) | Severe hypoaalbuminaemia associated with low plasma volume and generalised oedema where salt and water restriction with plasma volume expansion are required (with concentrated solutions 20%) | Adjunct in the treatment of hyperbilirubinaemia by exchange transfusion in the newborn (with concentrated solutions 20%) | Paracentesis of large volume ascites associated with portal hypertension (with concentrated solutions 20%)

**BY INTRAVENOUS INFUSION**

- Adult: (consult product literature)

#### CONTRA-INDICATIONS

- Cardiac failure - severe anaemia

#### CAUTIONS

- Correct dehydration when administering concentrated solution - history of cardiac disease (administer slowly to avoid rapid rise in blood pressure and cardiac failure, and monitor cardiovascular and respiratory function) - history of circulatory disease (administer slowly to avoid rapid rise in blood pressure and cardiac failure, and monitor cardiovascular and respiratory function) - increased capillary permeability

#### SIDE-EFFECTS

- Anaphylaxis - chills - fever - hypersensitivity reactions - hypotension - increased salivation - nausea - tachycardia - vomiting

#### MONITORING REQUIREMENTS

- Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

**PRESCRIBING AND DISPENSING INFORMATION**

A solution containing protein derived from plasma, serum, or normal placenta; at least 95% of the protein is albumin. The solution may be isotonic (containing 3.5–5% protein) or concentrated (containing 15–25% protein).

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

**Infusion**

- **Flexbumin** (Baxter Healthcare Ltd)

  Albumin solution human 200 gram per 1 litre Flexbumin 20% infusion 100ml bags | 1 bag | no price available | 12 bag | no price available
  Flexbumin 20% infusion 50ml bags | 1 bag | no price available | 24 bag | no price available

**Solution for infusion**

- **ALBUMIN SOLUTION (Non-proprietary)**

  Albumin solution human 50 mg per 1 ml Human albumin Grifols 5% solution for infusion 500ml bottles | 1 bottle | £9.50 | 6 bottle | no price available
  Human Albumin Biostat 5% solution for infusion 250ml vials | 1 vial | no price available
  Human albumin Grifols 5% solution for infusion 275ml bottles | 1 bottle | £4.75 | 10 bottle | no price available
  Human albumin Biostat 5% solution for infusion 100ml bottles | 1 bottle | £9.50 | 10 bottle | no price available

  Albumin solution human 200 mg per 1 ml Human Albumin Biotest 20% solution for infusion 50ml vials | 1 vial | no price available
  Human Albumin Biotest 20% solution for infusion 100ml vials | 1 vial | no price available
  Albumin solution human 45 mg per 1 ml Zenalb 4.5% solution for infusion 250ml bottles | 1 bottle | £36.31 | 10 bottle | no price available
  Zenalb 4.5% solution for infusion 50ml bottles | 1 bottle | £52.61 | 20 bottle | no price available

- Brands may include Albunorm; Alburex; Albutein; Zenalb

### PLASMA SUBSTITUTES

#### Dextran 70 with sodium chloride

**INDICATIONS AND DOSE**

Initial treatment of hypovolaemia with hypotension induced by traumatic injury

**BY INTRAVENOUS INFUSION**

- Adult: 250 ml, to be given over 2–5 minutes, followed immediately by administration of isotonic fluids, using RescueFlow®.

#### CAUTIONS

- Cardiac disease - hypoversomolality - severe hypoglycaemia - severe liver disease

#### SIDE-EFFECTS

- Rare
  - Severe anaphylactic reactions
  - Frequency not known
  - Hypersensitivity reactions - transient increase in bleeding time

#### PREGNANCY

Avoid — reports of anaphylaxis in mother causing fetal anoxia, neurological damage and death.

#### HEPATIC IMPAIRMENT

Use with caution in severe impairment.

#### RENAL IMPAIRMENT

Use with caution.

**MONITORING REQUIREMENTS**

- Where possible, monitor central venous pressure.
  - Urine output should be monitored. Care should be taken to avoid haemocrit concentration from falling below 25–30% and the patient should be monitored for hypersensitivity reactions.

- Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.
PRESCRIBING AND DISPENSING INFORMATION

Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

CAUTIONS
Cardiac disease • severe liver disease

SIDE-EFFECTS
Rare Severe anaphylactic reactions
Frequency not known Hypersensitivity reactions • transient increase in bleeding time

PREGNANCY
Manufacturer of Geloplasma® advises avoid at the end of pregnancy.

HEPATIC IMPAIRMENT
Use with caution in severe impairment.

RENAL IMPAIRMENT
Use with caution in renal impairment.

MONITORING REQUIREMENTS
Urine output should be monitored. Care should be taken to avoid haemorrhagic concentration from falling below 25–30% and the patient should be monitored for hypersensitivity reactions.

Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

PRESCRIBING AND DISPENSING INFORMATION
The gelatin is partially degraded.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Infusion

Gelspan (B.Braun Medical Ltd)
Gelatin 40 mg per 1 ml Gelspan 4% infusion 500ml Ecobags | 1 bag £5.78 (Hospital only) | 20 bag £115.56 (Hospital only)

Gelfusine (B.Braun Medical Ltd)
Gelatin 40 mg per 1 ml Gelfusine 4% infusion 1 litre Ecobags | 1 bag £130.04 | 10 bag £950.30 no price available
Gelfusine 4% infusion 500ml Ecobags | 1 bag £4.83 | 20 bag no price available

Geloplasma (Fresenius Kabi Ltd)
Gelatin 30 mg per 1 ml Geloplasma 3% infusion 500ml Freeflex bags | 15 bag £47.00 (Hospital only)

Isoplex (Beacon Pharmaceuticals Ltd)
Gelatin 40 mg per 1 ml Isoplex 4% infusion 500ml bags | 10 bag £67.30 (Hospital only)

Volplex (Beacon Pharmaceuticals Ltd)
Gelatin 40 mg per 1 ml Volplex 4% infusion 500ml bags | 10 bag £47.00 (Hospital only)
Volplex 4% infusion 1 litre bags | 6 bag £54.54 (Hospital only)

Tetrastarch

INDICATIONS AND DOSE

VOLULYTE® INFUSION
Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient

BY INTRAVENOUS INFUSION
Adult: Initially 10–20 mL, then increased to up to 30 mL/kg daily for a maximum duration of treatment of 24 hours, the initial dose must be given slowly and with careful monitoring of the patient to allow any anaphylactic reaction to be detected as early as possible

VOLUMEN® INFUSION
Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient

BY INTRAVENOUS INFUSION
Adult: Initially 10–20 mL, then increased to up to 30 mL/kg daily for a maximum duration of treatment of 24 hours, the initial dose must be given slowly and with careful monitoring of the patient to allow any anaphylactic reaction to be detected as early as possible

CONTRA-INDICATIONS
Burns • cerebral haemorrhage • critically ill patients • dehydration • hyperhydration • intracranial haemorrhage • pulmonary oedema • sepsis • severe coagulopathy

CAUTIONS
Cardiac disease • care should be taken to avoid haemorrhagic concentration from falling below 25–30% • children • renal impairment • severe liver disease • surgery • trauma

SIDE-EFFECTS
Rare Severe anaphylactic reactions
Frequency not known Hypersensitivity reactions • pruritus • raised serum amylase • transient increase in bleeding time

HEPATIC IMPAIRMENT
Avoid in severe impairment.

RENAL IMPAIRMENT
Avoid.

MONITORING REQUIREMENTS
Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times. Treatment with hydroxyethyl starches should be guided by continuous haemodynamic monitoring so that the infusion is stopped as soon as appropriate haemodynamic goals have been achieved.

Monitor renal function.
Monitor for hypersensitivity reactions.
Urine output should be monitored.

PRESCRIBING AND DISPENSING INFORMATION
A starch composed of more than 90% of amylopectin that has been etherified with hydroxyethyl groups; the term tetrastarch reflects the degree of etherification. Hydroxyethyl starches should only be used for the treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient; they should be used at the lowest effective dose for the first 24 hours of fluid resuscitation.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Infusion

Volulyte (Fresenius Kabi Ltd)
Magnesium chloride hexahydrate 300 mg per 1 litre, Potassium chloride 300 mg per 1 litre, Sodium acetate trihydrate 4.63 gram per 1 litre, Sodium chloride 6.02 gram per 1 litre, Tetrastarch 60 gram per 1 litre Volulyte 6% infusion 500ml Freeflex bags | 15 bag £229.60
2.2 Calcium imbalance

**Calcium**

**Calcium supplement**

Calcium supplements are usually only required where dietary calcium intake is deficient. This dietary requirement varies with age and is relatively greater in childhood, pregnancy, and lactation, due to an increased demand, and in old age, due to impaired absorption. In osteoporosis, a calcium intake which is double the recommended amount reduces the rate of bone loss. If the actual dietary intake is less than the recommended amount, a supplement of as much as 40 mmol is appropriate.

In severe acute hypocalcaemia or hypocalcaemic tetany, an initial slow intravenous injection of calcium gluconate p. 857 injection 10% should be given, with plasma-calcium and ECG monitoring (risk of arrhythmias if given too rapidly), and either repeated as required or, if only temporary improvement, followed by a continuous intravenous infusion to prevent recurrence. Calcium chloride p. 857 injection is also available, but is more irritant; care should be taken to prevent extravasation. Oral supplements of calcium and vitamin D may also be required in persistent hypocalcaemia. Concurrent hypomagnesaemia should be corrected with magnesium sulfate p. 858.

See the role of calcium gluconate in temporarily reducing the toxic effects of hypercalcaemia.

**Severe hypercalcaemia**

Severe hypercalcaemia calls for urgent treatment before detailed investigation of the cause. Dehydration should be corrected first with intravenous infusion of sodium chloride 0.9% p. 851. Drugs (such as thiazides and vitamin D compounds) which promote hypercalcaemia, should be discontinued and dietary calcium should be restricted.

If severe hypercalcaemia persists drugs which inhibit mobilisation of calcium from the skeleton may be required. The bisphosphonates are useful and pamidronate disodium p. 623 is probably the most effective.

**Corticosteroids** are widely given, but may only be useful where hypercalcaemia is due to sarcoidosis or vitamin D intoxication; they often take several days to achieve the desired effect.

Calcitonin (salmon)/salcatonin p. 627 can be used for the treatment of hypercalcaemia associated with malignancy; it is rarely effective where bisphosphonates have failed to reduce serum calcium adequately.

After treatment of severe hypercalcaemia the underlying cause must be established. Further treatment is governed by the same principles as for initial therapy. Salt and water depletion and drugs promoting hypercalcaemia should be avoided; oral administration of a bisphosphonate may be useful.

**Hyperparathyroidism**

Paricalcitol p. 888 is licensed for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. Parathyroidectomy may be indicated for hyperparathyroidism.

---

**Hypercalciuria**

Hypercalciuria should be investigated for an underlying cause, which should be treated. Where a cause is not identified (idiopathic hypercalciuria), the condition is managed by increasing fluid intake and giving bendroflumethiazide p. 159. Reducing dietary calcium intake may be beneficial but severe restriction of calcium intake has not proved beneficial and may even be harmful.

2.3 Hypercalcaemia and hypercalciuria

**CALCIMIMETIC AGENTS**

**Cinacalcet**

- **DRUG ACTION** Cinacalcet reduces parathyroid hormone which leads to a decrease in serum calcium concentrations.

<table>
<thead>
<tr>
<th><strong>INDICATIONS AND DOSE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary hyperparathyroidism in patients with end-stage renal disease on dialysis</strong></td>
</tr>
<tr>
<td><strong>BY MOUTH</strong></td>
</tr>
<tr>
<td>Adult: Initially 30 mg once daily, dose to be adjusted every 2–4 weeks; maximum 180 mg per day</td>
</tr>
</tbody>
</table>

  **TREATMENT OF HYPERCALCEMIA IN PARATHYROID CARCINOMA**

  **BY MOUTH**

  Adult: Initially 30 mg twice daily (max. per dose 90 mg 4 times a day), dose to be adjusted every 2–4 weeks according to response

  **Dose adjustments due to interactions**

  Dose adjustment may be necessary if smoking started or stopped during treatment.

- **CAUTIONS** Treatment should not be initiated in patients with hyperparathyroidism

- **INTERACTIONS** → Appendix 1 (cinacalcet).

- **SIDE-EFFECTS**

  - **Common or very common** Anorexia - asthenia - dizziness - myalgia - nausea - paraesthesia - rash - reduced testosterone concentrations - vomiting

  - **Uncommon** Diarrhoea - dyspepsia - seizures

  - **Frequency not known** Allergic reactions - angioedema - heart failure - hypotension

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment. Monitor closely in hepatic impairment especially when increasing dose.

- **MONITORING REQUIREMENTS**

  - Measure serum–calcium concentration before initiation of treatment and within 1 week after starting treatment or adjusting dose, then monthly for secondary hyperparathyroidism, and every 2–3 months for primary hyperparathyroidism and parathyroid carcinoma.

  - In secondary hyperparathyroidism measure parathyroid hormone concentration 1–4 weeks after starting treatment or adjusting dose, then every 1–3 months.

---

**Voluven** (Fresenius Kabi Ltd)

- **Tetрастarch 100 mg per 1 ml** Voluven 10% infusion 500ml Freeflex bags | 20 bag Unit price £0.63
- **Tetрастarch 60 mg per 1 gram** Voluven 0% infusion 500ml Freeflex bags | 1 bag Unit price £1.36 | 15 bag Unit price £6.06

**BNF 70**

**Hypercalcaemia and hypercalciuria**

**Blood and nutrition**
Blood and nutrition

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (January 2007) NICE TA117

Cinacalcet is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis) only in those:

- who have ‘very uncontrolled’ plasma concentration of intact parathyroid hormone (defined as greater than 85 picomol/litre) refractory to standard therapy, and a normal or high adjusted serum calcium concentration, and
- in whom surgical parathyroidectomy is contraindicated, and in that the risks of surgery outweigh the benefits.

Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma concentration of intact parathyroid hormone of 30% or greater is seen within 4 months of treatment.

www.nice.org.uk/TA117

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

- Mimpara (Amgen Ltd)
- Cinacalcet (as Cinacalcet hydrochloride) 30 mg Mimpara 30mg tablets | 28 tablet (£28 15 0.75 g tablet) £125.75 DT price = £125.75
- Cinacalcet (as Cinacalcet hydrochloride) 60 mg Mimpara 60mg tablets | 28 tablet (£231.97 g tablet) £231.97
- Cinacalcet (as Cinacalcet hydrochloride) 90 mg Mimpara 90mg tablets | 28 tablet (£347.96 g tablet) £347.96

Calcium carbonate

2.4 Hypocalcaemia

CALCIUM

Calcium salts

CONTRA-INDICATIONS Conditions associated with hypercalcaemia (e.g. some forms of malignant disease) - conditions associated with hypercalcuria (e.g. some forms of malignant disease)

CAUTIONS History of nephrolithiasis • sarcoidosis

INTERACTIONS Appendix 1 (antacids, calcium salts).

SIDE-EFFECTS

RARE Gastro-intestinal disturbances

FREQUENCY NOT KNOWN Hypocalcaemia

SPECIFIC SIDE-EFFECTS

With intravenous use arrhythmias • bradycardia • fall in blood pressure • injection-site reactions • peripheral vasodilatation • severe tissue damage with extravasation • sweating

RENAL IMPAIRMENT Use with caution.

Calcium carbonate

INDICATIONS AND DOSE

Phosphate binding in renal failure and hyper-phosphataemia

BY MOUTH

- Adult: (consult product literature)

Calcium deficiency

BY MOUTH

- Adult: (consult product literature)

PRESCRIBING AND DISPENSING INFORMATION Flavours of soluble tablet formulations may include orange or fruit flavour.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, dispersible tablet, oral suspension, capsule

Tablet

CAUTIONARY AND ADVISORY LABELS 25

- CALCIUM CARBONATE (Non-proprietary)
- Calcium (as Calcium carbonate) 600 mg HealthAid Strong Calcium 600mg chewable tablets | 60 tablet £3.99
- Calcium carbonate 1.25 gram Calcium carbonate 1.25g tablets | 100 tablet no price available
- Calcium carbonate 1.25 gram Calcium carbonate 1.25g tablets sugar free (sugar-free) | 100 tablet £12.50 DT price = £9.33
- Adcal (ProStrakan Ltd)
- Calcium carbonate 1.5 gram Adcal 1500mg chewable tablets (sugar-free) | 100 tablet (£8.70 DT price = £8.70
- Calci chew (Forum Health Products Ltd)
- Calcium carbonate 1.25 gram Calci chew 1500mg chewable tablets (sugar-free) | 100 tablet (£3.33 DT price = £9.33
- Calcium carbonate 2.5 gram Calcichew Forte chewable tablets (sugar-free) | 60 tablet (£13.16 DT price = £13.16

Effervescent tablet

CAUTIONARY AND ADVISORY LABELS 13

- Cacic (Warner Chilcott Ltd)
- Calcium carbonate 1.25 gram Cacic 500mg effervescent tablets (sugar-free) | 76 tablet (£11.81 DT price = £11.81

Calcium carbonate with calcium lactate gluconate

The properties listed below are those particular to the combination only. For the properties of the components please consider, calcium carbonate above.

INDICATIONS AND DOSE

Calcium deficiency

BY MOUTH

- Adult: Dose according to requirements

PRESCRIBING AND DISPENSING INFORMATION Flavours of soluble tablet formulations may include orange.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Effervescent tablet

CAUTIONARY AND ADVISORY LABELS 13

EXCIPIENTS: May contain Aspartame

- CALCIUM CARBONATE (Non-proprietary)
- Calcium (as Calcium carbonate) 600 mg HealthAid Strong Calcium 600mg chewable tablets | 60 tablet £3.99
- Calcium carbonate 1.25 gram Calcium carbonate 1.25g tablets | 100 tablet no price available
- Calcium carbonate 1.25 gram Calcium carbonate 1.25g tablets sugar free (sugar-free) | 100 tablet (£12.50 DT price = £9.33
- Adcal (ProStrakan Ltd)
- Calcium carbonate 1.5 gram Adcal 1500mg chewable tablets (sugar-free) | 100 tablet (£8.70 DT price = £8.70
- Calci chew (Forum Health Products Ltd)
- Calcium carbonate 1.25 gram Calci chew 1500mg chewable tablets (sugar-free) | 100 tablet (£3.33 DT price = £9.33
- Calcium carbonate 2.5 gram Calcichew Forte chewable tablets (sugar-free) | 60 tablet (£13.16 DT price = £13.16

Effervescent tablet

CAUTIONARY AND ADVISORY LABELS 13

EXCIPIENTS: May contain Aspartame

- Cacic (Warner Chilcott Ltd)
- Calcium carbonate 1.25 gram Cacic 500mg effervescent tablets (sugar-free) | 76 tablet (£11.81 DT price = £11.81

Calcium carbonate

INDICATIONS AND DOSE

Phosphate binding in renal failure and hyper-phosphataemia

BY MOUTH

- Adult: (consult product literature)

Calcium deficiency

BY MOUTH

- Adult: (consult product literature)
### Calcium chloride

**INDICATIONS AND DOSE**

Severe acute hypocalcaemia or hypocalcaemic tetany

**BY INTRAVENOUS INJECTION**

- **Adult:** Dose according to requirements

#### CAUTIONS

- Avoid in respiratory acidosis - avoid in respiratory failure
- **DIRECTIONS FOR ADMINISTRATION** Care should be taken to avoid extravasation.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

##### Solution for injection

- calcium chloride dihydrate 100 mg per 1 ml calcium chloride 10% solution for injection 10ml ampoules | 10 ampoule

- calcium chloride dihydrate 100 mg per 1 ml calcium chloride 14.7% solution for injection 5ml ampoules | 10 ampoule

- calcium chloride 14.7% solution for injection 10ml ampoules | 10 ampoule

#### Calcium gluconate

**INDICATIONS AND DOSE**

Severe acute hypocalcaemia or hypocalcaemic tetany

**INITIALLY BY SLOW INTRAVENOUS INJECTION**

- **Adult:** Initially 10–20 ml, calcium gluconate injection 10% (providing approximately 2.25–4.5 mmol of calcium) should be administered with plasma-calcium and ECG monitoring, and either repeated as required or, if only temporary improvement, followed by a continuous intravenous infusion to prevent recurrence; (by continuous intravenous infusion) 100 ml, adjusted according to response, dose to be diluted, calcium gluconate 10% should be administered

##### Acute severe hyperkalaemia (plasma-potassium concentration above 6.5 mmol/litre or in the presence of ECG changes)

**BY SLOW INTRAVENOUS INJECTION**

- **Adult:** Dose according to requirements

**Dose equivalence and conversion**

- 0.11 mmol/kg is equivalent to 0.5 ml/kg of calcium gluconate 10%.

### Important safety information

The MHRA has advised that repeated or prolonged administration of calcium gluconate injection packaged in 10 ml glass containers is contra-indicated in children under 18 years and in patients with renal impairment owing to the risk of aluminium accumulation; in these patients the use of calcium gluconate injection packaged in plastic containers is recommended.

### Monitoring requirements

- Plasma-calcium and ECG monitoring required for administration by slow intravenous injection (risk of arrhythmias if given too rapidly).

#### DIRECTIONS FOR ADMINISTRATION

- For continuous intravenous infusion, dilute 100 ml of calcium gluconate 10% in 1 litre of glucose 5% or sodium chloride 0.9% and give at an initial rate of 50 ml/hour adjusted according to response. Avoid bicarbonates, phosphates, or sulfates.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, solution for infusion, oral solution, capsule

##### Effervescent tablet

**CAUTIONARY AND ADVISORY LABELS**

- ELECTROLYTES: May contain Sodium

- **CALCIC gluconate (Non-proprietary)**

- Calcium gluconate 1 gram calcium gluconate effervescent tablets | 28 tablet

- **SOLUTION FOR INJECTION**

- **CALCIC gluconate (Non-proprietary)**

- Calcium gluconate 100 mg per 1 ml calcium gluconate 10% solution for injection 10ml ampoules | 10 ampoule

2.5 **Hypomagnesaemia**

### Magnesium

Magnesium is an essential constituent of many enzyme systems, particularly those involved in energy generation; the largest stores are in the skeleton. Magnesium salts are not well absorbed from the gastrointestinal tract, which explains the use of magnesium sulfate p. 858 as an osmotic laxative. Magnesium is excreted mainly by the kidneys and is therefore retained in renal failure, but significant hypomagnesaemia (causing muscle weakness and arrhythmias) is rare.

#### Hypomagnesaemia

Since magnesium is secreted in large amounts in the gastrointestinal fluid, excessive losses in diarrhoea, stoma or fistula are the most common causes of hypomagnesaemia; deficiency may also occur in alcoholism or as a result of treatment with certain drugs. Hypomagnesaemia often causes secondary hypocalcaemia, and also hypokalaemia and hyponatraemia.

Symptomatic hypomagnesaemia is associated with a deficit of 0.5–1 mmol/kg; up to 160 mmol Mg²⁺ over up to 5 days may be required to replace the deficit (allowing for urinary losses). Magnesium is given initially by intravenous infusion or by intramuscular injection of magnesium sulfate; the intramuscular injection is painful. Plasma magnesium concentration should be measured to determine the rate
and duration of infusion and the dose should be reduced in renal impairment. To prevent recurrence of the deficit, magnesium may be given by mouth, but there is limited evidence of benefit; magnesium glycerophosphate below tablets and liquid [unlicensed] are available from ‘special-order’ manufacturers or specialist importing companies.

**Arrhythmias**
Magnesium sulfate injection has also been recommended for the emergency treatment of serious arrhythmias, especially in the presence of hypokalaemia (when hypomagnesaemia may also be present) and when salvos of rapid ventricular tachycardia show the characteristic twisting wave front known as *torsade de pointes*.

**Myocardial infarction**
Limited evidence that magnesium sulfate below prevents arrhythmias and reperfusion injury in patients with suspected myocardial infarction has not been confirmed by large studies. Routine use of magnesium sulfate for this purpose is not recommended.

**Eclampsia and pre-eclampsia**
Magnesium sulfate injection is the drug of choice for the treatment of seizures and the prevention of recurrent seizures in women with *eclampsia*. Regimens may vary between hospitals. Calcium gluconate p. 857 injection is used for the management of magnesium toxicity.

Magnesium sulfate injection is also of benefit in women in whom there is concern about suspected myocardial infarction in whom there is concern about developing eclampsia. The patient should be monitored carefully.

**MAGNESIUM**

**Magnesium glycerophosphate**

### INDICATIONS AND DOSE

**Prevent recurrence of magnesium deficit**

**BY MOUTH**
- Adult: 6 g daily in divided doses

**Dose equivalence and conversion**
Magnesium glycerophosphate 1 g is equivalent to Mg$^{2+}$ 4 mmol.

- **UNLICENSED USE** Not licensed.

- **INTERACTIONS** → Appendix 1 (magnesium salts, oral).

- **SIDE-EFFECTS** Arrhythmias - colic - coma - confusion - diarrhoea - drowsiness - flushing of skin - hypermagnesaemia associated side-effects - hypotension - loss of tendon reflexes - muscle weakness - nausea - respiratory depression - thirst - vomiting

- **RENAL IMPAIRMENT** Avoid or reduce dose. Increased risk of toxicity.

- **MONITORING REQUIREMENTS** Monitor blood pressure, respiratory rate, urinary output and for signs of overdosage (loss of patellar reflexes, weakness, nausea, sensation of warmth, flushing, drowsiness, double vision, and slurred speech).

- **DIRECTIONS FOR ADMINISTRATION** Tablets may be dispersed in water.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution, chewable tablet, powder, capsule

---

**Tablet**
- **MAGNESIUM GLYCEROPHOSPHATE (Non-proprietary)**
  - Magnesium (as Magnesium glycerophosphate) 97.2 mg
  - Tablets | 30 tablet £84.50

**Chewable tablet**
- **MAGNESIUM GLYCEROPHOSPHATE (Non-proprietary)**
  - Magnesium (as Magnesium glycerophosphate) 97.2 mg
  - Chewable tablets (sugar-free) | 30 tablet £84.50

**Capsule**
- **MAGNESIUM GLYCEROPHOSPHATE (Non-proprietary)**
  - Magnesium (as Magnesium glycerophosphate) 48.6 mg
  - Capsules | 30 capsule £85.70

**Oral solution**
- **LiquaMag GP** (Fontus Health Ltd)
  - Magnesium (as Magnesium glycerophosphate) 24.25 mg per 1 ml
  - Oral solution (sugar-free) | 250 ml £55.00

---

**Magnesium sulfate**

### INDICATIONS AND DOSE

**Severe acute asthma | Continuing respiratory deterioration in anaphylaxis**

**BY INTRAVENOUS INFUSION**
- Child 2-17 years: 40 mg/kg (max. per dose 2 g), to be given over 20 minutes
- Adult: 1.2–2 g, to be given over 20 minutes

### Prevention of seizures in *pre-eclampsia* **INITIALLY BY INTRAVENOUS INJECTION**
- Adult: Initially 4 g, to be given over 5–15 minutes, followed by (by intravenous infusion) 1 gram/hour for 24 hours, if seizure occurs, additional dose of 2 g by intravenous injection to be administered

### Treatment of seizures and prevention of seizure recurrence **INITIALLY BY INTRAVENOUS INJECTION**
- Adult: Initially 4 g, to be given over 5–15 minutes, followed by (by intravenous infusion) 1 gram/hour for 24 hours after seizure or delivery (whichever is later), if seizure recurs, increase the infusion rate to 1.5–2 g/hour or give an additional dose of 2 g by intravenous injection

### Hypomagnesaemia **BY INTRAVENOUS INFUSION OR BY INTRAMUSCULAR INJECTION**
- Adult: Up to 40 g, dose given over up to 5 days may be required to replace the deficit (allowing for urinary losses)

**Hypomagnesaemia maintenance (e.g. in intravenous nutrition)**
- **BY INTRAVENOUS INFUSION OR BY INTRAMUSCULAR INJECTION**
  - Adult: 2.5–5 g daily, usual dose 3 g daily

### Emergency treatment of serious arrhythmias **BY INTRAVENOUS INJECTION**
- Adult: 2 g, to be given over 10–15 minutes, dose may be repeated once if necessary

### Rapid bowel evacuation (acts in 2–4 hours) **BY MOUTH**
- Adult: 5–10 g, dose to be mixed in a glass of water, taken preferably before breakfast

**Dose equivalence and conversion**
Magnesium sulfate heptahydrate 1 g equivalent to Mg$^{2+}$ approx. 4 mmol.
Hyperphosphataemia

Solution for infusion
- **MAGNESIUM SULFATE (Non-proprietary)**
  - Magnesium sulfate heptahydrate 100 mg per 1 ml
  - Magnesium sulfate 10% (magnesium 0.4mmol/ml) solution for injection 10ml ampoules | 10 ampoule (PO) £0.46

**Powder**
- **MAGNESIUM SULFATE (Non-proprietary)**
  - Magnesium sulfate dried 1 mg per 1 mg
  - Numark Epsom Salts | 200 gram (GSL) £1.00
  - Magnesium sulfate powder | 300 gram (GSL) £1.91 | 500 gram (GSL) £3.20 DT price = £3.20 | 2000 gram (GSL) £5.60 | 5000 gram (GSL) £11.49
  - Epsom Salts | 200 gram (GSL) £0.91

2.6 Phosphate imbalance

**Phosphorus**

**Phosphate supplements**
Oral phosphate p. 861 supplements may be required in addition to vitamin D in a small minority of patients with hypophosphataemic vitamin D-resistant rickets. Phosphate infusion is occasionally needed in alcohol dependence or in phosphate deficiency arising from use of parenteral nutrition deficient in phosphate supplements; phosphate depletion also occurs in severe diabetic ketoacidosis.

For phosphate requirements in total parenteral nutrition regimens, see Intravenous nutrition p. 873.

**Phosphate-binding agents**
Calcium-containing preparations are used as phosphate-binding agents in the management of hyperphosphataemia complicating renal failure. Aluminum-containing preparations are rarely used as phosphate binding agents and can cause aluminum accumulation.

Sevelamer p. 861 is licensed for the treatment of hyperphosphataemia in patients on haemodialysis or peritoneal dialysis. Sevelamer carbonate is also licensed for the treatment of patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more.

Lanthanum p. 860 is licensed for the control of hyperphosphataemia in patients with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), and in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more that cannot be controlled by a low-phosphate diet.

2.7 Hyperphosphataemia

**ALUMINIUM**

**Aluminium hydroxide**

**INDICATIONS AND DOSE**

**Hyperphosphataemia in renal failure**

**BY MOUTH USING CAPSULES**
- Adult: 4–20 capsules daily in divided doses, to be taken with meals

**Antacid**

**INITIALLY BY MOUTH USING CAPSULES**
- Adult: 1 capsule 4 times a day and (by mouth) 1 capsule, to be taken at bedtime
Patients or carers should be given advice on how to administer Phosex® tablets, Renacet® tablets, and PhosLo® tablets.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosex (Pharmacosms UK Ltd) Calcium acetate 1 gram Phosex 1g tablets</td>
<td>180 tablet £19.79</td>
</tr>
<tr>
<td>Renacet (Stanningley Pharma Ltd) Calcium acetate 475 mg Renacet 475mg tablets</td>
<td>100 tablet £5.38</td>
</tr>
<tr>
<td>Renacet (Stanningley Pharma Ltd) Calcium acetate 950 mg Renacet 950mg tablets</td>
<td>100 tablet £10.25</td>
</tr>
<tr>
<td>PhosLo (Stanningley Pharma Ltd) Calcium acetate 667 mg PhosLo 667mg capsules</td>
<td>200 capsule £14.40</td>
</tr>
</tbody>
</table>

**PHOSPHATE BINDERS**

### Lanthanum

**INDICATIONS AND DOSE**
Hyperphosphataemia in patients with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) Hyperphosphataemia in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more that cannot be controlled by a low-phosphate diet

**BY MOUTH**

- Adult: 1.5–3 g daily in divided doses, dose to be adjusted according to serum-phosphate concentration every 2–3 weeks, to be taken with or immediately after meals

**CAUTIONS**
Acute peptic ulcer - bowel obstruction - Crohn’s disease - ulcerative colitis

**INTERACTIONS → Appendix 1 (lanthanum).**

**SIDE-EFFECTS**

- Common Gastro-intestinal disturbances - headache - hypocalcaemia
- Frequency not known Accumulation of lanthanum in bone - transient changes in QT interval

**PREGNANCY**
Manufacturer advises avoid—toxicity in animal studies.

**BREAST FEEDING**
Manufacturer advises caution—no information available.

**HEPATIC IMPAIRMENT**
Lanthanum excreted in bile—possible accumulation in obstructive jaundice.

**DIRECTIONS FOR ADMINISTRATION**
Tablets are to be chewed. Each sachet of powder to be mixed with soft food and consumed within 30 minutes.

**PATIENT AND CARER ADVICE**
Patient and carers should be given advice on how to administer lanthanum tablets and powder.

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (March 2007) that lanthanum (Fosrenol®) is accepted for restricted use within NHS Scotland for the control of...
Sevelamer

INDICATIONS AND DOSE

RENVELA®

Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis / Hyperphosphataemia in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more

BY MOUTH

- Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be taken with meals and adjusted according to serum-phosphate concentration; usual dose 6 g daily in 3 divided doses

RENAGEL®

Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis

BY MOUTH

- Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be given with meals and adjusted according to serum-phosphate concentration; usual dose 4–12 g daily in 3 divided doses

CONTRA-INDICATIONS Bowel obstruction

CAUTIONS Gastro-intestinal disorders

INTERACTIONS → Appendix 1 (sevelamer).

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

- Common or very common Abdominal pain · constipation · diarrhoea · dyspepsia · flatulence · nausea · vomiting
- Frequency not known Ileus · intestinal obstruction (higher incidence with sevelamer hydrochloride salt) · intestinal perforation · pruritus · rash

RENAGEL®

- Frequency not known Diverticulitis

PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING

RENAGEL®

Unlikely to be present in milk (however, manufacturer advises avoid).

RENAGEL®

Manufacturer advises use only if potential benefit outweighs risk.

DIRECTIONS FOR ADMINISTRATION

RENVELA®

For powder for oral suspension, each sachet to be dispersed in 60 mL water.

PATIENT AND CARER ADVICE

RENVELA®

Patients and carers should be advised on how to administer Renvela® powder for oral suspension.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

- Exipients: May contain Propylene glycol

RENAGEL®

Fosrenol 800 mg tablets | 180 tablet

DT price = £167.04

RENVELA®

Sevelamer hydrochloride 800 mg tablets | 180 tablet

DT price = £167.04

RENVELA®

Sevelamer hydrochloride 1000 mg tablets | 180 tablet

DT price = £167.04

RENAGEL®

Sevelamer hydrochloride 1200 mg tablets | 180 tablet

DT price = £167.04

INDICATIONS AND DOSE

Phosphate

INDICATIONS AND DOSE

Treatment of moderate to severe hypophosphataemia

BY INTRAVENOUS INFUSION

- Adult: (consult product literature)

For established hypophosphataemia (with monobasic potassium phosphate)

BY INTRAVENOUS INFUSION

- Adult: 9 mmol every 12 hours, increased if necessary up to 0.5 mmol/kg (max. per dose 50 mmol), dose only increased in critically ill patients; dose is approximately equivalent to 30 mmol in adults, dose to be infused over 6–12 hours, according to severity of hypophosphataemia

Vitamin D-resistant hypophosphataemic osteomalacia

BY MOUTH USING EFFERVESCENT TABLETS

- Adult: 4–6 tablets daily

SIDE-EFFECTS

- Common or very common Diarrhoea

FREQUENCY NOT KNOWN Acute renal failure · hypocalcaemia · hypotension · metastatic calcification · nausea · oedema · phlebitis · tissue necrosis on extravasation

SIDE-EFFECTS, FURTHER INFORMATION

Diarrhoea is a common side-effect and should prompt a reduction in dosage.

RENAL IMPAIRMENT Reduce dose. Monitor closely in renal impairment.

MONITORING REQUIREMENTS It is essential to monitor closely plasma concentrations of calcium, phosphate, potassium, and other electrolytes—excessive doses of phosphates may cause hypocalcaemia and metastatic calcification.

2.8 Hypophosphataemia
2.9 Hyperkalaemia

Drugs used for Hyperkalaemia not listed below; Calcium gluconate, p. 857 • Insulin, p. 603

CATION-EXCHANGE RESINS

Calcium polystyrene sulfonate

INDICATIONS AND DOSE

CALCIUM RESONIUM®

Hyperkalaemia associated with anuria or severe oliguria, and in dialysis patients

BY MOUTH

Adult: 15 g 3–4 times a day

BY RECTUM

Adult: 30 g, retained for 9 hours followed by irrigation to remove resin from colon

SORBISTERIT® POWDER

Hyperkalaemia associated with anuria or severe oliguria, and in dialysis patients

BY MOUTH

Adult: 20 g 1–3 times a day

BY RECTUM

Adult: 40 g 1–3 times a day, retained for 6 hours followed by irrigation to remove resin from colon

CONTRA-INDICATIONS Hyperparathyroidism • metastatic carcinoma • multiple myeloma • obstructive bowel disease • sarcoidosis

INTERACTIONS → Appendix 1 (polystyrene sulfonate resins).

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

Anorexia • constipation (discontinue treatment—avoid magnesium-containing laxatives) • diarrhoea • gastric irritation • gastro-intestinal obstruction • hypercalcaemia (including in dialysed patients and occasionally in those with renal impairment) • hypomagnesaemia • intestinal necrosis (reported with concomitant use of sorbitol) • ischaemic colitis • nausea • necrosis • ulceration • vomiting

SPECIFIC SIDE-EFFECTS

With oral use gastro-intestinal concretions

With rectal use faecal impaction

PREGNANCY Manufacturers advise use only if potential benefit outweighs risk—no information available.

BREAST FEEDING Manufacturers advise use only if potential benefit outweighs risk—no information available.

MONITORING REQUIREMENTS Monitor for electrolyte disturbances (stop if plasma-potassium concentration below 5 mmol/litre).

Sodium polystyrene sulfonate

INDICATIONS AND DOSE

Hyperkalaemia associated with anuria or severe oliguria, and in dialysis patients

BY MOUTH

Adult: 15 g 3–4 times a day

BY RECTUM

Adult: 30 g, retain for 9 hours followed by irrigation to remove resin from colon

CONTRA-INDICATIONS Obstructive bowel disease

CAUTIONS Congestive heart failure • hypertension • oedema

INTERACTIONS → Appendix 1 (polystyrene sulfonate resins).

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

Anorexia • constipation (discontinue treatment—avoid magnesium-containing laxatives) • diarrhoea • gastric irritation • gastro-intestinal obstruction • hypercalcaemia • hypomagnesaemia • intestinal necrosis (reported with concomitant use of sorbitol) • ischaemic colitis • nausea • necrosis • sodium retention • ulceration • vomiting

SPECIFIC SIDE-EFFECTS

With oral use gastro-intestinal concretions

With rectal use faecal impaction

PREGNANCY Manufacturers advise use only if potential benefit outweighs risk—no information available.

BREAST FEEDING Manufacturers advise use only if potential benefit outweighs risk—no information available.

MONITORING REQUIREMENTS Monitor for electrolyte disturbances (stop if plasma-potassium concentration below 5 mmol/litre).
2.10 Hypokalaemia

POTASSIUM

Potassium bicarbonate with potassium acid tartrate

**INDICATIONS AND DOSE**
Hyperchloraemic acidosis associated with potassium deficiency (as in some renal tubular and gastro-intestinal disorders)

**BY MOUTH**
- Adult: consult product literature

**CONTRA-INDICATIONS**
- Hypochloraemia
- Plasma-potassium concentration above 5 mmol/litre

**CAUTIONS**
- Cardiac disease
- Elderly

**INTERACTIONS**
- Appendix 1 (potassium salts)

**SIDE-EFFECTS**
- Abdominal pain
- Diarrhoea
- Flatulence
- Nausea
- Vomiting

**RENAL IMPAIRMENT**
- Avoid in severe impairment. Close monitoring required in renal impairment—high risk of hyperkalaemia.

**DIRECTIONS FOR ADMINISTRATION**
- To be dissolved in water before administration.

**PRESCRIBING AND DISPENSING INFORMATION**
- Tablets do not contain chloride.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Effervescent tablet**

**CAUTIONARY AND ADVISORY LABELS**

**Potassium bicarbonate with potassium acid tartrate**
- 300 mg, 500 mg

**Potassium acid tartrate**
- 56 tablet

**DIRECTIONS FOR ADMINISTRATION**
- To be dissolved in water before administration.

**PRESCRIBING AND DISPENSING INFORMATION**
- Tablets do not contain chloride.

**Potassium chloride**

**INDICATIONS AND DOSE**
Prevention of hypokalaemia (patients with normal diet)

**BY MOUTH**
- Adult: 2–4 g daily in divided doses

**CONTRA-INDICATIONS**
- Plasma-potassium concentration above 5 mmol/litre

**CAUTIONS**
- With intravenous use: Seek specialist advice in very severe potassium depletion or difficult cases
- With oral use: Cardiac disease; elderly

**INTERACTIONS**
- Appendix 1 (potassium salts)

**SIDE-EFFECTS**
- Common or very common
- Abdominal pain, diarrhoea, flatulence, nausea, vomiting
- Frequency not known
- With intravenous use: heart toxicity (with rapid infusion)

**RENAI IMPAIRMENT**
- Smaller doses must be used in the prevention of hypokalaemia, to reduce the risk of hyperkalaemia. Avoid in severe impairment. Close monitoring required in renal impairment—high risk of hyperkalaemia.

**MONITORING REQUIREMENTS**
- Regular monitoring of plasma-potassium concentration is essential in those taking potassium supplements.
- With intravenous use: ECG monitoring should be performed in difficult cases.

**DIRECTIONS FOR ADMINISTRATION**
- With intravenous use: Potassium chloride concentrate must be diluted with not less than 50 times its volume of sodium chloride intravenous infusion 0.9% or other suitable diluent and mixed well. Ready-mixed infusion solutions should be used where possible; alternatively, potassium chloride concentrate as ampoules containing 1.5 g (K+ 20 mmol) in 10 mL, is thoroughly mixed with 500 mL of sodium chloride 0.9% intravenous infusion and given slowly over 2 to 3 hours with specialist advice and ECG monitoring in difficult cases. For peripheral intravenous infusion, the concentration of potassium should not usually exceed 40 mmol/L. Higher concentrations of potassium chloride may be given in very severe depletion, but require specialist advice.
- With oral use: Potassium salts are preferably given as a liquid (or effervescent) preparation, they should be given as the chloride (the use of effervescent potassium tablets BPC 1968 should be restricted to hyperchloraemic states).

**PRESCRIBING AND DISPENSING INFORMATION**
- Potassium Tablets Do not confuse Effervescent Potassium Tablets BPC 1968 with effervescent potassium chloride tablets. Effervescent Potassium Tablets BPC 1968 do not contain chloride ions and their use should be restricted to hyperchloraemic states. Kay-Cee-L contains 1mmol/1ml of each potassium and chloride.

**PATIENT AND CARER ADVICE**
- Salt substitutes: A number of salt substitutes which contain significant amounts of potassium chloride are readily available as health food products (e.g. LoSalt® and Ruthmol®). These should not be used by patients with renal failure as potassium intoxication may result.
3 Metabolic disorders

3.1 Acute porphyrías

Acute porphyrías

The acute porphyrías (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and 5-aminolevulinic acid dehydratase deficiency porphyria) are hereditary disorders of haem biosynthesis; they have a prevalence of about 1 in 10,000 of the population.

Great care must be taken when prescribing for patients with acute porphyria, since certain drugs can induce acute porphyrinic crises. Since acute porphyrías are hereditary, relatives of affected individuals should be screened and advised about the potential danger of certain drugs.

Treatment of serious or life-threatening conditions should not be withheld from patients with acute porphyria. When there is no safe alternative, treatment should be started and urinary porphobilinogen excretion should be measured regularly; if it increases or symptoms occur, the drug can be withdrawn and the acute attack treated. If an acute attack of porphyria occurs during pregnancy, contact an expert porphyria service for further advice.

Haem arginate p. 865 is administered by short intravenous infusion as haem replacement in moderate, severe, or unremitting acute porphyria crises.

In the United Kingdom the National Acute Porphyria Service (NAPS) provides clinical support and treatment with haem arginate from three centres (University Hospital of Wales, Addenbrooke’s Hospital, and King’s College Hospital). To access the service telephone (029) 2074 7747 and ask for the Acute Porphyria Service.

Drugs unsafe for use in acute porphyrías

The following list contains drugs on the UK market that have been classified as ‘unsafe’ in porphyria because they have been shown to be porphyrinogenic in animals or in vitro, or have been associated with acute attacks in patients. Absence of a drug from the following lists does not necessarily imply that the drug is safe. For many drugs no information about porphyria is available.

An up-to-date list of drugs considered safe in acute porphyrías is available at www.wmic.wales.nhs.uk/porphyria_info.php. Further information may be obtained from www.porphyria-europe.org and also from:

Welsh Medicines Information Centre

University Hospital of Wales
Cardiff
(029) 2074 2979/3877

Quite modest changes in chemical structure can lead to changes in porphyrinogenicity but where possible general statements have been made about groups of drugs; these should be checked first.

Unsafe Drug Groups (check first)

- Alkylating drugs (contact Welsh Medicines Information Centre for further advice)
- Anabolic steroids
- Antidepressants (includes tricyclic (and related) antidepressants and MAOIs; fluoxetine, duloxetine, venlafaxine, and trazadone thought to be safe)
- Antihistamines (alimemazine, chlorphenamine, desloratadine, fexofenadine, ketotifen, loratadine, and promethazine thought to be safe)
- Barbiturates (includes primidone and thiopental)
- Calcium channel blockers (amlodipine, felodipine, and nifedipine thought to be safe)
- Contraceptives, hormonal (progestogens are more porphyrinogenic than oestradiols; oestradiols may be safe at least in replacement doses. Progestogens should be avoided whenever possible by all women susceptible to acute porphyria; however, when non-hormonal contraception is inappropriate, progestogens may be used with extreme caution if the potential benefit outweighs risk. The risk of an acute attack is greatest in women who have had a previous attack or are aged under 30 years. Long-acting progestogen preparations should never be used in those at risk of acute porphyria.)
- Ergot derivatives (includes ergometrine (oxytocin probably safe) and pergolide)
- Hormone replacement therapy (progestogens are more porphyrinogenic than oestradiols; oestradiols may be safe at least in replacement doses. Progestogens should be avoided whenever possible by all women susceptible to acute porphyria; however, when non-hormonal contraception is inappropriate, progestogens may be used with extreme caution if the potential benefit outweighs risk. The risk of an acute attack is greatest in women who have had a previous attack or are aged under 30 years. Long-acting progestogen preparations should never be used in those at risk of acute porphyria.)
- Imidazole antifungals (applies to oral and intravenous use; topical antifungals are thought to be safe due to low systemic exposure)
- Non-nucleoside reverse transcriptase inhibitors (contact Welsh Medicines Information Centre for further advice)
- Progestogens (progestogens are more porphyrinogenic than oestradiols; oestradiols may be safe at least in replacement doses. Progestogens should be avoided whenever possible by all women susceptible to acute porphyria; however, when non-hormonal contraception is inappropriate, progestogens may be used with extreme caution if the potential benefit outweighs risk. The risk of an acute attack is greatest in women who have had a previous attack or are aged under 30 years. Long-acting progestogen preparations should never be used in those at risk of acute porphyria.)
- Sulphonamides (includes co-trimoxazole and sulphasalazine)
- Sulfonamides (includes co-trimoxazole and sulphasalazine)
- Sulfonylureas (glipizide and glimepiride are thought to be safe)
- Taxanes (contact Welsh Medicines Information Centre for further advice)
Thiazolidinediones (contact Welsh Medicines Information Centre for further advice)

Triazole antifungals (applies to oral and intravenous use; topical antifungals are thought to be safe due to low systemic exposure)

Unsafe Drugs (check groups above first)

- Aceclofenac
- Alcohol
- Amiodarone
- Aprepitant (contact Welsh Medicines Information Centre for further advice)
- Artemether with lumefantrine
- Bexarotene
- Bosentan
- Bromocriptine
- Buspirone
- Cabergoline
- Carbamazepine
- Chloramphenicol
- Chloroform (small amounts in medicines probably safe)
- Clindamycin
- Cocaine
- Colistimethate sodium
- Danazol
- Dapsone
- Disopyramide
- Disulfiram
- Erythromycin
- Ethosuximide
- Ethylmorphine
- Flupentixol
- Flutamide
- Fosaprepitant (contact Welsh Medicines Information Centre for further advice)
- Fosphenytoin
- Griseofulvin
- Hydralazine
- Indapamide
- Isomethyptene mucate
- Isoniazid (safety uncertain, contact Welsh Medicines Information Centre for further advice)
- Ketamine
- Mefenamic acid (may be used with caution if safer alternative not available)
- Meprobamate
- Methyldopa
- Metolazone
- Metoclopramide
- Milipristone
- Minoxidil (may be used with caution if safer alternative not available)
- Mitotane
- Mouldidic acid
- Nitrazepam
- Nitrofurantoin
- Orphenadrine
- Oxcarbazepine
- Oxysbutynin
- Pentazocine (buprenorphine, codeine, diamorphine, dihydrocodeine, fentanyl, methadone, morphine, oxycodone, pethidine, and tramadol are thought to be safe)
- Pentoxifylline
- Phenoxybenzamine
- Phenytoin
- Pimelidilimil
- Porfimer
- Raloxifene
- Rifabutin (safety uncertain, contact Welsh Medicines Information Centre for further advice)
- Rifampicin
- Rituxole
- Risperidone
- Selegiline
- Spiranolactone
- Sulfapyrazine
- Tamoxifen
- Telithromycin
- Temoporfin
- Tiagabine
- Tibolone
- Tinidazole
- Topiramate
- Toremifene
- Trimethoprim
- Valproate
- Zidovudine (contact Welsh Medicines Information Centre for further advice)

Zuclopenthixol

HAEM DERIVATIVES

Haem arginate

(Human hemin)

INDICATIONS AND DOSE

Acute porphyrias | Acute intermittent porphyria | Porphyria variegata | Hereditary coproporphyria

BY INTRAVENOUS INFUSION

- Adult: Initially 3 mg/kg once daily for 4 days, if response inadequate, repeat 4-day course with close biochemical monitoring; maximum 250 mg per day

SIDE-EFFECTS

- Common or very common pain at injection site – thrombophlebitis at injection site
- Rare Fever - hypersensitivity reactions
- Frequency not known Headache

PREGNANCY

Manufacturer advises avoid unless essential.

BREAST FEEDING

Manufacturer advises avoid unless essential—no information available.

DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Normosang®), give intermittently in Sodium chloride 0.9%; dilute requisite dose in 100 mL infusion fluid in glass bottle and give over at least 30 minutes through a filter via large antecubital or central vein; administer within 1 hour after dilution.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

- Normosang (Orphan Europe (UK) Ltd)

Haem arginate 25 mg per 1 ml Normosang 250mg/10ml solution for infusion ampoules | 4 ampoule (pak) £1,737.00
3.2 Carnitine deficiency

CARNITINE DERIVATIVES

Levocarnitine (Carnitine)

INDICATIONS AND DOSE
Primary carnitine deficiency due to inborn errors of metabolism

BY MOUTH
- Adult: Up to 200 mg/kg daily in 2–4 divided doses; maximum 3 g per day
- Adult: Up to 100 mg/kg daily in 2–4 divided doses, to be administered over 2–3 minutes

Secondary carnitine deficiency in haemodialysis patients initially by slow intravenous injection
- Adult: 20 mg/kg, to be administered over 2–3 minutes, after each dialysis session, dosage adjusted according to plasma-carnitine concentration, then (by mouth) maintenance 1 g daily, administered if benefit is gained from first intravenous course

CAUTIONS
- Diabetes mellitus
- Abdominal pain · body odour · diarrhoea · nausea · vomiting

SIDE-EFFECTS
- Appropriate to use; no evidence of during first week and after any dose increase. Side-effects may be dose-related.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances
- Rash
- Rhinorrhoea
- Sleep disturbances
- Syncope
- Tachycardia
- Taste disturbances
- Tinnitus
- Tremor
- Urticaria

INDICATIONS AND DOSE

RENAL IMPAIRMENT
- Appropriate to use; no evidence of during first week and after any dose increase.
- Some side-effects may be dose-related.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances

SIDE-EFFECTS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances
- Rash
- Rhinorrhoea
- Sleep disturbances
- Syncope
- Tachycardia
- Taste disturbances
- Tinnitus
- Tremor
- Urticaria

INTERACTIONS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances

SIDE-EFFECTS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances
- Rash
- Rhinorrhoea
- Sleep disturbances
- Syncope
- Tachycardia
- Taste disturbances
- Tinnitus
- Tremor
- Urticaria

DRUG ACTION
- Agalsidase alfa, an enzyme produced by recombinant DNA technology are licensed for long-term enzyme replacement therapy in Fabry’s disease (a lysosomal storage disorder caused by deficiency of alpha-galactosidase A).

INDICATIONS AND DOSE

Fabry’s disease (specialist use only)
- Adult: 200 micrograms/kg every 2 weeks

INTERACTIONS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances

SIDE-EFFECTS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances
- Rash
- Rhinorrhoea
- Sleep disturbances
- Syncope
- Tachycardia
- Taste disturbances
- Tinnitus
- Tremor
- Urticaria

Fabry’s disease (specialist use only)
- Adult: 200 micrograms/kg every 2 weeks

INTERACTIONS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances

SIDE-EFFECTS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances
- Rash
- Rhinorrhoea
- Sleep disturbances
- Syncope
- Tachycardia
- Taste disturbances
- Tinnitus
- Tremor
- Urticaria

Agalsidase beta

ENZYMES

Agalsidase alfa

- Drug action: Agalsidase alfa, an enzyme produced by recombinant DNA technology are licensed for long-term enzyme replacement therapy in Fabry’s disease (a lysosomal storage disorder caused by deficiency of alpha-galactosidase A).

INDICATIONS AND DOSE

Fabry’s disease (specialist use only)
- Adult: 200 micrograms/kg every 2 weeks

INTERACTIONS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances

SIDE-EFFECTS
- Appropriate to use; no evidence of during first week and after any dose increase.
- Nausea
- Abdominal pain
- Diabetes mellitus
- Intestinal disturbances
- Rash
- Rhinorrhoea
- Sleep disturbances
- Syncope
- Tachycardia
- Taste disturbances
- Tinnitus
- Tremor
- Urticaria

Agalsidase beta

- Drug action: Agalsidase beta, an enzyme produced by recombinant DNA technology are licensed for long-term enzyme replacement therapy in Fabry’s disease (a lysosomal storage disorder caused by deficiency of alpha-galactosidase A).
Gaucher’s disease 867

3.4 Gaucher’s disease

Drugs used for Gaucher’s disease not listed below; Miglustat, p. 870

ENZYMES

Imiglucerase

DRUG ACTION Imiglucerase is an enzyme produced by recombinant DNA technology that is administered as enzyme replacement therapy for non-neurological manifestations of type I or type III Gaucher’s disease, a familial disorder affecting principally the liver, spleen, bone marrow, and lymph nodes.

INDICATIONS AND DOSE

Non-neurological manifestations of type I Gaucher’s disease (specialist use only) | Non-neurological manifestations of type III Gaucher’s disease (specialist use only)

BY INTRAVENOUS INFUSION

Adult: Initially 60 units/kg every 2 weeks; maintenance, adjusted according to response, doses as low as 15 units/kg once every 2 weeks may improve haematological parameters and organomegaly

SIDE-EFFECTS

Common or very common Angioedema · backache · cyanosis · flushing · hypersensitivity reactions · hypotension · paraesthesia · pruritus · rash · rhinorrhea · sleep disturbances · syncope · tachycardia · taste disturbances · tinnitus · tremor · urticaria

Uncommon Abdominal cramps · arthralgia · diarrhoea · dizziness · fatigue · fever · headache · injection-site reactions · nausea · vomiting

PREGNANCY Manufacturer advises use with caution—limited information available.

BREAST FEEDING No information available.

MONITORING REQUIREMENTS

Monitor for immunoglobulin G (IgG) antibodies to imiglucerase.

When stabilised, monitor all parameters and response to treatment at intervals of 6–12 months.

DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Cerezyme®), give intermittently in Sodium chloride 0.9%; initially reconstitute with water for injections (200 units in 5.1 mL, 400 units in 10.2 mL) to give 40 units/mL solution; dilute requisite dose with infusion fluid to a final volume of 100–200 mL and give initial dose at a rate not exceeding 0.5 units/kg/minute, subsequent doses to be given at a rate not exceeding 1 unit/kg/minute; administer within 3 hours after reconstitution.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

ELECTROLYTES: May contain Sodium

Cerezyme (Genzyme Therapeutics Ltd) Imiglucerase 400 unit Cerezyme 400 unit powder for solution for infusion vials | 1 vial | £1,071.29

Velaglucerase alfa

DRUG ACTION Velaglucerase alfa is an enzyme produced by recombinant DNA technology that is administered as enzyme replacement therapy for the treatment of type I Gaucher’s disease.

INDICATIONS AND DOSE

Type I Gaucher’s disease (specialist use only) BY INTRAVENOUS INFUSION

Adult: Initially 60 units/kg every 2 weeks; adjusted according to response to 15–60 units/kg every 2 weeks

SIDE-EFFECTS Abdominal pain · arthralgia · back pain · bone pain · dizziness · flushing · headache · hypersensitivity reactions · hypotension · paraesthesia · pruritus · rash · tachycardia · taste disturbances · tinnitus · tremor · urticaria

MONITORING REQUIREMENTS Monitor immunoglobulin G (IgG) antibody concentration in severe infusion-related reactions or if there is a lack or loss of effect with velaglucerase alfa.

DIRECTIONS FOR ADMINISTRATION For intravenous infusion (VPRIV®), give intermittently in Sodium chloride 0.9%; reconstitute each 400-unit vial with 4.3 mL water for injections to produce a 100 units/mL solution; dilute requisite dose in 100 mL infusion fluid; give over 60
3.6 **Mucopolysaccharidosis**

### Galsulfase

**DRUG ACTION**
Galsulfase is a recombinant form of human N-acetylgalactosamine-4-sulfatase.

**INDICATIONS AND DOSE**

- **Mucopolysaccharidosis VI** (specialist use only)
  - **BY INTRAVENOUS INFUSION**
    - Adult: 1 mg/kg once weekly

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related reactions
Infusion-related reactions often occur, they can be managed by slowing the infusion rate or interrupting the infusion, and can be minimised by pre-treatment with an antihistamine and an antipyretic. Recurrent infusion-related reactions may require pre-treatment with a corticosteroid—consult product literature for details.

- **PREGNANCY**
  - Manufacturer advises avoid unless essential.

- **BREAST FEEDING**
  - Manufacturer advises avoid—no information available.

**DIRECTIONS FOR ADMINISTRATION**
For intravenous infusion (Naglazyme®), give intermittently in Sodium chloride 0.9%; dilute requisite dose with infusion fluid to final volume of 250 mL and mix gently; infuse through a 0.2 micron in-line filter; give approx. 2.5% of the total volume over 1 hour, then infuse remaining volume over next 3 hours; if body-weight under 20 kg and at risk of fluid overload, dilute requisite dose in 100 mL infusion fluid and give over at least 4 hours.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
- Naglazyme (BioMarin Europe Ltd)
  - Galsulfase 1 mg per 1 ml Naglazyme 5mg/5ml solution for infusion vials | 1 vial no price available

### Idursulfase

**DRUG ACTION**
Idursulfase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in mucopolysaccharidosis II (Hunter syndrome), a lysosomal storage disorder caused by deficiency of idurionate-2-sulfatase.

**INDICATIONS AND DOSE**

- **Mucopolysaccharidosis II** (specialist use only)
  - **BY INTRAVENOUS INFUSION**
    - Adult: 500 micrograms/kg once weekly

**CAUTIONS**
Acute febrile respiratory illness (consider delaying treatment) - infusion-related reactions can occur - severe respiratory disease
Laronidase

**DRUG ACTION** Laronidase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in the treatment of non-neuropathological manifestations of mucopolysaccharidosis I, a lysosomal storage disorder caused by deficiency of alpha-L-iduronidase.

**INDICATIONS AND DOSE**

Non-neuropathological manifestations of mucopolysaccharidosis I (specialist use only)

**BY INTRAVENOUS INFUSION**

- Adult: 100 units/kg once weekly

**CAUTIONS** Infusion-related reactions can occur

**INTERACTIONS** → Appendix 1 (laronidase).

**SIDE-EFFECTS**

- Common or very common Abdominal pain, abdominal distension, diarrhoea, dyspepsia, headache, rash, flushing, pruritus, tachycardia, vomiting.
- Less common Abdominal distension, breathlessness, dyspnoea, flushing, hypotension, hypovolaemia, hypothermia, hypertension, pruritus, rash.
- Frequency not known Alcoholic hepatitis, anaemia, angioedema, asthma, allergic reactions, angina, anaphylaxis, anaphylactoid reactions, angina, arrhythmia, arthralgia, chest pain, diarrhea, dyspepsia, dyspnoea, dysuria, eczema, erythema, fever, flushing, hypotension, hypertension, hypovolaemia, hypothermia, pruritus, rash, urticaria.

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related reactions may occur, can be managed by slowing the infusion rate or interrupting the infusion, and can be minimised by pre-treatment with an antihistamine and an antipyretic. Recurrent infusion-related reactions may require pre-treatment with a corticosteroid—consult product literature for details.

**CONCESSION AND CONTRACEPTION** Contra-indicated in women of child-bearing potential.

**PREGNANCY** Manufacturer advises avoid.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**MONITORING REQUIREMENTS** Monitor immunoglobulin G (IgG) antibody concentration.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Aldurazyme®), give intermittently in Sodium chloride 0.9%; body-weight under 20 kg, use 100 mL infusion fluid; body-weight over 20 kg use 250 mL infusion fluid; withdraw volume of infusion fluid equivalent to volume of laronidase concentrate being added; give through in-line filter (0.22 micron) initially at a rate of 2 units/kg/hour then increase gradually every 15 minutes to max. 45 units/kg/hour.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- Elaprase (Shire Pharmaceuticals Ltd) ▼
  - Idursulfase 2 mg per 1 mL Elaprase 6mg/3ml concentrate for solution for infusion vials | 1 vial (£35) 1,985.00

**3.7 Nephropathic cystinosis**

**AMINO ACIDS AND DERIVATIVES**

**Mercaptamine**

**(Cysteamine)**

**INDICATIONS AND DOSE**

Nephropathic cystinosis (specialist use only)

**BY MOUTH**

- Adult (body-weight 50 kg and above): Initially one-sixth to one-quarter of the expected maintenance dose, increased gradually over 4–6 weeks to avoid intolerance, maintenance 2 g daily in 4 divided doses

**SAFE PRACTICE**

Mercaptamine has been confused with mercaptoacetamide; care must be taken to ensure the correct drug is prescribed and dispensed.

**CAUTIONS**

Dose of phosphate supplement may need to be adjusted if transferring from phoshocysteamine to mercaptamine

**SIDE-EFFECTS**

- Common or very common Abdominal pain, anorexia, breathlessness, body odour, diarrhoea, dyspepsia, encephalopathy, fever, gastroenteritis, headache, malaise, nausea, rash, vomiting.
- Uncommon Drowsiness, gastro-intestinal ulcer, hallucinations, leucopenia, nephrotic syndrome, nervousness, seizures.

**ALLERGY AND CROSS-SENSITIVITY**

Contraindicated if history of hypersensitivity to penicillamine.

**PREGNANCY** Avoid—teratogenic and toxic in animal studies.

**BREAST FEEDING** Avoid.

**MONITORING REQUIREMENTS** Leucocyte-cystine concentration and haematological monitoring required—consult product literature.
3.8 Niemann-Pick type C disease

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Miglustat

**DRUG ACTION** Miglustat is an inhibitor of glucosylceramide synthase.

**INDICATIONS AND DOSE**

Mild to moderate type I Gaucher’s disease for whom enzyme replacement therapy is unsuitable (under expert supervision)

*BY MOUTH*

- **Adult:** 100 mg 3 times a day, reduced if not tolerated to 100 mg 1–2 times a day

Treatment of progressive neurological manifestations of Niemann-Pick type C disease (under expert supervision)

*BY MOUTH*

- **Adult:** 200 mg 3 times a day

**SIDE-EFFECTS** Abdominal pain · anemia · anorexia · ataxia · chills · constipation · decreased libido · depression · diarrhoea · dizziness · dyspepsia · flatulence · headache · hypoesthesia · insomnia · malaise · muscle spasm · muscle weakness · nausea · paraesthesia · peripheral neuropathy · thrombocytopenia · tremor · vomiting · weight changes

**CONCEPTION AND CONTRACEPTION** Effective contraception must be used during treatment. Men should avoid fathering a child during and for 3 months after treatment.

**PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** No information available—manufacturer advises caution.

**RENAL IMPAIRMENT** For Gaucher’s disease initially 100 mg twice daily if eGFR 50–70 mL/minute/1.73 m². Initially 100 mg once daily if eGFR 30–50 mL/minute/1.73 m². For Niemann-Pick type C disease, initially 200 mg twice daily if eGFR 50–70 mL/minute/1.73 m². Initially 100 mg twice daily if eGFR 30–50 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- Monitor cognitive and neurological function.
- Monitor growth and platelet count in Niemann-Pick type C disease.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

---

870 Metabolic disorders

- PRESCRIBING AND DISPENSING INFORMATION

  Miglustat has a very unpleasant taste and smell, which can affect compliance.

- MEDICINAL FORMS

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

  **Capsule**

  - **Cautions and Advisory Labels 21**

    - **Cystagon (Orphan Europe (UK) Ltd)**
      - **Miglustat (as Miglustat bitartrate) 50 mg**
        - Cystagon 50mg capsules | 100 capsule (£3.00) £70.00
      - **Miglustat (as Miglustat bitartrate) 150 mg**
        - Cystagon 150mg capsules | 100 capsule (£3.00) £190.00

---

3.9 Pompe disease

**ENZYMES**

**Alglucosidase alfa**

**DRUG ACTION** Alglucosidase alfa is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in Pompe disease, a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase.

**INDICATIONS AND DOSE**

Pompe disease (specialist use only)

- **BY INTRAVENOUS INFUSION**

  - **Adult:** 20 mg/kg every 2 weeks

**CAUTIONS**

- Cardiac dysfunction · infusion-related reactions—consult product literature · respiratory dysfunction

**SIDE-EFFECTS**

- Common or very common Agitation · anaphylaxis · antibody formation · blood pressure changes · bronchospasm · chest discomfort · cold extremities · cough · cyanosis · diarrhoea · dizziness · facial oedema · fatigue · flushing · headache · hypersensitivity reactions · injection-site reactions · irritability · muscle spasm · myalgia · nausea · paraesthesia · pruritus · pyrexia · rash · restlessness · sweating · tachycardia · tachypnoea · tremor · urticaria · vomiting

- **Frequency not known** Infusion-related reactions · necrotising skin lesions · severe skin reactions · ulcerative skin lesions

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related reactions Infusion-related reactions very common, calling for use of anti-histamine, antipyretic, or corticosteroid; consult product literature for details.

**PREGNANCY**

- Toxicity in animal studies, but treatment should not be withheld.

**BREAST FEEDING**

- Manufacturer advises avoid—no information available.

**MONITORING REQUIREMENTS**

- Monitor closely if cardiac dysfunction.
- Monitor closely if respiratory dysfunction.
- Monitor immunoglobulin G (IgG) antibody concentration.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Myozyme®), give intermittently in Sodium chloride 0.9%; reconstitute 50 mg with 10.3 mL water for injections to produce 5 mg/mL solution; gently rotate vial without shaking; dilute requisite dose with infusion fluid to give a final concentration of 0.5–4 mg/mL; give through a low protein-binding in-line filter (0.2 micron) at an initial rate of 1 mg/kg/hour increased by 2 mg/kg/hour every 30 minutes to max. 7 mg/kg/hour.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- **Myozyme (Genzyme Therapeutics Ltd)**
  
  Alglucosidase alfa 50 mg Myozyme 50mg powder for concentrate for solution for infusion vials | 1 vial (£3.56) £156.06 (Hospital only)
3.10 Tyrosinaemia type I

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE INHIBITORS

Nitisinone (NTBC)

INDICATIONS AND DOSE

Hereditary tyrosinaemia type I (in combination with dietary restriction of tyrosine and phenylalanine) (specialist use only)

BY MOUTH

- Adult: Initially 500 micrograms/kg twice daily, adjusted according to response; maximum 2 mg/kg per day

- SIDE-EFFECTS
  - Common or very common Conjunctivitis - corneal opacity - eye pain - granulocytopenia - keratitis - leucopenia - photophobia - thrombocytopenia
  - Uncommon Blepharitis - erythematous rash - exfoliative dermatitis - leucocytosis - pruritus

- PREGNANCY
  - Manufacturer advises avoid unless potential benefit outweighs risks—no information available.

- BREAST FEEDING
  - Manufacturer advises avoid—present in milk in animal studies.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  - Orfadin (Swedish Orphan Biovitrum Ltd)
  - Nitisinone 2 mg Orfadin 2mg capsules | 60 capsule PON £564.00
  - Nitisinone 5 mg Orfadin 5mg capsules | 60 capsule PON £1,127.00
  - Nitisinone 10 mg Orfadin 10mg capsules | 60 capsule PON £2,062.00

3.11 Urea cycle disorders

AMINO ACIDS AND DERIVATIVES

Carglumic acid

INDICATIONS AND DOSE

Hyperammonaemia due to N-acetylglutamate synthase deficiency (under expert supervision)

BY MOUTH

- Adult: Initially 50–125 mg/kg twice daily, to be taken immediately before food, dose adjusted according to plasma-ammonia concentration; maintenance 5–50 mg/kg twice daily, the total daily dose may alternatively be given in 3–4 divided doses

Hyperammonaemia due to organic acidemia (under expert supervision)

BY MOUTH

- Adult: Initially 50–125 mg/kg twice daily, to be taken immediately before food, dose adjusted according to plasma-ammonia concentration, the total daily dose may alternatively be given in 3–4 divided doses

Important safety information

EMERGENCY MANAGEMENT OF UREA CYCLE DISORDERS

For further information on the emergency management of urea cycle disorders consult the British Inherited Metabolic Disease Group (BIMDG) website at www.bimdg.org.uk.

- SIDE-EFFECTS
  - Common or very common Sweating
  - Uncommon Bradycardia - diarrhoea - pyrexia - vomiting

- PREGNANCY
  - Manufacturer advises avoid unless essential—no information available.

- BREAST FEEDING
  - Manufacturer advises avoid—present in milk in animal studies.

- DIRECTIONS FOR ADMINISTRATION
  - Dispersible tablets must be dispersed in at least 5–10 mL of water and taken orally immediately, or administered via a nasogastric tube.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

**Dispersible tablet**

CAUTIONARY AND ADVISORY LABELS 13

- Carbaglu (Orphan Europe (UK) Ltd)
  - Carglumic acid 200 mg Carbaglu 200mg dispersible tablets (sugar-free) | 5 tablet PON £299.00 (sugar-free) | 60 tablet PON £3,499.00

AMMONIA LOWERING DRUGS

Sodium phenylbutyrate

INDICATIONS AND DOSE

Long-term treatment of urea cycle disorders (as adjunctive therapy in all patients with neonatal-onset disease and in those with late-onset disease who have a history of hyperammonaemic encephalopathy) (under expert supervision)

BY MOUTH

- Adult: 9.9–13 g/m² daily in divided doses, with meals; maximum 20 g per day

Important safety information

EMERGENCY MANAGEMENT OF UREA CYCLE DISORDERS

For further information on the emergency management of urea cycle disorders consult the British Inherited Metabolic Disease Group (BIMDG) website at www.bimdg.org.uk.

- CAUTIONS
  - Congestive heart failure (preparations contain significant amounts of sodium)

- INTERACTIONS
  - Appendix 1 (sodium phenylbutyrate).

- SIDE-EFFECTS
  - Common or very common Alkalosis - blood disorders - body odour - decreased appetite - depression - gastro-intestinal disturbances - headache - irritability - menstrual disorders - metabolic acidosis - oedema - rash - renal tubular acidosis - syncope - taste disturbance - weight gain
  - Uncommon Arrhythmias - pancreatitis - peptic ulcer - rectal bleeding

SIDE-EFFECTS, FURTHER INFORMATION

Gastro-intestinal side-effects may be reduced by giving smaller doses more frequently.

- CONCEPTION AND CONTRACEPTION
  - Manufacturer advises adequate contraception during administration in women of child-bearing potential.

- PREGNANCY
  - Avoid—toxicity in animal studies.
3.12 Wilson’s disease

Drugs used for Wilson’s disease not listed below; Penicillamine, p. 896

COPPER ABSORPTION INHIBITORS

Zinc acetate

**Drug Action**  Zinc prevents the absorption of copper in Wilson’s disease.

**INDICATIONS AND DOSE**

**Wilson’s disease (initiated under specialist supervision)**

*BY MOUTH*

- Adult: 50 mg 3 times a day (max. per dose 50 mg 5 times a day), adjusted according to response

*Dose equivalence and conversion*

Doses expressed as elemental zinc.

**Pharmacokinetics**

Symptomatic Wilson’s disease patients should be treated initially with a chelating agent because zinc has a slow onset of action. When transferring from chelating treatment to zinc maintenance therapy, chelating treatment should be co-administered for 2–3 weeks until zinc produces its maximal effect.

**Caution** Portal hypertension (risk of hepatic decompensation when switching from chelating agent)

**Interactions** → Appendix 1 (zinc).

**Side-effects**

- Common or very common  Gastric irritation (usually transient)
- Uncommon  Leucopenia - sideroblastic anaemia

**Further Information**

Transient gastric irritation may be reduced if first dose is taken mid-morning or with a little protein.

**Pregnancy**

Reduce dose to 25 mg 3 times daily adjusted according to plasma-copper concentration and urinary copper excretion.

**Breast-feeding**

Manufacturer advises avoid; present in milk—may cause zinc-induced copper deficiency in infant.

372 Trace element deficiencies

**Blood and nutrition**

- **Breast-feeding**  Manufacturer advises avoid—no information available.
- **Hepatic Impairment**  Manufacturer advises use with caution.
- **Renal Impairment**  Manufacturer advises use with caution (preparations contain significant amounts of sodium).
- **Directions for Administration**  Granules should be mixed with food before taking. Pheburane granules must not be administered by nasogastric or gastrostomy tubes.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, capsule, tablet.

**Tablet**

- **Amnomaps** (Swedish Orphan Biovitrum Ltd) Sodium phenylbutyrate 500 mg Amnomaps 500mg tablets 250 tablet £493.00
- **Pheburane** (Lucane Pharma Ltd) Sodium phenylbutyrate 483 mg per 1 gram Pheburane 483mg/g granules 174 gram £331.00

**Granules**

- **Amnomaps** (Swedish Orphan Biovitrum Ltd) Sodium phenylbutyrate 940 mg per 1 gram Amnomaps 940mg/g granules (sugar-free) 266 gram £660.00
- **Pheburane** (Lucane Pharma Ltd) Sodium phenylbutyrate 483 mg per 1 gram Pheburane 483mg/g granules 174 gram £331.00

**Pharmacokinetics**

When transferring from chelating agent because zinc has a slow onset of action. When transferring from chelating to zinc maintenance therapy, chelating on treatment to zinc maintenance therapy, chelating treatment should be co-administered for 2–3 weeks until zinc produces its maximal effect.

**Caution** Portal hypertension (risk of hepatic decompensation when switching from chelating agent)

**Interactions** → Appendix 1 (zinc).

**Side-effects**

- Common or very common  Gastric irritation (usually transient)
- Uncommon  Leucopenia - sideroblastic anaemia

**Further Information**

Transient gastric irritation may be reduced if first dose is taken mid-morning or with a little protein.

**Pregnancy**

Reduce dose to 25 mg 3 times daily adjusted according to plasma-copper concentration and urinary copper excretion.

**Breast-feeding**  Manufacturer advises avoid; present in milk—may cause zinc-induced copper deficiency in infant.

**Monitoring requirements**

Monitor full blood count and serum cholesterol.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

CAUTIONARY AND ADVISORY LABELS 23

- **Wilzin** (Orphan Europe (UK) Ltd) Zinc (as Zinc acetate) 25 mg Wilzin 25mg capsules 250 capsule £132.00
- Zinc (as Zinc acetate) 50 mg Wilzin 50mg capsules 250 capsule £242.00

**Copper Chelators**

**Trientine dihydrochloride**

**Indications and dose**

Wilson’s disease in patients intolerant of penicillamine

*By mouth*

- Adult: 1.2–2.4 g daily in 2–4 divided doses, adjusted according to response, to be taken before food

**Interactions**

- Common or very common  Nausea - rash
- Very rare  Anaemia
- Frequency not known  Colitis - duodenitis

**Pregnancy**

Teratogenic in animal studies—use only if benefit outweighs risk. Monitor maternal and neonatal serum-copper concentrations.

**Prescribing and dispensing information**

Trientine is not an alternative to penicillamine for rheumatoid arthritis or cystinuria. Penicillamine-induced systemic lupus erythematosus may not resolve on transfer to trientine.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

CAUTIONARY AND ADVISORY LABELS 6, 22

- **Trientine Dihydrochloride** (Non-proprietary)
  - Trientine dihydrochloride 300 mg Trientine dihydrochloride 300mg capsules 100 capsule no price available

4 Trace element deficiencies

**Trace elements**

**Selenium**

Selenium deficiency can occur as a result of inadequate diet or prolonged parenteral nutrition. A selenium supplement should not be given unless there is good evidence of deficiency.

**Zinc**

Zinc supplements should not be given unless there is good evidence of deficiency (hypoproteinaemia spuriously lowers plasma-zinc concentration) or in zinc-losing conditions. Zinc deficiency can occur as a result of inadequate diet or malabsorption; excessive loss of zinc can occur in trauma, burns, and protein-losing conditions. A zinc supplement is given until clinical improvement occurs, but it may need to be continued in severe malabsorption, metabolic disorders p. 864, or in zinc-losing states.
Zinc is used in the treatment of Wilson’s disease and acrodermatitis enteropathica, a rare inherited abnormality of zinc absorption.

Parenteral nutrition regimens usually include trace amounts of zinc. If necessary, further zinc can be added to intravenous feeding regimens.

4.1 Selenium deficiency

SELENIUM

INDICATIONS AND DOSE

Selenium deficiency

BY MOUTH OR BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION

Adult: 100–500 micrograms daily

INTERACTIONS Appendix 1 (selenium).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

➤ SELENIUM (Non-proprietary)
Selenium (selenite) 10 micrograms per 1 ml
Solgar Selenium 100microgram tablets | 100 tablet no price available
L-Selenomethionine 200 micrograms
Selenase 200 micrograms tablets | 30 tablet £8.60
Solgar Selenium 200 micrograms tablets | 50 tablet no price available | 250 tablet no price available
HealthAid Selenium 200 micrograms tablets | 60 tablet £3.90
Lamberts Selenium 200 micrograms tablets | 60 tablet £4.08
SelenoPrecise (Pharma Nord (UK) Ltd)
Selenium (as L-Selenomethionine) 100 micrograms
SelenoPrecise 100 microgram tablets | 60 tablet £6.75
L-Selenomethionine 200 micrograms
SelenoPrecise 200 microgram tablets | 60 tablet £4.02

Capsule

➤ SELENIUM (Non-proprietary)
SelenoPrecise 100 microgram capsules | 30 capsule £2.98 | 60 capsule £5.39

Oral solution

➤ Selense (Baxter Healthcare Ltd)
Selenium (sodium selenite) 50 micrograms per 1 ml
Selense 50 micrograms/2ml oral solution 2ml unit dose ampoules | 20 unit dose PLC no price available
Selense 500 micrograms/10ml oral solution unit dose vials | 10 unit dose PLC no price available

Solution for injection

➤ Selense (Baxter Healthcare Ltd)
Selenium (sodium selenite) 50 micrograms per 1 ml
Selense 100 micrograms/2ml solution for injection ampoules | 10 ampoule PLC no price available
Selense 500 micrograms/10ml solution for injection vials | 10 vial PLC no price available

Solution for infusion

➤ SELENIUM (Non-proprietary)
Selenium (sodium selenite) 10 micrograms per 1 ml
SelenoPrecise 10 micrograms/10mg solution for infusion vials | 10 vial PLC no price available

4.2 Zinc deficiency

ZINC

INDICATIONS AND DOSE

Zinc deficiency or supplementation in zinc-losing conditions

BY MOUTH USING EFFERVESCENT TABLETS

➤ Child (body-weight up to 10 kg): 22.5 mg daily, dose to be adjusted as necessary, to be dissolved in water and taken after food, dose expressed as elemental zinc

➤ Child (body-weight 10–30 kg): 22.5 mg 1–3 times a day, dose to be adjusted as necessary, to be dissolved in water and taken after food, dose expressed as elemental zinc

➤ Child (body-weight 30 kg and above): 45 mg 1–3 times a day, dose to be adjusted as necessary, to be dissolved in water and taken after food, dose expressed as elemental zinc

➤ Adult (body-weight 30 kg and above): 45 mg 1–3 times a day, dose to be adjusted as necessary, to be dissolved in water and taken after food, dose expressed as elemental zinc

Additional elemental zinc for intravenous nutrition

BY INTRAVENOUS INJECTION

Adult: 6.5 mg daily (Zn ²⁺ 100 micromol)

UNLICENSED USE Solvazine® is not licensed for use in acrodermatitis enteropathica.

INTERACTIONS ➤ Appendix 1 (zinc).

SIDE-EFFECTS Abdominal pain · diarrhoea · dyspepsia · gastric irritation · gastritis · headache · irritability · lethargy · nausea · vomiting

PREGNANCY Crosses placenta; risk theoretically minimal, but no information available.

BREAST FEEDING Present in milk; risk theoretically minimal, but no information available.

RENAL IMPAIRMENT Accumulation may occur in acute renal failure.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral solution, capsule, liquid

Effervescent tablet

CAUTIONARY AND ADVISORY LABELS 13, 21

➤ Solvazine (Galen Ltd)
Zinc sulfate monohydrate 125 mg Solvazine 125mg effervescent tablets (sugar-free) | 90 tablet £14.95 DT price = £14.95

5 Nutrition

5.1 Nutrition (intravenous)

Intravenous nutrition

When adequate feeding through the alimentary tract is not possible, nutrients may be given by intravenous infusion. This may be in addition to ordinary oral or tube feeding—supplemental parenteral nutrition, or may be the sole source of nutrition—total parenteral nutrition (TPN). Indications for this method include preparation of undernourished patients for surgery, chemotherapy, or radiation therapy; severe or prolonged disorders of the gastro-intestinal tract; major surgery, trauma, or burns;
Proprietary Infusion Fluids for Parenteral Feeding

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>1.2\textsuperscript{Energy} kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminoven 25 (Fresenius Kabi)</td>
<td>25.7</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 500 ml = £19.72</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinimix N9G20E (Baxter)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net price (dual compartment bag of amino acids with electrolytes 1000 mL and glucose 20% with calcium 1000 mL)</td>
<td>4.6</td>
<td>1680</td>
<td>30.0</td>
<td>2.5</td>
</tr>
<tr>
<td>2 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinimix N14G30E (Baxter)</td>
<td>7.0</td>
<td>2520</td>
<td>30.0</td>
<td>2.5</td>
</tr>
<tr>
<td>Net price (dual compartment bag of amino acids with electrolytes 1000 mL and glucose 30% with calcium 1000 mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ClinOleic 20% (Baxter)</td>
<td>3836</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 100 ml: no price available; Net price 250 ml: no price available; Net price 500 ml: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperamine 30 (B.Braun)</td>
<td>30.0</td>
<td>–</td>
<td>–</td>
<td>5.0</td>
</tr>
<tr>
<td>Net price 500 ml: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intralipid 10% (Fresenius Kabi)</td>
<td>4600</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 100 ml = £4.12; Net price 500 ml = £9.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intralipid 20% (Fresenius Kabi)</td>
<td>8400</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 100 ml = £6.21; Net price 250 ml = £10.16; Net price 500 ml = £13.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intralipid 30% (Fresenius Kabi)</td>
<td>12600</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 333 ml = £17.80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kabiven (Fresenius Kabi)</td>
<td>3275</td>
<td>32.0</td>
<td>23.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Net price (triple compartment bag of amino acids and electrolytes 300 mL, 450 mL, 600 mL, or 750 mL; glucose 526 mL, 790 mL, 1053 mL, or 1316 mL; lipid emulsion 200 mL, 300 mL, 400 mL, or 500 mL) 1.026 litre: no price available; Net price 1.54 litre = £44.09; Net price 2.053 litre = £57.42; Net price 2.566 litre = £59.92</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kabiven peripheral (Fresenius Kabi)</td>
<td>2625</td>
<td>26.0</td>
<td>17.0</td>
<td>2.8</td>
</tr>
<tr>
<td>Net price (triple compartment bag of amino acids and electrolytes 300 mL, 400 mL, or 500 mL; glucose 885 mL, 1180 mL, or 1475 mL; lipid emulsion 255 mL, 340 mL, or 425 mL) 1.44 litre = £30.77; Net price 1.92 litre = £44.09; Net price 2.4 litre = £55.72</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipidem (B.Braun)</td>
<td>7900</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 100 ml = £19.11; Net price 250 ml = £31.85; Net price 500 ml = £40.34</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipofundin MCT/LCT 10% (B.Braun)</td>
<td>4430</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 100 ml: no price available; Net price 500 ml = £13.70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipofundin MCT/LCT 20% (B.Braun)</td>
<td>8000</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Net price 100 ml = £13.28; Net price 250 ml: no price available; Net price 500 ml = £20.36</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2. Excludes protein- or amino acid-derived energy.
### Nutrition (intravenous)

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Preparation</th>
<th>Preparation</th>
<th>Preparation</th>
<th>Preparation</th>
<th>Preparation</th>
<th>Preparation</th>
<th>Preparation</th>
<th>Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutriflex basal (B.Braun)</td>
<td>4.6</td>
<td>2095</td>
<td>30.0</td>
<td>5.7</td>
<td>49.9</td>
<td>35.0</td>
<td>50.0</td>
<td>Ca** 3.6 mmol, acid phosphate 12.8 mmol, anhydrous glucose 125 g</td>
</tr>
<tr>
<td>Nutriflex peri (B.Braun)</td>
<td>5.7</td>
<td>1340</td>
<td>15.0</td>
<td>4.0</td>
<td>27.0</td>
<td>19.5</td>
<td>31.6</td>
<td>Ca** 2.5 mmol, acid phosphate 5.7 mmol, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>Nutriflex plus (B.Braun)</td>
<td>6.8</td>
<td>2510</td>
<td>25.0</td>
<td>5.7</td>
<td>37.2</td>
<td>22.9</td>
<td>35.5</td>
<td>Ca** 3.6 mmol, acid phosphate 20 mmol, anhydrous glucose 150 g</td>
</tr>
<tr>
<td>Nutriflex special (B.Braun)</td>
<td>10.0</td>
<td>4020</td>
<td>25.7</td>
<td>5.0</td>
<td>40.5</td>
<td>22.0</td>
<td>49.5</td>
<td>Ca** 4.1 mmol, acid phosphate 14.7 mmol, anhydrous glucose 240 g</td>
</tr>
<tr>
<td>NuTriflex Lipid peri (B.Braun)</td>
<td>4.56</td>
<td>2664</td>
<td>24.0</td>
<td>2.4</td>
<td>40.0</td>
<td>32.0</td>
<td>38.4</td>
<td>Ca** 2.4 mmol, Zn** 24 micromol, phosphate 6 mmol, anhydrous glucose 64 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>NuTriflex Lipid plus (B.Braun)</td>
<td>5.44</td>
<td>3600</td>
<td>28.0</td>
<td>3.2</td>
<td>40.0</td>
<td>36.0</td>
<td>36.0</td>
<td>Ca** 3.2 mmol, Zn** 24 micromol, phosphate 12 mmol, anhydrous glucose 120 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>NuTriflex Lipid plus without Electrolytes</td>
<td>5.44</td>
<td>3600</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>anhydrous glucose 120 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>(B.Braun)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTriflex Lipid special (B.Braun)</td>
<td>8.0</td>
<td>4004</td>
<td>37.6</td>
<td>4.24</td>
<td>53.6</td>
<td>48.0</td>
<td>48.0</td>
<td>Ca** 4.24 mmol, Zn** 32 micromol, phosphate 16 mmol, anhydrous glucose 144 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>NuTriflex Lipid special without Electrolytes (B.Braun)</td>
<td>8.0</td>
<td>4004</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>anhydrous glucose 144 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
</tbody>
</table>

1 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2 Excludes protein- or amino acid-derived energy
<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>1-2 Energy kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutriflex Omega plus (B.Braun)</td>
<td>5.4</td>
<td>3600</td>
<td>28.0</td>
<td>Ca(^{2+}) 3.2 mmol, Na(^{+}) 24 micromol, phosphate 12 mmol, anhydrous glucose 120 g, refined soya oil 16 g, medium-chain triglycerides 20 g, omega-3-acid triglycerides 4 g</td>
</tr>
<tr>
<td>Nutriflex Omega special (B.Braun)</td>
<td>8.0</td>
<td>4004</td>
<td>37.6</td>
<td>Ca(^{2+}) 4.24 mmol, Zn(^{2+}) 30 micromol, phosphate 16 mmol, anhydrous glucose 144 g, refined soya oil 16 g, medium-chain triglycerides 20 g, omega-3-acid triglycerides 4 g</td>
</tr>
<tr>
<td>OliClinomel N4-550E (Baxter)</td>
<td>3.6</td>
<td>2184</td>
<td>16.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 8.5 mmol, refined olive and soya oil 20 g, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>OliClinomel N4-720E (Baxter)</td>
<td>3.64</td>
<td>3024</td>
<td>24.0</td>
<td>Ca(^{2+}) 1.8 mmol, phosphate 8 mmol, refined olive and soya oil 40 g, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>OliClinomel N5-800E (Baxter)</td>
<td>4.6</td>
<td>3360</td>
<td>24.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 100 g</td>
</tr>
<tr>
<td>OliClinomel N6-900E (Baxter)</td>
<td>5.6</td>
<td>3696</td>
<td>24.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 120 g</td>
</tr>
<tr>
<td>OliClinomel N7-1000 (Baxter)</td>
<td>6.6</td>
<td>4368</td>
<td>24.0</td>
<td>phosphate 3 mmol, refined olive and soya oil 40 g, anhydrous glucose 160 g</td>
</tr>
<tr>
<td>OliClinomel N7-1000E (Baxter)</td>
<td>6.6</td>
<td>4368</td>
<td>24.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 160 g</td>
</tr>
<tr>
<td>OliClinomel N8-800 (Baxter)</td>
<td>8.25</td>
<td>3360</td>
<td>24.0</td>
<td>phosphate 2.25 mmol, refined olive and soya oil 30 g, anhydrous glucose 125 g</td>
</tr>
<tr>
<td>Omegaven (Fresenius Kabi)</td>
<td>-</td>
<td>4700</td>
<td>-</td>
<td>highly refined fish oil 100 g, glycerol 25 g, egg phosphatide 12 g</td>
</tr>
<tr>
<td>Plasma-Lyte 148 (water) (Baxter)</td>
<td>-</td>
<td>5.0</td>
<td>1.5</td>
<td>gluconate 23 mmol</td>
</tr>
</tbody>
</table>

1 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2 Excludes protein- or amino acid-derived energy.
**Nutrition (intravenous)**

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>Energy kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-Lyte 148 (dextrose 5%) (Baxter)</td>
<td>-</td>
<td>840</td>
<td>K⁺ Mg²⁺ Na⁺ Acet⁻ Cl⁻</td>
<td>gluconate 22 mmol, anhydrous glucose 30 g</td>
</tr>
<tr>
<td>Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma-Lyte M (dextrose 5%) (Baxter)</td>
<td>-</td>
<td>840</td>
<td>K⁺ Mg²⁺ Na⁺ Acet⁻ Cl⁻</td>
<td>Ca²⁺ 2.5 mmol, lactate 12 mmol, anhydrous glucose 50 g</td>
</tr>
<tr>
<td>Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMOFilipid (Fresenius Kabi) Net price 500 ml = £174.30</td>
<td>-</td>
<td>8400</td>
<td>-</td>
<td>fish oil 30 g, olive oil 50 g, soya oil 60 g, medium-chain triglycerides 60 g</td>
</tr>
<tr>
<td>Synthamin 9 (Baxter) Net price 500 ml: no price available; Net price 1 litre: no price available</td>
<td>9.1</td>
<td>-</td>
<td>60.0 5.0 70.0 100.0 70.0</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Synthamin 9 EF electrolyte-free (Baxter) Net price 500 ml: no price available; Net price 1 litre: no price available</td>
<td>9.1</td>
<td>-</td>
<td>-</td>
<td>44.0 22.0</td>
</tr>
<tr>
<td>Synthamin 14 (Baxter) Net price 500 ml: no price available; Net price 1 litre: no price available; Net price 3 litre: no price available</td>
<td>14.0</td>
<td>-</td>
<td>60.0 5.0 70.0 140.0 70.0</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Synthamin 14 EF electrolyte-free (Baxter) Net price 500 ml: no price available; Net price 1 litre: no price available; Net price 3 litre: no price available</td>
<td>14.0</td>
<td>-</td>
<td>-</td>
<td>68.0 34.0</td>
</tr>
<tr>
<td>Synthamin 17 (Baxter) Net price 500 ml: no price available; Net price 1 litre: no price available; Net price 3 litre: no price available</td>
<td>16.5</td>
<td>-</td>
<td>60.0 5.0 70.0 150.0 70.0</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Synthamin 17 EF electrolyte-free (Baxter) Net price 500 ml: no price available; Net price 1 litre: no price available; Net price 3 litre: no price available</td>
<td>16.5</td>
<td>-</td>
<td>-</td>
<td>82.0 40.0</td>
</tr>
<tr>
<td>Vamin 9 Glucose (Fresenius Kabi) Net price 100 ml = £3.90; Net price 500 ml = £7.95; Net price 1 litre = £13.80</td>
<td>9.4</td>
<td>1700</td>
<td>20.0 1.5 50.0 - 50.0</td>
<td>Ca²⁺ 2.5 mmol, anhydrous glucose 100 g</td>
</tr>
<tr>
<td>Vamin 14 (Fresenius Kabi) Net price 500 ml = £9.48; Net price 1 litre = £16.02</td>
<td>13.5</td>
<td>-</td>
<td>50.0 8.0 100.0 135.0 100.0</td>
<td>Ca²⁺ 5 mmol, SO₄⁻ 8 mmol</td>
</tr>
<tr>
<td>Vamin 14 electrolyte-free (Fresenius Kabi) Net price 500 ml = £9.48; Net price 1 litre = £16.02</td>
<td>13.5</td>
<td>-</td>
<td>-</td>
<td>90.0</td>
</tr>
<tr>
<td>Vamin 18 electrolyte-free (Fresenius Kabi) Net price 500 ml = £11.99; Net price 1 litre = £23.38</td>
<td>18.0</td>
<td>-</td>
<td>-</td>
<td>110.0</td>
</tr>
</tbody>
</table>

1 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2 Excludes protein- or amino acid-derived energy

Prolonged coma or refusal to eat; and some patients with renal or hepatic failure. The composition of proprietary preparations available is given under Proprietary Infusion Fluids for Parenteral Feeding p. 874.

Parenteral nutrition requires the use of a solution containing amino acids, glucose, fat, electrolytes, trace elements, and vitamins. This is now commonly provided by the pharmacy in the form of a 3-litre bag. A single dose of vitamin B₁₂, as hydroxocobalamin p. 837, is given by intramuscular injection; regular vitamin B₂ injections are not usually required unless total parenteral nutrition continues for many months. Folic acid p. 836 is given in a dose of 15 mg once or twice each week, usually in the nutrition solution. Other vitamins are usually given daily; they are generally introduced in the parenteral nutrition solution. Alternatively, if the patient is able to take small amounts by mouth, vitamins may be given orally.

The nutrition solution is infused through a central venous catheter inserted under full surgical precautions. Alternatively, infusion through a peripheral vein may be used for supplementary as well as total parenteral nutrition for periods of up to a month, depending on the availability of peripheral veins; factors prolonging cannula life and preventing thrombophlebitis include the use of soft polyurethane paediatric cannulas and use of feeds of low osmolality and neutral pH. Only nutritional fluids should be given by the dedicated intravenous line.

Before starting, the patient should be well oxygenated with a near normal circulating blood volume and attention should be given to renal function and acid-base status. Appropriate biochemical tests should have been carried out beforehand and serious deficits corrected. Nutritional and electrolyte status must be monitored throughout treatment.

Complications of long-term parenteral nutrition include gall bladder sludging, gall stones, cholestasis and abnormal osmolality.
liver function tests. For details of the prevention and management of parenteral nutrition complications, specialist literature should be consulted.

**Protein** is given as mixtures of essential and non-essential synthetic L-amino acids. Ideally, all essential amino acids should be included with a wide variety of nonessential ones to provide sufficient nitrogen together with electrolytes. Solutions vary in their composition of amino acids; they often contain an energy source (usually glucose p. 852) and electrolytes.

**Energy** is provided in a ratio of 0.6 to 1.1 megajoules (150–250 kcal) per gram of protein nitrogen. Energy requirements must be met if amino acids are to be utilised for tissue maintenance. A mixture of carbohydrate and fat energy sources (usually 30–50% as fat) gives better utilisation of amino acids than glucose alone.

Glucose p. 852 is the preferred source of carbohydrate, but if more than 180 g is given per day frequent monitoring of blood glucose is required, and insulin may be necessary. Glucose p. 852 in various strengths from 10 to 50% must be infused through a central venous catheter to avoid thrombosis.

In parenteral nutrition regimens, it is necessary to provide adequate phosphate in order to allow phosphorylation of glucose and to prevent hypophosphataemia; between 20 and 30 mmol of phosphate is required daily.

Fructose and sorbitol have been used in an attempt to avoid the problem of hyperosmolar hyperglycaemic nonketotic acidosis but other metabolic problems may occur, as with xylitol and ethanol which are now rarely used.

**Fat** emulsions have the advantages of a high energy to fluid volume ratio, neutral pH, and iso-osmolarity with plasma, and provide essential fatty acids. Several days of adaptation may be required to attain maximal utilisation. Reactions include occasional febrile episodes (usually only with 20% emulsions) and rare anaphylactic responses. Interference with biochemical measurements such as those for blood gases and calcium may occur if samples are taken before fat has been cleared. Daily checks are necessary to ensure complete clearance from the plasma in conditions where fat metabolism may be disturbed. **Additives should not be mixed with fat emulsions unless compatibility is known.**

**Administration**

Because of the complex requirements relating to parenteral nutrition full details relating to administration have been omitted. In all cases **product literature and other specialist literature should be consulted.**

### PARENTERAL NUTRITION

**Parenteral nutrition supplements**

| DIRECTIONS FOR ADMINISTRATION | Because of the complex requirements relating to parenteral nutrition, full details relating to administration have been omitted. In all cases **specialist pharmacy advice, product literature, and other specialist literature should be consulted.** Compatibility with the infusion solution must be ascertained before adding supplementary preparations. **Additives should not be mixed with fat emulsions unless compatibility is known.**
| **DIPEPTIVEN 20G/100ML CONCENTRATE FOR SOLUTION FOR INFUSION BOTTLES** | For addition to infusion solutions containing amino acids.
| **PEDITRACE®** | For addition to Vaminolact®, Vamin® 14 Electrolyte-Free solutions, and glucose intravenous infusions.
| **DECAN®** | For addition to infusion solutions.
| **ADDITRACE®** | For addition to Vamin® solutions and glucose intravenous infusions.
| **TRACUTIL®** | For addition to infusion solutions.
| **GLYCOPHOS®** | For addition to Vamin® and Vaminolact® solutions, and glucose intravenous infusions.
| **ADDIPHOS®** | For addition to Vamin® solutions and glucose intravenous infusions.
| **CERNEVIT®** | Dissolve in 5mL water for injection.
| **VITLIPID N INFANT** | For addition to Intralipid®.
| **VITLIPID®** | For addition to Intralipid®.
| **SOLIVITO®** | Dissolve in water for injections or glucose intravenous infusion for adding to glucose intravenous infusion or Intralipid®; dissolve in Vitlipid N® or Intralipid® for adding to Intralipid® only.
| **PRESCRIBING AND DISPENSING INFORMATION** | **DIPEPTIVEN®** Dipeptiven® solution contains N(2)-L-alanyl-glutamine 200mg/mL (providing L-alanine 82 mg, L-glutamine 134.6mg)
| **PEDITRACE®** | For use in neonates (when kidney function established, usually second day of life), infants, and children.
| **DECAN®** | For patients over 40kg.
| **ADDITRACE®** | For patients over 40kg.
| **TRACUTIL®** | For adults.
| **GLYCOPHOS®** | Glycophos® Sterile Concentration solution contains phosphate 20mmol, Na⁺ 40mmol/20mL
| **ADDIPHOS®** | Addiphos sterile solution contains phosphate 40mmol, K⁺ 30mmol, Na⁺ 30 mmol/20mL.
| **VITLIPID N ADULT®** | For adults and children over 11 years.
Enteral nutrition

The body’s reserves of protein rapidly become exhausted in severely ill patients, especially during chronic illness or in those with severe burns, extensive trauma, pancreatitis, or intestinal fistula. Much can be achieved by frequent meals and by persuading the patient to take supplementary snacks of ordinary food between the meals. However, extra calories, proteins, vitamin, other nutrients, and vitamins are often best given by supplementing ordinary meals with enteral sip or tube feeds.

When patients cannot feed normally, for example, patients with severe facial injury, oesophageal obstruction, or coma, a nutritionally complete diet of enteral feeds must be given. The advice of a dietitian should be sought to determine the protein and total energy requirement of the patient and the form and relative contribution of carbohydrate and fat to the energy requirements.

Most enteral feeds contain protein derived from cows' milk or soya. Elemental feeds containing protein hydrolysates or free amino acids can be used for patients who have diminished ability to break down protein, for example in inflammatory bowel disease or pancreatic insufficiency.

Even when nutritionally complete feeds are given, water and electrolyte balance should be monitored. Haematological and biochemical parameters should also be monitored, particularly in clinically unstable patients. Extra minerals (e.g. magnesium and zinc) may be needed in patients where gastro-intestinal secretions are being lost. Additional vitamins may also be needed.

Enteral nutrition in children

Children have special requirements and in most situations liquid feeds prepared for adults are totally unsuitable—the advice of a paediatric dietitian should be sought.

5.3 Phenylketonuria

Phenylketonuria

Phenylketonuria (hyperphenylalaninaemia, PKU), which results from the inability to metabolise phenylalanine, is managed by restricting dietary intake of phenylalanine to a small amount sufficient for tissue building and repair. Sapropterin dihydrochloride p. 880, a synthetic form of tetrahydrobiopterin, is licensed as an adjunct to dietary restriction of phenylalanine in the management of patients with phenylketonuria and tetrahydrobiopterin deficiency.
5.4 Special diets

Nutrition in special diets

These are preparations that have been modified to eliminate a particular constituent from a food or that are nutrient mixtures formulated as food substitutes for patients who either cannot tolerate or cannot metabolise certain common constituents of food. In certain clinical conditions, some food preparations are regarded as drugs and can be prescribed within the NHS if they have been approved by the Advisory Committee on Borderline Substances (ACBS).

Aspartame (used as a sweetener in some foods and medicines) contributes to the phenylalanine intake and may affect control of phenylketonuria. Where the presence of aspartame is specified in the product literature this is indicated in the BNF against the preparation; the patient should be informed of this.

Coeliac disease

Intolerance to gluten in coeliac disease is managed by completely eliminating gluten from the diet. A range of gluten-free products is available for prescription.

6 Vitamin deficiencies

Vitamins

Vitamins are used for the prevention and treatment of specific deficiency states or where the diet is known to be inadequate; they may be prescribed in the NHS to prevent or treat deficiency but not as dietary supplements.

Their use as general ‘pick-me-ups’ is of unproven value and, in the case of preparations containing vitamin A or D, may actually be harmful if patients take more than the prescribed dose. The 'fad' for mega-vitamin therapy with water-soluble vitamins, such as ascorbic acid p. 884 and pyridoxine hydrochloride p. 882, is unscientific and can be harmful.

Dietary reference values for vitamins are available in the Department of Health publication:


Dental patients

It is unjustifiable to treat stomatitis or glossitis with mixtures of vitamin preparations; this delays diagnosis and correct treatment.

Most patients who develop a nutritional deficiency despite an adequate intake of vitamins have malabsorption and if this is suspected the patient should be referred to a medical practitioner.

Vitamin A

Deficiency of vitamin A (retinol) is associated with ocular defects (particularly xerophthalmia) and an increased susceptibility to infections, but deficiency is rare in the UK (even in disorders of fat absorption).

Vitamin B group

Deficiency of the B vitamins, other than vitamin B₆, is rare in the UK and is usually treated by preparations containing thiamine p. 882 (B₁), riboflavin (B₂), and nicotinamide, which is used in preference to nicotinic acid, as it does not cause vasodilatation. Other members (or substances traditionally classified as members) of the vitamin B complex such as aminobenzoic acid, biotin, choline, inositol nicotinate p. 206, and pantothentic acid or panthenol may be included in vitamin B preparations but there is no evidence of their value.

The severe deficiency states Wernicke’s encephalopathy and Korsakoff’s psychosis, especially as seen in chronic alcoholism, are best treated initially by the parenteral administration of B vitamins (Pabrinex®), followed by oral...
administration of thiamine p. 882 in the longer term. Anaphylaxis has been reported with parenteral B vitamins.

As with other vitamins of the B group, pyridoxine hydrochloride p. 882 (B₆) deficiency is rare, but it may occur during isoniazid therapy or penicillamine treatment in Wilson’s disease and is characterised by peripheral neuritis. High doses of pyridoxine hydrochloride p. 882 are given in some metabolic disorders, such as hyperoxaluria, and it is also used in sideroblastic anaemia. There is evidence to suggest that pyridoxine hydrochloride may provide some benefit in premenstrual syndrome. It has been tried for a wide variety of other disorders, but there is little sound evidence to support the claims of efficacy.

Nicotinic acid p. 177 inhibits the synthesis of cholesterol and triglyceride. Folic acid p. 836 and vitamin B₁₂ are used in the treatment of megaloblastic anaemia. Folic acid p. 781 (available as calcium folinate) is used in association with cytotoxic therapy.

**Vitamin C**

Vitamin C (ascorbic acid p. 884) therapy is essential in scurvy, but less florid manifestations of vitamin C deficiency are commonly found, especially in the elderly. Severe scurvy causes gingival swelling and bleeding margins as well as petechiae on the skin. This is, however, exceedingly rare and a patient with these signs is more likely to have leukaemia. Investigation should not be delayed by a trial period of vitamin treatment.

Claims that vitamin C ameliorates colds or promotes treatment of various disorders associated with excessive fibrosis such as scleroderma and Peyronie’s disease. In Peyronie’s disease there is some evidence to support efficacy in reducing progression when given early in the disease; however, there is no evidence for reversal of the condition. The therapeutic value of potassium aminobenzoate in scleroderma is doubtful.

**Vitamin D**

The term Vitamin D is used for a range of compounds which possess the property of preventing or curing rickets. They include ergocalciferol p. 887 (calciferol, vitamin D₂), colecalciferol (vitamin D₃) p. 886, dihydrocholesterol p. 887, alfalcacidol (1α-hydroxycholecalciferol) p. 885, and calcitriol (1,25-dihydroxycholecalciferol) p. 885. Simple vitamin D deficiency can be prevented by taking an oral supplement of ergocalciferol (calciferol, vitamin D₂) or colecalciferol (vitamin D₃) daily. Vitamin D deficiency can occur in people whose exposure to sunlight is limited and in those whose diet is deficient in vitamin D. In these individuals, ergocalciferol orcolecalciferol daily by mouth may be given to treat vitamin D deficiency; higher doses may be necessary for severe deficiency. Patients who do not respond should be referred to a specialist.

Preparations containing calcium carbonate with colecalciferol p. 886 are available for the management of combined calcium and vitamin D deficiency, or for those at high risk of deficiency. Vitamin D deficiency caused by intestinal malabsorption or chronic liver disease usually requires vitamin D in pharmacological doses.

Vitamin D requires hydroxylation by the kidney to its active form, therefore the hydroxylated derivatives alfalcacidol p. 885 or calcitriol p. 885 should be prescribed if patients with severe renal impairment require vitamin D therapy. Calcitriol is also licensed for the management of postmenopausal osteoporosis.

Paricalcitol p. 888, a synthetic vitamin D analogue, is licensed for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

**Vitamin E**

The daily requirement of vitamin E (tocopherol) has not been well defined but is probably 3 to 15 mg daily. There is little evidence that oral supplements of vitamin E are essential in adults, even where there is fat malabsorption secondary to cholestasis. In young children with congenital cholestasis, abnormally low vitamin E concentrations may be found in association with neuromuscular abnormalities, which usually respond only to the parenteral administration of vitamin E. Vitamin E has been tried for various other conditions but there is little scientific evidence of its value.

**Vitamin K**

Vitamin K is necessary for the production of blood clotting factors and proteins necessary for the normal calcification of bone.

Because vitamin K is fat soluble, patients with fat malabsorption, especially in biliary obstruction or hepatic disease, may become deficient. Menadione sodium phosphate p. 889 is a water-soluble synthetic vitamin K derivative that can be given orally to prevent vitamin K deficiency in malabsorption syndromes.

Oral coumarin anticoagulants act by interfering with vitamin K metabolism in the hepatic cells and their effects can be antagonised by giving vitamin K.

**Other compounds**

Potassium aminobenzoate p. 882 has been used in the treatment of various disorders associated with excessive fibrosis such as scleroderma and Peyronie’s disease. In Peyronie’s disease there is some evidence to support efficacy in reducing progression when given early in the disease; however, there is no evidence for reversal of the condition. The therapeutic value of potassium aminobenzoate in scleroderma is doubtful.

**MULTIVITAMINS**

**Vitamins A and D**

**INDICATIONS AND DOSE**

Prevention of vitamin A and D deficiency

- **BY MOUTH**
  - Child: 1 capsule daily, 1 capsule contains 4000 units vitamin A and 400 units (10 micrograms) vitamin D
  - Adult: (consult product literature)

- **UNLICENSED USE** Not licensed in children under 6 months of age.

- **INTERACTIONS** → Appendix 1 (vitamins).

- **SIDE-EFFECTS**
  - Overdose Prolonged excessive ingestion of vitamins A and D can lead to hypervitaminosis.
  - PRESCRIBING AND DISPENSING INFORMATION This drug contains vitamin D; consult individual vitamin D monographs.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **VITAMINS A AND D (Non-proprietary)**
  - Vitamin A 4000 unit, Vitamin D 400 unit
  - Vitamins A and D capsules BPC 1973 | 28 capsule G55 £2.81 | 84 capsule £8.42 DT price = £8.42

**Vitamins A, C and D**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ascorbic acid p. 884, vitamin D p. 884.
882 Vitamin deficiencies

*PRESCRIBING AND DISPENSING INFORMATION* This drug contains vitamin D; consult individual vitamin D monographs. Available free of charge to children under 4 years in families on the Healthy Start Scheme, or alternatively may be available direct to the public—further information for healthcare professionals can be accessed at www.healthystart.nhs.uk. Beneficiaries can contact their midwife or health visitor for further information on where to obtain supplies.

*Health Start Vitamins for women* (containing ascorbic acid, vitamin D, and folic acid) are also available free of charge to women on the Healthy Start Scheme during pregnancy and until their baby is one year old, or alternatively may be available direct to the public—further information for healthcare professionals can be accessed at www.healthystart.nhs.uk. Beneficiaries can contact their midwife or health visitor for further information on where to obtain supplies.

**VITAMIN B GROUP**

Potassium aminobenzoate

*INDICATIONS AND DOSE*

Peyronie’s disease | Scleroderma

**BY MOUTH**

▶ Adult: 12 g daily in divided doses, to be taken after food

**INTERACTIONS** → Appendix 1 (potassium aminobenzoate).

**M EDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

CAUTIONARY AND ADVISORY LABELS 21

▶ Potaba (Cheplapharm Arzneimittel GmbH)

Potassium aminobenzoate 500 mg | Potaba 500mg capsules | 240 capsule £44.75

**Powder**

CAUTIONARY AND ADVISORY LABELS 13, 21

▶ Potaba (Cheplapharm Arzneimittel GmbH)

Potassium aminobenzoate 3 gram | Potaba 3g sachets | 40 sachet £34.31

Pyridoxine hydrochloride

(Vitamin B₆)

*INDICATIONS AND DOSE*

Deficiency states

**BY MOUTH**

▶ Adult: 20–50 mg 1–3 times a day

Isoniazid-induced neuropathy (prophylaxis)

**BY MOUTH**

▶ Adult: 10–20 mg daily

Isoniazid-induced neuropathy (treatment)

**BY MOUTH**

▶ Adult: 50 mg 3 times a day

**INTERACTIONS**

→ Appendix 1 (vitamins).

**SIDE-EFFECTS** Sensory neuropathy (with high doses when given for extended periods)

**Overdose**

Overdosage induces toxic effects.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral suspension, oral solution, capsule

**Tablet**

▶ PYRIDOXINE HYDROCHLORIDE (Non-proprietary)

Pyridoxine hydrochloride 10 mg | Pyridoxine 10mg tablets | 28 tablet £12.95 | 30 tablet £16.65 no price available | 60 tablet £24.85 no price available | 500 tablet £8.63

Pyridoxine (as Pyridoxine hydrochloride) 20 mg | Pyridoxine 20mg tablets | 500 tablet £8.53

Pyridoxine hydrochloride 50 mg | Pyridoxine 50mg tablets | 28 tablet no price available DT price = £4.33

▶ Brands may include Pyrid

**Capsule**

▶ PYRIDOXINE HYDROCHLORIDE (Non-proprietary)

Pyridoxine (as Pyridoxine hydrochloride) 100 mg | Pyridoxine 100mg capsules | 100 capsule no price available

Thiamine

(Vitamin B₁)

**INDICATIONS AND DOSE**

Mild deficiency

**BY MOUTH**

▶ Adult: 25–100 mg daily

Severe deficiency

**BY MOUTH**

▶ Adult: 200–300 mg daily in divided doses

**INTERACTIONS**

→ Appendix 1 (vitamins).

**SIDE-EFFECTS**

Although potentially serious allergic adverse reactions may rarely occur during, or shortly after, parenteral administration, the CHM has recommended that:

▶ This should not preclude the use of parenteral thiamine in patients where this route of administration is required, particularly in patients at risk of Wernicke-Korsakoff syndrome where treatment with thiamine is essential.

**UNLICENSED USE**

Not licensed for prophylaxis of pyridoxine in a dose of 10 mg daily is considered safe but the long-term use of pyridoxine in a dose of 200 mg or more daily has been associated with neuropathy. The safety of long-term pyridoxine supplementation with doses above 10 mg daily has not been established.

**Important safety information**

Prolonged use of pyridoxine in a dose of 10 mg daily is considered safe but the long-term use of pyridoxine in a dose of 200 mg or more daily has been associated with neuropathy. The safety of long-term pyridoxine supplementation with doses above 10 mg daily has not been established.
● Intravenous administration should be by infusion over 30 minutes;
● Facilities for treating anaphylaxis (including resuscitation facilities) should be available when parenteral thiamine is administered.

● CAUTIONS Anaphylaxis may occasionally follow injection
● BREAST FEEDING Severely thiamine-deficient mothers should avoid breast-feeding as toxic methyl-glyoxal present in milk.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

- THIAMINE (Non-proprietary)
  - Thiamine hydrochloride 50 mg Thiamine 50mg tablets  
    100 tablet £ no price available DT price = £7.13 | 100 tablet £7.13
  - Thiamine hydrochloride 100 mg Thiamine 100mg tablets  
    100 tablet £9.18 DT price = £11.55 | 100 tablet £ no price available DT price = £11.55
  - Benerva (Bayer Pic)
    Thiamine hydrochloride 50 mg Benerva 50mg tablets  
    100 tablet £3.98 DT price = £7.13
  - Thiamine hydrochloride 100 mg Benerva 100mg tablets  
    100 tablet £6.16 DT price = £11.55
  - Tyvera (Teva UK Ltd, Almus Pharmaceuticals Ltd)
    Thiamine hydrochloride 50 mg Tyvera 50mg tablets  
    100 tablet £5.46-£5.72 DT price = £7.13
  - Thiamine hydrochloride 100 mg Tyvera 100mg tablets  
    100 tablet £8.46-£8.18 DT price = £11.55

Modified-release tablet

- THIAMINE (Non-proprietary)
  - Thiamine hydrochloride 100 mg HealthAid Vitamin B1 100mg modified-release tablets  
    90 tablet £4.18

Vitamin B complex

INDICATIONS AND DOSE

Prophylaxis of deficiency
BY MOUTH USING TABLETS

- Adult: 1–2 tablets daily, this dose is for vitamin B compound tablets

Treatment of deficiency
BY MOUTH USING TABLETS

- Adult: 1–2 tablets 3 times daily as a single dose, this dose is for vitamin B compound strong tablets

LESS SUITABLE FOR PRESCRIBING Vitamin B compound tablets are less suitable for prescribing. Vitamin B compound strong tablets are less suitable for prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

- VITAMIN B COMPLEX (Non-proprietary)
  - Nicotinamide 15 mg, Riboflavin 1 mg, Thiamine hydrochloride 1 mg Vitamin B compound tablets | 28 tablet £ no price available DT price = £26.62 | 1000 tablet £10.50
  - Nicotinamide 20 mg, Pyridoxine hydrochloride 2 mg, Riboflavin 2 mg, Thiamine hydrochloride 5 mg Vitamin B compound strong tablets | 28 tablet £ no price available DT price = £1.95 | 1000 tablet £ no price available | 1000 tablet £ no price available

Psychosis following narcosis or electroconvulsive therapy
Toxicity from acute infections
BY INTRAVENOUS INFUSION OR BY DEEP INTRAMUSCULAR INJECTION

- Adult: 1 pair twice daily for up to 7 days, give deep intramuscular injection into the gluteal muscle

Haemodialysis
BY INTRAVENOUS INFUSION

- Adult: 1 pair every 2 weeks

UNLICENSED USE Pabrinex® doses in BNF may differ from those in product literature.

DIRECTIONS FOR ADMINISTRATION Give (Pabrinex® I/V High Potency) intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%. Ampoules contents should be mixed, diluted, and administered without delay, give over 30 minutes.

PRESCRIBING AND DISPENSING INFORMATION Some formulations of Pabrinex® may contain benzyl alcohol (avoid in neonates). Pabrinex® I/M High Potency injection is for intramuscular use only.

Pabrinex® I/V High Potency injection is for intravenous use only.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Not applicable
EXCipients: May contain Benzyl alcohol

- Pabrinex Intramuscular High Potency (Archimedes Pharma UK Ltd) Pabrinex Intramuscular High Potency solution for injection 5ml and 2ml ampoules | 20 ampoule £53 £22.53 DT price = £22.53
- Pabrinex Intravenous High Potency (Archimedes Pharma UK Ltd) Pabrinex Intravenous High Potency solution for injection 5ml and 5ml ampoules | 20 ampoule £53 £22.53 DT price = £22.53

Blood and nutrition
Vitamin deficiencies

Vitamins with minerals and trace elements

**INDICATIONS AND DOSE**

**KETOVITE® TABLETS**
Prevention of vitamin deficiency in disorders of carbohydrate or amino-acid metabolism / Adjunct in restricted, specialised, or synthetic diets

**BY MOUTH**
- Adult: 1 tablet 3 times a day, use with Ketrovite® Liquid for complete vitamin supplementation.

**FORCEVAL® CAPSULES**
Vitamin and mineral deficiency and as adjunct in synthetic diets

**BY MOUTH**
- Adult: 1 capsule daily, one hour after a meal

**PRESCRIBING AND DISPENSING INFORMATION**
To avoid potential toxicity, the content of all vitamin preparations, particularly vitamin A, should be considered when used together with other supplements.

**PATIENT AND CARER ADVICE**
**KETOVITE® TABLETS** Tablets may be crushed immediately before use.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **VITAMINS WITH MINERALS AND TRACE ELEMENTS (Non-proprietary)**
  - Ascorbic acid 500 mg, Biotin 15 mg, Calcium 60 mg, Copper 3 mg, Cyanocobalamin 25 microgram, Folic acid 250 microgram, Iron 12 mg, Iodine 140 microgram, Iodine 120 microgram, Iron 12 mg, Manganese 30 mg, Molybdenum 25 microgram, Nickel 250 microgram, Phosphorus 77 mg, Potassium 4 mg, Pyridoxine 2 mg, Riboflavin 1.6 mg, Selenium 50 microgram, Thiamine 1.2 mg, Tocopherol 10 mg, Vitamin A 2500 unit, Zinc 15 mg
- **Ascorbic acid 60 mg, Biotin 15 mg, Calcium 60 mg, Copper 3 mg, Cyanocobalamin 25 microgram, Folic acid 250 microgram, Iron 12 mg, Iodine 140 microgram, Iodine 120 microgram, Iron 12 mg, Manganese 30 mg, Molybdenum 25 microgram, Nickel 250 microgram, Phosphorus 77 mg, Potassium 4 mg, Pyridoxine 2 mg, Riboflavin 1.6 mg, Selenium 50 microgram, Thiamine 1.2 mg, Tocopherol 10 mg, Vitamin A 2500 unit, Zinc 15 mg

**Capsule**
- **Forceval** (Alliance Pharmaceuticals Ltd)
  - Ascorbic acid 60 mg, Biotin 100 microgram, Calcium 100 mg, Chromium 200 microgram, Copper 2 mg, Cyanocobalamin 3 microgram, Ergocalciferol 400 unit, Folic acid 400 microgram, Iodine 140 microgram, Iron 12 mg, Magnesium 30 mg, Manganese 3 mg, Molybdenum 250 microgram, Nicotinamide 18 mg, Pantothenic acid 4 mg, Phosphorus 77 mg, Potassium 4 mg, Pyridoxine 2 mg, Riboflavin 1.6 mg, Selenium 50 microgram, Thiamine 1.2 mg, Tocopherol 10 mg, Vitamin A 2500 unit, Zinc 15 mg

**VITAMIN C**
Ascorbic acid (Vitamin C)

**INDICATIONS AND DOSE**

**Prevention of scurvy**

**BY MOUTH**
- Adult: 25–75 mg daily

**Treatment of scurvy**

**BY MOUTH**
- Adult: Not less than 250 mg daily in divided doses

**PRESCRIBING AND DISPENSING INFORMATION**
- It is rarely necessary to prescribe more than 100 mg daily except early in the treatment of scurvy.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral suspension, solution for infusion, oral solution

**Tablet**
- **EXCIPIENTS:** May contain Aspartame
  - **ASCORBIC ACID (Non-proprietary)**
    - Ascorbic acid 50 mg Ascorbic acid 50mg tablets £12.42 DT price = £12.33 | 100 tablet [**GSS**] £4.32
      - 500 tablet [**GSS**] no price available
    - Ascorbic acid 100 mg Ascorbic acid 100mg tablets
      - 28 tablet [**GSS**] £14.30 DT price = £14.19
    - Ascorbic acid 200 mg Ascorbic acid 200mg tablets
      - 28 tablet [**GSS**] £18.60 DT price = £18.47 | 100 tablet [**GSS**] no price available
    - Ascorbic acid 500 mg Ascorbic acid 500mg tablets
      - 28 tablet [**GSS**] £26.87 DT price = £26.67 | 100 tablet [**GSS**] £11.53

**Chewable tablet**
- **CAUTIONARY AND ADVISORY LABELS 24**
- **EXCIPIENTS:** May contain Aspartame
  - **ASCORBIC ACID (Non-proprietary)**
    - Ascorbic acid 60 mg Ascorbic acid 60mg chewable tablets £60 no price available | 180 tablet no price available
    - Ascorbic acid (as Sodium ascorbate) 500 mg Ascorbic acid 500mg chewable tablets (sugar-free) | 60 tablet no price available
    - Ascorbic acid 500 mg Ascorbic acid 500mg chewable tablets
      - 60 tablet £3.90 | 100 tablet £5.58
  - **Brands may include Ascur and Halliborange Hallibonbons**

**Capsule**
- **ASCORBIC ACID (Non-proprietary)**
  - Ascorbic acid 500 mg Ascorbic acid 500mg capsules £100 no price available
  - **Also available in combination with vitamin B substances, p. 883.**

**VITAMIN D AND ANALOGUES**

**Vitamin D and analogues (systemic)**

**CONTRA-INDICATIONS**
- Hypercalcaemia - metastatic calcification

**INTERACTIONS**
- Appendix 1 (vitamins).

**SIDE-EFFECTS**

**Overdose**
- Symptoms of overdosage include anorexia, lassitude, nausea and vomiting, diarrhoea, constipation, weight loss, polypusia, sweating, headache, thirst, vertigo, and raised concentrations of calcium and phosphate in plasma and urine.

**PREGNANCY**
- High doses teratogenic in animals but therapeutic doses unlikely to be harmful.

**BREAST FEEDING**
- Caution with high doses; may cause hypercalcaemia in infant—monitor serum-calcium concentration.

**MONITORING REQUIREMENTS**
- **Important:** All patients receiving pharmacological doses of vitamin D should have their plasma-calcium concentration checked at intervals (initially once or twice weekly) and whenever nausea or vomiting occur.
Vitamin deficiencies 885

Alfacalcidol
(1α-Hydroxycholecalciferol)

**INDICATIONS AND DOSE**

Patients with severe renal impairment requiring vitamin D therapy

BY MOUTH OR BY INTRAVENOUS INJECTION

- Adult: Initially 1 microgram daily, dose to be adjusted to avoid hypercalcaemia; maintenance 0.25–1 microgram daily
- Elderly: Initially 500 nanograms daily, dose adjusted to avoid hypercalcaemia; maintenance 0.25–1 microgram daily

**SIDE-EFFECTS**

- Rare: Nephrolithiasis, pruritus, rash, urticaria

**RENAL IMPAIRMENT**

Monitor plasma-calcium concentration in renal impairment.

**MONITORING REQUIREMENTS**

Monitor plasma-calcium concentration in patients receiving high doses.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For injection, shake ampoule for at least 30 seconds.

**PRESCRIBING AND DISPENSING INFORMATION**

The concentration of alfacalcidol in One-Alpha® drops is 10 times greater than that of the former preparation One-Alpha® solution.

- **CAUTIONS**
  - Nephrolithiasis - take care to ensure correct dose in infants

- **SIDE-EFFECTS**
  - Rare: Nephrolithiasis - pruritus - rash - urticaria

- **EXCIPIENTS**
  - May contain Sesame oil

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Capsule**

- **EXCIPIENTS**: May contain Sesame oil
- **alfa-calcidol (non-proprietary)**
  - Alfacalcidol 250 nanogram One-Alpha 250nanogram capsules | 30 capsule [PoS] £6.33 DT price = £2.51
  - Alfacalcidol 500 nanogram One-Alpha 500nanogram capsules | 30 capsule [PoS] £11.25 DT price = £5.18
  - Alfacalcidol 1 microgram One-Alpha 1microgram capsules | 30 capsule no price available DT price = £5.74 | 30 capsule [PoS] £15.25 DT price = £5.74
  - One-Alpha (Leo Pharma)
  - Alfacalcidol 250 nanogram One-Alpha 250nanogram capsules | 30 capsule [PoS] £3.37 DT price = £2.51
  - Alfacalcidol 500 nanogram One-Alpha 0.5microgram capsules | 30 capsule [PoS] £6.27 DT price = £5.18

Calcitriol
(1,25-Dihydroxycholecalciferol)

**INDICATIONS AND DOSE**

**Renal osteodystrophy**

**BY MOUTH**

- Adult: Initially 250 nanograms daily, adjusted in steps of 250 nanograms every 2–4 weeks if required; usual dose 0.5–1 microgram daily

**Renal osteodystrophy (in patients with normal or only slightly reduced plasma-calcium concentration)**

**BY MOUTH**

- Adult: Initially 250 nanograms once daily on alternate days, adjusted in steps of 250 nanograms every 2–4 weeks if required; usual dose 0.5–1 microgram daily

**Established postmenopausal osteoporosis**

**BY MOUTH**

- Adult: 250 nanograms twice daily, plasma-calcium concentration and creatinine to be monitored (consult product literature)

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Capsule**

- **Calcitriol (non-proprietary)**
  - Calcitriol 250 nanogram Calcitriol 250nanogram capsules | 30 capsule [PoS] £18.04 | 100 capsule [PoS] no price available DT price = £34.08
  - Calcitriol 500 nanogram Calcitriol 500nanogram capsules | 30 capsule [PoS] £32.25 | 100 capsule [PoS] no price available DT price = £73.25
  - Rocaltrol (Roche Products Ltd)
  - Calcitriol 250 nanogram Rocaltrol 250nanogram capsules | 100 capsule [PoS] £18.04 DT price = £6.04
  - Calcitriol 500 nanogram Rocaltrol 500nanogram capsules | 100 capsule [PoS] £32.25 DT price = £32.25
Colecalciferol
(Cholecalciferol; Vitamin D₃)

INDICATIONS AND DOSE
Prevention of vitamin D deficiency
BY MOUTH
- Adult: 400 units daily
Treatment of vitamin D deficiency
BY MOUTH
- Adult: 800 units daily, higher doses may be necessary for severe deficiency

- RENAL IMPAIRMENT
  Monitor plasma-calcium concentration in renal impairment.
- MONITORING REQUIREMENTS
  Monitor plasma-calcium concentration in patients receiving high doses.
- DIRECTIONS FOR ADMINISTRATION
  INVITA D₃
  - May be mixed with a small amount of cold or lukewarm food immediately before administration.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral drops, oral solution, capsule

- Tablet
  - COLECALCIFEROL (Non-proprietary)
    Colecalciferol 400 unit Colecalciferol 400unit tablets | 120 tablet £3.21
    Colecalciferol 1000 unit Colecalciferol 1,000unit tablets | 28 tablet £20.95 | 90 tablet £34.50 | 180 tablet no price available
    Colecalciferol 5000 unit Colecalciferol 5,000unit tablets | 60 tablet £5.00 | 100 tablet £9.99 | 200 tablet £18.66
    Colecalciferol 20000 unit Colecalciferol 20,000unit tablets | 30 tablet no price available
  - Brands may include Aciferol D, Cucibole D3, Desunin, E-D3, Iso D3, Stexerol-D3, and SunVit D3

- Chewable tablet
  - COLECALCIFEROL (Non-proprietary)
    Colecalciferol 280 unit Colecalciferol 280unit chewable tablets | 180 tablet £5.00

- Orodispersible tablet
  - COLECALCIFEROL (Non-proprietary)
    Colecalciferol 2000 unit Colecalciferol 2,000unit chewable tablets (sugar-free) | 120 tablet £4.88

- Capsule
  CAUTIONARY AND ADVISORY LABELS 25
  - COLECALCIFEROL (Non-proprietary)
    Colecalciferol 400 unit Colecalciferol 400unit capsules | 30 capsule no price available | 60 capsule no price available | 100 capsule no price available
    Colecalciferol 500 unit Colecalciferol 500unit capsules | 90 capsule no price available
    Colecalciferol 600 unit Colecalciferol 600unit capsules | 60 capsule no price available | 120 capsule no price available
    Colecalciferol 800 unit Colecalciferol 800unit capsules | 30 capsule £3.60 DT price + £3.60
    Colecalciferol 1000 unit Colecalciferol 1,000unit capsules | 28 capsule £6.50 | 30 capsule £9.50
    Colecalciferol 2000 unit Colecalciferol 2,000unit capsules | 50 capsule no price available | 100 capsule no price available
    Colecalciferol 5000 unit Colecalciferol 5,000unit capsules | 40 capsule no price available

- Oral solution
  CAUTIONARY AND ADVISORY LABELS 21
  - COLECALCIFEROL (Non-proprietary)
    Colecalciferol 3000 unit per 1 ml Colecalciferol 3,000units/ml oral solution | 100 ml £119.70 DT price + £23.00

Colecalciferol with calcium carbonate

The properties listed below are those particular to the combination only. For the properties of the components please consider, colecaldierol above, calcium carbonate p. 856.

INDICATIONS AND DOSE
Prevention and treatment of vitamin D and calcium deficiency
BY MOUTH
- Adult: Dosed according to the deficit or daily maintenance requirements (consult product literature)

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

- Tablet
  EXCIPIENTS: May contain Propylene glycol
  - CALCIUM CARBONATE WITH COLECALCIFEROL (Non-proprietary)
    Calcium carbonate 400 mg, Colecalciferol 100 unit Calcium & Vitamin D tablets | 30 tablet £0.59
    - Accrete D3 (Internis Pharmaceuticals Ltd)
      Calcium carbonate 1.5 gram, Colecalciferol 400 unit Accrete D3 tablets | 60 tablet £2.95 DT price + £2.95
    - Adcal-D3 (Prostrakan Ltd)
      Calcium carbonate 750 mg, Colecalciferol 200 unit Adcal-D3 750mg/200unit caplets | 112 tablet £3.65 DT price + £3.65
    - Calcichew D3 (Forum Health Products Ltd)
      Calcium carbonate 1.25 gram, Colecalciferol 400 unit Calcichew D3 500mg/400unit caplets | 100 tablet £7.43 DT price + £7.43
    - Kalcips-D (Media Pharmaceuticals Ltd)
      Calcium carbonate 1.25 gram, Colecalciferol 800 unit Kalcips-D 500mg/800unit tablets | 30 tablet £4.21 DT price + £4.21

- Chewable tablet
  CAUTIONARY AND ADVISORY LABELS 24
  EXCIPIENTS: May contain Aspartame
  - CALCIUM CARBONATE WITH COLECALCIFEROL (Non-proprietary)
    Calcium carbonate 400 mg, Colecalciferol 100 unit Seven Seas Calcium and Vitamin D chewable tablets | 30 tablet £1.76
    Calcium carbonate 1.25 gram, Colecalciferol 400 unit Colecalciferol 400unit / Calcium carbonate 1.25g chewable tablets | 100 tablet £14.75-£15.69
Colecalfilerol with calcium phosphate

The properties listed below are those particular to the combination only. For the properties of the components please consider, colecalfilerol p. 886, calcium p. 856.

**INDICATIONS AND DOSE**
Calcium and vitamin D deficiency

**BY MOUTH**

- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder**

**CAUTIONARY AND ADVISORY LABELS 13, 21**
- Calfivit D3 (A. Menarini Farmaceutica Internazionale SRL)
- Calfovit D3 (Forum Health Products Ltd)
- Calfovit® Calcium phosphate 1 gram, Colecalciferol 800 unit Califivit D3 oral powder sachets | 30 sachet (P) £4.32 DT price = £4.32

**Dihydrotachysterol**

**INDICATIONS AND DOSE**

Acute, chronic, and latent forms of hypocalcaemic tetany due to hypoparathyroidism

**BY MOUTH**

- Adult: (consult product literature)

**RENAI IMPAIRMENT** Monitor plasma-calcium concentration in renal impairment.

**MONITORING REQUIREMENTS** Monitor plasma-calcium concentration in patients receiving high doses.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

**EXCIPIENTS:** May contain Arachis (peanut) oil

- AT10 (Intrapharm Laboratories Ltd)
- Dihydrotachysterol 250 microgram per 1 ml AT10
  - 250micrograms/ml oral solution (sugar-free) | 15 ml (P) £22.87

**Ergocalferol**

(Calciferol; Vitamin D₃)

**INDICATIONS AND DOSE**

Vitamin D deficiency caused by intestinal malabsorption or chronic liver disease

**BY MOUTH**

- Adult: Up to 40 000 units daily

Hypocalcaemia of hypoparathyroidism to achieve normocalcaemia

**BY MOUTH**

- Adult: Up to 100 000 units daily

Prevention of vitamin D deficiency

**BY MOUTH**

- Adult: 400 units daily

Treatment of vitamin D deficiency

**BY MOUTH**

- Adult: 800 units daily, higher doses may be necessary for severe deficiency

**CAUTIONS** Take care to ensure correct dose in infants

**RENAI IMPAIRMENT** Monitor plasma-calcium concentration in hepatic impairment.

**MONITORING REQUIREMENTS** Monitor plasma-calcium concentration in patients receiving high doses.

**PRESCRIBING AND DISPENSING INFORMATION** The BP directs that when calciferol is prescribed or demanded, colecalfilerol or ergocalferol should be dispensed or supplied. When the strength of the tablets ordered or prescribed is not clear, the intention of the prescriber with respect to the strength (expressed in micrograms or milligrams per tablet) should be ascertained.**

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, solution for injection, oral suspension, oral solution, capsule

**Tablet**

- **ERGOCALFEROL (Non-proprietary)**
  - Ergocalferol 12.5 microgram Ergocalferol 500unit tablets | 60 tablet £3.74
  - Ergoral (Cubic Pharmaceuticals Ltd)
  - Ergocalferol 125 microgram Ergoral D2 5,000unit tablets | 30 tablet £19.95
  - Ergocalferol 250 microgram Ergoral D2 10,000unit tablets | 30 tablet £23.95

**Capsule**

- **ERGOCALFEROL (Non-proprietary)**
  - Ergocalferol 1.25 mg Ergocalferol 50,000 unit capsules | 30 capsule £6.80 | 100 capsule £11.90
  - Brands may include Eciferol; Ergoral

**Oral solution**

- Eciferol (Disposable Medical Equipment Ltd)
- Ergocalferol 3000 unit per 1 ml Eciferol D2 3,000units/ml liquid | 60 ml £55.00

**Ergocalferol with calcium lactate and calcium phosphate**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ergocalferol above, calcium lactate p. 857.
### Vitamin E

**Alpha tocopherol (Tocopherol)**

**INDICATIONS AND DOSE**

Vitamin E deficiency because of malabsorption in congenital or hereditary chronic cholestasis

BY MOUTH USING ORAL SOLUTION

- Child: 17 mg/kg daily, dose to be adjusted as necessary

**SIDE-EFFECTS**

- Common or very common Diarrhoea
- Uncommon Alopecia, asthenia, disturbances in serum-potassium concentration, disturbances in serum-sodium concentration, headache, pruritus, rash
- PREGNANCY Manufacturer advises caution, no evidence of harm in animal studies.
- BREAST FEEDING Manufacturer advises use only if potential benefit outweighs risk—no information available.
- HEPATIC IMPAIRMENT Manufacturer advises caution—no information available. Manufacturer advises monitor closely in hepatic impairment.
- RENAL IMPAIRMENT Manufacturer advises caution. Risk of renal toxicity due to polyethylene glycol content. Manufacturer advises monitor closely in renal impairment.

**PRESCRIBING AND DISPENSING INFORMATION**

Tocofersolan is a water-soluble form of D-alpha tocopherol.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- Vedrop (Orphan Europe (UK) Ltd) ▼
  - D-alpha tocopherol (as Tocofersolan) 50 mg per 1 ml Vedrop 50mg/ml oral solution (sugar-free) | 20 ml [POT] £54.55 (sugar-free) | 60 ml [POT] £163.65

### Paricalcitol

**INDICATIONS AND DOSE**

For prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure

BY MOUTH

- Adult: (consult product literature)

**SIDE-EFFECTS**

- Acne, breast tenderness, dyspepsia, pruritus, rash, taste disturbance

**PREGNANCY**

Toxicity in animal studies—manufacturer advises avoid unless potential benefit outweighs risk.

**BREAST FEEDING**

Manufacturer advises caution—no information available.

**MONITORING REQUIREMENTS**

- Monitor plasma calcium and phosphate during dose titration and at least monthly when stabilised.
- Monitor parathyroid hormone concentration.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- Zemplar (AbbVie Ltd)
  - Paricalcitol 1 microgram Zemplar 1microgram capsules | 28 capsule [POT] £69.28
  - Paricalcitol 2 microgram Zemplar 2microgram capsules | 28 capsule [POT] £138.88

**Solution for injection**

**EXCIPIENTS:** May contain Propylene glycol

- Zemplar (AbbVie Ltd)
  - Paricalcitol 5 microgram per 1 ml Zemplar 5micrograms/1ml solution for injection ampoules | 5 ampoule [POT] £62.00 (Hospital only)

### Alphatocopheryl acetate (Tocopherol)

**INDICATIONS AND DOSE**

Vitamin E deficiency

BY MOUTH

- Child: 2–10 mg/kg daily, increased if necessary up to 20 mg/kg daily

Malabsorption in cystic fibrosis

BY MOUTH

- Child 1–11 months: 50 mg once daily, dose to be adjusted as necessary, to be taken with food and pancreatic enzymes
- Child 1–11 years: 100 mg once daily, dose to be adjusted as necessary, to be taken with food and pancreatic enzymes
- Child 12–17 years: 200–200 mg once daily, dose to be adjusted as necessary, to be taken with food and pancreatic enzymes
- Adult: 100–200 mg once daily, dose to be adjusted as necessary, to be taken with food and pancreatic enzymes
MEDICINAL FORMS

INTERACTIONS

CAUTIONS

VITAMIN K

Menadiol sodium phosphate

INDICATIONS AND DOSE

Prevention of Vitamin K deficiency in malabsorption syndromes

BY MOUTH

Adult: 10–40 mg daily, dose to be adjusted as necessary

CONTRA-INDICATIONS

CAUTIONS

G6PD deficiency (risk of haemolysis) - vitamin E deficiency (risk of haemolysis)

INTERACTIONS

PREGNANCY

Avoid in late pregnancy and labour unless benefit outweighs risk of neonatal haemolytic anaemia, hyperbilirubinemia, and kernicterus in neonate.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension, tablet

Tablet

Menadiol sodium phosphate (Non-proprietary)

Menadiol phosphate (as Menadiol sodium phosphate)

10 mg

Menadiol 10mg tablets | 100 tablet £128.60 DF price = £128.60

Phytomenadione

(Vitamin K<sub>1</sub>)

INDICATIONS AND DOSE

Major bleeding in patients on warfarin (in combination with dried prothrombin complex or fresh frozen plasma)

BY SLOW INTRAVENOUS INJECTION

Adult: 5 mg for 1 dose, stop warfarin treatment

INR > 8.0 with minor bleeding in patients on warfarin

BY SLOW INTRAVENOUS INJECTION

Adult: 1–3 mg, stop warfarin treatment, dose may be repeated if INR still too high after 24 hours, restart warfarin treatment when INR < 5

INR > 8.0 with no bleeding in patients on warfarin

BY MOUTH

Adult: 1–5 mg, intravenous preparation to be used orally, stop warfarin treatment, repeat dose if INR still too high after 24 hours, restart warfarin treatment when INR < 5

INR 5.0–8.0 with minor bleeding in patients on warfarin

BY SLOW INTRAVENOUS INJECTION

Adult: 1–3 mg, stop warfarin treatment, restart warfarin treatment when INR < 5

Peri-operative anticoagulation (after warfarin stopped)

BY MOUTH

Adult: 1–5 mg, intravenous preparation to be used orally, dose to be given the day before surgery if INR > 1.5

CAUTIONS

Intravenous injections should be given very slowly - risk of vascular collapse

KONAKION® MM

Reduce dose in elderly.

INTERACTIONS

Appendix 1 (vitamins).

SIDE-EFFECTS

KONAKION® MM

Anaphylactoid reactions.

PREGNANCY

Use if potential benefit outweighs risk.

BREAST FEEDING

Present in milk.

HEPATIC IMPAIRMENT

KONAKION® MM

Caution - glycocholic acid may displace bilirubin.

DIRECTIONS FOR ADMINISTRATION

KONAKION® MM

May be administered by slow intravenous injection or by intravenous infusion in glucose 5%: not for intramuscular injection. For intravenous infusion, give intermittently in glucose 5%; dilute with 55ml; may be injected into lower part of infusion apparatus.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, drops, oral solution

Capsule

PHOTOMENADIONE (Non-proprietary)

Phytomenadione 10 mg

Phytomenadione 10mg capsules | 50 capsule £29.00

Neokay (Neoceuticals Ltd)

Phytomenadione 1 mg

NeoKay 1mg capsules | 12 capsule 25p £3.95 DF price + £3.95 | 100 capsule 25p £34.00

Drops

Neookay (Neoceuticals Ltd)

Phytomenadione 200 microgram per 1 ml NeoKay 200micrograms/ml oral drops (sugar-free) | 25 ml £3.95
6.1 Neural tube defects
(prevention in pregnancy)

Neural tube defects (prevention in pregnancy)

Folic acid p. 836 supplements taken before and during pregnancy can reduce the occurrence of neural tube defects. The risk of a neural tube defect occurring in a child should be assessed and folic acid given as follows:

- Women at a low risk of conceiving a child with a neural tube defect should be advised to take folic acid as a medicinal or food supplement daily (at low-risk group dose) before conception and until week 12 of pregnancy. Women who have not been taking folic acid and who suspect they are pregnant should start at once and continue until week 12 of pregnancy.

- Couples are at a high risk of conceiving a child with a neural tube defect if either partner has a neural tube defect (or either partner has a family history of neural tube defects), if they have had a previous pregnancy affected by a neural tube defect, or if the woman has coeliac disease (or other malabsorption state), diabetes mellitus, sickle-cell anaemia, or is taking antiepileptic medicines.

- Women in the high-risk group who wish to become pregnant (or who are at risk of becoming pregnant) should be advised to take folic acid daily (at high-risk group dose) and continue until week 12 of pregnancy (women with Sickle-cell disease p. 820 should continue taking their normal dose of folic acid (or to increase the dose to high-risk group daily dose) and continue this throughout pregnancy).

There is no justification for prescribing multiple-ingredient vitamin preparations containing vitamin B₁₂ or folic acid.
Chapter 10
Musculoskeletal system

CONTENTS
1 Arthritis  page 891
2 Hyperuricaemia and gout  908
3 Neuromuscular disorders  910
3.1 Myasthenia gravis and Lambert-Eaton myasthenic syndrome  911
3.2 Nocturnal leg cramps  913
4 Pain and inflammation in musculoskeletal disorders  915
5 Soft tissue and joint disorders  939
5.1 Local inflammation of joints and soft tissue  939
5.2 Soft tissue disorders  940

1 Arthritis

Arthritis

Rheumatoid arthritis and other inflammatory disorders

A non-steroidal anti-inflammatory drug (NSAID) is indicated for pain and stiffness resulting from inflammatory rheumatic disease; analgesics such as paracetamol p. 354 or codeine phosphate p. 360 can also be used.

Drugs are also used to influence the rheumatic disease process itself. For rheumatoid arthritis these disease-modifying antirheumatic drugs (DMARDs) include methotrexate p. 762, cyclosporine p. 717, cyclophosphamide p. 750, leflunomide p. 895, penicillamine p. 896, gold, antimalarials (chloroquine p. 536 and hydroxychloroquine sulfate p. 894), and sulfasalazine p. 37. Corticosteroids also have a significant role in the management of rheumatoid arthritis.

Drugs which may affect the disease process in psoriatic arthritis include sulfasalazine, gold, azathioprine, methotrexate, leflunomide, and cytotoxic modulators.

Osteoarthritis and soft-tissue disorders

For pain relief in osteoarthritis and soft-tissue disorders, paracetamol p. 354 should be used first and may need to be taken regularly. A topical NSAID or topical capsaicin p. 37 should also be considered, particularly in knee or hand osteoarthritis. An oral NSAID can be substituted for, or used in addition to, paracetamol. If further pain relief is required in osteoarthritis, then the addition of an opioid analgesic may be considered, but with a substantial risk of adverse effects; however, an opioid analgesic should be considered in patients taking low-dose aspirin.

Intra-articular corticosteroid injections may produce temporary benefit in osteoarthritis, especially if associated with soft-tissue inflammation.

Non-drug measures, such as weight reduction and exercise, should also be encouraged.

Gluconamid p. 893 and rubefacients are not recommended for the treatment of osteoarthritis.

Hyaluronic acid and its derivatives are available for osteoarthritis of the knee, but are not recommended. Sodium hyaluronate (Durolane®, Euflexxa®, Fermlaron®, Hyalgan®, Orthovisc®, Ostenil®, Ostenil Plus®, Renenh Vis®, Suplasytn®, Synocrom®, Synovis®) is also licensed for the relief of pain and optimisation of recovery following ankle sprain, and for the relief of chronic pain and disability associated with tennis elbow.

Rheumatic disease, suppressing drugs

Certain drugs such as those affecting the immune response can suppress the disease process in rheumatoid arthritis and psoriatic arthritis; gold, penicillamine p. 896, hydroxychloroquine sulfate p. 894, chloroquine p. 536, and sulfasalazine p. 37 can also suppress the disease process in rheumatoid arthritis while sulfasalazine p. 37 and possibly gold can suppress the disease process in psoriatic arthritis. Unlike NSAIDs, which are used only for symptom control, disease-modifying anti-rheumatic drugs (DMARDS) can affect the progression of disease but may require 2–6 months of treatment for a full therapeutic response. Response to DMARDs may allow the NSAID dose to be reduced or withdrawn. All patients with suspected inflammatory joint disease should be referred to a specialist as soon as possible to confirm diagnosis and evaluate disease activity; early initiation of DMARDs is recommended to control the signs and symptoms, and to limit joint damage.

Choice

The choice of a disease-modifying antirheumatic drug should take into account co-morbidity and patient preference. Methotrexate p. 762, sulfasalazine p. 37, intramuscular gold, and penicillamine p. 896 are similar in efficacy. However, methotrexate or sulfasalazine may be better tolerated. A combination of DMARDs (including methotrexate and at least one other DMARD) and a short-term corticosteroid, should be given to patients with newly diagnosed active rheumatoid arthritis, ideally within 3 months of the onset of persistent symptoms. If the use of particular DMARDs is contra-indicated and combination therapy is not possible, monotherapy with a suitable DMARD should be given and the dose rapidly increased until clinically effective. In patients with established and stable rheumatoid arthritis, cautiously reduce drug doses to the lowest that are clinically effective. Response to drug treatment often produces a reduction in requirements of both corticosteroids and other drugs.

Gold and penicillamine p. 896 are effective in palindromic rheumatism. Systemic and discoid lupus erythematosus are
sometimes treated with chloroquine p. 536 or hydroxychloroquine sulfate p. 894.

If a disease-modifying anti-rheumatic drug does not lead to an objective benefit within 6 months, it should be replaced by a different one.

**Gold**

Gold can be given as sodium aurothiomalate p. 897 for active progressive rheumatoid arthritis; it must be given by deep intramuscular injection and the area gently massaged. A test dose must be given followed by doses at weekly intervals until there is definite evidence of remission. In patients who do respond, the interval between injections is then gradually increased to 4 weeks and treatment is continued for up to 5 years after complete remission. If relapse occurs the dosage frequency may be immediately increased and only once control has been obtained again should the dosage frequency be decreased; if no response is seen within 2 months, alternative treatment should be sought. It is important to avoid complete relapse since second courses of gold are not usually effective.

**Penicillamine**

Penicillamine p. 896 has a similar action to gold. More patients are able to continue treatment than with gold but side-effects are common.

Patients should be warned not to expect improvement for at least 6 to 12 weeks after treatment is initiated. Penicillamine should be discontinued if there is no improvement within 1 year.

**Sulfasalazine**

Sulfasalazine p. 37 has a beneficial effect in suppressing the inflammatory activity of rheumatoid arthritis. Sulfasalazine may also be used by specialists, in the management of psoriatic arthritis affecting peripheral joints [unlicensed indication]. Haematological abnormalities occur usually in the first 3 to 6 months of treatment and are reversible on cessation of treatment.

**Antimalarials**

The antimalarial hydroxychloroquine sulfate p. 894 is used to treat rheumatoid arthritis of moderate inflammatory activity; chloroquine p. 536 is also licensed for treating inflammatory disorders but is used much less frequently and is generally reserved for use if other drugs have failed.

Chloroquine and hydroxychloroquine sulfate are effective for mild systemic lupus erythematosus, particularly involving the skin and joints. These drugs should not be used for psoriatic arthritis. Chloroquine and hydroxychloroquine sulfate are better tolerated than gold or penicillamine. Retinopathy rarely occurs provided that the recommended doses are not exceeded; in the elderly it is difficult to distinguish drug-induced retinopathy from changes of ageing.

Mepacrine hydrochloride p. 438 is sometimes used in discoid lupus erythematosus [unlicensed].

**Drugs affecting the immune response**

Methotrexate p. 762 is a disease-modifying antirheumatic drug suitable for moderate to severe rheumatoid arthritis. Azathioprine p. 716, ciclosporin p. 717, cyclophosphamide p. 750, leflunomide p. 895, and the cytokine modulators are not considered more toxic and they are used in cases that have not responded to other disease-modifying drugs.

Methotrexate is usually given by mouth once a week, adjusted according to response. In patients who experience mucosal or gastro-intestinal side-effects with methotrexate, folic acid p. 836 given every week [unlicensed indication], on a different day from the methotrexate, may help to reduce the frequency of such side-effects.

Leflunomide acts on the immune system as a disease-modifying antirheumatic drug. Its therapeutic effect starts after 4–6 weeks and improvement may continue for a further 4–6 months. Leflunomide, which is similar in efficacy to sulfasalazine p. 37 and methotrexate p. 762, may be chosen when these drugs cannot be used.

Ciclosporin p. 717 is licensed for severe active rheumatoid arthritis when conventional second-line therapy is inappropriate or ineffective. There is some evidence that ciclosporin may retard the rate of erosive progression and improve symptom control in those who respond only partially to methotrexate.

Cyclophosphamide can also be given for severe systemic rheumatoid arthritis and for other connective tissue diseases (especially with active vasculitis).

Drugs that affect the immune response are also used in the management of severe cases of systemic lupus erythematosus and other connective tissue disorders. They are often given in conjunction with corticosteroids for patients with severe or progressive renal disease. They may be used in cases of polymyositis that are resistant to corticosteroids. They are used for their corticosteroid-sparing effect in patients whose corticosteroid requirements are excessive. Azathioprine p. 716 is usually used.

In the specialist management of psoriatic arthritis affecting peripheral joints, leflunomide p. 895, methotrexate p. 762, or azathioprine p. 716 [unlicensed indication] may be used.

**Juvenile idiopathic arthritis**

Many children with juvenile idiopathic arthritis (juvenile chronic arthritis) do not require disease-modifying antirheumatic drugs. Methotrexate p. 762 is effective; sulfasalazine p. 37 is an alternative [unlicensed indication] but it should be avoided in systemic-onset juvenile idiopathic arthritis. Gold and penicillamine p. 896 are no longer used.

Cytokine modulators have a role in juvenile idiopathic arthritis.

**Cytokine modulators**

Cytokine modulators should be used under specialist supervision.

Adalimumab p. 901, certolizumab pegol p. 902, etanercept p. 903, golimumab p. 904, and infliximab p. 906 inhibit the activity of tumour necrosis factor alpha (TNF-α).

Adalimumab is licensed for moderate to severe active rheumatoid arthritis when response to other disease modifying antirheumatic drugs (including methotrexate p. 762) has been inadequate; it is also licensed for severe, active, and progressive disease in adults not previously treated with methotrexate. In the treatment of rheumatoid arthritis, adalimumab should be used in combination with methotrexate, but it can be given alone if methotrexate is inappropriate. Adalimumab is also licensed for the treatment of active and progressive psoriatic arthritis and severe active ankylosing spondylitis that have not responded adequately to other disease-modifying antirheumatic drugs. It is also licensed for the treatment of severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to, or are intolerant of NSAIDs. Adalimumab also has a role in inflammatory bowel disease and plaque psoriasis.

Certolizumab pegol is licensed for use in patients with moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drugs (including methotrexate p. 762) has been inadequate.

Certolizumab pegol can be used in combination with
methotrexate, or as a monotherapy if methotrexate is not tolerated or is contra-indicated. Certolizumab pegol is also licensed for the treatment of severe active ankylosing spondylitis in patients who have had an inadequate response to, or are intolerant of NSAIDs. It is also licensed for the treatment of severe active axial spondylarthritis, without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to, or are intolerant of NSAIDs.

Etanercept p. 903 is licensed for the treatment of moderate to severe active rheumatoid arthritis either alone or in combination with methotrexate p. 762 when the response to other disease-modifying antirheumatic drugs is inadequate and in severe, active and progressive rheumatoid arthritis in patients not previously treated with methotrexate. It is also licensed for the treatment of active and progressive psoriatic arthritis inadequately responsive to other disease-modifying antirheumatic drugs, and for severe ankylosing spondylitis inadequately responsive to conventional therapy. Etanercept also has a role in plaque psoriasis.

Golimumab p. 904 is licensed in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drug (DMARD) therapy (including methotrexate) has been inadequate; it is also licensed in combination with methotrexate for patients with severe, active, and progressive rheumatoid arthritis not previously treated with methotrexate. Golimumab is also licensed for the treatment of active and progressive psoriatic arthritis, as monotherapy or in combination with methotrexate, when response to DMARD therapy has been inadequate; it is also licensed for the treatment of severe active ankylosing spondylitis when there is an inadequate response to conventional treatment.

Infliximab p. 906 is licensed for the treatment of active rheumatoid arthritis in combination with methotrexate when the response to other disease-modifying antirheumatic drugs, including methotrexate, is inadequate; it is also licensed in combination with methotrexate for patients not previously treated with methotrexate or other DMARDs who have severe, active, and progressive rheumatoid arthritis. Infliximab is also licensed for the treatment of ankylosing spondylitis, in patients with severe axial symptoms who have not responded adequately to conventional therapy, and in combination with methotrexate (or alone if methotrexate is not tolerated or is contra-indicated) for the treatment of active and progressive psoriatic arthritis which has not responded adequately to disease-modifying antirheumatic drugs.

Rituximab p. 734 is licensed in combination with methotrexate for the treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them. Rituximab has a role in malignant disease.

Abatacept p. 900 prevents the full activation of T-lymphocytes. It is licensed for moderate to severe active rheumatoid arthritis in combination with methotrexate, in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor). Abatacept is not recommended for use in combination with TNF inhibitors.

Anakinra p. 897 inhibits the activity of interleukin-1. Anakinra (in combination with methotrexate) is licensed for the treatment of rheumatoid arthritis which has not responded to methotrexate alone. Anakinra is not recommended for the treatment of rheumatoid arthritis except when used in a controlled long-term clinical study. Patients who are already receiving anakinra for rheumatoid arthritis should continue treatment until they and their specialist consider it appropriate to stop.

Belimumab p. 725 inhibits the activity of B-lymphocyte stimulator. Belimumab is licensed as adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy.

Tocilizumab p. 898 antagonises the actions of interleukin-6. Tocilizumab is licensed for use in patients with moderate to severe active rheumatoid arthritis when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs. Tocilizumab can be used in combination with methotrexate, or as monotherapy if methotrexate is not tolerated or is contra-indicated.

Ustekinumab p. 899 inhibits the activity of interleukins 12 and 23. It is licensed for the treatment of active psoriatic arthritis (in combination with methotrexate or alone) in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs.

CHONDROPROTECTIVE DRUGS

**Glucosamine**

- **DRUG ACTION** Glucosamine is a natural substance found in mucopolysaccharides, mucoproteins, and chitin.

**INDICATIONS AND DOSE**

**ALATERIS®**

Symptomatic relief of mild to moderate osteoarthritis of the knee

- Adult: 2 tablets once daily, review treatment if no benefit after 2–3 months

**DOLENO®**

Symptomatic relief of mild to moderate osteoarthritis of the knee

- Adult: 1 tablet once daily, review treatment if no benefit after 2–3 months

**GLUSARTEL®**

Symptomatic relief of mild to moderate osteoarthritis of the knee

- Adult: 1 sachet once daily, dose to be dissolved in at least 250 mL of water, review treatment if no benefit after 2–3 months

- **CAUTIONS** Asthma · impaired glucose tolerance · predisposition to cardiovascular disease

- **INTERACTIONS** → Appendix 1 (glucosamine).

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · constipation · diarrhoea · drowsiness · dyspepsia · fatigue · flatulence · headache · nausea
  - **Uncommon** Flushing · pruritus · rash
  - **Frequency not known** Hair loss · visual disturbances

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated if patient has a shellfish allergy.

- **PREGNANCY** Manufacturers advise avoid—no information available.

- **BREAST FEEDING** Manufacturers advise avoid—no information available.

- **MONITORING REQUIREMENTS**
  - Monitor blood-glucose concentration before treatment and periodically thereafter in patients with impaired glucose tolerance.
  - Monitor cholesterol in patients with predisposition to cardiovascular disease.
DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS

Hydroxychloroquine sulfate

**INDICATIONS AND DOSE**

Active rheumatoid arthritis (including juvenile idiopathic arthritis) (administered on expert advice) / Systemic and discoid lupus erythematosus (administered on expert advice) / Dermatological conditions caused or aggravated by sunlight (administered on expert advice)

**BY MOUTH**

- Adult: 200–400 mg daily, daily maximum dose to be based on ideal body-weight; maximum 6.5 mg/kg per day

**CAUTIONS**

Acute porphyrias p. 864 / elderly - G6PD deficiency - may aggravate myasthenia gravis - may exacerbate psoriasis - neurological disorders (especially in those with a history of epilepsy) - severe gastro-intestinal disorders

**CAUTIONS, FURTHER INFORMATION**

Screening for ocular toxicity: A review group convened by the Royal College of Ophthalmologists has updated guidelines for screening to prevent ocular toxicity on long-term treatment with chloroquine and hydroxychloroquine (Hydroxychloroquine and Ocular Toxicity: Recommendations on Screening 2009).

The following recommendations relate to hydroxychloroquine, which is only rarely associated with toxicity.

**Before treatment:**

- Assess renal and liver function (adjust dose if impaired)
- Ask patient about visual impairment (not corrected by glasses). If impairment or eye disease present, assessment by an optometrist is advised and any abnormality should be referred to an ophthalmologist
- Record near visual acuity of each eye (with glasses where appropriate) using a standard reading chart
- Initiate hydroxychloroquine treatment if no abnormality detected (at a dose not exceeding hydroxychloroquine sulfate 6.5 mg/kg daily)

**During treatment:**

- Ask patient about visual symptoms and monitor visual acuity annually using the standard reading chart
- Refer to ophthalmologist if visual acuity changes or if vision blurred and warn patient to seek prescribing doctor’s advice about stopping treatment
- If long-term treatment is required (more than 5 years), individual arrangement should be agreed with the local ophthalmologist

**INTERACTIONS** → Appendix 1 (chloroquine and hydroxychloroquine). Concurrent use of hepatotoxic drugs should be avoided.

**SIDE-EFFECTS**

- Common or very common / Gastro-intestinal disturbances - headache - pruritus - rashes / skin reactions
- Uncommon / Convulsions - discoloration of skin, nails, and mucous membranes / ECG changes / hair depigmentation / hair loss / keratopathy / otoxicity / retinal damage / visual changes
- Rare / Acute generalised exanthematous pustulosis / agranulocytosis / angioedema / aplastic anaemia / blood disorders / cardiomyopathy / emotional disturbances / exfoliative dermatitis / hepatic damage / mental changes / myopathy / neuromyopathy / photosensitivity / psychosis / Stevens-Johnson syndrome / thrombocytopenia
- Frequency not known / Bronchospasm - diffuse parenchymal lung disease / drug rash with eosinophilia and systemic symptoms

**Overdose** Hydroxychloroquine is very toxic in overdosage; overdosage is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).

**PREGNANCY** It is not necessary to withdraw an antimalarial drug during pregnancy if the rheumatic disease is well controlled; however, the manufacturer of hydroxychloroquine advises avoiding use.

**BREAST FEEDING** Avoid - risk of toxicity in infant.

**HEPATIC IMPAIRMENT** Caution in moderate to severe hepatic impairment.

**RENAL IMPAIRMENT** Manufacturer advises caution. Monitor plasma-hydroxychloroquine concentration in severe renal impairment.

**MONITORING REQUIREMENTS** Manufacturers recommend regular ophthalmological examination but the evidence of practical value is unsatisfactory (see advice of the Royal College of Ophthalmologists, above).

**PRESCRIBING AND DISPENSING INFORMATION** To avoid excessive dosage in obese patients, the dose of hydroxychloroquine should be calculated on the basis of ideal body-weight.

**PATIENT AND CARER ADVICE** Do not take antacids for at least 4 hours before or after hydroxychloroquine to reduce absorption.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

- The Scottish Medicines Consortium has advised (May 2008) that glucosamine (Alateris®) and (July 2011) glucosamine (Glusartel®) are not recommended for use within NHS Scotland for the symptomatic relief of mild to moderate osteoarthritis of the knee.

**LESS SUITABLE FOR PRESCRIBING** Less suitable for prescribing - the mechanism of action is not understood and there is limited evidence to show it is effective.
Leflunomide

INDICATIONS AND DOSE
Moderate to severe active rheumatoid arthritis (specialist use only)

BY MOUTH
- Adult: Initially 100 mg once daily for 3 days, then reduced to 10–20 mg once daily

Active psoriatic arthritis

BY MOUTH
- Adult: Initially 100 mg once daily for 3 days, then reduced to 20 mg once daily

CONTRA-INDICATIONS
Serious infection - severe hypoproteinaemia - severe immunodeficiency

CAUTIONS
Anaemia (avoid if significant and due to causes other than rheumatoid arthritis) - history of tuberculosis - impaired bone-marrow function (avoid if significant and due to causes other than rheumatoid arthritis) - leucopenia (avoid if significant and due to causes other than rheumatoid arthritis) - thrombocytopenia (avoid if significant and due to causes other than rheumatoid arthritis)

INTERACTIONS
Appendix 1 (leflunomide).

Increased risk of toxicity with other haematotoxic and hepatotoxic drugs. Caution if recent treatment with other hepatotoxic disease-modifying anti-rheumatic drugs. Caution if recent treatment with other myelotoxic disease-modifying anti-rheumatic drugs. Caution—washout procedures recommended before switching to other disease-modifying antirheumatic drugs (consult product literature).

SIDE-EFFECTS
- Common or very common Abdominal pain - alopecia - anorexia - arthralgia - diarrhoea - dizziness - dry skin - headache - increased blood pressure - leucopenia - nausea - oral mucosal disorders - paraesthesia - pruritus - rash - tenosynovitis - vomiting
- Uncommon Anaemia - anxiety - hyperlipidaemia - hypokalaemia - hypophosphataemia - taste disturbance - tendon rupture - thrombocytopenia
- Rare Eosinophilia - hepatitis - interstitial lung disease - jaundice - pancytopenia - severe infection
- Very rare Hepatic failure - pancreatitis - peripheral neuropathy - progressive multifocal leucoencephalopathy - Stevens-Johnson syndrome - toxic epidermal necrolysis - vasculitis
- Frequency not known Bone-marrow toxicity - hypouricaemia - malignancy - reduced sperm count - renal failure

SIDE-EFFECTS, FURTHER INFORMATION
Discontinue treatment and institute washout procedure in case of serious side-effect (consult product literature).

Hepatotoxicity
Potentially life-threatening hepatotoxicity reported usually in the first 6 months. Discontinue treatment (and institute washout procedure—consult product literature) or reduce dose according to liver-function abnormality; if liver-function abnormality persists after dose reduction, discontinue treatment and institute washout procedure.

CONCEPTION AND CONTRACEPTION
Effective contraception essential during treatment and for at least 2 years after treatment in women and at least 3 months after treatment in men (plasma concentration monitoring required; waiting time before conception may be reduced with washout procedure). The concentration of the active metabolite after washout should be less than 20 micrograms/litre (measured on 2 occasions 14 days apart) in men or women before conception—consult product literature.

PREGNANCY
Avoid—active metabolite teratogenic in animal studies.

BREAST FEEDING
Present in milk in animal studies—manufacturer advises avoid.

HEPATIC IMPAIRMENT
Avoid—active metabolite may accumulate.

RENAL IMPAIRMENT
Manufacturer advises avoid in moderate or severe impairment—no information available.

PRE-TREATMENT SCREENING
Exclude pregnancy before treatment.

MONITORING REQUIREMENTS
- Monitor full blood count (including differential white cell count and platelet count) before treatment and every 2 weeks for 6 months then every 8 weeks.
- Monitor liver function before treatment and every 2 weeks for first 6 months then every 8 weeks.
- Monitor blood pressure.

TREATMENT CESSATION
Washout Procedure The active metabolite persists for a long period; to aid drug elimination in case of serious adverse effect, or before starting another disease-modifying antirheumatic drug, or before conception, stop treatment and give either colestyramine p. 173 or charcoal, activated p. 1130. Procedure may be repeated as necessary.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 4
- LEFLUNOMIDE (Non-proprietary)
  Leflunomide 10 mg Leflunomide 10mg tablets | 30 tablet £11.28
  Leflunomide 15 mg Leflunomide 15mg tablets | 30 tablet £16.00
  Leflunomide 20 mg Leflunomide 20mg tablets | 30 tablet £11.90
  Arava (Sanofi)
  Leflunomide 10 mg Arava 10mg tablets | 30 tablet £11.28
  Leflunomide 20 mg Arava 20mg tablets | 30 tablet £11.90
  Leflunomide 100 mg Arava 100mg tablets | 3 tablet £30.67
896 Arthritis

Penicillamine

**DRUG ACTION** Penicillamine aids the elimination of copper ions in Wilson’s disease (hepatolenticular degeneration).

**INDICATIONS AND DOSE**

Severe active rheumatoid arthritis (administered on expert advice)

**BY MOUTH**

- **Adult:** Initially 125–250 mg daily for 1 month, then increased in steps of 125–250 mg, at intervals of not less than 4 weeks; maintenance 500–750 mg daily in divided doses, then reduced in steps of 125–250 mg every 12 weeks, dose reduction attempted only if remission sustained for 6 months; maximum 1.5 g per day
- **Elderly:** Initially up to 125 mg daily for 1 month, then increased in steps of up to 125 mg, at intervals of at least 4 weeks; maximum 1 g per day

Wilson’s disease

**BY MOUTH**

- **Adult:** 1.5–2 g daily in divided doses, to be taken before food; maintenance 0.75–1 g daily for 1 year; maximum 2 g per day
- **Elderly:** 20 mg/kg daily in divided doses, adjusted according to response; maximum 2 g per day

Autoimmune hepatitis (used rarely; after disease controlled with corticosteroids)

**BY MOUTH**

- **Adult:** Initially 500 mg daily in divided doses, to be increased slowly over 3 months; maintenance 1.25 g daily

Cystinuria, therapeutic

**BY MOUTH**

- **Adult:** 1–3 g daily in divided doses, to be adjusted to maintain urinary cystine below 200 mg/litre, to be taken before food

Cystinuria, prophylactic

**BY MOUTH**

- **Adult:** 0.5–1 g daily, maintain urinary cystine below 300 mg/litre and adequate fluid intake (at least 3 litres daily), to be taken at bedtime
- **Elderly:** Minimum dose to maintain urinary cystine below 200 mg/litre is recommended

**CONTRA-INDICATIONS** Lupus erythematosus

**CAUTIONS** Neurological involvement in Wilson’s disease

**INTERACTIONS** Appendix 1 (penicillamine). Caution with gold treatment (avoid concomitant use if adverse reactions to gold). Caution with concomitant nephrotoxic drugs (increased risk of toxicity).

**SIDE-EFFECTS**

- **Common or very common** Anorexia · fever · nausea · proteinuria · rash · thrombocytopenia
- **Rare** Alopecia · breast enlargement (male and female) · elastosis perforans · haematuria (withdraw immediately if cause unknown) · mouth ulceration · pseudoxanthoma elasticum · skin laxity · stomatitis
- **Frequency not known** Agranulocytosis · aplastic anaemia · blood disorders · bronchiolitis · cholestatic jaundice · dermatomyositis · glomerulonephritis · Goodpasture's syndrome · haemolytic anaemia · haemolytic uropoenopha - late rashes (consider dose reduction) · lupus erythematosus · myasthenia gravis · nephrotic syndrome · neuropathy (especially if neurological involvement in Wilson’s disease—prophylactic pyridoxine recommended) · neutropenia · pancreatitis · pemphigus · pneumonitis · polymyositis · pulmonary haemorrhage · rheumatoid arthritis · septic arthritis (in patients with rheumatoid arthritis) · Stevens-Johnson syndrome · taste loss (mineral supplements not recommended) · urticaria · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Proteinuria Proteinuria, associated with immune complex nephritis, occurs in up to 30% of patients, but may resolve despite continuation of treatment; treatment may be continued provided that renal function tests remain normal, oedema is absent, and the 24-hour urinary excretion of protein does not exceed 2 g.

Rash Rash is a common side-effect. Those that occur in the first few months of treatment disappear when the drug is stopped and treatment may then be re-introduced at a lower dose level and gradually increased.

Taste loss Loss of taste can occur about 6 weeks after treatment is started but usually returns 6 weeks later irrespective of whether treatment is discontinued.

Nausea Nausea may occur but is not usually a problem provided that penicillamine is taken before food or on retiring and that low initial doses are used and only gradually increased.

**ALLERGY AND CROSS-SENSITIVITY** Patients who are hypersensitive to penicillin may react rarely to penicillamine.

**PREGNANCY** Fetal abnormalities reported rarely; avoid if possible.

**BREAST FEEDING** Manufacturer advises avoid unless potential benefit outweighs risk—no information available.

**RENAI IMPAIRMENT** Reduce dose and monitor renal function or avoid (consult product literature).

**MONITORING REQUIREMENTS**

- Blood counts, including platelets, and urine examinations should be carried out before starting treatment and then every 1 or 2 weeks for the first 2 months then every 4 weeks to detect blood disorders and proteinuria (they should also be carried out in the week after any dose increase).
- A reduction in platelet count calls for discontinuation with subsequent re-introduction at a lower dosage and then, if possible, gradual increase.
- Longer intervals may be adequate in cystinuria and Wilson’s disease.
- Consider withdrawal if platelet count falls below 120 000/mm³ or white blood cells below 2000/mm³ or if 3 successive falls within reference range (can restart at reduced dose when counts return to within reference range but permanent withdrawal necessary if recurrence of leucopenia or thrombocytopenia).

**PATIENT AND CARER ADVICE** Counselling on the symptoms of blood disorders is advised. Warn patient and carers to tell doctor immediately if sore throat, fever, infection, non-specific illness, unexplained bleeding and bruising, purpura, mouth ulcers, or rashes develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>6, 22</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PENICILLAMINE (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Penicillamine 125 mg Penicillamine 125mg tablets</td>
<td>56 tablet (PBM) £29.80 DT price = £11.20</td>
</tr>
<tr>
<td>Penicillamine 250 mg Penicillamine 250mg tablets</td>
<td>56 tablet (PBM) £52.45 DT price = £21.46</td>
</tr>
<tr>
<td>Distamine (Alliance Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Penicillamine 125 mg Distamine 125mg tablets</td>
<td>100 tablet (PBM) £10.34</td>
</tr>
<tr>
<td>Penicillamine 250 mg Distamine 250mg tablets</td>
<td>100 tablet (PBM) £11.78</td>
</tr>
</tbody>
</table>
Sodium aurothiomalate

**INDICATIONS AND DOSE**
Active progressive rheumatoid arthritis (administered on expert advice)

**BY DEEP INTRAMUSCULAR INJECTION**
- Adult: Test dose 10 mg, followed by 50 mg once weekly. If there is definite evidence of remission, then gradually reduced to 50 mg every 4 weeks for up to 5 years after complete remission. Benefit is not expected until 300–500 mg has been given; it should be discontinued if there is no remission after 1 g has been given.
- Relapse in patients who have previously received sodium aurothiomalate therapy for active progressive rheumatoid arthritis (administered on expert advice)

**BY DEEP INTRAMUSCULAR INJECTION**
- Adult: 50 mg once weekly until control has been obtained again, then reduced to 50 mg every 4 weeks continued for up to 5 years after complete remission, if no response is seen within 2 months, alternative treatment should be sought.

**CONTRA-INDICATIONS**
- Exfoliative dermatitis
- History of blood disorders
- History of bone marrow aplasia
- Necrotising enterocolitis
- Pulmonary fibrosis
- Systemic lupus erythematosus

**CAUTIONS**
- Colitis
- Eczema
- Elderly
- History of urticaria

**CAUTIONS, FURTHER INFORMATION**
Sodium aurothiomalate should be discontinued in the presence of blood disorders, gastrointestinal bleeding (associated with ulcerative enterocolitis), or unexplained proteinuria (associated with immune complex nephritis) which is repeatedly above 300 mg/litre.

**INTERACTIONS** → Appendix 1 (sodium aurothiomalate).

**SIDE-EFFECTS**
- Alopecia
- Blood disorders (sometimes sudden and fatal)
- Colitis
- Gold deposits in eye
- Hepatotoxicity with cholestatic jaundice
- Irreversible pigmentation in sun-exposed areas
- Muscle wasting
- Neutropenia reported commonly
- Peripheral neuropathy
- Proteinuria
- Pulmonary fibrosis
- Severe anaphylactic reactions
- Skin reactions
- Stomatitis
- Taste disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**
Rashes with pruritus often occur after 2 to 6 months of treatment and may necessitate discontinuation.

**PREGNANCY**
Consider reducing dose and frequency. Manufacturer advises avoid but limited data suggests usually not necessary to withdraw if condition well controlled.

**BREAST FEEDING**
Manufacturer advises avoid—present in milk; theoretical possibility of rashes and idiosyncratic reactions.

**HEPATIC IMPAIRMENT**
Caution in mild to moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT**
Caution in mild to moderate impairment. Avoid in severe impairment.

**MONITORING REQUIREMENTS**
- Urine tests and full blood counts (including total and differential white cell and platelet counts) must be performed before starting treatment and before each intramuscular injection.
- Monitor for pulmonary fibrosis with annual chest X-ray.

**PATIENT AND CARER ADVICE**
Patients should be advised to seek prompt medical attention if diarrhoea, sore throat, fever, infection, non-specific illness, unexplained bleeding and bruising, purpura, mouth ulcers, metallic taste, rash, breathlessness, or cough develop.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium aurothiomalate 20 mg per 1 ml Myocrisin 10mg/0.5ml solution for injection ampoules</td>
</tr>
<tr>
<td>Sodium aurothiomalate 100 mg per 1 ml Myocrisin 50mg/0.5ml solution for injection ampoules</td>
</tr>
</tbody>
</table>

**INTERLEUKIN INHIBITORS**

### Anakinra

**INDICATIONS AND DOSE**
Treatment of rheumatoid arthritis (in combination with methotrexate) which has not responded to methotrexate alone

**BY SUBCUTANEOUS INJECTION**
- Adult: 100 mg once daily

**CONTRA-INDICATIONS**
- Neutropenia

**CAUTIONS**
- History of asthma (risk of serious infection)
- Predisposition to infection

**INTERACTIONS** → Appendix 1 (anakinra).

**SIDE-EFFECTS**
- Common or very common
  - Neutropenia
- Frequency not known
  - Antibody formation
  - Headache
  - Infections
  - Injection-site reactions
  - Malignancy

**SIDE-EFFECTS, FURTHER INFORMATION**

**Blood disorders**
- Neutropenia reported commonly—discontinue if neutropenia develops.

**CONCEPTION AND CONTRACEPTION**
Effective contraception must be used during treatment.

**PREGNANCY**
Manufacturer advises avoid.

**BREAST FEEDING**
Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT**
Caution if eGFR less than 30 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
Monitor neutrophil count before treatment, then every month for 6 months, then every 3 months.

**PATIENT AND CARER ADVICE**
Blood disorders. Patients should be instructed to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat, bruising or bleeding) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (July 2002) that anakinra is not recommended for the treatment of rheumatoid arthritis within NHS Scotland.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

<table>
<thead>
<tr>
<th>Kineret (Swedish Orphan Biovitrum Ltd)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anakinra 150 mg per 1 ml</td>
</tr>
</tbody>
</table>
Tocilizumab

**INDICATIONS AND DOSE**
Moderate to severe active rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs.

**BY INTRAVENOUS INFUSION**
- Adult: 8 mg/kg every 4 weeks (max. per dose 800 mg); for dose adjustment in patients with liver enzyme abnormalities, or low absolute neutrophil or platelet count, consult product literature.

**CONTRA-INDICATIONS**
- Do not initiate if absolute neutrophil count less than 2 x 10^9/litre · severe active infection.

**CAUTIONS**
- History of diverticulitis · history of intestinal ulceration · history of recurrent or chronic infection (interrupt treatment if serious infection occurs) · low absolute neutrophil count · low platelet count · predisposition to infection (interrupt treatment if serious infection occurs).

**CAUTIONS, FURTHER INFORMATION**
- **Tuberculosis** Patients with latent tuberculosis should be treated with standard therapy before starting tocilizumab.
- **INTERACTIONS** → Appendix 1 (tocilizumab).
- **SIDE-EFFECTS**
  - Common or very common · Abdominal pain · antibody formation · dizziness · gastritis · headache · hypercholesterolaemia · hypersensitivity · hypertension · infection · leucopenia · mouth ulceration · neutropenia · peripheral oedema · pruritus · raised hepatic transaminases · rash · upper respiratory-tract infection.
  - Uncommon · Anaphylaxis · gastric ulcer · gastro-intestinal perforation · hypertriglyceridaemia · hypothyroidism · infection related reactions · nephrolithiasis.
  - Frequency not known · Thrombocytopenia.

**SIDE-EFFECTS, FURTHER INFORMATION**
- **Neutrophil and platelet counts** Discontinue if absolute neutrophil count less than 0.5 x 10^9/litre or platelet count less than 50 x 10^9/microlitre.
- **CONCEPTION AND CONTRACEPTION**
  - Effective contraception required during and for 3 months after treatment.
- **PREGNANCY**
  - Manufacturer advises avoid unless essential—xicity in animal studies.
- **BREAST FEEDING**
  - Manufacturer advises use only if potential benefit outweighs risk—no information available.
- **HEPATIC IMPAIRMENT**
  - Manufacturer advises caution—consult product literature.
- **RENAL IMPAIRMENT**
  - Manufacturer advises monitor renal function closely in moderate or severe impairment.
- **PRE-TREATMENT SCREENING**
  - Tuberculosis Patients should be evaluated for tuberculosis before treatment.
- **MONITORING REQUIREMENTS**
  - Monitor hepatic transaminases every 4–8 weeks for first 6 months, then every 12 weeks.
  - Monitor neutrophil and platelet counts 4–8 weeks after starting treatment and then as indicated.
  - Monitor lipoprotein 4–8 weeks after starting treatment and then as indicated.
  - Monitor for demyelinating disorders.
- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (RoActemra®), give intermittently in Sodium chloride 0.9%; dilute requisite dose to a volume of 100 mL with infusion fluid and give over 1 hour.

**PATIENT AND CARER ADVICE**
- An alert card should be provided. Patients and their carers should be advised to seek immediate medical attention if symptoms of infection occur, or if symptoms of diverticular perforation such as abdominal pain, haemorrhage, or fever accompanying change in bowel habits occur.

**NATIONAL FUNDING/ACCESS DECISIONS**
- **NICE technology appraisals (TAs)**
  - **Tocilizumab for the treatment of rheumatoid arthritis (February 2012) NICE TA247**
  - Tocilizumab, in combination with methotrexate, is recommended as an option for the treatment of rheumatoid arthritis in adults if:
    - the disease has responded inadequately to disease-modifying anti-rheumatic drugs (DMARDs) and is used as described for tumour necrosis factor (TNF) inhibitor treatments (specifically the recommendations on disease activity and treatment) in the NICE guidance (October 2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, or
    - the disease has responded inadequately to DMARDs and a TNF inhibitor and the patient cannot receive rituximab because of contra-indications or intolerance, and tocilizumab is used as described for TNF inhibitor treatments (specifically the recommendations on disease activity) in the NICE guidance (August 2010) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor, or
    - the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab
  - and the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme.
  - Patients currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet these criteria should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
  - www.nice.org.uk/TA247

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (August 2012) that tocilizumab (RoActemra®) is accepted for restricted use within NHS Scotland as monotherapy in patients who are intolerant to methotrexate or where continued treatment with methotrexate is inappropriate, for the treatment of moderate to severe active rheumatoid arthritis in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying antirheumatic drugs or tumour necrosis factor inhibitors, in accordance with the British Society for Rheumatology guidance on prescribing TNF-α blockers in adults with rheumatoid arthritis (2005).

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **RoActemra** (Roche Products Ltd)
  - Tocilizumab 180 mg per 1 ml RoActemra 162mg/0.9ml solution for injection pre-filled syringes | 4 pre-filled disposable injection £913.12 (Hospital only).

**Solution for infusion**
- **RoActemra** (Roche Products Ltd)
  - Tocilizumab 20 mg per 1 ml RoActemra 400mg/20ml concentrate for solution for infusion vials | 1 vial £512.00 (Hospital only).
  - RoActemra 200mg/10ml concentrate for solution for infusion vials | 1 vial £256.00 (Hospital only).
  - RoActemra 80mg/4ml concentrate for solution for infusion vials | 1 vial £102.40 (Hospital only).
**Ustekinumab**

**INDICATIONS AND DOSE**
Severe plaque psoriasis that has not responded to at least 2 standard systemic treatments and photochemotherapy, or when these treatments cannot be used because of intolerance or contra-indications.

**BY SUBCUTANEOUS INJECTION**
- Adult (body-weight up to 100 kg): Initially 45 mg, then 45 mg after 4 weeks, then 45 mg every 12 weeks, discontinue if no response within 16 weeks.
- Adult (body-weight 100 kg and above): Initially 45–90 mg, then 45–90 mg after 4 weeks, then 45–90 mg every 12 weeks, discontinue if no response within 16 weeks.

**Active psoriatic arthritis (in combination with methotrexate or alone) in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs**

**CONTRA-INDICATIONS**
- Active infection
- CAUTIONS: Development of malignancy - elderly; history of malignancy; predisposition to infection - start appropriate treatment if widespread erythema and skin exfoliation develop, and stop ustekinumab treatment if exfoliative dermatitis suspected

**CAUTIONS, FURTHER INFORMATION**

**Tuberculosis**
Active tuberculosis should be treated with standard treatment for at least 2 months before starting ustekinumab. Patients who have previously received adequate treatment for tuberculosis can start ustekinumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting ustekinumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with ustekinumab.

**INTERACTIONS**
- Appendix 1 (ustekinumab).

**SIDE-EFFECTS**
- Common or very common: Arthralgia, diarrhoea, dizziness, headache, infections (sometimes severe), injection-site reactions, malaise, myalgia, nausea, opharyngitis, pain, pruritus.
- Uncommon: Depression, facial palsy, hypersensitivity reactions (possibly delayed onset), nasal congestion, pustular psoriasis.
- Rare: Exfoliative dermatitis.

**CONCEPTION AND CONTRACEPTION**
Manufacturer advises effective contraception during treatment and for 15 weeks after stopping treatment.

**PREGNANCY**
Avoid.

**BREAST FEEDING**
Manufacturer advises avoid—present in milk in animal studies.

**PRE-TREATMENT SCREENING**
Tuberculosis Patients should be evaluated for tuberculosis before treatment.

**MONITORING REQUIREMENTS**
- Monitor for non-melanoma skin cancer, especially in patients with a history of PUVA treatment or prolonged immunosuppressant therapy, or those over 60 years of age.
- Monitor for signs and symptoms of exfoliative dermatitis or erythrodermic psoriasis.

**PATIENT AND CARER ADVICE**
Exfoliative dermatitis Patients should be advised to seek prompt medical attention if symptoms suggestive of exfoliative dermatitis or erythrodermic psoriasis (such as increased redness and shedding of skin over a larger area of the body) develop.

Tuberculosis Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Ustekinumab for plaque psoriasis in adults (September 2009)
- Ustekinumab for treating active psoriatic arthritis (June 2015)

Ustekinumab is recommended for the treatment of severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Ustekinumab should be withdrawn if the response is not adequate after 16 weeks.

For patients weighing over 100 kg, the manufacturer should provide the 90-mg dose of ustekinumab at the same price as the 45 mg dose. [www.nice.org.uk/TA180](http://www.nice.org.uk/TA180)

**Ustekinumab for treating active psoriatic arthritis (June 2015)**

NICE TA340

Ustekinumab is an option, alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults only when:
- treatment with tumour necrosis factor (TNF) alpha inhibitors is contraindicated but would otherwise be considered (as described in the NICE guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (August 2010) and golimumab for the treatment of psoriatic arthritis (April 2011)) or
- the patient has had treatment with 1 or more TNF-alpha inhibitors.

Ustekinumab is recommended only if the manufacturer provides the 90 mg dose of ustekinumab for patients who weigh more than 100 kg at the same cost as the 45 mg dose, as agreed in the patient access scheme.

Ustekinumab treatment should be stopped if the patient’s psoriatic arthritis has not shown an adequate response using the Psoriatic Arthritis Response Criteria (PsARC) at 24 weeks.

Patients currently receiving ustekinumab whose disease does not meet the above criteria should have the option to continue treatment until they and their clinic consider it appropriate to stop. [www.nice.org.uk/TA340](http://www.nice.org.uk/TA340)

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (February 2014) that ustekinumab (Stelara®) is accepted for restricted use within NHS Scotland either alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have responded inadequately to previous therapy with a non-biological disease-modifying anti-rheumatic drug, and failed on, or are unsuitable for, treatment with a TNF inhibitor.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
 CAUTIONARY AND ADVISORY LABELS 10
- Stelara (Janssen-Cilag Ltd)
  - Ustekinumab 90 mg per 1 ml
  - Stelara 45mg/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection
  - £2,147/100
T-CELL ACTIVATION INHIBITORS

Abatacept

INDICATIONS AND DOSE
Moderate to severe active rheumatoid arthritis (in combination with methotrexate) in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor)

INITIALLY BY INTRAVENOUS INFUSION
- Adult (body-weight up to 60 kg): 500 mg every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 500 mg every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose
- Adult (body-weight 60-100 kg): 750 mg every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 750 mg every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose
- Adult (body-weight 101 kg and above): 1 g every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 1 g every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose

CONTRA-INDICATIONS
Severe infection

CAUTIONS Do not initiate until active infections are controlled. Elderly (increased risk of side-effects)
- Predisposition to infection (screen for latent tuberculosis and viral hepatitis)
- Progressive multifocal leucoencephalopathy (discontinue treatment if neurological symptoms present)

INTERACTIONS 

SIDE-EFFECTS

Common or very common
- Abdominal pain
- Conjunctivitis
- Cough
- Diarrhoea
- Dizziness
- Dyspepsia
- Fatigue
- Flushing
- Headache
- Hypertension
- Infection
- Leucopenia
- Nausea
- Pain in extremities
- Paraesthesia
- Stomatitis
- Vomiting

Uncommon
- Alopecia
- Anxiety
- Arthralgia
- Basal and squamous cell carcinoma
- Bradycardia
- Bronchospasm
- Bruising
- Depression
- Dry eye
- Dry skin
- Dysphonia
- Gastritis
- Hyperhidrosis
- Hypotension
- Menstrual disturbances
- Palpitation
- Psoriasis
- Skin papilloma
- Sleep disorder
- Tachycardia
- Thrombocytopenia
- Visual disturbance
- Weight gain

Frequency not known
- Lung cancer

CONCEPTION AND CONTRACEPTION 
Effective contraception required during treatment and for 14 weeks after last dose.

PREGNANCY 
Manufacturer advises avoid unless essential.

BREAST FEEDING 
Present in milk in animal studies—manufacturer advises avoid breast-feeding during treatment and for 14 weeks after last dose.

DIRECTIONS FOR ADMINISTRATION
For intravenous infusion, reconstitute each vial with 10 mL water for injections using the silicone-free syringe provided; dilute requisite dose in Sodium Chloride 0.9% to 100 mL (using the same silicone-free syringe); give over 30 minutes through a low protein-binding filter (pore size 0.2-1.2 micron).

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) NICE TA195
- Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.
- Adalimumab, etanercept, infliximab, or abatacept, in combination with methotrexate, are options for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. In patients who cannot use methotrexate because of intolerance or contra-indications, adalimumab or etanercept can be given as monotherapy. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months. www.nice.org.uk/TA195
- Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs (April 2013) NICE TA280
- Abatacept, in combination with methotrexate, is an option for the treatment of highly active rheumatoid arthritis in adults who have had an inadequate response to at least two conventional disease-modifying antirheumatic drugs, including methotrexate, if:
  - abatacept is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors (see Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis, and
  - the manufacturer provides abatacept with the discount agreed in the patient access scheme
- Patients already receiving abatacept for this indication, who do not fulfil the criteria for treatment should continue treatment until they and their specialist consider it appropriate to stop.
- The Scottish Medicines Consortium (SMC) Decision
The Scottish Medicines Consortium has advised (July 2013) that abatacept (Orencia®) is accepted for restricted use within NHS Scotland for adults with severe active rheumatoid arthritis, confirmed on at least two occasions, one month apart. This advice is contingent upon continuing availability of abatacept at the price agreed in the patient access scheme.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- ABATACEPT (Non-proprietary)
  - Abatacept 125 mg per 1 ml Orencia ClickJet 125mg/1ml solution for injection pre-filled pen
  - Pre-filled disposable injection
  - £1,209.60
- Orencia (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Abatacept 125 mg per 1 ml Orencia 125mg/1ml solution for injection pre-filled syringes
  - Pre-filled disposable injection
  - £1,209.60 (Hospital only)

Powder for solution for infusion
- ELECTROLYTES: May contain Sodium
  - Orencia (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Abatacept 250 mg Orencia 250mg powder for concentrate for solution for infusion vials
  - £302.40 (Hospital only)
Adalimumab

INDICATIONS AND DOSE

Severe plaque psoriasis either refractory to at least 2 standard systemic treatments or phototherapy, or when standard treatments cannot be used because of intolerance or contra-indications

BY SUBCUTANEOUS INJECTION

Adult: Initially 80 mg, then 40 mg every 2 weeks, to be started 1 week after initial dose; discontinue treatment if no response within 16 weeks

Moderate to severe active rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) when response to other disease-modifying drugs (including methotrexate) has been inadequate

Severe, active, and progressive rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) not previously treated with methotrexate

Adult: 40 mg every 2 weeks, then increased if necessary to 40 mg once weekly, dose to be increased only in patients receiving adalimumab alone, review treatment if no response within 12 weeks

Active and progressive psoriatic arthritis that has not responded adequately to other disease-modifying antirheumatic drugs. Severe active ankylosing spondylitis that has not responded adequately to other disease-modifying antirheumatic drugs. Severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to, or are intolerant of, NSAIDs

Adult: 40 mg every 2 weeks, discontinue treatment if no response within 12 weeks

Severe active Crohn’s disease

BY SUBCUTANEOUS INJECTION

Adult: Initially 80 mg, then 40 mg after 2 weeks; maintenance 40 mg every 2 weeks, increased if necessary to 40 mg once weekly, maximum 40 mg administered at a single site, review treatment if no response within 12 weeks of initial dose

Severe active Crohn’s disease (accelerated regimen)

BY SUBCUTANEOUS INJECTION

Adult: Initially 160 mg, dose can alternatively be given as divided injections over 2 days, then 80 mg after 2 weeks; maintenance 40 mg every 2 weeks, increased if necessary to 40 mg once weekly, maximum 40 mg administered at a single site, review treatment if no response within 12 weeks of initial dose

Severe active ulcerative colitis

BY SUBCUTANEOUS INJECTION

Adult: Initially 160 mg, dose can alternatively be given as divided injections over 2 days, then 80 mg after 2 weeks; maintenance 40 mg every 2 weeks, increased if necessary to 40 mg once weekly, maximum 40 mg administered at a single site, review treatment if no response within 8 weeks of initial dose

CONTRA-INDICATIONS

Moderate or severe heart failure - severe infection

CAUTIONS

Children should be brought up to date with current immunisation schedule before initiating therapy - demyelinating disorders (risk of exacerbation) - development of malignancy - do not initiate until active infections are controlled (discontinue if new serious infection develops) - hepatitis B virus—monitor for active infection - history of malignancy - mild heart failure (discontinue if symptoms develop or worsen) - predisposition to infection

CAUTIONS, FURTHER INFORMATION

Tuberculosis

Active tuberculosis should be treated with standard treatment for at least 2 months before starting adalimumab. Patients who have previously received adequate treatment for tuberculosis can start adalimumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting adalimumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with adalimumab.

INTERACTIONS

Appendix 1 (adalimumab).

SIDE-EFFECTS


Rare Autoimmune hepatitis - demyelinating disorders - myocardial infarction


SIDE-EFFECTS, FURTHER INFORMATION

Associated with infections, sometimes severe, including tuberculosis, septicemia, and hepatitis B reactivation.

CONCEPTION AND CONTRACEPTION

Manufacturer advises effective contraception required during treatment and for at least 5 months after last dose.

PREGNANCY

Avoid.

BREAST FEEDING

Avoid; manufacturer advises avoid for at least 5 months after last dose.

PRE-TREATMENT SCREENING

Tuberculosis

Patients should be evaluated for tuberculosis before treatment.

MONITORING REQUIREMENTS

Monitor for infection before, during, and for 4 months after treatment.

Monitor for non-melanoma skin cancer before and during treatment, especially in patients with a history of PUVA treatment for psoriasis or extensive immunosuppressant therapy.

PATIENT AND CARER ADVICE

An alert card should be provided.

Tuberculosis

Patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.
Blood disorders Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007) [NICE TA130]

  The tumour necrosis factor alpha (TNF-α) inhibitors adalimumab, etanercept, and infliximab are options for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-α inhibitors should be given in combination with methotrexate; however, when methotrexate cannot be used because of intolerance or contra-indications, adalimumab or etanercept can be given as monotherapy. Adalimumab, etanercept, and infliximab should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-α inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy. Use of TNF-α inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended. [www.nice.org.uk/TA130](www.nice.org.uk/TA130)

- Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008) [NICE TA143]

  Adalimumab or etanercept are treatment options for adults with severe active ankylosing spondylitis whose disease satisfies specific criteria for diagnosis where there is confirmation of sustained active spinal disease, and where treatment with two or more NSAIDs taken sequentially at maximum tolerated or recommended doses for 4 weeks has failed to control symptoms. Response to adalimumab or etanercept treatment should be assessed at 12-week intervals and continued only if response is adequate. If response to treatment is not maintained, a repeat assessment should be made after a further 6 weeks and treatment discontinued if there is an inadequate response. Patients who are intolerant of adalimumab or etanercept during the initial 12 weeks may receive the alternative TNF-α inhibitor (adalimumab or etanercept). However an alternative TNF-α inhibitor is not recommended in patients who fail to respond initially or fail to maintain an adequate response. Infliximab is not recommended for the treatment of ankylosing spondylitis. Patients who are already receiving infliximab for the treatment of ankylosing spondylitis can continue treatment until they and their specialist consider it appropriate to stop. See full NICE guidance for specific criteria to diagnose severe active ankylosing spondylitis, confirm sustained active spinal disease, and assess response to treatment. [www.nice.org.uk/TA143](www.nice.org.uk/TA143)

- Adalimumab for plaque psoriasis in adults (June 2008) [NICE TA146]

  Adalimumab is recommended for the treatment of severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and phototherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Adalimumab should be withdrawn if the response is not adequate after 16 weeks. [www.nice.org.uk/TA146](www.nice.org.uk/TA146)

- Infliximab and adalimumab for Crohn’s disease (May 2010) [NICE TA187]


- Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) [NICE TA195]


- Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010) [NICE TA199]


- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) NICE TA239

  NICE recommended. See Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) TA239 [www.nice.org.uk/TA239](www.nice.org.uk/TA239) p. 907

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium issued similar advice for plaque psoriasis to NICE TA146 in May 2008.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**CAUTIONARY AND ADVISORY LABELS**

- **Humira (AbbVie Ltd)**
  - Adalimumab 50 mg per 1 ml Humira 40mg/0.8ml solution for injection pre-filled syringes | 2 pre-filled disposable injection £704.28
  - Humira 40mg/0.8ml solution for injection vials | 2 vial £704.28
  - Humira 40mg/0.8ml solution for injection pre-filled disposable devices | 2 pre-filled disposable injection £704.28

**Certolizumab pegol**

**INDICATIONS AND DOSE**

Moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drugs (including methotrexate) has been inadequate (as monotherapy or in combination with methotrexate)

**BY SUBCUTANEOUS INJECTION**

- Adult: 400 mg every 2 weeks for 3 doses, then 200 mg every 2 weeks, review treatment if no response within 12 weeks

**Treatment of severe active ankylosing spondylitis**

- **Adult**: 400 mg every 2 weeks for 3 doses, then 200 mg every 2 weeks, alternately 400 mg every 4 weeks, review treatment if no response within 12 weeks

**CONTRA-INDICATIONS**

- Moderate to severe heart failure - severe active infection

**CAUTIONS**

- Demyelinating CNS disorders (risk of exacerbation) - do not initiate until active infections are controlled (discontinue if new serious infection develops and until infection controlled) - hepatitis B virus (monitor for active infection) - history or development of
malignancy • mild heart failure (discontinue if symptoms develop or worsen) • predisposition to infection

CAUTIONS, FURTHER INFORMATION

Tuberculosis Active tuberculosis should be treated with standard treatment for at least 2 months before starting certolizumab pegol. Patients who have previously received adequate treatment for tuberculosis can start certolizumab pegol but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting certolizumab pegol. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with certolizumab pegol.

INTERACTIONS ▶ Appendix 1 (certolizumab pegol).

SIDE-EFFECTS

Common or very common Hypertension • rash • sensory abnormalities

Uncommon Acne • alopecia • anxiety • appetite disorders • arrhythmias • ascites • asthma • benign tumours • cardiomyopathies • cholesterol • cough • dermatitis • dizziness • dyslipidaemia • ecchymosis • electrolyte disorders • gastro-intestinal disorders • gastro-intestinal perforation • gastro-intestinal ulcer • haematuria • haemorrhage • heart failure • hepatic disorders • impaired healing • influenza-like illness • ischaemic coronary artery disorders • leukaemia • lymphoma • malignancy • menstrual disorders • mood disorders • muscle disorders • nail disorders • new onset or worsening psoriasis • ocular inflammation • oedema • peripheral neuropathy • photosensitivity • pleural effusion • renal impairment • skin cancer • skin discoloration • solid tumours • syncope • tinnitus • tremor • visual disturbance

Rare Atrioventricular block • cerebrovascular accident • cholelithiasis • impaired coordination • interstitial lung disease • nephropathy • Raynaud’s phenomenon • seizures • sexual dysfunction • splenomegaly • thyroid disorders • trigeminal neuralgia

Frequency not known Abdominal pain • anaemia • antibody formation • aplastic anaemia • blood disorders • depression • fever • headache • hypersensitivity reactions • infections • injection-site reactions • leucopenia • lupus erythematosus-like syndrome • multiple sclerosis • nausea • pancytopenia • pruritus • thrombocytopenia • worsening heart failure

SIDE-EFFECTS, FURTHER INFORMATION

Infection Associated with infections, sometimes severe, including tuberculosis, septicemia, and hepatitis B reactivation.

CONCEPTION AND CONTRACEPTION Manufacturer advises adequate contraception during treatment and for at least 5 months after last dose.

PREGNANCY Avoid.

BREAST FEEDING Manufacturer advises use only if potential benefit outweighs risk—no information available.

PRE-TREATMENT SCREENING

Tuberculosis Patients should be evaluated for tuberculosis before treatment.

MONITORING REQUIREMENTS Monitor for infection before, during, and for 5 months after treatment.

PATIENT AND CARER ADVICE An alert card should be provided.

Blood disorders Patients should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

Tuberculosis Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g., persistent cough, weight loss and fever) develop.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Certolizumab pegol for the treatment of rheumatoid arthritis (February 2010) NICE TA186

Certolizumab pegol is an option for the treatment of patients with rheumatoid arthritis only if:

• certolizumab pegol is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors (see Adalimumab, Etanercept and Infliximab for the treatment of Rheumatoid Arthritis), and

• the manufacturer provides the first 12 weeks of certolizumab pegol (10 prefilled 200-mg syringes) free of charge to all patients starting treatment. www.nice.org.uk/TA186

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

CAUTIONARY AND ADVISORY LABELS 10

Cimzia (UCB Pharma Ltd)

Certolizumab pegol 200 mg per 1 ml Cimzia 200mg/1ml solution for injection pre-filled syringes | 2 syringe £715.00

Etanercept

INDICATIONS AND DOSE

Moderate to severe active rheumatoid arthritis (alone or in combination with methotrexate) when the response to other disease-modifying antirheumatic drugs is inadequate | Severe, active, and progressive rheumatoid arthritis not previously treated with methotrexate | Active and progressive psoriatic arthritis inadequately responsive to other disease-modifying antirheumatic drugs | Severe ankylosing spondylitis inadequately responsive to conventional therapy

BY SUBCUTANEOUS INJECTION

Adult: 25 mg twice weekly, alternatively 50 mg once weekly

Severe plaque psoriasis either refractory to at least 2 standard systemic treatments and photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications

BY SUBCUTANEOUS INJECTION

Adult: 25 mg twice weekly for up to 24 weeks, alternatively 50 mg once weekly for up to 24 weeks, discontinue if no response after 12 weeks

CONTRA-INDICATIONS Active infection

CAUTIONS Children should be brought up to date with current immunisation schedule before initiating therapy • development of malignancy • diabetes mellitus • heart failure (risk of exacerbation) • hepatitis B virus—monitor for active infection • hepatitis C infection (monitor for worsening infection) • history of blood disorders • history of malignancy • history or increased risk of demyelinating disorders • predisposition to infection (avoid if predisposition to septicaemia) • significant exposure to herpes zoster virus—interrupt treatment and consider varicella–zoster immunoglobulin

CAUTIONS, FURTHER INFORMATION

Tuberculosis Active tuberculosis should be treated with standard treatment for at least 2 months before starting etanercept. Patients who have previously received adequate treatment for tuberculosis can start etanercept but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting etanercept. In patients at high risk of tuberculosis...
who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with etanercept.

- **INTERACTIONS** → Appendix 1 (etanercept).
- **SIDE-EFFECTS**
  - **Uncommon** Interstitial lung disease, new onset or worsening psoriasis, rash, skin cancer, uveitis
  - **Rare** Demyelinating disorders, lymphoma, seizures, Stevens-Johnson syndrome, vasculitis
  - **Very rare** Toxic epidermal necrolysis
  - **Frequency not known** Abdominal pain, anaemia, antibody formation, aplastic anaemia, appendicitis, blood disorders, cutaneous ulcer, depression, diabetes mellitus, fever, gastritis, headache, hypersensitivity reactions, inflammatory bowel disease, injection-site reactions, leucopenia, leukaemia, lupus erythematosus-like syndrome, macrophage activation syndrome, malignancy, nausea, oesophagitis, pancytopenia, pruritus, solid tumours, thrombocytopenia, vomiting, worsening heart failure

**SIDE-EFFECTS, FURTHER INFORMATION**

Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception required during treatment and for 3 weeks after last dose.
- **PREGNANCY** Avoid—limited information available.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Use with caution in moderate to severe alcoholic hepatitis.
- **PRE-TREATMENT SCREENING** Tuberculosis Patients should be evaluated for tuberculosis before treatment.
- **MONITORING REQUIREMENTS** Monitor for skin cancer before and during treatment, particularly in those at risk (including patients with psoriasis or a history of PUVA treatment).
- **PATIENT AND CARER ADVICE** An alert card should be provided.

Blood disorders Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

Tuberculosis Patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Etanercept and efalizumab for plaque psoriasis in adults (July 2006)** NICE TA103
  Etanercept is recommended for severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to phototherapy, or when standard treatments cannot be used because of intolerance or contraindications. Etanercept should be withdrawn if the response is not adequate after 12 weeks. www.nice.org.uk/TA103

- **Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)** NICE TA130
  NICE recommended. See Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007) TA130 www.nice.org.uk/TA130 p. 902

- **Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)** NICE TA141
  NICE recommended. See Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008) TA143 www.nice.org.uk/TA143 p. 902

- **Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)** NICE TA195

- **Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)** NICE TA199
  Etanercept, infliximab, or adalimumab are recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying anti-rheumatic drugs (used alone or in combination).

Etanercept, infliximab, and adalimumab should be discontinued if there is an inadequate response at 12 weeks. www.nice.org.uk/TA199

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium issued similar advice to NICE TA103 on the use of etanercept for severe plaque psoriasis in adults (August 2009) and children over 6 years old (April 2012).

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **CAUTIONARY AND ADVISORY LABELS**
  - **Enbrel** (Pfizer Ltd)
    - Etanercept 50 mg per 1 ml Enbrel 50mg/1ml solution for injection pre-filled disposable injection £171.00
    - Enbrel 25mg/0.5ml solution for injection pre-filled syringes £135.75
    - Brands may include Enbrel MyClic

- **Powder and solvent for solution for injection**

  - **CAUTIONARY AND ADVISORY LABELS**
  - **Excipients**: May contain Benzyl alcohol
  - **Enbrel** (Pfizer Ltd)
    - Etanercept 10 mg Enbrel Paediatric 10mg powder and solvent for solution for injection vials | 4 vial £357.50
    - Etanercept 25 mg Enbrel Paediatric 25mg powder and solvent for solution for injection vials | 4 vial £357.50

**Golimumab**

**INDICATIONS AND DOSE**

Treatment of severe ulcerative colitis in patients whose condition has not responded adequately to conventional therapy, or who are intolerant of it

- **BY SUBCUTANEOUS INJECTION**
  - **Adult (body-weight up to 80 kg)**: Initially 200 mg, then 100 mg after 2 weeks; maintenance 50 mg every 4 weeks, review treatment if no response after 4 doses
  - **Adult (body-weight 80 kg and above)**: Initially 200 mg, then 100 mg after 2 weeks; maintenance 100 mg every 4 weeks, review treatment if no response after 4 doses
Treatment of moderate to severe active rheumatoid arthritis (in combination with methotrexate) when response to disease-modifying antirheumatic drug (DMARD) therapy (including methotrexate) has been inadequate | Treatment of severe, active, and progressive rheumatoid arthritis (in combination with methotrexate) in patients not previously treated with methotrexate | Treatment of active and progressive psoriatic arthritis as monotherapy or in combination with methotrexate when response to DMARD therapy has been inadequate | Treatment of severe active anklyosing spondylitis when there is inadequate response to conventional treatment

**CONTRA-INDICATIONS** Moderate or severe heart failure - severe active infection

**CAUTIONS** Active infection (do not initiate until active infections are controlled; discontinue if new serious infection develops until infection controlled) - demyelinating disorders (risk of exacerbation) - hepatitis B virus - monitor for active infection - history or development of malignancy - mild heart failure (discontinue if symptoms develop or worsen) - predisposition to infection - risk factors for dysplasia or carcinoma of the colon - screen for dysplasia regularly

**Tuberculosis** Active tuberculosis should be treated with standard treatment for at least 2 months before starting golimumab. Patients who have previously received adequate treatment for tuberculosis can start golimumab but should be monitored every 2 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting golimumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with golimumab. Patients who have tested negative for latent tuberculosis who cannot be assessed by tuberculin skin test after treatment should be reevaluated for tuberculosis 3 months after last dose. Patients who have previously received treatment for latent tuberculosis, and those who are receiving or who have completed treatment for latent tuberculosis, should be monitored closely for symptoms of active infection.

**INTERACTIONS** Appendix 1 (golimumab).

**SIDE-EFFECTS**

- **Common or very common** Asthenia - dizziness - dyspepsia - hypertension
- **Rare** Impaired wound healing

**SIDE-EFFECTS, FURTHER INFORMATION**

Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during treatment and for at least 6 months after last dose.

**PREGNANCY** Use only if essential.

**BREAST FEEDING** Manufacturer advises avoid during and for at least 6 months after treatment—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises caution—no information available.

**PRE-TREATMENT SCREENING**

Tuberculosis Patients should be evaluated for tuberculosis before treatment.

**MONITORING REQUIREMENTS** Monitor for infection before, during, and for 5 months after treatment.

**DIRECTIONS FOR ADMINISTRATION** For doses requiring multiple injections, each injection should be administered at a different site. Missed dose If dose administered more than 2 weeks late, subsequent doses should be administered on the next monthly due date.

**PATIENT AND CARER ADVICE** An alert card should be provided.

Tuberculosis All patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g., persistent cough, weight loss, and fever) develop.

Blood disorders Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Golimumab for the treatment of psoriatic arthritis (April 2011) NICE TA220**
  - Golimumab is an option for the treatment of active and progressive psoriatic arthritis in adults only if:
    - golimumab is used as described in the NICE guidance (August 2010) for other tumour necrosis factor (TNF) inhibitors, and
    - the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.
    - www.nice.org.uk/TA220

- **Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs (June 2011) NICE TA225**
  - Golimumab, in combination with methotrexate, is an option for the treatment of rheumatoid arthritis in adults who have had an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) only, including methotrexate, if:
    - golimumab is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors, and
    - the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.
  - Alternatively, golimumab, in combination with methotrexate, is an option for the treatment of rheumatoid arthritis in adults who have had an inadequate response to DMARDs including a TNF inhibitor, if:
    - golimumab is used as described in the NICE guidance (August 2010) for other TNF inhibitors, and
    - the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.
    - www.nice.org.uk/TA225

*BNF 70*  |  *Arthritis 905*
**Golimumab for the treatment of ankylosing spondylitis**

(August 2011) NICE TA233

Golimumab is an option for the treatment of severe, active ankylosing spondylitis in adults only if:

- Golimumab is used as described in the NICE guidance (May 2008) for adalimumab and etanercept, and
- the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.

Patients who are already receiving golimumab for the treatment of severe, active ankylosing spondylitis who do not fulfil the criteria for treatment with adalimumab and etanercept, described in the NICE guidance (May 2008), can continue treatment until they and their specialist consider it appropriate to stop. [www.nice.org.uk/TA233](www.nice.org.uk/TA233)

**Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy** (February 2015) NICE TA329

NICE recommended. See Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) TA329 [www.nice.org.uk/TA329](www.nice.org.uk/TA329) p. 907

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (June 2012) that golimumab (Simponi®) is accepted for restricted use within NHS Scotland at a dose of 50 mg, alone or in combination with methotrexate, for the treatment of active and progressive psoriatic arthritis in adults whose disease has not responded to adequate trials of at least two standard DMARDs, administered either individually or in combination.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**CAUTIONARY AND ADVISORY LABELS 10**

- Simponi (Merck Sharp & Dohme Ltd)

Golimumab 100 mg per 1 ml Simponi 50 mg/0.5 ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection [P] £762.97 Simponi 100 mg/1 ml solution for injection pre-filled pen | 1 pre-filled disposable injection [P] £1,525.94

Simponi 50 mg/0.5 ml solution for injection pre-filled syringes | 1 pre-filled disposable injection [P] £762.97

**Infliximab**

**INDICATIONS AND DOSE**

**Severe active Crohn’s disease**

**BY INTRAVENOUS INFUSION**

- Adult: Initially 5 mg/kg, then 5 mg/kg after 2 weeks, then 5 mg/kg after 4 weeks, if condition has responded, then maintenance 5 mg/kg every 8 weeks

**Fistulating Crohn’s disease**

**BY INTRAVENOUS INFUSION**

- Adult: Initially 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, if condition has responded consult product literature for guidance on further doses

**Severe active ulcerative colitis**

**BY INTRAVENOUS INFUSION**

- Adult: Initially 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 8 weeks, discontinue if no response 14 weeks after initial dose

**Rheumatoid arthritis (in combination with methotrexate)**

**BY INTRAVENOUS INFUSION**

- Adult: Initially 3 mg/kg, then 3 mg/kg after 2 weeks, followed by 3 mg/kg after 4 weeks, then 3 mg/kg every 8 weeks, dose to be increased only if response is inadequate after 12 weeks of initial treatment; increased in steps of 1.5 mg/kg every 8 weeks, increased if necessary up to 7.5 mg/kg every 8 weeks, alternatively increased if necessary to 3 mg/kg every 4 weeks, discontinue if no response by 12 weeks of initial infusion or after dose adjustment

**Ankylosing spondylitis**

**BY INTRAVENOUS INFUSION**

- Adult: 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 6–8 weeks, discontinue if no response by 6 weeks of initial infusion

**Psoriatic arthritis (in combination with methotrexate)**

**BY INTRAVENOUS INFUSION**

- Adult: 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, followed by 5 mg/kg every 8 weeks

**Plaque psoriasis**

**BY INTRAVENOUS INFUSION**

- Adult: 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 8 weeks, discontinue if no response within 14 weeks of initial infusion

**Important safety information**

Adequate resuscitation facilities must be available when infliximab is used.

**CONTRA-INDICATIONS**

Moderate or severe heart failure - severe infections

**CAUTIONS**

Demyelinating disorders (risk of exacerbation) - development of malignancy - hepatitis B virus - monitor for active infection - history of colon carcinoma (in inflammatory bowel disease) - history of dysplasia (in inflammatory bowel disease) - history of malignancy - history of prolonged immunosuppressant or PUVA treatment in patients with psoriasis - mild heart failure (discontinue if symptoms develop or worsen) - predisposition to infection (discontinue if new serious infection develops) - risk of delayed hypersensitivity reactions if drug-free interval exceeds 16 weeks

**CAUTIONS, FURTHER INFORMATION**

**Tuberculosis**

Active tuberculosis should be treated with standard treatment for at least 2 months before starting infliximab. Patients who have previously received adequate treatment for tuberculosis can start infliximab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting infliximab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with infliximab.

**Hypersensitivity reactions**

Hypersensitivity reactions (including fever, chest pain, hypotension, hypertension, dyspnoea, transient visual loss, pruritus, urticaria, serum sickness-like reactions, angioedema, anaphylaxis) reported during or within 1–2 hours after infusion (risk greatest during first or second infusion or in patients who discontinue other immunosuppressants). Prophylactic antipyretics, antihistamines, or hydrocortisone may be administered.

**INTERACTIONS** → Appendix 1 (infliximab).

**SIDE-EFFECTS**

- **Common or very common**

- **Common**

- **Uncommon**

- **Rare**

- **Very rare**

- **Unlikely**

- **Unknown**
Arthritis 907

National funding/access decisions

NICE technology appraisals (TAs)

- Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007) NICE TA130
NICE recommended. See Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007) TA130 www.nice.org.uk/TA130 p. 902

- Infliximab for plaque psoriasis in adults (January 2008) NICE TA134
Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks. www.nice.org.uk/TA134

- Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008) NICE TA143
NICE recommended. See Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)TA143 www.nice.org.uk/TA143 p. 902

- Infliximab for acute exacerbations of ulcerative colitis (December 2008) NICE TA163
Infliximab is recommended as an option for the treatment of acute exacerbations of severe ulcerative colitis when treatment with ciclosporin is contra-indicated or inappropriate. www.nice.org.uk/TA163

- Infliximab and adalimumab for Crohn’s disease (May 2010) NICE TA187
Infliximab or adalimumab is recommended for the treatment of severe active Crohn’s disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn’s disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) when conventional therapy cannot be used because of intolerance or contra-indications. Infliximab or adalimumab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease—in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, adalimumab or infliximab can be restarted [but see Hypersensitivity Reactions under Infliximab)]. www.nice.org.uk/TA187

- Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) NICE TA195

- Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010) NICE TA199

- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) NICE TA329
Infliximab, adalimumab and golimumab are options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and...
2 Hyperuricaemia and gout

Gout

It is important to distinguish drugs used for the treatment of acute attacks of gout from those used in the long-term control of the disease. The latter exacerbate and prolong the acute manifestations if started during an attack. The management of gout in adolescents requires specialist supervision.

Acute attacks of gout

Acute attacks of gout are usually treated with high doses of NSAIDs such as diclofenac sodium p. 921, diclofenac potassium p. 920, etoricoxib p. 925, indomethacin p. 929, ketoprofen p. 930, naproxen p. 934 or sulindac p. 937. Colchicine below is an alternative in patients in whom NSAIDs such as diclofenac sodium p. 921, etoricoxib p. 925, indomethacin p. 929, ketoprofen p. 930, naproxen p. 934 or sulindac p. 937 are contra-indicated. Aspirin p. 909 and other salicylates antagonise the uricosuric effects of these drugs.

Colchicine

Colchicine below is an alternative in patients in whom NSAIDs such as diclofenac sodium p. 921, etoricoxib p. 925, indomethacin p. 929, ketoprofen p. 930, naproxen p. 934 or sulindac p. 937 are contra-indicated. Aspirin p. 909 and other salicylates antagonise the uricosuric effects of these drugs.

Long-term control of gout

Frequent recurrence of acute attacks of gout, the presence of tophi, or signs of chronic gouty arthritis may call for the initiation of long-term (‘interval’) treatment. For long-term control of gout the formation of uric acid from purines may be reduced with the xanthine-oxidase inhibitors allopurinol p. 909 or febuxostat p. 910 alternatively the uricosuric drug sulfinpyrazone p. 909 may be used to increase the excretion of uric acid in the urine. Treatment should be continued indefinitely to prevent further attacks of gout by correcting the hyperuricaemia. These drugs should never be started during an acute attack; they are usually started 1–2 weeks after the attack has settled. The initiation of treatment may precipitate an acute attack, and therefore an anti-inflammatory analgesic or colchicine below should be used as a prophylactic and continued for at least one month after the hyperuricaemia has been corrected. However, if an acute attack develops during treatment, then the treatment should continue at the same dosage and the acute attack treated in its own right.

Allopurinol is widely used and is especially useful in patients with renal impairment or urate stones when uricosuric drugs cannot be used; it is not indicated for the treatment of asymptomatic hyperuricaemia. It can cause rashes.

Febuxostat is licensed for the treatment of chronic hyperuricaemia where urate deposition has already occurred; it is not indicated for patients in whom the rate of urate formation is greatly increased, such as in malignant disease or in Lesch-Nyhan syndrome.

Sulfinpyrazone p. 909 can be used instead of allopurinol or in conjunction with it in cases that are resistant to treatment.

Benzbromarone (available from ‘special-order’ manufacturers or specialist importing companies) is a uricosuric drug that can be used in patients with mild renal impairment. Crystallisation of urate in the urine can occur with the uricosuric drugs and it is important to ensure an adequate urine output especially in the first few weeks of treatment. As an additional precaution the urine may be rendered alkaline.

Aspirin and other salicylates antagonise the uricosuric drugs; they do not antagonise allopurinol but are nevertheless not indicated in gout.
### Cautionary and Advisory Labels

**SULFINPYRAZONE (Non-proprietary)**

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Price</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfipyrazone 100 mg</td>
<td>Tablets</td>
<td>£0.40</td>
<td>DT price</td>
</tr>
<tr>
<td>Sulfipyrazone 200 mg</td>
<td>Tablets</td>
<td>£0.82</td>
<td>DT price</td>
</tr>
</tbody>
</table>

### Xanthine Oxidase Inhibitors

#### Allopurinol

**Indications and Dose**

Prophylaxis of gout and of uric acid and calcium oxalate renal stones

**By Mouth**

- Adult: Initially 100 mg daily, adjust dose according to plasma or urinary uric acid concentration, dose to be taken preferably after food
- Prophylaxis of gout and of uric acid and calcium oxalate renal stones (usual maintenance in mild conditions)
- Prophylaxis of hyperuricaemia associated with cancer chemotherapy (usual maintenance in mild conditions)
- Adult: 100–200 mg daily, dose to be taken preferably after food
- Prophylaxis of gout and of uric acid and calcium oxalate renal stones (usual maintenance in moderately severe conditions)
- Prophylaxis of hyperuricaemia associated with cancer chemotherapy (usual maintenance in moderately severe conditions)
- Adult: 700–900 mg daily in divided doses (max. per dose 300 mg), dose to be taken preferably after food

**Contra-Indications**

- Not a treatment for acute gout but continue if attack develops when already receiving allopurinol, and treat attack separately
- Ensure adequate fluid intake (2–3 litres/day)

**Caution**

- For hyperuricaemia associated with cancer therapy, allopurinol treatment should be started before cancer therapy

**Contraindications, Further Information**

Administer prophylactic NSAID (not aspirin or salicylates) or colchicine until at least 1 month after hyperuricaemia corrected (usually for first 3 months) to avoid precipitating an acute attack.

**Cautions, Further Information**

Administer prophylactic NSAID (not aspirin or salicylates) or colchicine until at least 1 month after hyperuricaemia corrected (usually for first 3 months) to avoid precipitating an acute attack.

**Side-Effects**

- **Common or very common** Gastro-intestinal disorders - rashes (withdraw therapy); if rash mild re-introduce cautiously but discontinue promptly if recurrence
- Rare Alopecia, aplastic anaemia, arthralgia, blood disorders, drowsiness, eosinophilia resembling Stevens-Johnson syndrome, eosinophilia resembling toxic epidermal necrolysis, exfoliation, fever, gynaecomastia, haemolytic anaemia, headache, hepatitis, hepatotoxicity, hypersensitivity reactions, hypertension, leucopenia, lymphadenopathy, malaise, neuropathy, paraesthesia, renal impairment, taste disturbances, thrombocytopenia, vasculitis, vertigo, visual disturbances
- Very rare Seizures

#### Sulfinpyrazone

**Uricosurics**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Formulation</th>
<th>Price</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colchicine 500 microgram</td>
<td>Tablets</td>
<td>£7.72</td>
<td>DT price</td>
</tr>
</tbody>
</table>

**Frequency not known**

- Excessive doses may cause profuse diarrhoea, gastrointestinal haemorrhage, hepatic damage, rash, renal damage

**Pregnancy**

- Avoid—teratogenicity in animal studies.

**Breast Feeding**

- Present in milk but no adverse effects reported. Manufacturers advise caution.

**Hepatic Impairment**

- Use with caution.

**Renal Impairment**

- Reduce dose or increase dosage interval if eGFR less than 10 mL/minute/1.73m². Avoid if eGFR less than 10 mL/minute/1.73m².

**Medicinal Forms**

- There can be variation in the licensing of different medicines containing the same drug.
Febuxostat

**INDICATIONS AND DOSE**

Treatment of chronic hyperuricaemia in gout

**BY MOUTH**

- Adult: Initially 80 mg once daily, if after 2–4 weeks of initial dose, serum uric acid greater than 6 mg/100 mL, then increase dose; increased if necessary to 120 mg daily

**Important safety information**

**MHRA/CHM ADVICE: SERIOUS HYPERSENSITIVITY REACTIONS (JUNE 2012)**

There have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock with febuxostat. Patients should be advised of the signs and symptoms of severe hypersensitivity; febuxostat must be stopped immediately if these occur (early withdrawal is associated with a better prognosis), and must not be restarted in patients who have ever developed a hypersensitivity reaction to febuxostat. Most cases occur during the first month of treatment; a prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat.

**CONTRA-INDICATIONS**

Not a treatment for acute gout but continue if attack develops when already receiving febuxostat, and treat attack separately

**CAUTIONS**

Congestive heart failure - ischaemic heart disease - thyroid disorders - transplant recipients

**CAUTIONS, FURTHER INFORMATION**

Administer prophylactic NSAID (not aspirin or salicylates) or colchicine for at least 6 months after starting febuxostat to avoid precipitating an acute attack.

**INTERACTIONS**

- Appendix 1 (febuxostat).

**SIDE-EFFECTS**

- Common or very common Abnormal liver function tests - gastro-intestinal disturbances - headache - oedema - rash

**PREGNANCY**

Manufacturer advises avoid – limited information available.

**BREAST FEEDING**

Manufacturer advises avoid – present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Max. 80 mg daily in mild impairment. No dose information available in moderate or severe impairment.

**RENAL IMPAIRMENT**

Use with caution if eGFR less than 30 mL/minute/1.73 m² – no information available.

**PRE-TREATMENT SCREENING**

Monitor liver function tests before treatment as indicated.

**MONITORING REQUIREMENTS**

Monitor liver function tests periodically during treatment as indicated.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

- Febuxostat for the management of hyperuricaemia in patients with gout (December 2008) NICE TA164
- Febuxostat is recommended as an option for the management of chronic hyperuricaemia in gout only for patients who are intolerant of allopurinol or for whom allopurinol is contra-indicated.

For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant discontinuation, or to prevent full dose escalation for optimal effectiveness.

[www.nice.org.uk/TA164](http://www.nice.org.uk/TA164)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium issued similar advice to NICE guidance: Febuxostat for the management of hyperuricaemia in patients with gout (December 2008), in August 2010.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension.
immunosuppressant such as azathioprine p. 716 is frequently used to reduce the dose of corticosteroid. Plasmapheresis or infusion of intravenous immunoglobulin [unlicensed indication] may induce temporary remission in severe relapses, particularly where bulbar or respiratory function is compromised or before thymectomy. 

Anticholinesterases
Anticholinesterase drugs enhance neuromuscular transmission in voluntary and involuntary muscle in myasthenia gravis. Excessive dosage of these drugs can impair neuromuscular transmission and precipitate cholinergic crises by causing a depolarising block. This may be difficult to distinguish from a worsening myasthenic state.

Muscarinic side-effects of anticholinesterases include increased sweating, increased salivary and gastric secretions, increased gastro-intestinal and uterine motility, and bradycardia. These parasympathomimetic effects are antagonised by atropine sulfate p. 1099.

Neostigmine p. 912 produces a therapeutic effect for up to 4 hours. Its pronounced muscarinic action is a disadvantage, and simultaneous administration of an antimuscarinic drug such as atropine sulfate or propantheline bromide p. 74 may be required to prevent colic, excessive salivation, or diarrhoea. In severe disease neostigmine can be given every 2 hours. The maximum that most patients can tolerate is 180 mg daily.

Pyridostigmine bromide p. 912 is less powerful and slower in action than neostigmine but it has a longer duration of action. It is preferable to neostigmine because of its smoother action and the need for less frequent dosage. It is particularly preferred in patients whose muscles are weak on waking. It has a comparatively mild gastrointestinal effect but an antimuscarinic drug may still be required.

Neostigmine is also used to reverse the actions of the non-depolarising neuromuscular blocking drugs.

Immunosuppressant therapy
Corticosteroids are established as treatment for myasthenia gravis; although they are commonly given on alternate days there is little evidence of benefit over daily administration. Corticosteroid treatment is usually initiated under in-patient supervision and all patients should receive osteoporosis prophylaxis.

In generalised myasthenia gravis prednisolone p. 585 is given. About 10% of patients experience a transient but very serious worsening of symptoms in the first 2–3 weeks, especially if the corticosteroid is started at a high dose. Smaller doses of corticosteroid are usually required in ocular myasthenia. Once clinical remission has occurred (usually after 2–6 months), the dose of prednisolone should be reduced slowly to the minimum effective dose.

In generalised myasthenia gravis azathioprine p. 716 is usually started at the same time as the corticosteroid and it allows a lower maintenance dose of the corticosteroid to be used. Ciclosporin p. 717, methotrexate p. 762, or mycophenolate mofetil p. 725 can be used in patients unresponsive or intolerant to other treatments [unlicensed indications].

Acetylcholine-release enhancers
Amifampridine below is licensed for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare disorder of neuromuscular transmission.

Fampridine p. 726 is licensed for the improvement of walking in patients with multiple sclerosis who have a walking disability.

Skeletal muscle relaxants
The drugs described are used for the relief of chronic muscle spasm or spasticity associated with multiple sclerosis or other neurological damage; they are not indicated for spasm associated with minor injuries. Baclofen, diazepam, and tizanidine act principally on the central nervous system. Dantrolene has a peripheral site of action; cannabis extract has both a central and a peripheral action. Skeletal muscle relaxants differ in action from the muscle relaxants used in anaesthesia, which block transmission at the neuromuscular junction.

The underlying cause of spasticity should be treated and any aggravating factors (e.g. pressure sores, infection) remedied. Skeletal muscle relaxants are effective in most forms of spasticity except the rare alpha variety. The major disadvantage of treatment with these drugs is that reduction in muscle tone can cause a loss of splinting action of the spastic leg and trunk muscles and sometimes lead to an increase in disability.

Baclofen p. 914 inhibits transmission at spinal level and also depresses the central nervous system. The dose should be increased slowly to avoid the major side-effects of sedation and muscular hypotonia (other adverse events are uncommon).

A cannabis extract p. 913 containing dronabinol (delta-9-tetrahydrocannabinol) and cannabidiol is licensed as an adjunct treatment for moderate to severe spasticity associated with multiple sclerosis in patients who have not responded adequately to other skeletal muscle relaxants. The dose should be titrated over 2 weeks; response to treatment should be reviewed after 4 weeks and treatment stopped if an adequate response is not achieved.

Dantrolene sodium p. 1101 acts directly on skeletal muscle and produces fewer central adverse effects making it a drug of choice. The dose should be increased slowly. Diazepam p. 267 can also be used. Sedation and occasionally extensor hypotonus are disadvantages. Other benzodiazepines also have muscle-relaxant properties. Muscle-relaxant doses of benzodiazepines are similar to antispastic agents.

Tizanidine p. 913 is an alpha-2-adrenoceptor agonist indicated for spasticity associated with multiple sclerosis or spinal cord injury.

Other muscle relaxants
The clinical efficacy of methocarbamol p. 915 and meprobamate p. 265 as muscle relaxants is not well established, although they have been included in compound analgesic preparations.

3.1 Myasthenia gravis and Lambert-Eaton myasthenic syndrome

ACETYLCHELORINE-RELEASE ENHANCERS

Amifampridine

**INDICATIONS AND DOSE**
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (specialist use only)

**BY MOUTH**
- **Adult:** Initially 15 mg daily in 3 divided doses, then increased in steps of 5 mg every 4–5 days, increased to up to 60 mg daily in 3–4 divided doses (max. per dose 20 mg); maximum 60 mg per day

- **CONTRA-INDICATIONS** Congenital QT syndromes • epilepsy • uncontrolled asthma
- **CAUTIONS** Non-paraneoplastic form of Lambert-Eaton myasthenic syndrome
Pyridostigmine bromide

**INDICATIONS AND DOSE**

Myasthenia gravis

**BY MOUTH**

- Adult: 30–120 mg, dose to be given at suitable intervals throughout the day; usual dose 0.3–1.2 g daily in divided doses, it is advisable to exceed a total daily dose of 450 mg in order to avoid acetylcholine receptor downregulation; patients requiring doses exceeding 450 mg daily will usually require input from a specialised neuromuscular service. Immunosuppressant therapy is usually considered if the dose of pyridostigmine exceeds 360 mg daily.

**Neostigmine**

*(Neostigmine methylsulfate)*

**INDICATIONS AND DOSE**

Treatment of myasthenia gravis

**BY MOUTH**

- Adult: Initially 15–30 mg, dose repeated at suitable intervals throughout the day, total daily dose 75–300 mg, the maximum that most patients can tolerate is 180 mg daily

**BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**

- Adult: 1–2.5 mg, dose repeated at suitable intervals throughout the day (usual total daily dose 5–20 mg)

**Reversal of non-depolarising (competitive) neuromuscular blockade**

**BY INTRAVENOUS INJECTION**

- Adult: 2.5 mg (max. per dose 5 mg), repeated if necessary after or with glycopyrronium or atropine, to be given over 1 minute

**UNLICENSED USE**

Dose for treatment of myasthenia gravis by subcutaneous or intramuscular injection in neonate is unlicensed.

**CAUTIONS**

- With intravenous use glycopyrronium or atropine should also be given when reversing neuromuscular blockade

**INTERACTIONS**

→ Appendix 1 (parasympathomimetics).

**RENAL IMPAIRMENT**

May need dose reduction.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

NEOSTIGMINE (Non-proprietary)

Neostigmine bromide 15 mg Neostigmine 15mg tablets | 140 tablet | £9.60

Solution for injection

NEOSTIGMINE (Non-proprietary)

Neostigmine methylsulfate 2.5 mg per 1 ml Neostigmine 2.5mg/1ml solution for injection ampoules | 10 ampoule | £4.95-15.06

**Pyridostigmine bromide**

**DRUG ACTION**

Pyridostigmine bromide has weaker muscarinic action than neostigmine.

**INDICATIONS AND DOSE**

Myasthenia gravis

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Adult: 30–120 mg, dose to be given at suitable intervals throughout the day; usual dose 0.3–1.2 g daily in divided doses, it is advisable to exceed a total daily dose of 450 mg in order to avoid acetylcholine receptor downregulation; patients requiring doses exceeding 450 mg daily will usually require input from a specialised neuromuscular service. Immunosuppressant therapy is usually considered if the dose of pyridostigmine exceeds 360 mg daily.
3.2 Nocturnal leg cramps

Nocturnal leg cramps
Quinine salts, such as quinine sulfate are effective in reducing the frequency of nocturnal leg cramps by about 25% in ambulatory patients; however, because of potential toxicity, quinine is not recommended for routine treatment and should not be used unless cramps cause regular disruption to sleep. Quinine p. 540 should only be considered when cramps are very painful or frequent; when other treatable causes of cramp have been excluded; and when non-pharmacological treatments have not worked (e.g. passive stretching exercises). It may take up to 4 weeks for improvement to become apparent; if there is benefit, quinine treatment can be continued. Treatment should be interrupted at intervals of approximately 3 months to assess the need for further quinine treatment. In patients taking quinine long term, a trial discontinuation may be considered. Quinine is toxic in overdose and accidental fatalities have occurred.

3.3 Spasticity

Drugs used for Spasticity not listed below; Dantrolene sodium, p. 1101 · Diazepam, p. 267

Alpha₂-adrenoceptor agonists
Tizanidine

INDICATIONS AND DOSE
Spasticity associated with multiple sclerosis or spinal cord injury or disease

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

> Adult: Initially 2 mg for 1 dose, then increased in steps of 2 mg/24 hours every 3–4 days in divided doses, adjusted according to response; usual dose up to 24 mg daily in 3–4 divided doses; maximum 36 mg per day

> CAUTIONS Elderly

> INTERACTIONS → Appendix 1 (muscle relaxants).

> SIDE-EFFECTS

> Common or very common Altered liver enzymes (discontinue if persistently raised—consult product literature) · dizziness · drowsiness · dry mouth · fatigue · gastro-intestinal disturbance · hypotension · nausea

> Uncommon Bradycardia · Frequency not known Asthenia · blurred vision · confusion · convulsions · hallucinations · hepatitis · insomnia · liver failure · syncope

> PREGNANCY Avoid (toxicity in animal studies).

> BREAST FEEDING Avoid (present in milk in animal studies).

> HEPATIC IMPAIRMENT Avoid in severe impairment; use in moderate impairment only if potential benefit outweighs risk.

> RENAL IMPAIRMENT Manufacturer advises caution.

> MONITORING REQUIREMENTS Monitor liver function monthly for first 4 months and in those who develop unexplained nausea, anorexia or fatigue.

> TREATMENT CESSATION Avoid abrupt withdrawal (risk of rebound hypertension and tachycardia); to minimise risk, discontinue gradually and monitor blood pressure.

> PATIENT AND CARER ADVICE Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

Cannabis extract

INDICATIONS AND DOSE
Adjunct in moderate to severe spasticity in multiple sclerosis (specialist use only)

BY BUCCAL ADMINISTRATION

> Adult: (consult product literature)

> CONTRA-INDICATIONS Family history of psychosis · history of other severe psychiatric disorder · personal history of psychosis

> CAUTIONS History of epilepsy · significant cardiovascular disease

> INTERACTIONS → Appendix 1 (cannabis extract).

> SIDE-EFFECTS

> Common or very common Amnesia · blurred vision · constipation · depression · diarrhoea · disorientation · dissociation · dizziness · drowsiness · dry mouth · dystarhria · impaired attention · increased or decreased appetite · malaise · mood disturbance · mouth ulcers · nausea · oral pain · taste disturbance · vertigo · vomiting

> Uncommon Abdominal pain · delusions · hallucinations · hypertension · oromucosal discolouration · palpititation · paraesthesia · pharyngitis · stomatitis · suicidal thoughts · syncope · tachycardia · tooth discoloration

> Frequency not known Anxiety · seizures

> CONCEPTION AND CONTRACEPTION Manufacturer recommends effective contraception during and for 3 months after treatment in men and women.

> PREGNANCY Manufacturer advises use only if potential benefit outweighs risks.

> BREAST FEEDING Avoid—present in milk.

> HEPATIC IMPAIRMENT Manufacturer advises more frequent monitoring in significant hepatic impairment—possible risk of prolonged or enhanced effect.
Baclofen

**INDICATIONS AND DOSE**

Pain of muscle spasm in palliative care

**BY MOUTH**

- Adult: 5–10 mg 3 times a day

Hiccup due to gastric distension (in palliative care)

**BY MOUTH**

- Adult: 5 mg twice daily

Chronic severe spasticity resulting from disorders such as multiple sclerosis or traumatic partial section of spinal cord

**BY MOUTH**

- Adult: Initially 5 mg 3 times a day, gradually increased; maintenance up to 60 mg daily in divided doses, review treatment if no benefit within 6 weeks of achieving maximum dose; maximum 100 mg per day

Severe chronic spasticity unresponsive to oral antispastic drugs (or where side-effects of oral therapy unacceptable) or as alternative to ablative neurosurgical procedures (specialist use only)

**BY INTRATHECAL INJECTION**

- Adult: Test dose 25–50 micrograms, to be given over at least 1 minute via catheter or lumbar puncture, then increased in steps of 25 micrograms (max. per dose 100 micrograms), not given more often than every 24 hours to determine appropriate dose, then dose-titration phase, most often using infusion pump (implanted into chest wall or abdominal wall tissues) to establish maintenance dose (ranging from 12 micrograms to 2 mg daily for spasticity of spinal origin or 22 micrograms to 1.4 mg daily for spasticity of cerebral origin) retaining some spasticity to avoid sensation of paralysis

**CONTRA-INDICATIONS**

- With intrathecal use Local infection - systemic infection

**CAUTIONS**

**GENERAL CAUTIONS**

Cerebrovascular disease - diabetes - elderly - epilepsy - history of peptic ulcer - hypertonic bladder sphincter - Parkinson’s disease - psychiatric illness - respiratory impairment

**SPECIFIC CAUTIONS**

- With intrathecal use Coagulation disorders - malnutrition (increased risk of post-surgical complications) - previous spinal fusion procedure

**INTERACTIONS**


- Rare Abdominal pain - changes in hepatic function - dysarthria - erectile dysfunction - paraesthesia - taste disturbances

- Very rare Hypothermia

**PREGNANCY**

Manufacturer advises use only if potential benefit outweighs risk (toxicity in animal studies).

**BREAST FEEDING**

Present in milk—amount probably too small to be harmful.

**HEPATIC IMPAIRMENT**

- With oral use Manufacturer advises use with caution.

**RENAL IMPAIRMENT**

- With oral use Risk of toxicity—use smaller doses (e.g. 5 mg daily by mouth) and if necessary increase dosage interval; if eGFR less than 15 mL/minute/1.73 m² manufacturer advises use by mouth only if potential benefit outweighs risk. Excreted by kidney.

**TREATMENT CESSATION**

Avoid abrupt withdrawal (risk of hypertensive state, may exacerbate spasticity, and precipitate autonomic dysfunction including hyperthermia, psychiatric reactions and convulsions; to minimise risk, discontinue by gradual dose reduction over at least 1–2 weeks (longer if symptoms occur)).

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral liquid formulations may include raspberry.

**PATIENT AND CARER ADVICE**

Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Solvaco solution** 1 mg per 1 mL (sugar-free) price = £4.38
- **Solvaco tablets** 2.5 mg | 5 mg | 10 mg price = £3.02–£3.95
- **Lioresal oral suspension** 5mg | 10mg | 20mg | 40mg price = £3.50–£6.70
- **Solvaco oral suspension** 5mg/5mL | 10mg/10mL price = £3.50–£6.70
- **Solvaco oral solution** 5mg/5mL price = £3.50–£6.70
- **Lioresal oral solution** 5mg/5mL price = £3.50–£6.70
- **Solvaco oral solution** 10mg/10mL price = £5.99–£6.86
- **Lioresal oral solution** 10mg/10mL price = £7.72–£14.24
- **Solvaco tablets** 5 mg price = £4.99–£6.28
- **Lioresal tablets** 5 mg price = £4.99–£6.28
- **Solvaco tablets** 10 mg price = £5.49–£8.64
- **Lioresal tablets** 10 mg price = £6.13–£9.29
- **Solvaco tablets** 20 mg price = £11.74
- **Lioresal tablets** 20 mg price = £14.24
- **Lioresal injection** 10 mg/mL price = £2.36

**EXCIPIENTS:** May contain Gluten

- **Solvaco solution** 1 mg per 1 mL, Dronabinol 2.7 mg per 1 dose Sativex oromucosal spray 270 dose price = £375.00

**GAMMA-AMINOBUTYRIC ACID ANALOGUES AND DERIVATIVES**

**Baclofen**

**SIDE-EFFECTS**

- Rare Abdominal pain - changes in hepatic function - dysarthria - erectile dysfunction - paraesthesia - taste disturbances

- Very rare Hypothermia

- **CONTRA-INDICATIONS**

- With intrathecal use Local infection - systemic infection

- With oral use Avoid oral route in active peptic ulceration

**MEDICATIONS**

RENAL IMPAIRMENT

Manufacturer advises more frequent monitoring in significant renal impairment—possible risk of prolonged or enhanced effect.

**MONITORING REQUIREMENTS**

Monitor oral mucosa—interrupt treatment if lesions or persistent soreness.

**PATIENT AND CARER ADVICE**

For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including cannabis, see Drugs and Driving under Guidance on prescribing, p. 1

**RARITY**

Rare

**SIDE-EFFECTS**

Abdominal pain - changes in hepatic function - dysarthria - erectile dysfunction - paraesthesia - taste disturbances

**CONTRA-INDICATIONS**

- With intrathecal use Local infection - systemic infection

- With oral use Avoid oral route in active peptic ulceration

**CAUTIONS**

**GENERAL CAUTIONS**

Cerebrovascular disease - diabetes - elderly - epilepsy - history of peptic ulcer - hypertonic bladder sphincter - Parkinson’s disease - psychiatric illness - respiratory impairment

**SPECIFIC CAUTIONS**

- With intrathecal use Coagulation disorders - malnutrition (increased risk of post-surgical complications) - previous spinal fusion procedure

**INTERACTIONS**


- Rare Abdominal pain - changes in hepatic function - dysarthria - erectile dysfunction - paraesthesia - taste disturbances

- Very rare Hypothermia

**PREGNANCY**

Manufacturer advises use only if potential benefit outweighs risk (toxicity in animal studies).

**BREAST FEEDING**

Present in milk—amount probably too small to be harmful.

**HEPATIC IMPAIRMENT**

- With oral use Manufacturer advises use with caution.

**RENAL IMPAIRMENT**

- With oral use Risk of toxicity—use smaller doses (e.g. 5 mg daily by mouth) and if necessary increase dosage interval; if eGFR less than 15 mL/minute/1.73 m² manufacturer advises use by mouth only if potential benefit outweighs risk. Excreted by kidney.

**TREATMENT CESSATION**

Avoid abrupt withdrawal (risk of hypertensive state, may exacerbate spasticity, and precipitate autonomic dysfunction including hyperthermia, psychiatric reactions and convulsions; to minimise risk, discontinue by gradual dose reduction over at least 1–2 weeks (longer if symptoms occur)).

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral liquid formulations may include raspberry.

**PATIENT AND CARER ADVICE**

Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, oral suspension, oral solution

**Tablet**

| CAUTIONARY AND ADVISORY LABELS | 2, 8, 21 |
| EXCIPIENTS: May contain Gluten |
| **BACLOFEN (Non-proprietary)** |
| Baclofen 10 mg Baclofen 10mg tablets | 84 tablet | £9.99 DT price = £1.85 |
| Lioresal (Novartis Pharmaceuticals UK Ltd) |
| Baclofen 10 mg Lioresal 10mg tablets | 100 tablet | £12.38 |

**Oral solution**

| CAUTIONARY AND ADVISORY LABELS | 2, 8, 21 |
| **BACLOFEN (Non-proprietary)** |
| Baclofen 1 mg per 1 mL Baclofen 5mg/5mL oral solution sugar free (sugar-free) | 300 mL | £22.45 DT price = £4.59 |
| Lioresal (Novartis Pharmaceuticals UK Ltd) |
| Baclofen 1 mg per 1 mL Lioresal 5mg/5mL liquid (sugar-free) | 300 mL | £8.59 DT price = £4.59 |
| Brands may include Lyflex |

**Important safety information**

Consult product literature for details on test dose and titration—important to monitor patients closely in appropriately equipped and staffed environment during screening and immediately after pump implantation. Resuscitation equipment must be available for immediate use. Treatment with continuous pump-administered intrathecal baclofen should be initiated within 3 months of a satisfactory response to intrathecal baclofen testing.
Pain and inflammation in musculoskeletal disorders

**Non-steroidal anti-inflammatory drugs**

In single doses non-steroidal anti-inflammatory drugs (NSAIDs) have analgesic activity comparable to that of paracetamol p. 354, but paracetamol is preferred, particularly in the elderly.

In regular full dosage NSAIDs have both a lasting analgesic and an anti-inflammatory effect which makes them particularly useful for the treatment of continuous or regular pain associated with inflammation. Therefore, although paracetamol often gives adequate pain control in osteoarthritis, NSAIDs are more appropriate than paracetamol or the opioid analgesics in the inflammatory arthritides (e.g. rheumatoid arthritis) and in some cases of advanced osteoarthritis. NSAIDs can also be of benefit in the less well defined conditions of back pain and soft-tissue disorders.

**Choice**

Differences in anti-inflammatory activity between NSAIDs are small, but there is considerable variation in individual response and tolerance to these drugs. About 60% of patients will respond to any NSAID; of the others, those who do not respond to one may well respond to another. Pain relief starts soon after taking the first dose and a full analgesic effect should normally be obtained within a week, whereas an anti-inflammatory effect may not be achieved (or may not be clinically assessable) for up to 3 weeks. If appropriate responses are not obtained within these times, another NSAID should be tried.

NSAIDs reduce the production of prostaglandins by inhibiting the enzyme cyclo-oxygenase. They vary in their selectivity for inhibiting different types of cyclo-oxygenase; selective inhibition of cyclo-oxygenase-2 is associated with less gastro-intestinal intolerance. Several other factors also influence susceptibility to gastrointestinal effects, and a NSAID should be chosen on the basis of the incidence of gastro-intestinal and other side-effects.

Ibuprofen p. 927 is a propionic acid derivative with anti-inflammatory, analgesic, and antipyretic properties. It has fewer side-effects than other non-selective NSAIDs but its anti-inflammatory properties are weaker. It is unsuitable for conditions where inflammation is prominent, such as acute gout. DEXIBUPROFEN p. 919 is the active enantiomer of ibuprofen. It has similar properties to ibuprofen and is licensed for the relief of mild to moderate pain and inflammation.

Other propionic acid derivatives:

Naproxen p. 934 is one of the first choices because it combines good efficacy with a low incidence of side-effects (but more than ibuprofen).

Flurbiprofen may be slightly more effective. Both are associated with slightly more gastro-intestinal side-effects than ibuprofen.

**Pain and inflammation in musculoskeletal disorders**

**Solution for injection**

- **BACLOFEN (Non-proprietary)**
  - Baclofen 50 microgram per 1 ml Baclofen 50micrograms/1ml solution for injection ampoules | 1 ampoule (POM) £10.95 | 10 ampoule (POM) £27.60
  - Lioresal (Novartis Pharmaceuticals UK Ltd)
  - Baclofen 50 microgram per 1 ml Lioresal Intrathecal 50micrograms/1ml solution for injection ampoules | 1 ampoule (POM) £2.63

**Solution for infusion**

- **BACLOFEN (Non-proprietary)**
  - Baclofen 500 microgram per 1 ml Baclofen 10mg/20ml solution for infusion ampoules | 1 ampoule (POM) £57.00
  - Baclofen 2 mg per 1 ml Baclofen 10mg/5ml solution for infusion ampoules | 5 ampoule (POM) £243.10 | 10 ampoule (POM) £570.00
  - Lioresal (Novartis Pharmaceuticals UK Ltd)
  - Baclofen 500 microgram per 1 ml Lioresal Intrathecal 10mg/20ml solution for infusion ampoules | 1 ampoule (POM) £58.34
  - Baclofen 2 mg per 1 ml Lioresal Intrathecal 10mg/5ml solution for infusion ampoules | 1 ampoule (POM) £58.34

**MUSCLE RELAXANTS**

**Methocarbamol**

**INDICATIONS AND DOSE**

Short-term symptomatic relief of muscle spasm

**BY MOUTH**

- Adults: 1.5 g 4 times a day; reduced to 750 mg 3 times a day if required
- Elderly: Up to 750 mg 4 times a day, may be sufficient

- **CONTRA-INDICATIONS** Brain damage : coma : epilepsy : myasthenia gravis : pre-coma
- **INTERACTIONS** → Appendix 1 (muscle relaxants).
- **PREGNANCY** Manufacturer advises caution unless potential benefit outweighs risk.
- **BREAST FEEDING** Present in milk in animal studies — manufacturer advises caution.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution; half-life may be prolonged.
- **RENAL IMPAIRMENT** Manufacturer advises caution.
- **PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.
- **LESS SUITABLE FOR PRESCRIBING** Less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include:

- **Tablet** CAUTIONARY AND ADVISORY LABELS 2
  - METHOCARBAMOL (Non-proprietary)
  - Methocarbamol 750 mg Methocarbamol 750mg tablets | 100 tablet (POM) £12.65 DT price = £12.65
  - Robaxin (Almirall Ltd)
  - Methocarbamol 750 mg Robaxin 750 tablets | 100 tablet (POM) £12.65 DT price = £12.65
916 Pain and inflammation in musculoskeletal disorders

Drugs with properties similar to those of propionic acid derivatives:

Diclofenac sodium p. 921 and aceclofenac below are similar in efficacy to naproxen.

Etodolac p. 924 is comparable in efficacy to naproxen p. 934; it is licensed for symptomatic relief of osteoarthritis and rheumatoid arthritis.

Indomethacin p. 929 has an action equal to or superior to that of naproxen, but with a higher incidence of side-effects including headache, dizziness, and gastro-intestinal disturbances.

Mefenamic acid p. 932 has minor anti-inflammatory properties. It has occasionally been associated with diarrhoea and haemolytic anaemia which require discontinuation of treatment.

Meloxicam p. 933 is licensed for the short-term relief of pain in osteoarthritis and for long-term treatment of rheumatoid arthritis and ankylosing spondylitis.

Nabumetone p. 934 is comparable in effect to naproxen p. 934.

Phenylbutazone is licensed for ankylosing spondylitis, but is not recommended because it is associated with serious side-effects, in particular haematological reactions; it should be used only by a specialist in severe cases where other treatments have been found unsuitable.

Piroxicam p. 936 is as effective as naproxen and has a long duration of action which permits once-daily administration. However, it has more gastro-intestinal side-effects than most other NSAIDs, and is associated with more frequent serious skin reactions.

Sulindac p. 937 is similar in tolerance to naproxen. Tenoxicam p. 937 is similar in activity and tolerance to naproxen. Its long duration of action allows once-daily administration.

Tolprofen p. 381 is licensed for the treatment of migraine.

Ketorolac trometamol p. 1107 and the selective inhibitor of cyclo-oxygenase-2, parecoxib p. 1108, are licensed for the short-term management of postoperative pain. The selective inhibitors of cyclo-oxygenase-2, etoricoxib p. 925 and celecoxib p. 918, are as effective as non-selective NSAIDs such as diclofenac sodium and naproxen. Although selective inhibitors can cause serious gastro-intestinal events, available evidence appears to indicate that the risk of serious upper gastro-intestinal events is lower with selective inhibitors compared to non-selective NSAIDs; this advantage may be lost in patients who require concomitant low-dose aspirin.

Celecoxib and etoricoxib are licensed for the relief of pain in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; etoricoxib is also licensed for the relief of pain from acute gout.

Aspirin p. 104 has been used in high doses to treat rheumatoid arthritis, but other NSAIDs are now preferred.

Dental and orofacial pain

Most mild to moderate dental pain and inflammation is effectively relieved by NSAIDs. Those used for dental pain include ibuprofen p. 927, diclofenac sodium p. 921, and diclofenac potassium p. 920.

Asthma

Any degree of worsening of asthma may be related to the ingestion of NSAIDs, either prescribed or (in the case of ibuprofen and others) purchased over the counter.

NSAIDs and cardiovascular events

All NSAID use (including cyclo-oxygenase-2 selective inhibitors) can, to varying degrees, be associated with a small increased risk of thrombotic events (e.g. myocardial infarction and stroke) independent of baseline cardiovascular risk factors or duration of NSAID use; however, the greatest risk may be in those receiving high doses long term.

Cyclo-oxygenase-2 selective inhibitors, diclofenac (150 mg daily) and ibuprofen (2.4 g daily) are associated with an increased risk of thrombotic events. Although there are limited data regarding the thrombotic effects of aceclofenac, treatment advice has been updated in line with diclofenac, based on aceclofenac’s structural similarity to diclofenac and its metabolism to diclofenac. The increased risk for diclofenac is similar to that of licensed doses of etoricoxib. Naproxen (1 g daily) is associated with a lower thrombotic risk, and low doses of ibuprofen (1.2 g daily or less) have not been associated with an increased risk of myocardial infarction.

The lowest effective dose of NSAID should be prescribed for the shortest period of time to control symptoms and the need for long-term treatment should be reviewed periodically.

NSAIDs and gastro-intestinal events

All NSAIDs are associated with serious gastro-intestinal toxicity; the risk is higher in the elderly. Evidence on the relative safety of non-selective NSAIDs indicates differences in the risks of serious upper gastro-intestinal side-effects—piroxicam, ketoprofen, and ketorolac trometamol are associated with the highest risk; indometacin, diclofenac, and naproxen are associated with intermediate risk, and ibuprofen with the lowest risk (although high doses of ibuprofen have been associated with intermediate risk). Selective inhibitors of cyclo-oxygenase-2 are associated with a lower risk of serious upper gastro-intestinal side-effects than non-selective NSAIDs.

Recommendations are that NSAIDs associated with a low risk e.g. ibuprofen are generally preferred, to start at the lowest recommended dose and not to use more than one oral NSAID at a time.

The combination of a NSAID and low-dose aspirin can increase the risk of gastro-intestinal side-effects; this combination should be used only if absolutely necessary and the patient should be monitored closely.

While it is preferable to avoid NSAIDs in patients with active or previous gastro-intestinal ulceration or bleeding, and to withdraw them if gastro-intestinal lesions develop, nevertheless patients with serious rheumatic diseases (e.g. rheumatoid arthritis) are usually dependent on NSAIDs for effective relief of pain and stiffness.

Patients at risk of gastro-intestinal ulceration (including the elderly), who need NSAID treatment should receive gastroprotective treatment.

Systemic as well as local effects of NSAIDs contribute to gastro-intestinal damage; taking oral formulations with milk or food, or using enteric-coated formulations, or changing the route of administration may only partially reduce symptoms such as dyspepsia.

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

Aceclofenac

INDICATIONS AND DOSE

Pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis

BY MOUTH

Adult: 100 mg twice daily

- CONTRA-INDICATIONS Active gastro-intestinal bleeding • active gastro-intestinal ulceration • cerebrovascular disease • history of gastro-intestinal bleeding related to previous NSAID therapy • history of gastro-intestinal perforation related to previous NSAID therapy • history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) • history of recurrent gastro-intestinal
ulceration (two or more distinct episodes) • ischaemic heart disease • mild heart failure • peripheral arterial disease • severe heart failure

- **CAUTIONS** Allergic disorders • avoid in Acute porphyrias p. 864 • cardiac impairment (NSAIDs may impair renal function) • coagulation defects • connective-tissue disorders • Crohn’s disease (may be exacerbated) • elderly (risk of serious side-effects and fatalities) • history of cardiac failure • hypertension • left ventricular dysfunction • oedema • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated)

- **INTERACTIONS** → Appendix 1 (NSAIDs).

- **SIDE-EFFECTS**
  - Rare
  - Alveolitis • aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • hepatic damage • interstitial fibrosis associated with NSAIDs can lead to renal failure • pancreatitis • papillary necrosis associated with NSAIDs can lead to renal failure • pulmonary eosinophilia • Stevens-Johnson syndrome • toxic epidermal necrolysis • visual disturbances

  - Frequency not known
  - Angioedema • blood disorders • bronchospasm • colitis (induction of or exacerbation of) • Crohn’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness • drowsiness • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hypersensitivity reactions • insomnia • nausea • nervousness • photosensitivity • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • tinnitus • vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY** Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk. NSAIDs should be avoided during the third trimester because use is associated with a risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn. In addition, the onset of labour may be delayed and its duration may be increased.

- **BREAST FEEDING** Use with caution during breast-feeding. Manufacturer advises avoid.

- **HEPATIC IMPAIRMENT** Initially 100 mg daily. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT** Avoid if possible or use with caution; avoid in moderate to severe impairment. The lowest effective dose should be used for the shortest possible duration. In renal impairment, monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **MEDICAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

---

### Pain and inflammation in musculoskeletal disorders

#### Tablet

**INDICATIONS AND DOSE**

**Pain and inflammation in rheumatic disease**

**INDICATIONS AND DOSE**

**Pain and inflammation in other musculoskeletal disorders**

**Postoperative analgesia**

**BY MOUTH**

- Adult: 120 mg daily in divided doses, then increased if necessary to 180 mg daily in divided doses, dose to be taken with food

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding • active gastro-intestinal ulceration • history of gastro-intestinal bleeding related to previous NSAID therapy • history of gastro-intestinal perforation related to previous NSAID therapy • history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) • history of recurrent gastro-intestinal ulceration (two or more distinct episodes) • severe heart failure

**CAUTIONS** Allergic disorders • cardiac impairment (NSAIDs may impair renal function) • cerebrovascular disease • coagulation defects • connective-tissue disorders • Crohn’s disease (may be exacerbated) • elderly (risk of serious side-effects and fatalities) • epilepsy • heart failure • ischaemic heart disease • parkinsonism • peripheral arterial disease • psychiatric disturbances • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated) • uncontrolled hypertension

**INTERACTIONS** → Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- Rare
  - Alveolitis • aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • blood disorders • bronchospasm • colitis (induction of or exacerbation of) • Crohn’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness • drowsiness • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hypersensitivity reactions • insomnia • nausea • nervousness • photosensitivity • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • tinnitus • vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or...
any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY** Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk. NSAIDs should be avoided during the third trimester because use is associated with a risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn. In addition, the onset of labour may be delayed and its duration may be increased.

- **BREAST FEEDING** Use with caution during breast-feeding. Manufacturer advises avoid.

- **HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT** Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **MONITORING REQUIREMENTS** During prolonged therapy ophthalmic and blood examinations particularly advisable.

- **PATIENT AND CARER ADVICE** Dizziness may affect performance of skilled tasks (e.g. driving).

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

- **SIDE-EFFECTS, FURTHER INFORMATION** Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID. Contraindicated in patients with sulphonamide sensitivity.

- **CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY** Avoid (teratogenic in animal studies).

- **BREAST FEEDING** Avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Halve initial dose in moderate impairment. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT** Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. Avoid if eGFR less than 30 mL/minute/1.73 m². In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **MONITORING REQUIREMENTS** Monitor blood pressure before and during treatment.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Celecoxib**

**INDICATIONS AND DOSE**

- **Pain and inflammation in osteoarthritis**
  - **BY MOUTH**
    - Adult: 200 mg daily in 1–2 divided doses, then increased if necessary up to 200 mg twice daily, discontinue if no improvement after 2 weeks on maximum dose

- **Pain and inflammation in rheumatoid arthritis**
  - **BY MOUTH**
    - Adult: 100 mg twice daily, then increased if necessary to 200 mg twice daily, discontinue if no improvement after 2 weeks on maximum dose

- **Ankylosing spondylitis**
  - **BY MOUTH**
    - Adult: 200 mg daily in 1–2 divided doses, then increased if necessary up to 400 mg daily in 1–2 divided doses, discontinue if no improvement after 2 weeks on maximum dose

- **CONTRA-INDICATIONS** Active gastro-intestinal bleeding - active gastro-intestinal ulceration - cerebrovascular disease - inflammatory bowel disease - ischaemic heart disease - mild to severe heart failure - peripheral arterial disease

- **CAUTIONS** Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - history of cardiac failure - hypertension - left ventricular dysfunction - oedema - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated)

- **INTERACTIONS** Appendix 1 (NSAIDs).

- **SIDE-EFFECTS**
  - **Common or very common** Dyspnoea - influenza-like symptoms
  - **Uncommon** Cerebral infarction - fatigue - muscle cramps - palpitation - paraesthesia - stomatitis
  - **Rare** Alopecia - aloilitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - taste disturbance - toxic epidermal necrolysis - visual disturbances

  - **Very rare** Seizures
  - **Frequency not known** Angioedema - blood disorders - bronchospasm - chest pain - colitis (induction of or exacerbation of) - Crohn’s disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

**Celexor (Non-proprietary)**

- **Celecoxib 100 mg** Celecoxib 100 mg capsules | 60 capsule £21.55 DT price = £4.20
Pain and inflammation in musculoskeletal disorders

Dexibuprofen

**INDICATIONS AND DOSE**

Pain and inflammation associated with osteoarthritis and other musculoskeletal disorders | Mild to moderate pain and inflammation including dental pain

**BY MOUTH**

- Adult: 600–900 mg daily in up to 3 divided doses; increased if necessary up to 1.2 g daily (max. per dose 400 mg)

Mild to moderate pain and inflammation in dysmenorrhea

**BY MOUTH**

- Adult: 600–900 mg daily in up to 3 divided doses (max. per dose 300 mg); maximum 900 mg per day

- **CONTRA-INDICATIONS**
  
  Active gastro-intestinal bleeding
  
  - active gastro-intestinal ulceration
  
  - history of gastro-intestinal bleeding related to previous NSAID therapy
  
  - history of gastro-intestinal perforation related to previous NSAID therapy
  
  - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
  
  - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) — severe heart failure

- **CAUTIONS**

  Allergic disorders — cardiac impairment

  (NSAIDs may impair renal function)

  - cerebrovascular disease
  
  - coagulation defects
  
  - connective-tissue disorders
  
  - Crohn’s disease (may be exacerbated)
  
  - elderly (risk of serious side-effects and fatalities)
  
  - heart failure
  
  - ischaemic heart disease
  
  - peripheral arterial disease
  
  - risk factors for cardiovascular events
  
  - ulcerative colitis (may be exacerbated)
  
  - uncontrolled hypertension

- **INTERACTIONS**

  → Appendix 1 (NSAIDs).

- **SIDE-EFFECTS**

  - Rare
    
    Alveolitis — aspetic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)

  - Frequency not known

    Angioedema

    - blood disorders

    - bronchospasm

    - colitis (induction of or exacerbation of)

    - Crohn’s disease (induction of or exacerbation of)

    - depression

    - diarrhoea

    - dizziness

    - drowsiness

    - fluid retention (rarely precipitating congestive heart failure)

    - gastro-intestinal bleeding

    - gastro-intestinal discomfort

    - gastro-intestinal disturbances

    - gastro-intestinal ulceration

    - haematuria

    - headache

    - hearing disturbances

    - hypersensitivity reactions

    - insomnia

    - nausea

    - nervousness

    - photosensitivity

    - raised blood pressure

    - rashes

    - renal failure (especially in patients with pre-existing renal impairment)

    - tinnitus

    - vertigo

- **SIDE-EFFECTS, FURTHER INFORMATION**

  Serious Side-effects

  - For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- **ALLERGY AND CROSS-SENSITIVITY**

  Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION**

  Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY**

  Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

- **BREAST FEEDING**

  Use with caution during breast-feeding. Present in milk—but risk to infant minimal.

- **HEPATIC IMPAIRMENT**

  Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT**

  Avoid if possible or use with caution. Reduce initial dose. The lowest effective dose should be used for the shortest possible duration. Avoid if eGFR less than 30 mL/minute/1.73 m². In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**

  **CAUTIONARY AND ADVISORY LABELS 21**

  - Seractil (Thornton & Ross Ltd)

    Dexibuprofen 300 mg

    Seractil 300 mg tablets | 60 tablet | £3.47 DT price + £9.47

    Dexibuprofen 400 mg

    Seractil 400 mg tablets | 60 tablet | £3.97 DT price + £9.97

Dexketoprofen

**INDICATIONS AND DOSE**

Short-term treatment of mild to moderate pain including dysmenorrhea

**BY MOUTH**

- Adult: 12.5 mg every 4–6 hours, alternatively 25 mg every 8 hours, initial maximum daily dose of 50 mg to be given in elderly; maximum 75 mg per day

- Elderly: 12.5 mg every 4–6 hours, alternatively 25 mg every 8 hours, initial max. 50 mg; maximum 75 mg daily

- **CONTRA-INDICATIONS**

  Active gastro-intestinal bleeding

  - active gastro-intestinal ulceration

  - history of gastro-intestinal bleeding related to previous NSAID therapy

  - history of gastro-intestinal perforation related to previous NSAID therapy

  - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)

  - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) — severe heart failure

- **CAUTIONS**

  Allergic disorders — cardiac impairment

  (NSAIDs may impair renal function)

  - cerebrovascular disease

  - coagulation defects

  - connective-tissue disorders

  - Crohn’s disease (may be exacerbated)

  - elderly (risk of serious side-effects and fatalities)

  - heart failure

  - ischaemic heart disease

  - peripheral arterial disease

  - risk factors for cardiovascular events

  - ulcerative colitis (may be exacerbated)

  - uncontrolled hypertension

- **INTERACTIONS**

  → Appendix 1 (NSAIDs).

- **SIDE-EFFECTS**

  - Rare

    Alveolitis — aspetic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)

    - hepatic damage

    - interstitial fibrosis associated with NSAIDs can lead to renal failure

    - pancreatitis

    - papillary necrosis

    - peripheral arterial disease

    - raised blood pressure

    - renal failure (especially in patients with pre-existing renal impairment)

    - tinnitus

    - vertigo

    - serious side-effects and fatalities

    - haemorrhage (two or more distinct episodes)

    - ischaemic heart disease

    - peripheral arterial disease

    - risk factors for cardiovascular events

    - ulcerative colitis (may be exacerbated)

    - uncontrolled hypertension

**BNF 70**
associated with NSAIDs can lead to renal failure • pulmonary eosinophilia • Stevens-Johnson syndrome • toxic epidermal necrolysis • visual disturbances

**Frequency not known** Angioedema • blood disorders • bronchospasm • colitis (induction of or exacerbation of) • Crohn’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness • drowsiness • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal disturbances • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hypersensitivity reactions • insomnia • nausea • nervousness • photosensitivity • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • tinnitus • vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRA-INDICATIONS**

**CAUTIONS**—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING** Use with caution during breast-feeding. Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Reduce initial dose to max. 50 mg daily in mild to moderate impairment. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT** Avoid if possible or use with caution. Avoid in moderate to severe impairment. Reduce initial dose to 50 mg daily. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**UNLICENSED USE** Voltarol® Rapid not licensed for use in children under 14 years or in fever.

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding • active gastro-intestinal ulceration • cerebrovascular disease • history of gastro-intestinal bleeding related to previous NSAID therapy • history of gastro-intestinal perforation related to previous NSAID therapy • history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) • history of recurrent gastro-intestinal ulceration (two or more distinct episodes) • ischaemic heart disease • mild to severe heart failure • peripheral arterial disease

**CAUTIONS**

**GENERAL CAUTIONS** Allergic disorders • cardiac impairment (NSAIDs may impair renal function) • coagulation defects • connective-tissue disorders • Crohn’s disease (may be exacerbated) • history of cardiac failure • hypertension • left ventricular dysfunction • oedema • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated)

**SPECIFIC CAUTIONS** Elderly (risk of serious side-effects and fatalities) (in adults)

**INTERACTIONS** → Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

**Rare** Alveolitis • aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • hepatic damage • interstitial fibrosis associated with NSAIDs can lead to renal failure • pancreatitis • papillary necrosis associated with NSAIDs can lead to renal failure • pulmonary eosinophilia • Stevens-Johnson syndrome • toxic epidermal necrolysis • visual disturbances

**Frequency not known** Angioedema • blood disorders • bronchospasm • colitis (induction of or exacerbation of) • Crohn’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness • drowsiness • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal disturbances • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hypersensitivity reactions • insomnia • nausea • nervousness • photosensitivity • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • tinnitus • vertigo

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

---

**Diclofenac potassium**

**INDICATIONS AND DOSE**

**Pain and inflammation in rheumatic disease and other musculoskeletal disorders**

**BY MOUTH**

- **Child 14-17 years:** 75–100 mg daily in 2–3 divided doses
- **Adult:** 75–150 mg daily in 2–3 divided doses

**Acute gout**

**BY MOUTH**

- **Adult:** 75–150 mg daily in 2–3 divided doses

---

**Postoperative pain**

**BY MOUTH**

- **Child 9–13 years (body-weight 35 kg and above):** Up to 2 mg/kg daily in 3 divided doses; maximum 100 mg per day
- **Child 14–17 years:** 75–100 mg daily in 2–3 divided doses
- **Adult:** 75–150 mg daily in 2–3 divided doses

**Migraine**

**BY MOUTH**

- **Adult:** 50 mg, to be given at onset of migraine, then 50 mg after 2 hours if required, then 50 mg after 4–6 hours; maximum 200 mg per day

**Fever in ear, nose, or throat infection**

**BY MOUTH**

- **Child 9–17 years (body-weight 35 kg and above):** Up to 2 mg/kg daily in 3 divided doses; maximum 100 mg per day
Diclofenac sodium

INDICATIONS AND DOSE

Pain and inflammation in musculoskeletal disorders | Acute gout

BY MOUTH

Adult: 75–150 mg daily in 2–3 divided doses

BY RECTUM

Adult: 75–150 mg daily in divided doses

Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis

BY MOUTH

Adult: 75–150 mg daily in 2–3 divided doses

BY RECTUM

Adult: 75–150 mg daily in divided doses

Postoperative pain

BY MOUTH

Adult: 75–150 mg daily in 2–3 divided doses

BY RECTUM

Adult: 75–150 mg daily in divided doses

VOLTAROL® RETARD

Pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders | Acute gout | Postoperative pain

BY MOUTH

Adult: 1 tablet once daily

VOLTAROL® 75MG SR TABLETS

Pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders | Acute gout | Postoperative pain

BY MOUTH

Adult: 1 tablet 1–2 times a day

DICLOMAX SR®

Pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders | Acute gout | Postoperative pain

BY MOUTH

Adult: 1 capsule 1–2 times a day, alternatively 2 capsules once daily

MOTIFENE®

Pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders | Acute gout | Postoperative pain

BY MOUTH

Adult: 1 capsule once daily

DYLOJECT®

Acute exacerbations of pain and postoperative pain

BY DEEP INTRAMUSCULAR INJECTION

Adult: 75 mg once daily for maximum 2 days, to be administered into the gluteal muscle

Acute exacerbations of pain and postoperative pain (severe cases)

BY DEEP INTRAMUSCULAR INJECTION

Adult: 75 mg twice daily for maximum 2 days, to be administered into the gluteal muscle

Ureteric colic

BY DEEP INTRAMUSCULAR INJECTION

Adult: 75 mg, then 75 mg after 30 minutes if required

Acute postoperative pain (in supervised settings)

BY INTRAVENOUS INJECTION

Adult: 75 mg every 4–6 hours if required for maximum 2 days; maximum 150 mg per day

Prevention of postoperative pain

BY INTRAVENOUS INJECTION

Adult: 25–50 mg, to be given after surgery; further doses given after 4–6 hours if necessary; maximum 150 mg in 24 hours for 2 days

VOLTAROL® SOLUTION FOR INJECTION

Postoperative pain

BY DEEP INTRAMUSCULAR INJECTION

Adult: 75 mg 1–2 times a day for maximum 2 days, twice daily administration in severe cases, to be injected into the gluteal muscle

Acute exacerbations of pain

BY DEEP INTRAMUSCULAR INJECTION

Adult: 75 mg 1–2 times a day for maximum 2 days, twice daily administration in severe cases, to be injected into the gluteal muscle

Ureteric colic

BY DEEP INTRAMUSCULAR INJECTION

Adult: 75 mg, then 75 mg after 30 minutes if required

Acute postoperative pain (in hospital setting)

BY INTRAVENOUS INFUSION

Adult: 75 mg, then 75 mg after 4–6 hours if required for maximum 2 days; maximum 150 mg per day
Prevention of postoperative pain (in hospital setting)
BY INTRAVENOUS INFUSION
- Adult: Initially 25–50 mg, to be given after surgery over 15–60 minutes, then 5 mg/hour for maximum 2 days; maximum 150 mg per day

VOLTAROL® EMULGEL
Relief of pain in musculoskeletal conditions | Adjunctive treatment in knee or hand osteoarthritis
TO THE SKIN
- Adult: Apply 3–4 times a day, therapy should be reviewed after 14 days (or after 28 days for osteoarthritis)

SOLARAZE®
Actinic keratosis
TO THE SKIN
- Adult: Apply twice daily for 60–90 days, to be applied thinly; maximum 8 g per day

VOLTAROL® GEL PATCH
Ankle sprain
TO THE SKIN
- Adult: Apply 1 patch daily for up to 3 days

Epicondylitis
TO THE SKIN
- Adult: Apply 1 patch twice daily for up to 14 days

CONTRA-INDICATIONS
- With systemic use Active gastro-intestinal bleeding, -active gastro-intestinal ulceration, -avoid suppositories in proctitis, -cerebrovascular disease, -history of gastro-intestinal bleeding related to previous NSAID therapy, -history of gastro-intestinal perforation related to previous NSAID therapy, -history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes), -history of recurrent gastro-intestinal ulceration (two or more distinct episodes), -ischaemic heart disease, -mild to severe heart failure, -peripheral arterial disease
- With intravenous use Dehydration, -history of asthma, -history of confirmed or suspected cerebrovascular bleeding, -history of haemorrhagic diathesis, -hypovolaemia, -operations with high risk of haemorrhage

CAUTIONS
- With systemic use Allergic disorders, -cardiac impairment (NSAIDs may impair renal function), -coagulation defects, -connective-tissue disorders, -Crohn’s disease (may be exacerbated), -elderly (risk of serious side-effects and fatalities), -history of cardiac failure, -hypertension, -left ventricular dysfunction, -oedema, -risk factors for cardiovascular events, -ulcerative colitis (may be exacerbated)
- With topical use Avoid contact with eyes, -avoid contact with inflamed or broken skin, -avoid contact with mucous membranes, -not for use with occlusive dressings, -topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

INTERACTIONS → Appendix 1 (NSAIDs).
- With intravenous use Contra-indicated in concomitant NSAID use. Contra-indicated in concomitant anticoagulant use (including low-dose heparins).
- With topical use Interactions do not generally apply to topical NSAIDs

SIDE-EFFECTS
- Rare
  - With systemic use Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), -hepatic damage, -interstitial fibrosis associated with NSAIDs can lead to renal failure, -pancreatitis, -papillary necrosis, -pulmonary eosinophilia, -Stevens-Johnson syndrome, -toxic epidermal necrolysis, -visual disturbances
  - Frequency not known
  - With systemic use Angioedema, -blood disorders, -bronchospasm, -collitis (induction of or exacerbation of), -Crohn’s disease (induction of or exacerbation of), -depression, -diarrhoea, -dizziness, -drowsiness, -fluid retention (rarely precipitating congestive heart failure), -gastro-intestinal bleeding, -gastro-intestinal discomfort, -gastro-intestinal disturbances, -gastro-intestinal ulceration, -haematuria, -headache, -hearing disturbances, -hypersensitivity reactions, -insomnia, -nausea, -nervousness, -photosensitivity, -raised blood pressure, -rashes, -renal failure (especially in patients with pre-existing renal impairment), -tinnitus, -vertigo
  - With parenteral use Injection site reactions
  - With rectal use Suppositories may cause rectal irritation
  - With topical use Paraeesthesia, -photosensitivity, -rash (discontinue use if develops)

SIDE-EFFECTS, FURTHER INFORMATION
- Serious side-effects: For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.
- With topical use Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

ALLERGY AND CROSS-SENSITIVITY
Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION
- With systemic use Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY
- With systemic use Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
- With topical use Patient packs for topical preparations carry a warning to avoid during pregnancy

BREAST FEEDING
- With systemic use Use with caution during breast-feeding. Amount in milk too small to be harmful.

HEPATIC IMPAIRMENT
- With systemic use Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT
- With systemic use Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.
- With intravenous use Avoid intravenous use if serum creatinine greater than 160 micromol/litre. Contra-indicated in moderate or severe renal impairment.

DIRECTIONS FOR ADMINISTRATION: For intravenous infusion (Voltarol®), give continuously or intermittently in Glucose 5% or Sodium chloride 0.9%. Dilute 75 mg with 100–500 mL infusion fluid (previously buffered with 0.5 mL sodium bicarbonate 8.4% solution or with 1 mL sodium bicarbonate 4.2% solution). For intermittent infusion give 25–50 mg over 15–60 minutes or 75 mg over 30–120 minutes. For continuous infusion give at a rate of
**Diclofenac sodium with misoprostol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, diclofenac sodium p. 921, misoprostol p. 709.

**INDICATIONS AND DOSE**

**MISOFEN® 50/200**

Prophylaxis against NSAID-induced gastrointestinal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis

**BY MOUTH**

- Adult: 1 tablet 2–3 times a day, take with food

**MISOFEN® 75/200**

Prophylaxis against NSAID-induced gastrointestinal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis

**BY MOUTH**

- Adult: 1 tablet twice daily, take with food

**ARTHROTEC® 50/200**

Prophylaxis against NSAID-induced gastrointestinal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis

- Adult: 1 tablet 2–3 times a day, take with food

**Diclofenac sodium with misoprostol**

5 mg/hour. For topical preparations, apply with a gentle massage only.

- **PRESCRIBING AND DISPENSING INFORMATION** Voltarol® dispersible tablets are more suitable for short-term use in acute conditions for which treatment required for no more than 3 months (no information on use beyond 3 months). Caution—topical preparations not generally suitable for children.

- **PATIENT AND CARER ADVICE**

  For topical preparations, patients and their carers should be advised to wash hands immediately after use. Photosensitivity: Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.

- **PROFESSION SPECIFIC INFORMATION**

  Dental practitioners’ formulary Diclofenac Sodium Tablets may be prescribed.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  Scottish Medicines Consortium (SMC) Decisions

  The Scottish Medicines Consortium has advised (February 2008) that Dylotech® is accepted for restricted use within NHS Scotland for the treatment or prevention of postoperative pain by intravenous injection in supervised healthcare settings.

- **EXCEPTIONS TO LEGAL CATEGORY**

  Various pack sizes of gel preparations may be available on sale to the public.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: dispersible tablet, oral suspension, oral solution.

  **Dispersible tablet**

  CAUTIONARY AND ADVISORY LABELS 13, 21

  Diclofenac sodium 50 mg Voltarol 50mg dispersible tablets (sugar-free) | 21 tablet (PSt) £6.19 DT price = £6.19

  **Modified-release tablet**

  CAUTIONARY AND ADVISORY LABELS 21, 25

  Diclofenac sodium 75 mg Diclofenac sodium 75mg modified-release tablets | 28 tablet (PSt) £6.46 | 56 tablet (PSt) no price available DT price = £12.92

  Diclofenac sodium 100 mg Diclofenac sodium 100mg modified-release tablets | 28 tablet (PSt) £9.47 DT price = £9.47

  Diclofenac sodium 100 mg Voltarol 100mg tablets | 28 tablet (PSt) £9.47 DT price = £9.47

  Diclofenac sodium 100 mg Voltarol Retard 100mg tablets | 28 tablet (PSt) £9.47 DT price = £9.47

  Diclofenac sodium 75 mg Voltarol 75mg SR tablets | 28 tablet (PSt) £6.46 | 56 tablet (PSt) £12.92 DT price = £12.92

  - Brands may include Dicloflex Retard; Dicloflex SR; Econac SR; Econac XL; Enstarel XL; Fenactol Retard; Fenactol SR; Flamraser SR; Volsaid Retard

  **Gastro-resistant tablet**

  CAUTIONARY AND ADVISORY LABELS 5, 25

  Diclofenac sodium 25 mg Diclofenac sodium 25mg gastro-resistant tablets | 28 tablet (PSt) £1.78 DT price = £1.93 | 84 tablet (PSt) £2.93

  Diclofenac sodium 50 mg Diclofenac sodium 50mg gastro-resistant tablets | 28 tablet (PSt) £1.52 DT price = £1.63 | 84 tablet (PSt) £2.99 | 100 tablet (PSt) £3.15

  Diclofenac sodium 75 mg Voltarol 25mg gastro-resistant tablets | 84 tablet (PSt) £2.94

  - Brands may include Dicloflex; Fenactol

  **Modified-release capsule**

  CAUTIONARY AND ADVISORY LABELS 21, 25

  Diclofenac sodium 75 mg Diclofenac sodium 75mg modified-release capsules | 56 capsule (PSt) £3.69 DT price = £3.69

  Diclofenac sodium 100 mg Diclofenac sodium 100mg modified-release capsules | 28 capsule (PSt) no price available DT price = £6.97

  - Brands may include Dicloxam Retard; Dicloxam SR; Motifene; Rhumalgan XL

  **Solution for injection**

  EXCIPENTS: May contain Benzyl alcohol, propylene glycol

  Diclofenac sodium 37.5 mg per 1 ml Diclofenac sodium 37.5mg/ml solution for injection vials | 10 vial (PSt) £0.58 DT price = £0.58

  Diclofenac sodium 25 mg per 1 ml Voltarol 75mg/ml solution for injection ampoules | 10 ampoule (PSt) £0.26 DT price = £0.26

  **Suppository**

  Diclofenac sodium 100 mg Diclofenac sodium 100 suppositories | 10 suppository (PSt) £7.75 DT price = £3.03

  Diclofenac sodium 12.5 mg Voltarol 12.5mg suppositories | 10 suppository (PSt) £0.58 DT price = £0.58

  Diclofenac sodium 25 mg Voltarol 25mg suppositories | 10 suppository (PSt) £1.03 DT price = £1.03

  Diclofenac sodium 50 mg Voltarol 50mg suppositories | 10 suppository (PSt) £1.70 DT price = £1.70

  Diclofenac sodium 100 mg Voltarol 100mg suppositories | 10 suppository (PSt) £3.03 DT price = £3.03

  - Brands may include Econac Gel

  EXCIPENTS: May contain benzyl alcohol, fragrances, propylene glycol

  VOLTAROL 1.16% EMULGEL (Novartis Consumer Health UK Ltd) Diclofenac diethylammonium 11.6 mg per 1 gram | 100 gram (PSt) - NHS indicative price = £5.63 DT price = £5.63

  VOLTAROL 12 HOUR EMULGEL P 3.2% GEL (Novartis Consumer Health UK Ltd) Diclofenac diethylammonium 23.2 mg per 1 gram | 30 gram (PSt) - NHS indicative price = £4.19 | 50 gram (PSt) - NHS indicative price = £5.99 | 100 gram (PSt) - NHS indicative price = £10.79

  SOLARAZE 3%GEL (Almirall Ltd) Diclofenac sodium 30 mg per 1 gram | 50 gram (PSt) - NHS indicative price = £38.30 DT price = £38.30 | 100 gram (PSt) - NHS indicative price = £76.60

**Diclofenac sodium and indomethacin**

For the properties of the component please consider, diclofenac sodium p. 921, indomethacin p. 709.
924 Pain and inflammation in musculoskeletal disorders

Musculoskeletal system

**ARHTROTEC® 75/200**
Prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis

**CAUTIONS**
- Adult: 1 tablet twice daily, take with food

- **UNLICENSED USE** The BNF recommends a higher starting dose of misoprostol for prophylaxis against NSAID-induced gastroduodenal ulceration than that provided by the combination preparations of diclofenac and misoprostol.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant tablet**

**DICLOFENAC SODIUM WITH MISOPROSTOL (Non-proprietary)**
- Diclofenac sodium 50 mg, Misoprostol 200 microgram
  - Diclofenac sodium 50mg gastro-resistant / Misoprostol 200microgram tablets | 60 tablet (PTD) £11.14 DT price = £11.98
  - Diclofenac sodium 75 mg, Misoprostol 200 microgram
    - Diclofenac sodium 75mg gastro-resistant / Misoprostol 200microgram tablets | 60 tablet (PTD) £15.83 DT price = £15.83
  - Arthrotec (Pfizer Ltd)
  - Diclofenac sodium 50 mg, Misoprostol 200 microgram
    - Arthrotec 50 gastro-resistant tablets | 60 tablet (PTD) £11.98 DT price = £11.98
  - Diclofenac sodium 75 mg, Misoprostol 200 microgram
    - Arthrotec 75 gastro-resistant tablets | 60 tablet (PTD) £15.83 DT price = £15.83
  - Misofen (Morningside Healthcare Ltd)
  - Diclofenac sodium 50 mg, Misoprostol 200 microgram
    - Misofen 50mg/200microgram gastro-resistant tablets | 60 tablet (PTD) £11.98 DT price = £11.98
  - Diclofenac sodium 75 mg, Misoprostol 200 microgram
    - Misofen 75mg/200microgram gastro-resistant tablets | 60 tablet (PTD) £15.83 DT price = £15.83
  - Brands may include Masidemen

---

**Etodolac**

**INDICATIONS AND DOSE**

Pain and inflammation in rheumatoid arthritis and osteoarthritis

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: 300–600 mg daily in 1–2 divided doses

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- Adult: 600 mg daily

- **CONTRA-INDICATIONS**
  - Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

- **CAUTIONS**
  - Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

- **INTERACTIONS**
  - Appendix 1 (NSAIDs).

- **SIDE-EFFECTS**
  - Rare Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

  - **Frequency not known**

---

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects**

For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION**
  - Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY**
  - Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

- **BREAST FEEDING**
  - Use with caution during breast-feeding. Manufacturer advises avoid.

- **HEPATIC IMPAIRMENT**
  - Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT**
  - The lowest effective dose should be used for the shortest possible duration. Avoid if possible or use with caution. Avoid in severe impairment. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS**

**ETODOLAC (Non-proprietary)**
- Etodolac 600 mg
  - Etodolac 600mg modified-release tablets | 30 tablet (PTD) £15.50 DT price = £15.50
  - Etofpan XL (Taro Pharmaceuticals (UK) Ltd)
  - Etodolac 600 mg
    - Etofpan XL 600mg tablets | 30 tablet (PTD) £14.60 DT price = £15.50
  - Lodine SR (Almirall Ltd)
  - Etodolac 600 mg
    - Lodine SR 600mg tablets | 30 tablet (PTD) £15.50 DT price = £15.50

**Capsule**
- Eccoxolac (Meda Pharmaceuticals Ltd)
  - Eccoxolac 300 mg
    - Eccoxolac 300mg capsules | 60 capsule (PTD) £8.14 DT price = £8.14
Etoricoxib

**INDICATIONS AND DOSE**

**Pain and inflammation in osteoarthritis**

*BY MOUTH*
- **Child 16–17 years**: 30 mg once daily, then increased if necessary to 60 mg once daily
- **Adult**: 30 mg once daily, then increased if necessary to 60 mg once daily

**Pain and inflammation in rheumatoid arthritis | Ankylosing spondylitis**

*BY MOUTH*
- **Child 16–17 years**: 90 mg once daily
- **Adult**: 90 mg once daily

**Acute gout**

*BY MOUTH*
- **Child 16–17 years**: 120 mg once daily for maximum 8 days
- **Adult**: 120 mg once daily for maximum 8 days

**SIDE-EFFECTS**

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding - active gastro-intestinal ulceration - cerebrovascular disease - inflammatory bowel disease - ischaemic heart disease - mild to severe heart failure - peripheral arterial disease - uncontrolled hypertension (persistently above 140/90 mmHg)

**CAUTIONS**

**GENERAL CAUTIONS** Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - dehydration - history of cardiac failure - hypertension - left ventricular dysfunction - oedema - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated)

**SPECIFIC CAUTIONS** Elderly (risk of serious side-effects and fatalities)

**INTERACTIONS** → Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- **Common or very common** Ecchymosis - fatigue - influenza-like symptoms - palpitation
- **Uncommon** Anxiety - appetite change - arthralgia - atrial fibrillation - chest pain - cough - dry mouth - dyspnoea - electrolyte disturbance - epistaxis - flushing - mental acuity impaired - mouth ulcer - myalgia - paraesthesia - taste disturbance - transient ischaemic attack - weight change
- **Rare** Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances
- **Very rare** Confusion - hallucinations
- **Frequency not known** Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rash - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY** Manufacturer advises avoid (teratogenic in animal studies). Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING** Use with caution during breast-feeding. Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Max. 60 mg daily in mild impairment. Max. 60 mg on alternate days or 30 mg once daily in moderate impairment. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT** Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- With systemic use in adults Avoid if eGFR less than 30 mL/minute/1.73 m².
- With systemic use in children Avoid if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor blood pressure before treatment, 2 weeks after initiation and periodically during treatment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Arcoxia** (Grunenthal Ltd)
  - Etoricoxib 30 mg Arcoxia 30mg tablets | 28 tablet DT price = £13.99 DT price = £13.99
  - Etoricoxib 60 mg Arcoxia 60mg tablets | 28 tablet DT price = £20.11 DT price = £20.11
  - Etoricoxib 90 mg Arcoxia 90mg tablets | 5 tablet | £4.10 | 28 tablet DT price = £22.96 DT price = £22.96
  - Etoricoxib 120 mg Arcoxia 120mg tablets | 7 tablet | £6.03 | 28 tablet DT price = £24.11 DT price = £24.11

Felbinac

**DRUG ACTION** Felbinac is an active metabolite of the NSAID fenbufen.

**INDICATIONS AND DOSE**

**Relief of pain in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

**TO THE SKIN**

- **Adult**: Apply 2–4 times a day, therapy should be reviewed after 14 days; maximum 25 g per day

**CAUTIONS** Avoid contact with eyes - avoid contact with inflamed or broken skin - avoid contact with mucous membranes - not for use with occlusive dressings - topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)
Men in white coats, 10 o'clock. Share the latest evidence, discuss the most pressing issues. Engage with experts from the field in an interactive and dynamic environment. Join us at our upcoming conference on the state of the art in pain management.

**Pain and inflammation in musculoskeletal disorders**

---

**INTERACTIONS** → Appendix 1 (NSAIDs). Interactions do not generally apply to topical NSAIDs.

**SIDE-EFFECTS** Rash (discontinue use if develops)

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects.** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**PREGNANCY** Patient packs for topical preparations carry a warning to avoid during pregnancy.

**BREAST FEEDING** Patient packs for topical preparations carry a warning to avoid during breast-feeding.

**RENAI IMPAIRMENT** Deterioration in renal function has also been reported after topical use.

**DIRECTIONS FOR ADMINISTRATION** For topical preparations, apply with gentle massage only.

**PRESCRIBING AND DISPENSING INFORMATION** Caution—topical preparations not generally suitable for children.

**PATIENT AND CARER ADVICE** For topical preparations patients and carers should be advised to wash hands immediately after use. Photosensitivity Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Foam**

CAUTIONARY AND ADVISORY LABELS 15

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

**Fenoprofen**

- Traxam (AMCo) Felbinac 31.7 mg per 1 gram Traxam 3.17% foam | 100 gram £8.41 DT price = £8.41

**Gel**

- Traxam (AMCo) Felbinac 30 mg per 1 gram Traxam 3% gel | 100 gram £8.03 DT price = £8.03

**Fenoprofen**

**INDICATIONS AND DOSE**

- Pain and inflammation in rheumatic disease and other musculoskeletal disease | Mild to moderate pain
- BY MOUTH
  - Adult: 300–600 mg 3–4 times a day; maximum 3 g per day

**CONTRA-INDICATIONS**

Active gastro-intestinal bleeding • active gastro-intestinal ulceration • history of gastro-intestinal bleeding related to previous NSAID therapy • history of gastro-intestinal perforation related to previous NSAID therapy • history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) • history of recurrent gastro-intestinal ulceration (two or more distinct episodes) • severe heart failure

**CAUTIONS**

Allergic disorders • cardiac impairment (NSAIDs may impair renal function) • cerebrovascular disease • coagulation defects • connective-tissue disorders • Crohn’s disease (may be exacerbated) • elderly (risk of serious side-effects and fatalities) • heart failure • ischaemic heart disease • peripheral arterial disease • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated) • uncontrolled hypertension

**INTERACTIONS** → Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- Rare Alveolitis • aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • hepatic damage • interstitial fibrosis associated with NSAIDs can lead to renal failure • pancreatitis • papillary necrosis associated with NSAIDs can lead to renal failure • pulmonary eosinophilia • Stevens-Johnson syndrome • toxic epidermal necrolysis • visual disturbances

- Frequency not known Angioedema • blood disorders • bronchoospasm • colitis (induction of or exacerbation of) • Crohn’s disease (induction of or exacerbation of) • cystitis • depression • diarrhoea • dizziness • drowsiness • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal disturbances • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hypersensitivity reactions • insomnia • nasopharyngitis • nausea • nervousness • photosensitivity • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • tinnitus • upper respiratory-tract infection • vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION**

Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY**

Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING**

Use with caution during breast-feeding. Amount too small to be harmful.

**HEPATIC IMPAIRMENT**

Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAI IMPAIRMENT**

Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

Fenoprofen (Tyrpharm Ltd)

Fenoprofen (as Fenoprofen calcium) 300 mg Fenoprofen 300 tablets | 100 tablet £3.45
Flurbiprofen

**INDICATIONS AND DOSE**

Pain and inflammation in rheumatic disease and other musculoskeletal disorders | Migraine | Postoperative analgesia | Mild to moderate pain

**BY MOUTH**
- Child 12-17 years: 150–200 mg daily in 2–4 divided doses, then increased to 300 mg daily, dose to be increased only in acute conditions
- Adult: 150–200 mg daily in 2–4 divided doses, then increased to 300 mg daily, dose to be increased only in acute conditions

**SIDE-EFFECTS**

- **Dysmenorrhoea**
  - **BY MOUTH**
    - Child 12-17 years: Initially 100 mg, then 50–100 mg every 4–6 hours; maximum 300 mg per day
    - Adult: Initially 100 mg, then 50–100 mg every 4–6 hours; maximum 300 mg per day

**CONTRA-INDICATIONS**

Active gastro-intestinal bleeding | active gastro-intestinal ulceration | history of gastro-intestinal bleeding related to previous NSAID therapy | history of gastro-intestinal perforation related to previous NSAID therapy | history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) | history of recurrent gastro-intestinal ulceration (two or more distinct episodes) | severe heart failure

**CAUTIONS**

Allergic disorders | cardiac impairment (NSAIDs may impair renal function) | cerebrovascular disease | coagulation defects | connective-tissue disorders | Crohn’s disease (may be exacerbated) | elderly (risk of serious side-effects and fatalities) (in adults) | heart failure | ischaemic heart disease | peripheral arterial disease | risk factors for cardiovascular events | ulcerative colitis (may be exacerbated) | uncontrolled hypertension

**INTERACTIONS**

→ Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- **Common or very common**
  - Stomatitis
- **Uncommon**
  - Confusion | fatigue | hallucinations | paraesthesia
- **Rare**
  - Alveolitis | aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) | hepatic damage | interstitial fibrosis associated with NSAIDs can lead to renal failure | pancreatitis | papillary necrosis associated with NSAIDs can lead to renal failure | pulmonary eosinophilia | Stevens-Johnson syndrome | toxic epidermal necrolysis | visual disturbances
- **Frequency not known**
  - Angioedema | blood disorders | bronchospasm | colitis (induction of or exacerbation of) | Crohn’s disease (induction of or exacerbation of) | depression | diarrhoea | dizziness | drowsiness | fluid retention (rarely precipitating congestive heart failure) | gastro-intestinal bleeding | gastro-intestinal discomfort | gastro-intestinal disturbances | haematuria | headache | hearing disturbances | hypersensitivity reactions | insomnia | nausea | nervousness | photosensitivity | raised blood pressure | rashes | renal failure (especially in patients with pre-existing renal impairment) | tinnitus | vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects**

For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY**

Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

---

Ibuprofen

**INDICATIONS AND DOSE**

Pain and inflammation in rheumatic disease and other musculoskeletal disorders | Mild to moderate pain

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Child 10: 3 mg times a day; maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day
- Child 12: 5 mg times a day; maximum daily dose to be given in 3–4 divided doses; maximum 40 mg/kg per day
- Child 15: 10 mg times a day; maximum daily dose to be given in 3–4 divided doses; maximum 80 mg/kg per day
- Child 17: 15 mg times a day; maximum daily dose to be given in 3–4 divided doses; maximum 120 mg/kg per day

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- Child 7–9: 10 mg times a day; maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day
- Child 10: 15 mg times a day; maximum daily dose to be given in 3–4 divided doses; maximum 40 mg/kg per day
- Child 12: 20 mg times a day; maximum daily dose to be given in 3–4 divided doses; maximum 50 mg/kg per day

---

**CONCEPTION AND CONTRACEPTION**

Caution—Long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY**

Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING**

Use with caution during breast-feeding. Small amount present in milk—manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT**

Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. Avoid in severe impairment. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

- FLURBIPROFEN (Non-proprietary)
- Flurbiprofen 50 mg Flurbiprofen 50mg tablets 100 tablet £21.30 0T price = £21.30
- Flurbiprofen 100 mg Flurbiprofen 100mg tablets 100 tablet £38.10 0T price = £38.10

---

**Flurbiprofen 50 mg**

| Flurbiprofen 50 mg tablets 100 tablet | £21.30 0T price | £21.30 |
| Flurbiprofen 100 mg Flurbiprofen 100mg tablets 100 tablet | £38.10 0T price | £38.10 |
▶ Child 12–17 years: Initially 300–400 mg 3–4 times a day; (by mouth) increased if necessary up to 600 mg 4 times a day; (by mouth) maintenance 200–400 mg 3 times a day, may be adequate

**Pain and inflammation**

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**

- Child 12–17 years: 1.6 g once daily, dose preferably taken in the early evening, increased to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases

**Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis**

**BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- Child 3–17 months: Maximum 0.2 g/kg daily in 3–4 divided doses; maximum 2.4 g per day

**Post-immunisation pyrexia in infants (on doctor’s advice only)**

**Pain relief in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

TO THE SKIN

- Adult: Apply up to 3 times a day, ibuprofen gel 5% gel to be administered

**IBUGE® FORTE**

**Pain relief in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

TO THE SKIN

- Adult: Apply up to 3 times a day

**FENBIO® FORTE**

**Pain relief in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

TO THE SKIN

- Adult: Apply up to 4 times a day, therapy should be reviewed after 14 days

**UNLICENSED USE** Not licensed for use in children under 3 months or body weight under 5 kg. Maximum dose for systemic juvenile idiopathic arthritis is unlicensed.

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

**CAUTIONS**

- With oral use Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

- With topical use Avoid contact with eyes - avoid contact with inflamed or broken skin - avoid contact with mucous membranes - not for use with occlusive dressings - topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

**INTERACTIONS** Appendix 1 (NSAIDs). Interactions do not generally apply to topical NSAIDs.

**SIDE-EFFECTS**

- Rare

- **With oral use** Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

- **Frequency not known**

- **With oral use** Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn’s disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

- **With topical use** Photosensitivity - rash (discontinue use if develops)

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- With topical use in adults Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

- **Overdose** Overdosage with ibuprofen may cause nausea, vomiting, epigastric pain, and tinnitus, but more serious toxicity is very uncommon. Charcoal, activated p. 1130 followed by symptomatic measures are indicated if more than 100 mg/kg has been ingested within the preceding hour. For details on the management of poisoning, see Emergency treatment of poisoning p. 1123.

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY**

- With oral use Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

- With topical use Patient packs for topical preparations carry a warning to avoid during pregnancy.

**BREAST FEEDING**

- With oral use Use with caution during breast-feeding. Amount too small to be harmful but some manufacturers advise avoid.

- With topical use Patient packs for topical preparations carry a warning to avoid during breast-feeding.

**HEPATIC IMPAIRMENT**

- With oral use Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT**

- With oral use Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for
the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- With topical use Deterioration in renal function has also been reported after topical use.

DIRECTIONS FOR ADMINISTRATION For topical preparations, apply with gentle massage only.

PRESCRIBING AND DISPENSING INFORMATION Flavours of syrup may include orange. Caution—topical preparations not generally suitable for children.

PATIENT AND CARER ADVICE Medicines for Children leaflet: Ibuprofen for pain and inflammation www.medicinesforchildren.org.uk/ibuprofen-for-pain-and-inflammation

For topical preparations, patients and their carers should be advised to wash hands immediately after use. Photosensitivity For topical preparations, patients or their carers should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.

PROFESSION SPECIFIC INFORMATION Dental practitioners’ formulary Ibuprofen Oral Suspension Sugar-free may be prescribed. Ibuprofen Tablets may be prescribed.

EXCEPTIONS TO LEGAL CATEGORY Smaller pack sizes of gel preparations may be available on sale to the public. Oral preparations can be sold to the public in certain circumstances.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

<table>
<thead>
<tr>
<th>Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTIONARY AND ADVISORY LABELS 21</td>
</tr>
</tbody>
</table>

IBUPROFEN (Non-proprietary)

- Ibuprofen 200 mg Ibuprofen 200mg tablets 16 tablet (P) £0.14–£0.20 24 tablet (P) £0.11 DT price = £0.02 48 tablet (P) £0.04 84 tablet (P) £0.37 DT price = £0.02 96 tablet (P) £0.69 Ibuprofen 200mg tablets sugar coated 84 tablet (P) £0.92 DT price = £0.07 Ibuprofen 200mg tablets film coated 24 tablet (P) £0.02 96 tablet (P) £0.38 DT price = £0.03 Ibuprofen 200mg caplets 16 tablet (P) £0.20 24 tablet (P) no price available DT price = £0.02 48 tablet (P) no price available 96 tablet (P) no price available 100 tablet (P) no price available

- Ibuprofen 400 mg Ibuprofen 400mg tablets film coated 24 tablet (P) £0.03 DT price = £0.03 84 tablet (P) £0.61 DT price = £0.08 Ibuprofen 400mg tablets film coated 24 tablet (P) £0.07 DT price = £0.03 96 tablet (P) £0.93 Ibuprofen 400mg caplets 250 tablet (P) £0.74

- Ibuprofen 600 mg Ibuprofen 600mg tablets 84 tablet (P) £0.09 600mg tablets film coated 84 tablet (P) £0.09 DT price = £0.09

- Brufen (BGP Products Ltd)

- Ibuprofen 400 mg Brufen 400mg tablets 60 tablet (P) £4.90 600 mg Brufen 600mg tablets 60 tablet (P) £7.34

- Brands may include Cuprofen; Feminax Express; Ibucalm; Nurofen; Nurofen Express; Nurofen Migraine Pain; Nurofen Tension Headache

Grodispersible tablet

Nurofen Meltlets (Reckitt Benckiser Healthcare (UK) Ltd)

- Ibuprofen 200 mg Nurofen Meltlets 200mg tablets (sugar-free) 12 tablet (P) £1.83

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25, 27

- Brufen Retard (BGP Products Ltd)

- Ibuprofen 800 mg Brufen Retard 800mg tablets 56 tablet (P) £7.74 DT price = £7.74

- Capsule

IBUPROFEN (Non-proprietary)

- Ibuprofen 200 mg Ibuprofen 200mg capsules 24 capsule (P) £0.05 30 capsule (P) no price available 32 capsule (P) £0.79

- Ibuprofen 400 mg Ibuprofen 400mg capsules 20 capsule (P) no price available

- Brands may include Nurofen Express

- Modified-release capsule

IBUPROFEN (Non-proprietary)

- Ibuprofen 200 mg LloydsPharmacy Ibuprofen Long Lasting 200mg capsules 16 capsule (P) no price available

- Brands may include Nurofen Back Pain SR

Effervescent granules

CAUTIONARY AND ADVISORY LABELS 13, 21

- ELECTROLYTES: May contain Sodium

- Brufen (BGP Products Ltd)

- Ibuprofen 600 mg Brufen 600mg effervescent granules sachets 20 sachet (P) £6.80 DT price = £6.80

Oral suspension

CAUTIONARY AND ADVISORY LABELS 21

- IBUPROFEN (Non-proprietary)

- Ibuprofen 20 mg per 1 ml Junior Ibuprofen 100mg/5ml oral suspension (sugar-free) 100 ml (P) £0.86 DT price = £1.47 Ibuprofen for Children 100mg/5ml oral suspension (sugar-free) 100 ml (P) no price available DT price = £1.47 Ibuprofen 100mg/5ml oral suspension sugar free (sugar-free)

- Brufen (BGP Products Ltd)

- Ibuprofen 20 mg per 1 ml Brufen 100mg/5ml syrup 500 ml (P) £8.88 DT price = £8.88

- Brands may include Calprofen; Mandafen; Nurofen; Orifene

Solution for infusion

- Pedea (Orphan Europe (UK) Ltd)

- Ibuprofen 5 mg per 1 ml Pedea 10mg/2ml solution for infusion ampoules 4 ampoule (P) £288.00 (Hospital only)

- Foam

- Ibumousse (Dermal Laboratories Ltd)

- Ibuprofen 50 mg per 1 gram Ibumousse 5% 125 gram (P) £5.85

- Gel

- EXCIPIENTS: May contain Benzyl alcohol

- IBUPROFEN (Non-proprietary)

- Ibuprofen 50 mg per 1 gram Mentholatum Ibuprofen 5% gel 100 gram (P) £5.01 DT price = £4.57 Ibuprofen 5% gel 30 gram (P) £1.36 50 gram (P) £2.77 DT price = £2.29 100 gram (P) £5.33 DT price = £4.57

- Ibuprofen 100 mg per 1 gram Ibuprofen 10% gel 30 gram (P) £1.74 50 gram (P) £3.32 100 gram (P) £5.79 DT price = £4.92 Ibuprofen Pain Relief Maximum Strength 10% gel 50 gram (P) £2.08 LloydsPharmacy Maximum Strength Ibuprofen 10% gel 30 gram (P) no price available

- Brands may include Fenbid; Ibugel; Ibuleve; Phorpain

Spray

- IBUPROFEN (Non-proprietary)

- Ibuprofen 50 mg per 1 ml Ibuprofen 5% spray 100 ml (P) no price available

- Brands may include Ibupspray

Powder

- Nurofen Express (Reckitt Benckiser Healthcare (UK) Ltd)

- Ibuprofen (as ibuprofen lysine) 400 mg Nurofen Express Soluble 400mg oral powder sachets 10 sachet (P) £3.23

Indometacin

(Indomethacin)

INDICATIONS AND DOSE

Pain and moderate to severe inflammation in rheumatic disease and other musculoskeletal disorders

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: 50–200 mg daily in divided doses

BY RECTUM

- Adult: 100 mg twice daily if required, dose to be administered at night and in the morning, combined oral and rectal treatment, maximum total daily dose 150–200 mg

BY MOUTH USING MODIFIED-RELEASE MEDICINES

- Adult: 75 mg 1–2 times a day

Acute gout

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- Adult: 150–200 mg daily in divided doses continued
930 Pain and inflammation in musculoskeletal disorders

**BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- **Adult:** 75 mg 1–2 times a day

*Indometacin*

**CONTRA-INDICATIONS**
- Activity of gastrointestinal bleeding, active gastrointestinal ulceration, history of gastrointestinal ulceration related to previous NSAID therapy, history of recurrent gastrointestinal haemorrhage (two or more distinct episodes), history of recurrent gastrointestinal ulceration (two or more distinct episodes), severe heart failure

**SIDE-EFFECTS**
- **RARE**
  - Headache
  - Dizziness
  - Nausea
  - Vomiting
  - Diarrhoea
  - Rash
  - Fever
  - Urticaria
  - Anaphylaxis
  - Photosensitivity
  - Raised blood pressure
  - Fluid retention
  - Hyperkalaemia
  - Hypersensitivity reactions
  - Insomnia
  - Nervousness
  - Photosensitivity
  - Raised blood pressure
  - Rashes
  - Renal failure
  - Especially in patients with pre-existing renal impairment
  - Tinnitus
  - Vertigo

**SPECIFIC SIDE-EFFECTS**
- **Pre-existing conditions**
  - Active gastro-intestinal ulceration, history of previous gastro-intestinal ulceration related to previous NSAID therapy. In such cases, the use of indometacin is contraindicated.
  - A history of any other NSAID is associated with reduced female fertility. This effect is reversible on stopping treatment.

**MONITORING REQUIREMENTS**
- During prolonged therapy ophthalmic and blood examinations particularly advisable.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include:
  - Oral suspension, oral solution
  - Capsule
    - Indometacin 25 mg
    - Indometacin 50 mg
    - Indometacin 100 mg
  - Modified-release capsule
    - Indometacin 25 mg
    - Indometacin 50 mg
    - Indometacin 100 mg
  - Suppository
    - Indometacin 25 mg
    - Indometacin 50 mg
    - Indometacin 100 mg
  - Ketoprofen
    - Capsule
      - Ketoprofen 25 mg
      - Ketoprofen 50 mg
      - Ketoprofen 100 mg
    - Modified-release capsule
      - Ketoprofen 25 mg
      - Ketoprofen 50 mg
      - Ketoprofen 100 mg
    - Suppository
      - Ketoprofen 25 mg
      - Ketoprofen 50 mg
      - Ketoprofen 100 mg

**INDICATIONS AND DOSE**
- **Pain and mild inflammation in rheumatic disease**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
    - **Adult:** 100–200 mg daily in 2–4 divided doses
  - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
    - **Adult:** 100–200 mg once daily, to be taken with food
  - **BY RECTUM**
    - **Adult:** 100 mg once daily, to be administered at bedtime, combined oral and rectal treatment, maximum total daily dose 200 mg
  - **Pain in musculoskeletal disorders**
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - **Adult:** 50 mg up to 3 times a day
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
      - **Adult:** 100–200 mg once daily, to be taken with food
Pain and inflammation in musculoskeletal disorders 931

Relief of pain in musculoskeletal disorders | Treatment in knee or hand osteoarthritis (adjunct)

**TO THE SKIN**
- Adult: Apply 2–4 times a day for up to 7 days, ketoprofen 2.5% gel to be administered; maximum 15 g per day

**POWERGEL**
Relief of pain in musculoskeletal conditions | Adjunctive treatment in knee or hand osteoarthritis

**TO THE SKIN**
- Adult: Apply 2–3 times a day for up to max. 10 days

- **CONTRA-INDICATIONS**
  - With systemic use Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding - history of gastro-intestinal perforation - history of gastro-intestinal ulceration - severe heart failure
  - With topical use Avoid contact with mucous membranes - not for use with occlusive dressings - topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

- **INTERACTIONS**
  - ▶ Appendix 1 (NSAIDs). Interactions do not generally apply to topical NSAIDs.

- **SIDE-EFFECTS**
  - General side-effects Photosensitivity
  - Specific side-effects
    - Rare
      - With systemic use Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances
  - Frequency not known
  - With rectal use Suppositories may cause rectal irritation
  - With systemic use Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn’s disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo
  - With topical use Rash (discontinue use if develops)

**SIDE-EFFECTS, FURTHER INFORMATION**

- Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915. Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

- **ALLERGY AND CROSS-SENSITIVITY**
  - Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION**
  - ▶ With systemic use Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY**
  - ▶ With systemic use Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
  - ▶ With topical use Patient packs for topical preparations carry a warning to avoid during pregnancy.

- **BREAST FEEDING**
  - ▶ With systemic use Use with caution during breast-feeding. Amount probably too small to be harmful but manufacturers advise avoid.
  - ▶ With topical use Patient packs for topical preparations carry a warning to avoid during breast-feeding.

- **HEPATIC IMPAIRMENT**
  - ▶ With systemic use Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Should be avoided in severe liver disease.

- **RENAL IMPAIRMENT**
  - ▶ With systemic use Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.
  - ▶ With topical use Deterioration in renal function has also been reported after topical use.

- **DIRECTIONS FOR ADMINISTRATION**
  - For topical preparations apply with gentle massage only.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Caution—topical preparations not generally suitable for children. Flavours of oral liquid formulations may include strawberry.

- **PATIENT AND CARER ADVICE**
  - For topical preparations, patients and their carers should be advised to wash hands immediately after use.
  - ▶ With topical use Photosensitivity Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity. Patients should be advised not to expose area treated to sunbeds or sunlight (even on a bright but cloudy day) during, and for two weeks after stopping treatment; treated areas should be protected with clothing.

- **EXCEPTIONS TO LEGAL CATEGORY**
  - Smaller pack sizes of gel preparations may be available on sale to the public.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Capsule**
- **CAUTIONARY AND ADVISORY LABELS 21**
  - ▶ Tiloket (Tillomed Laboratories Ltd)
    - Ketoprofen 50 mg | Tiloket 50mg capsules | 28 capsule £3.99 | 112 capsule £17.20 DT price = £15.14

**Modified-release capsule**
- **CAUTIONARY AND ADVISORY LABELS 21, 25**
  - ▶ KETOPROFEN (Non-proprietary)
    - Ketoprofen 200 mg | Tiloket CR 200mg capsules | 28 capsule £10.70 DT price = £23.85
    - Ketoprofen 200mg modified-release capsules | 28 capsule £23.85
Mefenamic acid

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - inflammatory bowel disease - severe heart failure

**CAUTIONS** Acute porphyrias p. 864 - allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - epilepsy - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

**INTERACTIONS** → Appendix 1 (NSAIDs).

**SIDE-EFFECTS**
- **Common or very common** Diarrhoea (withdraw treatment) - rashes (withdraw treatment) - stomatitis
- **Uncommon** Fatigue - paraesthesia
- **Rare** Alveolitis - aplastic anaemia - aspetic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - glucose intolerance - haemolytic anaemia (positive Coombs’ test) - hepatic damage - hypotension - interstitial fibrosis associated with NSAIDs can lead to renal failure - malabsorption - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - thrombocytopenia - toxic epidermal necrolysis - visual disturbances
- **Frequency not known** Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn’s disease (induction of or exacerbation of) - depression - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

**SIDE-EFFECTS, FURTHER INFORMATION** Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

Overdose Mefenamic acid has important consequences in overdosage because it can cause convulsions, which if prolonged or recurrent, require treatment. For details on the management of poisoning, see Emergency treatment of poisoning p. 1122, in particular, Convulsions.

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING** Use with caution during breast-feeding. Amount too small to be harmful but manufacturer advises avoid.

**HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT** The lowest effective dose should be used for the shortest possible duration. Avoid if possible or use with caution. Avoid in severe impairment. In renal impairment monitor renal function; sodium and water

---

**Ketoprofen with omeprazole**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ketoprofen p. 930, omeprazole p. 69.

**INDICATIONS AND DOSE**

Patients requiring ketoprofen for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, who are at risk of NSAID associated duodenal or gastric ulcer or gastroduodenal erosions.

**BY MOUTH**
- **Adult:** Initially 100/20 mg daily, increased if necessary to 200/20 mg daily, depending on severity of symptoms, dose expressed as x/y mg ketoprofen/omeprazole

**PRESCRIBING AND DISPENSING INFORMATION** Capsules enclose microgranules containing modified-release ketoprofen and gastro-resistant omeprazole.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS** 21, 25

**EXCIPIENTS:** May contain Propylene glycol

**Axorid** (Meda Pharmaceuticals Ltd)

Ketoprofen 100 mg, Omeprazole 20 mg
Ketoprofen 150 mg, Omeprazole 20 mg
Ketoprofen 200 mg, Omeprazole 20 mg

**Brand** may include Larafen Cr; Tilotok Cr; Valket Retard Gel

**Excipients:** May contain Fragrances

**KETOPROFEN (Non-proprietary)**

**Ketoprofen 25 mg per 1 gram** Ketoprofen 2.5% gel
Ketoprofen 50 mg/gram
Ketoprofen 100 mg/gram
Ketoprofen 150 mg/gram
Ketoprofen 200 mg/gram

**Price = £**

**DT price = £**

---

**Mefenamic acid**

**INDICATIONS AND DOSE**

Pain and inflammation in rheumatoid arthritis and osteoarthritis | Postoperative pain | Mild to moderate pain.

**BY MOUTH**
- Adult: 500 mg 3 times a day
- Acute pain including dysmenorrhoea | Menorrhagia
- Child 12-17 years: 500 mg 3 times a day
- Adult: 500 mg 3 times a day

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - inflammatory bowel disease - severe heart failure

---

**932 Pain and inflammation in musculoskeletal disorders**
Meloxicam

**INDICATIONS AND DOSE**

**Exacerbation of osteoarthritis (short-term)**

**BY MOUTH**

- Child 16-17 years: 7.5 mg once daily, then increased if necessary up to 15 mg once daily
- Adult: 7.5 mg once daily, then increased if necessary up to 15 mg once daily

**Pain and inflammation in rheumatic disease / Ankylosing spondylitis**

**BY MOUTH**

- Child 16-17 years: 15 mg once daily, then reduced to 7.5 mg once daily if required
- Adult: 15 mg once daily, then reduced to 7.5 mg once daily if required
- Elderly: 7.5 mg once daily

**Relief of pain and inflammation in juvenile idiopathic arthritis and other musculoskeletal disorders in children intolerant to other NSAIDs**

**BY MOUTH**

- Child 16-17 years (body-weight up to 50 kg): 7.5 mg once daily
- Child 16-17 years (body-weight 50 kg and above): 15 mg once daily

**CONTRA-INDICATIONS**

- Active gastro-intestinal bleeding
- Active gastro-intestinal ulceration
- History of gastro-intestinal bleeding related to previous NSAID therapy
- History of gastro-intestinal perforation related to previous NSAID therapy
- History of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
- History of recurrent gastro-intestinal ulceration (two or more distinct episodes)
- Severe heart failure

**CAUTIONS**

- Allergic disorders
- Cardiac impairment (NSAIDs may impair renal function)
- Cerebrovascular disease
- Coagulation defects
- Connective-tissue disorders
- Crohn’s disease (may be exacerbated)
- Elderly (risk of serious side-effects and fatalities)
- Heart failure
- Ischaemic heart disease
- Peripheral arterial disease
- Risk factors for cardiovascular events
- Ulcerative colitis (may be exacerbated)
- Uncontrolled hypertension (in adults)

**INTERACTIONS**

- Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- Rare
  - Alveolitis
  - Aseptic meningitis
  - Cardiac impairment (NSAIDs may impair renal function)
  - Connective-tissue disorders
  - Hepatic damage
  - Interstitial fibrosis
  - NSAIDs can lead to renal failure
  - Pancreatitis
  - Papillary necrosis
  - Toxic epidermal necrolysis
  - Visual disturbances

- Frequency not known
  - Angioedema
  - Blood disorders
  - Bronchospasm
  - Colitis (induction of or exacerbation of)
  - Crohn’s disease (induction of or exacerbation of)
  - Depression
  - Diarrhoea
  - Dizziness
  - Drowsiness
  - Fluid retention
  - Gastro-intestinal bleeding
  - Gastro-intestinal discomfort
  - Gastro-intestinal disturbances
  - Gastro-intestinal ulceration
  - Haematuria
  - Headache
  - Renal retention
  - Nervousness
  - Photosensitivity
  - Raised blood pressure
  - Rashes
  - Renal failure

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects**

For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY**

Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONCEPTION**

Caution—Long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY**

Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING**

Use with caution during breast-feeding. Present in milk in animal studies—manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

Use with caution; there is an associated risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT**

Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- In adults: Avoid if eGFR less than 25 mL/minute/1.73 m².
- In children: Avoid if estimated glomerular filtration rate less than 25 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Meloxicam** (Non-proprietary)
  - **Meloxicam 7.5 mg** Meloxicam 7.5mg tablets | 30 tablet £8.20
  - **DT price = £1.16**
  - **Meloxicam 15 mg** Meloxicam 15mg tablets | 30 tablet £4.00
  - **DT price = £1.39**
Nabumetone

**INDICATIONS AND DOSE**

**Pain and inflammation in osteoarthritis and rheumatoid arthritis**

**BY MOUTH**

- **Adult:** 1 g once daily, dose to be taken at night
- **Elderly:** 0.5–1 g daily

**Pain and inflammation in osteoarthritis and rheumatoid arthritis (severe and persistent symptoms)**

**BY MOUTH**

- **Adult:** 0.5–1 g, dose to be taken in the morning and 1 g, dose to be taken at night

**CONTRA-INDICATIONS**

- Active gastro-intestinal bleeding
- active gastro-intestinal ulceration
- history of gastro-intestinal bleeding related to previous NSAID therapy
- history of gastro-intestinal perforation related to previous NSAID therapy
- history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
- history of recurrent gastro-intestinal ulceration (two or more distinct episodes)
- severe heart failure

**CAUTIONS**

- Allergic disorders
- cardiac impairment (NSAIDs may impair renal function)
- cerebrovascular disease
- coagulation defects
- connective-tissue disorders
- Crohn’s disease (may be exacerbated)
- elderly (risk of serious side-effects and fatalities)
- heart failure
- ischaemic heart disease
- peripheral arterial disease
- risk factors for cardiovascular events
- ulcerative colitis (may be exacerbated)
- uncontrolled hypertension

**INTERACTIONS**

- Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- Rare
  - Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)
  - hepatic damage
  - interstitial fibrosis associated with NSAIDs can lead to renal failure
  - pancreatitis
  - papillary necrosis associated with NSAIDs can lead to renal failure
  - pulmonary eosinophilia
  - Stevens-Johnson syndrome
  - toxic epidermal necrolysis
  - visual disturbances

**Frequency not known**

- Angioedema
- blood disorders
- bronchospasm
- colitis (induction of or exacerbation of)
- Crohn’s disease (induction of or exacerbation of)
- depression
- diarrhoea
- dizziness
- drowsiness
- fluid retention (rarely precipitating congestive heart failure)
- gastro-intestinal bleeding
- gastro-intestinal discomfort
- gastro-intestinal disturbances
- gastro-intestinal ulceration
- haematuria
- headache
- hearing disturbances
- hypersensitivity reactions
- insomnia
- nausea
- nervousness
- photosensitivity
- raised blood pressure
- rashes
- renal failure (especially in patients with pre-existing renal impairment)
- tinnitus
- vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Serious side-effects**
  - For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY**

- Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONTRA-INDICATIONS**
  - Active gastro-intestinal bleeding
  - active gastro-intestinal ulceration
  - history of gastro-intestinal bleeding related to previous NSAID therapy
  - history of gastro-intestinal perforation related to previous NSAID therapy
  - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
  - history of recurrent gastro-intestinal ulceration (two or more distinct episodes)
  - severe heart failure

- **CAUTIONS**
  - Allergic disorders
  - cardiac impairment (NSAIDs may impair renal function)
  - cerebrovascular disease
  - coagulation defects
  - connective-tissue disorders
  - Crohn’s disease (may be exacerbated)
  - elderly (risk of serious side-effects and fatalities)
  - heart failure
  - ischaemic heart disease
  - peripheral arterial disease
  - risk factors for cardiovascular events
  - ulcerative colitis (may be exacerbated)
  - uncontrolled hypertension

- **INTERACTIONS**
  - Appendix 1 (NSAIDs).

- **SIDE-EFFECTS**
  - Rare
    - Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)
    - hepatic damage
    - interstitial fibrosis associated with NSAIDs can lead to renal failure
    - pancreatitis
    - papillary necrosis associated with NSAIDs can lead to renal failure
    - pulmonary eosinophilia
    - Stevens-Johnson syndrome
    - toxic epidermal necrolysis
    - visual disturbances

**Naproxen**

**INDICATIONS AND DOSE**

**Pain and inflammation in rheumatic disease**

**BY MOUTH**

- **Adult:** 0.5–1 g daily in 1–2 divided doses

**Pain and inflammation in musculoskeletal disorders**

**BY MOUTH**

- **Adult:** Initially 500 mg, then 250 mg every 6–8 hours as required, maximum dose after the first day 1.25 g daily

**Acute gout**

**BY MOUTH**

- **Adult:** Initially 750 mg, then 250 mg every 8 hours until attack has passed

**CONTRA-INDICATIONS**

- Active gastro-intestinal bleeding
- active gastro-intestinal ulceration
- history of gastro-intestinal bleeding related to previous NSAID therapy
- history of gastro-intestinal perforation related to previous NSAID therapy
- history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
- history of recurrent gastro-intestinal ulceration (two or more distinct episodes)
- severe heart failure

**CAUTIONS**

- Allergic disorders
- cardiac impairment (NSAIDs may impair renal function)
- cerebrovascular disease
- coagulation defects
- connective-tissue disorders
- Crohn’s disease (may be exacerbated)
- elderly (risk of serious side-effects and fatalities)
- heart failure
- ischaemic heart disease
- peripheral arterial disease
- risk factors for cardiovascular events
- ulcerative colitis (may be exacerbated)
- uncontrolled hypertension

**INTERACTIONS**

- Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- Rare
  - Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)
  - hepatic damage
  - interstitial fibrosis associated with NSAIDs can lead to renal failure
  - pancreatitis
  - papillary necrosis associated with NSAIDs can lead to renal failure
  - pulmonary eosinophilia
  - Stevens-Johnson syndrome
  - toxic epidermal necrolysis
  - visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Serious side-effects**
  - For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY**

- Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION**

Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY**

Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING**

Use with caution during breast-feeding. Manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT**

Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Table**

**CAUTIONARY AND ADVISORY LABELS**

- **NABUMETONE (Non-proprietary)**
  - Nabumetone 500 mg Nabumetone 500mg tablets | 56 tablet [PO] £20.00 DT price = £8.56
  - Reflex (Meda Pharmaceuticals Ltd)
  - Nabumetone 500 mg Reflex 500mg tablets | 56 tablet [PO] £6.18 DT price = £8.56

**DT price**

- **Meloxicam 7.5 mg Meloxicam 7.5mg orodispersible tablets sugar free (sugar-free) | 30 tablet [PO] £5.30
  - Meloxicam 15 mg Meloxicam 15mg orodispersible tablets sugar free (sugar-free) | 30 tablet [PO] £5.50**

**BNF 70**

- **Reliefex**
  - Meloxicam 5 mg orodispersible tablets sugar free (sugar-free) | 28 tablet [PO] £8.56
  - Meloxicam 7.5 mg orodispersible tablets sugar free (sugar-free) | 28 tablet [PO] £9.15

**BY MOUTH**

- **Adult:** Initially 500 mg, then 250 mg every 6–8 hours as required, maximum dose after the first day 1.25 g daily

**Acute gout**

- **Adult:** Initially 750 mg, then 250 mg every 8 hours until attack has passed

**CONTRA-INDICATIONS**

- Active gastro-intestinal bleeding
- active gastro-intestinal ulceration
- history of gastro-intestinal bleeding related to previous NSAID therapy
- history of gastro-intestinal perforation related to previous NSAID therapy
- history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
- history of recurrent gastro-intestinal ulceration (two or more distinct episodes)
- severe heart failure

**CAUTIONS**

- Allergic disorders
- cardiac impairment (NSAIDs may impair renal function)
- cerebrovascular disease
- coagulation defects
- connective-tissue disorders
- Crohn’s disease (may be exacerbated)
- elderly (risk of serious side-effects and fatalities)
- heart failure
- ischaemic heart disease
- peripheral arterial disease
- risk factors for cardiovascular events
- ulcerative colitis (may be exacerbated)
- uncontrolled hypertension

**INTERACTIONS**

- Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- Rare
  - Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)
  - hepatic damage
  - interstitial fibrosis associated with NSAIDs can lead to renal failure
  - pancreatitis
  - papillary necrosis associated with NSAIDs can lead to renal failure
  - pulmonary eosinophilia
  - Stevens-Johnson syndrome
  - toxic epidermal necrolysis
  - visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Serious side-effects**
  - For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY**

- Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.
damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

- **Frequency not known** Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn’s disease (induction of or exacerbation of) - depression - diarrhea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

**Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- **ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONCEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed or duration may be increased.

- **BREAST FEEDING** Use with caution during breast-feeding. Amount too small to be harmful but manufacturer advises avoid.

- **HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT** Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. Avoid if eGFR less than 30 mL/minute/1.73 m². In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **EXCEPTIONS TO LEGAL CATEGORY** Can be sold to the public for the treatment of primary dysmenorrhoea in women aged 15–50 years subject to max. single dose of 500 mg, max. daily dose of 750 mg for max. 3 days, and a max. pack size of 9 x 250 mg tablets.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

  **Tablet**

  **CAUTIONARY AND ADVISORY LABELS 21**

  - **NAPROXEN (Non-proprietary)**
    - Naproxen 250 mg Naproxen 250mg tablets | 28 tablet [POT] £6.98 DT price = £1.21 | 56 tablet [POT] £4.46
    - Naproxen 500 mg Naproxen 500mg tablets | 28 tablet [POT] £8.76 DT price = £1.67 | 56 tablet [POT] £5.54
    - Naprosyn (Roche Products Ltd)
    - Naproxen 250 mg Naprosyn 250mg tablets | 56 tablet [POT] £4.29
    - Naproxen 500 mg Naprosyn 500mg tablets | 56 tablet [POT] £8.56

- **Gastro-resistant tablet**

  **CAUTIONARY AND ADVISORY LABELS 5, 25**

  - NAPROXEN (Non-proprietary)
    - Naproxen 250 mg Naproxen 250mg gastro-resistant tablets | 56 tablet [POT] £12.90 DT price = £0.43
    - Naproxen 375 mg Naproxen 375mg gastro-resistant tablets | 56 tablet [POT] £6.82 DT price = £0.64
    - Naproxen 500 mg Naproxen 500mg gastro-resistant tablets | 56 tablet [POT] £16.90 DT price = £0.78
    - Naprosyn EC (Roche Products Ltd)
    - Naproxen 250 mg Naprosyn EC 250mg tablets | 56 tablet [POT] £4.29 DT price = £0.03
    - Naproxen 375 mg Naprosyn EC 375mg tablets | 56 tablet [POT] £6.42 DT price = £0.64
    - Naproxen 500 mg Naprosyn EC 500mg tablets | 56 tablet [POT] £8.56 DT price = £0.18
  - Brands may include Feminax Ultra

**Naproxen with esomeprazole**

The properties listed below are those particular to the combination only. For the properties of the components please consider, esomeprazole p. 67, naproxen p. 934.

**INDICATIONS AND DOSE**

Patients requiring naproxen for osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis, who are at risk of NSAID-associated duodenal or gastric ulcer and when treatment with lower doses of naproxen or other NSAIDs ineffective

**BY MOUTH**

- Adult: 1 tablet twice daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 22, 25**

- **esomeprazole with naproxen (Non-proprietary)**
  - Esomeprazole (as Esomeprazole magnesium trihydrate) 20 mg, Naproxen 500 mg Naproxen 500mg / Esomeprazole 20mg modified-release tablets | 60 tablet [POT] no price available
  - Vimovo (AstraZeneca UK Ltd)
  - Esomeprazole (as Esomeprazole magnesium trihydrate) 20 mg, Naproxen 500 mg Vimovo 500mg/20mg modified-release tablets | 60 tablet [POT] £14.95

**Naproxen with misoprostol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, misoprostol p. 709, naproxen p. 934.

**INDICATIONS AND DOSE**

Patients requiring naproxen for rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis, with prophylaxis against NSAID-induced gastroduodenal ulceration

**BY MOUTH**

- Adult: 500 mg twice daily, naproxen and 200 micrograms twice daily, misoprostol, taken together with food

**PRESCRIBING AND DISPENSING INFORMATION** The BNF recommends a higher starting dose of misoprostol for prophylaxis against NSAID-induced gastroduodenal ulceration than that provided by the misoprostol with naproxen combination pack.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Musculoskeletal system
With systemic use
▶ Rare
SIDE-EFFECTS
INTERACTIONS
With topical use
CAUTIONS
INDICATIONS AND DOSE
Rheumatoid arthritis (initiated by a specialist) | Osteoarthritis (initiated by a specialist) | Ankylosing spondylitis (initiated by a specialist)
BY MOUTH
Adult: Up to 20 mg once daily
Pain relief in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)
TO THE SKIN
Adult: Apply 3–4 times a day, 0.5% gel to be applied; review treatment after 4 weeks

Important safety information
CHMP ADVICE—PIROXICAM (JUNE 2007)
The CHMP has recommended restrictions on the use of piroxicam because of the increased risk of gastro-intestinal side effects and serious skin reactions. The CHMP has advised that:
- piroxicam should be initiated only by physicians experienced in treating inflammatory or degenerative rheumatic diseases
- piroxicam should not be used as first-line treatment
- in adults, use of piroxicam should be limited to the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
- piroxicam dose should not exceed 20 mg daily
- piroxicam should no longer be used for the treatment of acute painful and inflammatory conditions
- treatment should be reviewed 2 weeks after initiating piroxicam, and periodically thereafter
- concomitant administration of a gastro-protective agent should be considered.
Topical preparations containing piroxicam are not affected by these restrictions.

CONTRA-INDICATIONS
- With systemic use Active gastro-intestinal bleeding, active gastro-intestinal ulceration, history of gastro-intestinal bleeding, history of gastro-intestinal perforation, history of gastro-intestinal ulceration, inflammatory bowel disease, severe heart failure

CAUTIONS
- With systemic use Allergic disorders, cardiac impairment (NSAIDs may impair renal function), cerebrovascular disease, coagulation defects, connective-tissue disorders, Crohn’s disease (may be exacerbated), elderly (risk of serious side-effects and fatalities), heart failure, ischaemic heart disease, peripheral arterial disease, risk factors for cardiovascular events, ulcerative colitis (may be exacerbated), uncontrolled hypertension
- With topical use Avoid contact with eyes; avoid contact with inflamed or broken skin; avoid contact with mucous membranes; not for use with occlusive dressings; topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

INTERACTIONS → Appendix 1 (NSAIDs). Interactions do not generally apply to topical NSAIDs.

SIDE-EFFECTS
- Rare
- With systemic use Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), hepatic damage, interstitial fibrosis associated with NSAIDs can lead to renal failure, pancreatitis, papillary necrosis associated with NSAIDs can lead to renal failure, pulmonary eosinophilia, Stevens-Johnson syndrome, toxic epidermal necrolysis, visual disturbances
- Frequency not known
- With systemic use Angioedema, blood disorders, bronchospasm, colitis (induction of or exacerbation of), Crohn’s disease (induction of or exacerbation of), depression, diarrhoea, dizziness, drowsiness, fluid retention (rarely precipitating congestive heart failure), gastro-intestinal bleeding, gastro-intestinal discomfort, gastro-intestinal disturbances, gastro-intestinal ulceration, haematuria, headache, hearing disturbances, hypersensitivity reactions, insomnia, nausea, nervousness, photosensitivity, raised blood pressure, rashes, renal failure (especially in patients with pre-existing renal impairment), tinnitus, vertigo
- With topical use Photosensitivity; rash (discontinue use if develops)

SIDE-EFFECTS, FURTHER INFORMATION
Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915. Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).
- ALLERGY AND CROSS-SENSITIVITY Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.
- CONCEPTION AND CONTRACEPTION
- With systemic use Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.
- PREGNANCY
- With systemic use Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
- With topical use Patient packs for topical preparations carry a warning to avoid during pregnancy.
- BREAST FEEDING
- With systemic use Use with caution during breast-feeding. Amount too small to be harmful.
- With topical use Patient packs for topical preparations carry a warning to avoid during breast-feeding.
- HEPATIC IMPAIRMENT
- With systemic use Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.
- With topical use Deterioration in renal function has also been reported after topical use.
- DIRECTIONS FOR ADMINISTRATION For topical preparations apply with gentle massage only. Piroxicam orodispersible tablets can be taken by placing on the tongue and allowing to dissolve or by swallowing.
- PRESCRIBING AND DISPENSING INFORMATION Caution—topical preparations not generally suitable for children.
PATIENT AND CARER ADVICE  For topical preparations, patients and their carers should be advised to wash hands immediately after use. Photosensitivity Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.

LESS SUITABLE FOR PRESCRIBING  With oral use Piroxicam is less suitable for prescribing.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Orodispersible tablet

CAUTIONARY AND ADVISORY LABELS 10, 21

EXCIPIENTS: May contain Aspartame → Feldene Melt (Pfizer Ltd)
Piroxicam 20 mg Feldene Melt 20mg tablets (sugar-free) | 30 tablet (Pf) £10.53 DT price = £10.53

Capsule

CAUTIONARY AND ADVISORY LABELS 21

PIROXICAM (Non-proprietary)
Piroxicam 10 mg Piroxicam 10mg capsules | 56 capsule (Pf) £16.82 DT price = £4.59
Piroxicam 20 mg Piroxicam 20mg capsules | 28 capsule (Pf) £17.60 DT price = £4.30
Feldene (Pfizer Ltd)
Piroxicam 10 mg Feldene 10mg capsules | 30 capsule (Pf) £3.86
Piroxicam 20 mg Feldene 20 mg capsules | 30 capsule (Pf) £7.71

Gel

EXCIPIENTS: May contain Benzyl alcohol, propylene glycol → PIROXICAM (Non-proprietary)
Piroxicam 5 mg per 1 gram Piroxicam 0.5% gel | 60 gram (Pf) £4.04 DT price = £4.04 | 112 gram (Pf) £8.47 DT price = £7.54
Feldene (Pfizer Ltd)
Piroxicam 5 mg per 1 gram Feldene 0.5% gel | 60 gram (Pf) £6.00 DT price = £4.04 | 112 gram (Pf) £9.41 DT price = £7.54

Sulindac

INDICATIONS AND DOSE
Pain and inflammation in rheumatic disease and other musculoskeletal disorders  Acute gout

BY MOUTH

Adult: 200 mg twice daily for 7–10 days in peri-articular disorders; acute gout should respond within 7 days, dose may be reduced according to response; maximum 400 mg per day

CONTRA-INDICATIONS  Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

CAUTIONS  Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - ensure adequate hydration - heart failure - history of renal stones - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

INTERACTIONS  → Appendix 1 (NSAIDs).

SIDE-EFFECTS

Rare  Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis

associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances


SIDE-EFFECTS, FURTHER INFORMATION
Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

ALLERGY AND CROSS-SENSITIVITY  Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION  Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY  Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

BREAST FEEDING  Use with caution during breast-feeding.

HEPATIC IMPAIRMENT  Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT  Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

SULINDAC (Non-proprietary)
Sulindac 100 mg Sulindac 100mg tablets | 56 tablet (Pf) £43.75 DT price = £23.78
Sulindac 200 mg Sulindac 200mg tablets | 56 tablet (Pf) £56.25 DT price = £38.29

Tenoxicam

INDICATIONS AND DOSE
Pain and inflammation in rheumatic disease

BY MOUTH

Adult: 20 mg daily

BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION

Adult: 20 mg daily as initial treatment for 1–2 days if oral administration not possible

continued →
Pain and inflammation in acute musculoskeletal disorders

BY MOUTH
- Adult: 20 mg daily for 7 days; maximum duration of treatment 14 days (including treatment by intravenous or intramuscular injection)

BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION
- Adult: 20 mg daily as initial treatment for 1–2 days if oral administration not possible

- CONTRA-INDICATIONS
  - Active gastro-intestinal bleeding
  - Active gastro-intestinal ulceration
  - History of gastro-intestinal bleeding related to previous NSAID therapy
  - History of gastro-intestinal perforation related to previous NSAID therapy
  - History of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
  - History of recurrent gastro-intestinal ulceration (two or more distinct episodes)
  - Severe heart failure

- CAUTIONS
  - Allergic disorders
  - Cardiac impairment (NSAIDs may impair renal function)
  - Cerebrovascular disease
  - Coagulation defects
  - Connective-tissue disorders
  - Crohn’s disease (may be exacerbated)
  - Elderly (risk of serious side-effects and fatalities)
  - Heart failure
  - Ischaemic heart disease
  - Peripheral arterial disease
  - Risk factors for cardiovascular events
  - Ulcerative colitis (may be exacerbated)
  - Uncontrolled hypertension

- INTERACTIONS

- SIDE-EFFECTS
  - Rare: Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); hepatic damage; interstitial fibrosis associated with NSAIDs can lead to renal failure; pancreatitis; papillary necrosis associated with NSAIDs can lead to renal failure; pulmonary eosinophilia; Stevens-Johnson syndrome; toxic epidermal necrolysis; visual disturbances
  - Frequency not known: Angioedema; blood disorders; bronchospasm; colitis (induction of or exacerbation of); Crohn’s disease (induction of or exacerbation of); depression; diarrhoea; dizziness; drowsiness; fluid retention (rarely precipitating congestive heart failure); gastro-intestinal bleeding; gastro-intestinal discomfort; gastro-intestinal disturbances; gastro-intestinal ulceration; haematuria; headache; hearing disturbances; hypersensitivity reactions; insomnia; nausea; nervousness; photosensitivity; raised blood pressure; rashes; renal failure (especially in patients with pre-existing renal impairment); tinnitus; vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects: For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- ALLERGY AND CROSS-SENSITIVITY
  - Contraindicated in patients with a history of hypersensitivity to aspirin or other NSAIDs—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or other NSAIDs.

- CONCEPTION AND CONTRACEPTION
  - Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- PREGNANCY
  - Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

- BREAST FEEDING
  - Use with caution during breast-feeding. Present in milk in animal studies.

- HEPATIC IMPAIRMENT
  - Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- RENAL IMPAIRMENT
  - Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21
- TENOXICAM (Non-proprietary)
  - Tenoxicam 20 mg

Powder and solvent for solution for injection

- TENOXICAM (Non-proprietary)
  - Tenoxicam 20 mg

Tiaprofenic acid

INDICATIONS AND DOSE

Pain and inflammation in rheumatic disease and other musculoskeletal disorders

BY MOUTH
- Adult: 300 mg twice daily

Important safety information

CSM ADVICE

Following reports of severe cystitis the CSM has recommended that tiaprofenic acid should not be given to patients with urinary-tract disorders and should be stopped if urinary symptoms develop. Patients should be advised to stop taking tiaprofenic acid and to report to their doctor promptly if they develop urinary-tract symptoms (such as increased frequency, nocturia, urgency, pain on urinating, or blood in urine).

- CONTRA-INDICATIONS
  - Active bladder disease (or symptoms)
  - Active gastro-intestinal bleeding
  - Active gastro-intestinal ulceration
  - Active prostate disease (or symptoms)
  - History of gastro-intestinal bleeding related to previous NSAID therapy
  - History of gastro-intestinal perforation related to previous NSAID therapy
  - History of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
  - History of recurrent gastro-intestinal ulceration (two or more distinct episodes)
  - History of recurrent urinary-tract disorders (if urinary symptoms develop do not discontinue immediately and perform urine tests and culture)
  - Severe heart failure

- CAUTIONS
  - Allergic disorders
  - Cardiac impairment (NSAIDs may impair renal function)
  - Cerebrovascular disease
  - Coagulation defects
  - Connective-tissue disorders
  - Crohn’s disease (may be exacerbated)
  - Elderly (risk of serious side-effects and fatalities)
  - Heart failure
  - Ischaemic heart disease
  - Peripheral arterial disease
  - Risk factors for cardiovascular events
  - Ulcerative colitis (may be exacerbated)
  - Uncontrolled hypertension

INTERACTIONS

- Appendix 1 (NSAIDs).

SIDE-EFFECTS

- Rare: Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); hepatic damage; interstitial fibrosis associated with NSAIDs can lead to renal failure; papillary necrosis associated with NSAIDs can lead to renal failure; pulmonary eosinophilia; Stevens-Johnson syndrome; toxic epidermal necrolysis; visual disturbances

- Frequency not known: Angioedema; blood disorders; bronchospasm; colitis (induction of or exacerbation of); Crohn’s disease (induction of or exacerbation of); depression; diarrhoea; dizziness; drowsiness; fluid retention (rarely precipitating congestive heart failure); gastro-intestinal bleeding; gastro-intestinal discomfort; gastro-intestinal disturbances; gastro-intestinal ulceration; haematuria; headache; hearing disturbances; hypersensitivity reactions; insomnia; nausea; nervousness; photosensitivity; raised blood pressure; rashes; renal failure (especially in patients with pre-existing renal impairment); tinnitus; vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects: For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

- ALLERGY AND CROSS-SENSITIVITY
  - Contraindicated in patients with a history of hypersensitivity to aspirin or other NSAIDs—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or other NSAIDs.

- CONCEPTION AND CONTRACEPTION
  - Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- PREGNANCY
  - Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

- BREAST FEEDING
  - Use with caution during breast-feeding. Present in milk in animal studies.

- HEPATIC IMPAIRMENT
  - Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.
5 Soft tissue and joint disorders

5.1 Local inflammation of joints and soft tissue

Corticosteroids, inflammatory disorders

Systemic corticosteroids

Short-term treatment with corticosteroids can help to rapidly improve symptoms of rheumatoid arthritis. Long-term treatment in rheumatoid arthritis should be considered only after evaluating the risks and all other treatment options have been considered. Corticosteroids can induce osteoporosis, and prophylaxis should be considered on long-term treatment.

In severe, possibly life-threatening, situations a high initial dose of corticosteroid is given to induce remission and the dose is then reduced gradually and discontinued altogether. Relapse may occur as the dose of corticosteroid is reduced, particularly if the reduction is too rapid. The tendency is therefore to increase the maintenance dose and consequently the patient becomes dependent on corticosteroids. For this reason pulse doses of corticosteroids (e.g. methylprednisolone p. 584 up to 1 g intravenously on 3 consecutive days) are used to suppress highly active inflammatory disease while longer-term treatment with a disease-modifying drug is commenced.

Prednisolone p. 585 may reduce the rate of joint destruction in moderate to severe rheumatoid arthritis of less than 2 years’ duration. The reduction in joint destruction must be distinguished from mere symptomatic improvement (which lasts only 6 to 12 months at this dose) and care should be taken to avoid increasing the dose above 7.5 mg daily. Evidence supports maintenance of this anti-erosive dose for 2–4 years only after which treatment should be tapered off to reduce long-term adverse effects. A modified-release preparation of prednisone p. 586 is also available for the treatment of moderate to severe rheumatoid arthritis.

Polymyalgia rheumatica and giant cell (temporal) arteritis

are always treated with corticosteroids. Relapse is common if therapy is stopped prematurely. Many patients require treatment for at least 2 years and in some patients it may be necessary to continue long-term low-dose corticosteroid treatment.

Polyarteritis nodosa and polymyositis

are usually treated with corticosteroids.

Systemic lupus erythematosus

is treated with corticosteroids when necessary using a similar dosage regimen to that for polyarteritis nodosa and polymyositis. Patients with pleurisy, pericarditis, or other systemic manifestations will respond to corticosteroids. It may then be possible to reduce the dosage; alternate-day treatment is sometimes adequate, and the drug may be gradually withdrawn. In some mild cases corticosteroid treatment may be stopped after a few months. Many mild cases of systemic lupus erythematosus do not require corticosteroid treatment. Alternative treatment with anti-inflammatory analgesics, and possibly chloroquine p. 536 or hydroxychloroquine sulfate p. 894, should be considered.

Ankylosing spondylitis

should not be treated with long-term corticosteroids; rarely, pulse doses may be needed and may be useful in extremely active disease that does not respond to conventional treatment.
Local corticosteroid injections
Corticosteroids are injected locally for an anti-inflammatory effect. In inflammatory conditions of the joints, particularly in rheumatoid arthritis, they are given by intra-articular injection to relieve pain, increase mobility, and reduce deformity in one or a few joints; they can also provide symptomatic relief while waiting for DMARDs to take effect. Full aseptic precautions are essential; infected areas should be avoided. Occasionally an acute inflammatory reaction develops after an intra-articular or soft-tissue injection of a corticosteroid. This may be a reaction to the microcrystalline suspension of the corticosteroid used, but must be distinguished from sepsis introduced into the injection site.
Smaller amounts of corticosteroids may also be injected directly into soft tissues for the relief of inflammation in conditions such as tennis or golfer’s elbow or compression neurapathies. In tendinitis, injections should be made into the tendon sheath and not directly into the tendon (due to the absence of a true tendon sheath and a high risk of rupture, the Achilles tendon should not be injected).
Hydrocortisone p. 583 acetate or one of the synthetic analogues is generally used for local injection. Intra-articular corticosteroid injections can cause flushing and may affect the hyaline cartilage. Each joint should not usually be treated more than 4 times in one year.
Corticosteroid injections are also injected into soft tissues for the treatment of skin lesions.

CORTICOSTEROIDS

Methylprednisolone with lidocaine
The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1116, methylprednisolone p. 584.

INDICATIONS AND DOSE
Local inflammation of joints
BY INTRA-ARTICULAR INJECTION
- Adult: 4–80 mg, dose adjusted according to size; where appropriate may be repeated at intervals of 7–35 days, for details consult product literature

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Suspension for injection
EXCipients: May contain benzyl alcohol
- TRIAMCINOLONE HEXACETONIDE (Non-proprietary)
Triamcinolone hexacetonide 20 mg per 1 ml Triamcinolone hexacetonide 20mg/1ml suspension for injection ampoules | 10 ampoule | £10.00

5.2 Soft tissue disorders

Soft-tissue disorders

Extravasation
Local guidelines for the management of extravasation should be followed where they exist or specialist advice sought.
Extravasation injury follows leakage of drugs or intravenous fluids from the veins or inadvertently administration into the subcutaneous or subdermal tissue. It must be dealt with promptly to prevent tissue necrosis. Acidic or alkaline preparations and those with an osmolarity greater than that of plasma can cause extravasation injury; excipients including alcohol and polyethylene glycol have also been implicated. Cytotoxic drugs commonly cause extravasation injury. In addition, certain patients such as the very young and the elderly are at increased risk. Those receiving anticoagulants are more likely to lose blood into surrounding tissues if extravasation occurs, while those receiving sedatives or analgesics may not notice the early signs or symptoms of extravasation.

Prevention of extravasation
Precautions should be taken to avoid extravasation; ideally, drugs likely to cause extravasation injury should be given through a central line and patients receiving repeated doses of hazardous drugs peripherally should have the cannula resited at regular intervals. Attention should be paid to the manufacturers’ recommendations for administration. Placing a glyceryl trinitrate p. 190 patch distal to the cannula may improve the patency of the vessel in patients with small veins or in those whose veins are prone to collapse.

Patients should be asked to report any pain or burning at the site of injection immediately.

Management of extravasation
If extravasation is suspected the infusion should be stopped immediately but the cannula should not be removed until after an attempt has been made to aspirate the area (through the cannula) in order to remove as much of the drug as possible. Aspiration is sometimes possible if the extravasation presents with a raised bleb or blister at the injection site and is surrounded by hardened tissue, but it is often unsuccessful if the tissue is soft or soggy.

Corticosteroids are usually given to treat inflammation, although there is little evidence to support their use in extravasation. Hydrocortisone p. 583 or dexamethasone p. 581 can be given either locally by subcutaneous injection or intravenously at a site distant from the injury. Antihistamines and analgesics may be required for symptom relief.
The management of extravasation beyond these measures is not well standardised and calls for specialist advice. Treatment depends on the nature of the offending substance; one approach is to localise and neutralise the substance whereas another is to spread and dilute it.

The first method may be appropriate following extravasation of vesicant drugs and involves administration of an antidote (if available) and the application of cold compresses 3–4 times a day (consult specialist literature for details of specific antidotes). Spreading and diluting the offending substance involves infiltrating the area with physiological saline, applying warm compresses, elevating the affected limb, and administering hyaluronidase below. A saline flush-out technique (involving flushing the subcutaneous tissue with physiological saline) may be effective but requires specialist advice. Hyaluronidase should not be administered following extravasation of vesicant drugs (unless it is either specifically indicated or used in the saline flush-out technique). Dexrazoxane p. 782 is licensed for the treatment of anthracycline-induced extravasation.

**Enzymes**

**Collagenase**

Collagenase below are proteolytic enzymes that are derived from the fermentation of *Clostridium histolyticum* and have the ability to break down collagen. A preparation containing a mixture of two collagenases is licensed for the treatment of Dupuytren’s contracture; the preparation should be injected into a palpable cord with a contracture of a metacarpophalangeal joint or proximal interphalangeal joint.

**Hyaluronidase**

Hyaluronidase is used to render the tissues more readily permeable to injected fluids, e.g. for introduction of fluids by subcutaneous infusion (termed hypodermoclysis).

**Rubefacients, topical NSAIDs, capsaicin, and poultices**

Rubefacients act by counter-irritation. Pain, whether superficial or deep-seated, is relieved by any method that itself produces irritation of the skin. Topical rubefacient preparations may contain nicotinate and salicylate compounds, essential oils, capsaicum, and camphor. The evidence available does not support the use of topical rubefacients in acute or chronic musculoskeletal pain.

**Topical NSAIDs**

The use of a NSAID by mouth is effective for relieving musculoskeletal pain. **Topical NSAIDs** (e.g. felbinac p. 925, ibuprofen p. 927, ketoprofen p. 930, and piroxicam p. 936 may provide some relief of pain in musculoskeletal conditions; they can be considered as an adjunctive treatment in knee or hand osteoarthritis.

**Capsaicin**

A preparation containing capsaicin p. 383 0.025% can be considered as an adjunct in hand or knee osteoarthritis. It may need to be used for 1–2 weeks before pain is relieved.

A capsaicin 0.075% cream is licensed for the symptomatic relief of postherpetic neuralgia after lesions have healed, and for the relief of painful diabetic neuropathy. A self-adhesive patch containing capsaicin 8% is licensed for the treatment of peripheral neuropathic pain in non-diabetic patients.

**Collagenase**

**INDICATIONS AND DOSE**

Dupuytren’s contracture in patients with a palpable cord

**BY INTRALESIONAL INJECTION**

- Adult: 580 micrograms, then 580 micrograms every 4 weeks if required, inject into palpable cord, maximum 3 injections per cord, maximum 8 injections in total and only one cord may be treated at a time

**CONTRA-INDICATIONS** Avoid injecting into other structures containing collagen (e.g. tendons, nerves, and blood vessels)—risk of tendon rupture or ligament damage

**CAUTIONS** Coagulation disorders · use of anticoagulants

**SIDE-EFFECTS**

- Common or very common Arthralgia · burning sensation · ecchymosis · hyperhidrosis · hypoesthesia · injection site reactions · joint swelling · lymphadenopathy · myalgia · paraesthesia

- Uncommon Complex regional pain syndrome · crepitus · ligament injury · monoplegia · muscle spasm · muscle weakness · tendon rupture · tremor · wound dehiscence

**PREGNANCY** Manufacturer advises avoid.

**BREAST FEEDING** Systemic absorption by mother negligible.

**DIRECTIONS FOR ADMINISTRATION** Reconstitution and injected volumes vary with site of injection—consult product literature.

**ENZYMES**

**Hyaluronidase**

**INDICATIONS AND DOSE**

Enhance permeation of subcutaneous or intramuscular injections

**BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**

- Adult: 1500 units, to be dissolved directly into the solution to be injected (ensure compatibility)

Enhance permeation of local anaesthetics TO THE SKIN

- Adult: 1500 units, to be mixed with the local anaesthetic solution continued →
Hypodermoclysis
BY SUBCUTANEOUS INJECTION
- Adult: 1500 units, to be dissolved in 1 mL water for injections or 0.9% sodium chloride injection, administered before start of 500–1000 mL infusion fluid

Extravasation
BY LOCAL INFILTRATION
- Adult: 1500 units, to be dissolved in 1 mL water for injections or 0.9% sodium chloride and infiltrated into affected area as soon as possible after extravasation

Haematoma
BY LOCAL INFILTRATION
- Adult: 1500 units, to be dissolved in 1 mL water for injections or 0.9% sodium chloride and infiltrated into affected area

Enhance permeation of ophthalmic local anaesthetic
TO THE EYE
- Adult: 15 units/mL, to be mixed with the local anaesthetic solution

- UNLICENSED USE Licensed for use in children, but age range not specified by the manufacturer.
- CONTRA-INDICATIONS Avoid sites where infection is present • avoid sites where malignancy is present • do not apply direct to cornea • not for anaesthesia in unexplained premature labour • not for intravenous administration • not to be used to enhance the absorption and dispersion of dopamine and/or alpha-adrenoceptor agonists • not to be used to reduce swelling of bites • not to be used to reduce swelling of stings
- CAUTIONS Elderly (control speed and total volume and avoid overhydration especially in renal impairment) • infants (control speed and total volume and avoid overhydration especially in renal impairment)
- SIDE-EFFECTS
- Common or very common Oedema
- Rare Bleeding • bruising • infection • local irritation
- Frequency not known Anaphylaxis • severe allergy

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection
- HYALURONIDASE (Non-proprietary)
  Hyaluronidase 1500 unit Hyaluronidase 1,500 unit powder for solution for injection ampoules | 10 ampoule P+V £104.24
Chapter 11
Eye

CONTENTS
1 Allergic and inflammatory eye conditions page 944
  1.1 Allergic conjunctivitis 945
  1.2 Inflammatory eye conditions 947
  1.3 Uveitis, anterior 949
2 Dry eye conditions 950
3 Eye infections 954
  3.1 Bacterial eye infection 955
  3.2 Herpes simplex infection 958
4 Eye procedures page 958
  4.1 Post-operative pain and inflammation 960
5 Glaucoma and ocular hypertension 962
6 Retinal disorders 971
  6.1 Macular degeneration 971
  6.2 Macular oedema 974
  6.3 Vitreomacular traction 975

Eye

Administration of drugs to the eye

Drugs are most commonly administered to the eye by topical application as eye drops or eye ointments. When a higher drug concentration is required within the eye, a local injection may be necessary.

Eye-drop dispenser devices are available to aid the instillation of eye drops from plastic bottles and some are prescribable on the NHS. Product-specific devices may be supplied by manufacturers—consult individual manufacturers for information. They are particularly useful for the elderly, visually impaired, arthritic, or otherwise physically limited patients.

Eye drops and eye ointments

Eye drops are generally instilled into the pocket formed by gently pulling down the lower eyelid and keeping the eye closed for as long as possible after application; one drop is all that is needed. Instillation of more than one drop should be discouraged because it may increase systemic side-effects. A small amount of eye ointment is applied similarly; the ointment melts rapidly and blinking helps to spread it.

When two different eye-drop preparations are used at the same time of day, dilution and overflow may occur when one immediately follows the other. The patient should therefore leave an interval of at least 5 minutes between the two; the interval should be extended when eye drops with a prolonged contact time, such as gels and suspensions, are used. Eye ointment should be applied after drops.

Systemic effects may arise from absorption of drugs into the general circulation from conjunctival vessels or from the nasal mucosa after the excess preparation has drained down through the tear ducts. The extent of systemic absorption following ocular administration is highly variable; nasal drainage of drugs is associated with eye drops much more often than with eye ointments. Pressure on the lacrimal punctum for at least a minute after applying eye drops reduces nasolacrimal drainage and therefore decreases systemic absorption from the nasal mucosa.

After using eye drops or eye ointments, patients should be warned not to drive or perform other skilled tasks until vision is clear.

Also see warnings relating to eye drops and contact lenses.

Eye lotions

These are solutions for the irrigation of the conjunctival sac. They act mechanically to flush out irritants or foreign bodies as a first-aid treatment. Sterile sodium chloride 0.9% solution is usually used. Clean water will suffice in an emergency.

Other preparations administered to the eye

Subconjunctival injection may be used to administer anti-infective drugs, mydriatics, or corticosteroids for conditions not responding to topical therapy; intracameral and intravitreal routes can also be used to administer certain drugs, for example antibiotics. These injections should only be used under specialist supervision.

Drugs such as antimicrobials and corticosteroids may be administered systemically to treat susceptible eye conditions.

Ophthalmic Specials

Certain eye drops, e.g. amphotericin, cefazidime, cefuroxime, colistimethate sodium, desferrioxamine mesilate, dexamethasone, gentamicin, and vancomycin can be prepared aseptically from material supplied for injection.

The Royal College of Ophthalmologists and the UK Ophthalmic Pharmacy Group have produced the Ophthalmic Specials Guidance to help prescribers and pharmacists manage and restrict the use of unlicensed eye preparations. ‘Specials’ should only be prescribed in situations where a licensed product is not suitable for a patient’s needs. The Ophthalmic Specials Guidance can be accessed on the Royal College of Ophthalmologists website (www.rcophth.ac.uk). The guidance will be reviewed every six months to ensure the most accurate and up-to-date information is available.

Preservatives and sensitisers

Information on preservatives and substances identified as skin sensitisers is provided under Excipients statements in preparation entries. Very rarely, cases of corneal calcification have been reported with the use of phosphate-containing eye drops in patients with significantly damaged corneas—consult product literature for further information.

Control of microbial contamination

Preparations for the eye should be sterile when issued. Care should be taken to avoid contamination of the contents during use.

Eye drops in multiple-application containers for domiciliary use should not be used for more than 4 weeks after first opening (unless otherwise stated by the manufacturer).

Multiple application eye drops for use in hospital wards are normally discarded 1 week after first opening—local...
practice may vary. Individual containers should be provided for each patient. A separate container should be supplied for each eye only if there are special concerns about contamination. Containers used before an eye operation should be discarded at the time of the operation and fresh containers supplied postoperatively. A fresh supply should also be provided upon discharge from hospital; in specialist ophthalmology units, it may be acceptable to issue containers that have been dispensed to the patient on the day of discharge.

In out-patient departments single-application containers should be used; if multiple-application containers are used, they should be discarded after single patient use within one clinical session.

In eye surgery single-application containers should be used if possible; if a multiple-application container is used, it should be discarded after single use. Preparations used during intra-ocular procedures and others that may penetrate into the anterior chamber must be isotonic and without preservatives and buffered if necessary to a neutral pH. Specially formulated fluids should be used for intra-ocular surgery; intravenous infusion preparations are not usually suitable for this purpose (Hartmann’s solution may be used in some ocular surgery). For all surgical procedures, a previously unopened container is used for each patient.

**Contact lenses**

For cosmetic reasons many people prefer to wear contact lenses rather than spectacles; contact lenses are also sometimes required for medical indications. Visual defects are corrected by either rigid (‘hard’ or gas permeable) lenses or soft (hydrogel or silicone hydrogel—in adults only) lenses; soft lenses are the most popular type, because they are initially the most comfortable, but they may not give the best vision. Lenses should usually be worn for a specified number of hours each day and removed for sleeping. The risk of infectious and non-infectious keratitis is increased by extended continuous contact lens wear, which is not recommended, except when medically indicated.

Contact lenses require meticulous care. Poor compliance with directions for use, and with daily cleaning and disinfection, can result in complications including ulcerative keratitis or conjunctivitis. One-day disposable lenses, which are worn only once and therefore require no disinfection or cleaning, are becoming increasingly popular.

*Acanthamoeba keratitis*, a painful and sight-threatening condition, is associated with ineffective lens cleaning and disinfection, the use of contaminated lens cases, or tap water coming into contact with the lenses. The condition is especially associated with the use of soft lenses (including frequently replaced lenses) and should be treated by specialists.

**Contact lenses and drug treatment**

Special care is required in prescribing eye preparations for contact lens users. Some drugs and preservatives in eye preparations can accumulate in hydrogel lenses and may induce toxic and adverse reactions. Therefore, unless medically indicated, the lenses should be removed before instillation of the eye preparation and not worn during the period of treatment. Alternatively, unpreserved drops can be used. Eye drops may, however, be instilled while patients are wearing rigid corneal contact lenses. Ointment preparations should never be used in conjunction with contact lenses; oily eye drops should also be avoided.

Many drugs given systemically can also have adverse effects on contact lens wear. These include oral contraceptives (particularly those with a higher oestrogen content), drugs which reduce blink rate (e.g. anxiolytics, hypnotics, antihistamines, and muscle relaxants), drugs which reduce lacrimation (e.g. antihistamines, antimuscarinics, phenothiazines and related drugs, some beta-blockers, diuretics, and tricyclic antidepressants), and drugs which increase lacrimation (including ephedrine hydrochloride and hydralazine hydrochloride). Other drugs that may affect contact lens wear are isotretinoin (can cause conjunctival inflammation), aspirin (salicylic acid appears in tears and can be absorbed by contact lenses—leading to irritation), and rifampicin and sulfasalazine (can discolor lenses).

## 1 Allergic and inflammatory eye conditions

### Eye, allergy and inflammation

**Corticosteroids**

Corticosteroids administered locally to the eye or given by mouth are effective for treating anterior segment inflammation, including that which results from surgery. *Topical corticosteroids* are applied frequently for the first 24–48 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:

- a ‘red eye’, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye.
- Bacterial, fungal, and amoebic infections pose a similar hazard;
- ‘steroid glaucoma’ can follow the use of corticosteroid eye preparations in susceptible individuals;
- a ‘steroid cataract’ can follow prolonged use.

Combination products containing a corticosteroid with an anti-infective drug are sometimes used after ocular surgery to reduce inflammation and prevent infection; use of combination products is otherwise rarely justified.

*Systemic corticosteroids* may be useful for ocular conditions. The risk of producing a ‘steroid cataract’ increases with the dose and duration of corticosteroid use.

**Intravitreal corticosteroids**

An intravitreal implant containing dexamethasone p. 947 *(Ozurdex®)* is licensed for the treatment of adults with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion; it is also licensed for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

An intravitreal implant containing fluocinolone acetonide p. 974 *(Iluvien®)* is licensed for the treatment of visual impairment associated with chronic diabetic macular oedema which is insufficiently responsive to available therapies. It should be administered by specialists experienced in the use of intravitreal injections.

**Other anti-inflammatory preparations**

Other preparations used for the topical treatment of inflammation and allergic conjunctivitis include antihistamines, lodoxamide p. 946, and sodium cromoglicate p. 946.

Eye drops containing antihistamines, such as *antazoline* (with xylometazoline hydrochloride p. 983 as *Otrivine- Antistin®*), azelastine hydrochloride p. 945, epinastine hydrochloride p. 945, ketotifen p. 945, and olopatadine p. 946, can be used for allergic conjunctivitis.

Sodium cromoglicate p. 946 (sodium cromoglycate) and nedocromil sodium p. 946 eye drops can be useful for vernal
Allergic conjunctivitis

1.1 Allergic conjunctivitis

ANTIHISTAMINES

Antazoline with xylometazoline

INDICATIONS AND DOSE

Allergic conjunctivitis

TO THE EYE

- Child 12-17 years: Apply 2–3 times a day for maximum 7 days
- Adult: Apply 2–3 times a day for maximum 7 days

SIDE-EFFECTS

- Common or very common: Transient stinging
- Frequency not known: Blurred vision, eye irritation, mydriasis

SIDE-EFFECTS, FURTHER INFORMATION

Absorption of antazoline and xylometazoline may result in the possibility of interaction with other drugs.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Eye drops

EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate

Otrivine Antistin (Spectrum Thea Pharmaceuticals Ltd)

Antazoline sulfate 5 mg per 1 ml, Xylometazoline hydrochloride 500 microgram per 1 ml

10 ml £2.35 DT price = £2.35

Epinastine hydrochloride

INDICATIONS AND DOSE

Seasonal allergic conjunctivitis

TO THE EYE

- Child 3-17 years: Apply twice daily
- Adult: Apply twice daily

SIDE-EFFECTS

- Common or very common: Burning
- Uncommon: Conjunctival hyperaemia, dry eye, eye pain, eye pruritus, headache, increased lacrimation, nasal irritation, rhinitis, taste disturbance, visual disturbance

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Eye drops

EXCIPIENTS: May contain Benzalkonium chloride

Otrivine Antistin (Spectrum Thea Pharmaceuticals Ltd)

Emadine (as Emadine difumarate) 500 microgram per 1 ml

5 ml £7.31 DT price = £7.31

Ketotifen

INDICATIONS AND DOSE

Seasonal allergic conjunctivitis

TO THE EYE

- Child 3-17 years: Apply twice daily
- Adult: Apply twice daily

INTERACTIONS

- Appendix 1 (antihistamines). Sedative antihistamine interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action.
### Nedocromil sodium

**INDICATIONS AND DOSE**

**Seasonal and perennial conjunctivitis**

TO THE EYE

- Child 6–17 years: Apply twice daily, increased if necessary to 4 times a day for maximum 12 weeks treatment for seasonal allergic conjunctivitis
- Adult: Apply twice daily, increased if necessary to 4 times a day for maximum 12 weeks treatment for seasonal allergic conjunctivitis

**Seasonal keratoconjunctivitis**

TO THE EYE

- Child 6–17 years: Apply 4 times a day
- Adult: Apply 4 times a day

#### SIDE-EFFECTS

Distinctive taste - transient burning - transient stinging

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- EXCEPTIENS: May contain Benzalkonium chloride
- **Zaditen** (Spectrum Thea Pharmaceuticals Ltd)
  - Ketotifen (as Ketotifen fumarate) 250 microgram per 1 ml
  - Zaditen 250 micrograms/ml eye drops | 5 ml [POT] £7.80 DT price = £7.80

---

### Sodium cromoglicate

(Sodium cromoglicate)

**INDICATIONS AND DOSE**

**Allergic conjunctivitis | Seasonal keratoconjunctivitis**

TO THE EYE

- Child: Apply 4 times a day
- Adult: Apply 4 times a day

#### SIDE-EFFECTS

Transitory burning - transient stinging

#### EXCEPTIONS TO LEGAL CATEGORY

Sodium cromoglicate 2% eye drops can be sold to the public (in max. pack size of 10 ml) for treatment of acute seasonal and perennial allergic conjunctivitis.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Eye drops**

- **SODIUM CROMOGLICATE (Non-proprietary)**
  - Sodium cromoglicate 20 mg per 1 ml Sodium cromoglicate 2% eye drops | 13.5 ml [POT] £6.30 DT price = £1.86
  - Lloyds pharmacy Allergy 2% eye drops | 10 ml [POT] no price available
  - Numark Allergy 2% eye drops | 10 ml [POT] £1.53
- **Catacrom** (Moorfields Pharmaceuticals)
  - Sodium cromoglicate 20 mg per 1 ml Catacrom 2% eye drops | 30 ml unit dose | 30 unit dose [POT] £8.99 DT price = £8.99
- **Cromolux** (Tubilux Pharma Ltd)
  - Sodium cromoglicate 20 mg per 1 ml Cromolux 2% eye drops | 13.5 ml [POT] £3.20 DT price = £1.86
- **Opticrom** (Sanofi)
  - Sodium cromoglicate 20 mg per 1 ml Opticrom Allergy 2% eye drops | 5 ml [POT] £2.74 | 10 ml [POT] £3.35
  - Opticrom Aqueous 2% eye drops | 13.5 ml [POT] £8.03 DT price = £1.86
- **Optrex Allergy** (Reckitt Benckiser Healthcare (UK) Ltd)
  - Sodium cromoglicate 20 mg per 1 ml Optrex Allergy 2% eye drops | 10 ml [POT] £3.38
- **Pollenase (sodium cromoglicate)** (Peach Ethical Ltd)
  - Sodium cromoglicate 20 mg per 1 ml Pollenase Allergy 2% eye drops | 10 ml [POT] £2.08
- **Vividrin** (Bausch & Lomb UK Ltd)
  - Sodium cromoglicate 20 mg per 1 ml Vividrin 2% eye drops | 13.5 ml [POT] £10.95 DT price = £1.86

---

### Lodoxamide

**INDICATIONS AND DOSE**

Allergic conjunctivitis

TO THE EYE

- Child 4–17 years: Apply 4 times a day, improvement of symptoms may sometimes require treatment for up to 4 weeks
- Adult: Apply 4 times a day, improvement of symptoms may sometimes require treatment for up to 4 weeks

#### SIDE-EFFECTS

- Common or very common: Blurred vision - burning - itching - ocular discomfort - stinging - tear production disturbance
- Uncommon: Blepharitis - dizziness - drowsiness - flushing - headache - keratitis - nasal dryness

#### EXCEPTIONS TO LEGAL CATEGORY

Lodoxamide 0.1% eye drops can be sold to the public for treatment of allergic conjunctivitis in adults and children over 4 years.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- EXCEPTIENS: May contain Benzalkonium chloride, disodium edetate
- **Alomide** (Alcon Laboratories (UK) Ltd)
  - Lodoxamide (as Lodoxamide trometamol) 1 mg per 1 ml Alomide 0.2% eye drops | 10 ml [POT] £5.21 DT price = £5.21
  - Alomide Allergy 0.1% eye drops | 5 ml [POT] £1.12
- **Optrex Allergy** (Reckitt Benckiser Healthcare (UK) Ltd)
  - Sodium cromoglicate 20 mg per 1 ml Optrex Allergy 2% eye drops | 10 ml [POT] £3.38
- **Pollenase (sodium cromoglicate)** (Peach Ethical Ltd)
  - Sodium cromoglicate 20 mg per 1 ml Pollenase Allergy 2% eye drops | 10 ml [POT] £2.08
- **Vividrin** (Bausch & Lomb UK Ltd)
  - Sodium cromoglicate 20 mg per 1 ml Vividrin 2% eye drops | 13.5 ml [POT] £10.95 DT price = £1.86
1.2 Inflammatory eye conditions

CORTICOSTEROIDS

Betamethasone

**INDICATIONS AND DOSE**
Local treatment of inflammation (short term)
TO THE EYE USING EYE DROP
▶ Child: Apply every 1–2 hours until controlled then reduce frequency
▶ Adult: Apply every 1–2 hours until controlled then reduce frequency
TO THE EYE USING EYE OINTMENT
▶ Child: Apply 2–4 times a day, alternatively apply at night when used in combination with eye drops
▶ Adult: Apply 2–4 times a day, alternatively apply at night when used in combination with eye drops

**SIDE-EFFECTS**
Adrenal suppression following prolonged use in neonates - corneal thinning - scleral thinning

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Ear/eye/nose drops solution**
**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
▶ Betamethasone sodium phosphate 1 mg per 1 ml
▶ Betnesol (Focus Pharmaceuticals Ltd)
▶ Betnesol-N (Focus Pharmaceuticals Ltd)
▶ Vistamethasone (Martindale Pharmaceuticals Ltd)

**Eye ointment**
▶ Betnesol (Focus Pharmaceuticals Ltd)
▶ Betnesol sodium phosphate 1 mg per 1 gram

**Betamethasone with neomycin**
The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 947.

**INDICATIONS AND DOSE**
Local treatment of eye inflammation and bacterial infection (short-term)
TO THE EYE USING EYE DROP
▶ Adult: Apply up to 6 times a day

**LESS SUITABLE FOR PRESCRIBING**
Betamethasone with neomycin eye-drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Ear/eye/nose drops solution**
**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
▶ Betnesol-N (Focus Pharmaceuticals Ltd)
▶ Betamethasone (as Betamethasone sodium phosphate) 1 mg per 1 ml
▶ Neomycin sulfate 5 mg per 1 ml
▶ Betnesol-N ear/eye/nose drops | 10 ml

Dexamethasone

**INDICATIONS AND DOSE**
Local treatment of inflammation (short term)
INITIALLY TO THE EYE USING EYE DROP
▶ Child: Apply 4–6 times a day
▶ Adult: Apply every 30–60 minutes until controlled, then (to the eye) reduced to 4–6 times a day

Short term local treatment of inflammation (severe conditions)
TO THE EYE USING EYE DROP
▶ Child: Apply every 30–60 minutes until controlled, reduce frequency when control achieved

Macular oedema following either branch retinal vein occlusion or central retinal vein occlusion (specialist use only)
Visual impairment due to diabetic macular oedema in adults who are pseudophoric, or who are insufficiently responsive to, or unsuitable for non-corticosteroid therapy (specialist use only)
For the treatment of inflammation of the posterior segment of the eye presenting as non-infectious uveitis (specialist use only)
BY INTRAVITREAL INJECTION
▶ Adult: 700 micrograms, to be administered into the affected eye, concurrent administration to both eyes not recommended. For further information on pre-treatment, administration and repeat dosing, consult product literature

**UNLICENSED USE**

**CONTRA-INDICATIONS**
With intravitreal use active ocular herpes simplex - active or suspected ocular infection - active or suspected periocular infection - rupture of the posterior lens capsule in patients with aphakia, iris or transscleral fixated intra-ocular lens or anterior chamber intra-ocular lens - uncontrolled advanced glaucoma

**CAUTIONS**
With intravitreal use history of ocular viral infection (including herpes simplex) - posterior capsule tear or iris defect (risk of implant migration into the anterior chamber which may cause corneal oedema and, in persistent severe cases, the need for corneal transplantation) - retinal vein occlusion with significant retinal ischaemia

**INTERACTIONS**
With intravitreal use Caution with concomitant administration of anticoagulant or antiplatelet drugs—increased risk of haemorrhagic events

**SIDE-EFFECTS**
With intravitreal use Eyelid pruritus - glaucoma - migraine - necrotising retinitis

**FREQUENCY NOT KNOWN**
When used by eye Adrenal suppression following prolonged use in neonates - corneal thinning - scleral thinning

**PREGNANCY**
With intravitreal use Manufacturer advises avoid unless potential benefit outweighs risk—no information available

**BREAST FEEDING**
With intravitreal use Manufacturer advises avoid unless potential benefit outweighs risk—no information available
Dexamethasone with framycetin sulfate and gramicidin

The properties listed below are those particular to the combination only. For the properties of the components please consider dexamethasone p. 947.

Dexamethasone with tobramycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 947, tobramycin p. 957.
Fluorometholone

**INDICATIONS AND DOSE**
Local treatment of inflammation (short term)

**TO THE EYE**
- Child 2–17 years: Apply every 1 hour for 24–48 hours, then reduced to 2–4 times a day
- Adult: Apply every 1 hour for 24–48 hours, then reduced to 2–4 times a day

**SIDE-EFFECTS**
Adrenal suppression following prolonged use in neonates - corneal thinning - scleral thinning

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate, polysorbates
- **FML Liquifilm** (Allergan Ltd)
  - Fluorometholone 1 mg per 1 ml FML Liquifilm 0.1% ophthalmic suspension | 5 ml (Pod) £1.71 DT price = £1.71 | 10 ml (Pod) £2.95 DT price = £2.95
  - Fluridol 10 mg per 1 ml FLUOROMETHOLONE 10 mg per 1 ml 10% eye drops | 5 ml (Pod) £2.00 DT price = £2.00

Prednisolone

**INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)

**TO THE EYE**
- Child: Apply every 1–2 hours until controlled then reduce frequency
- Adult: Apply every 1–2 hours until controlled then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**
Dexamethasone with tobramycin eye drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate, polysorbates
- **Tobradex** (Allergan Ltd)
  - Tobradex 2mg/ml / 1mg/ml eye drops | 5 ml (Pod) £11.78 DT price = £11.78
- **Pred Forte** (Allergan Ltd)
  - Pred Forte 1% eye drops | 5 ml (Pod) £1.82 DT price = £1.82 | 10 ml (Pod) £3.66 DT price = £3.66

**SIDE-EFFECTS**
Adrenal suppression following prolonged use in neonates - corneal thinning - scleral thinning

**UNLICENSED USE**
*Pred Forte*® not licensed for use in children (age range not specified by manufacturer).

**SIDE-EFFECTS**
Adrenal suppression following prolonged use in neonates - corneal thinning - scleral thinning

**PRESCRIBING AND DISPENSING INFORMATION**
Although multi-dose prednisolone eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Ear/eye drops solution**
**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
- **Predsol** (Focus Pharmaceuticals Ltd)
  - Predsol 0.5% ear/eye drops | 10 ml (Pod) £2.00 DT price = £2.00

**Antimuscarnicins**

**Antimuscarinic (eye)**

**CAUTIONS**
Darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage - mydriasis can precipitate acute angle-closure glaucoma (usually in those aged over 60 years and hypermetropic (long-sighted), who are predisposed to the condition because of a shallow anterior chamber)

**SIDE-EFFECTS**
Conjunctivitis (on prolonged administration) - contact dermatitis - eye oedema (on prolonged administration) - hyperaemia (on prolonged administration) - local irritation (on prolonged administration)
Dry eye conditions

**Atropine sulfate**

**INDICATIONS AND DOSE**

**Cycloplegia**  
TO THE EYE USING EYE DROP  
- Adult: (consult product literature)
- Child 12–17 years: Apply 1 drop 30–60 minutes before examination, using 0.5% eye drops
- Child 3 months–11 years: Apply 1 drop 30–60 minutes before examination, using 1% eye drops

**Uveitis**  
TO THE EYE  
- Child 3 months–11 years: Apply 1 drop 2–4 times a day, using 0.5% eye drops (1% for deeply pigmented eyes)
- Adult: (consult product literature)

**SIDE-EFFECTS, FURTHER INFORMATION**  
Systemic side-effects can occur, particularly in children and the elderly.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, eye ointment

- **Eye drops**  
  - ATMOPINE SULFATE (Non-proprietary)
  - Atropine sulfate 10 mg per 1 ml
  - Atropine sulfate 10 mg per 1 ml (Intrapharm Laboratories Ltd)

**Cyclopentolate hydrochloride**

**INDICATIONS AND DOSE**

**Cycloplegia**  
TO THE EYE USING EYE DROP  
- Adult: (consult product literature)
- Child 12–17 years: Apply 1 drop 30–60 minutes before examination, using 1% eye drops
- Child 3 months–11 years: Apply 1 drop 30–60 minutes before examination, using 0.5% eye drops

**Uveitis**  
TO THE EYE  
- Child 3 months–11 years: Apply 1 drop 2–4 times a day, using 0.5% eye drops (1% for deeply pigmented eyes)
- Adult: (consult product literature)

**SIDE-EFFECTS, FURTHER INFORMATION**  
Systemic side-effects can occur, particularly in children and the elderly.

**PRESCRIBING AND DISPENSING INFORMATION**  
Although multi-dose cyclopentolate eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Eye drops**  
  - May contain Benzalkonium chloride
  - CYCLOPENTOLATE HYDROCHLORIDE (Non-proprietary)
  - Cyclopentolate hydrochloride 5 mg per 1 ml
  - Cyclopentolate hydrochloride 10 mg per 1 ml
  - Mydrilate (Intrapharm Laboratories Ltd)
  - Cyclopentolate hydrochloride 5 mg per 1 ml Mydrilate 0.5% solution | 5 ml (Pip) £6.73 DT price = £6.73
  - Cyclopentolate hydrochloride 10 mg per 1 ml Mydrilate 1% solution | 5 ml (Pip) £6.73 DT price = £6.73

**Homatropine hydrobromide**

**INDICATIONS AND DOSE**

**Anterior uveitis**  
TO THE EYE  
- Adult: (consult product literature)

**SIDE-EFFECTS, FURTHER INFORMATION**  
Systemic side-effects can occur, particularly in children and the elderly.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**2 Dry eye conditions**

**Dry eye**

**Tear deficiency, ocular lubricants, and astringents**

Chronic soreness of the eyes associated with reduced or abnormal tear secretion (e.g. in Sjögren’s syndrome) often responds to tear replacement therapy or pilocarpine p. 988 given by mouth in adults. The severity of the condition and patient preference will often guide the choice of preparation.

Hyromellose p. 952 is the traditional choice of treatment for tear deficiency. It may need to be instilled frequently (e.g. hourly) for adequate relief. Ocular surface mucin is often abnormal in tear deficiency and the combination of hyromellose p. 952 with a mucolytic such as acetylcysteine below can be helpful.

The ability of carbomers to cling to the eye surface may help reduce frequency of application to 4 times daily.

Polyvinyl alcohol p. 952 increases the persistence of the tear film and is useful when the ocular surface mucin is reduced.

Sodium hyaluronate p. 953 eye drops are also used in the management of tear deficiency.

Sodium chloride p. 953 0.9% drops are sometimes useful in tear deficiency, and can be used as ‘comfort drops’ by contact lens wearers, and to facilitate lens removal. They are also used to irrigate the eye. Special presentations of sodium chloride p. 953 0.9% and other irrigation solutions are used routinely for intra-ocular surgery. Sodium chloride p. 953 5% eye drops are used for the short-term treatment of corneal oedema in adults.

Eye ointments containing a paraffin can be used to lubricate the eye surface, especially in cases of recurrent corneal epithelial erosion. They may cause temporary visual disturbance and are best suited for application before sleep. Ointments should not be used during contact lens wear.

**OCULAR LUBRICANTS**

**Acetylcysteine**

**INDICATIONS AND DOSE**

**Tear deficiency | Impaired or abnormal mucus production**  
TO THE EYE  
- Adult: Apply 3–4 times a day
**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Eye drops**

**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate

- **Ilube** (Moorfields Pharmaceuticals)
  - Acetylcysteine 50 mg per 1 ml | Ilube 5% eye drops | 10 ml [P32]
  - £14.93 DT price = £10.09

---

### Carbomers (Polyacrylic acid)

**INDICATIONS AND DOSE**

Dry eyes including keratoconjunctivitis sicca, unstable tear film

**TO THE EYE**

- **Child:** Apply 3–4 times a day or when required
- **Adult:** Apply 3–4 times a day or when required

**UNLICENSED USE** Some preparations not licensed for use in children.

**PRESCRIBING AND DISPENSING INFORMATION** Synthetic high molecular weight polymers of acrylic acid cross-linked with either allyl ethers of sucrose or allyl ethers of pentaerythritol.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **CARBOMERS (Non-proprietary)**
  - **Carbomer 980 2 mg per 1 gram** | EyeGel 0.2% eye gel | 10 gram £2.80 DT price = £2.80
  - **Carbomer 980 0.2% eye drops** | 10 gram [P] £2.80 DT price = £2.80
  - **Artelac Nighttime** (Bausch & Lomb UK Ltd)
    - **Carbomer 980 2 mg per 1 gram** | Artelac Nighttime 0.2% eye gel | 10 gram £2.96 DT price = £2.80
  - **Clinitas Carboram** (Alcon Ltd)
    - **Carbomer 980 2 mg per 1 gram** | Clinitas Carbomer 0.2% eye gel | 10 gram £1.49 DT price = £2.80
  - **GetTears** (Bausch & Lomb UK Ltd)
    - **Carbomer 980 2 mg per 1 gram** | GetTears 0.2% gel | 10 gram [P] £2.80 DT price = £2.80
  - **Lumecare Long Lasting** (Medicon Healthcare Ltd)
    - **Carbomer 980 2 mg per 1 gram** | Lumecare Carbomer 0.2% eye gel | 10 gram £1.51 DT price = £2.80
  - **Viscoatears** (Alcon Laboratories (UK) Ltd)
    - **Carbomer 980 2 mg per 1 gram** | Viscoatears 2mg/g liquid gel | 10 gram [P] £1.59 DT price = £2.80
  - **Viscoatears 2mg/g eye gel 0.6ml unit dose** | 30 unit dose [P] £5.42
  - **Xailin** (Nicox Pharma)
    - **Carbomer 980 2 mg per 1 gram** | Xailin 0.2% eye gel | 10 gram £3.25 DT price = £2.80

**Eye gel**

**EXCIPIENTS:** May contain Benzalkonium chloride, cetrimide, disodium edetate

- **Blephagel** (Spectrum Thea Pharmaceuticals Ltd)
  - **Carbomer 3.5 mg per 1 gram** | Blephagel 0.35% eye gel | 40 gram £6.66
  - **Carbomer 3.6 mg per 1 gram** | Blephagel 0.36% eye gel preservative free | 30 gram £7.53
  - **Liquivisc** (Spectrum Thea Pharmaceuticals Ltd)
    - **Carbomer 974XP 2.5 mg per 1 gram** | Liquivisc 0.25% eye gel | 10 gram [P] £4.50 DT price = £4.50

---

### Carmellose sodium

**INDICATIONS AND DOSE**

Dry eye conditions

**TO THE EYE**

- **Child:** Apply as required
- **Adult:** Apply as required

**UNLICENSED USE** Some preparations are contained units which are resealable and may be used for up to 12 hours.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **CARMELLOSE SODIUM (Non-proprietary)**
  - **Carmellose sodium 5 mg per 1 ml** | Carmellose 0.5% eye drops | 0.4ml unit dose preservative free | 30 unit dose [P] no price available
  - **DT price = £4.80** 30 unit dose £5.75 DT price = £4.80 90 unit dose [P] no price available
  - **PF Drops Carmellose 0.5% eye drops preservative free** | 10 ml [P] £7.49
  - **Lumecare Advance Carmellose 0.5% eye drops** | 10 ml £5.99
  - **Carmellose 0.5% eye drops** | 10 ml £7.49
  - **PF Drops Carmellose 3% eye drops preservative free** | 10 ml £7.49
  - **Carmellose 1% eye drops 0.4ml unit dose preservative free** | 30 unit dose [P] no price available DT price = £3.00 30 unit dose [P] no price available
  - **Carmelose (Martindale Pharmaceuticals Ltd)**
    - **Carmelose sodium 5 mg per 1 ml** | Melophthal 0.5% eye drops | 0.4ml unit dose | 30 unit dose £3.00 DT price = £3.00
    - **Melophthal 1% eye drops 0.4ml unit dose** | 30 unit dose £3.00 DT price = £3.00
    - **Melophthal 0.5% eye drops** | 10 ml £7.49
  - **Carmize** (Aspire Pharma Ltd)
    - **Carmelose sodium 5 mg per 1 ml** | Carmize 0.5% eye drops 0.4ml unit dose preservative free | 30 unit dose £3.00 DT price = £3.00 90 unit dose £15.53
  - **Carmize 1% eye drops** | 10 ml £8.49
  - **Carmize 2% eye drops 0.4ml unit dose preservative free** | 30 unit dose £3.00 DT price = £3.00 60 unit dose £6.00
  - **Carmize 0.5% eye drops** | 10 ml £7.49
  - **Cellusan** (Farmiga S.p.A.)
    - **Carmelose sodium 5 mg per 1 ml** | Cellusan Light 0.5% eye drops | 0.4ml unit dose preservative free | 30 unit dose £3.00 DT price = £3.00
    - **Cellusan 1% eye drops 0.4ml unit dose preservative free** | 30 unit dose £3.00 DT price = £3.00
  - **Celluvisc (Allergan Ltd)**
    - **Carmellose sodium 5 mg per 1 ml** | Celluvisc 0.5% eye drops 0.4ml unit dose | 30 unit dose [P] £4.80 DT price = £4.80 90 unit dose [P] £15.53
    - **Celluvisc 1% eye drops 0.4ml unit dose** | 30 unit dose £3.00 DT price = £3.00 60 unit dose £6.00
    - **Celluvisc 0.5% eye drops** | 10 ml £7.49
  - **Lumecare (Carmellose)** (Medicon Healthcare Ltd)
    - **Carmelose sodium 5 mg per 1 ml** | Lumecare Singles Carmellose 0.5% eye drops 0.4ml unit dose | 30 unit dose £4.60 DT price = £4.80

---

### Hyroxyethylcellulose

**INDICATIONS AND DOSE**

Tear deficiency

**TO THE EYE**

- **Child:** Apply as required
- **Adult:** Apply as required

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **HYDROXYETHYCELLULOSE (Non-proprietary)**
  - **Hydroxyethylcellulose 4.4 mg per 1 ml** | Minims artificial tears 0.44% eye drops 0.5ml unit dose | 20 unit dose [P] £8.97

---

### Hydroxypropyl guar with polyethylene glycol and propylene glycol

**INDICATIONS AND DOSE**

Dry eye conditions
Hypromellose

INDICATIONS AND DOSE

Tear deficiency

TO THE EYE

Child: Apply as required

Adult: Apply as required

PRESCRIBING AND DISPENSING INFORMATION The Royal Pharmaceutical Society has stated that where it is not possible to ascertain the strength of hypromellose prescribed, the prescriber should be contacted to clarify the strength intended. Although multi-dose hypromellose eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

EXCipients: May contain Benzalkonium chloride, disodium edetate

- HYDROMELLOSE (Non-proprietary)
  - Hypromellose 2.5 mg per 1 ml Hypromellose 0.25% eye drops preservative free | 10 ml £14.16
  - Hypromellose 3 mg per 1 ml Hypromellose 0.3% eye drops preservative free | 10 ml £5.75
  - PF Drops Hypromellose 0.3% eye drops preservative free | 10 ml £5.75
  - Hypromellose 0.3% eye drops | 10 ml £3.00 DT price = £1.17
  - Artelac (Bausch & Lomb UK Ltd)
    - Hypromellose 3.2 mg per 1 ml Artelac Single Dose Unit 0.32% eye drops 0.5ml unit dose | 30 unit dose £16.95 | 60 unit dose £32.85
    - Artelac 0.32% eye drops | 10 ml £4.99
  - Hydromooor (Moorfields Pharmaceutical)
    - Hydromoor 0.3% eye drops 0.4ml unit dose preservative free | 30 unit dose £5.75
  - Hypronol (Enogones Healthcare Ltd)
    - Hypromellose 3 mg per 1 ml Hypronol 0.3% eye drops preservative free | 10 ml £5.75
    - Hypronol 0.3% eye drops preservative free | 10 ml £4.14
  - Isopto Alkaline (Alcon Laboratories (UK) Ltd)
    - Hypromellose 10 mg per 1 ml Isopto Alkaline 1% eye drops | 10 ml £0.94 DT price = £0.94
  - Isopto Plain (Alcon Laboratories (UK) Ltd)
    - Hypromellose 5 mg per 1 ml Isopto Plain 0.5% eye drops | 10 ml £0.81 DT price = £0.81
    - Lumecare Tear Drops (Medicom Healthcare Ltd)
      - Hypromellose 3 mg per 1 ml Lumecare Hypromellose 0.3% eye drops | 10 ml £1.17
  - Mandanol (Hydroxypropyl methylcellulose) (M & A Pharmachem Ltd)
    - Hypromellose 3 mg per 1 ml Mandanol eye drops | 10 ml £1.33 DT price = £1.17
    - SoftDrops (Farmiga S.A.)
      - Hypromellose 3 mg per 1 ml SoftDrops 0.3% eye drops | 10 ml £1.67 DT price = £1.17
      - SoftDrops 0.3% eye drops 0.5ml unit dose preservative free | 30 unit dose £5.75
    - Tear-Lac (Scope Ophthalmics Ltd)
      - Hypromellose 3 mg per 1 ml Tear-Lac 0.3% eye drops preservative free | 10 ml £5.75
      - Xaillin Hydrate (Nicox Pharma)
        - Hypromellose 3 mg per 1 ml Xaillin Hydrate 0.3% eye drops preservative free | 10 ml £4.60

Hypromellose with dextran 70

The properties listed below are those particular to the combination only. For the properties of the components please consider, hypromellose above.

INDICATIONS AND DOSE

Tear deficiency

TO THE EYE

Child: Apply as required

Adult: Apply as required

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Eye drops

EXCipients: May contain Benzalkonium chloride, disodium edetate

- Tears Naturale (Alcon Laboratories (UK) Ltd)
  - Dextran 70 1 mg per 1 ml, Hypromellose 3 mg per 1 ml Tears Naturale eye drops | 15 ml £1.89
  - Tears Naturale eye drops 0.4ml unit dose | 28 unit dose £13.26

Polyvinyl alcohol

INDICATIONS AND DOSE

Tear deficiency

TO THE EYE

Child: Apply as required

Adult: Apply as required

PRESCRIBING AND DISPENSING INFORMATION Although multi-dose polyvinyl alcohol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

EXCipients: May contain Benzalkonium chloride, disodium edetate

- POLYVINYL ALCOHOL (Non-proprietary)
  - Polyvinyl alcohol 14 mg per 1 ml PVA 1.4% eye drops | 15 ml £1.63
  - Polyvinyl alcohol 1.4% eye drops 0.4ml unit dose preservative free | 30 unit dose £0 no price available
  - Polyvinyl alcohol 1.4% eye drops | 10 ml £0 no price available
  - Liquifilm Tears (Allergan Ltd)
    - Polyvinyl alcohol 14 mg per 1 ml Liquifilm Tears 1.4% eye drops | 15 ml £1.93
  - Liquifilm Tears 1.4% eye drops 0.4ml unit dose preservative free | 30 unit dose £3.35
  - Refresh Ophthalmic (Allergan Ltd)
    - Polyvinyl alcohol 14 mg per 1 ml Refresh Ophthalmic 1.4% eye drops 0.4ml unit dose | 30 unit dose £2.25
    - Sno Tears (Bausch & Lomb UK Ltd)
      - Polyvinyl alcohol 14 mg per 1 ml Sno Tears 1.4% eye drops | 10 ml £1.06

Retinol palmitate with white soft paraffin and light liquid paraffin and liquid paraffin and wool

INDICATIONS AND DOSE

Dry eye conditions

TO THE EYE

Adult: (consult product literature)

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.
Eye ointment

▶ Vita-POS (Scope Ophthalmics Ltd)
Vita-POS eye ointment preservative free | 5 gram £2.75

Sodium chloride

INDICATIONS AND DOSE
Irrigation, including first-aid removal of harmful substances
TO THE EYE
▶ Child: Apply as required
▶ Adult: Apply as required

TOURS OF OBSTRUCTION | Ocular lubricants and astringents | Irrigation of the eye | Intra-ocular or topical irritation during surgical procedures | Corneal oedema
TO THE EYE
▶ Child: Apply as required
▶ Adult: Apply as required

PRESCRIBING AND DISPENSING INFORMATION
Although multi-dose sodium chloride eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, eye ointment

Eye drops
▶ SODIUM CHLORIDE (Non-proprietary)
Sodium chloride 9 mg per 1 ml Minims saline 0.9% eye drops 0.35ml unit dose | 20 unit dose | £7.14 DT price = £7.14
Sodium chloride 50 mg per 1 ml PF Drops Sodium Chloride 5% eye drops preservative free | 10 ml £2.20 DT price = £2.20
Sodium chloride 5% eye drops | 10 ml £2.25
NaCl 5% eye drops 0.45ml unit dose preservative free | 20 unit dose £1.70
▶ Hypersal (Enogen Healthcare Ltd)
Sodium chloride 50 mg per 1 ml Hypersal 5% eye drops | 10 ml £2.25
▶ SYLCHLORIDE (Non-proprietary)
Sodium chloride 5% eye ointment preservative free | 5 gram £2.50

Sodium hyaluronate

INDICATIONS AND DOSE
Dry eye conditions
TO THE EYE
▶ Adult: Apply as required

PRESCRIBING AND DISPENSING INFORMATION
Some preparations are contained in units which are resealable and may be used for up to 12 hours. Although multi-dose sodium hyaluronate eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Eye drops
▶ Artelac Rebalance (Bausch & Lomb UK Ltd)
Artelac Rebalance 0.15% eye drops | 10 ml £4.00
▶ Artelac Splash (Bausch & Lomb UK Ltd)
Artelac Splash 0.2% eye drops 0.5ml unit dose | 30 unit dose £7.00 | 60 unit dose £11.20
▶ Blink Intensive (AMO UK Ltd)
Blink Intensive Tears 0.2% eye drops 0.4ml unit dose | 20 unit dose £2.97
Blink Intensive Tears 0.2% eye drops | 10 ml £2.97
▶ Clinitas (Altacor Ltd)
Clinitas Multi 0.4% eye drops preservative free | 10 ml £6.99
Clinitas 0.4% eye drops 0.5ml unit dose | 30 unit dose £5.70
▶ Hy-Opti (Alissa Healthcare Research Ltd)
Hy-Opti 0.2% eye drops preservative free | 10 ml £9.50
▶ Hyabak (Spectrum Thea Pharmaceuticals Ltd)
Hyabak UD 0.15% eye drops 0.4ml unit dose preservative free | 30 unit dose £4.99
Hyabak 0.15% eye drops | 10 ml £7.99
▶ Hycosan (Scope Ophthalmics Ltd)
Hycosan Extra 0.2% eye drops | 7.5 ml no price available
▶ HydraMed (Farmigia S.p.A.)
HydraMed 0.2% eye drops preservative free | 10 ml £10.00
HydraMed 0.2% eye drops 0.5ml unit dose preservative free | 30 unit dose £8.00
▶ HylO-Conod (Scope Ophthalmics Ltd)
HylO-Forte 0.2% eye drops preservative free | 10 ml £9.50
▶ Lubristil (Moorfields Pharmaceuticals)
Lubristil 0.15% eye drops 0.3ml unit dose preservative free | 20 unit dose £4.99
▶ Ocusan (Agepha Pharma s.r.o.)
Ocusan 0.2% eye drops 0.5ml unit dose | 20 unit dose £5.31
▶ Optive Fusion (Allergan Ltd)
Optive Fusion 0.1% eye drops | 10 ml £7.49
▶ Oxyal (Bausch & Lomb UK Ltd)
Oxyal 0.15% eye drops | 10 ml £4.15
▶ Rohto Dry Eye Relief (The Menolatomun Company Ltd)
Rohto Dry Eye Relief 0.2% eye drops 0.5ml unit dose | 20 unit dose £4.75
Rohto Dry Eye Relief 0.2% eye drops | 10 ml £4.10
▶ Vismed (TRB Chemidica (UK) Ltd)
Vismed Multi 0.18% eye drops preservative free | 10 ml £6.81
▶ Xailin HA (Bausch & Lomb UK Ltd)
Xailin HA | 10 ml £7.13

Eye gel
▶ Rubristil (Moorfields Pharmaceuticals)
Rubristil 0.15% eye gel 0.4ml unit dose preservative free | 20 unit dose £6.49
▶ Vismed (TRB Chemidica (UK) Ltd)
Vismed 0.3% eye gel 0.45ml unit dose preservative free | 20 unit dose £5.98

Soybean oil

INDICATIONS AND DOSE
Dry eye conditions
TO THE EYE
▶ Child: Apply up to 4 times a day
▶ Adult: Apply up to 4 times a day

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Eye drops
▶ Emustil (Moorfields Pharmaceuticals)
Emustil eye drops 0.3ml unit dose preservative free | 20 unit dose £6.22

PARAFFINS

Liquid paraffin with white soft paraffin and wool alcohols

INDICATIONS AND DOSE
Dry eye conditions
TO THE EYE
▶ Child: Apply as required, best suited for application before sleep
▶ Adult: Apply as required, best suited for application before sleep

PATIENT AND CARER ADVICE
May cause temporary visual disturbance. Should not be used during contact lens wear.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Eye infections

Most acute superficial eye infections can be treated topically. Bacterial conjunctivitis is often caused by staphylococci; keratitis and endophthalmitis may be bacterial, viral, or fungal. Bacterial blepharitis is treated by application of an antibacterial eye ointment to the conjunctival sac or to the lid margins. Systemic treatment may occasionally be required and is usually undertaken after culturing organisms from the lid margin and determining their antimicrobial sensitivity; antibiotics such as the tetracyclines given for 3 months or longer may be appropriate. Most cases of acute bacterial conjunctivitis are self-limiting; where treatment is appropriate, antibacterial eye drops or an eye ointment are used. A poor response might indicate viral or allergic conjunctivitis. Corneal ulcer and keratitis require specialist treatment and may call for hospital admission for intensive therapy. Endophthalmitis is a medical emergency which also calls for specialist management and requires intravitreal administration of antimicrobials; concomitant systemic treatment is required in some cases. Surgical intervention, such as vitrectomy, is sometimes indicated.

Antibacterials
Bacterial eye infections are generally treated topically with eye drops and eye ointments. Systemic administration is sometimes appropriate in blepharitis. Chloramphenicol p. 955 has a broad spectrum of activity and is the drug of choice for superficial eye infections. Chloramphenicol eye drops are well tolerated and the recommendation that chloramphenicol eye drops should be avoided because of an increased risk of aplastic anaemia is not well founded. Other antibacterials with a broad spectrum of activity include the quinolones, ciprofloxacin p. 956, levofloxacin p. 956, moxifloxacin p. 957, and ofloxacin p. 957; the aminoglycosides, gentamicin p. 956 and tobramycin p. 957 are also active against a wide variety of bacteria.

Gentamicin, tobramycin, quinolones (except moxifloxacin), and polymyxin B are effective for infections caused by Pseudomonas aeruginosa.

Ciprofloxacin eye drops are licensed for corneal ulcers; intensive application (especially in the first 2 days) is required throughout the day and night. Azithromycin p. 955 eye drops are licensed for trachomatous conjunctivitis caused by Chlamydia trachomatis and for purulent bacterial conjunctivitis. Trachoma which results from chronic infection with Chlamydia trachomatis can be treated with azithromycin by mouth [unlicensed indication]. Fusidic acid is useful for staphylococcal infections. Propamidine isetionate p. 957 is of little value in bacterial infections but is used by specialists to treat the rare, but potentially sight-threatening, condition of acanthamoeba keratitis [unlicensed indication].

With corticosteroids
Many antibacterial preparations also incorporate a corticosteroid but such mixtures should not be used unless a patient is under close specialist supervision. In particular they should not be prescribed for undiagnosed ‘red eye’ which is sometimes caused by the herpes simplex virus and may be difficult to diagnose.

Administration
Frequency of application depends on the severity of the infection and the potential for irreversible ocular damage; antibacterial eye preparations are usually administered as follows:

- **Eye drops**, apply 1 drop at least every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing.
- **Eye ointment**, apply either at night (if eye drops used during the day) or 3–4 times daily (if eye ointment used alone).

Antifungals
Fungal infections of the cornea are rare but can occur after agricultural injuries, especially in hot and humid climates. Orbital mycosis is rarer, and when it occurs it is usually because of direct spread of infection from the paranasal sinuses. Increasing age, debility, or immunosuppression can encourage fungal proliferation. The spread of infection through blood occasionally produces metastatic endophthalmitis. Many different fungi are capable of producing ocular infection; they can be identified by appropriate laboratory procedures.

Antifungal preparations for the eye are not generally available. Treatment will normally be carried out at specialist centres, but requests for information about supplies of preparations not available commercially should be addressed to the Strategic Health Authority (or equivalent), or to the nearest hospital ophthalmology unit, or to Moorfields Eye Hospital, 162 City Road, London EC1V 2PD (tel. (020) 7253 3411) or www.moorfields.nhs.uk.

**Antivirals**

Herpes simplex infections producing, for example, dendritic corneal ulcers can be treated with aciclovir p. 958 or ganciclovir p. 958. Aciclovir p. 958 eye ointment is used in combination with systemic treatment for ophthalmic zoster. Slow-release ocular implants containing ganciclovir p. 958 (available on a named-patient basis from specialist importing companies) may be inserted surgically to treat immediate sight-threatening CMV retinitis. Local treatments do not protect against systemic infection or infection in the other eye. See systemic treatment of CMV retinitis.
3.1 Bacterial eye infection

**Azithromycin**

**INDICATIONS AND DOSE**
Trachomatous conjunctivitis caused by *Chlamydia trachomatis* | Purulent bacterial conjunctivitis

**TO THE EYE**
- Child: Apply daily, to be applied at night (if eye drops used during the day), alternatively apply 3–4 times a day, if ointment used alone
- Adult: Apply daily, to be applied at night (if eye drops used during the day), alternatively apply 3–4 times a day, if ointment used alone

**SIDE-EFFECTS**
- Common or very common: Blurred vision, ocular burning, ocular discomfort, ocular pruritus
- Uncommon: Conjunctival hyperaemia, eyelid eczema, eyelid erythema, eyelid oedema, keratitis

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **Azyter** (Spectrum Thea Pharmaceuticals Ltd)
  - Azithromycin dihydrate 15 mg per 1 gram
  - Azyter 15mg/g eye drops 0.25g unit dose | 6 unit dose (P) $6.99 DT price = $6.99

**Cefuroxime**

**INDICATIONS AND DOSE**
APROKAM® INTRACAMERAL INJECTION
Prophylaxis of endophthalmitis after cataract surgery

**BY INTRACAMERAL INJECTION**
- Adult: 1 mg, dose to be injected into the anterior chamber of the eye at the end of cataract surgery

**CAUTIONS**
- APROKAM® INTRACAMERAL INJECTION
  - Combined operations with cataract surgery - complicated cataracts - reduced corneal endothelial cells (less than 2000) - severe risk of infection - severe thyroid disease
- PREGNANCY: Not known to be harmful.
- BREAST FEEDING: Present in milk in low concentration, but appropriate to use.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- **Aprokan** (Spectrum Thea Pharmaceuticals Ltd)
  - Cefuroxime (as Cefuroxime sodium) 50 mg Aprokan 50mg powder for solution for injection vials | 10 vial (P) $79.50

**Chloramphenicol**

**DRUG ACTION**
Chloramphenicol is a potent broad-spectrum antibiotic.

**INDICATIONS AND DOSE**
Superficial eye infections

**TO THE EYE USING EYE DROP**
- Child: Apply 1 drop every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing, frequency dependent on the severity of the infection. For less severe infection 3–4 times daily is generally sufficient
- Adult: Apply 1 drop every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing, frequency dependent on the severity of the infection. For less severe infection 3–4 times daily is generally sufficient

**UNLICENSED USE**
Oral azithromycin not licensed for trachoma which results from chronic infection with *Chlamydia trachomatis*.

**SIDE-EFFECTS**
- Transient stinging

**PREGNANCY**
Avoid unless essential—no information on topical use but risk of ‘neonatal grey-baby syndrome’ with oral use in third trimester.

**BREAST FEEDING**
Avoid unless essential—theoretical risk of bone-marrow toxicity.

**PRESCRIBING AND DISPENSING INFORMATION**
Although multi-dose chloramphenicol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**EXCEPTIONS TO LEGAL CATEGORY**
Chloramphenicol 0.5% eye drops (in max. pack size 10 mL) and 1% eye ointment (in max. pack size 4 g) can be sold to the public for treatment of acute bacterial conjunctivitis in adults and children over 2 years; max. duration of treatment 5 days.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
EXCIPIENTS: May contain Phenylmercuric acetate
- **CHLORAMPHENICOL (Non-proprietary)**
  - Chloramphenicol 5 mg per 1 mL Chloramphenicol Antibiotic 0.5% eye drops | 10 mL (P) $1.70 DT price = $1.50
  - Golden Eye Antibiotic 0.5% eye drops | 10 mL (P) $3.26 DT price = $1.50
  - Minims chloramphenicol 0.5% eye drops 0.5ml unit dose | 20 unit dose (P) $10.99 DT price = $10.99
  - Chloramphenicol 0.5% eye drops | 10 mL (P) $2.68 DT price = $1.50
  - Tubilux Infected Eyes 0.5% eye drops | 10 mL (P) $2.75 DT price = $1.50
  - **Brochlor** (Sanofi)
    - Chloramphenicol 5 mg per 1 mL Brochlor 0.5% eye drops | 10 mL (P) $2.83 DT price = $1.50
    - Chloramphenicol (AMCo)
    - Chloramphenicol 5 mg per 1 mL Chloramphenicol Reddrops 0.5% | 5 mL (P) $1.65 | 10 mL (P) $0.90 DT price = $1.50
    - **Optrex Infected Eyes** (Reckitt Benckiser Healthcare (UK) Ltd)
      - Chloramphenicol 5 mg per 1 mL Optrex Infected Eyes 0.5% eye drops | 10 mL (P) $3.75 DT price = $1.50

**Eye ointment**
- **CHLORAMPHENICOL (Non-proprietary)**
  - Chloramphenicol 10 mg per 1 gram Chloramphenicol 1% eye ointment | 4 gram (P) $4.26 DT price = $1.95
  - Golden Eye Antibiotic 1% eye ointment | 4 gram (P) $3.49 DT price = $1.95
  - **Brochlor** (Sanofi)
    - Chloramphenicol 10 mg per 1 gram Brochlor 1% eye ointment | 4 gram (P) $2.95 DT price = $1.95
    - Chloramphenicol (AMCo)
    - Chloramphenicol 10 mg per 1 gram Chloramphenicol 1% eye ointment | 4 gram (P) $1.68 DT price = $1.95
    - **Optrex Infected Eyes** (Reckitt Benckiser Healthcare (UK) Ltd)
      - Chloramphenicol 10 mg per 1 gram Optrex Infected Eyes 1% eye ointment | 4 gram (P) $3.88 DT price = $1.95
Ciprofloxacin

INDICATIONS AND DOSE

Superficial bacterial eye infection

TO THE EYE USING EYE DROP
- Child: Apply 4 times a day for maximum duration of treatment 21 days
- Adult: Apply 4 times a day for maximum duration of treatment 21 days

TO THE EYE USING EYE OINTMENT
- Child 1-17 years: Apply 1.25 centimetres 3 times a day for 2 days, then apply 1.25 centimetres twice daily for 5 days
- Adult: Apply 1.25 centimetres 3 times a day for 2 days, then apply 1.25 centimetres twice daily for 5 days

Superficial bacterial eye infection (severe infection)

TO THE EYE USING EYE DROP
- Child: Apply every 2 hours during waking hours for 2 days, then apply 4 times a day for maximum duration of treatment 21 days
- Adult: Apply every 2 hours during waking hours for 2 days, then apply 4 times a day for maximum duration of treatment 21 days

Corneal ulcer

TO THE EYE USING EYE DROP
- Child: Apply every 15 minutes for 6 hours, then apply every 30 minutes for the remainder of day 1, then apply every 1 hour on day 2, then apply every 4 hours on days 3–14, maximum duration of treatment 21 days, to be administered throughout the day and night
- Adult: Apply every 15 minutes for 6 hours, then apply every 30 minutes for the remainder of day 1, then apply every 1 hour on day 2, then apply every 4 hours on days 3–14, maximum duration of treatment 21 days, to be administered throughout the day and night
- Child 1-17 years: Apply 1.25 centimetres every 1–2 hours for 2 days, then apply 1.25 centimetres every 4 hours for the next 12 days, to be administered throughout the day and night
- Adult: Apply 1.25 centimetres every 1–2 hours for 2 days, then apply 1.25 centimetres every 4 hours for the next 12 days, to be administered throughout the day and night.

UNLICENSED USE
Eye ointment not licensed for use in children under 1 year.

SIDE-EFFECTS
- Common or very common: Corneal deposits (reversible after completion of treatment) - ocular discomfort - ocular hyperaemia - taste disturbance
- Rare: Abdominal pain - asthenopia - corneal disorders - corneal epithelium defect - dermatitis - diarrhoea - diplopia - dizziness - ear pain - eye hypoaesthesia - keratitis - paranasal sinus hypersecretion - rhinitis
- PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING
Manufacturer advises caution.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

Eye drops
EXCIPIENTS: May contain Benzalkonium chloride
- Ciloxan (Alcon Laboratories (UK) Ltd) Ciprofloxacin (as Ciprofloxacin hydrochloride) 3 mg per 1 ml Ciloxan 0.3% eye drops 5 ml POM £4.70 OT price = £4.70

Eye ointment
- Ciloxan (Alcon Laboratories (UK) Ltd) Ciprofloxacin (as Ciprofloxacin hydrochloride) 3 mg per 1 gram Ciloxan 3 mg/g eye ointment 3.5 gram POM £3.22

Fusidic acid
- DRUG ACTION Fusidic acid and its salts are narrow-spectrum antibiotics used for staphylococcal infections.

INDICATIONS AND DOSE

Staphylococcal eye infections

TO THE EYE
- Child: Apply twice daily
- Adult: Apply twice daily

 MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Medicines not identified.

Gentamicin

INDICATIONS AND DOSE

Bacterial eye infections

TO THE EYE
- Child: Apply 1 drop every 2 hours, reduce frequency as infection is controlled and continue for 48 hours after healing, frequency of eye drops depends on the severity of the infection and the potential for irreversible ocular damage; for less severe infection 3–4 times daily is generally sufficient
- Adult: Apply 1 drop every 2 hours, reduce frequency as infection is controlled and continue for 48 hours after healing, frequency of eye drops depends on the severity of the infection and the potential for irreversible ocular damage; for less severe infection 3–4 times daily is generally sufficient

 MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

Ear/eye drops solution
EXCIPIENTS: May contain Benzalkonium chloride
- GENTAMICIN (Non-proprietary) Gentamicin (as Gentamicin sulphate) 3 mg per 1 ml Gentamicin 0.3% ear/eye drops 10 ml POM £2.13 OT price = £2.13
- Gentamicin 0.3% eye/ear drops 10 ml POM £2.13 OT price = £2.13
- Gentamicin (AMCO) Gentamicin (as Gentamicin sulphate) 3 mg per 1 ml Gentamicin 0.3% eye/ear drops 10 ml POM £2.12 OT price = £2.12

Levofloxacin

INDICATIONS AND DOSE

Local treatment of eye infections

TO THE EYE
- Child 1-17 years: Apply every 2 hours for first 2 days, to be applied maximum 8 times a day, then apply 4 times a day for 3 days
- Adult: Apply every 2 hours for first 2 days, to be applied maximum 8 times a day, then apply 4 times a day for 3 days
**Moxifloxacin**

**INDICATIONS AND DOSE**
Local treatment of infections

**TO THE EYE**
- Child: Apply 3 times a day for 2–3 days after infection improves; review if no improvement within 5 days
- Adult: Apply 3 times a day for 2–3 days after infection improves; review if no improvement within 5 days

**CAUTIONS**
- Not recommended for neonates

**SIDE-EFFECTS**
- **Common or very common**
  - Hyperaemia - ocular discomfort - ocular dryness - ocular irritation - ocular pain - taste disturbances

- **Uncommon**
  - Conjunctival haemorrhage - corneal disorders - corneal erosion - corneal keratitis - corneal staining - eyelid erythema - headache - nasal discomfort - paraesthesia - pharyngolaryngeal pain - visual disturbances - vomiting

- **Frequency not known**
  - Dizziness - dyspnoea - nausea - palpitation - photophobia - pruritus - raised intra-ocular pressure - rash

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride
- Ofloxacin (Santen)
  - Levofloxacin (as Levofloxacin hemihydrate) 5 mg per 1 ml Ofloxacin 5mg/ml eye drops 0.5ml unit dose | 30 unit dose | £17.95
  - Ofloxacin 5mg/ml eye drops | 5 ml | £6.95

---

**Propamidine isetionate**

**INDICATIONS AND DOSE**
**Acanthamoeba keratitis infections (specialist use only)**
Local treatment of eye infections

**TO THE EYE USING EYE OINTMENT**
- Adult: Apply 1–2 times a day

**CAUTIONS**
- Not licensed for *acanthamoeba keratitis* infections.

**SIDE-EFFECTS**
- Eye irritation - eye pain

**PRENANCY**
- Manufacturer advises avoid unless essential—no information available.

**BREAST FEEDING**
- Manufacturer advises avoid unless essential—no information available.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride
- **PROPAMIDINE ISETIONATE (Non-proprietary)**
  - Propamidine isetionate 1 mg per 1 ml Golden Eye 0.1% drops | 10 ml | £3.26
  - Brolene (Propamidine) (Sanofi)
    - Propamidine isetionate 1 mg per 1 ml Brolene 0.1% eye drops | 10 ml | £2.80

**Eye ointment**
- **PROPAMIDINE ISETIONATE (Non-proprietary)**
  - Dibrompropamidine isetionate 1.5 mg per 1 gram Golden Eye 0.15% ointment | 5 gram | £3.49 DT price = £3.49
  - Brolene (Dibrompropamidine) (Sanofi)
    - Dibrompropamidine isetionate 1.5 mg per 1 gram Brolene 0.15% eye ointment | 5 gram | £2.92 DT price = £3.49

---

**Ofloxacin**

**INDICATIONS AND DOSE**
Local treatment of infections

**TO THE EYE**
- Child 1–17 years: Apply every 2–4 hours for the first 2 days, then reduced to 4 times a day for maximum 10 days treatment
- Adult: Apply every 2–4 hours for the first 2 days, then reduced to 4 times a day for maximum 10 days treatment

**CAUTIONS**
- Corneal ulcer (risk of corneal perforation) - epithelial defect (risk of corneal perforation)

**SIDE-EFFECTS**
- **Common or very common**
  - Eye irritation - ocular discomfort

- **Frequency not known**
  - Dry eyes - facial oedema - increased lacrimation - keratitis - ocular hyperaemia - ocular oedema - photophobia - visual disturbances

**PRENANCY**
- Manufacturer advises use only if benefit outweighs risk (systemic quinolones have caused arthropathy in animal studies).

**BREAST FEEDING**
- Manufacturer advises avoid.

**MEDICATIONS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride
- Exocin (Allergan Ltd)
  - Ofloxacin 3 mg per 1 ml Exocin 0.3% eye drops | 5 ml | £2.17
  - DT price = £2.17

---

**Tobramycin**

**INDICATIONS AND DOSE**
Local treatment of infections

**TO THE EYE**
- Child 1–17 years: Apply twice daily for 6–8 days
- Adult: Apply twice daily for 6–8 days

**Local treatment of infections (severe infection)**

**TO THE EYE**
- Child 1–17 years: Apply 4 times a day for first day, then apply twice daily for 5–7 days
- Adult: Apply 4 times a day for first day, then apply twice daily for 5–7 days
3.2 Herpes simplex infection

Aciclovir (Acyclovir)

**INDICATIONS AND DOSE**

Herpes simplex infection (local treatment) TO THE EYE USING EYE OINTMENT
- Child: Apply 1 centimetre 5 times a day continue for at least 3 days after complete healing
- Adult: Apply 1 centimetre 5 times a day continue for at least 3 days after complete healing

**SIDE-EFFECTS**
- Common or very common Local inflammation - local irritation - superficial punctate keratopathy
- Rare Blepharitis
- Very rare Angioedema - hypersensitivity reactions

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Aciclovir eye ointment for herpes simplex infections www.medicinesforchildren.org.uk/aciclovir-eye-ointment-for-herpes-simplex-infection

**MEDICINAL FORMS**
- Zovirax (GlaxoSmithKline UK Ltd)
  - Aciclovir 30 mg per 1 gram Zovirax 3% ophthalmic ointment | 4.5 gram BD price = £9.34

Ganciclovir

**INDICATIONS AND DOSE**

Local treatment of herpes simplex infections TO THE EYE
- Adult: Apply 5 times a day until healing complete, then apply 3 times a day for a further 7 days

**SIDE-EFFECTS**
- Burning sensation - superficial punctate keratitis - tingling

**ALLERGY AND CROSS-SENSITIVITY**
- Contra-indicated in patients hypersensitive to valganciclovir, aciclovir, or valaciclovir.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- Tropicamide 5 mg per 1 ml Tropicamide 5% eye drops | 0.5ml unit dose | 20 unit dose BD price = £10.75
- Tropicamide 10 mg per 1 ml Tropicamide 1% eye drops | 0.5ml unit dose | 20 unit dose BD price = £10.77
- Mydriacyl (Alcon Laboratories (UK) Ltd)
- Tropicamide 5 mg per 1 ml Mydriacyl 0.5% eye drops | 5 ml BD price = £1.29
- Tropicamide 10 mg per 1 ml Mydriacyl 1% eye drops | 5 ml BD price = £1.60

**PRESCRIBING AND DISPENSING INFORMATION**
- Although multi-dose tropicamide eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- Ganciclovir 1.5 mg per 1 gram Ganciclovir 0.15% eye gel | 5 gram BD price = £19.99

4 Eye procedures

**Mydriatics and cycloplegics**

Antimuscarinics dilate the pupil and paralyse the ciliary muscle; they vary in potency and duration of action.

Short-acting, relatively weak mydriatics, such as tropicamide below 0.5% (action lasts for 4–6 hours), facilitate the examination of the fundus of the eye. Longer-acting options include cyclopentolate hydrochloride p. 950 1% (action up to 24 hours) or atropine sulfate p. 950 (action up to 7 days).

Phenylephrine hydrochloride p. 959 is used for mydriasis in diagnostic or therapeutic procedures; mydriasis occurs within 60–90 minutes and lasts up to 5–7 hours.

Mydriatics and cycloplegics are used in the treatment of anterior uveitis, usually as an adjunct to corticosteroids. Atropine sulfate p. 950 is used in anterior uveitis mainly to prevent posterior synechiae and to relieve ciliary spasm; cyclopentolate hydrochloride p. 950 or homatropine hydrobromide p. 950 (action up to 3 days) can also be used and may be preferred because they have a shorter duration of action.

**Drugs used for Eye procedures not listed below; Fluorescein with lidocaine, p. 960**

**ANTIMUSCARINICS**

**Tropicamide**

The properties listed below are those particular to the drug only. For the properties common to the class, see Antimuscarinics (eye) p. 949.

**INDICATIONS AND DOSE**

Funduscropy TO THE EYE
- Child: 0.5% eye drops to be applied 20 minutes before examination
- Adult: (consult product literature)

**Phenylephrine with tropicamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, phenylephrine hydrochloride p. 959, tropicamide above.
**INDICATIONS AND DOSE**

Pre-operative mydriasis | Diagnostic procedures when monotherapy insufficient

**TO THE EYE**

- **Adult:** One insert to be applied into the lower conjunctival sac up to max. 2 hours before procedure; remove insert within 30 minutes of satisfactory mydriasis, and within 2 hours of application

**DIRECTIONS FOR ADMINISTRATION**

Patients with severe dry eyes may require a drop of saline to improve insert tolerance.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Ophthalmic insert**

  - **Mydriaser (Spectrum Thea Pharmaceuticals Ltd)**
  - Phenylephrine hydrochloride 5.4 mg, Tropicamide 0.28 mg
  - Mydriaser 5.4mg / 0.28mg ophthalmic inserts | 20 insert | £84.00

**SIDE-EFFECTS**

- Bradycardia
- Hypertension
- Extrasystoles
- Palpitation
- Photophobia
- Raised intraocular pressure
- Arterial oedema on prolonged administration
- Local irritation on prolonged administration
- Conjunctivitis
- Transient stinging
- Hypersensitivity
- Local reactions
- Phototoxicity

**CAUTIONS**

- Asthma
- Gastro-intestinal spasm
- Heart failure
- Hyperthyroidism
- Parkinsonism
- Peptic ulcer
- Urinary tract obstruction
- Mydriasis can precipitate acute angle-closure glaucoma in a few patients, usually 60 years and hypermetropic (long-sighted) or pre-disposed to the condition because of a shallow anterior chamber.

**INTERACTIONS**

Use only if potential benefit outweighs risk.

**PREGNANCY**

Use only if potential benefit outweighs risk.

**BREAST FEEDING**

Use only if potential benefit outweighs risk—no information available.

**PRESERVING AND DISPENSING INFORMATION**

Although multi-dose phenylephrine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**PATIENT AND CARER ADVICE**

Patients should be warned not to undertake skilled tasks (e.g. driving) until vision clears after mydriasis.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Excipients:** May contain Disodium edetate, Sodium metabisulfite

- **Phenylephrine hydrochloride (Non-proprietary)**
  - Phenylephrine hydrochloride 25 mg per 1 ml | 10 minutes phenylephrine hydrochloride 2.5% eye drops 0.5% unit dose | 20 unit dose | £11.41
  - Phenylephrine hydrochloride 100 mg per 1 ml | 10 minutes phenylephrine hydrochloride 10% eye drops 0.5% unit dose | 20 unit dose | £11.41

**DIAGNOSTIC DYES**

**Fluorescein sodium**

**INDICATIONS AND DOSE**

Detection of lesions and foreign bodies TO THE EYE USING EYE DROP

- **Adult:** Use sufficient amount to stain damaged areas

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Eye drops**

  - FLUORESCEIN SODIUM (Non-proprietary)
    - Fluorescein sodium 10 mg per 1 ml | Minims fluorescein sodium 1% eye drops 0.5ml unit dose | 20 unit dose | £8.89
    - Fluorescein sodium 20 mg per 1 ml | Minims fluorescein sodium 2% eye drops 0.5ml unit dose | 20 unit dose | £18.89

**SIDE-EFFECTS**

- Photophobia
- Raised intraocular pressure
- Conjunctivitis
- Transient stinging

**CAUTIONS**

- Asthma
- Cerebral arteriosclerosis (in adults)
- Corneal epithelial damage
- Darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage.
- Diabetes (avoid eye drops in long standing diabetes)
- Mydriasis can precipitate acute angle-closure glaucoma in a few patients, usually over 60 years and hypermetropic (long-sighted) or pre-disposed to the condition because of a shallow anterior chamber.

**INTERACTIONS**

Use only if potential benefit outweighs risk.

**PREGNANCY**

Avoid unless potential benefit outweighs risk—no information available.

**BREAST FEEDING**

Avoid unless potential benefit outweighs risk—no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Irrigation**

  - Miochol-E (Bausch & Lomb UK Ltd)
  - Acetylcholine chloride 20 mg | Miochol-E 20mg powder and solvent for solution for intracocular irrigation vials | 1 vial (vials) | £7.28
  - Miphell (Alan Pharmaceuticals)
  - Acetylcholine chloride 20 mg | Miphell 20mg powder and solvent for solution for intracocular irrigation ampoules | 6 ampoule (ampoule) | £6.55 (Hospital only)

**SYMPATHOMIMETICS (VASOCONSTRICTOR)**

**Phenylephrine hydrochloride**

**INDICATIONS AND DOSE**

Mydriasis TO THE EYE

- **Adult:** Apply 1 drop, to be administered before procedure, a drop of proxymetacaine topical anaesthetic may be applied to the eye a few minutes before using phenylephrine to prevent stinging
- **Adult:** Apply 1 drop, to be administered before procedure, then apply 1 drop after 60 minutes if required, a drop of topical anaesthetic may be applied to the eye a few minutes before using phenylephrine to prevent stinging

**CONTRA-INDICATIONS**

Hypertension · 10% strength eye drops in neonates, children and the elderly · Aneurysms · Cardiovascular disease · Thyrotoxicosis

**CAUTIONS**

- Asthma · Cerebral arteriosclerosis (in adults) · Corneal epithelial damage · Darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage · Diabetes (avoid eye drops in long standing diabetes) · Mydriasis can precipitate acute angle-closure glaucoma in a few patients, usually over 60 years and hypermetropic (long-sighted) or pre-disposed to the condition because of a shallow anterior chamber · Mydriasis can precipitate acute angle-closure glaucoma in the very few children who are predisposed to the condition because of a shallow anterior chamber · Ocular hyperaemia · Susceptibility to angle-closure glaucoma

**INTERACTIONS**

Appendix 1 (sympathomimetics).

Phenylephrine may interact with systemically administered monoamine-oxidase inhibitors.

**SIDE-EFFECTS**

Arrhythmias · Blurred vision · Conjunctivitis on prolonged administration · Coronary artery spasm · Extrasystoles · Hyperaemia on prolonged administration · Hypertension · Local irritation on prolonged administration · Myocardial infarction (usually after use of 10% strength in patients with pre-existing cardiovascular disease) · Oedema on prolonged administration · Palpitation · Photophobia · Raised intraocular pressure · Tachycardia · Transient stinging

**PREGNANCY**

Use only if potential benefit outweighs risk.

**BREAST FEEDING**

Use only if potential benefit outweighs risk—no information available.

**PRESCRIBING AND DISPENSING INFORMATION**

Although multi-dose phenylephrine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**PATIENT AND CARER ADVICE**

Patients should be warned not to undertake skilled tasks (e.g. driving) until vision clears after mydriasis.
4.1 Post-operative pain and inflammation

Eye, surgical and peri-operative drug use

Ocular peri-operative drugs

Drugs used to prepare the eye for surgery, drugs that are injected into the anterior chamber at the time of surgery, and those used after eye surgery, are included here.

Cefuroxime p. 955, administered by intra-ocular injection into the anterior chamber of the eye (intra-cameral use), is used for the prophylaxis of endophthalmitis after cataract surgery.

Non-steroidal anti-inflammatory eye drops such as diclofenac sodium p. 961, flurbiprofen p. 961, ketorolac trometamol p. 961, and nepafenac p. 961, are used for the prophylaxis and treatment of inflammation, pain, and other symptoms associated with ocular surgery or laser treatment of the eye. Bromfenac p. 961 is used for the treatment of postoperative inflammation following cataract surgery. Diclofenac sodium p. 961 and flurbiprofen are also used to prevent miosis during ocular surgery.

Apraclonidine p. 963, an alpha-, adrenoreceptor agonist, reduces intra-ocular pressure possibly by reducing the production of aqueous humour. It is used to control increases in intra-ocular pressure associated with ocular surgery and as short-term treatment to reduce intraocular pressure prior to surgery.

Acetycholine chloride p. 959, administered into the anterior chamber of the eye during surgery, rapidly produces miosis which lasts approximately 20 minutes. If prolonged miosis is required, it can be applied again.

Intra-ocular sodium hyaluronate p. 953 and balanced salt solution are used during surgical procedures on the eye.

Povidone-iodine is used for peri-ocular and conjunctival antisepsis before ocular surgery to support postoperative infection control.

Local anaesthetics

Oxybuprocaine hydrochloride below and tetracaine p. 961 are widely used topical local anaesthetics. Proxymetacaine hydrochloride below causes less initial stinging and is useful in children. Oxybuprocaine hydrochloride below or a combined preparation of lidocaine hydrochloride and fluorescein sodium p. 984 is used for tonometry. Tetracaine produces a more profound anaesthesia and is suitable for use before minor surgical procedures, such as the removal of corneal sutures. It has a temporary disruptive effect on the corneal epithelium. Lidocaine hydrochloride, with or without adrenaline/epinephrine p. 196, is injected into the eyelids for minor surgery. Local anaesthetics should never be used for the management of ocular symptoms.

CORTICOSTEROIDS

Loteprednol etabonate

Indications and dose

Treatment of post-operative inflammation following ocular surgery TO THE EYE

Adult: Apply 4 times a day for maximum duration of treatment of 14 days, to be started 24 hours after surgery

Side-effects

Corneal thinning, scleral thinning

Local anaesthetics

Fluorescein with lidocaine

Oxybuprocaine hydrochloride (Benoxinate hydrochloride)

Indications and dose

Local anaesthetic TO THE EYE

Adult: As required

Prescribing and dispensing information

Although multi-dose oxybuprocaine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

Local anaesthetics

Fluorescein with lidocaine

Programmed text can be used for peri-ocular and conjunctival antisepsis before ocular surgery to support postoperative infection control.
**Tetracaine**  
(Anethocaine)

### INDICATIONS AND DOSE
- **Local anaesthetic**
- **TO THE EYE**
  - **Adult:** Apply as required

### PRESCRIBING AND DISPENSING INFORMATION
Although multi-dose tetracaine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **TETRACAINE (Non-proprietary)**
  - Tetracaine hydrochloride 5 mg per 1 ml Minims tetracaine hydrochloride 0.5% eye drops 0.5ml unit dose | 20 unit dose £10.16
  - Tetracaine hydrochloride 10 mg per 1 ml Minims tetracaine hydrochloride 1% eye drops 0.5ml unit dose | 20 unit dose £10.16

**NON-STERoidal ANti-INFLAMMATORY drugs**

**Bromfenac**

### INDICATIONS AND DOSE
**Postoperative inflammation following cataract surgery**

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate, sulfates
  - **Yellow (Bausch & Lomb UK Ltd)**
    - Tetracaine (as Bromfenac sodium sesquihydrate) 900 microgram per 1 ml Yellow 900micrograms/ml eye drops | 5 ml £18.50

**Diclofenac sodium**

### INDICATIONS AND DOSE
- **Inhibition of intra-operative miosis during cataract surgery**
- **Postoperative inflammation in cataract surgery, strabismus surgery or argon laser trabecuoplasty**
- **Pain in corneal epithelial defects after photorefractive keratectomy, radial keratotomy or accidental trauma**
- **Seasonal allergic conjunctivitis**

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate, propylene glycol
  - **Voltarol Ophtha (Spectrum Thea Pharmaceuticals Ltd)**
    - Diclofenac sodium 1 mg per 1 ml Voltarol Ophtha 0.1% eye drops 0.3ml unit dose | 5 unit dose £4.00 | 40 unit dose £32.00

### SIDE-EFFECTS
- **Common or very common**: Punctate keratitis
- **Uncommon**: Allergic conjunctivitis, blurred vision, choroidal effusion, conjunctival hyperaemia, corneal deposits, corneal epithelium defect, dry eye, eye pruritus, headache, increased lacrimation, iritis, keratitis, nausea, ocular discomfort, photophobia
- **Frequency not known**: Corneal opacity, dermatographia, difficulty in accommodation, dryness, eye swelling, impaired corneal healing, reduced visual acuity

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Flurbiprofen**

### INDICATIONS AND DOSE
**Inhibition of intra-operative miosis (but does not possess intrinsic mydriatic properties)**

**TO THE EYE**
- **Adult:** (consult product literature)

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **Ocufen (Allergan Ltd)**
  - Flurbiprofen sodium 300 microgram per 1 ml Ocufen 0.03% eye drops 0.4ml unit dose | 40 unit dose £37.15

**Ketorolac trometamol**

### INDICATIONS AND DOSE
**Prophylaxis and reduction of inflammation and associated symptoms following ocular surgery**

**TO THE EYE**
- **Adult:** (consult product literature)

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - **Acular (Allergan Ltd)**
    - Ketorolac trometamol 5 mg per 1 ml Acular 0.5% eye drops | 5 ml £3.00 DT price = £3.00

**Nepafenac**

### INDICATIONS AND DOSE
**Prophylaxis and treatment of postoperative pain and inflammation associated with cataract surgery**

**Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients**

**TO THE EYE**
- **Adult:** (consult product literature)

### CAUTIONS
Avoid sunlight, corneal epithelial breakdown (if evidence of, then discontinue immediately)

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

- **Common or very common**: Punctate keratitis
- **Uncommon**: Allergic conjunctivitis, blurred vision, choroidal effusion, conjunctival hyperaemia, corneal deposits, corneal epithelium defect, dry eye, eye pruritus, headache, increased lacrimation, iritis, keratitis, nausea, ocular discomfort, photophobia
- **Frequency not known**:
  - Corneal opacity, dermatographia, difficulty in accommodation, dryness, eye swelling, impaired corneal healing, reduced visual acuity
Glucoma and ocular hypertension

**Glucoma**

Glucoma describes a group of disorders characterised by a loss of visual field associated with cupping of the optic disc and optic nerve damage. While glucoma is generally associated with raised intra-ocular pressure, it can occur when the intra-ocular pressure is within the normal range.

The most common form of glucoma is primary open-angle glucoma (chronic open-angle glucoma), where drainage of the aqueous humour through the trabecular meshwork is restricted. The condition is often asymptomatic, but the patient may present with significant loss of visual field. Patients with ocular hypertension are at high risk of developing primary open-angle glucoma.

Drugs that reduce intra-ocular pressure by different mechanisms are available for managing ocular hypertension and glucoma. A topical beta-blocker or a prostaglandin analogue is usually the drug of first choice for the treatment of ocular hypertension. A prostaglandin analogue should be used to manage patients with early or moderate primary open-angle glucoma. After checking compliance and eye drop instillation technique, it may be necessary to combine these drugs or add others, such as sympathomimetics, carbonic anhydrase inhibitors, or miotics to control intra-ocular pressure.

**Acute angle-closure glucoma**

Acute angle-closure glucoma occurs when the outflow of aqueous humour from the eye is obstructed by bowing of the iris against the trabecular meshwork; it is a medical emergency that requires urgent reduction of intra-ocular pressure to prevent loss of vision. Patients with acute angle-closure glucoma should be referred immediately for specialist ophthalmology assessment and treatment.

Standard antiglucoma therapy is used if supplementary treatment is required after iridotomy, iridectomy, laser treatment, or drainage surgery in either primary open-angle or acute angle-closure glucoma.

**Beta-blockers**

Topical application of a beta-blocker to the eye reduces intra-ocular pressure effectively in primary open-angle glucoma, probably by reducing the rate of production of aqueous humour. Administration by mouth also reduces intra-ocular pressure but this route is not used since side-effects may be troublesome.

Beta-blockers used as eye drops include betaxolol p. 964, carteol hydrochloride p. 964, levobunolol hydrochloride p. 964, and timolol maleate p. 965.

**Prostaglandin analogues and prostanides**

The prostaglandin analogues latanoprost p. 969, tafluprost p. 969 and travoprost p. 970, and the synthetic prostanamide, bimatoprost p. 968, increase uveoscleral outflow and subsequently reduce intra-ocular pressure. They are used to reduce intra-ocular pressure in ocular hypertension or open-angle glucoma.

**Sympathomimetics**

Brimonidine tartrate p. 963, a selective alpha₂-adrenoceptor agonist, is thought to lower intra-ocular pressure by reducing aqueous humour formation and increasing uveoscleral outflow. It is licensed for the reduction of intra-ocular pressure in open-angle glucoma or ocular hypertension in patients for whom beta-blockers are inappropriate; it may also be used as adjunctive therapy when intra-ocular pressure is inadequately controlled by other anti-glucoma therapy.

Apraclonidine p. 963 is another alpha₂-adrenoceptor agonist that lowers intra-ocular pressure by reducing aqueous humour formation. Eye drops containing apraclonidine p. 963 0.5% are used short-term to delay laser treatment or surgery in patients with glucoma not adequately controlled by another drug; eye drops containing 1% are used for control of intra-ocular pressure after anterior segment laser surgery.

Apraclonidine may not provide additional benefit in patients already using two drugs that suppress the production of aqueous humour.

**Carbonic anhydrase inhibitors and systemic drugs**

The *carbonic anhydrase inhibitors*, acetazolamide p. 965, brinzolamide p. 966, and dorzolamide p. 967, reduce intra-ocular pressure by reducing aqueous humour production. Systemic use of acetazolamide also produces weak diuresis.

Acetazolamide is given by mouth or by intravenous injection (intramuscular injections are painful because of the alkaline pH of the solution). It is used as an adjunct to other treatment for reducing intra-ocular pressure.

Acetazolamide is not generally recommended for long-term use.

Dorzolamide and brinzolamide are topical carbonic anhydrase inhibitors. They are licensed for use in patients resistant to beta-blockers or those in whom beta-blockers are contra-indicated. They are used alone or as an adjunct to a topical beta-blocker. Brinzolamide can also be used as an adjunct to a prostaglandin analogue. Systemic
absorption can rarely cause sulfonamide-like side-effects and may require discontinuation if severe.

The osmotic diuretics, intravenous hypertonic mannitol p. 202 or glycerol by mouth are useful short-term ocular hypotensive drugs.

**Miotics**

Miotics act by opening the inefficient drainage channels in the trabecular meshwork.

Pilocarpine p. 967, a miotic, is not commonly used for the treatment of primary open-angle glaucoma because side-effects are poorly tolerated. It is used mainly in the treatment of primary angle-closure glaucoma and in some secondary glaucomas.

### ALPHA₂-ADRENOCEPTOR AGONISTS

**Apraclonidine**

- **DRUG ACTION** Apraclonidine is an alpha₂-adrenoceptor agonist that lowers intra-ocular pressure by reducing aqueous humour formation. It is a derivative of clonidine.

- **INDICATIONS AND DOSE**
  - Control or prevention of postoperative elevation of intraocular pressure after anterior segment laser surgery
  - TO THE EYE
    - Adult: Apply 1 drop 1 hour before laser procedure, then 1 drop immediately after completion of procedure, 1% eye drops to be administered
  - Short-term adjunctive treatment of chronic glaucoma in patients not adequately controlled by another drug
  - TO THE EYE
    - Adult: Apply 1 drop 3 times a day usually for maximum 1 month, 0.5% eye drops to be administered, may not provide additional benefit if patient already using two drugs that suppress the production of aqueous humour

- **CONTRA-INDICATIONS** History of severe or unstable and uncontrolled cardiovascular disease
- **CAUTIONS** Cerebrovascular disease - depression - heart failure - history of angina - hypertension - loss of effect may occur over time - Parkinson’s syndrome - Raynaud’s syndrome - recent myocardial infarction - reduction in vision in end-stage glaucoma (suspend treatment) - severe corneal insufficiency - thromboangiitis obliterans - vasovagal attack

- **SIDE-EFFECTS**
  - Common or very common Conjunctivitis - dry eye - ocular intolerance - rhinitis - taste disturbance

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Ocular intolerance: Withdraw if eye pruritus, ocular hyperaemia, increased lacrimation, or oedema of the eyelids and conjunctiva occur.
  - Systemic effects: Since absorption may follow topical application, see clonidine hydrochloride p. 137.

- **PREGNANCY** Manufacturer advises avoid—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution.

- **RENAL IMPAIRMENT** Use with caution in chronic renal failure.

- **MONITORING REQUIREMENTS**
  - Monitor intra-ocular pressure and visual fields.
  - Monitor for excessive reduction in intra-ocular pressure following peri-operative use.

- **PATIENT AND CARER ADVICE**
  - Drowsiness may affect performance of skilled tasks (e.g. driving).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  - EXCipients: May contain Benzalkonium chloride
  - Iopidine (Alcon Laboratories (UK) Ltd)
    - Apraclonidine (as Apraclonidine hydrochloride) 5 mg per 1 ml
      - 5 ml (£10.88 OT price = £10.88)
    - Apraclonidine (as Apraclonidine hydrochloride) 10 mg per 1 ml
      - 2% eye drops 0.25ml unit dose | 24 unit dose (£17.85 OT price = £17.85)

### Brimonidine tartrate

- **DRUG ACTION** Brimonidine, an alpha₂-adrenoceptor agonist, is thought to lower intra-ocular pressure by reducing aqueous humour formation and increasing uveoscleral outflow.

- **INDICATIONS AND DOSE**
  - Raised intra-ocular pressure in open-angle glaucoma in patients for whom beta-blockers are inappropriate | Ocular hypertension in patients for whom beta-blockers are inappropriate | Adjunctive therapy when intra-ocular pressure is inadequately controlled by other antiglaucoma therapy
  - TO THE EYE
    - Adult: Apply twice daily

- **CONTRA-INDICATIONS** Neonates and children under 2 years (risk of severe systemic side-effects)

- **CAUTIONS** Cerebral insufficiency - children 2–12 years (increased risk of drowsiness) - coronary insufficiency - depression - postural hypotension - Raynaud’s syndrome - severe cardiovascular disease - thromboangiitis obliterans

- **INTERACTIONS:** Appendix 1 (brimonidine).

- **SIDE-EFFECTS**
  - Common or very common: Burning sensation at application site - conjunctival blanching - conjunctival disturbances - conjunctival follicles - conjunctival infection - corneal erosion - corneal staining - dizziness - drowsiness - dry mouth - eyelid inflammation - gastro-intestinal disturbances - headache - malaise - ocular disturbances - ocular dryness - ocular hyperaemia - ocular pain - ocular pruritus - photophobia - stinging at application site - taste disturbances - upper respiratory symptoms - visual disturbances
  - Uncommon: Arrhythmia - bradycardia - depression - nasal dryness - palpititation - tachycardia
  - Rare: Dysphoria
  - Very rare: Hypertension - hypotension - insomnia - irritis - miosis - syncope

- **PREGNANCY** Limited information available; manufacturer advises use only if benefit outweighs risk (eye drops).

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Manufacturer advises use with caution.

- **RENAL IMPAIRMENT** Manufacturer advises use with caution.
Brimonidine with timolol

The properties listed below are those particular to the combination only. For the properties of the components please consider, brimonidine tartrate p. 963, timolol maleate p. 965.

**INDICATIONS AND DOSE**
Raised intraocular pressure in open-angle glaucoma and for ocular hypertension when beta-blocker alone not adequate
**TO THE EYE**
- Adult: Apply twice daily

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCipients:** May contain Benzalkonium chloride
- **BRIMONIDINE TARTRATE** (Non-proprietary)
  - Brimonidine tartrate 2 mg per 1 ml Brimonidine 0.2% eye drops | 5 ml (Pos) £6.85 DT price = £2.32
- **Alphagan** (Allergan Ltd)
  - Brimonidine tartrate 2 mg per 1 ml Alphagan 0.2% eye drops | 5 ml (Pos) £6.85 DT price = £2.32
- **Brymont** (Blumont Pharma Ltd)
  - Brimonidine tartrate 2 mg per 1 ml Brymont 2mg/ml eye drops | 5 ml (Pos) £6.55 DT price = £2.32

**SIDE-EFFECTS**
- **BETA-ADRENOCEPTOR BLOCKERS**
  - **CONTRA-INDICATIONS** Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block
  - **CAUTIONS** Patients with corneal disease
  - **INTERACTIONS** → Appendix 1 (beta-blockers).
  - Since systemic absorption may follow topical application the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind.
  - **SIDE-EFFECTS** Anaphylaxis - blepharoconjunctivitis - burning - corneal disorders - dry eyes - erythema - itching - ocular stinging - pain
  - **SIDE-EFFECTS, FURTHER INFORMATION** Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.
  - **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose bex tremol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCipients:** May contain Benzalkonium chloride, disodium edetate
  - **BETAXOLOL** (as Betaxolol hydrochloride) 5 mg per 1 ml Betaxolol 0.5% eye drops | 5 ml (Pos) £1.90 DT price = £1.90
  - **Betoptic** (Alcon Laboratories (UK) Ltd)
    - Betaxolol (as Betaxolol hydrochloride) 2.5 mg per 1 ml Betoptic 0.25% suspension eye drops | 5 ml (Pos) £2.66 DT price = £2.66
    - Betoptic 0.25% eye drops suspension 0.25ml unit dose | 50 unit dose (Pos) £11.77
    - Betaxolol (as Betaxolol hydrochloride) 5 mg per 1 ml Betoptic 0.5% eye drops | 5 ml (Pos) £1.90 DT price = £1.90

**Carteolol hydrochloride**

**INDICATIONS AND DOSE**
Primary open-angle glaucoma
**TO THE EYE**
- Adult: Apply twice daily

**CONTRA-INDICATIONS** Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block

**CAUTIONS** Patients with corneal disease

**INTERACTIONS** → Appendix 1 (beta-blockers).
Since systemic absorption may follow topical application the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind.

**SIDE-EFFECTS** Anaphylaxis - blepharoconjunctivitis - burning - corneal disorders - dry eyes - erythema - itching - ocular stinging - pain

**SIDE-EFFECTS, FURTHER INFORMATION** Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.

**MEDIcINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCipients:** May contain Benzalkonium chloride
  - **Teoptic** (Spectrum Thea Pharmaceuticals Ltd)
    - Carteolol hydrochloride 10 mg per 1 ml Teoptic 1% eye drops | 5 ml (Pos) £7.60 DT price = £7.60
    - Carteolol hydrochloride 20 mg per 1 ml Teoptic 2% eye drops | 5 ml (Pos) £8.40 DT price = £8.40

**Levobunolol hydrochloride**

**INDICATIONS AND DOSE**
Primary open-angle glaucoma
**TO THE EYE**
- Adult: Apply 1–2 times a day

**CONTRA-INDICATIONS** Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block

**CAUTIONS** Patients with corneal disease
CAUTIONS, FURTHER INFORMATION
Systemic absorption can follow topical application to the eyes; consider cautions listed for systemically administered beta blockers.

**INTERACTIONS** → Appendix 1 (beta-blockers).
Since systemic absorption may follow topical application the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind.

**SIDE-EFFECTS**
Anaphylaxis - anterior uveitis - blepharoconjunctivitis - burning - corneal disorders - dry eyes - erythema - itching - ocular stinging - pain

**FURTHER INFORMATION**
Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.

**PRESCRIBING AND DISPENSING INFORMATION**
Although multi-dose timolol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**EYEdrops**
**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate, sodium metabisulphite

- **Betagan** (Allergan Ltd)
  Levobunolol hydrochloride 5 mg per 1 ml
  Betagan 0.5% eye drops | 5 ml (PvP) £1.85 DT price = £1.85
  Betagan Unit Dose 0.5% eye drops 0.4ml unit dose | 30 unit dose (PvP) £9.98

Timolol maleate

**INDICATIONS AND DOSE**
Reduction of intra-ocular pressure in primary open-angle glaucoma

- TO THE EYE
  - **Adult:** Apply twice daily

**TIMOPTOL-LA**
Reduction of intra-ocular pressure in primary open-angle glaucoma

- TO THE EYE
  - **Adult:** Apply once daily

**TIOPLEX**
Reduction of intra-ocular pressure in primary open-angle glaucoma

- TO THE EYE
  - **Adult:** Apply once daily, to be applied in the morning

**CONTRA-INDICATIONS**
Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block

**CAUTIONS**
Also consider cautions listed for systemically administered beta blockers - patients with corneal disease

**INTERACTIONS** → Appendix 1 (beta-blockers).
Since systemic absorption may follow topical application the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind.

**SIDE-EFFECTS**
Anaphylaxis - blepharoconjunctivitis - burning - corneal disorders - dry eyes - erythema - itching - ocular stinging - pain

**FURTHER INFORMATION**
Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.

**PRESCRIBING AND DISPENSING INFORMATION**
Although multi-dose timolol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**NATIONAL FUNDING/ACCESS DECISIONS**
**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (February 2014) that timolol gel eye drops (Tiopex) are accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure in patients with ocular hypertension or chronic open angle glaucoma who have proven sensitivity to preservatives.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**EYEdrops**
**EXCIPIENTS:** May contain Benzalkonium chloride

- **TIMOLOL MALEATE (Non-proprietary)**
  - **Timolol (as Timolol maleate) 2.5 mg per 1 ml**
  - **Timolol (as Timolol maleate) 5 mg per 1 ml**

- **Timoptol** (Merck Sharp & Dohme Ltd)
  - **Timolol (as Timolol maleate) 2.5 mg per 1 ml**
  - **Timolol (as Timolol maleate) 5 mg per 1 ml**

- **Tiopex** (Thea Pharmaceuticals Ltd)
  - **Timolol (as Timolol maleate) 1 mg per 1 gram**

Also available in combination with Bimatoprost, p. 968 - Brimonidine, p. 964 - Brinzolamide, p. 966 - Dorzolamide, p. 967 - Latanoprost, p. 969 - Traroprost, p. 970

**CARBONIC ANHYDRASE INHIBITORS**

**Acetazolamide**

**INDICATIONS AND DOSE**
Reduction of intra-ocular pressure in open-angle glaucoma | Reduction of intra-ocular pressure in secondary glaucoma | Reduction of intra-ocular pressure in angle-closure glaucoma

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES OR BY INTRAVENOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
  - **Adult:** 0.25–1 g daily in divided doses, intramuscular injection preferably avoided because of alkalinity

**Glaucma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - **Adult:** 1–2 capsules daily

**CONTRA-INDICATIONS**
Adrenocortical insufficiency - hyperchloreaemic acidosis - hypokalaemia - hyponatraemia - long-term administration in chronic angle-closure glaucoma

**CAUTIONS**
Avoid extravasation at injection site (risk of necrosis) - diabetes mellitus - elderly - impaired alveolar ventilation (risk of acidosis) - not generally recommended for long-term use - pulmonary obstruction (risk of acidosis) - renal calculi

**INTERACTIONS** → Appendix 1 (diuretics).

**SIDE-EFFECTS**
- Common or very common Ataxia - depression - diarrhoea - dizziness - excitement - fatigue - flushing - headache - irritability - loss of appetite - nausea - paraesthesia -
polyuria · reduced libido · taste disturbance · thirst · vomiting

▸ **Uncommon** Blood disorders · bone marrow suppression · confusion · crystalluria · drowsiness · electrolyte disturbances on long-term therapy · fever · glycosuria · haematuria · hearing disturbances · melaena · metabolic acidosis · rash · renal calculi · renal colic · renal failure · renal lesions · Stevens-Johnson syndrome · toxic epidermal necrosis · ureretic colic

▸ **Rare** Cholestatic jaundice · convulsions · flaccid paralysis · fulminant hepatic necrosis · hepatic · photosensitivity

▸ **Frequency not known** Transient myopia

**SIDE-EFFECTS, FURTHER INFORMATION**

Acetazolamide is a sulfonamide derivative; blood disorders, rashes, and other sulfonamide-related side-effects occur occasionally—patients should be told to report any unusual skin rash. If electrolyte disturbances and metabolic acidosis occur, these can be corrected by administering potassium bicarbonate (as effervescent potassium tablets).

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if history of sulfonamide hypersensitivity.

**PREGNANCY** Manufacturer advises avoid, especially in first trimester (toxicity in animal studies).

**BREAST FEEDING** Amount too small to be harmful.

**HEPATIC IMPAIRMENT** Manufacturer advises avoid.

**RENAL IMPAIRMENT** Avoid—risk of metabolic acidosis.

**MONITORING REQUIREMENTS** Monitor blood count and plasma electrolyte concentrations with prolonged use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Tablet

**ACETAZOLAMIDE (Non-proprietary)**

<table>
<thead>
<tr>
<th>Brand</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetazolamide</td>
<td>250 mg</td>
<td>£3.89 (48 tablets)</td>
</tr>
</tbody>
</table>

**Modified-release capsule**

**DIAMOX SR (AMCo)**

<table>
<thead>
<tr>
<th>Brand</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diamox SR 250 mg</td>
<td>30 capsule</td>
<td>£16.66 (DT price)</td>
</tr>
</tbody>
</table>

**Powder for solution for injection**

**DIAMOX (AMCo)**

<table>
<thead>
<tr>
<th>Brand</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diamox Sodium Parenteral</td>
<td>500 mg</td>
<td>£1.76 (1 vial)</td>
</tr>
</tbody>
</table>

**SIDE-EFFECTS**

▸ **Common or very common** Corneal erosion · corneal oedema · dry mouth · headache · ocular disturbances · photophobia · reduced visual acuity · taste disturbances

▸ **Uncommon** Alopecia · amnesia · bradycardia · chest pain · cough · decreased libido · depression · diarrhoea · dizziness · drowsiness · dyspepsia · dysphoria · epistaxis · erectile dysfunction · flatulence · malaise · nasal dryness · nausea · nervousness · oesophagitis · oral hypoesthesia and paraesthesia · palpitation · paraesthesia · pharyngitis · renal pain · sinusitis · sleep disturbances · throat irritation · tinnitus · upper respiratory tract congestion · vomiting

▸ **Frequency not known** Arrhythmia · asthma · dermatitis · erythema · hypertension · peripheral oedema · rhinitis · tachycardia · tremor · vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

Systemic absorption can rarely cause sulfonamide-like side-effects and may require discontinuation if severe.

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if history of sulfonamide hypersensitivity.

**PREGNANCY** Avoid—toxicity in animal studies.

**BREAST FEEDING** Use only if benefit outweighs risk.

**HEPATIC IMPAIRMENT** Manufacturer advises avoid.

**RENAL IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

**BRINZOLAMIDE (Non-proprietary)**

<table>
<thead>
<tr>
<th>Brand</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brinzolamide 10 mg/ml eye drops</td>
<td>5 ml</td>
<td>£6.92 (DT price)</td>
</tr>
<tr>
<td>Azopt (Alcon Laboratories (UK) Ltd) 10 mg/ml eye drops</td>
<td>5 ml</td>
<td>£6.92 (DT price)</td>
</tr>
</tbody>
</table>

**Brinzolamide with timolol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, brinzolamide above, timolol maleate p. 965.

**INDICATIONS AND DOSE**

Raised intra-ocular pressure in open-angle glaucoma or ocular hypertension when beta-blocker alone not adequate

**TO THE EYE**

▸ Adult: Apply twice daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

**BRINZOLAMIDE (Non-proprietary)**

<table>
<thead>
<tr>
<th>Brand</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brinzolamide 10 mg/ml eye drops</td>
<td>5 ml</td>
<td>£11.05 (DT price)</td>
</tr>
</tbody>
</table>

**Brinzolamide with timolol**

<table>
<thead>
<tr>
<th>Brand</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azarga (Alcon Laboratories (UK) Ltd) 10 mg/ml eye drops</td>
<td>5 ml</td>
<td>£11.05 (DT price)</td>
</tr>
</tbody>
</table>
Dorzolamide

INDICATIONS AND DOSE
Raised intra-ocular pressure in ocular hypertension used alone in patients unresponsive to beta-blockers or if beta-blockers contra-indicated | Open-angle glaucoma used alone in patients unresponsive to beta-blockers or if beta-blockers contra-indicated
TO THE EYE
Adult: Apply up to 4 times a day

Raised intra-ocular pressure in ocular hypertension as adjunct to beta-blocker | Open-angle glaucoma as adjunct to beta-blocker | Pseudo-exfoliative glaucoma as adjunct to beta-blocker
TO THE EYE
Adult: Apply twice daily

CONTRA-INDICATIONS
Hyperchloraemic acidosis

CAUTIONS
Chronic corneal defects - history of intra-ocular surgery - history of renal calculi - low endothelial cell count - systemic absorption follows topical application

INTERACTIONS
Since systemic absorption may follow topical application of dorzolamide to the eye, the possibility of interactions should be borne in mind.

SIDE-EFFECTS

Common or very common
- Asthenia - bitter taste - blurred vision - conjunctivitis - eye redness - headache - lacrimation - nausea - ocular irritation - superficial punctate keratitis

Uncommon
- Iridocyclitis

Rare
- Contact dermatitis - corneal oedema - dizziness - dry mouth - epistaxis - eyelid crusting - paraesthesia - Stevens-Johnson syndrome - throat irritation - toxic epidermal necrolysis - transient myopia - urolithiasis

SIDE-EFFECTS, FURTHER INFORMATION
Systemic absorption can rarely cause sulfonamide-like side-effects and may require discontinuation if severe.

ALLERGY AND CROSS-SENSITIVITY
Contra-indicated if history of sulfonamide hypersensitivity

PREGNANCY
Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING
Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
Manufacturer advises caution—no information available.

RENAL IMPAIRMENT
Avoid if eGFR less than 30 ml/minute/1.73 m².

PRESCRIBING AND DISPENSING INFORMATION
Although multi-dose dorzolamide eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

MEDICINAL FORMS
Available as 0.02% and 0.04% solutions.

EXCIPIENTS: May contain Benzalkonium chloride

Dorzolamide (as Dorzolamide hydrochloride) 20 mg per 1 ml
Dorzolamide 2% eye drops | 5 ml (PoS) £6.33 DT price = £2.33
Trusopt (Merck Sharp & Dohme Ltd)
Dorzolamide (as Dorzolamide hydrochloride) 20 mg per 1 ml
Trusopt 2% eye drops | 5 ml (PoS) £6.33 DT price = £2.33
Trusopt 2% eye drops 0.2ml unit dose preservative free | 60 unit dose (PoS) £24.18 DT price = £24.18

Dorzolamide with timolol
The properties listed below are those particular to the combination only. For the properties of the components please consider, timolol maleate p. 965, dorzolamide above.

INDICATIONS AND DOSE
Raised intra-ocular pressure in ocular hypertension when beta-blockers alone not adequate | Raised intra-ocular pressure in open-angle glaucoma when beta-blockers alone not adequate | Raised intra-ocular pressure in pseudo-exfoliative glaucoma when beta-blockers alone not adequate
TO THE EYE
Adult: Apply twice daily

PRESCRIBING AND DISPENSING INFORMATION
Although multi-dose dorzolamide with timolol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

PARASYMPATHOMIMETICS

Pilocarpine

DRUG ACTION
Pilocarpine acts by opening the inefficient drainage channels in the trabecular meshwork.

INDICATIONS AND DOSE
Primary angle-closure glaucoma | Some secondary glaucomas
TO THE EYE
Adult: Apply up to 4 times a day

CONTRA-INDICATIONS
Acute inflammatory disease of the anterior segment - acute iritis - anterior uveitis - conditions where pupillary constriction is undesirable - some forms of secondary glaucoma (where pupillary constriction is undesirable)

CAUTIONS
A darkly pigmented iris may require a higher concentration of the miotic or more frequent administration and care should be taken to avoid overdosage - asthma - cardiac disease - care in conjunctival damage - care in corneal damage - epilepsy - gastro-intestinal spasm - hypertension - hypothyroidism - hypotension - marked vasomotor instability - Parkinson's disease - peptic ulceration - retinal detachment has occurred in susceptible individuals and those with retinal disease - urinary-tract obstruction

INTERACTIONS
Since systemic absorption follows topical application to the eye.

SIDE-EFFECTS

Rare
- Parasympathomimetics systemic side effects

Frequency not known
- Blurred vision - ciliary spasm (leads to headache and brouache which may be more severe in
the initial 2–4 weeks of treatment—a particular disadvantage in patients under 40 years of age). conjunctival vascular congestion, lens changes (with chronic use), myopia, ocular burning, ocular itching, pupillary block, smarting, vitreous haemorrhage.

- **PREGNANCY** Avoid unless the potential benefit outweighs risk—limited information available.
- **BREAST FEEDING** Avoid unless the potential benefit outweighs risk—no information available.
- **PRE-TREATMENT SCREENING** Fundus examination is advised before starting treatment with a miotic (retinal detachment has occurred).
- **MONITORING REQUIREMENTS** Intra-ocular pressure and visual fields should be monitored in those with chronic simple glaucoma and those receiving long-term treatment with a miotic.
- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose pilocarpine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.
- **PATIENT AND CARER ADVICE** Blurred vision may affect performance of skilled tasks (e.g. driving) particularly at night or in reduced lighting.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Eye drops**

- **EXCIPIENTS:** May contain Benzalkonium chloride

- **PILOCARPINE (Non-proprietary)**
  - Pilocarpine hydrochloride 10 mg per 1 ml
  - Pilocarpine hydrochloride 1% eye drops | 10 ml (POD) £3.15 DT price = £2.92
  - Pilocarpine hydrochloride 20 mg per 1 ml
  - Pilocarpine hydrochloride 2% eye drops | 10 ml (POD) £3.63 DT price = £3.63
  - Pilocarpine nitrate 20 mg per 1 ml Minims pilocarpine nitrate 2% eye drops 0.5ml unit dose | 20 unit dose (POD) £11.99
  - Pilocarpine hydrochloride 40 mg per 1 ml
  - Pilocarpine hydrochloride 4% eye drops | 10 ml (POD) £5.40 DT price = £4.35

- **PROSTAGLANDIN ANALOGUES AND PROSTAMIDES**

**Bimatoprost**

**INDICATIONS AND DOSE**

Raised intra-ocular pressure in open-angle glaucoma | Ocular hypertension to the eye

- Adult: Apply once daily, to be administered preferably in the evening

- **CAUTIONS** Angle-closure glaucoma (no experience of use), aphakia - asthmatic - chronic obstructive pulmonary disease - compromised respiratory function - congenital glaucoma (no experience of use), contact lens wearers, history of significant ocular viral infections, inflammatory ocular conditions (no experience of use), narrow-angle glaucoma (no experience of use), neovascular glaucoma (no experience of use), predisposition to bradycardia, predisposition to hypotension, pseudophakia with torn posterior lens capsule or anterior chamber lenses, risk factors for cystoid macular oedema, risk factors for iritis, risk factors for uveitis

- **SIDE-EFFECTS**

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Use with caution in moderate to severe impairment—no information available.
- **RENAL IMPAIRMENT** Use with caution—no information available.
- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose bimatoprost eye drops commonly contain preservatives, preservative-free unit dose vials may be available.
- **PATIENT AND CARER ADVICE** Changes to eye colour Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.

- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2013) that bimatoprost 300 micrograms/ml preservative-free eye drops (Lumigan® single-dose eye drops) are accepted for restricted use within NHS Scotland for the reduction of elevated intra-ocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers) in adults who have proven sensitivity to benzalkonium chloride.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **EXCIPIENTS:** May contain Benzalkonium chloride

- **Lumigan (Allergan Ltd)**
  - **Bimatoprost 100 microgram per 1 ml**
    - Lumigan 100micrograms/ml eye drops | 3 ml (POD) £11.71 DT price = £11.71 | 9 ml (POD) £35.13
  - **Bimatoprost 300 microgram per 1 ml**
    - Lumigan 300micrograms/ml eye drops | 3 ml (POD) £10.30 DT price = £10.30 | 9 ml (POD) £30.90
    - Lumigan 300micrograms/ml unit dose 0.4ml unit dose | 30 unit dose (POD) £13.75 DT price = £13.75

**Bimatoprost with timolol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, bimatoprost above, timolol maleate p. 965.

**INDICATIONS AND DOSE**

Raised intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate to the eye

- Adult: Apply once daily
Glucoma and ocular hypertension

**PATIENT AND CARER ADVICE**
Changes in eye colour Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions The Scottish Medicines Consortium has advised (October 2013) that Ganfort 5 unit dose eye drops are accepted for restricted use within NHS Scotland for the reduction of intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension insufficiently responsive to topical beta-blockers or prostaglandin analogues who have proven sensitivity to preservatives.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride
  - **Bimatoprost 300 microgram per 1 ml, Timolol (as Timolol maleate) 5 mg per 1 ml** Ganfort 0.3mg/ml / 5mg/ml eye drops | 3 ml (PBM) £13.95 DT price = £13.95 | 9 ml (PBM) £37.59
  - **Ganfort 0.3mg/ml / 5mg/ml eye drops 0.4ml unit dose | 30 unit dose (PBM) £17.50**

### Latanoprost

#### INDICATIONS AND DOSE

**Raised intra-ocular pressure in open-angle glaucoma**

**TO THE EYE**
- **Adult:** Apply daily, to be administered preferably in the evening
  - **CONTRA-INDICATIONS** Active herpes simplex keratitis - history of recurrent herpetic keratitis associated with prostaglandin analogues
  - **CAUTIONS** Angle-closure glaucoma (no experience of use) - aphakia - asthmatic - chronic obstructive pulmonary disease - compromised respiratory function - congenital glaucoma (no experience of use) - contact lens wearers - do not use within 5 minutes of thiomersal-containing preparations - history of significant ocular viral infections - inflammatory ocular conditions (no experience of use) - narrow-angle glaucoma (no experience of use) - neovascular glaucoma (no experience of use) - peri-operative period of cataract surgery - pseudophakia with torn posterior lens capsule or anterior chamber lenses - risk factors for cystoid macular oedema - risk factors for iritis - risk factors for uveitis
  - **SIDE-EFFECTS**
    - **Common or very common** Blepharitis - blood pressure changes - brown pigmentation particularly in those with mixed-colour irides - conjunctival disorders - corneal erosion - darkening, thickening and lengthening of eye lashes - eyelash and vellus hair changes - headache - ocular discomfort - photophobia - pigmentation of periorcular skin - punctate keratitis - reduced visual acuity - transient punctate epithelial erosion
    - **Uncommon** Asthenopia - dizziness - skin rash
    - **Rare** Arthralgia - darkening of palpebral skin - facial oedema - iritis - macular oedema - myalgia - uveitis
    - **Very rare** Chest pain - exacerbation of angina - palpitation - periorbital changes resulting in deepening of the eyelid sulcus
    - **Frequency not known** Asthma - dyspnoea - exacerbation of asthma - exacerbation of COPD - iris cyst - nasopharyngitis - pyrexia
  - **PREGNANCY** Manufacturer advises avoid.
  - **BREAST FEEDING** May be present in milk—manufacturer advises avoid.
  - **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose latanoprost eye drops commonly contain preservatives, preservative-free unit dose vials may be available

### Latanoprost with timolol

The properties listed below are those particular to the combination only. For the properties of the components please consider, latanoprost above, timolol maleate p. 965.

#### INDICATIONS AND DOSE

**Raised intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate**

**TO THE EYE**
- **Adult:** Apply once daily

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **EXCIPIENTS:** May contain Benzalkonium chloride
  - **LATA NOPROST (Non-proprietary)**
    - **Latanoprost 50 microgram per 1 ml** Latanoprost 50 micrograms/ml eye drops | 2.5 ml (PBM) £12.48 DT price = £12.16
    - **Monopost (Pfizer Ltd)**
      - **Latanoprost 50 microgram per 1 ml** Monopost 50 micrograms/ml eye drops 0.2ml unit dose | 30 unit dose (PBM) £8.49 DT price = £8.49 | 90 unit dose (PBM) £25.47 DT price = £25.47
  - **Xalatan (Pfizer Ltd)**
    - **Latanoprost 50 microgram per 1 ml** Xalatan 50 micrograms/ml eye drops | 2.5 ml (PBM) £12.48 DT price = £12.16

### Tafluprost

#### INDICATIONS AND DOSE

**Raised intra-ocular pressure in open-angle glaucoma**

**TO THE EYE**
- **Adult:** Apply daily, to be administered preferably in the evening
**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

EXCIPIENTS: May contain Disodium edetate

- **Saflutan** (Merck Sharp & Dohme Ltd)
- **Tafluprost 15 microgram per 1 ml** Saflutan 15micrograms/ml eye drops 0.3ml unit dose | 30 unit dose (£95) £12.20 DT price = £12.20

**Travoprost**

**INDICATIONS AND DOSE**

Raised intra-ocular pressure in open-angle glaucoma | Ocular hypertension

TO THE EYE

- Adult: Apply daily, to be administered preferably in the evening

**Side-effects**

- **Rare** Mydriasis
- **Uncommon** Angle-closure glaucoma (no experience of use)

**PATIENT AND CARER ADVICE**

Changes to eye colour

Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

EXCIPIENTS: May contain Propylene glycol

- **Travatan (Alcon Laboratories (UK) Ltd)** Travoprost 40 microgram per 1 ml Travatan 40micrograms/ml eye drops | 2.5 ml (£95) £10.95 DT price = £10.95

Timolol with travoprost

The properties listed below are those particular to the combination only. For the properties of the components please consider, timolol maleate p. 965, travoprost above.

**INDICATIONS AND DOSE**

Raised intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate

TO THE EYE

- Adult: Apply once daily
Retinal disorders

6.1 Macular degeneration

Subfoveal choroidal neovascularisation

Aflibercept below, pegaptanib sodium p. 972 and ranibizumab p. 973 are vascular endothelial growth factor inhibitors licensed for the treatment of neovascular (wet) age-related macular degeneration. Aflibercept is also licensed for the treatment of macular oedema secondary to central retinal vein occlusion, and diabetic macular oedema; ranibizumab is also licensed for the treatment of visual impairment due to diabetic macular oedema, macular oedema secondary to branch or central retinal vein occlusion, and choroidal neovascularisation secondary to pathologic myopia. Ranibizumab can be administered concomitantly with laser photocoagulation for the treatment of diabetic macular oedema and for macular oedema secondary to branch retinal vein occlusion.

PHOTOSENSITISERS

Verteporfin

DRUG ACTION Following intravenous infusion, verteporfin is activated by local irradiation using non-thermal red light to produce cytotoxic derivatives.

INDICATIONS AND DOSE

Photodynamic treatment of age-related macular degeneration associated with predominantly classic subfoveal choroidal neovascularisation or with pathological myopia (specialist use only)

BY INTRAVENOUS INFUSION

▶ Adult: 6 mg/m², dose to be given over 10 minutes

CONTRA-INDICATIONS Acute porphyria

CAUTIONS Avoid extravasation · biliary obstruction · photosensitivity

INTERACTIONS Caution on concomitant use with other photosensitising drugs.

SIDE-EFFECTS

▶ Common or very common Back pain · flashing lights · hypercholesterolaemia · malaise · nausea · photosensitivity · reduced visual acuity · visual disturbances · visual-field defects

▶ Uncommon Hypoaesthesia · hypertension · pyrexia · retinal detachment · subretinal, retinal or vitreous haemorrhage

▶ Rare Retinal or choroidal vessel non-perfusion

▶ Frequency not known Chest pain · macular oedema · myocardial infarction · retinal oedema · vasovagal reactions

PREGNANCY Manufacturer advises use only if potential benefit outweighs risk (teratogenic in animal studies).

VESTED INTERESTS

Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor and binds to vascular endothelial growth factors A and B (VEGF-A, VEGF-B) and placental growth factor (PIGF). Aflibercept inhibits the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

INDICATIONS AND DOSE

Neovascular (wet) age-related macular degeneration (specialist use only)

BY INTRAVITREAL INJECTION

▶ Adult: Initially 2 mg once a month for 3 months, to be injected into the affected eye, then 2 mg every 2 months, review treatment frequency after 12 months

Macular oedema secondary to central retinal vein occlusion (specialist use only)

BY INTRAVITREAL INJECTION

▶ Adult: Initially 2 mg once a month, to be injected into the affected eye, monitor visual and anatomic outcomes monthly; continue treatment until visual and anatomic outcomes are stable for 3 monthly assessments (discontinue treatment if no improvement in visual and anatomic outcomes after initial 3 injections); if necessary subsequent doses may be given at least 1 month apart continued →

BREAST FEEDING No information available—manufacturer advises avoid breast-feeding for 48 hours after administration.

HEPATIC IMPAIRMENT Use with caution in moderate hepatic impairment. Avoid in severe hepatic impairment.

DIRECTIONS FOR ADMINISTRATION For information on administration and light activation, consult product literature. For intravenous infusion (Visudyne®), give intermittently in Glucose 5%; reconstitute each 15 mg with 7 ml water for injections to produce a 2 mg/ml solution then dilute requisite dose with infusion fluid to a final volume of 30 ml and give over 10 minutes; protect infusion from light and administer within 4 hours of reconstitution. Incompatible with sodium chloride infusion.

PATIENT AND CARER ADVICE Photosensitivity—avoid exposure of unprotected skin and eyes to bright light during infusion and for 48 hours afterwards.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

▶ Verteporfin photodynamic therapy for wet age-related macular degeneration (September 2003) NICE TA68

Photodynamic therapy is recommended for wet age-related macular degeneration with a confirmed diagnosis of classic (no occult) subfoveal choroidal neovascularisation and best-corrected visual acuity of 6/60 or better.

Photodynamic therapy is not recommended for wet age-related macular degeneration with predominantly classic but partly occult subfoveal choroidal neovascularisation except in clinical studies. www.nice.org.uk/TA68
Diabetic macular oedema (specialist use only)

**BY INTRAVITREAL INJECTION**
- Adult: Initially 2 mg once a month for 5 months, then maintenance 2 mg every 2 months, to be injected into the affected eye, review treatment frequency after 12 months (discontinue treatment if no improvement in visual and anatomic outcomes)

**CONTRA-INDICATIONS** Clinical signs of irreversible ischaemic visual function loss - ocular or periorcular infection - severe intra-ocular inflammation

**CAUTIONS** Active systemic infection - diabetic patients with uncontrolled hypertension - discontinue treatment if stage 3 or 4 macular holes develop—consult product literature for full details - discontinue treatment in the event of a retinal break—consult product literature for full details - discontinue treatment in the event of rhegmatogenous retinal detachment—consult product literature for full details - patients at risk of retinal pigment epithelial tear - poorly controlled glaucoma - recent history of myocardial infarction - recent history of stroke - recent history of transient ischaemic attack

**SIDE-EFFECTS**

**SPECIFIC SIDE-EFFECTS**
- Common or very common
  - With intravitreal use anterior chamber flare - blindness - corneal epithelial defect - eyelid irritation - iridocyclitis - iritis - lenticular opacities - retinal detachment - retinal tear - uveitis
- Rare
  - With intravitreal use hypopyon - vitritis
- **CONCEPTION AND CONTRACEPTION** Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.
- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **MONITORING REQUIREMENTS** Monitor intra-ocular pressure following injection.
- **DIRECTIONS FOR ADMINISTRATION** For further information on administration, consult product literature.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Aflibercept solution for injection for treating wet age-related macular degeneration (July 2013) NICE TA294

It is used in accordance with the recommendations for ranibizumab in NICE TA 155 and

the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme www.nice.org.uk/TA294

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (February 2014) NICE TA305

Aflibercept solution for injection is recommended as an option for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion only if the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme. www.nice.org.uk/TA305

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Eylea (Bayer Plc)**
  - Aflibercept 40 mg per 1 ml Eylea 2mg/microlitres solution for injection vials | 1 vial £816.00

**Pegaptanib sodium**

**INDICATIONS AND DOSE**

Treatment of neovascular (wet) age-related macular degeneration (specialist use only)

**BY INTRAVITREAL INJECTION**
- Adult: 300 micrograms every 6 weeks, to be administered into the affected eye, review treatment if no benefit after 2 consecutive injections

**CONTRA-INDICATIONS** Ocular or periorcular infection

**CAUTIONS**

**CAUTIONS, FURTHER INFORMATION**

Pegaptanib is given by intravitreal injection by specialists experienced in the management of this condition. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections—patients should be advised to report any signs of infection immediately.

**SIDE-EFFECTS**

- **Common or very common** Anterior chamber inflammation - cataract - conjunctival haemorrhage - conjunctival hyperaemia - corneal abrasion or oedema - corneal erosion - eye pain - eyelid oedema - foreign body sensation in eye - increased lacrimation - injection-site haemorrhage - injection-site pain - ocular hyperaemia - punctate keratitis - raised intra-ocular pressure - reduced visual acuity - retinal degeneration - retinal pigment epithelium detachment - retinal pigment epithelium tear - vitreous detachment - vitreous floaters - vitreous haemorrhage
- **Uncommon**
- **Rare**
- **With intravitreal use** hypopyon - vitritis
- **CONCEPTION AND CONTRACEPTION** Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.
- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **MONITORING REQUIREMENTS** Monitor intra-ocular pressure following injection.
- **DIRECTIONS FOR ADMINISTRATION** For further information on administration, consult product literature.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Pegaptanib sodium 2mg/microlitres solution for injection vials | 1 vial £305
    - Pegaptanib sodium 2mg/microlitres solution for injection vials | 1 vial £155

Changes in vision - eye pain - injection-site reactions - increased intra-ocular pressure - vitreous haemorrhage - vitreous disorders - vitreous floaters


**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**MONITORING REQUIREMENTS**

Monitor intra-ocular pressure (transient increase may occur following injection, and small, sustained increases reported after repeated dosing).
- Monitor for vitreous haemorrhage and for signs of ocular infection for 2 weeks following injection.
- **DIRECTIONS FOR ADMINISTRATION** For further information on administration, consult product literature.
- **NATIONAL FUNDING/ACCESS DECISIONS**

  **NICE technology appraisals (TAs)**

  Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012) NICE TA155

  Pegaptanib is not recommended for the treatment of wet age-related macular degeneration; patients currently receiving pegaptanib for any lesion type can continue therapy until they and their specialist consider it appropriate to stop. [www.nice.org.uk/TA155](http://www.nice.org.uk/TA155)

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Solution for injection**

  - Macugen (Pfizer Ltd)
  - Pegaptanib oligonucleotide (as Pegaptanib sodium) 3.33 mg per 1 ml Macugen 300micrograms/0.9ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (PFS) £514.00 (Hospital only)

### Ranibizumab

**INDICATIONS AND DOSE**

**Neovascular (wet) age-related macular degeneration (specialist use only)**

**BY INTRAVITREAL INJECTION**

- **Adult:** 500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart

  **Diabetic macular oedema** | **Macular oedema secondary to retinal vein occlusion (specialist use only)**

  **BY INTRAVITREAL INJECTION**

  - **Adult:** Initially 500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months (discontinue treatment if no improvement in visual acuity after initial 3 injections), thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart

  **Choroidal neovascularisation secondary to pathologic myopia (specialist use only)**

  **BY INTRAVITREAL INJECTION**

  - **Adult:** Initially 500 micrograms, to be administered as a single injection into the affected eye, monitor for disease activity monthly for first 2 months, then at least every 3 months thereafter during the first year, then as required, if necessary subsequent doses may be given at least 1 month apart

  **Concomitant treatment of diabetic macular oedema, or macular oedema secondary to branch retinal vein occlusion, with laser photocoagulation (specialist use only)**

  **BY INTRAVITREAL INJECTION**

  - **Adult:** 500 micrograms, to be administered at least 30 minutes after laser photocoagulation

- **CONTRA-INDICATIONS**

  - Ocular or periocular infection
  - Severe intra-ocular inflammation
  - Signs of irreversible ischaemic visual function loss in patients with retinal vein occlusion

- **CAUTIONS**

  - Active systemic infection
  - Diabetic macular oedema due to type 1 diabetes (limited information available)
  - Diabetic patients with HbA1c over 12%
  - History of stroke
  - History of transient ischaemic attack
  - Patients at risk of retinal pigment epithelial tear
  - Previous intravitreal injections
  - Proliferative diabetic retinopathy
  - Retinal detachment or macular hole
  - Uncontrolled hypertension

  The manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

**SIDE-EFFECTS**

- **Common or very common**

  - Allergic skin reactions
  - Anaemia
  - Anterior chamber flare
  - Anxiety
  - Arthralgia
  - Blepharitis
  - Cataract
  - Conjunctival disorders
  - Conjunctivitis
  - Cough
  - Eyelid oedema
  - Headache
  - Iridocyclitis
  - Iritis
  - Nasopharyngitis
  - Nausea
  - Ocular discomfort
  - Photophobia
  - Photopsia
  - Posterior capsule opacification
  - Punctuate keratitis
  - Raised intra-ocular pressure
  - Retinal disorders
  - Urinary tract infection
  - Uveitis
  - Visual disturbance
  - Vitreous disorders

- **Uncommon**

  - Blindness
  - Corneal disorders
  - Hypertension
  - Hypopyon
  - Iris adhesion
  - Keratopathy

- **CONCEPTION AND CONTRACEPTION**

  Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.

- **PREGNANCY**

  Manufacturer advises avoid unless potential benefit outweighs risk.

- **BREAST FEEDING**

  Manufacturer advises avoid—no information available.

- **MONITORING REQUIREMENTS**

  - Monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection.
  - Monitor visual acuity, see individual indications and dose for frequency.

- **DIRECTIONS FOR ADMINISTRATION** For further information on administration, consult product literature.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **NICE technology appraisals (TAs)**

  Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012) NICE TA155

  Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:

  - The best corrected visual acuity is between 6/12 and 6/96;
  - There is no permanent structural damage to the central fovea;
  - The lesion size is less than or equal to 12 disc areas in greatest linear dimension;
  - There is evidence of recent disease progression;
  - The manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

  Ranibizumab should only be continued in patients who maintain adequate response to therapy. [www.nice.org.uk/TA155](http://www.nice.org.uk/TA155)

- **Ranibizumab for the treatment of diabetic macular oedema (February 2013) NICE TA274**

  Ranibizumab is recommended as an option for the treatment of visual impairment due to diabetic macular oedema only if:

  - The eye has a central retinal thickness of 400 micrometres or more at the start of treatment and
  - The manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).
Patients currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA274

- Ranibizumab for the treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion (May 2013) NICE TA283

Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema:
- following central retinal vein occlusion or
- following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage and
- only if the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 274. www.nice.org.uk/TA283

- Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (November 2013) NICE TA298

Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme. www.nice.org.uk/TA298

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (May 2007) that ranibizumab (Lucentis®) is accepted for use within NHS Scotland for the treatment of neovascular (wet) age-related macular degeneration. The Scottish Medicines Consortium has advised (October 2011 and April 2013) that ranibizumab (Lucentis®) is accepted for use within NHS Scotland for the treatment of macular oedema secondary to branch or central retinal vein occlusion, and (November 2012) for restricted use for the treatment of visual impairment due to diabetic macular oedema in adults with best corrected visual acuity 75 Early Treatment Diabetic Retinopathy Study letters or less at baseline, and (October 2013) for the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults; SMC advice is contingent upon the continuing availability of ranibizumab at the price agreed in the patient access scheme.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Lucentis (Novartis Pharmaceuticals UK Ltd) Ranibizumab 10 mg per 1 ml Lucentis 2.3mg/0.23ml solution for injection vials | 1 vial (£74.00 (Hospital only)
Lucentis 1.65mg/0.165ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (£74.00

6.2 Macular oedema

Drugs used for Macular oedema not listed below; Aflibercept, p. 971; Ranibizumab, p. 973

Fluocinolone acetonide

INDICATIONS AND DOSE
Treatment of visual impairment associated with chronic diabetic macular oedema which is insufficiently responsive to available therapies (specialist use only)

BY INTRAVITREAL INJECTION
- Adults: 190 micrograms, to be administered into the affected eye

- CONTRA-INDICATIONS Active or suspected ocular infection · active or suspected peri-ocular infection · pre-existing glaucoma
- CAUTIONS Raised baseline intra-ocular pressure
- INTERACTIONS Caution with concomitant administration of antiocoagulant or antiplatelet drugs (higher incidence of conjunctival haemorrhage).
- SIDE-EFFECTS
- Common or very common Blurred vision · cataract · conjunctival haemorrhage · glaucoma · ocular discomfort · raised intra-ocular pressure · reduced visual acuity · vitreous floaters · vitreous haemorrhage
- Uncommon Conjunctival ulcer · endophthalmitis · eye discharge · eye pruritus · headache · iris adhesions · iris neovascularisation · maculopathy · ocular hyperaemia · optic atrophy · optic nerve disorder · posterior capsule opacification · retinal exudates · retinal vascular occlusion · sclera thinning · vitreous degeneration · vitreous detachment
- PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk—no information available.
- BREAST FEEDING Manufacturer advises avoid unless essential.
- MONITORING REQUIREMENTS
- Monitor for raised intra-ocular pressure (particularly if raised at baseline), retinal detachment, endophthalmitis, vitreous haemorrhage or detachment within 2–7 days following the procedure.
- Monitor intra-ocular pressure at least every 3 months thereafter (for approximately 36 months).
- DIRECTIONS FOR ADMINISTRATION Concurrent administration to both eyes not recommended. For further information on administration and repeat dosing, consult product literature.
- NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (November 2013) NICE TA301

Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if:
- the implant is to be used in an eye with an intra-ocular (pseudophakic lens) and
- the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme. www.nice.org.uk/TA301

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2014) that fluocinolone acetonide intravitreal implant (Iluvien®) is recommended for restricted use within NHS Scotland for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies, only in patients in whom the affected eye is pseudophakic (has an artificial lens after cataract surgery), and retreatment would take place only if the patient had previously responded to treatment with
fluocinolone acetonide and subsequently best corrected visual acuity had deteriorated to less than 20/32.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Implant**
- Iluvien (Alimera Sciences Ltd)
  Fluocinolone acetonide 190 microgram intravitreal implant in applicator | 1 device | £5,500.00

---

### 6.3 Vitreomacular traction

**RECOMBINANT PROTEOLYTIC ENZYMES**

**Ocriplasmin**

**INDICATIONS AND DOSE**
Treatment of vitreomacular traction, including when associated with a macular hole of diameter less than or equal to 400 microns (specialist use only)

**BY INTRAVITREAL INJECTION**
- Adult: 125 micrograms for 1 dose, to be administered into the affected eye, concurrent administration to both eyes is not recommended

**CONTRA-INDICATIONS**
Active or suspected ocular or periocular infection - aphakia - exudative age-related macular degeneration - high myopia - history of rhegmatogenous retinal detachment - ischaemic retinopathies - large diameter macular hole (> 400 microns) - lens zonule instability - proliferative diabetic retinopathy - recent intra-ocular injection (including laser therapy) - recent ocular surgery - retinal vein occlusions - vitreous haemorrhage

**CAUTIONS**
History of uveitis (including severe active inflammation) - non-proliferative diabetic retinopathy - significant eye trauma

**SIDE-EFFECTS**
- Common or very common  Abnormal retinograph - anterior chamber cell or flare - chromatopsia - conjunctival disorders - eyelid oedema - iritis - macular degeneration - macular hole - macular oedema - metamorphopsia - ocular discomfit - ocular hyperaemia - photophobia - photopsia - raised intra-ocular pressure - reduced visual acuity - retinal disorders - retinal pigment epitheliopathy - vitreous disorders
- Uncommon  Anterior chamber inflammation - corneal abrasion - diplopia - eye inflammation - hyphaema - lens subluxation - miosis - scotoma - transient blindness - unequal pupils - visual field defect

**PREGNANCY**
Manufacturer advises use only if potential benefit outweighs risk—no information available.

**BREAST FEEDING**
Manufacturer advises use only if potential benefit outweighs risk—no information available.

**MONITORING REQUIREMENTS**
Monitor intra-ocular pressure, visual acuity, and for signs of intra-ocular inflammation or infection following injection.

**DIRECTIONS FOR ADMINISTRATION**
For further information on administration, consult product literature.

**NATIONAL FUNDING/ACCESS DECISIONS**
**NICE technology appraisals (TAs)**
- Ocriplasmin for treating vitreomacular traction (October 2013) NICE TA297
  Ocriplasmin is recommended as an option for treating vitreomacular traction in adults, only if:
  - they have a stage II full-thickness macular hole with a diameter of 400 microns or less and/or
  - they have severe symptoms. [www.nice.org.uk/TA297](http://www.nice.org.uk/TA297)

**Scottish Medicines Consortium (SMC) Decisions**
The [Scottish Medicines Consortium](http://www.scottishmedicines.org.uk) has advised (July 2014) that ocriplasmin (Jetrea®) is accepted for restricted use within NHS Scotland for the treatment of patients with vitreomacular traction plus macular hole, regardless of whether they have epiretinal membrane formation, and in patients with vitreomacular traction alone (no epiretinal membrane and no macular hole).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Jetrea (Alcon Laboratories (UK) Ltd)
  Ocriplasmin 2.5 mg per 1 ml Jetrea 0.5mg/0.2ml concentrate for solution for injection vials | 1 vial | £2,500.00

---

**BNF 70 Vitreomacular traction 975**
Chapter 12

Ear, nose and oropharynx

CONTENTS

1 Ear  page 976
  1.1 Otitis externa  977
  1.2 Removal of ear wax  978

2 Nose  980
  2.1 Nasal congestion  982
  2.2 Nasal inflammation, nasal polyps and rhinitis  983
  2.3 Nasal staphylococcal infection  986

3 Oropharynx  987

1 Ear

Otitis externa

Otitis externa is an inflammatory reaction of the meatal skin. It is important to exclude an underlying chronic otitis media before treatment is commenced. Many cases recover after thorough cleansing of the external ear canal by suction or dry mopping. A frequent problem in resistant cases is the difficulty in applying lotions and ointments satisfactorily to the relatively inaccessible affected skin. The most effective method is to introduce a ribbon gauze dressing or sponge wick soaked with corticosteroid ear drops or with an astringent such as aluminium acetate solution p. 451. When this is not practical, the ear should be gently cleansed with a probe covered in cotton wool and the patient encouraged to lie with the affected ear uppermost for ten minutes after the canal has been filled with a liberal quantity of the appropriate solution. If infection is present, a topical anti-infective which is not used systemically (such as neomycin sulfate p. 451 or clioquinol) may be used, but for only about a week as excessive use may result in fungal infections; these may be difficult to treat and require expert advice. Sensitivity to the anti-infective or solvent may occur and resistance to antibacterials is a possibility with prolonged use. Aluminium acetate p. 979 ear drops are also effective against bacterial infection and inflammation of the ear. Chloramphenicol p. 955 may be used but the ear drops contain propylene glycol and cause hypersensitivity reactions in about 10% of patients. Solutions containing an anti-infective and a corticosteroid are used for treating cases where infection is present with inflammation and eczema.

In view of reports of ototoxicity, manufacturers contraindicate treatment with topical aminoglycosides or polymyxins in patients with a perforated tympanic membrane (eardrum) or patent grommet. However, some specialists do use these drops cautiously in the presence of a perforation or patent grommet in patients with chronic suppurative otitis media and when other measures have failed for otitis externa; treatment should be considered only by specialists in the following circumstances:

- patients should be counselled on the risk of ototoxicity and given justification for the use of these topical antibiotics;
- baseline audiometry should be performed, if possible, before treatment is commenced.

Clinical expertise and judgement should be used to assess the risk of treatment versus the benefit to the patient in such circumstances.

A solution of acetic acid 2% acts as an antifungal and antibacterial in the external ear canal. It may be used to treat mild otitis externa but in severe cases an antiinflammatory preparation with or without an anti-infective drug is required. A proprietary preparation containing acetic acid 2% (EarCalm® spray) is on sale to the public.

For severe pain associated with otitis externa, a simple analgesic, such as paracetamol p. 354 or ibuprofen p. 927, can be used. A systemic antibacterial can be used if there is spreading cellulitis or if the patient is systemically unwell. When a resistant staphylococcal infection (a boil) is present spreading cellulitis or if the patient is systemically unwell. When a resistant staphylococcal infection (a boil) is present ciprofloxacin p. 956 (or an aminoglycoside) may be needed in pseudomonal infections which may occur if the patient has diabetes or is immunocompromised.

The skin of the pinna adjacent to the ear canal is often affected by eczema. A topical corticosteroid cream or ointment is then required, but prolonged use should be avoided.

Otitis media

Acute otitis media

Acute otitis media is the commonest cause of severe aural pain in small children. Many infections, especially those accompanying coryza, are caused by viruses. Most uncomplicated cases resolve without antibacterial treatment and a simple analgesic, such as paracetamol p. 354, may be sufficient. In children without systemic features, a systemic antibacterial may be started after 72 hours if there is no improvement, or earlier if there is deterioration, if the patient is systemically unwell, if the patient is at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis), if mastoiditis is present, or in children under 2 years of age with bilateral otitis media. Perforation of the tympanic membrane in patients with acute otitis media usually heals spontaneously without treatment; if there is no improvement, e.g. pain or discharge persists, a systemic antibacterial can be given. Topical treatment of acute otitis media is ineffective and there is no place for drops containing a local anaesthetic.
Otitis media with effusion

Otitis media with effusion (glue ear) occurs in about 10% of children and in 90% of children with cleft palates. Systemic antibacterials are not usually required. If glue ear persists for more than a month or two, the child should be referred for assessment and follow up because of the risk of long-term hearing impairment which can delay language development. Untreated or resistant glue ear may be responsible for some types of chronic otitis media.

Chronic otitis media

Opportunistic organisms are often present in the debris, keratin, and necrotic bone of the middle ear and mastoid in patients with chronic otitis media. The mainstay of treatment is thorough cleansing with aural microsuction which may completely resolve long-standing infection. Local cleansing of the meatal and middle ear may be followed by treatment with a sponge wick or ribbon gauze containing the same drug. There can be variation in the licensing of different medicines containing the same drug.

Removal of ear wax

Ear wax (cerumen) is a normal bodily secretion which provides a protective film on the meatal skin and need only be removed if it causes hearing loss or interferes with a proper view of the ear drum. Ear wax can be softened using simple remedies such as olive oil ear drops or almond oil ear drops; sodium bicarbonate p. 579 ear drops are also effective, but may cause dryness of the ear canal. If the wax is hard and impacted, the drops can be used twice daily for several days and this may reduce the need for mechanical removal of the wax. The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear. Some proprietary preparations containing organic solvents can irritate the meatal skin, and in most cases the simple remedies indicated above are just as effective and less likely to cause irritation. Docosate sodium p. 980 or urea hydrogen peroxide p. 980 are ingredients in a number of proprietary preparations for softening ear wax.

If necessary, wax may be removed by irrigation with water (warmed to body temperature). Ear irrigation is generally best avoided in young children, in patients unable to cooperate with the procedure, in those with otitis media in the last six weeks, in otitis externa, in patients with cleft palate, a history of ear drum perforation, or previous ear surgery. A person who has hearing in one ear only should not have that ear irrigated because even a very slight risk of damage is unacceptable in this situation.

1.1 Otitis externa

ANTI-INFECTIVES

Chloramphenicol

• DRUG ACTION Chloramphenicol is a potent broad-spectrum antibiotic.

INDICATIONS AND DOSE

Bacterial infection in otitis externa

TO THE EAR

• Child: Apply 2–3 drops 2–3 times a day
• Adult: Apply 2–3 drops 2–3 times a day

• CAUTIONS Avoid prolonged use

• SIDE-EFFECTS

• Common or very common High incidence of sensitivity reactions to vehicle

• PATIENT AND CARER ADVICE

Medicines for children leaflet: Chloramphenicol ear drops for ear infections (otitis externa)

www.medicinesforchildren.org.uk/chloramphenicoleardroppersinfectionsotitisexterna

• LESS SUITABLE FOR PRESCRIBING Chloramphenicol ear drops are less suitable for prescribing.

• MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Ear drops

EXCIPIENTS: May contain Propylene glycol

• CHLORAMPHENICOL (Non-proprietary)

Chloramphenicol 50 mg per 1 ml Chloramphenicol 5% ear drops | 10 ml (P) £5.14 DT price = £5.14

Chloramphenicol 100 mg per 1 ml Chloramphenicol 10% ear drops | 10 ml (P) £27.36

Clioquinol with flumetasone pivalate

INDICATIONS AND DOSE

Eczematous inflammation in otitis externa | Mild bacterial or fungal infections in otitis externa

TO THE EAR

• Child 2-17 years: 2–3 drops twice daily for 7–10 days, to be instilled into the ear
• Adult: 2–3 drops twice daily for 7–10 days, to be instilled into the ear

• CONTRA-INDICATIONS Iodine sensitivity

• CAUTIONS Avoid prolonged use - manufacturer advises avoid in perforated tympanic membrane (but used by specialists for short periods)

• SIDE-EFFECTS Local sensitivity

• PATIENT AND CARER ADVICE Clioquinol stains skin and clothing
Ear, nose and oropharynx

Gentamicin

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Ear drops
- CLOQUINOL WITH FLUMETASONE PIVALATE (Non-proprietary)
  Cloquinol 10 mg per 1 ml, Flumetasone pivalate 200 microgram per 1 ml
  Flumetasone 0.02% / Cloquinol 1% ear drops
  7.5 ml [POD] £6.04 DT price = £6.04 | 10 ml [POD] £8.05 DT price = £8.05

SIDE-EFFECTS
Local irritation - local sensitivity

CAUTIONS
Avoid prolonged use

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, oral suspension, oral solution, cream.

Ear/eye drops solution
EXCIPIENTS: May contain Benzalkonium chloride
- GENTAMICIN (Non-proprietary)
  Gentamicin (as Gentamicin sulfate) 3 mg per 1 ml
  Gentamicin 0.3% ear/eye drops
  10 ml [POD] £2.13 DT price = £2.13

- Gentamicin (AMCo)
  Gentamicin (as Gentamicin sulfate) 3 mg per 1 ml
  Gentamicin 0.3% eye/ear drops
  10 ml [POD] £2.13 DT price = £2.13

Clotrimazole

INDICATIONS AND DOSE
Fungal infection in otitis externa

TO THE EAR
- Child: Apply 2–3 times a day continue for at least 14 days after disappearance of infection
- Adult: Apply 2–3 times a day continue for at least 14 days after disappearance of infection

SIDE-EFFECTS
Local irritation

CAUTIONS
Avoid prolonged use

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops containing the same drug.

Liquid
- Canesten (clotrimazole) (Bayer Plc)
  Clotrimazole 10 mg per 1 ml
  Canesten 1% solution
  20 ml [P] £2.30 DT price = £2.30

Framycetin sulfate with dexamethasone and gramicidin

INDICATIONS AND DOSE
Eczematous inflammation in otitis externa

TO THE EAR
- Child: 2–3 drops 3–4 times a day
- Adult: 2–3 drops 3–4 times a day

CONTRA-INDICATIONS
Perforated tympanic membrane

CAUTIONS
Avoid prolonged use

SIDE-EFFECTS
Local sensitivity

LESS SUITABLE FOR PRESCRIBING
Sofradex® is less suitable for prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Ear drops solution
EXCIPIENTS: May contain Polysorbates
- Sofradex (Sanoﬁ)
  Dexamethasone (as Dexamethasone sodium metasulphobenzoate) 500 microgram per 1 ml, Framycetin sulfate 5 mg per 1 ml, Gramicidin 50 microgram per 1 ml
  Sofradex ear/eye drops
  10 ml [POD] £6.25

Gentamicin

INDICATIONS AND DOSE
Bacterial infection in otitis externa

TO THE EAR
- Child: Apply 2–3 drops 4–5 times a day (including a dose at bedtime)
- Adult: Apply 2–3 drops 4–5 times a day (including a dose at bedtime)

CONTRA-INDICATIONS
Patent grommet (although may be used by specialists, see Ear p. 976) - perforated tympanic membrane

CAUTIONS
Avoid prolonged use

SIDE-EFFECTS
Local sensitivity

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Neomycin sulfate with dexamethasone and glacial acetic acid

**INDICATIONS AND DOSE**

Eczematous inflammation in otitis externa

**TO THE EAR**

- **Child 2–17 years:** Apply 1 spray 3 times a day
- **Adult:** Apply 1 spray 3 times a day

- **CONTRA-INDICATIONS**
  - Patient grommet (although may be used by specialists, see Ear p. 976) • perforated tympanic membrane (although may be used by specialists, see Ear p. 976)

- **CAUTIONS**
  - Avoid prolonged use

- **SIDE-EFFECTS**
  - Local sensitivity

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Spray**

- **EXCIPIENTS:** May contain Hydroxybenzoates (parabens)
  - Otozine (Forest Laboratories UK Ltd)
  - Acetic acid glacial 20 mg per 1 gram, Dexamethasone 1 mg per 1 gram, Neomycin sulfate 5 mg per 1 gram Otozine ear spray 1 ml, Neomycin sulfate 5 mg per 1 ml Otozine ear/spray containing the same drug. Forms available from special-order

**ASTRINGENTS**

Aluminium acetate

**INDICATIONS AND DOSE**

Inflammation in otitis externa

**TO THE EAR**

- **Adult:** To be inserted into meatus or apply on a ribbon gauze dressing or sponge wick which should be kept saturated with the ear drops

- **DIRECTIONS FOR ADMINISTRATION**
  - For ear drops 8%—dilute 8 parts aluminium acetate ear drops (13%) with 5 parts purified water. Must be freshly prepared.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ear drops

CORTICOSTEROIDS

Betamethasone

**INDICATIONS AND DOSE**

**BETNESOL®**

Eczematous inflammation in otitis externa

**TO THE EAR**

- **Adult:** Apply 2–3 drops every 2–3 hours, reduce frequency when relief obtained

**VISTAMETHASONE®**

Eczematous inflammation in otitis externa

**TO THE EAR**

- **Adult:** Apply 2–3 drops every 3–4 hours, reduce frequency when relief obtained

- **CONTRA-INDICATIONS**
  - Avoid alone in the presence of untreated infection (combine with suitable anti-infective)

**MEDICATIONS**

There can be variation in the licensing of different medicines containing the same drug.

**Ear/eye drops solution**

- **BETAMETHASONE (Non-proprietary)**
  - Betamethasone sodium phosphate 1 mg per 1 ml Betamethasone 0.1% ear/eye/nose drops 10 ml (no price available)
  - Betnesol (Focus Pharmaceuticals Ltd)
  - Betamethasone sodium phosphate 1 mg per 1 ml Betnesol 0.1% eye/ear/nose drops 10 ml (no price available)
  - Vistamethasone (Martindale Pharmaceuticals Ltd)
  - Betamethasone sodium phosphate 1 mg per 1 ml Vistamethasone 0.1% ear/eye/nose drops 5 ml (no price available)

**INDICATIONS AND DOSE**

**TO THE EAR**

- **Child:** Apply 2–3 drops every 2–3 hours, frequency to be reduced when relief obtained
- **Adult:** Apply 2–3 drops every 2–3 hours, frequency to be reduced when relief obtained

**CAUTIONS**

- Avoid alone in the presence of untreated infection (combine with suitable anti-infective)

**SIDE-EFFECTS**

- Local sensitivity reactions

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ear drops

**Ear/eye drops solution**

- **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - Predsol (Focus Pharmaceuticals Ltd)
  - Prednisolone sodium phosphate 5 mg per 1 ml Predsol 0.5% ear/eye drops 10 ml (no price available)

**1.2 Removal of ear wax**

**BICARBONATE**

**Sodium bicarbonate**

**INDICATIONS AND DOSE**

Removal of ear wax (with 5% ear drop solution)

**TO THE EAR**

- **Child:** (consult product literature)
- **Adult:** (consult product literature)

**SIDE-EFFECTS**

- Dryness of the ear canal

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ear drops**

- **SODIUM BICARBONATE (Non-proprietary)**
  - Sodium bicarbonate 50 mg per 1 ml Sodium bicarbonate 5% ear drops 10 ml £1.25
SOFTENING DRUGS

Almond oil

**INDICATIONS AND DOSE**
Removal of ear wax

**TO THE EAR**
- Adult: Allow drops to warm to room temperature before use (consult product literature)
- Child: Allow drops to warm to room temperature before use (consult product literature)

**DIRECTIONS FOR ADMINISTRATION** The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ear drops

- **Liquid**
  - **ALMOND OIL (Non-proprietary)**
    - Almond oil 1 ml per 1 ml Almond oil liquid | 50 ml £0.76 DT price = £0.76 | 70 ml £0.73 | 200 ml £2.01 | 500 ml £11.56–£11.67 | 2000 ml £19.56 | 200 ml £20.18–£20.38

Arachis oil with chlorobutanol

**INDICATIONS AND DOSE**
Removal of ear wax

**TO THE EAR**

**LESS SUITABLE FOR PRESCRIBING** Arachis (peanut) oil with chlorobutanol ear drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Ear drops**
  - Cerumol (Thornton & Ross Ltd)
    - Arachis oil 573 mg per 1 ml, Chlorobutanol 50 mg per 1 ml Cerumol ear drops | 11 ml | $2.05
  - Exterol (Dermal Laboratories Ltd)
    - Arachis oil 573 mg per 1 ml, Chlorobutanol 50 mg per 1 ml Exterol ear drops | 11 ml | $2.05

Docusate sodium

(Diociyl sodium sulphosuccinate)

**INDICATIONS AND DOSE**
Removal of ear wax

**TO THE EAR**
- Adult: (consult product literature)

**LESS SUITABLE FOR PRESCRIBING** Ear drops less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Ear drops**
  - Molcer (Wallace Manufacturing Chemists Ltd)
    - Docusate sodium 50 mg per 1 ml Molcer ear drops | 15 ml | $0.18
  - Waxsol (Meda Pharmaceuticals Ltd)
    - Docusate sodium 5 mg per 1 ml Waxsol ear drops | 10 ml | $1.95

Olive oil

**INDICATIONS AND DOSE**
Removal of ear wax

**TO THE EAR**
- Adult: Apply twice daily for several days (if wax is hard and impacted)
- Child: Apply twice daily for several days (if wax is hard and impacted)

**DIRECTIONS FOR ADMINISTRATION** The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear. Allow ear drops to warm to room temperature before use.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Ear drops**
  - OLIVE OIL (Non-proprietary)
    - Care olive oil ear drops | 10 ml £1.42
    - Olive oil ear drops | 10 ml £1.42 | 20 ml £2.70
    - Arjun ear drops | 10 ml £1.25
  - Cerumol (olive oil) (Thornton & Ross Ltd)
    - Cerumol olive oil ear drops | 10 ml no price available

- **Spray**
  - Earol (HL Healthcare Ltd)
    - Earol olive oil ear spray | 10 ml no price available

Urea hydrogen peroxide

**INDICATIONS AND DOSE**
Softening and removal of ear wax

**TO THE EAR**
- Adult: (consult product literature)

**PATIENT AND CARER ADVICE** The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear.

**LESS SUITABLE FOR PRESCRIBING** Urea-hydrogen peroxide ear drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Ear drops**
  - Exterol (Dermal Laboratories Ltd)
    - Urea hydrogen peroxide 50 mg per 1 gram Exterol 5% ear drops | 8 ml | $1.75
  - Otex (Dendron Ltd)
    - Urea hydrogen peroxide 50 mg per 1 gram Otex 5% ear drops | 8 ml | $2.89

2 **Nose**

**Nose**

Rhinitis is often self-limiting but bacterial sinusitis may require treatment with antibacterials. There are few indications for nasal sprays and drops except in allergic rhinitis and perennial rhinitis. Many nasal preparations contain sympathomimetic drugs which may damage the nasal cilia. Sodium chloride 0.9% solution may be used as a douche or ‘sniff’ following endonasal surgery.
**Drugs used in nasal allergy**

Mild allergic rhinitis is controlled by antihistamines (see under Antihistamines, allergen immunotherapy and allergic emergencies p. 241) or topical nasal corticosteroids; systemic nasal decongestants are of doubtful value. Topical nasal decongestants can be used for a short period to relieve congestion and allow penetration of a topical nasal corticosteroid.

More persistent symptoms and nasal congestion can be relieved by topical nasal corticosteroids. The topical antihistamine azelastine hydrochloride p. 945 is useful for controlling breakthrough symptoms in allergic rhinitis. Topical antihistamines are considered less effective than topical corticosteroids but probably more effective than cromoglicate. In seasonal allergic rhinitis (e.g. hay fever), treatment should begin 2 to 3 weeks before the season commences and may have to be continued for several months; continuous treatment may be required for years in perennial rhinitis.

Montelukast p. 233 is less effective than topical nasal corticosteroids; montelukast can be used in patients with seasonal allergic rhinitis and concomitant asthma. Sometimes allergic rhinitis is accompanied by vasomotor rhinitis. In this situation, the addition of topical nasal ipratropium bromide can reduce watery rhinorrhea.

Very disabling symptoms occasionally justify the use of systemic corticosteroids for short periods, for example, in students taking important examinations. They may also be used at the beginning of a course of treatment with a corticosteroid spray to relieve severe mucosal oedema and allow the spray to penetrate the nasal cavity.

**Corticosteroids**

Corticosteroid nasal preparations should be avoided in the presence of untreated nasal infections, after nasal surgery (until healing has occurred), and in pulmonary tuberculosis. Patients transferred from systemic corticosteroids may experience exacerbation of some symptoms. Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; for cautions and side-effects of systemic corticosteroids. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays. The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.

**Nasal polyps**

Short-term use of corticosteroid nasal drops helps to shrink nasal polyps; to be effective, the drops must be administered with the patient in the 'head down' position. A short course of a systemic corticosteroid may be required initially to shrink large polyps. A corticosteroid nasal spray can be used to maintain the reduction in swelling and also for the initial treatment of small polyps.

**Pregnancy**

If a pregnant woman cannot tolerate the symptoms of allergic rhinitis, treatment with nasal beclometasone dipropionate p. 984, budesonide p. 984, or fluticasone p. 985 may be considered.

**Topical nasal decongestants**

The nasal mucosa is sensitive to changes in atmospheric temperature and humidity and these alone may cause slight nasal congestion. The nose and nasal sinuses produce a litre of mucus in 24 hours and much of this finds its way silently into the stomach via the nasopharynx. Slight changes in the nasal airway, accompanied by an awareness of mucus passing along the nasopharynx causes some patients to be inaccurately diagnosed as suffering from chronic sinusitis. These symptoms are particularly noticeable in the later stages of the common cold. Sodium chloride 0.9% given as nasal drops or spray may relieve nasal congestion by helping to liquefy mucus secretions.

Inhalation of warm moist air is useful in the treatment of symptoms of acute infective conditions. The addition of volatile substances such as menthol and eucalyptus may encourage the use of warm moist air (see under Aromatic inhalations, cough preparations and systemic nasal decongestants p. 258).

Symptoms of nasal congestion associated with vasomotor rhinitis and the common cold can be relieved by the short-term use (usually not longer than 7 days) of decongestant nasal drops and sprays. These all contain sympathomimetic drugs which exert their effect by vasconstriction of the mucosal blood vessels which in turn reduces oedema of the nasal mucosa. They are of limited value because they can give rise to a rebound congestion (rhinitis medicamentosa) on withdrawal, due to a secondary vasodilatation with a subsequent temporary increase in nasal congestion. This in turn tempts the further use of the decongestant, leading to a vicious cycle of events. Ephedrine hydrochloride p. 982 nasal drops is the safest sympathomimetic preparation and can give relief for several hours. The more potent sympathomimetic drugs oxymetazoline and xylometazoline hydrochloride p. 983 are more likely to cause a rebound effect.

Non-allergic watery rhinorrhea often responds well to treatment with the antimuscarinic ipratropium bromide p. 983.

**Sinusitis and oral pain**

Sinusitis affecting the maxillary antrum can cause pain in the upper jaw. Where this is associated with blockage of the opening from the sinus into the nasal cavity, it may be helpful to relieve the congestion with inhalation of warm moist air or with ephedrine hydrochloride p. 982 nasal drops.

Systemic antibacterials may sometimes be required for sinusitis (see under Nose infections, bacterial p. 446).

**Nasal preparations for infection**

There is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis; see elimination of nasal staphylococci.

**Nasal staphylococci**

Elimination of organisms such as staphylococci from the nasal vestibule can be achieved by the use of a cream containing chlorhexidine and neomycin (Noseptin®), but re-colonisation frequently occurs. Coagulase-positive staphylococci are present in the noses of 40% of the population. A nasal ointment containing mupirocin p. 987 is also available; it should probably be held in reserve for resistant infections. In hospitals or in care establishments, mupirocin nasal ointment should be reserved for the eradication (in both patients and staff) of nasal carriage of meticillin-resistant Staphylococcus aureus (MRSA). A sample should be taken 2 days after treatment to confirm eradication. The course may be repeated if the sample is positive (and the throat is not colonised). To avoid the development of resistance, the treatment course should not exceed 7 days and the course should not be repeated on more than one occasion. If the MRSA strain is mupirocin-resistant or does not respond after 2 courses, consider alternative products such as chlorhexidine and neomycin cream.
2.1 Nasal congestion

**SYMPATHOMIMETICS (VASOCONSTRICTOR)**

**Ephedrine hydrochloride**

**INDICATIONS AND DOSE**

Nasal congestion | Sinusitis affecting the maxillary antrum

- **BY INTRanasAL ADMINISTRATION**
  - Child 12-17 years: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril, administer ephedrine 0.5% nasal drops
  - Adult: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril

- **INTERACTIONS** → Appendix 1 (sympathomimetics).

- **SIDE-EFFECTS**
  - Common or very common | Headache · nausea
  - Frequency not known | After excessive use tolerance with diminished effect · cardiovascular effect · local irritation · rebound congestion

- **PREGNANCY** | Manufacturer advises avoid.

- **BREAST FEEDING** | Present in milk; manufacturer advises avoid—irritability and disturbed sleep reported.

- **PRESCRIBING AND DISPENSING INFORMATION** | For nasal drops, the BP directs that if no strength is specified 0.5% drops should be supplied.

- **PROFESSION SPECIFIC INFORMATION**
  - Dental practitioners’ formulary | Ephedrine nasal drops may be prescribed.
  - EXCEPTIONS TO LEGAL CATEGORY | Ephedrine nasal drops can be sold to the public provided no more than 180 mg of ephedrine base (or salts) are supplied at one time, and pseudoephedrine salts are not supplied at the same time; for conditions that apply to supplies made at the request of a patient, see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: spray, nasal drops
  - Nasal drops
    - **EPHEDRINE HYDROCHLORIDE (Non-proprietary)**
      - Ephedrine hydrochloride 5 mg per 1 ml Ephedrine 0.9% nasal drops | 10 ml £1.53 DT price = £1.53
      - Ephedrine hydrochloride 10 mg per 1 ml Ephedrine 1% nasal drops | 10 ml £1.58 DT price = £1.58

**Pseudoephedrine hydrochloride**

**INDICATIONS AND DOSE**

Congestion of mucous membranes of upper respiratory tract

- **BY MOUTH**
  - Child 6-11 years: 30 mg 3–4 times a day
  - Child 12-17 years: 60 mg 3–4 times a day

**INTERACTIONS**

- **CAUTIONS** | Diabetes · heart disease · hypertension · hyperthyroidism · ischaemic heart disease (in adults) · prostatic hypertrophy (in adults) · raised intra-ocular pressure (in children) · susceptibility to angle-closure glaucoma (in adults)

- **SIDE-EFFECTS**
  - Very rare | Angle-closure glaucoma
  - Rare | Urinary retention

- **PREGNANCY** | Defective closure of the abdominal wall (gastrochisis) reported very rarely in newborns after first trimester exposure.

- **BREAST FEEDING** | May suppress lactation; avoid if lactation not well established or if milk production insufficient.

- **HEPATIC IMPAIRMENT** | Manufacturer advises use with caution in severe impairment.

- **RENAL IMPAIRMENT** | Use with caution in mild to moderate renal impairment. Manufacturer advises avoid in severe renal impairment.

**LESS SUITABLE FOR PRESCRIBING** | Pseudoephedrine hydrochloride is less suitable for prescribing.

**EXCEPTIONS TO LEGAL CATEGORY**

Galpseud® and Sudafed® can be sold to the public provided no more than 720 mg of pseudoephedrine salts are supplied, and ephedrine base (or salts) are not supplied at the same time; for details see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition).
**Xylometazoline hydrochloride**

**DRUG ACTION** Xylometazoline is a sympathomimetic.

**INDICATIONS AND DOSE**

**Nasal congestion**

**BY INTRanasal ADMINISTRATION USING NASAL DROPS**
- Child 6-11 years: 1–2 drops 1–2 times a day as required for maximum duration of 5 days, 0.05% solution to be administered into each nostril
- Child 12-17 years: 2–3 drops 2–3 times a day as required for maximum duration of 7 days, 0.1% solution to be administered into each nostril
- Adult: 2–3 drops 2–3 times a day as required for maximum duration of 7 days, 0.1% solution to be administered into each nostril

**BY INTRanasal ADMINISTRATION USING NASAL SPRAY**
- Child 12-17 years: 1 spray 1–3 times a day as required for maximum duration of 7 days, to be administered into each nostril
- Adult: 1 spray 1–3 times a day as required for maximum duration of 7 days, to be administered into each nostril

**Important safety information**

The CHM/MHRA has stated that non-prescription cough and cold medicines containing ephedrine, oxymetazoline, or xylometalzoline can be considered for up to 5 days’ treatment in children aged 6–12 years after basic principles of best care have been tried; these medicines should not be used in children under 6 years of age.

**CAUTIONS**

- Angle-closure glaucoma - avoid excessive or prolonged use - cardiovascular disease (in children) - diabetes mellitus - elderly - hypertension - hyperthyroidism - ischaemic heart disease (in adults) - prostatic hypertrophy (risk of acute retention) (in adults) - rebound congestion

**SIDE-EFFECTS**

Cardiovascular effects - hallucinations in small children - headache - local irritation - nausea - rebound congestion - restlessness in small children - sleep disturbances in small children - tolerance with diminished effect (after excessive use) - transient visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

Hallucinations (in small children) - Discontinue treatment if the hallucinations occur.

**PREGNANCY**

Manufacturer advises avoid.

**BREAST FEEDING**

Manufacturer advises caution - no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Spray**
- Otrivine (Novartis Consumer Health UK Ltd)
  - Xylometazoline hydrochloride 1 mg per 1 ml Otrivine Congestion Relief 0.1% nasal spray | 10 ml (£5) £2.93 DT price = £2.10
  - Otrivine Adult Measured Dose Sinusitis spray | 10 ml (£5) £2.55 DT price = £2.10
  - Otrivine Allergy Relief 0.1% nasal spray | 10 ml (£5) £2.55 DT price = £2.10
  - Otrivine Adult nasal spray | 10 ml (£5) £2.10 DT price = £2.10

**Corticosteroids (intranasal)**

**CAUTIONS**

- Avoid after nasal surgery (until healing has occurred) - avoid in pulmonary tuberculosis - avoid in the presence of untreated nasal infections - patients transferred from systemic corticosteroids may experience exacerbation of some symptoms

---

**2.2 Nasal inflammation, nasal polyps and rhinitis**

**Drugs used for Nasal inflammation, nasal polyps and rhinitis not listed below:** Desloratadine, p. 247 - Fexofenadine hydrochloride, p. 247 - Ketotifen, p. 249

**Antimuscarinics**

**Ipratropium bromide**

**INDICATIONS AND DOSE**

Rhinorrhoea associated with allergic and non-allergic rhinitis

**BY INTRanasal ADMINISTRATION**
- Child 12-17 years: 2 sprays 2–3 times a day, dose to be sprayed into each nostril
- Adult: 2 sprays 2–3 times a day, dose to be sprayed into each nostril

**Dose equivalence and conversion**

1 metered spray of nasal spray = 21 micrograms.
**CAUTIONS, FURTHER INFORMATION**

**Systemic absorption** Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; therefore also consider the cautions and side-effects of systemic corticosteroids. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays.

- **SIDE-EFFECTS**
  - Rare Glaucoma - raised intra-ocular pressure
  - Very rare Nasal septal perforation (usually following nasal surgery)
  - Frequency not known Aggregation (particularly in children) - anxiety (particularly in children) - bronchospasm - depression (particularly in children) - dryness - epistaxis - headache - hyperactivity (particularly in children) - hypersensitivity reactions - nasal irritation - nasal ulceration - sleep disturbances (particularly in children) - smell disturbances - taste disturbances - throat irritation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Systemic absorption** Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged. Therefore also consider the side-effects of systemic corticosteroids. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays.

### Beclometasone dipropionate (Beclometasone dipropionate)

#### INDICATIONS AND DOSE

**Prophylaxis and treatment of allergic and vasomotor rhinitis**

**BY INTRANASAL ADMINISTRATION**

- Child 6-17 years: 100 micrograms twice daily, dose to be administered into each nostril, reduced to 50 micrograms twice daily, dose to be administered into each nostril, dose to be reduced when symptoms controlled; maximum 400 micrograms per day
- Adult: 100 micrograms twice daily, dose to be administered into each nostril, reduced to 50 micrograms twice daily, dose to be administered into each nostril, dose to be reduced when symptoms controlled; maximum 400 micrograms per day

- **EXCEPTIONS TO LEGAL CATEGORY** Preparations of beclometasone dipropionate can be sold to the public for nasal administration as a nasal spray if supplied for the prevention and treatment of allergic rhinitis in adults over 18 years subject to max. single dose of 100 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. 3 months, and a pack size of 20 mg.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Spray**
    - **EXCIPIENTS:** May contain Benzalkonium chloride, polysorbates
    - **Beclometasone dipropionate 50 microgram per 1 dose** Numark Hayfever Relief 50micrograms/dose nasal spray | 100 dose | 0.50 | £2.04 | 200 dose | 0.33 | £2.33 DT price = £2.30
    - **Beclometasone Hayfever Relief 50micrograms/dose nasal spray** | 200 dose | 0.56 | £2.56 DT price = £2.30
    - **Beclometasone 50micrograms/dose nasal spray** | 180 dose | no price available | 200 dose | 0.50 | no price available DT price = £2.30 | 200 dose | 0.55 | £1.95 DT price = £2.30

- **Betamethasone**
  - **INDICATIONS AND DOSE**
  - **VISTAMETHASONE®**
  - **Non-infected inflammatory conditions of nose**
  - **BY INTRANASAL ADMINISTRATION**
    - Adult: Apply 2–3 drops twice daily, dose to be applied into each nostril

- **Budesonide**
  - **INDICATIONS AND DOSE**
  - **Rhinitis**
    - **BY INTRANASAL ADMINISTRATION**
      - Adult: 128 micrograms once daily, dose to be administered into each nostril in the morning,
Fluticasone

EXCEPTIONS TO LEGAL CATEGORY
Preparations of budesonide can be sold to the public for nasal administration as a nasal spray if supplied for the prevention and treatment of seasonal allergic rhinitis in adults over 18 years subject to max. single dose of 200 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. period of 3 months, and a pack size of 10 mg.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Spray
EXCIPENTS: May contain Dismodium edetate, polysorbates, potassium sorbate

Budesonide (Non-proprietary)
Budesonide 64 microgram per 1 dose
Budesonide 64 micrograms/dose nasal spray | 120 dose | £4.77 DT price = £4.76

Rhinocort (AstraZeneca UK Ltd)
Budesonide 64 microgram per 1 dose
Rhinocort Aqua 64 nasal spray | 120 dose | £3.49 DT price = £4.76

Fluticasone with azelastine

INDICATIONS AND DOSE
Prophylaxis and treatment of allergic rhinitis and perennial rhinitis

BY INTRANASAL ADMINISTRATION USING NASAL SPRAY

Adult: 64 micrograms once daily when control achieved. Use for maximum 3 months, doses to be administered into each nostril

Nasal polyps
BY INTRANASAL ADMINISTRATION USING NASAL DROPS

Child 12-17 years: 200 micrograms 1–2 times a day, to be administered into each nostril, dose of 200 micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4–6 weeks

Adult: 200 micrograms 1–2 times a day, to be administered into each nostril, dose of 200 micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4–6 weeks

AVAMYS® SPRAY

Prophylaxis and treatment of allergic rhinitis
BY INTRANASAL ADMINISTRATION

Adult: 55 micrograms once daily, dose to be sprayed into each nostril, reduced to 27.5 micrograms once daily, to be sprayed into each nostril, dose to be reduced once control achieved; use minimum effective dose

Dose equivalence and conversion
1 spray equivalent to 27.5 micrograms.

SIDE-EFFECTS

SIDE-EFFECTS, FURTHER INFORMATION

Nasal ulceration Nasal ulceration occurs commonly with nasal preparations containing fluticasone furoate.

EXCEPTIONS TO LEGAL CATEGORY
Preparations of fluticasone propionate can be sold to the public for nasal administration (other than by pressurised nasal spray) if supplied for the prevention and treatment of allergic rhinitis in adults over 18 years, subject to max. single dose of 100 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. 3 months, and a pack size of 3 mg.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Spray
EXCIPENTS: May contain Benzalkonium chloride, disodium edetate, polysorbates

FLUTICASONE (Non-proprietary)
Fluticasone propionate 50 microgram per 1 dose
Fluticasone propionate 50 micrograms/dose nasal spray | 60 dose | no price available
Fluticasone propionate 50 micrograms/dose nasal spray | 150 dose | £29.50 DT price = £11.01

Avamys (GlaxoSmithKline UK Ltd)
Fluticasone furoate 27.5 microgram per 1 dose
Fluticasone furoate 27.5 micrograms/dose nasal spray | 120 dose | £6.44 DT price = £6.44

Flixonase (GlaxoSmithKline UK Ltd)
Flixonase (Non-proprietary)
Flixonase propionate 50 microgram per 1 dose
Flixonase propionate 50 micrograms/dose nasal spray | 150 dose | £11.01 DT price = £11.01

Boots Pharmacy

<table>
<thead>
<tr>
<th>Product</th>
<th>Pack size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flixonase nasal spray 150 doses</td>
<td>£11.01</td>
<td></td>
</tr>
<tr>
<td>Flixonase nasal spray 300 doses</td>
<td>£22.02</td>
<td></td>
</tr>
</tbody>
</table>

Flixonase Nasule

Fluticasone propionate 400 microgram
Fluticasone Nasule 400 micrograms/dose nasal drops | 28 unit dose | £12.99 DT price = £12.99

Fluticasone with azelastine

The properties listed below are those particular to the combination only. For the properties of the components please consider, azelastine hydrochloride p. 945, fluticasone above.

INDICATIONS AND DOSE

Moderate to severe seasonal and perennial allergic rhinitis, if monotherapy with antihistamine or corticosteroid is inadequate

BY INTRANASAL ADMINISTRATION

Child 12-17 years: 1 spray twice daily, dose to be administered into each nostril

Adult: 1 spray twice daily, dose to be administered into each nostril

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Spray
EXCIPENTS: May contain Benzalkonium chloride, polysorbates

Dymista (Meda Pharmaceuticals Ltd)
Azelastine hydrochloride 137 microgram per 1 actuation,
Fluticasone propionate 50 microgram per 1 actuation

<table>
<thead>
<tr>
<th>Product</th>
<th>Pack size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dymista 137 micrograms/dose nasal spray</td>
<td>120 dose</td>
<td>£14.80</td>
</tr>
</tbody>
</table>
Mometasone furoate

**INDICATIONS AND DOSE**

**Prophylaxis and treatment of allergic rhinitis by intranasal administration**

- Child 6–11 years: 50 micrograms daily, dose to be sprayed into each nostril
- Child 12–17 years: 100 micrograms daily, increased if necessary up to 200 micrograms daily, dose to be sprayed into each nostril; reduced to 50 micrograms daily, dose to be reduced when control achieved, dose to be sprayed into each nostril
- Adult: 100 micrograms daily, increased if necessary up to 200 micrograms daily, dose to be sprayed into each nostril; reduced to 50 micrograms daily, dose to be reduced when control achieved, dose to be sprayed into each nostril

**Nasal polyps by intranasal administration**

- Adult: Initially 100 micrograms daily for 5–6 weeks, dose to be sprayed into each nostril, then increased if necessary to 100 micrograms twice daily, dose to be sprayed into each nostril, consider alternative treatment if no improvement after further 5–6 weeks, reduce to the lowest effective dose when control achieved

**SIDE-EFFECTS**

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Nasal ulceration**: Nasal ulceration occurs commonly with preparations containing mometasone furoate.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Spray**
  - **EXCIPIENTS**: May contain Benzalkonium chloride, polysorbates
  - **MOMETASONE Furoate (Non-proprietary)**
    - Mometasone furoate 50 microgram per 1 dose Nasonex
    - Mometasone 50 micrograms/dose nasal spray | 140 dose price = £7.39
  - **Nasacort (Sanofi)**
    - Triamcinolone acetonide 55 microgram per 1 dose Nasacort
    - Allergy 55 micrograms/dose nasal spray | 30 dose price = £3.01
    - Nasacort 55 micrograms/dose nasal spray | 120 dose price = £7.39

**MAST CELL STABILISERS**

**Sodium cromoglicate**

(Sodium cromoglicate)

**INDICATIONS AND DOSE**

**Prophylaxis of allergic rhinitis by intranasal administration**

- Child: 1 spray 2–4 times a day, to be administered into each nostril
- Adult: 1 spray 2–4 times a day, to be administered into each nostril

**SIDE-EFFECTS**

- **RARE**: Transient bronchospasm
- **Frequency not known**: Local irritation
- **PREGNANCY**: Not known to be harmful.
- **BREAST FEEDING**: Unlikely to be present in milk.

**MEDICINAL FORMS**

- Medicines not identified.

### 2.3 Nasal staphylococcal infection

**ANTI-INFECTIVES**

**Betamethasone with neomycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 984, neomycin sulfate p. 451.

**INDICATIONS AND DOSE**

**Nasal infection by intranasal administration using nasal drops**

- Child: Apply 2–3 drops 2–3 times a day, to be applied into each nostril
- Adult: Apply 2–3 drops 2–3 times a day, to be applied into each nostril

**LESS SUITABLE FOR PRESCRIBING**

Betamethasone with neomycin nasal-drops are less suitable for prescribing; there is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Drops solution**
  - **EXCIPIENTS**: May contain Benzalkonium chloride, disodium edetate
  - **Betnesol-N ear/eye/nose drops** (Focus Pharmaceuticals)
    - Betamethasone (as Betamethasone sodium phosphate) 1 mg per 1 mL, Neomycin sulfate 5 mg per 1 mL | 10 mL price = £2.39
Chlorhexidine with neomycin

**INDICATIONS AND DOSE**

**Eradication of nasal carriage of staphylococci**

**BY INTRanasAL ADMINISTRATION**

- Child: Apply 4 times a day for 10 days
- Adult: Apply 4 times a day for 10 days

**Preventing nasal carriage of staphylococci**

**BY INTRanasAL ADMINISTRATION**

- Child: Apply twice daily
- Adult: Apply twice daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

EXCIPIENTS: May contain Arachis (peanut) oil, cetostearyl alcohol (including cetyl and stearyl alcohol)

- **Naseptin** (Alliance Pharmaceuticals Ltd)
  - Chlorhexidine hydrochloride 1 mg per 1 gram, Neomycin sulfate 5 mg per 1 gram
  - Naseptin nasal cream | 15 gram (£1.90 DT price = £3.90)

Mupirocin

**INDICATIONS AND DOSE**

**BACTROBAN NASAL®**

For eradication of nasal carriage of staphylococci, including meticillin-resistant *Staphylococcus aureus* (MRSA)

**BY INTRanasAL ADMINISTRATION**

- Child: Apply 2–3 times a day for 5 days; a sample should be taken 2 days after treatment to confirm eradication. Course may be repeated if sample positive (and throat not colonised), dose to be applied to the inner surface of each nostril
- Adult: Apply 2–3 times a day for 5 days; a sample should be taken 2 days after treatment to confirm eradication. Course may be repeated if sample positive (and throat not colonised), dose to be applied to the inner surface of each nostril

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Nasal ointment**

- **Bactroban** (GlaxoSmithKline Ltd)
- **Mupirocin (as Mupirocin calcium) 20 mg per 1 gram** Bactroban 2% nasal ointment | 3 gram (£3.89 DT price = £3.89

3 Oropharynx

3.1 Dry mouth

**Treatment of dry mouth**

Dry mouth (xerostomia) may be caused by drugs with antimuscarinic (anticholinergic) side-effects (e.g. antispasmodics, tricyclic antidepressants, and some antipsychotics), by diuretics, by irradiation of the head and neck region or by damage to or disease of the salivary glands. Patients with a persistently dry mouth may develop a burning or scalded sensation and have poor oral hygiene; they may develop increased dental caries, periodontal disease, intolerance of dentures, and oral infections (particularly candidiasis). Dry mouth may be relieved in many patients by simple measures such as frequent sips of cool drinks or sucking pieces of ice or sugar-free fruit pastilles. Sugar-free chewing gum stimulates salivation in patients with residual salivary function.

**Artificial saliva** can provide useful relief of dry mouth. A properly balanced artificial saliva should be of a neutral pH and contain electrolytes (including fluoride) to correspond approximately to the composition of saliva. The acidic pH of some artificial saliva products may be inappropriate. Of the proprietary preparations, *Aquoral®*, *Biotène Oralbalance®* gel or *Xerolin®* can be used for any condition giving rise to a dry mouth. *BioXtra®, Glandsosane®, Saliva Orthana®,* and *Saliveze®,* have ACBS approval for dry mouth associated only with radiotherapy or sicca syndrome. *Salivex®* pastilles, which act locally as salivary stimulants, are also available for any condition leading to a dry mouth and SST tablets may be prescribed for dry mouth in patients with salivary gland impairment (and patent salivary ducts). Pilocarpine p. 988 tablets are licensed for the treatment of xerostomia following irradiation for head and neck cancer and for dry mouth and dry eyes (xerophthalmia) in Sjögren’s syndrome. They are effective only in patients who have some residual salivary gland function, and therefore should be withdrawn if there is no response.

**Artificial saliva products**

- **ARTIFICIAL SALIVA PRODUCTS**
  - **AS SALIVA ORTHANA® LOZENGES**
    - Mucin 65 mg, xylitol 59 mg, in a sorbitol basis, pH neutral
  - **AS SALIVA ORTHANA® SPRAY**
    - Gastric mucin (porcine) 3.5%, xylitol 2%, sodium fluoride 4.2 mg/litre, with preservatives and flavouring agents, pH neutral

**INDICATIONS AND DOSE**

Dry mouth as a result of having (or having undergone) radiotherapy | Sicca syndrome

**BY MOUTH**

- Adult: 1 lozenge as required, allow to dissolve slowly in the mouth

**PRESCRIBING AND DISPENSING INFORMATION**

Lozenges do not contain fluoride.

- **AS Saliva Orthana lozenges (A S Pharma Ltd)**
  - 30 lozenge (ACBS) • NHS indicative price = £3.50

**ARTIFICIAL SALIVA ORTHANA® GEL**

Lactoperoxidase, lactoferrin, lysozyme, whey colostrum, and pharyngeal mucosa

**INDICATIONS AND DOSE**

Symptomatic treatment of dry mouth

**BY MOUTH**

- Adult: Apply 2–3 sprays as required, spray onto oral and pharyngeal mucosa

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulation

*AS Saliva Orthana® Oral Spray* may be prescribed.

**BIOXTRA GEL**

Lactoperoxidase, lactoferrin, lysozyme, whey colostrum, xylitol and other ingredients.

**INDICATIONS AND DOSE**

Dry mouth as a result of having (or having undergone) radiotherapy (ACBS) | Dry mouth as a result of sicca syndrome (ACBS)

**BY MOUTH**

- Adult: Apply as required, apply to oral mucosa

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulation

*BioXtra®* Gel may be prescribed.
Ear, nose and oropharynx

- BioXtra moisturising gel for dry mouths (R.L.S. Products Ltd)
  40 ml (ACBS) • NHS indicative price = £3.94

**BIOTENE ORALBALANCE**
Lactoperoxidase, lactoferrin, lysozyme, glucose oxidase, xylitol in a gel basis.

**INDICATIONS AND DOSE**
Symptomatic treatment of dry mouth
- Adult: As required, apply to gums and tongue

**PATIENT AND CARER ADVICE**
Avoid use with toothpastes containing detergents (including foaming agents).

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
- Biotene Oralbalance® Saliva Replacement Gel may be prescribed as Artificial Saliva Gel.
- Biotene Oralbalance dry mouth saliva replacement gel (GlaxoSmithKline Consumer Healthcare)
  - Glucose oxidase 12000 unit, Lactoferrin 12 mg, Lactoperoxidase 12000 unit, Muramidase 12 mg | 50 gram • NHS indicative price = £4.46

**GLANDOSANE**
Carmellose sodium 500 mg, sorbitol 1.5 g, potassium chloride 60 mg, sodium chloride 42.2 g, magnesium chloride 2.6 g, calcium chloride 7.3 mg, and dipotassium hydrogen phosphate 17.1 g/50 g, pH 5.75.

**INDICATIONS AND DOSE**
Dry mouth as a result of having (or having undergone) radiotherapy (ACBS) | Sicca syndrome (ACBS)
- Adult: As required, apply to gums and tongue

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
- Glandosane® Aerosol spray may be prescribed.
- Glandosane synthetic saliva spray lemon (Fresenius Kabi Ltd)
  50 ml (ACBS) • NHS indicative price = £5.52
- Glandosane synthetic saliva spray natural (Fresenius Kabi Ltd)
  50 ml (ACBS) • NHS indicative price = £5.52
- Glandosane synthetic saliva spray peppermint (Fresenius Kabi Ltd)
  50 ml (ACBS) • NHS indicative price = £5.52

**SS7**
Sugar-free, citric acid, malic acid and other ingredients in a sorbitol base.

**INDICATIONS AND DOSE**
Symptomatic treatment of dry mouth in patients with impaired salivary gland function and patent salivary ducts
- Adult: 1 tablet as required, allow tablet to dissolve slowly in the mouth

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
- May be prescribed as Saliva Stimulating Tablets.
- SS7 saliva stimulating tablets (Sinclair IS Pharma Plc)
  100 tablet • NHS indicative price = £4.86

**SALIVEZE**
Carmellose sodium (sodium carboxymethylcellulose), calcium chloride, magnesium chloride, potassium chloride, sodium chloride, and dibasic sodium phosphate, pH neutral

**INDICATIONS AND DOSE**
Dry mouth as a result of having (or having undergone) radiotherapy (ACBS) | Sicca syndrome (ACBS)
- Adult: Apply 1 spray as required, spray onto oral mucosa

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
- Saliveze® Oral spray may be prescribed.
- Saliveze mouth spray (Wyvern Medical Ltd)
  50 ml (ACBS) • NHS indicative price = £3.50

**SALIVIX**
Sugar-free, reddish-amber, acacia, malic acid and other ingredients.

**INDICATIONS AND DOSE**
Symptomatic treatment of dry mouth
- Adult: 1 unit as required, suck pastille

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
- Salivix® Pastilles may be prescribed as Artificial Saliva Pastilles.
- Salivix pastilles (Galen Ltd)
  50 pastille • NHS indicative price = £3.55

**XEROTIN**
Sugar-free, water, sorbitol, carmellose (carboxymethylcellulose), potassium chloride, sodium chloride, potassium phosphate, magnesium chloride, calcium chloride and other ingredients, pH neutral.

**INDICATIONS AND DOSE**
Symptomatic treatment of dry mouth
- Adult: 1 spray as required

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
- Xerotin® Oral Spray may be prescribed as Artificial Saliva Oral Spray.
- Xerotin spray (SpePharm UK Ltd)
  100 ml • NHS indicative price = £6.86

**PARASYMPATHOMIMETICS**

**Pilocarpine**

**INDICATIONS AND DOSE**
Xerostomia following irradiation for head and neck cancer
- Adult: 5 mg 3 times a day for 4 weeks, then increased if tolerated to up to 30 mg daily in divided doses if required, dose to be taken with or immediately after meals (last dose always with evening meal), maximum therapeutic effect normally within 4–8 weeks; discontinue if no improvement after 2–3 months

**Dry mouth and dry eyes in Sjögren’s syndrome**
- Adult: 5 mg 4 times a day; increased if tolerated to up to 30 mg daily in divided doses if required, dose to be taken with meals and at bedtime, discontinue if no improvement after 2–3 months

**CONTRA-INDICATIONS**
Acute iritis • chronic obstructive pulmonary disease (increased bronchial secretions and increased airways resistance) • uncontrolled asthma (increased bronchial secretions and increased airways resistance) • uncontrolled cardiac failure
CAUTIONS Asthma (avoid if uncontrolled) - biliary-tract disease - cardiovascular disease (avoid if uncontrolled) - cholelithiasis - chronic obstructive pulmonary disease (avoid if uncontrolled) - cognitive disturbances - maintain adequate fluid intake to avoid dehydration associated with excessive sweating - pepsic ulceration - psychiatric disturbances - risk of increased renal colic - risk of increased urethral smooth muscle tone - susceptibility to angle-closure glaucoma

INTERACTIONS Appendix 1 (parasympathomimetics).

SIDE-EFFECTS

Common or very common Influenza-like symptoms - abdominal pain - asthena - conjunctivitis - constipation - diarrhoea - dizziness - dyspepsia - flushing - headache - hypertension - increased urinary frequency - lacrimation - nausea - ocular pain - palpitation - pruritis - rash - rhinitis - sweating - visual disturbances - vomiting

Uncommon Flatulence - urinary urgency

PREGNANCY Avoid – smooth muscle stimulant; toxicity in animal studies.

BREAST FEEDING Manufacturer advises avoid – present in milk in animal studies.

HEPATIC IMPAIRMENT Reduce initial oral dose in moderate or severe cirrhosis.

RENAL IMPAIRMENT Manufacturer advises caution with tablets.

PATIENT AND CARER ADVICE Blurred vision may affect performance of skilled tasks (e.g. driving) particularly at night or in reduced lighting.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 21, 27

> Salagen (Novartis Pharmaceudicals UK Ltd)

Pilocarpine hydrochloride 5 mg Salagen 5mg tablets 84 tablet 141.14 07 price 141.14

3.2 Oral hygiene

Mouthwashes and other preparations for oropharyngeal use

Lozenges and sprays

There is no convincing evidence that antiseptic lozenges and sprays have a beneficial action and they sometimes irritate and cause sore tongue and sore lips. Some of these preparations also contain local anaesthetics which relieve pain but may cause sensitisation.

Mouthwashes, gargles, and dentifrices

Superficial infections of the mouth are often helped by warm mouthwashes which have a mechanical cleansing effect and cause some local hyperaemia. However, to be effective, they must be used frequently and vigorously. A warm saline mouthwash is ideal and can be prepared either by dissolving half a teaspoonful of salt in a glassful of warm water or by diluting compound sodium chloride mouthwash with an equal volume of warm water.

Mouthwashes containing an oxidising agent, such as hydrogen peroxide p. 990, may be useful in the treatment of acute ulcerative gingivitis (Vincent’s infection) since the organisms involved are anaerobes. It also has a mechanical cleansing effect arising from frothing when in contact with oral debris.

Chlorhexidine is an effective antiseptic which has the advantage of inhibiting plaque formation on the teeth. It does not, however, completely control plaque deposition and is not a substitute for effective toothbrushing. Moreover, chlorhexidine preparations do not penetrate significantly into stagnation areas and are therefore of little value in the control of dental caries or of periodontal disease once pocketing has developed.

Chlorhexidine mouthwash is used in the treatment of denture stomatitis. It is also used in the prevention of oral candidiasis in immunocompromised patients. Chlorhexidine mouthwash reduces the incidence of alveolar osteitis following tooth extraction. Chlorhexidine mouthwash should not be used for the prevention of endocarditis in patients undergoing dental procedures.

Chlorhexidine can be used as a mouthwash, spray or gel for secondary infection in mucosal ulceration and for controlling gingivitis, as an adjunct to other oral hygiene measures. These preparations may also be used instead of toothbrushing where there is a painful periodontal condition (e.g. primary herpetic stomatitis) or if the patient has a haemorrhagic disorder, or is disabled.

Chlorhexidine preparations are of little value in the control of acute nercotising ulcerative gingivitis. With prolonged use, chlorhexidine causes reversible brown staining of teeth and tongue. Chlorhexidine may be incompatible with some ingredients in toothpaste, causing an unpleasant taste in the mouth; rinse the mouth thoroughly with water between using toothpaste and chlorhexidine-containing products.

There is no convincing evidence that gargles are effective in adults.

Chlorhexidine

INDICATIONS AND DOSE

Oral hygiene and plaque inhibition | Oral candidiasis | Gingivitis | Management of apthous ulcers

BY MOUTH USING MOUTHWASH

> Child: Rinse or gargle 10 mL twice daily (rinse or gargle for about 1 minute)
> Adult: Rinse or gargle 10 mL twice daily (rinse or gargle for about 1 minute)

Denture stomatitis

MOUTHWASH

> Adult: Cleanse and soak dentures in mouthwash solution for 15 minutes twice daily

Oral hygiene and plaque inhibition and gingivitis

BY MOUTH USING DENTAL GEL

> Child: Apply 1–2 times a day, to be brushed on the teeth
> Adult: Apply 1–2 times a day, to be brushed on the teeth

Oral candidiasis | Management of apthous ulcers

BY MOUTH USING DENTAL GEL

> Child: Apply 1–2 times a day, to affected areas
> Adult: Apply 1–2 times a day, to affected areas

Oral hygiene and plaque inhibition | Oral candidiasis | Gingivitis | Management of apthous ulcers

BY MOUTH USING OROMUCOSAL SPRAY

> Child: Apply up to 12 sprays twice daily as required, to be applied to tooth, gingival, or ulcer surfaces
> Adult: Apply up to 12 sprays twice daily as required, to be applied to tooth, gingival, or ulcer surfaces

SIDE-EFFECTS Anaphylaxis - hypersensitivity - mucosal irritation - parotid gland swelling - reversible brown staining of composite restorations - reversible brown
Chlorhexidine with chlorobutanol

**Indications and dose**

**Adult:**
- Rinse or gargle 15 ml 2-3 times a day.

**Child:**
- Rinse or gargle 10-15 ml 2-3 times a day.

**SIDE EFFECTS**

- Very rare: Taste disturbance.
- Frequency not known: Local irritation.

**Test results**

- Chlorhexidine gluconate 2 mg per 1 ml (GlaxoSmithKline Consumer Healthcare) DT price = £48.06
- Chlorhexidine gluconate 2 mg per 1 ml (GlaxoSmithKline Consumer Healthcare) DT price = £46.46
- Chlorhexidine gluconate 10 mg per 1 gram (sugar-free) DT price = £28.28
- Chlorhexidine gluconate 10 mg per 1 gram (sugar-free) DT price = £28.43

**Handing and storage**

- Chlorhexidine Oral Spray may be prescribed as Chlorhexidine Gluconate Gel; Corsodyl.

**Prescription specific information**

- Adult: Rinse or gargle 15 ml 2-3 times a day.

**Local irritation**

- There can be variation in the licensing of different medicines containing the same drug.

**Indications and dose**

**Adult:**
- Rinse or gargle 15 ml 2-3 times a day.

**Child:**
- Rinse or gargle 10-15 ml 2-3 times a day.

**SIDE EFFECTS**

- Very rare: Taste disturbance.
- Frequency not known: Local irritation.

**Test results**

- Chlorhexidine gluconate 10 mg per 1 gram (Colgate Pro Gum Health) DT price = £1.50
- Chlorhexidine gluconate 2 mg per 1 ml (Colgate Pro Gum Health) DT price = £1.00
- Chlorhexidine gluconate 2 mg per 1 ml (GlaxoSmithKline Consumer Healthcare) DT price = £0.99
- Chlorhexidine gluconate 10 mg per 1 gram (McNeil Products Ltd) DT price = £0.09

**Handing and storage**

- Chlorhexidine Oral Spray may be prescribed as Chlorhexidine Gluconate Gel; Corsodyl.

**Prescription specific information**

- Adult: Rinse or gargle 15 ml 2-3 times a day.

**Local irritation**

- There can be variation in the licensing of different medicines containing the same drug.

**Indications and dose**

**Adult:**
- Rinse or gargle 15 ml 2-3 times a day.

**Child:**
- Rinse or gargle 10-15 ml 2-3 times a day.

**SIDE EFFECTS**

- Very rare: Taste disturbance.
- Frequency not known: Local irritation.

**Test results**

- Chlorhexidine gluconate 10 mg per 1 gram (Colgate Pro Gum Health) DT price = £1.50
- Chlorhexidine gluconate 2 mg per 1 ml (Colgate Pro Gum Health) DT price = £1.00
- Chlorhexidine gluconate 2 mg per 1 ml (GlaxoSmithKline Consumer Healthcare) DT price = £0.99
- Chlorhexidine gluconate 10 mg per 1 gram (McNeil Products Ltd) DT price = £0.09

**Handing and storage**

- Chlorhexidine Oral Spray may be prescribed as Chlorhexidine Gluconate Gel; Corsodyl.

**Prescription specific information**

- Adult: Rinse or gargle 15 ml 2-3 times a day.

**Local irritation**

- There can be variation in the licensing of different medicines containing the same drug.

**Indications and dose**

**Adult:**
- Rinse or gargle 15 ml 2-3 times a day.

**Child:**
- Rinse or gargle 10-15 ml 2-3 times a day.

**SIDE EFFECTS**

- Very rare: Taste disturbance.
- Frequency not known: Local irritation.

**Test results**

- Chlorhexidine gluconate 10 mg per 1 gram (Colgate Pro Gum Health) DT price = £1.50
- Chlorhexidine gluconate 2 mg per 1 ml (Colgate Pro Gum Health) DT price = £1.00
- Chlorhexidine gluconate 2 mg per 1 ml (GlaxoSmithKline Consumer Healthcare) DT price = £0.99
- Chlorhexidine gluconate 10 mg per 1 gram (McNeil Products Ltd) DT price = £0.09

**Handing and storage**

- Chlorhexidine Oral Spray may be prescribed as Chlorhexidine Gluconate Gel; Corsodyl.

**Prescription specific information**

- Adult: Rinse or gargle 15 ml 2-3 times a day.

**Local irritation**

- There can be variation in the licensing of different medicines containing the same drug.
Sodium bicarbonate with sodium chloride

**INDICATIONS AND DOSE**
- Oral hygiene
  - Adult: (consult product literature)

**DIRECTIONS FOR ADMINISTRATION** For mouthwash, extemporaneous preparations should be prepared according to the following formula: sodium chloride 1.5 g, sodium bicarbonate 1 g, concentrated peppermint emulsion 2.5 mL, double-strength chloroform water 50 mL, water to 100 mL. To be diluted with an equal volume of warm water prior to administration.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of mouthwash may include peppermint.

**PROFESSION SPECIFIC INFORMATION**
- Dental practitioners' formulary
  - Compound sodium chloride mouthwash may be prescribed.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: mouthwash
  - Peroxyl (Colgate-Palmolive (UK) Ltd)
  - Hydrogen peroxide 15 mg per 1 ml Peroxyl 1.5% mouthwash (sugar-free) | 300 ml [SSL] £2.94

3.3 Oral hygiene, dental caries

**Dental caries**

**Fluoride**

Availability of adequate fluoride confers significant resistance to dental caries. It is now considered that the topical action of fluoride on enamel and plaque is more important than the systemic effect.

When the fluoride content of drinking water is less than 700 micrograms per litre (0.7 parts per million), daily administration of fluoride tablets or drops provides suitable supplementation. Systemic fluoride supplements should not be prescribed without reference to the fluoride content of the local water supply. Infants need not receive fluoride supplementation. Systemic fluoride supplements should not be prescribed without reference to the fluoride content of the local water supply. Infants need not receive fluoride supplementation.

Clinical advice and expert opinion are required to prevent children from swallowing any excess. Less concentrated gels are available for home use. Varnishes are also available and are particularly valuable for young or disabled children since they adhere to the teeth and set in the presence of moisture.

**Fluoride**

**Sodium fluoride**

**INDICATIONS AND DOSE**
- Prophylaxis of dental caries for water content less than 300 micrograms/litre (0.3 parts per million) of fluoride ion
  - BY MOUTH USING TABLETS
    - Child 6 months–2 years: 250 micrograms daily, doses expressed as fluoride ion (F–)
    - Child 3–5 years: 500 micrograms daily, doses expressed as fluoride ion (F–)
    - Child 6–17 years: 1 mg daily, doses expressed as fluoride ion (F–)
    - Adult: 1 mg daily, doses expressed as fluoride ion (F–)

- Prophylaxis of dental caries for water content between 300 and 700 micrograms/litre (0.3–0.7 parts per million) of fluoride ion
  - BY MOUTH USING TABLETS
    - Child 3–5 years: 250 micrograms daily, doses expressed as fluoride ion (F–)
    - Child 6–17 years: 500 micrograms daily, doses expressed as fluoride ion (F–)
    - Adult: 500 micrograms daily, doses expressed as fluoride ion (F–)

- Prophylaxis of dental caries for water content above 700 micrograms/litre (0.7 parts per million) of fluoride ion
  - Child 6 months–7 years: Supplements not advised
  - Adult: Supplements not advised

**PROPHYLAXIS OF DENTAL CARRIES FOR INDIVIDUALS WHO ARE CARRIES PRONE OR MEDICALLY COMPROMISED**
- BY MOUTH USING MOUTHWASH
  - Child 6–17 years: Rinse or gargle 10 mL daily
  - Adult: Rinse or gargle 10 mL daily

**Dose equivalence and conversion**
- Sodium fluoride 2.2 mg provides approx. 1 mg fluoride ion.

- These doses reflect the recommendations of the British Dental Association, the British Society of Paediatric Dentistry and the British Association for the Study of Community Dentistry (Br Dent J 1997; 182: 6–7).

**COLGATE DURAPHAT® 2800PPM FLUORIDE TOOTHPASTE**
- Prophylaxis of dental caries
  - BY MOUTH USING PASTE
    - Child 10–17 years: Apply 1 centimetre twice daily, to be applied using a toothbrush
    - Adult: Apply 1 centimetre twice daily, to be applied using a toothbrush

**COLGATE DURAPHAT® 5000PPM FLUORIDE TOOTHPASTE**
- Prophylaxis of dental caries
  - BY MOUTH USING PASTE
    - Child 16–17 years: Apply 2 centimetres 3 times a day, to be applied after meals using a toothbrush
    - Adult: Apply 2 centimetres 3 times a day, to be applied after meals using a toothbrush

**EN-DE-KAY® FLORINSE**
- Prophylaxis of dental caries for individuals who are caries prone or medically compromised
  - INITIALLY BY MOUTH USING MOUTHWASH
    - Adult: 5 drops daily, dilute 5 drops to 10 mL of water, alternatively (by mouth) 20 drops once daily, dilute 20 drops to 10 mL

**CONTRA-INDICATIONS**
- Not for areas where drinking water is fluoridated

**SIDE-EFFECTS**
- **Uncommon** Occasional white flecks on teeth with recommended doses
- **Rare** Yellowish-brown discoloration if recommended doses are exceeded
PROFESSION SPECIFIC INFORMATION

Flavours of oral tablet formulations may include orange.

PATIENT AND CARER ADVICE

Mouthwash

Avoid eating, drinking, or rinsing mouth for 30 minutes after use.

Colgate Duraphat®

Dental practitioners®

administer Sodium fluoride toothpaste.

Avoid drinking or rinsing mouth for 30 minutes after use.

Colgate Duraphat®

May be prescribed as Sodium Fluoride Toothpaste. Avoid drinking or rinsing mouth for 30 minutes after use.

Fluoride gels are not prescribable on form FP

School dental schemes, and they may also be supplied in

▶ Colgate Duraphat®

Paste

▶ Oral drops

▶ Chewable tablet

▶ Sodium fluoride 1.1 mg

Endekay Fluor-a-day (Dental Health Products Ltd)

Sodium fluoride 1.1 mg Fluor-a-day chewable tablets (sugar-free) | 200 tablet | £2.38 DT price = £2.38

Sodium fluoride 2.2 mg Fluor-a-day 2.2 mg chewable tablets (sugar-free) | 200 tablet | £2.38 DT price = £2.38

Oral drops

Endekay® (Manx Healthcare Ltd)

Sodium fluoride 3.7 mg per 1 ml Endekay Fluidrops 0.37% drops paediatric (sugar-free) | 60 ml | £2.38 DT price = £2.38

Pastes

Colgate Duraphat®

Flouride (as Sodium fluoride) 2.8 mg per 1 gram Colgate Duraphat 2800ppm fluoride toothpaste (sugar-free) | 75 ml | £3.26 DT price = £3.26

Flouride (as Sodium fluoride) 5 mg per 1 gram Colgate Duraphat 5000ppm fluoride toothpaste (sugar-free) | 51 gram | £6.50 DT price = £6.50

DIRECTIONS FOR ADMINISTRATION

With oral use Tablets should be sucked or dissolved in the mouth and taken preferably in the evening.

With oral (topical) use For mouthwash, rinse mouth for 1 minute and then spit out.

COLGATE DURAPHAT® 2800PPM FLUORIDE TOOTHPASTE

Brush teeth for 1 minute before spitting out.

COLGATE DURAPHAT® 5000PPM FLUORIDE TOOTHPASTE

Brush teeth for 3 minutes before spitting out.

PRESCRIBING AND DISPENSING INFORMATION

Mouthwash

Avoid eating, drinking, or rinsing mouth for 15 minutes after use.

Colgate Duraphat®

May be prescribed as Sodium Fluoride Toothpaste. Avoid drinking or rinsing mouth for 30 minutes after use.

Colgate Duraphat®

May be prescribed as Sodium Fluoride Toothpaste 0.619%.

Dental practitioners’ formulary

Dental practitioners’ formulary

Dental practitioners’ formulary

Dental practitioners’ formulary

Dental practitioners’ formulary

Dental practitioners’ formulary

Dental practitioners’ formulary

Mouthwash

SODIUM FLUORIDE (Non-proprietary)

Sodium fluoride 1.1 mg per 1 gram 400 ml £4.55

Sodium fluoride 500 microgram per 1 ml Sodium fluoride sugar free (sugar-free) | 250 ml | no price available (sugar-free) | 500 ml | no price available (sugar-free) | £38

Brands may include Colgate, Endekay; Oral-B

3.4 Oral ulceration and inflammation

Oral ulceration and inflammation

Ulceration and inflammation

Oral ulceration and inflammation

Ulceration of the oral mucosa may be caused by trauma (physical or chemical), recurrent aphthae, infections, carcinoma, dermatological disorders, nutritional deficiencies, gastro-intestinal disease, haematopoietic disorders, and drug therapy (see also Chemotherapy induced mucositis and myelosuppression under Cytotoxic drugs p. 744). It is important to establish the diagnosis in each case as the majority of these lesions require specific management in addition to local treatment. Local treatment aims to protect the ulcerated area, to relieve pain, to reduce inflammation, or to control secondary infection. Patients with an unexplained mouth ulcer of more than 3 weeks’ duration require urgent referral to hospital to exclude oral cancer.

Simple mouthwashes

A saline mouthwash may relieve the pain of traumatic ulceration. The mouthwash is made up with warm water and used at frequent intervals until the discomfort and swelling subside.

Antiseptic mouthwashes

Secondary bacterial infection may be a feature of any mucosal ulceration; it can increase discomfort and delay healing. Use of a chlorhexidine mouthwash p. 989 is often beneficial and may accelerate healing of recurrent aphthae.

Corticosteroids

Topical corticosteroid therapy may be used for some forms of oral ulceration. In the case of aphthous ulcers it is most effective if applied in the ‘prodromal’ phase.

Thrush or other types of candidiasis are recognised complications of corticosteroid treatment.

Hydrocortisone oromucosal tablets p. 993 are allowed to dissolve next to an ulcer and are useful in recurrent aphthae and erosive lichenoid lesions.

Beclometasone dipropionate inhaler p. 993 sprayed on the oral mucosa is used to manage oral ulceration [unlicensed indication]. Alternatively, betamethasone soluble tablets p. 993 dissolved in water can be used as a mouthwash to treat oral ulceration [unlicensed indication].

Systemic corticosteroid therapy (see under Corticosteroids, inflammatory disorders p. 939), is reserved for severe conditions such as pemphigus vulgaris.

Local analgesics

Local analgesics have a limited role in the management of oral ulceration. When applied topically their action is of a relatively short duration so that analgesia cannot be maintained continuously throughout the day. The main indication for a topical local analgesic is to relieve the pain of otherwise intractable oral ulceration particularly when it is due to major aphthae. For this purpose lidocaine hydrochloride 5% p. 994 ointment or lozenges containing a local anaesthetic are applied to the ulcer. Lidocaine hydrochloride 10% p. 994 solution as spray can be applied
thinly to the ulcer [unlicensed indication] using a cotton bud. When local anaesthetics are used in the mouth care must be taken not to produce anaesthesia of the pharynx before meals as this might lead to choking.

Preparations on sale to the public: many mouth ulcer preparations, throat lozenges, and throat sprays on sale to the public contain a local anaesthetic. To identify the active ingredients in such preparations, consult the product literature of the manufacturer—the correct proprietary name should be ascertained as many products have very similar names but different active ingredients.

Benzydamine hydrochloride below and flurbiprofen p. 994 are non-steroidal anti-inflammatory drugs (NSAIDs). Benzydamine hydrochloride below mouthwash or spray may be useful in reducing the discomfort associated with a variety of ulcerative conditions. It has also been found to be effective in reducing the discomfort of tonsillectomy and post-irradiation mucositis. Some patients find the full-strength mouthwash causes some stinging and, for them, it should be diluted with an equal volume of water. Flurbiprofen lozenges are licensed for the relief of sore throat.

Choline salicylate p. 994 is a derivative of salicylic acid and has some analgesic action. The dental gel may provide relief for recurrent aphthae, but excessive application or confinement under a denture irritates the mucosa and can itself cause ulceration.

Other preparations

Doxycycline p. 995 rinsed in the mouth may be of value for recurrent aphthous ulceration.

Periodontitis

Low-dose doxycycline p. 995 (Periostat®) is licensed as an adjunct to scaling and root planing for the treatment of periodontitis; a low dose of doxycycline reduces collagenase activity without inhibiting bacteria associated with periodontitis.

For anti-infectives used in the treatment of destructive (refractory) forms of periodontal disease, see under Oropharynx infections, bacterial p. 995. See also Mouthwashes and other preparations for oropharyngeal use p. 989 for mouthwashes used for oral hygiene and plaque inhibition.

CORTICOSTEROIDS

Beclometasone dipropionate (Beclohexasone dipropionate)

INDICATIONS AND DOSE
Management of oral ulceration

BY BUCCAL ADMINISTRATION

> Adult: 50–100 micrograms twice daily, use inhaler device to spray dose on to the oral mucosa

> UNLICENSED USE Use of soluble tablets and inhaler unlicensed in oral ulceration.

> MEDICINAL FORMS

For preparations see inhaled beclomethasone p. 228.

Betamethasone

INDICATIONS AND DOSE
Oral ulceration

BY MOUTH USING SOLUBLE TABLETS

> Child 12–17 years: 500 micrograms 4 times a day, to be dissolved in 20 mL water and rinsed around the mouth; not to be swallowed

> Adult: 500 micrograms 4 times a day, to be dissolved in 20 mL water and rinsed around the mouth; not to be swallowed

> UNLICENSED USE Betamethasone soluble tablets not licensed for use as mouthwash or in oral ulceration.

> CONTRA-INDICATIONS Untreated local infection

> SIDE-EFFECTS Candidial infection • exacerbation of local infection

> PATIENT AND CARER ADVICE Patient counselling is advised for betamethasone soluble tablets (administration).

> PROFESSION SPECIFIC INFORMATION

Dental practitioners' formulation
Betamethasone Soluble Tablets 500 micrograms may be prescribed for oral ulceration.

> MEDICINAL FORMS

Soluble tablet

CAUTIONARY AND ADVISORY LABELS 10, 13, 21

> BETAMETHASONE (Non-proprietary)

Betamethasone (as Betamethasone sodium phosphate) 500 microgram Betamethasone 500microgram soluble tablets sugar free (sugar-free) | 100 tablet (PDR) £29.85 DT price = £29.70

Hydrocortisone

INDICATIONS AND DOSE
Oral and perioral lesions

BY BUCCAL ADMINISTRATION

> Child 1 month–11 years: Only on medical advice

> Child 12–17 years: 1 lozenge 4 times a day, allowed to dissolve slowly in the mouth in contact with the ulcer

> Adult: 1 lozenge 4 times a day, allowed to dissolve slowly in the mouth in contact with the ulcer

> UNLICENSED USE Hydrocortisone mucosalhesive buccal tablets licensed for use in children (under 12 years—on medical advice only).

> CONTRA-INDICATIONS Untreated local infection

> SIDE-EFFECTS Candidial infection • exacerbation of local infection

> PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulation
Mucosalhesive buccal tablets may be prescribed as Hydrocortisone Oromucosal Tablets.

> MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: pastille

Muco-adhesive buccal tablet

HYDROCORTISONE (Non-proprietary)

Hydrocortisone (as Hydrocortisone sodium succinate) 2.5 mg Hydrocortisone2.5 mg muco-adhesive buccal tablets sugar free (sugar-free) | 20 tablet (PDR) £4.55 DT price = £4.55

NON-STERoidal ANTI-INFLAMMATORY DRUGS

Benzydamine hydrochloride

INDICATIONS AND DOSE

Painful inflammatory conditions of oropharynx

BY MOUTH USING MOUTHWASH

> Child 13–17 years: Rinse or gargle 15 mL every 1.5–3 hours as required usually for not more than 7 days, dilute with an equal volume of water if stinging occurs

> Adult: Rinse or gargle 15 mL every 1.5–3 hours as required usually for not more than 7 days, dilute with an equal volume of water if stinging occurs Continued →
BY MOUTH USING OROMUCOSAL SPRAY
- Child 1 month-5 years: 1 spray every 1.5–3 hours (max. per dose 4 sprays every 1.5–3 hours), one spray per 4 kg body-weight. To be administered to the affected area
- Child 6–11 years: 4 sprays every 1.5–3 hours, to be administered onto affected area
- Child 12–17 years: 4–8 sprays every 1.5–3 hours, to be administered onto affected area
- Adult: 4–8 sprays every 1.5–3 hours, to be administered onto affected area

**SIDE-EFFECTS**
- **Rare** Hypersensitivity reactions
- **Frequency not known** Occasional numbness or stinging

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Spray**
- BENZAMINE HYDROCHLORIDE (Non-proprietary)
  Benzydamine hydrochloride 1.5 mg per 1 ml
  Benzydamine 150 mg oral solution
  Benzydamine mouthwash 1.5 mg per 1 ml

**Mouthwash**
- BENZAMINE HYDROCHLORIDE (Non-proprietary)
  Benzydamine hydrochloride 1.5 mg per 1 ml
  Benzydamine mouthwash 1.5 mg per 1 ml

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary

**Renal Impairment**
Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**renal impairment**
Deterioration in renal function has also been reported after topical use.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Lozenge**
- STRENGTH (Reckitt Benckiser Healthcare (UK) Ltd)
  Flurbiprofen 8.75 mg

**Benzydamine mouthwash**
May be prescribed as
- STREFEN containing the same drug.

**Flurbiprofen**
Relief of sore throat

**INDICATIONS AND DOSE**
Relief of sore throat
BY MOUTH USING LOZENGES
- Child 12–17 years: 1 lozenge every 3–6 hours for maximum 3 days, allow lozenge to dissolve slowly in the mouth; maximum 5 lozenges per day
- Adult: 1 lozenge every 3–6 hours for maximum 3 days, allow lozenge to dissolve slowly in the mouth; maximum 5 lozenges per day

**INTERACTIONS** → Appendix 1 (NSAIDs).
**SIDE-EFFECTS**
Mouth ulcers (move lozenge around mouth) - taste disturbance
**ALLERGY AND CROSS-SENSITIVITY**
Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**SALICYLATES**
Choline salicylate

**INDICATIONS AND DOSE**
Mild oral and perioral lesions
TO THE LESION
- Child 16–17 years: Apply 0.5 inch, apply with gentle massage, not more often than every 3 hours
- Adult: Apply 0.5 inch, apply with gentle massage, not more often than every 3 hours

**CONTRA-INDICATIONS**
Children under 16 years

**REYE’S SYNDROME**
The CHM has advised that topical oral pain relief products containing salicylate salts should not be used in children under 16 years, as a cautionary measure due to the theoretical risk of Reye’s syndrome.
Salicylic acid with rhubarb extract

**INDICATIONS AND DOSE**
Mild oral and perioral lesions

**BY MOUTH**
- Child 16–17 years: Apply 3–4 times a day maximum duration 7 days
- Adult: Apply 3–4 times a day maximum duration 7 days

**CONTRA-INDICATIONS**
Children under 16 years

**CONTRA-INDICATIONS, FURTHER INFORMATION**
Reye’s syndrome: The CHM has advised that topical oral pain relief products containing salicylate salts should not be used in children under 16 years, as a cautionary measure due to the theoretical risk of Reye’s syndrome.

**CAUTIONS**
**GENERAL CAUTIONS**
Frequent application, especially in children, may give rise to salicylate poisoning

**SPECIFIC CAUTIONS**
Not to be applied to dentures—leave at least 30 minutes before re-insertion of dentures

**SIDE-EFFECTS**
Transient local burning sensation

**PATIENT AND CARER ADVICE**
May cause temporary discolouration of teeth and oral mucosa.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

### Oromucosal gel
- **Bonjela** (Reckitt Benckiser Healthcare (UK) Ltd)
  - Choline salicylate 87 mg per 1 gram
  - Bonjela Cool Mint gel (sugar-free) | 15 gram GSK £2.58 DT price = £2.26
  - Bonjela Original gel (sugar-free) | 15 gram GSK £2.26 DT price = £2.26

### Supplement

### BENEFITS
- **See below for indications and dosages.**

### SIDE-EFFECTS
- Transient local burning sensation
- Temporary discolouration of oral mucosa

### CONTRA-INDICATIONS
- **Children under 16 years**

### CAUTIONS
**GENERAL CAUTIONS**
Frequent application, especially in children, may give rise to salicylate poisoning

**SPECIFIC CAUTIONS**
Not to be applied to dentures—leave at least 30 minutes before re-insertion of dentures

**SIDE-EFFECTS**
Temporary discolouration of oral mucosa.

**PATIENT AND CARER ADVICE**
May cause temporary discolouration of teeth and oral mucosa.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

### Paint
- **EXCIPIENTS: May contain Ethanol**
- **Rhubarb extract** 50 mg per 1 ml, **Salicylic acid** 10 mg per 1 ml
- **Pyralvex solution** | 10 ml £3.25

### Acne vulgaris

### TREATMENT OPTIONS
- **Antibacterial therapy**

#### Acne vulgaris

### Doxycycline

**INDICATIONS AND DOSE**
Treatment of recurrent aphthous ulceration

**BY MOUTH USING SOLUBLE TABLETS**
- **Child 12–17 years:** 100 mg 4 times a day usually for 3 days, dispersible tablet can be stirred into a small amount of water then rinsed and swallowed for 2–3 minutes, it should preferably not be swallowed
- **Adult:** 100 mg 4 times a day usually for 3 days, dispersible tablet can be stirred into a small amount of water then rinsed and swallowed for 2–3 minutes, it should preferably not be swallowed

### Antibacterial therapy

#### Pericoronitis
- **Antibacterial required only in presence of systemic features of infection, or of trismus, or persistent swelling despite local treatment.**
  - **Metronidazole p. 475, or alternatively, amoxicillin**
    - **Suggested duration of treatment** 3 days or until symptoms resolve.

#### Gingivitis: acute necrotising ulcerative
- **Antibacterial required only if systemic features of infection.**
  - **Metronidazole p. 475, or alternatively, amoxicillin**
    - **Suggested duration of treatment** 3 days or until symptoms resolve.

#### Periapical or periodontal abscess
- **Antibacterial required only in severe disease with cellulitis or if systemic features of infection.**
  - **Amoxicillin p. 482, or alternatively, metronidazole**
    - **Suggested duration of treatment** 5 days.

#### Pierodontitis
- **Antibacterial used as an adjunct to debridement in severe disease or disease unresponsive to local treatment alone.**
  - **Metronidazole p. 475, or alternatively in adults and children over 12 years, doxycycline below**

#### Throat infections
Most throat infections are caused by viruses and many do not require antibacterial therapy. Consider antibacterial, if history of valvular heart disease, if marked systemic upset, if peritonsillar cellulitis or abscess, or if at increased risk from acute infection (e.g. in immunosuppression, cystic fibrosis); prescribe antibacterial for beta-haemolytic streptococcal pharyngitis.

- **Phenoxybenzamidopenicillin**
  - In severe infection, initial parenteral therapy with benzylpenicillin sodium p. 480, then oral therapy with phenoxybenzamidopenicillin p. 481 or amoxicillin p. 482 (or ampicillin p. 483). **Avoid** amoxicillin if possibility of glandular fever.
    - **Suggested duration of treatment** 10 days.

- **If penicillin-allergic, clarithromycin p. 470 or azithromycin p. 469 or erythromycin p. 471**
  - **Suggested duration of treatment** 10 days
Ear, nose and oropharynx

Unlicensed use
Not licensed for severe recurrent aphthous ulceration.

Cautions
Alcohol dependence

Interactions
The metabolism of doxycycline may be influenced by antiepileptics.

Side-effects
Anorexia - anxiety - dry mouth - flushing - fungal superinfection (when used for periodontitis) - tinnitus

Renal impairment
Use with caution (avoid excessive doses).

Monitoring requirements
When used for periodontitis, monitor for superficial fungal infection, particularly if predisposition to oral candidiasis.

Patient and carer advice
Photophobia - Patients should be advised to avoid exposure to sunlight or sunlamps.

Professional specific information
Dental practitioners' formulary
Dispersible tablets may be prescribed as Dispersible Doxycycline Tablets.
Tablets may be prescribed as Doxycycline Tablets 20 mg.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

Cautionary and Advisory Labels 6, 11, 27

Doxycycline (as Doxycycline hyclate) 20 mg Periostat 20mg tablets 56 tablet (PMS) £17.30 DT price = £17.30

Dispersible tablet

Cautionary and Advisory Labels 6, 9, 11, 13

Vibramycin-D (Pfizer Ltd)

Doxycycline (as Doxycycline monohydrate) 100 mg Vibramycin-D 100mg dispersible tablets (sugar-free) 8 tablet (PMS) £4.91 DT price = £4.91

3.6 Oropharyngeal fungal infections

Oropharyngeal fungal infections
Fungal infections of the mouth are usually caused by Candida spp. (candidiasis or candidosis). Different types of oropharyngeal candidiasis are managed as follows:

Thrush
Acute pseudemembranous candidiasis (thrush), is usually an acute infection but it may persist for months in patients receiving inhaled corticosteroids, cytotoxics or broad-spectrum antibacterials. Thrush also occurs in patients with serious systemic disease associated with reduced immunity such as leukaemia, other malignancies, and HIV infection. Any predisposing condition should be managed appropriately. When thrush is associated with corticosteroid inhalers, rinsing the mouth with water (or cleaning a child's teeth) immediately after using the inhaler may avoid the problem. Treatment with nystatin p. 997 or miconazole p. 1011 may be needed. Fluconazole p. 518 is effective for unresponsive infections or if a topical antifungal drug cannot be used or if the patient has dry mouth. Topical therapy may not be adequate in immunocompromised patients and an oral triazole antifungal is preferred.

Acute erythematous candidiasis
Acute erythematous (atrophic) candidiasis is a relatively uncommon condition associated with corticosteroid and broad-spectrum antibacterial use and with HIV disease. It is usually treated with fluconazole p. 518.

Denture stomatitis
Patients with denture stomatitis (chronic atrophic candidiasis), should cleanse their dentures thoroughly and leave them out as often as possible during the treatment period. To prevent recurrence of the problem, dentures should not normally be worn at night. New dentures may be required if these measures fail despite good compliance.

Miconazole p. 1011 oral gel can be applied to the fitting surface of the denture before insertion (for short periods only). Denture stomatitis is not always associated with candidiasis and other factors such as mechanical or chemical irritation, bacterial infection, or rarely allergy to the dental base material, may be the cause.

Chronic hyperplastic candidiasis
Chronic hyperplastic candidiasis (candidal leucoplakia) carries an increased risk of malignancy; biopsy is essential—this type of candidiasis may be associated with varying degrees of dysplasia, with oral cancer present in a high proportion of cases. Chronic hyperplastic candidiasis is treated with a systemic antifungal such as fluconazole p. 518 to eliminate candidal overgrowth. Patients should avoid the use of tobacco.

Angular cheilitis
Angular cheilitis (angular stomatitis) is characterised by soreness, erythema and fissuring at the angles of the mouth. It is commonly associated with denture stomatitis but may represent a nutritional deficiency or it may be related to oro-facial granulomatosis or HIV infection. Both yeasts (Candida spp.) and bacteria (Staphylococcus aureus and beta-haemolytic streptococci) are commonly involved as interacting, infective factors. A reduction in facial height related to ageing and tooth loss with maceration in the deep occlusive folds that may subsequently arise, predisposes to such infection. While the underlying cause is being identified and treated, it is often helpful to apply miconazole p. 1011 cream or fusidic acid p. 1008 ointment; if the angular cheilitis is unresponsive to treatment, hydrocortisone with miconazole p. 1011 cream or ointment can be used.

Immune compromised patients
See advice on prevention of fungal infections in Immune Compromised patients under Antifungals, systemic use p. 512.

Drugs used in oropharyngeal candidiasis
Nystatin p. 997 is not absorbed from the gastro-intestinal tract and is applied locally (as a suspension) to the mouth for treating local fungal infections. Miconazole p. 1011 is applied locally (as an oral gel) to the mouth but it is absorbed to the extent that potential interactions need to be considered. Miconazole also has some activity against Gram-positive bacteria including streptococci and staphylococci. Fluconazole p. 518 is given by mouth for infections that do not respond to topical therapy or when topical therapy cannot be used. It is reliably absorbed and effective. Itraconazole p. 519 can be used for fluconazole-resistant infections.

If candidal infection fails to respond to 1 to 2 weeks of treatment with antifungal drugs the patient should be sent for investigation to eliminate the possibility of underlying disease. Persistent infection may also be caused by reinfection from the genito-urinary or gastro-intestinal tract. Infection can be eliminated from these sources by appropriate anti-candidal therapy; the patient's partner may also require treatment to prevent reinfection.

Antiseptic mouthwashes are used in the prevention of oral candidiasis in immunocompromised patients and in the treatment of denture stomatitis.
Miconazole

**INDICATIONS AND DOSE**
Prevention and treatment of oral candidiasis

**BY MOUTH USING ORAL GEL**
- Child 2-17 years: 2.5 mL 4 times a day treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared, to be administered after meals, retain near oral lesions before swallowing (dental prostheses and orthodontic appliances should be removed at night and brushed with gel)
- Adult: 2.5 mL 4 times a day treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared, to be administered after meals, retain near oral lesions before swallowing (dental prostheses and orthodontic appliances should be removed at night and brushed with gel)

**Prevention and treatment of intestinal candidiasis**

- Child 4 months-17 years: 5 mg/kg 4 times a day (max. per dose 250 mg (10 mL) 4 times a day), treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared
- Adult: 5 mg/kg 4 times a day (max. per dose 250 mg (10 mL) 4 times a day), treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared

**SIDE-EFFECTS**
- Very rare diarrhoea (usually on long term treatment) - hepatitis - rash (in children) - Stevens-Johnson syndrome - toxic epidermal necrolysis

**PREGNANCY**
Manufacturer advises caution—toxicity at high doses in animal studies.

**BREAST FEEDING**
Manufacturer advises avoid if possible—no information available.

**HEPATIC IMPAIRMENT**
Avoid.

**DIRECTIONS FOR ADMINISTRATION**
Oral gel should be held in mouth, after food.

**PRESCRIBING AND DISPENSING INFORMATION**
Flavours of oral gel may include orange.

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on how to administer miconazole oromucosal gel.

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary

**CONTRA-INDICATIONS**
Infants with impaired swallowing reflex

**CAUTIONS**
Avoid in Acute porphyrias p. 864

**INTERACTIONS**
- Appendix 1 (antifungals, imidazole).

**CONTRA-INDICATIONS**
Infants with impaired swallowing reflex

**CAUTIONS**
Avoid in Acute porphyrias p. 864

**INTERACTIONS**
- Appendix 1 (antifungals, imidazole).

**SIDE-EFFECTS**
- Local irritation - local sensitisation - nausea

**PATIENT AND CARER ADVICE**
Medicines for Children leaflet: Nystatin for Candida infection www.medicinesforchildren.org.uk/
nystatin-for-candida-infection

Counselling advised with oral suspension (use of pipette, hold in mouth, after food).

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary

**MEDICAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Oropharyngeal viral infections**

Viral infections are the most common cause of a sore throat. They do not benefit from anti-infective treatment. The management of primary herpetic gingivostomatitis is a soft diet, adequate fluid intake, and analgesics as required, including local use of benzoylamine hydrochloride p. 993. The use of chlorhexidine p. 989 mouthwash will control plaque accumulation if toothbrushing is painful and will also help to control secondary infection in general.

In the case of severe herpetic stomatitis, a systemic antiviral such as aciclovir p. 550 is required. Valaciclovir p. 552 and famciclovir p. 552 are suitable alternatives for oral lesions associated with herpes zoster. Aciclovir and valaciclovir are also used for the prevention of frequently recurring herpes simplex lesions of the mouth, particularly when implicated in the initiation of erythema multiforme.
Chapter 13
Skin

Skin conditions, management

Vehicles
The British Association of Dermatologists list of preferred unlicensed dermatological preparations (specials) is available at www.bad.org.uk/specials.

Both vehicle and active ingredients are important in the treatment of skin conditions; the vehicle alone may have more than a mere placebo effect. The vehicle affects the degree of hydration of the skin, has a mild anti-inflammatory effect, and aids the penetration of active drug.

Applications are usually viscous solutions, emulsions, or suspensions for application to the skin (including the scalp) or nails.

Collodions are painted on the skin and allowed to dry to leave a flexible film over the site of application.

Creams are emulsions of oil and water and are generally well absorbed into the skin. They may contain an antimicrobial preservative unless the active ingredient or basis is intrinsically bactericidal and fungicidal. Generally, creams are cosmetically more acceptable than ointments because they are less greasy and easier to apply.

Gels consist of active ingredients in suitable hydrophilic or hydrophobic bases; they generally have a high water content. Gels are particularly suitable for application to the face and scalp.

Lotions have a cooling effect and may be preferred to ointments or creams for application over a hairy area. Lotions in alcoholic basis can sting if used on broken skin. Shake lotions (such as calamine lotion) contain insoluble powders which leave a deposit on the skin surface.

Ointments are greasy preparations which are normally anhydrous and insoluble in water, and are more occlusive than creams. They are particularly suitable for chronic, dry lesions. The most commonly used ointment bases consist of soft paraffin or a combination of soft, liquid, and hard paraffin. Some ointment bases have both hydrophilic and lipophilic properties; they may have occlusive properties on the skin surface, encourage hydration, and also be miscible with water; they often have a mild anti-inflammatory effect.

Water-soluble ointments contain macrogols which are freely soluble in water and are therefore readily washed off; they have a limited but useful role where ready removal is desirable.

Pastes are stiff preparations containing a high proportion of finely powdered solids such as zinc oxide and starch suspended in an ointment. They are used for circumscribed lesions such as those which occur in lichen simplex, chronic eczema, or psoriasis. They are less occlusive than ointments and can be used to protect inflamed, lichenified, or excoriated skin.

Dusting powders are used only rarely. They reduce friction between opposing skin surfaces. Dusting powders should not be applied to moist areas because they can cake and abrade the skin. Talc is a lubricant but it does not absorb moisture; it can cause respiratory irritation. Starch is less lubricant but absorbs water.

Dilution
The BP directs that creams and ointments should not normally be diluted but that should dilution be necessary care should be taken, in particular, to prevent microbial contamination. The appropriate diluent should be used and heating should be avoided during mixing; excessive dilution may affect the stability of some creams. Diluted creams should normally be used within 2 weeks of preparation.

Suitable quantities of dermatological preparations to be prescribed for specific areas of the body

<table>
<thead>
<tr>
<th>Area of body</th>
<th>Creams and Ointments</th>
<th>Lotions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face</td>
<td>15–30 g</td>
<td>100 ml</td>
</tr>
<tr>
<td>Both hands</td>
<td>25–50 g</td>
<td>200 ml</td>
</tr>
<tr>
<td>Scalp</td>
<td>50–100 g</td>
<td>200 ml</td>
</tr>
<tr>
<td>Both arms or both legs</td>
<td>100–200 g</td>
<td>200 ml</td>
</tr>
<tr>
<td>Trunk</td>
<td>400 g</td>
<td>500 ml</td>
</tr>
<tr>
<td>Groins and genitalia</td>
<td>15–25 g</td>
<td>100 ml</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for twice daily application for 1 week. The recommendations do not apply to corticosteroid preparations. For suitable quantities of corticosteroid preparations, see relevant table on p. 1021.
Dry and scaling skin disorders

Emollient and barrier preparations

Borderline substances

The preparations marked ‘ACBS’ are regarded as drugs when prescribed in accordance with the advice of the Advisory Committee on Borderline Substances for the clinical conditions listed. Prescriptions issued in accordance with this advice and endorsed ‘ACBS’ will normally not be investigated.

Emollients

Emollients soothe, smooth and hydrate the skin and are indicated for all dry or scaling disorders. Their effects are short lived and they should be applied frequently even after improvement occurs. They are useful in dry and eczematous disorders, and to a lesser extent in psoriasis. The choice of an appropriate emollient will depend on the severity of the condition, patient preference, and the site of application. Some ingredients rarely cause sensitisation and this should be suspected if an eczematous reaction occurs. The use of aqueous cream as a leave-on emollient may increase the risk of skin reactions, particularly in eczema.

Preparations such as aqueous cream and emulsifying ointment can be used as soap substitutes for hand washing and in the bath; the preparation is rubbed on the skin before rinsing off completely. The addition of a bath oil may also be helpful.

Urea is occasionally used with other topical agents such as corticosteroids to enhance penetration of the skin.

Emollient bath and shower preparations

Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. In dry skin conditions soap should be avoided.

Barrier preparations

Barrier preparations often contain water-repellent substances such as dimethicone p. 1014 or other silicones. They are used on the skin around stomas, bedsores, and pressure areas in the elderly where the skin is intact. Where the skin has broken down, barrier preparations have a limited role in protecting adjacent skin. Barrier preparations are not a substitute for adequate nursing care.

Nappy rash

The first line of treatment is to ensure that nappies are changed frequently and that tightly fitting water-proof pants are avoided. The rash may clear when left exposed to the air and a barrier preparation, applied with each nappy change, can be helpful. A mild corticosteroid such as hydrocortisone 0.5% or 1% can be used if inflammation is causing discomfort, but it should be avoided in neonates. The barrier preparation should be applied after the corticosteroid preparation to prevent further damage. Preparations containing hydrocortisone should be applied for no more than a week; the hydrocortisone should be discontinued as soon as the inflammation subsides. The occlusive effect of nappies and waterproof pants may increase absorption of corticosteroids. If the rash is associated with candidal infection, a topical antifungal such as clotrimazole p. 1010 cream can be used. Topical antibacterial preparations can be used if bacterial infection is present; treatment with an oral antibacterial may occasionally be required in severe or recurrent infection. Hydrocortisone can be used in combination with antimicrobial preparations if there is considerable inflammation, erosion, and infection.

BARRIER PREPARATIONS

Barrier creams and ointments

INDICATIONS AND DOSE

For use as a barrier preparation

**TO THE SKIN**

- Child: (consult product literature)
- Adult: (consult product literature)

**PREScribing AND DISPensing INFORMATION** When prepared extemporaneously, the BP states Zinc and Castor Oil Ointment, BP consists of zinc oxide 7.5%, castor oil 50%, arachis (peanut) oil 30.5%, white beeswax 10% and cetostearyl alcohol 2%.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

Cream

**EXCIPIENTS:** May contain Beeswax, butylated hydroxyanisole, butylated hydroxytoluene, cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol, fragrances, hydroxybenzoates (parabens), propylene glycol, wool fat and related substances including lanolin

- **Conotrane** (Astellas Pharma Ltd)
  - Benzalkonium chloride 1 mg per 1 gram, Dimeticone 220 mg per 1 gram Conotrane cream | 100 gram £3.51
  - Drapolene (Omega Pharma Ltd)
  - Benzalkonium chloride 100 microgram per 1 gram, Cetrimide 2 mg per 1 gram Drapolene cream | 100 gram £1.76
  - **Siopel** (Derma UK Ltd)
  - Cetrimide 3 mg per 1 gram, Dimeticone 1000 100 mg per 1 gram Siopel cream | 50 gram £2.15
Sudocrem (Forest Laboratories UK Ltd)
Benzy alcohol 3.9 mg per 1 gram, Benzy benzoate 10.1 mg per 1 gram, Benzy cinnamate 1.5 mg per 1 gram, Wool fat hydroxys 40 mg per 1 gram, Zinc oxide 152.5 mg per 1 gram Sudocrem antiseptic healing cream | 60 gram | £1.45 | 125 gram | £2.15 | 250 gram | £3.67 | 400 gram | £5.25

Ointment
EXCIPIENTS: May contain Wool fat and related substances including lanolin.

• BARRIER CREAMS AND OINTMENTS (Non-proprietary)
Titanium dioxide 200 mg per 1 gram, Titanium peroxide 50 mg per 1 gram | 30 gram | £2.24
Castor oil 500 mg per 1 gram, Zinc Oxide 75 mg per 1 gram, Arachis oil 305 mg per 1 gram | 500 gram | £4.99

• Brands may include Metanium ointment

Spray
CAUTIONARY AND ADVISORY LABELS | 15
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), wool fat and related substances including lanolin.

• Sprilon (Ayrton Saunders Ltd)
Dimeticone 10.4 mg per 1 gram, Zinc oxide 125 mg per 1 gram
Sprilon aerosol spray | 115 gram | £8.90 DT price = £8.90

EMOLLIENTS

Emollient bath and shower products, antimicrobial-containing

INDICATIONS AND DOSE
DERMOL® 200 SHOWER EMOLLIENT
Dry and pruritic skin conditions including eczema and dermatitis
TO THE SKIN
Adult: To be applied to the skin or used as a soap substitute
DERMOL® 600® BATH EMOLLIENT
Dry and pruritic skin conditions including eczema and dermatitis
TO THE SKIN
Child 1–23 months: 5–15 mL/bath, not to be used undiluted
Adult: 15–30 mL/bath, not to be used undiluted
DERMOL® WASH EMULSION
Dry and pruritic skin conditions including eczema and dermatitis
TO THE SKIN
Adult: To be applied to the skin or used as a soap substitute
EMULSIDERM®
Dry skin conditions including eczema and ichthyosis
TO THE SKIN
Adult: 7–30 mL/bath, alternatively, to be rubbed into dry skin until absorbed
OILATUM® PLUS
Topical treatment of eczema, including eczema at risk from infection
TO THE SKIN
Child 6–11 months: 1 mL/bath, not to be used undiluted
Adult: 1–2 capfuls/bath, not to be used undiluted

Important safety information
FIRE HAZARD WITH PARAFFIN-BASED EMOLLIENTS
Emulsifying ointment or 50% Liquid Paraffin and 50% White Soft Paraffin Ointment in contact with dressings and clothing is easily ignited by a naked flame. The risk is greater when these preparations are applied to large areas of the body, and clothing or dressings become soaked with the ointment. Patients should be told to keep away from fire or flames, and not to smoke when using these preparations. The risk of fire should be considered when using large quantities of any paraffin-based emollient. These preparations make skin and surfaces slippery—particular care is needed when bathing.

DIRECTIONS FOR ADMINISTRATION
Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

PRESCRIBING AND DISPENSING INFORMATION
Preparations containing an antibacterial should be avoided unless infection is present or is a frequent complication. When prepared extemporaneously, the BP states Aqueous Cream, BP consists of emulsifying ointment 30%, phenoxyethanol 1% in freshly boiled and cooled purified water. Hydrous Ointment, BP consists of dried magnesium sulphate 0.5%, phenoxyethanol 1%, wool alcohols ointment 50%, in freshly boiled and cooled purified water.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Liquid
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

• Dermol 200 (Dermal Laboratories Ltd)
Benzalkonium chloride 1 mg per 1 gram, Chlorhexidine hydrochloride 1 mg per 1 gram, Isopropyl myristate 25 mg per 1 gram, Liquid paraffin 25 mg per 1 gram Dermol 200 shower emollient | 200 ml | £3.55

• Dermol Wash (Dermal Laboratories Ltd)
Benzalkonium chloride 1 mg per 1 gram, Chlorhexidine hydrochloride 1 mg per 1 gram, Isopropyl myristate 25 mg per 1 gram, Liquid paraffin 25 mg per 1 gram Dermol Wash cutaneous emulsion | 200 ml | £3.55

Bath additive
EXCIPIENTS: May contain Acetylated lanolin alcohols, isopropyl palmitate, polyisobutylene

• Dermol 600 (Dermal Laboratories Ltd)
Benzalkonium chloride 5 mg per 1 gram, Isopropyl myristate 250 mg per 1 gram, Liquid paraffin 250 mg per 1 gram Dermol 600 bath emollient | 600 ml | £7.55

• Emulsiderm (Dermal Laboratories Ltd)
Benzalkonium chloride 5 mg per 1 gram, Isopropyl myristate 250 mg per 1 gram, Liquid paraffin 250 mg per 1 gram Emulsiderm emollient | 300 ml | £3.85 | 1000 ml | £12.00

• Oiatum Plus (GlaxoSmithKline Consumer Healthcare)
Benzalkonium chloride 60 mg per 1 gram, Liquid paraffin light 525 mg per 1 gram, Tricosanol 20 mg per 1 gram Oiatum Plus bath additive | 500 ml | £6.98

Emollient bath and shower products, colloidal oatmeal-containing

INDICATIONS AND DOSE
Endogenous and exogenous eczema | Xeroderma | Ichthyosis
TO THE SKIN
Child 2–17 years: 20–30 mL/bath, alternatively apply to wet skin and rinse
Adult: 20–30 mL/bath, alternatively apply to wet skin and rinse

BNF 70
Pruritus of the elderly associated with dry skin

**TO THE SKIN**
- Elderly: 20–30 mL/bath, alternatively apply to wet skin and rinse

**Important safety information**
These preparations make skin and surfaces slippery—particular care is needed when bathing.

**DIRECTIONS FOR ADMINISTRATION**
Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Bath additive**
**EXCIPIENTS:** May contain Beeswax, fragrances
- EMOLLIENT BATH AND SHOWER PRODUCTS, COLLOIDAL OATMEAL-CONTAINING (Non-proprietary) 250 ml (ACBS) £4.49
- Brands may include Aveeno bath oil

### Emollient bath and shower products, paraffin-containing

**INDICATIONS AND DOSE**

#### AQUAMAX® WASH
**Dry skin conditions**
- **TO THE SKIN**
  - Child: To be applied to wet or dry skin and rinse
  - Adult: To be applied to wet skin and rinse

#### CETRABEN® BATH
**Dry skin conditions, including eczema**
- **TO THE SKIN**
  - Child 1 month–11 years: 0.5–1 capful/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 1–2 capfuls/bath, alternatively, to be applied to wet skin and rinse

#### DERMALO®
**Dermatitis | Dry skin conditions including eczema**
- **TO THE SKIN**
  - Child 1 month–11 years: 5–10 mL/bath, alternatively, to be applied to wet skin and rinse
  - Child 12–17 years: 15–20 mL/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 15–20 mL/bath, alternatively, to be applied to wet skin and rinse

#### Pruritus of the elderly
**TO THE SKIN**
- Elderly: 15–20 mL/bath, alternatively, to be applied to wet skin and rinse

#### DOUBLEBASE® EMOLLIENT BATH ADDITIVE
**Dry skin conditions including dermatitis and ichthyosis**
- **TO THE SKIN**
  - Child 1 month–11 years: 5–10 mL/bath
  - Child 12–17 years: 15–20 mL/bath
  - Adult: 15–20 mL/bath

#### Pruritus of the elderly
**TO THE SKIN**
- Elderly: 15–20 mL/bath

#### DOUBLEBASE® EMOLLIENT SHOWER GEL
**Dry, chapped, or itchy skin conditions**
- **TO THE SKIN**
  - Child: To be applied to wet or dry skin and rinse, or apply to dry skin after showering
  - Adult: To be applied to wet or dry skin and rinse, or apply to dry skin after showering

#### E45® WASH CREAM
**Endogenous and exogenous eczema, xeroderma, and ichthyosis**
- **TO THE SKIN**
  - Child: To be used as a soap substitute
  - Adult: To be used as a soap substitute

#### Pruritus of the elderly associated with dry skin
**TO THE SKIN**
- Elderly: To be used as a soap substitute

#### E45® BATH OIL
**Endogenous and exogenous eczema, xeroderma, and ichthyosis**
- **TO THE SKIN**
  - Adult: 15 mL/bath, alternatively, to be applied to wet skin and rinse

#### HYDROMOL® BATH AND SHOWER EMOLLIENT
**Dry skin conditions | Eczema | Ichthyosis**
- **TO THE SKIN**
  - Child 1 month–11 years: 0.5–2 capfuls/bath, alternatively apply to wet skin and rinse
  - Child 12–17 years: 1–3 capfuls/bath, alternatively apply to wet skin and rinse
  - Adult: 1–3 capfuls/bath, alternatively apply to wet skin and rinse

#### Pruritus of the elderly
**TO THE SKIN**
- Elderly: 1–3 capfuls/bath, alternatively apply to wet skin and rinse

#### LPL 63.4®
**Dry skin conditions**
- **TO THE SKIN**
  - Child 1 month–11 years: 0.5–2 capfuls/bath, alternatively, to be applied to wet skin and rinse
  - Child 12–17 years: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse

#### Pruritus of the elderly
**TO THE SKIN**
- Elderly: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse

#### OILATUM®
**EMOLLIENT BATH ADDITIVE**
**Dry skin conditions including dermatitis, and ichthyosis**
- **TO THE SKIN**
  - Child 1 month–11 years: Apply 0.5–2 capfuls/bath, alternatively, to be applied to wet skin and rinse
  - Child 12–17 years: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse

#### Pruritus of the elderly
**TO THE SKIN**
- Elderly: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse

#### OILATUM® JUNIOR BATH ADDITIVE
**Dry skin conditions including dermatitis and ichthyosis**
- **TO THE SKIN**
  - Child 1 month–11 years: 0.5–2 capfuls/bath, alternatively, apply to wet skin and rinse

continued →
Pruritus of the elderly

EMOLLIENT BATH AND SHOWER PRODUCTS, PARAFFIN-CONTAINING (Non-proprietary)

- **Liquid paraffin light 700 mg per 1 gram** | 150 gram (GSL) £1.15 | 150 gram (GSL) £1.25
- **Doublebase** (Dermal Laboratories Ltd)
  - Isopropyl myristate 150 mg per 1 gram, Liquid paraffin 150 mg per 1 gram
  - Doublebase emollient wash gel | 200 gram (GSL) £3.21
  - Doublebase emollient bath gel | 100 gram (GSL) £2.25
- **E45 emollient bath** (Forum Health Products Ltd)
  - E45 emollient bath oil | 250 ml (ACBS) £3.19 | 500 ml (ACBS) £5.11
- **Zerodouble** (Thornton & Ross Ltd)
  - Isopropyl myristate 150 mg per 1 gram, Liquid paraffin 150 mg per 1 gram
  - Zerodouble gel | 100 gram £2.25, DT price = £2.65 | 475 gram £4.71
- Brands may include Oilatum gel, Oilatum shower gel

**Bath additive**

- **EMOLLIENT BATH AND SHOWER PRODUCTS, PARAFFIN-CONTAINING (Non-proprietary)**
  - Liquid paraffin light 828 mg per 1 gram | 500 ml (GSL) £5.75
  - Liquid paraffin light 634 mg per 1 ml | 150 ml (GSL) £2.82 | 250 ml (GSL) £3.25 | 300 ml (GSL) £3.50 | 600 ml (GSL) £3.89 | 500 ml £3.10
  - Liquid paraffin light 850.9 mg per 1 gram | 250 ml £2.88 | 500 ml £4.71
  - Isopropyl myristate 130 mg per 1 ml, Liquid paraffin light 378 mg per 1 ml | 350 ml £3.88 | 500 ml £4.42 | 1000 ml £8.80
- **Zerolatum** (Dermal Laboratories Ltd)
  - Acetylated wool alcohols 50 mg per 1 gram, Liquid paraffin 650 mg per 1 gram
  - Doublebase emollient bath (Dermal Laboratories Ltd)
  - Doublebase emollient bath additive | 500 ml (GSL) £5.45
  - Zerolatum (Thornton & Ross Ltd)
  - Acetylated wool alcohols 50 mg per 1 gram, Liquid paraffin 650 mg per 1 gram
  - Zerolatum Emollient bath additive | 500 ml £4.79
- Brands may include Ceratrol, Hydromol, LPL, Oilatum, QV

**Wash**

- **EMOLLIENT BATH AND SHOWER PRODUCTS, PARAFFIN-CONTAINING (Non-proprietary)**
  - Liquid paraffin 650 mg per 1 gram
  - Doublebase emollient bath additive | 500 ml (GSL) £5.45
  - Zerolatum (Thornton & Ross Ltd)
  - Acetylated wool alcohols 50 mg per 1 gram, Liquid paraffin 650 mg per 1 gram
  - Zerolatum Emollient bath additive | 500 ml £4.79
- Brands may include Aquamax wash, QV Gentle wash
Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Bath additive**
EXCIPIENTS: May contain Isopropyl palmitate, polysorbates

- **EMOLLIENT BATH AND SHOWER PRODUCTS, TAR-CONTAINING (Proprietary)**
  - Coal tar distilled 400 mg per 1 ml | 200 ml £2.74
  - Polytar (GlaxoSmithKline Consumer Healthcare)
    - Arachis oil extract of crude coal tar 75 mg per 1 gram, Cade oil 75 mg per 1 gram, Coal tar solution 25 mg per 1 gram. Liquid paraffin light 350 mg per 1 gram, Pine tar 75 mg per 1 gram Polytar Emollient | 500 ml £5.78
  - Brands may include Psoriderm Emulsion 40% bath additive

**Emollient creams and ointments, antimicrobial-containing**

**INDICATIONS AND DOSE**
Dry and pruritic skin conditions including eczema and dermatitis

**TO THE SKIN**
- Child: To be applied to the skin or used as a soap substitute
- Adult: To be applied to the skin or used as a soap substitute

**DIRECTIONS FOR ADMINISTRATION** Emollients should be applied immediately after washing or bathing to maximise the effect of skin hydration. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**PRESCRIBING AND DISPENSING INFORMATION**
Preparations containing an antibacterial should be avoided unless infection is present or a frequent complication.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Liquid**
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

- Dermol 500 (Dermal Laboratories Ltd)
  - Benzalkonium chloride 1 mg per 1 gram, Chlorhexidine hydrochloride 1 mg per 1 gram, Isopropyl myristate 25 mg per 1 gram. Liquid paraffin 25 mg per 1 gram Dermol 500 lotion | 500 ml £6.04

**Cream**
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

- Dermol (Dermal Laboratories Ltd)
  - Benzalkonium chloride 1 mg per 1 gram, Chlorhexidine hydrochloride 1 mg per 1 gram, Isopropyl myristate 100 mg per 1 gram, Liquid paraffin 100 mg per 1 gram Dermol cream | 100 gram £2.86 | 500 gram £6.63

**Emollient creams and ointments, colloidal oatmeal-containing**

**INDICATIONS AND DOSE**
Endogenous and exogenous eczema | Xeroderma | Ichthyosis

**TO THE SKIN**
- Child: (consult product literature)
- Adult: (consult product literature)
Emollient creams and ointments, paraffin-containing

INDICATIONS AND DOSE

Dry skin conditions | Eczema | Psoriasis | Ichthyosis | Pruritus TO THE SKIN

Adult: (consult product literature)

Brands may include Aveeno

EMOLLIENT CREAMS AND OINTMENTS, PARAFFIN-CONTAINING (Non-proprietary)
- Isopropyl myristate 50 mg per 1 gram, Liquid paraffin 100 mg per 1 gram, Sodium lactate 10 mg per 1 gram, Sodium picolinate 25 mg per 1 gram | 50 gram (GSL) £2.19 | 100 gram (GSL) £4.09 | 500 gram (GSL) £11.92
- Glycerol 100 mg per 1 gram, Liquid paraffin light 100 mg per 1 gram, White soft paraffin 50 mg per 1 gram | 100 gram £2.04 | 500 gram £5.86 | 1050 gram £11.94
- Liquid paraffin light 105 mg per 1 gram, White soft paraffin 112 mg per 1 gram | 50 gram £1.40 | 150 gram £3.98 | 500 gram £5.99 | 1050 gram £11.62
- Liquid paraffin 126 mg per 1 gram, White soft paraffin 145 mg per 1 gram | 50 gram £1.17 | 500 gram £4.98
- Liquid paraffin light 60 mg per 1 gram, White soft paraffin 150 mg per 1 gram | 50 gram (GSL) £1.63 | 150 gram (GSL) £2.46 | 500 ml (GSL) £4.99 | 1050 ml (GSL) £9.98
- Aquamol (Thorton & Ross Ltd)
  - Aquamol cream | 50 gram £1.22 | 500 gram £6.40
- E4S (Forum Health Products Ltd)
  - Liquid paraffin light 126 mg per 1 gram, White soft paraffin 145 mg per 1 gram, Wool fat 10 mg per 1 gram | £45 cream | 50 gram (GSL) £1.62 | 125 gram (GSL) £2.90 | 350 gram (GSL) £3.17 | 500 gram (GSL) £5.62
- Enopen (Enogen Healthcare Ltd)
  - Liquid paraffin light 105 mg per 1 gram, White soft paraffin 132 mg per 1 gram, Enopen cream | 50 gram £5.99
- Epaderm (Melville Health Care Ltd)
  - Epaderm cream | 50 gram £1.70 | 500 gram £6.95
- Lipobase (Astellas Pharma Ltd)
  - Lipobase cream | 50 gram £1.46
  - Soffen (Vitale Ltd)
  - Liquid paraffin light 105 mg per 1 gram, White soft paraffin 132 mg per 1 gram, Soffen cream | 500 gram £4.79
- Unguentum M (Almirall Ltd)
  - Unguentum M cream | 50 gram (GSL) £1.41 | 100 gram (GSL) no price available | 200 ml (GSL) £2.78
- ZeroAQS (Thorton & Ross Ltd)
  - ZeroAQS emollient cream | 500 gram £3.29
  - ZeroBase (Thorton & Ross Ltd)
  - Liquid paraffin 110 mg per 1 gram, ZeroBase 1% cream | 50 gram £0.10 | 500 gram £5.26
  - Zeroquent (Thorton & Ross Ltd)
  - Liquid paraffin light 80 mg per 1 gram, Soya oil 50 mg per 1 gram, White soft paraffin 40 mg per 1 gram, Zeroquent cream | 100 gram £2.33 | 500 gram £6.99
- Brands may include Aquamol, Cetraben, Diprobase, Hydromol, Olitrium, Ov, Ultrabase, Zerocream

Gel

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)
- Doublebase (Dermal Laboratories Ltd)
  - Isopropyl myristate 150 mg per 1 gram, Liquid paraffin 150 mg per 1 gram | Doublebase Dayleeve gel | 100 gram (P) £2.65 DT price = £2.65 | 500 gram (P) £6.25 DT price = £5.83
  - Doublebase gel | 100 gram (P) £2.65 DT price = £2.65 | 500 gram (P) £5.83 DT price = £5.83

Ointment

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates
- EMOLLIENT CREAMS AND OINTMENTS, PARAFFIN-CONTAINING (Non-proprietary)
  - Yellow soft paraffin 1 mg per 1 gram, Yellow soft paraffin solid | 15 gram (GSL) £0.85-£1.11 | 500 gram (GSL) £10.18 DT price = £10.18 | 4500 gram (GSL) £18.29
  - Magnesium sulphate dried 5 mg per 1 gram, Phenoxethanol 10 mg per 1 gram, Wool alcohols ointment 500 mg per 1 gram | 500 gram (GSL) £8.80 DT price = £4.89
  - White soft paraffin 1 mg per 1 gram, White soft paraffin solid | 500 gram (GSL) £4.18 DT price = £3.23 | 4500 gram (GSL) £18.62-£25.07

*Fire hazard with paraffin-based emollients*
Emollients, urea-containing

**DRUG ACTION** Urea is a keratin softener and hydrating agent used in the treatment of dry, scaling conditions (including ichthyosis) and may be useful in elderly patients.

**INDICATIONS AND DOSE**

**AQUADRAT®**

Dry, scaling and itching skin

TO THE SKIN

- Child: Apply twice daily, to be applied thinly
- Adult: Apply twice daily

**BALNEUM® CREAM**

Dry skin conditions

TO THE SKIN

- Child: Apply twice daily
- Adult: Apply twice daily

**BALNEUM® PLUS CREAM**

Dry, scaling and itching skin

TO THE SKIN

- Child: Apply twice daily
- Adult: Apply twice daily

**CALMURID®**

Dry, scaling and itching skin

TO THE SKIN

- Child: Apply twice daily, daily to a thick layer for 3–5 minutes, massage into area, and remove excess. Can be diluted with aqueous cream (life of diluted cream is 14 days). Half-strength cream can be used for 1 week if stinging occurs
- Adult: Apply twice daily, apply a thick layer for 3–5 minutes, massage into area, and remove excess. Can be diluted with aqueous cream (life of diluted cream is 14 days). Half-strength cream can be used for 1 week if stinging occurs

**DERMATONICS ONCE HEEL BALM®**

Dry skin on soles of feet

TO THE SKIN

- Child 12-17 years: Apply daily
- Adult: Apply daily

**E45® ITCH RELIEF CREAM**

Dry, scaling, and itching skin

TO THE SKIN

- Child: Apply twice daily
- Adult: Apply twice daily

**EUCERIN® INTENSIVE CREAM**

Dry skin conditions including eczema, ichthyosis, xeroderma, and hyperkeratosis

TO THE SKIN

- Child: Apply twice daily, to be applied thinly and rubbed into area
- Adult: Apply twice daily, to be applied thinly and rubbed into area

**EUCERIN® INTENSIVE LOTION**

Dry skin conditions including eczema, ichthyosis, xeroderma and hyperkeratosis

TO THE SKIN

- Child: Apply twice daily, to be applied sparingly and rubbed into area
- Adult: Apply twice daily, to be applied sparingly and rubbed into area

**FLEXITOL®**

Dry skin on soles of feet and heels

TO THE SKIN

- Child 12-17 years: Apply 1–2 times a day
- Adult: Apply 1–2 times a day

**HYDROMOL® INTENSIVE**

Dry, scaling and itching skin

TO THE SKIN

- Child: Apply twice daily, to be applied thinly
- Adult: Apply twice daily, to be applied thinly

**NUTRAPLUS®**

Dry, scaling and itching skin

TO THE SKIN

- Child: Apply 2–3 times a day
- Adult: Apply 2–3 times a day

**DIRECTIONS FOR ADMINISTRATION**

Emollients should be applied immediately after washing or bathing to maximise the effect of skin hydration. Emollient preparations contained in tubes should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Liquid**

EXCIPIENTS: May contain Benzyl alcohol, isopropyl palmitate

- Eucerin (Beiersdorf UK Ltd)

**Cream**

EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), isopropyl palmitate, polysorbates, propylene glycol, wool fat and related substances including lanolin

- EMOILLETS, UREA-CONTAINING (Non-proprietary)

  - Lauromacrogols 30 mg per 1 gram, Urea 50 mg per 1 gram | 100 gram (GSL) £3.29 | 500 gram (GSL) £14.99
  - Urea 100 mg per 1 gram | 10 gram (P) £10.27
  - Aquadrade (Alliance Pharmaceuticals Ltd)

- Calmurd (Galderma (UK) Ltd)

**Lactic acid 50 mg per 1 gram, Urea 100 mg per 1 gram**

- Calmurd cream | 100 gram (P) £9.27 DT price = £9.27 | 500 gram (P) £35.70 DT price = £35.70
13

Skin Infections

Antibacterial preparations

Cellulitis, a rapidly spreading deeply seated inflammation of the skin and subcutaneous tissue, requires systemic antibacterial treatment. Lower leg infections or infections spreading around wounds are almost always cellulitis.

Erysipelas, a superficial infection with clearly defined edges (and often affecting the face), is also treated with a systemic antibacterial.

In the community, acute impetigo on small areas of the skin may be treated by short-term topical application of fusidic acid p. 1008; mupirocin p. 1009 should be used only to treat meticillin-resistant Staphylococcus aureus. If the impetigo is extensive or longstanding, an oral antibacterial such as flucloxacillin p. 486 (or clarithromycin p. 487) in penicillin allergy should be used. Mild antiseptics can be used to soften crusts.

Although many antibacterial drugs are available in topical preparations, some are potentially hazardous and frequently their use is not necessary if adequate hygienic measures can be taken. Moreover, not all skin conditions that are oozing, crusted, or characterised by pus/tules are actually infected. Topical antibacterials should be avoided on leg ulcers unless used in short courses for defined infections; treatment of bacterial colonisation is generally inappropriate.

To minimise the development of resistant organisms it is advisable to limit the choice of antibacterials applied topically to those not used systemically. Unfortunately some of these, for example neomycin sulfate p. 1009, may cause sensitisation, and there is cross-sensitivity with other aminoglycoside antibiotics, such as gentamicin p. 450. If large areas of skin are being treated, ototoxicity may also be a hazard with aminoglycoside antibiotics (and also with polymyxins), particularly in children, in the elderly, and in those with renal impairment. Resistant organisms are more common in hospitals, and whenever possible swabs should be taken for bacteriological examination before beginning treatment.

Mupirocin p. 1009 is not related to any other antibacterial in use; it is effective for skin infections, particularly those due to Gram-positive organisms but it is not indicated for pseudomonal infection. Although Staphylococcus aureus strains with low-level resistance to mupirocin are emerging, it is generally useful in infections resistant to other antibacterials. To avoid the development of resistance, mupirocin or fusidic acid p. 1008 should not be used for longer than 10 days and local microbiology advice should be sought before using it in hospital. In the presence of mupirocin-resistant MRSA infection, a topical antiseptic such as povidone-iodine p. 1053, chlorhexidine p. 1051 p. 989, or alcohol can be used; their use should be discussed with the local microbiologist.

Retapamulin p. 1009 can be used for impetigo and other superficial bacterial skin infections caused by Staphylococcus aureus and Streptococcus pyogenes that are resistant to first-line topical antibacterials. However, it is not effective against MRSA.

Silver sulfadiazine p. 1010 is used in the treatment of infected burns.

Antibacterial preparations also used systemically

Fusidic acid p. 1008 is a narrow-spectrum antibacterial used for staphylococcal infections. Fusidic acid has a role in the treatment of impetigo.

An ointment containing fusidic acid is used in the fissures of angular chelitis when associated with staphylococcal infection. See Oropharynx infections, fungal p. 596 for further information on angular chelitis.

Metronidazole p. 1008 is used topically for rosacea and to reduce the odour associated with anaerobic infections; oral metronidazole is used to treat wounds infected with anaerobic bacteria.

Antifungal preparations

Most localised fungal infections are treated with topical preparations. To prevent relapse, local antifungal treatment should be continued for 1–2 weeks after the disappearance of all signs of infection. Systemic therapy is necessary for scalp infection or if the skin infection is widespread, disseminated, or intractable; although topical therapy may be used to treat some nail infections, systemic therapy is more effective. Skin scrapings should be examined if systemic therapy is being considered or where there is doubt about the diagnosis.

Dermatophytes

Ringworm infection can affect the scalp (tinea capitis), body (tinea corporis), groin (tinea cruris), hand (tinea manuum), foot (tinea pedis, athlete’s foot), or nail (tinea unguium). Scalp infection requires systemic treatment; additional application of a topical antifungal, during the early stages of treatment, may reduce the risk of transmission. A topical antifungal can also be used to treat asymptomatic carriers of scalp ringworm. Most other local ringworm infections can be treated adequately with topical antifungal preparations (including shampoos). The imidazole antifungals clotrimazole p. 1010, econazole nitrate p. 1011, ketoconazole p. 1011, and miconazole p. 1011 are all effective. Terbinafine p. 1013 cream is also effective but it is more expensive. Other topical antifungals include griseofulvin p. 1012 and the undecenoates. Compound benzoic acid ointment (Whitfield’s ointment) has been used for ringworm infections but it is cosmetically less acceptable than proprietary preparations. Topical preparations for athlete’s foot containing tolnaflate are on sale to the public.

Antifungal dusting powders are of little therapeutic value in the treatment of fungal skin infections and may cause skin irritation; they may have some role in preventing re-infection.

Antifungal treatment may not be necessary in asymptomatic patients with tinea infection of the nails. If treatment is necessary, a systemic antifungal is more effective than topical therapy. However, topical application of amorolfine p. 1012 or tioconazole p. 1012 may be useful for treating early onychomycosis when involvement is limited to mild distal disease, or for superficial white onychomycosis, or where there are contra-indications to systemic therapy.
Pityriasis versicolor

Pityriasis (tinea) versicolor can be treated with ketoconazole shampoo p. 1011. Alternatively, selenium sulphide shampoo (unlicensed indication) can be used as a lotion (diluting with a small amount of water can reduce irritation) and left on the affected area for 10 minutes before rinsing off; it should be applied once daily for 7 days, and the course repeated if necessary.

Topical imidazole antifungals such as clotrimazole p. 1010, econazone nitrate p. 1011, ketoconazole p. 1011, and miconazole p. 997, or topical terbinafine p. 514 are alternatives, but large quantities may be required.

If topical therapy fails, or if the infection is widespread, pityriasis versicolor is treated systemically with a triazole antifungal. Relapse is common, especially in the immunocompromised.

Candidiasis

Candidal skin infections can be treated with a topical imidazole antifungal, such as clotrimazole p. 1010, econazone nitrate p. 1011, ketoconazole p. 1011, or miconazole p. 1011; topical terbinafine p. 1013 is an alternative. Topical application of nystatin p. 997 is also effective for candidiasis but it is ineffective against dermatophytosis. Refractory candidiasis requires systemic treatment generally with a triazole such as fluconazole p. 518; systemic treatment with terbinafine is not appropriate for refractory candidiasis.

Angular cheilitis

Miconazole p. 1011 cream is used in the fissures of angular cheilitis when associated with Candida.

Compound topical preparations

Combination of an imidazole and a mild corticosteroid (such as hydrocortisone 1% p. 993) may be of value in the treatment of eczematous intertrigo and, in the first few days only, of a severely inflamed patch of ringworm.

Combination of a mild corticosteroid with either an imidazole or nystatin p. 997 may be of use in the treatment of intertrigo associated with candida.

Antiviral preparations

Aciclovir cream p. 1016 is licensed for the treatment of initial and recurrent labial and genital herpes simplex infections; treatment should begin as early as possible. Systemic treatment is necessary for buccal or vaginal infections and for herpes zoster (shingles).

Herpes labialis

Aciclovir cream can be used for the treatment of initial and recurrent labial herpes simplex infections (cold sores). It is best applied at the earliest possible stage, usually when prodromal changes of sensation are felt in the lip and before vesicles appear.

Penciclovir cream is also licensed for the treatment of herpes labialis; it needs to be applied more frequently than aciclovir cream.

Systemic treatment is necessary if cold sores recur frequently or for infections in the mouth.

Parasiticidal preparations

Suitable quantities of parasiticidal preparations

<table>
<thead>
<tr>
<th>Area of body</th>
<th>Skin creams</th>
<th>Lotions</th>
<th>Cream rinses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scalp (head lice)</td>
<td>applied once daily for 7 days</td>
<td>50–100 mL</td>
<td>50–100 mL</td>
</tr>
<tr>
<td>Body (scabies)</td>
<td>30–60 g</td>
<td>100 mL</td>
<td></td>
</tr>
<tr>
<td>Body (crab lice)</td>
<td>30–60 g</td>
<td>100 mL</td>
<td></td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for single application.

Scabies

Permethrin p. 1015 is used for the treatment of scabies (Sarcoptes scabiei); malathion p. 1015 can be used if permethrin is inappropriate.

Benzyl benzoate p. 1014 is an irritant and should be avoided in children; it is less effective than malathion and permethrin.

Ivermectin p. 1015 (available on a named patient basis from ‘special-order’ manufacturers or specialist importing companies) by mouth has been used, in combination with topical drugs, for the treatment of hyperkeratotic (crusted or ‘Norwegian’) scabies that does not respond to topical treatment alone; further doses may be required.

Application

Although acaricides have traditionally been applied after a hot bath, this is not necessary and there is even evidence that a hot bath may increase absorption into the blood, removing them from their site of action on the skin.

All members of the affected household should be treated simultaneously. Treatment should be applied to the whole body including the scalp, neck, face, and ears. Particular attention should be paid to the webs of the fingers and toes and lotion brushed under the ends of nails. It is now recommended that malathion and permethrin should be applied twice, one week apart; in the case of benzyl benzoate in adults, up to 3 applications on consecutive days may be needed. It is important to warn users to reapply treatment to the hands if they are washed. Patients with hyperkeratotic scabies may require 2 or 3 applications of acaricide on consecutive days to ensure that enough penetrates the skin crusts to kill all the mites.

Itching

The itch and eczema of scabies persists for some weeks after the infestation has been eliminated and treatment for pruritus and eczema may be required. Application of crotamiton p. 1040 can be used to control itching after treatment with more effective acaricides. A topical corticosteroid may help to reduce itch and inflammation after scabies has been treated successfully; however, persistent symptoms suggest that scabies eradication was not successful. Oral administration of a sedating antihistamine at night may also be useful.

Head lice

Dimeticone p. 1014 is effective against head lice (Pediculus humanus capitis). It coats head lice and interferes with water balance in lice by preventing the excretion of water; it is less active against eggs and treatment should be repeated after 7 days. Malathion p. 1015, an organophosphorus insecticide, is an alternative, but resistance has been reported. Benzyl benzoate p. 1014 is licensed for the treatment of head lice but it is less effective than other drugs and not recommended for use in children. Permethrin is active against head lice but the formulation and licensed methods of application of the current products make them unsuitable for the treatment of head lice.

Head lice infestation (pediculosis) should be treated using lotion or liquid formulations only if live lice are present. Shampoos are diluted too much in use to be effective. A contact time of 8–12 hours or overnight treatment is recommended for lotions and liquids; a 2-hour treatment is not sufficient to kill eggs.

In general, a course of treatment for head lice should be 2 applications of product 7 days apart to kill lice emerging from any eggs that survive the first application. All affected household members should be treated simultaneously.

Wet combing methods

Head lice can be mechanically removed by combing wet hair meticulously with a plastic detection comb (probably for at least 30 minutes each time) over the whole scalp at 4-day intervals for a minimum of 2 weeks, and continued until no
lice are found on 3 consecutive sessions; hair conditioner or vegetable oil can be used to facilitate the process. Several devices for the removal of head lice such as combs and topical solutions, are available and some are prescribable on the NHS.

The Drug Tariffs can be accessed online at:
- National Health Service Drug Tariff for England and Wales: www.ppa.org.uk/ppa/edt_intro.htm
- Health and Personal Social Services for Northern Ireland Drug Tariff: www.dhsspsni.gov.uk/pas-tariff
- Scottish Drug Tariff: www.idscotland.org/Health-topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/

Crab lice
Permethrin p. 1015 and malathion p. 1015 are used to eliminate crab lice (Phthirus pubis). An aqueous preparation should be applied, allowed to dry naturally and washed off after 12 hours; a second treatment is needed after 7 days to kill lice emerging from surviving eggs. All surfaces of the body should be treated, including the scalp, neck, and face (paying particular attention to the eyebrow and other facial hair). A different insecticide should be used if a course of treatment fails.

2.1 Bacterial skin infections

Bacitracin with polymyxin B

**INDICATIONS AND DOSE**

**Bacterial skin infections**

**TO THE SKIN**
- **Child:** Apply twice daily, can be applied more frequently if required
- **Adult:** Apply twice daily, can be applied more frequently if required

**CAUTIONS** Nephrotoxicity - neurotoxicity  
**CAUTIONS, FURTHER INFORMATION**

If large areas of skin are being treated nephrotoxicity and neurotoxicity may be a hazard, particularly in children with renal impairment.

**SIDE-EFFECTS**
- **Frequency not known** Contact sensitisation

**RENAI IMPAIRMENT** Renal impairment increases the risk of nephrotoxicity and neurotoxicity.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ointment**
- **Polyfax (Teva UK Ltd)**
  - Bacitracin zinc 500 unit per 1 gram, Polymyxin B sulfate 10000 unit per 1 gram Polyfax ointment | 4 gram £2.23 | 20 gram £4.62 DT price = £4.62

Fusidic acid

**DRUG ACTION** Fusidic acid and its salts are narrow-spectrum antibiotics used for staphylococcal infections.

**INDICATIONS AND DOSE**

**Staphylococcal skin infection**

**TO THE SKIN**
- **Child:** Apply 3–4 times a day usually for 7 days
- **Adult:** Apply 3–4 times a day

**CAUTIONS** Avoid contact of cream or ointment with eyes

Metronidazole

**DRUG ACTION** Metronidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa.

**INDICATIONS AND DOSE**

ACEA®

**Acute inflammatory exacerbation of rosacea**

**TO THE SKIN**
- **Adult:** Apply twice daily for 8 weeks, to be applied thinly

ANABACT®

**Malodorous fungating tumours and malodorous gravitational and decubitus ulcers**

**TO THE SKIN**
- **Adult:** Apply 1–2 times a day, to be applied to clean wound and covered with non-adherent dressing

METROGEL®

**Acute inflammatory exacerbation of rosacea**

**TO THE SKIN**
- **Adult:** Apply twice daily for 8–9 weeks, to be applied thinly

**Malodorous fungating tumours**

**TO THE SKIN**
- **Adult:** Apply 1–2 times a day, to be applied to clean wound and covered with non-adherent dressing

METROSA®

**Acute exacerbation of rosacea**

**TO THE SKIN**
- **Adult:** Apply twice daily for up to 8 weeks, to be applied thinly

ROSICED®

**Inflammatory papules and pustules of rosacea**

**TO THE SKIN**
- **Adult:** Apply twice daily for 6 weeks (longer if necessary)
Neomycin sulfate

**INDICATIONS AND DOSE**

**Bacterial skin infections**

TO THE SKIN

- **Adult:** Apply up to 3 times a day, for short-term use only
- **Child:** Apply up to 3 times a day, for short-term use only

**CONTRA-INDICATIONS**

Neonates

**CAUTIONS**

Large areas If large areas of skin are being treated otoxicity may be a hazard, particularly in children and the elderly, and in those with renal impairment.

**SIDE-EFFECTS**

Sensitisation (cross sensitivity with other aminoglycosides may occur)

**LESS SUITABLE FOR PRESCRIBING**

Neomycin sulfate cream is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream, gel

**Cream**

EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol, propylene glycol

- Rosiced (Pierre Fabre Dermo-Cosmetique)
- Metronidazole 7.5 mg per 1 gram Rosiced 0.75% cream | 30 gram (£15.50 DT price = £6.60)
- Rozex (Galdemen (UK) Ltd)
- Metronidazole 7.5 mg per 1 gram Rozex 0.75% cream | 30 gram (£6.60 DT price = £6.60) + 40 gram (£9.88 DT price = £9.88)

**Gel**

EXCIPIENTS: May contain Benzyl alcohol, disodium edetate, hydroxybenzoates (parabens), propylene glycol

- METRONIDAZOLE (Non-proprietary)
  - Metronidazole 7.5 mg per 1 gram Metronidazole 0.75% gel | 15 gram no price available | 30 gram (£12.00) + 40 gram (£19.90)
- Acea (Ferndale Pharmaceuticals Ltd)
  - Metronidazole 7.5 mg per 1 gram Acea 0.75% gel | 40 gram (£9.95)
- Anabact (Cambridge Healthcare Supplies Ltd)
  - Metronidazole 7.5 mg per 1 gram Anabact 0.75% gel | 15 gram (£4.47) + 30 gram (£7.89)
- Metrogel (Galdemen (UK) Ltd)
  - Metronidazole 7.5 mg per 1 gram Metrogel 0.75% gel | 40 gram (£22.63)
- Metrox (Lindnera Ltd)
  - Metronidazole 7.5 mg per 1 gram Metrox 0.75% gel | 30 gram (£12.00) + 40 gram (£19.90)
- Rozex (Galdemen (UK) Ltd)
  - Metronidazole 7.5 mg per 1 gram Rozex 0.75% gel | 30 gram (£6.60) + 40 gram (£9.88)
- Zyomet (AMCo)
  - Metronidazole 7.5 mg per 1 gram Zyomet 0.75% gel | 30 gram (£12.00)

**Retapamulin**

**INDICATIONS AND DOSE**

Superficial bacterial skin infection caused by Staphylococcus aureus and Streptococcus pyogenes (if resistant to first line topical antibiotics)

TO THE SKIN

- **Child:** 9 months-17 years: Apply twice daily for 5 days, to be applied thinly, maximum area of skin treated 2% of body surface area, review treatment if no response within 2–3 days
- **Adult:** Apply twice daily for 5 days, to be applied thinly, maximum area of skin treated 100 cm² or lesion length 10 cm, review treatment if no response within 2–3 days

**CONTRA-INDICATIONS**

Contact with eyes - contact with mucous membranes

**SIDE-EFFECTS**

Contact dermatitis - localised erythema - localised irritation - localised pain - pruritus

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2008) that retapamulin (Altargo®) is not recommended
for use within NHS Scotland for the treatment of superficial skin infections.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

- **CAUTIONARY AND ADVISORY LABELS**
- 28
- **EXCIPIENTS:** May contain Butylated hydroxytoluene
- 4
- **Altargo** (GlaxoSmithKline UK Ltd)

**Silver sulfadiazine**

**INDICATIONS AND DOSE**

- **Prophylaxis and treatment of infection in burn wounds**
  - **TO THE SKIN**
    - **Child:** Apply daily, may be applied more frequently if very exudative
    - **Adult:** Apply daily, may be applied more frequently if very exudative

- **For conservative management of finger-tip injuries**
  - **TO THE SKIN**
    - **Child:** Apply every 2–3 days, consult product literature for details
    - **Adult:** Apply every 2–3 days, consult product literature for details

- **Adjunct to prophylaxis of infection in skin graft donor sites and extensive abrasions**
  - **TO THE SKIN**
    - **Adult:** (consult product literature)

- **Adjunct to short-term treatment of infection in pressure sores**
  - **TO THE SKIN**
    - **Adult:** Apply once daily or on alternate days

As an adjunct to short-term treatment of infection in leg ulcers

- **TO THE SKIN**
  - **Adult:** Apply once daily or on alternate days, not recommended if ulcer is very exudative

**CONTRA-INDICATIONS**
Not recommended for neonates

**CAUTIONS**

- **G6PD deficiency**
- **CAUTIONS, FURTHER INFORMATION**
- **Large areas** Plasma-sulfadiazine concentrations may approach therapeutic levels with *side-effects* and *interactions* as for sulfonamides if large areas of skin are treated.

**INTERACTIONS**

- Appendix 1 (sulfonamides)—if large amounts given.
- May inactivate enzymatic debriding agents—concomitant use may be inappropriate.

**SIDE-EFFECTS**

- Allergic reactions - argyria (following treatment of large areas of skin or prolonged use)
- Burning - itching - leucopenia - rashes

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Severe blood and skin disorders**
  - Owing to the association of sulfonamides with severe blood and skin disorders, treatment should be stopped immediately if blood disorders or rashes develop. Leucopenia developing 2–3 days after starting treatment of burns patients is reported usually to be self-limiting and silver sulfadiazine need not usually be discontinued provided blood counts are monitored carefully to ensure return to normality within a few days.

**ALLERGY AND CROSS-SENSITIVITY**
Contra-indicated in patients with sensitivity to sulfonamides.

**PREGNANCY**
Risk of neonatal haemolysis and methaemoglobinemia in third trimester.

**BREAST FEEDING**
Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants.

**HEPATIC IMPAIRMENT**
Manufacturer advises caution if significant impairment.

**RENAL IMPAIRMENT**
Manufacturer advises caution if significant impairment.

**MONITORING REQUIREMENTS**
Monitor for leucopenia.

**2.2 Fungal skin infections**

**IMIDAZOLE ANTI-FUNGALS**

**Clotrimazole**

**INDICATIONS AND DOSE**

- **Fungal skin infections**
  - **TO THE SKIN**
    - **Child:** Apply 2–3 times a day
    - **Adult:** Apply 2–3 times a day

**CAUTIONS**

- Contact with eyes and mucous membranes should be avoided.

**SIDE-EFFECTS**

- Local irritation - erythema - hypersensitivity reactions - itching - mild burning sensation

**SIDE-EFFECTS, FURTHER INFORMATION**

- Treatment should be discontinued if side-effects are severe.

**PREGNANCY**
Minimal absorption from skin; not known to be harmful.

**PRESCRIBING AND DISPENSING INFORMATION**

- Spray may be useful for application of clotrimazole to large or hairy areas of the skin.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol

- **Flamazine** (Smith & Nephew Healthcare Ltd)

- **Sulfadiazine silver 10 mg per 1 gram**

  - **Flamazine 1% cream**
    - 20 gram (£2.91) | 50 gram (£3.85 DT price = £3.85) | 250 gram (£40) £10.32 DT price = £10.32 | 500 gram (£89) £18.27 DT price = £18.27

- **Silver sulfadiazine**

  - **Altargo** 10 mg per 1 gram

    - **Retapamulin 10 mg per 1 gram** (GlaxoSmithKline UK Ltd)

- **Child:** Apply twice daily

- **Adult:** Apply daily, may be applied more frequently if very exudative

- **TO THE SKIN**

  - **Apply every 2–3 days, consult product literature**

  - **Apply every 3 days, consult product literature**

- **Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants.**

- **Risk of neonatal haemolysis and methaemoglobinaemia in third trimester.**

- **Significant impairment.**
Econazole nitrate

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
<th>Fungal skin infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO THE SKIN</td>
<td></td>
</tr>
<tr>
<td>Child: Apply twice daily</td>
<td></td>
</tr>
<tr>
<td>Adult: Apply twice daily</td>
<td></td>
</tr>
</tbody>
</table>

Fungal nail infections

- **By transungual application**
  - Child: Apply once daily, applied under occlusive dressing
  - Adult: Apply once daily, applied under occlusive dressing

**CAUTIONS** Avoid contact with eyes and mucous membranes

**SIDE-EFFECTS** Burning sensation, erythema, hypersensitivity reactions, itching, occasional local irritation

**SIDE-EFFECTS, FURTHER INFORMATION** Treatment should be discontinued if side-effects are severe.

**PREGNANCY** Minimal absorption from skin; not known to be harmful.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

- **Cream**
  - **Excipients**: May contain Butylated hydroxyanisole, fragrances
  - **Pevaryl** (Janssen-Cilag Ltd)
    - Econazole nitrate 10 mg per 1 gram Pevaryl 1% cream | 30 gram (£) £3.71
  - Brands may include Gyno-Pevaryl 1% cream

Ketoconazole

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
<th>Tinea pedis</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO THE SKIN USING CREAM</td>
<td></td>
</tr>
<tr>
<td>Adult: Apply 1–2 times a day</td>
<td></td>
</tr>
</tbody>
</table>

**Treatment of seborrhoeic dermatitis and dandruff**

- **To the skin**
  - Child 12-17 years: Apply twice weekly for 2–4 weeks, leave preparation on for 3–5 minutes before rinsing
  - Adult: Apply twice weekly for 2–4 weeks, leave preparation on for 3–5 minutes before rinsing

**Prophylaxis of seborrhoeic dermatitis and dandruff**

- **To the skin**
  - Child 12-17 years: Apply every 1–2 weeks, leave preparation on for 3–5 minutes before rinsing
  - Adult: Apply every 1–2 weeks, leave preparation on for 3–5 minutes before rinsing

**Treatment of pityriasis versicolor**

- **To the skin**
  - Child 12-17 years: Apply once daily for maximum 5 days, leave preparation on for 3–5 minutes before rinsing

**CAUTIONS** Avoid contact with eyes, avoid contact with mucous membranes

**INTERACTIONS** → Appendix 1 (antifungals, imidazole).

**SIDE-EFFECTS** Erythema, hypersensitivity reactions, itching, mild burning sensation, occasional local irritation

**SIDE-EFFECTS, FURTHER INFORMATION** Treatment should be discontinued if side-effects are severe.

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NHS restrictions** Ketoconazole cream is not prescribable on the NHS except for seborrhoeic dermatitis and pityriasis versicolor and endorsed 'SLS'.

- **Exceptions to legal category**
  - For Fungal skin infections in adults A 15-g tube is available for sale to the public for the treatment of tinea pedis, tinea cruris, and candidal intertrigo.
  - For Seborrhoeic dermatitis and dandruff Can be sold to the public for the prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp as a shampoo formulation containing ketoconazole maximum 2% in a pack containing maximum 120 mL and labelled to show a maximum frequency of application of once every 3 days.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

- **Shampoo**
  - **Excipients**: May contain Emulsifiers, surfactants, stabilisers
  - **Ketoconazole** 20 mg per 1 gram Nizoral 2% shampoo | 120 mL (£) £4.24 07 price = £4.24
  - Brands may include Daktarin Gold 2% shampoo

Miconazole

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
<th>Fungal skin infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO THE SKIN</td>
<td></td>
</tr>
<tr>
<td>Child: Apply twice daily continuing for 10 days after lesions have healed</td>
<td></td>
</tr>
<tr>
<td>Adult: Apply twice daily continuing for 10 days after lesions have healed</td>
<td></td>
</tr>
</tbody>
</table>

**Fungal nail infections**

- **To the skin**
  - Child: Apply 1–2 times a day
  - Adult: Apply 1–2 times a day

**CAUTIONS** Avoid in acute porphyrias p. 864 - contact with eyes and mucous membranes should be avoided
**INTERACTIONS** → Appendix 1 (antifungals, imidazole).

**SIDE-EFFECTS**
- Common or very common: Nausea, rash, vomiting
- Frequency not known: Burning sensation, erythema, hypersensitivity reactions, itching, occasional local irritation

**SIDE-EFFECTS, FURTHER INFORMATION**
Treatment should be discontinued if side effects are severe.

**PREGNANCY** Absorbed from the skin in small amounts; manufacturer advises caution.

**BREAST FEEDING** Manufacturer advises caution—no information available.

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary

**NATIONAL FUNDING/ACCESS DECISIONS**
NHS restrictions: Miconazole nitrate 2% powder is not prescribable on the NHS.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Cream**
  - **Excipients:** May contain Butylated hydroxyanisole
  - **Miconazole nitrate 20 mg per 1 g**: Daktarin 2% cream (McNeil Products Ltd)
  - **Miconazole nitrate 1.6 mg per 1 g**: Daktarin Aktiv 0.16% spray powder (100 gram GSK) £3.17 DT price = £3.17

- **Spray**
  - **CAUTIONARY AND ADVISORY LABELS 15**
  - **Miconazole nitrate 1.6 mg per 1 g**: Daktarin Aktiv 0.16% spray powder (100 gram GSK) £3.17 DT price = £3.17

- **Powder**
  - **Daktarin (McNeil Products Ltd)**
  - **Miconazole nitrate 20 mg per 1 g**: Daktarin 2% powder (20 gram) £2.58

**Tioconazole**

**INDICATIONS AND DOSE**
Fungal nail infection

**BY TRANSGINGUAL APPLICATION**
- **Child:** Apply twice daily usually for up to 6 months (may be extended to 12 months), apply to nails and surrounding skin
- **Adult:** Apply twice daily usually for up to 6 months (may be extended to 12 months), apply to nails and surrounding skin

**CAUTIONS** Contact with eyes and mucous membranes should be avoided - use with caution if child likely to suck affected digits

**SIDE-EFFECTS** Burning sensation, dry skin, erythema, exfoliation, hypersensitivity reactions, itching, local oedema, nail discoloration, nail pain, occasional local irritation, periangual inflammation, rash

**SIDE-EFFECTS, FURTHER INFORMATION**
Treatment should be discontinued if side-effects are severe.

**PREGNANCY** Manufacturer advises avoid.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Paint**
  - Tioconazole 283 mg per 1 ml: Trosyl (Pfizer Ltd)
  - Tioconazole 283 mg per 1 ml: Trosyl (Riner) Spray 283 mg/ml nail solution £27.38 DT price = £27.38

**OTHER ANTIFUNGALS**

**Amorolfine**

**INDICATIONS AND DOSE**
Fungal nail infections

**BY TRANSGINGUAL APPLICATION**
- **Child:** Apply 1 – 2 times a week for 6 months to treat finger nail and for toe nails 9 – 12 months (review at intervals of 3 months), apply to infected nails after filing and cleansing, allow to dry for approximately 3 minutes
- **Adult:** Apply 1 – 2 times a week for 6 months to treat finger nail and for toe nails 9 – 12 months (review at intervals of 3 months), apply to infected nails after filing and cleansing, allow to dry for approximately 3 minutes

**UNLICENSED USE** Not licensed for use in children under 12 years.

**CAUTIONS** Avoid contact with ears, avoid contact with eyes and mucous membranes - use with caution in child likely to suck affected digits

**SIDE-EFFECTS** Burning sensation, erythema, hypersensitivity reactions, itching, occasional local irritation

**SIDE-EFFECTS, FURTHER INFORMATION**
Treatment should be discontinued if side-effects are severe.

**PATIENT AND CARER ADVICE** Avoid nail varnish or artificial nails during treatment.

**EXCEPTIONS TO LEGAL CATEGORY** Amorolfine nail lacquer can be sold to the public if supplied for the treatment of mild cases of distal and lateral subungual onychomycoses caused by dermatophytes, yeasts and moulds; subject to treatment of max. 2 nails, max. strength of nail lacquer amorolfine 5% and a pack size of 3 mL.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Medicated nail lacquer**
  - **CAUTIONARY AND ADVISORY LABELS 10**
  - **AMOROLFINE (Non-proprietary)**
    - Amorolfine (as Amorolfine hydrochloride) 50 mg per 1 ml: Amorolfine 5% medicated nail lacquer (3 ml) £12.00
    - Amorolfine (as Amorolfine hydrochloride) 50 mg per 1 ml: Loceryl (Galdemar (UK) Ltd) £16.21 DT price = £5.81
  - Amorolfine (as Amorolfine hydrochloride) 50 mg per 1 ml: Loceryl 5% medicated nail lacquer (2.5 ml) £7.26
  - Brands may include Curaful 5% medicated nail lacquer, Omniric 5% medicated nail lacquer

**Griseofulvin**

**INDICATIONS AND DOSE**
Tinea pedis

**TO THE SKIN**
- **Adult:** Apply 400 micrograms once daily, apply to an area approximately 13 cm², increased if necessary to 1.2 mg once daily for maximum treatment duration of 4 weeks, allow each spray to dry between application
SIDE-EFFECTS, FURTHER INFORMATION

Treatment should be discontinued if side-effects are severe.

- PREGNANCY  Manufacturer advises avoid unless potential benefit outweighs risk.
- BREAST FEEDING  Manufacturer advises avoid unless potential benefit outweighs risk.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Spray

CAUTIONARY AND ADVISORY LABELS 15

EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetostearyl alcohol hydroxypropyl betaine), polyethylene glycol 400, propylene glycol, salicylic acid, water (including sodium chloride).

Grisol AF (Transdermal Ltd)

Grisofulvin 10 mg per 1 gram  Grisol AF 1% spray | 20 ml £1.35

TERBINAFINE (Non-proprietary)

Terbinafine hydrochloride 10 mg per 1 gram  Terbinafine 1% cream | 7.5 gram £0.95 | 15 gram £4.86 DT price = £1.69 | 30 gram £9.38 DT price = £3.38

Lamisil (Novartis Consumer Health UK Ltd)

Terbinafine hydrochloride 10 mg per 1 gram  Lamisil 1% cream | 30 gram £8.76 DT price = £3.38

Benzoic acid with salicylic acid

INDICATIONS AND DOSE

Ringworm (tinea)

TO THE SKIN

- Child: Apply twice daily
- Adult: Apply twice daily

- CAUTIONS

Avoid broken or inflamed skin  avoid contact with eyes avoid contact with mucous membranes

CAUTIONS, FURTHER INFORMATION

Salicylate toxicity  Salicylate toxicity may occur particularly if applied on large areas of skin.

SIDE-EFFECTS

Erythema  hypersensitivity reactions  itching  mild burning sensation  occasional local irritation

SIDE-EFFECTS, FURTHER INFORMATION

Treatment should be discontinued if side effects are severe.

- PRESCRIBING AND DISPENSING INFORMATION

Benzoic Acid Ointment, Compound, BP (a preparation containing benzoic acid and salicylic acid) has also been referred to as Whitfield’s ointment. When prepared extemporaneously, the BP states Benzoic Acid Ointment, Compound BP (Whitfield’s ointment) consists of benzoic acid 6%, salicylic acid 3%, in emulsifying ointment.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, cream

Boric acid with salicylic acid and tannic acid

INDICATIONS AND DOSE

Fungal nail infection, particularly tinea

BY TRANSGUNGAL APPLICATION

- Child 5–17 years: Apply twice daily, and after washing
- Adult: Apply twice daily, and after washing

- CAUTIONS

Avoid broken or inflamed skin  contact with eyes and mucous membranes should be avoided - use with caution in children likely to suck affected digits

CAUTIONS, FURTHER INFORMATION

Salicylate toxicity  Salicylate toxicity can occur particularly if applied on large areas of skin.

SIDE-EFFECTS

Burning sensation  erythema  hypersensitivity reactions  itching  occasional local irritation

SIDE-EFFECTS, FURTHER INFORMATION

Treatment should be discontinued if side-effects are severe.

- PREGNANCY  Avoid.

LESS SUITABLE FOR PRESCRIBING  Phytex® is less suitable for prescribing.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.
2.3 Parasitic skin infections

**Parasiticides**

**Benzyl benzoate**

**INDICATIONS AND DOSE**

*Scabies*

**TO THE SKIN**

- **Child:** Apply over the whole body; repeat without bathing on the following day and wash off 24 hours later; a third application may be required in some cases

**CAUTIONS**

- Avoid contact with eyes and mucous membranes - children (not recommended) - do not use on broken or secondarily infected skin

**SIDE-EFFECTS**

- Burning sensation (especially on genitalia and excoriations) - rashes - skin irritation

**BREAST FEEDING**

Suspend feeding until product has been washed off.

**PRESCRIBING AND DISPENSING INFORMATION**

Not recommended for children—dilution to reduce irritant effect also reduces efficacy. Some manufacturers recommend application to the body but to exclude the head and neck. However, application should be extended to the scalp, neck, face, and ears. When prepared extemporaneously, the BP states Benzyl Benzoate Application, BP consists of benzyl benzoate 25% in an emulsion basis.

**LESS SUITABLE FOR PRESCRIBING**

Benzyl benzoate is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

---

**Undecenoic acid with zinc undecenoate**

**INDICATIONS AND DOSE**

*Treatment of athletes foot*

**TO THE SKIN**

- **Child:** Apply twice daily, continue use for seven days after lesions have healed
- **Adult:** Apply twice daily, continue use for seven days after lesions have healed

**Prevention of athletes foot**

**TO THE SKIN**

- **Child:** Apply once daily
- **Adult:** Apply once daily

**CAUTIONS**

- Avoid broken skin - contact with eyes should be avoided - contact with mucous membranes should be avoided

**SIDE-EFFECTS**

- Erythema - hypersensitivity reactions - itching - local irritation - mild burning sensation

**SIDE-EFFECTS, FURTHER INFORMATION**

Treatment should be discontinued if side effects are severe.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances

- **UNDECENOIC ACID WITH ZINC UNDECENOATE (Non-proprietary)**
  - Undecenoic acid 50 mg per 1 gram, Zinc undecenoate 200 mg per 1 gram 25 gram £0.01
  - Brands may include Mycota

---

**Dimeticone**

**INDICATIONS AND DOSE**

*Head lice*

**TO THE SKIN**

- **Child:** Apply once weekly for 2 doses, rub into hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight)
- **Adult:** Apply once weekly for 2 doses, rub into hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight)

**UNLICENSED USE**

Not licensed for use in children under 6 months except under medical supervision.

**CAUTIONS**

- Avoid contact with eyes - children under 6 months, medical supervision required

**SIDE-EFFECTS**

- Skin irritation

**PATIENT AND CARER ADVICE**

Patients should be told to keep hair away from fire and flames during treatment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Malathion

**INDICATIONS AND DOSE**

**Head lice**
- **TO THE SKIN**
  - Child: Apply once weekly for 2 doses, apply 0.5% preparation over whole body, and wash off after 24 hours,
  - Adult: Apply once weekly for 2 doses, apply 0.5% preparation over whole body, and wash off after 24 hours,

**Crab lice**
- **TO THE SKIN**
  - Child: Apply once weekly for 2 doses, apply 0.5% preparation over whole body, and wash off after 24 hours,
  - Adult: Apply once weekly for 2 doses, apply 0.5% preparation over whole body, and wash off after 24 hours,

**Scabies**
- **TO THE SKIN**
  - Child: Apply once weekly for 2 doses, apply 0.5% preparation over whole body, and wash off after 24 hours,
  - Adult: Apply once weekly for 2 doses, apply 0.5% preparation over whole body, and wash off after 24 hours,

**SIDE-EFFECTS**
- Chemical burns · hypersensitivity reactions · skin irritation

**PRESCRIBING AND DISPENSING INFORMATION**
- For scabies, manufacturer recommends application to the body but not necessarily to the head and neck.
- However, application should be extended to the scalp, neck, face, and ears.

Ivermectin

**INDICATIONS AND DOSE**

**Scabies**, in combination with topical drugs, for the treatment of hyperkeratotic (crusted or ‘Norwegian’) scabies that does not respond to topical treatment alone
- **BY MOUTH**
  - **Adult:** 200 micrograms/kg for 1 dose, further doses of 200 micrograms/kg may be required

**SIDE-EFFECTS**
- Aggravation of itching · aggravation of rash

**CAUTIONARY AND ADVISORY LABELS**
- Chemical burns

**UNLICENSED USE**
- Ivermectin is an unlicensed drug.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- **Liquid**
  - **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances, hydroxybenzoates (parabens)
  - **Derbac-M** (G.R. Lane Health Products Ltd)
    - Malathion 5 mg per 1 gram Derbac-M 0.5% liquid | 50 ml [£] 3.23
      DT price = £3.23 | 200 ml [£] 7.76 DT price = £7.76

**Permethrin**

**INDICATIONS AND DOSE**

**Scabies**
- **TO THE SKIN**
  - Child 2 months–17 years: Apply once weekly for 2 doses, apply 5% preparation over whole body including face, neck, scalp and ears then wash off after 8–12 hours.
  - Adult: Apply once weekly for 2 doses, apply 5% preparation over whole body including face, neck, scalp and ears then wash off after 8–12 hours.
    - If hands are washed with soap they should be treated again with cream
  - **Head lice**
    - **TO THE SKIN**
      - Child 2 months–17 years: Apply once weekly for 2 doses, apply 5% cream over whole body, allow to dry naturally and wash off after 12 hours or after leaving on overnight
  - **Crab lice**
    - **TO THE SKIN**
      - Adult: Not recommended; no information given

**SIDE-EFFECTS**
- Rare Oedema · rashes · erythema · pruritus · stinging

**PRESCRIBING AND DISPENSING INFORMATION**
- Manufacturer recommends application to the body but to exclude head and neck. However, application should be extended to the scalp, neck, face, and ears.
- Large children may require up to two 30-g packs for adequate treatment.

**LESS SUITABLE FOR PRESCRIBING**
- Lyclear® Creme Rinse is less suitable for prescribing.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- **Liquid**
  - **EXCIPIENTS:** May contain Fatty alcohol, squalene and related substances including lanolin
  - **PERMETHRIN (Non-proprietary)**
  - Permethrin 50 mg per 1 gram Permethrin 5% cream |
  - 30 gram [£] 7.46 DT price = £7.46
  - Brands may include Lyclear 5% dermal cream
2.4 Viral skin infections

NUCLEOSIDE ANALOGUES

Aciclovir
(Acylovir)

INDICATIONS AND DOSE
Herpes simplex infection (local treatment)

TO THE SKIN
- Child: Apply 5 times a day for 5–10 days, to be applied to lesions every 4 hours, starting at first sign of attack
- Adult: Apply 5 times a day for 5–10 days, to be applied to lesions every 4 hours, starting at first sign of attack

CAUTIONS
- Avoid cream coming into contact with eyes and mucous membranes
- SIDE-EFFECTS: Drying of the skin, erythema, itching of the skin, transient burning, transient stinging
- PREGNANCY: Limited absorption from topical aciclovir preparations.
- PATIENT AND CARER ADVICE
  - Medicines for Children leaflet: Aciclovir cream for herpes
  - www.medicinesforchildren.org.uk/aciclovir-cream-for-herpes
- PROFESSION SPECIFIC INFORMATION
  - Dental practitioners’ formulary
  - Aciclovir Cream may be prescribed.
- EXCEPTIONS TO LEGAL CATEGORY
  - A 2-g tube and a pump pack are on sale to the public for the treatment of cold sores.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.
- Cream
  - Excipients: May contain cetostearyl alcohol (including cetyl and stearyl alcohol), propylene glycol
  - Aciclovir (Non-proprietary)
    - Aciclovir 50 mg per 1 gram
    - Aciclovir 5% cream | 2 gram (£0.41 DT price + £1.33) | 10 gram (£0.01236 DT price + £6.65)
    - Zovirax (GlaxoSmithKline UK Ltd)
    - Aciclovir 50 mg per 1 gram
    - Zovirax 5% cream | 2 gram (£4.63 DT price + £1.33) | 10 gram (£11.36 DT price + £6.65)

3 Inflammatory skin conditions

3.1 Eczema and psoriasis

Eczema

Eczema (dermatitis) has several causes, which may influence treatment. The main types of eczema are irritant, allergic contact, atopic, venous and discoid; different types may co-exist. Lichenification, due to scratching and rubbing, may complicate any chronic eczema. Atopic eczema is the most common type and it usually involves dry skin as well as infection and lichenification.

Management of eczema involves the removal or treatment of contributory factors including occupational and domestic irritants. Known or suspected contact allergens should be avoided. Rarely, ingredients in topical medicinal products may sensitize the skin; the BNF lists active ingredients together with excipients that have been associated with skin sensitisation.

Skin dryness and the consequent irritant eczema requires emollients applied regularly (at least twice daily) and liberally to the affected area; this can be supplemented with bath or shower emollients. The use of emollients should continue even if the eczema improves or if other treatment is being used.

Topical corticosteroids are also required in the management of eczema; the potency of the corticosteroid should be appropriate to the severity and site of the condition. Mild corticosteroids are generally used on the face and on flexures; potent corticosteroids are generally required for use on adults with discoid or lichenified eczema or with eczema on the scalp, limbs, and trunk. Treatment should be reviewed regularly, especially if a potent corticosteroid is required. In patients with frequent flares (2–3 per month), a topical corticosteroid can be applied on 2 consecutive days each week to prevent further flares.

Bandages (including those containing ichthammol with zinc oxide p. 1019) are sometimes applied over topical corticosteroids or emollients to treat eczema of the limbs. Dry-wrap dressings can be used to provide a physical barrier to help prevent scratching and improve retention of emollients. See Wound management products and elasticated garments p. 1294 for details of elasticated viscose stockinette tubular bandages and garments, and silk clothing.

See Eczema and psoriasis, drugs affecting the immune system p. 1017 for the role of topical pimecrolimus p. 1019 and tacrolimus p. 1020 in atopic eczema.

Infection

Bacterial infection (commonly with Staphylococcus aureus and occasionally with Streptococcus pyogenes) can exacerbate eczema and requires treatment with topical or systemic antibacterial drugs. Antibacterial drugs should be used in short courses (typically 1 week) to reduce the risk of drug resistance or skin sensitisation. Associated eczema is treated simultaneously with a topical corticosteroid which can be combined with a topical antimicrobial. Eczema involving widespread or recurrent infection requires the use of a systemic antibacterial that is active against the infecting organism. Products that combine an antiseptic with an emollient application and with a bath emollient can also be used; antiseptic shampoos can be used on the scalp.

Intertriginous eczema commonly involves candida and bacteria; it is best treated with a mild or moderately potent topical corticosteroid and a suitable antimicrobial drug.

Widespread herpes simplex infection may complicate atopic eczema and treatment with a systemic antiviral drug is indicated.

Management of other features of eczema

Lichenification, which results from repeated scratching is treated initially with a potent corticosteroid. Bandages containing ichthammol paste p. 1019 (to reduce pruritus) and other substances such as zinc oxide can be applied over the corticosteroid or emollient. Coal tar and ichthammol can be useful in some cases of chronic eczema.

A non-sedating antihistamine may be of some value in relieving severe itching or urticaria associated with eczema. A sedating antihistamine can be used if itching causes sleep disturbance.

Exudative (weeping) eczema requires a potent corticosteroid initially; infection may also be present and require specific treatment. Potassium permanganate p. 1052 solution (1 in 10,000) can be used in exudating eczema for its antiseptic and astringent effects; treatment should be stopped when exudation stops.

Severe refractory eczema

Severe refractory eczema is best managed under specialist supervision; it may require phototherapy or drugs that act on the immune system. Alitretinoin p. 1033 is licensed for...
the treatment of severe chronic hand eczema refractory to potent topical corticosteroids; patients with hyperkeratotic features are more likely to respond to alitretinoin than those with pompholyx.

**Seborrhoeic dermatitis**
Seborrhoeic dermatitis (seborrhoeic eczema) is associated with species of the yeast *Malassezia* and affects the scalp, paranasal areas, and eyebrows. Shampoos active against the yeast (including those containing ketoconazole p. 1011 and coal tar) and combinations of mild corticosteroids with suitable antimicrobials are used.

---

### Eczema and psoriasis, drugs affecting the immune response

Drugs affecting the immune response are used for eczema or psoriasis. Systemic drugs acting on the immune system are used under specialist supervision.

- **Pimecrolimus** p. 1019 by topical application is licensed for mild to moderate atopic eczema. Tacrolimus p. 1020 is licensed for topical use in moderate to severe atopic eczema. Both are drugs whose long-term safety is still being evaluated and they should not usually be considered first-line treatments unless there is a specific reason to avoid or reduce the use of topical corticosteroids. Treatment of atopic eczema with topical pimecrolimus or topical tacrolimus should be initiated only by prescribers experienced in managing the condition. Topical tacrolimus and pimecrolimus have a role in the treatment of psoriasis.

- A short course of a systemic corticosteroid can be given for eczema flares that have not improved despite appropriate topical treatment.

- Ciclosporin p. 717 by mouth can be used for severe psoriasis and for severe eczema. Azathioprine p. 716 or mycophenolate mofetil p. 725 are used for severe refractory eczema [unlicensed indication].

- Methotrexate p. 762 can be used for severe psoriasis, the dose being adjusted according to severity of the condition and haematological and biochemical measurements. Folic acid p. 836 should be given to reduce the possibility of side-effects associated with methotrexate. Folic acid can be given once weekly [unlicensed indication], on a different day from the methotrexate; alternative regimens of folic acid may be used in some settings.

- Etanercept p. 903, adalimumab p. 901, and infliximab p. 906 inhibit the activity of tumour necrosis factor (TNFα).

They are used for severe plaque psoriasis either refractory to at least 2 standard systemic treatments and phototherapy, or when standard treatments cannot be used because of intolerance or contra- indications; while either etanercept or adalimumab is considered to be the first choice in stable disease, infliximab or adalimumab may be useful when rapid disease control is required. Ustekinumab p. 899 (a monoclonal antibody that inhibits interleukins 12 and 23) can be used for severe plaque psoriasis that has not responded to at least 2 standard systemic treatments and phototherapy, or when these treatments cannot be used because of intolerance or contra- indications. Adalimumab, etanercept, infliximab and ustekinumab are also licensed for psoriatic arthritis.

---

### Psoriasis

Psoriasis is characterised by epidermal thickening and scaling. It commonly affects extensor surfaces and the scalp.

Occasionally, psoriasis is provoked or exacerbated by drugs such as lithium, chloroquine and hydroxychloroquine, beta-blockers, non-steroidal anti-inflammatory drugs, and ACE inhibitors. Psoriasis may not be seen until the drug has been taken for weeks or months.

**Emollients**, in addition to their effects on dryness, scaling and cracking, may have an anti-proliferative effect in psoriasis, and may be the only treatment necessary for mild psoriasis. They are particularly useful in inflammatory psoriasis and in plaque psoriasis of palms and soles, in which irritant factors can perpetuate the condition. Emollients are useful adjuncts to other more specific treatment.

More specific topical treatment for chronic stable plaque psoriasis on extensor surfaces of trunk and limbs involves the use of vitamin D analogues, coal tar p. 1018, and the retinoid tazarotene p. 1034. However, they can irritate the skin and they are not suitable for the more inflammatory forms of psoriasis; their use should be suspended during an inflammatory phase of psoriasis. The efficacy and the irritancy of each substance varies between patients. If a substance irritates significantly, it should be stopped or the concentration reduced; if it is tolerated, its effects should be assessed after 4 to 6 weeks and treatment continued if it is effective.

**Scalp psoriasis** is usually scaly, and the scale may be thick and adherent; this will require softening with an emollient cream, ointment, or oil. A tar-based shampoo is first-line treatment for scalp psoriasis; a keratolytic, such as salicylic acid, should also be used if there is significant scaling, to allow other treatments to work.

Some preparations prescribed for psoriasis affecting the scalp, combine salicylic acid with coal tar or sulfur. The product should be applied generously, and an adequate quantity should be prescribed. It should be left on for at least an hour, often more conveniently overnight, before washing off. The use of scalp preparations containing a potent corticosteroid or a vitamin D analogue, either alone or in combination, can also be helpful.

**Facial, flexural and genital psoriasis** can be managed with short-term use of a mild or moderate potency topical corticosteroid (a mild potency topical corticosteroid is preferred for the initial treatment of facial psoriasis). Calcipotriol p. 1037 or tacalcitol p. 1037 can be used for longer-term treatment, or if the response to mild or moderate potency topical corticosteroids is inadequate; calcipotriol p. 1036 is more likely to cause irritation. Low strength tar preparations can also be used. Pimecrolimus p. 1019 or tacrolimus p. 1020 by topical application [unlicensed indication] can be used short-term, under specialist supervision, in patients whose condition has not responded adequately to other treatments, or who are intolerant of them.

Widespread unstable psoriasis of erythrodermic or generalised pustular type requires urgent specialist assessment. Initial topical treatment should be limited to using emollients frequently and generously; emollients should be prescribed in quantities of 1 kg or more. More localised acute or subacute inflammatory psoriasis with hot, spreading or itchy lesions, should be treated topically with emollients or with a corticosteroid of moderate potency.

Calcipotriol and tacalcitol are analogues of vitamin D that affect cell division and differentiation. Calcitriol is an active form of vitamin D. Vitamin D and its analogues are used first-line for the long-term treatment of plaque psoriasis; they do not smell or stain and they may be more acceptable than tar or dithranol products. Of the vitamin D analogues, tacalcitol and calcitriol are less likely to irritate.

**Coal tar** has anti-inflammatory properties that are useful in chronic plaque psoriasis; it also has antisingulating properties. Crude coal tar (coal tar, BP) is the most effective form, typically in a concentration of 1 to 10% in a soft paraffin base, but few outpatients tolerate the smell and mess. Cleaner extracts of coal tar included in proprietary preparations, are more practicable for home use but they are less effective and improvement takes longer. Contact of
coal tar products with normal skin is not normally harmful and they can be used for widespread small lesions; however, irritation, contact allergy, and sterile folliculitis can occur. The milder tar extracts can be used on the face and flexures. Tar baths and tar shampoos are also helpful.

Dithranol below is effective for chronic plaque psoriasis. Its major disadvantages are irritation (for which individual susceptibility varies) and staining of skin and of clothing. Dithranol below is not generally suitable for widespread small lesions nor should it be used in the flexures or on the face. Proprietary preparations are more suitable for home use; they are usually washed off after 5 to 60 minutes (‘short contact’). Specialist nurses may apply intensive treatment with dithranol below paste which is covered by stockinette dressings and usually retained overnight. Dithranol below should be discontinued if even a low concentration causes acute inflammation; continued use can result in the psoriasis becoming unstable.

Tazarotene p. 1034, a retinoid, has a similar efficacy to vitamin D and its analogues, but is associated with a greater incidence of irritation. Although irritation is common, it is minimised by applying tazarotene sparingly to the plaques and avoiding normal skin; application to the face and in flexures should also be avoided. Tazarotene does not stain and is odourless.

A topical corticosteroid is not generally suitable for long-term use or as the sole treatment of extensive chronic plaque psoriasis; any early improvement is not usually maintained and there is a risk of the condition deteriorating or of precipitating an unstable form of psoriasis (e.g. erythrodermic psoriasis or generalised pustular psoriasis) on withdrawal. Topical use of potent corticosteroids on widespread psoriasis can also lead to systemic as well as local side-effects. However, topical corticosteroids used short-term may be appropriate to treat psoriasis in specific sites such as the face or flexures (with a mild or moderate corticosteroid), and psoriasis of the scalp, palms, and soles (with a potent corticosteroid). Very potent corticosteroids should only be used under specialist supervision.

Combining the use of a corticosteroid with another specific topical treatment may be beneficial in chronic plaque psoriasis; the drugs may be used separately at different times of the day or used together in a single formulation. Eczema co-existing with psoriasis may be treated with a corticosteroid, or coal tar, or both.

Phototherapy
Phototherapy is available in specialist centres under the supervision of a dermatologist. Ultraviolet B (UVB) radiation is usually effective for chronic stable psoriasis and for guttate psoriasis. It may be considered for patients with moderately severe psoriasis in whom topical treatment has failed, but it may irritate inflammatory psoriasis.

Photochemotherapy combining long-wave ultraviolet A radiation with a psoralen (PUVA) is available in specialist centres under the supervision of a dermatologist. The psoralen, which enhances the effect of irradiation, is administered either by mouth or topically. PUVA is effective in most forms of psoriasis, including localised palmoplantar pustular psoriasis. Early adverse effects include phototoxicity and pruritus. Higher cumulative doses exaggerate skin ageing, increase the risk of dysplastic and neoplastic skin lesions, especially squamous cancer, and pose a theoretical risk of catareata.

Phototherapy combined with coal tar, dithranol, tazarotene, topical vitamin D or vitamin D analogues, or oral acitretin, allows reduction of the cumulative dose of phototherapy required to treat psoriasis.

Systemic treatment
Systemic treatment is required for severe, resistant, unstable or complicated forms of psoriasis, and it should be initiated only under specialist supervision. Systemic drugs for psoriasis include acitretin and drugs that affect the immune response (such as ciclosporin p. 717 and methotrexate p. 762).

Systemic corticosteroids should be used only rarely in psoriasis because rebound deterioration may occur on reducing the dose.

Acitretin p. 1032, a metabolite of etretinate, is a retinoid (vitamin A derivative); it is prescribed by specialists. The main indication for acitretin is psoriasis, but it is also used in disorders of keratinisation such as severe Darier’s disease (keratosis follicularis), and some forms of ichthyosis. Although a minority of cases of psoriasis respond well to acitretin alone, it is only moderately effective in many cases and it is combined with other treatments. A therapeutic effect occurs after 2 to 4 weeks and the maximum benefit after 4 months. Consideration should be given to stopping acitretin if the response is inadequate after 4 months at the optimum dose. The manufacturers of acitretin do not recommend continuous treatment for longer than 6 months. However, some patients may benefit from longer treatment, provided that the lowest effective dose is used, patients are monitored carefully for adverse effects, and the need for treatment is reviewed regularly.

Apart from teratogenicity, which remains a risk for 3 years after stopping, acitretin is the least toxic systemic treatment for psoriasis; in women with a potential for child-bearing, the possibility of pregnancy must be excluded before treatment and effective contraception must be used during treatment and for at least 3 years afterwards (oral progestogen-only contraceptives not considered effective).

Topical treatment
The vitamin D and analogues, calcipotriol p. 1036, calcitriol p. 1037, and tacalcitol p. 1037 are used for the management of plaque psoriasis. They should be avoided by those with calcium metabolism disorders, and used with caution in generalised pustular or erythrodermic exfoliative psoriasis (enhanced risk of hypercalcaemia).

ANTRACEN DERIVATIVES

Dithranol (Anthralin)

**INDICATIONS AND DOSE**

**Subacute and chronic psoriasis**

**TO THE SKIN**

- Adult: (consult product literature)

**DITHROCREAM®**

**Subacute and chronic psoriasis**

**TO THE SKIN**

- Adult: For application to skin or scalp, 0.1–0.5% cream suitable for overnight treatment, 1–2% cream for maximum 1 hour (consult product literature)

**MICANOL®**

**Subacute and chronic psoriasis**

**TO THE SKIN**

- Adult: Apply once daily, for application to skin or scalp, to be applied for up to 30 minutes, apply 1% cream, if necessary 3% cream can be used under medical supervision

- **CONTRA-INDICATIONS** Acute and pustular psoriasis - hypersensitivity
- **CAUTIONS** Avoid sensitive areas of skin - avoid use near eyes
- **SIDE-EFFECTS** Local burning sensation - local irritation - stains hair - stains skin
- **PREGNANCY** No adverse effects reported.
- **BREAST FEEDING** No adverse effects reported.
**DIRECTIONS FOR ADMINISTRATION** When applying dithranol, hands should be protected by gloves or they should be washed thoroughly afterwards. Dithranol should be applied to chronic extensor plaques only, carefully avoiding normal skin.

**MICANOL** At the end of contact time, use plenty of lukewarm (not hot) water to rinse off cream; soap may be used after the cream has been rinsed off; use shampoo before applying cream to scalp and if necessary after cream has been rinsed off.

**PRESCRIBING AND DISPENSING INFORMATION** Treatment should be started with a low concentration such as dithranol 0.1%, and the strength increased gradually every few days up to 3%, according to tolerance. When prepared extemporaneously, the BP states Dithranol Paste, BP consists of dithranol in zinc and salicylic acid (Lassar’s) paste. Usual strengths 0.1–1% of dithranol. Dithranol Ointment BP, consists of dithranol, in yellow soft paraffin; usual strengths 0.1–2%. Part of basis may be replaced by hard paraffin if a stiffer preparation is required.

**PATIENT AND CARER ADVICE** Dithranol can stain the skin, hair and fabrics.

**EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine if dithranol content more than 1%, otherwise may be sold to the public.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, paste.

**SIDE-EFFECTS** Skin irritation

**PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Ichthammol Ointment, BP 1980 consists of ichthammol 10%, white soft paraffin 45% and wool fat 45%.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: paste, ointment.

**ICHTHAMMOL (Non-proprietary)** Ichthammol 1 mg per 1 mg

- Ichthammol liquid | 100 gram £11.42
- 500 gram £34.27

**MICANOL** Ichthammol with zinc oxide

The properties listed below are those particular to the combination only. For the properties of the components please consider, ichthammol above.

**INDICATIONS AND DOSE** Chronic lichenified eczema

- **TO THE SKIN**
  - Child 1–17 years: Apply 1–3 times a day
  - Adult: Apply 1–3 times a day

**PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Ichthammol Ointment, BP 1980 consists of ichthammol 10%, white soft paraffin 45% and wool fat 45%.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, cream.

**ICHTHAMMOL WITH ZINC OXIDE (Non-proprietary)** Ichthammol 1 mg per 1 mg

- Ichthammol liquid | 50 gram £11.42
- 100 gram £27.87
- 500 gram £50.00
- 1 bandage £3.67

**CALCINEURIN INHIBITORS AND RELATED DRUGS**

**Pimecrolimus**

**INDICATIONS AND DOSE** Short-term treatment of mild to moderate atopic eczema (including flares) when topical corticosteroids cannot be used (initiated by a specialist)

- **TO THE SKIN**
  - Adult: Apply twice daily until symptoms resolve (stop treatment if eczema worsens or no response after 6 weeks)

Short-term treatment of facial, flexural, or genital psoriasis in patients unresponsive to, or intolerant of other topical therapy (initiated by a specialist)

- **TO THE SKIN**
  - Adult: Apply twice daily until symptoms resolve (maximum duration of treatment 4 weeks)

**UNLICENSED USE** Pimecrolimus is not licensed for short-term treatment of facial, flexural, or genital psoriasis in patients unresponsive to, or intolerant of other topical therapy.
Tacrolimus

**INDICATIONS** Application to malignant or potentially malignant skin lesions - application under occlusion - congenital epidermal barrier defects - contact with eyes - contact with mucous membranes - generalised erythroderma - immunodeficiency - infection at treatment site

**CAUTIONS** Alcohol consumption (risk of facial flushing and skin irritation) - avoid other topical treatments except emollients at treatment site - UV light (avoid excessive exposure to sunlight and sunlamps)

**INTERACTIONS** Concomitant use with drugs that cause immunosuppression is contra-indicated (may be prescribed in exceptional circumstances by specialists).

**SIDE-EFFECTS**
- Common or very common Burning sensation - erythema - folliculitis - pruritus - skin infections
- Uncommon Herpes simplex - herpes zoster - impetigo - molluscum contagiosum
- Rare Dryness - local reactions including pain - oedema - papilloma - paraesthesia - peeling - skin discoloration - worsening of eczema
- Frequency not known Skin malignancy

**PREGNANCY** Manufacturer advises avoid; toxicity in animal studies following systemic administration.

**BREAST FEEDING** Manufacturer advises caution; ensure infant does not come in contact with treated areas.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Tacrolimus and pimecrolimus for atopic eczema (August 2004) NICE TA82
  Topical pimecrolimus is an option for atopic eczema not controlled by maximal topical corticosteroid treatment or if there is a risk of important corticosteroid side-effects (particularly skin atrophy). Topical pimecrolimus is recommended for moderate atopic eczema on the face and neck of children aged 2–16 years. Pimecrolimus should be used within its licensed indications. www.nice.org.uk/TA82

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**CAUTIONARY AND ADVISORY LABELS** 4, 11, 28

**EXCIPIENTS:** May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), propylene glycol

- **Elidel** (Meda Pharmaceuticals Ltd)

  **Pimecrolimus 10 mg per 1 gram** Elidel 1% cream | 30 gram £37.41 DT price + £13.69 | 60 gram £69.74 DT price + £37.41 | 100 gram £93.07 DT price + £53.07

**Tarrocin**

**DRUG ACTION** Tacrolimus is a calcineurin inhibitor.

**INDICATIONS AND DOSE**

**Short-term treatment of moderate to severe atopic eczema (including flares) in patients unresponsive to, or intolerant of conventional therapy**

**TO THE SKIN**

- **Adult:** Apply twice daily until lesion clears (consider other treatment if eczema worsens or no improvement after 2 weeks), initially 0.1% ointment to be applied thinly, reduce frequency to once daily or strength of ointment to 0.03% if condition allows

**Prevention of flares in patients with moderate to severe atopic eczema and 4 or more flares a year who have responded to initial treatment with topical tacrolimus**

**TO THE SKIN**

- **Adult:** Apply twice weekly, 0.1% ointment to be applied thinly, with an interval of 2–3 days between applications, use short-term treatment regimen during an acute flare; review need for preventative therapy after 1 year

**Short-term treatment of facial, flexural, or genital psoriasis in patients unresponsive to, or intolerant of other topical therapy**

**TO THE SKIN**

- **Adult:** Apply twice daily until symptoms resolve, 0.1% ointment to be applied thinly, reduce to once daily or switch to 0.03% ointment if condition allows, maximum duration of treatment 4 weeks

**UNLICENSED USE** Short-term treatment of facial, flexural, or genital psoriasis is unlicensed.

**CONTRA-INDICATIONS**

Application to malignant or potentially malignant skin lesions - application under occlusion - avoid contact with eyes - avoid contact with mucous membranes - congenital epidermal barrier defects - generalised erythroderma - immunodeficiency - infection at treatment site

**SIDE-EFFECTS**

- **Common or very common** Acne, CUTANEOUS LYMPHOMA, MALIGNANCIES, OTHER TYPES OF LYPHOMAS, ROSACEA, SKIN MALIGNANCY

**PREGNANCY**

Manufacturer advises avoid unless essential; toxicity in animal studies following systemic administration.

**BREAST FEEDING**

Avoid—present in milk (following systemic administration).

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Tacrolimus and pimecrolimus for atopic eczema (August 2004) NICE TA82

Topical tacrolimus is an option for atopic eczema not controlled by maximal topical corticosteroid treatment or if there is a risk of important corticosteroid side-effects (particularly skin atrophy).

Topical tacrolimus is recommended for moderate to severe atopic eczema in adults and children over 2 years. Tacrolimus should be used within its licensed indications. www.nice.org.uk/TA82

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (March 2010) that tacrolimus ointment (Protopic®) is accepted for restricted use within NHS Scotland for the prevention of flares in patients aged over 2 years with moderate to severe atopic eczema in accordance with the licensed indications; initiation of treatment is restricted to doctors (including general practitioners) with a specialist interest and experience in treating atopic eczema with immunomodulatory therapy.
CORTICOSTEROIDS

Topical corticosteroids

Topical corticosteroids are used for the treatment of inflammatory conditions of the skin (other than those arising from an infection), in particular eczema, contact dermatitis, insect stings, and eczema of scabies. Corticosteroids suppress the inflammatory reaction during use; they are not curative and on discontinuation a rebound exacerbation of the condition may occur. They are generally used to relieve symptoms and suppress signs of the disorder when other measures such as emollients are ineffective.

Topical corticosteroids are not recommended in the routine treatment of urticaria; treatment should only be initiated and supervised by a specialist. They should not be used indiscriminately in pruritus (where they will only be effective when other measures such as emollients are ineffective).

Systemic or very potent topical corticosteroids should be avoided or given only under specialist supervision in psoriasis because, although they may suppress the psoriasis in the short term, relapse or vigorous rebound occurs on withdrawal (sometimes precipitating severe pustular psoriasis). See the role of topical corticosteroids in the treatment of psoriasis.

In general, the most potent topical corticosteroids should be reserved for recalcitrant dermatoses such as chronic discoid lupus erythematosus, lichen simplex chronicus, hypertrophic lichen planus, and palmoplantar pustulosis.

Potent corticosteroids should generally be avoided on the face and skin flexures, but specialists occasionally prescribe them for use on these areas in certain circumstances.

When topical treatment has failed, intraleisional corticosteroid injections may be used. These are more effective than the very potent topical corticosteroid preparations and should be reserved for severe cases where there are localised lesions such as keloid scars, hypertrophic lichen planus, or localised alopecia areata.

Perioral lesions

Hydrocortisone cream 1% p. 993 can be used for up to 7 days to treat uninfected inflammatory lesions on the lips. Hydrocortisone with miconazole p. 1031 cream or ointment is useful where infection by susceptible organisms and inflammation co-exist, particularly for initial treatment (up to 7 days) e.g. in angular cheilitis. Organisms susceptible to miconazole include Candida spp. and many Gram-positive bacteria including streptococci and staphylococci.

Choice of formulation

Water-miscible corticosteroid creams are suitable for moist or weeping lesions whereas ointments are generally chosen for dry, lichenified or scaly lesions or where a more occlusive effect is required. Lotions may be useful when minimal application to a large or hair-bearing area is required or for the treatment of exudative lesions. Occlusive polythene or hydrocolloid dressings increase absorption, but also increase the risk of side effects; they are therefore used only under supervision on a short-term basis for areas of very thick skin (such as the palms and soles). The inclusion of urea or salicylic acid also increases the penetration of the corticosteroid.

In the BNF publications topical corticosteroids for the skin are categorised as ‘mild’, ‘moderately potent’, ‘potent’ or ‘very potent’; the least potent preparation which is effective should be chosen but dilution should be avoided whenever possible.

Absorption through the skin

Mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids. Absorption through the skin can rarely cause adrenal suppression and even Cushing’s syndrome, depending on the area of the body being treated and the duration of treatment. Absorption is greatest where the skin is thin or raw, and from intertriginous areas; it is increased by occlusion.

Suitable quantities of corticosteroid preparations to be prescribed for specific areas of the body

<table>
<thead>
<tr>
<th>Area of body</th>
<th>Creams and Ointments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face and neck</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Both hands</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Scalp</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Both arms</td>
<td>30 to 60 g</td>
</tr>
<tr>
<td>Both legs</td>
<td>100 g</td>
</tr>
<tr>
<td>Trunk</td>
<td>100 g</td>
</tr>
<tr>
<td>Groins and genitalia</td>
<td>15 to 30 g</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for a single daily application for 2 weeks.

Compound preparations

The advantages of including other substances (such as antibacterials or antifungals) with corticosteroids in topical preparations are uncertain, but such combinations may have a place where inflammatory skin conditions are associated with bacterial or fungal infection, such as infected eczema. In these cases the antimicrobial drug should be chosen according to the sensitivity of the infecting organism and used regularly for a short period (typically twice daily for 1 week). Longer use increases the likelihood of resistance and of sensitisation.

The keratolytic effect of salicylic acid p. 1057 facilitates the absorption of topical corticosteroids; however, excessive and prolonged use of topical preparations containing salicylic acid p. 1057 may cause salicylism.

Topical corticosteroid preparation potencies

Potency of a topical corticosteroid preparation is a result of the formulation as well as the corticosteroid. Therefore, proprietary names are shown.

- **Mild**
  - Hydrocortisone 0.1–2.5%
  - Dioderm
  - Mildson
  - Synalar 1 in 10 dilution

- **Mild with antimicrobials**
  - Canesten HC
  - Daktacort
  - Econacort
  - Fucidin H
  - Nystaform-HC
  - Terra-Cortril
  - Timodine

- **Moderate**
  - Miconazole 2.5%
  - Miconazole 3%
  - Miconazole 5%

- **Potent**
  - Miconazole 10%
  - Miconazole 20%
  - Miconazole 30%

- **Very potent**
  - Miconazole 40%

- **Topical corticosteroids**
  - Hydrocortisone 0.1–2.5%
  - Dioderm
  - Mildson
  - Synalar 1 in 10 dilution

- **Mild with antimicrobials**
  - Canesten HC
  - Daktacort
  - Econacort
  - Fucidin H
  - Nystaform-HC
  - Terra-Cortril
  - Timodine

- **Moderate**
  - Miconazole 2.5%
  - Miconazole 3%
  - Miconazole 5%

- **Potent**
  - Miconazole 10%
  - Miconazole 20%
  - Miconazole 30%

- **Very potent**
  - Miconazole 40%

- **Topical corticosteroids**
  - Hydrocortisone 0.1–2.5%
  - Dioderm
  - Mildson
  - Synalar 1 in 10 dilution

- **Mild with antimicrobials**
  - Canesten HC
  - Daktacort
  - Econacort
  - Fucidin H
  - Nystaform-HC
  - Terra-Cortril
  - Timodine

- **Moderate**
  - Miconazole 2.5%
  - Miconazole 3%
  - Miconazole 5%

- **Potent**
  - Miconazole 10%
  - Miconazole 20%
  - Miconazole 30%

- **Very potent**
  - Miconazole 40%

- **Topical corticosteroids**
  - Hydrocortisone 0.1–2.5%
  - Dioderm
  - Mildson
  - Synalar 1 in 10 dilution

- **Mild with antimicrobials**
  - Canesten HC
  - Daktacort
  - Econacort
  - Fucidin H
  - Nystaform-HC
  - Terra-Cortril
  - Timodine

- **Moderate**
  - Miconazole 2.5%
  - Miconazole 3%
  - Miconazole 5%

- **Potent**
  - Miconazole 10%
  - Miconazole 20%
  - Miconazole 30%

- **Very potent**
  - Miconazole 40%

- **Topical corticosteroids**
  - Hydrocortisone 0.1–2.5%
  - Dioderm
  - Mildson
  - Synalar 1 in 10 dilution

- **Mild with antimicrobials**
  - Canesten HC
  - Daktacort
  - Econacort
  - Fucidin H
  - Nystaform-HC
  - Terra-Cortril
  - Timodine

- **Moderate**
  - Miconazole 2.5%
  - Miconazole 3%
  - Miconazole 5%

- **Potent**
  - Miconazole 10%
  - Miconazole 20%
  - Miconazole 30%

- **Very potent**
  - Miconazole 40%

- **Topical corticosteroids**
  - Hydrocortisone 0.1–2.5%
  - Dioderm
  - Mildson
  - Synalar 1 in 10 dilution

- **Mild with antimicrobials**
  - Canesten HC
  - Daktacort
  - Econacort
  - Fucidin H
  - Nystaform-HC
  - Terra-Cortril
  - Timodine

- **Moderate**
  - Miconazole 2.5%
  - Miconazole 3%
  - Miconazole 5%

- **Potent**
  - Miconazole 10%
  - Miconazole 20%
  - Miconazole 30%

- **Very potent**
  - Miconazole 40%
Skin

Corticosteroids (topical)

- **CONTRA-INDICATIONS** Acne · perioral dermatitis · potent corticosteroids in widespread plaque psoriasis · rosacea · untreated bacterial, fungal or viral skin lesions
- **CAUTIONS** Avoid prolonged use (particularly on the face) · cautions applicable to systemic corticosteroids may also apply if absorption occurs following topical and local use · infection - keep away from eyes · use potent or very potent topical corticosteroids under specialist supervision in psoriasis (can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity)

- **SIDE-EFFECTS**
  - **Rare** Adrenal suppression - Cushing’s syndrome
  - **Frequency not known** Acne · contact dermatitis · hypertrichosis · irreversible striae atrophicae · irreversible telangiectasia · mild depigmentation (may be reversible) · perioral dermatitis · side-effects applicable to systemic corticosteroids may also apply if absorption occurs following topical and local use · spread and worsening of untreated infection · thinning of the skin (may be restored over a period after stopping treatment but the original structure may never return) · worsening of acne · worsening of rosacea

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - In order to minimise the side-effects of a topical corticosteroid, it is important to apply it thinly to affected areas only, no more frequently than twice daily, and to use the least potent formulation which is fully effective.

- **DIRECTIONS FOR ADMINISTRATION** Topical corticosteroid preparations should be applied no more frequently than twice daily; once daily is often sufficient. Topical corticosteroids should be spread thinly on the skin but in sufficient quantity to cover the affected areas. The length of cream or ointment expelled from a tube may be used to specify the quantity to be applied to a given area of skin. This length can be measured in terms of a **fingertip unit** (the distance from the tip of the adult index finger to the first crease). One **fingertip unit** (approximately 500 mg from a tube with a standard 5 mm diameter nozzle) is sufficient to cover an area that is twice that of the flat adult handprint (palm and fingers). Mixing topical preparations on the skin should be avoided where possible; several minutes should elapse between application of different preparations.

- **PRESCRIBING AND DISPENSING INFORMATION** The potency of each topical corticosteroid should be included on the label with the directions for use. The label should be attached to the container (for example, the tube) rather than the outer packaging.

- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer corticosteroid creams and ointments. If a patient is using topical corticosteroids of different potencies, the patient should be told when to use each corticosteroid. Patients and their carers should be reassured that side effects such as skin thinning and systemic effects rarely occur when topical corticosteroids are used appropriately.

**Alclometasone dipropionate**

- **INDICATIONS AND DOSE**
  - **Inflammatory skin disorders such as eczemas**
    - **TO THE SKIN**
      - Child: Apply 1–2 times a day, to be applied thinly
      - Adult: Apply 1–2 times a day, to be applied thinly

**Use in children**

Children, especially infants, are particularly susceptible to side-effects. However, concern about the safety of topical corticosteroids in children should not result in the child being undertreated. The aim is to control the condition as well as possible; inadequate treatment will perpetuate the condition. A mild corticosteroid such as hydrocortisone 0.5% or 1% p. 993 is useful for treating nappy rash and hydrocortisone 1% for atopic eczema in childhood. A moderately potent or potent corticosteroid may be appropriate for severe atopic eczema on the limbs, for 1–2 weeks only, switching to a less potent preparation as the condition improves. In an acute flare-up of atopic eczema, it may be appropriate to use more potent formulations of topical corticosteroids for a short period to regain control of the condition. A very potent corticosteroid should be initiated under the supervision of a specialist. Continuous daily application of a mild corticosteroid such as hydrocortisone 1% is equivalent to a potent corticosteroid such as betamethasone 0.1% p. 993 applied intermittently. Carers of young children should be advised that treatment should not necessarily be reserved to ’treat only the worst areas’ and they may need to be advised that patient information leaflets may contain inappropriate advice for the patient’s condition.
Beclometasone dipropionate

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **CAUTIONARY AND ADVISORY LABELS 28**
- **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol, propylene glycol

- **ALCLOMETASONE DIPROPIONATE (Non-proprietary)**
  - Alcrometasone dipropionate 500 microgram per 1 gram
  - Modrasone (Teva UK Ltd)
  - Alcrometasone dipropionate 500 microgram per 1 gram
  - Modrasone 0.05% cream
  - 50 gram (POM) £2.68 DT price = £2.68

---

Betamethasone

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

**TO THE SKIN**
- **Child:** Apply 1–2 times a day, thin layer to be applied
- **Adult:** Apply 1–2 times a day, thin layer to be applied

**Potency**
Beclometasone dipropionate cream and ointment 0.025%: potent.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream, ointment, liquid, cream, ointment, scalp application, and foam (application).

**Cream**

- **CAUTIONARY AND ADVISORY LABELS 28**
- **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polyethylene glycol

- **BETAMETHASONE (Non-proprietary)**
  - Betamethasone (as Betamethasone dipropionate) 500 microgram per 1 gram
  - Diprosone (Dermal Laboratories Ltd)
  - Betamethasone (as Betamethasone dipropionate) 500 microgram per 1 gram
  - Diprosone (Dermal Laboratories Ltd)

- **BETAMETHASONE (Non-proprietary)**
  - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram
  - Betnovate (GlaxoSmithKline Ltd)
  - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram
  - Betnovate (GlaxoSmithKline Ltd)

- **Liquid**

- **CAUTIONARY AND ADVISORY LABELS 15, 28**
- **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens)

- **Betacap**, **Betnovate** and **Betnovate-RD** are not licensed for use in children under 1 year.

**Ointment**

- **CAUTIONARY AND ADVISORY LABELS 28**
- **BETAMETHASONE (Non-proprietary)**
  - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram
  - Betnovate (GlaxoSmithKline Ltd)
  - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram
  - Betnovate (GlaxoSmithKline Ltd)

- **Betnovate** (GlaxoSmithKline Ltd)
  - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram
  - Betnovate 0.1% scalp application
  - 100 ml (POM) £3.19 DT price = £3.19

- **Betnovate** (GlaxoSmithKline Ltd)
  - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram
  - Betnovate 0.1% scalp application
  - 100 ml (POM) £6.49 DT price = £3.19

- **Betnovate** (GlaxoSmithKline Ltd)
  - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram
  - Betnovate 0.1% cream
  - 30 gram (POM) £5.99 DT price = £5.99

---

**BETAMETHASONE (Non-proprietary)**

- **Betamethasone (as Betamethasone valerate) 1 mg per 1 gram**
  - Betnovate RD 0.025% cream
  - 100 gram (POM) £3.15 DT price = £3.15

- **Betamethasone (as Betamethasone valerate) 1 mg per 1 gram**
  - Betnovate RD 0.025% cream
  - 100 gram (POM) £1.43 DT price = £1.43

- **Betamethasone (as Betamethasone valerate) 1 mg per 1 gram**
  - Diprosone (Merck Sharp & Dohme Ltd)
  - Diprosone (Merck Sharp & Dohme Ltd)
  - Diprosone (Merck Sharp & Dohme Ltd)

**BETAMETHASONE (Non-proprietary)**

- **Betamethasone (as Betamethasone valerate) 1 mg per 1 gram**
  - 250 microgram

**BRANDS**

- **Betacap**, **Betnovate** and **Betnovate-RD** are not licensed for use in children under 1 year.

---

**Betamethasone**

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

**TO THE SKIN**
- **Child:** Apply 1–2 times a day, to be applied thinly
- **Adult:** Apply 1–2 times a day, to be applied thinly

**Potency**
Betamethasone valerate 0.025% cream and ointment: moderate.
Betamethasone valerate 0.1% cream, lotion, medicated plasters, ointment, and scalp application: potent.
Betamethasone valerate 0.12% foam: potent.
Betamethasone dipropionate 0.05% cream, lotion, and ointment: potent.

**UNLICENSED USE**
**Betacap**, **Betnovate** and **Betnovate-RD** are not licensed for use in children under 1 year.

---

**BETAMETHASONE (Non-proprietary)**

- **Betamethasone (as Betamethasone valerate) 1 mg per 1 gram**
  - 250 microgram

**BRANDS**

- **Betacap**, **Betnovate** and **Betnovate-RD** are not licensed for use in children under 1 year.
Betamethasone with clioquinol

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 993.

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- Child 1-17 years: (consult product literature)
- Adult: (consult product literature)

**Potency**
Betamethasone (as valerate) 0.1% with clioquinol cream and ointment: potent.

**PATIENT AND CARER ADVICE**
Stains clothing. Patients or carers should be counselled on application of betamethasone with clioquinol preparations.

**MEDICINAL FORMS**
There can be variation in the listing of different medicines containing the same drug.

**Cream**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol
- BETAMETHASONE WITH CLIQUINOIL (Non-proprietary)
  Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Clioquinol 30 mg per 1 gram Betamethasone valerate 0.1% / Clioquinol 3% cream | 30 gram (PO) £18.88 DT price = £18.88

**Ointment**
CAUTIONARY AND ADVISORY LABELS 28
- BETAMETHASONE WITH CLIQUINOIL (Non-proprietary)
  Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Clioquinol 30 mg per 1 gram Betamethasone valerate 0.1% / Clioquinol 3% ointment | 30 gram (PO) £18.88 DT price = £18.88

Betamethasone with clotrimazole

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 993, clotrimazole p. 1010.

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- Child 12-17 years: (consult product literature)
- Adult: (consult product literature)

**Potency**
Betamethasone dipropionate 0.064% (=betamethasone 0.5%) with clotrimazole cream: potent.

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on how to administer betamethasone with clotrimazole cream.

**MEDICINAL FORMS**
There can be variation in the listing of different medicines containing the same drug.

**Cream**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Benzy alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), propylene glycol
- Lotriderm (Teva UK Ltd)
  Betamethasone dipropionate 640 microgram per 1 gram, Clotrimazole 10 mg per 1 gram Lotriderm cream | 30 gram (PO) £6.34 DT price = £6.34

Betamethasone with fusidic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 993, fusidic acid p. 956.

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- Child 6-17 years: (consult product literature)
- Adult: (consult product literature)

**Potency**
Betamethasone (as valerate) 0.1% with fusidic acid cream: potent.

**PATIENT AND CARER ADVICE**
Patients or carers should be counselled on application of betamethasone with fusidic acid preparations.

**MEDICINAL FORMS**
There can be variation in the listing of different medicines containing the same drug.

**Cream**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol, hydroxybenzoates (parabens)
- Fucibet (LEO Pharma)
  Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Fusidic acid 20 mg per 1 gram Fucibet cream | 30 gram (PO) £6.38 DT price = £6.38 | 60 gram (PO) £12.75 DT price = £12.75
  Fucibet Lipid cream | 30 gram (PO) £6.74 DT price = £6.38

Betamethasone with neomycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 993, neomycin sulfate p. 1009.

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- Child 2-17 years: Apply 1–2 times a day, to be applied thinly
- Adult: Apply 1–2 times a day, to be applied thinly

**Potency**
Betamethasone (as valerate) 0.1% with neomycin cream and ointment: potent.

**PATIENT AND CARER ADVICE**
Patient counselling is advised for betamethasone with neomycin cream and ointment (application).

**MEDICINAL FORMS**
There can be variation in the listing of different medicines containing the same drug.

**Cream**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol
- BETAMETHASONE WITH NEOCYMYCIN (Non-proprietary)
  Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Neomycin sulfate 5 mg per 1 gram Betamethasone valerate 0.1% / Neomycin 0.5% cream | 30 gram (PO) £18.88 DT price = £18.88 | 100 gram (PO) £38.00 DT price = £38.00

**Ointment**
CAUTIONARY AND ADVISORY LABELS 28
- BETAMETHASONE WITH NEOCYMYCIN (Non-proprietary)
  Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Neomycin sulfate 5 mg per 1 gram Betamethasone valerate 0.1% / Neomycin 0.5% ointment | 30 gram (PO) £18.88 DT price = £18.88 | 100 gram (PO) £38.00 DT price = £38.00
Betamethasone with salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 993, salicylic acid p. 1027.

INDICATIONS AND DOSE

**DIPROSALIC® OINTMENT**

Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- **Child:** Apply 1–2 times a day. max. 60 g per week
- **Adult:** Apply 1–2 times a day. max. 60 g per week

**Potency**

Betamethasone (as dipropionate) 0.05% with salicylic acid 3%: potent.

**DIPROSALIC® SCALP APPLICATION**

Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- **Child:** Apply 1–2 times a day, apply a few drops
- **Adult:** Apply 1–2 times a day, apply a few drops

**Potency**

Betamethasone (as dipropionate) 0.05% with salicylic acid 2%: potent.

**PATIENT AND CARER ADVICE**

Patients or carers should be counselled on application of betamethasone and salicylic acid preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, cream, shampoo.

**Liquid**

CAUTIONARY AND ADVISORY LABELS 28

EXCEPTIONS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol

- **Clarelux** (Pierre Fabre Dermo-Cosmetique)
  - Clobetasol propionate 500 microgram per 1 gram: Clarelux 500 micrograms/g foam | 100 gram (POM) £11.06

**Ointment**

CAUTIONARY AND ADVISORY LABELS 28

EXCEPTIONS: May contain Beeswax, Cetostearyl alcohol (including cetyl and stearyl alcohol), Chlorocresol, propylene glycol

- **CLOBETASOL PROPIONATE (Non-proprietary)**
  - Clobetasol propionate 500 microgram per 1 gram: Clobetasol 0.05% cream | 30 gram (POM) £3.18 DT price = £3.18 | 100 gram (POM) £10.10 DT price = £10.10

**Cream**

CAUTIONARY AND ADVISORY LABELS 28

EXCEPTIONS: May contain Propylene glycol

- **CLOBETASOL PROPIONATE (Non-proprietary)**
  - Clobetasol propionate 500 microgram per 1 gram: Clobetasol 0.05% ointment | 30 gram (POM) no price available DT price = £2.69 | 100 gram (POM) no price available DT price = £7.90

**Shampoo**

CAUTIONARY AND ADVISORY LABELS 28

EXCEPTIONS: May containPROPYLNE glycol

- **CLOBETASOL PROPIONATE (Non-proprietary)**
  - Clobetasol propionate 500 microgram per 1 gram: Clobetasol 0.05% ointment | 30 gram (POM) £2.69 DT price = £2.69 | 100 gram (POM) £7.90 DT price = £7.90

**Scalp application**

Severe inflammatory skin disorders such as Psoriasis associated with infection

- **ETRIVEX®**
  - Moderate scalp psoriasis

  **TO THE SKIN**

  - **Adult:** Apply once daily maximum duration of treatment 4 weeks, to be applied thinly then rinsed off after 15 minutes; frequency of application should be reduced after clinical improvement

**UNLICENSED USE**

Dermovate® not licensed for use in children under 1 year.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer clobetasol propionate foam, liquid (sculp application), cream, ointment and shampoo.

Scalp application Patients or carers should be advised to apply foam directly to scalp lesions (foam begins to subside immediately on contact with skin).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream, ointment

**Foam**

CAUTIONARY AND ADVISORY LABELS 15, 28

EXCEPTIONS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol

- **Dermovate** (Glaicosmithline UK Ltd)
  - Clobetasol propionate 500 microgram per 1 gram: Dervomate 0.05% scalp application | 30 ml (POM) £3.07 DT price = £3.07 | 100 ml (POM) £10.42 DT price = £10.42

**Clobetasol propionate with neomycin sulfate and nystatin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, clobetasol propionate above, neomycin sulfate p. 1009.

INDICATIONS AND DOSE

Short-term treatment only of severe resistant inflammatory skin disorders such as recalcitrant eczemas associated with infection and unresponsive to less potent corticosteroids | Psoriasis associated with infection

- **Adult:** (consult product literature)
## Clobetasone butyrate with nystatin and oxytetracycline

The properties listed below are those particular to the combination only. For the properties of the components please consider, clobetasone butyrate above, oxytetracycline p. 498.

### INDICATIONS AND DOSE
Steroid-responsive dermatoses where candidal or bacterial infection is present

- **TO THE SKIN**
  - Adult: (consult product literature)

### Potency
Clobetasone butyrate 0.05% with nystatin and oxytetracycline cream: moderate.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

- **Cream**
  - **CAUTIONARY AND ADVISORY LABELS 2B**
  - Clobetasol propionate with neomycin sulfate and nystatin (GlaxoSmithKline Consumer Healthcare, GlaxoSmithKline UK Ltd)
    - **Cream**: very potent.
    - **Ointment**: very potent.

### Diffucortolone valerate

#### INDICATIONS AND DOSE
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids (using 0.3% diffucortolone valerate) | Short-term treatment of severe exacerbations (using 0.3% diffucortolone valerate) | Psoriasis (using 0.3% diffucortolone valerate)

- **TO THE SKIN**
  - Child: Apply 1–2 times a day for up to 2 weeks, reducing strength as condition responds, to be applied thinly; maximum 60 g per week
  - Adult: Apply 1–2 times a day for up to 2 weeks, reducing strength as condition responds, to be applied thinly; maximum 60 g per week

Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids (using 0.3% diffucortolone valerate) | Psoriasis (using 0.1% diflucortolone valerate)

- **TO THE SKIN**
  - Child: Apply 1–2 times a day for up to 4 weeks, to be applied thinly
  - Adult: Apply 1–2 times a day for up to 4 weeks, to be applied thinly

### Potency
Diflucortolone valerate 0.1% cream and ointment: potent.

Diflucortolone valerate 0.3% cream and ointment: very potent.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

- **Cream**
  - **CAUTIONARY AND ADVISORY LABELS 2B**
  - May contain Beeswax, cetylstearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens)
Fludroxycortide (Flurandrenolone)

**INDICATIONS AND DOSE**

Inflammatory skin disorders such as eczemas

**TO THE SKIN**

- **Child:** Apply 1–2 times a day, to be applied thinly
- **Adult:** Apply 1–2 times a day, to be applied thinly

**Potency**

Fludroxycortide 0.0125% cream and ointment: moderate

**HAELEN® TAPE**

Chronic localised recalcitrant dermatoses (but not acute or weeping)

**TO THE SKIN**

- **Child:** Cut tape to fit lesion, apply to clean, dry skin shorn of hair, usually for 12 hours daily
- **Adult:** Cut tape to fit lesion, apply to clean, dry skin shorn of hair, usually for 12 hours daily

**PATIENT AND CARER ADVICE**

Patients or carers should be counselled on application of fludroxycortide cream and ointment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**CAUTIONARY AND ADVISORY LABELS**

- **EXCIPIENTS:** May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol
- **Fluocinolone acetonide 25 microgram per 1 gram** Synalar 1 in 10
  - Dilution 0.0025% cream | 50 gram | £4.58 DT price = £4.58
  - Fluocinolone acetonide 62.5 microgram per 1 gram Synalar 1 in 4
    - Dilution 0.00625% cream | 50 gram | £4.84 DT price = £4.84
    - Fluocinolone acetonide 250 microgram per 1 gram Synalar 1
      - 0.025% cream | 30 gram | £4.14 DT price = £4.14
      - 100 gram | £11.75 DT price = £11.75

**Ointment**

**CAUTIONARY AND ADVISORY LABELS**

- **EXCIPIENTS:** May contain Propylene glycol, wool fat and related substances including lanolin
- **Fluocinolone acetonide 62.5 microgram per 1 gram** Synalar 1 in 4
  - Dilution 0.00625% ointment | 50 gram | £4.84 DT price = £4.84
  - Fluocinolone acetonide 250 microgram per 1 gram Synalar 1
    - 0.025% ointment | 30 gram | £4.14 DT price = £4.14
    - 100 gram | £11.75 DT price = £11.75

**Gel**

**CAUTIONARY AND ADVISORY LABELS**

- **EXCIPIENTS:** May contain Hydroxybenzoates (parabens), propylene glycol
- **Fluocinolone acetonide 250 microgram per 1 gram** Synalar 1
  - 0.025% gel | 30 gram | £5.56 DT price = £5.56
  - 60 gram | £10.02 DT price = £10.02

Fluocinolone acetonide with clioquinol

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluocinolone acetonide above.

**INDICATIONS AND DOSE**

Inflammatory skin disorders such as eczemas associated with infection | Psoriasis associated with infection

**TO THE SKIN**

- **Adult:** Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds

**Potency**

Clioquinol 3% with fluocinolone acetonide 0.025% cream and ointment: potent

**PATIENT AND CARER ADVICE**

Patient counselling is advised for clioquinol with fluocinolone acetonide cream and ointment (application). Ointment stains clothing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**CAUTIONARY AND ADVISORY LABELS**

- **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens), polysorbates, propylene glycol
- **Fluocinolone acetonide 0.025% cream, gel, and ointment:** potent
  - Fluocinolone acetonide 0.00625% cream and ointment: moderate
  - Fluocinolone acetonide 0.0025% cream: mild.

**Fluocinolone acetonide**

**INDICATIONS AND DOSE**

Severe inflammatory skin disorders such as eczemas | Psoriasis

**TO THE SKIN**

- **Child 1–7 years:** Apply 1–2 times a day, to be applied thinly, reduce strength as condition responds
- **Adult:** Apply 1–2 times a day, to be applied thinly, reduce strength as condition responds

**Potency**

Fluocinolone acetonide 0.025% cream, gel, and ointment: potent

**PATIENT AND CARER ADVICE**

Patient counselling is advised for fluocinolone acetonide cream, gel and ointment (application). Ointment stains clothing.
Fluocinolone acetonide with neomycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluocinolone acetonide p. 1027, neomycin sulfate p. 1009.

### INDICATIONS AND DOSE

Inflammatory skin disorders such as eczemas associated with infection | Psoriasis associated with infection

**TO THE SKIN**
- Child 1-17 years: Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds
- Adult: Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds

**Potency**
Fluocinolone acetonide 0.025% with neomycin 0.5% cream and ointment: potent.

#### PATIENT AND CARER ADVICE
Patients or carers should be counselled on the application of fluocinolone acetonide with neomycin preparations.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Cream**
- **INDICATIONS AND ADVISORY LABELS** 28
- EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), polysorbates, propylene glycol
- Synalar C (Derma UK Ltd)
  - Fluocinolone acetonide 250 microgram per 1 gram
  - Neomycin sulfate 5 mg per 1 gram

**Ointment**
- **INDICATIONS AND ADVISORY LABELS** 28
- EXCIPIENTS: May contain Propylene glycol, wool fat and related substances including lanolin
- Synalar C (Derma UK Ltd)
  - Fluocinolone acetonide 250 microgram per 1 gram
  - Neomycin sulfate 5 mg per 1 gram

**Fluticasone**

#### INDICATIONS AND DOSE

Severe inflammatory skin disorders such as dermatitis and eczemas unresponsive to less potent corticosteroids | Psoriasis

**TO THE SKIN**
- Adult: Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds

**Potency**
Fluticasone pivalate 2.5 mg per 1 gram

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on application of fluticasone creams and ointments.
Hydrocortisone

INDICATIONS AND DOSE
Mild inflammatory skin disorders such as eczema

TO THE SKIN
Child: Apply 1–2 times a day, to be applied thinly
Adult: Apply 1–2 times a day, to be applied thinly

Nappy rash

TO THE SKIN
Child
Apply as required for no more than 1 week, discontinued as soon as the inflammation subsides

Potency
Hydrocortisone cream and ointment 0.5 to 2.5%: mild

PRESCRIBING AND DISPENSING INFORMATION
When hydrocortisone cream or ointment is prescribed and no strength is stated, the 1% strength should be supplied.

DIODERM®
Although Dioderm® contains only 0.1% hydrocortisone, the formulation is designed to provide a clinical activity comparable to that of Hydrocortisone Cream 1% BP.

PATIENT AND CARER ADVICE
Medicines for children leaflet: Hydrocortisone (topical) for eczema
www.medicinesforchildren.org.uk/hydrocortisone-topical-for-eczema

Patient counselling is advised for hydrocortisone cream and ointment (application).

PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulary Hydrocortisone Cream 1% 15g may be prescribed.

EXCEPTIONS TO LEGAL CATEGORY
• Over-the-counter hydrocortisone preparations Skin creams and ointments containing hydrocortisone (alone or with other ingredients) can be sold to the public for the treatment of allergic contact dermatitis, irritant dermatitis, insect bite reactions and mild to moderate eczema in patients over 10 years, to be applied sparingly over the affected area 1–2 times daily for max. 1 week. Over-the-counter hydrocortisone preparations should not be sold without medical advice for children under 10 years or for pregnant women; they should not be sold for application to the face, anogenital region, broken or infected skin (including cold sores, acne, and athlete’s foot).

MEDICINAL FORMS
Cream

CAUTIONARY AND ADVISORY LABELS 28
EXCipients: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), imidurea, propylene glycol

Cutivate (GlauxsmithKline UK Ltd)
Fluticasone propionate 500 microgram per 1 gram Cutivate 0.05% cream | 15 gram (PSt) £2.27 DT price = £2.27 | 30 gram (PSt) £4.24 DT price = £4.24

Ointment

CAUTIONARY AND ADVISORY LABELS 28
EXCipients: May contain Propylene glycol

Cutivate (GlauxsmithKline UK Ltd)
Fluticasone propionate 50 microgram per 1 gram Cutivate 0.005% ointment | 15 gram (PSt) £2.27 DT price = £2.27 | 30 gram (PSt) £4.24 DT price = £4.24

Hydrocortisone butyrate

INDICATIONS AND DOSE
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids

TO THE SKIN
Child 1–17 years: Apply 1–2 times a day, to be applied thinly
Adult: Apply 1–2 times a day, to be applied thinly

Potency
Hydrocortisone butyrate 0.1% cream, liquid, and ointment: potent

PATIENT AND CARER ADVICE
Medicines for children leaflet: Hydrocortisone (topical) for eczema
www.medicinesforchildren.org.uk/hydrocortisone-topical-for-eczema

Patients or carers should be given advice on how to administer hydrocortisone butyrate lotion, cream, ointment and scalp lotion.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Liquid

CAUTIONARY AND ADVISORY LABELS 15, 28
EXCipients: May contain Butylated hydroxytoluene, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), propylene glycol

Locoid® (Astellas Pharma Ltd)
Hydrocortisone butyrate 1 mg per 1 ml Locoid 0.1% scalp lotion | 100 ml (PSt) £6.83 DT price = £6.83
Locoid Crelo (Astellas Pharma Ltd)
Hydrocortisone butyrate 1 mg per 1 gram Locoid Crelo 0.1% topical emulsion | 100 gram (PSt) £5.91

Cream

CAUTIONARY AND ADVISORY LABELS 28
EXCipients: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens)

Locoid® (Astellas Pharma Ltd)
Hydrocortisone butyrate 1 mg per 1 gram Locoid 0.1% cream | 30 gram (PSt) £1.60 DT price = £1.60 | 100 gram (PSt) £4.93 DT price = £4.93

Hydrocortisone (Non-proprietary)

Hydrocortisone 5 mg per 1 gram
Hydrocortisone 0.5% cream | 15 gram (PSt) £4.80 DT price = £1.42 | 30 gram (PSt) £8.40 DT price = £2.84–£4.90

Hydrocortisone 10 mg per 1 gram
Hydrocortisone 1% cream | 15 gram (PSt) £11.41 DT price = £1.15 | 15 gram (PSt) £11.41 DT price = £1.15 | 30 gram (PSt) £23.80 DT price = £2.30 | 50 gram (PSt) £27.75 DT price = £3.83

Hydrocortisone 25 mg per 1 gram
Hydrocortisone 2.5% cream | 15 gram (PSt) £41.30 DT price = £7.05 | 30 gram (PSt) £44.00

Dioderm (Dermal laboratories Ltd)
Hydrocortisone 1 mg per 1 gram
Dioderm 0.1% cream | 30 gram (PSt) £2.03 DT price = £2.03

Mildison Lipocream (Castellas Pharma Ltd)
Hydrocortisone 10 mg per 1 gram
Mildison Lipocream 1% cream | 30 gram (PSt) £1.71 DT price = £2.30

Brands may include Derma Care Hydrocortisone, Dermacort, Hc45, Zenoxone

Ointment

CAUTIONARY AND ADVISORY LABELS 28

Hydrocortisone 5 mg per 1 gram
Hydrocortisone 0.5% ointment | 15 gram (PSt) £4.95 DT price = £4.80 | 30 gram (PSt) £9.60–£12.00

Hydrocortisone 10 mg per 1 gram
Hydrocortisone 1% ointment | 15 gram (PSt) £11.41 DT price = £1.26 | 30 gram (PSt) £13.31 DT price = £2.52 | 30 gram (PSt) £13.31 DT price = £2.52 | 50 gram (PSt) £22.75 DT price = £3.20

Hydrocortisone 25 mg per 1 gram
Hydrocortisone 2.5% ointment | 15 gram (PSt) £25.37 DT price = £4.24 | 30 gram (PSt) £48.72

Brands may include Lanacort
Hydrocortisone with benzalkonium chloride, dimeticone and nystatin

The properties listed below are those particular to the combination only. For the properties of the components please consider, dimeticone p. 1014, hydrocortisone p. 993.

**INDICATIONS AND DOSE**

Mild inflammatory skin disorders such as eczemas TO THE SKIN

- **Child:** Apply 1–2 times a day, to be applied thinly
- **Adult:** Apply 1–2 times a day, to be applied thinly

**Potency**

Benzalkonium with dimeticone, hydrocortisone acetate 1%, and nystatin cream: mild.

**PATIENT AND CARER ADVICE**

Patients or carers should be advised on application of benzalkonium with dimeticone and hydrocortisone and nystatin preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

| CAUTIONARY AND ADVISORY LABELS 28 |
| EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polyisobutanes, sorbic acid, sodium metabisulfite, sorbic acid |

- **Locoid (Astellas Pharma Ltd)**
  Hydrocortisone butyrate 1 mg per 1 gram Locoid 0.1%
  Lipocream | 30 gram | £1.69 DT price = £1.60 | 100 gram | £5.17 DT price = £4.93

- **Ointment**
  CAUTIONARY AND ADVISORY LABELS 28

- **Locoid (Astellas Pharma Ltd)**
  Hydrocortisone butyrate 1 mg per 1 gram Locoid 0.1%
  Ointment | 30 gram | £1.60 DT price = £1.60 | 100 gram | £4.93 DT price = £4.93

Hydrocortisone with chlorhexidine hydrochloride and nystatin

The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine p. 993.

**INDICATIONS AND DOSE**

Mild inflammatory skin disorders such as eczemas TO THE SKIN

- **Child:** To be applied thinly (consult product literature)
- **Adult:** To be applied thinly (consult product literature)

**Potency**

Chlorhexidine hydrochloride 1% with hydrocortisone 0.5% and nystatin cream: mild

Chlorhexidine hydrochloride 1% with hydrocortisone 1% and nystatin ointment: mild

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on application of chlorhexidine hydrochloride with hydrocortisone and nystatin preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

| CAUTIONARY AND ADVISORY LABELS 28 |
| EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polyisobutanes, sorbic acid, sodium metabisulfite, sorbic acid |

- **Canesten HC cream (Bayer Plc)**
  Clotrimazole 10 mg per 1 gram, Hydrocortisone 5 mg per 1 gram, Nystatin 100000 unit per 1 gram Nystaform HC cream | 30 gram | £2.66

- **Nystaform HC (Typharm Ltd)**
  Chlorhexidine acetate 10 mg per 1 gram, Hydrocortisone 10 mg per 1 gram, Nystatin 100000 unit per 1 gram Nystaform HC ointment | 30 gram | £2.66

Hydrocortisone with clortrimazole

The properties listed below are those particular to the combination only. For the properties of the components please consider, clortrimazole p. 1010, hydrocortisone p. 993.

**INDICATIONS AND DOSE**

Mild inflammatory skin disorders such as eczemas (associated with fungal infection) TO THE SKIN

- **Child:** (consult product literature)
- **Adult:** (consult product literature)

**Potency**

Clotrimazole with hydrocortisone 1% cream: mild

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer clortrimazole with hydrocortisone cream.

**EXCEPTIONS TO LEGAL CATEGORY**

A 15-g tube is on sale to the public for the treatment of athlete’s foot and fungal infection of skin folds with associated inflammation in patients 10 years and over.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

| CAUTIONARY AND ADVISORY LABELS 28 |
| EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol) |

- **Canesten HC (Bayer Plc)**
  Clotrimazole 10 mg per 1 gram, Hydrocortisone 10 mg per 1 gram Canesten HC cream | 30 gram | £2.42 DT price = £2.42

- **Brands may include Canesten Hydrocortisone cream**

Hydrocortisone with fusidic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, fusidic acid p. 956, hydrocortisone p. 993.

**INDICATIONS AND DOSE**

Mild inflammatory skin disorders such as eczemas TO THE SKIN

- **Child:** To be applied thinly (consult product literature)
- **Adult:** To be applied thinly (consult product literature)

**Potency**

Hydrocortisone with fusidic acid cream: mild

**PATIENT AND CARER ADVICE**

Patients or carers should be advised on application of hydrocortisone with fusidic acid preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Hydrocortisone with miconazole

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 993, miconazole p. 1011.

### INDICATIONS AND DOSE

Mild inflammatory skin disorders such as eczemas associated with infections

**TO THE SKIN**
- **Adult:** (consult product literature)

**Potency**
- Hydrocortisone 1% with miconazole cream and ointment: mild

### INTERACTIONS
- Appendix 1 (antifungals, imidazole).

### PATIENT AND CARER ADVICE
- Patients or carers should be advised on application of hydrocortisone with miconazole preparations.

### PROFESSION SPECIFIC INFORMATION
- Dental practitioners’ formulary
  - May be prescribed as Miconazole and Hydrocortisone Cream or Ointment for max. 7 days.

### EXCEPTIONS TO LEGAL CATEGORY
- A 15-g tube of hydrocortisone with miconazole cream is on sale to the public for the treatment of athlete’s foot and candidal intertrigo.

### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.

#### Cream
- CAUTIONARY AND ADVISORY LABELS 28
- EXCIPIENTS: May contain Butylated hydroxyanisole, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, potassium sorbate
  - Fusidin H (Fusidic acid / Hydrocortisone) (LEO Pharma)
  - Fusidic acid 20 mg per 1 gram, Hydrocortisone acetate 10 mg per 1 gram Fusidin H cream | 30 gram £5.02 DT price = £5.02 | 60 gram £10.04 DT price = £10.04

#### Ointment
- CAUTIONARY AND ADVISORY LABELS 28
- **Fucidin H** (Fusidic acid / Hydrocortisone) (LEO Pharma)
  - Fusidic acid 20 mg per 1 gram, Hydrocortisone acetate 10 mg per 1 gram Fucidin H cream | 30 gram £5.02 DT price = £5.02 | 60 gram £10.04 DT price = £10.04

Hydrocortisone with oxytetracycline

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 993, oxytetracycline p. 1093.

### INDICATIONS AND DOSE

Mild inflammatory skin disorders such as eczemas

**TO THE SKIN**
- **Child 0-2 years:** To be applied thinly (consult product literature)
- **Child 2-17 years:** Apply once daily, to be applied thinly (to scalp in case of lotion)
- **Adult:** Apply once daily, to be applied thinly (to scalp in case of lotion)

**Potency**
- Hydrocortisone 1% with oxytetracycline ointment: mild.

### CONTRA-INDICATIONS
- Children under 12 years

### PREGNANCY
- Tetracyclines should not be given to pregnant women. Effects on skeletal development have been documented when tetracyclines have been used in the first trimester in animal studies. Administration during the second or third trimester may cause discolouration of the child’s teeth.

### MEDICATION FORMS
- There can be variation in the licensing of different medicines containing the same drug.

#### Cream
- CAUTIONARY AND ADVISORY LABELS 28
- **Daktacort** (McNeil Products Ltd, Janssen-Cilag Ltd)
  - Hydrocortisone 10 mg per 1 gram, Miconazole nitrate 20 mg per 1 gram Daktacort Hydrocortisone cream 1 gram £2.49 DT price = £2.49
  - Hydrocortisone 10 mg per 1 gram, Miconazole nitrate 20 mg per 1 gram Daktacort cream | 30 gram £7.03 DT price = £7.03

#### Ointment
- CAUTIONARY AND ADVISORY LABELS 28
- **Daktacort** (McNeil Products Ltd, Janssen-Cilag Ltd)
  - Hydrocortisone 10 mg per 1 gram, Miconazole nitrate 20 mg per 1 gram Daktacort ointment | 30 gram £2.50 DT price = £2.50

Mometasone furoate

### INDICATIONS AND DOSE

Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids

**TO THE SKIN**
- **Child 2-17 years:** Apply once daily, to be applied thinly (to scalp in case of lotion)
- **Adult:** Apply once daily, to be applied thinly (to scalp in case of lotion)

**Potency**
- Mometasone furoate 0.1% cream, ointment, and scalp lotion: potent.

### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment.
## Triamcinolone with chlortetracycline

### INDICATIONS AND DOSE

Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids (associated with infection) | Psoriasis (associated with infection)
---|---
**TO THE SKIN**
- Child 8-17 years: To be applied thinly (consult product literature)
- Adult: To be applied thinly (consult product literature)

### Potency

Triamcinolone acetonide 0.1%, chlortetracycline hydrochloride 3% ointment: potent.

### PATIENT AND CARER ADVICE

Stains clothing. Patients or carers should be counselled on the application of chlortetracycline with triamcinolone products.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

### Ointment

**CAUTIONARY AND ADVISORY LABELS 28**

**EXCIPIENTS:** May contain Wool fat and related substances including lanolin.

- **Aureocort (AMCo)**
  - Chlortetracycline hydrochloride 30.9 mg per 1 gram,
  - Triamcinolone acetonide 1 mg per 1 gram
  - Aureocort ointment | 15 gram [P] £3.51

### RETINOID AND RELATED DRUGS

**Acitretin**

**DRUG ACTION** Acitretin is a metabolite of etretinate.

### INDICATIONS AND DOSE

**Severe extensive psoriasis resistant to other forms of therapy** | **Palmoplantar pustular psoriasis** | **Severe congenital ichthyosis (under expert supervision)**
---|---|---
**BY MOUTH**
- Adult: Initially 25–30 mg daily for 2–4 weeks, then adjusted according to response to 25–50 mg daily, increased to up to 75 mg daily, dose only increased to 75 mg daily for short periods in psoriasis

### Severe Darier’s disease (keratosis follicularis) (under expert supervision)

**BY MOUTH**

- Adult: Initially 10 mg daily for 2–4 weeks, then adjusted according to response to 25–50 mg daily

### CONTRA-INDICATIONS

- Hyperlipidaemia

### CAUTIONS

- Avoid excessive exposure to sunlight and unsupervised use of sunlamps—diabetes (can alter glucose tolerance—initial frequent blood glucose checks) | do not donate blood during and for 2 years after stopping therapy (teratogenic risk) | in children use only in exceptional circumstances and monitor growth parameters and bone development (premature epiphyseal closure reported) | investigate atypical musculoskeletal symptoms

### INTERACTIONS

- → Appendix 1 (retinoids).

Avoid concomitant use of keratolytics.

### SIDE-EFFECTS

- **Common or very common** Abdominal pain | abnormal hair texture | alopecia (reversible on withdrawal) | arthralgia | brittle nails | dermatitis | diarrhoea | dryness and inflammation of mucous membranes | dryness of conjunctiva | epidermal fragility | erythema | headache | myalgia | nausea | paronychia | peripheral oedema | pruritus | reversible increase in serum-cholesterol (with high doses) | reversible increase in serum-triglyceride concentrations (with high doses) | skin exfoliation | sticky skin | vomiting

- **Uncommon** Dizziness | headaches | photosensitivity | visual disturbances

- **Rare** Peripheral neuropathy

- **Very rare** Benign intracranial hypertension | bone pain | exostosis | night blindness | ulcerative keratitis

- **Frequency not known** Drowsiness | dry skin | flushing | granulomatous lesions | impaired hearing | initial worsening of psoriasis | malaise | rectal haemorrhage | sweating | taste disturbance | tinnitus

### SIDE-EFFECTS, FURTHER INFORMATION

**Exostosis** Skeletal hyperostosis and extra-osseous calcification reported following long-term treatment with etretinate (of which Acitretin is a metabolite) and premature epiphyseal closure in children.

**Benign intracranial hypertension** Discontinue if severe headache, nausea, vomiting, or visual disturbances occur.

### CONCEPTION AND CONTRACEPTION

Effective contraception must be used.

**Pregnancy prevention** In females of child-bearing potential (including those with a history of infertility), exclude pregnancy up to 3 days before treatment, every month during treatment, and every 1–3 months for 3 years after stopping treatment. Treatment should be started on day 2 or 3 of menstrual cycle. Females of child-bearing age must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 3 years after stopping treatment. Females should be advised to use at least 1 method of contraception, but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods. Females should be advised to seek medical attention immediately if they become pregnant during treatment or within 3 years of stopping treatment. They should also be advised to avoid alcohol during treatment and for 2 months after stopping treatment.

- **PREGNANCY** Avoid—teratogenic.

- **BREAST FEEDING** Avoid.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment—risk of further impairment.
Alitretinoin

**INDICATIONS AND DOSE**

Severe chronic hand eczema refractory to potent topical corticosteroids

**BY MOUTH**

- Adult (prescribed by or under supervision of a consultant dermatologist): 30 mg once daily; reduced if not tolerated to 10 mg once daily for 12–24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse

Severe chronic hand eczema refractory to potent topical corticosteroids in patients with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease

**BY MOUTH**

- Adult (prescribed by or under supervision of a consultant dermatologist): Initially 10 mg once daily, increased if necessary up to 30 mg once daily for 12–24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse

**CONTRA-INDICATIONS**

- Hypervitaminosis A
- Uncontrolled hyperlipidaemia
- Uncontrolled hypothyroidism

**CAUTIONS**

- Avoid blood donation during treatment and for at least 1 month after stopping treatment • dry eye syndrome • history of depression

**INTERACTIONS**

- Appendix 1 (retinoids).

**SIDE-EFFECTS**

- Common or very common: Alopecia • anaemia • arthralgia • changes in thyroid function tests • cheilitis • conjunctivitis • dry eyes • dryness of lips • dryness of skin • erythema • eye irritation • flushing • headache • myalgia • raised creatinine kidney • raised serum concentration of triglycerides and of cholesterol (risk of pancreatitis if triglycerides above 9 mmol/litre)

- Uncommon: Ankylosing spondylitis • asthetotic eczema • blurred vision • cataracts • epistaxis • hyperostrosis • pruritus

- Rare: Benign intracranial hypertension • vasculitis

- Frequency not known: Decreased tolerance to contact lenses • depression • impaired night vision • keratitis • mood changes • suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

**Dry eyes**

- Dry eyes may respond to lubricating eye ointment or tear replacement therapy.

**Benign intracranial hypertension**

- Discontinue treatment if severe headache, nausea, vomiting, papilloedema, or visual disturbances occur.

**CONCEPTION AND CONTRACEPTION**

- Effective contraception must be used.

- Pregnancy prevention

- In women of child-bearing potential, exclude pregnancy 1 month before treatment, up to 3 days before treatment, every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment—perform pregnancy test in the first 3 days of the menstrual cycle. Women must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods. Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.

**PREGNANCY**

- Avoid—teratogenic.

**BREAST FEEDING**

- Manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

- Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT**

- Manufacturer advises avoid in severe impairment—no information available.

**MONITORING REQUIREMENTS**

- Monitor serum lipids (more frequently in those with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease)—discontinue if uncontrolled hyperlipidaemia.

**PRESCRIBING AND DISPENSING INFORMATION**

- Prescribing for women of child-bearing potential. Each prescription for alitretinoin should be limited to a supply of up to 30 days’ treatment and dispensed within 7 days of the date stated on the prescription.

- Alitretinoin is teratogenic and must not be given to women of child-bearing potential unless they practise effective contraception and then only after detailed assessment and explanation by the physician.

- Women of child-bearing potential must be counselled on pregnancy prevention.

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**

  - Alitretinoin for the treatment of severe chronic hand eczema in adults (August 2009) NICE TA177

- Alitretinoin is recommended for the treatment of severe chronic hand eczema that has not responded to potent topical corticosteroids. Treatment should be stopped as soon as an adequate response has been achieved (hands clear or almost clear), or if the eczema remains severe after 12 weeks, or if an adequate response has not been achieved by 24 weeks. www.nice.org.uk/TA177

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.
### 1034 Inflammatory skin conditions

**Capsule**

*CAUTIONARY AND ADVISORY LABELS 10, 11, 21*

- **Tocino** (Stiefel Laboratories (UK) Ltd)
  - Alitretinoin 10 mg: Tocino 10mg capsules | 30 capsule **£411.43**
  - Alitretinoin 30 mg: Tocino 30mg capsules | 30 capsule **£411.43**

**Salicylic acid with zinc oxide**

- **INDICATIONS AND DOSE**
  - **Hyperkeratotic skin disorders**
  - **Adult:** Apply twice daily

  **CAUTIONS** Avoid broken skin - avoid inflamed skin

**SIDE-EFFECTS** Excessive drying - irritation - sensitivity - systemic effects (after widespread use)

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Zinc and Salicylic Acid Paste BP is also referred to as Lassar’s Paste.
  - When prepared extemporaneously, the BP states Zinc and Salicylic Acid Paste BP is also referred to as Lassar’s Paste, zinc oxide 24%, salicylic acid 2%, starch 24%, white soft paraffin 50%.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, paste.

**Tars**

**Coal tar**

- **INDICATIONS AND DOSE**
  - **Psoriasis** | **Chronic atopic eczema**
  - **Adult:** Apply once daily usually for up to 12 weeks, apply in the evening

- **CONTRA-INDICATIONS** Avoid broken or inflamed skin. Can be diluted with a few drops of water before applying

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, paste.

**Exorex**

- **Aliphosyl 1 in 1**
  - **Shampoo**
  - **Psoriasis** | **Seborrhoeic dermatitis** | **Scaling** | **Itching**
  - **Adult:** Apply every 2–3 days

- **Dandruff**
  - **Adult:** Apply 1–2 times a week as required

**Exorex**

- **Lotion**
  - **Psoriasis**
  - **Adult:** Apply 2–3 times a day, to be applied to skin or scalp. Can be diluted with a few drops of water before applying

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, paste, cream, ointment.

**Bath additive**

- **Coal Tar** (Non-proprietary)
  - **Coal tar distilled 400 mg per 1 ml** Psoriderm Emulsion 40% bath additive | 200 mL **£2.74**

**Shampoo**

- **Exciipients:** May contain Fragrances, hydroxybenzoates (parabens)
- **Coal Tar** (Non-proprietary)
  - **Coal tar extract 20 mg per 1 gram** Coal tar extract 2% shampoo | 125 mL **GSK no price available** | 250 mL **GSK no price available**
  - **Brands may include Aliphosyl 2 in 1, Neutrogena T/Gel Therapeutic**
Coal tar with cade oil, arachis oil extract of coal tar, light liquid paraffin and tar

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1034.

**INDICATIONS AND DOSE**

Psoriasis | Eczema | Atopic dermatoses | Pruritic dermatoses

**TO THE SKIN**

- **Child:** 2–4 capfuls/bath, alternatively 15–30 mL, to be added in an adult-size bath and soak for 20 minutes (proportionally less for a child’s bath)
- **Adult:** 2–4 capfuls/bath, alternatively 15–30 mL, to be added in an adult-size bath and soak for 20 minutes (proportionally less for a child’s bath)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Bath additive**

**EXCIPIENTS:** May contain Isopropyl palmitate

- **Polytar** (GlaxoSmithKline Consumer Healthcare)

Arachis oil extract of crude coal tar 75 mg per 1 gram, Cade oil 75 mg per 1 gram, Coal tar solution 25 mg per 1 gram, Liquid paraffin light 350 mg per 1 gram, Pine tar 75 mg per 1 gram

Polytar Emollient | 500 ml (GSK) £5.78

---

Coal tar with calamine

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1034.

**INDICATIONS AND DOSE**

Psoriasis | Chronic atopic eczema (occasionally)

**TO THE SKIN**

- **Adult:** Apply 1–2 times a day

**PRESCRIBING AND DISPENSING INFORMATION**

When prepared extemporaneously, the BP states Calamine and Coal Tar Ointment, BP consists of calamine 12.5 g, strong coal tar solution 2.5 g, zinc oxide 12.5 g, hydrous wool fat 25 g, white soft paraffin 47.5 g.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment

Coal tar with coconut oil and salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, salicylic acid p. 1057, coal tar p. 1034.

**INDICATIONS AND DOSE**

Scaly scalp disorders | Psoriasis | Seborrhoeic dermatitis | Dandruff | Cradle cap

**TO THE SKIN USING SHAMPOO**

- **Child:** Apply daily as required
- **Adult:** Apply daily as required

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Shampoo**

- **Capasal** (Dermal Laboratories Ltd)

  Coal tar distilled 60 mg per 1 gram, Lecithin 4 mg per 1 gram

  Psoriderm shampoo | 250 ml [£] £4.69

---

Coal tar with dithranol and salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, dithranol p. 1018, salicylic acid p. 1057, coal tar p. 1034.

**INDICATIONS AND DOSE**

Subacute and chronic psoriasis

**TO THE SKIN**

- **Child:** Apply up to twice daily
- **Adult:** Apply up to twice daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment

Coal tar with lecithin

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1034.

**INDICATIONS AND DOSE**

**PSORIDERM** CREAM

Psoriasis

**TO THE SKIN**

- **Child:** Apply 1–2 times a day, cream to be applied to the skin or scalp
- **Adult:** Apply 1–2 times a day, cream to be applied to the skin or scalp

**PSORIDERM** SCALP LOTION

Scalp psoriasis

**TO THE SKIN**

- **Child:** Apply as required
- **Adult:** Apply as required

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**EXCIPIENTS:** May contain Isopropyl palmitate, propylene glycol

- **COAL TAR WITH LECITHIN (Non-proprietary)**

  Coal tar distilled 60 mg per 1 gram, Lecithin 4 mg per 1 gram

  Psoriderm cream | 225 ml [£] £3.42

**Shampoo**

**EXCIPIENTS:** May contain Disodium edetate

- **COAL TAR WITH LECITHIN (Non-proprietary)**

  Coal tar distilled 25 mg per 1 mL, Lecithin 3 mg per 1 mL

  Psoriderm scalp lotion | 250 mL [£] £4.74

---

Coal tar with salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, salicylic acid p. 1057, coal tar p. 1034.

**INDICATIONS AND DOSE**

Psoriasis | Chronic atopic eczema

**TO THE SKIN USING OINTMENT**

- **Child:** Apply 1–2 times a day

---
**Coal tar with salicylic acid and precipitated sulfur**

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1034.

**INDICATIONS AND DOSE**

**COCOIS® OINTMENT**
Scaly scalp disorders including psoriasis, eczema, seborrhoeic dermatitis and dandruff

**INITIALLY TO THE SKIN USING SCALP OINTMENT**
- Child 5-11 years: Medical supervision required
- Child 12-17 years: Apply once weekly as required, alternatively (to the skin) apply daily for the first 3–7 days (if severe), shampoo off after 1 hour
- Adult: Apply once weekly as required, alternatively (to the skin) apply daily for the first 3–7 days (if severe), shampoo off after 1 hour

**SEBCO® OINTMENT**
Scaly scalp disorders including psoriasis, eczema, seborrhoeic dermatitis and dandruff

**INITIALLY TO THE SKIN USING SCALP OINTMENT**
- Child 6–11 years: Medical supervision required
- Adult: Apply as required, alternatively (to the skin) apply daily for the first 3–7 days (if severe), shampoo off after 1 hour

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, cream.

**Extract of coal tar with arachis oil**

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1034.

**INDICATIONS AND DOSE**

**Scalp disorders | Psoriasis | Seborrhoea | Eczema | Pruritus | Dandruff**

**TO THE SKIN**
- Child: Apply 1–2 times a week, to the scalp
- Adult: Apply 1–2 times a week, to the scalp

**VITAMIN D AND ANALOGUES**

**Calcipotriol**

**INDICATIONS AND DOSE**

**Plaque psoriasis**

**TO THE SKIN USING OINTMENT**
- Adult: Apply 1–2 times a day, when preparations are used together maximum total calcipotriol 5 mg in any one week (e.g. scalp solution 60 mL with ointment 30 g or scalp solution 30 mL with ointment 60 g); maximum 100 g per week

**Scalp psoriasis**

**TO THE SKIN USING SCALP LOTION**
- Adult: Apply twice daily, when preparations are used together maximum total calcipotriol 5 mg in any one week (e.g. scalp solution 60 mL with ointment 30 g or scalp solution 30 mL with ointment 60 g); maximum 60 mL per week

**CONTRA-INDICATIONS**
Calcium metabolism disorders

**CAUTIONS**
Avoid excessive exposure to sunlight and sunlamps; avoid use on face; erythrodermic exfoliative psoriasis (enhanced risk of hypercalcaemia) - generalised pustular psoriasis (enhanced risk of hypercalcaemia)

**SIDE-EFFECTS**
- Common or very common Burning, dermatitis, erythema, itching, local skin reactions, paraesthesia
- Rare Facial dermatitis, perioral dermatitis
- Frequency not known Aggravation of psoriasis, dry skin, photosensitivity

**PREGNANCY**
Manufacturers advise avoid unless essential.

**BREAST FEEDING**
No information available.
Calcipotriol with betamethasone

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1036, calcipotriol p. 993, calcipotriol ointment 50 microgram per g ointment; maximum 5 mg in any one week.

INDICATIONS AND DOSE

DOVOBET® GEL

Scalp psoriasis

TO THE SKIN

Adult: Apply 1–4 g once daily usual duration of therapy 4 weeks; if necessary, treatment may be continued beyond 4 weeks or repeated, on the advice of a specialist, shampoo off leaving on scalp overnight or during day, when different preparations containing calcipotriol used together, maximum total calcipotriol 5 mg in any one week.

Mild to moderate plaque psoriasis

TO THE SKIN

Adult: Apply once daily for 8 weeks; if necessary, treatment may be continued beyond 8 weeks or repeated, on the advice of a specialist, apply to maximum 30% of body surface, when different preparations containing calcipotriol used together, max. total calcipotriol 5 mg in any one week; maximum 15 g per day.

DOVOBET® OINTMENT

Stable plaque psoriasis

TO THE SKIN

Adult: Apply once daily for 4 weeks; if necessary, treatment may be continued beyond 4 weeks or repeated, on the advice of a specialist, apply to a maximum 30% of body surface, when different preparations containing calcipotriol used together, max. total calcipotriol 5 mg in any one week; maximum 15 g per day.

CONTRA-INDICATIONS


SIDE-EFFECTS

· Common or very common Burning, dermatitis, erythema, itching, local skin reactions, paraesthesia.
· Frequency not known Aggravation of psoriasis.

DOVOBET® GEL

Calcipotriol 50 microgram per 1 g ointment | 30 gram £6.93 DT price = £6.93
Calcipotriol 50 microgram per 1 g ointment | 60 gram £13.86 | 120 gram £27.72
Calcipotriol 50 microgram per 1 g ointment | 30 gram £6.93 DT price = £6.93

Calcipotriol (Non-proprietary)

Calcipotriol as Calcipotriol hydrate 50 microgram per 1 g. Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 gram. Calcipotriol (as Calcipotriol hydrate) 50 microgram per 1 gram. Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 gram.

Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 gram. Calcipotriol (as Calcipotriol monohydrate) 1 microgram per 1 ml. Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 ml. Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 ml. Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 ml.

Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 gram. Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 gram.

Calcitriol (1,25-Dihydroxycholecalciferol)

INDICATIONS AND DOSE

Mild to moderate plaque psoriasis

TO THE SKIN

Adult: Apply twice daily, not more than 35% of body surface to be treated daily; maximum 30 g per day.

CONTRA-INDICATIONS


SIDE-EFFECTS

· Common or very common Burning, dermatitis, erythema, itching, local skin reactions, paraesthesia.
· Frequency not known Aggravation of psoriasis.

DOVOBET® GEL

Calcitriol 3 microgram per 1 g ointment | 100 gram £18.06 DT price = £18.06
Calcitriol 3 microgram per 1 g ointment | 50 microgram per 1 g ointment | 30 gram £6.93 DT price = £6.93
Calcitriol 3 microgram per 1 g ointment | 60 gram £13.86 | 120 gram £27.72
Calcitriol 3 microgram per 1 g ointment | 30 gram £6.93 DT price = £6.93

Tacalcitol

INDICATIONS AND DOSE

Plaque psoriasis

TO THE SKIN

Adult: Apply once daily, preferably at bedtime, maximum 10 g ointment or 10 mL lotion daily, when lotion and ointment used together, maximum total tacalcitol 280 micrograms in any one week (e.g. lotion 30 mL with ointment 40 g).

CONTRA-INDICATIONS

Calcium metabolism disorders.

SIDE-EFFECTS

· Common or very common Burning, dermatitis, erythema, itching, local skin reactions, paraesthesia.
· Frequency not known Aggravation of psoriasis.
4 Perspiration

Antiperspirants

Aluminium chloride hexahydrate below is a potent antiperspirant used in the treatment of hyperhidrosis. Aluminium salts are also incorporated in preparations used for minor fungal skin infections associated with hyperhidrosis.

In more severe cases specialists use glycopyrronium bromide as a 0.05% solution below in the iontophoretic treatment of hyperhidrosis of plantar and palmar areas. Botox® contains botulinum toxin type A complex p. 322 and is licensed for use intradermally for severe hyperhidrosis of the axillae unresponsive to topical antiperspirant or other anticholinergic topical treatments.

4.1 Hyperhidrosis

Aluminium chloride hexahydrate

INDICATIONS AND DOSE

Hyperhidrosis affecting axillae, hands or feet

TO THE SKIN

Adult: Apply once daily, apply liquid formulation at night to dry skin, wash off the following morning, reduce frequency as condition improves—do not bathe immediately before use

Hyperhidrosis | Bromhidrosis | Intertrigo | Prevention of lineae pedis and related conditions

TO THE SKIN

Adult: Apply powder to dry skin

• CAUTIONS Avoid contact with eyes · avoid contact with mucous membranes · avoid use on broken or irritated skin · do not shave axillae or use depilatories within 12 hours of application

• SIDE-EFFECTS Skin irritation

PATIENT AND CARER ADVICE

Avoid contact with clothing.

EXCEPTIONS TO LEGAL CATEGORY

A 30 mL pack of aluminium chloride hexahydrate 20% is on sale to the public.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Liquid

Aluminium chloride hexahydrate (Non-proprietary)

Aluminium chloride 200 mg per 1 ml | Aluminium chloride 20% solution | 60 ml (£) no price available

Anhydrol (Dermal Laboratories Ltd)

Aluminium chloride 200 mg per 1 ml | Anhydrol Forte 20% solution | 60 ml (£) £2.51

Driclor (GlaxoSmithKline Consumer Healthcare)

Aluminium chloride 200 mg per 1 ml | Driclor 20% solution | 20 ml (PO) £3.01 | 75 ml (£) £3.01

Spray

Aluminium chloride hexahydrate (Non-proprietary)

Aluminium chloride 200 mg per 1 ml | Aluminium chloride 20% spray | 30 ml no price available

Odaban (Brucey’s Pharmaceuticals Ltd)

Aluminium chloride 200 mg per 1 ml | Odaban 20% spray | 30 ml £6.69

ANTIMUSCARINICS

Glycopyrronium bromide (Glycopyrrolate)

INDICATIONS AND DOSE

Iontophoretic treatment of hyperhidrosis

TO THE SKIN

Adult: Only 1 site to be treated at a time, maximum 2 sites treated in any 24 hours, treatment not to be repeated within 7 days (consult product literature)

CONTRA-INDICATIONS

Infections affecting the treatment site

CONTRA-INDICATIONS, FURTHER INFORMATION

Contra-indications applicable to systemic use should be considered; however, glycopyrronium is poorly absorbed and systemic effects unlikely with topical use.

CAUTIONS

Cautions applicable to systemic use should be considered; however, glycopyrronium is poorly absorbed and systemic effects unlikely with topical use.

SIDE-EFFECTS

Tingling at administration site

SIDE-EFFECTS, FURTHER INFORMATION

The possibility of systemic side-effects should be considered; however, glycopyrronium is poorly absorbed and systemic effects unlikely with topical use.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for iontophoresis

Robinul (AMCo)

Glycopyrronium bromide 1 mg per 1 mg | Robinul powder for solution for iontophoresis | 3 gram (£) £266.00
5 Photodamage

Photodamage

Patients should be advised to use a high-SPF sunscreen and to minimise exposure of the skin to direct sunlight or sun lamps.

Topical treatments can be used for actinic keratosis. An emollient may be sufficient for mild lesions. Diclofenac sodium p. 521 is suitable for the treatment of superficial lesions in mild disease. Fluorouracil cream p. 761 is effective against most types of non-hypertrrophic actinic keratosis; a solution containing fluorouracil and salicylic acid is available for the treatment of low or moderately thick hyperkeratotic actinic keratosis. Imiquimod p. 1057 is used for lesions on the face and scalp when cryotherapy or other topical treatments cannot be used. Fluorouracil and imiquimod produce a more marked inflammatory reaction than diclofenac but lesions resolve faster. A short course of ingenol mebutate below is licensed for the treatment of non-hypertrrophic actinic keratosis; response to treatment can usually be assessed 8 weeks after the course. Photodynamic therapy in combination with methyl-aminolevulinate cream (Metvix, available from Galderma) or 5-aminolevulinic acid gel (Ameluz, available from Spirit Healthcare) is used in specialist centres for treating superficial and confluent, non-hypertrrophic actinic keratosis when other treatments are inadequate or unsuitable; it is particularly suitable for multiple lesions, for periorbital lesions, or for lesions located at sites of poor healing.

Imiquimod or topical fluorouracil is used for treating superficial basal cell carcinomas. Photodynamic therapy in combination with methyl-5-aminolevulinate cream is used in specialist centres for treating superficial, nodular basal cell carcinomas when other treatments are unsuitable.

Antimetabolites

Fluorouracil

Indications and Dose

Superficial malignant and pre-malignant skin lesions

Adult: Apply 1–2 times a day for 3–4 weeks (usual duration of initial therapy), apply thinly to the affected area, maximum area of skin 500 cm² (e.g. 23 cm x 23 cm) treated at one time, alternative regimens may be used in some settings.

Caution: Avoid contact with broken skin - avoid contact with eyes - avoid contact with inside of ears - avoid contact with inside of nostrils - avoid contact with lips - avoid occlusive dressings on treated area.

Side-effects: Erythema multiforme - photosensitivity - local irritation (use an emollient if necessary).

Pregnancy: Not absorbed from skin; ensure infant does not come in contact with treated area for 6 hours after application.

Breastfeeding: Not absorbed from skin; ensure infant does not come in contact with treated area.

Medicinal forms: There can be variation in the licensing of different medicines containing the same drug.

Cream

Excipients: May contain benzyl alcohol, hydroxybenzoates (parabens), polyethylene glycol, sodium hydroxide, sorbitol, titanium dioxide, xanthan gum.

Efudix (Meda Pharmaceuticals Ltd), Fluorouracil 50 mg per 1 gram

P: £32.90 GT price = £32.90

Fluorouracil with salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluorouracil p. 761, salicylic acid p. 1057.

Indications and Dose

Low or moderately thick hyperkeratotic actinic keratosis

To the skin

Adult: Apply once daily for up to 12 weeks, reduced to 3 times a week if severe side effects occur and until side effects improve, to be applied to the affected area, if treating area with thin epidermis, reduce frequency of application and monitor response more often; maximum area of skin treated at one time, 25 cm² (e.g. 5 cm x 5 cm).

Medicinal forms: There can be variation in the licensing of different medicines containing the same drug.

Cutaneous solution

Contraindications and Advisory Labels 15

Actikerall (Almirall Ltd) Fluorouracil 5 mg/g, salicylic acid 100 mg/g

Actikerall 5 mg/g & 100 mg/g cutaneous solution | 25 ml £83.30

Protein kinase C activators

Ingenol mebutate

Indications and Dose

Actinic keratosis on face and scalp

To the skin

Adult: Apply once daily for 3 days, use the 150 microgram/g gel

Actinic keratosis on trunk and extremities

To the skin

Adult: Apply once daily for 2 days, use the 500 microgram/g gel

Caution: Avoid contact with broken skin - avoid contact with eyes - avoid contact with inside of ears - avoid contact with inside of nostrils - avoid contact with lips - avoid occlusive dressings on treated area.


Pregnancy: Not absorbed from skin, but manufacturer advises avoid.

Breastfeeding: Not absorbed from skin; ensure infant does not come in contact with treated area for 6 hours after application.

Directions for Administration

One tube covers skin area of 25 cm². Allow gel to dry on treatment area for 15 minutes. Avoid washing or touching the treated area for 6 hours after application; after this time, area may be washed with mild soap and water. Avoid use immediately after shower or less than 2 hours before bedtime.

Medicinal forms: There can be variation in the licensing of different medicines containing the same drug.

Gel

Drug master file 15

Excipients: May contain benzyl alcohol

Picato (LEO Pharma) Ingenuel mebutate 150 microgram per 1 gram

Picato 150 micrograms/g gel | 1.41 gram £65.00

Picato 500 micrograms/g gel | .94 gram £65.00
6 Pruritus

Topical local antipruritics

Pruritus may be caused by systemic disease (such as obstructive jaundice, endocrine disease, chronic renal disease, iron deficiency, and certain malignant diseases), skin disease (e.g. psoriasis, eczema, urticaria, and scabies), drug hypersensitivity, or as a side-effect of opioid analgesics. Where possible, the underlying causes should be treated. An emollient may be of value where the pruritus is associated with dry skin. Pruritus that occurs in otherwise healthy elderly people can also be treated with an emollient.

Levomenthol cream below can be used to relieve pruritus; it exerts a cooling effect on the skin. Local antipruritics have a role in the treatment of pruritus in palliative care.

Preparations containing crotamiton below are sometimes used but are of uncertain value. Preparations containing calamine are often ineffective.

A topical preparation containing doxepin 5% below is licensed for the relief of pruritus in eczema; it can cause drowsiness and there may be a risk of sensitisation.

Pruritus is common in biliary obstruction, especially in primary biliary cirrhosis and drug-induced cholestasis. Oral administration of colestyramine p. 168 is the treatment of choice.

Topical antihistamines and local anaesthetics are only marginally effective and occasionally cause hypersensitisation. For insect stings and insect bites, a short course of a topical corticosteroid is appropriate. Short-term treatment with a sedating antihistamine may help in insect stings and in intractable pruritus where sedation is desirable. Calamine preparations are of little value for the treatment of insect stings or bites and are no longer widely available.

Topical local anaesthetics are indicated for the relief of local pain. Preparations may be absorbed, especially through mucosal surfaces, therefore excessive application should be avoided and they should preferably not be used for more than 3 days; not generally suitable for young children and are less suitable for prescribing.

Topical antihistamines should be avoided in eczema and are not recommended for longer than 3 days. They are less suitable for prescribing.

ANTIPRURITICS

Crotamiton

INDICATIONS AND DOSE
Pruritus (including pruritus after scabies)

TO THE SKIN

- Child 1 month–2 years (on doctor’s advice only): Apply once daily
- Child 3–17 years: Apply 2–3 times a day
- Adult: Apply 2–3 times a day

CONTRA-INDICATIONS Acute exudative dermatoses

CAUTIONS Avoid use in buccal mucosa • avoid use near eyes • avoid use on broken skin • avoid use on very inflamed skin • use on doctor’s advice for children under 3 years

PREGNANCY Manufacturer advises avoid, especially during the first trimester—no information available.

BREAST FEEDING No information available; avoid application to nipple area.

MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

Doxepin

INDICATIONS AND DOSE
Pruritus in eczema

TO THE SKIN

- Child 12–17 years: Apply up to 3 g 3–4 times a day, apply thinly; coverage should be less than 10% of body surface area; maximum 12 g per day
- Adult: Apply up to 3 g 3–4 times a day, apply thinly; coverage should be less than 10% of body surface area; maximum 12 g per day

CAUTIONS Avoid application to large areas • cardiac arrhythmias • mania • severe heart disease • susceptibility to angle-closure glaucoma • urinary retention

SIDE-EFFECTS

- Common or very common Dizziness • drowsiness
- Frequency not known Antimuscarinic effects • fever • gastro-intestinal disturbances • headache • irritation • local burning • rash • stinging • tingling

PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING Manufacturer advises use only if potential benefit outweighs risk.

HEPATIC IMPAIRMENT Manufacturer advises caution in severe liver disease.

PATIENT AND CARER ADVICE Drowsiness may affect performance of skilled tasks (e.g. driving). Effects of alcohol enhanced. A patient information leaflet should be provided.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Levomenthol

INDICATIONS AND DOSE
Pruritus

TO THE SKIN

- Adult: Apply 1–2 times a day

PRESCRIBING AND DISPENSING INFORMATION When prepared extemporaneously, the BP states Levomenthol cream, BP (Menthol in Aqueous Cream) consists of levomenthol 0.5%.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream
Rosacea and acne

Acne

Treatment of acne should be commenced early to prevent scarring. Patients should be counselled that an improvement may not be seen for at least a couple of months. The choice of treatment depends on whether the acne is predominantly inflammatory or comedonal and its severity.

Mild to moderate acne is generally treated with topical preparations. Systemic treatment with oral antibacterials is generally used for moderate to severe acne or where topical preparations are not tolerated or are ineffective or where application to the site is difficult. Another oral preparation used for acne is the hormone treatment co-cyprindiol (cyproterone acetate with ethinylestradiol) for women only.

Severe acne, acne unresponsive to prolonged courses of oral antibacterials, scarring, or acne associated with psychological problems calls for early referral to a consultant dermatologist who may prescribe isotretinoin for administration by mouth.

Topical preparations for acne

In mild to moderate acne, comedones and inflamed lesions respond well to benzoyl peroxide p. 1044 or to a topical retinoid. Alternatively, topical application of an antibacterial such as erythromycin p. 1043 or clindamycin p. 467 may be effective for inflammatory acne. If topical preparations prove inadequate, oral preparations may be needed.

Benzoyl peroxide and azelaic acid

Benzoyl peroxide p. 1044 is effective in mild to moderate acne. Both comedones and inflamed lesions respond well to benzoyl peroxide. The lower concentrations seem to be as effective as higher concentrations in reducing inflammation. It is usual to start with a lower strength and to increase the concentration of benzoyl peroxide gradually. Adverse effects include local skin irritation, particularly when therapy is initiated, but the scaling and redness often subside with treatment continued at a reduced frequency of application. If the acne does not respond after 2 months then use of a topical antibacterial should be considered.

Azelaic acid p. 1043 has antimicrobial and antiinflammatory properties. It may be an alternative to benzoyl peroxide or to a topical retinoid for treating mild to moderate comedonal acne, particularly of the face. Some patients prefer azelaic acid because it is less likely to cause local irritation than benzoyl peroxide.

Topical antibacterials for acne

For many patients with mild to moderate inflammatory acne, topical antibacterials may be no more effective than topical benzoyl peroxide or tretinoin. Topical antibacterials are probably best reserved for patients who wish to avoid oral antibacterials or who cannot tolerate them. Topical preparations of erythromycin p. 1043 and clindamycin p. 467 are effective for inflammatory acne. Topical antibacterials can produce mild irritation of the skin, and on rare occasions cause sensitisation; gastro-intestinal disturbances have been reported with topical clindamycin.

Antibacterial resistance of Propionibacterium acnes is increasing; there is cross-resistance between erythromycin and clindamycin. To avoid development of resistance:

- when possible use non-antibiotic antimicrobials (such as benzoyl peroxide or azelaic acid);
- avoid concomitant treatment with different oral and topical antibacterials;
- if a particular antibacterial is effective, use it for repeat courses if needed (short intervening courses of benzoyl peroxide or azelaic acid may eliminate any resistant propionibacteria);
- do not continue treatment for longer than necessary (however, treatment with a topical preparation should be continued for at least 6 months).

Some manufacturers of topical antibacterial preparations for acne advise that preparations containing alcohol are not suitable for use with benzoyl peroxide.

Topical retinoids and related preparations for acne

Topical tretinoin p. 765, its isomer isotretinoin p. 1045, and adapalene p. 1045 (a retinoid-like drug), are useful for treating comedones and inflammatory lesions in mild to moderate acne. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop. Isotretinoin is given by mouth in severe acne.

Other topical preparations for acne

Preparations containing aluminium oxide p. 1042 are not considered beneficial in acne. A topical preparation of nicotinamide p. 1048 is available for inflammatory acne.

Oral preparations for acne

Systemic antibacterial treatment is useful for inflammatory acne if topical treatment is not adequately effective or if it is inappropriate. Anticomendoidal treatment (e.g. with topical benzoyl peroxide p. 1044) may also be required. Either oxytetracycline p. 498 or tetracycline p. 498 is usually given for acne. If there is no improvement after the first 3 months another oral antibacterial should be used. Maximum improvement usually occurs after 4 to 6 months but in more severe cases treatment may need to be continued for 2 years or longer.

Doxycycline p. 995 and lymecycline p. 497 are alternatives to tetracycline.

Although minocycline p. 498 is as effective as other tetracyclines for acne, it is associated with a greater risk of lupus erythematosus–like syndrome. Minocycline sometimes causes irreversible pigmentation; it is given in a once or twice daily dose.

Erythromycin p. 1043 in a twice daily dose is an alternative for the management of acne but proprionibacteria strains resistant to erythromycin are becoming widespread and this may explain poor response.

Trimethoprim p. 462 may be used for acne resistant to other antibacterials [unlicensed indication]. Prolonged treatment with trimethoprim may depress haematopoiesis; it should generally be initiated by specialists.

Concomitant use of different topical and systemic antibacterials is undesirable owing to the increased likelihood of the development of bacterial resistance.

Hormone treatment for acne

Co-cyprindiol (cyproterone acetate with ethinylestradiol p. 1042) contains an anti-androgen. It is licensed for use in women with moderate to severe acne that has not
responded to topical therapy or oral antibacterials, and for moderately severe hirsutism. Although it is an effective hormonal contraceptive, it should not be used solely for contraception.

Improvement of acne with co-cyprindiol probably occurs because of decreased sebum secretion which is under androgen control. Some women with moderately severe hirsutism may also benefit because hair growth is also androgen-dependent.

**Skin irritation**

Isotretinoin is a toxic drug that should be prescribed only by, or under the supervision of, a consultant dermatologist. It is given for at least 15 weeks; repeat courses are not normally required.

**Side-effects of isotretinoin include severe dryness of the skin and mucous membranes, nose bleeds, and joint pains.** The drug is teratogenic and must not be given to women of child-bearing age unless they practise effective contraception (oral progesterone-only contraceptives not considered effective) and then only after detailed assessment and explanation by the physician. Women must also be registered with a pregnancy prevention programme.

Although a causal link between isotretinoin use and psychiatric changes (including suicidal ideation) has not been established, the possibility should be considered before initiating treatment; if psychiatric changes occur during treatment, isotretinoin should be stopped, the prescriber informed, and specialist psychiatric advice should be sought.

**Rosacea**

Rosacea is not comedonal (but may exist with acne which may be comedonal). Brimonidine tartrate p. 1045 is licensed for the treatment of facial erythema in rosacea. The pustules and papules of rosacea respond to topical metronidazole p. 1008 or topical azelaic acid p. 1043. Alternatively oral administration of oxytetracycline p. 498 or tetracycline p. 498, or erythromycin p. 1043, can be used; courses usually last 6–12 weeks and are repeated intermittently. Doxycycline p. 995 can be used [unlicensed indication] if oxytetracycline or tetracycline is inappropriate (e.g. in renal impairment). A modified-release preparation of doxycycline is licensed in low daily doses for the treatment of facial rosacea. Isotretinoin p. 1045 is occasionally given in refractory cases [unlicensed indication]. Camouflagers may be required for the redness.

**Anti-androgens**

**Co-cyprindiol**

**INDICATIONS AND DOSE**

Moderate to severe acne in women of child-bearing age refractory to topical therapy or oral antibacterials.

**Moderately severe hirsutism**

**INDICATIONS**

Acute porphyria · gallstones · heart disease associated with pulmonary hypertension or risk of embolus · history during pregnancy of cholestatic jaundice · history during pregnancy of chorea · history during pregnancy of pemphigoid gestationis · history during pregnancy of pruritus · history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptabe · history of haemolytic uraemic syndrome · migraine with aura · personal history of venous or arterial thrombosis · sclerosing treatment for varicose veins · severe or multiple risk factors for arterial disease or for venous thromboembolism · systemic lupus erythematosus with (or unknown) antiphospholipid antibodies · transient cerebral ischaemic attacks without headaches · undiagnosed vaginal bleeding

**CONTRA-INDICATIONS**

Acute porphyria · gallstones · heart disease associated with pulmonary hypertension or risk of embolus · history during pregnancy of cholestatic jaundice · history during pregnancy of chorea · history during pregnancy of pemphigoid gestationis · history during pregnancy of pruritus · history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptabe · history of haemolytic uraemic syndrome · migraine with aura · personal history of venous or arterial thrombosis · sclerosing treatment for varicose veins · severe or multiple risk factors for arterial disease or for venous thromboembolism · systemic lupus erythematosus with (or unknown) antiphospholipid antibodies · transient cerebral ischaemic attacks without headaches · undiagnosed vaginal bleeding

**CAUTIONS**

Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice · arterial disease · gene mutations associated with breast cancer (e.g. BRCA 1) · history of severe depression especially if induced by hormonal contraceptive · hyperprolactinaemia—seek specialist advice · inflammatory bowel disease including Crohn’s disease · migraine · personal or family history of hypertriglyceridaemia (increased risk of pancreatitis) · risk factors for venous thromboembolism · sickle-cell disease · undiagnosed breast mass

**CAUTIONS, FURTHER INFORMATION**

Venous thromboembolism There is an increased risk of venous thromboembolism in women taking co-cyprindiol, particularly during the first year of use. The incidence of venous thromboembolism is 1.5–2 times higher in women using co-cyprindiol than in women using combined oral contraceptives containing levonorgestrel, but the risk may be similar to that associated with use of combined oral contraceptives containing third generation progestogens (desogestrel and gestodene) or drospirenone. Women requiring co-cyprindiol may have an inherently increased risk of cardiovascular disease.

**INTERACTIONS** → Appendix 1 (oestrogens).


**SIDE-EFFECTS**
- **Rare** Rarely gallstones, systemic lupus erythematosus
- **Very rare** Photosensitivity
- **Frequency not known** Abdominal cramps, absence of withdrawal bleeding, amenorrhoea after discontinuation, breast enlargement, breast secretion, breast tenderness, changes in libido, changes in lipid metabolism, changes in vaginal discharge, chloasma, chorea, contact lenses may irritate, depression, fluid retention, headache, hepatic tumours, hypertension, irritability, leg cramps, liver impairment, nausea, nervousness, reduced menstrual loss, skin reactions, thrombosis (more common when factor V Leiden present in blood groups A, B, and AB), visual disturbances, vomiting, “spotting” in early cycles

**PREGNANCY** Avoid—risk of feminisation of male fetus with cyproterone.

**BREAST FEEDING** Manufacturer advises avoid; possibility of anti-androgen effects in neonate with cyproterone.

**HEPATIC IMPAIRMENT** Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

**PRESCRIBING AND DISPENSING INFORMATION** A mixture of cyproterone acetate and ethinylestradiol in the mass proportions 2000 parts to 35 parts, respectively.

**MEDICINAL FORMS**

<table>
<thead>
<tr>
<th>Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-CYPRODIROL (Non-proprietary)</td>
</tr>
<tr>
<td>Cyproterone acetate 2 mg, Ethinylestradiol 35 microgram</td>
</tr>
<tr>
<td>Dianette (Mylan Ltd, Bayer Plc)</td>
</tr>
<tr>
<td>Cyproterone acetate 2 mg, Ethinylestradiol 35 microgram</td>
</tr>
<tr>
<td>Brands may include Clairette tablets</td>
</tr>
</tbody>
</table>

**Azelaic acid**

**INDICATIONS AND DOSE**

**FINACEA®**

<table>
<thead>
<tr>
<th>Facial acne vulgaris</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO THE SKIN</td>
</tr>
<tr>
<td>Child 12-17 years: Apply twice daily, discontinue if no improvement after 1 month</td>
</tr>
<tr>
<td>Adult: Apply twice daily, discontinue if no improvement after 1 month</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Papulopustular rosacea</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO THE SKIN</td>
</tr>
<tr>
<td>Adult: Apply twice daily, discontinue if no improvement after 2 months</td>
</tr>
</tbody>
</table>

**SKINOREN®**

<table>
<thead>
<tr>
<th>Acne vulgaris</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO THE SKIN</td>
</tr>
<tr>
<td>Child 12-17 years: Apply twice daily</td>
</tr>
<tr>
<td>Adult: Apply twice daily</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acne vulgaris in patients with sensitive skin</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO THE SKIN</td>
</tr>
<tr>
<td>Child 12-17 years: Apply once daily for 1 week, then apply twice daily</td>
</tr>
<tr>
<td>Adult: Apply once daily for 1 week, then apply twice daily</td>
</tr>
</tbody>
</table>

**CAUTIONS** Avoid contact with eyes, avoid contact with mouth, avoid contact with mucous membranes

**ANTICOMEDONALS**

**SIDE-EFFECTS**
- **Common or very common** Local irritation (reduce frequency or discontinue temporarily)
- **Uncommon** Skin discoloration
- **Frequency not known** Worsening of asthma

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**
- EXCIPIENTS: May contain Propylene glycol
- **Skinoren** (Bayer Plc)
  - Azelaic acid 200 mg per 1 gram Skinoren 20% cream | 30 g [POT] £3.74 DT price = £3.74

**Gel**
- EXCIPIENTS: May contain Disodium edetate, polysorbates, propylene glycol
- **Finacea** (Bayer Plc)
  - Azelaic acid 150 mg per 1 gram Finacea 15% gel | 30 gram [POT] £7.48 DT price = £7.48

**ANTI-INFECTIVES**

**Erythromycin**

The properties listed below are those particular to the drug only. For properties common to the class, see macrolides, p. 469.

**INDICATIONS AND DOSE**

**Rosacea**
- **BY MOUTH**
  - Adult: 500 mg twice daily courses usually last 6–12 weeks and are repeated intermittently

**Acne**
- **BY MOUTH**
  - Adult: 500 mg twice daily

**STIEMYCIN®**

**Acne vulgaris**
- **TO THE SKIN**
  - Child 12-17 years: Apply twice daily, to be applied thinly
  - Adult: Apply twice daily, to be applied thinly

**CAUTIONS**
- With systemic use avoid in acute porphyrrias p. 864

**STIEMYCIN®**

Some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide

**INTERACTIONS** → Appendix 1 (macrolides).
- Caution with concomitant use of drugs that prolong the QT interval.
- With topical use Interactions do not apply to small amounts of erythromycin used topically.

**PREGNANCY**
- With systemic use Not known to be harmful.

**BREAST FEEDING**
- With systemic use Only small amounts in milk—not known to be harmful.

**HEPATIC IMPAIRMENT**
- With systemic use May cause idiosyncratic hepatotoxicity.

**RENAL IMPAIRMENT**
- With systemic use in adults: Max. 1.5 g daily in severe renal impairment (ototoxicity).
- With systemic use in children: Reduce dose in severe renal impairment (ototoxicity).

**PRESCRIBING AND DISPENSING INFORMATION**
- With oral use Flavours of oral liquid formulations may include banana

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: gel, ointment
### Erythromycin with zinc acetate

**INDICATIONS AND DOSE**

**Acne vulgaris**

**TO THE SKIN**

- **Child:** Apply twice daily
- **Adult:** Apply twice daily

- **CAUTIONS** Some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

---

### Benzoyl peroxide

#### BENZOYL PEROXIDE

**INDICATIONS AND DOSE**

**Acne vulgaris**

**TO THE SKIN**

- **Child 12-17 years:** Apply 1–2 times a day, preferably after washing with soap and water, start treatment with lower-strength preparations
- **Adult:** Apply 1–2 times a day, preferably after applying washing with soap and water, start treatment with lower-strength preparations

- **CAUTIONS** Avoid contact with broken skin - avoid contact with eyes - avoid contact with mouth - avoid contact with mucous membranes - avoid excessive exposure to sunlight

- **SIDE-EFFECTS** Skin irritation

**SIDE-EFFECTS, FURTHER INFORMATION**

Skin irritation Reduce frequency or suspend use until irritation subsides and re-introduce at reduced frequency.

**PATIENT AND CARER ADVICE** May bleach fabrics and hair.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances, isopropyl palmitate, propylene glycol

- **Brevoxyl** (GlaxoSmithKline Consumer Healthcare)
- **Benzoyl peroxide 40 mg per 1 gram Brevoxyl 4% cream**
  
  50 gram £4.13 DT price = £4.13

- **PanOxyl** (GlaxoSmithKline Consumer Healthcare)

- **Benzoyl peroxide 50 mg per 1 gram PanOxyl 5 cream**
  
  40 gram £1.89 DT price = £1.89

**Gel**

EXCIPIENTS: May contain Fragrances, propylene glycol

- **Acnecide** (Galderma (UK) Ltd)

- **Benzoyl peroxide 50 mg per 1 gram Acnecide 5% gel**
  
  30 gram £5.46 DT price = £5.46 | 60 gram £12.56

  Acnecide Wash 5% gel | 50 gram £5.44

  - Brands may include PanOxyl Acnecid, PanOxyl Aquagel

**Wash**

EXCIPIENTS: May contain Imidurea

- **PanOxyl** (GlaxoSmithKline Consumer Healthcare)

- **Benzoyl peroxide 100 mg per 1 gram PanOxyl 10 wash**
  
  150 ml £6.40 DT price = £6.40

---

**Benzoyl peroxide with clindamycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, benzoyl peroxide above, clindamycin p. 467.

**INDICATIONS AND DOSE**

**Acne vulgaris**

**TO THE SKIN**

- **Child 12-17 years:** Apply once daily, dose to be applied in the evening
- **Adult:** Apply once daily, dose to be applied in the evening

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Adapalene

**INDICATIONS AND DOSE**

**Mild to moderate acne vulgaris**

- **TO THE SKIN**
  - Child 12–17 years: Apply once daily, apply thinly in the evening
  - Adult: Apply once daily, apply thinly in the evening

- **CAUTIONS** Avoid accumulation in angles of the nose - avoid contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin - avoid exposure to UV light (including sunlight, solariums) - avoid in severe acne involving large areas - caution in sensitive areas such as the neck

- **PREGNANCY** Avoid.

- **BREAST FEEDING** Amount of drug in milk probably too small to be harmful; ensure infant does not come in contact with treated areas.

- **PATIENT AND CARER ADVICE** If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **CAUTIONARY AND ADVISORY LABELS**
  - Adaplene may contain Disodium edetate, hydroxybenzoates (parabens)
  - **ADAPALENE (Non-proprietary)**
    - Adapalene 1 mg per 1 gram Adapalene 0.1% cream | 45 gram | £16.43 DT price = £16.43
    - Differin (Galderma (UK) Ltd) Adapalene 1 mg per 1 gram Differin 0.1% cream | 45 gram | £16.43 DT price = £16.43

**Gel**

- **CAUTIONARY AND ADVISORY LABELS**
  - Adapalene may contain Disodium edetate, hydroxybenzoates (parabens), propylene glycol
  - **ADAPALENE (Non-proprietary)**
    - Adapalene 1 mg per 1 gram Adapalene 0.1% gel | 45 gram | £16.43 DT price = £16.43
    - Differin (Galderma (UK) Ltd) Adapalene 1 mg per 1 gram Differin 0.1% gel | 45 gram | £16.43 DT price = £16.43

**Adapalene with benzoyl peroxide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, adapalene above, benzoyl peroxide p. 1044.

**INDICATIONS AND DOSE**

**Acne vulgaris**

- **TO THE SKIN**
  - Child 9–17 years: Apply once daily, to be applied thinly in the evening
  - Adult: Apply once daily, to be applied thinly in the evening

**PATIENT AND CARER ADVICE** Gel may bleach clothing and hair.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (March 2014) that Epilduo® should be restricted for use in mild to moderate facial acne when monotherapy with benzoyl peroxide or adapalene is inappropriate.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**

- **CAUTIONARY AND ADVISORY LABELS**
  - Adapalene 1 mg per 1 gram, benzoyl peroxide 50 mg per 1 gram Duvac Once Daily gel (3% and 1%) | 30 gram | £13.14 DT price = £13.14
  - £10.95 DT price = £10.95
  - 25 gram | £21.89 DT price = £21.89

**Isotretinoin**

**INDICATIONS AND DOSE**

**Topical treatment of mild to moderate acne**

- **TO THE SKIN**
  - Adult: Apply 1–2 times a day, to be applied thinly
  - Severe acne (under expert supervision) | Acne which is associated with psychological problems (under expert supervision) | Acne which has not responded to an adequate course of a systemic antibacterial (under expert supervision) | Acne with scarring (under expert supervision) | Systemic treatment of nodulo-cystic and conglobate acne (under expert supervision)

- **BY MOUTH**
  - Adult: Initially 500 micrograms/kg daily in 1–2 divided doses, increased if necessary to 1 mg/kg daily for 16–24 weeks, repeat treatment course after a period of at least 8 weeks if relapse after first course; maximum 150 mg/kg per course

**CONTRA-INDICATIONS**

- With oral use hypolipaemia - hypervitaminosis A
- With topical use perioral dermatitis - rosacea

**CAUTIONS**

- With oral use avoid blood donation during treatment and for at least 1 month after treatment - diabetes - dry eye syndrome (associated with risk of keratitis) - history of depression - monitor for depression
- With topical use allow peeling (resulting from other irritant treatments) to subside before using a topical retinoid - alternating a preparation that causes peeling with a topical retinoid may give rise to contact dermatitis (reduce frequency of retinoid application) - avoid accumulation in angles of the nose - avoid contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin - avoid exposure to UV light (including sunlight, solariums) - avoid in severe acne involving large areas - avoid use of topical retinoids with abrasive cleaners, comedogenic or astringent cosmetics - caution in sensitive areas such as the neck - personal or familial history of non-melanoma skin cancer

**INTERACTIONS**

- With oral use → Appendix 1 (retinoids). Avoid keratolytics.

**SIDE-EFFECTS**

- Common or very common
- With oral use anaemia - arthralgia - dryness of eyes (with blepharitis and conjunctivitis) - dryness of lips (sometimes cheilitis) - dryness of nasal mucosa (with epistaxis) - dryness of pharyngeal mucosa (with hoarseness) - dryness of skin (with dermatitis, scaling, thinning, erythema, pruritus) - epidermal fragility (trauma may cause
blistering) - haematuria - headache - myalgia - neutropenia - proteinuria - raised blood-glucose concentration - raised plasma-triglyceride concentration - raised serum-cholesterol concentration (with reduced high-density lipoprotein concentration) - raised serum-transaminase concentration - thrombocytopenia - thrombocytosis

▶ Rare
▶ With oral use aggressive behaviour - alopecia - anxiety - depression - mood changes - skin reactions
▶ Very rare
▶ With oral use acne fulminans - allergic vasculitis - arthritis - benign intracranial hypertension - blurred vision - bone changes following long-term administration - calcification of tendons and ligaments following long-term administration - cataracts - colour blindness - convulsions - corneal opacities - decreased night vision - decreased tolerance to contact lenses - diabetes mellitus - dizziness - drowsiness - early ephaptic closure following long-term administration - exacerbation of acne - gastrointestinal haemorrhage - glomerulonephritis - Gram-positive infections of skin and mucous membranes - granulomatous lesions - haemorrhagic diarrhoea - hepatitis - hirsutism - hyperuricaemia - impaired hearing - increased sweating - inflammatory bowel disease - keratitis - lymphadenopathy - malaise - nail dystrophy - nausea - papilloedema - paronychia - photophobia - photosensitivity - psychosis - raised serum-creatinine kinase concentration - reduced bone density following long-term administration - skeletal hyperostosis following long-term administration - skin hyperpigmentation - suicidal ideation - tendinitis - visual disturbances
▶ Frequency not known
▶ With oral use Stevens-Johnson syndrome - toxic epidermal necrolysis
▶ With topical use blistering of skin - burning - crusting of skin - dry or peeling skin - erythema - eye irritation - increased sensitivity to UVB light or sunlight - oedema - pruritus - stinging

SIDE-EFFECTS, FURTHER INFORMATION
Management of side-effects Risk of pancreatitis if triglycerides above 9 mmol/litre—discontinue if uncontrolled hypertriglyceridaemia or pancreatitis. Psychiatric side-effects require expert referral. Discontinue treatment if skin peeling severe or haemorrhagic diarrhoea develops. Visual disturbances require expert referral and possible withdrawal.

CONCEPTION AND CONTRACEPTION
▶ With oral use Effective contraception must be used. In women of child-bearing age with potential, exclude pregnancy up to 3 days before treatment (start treatment on day 2 or 3 of menstrual cycle), every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment—perform pregnancy test in the first 3 days of the menstrual cycle. Women must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception, but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone, but can be used in conjunction with other contraceptive methods. Each prescription for isotretinoin should be limited to a supply of up to 30 days' treatment and dispensed within 7 days of the date stated on the prescription; repeat prescriptions or faxed prescriptions are not acceptable. Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.

▶ With topical use Females of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered sufficiently effective).
▶ PREGNANCY Contra-indicated in pregnancy (teratogenic).
▶ BREAST FEEDING Avoid.
▶ HEPATIC IMPAIRMENT
▶ With oral use Avoid—further impairment may occur.
▶ RENAL IMPAIRMENT
▶ With oral use In severe impairment, reduce initial dose (e.g. 10 mg daily) and increase gradually up to 1 mg/kg daily as tolerated.

MONITORING REQUIREMENTS
With oral use Measure hepatic function and serum lipids before treatment, 1 month after starting and then every 3 months (reduce dose or discontinue if transaminase or serum lipids persistently raised).

PRESCRIBING AND DISPENSING INFORMATION Isotretinoin is an isomer of tretinoin.

PATIENT AND CARER ADVICE
▶ With oral use Warn patient to avoid wax epilation (risk of epidermal stripping), dermabrasion, and laser skin treatments (risk of scarring) during treatment and for at least 6 months after stopping; patient should avoid exposure to UV light (including sunlight) and use sunscreen and emollient (including lip balm) preparations from the start of treatment. Patients and carers should be told how to recognise signs and symptoms of psychiatric disorders such as depression, anxiety, and rarely suicidal thoughts.

▶ With topical use Patients should be warned that some redness and skin peeling can occur initially but settles with time. If undue irritation occurs, the frequency of application should be reduced or treatment suspended until the reaction subsides; if irritation persists, discontinue treatment. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop. If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.

MEDIcINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule
CAUTIONARY AND ADVISORY LABELS 10, 11, 21
▶ ISOTRETINOIN (Non-proprietary)
Isotretinoin 5 mg Isotretinoin 5mg capsules | 30 capsule £10.46 | 56 capsule £20.18
Isotretinoin 10 mg Isotretinoin 10mg capsules | 30 capsule £14.54 | 56 capsule £27.68
Isotretinoin 20 mg Isotretinoin 20mg capsules | 30 capsule £20.00 DT price = £19.55 | 56 capsule £37.85
Isotretinoin 40 mg Isotretinoin 40mg capsules | 30 capsule £38.98 DT price = £38.58
Roaccutane (Roche Products Ltd) Isotretinoin 10 mg Roaccutane 10mg capsules | 30 capsule £14.54 DT price = £14.54
Isotretinoin 20 mg Roaccutane 20mg capsules | 30 capsule £20.02 DT price = £19.55

Gel
CAUTIONARY AND ADVISORY LABELS 11
EXCIPIENTS: May contain Butylated hydroxytoluene
▶ Isotrex (Stiefel Laboratories (UK) Ltd) Isotretinoin 500 microgram per 1 gram Isotrex 0.05% gel | 30 gram £5.94 DT price = £5.94
Isotretinoin with erythromycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, erythromycin p. 1043, isotretinoin p. 1045.

**INDICATIONS AND DOSE**

**TO THE SKIN**
- ***Adult:*** (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**

**CAUTIONARY AND ADVISORY LABELS**
- **11**
- **EXCIPIENTS:** May contain Butylated hydroxytoluene
- **Isotrexin (Stiefel Laboratories (UK) Ltd)**
  - Erythromycin 20 mg per 1 gram, isotretinoin 500 microgram per 1 gram isotrexin gel | 30 gram (£7.47 DT price = £7.47)

**SIDE-EFFECTS**

- **Topical treatment of mild to moderate acne**
  - **Adult:** (to be applied thinly at bedtime)

**CONTRA-INDICATIONS**

Perioral dermatitis · personal or familial history of non-melanoma skin cancer · rosacea

**CAUTIONS**

Allow peeling (resulting from other irritant treatments) to subside before using a topical retinoid - alternating a preparation that causes peeling with a topical retinoid may give rise to contact dermatitis (reduce frequency of retinoid application) - avoid accumulation in angles of the nose - avoid contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin - avoid exposure to UV light (including sunlight, solariums) - avoid in severe acne involving large areas - avoid use of topical retinoids with abrasive cleaners, comedogenic or astringent cosmetics · caution in sensitive areas such as the neck

**SIDE-EFFECTS**

- Blistering of skin · burning · crusting of skin · dry or peeling skin (discontinue if severe) · erythema · eye irritation · increased sensitivity to UVB light or sunlight · oedema · pruritus · stinging · temporary changes of skin pigmentation

**CONCEPTION AND CONTRACEPTION**

Females of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered sufficiently effective).

**PREGNANCY**

Contra-indicated in pregnancy.

**BREAST FEEDING**

Amount of drug in milk after topical application probably too small to be harmful; ensure infant does not come in contact with treated areas.

**PATIENT AND CARER ADVICE**

If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used. Patients and carers should be warned that some redness and skin peeling can occur initially but settles with time. If undue irritation occurs, the frequency of application should be reduced or treatment suspended until the reaction subsides; if irritation persists, discontinue treatment. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**

**CAUTIONARY AND ADVISORY LABELS**
- **11**
- **EXCIPIENTS:** May contain Butylated hydroxytoluene, hydroxybenzoates (parabens), polysorbates
- **Treclin (Meda Pharmaceuticals Ltd)**
  - Clindamycin (as Clindamycin phosphate) 10 mg per 1 gram, Tretinoin 250 microgram per 1 gram Treclin 1%/0.025% gel | 30 gram (£7.47 DT price = £7.47)

**Tretinoin with clindamycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, erythromycin p. 1043, tretinoin p. 769.

**INDICATIONS AND DOSE**

**Acne**

**TO THE SKIN**
- ***Child:** Apply 1–2 times a day, apply thinly
- ***Adult:** Apply 1–2 times a day, apply thinly

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**

**CAUTIONARY AND ADVISORY LABELS**
- **11**
- **EXCIPIENTS:** May contain Butylated hydroxytoluene, hydroxybenzoates (parabens), polysorbates
- **Treclin (Meda Pharmaceuticals Ltd)**
  - Clindamycin (as Clindamycin phosphate) 10 mg per 1 gram, Tretinoin 250 microgram per 1 gram Treclin 1%/0.025% gel | 30 gram (£7.47 DT price = £7.47)
8 Scalp and hair conditions

Scalp and hair conditions

Dandruff is considered to be a mild form of seborrhoeic dermatitis. Shampoos containing antimicrobial agents such as pyrithione zinc (which are widely available) and selenium p. 1049 may have beneficial effects. Shampoos containing tar extracts may be useful and they are also used in psoriasis. Ketoconazole shampoo p. 1011 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1035 may also be useful. A cream or an ointment containing coal tar with salicylic acid p. 1035 is very helpful in Psoriasis p. 1017 that affects the scalp. Patients who do not respond to these treatments may need to be referred to exclude the possibility of other skin conditions.

Cradle cap in infants may be treated with coconut oil or olive oil applications followed by shampooing.

Hirsutism

Hirsutism may result from hormonal disorders or as a side-effect of drugs such as minoxidil p. 1049, corticosteroids, anabolic steroids, androgens, danazol p. 636, and progestogens.

Weight loss can reduce hirsutism in obese women. Women should be advised about local methods of hair removal, and in the mildest cases this may be all that is required.

Eflornithine p. 1050 an antiprotozoal drug, inhibits the enzyme ornithine decarboxylase in hair follicles. Topical eflornithine can be used as an adjunct to laser therapy for facial hirsutism in women.

Co-cyprindiol p. 1042 may be effective for moderately severe hirsutism. Metformin hydrochloride p. 594 is an alternative in women with polycystic ovary syndrome [unlicensed indication]. Systemic treatment is required for 6–12 months before benefit is seen.

Androgenetic alopecia

Finasteride p. 676 is licensed for the treatment of androgenetic alopecia in men. Continuous use for 3–6 months is required before benefit is seen, and effects are reversed 6–12 months after treatment is discontinued.

Topical application of minoxidil p. 1049 may stimulate limited hair growth in a small proportion of adults but only for as long as it is used.
**Antiseptics and Disinfectants**

**Benzalkonium chloride**

**Indications and Dose**

Seborrhoeic scalp conditions associated with dandruff and scaling

To the skin

- Child: Apply as required
- Adult: Apply as required

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

Shampoo

- Dermax (Derma Laboratories Ltd)
  - Benzalkonium chloride 5 mg per 1 ml Dermax Therapeutic 0.5% shampoo | 250 ml £5.69

**Cetrimide with undecenoic acid**

**Indications and Dose**

Scalp psoriasis | Seborrhoeic dermatitis | Dandruff

To the skin

- Child: Apply 3 times a week for 1 week, then apply twice weekly
- Adult: Apply 3 times a week for 1 week, then apply twice weekly

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

Shampoo

- Ceanel (Alliance Pharmaceuticals Ltd)
  - Cetrimide 100 mg per 1 ml, Phenylethyl alcohol 75 mg per 1 ml, Undecenoic acid 10 mg per 1 ml Ceanel Concentrate shampoo | 150 ml £3.40 | 500 ml £9.80

**Essential Trace Elements**

**Selenium**

**Indications and Dose**

Seborrhoeic dermatitis | Dandruff

To the skin

- Child 5-17 years: Apply twice weekly for 2 weeks, then apply once weekly for 2 weeks, then apply as required
- Adult: Apply twice weekly for 2 weeks, then apply once weekly for 2 weeks, then apply as required

**Pityriasis versicolor**

Adult: Apply daily for 7 days, apply to the affected area and leave on for 10 minutes before rinsing off. The course may be repeated if necessary. Diluting with a small amount of water prior to application can reduce irritation

**Unlicensed Use**

The use of selenium sulfide shampoo as a lotion for the treatment of pityriasis (tinea) versicolor is an unlicensed indication.

**Patient and Carer Advice**

Avoid using 48 hours before or after applying hair colouring, straightening or waving preparations.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

---

**8.1 Alopecia**

**Peripheral Vasodilators**

**Minoxidil**

**Indications and Dose**

**Regaine® for Men Extra Strength Foam**

Androgenetic alopecia

To the skin

- Adult: Apply 0.5 capful twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 16 weeks

**Regaine® for Men Extra Strength Solution**

Androgenetic alopecia

To the skin

- Adult: Apply 1 mL twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 1 year

**Contra-Indications**

Phaeochromocytoma

**CAUTIONS**

Avoid contact with broken, infected, shaved, or inflamed skin - avoid contact with eyes - avoid contact with mouth - avoid contact with mucous membranes - avoid inhalation of spray mist - avoid occlusive dressings

**Side-Effects, Further Information**

When used topically systemic effects unlikely; only about 1–2% absorbed (greater absorption may occur with use on inflamed skin).

**Interactions**

Caution—avoid topical drugs which enhance absorption.

**Side-Effects**

- Common or very common Headache · local irritation
- Uncommon Changes in hair colour or texture (discontinue if increased hair loss persists for more than 2 weeks) · hypotension

**SIDE-EFFECTS, FURTHER INFORMATION**

When used topically systemic effects unlikely; only about 1–2% absorbed (greater absorption may occur with use on inflamed skin).

**Pregnancy**

Avoid—possible toxicity including reduced placental perfusion. Neonatal hirsutism reported.

**Breast Feeding**

Present in milk but not known to be harmful.

**Patient and Carer Advice**

Ensure hair and scalp dry before application. Patients and their carers should be advised to wash hands after application of liquid or foam.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.
8.2 Hirsutism

**Efornithine**

- **DRUG ACTION** An antiprotozoal drug that inhibits the enzyme ornithine decarboxylase in hair follicles.

**INDICATIONS AND DOSE**

Adjuvant to laser therapy for facial hirsutism in women

**TO THE SKIN**

- **Adult:** Apply twice daily, to be applied thinly, discontinue use if no improvement after 4 months of treatment

- **SIDE-EFFECTS**
  - **Common or very common** Acne, burning at application site, rash, stinging at application site
  - **Uncommon** Abnormal hair growth, abnormal hair texture

- **PREGNANCY** Toxicity in animal studies—manufacturer advises avoid.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **PATIENT AND CARER ADVICE** Medicines must be rubbed in thoroughly. Cosmetics may be applied over treated area 5 minutes after efornithine, do not wash treated area for 4 hours after application.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **Scottish Medicines Consortium (SMC) Decisions**

  The Scottish Medicines Consortium has advised (September 2005) that efornithine for facial hirsutism be restricted for use in women in whom alternative drug treatment cannot be used.

- **MEDICINAL FORMS**

  There are variations in the licensing of different medicines containing the same drug.

  - **Cream**
    - **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens)
    - **Vaniqa (Almirall Ltd)**
      - Efornithine (as Efornithine monohydrate chloride) 115 mg per 1 gram
      - Vaniqa 11.5% cream | 60 gram (£6.87)

  - **Liquid**
    - **EXCIPIENTS:** May contain Propylene glycol
      - **Regaine (McNeil Products Ltd)**
        - Minoxidil 20 mg per 1 ml | Regaine for Women Regular Strength | 60 ml (£39.71)
        - Minoxidil 50 mg per 1 ml | Regaine for Men Extra Strength | 60 ml (£34.36)

- **INTERACTIONS**

  For the interactions following the ingestion of alcohol, see Appendix 1 (alcohol).

- **SIDE-EFFECTS**

  Features of acute alcohol intoxication include ataxia, dysarthria, nystagmus, and drowsiness, which may progress to coma, with hypotension and acidosis.
**Antiseptics and disinfectants**

**indications and dose**

**Cepton® lotion**

For skin disinfection in acne

- **Adult:** (consult product literature)
- **Child:** (consult product literature)

**Cepton® skin wash**

For use as skin wash in acne

- **Adult:** (consult product literature)
- **Child:** (consult product literature)

**Chloraprep®**

For skin disinfection before invasive procedures

- **Child 2 months-17 years:** (consult product literature)
- **Adult:** (consult product literature)

**CX antiseptic dusting powder**

For skin disinfection

- **Adult:** (consult product literature)

**Hibiscrub®**

Pre-operative hand and skin disinfection | General hand and skin disinfection

- **Child:** Use as alternative to soap (consult product literature)
- **Adult:** Use as alternative to soap (consult product literature)

**Hibitane® plus 5% concentrate solution**

General and pre-operative skin disinfection

- **Child:** (consult product literature)

**Hibitane® obstetric®**

For use in obstetrics and gynaecology as an antiseptic and lubricant

- **Adult:** To be applied to skin around vulva and perineum and to hands of midwife or doctor

**Prescribing and dispensing information**

When prepared extemporaneously, the BP states Surgical Spirit, BP consists of methyl salicylate 0.5 mL, diethanolamine 2%, castor oil 2.5%, in industrial methylated spirit.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

- **Alcohol (Non-proprietary)**
  - Industrial methylated spirit 70% | 600 mL £5.71
  - Ethanol 950 mL per 1 litre, Wood naphtha 50 mL per 1 litre | Industrial methylated spirit 95% | 600 mL £5.82 | 1000 mL £4.29-£6.02

**Antiseptics and disinfectants**

**Chlorhexidine**

**Indications and dose**

**Cepton® lotion**

For skin disinfection in acne

- **Adult:** (consult product literature)
- **Child:** (consult product literature)

**Cepton® skin wash**

For use as skin wash in acne

- **Adult:** (consult product literature)
- **Child:** (consult product literature)

**Chloraprep®**

For skin disinfection before invasive procedures

- **Child 2 months-17 years:** (consult product literature)
- **Adult:** (consult product literature)

**Cx antiseptic dusting powder**

For skin disinfection

- **Adult:** (consult product literature)

**Hibiscrub®**

Pre-operative hand and skin disinfection | General hand and skin disinfection

- **Child:** Use as alternative to soap (consult product literature)
- **Adult:** Use as alternative to soap (consult product literature)

**Hibitane® plus 5% concentrate solution**

General and pre-operative skin disinfection

- **Child:** (consult product literature)

**Hibitane® obstetric®**

For use in obstetrics and gynaecology as an antiseptic and lubricant

- **Adult:** To be applied to skin around vulva and perineum and to hands of midwife or doctor

**Contra-indications**

Alcoholic solutions not suitable before diathermy; alcoholic solutions not suitable for use on neonatal skin - not for use in body cavities.

**Caution**

Avoid contact with brain - avoid contact with eyes - avoid contact with meninges - avoid contact with middle ear.

**Side-effects**

Chemical burns in preterm neonates - sensitivity.

**Directions for administration**

Hibitane® plus 5% concentrate solution

For pre-operative skin preparation, dilute 1 in 10 (0.5%) with alcohol 70%. For general skin disinfection, dilute 1 in 100 (0.05%) with water. Alcoholic solutions not suitable for use before diathermy or on neonatal skin.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid, alcohol, syrup, 10% solution, 2.5% solution.

**Liquid**

- **Chlorhexidine (Non-proprietary)**
  - Chlorhexidine gluconate 500 microgram per 1 ml | Chlorhexidine gluconate 0.05% solution 100ml sachets | 10 sachet | no price available
  - Cepton (Boston Healthcare Ltd)
  - Chlorhexidine gluconate 5 mg per 1 gram | 150 mL | £5.10
  - Hibitane (Molnlycke Healthcare Ltd)
  - Chlorhexidine gluconate 50 mg per 1 mL | Hibitane Plus 5% concentrate solution | 500 mL | £14.50
  - Hydrex (Ecolab Healthcare Division)
  - Chlorhexidine gluconate 5 mg per 1 mL | Hydrex pink chlorhexidine 4% solution | 250 mL | £4.25 | 500 mL | £5.25 | 1000 mL | £24.00
  - Chlorhexidine gluconate 40 mg per 1 mL | Habiscrib 4% Surgical Scrub | 250 mL | £3.39 | 500 mL | £3.59 | 1000 mL | £26.96

**Cream**

- **Chlorhexidine (Non-proprietary)**
  - Chlorhexidine hydrochloride 5 mg per 1 gram | 30 gram | £2.07
  - Brands may include Acriflex, Eczmol, Hibitane

**Gel**

- **Cepton (Boston Healthcare Ltd)**
  - Chlorhexidine gluconate 5 mg per 1 gram | 30 gram | £2.97

Skin cleansers, antiseptics and desloughing agents

**Hydrogen peroxide**

**Drug Action** Hydrogen peroxide is an oxidising agent.

**Indications and dose**

For skin disinfection, particularly cleansing and deodorising wounds and ulcers

**To the skin**

- Adult: Use 3% and 6% solutions (consult product literature)

**Crystacide**

Superficial bacterial skin infection

**To the skin**

- Child: Apply 2–3 times a day for up to 3 weeks
- Adult: Apply 2–3 times a day for up to 3 weeks

**Contra-indications** Closed body cavities, deep wounds, large wounds; use as disinfectant agent for surgical instruments - use as emer - use during surgery

**Caution** Avoid on eyes; avoid on healthy skin; incompatible with products containing iodine or potassium permanganate

**Prescribing and dispensing information** The BP directs that when hydrogen peroxide is prescribed, hydrogen peroxide solution 6% (20 vols) should be dispensed. Strong solutions of hydrogen peroxide which contain 27% (90 vols) and 30% (100 vols) are only for the preparation of weaker solutions. When prepared extemporaneously, the BP states Hydrogen Peroxide Solution, BP consists of hydrogen peroxide 6% (20 vols) or hydrogen peroxide 3% (10 vols).

**Handling and Storage** Hydrogen peroxide bleaches fabric.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

**Irrigation solution**

- **Hydrogen peroxide 60 mg per 1 ml** Hydrogen peroxide 6% solution | 200 ml GSK £0.57 | 500 ml GSK £2.47 | 2000 ml GSK £7.52
- **Hydrogen peroxide 90 mg per 1 ml** Hydrogen peroxide 9% solution | 200 ml GSK £0.61–£0.62
- **Hydrogen peroxide 30 ml per 1 litre** Hydrogen peroxide 3% solution | 200 ml GSK £0.55

**Cream**

**Excipients:** May contain Edetic acid (edta), propylene glycol

- **Crystacide** (Germa UK Ltd)
  - Hydrogen peroxide 10 mg per 1 gram Crystacide 1% cream | 25 gram £8.07 DT price = £8.07 | 40 gram £11.62

**Proflavine**

**Indications and dose**

Infected wounds | Infected burns

**To the skin**

- Adult: (consult product literature)

**Patient and carer advice** Stains clothing.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

**Astringents**

**Potassium permanganate**

**Indications and dose**

Cleansing and deodorising suppurating eczematous reactions and wounds

**To the skin**

- Adult: For wet dressings or baths, use approximately 0.01% (1 in 10 000) solution

**Caution** Irritant to mucous membranes

**Directions for administration** Potassium permanganate 0.1% solution to be diluted 1 in 10 to provide a 0.01% (1 in 10 000) solution. With potassium permanganate tablets for solution, 1 tablet dissolved in 4 litres of water provides a 0.01% (1 in 10 000) solution.

**Patient and carer advice** Can stain clothing, skin and nails (especially with prolonged use).

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

**Tablet for cutaneous solution**

- **Potassium permanganate (Non-proprietary)**
  - Potassium permanganate 400 mg
    - Potassium permanganate 400 mg tablets for cutaneous solution | 30 tablet no price available DT price = £15.95
    - EN-Potab 400mg tablets for cutaneous solution | 30 tablet no price available DT price = £15.95
  - Permitabs (Alliance Pharmaceuticals Ltd)
    - Potassium permanganate 400 mg Permitabs 400mg tablets for cutaneous solution | 30 tablet £15.95 DT price = £15.95

**Chlorhexidine gluconate with isopropyl alcohol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine p. 1051.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Liquid**

**Cautionary and advisory labels** 15

- **Chlorhexidine** (CareFusion UK Ltd)
- Chlorhexidine gluconate 20 mg per 1 ml, isopropyl alcohol 700 ml per 1 litre Chloraprep with tint solution 10.5ml applicators | 25 applicator GSK £76.05
- Chloraprep with tint solution 26ml applicators | 25 applicator GSK £170.75
- Chloraprep solution 3ml applicators | 25 applicator GSK £21.25
- Chloraprep solution 1.5ml applicators | 20 applicator GSK £11.00
- Chloraprep with tint solution 3ml applicators | 25 applicator GSK £22.31
- Chloraprep solution 0.67ml applicators | 200 applicator GSK £80.00
- Chloraprep solution 10.5ml applicators | 25 applicator GSK £73.00
- Chloraprep solution 26ml applicators | 25 applicator GSK £162.50
Skin cleansers, antiseptics and desloughing agents

**IODINE PRODUCTS**

**Povidone-iodine**

**INDICATIONS AND DOSE**

Skin disinfection

TO THE SKIN

- **Child:** (consult product literature)
- **Adult:** (consult product literature)

**BETADINE® DRY POWDER SPRAY**

Skin disinfection, particularly minor wounds and infections

TO THE SKIN

- **Adult:** Not for use in serous cavities (consult product literature)

**SAVLON® DRY**

Skin disinfection of minor wounds

TO THE SKIN

- **Adult:** (consult product literature)

**VIDENE® SOLUTION**

Skin disinfection

TO THE SKIN

- **Child:** Apply undiluted in pre-operative skin disinfection and general antisepsis
- **Adult:** Apply undiluted in pre-operative skin disinfection and general antisepsis

**VIDENE® SURGICAL SCRUB®**

Skin disinfection

TO THE SKIN

- **Child:** Use as a pre-operative scrub for hand and skin disinfection
- **Adult:** Use as a pre-operative scrub for hand and skin disinfection

**VIDENE® TINCTURE**

Skin disinfection

TO THE SKIN

- **Adult:** Apply undiluted in pre-operative skin disinfection

**CONTRA-INDICATIONS**

Avoid regular use in patients with thyroid disorders, concomitant use of lithium, corrected gestational age under 32 weeks, infants body-weight under 1.5 kg, regular use in neonates

**CAUTIONS**

Broken skin, large open wounds

**CAUTIONS, FURTHER INFORMATION**

Large open wounds: The application of povidone-iodine to large wounds or severe burns may produce systemic adverse effects such as metabolic acidosis, hypernatraemia and impairment of renal function.

**VIDENE® TINCTURE**

Procedures involving hot wire cautery and diathermy

**SIDE-EFFECTS**

- Rare: Sensitivity
- **PREGNANCY** Sufficient iodine may be absorbed to affect the fetal thyroid in the second and third trimester.
- **BREAST FEEDING** Avoid regular or excessive use.
- **RENAI IMPAIRMENT** Avoid regular application to inflamed or broken skin or mucosa.

**EFFECT ON LABORATORY TESTS**

May interfere with thyroid function tests.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

**Liquid**

**CAUTIONARY AND ADVISORY LABELS 15**

- **Videne (Ecolab Healthcare Division)**
  - Povidone-iodine 75 mg per 1 ml Videne 7.5% surgical scrub solution | 500 ml £15.43

**Irrigation solutions**

**IRRIGATION SOLUTIONS**

- Flowfusor sodium chloride 0.9% irrigation solution 120ml bottles (Fresenius Kabi Ltd)
  - 1 bottle: NHS indicative price = £1.53 • Drug Tariff (Part IXa)
- Irrileens sodium chloride 0.9% irrigation solution aerosol spray (Convatec Ltd)
  - 240 ml: NHS indicative price = £4.49 • Drug Tariff (Part IXa)
- Normasol sodium chloride 0.9% irrigation solution 100ml sachets (Molnlycke Health Care Ltd)
  - 10 unit dose: NHS indicative price = £7.80 • Drug Tariff (Part IXa)
- Normasol sodium chloride 0.9% irrigation solution 25ml sachets (Molnlycke Health Care Ltd)
  - 25 unit dose: NHS indicative price = £6.42 • Drug Tariff (Part IXa)
- Sodium chloride 0.9% irrigation solution 20ml Clinipod unit dose (Mayors Healthcare Ltd)
  - 25 unit dose: NHS indicative price = £4.95 • Drug Tariff (Part IXa)
- Sodium chloride 0.9% irrigation solution 20ml ISO-Pod unit dose (St Georges Medical Ltd)
  - 25 unit dose: NHS indicative price = £4.95 • Drug Tariff (Part IXa)
- Sodium chloride 0.9% irrigation solution 20ml Irripod unit dose (C D Medical Ltd)
  - 25 unit dose: NHS indicative price = £5.84 • Drug Tariff (Part IXa)
- Sodium chloride 0.9% irrigation solution 20ml Sal-e Pods unit dose (Ennogen Healthcare Ltd)
  - 25 unit dose: NHS indicative price = £7.91 • Drug Tariff (Part IXa)
- Sodium chloride 0.9% irrigation solution 20ml Steripod unit dose (Molnlycke Health Care Ltd)
  - 25 unit dose: NHS indicative price = £7.90 • Drug Tariff (Part IXa)

**SKIN CLEANSERS**

**Diethyl phthalate with methyl salicylate**

**INDICATIONS AND DOSE**

Skin preparation before injection

TO THE SKIN

- **Adult:** Apply, to the area to be disinfected

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Liquid**

**CAUTIONARY AND ADVISORY LABELS 15**

- **DIETHYL PHTHALATE WITH METHYL SALICYLATE (Non-proprietary)**
  - Castor oil 25 ml per 1 litre, Diethyl phthalate 20 ml per 1 litre, Industrial methylated spirit 950 ml per 1 litre, Methyl salicylate 5 ml per 1 litre Surgical spirit | 200 ml NHS indicative price = £1.06 • 500 ml NHS indicative price = £1.89–£1.90 • 1000 ml NHS indicative price = £3.26

**SKIN CLEANSERS**

- **Betadine® 100 mg per 1 ml** Videne 10% antiseptic solution | 500 ml £5.43
- **Savlon Dry** (Novartis Consumer Health UK Ltd)
  - Povidone-iodine 11.4 mg per 1 gram Savlon Dry 1.14% spray | 50 ml NHS indicative price = £2.51
- **Impregnated dressing**
  - **BETADINE-IODINE (Non-proprietary)**
    - Povidone-iodine 100 mg per 1 gram Poviuluke dressing 9.5cm x 9.5cm | 1 dressing £0.42 | 10 dressing no price available
    - Poviuluke dressing 5cm x 5cm | 1 dressing £0.28 | 25 dressing no price available
  - **Inadine** (Syagenex Wound Management Ltd)
    - Povidone-iodine 100 mg per 1 gram Inadine dressing 5cm x 5cm | 1 dressing £0.49 | 10 dressing no price available

**SAVLON® DRY**

Skin disinfection

TO THE SKIN

- **Adult:** (consult product literature)

**TINCTURE**

Skin disinfection of minor wounds

TO THE SKIN

- **Adult:** (consult product literature)

**SPRAY**

- **Betadine® (J M Loveridge Ltd)
  - Povidone-iodine 25 mg per 1 gram Betadine 2.5% dry powder spray | 100 ml NHS indicative price = £3.05
- **Savlon Dry** (Novartis Consumer Health UK Ltd)
  - Povidone-iodine 11.4 mg per 1 gram Savlon Dry 1.14% spray | 50 ml NHS indicative price = £2.51

**VIDENE® (Ecolab Healthcare Division)**

- Povidone-iodine 75 mg per 1 ml Videne 7.5% surgical scrub solution | 500 ml £15.43
9.1 Minor cuts and abrasions

Minor cuts and abrasions

Many preparations traditionally used to manage minor burns, and abrasions have fallen out of favour. Preparations containing camphor and sulfonamides should be avoided. Preparations such as magnesium sulfate paste are now rarely used to treat carbuncles and boils as these are best treated with antibiotics.

Cetrimide is used to treat minor cuts and abrasions and prolavine p. 1052 may be used to treat infected wounds or burns, but its use has now been largely superseded by other antiseptics or suitable antibacterials. The effervescent effect of hydrogen peroxide p. 1052 is used to clean minor cuts and abrasions. When prepared extemporaneously, the BP states Cetrimide Cream 0.5% in a suitable water-miscible basis such as cetostearyl alcohol 5%, consists of liquid paraffin 50% in freshly boiled and cooled purified water.

Flexible collodion (see castor oil with collodion and colophony below) may be used to seal minor cuts and wounds that have partially healed; skin tissue adhesives are used similarly, and also for additional suture support.

Antiseptics and disinfectants

Cetrimide with chlorhexidine

The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine p. 1051.

**INDICATIONS AND DOSE**

Skin disinfecion such as wound cleansing and obstetrics

**TO THE SKIN**

- Adult: To be used undiluted
- Child: To be used undiluted

**MEDICINAL FORMS**

<table>
<thead>
<tr>
<th>Form</th>
<th>Trade Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid</td>
<td>Sterets Tisept</td>
<td>Molynex Health Care Ltd</td>
</tr>
<tr>
<td>Cream</td>
<td>CETRIMIDE WITH CHLORHEXIDINE (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Irrigation solution</td>
<td>CETRIMIDE WITH CHLORHEXIDINE (Non-proprietary)</td>
<td></td>
</tr>
</tbody>
</table>

**COLLODIANS**

Castor oil with collodion and colophony

**INDICATIONS AND DOSE**

Used to seal minor cuts and wounds that have partially healed

**TO THE SKIN**

- Child: (consult product literature)
- Adult: (consult product literature)

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if patient has an allergy to colophony in elastic adhesive plasters and tape.

- **PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Collodion, Flexible, BP consists of castor oil 2.5%, colophony 2.5% in a collodion basis, prepared by dissolving pyroxylin (10%) in a mixture of 3 volumes of ether and 1 volume of alcohol (90%).

**MAGNESIUM**

Glycerol with magnesium sulfate and phenol

**INDICATIONS AND DOSE**

Treatment of carbuncles and boils

**TO THE SKIN**

- Adult: To be applied under dressing

- **DIRECTIONS FOR ADMINISTRATION** Paste should be stirred before use.

- **MEDICINAL FORMS**

**Skin adhesives**

- **SKIN ADHESIVES**

  - Derma+Flex skin adhesive (Chenewe Ltd)
  - Dermabond ProPen skin adhesive (Ethicon Ltd)
  - Histaocryl L skin adhesive (B Braun Medical Ltd)
  - Indermil skin adhesive (Covidien (UK) Commercial Ltd)
  - LiquiBand flow control tissue adhesive (MedLogic Global Ltd)
  - LiquiBand tissue adhesive (MedLogic Global Ltd)

**Drug Tariff (Part IXa)**

- 25 ml - NHS indicative price = £5.36 - Drug Tariff (Part IXa)
- 5 ml - NHS indicative price = £10.08 - Drug Tariff (Part IXa)
- 2.5 gram - NHS indicative price = £6.72 - Drug Tariff (Part IXa)
- 5 gram - NHS indicative price = £6.61 - Drug Tariff (Part IXa)
- 50 gram - NHS indicative price = £6.50 - Drug Tariff (Part IXa)
10 Skin disfigurement

Camouflagers

Disfigurement of the skin can be very distressing to patients and may have a marked psychological effect. In skilled hands, or with experience, camouflages can be very effective in concealing scars and birthmarks. The depigmented patches in vitiligo are also very disfiguring and camouflage creams are of great cosmetic value.

Opaque cover foundation or cream is used to mask skin pigment abnormalities; careful application using a combination of dark- and light-coloured cover creams set with powder helps to minimise the appearance of skin deformities.

Borderline substances

The preparations marked ‘ACBS’ cannot be prescribed on the NHS for postoperative scars and other deformities except as adjunctive therapy in the relief of emotional disturbances due to disfiguring skin disease, such as vitiligo.

Camouflages

- **CAMOUFLAGES**
  - Covemark classic foundation (Derma UK Ltd)
  - 15 ml (ACBS) - NHS indicative price = £11.86 (22 shades)
  - Covemark finishing powder (Derma UK Ltd)
  - 25 gram (ACBS) - NHS indicative price = £11.86
  - Covemark removing cream (Camouflage Cosmetics Ltd)
  - 200 ml - No NHS indicative price available
  - Dermablend Dermasmooth Corrective Foundation (Vichy)
  - 30 ml - No NHS indicative price available (12 shades)
  - Dermacolor Creme Effectiv (Charles H Fox Ltd)
  - 50 ml - NHS indicative price = £5.48
  - Dermacolor body cover (Charles H Fox Ltd)
  - 75 ml - No NHS indicative price available (51 shades)
  - Dermacolor camouflage creme (Charles H Fox Ltd)
  - 25 ml (ACBS) - NHS indicative price = £10.52 (150 shades)
  - Dermacolor cleansing cream (Charles H Fox Ltd)
  - 75 gram - No NHS indicative price available
  - Dermacolor fixing powder (Charles H Fox Ltd)
  - 20 gram (ACBS) - NHS indicative price = £3.05 (8 shades)
  - Keromask finishing powder (Bellava Ltd)
  - 20 gram (ACBS) - NHS indicative price = £5.68 (28 shades)
  - Veil cleansing cream (Thomas Blake Cosmetic Creams Ltd)
  - 50 gram - NHS indicative price = £2.45/100 gram - NHS indicative price = £4.00
  - Veil cover cream (Thomas Blake Cosmetic Creams Ltd)
  - 19 gram (ACBS) - NHS indicative price = £22.42/gram (ACBS) - NHS indicative price = £33.57/gram (ACBS) - NHS indicative price = £42.10 (40 shades)
  - Veil finishing powder (Thomas Blake Cosmetic Creams Ltd)
  - 35 gram (ACBS) - NHS indicative price = £24.58 (2 shades)

11 Superficial soft-tissue injuries and superficial thrombophlebitis

Topical circulatory preparations

These preparations are used to improve circulation in conditions such as bruising, superficial thrombophlebitis, chilblains and varicose veins but are of little value. Chilblains are best managed by avoidance of exposure to cold; neither systemic nor topical vasodilator therapy is established as being effective.

12 Warts and calluses

Warts and calluses

Warts (verrucae) are caused by a human papillomavirus, which most frequently affects the hands, feet (plantar warts), and the anogenital region; treatment usually relies on local tissue destruction. Warts may regress on their own and treatment is required only if the warts are painful, unsightly, persistent, or cause distress.

Preparations of salicylic acid p. 1057, formaldehyde, glutaraldehyde or silver nitrate p. 1056 are available for purchase by the public; they are suitable for the removal of warts on hands and feet. Salicylic acid is a useful keratolytic which may be considered first-line; it is also suitable for the removal of corns and calluses. Preparations of salicylic acid in a collodion basis are available but some patients may develop an allergy to colophony in the formulation; collodion should be avoided in children allergic to elastic adhesive plaster. Cryotherapy causes pain, swelling, and blistering, and may be no more effective than topical salicylic acid in the treatment of warts.

Anogenital warts

The treatment of anogenital warts (condylomata acuminata) should be accompanied by screening for other sexually transmitted infections. Podophyllotoxin (the major active ingredient of podophyllum) may be used for soft, non-keratinised external anogenital warts. Patients with a limited number of external warts or keratinised lesions may be better treated with cryotherapy or other forms of physical ablation.

Imiquimod cream p. 1057 is licensed for the treatment of external anogenital warts; it may be used for both keratinised and non-keratinised lesions. It is also licensed for the treatment of superficial basal cell carcinoma and actinic keratosis.

Insine pranobex p. 550 is licensed for adjunctive treatment of genital warts but it has been superseded by more effective drugs.
## ALDEHYDES AND DERIVATIVES

### Formaldehyde

**INDICATIONS AND DOSE**

Warts, particularly plantar warts

**TO THE SKIN**
- **Child**: Apply twice daily
- **Adult**: Apply twice daily

**CAUTIONS**
- Impaired peripheral circulation - not suitable for application to anogenital region - not suitable for application to face - not suitable for application to large areas - patients with diabetes at risk of neuropathic ulcers - protect surrounding skin and avoid broken skin - significant peripheral neuropathy

**SIDE-EFFECTS**
- Skin irritation - skin ulceration (with high concentrations)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

- **Liquid**
  - **FORMALDEHYDE (Non-proprietary)**
    - Formaldehyde 40 mg per 1 ml Formaldehyde (Buffered) 4% solution | 1000 ml £3.56-£3.90

- **Gel**
  - **Veracur** (Typharm Ltd)
    - Formaldehyde 7.5 mg per 1 gram Veracur 0.75% gel | 15 gram £3.91 

### Glutaraldehyde

**INDICATIONS AND DOSE**

Warts, particularly plantar warts

**TO THE SKIN**
- **Child**: Apply twice daily
- **Adult**: Apply twice daily

**CAUTIONS**
- Not for application to anogenital areas - not for application to face - not for application to mucosa - protect surrounding skin

**SIDE-EFFECTS**
- Rash - skin irritation (discontinue if severe) - stains skin brown

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Paint**
  - **Glutarol** (Dermal Laboratories Ltd)
    - Glutaraldehyde 100 mg per 1 ml Glutarol 10% cutaneous solution | 10 ml £2.07 DT price + £2.07

### Podophyllotoxin

**INDICATIONS AND DOSE**

**CONDYLINE**

Condylomata acuminata affecting the penis or the female external genitalia

**TO THE SKIN**
- **Adult**: Apply twice daily for 3 consecutive days, treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses, direct medical supervision for lesions greater than 4 cm²

**WARTICON**

Condylomata acuminata affecting the penis or the female external genitalia

**TO THE SKIN**
- **Adult**: Apply twice daily for 3 consecutive days, treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses, direct medical supervision for lesions greater than 4 cm², maximum 50 single applications (‘loops’) per session (consult product literature)

**CAUTIONS**
- Avoid normal skin - avoid open wounds - keep away from face - very irritant to eyes

**SIDE-EFFECTS**
- Local irritation

**PREGNANCY**
- Avoid.

**BREAST FEEDING**
- Avoid.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Liquid**

**CAUTIONARY AND ADVISORY LABELS**

1. **Condylone** (Takeda UK Ltd)
   - Podophyllotoxin 5 mg per 1 ml Condylone 0.5% solution | 3.5 ml £14.49

2. **Warticon** (Stiefel Laboratories (UK) Ltd)
   - Podophyllotoxin 5 mg per 1 ml Warticon 0.5% solution | 3 ml £14.86

- **Cream**
  - **CONDYLINE** (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), sorbic acid
  - **Warticon** (Stiefel Laboratories (UK) Ltd)
    - Podophyllotoxin 1.5 mg per 1 gram Warticon 0.15% cream | 5 gram £17.83 DT price + £17.83

## CAUSTIC DRUGS

### Silver nitrate

**INDICATIONS AND DOSE**

Common warts

**TO THE SKIN**
- **Child**: Apply every 24 hours for up to 3 applications, apply moistened caustic pencil tip for 1–2 minutes. Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application
- **Adult**: Apply every 24 hours for up to 3 applications, apply moistened caustic pencil tip for 1–2 minutes. Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application

**Verrucas**

**TO THE SKIN**
- **Child**: Apply every 24 hours for up to 6 applications, apply moistened caustic pencil tip for 1–2 minutes. Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application
- **Adult**: Apply every 24 hours for up to 6 applications, apply moistened caustic pencil tip for 1–2 minutes.
Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application.

**Umbilical granulomas**

**TO THE SKIN**

- **Child:** Apply moistened caustic pencil tip (usually containing silver nitrate 40%) for 1–2 minutes, protect surrounding skin with soft paraffin.
- **Adult:** Apply moistened caustic pencil tip (usually containing silver nitrate 40%) for 1–2 minutes, protect surrounding skin with soft paraffin.

**CAUTIONS** Avoid broken skin • not suitable for application to ano-genital region • not suitable for application to face • not suitable for application to large areas • protect surrounding skin.

**SIDE-EFFECTS** Chemical burns on surrounding skin • stains skin.

**PATIENT AND CARER ADVICE** Patients should be advised that silver nitrate may stain fabric.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid stick.

- **Avoca (Bray Group Ltd)**
  - Silver nitrate 400 mg per 1 gram Avoca 40% silver nitrate pencil | 1 applicator £1.01.
  - Silver nitrate 750 mg per 1 gram Avoca 75% silver nitrate applicators | 100 applicator £43.73.
  - Avoca 5% silver nitrate applicators with thick handles | 50 applicator £42.49.
  - Silver nitrate 950 mg per 1 gram Avoca 95% silver nitrate applicators | 100 applicator £43.73.
  - Avoca 95% silver nitrate pencils | 1 applicator £1.96 DT price = £2.44 | 12 applicator £23.04.
  - Avoca wart and verruca treatment set | 1 applicator £2.44 DT price = £2.44 | 6 applicator £14.37.

**IMMUNE RESPONSE MODIFIERS**

**Imiquimod**

**INDICATIONS AND DOSE**

**ALDARA®**

**Warts (external genital and perianal)**

**TO THE SKIN**

- **Child:** Apply 3 times a week until lesions resolve (maximum 16 weeks), to be applied thinly at night.
- **Adult:** Apply daily for 5 nights of each week for 6 weeks, to be applied to lesion and 1 cm beyond it, assess response 12 weeks after completing treatment.

**Actinic keratosis**

**TO THE SKIN**

- **Adult:** Apply 3 times a week for 4 weeks, to be applied to lesion at night, assess response after a 4-week treatment-free interval; repeat 4-week course if lesions persist, maximum 2 courses.

**ZYCLARA®**

**Actinic keratosis**

**TO THE SKIN**

- **Adult:** Apply once daily for 2 weeks, to be applied at bedtime to lesion on face or balding scalp, repeat course after a 2-week treatment-free interval, assess response 8 weeks after second course; maximum 2 sachets per day.

**CAUTIONS** Autoimmune disease • avoid broken skin • avoid contact with eyes • avoid contact with lips • avoid contact

with nostrils • avoid open wounds • immunosuppressed patients • not suitable for internal genital warts • uncircumcised males (risk of phimosis or stricture of foreskin).

**SIDE-EFFECTS**

- **Common or very common** Burning sensation • erosion • erythema • excoriations • headache • influenza-like symptoms • itching • local reactions • myalgia • oedema • scabbing.
- **Uncommon** Alopecia • local ulceration.
- **Rare** Cutaneous lupus erythematosus-like effect • Stevens-Johnson syndrome.
- **Very rare** Dysuria.
- **Frequency not known** Permanent hyperpigmentation • permanent hypopigmentation.

**CONCEPTION AND CONTRACEPTION** May damage latex condoms and diaphragms.

**PREGNANCY** No evidence of teratogenicity or toxicity in animal studies; manufacturer advises caution.

**BREAST FEEDING** No information available.

**DIRECTIONS FOR ADMINISTRATION**

**ALDARA®**

**Important** Should be rubbed in and allowed to stay on the treated area for 6–12 hours for warts or for 8 hours for basal cell carcinoma and actinic keratosis, then washed off with mild soap and water (uncircumcised males treating warts under foreskin should wash the area daily).

The cream should be washed off before sexual contact.

**ZYCLARA®**

**Important** Should be rubbed in and allowed to stay on the treated area for 8 hours, then washed off with mild soap and water.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**CAUTIONARY AND ADVISORY LABELS**

**DIRECTIONS FOR ADMINISTRATION**

**ALDARA®**

**Important** Should be rubbed in and allowed to stay on the treated area for 6–10 hours for warts or for 8 hours for basal cell carcinoma and actinic keratosis, then washed off with mild soap and water (uncircumcised males treating warts under foreskin should wash the area daily). The cream should be washed off before sexual contact.

**ZYCLARA®**

**Important** Should be rubbed in and allowed to stay on the treated area for 8 hours, then washed off with mild soap and water.

**INDICATIONS AND DOSE**

**OCCULAS®**

**Common and plantar warts**

**TO THE LESION**

- **Child:** Apply daily, treatment may need to be continued for up to 3 months.

- **Adult:** Apply daily, treatment may need to be continued for up to 3 months.

**VERRUGON®**

**For plantar warts**

**TO THE LESION**

- **Child:** Apply daily, treatment may need to be continued for up to 3 months.

- **Adult:** Apply daily, treatment may need to be continued for up to 3 months.

**UNLICENSED USE** Not licensed for use in children under 2 years.

**CAUTIONS** Avoid broken skin • impaired peripheral circulation • not suitable for application to ano-genital.
Salicylic acid with lactic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, salicylic acid p. 1057.

**INDICATIONS AND DOSE**

**CUPLEX®**
- Plantar and mosaic warts | Corns | Calluses
  - TO THE LESION
  - Adult: Apply twice daily

**DUOFILM®**
- Plantar and mosaic warts
  - TO THE LESION
  - Adult: Apply daily

**SALATAC®**
- Warts | Verrucas | Corns | Calluses
  - TO THE LESION
  - Adult: Apply daily

**SALACTOL®**
- Warts (particularly plantar warts) | Verrucas | Corns | Calluses
  - TO THE LESION
  - Adult: Apply daily

**PRESCRIBING AND DISPENSING INFORMATION**

**CUPLEX® AND SALACTOL®**

Preparations of salicylic acid in a collodion basis are available but some patients may develop an allergy to colophony in the formulation.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, cream

**Gel**

- Lactic acid 40 mg per 1 gram, Salicylic acid 110 mg per 1 gram CUPLEX (Crawford Healthcare Ltd) Lactic acid 40 mg per 1 gram, Salicylic acid 120 mg per 1 gram CUPLEX Verruca gel | 5 gram (£3.98) DT price = £2.88
- Salatac (Dermal Laboratories Ltd) Lactic acid 40 mg per 1 gram, Salicylic acid 120 mg per 1 gram Salatac gel | 8 gram (£2.98) DT price = £2.98
- Brands may include Bazuka gel

**Paint**

- LACTIC ACID WITH SALICYLIC ACID (Non-proprietary)
  - Lactic acid 167 mg per 1 gram, Salicylic acid 167 mg per 1 gram GEL (Optima Consumer Health Ltd) Lactic acid 40 mg per 1 gram, Salicylic acid 110 mg per 1 gram Bazuka Extra Strength (Dendron Ltd) Lactic acid 40 mg per 1 gram, Salicylic acid 120 mg per 1 gram Bazuka Extra Strength 26% gel | 5 gram (£3.95) DT price = £3.95
- Brands may include Pickles 50% ointment, Wartex 50% ointment

**Preparations of Salicylic acid with Lactic acid**

- brands may include Scholl Corn Removal

**EXCIPIENTS:** May contain Colophony

- Bazuka Extra Strength (Dendron Ltd) Lactic acid 40 mg per 1 gram, Salicylic acid 110 mg per 1 gram Bazuka Extra Strength 26% gel | 5 gram (£3.95) DT price = £3.95

**Medicated plaster**

- LACTIC ACID (Non-proprietary)
  - Salicylic acid 400 mg per 1 gram 30 plaster (£3.91)
- Brands may include Scholl Corn Removal

**Side-effects**

Skin irritation • skin ulceration (with high concentrations)

**Patient and carer advice**

Advise patient to apply carefully to wart and to protect surrounding skin (e.g. with soft paraffin or specially designed plaster); rub wart surface gently with file or pumice stone once weekly.
Chapter 14
Vaccines

CONTENTS

1 Immunoglobulin therapy page 1059
2 Post-exposure prophylaxis 1065
3 Tuberculosis diagnostic test page 1066
4 Vaccination 1066

1 Immunoglobulin therapy

Immunoglobulins

Passive immunity
Immunology with immediate protection against certain infectious organisms can be obtained by injecting preparations made from the plasma of immune individuals with adequate levels of antibody to the disease for which protection is sought. The duration of this passive immunity varies according to the dose and the type of immunoglobulin. Passive immunity may last only a few weeks; when necessary, passive immunisation can be repeated. Antibodies of human origin are usually termed immunoglobulins. The term antiserum is applied to material prepared in animals. Because of serum sickness and other allergic-type reactions that may follow injections of antiserum, this therapy has been replaced wherever possible by the use of immunoglobulins. Reactions are theoretically possible after injection of human immunoglobulins but reports of such reactions are very rare.

Two types of human immunoglobulin preparation are available, normal immunoglobulin p. 1063 and disease-specific immunoglobulins.

Human immunoglobulin is a sterile preparation of concentrated antibodies (immune globulins) recovered from pooled human plasma or serum obtained from outside the UK, tested and found non-reactive for hepatitis B surface antigen and for antibodies against hepatitis C virus and human immunodeficiency virus (types 1 and 2). A global shortage of human immunoglobulin and the rapidly increasing range of clinical indications for treatment with immunoglobulins has resulted in the need for a Demand Management programme in the UK, for further information consult www.ivig.nhs.uk and Clinical Guidelines for Immunoglobulin Use, www.gov.uk/dh.

Further information on the use of immunoglobulins is included in Public Health England’s Immunoglobulin Handbook www.gov.uk/phe, and in the Department of Health’s publication, Immunisation against Infectious Disease, www.gov.uk/dh.

Availability
Normal immunoglobulin for intramuscular administration is available from some regional Public Health laboratories for protection of contacts and the control of outbreaks of hepatitis A, measles, and rubella only. For other indications, subcutaneous or intravenous normal immunoglobulin should be purchased from the manufacturer.

Disease-specific immunoglobulins are available from some regional Public Health laboratories, with the exception of tetanus immunoglobulin p. 1065 which is available from BPL, hospital pharmacies, or blood transfusion departments. Rabies immunoglobulin p. 1064 is available from the Specialist and Reference Microbiology Division, Public Health England, Colindale. Hepatitis B immunoglobulin p. 1062 required by transplant centres should be obtained commercially.

In Scotland all immunoglobulins are available from the Scottish National Blood Transfusion Service (SNBTS).

In Wales all immunoglobulins are available from the Welsh Blood Service (WBS).

In Northern Ireland all immunoglobulins are available from the Northern Ireland Blood Transfusion Service (NIIBTS).

Normal immunoglobulin
Human normal immunoglobulin p. 1063 (‘HNIG’) is prepared from pools of at least 1000 donations of human plasma; it contains immunoglobulin G (IgG) and antibodies to hepatitis A, measles, mumps, rubella, varicella, and other viruses that are currently prevalent in the general population.

Uses
Normal immunoglobulin p. 1063 (containing 10%–18% protein) is administered by intramuscular injection for the protection of susceptible contacts against hepatitis A virus (infectious hepatitis), measles and, to a lesser extent, rubella. Injection of immunoglobulin produces immediate protection lasting several weeks.

Normal immunoglobulin p. 1063 (containing 3%–12% protein) for intravenous administration is used as replacement therapy for patients with congenital agammaglobulinaemia and hypogammaglobulinaemia, and for the short-term treatment of idiopathic thrombocytopenic purpura and Kawasaki disease; it is also used for the prophylaxis of infection following bone-marrow transplantation and in children with symptomatic HIV infection who have recurrent bacterial infections. Normal immunoglobulin for replacement therapy may also be given intramuscularly or subcutaneously, but intravenous formulations are normally preferred. Intravenous immunoglobulin is also used in the treatment of Guillain-Barré syndrome as an alternative to plasma exchange.

For guidance on the use of intravenous normal immunoglobulin and alternative therapies for certain conditions, consult Clinical Guidelines for Immunoglobulin Use (www.gov.uk/dh).

Hepatitis A
Hepatitis A vaccine p. 1081 is preferred for individuals at risk of infection including those visiting areas where the disease is highly endemic (all countries excluding Northern and Western Europe, North America, Japan, Australia, and New Zealand). In unimmunised individuals, transmission of hepatitis A is reduced by good hygiene. Intramuscular normal immunoglobulin p. 1063 is no longer recommended for routine prophylaxis in travellers, but it may be indicated for immunocompromised patients if their antibody response to the vaccine is unlikely to be adequate.

Intramuscular normal immunoglobulin is recommended for prevention of infection in close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV
infection, or who are immunosuppressed or over 50 years of age; normal immunoglobulin should be given as soon as possible, preferably within 14 days of exposure to the primary case. However, normal immunoglobulin can still be given to contacts at risk of severe disease up to 28 days after exposure to the primary case. Hepatitis A vaccine p. 1081 can be given at the same time, but it should be given at a separate injection site.

Measles
Intravenous or subcutaneous normal immunoglobulin p. 1063 may be given to prevent or attenuate an attack of measles in individuals who do not have adequate immunity. Patients with compromised immunity who have come into contact with measles should receive intravenous or subcutaneous normal immunoglobulin as soon as possible after exposure. It is most effective if given within 72 hours but can be effective if given within 6 days.

Subcutaneous or intramuscular normal immunoglobulin should also be considered for the following individuals if they have been in contact with a confirmed case of measles or with a person associated with a local outbreak:
- non-immune pregnant women
- infants under 9 months

Further advice should be sought from the Centre for Infections, Public Health England (tel. (020) 8200 6868). Individuals with normal immunity who are not in the above categories and who have not been fully immunised against measles, can be given measles, mumps and rubella vaccine, live p. 1087 for prophylaxis following exposure to measles.

Rubella
Intramuscular immunoglobulin after exposure to rubella does not prevent infection in non-immune contacts and is not recommended for protection of pregnant women exposed to rubella. It may, however, reduce the likelihood of a clinical attack which may possibly reduce the risk to the fetus. Risk of intra-uterine transmission is greatest in the first 11 weeks of pregnancy, between 16 and 20 weeks there is minimal risk of deafness only, after 20 weeks there is no increased risk. Intramuscular normal immunoglobulin p. 1063 should be used only if termination of pregnancy would be unacceptable to the pregnant woman—it should be given as soon as possible after exposure. Serological follow-up of recipients is essential to determine if the woman has become infected despite receiving immunoglobulin.

Rubella vaccine p. 1090 should also be given intramuscularly at a different site (for details see rubies vaccine). If there is delay in giving the rubies immunoglobulin p. 1064, it should be given within 7 days of starting the course of rubies vaccine.

Tetanus immunoglobulin
For the management of tetanus-prone wounds, tetanus immunoglobulin p. 1065 should be used in addition to wound cleansing and, where appropriate, antibacterial prophylaxis and a tetanus-containing vaccine. Tetanus immunoglobulin, together with metronidazole p. 1008 and wound cleansing, should also be used for the treatment of established cases of tetanus.

Varicella-zoster immunoglobulin
Varicella-zoster immunoglobulin p. 1065 (VZIG) is recommended for individuals who are at increased risk of severe varicella and who have no antibodies to varicella–zoster virus and who have significant exposure to chickenpox or herpes zoster. Those at increased risk include:
- neonates whose mothers develop chickenpox in the period 7 days before to 7 days after delivery;
- susceptible neonates exposed in the first 7 days of life;
- susceptible neonates or infants exposed whilst requiring intensive or prolonged special care nursing;
- susceptible women exposed at any stage of pregnancy (but when supplies of VZIG are short, may only be issued to those exposed in the first 20 weeks’ gestation or to those near term) providing VZIG is given within 10 days of contact;
- immunocompromised individuals including those who have received corticosteroids in the previous 3 months at the following dose equivalents of prednisolone: children 2 mg/kg daily for at least 1 week or 1 mg/kg daily for 1 month; adults about 40 mg daily for more than 1 week.

Important: for full details consult Immunisation against Infectious Disease. Varicella-zoster vaccine p. 1092 is available.

Anti-D (Rh0) immunoglobulin
Anti-D (Rh0) immunoglobulin p. 1061 is prepared from plasma taken from rhesus-negative donors who have been immunised against the anti-D-antigen. Anti-D (Rh0) immunoglobulin is used to prevent a rhesus-negative mother from forming antibodies to fetal rhesus-positive cells which may pass into the maternal circulation. The objective is to protect any subsequent child from the hazard of haemolytic disease of the newborn.

Anti-D (Rh0) immunoglobulin p. 1061 should be administered to the mother following any sensitising episode (e.g. abortion, miscarriage and birth); it should be injected within 72 hours of the episode but even if a longer period has elapsed it may still give protection and should be administered. Anti-D (Rh0) immunoglobulin p. 1061 is also given when significant fetal-maternal haemorrhage occurs in rhesus-negative women during delivery. The dose of anti-
D (Rh<sub>D</sub>) immunoglobulin below is determined according to the level of exposure to rhesus-positive blood.

Use of routine antenatal anti-D prophylaxis should be given irrespective of previous anti-D prophylaxis for a sensitising event early in the same pregnancy. Similarly, postpartum anti-D prophylaxis should be given irrespective of previous routine antenatal anti-D prophylaxis or antenatal anti-D prophylaxis for a sensitising event in the same pregnancy.

Anti-D (Rh<sub>D</sub>) immunoglobulin below is also given to women of child-bearing potential after the inadvertent transfusion of rhesus-incompatible blood components and is used for the treatment of idiopathic thrombocytopenia purpura.

**MMR vaccine**

Measles, mumps and rubella vaccine, live p. 1087 may be given in the postpartum period with anti-D (Rh<sub>D</sub>) immunoglobulin below injection provided that separate syringes are used and the products are administered into different limbs. If blood is transfused, the antibody response to the vaccine may be inhibited—measure rubella antibodies after 6–8 weeks and revaccinate if necessary.

**IMMUNOGLOBULINS**

**Anti-D (Rh<sub>D</sub>) immunoglobulin**

**INDICATIONS AND DOSE**

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, following birth of rhesus-positive infant

**BY DEEP INTRAMUSCULAR INJECTION**

- Females of childbearing potential: 500 units, dose to be administered immediately or within 72 hours; for transplacental bleed of over 4 mL fetal red cells, extra 100–125 units per mL fetal red cells, subcutaneous route used for patients with bleeding disorders

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) up to 20 weeks’ gestation

**BY DEEP INTRAMUSCULAR INJECTION**

- Females of childbearing potential: 250 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) after 20 weeks’ gestation

**BY DEEP INTRAMUSCULAR INJECTION**

- Females of childbearing potential: 500 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, antenatal prophylaxis

**BY DEEP INTRAMUSCULAR INJECTION**

- Females of childbearing potential: 500 units per episode, dose to be given at weeks 28 and 34 of pregnancy, a further dose is still needed immediately or within 72 hours of delivery, subcutaneous route used for patients with bleeding disorders

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, antenatal prophylaxis (alternative NICE recommendation)

**BY DEEP INTRAMUSCULAR INJECTION**

- Females of childbearing potential: 1000–1650 units, dose to be given at weeks 28 and 34 of pregnancy,

alternatively 1500 units for 1 dose, dose to be given between 28 and 34 weeks gestation

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, following Rh<sub>D</sub>(D) incompatible blood transfusion

**BY DEEP INTRAMUSCULAR INJECTION**

- Females of childbearing potential: 100–125 units/mL, dose per mL transfused rhesus-positive red cells given, subcutaneous route used for patients with bleeding disorders

**RHOPHYLAC®**

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, following birth of rhesus-positive infant

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**

- Females of childbearing potential: 1000 units per episode, dose to be administered immediately or within 72 hours, intravenous route recommended for patients with bleeding disorders, higher doses may be required after 12 weeks gestation

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, following any potentially sensitising episode (e.g. abortion, amniocentesis, chorionic villous sampling) up to 12 weeks’ gestation

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**

- Females of childbearing potential: 1500 units, dose to be given between weeks 28–30 of pregnancy; if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, intravenous route recommended for patients with bleeding disorders

To rhesus-negative woman for prevention of Rh<sub>D</sub>(D) sensitisation, following Rh<sub>D</sub>(D) incompatible blood transfusion

**BY INTRAVENOUS INJECTION**

- Females of childbearing potential: 50 units/mL, dose per mL of transfused rhesus-positive blood, alternatively 100 units/mL, dose per mL of erythrocyte concentrate, intravenous route recommended for patients with bleeding disorders

**CONTRA-INDICATIONS** Treatment of idiopathic thrombocytopenia purpura in rhesus negative patients · treatment of idiopathic thrombocytopenia purpura in splenectomised patients

**CAUTIONS** Immunoglobulin A deficiency · possible interference with live virus vaccines

**CAUTIONS, FURTHER INFORMATION**

MMR vaccine may be given in the postpartum period with anti-D (Rh<sub>D</sub>) immunoglobulin injection provided that separate syringes are used and the products are administered into different limbs. If blood is transfused, the antibody response to the vaccine may be inhibited—measure rubella antibodies after 6–8 weeks and revaccinate if necessary.

**INTERACTIONS** → Appendix 1 (immunoglobulins).

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Rare Anaphylaxis · dyspnoea · hypotension · tachycardia · urticaria
- Frequency not known Abdominal pain · arthralgia · asthenia · back pain · diarrhoea · dizziness · drowsiness ·
MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- D-Gam (Bio-Products Laboratory Ltd)
  - Anti-D (RHO) immunoglobulin 250 unit: 1 vial £23.75
  - Anti-D (RHO) immunoglobulin 500 unit: 1 vial £33.75
  - Anti-D (RHO) immunoglobulin 1500 unit: 1 vial £58.00
- Rhophylac (CSL Behring UK Ltd)
  - Anti-D (RHO) immunoglobulin 750 unit per 1 ml: 1 vial £39.52

**Hepatitis B immunoglobulin**

**INDICATIONS AND DOSE**

Prophylaxis against hepatitis B infection
BY INTRAMUSCULAR INJECTION
- Adult: 500 units, dose to be administered as soon as possible after exposure; ideally within 12–48 hours, but no later than 7 days after exposure

Prophylaxis against hepatitis B infection, after exposure to hepatitis B virus–contaminated material
BY INTRAVENOUS INFUSION
- Adult: Dose to be administered as soon as possible after exposure, but no later than 72 hours (consult product literature)

Prevention of hepatitis B in haemodialysed patients
BY INTRAVENOUS INFUSION
- Adult: (consult product literature)

Prophylaxis against re-infection of transplanted liver
BY INTRAVENOUS INFUSION
- Adult: (consult product literature)

**PREVENTION OF HEPATITIS B RE-INFECTION MORE THAN 6 MONTHS AFTER LIVER TRANSPLANTATION IN STABLE HBV–DNA NEGATIVE PATIENTS**

**BY SUBCUTANEOUS INJECTION**
- Adult (body-weight up to 75 kg): 500 units once weekly, increased if necessary up to 1000 units once weekly, dose to be started 2–3 weeks after last dose of intravenous hepatitis B immunoglobulin
- Adult (body-weight 75 kg and above): 1000 units once weekly, dose to be started 2–3 weeks after last dose of intravenous hepatitis B immunoglobulin

**CAUTIONS**
- IgA deficiency
- Interference with live virus vaccines

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Common or very common
  - Injection site reactions
- Uncommon
  - Abdominal pain
  - Anaphylaxis
  - Arthralgia
  - Buccal ulceration
  - Chest pain
  - Dizziness
  - Dyspnoea
  - Glossitis
  - Headache
  - Tremor

**SPECIFIC SIDE-EFFECTS**
- With intravenous use
  - Abdominal distension
  - Abdominal pain
  - Blood pressure fluctuations
  - Deep vein thrombosis
  - Haemolytic anaemia
  - Injection site reactions
  - Myocardial infarction
  - Pulmonary embolism
  - Stroke
  - Thromboembolic events

**PREScribing and dispensing information**
Vials containing 200 units or 500 units (for intramuscular injection), available from selected Public Health England and NHS laboratories (except for Transplant Centres), also available from BPL.

**HANDLING AND STORAGE**
Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Hepatitis B immunoglobulin human 200 unit: 1 vial £122.44
- Hepatitis B immunoglobulin human 500 unit: 1 vial £66.33
- Zulectra (Biotest (UK) Ltd)
  - Zulectra 500 units: 1 ml solution for injection pre-filled syringes: 5 syringe (PCT) no price available

**Solution for infusion**
- Hepact CP (Biotest (UK) Ltd)
  - Hepact B immunoglobulin human 50 unit per 1 ml: 1 vial (PCT) no price available
  - Hepact CP 100 units/2 ml solution for infusion vials: 1 vial (PCT) no price available
  - Hepact CP 200 units/40 ml solution for infusion vials: 1 vial (PCT) no price available
  - Hepact CP 500 units/10 ml solution for infusion vials: 1 vial (PCT) no price available
  - Hepact CP 5000 units/100 ml solution for infusion vials: 1 vial (PCT) no price available
Normal immunoglobulin

INDICATIONS AND DOSE

To control outbreaks of hepatitis A
BY DEEP INTRAMUSCULAR INJECTION
▶ Adult: 500 mg
Rubella in pregnancy, prevention of clinical attack
BY DEEP INTRAMUSCULAR INJECTION
▶ Females of childbearing potential: 750 mg
Antibody deficiency syndromes
BY SUBCUTANEOUS INFUSION
▶ Adult: (consult product literature)

Subgam®
Hepatitis A prophylaxis in outbreaks
BY INTRAMUSCULAR INJECTION
▶ Adult: 750 mg

UNLICENSED USE
Subgam® is not licensed for prophylactic use, but due to difficulty in obtaining suitable immunoglobulin products, Public Health England recommends intramuscular use for prophylaxis against hepatitis A or rubella.

CONTRA-INDICATIONS
Patients with selective IgA deficiency who have known antibody against IgA

FLEBOGAMMA® DIF SOLUTION FOR INFUSION
Hereditary fructose intolerance (contains sorbitol)

GAMMAPLEX® SOLUTION FOR INFUSION
Hereditary fructose intolerance (contains sorbitol)

HIZENTRA® SOLUTION FOR INFUSION
Hyperprolinaemia (contains L-proline)

PRIVIGEN® SOLUTION FOR INFUSION
Hyperprolinaemia (contains L-proline)

CAUTIONS

GENERAL CAUTIONS
Agammaglobulinaemia with or without IgA deficiency - hypogammaglobulinaemia with or without IgA deficiency - interference with live virus vaccines

SPECIFIC CAUTIONS
With intravenous use ensure adequate hydration - obesity - renal insufficiency - risk factors for arterial thromboembolic events - risk factors for venous thromboembolic events - thrombophilic disorders

OCTAGAM® SOLUTION FOR INFUSION
Falsely elevated results with blood glucose testing systems (contains maltose)

CAUTIONS, FURTHER INFORMATION
Interference with live virus vaccines Normal immunoglobulin may interfere with the immune response to live virus vaccines which should therefore only be given at least 3 weeks before or 3 months after an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).

INTERACTIONS
▶ Appendix 1 (immunoglobulins).

SIDE-EFFECTS

GENERAL SIDE-EFFECTS
▶ Rare Acute renal failure - anaphylaxis - aseptic meningitis - cutaneous skin reactions - hypotension
▶ Frequency not known Arthralgia - chills - diarrhoea - dizziness - fever - headache - low back pain - muscle spasms - myalgia - nausea

SPECIFIC SIDE-EFFECTS
▶ With intravenous use abdominal distension - abdominal pain - blood pressure fluctuations - deep vein thrombosis - haemolytic anaemia - injection site reactions - myocardial infarction - pulmonary embolism - stroke - thromboembolic events

SIDE-EFFECTS, FURTHER INFORMATION
Adverse reactions are more likely to occur in patients receiving normal immunoglobulin for the first time, or following a prolonged period between treatments, or when a different brand of normal immunoglobulin is administered.

MONITORING REQUIREMENTS
Monitor for acute renal failure; consider discontinuation if renal function deteriorates. Intravenous preparations with added sucrose have been associated with cases of renal dysfunction and acute renal failure.

DIRECTIONS FOR ADMINISTRATION
Preparations for subcutaneous use may be administered by intramuscular injection if subcutaneous route not possible; intramuscular route not for patients with thrombocytothrombocytopenia or other bleeding disorders.

For intravenous use

KIOVIG® SOLUTION FOR INFUSION
Use Glucose 5% intravenous infusion if dilution prior to infusion is required.

GAMUNEX® SOLUTION FOR INFUSION
Use Glucose 5% intravenous infusion if dilution prior to infusion is required.

PRESCRIBING AND DISPENSING INFORMATION
Antibody titres can vary widely between normal immunoglobulin preparations from different manufacturers—formulations are not interchangeable; patients should be maintained on the same formulation throughout long-term treatment to avoid adverse effects.

With intramuscular use Available from the Centre for Infections and other regional Public Health England offices (for contacts and control of outbreaks only).

HANDLING AND STORAGE
Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

ELECTROLYTES: May contain Sodium
▶ Gammanorm (Octapharma Ltd)
Normal immunoglobulin human 165 mg per 1 ml Gammanorm 3.3g/20ml solution for injection vials | 1 vial (P) £133.55 Gammanorm 1.65g/10ml solution for injection vials | 1 vial (P) £96.77
▶ Subcuvia (Baxter Healthcare Ltd)
Normal immunoglobulin human 160 mg per 1 ml Subcuvia 800mg/5ml solution for injection vials | 1 vial (P) no price available Subcuvia 1.6g/10ml solution for injection vials | 1 vial (P) no price available
▶ Subgam (Bio Products Laboratory Ltd)
Normal immunoglobulin human 150 mg per 1 ml Subgam 750mg/5ml solution for injection vials | 1 vial (P) £34.20 Subgam 1.5g/10ml solution for injection vials | 1 vial (P) £68.40

Powder and solvent for solution for injection
▶ Gammagard S/D (Baxter Healthcare Ltd)
Normal immunoglobulin human 5 gram Gammagard S/D 5g powder and solvent for solution for injection bottles | 1 bottle (P) no price available Normal immunoglobulin human 10 gram Gammagard S/D 10g powder and solvent for solution for injection bottles | 1 bottle (P) no price available
Solution for infusion

**EXCipients:** May contain Glucose, maltose, sorbitol, sucrose

> **NORMAL IMMUNOGLOBULIN (Non-proprietary)**
> Normal immunoglobulin human 100 mg per 1 ml
> Normal immunoglobulin human 5g/50ml solution for infusion vials | 1 vial (PMP) no price available
> Normal immunoglobulin human 2.5g/25ml solution for infusion vials | 1 vial (PMP) no price available
> Normal immunoglobulin human 20g/200ml solution for infusion vials | 1 vial (PMP) no price available
> Normal immunoglobulin human 10g/100ml solution for infusion vials | 1 vial (PMP) no price available
> Normal immunoglobulin human 5g/50ml solution for infusion vials | 1 vial (PMP) no price available

> **Aracam** (Oxfordbridge Pharma Ltd)
> Normal immunoglobulin human 50 mg per 1 ml
> Aracam 5g/100ml solution for infusion vials | 1 vial (PMP) no price available
> Aracam 2.5g/50ml solution for infusion vials | 1 vial (PMP) no price available

> **Flebogammad** (Grifols UK Ltd)
> Normal immunoglobulin human 50 mg per 1 ml
> Flebogammad DIF 10g/200ml solution for infusion vials | 1 vial (PMP) £110.00
> Flebogammad DIF 2.5g/50ml solution for infusion vials | 1 vial (PMP) £25.00
> Flebogammad DIF 5g/100ml solution for infusion vials | 1 vial (PMP) £25.00
> Flebogammad DIF 5g/100ml solution for infusion vials | 1 vial (PMP) £110.00
> Flebogammad DIF 20g/400ml solution for infusion vials | 1 vial (PMP) £1,020.00

> **Gammaplex** (Bio Products Laboratory Ltd)
> Normal immunoglobulin human 50 mg per 1 ml
> Gammaplex 10g/200ml solution for infusion vials | 1 vial (PMP) £200.00 (Hospital only)
> Gammaplex 5g/50ml solution for infusion vials | 1 vial (PMP) £51.00
> Gammaplex 2.5g/50ml solution for infusion vials | 1 vial (PMP) £51.00

> **Gamunex** (Grifols UK Ltd)
> Normal immunoglobulin human 100 mg per 1 ml
> Gamunex 10g/100mg solution for infusion vials | 1 vial (PMP) £42.50
> Gamunex 10g/100mg solution for infusion vials | 1 vial (PMP) £42.50
> Gamunex 20g/200mg solution for infusion vials | 1 vial (PMP) £85.00
> Gamunex 10g/50mg solution for infusion vials | 1 vial (PMP) £212.50

> **Hizentra** (CSL Behring UK Ltd)
> Normal immunoglobulin human 200 mg per 1 ml
> Hizentra 2g/10ml solution for infusion vials | 1 vial (PMP) £91.80
> Hizentra 1g/5ml solution for infusion vials | 1 vial (PMP) £45.90
> Hizentra 4g/20ml solution for infusion vials | 1 vial (PMP) £183.60

> **Intratec** (Bioident UK Ltd)
> Normal immunoglobulin human 50 mg per 1 ml
> Intratec 5g/100ml solution for infusion vials | 1 vial (PMP) £225.00
> Intratec 1g/20ml solution for infusion vials | 1 vial (PMP) £45.00
> Intratec 2.5g/50ml solution for infusion vials | 1 vial (PMP) £112.50
> Intratec 10g/200ml solution for infusion vials | 1 vial (PMP) £450.00

> **Privigen** (CSL Behring UK Ltd)
> Normal immunoglobulin human 100 mg per 1 ml
> Privigen 5g/50ml solution for infusion vials | 1 vial (PMP) £329.50
> Privigen 20g/200ml solution for infusion vials | 1 vial (PMP) £198.00
> Privigen 10g/100ml solution for infusion vials | 1 vial (PMP) £459.00
> Privigen 2.5g/50ml solution for infusion vials | 1 vial (PMP) £114.75
> Privigen 10g/200ml solution for infusion vials | 1 vial (PMP) £117.70 (Hospital only)

**Indications and Dose**

Post-exposure prophylaxis against rabies infection by local infiltration or by intramuscular injection

- **Child:** 20 units/kg, dose administered by infiltration in and around the cleansed wound; if the wound not visible or healed or if infiltration of whole volume not possible, give remainders by intramuscular injection into anterolateral thigh (remote from vaccination site)

- **Adult:** 20 units/kg, dose administered by infiltration in and around the cleansed wound; if the wound not visible or healed or if infiltration of whole volume not possible, give remainders by intramuscular injection into anterolateral thigh (remote from vaccination site)

**Caution**

IgA deficiency - interference with live virus vaccines

**Side-effects**

- Rare: Anaphylaxis - arthralgia - buccal ulceration - chest tightness - dizziness - dyspnoea - glossitis - tremor

**Frequency not known**

Facial oedema - injection site pain - injection site swelling

**Prescribing and dispensing information**

The potency of individual batches of rabies immunoglobulin from the manufacturer may vary; potency may also be described differently by different manufacturers. It is therefore critical to know the potency of the batch to be used and the weight of the patient in order to calculate the specific volume required to provide the necessary dose. Available from Specialist and Reference Microbiology Division, Public Health England (also from BPL).

**Handling and storage**

Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.
Solution for injection

➤ RABIES IMMUNOGLOBULIN (Non-proprietary)
Rabies immunoglobulin human 500 unit Rabies immunoglobulin human 500 unit solution for injection vials | 1 vial £412.13

Tetanus immunoglobulin

INDICATIONS AND DOSE
Post-exposure prophylaxis
BY INTRAMUSCULAR INJECTION
➤ Child: Initially 250 units, then increased to 500 units, dose is only increased if more than 24 hours have elapsed or there is risk of heavy contamination or following burns
➤ Adult: Initially 250 units, then increased to 500 units, dose is only increased if more than 24 hours have elapsed or there is risk of heavy contamination or following burns

Treatment of tetanus infection
BY INTRAMUSCULAR INJECTION
➤ Child: 150 units/kg, dose may be given over multiple sites
➤ Adult: 150 units/kg, dose may be given over multiple sites

• CAUTIONS IgA deficiency • interference with live virus vaccines
• SIDE-EFFECTS
  ➤ Rare Anaphylaxis • arthralgia • buccal ulceration • chest tightness • dizziness • dyspnoea • glossitis • tremor
  ➤ Frequency not known Facial oedema • injection site swelling • pain at injection site
• HANDLING AND STORAGE Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

• MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
➤ TETANUS IMMUNOGLOBULIN (Non-proprietary)
Tetanus immunoglobulin human 250 unit Tetanus immunoglobulin human 250 unit solution for injection vials | 1 vial £45.00

Varicella-zoster immunoglobulin
(Varicella-zoster Immunoglobulin)

INDICATIONS AND DOSE
Prophylaxis against varicella infection
BY DEEP INTRAMUSCULAR INJECTION
➤ Adult: 1 g, to be administered as soon as possible—not later than 10 days after exposure, second dose to be given if further exposure occurs more than 3 weeks after first dose, no evidence that effective in severe disease

• CAUTIONS IgA deficiency • interference with live virus vaccines
• SIDE-EFFECTS
  ➤ Rare Anaphylaxis
  ➤ Frequency not known Injection site pain • injection site swelling

Post-exposure prophylaxis

ANTITOXINS

Botulinum antitoxin

• DRUG ACTION A preparation containing the specific antitoxin globulins that have the power of neutralising the toxins formed by types A, B, and E of Clostridium botulinum.

INDICATIONS AND DOSE
Post exposure prophylaxis of botulism
BY INTRAMUSCULAR INJECTION
➤ Adult: (consult product literature)

• SIDE-EFFECTS
  ➤ Hypersensitivity reactions
• SIDE-EFFECTS, FURTHER INFORMATION
  ➤ Hypersensitivity reactions It is essential to read the contra-indications, warnings, and details of sensitivity tests on the package insert. Prior to treatment checks should be made regarding previous administration of any antitoxin and history of any allergic condition, e.g. asthma, hay fever, etc.

• PRE-TREATMENT SCREENING All patients should be tested for sensitivity (diluting the antitoxin if history of allergy).

• PRESCRIBING AND DISPensing INFORMATION
Available from selected Public Health England and NHS laboratories (also from BPL).

Solution for infusion
➤ BOTULISM ANTITOXIN (Non-proprietary)
Botulinum antitoxin type A 750 unit per 1 ml Botulinum antitoxin type A 750 unit solution for injection vials | 1 ml £50.00

Botulinum antitoxin type B 500 unit per 1 ml Botulinum antitoxin type B 500 unit solution for injection vials | 1 ml £50.00

2 Post-exposure prophylaxis

There can be variation in the licensing of different medicines containing the same drug.
Diphtheria antitoxin  
(Dip/Ser)

**INDICATIONS AND DOSE**
Passive immunisation in suspected cases of diphtheria

**BY INTRAVENOUS INFUSION**
- Adult: Dose should be given without waiting for bacteriological confirmation (consult product literature)

**SIDE-EFFECTS**
- Common or very common: Hypersensitivity reactions

**CAUTIONS**
Hypersensitivity
- Dose should be given without waiting for bacteriological confirmation (consult product literature)

**PRE-TREATMENT SCREENING**
Diphtheria antitoxin is derived from horse serum and reactions are common; tests for hypersensitivity should be carried out before use.

**PRESCRIBING AND DISPENSING INFORMATION**
Available from Centre for Infections (Tel (020) 8200 6868) or in Northern Ireland from Public Health Laboratory, Belfast City Hospital (Tel (028) 9032 9241).

---

### 3 Tuberculosis diagnostic test

#### DIAGNOSTICS

**Tuberculin purified protein derivative** (Tuberculin PPD)

**INDICATIONS AND DOSE**

**Mantoux test**  
**BY INTRADERMAL INJECTION**
- Child: 2 units for one dose  
- Adult: 2 units for one dose

**Mantoux test (if first test is negative and a further test is considered appropriate)**

**Dose equivalence and conversion**
2 units is equivalent to 0.1 mL of 20 units/mL strength. 10 units is equivalent to 0.1 mL of 100 units/mL strength.

**CAUTIONS**
Mantoux test
- Response to tuberculin may be suppressed by live viral vaccines, viral infection, sarcoidosis, corticosteroid therapy, or immunosuppression due to disease or treatment. Tuberculin testing should not be carried out within 4 weeks of receiving a live viral vaccine.

**PRESCRIBING AND DISPENSING INFORMATION**
Available from ImmForm (SSI brand). The strength of tuberculin PPD in currently available products may be different to the strengths of products used previously for the Mantoux test; care is required to select the correct strength.

---

### 4 Vaccination

#### Vaccines

**Active immunity**
Active immunity can be acquired by natural disease or by vaccination. Vaccines stimulate production of antibodies and other components of the immune mechanism; they consist of either:

- A **live attenuated** form of a virus (e.g. measles, mumps and rubella vaccine) or bacteria (e.g. BCG vaccine),
- **Inactivated** preparations of the virus (e.g. influenza vaccine) or bacteria, or
- **Detoxified exotoxins** produced by a micro-organism (e.g. tetanus vaccine), or
- **Extracts of** a micro-organism, which may be derived from the organism (e.g. pneumococcal vaccine) or produced by recombinant DNA technology (e.g. hepatitis B vaccine).

**Live attenuated vaccines** usually produce a durable immunity, but not always as long-lasting as that resulting from natural infection.

**Inactivated vaccines** may require a primary series of injections of vaccine to produce an adequate antibody response, and in most cases booster (reinforcing) injections are required; the duration of immunity varies from months to many years. Some inactivated vaccines are adsorbed onto an adjuvant (such as aluminium hydroxide) to enhance the antibody response.

Advice reflects that in the handbook **Immunisation against Infectious Disease** (2006), which in turn reflects the guidance of the Joint Committee on Vaccination and Immunisation (JCVI).

Chapters from the handbook are available at [www.immunisation.dh.gov.uk](http://www.immunisation.dh.gov.uk)

The advice also incorporates changes announced by the Chief Medical Officer and Health Department Updates.

#### Immunisation schedule

Vaccines for the childhood immunisation schedule should be obtained from local health organisations or from ImmForm ([www.immform.dh.gov.uk](http://www.immform.dh.gov.uk)—not to be prescribed on FP10 (HS21 in Northern Ireland; GP10 in Scotland; WP10 in Wales). For most up to date immunisation schedule consult The complete routine immunisation schedule available at ([www.gov.uk](http://www.gov.uk)).

**Preterm birth**
Babies born preterm should receive all routine immunisations based on their actual date of birth. The risk of apnoea following vaccination is increased in preterm babies, particularly in those born at or before 28 weeks gestational age. If babies at risk of apnoea are in hospital at the time of their first immunisation, they should be monitored for 48 hours after immunisation. If a baby develops apnoea, bradycardia, or desaturation after the first immunisation, the second immunisation should also be given in hospital with similar monitoring. Seroconversion may be unreliable in babies born earlier than 28 weeks’ gestation or in babies treated with corticosteroids for chronic lung disease; consideration should be given to testing for antibodies against *Haemophilus influenzae* type b, meningococcal C, and hepatitis B after primary immunisation.
### Vaccination

<table>
<thead>
<tr>
<th>When to immunise</th>
<th>Vaccine given and dose schedule (for details of dose, see under individual vaccines)</th>
</tr>
</thead>
</table>
| **Neonates at risk only** | Bacillus Calmette-Guérin vaccine p. 1078  
Hepatitis B vaccine p. 1083 |
| **2 months** | Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus p. 1079 First dose  
Pneumococcal vaccine p. 1089 First dose  
Rotavirus vaccine p. 1090 First dose |
| **3 months** | Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus p. 1079 Second dose  
Meningococcal group C vaccine p. 1088 First dose  
Rotavirus vaccine p. 1090 Second dose |
| **4 months** | Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus p. 1079 Third dose  
Pneumococcal vaccine p. 1089 Second dose |
| **12-13 months** | Measles, mumps and rubella vaccine, live p. 1087 First dose  
Pneumococcal vaccine p. 1089 Single booster dose  
Haemophilus influenzae type B with meningococcal group C vaccine p. 1080 Single booster dose |
| **Between 3 years and 4 months, and 5 years** | Diphtheria with pertussis, poliomyelitis vaccine and tetanus p. 1080 Single booster dose.  
**Note:** Preferably allow interval of at least 3 years after completing primary course |
| **11-14 years (females only). First dose of HPV vaccine will be offered to females aged 12-13 years of age in England, Wales, and Northern Ireland, and 11-14 years of age in Scotland.** | Human papillomavirus vaccines p. 1085 If a 3-dose course of HPV vaccine has been started under the 2013/2014 programme, where possible, the course should be completed. The two human papillomavirus vaccines are not interchangeable and, ideally, one vaccine product should be used for the entire course. However, for those females who started the schedule with Cervarix® under the national immunisation programme, but did not complete the vaccination course, the course can be completed with Gardasil®. |
| **13-15 years** | Meningococcal group C vaccine p. 1088 Single booster dose |
| **13-18 years** | Diphtheria with poliomyelitis and tetanus vaccine p. 1080 Single booster dose. **Note:** Can be given at the same time as the booster dose of meningococcal group C conjugate vaccine at 13-15 years of age. |
| **During adult life, women of child-bearing age susceptible to rubella** | Measles, mumps and rubella vaccine, live p. 1087 Women of child-bearing age who have not received 2 doses of a rubella-containing vaccine or who do not have a positive antibody test for rubella should be offered rubella immunisation (using the MMR vaccine)—exclude pregnancy before immunisation. |
| **During adult life, those entering or being at university who are at risk of meningococcal group C disease** | Meningococcal group C vaccine p. 1088 Single dose. **Note:** Should be offered to those of any age entering or being at university who have never been vaccinated against meningococcal group C disease, or those born after September 1995 who are entering university and only received meningococcal group C vaccine under the age of 10 years |
| **During adult life, if not previously immunised** | Diphtheria with poliomyelitis and tetanus vaccine p. 1080 |
| **70 years** | Varicella-zoster vaccine p. 1092 Single dose |

### Vaccines and HIV infection

HIV-positive individuals with or without symptoms can receive the following live vaccines:

- MMR (but avoid if immunity significantly impaired; use of normal immunoglobulin should be considered after exposure to measles), varicella-zoster vaccine against chickenpox (but avoid if immunity significantly impaired—consult product literature; varicella—zoster immunoglobulin should be considered after exposure to chickenpox or herpes zoster), rotavirus; and the following inactivated vaccines:
  - anthrax, cholera (oral), diphtheria, haemophilus influenzae type b, hepatitis A, hepatitis B, human papillomavirus, influenza (injection), meningococcal, pertussis, pneumococcal, poliomyelitis, rabies, tetanus, tick-borne encephalitis, typhoid (injection).
- HIV-positive individuals should not receive:
  - BCG, influenza nasal spray (unless stable HIV infection and receiving antiretroviral therapy), typhoid (oral), yellow fever (if yellow fever risk is unavoidable, specialist advice should be sought)

The above advice differs from that for other immunocompromised patients; *Immunisation Guidelines for HIV-infected Adults* issued by British HIV Association (BHIVA) are available at [www.bhiva.org](http://www.bhiva.org)

### Vaccines and asplenia

The following vaccines are recommended for asplenic patients or those with splenic dysfunction:

- haemophilus influenzae type b; influenza; pneumococcal A, C, W135, and Y conjugate; pneumococcal.

### Vaccines and antisera availability

Anthrax vaccine p. 1078 and yellow fever vaccine, live p. 1092, botulism antitoxin p. 1065, diphtheria antitoxin p. 1066, and snake and spider venom antitoxins are available from local designated holding centres.

For antivenom, see Emergency treatment of poisoning p. 1123.

Enquiries for vaccines not available commercially can also be made to:

**Public Health England**

Vaccines and Countermeasures Response Department  
Public Health England  
Wellington House  
133-155 Waterloo Road  
London SE1 8UG  
vaccinesupply@phe.gov.uk
In Scotland information about availability of vaccines can be obtained from a Specialist in Pharmaceutical Public Health.

In Wales enquiries for vaccines not available commercially should be directed to:

**University Hospital of Wales**
Welsh Medicines Information Centre
University Hospital of Wales
Cardiff CF14 4XW
(029) 2074 2979

In Northern Ireland:

**Northern Health and Social Care Trust**
Pharmacy and Medicines Management Centre
Northern Health and Social Care Trust
Beech House
Antrim Hospital Site
Bush Road
Antrim BT41 2RL
rhps.admin@northerntrust.hscni.net

For further details of availability, see under individual vaccines.

**Anthrax vaccine**

Anthrax vaccine p. 1078 is made from antigens from *B. anthracis*. Anthrax immunisation is indicated for individuals who handle infected animals, for those exposed to imported infected animal products, and for laboratory staff who work with *B. anthracis*. A 4-dose regimen is used for primary immunisation; booster doses should be given annually to workers at continued risk of exposure to anthrax.

In the event of possible contact with *B. anthracis*, post-exposure immunisation may be indicated, in addition to antimicrobial prophylaxis. Advice on the use of anthrax vaccine p. 1078 for post-exposure prophylaxis must be obtained from Public Health England Colindale (tel. 020 8200 4400).

**BCG vaccine**

BCG (Bacillus Calmette-Guérin) vaccine p. 1078 should be given intradermally by operators skilled in the technique. The expected reaction to successful BCG vaccine is induration at the site of injection followed by a local lesion which starts as a papule 2 or more weeks after vaccination; the lesion may ulcerate then subside over several weeks or months, leaving a small, flat scar. A dry dressing may be used if the ulcer discharges, but air should not be excluded.

BCG is recommended for the following groups if BCG immunisation has not previously been carried out and they are negative for tuberculoprotein hypersensitivity:

- neonates with a family history of tuberculosis in the last 5 years;
- all neonates and infants (0–12 months) born in areas where the incidence of tuberculosis is greater than 40 per 100 000;
- neonates, infants, and children under 16 years with a parent or grandparent born in a country with an incidence of tuberculosis greater than 40 per 100 000;
- new immigrants aged under 16 years who were born in, or lived for more than 2 months in a country with an incidence of tuberculosis greater than 40 per 100 000;
- new immigrants aged 16–35 years from Sub-Saharan Africa or a country with an incidence of tuberculosis greater than 500 per 100 000;
- contacts aged under 36 years of those with active respiratory tuberculosis (for healthcare or laboratory workers who have had contact with clinical materials or patients with tuberculosis, age limit does not apply);
- healthcare workers and laboratory staff (irrespective of age) who are likely to have contact with patients, clinical materials, or derived isolates; other individuals under 35 years (there is inadequate evidence of protection by BCG vaccine in adults aged over 35 years; however, vaccination is recommended for healthcare workers irrespective of age because of the increased risk to them or their patients) at occupational risk including veterinary and other staff who handle animal species susceptible to tuberculosis, and staff working directly with prisoners, in care homes for the elderly, or in hostels or facilities for the homeless or refugees;
- individuals under 16 years intending to live with local people for more than 3 months in a country with an incidence of tuberculosis greater than 40 per 100 000.

List of countries or primary care trusts where the incidence of tuberculosis is greater than 40 cases per 100 000 is available at www.gov.uk/phe.

Bladder instillations of BCG are licensed for the management of bladder carcinoma.

See also Tuberculosis p. 501 for advice on chemoprophylaxis; for the treatment of infection following vaccination, seek expert advice.

**Tuberculosis Diagnostic Agents**

The Mantoux test is recommended for tuberculin skin testing, but no licensed preparation is currently available. Guidance for healthcare professionals is available at www.dh.gov.uk/immunisation.

In the Mantoux test, the diagnostic dose is administered by intradermal injection of tuberculin purified protein derivative p. 1066 (PPD).

The Heaf test (involving the use of multiple-puncture apparatus) is no longer available.

Two interferon gamma release assay (IGRA) tests are also available as an aid in the diagnosis of tuberculosis infection: Quantiferon® TB Gold and T-Spot®. Both tests measure T-cell mediated immune response to synthetic antigens. For further information on the use of interferon gamma release assay tests for tuberculosis, see www.gov.uk/phe.

**Botulinum antitoxin**

A polyvalent botulinum antitoxin p. 1065 is available for the post-exposure prophylaxis of botulism and for the treatment of persons thought to be suffering from botulism. It specifically neutralises the toxins produced by *Clostridium botulinum* types A, B, and E. It is not effective against infantile botulism as the toxin (type A) is seldom, if ever, found in the blood in this type of infection.

**Cholera vaccine**

Cholera vaccine p. 1079 (oral) contains inactivated Inaba (including El-Tor biotype) and Ogawa strains of *Vibrio cholerae*, serotype O1 together with recombinant B-subunit of the cholera toxin produced in Inaba strains of *V.cholerae*, serotype O1.

Oral cholera vaccine is licensed for travellers to endemic or epidemic areas on the basis of current recommendations. Immunisation should be completed at least 1 week before potential exposure. However, there is no requirement for cholera vaccination for international travel. Injectable cholera vaccine provides unreliable protection and is no longer available in the UK.

**Diphtheria vaccine**

Diphtheria-containing vaccines are prepared from the toxin of *Corynebacterium diphtheriae* and adsorption on aluminium hydroxide or aluminium phosphate improves antigenicity. The vaccine stimulates the production of the protective antibody. The quantity of diphtheria toxoid in a preparation determines whether the vaccine is defined as ‘high dose’ or ‘low dose’. Vaccines containing the higher dose of diphtheria toxoid are used for primary
immunisation of children under 10 years of age. Vaccines containing the lower dose of diphtheria toxoid are used for primary immunisation in adults and children over 10 years. Single-antigen diphtheria vaccine is not available and adsorbed diphtheria vaccine is given as a combination product containing other vaccines.

For primary immunisation of children aged between 2 months and 10 years vaccination is recommended usually in the form of 3 doses (separated by 1-month intervals) of diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed) (see Immunisation schedule). In unimmunised individuals aged over 10 years the primary course comprises of 3 doses of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine.

A booster dose should be given 3 years after the primary course (this interval can be reduced to a minimum of 1 year if the primary course was delayed). Children under 10 years should receive either adsorbed diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine or adsorbed diphtheria [low dose], tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine. Individuals aged over 10 years should receive adsorbed diphtheria [low dose], tetanus, and poliomyelitis (inactivated) vaccine.

A second booster dose, of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine, should be given 10 years after the previous booster dose (this interval can be reduced to a minimum of 5 years if previous doses were delayed).

Diphtheria-containing vaccines for children over 10 years and adults

A low dose of diphtheria toxoid is sufficient to recall immunity in individuals previously immunised against diphtheria but whose immunity may have diminished with time; it is insufficient to cause serious reactions in an individual who is already immune. Preparations containing low dose diphtheria should be used for adults and children over 10 years, for both primary immunisation and booster doses.

Travel

Those intending to travel to areas with a risk of diphtheria infection should be fully immunised according to the UK schedule. If more than 10 years have lapsed since completion of the UK schedule, a dose of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine should be administered.

Contacts

Staff in contact with diphtheria patients or with potentially pathogenic clinical specimens or working directly with C. diphtheriae or C. ulcerans should receive a booster dose if fully immunised (with 5 doses of diphtheria-containing vaccine given at appropriate intervals); further doses should be given at 10-year intervals if risk persists. Individuals at risk who are not fully immunised should complete the primary course; a booster dose should be given after 5 years and then at 10-year intervals. Adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine is used for this purpose; immunity should be checked by antibody testing at least 3 months after completion of immunisation.

Advice on the management of cases, carriers, contacts and outbreaks must be sought from health protection units. The immunisation history of infected individuals and their contacts should be determined; those who have been incompletely immunised should complete their immunisation and fully immunised individuals should receive a reinforcing dose. See advice on antibacterial treatment to prevent a secondary case of diphtheria in a non-immune individual.

Haemophilus influenzae type B conjugate vaccine

Haemophilus influenzae type b (Hib) vaccine is made from capsular polysaccharide; it is conjugated with a protein such as tetanus toxoid to increase immunogenicity, especially in young children. Haemophilus influenzae type b vaccine immunisation is given in combination with diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine, as a component of the primary course of childhood immunisation (see Immunisation schedule). For infants under 1 year, the course consists of 3 doses of a vaccine containing Haemophilus influenzae type b component with an interval of 1 month between doses. A booster dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) should be given at 12–13 months of age.

Children 1–10 years who have not been immunised against Haemophilus influenzae type b need to receive only 1 dose of Haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine). However, if a primary course of immunisation has not been completed, these children should be given 3 doses of diphtheria, tetanus, pertussis (acellular, component), and poliomyelitis (inactivated). The risk of infection falls sharply in older children and the vaccine is not normally required for children over 10 years.

Haemophilus influenzae type b vaccine may be given to those over 10 years who are considered to be at increased risk of invasive H. influenzae type b disease (such as those with sickle-cell disease or complement deficiency, or those receiving treatment for malignancy).

Invasive Haemophilus influenzae type b disease

After recovery from infection, unimmunised and partially immunised index cases under 10 years of age should complete their age-specific course of immunisation. Previously vaccinated cases under 10 years of age should be given an additional dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) if Hib antibody concentrations are low or if it is not possible to measure antibody concentrations. Index cases of any age with asplenia or splenic dysfunction should complete their immunisation according to the recommendations below; fully vaccinated cases with asplenia or splenic dysfunction should be given an additional dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) if they received their previous dose over 1 year ago. See also use of rifampicin p. 508 in the prevention of secondary cases of Haemophilus influenzae type b disease.

Individuals diagnosed with asplenia, splenic dysfunction, or complement deficiency at:

- under 2 years of age should be vaccinated according to the Immunisation Schedule. The booster dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine), given at 12–13 months of age, should be followed at least 1 month later by one dose of meningococcal A, C, W135, and Y conjugate vaccine. An additional dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) should be given after the second birthday;
- over 2 years of age should receive one dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine), followed 1 month later by one dose of meningococcal A, C, W135, and Y conjugate vaccine.

Hepatitis A vaccine

Hepatitis A vaccine p. 1081 is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. Immunisation is recommended for:
Vaccines

- laboratory staff who work directly with the virus;
- staff and residents of homes for those with severe learning difficulties;
- workers at risk of exposure to untreated sewage;
- individuals who work with primates;
- patients with haemophilia or other conditions treated with plasma-derived clotting factors;
- patients with severe liver disease;
- travellers to high-risk areas;
- individuals who are at risk due to their sexual behaviour;
- parenteral drug abusers. Immunisation should be considered for:
  - patients with chronic liver disease including chronic hepatitis B or chronic hepatitis C;
  - prevention of secondary cases in close contacts of confirmed cases of hepatitis A, within 14 days of exposure to the primary case (within 8 weeks of exposure to the primary case where there is more than 1 contact in the household).

A booster dose is usually given 6–12 months after the initial dose. A second booster dose can be given 20 years after the previous booster dose to those who continue to be at risk. Specialist advice should be sought on re-immunisation of immunocompromised individuals.

For rapid protection against hepatitis A after exposure or during an outbreak, in adults a single dose of a monovalent vaccine is recommended; for children under 16 years, a single dose of the combined vaccine Ambirix® can also be used.

Intramuscular normal immunoglobulin p. 1063 is recommended for use in addition to hepatitis A vaccine p. 1081 for close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV infection, or who are immunosuppressed or over 50 years of age.

Post-exposure prophylaxis is not required for healthy children under 1 year of age, so long as all those involved in nappy changing are vaccinated against hepatitis A. However, children 2–12 months of age can be given a dose of hepatitis A vaccine if it is not possible to vaccinate their carers, or if the child becomes a source of infection to others [unlicensed use]; in these cases, if the child goes on to require long-term protection against hepatitis A after the first birthday, the full course of 2 doses should be given.

Hepatitis B vaccine

Hepatitis B vaccine p. 1083 contains inactivated hepatitis B virus surface antigen (HBsAg) adsorbed onto aluminium hydroxide adjuvant. It is made biosynthetically using recombinant DNA technology. The vaccine is used in individuals at high risk of contracting hepatitis B.

In the UK, groups at high-risk of hepatitis B include:
- parenteral drug misusers, their sexual partners, and household contacts; others drug misusers who are likely to ‘progress’ to injecting;
- individuals who change sexual partners frequently;
- close family contacts of a case or individual with chronic hepatitis B infection;
- babies whose mothers have had acute hepatitis B during pregnancy or are positive for hepatitis B surface antigen (regardless of e-antigen markers); hepatitis B vaccination is started immediately on delivery and hepatitis B immunoglobulin given at the same time (but preferably at a different site). Babies whose mothers are positive for hepatitis B surface antigen and for e-antigen antibody should receive the vaccine only (but babies weighing 1.5 kg or less should also receive the immunoglobulin regardless of the mother’s e-antigen antibody status);
- individuals with haemophilia, those receiving regular blood transfusions or blood products, and carers responsible for the administration of such products;
- patients with chronic renal failure including those on haemodialysis. Haemodialysis patients should be monitored for antibodies annually and re-immunised if necessary. Home carers (of dialysis patients) should be vaccinated;
- individuals with chronic liver disease;
- healthcare personnel (including trainees) who have direct contact with blood or blood-stained body fluids or with patients’ tissues;
- laboratory staff who handle material that may contain the virus;
- other occupational risk groups such as morticians and embalmers;
- staff and patients of day-care or residential accommodation for those with severe learning difficulties;
- staff and inmates of custodial institutions;
- those travelling to areas of high or intermediate prevalence who are at increased risk or who plan to remain there for lengthy periods;
- families adopting children from countries with a high or intermediate prevalence of hepatitis B;
- foster carers and their families.

Different immunisation schedules for hepatitis B vaccine are recommended for specific circumstances. Generally, three or four doses are required for primary immunisation; an ‘accelerated schedule’ is recommended for pre-exposure prophylaxis in high-risk groups where rapid protection is required, and for post-exposure prophylaxis.

Immunisation may take up to 6 months to confer adequate protection; the duration of immunity is not known precisely, but a single booster 5 years after the primary course may be sufficient to maintain immunity for those who continue to be at risk.

Immunisation does not eliminate the need for commonsense precautions for avoiding the risk of infection from known carriers by the routes of infection which have been clearly established, consult Guidance for Clinical Health Care Workers: Protection against Infection with Blood-borne Viruses (available at www.dh.gov.uk). Accidental inoculation of hepatitis B virus-infected blood into a wound, incision, needle-prick, or abrasion may lead to infection, whereas it is unlikely that indirect exposure to a carrier will do so.

Following significant exposure to hepatitis B, an accelerated schedule, with the second dose given 1 month, and the third dose 2 months after the first dose, is recommended. For those at continued risk, a fourth dose should be given 12 months after the first dose. More detailed guidance is given in the handbook Immunisation Against Infectious Disease. Specific hepatitis B immunoglobulin p. 1062 (‘HBIG’) is available for use with the vaccine in those accidentally inoculated and in neonates at special risk of infection.

A combined hepatitis A and B vaccine p. 1082 is also available.

Human papillomavirus vaccine

Human papillomavirus vaccines p. 1085 is available as a bivalent vaccine (Cervarix®) or a quadrivalent vaccine (Gardasil®). Cervarix® is licensed for use in females for the prevention of cervical cancer and other pre-cancerous lesions caused by human papillomavirus types 16 and 18. Gardasil® is licensed for use in females for the prevention of cervical and anal cancers, genital warts and pre-cancerous genital (cervical, vulvar, and vaginal) and anal lesions caused by the vaccine papillomavirus types 6, 11, 16, and 18. The vaccines may also provide limited protection against disease caused by other types of human papillomavirus. The two vaccines are not interchangeable and one vaccine product should be used for an entire course.
Human papillomavirus vaccines will be most effective if given before sexual activity starts. From September 2014, a 2-dose schedule is recommended, as long as the first dose is received before the age of 15 years. The first dose is given to females aged 11 to 14 years, and the second dose is given 6–24 months after the first dose (for the purposes of planning the national immunisation programme, it is appropriate to give the second dose 12 months after the first (see Immunisation Schedule). If the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more. Females receiving their first dose aged 15 years or older require a 3-dose schedule (see Cervarix® and Gardasil®), with the second and third doses given 1 and 4–6 months after the first dose; all 3 doses should be given within a 12-month period. If the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses. If a 3-dose course of vaccination has been started before September 2014, then where possible this should be completed; if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses. Under the national programme in England, females remain eligible to receive the human papillomavirus vaccines p. 1085 up to the age of 18 years if they did not receive the vaccine when scheduled. Where appropriate, immunisation with human papillomavirus vaccines should be offered to females coming into the UK as they may not have been offered protection in their country of origin. The duration of protection has not been established, but current studies suggest that protection is maintained for at least 6 years after completion of the primary course.

As the vaccines do not protect against all strains of human papillomavirus, routine cervical screening should continue.

**Influenza vaccine**

While most viruses are antigenically stable, the influenza viruses A and B (especially A) are constantly altering their antigenic structure as indicated by changes in the haemagglutinins (H) and neuraminidases (N) on the surface of the viruses. It is essential that influenza vaccine p. 1085 in use contain the H and N components of the prevalent strain or strains as recommended each year by the World Health Organization.

Immunisation is recommended for persons at high risk, and to reduce transmission of infection. Annual immunisation is strongly recommended for individuals aged over 6 months with the following conditions:

- chronic respiratory disease (includes asthma treated with continuous or repeated use of inhaled or systemic corticosteroids or asthma with previous exacerbations requiring hospital admission);
- chronic heart disease;
- chronic liver disease;
- chronic renal disease;
- chronic neurological disease;
- diabetes mellitus;
- immunosuppression because of disease (including asplenia or splenic dysfunction) or treatment (including prolonged systemic corticosteroid treatment [for over 1 month at dose equivalents of prednisolone: adult and child over 20 kg, 20 mg or more daily; child under 20 kg, 1 mg/kg or more daily] and chemotherapy);
- HIV infection (regardless of immune status).

Seasonal influenza vaccine p. 1085 is also recommended for all pregnant women, for all persons aged over 65 years, for residents of nursing or residential homes for the elderly and other long-stay facilities, and for carers of persons whose welfare may be at risk if the carrier falls ill. Influenza immunisation should also be considered for household contacts of immunocompromised individuals.

As part of winter planning, NHS employers should offer vaccination to healthcare workers who are directly involved in patient care. Employers of social care workers should consider similar action.

Unless contra-indicated, the live influenza vaccine p. 1085, FluMux Tetra®, is preferred in children aged 2–18 years because it provides a higher level of protection than inactivated influenza vaccine p. 1085. From 1 September 2014, seasonal influenza vaccine will also be offered to all children aged 2–4 years (i.e. those born between 2 September 2009 and 1 September 2012). Information on pandemic influenza, avian influenza and swine influenza may be found at www.dh.gov.uk/pandemicflu and at www.gov.uk/phe.

**Japanese encephalitis vaccine**

Japanese encephalitis vaccine p. 1086 is indicated for travellers to areas in Asia and the Far East where infection is endemic and for laboratory staff at risk of exposure to the virus. The primary immunisation course of 2 doses should be completed at least one week before potential exposure to Japanese encephalitis virus.

Up-to-date information on the risk of Japanese encephalitis in specific countries can be obtained from the National Travel Health Network and Centre (www.nathnae.org).

**Measles, Mumps and Rubella vaccine**

**Measles vaccine** has been replaced by a combined live measles, mumps and rubella vaccine, live p. 1087 (MMR vaccine).

Measles, mumps and rubella vaccine, live aims to eliminate measles, mumps, and rubella (German measles) and congenital rubella syndrome. Every child should receive two doses of measles, mumps and rubella vaccine, live by entry to primary school, unless there is a valid contra-indication. Measles, mumps and rubella vaccine, live should be given irrespective of previous measles, mumps, or rubella infection or vaccination.

The first dose of measles, mumps and rubella vaccine, live is given to children aged 12–13 months. A second dose is given before starting school at 3 years and 4 months–5 years of age (see Immunisation Schedule).

Children presenting for pre-school booster who have not received the first dose of measles, mumps and rubella vaccine, live should be given a dose of measles, mumps and rubella vaccine, live followed 2 months later by a second dose.

At school-leaving age or at entry into further education, measles, mumps and rubella vaccine, live immunisation should be offered to individuals of both sexes who have not received 2 doses during childhood. In those who have received only a single dose of measles, mumps and rubella vaccine, live in childhood, a second dose is recommended to achieve full protection. If 2 doses of measles, mumps and rubella vaccine, live are required, the second dose should be given one month after the initial dose. The decision on whether to vaccinate adults should take into consideration their vaccination history, the likelihood of the individual remaining susceptible, and the future risk of exposure and disease.

Measles, mumps and rubella vaccine, live should be used to protect against rubella in seronegative women of child-bearing age (see Immunisation Schedule); unimmunised healthcare workers who might put pregnant women and other vulnerable groups at risk of rubella or measles should be vaccinated. Measles, mumps and rubella vaccine, live may also be offered to previously unimmunised and seronegative post-partum women (see measles, mumps and rubella vaccine, live)—vaccination a few days after delivery.
Vaccines

is important because about 60% of congenital abnormalities from rubella infection occur in babies of women who have borne more than one child. Immigrants arriving after the age of school immunisation are particularly likely to require immunisation.

Contacts

Measles, mumps and rubella vaccine, live may also be used in the control of outbreaks of measles and should be offered to susceptible children aged under 1 year (and other children who are contacts of a case, within 3 days of exposure to infection. Children immunised before 12 months of age should still receive two doses of measles, mumps and rubella vaccine, live at the recommended ages. If one dose of measles, mumps and rubella vaccine, live has already been given to a child, then the second dose may be brought forward to at least one month after the first, to ensure complete protection. If the child is under 18 months of age and the second dose is given within 3 months of the first, then the routine dose before starting school at 3 years and 4 months–5 years should still be given. Children aged under 9 months for whom avoidance of measles infection is particularly important (such as with history of recent severe illness) can be given normal immunoglobulin after exposure to measles; routine measles, mumps and rubella vaccine, live p. 1087 immunisation should then be given after at least 3 months at the appropriate age.

Measles, mumps and rubella vaccine, live is not suitable for prophylaxis following exposure to mumps or rubella since the antibody response to the mumps and rubella components is too slow for effective prophylaxis.

Children and adults with impaired immune response should not receive live vaccines (see advice on HIV). If they have been exposed to measles infection they should be given normal immunoglobulin.

Travel

Unimmunised travellers, including children over 6 months, to areas where measles is endemic or epidemic should receive measles, mumps and rubella vaccine, live. Children immunised before 12 months of age should still receive two doses of measles, mumps and rubella vaccine, live at the recommended ages. If one dose of measles, mumps and rubella vaccine, live has already been given to a child, then the second dose should be brought forward to at least one month after the first, to ensure complete protection. If the child is under 18 months of age and the second dose is given within 3 months of the first, then the routine dose before starting school at 3 years and 4 months–5 years should still be given.

Meningococcal vaccine

Almost all childhood meningococcal disease in the UK is caused by Neisseria meningitidis serogroups B and C. Meningococcal group C conjugate vaccine protects only against infection by serogroup C. The risk of meningococcal disease declines with age—immunisation is not generally recommended after the age of 25 years.

Tetravalent meningococcal vaccines that cover serogroups A, C, W135, and Y are available. Although the duration of protection has not been established, the meningococcal groups A, C, W135, and Y conjugate vaccine is likely to provide longer-lasting protection than the unconjugated meningococcal polysaccharide vaccine. The antibody response to serogroup C in unconjugated meningococcal polysaccharide vaccines in young children may be suboptimal (not currently available in the UK).

A meningococcal group B vaccine, Bexsero®, is licensed in the UK against infection caused by Neisseria meningitidis serogroup B. Bexsero® contains 3 recombinant Neisseria meningitidis serogroup B proteins and the outer membrane vesicles from the NZ 98/254 strain, in order to achieve broad protection against Neisseria meningitidis serogroup B; the proteins are adsorbed onto an aluminium compound to stimulate an enhanced immune response.

Childhood immunisation

Meningococcal group C conjugate vaccine provides long-term protection against infection by serogroup C of Neisseria meningitidis. Immunisation consists of 1 dose given at 3 months of age; 2 booster doses are recommended, the first is given at 12–13 months of age (combined with haemophilus influenzae type b vaccine), and the second at 13–15 years of age (see Immunisation Schedule).

Unimmunised children aged 4–12 months should be given 1 dose of meningococcal group C conjugate vaccine and then they should be vaccinated according to the Immunisation Schedule. Unimmunised children aged 1–10 years should be given 1 dose of meningococcal group C conjugate vaccine, followed by a booster dose at 13–15 years of age. Unimmunised individuals aged 10–25 years should be given 1 dose of meningococcal group C conjugate vaccine, but a booster dose is not required.

From August 2014 there will be a catch-up programme for individuals aged under 25 years who are attending university for the first time and who did not receive a dose of meningococcal group C conjugate vaccine at 13–15 years of age.

Patients under 25 years of age with confirmed serogroup C disease, who have previously been immunised with meningococcal group C vaccine, should be offered meningococcal group C conjugate vaccine before discharge from hospital.

Travel

Individuals travelling to countries of risk should be immunised with meningococcal groups A, C, W135, and Y conjugate vaccine, even if they have previously received meningococcal group C conjugate vaccine. If an individual has recently received meningococcal group C conjugate vaccine, an interval of at least 4 weeks should be allowed before administration of the tetravalent (meningococcal groups A, C, W135, and Y) vaccine.

Vaccination is particularly important for those living or working with local people or visiting an area of risk during outbreaks.

Immunisation recommendations and requirements for visa entry for individual countries should be checked before travelling, particularly to countries in Sub-Saharan Africa, Asia, and the Indian sub-continent where epidemics of meningococcal school and infection are reported. Country-by-country information is available from the National Travel Health Network and Centre (www.nathnac.org).

Proof of vaccination with the tetravalent meningococcal groups A with C and W135 and Y vaccine p. 1089 is required for those travelling to Saudi Arabia during the Hajj and Umrah pilgrimages (where outbreaks of the W135 strain have occurred).

Contacts

For advice on the immunisation of laboratory workers and close contacts of cases of meningococcal disease in the UK and on the role of the vaccine in the control of local outbreaks, consult Guidance for Public Health Management of Meningococcal Disease in the UK at www.gov.uk/phe. Also see for antibacterial prophylaxis for prevention of secondary cases of meningococcal meningitis.

The need for immunisation of laboratory staff who work directly with Neisseria meningitidis should be considered.

Pertussis vaccine

Pertussis vaccine is given as a combination preparation containing other vaccines. Acellular vaccines are derived from highly purified components of Bordetella pertussis. Primary immunisation against pertussis (whooping cough)
requires 3 doses of an acellular pertussis-containing vaccine (see Immunisation schedule), given at intervals of 1 month from the age of 2 months.

All children up to the age of 10 years should receive primary immunisation with diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed).

A booster dose of an acellular pertussis-containing vaccine should ideally be given 3 years after the primary course, although, the interval can be reduced to 1 year if the primary course was delayed. Children aged 1–10 years who have not received a pertussis-containing vaccine as part of their primary immunisation should be offered 1 dose of a suitable pertussis-containing vaccine; after an interval of at least 1 year, a booster dose of a suitable pertussis-containing vaccine should be given. Immunisation against pertussis is not routinely recommended in individuals over 10 years of age.

**Vaccination of pregnant women against pertussis**

In response to the pertussis outbreak, the UK health departments introduced a temporary programme (October 2012) to vaccinate pregnant women against pertussis, and this programme will continue until further notice. The aim of the programme is to boost the levels of pertussis–specific antibodies that are transferred through the placenta, from the mother to the fetus, so that the newborn is protected before routine immunisation begins at 2 months of age.

Pregnant women should be offered a single dose of acellular pertussis-containing vaccine (as adsorbed diphtheria [low dose], tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine; *Boostrix*-IPV®) between 28 to 38 weeks of pregnancy; the optimal time for vaccination is between 28–32 weeks of pregnancy. Pregnant women should be offered a single dose of acellular pertussis-containing vaccine up to the onset of labour if they missed the opportunity for vaccination at 28–38 weeks of pregnancy. A single dose of acellular pertussis-containing vaccine may also be offered to new mothers, who have never previously been vaccinated against pertussis, until the child receives the first vaccination.

While this programme is in place, women who become pregnant again should be offered vaccination during each pregnancy to maximise transplacental transfer of antibody.

**Contacts**

Vaccination against pertussis should be considered for close contacts of cases with pertussis who have been offered antibacterial prophylaxis. Unimmunised or partially immunised contacts under 10 years of age should complete their vaccination against pertussis. A booster dose of an acellular pertussis-containing vaccine is recommended for contacts aged over 10 years who have not received a pertussis-containing vaccine in the last 5 years and who have not received adsorbed diphtheria [low dose], tetanus, and poliomyelitis (inactivated) vaccine in the last month.

**Side-effects**

Local reactions do not contra-indicate further doses.

The vaccine should not be withheld from children with a history to a preceding dose of:
- fever, irrespective of severity;
- persistent crying or screaming for more than 3 hours;
- severe local reaction, irrespective of extent.

**Pneumococcal vaccine**

Pneumococcal vaccine p. 1089 protects against infection with *Streptococcus pneumoniae* (pneumoccus); the vaccines contain polysaccharide from capsular pneumococci. **Pneumococcal polysaccharide vaccine** contains purified polysaccharide from 23 capsular types of pneumococci, whereas **pneumococcal polysaccharide conjugate vaccine (adsorbed)** contains polysaccharide from either 10 capsular types (*Synflorix®*) or 13 capsular types (*Prevenar 13®*) and the polysaccharide is conjugated to protein.

The 13-valent conjugate vaccine (*Prevenar 13®*) is used in the childhood immunisation schedule. The recommended schedule consists of 3 doses, the first at 2 months of age, the second at 4 months, and the third at 12–15 months (see Immunisation Schedule).

Pneumococcal vaccine is recommended for individuals at increased risk of pneumococcal infection as follows:
- age over 65 years;
- asplenia or splenic dysfunction (including homozygous sickle cell disease and coeliac disease which could lead to splenic dysfunction);
- chronic respiratory disease (includes asthma treated with continuous or frequent use of a systemic corticosteroid);
- chronic heart disease;
- chronic renal disease;
- chronic liver disease;
- diabetes mellitus requiring insulin or oral hypoglycaemic drugs;
- immune deficiency because of disease (e.g. HIV infection) or treatment (including prolonged systemic corticosteroid treatment for over 1 month at dose equivalents of prednisolone: *adult and child over 20 kg*, 20 mg or more daily; *child under 20 kg*, 1 mg/kg or more daily);
- presence of cochlear implant;
- conditions where leakage of cerebrospinal fluid may occur;
- child under 5 years with a history of invasive pneumococcal disease;
- at risk of occupational exposure to metal fume (e.g. welders).

Where possible, the vaccine should be given at least 2 weeks before splenectomy, cochlear implant surgery, chemotherapy, or radiotherapy; patients should be given advice about increased risk of pneumococcal infection. If it is not practical to vaccinate at least 2 weeks before splenectomy, chemotherapy, or radiotherapy, the vaccine should be given at least 2 weeks after the splenectomy or, where possible, at least 3 months after completion of chemotherapy or radiotherapy. Prophylactic antibacterial therapy against pneumococcal infection should not be stopped after immunisation. A patient card and information leaflet for patients with asplenia are available from the Department of Health or in Scotland from the Scottish Executive, Public Health Division 1 (Tel (0131) 244 2501).

**Choice of vaccine**

Children under 2 years at increased risk of pneumococcal infection (see list) should receive the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) at the recommended ages, followed by a single dose of the 23-valent pneumococcal polysaccharide vaccine after their second birthday. Children at increased risk of pneumococcal infection presenting late for vaccination should receive 2 doses (separated by at least 1 month) of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) before the age of 12 months, and a third dose at 12–13 months. Children over 12 months and under 5 years (who have not been vaccinated or not completed the primary course) should receive a single dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) (2 doses separated by an interval of 2 months in the immunocompromised or those with asplenia or splenic dysfunction). All children under 5 years at increased risk of pneumococcal infection should receive a single dose of the 23-valent pneumococcal polysaccharide vaccine after their second birthday and at least 2 months after the final dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed).
Children over 5 years and adults who are at increased risk of pneumococcal disease should receive a single dose of the 23-valent unconjugated pneumococcal polysaccharide vaccine.

Revaccination
In individuals with higher concentrations of antibodies to pneumococcal polysaccharides, revaccination with the 23-valent pneumococcal polysaccharide vaccine more commonly produces adverse reactions. Revaccination is therefore not recommended, except every 5 years in individuals in whom the antibody concentration is likely to decline rapidly (e.g. asplenia, splenic dysfunction and nephrotic syndrome). If there is doubt, the need for revaccination should be discussed with a haematologist, immunologist, or microbiologist.

Polio vaccine
Two types of polio vaccines (containing strains of poliovirus types 1, 2, and 3) are available, inactivated polio vaccine (for injection) and live (oral) polio vaccine. Inactivated polio vaccines, only available in combined preparation, are recommended for routine immunisation.

A course of primary immunisation consists of 3 doses of a combined preparation containing inactivated poliovirus vaccines, starting at 2 months of age with intervals of 1 month between doses (see Immunisation schedule). A course of 3 doses should also be given to all unimmunised adults; no adult should remain unimmunised against poliomyelitis.

Two booster doses of a preparation containing inactivated poliovirus vaccines are recommended, the first before school entry and the second before leaving school (see Immunisation schedule). Further booster doses are only necessary for adults at special risk, such as travellers to endemic areas, or laboratory staff likely to be exposed to the viruses, or healthcare workers in possible contact with cases; booster doses should be given to such individuals every 10 years.

Live (oral) polio vaccine is no longer available for routine use; its use may be considered during large outbreaks, but advice should be sought from Public Health England. The live (oral) vaccine poses a very rare risk of vaccine-associated paralytic polio because the attenuated strain of the virus can revert to a virulent form. For this reason the live (oral) vaccine must not be used for immunosuppressed individuals or their household contacts. The use of inactivated polio vaccines removes the risk of vaccine-associated paralytic polio altogether.

Travel
Unimmunised travellers to areas with a high incidence of poliomyelitis should receive a full 3-dose course of a preparation containing inactivated poliovirus vaccines. Those who have not been vaccinated in the last 10 years should receive a booster dose of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine.

Information about countries with a high incidence of poliomyelitis can be obtained from www.travax.nhs.uk or from the National Travel Health Network and Centre (www.nathnac.org).

Rabies vaccine
Rabies vaccine p. 1090 contains inactivated rabies virus cultivated in either human diploid cells or purified chick embryo cells; vaccines are used for pre- and post-exposure prophylaxis.

Pre-exposure prophylaxis
Immunisation should be offered to those at high risk of exposure to rabies—laboratory staff who handle the rabies virus, those working in quarantine stations, animal handlers, veterinary surgeons and field workers who are likely to be bitten by infected wild animals, certain port officials, and bat handlers. Transmission of rabies by humans has not been recorded but it is advised that those caring for patients with the disease should be vaccinated.

Immunisation against rabies is also recommended where there is limited access to prompt medical care for those living in areas where rabies is enzootic, for those travelling to such areas for longer than 1 month, and for those on shorter visits who may be exposed to unusual risk.

Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.

Up-to-date country-by-country information on the incidence of rabies can be obtained from the National Travel Health Network and Centre (www.nathnac.org) and, in Scotland, from Health Protection Scotland (www.hps.scot.nhs.uk).

Immunisation against rabies requires 3 doses of rabies vaccine p. 1090, with further booster doses for those who remain at frequent risk. To ensure continued protection in persons at high risk (e.g. laboratory workers), the concentration of antirabies antibodies in plasma is used to determine the intervals between doses.

Post-exposure management
Following potential exposure to rabies, the wound or site of exposure (e.g. mucous membrane) should be cleansed under running water and washed for several minutes with soapy water as soon as possible after exposure. Disinfectant and a simple dressing can be applied, but suturing should be delayed because it may increase the risk of introducing rabies virus into the nerves.

Post-exposure prophylaxis against rabies depends on the level of risk in the country, the nature of exposure, and the individual’s immunity. In each case, expert risk assessment and advice on appropriate management should be obtained from the local Public Health England Centre or Public Health England’s Virus Reference Department, Colindale (tel. (020) 8200 4400) or the PHE Colindale Duty Doctor (tel. (020) 8200 6868), in Wales from the Public Health Wales local Health Protection Team or Public Health Wales Virus Reference Laboratory (tel. (029) 2074 7747), in Scotland from the local on-call infectious diseases consultant, and in Northern Ireland from the Public Health Agency Duty Room (tel. (028) 9055 3997 / (028) 9063 2662) or the Regional Virology Service (tel. (028) 9024 0503).

There are no specific contra-indications to the use of rabies vaccine for post-exposure prophylaxis and its use should be considered whenever a patient has been attacked by an animal in a country where rabies is enzootic, even if there is no direct evidence of rabies in the attacking animal. Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis.

For post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine), 2 doses of cell-derived vaccine are likely to be sufficient; the first dose is given on day 0 and the second dose is given between day 3–7. Rabies immunoglobulin is not necessary in such cases.

Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete) comprises 5 doses of rabies vaccine given over 1 month (on days 0, 3, 7, 14, and the fifth dose is given between day 28–30); also, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin p. 1064 is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine. The immunisation
course can be discontinued if it is proved that the individual was not at risk.

**Rotavirus vaccine**

Rotavirus vaccine p. 1090 is a live, oral vaccine that protects young children against gastro-enteritis caused by rotavirus infection. The recommended schedule consists of 2 doses, the first at 2 months of age, and the second at 3 months of age (see Immunisation schedule). The first dose of rotavirus vaccine must be given between 6–15 weeks of age and the second dose should be given after an interval of at least 4 weeks; the vaccine should not be started in children 15 weeks of age or older. Ideally, the full course should be completed before 16 weeks of age to provide protection before the main burden of disease, and to avoid a temporal association between vaccination and intussusception; the course must be completed before 24 weeks of age.

The rotavirus vaccine p. 1090 virus is excreted in the stool and may be transmitted to close contacts; however, vaccination of those with immunosuppressed close contacts may protect the contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus. Carers of a recently vaccinated baby should be advised of the need to wash their hands after changing the baby’s nappies.

**Smallpox vaccine**

Limited supplies of smallpox vaccine are held at the Specialist and Reference Microbiology Division, Public Health England Colindale (Tel. (020) 8200 4400) for the exclusive use of workers in laboratories where pox viruses (such as vaccinia) are handled.

If a wider use of the vaccine is being considered, Guidelines for smallpox response and management in the post-eradication era should be consulted at www.gov.uk/jphe.

**Tetanus vaccine**

Tetanus vaccine contains a cell-free purified toxin of Clostridium tetani adsorbed on aluminium hydroxide or aluminium phosphate to improve antigenicity.

Primary immunisation for children under 10 years consists of 3 doses of a combined preparation containing adsorbed tetanus vaccine, with an interval of 1 month between doses. Following routine childhood vaccination, 2 booster doses of a preparation containing adsorbed tetanus vaccine are recommended, the first before school entry and the second before leaving school (see Immunisation schedule).

The recommended schedule of tetanus vaccination not only gives protection against tetanus in childhood but also gives the basic immunity for subsequent booster doses. In most circumstances, a total of 5 doses of tetanus vaccine is considered sufficient for long term protection.

For primary immunisation of adults and children over 10 years previously unimmunised against tetanus, 3 doses of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine are given with an interval of 1 month between doses (see Diphtheria-containing Vaccines).

When an individual presents for a booster dose but has been vaccinated following a tetanus-prone wound, the vaccine preparation administered at the time of injury should be determined. If this is not possible, the booster should still be given to ensure adequate protection against all antigens in the booster vaccine.

Very rarely, tetanus has developed after abdominal surgery; patients awaiting elective surgery should be asked about tetanus immunisation and immunised if necessary.

Parenteral drug abuse is also associated with tetanus; those abusing drugs by injection should be vaccinated if unimmunised—booster doses should be given if there is any doubt about their immunisation status.

All laboratory staff should be offered a primary course if unimmunised.

**Wounds**

Wounds are considered to be tetanus-prone if they are sustained more than 6 hours before surgical treatment or at any interval after injury and are puncture-type (particularly if contaminated with soil or manure) or show much devitalised tissue or are septic or are compound fractures or contain foreign bodies. All wounds should receive thorough cleansing.

- For clean wounds: fully immunised individuals (those who have received a total of 5 doses of a tetanus-containing vaccine at appropriate intervals) and those whose primary immunisation is complete (with boosters up to date), do not require tetanus vaccine; individuals whose primary immunisation is incomplete or whose boosters are not up to date require a reinforcing dose of a tetanus-containing vaccine (followed by further doses as required to complete the schedule); non-immunised individuals (or those whose immunisation status is not known or who have been fully immunised but are now immunocompromised) should be given a dose of the appropriate tetanus-containing vaccine immediately (followed by completion of the full course of the vaccine if records confirm the need)

- For tetanus-prone wounds: management is as for clean wounds with the addition of a dose of tetanus immunoglobulin given at a different site; in fully immunised individuals and those whose primary immunisation is complete (with boosters up to date) the immunoglobulin is needed only if the risk of infection is especially high (e.g. contamination with manure). Antibacterial prophylaxis (with benzylpenicillin, co-amoxiclav, or metronidazole) may also be required for tetanus-prone wounds.

**Tick-borne encephalitis vaccine**

Tick-borne encephalitis vaccine, inactivated p. 1091 contains inactivated tick-borne encephalitis virus cultivated in chick embryo cells. It is recommended for immunisation of those working in, or visiting, high-risk areas (see International Travel). Those working, walking or camping in warm forested areas of Central and Eastern Europe, Scandinavia, Northern and Eastern China, and some parts of Japan, particularly from April to November when ticks are most prevalent, are at greatest risk of tick-borne encephalitis. For full protection, 3 doses of the vaccine are required; booster doses are required every 3–5 years for those still at risk. Ideally, immunisation should be completed at least one month before travel.

**Typhoid vaccine**

Typhoid vaccine p. 1091 is available as Vi capsular polysaccharide (from Salmonella typhi) vaccine for injection and as live attenuated Salmonella typhi for oral use.

Typhoid immunisation is advised for:

- travellers to areas where typhoid is endemic, especially if staying with or visiting local people;
- travellers to endemic areas where frequent or prolonged exposure to poor sanitation and poor food hygiene is likely;
- laboratory personnel who, in the course of their work, may be exposed to Salmonella typhi.

Typhoid vaccination is not a substitute for scrupulous personal hygiene.

Capsular polysaccharide typhoid vaccine p. 1091 is usually given by intramuscular injection. Children under 2 years may respond suboptimally to the vaccine, but children aged between 1–2 years should be immunised if the risk of typhoid fever is considered high (immunisation is not recommended for infants under 12 months). Revaccination is needed every 3 years on continued exposure.
All travellers should have immunity to tetanus and poliomyelitis (and childhood immunisations should be up to date); Tick-borne encephalitis vaccine is recommended for immunisation of those working in, or visiting, high-risk areas. Certain special precautions are required in non-European areas surrounding the Mediterranean, in Africa, the Middle East, Asia, and South America.

Travellers to areas that have a high incidence of poliomyelitis or tuberculosis should be immunised with the appropriate vaccine; in the case of poliomyelitis previously immunised travellers may be given a booster dose of a preparation containing inactivated poliomyelitis vaccine. BCG immunisation is recommended for travellers aged under 16 years proposing to stay for longer than 3 months (or in close contact with the local population) in countries with an incidence of tuberculosis greater than 40 per 100 000 (list of countries where the incidence of tuberculosis is greater than 40 cases per 100 000 is available from www.gov.uk/phe); it should preferably be given 3 months or more before departure.

Yellow fever immunisation is recommended for travel to the endemic zones of Africa and South America. Many countries require an International Certificate of Vaccination from individuals arriving from, or who have been travelling through, endemic areas; other countries require a certificate from all entering travellers (consult the Department of Health handbook, Health Information for Overseas Travel, www.dh.gov.uk).

Immunisation against meningococcal meningitis is recommended for a number of areas of the world. Protection against hepatitis A is recommended for travellers to high-risk areas outside Northern and Western Europe, North America, Japan, Australia and New Zealand. Hepatitis A vaccine is preferred and it is likely to be effective even if given shortly before departure; normal immunisation is not required if no longer given routinely but may be indicated in the immunocompromised. Special care must also be taken with food hygiene.

Hepatitis B vaccine is recommended for those travelling to areas of high or intermediate prevalence who intend to seek employment as healthcare workers or who plan to remain there for lengthy periods and who may therefore be at increased risk of acquiring infection as the result of medical or dental procedures carried out in those countries. Short-term tourists or business travellers are not generally at increased risk of infection but may put themselves at risk by their sexual behaviour when abroad. Prophylactic immunisation against typhoid is recommended for travellers to enzootic areas on long journeys or to areas out of reach of immediate medical attention.

Travellers who have not had a tetanus booster in the last 10 years and are visiting areas where medical attention may not be accessible should receive a booster dose of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine, even if they have received 5 doses of a tetanus-containing vaccine previously.

Typhoid vaccine is indicated for travellers to countries where typhoid is endemic, but the vaccine is no substitute for personal precautions.

There is no requirement for cholera vaccination as a condition for entry into any country, but oral cholera vaccine should be considered for backpackers and those travelling to situations where the risk is greatest (e.g. refugee camps). Regardless of vaccination, travellers to areas where cholera is endemic should take special care with food hygiene.

Advice on diphtheria, on Japanese encephalitis, and on tick-borne encephalitis is included in Health Information for Overseas Travel.

**Travel vaccinations**

See advice on Malaria, treatment p. 529.

No special immunisation is required for travellers to the United States, Europe, Australia, or New Zealand, although
**Food hygiene**
In areas where sanitation is poor, good food hygiene is important to help prevent hepatitis A, typhoid, cholera, and other diarrhoeal diseases (including travellers’ diarrhoea). Food should be freshly prepared and hot, and uncooked vegetables (including green salads) should be avoided; only fruits which can be peeled should be eaten. Only suitable bottled water, or tap water that has been boiled or treated with sterilising tablets, should be used for drinking.

**Information on health advice for travellers**
Health professionals and travellers can find the latest information on immunisation requirements and precautions for avoiding disease while travelling from: www.nathnac.org. The handbook, Health Information for Overseas Travel (2010), which draws together essential information for healthcare professionals regarding health advice for travellers, can also be obtained from this website. Immunisation requirements change from time to time, and information on the current requirements for any particular country may be obtained from the embassy or legation of the appropriate country or from:

**National Travel Health Network and Centre**
UCLH NHS Foundation Trust
3rd Floor Central
250 Euston Road
London NW1 2PG
Tel: 0845 602 6712 (8:30–11:45 a.m., 1–3:15 p.m. weekdays for healthcare professionals only)
www.nathnac.org

**Travel Medicine Team**
Health Protection Scotland
Meridian Court
5 Cadogan Street
Glasgow G2 6QE
Tel: (0141) 300 1130 (2–4 p.m. Monday to Wednesday, 9:30–11:30 a.m. Friday; for registered TRAVAX users only)
www.travax.nhs.uk (free for NHS Scotland users, registration required; subscription fee may be payable for users outside NHS Scotland)

**Welsh Assembly Government**
Tel (029) 2082 5397 (9 a.m.–5:30 p.m. weekdays)

**Department of Health, Social Services and Public Safety**
Castle Buildings
Stormont
BT4 3SQ
Tel: (028) 9052 2118 (9 a.m.–5 p.m. weekdays)
www.dhsspsni.gov.uk

**VACCINES**

<table>
<thead>
<tr>
<th>Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTRA-INDICATIONS</strong></td>
</tr>
<tr>
<td>Impaired immune response</td>
</tr>
<tr>
<td><strong>CAUTIONS</strong></td>
</tr>
<tr>
<td>Acute illness</td>
</tr>
</tbody>
</table>

**Vaccination**

<table>
<thead>
<tr>
<th>Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTRA-INDICATIONS</strong></td>
</tr>
<tr>
<td>Impaired immune response</td>
</tr>
<tr>
<td><strong>SIDE-EFFECTS</strong></td>
</tr>
<tr>
<td>Common or very common</td>
</tr>
<tr>
<td>Very rare</td>
</tr>
<tr>
<td>Frequency not known</td>
</tr>
<tr>
<td>Specific side-effects</td>
</tr>
<tr>
<td>With intradermal use or intramuscular use or subcutaneous use</td>
</tr>
<tr>
<td>→ Appendix 1 (vaccines).</td>
</tr>
<tr>
<td><strong>SIDE-EFFECTS, FURTHER INFORMATION</strong></td>
</tr>
<tr>
<td>Occasionally serious adverse reactions can occur—these should always be reported to the CHM. Post-immunisation pyrexia in infants: The parent should be advised that if pyrexia develops after childhood immunisation, and the infant seems distressed, paracetamol can be given. Ibuprofen can be used if paracetamol is unsuitable. The parent should be warned to seek medical advice if the pyrexia persists. Allergy and cross-sensitivity: Contra-indicated in patients with a confirmed anaphylactic reaction to a preceding dose of a vaccine containing the same antigens or vaccine component (such as antibacterials in viral vaccines).</td>
</tr>
</tbody>
</table>
Anthrax vaccine

**INDICATIONS AND DOSE**

Pre-exposure immunisation against anthrax | Post-exposure immunisation

- **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 1 dose every 3 weeks for 3 doses, followed by 1 dose after 6 months, to be administered in the deltoid region, 1 dose is equivalent to 0.5 mL

**Booster**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 1 dose every 12 months, to be administered in deltoid region, 1 dose is equivalent to 0.5 mL

**PRESCRIBING AND DISPENSING INFORMATION**

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

**EXCIPIENTS:** May contain Thiomersal

- **ANTHRAX VACCINE (Non-proprietary)**
  - Anthrax vaccine (alum precipitated sterile filtrate) suspension for injection 0.5ml ampoules | 5 ampoule (Pres) no price available

**Bacillus Calmette-Guérin vaccine**

**(BCG Vaccine)**

- **DRUG ACTION**
  - BCG (Bacillus Calmette-Guérin) is a live attenuated strain derived from *Mycobacterium bovis* which stimulates the development of immunity to *M. tuberculosis*.

**INDICATIONS AND DOSE**

Immunisation against tuberculosis

- **BY INTRADERMAL INJECTION**
  - Child 1-11 months: 0.05 mL, to be injected at insertion of deltoid muscle onto humerus (keloid formation more likely with sites higher on arm); tip of shoulder should be avoided
  - Child 1-7 years: 0.1 mL, to be injected at insertion of deltoid muscle onto humerus (keloid formation more likely with sites higher on arm); tip of shoulder should be avoided
  - Adult: 0.1 mL, to be injected at insertion of deltoid muscle onto humerus (keloid formation more likely with sites higher on arm); tip of shoulder should be avoided

- **CONTRA-INDICATIONS**
  - Generalised septic skin conditions
  - Neonate in household contact with known or suspected case of active tuberculosis
  - CONTRA-INDICATIONS, FURTHER INFORMATION
  - A lesion-free site should be used to administer BCG vaccine to patients with eczema.

- **CAUTIONS**
  - BCG vaccine can be given simultaneously with another live vaccine, but if they are not given at the same time an interval of 4 weeks should normally be allowed. When BCG is given to infants, there is no need to delay routine primary immunisations. No further vaccination should be given in the arm used for BCG vaccination for at least 3 months because of the risk of regional lymphadenitis.

- **SIDE-EFFECTS**
  - Rare: Disseminated complications - osteitis - osteomyelitis
  - Frequency not known: Prolonged ulceration at the injection site · subcutaneous abscess at the injection site

- **PRE-TREATMENT SCREENING**
  - Apart from children under 6 years, any person being considered for BCG immunisation must first be given a skin test for hypersensitivity to tuberculoprotein (see tuberculin purified protein derivative p. 1066). A skin test is not necessary for a child under 6 years provided that the child has not stayed for longer than 3 months in a country with an incidence of tuberculosis greater than 40 per 100 000, the child has not had contact with a person with tuberculosis, and there is no family history of tuberculosis within the last 5 years.

- **DIRECTIONS FOR ADMINISTRATION**
  - Intradermal injection technique Skin is stretched between thumb and forefinger and needle (size 25G or 26G) inserted (bevel upwards) for about 3 mm into superficial layers of dermis (almost parallel with surface). Needle should be short with short bevel (can usually be seen through epidermis during insertion). Tense raised blanched bleb showing tips of hair follicles is sign of correct injection; 7 mm bleb $\equiv$ 0.1 mL injection, 3 mm bleb $\equiv$ 0.05 mL injection; if considerable
Cholera vaccine

**INDICATIONS AND DOSE**
Immunisation against cholera (for travellers to endemic or epidemic areas on the basis of current recommendations)

**BY MOUTH**
- Child 2-5 years: 1 dose every 1–6 weeks for 3 doses, if more than 6 weeks have elapsed between doses, the primary course should be restarted, immunisation should be completed at least one week before potential exposure
- Child 6-17 years: 1 dose every 1–6 weeks for 2 doses, if more than 6 weeks have elapsed between doses, the primary course should be restarted, immunisation should be completed at least one week before potential exposure
- Adult: 1 dose every 1–6 weeks for 2 doses, if more than 6 weeks have elapsed between doses, the primary course should be restarted, immunisation should be completed at least one week before potential exposure

**Booster**
**BY MOUTH**
- Child 2-5 years: A single booster dose can be given within 6 months after primary course, if more than 6 months have elapsed since the last vaccination, the primary course should be repeated
- Child 6-17 years: A single booster dose can be given within 2 years after primary course, if more than 2 years have elapsed since the last vaccination, the primary course should be repeated
- Adult: A single booster dose can be given within 2 years after primary course, if more than 2 years have elapsed since the last vaccination, the primary course should be repeated

**CONTRA-INDICATIONS**
Acute gastro-intestinal illness

**SIDE-EFFECTS**
- Rare: Cough - respiratory symptoms - rhinitis
- Very rare: Insomnia - sore throat
- Frequency not known: Abdominal pain and cramps - diarrhoea - nausea - vomiting

**DIRECTIONS FOR ADMINISTRATION**
- In children: Dissolve effervescent sodium bicarbonate granules in a glassful of water or chlorinated water (approximately 150 mL). For children over 6 years, add vaccine suspension to make one dose. For child 2–6 years, discard half (approximately 75 mL) of the solution, then add vaccine suspension to make one dose. Drink within 2 hours. Food, drink, and other oral medicines should be avoided for 1 hour before and after vaccination.
- In adults: Dissolve effervescent sodium bicarbonate granules in a glassful of water or chlorinated water (approximately 150 mL). Add vaccine suspension to make one dose. Drink within 2 hours. Food, drink, and other oral medicines should be avoided for 1 hour before and after vaccination.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for suspension for injection**
- Bacillus Calmette-Guerin vaccine (Non-proprietary)
  - Dukoral (Janssen-Cilag Ltd)
  - Pediacel (GlaxoSmithKline UK Ltd)
  - Infanrix-IPV + Hib (GSK) (£32.00)

**SIDE-EFFECTS**
- Atopic dermatitis - hypotonia - restlessness - sleep disturbances - unusual crying in infants

**SIDE-EFFECTS, FURTHER INFORMATION**
Side effects of vaccines containing pertussis: The incidence of local and systemic effects is generally lower with vaccines containing acellular pertussis components than with the whole-cell pertussis vaccine used previously. However, compared with primary vaccination, booster doses with vaccines containing acellular pertussis are reported to increase the risk of injection-site reactions (some of which affect the entire limb); local reactions do not contra-indicate further doses. The vaccine should not be withheld from children with a history to a preceding dose of:
- Fever, irrespective of severity;
- Persistent crying or screaming for more than 3 hours;
- Severe local reaction, irrespective of extent.

**PRESCRIBING AND DISPENSING INFORMATION**
Available as part of childhood schedule from health organisations or ImnForm.

Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus

**INDICATIONS AND DOSE**
Primary immunisation

**BY INTRAMUSCULAR INJECTION**
- Child 2-5 months-10 years: 0.5 mL every month for 3 doses

**UNLICENSED USE**
Infanrix-IPV + Hib not licensed for use in children over 36 months; Pediacel not licensed in children over 4 years. However, the Department of Health recommends that these be used for children up to 10 years.

**SIDE-EFFECTS**
Atopic dermatitis - hypotonia - restlessness - sleep disturbances - unusual crying in infants

**SIDE-EFFECTS, FURTHER INFORMATION**
Side effects of vaccines containing pertussis: The incidence of local and systemic effects is generally lower with vaccines containing acellular pertussis components than with the whole-cell pertussis vaccine used previously. However, compared with primary vaccination, booster doses with vaccines containing acellular pertussis are reported to increase the risk of injection-site reactions (some of which affect the entire limb); local reactions do not contra-indicate further doses. The vaccine should not be withheld from children with a history to a preceding dose of:
- Fever, irrespective of severity;
- Persistent crying or screaming for more than 3 hours;
- Severe local reaction, irrespective of extent.

**PRESCRIBING AND DISPENSING INFORMATION**
Available as part of childhood schedule from health organisations or ImnForm.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**
- Exipients: May contain neomycin, polymyxin b, streptomycin
  - Pediacel (Sanofi pasteur MSD Ltd)
    - Pediacel vaccine suspension for injection 0.5mL vials | 1 vial (£34)
    - £32.00
  - Infanrix-IPV + Hib (GSK)
    - Infanrix-IPV + Hib vaccine powder and solvent for suspension for injection 0.5mL pre-filled syringes | 1 pre-filled disposable injection (£50) no price available
Diphtheria with pertussis, poliomyelitis vaccine and tetanus

**INDICATIONS AND DOSE**

First booster dose

**BY INTRAMUSCULAR INJECTION**

- Child 3–10 years: 0.5 mL to be given 3 years after primary immunisation

Vaccination of pregnant women against pertussis

**BY INTRAMUSCULAR INJECTION**

- Females of childbearing potential: 0.5 mL for 1 dose

**SIDE-EFFECTS**

Restlessness • sleep disturbances • unusual crying in infants

**SIDE-EFFECTS, FURTHER INFORMATION**

Side effects of vaccines containing pertussis

The incidence of local and systemic effects is generally lower with vaccines containing acellular pertussis components than with the whole-cell pertussis vaccine used previously. However, compared with primary vaccination, booster doses with vaccines containing acellular pertussis are reported to increase the risk of injection-site reactions (some of which affect the entire limb); local reactions do not contra-indicate further doses.

The vaccine should not be withheld from children with a history to a preceding dose of:

- Fever, irrespective of severity;
- Persistent crying or screaming for more than 3 hours;
- Severe local reaction, irrespective of extent.

**PREGNANCY**

Contra-indicated in pregnant women with a history of encephalopathy of unknown origin within 7 days of previous immunisation with a pertussis-containing vaccine. Contra-indicated in pregnant women with a history of transient thrombocytopenia or neurological complications following previous immunisation against diphtheria or tetanus.

**PRESCRIBING AND DISPENSING INFORMATION**

Available as part of childhood immunisation schedule from health organisations or ImmForm. Available for vaccination of pregnant women from ImmForm.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

**EXCipients:** May contain Neomycin, polymyxin b, streptomycin

- *Boostrix*-IPV (GlaxoSmithKline UK Ltd)
  - Boostrix-IPV suspension for injection 0.5 mL pre-filled syringes [1 pre-filled disposable injection (PDI)] £1.95
- *Infanrix*-IPV (GlaxoSmithKline UK Ltd)
  - Infanrix-IPV vaccine suspension for injection 0.5 mL pre-filled syringes [1 pre-filled disposable injection (PDI)] £1.75
- *Repevax* (sanofi pasteur MSD Ltd)
  - Repevax vaccine suspension for injection 0.5 mL pre-filled syringes [1 pre-filled disposable injection (PDI)] £21.00

**Diphtheria with poliomyelitis and tetanus vaccine**

**INDICATIONS AND DOSE**

Primary immunisation

**BY INTRAMUSCULAR INJECTION**

- Child 10–17 years: 0.5 mL every month for 3 doses
- Adult: 0.5 mL every month for 3 doses

Booster doses

**BY INTRAMUSCULAR INJECTION**

- Child 10–17 years: 0.5 mL for 1 dose, first booster dose—should be given 3 years after primary course (this interval can be reduced to a minimum of 1 year if the primary course was delayed), then 0.5 mL for 1 dose, second booster dose—should be given 3 years after primary course (this interval can be reduced to a minimum of 1 year if the primary course was delayed), then 0.5 mL for 1 dose, second booster dose—should be given 10 years after first booster dose (this interval can be reduced to a minimum of 5 years if previous doses were delayed), second booster dose may also be used as first booster dose in those over 10 years who have received only 3 previous doses of a diphtheria-containing vaccine

- Adult: 0.5 mL for 1 dose, first booster dose—should be given 3 years after primary course (this interval can be reduced to a minimum of 1 year if the primary course was delayed), then 0.5 mL for 1 dose, second booster dose—should be given 10 years after first booster dose (this interval can be reduced to a minimum of 5 years if previous doses were delayed), second booster dose may also be used as first booster dose in those over 10 years who have received only 3 previous doses of a diphtheria-containing vaccine

**SIDE-EFFECTS**

Restlessness • sleep disturbances • unusual crying in infants

**PRESCRIBING AND DISPENSING INFORMATION**

Available as part of childhood schedule from health organisations or ImmForm.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

**EXCipients:** May contain Neomycin, polymyxin b, streptomycin

- *Revaxis* (sanofi pasteur MSD Ltd)
  - Revaxis vaccine suspension for injection 0.5 mL pre-filled syringes [1 pre-filled disposable injection (PDI)] £16.50

Haemophilus influenzae type b with meningococcal group C vaccine

**INDICATIONS AND DOSE**

Booster dose (for infants who have received primary immunisation with a vaccine containing *Haemophilus influenzae* type b component)

**BY INTRAMUSCULAR INJECTION**

- Child 12–13 months: 0.5 mL for 1 dose

Booster dose (for children who have not been immunised against *Haemophilus influenzae* type b) • Booster dose after recovery from *Haemophilus influenzae* type b disease (for index cases previously vaccinated, with low Hib antibody concentration or if it is not possible to measure antibody concentration)

**BY INTRAMUSCULAR INJECTION**

- Child 1–9 years: 0.5 mL for 1 dose

Booster dose after recovery from *Haemophilus influenzae* type b disease (for fully vaccinated index cases with asplenia or splenic dysfunction, if previous dose received over 1 year ago)

**BY INTRAMUSCULAR INJECTION**

- Child 1–7 years: 0.5 mL for 1 dose
- Adult: 0.5 mL for 1 dose

Booster dose (for patients diagnosed with asplenia, splenic dysfunction or complement deficiency at under 2 years of age)

**BY INTRAMUSCULAR INJECTION**

- Child 12–13 months: 0.5 mL for 1 dose, this booster dose should be followed 1 month later by one dose of meningococcal A, C, W135, and Y conjugate vaccine, followed by 0.5 mL for 1 dose, the second dose should be given after the second birthday
Hepatitis A vaccine

**INDICATIONS AND DOSE**

**AVAXIM®**

**Immunisation against hepatitis A infection**

**BY INTRAMUSCULAR INJECTION**

- Child 2–17 years: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders; not to be injected into the buttock (vaccine efficacy reduced)
- Adult: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders; not to be injected into the buttock (vaccine efficacy reduced)

**VAQTA® PAEDIATRIC**

**Immunisation against hepatitis A infection**

**BY INTRAMUSCULAR INJECTION**

- Child 1–17 years: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–18 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders (but immune response may be reduced)

**HAVRIX MONODOSE®**

**Immunisation against hepatitis A infection**

**BY INTRAMUSCULAR INJECTION**

- Child 1–15 years: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders
- Child 16–17 years: Initially 1 mL for 1 dose, then 1 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders
- Adult: Initially 1 mL for 1 dose, then 1 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders

**VAQTA® ADULT**

**Immunisation against hepatitis A infection**

**BY INTRAMUSCULAR INJECTION**

- Adult: Initially 1 mL for 1 dose, then 1 mL after 6–18 months, dose given as booster, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders (but immune response may be delayed)

**EPAXAL®**

**Immunisation against hepatitis A infection**

**BY INTRAMUSCULAR INJECTION**

- Child 1–17 years: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–18 months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders
- Adult: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders

**Immunisation against hepatitis A infection (splenectomised patients)**

**BY INTRAMUSCULAR INJECTION**

- Child 1–17 years: Initially 0.5 mL for 1 dose, then 0.5 mL after 1–6 months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders
- Adult: Initially 0.5 mL for 1 dose, then 0.5 mL after 1–6 months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders

**ALLERGY AND CROSS-SENSITIVITY**

*Epaxal®* contains influenza virus haemagglutinin grown in the allantoic cavity of chick embryos, therefore contra-indicated in those hypersensitive to eggs or chicken proteins.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.
Hepatitis A and B vaccine

The properties listed below are those particular to the combination only. For the properties of the components please consider, hepatitis A vaccine p. 1081, hepatitis B vaccine p. 1083.

INDICATIONS AND DOSE

**TWINRIX® PAEDIATRIC**

**Immunisation against hepatitis A and hepatitis B infection by intramuscular injection**

- Child 1-15 years: Initially 0.5 mL every month for 2 doses, then 0.5 mL after 5 months for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh is the preferred site in infants; not to be injected into the buttoc (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

**TWINRIX® ADULT**

**Immunisation against hepatitis A and hepatitis B infection by intramuscular injection**

- Child 16-17 years: Initially 1 mL every month for 2 doses, then 1 mL after 5 months for 1 dose, the deltoid region is the preferred site of injection in adults and older children; not to be injected into the buttoc (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

- Adult: Initially 1 mL for 1 dose, then 1 mL after 7 days for 1 dose, then 1 mL after 14 days for 1 dose, then 1 mL for 1 dose given 12 months after the first dose, the deltoid region is the preferred site of injection in adults and older children; not to be injected into the buttoc (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

**AMBIRIX®**

**Immunisation against hepatitis A and hepatitis B infection by intramuscular injection**

- Child 1-15 years: Initially 1 mL for 1 dose, then 1 mL after 6–12 months for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh is the preferred site in infants; not to be injected into the buttoc (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

**VIATIM®**

**Immunisation against hepatitis A and typhoid infection (primary course) by intramuscular injection**

- Child 16-17 years: 1 mL for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced). The subcutaneous route may be used for patients with bleeding disorders, booster dose given using single component vaccines

- Adult: 1 mL for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced). The subcutaneous route may be used for patients with bleeding disorders (but immune response may be reduced)

Important safety information

Ambirix® and TWINRIX® are not recommended for post-exposure prophylaxis following percutaneous (needle-stick),ocular, or mucous membrane exposure to hepatitis B virus.

**PRESCRIBING AND DISPENSING INFORMATION**

AMBIRIX®

Primary course should be completed with Ambirix® (single component vaccines given at appropriate intervals may be used for booster dose).

TWINRIX® PREPARATIONS

Primary course should be completed with Twinrix® (single component vaccines given at appropriate intervals may be used for booster dose).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

EXCIPIENTS: May contain Neomycin

- Ambirix® (GliaxoSmithKline UK Ltd)
  - Ambirix vaccine suspension for injection 1mL pre-filled syringes | 1 pre-filled disposable injection (PPh) £22.43
  - Twinrix® (GliaxoSmithKline UK Ltd)
  - Twinrix Paediatric vaccine suspension for injection 0.5mL pre-filled syringes | 1 pre-filled disposable injection (PPh) £16.77 | 10 pre-filled disposable injection (PPh) £167.68

**Emulsion for injection**

- Epaxal® (Janssen-Cilag Ltd)
  - Epaxal vaccine emulsion for injection 0.5mL pre-filled syringes | 1 pre-filled disposable injection (PPh) £14.74

**Importance of the interval**

- For the properties of the components please consider, hepatitis A vaccine p. 1081, hepatitis B vaccine p. 1083.

Hepatitis A with typhoid vaccine

The properties listed below are those particular to the combination only. For the properties of the components please consider, hepatitis A vaccine p. 1081, typhoid vaccine p. 1091.

**INDICATIONS AND DOSE**

**VIATIM®**

**Immunisation against hepatitis A and typhoid infection (primary course) by intramuscular injection**

- Child 16-17 years: 1 mL for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced). The subcutaneous route may be used for patients with bleeding disorders, booster dose given using single component vaccines

- Adult: 1 mL for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced). The subcutaneous route may be used for patients with bleeding disorders (but immune response may be reduced)
route may be used for patients with bleeding disorders, booster dose given using single component vaccines

**HEPATYRIX®**

**Immunisation against hepatitis A and typhoid infection (primary course)**

**BY INTRAMUSCULAR INJECTION**

- **Child 15-17 years:** 1 mL for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced). The subcutaneous route may be used for patients with bleeding disorders, booster dose given using single component vaccines
- **Adult:** 1 mL for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced). The subcutaneous route may be used for patients with bleeding disorders, booster dose given using single component vaccines

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

**EXCIPIENTS:** May contain Neomycin

- **Hepatyrix (GlaxoSmithKline UK Ltd)**
  - Hepatyrix vaccine suspension for injection 1 mL pre-filled disposable syringes | 1 mL pre-filled disposable injection £37.21 | 10 mL pre-filled disposable injection £372.10
- **ViATIM (sanofi pasteur MSD Ltd)**
  - ViATIM vaccine suspension for injection 1 mL pre-filled syringes | 1 mL pre-filled disposable injection £29.80

**Hepatitis B vaccine**

**INDICATIONS AND DOSE**

**ENGERIX B®**

**Immunisation against hepatitis B infection**

**BY INTRAMUSCULAR INJECTION**

- **Neonate:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.
- **Child 1 month-15 years:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced)
- **Adult:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced)

**Immunisation against hepatitis B infection (accelerated schedule)**

**BY INTRAMUSCULAR INJECTION**

- **Neonate:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.
- **Child 1 month-15 years:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced)
- **Adult:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced)

**Immunisation against hepatitis B infection in renal insufficiency, including haemodialysis patients**

**BY INTRAMUSCULAR INJECTION**

- **Neonate:** 10 micrograms once a month for 3 months, first dose to be given at birth with hepatitis B immunoglobulin injection (separate site), followed by 10 micrograms after 10 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced)

**Immunisation against hepatitis B infection**

**INJECTION**

- **BY INTRAMUSCULAR INJECTION**
  - **Neonate:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.
  - **Child 1 month-15 years:** 10 micrograms every 3 months, followed by 10 micrograms after 9 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young
children; not to be injected into the buttock (vaccine efficacy reduced)

- Child 16-17 years: 40 micrograms every month for 3 months, followed by 40 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced)
- Adult: 40 micrograms every month for 3 months, followed by 40 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced)

Immunisation against hepatitis B infection (accelerated schedule)

**BY INTRAMUSCULAR INJECTION**

- Neonate: 10 micrograms every month for 3 months, followed by 10 micrograms after 10 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.
- Child 1 month-15 years: 10 micrograms every month for 3 months, followed by 10 micrograms after 10 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced)
- Adult: 10 micrograms every month for 3 months, followed by 10 micrograms after 9 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced)

**HBVAXPRO®**

Immunisation against hepatitis B infection

**BY INTRAMUSCULAR INJECTION**

- Neonate: 5 micrograms for 1 dose, followed by 5 micrograms after 1 month for 1 dose, then 5 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.
- Child 1 month-15 years: 5 micrograms for 1 dose, followed by 5 micrograms after 1 month for 1 dose, then 5 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced)
- Child 16-17 years: 10 micrograms for 1 dose, followed by 10 micrograms after 1 month for 1 dose, then 10 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced)
- Adult: 10 micrograms for 1 dose, followed by 10 micrograms after 1 month for 1 dose, then 10 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced)

**FENDRIX®**

Immunisation against hepatitis B infection in renal insufficiency (including pre-haemodialysis and haemodialysis patients)

**BY INTRAMUSCULAR INJECTION**

- Child 15-17 years: 20 micrograms every month for 3 months, followed by 20 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced)
Human papillomavirus vaccines

**INDICATIONS AND DOSE**

**GARDASIL®**

Prevention of premalignant genital (cervical, vulvar and vaginal) and anal lesions, cervical and anal cancers, and genital warts

**BY INTRAMUSCULAR INJECTION**

- Child 9-17 years (female): 0.5 mL for 1 dose, followed by 0.5 mL after 1 month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL after 3 months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

- Adult (female): 0.5 mL for 1 dose, followed by 0.5 mL after 1 month for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL after 3 months, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

**Prevention of premalignant genital (cervical, vulvar, and vaginal) and anal lesions, cervical and anal cancers, and genital warts (alternative schedule)**

**BY INTRAMUSCULAR INJECTION**

- Child 9-13 years (female): 0.5 mL for 1 dose, followed by 0.5 mL after 6 months for 1 dose, if the second dose is administered earlier than 6 months after the first dose, a third dose should be administered, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more.

**CERVARIX®**

Prevention of premalignant genital lesions and cervical cancer

**BY INTRAMUSCULAR INJECTION**

- Child 9-14 years (female): 0.5 mL for 1 dose, followed by 0.5 mL after 5–7 months for 1 dose, if second dose administered earlier than 5 months after the first, a third dose should be administered, dose to be administered into deltoid region, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more.

- Child 15-17 years (female): 0.5 mL for 1 dose, followed by 0.5 mL after 1–2.5 months for 1 dose, then 0.5 mL after 5–12 months for 1 dose, dose to be administered into deltoid region, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

- Adult (female): 0.5 mL for 1 dose, followed by 0.5 mL after 1–2.5 months for 1 dose, then 0.5 mL after 5–12 months for 1 dose, dose to be administered into deltoid region, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

**PREGNANCY**

Not known to be harmful, but vaccination should be postponed until completion of pregnancy.

**PRESCRIBING AND DISPENSING INFORMATION**

To avoid confusion, prescribers should specify the brand to be dispensed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

**EXCipients:** May contain Thiomerosal

- **Engerix** B (GlaxoSmithKline UK Ltd)
  - Hepatitis B virus surface antigen 20 microgram per 1 mL
  - Pre-filled disposable injection [POD] £12.34 | 10 vial [POD] £123.41
  - 1 pre-filled disposable injection [POD] £9.67
  - 10 pre-filled disposable injection [POD] £129.92

- **Fendrix** (GlaxoSmithKline UK Ltd)
  - Hepatitis B virus surface antigen 40 microgram per 1 mL
  - Pre-filled disposable injection [POD] £38.10

- **HBVAXPRO** (sanofi pasteur MSD Ltd)
  - Hepatitis B virus surface antigen 10 microgram per 1 mL
  - Pre-filled disposable injection [POD] £12.20
  - 1 pre-filled disposable injection [POD] £18.95

- **HVBAXPRO** 40micrograms/1mL vaccine suspension for injection vials | 1 vial [POD] £27.60

**Influenza vaccine**

**INDICATIONS AND DOSE**

Annual immunisation against seasonal influenza (for children who have not received seasonal influenza vaccine previously)

**BY INTRAMUSCULAR INJECTION**

- Child 6 months-9 years: 0.5 mL for 1 dose, followed by 0.5 mL after at least 4 weeks for 1 dose

**BY INTRanasAL ADMINISTRATION**

- Child 2-9 years: 0.1 mL for 1 dose, followed by 0.1 mL after at least 4 weeks for 1 dose, 0.1 mL dose to be administered into each nostril

**Annual immunisation against seasonal influenza**

**BY INTRAMUSCULAR INJECTION**

- Child 6 months-17 years: 0.5 mL for 1 dose
- Adult: 0.5 mL for 1 dose
FLUENZ TETRA® SPRAY
Avoid close contact with severely immunocompromised patients for 1–2 weeks after vaccination.

MEDIcular FORMS
There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection
EXCIPIENTS: May contain Gentican, kanamycin, neomycin penicillins, polymyxin b, thiomenal

INFLUENZA VACCINE (Non-proprietary)
Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection £5.55–6.59 | 10 pre-filled disposable injection £65.90
Influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection £61.50

Agrippal (Novartis Vaccines and Diagnostics Ltd)
Agrippal vaccine suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection £58.50

Enzira (Pfizer Ltd)
Enzira vaccine suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection £65.90

Fluarix Tetra vaccine nasal suspension
Fluarix Tetra vaccine suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection £65.90

Imvac (BGP Products Ltd)
Imvac vaccine suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection £65.90

Influvac Sub-unit (BGP Products Ltd)
Influvac Sub-unit vaccine suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection £65.90

Intanza (sanofi pasteur MSD Ltd)
Intanza 15microgram strain vaccine suspension for injection 0.1ml pre-filled syringes | 1 pre-filled disposable injection £3.05 | 10 pre-filled disposable injection £30.50
Intanza 9microgram strain vaccine suspension for injection 0.1ml pre-filled syringes | 1 pre-filled disposable injection £3.05

Optafu (Novartis Vaccines and Diagnostics Ltd)
Optafu vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection £65.90

Emulsion and suspension for emulsion for injection

Pandemrix H1N1 (GlaxoSmithKline UK Ltd)
Pandemrix vaccine emulsion and suspension for emulsion for injection | 500 dose £49 no price available

Spray
EXCIPIENTS: May contain Gentican, gentamicin

Fluenz Tetra (AstraZeneca UK Ltd)
Fluenz Tetra vaccine nasal suspension 0.2ml unit dose | 10 unit dose £180.00

Japanese encephalitis vaccine

INDICATIONS AND DOSE
Immunisation against Japanese encephalitis

BY INTRAMUSCULAR INJECTION

Child 2 months-2 years: 0.25 mL every 28 days for 2 doses, anterolateral thigh is preferred site of injection in infants, the subcutaneous route may be used for patients with bleeding disorders
Child 3-17 years: 0.5 mL every 28 days for 2 doses, deltoid muscle is preferred site in older children; anterolateral thigh is preferred in infants, the subcutaneous route may be used for patients with bleeding disorders
Adult: 0.5 mL every 28 days for 2 doses, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders

BY INTRADERMAL INJECTION

Adult 18-59 years: 9 micrograms for 1 dose, dose to be injected into deltoid region
Adult 60 years and over: 15 micrograms for 1 dose, dose to be injected into deltoid region

BY INTRanasAL ADMINISTRATION

Child 2-17 years: 0.1 mL for 1 dose, dose to be administered into each nostril

UNLICENSED USE
Some products containing inactivated influenza vaccine (surface antigen) are not licensed for use in children under 4 years—check product literature.

Severe asthma, active wheezing, concomitant use with antiviral therapy for influenza

CONTRA-INDICATIONS, FURTHER INFORMATION

FLUENZ TETRA® SPRAY
Concomitant use with antivirals
Avoid antivirals for at least 2 weeks after immunisation; avoid immunisation for at least 48 hours after stopping the antiviral.

CAUTIONS
Increased risk of fever in child 5–9 with preparations marketed by Pfizer or CSL Biotherapies

ENZIRA® SUSPENSION FOR INJECTION
Child 5–9 years (increased risk of fever)—use alternative influenza vaccine if available

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

Uncommon Epistaxis
Frequency not known Febrile convulsions - transient thrombocytopenia - vasculitis (in adults)

SPECIFIC SIDE-EFFECTS

With intranasal use Rhinorrhea

ALLERGY AND CROSS-SENSITIVITY
Individuals with a history of egg allergy can be immunised with an egg free influenza vaccine, if available, or an influenza vaccine with an ovalbumin content less than 120 nanograms/mL (facilities should be available to treat anaphylaxis). Vaccines with an ovalbumin content more than 120 nanograms/mL or where content is not stated should not be used in individuals with egg allergy. If an influenza vaccine containing ovalbumin is being considered in those with a history of anaphylaxis to egg or egg allergy with uncontrolled asthma, these individuals should be referred to a specialist in hospital.

Pregnancy
Inactivated vaccines not known to be harmful.

FLUENZ TETRA® SPRAY
Avoid in pregnancy.

Breastfeeding
Inactivated vaccines not known to be harmful.

FLUENZ TETRA® SPRAY
Avoid in breast-feeding.

PRESCRIBING AND DISPENSING INFORMATION

FLUARIX TETRA® SUSPENSION FOR INJECTION
Ovalbumin content less than 100 nanograms/mL.

PATIENT AND CARER ADVICE
Driving and skilled tasks
May affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced.
Measles, mumps and rubella vaccine, live

INDICATIONS AND DOSE
Primary immunisation against measles, mumps, and rubella (first dose)
- BY INTRAMUSCULAR INJECTION OR BY DEEP SUBCUTANEOUS INJECTION
  - Child 12-13 months: 0.5 mL for 1 dose
Primary immunisation against measles, mumps, and rubella (second dose)
- BY INTRAMUSCULAR INJECTION OR BY DEEP SUBCUTANEOUS INJECTION
  - Child 40 months-5 years: 0.5 mL for 1 dose
Rubella immunisation (in seronegative women, susceptible to rubella and in unimunised, seronegative women, post-partum)
- BY INTRAMUSCULAR INJECTION OR BY DEEP SUBCUTANEOUS INJECTION
  - Females of childbearing potential: consult product literature or local protocols
Children presenting for pre-school booster, who have not received the primary immunisation (first dose)
- Immunisation for patients at school-leaving age or at entry into further education, who have not completed the primary immunisation course Control of measles outbreak Immunisation for patients travelling to areas where measles is endemic or epidemic, who have not completed the primary immunisation
- BY INTRAMUSCULAR INJECTION OR BY DEEP SUBCUTANEOUS INJECTION
  - Child 6 months-17 years: consult product literature or local protocols
  - Adult: consult product literature or local protocols

SIDE-EFFECTS
- Uncommon Cough (in children) - migraine (in adults) - vertigo (in adults)
- Rare Dyspnoea (in adults) - neuritis (in adults) - palpitation (in adults) - tachycardia (in adults) - thrombocytopenia (in adults)
- PREGNANCY Although manufacturer advises avoid because of limited information, miscarriage has been associated with Japanese encephalitis virus infection acquired during the first 2 trimesters of pregnancy.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection
- Ixiaro (Novartis Vaccines and Diagnostics Ltd)
  - Ixiaro vaccine suspension for injection 0.5ml pre-filled syringes £59.50

UNLICENSED USE Not licensed for use in children under 9 months.

Important safety information
MMR VACCINATION AND BOWEL DISEASE OR AUTISM
- Vaccination and bowel disease or autism. The Chief Medical Officers have advised that the MMR vaccine is the safest and best way to protect children against measles, mumps, and rubella. Information (including fact sheets and a list of references) may be obtained from www.dh.gov.uk/immunisation.

CAUTIONS
- Antibody response to measles component may be reduced after immunoglobulin administration or blood transfusion - leave an interval of at least 3 months before MMR immunisation
- MMR vaccine should not be administered on the same day as yellow fever vaccine; there should be a 4-week minimum interval between the vaccines. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of MMR may be considered.
- MMR and varicella-zoster vaccine can be given on the same day or separated by a 4-week minimum interval. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of the vaccine given second may be considered.

SIDE-EFFECTS
- Uncommon Parotid swelling (usually in the third week) - sleep disturbances - unusual crying in infants
- Rare Arthropathy (2 to 3 weeks after immunisation) - idiopathic thrombocytopenic purpura
- Frequency not known Optic neuritis - peripheral neuritis

SIDE-EFFECTS, FURTHER INFORMATION
Malaise, fever, or a rash can occur after the first dose of MMR vaccine—most commonly about a week after vaccination and lasting about 2 to 3 days. Leaflets are available for parents on advice for reducing fever (including the use of paracetamol). Febrile seizures—occur rarely 6 to 11 days after MMR vaccination (the incidence is lower than that following measles infection)
- Idiopathic thrombocytopenic purpura
  - Idiopathic thrombocytopenic purpura has occurred rarely following MMR vaccination, usually within 6 weeks of the first dose.
  - The risk of idiopathic thrombocytopenic purpura after MMR vaccine is much less than the risk after infection with wild measles or rubella virus. Children who develop idiopathic thrombocytopenic purpura within 6 weeks of the first dose of MMR should undergo serological testing before the second dose is due; if the results suggest incomplete immunity against measles, mumps or rubella then a second dose of MMR is recommended. The Specialist and Reference Microbiology Division, Health Protection Agency offers free serological testing for children who develop idiopathic thrombocytopenic purpura within 6 weeks of the first dose of MMR.
- Aseptic meningitis
  - Post-vaccination aseptic meningitis was reported (rarely and with complete recovery)
  - Following vaccination with MMR vaccine containing Urabe mumps vaccine, which has now been discontinued; no cases have been confirmed in association with the currently used Jeryl Lynn mumps vaccine. Children with post-vaccination symptoms are not infectious.
- Frequency of side effects
  - Adverse reactions are considerably less frequent after the second dose of MMR vaccine than after the first.

ALLERGY AND CROSS-SENSITIVITY
MMR vaccine can be given safely even when the child has had an anaphylactic reaction to food containing egg, or confirmed anaphylactic reactions to egg-containing food is not a contra-indication to MMR vaccination. Children with a confirmed anaphylactic reaction to the MMR vaccine should be assessed by a specialist.
Meningococcal group C vaccine

INDICATIONS AND DOSE
Primary immunisation against Neisseria meningitidis BY INTRAMUSCULAR INJECTION
• Child 3 months: 0.5 mL for 1 dose, the primary immunisation dose is followed by a booster dose of meningococcal group C conjugate vaccine combined with haemophilus influenzae type b vaccine at 12–13 months of age

Second booster dose for immunisation against Neisseria meningitidis BY INTRAMUSCULAR INJECTION
• Child 13-15 years: 0.5 mL for 1 dose

Immunisation against Neisseria meningitidis in an unimmunised patient BY INTRAMUSCULAR INJECTION
• Child 4–11 months: 0.5 mL for 1 dose, the primary immunisation dose is followed by a booster dose of meningococcal group C conjugate vaccine combined with haemophilus influenzae type b vaccine at 12–13 months of age, then 0.5 mL for 1 dose, this second booster dose to be given at 13–15 years of age
• Child 1–9 years: 0.5 mL for 1 dose, then 0.5 mL for 1 dose, this booster dose to be given at 13–15 years of age
• Child 10–17 years: 0.5 mL for 1 dose, booster dose is not required
• Adult 18–24 years: 0.5 mL for 1 dose, booster dose is not required

Patients attending university for the first time (who did not receive second booster dose at 13–15 years) BY INTRAMUSCULAR INJECTION
• Adult 18–24 years: 0.5 mL for 1 dose

Patients with confirmed serogroup C disease (who have previously been immunised) BY INTRAMUSCULAR INJECTION
• Child 4–15 years: 0.5 mL for 1 dose, dose to be given before discharge from hospital
• Adult 18–24 years: 0.5 mL for 1 dose, dose to be given before discharge from hospital

SIDE-EFFECTS
• Rare Symptoms of meningitis (but no evidence that vaccine causes meningococcal C meningitis)

DIRECTIONS FOR ADMINISTRATION Meningigate Kit® may be used via subcutaneous route in children with bleeding disorders.

PRESCRIBING AND DISPENSING INFORMATION Available as part of childhood immunisation schedule from www.immform.dh.gov.uk.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for suspension for injection
• Meningitec (Novartis Vaccines and Diagnostics Ltd)
• NeisVac-C (Pfizer Ltd)

Meningitec vaccine suspension for injection 0.5mL pre-filled syringes 10 pre-filled disposable injection (Peg) 43.30

NeisVac-C vaccine suspension for injection 0.5mL pre-filled syringes 10 pre-filled disposable injection (Peg) 119.50
**Meningococcal groups A with C and W135 and Y vaccine**

### INDICATIONS AND DOSE

**MENVEO®**

Immunisation against *Neisseria meningitidis*

**BY INTRAMUSCULAR INJECTION**

- Child 3–11 months: 0.5 mL for 1 dose, dose preferably injected into deltoid region
- Child 1–7 years: 0.5 mL for 1 dose, dose preferably injected into deltoid region
- Adult: 0.5 mL for 1 dose, dose preferably injected into deltoid region

**NIMENRIX®**

Immunisation against *Neisseria meningitidis*

**BY INTRAMUSCULAR INJECTION**

- Child 1–7 years: 0.5 mL for 1 dose, to be injected preferably into deltoid region (or anterolateral thigh in child 1–2 years), then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of *Neisseria meningitidis* serogroup A infection
- Adult: 0.5 mL for 1 dose, to be injected preferably into deltoid region, then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of *Neisseria meningitidis* serogroup A infection

### UNLICENSED USE

**MENVEO®** 

*MENVEO*® is not licensed for use in children under 2 years.

### SIDE-EFFECTS

**Rare** Symptoms of meningitis reported (but no evidence that the vaccine causes meningococcal C meningitis)

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug:  

**Powder and solvent for solution for injection**

- *Menveo* (Novartis Vaccines and Diagnostics Ltd)
  - Menveo vaccine powder and solvent for solution for injection 0.5 mL vials | 1 vial £30.00
- *Nimenrix* (GlucoSmithKline UK Ltd)
  - Nimenrix vaccine powder and solvent for solution for injection 0.5 mL pre-filled syringes | 1 pre-filled disposable injection £30.00

**Pneumococcal vaccine**

### INDICATIONS AND DOSE

Immunisation against pneumococcal infection

**BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION**

- Child 2–17 years: 0.5 mL for 1 dose
- Adult: 0.5 mL for 1 dose

Immunisation in patients at increased risk of pneumococcal disease

**BY INTRAMUSCULAR INJECTION OR BY SUBCUTANEOUS INJECTION**

- Child 2–4 years: 0.5 mL for 1 dose, dose should be administered after the second birthday or at least 2 months after the final dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed)
- Child 5–17 years: 0.5 mL for 1 dose
- Adult: 0.5 mL for 1 dose

### PREVENAR 13®

Primary immunisation against pneumococcal infection (first dose)

**BY INTRAMUSCULAR INJECTION**

- Child 2 months: 0.5 mL for 1 dose, anterolateral thigh is preferred site of injection in infants

Primary immunisation against pneumococcal infection (second dose)

**BY INTRAMUSCULAR INJECTION**

- Child 4 months: 0.5 mL for 1 dose, anterolateral thigh is preferred site of injection in infants

Primary immunisation against pneumococcal infection (third dose)

**BY INTRAMUSCULAR INJECTION**

- Child 12–13 months: 0.5 mL for 1 dose, anterolateral thigh is preferred site of injection in infants

Immunisation against pneumococcal infection (in patients who have not been vaccinated or not completed the primary course)

**BY INTRAMUSCULAR INJECTION**

- Child 12 months–4 years: 0.5 mL for 1 dose, Deltoid muscle is preferred site of injection in young children; anterolateral thigh is preferred site in infants

Immunisation against pneumococcal infection, in immunocompromised or asplenic patients or patients with splenic dysfunction (who have not been vaccinated or not completed the primary course)

**BY INTRAMUSCULAR INJECTION**

- Child 12 months–4 years: 0.5 mL every 2 months for 2 doses

**SYNFLORIX®**

Immunisation against pneumococcal infection

**BY INTRAMUSCULAR INJECTION**

- Child 6 weeks–5 years: Deltoid muscle is preferred site of injection in young children; anterolateral thigh is preferred site in infants (consult product literature)

### UNLICENSED USE

**PREVENAR 13®**

The dose in BNF publications may differ from that in product literature.

### CONTRA-INDICATIONS

Concomitant use of high potency varicella-zoster vaccine (*Zostavax®*) with pneumococcal polysaccharide vaccine (in adults)

### PRESCRIBING AND DISPENSING INFORMATION

**PREVENAR 13®**

Available as part of childhood immunisation schedule from Immform www.immform.dh.gov.uk

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **PNEUMOCOCCAL VACCINE (Non-proprietary)**
  - Pneumococcal polysaccharide vaccine solution for injection 0.5 mL vials | 1 vial £8.32

**Suspension for injection**

- **Prevenar** (Pfizer Ltd)
  - Prevenar 13 vaccine suspension for injection 0.5 mL pre-filled syringes | 1 pre-filled disposable injection £49.10 | 10 pre-filled disposable injection £491.00
- **Synflorix** (GlucoSmithKline UK Ltd)
  - Synflorix vaccine suspension for injection 0.5 mL pre-filled syringes | 1 pre-filled disposable injection £27.60
Rabies vaccine

**INDICATIONS AND DOSE**

**Pre-exposure prophylaxis**

**BY INTRAMUSCULAR INJECTION**

- Child: 1 mL every week for 2 doses (on days 0 and 7), followed by 1 mL after 21 days for 1 dose (on day 28), to be administered in deltoid region or anterolateral thigh in infants, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5 units/mL, final dose may be given from day 21, if insufficient time before travel

- Adult: 1 mL every week for 2 doses (on days 0 and 7), followed by 1 mL after 21 days for 1 dose (on day 28), to be administered in deltoid region, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5 units/mL, final dose may be given from day 21, if insufficient time before travel

**Adult (administered on expert advice):**

- BY INTRAMUSCULAR INJECTION

  - Child: 1 mL after 1 year for 1 dose, then 1 mL every 3–5 years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies

  - Adult: 1 mL after 1 year for 1 dose, then 1 mL every 3–5 years for 1 dose, to be administered in deltoid region, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies

**Pre-exposure prophylaxis booster dose (for patients at frequent risk of exposure)**

**BY INTRAMUSCULAR INJECTION**

- Child: 1 mL after 10 years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants

- Adult: 1 mL after 10 years for 1 dose, to be administered in deltoid region

**Post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine)**

**BY INTRAMUSCULAR INJECTION**

- Child (administered on expert advice): 1 mL for 1 dose, followed by 1 mL after 3–7 days for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, rabies immunoglobulin is not necessary

- Adult (administered on expert advice): 1 mL for 1 dose, followed by 1 mL after 3–7 days for 1 dose, to be administered in deltoid region, rabies immunoglobulin is not necessary

**Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete)**

**BY INTRAMUSCULAR INJECTION**

- Child (administered on expert advice): 1 mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28–30, to be administered in deltoid region or anterolateral thigh in infants, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk

**Adult (administered on expert advice):** 1 mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28–30, to be administered in deltoid region, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk

**SIDE-EFFECTS** Paresis

**PREGNANCY** Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis. Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

<table>
<thead>
<tr>
<th>EXCIPIENTS: May contain Neomycin</th>
<th>Rabipur (Novartis Vaccines and Diagnostics Ltd)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabipur vaccine powder and solvent for solution for injection 1ml vials</td>
<td>1 vial (£28.80)</td>
</tr>
</tbody>
</table>

**Powder and solvent for suspension for injection**

<table>
<thead>
<tr>
<th>EXCIPIENTS: May contain Neomycin</th>
<th>RABIES VACCINE (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabies vaccine powder and solvent for suspension for injection 1ml vials</td>
<td>1 vial (£33.90)</td>
</tr>
</tbody>
</table>

Rotavirus vaccine

**INDICATIONS AND DOSE**

Immunisation against gastro-enteritis caused by rotavirus

**BY MOUTH**

- 6–24 weeks: 1.5 mL at least every 4 weeks for 2 doses, first dose must be given between 6–15 weeks of age; course should be completed before 24 weeks of age (preferably before 16 weeks)

**CONTRA-INDICATIONS** History of intussusception - predisposition to intussusception - severe combined immunosuppression

**CONTRA-INDICATIONS, FURTHER INFORMATION**

Immunosuppression With the exception of severe combined immunodeficiency, rotavirus vaccine is not contra-indicated in immunosuppressed patients—benefit from vaccination is likely to outweigh the risk, if there is any doubt, seek specialist advice.

**CAUTIONS** Diarrhoea (postpone vaccination) - immunosuppressed close contacts - vomiting (postpone vaccination)

**CAUTIONS, FURTHER INFORMATION**

The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; however, vaccination of those with immunosuppressed close contacts may protect the contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus.

**SIDE-EFFECTS** Abdominal cramps - abdominal pain - diarrhoea - nausea - vomiting

**PATIENT AND CARER ADVICE**

The rotavirus vaccine virus is excreted in the stool and may be transmitted to close
contacts; carers of a recently vaccinated baby should be  
advised of the need to wash their hands after changing  
the baby’s nappies.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different 
medicines containing the same drug.

**Oral suspension**
- **Rotarix** (GSK)
  Rotarix live oral suspension 1.5ml pre-filled syringes | 1 unit dose (£34.76)

---

**Tick-borne encephalitis vaccine, inactivated**

**INDICATIONS AND DOSE**

- **Initial immunisation against tick-borne encephalitis by intramuscular injection**
  - Child 1-5 years: 0.25 ml for 1 dose, followed by 0.25 ml after 1–3 months for 1 dose, then 0.25 ml after 5–12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region or anterolateral thigh in infants, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved
  - Child 6-17 years: 0.5 ml for 1 dose, followed by 0.5 ml after 1–3 months for 1 dose, then 0.5 ml after 5–12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved
  - Adult: 0.5 ml for 1 dose, followed by 0.5 ml after 1–3 months for 1 dose, then 0.5 ml after 5–12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved

- **Immunisation against tick-borne encephalitis, booster doses by intramuscular injection**
  - Child 1-7 years: First dose to be given within 3 years after initial course completed and then every 3–5 years (consult product literature)
  - Adult: First dose to be given within 3 years after initial course completed and then every 3–5 years (consult product literature)

- **ALLERGY AND CROSS-SENSITIVITY** Individuals with evidence of previous anaphylactic reaction to egg should not be given tick-borne encephalitis vaccine.

---

**Typhoid vaccine**

- **INDICATIONS AND DOSE**
  - **Immunisation against typhoid fever by intramuscular injection**
  - **Adult**: 0.5 ml for 1 dose, should be given at least 2 weeks before potential exposure to typhoid infection
  - **By mouth**
    - **Adult**: 1 capsule every 2 days for 3 doses

- **CONTRA-INDICATIONS**
  - With oral use acute gastro-intestinal illness

- **INTERACTIONS**
  - Appendix 1 (vaccines).

  Oral typhoid vaccine is inactivated by concomitant administration of antibacterials or antimalarials:
  - antibacterials should be avoided for 3 days before and after oral typhoid vaccination;
  - **Mefloquine** should be avoided for at least 12 hours before or after oral typhoid;
  - For other antimalarials vaccination with oral typhoid vaccine should be completed at least 3 days before the first dose of the antimalarial (except proguanil hydrochloride with atovaquone, which may be given concomitantly).

- **SIDE-EFFECTS**
  - With oral use abdominal cramps · abdominal pain · diarrhoea · nausea · vomiting

- **DIRECTIONS FOR ADMINISTRATION** Capsule should be taken one hour before a meal. Swallow as soon as possible after placing in mouth with a cold or lukewarm drink.

- **HANDLING AND STORAGE**
  - With oral use It is important to store capsules in a refrigerator.

- **PATIENT AND CARER ADVICE**
  - With oral use Patients or carers should be given advice on how to administer and store typhoid vaccine capsules.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant capsule**

- **CAUTIONARY AND ADVISORY LABELS** 25
  - **Vivotif** (PaxVax Ltd)
    Vivotif vaccine gastro-resistant capsules | 3 capsule (£14.77)

- **Solution for injection**
  - **Typhervax** (GSK)
    Typhervax Vi capsular polysaccharide 50 microgram per 1 ml Typhervax 25 micrograms/0.5ml vaccine solution for injection pre-filled syringes | 1 pre-filled disposable injection (£9.93) | 10 pre-filled disposable injection (£93.32)
  - **Typhim VI** (canonil pasteur MSD Ltd)
    Typhim VI capsular polysaccharide 50 microgram per 1 ml Typhim VI 25 micrograms/0.5ml vaccine solution for injection pre-filled syringes | 1 pre-filled disposable injection (£9.30) | 10 pre-filled disposable injection (£93.00)
Varicella-zoster vaccine

**INDICATIONS AND DOSE**

**VARILRIX®**

Prevention of varicella infection (chickenpox)

**BY SUBCUTANEOUS INJECTION**
- Child 1-17 years: 0.5 mL every 4–6 weeks for 2 doses, to be administered preferably into the deltoid region
- Adult: 0.5 mL every 4–6 weeks for 2 doses, to be administered preferably into the deltoid region

**VARIVAX®**

Prevention of varicella infection (chickenpox)

**BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
- Child 1-12 years: 0.5 mL for 2 doses, interval of at least 4 weeks between each dose, to be administered into the deltoid region (or higher anterolateral thigh)
- Child 13-17 years: 0.5 mL every 4–8 weeks for 2 doses, to be administered preferably into the deltoid region (or higher anterolateral thigh in children)
- Adult: 0.5 mL every 4–8 weeks for 2 doses, to be administered preferably into the deltoid region

Prevention of varicella infection (chickenpox) in children with asymptomatic HIV infection

**BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION**
- Child 1-12 years: 0.5 mL every 12 weeks for 2 doses, to be administered into the deltoid region (or higher anterolateral thigh)

**ZOSTAVAX®**

Prevention of herpes zoster (shingles)

**BY SUBCUTANEOUS INJECTION**
- Adult 70-79 years: 0.65 mL for 1 dose, to be administered preferably into the deltoid region

**CAUTIONS**

Post-vaccination close contact with susceptible individuals

**CAUTIONS, FURTHER INFORMATION**

Rarely, the varicella–zoster vaccine virus has been transmitted from the vaccinated individual to close contacts. Therefore, contact with the following should be avoided if a vaccine-related cutaneous rash develops within 4–6 weeks of the first or second dose:
- varicella-susceptible pregnant women;
- individuals at high risk of severe varicella, including those with immunodeficiency or those receiving immunosuppressive therapy.

Healthcare workers who develop a generalised papular or vesicular rash on vaccination should avoid contact with patients until the lesions have crusted. Those who develop a localised rash after vaccination should cover the lesions and be allowed to continue working unless in contact with patients at high risk of severe varicella.

**Administration with MMR vaccine**

Varicella–zoster and MMR vaccines can be given on the same day or separated by a 4-week minimum interval. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of the vaccine given second may be considered.

**SIDE-EFFECTS**

- **CONTRA-INDICATIONS**
  - Children under 6 months - history of thymus dysfunction

- **CAUTIONS**
  - Individuals over 60 years—greater risk of vaccine-associated adverse effects (in adults)

- **CAUTIONS, FURTHER INFORMATION**
  - Administration with MMR vaccine
  - Yellow fever and MMR vaccines should not be administered on the same day; there should be a 4-week minimum interval between the vaccines. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of MMR may be considered.

- **SIDE-EFFECTS**
  - Neurotropic disease - viscerotropic disease

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Vaccine-associated adverse effects
  - Very rare adverse effects, such as viscerotropic disease (yellow-fever vaccine-associated viscerotropic disease, YEL-AVD), a syndrome which may include metabolic acidosis, muscle and liver cirrhosis, and multi-organ failure. Neurological disorders (yellow fever vaccine-associated neurotropic disease, YEL-AND) such as encephalitis have also been reported. These very rare adverse effects usually occur after the first dose of yellow fever vaccine in those with no previous immunity.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Yellow fever vaccine should only be considered under the guidance of a specialist in individuals with evidence of previous anaphylactic reaction to egg.

- **PREGNANCY**
  - Live yellow fever vaccine should not be given during pregnancy because there is a theoretical risk of fetal infection. Pregnant women should be advised not to travel to areas at high risk of yellow fever. If exposure cannot be avoided during pregnancy, then the vaccine should be given if the risk from disease in the mother outweighs the risk to the fetus from vaccination.

- **BREAST FEEDING**
  - Avoid; seek specialist advice if exposure to virus cannot be avoided.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
Chapter 15

Anaesthesia

1 General anaesthesia

Anaesthetic adjuvants

Several different types of drug are given together during general anaesthesia. Anaesthesia is induced with either a volatile drug given by inhalation or with an intravenously administered drug; anaesthesia is maintained with an intravenous or inhalational anaesthetic. Analgesics, usually short-acting opioids, are also used. The use of neuromuscular blocking drugs necessitates intermittent positive-pressure ventilation. Following surgery, anticholinesterases can be given to reverse the effects of neuromuscular blocking drugs; specific antagonists can be used to reverse central and respiratory depression caused by some drugs used in surgery. A local topical anaesthetic can be used to reduce pain at the injection site.

Individual requirements vary considerably and the recommended doses are only a guide. Smaller doses are indicated in ill, shocked, or debilitated patients and in significant hepatic impairment, while robust individuals may require larger doses. The required dose of induction agent may be less if the patient has been premedicated with a sedative agent or if an opioid analgesic has been used.

Intravenous anaesthetics

Intravenous anaesthetics may be used either to induce anaesthesia or for maintenance of anaesthesia throughout surgery. Intravenous anaesthetics nearly all produce their effect in one arm-brain circulation time. Extreme care is required in surgery of the mouth, pharynx, or larynx where the airway may be difficult to maintain (e.g. in the presence of a tumour in the pharynx or larynx).

To facilitate tracheal intubation, induction is usually followed by a neuromuscular blocking drug or a short-acting opioid.

The doses of all intravenous anaesthetic drugs should be titrated to effect (except when using ‘rapid sequence induction’); lower doses may be required in premedicated patients.

Total intravenous anaesthesia

This is a technique in which major surgery is carried out with all drugs given intravenously. Respiration can be spontaneous, or controlled with oxygen-enriched air. Neuromuscular blocking drugs can be used to provide relaxation and prevent reflex muscle movements. The main problem to be overcome is the assessment of depth of anaesthesia. Target Controlled Infusion (TCI) systems can be used to titrate intravenous anaesthetic infusions to predicted plasma-drug concentrations in ventilated adult patients.

Drugs used for intravenous anaesthesia

Propofol p. 1095, the most widely used intravenous anaesthetic, can be used for induction or maintenance of anaesthesia in adults and children, but it is not commonly used in neonates. Propofol is associated with rapid recovery and less hangover effect than other intravenous anaesthetics. Propofol can also be used for sedation during diagnostic procedures and sedation in adults in intensive care.

Thiopental sodium p. 412 is a barbiturate that is used for induction of anaesthesia, but has no analgesic properties. Induction is generally smooth and rapid, but dose-related cardiovascular and respiratory depression can occur. Awakening from a moderate dose of thiopental sodium is rapid because the drug redistributes into other tissues, particularly fat. However, metabolism is slow and sedative effects can persist for 24 hours. Repeated doses have a cumulative effect and recovery is much slower. Etomidate p. 1095 is an intravenous agent associated with rapid recovery without a hangover effect. Etomidate causes less hypotension than thiopental sodium and propofol during induction. It produces a high incidence of extraneous muscle movements, which can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction.

Ketamine p. 1110 is used rarely. Ketamine causes less hypotension than thiopental sodium and propofol during induction. It is used mainly for paediatric anaesthesia, particularly when repeated administration is required (such as for serial burns dressings); recovery is relatively slow and there is a high incidence of extraneous muscle movements. The main disadvantage of ketamine is the high incidence of hallucinations, nightmares, and other transient psychotic effects; these can be reduced by a benzodiazepine such as diazepam p. 267 or midazolam p. 414.

Inhalational anaesthetics

Inhalational anaesthetics include gases and volatile liquids. Gaseous anaesthetics require suitable equipment for storage and administration. Volatile liquid anaesthetics are administered using calibrated vaporisers, using air, oxygen, or nitrous oxide-oxygen mixtures as the carrier gas. To prevent hypoxia, the inspired gas mixture should contain a minimum of 25% oxygen at all times. Higher concentrations of oxygen (greater than 30%) are usually required during inhalational anaesthesia when nitrous oxide p. 1096 is being administered.

Volatile liquid anaesthetics

Volatile liquid anaesthetics can be used for induction and maintenance of anaesthesia, and following induction with an intravenous anaesthetic.

Isoflurane p. 1098 is a volatile liquid anaesthetic. Heart rhythm is generally stable during isoflurane anaesthesia, but heart-rate can rise, particularly in younger patients.
Systemic arterial pressure and cardiac output can fall, owing to a decrease in systemic vascular resistance. Muscle relaxation occurs and the effects of muscle relaxant drugs are potentiated. Isoflurane is the preferred inhalational anaesthetic for use in obstetrics. Desflurane p. 1097 is a rapid acting volatile liquid anaesthetic; it is reported to have about one-fifth the potency of isoflurane. Emergence and recovery from anaesthesia are particularly rapid because of its low solubility. Desflurane is not recommended for induction of anaesthesia as it is irritant to the upper respiratory tract. Sevoflurane p. 1098 is a rapid acting volatile liquid anaesthetic and is more potent than desflurane. Emergence and recovery are particularly rapid, but slower than desflurane. Sevoflurane is non-irritant and is therefore often used for inhalational induction of anaesthesia; it has little effect on heart rhythm compared with other volatile liquid anaesthetics.

**Nitrous oxide**

Nitrous oxide p. 1096 is used for maintenance of anaesthesia and, in sub-anaesthetic concentrations, for analgesia. For *anaesthesia*, nitrous oxide is commonly used in a concentration of 50 to 66% in oxygen as part of a balanced technique in association with other inhalational or intravenous agents. Nitrous oxide is unsatisfactory as a sole anaesthetic owing to lack of potency, but is useful as part of a combination of drugs since it allows a significant reduction in dosage.

For analgesia (without loss of consciousness), a mixture of nitrous oxide and oxygen containing 50% of each gas (Entonox®, Equanox®) is used. Self-administration using a demand valve is popular in obstetric practice, for changing painful dressings, as an aid to postoperative physiotherapy, and in emergency ambulances.

Nitrous oxide may have a deleterious effect if used in patients with an air-containing closed space since nitrous oxide diffuses into such a space with a resulting increase in pressure. This effect may be dangerous in conditions such as pneumothorax, which may enlarge to compromise respiration, or in the presence of intracranial air after head injury, entrapped air following recent underwater dive, or recent intra-ocular gas injection.

**Malignant hyperthermia**

Malignant hyperthermia is a rare but potentially lethal complication of anaesthesia. It is characterised by a rapid rise in temperature, increased muscle rigidity, tachycardia, and acidosis. The most common triggers of malignant hyperthermia are the volatile anaesthetics. Suxamethonium chloride (Siprad, Equanox) has also been implicated, but malignant hyperthermia is more likely if it is given following a volatile anaesthetic. Volatile anaesthetics and suxamethonium chloride should be avoided during anaesthesia in patients at high risk of malignant hyperthermia. Dantrolene sodium p. 1101 is used in the treatment of malignant hyperthermia.

**Surgery and long-term medication**

The risk of losing disease control on stopping long-term medication before surgery is often greater than the risk posed by continuing it during surgery. It is vital that the anaesthetist knows about all drugs that a patient is (or has been) taking.

Patients with adrenal atrophy resulting from long-term corticosteroid use may suffer a precipitous fall in blood pressure unless corticosteroid cover is provided during anaesthesia and in the immediate postoperative period. Anaesthetists must therefore know whether a patient is, or has been, receiving corticosteroids (including high-dose inhaled corticosteroids).

Other drugs that should normally not be stopped before surgery include antiepileptics, antiparkinsonian drugs, antipsychotics, anxiolytics, bronchodilators, cardiovascular drugs (but see potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-II receptor antagonists), glaucoma drugs, immunosuppressants, drugs of dependence, and thyroid or antithyroid drugs. Expert advice is required for patients receiving antivirals for HIV infection. See general advice on surgery in diabetic patients.

Patients taking antiplatelet medication or an oral anticoagulant present an increased risk for surgery. In these circumstances, the anaesthetist and surgeon should assess the relative risks and decide jointly whether the antiplatelet or the anticoagulant drug should be stopped or replaced with heparin (unfractionated) or low molecular weight heparin therapy.

Drugs that should be stopped before surgery include combined oral contraceptives; for advice on hormone replacement therapy. MAOIs can have important interactions with some drugs used during surgery, such as pethidine hydrochloride. Tricyclic antidepressants need not be stopped, but there may be an increased risk of arrhythmias and hypotension (and dangerous interactions with vasopressor drugs); therefore, the anaesthetist should be informed if they are not stopped. Lithium should be stopped 24 hours before major surgery but the normal dose can be continued for minor surgery (with careful monitoring of fluids and electrolytes). Potassium-sparing diuretics may need to be withheld on the morning of surgery because hyperkalaemia may develop if renal perfusion is impaired or there is tissue damage. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor antagonists can be associated with severe hypotension after induction of anaesthesia; these drugs may need to be discontinued 24 hours before surgery. Herbal medicines may be associated with adverse effects when given with anaesthetic drugs and consideration should be given to stopping them before surgery.

**Anaesthesia, sedation, and resuscitation in dental practice**

Sedation for dental procedures should be limited to conscious sedation. Diazepam p. 267 and temazepam p. 420 are effective anxiolytics for dental treatment in adults.

For details of anaesthesia, sedation, and resuscitation in dental practice see *A Conscious Decision: A review of the use of general anaesthesia and conscious sedation in primary dental care*; report by a group chaired by the Chief Medical Officer and Chief Dental Officer, July 2000 and associated documents. Further details can also be found in the *Conscious Sedation in the Provision of Dental Care*; report of an Expert Group on Sedation for Dentistry (commissioned by the Department of Health), 2003.

Guidance is also included in *Conscious Sedation in Dentistry: Dental Clinical Guidance*, Scottish Dental Clinical Effectiveness Programme, June 2012 (www.sdcop.org.uk).
ANAESTHETICS (GENERAL, INTRAVENOUS)

Etomidate

INDICATIONS AND DOSE

Induction of anaesthesia

BY SLOW INTRAVENOUS INJECTION

- Adult: 150–300 micrograms/kg (max. per dose 60 mg), to be administered over 30–60 seconds (over 60 seconds in patients in whom hypotension might be hazardous)
- Elderly: 150–200 micrograms/kg (max. per dose 60 mg), to be administered over 30–60 seconds (over 60 seconds in patients in whom hypotension might be hazardous)

Important safety information

Etomidate should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

★ CAUTIONS

Acute porphyrias p. 864 (avoid) • acute circulatory failure (shock) • adrenal insufficiency • cardiovascular disease • elderly • fixed cardiac output • hypovolaemia

CAUTIONS, FURTHER INFORMATION

Adrenal insufficiency

Etomidate suppresses adrenocortical function, particularly during continuous administration, and it should not be used for maintenance of anaesthesia. It should be used with caution in patients with underlying adrenal insufficiency, for example, those with sepsis.

★ INTERACTIONS ➔ Appendix 1 (anaesthetics, general).

★ SIDE-EFFECTS

- Common or very common
  - Apathy
  - Hypertension
  - Hypotension
  - Nausea
  - Rash
  - Stridor
  - Vomiting

- Uncommon
  - Arrhythmias
  - Cough
  - Hiccups
  - Hypersalivation
  - Hyperventilation

- Frequency unknown
  - AV block
  - Cardiac arrest
  - Extraneous muscle movement (high incidence)
  - Pain on injection
  - Respiratory depression
  - Seizures
  - Shivering
  - Stevens-Johnson syndrome

SIDE-EFFECTS, FURTHER INFORMATION

Pain on injection: Can be reduced by injecting into a larger vein or by giving an opioid analgesic just before induction.

Extraneous muscle movement

Extraneous muscle movements can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction.

★ PREGNANCY

May depress neonatal respiration if used during delivery.

★ BREAST FEEDING

Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

★ HEPATIC IMPAIRMENT

Reduce dose in liver cirrhosis.

★ DIRECTIONS FOR ADMINISTRATION

To be administered over 30–60 seconds (over 60 seconds in patients in whom hypotension might be hazardous).

★ PATIENT AND CARER ADVICE

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

★ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Propylene glycol

- Hypnomidate (Janssen-Cilag Ltd)
  - Etomidate 2 mg per 1 ml Hypnomidate 20mg/10ml solution for injection ampoules | 5 ampoules £6.00

Emulsion for injection

- ETOMIDATE (Non-proprietary)
  - Etomidate 2 mg per 1 ml Etomidate-Lipuro 20mg/10ml emulsion for injection ampoules | 10 ampoules £15.62

Propofol

INDICATIONS AND DOSE

Induction of anaesthesia using 0.5% or 1% injection

BY SLOW INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION

- Adult 18–54 years: Usual dose 1.5–2.5 mg/kg, to be administered at a rate of 20–40 mg every 10 seconds until response. For debilitated patients use dose for 55 years and over
- Adult 55 years and over: Usual dose 1–1.5 mg/kg, to be administered at a rate of 20 mg every 10 seconds until response

Induction of anaesthesia using 2% injection

BY INTRAVENOUS INFUSION

- Adult 18–54 years: Usual dose 1.5–2.5 mg/kg, to be administered at a rate of 20–40 mg every 10 seconds until response. For debilitated patients use dose for 55 years and over
- Adult 55 years and over: Usual dose 1–1.5 mg/kg, to be administered at a rate of 20 mg every 10 seconds until response

Maintenance of anaesthesia using 1% injection

INITIALLY BY INTRAVENOUS INFUSION

- Adult: Usual dose 4–12 mg/kg/hour, alternatively (by slow intravenous injection) 25–50 mg, dose may be repeated according to response, for debilitated patients use dose for elderly
- Elderly: Usual dose 3–6 mg/kg/hour, alternatively (by slow intravenous injection) 25–50 mg, dose may be repeated according to response

Maintenance of anaesthesia using 2% injection

BY INTRAVENOUS INFUSION

- Adult: Usual dose 4–12 mg/kg/hour, for debilitated patients use dose for elderly
- Elderly: Usual dose 3–6 mg/kg/hour

Sedation of ventilated patients in intensive care using 1% or 2% injection

BY CONTINUOUS INTRAVENOUS INFUSION

- Adult: Usual dose 0.3–4 mg/kg/hour, adjusted according to response

Induction of sedation for surgical and diagnostic procedures using 0.5% or 1% injection

BY SLOW INTRAVENOUS INJECTION

- Adult: Initially 0.5–1 mg/kg, to be administered over 1–5 minutes, dose and rate of administration adjusted according to desired level of sedation and response

Maintenance of sedation for surgical and diagnostic procedures using 0.5% or 1% injection

INITIALLY BY INTRAVENOUS INFUSION

- Adult: Initially 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10–20 mg, (if rapid increase in sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration
1096 General anaesthesia

Maintenance of sedation for surgical and diagnostic procedures using 2% injection
INITIALLY BY INTRAVENOUS INFUSION
- Adult: Initially 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10–20 mg using 0.5% or 1% injection (if rapid increase in sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration.

Important safety information
Propofol should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- CAUTIONS Acute circulatory failure (shock) - cardiac impairment - cardiovascular disease - elderly - epilepsy - fixed cardiac output - hypotension - hypervolaemia - raised intracranial pressure - respiratory impairment
- INTERACTIONS → Appendix 1 (anaesthetics, general).
- SIDE-EFFECTS
  - Common or very common Headache - hypotension - tachycardia - transient apnoea
  - Uncommon Phlebitis - thrombosis
  - Rare Anaphylaxis - arrhythmia - convulsions (onset can be delayed) - delayed recovery from anaesthesia - euphoria
  - Very rare Discoloration of urine - pancreatitis - pulmonary oedema - sexual disinhibition
- FREQUENCY NOT KNOWN Bradycardia - pain on intravenous injection - propofol infusion syndrome - significant extraneous muscle movements

SIDE-EFFECTS, FURTHER INFORMATION
Bradycardia Bardycardia may be profound and may be treated with intravenous administration of an antimuscarinic drug.
Extraneous muscle movement Extraneous muscle movements can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction.

Pain on injection Can be reduced by intravenous lidocaine.

Propofol infusion syndrome Prolonged infusion of propofol doses exceeding 4 mg/kg/hour may result in potentially fatal effects, including metabolic acidosis, arrhythmias, cardiac failure, rhabdomyolysis, hyperlipidaemia, hyperkalaemia, hepatomegaly, and renal failure.

- PREGNANCY Max. dose for maintenance of anaesthesia 5 mg/kg/hour. May depress neonatal respiration if used during delivery.
- BREAST FEEDING Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.
- HEPATIC IMPAIRMENT Use with caution.
- RENAL IMPAIRMENT Use with caution.
- MONITORING REQUIREMENTS Monitor blood-lipid concentration if risk of fat overload or if sedation longer than 3 days.
- DIRECTIONS FOR ADMINISTRATION Shake before use; microbiological filter not recommended; may be administered via a Y-piece close to injection site co-administered with Glucose 5% or Sodium chloride 0.9%. 0.5% emulsion for injection or intermittent infusion; may be administered undiluted, or diluted with Glucose 5% or Sodium chloride 0.9%; dilute to a concentration not less than 1 mg/mL. 1% emulsion for injection or infusion; may be administered undiluted, or diluted with Glucose 5% (Diprivan®) or (Propofol-Lipuro®) or Sodium chloride 0.9% (Propofol-Lipuro® only); dilute to a concentration not less than 2 mg/mL; use within 6 hours of preparation. 2% emulsion for infusion; do not dilute.

- PATIENT AND CARER ADVICE Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.
- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Emulsion for injection
- PROPOFOL (Non-proprietary) Propofol 5 mg per 1 ml Propofol-Lipuro 0.5% emulsion for injection 20ml ampoules | 5 ampoule (PSt) £14.71
- Diprivan (AstraZeneca UK Ltd) Propofol 10 mg per 1 ml Diprivan 1% emulsion for injection 20ml ampoules | 5 ampoule (PSt) £15.36 (Hospital only)

Emulsion for infusion
- Diprivan (AstraZeneca UK Ltd) Propofol 10 mg per 1 ml Diprivan 1% emulsion for infusion 50ml pre-filled syringes | 1 pre-filled disposable injection (PSt) £10.68
- Propofol 20 mg per 1 ml Diprivan 2% emulsion for infusion 50ml pre-filled syringes | 1 pre-filled disposable injection (PSt) £15.16

ANAESTHETICS (VOLATILE LIQUID)
Nitrous oxide

INDICATIONS AND DOSE
Maintenance of anaesthesia in conjunction with other anaesthetic agents
BY INHALATION
- Adult: 50–66 %, to be administered using suitable anaesthetic apparatus in oxygen
Analgesia
BY INHALATION
- Adult: Up to 50 %, to be administered using suitable anaesthetic apparatus in oxygen, adjusted according to the patient’s needs

Important safety information
Nitrous oxide should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- CAUTIONS Entrapped air following recent underwater dive - pneumothorax - presence of intracranial air after head injury - recent intra-ocular gas injection
- CAUTIONS, FURTHER INFORMATION Nitrous oxide may have a deleterious effect if used in patients with an air-containing closed space since nitrous oxide diffuses into such a space with a resulting increase in pressure. This effect may be dangerous in conditions such as pneumothorax, which may enlarge to compromise respiration, or in the presence of intracranial air after head injury, entrapped air following recent underwater dive, or recent intra-ocular gas injection.

INTERACTIONS → Appendix 1 (anaesthetics, general).
- SIDE-EFFECTS Depression of white cell formation - hypoxia - megaloblastic anaemia - neurological toxic effects
SIDE-EFFECTS, FURTHER INFORMATION
Hypoxia Hypoxia can occur immediately following the administration of nitrous oxide; additional oxygen should always be given for several minutes after stopping the flow of nitrous oxide.

Prolonged exposure Exposure of patients to nitrous oxide for prolonged periods, either by continuous or by
intermittent administration, may result in megaloblastic anaemia owing to interference with the action of vitamin B₁₂; neurological toxic effects can occur without preceding overt haematological changes. Depression of white cell formation may also occur.

- **PREGNANCY** May depress neonatal respiration if used during delivery.
- **BREAST FEEDING** Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

- **MONITORING REQUIREMENTS**
  - Assessment of plasma-vitamin B₁₂ concentration should be considered in those at risk of deficiency, including the elderly, those who have a poor, vegetarian, or vegan diet, and those with a history of anaemia.
  - Nitrous oxide should not be given continuously for longer than 24 hours or more frequently than every 4 days without close supervision and haematological monitoring.

- **DIRECTIONS FOR ADMINISTRATION** For analgesia (without loss of consciousness), a mixture of nitrous oxide and oxygen containing 50% of each gas (Entonox® Equanox®) is used.

- **HANDLING AND STORAGE** Exposure of theatre staff to nitrous oxide should be minimised (risk of serious side-effects).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

### Inhalation gas

- **NITROUS OXIDE (Non-proprietary)**
  - Nitrous oxide 1 ml per 1 ml
  - Nitrous oxide cylinders size E | 1800 litre (no price available)
  - Medical Nitrous Oxide cylinders size D | 900 litre (no price available)
  - Medical Nitrous Oxide cylinders size G | 9000 litre (no price available)
  - Nitrous oxide cylinders size F | 3600 litre (no price available)
  - Nitrous oxide cylinders size J | 18000 litre (no price available)
  - Nitrous oxide cylinders size G | 9000 litre (no price available)
  - Nitrous oxide cylinders size C | 450 litre (no price available)
  - Medical Nitrous Oxide cylinders size F | 3600 litre (no price available)
  - Nitrous oxide cylinders size D | 900 litre (no price available)
  - Medical Nitrous Oxide cylinders size E | 1800 litre (no price available)

### Volatile halogenated anaesthetics

**Important safety information**

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- **CONTRA-INDICATIONS** Susceptibility to malignant hyperthermia
- **CAUTIONS** Can trigger malignant hyperthermia • raised intracranial pressure (can increase cerebrospinal pressure)
- **SIDE-EFFECTS**
  - Common or very common • Arrhythmias • cardiorespiratory depression • hypotension
  - Frequency not known • Convulsions • mood changes (that can last several days)
- **ALLERGY AND CROSS-SENSITIVITY** Can cause hepatotoxicity in those sensitised to halogenated anaesthetics.

### DIRECTIONS FOR ADMINISTRATION

Volatile liquid anaesthetics are administered using calibrated vapourisers, using air, oxygen, or nitrous oxide-oxygen mixtures as the carrier gas. To prevent hypoxia, the inspired gas mixture should contain a minimum of 25% oxygen at all times.

- **PATIENT AND CARER ADVICE** Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of driving or undertaking skilled tasks afterwards. For a short general anaesthetic, the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

### Desflurane

#### INDICATIONS AND DOSE

**Induction of anaesthesia (but not recommended)**

**BY INHALATION**
- **Adult:** 4–11%, to be inhaled through specifically calibrated vaporiser

**Maintenance of anaesthesia (in nitrous oxide–oxygen)**

**BY INHALATION**
- **Adult:** 2–6%, to be inhaled through a specifically calibrated vaporiser

**Maintenance of anaesthesia (in oxygen or oxygen-enriched air)**

**BY INHALATION**
- **Adult:** 2.5–8.5%, to be inhaled through a specifically calibrated vaporiser

**Important safety information**

Desflurane should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- **INTERACTIONS** ➜ Appendix 1 (anaesthetics, general).
- **SIDE-EFFECTS** Apnoea • breath-holding • cough • increased secretions • laryngospasm
- **PREGNANCY** May depress neonatal respiration if used during delivery.
- **BREAST FEEDING** Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

- **PATIENT AND CARER ADVICE** Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**

- **Suprane** (Baxter Healthcare Ltd)
  - Desflurane 1 ml per 1 ml | Suprane volatile liquid | 240 ml (no price available) (Hospital only)
**Isoflurane**

**INDICATIONS AND DOSE**

**Induction of anaesthesia (in oxygen or nitrous oxide-oxygen)**

**BY INHALATION**

- Adult: Initially 0.5 %, increased to 3 %, adjusted according to response, administered using specifically calibrated vaporiser

**Maintenance of anaesthesia (in nitrous oxide-oxygen)**

**BY INHALATION**

- Adult: 1–2.5 %, to be administered using specifically calibrated vaporiser; an additional 0.5–1 % may be required when given with oxygen alone

**Breast-feeding**

- May depress neonatal respiration if used during delivery.

**Pregnancy**

- Caution should also be emphasised.

**Renal impairment**

- Use with caution.

**Patient and carer advice**

- Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**

- **Isoflurane (non-proprietary)**
  - Isoflurane 1 ml per 1 ml (Baxter Healthcare Ltd) $£47.50 (Hospital only)
  - Isoflurane volatile liquid 1 ml (Baxter Healthcare Ltd) $£35.29 (Hospital only)

**Sevoflurane**

**Indications and dose**

**Induction of anaesthesia (in oxygen or nitrous oxide-oxygen)**

**By Inhalation**

- Adult: Initially 0.5–1 %, adjusted according to response, then increased to up to 8 %, to be administered using specifically calibrated vaporiser

**Maintenance of anaesthesia (in oxygen or nitrous oxide-oxygen)**

**By Inhalation**

- Adult: 0.5–3 %, adjusted according to response, to be administered using specifically calibrated vaporiser

**Important safety information**

Sevoflurane should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

**Caution**

- Susceptibility to QT-interval prolongation

**Interactions**

- May depress neonatal respiration if used during delivery.

**Breast-feeding**

Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

**Renal impairment**

Use with caution.

**Patient and carer advice**

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

**Pre-medication and peri-operative drugs**

**Drugs that affect gastric pH**

Regurgitation and aspiration of gastric contents (Mendelson’s syndrome) can be an important complication of general anaesthesia, particularly in obstetrics and during emergency surgery, and requires prophylaxis against acid aspiration. Prophylaxis is also needed in those with gastro-oesophageal reflux disease and in circumstances where gastric emptying may be delayed.

A H[subscript:2]-receptor antagonist can be used before surgery to increase the pH and reduce the volume of gastric fluid. It does not affect the pH of fluid already in the stomach and this limits its value in emergency procedures; an oral H[subscript:2]-receptor antagonist can be given 1–2 hours before the procedure. Antacids are frequently used to neutralise the acidity of the fluid already in the stomach; ‘clear’ (non-particulate) antacids such as sodium citrate are preferred.
Anaesthetic adjuvants 1099

Antimuscarinic drugs
Antimuscarinic drugs are used (less commonly nowadays) as premedicants to dry bronchial and salivary secretions which are increased by intubation, upper airway surgery, or some inhalational anaesthetics. They are also used before or with neostigmine p. 912 to prevent bradycardia, excessive salivation, and other muscarinic actions of neostigmine. They also prevent bradycardia and hypotension associated with drugs such as propofol and suxamethonium chloride.

Atropine sulphate below is now rarely used for premedication but still has an emergency role in the treatment of vagotonic side-effects. Atropine sulphate may have a role in acute arrhythmias after myocardial infarction.

Hyoscine hydrobromide p. 344 reduces secretions and also provides a degree of amnesia, sedation, and anti-emesis. Unlike atropine sulphate it may produce bradycardia rather than tachycardia.

Glycopyrronium bromide p. 1100 reduces salivary secretions. When given intravenously it produces less tachycardia than atropine sulphate. It is widely used with neostigmine for reversal of non-depolarising neuromuscular blocking drugs.

Phenothiazines do not effectively reduce secretions when used alone.

Sedative drugs
Fear and anxiety before a procedure (including the night before) can be minimised by using a sedative drug, usually a benzodiazepine. Premedication may also augment the action of anaesthetics and provide some degree of pre-operative amnesia. The choice of drug depends on the individual, the nature of the procedure, the anaesthetic to be used, and other prevailing circumstances such as outpatients, obstetrics, and availability of recovery facilities. The choice also varies between elective and emergency procedures.

Premeditants can be given the night before major surgery; a further, smaller dose may be required before surgery. Alternatively, the first dose may be given on the day of the procedure.

Benzodiazepines
Benzodiazepines possess useful properties for premedication including relief of anxiety, sedation, and amnesia; short-acting benzodiazepines taken by mouth are the most common premedicants. Benzodiazepines are also used in intensive care units for sedation, particularly in those receiving assisted ventilation. Flumazenil p. 1132 is used to antagonise the effects of benzodiazepines.

Diazepam p. 267 is used to produce mild sedation with amnesia. It is a long-acting drug with active metabolites and a second period of drowsiness can occur several hours after its administration. Peri-operative use of diazepam in children is not recommended; its effect and timing of response are unreliable and paradoxical effects may occur.

Diazepam is relatively insoluble in water and preparations formulated in organic solvents are painful on intravenous injection and give rise to a high incidence of venous thrombosis (which may not be noticed for several days after the injection). Intramuscular injection of diazepam is painful and absorption is erratic. An emulsion formulated for intravenous injection is less irritant and reduces the risk of venous thrombosis; it is not suitable for intramuscular injection.

Temazepam p. 420 is given by mouth for premedication and has a shorter duration of action and a more rapid onset than oral diazepam; anxiolytic and sedative effects last about 90 minutes although there may be residual drowsiness.

Lorazepam p. 412 produces more prolonged sedation than temazepam and it has marked amnesic effects.

Midazolam p. 414 is a water-soluble benzodiazepine that is often used in preference to intravenous diazepam; recovery is faster from diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing. Midazolam is associated with profound sedation when high doses are given intravenously or when it is used with certain other drugs.

Other drugs for sedation
Dexmedetomidine p. 1110 and clonidine hydrochloride p. 137 are alpha2-adrenergic agonists with sedative properties. Dexmedetomidine p. 1110 is licensed for the sedation of patients receiving intensive care who need to remain responsive to verbal stimulation. Clonidine hydrochloride p. 137 [unlicensed indication] can be used by mouth or by intravenous injection as a sedative agent when adequate sedation cannot be achieved with standard treatment.

Antagonists for central and respiratory depression
Respiratory depression is a major concern with opioid analgesics and it may be treated by artificial ventilation or be reversed by naloxone hydrochloride p. 1133. Naloxone hydrochloride will immediately reverse opioid-induced respiratory depression but the dose may have to be repeated because of the short duration of action of naloxone hydrochloride; however, naloxone hydrochloride will also antagonise the analgesic effect.

Flumazenil p. 1132 is a benzodiazepine antagonist for the reversal of the central sedative effects of benzodiazepines after anaesthetic and similar procedures. Flumazenil has a shorter half-life and duration of action than diazepam or midazolam so patients may become resedated.

Doxapram hydrochloride p. 261 is a central and respiratory stimulant but is of limited value in anaesthesia.

ANTIMUSCARINICS

Atropine sulfate
The properties listed below are those particular to the drug only. For properties common to the class, see Antimuscarinics Systemic, p. 668.

INDICATIONS AND DOSE
Premedication
BY INTRAVENOUS INJECTION
– Child 12-17 years: 300–600 micrograms, to be administered immediately before induction of anaesthesia
– Adult: 300–600 micrograms, to be administered immediately before induction of anaesthesia

BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION
– Child 12-17 years: 300–600 micrograms, to be administered 30–60 minutes before induction of anaesthesia
– Adult: 300–600 micrograms, to be administered 30–60 minutes before induction of anaesthesia

Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block
BY INTRAVENOUS INJECTION
– Child 12-17 years: 0.6–1.2 mg
– Adult: 0.6–1.2 mg

Intra-operative bradycardia
BY INTRAVENOUS INJECTION
– Child 12-17 years: 300–600 micrograms, larger doses may be used in emergencies
– Adult: 300–600 micrograms, larger doses may be used in emergencies
1100 General anaesthesia

Treatment of poisoning by organophosphorus insecticide or nerve agent (in combination with pralidoxime chloride)

**BY INTRAVENOUS INJECTION**
- Child: 20 micrograms/kg every 5–10 minutes (max. per dose 2 mg) until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning
- Adult: 2 mg every 5–10 minutes until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning

**EXCEPTIONS TO LEGAL CATEGORY**
- With oral use

**MONITORING REQUIREMENTS**
- Bowel colic in palliative care

**PREGNANCY**
- Not licensed for use in children under 12 years for intra-operative bradycardia or by intravenous route for premedication. Not licensed for the control of muscarinic side-effects of edrophonium in reversal of competitive neuromuscular block.

**UNLICENSED USE**
- With use in children

**Important safety information**
Antimuscarinic drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.

**INDICATIONS AND DOSE**

1. Premedication at induction

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**
- Adult: 200–400 micrograms, alternatively 4–5 micrograms/kg (max. per dose 400 micrograms)

2. Intra-operative bradycardia

**BY INTRAVENOUS INJECTION**
- Adult: 200–400 micrograms, alternatively 4–5 micrograms/kg (max. per dose 400 micrograms), repeated if necessary

3. Control of muscarinic side-effects of neostigmine in reversal of non-depolarising neuromuscular block

**BY INTRAVENOUS INJECTION**
- Adult: 10–15 micrograms/kg, alternatively, 200 micrograms per 1 mg of neostigmine to be administered

4. Bowel colic in palliative care

**EXCEPTIONS TO LEGAL CATEGORY**
- With intravenous use or intravenous use or subcutaneous use

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

- **ATROPINE SULFATE (Non-proprietary)**
  - Atropine sulfate 600 microgram tablets | 28 tablet (P) £25.75 DT price = £25.75

Solution for injection

- **ATROPINE SULFATE (Non-proprietary)**
  - Atropine sulfate 200 microgram per 1 ml Atropine 1mg/5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (P) £7.08 | 10 pre-filled disposable injection (P) £130.00
  - Atropine sulfate 300 microgram per 1 ml Atropine 3mg/10ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (P) 16.78–17.08 | 10 pre-filled disposable injection (P) £130.00

**Atropine sulfate 400 microgram per 1 ml**
- Atropine 400microgram/1ml solution for injection ampoules | 10 ampoule (P) £64.55

**Atropine sulfate 600 microgram per 1 ml**
- Atropine 600microgram/1ml solution for injection ampoules | 10 ampoule (P) £11.71 DT price = £11.69
- Atropine 600micrograms/1ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (P) £7.08

**Atropine sulfate 1 mg per 1 ml**
- Atropine 1mg/1ml solution for injection ampoules | 10 ampoule (P) £54.91

**Glycopyrronium bromide**

(Glycopyrrolate)

The properties listed below are those particular to the drug only. For properties common to the class, see Antimuscarinics Systemic, p. 668.

**INDICATIONS AND DOSE**

**Premedication at induction**

**BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**
- Child: 40 micrograms/kg (max. per dose 3 mg)
- Adult: 3 mg

**Excessive bradycardia associated with beta-blocker use**

**BY INTRAVENOUS INJECTION**
- Adult: 0.6–2.4 mg in divided doses (max. per dose 600 micrograms)

**Bradycardia following myocardial infarction (particularly if complicated by hypotension)**

**BY INTRAVENOUS INJECTION**
- Adult: 500 micrograms every 3–5 minutes; maximum 3 mg

**Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm**

**BY MOUTH**
- Adult: 0.6–1.2 mg daily, dose to be taken at night

**LESS SUITABLE FOR PRESCRIBING**
- With oral use

**Important safety information**
Antimuscarinic drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **GLICYCYPYRRIUM BROMIDE (Non-proprietary)**
  - Glycopyrronium bromide 1 mg tablets | 30 tablet (P) £102.60–£113.69 DT price = £110.85
  - Glycopyrronium bromide 2 mg tablets | 30 tablet (P) £131.10–£145.26 DT price = £141.63
1.2 Malignant hyperthermia

MUSCLE RELAXANTS

Dantrolene sodium

**DRUG ACTION** Acts on skeletal muscle cells by interfering with calcium efflux, thereby stopping the contractile process.

**INDICATIONS AND DOSE**

Malignant hyperthermia

*BY RAPID INTRAVENOUS INJECTION*

- **Adult:** Initially 2–3 mg/kg, then 1 mg/kg, repeated if necessary; maximum 10 mg per course

Chronic severe spasticity of voluntary muscle

*BY MOUTH*

- **Adult:** Initially 25 mg daily, then increased to up to 100 mg 4 times a day, dose increased at weekly intervals; usual dose 75 mg 3 times a day

**SIDE-EFFECTS, FURTHER INFORMATION**

**Hepatotoxicity** Potentially life-threatening hepatotoxicity reported—discontinue if abnormal liver function tests or symptoms of liver disorder; re-introduce only if complete reversal of hepatotoxicity.

**PREGNANCY**

- With intravenous use Use only if potential benefit outweighs risk.
- With oral use Avoid use in chronic spasticity—embryotoxic in animal studies.

**BREAST FEEDING**

- With intravenous use Present in milk—use only if potential benefit outweighs risk.
- With oral use Present in milk—manufacturer advises avoid use in chronic spasticity.

**HEPATIC IMPAIRMENT** Avoid—may cause severe liver damage (injection may be used in an emergency for malignant hyperthermia).

**MONITORING REQUIREMENTS**

- With oral use Test liver function before and at intervals during therapy.

**PATIENT AND CARER ADVICE** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

- With oral use Hepatotoxicity Patients should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, oral suspension

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 2**

- Dantrolium (Norgine Pharmaceuticals Ltd)
  - Dantrolene sodium 25 mg
  - Dantrolene sodium 100 mg
  - Dantrolene sodium 20 mg

**Powder for solution for injection**

- Dantrolium (Norgine Pharmaceuticals Ltd)
  - Dantrolene sodium 20 mg

**ANNEX**

**CONTRA-INDICATIONS**

- With oral use acute muscle spasm—avoid when spasticity is useful, for example, locomotion

**CAUTIONS**

- With intravenous use avoid extravasation (risk of tissue necrosis)
- With oral use females (hepatotoxicity)· history of liver disorders (hepatotoxicity)· if doses greater than 400 mg daily (hepatotoxicity)· impaired cardiac function· impaired pulmonary function· patients over 30 years (hepatotoxicity)· therapeutic effect may take a few weeks to develop—discontinue if no response within 6–8 weeks

**INTERACTIONS** → Appendix 1 (muscle relaxants).

- With oral use Caution if concomitant use of hepatotoxic drugs.

**SIDE-EFFECTS**

- Common or very common → With oral use abdominal pain· anorexia· asthenia· chills· diarrhoea (withdraw if severe, discontinue treatment if recurs on re-introduction)· dizziness· drowsiness· fatigue· fever· headache· hepatotoxicity· nausea· pericarditis· pleural effusion· rash· respiratory depression· seizures· speech disturbances· visual disturbances· vomiting

- Uncommon → With oral use confusion· constipation· crystalluria· depression· dysphagia· dysphonia· erratic blood pressure· exacerbation of cardiac insufficiency· haematuria· increased sweating· increased urinary frequency· insomnia· nervousness· tachycardia· urinary incontinence· urinary retention

- Frequency not known → With intravenous use dizziness· erythema· hepatotoxicity· injection-site reactions· pulmonary oedema· rash· swelling· thrombophlebitis· weakness

1.3 Neuromuscular blockade

**Neuromuscular blockade**

**Neuromuscular blocking drugs**

Neuromuscular blocking drugs used in anaesthesia are also known as muscle relaxants. By specific blockade of the neuromuscular junction they enable light anaesthesia to be used with adequate relaxation of the muscles of the abdomen and diaphragm. They also relax the vocal cords and allow the passage of a tracheal tube. Their action differs from the muscle relaxants used in muscular skeletal disorders that act on the spinal cord or brain.

Patients who have received a neuromuscular blocking drug should always have their respiration assisted or controlled until the drug has been inactivated or antagonised. They should also receive sufficient concomitant inhalational or intravenous anaesthetic or sedative drugs to prevent awareness.

**Non-depolarising neuromuscular blocking drugs**

Non-depolarising neuromuscular blocking drugs (also known as competitive muscle relaxants) compete with
acetylcholine for receptor sites at the neuromuscular junction and their action can be reversed with anticholinesterases such as neostigmine p. 912. Non-depolarising neuromuscular blocking drugs can be divided into the aminosteroid group, comprising pancuronium bromide p. 1104, rocuronium bromide p. 1105, and vecuronium bromide p. 1105; and the benzylisoquinolinium group, comprising atracurium besilate p. 1103, cisatracurium p. 1104, and mivacurium p. 1104.

Non-depolarising neuromuscular blocking drugs have a slower onset of action than suxamethonium chloride. These drugs can be classified by their duration of action as short-acting (15–30 minutes), intermediate-acting (30–40 minutes), and long-acting (60–120 minutes), although duration of action is dose-dependent. Drugs with a shorter or intermediate duration of action, such as atracurium besilate and vecuronium bromide, are more widely used than those with a longer duration of action, such as pancuronium bromide.

Non-depolarising neuromuscular blocking drugs have no sedative or analgesic effects and are not considered to trigger malignant hyperthermia.

For patients receiving intensive care and who require tracheal intubation and mechanical ventilation, a non-depolarising neuromuscular blocking drug is chosen according to its onset of effect, duration of action, and side-effects. Rocuronium bromide, with a rapid onset of effect, may facilitate intubation. Atracurium besilate or cisatracurium may be suitable for long-term neuromuscular blockade since their duration of action is not dependent on elimination by the liver or the kidneys.

Atracurium besilate, a mixture of 10 isomers, is a benzylisoquinolinium neuromuscular blocking drug with an intermediate duration of action. It undergoes non-enzymatic metabolism which is independent of liver and kidney function, thus allowing its use in patients with hepatic or renal impairment. Cardiovascular effects are associated with significant histamine release; histamine release can be minimised by administering slowly or in divided doses over at least 1 minute.

Cisatracurium is a single isomer of atracurium besilate. It is more potent and has a slightly longer duration of action than atracurium besilate and provides greater cardiovascular stability because cisatracurium lacks histamine-releasing effects.

Mivacurium, a benzylisoquinolinium neuromuscular blocking drug, has a short duration of action. It is metabolised by plasma cholinesterase and muscle paralysis is prolonged in individuals deficient in this enzyme. It is not associated with vagolytic activity or ganglionic blockade although histamine release can occur, particularly with rapid injection.

Pancuronium bromide, an aminosteroid neuromuscular blocking drug, has a long duration of action and is often used in patients receiving long-term mechanical ventilation in intensive care units. It lacks a histamine-releasing effect, but vagolytic and sympathomimetic effects can cause tachycardia and hypertension.

Rocuronium bromide exerts an effect within 2 minutes and has the most rapid onset of any of the non-depolarising neuromuscular blocking drugs. It is an aminosteroid neuromuscular blocking drug with an intermediate duration of action. It is reported to have minimal cardiovascular effects; high doses produce mild vagolytic activity.

Vechuronium bromide, an aminosteroid neuromuscular blocking drug, has an intermediate duration of action. It does not generally produce histamine release and lacks cardiovascular effects.

Depolarising neuromuscular blocking drugs
Suxamethonium chloride below has the most rapid onset of action of any of the neuromuscular blocking drugs and is ideal if fast onset and brief duration of action are required, e.g. with tracheal intubation. Unlike the non-depolarising neuromuscular blocking drugs, its action cannot be reversed and recovery is spontaneous; anticholinesterases such as neostigmine potentiate the neuromuscular block.

Suxamethonium chloride (below) should be given after anaesthetic induction because paralysis is usually preceded by painful muscle fasciculations. While tachycardia occurs with single use, bradycardia may occur with repeated doses in adults and with the first dose in children. Premedication with atropine reduces bradycardia as well as the excessive salivation associated with suxamethonium chloride below.

Prolonged paralysis may occur in dual block, which occurs with high or repeated doses of suxamethonium chloride below and is caused by the development of a non-depolarising block following the initial depolarising block. Individuals with myasthenia gravis are resistant to suxamethonium chloride below but can develop dual block resulting in delayed recovery. Prolonged paralysis may also occur in those with low or atypical plasma cholinesterase. Assisted ventilation should be continued until muscle function is restored.

Drugs for reversal of neuromuscular blockade

Anticholinesterases
Anticholinesterases reverse the effects of the non-depolarising (competitive) neuromuscular blocking drugs such as pancuronium bromide but they prolong the action of the depolarising neuromuscular blocking drug suxamethonium chloride.

Neostigmine is used specifically for reversal of non-depolarising (competitive) blockade. It acts within one minute of intravenous injection and its effects last for 20 to 30 minutes; a second dose may then be necessary. Glycopyronium bromide p. 1100 or alternatively atropine sulfate p. 1099, given before or with neostigmine, prevent bradycardia, excessive salivation, and other muscarinic effects of neostigmine.

Other drugs for reversal of neuromuscular blockade
Sugammadex p. 1106 is a modified gamma cyclodextrin that can be used for rapid reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide. In practice, sugammadex is used mainly for rapid reversal of neuromuscular blockade in an emergency.

NEUROMUSCULAR BLOCKING DRUGS
(DEPOLARISING)

Suxamethonium chloride
(Succinylcholine chloride)

**Drug Action** Suxamethonium acts by mimicking acetylcholine at the neuromuscular junction but hydrolysis is much slower than for acetylcholine; depolarisation is therefore prolonged, resulting in neuromuscular blockade.

**Indications and Dose**
**Neuromuscular blockade (short duration) during surgery and intubation**
- **By Intravenous Injection**
  - Adult: 1–1.5 mg/kg

**Important safety information**
Should only be administered by, or under the direct supervision of, personnel experienced in its use.

**Contra-indications** Duchenne muscular dystrophy - family history of malignant hyperthermia - hyperkalaemia - low plasma-cholinesterase activity (including severe liver
Non-depolarising neuromuscular blocking drugs (NON-DEPOLARISING)

Important safety information
Non-depolarising neuromuscular blocking drugs should only be administered by, or under direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

Cautions
Burns (resistance can develop, increased doses may be required) - cardiovascular disease (reduce rate of administration) - electrolyte disturbances (response unpredictable) - fluid disturbances (response unpredictable) - hypothermia (activity prolonged, lower doses required) - myasthenia gravis (activity prolonged, lower doses required) - neuromuscular disorders (response unpredictable)

Interactions
Appendix 1 (muscle relaxants).

Allergy and cross-sensitivity
Allergic cross-reactivity between neuromuscular blocking drugs has been reported; caution is advised in cases of hypersensitivity to these drugs.

Pregnancy
Non-depolarising neuromuscular blocking drugs are highly ionised at physiological pH and are therefore unlikely to cross the placenta in significant amounts.

Breast feeding
Non-depolarising neuromuscular blocking drugs are ionised at physiological pH and are unlikely to be present in milk in significant amounts. Breast-feeding may be resumed once the mother has recovered from neuromuscular block.

Atracurium besilate
(Atracurium besylate)

Indications and dose
Neuromuscular blockade (short to intermediate duration) for surgery and intubation
- Adult: Initially 300–600 micrograms/kg, then (by intravenous injection) 100–200 micrograms/kg as required, alternately (by intravenous injection) initially 300–600 micrograms/kg, followed by (by intravenous infusion) 300–600 micrograms/kg/hour

Neuromuscular blockade during intensive care
- Adult: Initially 300–600 micrograms/kg, initial dose is optional, then (by intravenous infusion) 270–1770 micrograms/kg/hour; (by intravenous infusion) usual dose 650–780 micrograms/kg/hour

Doses at extremes of body weight
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body weight.

Side-effects
- Very rare Anaphylactoid reactions
- Frequency not known Acute myopathy (after prolonged use in intensive care) - bronchospasm - hypotension - seizures - skin flushing - tachycardia

Directions for administration
For intravenous infusion (Tracrium®; Atracurium besilate injection, Hospira; Atracurium injection/infusion, Genus), give continuously in Glucose 5% or Sodium Chloride 0.9%; stability varies with diluent; dilute requisite dose with infusion fluid to a concentration of 0.5–5 mg/mL.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

Solution for injection
- SUXAMETHONIUM CHLORIDE (Non-proprietary)
  - Suxamethonium chloride 50 mg per 1 ml Suxamethonium chloride 100mg/2ml solution for injection ampoules | 10 ampoule (£0.50)
  - £5.76–7.00
- Anectine (GlaxoSmithKline Ltd)
  - Suxamethonium chloride 50 mg per 1 ml Anectine 100mg/2ml solution for injection ampoules | 5 ampoule (£0.57)

Neuromuscular blockade
1103

Anaesthesia
Cisatracurium

**INDICATIONS AND DOSE**

Neuromuscular blockade (intermediate duration) during surgery and intubation

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: Initially 150 micrograms/kg, then (by intravenous injection) maintenance 30 micrograms/kg every 20 minutes, alternatively (by intravenous infusion) initially 180 micrograms/kg/hour, then (by intravenous infusion) maintenance 60–120 micrograms/kg/hour, maintenance dose administered after stabilisation

**Neuromuscular blockade (intermediate duration) during intensive care**

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: Initially 150 micrograms/kg, initial dose is optional, then (by intravenous infusion) 180 micrograms/kg/hour, adjusted according to response; (by intravenous infusion) usual dose 30–600 micrograms/kg/hour

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

- **SIDE-EFFECTS** Acute myopathy (after prolonged use in intensive care) - bradycardia

- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use For intravenous infusion (Nimbex®, Nimbex Forte®), give continuously in Glucose 5% or Sodium Chloride 0.9%; solutions of 2 mg/mL and 5 mg/mL may be infused undiluted; alternatively dilute with infusion fluid to a concentration of 0.1–2 mg/mL.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **Cisatracurium (Non-proprietary)**
      - Cisatracurium (as Cisatracurium besilate) 2 mg per 1 ml Cisatracurium besilate 20mg/10ml solution for injection vials | 5 vial [P3] £37.75 (Hospital only) | 5 vial [P3] £37.75
      - Cisatracurium (as Cisatracurium besilate) 5 mg per 1 ml Cisatracurium besilate 150mg/30ml solution for injection vials | 1 vial [P3] £45.00 (Hospital only) | 1 vial [P3] £18.66
    - **Nimbex** (GlaxoSmithKline UK Ltd)
      - Cisatracurium (as Cisatracurium besilate) 2 mg per 1 ml Nimbex 20mg/10ml solution for injection ampoules | 5 ampoule [P3] £37.75
      - Cisatracurium (as Cisatracurium besilate) 5 mg per 1 ml Nimbex Forte 150mg/30ml solution for injection vials | 1 vial [P3] £31.09

Mivacurium

**INDICATIONS AND DOSE**

Neuromuscular blockade (short duration) during surgery and intubation

**INITIALLY BY INTRAVENOUS INJECTION**

- Adult: 70–250 micrograms/kg; (by intravenous injection) maintenance 100 micrograms/kg every 15 minutes, alternatively (by intravenous infusion) maintenance 8–10 micrograms/kg/minute, (by intravenous infusion) adjusted in steps of 1 microgram/kg/minute every 3 minutes if required; (by intravenous infusion) usual dose 6–7 micrograms/kg/minute

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

- **SIDE-EFFECTS** Burns (low plasma cholinesterase activity; dose titration required) - elderly

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **Mivacron** (GlaxoSmithKline UK Ltd)
      - Mivacurium (as Mivacurium chloride) 2 mg per 1 ml Mivacron 10mg/5ml solution for injection ampoules | 5 ampoule [P3] £13.95

Pancuronium bromide

**INDICATIONS AND DOSE**

Neuromuscular blockade (long duration) during surgery and intubation

**BY INTRAVENOUS INJECTION**

- Adult: Initially 100 micrograms/kg, then 20 micrograms/kg as required

**Neuromuscular blockade (long duration) during intensive care**

**BY INTRAVENOUS INJECTION**

- Adult: Initially 100 micrograms/kg, initial dose is optional, then 60 micrograms/kg every 60–90 minutes

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

- **SIDE-EFFECTS** Acute myopathy (after prolonged use in intensive care) - hypertension - tachycardia

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Pancuronium lacks histamine-releasing effect, but vagolytic and sympathomimetic effects can cause tachycardia and hypertension.

- **HEPATIC IMPAIRMENT** Possibly slower onset, higher dose requirement, and prolonged recovery time.

- **RENAI IMPAIRMENT** Use with caution; prolonged duration of block.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **PANCURONIUM BROMIDE (Non-proprietary)**
      - Pancuronium bromide 2 mg per 1 ml Pancuronium bromide 4mg/2ml solution for injection ampoules | 10 ampoule [P3] £50.00
Vecuronium bromide

**INDICATIONS AND DOSE**
Neuromuscular blockade (intermediate duration) during surgery and intubation

**INITIALLY BY INTRAVENOUS INJECTION**
- Adult: Initially 600 micrograms/kg; (by intravenous injection) maintenance 150 micrograms/kg, alternatively (by intravenous infusion) maintenance 300–600 micrograms/kg/hour, adjusted according to response
- Elderly: Initially 600 micrograms/kg; (by intravenous injection) maintenance 75–100 micrograms/kg, alternatively (by intravenous infusion) maintenance up to 400 micrograms/kg/hour, adjusted according to response

Neuromuscular blockade (intermediate duration) during intensive care

**INITIALLY BY INTRAVENOUS INJECTION**
- Adult: Initially 600 micrograms/kg, initial dose is optional; (by intravenous infusion) maintenance 300–600 micrograms/kg/hour for first hour, then (by intravenous infusion), adjusted according to response

**Doses at extremes of body-weight**
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal bodyweight.

**SIDE-EFFECTS**
- Very rare: Anaphylactoid reactions
- Frequency not known: Acute myopathy (after prolonged use in intensive care) - bronchospasm - hypotension - skin flushing - tachycardia

**HEPATIC IMPAIRMENT**
Use with caution in significant impairment.

**RENAL IMPAIRMENT**
Use with caution.

**DIRECTIONS FOR ADMINISTRATION**
Reconstitute each vial with 5 mL. Water for Injections to give 2 mg/mL solution; alternatively reconstitute with up to 10 mL Glucose 5% or Sodium Chloride 0.9% or Water for Injections—unsuitable for further dilution if not reconstituted with Water for Injections. For continuous intravenous infusion, dilute reconstituted solution to a concentration up to 40 micrograms/L with Glucose 5% or Sodium Chloride 0.9%; reconstituted solution can also be given via drip tubing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- Norcuron (Merck Sharp & Dohme Ltd)
  Vecuronium bromide 10 mg powder and solvent for solution for injection vials | 10 vial (£33.73) (Hospital only)

1.4 Neuromuscular blockade reversal

**Drugs used for Neuromuscular blockade reversal not listed below; Neostigmine, p. 912**

Glycopyrrolonium bromide with neostigmine

The properties listed below are those particular to the combination only. For the properties of the components please consider, glycopyrrolonium bromide p. 1100, neostigmine p. 912.

**INDICATIONS AND DOSE**
Reversal of non-depolarising neuromuscular blockade

**BY INTRAVENOUS INJECTION**
- Adult: 1–2 mL, repeated if necessary, alternatively 0.02 mL/kilogram (max. per dose 2 mL), repeated if necessary, dose to be given over 10–30 seconds

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- GLYCOPPYRROLONIUM BROMIDE WITH NEOSTIGMINE (Non-proprietary)
  Glycopyrrolonium bromide 500 microgram per 1 mL, Neostigmine metilsulfate 2.5 mg per 1 mL (Merck Sharp & Dohme Ltd)
  Glycopyrrolonium bromide 500 micrograms/1ml solution for injection ampoules | 10 ampoule (£9.11)
postoperative use. Diclofenac and paracetamol can be given by injection as well as by mouth. Diclofenac sodium, can be given by intravenous infusion for the treatment or prevention of postoperative pain. Intramuscular injections of diclofenac sodium and ketoprofen are rarely used; they are given deep into the gluteal muscle to minimise pain and tissue damage. Ketorolac trometamol is less irritant on intramuscular injection but pain has been reported; it can also be given by intravenous injection.

Suppositories of diclofenac sodium and ketoprofen may be effective alternatives to the parenteral use of these drugs.

**Opioid analgesics**

Opioid analgesics are now rarely used as premedicants; they are more likely to be administered at induction. Preoperative use of opioid analgesics is generally limited to those patients who require control of existing pain. See general notes on opioid analgesics and their use in postoperative pain. See also the management of opioid-induced respiratory depression.

**Intra-operative analgesia**

Opioid analgesics given in small doses before or with induction reduce the dose requirement of some drugs used during anaesthesia. Alfentanil p. 357, fentanyl p. 362, and remifentanil p. 1108 are particularly useful because they act within 1–2 minutes and have short durations of action. The initial doses of alfentanil or fentanyl are followed either by successive intravenous injections or by an intravenous infusion; prolonged infusions increase the duration of effect. Repeated intra-operative doses of alfentanil or fentanyl should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive. Alfentanil, fentanyl, and remifentanil can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs. are followed either by successive intravenous injections or by an intravenous infusion; prolonged infusions increase the duration of effect.

In contrast to other opioids which are metabolised in the liver, remifentanil undergoes rapid metabolism by nonspecific blood and tissue esterases; its short duration of action allows prolonged administration at high dosage, without accumulation, and with little risk of residual postoperative respiratory depression. Remifentanil should not be given by intravenous injection intraoperatively, but it is well suited to continuous infusion; a supplementary analgesic is given before stopping the infusion of remifentanil.

**Bupivacaine with fentanyl**

The properties listed below are those particular to the combination only. For the properties of the components please consider, bupivacaine hydrochloride p. 1113, fentanyl p. 362.

---

**1.5 Peri-operative analgesia**

**Peri-operative analgesia**

**Non-opioid analgesics**

Since non-steroidal anti-inflammatory drugs (NSAIDs) do not depress respiration, do not impair gastro-intestinal motility, and do not cause dependence, they may be useful alternatives or adjuncts to opioids for the relief of postoperative pain. NSAIDs may be inadequate for the relief of severe pain. Acmetacin p. 917, diclofenac sodium p. 921, diclofenac potassium p. 920, flurbiprofen p. 994, ibuprofen p. 927, ketoprofen p. 930, paracetamol p. 354, parecoxib p. 1108, and ketorolac trometamol p. 1107 are licensed for
During labour (once epidural block established)

**BY CONTINUOUS LUMBAR EPIDURAL INFUSION**

- Adult: 10–18.75 mg/hour of bupivacaine to be administered and 16–30 micrograms/hour of fentanyl to be administered

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion, infusion

**Solution for infusion**

- Bufyl (AMCo)
  - Bupivacaine hydrochloride 1 mg per 1 ml, Fentanyl 2 microgram per 1 ml
  - [20 bag £9.00](Hospital only) Schedule 2 (CD)
  - Bupivacaine hydrochloride 1.25 mg per 1 ml, Fentanyl (as Fentanyl citrate) 2 microgram per 1 ml
  - [Bufyl 1.25mg/ml and 2micrograms/ml 250ml infusion bags £18.00](Hospital only) Schedule 2 (CD)
  - Bufyl 1.25mg/ml and 2micrograms/ml 500ml infusion bags | 10 bag £92.00 (Hospital only) Schedule 2 (CD)

**NON-Steroidal ANTI-INFLAMMATORY DRUGS**

**Ketorolac trometamol**

**INDICATIONS AND DOSE**

**Short-term management of moderate to severe acute postoperative pain only**

- **BY INTRAMUSCULAR INJECTION OR BY INTRAVENOUS INJECTION**
  - Adult (body-weight up to 50 kg): Initially 10 mg, then 10–30 mg every 4–6 hours as required for maximum duration of treatment 2 days, to be given over at least 15 seconds, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 60 mg per day
  - Adult (body-weight 50 kg and above): Initially 10 mg, then 10–30 mg every 4–6 hours as required for maximum duration of treatment 2 days, to be given over at least 15 seconds, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 90 mg per day
  - Elderly: Initially 10 mg, then 10–30 mg every 4–6 hours as required for maximum duration of treatment 2 days, to be given over at least 15 seconds, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 60 mg per day

**CONTRA-INDICATIONS**

Active or history of gastro-intestinal bleeding - active or history of gastro-intestinal ulceration - coagulation disorders - complete or partial syndrome of nasal polyps - confirmed or suspected cerebrovascular bleeding - dehydration - following operations with high risk of haemorrhage or incomplete haemostasis - haemorrhagic diatheses - history of gastro-intestinal perforation - hypovolaemia - severe heart failure

**CAUTIONS**

Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

**INTERACTIONS**

Appendix 1 (NSAIDs).

**SIDE-EFFECTS**

- Rare - Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis


**SIDE-EFFECTS, FURTHER INFORMATION**

Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY**

Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION**

Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY**

Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosis in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING**

Amount too small to be harmful.

**HEPATIC IMPAIRMENT**

Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT**

- With intramuscular use or intravenous use The lowest effective dose should be used for the shortest possible duration. Max. 60 mg daily by intramuscular injection or intravenous injection. Avoid if possible or use with caution. Avoid if serum creatinine greater than 160 micromol/litre. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **KETOROLAC TROMETAMOL (Non-proprietary)**
  - Ketorolac trometamol 30 mg per 1 ml
  - [Ketorolac 30mg/1ml solution for injection ampoules £6.56](Roche Products Ltd)
  - Toradol (Roche Products Ltd)
  - Toradol 30mg/1mg solution for injection ampoules | 5 ampoule £5.36
**Parecoxib**

**DRUG ACTION** Parecoxib is a selective inhibitor of cyclooxygenase-2.

**INDICATIONS AND DOSE** Short-term management of acute postoperative pain by deep intramuscular injection or by intravenous injection.

- **Adult:** Initially 40 mg, then 20–40 mg every 6–12 hours as required for up to 3 days; maximum 80 mg per day.
- **Elderly** (body-weight up to 50 kg): Initially 20 mg; maximum 40 mg per day.

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding, active gastro-intestinal ulceration, cerebrovascular disease, inflammatory bowel disease, ischaemic heart disease, mild to severe heart failure, peripheral arterial disease.

**CAUTIONS** Allergic disorders, cardiac impairment (NSAIDs may impair renal function), coagulation defects, connective-tissue disorders, Crohn’s disease (may be exacerbated), dehydration, elderly (risk of serious side-effects and fatalities), following coronary artery bypass graft surgery, history of cardiac failure, hypertension, left ventricular dysfunction, oedema, risk factors for cardiovascular events, ulcerative colitis (may be exacerbated).

**INTERACTIONS** Appendix I (NSAIDs).

**SIDE-EFFECTS**

- Common or very common: Alveolar oedema, flatulence, hypoaesthesia, hypokalaemia, hypotension, postoperative anaemia, sweating.
- Uncommon: Anorexia, arthralgia, bradycardia, cardiovascular events, ecchymosis, hyperglycaemia, malaise, pulmonary embolism.
- Rare: Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), hepatic damage, interstitial fibrosis associated with NSAIDs can lead to renal failure, pancreatitis, papillary necrosis associated with NSAIDs can lead to renal failure, pulmonary eosinophilia, Stevens-Johnson syndrome, toxic epidermal necrolysis, visual disturbances.
- Frequency not known: Angioedema, blood disorders, blood pressure may be raised, bronchospasm, circulatory collapse, colitis (induction of or exacerbation of), Crohn’s disease (induction of or exacerbation of), depression, diarrhoea, dizziness, drowsiness, fluid retention (rarely precipitating congestive heart failure), gastro-intestinal bleeding, gastro-intestinal discomfort, gastro-intestinal disturbances, gastro-intestinal ulceration, haematuria, headache, hearing disturbances, hypersensitivity reactions, insomnia, nausea, nervousness, photosensitivity, rash(es), renal failure (especially in patients with pre-existing renal impairment), tachycardia, tinnitus, vertigo.

**SIDE-EFFECTS, FURTHER INFORMATION**

Serious side-effects: For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 915.

**ALLERGY AND CROSS-SENSITIVITY** Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID. Contraindicated in patients with a history of allergic drug reactions including sulphonamide hypersensitivity.

**SIDE-EFFECTS**

- Common: Anaphylaxis, angioedema, bronchospasm, collapse, cutaneous reactions including urticaria, earache, rashes, headache, hypoaesthesia, hyporesponsiveness, hypotension, nausea, palpitations, pruritus, rash, rhinitis, rhinorrhea, rigors, sweating, tachycardia, tinnitus.
- Rare: Anaphylactic reaction, angioedema, bronchospasm, collapse, cutaneous reactions, fever, headache, hypoaesthesia, hyporesponsiveness, hypotension, nausea, palpitations, pruritus, rash, rhinitis, rhinorrhea, rigors, sweating, tachycardia, tinnitus.
- Frequency not known: Headache, hypoaesthesia, hyporesponsiveness, hypotension, nausea, palpitations, pruritus, rash, rhinitis, rhinorrhea, rigors, sweating, tachycardia, tinnitus.

**RECOMMENDATION**

Always check packaging for further information and contraindications.

**CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING** Avoid—present in milk.

**HEPATIC IMPAIRMENT** Halve dose in moderate impairment (max. 40 mg daily). Use with caution; there is an increased risk of gastrointestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT** The lowest effective dose should be used for the shortest possible duration. Avoid if possible or use with caution. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2003) that parecoxib is not recommended for use within NHS Scotland.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- Dynastat (Pfizer Ltd) Parecoxib (as Parecoxib sodium) 40 mg
- Dynastat 40 mg powder for solution for injection vials | 10 vial | PO £49.60

**Powder and solvent for solution for injection**

- Dynastat (Pfizer Ltd) Parecoxib (as Parecoxib sodium) 40 mg
- Dynastat 40 mg powder and solvent for solution for injection vials | 5 vial | PO £28.34

**OPIOIDS**

Remifentanil

The properties listed below are those particular to the drug only. For properties common to the class, see Opioids, p. 357.

**INDICATIONS AND DOSE**

Analgesia and enhancement of anaesthesia at induction initially by intravenous injection.

- **Adult:** Initially 0.25–1 microgram/kg, dose to be administered over at least 30 seconds, then (by intravenous infusion) 30–60 micrograms/kg/hour, alternatively (by intravenous infusion) initially 30–60 micrograms/kg/hour, if patient to be intubated more than 8 minutes after start of intravenous infusion, initial intravenous injection dose is not necessary.

Assisted ventilation: Analgesia and enhancement of anaesthesia during maintenance of anaesthesia initially by intravenous injection.

- **Adult:** Initially 0.25–1 microgram/kg, dose to be administered over at least 30 seconds, according to anaesthetic technique and adjusted according to response, followed by (by intravenous infusion) 3–120 micrograms/kg/hour, intravenous infusion may be given with or without initial intravenous injection dose; in light anaesthesia supplemental doses by intravenous injection every 2–5 minutes.
**Assisted ventilation: analgesia and sedation in intensive-care patients (for max 3 days)**

BY INTRAVENOUS INFUSION

- Adult: Initially 6–9 micrograms/kg/hour, then adjusted in steps of 1.5 micrograms/kg/hour, allow at least 5 minutes between dose adjustments; usual dose 0.36–4.4 micrograms/kg/hour, if an infusion rate of 12 micrograms/kg/hour does not produce adequate sedation add another sedative (consult product literature for details)

**Assisted ventilation: additional analgesia during stimulating or painful procedures in intensive-care patients**

BY INTRAVENOUS INFUSION

- Adult: Usual dose 15–45 micrograms/kg/hour, maintain infusion rate of at least 6 micrograms/kg/hour for at least 5 minutes before procedure and adjust every 2–5 minutes according to requirements

**Spontaneous respiration: analgesia and enhancement of anaesthesia during maintenance of anaesthesia**

BY INTRAVENOUS INFUSION

- Adult: Initially 2.4 micrograms/kg/hour, adjusted according to response; usual dose 1.5–6 micrograms/kg/hour

**Cardiac surgery**

- Adult: (consult product literature)

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal bodyweight.

**UNLICENSED USE** Remifentanil doses in BNF may differ from those in product literature.

**CONTRA-INDICATIONS** Analgesia in conscious patients

**SIDE-EFFECTS**

- Common or very common: Hypertension
- Uncommon: Hypoxia
- Rare: Asystole
- Frequency not known: AV block - convulsions

**SIDE-EFFECTS, FURTHER INFORMATION**

**Muscle rigidity** Alfentanil can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.

**Respiratory depression** In contrast to other opioids which are metabolised in the liver, remifentanil undergoes rapid metabolism by non-specific blood and tissue esterases; its short duration of action allows prolonged administration at high dosage, without accumulation, and with little risk of residual postoperative respiratory depression.

**PREGNANCY** No information available.

**BREAST FEEDING** Avoid breast-feeding for 24 hours after administration—present in milk in animal studies.

**RENAL IMPAIRMENT** No dose adjustment necessary in renal impairment.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use: For intravenous infusion (Ultiva®), give continuously in Glucose 5% or Sodium Chloride 0.9% or Water for Injections; reconstitute with infusion fluid to a concentration of 1 mg/mL then dilute further to a concentration of 20–250 micrograms/mL (50 micrograms/mL recommended for general anaesthesia, 20–50 micrograms/mL recommended when used with target controlled infusion (TCI) device).

**PRESCRIBING AND DISPENSING INFORMATION**

Remifentanil should not be given by intravenous injection intra-operatively, but it is well suited to continuous infusion; a supplementary analgesic is given before stopping the infusion of remifentanil.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **REMIFENTANIL (Non-proprietary)**
  - Remifentanil (as Remifentanyl hydrochloride) 1 mg Remifentanil 1mg powder for concentrate for solution for injection vials | 5 vial (PQ) £25.58–£26.60 (Hospital only) Schedule 2 (CD)
  - Remifentanil (as Remifentanyl hydrochloride) 2 mg Remifentanil 2mg powder for concentrate for solution for injection vials | 5 vial (PQ) £29.13–£31.15 (Hospital only) Schedule 2 (CD)
  - Remifentanil (as Remifentanyl hydrochloride) 5 mg Remifentanil 5mg powder for concentrate for solution for injection vials | 5 vial (PQ) £117.00–£127.00 (Hospital only) Schedule 2 (CD)
  - **Ultiva** (GlaxoSmithKline UK Ltd)
    - Remifentanil (as Remifentanyl hydrochloride) 1 mg Ultiva 1mg powder for solution for injection vials | 5 vial (PQ) no price available (Hospital only) Schedule 2 (CD)
    - Remifentanil (as Remifentanyl hydrochloride) 2 mg Ultiva 2mg powder for solution for injection vials | 5 vial (PQ) no price available (Hospital only) Schedule 2 (CD)
    - Remifentanil (as Remifentanyl hydrochloride) 5 mg Ultiva 5mg powder for solution for injection vials | 5 vial (PQ) no price available (Hospital only) Schedule 2 (CD)

**INDICATIONS AND DOSE**

**Premedication**

- By subcutaneous injection or by intramuscular injection
  - Adult: 0.5–1 mL

**LESS SUITABLE FOR PRESCRIBING** Hyoscine hydrobromide with papaveretum is less suitable for prescribing.

**MEDICINAL FORMS**

Medicines not identified.

1.6 **Peri-operative sedation**

**Conscious sedation for clinical procedures**

Sedation of patients during diagnostic and therapeutic procedures is used to reduce fear and anxiety, to control pain, and to minimise excessive movement. The choice of sedative drug will depend upon the intended procedure; some procedures are safer and more successful under anaesthesia. The patient should be monitored carefully; monitoring should begin as soon as the sedative is given or when the patient becomes drowsy, and should be continued until the patient wakes up.

**Hyoscine hydrobromide with papaveretum**

The properties listed below are those particular to the combination only. For the properties of the components please consider, hyoscine hydrobromide p. 344, papaveretum p. 371.

**Hyoscine hydrobromide with papaveretum**

- **INDICATIONS AND DOSE**
  - **Premedication**
    - By subcutaneous injection or by intramuscular injection
      - Adult: 0.5–1 mL
    - **Less suitable for prescribing**
      - Hyoscine hydrobromide with papaveretum is less suitable for prescribing.
    - **MEDICINAL FORMS**
      - Medicines not identified.
1110 General anaesthesia

**ALPHA₂-ADRENOCEPTOR AGONISTS**

**Dexmedetomidine**

**INDICATIONS AND DOSE**

Maintenance of sedation during intensive care

BY INTRAVENOUS INFUSION
- Adult: 0.7 microgram/kg/hour, adjusted according to response; usual dose 0.2–1.4 micrograms/kg/hour

**DIRECTIONS FOR ADMINISTRATION**

**HEPATIC IMPAIRMENT**

**SIDE-EFFECTS**

- Common or very common Agitation, blood pressure changes, bradycardia, changes in blood sugar, dry mouth, hyperthermia, myocardial infarction, myocardial ischaemia, nausea, tachycardia, vomiting
- Uncommon Abdominal distension, AV block, decreased cardiac output, dyspnœa, hallucination, hypoalbuminaemia, metabolic acidosis, thirst
- PREGNANCY**

Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid unless potential benefit outweighs risk—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Dose reduction may be required. Manufacturer advises caution.

**MONITORING REQUIREMENTS**

Monitor cardiac function. Monitor respiratory function in non-intubated patients.

**DIRECTIONS FOR ADMINISTRATION**

To be diluted before use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **Dexdor** (Orion Pharma (UK) Ltd)
  - Dexmedetomidine (as Dexmedetomidine hydrochloride) 100 microgram per 1 ml
  - Dexdor 1mg/10ml concentrate for solution for infusion vials | 4 vial (£20.89) 113.20 (Hospital only)
  - Dexdor 400micrograms/4ml concentrate for solution for infusion vials | 4 vial (£20.89) 1125.28 (Hospital only)
  - Dexdor 200micrograms/2ml concentrate for solution for infusion ampoules | 5 ampoule (£20.89) 78.30 (Hospital only) | 25 ampoule (£20.89) 391.50 (Hospital only)

**ANAESTHETICS (GENERAL, INTRAVENOUS, NMDA RECEPTOR ANTAGONISTS)**

**Ketamine**

**INDICATIONS AND DOSE**

Induction and maintenance of anaesthesia for short procedures

BY INTRAMUSCULAR INJECTION
- Adult: Initially 6.5–13 mg/kg, adjusted according to response, a dose of 10 mg/kg usually produces 12–25 minutes of surgical anaesthesia

**BY INTRAVENOUS INJECTION**

- Adult: Initially 1–4.5 mg/kg, adjusted according to response, to be administered over at least 60 seconds, a dose of 2 mg/kg usually produces 5–10 minutes of surgical anaesthesia

**Diagnostic manoeuvres and procedures not involving intense pain**

- Adult: Initially 4 mg/kg

**Induction and maintenance of anaesthesia for long procedures**

- Adult: Initially 0.5–2 mg/kg, using an infusion solution containing 1 mg/ml; maintenance 10–45 micrograms/kg/minute, adjusted according to response

**Important safety information**

Ketamine should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management.

**CONTRA-INDICATIONS**

Acute porphyrias p. 864; eclampsia; head trauma; hypertension; pre-eclampsia; raised intracranial pressure; severe cardiac disease; stroke

**CAUTIONS**

Acute circulatory failure (shock); cardiovascular disease; dehydration; elderly; fixed cardiac output; hallucinations; head injury; hypertension; hypovolaemia; increased cerebrospinal fluid pressure; intracranial mass lesions; nightmares; predisposition to seizures; psychiatric disorders; raised intra-ocular pressure; respiratory tract infection; thyroid dysfunction

**INTERACTIONS**

→ Appendix 1 (anaesthetics, general).

**SIDE-EFFECTS**

- Common or very common Diplopia; hallucinations; hypertension; nausea; nightmares; nystagmus; rash; tachycardia; transient psychotic effects; vomiting
- Uncommon Arrhythmias; bradycardia; hypotension; laryngospasm; respiratory depression
- Rare Apnoea; cystitis; cytisitis; haemorrhagic cystitis; hypersalivation; insomnia
- Frequency not known Raised intra-ocular pressure

**SIDE-EFFECTS, FURTHER INFORMATION**

Transient psychotic effects: Incidence of hallucinations, nightmares, and other transient psychotic effects can be reduced by a benzodiazepine such as diazepam or midazolam.

**PREGNANCY**

May depress neonatal respiration if used during delivery.

**BREAST FEEDING**

Avoid for at least 12 hours after last dose.

**HEPATIC IMPAIRMENT**

Consider dose reduction.

**DIRECTIONS FOR ADMINISTRATION**

For continuous intravenous infusion, dilute to a concentration of 1 mg/ml with Glucose 5% or Sodium Chloride 0.9%; use microdrip infusion for maintenance of anaesthesia.

For intravenous injection, dilute 100 mg/mL strength to a concentration of not more than 50 mg/mL with Glucose 5% or Sodium Chloride 0.9% or Water for Injections.

**PATIENT AND CARER ADVICE**

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available...
Local anaesthesia

Local anaesthesia

The use of local anaesthetics by injection or by application to mucous membranes to produce local analgesia is discussed in this section.

Local anaesthetic drugs act by causing a reversible block to conduction along nerve fibres. They vary widely in their potency, toxicity, duration of action, stability, solubility in water, and ability to penetrate mucous membranes. These factors determine their application, e.g. topical (surface), infiltration, peripheral nerve block, intravenous regional anaesthesia (Bier's block), plexus, epidural (extradural), or spinal (intrathecal or subarachnoid) block. Local anaesthetics may also be used for postoperative pain relief, thereby reducing the need for analgesics such as opioids.

Bupivacaine hydrochloride p. 1113 has a longer duration of action than other local anaesthetics. It has a slow onset of action, taking up to 30 minutes for full effect. It is often used in lumbar epidural blockade and is particularly suitable for continuous epidural analgesia in labour, or for postoperative pain relief. It is the principal drug used for spinal anaesthesia. Hyperbaric solutions containing glucose may be used for spinal block.

Chloroprocaine hydrochloride p. 1114, a paraaminobenzoic acid ester, is used for spinal anaesthesia in adults where the planned procedure should not exceed 40 minutes.

Levobupivacaine p. 1115, an isomer of bupivacaine, has anaesthetic and analgesic properties similar to bupivacaine hydrochloride, but is thought to have fewer adverse effects.

Lidocaine hydrochloride p. 1116 is effectively absorbed from mucous membranes and is a useful surface anaesthetic in concentrations up to 10%. Except for surface anaesthesia and dental anaesthesia, solutions should not usually exceed 1% in strength. The duration of the block (with adrenaline/epinephrine p. 1156) is about 90 minutes.

Prilocaine hydrochloride p. 1120 is a local anaesthetic of low toxicity which is similar to lidocaine hydrochloride. A hyperbaric solution of prilocaine hydrochloride (containing glucose) may be used for spinal anaesthesia.

Ropivacaine hydrochloride p. 1121 is an amide-type local anaesthetic agent similar to bupivacaine hydrochloride. It is less cardiotoxic than bupivacaine hydrochloride, but also less potent.

Tetracaine p. 1122, a para-aminobenzoic acid ester, is an effective local anaesthetic for topical application; a 4% gel is indicated for anaesthesia before venepuncture or venous cannulation. It is rapidly absorbed from mucous membranes and should never be applied to inflamed, traumatised, or highly vascular surfaces. It should never be used to provide anaesthesia for bronchoscopy or cystoscopy because lidocaine hydrochloride is a safer alternative.

Administration

The dose of local anaesthesia depends on the injection site and the procedure used. In determining the safe dosage, it is important to take account of the rate of absorption and excretion, and of the potency. The patient's age, weight, physique, and clinical condition, and the vascularity of the administration site and the duration of administration, must also be considered.

Uptake of local anaesthetics into the systemic circulation determines their duration of action and produces toxicity. Great care must be taken to avoid accidental intravascular injection; local anaesthetic injections should be given slowly in order to detect inadvertent intravascular administration. When prolonged analgesia is required, a long-acting local anaesthetic is preferred to minimise the likelihood of cumulative systemic toxicity. Local anaesthesia around the oral cavity may impair swallowing and therefore increases the risk of aspiration.

Epidural anaesthesia is commonly used during surgery, often combined with general anaesthesia, because of its protective effect against the stress response of surgery. It is often used when good postoperative pain relief is essential.

Use of vasoconstrictors

Local anaesthetics cause dilatation of blood vessels. The addition of a vasoconstrictor such as adrenaline/epinephrine to the local anaesthetic preparation diminishes local blood flow, slowing the rate of absorption and thereby prolonging the anaesthetic effect. Great care should be taken to avoid inadvertent intravenous administration of a preparation containing adrenaline/epinephrine, and it is not advisable to give adrenaline/epinephrine with a local anaesthetic injection in digits or appendages because of the risk of ischaemic necrosis.

Adrenaline/epinephrine must be used in a low concentration when administered with a local anaesthetic. Care must also be taken to calculate a safe maximum dose of local anaesthetic when using combination products.

In patients with severe hypertension or unstable cardiac rhythm, the use of adrenaline/epinephrine with a local anaesthetic may be hazardous. For these patients an anaesthetic without adrenaline/epinephrine should be used.

Dental anaesthesia

Lidocaine hydrochloride is widely used in dental procedures; it is most often used in combination with adrenaline/epinephrine. Lidocaine hydrochloride 2% combined with adrenaline/epinephrine 1 in 80 000 (12.5 micrograms/mL) is a safe and effective preparation; there is no justification for using higher concentrations of adrenaline/epinephrine.

The amide-type local anaesthetics articaine and mepivacaine hydrochloride p. 1119 are also used in dentistry; they are available in cartridges suitable for dental use. Mepivacaine hydrochloride is available with or without adrenaline/epinephrine and articaine is available with adrenaline.

In patients with severe hypertension or unstable cardiac rhythm, mepivacaine hydrochloride without adrenaline/epinephrine may be used. Alternatively, prilocaine hydrochloride with or without felypressin can be used but there is no evidence that it is any safer. Felypressin...
Severe local anaesthetic-induced cardiovascular toxicity

After injection of a bolus of local anaesthetic, toxicity may develop at any time in the following hour. In the event of signs of toxicity during injection, the administration of the local anaesthetic must be stopped immediately.

Cardiovascular status must be assessed and cardiopulmonary resuscitation procedures must be followed.

In the event of local anaesthetic-induced cardiac arrest, standard cardiopulmonary resuscitation should be initiated immediately. Lidocaine must not be used as anti-arrhythmic therapy.

If the patient does not respond rapidly to standard procedures, 20% lipid emulsion such as Intralipid® [unlicensed indication] should be given intravenously at an initial bolus dose of 1.5 mL/kg over 1 minute, followed by an infusion of 15 mL/kg/hour. After 5 minutes, if cardiovascular stability has not been restored or circulation deteriorates, give a maximum of two further bolus doses of 1.5 mL/kg over 1 minute, 5 minutes apart, and increase the infusion rate to 30 mL/kg/hour. Continue infusion until cardiovascular stability and adequate circulation are restored or maximum cumulative dose of 12 mL/kg is given.

Standard cardiopulmonary resuscitation must be maintained throughout lipid emulsion treatment.

Propofol is not a suitable alternative to lipid emulsion.

Further advice on ongoing treatment should be obtained from the National Poisons Information Service.

Detailed treatment algorithms and accompanying notes are available at www.toxbase.org or can be found in the Association of Anaesthetists of Great Britain and Ireland safety guideline, Management of Severe Local Anaesthetic Toxicity and Management of Severe Local Anaesthetic Toxicity – Accompanying notes.

ANAESTHETICS (LOCAL)

Articaine hydrochloride with adrenaline (Carticaine hydrochloride with epinephrine)

INDICATIONS AND DOSE

Infiltration anaesthesia in dentistry

Enteral: Consult expert dental sources

Doses at extremes of body-weight

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight.

Important safety information

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

CONTRA-INDICATIONS Application to damaged skin - application to the middle ear (may cause otoxicity) - complete heart block - injection into infected tissues - injection into inflamed tissues - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block)

CONTRA-INDICATIONS, FURTHER INFORMATION

Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.


SIDE-EFFECTS

- Toxic effects after administration of local anaesthetics mainly involves the central nervous and cardiovascular systems.
- For patients with severe cardiovascular disease, arrhythmias occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.
- Use only if potential benefit outweighs risk - no information available.
- Avoid breast-feeding for 48 hours after administration.
Bupivacaine hydrochloride

INDICATIONS AND DOSE

Surgical anaesthesia, lumbar epidural block

BY REGIONAL ADMINISTRATION
> Adult: 75–150 mg, dose administered using a 5 mg/mL (0.5%) solution

Surgical anaesthesia, field block

BY REGIONAL ADMINISTRATION
> Adult: Up to 150 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

Surgical anaesthesia, thoracic epidural block

BY THORACIC EPIDURAL
> Adult: 12.5–50 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

Surgical anaesthesia, caudal epidural block

BY REGIONAL ADMINISTRATION
> Adult: 50–150 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

Surgical anaesthesia, major nerve block

BY REGIONAL ADMINISTRATION
> Adult: 50–175 mg, dose administered using 5 mg/mL (0.5%) solution

Acute pain, intra-articular block

BY INTRA-ARTICULAR INJECTION
> Adult: Up to 100 mg, dose administered using a 2.5 mg/mL (0.25%) solution; when co-administered with bupivacaine by another route, total max. 150 mg

Acute pain, thoracic epidural block

BY CONTINUOUS EPIDURAL INFUSION
> Adult: 1.25 mg/mL (0.125%) or 2.5 mg/mL (0.25%) solution; maximum 400 mg per day

Acute pain, lumbar epidural block

INITIALLY BY LUMBAR EPIDURAL
> Adult: 15–37.5 mg, then (by lumbar epidural) 15–37.5 mg at least every 30 minutes, repeated when required, alternatively (by continuous epidural infusion) 12.5–18.8 mg/hour, dose administered using a 1.25 mg/mL (0.125%) or 2.5 mg/mL (0.25%) solution

Acute pain, field block

BY REGIONAL ADMINISTRATION
> Adult: Up to 150 mg, dose administered using a 2.5 mg/mL (0.25%) solution

Doses at extremes of body-weight

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight.

**MCRAIN HEAVY**

Intrathecal anaesthesia for surgery

BY INTRATHECAL INJECTION
> Adult: 10–20 mg

Important safety information

The licensed doses stated may not be appropriate in some settings and expert advice should be sought. Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

**CONTRA-INDICATIONS**

Application to the middle ear (can cause ototoxicity). Avoid injection into infected tissues. Avoid injection into inflamed tissues. Complete heart block - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - should not be applied to damaged skin

**CONTRA-INDICATIONS, FURTHER INFORMATION**

Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

**CAUTIONS**

Cardiovascular disease - cerebral atheroma - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypertension - hypotension - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - myocardial depression may be more severe and more resistant to treatment - shock

**INTERACTIONS**

> Appendix 1 (bupivacaine).

**SIDE-EFFECTS**

Arrhythmias - blurred vision - cardiac arrest - convulsions - dizziness - drowsiness - feeling of inebriation - headache - lightheadedness - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nausea - numbness of the tongue and perioral region - paraesthesia (including sensations of hot and cold) - peripheral vasodilatation (resulting in hypotension and bradycardia) - restlessness - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

**Toxic effects**

Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection. The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

**ALLERGY AND CROSS-SENSITIVITY**

Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-

**EXCIPIENTS:** May contain Sulfites
sensitivity reactions may be avoided by using the alternative chemical type.

- **PREGNANCY** Use lower doses for intrathecal use during late pregnancy. Large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after epidural block.
- **BREAST FEEDING** Amount too small to be harmful.
- **HEPATIC IMPAIRMENT** Use with caution in severe impairment.
- **RENAL IMPAIRMENT** Use with caution in severe impairment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, infusion, solution for infusion

  - **Solution for injection**
    - **BUPIVACAINE HYDROCHLORIDE (Non-proprietary)**
      - Bupivacaine hydrochloride 2.5 mg per 1 ml
        - Bupivacaine 0.25% solution for injection 10ml Sure-Amp ampoules | 20 ampoule £17.50
        - Bupivacaine hydrochloride 5 mg per 1 ml
          - Bupivacaine 0.5% solution for injection 10ml Sure-Amp ampoules | 20 ampoule £18.30
        - Bupivacaine hydrochloride 50 mg/10 ml (0.5%) solution for injection ampoules | 10 ampoule no price available
        - **Marcain (AstraZeneca UK Ltd)**
          - Bupivacaine hydrochloride 2.5 mg per 1 ml
            - Marcain 0.25% solution for injection 10ml Polyamp Steripack ampoules | 5 ampoule £7.92
          - Bupivacaine hydrochloride 5 mg per 1 ml
            - Marcain 0.5% solution for injection 10ml Polyamp Steripack ampoules | 5 ampoule £9.25
    - **Infusion**
      - **BUPIVACAINE HYDROCHLORIDE (Non-proprietary)**
        - Bupivacaine hydrochloride 1 mg per 1 ml
          - Bupivacaine 500ng/100 ml (0.1%) infusion bags | 20 bag £9.00 no price available
          - Bupivacaine hydrochloride 250 ng/250 ml (0.1%) infusion bags | 20 bag no price available
        - Bupivacaine hydrochloride 1.25 mg per 1 ml
          - Bupivacaine 525ng/250 ml (0.125%) infusion bags | 20 bag £9.00 no price available

- **Bupivacaine with adrenaline**
  - The properties listed below are those particular to the combination only. For the properties of the components please consider, adrenaline/epinephrine p. 196, bupivacaine hydrochloride p. 1112.

  - **INDICATIONS AND DOSE**
    - **Surgical anaesthesia**
      - **BY LUMBAR EPIDURAL OR BY LOCAL INFILTRATION OR BY CAUDAL EPIDURAL**
        - Adult: (consult product literature)
      - **Acute pain management**
        - **BY LUMBAR EPIDURAL OR BY LOCAL INFILTRATION**
        - Adult: (consult product literature)

  - **CAUTIONS**

  - **CAUTIONS, FURTHER INFORMATION**
    - In patients with severe hypertension or unstable cardiac rhythm, the use of adrenaline with a local anaesthetic may be hazardous. For these patients an anaesthetic without adrenaline should be used.

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

    - **Solution for injection**
      - **ADRENALINE WITH BUPIVACAINE (Non-proprietary)**
        - Adrenaline (as Adrenaline acid tartrate) 5 microgram per 1 ml
        - Bupivacaine hydrochloride 2.5 mg per 1 ml
      - Bupivacaine hydrochloride 2.5 mg/10 ml (0.25%) / Adrenaline (base) 50 micrograms/10 ml (1 in 200,000) solution for injection ampoules | 10 ampoule £25.00
      - Adrenaline (as Adrenaline acid tartrate) 5 microgram per 1 ml
        - Bupivacaine hydrochloride 5 mg per 1 ml
        - Bupivacaine hydrochloride 50 mg/10 ml (0.5%) / Adrenaline (base) 50 micrograms/10 ml (1 in 200,000)
        - solution for injection ampoules | 10 ampoule £27.00

### Chloroprocaine hydrochloride

**INDICATIONS AND DOSE**

- **Intrathecal anaesthesia for surgical procedures lasting up to 40 minutes**
- **BY SLOW INTRATHECAL INJECTION**
  - Adult: 40–50 mg, dose depends on desired length of block

- **Doses at extremes of body-weight**
  - To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight.

**Important safety information**

The licensed doses stated above may not be appropriate in some settings and expert advice should be sought. Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

- **CONTRA-INDICATIONS** Application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues - complete heart block - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - severe anaemia - should not be applied to damaged skin

- **CONTRA-INDICATIONS, FURTHER INFORMATION**
  - **Injection site** Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

- **CAUTIONS**

  - Acute porphyrias p. 864 - cardiovascular disease - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - shock

- **INTERACTIONS** ➔ Appendix 1 (chloroprocaine).

- **SIDE-EFFECTS**

  - **Uncommon** Hypertension

  - **Frequency not known** Arrhythmias - blurred vision - cardiac arrest - convulsions - dizziness - drowsiness - feeling of inebriation - headache - light-headedness - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nausea - numbness of the tongue and perioral region - paraesthesia (including sensations of hot and cold) - peripheral vasodilatation (resulting in hypotension and bradycardia) - restlessness - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**

  - **Toxic effects** Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful
surveillance for toxic effects is necessary during the first 30 minutes after injection. The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- **ALLERGY AND CROSS-SENSITIVITY** Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- **PREGNANCY** Avoid—no information available.

- **BREAST FEEDING** Avoid—no information available.

- **HEPATIC IMPAIRMENT** Use with caution in severe impairment.

- **RENAL IMPAIRMENT** Use with caution in severe impairment.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

- **Solution for injection**
  - Ampres (AMCO)
  - Chloroprocaine hydrochloride 10 mg per 1 ml Ampres 50mg/5ml solution for injection ampoules | 10 ampoule \( £8.50 \)

---

### Levobupivacaine

#### INDICATIONS AND DOSE

**Acute postoperative pain**

- **BY CONTINUOUS EPIDURAL INFUSION**
  - Adult: 12.5–18.75 mg/hour, dose administered using a 1.25 mg/mL (0.125%) or 2.5 mg/mL (0.25%) solution; maximum 400 mg per day

- **Acute labour pain**
  - Initially by lumbar epidural
    - Adult: 15–25 mg every 15 minutes as required, dose administered using a 2.5 mg/mL (0.25%) solution, alternatively (by continuous epidural infusion) 5–12.5 mg/hour, dose administered using a 1.25 mg/mL (0.125%) solution

- **Surgical anaesthesia, peripheral nerve block**
  - By regional administration
    - Adult: 2.5–150 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

- **Surgical anaesthesia, peribulbar nerve block**
  - By regional administration
    - Adult: 7.5–112.5 mg, dose administered using a 7.5 mg/mL (0.75%) solution

- **Surgical anaesthesia for caesarean section**
  - By lumbar epidural
    - Adult: 75–150 mg, to be given over 15–20 minutes, dose administered using a 5 mg/mL (0.5%) solution

- **Surgical anaesthesia**
  - By lumbar epidural
    - Adult: 50–150 mg, to be given over 5 minutes, dose administered using a 5 mg/mL (0.5%) or 7.5 mg/mL (0.75%) solution
  - By intrathecal injection
    - Adult: 15 mg, dose administered using a 5 mg/mL (0.5%) solution
  - By local infiltration
    - Adult: 2.5–150 mg, dose administered using a 2.5 mg/mL (0.25%) solution

---

### Doses at extremes of body-weight

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight.

#### Important safety information

The licensed doses stated may not be appropriate in some settings and expert advice should be sought. Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthetics and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

- **CONTRA-INDICATIONS** Application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues - complete heart block - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - should not be applied to damaged skin

- **SIDE-EFFECTS** Anaemia - arthralgia - blurred vision - cardiac arrest - convulsions - dizziness - drowsiness - feeling of inebriation - headache - lightheadedness - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nausea - numbness of the tongue and perioral region - paraesthesia (including sensations of hot and cold) - peripheral vasodilatation (resulting in hypotension and bradycardia) - paresthesia - restlessness - sweating - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

#### Toxic effects

Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection. The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- **ALLERGY AND CROSS-SENSITIVITY** Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- **PREGNANCY** Large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after epidural block. Avoid if possible in the first trimester—tolerance in animal studies. May cause fetal
Lidozaine hydrochloride
(Lignocaine hydrochloride)

INDICATIONS AND DOSE

Dental practice
BY BUCCAL ADMINISTRATION USING OINTMENT
Adult: Rub gently into dry gum

Infiltration anaesthesia
BY LOCAL INFLTRATION
Adult: Dose to be given according to patient’s weight and nature of procedure; max. 200 mg, maximum dose 500 mg if given in solutions containing adrenaline

Intravenous regional anaesthesia and nerve block
Adult: Seek expert advice

Pain relief (in anal fissures, haemorrhoids, pruritis ani, pruritis vulvae, herpes zoster, or herpes labialis)

Lubricant in cystoscopy | Lubricant in proctoscopy

TO THE SKIN USING OINTMENT
Adult: Apply 1–2 ml as required, avoid long-term use

Sore nipples from breast-feeding

TO THE SKIN USING OINTMENT
Adult: Apply using gauze and wash off immediately before next feed

LARYNGOJET®

Anaesthesia of mucous membranes of oropharynx, trachea, or respiratory tract
TO MUCOUS MEMBRANES
Adult: 40–200 mg; to be given as a single dose sprayed, instilled (if a cavity), or applied with a swab (reduce dose according to size, age and condition of patient); usual dose 160 mg

Important safety information

For local infiltration, the licensed doses stated may not be appropriate in some settings and expert advice should be sought.

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

CONTRA-INDICATIONS

GENERAL CONTRA-INDICATIONS
All grades of atrioventricular block - severe myocardial depression - sino-atrial disorders

SPECIFIC CONTRA-INDICATIONS
When used by regional administration Application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues -
preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - severe myocardial depression - should not be applied to damaged skin

CONTRA-INDICATIONS, FURTHER INFORMATION

- When used by regional administration
  - Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

- CAUTIONS
  - With intravenous use Acute porphyria (consider infusion with glucose for its anti-porphyrinogenic effects) - congestive cardiac failure (consider lower dose) - post cardiac surgery (consider lower dose)
  - With used by regional administration Acute porphyria (consider infusion with glucose for its anti-porphyrinogenic effects) - congestive cardiac failure (consider lower dose) - post cardiac surgery (consider lower dose) - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - shock
  - With oral (topical) use Avoid anaesthesia of the pharynx before meals - risk of choking - can damage plastic cuffs of endotrachial tubes

- INTERACTIONS → Appendix 1 (lidocaine). Interactions less likely when lidocaine used topically.

- SIDE-EFFECTS
  - Common or very common
  - With intravenous use Bradycardia (may lead to cardiac arrest) - confusion - convulsions - dizziness (particularly if injection too rapid) - drowsiness (particularly if injection too rapid) - hypotension (may lead to cardiac arrest) - paraesthesia (particularly if injection too rapid) - respiratory depression
  - When used by regional administration Bradycardia (may lead to cardiac arrest) - confusion - convulsions - hypotension (may lead to cardiac arrest) - respiratory depression
  - Rare
  - With intravenous use or by regional administration
  - Anaphylaxis
  - Frequency not known
  - When used by regional administration
    - Arrhythmias - blurred vision - cardiac arrest - feeling of inebriation - headache - hypoglycaemia (following intrathecal or extradural administration) - methaemoglobinemia - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nausea - numbness of the tongue and perioral region - myasthenia - peripheral vasodilatation (resulting in hypotension and bradycardia) - rash - restlessness - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Topical application A single application of a topical lidocaine preparation does not generally cause systemic side-effects.

Toxic effects Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection. The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

Methaemoglobininaemia Methaemoglobininaemia can be treated with an intravenous injection of methyliodihium chloride; neonates and infants under 6 months are particularly susceptible to methaemoglobinemia.

- ALLERGY AND CROSS-SENSITIVITY Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- PREGNANCY Crosses the placenta but not known to be harmful in animal studies—use if benefit outweighs risk. When used as a local anaesthetic, large doses can cause fetal bradycardia; if given during delivery can also cause neonatal respiratory depression, hypotonia, or bradycardia after paracervical or spinal block.

- BREAST FEEDING Present in milk but amount too small to be harmful.

- HEPATIC IMPAIRMENT Caution—increased risk of side-effects.

- RENAL IMPAIRMENT Possible accumulation of lidocaine and active metabolite; caution in severe impairment.

- PROFESSION SPECIFIC INFORMATION
  - Dental practitioners’ formulary Lidocaine ointment 5% may be prescribed. Spray may be prescribed as Lidocaine Spray 10%.

- NATIONAL FUNDING/ACCESS DECISIONS

VERSATIS®

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (July 2008) that Versatis® is accepted for restricted use within NHS Scotland for the treatment of postherpetic neuralgia in patients who are intolerant of first-line systemic therapies or when they have been ineffective.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, gel, ointment, liquid, nebuliser liquid, mouthwash, lozenge

Solution for injection

- LIDOCAINE HYDROCHLORIDE (Non-proprietary)

Lidocaine hydrochloride 5 mg per 1 ml Lidocaine 50mg/10ml (0.5%) solution for injection ampoules £10.89 Lidocaine 100mg/10ml (1%) solution for injection ampoules £10.80 Lidocaine hydrochloride 10 mg per 1 ml Lidocaine 100mg/10ml (1%) solution for injection ampoules £4.50 Lidocaine 200mg/20ml (1%) solution for injection vials £8.40 Lidocaine 200mg/20ml (1%) solution for injection ampoules 10 vial (PFR) £18.00-£19.00 Lidocaine 200mg/20ml (3%) solution for injection ampoules 10 ampoule (PFR) £7.00 Lidocaine hydrochloride 20 mg per 1 ml Lidocaine 50mg/5ml (2%) solution for injection ampoules 10 ampoule (PFR) £2.43 Lidocaine 400mg/20ml (2%) solution for injection vials 10 vial (PFR) £18.50-£19.50 Lidocaine 200mg/10ml (2%) solution for injection Mini-Plasco ampoules 20 ampoule (PFR) £14.52 Lidocaine 40mg/2ml (2%) solution for injection ampoules 10 ampoule (PFR) £4.00 DT price = £2.13 Lidocaine hydrochloride 20 mg per 1 ml Lidocaine 100mg/5ml (2%) solution for injection ampoules 10 ampoule (PFR) £5.00 Lidocaine 400mg/20ml (2%) solution for injection ampoules 10 ampoule (PFR) £8.00-£10.00 DT price = £3.07
Lidocaine with adrenaline

The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1116, adrenaline p. 1116.

**INDICATIONS AND DOSE**

Anaesthesia before nasal surgery, endoscopy, laryngoscopy, or removal of foreign bodies from the nose

**BY INTRANASAL ADMINISTRATION**

- Adult: Up to 8 sprays

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Spray**

- **LIDOCAINE WITH PHENYLEPHRINE (Non-proprietary)**
  - Lidocaine hydrochloride 50 mg per 1 ml, Phenylephrine hydrochloride 5 mg per 1 ml
  - Lidocaine 5% / Phenylephrine 0.5% nasal spray | 2.5 ml | £11.48

Lidocaine with prilocaine

The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1116, prilocaine hydrochloride p. 1120.

**INDICATIONS AND DOSE**

Anaesthesia before minor skin procedures including venepuncture

**TO THE SKIN**

- Child 1-2 months: Apply up to 1 g for maximum 1 hour before procedure, to be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca); maximum 1 dose per day
- Child 3-11 months: Apply up to 2 g for maximum 4 hours before procedure, to be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca); maximum 2 doses per day
- Child 1-11 years: Apply 1–5 hours before procedure (2–5 hours before procedures on large areas e.g. split skin grafting), a thick layer should be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca); maximum 2 doses per day
- Child 12-17 years: Apply 1–5 hours before procedure (2–5 hours before procedures on large areas e.g. split skin grafting), a thick layer should be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca)
- Adult: Apply 1–5 hours before procedure (2–5 hours before procedures on large areas e.g. split skin grafting), a thick layer should be applied under occlusive dressing

Anaesthesia on genital skin before injection of local anaesthetics

**TO THE SKIN**

- Adult: Apply for 15 minutes (in adult men) and 60 minutes (in adult women), to be applied under occlusive dressing
Anaesthesia before surgical treatment of lesions on genital mucosa
TO THE SKIN
- Adult: Apply up to 10 g, to be applied 5–10 minutes before procedure

Anaesthesia before cervical curettage
TO THE SKIN
- Adult: Apply 10 g in lateral vaginal fornices for 10 minutes

Anaesthesia before mechanical cleansing or debridement of leg ulcer
TO THE SKIN
- Adult: Apply up to 10 g for 30–60 minutes, to be applied under occlusive dressing

- CONTRA-INDICATIONS Use in child less than 37 weeks corrected gestational age
- PATIENT AND CARER ADVICE
  Medicine for Children leaflet: EMLA cream for local anaesthesia
  www.medicinesforchildren.org.uk/emla-cream-for-local-anaesthesia
- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  Cream
  - Lidocaine with Prilocaine (Non-proprietary)
  - Lidocaine 25 mg per 1 gram, Prilocaine 25 mg per 1 gram
  - Lidocaine 2.5% / Prilocaine 2.5% cream | 5 gram | no price available
  - Emla (AstraZeneca UK Ltd)
  - Lidocaine 25 mg per 1 gram, Prilocaine 25 mg per 1 gram
  5% cream | 5 gram | £2.25–£2.99
  25 gram | £11.70
  30 gram | £12.30
  - Brands may include Denela

Lidocaine with tetracaine
The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1116, tetracaine p. 1122.

INDICATIONS AND DOSE
Anaesthesia before dermatological procedures and venepuncture
TO THE SKIN
- Adult: Apply 1 mm layer using a spatula 30 minutes before procedure, then peel off immediately before procedure; max. application area 400 cm², application time of 60 minutes indicated for certain procedures, such as laser-assisted tattoo removal and laser leg vein ablation

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  Cream
  - Excipients: May contain Hydroxybenzoates (parabens)
  - Pipaglis (Galderma (UK) Ltd)
  - Lidocaine 70 mg, Tetracaine 70 mg
  - Pipaglis 70mg/g / 70mg/g cream | 15 gram | £22.95

Mepivacaine hydrochloride

INDICATIONS AND DOSE
Infiltration anaesthesia and nerve block in dentistry
- Child 3-17 years: Consult expert dental sources
- Adult: Consult expert dental sources

Doses at extremes of body-weight
To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight.

- CONTRA-INDICATIONS Application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues - complete heart block - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - should not be applied to damaged skin
- CAUTIONS
  - Cardiovascular disease
  - Children (consider dose reduction)
  - Debilitated patients (consider dose reduction)
  - Elderly (consider dose reduction)
  - Epilepsy
  - Hyponatraemia
  - Impaired cardiac conduction
  - Impaired respiratory function
  - Myasthenia gravis
  - Shock
- SIDE-EFFECTS
  - Arrhythmias
  - Blurred vision
  - Cardiac arrest
  - Convulsions
  - Dizziness
  - Drowsiness
  - Feeling of inebriation
  - Headache
  - Lightheadedness
  - Muscle twitching
  - Myocardial depression (resulting in hypotension and bradycardia)
  - Nausea
  - Number of the tongue and perioral region
  - Parasthesia (including sensations of hot and cold)
  - Peripheral vasodilatation (resulting in hypotension and bradycardia)
  - Restlessness
  - Tinnitus
  - Transient excitement (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma)
  - Tremors
  - Vomiting
- ALLERGY AND CROSS-SENSITIVITY
  - Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.
- PREGNANCY
  - Use with caution in early pregnancy.
- BREAST FEEDING
  - Use with caution.
- HEPATIC IMPAIRMENT
  - Use with caution; increased risk of side-effects in severe impairment.
- RENAL IMPAIRMENT
  - Use with caution; increased risk of side-effects.
1120 Local anaesthesia

**CONTRA-INDICATIONS**

**Injection site** Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

**CAUTIONS** Acute porphyrias p. 864 - cardiovascular disease - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - neonates and infants under 6 months are particularly susceptible to methaemoglobinaemia - severe or untreated hypertension - shock

**INTERACTIONS** → Appendix 1 (prilocaine). Caution with concomitant use of drugs that cause methaemoglobinaemia.

**SIDE-EFFECTS** Arrhythmias - blurred vision - cardiac arrest - convulsions - dizziness - drowsiness - feeling of inebriation - headache - hypertension - lightheadedness - methaemoglobinaemia (with high doses) - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nussa - numbness of the tongue and perioral region - paraesthesia (including sensations of hot and cold) - peripheral vasodilatation (resulting in hypotension and bradycardia) - restlessness - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

**Toxic effects** Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection. The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

**Methaemoglobinaemia** Methaemoglobinaemia can be treated with an intravenous injection of methylthioninium chloride.

**ALLERGY AND CROSS-SENSITIVITY** Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as lidocaine, mepivacaine, lidocaine, prilocaine, ropivacaine, and mepivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

**PREGNANCY** Use lower doses for intrathecal use during late pregnancy. Large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after epidural block. Avoid paracervical or pudendal block in obstetrics (neonatal methaemoglobinaemia reported).

**BREAST FEEDING** Present in milk but not known to be harmful.

**HEPATIC IMPAIRMENT** Lower doses may be required for intrathecal anaesthesia. Use with caution.

**RENAL IMPAIRMENT** Lower doses may be required for intrathecal anaesthesia. Use with caution.

**NATIONAL FUNDING/ACCESS DECISIONS**

**PRILOTEKAL**

**Scottish Medicines Consortium (SMC) Decisions**

With intrathecal use The Scottish Medicines Consortium has advised (December 2010) that prilocaine 2% hyperbaric...
solution for injection (Prilotekal®) is accepted for restricted use within NHS Scotland for use in spinal anaesthesia in ambulatory surgery settings.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- **Citanest** (AstraZeneca UK Ltd)
  - Prilocaine hydrochloride 10 mg per 1 ml Citanest 3% solution for injection 50ml vials | 1 vial (pH) £5.06
- **Prilotekal** (AMCo)
  - Prilocaine hydrochloride 20 mg per 1 ml Prilotekal 100mg/5ml solution for injection ampoules | 10 ampoule (pH) £7.75

**Prilocaine with felypressin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, prilocaine hydrochloride p. 1120.

**INDICATIONS AND DOSE**

**Dental anaesthesia**

**BY REGIONAL ADMINISTRATION**

- Adult: Consult expert dental sources for specific advice

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Citanest with Octapressin** (Dentsply Ltd)
  - Felypressin 0.03 unit per 1 ml, Prilocaine hydrochloride 30 mg per 1 ml Citanest 3% with Octapressin Dental 0.054units/1.8ml solution for injection self aspirating cartridges | 100 cartridge (pH) no price available
  - Citanest 3% with Octapressin Dental 0.066units/2.2ml solution for injection self aspirating cartridges | 100 cartridge (pH) no price available

**Ropivacaine hydrochloride**

**INDICATIONS AND DOSE**

**Acute pain, peripheral nerve block**

**BY REGIONAL ADMINISTRATION**

- Adult: 10–20 mg/hour, dose administered as a continuous infusion or by intermittent injection using a 2 mg/mL (0.2%) solution

**Acute pain, field block**

**BY REGIONAL ADMINISTRATION**

- Adult: 2–200 mg, dose administered using a 2 mg/mL (0.2%) solution

**Acute pain, lumbar epidural block**

**BY LUMBAR EPIDURAL**

- Adult: 20–40 mg, followed by 20–30 mg at least every 30 minutes, dose administered using a 2 mg/mL (0.2%) solution

**Acute labour pain**

**BY CONTINUOUS EPIDURAL INFUSION**

- Adult: 12–20 mg/hour, dose administered using a 2 mg/mL (0.2%) solution

**Acute postoperative pain**

**BY CONTINUOUS EPIDURAL INFUSION**

- Adult: Up to 28 mg/hour, dose administered using a 2 mg/mL (0.2%) solution

**Postoperative pain, thoracic epidural block**

**BY CONTINUOUS EPIDURAL INFUSION**

- Adult: 12–28 mg/hour, dose administered using a 2 mg/mL (0.2%) solution

**Surgical anaesthesia, field block**

**BY REGIONAL ADMINISTRATION**

- Adult: 7.5–225 mg, dose administered using a 7.5 mg/mL (0.75%) solution

**Surgical anaesthesia, major nerve block (brachial plexus block)**

**BY REGIONAL ADMINISTRATION**

- Adult: 225–300 mg, dose administered using a 7.5 mg/mL (0.75%) solution

**Surgical anaesthesia, thoracic epidural block (to establish block for postoperative pain)**

**BY THORACIC EPIDURAL**

- Adult: 38–113 mg, dose administered using a 7.5 mg/mL (0.75%) solution

**Surgical anaesthesia for caesarean section**

**BY LUMBAR EPIDURAL**

- Adult: 113–150 mg, to be administered in incremental doses using a 7.5 mg/mL (0.75%) solution

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal bodyweight.

**Important safety information**

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

**CONTRA-INDICATIONS**

Application to the middle ear (can cause ototoxicity) . avoid injection into infected tissues . avoid injection into inflamed tissues . complete heart block . preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) . should not be applied to damaged skin.

**CONTRA-INDICATIONS, FURTHER INFORMATION**

**Injection site**

Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

**CAUTIONS**

Acute porphyrias p. 864 . cardiovascular disease . debilitated patients (consider dose reduction) . elderly (consider dose reduction) . epilepsy . hypovolaemia . impaired cardiac conduction . impaired respiratory function . myasthenia gravis . shock

**INTERACTIONS**

Appendix 1 (ropivacaine).

**SIDE-EFFECTS**

- Common or very common  Hypertension . pyrexia
- Uncommon  Hypothermia . syncope
- Frequency not known  Arrhythmias . blurred vision . cardiac arrest . convulsions . dizziness . drowsiness . feeling of inebriation . headache . lightheadedness . muscle twitching . myocardial depression (resulting in hypotension and bradycardia) . nausea . numbness of the tongue and perioral region . paraesthesia (including sensations of hot and cold) . peripheral vasodilatation (resulting in hypotension and bradycardia) . restlessness . tinnitus . transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) . tremors . vomiting
SIDE-EFFECTS, FURTHER INFORMATION

Toxic effects  Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravenous injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection. The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- ALLERGY AND CROSS-SENSITIVITY  Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.
- PREGNANCY  Not known to be harmful. Do not use for paracervical block in obstetrics.
- Breast feeding  Not known to be harmful.
- HEPATIC IMPAIRMENT  Use with caution in severe impairment.
- RENAL IMPAIRMENT  Caution in severe impairment. Increased risk of systemic toxicity in chronic renal failure.

- MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**  ELECTROLYTES: May contain Sodium

- ropivacaine hydrochloride 2 mg per 1 ml Ropivacaine 20mg/10ml solution for injection ampoules | 10 ampoule POM £16.50 (Hospital only)
- ropivacaine hydrochloride 7.5 mg per 1 ml Ropivacaine 75mg/10ml solution for injection ampoules | 10 ampoule POM £25.00 (Hospital only)
- ropivacaine hydrochloride 10 mg per 1 ml Ropivacaine 100mg/10ml solution for injection ampoules | 10 ampoule POM £30.00 (Hospital only)

- Naropin (AstraZeneca UK Ltd)
  - ropivacaine hydrochloride 2 mg per 1 ml Naropin 20mg/10ml solution for injection ampoules | 5 ampoule POM £12.79
  - ropivacaine hydrochloride 7.5 mg per 1 ml Naropin 75mg/10ml solution for injection ampoules | 5 ampoule POM £15.90
  - ropivacaine hydrochloride 10 mg per 1 ml Naropin 100mg/10ml solution for injection ampoules | 5 ampoule POM £19.22

**Infusion**  ELECTROLYTES: May contain Sodium

- ropivacaine hydrochloride 2 mg per 1 ml Ropivacaine 400mg/200ml infusion bags | 5 bag POM £72.25 | 10 bag POM £137.00 (Hospital only)
- Naropin (AstraZeneca UK Ltd)
  - ropivacaine hydrochloride 2 mg per 1 ml Naropin 400mg/200ml infusion Polybags | 5 bag POM £86.70

---

**Tetracaine (Amethocaine)**

INDICATIONS AND DOSE  Anaesthesia before venepuncture or venous cannulation

- Child 1 month-4 years: Apply contents of up to 1 tube (applied at separate sites at a single time or appropriate proportion) to site of venepuncture or venous cannulation and cover with occlusive dressing; remove gel and dressing after 30 minutes for venepuncture and after 45 minutes for venous cannulation

- CONTRA-INDICATIONS  Should not be applied to damaged skin

- SIDE-EFFECTS  Local skin reactions

- SIDE-EFFECTS, FURTHER INFORMATION  The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems; systemic side effects unlikely as minimal absorption following topical application.

- ALLERGY AND CROSS-SENSITIVITY  Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- BREAST FEEDING  Not known to be harmful.

- PATIENT AND CARER ADVICE  Medicines for Children leaflet: tetracaine gel for local anaesthesia  www.medicinesforchildren.org.uk/tetracaine-gel-for-local-anaesthesia

- MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream

**Gel**  EXCIPIENTS: May contain Hydroxybenzoates (parabens)

- Ametop (Smith & Nephew Healthcare Ltd)
  - Tetracaine 40 mg per 1 gram Ametop 4% gel | 1.5 gram P £1.08 | 18 gram P no price available

Also available in combination with lidocaine, p. 1119
Emergency treatment of poisoning

These notes provide only an overview of the treatment of poisoning, and it is strongly recommended that either TOXBASE or the UK National Poisons Information Service be consulted when there is doubt about the degree of risk or about management.

Hospital admission
Patients who have features of poisoning should generally be admitted to hospital. Patients who have taken poisons with delayed action should also be admitted, even if they appear well. Delayed-action poisons include aspirin p. 104, iron, paracetamol p. 354, tricyclic antidepressants, and co-phenotrope p. 55 (diphenoxylate with atropine, Lomotil®); the effects of modified-release preparations are also delayed. A note of all relevant information, including what treatment has been given, should accompany the patient to hospital.

Further information
TOXBASE, the primary clinical toxicology database of the National Poisons Information Service, is available on the internet to registered users at www.toxbase.org (a backup site is available at www.toxbasebackup.org if the main site cannot be accessed). It provides information about routine diagnosis, treatment, and management of patients exposed to drugs, household products, and industrial and agricultural chemicals.

Specialist information and advice on the treatment of poisoning is available day and night from the UK National Poisons Information Service on the following number: Tel: 0844 892 0111.

Advice on laboratory analytical services can be obtained from TOXBASE or from the National Poisons Information Service. Help with identifying capsules or tablets may be available from a regional medicines information centre or from the National Poisons Information Service (out of hours).

General care
It is often impossible to establish with certainty the identity of the poison and the size of the dose. This is not usually important because only a few poisons (such as opioids, paracetamol p. 354, and iron) have specific antidotes; few patients require active removal of the poison. In most patients, treatment is directed at managing symptoms as they arise. Nevertheless, knowledge of the type and timing of poisoning can help in anticipating the course of events. All relevant information should be sought from the poisoned individual and from carers or parents. However, such information should be interpreted with care because it may not be complete or entirely reliable. Sometimes symptoms arise from other illnesses and patients should be assessed carefully. Accidents may involve domestic and industrial products (the contents of which are not generally known). The National Poisons Information Service should be consulted when there is doubt about any aspect of suspected poisoning.

Respiration
Respiration is often impaired in unconscious patients. An obstructed airway requires immediate attention. In the absence of trauma, the airway should be opened with simple measures such as chin lift or jaw thrust. An oropharyngeal or nasopharyngeal airway may be useful in patients with reduced consciousness to prevent obstruction, provided ventilation is adequate. Intubation and ventilation should be considered in patients whose airway cannot be protected or who have respiratory acidosis because of inadequate ventilation; such patients should be monitored in a critical care area.

Most poisons that impair consciousness also depress respiration. Assisted ventilation (either mouth-to-mouth or using a bag-valve-mask device) may be needed. Oxygen is not a substitute for adequate ventilation, although it should be given in the highest concentration possible in poisoning with carbon monoxide and irritant gases.

Blood pressure
Hypotension is common in severe poisoning with central nervous system depressants. A systolic blood pressure of less than 70 mmHg may lead to irreversible brain damage or renal tubular necrosis. Hypotension should be corrected initially by raising the foot of the bed and administration of an infusion of either sodium chloride p. 851 or a colloid. Vasoconstrictor sympathomimetics are rarely required and their use may be discussed with the National Poisons Information Service.

Fluid depletion without hypotension is common after prolonged coma and after aspirin p. 104 poisoning due to vomiting, sweating, and hyperpnoea.

Hypertension, often transient, occurs less frequently than hypotension in poisoning; it may be associated with sympathomimetic drugs such as amphetamines, phencyclidine, and cocaine.

Heart
Cardiac conduction defects and arrhythmias can occur in acute poisoning, notably with tricyclic antidepressants, some antipsychotics, and some antihistamines. Arrhythmias
Emergency treatment of poisoning

often respond to correction of underlying hypoxia, acidosis, or other biochemical abnormalities, but ventricular arrhythmias that cause serious hypotension require treatment. If the QT interval is prolonged, specialist advice should be sought because the use of some anti-arrhythmic drugs may be inappropriate. Supraventricular arrhythmias are seldom life-threatening and drug treatment is best withheld until the patient reaches hospital.

**Body temperature**

Hypothermia may develop in patients of any age who have been deeply unconscious for some hours, particularly following overdose with barbiturates or phenothiazines. It may be missed unless core temperature is measured using a low-reading rectal thermometer or by some other means. Hypothermia should be managed by prevention of further heat loss and appropriate re-warming as clinically indicated.

Hypothermia can develop in patients taking CNS stimulants; children and the elderly are also at risk when taking therapeutic doses of drugs with antimuscarinic properties. Hyperthermia is initially managed by removing all unnecessary clothing and using a fan. Sponging with tepid water will promote evaporation. Advice should be sought from the National Poisons Information Service on the management of severe hyperthermia resulting from conditions such as the serotonin syndrome.

Both hypothermia and hyperthermia require urgent hospitalisation for assessment and supportive treatment.

**Convolusions**

Single short-lived convulsions (lasting less than 5 minutes) do not require treatment. If convulsions are protracted or recur frequently, lorazepam p. 412 or diazepam p. 267 (preferably as emulsion) should be given by slow intravenous injection into a large vein. Benzendiazepines should not be given by the intramuscular route for convulsions. If the intravenous route is not readily available, midazolam oromucosal solution p. 414 [unlicensed use in adults and children under 3 months] can be given by the buccal route or diazepam can be administered as a rectal solution.

**Methaemoglobinaemia**

Drug- or chemical-induced methaemoglobinaemia should be treated with methylythioninium chloride p. 1135 if the methylnitrogen concentration is 30% or higher, or if symptoms of tissue hypoxia are present despite oxygen therapy. Methylthioninium chloride reduces the ferric iron of methaemoglobin back to the ferrous iron of haemoglobin; in high doses, methylthioninium chloride can itself cause methaemoglobinaemia.

**Removal and elimination**

Prevention of absorption

Given by mouth, activated charcoal p. 1130 can bind many poisons in the gastro-intestinal system, thereby reducing their absorption. The sooner it is given the more effective it is, but it may still be effective up to 1 hour after ingestion of the poison—longer in the case of modified-release preparations or of drugs with antimuscarinic (anticholinergic) properties. It is particularly useful for the prevention of absorption of poisons that are toxic in small amounts, such as antidepressants.

Active elimination techniques

Repeated doses of activated charcoal by mouth enhance the elimination of some drugs after they have been absorbed; repeated doses are given after overdosage with:

- Carbamazepine
- Dapsone
- Phenobarbital
- Quinine
- Theophylline

If vomiting occurs after dosing it should be treated (e.g. with an antiemetic drug) since it may reduce the efficacy of charcoal treatment. In cases of intolerance, the dose may be reduced and the frequency increased but this may compromise efficacy.

Activated charcoal p. 1130 should not be used for poisoning with petroleum distillates, corrosive substances, alcohols, malathion, cyanides and metal salts including iron and lithium salts.

Other techniques intended to enhance the elimination of poisons after absorption are only practicable in hospital and are only suitable for a small number of severely poisoned patients. Moreover, they only apply to a limited number of poisons. Examples include:

- haemodialysis for ethylene glycol, lithium, methanol, phenobarbital, salicylates, and sodium valproate;
- alkalisation of the urine for salicylates.

**Removal from the gastro-intestinal tract**

Gastric lavage is rarely required; for substances that cannot be removed effectively by other means (e.g. iron), it should be considered only if a life-threatening amount has been ingested within the previous hour. It should be carried out only if the airway can be protected adequately. Gastric lavage is contra-indicated if a corrosive substance or a petroleum distillate has been ingested, but it may occasionally be considered in patients who have ingested drugs that are not adsorbed by charcoal, such as iron or lithium. Induction of emesis (e.g. with ipecacuanha) is not recommended because there is no evidence that it affects absorption and it may increase the risk of aspiration.

**Whole bowel irrigation** (by means of a bowel cleansing preparation) has been used in poisoning with certain modified-release or enteric-coated formulations, in severe poisoning with iron and lithium salts, and if illicit drugs are carried in the gastro-intestinal tract (‘body-packing’). However, it is not clear that the procedure improves outcome and advice should be sought from the National Poisons Information Service.

**Specific Drugs**

**Alcohol**

Acute intoxication with alcohol (ethanol) is common in adults but also occurs in children. The features include ataxia, dysarthria, nystagmus, and drowsiness, which may progress to coma, with hypotension and acidosis. Aspiration of vomit is a special hazard and hypoglycaemia may occur in children and some adults. Patients are managed supportively, with particular attention to maintaining a clear airway and measures to reduce the risk of aspiration of gastric contents. The blood glucose is measured and glucose given if indicated.

**Analgesics**

**Aspirin**

The main features of salicylate poisoning are hyperventilation, tinnitus, deafness, vasodilatation, and sweating. Coma is uncommon but indicates very severe poisoning. The associated acid-base disturbances are complex.

Treatment must be in hospital, where plasma salicylate, pH, and electrolytes can be measured; absorption of aspirin may be slow and the plasma-salicylate concentration may continue to rise for several hours, requiring repeated measurement. Plasma-salicylate concentration may not correlate with clinical severity in the young and the elderly, and clinical and biochemical assessment is necessary. Generally, the clinical severity of poisoning is less below a plasma-salicylate concentration of 500 mg/litre (3.6 mmol/litre), unless there is evidence of metabolic acidosis. Activated charcoal can be given within 1 hour of ingesting more than 125 mg/kg of aspirin. Fluid losses
should be replaced and intravenous sodium bicarbonate may be given (ensuring plasma-potassium concentration is within the reference range) to enhance urinary salicylate excretion (optimum urinary pH 7.5–8.5). Plasma-potassium concentration should be corrected before giving sodium bicarbonate as hypokalaemia may complicate alkalinisation of the urine.

Haemodialysis is the treatment of choice for severe salicylate poisoning and should be considered when the plasma-salicylate concentration exceeds 700 mg/litre (5.1 mmol/litre) or in the presence of severe metabolic acidosis.

Opioids
Opioids (narcotic analgesics) cause coma, respiratory depression, and pinpoint pupils. The specific antidote naloxone hydrochloride p. 1133 is indicated if there is coma or bradypnoea. Since naloxone has a shorter duration of action than many opioids, close monitoring and repeated injections are necessary according to the respiratory rate and depth of coma. When repeated administration of naloxone is required, it can be given by continuous intravenous infusion instead and the rate of infusion adjusted according to vital signs. The effects of some opioids, such as buprenorphine, are only partially reversed by naloxone. Dextropropoxyphene and methadone have very long durations of action; patients may need to be monitored for long periods following large overdoses.

Naloxone reverses the opioid effects of dextropropoxyphene; the long duration of action of dextropropoxyphene calls for prolonged monitoring and further doses of naloxone may be required.

Norpropoxyphene, a metabolite of dextropropoxyphene, also has cardiotoxic effects which may require treatment with sodium bicarbonate p. 848, or magnesium sulfate p. 858, or both; arrhythmias may occur for up to 12 hours.

Paracetamol
In cases of intravenous paracetamol poisoning contact the National Poisons Information Service for advice on risk assessment and management.

Toxic doses of paracetamol may cause severe hepatocellular necrosis and, much less frequently, renal tubular necrosis. Nausea and vomiting, the only early features of poisoning, usually settle within 24 hours. Persistence beyond this time, often associated with the onset of right subcostal pain and tenderness, usually indicates development of hepatic necrosis. Liver damage is maximal 3–4 days after paracetamol overdose and may lead to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Therefore, despite a lack of significant early symptoms, patients who have taken an overdose of paracetamol should be transferred to hospital urgently.

To avoid underestimating the potentially toxic paracetamol dose ingested by obese patients who weigh more than 110 kg, use a body-weight of 110 kg (rather than their actual body-weight) when calculating the total dose of paracetamol ingested (in mg/kg).

Acetylcysteine p. 1134 protects the liver if infused up to, and possibly beyond, 24 hours of ingesting paracetamol. It is most effective if given within 8 hours of ingestion, after which effectiveness declines. Very rarely, giving
Emergency treatment of poisoning

Acetylcysteine by mouth (unlicensed route) is an alternative if intravenous access is not possible—contact the National Poisons Information Service for advice.

Neonates less than 45 weeks corrected gestational age may be more susceptible to paracetamol-induced liver toxicity, therefore, treatment with acetylcysteine should be considered in all paracetamol overdoses, and advice should be sought from the National Poisons Information Service.

Acute overdose

Hepatotoxicity may occur after a single ingestion of more than 150 mg/kg of paracetamol taken in less than 1 hour. Rarely, hepatotoxicity may develop with single ingestions as low as 75 mg/kg of paracetamol taken in less than 1 hour. Patients who have ingested 75 mg/kg or more of paracetamol in less than 1 hour should be referred to hospital. Administration of charcoal, activated p. 1130 should be considered if paracetamol in excess of 150 mg/kg is thought to have been ingested within the previous hour.

Patients at risk of liver damage and, therefore, requiring acetylcysteine, can be identified from a single measurement of the plasma-paracetamol concentration, related to the time from ingestion, provided this time interval is not less than 4 hours; earlier samples may be misleading. The concentration is plotted on a paracetamol treatment graph, with a reference line (‘treatment line’) joining plots of 100 mg/litre (0.66 mmol/litre) at 4 hours and 3.13 mg/litre (0.02 mmol/litre) at 24 hours. Acetylcysteine treatment should commence immediately in patients:

- whose plasma-paracetamol concentration falls on or above the treatment line on the paracetamol treatment graph;
- who present 8–24 hours after taking an acute overdose of more than 150 mg/kg of paracetamol, even if the plasma-paracetamol concentration is not yet available; acetylcysteine can be discontinued if the plasma-paracetamol concentration is later reported to be below the treatment line on the paracetamol treatment graph, provided that the patient is asymptomatic and liver function tests, serum creatinine and INR are normal.

The prognostic accuracy of a plasma-paracetamol concentration taken after 15 hours is uncertain, but a concentration on or above the treatment line on the paracetamol treatment graph should be regarded as carrying a serious risk of liver damage. If more than 15 hours have elapsed since ingestion, or there is doubt about appropriate management, advice should be sought from the National Poisons Information Service.

‘Staggered’ overdose, uncertain time of overdose, or therapeutic excess

A ‘staggered’ overdose involves ingestion of a potentially toxic dose of paracetamol over more than one hour, with the possible intention of causing self-harm. Therapeutic excess is the inadvertent ingestion of a potentially toxic dose of paracetamol during its clinical use. The paracetamol treatment graph is unreliable if a ‘staggered’ overdose is taken, if there is uncertainty about the time of the overdose, or if there is therapeutic excess. In these cases, patients who have taken more than 150 mg/kg of paracetamol in any 24-hour period are at risk of toxicity and should be commenced on acetylcysteine immediately, unless it is more than 24 hours since the last ingestion, the patient is asymptomatic, the plasma-paracetamol concentration is undetectable, and liver function tests, serum creatinine and INR are normal.

Rarely, toxicity can occur with paracetamol doses between 75–150 mg/kg in any 24-hour period; clinical judgement of the individual case is necessary to determine whether to treat those who have ingested this amount of paracetamol. For small adults, this may be within the licensed dose, but ingestion of a licensed dose of paracetamol is not considered an overdose.

Although there is some evidence suggesting that factors such as the use of liver enzyme-inducing drugs (e.g. carbamazepine p. 387, efavirenz p. 558, nevirapine p. 560, phenobarbital p. 409, phenytoin p. 398, primidone p. 401, rifabutin p. 507, rifampicin p. 508, St John’s wort), chronic alcoholism, and starvation may increase the risk of hepatotoxicity, the CHM has advised that these should no longer be used in the assessment of paracetamol toxicity.

Significant toxicity is unlikely if, 24 hours or longer after the last paracetamol ingestion, the patient is asymptomatic, the plasma-paracetamol concentration is undetectable, and liver function tests, serum creatinine and INR are normal. Patients with clinical features of hepatic injury such as jaundice or hepatic tenderness should be treated urgently with acetylcysteine. If there is uncertainty about a patient’s risk of toxicity after paracetamol overdose, treatment with acetylcysteine should be commenced. Advice should be sought from the National Poisons Information Service whenever necessary.

Acetylcysteine dose and administration

For paracetamol overdosage, acetylcysteine p. 1134 is given in a total dose that is divided into 3 consecutive intravenous infusions over a total of 21 hours. The tables below include the dose of acetylcysteine, for adults and children of body-weight 40 kg and over, in terms of the volume of Acetylcysteine Concentrate for Intravenous Infusion required for each of the 3 infusions. The requisite dose of acetylcysteine is added to Glucose Intravenous Infusion 5% p. 852.

First infusion (based on an acetylcysteine dose of approx. 150mg/kg)—add requisite volume of Acetylcysteine Concentrate for Intravenous Infusion to 200mL Glucose Intravenous Infusion 5%; infuse over 1 hour.

Second infusion (based on an acetylcysteine dose of approx. 50mg/kg; start immediately after completion of first infusion)—add requisite volume of Acetylcysteine Concentrate for Intravenous Infusion to 500mL Glucose Intravenous Infusion 5%; infuse over 4 hours.
Third infusion

Third infusion (based on an acetylcysteine dose of approx. 100mg/kg; start immediately after completion of second infusion)—add requisite volume of Acetylcysteine Concentrate for Intravenous Infusion to 1 litre Glucose Intravenous Infusion 5%; infuse over 16 hours.

### Third infusion

<table>
<thead>
<tr>
<th>Body-weight</th>
<th>Volume of Acetylcysteine Concentrate for Intravenous Infusion 200 mg/mL required to prepare third infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>40-49 kg</td>
<td>23 mL</td>
</tr>
<tr>
<td>50-59 kg</td>
<td>28 mL</td>
</tr>
<tr>
<td>60-69 kg</td>
<td>33 mL</td>
</tr>
<tr>
<td>70-79 kg</td>
<td>38 mL</td>
</tr>
<tr>
<td>80-89 kg</td>
<td>43 mL</td>
</tr>
<tr>
<td>90-99 kg</td>
<td>48 mL</td>
</tr>
<tr>
<td>100-109 kg</td>
<td>53 mL</td>
</tr>
<tr>
<td>&gt;110 kg</td>
<td>55 mL (max. dose)</td>
</tr>
</tbody>
</table>

### Antidepressants

**Tricyclic and related antidepressants**

Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. Metabolic acidosis may complicate severe poisoning; delirium with confusion, agitation, and visual and auditory hallucinations are common during recovery.

Assessment in hospital is strongly advised in case of poisoning by tricyclic and related antidepressants but symptomatic treatment can be given before transfer. Supportive measures to ensure a clear airway and adequate ventilation during transfer are mandatory. Intravenous lorazepam or intravenous diazepam (preferably in emulsion form) may be required to treat convulsions. Activated charcoal given within 1 hour of the overdose reduces absorption of the drug. Although arrhythmias are worrying, some will respond to correction of hypoxia and acidosis.

The use of anti-arrhythmic drugs is best avoided, but intravenous infusion of sodium bicarbonate can arrest arrhythmias or prevent them in those with an extended QRS duration. Diazepam given by mouth is usually adequate to sedate delirious patients but large doses may be required.

The National Poisons Information Service (Tel: 0844 892 0111) will provide specialist advice on all aspects of poisoning day and night.

### Selective serotonin re-uptake inhibitors (SSRIs)

Symptoms of poisoning by selective serotonin re-uptake inhibitors include nausea, vomiting, agitation, tremor, nystagmus, drowsiness, and sinus tachycardia; convulsions may occur. Rarely, severe poisoning results in the serotonin syndrome, with marked neuropsychiatric effects, neuromuscular hyperactivity, and autonomic instability; hyperthermia, rhabdomyolysis, renal failure, and coagulopathies may develop.

Management of SSR1 poisoning is supportive. Activated charcoal given within 1 hour of the overdose reduces absorption of the drug. Convulsions can be treated with lorazepam, diazepam, or midazolam oromucosal solution [unlicensed use in adults and children under 3 months] (see Convulsions) p. 1124. Contact the National Poisons Information Service for the management of hyperthermia or the serotonin syndrome.

### Antimarialls

Overdosage with quinine, chloroquine, or hydroxychloroquine is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).

### Antipsychotics

**Phenothiazines and related drugs**

Phenothiazines cause less depression of consciousness and respiration than other sedatives. Hypotension, hypothermia, sinus tachycardia, and arrhythmias may complicate poisoning. Dystonic reactions can occur with therapeutic doses (particularly with prochlorperazine and trifluoperazine), and convulsions may occur in severe cases. Arrhythmias may respond to correction of hypoxia, acidosis, and other biochemical abnormalities, but specialist advice should be sought if arrhythmias result from a prolonged QT interval; the use of some anti-arrhythmic drugs can worsen such arrhythmias. Dystonic reactions are rapidly abolished by injection of drugs such as procyclidine hydrochloride p. 326 or diazepam p. 267 (emulsion preferred).

**Second-generation antipsychotic drugs**

Features of poisoning by second-generation antipsychotic drugs include drowsiness, convulsions, extrapyramidal symptoms, hypotension, and ECG abnormalities (including prolongation of the QT interval). Management is supportive. Charcoal, activated p. 1130 can be given within 1 hour of ingesting a significant quantity of a second-generation antipsychotic drug.

### Benzodiazepines

Benzodiazepines taken alone cause drowsiness, ataxia, dysarthria, nystagmus, and occasionally respiratory depression, and coma. Charcoal, activated p. 1130 can be given within 1 hour of ingesting a significant quantity of benzodiazepine, provided the patient is awake and the airway is protected. Benzodiazepines potentiate the effects of other central nervous system depressants taken concomitantly. Use of the benzodiazepine antagonist flumazenil p. 1132 [unlicensed indication] can be hazardous, particularly in mixed overdoses involving tricyclic antidepressants or in benzodiazepine-dependent patients. Flumazenil may prevent the need for ventilation, particularly in patients with severe respiratory disorders; it should be used on expert advice only and not as a diagnostic test in patients with a reduced level of consciousness.

### Beta blockers

Therapeutic overdosages with beta-blockers may cause lightheadedness, dizziness, and possibly syncope as a result of bradycardia and hypotension; heart failure may be precipitated or exacerbated. These complications are most likely in patients with conduction system disorders or impaired myocardial function. Bradycardia is the most common arrhythmia caused by beta-blockers, but sotalol may induce ventricular tachyarrhythmias (sometimes of the torsade de pointes type). The effects of massive overdose can vary from one beta-blocker to another; propranolol overdose in particular may cause coma and convulsions. *Acute massive overdose* must be managed in hospital and expert advice should be obtained. Maintenance of a clear airway and adequate ventilation is mandatory. An intravenous injection of atropine sulfate p. 1099 is required to treat bradycardia. Cardiogenic shock unresponsive to atropine sulfate is probably best treated with an intravenous injection of glucagon p. 618 [unlicensed] in glucose 5% (with precautions to protect the airway in case of vomiting) followed by an intravenous infusion. If glucagon is not...
available, intravenous isoprenaline (available from ‘special-order’ manufacturers or specialist importing companies) is an alternative. A cardiac pacemaker can be used to increase the heart rate.

**Calcium-channel blockers**

Features of calcium-channel blocker poisoning include nausea, vomiting, dizziness, agitation, confusion, and coma in severe poisoning. Metabolic acidosis and hyperglycaemia may occur. Verapamil and diltiazem have a profound cardiac depressant effect causing hypotension and arrhythmias, including complete heart block and asystole. The dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

Charcoal, activated p. 1130 should be considered if the patient presents within 1 hour of overdosage with a calcium-channel blocker; repeated doses of activated charcoal are considered if a modified-release preparation is involved. In patients with significant features of poisoning, calcium chloride p. 857 or calcium gluconate p. 857 is given by injection; atropine sulfate p. 1099 is given to correct symptomatic bradycardia. In severe cases, an insulin and glucose infusion may be required in the management of hypotension and myocardial failure. For the management of hypotension, the choice of inotropic sympathomimetic depends on whether hypotension is secondary to vasodilatation or to myocardial depression—advice should be sought from the National Poisons Information Service.

**Iron salts**

Iron poisoning in childhood is usually accidental. The symptoms are nausea, vomiting, abdominal pain, diarrhoea, haematemesis, and rectal bleeding. Hypotension and hepato-cellular necrosis can occur later. Coma, shock, and metabolic acidosis indicate severe poisoning.

Advice should be sought from the National Poisons Information Service if a significant quantity of iron has been ingested within the previous hour. Mortality is reduced by intensive and specific therapy with desferrioxamine mesylate p. 839, which chelates iron. The serum iron concentration is measured as an emergency and intravenous desferrioxamine mesylate given to chelate absorbed iron in excess of the expected iron binding capacity. In severe toxicity intravenous desferrioxamine mesylate should be given immediately without waiting for the result of the serum-iron measurement.

**Lithium**

Most cases of lithium intoxication occur as a complication of long-term therapy and are caused by reduced excretion of the drug because of a variety of factors including dehydration, deterioration of renal function, infections, and co-administration of diuretics or NSAIDs (or other drugs that interact). Acute deliberate overdoses may also occur with delayed onset of symptoms (12 hours or more) owing to slow entry of lithium into the tissues and continuing absorption from modified-release formulations.

The early clinical features are non-specific and may include apathy and restlessness which could be confused with mental changes arising from the patient’s depressive illness. Vomiting, diarrhoea, ataxia, weakness, dysarthria, muscle twitching, and tremor may follow. Severe poisoning is associated with convulsions, coma, renal failure, electrolyte imbalance, dehydration, and hypotension.

Therapeutic serum-lithium concentrations are within the range of 0.4–1 mmol/litre; concentrations in excess of 2 mmol/litre are usually associated with serious toxicity and such cases may need treatment with haemodialysis if neurological symptoms or renal failure are present. In acute overdosage much higher serum-lithium concentrations may be present without features of toxicity and all that is usually necessary is to take measures to increase urine output (e.g. by increasing fluid intake but avoiding diuretics). Otherwise, treatment is supportive with special regard to electrolyte balance, renal function, and control of convulsions. Gastric lavage may be considered if it can be performed within 1 hour of ingesting significant quantities of lithium. Whole-bowel irrigation should be considered for significant ingestion, but advice should be sought from the National Poisons Information Service.

**Stimulants**

Amphetamines cause wakefulness, excessive activity, paranoia, hallucinations, and hypertension followed by exhaustion, convulsions, hyperthermia, and coma. The early stages can be controlled by diazepam p. 267 or lorazepam p. 412; advice should be sought from the National Poisons Information Service on the management of hypertension. Later, tepid sponging, anticonvulsants, and artificial respiration may be needed.

**Cocaine**

Cocaine stimulates the central nervous system, causing agitation, dilated pupils, tachycardia, hypertension, hallucinations, hyperthermia, hypertonia, and hyperreflexia; cardiac effects include chest pain, myocardial infarction, and arrhythmias.

Initial treatment of cocaine poisoning involves intravenous administration of diazepam p. 267 to control agitation and cooling measures for hyperthermia (see Body temperature); hypertension and cardiac effects require specific treatment and expert advice should be sought.

**Ecstasy**

Ecstasy (methylenedioxymethamphetamine, MDMA) may cause severe reactions, even at doses that were previously tolerated. The most serious effects are delirium, coma, convulsions, ventricular arrhythmias, hyperthermia, rhabdomyolysis, acute renal failure, acute hepatitis, disseminated intravascular coagulation, adult respiratory distress syndrome, hyperreflexia, hypotension and intracerebral haemorrhage; hyponatraemia has also been associated with ecstasy use.

Treatment of methylenedioxymethamphetamine poisoning is supportive, with diazepam p. 267 to control severe agitation or persistent convulsions and close monitoring including ECG. Self-induced water intoxication should be considered in patients with ecstasy poisoning.

‘Liquid ecstasy’ is a term used for sodium oxybate (gamma-hydroxybutyrate, GHB), which is a sedative.

**Theophylline**

Theophylline and related drugs are often prescribed as modified-release formulations and toxicity can therefore be delayed. They cause vomiting (which may be severe and intractable), agitation, restlessness, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemesis, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly.

Repeated doses of activated charcoal can be used to eliminate theophylline even if more than 1 hour has elapsed after ingestion and especially if a modified-release preparation has been taken (see also under Active Elimination Techniques). Ondansetron p. 349 may be effective for severe vomiting that is resistant to other antiemetics [unlicensed indication]. Hypokalaemia is corrected by intravenous infusion of potassium chloride p. 863 and may be so severe as to require 60 mmol/hour (high doses require ECG monitoring). Convulsions should be...
Sulfur dioxide, chlorine, phosgene, ammonia
All of these gases can cause upper respiratory tract and conjunctival irritation. Pulmonary oedema, with severe breathlessness and cyanosis may develop suddenly up to 36 hours after exposure. Death may occur. Patients are kept under observation and those who develop pulmonary oedema are given oxygen. Assisted ventilation may be necessary in the most serious cases.

**CS spray**
CS spray, which is used for riot control, irritates the eyes (hence ‘tear gas’) and the respiratory tract; symptoms normally settle spontaneously within 15 minutes. If symptoms persist, the patient should be removed to a well-ventilated area, and the exposed skin washed with soap and water after removal of contaminated clothing. Contact lenses should be removed and rigid ones washed (soft ones should be discarded). Eye symptoms should be treated by irrigating the eyes with physiological saline (or water if saline is not available) and advice sought from an ophthalmologist. Patients with features of severe poisoning, particularly respiratory complications, should be admitted to hospital for symptomatic treatment.

**Nerve agents**
Treatment of nerve agent poisoning is similar to organophosphorus insecticide poisoning, but advice must be sought from the National Poisons Information Service.

The risk of cross-contamination is significant; adequate decontamination and protective clothing for healthcare personnel are essential. In emergencies involving the release of nerve agents, kits (‘NAAS pods’) containing pralidoxime chloride p. 1131 can be obtained through the Ambulance Service from the National Blood Service (or the Welsh Blood Service in South Wales or designated hospital pharmacies in Northern Ireland and Scotland—see TOXBASE for list of designated centres).

**Pesticides**
Organophosphorus insecticides
Organophosphorus insecticides are usually supplied as powders or dissolved in organic solvents. All are absorbed through the bronchi and intact skin as well as through the gut and inhibit cholinesterase activity, thereby prolonging and intensifying the effects of acetylcholine. Toxicity between different compounds varies considerably, and onset may be delayed after skin exposure. Anxiety, restlessness, dizziness, headache, miosis, nausea, hypersalivation, vomiting, abdominal colic, diarrhoea, bradycardia, and sweating are common features of organophosphorus poisoning. Muscle weakness and fasciculation may develop and progress to generalised flaccid paralysis, including the ocular and respiratory muscles. Convulsions, coma, pulmonary oedema with copious bronchial secretions, hypoxia, and arrhythmias occur in severe cases. Hyperglycaemia and glycosuria without ketonuria may also be present.

Further absorption of the organophosphorus insecticide should be prevented by moving the patient to fresh air, removing soiled clothing, and washing contaminated skin. In severe poisoning it is vital to ensure a clear airway, frequent removal of bronchial secretions, and adequate ventilation and oxygenation; gastric lavage may be considered provided that the airway is protected. Atropine sulphate p. 1099 will reverse the muscarinic effects of acetylcholine and is given by intravenous injection until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished.

Pralidoxime chloride p. 1131, a cholinesterase reactivator, is used as an adjunct to atropine sulphate in moderate or severe poisoning. It improves muscle tone within 30 minutes of administration. Pralidoxime chloride is
Emergency treatment of poisoning
National Poisons Information Service

Snake bites and animal stings
Snake bites
Envenoming from snake bite is uncommon in the UK. Many exotic snakes are kept, some illegitimately, but only indigenous venomous snake is the adder (Vipera berus). The bite may cause local and systemic effects. Local effects include pain, swelling, bruising, and tender enlargement of regional lymph nodes. Systemic effects include early anaphylactic symptoms (transient hypotension with syncope, angioedema, urticaria, abdominal colic, diarrhoea, and vomiting), with later persistent or recurrent hypotension, ECG abnormalities, spontaneous systemic bleeding, coagulopathy, adult respiratory distress syndrome, and acute renal failure. Fatal envenoming is rare but the potential for severe envenoming must not be underestimated.

Early anaphylactic symptoms should be treated with adrenaline/epinephrine p. 196. Indications for European viper snake venom antiserum treatment p. 1136 include systemic envenoming, especially hypotension, ECG abnormalities, vomiting, haemostatic abnormalities, and marked local envenoming such that after bites on the hand or foot, swelling extends beyond the wrist or ankle within 4 hours of the bite. For those patients who present with clinical features of severe envenoming (e.g. shock, ECG abnormalities, or local swelling that has advanced from the foot to above the knee or from the hand to above the elbow within 2 hours of the bite), a higher initial dose of the European viper snake venom antiserum is recommended; if symptoms of systemic envenoming persist contact the National Poisons Information Service.

Adrenaline/epinephrine injection must be immediately to hand for treatment of anaphylactic reactions to the European viper snake venom antiserum.

Antivenom is available for bites by certain foreign snakes and spiders, stings by scorpions and fish. For information on identification, management, and supply in an emergency telephone the National Poisons Information Service. Whenever possible the TOXBASE entry should be read, and relevant information collected, before telephoning the National Poisons Information Service.

Insect stings
Stings from ants, wasps, hornets, and bees cause local pain and swelling but seldom cause severe direct toxicity unless many stings are inflicted at the same time. If the sting is in the mouth or on the tongue local swelling may threaten the upper airway. The stings from these insects are usually treated by cleaning the area with a topical antiseptic. Bee stings should be removed as quickly as possible. Anaphylactic reactions require immediate treatment with intramuscular adrenaline/epinephrine p. 196; self-administered intramuscular adrenaline/epinephrine (e.g. EpiPen®) is the best first-aid treatment for patients with severe hypersensitivity. An inhaled bronchodilator should be used for asthmatic reactions, see also the management of anaphylaxis. A short course of an oral antihistamine or a topical corticosteroid may help to reduce inflammation and relieve itching. A vaccine containing extracts of bee and wasp venom can be used to reduce the risk of anaphylaxis and systemic reactions in patients with systemic hypersensitivity to bee or wasp stings.

Marine stings
The severe pain of weeverfish (Trachinus vulpe) and Portuguese man-o’-war stings can be relieved by immersing the stung area immediately in uncomfortably hot, but not scalding, water (not more than 45°C). People stung by jellyfish and Portuguese man-o’-war around the UK coast should be removed from the sea as soon as possible. Adherent tentacles should be lifted off carefully (wearing gloves or using tweezers) or washed off with seawater. Alcoholic solutions, including suntan lotions, should not be applied because they can cause further discharge of stinging hairs. Ice packs can be used to reduce pain.

Other poisons
Consult either the National Poisons Information Service or TOXBASE.

The National Poisons Information Service (Tel: 0844 892 0111) will provide specialist advice on all aspects of poisoning day and night.

1 Active elimination from the gastro-intestinal tract

CHELATORS AND ANTIDOTES
Charcoal, activated

INDICATIONS AND DOSE
Reduction of absorption of poisons in the gastro-intestinal system

BY MOUTH
▶ Neonate: 1 g/kg.
▶ Child 1 month-11 years: 1 g/kg (max. per dose 50 g)
▶ Child 12-17 years: 50 g
▶ Adult: 50 g

Active elimination of poisons

BY MOUTH
▶ Neonate: 1 g/kg every 4 hours, dose may be reduced and the frequency increased if not tolerated.
▶ Child 1 month-11 years: 1 g/kg every 4 hours (max. per dose 50 g), dose may be reduced and the frequency increased if not tolerated.
▶ Child 12-17 years: Initially 50 g, then 50 g every 4 hours, reduced if not tolerated to 25 g every 2 hours, alternatively 12.5 g every 1 hour, dose may be reduced if higher doses not tolerated but this may compromise efficacy.
▶ Adult: Initially 50 g, then 50 g every 4 hours. reduced if not tolerated to 25 g every 2 hours, alternatively 12.5 g every 1 hour, dose may be reduced if higher doses not tolerated but this may compromise efficacy.

Accelerated elimination of teriflunomide

BY MOUTH USING GRANULES
▶ Adult: 50 g every 12 hours for 11 days

Accelerated elimination of leflunomide (washout procedure)

BY MOUTH USING GRANULES
▶ Adult: 50 g 4 times a day for 11 days

UNLICENSED USE Activated charcoal doses in BNF may differ from those in product literature.

CAUTIONS Comatose patient (risk of aspiration—ensure airway is protected) - drowsy patient (risk of aspiration—ensure airway protected) - reduced gastrointestinal motility (risk of obstruction)

SIDE-EFFECTS Black stools

DIRECTIONS FOR ADMINISTRATION Suspension or reconstituted powder may be mixed with soft drinks (e.g. caffeine-free diet cola) or fruit juices to mask the taste.
2 Chemical toxicity

2.1 Cyanide toxicity

CHELATORS AND ANTIDOTES

Dicobalt edetate

**INDICATIONS AND DOSE**

**Severe poisoning with cyanides**

**BY INTRAVENOUS INJECTION**

- Child: Consult the National Poisons Information Service
- Adult: 300 mg, to be given over 1 minute (or 5 minutes if condition less serious), dose to be followed immediately by 50 mL of glucose intravenous infusion 50%; if response inadequate a second dose of both may be given, but risk of cobalt toxicity

- **CAUTIONS** Owing to toxicity to be used only for definite cyanide poisoning when patient tending to lose, or has lost, consciousness
- **SIDE-EFFECTS** Anaphylactoid reactions - cardiac abnormalities - facial oedema - hypotension - laryngeal oedema - tachycardia - vomiting
- **EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply where administration is for saving life in emergency.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **DICOBALT EDTATE (Non-proprietary)**
  Dicobalt edetate 15 mg per 1 mL Dicobalt edetate 300 mg/20 mL solution for injection ampoules | 6 ampoule (BNF) £11.72

Sodium nitrite

**INDICATIONS AND DOSE**

Poisoning with cyanides (used in conjunction with sodium thiosulfate)

**BY INTRAVENOUS INJECTION**

- Child: 4–10 mg/kg (max. per dose 300 mg), to be given over 5–20 minutes followed by sodium thiosulfate injection
- Adult: 300 mg, to be given over 5–20 minutes (as sodium nitrite injection 30 mg/mL)

**Dose equivalence and conversion**

4–10 mg/kg equates to 0.13–0.33 mL/kg of a 3% solution.

Dose max. of 300 mg equates to 10 mL of a 3% solution.

- **SIDE-EFFECTS** Flushing (due to vasodilatation) - headache (due to vasodilatation)
- **EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply where administration is for saving life in emergency.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

Sodium thiosulfate

**INDICATIONS AND DOSE**

Poisoning with cyanides (used in conjunction with sodium nitrite)

**BY INTRAVENOUS INJECTION**

- Child: 400 mg/kg (max. per dose 12.5 g), to be given over 10 minutes, dose may be repeated in severe cyanide poisoning if dicobalt edetate not available
- Adult: 12.5 g, to be given over 10 minutes (as sodium thiosulfate injection 500 mg/mL), dose may be repeated in severe cyanide poisoning if dicobalt edetate not available

**Dose equivalence and conversion**

400 mg/kg equates to 0.8 mL/kg of a 50% solution.

- **EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply where administration is for saving life in emergency.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for infusion, liquid

2.2 Organophosphorous toxicity

**Drugs used for Organophosphorous toxicity not listed below**: Atropine sulfate, p. 1099

CHELATORS AND ANTIDOTES

Pralidoxime chloride

**INDICATIONS AND DOSE**

Adjunct to atropine in the treatment of poisoning by organophosphorous insecticide or nerve agent

**BY INTRAVENOUS INFUSION**

- Child: Initially 30 mg/kg, to be given over 20 minutes, followed by 8 mg/kg/hour; maximum 12 g per day

continued →
1132 Drug toxicity

3 Drug toxicity

3.1 Benzodiazepine toxicity

BENZODIAZEPINE ANTAGONISTS

Flumazenil

INDICATIONS AND DOSE

- Reversal of sedative effects of benzodiazepines in anaesthesia and clinical procedures
  - Adult: 200 micrograms, dose to be administered over 15 seconds, then 100 micrograms every 1 minute if required; usual dose 300–600 micrograms; maximum 1 mg per course
- Reversal of sedative effects of benzodiazepines in intensive care
  - Adult: 300 micrograms, dose to be administered over 15 seconds, then 100 micrograms every 1 minute if required; maximum 2 mg per course

Reversal of sedative effects of benzodiazepines in intensive care (if drowsiness recurs after initial dose)

Initially by intravenous infusion
- Adult: 100–400 micrograms/hour, adjusted according to response, alternatively (by intravenous injection) 300 micrograms, adjusted according to response

Important safety information

Should only be administered by, or under the direct supervision of, personnel experienced in their use.

- CONTRA-INDICATIONS Life-threatening condition (e.g. raised intracranial pressure, status epilepticus) controlled by benzodiazepines
- CAUTIONS Avoid rapid injection following major surgery • avoid rapid injection in high-risk or anxious patients • benzodiazepine dependence (may precipitate withdrawal symptoms) • elderly • ensure neuromuscular blockade cleared before giving • head injury (rapid reversal of benzodiazepine sedation may cause convulsions) • history of panic disorders (risk of recurrence) • prolonged benzodiazepine therapy for epilepsy (risk of convulsions) • short-acting (repeat doses may be necessary) benzodiazepine effects may persist for at least 24 hours
- SIDE-EFFECTS
  - Common or very common Nausea • vomiting
  - Uncommon Anxiety • fear • palpitation
  - Frequency not known Agitation • chills • convulsions (particularly in those with epilepsy) • dizziness • flushing • sensory disturbance • sweating • tachycardia • transient hypertension
- PREGNANCY Not known to be harmful.
- BREAST FEEDING Avoid breast-feeding for 24 hours.
- HEPATIC IMPAIRMENT Carefully titrate dose.
- DIRECTIONS FOR ADMINISTRATION For continuous intravenous infusion, dilute with Glucose 5% or Sodium Chloride 0.9%

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- FLUMAZENIL (Non-proprietary)
  - Flumazenil 100 microgram per 1 ml Flumazenil
  - 500micrograms/5ml solution for injection ampoules
  | 5 ampoule (£67.50–£72.46

3.2 Digoxin toxicity

CHELATORS AND ANTIDOTES

Digoxin-specific antibody

INDICATIONS AND DOSE

Treatment of known or strongly suspected life-threatening digoxin toxicity associated with ventricular arrhythmias or bradycardia unresponsive to atropine and when measures beyond the withdrawal of digoxin and correction of any electrolyte abnormalities are considered necessary

Initially by intravenous infusion
- Child: Serious cases of digoxin toxicity should be discussed with the National Poisons Information Service (consult product literature)
- Adult: Serious cases of digoxin toxicity should be discussed with the National Poisons Information Service (consult product literature)
3.3 Heparin toxicity

CHELATORS AND ANTIDOTES

Protein sulfate

INDICATIONS AND DOSE

Overdosage with intravenous injection of unfractionated heparin

BY INTRAVENOUS INJECTION

- Adult: Dose to be administered at a rate not exceeding 5 mg/minute, 1 mg neutralises 80–100 units heparin when given within 15 minutes; if longer than 15 minutes, heparin, less protamine required (consult product literature for details) as heparin rapidly excreted; maximum 50 mg

Overdosage with intravenous infusion of unfractionated heparin

BY INTRAVENOUS INJECTION

- Adult: Dose to be administered once heparin infusion stopped at a rate not exceeding 5 mg/minute

Overdosage with subcutaneous injection of unfractionated heparin

INITIALLY BY INTRAVENOUS INJECTION

- Adult: Initially 25–50 mg, to be administered at a rate not exceeding 5 mg/minute, 1 mg neutralises 100 units heparin, then (by intravenous infusion), any remaining dose to be administered over 8–16 hours; maximum 50 mg per course

Overdosage with subcutaneous injection of low molecular weight heparin

BY INTRAVENOUS INJECTION OR BY CONTINUOUS INTRAVENOUS INFUSION

- Adult: Dose to be administered by intermittent intravenous injection at a rate not exceeding 5 mg/minute, 1 mg neutralises approx. 100 units low molecular weight heparin (consult product literature of low molecular weight heparin for details); maximum 50 mg

CAUTIONS

- Excessive doses can have an anticoagulant effect

SIDE-EFFECTS

- Anaphylaxis, angioedema, back pain, bradycardia, dyspnoea, flushing, hypersensitivity reactions, hypertension, hypotension, lassitude, nausea, pulmonary oedema, rebound bleeding, vomiting

ALLERGY AND CROSS-SENSITIVITY

- Caution if increased risk of allergic reaction to protamine (includes previous treatment with protamine or protamine insulin, allergy to fish, men who are infertile, or who have had a vasectomy and who may have antibodies to protamine).

MONITORING REQUIREMENTS

- Monitor activated partial thromboplastin time or other appropriate blood clotting parameters.

3.4 Opioid toxicity

OPIOID RECEPTOR ANTAGONISTS

Naloxone hydrochloride

INDICATIONS AND DOSE

Overdosage with opioids

BY INTRAVENOUS INJECTION OR BY SUBCUTANEOUS INJECTION OR BY INTRAMUSCULAR INJECTION

- Neonate: Initially 100 micrograms/kg, if no response, repeat at intervals of 1 minute to a total max. 2 mg, then review diagnosis; further doses may be required if respiratory function deteriorates.

- Child 1 month-11 years: Initially 100 micrograms/kg, if no response, repeat at intervals of 1 minute to a total max. 2 mg, then review diagnosis; further doses may be required if respiratory function deteriorates.

- Child 12-17 years: Initially 400 micrograms, then 800 micrograms for up to 2 doses at 1 minute intervals if no response to preceding dose, then increased to 2 mg for 1 dose if still no response, then review diagnosis; further doses may be required if respiratory function deteriorates, 4 mg dose may be required in seriously poisoned patients

- Adult: Initially 400 micrograms, then 800 micrograms for up to 2 doses at 1 minute intervals if no response to preceding dose, then increased to 2 mg for 1 dose if still no response, then review diagnosis; further doses may be required if respiratory function deteriorates, 4 mg dose may be required in seriously poisoned patients

BY CONTINUOUS INTRAVENOUS INFUSION

- Neonate: Using an infusion pump, adjust rate according to response (initially, rate may be set at 60% of the initial resuscitative intravenous injection dose per hour). The initial resuscitative intravenous injection dose is that which maintained satisfactory ventilation for at least 15 minutes

- Child: Using an infusion pump, adjust rate according to response (initially, rate may be set at 60% of the initial resuscitative intravenous injection dose per hour). The initial resuscitative intravenous injection dose is that which maintained satisfactory ventilation for at least 15 minutes

- Adult: Using an infusion pump, adjust rate according to response (initially, rate may be set at 60% of the initial resuscitative intravenous injection dose per hour). The initial resuscitative intravenous injection dose is...
**Common or very common**
- vomit
- tachycardia
- hypotension
- dizziness
- hypoventilation in (children)
- hypotension
- nausea
- pulmonary oedema (in children)
- tachycardia
- ventricular fibrillation (in children)

**Rare**
- seizures (in adults)
- anaphylaxis (in adults)
- cardiac arrest (in adults)
- erythema multiforme
- hypersensitivity reactions (in adults)
- pulmonary oedema (in adults)
- seizures (in children)

**Frequency not known**
- Agitation (in adults)

**Pregnancy**
- Use only if potential benefit outweighs risk.

**Breastfeeding**
- Not orally bioavailable.

**Pharmacokinetics**
Naloxone has a short duration of action; repeated doses or infusion may be necessary to reverse effects of opioids with longer duration of action.

**Important**
- Only give by subcutaneous or intramuscular routes if intravenous route is not feasible; intravenous administration has more rapid onset of action.

**Unlicensed use**
Naloxone doses in BNF may differ from those in product literature.

**Caution**
Cardiovascular disease or those receiving cardiotoxic drugs (serious adverse cardiovascular effects reported) - maternal physical dependence on opioids (may precipitate withdrawal in newborn) - pain - physical dependence on opioids (precipitates withdrawal)

**Caution, Further Information**
Titration of dose
In postoperative use, the dose should be titrated for each patient in order to obtain sufficient respiratory response; however, naloxone antagonises analgesia.

**Side-effects**
- Common or very common
  - Cardiac arrest (in children)
  - Dizziness
  - Dyspnoea (in children)
  - Headache
  - Hypertension
  - Hyperventilation in (children)
  - Hypotension
  - Nausea
  - Pulmonary oedema (in children)
  - Tachycardia
  - Ventricular fibrillation (in children)
  - Vomiting

**Uncommon**
- Agitation (in children)
- Arrhythmia (in adults)
- Bradycardia (in adults)
- Diarrhoea
- Dry mouth
- Excitement (in children)
- Hyperventilation (in adults)
- Parasthesia (in children)
- Sweating
- Tremor

**Medicinal Forms**
- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Naloxone hydrochloride (Non-proprietary)**
  - Naloxone hydrochloride 20 microgram per 1 ml
  - Naloxone 40 micrograms/2 ml solution for injection ampoules
  - 10 ampoules (PSt) £55.00
  - Naloxone hydrochloride 400 microgram per 1 ml
  - Naloxone 400 micrograms/1 ml solution for injection Minijet pre-filled syringes
  - 1 pre-filled disposable injection (PSt) £20.40
  - Naloxone 2 mg/5 mL solution for injection Minijet pre-filled syringes
  - 1 pre-filled disposable injection (PSt) £20.40
  - Naloxone 400 micrograms/1 ml solution for injection Minijet pre-filled syringes
  - 1 pre-filled disposable injection (PSt) £17.70
  - 10 ampoules (PSt) £41.00–£53.70
  - Naloxone 800 micrograms/2 ml solution for injection Minijet pre-filled syringes
  - 1 pre-filled disposable injection (PSt) £20.40
  - Naloxone hydrochloride 1 mg per 1 ml
  - Naloxone 2 mg/2 ml solution for injection pre-filled syringes
  - 1 pre-filled disposable injection (PSt) £16.80
  - **Prenoxad** (Martindale Pharmaceuticals Ltd)
  - Naloxone hydrochloride 1 mg per 1 ml
  - Prenoxad 2 mg/2 ml solution for injection pre-filled syringes
  - 1 pre-filled disposable injection (PSt) £18.00

**3.5 Paracetamol toxicity**

**Chelators and Antidotes**

**Acetylcysteine**

**Indications and Dose**

**Paracetamol overdose**

**By intravenous infusion**
- **Child (body-weight up to 20 kg):** Initially 150 mg/kg over 1 hour, dose to be administered in 3 mL/kg glucose 5%, followed by 50 mg/kg over 4 hours, dose to be administered in 7 mL/kg glucose 5%, then 100 mg/kg over 16 hours, dose to be administered in 14 mL/kg glucose 5%
- **Child (body-weight 20–39 kg):** Initially 150 mg/kg over 1 hour, dose to be administered in 100 mL glucose 5%, followed by 50 mg/kg over 4 hours, dose to be administered in 250 mL glucose 5%, then 100 mg/kg over 16 hours, dose to be administered in 500 mL glucose 5%
- **Child (body-weight 40 kg and above):** 150 mg/kg over 1 hour, dose to be administered in 200 mL glucose
Methaemoglobinaemia

**CHELATORS AND ANTIDOSES**

**Methylothioninium chloride**
(Methylene blue)

**INDICATIONS AND DOSE**

**Drug- or chemical-induced methaemoglobinaemia**

**BY SLOW INTRAVENOUS INJECTION**

- **Child 3 months-17 years:** Initially 1–2 mg/kg, then 1–2 mg/kg after 30–60 minutes if required, to be given over 5 minutes, seek advice from National Poisons Information Service if further repeat doses are required; maximum 7 mg/kg per course

**Aniline- or dapsone-induced methaemoglobinaemia**

**BY SLOW INTRAVENOUS INJECTION**

- **Child 3 months-17 years:** Initially 1–2 mg/kg, then 1–2 mg/kg after 30–60 minutes if required, to be given over 5 minutes, seek advice from National Poisons Information Service if further repeat doses are required; maximum 4 mg/kg per course

**SAFETY**

- **CAUTIONS** Asthma (see Side-effects for management of asthma but do not delay acetylcysteine treatment) • atopy • may slightly increase INR • may slightly increase prothrombin time

**SIDE-EFFECTS**

Hypersensitivity-like reactions • rash • slight increase in INR and prothrombin time

**FURTHER INFORMATION**

Hypersensitivity-like reactions

- **SIDE-EFFECTS**
- **INTERACTIONS**
- **DIRECTIONS FOR ADMINISTRATION**
- **MEDICINAL FORMS**

**ACETYLCYSTEINE (Non-proprietary)**

- Acetylcysteine 200 mg per 1 ml
- Acetylcysteine 2g/10ml

**PARVOLEX (Phoenix Labs Ltd)**

- Acetylcysteine 200 mg per 1 ml
- Parvolex 2g/10ml

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: granules, tablet, eye drops, effervescent tablet, oral solution, capsule, liquid

**Solution for injection**

- May contain Sodium

**Electrolytes**

- Parvolex

**RECOMMENDATIONS**

- **MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, irrigation solution

**Solution for injection**

- **METHYLTIONIUM CHLORIDE (Non-proprietary)**
- Methylothioninium chloride 5 mg per 1 ml
- Methylothioninium chloride Proveblue 50mg/10ml

**SIDE-EFFECTS**

- **INR**
- **Prothrombin time**

**INTERACTIONS**

- **Appendix 1 (methylthioninium).**

**DIRECTIONS FOR ADMINISTRATION**

- **With intravenous use in children**

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, irrigation solution

**Solution for injection**

- **METHYLTIONIUM CHLORIDE (Non-proprietary)**
- Methylothioninium chloride 5 mg per 1 ml
- Methylothioninium chloride Proveblue 50mg/10ml
**5 Snake bites**

**ANTISERA**

**European viper snake venom antiserum**

**INDICATIONS AND DOSE**

Systemic envenoming from snake bites

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- **Child:** Initially 10 mL for 1 dose, then 10 mL after 1–2 hours if required, the second dose should only be given if symptoms of systemic envenoming persist after the first dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service
- **Adult:** Initially 10 mL for 1 dose, then 10 mL after 1–2 hours if required, the second dose should only be given if symptoms of systemic envenoming persist after the first dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service

Severe systemic envenoming from snake bites in patients presenting with clinical features

**BY INTRAVENOUS INJECTION OR BY INTRAVENOUS INFUSION**

- **Child:** Initially 20 mL for 1 dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service
- **Adult:** Initially 20 mL for 1 dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service

**DIRECTIONS FOR ADMINISTRATION**

- By intravenous injection give over 10–15 minutes or by intravenous infusion over 30 minutes after diluting in sodium chloride 0.9% (use 5 mL diluent/kg body-weight).

**PRESCRIBING AND DISPENSING INFORMATION**

To order, email immform@dh.gsi.gov.uk.

The National Poisons Information Service (Tel: 0844 892 0111) will provide specialist advice on all aspects of poisoning day and night.
Appendix 1 Interactions

Two or more drugs given at the same time may exert their effects independently or may interact. The interaction may be potentiation or antagonism of one drug by another, or occasionally some other effect. Adverse drug interactions should be reported to the Medicines and Healthcare products Regulatory Agency (MHRA), through the Yellow Card Scheme (see Adverse Reactions to Drugs), as for other adverse drug reactions.

Drug interactions may be pharmacodynamic or pharmacokinetic.

Pharmacodynamic interactions

These are interactions between drugs which have similar or antagonistic pharmacological effects or side-effects. They may be due to competition at receptor sites, or occur between drugs acting on the same physiological system. They are usually predictable from a knowledge of the pharmacology of the interacting drugs; in general, those demonstrated with one drug are likely to occur with related drugs. They occur to a greater or lesser extent in most patients who receive the interacting drugs.

Pharmacokinetic interactions

These occur when one drug alters the absorption, distribution, metabolism, or excretion of another, thus increasing or reducing the amount of drug available to produce its pharmacological effects. They are not easily predicted and many of them affect only a small proportion of patients taking the combination of drugs. Pharmacokinetic interactions occurring with one drug cannot be assumed to occur with related drugs unless their pharmacokinetic properties are known to be similar.

Pharmacokinetic interactions are of several types:

Affecting absorption The rate of absorption or the total amount absorbed can both be altered by drug interactions. Delayed absorption is rarely of clinical importance unless high peak plasma concentrations are required (e.g. when giving an analgesic). Reduction in the total amount absorbed, however, may result in ineffective therapy.

Due to changes in protein binding To a variable extent most drugs are loosely bound to plasma proteins. Protein-binding sites are non-specific and one drug can displace another thereby increasing its proportion free to diffuse from plasma to its site of action. This only produces a detectable increase in effect if it is an extensively bound drug (more than 90%) that is not widely distributed throughout the body. Even so displacement rarely produces more than transient potentiation because this increased concentration of free drug results in an increased rate of elimination.

Displacement from protein binding plays a part in the potentiation of warfarin by sulfonamides and tolbutamide but the importance of these interactions is due mainly to the fact that warfarin metabolism is also inhibited.

Affecting metabolism Many drugs are metabolised in the liver. Induction of the hepatic microsomal enzyme system by one drug can gradually increase the rate of metabolism of another, resulting in lower plasma concentrations and a reduced effect. On withdrawal of the inducer plasma concentrations increase and toxicity may occur.

Barbiturates, griseofulvin, many antiepileptics, and rifampicin are the most important enzyme inducers. Drugs affected include warfarin and the oral contraceptives.

Conversely when one drug inhibits the metabolism of another higher plasma concentrations are produced, rapidly resulting in an increased effect with risk of toxicity. Some drugs which potentiate warfarin and phenytoin do so by this mechanism.

Isoenzymes of the hepatic cytochrome P450 system interact with a wide range of drugs. Drugs may be substrates, inducers or inhibitors of the different isoenzymes; however, since drugs are eliminated by a number of different metabolic routes as well as renal excretion, the clinical effects of interactions cannot be predicted accurately from laboratory data on the cytochrome P450 isoenzymes. Except where a combination of drugs is specifically contra-indicated, the BNF presents only interactions that have been reported in clinical practice. In all cases the possibility of an interaction must be considered if toxic effects occur or if the activity of a drug diminishes.

Affecting renal excretion Drugs are eliminated through the kidney both by glomerular filtration and by active tubular secretion. Competition occurs between those which share active transport mechanisms in the proximal tubule. For example, salicylates and some other NSAIDs delay the excretion of methotrexate; serious methotrexate toxicity is possible.

Relative importance of interactions

Many drug interactions are harmless and many of those which are potentially harmful only occur in a small proportion of patients; moreover, the severity of an interaction varies from one patient to another. Drugs with a small therapeutic ratio (e.g. phenytoin) and those which require careful control of dosage (e.g. anticoagulants, antihypertensives, and antidiabetics) are most often involved.

Patients at increased risk from drug interactions include the elderly and those with impaired renal or liver function.

Serious interactions The symbol ● has been placed against interactions that are potentially serious and where concomitant administration of the drugs involved should be avoided (or only undertaken with caution and appropriate monitoring).

Interactions that have no symbol do not usually have serious consequences.
List of drug interactions

The following is an alphabetical list of drugs and their interactions, to avoid excessive cross-referencing each drug or group is listed twice: in the alphabetical list and also against the drug or group with which it interacts.

**Abacavir**
- Analgesics: abacavir possibly reduces plasma concentration of METHADONE
- Antibacterials: plasma concentration of abacavir possibly reduced by RIFAMPICIN
- Antiepileptics: plasma concentration of abacavir possibly reduced by FOSPHENTOIN, PHENOBARBITAL, PHENTOIN and PHTHALOGEN
- Antivirals: abacavir possibly reduces effects of RIBAVIRIN; plasma concentration of abacavir reduced by TIPRANAVIR
- Orlistat: absorption of abacavir possibly reduced by ORLISTAT

**Abatacept**
- Cytotoxics: increased risk of side-effects when abatacept given with ADALIMUMAB; avoid concomitant use of abatacept with CERTOLIZUMAB PEGOL, GOLIMUMAB or INFlixIMAB
- Etanercept: avoid concomitant use of abatacept with ETANERCEPT
- Vaccines: risk of generalised infections when abatacept given with live VACCINES—avoid concomitant use

**Abiraterone**
- Analgesics: abiraterone increases plasma concentration of DEXTROMETHORPHAN
- Antibacterials: plasma concentration of abiraterone possibly reduced by RIFABUTIN—manufacturer of abiraterone advises avoid concomitant use; plasma concentration of abiraterone reduced by RIFAMPICIN—manufacturer of abiraterone advises avoid concomitant use
- Antidepressants: plasma concentration of abiraterone possibly reduced by ST JOHN’S WORT—manufacturer of abiraterone advises avoid concomitant use
- Antiepileptics: plasma concentration of abiraterone possibly reduced by CARBAMAZEPINE, FOSPHENTOIN, PHENOBARBITAL, PHENTOIN and PRIMIDONE—manufacturer of abiraterone advises avoid concomitant use

**Acarbose** see Antidiabetics

**ACE inhibitors**
- Alcohol: enhanced hypotensive effect when ACE inhibitors given with ALCOHOL.
- Aldesleukin: enhanced hypotensive effect when ACE inhibitors given with ALDESLEUKIN.
- Aliskiren: increased risk of hyperkalaemia, hypotension, and impaired renal function when ACE inhibitors given with ALISKIREN—avoid concomitant use
- Allopurinol: manufacturers state possible increased risk of leucopenia and hypersensitivity reactions when ACE inhibitors given with ALLOPURINOL especially in renal impairment
- Alpha-blockers: enhanced hypotensive effect when ACE inhibitors given with ALPHA-BLOCKERS
- Anaesthetics, General: enhanced hypotensive effect when ACE inhibitors given with GENERAL ANAESTHETICS
- Analgesics: increased risk of renal impairment when ACE inhibitors given with NSAIDS, also hypotensive effect antagonised
- Angiotensin-II Receptor Antagonists: increased risk of hyperkalaemia, hypotension, and impaired renal function when ACE inhibitors given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS—avoid concomitant use
- Antacids: absorption of ACE inhibitors possibly reduced by ANTACIDS; absorption of captopril, enalapril and fosinopril reduced by ANTACIDS
- Antibacterials: plasma concentration of active metabolite of imidapril reduced by RIFAMPICIN (reduced antihypertensive effect); quinapril tablets reduce absorption of TETRACYCLINES (quinapril tablets contain magnesium carbonate); possible increased risk of hyperkalaemia when ACE inhibitors given with TRIMETHOPRIM
- Anticoagulants: increased risk of hyperkalaemia when ACE inhibitors given with HEPARINS

**ACE inhibitors (continued)**
- Antidepressants: hypotensive effect of ACE inhibitors possibly enhanced by MAOIS.
- Antidiabetics: ACE inhibitors possibly enhance hypoglycaemic effect of INSULIN, METFORMIN and SULFONYLUREAS.
- Antipsychotics: enhanced hypotensive effect when ACE inhibitors given with ANTIPSYCHOTICS
- Anxiolytics and Hypnotics: enhanced hypotensive effect when ACE inhibitors given with ANXIOLYTICS AND HYPNOTICS
- Avanafil: hypotensive effect of enalapril possibly enhanced by AVANAFIL
- Azathioprine: increased risk of anaemia or leucopenia when captopril given with AZATHIOPRINE especially in renal impairment; increased risk of anaemia when enalapril given with AZATHIOPRINE especially in renal impairment
- Bee Venom Extracts: possible severe anaphylactoid reaction when ACE inhibitors given with BEE VENOM EXTRACTS
- Beta-blockers: enhanced hypotensive effect when ACE inhibitors given with BETA-BLOCKERS
- Calcium-Channel Blockers: enhanced hypotensive effect when ACE inhibitors given with CALCIUM-CHANNEL BLOCKERS
- Cardiac Glycosides: captopril possibly increases plasma concentration of DIGOXIN
- Cilostazol: increased risk of severe hyperkalaemia when ACE inhibitors given with CILOSTAZOL
- Clonidine: enhanced hypotensive effect when ACE inhibitors given with CLONIDINE; antihypertensive effect of captopril possibly delayed by previous treatment with CLONIDINE
- Corticosteroids: hypotensive effect of ACE inhibitors antagonised by CORTICOSTEROIDS
- Cytoxotics: increased risk of angioedema when ACE inhibitors given with EVEROLIMUS
- Diazoxide: enhanced hypotensive effect when ACE inhibitors given with DIAZoxide
- Diuretics: enhanced hypotensive effect when ACE inhibitors given with DIURETICS; increased risk of severe hyperkalaemia when ACE inhibitors given with POTASSIUM-SPARING DIURETICS AND ALDOSTERONE ANTAGONISTS
- Dopaminergics: enhanced hypotensive effect when ACE inhibitors given with CO-BENELDOPA, CO-CARELDOPA or LEVODOPA
- Lithium: ACE inhibitors reduce excretion of LITHIUM (increased plasma concentration)
- Methyldopa: enhanced hypotensive effect when ACE inhibitors given with METHYLDOPA
- Moxisylyte: enhanced hypotensive effect when ACE inhibitors given with MOXISYLYTE
- Moxonidine: increased risk of severe hyperkalaemia when ACE inhibitors given with MOXONIDINE
- Muscle Relaxants: enhanced hypotensive effect when ACE inhibitors given with BACLOFEN or TIZANIDINE
- Nitrates: enhanced hypotensive effect when ACE inhibitors given with NITRATES
- Oestrogens: enhanced hypotensive effect of ACE inhibitors antagonised by OESTROGENS
- Potassium Salts: increased risk of severe hyperkalaemia when ACE inhibitors given with POTASSIUM SALTS
- Prostaglandins: enhanced hypotensive effect when ACE inhibitors given with PROSTAGLANDINS
- Sodium Aurothiomalate: flushing and hypotension reported when ACE inhibitors given with SODIUM AUROTHIOMALATE
- Vasodilator Antihypertensives: enhanced hypotensive effect when ACE inhibitors given with HYDRAZINE, MINOXIDIL or SODIUM NITROPRUSSIATE
- Wasp Venom Extracts: possible severe anaphylactoid reaction when ACE inhibitors given with WASP VENOM EXTRACTS

**Acebutolol** see Beta-blockers

**Aceclofenac** see NSAIDs

**Acemetacin** see NSAIDs

**Acenocoumarol** see Coumarins

**Acetazolamide** see Diuretics

**Aciclovir**
- NOTE Interactions do not apply to topical aciclovir preparations
- Aminophylline: aciclovir possibly increases plasma concentration of AMINOPHYLLINE
Adalimumab

- Adalimumab: increased risk of nephrototoxicity when adalimumab given with theophylline.
- Adaline: increased risk of nephrotoxicity when adaline given with tacrolimus.
- Adrenergic Neurone Blockers: increased risk of nephrotoxicity when adrenergic neurone blockers given with tacrolimus.
- Adrenaline (epinephrine): increased risk of nephrotoxicity when adrenergic neurone blockers given with tacrolimus.
- Theophylline: increased risk of nephrotoxicity when adrenergic neurone blockers given with tacrolimus.
- Acitretin: see Retinooids.
- Aciclovir: see Antivirals.
- Aclidinium: see Antimuscarinics.
- Aclidinium: see Antimuscarinics.
- Adefovir: increased risk of nephrotoxicity when adalimumab given with Adefovir.

Antidepressants:

- Analgesics:
- Anaesthetics, General:
- Alpha-blockers:
- Alcohol:
- Theophylline:
- Nicotine:
- Dipyridamole:
- Caffeine citrate:
- Beta-blockers:
- Antipsychotics:
- Adenosine:
- Interferons:
- Vaccines:
- Antibodies: See live vaccines.

- Antibiotics: See live vaccines.
- Antivirals: See live vaccines.
- Antibacterials: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
- Prostaglandins: See live vaccines.
Afatinib (continued)  
▶ Ciclosporin: plasma concentration of afatinib possibly increased by Ciclosporin—manufacturer of afatinib advises separating administration of ciclosporin by 6 to 12 hours  
▶ Tacrolimus: plasma concentration of afatinib possibly increased by Tacrolimus—manufacturer of afatinib advises separating administration of tacrolimus by 6 to 12 hours

Agalsidase Alfa and Beta  
▶ Anti-arrhythmics: effects of agalsidase alfa and beta possibly inhibited by Amiodarone (manufacturers of agalsidase alfa and beta advise avoid concomitant use)  
▶ Antibacterials: effects of agalsidase alfa and beta possibly inhibited by Gentamicin (manufacturers of agalsidase alfa and beta advise avoid concomitant use)  
▶ Antimalarials: effects of agalsidase alfa and beta possibly inhibited by Chloroquine and Hydroxychloroquine (manufacturers of agalsidase alfa and beta advise avoid concomitant use)

Agomelatine  
● Antibacterials: manufacturer of agomelatine advises avoid concomitant use with Ciclosporin

Antidepressants: metabolism of agomelatine inhibited by Fluvoxamine (increased plasma concentration)  
Antimalarials: avoidance of antidepressants advised by manufacturer of Arteether with Lumefantrine and Arteminol with Piperaquine  
Atomoxetine: possible increased risk of convulsions when antidepressants given with Atomoxetine

Albendazole  
Antihistamines: plasma concentration of both drugs possibly reduced when albendazole given with Levamisole  
Antiepileptics: plasma concentration of albendazole reduced by Carbamazepine, Phenytoin, Phenobarbital, Phenytoin and Primidone—consider increasing albendazole dose when given for systemic infections  
Antivirals: plasma concentration of active metabolite of albendazole reduced by Ritonavir—consider increasing albendazole dose when given for systemic infections  
Corticosteroids: plasma concentration of active metabolite of albendazole increased by Dexamethasone  
Grapefruit juice: plasma concentration of active metabolite of albendazole increased by Grapefruit Juice  
Ulcer-healing Drugs: effects of albendazole possibly enhanced by Cimetidine

Alcohol  
ACE Inhibitors: enhanced hypotensive effect when alcohol given with ACE inhibitors  
Adrenergic Neurone Blockers: enhanced hypotensive effect when alcohol given with Adrenergic Neurone Blockers  
Alpha-blockers: increased sedative effect when alcohol given with Indoramin; enhanced hypotensive effect when alcohol given with Alpha-blockers  
Analgesics: enhanced hypotensive and sedative effects when alcohol given with Opioid Analgesics  
Antihistamines: enhanced hypotensive and sedative effects when alcohol given with Antihistamines  
Anticoagulants: major changes in consumption of alcohol may affect anticoagulant control with Coumarins or Phenindione  
Antidepressants: some beverages containing alcohol and some dealkoholised beverages contain tyramine which interacts with Madi (hypertensive crisis)—if no tyramine, enhanced hypotensive effect; sedative effects possibly increased when alcohol given with SSRIs; increased sedative effect when alcohol given with Mirtazapine, Tricyclic-related Antidepressants or Tricyclics  
Antidiabetics: alcohol enhances hypoglycaemic effect of Antidiabetics; increased risk of lactic acidosis when alcohol given with Metformin

Alcohol (continued)  
Antiepileptics: alcohol possibly increases CNS side-effects of Carbamazepine; chronic heavy consumption of alcohol possibly reduces plasma concentration of Phenytoin and Phenytoin; increased sedative effect when alcohol given with Phenobarbital or Primidone; increased risk of blurred vision when alcohol given with Retigabine  
Antifungals: possibility of disulfiram-like reaction when alcohol given with Ketoconazole; effects of alcohol possibly enhanced by Griseofulvin  
Antihistamines: increased sedative effect when alcohol given with Antihistamines (possibly less effect with non-sedating antihistamines)  
Antimuscarinics: increased sedative effect when alcohol given with Hydroxyzine  
Antipsychotics: increased sedative effect when alcohol given with Antipsychotics  
Anxiolytics and Hypnotics: increased sedative effect when alcohol given with Anxiolytics and Hypnotics  
Avasif: possible enhanced hypotensive effect when alcohol given with Avasif  
Beta-blockers: enhanced hypotensive effect when alcohol given with Beta-blockers  
Calcium-channel Blockers: enhanced hypotensive effect when alcohol given with Calcium-channel Blockers; plasma concentration of alcohol possibly increased by Verapamil  
Clonidine: enhanced hypotensive effect when alcohol given with Clonidine  
Cytotoxics: disulfiram-like reaction when alcohol given with Procarbazine; avoidance of alcohol advised by manufacturer of Trecetidine  
Dapoxetine: increased sedative effect when alcohol given with Dapoxetine  
Diuretics: enhanced hypotensive effect when alcohol given with Diuretics  
Dopaminergics: alcohol reduces tolerance to Bromocriptine  
Lipid-regulating Drugs: avoidance of alcohol advised by manufacturer of Lomitapide  
Lofexidine: increased sedative effect when alcohol given with Lofexidine  
Methylalpha: enhanced hypotensive effect when alcohol given with Methylalpha  
Metoclopromide: absorption of alcohol possibly increased by Metoclopromide  
Moxonidine: enhanced hypotensive effect when alcohol given with Moxonidine  
Muscle Relaxants: increased sedative effect when alcohol given with Baclofen, Methocarbamol or Tizanidine  
Nicorandil: alcohol possibly enhances hypotensive effect of Nicorandil  
Nitrates: enhanced hypotensive effect when alcohol given with Nitrates  
Paraldehyde: increased sedative effect when alcohol given with Paraldehyde  
Retinoids: presence of alcohol causes etretinate to be formed from Acitretin (increased risk of teratogenicity in women of child-bearing potential)  
Sympathomimetics: alcohol possibly enhances effects of Methylphenidate  
vasodilator Antihypertensives: enhanced hypotensive effect when alcohol given with Hydralazine, Minoxidil or Sodium Nitroprusside

Aldesleukin  
ACE Inhibitors: enhanced hypotensive effect when aldesleukin given with ACE inhibitors  
Alpha-blockers: enhanced hypotensive effect when aldesleukin given with Alpha-blockers  
Antiangiostatin-II Receptor Antagonists: enhanced hypotensive effect when aldesleukin given with Angiostatin-II Receptor Antagonists  
Antivirals: aldesleukin possibly increases plasma concentration of Indinavir

Antidotes: effects of alcohol possibly increased by Antidotes; increased sedative effect when alcohol given with Antidotes; increased risk of lactic acidosis when alcohol given with Metformin

Antidiabetics: alcohol enhances hypoglycaemic effect of Antidiabetics; increased risk of lactic acidosis when alcohol given with Metformin
Aliskiren (continued)

- Beta-blockers: enhanced hypotensive effect when aliskiren given with beta blockers.
- Calcium-channel Blockers: enhanced hypotensive effect when aliskiren given with calcium-channel blockers.
- Clonidine: enhanced hypotensive effect when aliskiren given with clonidine.
  - Corticosteroids: manufacturer of aliskiren advises avoid concomitant use with corticosteroids.
  - Cytoxotics: manufacturer of aliskiren advises avoid concomitant use with cisplatin, dacarbazine, and vinblastine.
- Diazoxide: enhanced hypotensive effect when aliskiren given with diazoxide.
- Diuretics: enhanced hypotensive effect when aliskiren given with diuretics.
- Moxonidine: enhanced hypotensive effect when aliskiren given with moxonidine.
- Nitrates: enhanced hypotensive effect when aliskiren given with nitrates.
- Vasodilator Antihypertensives: enhanced hypotensive effect when aliskiren given with hydralazine, minoxidil of sodium nitropusside.

Almuzumab

- Antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis).
- Vaccines: risk of generalised infections when monoclonal antibodies given with live vaccines—avoid concomitant use.

Aldromeric Acid see Bisphosphonates

Alfacacidol see Vitamins

Alfatentanil see Opioid Analgesics

Alfuzosin see Alpha-blockers

Alimemazine see Antihistamines

Alikiren

- ACE Inhibitors: increased risk of hyperkalaemia, hypotension, and impaired renal function when aliskiren given with ACE INHIBITORS—avoid concomitant use.
- Analgesics: hypotensive effect of aliskiren possibly antagonised by NSAIDS.
- Angiotensin-II Receptor Antagonists: increased risk of hyperkalaemia, hypotension, and impaired renal function when aliskiren given with angiotensin-II receptor antagonists—avoid concomitant use.
- Antibacterials: plasma concentration of aliskiren reduced by rifampicin.
- Anticoagulants: increased risk of hyperkalaemia when aliskiren given with heparins.
- Antifungals: plasma concentration of aliskiren increased by ketoconazole; plasma concentration of aliskiren increased by itraconazole—avoid concomitant use.
- Calcium-channel Blockers: plasma concentration of aliskiren increased by verapamil.
- Ciclosporin: plasma concentration of aliskiren increased by ciclosporin—avoid concomitant use.
- Diuretics: aliskiren reduces plasma concentration of furosemide; increased risk of hyperkalaemia when aliskiren given with potassium-sparing diuretics and aldosterone antagonists.
- Grapefruit juice: plasma concentration of aliskiren reduced by grapefruit juice—avoid concomitant use.
- Potassium Salts: increased risk of hyperkalaemia when aliskiren given with potassium salts.

Alitretinoin see Retinoids

Alkylating Drugs see Bendamustine, Busulfan, Carmustine, Cyclophosphamide, Estramustine, Ifosfamide, Lomustine, Melphalan, and Thiopeta

Allopurinol

- ACE Inhibitors: manufacturers state possible increased risk of leucopenia and hypersensitivity reactions when allopurinol given with ACE INHIBITORS especially in renal impairment.
- Aminophylline: allopurinol possibly increases plasma concentration of aminophylline.

Allopurinol (continued)

- Antibacterials: increased risk of rash when allopurinol given with amoxicillin, ampicillin or co-amoxiclav.
- Anticoagulants: allopurinol possibly enhances anticoagulant effect of coumarins.
- Antidiabetics: allopurinol increases plasma concentration of diabates (risk of toxicity)—avoid concomitant use.
- Azathioprine: allopurinol enhances effects and increases toxicity of azathioprine (reduce dose of azathioprine to one quarter of usual dose).
- Ciclosporin: allopurinol possibly increases plasma concentration of ciclosporin (risk of nephrotoxicity).
- Cytoxotics: avoidance of allopurinol advised by manufacturer of capetibamine; allopurinol enhances effects and increases toxicity of mercaptopurine (reduce dose of mercaptopurine to one quarter of usual dose).
- Diuretics: increased risk of hypersensitivity when allopurinol given with thiazides and related diuretics especially in renal impairment.
- Theophylline: allopurinol possibly increases plasma concentration of theophylline.

Almotriptan see 5HT1-receptor Agonists (under HT)

Alogliptin see Antidiabetics

Alpha-adrenoceptor Stimulants see Apraclonidine, Brimonidine, Clonidine, and Methylodopa

Alpha-blockers

- ACE Inhibitors: enhanced hypotensive effect when alpha-blockers given with ACE INHIBITORS.
- Adrenergic Neurone Blockers: enhanced hypotensive effect when alpha-blockers given with adrenergic neurone blockers.
- Alcohol: enhanced hypotensive effect when alpha-blockers given with alcohol; increased sedative effect when indoramin given with alcohol.
- Aldesleukin: enhanced hypotensive effect when alpha-blockers given with aldesleukin.
- Analgesics: enhanced hypotensive effect when alpha-blockers given with general analgesics.
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when alpha-blockers given with angiotensin-receptor antagonists.
- Antidepressants: manufacturer of indoramin advises avoid concomitant use with maois.
- Antifungals: plasma concentration of alfuzosin possibly increased by ketoconazole; plasma concentration of tamsulosin increased by ketoconazole.
- Antipsychotics: enhanced hypotensive effect when alpha-blockers given with antipsychotics.
- Antivirals: plasma concentration of doxazosin and tamsulosin possibly increased by boceprevir—manufacturer of boceprevir advises avoid concomitant use; plasma concentration of alfuzosin possibly increased by ritonavir—avoid concomitant use; avoidance of alfuzosin advised by manufacturer of telaprevir.
- Anxiolytics and Hypnotics: enhanced hypotensive and sedative effects when alpha-blockers given with anxiolytics and hypnotics.
- Avanafil: enhanced hypotensive effect when alpha-blockers given with avanafil—when patient is stable on the alpha blocker initiate avanafil at the lowest possible dose.
- Beta-blockers: enhanced hypotensive effect when alpha-blockers given with beta-blockers, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin.
- Calcium-channel Blockers: enhanced hypotensive effect when alpha-blockers given with calcium-channel blockers, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin.
- Cardiac Glycosides: prazosin increases plasma concentration of digoxin.
- Clonidine: enhanced hypotensive effect when alpha-blockers given with clonidine.
Alpha-blockers (continued)
- Cobicistat: plasma concentration of alfuzosin possibly increased by Cobicistat - manufacturer of cobicistat advises avoid concomitant use
- Corticosteroids: hypotensive effect of alpha-blockers antagonised by corticosteroids
- Cytotoxics: avoidance of alfuzosin advised by manufacturer of Idelalisib
- Diazoxide: enhanced hypotensive effect when alpha-blockers given with Diazoxide
- Diuretics: enhanced hypotensive effect when alpha-blockers given with Diuretics, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin
- Dopaminergics: enhanced hypotensive effect when alpha-blockers given with Methyldopa
- Mostylyte: possible severe postural hypotension when alpha-blockers given with Mostylyte
- Moxonidine: enhanced hypotensive effect when alpha-blockers given with Moxonidine
- Muscle Relaxants: enhanced hypotensive effect when alpha-blockers given with Baclofen or Tizanidine
- Nitrates: enhanced hypotensive effect when alpha-blockers given with Nitrates
- Oestrogens: hypotensive effect of alpha-blockers antagonised by Oestrogens
- Prostaglandins: enhanced hypotensive effect when alpha-blockers given with Alprostadil
- Sildenafil: enhanced hypotensive effect when alpha-blockers given with Sildenafil (avoid alpha-blockers for 4 hours after sildenafil)—when patient is stable on the alpha blocker initiate sildenafil at the lowest possible dose
- Sympathomimetics: avoid concomitant use of tolazoline with Adrenaline (epinephrine) or Dopamine
- Tadalafil: enhanced hypotensive effect when alpha-blockers given with Tadalafil—when patient is stable on the alpha blocker initiate tadalafil at the lowest possible dose; enhanced hypotensive effect when doxazosin given with Tadalafil—manufacturer of tadalafil advises avoid concomitant use
- Ulcer-healing Drugs: effects of tolazoline antagonised by Cimetidine and Ranitidine
- Vardenafil: enhanced hypotensive effect when alpha-blockers given with Vardenafil—when patient is stable on the alpha blocker initiate vardenafil at the lowest possible dose—separate doses by 6 hours (except with tamsulosin)
- Vasodilator Antihypertensives: enhanced hypotensive effect when alpha-blockers given with Hydralazine, Minoxidil or Sodium Nitroprusside

**Alpha-blockers (post-synaptic)** see Alpha-blockers

Alphazolam see Anxiolytics and Hypnotics

Alprostadil see Prostaglandins

Aluminium Hydroxide see Antacids

Amantadine
- Antimalarials: plasma concentration of amantadine possibly increased by Quinine
- Antipsychotics: increased risk of extrapyramidal side-effects when amantadine given with Antipsychotics
- Bupropion: increased risk of side-effects when amantadine given with Bupropion
- Memantine: increased risk of CNS toxicity when amantadine given with Memantine (manufacturer of memantine advises avoid concomitant use); effects of dopaminergics possibly enhanced by Memantine
- Methyldopa: increased risk of extrapyramidal side-effects when amantadine given with Methyldopa; antiparkinsonian effect of dopaminergics antagonised by Methyldopa
- Tetrabenazine: increased risk of extrapyramidal side-effects when amantadine given with Tetrabenazine

Ambrisentan
- Antibacterials: plasma concentration of ambrisentan possibly increased by Rifampicin

Ambrisentan (continued)
- Ciclosporin: plasma concentration of ambrisentan increased by Cyclosporin (see under Ambrisentan, p. 162)

Amikacin see Aminoglycosides

Amiloride see Diuretics

Aminoglycosides
- Agalasidase Alfa and Beta: gentamicin possibly inhibits effects of Agalasidase Alfa and Beta (manufacturers of agalasidase alfa and beta advise avoid concomitant use)
- Analgesics: plasma concentration of amikacin and gentamicin in neonates possibly increased by Indometacin
- Antibacterials: neomycin reduces absorption of Phenoxybenzamine; increased risk of nephrotoxicity when aminoglycosides given with Colistimethate Sodium or Polymyxins; increased risk of nephrotoxicity and ototoxicity when amikacin given with Cephradine or Vancomycin; possible increased risk of nephrotoxicity when aminoglycosides given with Cephalosporins
- Anticoagulants: experience in anticoagulant clinics suggests that INR possibly altered when neomycin (given for local action on gut) is given with Conjugates or Phenindione
- Antidiabetics: neomycin possibly enhances hypoglycaemic effect of Acarbose, also severity of gastro-intestinal effects increased
- Antifungals: increased risk of nephrotoxicity when aminoglycosides given with Ambroten and Bisphosphonates
- Cardiac Glycosides: gentamicin possibly increases plasma concentration of Digoxin; neomycin reduces absorption of Digoxin
- Ciclosporin: increased risk of nephrotoxicity when aminoglycosides given with Ciclosporin
- Cytotoxics: neomycin possibly reduces absorption of Methotrexate; neomycin reduces bioavailability of Sorafenib; increased risk of nephrotoxicity and possibly of ototoxicity when aminoglycosides given with Platinum Compounds
- Diuretics: increased risk of otoxicity when aminoglycosides given with Loop Diuretics
- Mannitol: manufacturer of tobramycin advises avoid concomitant use with Mannitol
- Muscle Relaxants: aminoglycosides enhance effects of Non-depolarising muscle relaxants and Succinylcholine
- Parasympathomimetics: aminoglycosides antagonise effects of Neostigmine and Pyridostigmine
- Tacrolimus: increased risk of nephrotoxicity when aminoglycosides given with Tacrolimus
- Vaccines: antibacterials inactivate Oral Typhoid Vaccine—see under Typhoid Vaccine in BNF
- Vitamins: neomycin possibly reduces absorption of Vitamin A

Aminophylline
- Allopurinol: plasma concentration of aminophylline possibly increased by Allopurinol
- Anaesthetics, General: increased risk of convulsions when aminophylline given with Ketamine
- Anti-arrhythmics: aminophylline antagonises anti-arrhythmic effect of Adenosine—manufacturer of adenosine advises avoid aminophylline for 24 hours before adenosine; plasma concentration of aminophylline increased by Propranolone
- Antibacterials: plasma concentration of aminophylline possibly increased by Clarithromycin and Isoniazid; plasma concentration of aminophylline increased by Erythromycin (also aminophylline may reduce absorption of oral erythromycin); plasma concentration of aminophylline increased by Ciprofloxacin and Norfloxacin; metabolism of aminophylline accelerated by Rifampicin (reduced plasma concentration); possible increased risk of convulsions when aminophylline given with Quinolones
- Antidepressants: plasma concentration of aminophylline increased by Fluvoxamine (concomitant use should usually be avoided, but where not possible halve aminophylline dose and monitor plasma-aminophylline concentration); plasma concentration of aminophylline possibly reduced by St John’s Wort
Aminophylline (continued)
- Antiarrhythmics: metabolism of aminophylline accelerated by CARBAMAZEPINE, PHENOBARBITAL and PRIMODONE (reduced effect); plasma concentration of both drugs reduced when aminophylline given with FOSPHENYTIOIN and PHENYTOIN
- Antifungals: plasma concentration of aminophylline possibly increased by FLUCONAZOLE and KETOCONAZOLE
- Antivirals: plasma concentration of aminophylline possibly increased by ACICLOVIR and VALACLOVIR; metabolism of amiodarone possibly accelerated by RITONAVIR (reduced plasma concentration)
- Anxiolytics and Hypnotics: aminophylline possibly reduces effects of BENZODIAZEPINES
- Calcium-channel Blockers: plasma concentration of aminophylline possibly increased by CALCIUM-CHANNEL BLOCKERS (enhanced effect); plasma concentration of aminophylline increased by DILTIAZEM; plasma concentration of pentoxifylline, plasma coned by VERAPAMIL (enhanced effect)
- Corticosteroids: increased risk of hypokalaemia when aminophylline given with CORTICOSTEROIDS
- Cytotoxics: plasma concentration of aminophylline possibly increased by METHOTREXATE
- Diuretics: plasma concentration of aminophylline increased by DEFERASIROX (consider reducing dose of aminophylline)
- Disulfiram: metabolism of aminophylline inhibited by DISULFIRAM (increased risk of toxicity)
- Diuretics: increased risk of hypokalaemia when aminophylline given with ACEIZOTOLAMIDE, LOOP DIURETICS or THIAZIDES and RELATED DIURETICS
- Droxapram: increased CNS stimulation when aminophylline given with DOXAPRAM
- Interferons: metabolism of aminophylline inhibited by INTERFERON-ALFA and INTERFERON-ALFA (consider reducing dose of aminophylline)
- Leukotriene Receptor Antagonists: plasma concentration of aminophylline possibly increased by ZAFIRLUKAST, also plasma concentration of zafirlukast reduced
- Lithium: aminophylline increases excretion of LITHIUM (reduced plasma concentration)
- Oestrogens: plasma concentration of aminophylline increased by OESTROGENS (consider reducing dose of aminophylline)
- Pentoxifylline: plasma concentration of aminophylline increased by PENTOXIFYLLINE
- Rotflumilast: avoidance of aminophylline advised by manufacturer of ROTFLUMILAST
- Sulfipyrazone: plasma concentration of aminophylline reduced by SULFOPYRAZONE
- Symptomimetics: manufacturer of aminophylline advises avoid concomitant use with EPHEDRINE in children
- Symptomimetics: Beta₂ increased risk of hypokalaemia when aminophylline given with high doses of BETA₂ SYMPTOMIMETICS
- Ulcer-healing Drugs: metabolism of aminophylline inhibited by CIMETIDINE (increased plasma concentration); absorption of aminophylline possibly reduced by SUCRALFATE (give at least 2 hours apart)
- Vaccines: plasma concentration of aminophylline possibly increased by INFLUENZA VACCINE

Aminosaliclylates see individual drugs

Amiodarone

NOTE: Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped.

- Antiarrhythmics: metabolism of aminophylline inhibited by AGALSIDASE ALFA AND BETA (manufacturers of agalsidase alfa and beta advise avoid concomitant use)
- Anasetics: Localised increased myocardial depression when anti-arrhythmics given with BUPIVACAINE, LEVOBUPIVACAINE, PRILOCAIN or ROPIVACAINE
- Antiarrhythmics: increased myocardial depression when anti-arrhythmics given with other ANTI-ARRHYTHMICS; increased risk of ventricular arrhythmias when amiodarone given with DISOPYRAMIDE or DRONEDARONE—avoid concomitant use

Amiodarone
- Antiarrhythmics (continued): amiodarone increases plasma concentration of FLECAINIDE (halve dose of flecainide)
- Antibacterials: increased risk of ventricular arrhythmias when amiodarone given with piperacillin—erythromycin—avoid concomitant use; increased risk of ventricular arrhythmias when amiodarone given with LEVOFLOXACIN or MOXIFLOXACIN—avoid concomitant use; possible increased risk of ventricular arrhythmias when amiodarone given with SULTAMETHOXAZOLE and TRIMETHOPRIM (as co-trimoxazole)—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole; increased risk of ventricular arrhythmias when amiodarone given with DELAMANIDE; avoidance of amiodarone advised by manufacturer of FIDAXOMICIN; possible increased risk of ventricular arrhythmias when amiodarone given with TELITHROMYCIN
- Anticoagulants: amiodarone inhibits metabolism of COUMARINS and PHENINDIONE (enhanced anticoagulant effect); amiodarone increases plasma concentration of DEFERASIROX (see under Deferasirox, p. 117)
- Antidepressants: avoidance of amiodarone advised by manufacturer of CITRALOPRAM and ESCITALOPRAM (risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when amiodarone given with TRICYCLES—avoid concomitant use
- Antiarrhythmics: amiodarone inhibits metabolism of FOSPHENYTIOIN and PHENYTOIN (increased plasma concentration)
- Antihistamines: increased risk of ventricular arrhythmias when amiodarone given with MIZOLASTINE—avoid concomitant use
- Antimalarials: avoidance of amiodarone advised by manufacturer of ARTEMETHER WITH LUMEFANTRINE (risk of ventricular arrhythmias); avoidance of amiodarone advised by manufacturer of ARTENIMOL WITH Piperidine (possible risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when amiodarone given with CHLOROQUINE, HYDROXYCHLOROQUINE, MELFOQUINE or QUININE—avoid concomitant use
- Antimuscarinics: increased risk of ventricular arrhythmias when amiodarone given with TOLERTODINE
- Antipsychotics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with ANTIPSYCHOTICS; that prolong the QT interval; increased risk of ventricular arrhythmias when amiodarone given with BERPEDIOL—manufacturer of benperidol advises avoid concomitant use; increased risk of ventricular arrhythmias when amiodarone given with AMILSULPRIDE, DROPERIDOL, HALOPERIDOL, PHENOTHIAZINES, PIMOCID or ZUCLOPENTHIXOL—avoid concomitant use; increased risk of ventricular arrhythmias when amiodarone given with SULPIRIDE
- Antivirals: plasma concentration of amiodarone possibly increased by ATAZANAVIR, possibly increased increased risk of bradycardia when amiodarone given with DACLATASVIR and SIMPREVIR (with sofosbuvir)—see under Amiodarone, p. 88; plasma concentration of amiodarone possibly increased by FOSAPRENAVIR (increased risk of ventricular arrhythmias—avoid concomitant use); plasma concentration of amiodarone possibly increased by INDINAVIR—avoid concomitant use; plasma concentration of amiodarone increased by RITONAVIR (increased risk of ventricular arrhythmias—avoid concomitant use); increased risk of ventricular arrhythmias when amiodarone given with SAAVNAVIR—avoid concomitant use; possible increased increased risk of bradycardia when amiodarone given with SOFOSBUVIR—see under Amiodarone, p. 88; avoidance of amiodarone advised by manufacturer of TELAPREVIR (risk of ventricular arrhythmias)
- Atomoxetine: increased risk of ventricular arrhythmias when amiodarone given with ATOMOXETINE
- Beta-blockers: increased risk of bradycardia, AV block and myocardial depression when amiodarone given with BETA-BLOCKERS; increased myocardial depression when anti-
Amiodarone
- Beta-blockers (continued)
  - arrhythmics given with Beta-blockers; increased risk of ventricular arrhythmias when amiodarone given with SOTALOL—avoid concomitant use
  - Calcium-channel Blockers: increased risk of bradycardia, AV block and myocardial depression when amiodarone given with DILTIAZEM or VERAPAMIL
  - Cardiac Glycosides: amiodarone increases plasma concentration of DIGOXIN (halve dose of digoxin)
  - Ciclosporin: amiodarone possibly increases plasma concentration of CICLOSPORIN
  - Cobicistat: plasma concentration of amiodarone possibly increased by COBICISTAT—manufacturer of cobicistat advises avoid concomitant use
  - Colchicine: amiodarone possibly increases risk of COLCHICINE toxicity
  - Cytoxotics: amiodarone possibly increases the plasma concentration of AFATINIB—manufacturer of afatinib advises separating administration of amiodarone by 6 to 12 hours; possible increased risk of ventricular arrhythmias when amiodarone given with BOSTINIB; amiodarone possibly increases the plasma concentration of IBRUTINIB—reduce dose of ibrutinib (see under Ibrutinib, p. 809); avoidance of amiodarone advised by manufacturer of IDEALISAL; possible increased risk of ventricular arrhythmias when amiodarone given with VANETANIB—avoid concomitant use; increased risk of ventricular arrhythmias when amiodarone given with ARSENIC TRIODIDE
  - Diuretics: increased cardiac toxicity with amiodarone if hypokalaemia occurs with ACETAZOLAMIDE, LOOP DIURETICS or THIAZIDES AND RELATED DIURETICS; amiodarone increases plasma concentration of EPERLENONE (reduce dose of eperlenone)
  - Fingolimod: possible increased risk of bradycardia when amiodarone given with FINGOLIMOD
  - Grapefruit Juice: plasma concentration of amiodarone increased by GRAPEFRUIT JUICE
  - Ibratrudine: increased risk of ventricular arrhythmias when amiodarone given with IBRUTINIB
  - Lipid-regulating Drugs: increased risk of myopathy when amiodarone given with SIMVASTATIN (see under Simvastatin, p. 181); separating administration from amiodarone by 12 hours advised by manufacturer of LOMITAPIDE
  - Lithium: manufacturer of amiodarone advises avoid concomitant use with LITHIUM (risk of ventricular arrhythmias)
  - Orlisat: plasma concentration of amiodarone possibly decreased by ORLISTAT
  - Pentamidine isetionate: increased risk of ventricular arrhythmias when amiodarone given with PENTAMIDINE ISETINATE—avoid concomitant use
  - Thyroid Hormones: amiodarone can affect serum concentrations of THYROID HORMONES—monitor thyroid function closely
  - Ulcer-healing Drugs: plasma concentration of amiodarone increased by CIMEIDINE

Amisulpride see Antipsychotics

Amiriptyline see Antidepressants, Tricyclic

Amiodipine see Calcium-channel Blockers

Amodiliciin see Penicillins

Amphotericin
- NOTE Close monitoring required with concomitant administration of nephrotoxic drugs or cytoxotics
- Antibacterials: increased risk of nephrotoxicity when amphotericin given with AMINOGLYCOSIDES or POLYMIXINS; possible increased risk of nephrotoxicity when amphotericin given with VANCOMYCIN
- Antifungals: amphotericin reduces renal excretion and increases cellular uptake of FLUCYTOSINE (toxicity possibly increased); effects of amphotericin possibly antagonised by IMIDAZOLES and TRIAZOLES; plasma concentration of amphotericin possibly increased by MICAFUNGIN
- Cardiac Glycosides: hypokalaemia caused by amphotericin increases cardiac toxicity with CARDIAC GLYCOSIDES

Amphotericin (continued)
- Ciclosporin: increased risk of nephrotoxicity when amphotericin given with CICLOSPORIN
- Corticosteroids: increased risk of hypokalaemia when amphotericin given with CORTICOSTEROIDS—avoid concomitant use unless corticosteroids needed to control reactions
- Cytoxotics: increased risk of ventricular arrhythmias when amphotericin given with ARSENIC TRIODIDE
- Diuretics: increased risk of hypokalaemia when amphotericin given with LOOP DIURETICS or THIAZIDES AND RELATED DIURETICS
- Pentamidine isetionate: possible increased risk of nephrotoxicity when amphotericin given with PENTAMIDINE ISETINATE
- Sodium Stibogluconate: possible increased risk of arrhythmias when amphotericin given after SODIUM STIBOGLUCONATE—manufacturer of sodium stibogluconate advises giving 14 days apart
- Tacrolimus: increased risk of nephrotoxicity when amphotericin given with TACROLIMUS

Ampicillin see Penicillins

Anabolic Steroids
- Anticoagulants: anabolic steroids enhance anticoagulant effect of CLOMARINS and PHENINDIONE
- Antidiabetics: anabolic steroids possibly enhance hypoglycaemic effect of ANTI DIABETICS

Anaesthetics, General
- NOTE See also Surgery and Long-term Medication, Under General Anaesthesia in BNF
- ACE inhibitors: enhanced hypotensive effect when general anaesthetics given with ACE INHIBITORS
- Adrenergic Neurone Blockers: enhanced hypotensive effect when general anaesthetics given with ADRENERGIC NEURONE BLOCKERS
- Alpha-blockers: enhanced hypotensive effect when general anaesthetics given with ALPHA-BLOCKERS
- Aminophylline: increased risk of convulsions when ketamine given with AMINOPHYLLINE
- Analgesics: metabolism of etomidate inhibited by FENTANYL (consider reducing dose of etomidate); effects of thiopental possibly enhanced by ASPIRIN; effects of intravenous general anaesthetics and volatile liquid general anaesthetics possibly enhanced by OPIOID ANALGESICS
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when general anaesthetics given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Antibacterials: increased risk of hepatotoxicity when isoflurane given with SULFONAMIDES; hypersensitivity-like reactions can occur when general anaesthetics given with intravenous VANCOMYCIN
- Antidepressants: increased risk of arrhythmias and hypotension when general anaesthetics given with TRICYCLICS
- Antipsychotics: enhanced hypotensive effect when general anaesthetics given with ANTI PSYCHOTICS; effects of thiopental enhanced by DROPERIDOL
- Anxiolytics and Hypnotics: increased sedative effect when general anaesthetics given with ANXIOLYTICS AND HYPNOTICS
- Beta-blockers: enhanced hypotensive effect when general anaesthetics given with beta-BLOCKERS
- Calcium-channel Blockers: enhanced hypotensive effect when general anaesthetics or isoflurane given with CALCIUM-CHANNEL BLOCKERS; general anaesthetics enhance hypotensive effect of VERAPAMIL (also AV delay)
- Clonidine: enhanced hypotensive effect when general anaesthetics given with CLONIDINE
- Cytoxotics: nitrous oxide increases antifolate effect of METHOTREXATE—avoid concomitant use
- Diazoxide: enhanced hypotensive effect when general anaesthetics given with DIAZOXIDE
- Diuretics: enhanced hypotensive effect when general anaesthetics given with DIURETICS
- Dopaminergics: increased risk of arrhythmias when volatile liquid general anaesthetics given with CO-BENELDOPA, CO-CARELDOPA or LEVODOPA
Anaesthetics, General (continued)

- Doxapram: increased risk of arrhythmias when volatile liquid general anaesthetics given with doxapram (avoid doxapram for at least 10 minutes after volatile liquid general anaesthetics)
- Memantine: increased risk of CNS toxicity when ketamine given with memantine (manufacturer of memantine advises avoid concomitant use)
- Methyldopa: enhanced hypotensive effect when general anaesthetics given with methyldopa
- Metoclopramide: effects of thiopental enhanced by metoclopramide
- Moxonidine: enhanced hypotensive effect when general anaesthetics given with moxonidine
- Muscle Relaxants: increased risk of myocardial depression and bradycardia when propofol given with suxamethonium; volatile liquid general anaesthetics enhance effects of non-depolarising muscle relaxants and suxamethonium; ketamine enhances effects of atracurium
- Nitrates: enhanced hypotensive effect when general anaesthetics given with nitrates
- Oxytocin: oxytocin effect possibly reduced, also enhanced hypotensive and risk of arrhythmias when volatile liquid general anaesthetics given with oxytocin
- Sympathomimetics: manufacturer of isoflurane advises avoid concomitant use with sympathomimetics (risk of ventricular arrhythmias); increased risk of arrhythmias when volatile liquid general anaesthetics given with adrenaline (epinephrine) or noradrenaline (norepinephrine); increased risk of hypertension when volatile liquid general anaesthetics given with methylephedrinate
- Theophylline: increased risk of convulsions when ketamine given with theophylline
- Vasodilator Antihypertensives: enhanced hypotensive effect when general anaesthetics given with hydralazine, minoxidil or sodium nitroprusside

Anaesthetics, General (Intravenous) see Anaesthetics, General

Anaesthetics, General (Volatile liquids) see Anaesthetics, General

Anaesthetics, Local see Bupivacaine, Chloroprocaine, Levobupivacaine, Lidocaine, Prilocaine, and Ropivacaine

Anagrelide
- Cilostazol: manufacturer of anagrelide advises avoid concomitant use with cilostazol
- Phosphodiesterase Type-5 inhibitors: manufacturer of anagrelide advises avoid concomitant use with enoximidine and milrinone

Anakinra
- Cytotoxics: avoid concomitant use of anakinra with alumlumab, certolizumab pegol, golimumab or infliximab
- Etanercept: avoid concomitant use of anakinra with etanercept
- Vaccines: risk of generalised infections when anakinra given with live vaccines—avoid concomitant use

Analgesics see Aspirin, Nefopam, NSAIDs, Opioid Analgesics, and Paracetamol

Angiotensin-II Receptor Antagonists (continued)

- Alpha-blockers: enhanced hypotensive effect when angiotensin-II receptor antagonists given with alpha-blockers
- Anagrelide: enhanced hypotensive effect when angiotensin-II receptor antagonists given with general anaesthetics
- Analgesics: increased risk of renal impairment when angiotensin-II receptor antagonists given with NSAIDs, also hypotensive effect antagonised
- Antibacterials: plasma concentration of losartan and its active metabolite reduced by rifampicin; possible increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with trimethoprim
- Antidepressants: hypotensive effect of angiotensin-II receptor antagonists possibly enhanced by maois
- Antipsychotics: enhanced hypotensive effect when angiotensin-II receptor antagonists given with antipsychotics and antidepressants

Anticoagulants
- Lithium: enhanced hypotensive effect when angiotensin-II receptor antagonists given with co-beneldopa, co-careldopa or levodopa
- Methylprednisolone: enhanced hypotensive effect when angiotensin-II receptor antagonists given with methylprednisolone
- Moxisylyte: enhanced hypotensive effect when angiotensin-II receptor antagonists given with moxisylyte
- Moxonidine: enhanced hypotensive effect when angiotensin-II receptor antagonists given with moxonidine
- Muscle relaxants: enhanced hypotensive effect when angiotensin-II receptor antagonists given with baclofen or tizanidine
- Nitrates: enhanced hypotensive effect when angiotensin-II receptor antagonists given with nitrates
- Oestrogens: hypotensive effect of angiotensin-II receptor antagonists antagonised by oestrogens
- Potassium salts: increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with potassium salts
- Tacrolimus: increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with tacrolimus
- Vasodilator Antihypertensives: enhanced hypotensive effect when angiotensin-II receptor antagonists given with hydralazine, minoxidil or sodium nitroprusside

Antacids

NOTE: Antacids should preferably not be taken at the same time as other drugs since they may impair absorption

- ACE inhibitors: antacids possibly reduce absorption of ACE inhibitors; antacids reduce absorption of captopril, enalapril and fosinopril
Interactions

Antacids (continued)

- Analgesics: antacids possibly reduce absorption of 
  ACETAMINOPHEN, ASPIRIN, ORAL MAGNESIUM SALT.
- Antihistamines: cimetidine and ranitidine can reduce plasma concentration of 
  BRAZAMINE.
- Antibacterials: antacids reduce absorption of 
  SULFOTOMYCIN, CEFACLOR, CIPROFLOXACIN, ISONIAZID.
- Antifungals: fluconazole reduces absorption of 
  DURATAZOLE.
- Anthelmintics: antacids reduce absorption of 
  HYDROXYCHLOROQUINE, MEfloKINE, NITAZOXANIDE.
- Antihypertensives: antacids reduce absorption of 
  Labetalol, Metoprolol, Nifedipine.
- Antipsychotics: antacids reduce absorption of 
  LITHOTRITYLATE, PALOMETYN.
- Antidepressants, Tricyclic: antacids reduce absorption of 
  DOLOFAZINE, IMIPRAMINE, NORTIPIRIDE.
- Antidepressants, Noradrenaline Re-uptake Inhibitors: antacids reduce absorption of 
  DULOXETINE, GALANTIMIDINE, ROXITHROMYCIN.
- Antidiabetics: antacids reduce absorption of 
  ACETOGLUCOSE, GLIMEPIRIDE.
- Anticoagulants: antacids reduce absorption of 
  DOLESAZOLE, RUFANTEREN, TENDOSOL.
- Anticoagulants: antacids reduce absorption of 
  DIETHYLCARBAZINE.
- Antineoplastics: antacids reduce absorption of 
  BENDAMUSTINE, ETOPIRONATE, PEGSOLYSINE.
- Antimicrobials: antacids reduce absorption of 
  ALTAMOX, CILASTATIN, IMPATRINE.
- Antipsychotics: antacids reduce absorption of 
  RESERPOZINE, ZOLOXIDE.
- Antituberculars: antacids reduce absorption of 
  الأنابيب، الاريباسول، أوراسون، دينيراديل، فيلاريدارين، مقاومة Mobility, POLYPSITIFIN.
- Antitumor agents: antacids reduce absorption of 
  gpu, ralitriamid.
- Antiulcer drugs: antacids reduce absorption of 
  TACRAZONE, KETOACID.
- Anxiolytics: antacids reduce absorption of 
  BUSPIRONE, LORAZEPONE.
- Antioxidants: antacids reduce absorption of 
  FERITIMIDE, LUKANTIN.
- Antipruritics: antacids reduce absorption of 
  VERNALITIN, XANDIPHTER.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antiulcer drugs: antacids reduce absorption of 
  DURATAZOLE.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
- Antivirals: antacids reduce absorption of 
  AZAFLAVIN, DOLUTEGRAVIR.
- Antiulcer drugs: antacids reduce absorption of 
  IRON, MAGNESIUM, ZINC.
Antidepressants, SSRI

- Antipsychotics (continued) be started until 2 weeks after stopping • MAOI, also MAOIs should not be started until at least 5 weeks after stopping fluoxetine; CNS effects of SSRIs increased by • MAOI (risk of serious toxicity); increased risk of CNS toxicity when escitalopram given with • MOCLOBEMIDE, preferably avoid concomitant use; after stopping citalopram, fluvoxamine, paroxetine or sertraline do not start • MOCLOBEMIDE for at least 1 week; after stopping fluoxetine do not start • MOCLOBEMIDE for 5 weeks; increased serotonergic effects when SSRIs given with • ST JOHN’S WORT—avoid concomitant use; fluvoxamine inhibits metabolism of • AGOMELATINE (increased plasma concentration); possible increased serotonergic effects when fluoxetine or fluvoxamine given with SSRIs; increased plasma concentration of some • TRICYCLICS; manufacturer of citalopram and escitalopram advises avoid concomitant use with • TRICYCLICS (risk of ventricular arrhythmias)

- Antimuscarinics: manufacturer of citalopram and escitalopram advise avoid concomitant use with • TRICYCLICS

- Antihistamines: manufacturer of citalopram and escitalopram advise avoid concomitant use with • MIZOLASTINE (risk of ventricular arrhythmias); antihistaminic effect of SSRIs possibly antagonised by • CYPROHEPTADINE

- Antifungals: avoidance of antidepressants advised by manufacturer of • ARTEMETHER WITH LUMEFLANTRINE and • ARTEMINOL WITH PIPERIQUE; possible increased risk of ventricular arrhythmias when citalopram or escitalopram given with • ARTEMETHER WITH LUMEFLANTRINE—avoid concomitant use; possible increased risk of ventricular arrhythmias when citalopram or escitalopram given with • ARTEMINOL WITH PIPERIQUE—avoid concomitant use; possible increased risk of ventricular arrhythmias when citalopram or escitalopram given with • CHLOROQUINE; possible increased risk of ventricular arrhythmias when citalopram or escitalopram given with • QUININE—avoid concomitant use

- Antiretrovirals: paroxetine increases plasma concentration of • DARIFENACIN and • PROCYCLIDINE

- Antipsychotics: avoidance of fluoxetine, fluvoxamine and sertraline advised by manufacturer of • DROPERIDOL (risk of ventricular arrhythmias); manufacturer of citalopram and escitalopram advises avoid concomitant use with • HALOPERIDOL (risk of ventricular arrhythmias); fluoxetine increases plasma concentration of • CLOzapine, • HALOPERIDOL and • RISPERIDONE; fluvoxamine possibly increases plasma concentration of • ASENAPINE and • HALOPERIDOL; paroxetine inhibits metabolism of • PERPHENAZINE (reduce dose of phenothiazine); fluoxetine and paroxetine possibly increase plasma concentration of • ARIPIPRAZOLE (reduce dose of aripiprazole—consult aripiprazole product literature); plasma concentration of paroxetine possibly increased by • ASENAPINE; fluvoxamine, paroxetine and sertraline increase plasma concentration of • CLOzapine; citalopram possibly increases plasma concentration of • CLOzapine (increased risk of toxicity); fluvoxamine increases plasma concentration of • OLANZAPINE; manufacturer of citalopram and escitalopram advises avoid concomitant use with • PHENOTHIAZINES (risk of ventricular arrhythmias); manufacturer of citalopram and escitalopram advises avoid concomitant use with • PIMOZIDE (risk of ventricular arrhythmias); SSRIs possibly increase plasma concentration of • PIMOZIDE (increased risk of ventricular arrhythmias—avoid concomitant use); paroxetine possibly increases plasma concentration of • RISPERIDONE (increased risk of toxicity)

- Antivirals: plasma concentration of paroxetine and sertraline possibly reduced by • DARUNAVIR; plasma concentration of SSRIs possibly increased by • RITONAVIR; possible increased risk of ventricular arrhythmias when citalopram or escitalopram given with • RITONAVIR, • FLUCONAZOLE; fluoxetine increases plasma concentration of • ALPRAZOLAM; fluoxetine increases plasma concentration of some • BENZODIAZEPINES; fluoxetine increases plasma concentration of • MELATONIN—avoid concomitant use; sedative effects possibly increased when sertraline given with • ZOLPIDEM

- Atomoxetine: possible increased risk of convulsions when antidepressants given with • ATOMOXETINE; fluoxetine and paroxetine possibly inhibit metabolism of • ATOMOXETINE

- Beta-blockers: citalopram and escitalopram increase plasma concentration of • METOPROLOL; paroxetine possibly increases plasma concentration of • METOPROLOL—increased risk of AV block (manufacturer of paroxetine advises avoid concomitant use in cardiac insufficiency); fluvoxamine increases plasma concentration of • PROPRANOLOL; increased risk of ventricular arrhythmias when citalopram given with • SOTALOL—avoid concomitant use; manufacturer of escitalopram advises avoid concomitant use with • SOTALOL (risk of ventricular arrhythmias)

- Bupropion: plasma concentration of citalopram possibly increased by • BUPROPION

- Calcium-channel blockers: fluoxetine possibly inhibits metabolism of • NIFEDIPINE (increased plasma concentration)

- Clopidogrel: fluoxetine and fluvoxamine possibly reduce antiplatelet effect of • CLOPIDOGREL

- Dopamine: possible increased risk of serotonergic effects when SSRIs given with • DOPAXETINE (manufacturer of dapoxetine advises SSRIs should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping SSRIs)

- Dopaminergic: increased risk of CNS toxicity when SSRIs given with • RASAGILINE; fluoxetine should not be started until 2 weeks after stopping • RASAGILINE; fluoxetine should not be started until 2 weeks after stopping • RASAGILINE, also rasagiline should not be started until at least 5 weeks after stopping fluoxetine; avoid fluoxetine or sertraline for 5 weeks after stopping selegiline; increased risk of hypertension and CNS excitation when fluoxetine or sertraline given with • SELEGILINE (selegiline should not be started until 1 week after stopping fluvoxamine or sertraline, avoid fluoxetine or sertraline for 2 weeks after stopping selegiline); increased risk of hypertension and CNS excitation when fluoxetine or sertraline given with • SELEGILINE (selegiline should not be started until 2 weeks after stopping paroxetine, avoid paroxetine for 2 weeks after stopping selegiline); increased risk of hypertension and CNS excitation when fluoxetine given with • SELEGILINE (selegiline should not be started until 5 weeks after stopping fluoxetine, avoid fluoxetine for 2 weeks after stopping selegiline)

- Grapefruit juice: plasma concentration of sertraline possibly increased by • GRAPEFRUIT JUICE

- Hormone Antagonists: fluoxetine and paroxetine possibly inhibit metabolism of • TAMOXIFEN to active metabolite (avoid concomitant use)

- SHT-receptor Agonists: increased risk of CNS toxicity when citalopram given with • SHT, AGONISTS (manufacturer of citalopram advises avoid concomitant use); fluvoxamine inhibits the metabolism of • FROVATRIPTAN; possible increased serotonergic effects when SSRIs given with • NARATRIPTAN; CNS toxicity reported when sertraline given with • SUMATRIPTAN; increased risk of CNS toxicity when citalopram, escitalopram, fluoxetine, fluvoxamine or paroxetine given with • SUMATRIPTAN; fluoxetine possibly inhibits metabolism of • ZOLMITRIPTAN (reduce dose of zolmitriptan)

- SHT-receptor Antagonists: possible increased serotonergic effects when SSRIs given with • SHT, ANTAGONISTS
Antidepressants, SSRI (continued)

Lipid-regulating Drugs: separating administration from fluoxetine and fluvoxamine by 12 hours advised by manufacturer of LOMITAPIDE

Lithium: increased risk of CNS effects when SSRIs given with lithium (lithium toxicity reported)

Methylthioninium: risk of CNS toxicity when SSRIs given with methylthioninium (separate administration for up to 4 hours after administration)

Metoclopamide: CNS toxicity reported when SSRIs given with METOCLOPRAMIDE

Muscle Relaxants: fluvoxamine increases plasma concentration of TIZANIDINE (increased risk of toxicity)—avoid concomitant use

Parasympathomimetics: paroxetine increases plasma concentration of GALANTAMINE

Pentamidine isetionate: manufacturer of cilostrol and escitalopram advises avoid concomitant use with PENTAMIDINE ISETIONATE (risk of ventricular arrhythmias)

Pirfenidone: fluvoxamine increases plasma concentration of PIRFENIDONE—manufacturer of pirfenidone advises avoid concomitant use

Pomalidomide: fluvoxamine increases plasma concentration of POMALIDOMIDE

Ranolazine: paroxetine increases plasma concentration of RANOLAZINE

Roflumilast: fluvoxamine inhibits the metabolism of ROFLUMILAST

Sympathomimetics: metabolism of SSRIs possibly inhibited by METHYLPHENIDATE

Theophylline: fluvoxamine increases plasma concentration of THEOPHYLLINE (concomitant use should usually be avoided, but where not possible halve theophylline dose and monitor plasma—theophylline concentration)

Ticagrelor: possible increased risk of bleeding when cilostrol, paroxetine or sertraline given with TICAGRELOR

Ulcer-healing Drugs: plasma concentration of cilostrol, escitalopram and sertraline increased by CIMETIDINE; fluvoxamine possibly increases plasma concentration of Lansoprazole; plasma concentration of escitalopram increased by OMEPRAZOLE

Antidepressants, SSRI (related) see Duloxetine and Venlafaxine

Antidepressants, Tricyclic

Adrenergic Neurone Blockers: tricyclics antagonise hypotensive effect of ADRENERGIC NEURONE BLOCKERS

Alcohol: increased sedative effect when tricyclics given with ALCOHOL

Alpha-2-adrenoceptor Stimulants: avoidance of tricyclics advised by manufacturer of APRACLOLIDINE and BRIMONIDINE

Anaesthetics, General: increased risk of arrhythmias and hypotension when tricyclics given with GENERAL ANAESTHETICS

Analgesics: increased risk of CNS toxicity when tricyclics given with TRAMADOL; side-effects possibly increased when tricyclics given with NEFOPAM; sedative effects possibly increased when tricyclics given with OPIOID ANALGESICS

Anti-arrhythmics: increased risk of ventricular arrhythmias when tricyclics given with NICOTINIC; avoid concomitant use; increased risk of ventricular arrhythmias when tricyclics given with DISOPYRAMIDE or Flecaidine; avoidance of tricyclics advised by manufacturer of DRONEDARONE (risk of ventricular arrhythmias); increased risk of arrhythmias when tricyclics given with PROPafenONE

Antibacterials: increased risk of ventricular arrhythmias when tricyclics given with MOXIFLOXACIN—avoid concomitant use; possible increased risk of ventricular arrhythmias when tricyclics that prolong the QT interval given with

DELAMANID; possible increased risk of ventricular arrhythmias when tricyclics given with TELITHROMYCIN

Anticoagulants: tricyclics may enhance or reduce anticoagulant effect of OUMARINS

Antidepressants: avoidance of tricyclics advised by manufacturer of CITOPRAM and ESCITALOPRAM (risk of ventricular arrhythmias); possible increased serotonergic

Antidepressants, Tricyclic

Antidepressants (continued)

effects when amitriptyline or clomipramine given with DULOXETINE; increased risk of hypertension and CNS excitation when tricyclics given with MAOIs, tricyclics should not be started until 2 weeks after stopping MAOIs (3 weeks if starting clomipramine or imipramine), also MAOIs should not be started for at least 1–2 weeks after stopping tricyclics (5 weeks in the case of clomipramine or imipramine); after stopping tricyclics do not start MOLOCROMIDE for at least 1 week; plasma concentration of some tricyclics increased by SSRI; plasma concentration of amitriptyline reduced by ST JOHN'S WORT

Antiepileptics: tricyclics antagonise anti-convulsant effect of

Antiepileptics: tricyclics antagonise anti-convulsant effect of ANTIEPILEPTICS (convulsive threshold lowered); metabolism of tricyclics accelerated by CARBAMAZEPINE (reduced plasma concentration and reduced effect); plasma concentration of tricyclics possibly reduced by FOSPHENOTIN and PHENYTOIN; metabolism of tricyclics possibly accelerated by PHENOBARBITAL and PRIMIDONE (reduced plasma concentration)

Antifungals: plasma concentration of amitriptyline and nortriptyline possibly increased by Fluconazole; plasma concentration of tricyclics possibly increased by TERTIBAFINE

Antihistamines: increased antimuscarinic and sedative effects when tricyclics given with ANTIHISTAMINES

Antimicrobials: avoidance of antidepressants advised by manufacturer of ARTEMETHER with LUMEFANTRINE and ARTENIOMIL with PIPERAQUINE

Antimuscarinics: increased risk of antimuscarinic side-effects when tricyclics given with ANTUSCUMARINICS

Antipsychotics: avoidance of tricyclics advised by manufacturer of DROPERIDOL, FLUPHENAZINE, HALOPERIDOL, SULPRAZIDE and ZUCLOPENTHIXOL (risk of ventricular arrhythmias); possible increased antimuscarinic side-effects when tricyclics given with CLOzapine; increased risk of antimuscarinic side-effects when tricyclics given with PHENOThiAZINES; possible increased risk of ventricular arrhythmias when tricyclics given with RISPERIDONE

Antivirals: plasma concentration of tricyclics possibly increased by RITONAVIR; increased risk of ventricular arrhythmias when tricyclics given with SAQUINAVIR—avoid concomitant use

Antidepressants, SSRI (related) see Duloxetine and Venlafaxine
Antidepressants, Tricyclic (related) (continued)

- Antimuscarinics: possible increased antimuscarinic side-effects when tricyclic-related antidepressants given with
  - **ANTIMUSCARINICS**
- Antivirals: plasma concentration of trazodone increased by
  - **RIFAPRICIN** (increased risk of toxicity); increased risk of ventricular arrhythmias when trazodone given with
  - **SAQUINAVIR**—avoid concomitant use; plasma concentration of trazodone possibly increased by **TELAPREVIR**
- Antihistamines and Hypnotics: increased sedative effect when tricyclic-related antidepressants given with
  - **ANXIOLYTES AND HYPNOTICS**
- Benzodiazepines: possible increased risk of convulsions when tricyclic-related antidepressants given with **ATOMOXETINE**
- Diazoxide: enhanced hypotensive effect when tricyclic-related antidepressants given with **DIAZoxide**
- Nitrates: tricyclic-related antidepressants possibly reduce effects of sublingual tablets of **NITRATES** (failure to dissolve under tongue owing to dry mouth)
- Vasodilators: Antihypertensives: enhanced hypotensive effect when tricyclic-related antidepressants given with **HYDRALazine or SODIUM NITROPRUSSIDE**

**Antidiabetics**

**NOTE** Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after exenatide injection, or taken with a meal when lirinisenate is not administered, to minimise possible interference with absorption

**NOTE** Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after exenatide injection, or taken with a meal when lirinisenate is not administered, to minimise possible interference with absorption

- **ACE Inhibitors**: hypoglycaemic effect of insulin, metformin and sulfonylureas possibly enhanced by **ACE INHIBITORS**
- Alcohol: hypoglycaemic effect of antiadibiotics enhanced by **ALCOHOL**; increased risk of lactic acidosis when metformin given with **ALCOHOL**
- Anabolic Steroids: hypoglycaemic effect of antiadiabtics possibly enhanced by **ANABOLIC STEROIDS**
- Analgesics: effects of sulfonylureas possibly enhanced by
  - **NEOXYLIN**; lirinisenate possibly reduces the absorption of **PARACETAMOL** when given 1 to 4 hours before paracetamol
- Anti-arrhythmics: hypoglycaemic effect of gliclazide, insulin and metformin possibly enhanced by **DISOPYRAMIDE**
- Antibacterials: hypoglycaemic effect of acarbose possibly enhanced by **NEOXYLIN**; also severity of gastro-intestinal effects increased; effects of repaglinide enhanced by **CLARITHROMYCIN**; effects of glibenclamide possibly enhanced by **NORFLOXACIN**; plasma concentration of canagliflozin and nateglinide reduced by **RIFAMPICIN**; effects of linagliptin possibly reduced by **RIFAMPICIN**; hypoglycaemic effect of repaglinide possibly antagonised by **RIFAMPICIN**; effects of sulfonylureas enhanced by
  - **CHLORAMPHENICOL**; metabolism of tolbutamide accelerated by **RIFAMPICIN** (reduced effect); metabolism of sulfonylureas possibly accelerated by
  - **RIFAMPICIN** (reduced effect); effects of sulfonylureas rarely enhanced by **SULFONAMIDES and TRIMETHOPRIM**; hypoglycaemic effect of sulfonylureas possibly enhanced by **TETRACYCLINES**; hypoglycaemic effect of repaglinide possibly enhanced by **TRIMETHOPRIM**—manufacturer advises avoid concomitant use
- Anticoagulants: exenatide possibly enhances anticoagulant effect of **WARFARIN**; hypoglycaemic effect of sulfonylureas possibly enhanced by **COUMARINS**, also possible changes to anticoagulant effect
- Antidepressants: hypoglycaemic effect of antiadibiotics possibly enhanced by **MAOIs**; hypoglycaemic effect of insulin, metformin and sulfonylureas enhanced by **MAOIs**
- Antidiabetics: manufacturer of dapagliflozin advises avoid concomitant use with **PIOGLITAZONE**
- Antiepileptics: tolbutamide transiently increases plasma concentration of **FOSPHENYTOIN** and **PHENYTOIN** (possibility of toxicity); plasma concentration of glibenclamide possibly reduced by **TOPIRAMATE**; plasma concentration of metformin possibly increased by **TOPIRAMATE**
- Antifungals: plasma concentration of pioglitazone, saxagliptin and tolbutamide increased by **KETOCONAZOLE**; plasma...
### Antidiabetics

- **Antifungals (continued)**
  - Concentration of sulfonylureas increased by **FLUCONAZOLE** and **MICAZOLE**; hypoglycaemic effect of glipizide and glimepiride enhanced by **MICAZOLE**—avoid concomitant use; **hypoglycaemic effect of nateglinide possibly enhanced by FLUCONAZOLE**; hypoglycaemic effect of repaglinide possibly enhanced by **FLUCONAZOLE**; hypoglycaemic effect of repaglinide possibly enhanced by **ITRACONAZOLE**; hypoglycaemic effect of glipizide possibly enhanced by **POSACONAZOLE**; plasma concentration of repaglinide possibly increased by **VIRCONEZOLE**
  - Antihistamines: thombocytoc count depressed when metformin given with **KETOTIFEN** (manufacturer of ketotifen advises avoid concomitant use)
  - Antipsychotics: hypoglycaemic effect of sulfonylureas possibly antagonised by **PHENOTHAZINES**
  - Antivirals: plasma concentration of tolbutamide possibly increased by **RITONAVIR**; plasma concentration of metformin increased by **TELAPREVIR** (consider reducing dose of metformin)
  - Aprepitant: plasma concentration of tolbutamide reduced by **APEPPITANT**
  - beta-blockers: warning signs of hypoglycaemia (such as tremor) with antidiabetics may be masked when given with **BETA-BLOCKERS**; hypoglycaemic effect of insulin enhanced by **BETA-BLOCKERS**
  - Bosentan: increased risk of hepatotoxicity when glibenclamide given with **BOSENTAN**—avoid concomitant use
  - Calcium-channel blockers: glucose tolerance occasionally impaired when insulin given with **NIFEDIPINE**
  - Carboxy Glicosides: canagliflozin and sitagliptin increase plasma concentration of **DIOXIGIN**; acarbose possibly reduces plasma concentration of **DIOXIGIN**
  - Ciclosporin: hypoglycaemic effect of repaglinide possibly enhanced by **CICLOSPORIN**
  - Corticosteroids: hypoglycaemic effect of antidiabetics antagonised by **CORTICOSTEROIDS**
  - Cytotoxics: avoidance of repaglinide advised by manufacturer of **LAPATINIB**; plasma concentration of metformin possibly increased by **VANDETANIB** (consider reducing dose of metformin)
  - Deferasirox: plasma concentration of repaglinide increased by **DEFERASIROX**
  - Diazoxide: hypoglycaemic effect of antidiabetics antagonised by **DIAZOXIDE**
  - Diuretics: canagliflozin possibly enhances diuretic effect of **DIURETICS**; manufacturer of canagliflozin advises avoid concomitant use with **LOOP DIURETICS**; hypoglycaemic effect of antidiabetics antagonised by **LOOP DIURETICS and THIAZIDES and RELATED DIURETICS**; dapagliflozin possibly enhances diuretic effect of **LOOP DIURETICS and THIAZIDES and RELATED DIURETICS**
  - Fosaprepitant: plasma concentration of tolbutamide reduced by **FOSAPREPTANT**
  - Hormone Antagonists: requirements for antidiabetics possibly reduced by **LAMERTIDE, OCRETIDINE and PASIRETIDINE**
  - Leflunomide: hypoglycaemic effect of tolbutamide possibly enhanced by **LEFLUNOMIDE**
  - Lipid-regulating Drugs: absorption of glibenclamide and glipizide reduced by **COLESEVELAM**; absorption of glimepiride reduced by **COLESEVELAM**—manufacturer of glimepiride advises give at least 4 hours before colesevelam; hypoglycaemic effect of acarbose possibly enhanced by **COLESTRYRAMINE**; hypoglycaemic effect of nateglinide possibly enhanced by **SEMIFIBROLIZ**—increased risk of severe hypoglycaemia when repaglinide given with **SEMIFIBROLIZ**—avoid concomitant use; plasma concentration of glibenclamide possibly increased by **FLUVASTATIN**; manufacturer of canagliflozin advises give at least 1 hour before or 4–6 hours after **ACE-039 SEQUESTRANTS**; may be improved glucose tolerance and an additive effect when insulin or sulfonylureas given with **FIBRATES**; separating administration from linagliptin by 12 hours advised by manufacturer of **LOMITAPIDE**
  - Oestrogens: hypoglycaemic effect of antidiabetics antagonised by **OESTROGENS**

### Antidiabetics (continued)

- **Orlistat**: avoidance of acarbose advised by manufacturer of **ORLISTAT**
- Pancreatin: hypoglycaemic effect of acarbose antagonised by **PANCREATIN**
- Progestogens: hypoglycaemic effect of antidiabetics antagonised by **PROGESTOGENS**
- Sulfinpyrazone: effects of sulfonylureas enhanced by **SULFINPYRAZONE**
- Teriflunomide: plasma concentration of repaglinide increased by **TERIFLUNOMIDE**
- Testosterone: hypoglycaemic effect of antidiabetics possibly enhanced by **TESTOSTERONE**
- Ulcer-healing Drugs: excretion of metformin reduced by **CIMETIDINE** (increased plasma concentration); hypoglycaemic effect of sulfonylureas enhanced by **CIMETIDINE**

### Antiepileptics

- **See Carbamazepine, Eslicarbazepine, Ethosuximide, Fosphenytoin, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Oxcarbazepine, Perampanel, Phenoeharbital, Phenytoin, Pregabalin, Primidone, Reticapine, Rufinamide, Sodium valproate, Stiripentol, Tiagabine, Topiramate, Valproic acid, Vigabatrin, and Zonisamide**

### Antifungals

- **See Amphotericin; Antifungals, Imidazole; Antifungals, Triazole; Caspofungin; Fluconazole; Griseofulvin; Micafungin; Terbinafine**

### Antifungals, Imidazole

- **Alcohol**: possibility of disulfram-like reaction when ketoconazole given with **ALCOHOL**
- **Aliskiren**: ketoconazole increases plasma concentration of **ALISKIREN**
  - Alpha-blockers: ketoconazole possibly increases plasma concentration of **ALFUZOSIN**; ketoconazole increases plasma concentration of **TAMSULOSIN**
  - Aminophylline: ketoconazole possibly increases plasma concentration of **AMINOPHYLLINE**
  - Analgesics: ketoconazole inhibits metabolism of **BUPRENORPHINE** (reduce dose of buprenorphine); possible increased risk of ventricular arrhythmias when ketoconazole given with **METHADONE**—manufacturer of ketoconazole advises avoid concomitant use; ketoconazole increases plasma concentration of **OXYCODONE**; manufacturer of ketoconazole advises avoid concomitant use with **PARACETAMOL**
  - Antacids: absorption of ketoconazole reduced by **ANTACIDS**
  - Antihelminics: ketoconazole increases plasma concentration of **PRAZIQUANTEL**
  - Anti-arrhythmic: increased risk of ventricular arrhythmias when ketoconazole given with **DISOPYRAMIDE**—avoid concomitant use; ketoconazole increases plasma concentration of **DRONEDARONE**—avoid concomitant use
  - Antibacterials: manufacturer of ketoconazole advises avoid concomitant use **CLARITHROMYCIN** in severe renal impairment; metabolism of ketoconazole accelerated by **RIFAMPICIN** (reduced plasma concentration); also plasma concentration of rifampicin may be reduced by ketoconazole; ketoconazole increases plasma concentration of **BEDAQUILINE**—avoid concomitant use if ketoconazole given for more than 14 days; avoidance of ketoconazole advised by manufacturer of **FIDASOMICIN**; plasma concentration of ketoconazole possibly reduced by **ISONIAZID**; ketoconazole increases the plasma concentration of **TELITHROMYCIN**—avoid in severe renal and hepatic impairment
  - Anticoagulants: ketoconazole increases plasma concentration of **APIXABAN**—manufacturer of apixaban advises avoid concomitant use; miconazole enhances anticoagulant effect of **COUMARINS** (miconazole oral gel and possibly vaginal and topical formulations absorbed); ketoconazole enhances anticoagulant effect of **COUMARINS**; ketoconazole increases plasma concentration of **DABIGATRAN** and **RIVAROXABAN**—avoid concomitant use
  - Antidepressants: avoidance of imidazoles advised by manufacturer of **REBOXETINE**; ketoconazole increases plasma concentration of **MIRTAZAPINE**
  - Antidiabetics: miconazole enhances hypoglycaemic effect of **GLICOZIDE and GLIPIZIDE**—avoid concomitant use;
Antifungals, Imidazole
- Antidiabetics (continued)
  - ketoconazole increases plasma concentration of 
    PIPIGLITAZONE, SAXAGLITOPIN and TOLBUTAMIDE; miconazole increases plasma concentration of 
    SULFONYLUREAS
- Antiepileptics: miconazole possibly increases plasma concentration of CARBAMAZEPINE; plasma concentration of 
  ketocanazole possibly reduced by CARBAMAZEPINE, also plasma concentration of carbamazepine possibly increased; 
  pipeline concentration of ketonazole reduced by 
    FOSPHENOTIOIN and PHENTOYIN; miconazole enhances anticonvulsant effect of 
    FOSPHENOTIOIN and PHENTOYIN (plasma concentration of fosphenytoin and phenytoin increased); ketocanazole increases plasma concentration of 
  PERAMAPANE
- Antifungals: imidazoles possibly antagonise effects of 
  AMPHOTERICIN
- Antihistamines: imidazoles possibly inhibit metabolism of 
  MIZOLASTINE (avoid concomitant use)
- Antimalarials: avoidance of imidazoles advised by manufacturer of 
  ARTEMETHER WITH LUMEFANTRINE; avoidance of imidazoles advised by manufacturer of 
  ARTEMINOL WITH PIPERAQUIN (possible risk of ventricular arrhythmias); ketocanazole increases plasma concentration of 
  MEfloquine
- Antimuscarinics: absorption of ketocanazole reduced by 
  ANTIMUSCARINICS; ketocanazole increases plasma concentration of 
  DARIFENACIN—avoid concomitant use; manufacturer of fosfoterodine advises dose reduction when 
  ketocanazole given with FOSFOTERODINE—consult fosfoterodine product literature; ketocanazole increases plasma concentration of 
  OXYBUTYNIN; ketocanazole increases plasma concentration of 
  SOLIFENACIN—see under Solifenacin, p. 670; avoidance of ketocanazole advised by manufacturer of 
  TOLTERODINE
- Antivirals: ketocanazole inhibits metabolism of 
  ARIPIPRAZOLE (reduce dose of aripiprazole); ketocanazole increases plasma concentration of 
  LURASIDONE—avoid concomitant use; increased risk of ventricular arrhythmias when imidazoles given with 
  PIMOZIDE—avoid concomitant use; imidazoles possibly increase plasma concentration of 
  QUETIAPINE—manufacturer of quetiapine advises avoid concomitant use
- Antivirals: ketocanazole increases plasma concentration of 
  BOCEPREVIR; ketocanazole increases the plasma concentration of 
  DAclatasvir in plasma concentration of daclatasvir (see under Daclatasvir, p. 544); plasma concentration of both drugs increased when ketocanazole given with 
  DURANAVIR; plasma concentration of ketocanazole reduced by 
  EFAVIRENZ; plasma concentration of ketocanazole increased by 
  SAMPEZUMIR (also fosamprenavir possibly increased); ketocanazole increases plasma concentration of 
  INDINAVIR and MARAriVoC (consider reducing dose of indinavir and maraviroc); plasma concentration of ketocanazole reduced by 
  NEVIRapine—avoid concomitant use; plasma concentration of 
  ketonazole increased by 
  RITONAVIR (reduce dose of ketonazole); imidazoles possibly increase plasma concentration of 
  SAquinavIR; ketocanazole increases plasma concentration of 
  QUINAPril—manufacturer of quinapril advises avoid concomitant use; avoidance of ketocanazole advised by manufacturer of 
  SIMprevIR; plasma concentration of both drugs possibly increased when ketocanazole given with 
  TELAPrevIR (increased risk of ventricular arrhythmias)—reduce dose of ketocanazole
- Anxiolytics and Hypnotics: ketocanazole increases plasma concentration of 
  ALPRAZOLAM—manufacturer of 
  ketocanazole advises avoid concomitant use; ketocanazole increases plasma concentration of 
  MIDAZolAM (risk of prolonged sedation—avoid concomitant use of oral midazolam); ketocanazole increases plasma concentration of 
  ZOLPIDEM
- Aprepitant: ketocanazole increases plasma concentration of 
  AprepitAnt
- Avanafil: ketocanazole increases plasma concentration of 
  AVANafiL—avoid concomitant use

Antifungals, Imidazole (continued)
- Beta-blockers: ketoconazole possibly increases plasma concentration of 
  NADOLOL
- Bosentan: ketocanazole increases plasma concentration of 
  BOsentAN
- Calcium-channel Blockers: ketoconazole inhibits metabolism of 
  FELODIPINE (increased plasma concentration)—manufacturer of ketoconazole advises avoid concomitant use; avoidance of ketoconazole advised by manufacturer of 
  LERICANDIPINE; ketoconazole possibly inhibits metabolism of 
  DHYDROPYRIDINES (increased plasma concentration)
- Cannabis Extract: ketoconazole increases plasma concentration of 
  CANNABIS EXTRACT
- Ciclosporin: ketoconazole inhibits metabolism of 
  CICLOSPORIN (increased plasma concentration); miconazole possibly inhibits metabolism of 
  CICLOSPORIN (increased plasma concentration)
- Cisplatin: ketoconazole increases plasma concentration of 
  CILoSTAzoL (see under Cisplatin, p. 206)
- CINACalcET (increased plasma concentration)
- Clopidogrel: ketoconazole possibly reduces antiplatelet effect of 
  CLOPiDOgREL
- Coxcistat: plasma concentration of ketoconazole possibly increased by 
  COXCISTAT—manufacturer of coxcistat advises reduce dose of ketoconazole
- Colchicine: ketoconazole possibly increases risk of 
  COLCHICINE—toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Corticosteroids: ketoconazole possibly inhibits metabolism of 
  CORTICOSTEROIDS; ketoconazole increases plasma concentration of 
  INHALED FLUTICASone; ketoconazole inhibits the metabolism of 
  METHYLPREDNISOLONE; ketoconazole increases plasma concentration of 
  INHALED MIMEsTASone
- Cytoxic: ketoconazole inhibits the metabolism of 
  IFOFAMIDE; possible increased risk of neuropenia when 
  ketoconazole given with 
  BRENTuxIMAB VEDOTIN; ketoconazole possibly increases the plasma concentration of 
  AFAtinIB—manufacturer of afatinib advises separating administration of ketoconazole by 6 to 12 hours; 
  ketoconazole increases plasma concentration of 
  AEXiTINIB (reduce dose of axitinib—consult axitinib product literature); ketoconazole increases the plasma concentration of 
  BOSUtINIB—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; ketoconazole increases plasma concentration of 
  DASAtINIB; ketoconazole increases metabolism of 
  ERLOtinIB and SUnItINIB (increased plasma concentration)
- Daclatasvir: plasma concentration of daclatasvir and 
  DAclatasvir—consult daclatasvir product literature; ketocanazole increases plasma concentration of 
  DASAtINIB; ketoconazole inhibits metabolism of 
  ERLOtinIB and SUnItINIB (increased plasma concentration)
- Docetaxel: plasma concentration of docetaxel and 
  DocaTeXeL (consult docetaxel product literature); ketocanazole reduces plasma concentration of 
  IRINOTeCAN (but concentration of irinotecan increased)—avoid concomitant use; ketoconazole increases plasma concentration of 
  VINfluNINE—manufacturer of vinflunine advises avoid concomitant use
Antifungals, Imidazole (continued)
- Dopamine: ketonazole increases plasma concentration of dopamine—manufacturer of dopamine advises avoid concomitant use
- Diuretics: ketonazole increases plasma concentration of diuretics—avoid concomitant use
- Domperidone: manufacturer of ketonazole advises avoid concomitant use with domperidone (risk of ventricular arrhythmias)
- Ergot Alkaloids: manufacturer of ketonazole advises avoid concomitant use with ergot alkaloids; increased risk of ergotism when imidazoles given with ergotamine—avoid concomitant use
- Fingolimod: ketonazole increases plasma concentration of fingolimod
- Fosaprepitant: ketonazole increases plasma concentration of fosaprepitant
- Hormone Antagonists: manufacturer of ketonazole advises avoid concomitant use with pasireotide
- SERT—receptor Agonists: ketonazole increases plasma concentration of almotriptan (increased risk of toxicity); ketonazole increases plasma concentration of eliptptan (risk of toxicity)—avoid concomitant use
- Ivaloxidine: ketonazole increases plasma concentration of ivaloxidine
- Ivacaftor: ketonazole increases plasma concentration of ivacaftor (see under ivacaftor, p. 257)
- Lanthanum: absorption of ketonazole possibly reduced by lanthanum (give at least 2 hours apart)
- Lenalidomide: ketonazole possibly increases plasma concentration of lenalidomide (increased risk of toxicity)
- Lipid-regulating Drugs: possible increased risk of myopathy when imidazoles given with atorvastatin; possible increased risk of myopathy when ketonazole given with atorvastatin—manufacturer of ketonazole advises avoid concomitant use; increased risk of myopathy when ketonazole given with simvastatin (avoid concomitant use); possible increased risk of myopathy when miconazole given with simvastatin; ketonazole increases plasma concentration of comitapide—avoid concomitant use
- Macitentan: ketonazole increases plasma concentration of macitentan
- Mirabegron: when given with ketonazole avoid or reduce dose of mirabegron in hepatic or renal impairment—see mirabegron, p. 671
- Nintedanib: ketonazole increases plasma concentration of nintedanib
- Dostrojen: anecdotal reports of contraceptive failure when imidazoles given with dostrojen
- Parasympathomimetics: ketonazole increases plasma concentration of galantamine
- Ranolazine: ketonazole increases plasma concentration of ranolazine—avoid concomitant use
- Retinoids: ketonazole increases plasma concentration of retinoids—ketonazole possibly increases risk of retinoid toxicity
- Tretinoin: ketonazole increases plasma concentration of tretinoin—avoid concomitant use
- Riociguat: avoidance of ketonazole advised by manufacturer of riociguat
- Sildenafil: ketonazole increases plasma concentration of sildenafil—reduce initial dose of sildenafil for erectile dysfunction and avoid concomitant use of sildenafil for pulmonary hypertension
- Sirolimus: ketonazole increases plasma concentration of sirolimus—avoid concomitant use; miconazole increases plasma concentration of sirolimus
- sympathomimetics, beta: ketonazole increases plasma concentration of olodaterol; ketonazole inhibits metabolism of salmeterol (increased plasma concentration)
- Tacrolimus: ketonazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus); miconazole oral gel possibly increases plasma concentration of tacrolimus
- Tadalafil: ketonazole increases plasma concentration of tadalafil—avoid concomitant use of tadalafil for pulmonary hypertension

Antifungals, imidazole (continued)
- Theophylline: ketonazole possibly increases plasma concentration of theophylline
- Ticagrelor: ketonazole increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use
- Tolvaptan: ketonazole increases plasma concentration of tolvaptan—manufacturer of ketonazole advises avoid concomitant use
- Ulcera-Healing Drugs: absorption of ketonazole reduced by histamine H₂-antagonists, proton pump inhibitors and sucralfate
- Ulipristal: ketonazole increases plasma concentration of low-dose ulipristal—manufacturer of low-dose ulipristal advises avoid concomitant use
- Vardenafil: ketonazole increases plasma concentration of vardenafil—avoid concomitant use
- Vitamins: miconazole possibly reduces effects of alfacalcidol, calcitriol, colecalciferol, dihydroxycholesterol, ergocalciferol, paricalcitol and vitamin D; ketonazole possibly increases plasma concentration of paricalcitol

Antifungals, Polyene see Amphotericin B

Antifungals, Triazole
NOTE In general, fluconazole interactions relate to multiple-dose treatment
- Aliskiren: itraconazole increases plasma concentration of aliskiren—avoid concomitant use
- Aminophylline: fluconazole possibly increases plasma concentration of aminophylline
- Analgesics: fluconazole increases plasma concentration of celecoxib (halve dose of celecoxib); voriconazole increases plasma concentration of diclofenac, ibuprofen and oxycodeone; fluconazole increases plasma concentration of flurbiprofen, ibuprofen and methadone; fluconazole increases plasma concentration of parecoxib (reduce dose of parecoxib); voriconazole increases plasma concentration of alfentanil and methadone; itraconazole possibly increases plasma concentration of alfentanil; triazoles possibly increase plasma concentration of fentanyl; itraconazole possibly increases plasma concentration of methadone (increased risk of ventricular arrhythmias); itraconazole increases plasma concentration of oxycodeone
- Antacids: absorption of itraconazole reduced by antacids
- Anti-arrhythmics: manufacturer of itraconazole advises avoid concomitant use with disopyramide; avoidance of itraconazole, posaconazole and voriconazole advised by manufacturer of disopyramide
- Antibacterials: plasma concentration of itraconazole increased by clarithromycin; manufacturer of fluconazole advises avoid concomitant use with erythromycin; itraconazole, posaconazole and voriconazole advised by manufacturer of disopyramide
- Anticoagulants: plasma concentration of itraconazole increased by clarithromycin; manufacturer of fluconazole advises avoid concomitant use with erythromycin; itraconazole, posaconazole and voriconazole advised by manufacturer of disopyramide
Antifungals, Triazole

- Anticoagulants (continued)
  - Antivirals: concentration of **ATAZANAVIR**; itraconazole, posaconazole and voriconazole possibly increase the plasma concentration of **DACLATASVIR**—reduce dose of daclatasvir (see under Daclatasvir, p. 544); plasma concentration of voriconazole reduced by **EFAVIRENZ**, also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose); plasma concentration of itraconazole and posaconazole reduced by **EFAVIRENZ**; plasma concentration of both drugs may increase when itraconazole given with **FOSAMPRENAVIR**; plasma concentration of posaconazole possibly reduced by **FOSAMPRENAVIR**; itraconazole increases plasma concentration of **INDINAVIR** (consider reducing dose of indinavir); fluorconazole increases plasma concentration of **NEVIRAPINE**, **RITONAVIR** and **TIPRANAVIR**; plasma concentration of itraconazole possibly reduced by **NEVIRAPINE**—consider increasing dose of itraconazole; plasma concentration of voriconazole reduced by **RITONAVIR**—avoid concomitant use; combination of itraconazole with **RITONAVIR** may increase plasma concentration of either drug (or both); triazoles possibly increase plasma concentration of **SAQUINAVIR**; fluconazole, itraconazole, posaconazole and voriconazole possibly increase plasma concentration of **SIMEPREVIR**—manufacturer of simeprevir advises avoid concomitant use; plasma concentration of voriconazole possibly affected by **TELAPREVI** (possible increased risk of ventricular arrhythmias); plasma concentration of posaconazole possibly increased by **TELAPREVI** (increased risk of ventricular arrhythmias); plasma concentration of itraconazole possibly increased by **TELAPREVI**; voriconazole increases plasma concentration of **ZIDOVUDINE** (increased risk of toxicity)

- Anxiolytics and Hypnotics: itraconazole increases plasma concentration of **ALPRAZOLAM**; fluconazole and voriconazole increase plasma concentration of **DIAZEPAM** (risk of prolonged sedation); fluconazole, itraconazole, posaconazole and voriconazole increase plasma concentration of **MIDAZOLAM** (risk of prolonged sedation); itraconazole increases plasma concentration of **BUSBIPRO** (reduce dose of busipiron)

- Aripiprazole: itraconazole and voriconazole possibly increase plasma concentration of **AVANAFIL**—manufacturer of avanafil advises avoid concomitant use; fluconazole possibly increases plasma concentration of **AVANAFIL**—see under Avanafil, p. 698

- Bosantan: fluconazole possibly increases plasma concentration of **BOSENTAN**—avoid concomitant use; itraconazole possibly increases plasma concentration of **BOSENTAN**

- Calcium-channel Blockers: negative inotropic effect possibly increased when itraconazole given with **CALCIUM-CHANNEL BLOCKERS**; itraconazole inhibits metabolism of **FELODIPINE** (increased plasma concentration); avoidance of itraconazole advised by manufacturer of **LECADIRIPINE**; itraconazole possibly inhibits metabolism of **DHYDROPYRIDINES** (increased plasma concentration)

- Cardiac Glycosides: itraconazole increases plasma concentration of **DIGOXIN**

- Ciclosporin: fluconazole, itraconazole, posaconazole and voriconazole inhibit metabolism of **CICLOSPORIN** (increased plasma concentration)

- Cilostazol: itraconazole possibly increases plasma concentration of **CILOSTAZOL** (see under Cilostazol, p. 206)

- Clopidogrel: fluconazole, itraconazole and voriconazole possibly reduce antiplatelet effect of **CLOPIDOGREL**

- Cobicitstat: plasma concentration of itraconazole possibly increased by **COBICISTAT**—manufacturer of cobicitstat advises reduce dose of itraconazole

- Colchicine: itraconazole possibly increases risk of **COLCHICINE** toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)

- Corticosteroids: itraconazole possibly inhibits metabolism of **CORTICOSTEROIDS** and **METHYLPRERNSOLO**; itraconazole increases the plasma concentration of **inhaled and oral** (and
Antifungals, Triazole
- Corticosteroids (continued)
  - possibly also intranasal and rectal
  - BUDESONIDE; itraconazole increases plasma concentration of inhaled FLUTICASONE
- Cytotoxics: itraconazole inhibits metabolism of BUSULFAN (increased risk of toxicity); fluconazole and itraconazole possibly increase side-effects of CYCLOPHOSPHAMIDE; itraconazole possibly increases the plasma concentration of Arafibine—manufacturer of afatinib advises parating administration of itraconazole by 6 to 12 hours; itraconazole possibly increases plasma concentration of AXTINIB (reduce dose of axitinib—consult axitinib product literature); fluconazole, itraconazole, posaconazole and voriconazole possibly increase the plasma concentration of • BUSULFAN—manufacturer of busulfan advises reducing dose of busulfan; itraconazole possibly increases plasma concentration of CAPOZANTINIB; itraconazole and voriconazole possibly increase plasma concentration of • CRIZOTINIB—manufacturer of crizotinib advises avoid concomitant use; avoidance of itraconazole advised by manufacturer of DASATINIB and • TEMSIROLIMUS (plasma concentration of dasatinib and temsirolimus possibly increased); itraconazole, posaconazole and voriconazole possibly increase plasma concentration of • EVEROLIMUS—manufacturer of everolimus advises avoid concomitant use; itraconazole increases plasma concentration of GEFINIBIN; fluconazole, itraconazole and voriconazole possibly increase the plasma concentration of • IBRUTINIB—reduce dose of ibritunib (see under Ibrutinib, p. 809); avoidance of itraconazole, posaconazole and voriconazole advised by manufacturer of • LAPIX; avoidance of itraconazole and voriconazole advised by manufacturer of • Nilotinib; itraconazole and voriconazole possibly increase plasma concentration of • RAZONTAXEL—manufacturer of raxotaxel advises avoiding concomitant use; itraconazole and voriconazole possibly increase plasma concentration of • PONATINIB—consider reducing initial dose of ponatinib (see under Ponatinib, p. 814); manufacturer of ruxolitinib advises dose reduction when fluconazole, itraconazole, posaconazole and voriconazole given with • RUXOLITINIB—consult ruxolitinib product literature; itraconazole and voriconazole possibly increase the plasma concentration of • CABAZITAXEL—manufacturer of cabazitaxel advises avoid or consider reducing dose of cabazitaxel; itraconazole and voriconazole possibly increase plasma concentration of • DOCETAXEL—manufacturer of docetaxel advises avoid concomitant use or consider reducing docetaxel dose; increased risk of toxicity when itraconazole given with • RINFOTECAN—avoid concomitant use; itraconazole possibly increases plasma concentration of • VINDESINE, • VINFLUNINE and • VINOERIBINE toxicity; posaconazole possibly inhibits metabolism of • VINBLASTINE and • VINCristine (increased risk of neurotoxicity); itraconazole increases risk of • VINCristine toxicity
- Dopamine: manufacturer of dopaemine advises dose reduction when fluconazole given with • DOPAEMINE (see under Dapoxetine, p. 705); avoidance of itraconazole advised by manufacturer of • DAPoxetine (increased risk of toxicity)
- Diuretics: fluconazole increases plasma concentration of • Eplerenone (reduce dose of eplerenone); itraconazole increases plasma concentration of • Eplerenone—avoid concomitant use; plasma concentration of fluconazole increased by HYDROCHLOROTHIAZIDE
- Dopemonedone: possible increased risk of ventricular arrhythmias when itraconazole or voriconazole given with • DOPERINDONE—avoid concomitant use
- Ergot Alkaloids: increased risk of ergotism when voriconazole given with • ERGOMETRINE—avoid concomitant use; manufacturer of itraconazole advises avoid concomitant use with • ERGOMETRINE (increased risk of ergotism); increased risk of ergotism when triazoles given with • ERGOTAMINE—avoid concomitant use
- SHT-receptor Agonists: itraconazole increases plasma concentration of • ELETRIPATAN (risk of toxicity)—avoid concomitant use

Antifungals, Triazole (continued)
- Ivarabine: fluconazole increases plasma concentration of IVABRADINE—reduce initial dose of ivabradine; itraconazole possibly increases plasma concentration of • IVABRADINE—avoid concomitant use
- Ivacarif, itraconazole, posaconazole and voriconazole possibly increase plasma concentration of • WACAFOR (see under Ivacarif, p. 257); fluconazole increases plasma concentration of • IVAFACTOR (see under Ivacarif, p. 257)
- Lenalidomide: itraconazole possibly increases plasma concentration of • LENALIDOMIDE (increased risk of toxicity)
- Leukotriene Receptor Antagonists: fluconazole increases plasma concentration of ZAFIRILUKAST
- Lipid-regulating Drugs: increased risk of myopathy when itraconazole, posaconazole or voriconazole given with • ATORVASTATIN; possible increased risk of myopathy when fluconazole given with • ATORVASTATIN or • SIMVASTATIN; fluconazole increases plasma concentration of FLUVASTATIN—possible increased risk of myopathy; itraconazole increases plasma concentration of • ROSUVASTATIN—adjust dose of rosuvastatin (consult product literature); increased risk of myopathy when itraconazole or posaconazole given with • SIMVASTATIN (avoid concomitant use); increased risk of myopathy when voriconazole given with • SIMVASTATIN; avoidance of triazoles advised by manufacturer of • LOMIPATIDE (plasma concentration of lomitapide possibly increased)
- Mirabegron: when given with itraconazole avoid or reduce dose of Mirabegron in hepatic or renal impairment—see Mirabegron, p. 671
- Oestrogens: plasma concentration of voriconazole increased by OESTROGENS
- Progestogens: plasma concentration of voriconazole possibly increased by PROGESTOGENS
- Ranolazine: itraconazole, posaconazole and voriconazole possibly increase plasma concentration of • RANOLAZINE—manufacturer of ranolazine advises avoid concomitant use
- Retinoids: fluconazole and voriconazole possibly increase risk of • TRETINOIN toxicity
- Rofecoxib: avoidance of itraconazole and voriconazole advised by manufacturer of RICOGUT
- Sildenafil: itraconazole increases plasma concentration of SILDENAFIL—reduce initial dose of sildenafil
- Sirolimus: fluconazole and posaconazole possibly increase plasma concentration of SIROLIMUS; itraconazole and voriconazole increase plasma concentration of • SIROLIMUS—avoid concomitant use
- Tacrolimus: fluconazole, itraconazole, posaconazole and voriconazole increase plasma concentration of • TACROLIMUS (consider reducing dose of tacrolimus)
- Tadalafil: itraconazole possibly increases plasma concentration of TADALAFIL
- Theophylline: fluconazole possibly increases plasma concentration of • THEOPHYLLINE
- Ulcer-healing Drugs: plasma concentration of posaconazole reduced by • Cimetidine and • Esomeprazole—manufacturer of posaconazole suspension advises avoid concomitant use; plasma concentration of posaconazole possibly reduced by • Famotidine, • Lansoprazole, • Nizatidine, • Omeprazole, • Pantoprazole, • Rabeprazole and • Ranitidine—manufacturer of posaconazole suspension advises avoid concomitant use; voriconazole possibly increases plasma concentration of ESOMEPRAZOLE; voriconazole increases plasma concentration of OMEPRAZOLE (consider reducing dose of omeprazole); absorption of itraconazole reduced by • Histamine H2-ANTAGONISTS and • Proton Pump Inhibitors
- Ulipristal: avoidance of itraconazole advised by manufacturer of ULIPRISTAL
- Vardenafil: itraconazole possibly increases plasma concentration of • VARDENAFIL—avoid concomitant use

Antihistamines
- NOTE Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)
Antihistamines (continued)
- Alcohol: increased sedative effect when antihistamines given with ALCOHOL (possibly less effect with non-sedating antihistamines)
- Analgesics: sedative effects possibly increased when sedating antihistamines given with OPIOID ANALGESICS
- Antacids: absorption of fexofenadine reduced by ANTACIDS
- Anti-arrhythmics: increased risk of ventricular arrhythmias when mizolastine given with AMIODARONE, DISOPYRAMIDE or FLECAINIDE—avoid concomitant use; manufacturer of mizolastine advises avoid concomitant use with PROPafenONE (possible risk of ventricular arrhythmias)
- Antibacterials: manufacturer of lortadine advises plasma concentration possibly increased by ERYTHROMYCIN; metabolism of mizolastine possibly inhibited by MACROLIDES (avoid concomitant use)
- Antidepressants: avoidance of mizolastine advised by manufacturer of CITALOPRAM and ESCITALOPRAM (risk of ventricular arrhythmias); increased antimuscarinic and sedative effects when antihistamines given with MAOiS or TRICYCLICs; manufacturer of promethazine advises avoid for 2 weeks after stopping MAOiS; manufacturer of hydroxyzine advises avoid concomitant use with MAOiS; cyproheptadine possibly antagonises antidepressant effect of SSRIiS; possible increased antimuscarinic and sedative effects when antihistamines given with TRICYCLIC-RELATED ANTIDEPRESSANTS
- Antiarrhythmics: increased risk of ventricular arrhythmias when mizolastine given with CICLOSPORIN
- Anti-diabetics: thomboctye count depressed when ketotifen given with METFORMIN (manufacturer of ketotifen advises avoid concomitant use)
- Anti-epileptics: metabolism of mizolastine inhibited by ITRACONAZOLE—avoid concomitant use; metabolism of mizolastine possibly inhibited by IMIDAZOLES (avoid concomitant use)
- Antimalarials: avoidance of mizolastine advised by manufacturer of ARTEMIONIL with PIPERAQUIN (possible risk of ventricular arrhythmias)
- Antimuscarinics: increased risk of antimuscarinic side-effects when antihistamines given with ANTIMUSCARINICS
- Antivirals: plasma concentration of chlorphenamine possibly increased by LOPINAVIR; plasma concentration of non-sedating antihistamines possibly increased by RITONAVIR; increased risk of ventricular arrhythmias when mizolastine given with SAQUINAVIR—avoid concomitant use
- Anxiolytics and Hypnotics: increased sedative effect when antihistamines given with ANXIOLYTICS and HYPNOTICS
- Beta-blockers: increased risk of ventricular arrhythmias when mizolastine given with SOLFITOL—avoid concomitant use
- Betahistine: antihistamines theoretically antagonise effect of BETAHISTINE
- Cytotoxics: possible increased risk of ventricular arrhythmias when mizolastine given with VANDETANIB—avoid concomitant use
- Grapefruit Juice: plasma concentration of bilastine reduced by GRAPEFRUIT JUICE
- Histamine: antihistamines theoretically antagonise effects of HISTAMINE—manufacturer of histamine advises avoid concomitant use
- Ulcer-healing Drugs: manufacturer of loratadine advises plasma concentration possibly increased by CIMETIDINE; plasma concentration of hydroxyzine increased by CIMETIDINE
- Ulipristal: manufacturer of ulipristal advises give fexofenadine at least 1.5 hours before or after ULIPRISTAL

Antihistamines, Non-sedating see Antihistamines

Antihistamines, Sedating see Antihistamines

Antimalarials see Antimalarial

Antimetabolites see Cepacitabin, Ciprofloxacin, Docetaxel, Fluorouracil, Gomecitabine, Mercaptopurine, Methotrexate, Pemetrexed, Raltitrexed, Tegafur, and Tioguanine

Antimetabolites (continued)
- Mercaptopurine, Methotrexate, Pemetrexed, Raltitrexed, Tegafur, and Tioguanine

Antimuscarinics
- Note: Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation
- Alcohol: increased sedative effect when hyoscine given with ALCOHOL
- Analgesics: possible increased risk of antimuscarinic side-effects when antimuscarinics given with CODEINE; increased risk of antimuscarinic side-effects when antimuscarinics given with NEFOFAM
- Anti-arrhythmics: increased risk of ventricular arrhythmias when toterodine given with AMIODARONE, DISOPYRAMIDE or FLECAINIDE—avoid concomitant use; increased risk of antimuscarinic side-effects when antimuscarinics given with CODEINE
- Antibacterials: manufacturer of fesoterodine advises dose reduction when fesoterodine given with CLARITHROMYCIN and TELITHROMYCIN—consult fesoterodine product literature; manufacturer of toterodine advises avoid concomitant use with CLARITHROMYCIN and ERYTHROMYCIN; plasma concentration of darifenacin possibly increased by ERYTHROMYCIN; plasma concentration of active metabolite of fesoterodine reduced by RIFAMPICIN
- Antidepressants: plasma concentration of darifenacin and procyclidine increased by PAROXETINE; increased risk of antimuscarinic side-effects when antimuscarinics given with MAOiS or TRICYCLICs; possible increased antimuscarinic side-effects when antimuscarinics given with TRICYCLIC-RELATED ANTIDEPRESSANTS
- Antifungalis: antimuscarinics reduce absorption of KETOCONAZOLE; manufacturer of darifenacin advises dose reduction when fesoterodine given with ITRACONAZOLE and KETOCONAZOLE—consult fesoterodine product literature; plasma concentration of darifenacin increased by KETOCONAZOLE—avoid concomitant use; plasma concentration of solifenacin increased by KETOCONAZOLE—see under Solifenacin, p. 670; plasma concentration of oxybutynin increased by KETOCONAZOLE; manufacturer of toterodine advises avoid concomitant use with ITRACONAZOLE and KETOCONAZOLE; manufacturer of darifenacin advises avoid concomitant use with Ritonavir; plasma concentration of solifenacin possibly increased by ITRACONAZOLE—see under Solifenacin, p. 670
- Antihistamines: increased risk of antimuscarinic side-effects when antimuscarinics given with ANTIMUSCARINICS
- Antipsychotics: antimuscarinics possibly reduce effects of HALOPERIDOL; increased risk of antimuscarinic side-effects when antimuscarinics given with clozapine; antimuscarinics reduce plasma concentration of PHENOThIAZINES, but risk of antimuscarinic side-effects increased
- Antivirals: manufacturer of fesoterodine advises dose reduction when fesoterodine given with ATAZANAVIR, INDINAVIR, RITONAVIR and SAQUINAVIR—consult fesoterodine product literature; manufacturer of darifenacin advises avoid concomitant use with ATAZANAVIR, FOSAMPRENAVIR, INDINAVIR, LOPINAVIR, RITONAVIR, SAQUINAVIR and TIPRANAVIR; manufacturer of toterodine advises avoid concomitant use with FOSAMPRENAVIR, INDINAVIR, LOPINAVIR, RITONAVIR and SAQUINAVIR; plasma concentration of solifenacin possibly increased by RITONAVIR—see under Solifenacin, p. 670
- Beta-blockers: increased risk of ventricular arrhythmias when toterodine given with SOLITOL
- Calcium-channel Blockers: plasma concentration of solifenacin increased by VERAPAMIL; manufacturer of darifenacin advises avoid concomitant use with VERAPAMIL
- Carbamazepine: antimuscarinics possibly increase plasma concentration of DIGOXIN
- Ciclosporin: manufacturer of darifenacin advises avoid concomitant use with CICLOSPORIN
- Biperiden: antimuscarinics antagonise effects of DOMPERIDONE on gastro-intestinal activity
Antimuscarinics (continued)

- Dopaminergics: antimuscarinics possibly reduce absorption of CO-BENELDOPA, CO-CARELDOPA and LEVODOPA
- Hormone Antagonists: possible increased risk of bradycardia when ipratropium or oxybutynin given with PASIRETIDE
- Membrane effects of antimuscarinics possibly enhanced by MEMANTINE
- Metoclopramide: antimuscarinics antagonist effects of METOCLOPRAMIDE on gastro-intestinal activity
- Nitrate: antimuscarinics possibly reduce effects of sublingual tablets of NITRATES (failure to dissolve under tongue owing to dry mouth)
- Parasympathomimetics: antimuscarinics antagonist effects of PARASYMPATHOMIMETICS

Antiparkinsonian Neurone Blockers

- Antiarrhythmics: increased risk of ventricular arrhythmias when amisulpride given with AMIODARONE; higher doses of chlorpromazine antagonise effects of ADRENERGIC NEURONE BLOCKERS; haloperidol antagonises hypotensive effect of ADRENERGIC NEURONE BLOCKERS
- Adsorbents: absorption of phenothiazines possibly reduced by KAOLIN
- Alcohol: enhanced sedative effect when antipsychotics given with ALCOHOL
- Alpha-blockers: enhanced hypotensive effect when antipsychotics given with ALPHA-BLOCKERS
- Anaesthetics, General: droperidol enhances effects of THIOPENTAL; enhanced hypotensive effect when antipsychotics given with GENERAL ANAESTHETICS
- Analgesics: possible severe drowsiness when haloperidol given with ACEMETACIN or INDOMETACIN; increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with METHADONE; increased risk of ventricular arrhythmias when amisulpride given with METHADONE—avoid concomitant use; increased risk of convulsions when antipsychotics given with TRAMADOL; enhanced hypotensive and sedative effects when antipsychotics given with OPIOID ANALGESICS
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when antipsychotics given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Antacids: absorption of phenothiazines and sulphide reduced by ANTACIDS
- Anti-arrhythmics: increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with
  - ANTI-ARRHYTHMIKS that prolong the QT interval; increased risk of ventricular arrhythmias when amisulpride, droperidol, haloperidol, phenothiazines, pimozide or zuclopenthixol given with AMIODARONE—avoid concomitant use; increased risk of ventricular arrhythmias when benperidol given with AMIODARONE—manufacturer of benperidol advises avoid concomitant use; increased risk of ventricular arrhythmias when sulphide given with AMIODARONE or DISOPYRAMIDE; increased risk of ventricular arrhythmias when amisulpride, droperidol, pimozide or zuclopenthixol given with DISOPYRAMIDE—avoid concomitant use; possible increased risk of ventricular arrhythmias when haloperidol given with DISOPYRAMIDE—avoid concomitant use; increased risk of ventricular arrhythmias when phenothiazines given with DISOPYRAMIDE; avoidance of phenothiazines advised by manufacturer of DRONERADONE (risk of ventricular arrhythmias); increased risk of arrhythmias when clozapine given with FLECAINIDE
- Antimicrobials: plasma concentration of lurasidone possibly increased by CLARITHROMYCIN and TEFLUTHYMICIN—avoid concomitant use; increased risk of ventricular arrhythmias when pimozide given with CLARITHROMYCIN, MOXIFLOXACIN or TEFLUTHYMICIN—avoid concomitant use; plasma concentration of quetiapine possibly increased by CLARITHROMYCIN—manufacturer of quetiapine advises avoid concomitant use; plasma concentration of lurasidone possibly increased by ERYTHROMYCIN (see also Lurasidone, p. 315); increased risk of ventricular arrhythmias when amisulpride given with ERYTHROMYCIN—avoid concomitant use; plasma concentration of clozapine possibly increased by ERYTHROMYCIN (possible increased risk of convulsions); possible increased risk of ventricular arrhythmias when pimozide given with ERYTHROMYCIN—avoid concomitant use; plasma concentration of quetiapine increased by ERYTHROMYCIN—manufacturer of quetiapine advises avoid concomitant use; increased risk of ventricular arrhythmias when sulphide given with parenteral ERYTHROMYCIN; increased risk of ventricular arrhythmias when zuclopenthixol given with parenteral ERYTHROMYCIN—avoid concomitant use; plasma concentration of clozapine increased by CIPROFLOXACIN; plasma concentration of olanzapine possibly increased by CIPROFLOXACIN; increased risk of ventricular arrhythmias when droperidol, haloperidol, phenothiazines or zuclopenthixol given with MOXIFLOXACIN—avoid concomitant use; increased risk of ventricular arrhythmias when benperidol given with MOXIFLOXACIN—manufacturer of benperidol advises avoid concomitant use; plasma concentration of aripiprazole possibly reduced by CIPROFLOXACIN; plasma concentration of lorazepam possibly increased by CIPROFLOXACIN; increased risk of ventricular arrhythmias when droperidol, haloperidol, phenothiazines or zuclopenthixol given with THIOPENTAL; increased risk of ventricular arrhythmias when benperidol given with THIOPENTAL; increased risk of ventricular arrhythmias when droperidol, haloperidol or pimozide given with DELAMANID; increased risk of ventricular arrhythmias when phenothiazines that prolong the QT interval given with DELAMANID; manufacturer of droperidol advises avoid concomitant use with MACROLIDES (risk of ventricular arrhythmias); possible increased risk of ventricular arrhythmias when chlorpromazine given with TELITHROMYCIN; plasma concentration of quetiapine possibly increased by TELITHROMYCIN
- Antidepressants: plasma concentration of clozapine possibly increased by CITALOPRAM (increased risk of toxicity); avoidance of haloperidol, phenothiazines and pimozide advised by manufacturer of CITALOPRAM (risk of ventricular arrhythmias); avoidance of haloperidol, phenothiazines and pimozide advised by manufacturer of ESICITALOPRAM (risk of ventricular arrhythmias); plasma concentration of aripiprazole possibly increased by FLUOXETINE and PAROXETINE (reduce dose of aripiprazole—consult aripiprazole product literature); plasma concentration of lorazepam reduced by FLUOXETINE; manufacturer of droperidol advises avoid concomitant use with FLUOXETINE, FLUKETINE, FLUVAXAMINE, SERTRALINE and TRICYCLICS (risk of ventricular arrhythmias); plasma concentration of asenapine and haloperidol possibly increased by FLUVAXAMINE; plasma concentration of clozapine and olanzapine increased by FLUVAXAMINE; asenapine possibly increases plasma concentration of PAROXETINE; plasma concentration of clozapine increased by PAROXETINE and SERTRALINE; plasma concentration of risperidone possibly increased by PAROXETINE (increased risk of toxicity); metabolism of haloperidol accelerated by SERTRALINE and perphenazine inhibited by PAROXETINE (reduce dose of perphenazine); plasma concentration of haloperidol increased by VENLAFAXINE; clozapine possibly increases CNS effects of MAOIS; plasma concentration of pimozide possibly increased by SSRI (increased risk of ventricular arrhythmias—avoid concomitant use); plasma concentration of lorazepam possibly reduced by ST JOHN’S WORT—avoid concomitant use; plasma concentration of aripiprazole possibly reduced by ST JOHN’S WORT (avoid concomitant use or consider increasing the dose of aripiprazole—consult

Antipsychotics

- Antibacterials (continued) concomitant use; plasma concentration of lurasidone possibly increased by ERYTHROMYCIN (see also Lurasidone, p. 315); increased risk of ventricular arrhythmias when amisulpride given with ERYTHROMYCIN—avoid concomitant use; plasma concentration of clozapine possibly increased by ERYTHROMYCIN (possible increased risk of convulsions); possible increased risk of ventricular arrhythmias when pimozide given with ERYTHROMYCIN—avoid concomitant use; plasma concentration of quetiapine possibly increased by ERYTHROMYCIN—manufacturer of quetiapine advises avoid concomitant use; increased risk of ventricular arrhythmias when sulphide given with parenteral ERYTHROMYCIN; increased risk of ventricular arrhythmias when zuclopenthixol given with parenteral ERYTHROMYCIN—avoid concomitant use; plasma concentration of clozapine increased by CIPROFLOXACIN; plasma concentration of olanzapine possibly increased by CIPROFLOXACIN; increased risk of ventricular arrhythmias when droperidol, haloperidol, phenothiazines or zuclopenthixol given with MOXIFLOXACIN—avoid concomitant use; increased risk of ventricular arrhythmias when benperidol given with MOXIFLOXACIN—manufacturer of benperidol advises avoid concomitant use; plasma concentration of aripiprazole possibly reduced by CIPROFLOXACIN; plasma concentration of lorazepam possibly increased by CIPROFLOXACIN; increased risk of ventricular arrhythmias when droperidol, haloperidol, phenothiazines or zuclopenthixol given with THIOPENTAL; increased risk of ventricular arrhythmias when benperidol given with THIOPENTAL; increased risk of ventricular arrhythmias when droperidol, haloperidol or pimozide given with DELAMANID; increased risk of ventricular arrhythmias when phenothiazines that prolong the QT interval given with DELAMANID; manufacturer of droperidol advises avoid concomitant use with MACROLIDES (risk of ventricular arrhythmias); possible increased risk of ventricular arrhythmias when chlorpromazine given with TELITHROMYCIN; plasma concentration of quetiapine possibly increased by TELITHROMYCIN
- Antidepressants: plasma concentration of clozapine possibly increased by CITALOPRAM (increased risk of toxicity); avoidance of haloperidol, phenothiazines and pimozide advised by manufacturer of CITALOPRAM (risk of ventricular arrhythmias); avoidance of haloperidol, phenothiazines and pimozide advised by manufacturer of ESICITALOPRAM (risk of ventricular arrhythmias); plasma concentration of aripiprazole possibly increased by FLUOXETINE and PAROXETINE (reduce dose of aripiprazole—consult aripiprazole product literature); plasma concentration of lorazepam reduced by FLUOXETINE; manufacturer of droperidol advises avoid concomitant use with FLUOXETINE, FLUKETINE, FLUVAXAMINE, SERTRALINE and TRICYCLICS (risk of ventricular arrhythmias); plasma concentration of asenapine and haloperidol possibly increased by FLUVAXAMINE; plasma concentration of clozapine and olanzapine increased by FLUVAXAMINE; asenapine possibly increases plasma concentration of PAROXETINE; plasma concentration of clozapine increased by PAROXETINE and SERTRALINE; plasma concentration of risperidone possibly increased by PAROXETINE (increased risk of toxicity); metabolism of haloperidol accelerated by SERTRALINE and perphenazine inhibited by PAROXETINE (reduce dose of perphenazine); plasma concentration of haloperidol increased by VENLAFAXINE; clozapine possibly increases CNS effects of MAOIS; plasma concentration of pimozide possibly increased by SSRI (increased risk of ventricular arrhythmias—avoid concomitant use); plasma concentration of lorazepam possibly reduced by ST JOHN’S WORT—avoid concomitant use; plasma concentration of aripiprazole possibly reduced by ST JOHN’S WORT (avoid concomitant use or consider increasing the dose of aripiprazole—consult
Antipsychotics

• Antidepressants (continued)
  • Aripiprazole product literature; manufacturer of fluphenazine, haloperidol, sulphpride and zuclopentixol advises avoid concomitant use with • Tricyclics (risk of ventricular arrhythmias); increased risk of antimuscarinic side-effects when phenothiazines given with • Tricyclics; possible increased risk of ventricular arrhythmias when risperidone given with • Tricyclics; possible increased antimuscarinic side-effects when clozapine given with • Tricyclics

• Antidabetics: phenothiazines possibly antagonise hypoglycaemic effect of sulfonylureas

• Antiepileptics: antipsychotics antagonise anticonvulsant effect of • Antiepileptics (convulsive threshold lowered); metabolism of haloperidol, olanzapine, quetiapine and risperidone accelerated by • Carbamazepine (reduced plasma concentration); metabolism of clozapine accelerated by • Carbamazepine (reduced plasma concentration), also avoid concomitant use of drugs with substantial potential for causing agranulocytosis; plasma concentration of aripiprazole reduced by • Carbazapime (avoid concomitant use or consider increasing the dose of aripiprazole — consult aripiprazole product literature); plasma concentration of pimozide reduced by • Carbamazepine; plasma concentration of lurasidone possibly reduced by • Carbamazepine; • Fosphenytoin, • Phenoobarbital, • Phenytoin and • Pramidone—avoid concomitant use; chlorpromazine possibly increases or decreases plasma concentration of • Fosphenytoin and • Phenophytin; metabolism of clozapine, olanzapine and quetiapine accelerated by • Phenobarbital (reduced plasma concentration); plasma concentration of aripiprazole possibly reduced by • Fosphenytoin, • Phenoobarbital, • Phenytoin and • Pramidone (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature); plasma concentration of haloperidol reduced by • Fosphenytoin and • Phenophytin; metabolism of haloperidol accelerated by • Phenoobarbital and • Pramidone (reduced plasma concentration); plasma concentration of both drugs reduced when chlorpromazine given with • Phenoobarbital and • Pramidone; plasma concentration of clozapine possibly reduced by • Phenoobarbital and • Pramidone; metabolism of clozapine and quetiapine accelerated by • Phenophytin (reduced plasma concentration); increased risk of antimuscarinic side-effects including neutropenia when olanzapine given with • Sodium Valproate and • Valproic Acid; plasma concentration of clozapine possibly increased or decreased by • Sodium Valproate and • Valproic Acid

• Antimuscarinics: plasma concentration of lurasidone increased by • Ketoconazole—avoid concomitant use; metabolism of aripiprazole inhibited by • Ketoconazole (reduce dose of aripiprazole); plasma concentration of lurasidone possibly increased by • Flucanazole (see under Lurasidone, p. 315); plasma concentration of lurasidone possibly increased by • Itraconazole, • Posaconazole and • Voriconazole—avoid concomitant use; plasma concentration of aripiprazole possibly increased by • Itraconazole (reduce dose of aripiprazole—consult aripiprazole product literature); side-effects of aripiprazole possibly increased by • Itraconazole; plasma concentration of haloperidol possibly increased by • Itraconazole; increased risk of ventricular arrhythmias when pimozide given with • Midazoles or • Triazoles—avoid concomitant use; plasma concentration of quetiapine possibly increased by • Midazoles and • Triazoles—manufacturer of quetiapine advises avoid concomitant use

• Antimalarials: avoidance of antipsychotics advised by manufacturer of • Arteether with Lumefantrine; avoidance of droperidol, haloperidol, phenothiazines and pimozide advised by manufacturer of • Arteether with Piperaquine (possible risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when droperidol given with • Chloroquine, • Hydroxychloroquine or • Quinine—avoid concomitant use; possible increased risk of ventricular arrhythmias when haloperidol given with • Mefloquine or • Mefloquine or • Quinine—avoid concomitant use; manufacturer of risperidone advises possible risk of ventricular arrhythmias when risperidone given with • Mefloquine; increased risk of ventricular arrhythmias when pimozide given with • Mefloquine or • Quinine—avoid concomitant use; manufacturer of amisulpride advises avoid concomitant use with • Mefloquine; possible increased risk of ventricular arrhythmias when risperidone given with • Quinine

• Antimuscarinics: increased risk of antimuscarinic side-effects when clozapine given with • Antimuscarinics; plasma concentration of phenothiazines reduced by • Antimuscarinics, but risk of antimuscarinic side-effects increased; effects of haloperidol possibly reduced by • Antimuscarinics

• Antipsychotics: increased risk of ventricular arrhythmias when amisulpride, pimozide or sulphpride given with • Droperidol—avoid concomitant use; increased risk of ventricular arrhythmias when phenothiazines that prolong the QT interval given with • Droperidol—avoid concomitant use; avoid concomitant use of clozapine with depot formulation of • Fluphenazine, • Haloperidol, • Pipotiazine, • Risperidone or • Zuclopentixol as cannot be withdrawn quickly if neutropenia occurs; increased risk of ventricular arrhythmias when sulphpride given with • Haloperidol; chlorpromazine possibly increases plasma concentration of • Haloperidol; increased risk of ventricular arrhythmias when droperidol given with • Haloperidol—avoid concomitant use; increased risk of ventricular arrhythmias when pimozide given with • Phenoxythiazines—avoid concomitant use; lurasidone possibly increases plasma concentration of • Pimozide (increased risk of toxicity); possible increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with • Risperidone—increased risk of ventricular arrhythmias when pimozide given with • Sulphpride

• Antivirals: plasma concentration of aripiprazole possibly increased by • Atazanavir, • Darunavir, • Fosamprenavir, • Indinavir, • Lopinavir, • Ritonavir, • Saquinavir and • Tiplanavir (reduce dose of aripiprazole—consult aripiprazole product literature); plasma concentration of quetiapine possibly increased by • Atazanavir, • Boceprevir, • Darunavir, • Fosamprenavir, • Indinavir, • Lopinavir, • Ritonavir, • Saquinavir, • Telaprevir and • Tipranavir (reduce dose of aripiprazole—consult aripiprazole product literature); • Quinine—avoid concomitant use; plasma concentration of pimozide possibly increased by • Atazanavir—avoid concomitant use; avoidance of pimozide advised by manufacturer of • Boceprevir and • Telaprevir; plasma concentration of lurasidone possibly increased by • Boceprevir, • Indinavir, • Ritonavir, • Saquinavir and • Telaprevir—avoid concomitant use; plasma concentration of aripiprazole possibly reduced by • Efavirenz and • Nevirapine (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature); plasma concentration of pimozide possibly increased by • Efavirenz, • Indinavir and • Saquinavir (increased risk of ventricular arrhythmias—avoid concomitant use); plasma concentration of pimozide increased by • Fosamprenavir and • Ritonavir (increased risk of ventricular arrhythmias—avoid concomitant use); plasma concentration of antipsychotics possibly increased by • Ritonavir; plasma concentration of olanzapine reduced by • Ritonavir—consider increasing dose of olanzapine; avoidance of clozapine advised by manufacturer of • Ritonavir (increased risk of toxicity); increased risk of ventricular arrhythmias when clozapine, haloperidol or phenothiazines given with • Saquinavir—avoid concomitant use

• Anxiolytics and Hypnotics: increased sedative effect when antipsychotics given with • Anxiolytics and Hypnotics; plasma concentration of haloperidol possibly increased by • Alprazolam; lurasidone increases plasma concentration of • Alprazolam; serious adverse events reported with concomitant use of clozapine and • Alprazolam
Dopaminergics:
- **Diazoxide:** increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with; increased risk of ventricular arrhythmias when haloperidol given with quetiapine advised by manufacturer of zuclopenthixol given with chlorpromazine, haloperidol, pimozide, sulpiride or increased risk of ventricular arrhythmias when amisulpride, avoidance of antipsychotics advised by manufacturer of concomitant use increased risk of ventricular arrhythmias when haloperidol given with sotalol;—avoid concomitant use
- **Calcium-channel Blockers:** enhanced hypotensive effect when antipsychotics given with calcium-channel blockers; plasma concentration of lurusidone increased by diltiazem (see under lurusidone, p. 315); plasma concentration of lurusidone possibly increased by verapamil (see under lurusidone, p. 315)
- **Clonidine:** enhanced hypotensive effect when phenothiazines given with clonidine
- **Cobicistat:** plasma concentration of lurusidone possibly increased by cobicitat—avoid concomitant use; plasma concentration of pimozide possibly increased by cobicitat—manufacturer of cobicistat advises avoid concomitant use
- **Cytotoxics:** avoid concomitant use of clozapine with cyanotoxins (increased risk of agranulocytosis); possible increased risk of ventricular arrhythmias when haloperidol given with bosutinib; caution with pimozide advised by manufacturer of crizotinib; avoidance of pimozide and quetiapine advised by manufacturer ofidelalisib; avoidance of pimozide advised by manufacturer of lapatinib; possible increased risk of ventricular arrhythmias when amisulpride, chlorpromazine, haloperidol, pimozide, sulpiride or zuclopenthixol given with vanetanib—avoid concomitant use; increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with arsenic trioxide; increased risk of ventricular arrhythmias when haloperidol given with arsenic trioxide;—deferasirox: avoidance of clozapine advised by manufacturer of deferasirox
- **Desferrioxamine:** manufacturer of leovemopromazine advises avoid concomitant use with desferrioxamine; avoidance of prochlorperazine advised by manufacturer of desferrioxamine
- **Diazoxide:** enhanced hypotensive effect when phenothiazines given with diazoxide
- **Diuretics:** risk of ventricular arrhythmias with amisulpride increased by hypokalaemia caused by diuretics; risk of ventricular arrhythmias with pimozide increased by hypokalaemia caused by diuretics (avoid concomitant use); enhanced hypotensive effect when phenothiazines given with diuretics
- **Dopaminergics:** increased risk of extrapyramidal side-effects when antipsychotics given with amantadine; antipsychotics antagonise effects of apomorphine, benelodopa, co-careldopa, levodopa and pergolide; antipsychotics antagonise hydroprolactiamaic and antiparkinsonian effects of bromocriptine and cabergoline; manufacturer of carbidopa advises avoid concomitant use of co-careldopa, co-careldopa and levodopa (antagonism of effect); avoidance of antipsychotics advised by manufacturer of pramipexole, ropinirole and rotigotine (antagonism of effect)
### Interactions (continued)

**Anxiolytics and Hypnotics**

- **Adrenergic Neurone Blockers:** enhanced hypotensive effect when anxiolytics and hypnotics given with ADRENERGIC NEURONE BLOCKERS.
- **Alcohol:** increased sedative effect when anxiolytics and hypnotics given with ALCOHOL.
- **Alpha-blockers:** enhanced hypotensive and sedative effects when anxiolytics and hypnotics given with ALPHA-BLOCKERS.
- **Aminophylline:** effects of benzodiazepines possibly reduced by AMINOPHylline.
- **Anaesthetics, General:** increased sedative effect when anxiolytics and hypnotics given with GENERAL ANAESTHETICS.
- **Analgesics:** metabolism of midazolam possibly inhibited by FENTANYL; increased sedative effect when anxiolytics and hypnotics given with OPIOID ANALGESICS.
- **Anxiolytics and Hypnotics:** enhanced hypotensive effect when anxiolytics and hypnotics given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS.
- **Antibacterials:** metabolism of midazolam inhibited by CLARITHROMYCIN, ERYTHROMYCIN and TELITHROMYCIN (increased plasma concentration with increased sedation); metabolism of buspirone increased by ERYTHROMYCIN (reduce dose of buspirone); metabolism of zopiclone inhibited by ERYTHROMYCIN; manufacturer of zopiclone advises avoid concomitant use with CIPROFLOXACIN; metabolism of benzodiazepines possibly accelerated by RIFAMPICIN (reduced plasma concentration); metabolism of diazepam and zaleplon accelerated by RIFAMPICIN (reduced plasma concentration and reduced effect); plasma concentration of zopiclone significantly reduced by RIFAMPICIN; metabolism of diazepam inhibited by ISONIAZID.
- **Anticoagulants:** chloral may transiently enhance anticoagulant effect of COUMARINS.
- **Antidepressants:** plasma concentration of alprazolam increased by FLUOXETINE; plasma concentration of melatonin increased by FLUOXETINE—avoid concomitant use; plasma concentration of some benzodiazepines increased by FLUOXETINE; sedative effects possibly increased when zolpidem given with SERTRALINE; manufacturer of buspirone advises avoid concomitant use with MAOIs; avoidance of buspirone for 14 days after stopping TRANLYCPROMINE and manufacturer of hypnotics given with ST JOHN’S WORT; increased sedative effect when anxiolytics and hypnotics given with MIRTAZAPINE, TRICYCLIC-RELATED ANTIDEPRESSANTS or TRICYCLICS.
- **Antifungals:** plasma concentration of midazolam reduced by CARBAMAZEPINE and PERAMPANFL; plasma concentration of clonazepam often reduced by CARBAMAZEPINE, FOSPHENTHOIN, PHENOBARBITAL, PHENOTIN and PRIMIDONE; benzodiazepines possibly increase or decrease plasma concentration of FOSPHENTHOIN and PHENOTIN; diazepam increases or decreases plasma concentration of FOSPHENTHOIN and PHENOTIN; increased sedative effect when anxiolytics and hypnotics given with PHENOBARBITAL or PRIMIDONE; clonazepam possibly increases plasma concentration of SODIUM VALPROATE and VALPROIC ACID; plasma concentration of diazepam and lorazepam possibly increased by SODIUM VALPROATE; increased risk of side-effects when clonazepam given with SODIUM VALPROATE or VALPROIC ACID; plasma concentration of clonazepam possibly increased by VALPROIC ACID.
- **Antifungals:** plasma concentration of alprazolam increased by KETOCONAZOLE—manufacturer of ketoconazole advises avoid concomitant use; plasma concentration of midazolam increased by KETOCONAZOLE (risk of prolonged sedation—avoid concomitant use of oral midazolam); plasma concentration of zolpidem increased by KETOCONAZOLE; plasma concentration of diazepam and midazolam increased by FLUCONAZOLE (risk of prolonged sedation); plasma concentration of alprazolam increased by ITRAconazole; plasma concentration of midazolam increased by ITRAconazole.
- **Antivirals:** plasma concentration of midazolam possibly increased by ATAZANAVIR—avoid concomitant use of oral midazolam; plasma concentration of oral midazolam increased by BOCEPREVIR—manufacturer of boceprevir advises avoid concomitant use; increased risk of prolonged sedation when midazolam given with EFAVIRENZ—avoid concomitant use; plasma concentration of midazolam possibly increased by FOSAMPRENAVIR, INDINAVIR, RITONAVIR and TELAPREVIR (risk of prolonged sedation—avoid concomitant use of oral midazolam); increased risk of prolonged sedation when alprazolam given with INDINAVIR—avoid concomitant use; plasma concentration of anxiolytics and hypnotics possibly increased by RITONAVIR; plasma concentration of alprazolam, diazepam, flurazepam and zolpidem possibly increased by RITONAVIR (risk of extreme sedation and respiratory depression—avoid concomitant use); plasma concentration of buspirone increased by RITONAVIR (increased risk of toxicity); plasma concentration of midazolam increased by SAQUINAVIR (risk of prolonged sedation—avoid concomitant use of oral midazolam); plasma concentration of oral midazolam increased by SIMPREVIR.
- **Aprepitant:** plasma concentration of midazolam increased by Aprepitant (risk of prolonged sedation).
- **Beta-blockers:** enhanced hypotensive effect when anxiolytics and hypnotics given with BETA-BLOCKERS.
- **Calcium-channel blockers:** enhanced hypotensive effect when anxiolytics and hypnotics given with CALCIUM-CHANNEL BLOCKERS; midazolam increases absorption of LERCANIDIPINE; metabolism of midazolam inhibited by DILTAZEM and VERAPAMIL (increased plasma concentration with increased sedation); plasma concentration of buspirone increased by DILTAZEM and VERAPAMIL (reduce dose of buspirone).
- **Cardiac Glycosides:** alprazolam increases plasma concentration of DIGOXIN (increased risk of toxicity).
- **Clonidine:** enhanced hypotensive effect when anxiolytics and hypnotics given with CLONIDINE.
- **Cobicistat:** avoidance of oral midazolam advised by manufacturer of Cobicistat.
- **Cyclosporines:** plasma concentration of midazolam increased by CRYSTONIB and NILDONIB, avoidance of oral midazolam advised by manufacturer of IDENTILISIB.
- **Diflunisal:** plasma concentration of midazolam possibly reduced by DEREFASIRON.
- **Disulfiram:** enhanced hypotensive effect when anxiolytics and hypnotics given with DISULFIRAM (increased sedative effects); increased risk of temazepam toxicity when given with DISULFIRAM.
- **Diuretics:** enhanced hypotensive effect when anxiolytics and hypnotics given with DIURETICS; administration of chloral with parenteral EUROSEMI may displace thyroid hormone from binding sites.
- **Dopaminergic:** benzodiazepines possibly antagonise effects of CO-BENELDOPA, CO-CARELDOPA and LEVODOPA.
- **Fluoxetine:** plasma concentration of midazolam increased by FOSAMPRENAVIR (risk of prolonged sedation).
### Appendix 1 Interactions

#### Anxiolytics and Hypnotics (continued)
- Grapefruit Juice: plasma concentration of oral midazolam possibly increased by **GRAPFUIT JUICE**; plasma concentration of buspirone increased by **GRAPEFRUIT JUICE**
- Ivecafarin: plasma concentration of midazolam increased by **IVECAFARIN**
- Lipid-regulating Drugs: plasma concentration of midazolam possibly increased by **ATORVASTATIN**; separating administration from alprazolam by 12 hours advised by **ATORVASTATIN**
- Lithium: increased risk of neurotoxicity when clonazepam given with **LITHIUM**
- Lofexidine: increased sedative effect when anxiolytics and hypnotics given with **LOFEXIDINE**
- Methyldopa: enhanced hypotensive effect when anxiolytics and hypnotics given with ** METHYLDOPA**
  - Methyldiphene: possible risk of CNS toxicity when buspirone given with **METHYLDOPHENE**—avoid concomitant use (if avoidance not possible, use lowest possible dose of methyldiphene and observe patient for up to 4 hours after administration)
- Moxonidine: enhanced hypotensive effect when anxiolytics and hypnotics given with **MOXONIDINE**; sedative effects possibly increased when benzodiazepines given with **MOXONIDINE**
- Muscle Relaxants: increased sedative effect when anxiolytics and hypnotics given with **BACLOFEN** or **TIZANIDINE**
- Nitrates: enhanced hypotensive effect when anxiolytics and hypnotics given with **NITRATES**
- Oestrogens: plasma concentration of melatonin increased by **OESTROGENS**; plasma concentration of chloridiazepoxide, diazepam and nitrazepam possibly increased by **OESTROGENS**; plasma concentration of lorazepam, oxazepam and temazepam possibly reduced by **OESTROGENS**
- Progestogens: plasma concentration of chloridiazepoxide, diazepam and nitrazepam possibly increased by **PROGESTOGENS**; plasma concentration of lorazepam, oxazepam and temazepam possibly reduced by **PROGESTOGENS**
  - Sodium Oxybate: benzodiazepines enhance effects of **SODIUM OXABATE** (avoid concomitant use)
- Theophylline: effects of benzodiazepines possibly reduced by **THEOPHYLLINE**
- Ulcer-healing Drugs: plasma concentration of melatonin increased by **CIMETIDINE**; metabolism of benzodiazepines, clomethiazole and zaleplon inhibited by **CIMETIDINE** (increased plasma concentration); metabolism of diazepam possibly inhibited by **ESOMEPRAZOLE** and **OMEPRAZOLE** (increased plasma concentration)
- Vasodilators: enhanced hypotensive effect when anxiolytics and hypnotics given with **HYDRAZINE, MINOXYLID** or **SODIUM NITROPRUSSIDE**

#### Apixaban (continued)
- Analgesics: increased risk of haemorrhage when anticoagulants given with **INTRAPEPTAN** —manufacturer of apixaban advises avoid concomitant use when given for treatment of deep-vein thrombosis or pulmonary embolism
- Antiplatelets: plasma concentration of apixaban possibly reduced by **CARBAMAZEPINE**—manufacturer of apixaban advises avoid concomitant use when given for treatment of deep-vein thrombosis or pulmonary embolism
  - Fosphenytoin, **PHENOBARBITAL**, **PHENYTOIN** and **PRIMIDONE**
- Antifungals: plasma concentration of apixaban increased by **KETOCONAZOLE**—manufacturer of apixaban advises avoid concomitant use; manufacturer of apixaban advises avoid concomitant use with **ITRACONAZOLE, POSACONAZOLE** and **VORICONAZOLE**
- Antivirals: manufacturer of apixaban advises avoid concomitant use with **ATAZANAVIR, BOCEPREVIR, DARUNAVIR, FOSAMPRENAVIR, INDINAVIR, LOPINAVIR, RITONAVIR, SACHUINAVIR, TELAPREVIR** and **TIPRANAVIR**
- Antidepressants: manufacturer of apixaban advises avoid concomitant use with **COBICISTAT**
- Sulfinpyrazone: increased risk of bleeding when apixaban given with **SULFINPYRAZONE**

#### Apomorphine
- Antipsychotics: effects of apomorphine antagonised by **ANTIPSYCHOTICS**
- Dopaminergics: effects of apomorphine possibly enhanced by **ANTIPSYCHOTICS**

#### Apraclonidine
- Antidepressants: manufacturer of apraclonidine advises avoid concomitant use with **MAOIS, TRICYCLIC-RELATED ANTIDEPRESSANTS AND TRICYCLICS**
- Sympathomimetics: manufacturer of apraclonidine advises avoid concomitant use with **SYMPATHOMIMETICS**

#### Aprindine
- Antibacterials: plasma concentration of aprindine possibly increased by **CLARITHROMYCIN** and **TELITHROMYCIN**; plasma concentration of aprindine reduced by **RIFAMPICIN**
- Anticoagulants: aprindine possibly reduces anticoagulant effect of **WARFARIN**
- Antidepressants: manufacturer of aprindine advises avoid concomitant use with **ST JOHN’S WORT**
- Antidiabetics: aprindine reduces plasma concentration of **TOLBUTAMIDE**
- Antiepileptics: plasma concentration of aprindine possibly increased by **CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYTOIN** and **PRIMIDONE**
- Antifungals: plasma concentration of aprindine increased by **KETOCONAZOLE**
- Antipsychotics: manufacturer of aprindine advises avoid concomitant use with **PIMOZIDE**
- Antivirals: plasma concentration of aprindine possibly increased by **RITONAVIR**
- Anxiolytics and Hypnotics: aprindine increases plasma concentration of midazolam (risk of prolonged sedation)
- Apanin: aprindine possibly increases plasma concentration of **AVANAFIL**—see under Apanin, p. 698
- Calcium-channel Blockers: plasma concentration of both drugs may increase when aprindine given with **DILTIAZEM**
- Corticosteroids: aprindine inhibits metabolism of **DEXAMETHASONE** and **METHYLPRIDENISOLONE** (reduce dose of dexamethasone and methylprednisolone)
- Cytokines: aprindine possibly increases the plasma concentration of **IBRUTINIB**—manufacturer of bortinib advises avoid or consider reducing dose of bortinib; aprindine possibly increases the plasma concentration of **IBRUTINIB**—reduce dose of ibritinib (see under Ibrutinib, p. 809)
- Dopamine: manufacturer of dopoxetine advises dose reduction when aprindine given with **DAPoxetine** (see under Dapoxetine, p. 703)
Aprepitant (continued)
- Oestrogens: aprepetit possibly causes contraceptive failure of hormonal contraceptives containing • OESTROGENS (alternative contraception recommended)
- Progestogens: aprepetit possibly causes contraceptive failure of hormonal contraceptives containing • PROGESTOGENS (alternative contraception recommended)

Argatroban
- Analgesics: increased risk of haemorrhage when anti-inflammatory given with intravenous • DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with • KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when other anticoagulants given with • APIXABAN, • DABIGATRAN and • RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)

Artemether with Lumeferantrine
- Anti-arrhythmics: increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • AMIODARONE or • DISOPYRAMIDE
- Antibacterials: increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • DELAMANID, • ERYTHROMYCIN, • LEVOFLOXACIN or • MOXIFLOXACIN
- Antidepressants: increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • AMITRIPTYLINE or • CLOMIPRAMINE
- Antifungals: increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • AMPHOTERICIN
- Antimalarials: avoidance of artemether with lumeferantrine advised by • ARTEMETHER WITH LUMEFANTRINE
- Antipsychotics: increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • HALOPERIDOL; avoid concomitant use with • CLOzapine (increased risk of agranulocytosis)
- Beta-blockers: increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • SOTALOL
- Cytotoxics: possible increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • VANDETANIB — avoid concomitant use with • RIFAMPICIN
- Diuretics: risk of ventricular arrhythmias with artemether with lumeferantrine increased by hypokalaemia caused by • ACETAZOLAMIDE, • LOOP DIURETICS or • THIAZIDES AND RELATED DIURETICS
- Lithium: increased risk of ventricular arrhythmias when artemether with lumeferantrine given with • LITHIUM

Arsenic Trioxide
- Antiarhythmics: increased risk of ventricular arrhythmias when arsenic trioxide given with • AMIODARONE or • DISOPYRAMIDE
- Antibacterials: increased risk of ventricular arrhythmias when arsenic trioxide given with • DELAMANID, • ERYTHROMYCIN, • LEVOFLOXACIN or • MOXIFLOXACIN
- Antidepressants: increased risk of ventricular arrhythmias when arsenic trioxide given with • AMITRIPTYLINE or • CLOMIPRAMINE
- Antifungals: increased risk of ventricular arrhythmias when arsenic trioxide given with • AMPHOTERICIN
- Antimalarials: avoidance of arsenic trioxide advised by manufacturer of • ARTENIMOL WITH PIPERAQUINE
- Antipsychotics: increased risk of ventricular arrhythmias when arsenic trioxide given with • ANTIARRHYTHMICS that prolong the QT interval; increased risk of ventricular arrhythmias when arsenic trioxide given with • HALOPERIDOL; avoid concomitant use with • CLOzapine (increased risk of agranulocytosis)
- Beta-blockers: increased risk of ventricular arrhythmias when arsenic trioxide given with • SOTALOL
- Cytotoxics: possible increased risk of ventricular arrhythmias when arsenic trioxide given with • RIFAMPICIN
- Diuretics: risk of ventricular arrhythmias with arsenic trioxide increased by hypokalaemia caused by • ACETAZOLAMIDE, • LOOP DIURETICS or • THIAZIDES AND RELATED DIURETICS
- Lithium: increased risk of ventricular arrhythmias when arsenic trioxide given with • LITHIUM

Antibacterials
- Anti-arrhythmics: increased risk of ventricular arrhythmias when antibacterials given with intravenous • DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of ventricular arrhythmias when antibacterials given with • KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when antibacterials given with • APIXABAN, • DABIGATRAN and • RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)

Betablockers
- Anti-arrhythmics: increased risk of ventricular arrhythmias when antibacterials given with intravenous • DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when antibacterials given with • KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when antibacterials given with • APIXABAN, • DABIGATRAN and • RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)

Beta-blockers
- Anti-arrhythmics: increased risk of ventricular arrhythmias when antibacterials given with intravenous • DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when antibacterials given with • KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when antibacterials given with • APIXABAN, • DABIGATRAN and • RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)

Betablockers
- Anti-arrhythmics: increased risk of ventricular arrhythmias when antibacterials given with intravenous • DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when antibacterials given with • KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when antibacterials given with • APIXABAN, • DABIGATRAN and • RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)
Artemisinin with Piperazine (continued)

- Histamine: avoidance of antimalarials advised by manufacturer of histamine
- Pentamidine i.e.sionate: manufacturer of artemisinin with piperazine advises avoid concomitant use with
  - Pentamidine i.e.sionate (possible risk of ventricular arrhythmias)
- Vaccines: antimalarials inactivate oral typhoid vaccine—see under typhoid vaccine in BNF

Antacid acid see Vitamins

Asenapine see Antipsychotics

Aspirin

- Adsorbtion: absorption of aspirin possibly reduced by kaolin
- Anaesthetics: General: aspirin possibly enhances effects of thiopental
- Analgesics: avoid concomitant use of aspirin with NSAIDs (increased side-effects); antiplatelet effect of aspirin possibly reduced by ibuprofen
- Antacids: excretion of aspirin increased by alkaline urine due to some antacids
- Anticoagulants: increased risk of bleeding when aspirin given with coumarins or phenindione (due to antiplatelet effect); aspirin enhances anticoagulant effect of heparins
- Antidepressants: increased risk of bleeding when aspirin given with SSRIs or venlafaxine
- Anti-epileptics: aspirin enhances effects of fosphenytoin, phenytoin, sodium valproate and valproic acid
- Clopidogrel: increased risk of bleeding when aspirin given with clopidogrel
- Corticosteroids: increased risk of gastrointestinal bleeding and ulceration when aspirin given with corticosteroids, also corticosteroids reduce plasma concentration of salicylate
- Cytotoxics: aspirin reduces excretion of methotrexate (increased risk of toxicity); aspirin possibly reduces renal excretion of gemcitabine—consult product literature
- Diuretics: increased risk of toxicity when high-dose aspirin given with acetazolamide; aspirin antagonises diuretic effect of spironolactone; possible increased risk of toxicity when high-dose aspirin given with loop diuretics (also possible reduced effect of loop diuretics)
- Iloprost: increased risk of bleeding when aspirin given with iloprost
- Leukotriene receptor antagonists: aspirin increases plasma concentration of zafirlukast
- Metoclopramide: rate of absorption of aspirin increased by metoclopramide (enhanced effect)
- Sulfapyrazine: aspirin antagonises effects of sulfapyrazine

Atazanavir

- Antacids: absorption of atazanavir reduced by antacids (give at least 2 hours before or 1 hour after antacids; consult fesoterodine product literature)
- Anti-arrhythmics: atazanavir possibly increases plasma concentration of amiodarone and lidocaine
- Antibacterials: plasma concentration of both drugs increased when atazanavir given with clarithromycin; atazanavir increases plasma concentration of rifabutin (reduce dose of rifabutin); plasma concentration of atazanavir reduced by rifampicin—avoid concomitant use; avoidance of concomitant atazanavir in severe renal and hepatic impairment advised by manufacturer of telithromycin
- Anti-cancer agents: atazanavir may enhance or reduce anticoagulant effect of warfarin; avoidance of atazanavir advised by manufacturer of apixaban and rivaroxaban
- Antidepressants: plasma concentration of atazanavir reduced by St John's Wort—avoid concomitant use
- Antifungals: plasma concentration of atazanavir increased by posaconazole; atazanavir increases or decreases the plasma concentration of voriconazole and plasma concentration of atazanavir also reduced
- Antimalarials: caution with atazanavir advised by manufacturer of artemether with lumefantrine; atazanavir possibly increases plasma concentration of quinine (increased risk of toxicity)
- Antimuscarinics: avoidance of atazanavir advised by manufacturer of darifenacin; manufacturer of fosoterodine advises dose reduction when atazanavir given with fosoterodine—consult fosoterodine product literature
- Antipsychotics: atazanavir possibly increases plasma concentration of aripiprazole (reduce dose of aripiprazole—consult aripiprazole product literature); atazanavir possibly increases plasma concentration of pimozone—avoid concomitant use; atazanavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use
- Antivirals: plasma concentration of atazanavir reduced by boceprevir; atazanavir increases the plasma concentration of daclatasvir—reduce dose of daclatasvir (see under daclatasvir, p. 544); absorption of atazanavir reduced by didanosine tablets (give at least 2 hours before or 1 hour after didanosine tablets); manufacturer of atazanavir advises avoid concomitant use with efavirenz (plasma concentration of atazanavir reduced); atazanavir boosted with ritonavir increases plasma concentration of elvitegravir (reduce dose of elvitegravir); avoid concomitant use of atazanavir with indinavir; atazanavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc); plasma concentration of atazanavir possibly reduced by nevirapine—avoid concomitant use; increased risk of ventricular arrhythmias when atazanavir given with saquinavir—avoid concomitant use; atazanavir possibly reduces plasma concentration of telaprevir, also plasma concentration of atazanavir possibly increased; plasma concentration of atazanavir reduced by tenofovir, also plasma concentration of tenofovir possibly increased; atazanavir increases plasma concentration of tipranavir (also plasma concentration of atazanavir reduced)
- Antioxidants and Hypotensives: atazanavir possibly increases plasma concentration of midazolam—avoid concomitant use of oral midazolam
- Avanafil: atazanavir possibly increases plasma concentration of avanafil—manufacturer of avanafil advises avoid concomitant use
- Calcium-channel blockers: atazanavir increases plasma concentration of diltiazem (reduce dose of diltiazem); atazanavir possibly increases plasma concentration of verapamil
- Ciclosporin: atazanavir possibly increases plasma concentration of ciclosporin
- Colchicine: atazanavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Cytotoxics: atazanavir possibly increases plasma concentration of axitinib (reduce dose of axitinib—consult axitinib product literature); atazanavir possibly increases the plasma concentration of bosutinib—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; atazanavir possibly increases plasma concentration of crizotinib and everolimus—manufacturer of crizotinib and everolimus advises avoid concomitant use; atazanavir possibly increases the plasma concentration of ibrutinib—reduce dose of ibrutinib (see under ibrutinib, p. 809); atazanavir possibly increases plasma concentration of pazopanib (reduce dose of pazopanib); avoidance of atazanavir advised by manufacturer of cabazitaxe; atazanavir possibly inhibits metabolism of rilotecan (increased risk of toxicity)
- Dapoxetine: avoidance of atazanavir advised by manufacturer of dapoxetine (increased risk of toxicity)
- Ergot alkaloids: atazanavir possibly increases plasma concentration of ergot alkaloids—avoid concomitant use
- Lipid-regulating drugs: possible increased risk of myopathy when atazanavir given with atorvastatin or pravastatin; atazanavir increases plasma concentration of rosuvastatin—adjust dose of rosuvastatin (consult product literature); increased risk of myopathy when atazanavir given with simvastatin (avoid concomitant use)
- Oestrogens: atazanavir increases plasma concentration of ethinylestradiol
- Orlistat: absorption of atazanavir possibly reduced by orlistat
- Progestogens: atazanavir increases plasma concentration of norethisterone
Atovaquone (continued)
- Ranolazine: Atovaquone possibly increases plasma concentration of RANOLAZINE—manufacturer of ranolazine advises avoid concomitant use.
- Sildenafil: Atovaquone possibly increases side-effects of SILDENAFIL.
- Sirolimus: Atovaquone possibly increases plasma concentration of SIROLIMUS.
- Tacrolimus: Atovaquone possibly increases plasma concentration of TACROLIMUS.
- Ticagrelor: Atovaquone possibly increases plasma concentration of TICAGRELOR—manufacturer of ticagrelor advises avoid concomitant use.
- Ulcer-healing Drugs: manufacturer of atovaquone advises adjust doses of both drugs when atazanavir given with Cimetidine and Nizatidine—consult atovaquone product literature; plasma concentration of atazanavir reduced by FAMOTIDINE and RANITIDINE (adjust doses of both drugs—consult atovaquone product literature); plasma concentration of atazanavir reduced by PROTON PUMP INHIBITORS—avoid or adjust dose of both drugs (consult product literature).
- Atenolol—see Beta-blockers.

Atovaquone
- Analgesics: Increased risk of venricular arrhytmias when atovaquone given with METHADONE; possible increased risk of convulsions when atovaquone given with TRAMADOL.
- Anti-arrhythmics: increased risk of venricular arrhythmmas when atovaquone given with AMIODARONE or DISOPYRAMIDE.
- Antibacterials: Increased risk of venricular arrhythmmas when atovaquone given with parenteral ETROTHROMYCIN; increased risk of venricular arrhythmmas when atovaquone given with MOXIFLOXACIN.
- Antidepressants: metabolism of atovaquone possibly inhibited by FLUOXETINE and PAROXETINE; possible increased risk of convulsions when atovaquone given with ANTIDEPRESSANTS; atovaquone should not be started until 2 weeks after stopping MAOIs, also MAOIs should not be started until at least 2 weeks after stopping atovaquone; increased risk of venricular arrhythmmas when atovaquone given with TRICYCLICS.
- Antimalarials: increased risk of venricular arrhythmmas when atovaquone given with MEFLOQUINE.
- Antipsychotics: increased risk of venricular arrhythmmas when atovaquone given with ANTIPSYCHOTICS that prolong the QT interval.
- Beta-blockers: increased risk of venricular arrhythmmas when atovaquone given with SOTALOL.
- Diuretics: possible increased risk of convulsions when atovaquone given with BUPROPION.
- Diuretics: risk of venricular arrhythmmas when atovaquone increased by hypokalaemia caused by DIURETICS.
- Sympathomimetics, Beta₂: Increased risk of cardiovascular side-effects when atovaquone given with parenteral SALBUTAMOL.

Avatrombostin see Statins.

Avatrombostin
- Antithromboses: manufacturer of avatrombostin advises avoid concomitant use with RIFABUTIN (plasma concentration of both drugs reduced); plasma concentration of avatrombostin reduced by Rifampicin (and concentration of rifampicin increased)—avoid concomitant use; plasma concentration of avatrombostin reduced by TETRACYCLINE.
- Antivirals: plasma concentration of avatrombostin reduced by EFAVIRENZ—avoid concomitant use; avatrombostin possibly reduces plasma concentration of INDINAVIR; plasma concentration of avatrombostin possibly reduced by RITONAVIR—manufacturer of avatrombostin advises avoid concomitant use; avatrombostin increases plasma concentration of ZIDOVUDINE (increased risk of toxicity).
- Cytostatics: avatrombostin possibly increases plasma concentration of ETOPOSIDE.
- Histamine: avoidance of avatrombostin advised by manufacturer of HISTAMINE.
- Metocalproamide: plasma concentration of avatrombostin reduced by METOCLOPRAMIDE—avoid concomitant use.

Atracurium see Muscle Relaxants.

Atropine see Antimuscarinics.

Avanafil
- ACE Inhibitors: avanafil possibly enhances hypotensive effect of ENALAPRIL.
- Alpha-blockers: enhanced hypotensive effect when avanafil given with ALPHA-BLOCKERS—when patient is stable on the alpha blocker initiate avanafil at the lowest possible dose.
- Antibacterials: plasma concentration of avanafil possibly increased by CLARITHROMYCIN and TELITHROMYCIN—manufacturer of avanafil advises avoid concomitant use; plasma concentration of avanafil increased by ERYTHROMYCIN—see under Avanafil, p. 698; plasma concentration of avanafil possibly reduced by RIFAMPICIN—manufacturer of avanafil advises avoid concomitant use.
- Anti-epileptics: plasma concentration of avanafil possibly reduced by CARBAMAZEPINE, PHENOBARBITAL and PRIMIDONE—manufacturer of avanafil advises avoid concomitant use.
- Antifungals: plasma concentration of avanafil increased by KETOCONAZOLE—avoid concomitant use; plasma concentration of avanafil possibly increased by FLUCONAZOLE—see under Avanafil, p. 698; plasma concentration of avanafil possibly increased by ITRACONAZOLE and VORICONAZOLE—manufacturer of avanafil advises avoid concomitant use.
- Antihistamines: Plasma concentration of avanafil possibly increased by RANITIDINE and NIZATIDINE (reduce dose of avanafil consult avanafil product literature).
- APREPITANT: plasma concentration of avanafil possibly increased by APREPITANT—see under Avanafil, p. 698.
- Bosentan: plasma concentration of avanafil significantly increased by Bosentan—manufacturer of avanafil advises avoid concomitant use.
- Calcium-channel Blocks: plasma concentration of avanafil possibly increased by DILTIAZEM and VERAPAMIL—see under Avanafil, p. 698.
- Fosaprepitant: plasma concentration of avanafil possibly increased by FOSAPREPITANT.
- Grapefruit Juice: plasma concentration of avanafil possibly increased by GRAPEFRUIT JUICE—manufacturer of avanafil advises avoid grapefruit juice for 24 hours before avanafil.
- Norendit: avanafil significantly enhances hypotensive effect of NITRATES (avoid concomitant use).
- Nitrate: avanafil significantly enhances hypotensive effect of NITRATES (avoid concomitant use).
- Riociguat: possible enhanced hypotensive effect when avanafil given with RIOCUIGHT—avoid concomitant use.

Axitinib
- Antibacterials: plasma concentration of axitinib possibly increased by CLARITHROMYCIN, ERYTHROMYCIN and TELITHROMYCIN (reduce dose of axitinib—consult axitinib product literature); plasma concentration of axitinib possibly decreased by RIFABUTIN (increase dose of axitinib—consult axitinib product literature); plasma concentration of axitinib decreased by RIFAMPICIN (increase dose of axitinib—consult axitinib product literature).
- Antidepressants: plasma concentration of axitinib possibly reduced by ST JOHN’S WORT—consider increasing dose of axitinib.
- Anti-epileptics: plasma concentration of axitinib possibly decreased by CARBAMAZEPINE, PHOSPHENITIN, PHENOBARBITAL and PHENOTIN and PRIMIDONE (increase dose of axitinib—consult axitinib product literature).
- Antifungals: plasma concentration of axitinib increased by KETOCONAZOLE (reduce dose of axitinib—consult axitinib product literature); plasma concentration of axitinib possibly decreased by KETONITIN.
Axitinib
Antifungals (continued)
increased by ITRACONAZOLE (reduce dose of axitinib—consult axitinib product literature)
▶ Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
▶ Antivirals: plasma concentration of axitinib possibly increased by ATAZANAVIR, INDINAVIR, RITONAVIR and SAQUINAVIR (reduce dose of axitinib—consult axitinib product literature)
Corticosteroids: plasma concentration of axitinib possibly decreased by DEXAMETHASONE (increase dose of axitinib—consult axitinib product literature)
Grapefruit Juice: plasma concentration of axitinib possibly increased by GRAPEFRUIT JUICE

Azathioprine
▶ ACE Inhibitors: increased risk of anaemia or leucopenia when azathioprine given with CAPTOPRIL especially in renal impairment; increased risk of anaemia when azathioprine given with ENALAPRIL especially in renal impairment
▶ Allepurinol: enhanced effects and increased toxicity of azathioprine when given with ALLOPURINOL (reduce dose of azathioprine to one quarter of usual dose)
▶ Antibacterials: increased risk of haematological toxicity when azathioprine given with SULFAMETHOXAZOLE (as co-trimoxazole); increased risk of haematological toxicity when azathioprine given with PIPERACILLIN (also with co-trimoxazole)
▶ Anticoagulants: azathioprine possibly reduces anticoagulant effect of COUMARINS
▶ Antivirals: myelosuppressive effects of azathioprine possibly enhanced by RIBAVIRIN
▶ Febuxostat: avoidance of azathioprine advised by manufacturer of FEBUXOSTAT

Azelastine see Antihistamines
Azilsartan see Angiotensin-II Receptor Antagonists
Azithromycin see Macrolides
Aztreonam
▶ Anticoagulants: aztreonam possibly enhances anticoagulant effect of COUMARINS
▶ Antibacterials: myelosuppressive effects of azithromycin possibly enhanced by RIBAVIRIN
▶ Febuxostat: avoidance of azathioprine advised by manufacturer of FEBUXOSTAT

Baclofen see Muscle Relaxants
Bambuterol see Sympathomimetics, Beta₂
Basiliximab
▶ Antibacterials: increased risk of generalised infections when monoclonal antibodies given with live VACCINES—avoid concomitant use

BCG Vaccine see Vaccines
Beclometasone see Corticosteroids
Bedaquiline
▶ Antivirals: plasma concentration of bedaquiline possibly increased by CIPROFLOXACIN, CLARITHROMYCIN and ERYTHROMYCIN—avoid concomitant use if ciprofloxacin, clarithromycin and erythromycin given for more than 14 days; manufacturer of bedaquiline advises avoid concomitant use with MOXIFLOXACIN; plasma concentration of bedaquiline possibly reduced by RIFABUTIN—manufacturer of bedaquiline advises avoid concomitant use; plasma concentration of bedaquiline reduced by RIFAMPICIN—manufacturer of bedaquiline advises avoid concomitant use; plasma concentration of bedaquiline possibly increased by posaconazole—risk increase of ventricular arrhythmias when bedaquiline given with CLOFAZIME
▶ Antidepressants: plasma concentration of bedaquiline possibly reduced by ST JOHN’S WORT—manufacturer of bedaquiline advises avoid concomitant use
▶ Antiepileptics: plasma concentration of bedaquiline possibly reduced by CARBAMAZEPINE, FOSFENOPYRON and PHENYTOIN—manufacturer of bedaquiline advises avoid concomitant use
▶ Antifungals: plasma concentration of bedaquiline increased by KETOCONAZOLE—avoid concomitant use if ketoconazole given for more than 14 days; plasma concentration of bedaquiline possibly increased by FLUCONAZOLE—avoid concomitant use if fluconazole given for more than 14 days

Bedaquiline (continued)
▶ Antivirals: plasma concentration of bedaquiline possibly reduced by EFAVIRENZ and ETRAVIRINE—manufacturer of bedaquiline advises avoid concomitant use; plasma concentration of bedaquiline possibly increased by RITONAVIR—avoid concomitant use if ritonavir given for more than 14 days
▶ Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Bee Venom Extracts
▶ ACE Inhibitors: possible severe anaphylactoid reaction when bee venom extracts given with ACE INHIBITORS

Belimumab
▶ Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
▶ Vaccines: risk of generalised infections when monoclonal antibodies given with live VACCINES—avoid concomitant use

Bendamustine
▶ Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
▶ Bendroflumethiazide see Diuretics
Benperidol see Antipsychotics
Benzodiazepines see Anxiolytics and Hypnotics
Benzthiazide see Diuretics
Benzylpenicillin see Penicillins
Beta-blockers
NOTE Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind
▶ ACE Inhibitors: enhanced hypotensive effect when beta-blockers given with ACE INHIBITORS
▶ Adrenergic Neurone Blockers: enhanced hypotensive effect when beta-blockers given with ADRENERGIC NEURONE BLOCKERS
▶ Alcohol: enhanced hypotensive effect when beta-blockers given with ALCOHOL
▶ Aldesleukin: enhanced hypotensive effect when beta-blockers given with ALDESLEUKIN
▶ Alpha-blockers: enhanced hypotensive effect when beta-blockers given with ALPHA-BLOCKERS, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin
▶ Anaesthetics, General: enhanced hypotensive effect when beta-blockers given with GENERAL ANAESTHETICS
▶ Anaesthetics, Local: propranolol increases risk of BUPIVACAINE toxicity
▶ Analgesics: hypotensive effect of beta-blockers antagonised by NSAIDS; plasma concentration of esmolol possibly increased by MORPHINE
▶ Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when beta-blockers given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
▶ Anti-arrhythmics: increased myocardial depression when beta-blockers given with ANTI-ARRHYTHMICS; increased risk of ventricular arrhythmias when sotalol given with AMIODARONE, DISOPYRAMIDE or DRONERADONE; increased risk of myocardial depression and bradyarrhythmia when beta-blockers given with AMIODARONE; plasma concentration of metoprolol and propranolol possibly increased by DRONERADONE; increased risk of myocardial depression when beta-blockers given with AMIODARONE; plasma concentration of metoprolol and propranolol possibly increased by DRONERADONE; increased risk of myocardial depression and bradyarrhythmia when beta-blockers given with FLECAINIDE; propranolol increases risk of LIDOCAINE toxicity; nadolol possibly increases risk of LIDOCAINE toxicity; plasma concentration of metoprolol and propranolol increased by PROPafenONE
▶ Antibacterials: increased risk of ventricular arrhythmias when sotalol given with MOXIFLOXACIN—avoid concomitant use; metabolism of bisoprolol and propranolol accelerated by RIFAMPICIN (plasma concentration significantly reduced); plasma concentration of carvedilol, celiprolol and metoprolol reduced by RIFAMPICIN; plasma concentration of oral timolol possibly reduced by RIFAMPICIN; increased risk of ventricular arrhythmias when sotalol given with DELAMANID
▶ Antidepressants: plasma concentration of metoprolol increased by CITALOPRAM and ESCITALOPRAM; Increased risk of
Beta-blockers  
- Antidepressants (continued)  
  ventricular arrhythmias when sotalol given with  
  CITALOPRAM—avoid concomitant use; avoidance of sotalol advised by manufacturer of  
  ESCITALOPRAM (risk of ventricular arrhythmias); plasma concentration of propranolol increased by FLUOXETINE; plasma concentration of metoprolol possibly increased by  
  PAROXETINE—increased risk of AV block (manufacturer of paroxetine advises avoid concomitant use in cardiac insufficiency); avoidance of sotalol advised by manufacturer of  
  ARTEMETH with LUMEFANTRINE; avoidance of sotalol advised by manufacturer of  
  ARTEMOL with PIPERAQUINE (possible risk of ventricular arrhythmias); increased risk of bradycardia when beta-blockers with  
  MEfloquine  
- Antimicrobials: increased risk of ventricular arrhythmias when sotalol given with  
  TOLERTODINE  
- Antipsychotics: increased risk of ventricular arrhythmias when sotalol given with  
  DROPERIDOL or  
  ZUCLOPENTHIXOL—avoid concomitant use; possible increased risk of ventricular arrhythmias when sotalol given with  
  HALOPERIDOL—avoid concomitant use; plasma concentration of both drugs may increase when propranolol given with  
  CHLORPROMAZINE; plasma concentration of sotalol increased by  
  Amsulpride, Phenothisaines, Pimozide or  
  Sulpride; enhanced hypotensive effect when beta-blockers given with  
  Phenothiazines; possible increased risk of ventricular arrhythmias when sotalol given with  
  Risperidone  
- Antivirals: increased risk of ventricular arrhythmias when sotalol given with  
  Aquamir—avoid concomitant use; avoidance of sotalol advised by manufacturer of  
  Telaprevir (risk of ventricular arrhythmias); avoidance of metoprolol for heart failure advised by manufacturer of  
  Tiranavir  
- Anxiolytics and Hypnotics: enhanced hypotensive effect when beta-blockers with  
  Baclofen, Carbimazepine or  
  Sedative and hypnotic; enhanced hypotensive effect when beta-blockers given with  
  Phenothiazines; possible increased risk of ventricular arrhythmias when sotalol given with  
  Atamoxetine  
- Calcium-channel Blockers: enhanced hypotensive effect when beta-blockers given with  
  Calcium-channel Blockers; possible severe hypotension and heart failure when beta-blockers given with  
  Nifedipine; increased risk of AV block and bradycardia when beta-blockers given with  
  Diltaizem; asystole, severe hypotension and heart failure when beta-blockers given with  
  Verapamil (see under Verapamil, p. 156);  
- Cardiac Glycosides: increased risk of AV block and bradycardia when beta-blockers given with  
  Ciclosporin: carvedilol increases plasma concentration of  
  Cyclosporin  
- Ciclosporin  
- Clonidine: increased risk of withdrawal hypertension when beta-blockers given with  
  Clonidine (withdraw beta-blockers several days before slowly withdrawing clonidine)  
- Corticosteroids: hypotensive effect of beta-blockers antagonised by  
  Corticosteroids  
- Cytosine: possible increased risk of ventricular arrhythmias when sotalol given with  
  Bosutinib; possible increased risk of bradycardia when beta-blockers given with  
  Crizotinib; possible increased risk of ventricular arrhythmias when sotalol given with  
  Vandetanib—avoid concomitant use; increased risk of ventricular arrhythmias when sotalol given with  
  Arsenic trioxide  

Beta-blockers  
- Diazoxide: increased hypotensive effect when beta-blockers given with  
- Diuretics: enhanced hypotensive effect when beta-blockers given with  
- Diuretics; risk of ventricular arrhythmias with sotalol increased by  
- Hypokalaemia caused by  
- Loop diuretics or  
- Thiazides and Related Diuretics  
- Dopaminergics: enhanced hypotensive effect when beta-blockers given with  
  CO-Beveldopa, Co-Careldopa or Lepdova  
- Ergot Alkaloids: increased peripheral vasoconstriction when beta-blockers given with  
  Ergotamine  
- Fingolimod: possible increased risk of bradycardia when beta-blockers given with  
  Fingolimod  
- Hormone Antagonists: possible increased risk of bradycardia when  
  Catechol, Metoprolol, Pranolol or sotalol given with  
  Pasireotide  
- SH2-receptor Agonists: propranolol increases plasma concentration of  
  RizatRIPTAN (manufacturer of rizatRIPTAN advises half dose and avoid within 2 hours of propranolol)  
- Ibradine: increased risk of ventricular arrhythmias when sotalol given with  
- Methyldopa: enhanced hypotensive effect when beta-blockers given with  
  Mirabegron: plasma concentration of metoprolol increased by  
- Moxisylyte: possible severe postural hypotension when beta-blockers given with  
- Moxisylyte  
- Moxonidine: enhanced hypotensive effect when beta-blockers given with  
- Muscle Relaxants: propranolol enhances effects of  
- Muscle Relaxants; enhanced hypotensive effect when beta-blockers given with  
- Nitrates: enhanced hypotensive effect when beta-blockers given with  
- Nitrates  
- Oestrogens: hypotensive effect of beta-blockers antagonised by  
- Neostigmine and Pyridostigmine; increased risk of  
  Nifedipine, Ranolazine  
- Prostaglandins: enhanced hypotensive effect when beta-blockers given with  
- Ranolazine: advice of sotalol given by manufacturer of  
- Ranolazine  
- Symptomimetics: increased risk of severe hypertension and  
- Adrenaline (epinephrine), also response to adrenaline (epinephrine) may be reduced; increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers with  
- Dobutamine; possible increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers with  
- Noradrenaline (norepinephrine)  
- Thyroid Hormones: metabolism of propranolol accelerated by  
- Ulcer-healing Drugs: plasma concentration of labetalol, metoprolol and propranolol increased by  
- Cimetidine; plasma concentration of  
- Orlistol possibly increased by  
- Cimetidine  
- Vasodilator Antihypertensives: enhanced hypotensive effect when beta-blockers given with  
- Hydralazine, Minoxidil or  
- Sodium Nitroprusside  

Beta-histine  
- Antihistamines: effect of betahistine theoretically antagonised by  
- Betamethasone see Corticosteroids  
- Betaxolol see Beta-blockers  

Beta-nechanol see Parasympathomimetics  

Bevacizumab  
- Antipsychotics: avoid concomitant use of cytotoxics with  
- Cytotoxics: increased risk of agranulocytosis)  
- Vaccines: risk of generalised infections when monoclonal antibodies given with live  
- Vaccines—avoid concomitant use  

Beaxorone  
- Antipsychotics: avoid concomitant use of cytotoxics with  
- Cytotoxics: increased risk of agranulocytosis)
Boceprevir (continued)
- Antipsychotics: boceprevir possibly increases plasma concentration of lurasidone—avoid concomitant use; manufacturer of boceprevir advises avoid concomitant use with lopinavir; boceprevir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use
- Antivirals: boceprevir reduces plasma concentration of atazanavir; boceprevir possibly increases the plasma concentration of daclatasvir—reduce dose of daclatasvir (see under Daclatasvir, p. 544); avoid concomitant use of boceprevir with darunavir; effects of both drugs possibly reduced when boceprevir given with etravirine; avoidance of boceprevir advised by manufacturer of fosamprenavir, nevirapine and tipranavir; manufacturers advise avoid concomitant use of boceprevir with lopinavir; boceprevir increases plasma concentration of maraviroc (consider reducing dose of maraviroc); plasma concentration of both drugs reduced when boceprevir given with ritonavir
- Anxiolytics and Hypnotics: boceprevir increases plasma concentration of oral midazolam—manufacturer of boceprevir advises avoid concomitant use
- Cardio Glycosides: boceprevir possibly increases side-effects of digoxin
- Ciclosporin: boceprevir increases plasma concentration of ciclosporin
- Cilostazol: boceprevir possibly increases plasma concentration of cilostazol (see under Cilostazol, p. 206)
- Cobicistat: avoidance of boceprevir advised by manufacturer of cobicistat
- Cytotoxics: boceprevir possibly increases the plasma concentration of bosutinib—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; manufacturer of boceprevir advises avoid concomitant use with dasatinib, erlotinib, geftinib, imatinib, lapatinib, nilotinib, pazopanib, sorafenib and sunitinib; manufacturer of ruxolitinib advises dose reduction when boceprevir given with ruxolitinib—consult ruxolitinib product literature
- Domeridone: possible increased risk of ventricular arrhythmias when boceprevir given with domperidone—avoid concomitant use
- Ergot Alkaloids: manufacturer of boceprevir advises avoid concomitant use with ergot alkaloids
- Lipid-regulating Drugs: boceprevir increases plasma concentration of atorvastatin (reduce dose of atorvastatin); boceprevir increases plasma concentration of pravastatin; manufacturers advise avoid concomitant use of boceprevir with simvastatin
- Progestogens: boceprevir increases plasma concentration of drospirenone (increased risk of toxicity)
- Sirolimus: boceprevir increases plasma concentration of sirolimus (increased risk of toxicity—reduce sirolimus dose)
- Tacrolimus: boceprevir increases plasma concentration of tacrolimus (reduce dose of tacrolimus)

Bosentan
- Antibacterials: plasma concentration of bosentan reduced by rifampicin—manufacturer of bosentan advises avoid concomitant use
- Antidepressants: plasma concentration of bosentan possibly reduced by dexamethasone—manufacturer of bosentan advises avoid concomitant use
- Antiepileptics: plasma concentration of bosentan possibly reduced by dexamethasone—manufacturer of bosentan advises avoid concomitant use
- Antifungals: plasma concentration of bosentan reduced by ketoconazole—manufacturer of bosentan advises avoid concomitant use with antifungals, ketoconazole, clotrimazole, fluconazole
- Antimalarials: manufacturer of bosentan monitors antimalarial effect of chloroquine
Bosentan (continued)

● Antidiabetics: increased risk of hepatotoxicity when bosentan given with • GLIBENCLAMIDE—avoid concomitant use
● Antibacterials: reduced plasma concentration of bosentan increased by • KETOCONAZOLE; plasma concentration of bosentan possibly increased by • FLUCONAZOLE—avoid concomitant use; plasma concentration of bosentan possibly increased by • ITRACONAZOLE
● Antivirals: avoidance of bosentan advised by manufacturer of ETV ENGRAVIR and TIPRANAVIR; bosentan possibly reduces plasma concentration of • INDINAVIR; plasma concentration of bosentan increased by • LOPINAVIR and • RITONAVIR (consider reducing dose of bosentan); bosentan possibly reduces plasma concentration of • TELAPREVIr, also plasma concentration of bosentan possibly increased

● Avanafil: bosentan possibly reduces plasma concentration of • AVANAFIL —manufacturer of avanafil advises avoid concomitant use
● Ciclosporin: plasma concentration of bosentan increased by • CICLOSPORIN (also plasma concentration of ciclosporin reduced—avoid concomitant use)
● Cobicistat: avoidance of bosentan advised by manufacturer of COBI CI STAT
● Cytoxotics: bosentan possibly reduces plasma concentration of • BOSENTAN—manufacturer of bosentan advises avoid concomitant use
● Lipid-regulating Drugs: bosentan reduces plasma concentration of • SIMVASTATIN
● Oestrogens: bosentan possibly causes contraceptive failure of hormonal contraceptives containing • OESTROژENS (alternative contraception recommended)
● Progestogens: bosentan possibly causes contraceptive failure of hormonal contraceptives containing • PROGESTOژENS (alternative contraception recommended)
● Ranitidine: bosentan reduces plasma concentration of • RANITIDINE
● Sildenafil: bosentan reduces plasma concentration of • SILDENAFIL, also plasma concentration of bosentan increased
● Tadalafil: bosentan reduces plasma concentration of • TADALAFIL

Bosutinib

● Analgesics: possible increased risk of ventricular arrhythmias when bosutinib given with • METHADONE
● Antacids: manufacturer of bosutinib advises separating administration with • ANTACIDS by about 12 hours
● Anti-arrhythmics: possible increased risk of ventricular arrhythmias when bosutinib given with • AMIODARONE and • DISOPYRAMIDE; plasma concentration of bosutinib possibly increased by • DRONEDARONE—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib
● Antihypertensives: plasma concentration of bosutinib possibly increased by • CIPROFLOXACIN, • CLARITHROMYCIN, • ERYTHROMYCIN and • TELITHROMYCIN—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; possible increased risk of ventricular arrhythmias when bosutinib given with • MOXIFLOXACIN; plasma concentration of bosutinib possibly reduced by • RIFABUTIN—manufacturer of bosutinib advises avoid concomitant use; plasma concentration of bosutinib reduced by • RIFAMPICIN—manufacturer of bosutinib advises avoid concomitant use
● Antidepressants: plasma concentration of bosutinib possibly reduced by • ST JOHN’S WORT—manufacturer of bosutinib advises avoid concomitant use
● Antiepileptics: plasma concentration of bosutinib possibly reduced by • CARBAMAZEPINE, • FOSPHENYTOIN, • PHENOBARBITAL, • PHENYTOIN and • PRIMIDONE—manufacturer of bosutinib advises avoid concomitant use
● Antifungals: plasma concentration of bosutinib increased by • KETOCONAZOLE—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; plasma concentration of bosutinib possibly increased by • FLUCONAZOLE, • ITRACONAZOLE, • POSACONAZOLE and • VORICONAZOLE—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib
● Antimalarials: possible increased risk of ventricular arrhythmias when bosutinib given with • CHLOROQUINE and • HYDROXYCHLOROQUINE

Bosutinib (continued)

● Antipsychotics: possible increased risk of ventricular arrhythmias when bosutinib given with • HALOPERIDOL; avoid concomitant use of cytoxotics with • CLOZAPINE (increased risk of agranulocytosis)
● Antibacterials: plasma concentration of bosutinib possibly increased by • ATAZANAVIR, • BOCEPREVIr, • DARUNAVIR, • FOSAMPRENAVIR, • INDINAVIR, • RITONAVIR, • SAQUINAVIR and • TELAPREVIr—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; plasma concentration of bosutinib possibly reduced by • EFAVIRENZ and • STRAVINE —manufacturer of bosutinib advises avoid concomitant use
● Aprepitant: plasma concentration of bosutinib possibly increased by • APREPIrant—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib
● Beta-blockers: possible increased risk of ventricular arrhythmias when bosutinib given with • SOTALOL
● Bosentan: plasma concentration of bosutinib possibly reduced by • BOSENTAN—manufacturer of bosutinib advises avoid concomitant use
● Calcium-channel Blockers: plasma concentration of bosutinib possibly increased by • DILTIAZEM and • VERAPAMIL—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib
● Cytoxotics: plasma concentration of bosutinib possibly increased by • MATINIB—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib
● Domperidone: manufacturer of bosutinib advises avoid concomitant use with • DOMPERIDONE (risk of ventricular arrhythmias)
● Fosaprepitant: plasma concentration of bosutinib possibly increased by • FOSAPREPIrant—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib
● Grapefruit juice: plasma concentration of bosutinib possibly increased by • GRAPEFRUIT JUICE—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib
● Modafinil: plasma concentration of bosutinib possibly reduced by • MODAFINIL—manufacturer of bosutinib advises avoid concomitant use
● Ulcer-healing Drugs: plasma concentration of bosutinib reduced by • Lansoprazole

Brentuximab vedotin

● Antibacterials: effects of brentuximab vedotin possibly reduced by • RIFAMPICIN
● Antibacterials: possible increased risk of neutropenia when brentuximab vedotin given with • KETOCONAZOLE
● Antipsychotics: avoid concomitant use of cytoxotics with • CLOZAPINE (increased risk of agranulocytosis)
● Cytoxotics: increased risk of pulmonary toxicity when brentuximab vedotin given with • BLEOMYCIN—avoid concomitant use
● Vaccines: risk of generalised infections when monoclonal antibodies given with live • VACCINES—avoid concomitant use

Brimonidine

● Antidepressants: manufacturer of brimonidine advises avoid concomitant use with • MAOIS, TRICYCLIC-RELATED ANTIDEPRESSANTS and TRICYCLICS

Brinzolamide see Diuretics

Bronocaprine

● Alcohol: tolerance of bromocaprine reduced by • ALCOHOL
● Antidepressants: plasma concentration of bromocaprine increased by • ERYTHROMYCIN (increased risk of toxicity); plasma concentration of bromocaprine possibly increased by • MACROLIDES (increased risk of toxicity)
● Antipsychotics: hyperprolactinemic and antiparkinsonian effects of bromocaprine antagonised by • ANTIpsYCHOTICS
● Domperidone: hyperprolactinemic effect of bromocaprine possibly antagonised by • DOMPERIDONE
● Hormone Antagonists: plasma concentration of bromocaprine increased by • OCTREOTIDE
● Memantine: effects of dopaminergic possibly enhanced by • MEMANTINE
● Methyldopa: antiparkinsonian effect of dopaminergic antagonised by • METHYLDOPA
● Metoclopramide: hyperprolactinemic effect of bromocaprine antagonised by • METOCLOPRAMIDE
Bromocriptine (continued)
- sympathomimetics: risk of toxicity when bromocriptine given with isometheptene

Buclizine see Antihistamines
Budesonide see Corticosteroids
Bumetanide see Diuretics
Bupivacaine
- anti-arrhythmics: increased myocardial depression when bupivacaine given with anti-arrhythmics
- beta-blockers: increased risk of bupivacaine toxicity given with propranolol

Buprenorphine see Opioid Analgesics

Bupropion
- antidepressants: bupropion possibly increases plasma concentration of citalopram; manufacturer of bupropion advises avoid concomitant use with saois; manufacturer of bupropion advises avoid concomitant use with moclobemide; bupropion possibly increases plasma concentration of tricyclics (possible increased risk of convulsions)
- antidepressants: plasma concentration of bupropion reduced by carbamazepine, fosphenytoin and phenytoin; metabolism of bupropion inhibited by sodium valproate and valproic acid
- antivirals: metabolism of bupropion accelerated by efavirenz (reduced plasma concentration); plasma concentration of bupropion reduced by ritonavir
- atomoxetine: possible increased risk of convulsions when bupropion given with atomoxetine
- dopaminergics: increased risk of side-effects when bupropion given with amantadine, co-beneldopa, co-careldopa or levodopa
- hormone antagonists: bupropion possibly inhibits metabolism of tamoxifen to active metabolite (avoid concomitant use)
- methylthioninium: possible risk of CNS toxicity when bupropion given with methylthioninium—avoid concomitant use (if avoidance not possible, use lowest possible dose of methylthioninium and observe patient for up to 4 hours after administration)

Buspirone see Anxiolytics and Hypnotics
Busulfan
- analgesics: metabolism of intravenous busulfan possibly inhibited by paracetamol (manufacturer of intravenous busulfan advises caution within 72 hours of paracetamol)
- antibacterials: plasma concentration of busulfan increased by metronidazole (increased risk of toxicity)
- antidepressants: plasma concentration of busulfan possibly reduced by fosphenytoin and phenytoin
- antifungals: metabolism of busulfan inhibited by itraconazole (increased risk of toxicity)
- antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)
- cytoxotics: increased risk of hepatotoxicity when busulfan given with tioguanine

Butyrophenones see Antipsychotics
Cabazitaxel
- antibacterials: plasma concentration of cabazitaxel possibly increased by clarithromycin and telithromycin—manufacturer of cabazitaxel advises avoid or consider reducing dose of cabazitaxel; manufacturer of cabazitaxel advises avoid concomitant use with rifabutin; plasma concentration of cabazitaxel reduced by rifampicin—manufacturer of cabazitaxel advises avoid concomitant use
- antidepressants: manufacturer of cabazitaxel advises avoid concomitant use with st john’s wort
- antiepileptics: manufacturer of cabazitaxel advises avoid concomitant use with ketoconazole; plasma concentration of cabazitaxel possibly increased by itraconazole and voriconazole—manufacturer of cabazitaxel advises avoid or consider reducing dose of cabazitaxel
- antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Cabergoline
- antibacterials: plasma concentration of cabergoline increased by erythromycin (increased risk of toxicity); plasma concentration of cabergoline possibly increased by macrolides (increased risk of toxicity)
- antipsychotics: hypnotolactamine and antiparkinsonian effects of cabergoline antagonised by antipsychotics
- Dopemidone: hypnotolactamine effect of cabergoline possibly antagonised by memantine
- methylidopa: antiparkinsonian effect of dopaminergics antagonised by methylidopa
- Metoclopramide: hypoprolactinaemic effect of cabergoline antagonised by metoclopramide

Cabozaartinib
- antibacterials: plasma concentration of cabozantinib possibly increased by clarithromycin and erythromycin; plasma concentration of cabozantinib reduced by rifampicin—avoid concomitant use
- antidepressants: plasma concentration of cabozantinib possibly reduced by st john’s wort—manufacturer of cabozantinib advises avoid concomitant use
- antiepileptics: plasma concentration of cabozantinib possibly reduced by carbamazepine, fosphenytoin, phenytoin, phenobarbital, phenytion and primidone—avoid concomitant use
- antifungals: plasma concentration of cabozantinib increased by ketoconazole; plasma concentration of cabozantinib possibly increased by itraconazole
- antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Caffeine citrate
- aminophylline: manufacturer of caffeine citrate advises avoid concomitant use with aminophylline
- anti-arrhythmics: caffeine citrate antagonises anti-arrhythmic effect of adenosine—manufacturer of adenosine advises avoid caffeine citrate for at least 12 hours before adenosine
- antiepileptics: plasma concentration of caffeine citrate reduced by fosphenytoin and phenytoin; caffeine citrate possibly antagonises effects of phenobarbital and primidone
- theophylline: manufacturer of caffeine citrate advises avoid concomitant use with theophylline
- ulcer-healing Drugs: plasma concentration of caffeine citrate increased by cimetidine

Calcitriol see Vitamins
Calcium Salts
Note see also Antacids
- antibacterials: calcium salts reduce absorption of ciprofloxacin and tetracycline
- antivirals: calcium salts reduce absorption of dolutegravir—manufacturer of dolutegravir advises give at least 2 hours before or 6 hours after calcium salts; manufacturer of rilpivirine advises give calcium salts 2 hours before or 4 hours after rilpivirine
- bisphosphonates: calcium salts reduce absorption of bisphosphonates
- cardiac glycosides: large intravenous doses of calcium salts can precipitate arrhythmias when given with cardiac glycosides
- corticosteroids: absorption of calcium salts reduced by corticosteroids
Appendix 1 Interactions

Calcium-channel Blockers

**Calcium-channel Blockers**

- **Alpha-blockers:** verapamil increases plasma concentration of TAMSULOSIN; enhanced hypotensive effect when calcium-channel blockers given with **general anaesthetics** (also AV delay)
- **Analgesics:** hypotensive effect of calcium-channel blockers antagonised by NSAIDS; diltiazem inhibits metabolism of ALFENTANIL (risk of prolonged or delayed respiratory depression)
- **Angiotensin-II Receptor Antagonists:** enhanced hypotensive effect when calcium-channel blockers given with **general anaesthetics**
- **Anti-arrhythmics:** increased risk of bradycardia, AV block and myocardial depression when diltiazem or verapamil given with **midodrine**; increased risk of myocardial depression and asystole when verapamil given with **disopyramide** or **flecainide**; increased risk of bradycardia and myocardial depression when diltiazem and verapamil given with **dronedarone**; nifedipine increases plasma concentration of **dronedarone**
- **Antibacterials:** metabolism of calcium-channel blockers possibly inhibited by **ciprofloxacin**, **erythromycin** and **telithromycin** (increased risk of side-effects); manufacturer of lercanidipine advises avoid concomitant use with **erythromycin**
- **Anticoagulants:** verapamil possibly increases plasma concentration of **dabigatran** (see under Dabigatran Etxedilate, p. 117)
- **Antidepressants:** metabolism of nifedipine possibly inhibited by **fluoxetine** (increased plasma concentration); diltiazem and verapamil increase plasma concentration of **imipramine**
- **Antiepileptics:** increased risk of bradycardia and myocardial depression when diltiazem or verapamil given with **midodrine**; increased risk of hypotensive effect when calcium-channel blockers given with **maois**; plasma concentration of nifedipine possibly reduced by **st john's wort**; plasma concentration of amlodipine and felodipine possibly reduced by **st john's wort**; plasma concentration of verapamil significantly reduced by **st john's wort**; diltiazem and verapamil possibly increase plasma concentration of **tricyclics**
- **Antihistamines:** glucose tolerance occasionally impaired when nifedipine given with **insulin**
- **Antileukemics:** effects of dihydropriazines, nicardipine and nifedipine probably reduced by **carbamazepine**
- **Antimuscarinics:** verapamil possibly increases plasma concentration of **aliskiren**; diltiazem and verapamil possibly increase plasma concentration of **telmisartan**
- **Antithyroidal:** glucose tolerance occasionally impaired when nifedipine given with **insulin**
- **Antivirals:** possibly inhibited by **ritonavir**; caution with diltiazem, felodipine, nicardipine and nifedipine advised by manufacturer of **telaprevir**; plasma concentration of amlodipine increased by **telaprevir** (consider reducing dose of amlodipine)
- **Antioxidants:** enhanced hypotensive effect when calcium-channel blockers given with **anxiolytics and hypnotics**
- **Antipsychotics:** enhanced hypotensive effect when calcium-channel blockers given with **anxiolytics and hypnotics**

Calcium-channel Blockers (continued)

- **Cytoxics:** calcium salts increase absorption of **estramustine**
- **Diuretics:** increased risk of hypercalcaemia when calcium salts given with **thiazides and related diuretics**
- **Ertrombopag:** calcium salts possibly reduce absorption of **ertrombopag** (give at least 4 hours apart)
- **Fluorides:** calcium salts reduce absorption of **fluorides**
- **Iron salts:** calcium salts reduce absorption of **oral iron salts**
- **Thyroid hormones:** calcium salts reduce absorption of **Levothyroxine**
- **Zinc:** calcium salts reduce absorption of **zinc**

Calcium-channel Blockers (continued)

- **ACE inhibitors:** enhanced hypotensive effect when calcium-channel blockers given with **ACE inhibitors**
- **Alpha-blockers:** enhanced hypotensive effect when calcium-channel blockers given with **Adrenergic Neurone Blockers**
- **ACE inhibitors:** enhanced hypotensive effect when calcium-channel blockers given with **aliskiren**
- **Adrenergic Neurone Blockers:** enhanced hypotensive effect when calcium-channel blockers given with **aliskiren**
- **Aliskiren:** enhanced hypotensive effect when calcium-channel blockers given with **aliskiren**
- **Alcohol:** enhanced hypotensive effect when calcium-channel blockers given with **alcohol**; verapamil possibly increases plasma concentration of **alcohol**
- **Aldesleukin:** enhanced hypotensive effect when calcium-channel blockers given with **aldesleukin**
- **Amlodipine:** verapamil possibly increases plasma concentration of **amlodipine**
- **Antidepressants:** increased risk of bradycardia and myocardial depression when diltiazem or verapamil given with **amiodarone**
- **Antihistamines:** possibly inhibited by **ritonavir**; caution with diltiazem, felodipine, nicardipine and nifedipine advised by manufacturer of **telaprevir**; plasma concentration of amlodipine increased by **telaprevir** (consider reducing dose of amlodipine)
- **Antivirals:** enhanced hypotensive effect when calcium-channel blockers given with **anxiolytics and hypnotics**
- **Antipsychotics:** enhanced hypotensive effect when calcium-channel blockers given with **anxiolytics and hypnotics**
Interactions

Appendix 1 Interactions

Calcium-channel Blockers
- Beta-blockers (continued)
  - AV block and bradycardia when diltiazem given with β-BLOCKERS; asystole, severe hypotension and heart failure when verapamil given with β-BLOCKERS (see under Verapamil, p. 156); possible severe hypotension and heart failure when nifedipine given with β-BLOCKERS
- Calcium-channel Blockers: plasma concentration of both drugs may increase when diltiazem given with NIFEDIPINE
  - Nipride: diltiazem, lercanidine and nifedipine increase plasma concentration of DIGOXIN; verapamil increases plasma concentration of DIGOXIN, also increased risk of AV block and bradycardia; nifedipine possibly increases plasma concentration of DIGOXIN
- Ciclosporin: diltiazem, nicardipine and verapamil increase plasma concentration of CICLOSPORIN; combination of lercanidine with CICLOSPORIN may increase plasma concentration of either drug (or both)—avoid concomitant use; plasma concentration of nifedipine possibly increased by CICLOSPORIN (increased risk of toxicity including gingival hyperplasia)
- Clobazam: diltiazem increases plasma concentration of CLOBAZAM (consider reducing dose of clobazam)
- Clonidine: enhanced hypertensive effect when calcium-channel blockers are co-administered with CLONIDINE
- Colchicine: diltiazem and verapamil possibly increase risk of COLCHICINE toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Corticosteroids: hypertensive effect of calcium-channel blockers antagonised by CORTICOSTEROIDS; diltiazem increases plasma concentration of METHYLprednisolone
- Cytoxics: verapamil possibly increases plasma concentration of DOXORUBICIN; verapamil possibly increases the plasma concentration of AFA tinib—manufacturer of afatinib advises separating administration of verapamil by 6 to 12 hours; diltiazem and verapamil possibly increase the plasma concentration of BOSUTINIB—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; possible increased risk of bradycardia when diltiazem or verapamil given with EVEROLIMUS (consider reducing the dose of everolimus—consult everolimus product literature); diltiazem and verapamil possibly increase the plasma concentration of IBRUTINIB—reduce dose of ibritinib (see under ibritinib, p. 809); nifedipine possibly inhibits metabolism of VINCristine
  - Dapoxetine: manufacturer of dapoxetine advises dose reduction when diltiazem and verapamil given with DAPoxetine (see under Dapoxetine, p. 705)
  - Dazoxiben: enhanced hypertensive effect when calcium-channel blockers given with DIAZOXIDE
- Diuretics: enhanced hypertensive effect when calcium-channel blockers given with DIURETICS; diltiazem and verapamil increase plasma concentration of Eplerenone (reduce dose of eplerenone)
  - Dopaminergics: enhanced hypertensive effect when calcium-channel blockers given with CO-BENELDOPA, CO-CAREldopa or LEVODopa
- Fingolimod: possible increased risk of bradycardia when diltiazem or verapamil given with FINGOLIMOD
- Fosaprepitant: plasma concentration of both drugs may increase when diltiazem given with FOSAPREpiTANT
  - Grapefruit Juice: plasma concentration of felodipine, isradipine, lacidipine, lercanidine, nifedipine, nimodipine and verapamil increased by GRAPEFRUIT JUICE; plasma concentration of amlopidine possibly increased by GRAPEFRUIT JUICE
- Hormone Antagonists: diltiazem and verapamil increase plasma concentration of DUTASTERIDE; possible increased risk of bradycardia when diltiazem or verapamil given with PASireotide
- Ivabradine: diltiazem and verapamil increase plasma concentration of IVABRAdINE—avoid concomitant use
- Lenalidomide: verapamil possibly increases plasma concentration of LENALIDOMIDE (increased risk of toxicity)

Calcium-channel Blockers (continued)
- Lipid-regulating Drugs: diltiazem increases plasma concentration of ATORVASTATIN—possible increased risk of myopathy; plasma concentration of verapamil increased by ATORVASTATIN, also possible increased risk of myopathy (consider reducing dose of atorvastatin); possible increased risk of myopathy when amloidpine and diltiazem given with SIMVASTATIN (see under Simvastatin, p. 181); increased risk of myopathy when verapamil given with SIMVASTATIN (see under Simvastatin, p. 181); separating administration from amloidpine and lacidipine by 12 hours advised by manufacturer of LIMOTAPIpE; avoidance of diltiazem and verapamil advised by manufacturer of LIMOTAPIpE (plasma concentration of lomitapide possibly increased)
- Lithium: neurotoxicity may occur when diltiazem or verapamil given with LITHIUM without increased plasma concentration of lithium
- Magnesium (parenteral): profound hypotension reported with concomitant use of nifedipine and PARENTERAL Magnesium in pre-eclampsia
- Methyldopa: enhanced hypertensive effect when calcium-channel blockers given with METHYLDopa
- Moxisylyte: enhanced hypertensive effect when calcium-channel blockers given with MOXYSLyTE
- Moxifloxacin: enhanced hypertensive effect when calcium-channel blockers given with MOXIFLOXAcIN
- Muscle Relaxants: verapamil enhances effects of NON-DEPOLARISING MUSCLE RELAXANTS and SUXAMETHONIum; enhanced hypertensive effect when calcium-channel blockers given with TACLOfin or TIZANIDINE; manufacturer of verapamil advises avoid concomitant use of Intravenous DANTROLENe; possible increased risk of ventricular arrhythmias when diltiazem given with Intravenous DANTROLENe—manufacturer of diltiazem advises avoiding concomitant use; calcium-channel blockers possibly enhance effects of NON-DEPOLARISING MUSCLE RELAXANTS
- Nitrites: enhanced hypertensive effect when calcium-channel blockers given with NITRATES
- Oestrogens: hypertensive effect of calcium-channel blockers antagonised by OESTROGENS
- Prostaglandins: enhanced hypertensive effect when calcium-channel blockers given with ALPROSTADIL
- Ranolazine: diltiazem and verapamil increase plasma concentration of RANOLAZINE (consider reducing dose of ranolazine)
- Sildenafil: enhanced hypertensive effect when amloidpine given with SILDEnALF
- Sirolimus: diltiazem increases plasma concentration of SIROLIMUS; plasma concentration of both drugs increased when verapamil given with SIROLIMUS; nifedipine possibly increases plasma concentration of SIROLIMUS
- Sulfipyrazone: plasma concentration of verapamil reduced by SULFINPYRAZoNE
- Tacrolimus: diltiazem, nicardipine and nifedipine increase plasma concentration of TACROLIMUS; felodipine and verapamil possibly increase plasma concentration of TACrolimus
- Theophylline: calcium-channel blockers possibly increase plasma concentration of THEOPHYLLINE (enhanced effect); diltiazem increases plasma concentration of THEOPHYLLINE; verapamil increases plasma concentration of THEOPHYLLINE (enhanced effect)
- Ticagrelor: diltiazem increases plasma concentration of TICAGRELOR
- Ulcer-healing Drugs: metabolism of calcium-channel blockers possibly inhibited by CIMETIDINE (increased plasma concentration); plasma concentration of isradipine increased by CIMETIDINE. (half dose of isradipine)
- Upralpristil: avoidance of verapamil advised by manufacturer of low-dose UPLRISTIL
- Vardenafil: enhanced hypertensive effect when nifedipine given with VARDENAFL
- Vasodilator Antihypertensives: enhanced hypertensive effect when calcium-channel blockers given with HYDRAZAlINE, MINOdoL or SODIUM NitroPrussIDE
Carbamazepine (continued)
- Anti-arrhythmics: carbamazepine possibly reduces plasma concentration of DRONEDARONE—avoid concomitant use
- Antibacterials: plasma concentration of carbamazepine increased by CLARITHROMYCIN (consider reducing dose of carbamazepine); plasma concentration of carbamazepine increased by ERITHROMYCIN; plasma concentration of carbamazepine reduced by RIFABUTIN; carbamazepine accelerates metabolism of DOXYCYCLINE (reduced effect); carbamazepine possibly reduces plasma concentration of BEDAQUILINE—manufacturer of bedaquiline advises avoid concomitant use; avoidance of carbamazepine advised by manufacturer of DELAMAND; plasma concentration of carbamazepine increased by ISOXAZOLIDINONE (also possibly increased isoxazolid hepatotoxicity); carbamazepine reduces plasma concentration of TELithromycin (avoid during and for 2 weeks after carbamazepine)
- Anticoagulants: carbamazepine possibly reduces plasma concentration of DABIGATRAN—manufacturer of apixaban advises avoid concomitant use when given for treatment of deep-vein thrombosis or pulmonary embolism; carbamazepine accelerates metabolism of COUMARINS (reduced anticoagulant effect); carbamazepine possibly reduces plasma concentration of DABIGATRAN—manufacturer of dabigatran advises avoid concomitant use; carbamazepine possibly reduces plasma concentration of RIVAROXABAN—manufacturer of rivaroxaban advises monitor for signs of thrombosis
- Antidepressants: carbamazepine possibly reduces plasma concentration of REBOXETINE; plasma concentration of carbamazepine increased by FLUOXETINE and FLUVORAMINE; carbamazepine reduces plasma concentration of MIAXERIN, MIRTAZAPINE and TRAZODONE; anticonvulsant effect of antiepileptics possibly antagonised by MAIS and TRICYCLICs (convulsive threshold lowered); manufacturer of carbamazepine advises avoid for 2 weeks after stopping MAIS, also antagonism of anticonvulsant effect; anticonvulsant effect of antiepileptics antagonised by SSRI and TRICYCLICs (convulsive threshold lowered); plasma concentration of carbamazepine possibly reduced by ST JOHN'S WORT; carbamazepine accelerates metabolism of TRICYCLICs (increased plasma concentration and reduced effect)
- Antiepileptics: carbamazepine possibly reduces plasma concentration of ESICARACEPTEIN but risk of side-effects increased; carbamazepine possibly reduces plasma concentration of ETHOSUXIMIDE and RETIGABINE; plasma concentration of both drugs often reduced when carbamazepine given with PHOSPHENYTIN or PHENOTHIN, also plasma concentration of fosphenytin or phenytoin may be increased; carbamazepine often reduces plasma concentration of LAMOTRIGINE, also plasma concentration of an active metabolite of carbamazepine sometimes raised (but evidence is conflicting); possible increased risk of carbamazepine toxicity when given with LEVITRACETAM; plasma concentration of carbamazepine sometimes reduced by OXCARABASTINE (but concentration of an active metabolite of carbamazepine may be increased), also plasma concentration of an active metabolite of oxcarbazepine often reduced; carbamazepine reduces plasma concentration of PERAMpanel (see under Perampanel, p. 398); carbamazepine possibly increases plasma concentration of PHENOBARBITAL and PRIMIDONE; plasma concentration of both drugs possibly reduced when carbamazepine given with RUFANAMIDE; carbamazepine reduces plasma concentration of SODIUM VALPROATE and VALPROIC ACID, also plasma concentration of active metabolite of carbamazepine increased; plasma concentration of carbamazepine increased by STRIPERMINOL; carbamazepine reduces plasma concentration of TIAGABINE and ZONISAMIDE; carbamazepine often reduces plasma concentration of TOPIMARTE
- Antifungals: plasma concentration of carbamazepine possibly increased by KETOCONAZOLE, also plasma concentration of ketoconazole possibly reduced; plasma concentration of carbamazepine possibly increased by FLUCONAZOLE and

**Appendix 1 Interactions**

**Calcium-channel Blockers (dihydropyridines)** see Calcium-channel Blockers

**Canagliflozin** see Antidiabetics

**Canakinumab**
- Anti-inflammatory: avoiding concomitant use of cytotoxics with CANAKINUMAB (increased risk of agranulocytosis)
- Vaccines: risk of generalised infections when monoclonal antibodies given with live VACCINES—avoid concomitant use

**Candesartan** see Angiotensin-II Receptor Antagonists

**Captopril**
- Cytotoxics: possibly antagonised by Captopril
- Antipsychotics: possibly antagonised by Captopril
- Antibacterials: possibly antagonised by Captopril
- Ulcer-healing Drugs: possibly antagonised by Captopril
- Pegfilgrastim: possibly antagonised by Captopril
- Folates: possibly antagonised by Captopril

**Cytotoxics**
- Antipsychotics: possibly antagonised by Cytotoxics
- Antibacterials: possibly antagonised by Cytotoxics
- Ulcer-healing Drugs: possibly antagonised by Cytotoxics

**Antiepileptics**
- Antidepressants: possibly antagonised by Antiepileptics
- Antiepileptics: possibly antagonised by Antidepressants

**Anticoagulants**
- Antibacterials: possibly antagonised by Anticoagulants
- Ulcer-healing Drugs: possibly antagonised by Anticoagulants

**Antifungals**
- Antibacterials: possibly antagonised by Antifungals
- Ulcer-healing Drugs: possibly antagonised by Antifungals

**Vaccines**
- Antibacterials: possibly antagonised by Vaccines
- Ulcer-healing Drugs: possibly antagonised by Vaccines

**Cannabis Extract**
- Antipsychotics: plasma concentration of cannabis extract reduced by Rifampicin—manufacturer of cannabis extract advises avoid concomitant use
- Antidepressants: plasma concentration of cannabis extract possibly reduced by Rifampicin—manufacturer of cannabis extract advises avoid concomitant use; possible increased risk of hypertension and tachycardia when cannabis extract given with Tricyclics
- Antiepileptics: plasma concentration of cannabis extract possibly reduced by Carbamazepine, Phenytoin, Primidone—manufacturer of cannabis extract advises avoid concomitant use
- Antipsychotics: plasma concentration of cannabis extract increased by Ketekonazole

**Capetabine**
- Allopurinol: manufacturer of capetabine advises avoid concomitant use with Allopurinol
- Antibacterials: metabolism of capetabine inhibited by Metronidazole (increased toxicity)
- Anticoagulants: capetabine enhances anticoagulant effect of Coumarins
- Antiepileptics: capetabine possibly inhibits metabolism of Phenytoin and Phenytoin (increased risk of toxicity)
- Cytotoxic: capetabine possibly increases plasma concentration of Eroltinib
- Filgrastim: neutropenia possibly exacerbated when capetabine given with Filgrastim
- Folates: toxicity of capetabine increased by Folic Acid—avoid concomitant use
- Liphagrilastim: neutropenia possibly exacerbated when capetabine given with Liphagrilastim
- Pegfilgrastim: neutropenia possibly exacerbated when capetabine given with Pegfilgrastim
- Ulcer-healing Drugs: metabolism of capetabine inhibited by Cimetidine (increased plasma concentration)

**Capreomycin**
- Antibacterials: increased risk of nephrotoxicity when capreomycin given with Colistimethate Sodium or Polymyxins; increased risk of nephrotoxicity and ototoxicity when capreomycin given with Aminoglycosides or Vancomycin
- Cytotoxic: increased risk of nephrotoxicity and ototoxicity when capreomycin given with Platinum Compounds
- Vaccines: antibiotics inactivate Oral Typhoid Vaccine—see under Typhoid Vaccine in BNF

**Captopril** see ACE Inhibitors

**Carbamazepine**
- Alcohol: CNS side-effects of carbamazepine possibly increased by Alcohol
- Aminophylline: carbamazepine accelerates metabolism of Aminophylline (reduced effect)
- Analgesics: effects of carbamazepine enhanced by Dextropropoxyphene; carbamazepine possibly accelerates metabolism of Fentanyl (reduced effect); carbamazepine reduces plasma concentration of Methadone; carbamazepine reduces effects of Tramadol; carbamazepine possibly accelerates metabolism of Paracetamol (also isolated reports of hepatotoxicity)
- Anthelmintics: carbamazepine reduces plasma concentration of Albendazole and Praziqantel—consider increasing albendazole and praziquantel dose when given for systemic infections
Carbamazepine

- **Antifungals**: carbamazepine possibly reduces plasma concentration of ITRACONAZOLE and POSaconazole; carbamazepine possibly reduces plasma concentration of voriconazole—avoid concomitant use; avoidance of carbamazepine advised by manufacturer of ARTENIOL with PIPERAZINE; anticonvulsant effect of antiepileptics antagonised by MELOQUINE
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by ANTIPSYCHOTICS (convulsive threshold lowered); carbamazepine accelerates metabolism of MACITENTAN, EPLERENONE, and SIPERIDINE (reduced plasma concentration); carbamazepine reduces plasma concentration of ARIPIPRAZOLE (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature); carbamazepine accelerates metabolism of CLOZAPINE (reduced plasma concentration), also avoid concomitant use of drugs with substantial potential for causing agranulocytosis; carbamazepine possibly reduces plasma concentration of LURASIDONE—avoid concomitant use; carbamazepine reduces plasma concentration of PALIPERIDONE
- Antivirals: avoidance of carbamazepine advised by manufacturer of BOCEPREVIR and RILPIRIVINE (plasma concentration of boceprevir and rilpivirine possibly reduced); carbamazepine possibly reduces plasma concentration of DAKLATAVIR and SIMERVIRI (manufacturer of daklatavir and simerviri advises avoid concomitant use); carbamazepine possibly reduces plasma concentration of DARUNAVIR, FOSAMPRENAVIR, LIPINAVIR, SAQUINAVIR and TIPRANAVIR; avoidance of carbamazepine advised by manufacturer of DOVITEGRAVIR, ELVITEGRAVIR, ETRAVIRINE, SOFOSBUVIR and TELAPREVIR; plasma concentration of both drugs reduced when carbamazepine given with EFAVIRENZ; carbamazepine possibly reduces plasma concentration of INIDINAVIR, also plasma concentration of carbamazepine possibly increased; carbamazepine reduces plasma concentration of NEVIRAPINE; plasma concentration of carbamazepine possibly increased by RITONAVIR
- Anxiolytics and Hypnotics: carbamazepine often reduces plasma concentration of CLONAZEPAM; carbamazepine reduces plasma concentration of MIDAZOLAM
- Aprepitant: carbamazepine possibly reduces plasma concentration of APREPITANT
- Avanafil: carbamazepine possibly reduces plasma concentration of AVANAFIL—manufacturer of avanafil advises avoid concomitant use
- Bupropion: carbamazepine reduces plasma concentration of BUPROPION
- Calcium-channel Blockers: carbamazepine reduces effects of FELODIPINE and IRADIPINE; carbamazepine probably reduces effects of DIHYDROPYRIDINES, NICARDIPINE and NIFEDIPINE; avoidance of carbamazepine advised by manufacturer of NIMODIPINE (plasma concentration of nimodipine possibly reduced); effects of carbamazepine enhanced by DILTIAZEM and VERAPAMIL
- Cannabis Extract: carbamazepine possibly reduces plasma concentration of CANNABIS EXTRACT—manufacturer of cannabis extract advises avoid concomitant use
- Ciclosporin: carbamazepine accelerates metabolism of CYCLOSPORIN (reduced plasma concentration)
- Clopidogrel: carbamazepine possibly reduces antiplatelet effect of CLOPIDOGREL
- Cobicistat: carbamazepine possibly reduces plasma concentration of COBICISTAT—manufacturer of cobicistat advises avoid concomitant use
- Corticosteroids: carbamazepine accelerates metabolism of CORTICOSTEROIDS (reduced effect)
- Cytotoxics: carbamazepine possibly decreases plasma concentration of AXTINIB (increase of axitinib—consult axitinib product literature); carbamazepine possibly reduces plasma concentration of BORTEZOMIB, Bosutinib, Crizotinib, Ibritinib, IDELASIB and PONATINIB—manufacturer of CARBAMAZEPINE
- **Cytotoxics**: carbamazepine possibly reduces plasma concentration of CICLOSPORIN—consider increasing dose of cyclosporin
- **Antimalarials**: avoidance of carbamazepine advised by manufacturer of ARTENIOL with PIPERAZINE; carbamazepine possibly reduces plasma concentration of CASPOFUNGIN—consider increasing dose of caspofungin
- **Antimicrobials**: avoidance of carbamazepine advised by manufacturer of ARTENIOL with PIPERAZINE; carbamazepine possibly reduces plasma concentration of CAFZITAXEL, DABRAFENIB, GEFITINIB and VEMURAFENIB; avoidance of carbamazepine advised by manufacturer of DASITANIB, VANDETANIB and VISMODEGIB (plasma concentration of dasatinib, vandetanib and vismodegib possibly reduced); carbamazepine reduces plasma concentration of IMATIB and LAPATINIB—avoid concomitant use; carbamazepine possibly reduces plasma concentration of Eribulin; carbamazepine reduces plasma concentration of IPRITOCAN and its active metabolite; manufacturer of procarbazine advises possible increased risk of hypersensitivity reactions when carbamazepine given with PROCARBAZINE
- **Diuretics**: increased risk of hyponatraemia when carbamazepine given with DIURETICS; plasma concentration of carbamazepine possibly increased by manufacturer of ETALOLAMIDE; carbamazepine reduces plasma concentration of FINGOLIMOD
- Fosaprepitant: carbamazepine possibly reduces plasma concentration of FOSAPREPIANT
- Hormone Antagonists: carbamazepine possibly reduces plasma concentration of ABRATERONE—manufacturer of abiraterone advises avoid concomitant use; avoidance of carbamazepine advised by manufacturer of DABRAFENIB and VEMURAFENIB; carbamazepine reduces plasma concentration of TOREMIFENE (reduced plasma concentration)
- Ivermectin: avoidance of carbamazepine advised by manufacturer of IVACAFOR—manufacturer of ivermectin advises avoid concomitant use
- Lipid-regulating Drugs: carbamazepine reduces plasma concentration of SIMVASTATIN—consider increasing dose of simvastatin
- Lithium: neurotoxicity may occur when carbamazepine given with LITHIUM without increased plasma concentration of lithium
- Macitentan: avoidance of carbamazepine advised by manufacturer of MACITENTAN
- Muscle Relaxants: carbamazepine antagonises muscle relaxant effect of NON-DEPOLARISING MUSCLE RELAXANTS (accelerated recovery from neuromuscular blockade)
- Oestrogens: carbamazepine accelerates metabolism of OESTROGENS (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, vaginal rings—see Contraceptive Interactions in BNF)
- Orlistat: possible increased risk of convulsions when carbamazepine given with ORLISTAT
- Progestogens: carbamazepine accelerates metabolism of PROGESTOGENS (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF)
- Retinoids: plasma concentration of carbamazepine possibly reduced by ISORETINOIN
- Roflumilast: carbamazepine possibly inhibits effects of ROFLUMILAST (manufacturer of roflumilast advises avoid concomitant use)
- Theophylline: carbamazepine accelerates metabolism of THEOPHYLLINE (reduced effect)
- Thyroid Hormones: carbamazepine accelerates metabolism of THYROID HORMONES (may increase requirements for thyroid hormones in hypothyroidism)
- Tirofiban: carbamazepine accelerates metabolism of TIBOLONE (reduced plasma concentration)
- Ticagrelor: carbamazepine possibly reduces plasma concentration of TICAGRELOR
Cardiac Glycosides (continued)

- Cardiotoxic: increased risk of hypokalaemia when cardiac glycosides given with CORTICOSTEROIDS
- Cytotoxics: absorption of digoxin tablets possibly reduced by BLOMYCIN, CARMUSTINE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, MELPHALAN, METHOTREXATE, PROCARBAZINE and VINCISTINE; possible increased risk of bradycardia when digoxin given with CRIZOTINIB: manufacturer of digoxin advises give IBUTINIB at least 6 hours before or after ibritinib; plasma concentration of digoxin increased by VANDENAB—possible increased risk of bradycardia
- Diuretics: increased cardiac toxicity with cardiac glycosides if hypokalaemia occurs with ACETAZOLAMIDE, LOOP DIURETICS or THIAZIDES AND RELATED DIURETICS; plasma concentration of digoxin possibly increased by POTASSIUM CANRENOATE; plasma concentration of digoxin increased by SPIRONOLACTONE
- Ivacafarin: plasma concentration of digoxin increased by IVACAFTOR
- Lenalidomide: plasma concentration of digoxin possibly increased by LENALIDOMIDE
- Lipid-regulating Drugs: absorption of cardiac glycosides possibly reduced by COLESTIPOI and COLESTYRAMINE; plasma concentration of digoxin possibly increased by ATORVASTATIN
- Mirabege: plasma concentration of digoxin increased by MIRAPEGON—reduce initial dose of digoxin
- Muscle Relaxants: risk of ventricular arrhythmias when cardiac glycosides given with SUXAMETHONIUM; possible increased risk of bradycardia when cardiac glycosides given with TIZANIDINE
- Penicillamine: plasma concentration of digoxin possibly reduced by PENICILLAMINE
- Ranolazine: plasma concentration of digoxin increased by RANOLAZINE
- Sympathomimetics, Beta—plasma concentration of digoxin possibly reduced by SALBUTAMOL
- Ticagrelor: plasma concentration of digoxin increased by TICAGRELOR
- Tolvaptan: plasma concentration of digoxin increased by TOLVAPATAN (increased risk of toxicity)
- Ulcer-healing Drugs: plasma concentration of digoxin possibly slightly increased by PROTON PUMP INHIBITORS; absorption of cardiac glycosides possibly reduced by SUCRALFATE
- Ulipristal: manufacturer of ulipristal advises give digoxin at least 1.5 hours before or after ULIPRISTAL

Carmustine

- Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
- Cardiac Glycosides: carmustine possibly reduces absorption of DIGOXIN tablets
- Ulcer-healing Drugs: myelosuppressive effects of carmustine possibly enhanced by CIMETIDINE

Carcinoids

- Antibacterials: plasma concentration of caspofungin possibly reduced by CARBAMAZEPINE, FOSPHENTOIN and PHENYTOIN; plasma concentration of digoxin increased by caspofungin reduces plasma concentration of caspofungin possibly increased by EFAVIREN and NEVIRAPINE—consider increasing dose of caspofungin
- Antivirals: plasma concentration of caspofungin possibly increased by CYCLOSPORIN (manufacturer of caspofungin recommends monitoring liver enzymes)
- Corticosteroids: plasma concentration of caspofungin possibly reduced by DEXAMETHASONE—consider increasing dose of caspofungin
- Tacrolimus: caspofungin reduces plasma concentration of TACROLIMUS

Catumaxomab

- Antibacterials: plasma concentration of caspofungin initially increased and then reduced by RIFAMPICIN (consider increasing dose of caspofungin)
- Antiepileptics: plasma concentration of caspofungin possibly reduced by CARBAMAZEPINE, FOSPHENTOIN and PHENYTOIN—consider increasing dose of caspofungin
- Antivirals: plasma concentration of caspofungin possibly increased by COBICISTAT—reduce initial dose of digoxin
- Colchicine: possible increased risk of myopathy when digoxin given with COLCHICINE
**Chloroquine (continued)**
- Agalsidase Alfa and Beta: chloroquine possibly inhibits effects of AGALSIDASE ALFA AND BETA (manufacturers of agalsidase alfa and beta advise avoid concomitant use)
- Antacids: absorption of chloroquine reduced by ANTACIDS
- Anthelmintics: chloroquine reduces plasma concentration of PRAZIQUANTEL—consider increasing praziquantel dose when given for systemic infections
- Anti-arrhythmics: increased risk of ventricular arrhythmias when chloroquine given with AMIODARONE—avoid concomitant use
- Antibacterials: increased risk of ventricular arrhythmias when chloroquine given with MOXIFLOXACIN—avoid concomitant use
- Antidepressants: possible increased risk of ventricular arrhythmias when chloroquine given with CITALOPRAM and ESCITALOPRAM
- Antimalarials: possible increased risk of ventricular arrhythmias when chloroquine given with DROPERIDOL—avoid concomitant use
- Cardiac Glycosides: chloroquine possibly increases plasma concentration of DIGOXIN
- Ciclosporin: chloroquine increases plasma concentration of CICLOSPORIN (increased risk of toxicity)
- Cytotoxics: possible increased risk of ventricular arrhythmias when chloroquine given with BSOSUNIB
- Histamine: avoidance of antimalarial advised by manufacturer of HISTAMINE
- Lanthanum: absorption of chloroquine possibly reduced by LANTHANUM (give at least 2 hours apart)
- Larondase: chloroquine possibly inhibits effects of LARONIDASE (manufacturer of larondase advises avoid concomitant use)
- Parasympathomimetics: chloroquine has potential to increase symptoms of myasthenia gravis and thus diminish effect of NEOSTIGMINE and PYRIDOSTIGMINE
- Ulcer-healing Drugs: metabolism of chloroquine inhibited by CIMETIDINE (increased plasma concentration)
- Vaccines: antimalarials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

**Chlorothiazide** see Diuretics
**Chlorphenamine** see Antihistamines
**Chlorpromazine** see Antipsychotics
**Ciclesonide** see Corticosteroids
**Ciclosporin**
- ACE Inhibitors: increased risk of hyperkalaemia when ciclosporin given with ACE INHIBITORS
- Aliskiren: ciclosporin increases plasma concentration of ALISKIREN—avoid concomitant use
- Allopurinol: plasma concentration of ciclosporin possibly increased by ALLOPURINOL (risk of nephrotoxicity)
- Ambrisentan: ciclosporin increases plasma concentration of AMBRISENTAN (see under Ambrisentan, p. 162)
- Analgesics: increased risk of nephrotoxicity when ciclosporin given with NSAIDS; ciclosporin increases plasma concentration of DICLOFENAC (halve dose of diclofenac)
- Angiotensin-II Receptor Antagonists: increased risk of hyperkalaemia when ciclosporin given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Anti-arrhythmics: plasma concentration of ciclosporin possibly increased by AMIODARONE and PROPafenone
- Antibacterials: metabolism of ciclosporin inhibited by CLARITHROMYCIN and ERTHROMYCIN (increased plasma concentration); metabolism of ciclosporin accelerated by RAFPICIN (reduced plasma concentration); plasma concentration of ciclosporin possibly reduced by SULFADIAZINE; increased risk of nephrotoxicity when ciclosporin given with AMINGLYCOSIDES, POLYMIXINS, QUINOLONES, SULFONAMIDES or VANCOMYCIN; plasma concentration of ciclosporin possibly increased by...
Appendix 1 Interactions 1175

Ciclosporin
- Antibacterials (continued)
  - CHLORAMPHENICOL and THIOHIDRAZINE; increased risk of myopathy when ciclosporin given with DAPTOMYCIN (preferably avoid concomitant use); avoidance of ciclosporin advised by manufacturer of FIDAXOMICIN; metabolism of ciclosporin possibly inhibited by MACROLIDES (increased plasma concentration); increased risk of nephrotoxicity when ciclosporin given with TRIMETHOPRIM, also plasma concentration of ciclosporin reduced by intravenous trimethoprim
  - Anticoagulants: ciclosporin possibly increases plasma concentration of dabigatran—manufacturer of dabigatran advises avoid concomitant use
  - Antidepressants: plasma concentration of ciclosporin reduced by ST JOHN’S WORT—avoid concomitant use
  - Anti-diabetics: ciclosporin possibly enhances hypoglycaemic effect of repaglinide
  - Antiepileptics: metabolism of ciclosporin accelerated by CARBAMAZEPINE, OXCARBAZEPINE, PHENOBARBITAL, PHENYTOIN, and PRIMIDONE (reduced plasma concentration); plasma concentration of ciclosporin possibly reduced by oxcarbazepine
  - Antifungals: metabolism of ciclosporin inhibited by FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE, POSaconazole and voriconazole (increased plasma concentration); metabolism of ciclosporin possibly inhibited by MICONAZOLE (increased plasma concentration); increased risk of nephrotoxicity when ciclosporin given with voriconazole; ciclosporin inhibits plasma concentration of caspofungin (manufacturer of caspofungin recommends monitoring liver enzymes); plasma concentration of ciclosporin possibly reduced by griseofulvin and terbinafine; plasma concentration of ciclosporin possibly increased by miconazole
  - Antimalarials: plasma concentration of ciclosporin increased by chloroquine and hydroxychloroquine (increased risk of toxicity)
  - Antimuscarinics: avoidance of ciclosporin advised by manufacturer of darifenacin
  - Antivirals: increased risk of nephrotoxicity when ciclosporin given with ACICLOVIR or VALACICLOVIR; plasma concentration of ciclosporin possibly increased by atazanavir and ritonavir; plasma concentration of both drugs may increase when ciclosporin given with saquinavir; plasma concentration of both drugs increased when ciclosporin given with telaprevir (reduce dose of ciclosporin)
  - Betablockers: plasma concentration of ciclosporin increased by carvedilol
  - Bile Acids: absorption of ciclosporin increased by ursodeoxycholic acid
  - Bosentan: ciclosporin increases plasma concentration of bosentan (also plasma concentration of ciclosporin reduced—avoid concomitant use)
  - Calcium-channel Blockers: combination of ciclosporin with lercanidipine may increase plasma concentration of either drug (or both)—avoid concomitant use; plasma concentration of ciclosporin increased by diltiazem, nicardipine and verapamil; ciclosporin possibly increases plasma concentration of nifedipine (increased risk of toxicity including gingival hyperplasia)
  - Cardiac Glycosides: ciclosporin increases plasma concentration of digoxin (increased risk of toxicity)
  - Colchicine: possible increased risk of nephrotoxicity and myotoxicity when ciclosporin given with colchicine—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
  - Colestilan: manufacturer of colestilan advises give ciclosporin at least 1 hour before or 3 hours after colestilan
  - Corticosteroids: plasma concentration of ciclosporin increased by high-dose methylprednisolone (risk of convulsions); ciclosporin increases plasma concentration of prednisolone
  - Cytoxics: increased risk of nephrotoxicity when ciclosporin given with melphalan; increased risk of neurotoxicity when ciclosporin given with doxorubicin; ciclosporin increases plasma concentration of epirubicin and idarubicin; ciclosporin reduces excretion of mitoxantrone (increased plasma concentration); risk of toxicity when ciclosporin given with methotrexate; ciclosporin possibly increases the plasma concentration of atafinib—manufacturer of atafinib advises separating administration of ciclosporin by 6 to 12 hours; caution with ciclosporin advised by manufacturer of crizotinib; ciclosporin increases plasma concentration of everolimus (consider reducing the dose of everolimus—consult everolimus product literature); plasma concentration of ciclosporin possibly increased by imatinib; in vitro studies suggest a possible interaction between ciclosporin and docetaxel (consult docetaxel product literature); ciclosporin possibly increases plasma concentration of etoposide (increased risk of toxicity)
  - Dextrazoxane: increased risk of immunosuppression with ciclosporin advised by manufacturer of dextrazoxane
  - Diuretics: plasma concentration of ciclosporin possibly increased by acacetolamide; increased risk of hyperkalaemia when ciclosporin given with potassium-sparing diuretics and aldosterone antagonists; increased risk of nephrotoxicity and possibly hypermagnesaemia when ciclosporin given with thiazides and related diuretics
  - Grapefruit juice: plasma concentration of ciclosporin increased by grapefruit juice (increased risk of toxicity)
  - Hormone Antagonists: metabolism of ciclosporin inhibited by danazol (increased plasma concentration); plasma concentration of ciclosporin reduced by lanreotide and octreotide; plasma concentration of ciclosporin possibly reduced by pasireotide
  - Lenvadomid: ciclosporin possibly increases plasma concentration of lenalidomide (increased risk of toxicity)
  - Lipid-regulating Drugs: absorption of ciclosporin reduced by colesvevalam; increased risk of renal impairment when ciclosporin given with bezafibrate or fenofibrate; increased risk of myopathy when ciclosporin given with atovastatin (see under atorvastatin, p. 179); increased risk of myopathy when ciclosporin given with fluvatatin or pravastatin; increased risk of myopathy when ciclosporin given with rosuvastatin or simvastatin (avoid concomitant use); plasma concentration of both drugs increased when ciclosporin given with ezetimibe; separating administration from ciclosporin by 12 hours advised by manufacturer of lonidamine
  - Lipid-modifying Drugs: possible increased risk of nephrotoxicity when ciclosporin given with manitol
  - Metoclopramide: plasma concentration of ciclosporin increased by metoclopramide
  - Mifamurtide: avoidance of ciclosporin advised by manufacturer of mifamurtide
  - Modafinil: plasma concentration of ciclosporin reduced by modafinil
  - Oestrogens: plasma concentration of ciclosporin possibly increased by oestrogens
  - Orlistat: absorption of ciclosporin possibly reduced by orlistat
  - Potassium Salts: increased risk of hyperkalaemia when ciclosporin given with potassium salts; increased risk of myopathy when ciclosporin given with progestogens; plasma concentration of ciclosporin possibly increased by progestogens; ranolazine: plasma concentration of both drugs may increase when ciclosporin given with ranolazine; sevelamer: plasma concentration of ciclosporin possibly reduced by sevelamer
  - Sirolimus: ciclosporin increases plasma concentration of sirolimus
  - Sulfipyrazone: plasma concentration of ciclosporin reduced by sulfipyrazone
  - Tacrolimus: increased risk of nephrotoxicity—avoid concomitant use
Ciclosporin (continued)
» Ticagrelor: ciclosporin increases plasma concentration of TICAGRELOR
» Ulcer-healing Drugs: plasma concentration of ciclosporin possibly increased by Cimetidine; plasma concentration of ciclosporin possibly affected by OMEPRAZOLE
» Vitamins: plasma concentration of ciclosporin possibly affected by VITAMIN E

Clarithromycin
» Antibacterials: plasma concentration of clarithromycin possibly increased by CAVIMETHINE (see under Clarithromycin, p. 206); plasma concentration of clarithromycin increased by RHYTHROMYCIN (see under Ciprofibrate, p. 206)
» Antifungals: plasma concentration of clarithromycin possibly increased by Ketoconazole (see under Clarithromycin, p. 206); plasma concentration of clarithromycin possibly increased by ITRACONAZOLE (see under Clarithromycin, p. 206)
» Ulcer-healing Drugs: plasma concentration of clarithromycin increased by OMEPRAZOLE (see under Ciprofibrate, p. 206)

Clonidine (continued)
» Anesthetics, General: enhanced hypotensive effect when clonidine given with GENERAL ANAESTHETICS
» Analgesics: hypotensive effect of clonidine antagonised by NSAIDS
» Antiglaucoma Agents: hypotensive effect of clonidine antagonised by TIMAZEPANE; hypotensive effect of clonidine antagonised by TRICYCLICS, also increased risk of hypertension on clonidine withdrawal
» Antipsychotics: enhanced hypotensive effect when clonidine given with PHENOTHIAZINES
» Antidepressants: enhanced hypotensive effect when clonidine given with ANTIHISTAMINES and HYPONOTICS
» Beta-blockers: increased risk of withdrawal hypertension when clonidine given with BETA-BLOCKERS (withdraw beta-blockers several days before slowly withdrawing clonidine)
» Calcium-channel Blockers: enhanced hypotensive effect when clonidine given with CALCIUM-CHANNEL BLOCKERS
» Corticosteroids: hypotensive effect of clonidine antagonised by CORTICOSTEROIDS
» Cytostatics: possible increased risk of bradycardia when clonidine given with CRIZOTINIB
» Diazoxide: enhanced hypotensive effect when clonidine given with DIAZoxide
» Diuretics: enhanced hypotensive effect when clonidine given with DIURETICS
» Dopaminergics: enhanced hypotensive effect when clonidine given with CO-BENELDOPA, CO-CARELDOPA or LEVODOPA
» Histamine: avoidance of clonidine advised by manufacturer of HISTAMINE
» Methylodopa: enhanced hypotensive effect when clonidine given with METHYLODOPA
» Moxisylyte: enhanced hypotensive effect when clonidine given with MOXYSLYTE
» Monoxidine: enhanced hypotensive effect when clonidine given with MONOXIDINE
» Muscle Relaxants: enhanced hypotensive effect when clonidine given with BACLOFEN or TIZANIDINE
» Nitrates: enhanced hypotensive effect when clonidine given with NITRATES
» Oestrogens: hypotensive effect of clonidine antagonised by OESTROGENS
» Prostaglandins: enhanced hypotensive effect when clonidine given with ALPROSTADIL
» Symptomametiotics: possible risk of hypertension when clonidine given with ADRENERGIC NEURONE BLOCKERS; hypotensive effect of clonidine antagonised by WARFARIN; antiepileptic action of clonipiprol enhances anticonvulsant effect of CLONIPIPRO and PHENITONINE; increased risk of bleeding when clonidine given with WARFARIN
» Antidepressants: antiepileptic effect of clonidine possibly reduced by FLUOXETINE, FLUOXAMINE and MOLOBEMIDE
» Antiepileptics: antiepileptic effect of clonidine possibly reduced by CARBAMAZEPINE and OXCARBAZEPINE
» Antifungals: antiepileptic effect of clonidine possibly reduced by FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE and VORICONAZOLE
Co-beneldopa (continued)

- Vasodilator Antihypertensives: enhanced hypotensive effect when co-beneldopa given with HYDRAZALINE, MINOXIDIL or SODIUM NITROPRUSSIDE

Cobicistat
- Alpha-blockers: cobicistat possibly increases plasma concentration of ALIFUZOSIN—manufacturer of cobicistat advises avoid concomitant use
- Anti-arrhythmics: cobicistat possibly increases plasma concentration of AMIODARONE—manufacturer of cobicistat advises avoid concomitant use
- Antibacterials: plasma concentration of cobicistat reduced by RIFABUTIN (adjust dose—consult product literature); plasma concentration of cobicistat possibly reduced by RIFAMPICIN—manufacturer of cobicistat advises avoid concomitant use
- Anticoagulants: avoidance of cobicistat advised by manufacturer of APIXABAN; cobicistat possibly enhances anticoagulant effect of Rivaroxaban—avoid concomitant use
- Antidepressants: plasma concentration of cobicistat possibly reduced by ST JOHN’S WORT—manufacturer of cobicistat advises avoid concomitant use
- Antiepileptics: plasma concentration of cobicistat possibly reduced by CARBAMAZEPINE, EPSOPHENYTOIN, PHENOBARBITAL, PHENYTIN and PRIMIDONE—manufacturer of cobicistat advises avoid concomitant use
- Antifungals: cobicistat possibly increases plasma concentration of ITRACONAZOLE and KETOCONAZOLE—manufacturer of cobicistat advises reduce dose of itraconazole and ketoconazole
- Antipsychotics: cobicistat possibly increases plasma concentration of LURASIDONE—avoid concomitant use; cobicistat possibly increases plasma concentration of PIMOXIDE—manufacturer of cobicistat advises avoid concomitant use
- Antivirals: manufacturer of cobicistat advises avoid concomitant use with BOCEPREVIR; cobicistat possibly increases the plasma concentration of DACLATASVIR—reduce dose of daclatasvir (see under Daclatasvir, p. 544); cobicistat possibly increases plasma concentration of MARAVIROC (reduce dose of maraviroc); avoidance of cobicistat advised by manufacturer of NEVIRAPINE; cobicistat possibly increases plasma concentration of SIMEPREVIR—manufacturer of simeprevir advises avoid concomitant use; plasma concentration of both drugs reduced when cobicistat given with TIPRANAVIR (avoid concomitant use)
- Anxiolytics and Hypnotics: manufacturer of cobicistat advises avoid concomitant use with ORIOL and MIDAZOLAM; Bosantan: manufacturer of cobicistat advises avoid concomitant use with BOSENTAN
- Cardiac Glycosides: cobicistat possibly increases plasma concentration of DIGOXIN—reduce initial dose of digoxin
- Cytoxicics: cobicistat possibly increases the plasma concentration of IBRUTINIB—reduce dose of ibritunib (see under Ibritunib, p. 809)
- Domperidone: possible increased risk of ventricular arrhythmias when cobicistat given with DOMPERIDONE—avoid concomitant use
- Ergot Alkaloids: cobicistat possibly increases plasma concentration of ERGOT ALKALOIDS—manufacturer of cobicistat advises avoid concomitant use
- Lipid-regulating Drugs: cobicistat possibly increases plasma concentration of ATORVASTATIN—manufacturer of cobicistat advises reduce dose of atorvastatin; manufacturer of cobicistat advises avoid concomitant use with SIMVASTATIN
- Estrogens: cobicistat accelerates metabolism of OESTROGENS (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)
- Progestogens: cobicistat increases plasma concentration of NORGESTIMATE
- Sildenafil: cobicistat possibly increases plasma concentration of SILDAFIL—manufacturer of cobicistat advises avoid concomitant use of sildenafil for pulmonary arterial
Interactions

Colchicine (continued)

- Antibiotics: possible increased risk of colchicine toxicity when given with: azithromycin, clarithromycin, erythromycin and telithromycin—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Antifungals: possible increased risk of colchicine toxicity when given with: itraconazole and ketoconazole—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Antivirals: possible increased risk of colchicine toxicity when given with: atazanavir, indinavir, ritonavir and telaprevir—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Calcium-channel blockers: possible increased risk of colchicine toxicity when given with: diltiazem and verapamil—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Cardiac glycosides: possible increased risk of myopathy when colchicine given with: digoxin
- Ciclosporin: possible increased risk of nephrotoxicity and myotoxicity when colchicine given with: ciclosporin—suspend or reduce dose of ciclosporin (avoid concomitant use in hepatic or renal impairment)
- Grapefruit juice: possible increased risk of colchicine toxicity when given with: grapefruit juice
- Lipid-regulating Drugs: possible increased risk of myopathy when colchicine given with: fibrates or statins

Colecaciferol see Vitamins

Colestevan

NOTE Other drugs should be taken at least 4 hours before or after colesvelam to reduce possible interference with absorption

- Anti-diabetics: colesvelam reduces absorption of glimepiride and glipizide; colesvelam reduces absorption of glimepiride—manufacturer of glimepiride advises give at least 4 hours before colesvelam; manufacturer of canagliflozin advises give bale acid sequestrants at least 1 hour after or 4–6 before canagliflozin
- Anti-epileptics: colesvelam possibly reduces absorption of fosphenytoin and phenytoin
- Cyclosporin: colesvelam reduces absorption of ciclosporin
- Lipid-regulating Drugs: bile acid sequestrants possibly reduce absorption of lomitapide (give at least 4 hours apart)
- Oestrogens: colesvelam reduces absorption of ethinylestradiol
- Thyroid Hormones: colesvelam reduces absorption of levothyroxine

Colestilan

NOTE Other drugs should be taken at least 1 hour before or 3 hours after colestilan to reduce possible interference with absorption

- Anti-diabetics: colesvelam reduces absorption of glimepiride and glipizide; colesvelam reduces absorption of glimepiride—manufacturer of glimepiride advises give at least 4 hours before colesvelam; manufacturer of canagliflozin advises give bile acid sequestrants at least 1 hour after or 4–6 before canagliflozin
- Anti-epileptics: colesvelam reduces absorption of fosphenytoin and phenytoin
- Cyclosporin: colesvelam reduces absorption of ciclosporin
- Lipid-regulating Drugs: bile acid sequestrants possibly reduce absorption of lomitapide (give at least 4 hours apart)
- Oestrogens: colesvelam reduces absorption of ethinylestradiol
- Thyroid Hormones: colesvelam reduces absorption of levothyroxine

Colestipol

NOTE Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption

- Anti-diabetics: colestipol possibly reduces absorption of tetracycline
- Anti-epileptics: manufacturer of canagliflozin advises give bile acid sequestrants at least 1 hour after or 4–6 before canagliflozin
- Cardiac glycosides: colestipol possibly reduces absorption of cardiac glycosides
- Diuretics: colestipol reduces absorption of thiazides and related diuretics (give at least 2 hours apart)
Colestipol (continued)
▶ Lipid-regulating Drugs: bile acid sequestrants possibly reduce
absorption of LOMITAPIDE (give at least 4 hours apart)
▶ Thyroid Hormones: colestipol reduces absorption of THYROID
HORMONES

Colestyramine
NOTE Other drugs should be taken at least 1 hour before or
4–6 hours after colestyramine to reduce possible interference
with absorption
▶ Analgesics: colestyramine increases the excretion of
MELOXICAM ; colestyramine reduces absorption of
PARACETAMOL
▶

Antibacterials: colestyramine possibly reduces absorption of
TETRACYCLINE ; colestyramine antagonises effects of oral
VANCOMYCIN

Anticoagulants: colestyramine may enhance or reduce
anticoagulant effect of l COUMARINS and l PHENINDIONE
▶ Antidiabetics: colestyramine possibly enhances hypoglycaemic
effect of ACARBOSE ; manufacturer of canagliflozin advises
give bile acid sequestrants at least 1 hour after or 4–6 before
l

CANAGLIFLOZIN
▶

Antiepileptics: colestyramine possibly reduces absorption of
SODIUM VALPROATE and VALPROIC ACID
▶ Bile Acids: colestyramine possibly reduces absorption of BILE
ACIDS
▶
▶
▶

▶
▶

Cardiac Glycosides: colestyramine possibly reduces absorption
of CARDIAC GLYCOSIDES
Diuretics: colestyramine reduces absorption of THIAZIDES AND
RELATED DIURETICS (give at least 2 hours apart)
Leflunomide: colestyramine significantly decreases effect of
LEFLUNOMIDE (enhanced elimination)—avoid unless drug
elimination desired
Lipid-regulating Drugs: bile acid sequestrants possibly reduce
absorption of LOMITAPIDE (give at least 4 hours apart)
Mycophenolate: colestyramine reduces absorption of
MYCOPHENOLATE

▶

Raloxifene: colestyramine reduces absorption of RALOXIFENE
(manufacturer of raloxifene advises avoid concomitant
administration)
▶ Teriflunomide: colestyramine significantly decreases effect of
TERIFLUNOMIDE (enhanced elimination)—avoid unless drug
elimination desired
▶ Thyroid Hormones: colestyramine reduces absorption of
THYROID HORMONES
▶

Vitamins: colestyramine possibly reduces absorption of
CALCITRIOL (give at least 1 hour before or 4 to 6 hours after
colestyramine)
Colistimethate Sodium see Polymyxins
Contraceptives, oral see Oestrogens and Progestogens
Corticosteroids
NOTE Interactions do not generally apply to corticosteroids
used for topical action (including inhalation) unless specified
▶ ACE Inhibitors: corticosteroids antagonise hypotensive effect
of ACE INHIBITORS
▶ Adrenergic Neurone Blockers: corticosteroids antagonise
hypotensive effect of ADRENERGIC NEURONE BLOCKERS
l Aldesleukin: avoidance of corticosteroids advised by
manufacturer of l ALDESLEUKIN
▶ Alpha-blockers: corticosteroids antagonise hypotensive effect
of ALPHA-BLOCKERS
▶ Aminophylline: increased risk of hypokalaemia when
corticosteroids given with AMINOPHYLLINE
▶ Analgesics: increased risk of gastro-intestinal bleeding and
ulceration when corticosteroids given with NSAID S ; increased
risk of gastro-intestinal bleeding and ulceration when
corticosteroids given with ASPIRIN , also corticosteroids
reduce plasma concentration of salicylate
▶ Angiotensin-II Receptor Antagonists: corticosteroids antagonise
hypotensive effect of ANGIOTENSIN-II RECEPTOR ANTAGONISTS
▶ Antacids: absorption of deflazacort reduced by ANTACIDS
▶ Anthelmintics: dexamethasone increases plasma concentration
of active metabolite of ALBENDAZOLE ; continuous use of
dexamethasone possibly reduces plasma concentration of
PRAZIQUANTEL
l

Antibacterials: plasma concentration of methylprednisolone
possibly increased by CLARITHROMYCIN ; metabolism of

Corticosteroids
l Antibacterials (continued)
corticosteroids possibly inhibited by ERYTHROMYCIN ;
metabolism of methylprednisolone inhibited by
ERYTHROMYCIN ; corticosteroids possibly reduce plasma
concentration of ISONIAZID ; metabolism of corticosteroids
accelerated by l RIFAMYCINS (reduced effect)
l Anticoagulants: corticosteroids may enhance or reduce
anticoagulant effect of l COUMARINS (high-dose
corticosteroids enhance anticoagulant effect); corticosteroids
may enhance or reduce anticoagulant effect of PHENINDIONE
▶ Antidiabetics: corticosteroids antagonise hypoglycaemic effect
of ANTIDIABETICS
l Antiepileptics: metabolism of corticosteroids accelerated by
l CARBAMAZEPINE , l FOSPHENYTOIN , l PHENOBARBITAL ,
l PHENYTOIN and l PRIMIDONE (reduced effect)
l Antifungals: metabolism of corticosteroids possibly inhibited
by ITRACONAZOLE and KETOCONAZOLE ; plasma concentration of
active metabolite of ciclesonide increased by
l KETOCONAZOLE ; plasma concentration of inhaled
mometasone increased by KETOCONAZOLE ; plasma
concentration of inhaled and oral (and possibly also
intranasal and rectal) budesonide increased by
l ITRACONAZOLE and l KETOCONAZOLE ; inhaled fluticasone
plasma concentration is possibly increased by KETOCONAZOLE ;
metabolism of methylprednisolone inhibited by
KETOCONAZOLE ; increased risk of hypokalaemia when
corticosteroids given with l AMPHOTERICIN —avoid
concomitant use unless corticosteroids needed to control
reactions; plasma concentration of inhaled fluticasone
increased by ITRACONAZOLE ; metabolism of
methylprednisolone possibly inhibited by ITRACONAZOLE ;
dexamethasone possibly reduces plasma concentration of
CASPOFUNGIN —consider increasing dose of caspofungin
l Antivirals: dexamethasone possibly reduces plasma
concentration of DACLATASVIR and SIMEPREVIR —manufacturer
of daclatasvir and simeprevir advises avoid concomitant use;
dexamethasone possibly reduces plasma concentration of
INDINAVIR , LOPINAVIR , SAQUINAVIR and TELAPREVIR ; avoidance
of dexamethasone (except when given as a single dose)
advised by manufacturer of l RILPIVIRINE ; plasma
concentration of inhaled and intranasal fluticasone increased
by l RITONAVIR —increased risk of adrenal suppression;
plasma concentration of budesonide (including inhaled,
intranasal, and rectal budesonide) possibly increased by
l RITONAVIR —increased risk of adrenal suppresion; plasma
concentration of corticosteroids possibly increased by
l RITONAVIR —increased risk of adrenal suppresision; plasma
concentration of inhaled and intranasal budesonide and
fluticasone possibly increased by TELAPREVIR
▶ Aprepitant: metabolism of dexamethasone and
methylprednisolone inhibited by APREPITANT (reduce dose of
dexamethasone and methylprednisolone)
▶ Beta-blockers: corticosteroids antagonise hypotensive effect of
BETA-BLOCKERS
▶

Calcium Salts: corticosteroids reduce absorption of CALCIUM
SALTS

▶

Calcium-channel Blockers: corticosteroids antagonise
hypotensive effect of CALCIUM-CHANNEL BLOCKERS ; plasma
concentration of methylprednisolone increased by DILTIAZEM
▶ Cardiac Glycosides: increased risk of hypokalaemia when
corticosteroids given with CARDIAC GLYCOSIDES
l Ciclosporin: high-dose methylprednisolone increases plasma
concentration of l CICLOSPORIN (risk of convulsions); plasma
concentration of prednisolone increased by CICLOSPORIN
▶ Clonidine: corticosteroids antagonise hypotensive effect of
CLONIDINE
▶

Cytotoxics: possible increased risk of hepatoxicity when
dexamethasone given with high-dose METHOTREXATE ;
dexamethasone possibly decreases plasma concentration of
AXITINIB (increase dose of axitinib—consult axitinib product
literature); dexamethasone possibly reduces plasma
concentration of CABOZANTINIB —manufacturer of
cabozantinib advises avoid concomitant use
▶ Diazoxide: corticosteroids antagonise hypotensive effect of
DIAZOXIDE

Interactions | Appendix 1

Appendix 1 Interactions 1179

BNF 70


Interactions

Corticosteroids (continued)

- Diuretics: corticosteroids antagonise diuretic effect of DIURETICS; increased risk of hypokalaemia when corticosteroids given with ACE-IZAMIDE, LOOP DIURETICS or RELATED DIURETICS
- Fosaprepitant: metabolism of dexamethasone and methylprednisolone inhibited by FOSAPREPITANT (reduce dose of dexamethasone and methylprednisolone)
- Grapefruit juice: plasma concentration of oral budesonide increased by GRAPEFRUIT JUICE—avoid concurrent use or separate administration by as much as possible and consider reducing oral budesonide dose
- Histamine: avoidance of corticosteroids advised by manufacturer of HISTAMINE
- Methyldopa: corticosteroids antagonise hypotensive effect of METHYLOPA
- Mefamurad: avoidance of corticosteroids advised by manufacturer of MEFAMURAD
- Mifepristone: effect of corticosteroids (including inhaled corticosteroids) may be reduced for 3–4 days after MIFEPRISTONE
- Moxonidine: corticosteroids antagonise hypotensive effect of MOXONIDINE
- Muscle Relaxants: corticosteroids possibly antagonise effects of pancuronium and vecuronium
- Nitrates: corticosteroids antagonise hypotensive effect of NITRATES
- Oestrogens: plasma concentration of corticosteroids increased by oral contraceptives containing OESTROGENS
- Sodium Benzolate: corticosteroids possibly reduce effects of SODIUM BENZOATE
- Sodium Phenylbutyrate: corticosteroids possibly reduce effects of SODIUM PHENYLButYRATE
- Somatropin: corticosteroids may inhibit growth—promoting effect of SOMATROPIN
- Sympathomimetens: metabolism of dexamethasone accelerated by EPHEDRINE
- Sympathomimetens, Beta-: increased risk of hypokalaemia when corticosteroids given with high doses of BETABlockers
- Theophylline: increased risk of hypokalaemia when corticosteroids given with THEOPHYLLINE
- Vaccines: high doses of corticosteroids impair immune response to VACCINES—avoid concomitant use with live vaccines
- Vasodilator Antihypertensives: corticosteroids antagonise hypotensive effect of HYDALAZINE, MINOXIDIL and SODIUM NITROPRUSIDE

Co-trimoxazole see Trimethoprim and Sulfamethoxazole

Corticotropin (continued)

- Anti-arrhythmics: metabolism of coumarins inhibited by AMIODARONE (enhanced anticoagulant effect); anticoagulant effect of warfarin may be enhanced or reduced by DISOPYRAMIDE; anticoagulant effect of coumarins possibly enhanced by MIFAMURTIDE; anticoagulant effect of warfarin enhanced by PROPafenONE
- Antibacterials: experience in anticoagulant clinics suggests that INR possibly altered when coumarins are given with NEOMYCIN (given for local action on gut); anticoagulant effect of coumarins enhanced by AZITHROMYCIN, AZTREONAM, CEPHALOSPORINS, CIPROFLOXACIN, LEVOFLOXACIN, TETRACYCLINES, TIGECYCLINE and TRIMETHOPRIM; anticoagulant effect of coumarins enhanced by CHLORAMPHENICOL, CLARITHROMYCIN, CYCLOTHYMICIN, METRONIDAZOLE, NALIDIXIC ACID, NORFLOXACIN, OFLOXACIN and SULFONAMIDES; plasma concentration of warfarin possibly increased by OROXACIN; an interaction between coumarins and broad-spectrum PENCILLINS has not been demonstrated in studies, but common experience in anticoagulant clinics is that INR can be and metabolism of coumarins accelerated by RIFAMYCINS (reduced anticoagulant effect)
- Anticoagulants: increased risk of haemorrhage when other anticoagulants given with APYRABAN, DABIGATRAN and RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)
- Antidepressants: anticoagulant effect of warfarin possibly enhanced by VENLAFAXINE; anticoagulant effect of warfarin may be enhanced or reduced by TRAZODONE; anticoagulant effect of coumarins possibly enhanced by SSRIS; anticoagulant effect of coumarins reduced by ST JOHN'S WORT (avoid concomitant use); anticoagulant effect of warfarin enhanced by MIRTAZAPINE; anticoagulant effect of coumarins may be enhanced or reduced by TRICYCLICS
- Antidiabetics: anticoagulant effect of warfarin possibly enhanced by CARBAMAZEPINE, PHENOBARBITAL and PRIMIDONE (reduced anticoagulant effect); plasma concentration of warfarin reduced by ESICARBAZEPINE; metabolism of coumarins accelerated by PHENYTOIN and PHENOTYPING (possibility of reduced anticoagulant effect, but enhancement also reported); anticoagulant effect of coumarins possibly enhanced by SODIUM VALPROATE and VALPROIC ACID
- Antifungals: anticoagulant effect of coumarins enhanced by FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE, ORICONAZOLE, VORICONAZOLE; anticoagulant effect of coumarins enhanced by MICONAZOLE (micronazole oral gel and possibly vaginal and topical formulations absorbed); anticoagulant effect of coumarins reduced by GRISEOFULVIN
- Antimalarials: isolated reports that anticoagulant effect of warfarin may be enhanced by PROGUANIL; plasma concentration of both drugs increased when warfarin given with QUININE
- Antivirals: anticoagulant effect of warfarin may be enhanced or reduced by ATAZANAVIR, NEVIRAPINE and RITONAVIR; plasma concentration of coumarins possibly affected by EFAVIRENZ; anticoagulant effect of coumarins may be enhanced or reduced by FOSAMPRENAVIR; anticoagulant effect of coumarins possibly enhanced by RITONAVIR; anticoagulant effect of warfarin possibly enhanced by SAQUINAVIR; plasma concentration of warfarin possibly affected by TELAPREVIR
- Antioxidants: metabolism of coumarins may be reduced by CHLORAL
- Aprapit: anticoagulant effect of warfarin possibly reduced by APREPATIN
- Azathioprine: anticoagulant effect of coumarins possibly reduced by AZATHIOPRINE
- Bosentan: monitoring anticoagulant effect of coumarins recommended by manufacturer of BOSENTAN

Note: Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control

- Alcohol: anticoagulant control with coumarins may be affected by major changes in consumption of ALCOHOL
- Alfaprin: anticoagulant effect of coumarins possibly enhanced by ALLOPURINOL
- Anabolic Steroids: anticoagulant effect of coumarins enhanced by ANABOLIC STEROIDS
- Analgesics: anticoagulant effect of coumarins possibly enhanced by NSAIDS; increased risk of haemorrhage when anticoagulants given with intravenous DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with KETOLOLAC (avoid concomitant use, including low-dose heparins); anticoagulant effect of coumarins enhanced by TRAMADOL; increased risk of bleeding when warfarin given with ASPRIN (due to antiplatelet effect); anticoagulant effect of coumarins possibly enhanced by prolonged regular use of PARACETAMOL
- Anthelmintics: anticoagulant effect of coumarins possibly enhanced by IVERMECTIN; anticoagulant effect of warfarin possibly enhanced by LEVAMISOLE
Appendix 1 Interactions

**Cumarins** (continued)
- **Clodigrel**: anticoagulant effect of cumarins enhanced due to antiplatelet action of **CLODIGREL**; avoidance of warfarin advised by manufacturer of **CLODIGREL**
- **Corticosteroids**: anticoagulant effect of cumarins may be enhanced or reduced by **CORTICOSTEROIDS** (high-dose corticosteroids enhance anticoagulant effect)
- **Cranberry Juice**: anticoagulant effect of cumarins possibly enhanced by **CRANBERRY JUICE**—avoid concomitant use
- **Cytoxotics**: anticoagulant effect of cumarins possibly enhanced by **ETOPOSIDE**, **IFOSFAMIDE** and **SORAFENIB**; anticoagulant effect of cumarins enhanced by **CAPECTABINE**, **FLUOROURACIL** and **TEGAFUR**; anticoagulant effect of warfarin possibly enhanced by **GETFINIB**, **GERMIBABINE** and **VEMARAFENIB**; anticoagulant effect of cumarins possibly reduced by **MERCAPTOPURINE** and **MITOTANE**; plasma concentration of warfarin reduced by **DABBRAFENIB**; increased risk of bleeding when cumarins given with **ERLOTINIB**; avoidance of cumarins advised by manufacturer of **BRUTINIB**; replacement of warfarin with a heparin advised by manufacturer of **MATINIB** (possibility of enhanced warfarin effect); increased risk of bleeding when warfarin given with **REGORAFENIB**
- **Dipyrindamide**: anticoagulant effect of cumarins enhanced due to antiplatelet action of **DESTROGENS**
- **Disulfiram**: anticoagulant effect of cumarins enhanced by **DISULFIRAM**
- **Dopaminergics**: anticoagulant effect of warfarin enhanced by **ENTACAPONE**
- **Enteral Foods—anticoagulant effect of cumarins antagonised by vitamin K (present in some **ENTERAL FEEDS**)**
  - **Fosapreplant**: anticoagulant effect of warfarin possibly reduced by **FOSAPREPLANT**
- **Glucosamine**: anticoagulant effect of warfarin enhanced by **GLUCOSAMINE** (avoid concomitant use)
- **Hormone Antagonists**: anticoagulant effect of cumarins possibly enhanced by **BICALUTAMIDE** and **Toremifene**; metabolism of cumarins inhibited by **DANAZOL** (enhanced anticoagulant effect); plasma concentration of cumarins possibly reduced by **ENALAPRILAMIDE**; anticoagulant effect of cumarins enhanced by **FLUTAMIDE** and **TAMOXIFEN**
  - **Iloprost**: anticoagulant effect of cumarins possibly enhanced by **ILOPROST**
  - **Lactulose**: anticoagulant effect of cumarins possibly enhanced by **LACTULOSE**
  - **Leflunomide**: anticoagulant effect of warfarin possibly enhanced by **LEFLUNOMIDE**
  - **Leukotriene Receptor Antagonists**: anticoagulant effect of warfarin enhanced by **ZAFVRUKAST**
  - **Levocabarnine**: anticoagulant effect of cumarins possibly enhanced by **LEVOCARNITINE**
  - **Lipid-regulating Drugs**: anticoagulant effect of cumarins may be enhanced or reduced by **COLESTYRAMINE**; anticoagulant effect of warfarin may be transiently reduced by **ATORVASTATIN**; anticoagulant effect of cumarins enhanced by **FIBRATES** and **FLUVASTATIN**; anticoagulant effect of cumarins possibly enhanced by **EZETIMIBE** and **ROSVUVASTATIN**; anticoagulant effect of cumarins can be enhanced by **SIMVASTATIN**; anticoagulant effect of warfarin possibly enhanced by **LOMITAPIDE**
  - **Memantine**: anticoagulant effect of warfarin possibly enhanced by **MEMANTINE**
  - **Oestrogens**: anticoagulant effect of cumarins may be enhanced or reduced by **OESTROGENS**
  - **Oritstat**: monitoring anticoagulant effect of cumarins recommended by manufacturer of **ORLISTAT**
  - **Prasugrel**: possible increased risk of bleeding when cumarins given with **PRASUGREL**
  - **Progesterones—anticoagulant effect of cumarins may be enhanced or reduced by **PROGESTOGENS**
  - **Raloxifene**: anticoagulant effect of cumarins antagonised by **RALOXIFENE**
  - **Retinoids**: anticoagulant effect of cumarins possibly reduced by **ACITRETIN**
  - **Sulfinpyrazone**: anticoagulant effect of cumarins enhanced by **SULFINPYRAZONE**

**Cumarins** (continued)
- **Sympathomimetics**: anticoagulant effect of cumarins possibly enhanced by **METHYLPHENIDATE**
- **Testolactone**: anticoagulant effect of cumarins enhanced by **TESTOLACTONE**
- **Testosterone**: anticoagulant effect of cumarins enhanced by **TESTOSTERONE**
- **Thyroid Hormones**: anticoagulant effect of cumarins enhanced by **THYROID HORMONES**
- **Ubidecarenone**: anticoagulant effect of warfarin may be enhanced or reduced by **UBIDEARENONE**
- **Ulcer-healing Drugs—metabolism of cumarins inhibited by **CIMETIDINE** (enhanced anticoagulant effect); anticoagulant effect of cumarins possibly enhanced by **ESOMEPRAZOLE** and **OMEPRAZOLE**; anticoagulant effect of cumarins might be enhanced by **PANTOPRAZOLE**; absorption of cumarins possibly reduced by **SUCRALFATE** (reduced anticoagulant effect)
- **Vaccines**: anticoagulant effect of warfarin possibly enhanced by **INFLUENZA VACCINE**
- **Vitamins**: anticoagulant effect of cumarins possibly enhanced by **VITAMIN E**; anticoagulant effect of cumarins antagonised by **VITAMIN K**

**Cranberry Juice**
- **Anticoagulants**: cranberry juice possibly enhances anticoagulant effect of **CUMARINS**—avoid concomitant use

**Crizotinib**
- **Analgesics**: manufacturer of crizotinib advises caution with **ALFENTANIL** and **FENTANYL**
- **Antibacterials**: plasma concentration of crizotinib possibly increased by **CLARITHROMYCIN** and **TELITHROMYCIN**—manufacturer of crizotinib advises avoid concomitant use; plasma concentration of crizotinib possibly reduced by **RIFABUTIN**—manufacturer of crizotinib advises avoid concomitant use; plasma concentration of crizotinib reduced by **RIFAMPICIN**—manufacturer of crizotinib advises avoid concomitant use
- **Antidepressants**: plasma concentration of crizotinib possibly reduced by **ST JOHN'S WORT**—manufacturer of crizotinib advises avoid concomitant use
- **Antiepileptics**: plasma concentration of crizotinib possibly reduced by **CARBAMAZEPINE**, **FOSPHENYTOIN**, **PHENOBARBITAL**, **PHENYTOIN** and **PRIMIDONE**—manufacturer of crizotinib advises avoid concomitant use
- **Antifungals**: plasma concentration of crizotinib increased by **KETOCONAZOLE**—avoid concomitant use; plasma concentration of crizotinib possibly increased by **ITRACONAZOLE** and **VORICONAZOLE**—manufacturer of crizotinib advises avoid concomitant use
- **Antimalarials**: possible increased risk of bradycardia when crizotinib given with **MEfloQUINE**
- **Antipsychotics**: avoid concomitant use of cytoxotics with **CLOZAPINE** (increased risk of agranulocytosis); manufacturer of crizotinib advises caution with **PIMOZIDE**
- **Antivirals**: plasma concentration of crizotinib possibly increased by **ATAZANAVIR**, **INDINAVIR**, **RITONAVIR** and **SAQUINAVIR**—manufacturer of crizotinib advises avoid concomitant use
- **Anxiolytics and Hypnotics**: crizotinib increases plasma concentration of **NIDAZOLAM**
  - **Beta-blockers**: possible increased risk of bradycardia when crizotinib given with **BETA-BLOCKERS**
  - **Calcium-channel blockers**: possible increased risk of bradycardia when crizotinib given with **DILTIAZEM** or **VERAPAMIL**
  - **Cardiac Glycosides**: possible increased risk of bradycardia when crizotinib given with **DIGOXIN**
  - **Ciclosporin**: manufacturer of crizotinib advises caution with **CICLOSPORIN**
  - **Clonidine**: possible increased risk of bradycardia when crizotinib given with **CLONIDINE**
  - **Cytotoxic**: crizotinib possibly increases the plasma concentration of **IBRUTINIB**—reduce dose of ibrutinib (see under ibrutinib, p. 809)
  - **Ergot Alkaloids**: manufacturer of crizotinib advises caution with **ERGOT ALKALOIDS**
Dabigatran
- Antidepressants (continued) - manufacturer of dabigatran advises avoid concomitant use
  - Antidepressants: plasma concentration of dabigatran possibly reduced by CARBAMAZEPINE, ROSANOFEN and PHENOTYN — manufacturer of dabigatran advises avoid concomitant use
  - Antifungals: plasma concentration of dabigatran increased by KETOCONAZOLE — avoid concomitant use; manufacturer of dabigatran advises avoid concomitant use with TACRIMACAZOLE
  - Antivirals: plasma concentration of dabigatran possibly increased by RILPIVIRINE and TELAPREVIR
- Calcium-channel Blockers: plasma concentration of dabigatran possibly increased by VERAPAMIL (see under Dabigatran)
- Clicosporin: plasma concentration of dabigatran possibly increased by CICLOSPORIN — manufacturer of dabigatran advises avoid concomitant use
- Sulfinpyrazine: possible increased risk of bleeding when dabigatran given with CICLOSPORIN
- Tacrolimus: manufacturer of dabigatran advises avoid concomitant use
  - TACRIMACAZOLE
- Ulipristal: manufacturer of ulipristal gives dabigatran at least 1.5 hours before or after ULIPRISTAL

Dabrafenib
- Antibacterials: manufacturer of dabrafenib gives advice to concomitant use with RIFAMPICIN
- Anticoagulants: dabrafenib reduces plasma concentration of WARFARIN
- Antidepressants: manufacturer of dabrafenib advises avoid concomitant use with ST JOHN'S WORT
- Antiepileptics: manufacturer of dabrafenib advises avoid concomitant use with CARBAMAZEPINE, ROSANOFEN, PHENOBARBITAL, PHENOTYN and PRIMIDONE
- Antifungals: plasma concentration of dabrafenib increased by KETOCONAZOLE
- Antipsychotics: avoid concomitant use of cytotoxics with CLOZAPINE (increased risk of agranulocytosis)
- Antivirals: plasma concentration of dabrafenib increased by GEMFIBROZIL
- Estrogens: manufacturer of dabrafenib advises contraceptive effect of hormonal contraceptives containing OESTROGENS possibly reduced (alternative contraceptive recommended)
- Progestogens: manufacturer of dabrafenib advises contraceptive effect of hormonal contraceptives containing PROGESTOGENS possibly reduced (alternative contraceptive recommended)
- Ulcer-healing Drugs: manufacturer of dabrafenib advises avoid concomitant use with PROTON PUMP INHIBITORS (plasma concentration of dabrafenib possibly reduced)

Dacarbazine
- Alcohol: avoidance of dacarbazine advised by manufacturer of ALDESELIUN
- Antipsychotics: avoid concomitant use of cytotoxics with CLOZAPINE (increased risk of agranulocytosis)

Dactasvir
- Anti-arrhythmics: possible increased risk of bleeding when dactasvir (with sofosbuvir) given with RIFAMPICIN — manufacturer of dabigatran advises avoid concomitant use
- Anticoagulants: plasma concentration of dactasvir possibly increased by CARBAMAZEPINE, ROSANOFEN and PHENOTYN — see under Amiodarone, p. 88
- Antibacterials: plasma concentration of dactasvir possibly increased by CLARITHROMYCIN and TELFORANCIN — reduce dose of dactasvir (see under Dactasvir, p. 544)
- Antidepressants: plasma concentration of dactasvir possibly increased by RIFABUTIN — manufacturer of dabigatran advises avoid concomitant use; plasma concentration of dactasvir possibly reduced by RIFAMPICIN — avoid concomitant use
- Antipsychotics: plasma concentration of dactasvir possibly increased by ST JOHN'S WORT — manufacturer of dactasvir advises avoid concomitant use
- Antiepileptics: plasma concentration of dactasvir possibly reduced by CARBAMAZEPINE, ROSANOFEN, OXCARBAMAZEPINE, PHENOBARBITAL, PHENOTYN and
Daclatasvir
- Antiepileptics: manufacturer of daclatasvir advises avoid concomitant use
- Antifungals: plasma concentration of daclatasvir increased by
  - KETOCONAZOLE—reduce dose of daclatasvir (see under Daclatasvir, p. 544); plasma concentration of daclatasvir possibly increased by
  - ITRACONAZOLE, POSaconazole and
  - voriconazole—reduce dose of daclatasvir (see under Daclatasvir, p. 544)
- Antivirals: plasma concentration of daclatasvir increased by
  - atazanavir and telaprevir—reduce dose of daclatasvir (see under Daclatasvir, p. 544); plasma concentration of daclatasvir possibly increased by
  - boceprevir—reduce dose of daclatasvir (see under Daclatasvir, p. 544); manufacturer of daclatasvir advises avoid concomitant use with darunavir and lopinavir (plasma concentration of daclatasvir possibly increased); plasma concentration of daclatasvir reduced by
  - Efavirenz—increase dose of daclatasvir (see under Daclatasvir, p. 544); manufacturer of daclatasvir advises avoid concomitant use
- Cardiac glycosides: daclatasvir increases plasma concentration of digoxin
- Corticosteroids: plasma concentration of daclatasvir possibly reduced by
dexamethasone—manufacturer of daclatasvir advises avoid concomitant use
- Lipid-regulating Drugs: daclatasvir increases plasma concentration of rosuvastatin

Dactinomycin
- Antipsychotics: avoid concomitant use of cytoxicities with
clozapine (increased risk of agranulocytosis)
- Vitamins: dactinomycin possibly reduces effects of alfalfacalcidol, calcitriol, colecalciferol, dihydrotrachysterol, ergocalciferol, paricalcitol and vitamin D

Dairy Products
- Antibacterials: dairy products reduce absorption of ciprofloxacin and norfloxacin; dairy products reduce absorption of tetracyclines (except doxycycline and minocycline)
- Cytotoxic: dairy products possibly reduce plasma concentration of mercaptopurine—manufacturer of mercaptopurine advises give at least 1 hour before or 2 hours after dairy products
- Ertrombopag: dairy products possibly reduce absorption of erthropag (give at least 4 hours apart)

Dalteparin see Heparins

Danaparoid
- Analgesics: increased risk of haemorrhage when anticoagulants given with intravenous diclofenac (enhanced anticoagulant effect)
- Antiepileptics: danaparoid inhibits metabolism of
  - Carbamazepine (increased risk of toxicity)
- Ciclosporin: danaparoid inhibits metabolism of
  - ciclosporin (increased plasma concentration)
- Lipid-regulating Drugs: possible increased risk of myopathy when danaparoid given with
  - simvastatin—avoid concomitant use
  - Tacrolimus: danaparoid possibly increases plasma concentration of tacrolimus

Dantrolene see Muscle Relaxants

Dapagliflozin see Antidiabetics

Dapoxetine
- Alcohol: increased sedative effect when dapoxetine given with
  - alcohol
- Analgesics: possible increased risk of serotonergic effects when dapoxetine given with
  - tramadol (manufacturer of dapoxetine advises tramadol should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping tramadol)
- Antibacterials: manufacturer of dapoxetine advises dose reduction when dapoxetine given with clarithromycin and erythromycin (see under Dapoxetine, p. 703); manufacturer of dapoxetine advises avoid concomitant use with
  - telithromycin (increased risk of toxicity)
- Antidepressants: possible increased risk of serotonergic effects when dapoxetine given with
  - SSRIs, St John’s Wort,
  - duloxetine, tricyclics and venlafaxine (manufacturer of dapoxetine advises SSRIs, St John’s Wort, duloxetine, tricyclics and venlafaxine should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping SSRIs, St John’s Wort, duloxetine, tricyclics and venlafaxine); increased risk of serotonergic effects when dapoxetine given with
  - MAOIs (MAOIs should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping MAOIs)
- Antifungals: plasma concentration of dapoxetine increased by
  - Ketoconazole—manufacturer of dapoxetine advises avoid concomitant use; manufacturer of dapoxetine advises dose reduction when dapoxetine given with fluconazole (see under Dapoxetine, p. 705); manufacturer of dapoxetine advises avoid concomitant use with
  - Itracnazole (increased risk of toxicity)
- Antivirals: manufacturer of dapoxetine advises avoid concomitant use with
  - atazanavir, ritonavir and
  - saquinavir (increased risk of toxicity); manufacturer of dapoxetine advises dose reduction when dapoxetine given with fosamprenavir (see under Dapoxetine, p. 705)
- Aprepitant: manufacturer of dapoxetine advises dose reduction when dapoxetine given with aprepitant (see under Dapoxetine, p. 705)
- Calcium-channel Blockers: manufacturer of dapoxetine advises dose reduction when dapoxetine given with diltiazem and verapamil (see under Dapoxetine, p. 705)
- SHT receptor agonists: possible increased risk of serotonergic effects when dapoxetine given with
  - sHT agonists (manufacturer of dapoxetine advises SHT agonists should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping SHT agonists)
- Lithium: possible increased risk of serotonergic effects when dapoxetine given with
  - lithium (manufacturer of dapoxetine advises lithium should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping lithium)
- Sildenafil: manufacturer of dapoxetine advises avoid concomitant use with sildenafil
- Tadalafil: manufacturer of dapoxetine advises avoid concomitant use with tadalafil
- Vardenafil: manufacturer of dapoxetine advises avoid concomitant use with vardenafil

Dapsone
- Antibacterials: plasma concentration of dapsone reduced by rifampcins; plasma concentration of both drugs may increase when dapsone given with trimethoprim
- Antivirals: increased risk of ventricular arrhythmias when dapsone given with
  - saquinavir—avoid concomitant use
- Vaccines: antibacterials inactivate oral typhoid vaccine—see under Typhoid Vaccine in BNF

Daptomycin
- Ciclosporin: increased risk of myopathy when daptomycin given with
  - ciclosporin (preferably avoid concomitant use)
- Lipid-regulating Drugs: increased risk of myopathy when daptomycin given with
  - fibrates or
  - statins (preferably avoid concomitant use)
### Appendix 1 Interactions

#### Darunavir
- **Antituberculars:** darunavir possibly increases plasma concentration of **LIDOCAINE**—avoid concomitant use
- **Antibacterials:** darunavir increases plasma concentration of **RIFABUTIN** (reduce dose of rifabutin); plasma concentration of darunavir significantly reduced by **RIFAMPICIN**—avoid concomitant use
- **Anticoagulants:** avoidance of darunavir advised by manufacturer of **APIXABAN** and **RIVAROXABAN**
- **Antidepressants:** darunavir possibly reduces plasma concentration of **PAROXETINE** and **SERTRALINE**; plasma concentration of darunavir reduced by **ST JOHN’S WORT**—avoid concomitant use
- **Antiepileptics:** plasma concentration of darunavir possibly increased by **CARBAMAZEPINE**, **FOSPHENYTOIN**, **PHENOBARBITAL**, **PHENYTOIN** and **PRIMIDONE**
- **Antifungals:** plasma concentration of both drugs increased when darunavir given with **KETOCONAZOLE**
- **Antimalarials:** plasma concentration of lumefantrine increased when darunavir given with **ARTEMETHER WITH LUMEFANTRINE**; darunavir possibly increases plasma concentration of **QUININE** (increased risk of toxicity)
- **Antipsychotics:** darunavir possibly increases plasma concentration of **ARIPIPRAZOLE** (reduce dose of aripiprazole—consult aripiprazole product literature); darunavir possibly increases plasma concentration of **QUETIAPINE**—manufacturer of quetiapine advises avoid concomitant use
- **Antivirals:** avoidance of darunavir with **BOCEPREVIR** or **TELPREVIR**; avoidance of darunavir advised by manufacturer of **DEFERASIROX** (plasma concentration of deferasirox possibly increased); manufacturer of darunavir advises take **DIDANOSINE** 1 hour before or 2 hours after darunavir; plasma concentration of darunavir reduced by **EFAVirenz** (adjust dose—consult product literature); plasma concentration of both drugs increased when darunavir given with **INDINAVIR**; plasma concentration of darunavir reduced by **LOPINAVIR**, also plasma concentration of lopinavir increased (avoid concomitant use); darunavir increases plasma concentration of **MARAViroC** (consider reducing dose of maraviroc); increased risk of rash when darunavir given with **Raltegravir**; plasma concentration of darunavir reduced by **SAQUINAVIR**; plasma concentration of both drugs increased when darunavir given with **SIMPEPREVIR**—manufacturer of simprevir advises avoid concomitant use
- **Cytotoxics:** darunavir possibly increases the plasma concentration of **BOsUTINIB**—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; darunavir possibly increases plasma concentration of **EVEROLimus**—manufacturer of everolimus advises avoid concomitant use; darunavir possibly increases the plasma concentration of **IBRUTINIB**—reduce dose of ibrutinib (see under ibrutinib, p. 809)
- **Ergot Alkaloids:** increased risk of ergotism when darunavir given with **ERGOT ALKALOIDS**—manufacturer of darunavir advises avoid concomitant use
- **Lipid-regulating Drugs:** possible increased risk of myopathy when darunavir given with **ATORVASTATIN**; darunavir possibly increases plasma concentration of **PRAVASTATIN**; darunavir increases plasma concentration of **ROSUVASTATIN**—adjust dose of rosuvastatin (consult product literature); avoidance of darunavir advised by manufacturer of **Lomitapide** (plasma concentration of lomitapide possibly increased)
- **Orlistat:** absorption of darunavir possibly reduced by **ORLSTAT**
- **Ranolazine:** darunavir possibly increases plasma concentration of **RANOLAZINE**—manufacturer of ranolazine advises avoid concomitant use

#### Dasatinib
- **Antibacterials:** manufacturer of dasatinib advises avoid concomitant use with **CLARITHROMYCIN**, **ERYTHROMYCIN** and **ERITROMYCIN (plasma concentration of dasatinib possibly increased); metabolism of dasatinib accelerated by **RIFAMPICIN** (reduced plasma concentration—avoid concomitant use)
- **Antiepileptics:** manufacturer of dasatinib advises avoid concomitant use with **CARBAMAZEPINE**, **FOSPHENYTOIN**, **PHENOBARBITAL**, **PHENYTOIN** and **PRIMIDONE** (plasma concentration of dasatinib possibly reduced)
- **Antifungals:** plasma concentration of dasatinib possibly increased by **KETOCONAZOLE**; manufacturer of dasatinib advises avoid concomitant use with **itraconazole** (plasma concentration of dasatinib possibly increased)
- **Antipsychotics:** avoid concomitant use of cytotoxics with **CLOZAPINE** (increased risk of agranulocytosis)
- **Antivirals:** avoidance of dasatinib advised by manufacturer of **BOCEPREVIR**; manufacturer of dasatinib advises avoid concomitant use with **RITONAVIR** (plasma concentration of dasatinib possibly increased)
- **Grapefruit Juice:** manufacturer of dasatinib advises avoid concomitant use with **GRAPEFRUIT JUICE** (plasma concentration of dasatinib possibly increased)
- **Lipid-regulating Drugs:** dasatinib possibly increases plasma concentration of **SIMVASTATIN**
- **Ulcer-healing Drugs:** plasma concentration of dasatinib possibly reduced by **FAMOTIDINE**

#### Decitabine
- **Antipsychotics:** avoid concomitant use of cytotoxics with **CLOZAPINE** (increased risk of agranulocytosis)

#### Deferasirox
- **Aminophylline:** deferasirox increases plasma concentration of **AMINOPHYLLINE** (consider reducing dose of aminophylline)
- **Antacids:** absorption of deferasirox possibly reduced by **ANTACIDS containing aluminium** (manufacturer of deferasirox advises avoid concomitant use)
- **Antibacterials:** plasma concentration of deferasirox reduced by **RIFAMPICIN**
- **Antidiabetics:** deferasirox increases plasma concentration of **RIPAGLINDIDE**
- **Antipsychotics:** manufacturer of deferasirox advises avoid concomitant use with **CLOZAPINE**
- **Anxiolytics and Hypnotics:** deferasirox possibly reduces plasma concentration of **MIDAZOLAM**
- **Muscle Relaxants:** manufacturer of deferasirox advises avoid concomitant use with **TIZANIDINE**
- **Theophylline:** deferasirox increases plasma concentration of **THEOPHYLLINE** (consider reducing dose of theophylline)

#### Deferiprone
- **Antacids:** absorption of deferiprone possibly reduced by **ANTACIDS containing aluminium** (manufacturer of deferiprone advises avoid concomitant use)

#### Deflazacort
- **Corticosteroids**

#### Delamanid
- **Analgesics:** increased risk of ventricular arrhythmias when delamanid given with **METHADONE**
- **Anti-arrhythmics:** increased risk of ventricular arrhythmias when delamanid given with **AMIODARONE** or **DISOPYRAMIDE**
- **Antibacterials:** possible increased risk of ventricular arrhythmias when delamanid given with **CLARITHROMYCIN** and **ERYTHROMYCIN**; increased risk of ventricular arrhythmias when delamanid given with **MOXIFLOXACIN**; plasma concentration of delamanid reduced by **RIFAMPICIN**; delamanid increases plasma concentration of **ETHAMBUTOL**
- **Antidepressants:** possible increased risk of ventricular arrhythmias when delamanid given with **TRICYCLICS** that prolong the QT interval
- **Antiepileptics:** manufacturer of delamanid advises avoid concomitant use with **CARBAMAZEPINE**
- **Antipsychotics:** increased risk of ventricular arrhythmias when delamanid given with **DROPERIDOL**, **HALOPERIDOL** or **PIIMODIZE**; increased risk of ventricular arrhythmias when delamanid given with **PHENObazETINES** that prolong the QT interval
**Delamanid (continued)**
- Antivirals: plasma concentration of delamanid increased by **LOPINAVIR** and **RITONAVIR**; increased risk of ventricular arrhythmias when delamanid given with **SAQUINAVIR**
- Beta-blockers: increased risk of ventricular arrhythmias when delamanid given with **SOTALOL**
- Cytoxics: increased risk of ventricular arrhythmias when delamanid given with **ARSENIC TRIOXIDE** or **VINFLUNINE**; possible increased risk of ventricular arrhythmias when delamanid given with **VINBLASTINE**, **VINCristine**, **VINDesine** and **VINORELBine**
- Domperidone: possible increased risk of ventricular arrhythmias when delamanid given with **DOMPERIDONE**
- Pentamidine isetionate: increased risk of ventricular arrhythmias when delamanid given with **PENTAMIDINE ISETIONATE**

**Diazoxide (continued)**
- Antioxidants: enhanced hypotensive effect when diazoxide given with **ANGIOTENSIN-II RECEPTOR ANTAGONISTS**
  - ACE inhibitors: enhanced hypotensive effect when diazoxide given with **ACE INHIBITORS**
  - Adrenergic Neurone Blockers: enhanced hypotensive effect when diazoxide given with **ADRENERGIC NEURONE BLOCKERS**
  - Alcohol: enhanced hypotensive effect when diazoxide given with **ALCOHOL**
  - Aldesleukin: enhanced hypotensive effect when diazoxide given with **ALDESLEUKIN**
  - Alpha-blockers: enhanced hypotensive effect when diazoxide given with **ALPHA-BLOCKERS**
  - Anaesthetics, General: enhanced hypotensive effect when diazoxide given with **GENERAL ANAESTHETICS**
  - Analgesics: hypotensive effect of diazoxide antagonised by **NSAIDS**
  - Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when diazoxide given with **ANGIOTENSIN-II RECEPTOR ANTAGONISTS**
  - Antidepressants: enhanced hypotensive effect when diazoxide given with **MAOIS** or **TRICYCLIC-RELATED ANTIDEPRESSANTS**
  - Antidiabetics: diazoxide antagonises hypoglycaemic effect of **ANTI DIABETICS**
  - Antiepileptics: diazoxide reduces plasma concentration of **FOSPHENYTOIN** and **PHENYTOIN**, also effect of diazoxide may be reduced
  - Antipsychotics: enhanced hypotensive effect when diazoxide given with **PHENOTHIAZINES**

**Dopamine (continued)**
- Antihistamines: enhanced hypotensive effect when diazoxide given with **ANTIHISTAMINES**
- Corticosteroids: enhanced hypotensive effect of diazoxide antagonised by **CORTICOSTEROIDS**
- Diuretics: enhanced hypotensive and hyperglycaemic effects when diazoxide given with **DIURETICS**
- Dopaminergics: enhanced hypotensive effect when diazoxide given with **CO-BENZEDOCA, CO-CARELDOPA or LEVODOPA**
  - Methyldopa: enhanced hypotensive effect when diazoxide given with **METHYLDOPA**
  - Moxisylyte: enhanced hypotensive effect when diazoxide given with **MOXISLYTE**
  - Moxonidine: enhanced hypotensive effect when diazoxide given with **MOXONIDINE**
  - Muscle Relaxants: enhanced hypotensive effect when diazoxide given with **BACLOFEN or TIZANIDINE**
  - Nitrates: enhanced hypotensive effect when diazoxide given with **NITRATES**
  - Prostaglandins: enhanced hypotensive effect when diazoxide given with **ALPROSTADIL**
  - Vasodilator Antihypertensives: enhanced hypotensive effect when diazoxide given with **HYDRAZALINE, MINOXIDIL or SODIUM NITROPRUSSIDE**

**Diclofenac (see NSAIDs)**

**Dicycloverine (see Antimuscarinics)**

**Didanosine**
- Analgesics: enhanced hypotensive effect when diazoxide given with **analgesics**
- Antacids in tablet formulation might affect absorption of other drugs—give at least 2 hours apart
- Allopurinol: plasma concentration of didanosine increased by **ALLOPURINOL** (risk of toxicity)—avoid concomitant use
- Analgesics: plasma concentration of didanosine possibly reduced by **METHADONE**
- Antibacterials: manufacturer of norfloxacin advises give didanosine at least 2 hours before or after **NORFLOXACIN**
- Antivirals: didanosine **tablets** reduce absorption of **ATAZANAVIR** (give at least 2 hours before or 1 hour after didanosine tablets); manufacturer of darunavir advises take didanosine 1 hour before or 2 hours after **DARUNAVIR**; plasma concentration of didanosine possibly increased by **GANCICLOVIR** and **VALGANCICLOVIR**; didanosine **tablets** reduce absorption of **INDINAVIR** (give at least 1 hour apart); increased risk of side-effects when didanosine given with **INDINAVIR**—avoid concomitant use; manufacturer of rilpivirine advises give didanosine 2 hours before or 4 hours after **RILPIVIRINE**; manufacturer of ritonavir advises didanosine and **RITONAVIR** should be taken 2.5 hours apart; increased risk of side-effects when didanosine given with **STAVUDINE**; plasma concentration of didanosine increased by **TENOFIVIR** (increased risk of toxicity)—avoid concomitant use; plasma concentration of didanosine reduced by **TIPRANAVIR**—manufacturer of tipranavir advises tipranavir and didanosine capsules should be taken at least 2 hours apart
- Cytotoxic: increased risk of toxicity when didanosine given with **HYDROXYCARBAMIDE**—avoid concomitant use
- Orlistat: absorption of didanosine possibly reduced by **ORLISTAT**
  - Ditogen (see Progestogens)

**Diethylcarbamazine**
- Antacids: excretion of diethylcarbamazine increased by **SODIUM BICARBONATE**

**Digoxin** (see Cardiac Glycosides)

**Dihydronephrine** (see Opioid Analgesics)

**Dihydrotachysterol** (see Vitamins)

**Diltiazem** (see Calcium-channel Blockers)

**Dimethyl sulfoxide**
- Analgesics: avoid concomitant use of dimethyl sulfoxide with **DICTOL** or **SULINDAC**

**Dimoprostine** (see Prostaglandins)
Disopyramide (continued)
- Antivirals: plasma concentration of disopyramide possibly increased by **RITONAVIR** (increased risk of toxicity); increased risk of ventricular arrhythmias when disopyramide given with **SAQUINAVIR**—avoid concomitant use; avoidance of disopyramide advised by manufacturer of **TELAPREVIR** (risk of ventricular arrhythmias)
- Atomoxetine: increased risk of ventricular arrhythmias when disopyramide given with **ATOMOXETINE**
- Beta-blockers: increased myocardial depression when anti-arrhythmics given with **BETA-BLOCKERS**; increased risk of ventricular arrhythmias when disopyramide given with **SOTALOL**—avoid concomitant use
- Calcium-channel Blockers: increased risk of myocardial depression and asystole when disopyramide given with **VERAPAMIL**
- Cytotoxics: possible increased risk of ventricular arrhythmias when disopyramide given with **BOUSUTINIB**; possible increased risk of ventricular arrhythmias when disopyramide given with **VANDETANIB**—avoid concomitant use; increased risk of ventricular arrhythmias when disopyramide given with **PHENYLTRIAZINE**

**Disopyramide**
- Anaesthetics, Local: increased myocardial depression when anti-arrhythmics given with **BUPIVACAINE**, **LEVOBUPIVACAINE**, **PRILOCaine** or **ROPIVACAINE**
- Anti-arrhythmics: increased myocardial depression when anti-arrhythmics given with **AMIODARONE** or **DRONEDARONE**—avoid concomitant use
- Antibacterials: plasma concentration of disopyramide possibly increased by **CLARITHROMYCIN** (increased risk of toxicity); plasma concentration of disopyramide possibly increased by **ERYTHROMYCIN** (increased risk of toxicity); increased risk of ventricular arrhythmias when disopyramide given with **MOXIFLOXACIN**—avoid concomitant use; increased risk of ventricular arrhythmias when disopyramide given with **RIFAMYCINS** (reduced plasma concentration); possible increased risk of ventricular arrhythmias when disopyramide given with **TELITHROMYCIN**
- Anticoagulants: disopyramide may enhance or reduce anticoagulant effect of **WARFARIN**
- Antidepressants: avoidance of disopyramide advised by manufacturer of **CITALOPRAM** and **ESCITALOPRAM** (risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when disopyramide given with **TRICYCLICS**
- Antidiabetics: disopyramide possibly enhances hypoglycaemic effect of **GLICLAZIDE**, **INSULIN** and **METFORMIN**
- Antiepileptics: plasma concentration of disopyramide reduced by **FOSPHENYTOIN** and **PHENYTOIN**; metabolism of disopyramide accelerated by **PHENOBARBITAL** and **PRIMIDONE** (reduced plasma concentration)
- Antifungals: increased risk of ventricular arrhythmias when disopyramide given with **KETOCONAZOLE**—avoid concomitant use; avoidance of disopyramide advised by manufacturer of **ITRACONAZOLE**
- Antihistamines: increased risk of ventricular arrhythmias when disopyramide given with **MIOLASTINE**—avoid concomitant use
- Antimalarias: avoidance of disopyramide advised by manufacturer of **ARTEMETHER WITH LUMEFANTRINE** (risk of ventricular arrhythmias); avoidance of disopyramide advised by manufacturer of **ARTEMETHOL WITH PIPERAQUINE** (possible risk of ventricular arrhythmias)
- Antimicrobials: recent increased risk of antimicrobial side-effects when disopyramide given with **ANTIMICROBIALS**; increased risk of ventricular arrhythmias when disopyramide given with **TOLTERODINE**
- Antipsychotics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with **ANTIPSYCHOTICS** that prolong the QT interval; increased risk of ventricular arrhythmias when disopyramide given with **AMISULPRIDE**, **DROPERIDOL**, **HALOPERIDOL** or **ZUCLOPENTHIXOL**—avoid concomitant use; possible increased risk of ventricular arrhythmias when disopyramide given with **HALOPERIDOL**—avoid concomitant use; increased risk of ventricular arrhythmias when disopyramide given with **PHENOTHIAZINES** or **SULPHIRIDE**

**NOTE** Since systemic absorption may follow topical application of brinzolamide to the eye, the possibility of interactions should be borne in mind

**Diuretics**
- Alcohol: disulfram reaction when disulfram given with **ALCOHOL**
- Aminophylline: disulfram inhibits metabolism of **AMINOPHYLLINE** (increased risk of toxicity)
- Antibacterials: psychotic reaction reported when disulfram given with **METRONIDAZOLE**; CNS effects of disulfram possibly increased by **ISONIAZID**
- Anticoagulants: disulfram enhances anticoagulant effect of **COUMARINS**
- Antidepressants: increased disulfram reaction with alcohol reported with concomitant **AMITRIPTYLINE**; disulfram inhibits metabolism of **TRICYCLICS** (increased plasma concentration)
- Anti-epileptics: disulfram inhibits metabolism of **FOSPHENYTOIN** and **PHENYTOIN** (increased risk of toxicity)
- Anxiolytics and Hypnotics: disulfram increases risk of **TEMAZEPAM** toxicity; disulfram inhibits metabolism of **BENZODIAZEPINES** (increased sedative effects)
- Paraldehyde: risk of toxicity when disulfram given with **PARALDEHYDE**
- Theophylline: disulfram inhibits metabolism of **THEOPHYLLINE** (increased risk of toxicity)
Anti-arrhythmics:

- Angiotensin-II Receptor Antagonists:
  - Increased risk of severe hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with ACE INHIBITORS.
  - Increased risk of hyperkalaemia when given with ADRENERGIC NEURONE BLOCKERS.
  - Alcohol: enhanced hypotensive effect when diuretics given with ALCOHOL.
  - Aminophylline: increased hypotensive effect when diuretics given with ALDESLEUKIN.
  - Allskiren: plasma concentration of furosemide reduced by ALISKIREN; increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS.
  - Allopurinol: increased risk of hyperkalaemia when given with ACE INHIBITORS; increased risk of toxicity when given with ACE INHIBITORS.
  - Alcohol: enhanced hypotensive effect when diuretics given with ALCOHOL.
  - Aminophylline: increased hypotensive effect when diuretics given with ALDESLEUKIN.
  - Allskiren: plasma concentration of furosemide reduced by ALISKIREN; increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS.
  - Allopurinol: increased risk of hyperkalaemia when given with ALDESLEUKIN.
  - Allskiren: plasma concentration of furosemide reduced by ALISKIREN; increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS.

Analgesics:

- Aminophylline: increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS.

ACE Inhibitors:

- ACE Inhibitors: enhanced hypotensive effect when diuretics given with ACE INHIBITORS; increased risk of severe hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with ACE INHIBITORS.

ADRENERGIC NEURONE BLOCKERS:

- Alcohol: enhanced hypotensive effect when diuretics given with ALCOHOL.

Alpha-blockers:

- Alcohol: enhanced hypotensive effect when diuretics given with ALCOHOL.

Alpha-blockers:

- Alcohol: enhanced hypotensive effect when diuretics given with ALCOHOL.

Alcohol:

- Alcohol: enhanced hypotensive effect when diuretics given with ALCOHOL.

Corticosteroids:

- Alcohol: enhanced hypotensive effect when diuretics given with ALCOHOL.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.

Calcium Salts:

- Calcium Salts: increased risk of hyperkalaemia when given with CALCIUM SALTS.

Calcium-channel Blockers:

- Calcium-channel Blockers: enhanced hypotensive effect when diuretics given with CALCIUM-SALTS.
Diuretics

Corticosteroids (continued)
acetazolamide, loop diuretics or thiazides and related diuretics given with CORTICOSTEROIDS

- Cytostatics: alkaline urine due to acetazolamide increases excretion of METHOTREXATE; hypokalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics increases risk of ventricular arrhythmias with
  - ARSENIC TROXIDE; avoidance of spironolactone advised by manufacturer of MITOTANE (antagonism of effect); increased risk of nephrotoxicity and ototoxicity when diuretics given with PLATINUM COMPOUNDS

- Diazoxide: enhanced hypotensive and hyperglycaemic effects when diuretics given with DIAZoxide
- Diuretics: increased risk of hypokalaemia when loop diuretics or thiazides and related diuretics given with ACETAZOLAMIDE; profound diuresis possible when metolazone given with FUROSEMIDE; increased risk of hypokalaemia when thiazides and related diuretics given with LOOP DIURETICS
- Dopaminergics: enhanced hypotensive effect when diuretics given with CO-BENELDOPA, CO-CARELDOPA or LEVODOPA
- Hormone Antagonists: increased risk of hypercalcaemia when thiazides and related diuretics given with TOREMIFENE
- Lipid-regulating Drugs: absorption of thiazides and related diuretics reduced by COLESTIPOL and COLESTYRAMINE (give at least 2 hours apart)

- Lithium: loop diuretics and thiazides and related diuretics reduce excretion of LITHIUM (increased plasma concentration and risk of toxicity)—loop diuretics safer than thiazides; potassium-sparing diuretics and aldosterone antagonists reduce excretion of LITHIUM (increased plasma concentration and risk of toxicity); acetazolamide increases the excretion of LITHIUM

- Methylodopa: enhanced hypotensive effect when diuretics given with MOXISYLYTE
- Moxonidine: enhanced hypotensive effect when diuretics given with MOXISULYSE

- Nitrites: enhanced hypotensive effect when diuretics given with NITRATES
- Oestrogens: diuretic effect of diuretics antagonised by OESTROGENS

- Potassium Salts: increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with POTASSIUM SALTS
- Progestogens: risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with DROSPIRENONE (monitor serum potassium during first cycle)

- Prostaglandins: enhanced hypotensive effect when diuretics given with ALPROSTADIL
- Sympathomimetics, Beta: increased risk of hypokalaemia when acetazolamide, loop diuretics or thiazides and related diuretics given with high doses of Beta,SYMPATHOMIMETICS

- Tacrolimus: increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with TACROLIMUS

- Theophylline: increased risk of hypokalaemia when acetazolamide, loop diuretics or thiazides and related diuretics given with THEOPHYLLINE

- Vasodilators Antihypertensives: enhanced hypotensive effect when diuretics given with HYDRAZINE, MINOXIDIL or SODIUM NITROPRUSSIDE

- Vitamins: increased risk of hypercalcaemia when thiazides and related diuretics given with ALFACALCICOL, CALCITRIOL, COLECALCIFEROL, DIHYDROTACHYSTEROL, EROGALCIFEROL, PARICALCITOL or VITAMIN D

Diuretics, Loop see Diuretics

Diuretics, Potassium-sparing and Aldosterone Antagonists see Diuretics

Diuretics, Thiazide and related see Diuretics

Dobutamine see Sympathomimetics

Docetaxel

- Antibacterials: plasma concentration of docetaxel possibly increased by CLARITHROMYCIN and TELITHROMYCIN—manufacturer of docetaxel advises avoid concomitant use or consider reducing docetaxel dose
- Antifungals: in vitro studies suggest a possible interaction between docetaxel and KETOCONAZOLE (consult docetaxel product literature); plasma concentration of docetaxel possibly increased by ITRACONAZOLE and VORICONAZOLE—manufacturer of docetaxel advises avoid concomitant use or consider reducing docetaxel dose
- Antipsychotics: avoid concomitant use of cytoxotics with CLOzapine (increased risk of agranulocytosis)
- Antivirals: plasma concentration of docetaxel possibly increased by INDINAVIR, RITONAVIR and SQuINAVIR—manufacturer of dolutegravir advises avoid concomitant use or consider reducing docetaxel dose

- Ciclosporin: in vitro studies suggest a possible interaction between docetaxel and CICLOSPORIN (consult docetaxel product literature)

- Cytostotics: possible increased risk of neutropenia when docetaxel given with LAPATINIB; plasma concentration of docetaxel increased by SoraFENIB

Dolutegravir

- Antacids: absorption of dolutegravir reduced by ALUMINIUM HYDROXIDE and ORAL MAGNESIUM SALTS—manufacturer of dolutegravir advises give at least 2 hours before or 6 hours after aluminium hydroxide and oral magnesium salts

- Antibacterials: plasma concentration of dolutegravir reduced by RIFAMPICIN (see under Dolutegravir, p. 557)

- Antidepressants: manufacturer of dolutegravir advises avoid concomitant use with ST JOHN’S WORT

- Antiepileptics: manufacturer of dolutegravir advises avoid concomitant use with CarbAMAZEPINE, FOSphenytoin, oxCARBAZEPINE, PHENOBARBITAL, PHENyTOIN and PrimidoNE

- Antivirals: plasma concentration of dolutegravir reduced by EFAVIRENZ, ETRAVIRINE and TIPRANAVIR (see under Dolutegravir, p. 557); plasma concentration of dolutegravir reduced by FOSSAMPRAVIR; plasma concentration of dolutegravir possibly reduced by NEvirapine (see under Dolutegravir, p. 557)

- Calcium Salts: absorption of dolutegravir reduced by CALCIUM SALTS—manufacturer of dolutegravir advises give at least 2 hours before or 6 hours after calcium salts

- Iron Salts: absorption of dolutegravir reduced by oral IRON SALTS—manufacturer of dolutegravir advises give at least 2 hours before or 6 hours after oral iron salts

Dopamnergics

- Analgesics: effects of dopamnergics on gastro-intestinal activity antagonised by OPIoid ANALGESICS

- Antibacterials: possible increased risk of ventricular arrhythmias when dopamnergics given with CLARITHROMYCIN or TELITHROMYCIN—avoid concomitant use; plasma concentration of dopamnergics increased by ERITHROMYCIN (increased risk of ventricular arrhythmias—avoid concomitant use); possible increased risk of ventricular arrhythmias when dopamnergics given with DELAMANID

- Antifungals: avoidance of dopamnergics advised by manufacturer of KETOCOZAOLE (risk of ventricular arrhythmias); possible increased risk of ventricular arrhythmias when dopamnergics given with ITRACONAZOLE or VORICONAZOLE—avoid concomitant use

- Antimalarias: avoidance of dopamnergics advised by manufacturer of ARTEMiNOL WITH PIPERAQUINE (possible risk of ventricular arrhythmias)

- Antimuscularins: effects of dopamnergic on gastro-intestinal activity antagonised by ANTIMuscULARINS

- Antivirals: possible increased risk of ventricular arrhythmias when dopamnergics given with BOCEpREViR, RITONAVIR, SAQuINAVIR or TelAPREViR—avoid concomitant use

- Cobicistat: possible increased risk of ventricular arrhythmias when dopamnergics given with COBicistat—avoid concomitant use

- Cytostotics: avoidance of dopamnergic advised by manufacturer of DOSUTiNIB (risk of ventricular arrhythmias)
Dronedarone (continued)

- Antiplatelet: plasma concentration of dronedarone possibly reduced by carbasalate, carbasalate, Divinylsulfone, Divinylsulfone, Phenoxybenzamine, Phenoxybenzamine, Prindolol—avoid concomitant use
- Antifungal: plasma concentration of dronedarone increased by ketoconazole—avoid concomitant use; manufacturer of dronedarone advises avoid concomitant use
- Antiviral: manufacturer of dronedarone advises avoid concomitant use
- Antipsychotics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with antipsychotics that prolong the QT interval; manufacturer of dronedarone advises avoid concomitant use
- Hypoglycaemics: reduced plasma concentration of sitagliptin (see under Sitagliptin, p. 809)
- Antidepressants: possible increased risk of bradycardia when duloxetine given with fingolimod
- Grapefruit Juice: plasma concentration of dronedarone increased by grapefruit juice—avoid concomitant use
- Lipid-regulating Drugs: dronedarone possibly increases plasma concentration of atorvastatin; dronedarone increases plasma concentration of rosuvastatin (consult product literature); increased risk of myopathy when dronedarone given with simvastatin; avoidance of dronedarone advised by manufacturer of Lomitapide (plasma concentration of lomitapide possibly increased)
- Sirolimus: manufacturer of dronedarone advises caution with sirolimus
- Tacrolimus: manufacturer of dronedarone advises caution with tacrolimus

Droxiprone (see Antipsychotics)

Drospirenone (see Progestogens)

Duloxetine

- Analgesics: possible increased serotonergic effects when SSRIs-related antidepressants given with fentanyl; possible increased serotonergic effects when duloxetine given with pethidine or tramadol
- Antidepressants: metabolism of duloxetine inhibited by ciprofloxacin—avoid concomitant use
- Antiemetics: possible increased risk of bleeding when SSRIs-related antidepressants given with omeprazole
- Antidepressants: metabolism of duloxetine inhibited by fluvoxamine—avoid concomitant use; possible increased serotonergic effects when duloxetine given with SSRIs, St John's Wort, amitriptyline, clobazam, moclobemide or venlafaxine; duloxetine should not be started until 2 weeks after stopping; also MAOIs should not be started until at least 5 days after stopping duloxetine; after stopping SSRI-related antidepressants do not start moclobemide for at least 1 week
- Antimalarials: manufacturer of dronedarone advises caution with doxapram given with amphotericin B, carboplatin, cisplatin, cyclophosphamide, ifosfamide, mitomycin C, oxaliplatin, pemetrexed, temozolomide
- Anticoagulants: increased risk of ventricular arrhythmias when amiodarone given with amiodarone, dofetilide, dronedarone, Ibutilide, olaparib, sorafenib, ticagrelor, vorinostat
- Antiplatelet: plasma concentration of clopidogrel increased by omeprazole; increased risk of bleeding when SSRIs-related antidepressants given with omeprazole
- Antithrombotics: possible increased risk of bleeding when SSRIs-related antidepressants given with omeprazole
- Antipsychotics: possible increased risk of bleeding when SSRIs-related antidepressants given with omeprazole
- Antineoplastics: possible increased risk of bleeding when SSRIs-related antidepressants given with omeprazole
- Antiepileptics: possible increased risk of bleeding when SSRIs-related antidepressants given with omeprazole
- Antithrombotics: possible increased risk of bleeding when SSRIs-related antidepressants given with omeprazole

Dropperidol (see Antipsychotics)
Dutasteride

Calcium-channel Blockers: plasma concentration of dutasteride increased by <i>LITIAZEM</i> and <i>VERAPAMIL</i>

Efavirenz

Analgesics: efavirenz reduces plasma concentration of <i>METHADONE</i>

Antibacterials: efavirenz reduces plasma concentration of <i>CLARITHROMYCIN</i>, also plasma concentration of active metabolite of clarithromycin increased; efavirenz reduces plasma concentration of <i>RIFABUTIN</i>—increase dose of rifabutin; plasma concentration of efavirenz reduced by <i>RIFAMPICIN</i>—increase dose of efavirenz; efavirenz possibly reduces plasma concentration of <i>BEDAQUILINE</i>—manufacturer of bedaquiline advises avoid concomitant use

Anticoagulants: efavirenz possibly affects plasma concentration of <i>CLOMARINS</i>

Antidepressants: plasma concentration of efavirenz reduced by <i>ST JOHN'S WORT</i>—avoid concomitant use

Antiepileptics: plasma concentration of both drugs reduced when efavirenz given with <i>CARBAMAZEPINE</i>

Antifungals: efavirenz reduces plasma concentration of <i>ITRACONAZOLE</i>, <i>KETOCONAZOLE</i> and <i>Posaconazole</i>; efavirenz reduces plasma concentration of <i>VORICONAZOLE</i>, also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose); efavirenz possibly reduces plasma concentration of <i>CASPOFUNGIN</i>—consider increasing dose of caspofungin

Antimalarials: efavirenz reduces plasma concentration of <i>ARTENETHER WITH LUMEFANTRINE</i>; efavirenz possibly affects plasma concentration of <i>PROGUANIL</i>

Antipsychotics: efavirenz reduces plasma concentration of <i>Aripiprazole</i> (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature); efavirenz possibly increases plasma concentration of <i>PIMOZIDE</i> (increased risk of ventricular arrhythmias—avoid concomitant use)

Antivirals: avoidance of efavirenz advised by manufacturer of <i>ATAZANAVIR</i> (plasma concentration of atazanavir reduced); efavirenz reduces the plasma concentration of <i>DACLATASVIR</i>—increase dose of daclatasvir (see under Daclatasvir, p. 544); efavirenz reduces plasma concentration of <i>DARUNAVIR</i> (adjust dose—consult product literature); efavirenz reduces the plasma concentration of <i>DOLUTEGRAVIR</i> (see under Dolutegravir, p. 557); avoidance of efavirenz advised by manufacturer of <i>ELVITEGRAVIR</i>; efavirenz possibly reduces plasma concentration of <i>ETRAVIRINE</i>—avoid concomitant use; efavirenz reduces plasma concentration of <i>INDINAVIR</i> and <i>SIMEPREVIR</i>; efavirenz reduces plasma concentration of <i>LOPINAVIR</i>—consider increasing dose of lopinavir; efavirenz possibly reduces plasma concentration of <i>Maraviroc</i>—consider increasing dose of maraviroc; plasma concentration of efavirenz reduced by <i>NEVIRAPINE</i>—avoid concomitant use; toxicity of efavirenz increased by <i>RITONAVIR</i>, monitor liver function tests—manufacturer of <i>Attril</i> advises avoid concomitant use with high-dose ritonavir; efavirenz significantly reduces plasma concentration of <i>Saquinarivir</i>; efavirenz reduces plasma concentration of <i>Teleprevir</i>—increase dose of telaprevir

Antioxidants: efavirenz increases risk of prolonged sedation when efavirenz given with <i>MIDAZOLAM</i>—avoid concomitant use

Antivirals: efavirenz reduces plasma concentration of <i>ATOVIRAVIRUS</i>—avoid concomitant use

Avanafil: efavirenz possibly reduces plasma concentration of <i>AVANAFIL</i>—manufacturer of avanafil advises avoid concomitant use

Bupropion: efavirenz accelerates metabolism of <i>BUPROPION</i> (reduced plasma concentration)

Calcium-channel Blockers: efavirenz reduces plasma concentration of <i>DILTIAZEM</i>

Ciclosporin: efavirenz possibly reduces plasma concentration of <i>BOSUTINIB</i>—manufacturer of bosutinib advises avoid concomitant use

Cytotoxics: efavirenz reduces plasma concentration of <i>PROGESTAGENS</i>

Ergot Alkaloids: increased risk of ergotism when efavirenz given with <i>ERGOT ALKALOIDS</i>—avoid concomitant use

Grapefruit Juice: plasma concentration of efavirenz possibly increased by <i>GRAPEFRUIT JUICE</i>

Lipid-regulating Drugs: efavirenz reduces plasma concentration of <i>ATORVASTATIN</i>, <i>PRAVASTATIN</i> and <i>SIMVASTATIN</i>

Orlistat: absorption of efavirenz possibly reduced by <i>ORLISTAT</i>

Progestogens: efavirenz possibly reduces contraceptive effect of <i>PROGESTAGENS</i>

Tacrolimus: efavirenz possibly affects plasma concentration of <i>TACROLIMUS</i>

Eltrombopag: absorption of eltrombopag reduced by <i>ELTROMBOPAG</i> (give at least 4 hours apart)

Antacids: plasma concentration of eltrombopag possibly reduced by <i>ANTACIDS</i> (give at least 4 hours apart)

Antivirals: plasma concentration of eltrombopag possibly reduced by <i>LOPINAVIR</i>

Calcium Salts: absorption of eltrombopag possibly reduced by <i>CALCIUM SALTS</i> (give at least 4 hours apart)

Dairy Products: absorption of eltrombopag possibly reduced by <i>DAIRY PRODUCTS</i> (give at least 4 hours apart)

Iron Salts: absorption of eltrombopag possibly reduced by <i>IRON SALTS</i> (give at least 4 hours apart)

Lipid-regulating Drugs: eltrombopag increases plasma concentration of <i>ROSUVASTATIN</i>—adjust dose of rosuvastatin (consult product literature)

Selenium: absorption of eltrombopag possibly reduced by <i>SELENIUM</i> (give at least 4 hours apart)

Zinc: absorption of eltrombopag possibly reduced by <i>ZINC</i> (give at least 4 hours apart)

Elvitegravir: absorption of elvitegravir reduced by <i>ALUMINUM HYDROXIDE</i> and <i>ORAL MAGNESIUM SALTS</i> (give at least 4 hours apart)

Antibacterials: plasma concentration of elvitegravir reduced by <i>RIFABUTIN</i>—also plasma concentration of active metabolite of rifabutin increased—reduce dose of rifabutin; manufacturer of elvitegravir advises avoid concomitant use with <i>RIFAMPICIN</i>

Antidepressants: manufacturer of elvitegravir advises avoid concomitant use with <i>ST JOHN'S WORT</i>

Antiepileptics: manufacturer of elvitegravir advises avoid concomitant use with <i>CARBAZAMPELINE</i>, <i>FOSPHENYTOIN</i>, <i>PHENOBARBITAL</i>, <i>PHENYTOIN</i> and <i>PRIMIDONE</i>

Antivirals: plasma concentration of elvitegravir increased by <i>ATAZANAVIR</i> and <i>LOPINAVIR</i> boosted with ritonavir (reduce dose of elvitegravir); manufacturer of elvitegravir advises avoid concomitant use with <i>EFAVIRENZ</i> and <i>NEVIRAPINE</i>

Bosentan: manufacturer of elvitegravir advises avoid concomitant use with <i>BOSENTAN</i>

Orlistat: absorption of elvitegravir possibly reduced by <i>ORLISTAT</i>
Ergot Alkaloids

- Antidepressants: possible risk of hypertension when ergotamine given with REBOXETINE
- Antifungals: avoidance of ergot alkaloids advised by manufacturer of KETOCONAZOLE; avoidance of ergotamine advised by manufacturer of TRICARIN; increased risk of ergotism; increased risk of ergotism when ergometrine given with VORICONAZOLE—avoid concomitant use; increased risk of ergotism when ergotamine given with IMIDAZOLES or TRIAZOLEs—avoid concomitant use
- Antipsychotics: plasma concentration of ergot alkaloids possibly increased by LURASIDONE (increased risk of toxicity)
- Antivirals: plasma concentration of ergot alkaloids possibly increased by ATAZANAVIR—avoid concomitant use; avoidance of ergot alkaloids advised by manufacturer of BOCEPREVIR and TELAPREVI; increased risk of ergotism when ergot alkaloids given with DARUNAVIR—manufacturer of darunavir advises avoid concomitant use; increased risk of ergotism when ergot alkaloids given with EFAVIRENZ—avoid concomitant use; increased risk of ergotism when ergotamine given with POSAMPRENAVIR, INDINAVIR, RITONAVIR or SAQUINAVIR—avoid concomitant use; increased risk of ergotism when ergometrine given with INDINAVIR or RITONAVIR—avoid concomitant use
- Beta-blockers: increased peripheral vasconstriction when ergotamine given with BETA-BLOCKERS
- Cobicistat: plasma concentration of ergot alkaloids possibly increased by COBICISTAT—manufacturer of cobicistat advises avoid concomitant use
- Cytotoxics: caution with ergot alkaloids advised by manufacturer of CRIZOTINIB; avoidance of ergotamine advised by manufacturer of IDEALIS
- SHT-receptor Agonists: increased risk of vasospasm when ergotamine given with ALMOPRIPITAN, RIZATRIPTAN, SUMATRIPTAN or ZOMITRIPTAN (avoid ergotamine for 6 hours after almotriptan, rizatriptan, sumatriptan or zolmitriptan, avoid almotriptan, rizatriptan, sumatriptan or zolmitriptan for 24 hours after ergotamine); increased risk of vasospasm when ergotamine given with ELETRIPTAN, FROVATRIPTAN or NARATRIPTAN (avoid ergotamine for 24 hours after eletriptan, frovatriptan or naratriptan, avoid eletriptan, frovatriptan or naratriptan for 24 hours after ergotamine)
- Sympathomimetics: increased risk of ergotism when ergotamine given with SYMPATHOMIMETICS
- Ticagrelor: plasma concentration of ergot alkaloids possibly increased by TICAGRELOR
- Ulcer-healing Drugs: increased risk of ergotism when ergotamine given with Cimetidine—avoid concomitant use

Ergotamine

- Antidepressants: possible risk of hypertension when ergotamine given with REBOXETINE
- Antifungals: avoidance of ergot alkaloids advised by manufacturer of KETOCONAZOLE; avoidance of ergotamine advised by manufacturer of TRICARIN; increased risk of ergotism; increased risk of ergotism when ergometrine given with VORICONAZOLE—avoid concomitant use; increased risk of ergotism when ergotamine given with IMIDAZOLES or TRIAZOLEs—avoid concomitant use; increased risk of ergotism when ergotamine given with TETRACYCLINES

Enfuvirtide

- See ACE Inhibitors

Entacapone

- See Phosphodiesterase Inhibitors

Entacapone

- Anticoagulants: entacapone enhances anticoagulant effect of WARFARIN
- Antidepressants: manufacturer of entacapone advises caution with MOXIBEMIDE, TRICYCLICS and VENLAFAXINE; avoid concomitant use of entacapone with non-selective MAOIS
- Dopaminergics: entacapone possibly enhances effects of APOMORPHINE; entacapone possibly reduces plasma concentration of RASAGILINE; manufacturer of entacapone advises max. dose of 10 mg SELEGILINE if used concomitantly
- Iron Salts: absorption of entacapone reduced by oral IRON SALTS
- Memantine: effects of dopaminergics possibly enhanced by MEMANTINE
- Metyldopa: entacapone possibly enhances effects of METHYLDOPA; antiparkinsonian effect of dopaminergics antagonised by METHYLDOPA
- Sympathomimetics: entacapone possibly enhances effects of ADRENALINE (EPINEPHRINE), DOBUTAMINE, DOPAMINE and NORDRENALINE (NOREPINEPHRINE)

Enteral Foods

- Anticoagulants: the presence of vitamin K in some enteral feeds can antagonise the anticoagulant effect of COUMARINS and PHENIDIONE
- Antiepileptics: enteral feeds possibly reduce absorption of FOSPHENOTYIN and PHENITOIN

Enzalutamide

- Antibacterials: manufacturer of enzalutamide advises avoid concomitant use with RIFAMPICIN
- Anticoagulants: enzalutamide possibly reduces plasma concentration of COUMARINS
- Lipid-regulating Drugs: plasma concentration of enzalutamide increased by GEMFIBROZIL—manufacturer of enzalutamide advises avoid concomitant use or halve dose of enzalutamide

Ephedrine

- See Sympathomimetics

Epinephrine

- See Sympathomimetics

Eripiprin

- Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
- Cyclosporin: plasma concentration of eripiprin increased by CICLOスポRIN
- Ulcer-healing Drugs: plasma concentration of eripiprin increased by CIMEtIDINE

Eplerenone

- See Diuretics

Eprosartan

- See Angiotensin-II Receptor Antagonists

Eptifibatide

- Iloprost: increased risk of bleeding when eptifibatide given with ILOPROST

Ergocorniferol

- See Vitamins

Ergometrine

- See Ergot Alkaloids

Ergot Alkaloids

- Antibacterials: increased risk of ergotism when ergometrine given with CLARITHROMYCIN or ERYTHROMYCIN—avoid concomitant use; increased risk of ergotism when ergotamine given with MACROLIDES or TETRACYCLINES—avoid concomitant use; increased risk of ergotism when ergotamine given with TETRACYCLINES

Ergotamine

- Antidepressants: possible risk of hypertension when ergotamine given with REBOXETINE
- Antifungals: avoidance of ergot alkaloids advised by manufacturer of KETOCONAZOLE; avoidance of ergotamine advised by manufacturer of TRICARIN; increased risk of ergotism; increased risk of ergotism when ergometrine given with VORICONAZOLE—avoid concomitant use; increased risk of ergotism when ergotamine given with IMIDAZOLES or TRIAZOLEs—avoid concomitant use; increased risk of ergotism when ergotamine given with TETRACYCLINES

Ergometrine

- Antidepressants: possible risk of hypertension when ergotamine given with REBOXETINE
- Antifungals: avoidance of ergot alkaloids advised by manufacturer of KETOCONAZOLE; avoidance of ergotamine advised by manufacturer of TRICARIN; increased risk of ergotism; increased risk of ergotism when ergometrine given with VORICONAZOLE—avoid concomitant use; increased risk of ergotism when ergotamine given with IMIDAZOLES or TRIAZOLEs—avoid concomitant use; increased risk of ergotism when ergotamine given with TETRACYCLINES

Ergonovine

- Antidepressants: possible risk of hypertension when ergotamine given with REBOXETINE
- Antifungals: avoidance of ergot alkaloids advised by manufacturer of KETOCONAZOLE; avoidance of ergotamine advised by manufacturer of TRICARIN; increased risk of ergotism; increased risk of ergotism when ergometrine given with VORICONAZOLE—avoid concomitant use; increased risk of ergotism when ergotamine given with IMIDAZOLES or TRIAZOLEs—avoid concomitant use; increased risk of ergotism when ergotamine given with TETRACYCLINES

Ergotamine

- Antidepressants: possible risk of hypertension when ergotamine given with REBOXETINE
- Antifungals: avoidance of ergot alkaloids advised by manufacturer of KETOCONAZOLE; avoidance of ergotamine advised by manufacturer of TRICARIN; increased risk of ergotism; increased risk of ergotism when ergometrine given with VORICONAZOLE—avoid concomitant use; increased risk of ergotism when ergotamine given with IMIDAZOLES or TRIAZOLEs—avoid concomitant use; increased risk of ergotism when ergotamine given with TETRACYCLINES

Elvitegravir

- See Antidiabetics

Emfuvirtide

- See ACE Inhibitors

Enoximone

- See Phosphodiesterase Inhibitors

Enzalutamide

- Anticoagulants: increased risk of ergotism when ergotamine given with REBOXETINE
- Antifungals: avoidance of ergot alkaloids advised by manufacturer of KETOCONAZOLE; avoidance of ergotamine advised by manufacturer of TRICARIN; increased risk of ergotism; increased risk of ergotism when ergometrine given with VORICONAZOLE—avoid concomitant use; increased risk of ergotism when ergotamine given with IMIDAZOLES or TRIAZOLEs—avoid concomitant use; increased risk of ergotism when ergotamine given with TETRACYCLINES

Ertapenem

- See Antibacterials

Evetolizumab

- See Antibioties
Erlotinib (continued)

- Cytotoxics: plasma concentration of erlotinib possibly increased by **CAPECITABINE**
- Ultra-healing Drugs: manufacturer of erlotinib advises avoid concomitant use with **CIMETIDINE, ESOMEPRAZOLE, FAMOTIDINE, Lansoprazole, NIZATIDINE, Pantoprazole** and **RABEPRAZOLE**; plasma concentration of erlotinib reduced by **RANITIDINE**—manufacturer of erlotinib advises give at least 2 hours before or 10 hours after ranitidine; plasma concentration of erlotinib reduced by **OMEPRAZOLE**—manufacturer of erlotinib advises avoid concomitant use

Ertapenem

- Antiepileptics: carbenapens reduce plasma concentration of **SODIUM VALPROATE** and **VALPROIC ACID**—avoid concomitant use
- Vaccines: antibacterials inactivate **ORTAL TYPOID VACCINE**—see under Typhoid Vaccine in BNF

Erythromycin see Macrolides

Escitalopram see Antidepressants, SSRI

Eslicarbazepine

- Anticoagulants: eslicarbazepine reduces plasma concentration of **WARFARIN**
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by **MAOIs** and **TRICYCLIC-RELATED ANTIDEPRESSANTS** (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by **SSRIS** and **TRICYCLICS** (convulsive threshold lowered)
- Antiepileptics: plasma concentration of eslicarbazepine possibly reduced by **CARBAMAZEPINE** but risk of side-effects increased; plasma concentration of eslicarbazepine reduced by **PHENOBARBITAL** and **PHENYTOIN**, also plasma concentration of fosphenytoin and phenytoin increased; manufacturer of eslicarbazepine advises avoid concomitant use with **OXCARBAZEPINE**
  - Antimalarials: anticonvulsant effect of antiepileptics antagonised by **MEFLOQUINE**
  - Antipsychotics: anticonvulsant effect of antiepileptics antagonised by **ANTIPSYCHOTICS** (convulsive threshold lowered)
- Lipid-regulating Drugs: eslicarbazepine reduces plasma concentration of **ROSUVASTATIN**; eslicarbazepine reduces plasma concentration of **SIMVASTATIN**—consider increasing dose of simvastatin
- Oestrogens: eslicarbazepine accelerates metabolism of **OESTROGENS** (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)
- Orlistat: possible increased risk of convulsions when antiepileptics given with **ORLISTAT**
- Progestogens: eslicarbazepine accelerates metabolism of **PROGESTGENS** (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF)

Esmolol see Beta-blockers

Esomeprazole see Proton Pump Inhibitors

Estradiol see Oestrogens

Estramustine

- Antacids: absorption of estramustine possibly reduced by **ALUMINIUM HYDROXIDE** and **ORAL MAGNESIUM SALTS**—manufacturer of estramustine advises avoid concomitant administration
- Antipsychotics: avoid concomitant use of cytotoxics with **CLOZAPINE** (increased risk of agranulocytosis)
- Bisphosphonates: plasma concentration of estramustine increased by **SODIUM CLORIDRATO**
- Calcium Salts: absorption of estramustine reduced by **CALCIUM SALTS** (manufacturer of estramustine advises avoid concomitant administration)

Estradiol see Oestrogens

Estrone see Oestrogens

Etenacept (continued)

- Anakinra: avoid concomitant use of etenacept with **ANAKINRA**
- Vaccines: risk of generalised infections when etenacept given with live **VACCINES**—avoid concomitant use

Etilomab see Oestrogens

Ethosuximide

- Antibacterials: metabolism of ethosuximide inhibited by **ISONIAZID** (increased plasma concentration and risk of toxicity)
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by **MAOIs** and **TRICYCLIC-RELATED ANTIDEPRESSANTS** (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by **SSRIS** and **TRICYCLICS** (convulsive threshold lowered)
- Antiepileptics: plasma concentration of ethosuximide possibly reduced by **CARBAMAZEPINE, PHENOBARBITAL** and **PRIMIDONE**; plasma concentration of ethosuximide possibly reduced by **FOSPHENYTOIN** and **PHENYOINT**, also plasma concentration of fosphenytoin and phenytoin possibly enhanced anticoagulant effect of antiepileptics antagonised by **SODIUM VALPROATE** and **VALPROIC ACID**
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by **MEFLOQUINE**
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by **ANTIPSYCHOTICS** (convulsive threshold lowered)
- Orlistat: possible increased risk of convulsions when antiepileptics given with **ORLISTAT**

Etodolac see NSAIDs

Etoricoxib see NSAIDs

Etoposide

- Anticoagulants: etoposide possibly enhances anticoagulant effect of **GUMARINS**
- Antiretrovirals: plasma concentration of etoposide possibly reduced by **FOSPHENYTOIN, PHENOBARBITAL, PHENYOINT** and **PRIMIDONE**
- Antifungals: plasma concentration of etoposide increased by **KETOCONAZOLE**
- Antipsychotics: avoid concomitant use of cytotoxics with **CLOZAPINE** (increased risk of agranulocytosis)
- Atovaquone: plasma concentration of etoposide possibly increased by **ATovaquone**
- Cilostazol: plasma concentration of etoposide possibly increased by **CILOSTAZOL** (increased risk of toxicity)

Etoricoxib see NSAIDs

Etravirine

- Antibacterials: etravirine reduces plasma concentration of **CLARITHROMYCIN** (but concentration of an active metabolite increased), also plasma concentration of etravirine increased; plasma concentration of both drugs reduced when etravirine given with **RIFABUTIN**; manufacturer of etravirine advises avoid concomitant use with **RIFAMPICIN**; etravirine possibly reduces plasma concentration of **BEDAQUILINE**—manufacturer of bedaquiline advises avoid concomitant use
- Antidepressants: manufacturer of etravirine advises avoid concomitant use with **ST JOHN’S WORT**
- Antiepileptics: manufacturer of etravirine advises avoid concomitant use with **CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYOINT** and **PRIMIDONE**
- Antimalarials: etravirine reduces plasma concentration of **ARTEMETHER WITH LUMEFANTRINE**
- Antivirals: effects of both drugs possibly reduced when etravirine given with **BOCEPIRIVINE**; avoidance of etravirine advised by manufacturer of **DACLATASVIR** (plasma concentration of daclatasvir possibly reduced); etravirine reduces the plasma concentration of **DOLUTEGRAVIR** (see under Dolutegravir, p. 557); plasma concentration of etravirine possibly reduced by **EFAVIRENZ** and **NEVIRAPINE**—
Etravirine
- Antivirals (continued) use; etravirine increases plasma concentration of • **fosamprenavir** (consider reducing dose of fosamprenavir), etravirine possibly reduces plasma concentration of • **indinavir**—avoid concomitant use; etravirine possibly reduces plasma concentration of **maraviroc**; avoidance of etravirine advised by manufacturer of **simeprevir**; plasma concentration of etravirine reduced by • **tipranavir**, also plasma concentration of tipranavir increased (avoid concomitant use)
  - Cardiac Glycosides: etravirine increases plasma concentration of **digoxin**
  - Clondipigrel: etravirine possibly reduces antiplatelet effect of • **clondipigrel**
  - Cytotoxics: etravirine possibly reduces plasma concentration of • **bosutinib**—manufacturer of bosutinib advises avoid concomitant use
  - Lipid regulating Drugs: etravirine possibly reduces plasma concentration of **clopidogrel**: also plasma concentration of tipranavir increased (avoid concomitant use)

Famotidine see Histamine H₂-antagonists
Fampidine
- Ulcer-healing Drugs: manufacturer of fampridine advises avoid concomitant use with • **cimetidine**

Fexofenadine see Antihistamines
Fenofibrate see Fibrates
Fenoprofen see NSAIDs
Fentanyl see Opioid Analgesics
Ferrous Sulfate see Iron salts
Ferrous Gluconate see Iron salts

Fesoterodine see Antimuscarinics
Fexofenadine see Antihistamines

Fibrates
- Antibacterials: increased risk of myopathy when fibrates given with • **daptomycin** (preferably avoid concomitant use)
- Anticoagulants: fibrates enhance anticoagulant effect of • **coumarins** and • **phenindione**
- Antidiabetics: fibrates may improve glucose tolerance and have an additive effect with **insulin** or **sulfonylureas**; gemfibrozil possibly enhances hypoglycaemic effect of **Nateglinide**; increased risk of severe hypoglycaemia when gemfibrozil given with • **repaglinide**—avoid concomitant use
  - Ciclosporin: increased risk of renal impairment when bezafibrate or fenofibrate given with **ciclosporin**
  - Colchicine: possible increased risk of myopathy when fibrates given with • **colchicine**
  - Cytotoxics: gemfibrozil increases plasma concentration of **dabrafenib**; gemfibrozil increases plasma concentration of • **bexarotene**—avoid concomitant use
  - Hormone Antagonists: gemfibrozil increases plasma concentration of • **enzalutamide**—manufacturer of enzalutamide advises avoid concomitant use or halve dose of enzalutamide
  - Leukotriene Receptor Antagonists: gemfibrozil increases plasma concentration of **Montelukast**

Fexofenadine see Antihistamines

Fidaxomicin
- Anti-arthrhythmics: manufacturer of fidaxomicin advises avoid concomitant use with **amiodarone** and **dronedarone**
- Anti-infectives: manufacturer of fidaxomicin advises avoid concomitant use with • **clarithromycin** and **erythromycin**
- Anti-inflamamts: manufacturer of fidaxomicin advises avoid concomitant use with **ketocanozole**
- Calcium-channel Blockers: manufacturer of fidaxomicin advises avoid concomitant use with **verapamil**
- Ciclosporin: manufacturer of fidaxomicin advises avoid concomitant use concomitant use with **ciclosporin**
- Vaccines: antibacterials inactivate **oral typhoid vaccine**—see under Typhoid Vaccine in BNF
Filgrastim
- Cytotoxics: neutropenia possibly exacerbated when filgrastim given with CAPECITABINE, FLUOROURACIL or TEGAFUR

Fingolimod
- Anti-arrhythmics: possible increased risk of bradycardia when fingolimod given with AMIODARONE, DISOPYRAMIDE or DRONEDARONE
- Antidepressants: plasma concentration of fingolimod possibly reduced by ST JOHN’S WORT—manufacturer of fingolimod advises avoid concomitant use
- Antiepileptics: plasma concentration of fingolimod reduced by CARBAMAZEPINE
- Antifungals: plasma concentration of fingolimod increased by KETOCONAZOLE
- Beta-blockers: possible increased risk of bradycardia when fingolimod given with LAMINAR
- Calcium-channel Blockers: possible increased risk of bradycardia when fingolimod given with DILTIAZEM or VERAPAMIL

Flavoxate
- see Antimuscarinics

Flecainide
- Anaesthetics, Local: increased myocardial depression when anti-arrhythmics given with BUPIVAÇANE, LEVOBUPIVAÇANE, PRILOCAZÉ or ROPIVAPAÇAZÉ
- Anti-arrhythmics: increased myocardial depression when anti-arrhythmics given with other ANTI-ARRHYTHMICS; plasma concentration of flecainide increased by AMIODARONE (halve dose of flecainide)
- Antidepressants: plasma concentration of flecainide increased by FLUOKETINE; increased risk of ventricular arrhythmias when flecainide given with TRICYCLICS
- Antihistamines: increased risk of ventricular arrhythmias when flecainide given with MIZOLASTINE—avoid concomitant use
- Antiarrhythmics: avoidance of flecainide advised by manufacturer of ARTEMETHER WITH LUMEFANTRINE (risk of ventricular arrhythmias); plasma concentration of flecainide increased by QUININE
- Antimuscarinics: increased risk of ventricular arrhythmias when flecainide given with FOLTERODINE
- Antipsychotics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with ANTIPSYCHOTICS that prolong the QT interval; increased risk of arrhythmias when flecainide given with CLOZAPINE
- Antivirals: plasma concentration of flecainide possibly increased by FOSAMPRENAVIR, INDINAVIR, RITONAVIR and PRONAVIR (increased risk of ventricular arrhythmias—avoid concomitant use); increased risk of ventricular arrhythmias when flecainide given with SAQUINAVIR—avoid concomitant use; caution with flecainide advised by manufacturer of TELAPREVIR (risk of ventricular arrhythmias)
- Beta-blockers: increased risk of myocardial depression and bradycardia when flecainide given with BETABLOCKERS; increased myocardial depression when anti-arrhythmics given with BETABLOCKERS
- Calcium-channel Blockers: increased risk of myocardial depression and asystole when flecainide given with VERAPAMIL
- Diuretics: increased cardiac toxicity with flecainide if hypokalaemia occurs with ACETAZOLAMIDE, LOOP DIURETICS or THIURAS AND RELATED DIURETICS
- Ulcer-healing Drugs: metabolism of flecainide inhibited by Cimetidine (increased plasma concentration)

Flucloxacillin see Penicillins

Fluconazole see Antifungals, Triazole

Flucytosine
- Antifungals: renal excretion of flucytosine decreased and cellular uptake increased by AMPHOTERICIN (toxicity possibly increased)
- Cytotoxics: plasma concentration of flucytosine possibly reduced by CYTARABINE

Fludarabine
- Antipsychotics: avoid concomitant use of cytoxotics with CLOZAPINE (increased risk of agranulocytosis)
- Cytotoxics: fludarabine increases intracellular concentration of CYTARABINE; increased pulmonary toxicity when

Fludarabine (continued)
- Cytotoxics (continued) fludarabine given with PENTOSTATIN (unacceptably high incidence of fatalities)
- Diprydiamole: effects of fludarabine possibly reduced by DIPRYDAMOLE

Fludrocortisone see Corticosteroids

Fluorides
- Calcium Salts: absorption of fluorides reduced by CALCIUM SALTS

Fluouracil
- Antibacterials: metabolism of fluorouracil inhibited by METRONIDAZOLE (increased toxicity)
- Anticoagulants: fluorouracil enhances anticoagulant effect of COUMARINS
- Antiepileptics: fluorouracil possibly prohibits metabolism of FOSPHENITOIN and PHENYTOIN (increased risk of toxicity)
- Antipsychotics: avoid concomitant use of cytoxotics with CLOZAPINE (increased risk of agranulocytosis)
- Filgrastim: neutropenia possibly exacerbated when fluorouracil given with FILGRASTIM
- Folate: toxicity of fluorouracil increased by FOLIC ACID—avoid concomitant use
- Filgrastim: neutropenia possibly exacerbated when fluorouracil given with FILGRASTIM
- PEGFILGRASTIM
- Pegfilgrastim: neutropenia possibly exacerbated when fluorouracil given with PEGFILGRASTIM
- Temoporfin: increased skin photosensitivity when topical fluorouracil used with TEMPORFIN
- Ulcer-healing Drugs: metabolism of fluorouracil inhibited by Cimetidine (increased plasma concentration)

Fluvastatin see Antidepressants, SSRI

Flupentixol see Antipsychotics

Fluphenazine see Antipsychotics

Flurazepam see Anxiolytics and Hypnotics

Flurbiprofen see NSAIDs

Flutamide
- Anticoagulants: flutamide enhances anticoagulant effect of COUMARINS

Fluticasone see Corticosteroids

Fluvastatin see Statins

Fluoxamine see Antidepressants, SSRI

Folates
- Aminosalicylates: absorption of folic acid possibly reduced by SULFASALAZINE
- Anticids: absorption of folic acid possibly reduced by ANTACIDS (manufacturer of folic acid advises give at least 2 hours apart)
- Antiepileptics: folates possibly reduce plasma concentration of FOSPHENITOIN, PHENOBARBITAL, PHENYTOIN and PRIMIDONE
- Cytotoxics: folic acid increases toxicity of CAPECITABINE, FLUOROURACIL and TEGERAF—avoid concomitant use; avoidance of folates advised by manufacturer of RALITREXED

Folic Acid see Folates

Folinic Acid see Folates

Fosamprenavir
- Acids: increased risk of haemorrhage when anticoagulants given with intravenous DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when other anticoagulants given with APIXABAN, DABIGATRAN and RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)

Formoterol see Symathomimetics, Beta2

Fosamprenavir
- Acids: increased risk of haemorrhage when anticoagulants given with intravenous DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when other anticoagulants given with APIXABAN, DABIGATRAN and RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)

Formoterol see Symathomimetics, Beta2

Fosamprenavir
- Acids: increased risk of haemorrhage when anticoagulants given with intravenous DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anticoagulants: increased risk of haemorrhage when other anticoagulants given with APIXABAN, DABIGATRAN and RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)

Formoterol see Symathomimetics, Beta2
Fosamprenavir
- Lipid-regulating Drugs (continued); use; avoidance of fosamprenavir advised by manufacturer of LOMITAPIDE (plasma concentration of lomitapide possibly increased)
- Oralist; absorption of fosamprenavir possibly reduced by ORLISTAT
- Ranolazone: fosamprenavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: fosamprenavir possibly increases plasma concentration of sildenafil
- Tacrolimus: fosamprenavir increases plasma concentration of tacrolimus
- Tadalafil: fosamprenavir possibly increases plasma concentration of tadalafil

Fosaprepitant
- Anticoagulants: fosaprepitant possibly reduces anticoagulant effect of warfarin
- Antidepressants: manufacturer of fosaprepitant advises avoid concomitant use with ST JOHN'S WORT
- Antidiabetics: fosaprepitant reduces plasma concentration of tolbutamide
- Antibacterials: fosaprepitant possibly increases plasma concentration of fosamprenavir
- Antifungals: fosaprepitant possibly increases plasma concentration of ketoconazole
- Antihistamines: caution with fosaprepitant by manufacturer of artemether with lumefantrine; fosaprepitant possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use
- Antivirals: manufacturer of fosaprepitant advises avoid concomitant use with boceprevir and raltegravir; fosaprepitant reduces plasma concentration of dolutedegravir; plasma concentration of fosamprenavir increased by etravirine (consider reducing dose of fosamprenavir); plasma concentration of fosamprenavir reduced by lopinavir, effect on lopinavir plasma concentration not predictable—avoid concomitant use; plasma concentration of fosamprenavir reduced by maraviroc—avoid concomitant use; plasma concentration of fosamprenavir possibly reduced by nevirapine—avoid unboosted fosamprenavir; manufacturers advise avoid concomitant use of fosamprenavir with telaprevir; plasma concentration of fosamprenavir reduced by tipranavir
- Anxiolytics and Hypnotics: fosamprenavir possibly increases plasma concentration of midazolam (risk of prolonged sedation)—avoid concomitant use of oral midazolam
- Avascular: fosamprenavir possibly increases plasma concentration of avanafil—see under avanafil, p. 698
- Ciclosporin: fosamprenavir increases plasma concentration of ciclosporin
- Cytotoxics: fosamprenavir possibly increases the plasma concentration of bosutinib—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; fosamprenavir possibly increases the plasma concentration of ibritinib—reduce dose of ibritinib (see under ibritinib, p. 809)
- Dapoxetine: manufacturer of dapoxetine advises dose reduction when fosamprenavir given with dapoxetine (see under dapoxetine, p. 703)
- Ergot Alkaloids: increased risk of ergotism when fosamprenavir given with ergotamine—avoid concomitant use
- Lipid-regulating Drugs: possible increased risk of myopathy when fosamprenavir given with atorvastatin; possible increased risk of myopathy when fosamprenavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; possible increased risk of myopathy when fosamprenavir given with simvastatin—avoid concomitant use
Fosphenytoin

- Analgesics (continued)
  - accelerates metabolism of FENTANYL (reduced effect); fosphenytoin accelerates metabolism of METHADONE (reduced effect and risk of withdrawal effects); fosphenytoin possibly increases risk of PETHIDINE toxicity; effects of fosphenytoin enhanced by ASPIRIN; fosphenytoin possibly accelerates metabolism of PARACETAMOL (also isolated reports of hepatotoxicity).
- Antihelmintics: fosphenytoin reduces plasma concentration of ALBENDAZOLE and PRAZIQUANTEL—consider increasing albendazole and praziquantel dose when given for systemic infections; plasma concentration of fosphenytoin possibly increased by LEVAMISOLE.
- Anti-arrhythmics: metabolism of fosphenytoin inhibited by AMIODARONE (increased plasma concentration); fosphenytoin reduces plasma concentration of DISOPRIMARY; fosphenytoin possibly reduces plasma concentration of DRONEDARONE—avoid concomitant use.
- Antibacterials: metabolism of fosphenytoin inhibited by CLARITHROMYCIN (increased plasma concentration); metabolism of fosphenytoin possibly inhibited by METRONIDAZOLE (increased plasma concentration); plasma concentration of fosphenytoin increased or decreased by CIPROFLOXACIN; fosphenytoin accelerates metabolism of DOXYCYCLINE (reduced plasma concentration); fosphenytoin possibly reduces plasma concentration of BEDAQUILINE—manufacturer of bedaquiline advises avoid concomitant use; plasma concentration of fosphenytoin increased by CHLORAMPHENICOL (increased risk of toxicity); metabolism of fosphenytoin possibly inhibited by SONIAZID (increased risk of toxicity); metabolism of fosphenytoin accelerated by SULFONAMIDES; fosphenytoin reduces plasma concentration of TELITHROMYCIN (avoid during and for 2 weeks after fosphenytoin); plasma concentration of fosphenytoin increased by TRIMETHOPRIM (also increased antifolate effect).
- Anticoagulants: fosphenytoin possibly reduces plasma concentration of APYXABAN; fosphenytoin accelerates metabolism of COUMARINS (possibility of reduced anticoagulant effect, but enhancement also reported); fosphenytoin possibly reduces plasma concentration of DABIGATRAN—manufacturer of dabigatran advises avoid concomitant use; fosphenytoin possibly reduces plasma concentration of Rivaroxaban—manufacturer of rivaroxaban advises monitor for signs of thrombosis.
- Antidepressants: plasma concentration of fosphenytoin increased by FLUDEXTROXIME; fosphenytoin reduces plasma concentration of MANSERIN, MIRTAZAPINE and PAROXETINE; plasma concentration of fosphenytoin possibly increased by SERTRALINE, also plasma concentration of sertraline possibly reduced; anticonvulsant effect of antiepileptics possibly antagonised by MAOI and TRICYCLIC-RELATED ANTIDEPRESSANTS (convulsive threshold lowered); anticonvulsant effect of antiepileptics possibly antagonised by SSRIS and TRICYCLICS (convulsive threshold lowered); plasma concentration of fosphenytoin possibly reduced by ST JOHN’S WORT—avoid concomitant use; fosphenytoin possibly reduces plasma concentration of TRICYCLICS.
- Antidiabetics: plasma concentration of fosphenytoin transiently increased by TOLBUTAMIDE (possibility of toxicity).
- Antiepileptics: plasma concentration of both drugs often reduced when fosphenytoin given with CARBAMAZEPINE, also plasma concentration of fosphenytoin may be increased; fosphenytoin reduces plasma concentration of ESILCARBAZEPINE, also plasma concentration of fosphenytoin may be increased; fosphenytoin reduces plasma concentration of lamotrigine, tiagabine and zonisamide; plasma concentration of fosphenytoin increased by oxcarbazepine, also plasma concentration of an active metabolite of oxcarbazepine reduced; fosphenytoin reduces plasma concentration of PERAMAPAN (see under Perampanel, p. 398); fosphenytoin often increases plasma concentration of PHENOBARBITAL and PRIMIDONE, plasma concentration of fosphenytoin often reduced but may be increased; fosphenytoin possibly reduces plasma concentration of retigabine; fosphenytoin possibly reduces plasma concentration of RUFINAMIDE, also plasma concentration of fosphenytoin increased or possibly reduced when given with SODIUM VALPROATE and VALPROIC ACID, also plasma concentration of sodium valproate and valproic acid reduced; plasma concentration of fosphenytoin increased by STRIPENTOL; plasma concentration of fosphenytoin increased by TOPRIMA (of topiramate reduced); plasma concentration of fosphenytoin reduced by VIGABATRIN.
- Antifungals: fosphenytoin reduces plasma concentration of KETOCONAZOLE and POSACONAZOLE; anticonvulsant effect of fosphenytoin enhanced by MICANAZOLE (plasma concentration of fosphenytoin increased); plasma concentration of fosphenytoin increased by FLUCONAZOLE (consider reducing dose of fosphenytoin); fosphenytoin reduces plasma concentration of TRICONAZOLE—avoid concomitant use; plasma concentration of fosphenytoin increased by VORICONAZOLE, also fosphenytoin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for fosphenytoin toxicity); fosphenytoin possibly reduces plasma concentration of caspofungin.
- Antimalarials: avoidance of fosphenytoin advised by manufacturer of ARTENIMIL with PIPERAQUINE; anticonvulsant effect of antiepileptics antagonised by MELOQUINE; anticonvulsant effect of antiepileptics possibly antagonised by PYRIMETHAMINE, also increased antifolate effect.
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by ANTIPSYCHOTICS (convulsive threshold lowered); fosphenytoin reduces plasma concentration of HALOPERIDOL; plasma concentration of fosphenytoin possibly increased or decreased by CHLORPromazine; fosphenytoin possibly reduces plasma concentration of Aripiprazole (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature); fosphenytoin accelerates metabolism of clozapine and quetiapine (reduced plasma concentration); fosphenytoin possibly reduces plasma concentration of Lurasidone—avoid concomitant use.
- Antivirals: fosphenytoin possibly reduces plasma concentration of ARAC, CARBAMAZEPINE, LOPINAVIR and SAQUINAVIR; avoidance of fosphenytoin advised by manufacturer of boceprevir and rilpivirine (plasma concentration of boceprevir and rilpivirine possibly reduced); fosphenytoin possibly reduces plasma concentration of DACLATASVIR and simeprevir—manufacturer of daclatasvir and simeprevir advises avoid concomitant use; avoidance of fosphenytoin advised by manufacturer of Dolutegravir, elvitegravir, etravirine and sofosbuvir and telaprevir; fosphenytoin possibly reduces plasma concentration of INDNAVIR, also plasma concentration of fosphenytoin possibly increased; fosphenytoin possibly reduces plasma concentration of ritonavir, also plasma concentration of fosphenytoin possibly affected; plasma concentration of fosphenytoin increased or decreased by zidovudine.
- Anxiolytics and Hypnotics: fosphenytoin often reduces plasma concentration of clonazepam; plasma concentration of fosphenytoin increased or decreased by diazepam; plasma concentration of fosphenytoin possibly increased or decreased by benzo diazepines.
- Aprepitant: fosphenytoin possibly reduces plasma concentration of aprepitant.
- Bupropion: fosphenytoin reduces plasma concentration of bupropion.
- Caffeine citrate: fosphenytoin reduces plasma concentration of caffeine citrate.
Fosphenytoin (continued)

- Calcium-channel Blockers: fosphenytoin reduces effects of feleodipine and verapamil; avoidance of fosphenytoin advised by manufacturer of isradipine; avoidance of fosphenytoin advised by manufacturer of nimodipine (plasma concentration of nimodipine possibly reduced); plasma concentration of fosphenytoin increased by diltilazem but also effect of diltilazem reduced.
- Cardiovascular: fosphenytoin possibly reduces plasma concentration of a cannabinoid extract—manufacturer of cannabis extract advises avoid concomitant use.
- Cardiac Glycosides: fosphenytoin possibly reduces plasma concentration of digoxin.
- Ciclosporin: fosphenytoin accelerates metabolism of ciclosporin.
- Ciclosporin: fosphenytoin possibly reduces plasma concentration of ciclosporin—manufacturer of ciclosporin advises avoid concomitant use.
- Corticosteroids: fosphenytoin possibly reduces plasma concentration of corticosteroids.
- Diazoxide: fosphenytoin possibly reduces plasma concentration of diazoxide; also effect of diazoxide may be reduced.
- Disulfiram: fosphenytoin increases plasma concentration of disulfiram and secobarbital; also effect of disulfiram may be increased.
- Divalproex: fosphenytoin possibly reduces plasma concentration of divalproex.
- Ezetimibe: fosphenytoin possibly reduces plasma concentration of ezetimibe.
- Ezetimibe: fosphenytoin possibly reduces plasma concentration of ezetimibe—manufacturer of ezetimibe advises avoid concomitant use.
- Fosphenytoin: plasma concentration of fosphenytoin possibly reduced by leflunomide.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ritonavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Leflunomide.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by fluvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by simvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by atorvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by pravastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by allopurinol.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by ciprofloxacin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by fluconazole.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by lamivudine.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by metformin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by ritonavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by saquinavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by telaprevir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by voriconazole.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Atorvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Leflunomide.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Fluvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Simvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Pravastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Allopurinol.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ciprofloxacin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Lamivudine.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Metformin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ritonavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Saquinavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Telaprevir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Voriconazole.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Atorvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Leflunomide.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Fluvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Simvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Pravastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Allopurinol.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ciprofloxacin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Lamivudine.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Metformin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ritonavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Saquinavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Telaprevir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Voriconazole.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Atorvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Leflunomide.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Fluvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Simvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Pravastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Allopurinol.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ciprofloxacin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Lamivudine.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Metformin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ritonavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Saquinavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Telaprevir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Voriconazole.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Atorvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Leflunomide.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Fluvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Simvastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Pravastatin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Allopurinol.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ciprofloxacin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Lamivudine.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Metformin.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Ritonavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Saquinavir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Telaprevir.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Voriconazole.
- Fosphenytoin: plasma concentration of fosphenytoin possibly increased by Atorvastatin.
Fusidic Acid (continued)
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Gabapentin
- Analgesics: bioavailability of gabapentin increased by:
  - RIFAMPICIN

- Antacids: absorption of gabapentin reduced by ANTACIDS

- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and TRICYCLIC-RELATED ANTIDEPRESSANTS (conversive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRI AND TRICYCLICS (conversive threshold lowered)

- Antimalarials: anticonvulsant effect of antiepileptics antagonised by ANTIPSYCHOTICS (conversive threshold lowered)

- Orlistat: possible increased risk of convulsions when antiepileptics given with ORLISTAT

Galantamine see Parasympathomimetics

Ganciclovir
- NOTE: Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature

- Antibacterials: increased risk of convulsions when ganciclovir given with IMPENEM WITH CILASTATIN

- Antivirals: ganciclovir possibly increases plasma concentration of DIDANOSINE—profound myelosuppression when ganciclovir given with ZIDOVUDINE (if possible avoid concomitant administration, particularly during initial ganciclovir therapy)

- Mycophenolate: plasma concentration of ganciclovir possibly increased by MYCOPHENOLATE, also plasma concentration of inactive metabolite of mycophenolate possibly increased

- Tacrolimus: possible increased risk of nephrotoxicity when ganciclovir given with TACROLISUM

Gefitinib
- Antibacterials: plasma concentration of gefitinib reduced by:
  - RIFAMPICIN—avoid concomitant use

- Anticoagulants: gefitinib possibly enhances anticoagulant effect of WARFARIN

- Antidepressants: manufacturer of gefitinib advises avoid concomitant use with ST JOHN’S WORT

- Antiepileptics: manufacturer of gefitinib advises avoid concomitant use with CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYTOIN and PHENINDINE

- Antifungals: plasma concentration of gefitinib increased by ITRACONAZOLE

- Antipsychotics: avoid concomitant use of cytotoxics with gefitinib

- Antivirals: avoidance of gefitinib advised by manufacturer of BUDESONIDE

- Ulcer-healing Drugs: plasma concentration of gefitinib reduced by RANITIDINE

Gemcitabine
- Anticoagulants: gemcitabine possibly enhances anticoagulant effect of WARFARIN

- Antipsychotics: avoid concomitant use of cytotoxics with gemcitabine

- Antivirals: avoidance of gemcitabine advised by manufacturer of BOCEPREVIR

- Ulcer-healing Drugs: plasma concentration of gemcitabine reduced by RANITIDINE

Gentamicin see Aminoglycosides

Gestodene see Progestogens

Glibenclamide see Antidiabetics

Gliclazide see Antidiabetics

Glibenpiride see Antidiabetics

Glipizide see Antidiabetics

Glucosamine
- Anticoagulants: glucosamine enhances anticoagulant effect of WARFARIN (avoid concomitant use)

Glyceryl Trinitrate see Nitrates

Glycopyrronium see Antimuscarinics

Golimumab (continued)
- Anakinra: avoid concomitant use of golimumab with ANAKINRA

- Antipsychotics: avoid concomitant use of cytoxotics with CLOzapine (increased risk of agranulocytosis)

- Vaccines: risk of generalised infections when monoclonal antibodies given with live VACCINES—avoid concomitant use

Granisetron see 5HT3-receptor Antagonists (under HT)

Grapefruit Juice
- Aliskiren: grapefruit juice reduces plasma concentration of ALISKIREN—avoid concomitant use

- Anthelmintics: grapefruit juice increases plasma concentration of active metabolite of ALBENDAZOLE; grapefruit juice increases plasma concentration of PRAZIQUANTEL

- Anti-arrhythmics: grapefruit juice increases plasma concentration of AMIODARONE

- Antihistamines: grapefruit juice reduces plasma concentration of BILASTINE

- Antipsychotics: avoidance of grapefruit juice advised by manufacturer of LURASIDONE and PIMOZIDE; grapefruit juice possibly increases plasma concentration of QUETIAPINE—manufacturer of quetiapine advises avoid concomitant use

- Antivirals: grapefruit juice possibly increases plasma concentration of Efavirenz

- Anxiolytics and Hypnotics: grapefruit juice possibly increases plasma concentration of ORAL MIDAZOLAM; grapefruit juice increases plasma concentration of BISPIRONE

- Avanafil: grapefruit juice possibly increases plasma concentration of AVANAFIL—manufacturer of avanafil advises avoid grapefruit juice for 24 hours before avanafil

- Calcium-channel Blockers: grapefruit juice possibly increases plasma concentration of ANGELICINE; grapefruit juice increases plasma concentration of FELODIPINE, ISRADIPINE, LACIDIPINE, LERCANDIPINE, NICARDIPINE, NIFEDIPINE, NIMODIPINE and VERAPAMIL

- Ciclosporin: grapefruit juice increases plasma concentration of CYCLOSPORIN (increased risk of toxicity)

- Colchicine: grapefruit juice possibly increases risk of COLCHICINE toxicity

- Corticosteroids: grapefruit juice increases plasma concentration of ORAL Budesonide—avoid concurrent use or separate administration by as much as possible and consider reducing oral budesonide dose

- Cytotoxics: grapefruit juice possibly increases plasma concentration of ANTIKINIB, CABOZANTINIB and PONATINIB; grapefruit juice possibly increases the plasma concentration of BOSUTINIB—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; grapefruit juice possibly increases plasma concentration of CRIZOTININ and VINFLUNINE—manufacturer of crizotinib and vinflunine advises avoid concomitant use; avoidance of grapefruit juice advised by manufacturer of DASATINIB (plasma concentration of dasatinib possibly increased); avoidance of grapefruit juice advised by manufacturer of EVEROLIMUS, IBRUTINIB, LAPATINIB, NILOTINIB and PAZOPANIB

- Ibrutinib: grapefruit juice increases plasma concentration of IVAFTOR—manufacturer of ibrutinib advises avoid concomitant use

- Lipid-regulating Drugs: grapefruit juice possibly increases plasma concentration of ATORVASTATIN; grapefruit juice increases plasma concentration of SIMVASTATIN—avoid concomitant use; avoidance of grapefruit juice advised by manufacturer of LOMITAPIDE

- Pirfenidone: avoidance of grapefruit juice advised by manufacturer of PIRFENIDONE
Grapefruit Juice (continued)
- Ranolazine: grapefruit juice possibly increases plasma concentration of RANOLAZINE — manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: grapefruit juice possibly increases plasma concentration of SILDENAFIL
- Sirolimus: grapefruit juice increases plasma concentration of SIROLIMUS — avoid concomitant use
- Tacrolimus: grapefruit juice increases plasma concentration of TACROLIMUS
- Tadalafil: grapefruit juice possibly increases plasma concentration of TADALAFIL
- Tolvaptan: grapefruit juice increases plasma concentration of TOLVAPタン — avoid concomitant use
- Vardenafil: grapefruit juice possibly increases plasma concentration of VARDENAFIL — avoid concomitant use

Griseofulvin
- Alcohol: griseofulvin possibly enhances effects of ALCOHOL
- Anticoagulants: griseofulvin reduces anticoagulant effect of COUMARINS
- Antibacterials: absorption of griseofulvin reduced by PHENOBARBITAL and PHENYTOIN (reduced effect)
- Cisoplatin: griseofulvin possibly reduces plasma concentration of CISPLATIN
- Oestrogens: anecdotal reports of contraceptive failure and increased risk of bleeding when griseofulvin given with OESTROGENS
- Progestogens: anecdotal reports of contraceptive failure and increased risk of bleeding when griseofulvin given with PROGESTOGENS

Guanethidine
- See Adrenergic Neurone Blockers

Haemophilus Vaccine
- See Vaccines

Haloperidol
- See Antipsychotics

Heparin
- See Heparins

Heparin
- ACE inhibitors: increased risk of hyperkalaemia when heparins given with ACE INHIBITORS
- Aflatoxins: increased risk of hyperkalaemia when heparins given with AFLATOXINS
- Analgesics: possible increased risk of bleeding when heparins given with NSAIDS; increased risk of haemorrhage when anticoagulants given with intravenous DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with KETOROLAC (avoid concomitant use, including low-dose heparins); anticoagulant effect of heparins enhanced by ASPIRIN
- Angiotensin-II Receptor Antagonists: increased risk of hyperkalaemia when heparins given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Anticoagulants: increased risk of haemorrhage when other anticoagulants given with APIXABAN, DABIGATRAN and RIVAROXABAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)
- Clopidogrel: increased risk of bleeding when heparins given with CLOPIDOGREL
- Dipryidamole: anticoagulant effect of heparins enhanced by DIPYRIDAMOLE
- Iloprost: anticoagulant effect of heparins possibly enhanced by ILOPROST
- Nitrate: anticoagulant effect of heparins reduced by infusion of GLYCEROL TRIHTRITRATE

Hepatitis Vaccines
- See Vaccines

Histamine
- Antidepressants: manufacturer of histamine advises avoid concomitant use with MAOIS; effects of histamine theoretically antagonised by ANTIHISTAMINES — manufacturer of histamine advises avoid concomitant use
- Antihistamines: effects of histamine theoretically antagonised by ANTIHISTAMINES — manufacturer of histamine advises avoid concomitant use
- Histamine (continued)
  - Antimalarials: manufacturer of histamine advises avoid concomitant use with ANTIMALARIALS
  - Antipsychotics: effects of histamine theoretically antagonised by ANTIPSYCHOTICS — manufacturer of histamine advises avoid concomitant use
  - Ato伐kone: manufacturer of histamine advises avoid concomitant use with ATOVAQUONE
  - Clonidine: manufacturer of histamine advises avoid concomitant use with CLONIDINE
  - Corticosteroids: manufacturer of histamine advises avoid concomitant use with CORTICOSTEROIDS
  - Ulcer-healing Drugs: effects of histamine theoretically antagonised by HISTAMINE H2-ANTAGONISTS — manufacturer of histamine advises avoid concomitant use

Histamine H2-antagonists
- Alpha-blockers: cinetidine and ranitidine antagonise effects of
  - TOLAZOLINE
- Aminophylline: cinetidine inhibits metabolism of
  - AMINOPHYLLINE (increased plasma concentration)
  - Analgesics: cinetidine inhibits metabolism of OPIOID ANALGESICS (increased plasma concentration)
  - Anti-arrhythmics: cinetidine increases plasma concentration of AMIODARONE and PROPafenone; cinetidine inhibits metabolism of FLECAINIDE (increased plasma concentration); cinetidine increases plasma concentration of LIDOCAINE (increased risk of toxicity)
  - Antibacterials: cinetidine increases plasma concentration of ERYTHROMYCIN (increased risk of toxicity, including deafness); cinetidine inhibits metabolism of METRONIDAZOLE (increased plasma concentration); cinetidine increases plasma concentration of TADALAFIL (increased plasma concentration)
  - Antidepressants: cinetidine increases plasma concentration of CITALOPRAM, ESCITALOPRAM, MIRTAZAPINE and SERTALINE; cinetidine inhibits metabolism of AMITRIPTYLINE, DOXEPIN, IMIPRAMINE and NORTRIPTYLINE (increased plasma concentration); cinetidine increases plasma concentration of MOXIBESTEMIDE (increased plasma concentration)
  - Antiemetics: cinetidine increases plasma concentration of METFORMIN (increased plasma concentration); cinetidine increases plasma concentration of TOLAZOLINE (increased plasma concentration)
  - Antiepileptics: cinetidine increases plasma concentration of CARBAMAZEPINE, FOSPHENTOIN, PHENTOIN, VALPROATE and VALPROIC ACID (increased plasma concentration)
  - Antifungals: cinetidine reduces plasma concentration of ITRACONAZOLE and KETOCONAZOLE; cinetidine reduces plasma concentration of POSACONAZOLE — manufacturer of posaconazole suspension advises avoid concomitant use; famotidine, nizatidine and ranitidine possibly reduce plasma concentration of POSACONAZOLE — manufacturer of posaconazole suspension advises avoid concomitant use; cinetidine increases plasma concentration of TRICYCLICs
  - Antihistamines: manufacturer of loratadine advises cinetidine possibly increases plasma concentration of LORATADINE; cinetidine increases plasma concentration of HYDROXYZINE
  - Antimalarials: avoidance of cinetidine advised by manufacturer of ARTEMETHER with LUMEFANTRINE; cinetidine inhibits metabolism of CHLOROQUINE, HYDROXYCHLOROQUINE and QUININE (increased plasma concentration)
  - Antipsychotics: cinetidine possibly enhances effects of ANTI PSYCHOTICS, CHLORPROMAZINE and CLOZAPINE
  - Antivirals: manufacturer of atazanavir advises adjust doses of both drugs when cinetidine and nizatidine given with ATAZANAVIR — consult atazanavir product literature; famotidine and ranitidine reduce the plasma concentration of ATAZANAVIR (adjust doses of both drugs — consult atazanavir product literature); famotidine increases plasma
Interactions

Appendix 1

Hormone Antagonists
- Antivirals: (continued) concentration of Raltegravir; avoidance of histamine H2-antagonists for 12 hours before or 4 hours after Rilpirivirine advised by manufacturer of rilpirivirine—consult product literature; cimetidine possibly increases plasma concentration of Saquinavir
- Anxiolytics and Hypnotics: cimetidine inhibits metabolism of Benzo Diazepines, Clomethazolone and Zaleplon (increased plasma concentration); cimetidine increases plasma concentration of Melatonin
- Beta-blockers: cimetidine increases plasma concentration of Levetisol, Metoprolol and Propranolol; cimetidine possibly increases plasma concentration of Oral Timolol
- Caffeine citrate: cimetidine increases plasma concentration of Caffeine Citrate
- Calcium-channel blockers: cimetidine possibly inhibits metabolism of Calcium-channel blockers (increased plasma concentration); cimetidine increases plasma concentration of Isradipine (halve dose of isradipine)
- Ciclosporin: cimetidine possibly increases plasma concentration of Ciclosporin
- Clopidogrel: cimetidine possibly reduces antiplatelet effect of Clopidogrel
- Cytotoxic: cimetidine possibly enhances myelosuppressive effects of Carmustin and Lomustine; cimetidine reduces plasma concentration of Doxorubicin; cimetidine increases plasma concentration of Epirubicin; cimetidine inhibits metabolism of Capetabine, Fluorouracil and Tegafur (increased plasma concentration); famotidine possibly reduces plasma concentration of Dasatinib; avoidance of cimetidine, famotidine and nizatidine advised by manufacturer of Erlotinib; ranitidine reduces plasma concentration of Erlotinib—manufacturer of erlotinib advises at least 2 hours before or 10 hours after ranitidine; ranitidine reduces plasma concentration of Gefitinib; histamine H1-antagonists possibly reduce absorption of Lapatinib; histamine H1-antagonists possibly reduce absorption of Pazopanib—manufacturer of pazopanib advises give at least 2 hours before or 10 hours after histamine H2-antagonists
- Dopaminergics: cimetidine reduces excretion of Pramipexole (increased plasma concentration)
- Ergot Alkaloids: increased risk of ergotism when cimetidine is given with Ergotamine—avoid concomitant use
- Fampridine: avoidance of cimetidine advised by manufacturer of Fampridine
- Histamine: histamine H1-antagonists theoretically antagonise effects of Histamine—manufacturer of histamine advises avoid concomitant use
- Hormone Antagonists: absorption of cimetidine possibly delayed by Octreotide
- SHT1-receptor Agonists: cimetidine inhibits metabolism of Zolmitriptan (reduce dose of zolmitriptan)
- Lipid-regulating Drugs: separating administration from cimetidine and ranitidine by 12 hours advised by manufacturer of Lomitapide
- Rivastigmin: cimetidine inhibits the metabolism of Rivastigmin
- Sildenafil: cimetidine increases plasma concentration of Sildenafil—consider reducing dose of sildenafil for erectile dysfunction
- Symptomometics: cimetidine possibly inhibits metabolism of Dobutamine
- Theophylline: cimetidine inhibits metabolism of Theophylline (increased plasma concentration)
- Thyroid Hormones: cimetidine reduces absorption of Levothyroxine

Hormone Antagonists see Antimuscarinics

Hormone Antagonists see Abiraterone, Bicalutamide, Danazol, Dutasteride, Enzalutamide, Exemestane, Flutamide, Lanreotide, Octreotide, Pasireotide, Tamoxifen, and Toremifene

SHT1-receptor Agonists see Antimuscarinics

Antibacterials: plasma concentration of eletriptan increased by Clarithromycin and Erythromycin (risk of toxicity)—

SHT1-receptor Agonists
- Antibacterials: (continued) avoid concomitant use; metabolism of zolmitriptan possibly inhibited by Quinolones (reduce dose of zolmitriptan)
- Antidepressants: increased risk of CNS toxicity when SHT1 agonists given with Citalopram (manufacturer of citalopram advises avoid concomitant use); increased risk of CNS toxicity when sumatriptan given with Citalopram, Escitalopram, Fluoxetine, Fluvoxamine or Paroxetine; metabolism of frovatriptan inhibited by Fluvoxamine; metabolism of zolmitriptan possibly inhibited by Fluvoxamine (reduce dose of zolmitriptan); CNS toxicity reported when sumatriptan given with Sertraline—possible increased serotonergic effects when SHT1 agonists given with Duloxetine or Venlafaxine; risk of CNS toxicity when rizatriptan or sumatriptan given with MAOIs (avoid rizatriptan or sumatriptan for 2 weeks after MAOIs); risk of CNS toxicity when zolmitriptan given with MAOIs or Moclobemide (avoid dose of zolmitriptan); risk of CNS toxicity when rizatriptan or sumatriptan given with Moclobemide (avoid rizatriptan or sumatriptan for 2 weeks after moclobemide); possible increased serotonergic effects when naratriptan given with SSRI—increased serotonergic effects when SHT1 agonists given with ST JOHN’S WORT—avoid concomitant use
- Antifungals: plasma concentration of eletriptan increased by Itraconazole and Ketoconazole (risk of toxicity)—avoid concomitant use; plasma concentration of almotriptan increased by Ketoconazole (increased risk of toxicity)
- Antivirals: plasma concentration of eletriptan increased by Indinavir and Ritonavir (risk of toxicity)—avoid concomitant use
- Beta-blockers: plasma concentration of rizatriptan increased by Propranolol (manufacturer of rizatriptan advises halve dose and avoid within 2 hours of propranolol)
- Dapoxetine: possible increased risk of serotonergic effects when SHT1 agonists given with Dapoxetine (manufacturer of dapoxetine advises SHT1 agonists should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping SHT1 agonists)
- Dopaminergics: avoidance of SHT1 agonists advised by manufacturer of Selegiline
- Ergot Alkaloids: increased risk of vasospasm when eletriptan, frovatriptan or naratriptan given with Ergotamine (avoid ergotamine for 24 hours after eletriptan, frovatriptan or naratriptan, avoid eletriptan, frovatriptan or naratriptan for 24 hours after ergotamine); increased risk of vasospasm when almotriptan, rizatriptan, sumatriptan or zolmitriptan given with Ergotamine (avoid ergotamine for 6 hours after almotriptan, rizatriptan, sumatriptan or zolmitriptan, avoid almotriptan, rizatriptan, sumatriptan or zolmitriptan for 24 hours after ergotamine)
- Lithium: possible risk of toxicity when sumatriptan given with Lithium
- Ulcer-healing Drugs: metabolism of zolmitriptan inhibited by Ciclosporin (reduce dose of zolmitriptan)

SHT1-receptor Antagonists
- Analgesics: ondansetron possibly antagonises effects of Tramadol
- Antibacterials: metabolism of ondansetron accelerated by Rifampicin (reduced effect)
- Antidepressants: possible increased serotonergic effects when SHT1 antagonists given with SSRI-related Antidepressants or SSRI
- Antiplatelet: metabolism of ondansetron accelerated by Carbamazepine, Fosphenytoin and Phenytoin (reduced effect)
- Cytotoxics: increased risk of ventricular arrhythmias when ondansetron given with Vanadotin—avoid concomitant use
- Dopaminergics: possible increased hypotensive effect when ondansetron given with Apomorphine—avoid concomitant use

Human papillomavirus vaccine see Vaccines

Hydralazine see Vasodilator Antihypertensives
Hydrochlorothiazide see Diuretics
Hydrocortisone see Corticosteroids
Hydroflumethiazide see Diuretics
Hydromorphone see Opioid Analgesics
Hydrotalcite see Antacids
Hydroxocobalamin
- Anticholinergics: response to hydroxocobalamin reduced by CHLORTHALIDONE
Hydroxyamphetamine
- Antiiptics: avoid concomitant use of cytoxotics with
- CLOZAINE (increased risk of agranulocytosis)
- Antivirals: increased risk of toxicity when hydroxyamphetamine given with DIONASE and STAUROLIN—avoid concomitant use

Hydroxychloroquine
- Absorbents: absorption of hydroxychloroquine reduced by 
- KALON
- Agalsidase Alfa and Beta: hydroxychloroquine possibly inhibits effects of AGALSIDASE ALFA AND BETA (manufacturers of agalsidase alfa and beta advise avoid concomitant use)
- Antacids: absorption of hydroxychloroquine reduced by ANTACIDS

- Anti-arrhythmics: increased risk of ventricular arrhythmias when hydroxychloroquine given with AMIODARONE—avoid concomitant use

- Antibacterials: increased risk of ventricular arrhythmias when hydroxychloroquine given with MOXIFLOXACIN—avoid concomitant use

- Antimalarials: avoidance of antimalarials advised by manufacturer of ARTEMET WITH LUMEFANTRINE; increased risk of convulsions when hydroxychloroquine given with MELOQUINE

- Antipsychotics: increased risk of ventricular arrhythmias when hydroxychloroquine given with DROPERIDOL—avoid concomitant use

- Cardiac Glycosides: hydroxychloroquine possibly increases plasma concentration of DIGOXIN

- Ciclosporin: hydroxychloroquine increases plasma concentration of CICLOSPORIN (increased risk of toxicity)

- Cytotoxics: possible increased risk of ventricular arrhythmias when hydroxychloroquine given with BUSULFAN

- Histamine: avoidance of antimalarials advised by manufacturer of HISTAMINE

- Lanthanum: absorption of hydroxychloroquine possibly reduced by LANTHANUM (give at least 2 hours apart)

- Laronidase: hydroxychloroquine possibly inhibits effects of LARONIDASE (manufacturer of laronidase advises avoid concomitant use)

- Parasympathomimetics: hydroxychloroquine has potential to increase symptoms of myasthenia gravis and thus diminish effect of NEOSTIGMINE and PYRIDOSTIGMINE

- Ulcer-healing Drugs: metabolism of hydroxychloroquine inhibited by CIMETIDINE (increased plasma concentration)

- Vaccines: antimalarials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Hydroxyzine see Antihistamines
Hyoscine see Antimuscarinics
Ibuprofen see NSAIDs
Ibrutinib
- Anti-arrhythmics: plasma concentration of ibrutinib possibly increased by AMIODARONE and DEXTROBEBON—reduce dose of ibrutinib (see under Ibrutinib, p. 809)
- Antibacterials: plasma concentration of ibrutinib possibly increased by CIPROFLOXACIN, CLARITHROMYCIN, ERYTHROMYCIN and TETRACYCLINIC—reduce dose of ibrutinib (see under Ibrutinib, p. 809); plasma concentration of ibrutinib reduced by RIFAMPICIN—avoid concomitant use

- Anticoagulants: manufacturer of ibrutinib advises avoid concomitant use with COUMARINS and PHENINDINE

- Antidepressants: plasma concentration of ibrutinib possibly increased by ST JOHN'S WORT—manufacturer of ibrutinib advises avoid concomitant use

- Antiepileptics: plasma concentration of ibrutinib possibly reduced by CARBAMAZEPINE, FOSPHENYTIOIN and

ibrutinib
- Antiepileptics (continued)
- PHENYTOIN—manufacturer of ibrutinib advises avoid concomitant use

- Anti-arrhythmics: plasma concentration of ibrutinib increased by KETOCONAZOLE—reduce dose of ibrutinib (see under Ibrutinib, p. 809); plasma concentration of ibrutinib possibly increased by FLUCONAZOLE, ITRACONAZOLE and VORICONAZOLE—reduce dose of ibrutinib (see under Ibrutinib, p. 809)

- Antipsychotics: avoid concomitant use of cytoxotics with CLOZAPINE (increased risk of agranulocytosis)

- Antivirals: plasma concentration of ibrutinib possibly increased by ATAZANAVIR, DARUNAVIR, FOSAMPRENAVIR, INDINAVIR, RITONAVIR and SAQUINAVIR—reduce dose of ibrutinib (see under Ibrutinib, p. 809)

- Aprepitant: plasma concentration of ibrutinib possibly increased by APREMPIANT—reduce dose of ibrutinib (see under Ibrutinib, p. 809)

- Calcium-channel Blockers: plasma concentration of ibrutinib possibly increased by CLOBASIC—reduce dose of ibrutinib (see under Ibrutinib, p. 809)

- Cardiac Glycosides: manufacturer of ibrutinib advises give DIGOXIN at least 6 hours before or after ibrutinib

- Cobicistat: plasma concentration of ibrutinib possibly increased by Cobicistat—reduce dose of ibrutinib (see under Ibrutinib, p. 809)

- Cytotoxics: plasma concentration of ibrutinib possibly increased by CRIZOTINIB and MATINIB—reduce dose of ibrutinib (see under Ibrutinib, p. 809)

- Fosaprepitant: plasma concentration of ibrutinib possibly increased by FOSAPREMITANT

- Grapefruit Juice: manufacturer of ibrutinib advises avoid concomitant use with GRAPEFRUIT JUICE

- Vitamins: manufacturer of ibrutinib advises avoid concomitant use with VITAMIN E

Ibuprofen see NSAIDs
Idarubicin
- Antipsychotics: avoid concomitant use of cytoxotics with CLOZAPINE (increased risk of agranulocytosis)

- Ciclosporin: plasma concentration of idarubicin increased by CICLOSPORIN

Idelalisib
- Alpha-blockers: manufacturer of idelalisib advises avoid concomitant use with ALZULON

- Anti-arrhythmics: manufacturer of idelalisib advises avoid concomitant use with AMIODARONE

- Antibacterials: plasma concentration of idelalisib reduced by RIFAMPICIN—avoid concomitant use

- Antidepressants: plasma concentration of idelalisib possibly reduced by ST JOHN'S WORT—manufacturer of idelalisib advises avoid concomitant use

- Antiepileptics: plasma concentration of idelalisib possibly reduced by CARBAMAZEPINE, FOSPHENYTIOIN and PHENYTOIN—manufacturer of idelalisib advises avoid concomitant use

- Antifungals: plasma concentration of idelalisib increased by KETOCONAZOLE

- Antipsychotics: avoid concomitant use of cytoxotics with CLOZAPINE (increased risk of agranulocytosis); manufacturer of idelalisib advises avoid concomitant use with PIMOZIDE and QUETIAPINE

- Anxiolytics and Hypnotics: manufacturer of idelalisib advises avoid concomitant use of oral MIDAZOLAM

- Ergot Alkaloids: manufacturer of idelalisib advises avoid concomitant use with ERGOTAMINE

- Lipid-regulating Drugs: manufacturer of idelalisib advises avoid concomitant use with SIMVASTATIN

- Sildenafil: manufacturer of idelalisib advises avoid concomitant use of SILDENAFIL for pulmonary arterial hypertension

- Symathomimetics, Beta: manufacturer of idelalisib advises avoid concomitant use with SALMETEROL

Ilosone
- Anticoagulants: ilosone possibly enhances anticoagulant effect of COUMARINS
Iloprost

- Analgesics: increased risk of bleeding when iloprost given with NSAIDS OR ASPIRIN
- Anticoagulants: iloprost possibly enhances anticoagulant effect of COUMARINS AND HEPARINS; increased risk of bleeding when iloprost given with CLOPIDOGREL
- Epithalidase: increased risk of bleeding when iloprost given with EPTIFIBATIDE
- Tirofiban: increased risk of bleeding when iloprost given with TIROFIBAN

Imatinib

- Analgesics: manufacturer of imatinib advises caution with PARACETAMOL
- Antibacterials: plasma concentration of imatinib reduced by RIFAMPICIN—avoid concomitant use
- Anticoagulants: manufacturer of imatinib advises replacement of WARFARIN with a heparin (possibility of enhanced warfarin effect)
- Antidepressants: plasma concentration of imatinib reduced by ST JOHN’S WORT—avoid concomitant use
- Antiepileptics: plasma concentration of imatinib reduced by CARBAMAZEPINE, FOSPHENITOIN, OXCARBAZEPINE and PHENYTOIN—avoid concomitant use
- Antifungals: plasma concentration of imatinib increased by CLOPIDOGREL
- Cytoxotics: imatinib possibly increases the plasma concentration of BOUSUTINIB—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; imatinib increases plasma concentration of EVEROLIMUS (consider reducing the dose of everolimus—consult everolimus product literature); imatinib possibly increases the plasma concentration of IBRUTINIB—reduce dose of ibrutinib (see under ibrutinib, p. 809)
- Lipid-regulating Drugs: imatinib increases plasma concentration of SIMVASTATIN
- Tacrolimus: imatinib increases plasma concentration of TACROLIMUS
- Thyroid Hormone: imatinib possibly reduces plasma concentration of LEVOTHYROXINE

Indapamide see ACE Inhibitors

Imipenem with Cilastatin

- Antiepileptics: carbapenems reduce plasma concentration of SODIUM VALPROATE and VALPROIC ACID—avoid concomitant use
- Antivirals: increased risk of convulsions when imipenem with cilastatin given with GANCICLOVIR OR VALGANCICLOVIR
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Imipramine see Antidepressants, Tricyclic

Immunoglobulins

- Vaccines: anti-d immunoglobulins and normal immunoglobulin might impair immune response to BCG VACCINE—give BCG vaccine at least 5 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; anti-d immunoglobulins and normal immunoglobulin might impair immune response to MMR VACCINE—give MMR vaccine at least 5 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; anti-d immunoglobulins and normal immunoglobulin might impair immune response to poliomyelitis vaccine—give oral polio vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; anti-d immunoglobulins and normal immunoglobulin might impair immune response to yellow fever vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; anti-d immunoglobulins and normal immunoglobulin might impair immune response to smallpox vaccine—give smallpox vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; anti-d immunoglobulins and normal immunoglobulin might impair immune response to varicella-zoster vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; anti-d immunoglobulins and normal immunoglobulin might impair immune response to yellow fever vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin

Indacaterol see Sympathomimetics, Beta2

Indapamide see Diuretics

Indinavir

- Aldesleukin: plasma concentration of indinavir possibly increased by ALDESELEUKIN
- Anti-arrhythmics: indinavir possibly increases plasma concentration of AMIODARONE—avoid concomitant use; indinavir possibly increases plasma concentration of FLECAINIDE (increased risk of ventricular arrhythmias—avoid concomitant use)
- Antibacterials: indinavir increases plasma concentration of RIFABUTIN, also plasma concentration of indinavir decreased (reduce dose of rifabutin and increase dose of indinavir); metabolism of indinavir accelerated by RIFAMPICIN (reduced plasma concentration—avoid concomitant use); avoidance of concomitant indinavir in severe renal and hepatic impairment advised by manufacturer of TELITHROMYCIN
- Antiepileptics: avoidance of indinavir advised by manufacturer of APIXABAN AND RIVAROXABAN
- Antidepressants: plasma concentration of indinavir reduced by ST JOHN’S WORT—avoid concomitant use
- Antiepileptics: plasma concentration of indinavir possibly reduced by CARBAMAZEPINE, FOSPHENITOIN and PHENYTOIN, also plasma concentration of carbamazepine, fosphenytin and phenytoin possibly increased; plasma concentration of indinavir possibly reduced by PHENOBARBITAL AND PRIMIDONE
- Antimalarials: caution with indinavir advised by manufacturer of ARTEMETHER WITH LUMEFANTRINE; indinavir possibly increases plasma concentration of QUININE (increased risk of toxicity)
- Antimuscarnics: avoidance of indinavir advised by manufacturer of DERIPENACIN AND TOLERODINE; manufacturer of fesoterodine advises dose reduction when indinavir given with FESOTERODINE—consult fesoterodine product literature
- Antipsychotics: indinavir possibly increases plasma concentration of ARIPIPRAZOLE (reduce dose of aripiprazole—consult aripiprazole product literature); indinavir possibly increases plasma concentration of LURASIDONE—avoid concomitant use; indinavir possibly increases plasma concentration of PIMOZIDE (increased risk of ventricular arrhythmias—avoid concomitant use); indinavir possibly increases plasma concentration of ST JOHN'S WORT
- Anticoagulants: indinavir increases plasma concentration of WARFARIN—avoid concomitant use; indinavir possibly increases plasma concentration of LEVOTHYROXINE
- Antiarrhythmics: indinavir increases plasma concentration of AMIODARONE—avoid concomitant use; indinavir possibly increases plasma concentration of FLECAINIDE (increased risk of ventricular arrhythmias—avoid concomitant use)
- Antibacterials: indinavir increases plasma concentration of RIFABUTIN, also plasma concentration of indinavir decreased (reduce dose of rifabutin and increase dose of indinavir); metabolism of indinavir accelerated by RIFAMPICIN (reduced plasma concentration—avoid concomitant use); avoidance of concomitant indinavir in severe renal and hepatic impairment advised by manufacturer of TELITHROMYCIN
- Antiepileptics: avoidance of indinavir advised by manufacturer of APIXABAN AND RIVAROXABAN
- Antidepressants: plasma concentration of indinavir reduced by ST JOHN’S WORT—avoid concomitant use
- Antiepileptics: plasma concentration of indinavir possibly reduced by CARBAMAZEPINE, FOSPHENITOIN and PHENYTOIN, also plasma concentration of carbamazepine, fosphenytin and phenytoin possibly increased; plasma concentration of indinavir possibly reduced by PHENOBARBITAL AND PRIMIDONE
- Antimalarials: caution with indinavir advised by manufacturer of ARTEMETHER WITH LUMEFANTRINE; indinavir possibly increases plasma concentration of QUININE (increased risk of toxicity)
- Antimuscarnics: avoidance of indinavir advised by manufacturer of DERIPENACIN AND TOLERODINE; manufacturer of fesoterodine advises dose reduction when indinavir given with FESOTERODINE—consult fesoterodine product literature
- Antipsychotics: indinavir possibly increases plasma concentration of ARIPIPRAZOLE (reduce dose of aripiprazole—consult aripiprazole product literature); indinavir possibly increases plasma concentration of LURASIDONE—avoid concomitant use; indinavir possibly increases plasma concentration of PIMOZIDE (increased risk of ventricular arrhythmias—avoid concomitant use); indinavir possibly increases plasma concentration of
Indinavir

> Antipsychotics (continued)
> 
> QUETIAPINE—manufacturer of quetiapine advises avoid concomitant use
> 
> ANTIvirals: avoid concomitant use of indinavir with
> 
> ATAZANAVIR: plasma concentration of both drugs increased when indinavir given with DARUNAVIR; absorption of indinavir reduced by DIDANOSINE tablets (give at least 1 hour apart); plasma concentration of indinavir reduced by EFAVIRENZ and NEVIRAPINE; plasma concentration of indinavir possibly reduced by 
> 
> ETRAVIRINE—avoid concomitant use; indinavir increases plasma concentration of MARAVIROC (consider reducing dose of maraviroc); plasma concentration of indinavir increased by RITONAVIR; indinavir increases plasma concentration of SAQUINAVIR
> 
> Cypotoxics: indinavir possibly increases plasma concentration of
> 
> AVANAFIL—manufacturer of avanafil advises avoid concomitant use
> 
> Bosentan: plasma concentration of indinavir possibly reduced by
> 
> BOSENtan
> 
> Ciclosporin: indinavir increases plasma concentration of
> 
> CICLOSPORIN
> 
> Colchicine: indinavir possibly increases risk of COLCHICINE toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
> 
> Corticosteroids: plasma concentration of indinavir possibly reduced by DEKAMETHASON
> 
> Cytotoxics: indinavir possibly increases plasma concentration of
> 
> AXTINIB (reduce dose of axtinib—consult axtinib product literature); indinavir possibly increases the plasma concentration of
> 
> BOSUTINIB and CARBAXATAXEL—manufacturer of bosutinib and cabazitaxel advises avoid or consider reducing dose of bosutinib and cabazitaxel; indinavir possibly increases plasma concentration of
> 
> CRIZOTINIB and EVEROLIMUS—manufacturer of crizotinib and everolimus advises avoid concomitant use; indinavir possibly increases the plasma concentration of
> 
> IBRUTINIB—consider reducing dose of ibrutinib (see under ibrutinib, p. 809); indinavir possibly increases plasma concentration of
> 
> PAZOPANIB (reduce dose of pazopanib); indinavir possibly increases plasma concentration of
> 
> PONATINIB—consider reducing initial dose of ponatinib (see under Ponatinib, p. 814); manufacturer of ruxolitinib advises dose reduction when indinavir given with
> 
> RUOXILITINIB—consult ruxolitinib product literature; indinavir possibly increases plasma concentration of
> 
> DOCETAXEL—manufacturer of docetaxel advises avoid concomitant use or consider reducing docetaxel dose
> 
> Ergot Alkaloids: increased risk of ergotism when indinavir given with
> 
> ERGOMETRINE or ERGOTAMINE—avoid concomitant use
> 
> SH2-receptor Agonists: indinavir increases plasma concentration of
> 
> ELECTRIPTAN (risk of toxicity)—avoid concomitant use
> 
> Lipid-regulating Drugs: possible increased risk of myopathy when indinavir given with ATORVASTATIN; possibly increased risk of myopathy when indinavir given with
> 
> ROSUVASTATIN—manufacturer of rosvastatin advises avoid concomitant use; increased risk of myopathy when indinavir given with
> 
> SIMVASTATIN (avoid concomitant use); avoidance of indinavir advised by manufacturer of
> 
> LOMITAPIDE (plasma concentration of lomitapide possibly increased)
> 
> Orlitrate: absorption of indinavir possibly reduced by
> 
> ORLISTAT
> 
> Ranolazine: indinavir possibly increases plasma concentration of
> 
> RANOLAZINE—manufacturer of ranolazine advises avoid concomitant use
> 
> Sildenafil: indinavir increases plasma concentration of
> 
> TADALAFIL—avoid concomitant use
> 
> Indinavir (continued)
> 
> Tadalafil: indinavir possibly increases plasma concentration of
> 
> LIPID-REGULATING DRUGS: avoid concomitant use of indinavir with
> 
> INFECTIONS: avoid concomitant use of indinavir with
> 
> ANTIHYPERTENSIVE: avoid concomitant use of indinavir with
> 
> ANTICOAGULANTS: avoid concomitant use of indinavir with
> 
> ANTICONVULSANTS: avoid concomitant use of indinavir with
> 
> ANTIHISTAMINES: avoid concomitant use of indinavir with
> 
> ANTIBIOTICS: avoid concomitant use of indinavir with
> 
> ANTIARRHYTHMICS: avoid concomitant use of indinavir with
> 
> ANGIOTENSIN-II RECEPTOR ANTAGONISTS: avoid concomitant use of indinavir with
> 
> ANTIARRHYTHMICS: avoid concomitant use of indinavir with
> 
> ANTIARRHYTHMIC: avoid concomitant use of indinavir with
> 
> ANTIHYPERTENSIVE: avoid concomitant use of indinavir with
> 
> ANTIARRHYTHMICS: avoid concomitant use of indinavir with
> 
> ANTIHYPERTENSIVE: avoid concomitant use of indinavir with
> 
> ANTIARRHYTHMIC: avoid concomitant use of indinavir with
> 
> ANTIHYPERTENSIVE: avoid concomitant use of indinavir with
Iron Salts (continued)

- Bisphosphonates: oral iron salts reduce absorption of BISPHOSPHONATES
- Calcium Salts: absorption of oral iron salts reduced by CALCIUM SALTS
- Dopaminergic: oral iron salts possibly reduce absorption of CO-BENELDOPA, CO-CARELDOPA and LEVODOPA; oral iron salts reduce absorption of ENTACAPONE
- Eltrombopag: oral iron salts possibly reduce absorption of ELTROMBOPEG (give at least 4 hours apart)
- Methyldopa: oral iron salts antagonise hypotensive effect of METHYLDOPA
- Mycophenolate: oral iron salts reduce absorption of MYCOPHENOLATE
- Penicillamine: oral iron salts reduce absorption of PENICILLAMINE
- Thyroid Hormones: oral iron salts reduce absorption of LEVOTHYROXINE (give at least 2 hours apart)
- Trientine: absorption of oral iron salts reduced by TRIENTINE
- Zinc: oral iron salts reduce absorption of ZINC, also absorption of oral iron salts reduced by zinc

Isocarboxazid see MAOIs

Isoflurane see Anaesthetics, General

Isomethypent see Sympathomimetics

Isoniazid

- Aminophylline: isoniazid possibly increases plasma concentration of AMINOPHYLLINE
- Anaesthetics, General: increased risk of hepatotoxicity when isoniazid given with ISOFLURANE
- Analgesics: avoidance of isoniazid advised by manufacturer of PETHIDINE
- Antacids: absorption of isoniazid reduced by ANTACIDS
- Antibacterials: increased risk of hepatotoxicity when isoniazid given with RIFAMPICIN; increased risk of CNS toxicity when isoniazid given with CYCLOSERINE
- Antiepileptics: isoniazid increases plasma concentration of CARBAMAZEPINE (also possibly increased isoniazid hepatotoxicity); isoniazid inhibits metabolism of ETHOSUXIMIDE (increased plasma concentration and risk of toxicity); isoniazid possibly inhibits metabolism of FOSPHENTOIN and PHENYTOIN (increased risk of toxicity)
- Antifungals: isoniazid possibly reduces plasma concentration of KETOCONAZOLE
- Anxiolytics and Hypnotics: isoniazid inhibits the metabolism of DIAZEPAM
- Corticosteroids: plasma concentration of isoniazid possibly reduced by CORTICOSTEROIDS
- Disulfram: isoniazid possibly increases CNS effects of DISULFRAZ
- Dopaminergic: isoniazid possibly reduces effects of CO-BENELDOPA, CO-CARELDOPA and LEVODOPA
- Lipid-regulating Drugs: separating administration from isoniazid by 12 hours advised by manufacturer of LOMITAPIDE
- Theophylline: isoniazid possibly increases plasma concentration of THEOPHYLLINE
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Isosorbide Dinitrate see Nitrates

Isosorbide Mononitrate see Nitrates

Isosceptin see Retinoids

Irsapride see Calcium-channel Blockers

Itraconazole see Antifungals, Triazole

Ivabradine

- Antifungals (continued) reduce initial dose of ivabradine; plasma concentration of ivabradine possibly increased by ITRACONAZOLE—avoid concomitant use
- Antimalarials: increased risk of ventricular arrhythmias when ivabradine given with MEfloquine
- Antipsychotics: increased risk of ventricular arrhythmias when ivabradine given with PIMOZIDE
- Antivirals: plasma concentration of ivabradine possibly increased by Ritonavir avoid concomitant use
- Beta-blockers: increased risk of ventricular arrhythmias when ivabradine given with SOTALOL
- Calcium-channel Blockers: plasma concentration of ivabradine increased by Diltiazem and VERAPAMIL—avoid concomitant use
- Grapefruit Juice: plasma concentration of ivabradine increased by GRAPEFRUIT JUICE
- Pentamidine isethionate: increased risk of ventricular arrhythmias when ivabradine given with PENTAMIDINE ISETIONATE

Ivacaftor

- Antibacterials: plasma concentration of ivacaftor possibly increased by CLARITHROMYCIN, ERYTHROMYCIN and TELITHROMYCIN (see under Ivacaftor, p. 257); plasma concentration of ivacaftor possibly reduced by rifabutin—manufacturer of ivacaftor advises avoid concomitant use; plasma concentration of ivacaftor reduced by rifampicin—manufacturer of ivacaftor advises avoid concomitant use
- Antidepressants: plasma concentration of ivacaftor possibly reduced by ST JOHN'S WORT—manufacturer of ivacaftor advises avoid concomitant use
- Antiepileptics: plasma concentration of ivacaftor possibly reduced by CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYTOIN, and PRIMIDONE—manufacturer of ivacaftor advises avoid concomitant use
- Antifungals: plasma concentration of ivacaftor increased by FLUCONAZOLE and KETOCONAZOLE (see under Ivacaftor, p. 257); plasma concentration of ivacaftor possibly increased by ITRACONAZOLE, POSACONAZOLE and VORICONAZOLE (see under Ivacaftor, p. 257)
- Anxiolytics and Hypnotics: ivacaftor increases plasma concentration of MIDAZOLAM
- Cardiac Glycosides: ivacaftor increases plasma concentration of DIGOXIN
- Grapefruit Juice: plasma concentration of ivacaftor possibly increased by GRAPEFRUIT JUICE—manufacturer of ivacaftor advises avoid concomitant use
- Lipid-regulating Drugs: separating administration from ivacaftor by 12 hours advised by manufacturer of LOMITAPIDE

Ivermectin

- Anthelmintics: plasma concentration of ivermectin possibly increased by LEVAMISOLE
- Anticoagulants: ivermectin possibly enhances anticoagulant effect of COUMARINS

Japanese Encephalitis Vaccine see Vaccines

KaoLin

- Analgesics: kaoLin possibly reduces absorption of ASPRIN
- Antibacterials: kaoLin possibly reduces absorption of TETRACYCLINES
- Antimalarials: kaoLin reduces absorption of CHLOROQUINE and HYDROXYCHLOROQUINE
- Antipsychotics: kaoLin possibly reduces absorption of PHENOTHIAZINES

Ketamine see Anaesthetics, General

Ketoconazole see Antifungals, Imidazole

Ketoprofen see NSAIDs

Ketorolac see NSAIDs

Ketotifen see Antihistamines

Labelatol see Beta-blockers

Lacidipine see Calcium-channel Blockers

Lacosamide

- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and TRICYCLIC-RELATED ANTIDEPRESSANTS (convulsive threshold lowered);
### Lacosamide
- **Antidepressants (continued)**
  - Anticonvulsant effect of antiepileptics antagonised by **SSRIS** and **TRICYCLICS** (convulsive threshold lowered)
  - Antimalarials: anticonvulsant effect of antiepileptics antagonised by **MELQOQUINE**
  - Antipsychotics: anticonvulsant effect of antiepileptics antagonised by **ANTIPISYCHOTICS** (convulsive threshold lowered)
  - Orlistat: possible increased risk of convulsions when antiepileptics given with **ORLISTAT**

#### Lactulose
- Anticoagulants: lactulose possibly enhances anticoagulant effect of **COUMARINS**

### Lamivudine
- Antibacterials: plasma concentration of lamivudine increased by **TRIMETHOPRIM** (as co-trimoxazole)—avoid concomitant use of high-dose co-trimoxazole
- Antivirals: avoidance of lamivudine advised by manufacturer of **EMTRICITABINE**
- Cytotoxics: manufacturer of lamivudine advises avoid concomitant use with **CLADIREBINE**
- Orlistat: absorption of lamivudine possibly reduced by **ORLISTAT**

### Lamotrigine
- Antidepressants: plasma concentration of lamotrigine reduced by **RIFAMPICIN**
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by **MAIDS** and **TRICYCLIC-RELATED ANTIDEPRESSANTS** (convulsive threshold lowered)
- Anticonvulsant effect of antiepileptics antagonised by **SSRIS** and **TRICYCLICS** (convulsive threshold lowered)
- Antiepileptics: plasma concentration of lamotrigine often reduced by **CARBAMAZEPINE**, also plasma concentration of an active metabolite of carbamazepine sometimes raised (but evidence is conflicting); plasma concentration of lamotrigine reduced by **FOSPHENYTOIN**, **PHENOIBARBITAL**, **PHENITOIN** and **PRIMIDONE**; plasma concentration of lamotrigine increased by **SODIUM VALPROATE** and **VALPROIC ACID** (increased risk of toxicity—reduce lamotrigine dose)
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by **MELQOQUINE**
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by **ANTIPISYCHOTICS** (convulsive threshold lowered)
- Antivirals: plasma concentration of lamotrigine possibly reduced by **RITONAVIR**
- Oestrogens: plasma concentration of lamotrigine reduced by **ESTROGENS**—consider increasing dose of lamotrigine
- Orlistat: possible increased risk of convulsions when antiepileptics given with **ORLISTAT**
- Progestogens: plasma concentration of lamotrigine possibly increased by **DESOGESTREL**

### Lanreotide
- Antidiabetics: lanreotide possibly reduces requirements for **ANTIDIABETICS**
- Ciclosporin: lanreotide reduces plasma concentration of **CICLOSPORIN**

### Lansoprazole
- see Proton Pump Inhibitors

### Lanthanum
- **Antibacterials:** lanthanum possibly reduces absorption of **QUINOLONES** (give at least 2 hours before or 4 hours after lanthanum)
- **Antifungals:** lanthanum possibly reduces absorption of **KETOCONAZOLE** (give at least 2 hours apart)
- **Antimalarials:** lanthanum possibly reduces absorption of **CHLOROQUINE** and **HYDROXYCHLOROQUINE** (give at least 2 hours apart)
- **Thyroid Hormones:** lanthanum reduces absorption of **LEVOITHYROIDINE** (give at least 2 hours apart)

### Lepirudin
- **Anticoagulants:** manufacturer of lepirudin advises avoid concomitant use with **RIFABUTIN**, **RIFAMPICIN** and **TELITHROMYCIN**

### Lapatinib
- **Antidepressants:** manufacturer of lapatinib advises avoid concomitant use with **ST JOHN’S WORT**
- **Antidiabetics:** manufacturer of lapatinib advises avoid concomitant use with **REPAGLINDINE**
- **Antiepileptics:** plasma concentration of lapatinib reduced by **CARBAMAZEPINE**—avoid concomitant use; manufacturer of lapatinib advises avoid concomitant use with **FOSPHENYTOIN** and **PHENITOIN**
- **Antifungals:** plasma concentration of lapatinib increased by **KETOCONAZOLE**—avoid concomitant use; manufacturer of lapatinib advises avoid concomitant use with **IRTRAZONAZOLE**, **POSACONAZOLE** and **VORICONAZOLE**
- **Antipsychotics:** avoid concomitant use of cytotoxics with **CLOzapine** (increased risk of agranulocytosis); manufacturer of lapatinib advises avoid concomitant use with **PIMOZIDE**
- **Antivirals:** avoidance of lapatinib advised by manufacturer of **BOCEPREVIR**; manufacturer of lapatinib advises avoid concomitant use with **RITONAVIR** and **SAQUINAVIR**
- **Cytotoxics:** lapatinib increases plasma concentration of **PAZOPANIB**; possible increased risk of neutropenia when lapatinib given with **DOCETAXEL**; increased risk of neutropenia when lapatinib given with **PACLITAXEL**; lapatinib increases plasma concentration of active metabolite of **IRINOTECAN**—consider reducing dose of irinotecan
- **Grapefruit Juice:** manufacturer of lapatinib advises avoid concomitant use with **GRAPEFRUIT JUICE**
- **Lipid-regulating Drugs:** separating administration from lapatinib by 12 hours advised by manufacturer of **LOMITAPIDE**
- **Lung-healing Drugs:** absorption of lapatinib possibly reduced by **HISTAMINE _H_2-ANTAGONISTS** and **POTASSIUM CHANNEL BLOCKERS**

### Laronidase
- **Antimalarials:** effects of laronidase possibly inhibited by **CHLOROQUINE** and **HYDROXYCHLOROQUINE** (manufacturer of laronidase advises avoid concomitant use)

### Leflunomide
- **NOTE** Increased risk of toxicity with other haematotoxic and hepatotoxic drugs
- **Antibacterials:** plasma concentration of active metabolite of leflunomide possibly increased by **RIFAMPICIN**
- **Anticoagulants:** leflunomide possibly enhances anticoagulant effect of **WARFARIN**
- **Antidiabetics:** leflunomide possibly enhances hypoglycaemic effect of **TOLBUTAMIDE**
- **Antiepileptics:** leflunomide possibly increases plasma concentration of **FOSPHENYTOIN** and **PHENITOIN**
- **Cytotoxics:** risk of toxicity when leflunomide given with **METHOTREXATE**
- **Lipid-regulating Drugs:** the effect of leflunomide is significantly decreased by **COLESTYMATE** (enhanced elimination)—avoid unless drug elimination desired
- **Vaccines:** risk of generalised infections when leflunomide given with live **VACCINES**—avoid concomitant use

### Lenalidomide
- **Antibacterials:** plasma concentration of lenalidomide possibly increased by **CLARITHROMYCIN** (increased risk of toxicity)
- **Antifungals:** plasma concentration of lenalidomide possibly increased by **IRTRAZONAZOLE** and **KETOCONAZOLE** (increased risk of toxicity)
- **Calcium-channel Blockers:** plasma concentration of lenalidomide possibly increased by **VERAPAMIL** (increased risk of toxicity)
- **Cardiac Glycosides:** lenalidomide possibly increases plasma concentration of **DIGOXIN**
- **Ciclosporin:** plasma concentration of lenalidomide possibly increased by **CICLOSPORIN** (increased risk of toxicity)

### Lercanidipine
- **see Calcium–channel Blockers**

### Leukotriene Receptor Antagonists
- **Antimicrobials:** zafirlukast possibly increases plasma concentration of **AMINOPHENYLIN**, also plasma concentration of zafirlukast reduced
- **Analgesics:** plasma concentration of zafirlukast increased by **ASPIRIN**
- **Antibacterials:** plasma concentration of zafirlukast reduced by **ERYTHROMYCIN**
Interactions | Appendix 1

**1206 Appendix 1 Interactions**

Leukotriene Receptor Antagonists (continued)

- Anticoagulants: zafirlukast enhances anticoagulant effect of WARFARIN.
- Antiepileptics: plasma concentration of montelukast reduced by PHEMBRITARIL and PRIMIDONE.
- Antifungals: plasma concentration of zafirlukast increased by FLUCONAZOLE.
- Lipid-regulating Drugs: plasma concentration of montelukast increased by GEMIFIBROZIL.
- Theophylline: zafirlukast possibly increases plasma concentration of THEOPHYLLINE, also plasma concentration of zafirlukast reduced.

**Levamisole**

- Alcohol: possibility of disulfiram-like reaction when levamisole given with ALCOHOL.
- Anthelmintics: plasma concentration of both drugs possibly reduced when levamisole given with ALBENDAZOLE; levamisole possibly increases plasma concentration of VERMECTIN.
- Anticoagulants: levamisole possibly enhances anticoagulant effect of WARFARIN.
- Antiepileptics: levamisole possibly increases plasma concentration of FOSPHENITOIN and PHENYTOIN.

**Levetiracetam**

- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIS and TRICYCLIC-RELATED ANTIDEPRESSANTS (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRISS and TRICYCLICS (convulsive threshold lowered).
- Anticoagulants: levetiracetam possibly increases risk of CARBAMAZEPINE toxicity.
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by MEFLOQUINE.
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by ANTIPSYCHOTICS (convulsive threshold lowered).
- Opioids: possible increased risk of convulsions when antiepileptics given with ORLISTAT.

**Levobunolol** see Beta-blockers.

**Levobupivacaine**

- Anti-arrhythmics: increased myocardial depression when levobupivacaine given with ANTI-ARRHYTHMICS.

**Levocabinine**

- Anticoagulants: levocabicaine possibly enhances anticoagulant effect of CARBAMATE ANTAGONISTS.

**Levocetirizine** see Antihistamines.

**Levodopa**

- ACE Inhibitors: enhanced hypertensive effect when levodopa given with ACE INHIBITORS.
- Adrenergic Neurone Blockers: enhanced hypertensive effect when levodopa given with ADRENERGIC NEURONE BLOCKERS.
- Alpha-blockers: enhanced hypertensive effect when levodopa given with ALPHA-BLOCKERS.
- Anaesthetics, General: increased risk of arrhythmias when levodopa given with VOLATILE LIQUID GENERAL ANAESTHETICS.
- Angiotensin-II Receptor Antagonists: enhanced hypertensive effect when levodopa given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS.
- Antibacterials: effects of levodopa possibly reduced by ISONIAZID.
- Antidepressants: risk of hypertensive crisis when levodopa given with MAOIS, avoid levodopa for at least 2 weeks after stopping MAOIs; increased risk of side-effects when levodopa given with MOLOBEMIDE.
- Antiepileptics: effects of levodopa possibly reduced by FOSPHENITOIN and PHENYTOIN.
- Antimuscarinics: absorption of levodopa possibly reduced by ANTIMUSCARINICS.
- Antipsychotics: effects of levodopa antagonised by ANTIPSYCHOTICS; avoidance of levodopa advised by manufacturer of AMISULPIIDE (antagonism of effect). Anxiolytics and Hypnotics: effects of levodopa possibly antagonised by BENZODIAZEPINES.
- Beta-blockers: enhanced hypertensive effect when levodopa given with Beta-blockers.

**Levodopa (continued)**

- Bupropion: increased risk of side-effects when levodopa given with BUPROPION.
- Calcium-channel Blockers: enhanced hypotensive effect when levodopa given with CALCIUM-CHANNEL BLOCKERS.
- Clonidine: enhanced hypertensive effect when levodopa given with CLONIDINE.
- Diazoxide: enhanced hypertensive effect when levodopa given with DIAZoxide.
- Diuretics: enhanced hypertensive effect when levodopa given with DIURETICS.
- Dopaminergics: enhanced effects and increased toxicity of levodopa when given with SELEGILINE (reduce dose of levodopa).
- Iron Salts: absorption of levodopa possibly reduced by oral IRON SALT.
- Memantine: effects of dopaminergics possibly enhanced by MEMANTINE.
- Methyldopa: enhanced hypertensive effect when levodopa given with METHYLDOPA; antiparkinsonian effect of dopaminergics antagonised by METHYLDOPA.
- Moxonidine: enhanced hypertensive effect when levodopa given with MOXONIDINE.
- Muscle Relaxants: possible agitation, confusion and hallucinations when levodopa given with BACLOFEN.
- Nitrates: enhanced hypertensive effect when levodopa given with NITRATES.
- Vasodilator Antihypertensives: enhanced hypertensive effect when levodopa given with HYDRAZALINE, MINOCIDIL or SODIUM NITROPRUSSIIDE.
- Vitamins: effects of levodopa reduced by PYRIDOXINE when given without dopa-decarboxylase inhibitor.

**Levofloxacin** see Quinolones.

**Levolofolic Acid** see Folic acids.

**Levomepramazine** see Antipsychotics.

**Levonorgestrel** see Progestogens.

**Levoxacin** see Thyroid Hormones.

**Lidocaine**

NOTE Interactions less likely when lidocaine used topically.

- Anaesthetics, Local: increased myocardial depression when anti-arrhythmics given with BUPIVACAINE, LEVOBUPIVACAINE, PRILOCAIN or ROPIVACAINE.
- Anti-arrhythmics: increased myocardial depression when anti-arrhythmics given with other ANTI-ARRHYTHMICS.
- Antipsychotics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with ANTIPSYCHOTICS that prolong the QT interval.
- Antivirals: plasma concentration of lidocaine possibly increased by ATAZANAVIR and LOPINAVIR; plasma concentration of lidocaine possibly increased by DARUNAVIR and FOSAMPRENAVIR—avoid concomitant use; increased risk of ventricular arrhythmias when lidocaine given with SAQUINAVIR—avoid concomitant use; caution with intravenous lidocaine advised by manufacturer of TELAPREvir.
- Beta-blockers: increased myocardial depression when anti-arrhythmics given with BETA-BLOCKERS; possible increased risk of lidocaine toxicity when given with NADOLOL; increased risk of lidocaine toxicity when given with PROPRANOLOL.
- Diuretics: action of lidocaine antagonised by hypokalaemia caused by ACETAZOLAMIDE; LOOP DIURETICS or THIAZIDES and RELATED DIURETICS.
- Muscle Relaxants: neuromuscular blockade enhanced and prolonged when lidocaine given with SUXAMETHONIUM.
- Ulcer-healing Drugs: plasma concentration of lidocaine increased by CIMITIDINE (increased risk of toxicity).

**Linaclotide** see Antidiabetics.

**Linezolid**

NOTE Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs.

- Antibacterials: plasma concentration of linezolid reduced by RIFAMPICIN (possible therapeutic failure of linezolid).
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF.

**Liothyronine** see Thyroid Hormones.
Lipophilic Drugs

- Cytotoxics: neutropenia possibly exacerbated when lipophilic drugs given with CAPECITABINE, FLUOROURACIL or TEGAFUR

Lipid-Regulating Drugs see Colesevelam, Colestipol, Colestevam, Ezetimibe, Fibrates, Lomitapide, Nicotinic Acid, and Statins

Liraglutide see Antidiabetics

Lisdexametamide see Symptomatics

Lisinopril see ACE Inhibitors

Lithium

- ACE inhibitors: excretion of lithium reduced by ACE inhibitors (increased plasma concentration)
- Aminophylline: excretion of lithium increased by AMINOPHYLLINE (reduced plasma concentration)
- Analgesics: excretion of lithium reduced by NSAIDS (increased risk of toxicity); excretion of lithium reduced by KETOROLAC (increased risk of toxicity)—avoid concomitant use
- Angiotensin-II Receptor Antagonists: excretion of lithium reduced by ANGIOTENSIN-II RECEPTOR ANTAGONISTS (increased plasma concentration)
- Antacids: excretion of lithium increased by SODIUM BICARBONATE (reduced plasma concentration)
- Anti-arrhythmics: avoidance of lithium advised by manufacturer of amiDRONE (risk of ventricular arrhythmias)
- Antibacterials: increased risk of lithium toxicity when given with METRONIDAZOLE
- Antidepressants: possible increased serotoninergic effects when lithium given with VENLAFAXINE; increased risk of CNS effects when lithium given with SSRIS (lithium toxicity reported); risk of toxicity when lithium given with TRICYCLICS
- Antiemetics: neurotoxicity may occur when lithium given with CARBAMAZEPINE, FOSPHENTOIN or PHENYTOIN without increased plasma concentration of lithium; plasma concentration of lithium possibly affected by TOPIRAMATE
- Antipsychotics: increased risk of extrapyramidal side-effects and possibly neurotoxicity when lithium given with CLOzapine, FLUENTIXOL, HALOPERIDOL, PHENOTHIAZINES;
- Anxiolytics and Hypnotics: increased risk of neurotoxicity when lithium given with OLanzapine; lithium possibly increases extrapyramidal side-effects of QUETIAPINE; increased risk of extrapyramidal side-effects when lithium given with SULPirIDE
- Anxiolytics and Hypnotics: increased risk of neurotoxicity when lithium given with CLONAZEPAM
- Calcium-channel Blockers: neurotoxicity may occur when lithium given with DILTIAZEM or VERAPAMIL without increased plasma concentration of lithium
- Cytotoxics: increased risk of ventricular arrhythmias when lithium given with ARSENIC TRIOXIDE
- Dapoxetine: possible increased risk of serotoninergic effects when lithium given with DAPoxetine (manufacturer of dapoxetine advises lithium should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping lithium
- Diuretics: excretion of lithium increased by ACETAZOLAMIDE; excretion of lithium reduced by LOOP DIURETICS and THIURAM DERIVATIVES; possible increased risk of toxicity when lithium given with SUMatriptAN
- Methyldopa: neurotoxicity may occur when lithium given with METHYLDOPA without increased plasma concentration of lithium
- Muscle relaxants: lithium enhances effects of muscle relaxants; hyperkinesis caused by lithium possibly aggravated by BACloFEN
- Parasympathomimetics: lithium antagonises effects of NEOSTIGMINE

Lithium (continued)

- Theophylline: excretion of lithium increased by THEOPHYLLINE (reduced plasma concentration)
- Lixisenatide see Antidiabetics
- Lofepramine see Antidepressants, Tricyclic
- Lofezidime
- Alcohol: increased sedative effect when lofezidime given with ALCOHOL
- Anxiolytics and Hypnotics: increased sedative effect when lofazidime given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Lomiptapide
- Alcohol: manufacturer of lomiptapide advises avoid concomitant use with ALCOHOL
- Anti-arrhythmics: manufacturer of lomiptapide advises separating administration from AMIODARONE by 12 hours; manufacturer of lomiptapide advises avoid concomitant use with DRONewARONE (plasma concentration of lomiptapide possibly increased)
- Antibacterials: manufacturer of lomiptapide advises separating administration from AZITHROMYCIN and ISONIAZID by 12 hours; manufacturer of lomiptapide advises avoid concomitant use with CLARITHROMYCIN, ERYTHROMYCIN and TELITHROMYCIN (plasma concentration of lomiptapide possibly increased)
- Anticoagulants: lomiptapide possibly enhances anticoagulant effect of WARFARIN
- Antidepressants: manufacturer of lomiptapide advises separating administration from FLUOXETINE and FLUOXAMINE by 12 hours
- Antidiabetics: manufacturer of lomiptapide advises separating administration from LIMAGLITIN by 12 hours
- Anti-inflammation: plasma concentration of lomiptapide increased by KETOCONAZOLE—avoid concomitant use; manufacturer of lomiptapide advises avoid concomitant use with DRONewARONE (plasma concentration of lomiptapide possibly increased)
- Antivirals: manufacturer of lomiptapide advises avoid concomitant use with DARunAVARI, FOSAMPRENAVARI, INDINAVARI, LOPINAVARI, RITONAVARI, SAQuINAVARI, TELAPREvari and TIPRANAVARI (plasma concentration of lomiptapide possibly increased)
- Anxiolytics and Hypnotics: manufacturer of lomiptapide advises separating administration from LAPIrATINIB, NILOThINIB and PazoPANIb by 12 hours
- Cytotoxics: manufacturer of lomiptapide advises separating administration from LAPASLO, NILOThINIB and PazoPANIb by 12 hours
- Calcium-channel Blockers: manufacturer of lomiptapide advises separating administration from AMlodipine and LAZOpine by 12 hours; manufacturer of lomiptapide advises avoid concomitant use with DILTIAZEM and VERAPAMIL (plasma concentration of lomiptapide possibly increased)
- Cisopropin: manufacturer of lomiptapide advises separating administration from CICLOsporin by 12 hours
- Clobazol: manufacturer of lomiptapide advises separating administration from CLOfaZol by 12 hours
- Cytotoxics: manufacturer of lomiptapide advises separating administration from LAPIrATINIB, NILOThINIB and PazoPANIb by 12 hours
- Spirogress: manufacturer of lomiptapide advises separating administration from OSLOTrIN by 12 hours
- Grapefruit juice: manufacturer of lomiptapide advises avoid concomitant use with GRAPEFRUIT JUICE
- Hormone Antagonists: manufacturer of lomiptapide advises separating administration from BICALAMITE by 12 hours
- Ivacaftor: manufacturer of lomiptapide advises separating administration from IVAcATOR by 12 hours
- Lipid-regulating Drugs: lomiptapide increases plasma concentration of ATorvasTATin—manufacturer of lomiptapide advises reduce dose of atorvasatin by half or separate administration by 12 hours; lomiptapide increases plasma concentration of SIMVASTATIN (see under Simvastatin, p. 181); absorption of lomiptapide possibly reduced by BILE ACID SEQUESTRANTS (give at least 4 hours apart)
- Oestrogens: manufacturer of lomiptapide advises separating administration from OESTROGENS by 12 hours
- Ranolazine: manufacturer of lomiptapide advises separating administration from RANOlAZINE by 12 hours
- Tacrolimus: manufacturer of lomiptapide advises separating administration from TACROlUMUS by 12 hours
- Ticagrelor: manufacturer of lomiptapide advises separating administration from TicaGRELoR by 12 hours
**Interactions**

**Eltrombopag:**
- **Cytotoxics:** avoid concomitant use of cytotoxics with eltrombopag.
- **Corticosteroids:** may suppress myelosuppressive effects of eltrombopag; possibly enhanced by cimetidine.

**Loperamide**
- Desmopressin: loperamide increases plasma concentration of oral desmopressin.

**Lopinavir**
- **Antipsychotics:** lopinavir increases plasma concentration of antipsychotics (increased risk of toxicity); aripiprazole possibly increases plasma concentration of lopipavir.
- **Antimuscarinics:** caution with lopinavir advised by manufacturer.
- **Antimalarials:** lopinavir possibly increases plasma concentration of antimalarials (increased risk of toxicity).
- **Antiepileptics:** lopinavir possibly increases plasma concentration of antiepileptics (increased risk of toxicity); phenytoin possibly increases plasma concentration of lopinavir.
- **Antidepressants:** lopinavir possibly increases plasma concentration of antidepressants.
- **Anticoagulants:** lopinavir increases plasma concentration of anticoagulants (increased risk of toxicity); rivaroxaban.
- **Anti-arrhythmics:** lopinavir increases plasma concentration of anti-arrhythmics (increased risk of toxicity). Erythromycin possibly increases plasma concentration of lopinavir; clarithromycin possibly increases plasma concentration of lopinavir.
- **Ulcer-healing Drugs:** lopinavir possibly increases plasma concentration of ulcer-healing drugs.
- **Lomitapide:** manufacturer of lomitapide advises separating administration from lopinavir by 12 hours.
- **Cimetidine:** manufacturer of lomitapide advises separating administration from cimetidine and ranitidine by 12 hours.

**Lumostine**
- Antipsychotics: avoid concomitant use of lumostine with antipsychotics.

**Lorazepam**
- **Anxiolytics and Hypnotics:** lorazepam may reduce absorption of aminophylline.

**Macitentan**
- **Antibacterials:** macitentan increases plasma concentration of antibacterials (increased risk of toxicity); clarithromycin and erythromycin given with macitentan may reduce absorption of oral erythromycin.
- **Antifungals:** macitentan reduces plasma concentration of antifungals (increased risk of toxicity).
- **Antihistamines:** macitentan possibly increases plasma concentration of antihistamines; azithromycin possibly increases plasma concentration of macitentan (increased risk of toxicity); clarithromycin possibly increases plasma concentration of macitentan (increased risk of toxicity). Macitentan possibly increases plasma concentration of clarithromycin advised by manufacturer of macitentan.

**Loratadine**
- **Antihistamines:** loratadine increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of loratadine.

**Losartone**
- **Anxiolytics and Hypnotics:** losartone may reduce absorption of aminophylline.

**Lurasidone**
- **Antipsychotics:** lurasidone increases plasma concentration of antipsychotics; aripiprazole increases plasma concentration of lurasidone (increased risk of toxicity); lurasidone possibly increases plasma concentration of aripiprazole (increased risk of toxicity).

**Lymecycline**
- **Tetracyclines:** lymecycline decreases plasma concentration of tetracyclines.

**Macrogols**
- **Lipid-regulating Drugs:** macrogols may reduce absorption of aminophylline.

**Lopinavir (continued)**
- **Anxiolytics and Hypnotics:** lopinavir increases plasma concentration of anxiolytics and hypnotics (increased risk of toxicity); citalopram advised by manufacturer.

**Loratadine (continued)**
- **Antihistamines:** loratadine increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of loratadine.

**Losartone (continued)**
- **Antihistamines:** losartone increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of losartone.

**Lurasidone (continued)**
- **Antipsychotics:** lurasidone increases plasma concentration of antipsychotics; aripiprazole increases plasma concentration of lurasidone (increased risk of toxicity); lurasidone possibly increases plasma concentration of aripiprazole (increased risk of toxicity).

**Lymecycline (continued)**
- **Tetracyclines:** lymecycline decreases plasma concentration of tetracyclines.

**Macrogols (continued)**
- **Lipid-regulating Drugs:** macrogols may reduce absorption of aminophylline.

**Lopinavir (continued)**
- **Antibacterials:** lopinavir increases plasma concentration of antibacterials (increased risk of toxicity); clarithromycin and erythromycin may reduce absorption of oral erythromycin.
- **Anti-arrhythmics:** lopinavir decreases plasma concentration of anti-arrhythmics (increased risk of toxicity); lopinavir possibly increases plasma concentration of anti-arrhythmics (increased risk of toxicity).

**Loratadine (continued)**
- **Antihistamines:** loratadine increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of loratadine.

**Losartone (continued)**
- **Antihistamines:** losartone increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of losartone.

**Lurasidone (continued)**
- **Antipsychotics:** lurasidone increases plasma concentration of antipsychotics; aripiprazole increases plasma concentration of lurasidone (increased risk of toxicity); lurasidone possibly increases plasma concentration of aripiprazole (increased risk of toxicity).

**Lymecycline (continued)**
- **Tetracyclines:** lymecycline decreases plasma concentration of tetracyclines.

**Macrogols (continued)**
- **Lipid-regulating Drugs:** macrogols may reduce absorption of aminophylline.

**Lopinavir (continued)**
- **Antibacterials:** lopinavir increases plasma concentration of antibacterials (increased risk of toxicity); clarithromycin and erythromycin may reduce absorption of oral erythromycin.
- **Anti-arrhythmics:** lopinavir decreases plasma concentration of anti-arrhythmics (increased risk of toxicity); lopinavir possibly increases plasma concentration of anti-arrhythmics (increased risk of toxicity).

**Loratadine (continued)**
- **Antihistamines:** loratadine increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of loratadine.

**Losartone (continued)**
- **Antihistamines:** losartone increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of losartone.

**Lurasidone (continued)**
- **Antipsychotics:** lurasidone increases plasma concentration of antipsychotics; aripiprazole increases plasma concentration of lurasidone (increased risk of toxicity); lurasidone possibly increases plasma concentration of aripiprazole (increased risk of toxicity).

**Lymecycline (continued)**
- **Tetracyclines:** lymecycline decreases plasma concentration of tetracyclines.

**Macrogols (continued)**
- **Lipid-regulating Drugs:** macrogols may reduce absorption of aminophylline.

**Lopinavir (continued)**
- **Antibacterials:** lopinavir increases plasma concentration of antibacterials (increased risk of toxicity); clarithromycin and erythromycin may reduce absorption of oral erythromycin.
- **Anti-arrhythmics:** lopinavir decreases plasma concentration of anti-arrhythmics (increased risk of toxicity); lopinavir possibly increases plasma concentration of anti-arrhythmics (increased risk of toxicity).

**Loratadine (continued)**
- **Antihistamines:** loratadine increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of loratadine.

**Losartone (continued)**
- **Antihistamines:** losartone increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of losartone.

**Lurasidone (continued)**
- **Antipsychotics:** lurasidone increases plasma concentration of antipsychotics; aripiprazole increases plasma concentration of lurasidone (increased risk of toxicity); lurasidone possibly increases plasma concentration of aripiprazole (increased risk of toxicity).

**Lymecycline (continued)**
- **Tetracyclines:** lymecycline decreases plasma concentration of tetracyclines.

**Macrogols (continued)**
- **Lipid-regulating Drugs:** macrogols may reduce absorption of aminophylline.

**Lopinavir (continued)**
- **Antibacterials:** lopinavir increases plasma concentration of antibacterials (increased risk of toxicity); clarithromycin and erythromycin may reduce absorption of oral erythromycin.
- **Anti-arrhythmics:** lopinavir decreases plasma concentration of anti-arrhythmics (increased risk of toxicity); lopinavir possibly increases plasma concentration of anti-arrhythmics (increased risk of toxicity).

**Loratadine (continued)**
- **Antihistamines:** loratadine increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of loratadine.

**Losartone (continued)**
- **Antihistamines:** losartone increases plasma concentration of antihistamines; ruxolitinib advises dose reduction of losartone.

**Lurasidone (continued)**
- **Antipsychotics:** lurasidone increases plasma concentration of antipsychotics; aripiprazole increases plasma concentration of lurasidone (increased risk of toxicity); lurasidone possibly increases plasma concentration of aripiprazole (increased risk of toxicity).

**Lymecycline (continued)**
- **Tetracyclines:** lymecycline decreases plasma concentration of tetracyclines.

**Macrogols (continued)**
- **Lipid-regulating Drugs:** macrogols may reduce absorption of aminophylline.
Macrolides
- Antibacterials (continued) when clarithromycin and erythromycin given with
  - DELAMANID; avoidance of clarithromycin and erythromycin advised by manufacturer of
    - FIDAXOMICIN; plasma concentration of clarithromycin reduced by
      - RIFAMYCINS
- Anticoagulants: avoidance of clarithromycin advised by manufacturer of
  - APIXABAN; clarithromycin and erythromycin enhance anticoagulant effect of
    - COUMARINS; azithromycin possibly enhances anticoagulant effect of
      - COUMARINS; possible increased risk of bleeding when clarithromycin given with
        - DABIGATRAN
- Antidepressants: avoidance of macrolides advised by manufacturer of
  - REBOXETINE; avoidance of intravenous erythromycin advised by manufacturer of
    - CITALOPRAM and
        - ESCITALOPRAM (risk of ventricular arrhythmias); clarithromycin possibly increases plasma concentration of
          - TRAZODONE
- Antidiabetics: clarithromycin enhances effects of
  - REPAGLINIDE
- Antiepileptics: clarithromycin increases plasma concentration of
  - CARBAMAZEPINE (consider reducing dose of carbamazepine); erythromycin increases plasma concentration of
    - CARBAMAZEPINE; clarithromycin inhibits metabolism of
      - FOSPHENYTOIN and PHENYTOIN (increased plasma concentration); erythromycin possibly inhibits metabolism of
        - SODIUM VALPROATE and VALPROIC ACID (increased plasma concentration)
- Antifungals: avoidance of concomitant clarithromycin in severe renal impairment advised by manufacturer of
  - KETOCONAZOLE; avoidance of erythromycin advised by manufacturer of
    - FLUCONAZOLE; clarithromycin increases plasma concentration of
      - ITROCONAZOLE
- Antihistamines: manufacturer of loratadine advises erythromycin possibly increases plasma concentration of
  - LORATADINE; macrolides possibly inhibit metabolism of
    - MIZOLASTINE (avoid concomitant use); erythromycin inhibits metabolism of
      - MIZOLASTINE—avoid concomitant use
- Antimalarials: avoidance of macrolides advised by manufacturer of
  - ARTEMETHER WITH LUMEFANTRINE; avoidance of macrolides advised by manufacturer of
    - ARTEMENOL WITH PIPERAPUINE (possible risk of ventricular arrhythmias)
- Antimuscarinics: erythromycin possibly increases plasma concentration of
  - DARIFENACIN; manufacturer of fosfoterodine advises dose reduction when clarithromycin given with
    - FOSFETERODINE—consult product literature; avoidance of clarithromycin and erythromycin advised by manufacturer of
      - TOLERIDONE
- Antipsychotics: avoidance of macrolides advised by manufacturer of
  - DROPERIDOL (risk of ventricular arrhythmias); increased risk of toxicity; avoidance of clarithromycin or erythromycin when
    - PARENTERAL erythromycin given with
      - ZUCLOPENTHIXOL—avoid concomitant use; increased risk of ventricular arrhythmias when erythromycin given with
        - AMISULPRIDE—avoid concomitant use; erythromycin possibly increases plasma concentration of
          - CLOzapine (possible increased risk of convulsions); clarithromycin possibly increases plasma concentration of
            - LURASIDONE—avoid concomitant use; erythromycin possibly increases the plasma concentration of
              - LURASIDONE (see under Lurasidone, p. 315); increased risk of ventricular arrhythmias when clarithromycin given with
                - PIMOZIDE—avoid concomitant use; possible increased risk of ventricular arrhythmias when erythromycin given with
                  - PIMOZIDE—avoid concomitant use; clarithromycin possibly increases plasma concentration of
                    - QUETIAPINE—manufacturer of quetiapine advises avoid concomitant use; erythromycin increases plasma concentration of
                        - QUETIAPINE
                    - PIMOZIDE—manufacturer of quetiapine advises avoid concomitant use; erythromycin increases plasma concentration of
                        - PIMOZIDE
- Antiplatelet drugs of both drugs possibly increased when clarithromycin given with
  - ATAZANAVIR; clarithromycin possibly increases the plasma concentration of
    - DACLATASVIR—reduce dose of daclatasvir (see under Daclatasvir, p. 544); plasma concentration of clarithromycin reduced by
      - EFAVIREN; also plasma concentration of active

Macrolides
- Antivirals (continued) metabolite of clarithromycin increased; plasma concentration of clarithromycin reduced by
  - ITRANAVIR and NEVIRAPINE (but concentration of an active metabolite increased, also plasma concentration of etravirine and nevirapine increased; clarithromycin possibly increases plasma concentration of
    - MARAVIROC (consider reducing dose of maraviroc); avoidance of clarithromycin and erythromycin advised by manufacturer of
      - NEVIRAPINE (plasma concentration of rilpivirine possibly increased); plasma concentration of azithromycin and erythromycin possibly increased by
        - RITONAVIR; plasma concentration of clarithromycin increased by
          - RITONAVIR (reduce dose of clarithromycin in renal impairment); increased risk of ventricular arrhythmias when erythromycin given with
            - RITONAVIR—avoid concomitant use; plasma concentration of both drugs possibly increased when clarithromycin given with
              - SAQUINAVIR and
                - TELAPREVIR (increased risk of ventricular arrhythmias); plasma concentration of both drugs possibly increased when erythromycin given with
                  - TELAPREVIR (increased risk of ventricular arrhythmias); plasma concentration of clarithromycin increased by
                    - TIPRANAVIR (reduce dose of clarithromycin in renal impairment), also clarithromycin increases plasma concentration of
                      - TIPRANAVIR; clarithromycin tablets reduce absorption of
                        - ZIDOVIDINE (give at least 2 hours apart)
- Antiplatelet drugs: clarithromycin and erythromycin inhibit metabolism of
  - MIZOLASTINE (increased plasma concentration); erythromycin increases plasma concentration of
    - BUSPIRONE (reduce dose of buspirone); erythromycin inhibits the metabolism of
      - ZOPICLONE—Aprepitant: clarithromycin possibly increases plasma concentration of
        - APREPITANT—Atomoxetine: increased risk of ventricular arrhythmias when
          - PARENTERAL erythromycin given with
            - ATOMOXETINE
- Avanafil: clarithromycin possibly increases plasma concentration of
  - AVANAFIL—manufacturer of avanafil advises avoid concomitant use; erythromycin increases plasma concentration of
    - AVANAFIL (see under Avanafil, p. 698)
- Calcium-channel blockers: clarithromycin and erythromycin possibly inhibit metabolism of
  - CALCULUM-CHANNEL BLOCKERS (increased risk of side-effects); avoidance of erythromycin advised by manufacturer of
    - LERCANDIPINE—Cardiac Glycosides: macrolides increase plasma concentration of
      - DIGOXIN (increased risk of toxicity)
- Ciclosporin: macrolides possibly inhibit metabolism of
  - CICLOSPORIN (increased plasma concentration); clarithromycin and erythromycin inhibit metabolism of
    - CICLOSPORIN (increased plasma concentration)
- Clopidogrel: clarithromycin possibly increases plasma concentration of
  - CILOSTAZOL (see under Clopidogrel, p. 206); erythromycin increases plasma concentration of
    - CILOSTAZOL (see under Clopidogrel, p. 206)
- Ciclosporin: erythromycin possibly reduces antiplatelet effect of
  - CLOPIDOGREL—Colchicine: azithromycin, clarithromycin and erythromycin possibly increase risk of
    - COLCHICINE toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Corticosteroids: erythromycin possibly inhibits metabolism of
  - CORTICOSTEROIDS; erythromycin inhibits the metabolism of
    - METHYLPRIDINOSOME; clarithromycin possibly increases plasma concentration of
      - METHYLPRIDINOSOME
- Cytotoxics: erythromycin possibly increases the plasma concentration of
  - AFINIB—manufacturer of afinityb advises separating administration of erythromycin by 6 to 12 hours; clarithromycin and erythromycin possibly increase plasma concentration of
    - AFINIB (reduce dose of afinityb—consult
Macrolides
- Cytotoxics (continued)
  - axitinib product literature; clarithromycin and erythromycin possibly increase the plasma concentration of
  - docetaxel—manufacturer of docetaxel advises avoid or reduce docetaxel dose; erythromycin increases plasma concentration of
  - clarithromycin and erythromycin possibly increase plasma concentration of cabozantinib; clarithromycin or erythromycin given with simvastatin (avoid concomitant use); separating administration from azithromycin by 12 hours advised by manufacturer of lomitapide; avoidance of clarithromycin and erythromycin advised by manufacturer of lomitapide (plasma concentration of lomitapide possibly increased)
  - mirabegron, when given with clarithromycin avoid or reduce dose of mirabegron in hepatic or renal impairment—see mirabegron, p. 673
- Oestrogens—erythromycin increases plasma concentration of estradiol
- Prostaglandins—erythromycin increases plasma concentration of galantamine
- Pentamidine isetionate: increased risk of ventricular arhythmias when parenteral erythromycin given with pentamidine
- Progestogens—erythromycin increases plasma concentration of Dienogest
- Ranolazine: clarithromycin possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: clarithromycin increases the plasma concentration of sildenafil—consider reducing initial dose of sildenafil for erectile dysfunction or reduce sildenafil dose frequency to twice daily for pulmonary hypertension; erythromycin increases plasma concentration of sildenafil—reduce initial dose of sildenafil for erectile dysfunction or reduce sildenafil dose frequency to twice daily for pulmonary hypertension
- Sirolimus: clarithromycin increases plasma concentration of sirolimus—avoid concomitant use; plasma concentration of both drugs increased when erythromycin given with sirolimus
- Tacrolimus: clarithromycin and erythromycin increase plasma concentration of tacrolimus
tadalafil: clarithromycin and erythromycin possibly increase plasma concentration of tadalafil
- Theophylline: clarithromycin possibly increases plasma concentration of theophylline; erythromycin increases plasma concentration of theophylline (also theophylline may reduce absorption of oral erythromycin)
- Ticagrelor: clarithromycin possibly increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use; erythromycin possibly increases plasma concentration of ticagrelor
- Ulipristal: avoidance of clarithromycin advised by manufacturer of low-dose ulipristal; erythromycin increases plasma concentration of low-dose ulipristal—manufacturer of low-dose ulipristal advises avoid concomitant use
- Vaccines: antibacterials inactivate oral typhoid vaccine—see under typhoid vaccine in BNF
- Vardenafil: clarithromycin possibly increases plasma concentration of vardenafil (consider reducing initial dose of vardenafil); erythromycin increases plasma concentration of vardenafil (reduce dose of vardenafil)

Magnum (parenteral)
- Calcium-channel Blockers: profound hypotension reported with concomitant use of parenteral magnesium and nifedipine in pre-eclampsia

Muscle Relaxants: parenteral magnesium enhances effects of non-depolarising muscle relaxants and succinylcholine

Magnesium Salts (oral) see Antacids

Mannitol
- Antibacterials: avoidance of mannitol advised by manufacturer of tobramycin

Lipid-regulating Drugs: clarithromycin increases plasma concentration of atorvastatin and pravastatin; possible interactions with lipid-regulating Drugs (continued)
Antiepileptics: possible increased risk of nephrotoxicity when mannitol given with ciclosporin

**MAOIs**

- **Ciclosporin**: possible increased risk of nephrotoxicity when mannitol given with ciclosporin

**NOTE** For interactions of reversible MAO-A inhibitors (RIMAs) see moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the bacterial Linezolid is a reversible, non-selective MAO inhibitor

- **ACE inhibitors**: MAOIs possibly enhance hypotensive effect of ACE inhibitors
- **Adrenergic Neurone Blockers**: increased risk of convulsions when MAOIs given with MAOIs (3 weeks if starting clomipramine or imipramine), also MAOIs should not be started for at least 1 week after stopping MAOIs
- **Alpha-blockers**: increased risk of hypertension and CNS excitation when MAOIs given with MAOIs (avoid concomitant use and for 2 weeks after stopping MAOIs; possible increased serumotonic effects and increased risk of convulsions when MAOIs given with tramadol—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs; avoidance of MAOIs advised by manufacturer of selegiline advises avoid concomitant use; for at least 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs); after stopping MAOIs do not start
- **Antidepressants**: MAOIs possibly enhance hypotensive effect of antidepressants; increased risk of hypertension and CNS excitation when MAOIs given with reboxetine should not be started until 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs; after stopping MAOIs do not start
- **Antihistamines**: risk of antimuscarinic side-effects when MAOIs given with MAOIs possibly enhance hypotensive effect when MAOIs given with alpha-blockers
- **Analgesics**: MAOIs possibly enhance hypotensive effect when MAOIs given with alpha-blockers
- **Analgesics**: possible increased serotonergic effects when MAOIs given with fentanyl; CNS excitation or depression (hypertension or hypotension) when MAOIs given with pethidine—avoid concomitant use and for 2 weeks after stopping MAOIs; possible increased serumotonic effects and increased risk of convulsions when MAOIs given with tramadol—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs
- **Angiotensin-II Receptor Antagonists**: possible increased risk of hypertension and CNS excitation or depression (hypertension or hypotension) when MAOIs given with opioid analgesics—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs

**Antipsychotics**

- **Antimuscarinics**: MAOIs possibly enhance hypotensive effect of antimuscarinics; increased risk of antimuscarinic side-effects when MAOIs given with antimuscarinics
- **Antisypotomimetics**: CNS effects of MAOIs possibly increased by clozapine
- **Antihistamines**: risk of antimuscarinic side-effects when MAOIs given with antimuscarinics
- **Antihistamines**: increased risk of antimuscarinic side-effects when MAOIs given with antimuscarinics
- **Antipsychotics**: CNS effects of MAOIs possibly increased by clozapine

**Antidepressants**

- **Antidepressants**: possible increased risk of precipitation of convulsions when MAOIs given with MAOIs possibly enhance hypotensive effect when MAOIs given with alpha-blockers
- **Analgesics**: MAOIs possibly enhance hypotensive effect when MAOIs given with alpha-blockers
- **Analgesics**: possible increased serotonergic effects when MAOIs given with fentanyl; CNS excitation or depression (hypertension or hypotension) when MAOIs given with pethidine—avoid concomitant use and for 2 weeks after stopping MAOIs; possible increased serumotonic effects and increased risk of convulsions when MAOIs given with tramadol—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs; avoidance of MAOIs advised by manufacturer of selegiline advises avoid concomitant use; for at least 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs; after stopping MAOIs do not start
- **Antidepressants**: increased risk of hypertension and CNS excitation when MAOIs given with reboxetine should not be started until 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs; after stopping MAOIs do not start
- **Antidepressants**: increased risk of hypertension and CNS excitation when MAOIs given with selective MAOIs with entacapone; risk of hypertensive crisis when MAOIs given with rasagiline, avoid MAOIs for at least 2 weeks after stopping rasagiline; enhanced hypertensive effect when MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of MAOIs with tolcapone
- **Antidepressants**: increased risk of serotoninergic effects when MAOIs given with dapoxtine (MAOIs should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping MAOIs)
- **Dopamine analogues**: risk of hypertensive crisis when MAOIs given with co-beneldopa, co-careldopa or levodopa, avoid co-beneldopa, co-careldopa or levodopa for at least 2 weeks after stopping MAOIs; avoid concomitant use of non-selective MAOIs with entacapone; risk of hypertensive crisis when MAOIs given with rasagiline, avoid MAOIs for at least 2 weeks after stopping rasagiline; enhanced hypertensive effect when MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of MAOIs with tolcapone
- **Antidepressants**: increased risk of serotoninergic effects when MAOIs given with dapoxtine (MAOIs should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping MAOIs)
- **Diazoxide**: enhanced hypotensive effect when MAOIs given with diazoxide
- **Diuretics**: enhanced hypotensive effect when MAOIs given with diuretics
- **Dopaminergic drugs**: risk of hypertensive crisis when MAOIs given with co-beneldopa, co-careldopa or levodopa, avoid co-beneldopa, co-careldopa or levodopa for at least 2 weeks after stopping MAOIs; avoid concomitant use of non-selective MAOIs with entacapone; risk of hypertensive crisis when MAOIs given with rasagiline, avoid MAOIs for at least 2 weeks after stopping rasagiline; enhanced hypertensive effect when MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of MAOIs with tolcapone
- **Dopaminergic drugs**: risk of hypertensive crisis when MAOIs given with co-beneldopa, co-careldopa or levodopa, avoid co-beneldopa, co-careldopa or levodopa for at least 2 weeks after stopping MAOIs; avoid concomitant use of non-selective MAOIs with entacapone; risk of hypertensive crisis when MAOIs given with rasagiline, avoid MAOIs for at least 2 weeks after stopping rasagiline; enhanced hypertensive effect when MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of MAOIs with tolcapone
- **Dopaminergic drugs**: risk of hypertensive crisis when MAOIs given with co-beneldopa, co-careldopa or levodopa, avoid co-beneldopa, co-careldopa or levodopa for at least 2 weeks after stopping MAOIs; avoid concomitant use of non-selective MAOIs with entacapone; risk of hypertensive crisis when MAOIs given with rasagiline, avoid MAOIs for at least 2 weeks after stopping rasagiline; enhanced hypertensive effect when MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of MAOIs with tolcapone
- **Dopaminergic drugs**: risk of hypertensive crisis when MAOIs given with co-beneldopa, co-careldopa or levodopa, avoid co-beneldopa, co-careldopa or levodopa for at least 2 weeks after stopping MAOIs; avoid concomitant use of non-selective MAOIs with entacapone; risk of hypertensive crisis when MAOIs given with rasagiline, avoid MAOIs for at least 2 weeks after stopping rasagiline; enhanced hypertensive effect when MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of MAOIs with tolcapone
Mefloquine (continued)
- Atomoxetine: increased risk of ventricular arrhythmias when mefloquine given with • ATOMOXETINE
- Beta-blockers: increased risk of bradycardia when mefloquine given with • BETABLOCKERS
- Calcium-channel blockers: possible increased risk of bradyarrhythmia when mefloquine given with • CALCIUM-CHANNEL BLOCKERS
- Cardiac glycosides: possible increased risk of bradyarrhythmia when mefloquine given with • DIGOXIN
- Cytotoxics: possible increased risk of bradyarrhythmia when mefloquine given with • CRIZOTINIB
- Histamine: avoidance of antimalarials advised by manufacturer of • HISTAMINE
- Ibrabradine: increased risk of ventricular arrhythmias when mefloquine given with • IBRABRADINE
- Vaccines: antimalarials inactivate • ORAL TYPHOID VACCINE — see under Typhoid Vaccine in BNF

Megestrol see Progestogens
Melatonin see Anxiolytics and Hypnotics
Meloxicam see NSAIDs

Mephalan
- Antibacterials: increased risk of melphalan toxicity when given with • NALIDIXIC ACID
- Antipsychotics: avoid concomitant use of cytoxotics with • CLOzapine (increased risk of agranulocytosis)
- Cardiac glycosides: melphalan possibly reduces absorption of • DIGOXIN tablets
- Ciclosporin: increased risk of nephrotoxicity when melphalan given with • CICLOSPORIN
- Memantine
  - Anaesthetics, General: increased risk of CNS toxicity when memantine given with • KETEMINE (manufacturer of memantine advises avoid concomitant use)
  - Analgesics: increased risk of CNS toxicity when memantine given with • DEXTROMETHORPHAN (manufacturer of memantine advises avoid concomitant use)
  - Anticoagulants: memantine possibly enhances anticoagulant effect of • WARFARIN
  - Antimuscarnics: memantine possibly enhances effects of • ANTIMUSCARINICS
- Antipsychotics: memantine possibly reduces effects of • ANTIpsychotics
- Dopaminergics: memantine possibly enhances effects of • DOPAMINERGICS and • SELEGILINE
- Memantine possibly reduces effects of • DOPAMINERGICS and • SELEGILINE
- Meningococcal Vaccines see Vaccines
Mepacrine
- Antimalarials: mepacrine increases plasma concentration of • PRIMAQUINE (increased risk of toxicity)
Meprobamate see Anxiolytics and Hypnotics
Meptazinol see Opioid Analgesics
Mercaptopurine
- Allopurinol: enhanced effects and increased toxicity of mercaptopurine when given with • ALLOPURINOL (reduce dose of mercaptopurine to one quarter of usual dose)
- Antimycobacterials: increased risk of haematological toxicity when mercaptopurine given with • SULFAMETHOXAZOLE (as co- trimoxazole); increased risk of haematological toxicity when mercaptopurine given with • TRIMETHOPRIM (also with co- trimoxazole)
- Anticoagulants: mercaptopurine possibly reduces anticoagulant effect of • COUMARINS
- Antipsychotics: avoid concomitant use of cytoxotics with • CLOzapine (increased risk of agranulocytosis)
- Dairy Products: plasma concentration of mercaptopurine possibly reduced by • DAILY PRODUCE — manufacturer of mercaptopurine advises give at least 1 hour before or 2 hours after dairy products
- Febuxostat: avoidance of mercaptopurine advised by manufacturer of • FEBUXOSTAT
Methotrexate
- Antiepileptics: carbapenems reduce plasma concentration of
  - SODIUM VALPROATE and VALPUROIC ACID—avoid concomitant use
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Methyldopa
- see Oestrogens

Metaraminol
- see Sympathomimetics

Methamphetamine
- see Opioid Analgesics

Methamphetamine
- Antacids; avoid concomitant use of methamphetamine with
  - ANTAGONISTS
- Antibacterials: increased risk of crystalluria when methamphetamine given with
  - SULFONAMIDES
- Diuretics: effects of methamphetamine antagonised by
  - ACETAZOLAMIDE
- Potassium Salts: avoid concomitant use of methamphetamine with
  - POTASSIUM CITRATE
- Sodium Citrate: avoid concomitant use of methamphetamine with
  - SODIUM CITRATE
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Methocarbamol
- see Muscle Relaxants

Methotrexate
- Aminophylline: methotrexate possibly increases plasma concentration of AMINOPHYLLINE
- Anaesthetics, General: antifolate effect of methotrexate increased by
  - NITROUS OXIDE—avoid concomitant use
- Analgesics: excretion of methotrexate possibly reduced by
  - NSAIDS (increased risk of toxicity); excretion of methotrexate reduced by
    - ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETACIN, KETOPIROFEN, MELOXICAM and
    - NAPROKEN (increased risk of toxicity)
- Antibacterials: absorption of methotrexate possibly reduced by
  - NEOMYCIN; excretion of methotrexate possibly reduced by
    - CIPROFLOXACIN (increased risk of toxicity); increased risk of haemato logical toxicity when methotrexate given with
    - SULFAMETHOXAZOLE (as co-trimoxazole); increased risk of methotrexate toxicity when given with
      - DOXYCYCLINE, SULFONAMIDES or TETRACYCLINE; excretion of methotrexate reduced by
        - PENCILLINS (increased risk of toxicity); increased risk of haemato logical toxicity when methotrexate given with
        - TRIMETHOPRIM (also with co-trimoxazole)
- Antiepileptics: antifolate effect of methotrexate increased by
  - FOSPHENYTIN and PHENYTOIN
- Antimalarials: antifolate effect of methotrexate increased by
  - PYRIMETHAMINE
- Antipsychotics: avoid concomitant use of cytoxotics with
  - CLOzapine (increased risk of agranulocytosis)
- Cardiac Glycosides: methotrexate possibly reduces absorption of DIGOXIN tablets
- Ciclosporin: risk of toxicity when methotrexate given with
  - CICLOSPORIN
- Corticosteroids: possible increased risk of hepatotoxicity when
  - high-dose methotrexate given with DEXAMETHASONE
- Cytotoxics: increased pulmonary toxicity when methotrexate given with
  - CISPLATIN
- Diuretics: excretion of methotrexate increased by alkaline urine due to ACETAZOLAMIDE
- Leflunomide: risk of toxicity when methotrexate given with
  - LEFLUNOMIDE
- Retinoids: plasma concentration of methotrexate increased by
  - ACITRETIN (also increased risk of hepatotoxicity)—avoid concomitant use
- Theophylline: methotrexate possibly increases plasma concentration of THEOPHYLLINE
- Ulcer-healing Drugs: excretion of methotrexate possibly reduced by PROTON PUMP INHIBITORS (increased risk of toxicity)

Methyldopa
- ACE inhibitors: enhanced hypotensive effect when methyldopa given with ACE INHIBITORS
- Adrenergic Neurone Blockers: enhanced hypotensive effect when methyldopa given with ADRENERGIC NEURONE BLOCKERS

Methyldopa (continued)
- Alcohol: enhanced hypotensive effect when methyldopa given with
  - ALCOHOL
- Aldesleukin: enhanced hypotensive effect when methyldopa given with
  - ALDESLEUKIN
- Alpha-blockers: enhanced hypotensive effect when methyldopa given with
  - ALPHA-BLOCKERS
- Anaesthetics, General: enhanced hypotensive effect when methyldopa given with
  - GENERAL ANAESTHETICS
- Analgesics: hypotensive effect of methyldopa antagonised by
  - NSAIDS:
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when methyldopa given with
  - ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Antidepressants: manufacturer of methyldopa advises avoid
  - concomitant use with
    - MAOIS
- Antipsychotics: enhanced hypotensive effect when methyldopa given with
  - ANTIPSYCHOTICS (also increased risk of extrapyramidal effects)
- Anticoagulants and Antihypertensives: enhanced hypotensive effect when methyldopa given with
  - ANTIHYPERTENSIVES and ANTICOAGULANTS
- Beta-blockers: enhanced hypotensive effect when methyldopa given with
  - BETA-BLOCKERS
- Calcium-channel Blockers: enhanced hypotensive effect when methyldopa given with
  - CALCIUM-CHANNEL BLOCKERS
- Clonidine: enhanced hypotensive effect when methyldopa given with
  - CLONIDINE
- Corticosteroids: hypotensive effect of methyldopa antagonised by
  - CORTICOSTEROIDS
- Diazoxide: enhanced hypotensive effect when methyldopa given with
  - DIAZOXIDE
- Diuretics: enhanced hypotensive effect when methyldopa given with
  - DIURETICS
- Dopaminergics: methyldopa antagonises antiparkinsonism effect of
  - Dopaminergics; increased risk of extrapyramidal side-effects when methyldopa given with
    - AMANTADINE; enhanced hypotensive effect when methyldopa given with
      - CO-BENELDOPA, CO-CARELDOPA or LEVDOPA; effects of methyldopa possibly enhanced by
        - ENTACAPONE
- Iron Salts: hypotensive effect of methyldopa antagonised by
  - ORAL IRON SALTS
- Lithium: neurotoxicity may occur when methyldopa given with
  - LITHIUM without increased plasma concentration of lithium
- Moxisylyte: enhanced hypotensive effect when methyldopa given with
  - MOXISYLYTE
- Moxisylyte: enhanced hypotensive effect when methyldopa given with
  - MOXONIDINE
- Muscle Relaxants: enhanced hypotensive effect when methyldopa given with
  - BACLOFEN or TIZANIDINE
- Nitrates: enhanced hypotensive effect when methyldopa given with
  - NITRATES
- Oestrogens: hypotensive effect of methyldopa antagonised by
  - OESTROGENS
- Prostaglandins: enhanced hypotensive effect when methyldopa given with
  - ALPROSTADIL
- Sympathomimetics, Alpha: acute hypotension reported when methyldopa given with infusion of
  - SALBUTAMOL
- Vasodilator Antihypertensives: possible risk of CNS toxicity when methyldopa given with
  - HYDRAZALINE, MINOXIDIL or SODIUM NITROPRUSSIATE

Methylphenidate
- see Sympathomimetics

Methylprednisolone
- see Corticosteroids

Methylothioninium
- Antidepressants: risk of CNS toxicity when methylothioninium given with
  - SSRI-RELATED ANTIDEPRESSANTS, SSRIS and
  - CLOMIPRAMINE—avoid concomitant use (if avoidance not possible, use lowest possible dose of methylothioninium and observe patient for up to 4 hours after administration); possible risk of CNS toxicity when methylothioninium given with
  - MIRTAZAPINE—avoid concomitant use (if avoidance not possible, use lowest possible dose of methylothioninium and observe patient for up to 4 hours after administration)
- Anxiolytics and Hypnotics: possible risk of CNS toxicity when methylothioninium given with
  - BUSPIRONE—avoid concomitant use (if avoidance not possible, use lowest
Methylthioninium
● Antipsychotics: increased risk of agranulocytosis
● Non-steroidal anti-inflammatory drugs: increased risk of bleeding

Antihistamines: increased risk of sedation

β-blockers: increased risk of bradycardia

Methylthioninium: possible increased risk of convulsions when antidepressants given with ATOMOXETINE

Clonidine: mirtazapine possibly antagonises hypotensive effect of CLONIDINE

Methylthioninium: possible increased risk of CNS toxicity when mirtazapine given with METHYLTHIONINIUM—avoid concomitant use (if avoidance not possible, use lowest possible dose of methylthioninium and observe patient for up to 4 hours after administration)

Ulcer-healing Drugs: plasma concentration of mirtazapine increased by Cimetidine

Mirtazapine
● Alcohol: increased sedative effect when mirtazapine given with ALCOHOL
● Analgesics: possible increased serotoninergic effects when mirtazapine given with TRAMADOL
● Anticoaguulants: mirtazapine enhances anticoagulant effect of WARFARIN

● Antidepressants: possible increased serotoninergic effects when mirtazapine given with MAOIS

● Antidepressants: avoid concomitant use of cytotoxics with METHYLTHIONINIUM—avoid concomitant use (if avoidance not possible, use lowest possible dose of methylthioninium and observe patient for up to 4 hours after administration)

Anticoaguulants: mirtazapine enhances anticoagulant effect of WARFARIN

Beta-blockers: increased risk of bradycardia

β-blockers: increased risk of bradycardia

Anticoaguulants: mirtazapine enhances anticoagulant effect of WARFARIN

Antidepressants: possible increased serotoninergic effects when mirtazapine given with MAOIS

Antidepressants: avoid concomitant use of cytotoxics with METHYLTHIONINIUM—avoid concomitant use (if avoidance not possible, use lowest possible dose of methylthioninium and observe patient for up to 4 hours after administration)

Ulcer-healing Drugs: plasma concentration of mirtazapine increased by Cimetidine

Mitomycin
● Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
Moxifloxacin
- Anticoagulants: mitoxantrone possibly reduces anticoagulant effect of CUMARINS
- Antipsychotics: avoid concomitant use of cytoxics with CLOzapine (increased risk of agranulocytosis)
- Diuretics: manufacturer of moxifloxacin advises avoid concomitant use of SPIRONOLACTONE (antagonism of effect)

Mitoxantrone
- Antipsychotics: avoid concomitant use of cytoxics with CLOzapine (increased risk of agranulocytosis)
- Ciclosporin: excretion of mitoxantrone reduced by CICLOSPORIN (increased plasma concentration)

Mivacurium see Muscle Relaxants
Mizolastine see Antihistamines
MMR Vaccine see Vaccines
Moclobemide
- Analgesics: possible CNS excitation or depression (hypertension or hypotension) when moclobemide given with DEXTROMETHORPHAN or PETHIDINE—avoid concomitant use; possible CNS excitation or depression (hypertension or hypotension) when moclobemide given with OPIOID ANALGESICS—manufacturer of moclobemide advises consider reducing dose of opioid analgesics
- Antidepressants: moclobemide should not be started for at least 1 week after stopping MAOIS, SSRl-RELATED ANTIDEPRESSANTS, OLANzapine, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, TRICYCLIC-RELATED ANTIDEPRESSANTS or TRICYCLICS; increased risk of CNS toxicity when moclobemide given with a ESCITALOPRAM, preferably avoid concomitant use; moclobemide should not be started until 5 weeks after stopping FLUOXETINE; possible increased serotonergic effects when moclobemide given with DULOXETINE
- Antimalarials: avoidance of antidepressants advised by manufacturer of ARTEMETHER WITH LUMEFANTRINE and ARTENIMOL WITH PIPERAQUINE
- Atomoxetine: possible increased risk of convulsions when antidepressants given with ATOMOXETINE
- Bupropion: avoidance of moclobemide advised by manufacturer of BUPROPION
- Clonidine: moclobemide possibly reduces antiplatelet effect of CLOPIDOGREL
- Dopaminergics: increased risk of side-effects when moclobemide given with CO-BENELDOPA, CO-CARELDOPA or LEVODOPA; caution with moclobemide advised by manufacturer of ENTACAPONE; avoid concomitant use of moclobemide with SELEGILINE
- SHT receptor Agonists: risk of CNS toxicity when moclobemide given with a RIZATRIPTAN or a SUMATRIPTAN (avoid rizatRIPTAN or sumatriptan for 2 weeks after moclobemide); risk of CNS toxicity when moclobemide given with ZOMITRIPTAN (reduce dose of zolmitriptan)
- Sympathomimetics: risk of hypertensive crisis when moclobemide given with SYMPATHOMIMETICS
- Ulcer-healing Drugs: plasma concentration of moclobemide increased by CIMETIDINE (half life of moclobemide)

Modafinil
- Antiepileptics: modafinil possibly increases plasma concentration of FOSPHENYTOIN and PHENYTOIN
- Ciclosporin: modafinil reduces plasma concentration of CICLOSPORIN
- Ciclosporin: modafinil reduces plasma concentration of BOSUTINIB—manufacturer of bosutinib advises avoid concomitant use
- Oestrogens: modafinil accelerates metabolism of OESTROGENS (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)

Moxepril see ACE Inhibitors
Mometasone see Corticosteroids
Monobactams see Aztreonam
Monoclonal antibodies see individual drugs
Montelukast see Leukotriene Receptor Antagonists
Morphine see Opioid Analgesics
Moxifloxacin see Quinolones

Moxisylyte
- ACE Inhibitors: enhanced hypotensive effect when moxisylyte given with ACE INHIBITORS
- Adrenergic Neurone Blockers: enhanced hypotensive effect when moxisylyte given with ADRENERGIC NEURONE BLOCKERS
- Alpha-blockers: possible severe postural hypotension when moxisylyte given with ALPHA-BLOCKERS
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when moxisylyte given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Beta-blockers: possible severe postural hypotension when moxisylyte given with BETA-BLOCKERS
- Calcium-channel Blockers: enhanced hypotensive effect when moxisylyte given with CALCIUM-CHANNEL BLOCKERS
- Clonidine: enhanced hypotensive effect when moxisylyte given with CLONIDINE
- Diazoxide: enhanced hypotensive effect when moxisylyte given with DIAZOXIDE
- Diuretics: enhanced hypotensive effect when moxisylyte given with DIURETICS
- Methyldopa: enhanced hypotensive effect when moxisylyte given with METHYLDOPA
- Moxonidine: enhanced hypotensive effect when moxisylyte given with MOXONIDINE
- Nitrate: enhanced hypotensive effect when moxisylyte given with NITRATES
- Vasodilator Antihypertensives: enhanced hypotensive effect when moxisylyte given with HYDRAZALINE, MINOXIDIL or SODIUM NITROPRUSSIDE

Moxonidine
- ACE Inhibitors: enhanced hypotensive effect when moxonidine given with ACE INHIBITORS
- Adrenergic Neurone Blockers: enhanced hypotensive effect when moxonidine given with ADRENERGIC NEURONE BLOCKERS
- Alcohol: enhanced hypotensive effect when moxonidine given with ALCOHOL
- Aidesleukin: enhanced hypotensive effect when moxonidine given with AIDESLEUKIN
- Alpha-blockers: enhanced hypotensive effect when moxonidine given with ALPHA-BLOCKERS
- Anaesthetics, General: enhanced hypotensive effect when moxonidine given with GENERAL ANAESTHETICS
- Analgesics: hypotensive effect of moxonidine antagonised by NSAIDS
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when moxonidine given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Antidepressants: enhanced hypotensive effect when moxonidine given with MAOIS; hypotensive effect of moxonidine possibly antagonised by TRICYCLICS (manufacturer of moxonidine advises avoid concomitant use)
- Antipsyehotics: enhanced hypotensive effect when moxonidine given with PHENOTHIAZINES
- Anxiolytics and Hypnotics: enhanced hypotensive effect when moxonidine given with ANXIOLYTICS AND HYPNOTICS; sedative effects possibly increased when moxonidine given with BENZODIAZEPINES
- Beta-blockers: enhanced hypotensive effect when moxonidine given with BETA-BLOCKERS
- Calcium-channel Blockers: enhanced hypotensive effect when moxonidine given with CALCIUM-CHANNEL BLOCKERS
- Clonidine: enhanced hypotensive effect when moxonidine given with CLONIDINE
- Corticosteroids: hypotensive effect of moxonidine antagonised by CORTICOSTEROIDS
- Diazoxide: enhanced hypotensive effect when moxonidine given with DIAZOXIDE
- Diuretics: enhanced hypotensive effect when moxonidine given with DIURETICS
- Dopaminergics: enhanced hypotensive effect when moxonidine given with CO-BENELDOPA, CO-CARELDOPA or LEVODOPA
- Methyldopa: enhanced hypotensive effect when moxonidine given with METHYLDOPA
- Moxisylyte: enhanced hypotensive effect when moxonidine given with MOXISYLYTE
Muscle Relaxants

Effects of non-depolarising muscle relaxants possibly antagonised by ACE INHIBITORS; effects of non-depolarising muscle relaxants and suxamethonium enhanced by CALCULIUM-CHANNEL BLOCKERS; possible increased risk of bradycardia when suxamethonium given with DILTIAZEM—manufacturer of diltiazem advises avoid concomitant use; effects of non-depolarising muscle relaxants and suxamethonium enhanced by VERAPAMIL; avoidance of intravenous dantrolene advised by manufacturer of VERAPAMIL.

Cardiac Glycosides; possible increased risk of bradycardia when tizanidine given with CARDIAC GLYCOSIDES; risk of ventricular arrhythmias when suxamethonium given with CARDIAC GLYCOSIDES.

Muscle Relaxants, depolarising

See Muscle Relaxants

Muscle Relaxants, non-depolarising

See Muscle Relaxants

Mycophenolate

Antacids: absorption of mycophenolate reduced by ANTACIDS.

Antibiotics: bioavailability of mycophenolate possibly reduced by METRONIDAZOLE and NORFLOXACIN; plasma concentration of mycophenolate possibly reduced by COAMOXICLAV; plasma concentration of active metabolite of mycophenolate reduced by rifampicin.

Antivirals: mycophenolate increases plasma concentration of ACICLOVIR and VALACICLOVIR, also plasma concentration of inactive metabolite of mycophenolate increased; mycophenolate possibly increases plasma concentration of...
Mycophenolate
Antivirals (continued)
GANCICLOVIR and VALGANCICLOVIR, also plasma concentration of inactive metabolite of mycophenolate possibly increased
> Colestilan: manufacturer of colestilan advises give mycophenolate at least 1 hour before or 3 hours after
COLESTILAN
> Iron Salts: absorption of mycophenolate reduced by oral IRON SALTS
Lipid-regulating Drugs: absorption of mycophenolate reduced by COLESTYRAMINE
> Sevelamer: plasma concentration of mycophenolate possibly reduced by SEVELAMER
Nabumetone see NSAIDs
Nadolol see Beta-blockers
Nalidixic Acid
see
Neostigmine
see
Antipsychotics:
Analgesics:
Neomycin
Antimuscarinics:
▶
Analgesics:
Nadolol
Nabumetone
see
Beta-blockers
Nalidixic Acid
see Quinolones
Nalmefene
▶
Analgesics: manufacturer of nalmefene advises avoid concomitant use with OPIOID ANALGESICS
Nandrolone see Anabolic Steroids
Naproxen see NSAIDs
Naratriptan see SHT1-receptor Agonists (under HT)
Natalizumab
▶
Analgesics: avoid concomitant use of cytoxotics with
CLOZAPINE (increased risk of agranulocytosis)
> Vaccines: risk of generalised infections when monoclonal antibodies given with live VACCINES—avoid concomitant use
Nateglinide see Antidiabetics
Nebivolol see Beta-blockers
Nefopam
▶
Antidepressants: manufacturer of nefopam advises avoid concomitant use with MAOIS; side-effects possibly increased when nefopam given with TRICYCLICS
▶
Antimuscarinics: increased risk of antimuscarinic side-effects when nefopam given with ANTIMUSCARINICS
Neomycin see Aminoglycosides
Neostigmine see Parasympathomimetics
Nevirapine
▶
Analgesics: nevirapine possibly reduces plasma concentration of METHADONE
▶
Antibacterials: nevirapine reduces plasma concentration of CLARITHROMYCIN (but concentration of an active metabolite increased), also plasma concentration of nevirapine increased; nevirapine possibly increases plasma concentration of RIFABUTIN; plasma concentration of nevirapine reduced by RIFAMPICIN—avoid concomitant use
▶
Anticoagulants: nevirapine may enhance or reduce anticoagulant effect of WARFARIN
▶
Antidepressants: plasma concentration of nevirapine reduced by ST JOHN’S WORT—avoid concomitant use
▶
Antiepileptics: plasma concentration of nevirapine reduced by CARBAMAZEPINE
▶
Antifungals: nevirapine reduces plasma concentration of KETOCONAZOLE—avoid concomitant use; plasma concentration of nevirapine increased by FLUCONAZOLE; nevirapine possibly reduces plasma concentration of CASPOFUNGIN and ITRACONAZOLE—consider increasing dose of caspofungin and itraconazone
▶
Antipsychotics: nevirapine possibly reduces plasma concentration of ARIPIPRAZOLE (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature)
▶
Antivirals: nevirapine possibly reduces plasma concentration of AZATANAVIR and ETARAVIRINE—avoid concomitant use; manufacturer of nevirapine advises avoid concomitant use with BOCEPREVIR and RILPIVIRINE; avoidance of nevirapine advised by manufacturer of DACLATASVIR (plasma concentration of daclatasvir possibly reduced); nevirapine possibly reduces the plasma concentration of DOLUTEGRAVIR (see under Dolutegravir, p. 557); nevirapine reduces plasma concentration of EFAVIRENZ—avoid concomitant use; avoidance of nevirapine advised by manufacturer of ELVITEGRAVIR; nevirapine possibly reduces plasma concentration of FOSAMPREVIR—avoid unboosted fosamprenavir; nevirapine reduces plasma concentration of Nevirapine
▶
Antivirals (continued)
INDINAVIR; nevirapine possibly reduces plasma concentration of LOPINAVIR and TELAPREVIR—consider increasing dose of lopinavir and telaprevir; nevirapine possibly reduces plasma concentration of SIMPREVIR—manufacturer of simprevir advises avoid concomitant use; increased risk of granulocytopenia when nevirapine given with ZIDOVUDINE
▶
Cobicistat: manufacturer of nevirapine advises avoid concomitant use with COBICISTAT
▶
Dose: nevirapine accelerates metabolism of OESTROGENS (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)
▶
Dristat: absorption of nevirapine possibly reduced by ORLISTAT
▶
Progestogens: nevirapine accelerates metabolism of PROGESTOGENS (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF)
Nicardipine see Calcium-channel Blockers
Nicorandil
▶
Alcohol: hypotensive effect of nicorandil possibly enhanced by ALCOHOL
▶
Antidepressants: enhanced hypotensive effect when nicorandil given with MAOIS; hypotensive effect of nicorandil possibly enhanced by TRICYCLICS
▶
Avanafil: hypotensive effect of nicorandil significantly enhanced by AVANAFIL (avoid concomitant use)
▶
Sildenafil: hypotensive effect of nicorandil significantly enhanced by SILDENAFIL (avoid concomitant use)
▶
Tadalafil: hypotensive effect of nicorandil significantly enhanced by TADALAFIL (avoid concomitant use)
▶
Vardenafil: possible increased hypotensive effect when nicorandil given with VARDENAFIL—avoid concomitant use
▶
Vasodilator Antihypertensives: possible enhanced hypotensive effect when nicorandil given with HYDRALAZINE, MINOXIDIL or SODIUM NITROPRUSSIDE
Nicotine
▶
Anti-arrhythmics: nicotine possibly enhances effects of ADENOSINE
Nicotinic Acid
▶
Lipid-regulating Drugs: increased risk of myopathy when nicotinic acid given with STATINS (applies to lipid regulating doses of nicotinic acid)
Nifedipine see Calcium-channel Blockers
Nilotinib
▶
Antibacterials: manufacturer of nilotinib advises avoid concomitant use with CLARITHROMYCIN and TELITHROMYCIN; plasma concentration of nilotinib reduced by RIFAMPICIN—avoid concomitant use
▶
Antifungals: plasma concentration of nilotinib increased by KETOCONAZOLE—avoid concomitant use; manufacturer of nilotinib advises avoid concomitant use with ITRACONAZOLE and VORICONAZOLE
▶
Antipsychotics: avoid concomitant use of cytoxotics with CLOZAPINE (Increased risk of agranulocytosis)
▶
Antivirals: avoidance of nilotinib advised by manufacturer of BOCEPREVIR; plasma concentration of nilotinib possibly increased by RITONAVIR—manufacturer of nilotinib advises avoid concomitant use
▶
Anxiolytics and Hypnotics: nilotinib increases plasma concentration of MIDAZOLAM
▶
Grapefruit Juice: manufacturer of nilotinib advises avoid concomitant use with GRAPEFRUIT JUICE
▶
Lipid-regulating Drugs: separating administration from nilotinib by 12 hours advised by manufacturer of Lomitapide
Nintedanib see Calcium-channel Blockers
Nintedanib
▶
Antibacterials: plasma concentration of nintedanib reduced by RIFAMPICIN—avoid concomitant use
▶
Antifungals: plasma concentration of nintedanib increased by KETOCONAZOLE
Nitrates

- ACE Inhibitors: enhanced hypotensive effect when nitrates given with ACE INHIBITORS
- Adrenergic Neurone Blockers: enhanced hypotensive effect when nitrates given with ADRENERGIC NEURONE BLOCKERS
- Alcohol: enhanced hypotensive effect when nitrates given with ALCOHOL
- Aldesleukin: enhanced hypotensive effect when nitrates given with ALDESELEUKIN
- Alpha-blockers: enhanced hypotensive effect when nitrates given with ALPHA-BLOCKERS
- Anaesthetics, General: enhanced hypotensive effect when nitrates given with GENERAL ANAESTHETICS
- Analgesics: hypotensive effect of nitrates antagonised by NSAIDS
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when nitrates given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
- Anti-arrhythmics: effects of sublingual tablets of nitrates reduced by DISOPYRAMIDE (failure to dissolve under tongue owing to dry mouth)
  - Anticoagulants: infusion of glyceryl trinitrate reduces anticoagulant effect of • HEPARINS
  - Antidepressants: enhanced hypotensive effect when nitrates given with MAOIS; effects of sublingual tablets of nitrates possibly reduced by TRICYCLIC-RELATED ANTIDEPRESSANTS (failure to dissolve under tongue owing to dry mouth); effects of sublingual tablets of nitrates reduced by TRICYCLICS (failure to dissolve under tongue owing to dry mouth)
  - Antimuscarinics: effects of sublingual tablets of nitrates possibly reduced by ANTIMUSCARINICS (failure to dissolve under tongue owing to dry mouth)
  - Antipsychotics: enhanced hypotensive effect when nitrates given with PHENOTHIAZINES
- Anxiolytics and Hypnotics: enhanced hypotensive effect when nitrates given with ANXIOLYTICS AND HYPNOTICS
  - Avanafil: hypotensive effect of nitrates significantly enhanced by • AVANAFIL (avoid concomitant use)
  - Beta-blockers: enhanced hypotensive effect when nitrates given with BETA-BLOCKERS
  - Calcium-channel Blockers: enhanced hypotensive effect when nitrates given with CALCIUM-CHANNEL BLOCKERS
  - Clonidine: enhanced hypotensive effect when nitrates given with CLONIDINE
  - Corticosteroids: hypotensive effect of nitrates antagonised by CORTICOSTEROIDS
  - Diazoxide: enhanced hypotensive effect when nitrates given with DIAZOXIDE
  - Diuretics: enhanced hypotensive effect when nitrates given with DIURETICS
  - Dopaminergics: enhanced hypotensive effect when nitrates given with CO-BENELDOPA, CO-CARELDOPA or LEVODOPA
  - Methyldopa: enhanced hypotensive effect when nitrates given with M ETHYLDOPA
  - Moxisylyte: enhanced hypotensive effect when nitrates given with MOXYSLYTE
  - Moxonidine: enhanced hypotensive effect when nitrates given with MOXONIDINE
  - Muscle Relaxants: enhanced hypotensive effect when nitrates given with BACLOFEN or TIZANIDINE
  - Oestrogens: hypotensive effect of nitrates antagonised by OESTROGENS
  - Prostaglandins: enhanced hypotensive effect when nitrates given with ALPROSTADIL
  - Riociguat: possible enhanced hypotensive effect when nitrates given with • RIOCIGUAT—avoid concomitant use
  - Sildenafil: hypotensive effect of nitrates significantly enhanced by • SILDENAFIL (avoid concomitant use)
  - Tadalafil: hypotensive effect of nitrates significantly enhanced by • TADALAFIL (avoid concomitant use)
  - Vardenafil: possible increased hypotensive effect when nitrates given with • VARDENAFIL—avoid concomitant use
  - Vasodilator: Antihypertensives: enhanced hypotensive effect when nitrates given with HYDRAZALINE, MINOXIDIL or SODIUM NITROPRUSSIDE

Nitrazepam see Anxiolytics and Hypnotics

Nitrofurantoin

- Antacids: absorption of nitrofurantoin reduced by ORAL MAGNESIUM SALTS (as magnesium trisilicate)
- Antibacterials: nitrofurantoin possibly antagonises effects of • NALIDIXIC ACID
- Sulfapyrazine: excretion of nitrofurantoin reduced by SULFINPYRAZONE (increased risk of toxicity)
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Nitromidazoles see Metronidazole and Tinidazole

Nitrous Oxide see Anaesthetics, General

Nizatidine see Histamine H2-antagonists

Nomegestrol see Progestogens

Noradrenaline (norepinephrine) see Sympathomimetics

Norelgestromin see Progestogens

Norepinephrine

NOTE Norepinephrine interactions as for noradrenaline, see under sympathomimetics

Norethisterone see Progestogens

Norfloxacin see Quinolones

Norgestimate see Progestogens

Normal Immunoglobulin see Immunoglobulins

Nortriptyline see Antidepressants, Tricyclic NSAIDs

NOTE See also Aspirin. Interactions do not generally apply to topical NSAIDs

- ACE Inhibitors: increased risk of renal impairment when NSAIDs given with ACE INHIBITORS, also hypotensive effect antagonised
- Adrenergic Neurone Blockers: NSAIDs antagonise hypotensive effect of ADRENERGIC NEURONE BLOCKERS
- Aliskiren: NSAIDs possibly antagonise hypotensive effect of ALISKIREN

• Alpha-blockers: NSAIDs antagonise hypotensive effect of ALPHA-BLOCKERS

• Analgesics: avoid concomitant use of NSAIDs with • NSAIDS or • ASPIRIN (increased side-effects); avoid concomitant use of NSAIDs with • KETOROLAC (increased side-effects and haemorrhage); ibuprofen possibly reduces antiplatelet effect of ASPIRIN

• Angiotensin-II Receptor Antagonists: increased risk of renal impairment when NSAIDs given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS, also hypotensive effect antagonised

• Antacids: absorption of acetaminophen possibly reduced by ANTACIDS

• Antibacterials: indomethacin possibly increases plasma concentration of AMIKACIN and GENTAMICIN in neonates; plasma concentration of cececoib, diclofenac and etoricoxib reduced by RIFAMPICIN; possible increased risk of convulsions when NSAIDs given with • QUINOLONES

• Antiinflammatory: enhanced risk of haemorrhage when intravenous diclofenac given with • ANTICOAGULANTS (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when ketorolac given with • ANTICOAGULANTS (avoid concomitant use, including low-dose heparins); NSAIDs possibly enhance anticoagulant effect of • COUMARINS and • PHENINDIONE; possible increased risk of bleeding when NSAIDs given with • DABIGATRAN or • HEPARINS

• Antidepressants: increased risk of bleeding when NSAIDs given with • SSRIS or • VENLAFAXINE

• Antidiabetics: NSAIDs possibly enhance effects of • SULFONYLUREAS

• Antiepileptics: acetaminophen possibly reduces excretion of FOSPHENYTIOIN and PHENYTOIN (increased risk of toxicity)

• Antifungals: plasma concentration of paroxetine increased by FLUCONAZOLE (reduce dose of paroxetine); plasma concentration of cececoib increased by FLUCONAZOLE (half dose of cececoib); plasma concentration of flurbiprofen and ibuprofen increased by FLUCONAZOLE; plasma concentration of diclofenac and ibuprofen increased by VORICONAZOLE

• Antipsychotics: possible severe drowsiness when acetaminophen or indomethacin given with HALOPERIDOL
Appendix 1 Interactions

NSAIDs (continued)

- Antivirals: plasma concentration of piroxicam increased by
  - Ritonavir (risk of toxicity)—avoid concomitant use; plasma concentration of NSAIDs possibly increased by ritonavir; increased risk of haematological toxicity when NSAIDs given with zidovudine
- Beta-blockers: NSAIDs antagonise hypotensive effect of beta-blockers
- Calcium channel blockers: NSAIDs antagonise hypotensive effect of calcium channel blockers
- Cardiac glycosides: NSAIDs possibly increase plasma concentration of cardiac glycosides, also possible exacerbation of heart failure and reduction of renal function
- Ciclosporin: increased risk of nephrotoxicity when NSAIDs given with ciclosporin; plasma concentration of ciclofenac increased by ciclosporin (halve dose of ciclofenac)
- Clonidine: NSAIDs antagonise hypotensive effect of clonidine
- Clonodigrel: increased risk of bleeding when NSAIDs given with clonodigrel
- Corticosteroids: increased risk of gastro-intestinal bleeding and ulceration when NSAIDs given with corticosteroids
- Cytoxics: NSAIDs probably reduce excretion of
  - Mesetranate (increased risk of toxicity); diclofenac, ibuprofen, indometacin, ketoprofen, meloxicam and naproxen reduce excretion of mesetranate (increased risk of toxicity); NSAIDs possibly reduce renal excretion of remotezade—consult product literature; increased risk of bleeding when NSAIDs given with erlotinib; avoidance of mefenamic acid advised by manufacturer of regorafenib; indometacin enhances effects of fentanyl; diazoxide: NSAIDs antagonise hypotensive effect of diazoxide
- Dimethyl sulfoxide: avoid concomitant use of sulindac with
- Diuretics: risk of nephrotoxicity of NSAIDs increased by diuretics, also antagonism of diuretic effect; indometacin and ketorolac antagonise effects of diuretics; excretion of acetaminophen possibly increased by furosemide; NSAIDs possibly antagonise diuretic effect of furosemide; occasional reports of reduced renal function when indometacin given with trametracin—avoid concomitant use; possible increased risk of hyperkalaemia when NSAIDs given with potassium-sparing diuretics and aldosterone antagonists; increased risk of hyperkalaemia when indometacin given with potassium-sparing diuretics and aldosterone antagonists
- Iloprost: increased risk of bleeding when NSAIDs given with iloprost
- Lipid regulating Drugs: excretion of meloxicam increased by colestipramine
- Lithium: NSAIDs reduce excretion of lithium (increased risk of toxicity); ketorolac reduces excretion of lithium (increased risk of toxicity)—avoid concomitant use
- Methyldopa: NSAIDs antagonise hypotensive effect of methyldopa
- Mifamurtide: avoidance of high doses of NSAIDs advised by manufacturer of mifamurtide
- Moxonidine: NSAIDs antagonise hypotensive effect of moxonidine
- Muscle relaxants: ibuprofen reduces excretion of baclofen (increased risk of toxicity); NSAIDs possibly reduce excretion of baclofen (increased risk of toxicity)
- Nitrites: NSAIDs antagonise hypotensive effect of nitrites
- Oestrogens: etoricoxib increases plasma concentration of ethylhexyladrol
- Penicillamine: possible increased risk of nephrotoxicity when NSAIDs given with penicillamine
- Pentoxyphylline: possible increased risk of bleeding when NSAIDs given with pentoxyphylline; increased risk of bleeding when ketorolac given with pentoxyphylline (avoid concomitant use)
- Prasugrel: possible increased risk of bleeding when NSAIDs given with prasugrel
- Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs given with tacrolimus; increased risk of nephrotoxicity when ibuprofen given with tacrolimus
- Vasodilator Antihypertensives: NSAIDs antagonise hypotensive effect of hydralazine, minoxidil and sodium nitroprusside

Obinutuzumab

- Antipsychotics: avoid concomitant use of cytoxins with clozapine (increased risk of agranulocytosis)
- Vaccines: risk of generalised infections when monoclonal antibodies given with live vaccines—avoid concomitant use

Octreotide

- Anti-infectives: octreotide possibly reduces requirements for antibiotics
- Ciclosporin: octreotide reduces plasma concentration of ciclosporin
- Dopaminergic: octreotide increases plasma concentration of bromocriptine
- Ulcer-healing Drugs: octreotide possibly delays absorption of cimetidine

Oestrogens

- ACE inhibitors: oestrogens antagonise hypotensive effect of ACE inhibitors
- Adrenergic Neurone Blockers: oestrogens antagonise hypotensive effect of adrenergic neurone blockers
- Alpha-blockers: oestrogens antagonise hypotensive effect of alpha-blockers
- Aminophylline: oestrogens increase plasma concentration of aminophylline (consider reducing dose of aminophylline)
- Analgesics: plasma concentration of ethylhexyladrol increased by etoricoxib
- Angiotensin II Receptor Antagonists: oestrogens antagonise hypotensive effect of angiotensin II receptor antagonists
- Antibacterials: plasma concentration of estradiol increased by erythromycin; metabolism of oestrogens accelerated by rifamycins (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see contraceptive interactions in BNF)
- Anticoagulants: oestrogens may enhance or reduce anticoagulant effect of coumarins; oestrogens antagonise anticoagulant effect of phenindione
- Antidepressants: contraceptive effect of oestrogens reduced by st john's wort (avoid concomitant use); oestrogens antagonise antidepressant effect of tricyclics (but side-effects of tricyclics possibly increased due to increased plasma concentration)
- Anti-diabetics: oestrogens antagonise hypoglycaemic effect of anti-diabetics
- Antiepileptics: metabolism of oestrogens accelerated by carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone, rifampicin and topiramate (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see contraceptive interactions in BNF); oestrogens reduce plasma concentration of lamotrigine—consider increasing dose of lamotrigine; ethylhexyladrol possibly reduces plasma concentration of sodium valproate and valproic acid
- Antifungals: oestrogens increase plasma concentration of voriconazole; anecdotal reports of contraceptive failure and menstrual irregularities when oestrogens given with griseofulvin; anecdotal reports of contraceptive failure when oestrogens given with midazolam; occasional reports of breakthrough bleeding when oestrogens (used for contraception) given with terbinafine
- Antivirals: plasma concentration of ethylhexyladrol increased by atazanavir; metabolism of oestrogens accelerated by nevirapine and ritonavir (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see contraceptive interactions in BNF); plasma concentration of ethylhexyladrol possibly reduced by clozapine—manufacturer of telaprevir advises additional contraceptive precautions
- Anxiolytics and Hypnotics: oestrogens possibly increase plasma concentration of chlor Diazepam, diazepam and nitrazepam; oestrogens possibly reduce plasma concentration of lorazepam, diazepam and temazepam; oestrogens increase plasma concentration of melatonin
Oestrogens (continued)

- Aprepitant: possible contraceptive failure of hormonal contraceptives containing oestrogens when given with Aprepitant (alternative contraception recommended)
- Beta-blockers: oestrogens antagonise hypotensive effect of Beta-blockers
- Bosentan: possible contraceptive failure of hormonal contraceptives containing oestrogens when given with Bosentan (alternative contraception recommended)
- Calcium-channel Blockers: oestrogens antagonise hypotensive effect of Calcium-channel Blockers
- Ciclosporin: oestrogens possibly increase plasma concentration of Ciclosporin
- Clonidine: oestrogens antagonise hypotensive effect of clonidine
- Cobicistat: metabolism of oestrogens accelerated by Cobicistat
- Dopaminergics: oestrogens possibly increase plasma concentration of Dopaminergics
- Diuretics: oestrogens antagonise diuretic effect of Diuretics
- Fosaprepitant: possible reduced contraceptive effect of oestrogens advised by manufacturer of fosaprepitant (alternative contraception recommended)
- Lipid-regulating Drugs: absorption of ethinylestradiol reduced by Lipid-regulating Drugs
- Moxonidine: oestrogens antagonise hypotensive effect of Moxonidine
- Muscle Relaxants: oestrogens possibly increase plasma concentration of Tizanidine (increased risk of toxicity)
- Nitrofurantoin: plasma concentration of Nitrofurantoin increased by Oestrogens
- Oxytocics: possible reduced contraceptive effect of oestrogens advised by manufacturer of Oxytocics
- Pethidine: increased plasma concentration of Opioid Analgesics when given with Pethidine
- Telithromycin: plasma concentration of Telithromycin increased by Oestrogens
Opioid Analgesics
- Antifungals: (continued) possibly increased by itraconazole (increased risk of ventricular arrhythmias); plasma concentration of alfentanil and methadone increased by voriconazole (consider reduced dosage of alfentanil and methadone); plasma concentration of fentanyl possibly increased by triazoles
- Antihistamines: sedative effects possibly increased when opioid analgesics given with sedating antihistamines
- Antimalarials: avoidance of methadone advised by manufacturer of artenimol with piperaquine (possible risk of ventricular arrhythmias)
- Antimuscarinics: of convulsions when tramadol given with SSRIS
- Antifungals
- Anticoagulants:
- Opioid Analgesics
- Antiepileptics: increased risk of ventricular arrhythmias when methadone given with antiepileptics; increased risk of ventricular arrhythmias when methadone given with amisulpride—avoid concomitant use
- Antivirals: plasma concentration of methadone possibly reduced by abacavir, nevirapine and rifilpridine; plasma concentration of methadone possibly affected by boceprevir; possible increased risk of prolonged sedation and respiratory depression when buprenorphine given with boceprevir; methadone possibly reduces plasma concentration of didanosine; plasma concentration of methadone reduced by efavirenz, fosamprenavir and ritonavir; plasma concentration of tuberine possibly increased by ritonavir; plasma concentration of dextromethorphan increased by ritonavir; plasma concentration of dextromethorphan possibly reduced by ritonavir; concentration of methadone possibly affected by plasma concentration of morphine possibly reduced by ritonavir; increased risk of ventricular arrhythmias when methadone given with saquinavir—avoid concomitant use; caution with methadone advised by manufacturer of telaprevir (risk of ventricular arrhythmias); buprenorphine possibly reduces plasma concentration of tipranavir; methadone possibly increases plasma concentration of zidovudine
- Antipsychotics and Hypnotics: increased sedative effects when opioid analgesics given with anxiolytics and hypnotics; fentanyl possibly inhibits metabolism of midazolam
- Antidepressants: increased risk of respiratory depression when methadone given with atomoxetine; possible increased risk of convulsions when tramadol given with atomoxetine
- Beta-blockers: morphine possibly increases plasma concentration of esmolol
- Calcium-channel Blockers: metabolism of alfentanil inhibited by diltiazem (risk of prolonged or delayed respiratory depression)
- Cytotoxics: possible increased risk of venous thrombosis when methadone given with busulfan; caution with alfentanil and fentanyl advised by manufacturer of crizotinib; possible increased risk of venous thrombosis when methadone given with vandetanib—avoid concomitant use
- Dapoxetine: increased risk of serotoninergic effects when tramadol given with dapoxetine (manufacturer of dapoxetine advises tramadol should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping tramadol)
- Domperidone: opioid analgesics antagonise effects of domperidone on gastro-intestinal activity
- Dopaminergics: avoid concomitant use of dextromethorphan with risperidone; risk of CNS toxicity when phenytoin given with rasagiline (avoid phenytoin for 2 weeks after rasagiline); avoidance of opioid analgesics advised by manufacturer of selegiline; hyperpyrexia and CNS toxicity reported when phenytoin given with selegiline (avoid concomitant use)

Opioid Analgesics (continued)
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIS and tricyclics (convulsive threshold lowered)
- Antiepileptics: oxcarbazepine sometimes reduces plasma concentration of carbamazepine (but concentration of an active metabolite of carbamazepine may be increased), also plasma concentration of an active metabolite of oxcarbazepine often reduced; avoidance of oxcarbazepine advised by manufacturer of eslicarbazepine; oxcarbazepine increases plasma concentration of fosphenytoin, phenobarbital, phenytoin and primidone, also plasma concentration of an active metabolite of oxcarbazepine reduced; oxcarbazepine reduces plasma concentration of perampanel (see under Perampanel, p. 398); plasma concentration of an active metabolite of oxcarbazepine sometimes reduced by sodium valproate and valproic acid
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by antipsychotics (convulsive threshold lowered)
- Antioxidants: oxcarbazepine possibly reduces plasma concentration of daclatasvir and simprevir—manufacturer of daclatasvir and simprevir advises avoid concomitant use; avoidance of oxcarbazepine advised by
Oxcarbazepine
- Antivirals (continued)
  manufacturer of DOLUTEGRAVIR and SOFOSBUVIR; avoidance of oxcarbazepine advised by manufacturer of RILPVIRINE (plasma concentration of rilpivirine possibly reduced)
- Ciclosporin: oxcarbazepine possibly reduces plasma concentration of CICLOSPORIN
- Clopidogrel: oxcarbazepine possibly reduces antiplatelet effect of CLOPIDOGREL
- Cytotoxics: oxcarbazepine reduces plasma concentration of IMATINIB—avoid concomitant use
- Oestrogens: oxcarbazepine accelerates metabolism of OESTROGENS (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)
- Orlstat: possible increased risk of convulsions when antiepileptics given with ORLSTAT
- Progestogens: oxcarbazepine accelerates metabolism of PROGESTOGENS (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, eugonestrêl-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF)

Oxaprozin see NSAIDs
Oxcarbazepine see Antiepileptics
Oxethazaine see Sympathomimetics
Oxetacycline see Tetracyclines
Oxycodone see Antidepressants
Oxymetazoline see Sympathomimetics
Oxytetracycline see Tetracyclines
Oxyprenolol see Beta-blockers
Oxybutynin see Antimuscarinics
Oxytocin
- Anaesthetics, General: oxytocic effect possibly reduced, also enhanced hypotensive effect and risk of arrhythmias when oxytocin given with VOLATILE LIQUID GENERAL ANAESTHETICS
- Prostaglandins: uterotonic effect of oxytocin potentiated by PROSTAGLANDINS
- Sympathomimetics: risk of hypertension when oxytocin given with vasoconstrictor SYMPATHOMIMETICS (due to enhanced vasopressor effect)

Pacitaxel
- Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
- Antivirals: plasma concentration of pacitaxel increased by RITONAVIR
- Cytotoxics: increased risk of neutropenia when pacitaxel given with LAPATINIB

Paliperidone see Antipsychotics
Pamidronate Disodium see Bisphosphonates
Pancreatin
- Antidiabetics: pancreatin antagonises hypoglycaemic effect of ACARBOSE
Pancuronium see Muscle Relaxants
Pantoprazole see Proton Pump Inhibitors
Papaveretum see Opioid Analgesics
Paracetamol
- Anticoagulants: prolonged regular use of paracetamol possibly enhances anticoagulant effect of COUMARINS
- Antidiabetics: absorption of paracetamol possibly reduced when given 1 to 4 hours after LIXISENATIDE
- Antiepileptics: metabolism of paracetamol possibly accelerated by CARBAZEPINE, FOSPHENITOIN, PHENOBARBITAL, PHENOBARBITONE and PRIMODONE (also isolated reports of hepatotoxicity)
- Antifungals: avoidance of paracetamol advised by manufacturer of KETOCONAZOLE
- Cytotoxics: paracetamol possibly reduces metabolism of intravenous BUSULFAN (manufacturer of intravenous busulfan advises caution within 72 hours of paracetamol); caution with paracetamol advised by manufacturer of IMATINIB
- Lipid-regulating Drugs: absorption of paracetamol reduced by COLESTYRAMINE
- Metoclopamide: rate of absorption of paracetamol increased by METOCLOPRAMIDE

Paraldehyde
- Alcohol: increased sedative effect when paraldehyde given with ALCOHOL
- Disulfiram: risk of toxicity when paraldehyde given with DISULFiram

Parasymptomatistics
- Anti-arrhythmics: effects of neostigmine and pyridostigmine possibly antagonised by PROPafenONE
- Antibacterials: plasma concentration of galantamine increased by ERITHROMYCIN; effects of neostigmine and pyridostigmine antagonised by AMINOGLYCOSIDES; effects of neostigmine and pyridostigmine antagonised by CLINDAMYCIN; effects of neostigmine and pyridostigmine antagonised by POLYMIXINS
- Antidepressants: plasma concentration of galantamine increased by PAROXETINE
- Antifungals: plasma concentration of galantamine increased by KETOCONAZOLE
- Antivirals: possible increased risk of bradycardia when plicarpine given with CRIZOTINIB
- C-Peptide: effects of neostigmine and pyridostigmine antagonised by ANTIMUSCARINICS
- Beta-blockers: increased risk of arrhythmias when plicarpine given with BETA-BLOCKERS; effects of neostigmine and pyridostigmine antagonised by PROPARNOLOL
- Cytotoxics: possible increased risk of bradycardia when plicarpine given with CRIZOTINIB
- Cytotoxic: increased risk of agranulocytosis
- Muscle Relaxants: doneypezil possibly enhances effects of SUXAMETHONIUM; galantamine, neostigmine, pyridostigmine and rivastigmine enhance effects of SUXAMETHONIUM; neostigmine, pyridostigmine and rivastigmine antagonise effects of NON-DEPOLARISING MUSCLE RELAXANTS; donepezil possibly antagonises effects of NON-DEPOLARISING MUSCLE RELAXANTS

Pasireotide see Antipsychotics
Parietol see NSAIDs
Paricalcitol see Vitamins
Paroxetine see Antidepressants, SSRI
Paroxetine see Antidepressants, SSRI
Paroxetine see Antidepressants, SSRI
Pazopanib
- Antibacterials: plasma concentration of pazopanib possibly increased by CLARITHROMYCIN and TELITHROMYCIN (reduce dose of pazopanib); plasma concentration of pazopanib possibly reduced by RIFAMPICIN
- Antifungals: plasma concentration of pazopanib increased by KETOCONAZOLE (reduce dose of pazopanib); plasma concentration of pazopanib possibly increased by ITRACONAZOLE and VORICONAZOLE (reduce dose of pazopanib)
- Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
- Antivirals: plasma concentration of pazopanib possibly increased by ATAZANAVIR, INDINAVIR and RITONAVIR (reduce dose of pazopanib); avoidance of pazopanib advised by manufacturer of BOCEPREVIR; increased risk of ventricular arrhythmias when pazopanib given with SAQUINAVIR—avoid concomitant use
Pazopanib (continued)
  ▶ Cytoxics: plasma concentration of pazopanib increased by
    • LAPATINIB
    • Grapefruit Juice: manufacturer of pazopanib advises avoid concomitant use with Grapefruit Juice
  ▶ Lipid regulating Drugs: separating administration from pazopanib by 12 hours advised by manufacturer of LOMITAPIDE
  ▶ Ulcer-healing Drugs: absorption of pazopanib possibly reduced by histamine H₂-antagonists—manufacturer of pazopanib advises give at least 2 hours before or 10 hours after histamine H₂-antagonists; absorption of pazopanib possibly reduced by PROTON PUMP INHIBITORS manufacturer of pazopanib advises give at the same time as proton pump inhibitors

Pegfilgrastim
  ▶ Cytoxics: neutropenia possibly exacerbated when pegfilgrastim given with CAPECITABINE, FLUROORURACIL or TEGAFUR

Penicillamin (continued)
  ▶ Analgesics: renal excretion of penetremex possibly reduced by NSAIDS and ASPIRIN consult product literature
  • Antimalarials: antifolate effect of penetremex increased by PYRIMETHAMINE
  • Antipsychotics: avoid concomitant use of cytoxotics with CLOzapine (increased risk of agranulocytosis)

Penicillamine
  ▶ Analgesics: possible increased risk of nephrotoxicity when penicillamine given with NSAIDS
  • Antacids: absorption of penicillamine reduced by ANTACIDS
  • Antipsychotics: avoid concomitant use of penicillamine with CLOzapine (increased risk of agranulocytosis)
  • Cardiac Glycosides: penicillamine possibly reduces plasma concentration of DIGOXIN
  • Iron Salts: absorption of penicillamine reduced by oral IRON SALTS
  • Sodium Aurothiomalate: manufacturer of penicillamine advises avoid concomitant use with SODIUM AUROTHIOMALATE (increased risk of toxicity)
  • Zinc: penicillamine reduces absorption of ZINC, also absorption of penicillamine reduced by zinc

Penicillins
  ▶ Allopurinol: increased risk of rash when amoxicillin, ampicillin or co-amoxiclav given with ALLOPURINOL
  • Antibacterials: absorption of phenoxymethylpenicillin reduced by NEOMYCIN; effects of penicillins possibly antagonised by TETRACYCLINES
  • Anticoagulants: an interaction between broad-spectrum penicillins and COUMARINS and PHENINDION has not been demonstrated in studies, but common experience in anticoagulant clinics is that INR can be altered
  • Antiepileptics: manufacturer of pivmecillinam advises avoid concomitant use with SODIUM VALPROATE and VALPROIC ACID
  • Cytoxotics: penicillins reduce excretion of METHOTREXATE (increased risk of toxicity)
  • Muscle Relaxants: piperacillin enhances effects of NON-DEPolarising MUsCLE Relaxants and SUXAMETHONIUM
  • Mycophenolate: co-amoxiclav possibly reduces plasma concentration of MYCOPHENOLATE
  • Sulfinpyrazone: excretion of penicillins reduced by SULFINPYRAZONE
  • Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Pentamidine Isetionate
  ▶ Antiarhythmics: increased risk of ventricular arrhythmias when pentamidine isetionate given with AMIODARONE—avoid concomitant use; possible increased risk of ventricular arrhythmias when pentamidine isetionate given with DISOPYRAMIDE
  • Antipyschotics: increased risk of ventricular arrhythmias when pentamidine isetionate given with QT-PROLONGING drugs
  • Antipsychotics: increased risk of ventricular arrhythmias when pentamidine isetionate given with VALPROIC ACID
  • Antibacterials: absorption of pentamidine isetionate reduced by zinc
  • Anticoagulant clinics is that INR can be altered
  • Antipsychotics: increased risk of ventricular arrhythmias when pentamidine isetionate given with AMISULPIDE or DROPERIDOL—avoid concomitant use; possible increased risk of ventricular arrhythmias when pentamidine isetionate given with PHENOTHIAZINES
  • Antivirals: increased risk of hypocalcaemia when pentamidine isetionate given with FOSCARINET; increased risk of ventricular arrhythmias when pentamidine isetionate given with TAQUIN—avoid concomitant use
  • Cytoxotics: possible increased risk of ventricular arrhythmias when pentamidine isetionate given with VANDETANIB—avoid concomitant use
  • Ibivradine: increased risk of ventricular arrhythmias when pentamidine isetionate given with IBIVRADINE

Pentazocine see Opioid Analgesics

Penstasin
  ▶ Cytoxotics: plasma concentration of penstasin increased by amphotericin B (increased risk of nephrotoxicity)
  ▶ Lipid regulating Drugs: separating administration from penstasin by 12 hours advised by manufacturer of LOMITAPIDE
  ▶ Ulcer-healing Drugs: absorption of penstasin possibly reduced by PIELDIA

Perampanel
  ▶Antidepressants: possible increased risk of bleeding when perampanel given with NSAIDS; increased risk of bleeding (risk of agranulocytosis)
  ▶ Anticonvulsants: increased risk of bleeding when perampanel given with KETOCONAZOLE
  ▶ Antipsychotics: possible increased risk of agranulocytosis when perampanel given with TETRACYCLINES
  ▶ Cytoxotics: possible increased risk of ventricular arrhythmias when perampanel given with FLUDARABINE (increased risk of toxicity)
  ▶ Cytotoxotics: plasma concentration of perampanel increased by ANTIMALARIALS and HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS

Periostat
  ▶ Cytotoxotics: increased risk of ventricular arrhythmias when periostat given with AMLODIPINE or DROPERIDOL (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by TRICYCLICs

Perphenazine
  ▶ Antipsychotics: increased risk of ventricular arrhythmias when perphenazine given with ORAL TYPHOID VACCINE

Periostat (continued)
  ▶ Antiepileptics given with PERIOSTAT—possible increased risk of convulsions when periprostaglandins given with PERIOSTAT—possible increased risk of convulsions when antiepileptics given with ORLSTAT

Periostat (continued)
  ▶ Progestogens: periprostaglandins increases metabolism of PROGESTOGENS (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF)
Phenindione (continued)
- Oestrogens: anticoagulant effect of phenindione antagonised by OESTROGENS
- Prasugrel: possible increased risk of bleeding when phenindione given with PRASUGREL
- Progestogens: anticoagulant effect of phenindione antagonised by PROGESTOGENS
- Testolactone: anticoagulant effect of phenindione enhanced by TESTOLACTONE
- Testosterone: anticoagulant effect of phenindione enhanced by TESTOSTERONE
- Thyroid Hormones: anticoagulant effect of phenindione enhanced by THYROID HORMONES
- Vitamins: anticoagulant effect of phenindione antagonised by VITAMIN K

Phenobarbital
- Alcohol: increased sedative effect when phenobarbital given with ALCOHOL
- Aminophylline: phenobarbital accelerates metabolism of AMINOPHYLLINE (reduced effect)
- Analgesics: phenobarbital reduces plasma concentration of METHADONE; phenobarbital possibly accelerates metabolism of PARACETAMOL (also isolated reports of hepatotoxicity)
- Antibacterials: phenobarbital reduces plasma concentration of ALBENDAZOLE and PRAZIQUANTEL—consider increasing albendazole and praziquantel dose when given for systemic infections
- Anti-arrhythmics: phenobarbital accelerates metabolism of DISOPYRAMIDE (reduced plasma concentration); phenobarbital possibly reduces plasma concentration of DRONERADONE; avoid concomitant use; phenobarbital possibly accelerates metabolism of PROPAFENONE
- Antifungals: phenobarbital reduces plasma concentration of METRONIDAZOLE (reduced effect); phenobarbital possibly reduces plasma concentration of RIFAMPICIN; phenobarbital accelerates metabolism of DOXYCYCLINE (reduced plasma concentration); phenobarbital possibly accelerates metabolism of CHLORAMPHENICOL (reduced plasma concentration); phenobarbital reduces plasma concentration of TELETHROMYCIN (avoid during and for 2 weeks after phenobarbital)
- Anticoagulants: phenobarbital possibly reduces plasma concentration of APIXABAN; phenobarbital accelerates metabolism of COUMARINS (reduced anticoagulant effect); phenobarbital possibly reduces plasma concentration of RIVAROXABAN; manufacturer of rivaroxaban advises monitor for signs of thrombosis
- Antidepressants: phenobarbital reduces plasma concentration of REBOSETINE; phenobarbital reduces plasma concentration of PAROXETINE; phenobarbital accelerates metabolism of MIANSERIN (reduced plasma concentration); anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and TRICYCLIC-RELATED ANTIDEPRESSANTS (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRI and TRICYCLICS (convulsive threshold lowered); plasma concentration of phenobarbital possibly reduced by ST JOHN'S WORT; avoid concomitant use; phenobarbital possibly accelerates metabolism of TRICYCLICS (reduced plasma concentration)
- Antiepileptics: plasma concentration of phenobarbital possibly increased by CARBAZEPINE; phenobarbital possibly reduces plasma concentration of ETHOSUXIMIDE, RUFINAMIDE and TOPIRAMATE; plasma concentration of phenobarbital often increased by FOSPHENITOIN and PHENYTOIN, plasma concentration of phenobarbital often reduced but may be increased; phenobarbital reduces plasma concentration of LAMOTRIGINE, TIAGABINE and ZONISAMIDE; plasma concentration of phenobarbital increased by OXCARBAZEPINE, also plasma concentration of an active metabolite of oxcarbazepine reduced; plasma concentration of phenobarbital increased by SODIUM VALPROATE and VALPROIC ACID (also plasma concentration of sodium valproate and valproic acid reduced); plasma concentration of phenobarbital increased by STRIPENREL
- Antifungals: phenobarbital possibly reduces plasma concentration of ITRACONAZOLE and POSACONAZOLE;
Phenobarbital

- Cytotoxics (continued)
  
  of hypersensitivity reactions when phenobarbital given with
  PROCARBAZINE
  
  - Diuretics: phenobarbital reduces plasma concentration of
    Eplerenone—avoid concomitant use; increased risk of
    osteomalacia when phenobarbital given with CARBONIC
    ANHYDRASE INHIBITORS
  
  ▶ Folates: plasma concentration of phenobarbital possibly
    reduced by FOLATES
  
  - Fosaprepitant: phenobarbital possibly reduces plasma
    concentration of FOSAPREPITAN
  
  - Hormone Antagonists: phenobarbital possibly reduces plasma
    concentration of ABRIRATON—manufacturer of
    abiraterone advises avoid concomitant use; phenobarbital
    accelerates metabolism of TOREMPINE (reduced plasma
    concentration)
  
  - Ivacaftor: phenobarbital possibly reduces plasma
    concentration of IVACAFTOR—manufacturer of ivacaftor
    advises avoid concomitant use
  
  - Leukotriene Receptor Antagonists: phenobarbital reduces
    plasma concentration of MONELUKAST
  
  - Oestrogens: phenobarbital accelerates metabolism of
    OESTROGENS (reduced contraceptive effect with combined
    oral contraceptives, contraceptive patches, and vaginal
    rings—see Contraceptive Interactions in BNF)
  
  - Orlistat: possible increased risk of convulsions when
    antiepileptics given with ORLISTAT
  
  - Progestogens: phenobarbital accelerates metabolism of
    PROGESTOGENS (reduced contraceptive effect with combined
    oral contraceptives, progestogen-only oral contraceptives,
    contraceptive patches, vaginal rings, etonogestrel-releasing
    implant, and emergency hormonal contraception—see
    Contraceptive Interactions in BNF)
  
  - Roflumilast: phenobarbital possibly inhibits effects of
    ROFLUMILAST (manufacturer of roflumilast advises avoid
    concomitant use)
  
  - Sodium Oxynate: avoidance of phenobarbital advised by
    manufacturer of SODIUM OXYBATE
  
  - Sympathomimetics: plasma concentration of phenobarbital
    possibly increased by METHYLPHENIDATE
  
  - Tacrolimus: phenobarbital reduces plasma concentration of
    TACROLIMUS
  
  - Theophylline: phenobarbital accelerates metabolism of
    THEOPHYLLINE (reduced effect)
  
  - Thyroid Hormones: phenobarbital accelerates metabolism of
    THYROID HORMONES (may increase requirements for thyroid
    hormones in hypothyroidism)
  
  - Ticagrelor: phenobarbital possibly reduces plasma
    concentration of TICAGRELOR
  
  - Ulipristal: avoidance of phenobarbital advised by
    manufacturer of ULIPRISTAL (contraceptive effect of
    ulipristal possibly reduced)
  
  - Vitamins: phenobarbital possibly increases requirements for
    ALFACALCOLID, CALCITRIOL, COLECALCIFEROL, DIHYDROTACHYSTEROL, ERGOCALCIFEROL, PARICALCITOL or
    VITAMIN D

Phenothiazines see Antipsychotics

Phenoxymethylpenicillin see Penicillins

Phentolamine see Alpha-blockers

Phenytoin see Sympathomimetics

Phenylalanine

- Alcohol: plasma concentration of phenylalanine possibly reduced
  by chronic heavy consumption of ALCOHOL
  
  - Aminophylline: plasma concentration of both drugs reduced when
    phenytoin given with AMINOPHYLLINE
  
  - Analgesics: excretion of phenytoin possibly reduced by
    ACEMETACIN (increased risk of toxicity); phenytoin possibly
    accelerates metabolism of FENTANYL (reduced effect); phenytoin
    accelerates metabolism of METHADONE (reduced effect and risk of withdrawal effects); phenytoin possibly
    increases risk of PETHIDINE toxicity; effects of phenytoin
    enhanced by ASPIRIN; phenytoin possibly accelerates
Phenytoin
- Analgesics (continued)
  - metabolism of paracetamol (also isolated reports of hepatotoxicity)
- Antacids: absorption of phenytoin reduced by antacids
- Antifungals: phenytoin reduces plasma concentration of albendazole and praziquantel dose when given for systemic infections; plasma concentration of phenytoin possibly reduced when given with sodium valproate and valproic acid, also plasma concentration of sodium valproate and valproic acid reduced; plasma concentration of phenytoin increased by stiripentol; plasma concentration of phenytoin increased by topiramate (also plasma concentration of topiramate reduced); plasma concentration of phenytoin reduced by vigabatrin
- Antifungals: phenytoin reduces plasma concentration of ketoconazole and posaconazole; anticonvulsant effect of phenytoin enhanced by miconazole (plasma concentration of phenytoin increased by fluconazole (consider reducing dose of phenytoin); phenytoin reduces plasma concentration of itraconazole—avoid concomitant use; plasma concentration of phenytoin increased by voriconazole, also phenytoin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for phenytoin toxicity); phenytoin possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin
- Antimalarial: avoidance of phenytoin advised by manufacturer of artesunate with piperaquine; anticonvulsant effect of antiepileptics antagonised by mefloquine; anticonvulsant effect of phenytoin antagonised by pyrimethamine, also increased antifolate effect
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by antipsychotics (convulsive threshold lowered); phenytoin reduces plasma concentration of haloperidol; plasma concentration of phenytoin possibly increased or decreased by chlorpromazine; phenytoin possibly reduces plasma concentration of aripiprazole (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature); phenytoin accelerates metabolism of clozapine and quetiapine (reduced plasma concentration); phenytoin possibly reduces plasma concentration of lub谏草—avoid concomitant use
- Antivirals: phenytoin possibly reduces plasma concentration of abacavir, darunavir, lopinavir and saquinavir; avoidance of phenytoin advised by manufacturer of darunavir and lopinavir
- Boceprevir and rilpivirine (plasma concentration of boceprevir and rilpivirine possibly reduced); phenytoin possibly reduces plasma concentration of daclatasvir and simeprevir; phenytoin possibly reduces plasma concentration of indinavir, also plasma concentration of phenytoin possibly increased; phenytoin possibly reduces plasma concentration of ritonavir, also plasma concentration of phenytoin possibly affected; plasma concentration of phenytoin increased or decreased by zidovudine
- Anxiolytics and Hypnotics: phenytoin often reduces plasma concentration of clonazepam; plasma concentration of phenytoin increased or decreased by diazepam; plasma concentration of phenytoin possibly increased or decreased by benzodiazepines
- Aprepitant: phenytoin possibly reduces plasma concentration of aprepitant
- Bupropion: phenytoin reduces plasma concentration of bupropion
- Caffeine citrate: phenytoin reduces plasma concentration of caffeine citrate
- Calcium-channel Blockers: phenytoin reduces effects of felodipine and verapamil; avoidance of phenytoin advised by manufacturer of isradipine; avoidance of phenytoin advised by manufacturer of nimodipine (plasma concentration of nimodipine possibly reduced); plasma concentration of phenytoin transiently increased by tolbutamide (possibility of toxicity)
- Antiepileptics: plasma concentration of both drugs often reduced when phenytoin given with carbamazepine, also plasma concentration of phenytoin may be increased; phenytoin reduces plasma concentration of eslicarbazine, also plasma concentration of phenytoin possibly increased; plasma concentration of phenytoin possibly increased by ethosuximide, also plasma concentration of ethosuximide possibly reduced; phenytoin reduces plasma concentration of lamotrigine, tiagabine and zonisamide; plasma concentration of phenytoin increased by oxcarbazine, also plasma concentration of an active metabolite of oxcarbazine reduced; phenytoin reduces plasma concentration of perampanel (see under Perampanel, p. 398); phenytoin often increases plasma concentration of phenobarbital and primidone, plasma concentration of phenytoin often reduced but may be increased; phenytoin possibly reduces plasma concentration of retigabine;
Phenytoin
- Calcium-channel Blockers (continued)
  - Concentration of phenytoin increased by • Dilatiazem but also effect of dilatiazem reduced
- Cannabis Extract: phenytoin possibly reduces plasma concentration of • Cannabis extract advises avoidance concomitant use
- Cardiac glycosides: phenytoin possibly reduces plasma concentration of • Digoxin
- Cholestyramine: phenytoin accelerates metabolism of • Ciclosporin (reduced plasma concentration)
- Cobimetaprost: manufacturer of cobimetaprost advises avoidance concomitant use
- Corticosteroids: phenytoin accelerates metabolism of • Corticosteroids (reduced effect)
- Cytotoxics: phenytoin possibly reduces plasma concentration of • Busulfan, eribulin and etoposide; metabolism of phenytoin possibly inhibited by • Capecitabine, Fluorouracil and tegafur (increased risk of toxicity); phenytoin increases antifolate effect of • Methotrexate; plasma concentration of phenytoin possibly decreases plasma concentration of • Axitinib (increase dose of axitinib—consult axitinib product literature); phenytoin possibly reduces plasma concentration of • Bortezomib, bosutinib, crizotinib, ibritinib,idelalisib and ponatinib—manufacturer of bortezomib, bosutinib, crizotinib, ibritinib, idelalisib and ponatinib advises avoidance concomitant use; phenytoin possibly reduces plasma concentration of • Cabozantinib—avoid concomitant use; avoidance of phenytoin advised by manufacturer of • Carbazatekel, dabrafenib, gefitinib, lapatinib and vemurafenib; avoidance of phenytoin advised by manufacturer of dacarbazine and • Vismodegib (plasma concentration of dasatinib and vinblastine possibly reduced); phenytoin reduces plasma concentration of • Matinib—avoid concomitant use; phenytoin reduces plasma concentration of • Irinotecan and its active metabolite; manufacturer of procarbazine advises possible increased risk of hypersensitivity reactions when phenytoin given with • Procarbazine
- Dexrazoxane: absorption of phenytoin possibly reduced by • Dexrazoxane
- Diazoxide: plasma concentration of phenytoin reduced by • Diazoxide, also effect of diazoxide may be reduced
- Disulfiram: metabolism of phenytoin inhibited by • Disulfiram (increased risk of toxicity)
- Diuretics: plasma concentration of phenytoin possibly increased by • Acetazolamide; phenytoin antagonises effects of • Furosemide; phenytoin reduces plasma concentration of • Eplerenone—avoid concomitant use; increased risk of osteomalacia when phenytoin given with • Carbonic Anhydrase Inhibitors
- Dopaminergics: phenytoin possibly reduces effects of • Co-beneldopa, Co-careldopa and levodopa
- Enteral Foods: absorption of phenytoin possibly reduced by • Enteral foods

Phenytoin (continued)
- Lithium: neurotoxicity may occur when phenytoin given with • Lithium without increased plasma concentration of lithium
- Macitentan: avoidance of phenytoin advised by manufacturer of • Macitentan
- Modafinil: plasma concentration of phenytoin possibly increased by • Modafinil
- Muscle Relaxants: long-term use of phenytoin reduces effects of • Non-depolarising muscle relaxants (but acute use of phenytoin might increase effects of non-depolarising muscle relaxants)
- Oestrogens: phenytoin accelerates metabolism of • Oestrogens (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)
- Orlistat: possible increased risk of convulsions when antiepileptics given with • Orlistat
- Progestogens: phenytoin accelerates metabolism of • Progestogens (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF)
- Roflumilast: phenytoin possibly inhibits effects of • Roflumilast (manufacturer of roflumilast advises avoid concomitant use)
- Sulfipyrazone: plasma concentration of phenytoin increased by • Sulfapyrazone
- Symptomatemics: plasma concentration of phenytoin increased by • Methylphenidate
- Tacrolimus: phenytoin reduces plasma concentration of • Tacrolimus, also plasma concentration of phenytoin possibly increased
- Theophylline: plasma concentration of both drugs reduced when phenytoin given with • Theophylline
- Thyroid Hormones (may increase requirements in hypothyroidism), also plasma concentration of phenytoin possibly increased
- Tibolone: phenytoin accelerates metabolism of • Tibolone
- Ticagrelor: phenytoin possibly reduces plasma concentration of • Ticagrelor
- Ulcer-healing Drugs: metabolism of phenytoin inhibited by • Cimetidine (increased plasma concentration); effects of phenytoin enhanced by • Esomeprazole; effects of phenytoin possibly enhanced by • Omeprazole; absorption of phenytoin reduced by • Sucralfate
- Ulipristal: avoidance of phenytoin advised by manufacturer of • Ulipristal (contraceptive effect of ulipristal possibly reduced)
- Vaccines: effects of phenytoin enhanced by • Influenza Vaccine
- Vitamins: phenytoin possibly increases requirements for • Alfacalcidol, calcitriol, colcaldiferol, dihydroxachysterol, ergocalciferol, paricalcitol or vitamin D

Phenolamine
- Antidepressants: manufacturer of phenolamine advises avoid for 2 weeks after stopping MAOIs

Phosphodiesterase Type 3 Inhibitors
- Anagrelide: avoidance of enoximone and nilorinone advised by manufacturer of • Anagrelide

Pilocarpine see Parasympathomimetics

Pimozide see Antipsychotics

Pindolol see Beta-blockers

Pipiklinazole see Anti-diabetics

Piperacillin see Piperacillin

Piperaquine see Arsenimol with Piperaquine

Pipotiazine see Antipsychotics

Pirfenidone
- Antibacterials: plasma concentration of pirfenidone increased by • Ciprofloxacain—see under Pirfenidone, p. 260
- Antidepressants: plasma concentration of pirfenidone increased by • Fluvoxamine—manufacturer of pirfenidone advises avoid concomitant use
- Grapefruit Juice: manufacturer of pirfenidone advises avoid concomitant use with • Grapefruit Juice

Phosphate Esters see Phosphate Esters
Piroxicam see NSAIDs
Pimavanserin see Pimavanserin
Pixantrone
- Antipsychotics: avoid concomitant use of cytoxicotins with CLOzapine (increased risk of agranulocytosis)
- Vaccines: risk of generalised infections when pixantrone given with live VACCINES—avoid concomitant use

Pizotifen
- Adrenergic Neurone Blockers: pizotifen antagonises hypotensive effect of ADRENERGIC NEURONE BLOCKERS

Platinum Compounds
- Aldesleukin: avoidance of cisplatin advised by manufacturer of ALDOSLEUKIN
- Antibacterials: increased risk of nephrotoxicity and possibly of ototoxicity when platinum compounds given with AMINOGLYCOSIDES or POLYMIXINS; increased risk of nephrotoxicity and ototoxicity when platinum compounds given with CAPREOMYCIN; increased risk of nephrotoxicity and possibly of ototoxicity when cisplatin given with VANCOMYCIN
- Antiepileptics: cisplatin possibly reduces plasma concentration of PRIMIDONE and PHENYTOIN
- Antipsychotics: avoid concomitant use of cytoxicotins with CLOzapine (increased risk of agranulocytosis)
- Cytotoxics: increased risk of nephrotoxicity and ototoxicity when platinum compounds given with PLATINUM COMPOUNDS
- Diuretics: increased risk of nephrotoxicity and ototoxicity when platinum compounds given with DIURETICS

Pneumococcal Vaccine see Vaccines
Polimyelitis Vaccine see Vaccines
Polymyxins
- Antibacterials: increased risk of nephrotoxicity when colistimethate sodium or polymyxins given with AMINOGLYCOSIDES; increased risk of nephrotoxicity when colistimethate sodium or polymyxins given with CAPREOMYCIN; increased risk of nephrotoxicity when polymyxins given with VANCOMYCIN; increased risk of nephrotoxicity and ototoxicity when colistimethate sodium given with VANCOMYCIN
- Antifungals: increased risk of nephrotoxicity when polymyxins given with AMPHOTERICIN
- Ciclosporin: increased risk of nephrotoxicity when polymyxins given with CICLOSPORIN
- Cytotoxics: increased risk of nephrotoxicity and possibly of ototoxicity when polymyxins given with PLATINUM COMPOUNDS
- Diuretics: increased risk of ototoxicity when polymyxins given with LOOP DIURETICS
- Muscle Relaxants: polymyxins enhance effects of NON-DEPOLARISING MUSCLE RELAXANTS and SUXAMETHONIUM
- Parasympathomimetics: polymyxins antagonise effects of NEOSTIGMINE and PYRIDOSTIGMINE
- Vaccines: antibacterials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Polysaccharide-Iron Complex see Iron salts
Polystyrene Sulfonate Resins
- Antacids: risk of intestinal obstruction when polystyrene sulfonate resins given with ALUMINUM HYDROXIDE; risk of metabolic alkalosis when polystyrene sulfonate resins given with ORAL MAGNESIUM SALTS
- Thyroid Hormones: polystyrene sulfonate resins reduce absorption of LEVOTHYROXINE

Pomalidomide
- Antidepressants: plasma concentration of pomalidomide increased by FLUVOXAMINE

Ponatinib (continued)
- Antidepressants: plasma concentration of ponatinib possibly reduced by ST JOHN’S WORT—manufacturer of ponatinib advises avoid concomitant use
- Antiepileptics: plasma concentration of ponatinib possibly reduced by CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYTOIN and PRIMIDONE—manufacturer of ponatinib advises avoid concomitant use
- Antifungals: plasma concentration of ponatinib increased by KETOCONAZOLE; plasma concentration of ponatinib possibly increased by ITRACONAZOLE and VORICONAZOLE—consider reducing initial dose of ponatinib (see under Ponatinib, p. 814)
- Antipsychotics: avoid concomitant use of cytoxicotins with CLOzapine (increased risk of agranulocytosis)
- Antivirals: plasma concentration of ponatinib possibly increased by INDINAVIR, RITONAVIR and SAQUINAVIR—consider reducing initial dose of ponatinib (see under Ponatinib, p. 814)

Ponatinib
- Antibacterials: plasma concentration of ponatinib possibly increased by CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYTOIN and PRIMIDONE—manufacturer of ponatinib advises avoid concomitant use
- Anticonvulsants: possible increased risk of bleeding when prasugrel given with NSAIDS
- Anticoagulants: possible increased risk of bleeding when prasugrel given with COUMARINS or PHENINDIONE
- Clopidogrel: possible increased risk of bleeding when prasugrel given with CLOPIDOGREL
- Pravastatin see Statins
Praziquantel
- Antibacterials: plasma concentration of praziquantel reduced by RIFAMPICIN—avoid concomitant use
- Antiepileptics: plasma concentration of praziquantel reduced by CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYTOIN and PRIMIDONE—consider increasing praziquantel dose when given for systemic infections
- Antifungals: plasma concentration of praziquantel increased by KETOCONAZOLE

Potassium Aminobenzoate see Antifungals, Triazole
Potassium Canrenoate see Diuretics
Potassium Citrate see Potassium Salts
Potassium Chloride see Potassium Salts
Potassium Salts
- Notes: Includes salt substitutes
  - ACE Inhibitors: increased risk of severe hyperkalaemia when potassium salts given with ACE INHIBITORS
  - Alikiren: increased risk of hyperkalaemia when potassium salts given with ALISKIREN
  - Angiotensin-II Receptor Antagonists: increased risk of hyperkalaemia when potassium salts given with ANGIOTENSIN-II RECEPTOR ANTAGONISTS
  - Antibacterials: avoid concomitant use of potassium citrate with METHENAMINE
  - Ciclosporin: increased risk of hyperkalaemia when potassium salts given with CICLOSPORIN
  - Diuretics: increased risk of hyperkalaemia when potassium salts given with POTASSIUM-SPARING DIURETICS AND ALDOSTERONE ANTAGONISTS
  - Tacrolimus: increased risk of hyperkalaemia when potassium salts given with TACROLIMUS
  - Ulcer-healing Drugs: avoidance of potassium citrate advised by manufacturer of SUCRALFATE

Pramipexole
- Antipsychotics: manufacturer of pramipexole advises avoid concomitant use of ANTIPSYCHOTICS (antagonism of effect)
- Memantine: effects of dopaminergics possibly enhanced by MEMANTINE
- Methyl dopa: antiparkinsonian effect of dopaminergics antagonised by METHYLDOPA
- Ulcer-healing Drugs: excretion of pramipexole reduced by CIMETIDINE (increased plasma concentration)

Prasugrel
- Analgesics: possible increased risk of bleeding when prasugrel given with NSAIDS
- Anticoagulants: possible increased risk of bleeding when prasugrel given with COUMARINS or PHENINDIONE
- Clopidogrel: possible increased risk of bleeding when prasugrel given with CLOPIDOGREL

Praziquantel see Antacids
Prazosin
- Antihypertensives: plasma concentration of prazosin increased by CLOzapine (increased risk of agranulocytosis)
- Antipsychotics: avoid concomitant use of cytoxicotins with CLOzapine (increased risk of agranulocytosis)
- Antivirals: plasma concentration of praziquantel increased by INDINAVIR, RITONAVIR and SAQUINAVIR—consider reducing initial dose of praziquantel (see under Praziquantel, p. 814)
- Antipsychotics: avoid concomitant use of cytoxicotins with CLOzapine (increased risk of agranulocytosis)
Praziquantel (continued)
- Antimalarials: plasma concentration of praziquantel reduced by chloroquine—consider increasing praziquantel dose when given for systemic infections
- Corticosteroids: plasma concentration of praziquantel possibly reduced by continuous use of dexamethasone
- Grapefruit juice: plasma concentration of praziquantel increased by grapefruit juice
- Ulcer-healing Drugs: plasma concentration of praziquantel increased by cimetidine

Prazosin
- See Alpha-blockers

Prednisolone
- See Corticosteroids

Prednisone
- See Corticosteroids

Pregabalin
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRI and tricyclics (convulsive threshold lowered)
- Antimarial: anticonvulsant effect of antiepileptics antagonised by antipsychotics
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by antipsychotics (convulsive threshold lowered)
- Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat

Prilocaine
- Anti-arythmics: increased myocardial depression when prilocaine given with anti-arythmics
- Antibacterials: increased risk of methaemoglobinemia when prilocaine given with sulphonamides

Primafine
- Antimalarials: avoidance of antimalarials advised by manufacturer of arteether with lumefantrine
- Histamine: avoidance of antimalarials advised by manufacturer of histamine
- Mepacrine: plasma concentration of primaquine increased by primaquine increased by methaemoglobinaemia when prilocaine given with sulphonamides

Primidone
- Antidepressants: possible increased risk of convulsions when antiepileptics given with antidepressants
- Ulcer-healing Drugs: possible increased risk of convulsions when antiepileptics given with ulcer-healing drugs
- Anticonvulsant effect of antiepileptics antagonised by antiepileptics given with antiepileptics

Primidone (continued)
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRI and tricyclics (convulsive threshold lowered); plasma concentration of primidone possibly reduced by St John’s Wort—avoid concomitant use; primidone possibly accelerates metabolism of tricyclics (convulsive threshold lowered); plasma concentration of primidone possibly reduced by alcohol—avoid concomitant use
- Antiepileptics: plasma concentration of primidone possibly increased by carbamazepine; primidone possibly reduces plasma concentration of ethosuximide, rufinamide and topiramate; plasma concentration of primidone often increased by fosphenytoin and phenytoin, plasma concentration of fosphenytoin and phenytoin often reduced but may be increased; primidone reduces plasma concentration of lamotrigine, tiagabine and zonisamide; plasma concentration of primidone increased by omeprazole and valproic acid (also plasma concentration of sodium valproate and valproic acid reduced); plasma concentration of primidone increased by stavudine
- Antifungals: primidone possibly reduces plasma concentration of voriconazole and posaconazole; primidone possibly reduces plasma concentration of voriconazole—avoid concomitant use; primidone reduces absorption of griseofulvin (reduced effect)
- Antiarrhythmics: avoidance of primidone advised by manufacturer of artemether with piperaquine; anticonvulsant effect of antiepileptics antagonised by mefloquine
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by antipsychotics (convulsive threshold lowered); primidone accelerates metabolism of haloperidol (reduced plasma concentration); plasma concentration of both drugs reduced when primidone given with haloperidol; plasma concentration of both drugs reduced when primidone given with chlorpromazine; primidone possibly reduces plasma concentration of aripiprazole (avoid concomitant use or consider increasing the dose of aripiprazole—consult aripiprazole product literature); primidone possibly reduces plasma concentration of clozapine; primidone possibly reduces plasma concentration of lurasidone—avoid concomitant use
- Antiarrhythmics: plasma concentration of abacavir, dolutegravir, fosamprenavir, indinavir, lopinavir and saquinavir; avoidance of primidone advised by manufacturer of boceprevir and rilpivirine (plasma concentration of boceprevir and rilpivirine possibly reduced); primidone possibly reduces plasma concentration of daclatasvir and simprevir—manufacturer of daclatasvir and simprevir advises avoid concomitant use; avoidance of primidone advised by manufacturer of elvitegravir, etravirine, fosofomivir and telaprevir
- Anxiolytics and Hypnotics: increased sedative effect when primidone given with anxiolytics and hypnotics; primidone often reduces plasma concentration of clonazepam
- Antiretrovirals: primidone possibly reduces plasma concentration of abacavir, darunavir, fosamprenavir, indinavir, lopinavir and saquinavir; avoidance of primidone advised by manufacturer of boceprevir and rilpivirine (plasma concentration of boceprevir and rilpivirine possibly reduced); primidone possibly reduces plasma concentration of daclatasvir and simprevir—manufacturer of daclatasvir and simprevir advises avoid concomitant use; avoidance of primidone advised by manufacturer of elvitegravir, etravirine, fosofomivir and telaprevir
- Antivirals: plasma concentration of abacavir, dolutegravir, fosamprenavir, indinavir, lopinavir and saquinavir; avoidance of primidone advised by manufacturer of boceprevir and rilpivirine (plasma concentration of boceprevir and rilpivirine possibly reduced); primidone possibly reduces plasma concentration of daclatasvir and simprevir—manufacturer of daclatasvir and simprevir advises avoid concomitant use; avoidance of primidone advised by manufacturer of elvitegravir, etravirine, fosofomivir and telaprevir
- Anticoagulants: plasma concentration of praziquantel possibly reduced by warfarin and rivaroxaban—manufacturer of rivaroxaban advises monitor for signs of thrombosis
- Antidepressants: primidone possibly reduces plasma concentration of reboxetine; primidone reduces plasma concentration of paroxetine; primidone accelerates metabolism of mianserin (reduced plasma concentration);
Interactions

Appendix 1

Primidone (continued)

- Ciclosporin: primidone accelerates metabolism of

  Ciclosporin (reduced plasma concentration)

- Cobicistat: primidone possibly reduces plasma concentration of

  Cobicistat — manufacturer of cobicistat advises avoid concomitant use

- Corticosteroids: primidone accelerates metabolism of

  CORTICOSTEROIDS (reduced effect)

- Cytotoxics: primidone possibly decreases plasma concentration of

  Antitumor agents (increase dose of antitinb—consult antitinb product literature); primidone possibly reduces plasma concentration of

  Bortezomib, Bosutinib, Crizotinib and Ponatinib — manufacturer of bortezomib, bosutinib, crizotinib and ponatinib advises avoid concomitant use;

  primidone possibly reduces plasma concentration of

  Carbamazepine, Fosphenytoin, Phenobarbital, Phenytoin and Primidone

- Antipsychotics: avoid concomitant use of cytoxotics with

  clozapine (increased risk of agranulocytosis)

- Cardiac Glycosides: procainamide possibly reduces absorption of

  DigiToxin tablets

Procarbazine see Antipsychotics

Procyclidine see Antimuscarinics

Progesterone see Progestogens

Progestogens

- Antibacterials: plasma concentration of dienogest increased by

  Erythromycin; metabolism of progestogens accelerated by

  Rifampicin (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see

  Contraceptive Interactions in BNF)

- Anticoagulants: progestogens may enhance or reduce anticoagulant effect of Coumarins; progestogens antagonise anticoagulant effect of

  Phenindione

- Antidepressants: concomitant use of progestogens reduced by

  St John’s Wort (avoid concomitant use)

- Antidiabetics: progestogens antagonise hypoglycaemic effect of

  Antidiabetics

- Antileptics: metabolism of progestogens accelerated by

  Carbamazepine, Edicarbazepine, Fosphenytoin, Oxcarbazepine, Perampanel, Phenobarbital, Phenytoin, Primidone, Rufinamide and Topiramate (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see

  Contraceptive Interactions in BNF); desogestrel possibly increases plasma concentration of

  Lamotrigin

- Antifungals: progestogens possibly increase plasma concentration of Voriconazole; anecdotal reports of contraceptive failure and menstrual irregularities when progestogens given with

  Griseofulvin; occasional reports of breakthrough bleeding when progestogens used for contraception given with

  Terbinafine

- Antivirals: plasma concentration of norethisterone increased by

  Atazanavir; plasma concentration of drospirenone increased by

  Boceprevir (increased risk of toxicity); contraceptive effect of progestogens possibly reduced by

  Efavirenz; plasma concentration of norgestimate increased by

  Elvitegravir; metabolism of progestogens accelerated by

  Nevirapine (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see

  Contraceptive Interactions in BNF)

- Anxiolytics and Hypnotics: progestogens possibly increase plasma concentration of Chloridiazepoxide, Diazepam and

  Nitrazen; progestogens possibly reduce plasma concentration of Darzapem, Oxazepam and Remazepam

- Aprepitant: possible contraceptive failure of hormonal

  contraceptives containing progestogens when given with

  Aprepitant (alternative contraception recommended)

- Bosentan: possible contraceptive failure of hormonal

  contraceptives containing progestogens when given with

  Bosentan (alternative contraception recommended)

- Ciclosporin: progestogens possibly increase plasma concentration of

  Ciclosporin

- Cobicistat: plasma concentration of norgestimate increased by

  Cobicistat

- Vitamins: primidone possibly increases requirements for

  Alfalcacidol, Calcitriol, Colecalciferol, Dihydrotachysterol, Ergocalciferol, Paricalcitol or Vitamin D

Procarbazine: alcohol: disulfiram-like reaction when procarbazine given with

Alcohol

Antiepileptics: manufacturer of procarbazine advises possible increased risk of hypersensitivity reactions when given with

Carbamazepine, Fosphenytoin, Phenobarbital, Phenytoin and Primidone

Primidone

- Antipsychotics: avoid concomitant use of cytoxotics with

  Clozapine (increased risk of agranulocytosis)

- Cardiac Glycosides: procainamide possibly reduces absorption of

  DigiToxin tablets

Procarbazine see Antipsychotics

Procyclidine see Antimuscarinics

Progesterone see Progestogens
**Propafenone**

- **Antivirals (continued)**
  - propafenone advised by manufacturer of **CRIZOTINIB** and **VEMURAFINIB**; possible reduced contraceptive effect of hormonal contraceptives containing propafenone advised by manufacturer of **DABRAFENIB** (alternative contraception recommended)
  - Diuretics: risk of hyperkalaemia when drosperine given with **POTASSIUM-SPARING DIURETICS AND ALDOSTERONE ANTAGONISTS** (possibility serum potassium during first cycle)
  - Dopaminergics: propafenone increase plasma concentration of **SELEGILINE**—manufacturer of selegiline advises avoid concomitant use
  - Fosaprepitant: possible contraceptive failure of hormonal contraceptives containing propafenone when given with **FOSAPREPITANT** (alternative contraception recommended)
  - Lipid-regulating Drugs: plasma concentration of norethisterone increased by **ATORVASTATIN**; plasma concentration of active metabolite of norgestimate increased by **ROSUVASTATIN**; plasma concentration of norgestrel increased by **ROSUVASTATIN**
  - Muscle Relaxants: propafenone possibly increased by **PANTOPRAZOLE**; plasma concentration of norgestrel increased by **ROSUVASTATIN**
  - Antihistamines: increased risk of ventricular arrhythmias when propafenone given with **CITALOPRAM**; increased risk of ventricular arrhythmias when propafenone administered together with **PROPRANOLOL** and **METOPROLOL**; increased risk of ventricular arrhythmias when propafenone given with **OMEPRAZOLE**
  - Anticoagulants: increased risk of ventricular arrhythmias when propafenone given with **OMEPRAZOLE**
  - Antimuscarinics: increased risk of ventricular arrhythmias when propafenone given with **OXYTOCIN**
  - Other: increased risk of ventricular arrhythmias when propafenone given with **PROPAINE**
  - Propantheline: increased risk of ventricular arrhythmias when propafenone given with **PROPAINE**
  - Ulcer-healing Drugs: plasma concentration of propafenone possibly increased by **CIMETIDINE**

**Propafenone**

- **Antivirals**: propafenone advised by manufacturer of **TELAPREVIR** (risk of ventricular arrhythmias)
  - **Beta-blockers**: increased myocardial depression when antithrombinics given with **BETA-BLOCKERS**; propafenone increases plasma concentration of **METOPROLOL** and **PROPRANOLOL**
  - **Cardiac Glycosides**: propafenone increases plasma concentration of **DIGOXIN** (halve dose of digoxin)
  - Ciclosporin: propafenone possibly increases plasma concentration of **CICLOSPORIN**
  - Parasympathomimetics: propafenone possibly antagonises effects of **NEOSTIGMINE** and **PYRIDOSTIGMINE**
  - Thalidomide: propafenone increases plasma concentration of **THEOPHYLLINE**
  - Ulcer-healing Drugs: plasma concentration of propafenone increased by **CIMETIDINE**

**Propafenone**

- **Antifungals**: propafenone advised by manufacturer of **FLUCONAZOLE** and **KALENZOLE**; plasma concentration of norgestrel increased by **ROSUVASTATIN**
  - **Benzodiazepines**: increased risk of ventricular arrhythmias when propafenone given with **BENZODIAZEPINES**
  - **Protein Kinase Inhibitors**: propafenone increases plasma concentration of **ANGIOTENSIN-II RECEPTOR ANTAGONISTS**
  - **Beta-blockers**: increased hypertensive effect when alprostadil given with **BETA-BLOCKERS**
  - **Calcium-channel Blockers**: increased hypertensive effect when alprostadil given with **CALCIMUS-CHANNEL BLOCKERS**
  - Clonidine: increased hypertensive effect when alprostadil given with **CLONIDINE**
  - Diazoxide: increased hypertensive effect when alprostadil given with **DIAZOXIDE**
  - Diuretics: increased hypertensive effect when alprostadil given with **DIURETICS**
  - Methyldopa: increased hypertensive effect when alprostadil given with **METHYLDOPA**
  - Moxonidine: increased hypertensive effect when alprostadil given with **MOXONIDINE**
  - Nitrates: increased hypertensive effect when alprostadil given with **NITRATES**
  - Oxytocin: prostaglandins potentiate uterotonie effect of **OXYTOCIN**
  - Vasodilator Antihypertensives: enhanced hypertensive effect when alprostadil given with **HYDRAZALIN** and **MINOXIDIL**

**Propanolol**

- Beta-blockers: increased anticoagulant effect of **HORMONAL CONTRACEPTIVES** containing progestogens when given with **PROPAINE**
  - Coagulants: increased risk of hyperkalaemia when propafenone given with **WARFARIN**
  - **Protein Kinase Inhibitors**: propafenone increases plasma concentration of **ANGIOTENSIN-II RECEPTOR ANTAGONISTS**
  - **Beta-blockers**: increased hypertensive effect when alprostadil given with **BETA-BLOCKERS**
  - **Calcium-channel Blockers**: increased hypertensive effect when alprostadil given with **CALCIMUS-CHANNEL BLOCKERS**
  - Clonidine: increased hypertensive effect when alprostadil given with **CLONIDINE**
  - Diazoxide: increased hypertensive effect when alprostadil given with **DIAZOXIDE**
  - Diuretics: increased hypertensive effect when alprostadil given with **DIURETICS**
  - Methyldopa: increased hypertensive effect when alprostadil given with **METHYLDOPA**
  - Moxonidine: increased hypertensive effect when alprostadil given with **MOXONIDINE**
  - Nitrates: increased hypertensive effect when alprostadil given with **NITRATES**
  - Oxytocin: prostaglandins potentiate uterotonie effect of **OXYTOCIN**
  - Vasodilator Antihypertensives: enhanced hypertensive effect when alprostadil given with **HYDRAZALIN** and **MINOXIDIL**

**Prostaglandins**

- **ACE Inhibitors**: enhanced hypertensive effect when alprostadil given with **ACE INHIBITORS**
  - Adrenergic Neurone Blockers: enhanced hypertensive effect when alprostadil given with **ADRENERGIC NEURONE BLOCKERS**
  - Alpha-blockers: enhanced hypertensive effect when alprostadil given with **ALPHA-BLOCKERS**
  - Angiotensin-II Receptor Antagonists: enhanced hypertensive effect when alprostadil given with **ANGIOTENSIN-II RECEPTOR ANTAGONISTS**
  - Beta-blockers: increased hypertensive effect when alprostadil given with **BETA-BLOCKERS**
  - Calcium-channel Blockers: enhanced hypertensive effect when alprostadil given with **CALCIMUS-CHANNEL BLOCKERS**
  - Clonidine: enhanced hypertensive effect when alprostadil given with **CLONIDINE**
  - Diazoxide: enhanced hypertensive effect when alprostadil given with **DIAZOXIDE**
  - Diuretics: enhanced hypertensive effect when alprostadil given with **DIURETICS**
  - Moxonidine: increased hypertensive effect when alprostadil given with **MOXONIDINE**
  - Nitrates: increased hypertensive effect when alprostadil given with **NITRATES**
  - Oxytocin: prostaglandins potentiate uterotonie effect of **OXYTOCIN**
  - Vasodilator Antihypertensives: enhanced hypertensive effect when alprostadil given with **HYDRAZALIN** and **MINOXIDIL**

**Protein Kinase Inhibitors**

- **Antacids**: absorption of lansoprazole possibly reduced by **ANTACIDS**
  - **Antibacterials**: plasma concentration of both drugs increased when omeprazole given with **CLARITHROMYCIN**
  - **Anticoagulants**: pantoprazole might enhance the anticoagulant effect of **COUMARINS**; esomeprazole and omeprazole possibly enhance anticoagulant effect of **COUMARINS**
  - **Antidepressants**: omeprazole increases plasma concentration of **ESCITALOPRAM**; plasma concentration of omeprazole possibly reduced by **ST JOHN’S WORT**
  - **Antiepileptics**: omeprazole possibly enhances effects of **FOSFENYTIOIN** and **PHENYTOIN**; esomeprazole enhances effects of **FOSFENYTIOIN** and **PHENYTOIN**
  - **Antifungals**: proton pump inhibitors reduce absorption of **ITRACONAZOLE** and **KETOCONAZOLE**; esomeprazole reduces plasma concentration of **POSACONAZOLE**—manufacturer of posaconazole suspension advises avoid concomitant use; lansoprazole, omeprazole, pantoprazole and rabeprazole
Pyrimethamine (continued)
- Cytotoxics: pyrimethamine increases antifolate effect of
  - METHOTREXATE and PEMETREXED
- Histamine: avoidance of antimalarials advised by manufacturer of HISTAMINE
- Vaccines: antimalarials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Quetiapine see Antipsychotics

Quinagolide
- Memantine: effects of dopaminergics possibly enhanced by
  - MEMANTINE
- Methyldopa: antiparkinsonian effect of dopaminergics antagonised by METHYLDOPA

Quinapril see ACE Inhibitors

Quinine
- Anti-arrhythmics: increased risk of ventricular arrhythmias when quinine given with
  - AMIODARONE—avoid concomitant use; quinine increases plasma concentration of
  - FLECAINIDE
- Antibacterials: increased risk of ventricular arrhythmias when quinine given with
  - NORFLOXACIN—avoid concomitant use; plasma concentration of quinine increased by
  - PRIMAPRON
- Anticoagulants: plasma concentration of both drugs increased when quinine given with
  - WARFARIN
- Antidepressants: possible increased risk of ventricular arrhythmias when quinine given with
  - CITOLOPRAM or
  - ESCITALOPRAM—avoid concomitant use
- Antimalarials: avoidance of antimalarials advised by manufacturer of
  - ARTEMETHER WITH LUMEFANTRINE; increased risk of ventricular arrhythmias when quinine given with
  - RITONAVIR (increased risk of toxicity); increased risk of ventricular arrhythmias when quinine given with
  - SAQUINAVIR—avoid concomitant use
- Antipsychotics: increased risk of ventricular arrhythmias when quinine given with
  - AMIODARONE—avoid concomitant use; possible increased risk of ventricular arrhythmias when quinine given with
  - DISOPYRAMIDE; increased risk of ventricular arrhythmias when quinine given with
  - MELOQUIN (but should not prevent the use of intravenous quinine in severe cases)
- Cardiac Glycosides: quinine increases plasma concentration of
  - DIGOXIN
- Dopaminergics: quinine possibly increases plasma concentration of
  - AMANTADINE
- Histamine: avoidance of antimalarials advised by manufacturer of
  - HISTAMINE
- Muscle Relaxants: quinine possibly increases effects of
  - SUXAMETHONIUM
- Ulcer-healing Drugs: metabolism of quinine inhibited by
  - CIMETIDINE (increased plasma concentration)
- Vaccines: antimalarials inactivate ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Quinolones
- Aminoglycins: possible increased risk of convulsions when quinolones given with
  - AMINOPHYLLINE; ciprofloxacin and norfloxacin increase plasma concentration of
  - AMINOPHYLLINE
- Analogics: possible increased risk of convulsions when quinolones given with
  - PROCAINAMIDE
- Anti-arrhythmics: increased risk of ventricular arrhythmias when levofloxacin or moxifloxacin given with
  - AMIODARONE—avoid concomitant use; possible increased risk of ventricular arrhythmias when moxifloxacin given with
  - DISOPYRAMIDE—avoid concomitant use
- Antipsychotics: increased risk of ventricular arrhythmias when moxifloxacin given with
  - PHENOTHIAZINE—avoid concomitant use; ciprofloxacin possibly increases plasma concentration of
Quinolones

- **Antibacterials** (continued)
  - Concentration of **Bedaquiline**—avoid concomitant use if ciprofloxacin given for more than 14 days; avoidance of moxifloxacin advised by manufacturer of **Bedaquiline**; increased risk of ventricular arrhythmias when moxifloxacin given with **Delamanid**; effects of nalidixic acid possibly antagonised by **Nitrofurantoin**; possible increased risk of ventricular arrhythmias when moxifloxacin given with **Telithromycin**.
  - **Anticoagulants**: nalidixic acid, norfloxacin and ofloxacin enhance anticoagulant effect of **Coumarins**; ciprofloxacin and levofloxacin possibly enhance anticoagulant effect of **Coumarins**; levofloxacin possibly enhances anticoagulant effect of **Phenindione**.
  - **Antihistamines**: increased risk of ventricular arrhythmias when moxifloxacin given with **Mizolastine**—avoid concomitant use.
  - **Antimalarials**: avoidance of quinolones advised by manufacturer of **Artemether with Lumefantrine**; avoidance of moxifloxacin advised by manufacturer of **ArtemiNom with Plerelarquine** (possible risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when moxifloxacin given with **Tricyclines**—avoid concomitant use.
  - **Antipsychotics**: increased risk of ventricular arrhythmias when moxifloxacin given with **Benperidol**—manufacturer of benperidol advises avoid concomitant use; increased risk of ventricular arrhythmias when moxifloxacin given with **Droperidol**, **Haloperidol**, **Phenothiazines**, **Ripamide** or **Zuclopenthixol**—avoid concomitant use; ciprofloxacin increases plasma concentration of **Clozapine**; ciprofloxacin possibly increases plasma concentration of **Danazol**.
  - **Antivirals**: manufacturer of norfloxacin advises give **Didanosine** at least 2 hours before or after norfloxacin; increased risk of ventricular arrhythmias when moxifloxacin given with **Saquinavir**—avoid concomitant use.
  - **Beta-blockers**: increased risk of ventricular arrhythmias when moxifloxacin given with **Sotalol**—avoid concomitant use; calcium salts: absorption of ciprofloxacin reduced by **Calcium Salts**.
  - **Ciclosporin**: increased risk of nephrotoxicity when quinolones given with **Ciclosporin**.
  - **Clapodogrel**: ciprofloxacin possibly reduces antiplatelet effect of **Clapodogrel**.
  - **Cytotoxics**: nalidixic acid increases risk of **Mephalan** toxicity; ciprofloxacin possibly reduces excretion of **Methotrexate** (increased risk of toxicity); possible increased risk of ventricular arrhythmias when moxifloxacin given with **Bosutinib**; ciprofloxacin possibly increases the plasma concentration of **Bosutinib**—manufacturer of bosutinib advises avoid or consider reducing dose of bosutinib; ciprofloxacin increases plasma concentration of **Erlotinib**; ciprofloxacin possibly increases the plasma concentration of **Ibrutinib**—reduce dose of ibrutinib (see under ibrutinib, p. 809); possible increased risk of ventricular arrhythmias when moxifloxacin given with **Vanetanib**—avoid concomitant use; increased risk of ventricular arrhythmias when levofloxacin or moxifloxacin given with **Arsenic Trioxide**.

Quinolones (continued)

- **Dairy Products**: absorption of ciprofloxacin and norfloxacin reduced by **Dairy Products**.
- **Dopaminergics**: ciprofloxacin increases plasma concentration of **Rasagiline**; ciprofloxacin inhibits metabolism of **Ropinirole** (increased plasma concentration).
- **HIV**-receptor Agonists: quinolones possibly inhibit metabolism of **Zolmitriptan** (reduce dose of zolmitriptan).
- **Iron Salts**: absorption of ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin reduced by oral **Iron Salts**; absorption of norfloxacin reduced by oral **Iron Salts** (give at least 2 hours apart).
- **Lanthanum**: absorption of quinolones possibly reduced by **Lanthanum** (give at least 2 hours before or 4 hours after lanthanum.
- **Muscle Relaxants**: ciprofloxacin increases plasma concentration of **Tizanidine**—risk of toxicity—avoid concomitant use; norfloxacin possibly increases plasma concentration of **Tizanidine**. (increased risk of toxicity).
- **Mycofenolate**: norfloxacin possibly reduces bioavailability of **Mycofenolate**.
- **Pentamidine Tetrionate**: increased risk of ventricular arrhythmias when moxifloxacin given with **Pentamidine Tetrionate**—avoid concomitant use.
- **Pifendine**: ciprofloxacin increases plasma concentration of **Pifendine**—see under Pifendine, p. 260.
- **Sevelamer**: bioavailability of ciprofloxacin reduced by **Sevelamer**.
- **Streptomycin Ranelate**: absorption of quinolones reduced by **Streptomycin Ranelate** (manufacturer of streptomycin ranelate advises avoid concomitant use).
- **Theophylline**: possible increased risk of convulsions when quinolones given with **Theophylline**; ciprofloxacin and norfloxacin increase plasma concentration of **Theophylline**.
- **Ulcer-healing Drugs**: absorption of ciproflxacin, levofloxacin, moxifloxacin and ofloxacin reduced by **Sucralfate**; absorption of norfloxacin reduced by **Sucralfate** (give at least 2 hours apart).
- **Vaccines**: antibacterials inactivate **Oral Typhoid Vaccine**—see under Typhoid Vaccine in BNF.
- **Zinc**: absorption of ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin reduced by **Zinc**; absorption of norfloxacin reduced by **Zinc** (give at least 2 hours apart).

**Rabeprazole** see Proton Pump Inhibitors

**Rabies Vaccine** see Vaccines

**Ranitidine** see Histamine H2-antagonists

**Ranolazine** see Histamine H2-antagonists

**Ranitidine** see Histamine H2-antagonists

**Ranolazine** see Histamine H2-antagonists

**Ranolazine** see Histamine H2-antagonists

**Ranolazine** see Histamine H2-antagonists

**Ranolazine** see Histamine H2-antagonists

**Ranolazine** see Histamine H2-antagonists

**Ranolazine** see Histamine H2-antagonists
Ranolazine (continued)

- Antimicrobials: plasma concentration of ranolazine possibly increased by clarithromycin and telithromycin—manufacturer of ranolazine advises avoid concomitant use; plasma concentration of ranolazine reduced by rifampicin—manufacturer of ranolazine advises avoid concomitant use
- Antidepressants: plasma concentration of ranolazine increased by paroxetine
- Antifungals: plasma concentration of ranolazine increased by ketoconazole—avoid concomitant use; plasma concentration of ranolazine possibly increased by itraconazole, posaconazole and voriconazole—manufacturer of ranolazine advises avoid concomitant use
- Antivirals: plasma concentration of ranolazine possibly increased by atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir and tipranavir—manufacturer of ranolazine advises avoid concomitant use
- Beta-blockers: manufacturer of ranolazine advises avoid concomitant use with amsertiol
- Calcium-channel blockers: plasma concentration of ranolazine increased by diltiazem and verapamil (consider reducing dose of ranolazine)
- Cardiac Glycosides: ranolazine increases plasma concentration of digoxin
- Cisplatin: plasma concentration of both drugs may increase when ranolazine given with cisplatin
- Grapefruit juice: plasma concentration of ranolazine possibly increased by grapefruit juice—manufacturer of ranolazine advises avoid concomitant use
- Lipid-regulating Drugs: ranolazine increases plasma concentration of simvastatin (see under simvastatin, p. 181); separating administration from ranolazine by 12 hours advised by manufacturer of lovastatin
- Tacrolimus: ranolazine increases plasma concentration of tacrolimus

Rasagiline

- NOTE Rasagiline is a MAO-B inhibitor
- Analgesics: avoid concomitant use of rasagline with dextromethorphan; risk of CNS toxicity when rasagline given with pethidine (avoid pethidine for 2 weeks after rasagline)
- Antimicrobials: plasma concentration of rasagline increased by ciprofloxacin
- Antidepressants: after stopping rasagline do not start fluoxetine for 2 weeks, also rasagline should not be started until at least 5 weeks after stopping fluoxetine; after stopping rasagline do not start fluvoxamine for 2 weeks; risk of hypertensive crisis when rasagline given with MAOIs, avoid MAOIs for at least 2 weeks after stopping rasagline; increased risk of CNS toxicity when rasagline given with SSRIs or tricyclics
- Dopaminergics: plasma concentration of rasagline possibly reduced by entacapone
- Memantine: effects of dopaminergics possibly enhanced by memantine
- Methyldopa: antiparkinsonian effect of dopaminergics antagonised by methyldopa
- Sympathomimetics: avoid concomitant use of rasagline with sympathomimetics

Reboxetine (continued)

- Antimalarials: avoidance of antidepressants advised by manufacturer of artemether with lumefantrine and artemisinin with piperaquine
- Atomoxetine: possible increased risk of convulsions when antidepressants given with atomoxetine
- Diuretics: possible increased risk of hypokalaemia when reboxetine given with loop diuretics or thiazides and related diuretics
- Ergot Alkaloids: possible risk of hypertension when reboxetine given with ergotamine

Regorafenib

- Analgesics: manufacturer of regorafenib advises avoid concomitant use with mefenamic acid
- Antibacterials: plasma concentration of regorafenib reduced by rifampicin—manufacturer of regorafenib advises avoid concomitant use
- Anticoagulants: increased risk of bleeding when regorafenib given with warfarin
- Antifungals: plasma concentration of regorafenib increased by ketoconazole—avoid concomitant use
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cytotoxics: regorafenib increases plasma concentration of irinotecan

Remifentanil see Opioid Analgesics

Regapride see Antidiabetics

Retigabine

- Alcohol: increased risk of blurred vision when retigabine given with alcohol
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered)
- Antiepileptics: plasma concentration of retigabine possibly reduced by carbamazepine, fosphenytoin and phenytoin
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by mefloquine
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by antipsychotics (convulsive threshold lowered)
- Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat

Retinoids

- Alcohol: etretinate formed from acitretin in presence of alcohol (increased risk of teratogenicity in women of child-bearing potential)
- Antimicrobials: possible increased risk of benign intracranial hypertension when retinoids given with tetracyclines (avoid concomitant use)
- Anticoagulants: acitretin possibly reduces anticoagulant effect of coumarins
- Antiepileptics: isoretinoin possibly reduces plasma concentration of carbamazepine
- Antifungals: plasma concentration of altretinoin increased by ketoconazole; possible increased risk of tretinoin toxicity when given with fluconazole, ketoconazole and voriconazole
- Cytotoxics: acitretin increases plasma concentration of methotrexate (also increased risk of hepatotoxicity)—avoid concomitant use
- Lipid-regulating Drugs: altretinoin reduces plasma concentration of simvastatin
- Vitamins: risk of hypervitaminosis A when retinoids given with vitamin A—avoid concomitant use

Ribavirin

- Antivirals: effects of ribavirin possibly reduced by abacavir; increased risk of side-effects when ribavirin given with didanosine—avoid concomitant use; increased risk of toxicity when ribavirin given with stavudine; increased risk of anaemia when ribavirin given with zidovudine—avoid concomitant use
- Azathioprine: ribavirin possibly enhances myelosuppressive effects of azathioprine
Rifabutin see Rifamycins
Rifampicin see Rifamycins
Rifamycins
NOTE Interactions do not apply to rifaximin
▶ ACE Inhibitors: rifampicin reduces plasma concentration of
active metabolite of IMIDAPRIL (reduced antihypertensive
effect)
▶ Aliskiren: rifampicin reduces plasma concentration of
ALISKIREN
▶

Ambrisentan: rifampicin possibly increases plasma
concentration of AMBRISENTAN
Aminophylline: rifampicin accelerates metabolism of
AMINOPHYLLINE (reduced plasma concentration)
▶ Analgesics: rifampicin reduces plasma concentration of
CELECOXIB , DICLOFENAC and ETORICOXIB ; rifampicin accelerates
metabolism of ALFENTANIL , CODEINE , FENTANYL , METHADONE
and MORPHINE (reduced effect); rifampicin possibly
accelerates metabolism of OXYCODONE
▶ Angiotensin-II Receptor Antagonists: rifampicin reduces plasma
concentration of LOSARTAN and its active metabolite
▶ Antacids: absorption of rifampicin reduced by ANTACIDS
l Anthelmintics: rifampicin reduces plasma concentration of
l PRAZIQUANTEL —avoid concomitant use
l Anti-arrhythmics: rifamycins accelerate metabolism of
l DISOPYRAMIDE (reduced plasma concentration); rifampicin
reduces plasma concentration of l DRONEDARONE —avoid
concomitant use; rifampicin accelerates metabolism of
l PROPAFENONE (reduced effect)
l Antibacterials: increased risk of side-effects including
neutropenia when rifabutin given with l AZITHROMYCIN ;
rifamycins reduce plasma concentration of CLARITHROMYCIN
and DAPSONE ; plasma concentration of rifabutin increased by
l CLARITHROMYCIN (increased risk of toxicity—reduce rifabutin
dose); plasma concentration of rifabutin possibly increased
by l ERYTHROMYCIN (increased risk of toxicity—reduce
rifabutin dose); rifampicin possibly reduces plasma
concentration of TINIDAZOLE and TRIMETHOPRIM ; rifampicin
reduces plasma concentration of DOXYCYCLINE —consider
increasing dose of doxycycline; rifabutin possibly reduces
plasma concentration of BEDAQUILINE —manufacturer of
bedaquiline advises avoid concomitant use; rifampicin
reduces plasma concentration of l BEDAQUILINE —
manufacturer of bedaquiline advises avoid concomitant use;
rifampicin accelerates metabolism of CHLORAMPHENICOL
(reduced plasma concentration); rifampicin reduces plasma
concentration of l DELAMANID ; increased risk of
hepatotoxicity when rifampicin given with l ISONIAZID ;
rifampicin reduces plasma concentration of LINEZOLID
(possible therapeutic failure of linezolid); rifampicin reduces
plasma concentration of l TELITHROMYCIN (avoid during and
for 2 weeks after rifampicin)
l Anticoagulants: rifampicin possibly reduces plasma
concentration of l APIXABAN —manufacturer of apixaban
advises avoid concomitant use when given for treatment of
deep-vein thrombosis or pulmonary embolism; rifamycins
accelerate metabolism of l COUMARINS (reduced
anticoagulant effect); rifampicin reduces plasma
concentration of l DABIGATRAN —manufacturer of dabigatran
advises avoid concomitant use; rifampicin reduces plasma
concentration of l RIVAROXABAN —manufacturer of
rivaroxaban advises monitor for signs of thrombosis
l Antidiabetics: rifamycins accelerate metabolism of
l TOLBUTAMIDE (reduced effect); rifampicin reduces plasma
concentration of l CANAGLIFLOZIN and NATEGLINIDE ; rifampicin
possibly reduces effects of LINAGLIPTIN ; rifampicin possibly
antagonises hypoglycaemic effect of REPAGLINIDE ; rifamycins
possibly accelerate metabolism of l SULFONYLUREAS (reduced
effect)
l Antiepileptics: rifabutin reduces plasma concentration of
l CARBAMAZEPINE ; rifamycins accelerate metabolism of
l FOSPHENYTOIN and l PHENYTOIN (reduced plasma
concentration); rifampicin reduces plasma concentration of
l LAMOTRIGINE ; plasma concentration of rifampicin possibly
reduced by PHENOBARBITAL and PRIMIDONE
▶

Rifamycins (continued)
l Antifungals: rifampicin accelerates metabolism of
l KETOCONAZOLE (reduced plasma concentration), also plasma
concentration of rifampicin may be reduced by ketoconazole;
plasma concentration of rifabutin increased by
l FLUCONAZOLE (increased risk of uveitis—reduce rifabutin
dose); rifampicin accelerates metabolism of l FLUCONAZOLE
(reduced plasma concentration); rifabutin and rifampicin
reduce plasma concentration of l ITRACONAZOLE —
manufacturer of itraconazole advises avoid concomitant use;
plasma concentration of rifabutin increased by
l POSACONAZOLE (also plasma concentration of posaconazole
reduced); rifampicin reduces plasma concentration of
l POSACONAZOLE and l TERBINAFINE ; plasma concentration of
rifabutin increased by l VORICONAZOLE , also rifabutin reduces
plasma concentration of voriconazole (increase dose of
voriconazole and also monitor for rifabutin toxicity);
rifampicin reduces plasma concentration of l VORICONAZOLE —
avoid concomitant use; rifampicin initially increases and
then reduces plasma concentration of CASPOFUNGIN (consider
increasing dose of caspofungin); plasma concentration of
rifabutin possibly increased by l TRIAZOLES (increased risk of
uveitis—reduce rifabutin dose)
▶ Antihistamines: rifampicin possibly reduces effects of
FEXOFENADINE
l

Antimalarials: avoidance of rifampicin advised by
manufacturer of ARTENIMOL WITH PIPERAQUINE ; rifampicin
reduces plasma concentration of l MEFLOQUINE —avoid
concomitant use; rifampicin reduces plasma concentration of
l

▶
l

l

QUININE

Antimuscarinics: rifampicin reduces plasma concentration of
active metabolite of FESOTERODINE
Antipsychotics: rifampicin accelerates metabolism of
l HALOPERIDOL (reduced plasma concentration); rifabutin and
rifampicin possibly reduce plasma concentration of
l ARIPIPRAZOLE (avoid concomitant use or consider increasing
the dose of aripiprazole—consult aripiprazole product
literature); rifampicin possibly reduces plasma concentration
of CLOZAPINE ; rifampicin reduces plasma concentration of
l LURASIDONE —avoid concomitant use
Antivirals: rifampicin possibly reduces plasma concentration
of ABACAVIR ; plasma concentration of rifabutin increased by
l ATAZANAVIR , l DARUNAVIR , l FOSAMPRENAVIR and
l TIPRANAVIR (reduce dose of rifabutin); rifampicin reduces
plasma concentration of l ATAZANAVIR , l DACLATASVIR ,
l LOPINAVIR , l NEVIRAPINE and l RILPIVIRINE —avoid
concomitant use; avoidance of rifampicin advised by
manufacturer of l BOCEPREVIR (plasma concentration of
boceprevir possibly reduced); rifabutin possibly reduces
plasma concentration of l DACLATASVIR and SIMEPREVIR —
manufacturer of daclatasvir and simeprevir advises avoid
concomitant use; rifampicin significantly reduces plasma
concentration of l DARUNAVIR , l FOSAMPRENAVIR and
l TELAPREVIR —avoid concomitant use; rifampicin reduces the
plasma concentration of l DOLUTEGRAVIR (see under
Dolutegravir, p. 557); rifampicin reduces plasma
concentration of EFAVIRENZ —increase dose of efavirenz;
plasma concentration of rifabutin reduced by EFAVIRENZ —
increase dose of rifabutin; avoidance of rifampicin advised by
manufacturer of l ELVITEGRAVIR , ETRAVIRINE , SOFOSBUVIR and
ZIDOVUDINE ; rifabutin reduces plasma concentration of
l ELVITEGRAVIR also plasma concentration of active
metabolite of rifabutin increased—reduce dose of rifabutin;
plasma concentration of both drugs reduced when rifabutin
given with l ETRAVIRINE ; rifampicin accelerates metabolism of
l INDINAVIR (reduced plasma concentration—avoid
concomitant use); plasma concentration of rifabutin
increased by l INDINAVIR , also plasma concentration of
indinavir decreased (reduce dose of rifabutin and increase
dose of indinavir); rifampicin reduces plasma concentration
of l MARAVIROC and l RALTEGRAVIR —consider increasing dose
of maraviroc and raltegravir; plasma concentration of
rifabutin possibly increased by NEVIRAPINE ; rifabutin
decreases plasma concentration of l RILPIVIRINE (increase
dose of rilpivirine—consult rilpivirine product literature);

Interactions | Appendix 1

Appendix 1 Interactions 1235

BNF 70


Interactions

Interactions

Rifamycins

- Antivirals (continued)
  - Plasma concentration of rifabutin increased by rifomycin reduces plasma concentration of ritonavir, ritonavir significantly reduces plasma concentration of saquinavir, also risk of hepatotoxicity—avoid concomitant use; plasma concentration of rifabutin reduced by saquinavir, ritonavir reduces plasma concentration of simprevir; manufacturer of simprevir advises avoid concomitant use; avoidance of rifabutin advised by manufacturer of ketoconazole and telaprevir, rifabutin possibly reduces plasma concentration of rifampicin—avoid concomitant use.

- Anxiolytics and Hypnotics: rifampicin accelerates metabolism of diazepam, zaleplon (reduced plasma concentration); rifampicin possibly accelerates metabolism of benzodiazepines (reduced plasma concentration); rifampicin possibly accelerates metabolism of buspirone; rifampicin accelerates metabolism of zolpidem (reduced plasma concentration and reduced effect); rifampicin significantly reduces plasma concentration of zopiclone.

- Arterial and Venous Hypertension: rifampicin accelerates metabolism of avanafil.

- Abrepro: rifampicin reduces plasma concentration of aprepitant.

- Atovaquone: avoidance of concomitant rifabutin advised by manufacturer of atovaquone (plasma concentration of both drugs reduced); rifampicin reduces plasma concentration of atovaquone (and concentration of rifampicin increased).

- Avanafil: rifampicin possibly reduces plasma concentration of avanafil—manufacturer of avanafil advises avoid concomitant use.

- Beta-blockers: rifampicin accelerates metabolism of bisoprolol and metoprolol; rifampicin possibly reduces plasma concentration of carvedilol, celiprolol, and metoprolol; rifampicin possibly reduces plasma concentration of oral timolol.

- Bosutinib: rifampicin reduces plasma concentration of bosutinib—avoid concomitant use.

- Calcium-channel blockers: rifampicin possibly reduces plasma concentration of felodipine; rifampicin possibly accelerates metabolism of isradipine and nicardipine (possible significantly reduced plasma concentration); rifampicin accelerates metabolism of diltiazem, nifedipine, nimodipine, and verapamil (plasma concentration significantly reduced).

- Cannabis extract: rifampicin reduces plasma concentration of cannabidiol extract—manufacturer of cannabis extract advises avoid concomitant use.

- Cardiac glycosides: rifampicin possibly reduces plasma concentration of digoxin.

- Ciclosporin: rifampicin accelerates metabolism of ciclosporin (reduced plasma concentration).

- Cobicistat: rifabutin reduces plasma concentration of cobicistat (adjust dose—consult product literature); rifampicin possibly reduces plasma concentration of cobicistat; cobicistat—manufacturer of cobicistat advises avoid concomitant use.

- Corticosteroids: rifamycins accelerate metabolism of corticosteroids (reduced effect).

- Cytotoxics: rifamycin possibly reduces effects of brentuximab vedotin; rifampicin reduces plasma concentration of afatinib, puxolitinib, sorafenib and trabectedin; rifabutin possibly decreases plasma concentration of axitinib (increase dose of axitinib—consult axitinib product literature); rifampicin decreases plasma concentration of axitinib (increase dose of axitinib—consult axitinib product literature); rifabutin possibly reduces plasma concentration of bosutinib, crizotinib, and ponatinib—manufacturer of bosutinib, crizotinib and ponatinib advises avoid concomitant use; rifampicin reduces plasma concentration of bortezomib, bosutinib, cabazitaxel, crizotinib, ponatinib, regorafenib and vanetanib—manufacturer of bortezomib, bosutinib, cabazitaxel, crizotinib, ponatinib, regorafenib and vanetanib—avoid concomitant use.

- Rifamycins (continued)
  - Cytotoxics: regorafenib and vanetanib advises avoid concomitant use; rifampicin reduces plasma concentration of cabozantinib, gefitinib, irubtinib, idelalisib, matuzumab, nilotinib—avoid concomitant use; avoidance of rifampicin advised by manufacturer of dabrafenib, lapatinib and vemurafenib; rifampicin accelerates metabolism of dastatinib (reduced plasma concentration—avoid concomitant use); rifampicin reduces plasma concentration of elotinib and sunitinib (reduced plasma concentration); rifampicin reduces plasma concentration of everolimus (avoid concomitant use or consider increasing the dose of everolimus—consult everolimus product literature); avoidance of rifabutin advised by manufacturer of cabazitaxel, lapatinib, and vemurafenib; rifampicin possibly reduces plasma concentration of eribulin and pazopanib; rifampicin reduces plasma concentration of active metabolite of temsirolimus—avoid concomitant use; rifampicin possibly reduces plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use; avoidance of rifampicin advised by manufacturer of vismodegib (plasma concentration of vismodegib possibly reduced).

- Deferasirox: rifampicin reduces plasma concentration of deferasirox.

- Diuretics: rifampicin reduces plasma concentration of eplerenone—avoid concomitant use.

- Fosaprepitant: rifampicin reduces plasma concentration of fosaprepitant.

- Hormone Antagonists: rifabutin possibly reduces plasma concentration of abiraterone—manufacturer of abiraterone advises avoid concomitant use; rifampicin reduces plasma concentration of abiraterone—manufacturer of abiraterone advises avoid concomitant use; avoidance of rifampicin advised by manufacturer of enzalutamide; rifampicin possibly reduces plasma concentration of exemestane; rifampicin accelerates metabolism of tamoxifen (reduced plasma concentration).

- SHT receptor Antagonists: rifampicin accelerates metabolism of ondansetron (reduced effect).

- Ivafor: rifabutin possibly reduces plasma concentration of iebrafor—manufacturer of ivafor advises avoid concomitant use; rifampicin reduces plasma concentration of ivafor—manufacturer of ivafor advises avoid concomitant use.

- Leflunomide: rifampicin possibly increases plasma concentration of active metabolite of leflunomide.

- Lipid-regulating Drugs: rifampicin possibly reduces plasma concentration of atorvastatin—manufacturer of atorvastatin; rifampicin possibly accelerates metabolism of fluvastatin (reduced effect).

- Macitentan: rifampicin reduces plasma concentration of macitentan—avoid concomitant use.

- Muscle Relaxants: rifampicin possibly reduces plasma concentration of tizanidine.

- Mycophenolate: rifampicin reduces plasma concentration of active metabolite of mycophenolate.

- Nintedanib: rifampicin reduces plasma concentration of nintedanib—avoid concomitant use.

- Oestrogens: rifampicin accelerates metabolism of oestrogens (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF).

- Progestogens: rifamycins accelerate metabolism of progestogens (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF).

- Ranolazine: rifampicin reduces plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use.

- Roflumilast: rifampicin inhibits effects of roflumilast (manufacturer of roflumilast advises avoid concomitant use).

- Sirolimus: rifabutin and rifampicin reduce plasma concentration of sirolimus—avoid concomitant use.
Rilpivirine

- Antacids: rifampicin reduces plasma concentration of TOLVAPTAN.
- Antidiabetics: rifampicin reduces plasma concentration of TADALAFIL.
- Antifungals: rifampicin reduces plasma concentration of TACROLIMUS.
- Antihistaminics: rifampicin reduces plasma concentration of TACROLIMUS.
- Antihypertensives: rifampicin reduces plasma concentration of TADALAFIL.
- Anticoagulants: rifampicin reduces plasma concentration of TELITROMYCIN.
- Antidepressants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiparkinsonians: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidepressants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiepileptics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiemetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihypertensives: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihistaminics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Anticoagulants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidiabetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidepressants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiparkinsonians: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiemetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihypertensives: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihistaminics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Anticoagulants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidiabetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidepressants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiparkinsonians: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiemetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihypertensives: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihistaminics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Anticoagulants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidiabetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidepressants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiparkinsonians: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiemetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihypertensives: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihistaminics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Anticoagulants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidiabetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidepressants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiparkinsonians: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiemetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihypertensives: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antihistaminics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Anticoagulants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidiabetics: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antidepressants: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiparkinsonians: rifampicin reduces plasma concentration of TELTROMYCIN.
- Antiemetics: rifampicin reduces plasma concentration of TELTROMYCIN.
Ritonavir (continued)
- Cilostazol: ritonavir possibly increases plasma concentration of cilostazol (see under Cilostazol, p. 266).
- Colchicine: ritonavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).
- Corticosteroids: ritonavir possibly increases plasma concentration of corticosteroids—increased risk of adrenal suppression; ritonavir possibly increases plasma concentration of budesonide (including inhaled, intranasal, and rectal budesonide)—increased risk of adrenal suppression; ritonavir increases plasma concentration of inhaled and intranasal fluticasone—increased risk of adrenal suppression.
- Cytostatics: ritonavir increases the plasma concentration of afatinib—manufacturer of afatinib advises separating administration of ritonavir by 6 to 12 hours; ritonavir possibly increases plasma concentration of axitinib (reduce dose of axitinib—consult axitinib product literature); ritonavir possibly increases the plasma concentration of bosutinib and cabazitaxel—manufacturer of bosutinib and cabazitaxel advises avoid or consider reducing dose of bosutinib and cabazitaxel; ritonavir possibly increases plasma concentration of cabozantinib and vinblastine; ritonavir possibly increases plasma concentration of crizotinib, everolimus, nilotinib and vinflunine—manufacturer of crizotinib, everolimus, nilotinib and vinflunine advises avoid concomitant use; avoidance of ritonavir advised by manufacturer of dasatinib (plasma concentration of dasatinib possibly increased); ritonavir possibly increases the plasma concentration of ibritinib—reduce dose of ibritinib (see under ibritinib, p. 809); avoidance of ritonavir advised by manufacturer of lapatinib; ritonavir possibly increases plasma concentration of pazopanib (reduce dose of pazopanib); ritonavir possibly increases plasma concentration of ponatinib—consider reducing initial dose of ponatinib (see under Ponatinib, p. 814); manufacturer of ruxolitinib advises dose reduction when ritonavir given with ruxolitinib—consult ruxolitinib product literature; ritonavir possibly increases plasma concentration of docetaxel—manufacturer of docetaxel advises avoid concomitant use or consider reducing docetaxel dose; ritonavir increases plasma concentration of paclitaxel.
- Dapoxetine: avoidance of ritonavir advised by manufacturer of dapoxetine (increased risk of toxicity).
- Diuretics: ritonavir increases plasma concentration of eplerenone—avoid concomitant use.
- Donperidon: possible increased risk of ventricular arrhythmias when ritonavir given with donperidon—avoid concomitant use.
- Ergot Alkaloids: increased risk of ergotism when ritonavir given with ergometrine or ergotamine—avoid concomitant use.
- Fosaprepitant: ritonavir possibly increases plasma concentration of fosaprepitant.
- 5HT1-receptor Agonists: ritonavir increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use.
- Ib Bradine: ritonavir possibly increases plasma concentration of ibradine—avoid concomitant use.
- Lipid-regulating Drugs: possible increased risk of myopathy when ritonavir given with atorvastatin; possible increased risk of myopathy when ritonavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when ritonavir given with simvastatin (avoid concomitant use); avoidance of ritonavir advised by manufacturer of lomitapide (plasma concentration of lomitapide possibly increased).
- Mirabegron: when given with ritonavir avoid or reduce dose of mirabegron in hepatic or renal impairment—see Mirabegron, p. 671.
- Oestrogens: ritonavir accelerates metabolism of oestrogens (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF).
Ritonavir (continued)

- Orlistat: absorption of ritonavir possibly reduced by \*ORLISTAT
- Ranolazine: ritonavir possibly increases plasma concentration of \*RANOLAZINE—manufacturer of ranolazine advises avoid concomitant use
- Ticagrelor: avoidance of ritonavir advised by manufacturer of \*TICAGRELOR
- Sildenafil: ritonavir significantly increases plasma concentration of \*SILDENAFIL—avoid concomitant use
- Symptomimetics: ritonavir possibly increases plasma concentration of \*DEXAMETHASONE
- Sympathomimetics, Beta₂: manufacturer of ritonavir advises avoid concomitant use with \*SALMETEROL
- Tacrolimus: ritonavir possibly increases plasma concentration of \*TACROLISUM
- Tadalafil: ritonavir increases plasma concentration of \*TADALAFIL—manufacturer of tadalafil advises avoid concomitant use
- Theophylline: ritonavir accelerates metabolism of \*THEOPHYLLINE
- Ticagrelor: ritonavir possibly increases plasma concentration of \*TICAGRELOR—manufacturer of ticagrelor advises avoid concomitant use
- Ulipristal: avoidance of ritonavir advised by manufacturer of \*ULIPRISTAL (contraceptive effect of ulipristal possibly reduced)
- Vardenafil: ritonavir increases plasma concentration of \*VARDAFENIL—avoid concomitant use

Rituximab

- Antipsychotics: avoid concomitant use of cytoxics with \*FLUOXAMINE (increased risk of agranulocytosis)
- Vaccines: risk of generalised infections when monoclonal antibodies given with live \*VACCINES—avoid concomitant use

Rivaroxaban

- Analgesics: increased risk of haemorrhage when anticoagulants given with \*INTRAVENTOUS \*DICLOFENAC (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with \*KETOROLAC (avoid concomitant use, including low-dose heparins)
- Anti-arrhythmics: manufacturer of rivaroxaban advises avoid concomitant use with \*DRONEDARONE
- Antibacterials: plasma concentration of rivaroxaban reduced by \*RIFAMPICIN—manufacturer of rivaroxaban advises monitor for signs of thrombosis
- Anticoagulants: increased risk of haemorrhage when rivaroxaban given with other \*ANTICOAGULANTS (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency); increased risk of haemorrhage when other anticoagulants given with \*APIXABAN and \*DABIGATRAN (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)
- Antidepressants: plasma concentration of rivaroxaban possibly reduced by \*ST JOHN’S WORT—manufacturer of rivaroxaban advises monitor for signs of thrombosis
- Antiepileptics: plasma concentration of rivaroxaban possibly reduced by \*CARBAMAZEPINE, \*PHENYTOIN, \*PHENOBARBITAL, \*PHENOTIN and \*PRIMIDONE—manufacturer of rivaroxaban advises monitor for signs of thrombosis
- Antifungals: plasma concentration of rivaroxaban increased by \*KETOCONAZOLE—avoid concomitant use; manufacturer of rivaroxaban advises avoid concomitant use with \*ITRACONAZOLE, \*POSACONAZOLE and \*VICORICAZOLE
- Antivirals: manufacturer of rivaroxaban advises avoid concomitant use with \*ATAZANAVIR, \*DARUNAVIR, \*FOSAMPRENAVIR, \*INDINAVIR, \*SAQUINAVIR and \*TIRAPANAVIR; manufacturers advise avoid concomitant use of rivaroxaban with \*LOPINAVIR; plasma concentration of rivaroxaban increased by \*RITONAVIR—avoid concomitant use
- Cobicistat: anticoagulant effect of rivaroxaban possibly enhanced by \*COBICISTAT—avoid concomitant use

Rivastigmine see Parasympathomimetics

Rizatriptan see 5HT₁-receptor Agonists (under HT)
Rocuronium see Muscle Relaxants

Roflumilast

- Aminophylline: manufacturer of roflumilast advises avoid concomitant use with \*AMINOPHYLLINE
- Antibacterials: effects of roflumilast inhibited by \*RIFAMPICIN (manufacturer of roflumilast advises avoid concomitant use)
- Antidepressants: metabolism of roflumilast inhibited by \*ANTIPSYCHOTICS
- Antiepileptics: effects of roflumilast possibly inhibited by \*CARBAMAZEPINE, \*PHENOBARBITAL, \*PHENOTIN and \*PRIMIDONE (manufacturer of roflumilast advises avoid concomitant use)
- Theophylline: manufacturer of roflumilast advises avoid concomitant use with \*THEOPHYLLINE
- Ulcer-healing Drugs: metabolism of roflumilast inhibited by \*CIMETIDINE

Ropinirole

- Antibacterials: metabolism of ropinirole inhibited by \*CIPROFLOXACIN (increased plasma concentration)
- Antipsychotics: manufacturer of ropinirole advises avoid concomitant use of \*ANTIPSYCHOTICS (antagonism of effect)
- Memantine: effects of dopaminergics possibly enhanced by \*MEMANTINE
- Methyldopa: antiparkinsonian effect of dopaminergics antagonised by \*METHYLDOPA
- Metoclopramide: manufacturer of ropinirole advises avoid concomitant use of \*METOCLOPRAMIDE (antagonism of effect)
- Oestrogens: plasma concentration of ropinirole increased by \*OESTROGENS

Ropivacaine

- Anti-arrhythmics: increased myocardial depression when ropivacaine given with \*ANTIPSYCHOTICS
- Antidepressants: metabolism of ropivacaine inhibited by \*VACCINES—avoid prolonged administration of ropivacaine

Rosuvastatin see Statins

Rotavirus Vaccine see Vaccines

Rotigotine

- Antipsychotics: manufacturer of rotigotine advises avoid concomitant use of \*ANTIPSYCHOTICS (antagonism of effect)
- Memantine: effects of dopaminergics possibly enhanced by \*MEMANTINE
- Methyldopa: antiparkinsonian effect of dopaminergics antagonised by \*METHYLDOPA
- Metoclopramide: manufacturer of rotigotine advises avoid concomitant use of \*METOCLOPRAMIDE (antagonism of effect)

Rufinamide

- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by \*MAOIS and \*TRICYCLIC-RELATED \*ANTIPSYCHOTICS (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by \*SSRIS and \*TRICYCLICS (convulsive threshold lowered)
- Antiepileptics: plasma concentration of both drugs possibly reduced when rufinamide given with \*CARBAMAZEPINE; plasma concentration of rufinamide possibly reduced by \*PHENYTOIN and \*PHENOTIN, also plasma concentration of phenytoin and phenotin possibly increased; plasma concentration of rufinamide possibly increased by \*SODIUM VALPROATE and \*VALPROIC ACID (reduce dose of rufinamide)
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by \*MEFLOQUINE
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by \*ANTIPSYCHOTICS (convulsive threshold lowered)
- Oestrogens: rufinamide accelerates metabolism of \*OESTROGENS (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)
- Orlisat: possible increased risk of convulsions when antiepileptics given with \*ORLISTAT
- Progestogens: rufinamide accelerates metabolism of \*PROGESTOGENS (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives,
Rufinamide ◆ Progestogens (continued)
contraceptive patches, vaginal rings, etonogestrel-releasing implant, and emergency hormonal contraception—see (Contraceptive Interactions in BNF)

Ruxolitinib ◆ Antituberculars: manufacturer of ruxolitinib advises dose reduction when ruxolitinib given with: clarithromycin and telithromycin—consult ruxolitinib product literature; plasma concentration of ruxolitinib reduced by rifampicin.
◆ Antifungal manufacturer of ruxolitinib advises dose reduction when ruxolitinib given with: fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole—consult ruxolitinib product literature.
◆ Antipsychotics: avoid concomitant use of cytoxotics with increased risk of convulsions when St John's wort possibly reduces plasma concentration of vandetanib and vinflunine.
◆ Antivirals: manufacturer of ruxolitinib advises dose reduction when ruxolitinib given with: boceprevir, indinavir, lopinavir, ritonavir, saquinavir and telaprevir—consult ruxolitinib product literature.

St John's Wort
» Aminophylline: St John's wort possibly reduces plasma concentration of aminophylline.
» Analgesics: St John's wort possibly reduces plasma concentration of methadone.
◆ Anti-arrhythmics: St John's wort possibly reduces plasma concentration of droperidol—avoid concomitant use.
◆ Antibacterials: St John's wort possibly reduces plasma concentration of bedaquiline—manufacturer of bedaquiline advises avoid concomitant use; St John's wort reduces plasma concentration of telithromycin (avoid during and for 2 weeks after St John's wort).
◆ Anticoagulants: St John's wort possibly reduces plasma concentration of apixaban—manufacturer of apixaban advises avoid concomitant use when given for treatment of deep-vein thrombosis or pulmonary embolism; St John's wort reduces anticoagulant effect of coumarins (avoid concomitant use); St John's wort possibly reduces plasma concentration of dabigatran—manufacturer of dabigatran advises avoid concomitant use; St John's wort possibly reduces plasma concentration of rivaroxaban—manufacturer of rivaroxaban advises monitor for signs of thrombosis.
◆ Antidepressants: possible increased serotonergic effects when St John's wort given with dapoxetine (manufacturer of dapoxetine advises St John's wort should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping St John's wort).
◆ SSRIs—avoid concomitant use.
◆ Antiepileptics: St John's wort possibly reduces plasma concentration of carbamazepine; St John's wort possibly reduces plasma concentration of fosphenytoin, phenobarbital, phenytoin and primidone—avoid concomitant use.
◆ Anti-fungals: St John's wort reduces plasma concentration of voriconazole—avoid concomitant use.
◆ Antimalarials: avoidance of antidepresants advised by manufacturer of arteether with lumefantrine and arteminol with piperaquine.
◆ Antipsychotics: St John's wort possibly reduces plasma concentration of aripiprazole; St John's wort possibly reduces plasma concentration of cabozantinib, crizotinib, everolimus, ibritinib,idelalisib, ponatinib and vinflunine—manufacturer of bortezomib, bosutinib, cabozantinib, crizotinib, everolimus, ibritinib,idelalisib, ponatinib and vinflunine advises avoid concomitant use; avoidance of St John's wort advised by manufacturer of cabazitaxel, dabrafenib, lenvatinib and vemurafenib; St John's wort reduces plasma concentration of imatinib—avoid concomitant use; avoidance of St John's wort advised by manufacturer of vandetanib and vismodegib (plasma concentration of vandetanib and vismodegib possibly reduced); St John's wort possibly reduces plasma concentration of eribulin; St John's wort accelerates metabolism of irinotecan (reduced plasma concentration—avoid concomitant use).
◆ Dapoxetine: possible increased risk of serotonergic effects when St John's wort given with dapoxetine (manufacturer of dapoxetine advises St John's wort should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping St John's wort).
◆ Diuretics: St John's wort reduces plasma concentration of eplerenone—avoid concomitant use.
◆ Fingolimod: St John's wort possibly reduces plasma concentration of fingolimod—manufacturer of fingolimod advises avoid concomitant use.
◆ Fosaprepitant: avoidance of St John's wort advised by manufacturer of fosaprepitant.
◆ Hormone Antagonists: St John's wort possibly reduces plasma concentration of abiraterone—manufacturer of abiraterone advises avoid concomitant use.
◆ Sirt-1 receptor Agonists: increased serotonergic effects when St John's wort given with sirt-1 agonists—avoid concomitant use.
◆ Ibrutinib: St John's wort possibly reduces plasma concentration of ibrutinib (manufacturer of ibrutinib advises avoid concomitant use).
◆ Lapatinib and vemurafenib; St John's wort reduces plasma concentration of lapatinib and vemurafenib; St John's wort possibly reduces plasma concentration of vinflunine.
◆ Macitentan: avoidance of St John's wort advised by manufacturer of macitentan.
◆ Oestrogens: St John's wort reduces contraceptive effect of oestrogens (avoid concomitant use).
◆ Progestogens: St John's wort reduces contraceptive effect of progestogens (avoid concomitant use).
◆ Tacrolimus: St John's wort possibly reduces plasma concentration of tacrolimus—avoid concomitant use.
◆ Cardiovascular Drugs: see section 5.1.
◆ Diuretics: Dapoxetine: possible increased risk of serotonergic effects when St John's wort given with dapoxetine (manufacturer of dapoxetine advises St John's wort should not be started until 1 week after stopping dapoxetine, avoid dapoxetine for 2 weeks after stopping St John's wort).
◆ Diuretics: St John's wort reduces plasma concentration of eplerenone—avoid concomitant use.
◆ Fingolimod: St John's wort possibly reduces plasma concentration of fingolimod—manufacturer of fingolimod advises avoid concomitant use.
◆ Fosaprepitant: avoidance of St John's wort advised by manufacturer of fosaprepitant.
◆ Hormone Antagonists: St John's wort possibly reduces plasma concentration of abiraterone—manufacturer of abiraterone advises avoid concomitant use.
◆ Sirt-1 receptor Agonists: increased serotonergic effects when St John's wort given with sirt-1 agonists—avoid concomitant use.
◆ Ibrutinib: St John's wort possibly reduces plasma concentration of ibrutinib (manufacturer of ibrutinib advises avoid concomitant use).
◆ Lapatinib and vemurafenib: St John's wort reduces plasma concentration of lapatinib and vemurafenib; St John's wort possibly reduces plasma concentration of vinflunine.
◆ Macitentan: avoidance of St John's wort advised by manufacturer of macitentan.
◆ Oestrogens: St John's wort reduces contraceptive effect of oestrogens (avoid concomitant use).
◆ Progestogens: St John's wort reduces contraceptive effect of progestogens (avoid concomitant use).
◆ Tacrolimus: St John's wort possibly reduces plasma concentration of tacrolimus—avoid concomitant use.
Interactions

St John’s Wort (continued)

- Theophylline: St John’s wort possibly reduces plasma concentration of THEOPHYLLINE.
- Ulcer-healing Drugs: St John’s wort possibly reduces plasma concentration of OMEPRAZOLE.
- Ulcerative: avoidance of St John’s wort advised by manufacturer of ULPRIPLAST (contraceptive effect of ulipristal possibly reduced)

Salbutamol see Symathomimetics, Beta2

Saimeterol see Symathomimetics, Beta2

Saquinavir

- Analgesics: increased risk of ventricular arrhythmias when saquinavir given with ALFENTANIL, FENTANYL or METHADONE—avoid concomitant use
- Anti-arrhythmics: increased risk of ventricular arrhythmias when saquinavir given with AMIODARONE, DISOPYRAMIDE, DRONEDARONE, FLECAINIDE, LIDOCAINE or PROPACAFENONE—avoid concomitant use
- Antibacterials: plasma concentration of both drugs possibly increased when saquinavir given with CLARITHROMYCIN (increased risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when saquinavir with DAPSONE, ERTHROMYCIN or MOXIFLOXACIN—avoid concomitant use; saquinavir increases plasma concentration of RIFABUTIN (also plasma concentration of saquinavir reduced)—reduce rifabutin dose; plasma concentration of saquinavir significantly reduced by RIFAMPICIN, also risk of hepatotoxicity—avoid concomitant use; increased risk of ventricular arrhythmias when saquinavir given with DELAMANID; plasma concentration of both drugs increased when saquinavir given with FUSIDIC ACID; avoidance of saquinavir advised by manufacturer of TELITHROMYCIN (risk of ventricular arrhythmias)
- Anti-coagulants: saquinavir possibly enhances anticoagulant effect of WARFARIN; avoidance of saquinavir advised by manufacturer of APHABAN and RIVAROXABAN
- Antidepressants: increased risk of ventricular arrhythmias when saquinavir given with TRAZODONE or TRICYCLICS—avoid concomitant use; plasma concentration of saquinavir reduced by ST JOHN’S WORT—avoid concomitant use
- Antiepileptics: plasma concentration of saquinavir possibly increased by CARBAMAZEPINE, FOSPHENYTOIN, PHENOBARBITAL, PHENYTOIN and PRIMIDONE
- Antifungals: plasma concentration of saquinavir increased by KETOKONAZOLE—manufacturer of ketoconazole advises avoid concomitant use; plasma concentration of saquinavir possibly increased by IMIDAZOLES and TRIAZOLES
- Antihistamines: increased risk of ventricular arrhythmias when saquinavir given with MIZOLASTINE—avoid concomitant use
- Antihypertensives: caution with saquinavir advised by manufacturer of ARTEMETHER with LUMESFANTRINE, avoidance of saquinavir advised by manufacturer of ARTEMOL with PIPERAQUNI (possible risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when saquinavir given with OZOLAPINE, HALOPERIDOL or PHENOTHIAZINES—avoid concomitant use; saquinavir possibly increases plasma concentration of ARIPIPRAZOLE (reduce dose of aripiprazole—consult aripiprazole product literature); saquinavir possibly increases plasma concentration of LURASIDONE—avoid concomitant use; saquinavir possibly increases plasma concentration of PIMOZIDE (increased risk of ventricular arrhythmias—avoid concomitant use); saquinavir possibly increases plasma concentration of QTETAPINE—manufacturer of quetiapine advises avoid concomitant use
- Antivirals: increased risk of ventricular arrhythmias when saquinavir given with ATAZANAVIR or LOPINAVIR—avoid concomitant use; saquinavir reduces plasma concentration of DARUNAVIR; plasma concentration of saquinavir significantly

Saquinavir

- Antivirals (continued) reduced by EFAVIRENZ; plasma concentration of saquinavir increased by INDINAVIR and RITONAVIR; saquinavir increases plasma concentration of MARAVIROC (consider reducing dose of maraviroc); plasma concentration of saquinavir reduced by TIPRANAVIR
- Anti-convulsants: increases plasma concentration of AVANAFIL—manufacturer of avanafil advises avoid concomitant use
- Beta-blockers: increased risk of ventricular arrhythmias when saquinavir given with SOTALOL—avoid concomitant use
- Ciclosporin: plasma concentration of both drugs increased when saquinavir given with CICLOSPORIN
- Corticosteroids: plasma concentration of saquinavir possibly reduced by DEXAMETHASONE
- Cytototics: saquinavir possibly increases the plasma concentration of AFATINIB—manufacturer of afatinib advises separating administration of saquinavir by 6 to 12 hours; saquinavir possibly increases plasma concentration of AXTINIB (reduce dose of axitinib—consult axitinib product literature); saquinavir possibly increases the plasma concentration of BOSUTINIB and CABAZITAXEL—manufacturer of bosutinib and cabazitaxel advises avoid or consider reducing dose of bosutinib and cabazitaxel; saquinavir possibly increases plasma concentration of CRIZOTINIB and EVEROLIMUS—manufacturer of crizotinib and everolimus advises avoid concomitant use; saquinavir possibly increases the plasma concentration of IBRUTINIB—reduce dose of ibrutinib (see under ibrutinib, p. 809); avoidance of saquinavir advised by manufacturer of LAPATINIB; increased risk of ventricular arrhythmias when saquinavir given with RAZOPANIB—avoid concomitant use; saquinavir possibly increases plasma concentration of PONATINIB—consider reducing initial dose of ponatinib (see under Ponatinib, p. 814); manufacturer of ruxolitinib advises dose reduction when saquinavir given with RUXOLITINIB—consult ruxolitinib product literature; saquinavir possibly increases plasma concentration of DOCETAXEL—manufacturer of docetaxel advises avoid concomitant use or consider reducing docetaxel dose
- Dapoxetine: avoidance of saquinavir advised by manufacturer of DAPoxetine (increased risk of toxicity)
- Diuretics: saquinavir increases plasma concentration of EPLENENONE (reduce dose of eplerenone)
- Domerperidone: possible increased risk of ventricular arrhythmias when saquinavir given with DOPERIDONE—avoid concomitant use
- Ergot Alkaloids: increased risk of ergotism when saquinavir given with ERGOTAMINE—avoid concomitant use
- Lipid-regulating Drugs: possible increased risk of myopathy when saquinavir given with ATORVASTATIN; possible increased risk of myopathy when saquinavir given with ROSUVASTATIN—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when saquinavir given with SIMVASTATIN (avoid concomitant use); avoidance of saquinavir advised by manufacturer of Lomitapide (plasma concentration of lomitapide possibly increased)
- Orlisat: absorption of saquinavir possibly reduced by ORLISTAT
- Pentamide: increased risk of ventricular arrhythmias when saquinavir given with PENTAMIDINE ISETONATE—avoid concomitant use
- Ranolazine: saquinavir possibly increases plasma concentration of RANOLAZINE—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: increased risk of ventricular arrhythmias when saquinavir given with SILDENAFIL—avoid concomitant use
- Tacrolimus: saquinavir increases plasma concentration of TACROLIMUS (consider reducing dose of tacrolimus)
- Tadalafil: increased risk of ventricular arrhythmias when saquinavir given with TADALAFIL—avoid concomitant use

Appendix 1 Interactions 1241
Selegiline

**NOTE** Selegiline is a MAO-B inhibitor.

- Analgesics: hyperpyrexia and CNS toxicity reported when selegiline given with *pefotidine* (avoid concomitant use); manufacturer of selegiline advises avoid concomitant use with *opioid analgesics*
- Antidepressants: manufacturer of selegiline advises avoid concomitant use with *citalopram* and *escitalopram*; increased risk of hypertension and CNS excitation when selegiline given with *fluoxetine* (selegiline should not be started until 5 weeks after stopping fluoxetine, avoid fluoxetine for 2 weeks after stopping selegiline); increased risk of hypertension and CNS excitation when selegiline given with *sertraline* or *venlafaxine* (selegiline should not be started until 1 week after stopping fluvoxamine, sertraline or venlafaxine, avoid fluvoxamine, sertraline or venlafaxine for 2 weeks after stopping selegiline); increased risk of hypertension and CNS excitation when selegiline given with *paroxetine* for 2 weeks after stopping selegiline); enhanced hypotensive effect when selegiline given with *MAOIs*—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of selegline with *moclobemide*; CNS toxicity reported when selegiline given with *tricyclics*
- Dopaminergics: selegiline enhances effects and increases toxicity of *CO-beneldopa, co-careldopa* or *levodopa* (reduce dose of co-beneldopa, co-careldopa or levodopa); max. dose of 10 mg selegline advised by manufacturer of *entacapone* if used concomitantly
- SHT-receptor Agonists: manufacturer of selegiline advises avoid concomitant use with *SHT, agonists*
- Tolbutamide: enhanced effects of dopaminergics and selegline possibly enhanced by *memantine*
- Metyldopa: antiparkinsonian effect of dopaminergics antagonised by *metyldopa*
- Oestrogens: plasma concentration of selegline increased by *oxestrols*—manufacturer of selegline advises avoid concomitant use
- Progestogens: plasma concentration of selegline increased by *progesterone*—manufacturer of selegline advises avoid concomitant use
- Symathomimetics: manufacturer of selegline advises avoid concomitant use with *sympathomimetics; risk of hypertensive crisis when selegline given with dopamine*

**Selenium**

- Eltrombopag: selenium possibly reduces absorption of *eltrombopag* (give at least 4 hours apart)
- Vitamins: absorption of selenium possibly reduced by *ascorbic acid* (give at least 4 hours apart)

**Sertraline** see Antidepressants, SSRI

**Sevelamer**

- Antioxidants: sevelamer reduces bioavailability of *ciprofloxacin*
- Ciclosporin: sevelamer possibly reduces plasma concentration of *ciclosporin*
- Mycophenolate: sevelamer possibly reduces plasma concentration of *mycophenolate*
- Tacrolimus: sevelamer possibly reduces plasma concentration of *tacrolimus*
- Thyroid Hormones: sevelamer possibly reduces absorption of *levothyroxine*
Sirolimus (continued)
» Ciclosporin: plasma concentration of sirolimus increased by **CICLOSPORIN**
» Cytoxics: caution with sirolimus advised by manufacturer of **CYCLOSPORINE**
» Grapefruit Juice: plasma concentration of sirolimus increased by **GRAPEFRUIT JUICE**—avoid concomitant use

Sitagliptin see Antidiabetics

Smallpox Vaccine see Vaccines

Sodium Aurothiomalate
» ACE inhibitors: flushing and hypotension reported when sodium aurothiomalate given with **ACE INHIBITORS**
» Penicillamine: avoidance of sodium aurothiomalate advised by manufacturer of **PENICILLAMINE** (increased risk of toxicity)

Sodium Benzoate
» Antiepileptics: effects of sodium benzoate possibly reduced by **SODIUM VALPROATE** and **VALPROIC ACID**
» Antipsychotics: effects of sodium benzoate possibly reduced by **HALOPERIDOL**

Sodium Bicarbonate see Antacids

Sodium Citrate
» Antibacterials: avoid concomitant use of sodium citrate with **TETRACYCLINE**

Sodium Oxymtine see Antispasmodics

Sodium Phenybutyrate
» Antiepileptics: effects of sodium phenybutyrate possibly reduced by **SODIUM VALPROATE** and **VALPROIC ACID**
» Antipsychotics: effects of sodium phenybutyrate possibly reduced by **HALOPERIDOL**

Sodium Stibogluconate see Antimonials

Sodium Valproate
» Analgesics: effects of sodium valproate enhanced by **OPPIOID ANALGESICS** (avoid concomitant use)
» Antidepressants: increased risk of side-effects when sodium valproate given with **TRICYCLICS**
» Antiepileptics: manufacturer of sodium valproate advises avoid concomitant use with **PHENOBARBITAL** and **PRIMIDONE**; plasma concentration of sodium valproate increased by **SODIUM VALPROATE** and **VALPROIC ACID** (see under Sodium Oxymtine, p. 425)
» Antipsychotics: effects of sodium oxybate possibly enhanced by **ANTIPSYCHOTICS**
» Antidepressants: plasma concentration of sodium oxybate enhanced by **BENZODIAZEPINES** (avoid concomitant use)

Sodium Phenylbutyrate
» Antiepileptics: effects of sodium phenylbutyrate possibly reduced by **SODIUM VALPROATE** and **VALPROIC ACID**
» Antipsychotics: effects of sodium phenylbutyrate possibly reduced by **HALOPERIDOL**

Sodium Stibogluconate see Antimonials

Sodium Valproate
» Analgesics: effects of sodium valproate enhanced by **ASPIRIN**

Sodium Valproate
» Antibacterials: metabolism of sodium valproate possibly inhibited by **ERYTHROMYCIN** (increased plasma concentration)
» avoidance of sodium valproate advised by manufacturer of **PIVMECILLIN**; plasma concentration of sodium valproate reduced by **CARBAPENEMES**—avoid concomitant use

Anticoagulants: sodium valproate possibly enhances anticoagulant effect of **CUMARINS**

Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by **MAOIS** and **TRICYCLIC-RELATED ANTIDEPRESSANTS** (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by **SSRIS** and **TRICYCLICS** (convulsive threshold lowered)

Antiepileptics: plasma concentration of sodium valproate reduced by **CARBAMAZEPINE**, also plasma concentration of active metabolite of carbamazepine increased; sodium valproate possibly increases plasma concentration of **ETHOSUXIMIDE**; sodium valproate increases or possibly...
Sodium Valproate
- Antiepileptics (continued)
  decreases plasma concentration of FOSPHONYTOIN and PHENOTYTIN, also plasma concentration of sodium valproate reduced; sodium valproate increases plasma concentration of LAMOTRIGINE (increased risk of toxicity—reduce lamotrigine dose); sodium valproate sometimes reduces plasma concentration of an active metabolite of OXCARBAZEPINE; sodium valproate increases plasma concentration of PHENOBARBITAL and PRIMIDONE (also plasma concentration of sodium valproate reduced); sodium valproate possibly increases plasma concentration of RUFINamide (reduce dose of rufinamide); hyperammonaemia and CNS toxicity reported when sodium valproate given with TOPIMARATE
  - Antimarial: anticonvulsant effect of antiepileptics antagonised by N-METHOQUINE
  - Antipsychotics: anticonvulsant effect of antiepileptics antagonised by ANTIPSYCHOTICS (convulsive threshold lowered); sodium valproate possibly increases or decreases plasma concentration of CLOZAPINE; increased risk of side-effects including neutropenia when sodium valproate given with ORLANZAPINE
  - Antivirals: plasma concentration of sodium valproate possibly reduced by RITONAVIR; sodium valproate possibly increases plasma concentration of ZIDOVUDINE (increased risk of toxicity)
  - Anxiolytics and Hypnotics: plasma concentration of sodium valproate possibly increased by CLOBAZAM; increased risk of side-effects when sodium valproate given with CLONAZEPAM; sulphur doxepin possibly increases plasma concentration of DIAZEPAM and LORAZEPAM
  - Bupropion: sodium valproate inhibits the metabolism of BUPROPION
  - Cytotoxics: sodium valproate increases plasma concentration of TEMOZOLOMIDE
  - Lipid-regulating Drugs: absorption of sodium valproate possibly reduced by COLSTEYRAMINE
  - Oestrogens: plasma concentration of sodium valproate possibly reduced by ETHINYLESTRADIOL
  - Orlistat: possible increased risk of convulsions when antiepileptics given with ORLISTAT
  - Sodium Benzoate: sodium valproate possibly reduces effects of SODIUM BENZOATE
- Sodium Oxbyte: sodium valproate increases the plasma concentration of SODIUM OXBYTE (see under Sodium Oxbyte, p. 425)
- Sodium Phenylbutyrate: sodium valproate possibly reduces effects of SODIUM PHENYL BUTYRATE
- Ulcer-healing Drugs: metabolism of sodium valproate inhibited by CIMETIDINE (increased plasma concentration)

Sofosbuvir
- Anti-arhythmics: possible increased risk of bradycardia when sofosbuvir given with AMIODARONE—see under Amiodarone, p. 88
- Antibacterials: manufacturer of sofosbuvir advises avoid concomitant use with RIFABUTIN and Rifampicin
- Antidepressants: manufacturer of sofosbuvir advises avoid concomitant use with ST JOHN’S WORT
- Antiepileptics: manufacturer of sofosbuvir advises avoid concomitant use with CARBAMAZEPINE, PHOSPHONYTOIN, OXCARBAZEPINE, FENOBARBITAL, PHENOTYTIN and PRIMIDONE

Solifenacin see Antimuscarinics

Somatropin
- Corticosteroids: growth-promoting effect of somatropin may be inhibited by CORTICOSTEROIDS
- Oestrogens: increased doses of somatropin may be needed when given with OESTROGENS (when used as oral replacement therapy)

Sorafenib
- Antibacterials: bioavailability of sorafenib reduced by NEOMYCIN; plasma concentration of sorafenib reduced by RIFAMPICIN
- Anticoagulants: sorafenib possibly enhances anticoagulant effect of COUMARINS

Sorafenib (continued)
- Antipsychotics: avoid concomitant use of cytotoxics with CLOzapine (increased risk of agranulocytosis)
- Antivirals: avoidance of sorafenib advised by manufacturer of BOCEPREVIR
- Cytotoxics: sorafenib increases plasma concentration of DOCETAXEL and DOXORUBICIN; sorafenib possibly increases plasma concentration of IRINOTECAN

Sotalol see Beta-blockers

Spironolactone see Diuretics

Statins
  - Antacids: absorption of rosuvastatin reduced by ANTACIDS
  - Anti-arrhythmics: increased risk of myopathy when simvastatin given with ATRIAMORE (see under Simvastatin, p. 181); plasma concentration of rosuvastatin increased by DRONEDARONE—adjust dose of rosuvastatin (consult product literature); increased risk of myopathy when simvastatin given with DRONEDARONE; plasma concentration of atorvastatin possibly increased by DRONEDARONE
  - Antibacterials: plasma concentration of atorvastatin and pravastatin increased by SODIUM DIOXABUTYRATE; increased risk of myopathy when simvastatin given with CLARITHROMYCIN; ERYTHROMYCIN or TELETHROMYCIN (avoid concomitant use); plasma concentration of rosuvastatin reduced by ERYTHROMYCIN; possible increased risk of myopathy when atorvastatin given with ERYTHROMYCIN; plasma concentration of pravastatin increased by ERYTHROMYCIN; plasma concentration of atorvastatin and simvastatin possibly reduced by RIFAMPICIN; metabolism of fluvastatin accelerated by RIFAMPICIN (reduced effect); increased risk of myopathy when statins given with PHENOBARBITAL and PHENYTOIN; possibly reduced by DAPTOMYCIN (preferably avoid concomitant use); risk of myopathy and rhabdomyolysis when statins given with FUSIDIC ACID—avoid concomitant use and for 7 days after last fusidic acid dose; increased risk of myopathy when atorvastatin given with TELITHROMYCIN (avoid concomitant use); possible increased risk of myopathy when pravastatin given with TELITHROMYCIN
  - Anticoagulants: atorvastatin may transiently reduce anticoagulant effect of WARFARIN; rosuvastatin possibly enhances anticoagulant effect of COUMARINS and PHENINDONE; simvastatin can enhance the anticoagulant effect of COUMARINS; fluvastatin enhances anticoagulant effect of COUMARINS
  - Antidepressants: plasma concentration of simvastatin reduced by ST JOHN’S WORT
  - Antidiabetics: fluvastatin possibly increases plasma concentration of GLIBENCLAMIDE
  - Antiepileptics: plasma concentration of simvastatin reduced by CARBAMAZEPINE and ESLICARB ZEPINE—consider increasing dose of simvastatin; plasma concentration of rosuvastatin reduced by ESLICARBZEPINE; combination of fluvastatin with FOSPHONYTOIN or PHENOTYTIN may increase plasma concentration of either drug (or both)
  - Antifungals: possible increased risk of myopathy when atorvastatin given with KETOCONAZOLE—manufacturer of ketoconazole advises avoid concomitant use; increased risk of myopathy when simvastatin given with IRaconazole, KETOCONAZOLE or POSACONAZOLE (avoid concomitant use); possible increased risk of myopathy when simvastatin given with FLUCONAZOLE or ITRACONAZOLE; possible increased risk of myopathy when atorvastatin given with FLUCONAZOLE or IMIDAZOLES; plasma concentration of fluvastatin increased by FLUCONAZOLE—possible increased risk of myopathy; plasma concentration of rosuvastatin increased by ITRACONAZOLE—adjust dose of rosuvastatin (consult product literature); increased risk of myopathy when atorvastatin given with IRaconazole, POSACONAZOLE or VORICONAZOLE; increased risk of myopathy when simvastatin given with VORICONAZOLE
  - Antivirals: possible increased risk of myopathy when atorvastatin or pravastatin given with ATAZANAVIR; plasma concentration of rosuvastatin increased by ATAZANAVIR, DARUNAVIR, LOPINAVIR and TIPRANAVIR—adjust dose of rosuvastatin (consult product literature); increased risk of myopathy when simvastatin given with ATAZANAVIR,
Statins
- Antivirals (continued)
  - INDINAVIR, RITONAVIR or SAQUINAVIR (avoid concomitant use); plasma concentration of pravastatin increased by BOCEPREVIR; plasma concentration of atorvastatin increased by BOCEPREVIR (reduce dose of atorvastatin); manufacturers advise avoid concomitant use of simvastatin with BOCEPREVIR and TELAPREVI; plasma concentration of rosuvastatin increased by DACLATASVIR; plasma concentration of pravastatin possibly increased by DARUNAVIR, FOSAMPRENAVIR, INIDINAVIR, LOPINAVIR, RITONAVIR or SAQUINAVIR; plasma concentration of atorvastatin, pravastatin and simvastatin reduced by EFAVIRENZ; plasma concentration of atorvastatin possibly reduced by ETRAVIRINE; possible increased risk of myopathy when atorvastatin given with DARUNAVIR, FOSAMPRENAVIR, INIDINAVIR, LOPINAVIR, RITONAVIR or SAQUINAVIR; plasma concentration of atorvastatin, pravastatin and simvastatin reduced by EFAVIRENZ; plasma concentration of atorvastatin increased by SIMPRENAVIR (consider reducing dose of atorvastatin, rosuvastatin and simvastatin); avoidance of atorvastatin advised by manufacturer of TELAPREVI; plasma concentration of simvastatin possibly increased by TIPRANAVIR—avoid concomitant use; increased risk of myopathy when atorvastatin given with TIPRANAVIR (see under Atorvastatin, p. 179)

- Anxiolytics and Hypnotics: atorvastatin possibly increases plasma concentration of MIDAZOLAM
  - Bosentan: plasma concentration of simvastatin reduced by BOSENTAN

- Calcium-channel Blockers: possible increased risk of myopathy when simvastatin given with AMIODOPRIN and DILTIAZEM (see under Simvastatin, p. 181); plasma concentration of atorvastatin increased by DILTIAZEM—possible increased risk of myopathy; increased risk of myopathy when simvastatin given with VERAPAMIL (see under Simvastatin, p. 181); atorvastatin increases plasma concentration of VERAPAMIL, also possible increased risk of myopathy (consider reducing dose of atorvastatin)

- Cardiac Glycosides: atorvastatin possibly increases plasma concentration of DIGOXIN

- Ciclosporin: increased risk of myopathy when rosuvastatin or simvastatin given with CICLOSPORIN (avoid concomitant use); increased risk of myopathy when atorvastatin given with CICLOSPORIN (see under Atorvastatin, p. 179); increased risk of myopathy when fluvastatin or pravastatin given with CICLOSPORIN; Ciclosporin (consult product literature)

- Clonidine: plasma concentration of rosuvastatin increased by CLOPIDOGREL—adjust dose of rosuvastatin (consult product literature)

- Cobistat: plasma concentration of atorvastatin possibly increased by COBICISTAT—manufacturer of cobistat advises reduce dose of atorvastatin; avoidance of simvastatin advised by manufacturer of COBICISTAT

- Colchicine: possible increased risk of myopathy when statins given with COLCHICINE

- Cytotoxic: plasma concentration of simvastatin possibly increased by DASATINIB; avoidance of simvastatin advised by manufacturer of IDEALISIS; plasma concentration of simvastatin increased by IMATINIB

- Eltrombopag: plasma concentration of rosuvastatin increased by ELTROMBOPAG—adjust dose of rosuvastatin (consult product literature)

- Grapefruit juice: plasma concentration of atorvastatin possibly increased by GRAPEFRUIT JUICE; plasma concentration of simvastatin increased by GRAPEFRUIT JUICE—avoid concomitant use

- Hormone Antagonists: possible increased risk of myopathy when simvastatin given with DANAZOL—avoid concomitant use

- Lipid-regulating Drugs: possible increased risk of myopathy when simvastatin given with BEZAFIBRATE (see under Simvastatin, p. 181); possible increased risk of myopathy

Statins
- Lipid-regulating Drugs (continued)
  - when simvastatin given with CIPROFIBRATE (see under Simvastatin, p. 181); when given with statins reduce maximum dose of FENOFLIBRATE (see under Fenofibrate, p. 172); increased risk of myopathy when atorvastatin, fluvastatin or pravastatin given with GEMFIBROZIL (preferably avoid concomitant use); increased risk of myopathy when simvastatin given with GEMFIBROZIL (avoid concomitant use); plasma concentration of rosuvastatin increased by EZETIMIBE—adjust dose of rosuvastatin (consult product literature); increased risk of myopathy when statins given with FIBRATES; increased risk of myopathy when rosuvastatin given with FIBRATES (see under Rosuvastatin, p. 180); plasma concentration of simvastatin increased by EZETIMIBE (see under Simvastatin, p. 181); plasma concentration of atorvastatin increased by LOMITAPIDE—manufacturer of lomitapide advises reduce dose of atorvastatin by half or separate administration by 12 hours; increased risk of myopathy when statins given with NICOTINE ACID (applies to lipid regulating doses of nicotine acid)

  - Oestrogens: atorvastatin and rosuvastatin increase plasma concentration of ETHINYLESTRADIOL

  - Progestogens: atorvastatin increases plasma concentration of NORETHISTERONE; rosuvastatin increases plasma concentration of active metabolite of NORGESTIMATE; rosuvastatin increases plasma concentration of NORGESTREL

- Ranolazine: plasma concentration of simvastatin increased by RANOLAZINE (see under Simvastatin, p. 181)

- Retinoids: plasma concentration of simvastatin reduced by ALITRETINOIN

- Teriflunomide: plasma concentration of rosuvastatin increased by TERYFLUNOMIDE (consider reducing dose of rosuvastatin)

- Ticagrelor: plasma concentration of simvastatin increased by TICAGRELOR (increased risk of toxicity)

- Stavudine
  - Antivirals: increased risk of side-effects when stavudine given with DIDANOSEN; increased risk of toxicity when stavudine given with DIBAVIRIN; effects of stavudine possibly inhibited by ZIDOVUDINE (manufacturers advise avoid concomitant use)

- Cytotoxics: effects of stavudine possibly inhibited by DOXORUBICIN; increased risk of toxicity when stavudine given with HYDROXYCARMABIDE—avoid concomitant use

- Orlistat: absorption of stavudine possibly reduced by ORLISTAT

- Striperntol
  - Antidepressants: anticonvulstant effect of antiepileptics possibly antagonised by MAOI S and TRICYCLIC-RELATED ANTIDEPRESSANTS (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRI S and TRICYCLICS (convulsive threshold lowered)

- Antiepileptics: striperntol increases plasma concentration of CARBAMAZEPINE, FOSFENYTIOIN, PHENOBARBITAL, PHENYTOIN and PRIMIDONE

- Antimalarials: anticonvulsant effect of antiepileptics antagonised by MEFLOQUINE

- Antipsychotics: anticonvulstant effect of antiepileptics antagonised by ANTI PSYCHOTICS (convulsive threshold lowered)

- Anxiolytics and Hypnotics: striperntol increases plasma concentration of CLOBAZAM

- Orlistat: possible increased risk of convulsions when antiepileptics given with ORLISTAT

- Streptomycin see Aminoglycosides

- Strontium Ranelate
  - Antibacterials: strontium ranelate reduces absorption of QUINOLONES and TETRACYCLINES (manufacturer of strontium ranelate advises avoid concomitant use)

- Sucralfate
  - Aminophylline: sucralfate possibly reduces absorption of AMINOPHYLLINE (give at least 2 hours apart)

  - Antibacterials: sucralfate reduces absorption of CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN, OFLOXACIN and TETRACYCLINES;
Interactions

**Sucralfate**
- Antibacterials (continued)
  - Sucralfate reduces absorption of **Norfloxacin** (give at least 2 hours apart)
  - Anticoagulants: sucralfate possibly reduces absorption of **Coumarins** (reduced anticoagulant effect)
  - Antiepileptics: sucralfate reduces absorption of **Fosphenytoin** and **Phenytoin**
  - Antifungals: sucralfate reduces absorption of **Ketoconazole**
  - Antipsychotics: sucralfate reduces absorption of **Sulpiride**
  - Cardiac Glycosides: sucralfate possibly reduces absorption of **Cardiac Glycosides**
- Potassium Salts: manufacturer of sucralfate advises avoid concomitant use with **Potassium Citrate**
  - Sodium Citrate: manufacturer of sucralfate advises avoid concomitant use with **Sodium Citrate**
- Theophylline: sucralfate possibly reduces absorption of **Theophylline** (give at least 2 hours apart)
- Thyroid Hormones: sucralfate reduces absorption of **Levothyroxine**
- Ulcer-healing Drugs: sucralfate possibly reduces absorption of **Lansoprazole**

**Sugammadex**
- Antibacterials: response to sugammadex possibly reduced by **Fusidic Acid**
- Progestagens: sugammadex possibly reduces plasma concentration of **Progestogens**—manufacturer of sugammadex advises additional contraceptive precautions

**Sulfadiazine** see Sulfonamides

**Sulfafoxide** see Sulfonamides

**Sulfamethoxazole** see Sulfonamides

**Sulfasalazine**
- Cardiac Glycosides: sulfasalazine possibly reduces absorption of **Digoxin**
- Folicates: sulfasalazine possibly reduces absorption of **Folic Acid**

**Sulfapyrazone**
- Aminophylline: sulfapyrazone reduces plasma concentration of **Aminophylline**
- Analgesics: effects of sulfapyrazone antagonised by **Aspirin**
  - Antibacterials: sulfapyrazone reduces excretion of **Nitrofurantoin** (increased risk of toxicity); sulfapyrazone reduces excretion of **Penicillins**; effects of sulfapyrazone antagonised by **Pyrazinamide**
- Antagonists: increased risk of bleeding when sulfapyrazone given with **Apixaban**; sulfapyrazone enhances anticoagulant effect of **Coumarins**; possible increased risk of bleeding when sulfapyrazone given with **Dabigatran**
- Antiepileptics: cs:sulfapyrazone enhances effects of **Sulfonylureas**
  - Antiepileptics: sulfapyrazone increases plasma concentration of **Fosphenytoin** and **Phenytoin**
  - Calcium-channel Blockers: sulfapyrazone reduces plasma concentration of **Verapamil**
- Ciclosporin: sulfapyrazone reduces plasma concentration of **Ciclosporin**
  - Theophylline: sulfapyrazone reduces plasma concentration of **Theophylline**

**Sulfonamides**
- Anaesthetics, General: sulfonamides enhance effects of **Thiopental**
  - Anaesthetics, Local: effects of sulfonamides possibly inhibited by **Chloroprocaine** (manufacturer of chloroprocaine advises avoid concomitant use); increased risk of methaemoglobinaemia when sulfonamides given with **Prilocaine**
  - Anti-arrhythmics: possible increased risk of ventricular arrhythmias when sulfamethoxazole (as co-trimoxazole) given with **Amiodarone**—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole
  - Antibacterials: increased risk of crystalluria when sulfonamides given with **Methenamine**

**Sulfonamides (continued)**
- Anticoagulants: sulfonamides enhance anticoagulant effect of **Coumarins**; sulfonamides possibly inhibit metabolism of **Phenindione**
  - Antidiabetics: sulfonamides rarely enhance the effects of **Sulfonylureas**
- Antiepileptics: sulfonamides possibly increase plasma concentration of **Fosphenytoin** and **Phenytoin**
- Antimalarials: increased antifolate effect when sulfonamides given with **Pyrimethamine**
- Antipsychotics: avoid concomitant use of sulfonamides with **Clozapine** (increased risk of agranulocytosis)
- Azathioprine: increased risk of haematological toxicity when sulfamethoxazole (as co-trimoxazole) given with **Azathioprine**
- Ciclosporin: increased risk of nephrotoxicity when sulfonamides given with **Ciclosporin**; sulfadiazine possibly reduces plasma concentration of **Ciclosporin**
- Cytotoxics: increased risk of haematological toxicity when sulfamethoxazole (as co-trimoxazole) given with **Mercaptopurine** or **Methotrexate**; sulfonamides increase risk of **Methotrexate** toxicity
- Potassium Aminobenzoate: effects of sulfonamides inhibited by **Potassium Aminobenzoate**
- Vaccines: antibacterials inactivate **Oral Typhoid Vaccine**—see under Typhoid Vaccine in BNF

**Sulfonylureas** see Antidiabetics

**Sulindac** see NSAIDs

**Sulpiride** see Antipsychotics

**Sumatriptan** see 5HT1-receptor Agonists (under HT)

**Sunitinib**
- Antibacterials: metabolism of sunitinib accelerated by **Rifampicin** (reduced plasma concentration)
- Antifungals: metabolism of sunitinib inhibited by **Ketoconazole** (increased plasma concentration)
- Antipsychotics: avoid concomitant use of cytotoxics with **Clozapine** (increased risk of agranulocytosis)
- Antivirals: avoidance of sunitinib advised by manufacturer of **Boceprevir**

**Suxamethonium** see Muscle Relaxants

**Sympathomimetics**
- Adrenergic Neurone Blockers: ephedrine, isometheptene, metaraminol, methylphenidate, noradrenaline (norepinephrine), oxymetazoline, phenylephrine, pseudoephedrine and xylometazoline antagonise hypotensive effect of **Aldrenergic Neurone Blockers**; dexametamfamine and lidexametamfaine antagonise hypotensive effect of **Guanethidine**; increased risk of hypertension when adrenaline (epinephrine) given with **Guanethidine**
- Alcohol: effects of methylphenidate possibly enhanced by **Alcohol**
  - Alpha-adrenoceptor Stimulants: avoidance of sympathomimetics advised by manufacturer of **Aprelonidine**
  - Alpha-blockers: avoid concomitant use of adrenaline (epinephrine) or dopamine with **Volatile**
  - Aminophylline: avoidance of ephedrine in children advised by manufacturer of **Aminophylline**
    - Anaesthetics, General: avoidance of sympathomimetics advised by manufacturer of **Isoflurane** (risk of ventricular arrhythmias); increased risk of arrhythmias when adrenaline (epinephrine) or noradrenaline (norepinephrine) given with **Volatile Liquid General Anaesthetics**; increased risk of hypertension when methylphenidate given with **Volatile Liquid General Anaesthetics**
  - Antacids: absorption of pseudoephedrine possibly increased by **Aluminium Hydroxide**
  - Anticoagulants: methylphenidate possibly enhances anticoagulant effect of **Coumarins**
  - Antidepressants: risk of hypertensive crisis when adrenaline (epinephrine), dobutamine, dopamine, noradrenaline (norepinephrine) or xylometazoline given with **Maois**; risk of hypertensive crisis when dexametamfamine, ephedrine, isometheptene, lisdexametamfaine, metaraminol,
Antivirals:
- Aminophylline: possibly reduced by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Antifungals:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Aminophylline:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Theophylline:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

▶ Oxytocin:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Ergot Alkaloids:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Doxapram:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

▶ Dopaminergics:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Sympathomimetics, Beta2:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Antivirals (continued):
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Cardiac Glycosides:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

β-blockers:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Sympathomimetics:
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.

Antidepressants (continued):
- Methylphenidate: possibly increased by enantioselective effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone; increased risk of hypertension and arrhythmias when adrenaline (epinephrine) given with methylphenidate; increased risk of severe hypertension and bradycardia when dobutamine given with norepinephrine; possibly enhanced by tedizolid; plasma concentration of tacrolimus possibly increased by ritonavir; plasma concentration of tacrolimus possibly reduced by saquinavir.
### Appendix 1 Interactions

#### Tacrolimus
- **Antivirals (continued)**
  - concentration of both drugs increased when tacrolimus given with **TELAPREVIR** (reduce dose of tacrolimus)
- **Calcium-channel Blockers**: plasma concentration of tacrolimus possibly increased by **FELODIPINE** and **VERAPAMIL**; plasma concentration of tacrolimus increased by **DILTIAZEM, NICARDIPINE** and **NIFEDIPINE**
- **Ciclosporin**: tacrolimus increases plasma concentration of **CICLOSPORIN** (increased risk of nephrotoxicity)—avoid concomitant use
- **Colestilan**: manufacturer of colestilan advises give tacrolimus at least 1 hour before or 3 hours after **COLESTILAN**
- **Cytoxics**: tacrolimus possibly increases the plasma concentration of **AFATINIB**—manufacturer of afatinib advises separating administration of tacrolimus by 6 to 12 hours; caution with tacrolimus advised by manufacturer of **CRIZOTINIB**; plasma concentration of tacrolimus increased by **IMatinib**
- **Dextrazoxane**: increased risk of immunosuppression with tacrolimus advised by manufacturer of **DEXRAZOXANE**
- **Diuretics**: increased risk of hyperkalaemia when tacrolimus given with **POTASSIUM-SPARING DIURETICS AND ALDOSTERONE ANTAGONISTS**
- **Grapefruit Juice**: plasma concentration of tacrolimus increased by **GRAPEFRUIT JUICE**
- **Hormone Antagonists**: plasma concentration of tacrolimus possibly increased by **Lomitapide**
- **Mifamurtide**: avoidance of tacrolimus advised by manufacturer of **MIFAMURTIDE**
- **Omeprazole**: plasma concentration of tacrolimus possibly increased by **OMEPRAZOLE**
- **Ranolazine**: plasma concentration of tacrolimus increased by **RANOLAZINE**
- **Sevelamer**: plasma concentration of tacrolimus possibly reduced by **SEVELAMER**
- **Ulcer-healing Drugs**: plasma concentration of tacrolimus possibly increased by **OMEPRAZOLE**

#### Tadalafil
- **Alpha-blockers**: enhanced hypotensive effect when tadalafil given with **DOXAZOSIN**—manufacturer of tadalafil advises avoid concomitant use; enhanced hypotensive effect when tadalafil given with **ALPHA-BLOCKERS**—when patient is stable on the alpha blocker initiate tadalafil at the lowest possible dose
- **Anti-arrhythmics**: avoidance of tadalafil advised by manufacturer of **DISOPYRAMIDE** (risk of ventricular arrhythmias)
- **Antibacterials**: plasma concentration of tadalafil possibly increased by **CLARITHROMYCIN** and **ERYTHROMYCIN**; plasma concentration of tadalafil reduced by **RIFAMPICIN**—manufacturer of tadalafil advises avoid concomitant use
- **Antifungals**: tadalafil concentration is increased by **KETOCONAZOLE**—avoid concomitant use of tadalafil for pulmonary hypertension; plasma concentration of tadalafil possibly increased by **ITRACONAZOLE**
- **Antivirals**: plasma concentration of tadalafil possibly increased by **FOSAMPRENAVIR** and **INDINAVIR**; plasma concentration of tadalafil increased by **RITONAVIR**—manufacturer of tadalafil advises avoid concomitant use; increased risk of ventricular arrhythmias when tadalafil given with **SAQUINAVIR**—avoid concomitant use; avoidance of high doses of tadalafil advised by manufacturer of **TELAPREVIR**—consult product literature
- **BoSENTAN**: plasma concentration of tadalafil reduced by **BOSENTAN**
- **Cobicistat**: plasma concentration of tadalafil possibly increased by **COBICISTAT**—manufacturer of cobicistat advises reduce dose of tadalafil (consult cobicistat product literature)
- **Dapoxetine**: avoidance of tadalafil advised by manufacturer of **DAPOXETINE**

#### Tadalafil (continued)
- **Grapefruit Juice**: plasma concentration of tadalafil possibly increased by **GRAPEFRUIT JUICE**
- **Nicorandil**: tadalafil significantly enhances hypotensive effect of **NICORANDIL** (avoid concomitant use)
- **Nitrazides**: tadalafil significantly enhances hypotensive effect of **NITRATES** (avoid concomitant use)
- **Riociguat**: possible enhanced hypotensive effect when tadalafil given with **RIOCIGUAT**—avoid concomitant use

#### Tamoxifen
- **Antibacterials**: metabolism of tamoxifen accelerated by **RIFAMPICIN** (reduced plasma concentration)
- **Anticoagulants**: tamoxifen enhances anticoagulant effect of **COUMARINS**
- **Antidepressants**: metabolism of tamoxifen to active metabolite possibly inhibited by **FLUOXETINE** and **PAROXETINE** (avoid concomitant use)
- **Antipsychotics**: avoidance of tamoxifen advised by manufacturer of **DROPERIDOL** (risk of ventricular arrhythmias)
- **Bupropion**: metabolism of tamoxifen to active metabolite possibly inhibited by **BUPROPION** (avoid concomitant use)
- **Cinacalcet**: metabolism of tamoxifen to active metabolite possibly inhibited by **CINACALCET** (avoid concomitant use)

#### Tamsulosin
see Alpha-blockers

#### Tapentadol
see Opioid Analgesics

#### Taxanes
see Cabazitaxel, Docetaxel, and Paclitaxel

#### Tegafur
- **Antibacterials**: metabolism of tegafur inhibited by **METRONIDAZOLE** (increased toxicity)
- **Anticoagulants**: tegafur enhances anticoagulant effect of **COUMARINS**
- **Antiepileptics**: tegafur possibly inhibits metabolism of **FOSPHENYTOIN** and **PHENYTOIN** (increased risk of toxicity)
- **Antipsychotics**: avoidance of concomitant use of cytoxotics with **CLOzapine** (increased risk of agranulocytosis)
- **Filgrastim**: neutropenia possibly exacerbated when tegafur given with **FILGRASTIM**
- **Folates**: toxicity of tegafur increased by **FOLIC ACID**—avoid concomitant use
- **Lipogfilgrastim**: neutropenia possibly exacerbated when tegafur given with **LIPOGFILGRASTIM**
- **PEGFILGRASTIM**: neutropenia possibly exacerbated when tegafur given with **PEGFILGRASTIM**
- **Ulcer-healing Drugs**: metabolism of tegafur inhibited by **CIMETIDINE** (increased plasma concentration)

#### Teicoplanin
- **Vaccines**: antibacterials inactivate **ORAL TYPHOID VACCINE** see under Typhoid Vaccine in BNF

#### Telaprevir
- **Alpha-blockers**: manufacturer of telaprevir advises avoid concomitant use with **ALFIZOSIN**
- **Analgesics**: manufacturer of telaprevir advises caution with **METHADONE** (risk of ventricular arrhythmias)
- **Anti-arrhythmics**: manufacturer of telaprevir advises avoid concomitant use with **AMIODARONE** and **DISOPYRAMIDE** (risk of ventricular arrhythmias); manufacturer of telaprevir advises caution with intravenous **LIDOCAINE**
- **Antibacterials**: plasma concentration of both drugs possibly increased when telaprevir given with **CLARITHROMYCIN**, **ERYTHROMYCIN** and **TELITHROMYCIN** (increased risk of ventricular arrhythmias); manufacturer of telaprevir advises avoid concomitant use with **RIFAMPICIN**—avoid concomitant use
- **Anticoagulants**: telaprevir possibly affects plasma concentration of **WARFARIN**; avoidance of telaprevir advised by manufacturer of **APIXABAN**; telaprevir possibly increases plasma concentration of **DABIGRATAN**
- **Antidepressants**: telaprevir possibly increases plasma concentration of **TRAZODONE**; manufacturer of telaprevir advises avoid concomitant use with **ST JOHN’S WORT**
### Telaprevir (continued)

- **Antidiabetics:** telaprevir increases plasma concentration of **metformin** (consider reducing dose of metformin).
- **Antiepileptics:** manufacturer of telaprevir advises avoid concomitant use with **carbamazepine**, **fosphenytoin**, **phenobarbital**, and **phenytoin**.
- **Antifungals:** plasma concentration of both drugs possibly increased when telaprevir given with **ketoconazole** (increased risk of ventricular arrhythmias)—reduce dose of ketoconazole; telaprevir possibly increases plasma concentration of **itraconazole**; telaprevir possibly increases plasma concentration of **posaconazole** (increased risk of ventricular arrhythmias); telaprevir possibly affects plasma concentration of **voriconazole** (possible increased risk of ventricular arrhythmias).
- **Antipsychotics:** telaprevir possibly increases plasma concentration of **loratadine**—avoid concomitant use; manufacturer of telaprevir advises avoid concomitant use with **pimozide**; telaprevir possibly increases plasma concentration of **quetiapine**—manufacturer of quetiapine advises avoid concomitant use.
- **Antivirals:** plasma concentration of telaprevir possibly reduced by **atazanavir**, also plasma concentration of atazanavir possibly increased; telaprevir increases the plasma concentration of **daclatasvir**—reduce dose of daclatasvir (see under Daclatasvir, p. 544); avoid concomitant use of telaprevir with **darunavir**; plasma concentration of telaprevir reduced by **efavirenz**—increase dose of telaprevir; manufacturers advise avoid concomitant use of telaprevir with **osampruvir** and **lorzepam**; telaprevir increases plasma concentration of **maraviroc** (consider reducing dose of maraviroc); plasma concentration of telaprevir possibly reduced by **nevirapine**—consider increasing dose of telaprevir; plasma concentration of telaprevir possibly reduced by **biktarvy**; plasma concentration of telaprevir possibly increased by **biktarvy** (increase dose of telaprevir).
- **Beta-blockers:** manufacturer of telaprevir advises avoid concomitant use with **sotolol** (risk of ventricular arrhythmias).
- **Bosentan:** plasma concentration of telaprevir possibly increased by **bosentan**, also plasma concentration of bosentan possibly increased.
- **Calcium-channel Blockers:** telaprevir increases plasma concentration of **amlodipine** (consider reducing dose of amlodipine); manufacturer of telaprevir advises caution with **diltiazem**, **felodipine**, **nicardipine**, **nifedipine** and **verapamil**.
- **Cardiac Glycosides:** telaprevir increases plasma concentration of **digoxin**.
- **Ciclosporin:** plasma concentration of both drugs increased when telaprevir given with **ciclosporin** (reduce dose of ciclosporin).
- **Cilostazol:** telaprevir possibly increases plasma concentration of **cilostazol** (see under Cilostazol, p. 206).
- **Colchicine:** telaprevir possibly increases risk of **colchicine** toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).
- **Corticosteroids:** telaprevir possibly increases plasma concentration of **inhaled** and **intranasal budesonide** and **fluticasone**; plasma concentration of telaprevir possibly reduced by **dexmethasone**.
- **Cytotoxic:** telaprevir possibly increases the plasma concentration of **busulphan**—manufacturer of busulphan advises avoid or consider reducing dose of busulphan; manufacturer of ruxolitinib advises dose reduction when telaprevir given with **ruxolitinib**—consult ruxolitinib product literature.
- **Domeridone:** possible increased risk of ventricular arrhythmias when telaprevir given with **domperidone**—avoid concomitant use.
- **Ergot Alkaloids:** manufacturer of telaprevir advises avoid concomitant use with **ergot alkaloids**.

### Telaprevir (continued)

- **Lipid-regulating Drugs:** manufacturer of telaprevir advises avoid concomitant use with **atorvastatin**; manufacturers advise avoid concomitant use of telaprevir with **simvastatin**; avoidance of telaprevir advised by manufacturer of **lovastatin** (plasma concentration oflovastatin possibly increased).
- **Dextrans:** telaprevir possibly reduces plasma concentration of **ethinylestradiol**—manafacturer of telaprevir advises additional contraceptive precautions.
- **Sildenafil:** manufacturer of telaprevir advises avoid concomitant use with **sildenafil**.
- **Sirolimus:** plasma concentration of both drugs increased when telaprevir given with **sirolimus** (reduce dose of sirolimus).
- **Symptomimetics, Beta2:** manufacturer of telaprevir advises avoid concomitant use with **salbutamol** (risk of ventricular arrhythmias).
- **Tacrolimus:** plasma concentration of both drugs increased when telaprevir given with **tacrolimus** (reduce dose of tacrolimus).
- **Tadalafil:** manufacturer of telaprevir advises avoid concomitant use with high doses of **tadalafil**—consult product literature.
- **Vardenafil:** manufacturer of telaprevir advises avoid concomitant use with **vardenafil**.

### Telaprevir (continued)

- **Vaccines:** antibacterials inactivate oral **typhoid vaccine**—see under Typhoid Vaccine in BNF.

### Telbivudine

- **Interferons:** increased risk of peripheral neuropathy when telbivudine given with **interferon alpha** and **peginterferon alpha**.

### Telithromycin

- **Analgesics:** possible increased risk of ventricular arrhythmias when telithromycin given with **ibuprofen**; telithromycin inhibits the metabolism of **oxycodeone**.
- **Anti-arrhythmics:** possible increased risk of ventricular arrhythmias when telithromycin given with **amiodarone** and **dofetilide**, increased risk of ventricular arrhythmias when telithromycin given with **dronedarone**—avoid concomitant use.
- **Antibacterials:** possible increased risk of ventricular arrhythmias when telithromycin given with **meropenem** and **levofloxacin**; plasma concentration of telithromycin reduced by **ritampicin** (avoid during and for 2 weeks after ritampicin).
- **Anticoagulants:** avoidance of telithromycin advised by manufacturer of **apixaban**.
- **Antidepressants:** possible increased risk of ventricular arrhythmias when telithromycin given with **clozapine** and **tricyclics**; plasma concentration of telithromycin reduced by **st john’s wort** (avoid during and for 2 weeks after St John’s wort).
- **Antiepileptics:** plasma concentration of telithromycin reduced by **carbamazepine**, **fosphenytoin**, **phenobarbital**, **phenytoin** and **primidone** (avoid during and for 2 weeks after carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone).
- **Antifungals:** plasma concentration of telithromycin increased by **ketoconazole**—avoid in severe renal and hepatic impairment.
- **Antimycobacterics:** manufacturer of fosoterodine advises dose reduction when telithromycin given with **fosoterodine**—consult fosoterodine product literature.
- **Antipsychotics:** possible increased risk of ventricular arrhythmias when telithromycin given with **chlorpromazine**; telithromycin possibly increases plasma concentration of **loratadine**—avoid concomitant use; increased risk of ventricular arrhythmias when telithromycin given with **pimozide**—avoid concomitant use; telithromycin possibly increases plasma concentration of **quetiapine**.
- **Antivirals:** manufacturer of telithromycin advises avoid concomitant use with **atazanavir**, **fosamprenavir**, **indinavir**, **lopinavir** and **ritonavir** and **tipranavir** in severe renal and hepatic impairment; telithromycin possibly increases the plasma concentration of **daclatasvir**—reduce
Telithromycin

- Antivirals (continued) dose of daclatasvir (see under Daclatasvir, p. 544); telithromycin possibly increases plasma concentration of:
  - MARAVIROC (consider reducing dose of maraviroc); manufacturer of telithromycin advises avoid concomitant use with:
  - SAQUINAVIR (risk of ventricular arrhythmias); telithromycin possibly increases plasma concentration of:
  - SIMEPREVIR—manufacturer of simeprevir advises avoid concomitant use; plasma concentration of both drugs possibly increased when telithromycin given with:
  - TELAPREVIR (increased risk of ventricular arrhythmias); telithromycin possibly increases plasma concentration of:
  - ANXIOLYtics and Hypnotics: telithromycin inhibits metabolism of:
  - MIDAZOLAM (increased plasma concentration with increased sedation)
  - Aprepitant: telithromycin possibly increases plasma concentration of Aprepitant
  - Dapoxetine: telithromycin possibly increases plasma concentration of:
  - DOMPERIDONE
  - Calcium-channel blockers: telithromycin possibly inhibits metabolism of:
    - CICLOSPORIN (increased risk of side-effects)
  - Cardiac Glycosides: telithromycin reduces plasma concentration of:
    - DIGOXIN
  - Cisplatin: telithromycin possibly increases plasma concentration of:
    - CICLOSPORIN
  - Colchicine: telithromycin possibly increases risk of:
    - COLCHICINE toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
  - Cytotoxics: telithromycin possibly increases plasma concentration of:
    - AXITINIB (reduce dose of axitinib—consult axitinib product literature); telithromycin possibly increases the plasma concentration of:
      - BOSONITIN and:
      - CABAZITAXEL—manufacturer of bosphitin and cabazitaxel advises avoid or consider reducing dose of bosphitin and cabazitaxel; telithromycin possibly increases plasma concentration of:
        - CRIZOTINIB and:
        - EVEROLIMUS—manufacturer of crizotinib and everolimus advises avoid concomitant use; avoidance of telithromycin advised by manufacturer of:
          - DASATINIB (plasma concentration of dasatinib possibly increased); telithromycin possibly increases the plasma concentration of:
            - IBRUTINIB—reduce dose of ibrutinib (see under ibrutinib, p. 809); avoidance of telithromycin advised by manufacturer of:
              - LAPATINIB and:
              - NILOTINIB; telithromycin possibly increases plasma concentration of:
                - PAAZOPANIB (reduce dose of pazolepin); telithromycin possibly increases plasma concentration of:
                  - PONATINIB—consider reducing initial dose of ponatinib (see under Ponatinib, p. 814); manufacturer of ruxolitinib advises dose reduction when telithromycin given with:
                    - RUXOLITINIB—consult ruxolitinib product literature; telithromycin possibly increases plasma concentration of:
                      - DOCETAXEL—manufacturer of docetaxel advises avoid concomitant use or consider reducing docetaxel dose
                      - Dapoxetine: avoidance of telithromycin advised by manufacturer of:
                        - DAPOXETINE (increased risk of toxicity)
  - Diuretics: telithromycin increases plasma concentration of:
    - EPLERENONE—avoid concomitant use
  - Domperidone: possible increased risk of ventricular arrhythmias when telithromycin given with:
    - DOMPERIDONE—avoid concomitant use
  - Ergot Alkaloids: increased risk of ergotism when telithromycin given with:
    - ERGOTAMINE—avoid concomitant use
  - Fosaprepitant: telithromycin possibly increases plasma concentration of:
    - IVABRADINE—avoid concomitant use
  - Ivermectin: telithromycin possibly increases plasma concentration of:
    - IVERMECTIN (when used for onchocerciasis)
  - Lipid-regulating Drugs: increased risk of myopathy when telithromycin given with:
    - ATORVASTATIN or:
    - SIMVASTATIN (avoid concomitant use); possible increased risk of myopathy when telithromycin given with:
      - PRAVASTATIN; avoidance of telithromycin advised by manufacturer of:
        - LOVASTATIN (plasma concentration of lomitapide possibly increased)

Telithromycin (continued)

- Pentamidine isethionate: possible increased risk of ventricular arrhythmias when telithromycin given with:
  - PENTAMIDINE ISETHIONATE
  - Ranolazine: telithromycin possibly increases plasma concentration of:
    - RANOLAZINE—manufacturer of ranolazine advises avoid concomitant use
  - Sildenafil: telithromycin possibly increases plasma concentration of:
    - SILDENAFIL—consider reducing initial dose of sildenafil for erectile dysfunction or reduce sildenafil dose frequency to once daily for pulmonary hypertension
  - Sirolimus: telithromycin increases plasma concentration of:
    - SIROLIMUS—avoid concomitant use
  - Tacrolimus: telithromycin possibly increases plasma concentration of:
    - TACROLIMUS
  - Ulipristal: avoidance of telithromycin advised by manufacturer of:
    - LOW-DOSE ULIPRISTAL
  - Vaccines: antibacterials inactivate:
    - ORAL TYPHOID VACCINE—see under Typhoid Vaccine in BNF

Temisipamil

- Angiotensin-II Receptor Antagonists
- ANXIOLytics and Hypnotics
- TEMOCILLin

Temoporfin

- Cytotoxics: increased skin photosensitivity when temoporfin given with topical:
  - FLUOROURACIL

Temozolomide

- Antiepileptics: plasma concentration of temozolomide increased by:
  - SODIUM VALPROATE and VALPROIC ACID
- Antipsychotics: avoid concomitant use of cytoxotics with:
  - CLOZAPINE (increased risk of agranulocytosis)

Temsirolimus

- NOTE The main active metabolite of temsirolimus is sirolimus—see also interactions of sirolimus and consult product literature
- Antibacterials: plasma concentration of active metabolite of temsirolimus reduced by:
  - RIFAMPCIN—avoid concomitant use
- Antifungals: plasma concentration of active metabolite of temsirolimus increased by:
  - KETOCONAZOLE—avoid concomitant use; manufacturer of temsirolimus advises avoid concomitant use with:
    - IRaconazole (plasma concentration of temsirolimus possibly increased)
- Antipsychotics: avoid concomitant use of cytoxotics with:
  - CLOZAPINE (increased risk of agranulocytosis)

Tenofivir

- Antivirals: manufacturer of tenofivir advises avoid concomitant use with:
  - ADEOFIVIR; tenofivir reduces plasma concentration of:
    - ATAZANAVIR, also plasma concentration of tenofivir possibly increased; tenofivir increases plasma concentration of:
      - DIDANOSES (increased risk of toxicity)—avoid concomitant use; plasma concentration of tenofivir increased by:
        - LOPINAVIR and TELAPREVIR
- Orlistat: absorption of tenofivir possibly reduced by:
  - ORLISTAT

Tenofovir

- see NSAIDs

Terazosin

- see Alpha-blockers

Terbinafine

- Antibacterials: plasma concentration of terbinafine reduced by:
  - RIFAMPCIN
- Antidepressants: terbinafine possibly increases plasma concentration of:
  - PAROXETINE and TRICYCLICS
- Antifungals: terbinafine increases plasma concentration of:
  - FLUCONAZOLE
- Ciclosporin: terbinafine possibly reduces plasma concentration of:
  - CICLOSPORIN
- Oestrogens: occasional reports of breakthrough bleeding when terbinafine given with:
  - OESTROGENS (when used for contraception)
- Progestogens: occasional reports of breakthrough bleeding when terbinafine given with:
  - PROGESTGENS (when used for contraception)
- Ulcer-healing Drugs: plasma concentration of terbinafine increased by:
  - CIMETIDINE

Terbutaline

- see Sympathomimetics, Beta2
Teriflunomide
  - Antibacterials: teriflunomide increases plasma concentration of CEFACLOR; plasma concentration of teriflunomide reduced by RIFAMPICIN.
  - Antiadrenergics: teriflunomide increases plasma concentration of PEPAGUANIDE.
  - Lipid-regulating Drugs: the effect of teriflunomide is significantly decreased by COLESTYRAMINE (enhanced elimination)—avoid unless drug elimination desired; teriflunomide increases plasma concentration of:
    - ROSUVASTATIN (consider reducing dose of rosuvastatin).
  - Oestrogens: teriflunomide increases plasma concentration of ETHINYLESTRODIOL.
  - Progestogens: teriflunomide increases plasma concentration of LEVONORGESTREL.
  - Vaccines: risk of generalised infections when teriflunomide given with live vaccines—avoid concomitant use.

Testolactone
  - Anticoagulants: testolactone enhances anticoagulant effect of:
    - COUMARINS and PHENIDIONE.

Testosterone
  - Anticoagulants: testosterone enhances anticoagulant effect of:
    - COUMARINS and PHENIDIONE.
  - Antidiabetics: testosterone possibly enhances hypoglycaemic effect of ANTIADIABETICS.
  - Tetrahydrozine
    - Antidepressants: risk of CNS toxicity when tetrabenzine given with MAOIS (avoid tetrabenzine for 2 weeks after MAOIS).
    - Antipsychotics: increased risk of extrapyramidal side-effects when tetrabenzine given with ANTIPSYCHOTICS.
    - Dopaminergics: increased risk of extrapyramidal side-effects when tetrabenzine given with AMANTADINE.
    - Metoclopramide: increased risk of extrapyramidal side-effects when tetrabenzine given with METOCLOPRAMIDE.

Tetracosactide
  - see Corticosteroids.

Tetracyclines see Tetracyclines

Tetracyclines
  - ACE inhibitors: absorption of tetracyclines reduced by QUINAPRIL tablets (quinapril tablets contain magnesium carbonate).
  - Adsorbents: absorption of tetracyclines possibly reduced by KAOLIN.
  - Antacids: absorption of tetracyclines reduced by ANTACIDS.
  - Antidiabetics: plasma concentration of doxycycline reduced by RIFAMPICIN—consider increasing dose of doxycycline; tetracyclines possibly antagonise effects of PENICILLINS.
  - Anticoagulants: tetracyclines possibly enhance anticoagulant effect of:
    - COUMARINS and PHENIDIONE.
  - Antidiabetics: tetracyclines possibly enhance hypoglycaemic effect of ANTIADIABETICS.
  - Tetrabenzine
    - Antidepressants: risk of CNS toxicity when tetrabenzine given with MAOIS (avoid tetrabenzine for 2 weeks after MAOIS).
    - Antipsychotics: increased risk of extrapyramidal side-effects when tetrabenzine given with ANTIPSYCHOTICS.
    - Dopaminergics: increased risk of extrapyramidal side-effects when tetrabenzine given with AMANTADINE.
    - Metoclopramide: increased risk of extrapyramidal side-effects when tetrabenzine given with METOCLOPRAMIDE.

Teriflunomide (continued)
  - Steroidal: absorption of tetracyclines reduced by STRONTIUM RANELATE (manufacturer of strontium ranelate advises avoid concomitant use).
  - Ulcer-healing Drugs: absorption of tetracyclines reduced by CLARITHROMYCIN and ISONIAZID; plasma concentration of tetracycline increased by CLARITHROMYCIN and CIPROFLOXACIN; metabolism of tetracycline accelerated by RIFAMPICIN (reduced plasma concentration); possible increased risk of convulsions when tetracycline given with QUINOLONES.
  - Antidepressants: plasma concentration of tetracycline increased by FLUOXETINE (concomitant use should usually be avoided, but where not possible halve tetracycline dose and monitor plasma-tetracycline concentration); plasma concentration of tetracycline possibly reduced by ST JOHN’S WORT.

Teriflunomide
  - Antiepileptics: metabolism of theophylline accelerated by CARBAMAZEPINE, PHENOBARBITAL and PRIMIDONE (reduced effect); plasma concentration of both drugs reduced when theophylline given with:
    - FOSFENITOIN and PHENITOIN.
  - Antifungals: plasma concentration of theophylline possibly reduced by:
    - FLUCONAZOLE and KETOCONAZOLE.
  - Antivirals: plasma concentration of theophylline possibly increased by:
    - ACICLOVIR and VALACICLOVIR; metabolism of theophylline accelerated by:
      - RITONAVIR (reduced plasma concentration).
    - Antipsychotics: plasma concentration of theophylline possibly reduces effects of BENZODIAZEPINES.

Teriflunomide
  - Caffeine citrate: avoidance of theophylline advised by manufacturer of CAFFEINE CITRATE.
  - Calcium-channel Blockers: plasma concentration of theophylline possibly reduced by:
    - CALCIUM-CHANNEL BLOCKERS (enhanced effect); plasma concentration of theophylline increased by:
      - DILTIAZEM; plasma concentration of theophylline increased by:
        - VERAPAMIL (enhanced effect).
    - Corticosteroids: increased risk of hypokalaemia when theophylline given with CORTICOSTEROIDS.
    - Cytotoxics: plasma concentration of theophylline possibly reduced by METHOTREXATE.

Teriflunomide
  - Deferasirox: plasma concentration of theophylline increased by:
    - DEFERASIRON (consider reducing dose of theophylline).
  - Disulfiram: metabolism of theophylline inhibited by:
    - DISULFiram (increased risk of toxicity).
  - Diuretics: increased risk of hypokalaemia when theophylline given with:
    - ACETAZOLAMIDE, LOOP DIURETICS and THIAZIDES AND RELATED DIURETICS.
  - Doxapram: increased CNS stimulation when theophylline given with:
    - DOXAPRAM.
  - Interferons: metabolism of theophylline inhibited by:
    - INTERFERON ALFA and PEIGNERIFERON ALFA (consider reducing dose of theophylline).
  - Leukotriene Receptor Antagonists: plasma concentration of theophylline possibly reduced by:
    - ZAFIRILUKAST, also plasma concentration of zafirlukast reduced.
  - Lithium: theophylline increases excretion of LITHIUM (reduced plasma concentration).
  - Oestrogens: plasma concentration of theophylline increased by:
    - OESTROGENS (consider reducing dose of theophylline).
Theophylline (continued)
- Pentoxifylline: plasma concentration of theophylline increased by pentoxifylline
- Roflumilast: avoidance of theophylline advised by manufacturer of roflumilast
- Sulfapyrazone: plasma concentration of theophylline reduced by sulfipyrazone
- Symptomimetics: manufacturer of theophylline advises avoid concomitant use with ephedrine in children
- Symptomimetics, Betas: increased risk of hypokalaemia when theophylline given with high doses of beta-sympathomimetics

- Ulcer-healing Drugs: metabolism of theophylline inhibited by:
  - Cimetidine (increased plasma concentration); absorption of theophylline possibly reduced by sucralfate (give at least 2 hours apart)
- Vaccines: plasma concentration of theophylline possibly increased by influenza vaccine

Thiazolidinediones see Antidiabetics
Thiotepa see Anaesthetics, General
Thiopentone
- Antipsychotics: avoid concomitant use of cytotoxics with:
  - Clozapine (increased risk of agranulocytosis)
- Muscle relaxants: thiopentone enhances effects of suxamethonium

Thioxanthenes see Antipsychotics
Thyroid Hormones
- Antacids: absorption of levothyroxine possibly reduced by antacids
- Anti-arrhythmics: serum concentrations of thyroid hormones can be affected by amiodarone—monitor thyroid function closely
- Antibacterials: metabolism of levothyroxine accelerated by rifampicin (may increase requirements for levothyroxine in hypothyroidism)
- Anticoagulants: thyroid hormones enhance anticoagulant effect of coumarins and phenindione
- Antidepressants: thyroid hormones enhance effects of amitriptyline and imipramine; thyroid hormones possibly enhance effects of tricyclics
- Antiepileptics: metabolism of thyroid hormones accelerated by carbamazepine, phenobarbitone and primidone (may increase requirements for thyroid hormones in hypothyroidism); metabolism of thyroid hormones accelerated by fosphenytoin and phenytoin (may increase requirements in hypothyroidism), also plasma concentration of fosphenytoin and phenytoin possibly increased
- Beta-blockers: levothyroxine accelerates metabolism of propranolol
- Calcium Salts: absorption of levothyroxine reduced by calcium salts
- Colestilan: manufacturer of colestilan advises give levothyroxine at least 1 hour before or 3 hours after colestilan
- Cytotoxics: plasma concentration of levothyroxine possibly reduced by imatinib
- Iron Salts: absorption of levothyroxine reduced by oral iron salts (give at least 2 hours apart)
- Lanthanum: absorption of levothyroxine reduced by lanthanum (give at least 2 hours apart)
- Lipid-regulating Drugs: absorption of levothyroxine reduced by colesvelelam; absorption of thyroid hormones reduced by colistipol and colestyramine
- Oestrogens: requirements for thyroid hormones in hypothyroidism may be increased by oestrogens
- Orlistat: possible increased risk of hypothyroidism when levothyroxine given with orlistat
- Polystyrene Sulfonate Resins: absorption of levothyroxine reduced by polystyrene sulfonate resins
- Sevelamer: absorption of levothyroxine possibly reduced by sevelamer
- Ulcer-healing Drugs: absorption of levothyroxine reduced by cimetidine and sucralfate

Tiagabine
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by maois and tricyclic-related antidepressants
- Antiepileptics: anticonvulsant effect of antiepileptics antagonised by antipsychotics (convulsive threshold lowered)
- Anticoagulants: possible increased risk of hypothyroidism when anticoagulants are given with ticagrelor
- Antibacterials: increased risk of toxicity when ticagrelor is given with alcohol
- Antibacterials inactivate oral typhoid vaccine—see under Typhoid Vaccine in BNF
- Beta-blockers: ticagrelor increases plasma concentration of dabigatran
- Cardiovascular Glycosides: ticagrelor increases plasma concentration of digoxin
- Ciclosporin: plasma concentration of ticagrelor increased by ciclosporin
- Ergot Alkaloids: ticagrelor possibly increases plasma concentration of ergot alkaloids
- Lipid-regulating Drugs: ticagrelor increases plasma concentration of simvastatin (increased risk of toxicity); separating administration from ticagrelor by 12 hours advised by manufacturer of lomitapide

Ticagrelor
- Antiepileptics: metabolism of ticagrelor possibly increased by clarithromycin—manufacturer of ticagrelor advises avoid concomitant use; plasma concentration of ticagrelor possibly increased by erythromycin; plasma concentration of ticagrelor reduced by rifampicin
- Anticoagulants: ticagrelor increases plasma concentration of dabigatran
- Antidepressants: possible increased risk of bleeding when ticagrelor given with citalopram, paroxetine or sertraline
- Antiepileptics: plasma concentration of ticagrelor possibly reduced by carbamazepine, fosphenytoin, phenobarbitone, phenytoin and primidone
- Antifungals: plasma concentration of ticagrelor increased by ketoconazole—manufacturer of ticagrelor advises avoid concomitant use
- Antivirals: plasma concentration of ticagrelor possibly increased by atazanavir and ritonavir—manufacturer of ticagrelor advises avoid concomitant use
- Calcium-channel Blockers: plasma concentration of ticagrelor increased by diltiazem
- Cardiac Glycosides: ticagrelor increases plasma concentration of digoxin
- Ciclosporin: plasma concentration of ticagrelor increased by ciclosporin
- Ergot Alkaloids: ticagrelor possibly increases plasma concentration of ergot alkaloids
- Lipid-regulating Drugs: ticagrelor increases plasma concentration of simvastatin (increased risk of toxicity); separating administration from ticagrelor by 12 hours advised by manufacturer of lomitapide

Ticarbilin see Penicillins
Tic-borne Encephalitis Vaccine see Vaccines
Tigecycline
- Anticoagulants: tigecycline possibly enhances anticoagulant effect of coumarins
- Vaccines: antibacterials inactivate oral typhoid vaccine—see under Typhoid Vaccine in BNF

Timolol see Beta-blockers
Tinidazole
- Alcohol: possibility of disulfiram-like reaction when tinidazole given with alcohol
- Antibacterials: plasma concentration of tinidazole possibly reduced by rifampicin
- Vaccines: antibacterials inactivate oral typhoid vaccine—see under Typhoid Vaccine in BNF

Tinzaparin see Heparins
Tioguanine
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cytotoxics: increased risk of hepatotoxicity when tioguanine given with busulfan

Tiotropium see Antimuscarinics
Tipranavir
- Analgesics: plasma concentration of tipranavir possibly reduced by buprenorphine
- Antacids: absorption of tipranavir reduced by antacids (give at least 2 hours apart)
- Antibacterials: tipranavir increases plasma concentration of clarithromycin (reduce dose of clarithromycin in renal impairment), also plasma concentration of tipranavir increased by clarithromycin; tipranavir increases plasma concentration of rifabutin (reduce dose of rifabutin); plasma concentration of tipranavir possibly reduced by rifampicin—avoid concomitant use; avoidance of concomitant tipranavir in severe renal and hepatic impairment advised by manufacturer of telithromycin
- Anticoagulants: tipranavir advised avoid concomitant use with warfarin and low molecular weight heparins
- Antidepressants: plasma concentration of tipranavir possibly reduced by st john's wort—avoid concomitant use
- Antiepileptics: plasma concentration of tipranavir possibly reduced by carbamazepine
- Antifungals: plasma concentration of tipranavir increased by fluconazole
- Antimalarials: caution with tipranavir advised by manufacturer of artemether with lumefantrine; tipranavir possibly increases plasma concentration of quinine (increased risk of toxicity)
- Antimuscarinics: avoidance of tipranavir advised by manufacturer of darifenacin
- Antipsychotics: tipranavir possibly increases plasma concentration of aripiprazole (reduce dose of aripiprazole—consult aripiprazole product literature); tipranavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use
- Antivirals: tipranavir reduces plasma concentration of abacavir, fosamprenavir, lopinavir, saquinavir and zidovudine; plasma concentration of tipranavir increased by atazanavir (also plasma concentration of atazanavir reduced); manufacturer of tipranavir advises avoid concomitant use with boceprevir and telaprevir; tipranavir reduces plasma concentration of didanosine—manufacturer of tipranavir advises tipranavir and didanosine capsules should be taken at least 2 hours apart; tipranavir reduces the plasma concentration of dolastegavir (see under dolastegavir, p. 557); tipranavir reduces plasma concentration of etravirine, also plasma concentration of tipranavir increased (avoid concomitant use)
- Beta-blockers: manufacturer of tipranavir advises avoid concomitant use with metoprolol for heart failure
- Beta-blockers: manufacturer of tipranavir advises avoid concomitant use with bosentan
- Cobicistat: plasma concentration of both drugs reduced when tipranavir given with cobicistat (avoid concomitant use)
- CYP3A4 inhibitors: increased risk of myopathy when tipranavir given with atorvastatin (see under atorvastatin, p. 179); tipranavir increases plasma concentration of rosuvastatin—adjust dose of rosuvastatin (consult product literature); tipranavir possibly increases plasma concentration of simvastatin—avoid concomitant use; avoidance of tipranavir advised by manufacturer of lomitapide (plasma concentration of lomitapide possibly increased)
- CYP3A4 inducers: absorption of tipranavir possibly reduced by orlistat
- CYP3A4 substrates: tipranavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- CYP3A4 substrates: manufacturer of tipranavir advises avoid concomitant use of sildenafil for pulmonary arterial hypertension
- CYP3A4 substrates: sympathomimetics, beta; manufacturer of tipranavir advises avoid concomitant use with salmeterol
- CYP3A4 substrates: ulcer-healing drugs: tipranavir reduces plasma concentration of esomeprazole and omeprazole
- CYP3A4 substrates: manufacturer of tipranavir advises caution with vardenafil

Tipranavir (continued)
- Vitamins: increased risk of bleeding when tipranavir given with high doses of vitamin e

Tirofiban
- Heparin: increased risk of bleeding when tirofiban given with heparin
- Tizanidine see muscle relaxants
- Tolbutamide see antidiabetics
- Tolcapone
- Antidepressants: avoid concomitant use of tolcapone with MAOIs
- Memantine: effects of dopaminergics possibly enhanced by memantine
- Methyldopa: antiparkinsonian effect of dopaminergics antagonised by methyldopa
- Tolnaftate see NSAIDs
- Tolterodine see antimuscarinics

Tolvaptan
- Antibacterials: plasma concentration of tolvaptan reduced by rifampicin
- Antifungals: plasma concentration of tolvaptan increased by ketoconazole—manufacturer of ketoconazole advises avoid concomitant use
- Cardiac Glycosides: tolvaptan increases plasma concentration of digoxin (increased risk of toxicity)
- Grapefruit juice: plasma concentration of tolvaptan increased by grapefruit juice—avoid concomitant use
- Lipid-regulating Drugs: separating administration from tolvaptan by 12 hours advised by manufacturer of lomitapide

Topiramate
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepresants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered)
- Antidiabetics: topiramate possibly increases plasma concentration of meformin; topiramate possibly reduces plasma concentration of glibenclamide
- Antiepileptics: plasma concentration of topiramate often reduced by carbamazepine; topiramate increases plasma concentration of fosphenytoin and phenytoin (also plasma concentration of topiramate reduced); topiramate reduces plasma concentration of perampanel; plasma concentration of topiramate possibly reduced by phenobarbital and primidone; hyperammonaemia and CNS toxicity reported when topiramate given with sodium valproate and valproic acid
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by mefloquine
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by antipsychotics (convulsive threshold lowered)
- Biuretics: plasma concentration of topiramate possibly increased by hydrochlorothiazide
- Lithium: topiramate possibly affects plasma concentration of lithium
- Oestrogens: topiramate accelerates metabolism of oestrogens (reduced contraceptive effect with combined oral contraceptives, contraceptive patches, and vaginal rings—see Contraceptive Interactions in BNF)
- Oestrogens: possible increased risk of convulsions when antiepileptics given with orlistat
- Progestogens: topiramate accelerates metabolism of progestogens (reduced contraceptive effect with combined oral contraceptives, progestogen-only oral contraceptives, contraceptive patches, vaginal rings, eutogestrel-releasing implant, and emergency hormonal contraception—see Contraceptive Interactions in BNF)
Interactions

Trimethoprim

- Anticoagulants: trimethoprim possibly increases plasma concentration of \textit{CUMARINS}
- Antiepileptics: metabolism of trimethoprim possibly accelerated by \textit{CARBAMAZEPINE} (reduced plasma concentration); metabolism of trimethoprim possibly accelerated by \textit{PHOSPHENYTOIN} and \textit{PHENYTOIN}; metabolism of trimethoprim accelerated by \textit{PHENOBARBITAL} and \textit{PRIMIDONE} (reduced plasma concentration)
- Cytotoxics: possible increased risk of ventricular arrhythmias when trimethoprim given with \textit{VANDENATANIB}—avoid concomitant use
- Diuretics: increased risk of hypercalcaemia when trimethoprim given with \textit{THIAZIDES AND RELATED DIURETICS}

Trantolapril

- Antiepileptics: metabolism of toremifene possibly enhanced by \textit{CARBAMAZEPINE} (reduced plasma concentration); metabolism of toremifene possibly accelerated by \textit{PHOSPHENYTOIN} and \textit{PHENYTOIN}; metabolism of toremifene accelerated by \textit{PHENOBARBITAL} and \textit{PRIMIDONE} (reduced plasma concentration)
- Cytotoxics: possible increased risk of haematological toxicity when trimethoprim given with \textit{METHOTREXATE}
- Diuretics: increased risk of hyperkalaemia when trimethoprim given with \textit{SPIRONOLACTONE}

Trihexyphenidyl

- Vaccines: antibacterials inactivate \textit{ORAL TYPHOID VACCINE}—see under Typhoid Vaccine in \textit{BNF}

Ulipristal

- Anticoagulants: ulipristal possibly reduced (contraceptive effect of ulipristal possibly reduced)
- Antidepressants: ulipristal possibly reduced (contraceptive effect of ulipristal possibly reduced)
- Antiepileptics: increased risk of nephrotoxicity when trimethoprim given with \textit{CICLOSPORIN}, also plasma concentration of ciclosporin reduced by \textit{INTRAENOUS}

Ursooxyhemic Acid

- Bile Acids

Vaccines

- Abacavir: risk of generalised infections when monoclonal antibodies given with live \textit{VACCINES}—avoid concomitant use
- Aminophylline: influenza vaccine possibly increases plasma concentration of \textit{AMINOPHYLLINE}
Vaccines (continued)

- Anakinra: risk of generalised infections when live vaccines given with • ANAKINRA—avoid concomitant use
- Antibacterials: oral typhoid vaccine inactivated by • ANTIBACTERIALS—see under Typhoid Vaccine in BNF
- Antivirals: influenza vaccine possibly enhances anticoagulant effect of WARFARIN
- Antiepileptics: influenza vaccine enhances effects of FOSPHENYTOIN and PHENYTOIN
- Antimalarials: oral typhoid vaccine inactivated by • ANTIMALARIALS—see under Typhoid Vaccine in BNF
- Corticosteroids: immune response to vaccines impaired by high doses of • CORTICOSTEROIDS—avoid concomitant use with live vaccines
- Cytotoxics: risk of generalised infections when live vaccines given with • DOXORUBICIN, • MONOCLONAL ANTIBODIES, • PIXANTRONE or • TRABECETIN—avoid concomitant use
- Dexamethasone: risk of generalised infections when live vaccines given with • DEXAMETHASONE—avoid concomitant use
- Etanercept: risk of generalised infections when live vaccines given with • ETANERCEPT—avoid concomitant use
- Immunglobulins: impaired immune response to oral poliomyelitis vaccine might occur with • ANTI-D IMMUNOGLOBULINS and • NORMAL IMMUNOGLOBULINS—give oral poliomyelitis vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; impaired immune response to BCG vaccine, MMR vaccine, oral typhoid vaccine, rotavirus vaccine, smallpox vaccine, varicella-zoster vaccine and yellow fever vaccine might occur with • ANTI-D IMMUNOGLOBULINS—give BCG vaccine, MMR vaccine, oral typhoid vaccine, rotavirus vaccine, smallpox vaccine, varicella-zoster vaccine and yellow fever vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins; impaired immune response to live influenza vaccine might occur with • ANTI-D IMMUNOGLOBULINS and • NORMAL IMMUNOGLOBULINS—give live influenza vaccine at least 3 weeks before or 3 months after anti-d immunoglobulins and normal immunoglobulin; impaired immune response to BCG vaccine, MMR vaccine, oral typhoid vaccine, rotavirus vaccine, smallpox vaccine, varicella-zoster vaccine and yellow fever vaccine might occur with • NORMAL IMMUNOGLOBULINS—give BCG vaccine, MMR vaccine, oral typhoid vaccine, rotavirus vaccine, smallpox vaccine, varicella-zoster vaccine and yellow fever vaccine at least 3 weeks before or 3 months after normal immunoglobulin
- Interferons: avoidance of vaccines advised by manufacturer of • INTERFERON GAMMA
- Leflunomide: risk of generalised infections when live vaccines given with • LEFLUNOMIDE—avoid concomitant use
- Teriflunomide: risk of generalised infections when live vaccines given with • TERIFLUNOMIDE—avoid concomitant use
- Theophylline: influenza vaccine possibly increases plasma concentration of THEOPHYLLINE

Valaciclovir

- Aminophylline: valaciclovir possibly increases plasma concentration of AMINOPHYLLINE
- Ciclosporin: increased risk of nephrotoxicity when valaciclovir given with • CICLOSPORIN
- Mycophenolate: plasma concentration of valaciclovir increased by MYCOPHENOLATE, also plasma concentration of inactive metabolite of mycophenolate increased
- Tacrolimus: possible increased risk of nephrotoxicity when valaciclovir given with • TACROLIMUS
- Theophylline: valaciclovir possibly increases plasma concentration of THEOPHYLLINE

Valganciclovir

- Antibacterials: increased risk of convulsions when valganciclovir given with • IMIPENEM WITH CLINSTATIN
- Anticancer drugs: valganciclovir possibly increases plasma concentration of DIDANOINE; profound myelosuppression when valganciclovir given with • ZIDOVUDINE (if possible avoid concomitant administration, particularly during initial valganciclovir therapy)
- Mycophenolate: plasma concentration of valganciclovir possibly increased by MYCOPHENOLATE, also plasma concentration of inactive metabolite of mycophenolate possibly increased
- Tacrolimus: possible increased risk of nephrotoxicity when valganciclovir given with • TACROLIMUS

Valproic Acid

- Analgesics: effects of valproic acid enhanced by • ASPIRIN
- Antibacterials: metabolism of valproic acid possibly inhibited by • ERYTHROMYCIN (increased plasma concentration, avoidance of valproic acid advised by manufacturer of • PIVMECILAMIN; plasma concentration of valproic acid reduced by • CARBAPENEMS—avoid concomitant use
- Anticoagulants: valproic acid possibly enhances anticoagulant effect of CUMARINS
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by • MAOIS and • TRICYCLIC-RELATED ANTIDEPRESSANTS (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by • SSRIS and • TRICYCLICS (convulsive threshold lowered)
- Antiepileptics: plasma concentration of valproic acid reduced by • CARBAMAZEPINE, also plasma concentration of active metabolite of carbamazepine increased; valproic acid possibly increases plasma concentration of • ETHOSUXIMIDE; valproic acid increases or possibly decreases plasma concentration of • FOSPHENYTOIN and • PHENYTOIN, also plasma concentration of valproic acid reduced; valproic acid increases plasma concentration of • LAMOTRIGINE (increased risk of toxicity—reduce lamotrigine dose); valproic acid sometimes reduces plasma concentration of an active metabolite of • OXCARBAZEPINE; valproic acid increases plasma concentration of • PHENOBARBITAL and • PRIMIDONE (also plasma concentration of valproic acid reduced); valproic acid possibly increases plasma concentration of • RUFINAMIDE (reduce dose of rufinamide); hyperammonaemia and CNS toxicity reported when valproic acid given with • TOPIRAMATE
- Antimalarials: anticonvulsant effect of antiepileptics antagonised by • MELFLOQUINE
- Antipsychotics: anticonvulsant effect of antiepileptics antagonised by • ANTI-PSYCHOTICS (convulsive threshold lowered); valproic acid possibly increases or decreases plasma concentration of • CLOZAPINE; increased risk of side-effects including neutropenia when valproic acid given with • OLANZAPINE
- Antivirals: plasma concentration of valproic acid possibly reduced by • RITONAVIR; valproic acid possibly increases plasma concentration of • ZIDOVUDINE (increased risk of toxicity)
- Anxiolytics and Hypnotics: plasma concentration of valproic acid possibly increased by • CLOBAZAM; increased risk of side-effects when valproic acid given with • CLONAZEPAM; valproic acid possibly increases plasma concentration of • DIAZEPAM and • LORAZEPAM
- Bupropion: valproic acid inhibits the metabolism of • BUPROPION
- Cytotoxics: valproic acid increases plasma concentration of • TEMOZOLOMIDE
- Lipid-regulating Drugs: absorption of valproic acid possibly reduced by • COLESTYRAMINE
- Oestrogens: plasma concentration of valproic acid possibly reduced by • ETHINYLESTRIADIOL
- Orlistat: possible increased risk of convulsions when antiepileptics given with • ORLISTAT
- Sodium Benzoate: valproic acid possibly reduces effects of • SODIUM BENZOATE
- Sodium Oxbate: valproic acid increases the plasma concentration of • SODIUM OXVATE (see under Sodium Oxbate, p. 425)
- Sodium Phenybutyrate: valproic acid possibly reduces effects of • SODIUM PHENYL BUTYRATE
- Ulcer-healing Drugs: metabolism of valproic acid inhibited by • CIMETIDINE (increased plasma concentration)

Valsartan see Angiotensin-II Receptor Antagonists

Vancomycin

- Anaesthetics, General: hypersensitivity-like reactions can occur when intravenous vancomycin given with • GENERAL ANAESTHETICS
Appendix 1 Interactions

Vandetanib

- **Hormone Antagonists:**
  - **Beta-blockers:** increased risk of nephrotoxicity when vandetanib given with **AMIODARONE** or **DISOPYRAMIDE**—avoid concomitant use.
  - **Antidiabetics:** increased risk of ventricular arrhythmias when vandetanib given with **CARBAMAZEPINE**, **NICOTINICOTINE**, **PHENOBARBITAL**, **PHENYTOIN**, **SULPIRIDE**, or **ZUCLOPENTHILOXIL**—avoid concomitant use; avoid concomitant use with **ST JOHN’S WORT** (plasma concentration of vandetanib possibly reduced).
  - **Diuretics:** increased risk of ventricular arrhythmias when vandetanib given with **LUMEFANTRINE**—consider reducing dose of vandetanib (consult cobicistat product literature).

- **Antidepressants:**
  - **Antidepressants:** manufacturer of vandetanib advises avoid concomitant use with **CARBAMAZEPINE**, **PHENOBARBITAL** and **PRIMIDONE** (plasma concentration of vandetanib possibly reduced).
  - **Antihistamines:** increased risk of ventricular arrhythmias when vandetanib given with **MIZOLASTINE**—avoid concomitant use.
  - **Antimalarials:** increased risk of ventricular arrhythmias when vandetanib given with **AMIFLUX**—avoid concomitant use.
  - **Antipsychotics:** increased risk of ventricular arrhythmias when vandetanib given with **AMISULPRIDE**, **HALOPERIDOL**, **PIMOZIDE**, **SULPIRIDE** or **ZUCLOPENTHILOXIL**—avoid concomitant use; avoid concomitant use of cytoxotics with **CLOZAPINE** (increased risk of agranulocytosis).

- **Analgesics:**
  - **Beta-blockers:** possible increased risk of ventricular arrhythmias when vandetanib given with **SOTALOL**—avoid concomitant use.
  - **Cardiac Glycosides:** vandetanib increases plasma concentration of **DIGOXIN**—possible increased risk of bradycardia.
  - **Cytotoxic:** possible increased risk of ventricular arrhythmias when vandetanib given with **ARSENIC TRIOXIDE**—avoid concomitant use.
  - **Hormone Antagonists:** possible increased risk of ventricular arrhythmias when vandetanib given with **Toremifene**—avoid concomitant use.
  - **SHT-receptor Antagonists:** increased risk of ventricular arrhythmias when vandetanib given with **ONDANSETRON**—avoid concomitant use.
  - **Pentamidine isonitate:** possible increased risk of ventricular arrhythmias when vandetanib given with **PENTAMIDINE ISONITRATE**—avoid concomitant use.

- **Antibacterials:**
  - **Antibacterials:** plasma concentration of vandetanib possibly increased by **FOSAMPRENAVIR**—avoid concomitant use; plasma concentration of vandetanib increased by **TIBFENIVIR**—avoid concomitant use; increased risk of ventricular arrhythmias when vandetanib given with **CRITIYBICSTAT**—avoid concomitant use; avoidance of vandetanib advised by manufacturer of **TIBFENIVIR**—caution with vandetanib advised by manufacturer of **TIBFENIVIR**.
  - **Cobain-channel Blockers:** enhanced hypotensive effect when vandetanib given with **NIFEDIPINE**.

- **Antivirals:**
  - **Antivirals:** plasma concentration of vandetanib possibly increased by **FOSAMPRENAVIR**—avoid concomitant use; plasma concentration of vandetanib increased by **INDINAVIR** and **RITONAVIR**—avoid concomitant use; increased risk of ventricular arrhythmias when vandetanib given with **SAMLOPINE**—avoid concomitant use; avoidance of vandetanib advised by manufacturer of **TIBFENIVIR**.
  - **Calcium-channel Blockers:** enhanced hypotensive effect when vandetanib given with **NIFEDIPINE**.

- **Anticonvulsants:**
  - **Anticonvulsants:** enhanced hypotensive effect when vandetanib given with **RUCTIGAN®**—avoid concomitant use.

- **Antihypertensives:**
  - **ACE Inhibitors:** enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with **ACE INHIBITORS**.
  - **Alpha-blockers:** enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with **ADRENERGIC NEURONE BLOCKERS**.
  - **Alcohol:** enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with **ALCOHOL**.
  - **Aldesleukin:** enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with **ALDESLEUKIN**.
  - **Alphablockers:** enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with **ALPHA-BLOCKERS**.
  - **Anaesthetic, General:** enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with **GENERAL ANAESTHETICS**.
  - **Analgesics:** enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with **GENERAL ANALGESICS**.

**Vardenafil**

- **Alpha-blockers:** enhanced hypotensive effect when vardenafil given with **ALPHA-BLOCKERS**—when patient is stable on the alpha blocker initiate vardenafil at the lowest possible dose—separate doses by 6 hours (except with tamsulosin).
- **Anti-arrhythmics:** avoidance of vardenafil advised by manufacturer of **DISOPYRAMIDE** (risk of ventricular arrhythmias).
- **Antibacterials:** plasma concentration of vardenafil possibly increased by **ERTHROMYCIN** (consider reducing initial dose of vardenafil); plasma concentration of vardenafil increased by **ERYTHROMYCIN** (reduce dose of vardenafil).
- **Antifungals:** plasma concentration of vardenafil increased by **KETOCONAZOLE**—avoid concomitant use; plasma concentration of vardenafil possibly increased by **ITRACONAZOLE**—avoid concomitant use.
- **Antivirals:** plasma concentration of vardenafil possibly increased by **FOSAMPRENAVIR**—avoid concomitant use; plasma concentration of vardenafil increased by **INDINAVIR** and **RITONAVIR**—avoid concomitant use; increased risk of ventricular arrhythmias when vardenafil given with **SAMLOPINE**—avoid concomitant use; avoidance of vardenafil advised by manufacturer of **TIBFENIVIR**—caution with vandetanib advised by manufacturer of **TIBFENIVIR**.
- **Calcium-channel Blockers:** enhanced hypotensive effect when vandetanib given with **RUCTIGAN®**—avoid concomitant use.
- **Anticonvulsants:** enhanced hypotensive effect when vandetanib given with **RUCTIGAN®**—avoid concomitant use.
- **Antihypertensives:** enhanced hypotensive effect when vandetanib given with **RUCTIGAN®**—avoid concomitant use.

**Varicella-zoster Vaccine**—see Vaccines.
Vasodilator Antihypertensives (continued)  
- Calcium-channel Blockers: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with CALCULUM CHANNEL BLOCKERS  
- Clonidine: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with CLONIDINE  
- Corticosteroids: hypotensive effect of hydralazine, minoxidil and sodium nitroprusside antagonised by CORTICOSTEROIDS  
- Diazoxide: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with DIAZOXIDE  
- Diuretics: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with DIURETICS  
- Dopaminergic: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with DOPIAMINERGIC  
- Vasodilator Antihypertensives: enhanced hypotensive effect when hydralazine given with MINOXIDIL or DUMOXIDINE  
  - Nitrates: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with NITRATES  
  - Oestrogens: hypotensive effect of hydralazine, minoxidil and sodium nitroprusside antagonised by OESTROGENS  
  - Prostaglandins: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside given with PROSTAGLANDIN  
  - Vasodilator Antihypertensives: enhanced hypotensive effect when hydralazine given with MINOXIDIL or DUMOXIDINE  

Vemurafenib  
- Analgesics: increased risk of bleeding when venlafaxine given with ANALGESICS  
- NSAIDS or ASPIRIN: possible increased serotonergic effects when SSRI-related antidepressants given with FENTANYL; possible increased serotonergic effects when venlafaxine given with TRAMADOL  
- Anticoagulants: venlafaxine possibly enhances anticoagulant effect of Warfarin; possible increased risk of bleeding when SSRI-related antidepressants given with DABIGATRAN  
- Antipsychotics: venlafaxine increases plasma concentration of HALOPERIDOL  
- Atomoxetine: possible increased risk of convulsions when antidepressants given with ATOMOXETINE  
- Dopamine: possible increased risk of serotonergic effects when venlafaxine given with DOPAMINERGIC  
- Ejaculation: manufacturer of vemurafenib advises avoid concomitant use of cytoxics with EJACULATION  
- PHENYTOIN—risk of CNS toxicity when SSRI-related antidepressants given with METHYLPHENOTHIAZINES  
- Dapoxetine: manufacturer of vemurafenib advises avoid venlafaxine for 2 weeks after stopping venlafaxine  
- Dopaminergic: caution with venlafaxine advised by manufacturer of ENTACAPONE; increased risk of hypertension and CNS excitation when venlafaxine given with Dopaminergic  
- Selegiline (selegiline should not be started until 1 week after stopping venlafaxine, avoid venlafaxine for 2 weeks after stopping selegiline)  
- Dopamine: possible increased risk of convulsions when given with dopaminergic  
- Antidepressants: possible increased risk of convulsions when given with antipsychotics  
- Antidepressants: possible increased risk of convulsions when given with MOCLOBEMIDE  
- Antipsychotics: venlafaxine increases plasma concentration of HALOPERIDOL  
- Atomoxetine: possible increased risk of convulsions when antidepressants given with ATOMOXETINE  
- Dopamine: possible increased risk of serotonergic effects when venlafaxine given with DOPAMINERGIC  
- PHENYTOIN—risk of CNS toxicity when SSRI-related antidepressants given with METHYLPHENOTHIAZINES  
- Dapoxetine: manufacturer of vemurafenib advises avoid concomitant use of cytoxics with DOPAMINERGIC  
- PHENYTOIN—risk of CNS toxicity when SSRI-related antidepressants given with METHYLPHENOTHIAZINES  
- Dapoxetine: manufacturer of vemurafenib advises avoid concomitant use of cytoxics with DOPAMINERGIC  
- PHENYTOIN—risk of CNS toxicity when SSRI-related antidepressants given with METHYLPHENOTHIAZINES  
- Dopaminergic: caution with venlafaxine advised by manufacturer of ENTACAPONE; increased risk of hypertension and CNS excitation when venlafaxine given with Dopaminergic  
- Selegiline (selegiline should not be started until 1 week after stopping venlafaxine, avoid venlafaxine for 2 weeks after stopping selegiline)  
- Dopamine: possible increased risk of convulsions when given with dopaminergic  
- Antidepressants: possible increased risk of convulsions when given with antipsychotics  
- Antidepressants: possible increased risk of convulsions when given with MOCLOBEMIDE  
- Antipsychotics: venlafaxine increases plasma concentration of HALOPERIDOL  
- Atomoxetine: possible increased risk of convulsions when antidepressants given with ATOMOXETINE  
- Dopamine: possible increased risk of serotonergic effects when venlafaxine given with DOPAMINERGIC
Vincristine

- Antibacterials: possible increased risk of ventricular arrhythmias when vincristine given with • DELAMANID
- Antifungals: possible increased risk of vincristine toxicity when given with • ITRACONAZOLE; metabolism of vincristine possibly inhibited by • POSACONAZOLE (increased risk of neurotoxicity)
- Antimalarials: avoid of vincristine advised by manufacturer of • ARTEMISOL WITH PIPERAQUINE
- Antipsychotics: avoid concomitant use of cytotoxics with • MICONAZOLE (increased risk of agranulocytosis)
- Calcium-channel Blockers: metabolism of vincristine possibly inhibited by • NIFEDIPINE
- Cardiac Glycosides: vincristine possibly reduces absorption of DIGOXIN tablets

Vinflunine

- Antibacterials: plasma concentration of vinflunine possibly reduced by • RIFAMPICIN — manufacturer of vinflunine advises avoid concomitant use; increased risk of ventricular arrhythmias when vinflunine given with • DELAMANID
- Antidepressants: plasma concentration of vinflunine possibly reduced by • ST JOHN’S WORT — manufacturer of vinflunine advises avoid concomitant use
- Antifungals: plasma concentration of vinflunine increased by • KETOCONAZOLE — manufacturer of vinflunine advises avoid concomitant use; possible increased risk of vinflunine toxicity when given with • ITRACONAZOLE
- Antimalarials: avoid of vincristine advised by manufacturer of • ARTEMISOL WITH PIPERAQUINE
- Antipsychotics: avoid concomitant use of cytotoxics with • CLOZAPINE (increased risk of agranulocytosis)
- Antivirals: plasma concentration of vinflunine possibly increased by • RITONAVIR — manufacturer of vinflunine advises avoid concomitant use
- Grapefruit juice: plasma concentration of vinflunine possibly increased by GRAPEFRUIT JUICE — manufacturer of vinflunine advises avoid concomitant use

Vinorelbine

- Antibacterials: possible increased risk of neutropenia when vinorelbine given with • CLARITHROMYCIN; possible increased risk of ventricular arrhythmias when vinorelbine given with • DELAMANID
- Antifungals: possible increased risk of vinorelbine toxicity when given with • ITRACONAZOLE
- Antimalarials: avoidance of vinorelbine advised by manufacturer of • ARTEMISOL WITH PIPERAQUINE
- Antipsychotics: avoid concomitant use of cytotoxics with • CLOZAPINE (increased risk of agranulocytosis)

Vismodegib

- Antibacterials: manufacturer of vismodegib advises avoid concomitant use with • RIFAMPICIN (plasma concentration of vismodegib possibly reduced)
- Antidepressants: manufacturer of vismodegib advises avoid concomitant use with • ST JOHN’S WORT (plasma concentration of vismodegib possibly reduced)
- Antiepileptics: manufacturer of vismodegib advises avoid concomitant use with • CARBAMAZEPINE, • FOSPHENYTOIN and • PHENYTOIN (plasma concentration of vismodegib possibly reduced)
- Antipsychotics: avoid concomitant use of cytotoxics with • CLOZAPINE (increased risk of agranulocytosis)

Vitamin A see Vitamins

Vitamin D see Vitamins

Vitamin E see Vitamins

Vitamin K (Phytonadione) see Vitamins

Vitamins

- Antitumoural: absorption of vitamin A possibly reduced by • NEOMYCIN

Vitamins (continued)

- Anticoagulants: vitamin E possibly enhances anticoagulant effect of • COUMARINS; vitamin K antagonises anticoagulant effect of • COUMARINS and • PHENIDIONE
- Antiepileptics: alfalcaldil, calcitriol, clocalciferol, dihydrotachysterol, ergocalciferol, paricalcit or vitamin D requirements possibly increased when given with • CARBAMAZEPINE; alfalcaldil, calcitriol, clocalciferol, dihydrotachysterol, ergocalciferol, paricalcit or vitamin D requirements possibly increased when given with • FOSPHENYTOIN; alfalcaldil, calcitriol, clocalciferol, dihydrotachysterol, ergocalciferol, paricalcit or vitamin D requirements possibly increased when given with • PHENYTOIN; alfalcaldil, calcitriol, clocalciferol, dihydrotachysterol, ergocalciferol, paricalcit or vitamin D requirements possibly increased when given with • PRIMODONE
- Antifungals: plasma concentration of paricalcit possibly increased by • ITRACONAZOLE; effects of alfalcaldil, calcitriol, clocalciferol, dihydrotachysterol, ergocalciferol, paricalcit and vitamin D possibly reduced by • MICONAZOLE
- Antivirals: increased risk of bleeding when high doses of vitamin E given with • RITONAVIR
- Ciclosporin: vitamin E possibly affects plasma concentration of • CICLOSPORIN
- Cytotoxics: effects of alfalcaldil, calcitriol, clocalciferol, dihydrotachysterol, ergocalciferol, paricalcit and vitamin D possibly reduced by • DACTINOMYCIN; avoidance of vitamin E advised by manufacturer of • IBRUTINIB
- Diuretics: increased risk of hypercalcaemia when alfalcaldil, calcitriol, clocalciferol, dihydrotachysterol, ergocalciferol, paricalcit or vitamin D given with • THIAZIDES AND RELATED DIURETICS
- Dopaminergics: pyridoxine reduces effects of • LEVODOPA when given without dopa-decarboxylase inhibitor
- Lipid-regulating Drugs: absorption of calcitriol possibly reduced by • COLESTYRAMINE (give at least 1 hour before or 4 to 6 hours after colestyramine)
- Retinoids: risk of hypervitaminosis A when vitamin A given with • RETINOIDs — avoid concomitant use
- Selenium: ascorbic acid possibly reduces absorption of • SELLERAM (give at least 4 hours apart)
- Sevelamer: absorption of calcitriol reduced by • SEVELAMER (give at least 1 hour before or 3 hours after sevelamer)
- Voriconazole see Antifungals, Triazole
- Warfarin see Coumarins
- Wasp Venom Extracts

• ACE inhibitors: possible severe anaphylactoid reaction when wasp venom extracts given with • ACE INHIBITORS

Xipamide see Diuretics

Xylometazoline see Sympathomimetics

Yellow Fever Vaccine see Vaccines

Zafirlukast see Leukotriene Receptor Antagonists

Zaleplon see Anxiolytics and Hypnotics

Zidovudine

**NOTE** Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature.

- Analgesics: increased risk of haematological toxicity when zidovudine given with • NSAIDS; plasma concentration of zidovudine possibly increased by • METHADONE
- Antibacterials: absorption of zidovudine reduced by • CLARITHROMYCIN tablets (give at least 2 hours apart); manufacturer of zidovudine advises avoid concomitant use with • RIFAMPICIN
- Antiepileptics: zidovudine increases or decreases plasma concentration of • FOSPHENYTOIN and • PHENYTOIN; plasma concentration of zidovudine possibly increased by • SODIUM VALPROATE and • VALPROIC ACID (increased risk of toxicity)
- Antifungals: plasma concentration of zidovudine increased by • FLUCONAZOLE (increased risk of toxicity)
- Antimalarials: increased antifolate effect when zidovudine given with • PYRIMETHAMINE
### Zidovudine (continued)

- **Antivirals:** profound myelosuppression when zidovudine given with • **GANCICLOVIR** or • **VALGANCICLOVIR** (if possible avoid concomitant administration, particularly during initial ganciclovir or valganciclovir therapy); increased risk of granulocytopenia when zidovudine given with • **NEVIRAPINE**; increased risk of anaemia when zidovudine given with • **RIBAVIRIN**—avoid concomitant use; zidovudine possibly inhibits effects of • **STAVUDINE** (manufacturers advise avoid concomitant use); plasma concentration of zidovudine reduced by • **TIPRANAVIR**

  - Atovaquone: plasma concentration of zidovudine increased by **ATOVAQUONE** (increased risk of toxicity)
  - Orlistat: absorption of zidovudine possibly reduced by • **ORLISTAT**

- **Zinc**
  - Antibacterials: zinc reduces absorption of **CIPROFLOXACIN**, **LEVOFLOXACIN**, **MOXIFLOXACIN** and **OFLOXACIN**; zinc reduces absorption of **NORFLOXACIN** (give at least 2 hours apart); zinc reduces absorption of **TETRACYCLINES**, also absorption of zinc reduced by tetracyclines
  - Calcium Salts: absorption of zinc reduced by **CALCIUM SALTS**
  - Eflornithine: zinc possibly reduces absorption of **ELTROMBOPAG** (give at least 4 hours apart)
  - Iron Salts: absorption of zinc reduced by oral **IRON SALTS**, also absorption of oral iron salts reduced by zinc
  - Penicillamine: absorption of zinc reduced by **PENICILLAMINE**, also absorption of penicillamine reduced by zinc
  - Trientine: absorption of zinc reduced by **TRIENTINE**, also absorption of trientine reduced by zinc

### Zoledronic Acid

- **see Bisphosphonates**

### Zolmitriptan

- **see 5HT₁-receptor Agonists (under HT)**

### Zolpidem

- **see Anxiolytics and Hypnotics**

### Zonisamide

- **Antidepressants:** anticonvulsant effect of antiepileptics possibly antagonised by • **MAOIs** and • **TRICYCLIC-RELATED ANTIDEPRESSANTS** (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by • **SSRIS** and • **TRICYCLICS** (convulsive threshold lowered)

- **Antiepileptics:** plasma concentration of zonisamide reduced by **CARBAMAZEPINE**, **FOSPHENYTOIN**, **PHENOBARBITAL**, **PHENYTOIN** and **PRIMIDONE**

- **Antimalarials:** anticonvulsant effect of antiepileptics antagonised by • **MEFLOQUINE**

- **Antipsychotics:** anticonvulsant effect of antiepileptics antagonised by • **ANTIPSYCHOTICS** (convulsive threshold lowered)

- **Diuretics:** manufacturer of zonisamide advises avoid concomitant use with **CARBONIC ANHYDRASE INHIBITORS** in children

- **Orlistat:** possible increased risk of convulsions when antiepileptics given with • **ORLISTAT**

### Zopiclone

- **see Anxiolytics and Hypnotics**

### Zuclopenthixol

- **see Antipsychotics**
Appendix 2
Borderline substances

CONTENTS

Enteral feeds (non-disease specific) page 1262
Enteral feeds (non-disease specific): less than 5 g protein/100 mL 1262
Enteral feeds (non-disease specific): 5 g (or more) protein/100 mL 1263
Enteral feeds (non-disease specific): Child under 12 years 1266
Nutritional supplements (non-disease specific) 1266
Nutritional supplements: less than 5 g protein/100 mL 1266
Nutritional supplements: 5 g (or more) protein/100 mL 1267
Specialised formulas 1271
Specialised formulas: Infant and child 1271
Specialised formulas for specific clinical conditions 1271
Feed supplements 1273
High-energy supplements 1273
Fibre, vitamin, and mineral supplements 1278
Feed additives 1279
Special additives for conditions of intolerance 1279

In certain conditions some foods (and toilet preparations) have characteristics of drugs and the Advisory Committee on Borderline Substances (ACBS) advises as to the circumstances in which such substances may be regarded as drugs. Prescriptions issued in accordance with the Committee’s advice and endorsed ‘ACBS’ will normally not be investigated.

Information
General Practitioners are reminded that the ACBS recommends products on the basis that they may be regarded as drugs for the management of specified conditions. Doctors should satisfy themselves that the products can safely be prescribed, that patients are adequately monitored and that, where necessary, expert hospital supervision is available.

Foods which may be prescribed on FP10, GP10 (Scotland), or WP10 (Wales)
All the food products listed in this appendix have ACBS approval. The clinical condition for which the product has been approved is included with each entry.

Note Foods included in this appendix may contain cariogenic sugars and patients should be advised to take appropriate oral hygiene measures.

Enteral feeds and supplements
For most enteral feeds and nutritional supplements, the main source of carbohydrate is either maltodextrin or glucose syrup; other carbohydrate sources are listed in the relevant table, below. Feeds containing residual lactose (less than 1 g lactose/100 mL formula) are described as ‘clinically lactose-free’ or ‘lactose-free’ by some manufacturers. The presence of lactose (including residual lactose) in feeds is indicated in the relevant table, below. The primary sources of protein or amino acids are included with each product entry. The fat or oil content is derived from a variety of sources such as vegetables, soya bean, corn, palm nuts, and seeds; where the fat content is derived from animal or fish sources, this information is included in the relevant table, below. The presence of medium chain triglycerides (MCT) is also noted where the quantity exceeds 30% of the fat content.

Enteral feeds and nutritional supplements can contain varying amounts of vitamins, minerals, and trace elements—the manufacturer’s product literature should be consulted for more detailed information. Feeds containing vitamin K may affect the INR in patients receiving warfarin. The suitability of food products for patients requiring a vegan, kosher, halal, or other compliant diet should be confirmed with individual manufacturers.

Note Feeds containing more than 6 g/100 mL protein or 2 g/100 mL fibre should be avoided in children unless recommended by an appropriate specialist or dietician.

Nutritional values
Nutritional values of products vary with flavour and pack size—consult product literature.

Other conditions for which ACBS products can be prescribed
This is a list of clinical conditions for which the ACBS has approved toilet preparations.

Birthmarks
Dermatitis
Eczema and Pruritis
Aveeno® Bath Oil; Aveeno® Cream; Aveeno® Lotion; E45® Emollient Bath Oil; E45® Emollient Wash Cream; E45® Lotion
Disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitiligo)
Covermark® classic foundation and finishing powder; Dermablend® Ultra corrective foundation; Dermacolor® Camouflage cream and fixing powder; Keromask® masking cream and finishing powder; Veil® Cover cream and Finishing Powder. (Cleansing Creams, Cleansing Milks, and Cleansing Lotions are excluded).
Disinfectants (antiseptics)
May be prescribed on an FP10 only when ordered in such quantities and with such directions as are appropriate for...
the treatment of patients, but not for general hygenic purposes.

**Dry mouth (xerostomia)**
For patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.

*AS Saliva Orthana®; Biotène Oralbalance®; BioXtra®; Glandosane®; Saliveze®*

**Photodermatoses (skin protection in)**
*Anthelios® XL SPF 50+ Melt-in cream; Sunsense® Ultra; Uvistat® Lipscreen SPF 50, Uvistat® Suncream SPF 30 and 50*

**Standard ACBS Indications**
Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula.
### Table 1: Enteral feeds (non-disease specific)

**Less than 5 g protein/100 mL**

*Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years.*

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 1500 Complete</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows' milk soya</td>
<td>13 g (sugars 0.9 g)</td>
<td>3.4 g</td>
<td>1.5 g</td>
<td>Gluten-free, Residual lactose, Contains fish oil</td>
<td>Standard, p. 1261 except bowel fistula and pre-operative preparation of malnourished patients. Not suitable for child under 2 years</td>
<td>Fresubin 1500 Complete liquid: 1.5 litre = £13.14</td>
</tr>
<tr>
<td>(Fresenius Kabi Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresubin® Original</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows' milk soya</td>
<td>13.8 g (sugars 3.5 g)</td>
<td>3.4 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose, Contains fish gelatin</td>
<td>Standard, p. 1261</td>
<td>Fresubin Original liquid: blackcurrant, chocolate, nut, peach, vanilla 200 ml = £2.12; unflavoured 500 ml = £4.12; 1000 ml = £8.17; 1500 ml = £12.26</td>
</tr>
<tr>
<td>(Fresenius Kabi Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresubin® Original Fibre</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows' milk soya</td>
<td>13 g (sugars 0.9 g)</td>
<td>3.4 g</td>
<td>1.5 g</td>
<td>Gluten-free, Residual lactose, Contains fish oil</td>
<td>Standard, p. 1261 except bowel fistula and pre-operative preparation of malnourished patients. Not suitable for child under 2 years</td>
<td>Fresubin Original Fibre liquid: 500 ml = £4.67; 1000 ml = £9.32</td>
</tr>
<tr>
<td>(Fresenius Kabi Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jevity® Control</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>449 kJ (107 kcal)</td>
<td>4 g caseinates</td>
<td>14.1 g (sugars 470 mg)</td>
<td>3.47 g</td>
<td>1.76 g</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261 except bowel fistula. Not suitable for child under 2 years</td>
<td>Jevity liquid: 500 ml = £4.87; 1000 ml = £9.16; 1500 ml = £13.75</td>
</tr>
<tr>
<td>(Abbott Laboratories Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novasource® Gl Control</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>444 kJ (106 kcal)</td>
<td>4.1 g cows' milk</td>
<td>14.4 g (sugars 500 mg)</td>
<td>3.5 g</td>
<td>2.2 g</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Novasource liquid: 500 ml = £5.43</td>
</tr>
<tr>
<td>(Nestlé)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutrison®</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g cows' milk</td>
<td>12.3 g (sugars 1 g)</td>
<td>3.9 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Nutrison liquid: 500 ml = £4.83; 500 ml = £4.35; 1000 ml = £8.48; 1500 ml = £12.70</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutrison® Multi Fibre</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g cows' milk</td>
<td>12.3 g (sugars 1 g)</td>
<td>3.9 g</td>
<td>1.5 g</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261 except bowel fistula.</td>
<td>Nutrison Multi Fibre liquid: 500 ml = £4.90; 500 ml = £5.22; 1000 ml = £9.81; 1500 ml = £14.71</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osmolite®</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>424 kJ (100 kcal)</td>
<td>4 g caseinates soy isolate</td>
<td>13.6 g (sugars 630 mg)</td>
<td>3.4 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Osmolite liquid: 500 ml = £4.19; 1000 ml = £7.87; 1500 ml = £11.81</td>
</tr>
<tr>
<td>(Abbott Laboratories Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SOYA PROTEIN FORMULA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresubin® Soya Fibre</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g soya protein</td>
<td>13.3 g (sugars 4.1 g)</td>
<td>3.6 g</td>
<td>2 g</td>
<td>Gluten-free, Lactose-free, Contains fish oil</td>
<td>Standard, p. 1261; also cows’ milk protein intolerance, lactose intolerance</td>
<td>Fresubin Soya Fibre liquid: 500 ml = £4.83</td>
</tr>
<tr>
<td>(Fresenius Kabi Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutrison® Soya</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g soya isolate</td>
<td>12.3 g (sugars 1 g)</td>
<td>3.9 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose, Milk protein-free</td>
<td>Standard, p. 1261; also cows’ milk protein and lactose intolerance</td>
<td>Nutrison Soya liquid: 500 ml = £5.21; 1000 ml = £10.43</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutrison® Soya Multi Fibre</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g soya isolate</td>
<td>12.3 g (sugars 700 mg)</td>
<td>3.9 g</td>
<td>1.5 g</td>
<td>Gluten-free, Residual lactose, Milk protein-free</td>
<td>Standard, p. 1261 except bowel fistula; also cows’ milk protein and lactose intolerance</td>
<td>Nutrison Soya Multi Fibre liquid: 1.5 litre = £17.35</td>
</tr>
</tbody>
</table>
## PEPTIDE-BASED FORMULA

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrison Peptisorb®</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>425 kJ (100 kcal)</td>
<td>4 g whey protein hydrolysate</td>
<td>17.6 g (sugars 1.7 g)</td>
<td>1.7 g (MCT 47 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Nutrison Peptisorb liquid: 500 ml = £75.9; 500 ml = £6.92; 1000 ml = £13.69</td>
</tr>
<tr>
<td>Peptamen®</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g whey peptides</td>
<td>12.7 g (sugars 480 mg)</td>
<td>3.7 g (MCT 70 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Peptamen liquid: vanilla 800 ml = £11.85; unflavoured 500 ml = £6.66; 1000 ml = £12.50</td>
</tr>
<tr>
<td>Survivmed® OPD</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4.5 g whey protein hydrolysate</td>
<td>14.3 g (sugars 1.1 g)</td>
<td>2.8 g (MCT 51 %)</td>
<td>0.1 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Standard, p. 1261; also growth failure</td>
<td>Survismed OPD: liquid 500 ml = £6.88 800 ml = £12.64 1000 ml = £13.77 HN liquid 500 ml = £6.63</td>
</tr>
</tbody>
</table>

### Enteral feeds: Less than 1 kcal/mL and less than 5 g protein/100 mL

<table>
<thead>
<tr>
<th>ENTRAL FEEDS</th>
<th>AMINO ACID FORMULA (ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1–6 years</td>
<td></td>
</tr>
</tbody>
</table>

#### Elemental 028® Extra (Nutricia Ltd)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elemental 028® Extra</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>360 kJ (86 kcal)</td>
<td>2.5 g (protein equivalent)</td>
<td>11 g (sugars 4.7 g)</td>
<td>3.5 g (MCT 35 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Elemental 028 Extra liquid summer fruits: 250 ml = £3.61</td>
</tr>
<tr>
<td>Standard dilution</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>374 kJ (89 kcal)</td>
<td>2.5 g (protein equivalent)</td>
<td>11.8 g (sugars 1.1 g)</td>
<td>3.5 g (MCT 35 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Elemental 028 Extra powder: plain, orange, banana 100 gram = £7.01</td>
</tr>
</tbody>
</table>

**Powder provides protein equivalent 12.5 g, carbohydrate 59 g, fat 17.45 g, energy 1871 kJ (443 kcal)/100 g**

#### Enteral feeds (non-disease specific): 5 g (or more) protein/100 mL

<table>
<thead>
<tr>
<th>ENTRAL FEEDS</th>
<th>AMINO ACID FORMULA (ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years</td>
<td></td>
</tr>
</tbody>
</table>

#### Fresubin® 2250 Complete (Fresenius Kabi Ltd)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 2250 Complete</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Standard, p. 1261</td>
<td>Fresubin 2250 Complete liquid: 1.5 litre = £14.66</td>
</tr>
</tbody>
</table>

#### Fresubin® Energy (Fresenius Kabi Ltd)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® Energy</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugar content varies with flavour)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish gelatin Strawberry flavour may contain traces of wheat starch and egg.</td>
<td>Standard, p. 1261</td>
<td>Fresubin Energy liquid: banana, blackcurrant, cappuccino, chocolate, lemon, strawberry, tropical fruits, vanilla 200 ml = £1.48 unflavoured 200 ml = £1.48</td>
</tr>
<tr>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugar 1.4 g)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Standard, p. 1261</td>
<td>Fresubin Energy liquid: 1000 ml = £9.92 1500 ml = £13.30</td>
<td></td>
</tr>
</tbody>
</table>

#### Borderline substances | Appendix 2
### Enteral feeds: 1.5 kcal/mL and 5 g (or more) protein/100 mL (product list continued)

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin\® Energy Fibre (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows' milk</td>
<td>18.5 g (sugar content varies with flavour)</td>
<td>5.8 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish gelatin</td>
<td>Standard, p. 1261</td>
<td>Banana, caramel, cherry, chocolate, strawberry 200 ml = £2.03</td>
</tr>
<tr>
<td></td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows' milk</td>
<td>18.5 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Standard, p. 1261</td>
<td>Fresubin Energy Fibre liquid: unflavoured 500 ml = £5.54 1000 ml = £10.56</td>
</tr>
<tr>
<td>Fresubin\® HP Energy (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>7.5 g cows' milk</td>
<td>17 g (sugars 1 g)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Standard, p. 1261; also CAPD and haemodialysis</td>
<td>Fresubin HP Energy liquid: 500 ml = £5.14; 1000 ml = £10.29</td>
</tr>
<tr>
<td>Jevity\® 1.5 kcal (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>649 kJ (154 kcal)</td>
<td>6.38 g caseinates and soy isolate</td>
<td>20.1 g (sugars 1.47 g)</td>
<td>4.9 g</td>
<td>2.2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Jevity 1.5kcal liquid: 500 ml = £5.77; 1000 ml = £11.03; 1500 ml = £16.87</td>
</tr>
<tr>
<td>Nutrison\® Energy (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows' milk</td>
<td>18.5 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Nutrison Energy liquid: 500 ml = £5.62; 500 ml = £5.26; 1000 ml = £10.58; 1500 ml = £15.82</td>
</tr>
<tr>
<td>Nutrison\® Energy Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows' milk</td>
<td>18.5 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Nutrison Energy Multi Fibre liquid: 500 ml = £5.88; 500 ml = £6.24; 1000 ml = £11.74; 1500 ml = £18.12</td>
</tr>
<tr>
<td>Osmolite\® 1.5 kcal (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows' milk soya protein isolate</td>
<td>20 g (sugars 4.9 g)</td>
<td>5 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Osmolite 1.5kcal tube feed liquid: 500 ml = £5.13; 1000 ml = £9.82; 1500 ml = £14.71</td>
</tr>
<tr>
<td>Resource\® Energy (Nestle Health Science)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows' milk</td>
<td>21 g (sugars 5.2 g)</td>
<td>5 g</td>
<td>less than 0.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Resource Energy liquid: apricot, banana, chocolate, coffee, strawberry &amp; raspberry, vanilla 800 ml = £7.67</td>
</tr>
<tr>
<td>Vital 1.5 kcal (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>631 kJ (150 kcal)</td>
<td>6.75 g caseinate whey protein hydrolysate</td>
<td>18.4 g (sugars 3.6 g)</td>
<td>5.5 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; except proven inflammatory bowel disease and following total gastrectomy; not recommended for use in children</td>
<td>Vital 1.5kcal liquid: 200 ml = £2.98; 1000 ml = £14.82</td>
</tr>
</tbody>
</table>

### Enteral feeds: Less than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin\® 1000 Complete (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>5.5 g cows' milk</td>
<td>12.5 g (sugars 1.1 g)</td>
<td>3.1 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Standard, p. 1261</td>
<td>Fresubin 1000 Complete liquid: 1 litre = £10.56</td>
</tr>
<tr>
<td>Fresubin\® 1200 Complete (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>500 kJ (120 kcal)</td>
<td>6 g cows' milk</td>
<td>15 g (sugars 1.22 g)</td>
<td>4.1 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Standard, p. 1261</td>
<td>Fresubin 1200 Complete liquid: 1 litre = £13.45</td>
</tr>
<tr>
<td>Brand Name</td>
<td>Type</td>
<td>Ingredient</td>
<td>Energy</td>
<td>Protein</td>
<td>Fat</td>
<td>Carbohydrate</td>
<td>Lactose</td>
<td>Gluten Free</td>
<td>Notes</td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>------------</td>
<td>--------</td>
<td>--------</td>
<td>-----</td>
<td>--------------</td>
<td>---------</td>
<td>-------------</td>
<td>-------</td>
</tr>
<tr>
<td>Fresubin® 1800 Complete (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>500 kJ (120 kcal)</td>
<td>6 g cows' milk</td>
<td>15 g (sugars 1.22 g)</td>
<td>4.1 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Contains fish oil</td>
<td>Standard, p. 1261</td>
</tr>
<tr>
<td>Jevity® Plus (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>514 kJ (122 kcal)</td>
<td>5.5 g caseinates soy isolates</td>
<td>15.1 g (sugars 890 mg)</td>
<td>3.93 g</td>
<td>2.2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Jevity Plus liquid: 500 ml = £5.32; 1000 ml = £10.74; 1500 ml = £16.12</td>
</tr>
<tr>
<td>Jevity® Plus HP (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>551 kJ (131 kcal)</td>
<td>8.13 g cows' milk soy isolates</td>
<td>14.2 g (sugars 950 mg)</td>
<td>4.33 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis Not suitable for child under 2 years; not recommended for child 2-10 years</td>
<td>Jevity Plus HP gluten free liquid: 500 ml = £5.36</td>
</tr>
<tr>
<td>Jevity® Promote (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>434 kJ (103 kcal)</td>
<td>5.55 g caseinates soy isolates</td>
<td>12 g (sugars 670 mg)</td>
<td>3.32 g</td>
<td>1.7 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Jevity Promote liquid: 1 litre = £10.50</td>
</tr>
<tr>
<td>Nutrison® 800 Complete Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>345 kJ (83 kcal)</td>
<td>5.5 g cows' milk pease protein soya protein</td>
<td>8.8 g (sugars 600 mg)</td>
<td>2.5 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Contains fish oil</td>
<td>Standard, p. 1261 except bowel fistula Not suitable for child under 6 years; not recommended for child 6-12 years</td>
</tr>
<tr>
<td>Nutrison® 1000 Complete Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>5.5 g cows' milk</td>
<td>11.3 g (sugars 700 mg)</td>
<td>3.7 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Disease related malnutrition in patients with low energy and/or low fluid requirements</td>
<td>Nutrison 1000 Complete Multi Fibre liquid: 1 litre = £10.89</td>
</tr>
<tr>
<td>Nutrison® 1200 Complete Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>505 kJ (120 kcal)</td>
<td>5.5 g cows' milk</td>
<td>15 g (sugars 1.2 g)</td>
<td>4.3 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 except bowel fistula</td>
<td>Nutrison 1200 Complete Multi Fibre liquid: 1000 ml = £11.52; 1500 ml = £17.30</td>
</tr>
<tr>
<td>Nutrison® MCT (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>5 g cows' milk</td>
<td>12.6 g (sugars 1 g)</td>
<td>3.3 g (MCT 61%)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Disease related malnutrition in patients with low energy and/or low fluid requirements</td>
<td>Nutrison MCT liquid: 1000 ml = £9.80</td>
</tr>
<tr>
<td>Nutrison® Protein Plus (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>525 kJ (125 kcal)</td>
<td>6.3 g cows' milk</td>
<td>14.2 g (sugars 1.1 g)</td>
<td>4.9 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Nutrison Protein Plus liquid: 1 litre = £10.07</td>
</tr>
<tr>
<td>Nutrison® Protein Plus Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>525 kJ (125 kcal)</td>
<td>6.3 g cow's milk</td>
<td>14.1 g (sugars 1.1 g)</td>
<td>4.9 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Disease related malnutrition</td>
<td>Nutrison Protein Plus Multifibre liquid: 1 litre = £11.22</td>
</tr>
<tr>
<td>Osmolite® Plus (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>508 kJ (121 kcal)</td>
<td>5.55 g caseinates</td>
<td>15.8 g (sugars 730 mg)</td>
<td>3.93 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Osmolite Plus liquid: 500 ml = £4.90; 1000 ml = £9.45; 1500 ml = £14.15</td>
</tr>
<tr>
<td>Peptamen® HN (Nestle Health Science)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>556 kJ (133 kcal)</td>
<td>6.6 g whey protein hydrolysates</td>
<td>15.6 g (sugars 1.4 g)</td>
<td>4.9 g (MCT 70%)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Hydrolysed with pork trypsin</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula Not suitable for child under 3 years</td>
<td>Peptamen HN liquid: 500 ml = £7.17</td>
</tr>
<tr>
<td>Perative® (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>552 kJ (131 kcal)</td>
<td>6.7 g caseinate whey protein hydrolysates</td>
<td>17.7 g (sugars 660 mg)</td>
<td>3.7 g (MCT 42%)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Perative liquid: 500 ml = £6.83; 1000 ml = £13.66</td>
</tr>
</tbody>
</table>
## Enteral feeds: More than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years.

### Table 2 Nutritional supplements (non-disease specific): Child under 12 years see BNF for Children

#### Nutritional supplements: 1 kcal/mL and less than 5 g protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Twocal</td>
<td>Liquid (sip or tube feed)</td>
<td>838 kJ</td>
<td>8.4 g</td>
<td>21 g</td>
<td>6.9 g</td>
<td>1 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; also haemodialysis and CAPD</td>
<td>Ensure Twocal liquid: banana, neutral, strawberry, vanilla 200 ml = £2.22</td>
</tr>
<tr>
<td>(Abbott Laboratories Ltd) per 100 mL</td>
<td>200 (kcal)</td>
<td>cows' milk</td>
<td>(sugars 4.5 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TwoCal®</td>
<td>Liquid (tube feed)</td>
<td>837 kJ</td>
<td>8.4 g</td>
<td>21 g</td>
<td>8.9 g</td>
<td>1 g</td>
<td>Gluten-free Residual lactose</td>
<td>Adults with or at risk of disease-related malnutrition, catabolic or fluid-restricted patients, and other patients requiring a 2 kcal/mL feed</td>
<td>TwoCal liquid: 1 litre = £13.22</td>
</tr>
<tr>
<td>(Abbott Laboratories Ltd) per 100 mL</td>
<td>200 (kcal)</td>
<td>cows' milk caseinates</td>
<td>(sugars 4.5 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Nutritional supplements: More than 1 kcal/mL and less than 5 g protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure®</td>
<td>Liquid (sip or tube feed)</td>
<td>423 kJ</td>
<td>4 g</td>
<td>13.6 g</td>
<td>3.36 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Ensure liquid: vanilla, chocolate, coffee 250 ml = £2.25</td>
</tr>
<tr>
<td>(Abbott Laboratories Ltd) per 100 mL</td>
<td>100 (kcal)</td>
<td>caseinates soy isolate</td>
<td>(sugars 3.93 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AYMES® Shake</td>
<td>Standard dilution of powder (57 g in 200 mL water) (sip feed)</td>
<td>530.5 kJ</td>
<td>4.5 g</td>
<td>17.5 g</td>
<td>4.2 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 1261; Use with caution in child 1-6 years.</td>
<td>Aymes Shake Sample Pack powder: 285 gram = £4.78 Aymes Shake powder: banana, chocolate, neutral, strawberry, vanilla 57 gram 399 gram = £5.46</td>
</tr>
<tr>
<td>(Aymes International Ltd) per 100 mL</td>
<td>126 (kcal)</td>
<td>cows' milk</td>
<td>(sugars 8.4 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder 57 g reconstituted with 200 mL whole milk provides: protein 15.8 g, carbohydrate 44.1 g, fat 16.4 g, energy 1625 kJ (388 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| Ensure®            | Liquid (sip feed)          | 638 kJ  | 4.8 g   | 32.7 g       | Nil  | Nil   | Gluten-free Residual lactose Non-milk taste | Standard, p. 1261 | Ensure Plus Juice liquid: assorted 880 ml apple, fruit punch, lemon &amp; lime, orange, peach 220 ml = £1.97 |
| (Abbott Laboratories Ltd) per 100 mL | 150 (kcal) | whey protein isolate | (sugars 9.4 g) |  |  |  |  |  |
| Fortijuce®         | Liquid (sip feed)          | 640 kJ  | 4.0 g   | 33.5 g       | Nil  | Nil   | Gluten-free Residual lactose Non-milk taste | Standard, p. 1261; Not suitable for child under 3 years | Fortijuce Starter Pack liquid: 800 ml = £8.08 Fortijuce liquid: apple, blackcurrant, forest fruits, lemon, orange, strawberry, tropical 200 ml = £2.02 assorted 800 ml |
| (Nutricia Ltd) per 100 mL | 150 (kcal) | cows' milk | (sugars 13.1 g) |  |  |  |  |  |
| Fresubin® Jucy Drink | Liquid (sip feed)          | 630 kJ  | 4 g     | 33.5 g       | Nil  | Nil   | Gluten-free Residual lactose | Standard, p. 1261; also CAPD, haemodialysis | Fresubin Jucy drink: apple, blackcurrant, cherry, orange, pineapple 800 ml = £7.72 |
| (Fresenius Kabi Ltd) per 100 mL | 150 (kcal) | whey protein | (sugars 8 g) |  |  |  |  |  |</p>
<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Plus Commence (Abbott Laboratories Ltd)</td>
<td>Starter pack (5–10 day’s supply), contains: Ensure® Plus Milkshake Style (various flavours), 1 pack (10 x 200 mL) = £20.23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure® Plus Fibre (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>652 kJ (155 kcal)</td>
<td>6.25 g cows’ milk</td>
<td>20.2 g (sugars 5.5 g)</td>
<td>4.92 g</td>
<td>2.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis.</td>
<td>Ensure Plus Fibre liquid: banana, chocolate, raspberry, strawberry, vanilla 200 mL = £2.02</td>
</tr>
<tr>
<td>Ensure® Plus Milkshake style (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20.2 g (sugars 6.89 g)</td>
<td>4.92 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis.</td>
<td>Ensure Plus milkshake style liquid: banana, chocolate, coffee, fruits of the forest, neutral, orange, peach, raspberry, strawberry, vanilla 220 mL = £2.02</td>
</tr>
<tr>
<td>Ensure® Plus Savoury (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20.2 g (sugars 1.13 g)</td>
<td>4.92 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis.</td>
<td>Ensure Plus savoury liquid: chicken, mushroom 220 mL = £2.02</td>
</tr>
<tr>
<td>Ensure® Plus Yoghurt (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20.2 g (sugars 11.7 g)</td>
<td>4.92 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis.</td>
<td>Ensure Plus yoghurt style liquid: orchard peach, strawberry swirl 220 mL = £2.02</td>
</tr>
<tr>
<td>Fortisip® Bottle (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows’ milk</td>
<td>18.4 g</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 Not suitable for child under 3 years; use with caution in child 3–5 years.</td>
<td>Fortisip Bottle: banana, caramel, chocolate, neutral, orange, strawberry, tropical fruit, vanilla 200 mL = £2.06 assorted 800 mL</td>
</tr>
<tr>
<td>Fortisip® Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows’ milk</td>
<td>18.4 g (sugars 7.0 g)</td>
<td>5.8 g</td>
<td>2.3 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 Not suitable for child under 3 years; use with caution in child 3–5 years.</td>
<td>Fortisip Multi Fibre liquid: 200 mL = £2.15</td>
</tr>
<tr>
<td>Fortisip® Savoury Multi Fibre</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>625 kJ (150 kcal)</td>
<td>7.5 g cows’ milk</td>
<td>12.8 g (sugars 900 mg)</td>
<td>7 g</td>
<td>2.3 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 except bowel fistula Not suitable for child under 3 years; use with caution in child 3–6 years.</td>
<td>Fortisip Savoury Multi Fibre: 2 x 200 mL = £4.32</td>
</tr>
</tbody>
</table>

Nutritional supplements: 5 g (or more) protein/100 mL

Nutritional supplements: 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1–5 years unless otherwise stated.
### Nutritional supplements: 1.5 kcal/mL and 5 g (or more) protein/100 mL (product list continued)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortisip® Yoghurt Style (Nutricia Ltd)</td>
<td>Liquid (sip feed per 100 mL)</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows' milk</td>
<td>18.7 g (sugars 10.8 g)</td>
<td>5.8 g</td>
<td>0.2 g</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 1261; Not suitable for child under 3 years</td>
<td>Fortisip Yogurt Style liquid vanilla &amp; lemon: 200 ml = £2.02</td>
</tr>
<tr>
<td>Fortisip® Range (Nutricia Ltd)</td>
<td>Starter pack contains 4 x Fortisip® Bottle, 4 x Fortijuce®, 2 x Fortisip® Yoghurt Style, 1 pack (10 x 200 mL) = £20.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresubin® Protein Energy Drink (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed per 100 mL)</td>
<td>630 kJ (150 kcal)</td>
<td>10 g cows' milk</td>
<td>12.4 g (sugars 6.4 g)</td>
<td>6.7 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish gelatin</td>
<td>Standard, p. 1261; also CAPD, haemodialysis.</td>
<td>Fresubin Protein Energy drink: cappuccino, chocolate, tropical fruits, vanilla, wild strawberry 200 ml = £2.02</td>
</tr>
<tr>
<td>Fresubin® Thickened (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed per 100 mL)</td>
<td>630 kJ (150 kcal)</td>
<td>10 g cows' milk</td>
<td>12.2 g (sugars 7.1 g)</td>
<td>6.7 g</td>
<td>0.48 g</td>
<td>Gluten-free Residual lactose</td>
<td>Dysphagia or disease-related malnutrition. Not suitable for child under 3 years; use with caution in child 3–4 years.</td>
<td>Fresubin Thickened Stage 1 syrup: vanilla, wild strawberry 800 ml = £9.12 Fresubin Thickened Stage 2 custard: vanilla, wild strawberry 800 ml = £9.12</td>
</tr>
<tr>
<td>Fresubin® YoCrème (Fresenius Kabi Ltd)</td>
<td>Semi-solid per 100 g</td>
<td>630 kJ (150 kcal)</td>
<td>7.5 g whey protein</td>
<td>19.5 g (sugars 16.8 g)</td>
<td>4.7 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Dysphagia, or presence or risk of malnutrition Not suitable for child under 3 years</td>
<td>Fresubin YoCrème dessert: apricot- peach, biscuit, lemon, raspberry 500 gram = £7.92</td>
</tr>
<tr>
<td>Nutriplen® Protein (Nuala Ltd)</td>
<td>Liquid (sip feed per 100 mL)</td>
<td>632 kJ (150 kcal)</td>
<td>10 g cows' milk soya protein</td>
<td>15 g (sugars 4.6 g)</td>
<td>5.6 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 Not suitable for child under 3 years; use with caution in child 3–6 years</td>
<td>Nutriplen Protein liquid: strawberry, vanilla 800 ml = £5.80</td>
</tr>
</tbody>
</table>

### Nutritional supplements: Less than 1.5 kcal/mL and 5 g (or more) protein/100 mL

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Plus Crème (Abbott Laboratories Ltd)</td>
<td>Semi-solid per 100 g</td>
<td>574 kJ (137 kcal)</td>
<td>5.68 g cow's milk soy protein isolates</td>
<td>18.4 g (sugars 12.4 g)</td>
<td>4.47 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains soya</td>
<td>Standard, p. 1261; also CAPD, haemodialysis. Not suitable for child under 3 years; use with caution in child 3–5 years.</td>
<td>Ensure Plus Creme: chocolate, neutral, vanilla 500 gram = £7.51</td>
</tr>
<tr>
<td>Nutricia® Fruit Stage 3 (Nutricia Ltd)</td>
<td>Semi-Solid per 100 g</td>
<td>560 kJ (133 kcal)</td>
<td>7 g whey isolate</td>
<td>16.7 g (sugars 11.3 g)</td>
<td>4 g</td>
<td>2.6 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 except bowel fistula; also CAPD, haemodialysis. Not suitable for child under 3 years; use with caution in child 3–5 years.</td>
<td>Nutricia Fruit Stage 3: apple, strawberry 450 gram = £7.08</td>
</tr>
<tr>
<td>Oral Impact® (Nestle Health Science)</td>
<td>Standard dilution of powder (74 g in 250 ml water) (sip feed per 100 mL)</td>
<td>425 kJ (101 kcal)</td>
<td>5.6 g cows' milk</td>
<td>13.4 g (sugars 7.4 g)</td>
<td>2.8 g</td>
<td>1 g</td>
<td>Residual lactose Contains fish oil</td>
<td>Pre-operative nutritional supplement for malnourished patients or patients at risk of malnourishment Not suitable for child under 3 years; use with caution in child 3–5 years.</td>
<td>Oral Impact oral powder 74g sachets: citrus, coffee, tropical 5 sachet = £16.93</td>
</tr>
</tbody>
</table>
### Nutritional supplements: More than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complan® Shake (Nutricia Ltd)</td>
<td>Powder per 57 g</td>
<td>1057 kJ (251 kcal)</td>
<td>8.8 g cows’ milk</td>
<td>35.2 g (sugars 22.7 g)</td>
<td>8.4 g</td>
<td>Trace g</td>
<td>Gluten-free, Contains lactose</td>
<td>Standard, p. 1261</td>
<td>Complan Shake Starter Pack sachets: 5 sachet = £4.79 Complan Shake oral powder 57 g sachets: banana, chocolate, milk, strawberry, vanilla 4 sachet = £3.40</td>
</tr>
<tr>
<td>Nutritional supplements (non-disease specific)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foodlink® Complete (Foodlink (UK) Ltd)</td>
<td>Powder per 100 g</td>
<td>1826 kJ (434 kcal)</td>
<td>21.3 g cows’ milk</td>
<td>56.7 g</td>
<td>13.5 g</td>
<td>Nil</td>
<td>Contains lactose</td>
<td>Standard, p. 1261</td>
<td>Foodlink Complete powder: banana, chocolate, natural, strawberry 450 gram = £3.25</td>
</tr>
<tr>
<td>Recommended serving = 4 heaped dessertspoonfuls in 200 mL full cream milk provides: protein 18.9 g, carbohydrate 41.8 g, fat 15.7 g, energy 1605 kJ (383 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foodlink® Complete with Fibre (Foodlink (UK) Ltd)</td>
<td>Powder per 100 g</td>
<td>1683 kJ (400 kcal)</td>
<td>19.4 g cows’ milk</td>
<td>52.7 g (sugars 27.3 g)</td>
<td>12.4 g</td>
<td>7.2 g</td>
<td>Contains lactose</td>
<td>Standard, p. 1261</td>
<td>Foodlink Complete powder with fibre: vanilla lactose free 450 gram = £3.54 vanilla 53 gram = £0.67 450 gram = £3.25</td>
</tr>
<tr>
<td>Recommended serving = 4 heaped dessertspoonfuls (or the contents of a 63 g sachet) in 200 mL full cream milk provides: protein 19.0 g, carbohydrate 42.7 g, fat 15.8 g, fibre 4.5 g, energy 1624 kJ (388 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forticreme® Complete (Nutricia Ltd)</td>
<td>Semi-solid per 100 g</td>
<td>675 kJ (160 kcal)</td>
<td>9.5 g cows’ milk</td>
<td>19.2 g (sugars 10.6 g)</td>
<td>5 g</td>
<td>0.1 g</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis. Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
<td>Forticreme Complete dessert: banana, chocolate, forest fruits, vanilla 500 gram = £7.84</td>
</tr>
<tr>
<td>Fortisip® Compact (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>1010 kJ (240 kcal)</td>
<td>9.6 g cows’ milk</td>
<td>29.7 g (sugars 15 g)</td>
<td>9.3 g</td>
<td>Nil</td>
<td>Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Fortisip Compact liquid: apricot, banana, forest fruit, mocha, strawberry, vanilla 500 ml = £8.08 chocolate 500 ml = £8.08</td>
</tr>
<tr>
<td>Fortisip® Compact Fibre (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>1000 kJ (240 kcal)</td>
<td>9.4 g cows’ milk</td>
<td>25.2 g (sugars 13.9 g)</td>
<td>10.4 g</td>
<td>3.6 g</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Fortisip Compact Fibre Starter Pack liquid: 500 ml = £8.36 Fortisip Compact Fibre liquid: mocha, strawberry, vanilla 500 ml = £8.36</td>
</tr>
<tr>
<td>Fortisip® Compact Protein (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>1010 kJ (240 kcal)</td>
<td>14.4 g cows’ milk</td>
<td>24.4 g (sugars 13.3 g)</td>
<td>9.4 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261</td>
<td>Fortisip Compact Protein Starter Pack liquid: 500 ml = £8.00 Fortisip Compact Protein liquid: banana, mocha, strawberry, vanilla 500 ml = £8.00</td>
</tr>
<tr>
<td>Fortisip® Extra (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>675 kJ (160 kcal)</td>
<td>10 g cows’ milk</td>
<td>18.1 g (sugars 9 g)</td>
<td>5.3 g</td>
<td>Nil</td>
<td>Gluten-free, Contains lactose</td>
<td>Standard, p. 1261</td>
<td>Fortisip Extra Starter Pack liquid: 800 ml = £8.56 Fortisip Extra liquid: chocolate, forest fruits, mocha, strawberry, vanilla 200 ml = £2.14</td>
</tr>
<tr>
<td>Fresubin® 2 kcal Drink (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>840 kJ (200 kcal)</td>
<td>10 g cows’ milk</td>
<td>22.5 g (sugars 5.8 g)</td>
<td>7.8 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis.</td>
<td>Fresubin 2kcal drink: apricot-peach, cappuccino, fruits of the forest, neutral, toffee, vanilla 200 ml = £1.96</td>
</tr>
</tbody>
</table>
### Nutritional supplements: More than 1.5 kcal/mL and 5 g (or more) protein/100 mL (product list continued)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 2 kcal Fibre Drink (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>840 kJ (200 kcal)</td>
<td>10 g cows’ milk</td>
<td>22.5 g (sugars 5.8 g)</td>
<td>7.8 g</td>
<td>1.6 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261; also CAPD, haemodialysis.</td>
<td>Fresubin 2 kcal Fibre drink: apricot-peach, cappuccino, chocolate, lemon, neutral 200 ml = £1.96</td>
</tr>
<tr>
<td>Fresubin® Powder Extra (Fresenius Kabi Ltd)</td>
<td>Powder per 100 g</td>
<td>1764 kJ (420 kcal)</td>
<td>17.5 g cows’ milk whey protein</td>
<td>63 g (sugars 24.7 g)</td>
<td>10.9 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 1261</td>
<td>Fresubin Powder Extra oral powder 62g sachets: chocolate, neutral, strawberry, vanilla 7 sachet = £5.60</td>
</tr>
<tr>
<td>Nutrilis® Complete Stage 1 (Nutricia Ltd)</td>
<td>Liquid (pre-thickened) per 100 mL</td>
<td>1010 kJ (240 kcal)</td>
<td>9.6 g cows’ milk</td>
<td>29.1 g (sugars 5.4 g)</td>
<td>9.3 g</td>
<td>3.2 g</td>
<td>Residual lactose</td>
<td>Not suitable for child under 3 years.</td>
<td>Nutrilis Complete Stage 1 liquid: strawberry, vanilla 500 ml = £8.84</td>
</tr>
<tr>
<td>Nutrilis® Complete Stage 2 (Nutricia Ltd)</td>
<td>Semi-solid per 100 g</td>
<td>1030 kJ (245 kcal)</td>
<td>9.6 g cows’ milk</td>
<td>29.1 g (sugars 11.8 g)</td>
<td>9.4 g</td>
<td>3.2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Not suitable for child under 3 years; use with caution in child 3–6 years.</td>
<td>Nutrilis Complete Stage 2 custard: chocolate, strawberry, vanilla 500 gram = £8.84</td>
</tr>
<tr>
<td>Nutricrem® (Nualtra Ltd)</td>
<td>Semi-solid per 100 g</td>
<td>756 kJ (180 kcal)</td>
<td>10 g cows’ milk soya protein</td>
<td>18.8 g (sugars 9.7 g)</td>
<td>7.2 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Not suitable for child under 3 years; use with caution in child 3–6 years.</td>
<td>Nutricrem dessert: strawberry, vanilla 500 gram = £5.60</td>
</tr>
<tr>
<td>Nutriplen® (Nualtra Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>1008 kJ (240 kcal)</td>
<td>9.6 g cows’ milk soya protein</td>
<td>28.8 g (sugars 11.6 g)</td>
<td>9.6 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Not suitable for child under 3 years; use with caution in child 3–6 years.</td>
<td>Nutriplen liquid: strawberry, vanilla 500 ml = £5.80</td>
</tr>
<tr>
<td>Renilon® 7.5 (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>840 kJ (200 kcal)</td>
<td>7.5 g cows’ milk</td>
<td>20 g (sugars 4.8 g)</td>
<td>10 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Not suitable for child under 3 years; use with caution in child 3–5 years.</td>
<td>Renilon 7.5 liquid: apricot, caramel 500 ml = £8.48</td>
</tr>
<tr>
<td>Resource® 2.0 Fibre (Nestle Health Science)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>836 kJ (200 kcal)</td>
<td>9 g cows’ milk</td>
<td>21.4 g (sugars 5.5 g)</td>
<td>8.7 g</td>
<td>2.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Not suitable for child under 6 years; use with caution in child 6–10 years.</td>
<td>Resource Fibre 2.0 liquid: apricot, coffee, neutral, strawberry, summer fruit, vanilla 200 ml = £1.88</td>
</tr>
<tr>
<td>Vegenat-med Balanced Protein (Vegenat)</td>
<td>Powder per 110 g serving</td>
<td>1924 kJ (458 kcal)</td>
<td>18 g cows’ milk</td>
<td>62 g</td>
<td>15.35 g</td>
<td>5.8 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 except bowel fistula Not suitable for child under 14 years</td>
<td>Vegenat-med balanced protein oral powder sachets: apple, chocolate, honey, orange 1320 gram = £36.26</td>
</tr>
<tr>
<td>Vegenat-med High Protein (Vegenat)</td>
<td>Powder per 110 g serving</td>
<td>1940 kJ (463 kcal)</td>
<td>23.3 g cows’ milk</td>
<td>57.2 g</td>
<td>15.6 g</td>
<td>6 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 1261 except bowel fistula Not suitable for child under 14 years</td>
<td>Vegenat-med high protein oral powder sachets: curry chicken 1320 gram = £48.95 chicken, fish, ham, lentils, veal 1320 gram = £50.76</td>
</tr>
</tbody>
</table>
Table 3 Specialised formulas
Specialised formulas: Infant and child see *BNF for Children*
Specialised formulas for specific clinical conditions

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alicalm®</td>
<td>Standard dilution (30%) of powder per 100 mL</td>
<td>567 kJ (135 kcal)</td>
<td>4.5 g caseinate whey</td>
<td>17.4 g (sugars 3.2 g)</td>
<td>5.3 g</td>
<td>Nil</td>
<td>Residual lactose</td>
<td>Crohn's disease Not suitable for child under 1 year; use as nutritional supplement only in children 1-6 years.</td>
<td>Alicalm oral powder: 400 gram = £21.09</td>
</tr>
<tr>
<td>Powder provides: protein 15 g, carbohydrate 58 g, fat 17.5 g, energy 1889 kJ (450 kcal)/100 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forticare®</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>675 kJ (160 kcal)</td>
<td>9 g cows' milk</td>
<td>19.1 g (sugars 13.6 g)</td>
<td>5.3 g</td>
<td>2.1 g</td>
<td>Residual lactose Contains fish oil</td>
<td>Nutritional supplement in patients with lung cancer undergoing chemotherapy, or with pancreatic cancer Not suitable in child under 3 years</td>
<td>Forticare liquid: cappuccino, orange &amp; lemon, peach &amp; ginger 500 ml = £8.76</td>
</tr>
<tr>
<td>Heparon® Junior</td>
<td>Standard dilution (18%) of powder per 100 mL</td>
<td>363 kJ (86 kcal)</td>
<td>2 g cows' milk</td>
<td>11.6 g (sugars 2.9 g)</td>
<td>3.6 g</td>
<td>Nil</td>
<td>Contains lactose Electrolytes/100 mL: Na⁺ 0.56 mmol K⁺ 1.19 mmol Ca²⁺ 2.3 mmol P³⁻ 1.6 mmol</td>
<td>Enteral feed or nutritional supplement for children with acute or chronic liver failure</td>
<td>Heparon Junior powder: 400 gram = £21.25</td>
</tr>
<tr>
<td>Powder provides: protein 11.1 g, carbohydrate 64.2 g, fat 19.9 g, energy 2016 kJ (480 kcal)/100 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KetoCal®</td>
<td>Standard dilution (20%) of powder per 100 mL</td>
<td>602 kJ (146 kcal)</td>
<td>3.1 g cows' milk with additional amino acids</td>
<td>600 mg (sugars 120 mg)</td>
<td>14.6 g (LCT 100 %)</td>
<td>Nil</td>
<td>Electrolytes/100 mL: Na⁺ 4.3 mmol K⁺ 4.1 mmol Ca²⁺ 2.15 mmol P³⁻ 2.77 mmol</td>
<td>Enteral feed or nutritional supplement as part of ketogenic diet in management of epilepsy resistant to drug therapy, in children over 1 year, only on the advice of secondary care physician with experience of ketogenic diet.</td>
<td>KetoCal 4:1 powder: unflavoured, vanilla 300 gram = £29.91</td>
</tr>
<tr>
<td>Powder provides: protein 15.25 g, carbohydrate 3 g, fat 73 g, energy 3011 kJ (730 kcal)/100 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KetoCal® 3:1</td>
<td>Standard dilution (9.5%) of powder per 100 mL</td>
<td>276 kJ (66 kcal)</td>
<td>1.5 g</td>
<td>680 mg (sugars 570 mg)</td>
<td>6.4 g</td>
<td>Nil</td>
<td>Electrolytes/100 mL: Na⁺ 1.3 mmol K⁺ 2.4 mmol Ca²⁺ 2 mmol P³⁻ 1.7 mmol</td>
<td>Enteral feed or nutritional supplement as part of ketogenic diet in management of drug resistant epilepsy or other conditions for which a ketogenic diet is indicated in children from birth to 6 years; as a nutritional supplement in children over 6 years.</td>
<td>KetoCal 3:1 powder: 300 gram = £28.95</td>
</tr>
<tr>
<td>Powder provides: protein 15.3 g, carbohydrate 7.2 g, fat 67.7 g, energy 2927 kJ (699 kcal)/100 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KetoCal® 4:1 LQ</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>620 kJ (150 kcal)</td>
<td>3.09 g casein and whey with additional amino acids</td>
<td>610 mg (sugars 230 mg)</td>
<td>14.8 g (LCT 100 %)</td>
<td>1.12 g</td>
<td>Electrolytes/100 mL: Na⁺ 4.9 mmol K⁺ 4.7 mmol Ca²⁺ 2.4 mmol P³⁻ 3.1 mmol</td>
<td>Enteral feed or nutritional supplement as part of ketogenic diet in management of drug resistant epilepsy or other conditions for which a ketogenic diet is indicated in children 1-10 years; as a nutritional supplement in children over 10 years.</td>
<td>KetoCal 4:1 LQ liquid: unflavoured, vanilla 200 ml = £4.27</td>
</tr>
</tbody>
</table>
## Specialised formulas for specific clinical conditions (product list continued)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (kJ)(kcal)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kindergen®&lt;sup&gt;x&lt;/sup&gt; (Nutricia Ltd)</td>
<td>Standard dilution (20 %) of powder per 100 mL</td>
<td>421 kJ (101 kcal)</td>
<td>1.5 g whey protein</td>
<td>11.8 g (sugars 1.2 g)</td>
<td>5.3 g (LCT 93 %)</td>
<td>Electrolytes/100 mL: Na⁺ 2 mmol K⁺ 0.6 mmol Ca²⁺ 2.8 mmol P⁻ 3 mmol Low Vitamin A</td>
<td>Enteral feed or nutritional supplement for children with chronic renal failure receiving peritoneal rapid overnight dialysis.</td>
<td>Kindergen powder: 400 gram = £28.52</td>
<td></td>
</tr>
<tr>
<td>Modulen IBD® (Nestle Health Science)</td>
<td>Standard dilution (20%) of powder (sip or tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.6 g casein</td>
<td>11 g (sugars 3.98 g)</td>
<td>4.7 g Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Crohn’s disease active phase, and in remission if malnourished</td>
<td>Modulen IBD powder: 400 gram = £15.06</td>
<td></td>
</tr>
<tr>
<td>Nepro®&lt;sup&gt;®&lt;/sup&gt; (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>838 kJ (200 kcal)</td>
<td>7 g cows’ milk</td>
<td>20.6 g (sugars 3.26 g)</td>
<td>9.6 g</td>
<td>1.56 g</td>
<td>Gluten-free Residual lactose Electrolytes/100 mL: Na⁺ 3.67 mmol K⁺ 2.72 mmol Ca²⁺ 3.43 mmol P⁻ 2.23 mmol</td>
<td>Enteral feed or nutritional supplement in patients with chronic renal failure who are on haemodialysis or CAPD, or with cirrhosis, or other conditions requiring a high energy, low fluid, low electrolyte diet. Not suitable for child under 1 year; use with caution in child 1-5 years.</td>
<td>Nepro HP liquid: strawberry 220 ml = £2.98 vanilla 220 ml = £2.98 500 ml = £6.12</td>
</tr>
<tr>
<td>ProSure®&lt;sup&gt;®&lt;/sup&gt; (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>536 kJ (127 kcal)</td>
<td>6.65 g cows’ milk</td>
<td>18.3 g (sugars 2.95 g)</td>
<td>2.56 g</td>
<td>2.07 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Nutritional supplement for patients with pancreatic cancer. Not suitable for child under 1 year; use with caution in child 1-4 years.</td>
<td>ProSure liquid: 240 ml = £3.34</td>
</tr>
<tr>
<td>Renamil®&lt;sup&gt;®&lt;/sup&gt; (Stanningley Pharma Ltd)</td>
<td>Powder (sip or tube feed when reconstituted) per 100 g</td>
<td>2003 kJ (477 kcal)</td>
<td>4.6 g cows’ milk</td>
<td>70.8 g</td>
<td>19.3 g Nil</td>
<td>Contains lactose Gluten-free Electrolytes/100 g: Na⁺ 1.04 mmol K⁺ 0.13 mmol Ca²⁺ 10.22 mmol P⁻ 1.06 mmol Contains no vitamin A or vitamin D</td>
<td>Enteral feed or nutritional supplement for adults and children over 1 year with chronic renal failure.</td>
<td>Renamil powder: 10 x 100 gram = £25.40</td>
<td></td>
</tr>
<tr>
<td>Renapro®&lt;sup&gt;®&lt;/sup&gt; (Stanningley Pharma Ltd)</td>
<td>Powder per 100 g</td>
<td>1580 kJ (372 kcal)</td>
<td>90 g whey protein</td>
<td>800 mg</td>
<td>1 g Nil</td>
<td>Gluten-free Residual lactose Electrolytes/100 g: Na⁺ 23 mmol K⁺ 2 mmol Ca²⁺ 4.99 mmol P⁻ 4.84 mmol</td>
<td>Nutritional supplement for biochemically proven hypoproteinaemia and patients undergoing dialysis. Not suitable for child under 1 year.</td>
<td>Renapro powder: 600 gram = £69.60</td>
<td></td>
</tr>
<tr>
<td>Product</td>
<td>Formulation</td>
<td>Energy</td>
<td>Protein</td>
<td>Carbohydrate</td>
<td>Fat</td>
<td>Fibre</td>
<td>Special Characteristics</td>
<td>ACBS Indications</td>
<td>Presentation &amp; Flavour</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
<td>----------</td>
<td>---------</td>
<td>--------------</td>
<td>-----</td>
<td>-------</td>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Renastart®</strong></td>
<td>Powder</td>
<td>414 kJ</td>
<td>1.5 g</td>
<td>12.5 g</td>
<td>4.8</td>
<td>Nil</td>
<td>Contains lactose</td>
<td>Dietary management of renal failure in child from birth to 10 years.</td>
<td>Renastart powder: 400 gram = £26.08</td>
</tr>
<tr>
<td>(Vitaflo International Ltd)</td>
<td>per 100 mL</td>
<td>(99 kcal)</td>
<td>cows' milk soya</td>
<td>(sugars 1.3 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder provides:</td>
<td>7.5 g, carbohydrate 62.5 g, fat 23.8 g, energy 2071 kJ (494 kcal)/100 g</td>
<td>20% of powder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respifor®</strong></td>
<td>Liquid (sip feed)</td>
<td>633 kJ</td>
<td>7.5 g</td>
<td>22.5 g</td>
<td>3.3</td>
<td>Nil</td>
<td>Contains lactose</td>
<td>Nutritional supplement for dietary management of disease-related malnutrition in patients with chronic obstructive pulmonary disease and body-mass index less than 20.</td>
<td>Respifor milkshake style liquid: chocolate, strawberry, vanilla 500 ml = £8.32</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 mL</td>
<td>(150 kcal)</td>
<td>cows' milk</td>
<td>(sugars 6.4 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Table 4 Feed supplements**

**High-energy supplements**

*Flavoured carbohydrate supplements are not suitable for child under 1 year; liquid supplements should be diluted before use in child under 5 years.*

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Caloreen®</strong></td>
<td>Powder</td>
<td>1640 kJ</td>
<td>Nil</td>
<td>96 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free, Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement. Not suitable for child under 3 years.</td>
<td>Caloreen powder: 500 g = £3.69</td>
</tr>
<tr>
<td>(Nestle Health Science)</td>
<td>per 100 g</td>
<td>(390 kcal)</td>
<td>Maltodextrin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maxijul Super Soluble®</strong></td>
<td>Powder</td>
<td>1615 kJ</td>
<td>Nil</td>
<td>95 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free, Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.</td>
<td>Maxijul Super Soluble powder: 200 g = £2.55; 528 g = £6.36; 2112 g; 25000 g = £152.66</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 g</td>
<td>(380 kcal)</td>
<td>Glucose polymer (sugars 8.6 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Polycal®</strong></td>
<td>Liquid</td>
<td>1050 kJ</td>
<td>Nil</td>
<td>61.9 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free, Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement. Liquid not suitable for child under 3 years.</td>
<td>Polycal liquid: neutral, orange 200 ml = £1.69</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 mL</td>
<td>(247 kcal)</td>
<td>Maltodextrin (sugars 12.2 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Polycal®</strong></td>
<td>Powder</td>
<td>1630 kJ</td>
<td>Nil</td>
<td>96 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free, Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.</td>
<td>Polycal powder: 400 g = £4.20</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 g</td>
<td>(384 kcal)</td>
<td>Maltodextrin (sugars 6 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## High-energy supplements: carbohydrate

Flavoured carbohydrate supplements are not suitable for children under 1 year; liquid supplements should be diluted before use in children under 5 years.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.O.S.®</td>
<td>Powder</td>
<td>1590 kJ</td>
<td>Nil</td>
<td>95 g (sugars 9 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>S.O.S. products are age-range specific-consult product literature</td>
<td>For use as an emergency regimen in the dietary management of inborn errors of metabolism in adults and children from birth.</td>
<td>S.O.S. 15 oral powder: 31 g sachets 30 sachet = £10.67; S.O.S. 10 oral powder: 21 g sachets 30 sachet = £7.23; S.O.S. 20 oral powder: 42 g sachets 30 sachet = £14.46; S.O.S. 25 oral powder: 52 g sachets 30 sachet = £17.89</td>
</tr>
</tbody>
</table>

Contents of each sachet should be reconstituted with water to a total volume of 200 mL.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitajoule®</td>
<td>Powder</td>
<td>1590 kJ</td>
<td>Nil</td>
<td>95 g Dried glucose syrup (sugars 9 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.</td>
<td>Vitajoule powder: 500 g = £4.33</td>
</tr>
</tbody>
</table>

## High-energy supplements: fat

Liquid supplements should be diluted before use in child under 5 years.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calogen®</td>
<td>Liquid (emulsion)</td>
<td>1850 kJ</td>
<td>Nil</td>
<td>100 mg</td>
<td>50 g (LCT 100 %)</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement.</td>
<td>Calogen emulsion: banana 500 ml = £10.72 neutral, strawberry 200 ml = £4.36 500 ml = £10.72</td>
</tr>
<tr>
<td>Fresubin® 5 kcal Shot</td>
<td>Liquid (emulsion)</td>
<td>2100 kJ</td>
<td>Nil</td>
<td>4.0 g (sucrose)</td>
<td>53.8 g</td>
<td>400 mg</td>
<td>Gluten-free Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement. Not suitable for child under 3 years.</td>
<td>Fresubin 5 kcal shot drink neutral: 480 ml = £11.08</td>
</tr>
<tr>
<td>Liquigen®</td>
<td>Liquid (emulsion)</td>
<td>1850 kJ</td>
<td>Nil</td>
<td>Nil</td>
<td>50 g (MCT 97 %) Fractionated coconut oil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease, liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in epilepsy, and in type 1 lipoproteinemia Not suitable for child under 1 year</td>
<td>Liquigen emulsion: 250 ml = £9.09</td>
</tr>
<tr>
<td>Product Name</td>
<td>Formulation</td>
<td>Energy per 100 mL</td>
<td>Protein</td>
<td>Carbohydrate</td>
<td>Fat</td>
<td>Fibre</td>
<td>Special Characteristics</td>
<td>ACBS Indications</td>
<td>Presentation &amp; Flavour</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td>------------------</td>
<td>---------</td>
<td>--------------</td>
<td>-----</td>
<td>-------</td>
<td>-------------------------</td>
<td>----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Medium-chain Triglyceride (MCT) Oil</td>
<td>Liquid</td>
<td>3515 kJ (855 kcal)</td>
<td>Nil</td>
<td>Nil</td>
<td>MCT 100 %</td>
<td>Nil</td>
<td>Nutritional supplement for steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease and liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in management of epilepsy, type 1 hyperlipoproteinaemia</td>
<td>MCT oil: 500 ml = £14.41</td>
<td></td>
</tr>
<tr>
<td><strong>FAT AND CARBOHYDRATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Product</strong></td>
<td><strong>Formulation</strong></td>
<td><strong>Energy</strong></td>
<td><strong>Protein</strong></td>
<td><strong>Carbohydrate</strong></td>
<td><strong>Fat</strong></td>
<td><strong>Fibre</strong></td>
<td><strong>Special Characteristics</strong></td>
<td><strong>ACBS Indications</strong></td>
<td><strong>Presentation &amp; Flavour</strong></td>
</tr>
<tr>
<td>Duocal® Super Soluble (Nutricia Ltd)</td>
<td>Powder per 100 g</td>
<td>2061 kJ (492 kcal)</td>
<td>Nil</td>
<td>72.7 g (sugars 6.5 g)</td>
<td>22.3 g (MCT 35 %)</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement.</td>
<td>Duocal Super Soluble powder: 400 gram = £17.75</td>
</tr>
<tr>
<td>Energivit® (Nutricia Ltd)</td>
<td>Standard dilution (15%) of powder per 100 mL</td>
<td>309 kJ (74 kcal)</td>
<td>Nil</td>
<td>10 g (sugars 900 mg)</td>
<td>3.75 g</td>
<td>Nil</td>
<td>Lactose-free With vitamins minerals and trace elements</td>
<td>For children requiring additional energy, vitamins, minerals, and trace elements following a protein-restricted diet</td>
<td>Energivit powder: 400 gram = £21.58</td>
</tr>
<tr>
<td><strong>High-energy supplements: protein</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Product</strong></td>
<td><strong>Formulation</strong></td>
<td><strong>Energy</strong></td>
<td><strong>Protein</strong></td>
<td><strong>Carbohydrate</strong></td>
<td><strong>Fat</strong></td>
<td><strong>Fibre</strong></td>
<td><strong>Special Characteristics</strong></td>
<td><strong>ACBS Indications</strong></td>
<td><strong>Presentation &amp; Flavour</strong></td>
</tr>
<tr>
<td>ProSource® Jelly (Nutrinovo Ltd)</td>
<td>Semi-solid per 100 mL</td>
<td>315 kJ (75 kcal)</td>
<td>16.9 g collagen protein hydrolysate whey protein isolate</td>
<td>Less than 1 g</td>
<td>Nil</td>
<td>Less than 1 g</td>
<td>Gluten-free Lactose-free Contains porcine derivatives</td>
<td>Hypoproteinaemia Not recommended for child under 3 years</td>
<td>ProSource jelly: fruit punch, orange 118 ml = £1.80</td>
</tr>
<tr>
<td>Protifar® (Nutricia Ltd)</td>
<td>Powder per 100 g</td>
<td>1580 kJ (373 kcal)</td>
<td>88.5 g cows' milk</td>
<td>less than 1.5 g</td>
<td>1.6 g</td>
<td>Nil</td>
<td>Residual lactose Electrolytes/100 mL: Na⁺ 1.3 mmol K⁺ 1.28 mmol Ca²⁺ 33.75 mmol P⁺ 22.58 mmol</td>
<td>Nutritional supplement for use in biochemically proven hypoproteinaemia.</td>
<td>Protifar powder: 225 gram = £8.54</td>
</tr>
</tbody>
</table>

Powder provides: carbohydrate 66.7 g, fat 25 g, energy 2059 kJ (492 kcal)/100 g
### High-energy supplements: protein (product list continued)

#### PROTEIN AND CARBOHYDRATE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dialamine®</td>
<td>Standard dilution</td>
<td>264 kJ</td>
<td>4.3 g</td>
<td>11.2 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Contains vitamin C</td>
<td>Hypoproteinaemia, chronic renal failure, wound fistula leakage with excessive protein loss, conditions requiring a controlled nitrogen intake, and haemodialysis. Not suitable for child under 6 months.</td>
<td>Dialamine powder: 400 gram = £72.09</td>
</tr>
<tr>
<td></td>
<td>(20%) of powder per 100 mL</td>
<td>(62 kcal)</td>
<td>protein equivalent (essential and non-essential amino acids)</td>
<td>(sugars 10.2 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ProSource® Liquid</td>
<td>Liquid per 30 mL</td>
<td>420 kJ</td>
<td>10 g</td>
<td>15 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free</td>
<td>Biochemically proven hypoproteinaemia Not recommended for child under 3 years.</td>
<td>ProSource liquid 30ml sachets: citrus berry, lemon, orange creme, original 100 sachet = £97.23</td>
</tr>
<tr>
<td>(Nutrinovo Ltd)</td>
<td></td>
<td>(100 kcal)</td>
<td>collagen protein whey protein isolate</td>
<td>(sugars 8 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ProSource® Plus</td>
<td>Liquid per 30 mL</td>
<td>420 kJ</td>
<td>15 g</td>
<td>11 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free</td>
<td>Hypoproteinaemia Not recommended for child under 3 years.</td>
<td>ProSource plus liquid 100 x 30ml sachets: unflavoured: £140.53</td>
</tr>
<tr>
<td>(Nutrinovo Ltd)</td>
<td></td>
<td>(100 kcal)</td>
<td>collagen protein whey protein isolate</td>
<td>(sugars 10 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Powder provides:** protein equivalent 25 g, carbohydrate 65 g, vitamin C 125 mg, energy 1530 kJ (360 kcal)/100 g

#### PROTEIN, FAT, AND CARBOHYDRATE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calogen® Extra</td>
<td>Liquid per 100 mL</td>
<td>1650 kJ</td>
<td>5 g</td>
<td>4.5 g</td>
<td>40.3 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains vitamins and minerals</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3-6 years. May require dilution for child 3-5 years.</td>
<td>Calogen Extra emulsion: neutral, strawberry 200 ml = £4.98</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td></td>
<td>(400 kcal)</td>
<td>cows’ milk</td>
<td>(sugars 3.5 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calogen® Extra Shots</td>
<td>Liquid per 100 mL</td>
<td>1650 kJ</td>
<td>5 g</td>
<td>4.5 g</td>
<td>40.3 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose With vitamins and minerals</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3-6 years. May require dilution for child 3-5 years.</td>
<td>Calogen Extra Shots emulsion: neutral, strawberry 240 ml = £5.75</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td></td>
<td>(400 kcal)</td>
<td>cows’ milk</td>
<td>(sugars 3.5 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product</td>
<td>Type</td>
<td>Powder/Aqueous</td>
<td>Energy (kJ)</td>
<td>Protein (g)</td>
<td>Carbohydrate (g)</td>
<td>Fat (g)</td>
<td>Lactose/Soya</td>
<td>Gluten-Free</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------</td>
<td>----------------</td>
<td>-------------</td>
<td>-------------</td>
<td>------------------</td>
<td>---------</td>
<td>--------------</td>
<td>-------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Calshake® (Fresenius Kabi Ltd)</td>
<td>Powder per 87 g</td>
<td>1841 (439 kcal)</td>
<td>4.1 g cows’ milk</td>
<td>56.4 g</td>
<td>22 g NIL</td>
<td>NIL</td>
<td>Contains lactose</td>
<td>Gluten-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year. Calshake powder: chocolate 7 x 90 g sachets = £16.52 banana, neutral, strawberry, vanilla 7 x 87 g sachets = £16.52</td>
</tr>
<tr>
<td>Enshake® (Abbott Laboratories Ltd)</td>
<td>Powder per 100 g</td>
<td>1893 (450 kcal)</td>
<td>8.4 g cows’ milk soy protein isolate</td>
<td>69 g (sugars 14.5 g)</td>
<td>15.6 g NIL</td>
<td>NIL</td>
<td>Residual lactose Contains vitamins and minerals</td>
<td>NIL</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year. Enshake oral powder: 96.5g sachets: banana, chocolate, strawberry, vanilla 6 sachet = £12.93</td>
</tr>
<tr>
<td>MCT Procal® (Vitaflo International Ltd)</td>
<td>Powder per 100 g</td>
<td>2742 (657 kcal)</td>
<td>12.5 g cows’ milk soy protein isolate</td>
<td>20.6 g (sugars 3.1 g)</td>
<td>63.1 g (MCT 99%) NIL</td>
<td>NIL</td>
<td>Contains lactose</td>
<td>NIL</td>
<td>Dietary management of disorders of long-chain fatty acid oxidation, fat malabsorption, and other disorders requiring a low LCT, high MCT supplement. Not suitable for child under 1 year. MCT procal oral powder: 16g sachets: 30 sachet = £23.51</td>
</tr>
<tr>
<td>Pro-Cal® (Vitaflo International Ltd)</td>
<td>Powder per 100 g</td>
<td>2787 (667 kcal)</td>
<td>13.6 g cows’ milk</td>
<td>28.2 g (sugars 16 g)</td>
<td>55.5 g NIL</td>
<td>NIL</td>
<td>Contains lactose</td>
<td>Gluten-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year; use with caution in child 1-6 years. Pro-Cal powder: 375 g = £15.66; 510 g = £14.51; 1500 g = £29.56; 3000 g = £69.77; 12500 g = £210.06</td>
</tr>
<tr>
<td>Pro-Cal® Shot (Vitaflo International Ltd)</td>
<td>Liquid per 100 mL</td>
<td>1385 (334 kcal)</td>
<td>6.7 g cows’ milk</td>
<td>13.2 g (sugars 13.3 g)</td>
<td>28.2 g NIL</td>
<td>NIL</td>
<td>Contains lactose Gluten-free Contains soya</td>
<td>NIL</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years. Pro-Cal: shot starter pack 240 ml = £4.82 750 ml = £15.05 neutral, strawberry 250 ml = £5.02 720 ml = £14.44 banana 250 ml = £5.02 720 ml = £14.44</td>
</tr>
<tr>
<td>Scandishake® Mix (Nutricia Ltd)</td>
<td>Powder per 100 g</td>
<td>2099 (500 kcal)</td>
<td>4.7 g cows’ milk</td>
<td>65 g (sugars 14.3 g)</td>
<td>24.7 g NIL</td>
<td>NIL</td>
<td>Gluten-free Contains lactose</td>
<td>NIL</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years. Scandishake Mix oral powder: 85g sachets: banana, caramel, chocolate, strawberry, unflavoured, vanilla 6 sachet = £14.46</td>
</tr>
</tbody>
</table>

Powder: 15 g provides: protein 2 g, carbohydrate 3.3 g, fat 10.1 g, energy 439 kJ (105 kcal)
### High-energy supplements: protein (product list continued)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitasavoury® (Vitaflo International Ltd)</td>
<td>Powder per 100 g</td>
<td>2562 kJ (619 kcal)</td>
<td>12 g cows' milk</td>
<td>22.5 g (sugars 1.4 g)</td>
<td>52 g</td>
<td>6.4 g</td>
<td>Contains lactose Contains soya (chicken flavour)</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years.</td>
<td>Vitasavoury 200 powder: chicken, golden vegetable, leek &amp; potato, mushroom 24 x 33 g = £30.75 Vitasavoury 300 powder: chicken, golden vegetable, leek &amp; potato, mushroom 10 x 50 g = £18.77</td>
</tr>
</tbody>
</table>

### Fibre, vitamin, and mineral supplements

#### High-fibre supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resource® Optifibre® (Nestle Health Science)</td>
<td>Powder per 100 g</td>
<td>323 kJ (76 kcal)</td>
<td>Nil</td>
<td>19 g guar gum partially hydrolysed</td>
<td>Nil</td>
<td>78 g</td>
<td>Gluten-free Lactose-free</td>
<td>Standard, p. 1261 except dysphagia Not suitable for child under 5 years</td>
<td>Resource Optifibre powder: 160 gram = £6.35; 250 gram = £10.28</td>
</tr>
</tbody>
</table>

#### Vitamin and Mineral supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>FruitiVits® (Vitaflo International Ltd)</td>
<td>Powder per 100 g</td>
<td>133 kJ (33 kcal)</td>
<td>Nil</td>
<td>8.3 g (sugars 400 mg)</td>
<td>less than 100 mg</td>
<td>3.3 g</td>
<td></td>
<td>Vitamin, mineral, and trace element supplement in children 3-10 years with restrictive therapeutic diets</td>
<td>Sachets: 30 x 6 g = £63.53 orange</td>
</tr>
<tr>
<td>Paediatric Seravit® (Nutricia Ltd)</td>
<td>Powder per 100 g</td>
<td>1275 kJ (300 kcal)</td>
<td>Nil</td>
<td>75 g (sugars 6.75 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Pineapple flavour not suitable for child under 6 months</td>
<td>Vitamin, mineral, and trace element supplement in infants and children with restrictive therapeutic diets. Seravit Paediatric powder: pineapple 200 gram = £18.72 unflavoured 200 gram = £17.58</td>
<td></td>
</tr>
<tr>
<td>Renavit® (Stanningley Pharma Ltd)</td>
<td>Tablet per 450 mg</td>
<td>3.15 kJ (0.75 kcal)</td>
<td>Nil</td>
<td>170 mg</td>
<td>Nil</td>
<td>Nil</td>
<td></td>
<td>Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis</td>
<td>Renavit tablets: 100 tablet = £12.50</td>
</tr>
</tbody>
</table>
Feed additives
Special additives for conditions of intolerance

Colief®
> For the relief of symptoms associated with lactose intolerance in infants, provided that lactose intolerance is confirmed by the presence of reducing substances and/or excessive acid in stools, a low concentration of the corresponding disaccharide enzyme on intestinal biopsy or by breath hydrogen test or lactose intolerance test. For dosage and administration details, consult product literature.
Liquid, lactose 50 000 units/g
Colief 50,000 units/g infant drops (Forum Health Products Ltd)
7 ml (ACBS) - NHS indicative price = £8.40

Fructose
> (Laevulose) For proven glucose/galactose intolerance

Glucose
> (Dextrose monohydrate) For use as an energy supplement in sucrose-isomaltase deficiency

VSL#3®
> Nutritional supplement for use under the supervision of a physician, for the maintenance of remission of ileoanal pouchitis induced by antibacterials in adults. For dosage and administration details, consult product literature.
POWDER, containing 8 strains of live, freeze-dried, lactic acid bacteria. Contains traces of soya, gluten, and lactose.
VSL#3® Probiotic Food Supplement oral powder 4.4g sachets (Ferring Pharmaceuticals Ltd)
10 sachet (ACBS) - NHS indicative price = £14.64 | 30 sachet (ACBS) - NHS indicative price = £41.66

Feed thickeners and pre-thickened drinks
Carobel, Instant®
> For thickening feeds in the treatment of vomiting. POWDER, carob seed flour.

Instant Carobel powder (Cow & Gate Ltd)
155 gram (ACBS) - NHS indicative price = £2.80

Multi-thick®
> For thickening of liquids and foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.
POWDER, modified maize starch, gluten- and lactose-free.

Multi-thick powder (Abbott Laboratories Ltd)
250 gram (ACBS) - NHS indicative price = £4.83

Nutilis® Clear
> For thickening of liquids or foods in dysphagia. Not suitable for children under 3 years.
POWDER, maltodextrin, xanthan gum, guar gum, gluten- and lactose-free.

Nutilis Clear powder (Nutricia Ltd)
175 gram (ACBS) - NHS indicative price = £8.46

Nutilis Powder
> For thickening of foods in dysphagia. Not suitable for children under 3 years.
POWDER, carbohydrate 86 g, energy 1520 kJ (358 kcal)/100 g, modified maize starch, gluten- and lactose-free.

Nutilis powder (Nutricia Ltd)
240 gram (ACBS) - NHS indicative price = £6.40 | 300 gram (ACBS) - NHS indicative price = £4.92

Resource® ThickenUp Clear
> For thickening of liquids or foods in dysphagia. Not suitable for children under 3 years.
POWDER, maltodextrin, xanthan gum, gluten- and lactose-free.

Resource ThickenUp Clear powder (Nestle Health Science)
24 x 1.2 g sachets (ACBS) - NHS indicative price = £5.28 | 125 gram (ACBS) - NHS indicative price = £8.46

Resource® ThickenUp®
> For thickening of foods in dysphagia. Not suitable for children under 1 year.
POWDER, modified maize starch. Gluten- and lactose-free.

Resource ThickenUp® Clear
POWDER, maltodextrin, xanthan gum, gluten- and lactose-free, net price 125 g = £8.46; 24 x 1.2-g sachets = £5.28

Resource® Thickened Drink
> For dysphagia. Not suitable for children under 1 year. LIQUID, carbohydrate 22 g, energy: orange 382 kJ (90 kcal); apple 376 kJ (89 kcal)/100 mL. Gluten- and lactose-free.

Resource Thickened Drink custard (Nestle Health Science)
apple, orange 114 ml (ACBS) - NHS indicative price = £0.71

Resource Thickened Drink syrup (Nestle Health Science)
apple, orange 114 ml (ACBS) - NHS indicative price = £0.71

SLO Drinks®
> Nutritional supplement for patient hydration in the dietary management of dysphagia. Not suitable for children under 3 years.
POWDER, carbohydrate content varies with flavour and chosen consistency (3 consistencies available), see product literature.

SLO Drink 1 oral powder (SLO Drinks Ltd)
lemon, orange, hot chocolate, white coffee, white tea 25 cup (ACBS) - NHS indicative price = £7.30

SLO Drink 2 oral powder (SLO Drinks Ltd)
hot chocolate, lemon, orange, white tea 25 cup (ACBS) - NHS indicative price = £7.50

SLO Drink 3 oral powder orange (SLO Drinks Ltd)
25 cup (ACBS) - NHS indicative price = £7.50

Thick and Easy®
> For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.
POWDER, modified maize starch

Thick & Easy powder (Fresenius Kabi Ltd)
225 gram (ACBS) - NHS indicative price = £5.06 | 900 gram (ACBS) - NHS indicative price = £31.00 | 4540 gram (ACBS) - NHS indicative price = £84.71

Thicken Aid®
> For thickening of foods in dysphagia. Not suitable for children under 1 year.
POWDER, modified maize starch, maltodextrin, gluten- and lactose-free.

Thicken Aid powder (M & A Pharmachem Ltd)
225 gram (ACBS) - NHS indicative price = £3.71 | 900 gram (ACBS) - NHS indicative price = £12.40

Thixo-D®
> For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.
POWDER, modified maize starch, gluten-free.

Thixo-D (Sutherland Health Ltd)
Cal-Free powder 375 gram (ACBS) - NHS indicative price = £7.50

Vitaquick®
> For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.
POWDER, modified maize starch.

Vitaquick powder (VitaFilo International Ltd)
500 gram (ACBS) - NHS indicative price = £7.05 | 2000 gram (ACBS) - NHS indicative price = £38.92

Flavouring preparations
Flavour Mix®
POWDER

Nestle Nutrition Flavour (Nestle Health Science)
Mix banana, Mix chocolate 60 gram (ACBS) - NHS indicative price = £7.17

FlavourPac®
> For use with VitaFilo’s range of unflavoured protein substitutes for metabolic diseases; not suitable for child under 3 years.
POWDER
Borderline substances  Appendix 2

Foods for special diets

Gluten-free foods

ACBS indications: established gluten-sensitive enteropathies including steatorrhoea due to gluten sensitivity, coeliac disease, and dermatitis herpetiformis.

Bread

LOAVES

Barkat® Loaf
GLUTEN-FREE

Barkat gluten free (Gluten Free Foods Ltd)
wholemeal bread sliced 500 gram (ACBS) - NHS indicative price = £3.98
brown rice bread, wheat free multigrain bread, white rice bread 500 gram (ACBS) - NHS indicative price = £3.73
apr baked white bread sliced 500 gram (ACBS) - NHS indicative price = £4.13
brown rice bread riso 480 gram (ACBS) - NHS indicative price = £3.78
home fresh country loaf 250 gram (ACBS) - NHS indicative price = £4.35

Genius Gluten Free® Loaf
GLUTEN-FREE

Genius gluten free brown bread (Genius Foods Ltd)
unsliced 400 gram (ACBS) - NHS indicative price = £2.67
sliced 400 gram (ACBS) - NHS indicative price = £2.77

Genius gluten free brown sandwich bread sliced (Genius Foods Ltd)
535 gram (ACBS) - NHS indicative price = £3.59

Genius gluten free white bread (Genius Foods Ltd)
unsliced 400 gram (ACBS) - NHS indicative price = £2.67
sliced 400 gram (ACBS) - NHS indicative price = £2.77

Genius gluten free white sandwich bread sliced (Genius Foods Ltd)
535 gram (ACBS) - NHS indicative price = £3.59

Glutafin® Loaves
GLUTEN-FREE

Glutafin gluten free (Dr Schar UK Ltd)
fibre loaf sliced, white loaf sliced 400 gram (ACBS) - NHS indicative price = £3.85

Glutafin Select Loaves
GLUTEN-FREE

Glutafin gluten free Select fibre loaf sliced (Dr Schar UK Ltd)
400 gram (ACBS) - NHS indicative price = £3.43

Glutafin gluten free Select fresh (Dr Schar UK Ltd)
brown loaf sliced, white loaf sliced 400 gram (ACBS) - NHS indicative price = £3.43

Glutafin gluten free Select seeded loaf sliced (Dr Schar UK Ltd)
400 gram (ACBS) - NHS indicative price = £3.72

Glutafin gluten free Select white loaf sliced (Dr Schar UK Ltd)
400 gram (ACBS) - NHS indicative price = £3.45

Juvela® Loaf
GLUTEN-FREE

Juvela gluten free fibre loaf (Hero UK Ltd)
sliced, unsliced 400 gram (ACBS) - NHS indicative price = £3.54

Juvela gluten free fresh (Hero UK Ltd)
fibre loaf sliced 400 gram (ACBS) - NHS indicative price = £3.39
white loaf sliced 400 gram (ACBS) - NHS indicative price = £3.69

Juvela gluten free loaf unsliced (Hero UK Ltd)
400 gram (ACBS) - NHS indicative price = £3.54

Juvela gluten free part baked (Hero UK Ltd)
blonde loaf 400 gram (ACBS) - NHS indicative price = £3.80
brown loaf 400 gram (ACBS) - NHS indicative price = £3.95

Lifestyle® Loaf
GLUTEN-FREE

Lifestyle gluten free (Ultrapharm Ltd)
high fibre bread sliced 400 gram - NHS indicative price = £2.82
brown bread sliced, white bread sliced 400 gram (ACBS) - NHS indicative price = £2.82

Livwell® Loaf
GLUTEN-FREE

Livwell gluten free (Livwell Ltd)
multi grain bread sliced 200 gram - NHS indicative price = £2.25
white bread sliced 200 gram (ACBS) - NHS indicative price = £2.25

Proceli® Loaf
GLUTEN-FREE

Proceli gluten free (Ambe Ltd)
sandwich bread classic 510 gram - NHS indicative price = £5.32
rice bread riso 480 gram - NHS indicative price = £3.71

Warburtons® Loaf
GLUTEN-FREE

Warburtons gluten free (Warburtons Ltd)
brown bread sliced, white bread sliced 400 gram (ACBS) - NHS indicative price = £3.06

Wellfoods® Loaf
GLUTEN-FREE

Wellfoods gluten free loaf (Wellfoods Ltd)
unsliced 600 gram (ACBS) - NHS indicative price = £4.85
sliced 600 gram (ACBS) - NHS indicative price = £4.95

BAGUETTES, BUNS AND ROLLS

Barkat® Baguettes and rolls
GLUTEN-FREE

Barkat gluten free par baked (Gluten Free Foods Ltd)
baguettes 200 gram (ACBS) - NHS indicative price = £4.35
rolls 200 gram (ACBS) - NHS indicative price = £3.98

Ener-G® Rolls
GLUTEN-FREE

Ener-G gluten free (General Dietary Ltd)
white round rolls, white long rolls 220 gram (ACBS) - NHS indicative price = £2.95
dinner rolls 280 gram (ACBS) - NHS indicative price = £3.67

Glutafin® Baguettes and rolls
GLUTEN-FREE

Glutafin gluten free (Dr Schar UK Ltd)
4 white rolls, part baked 4 fibre rolls 200 gram (ACBS) - NHS indicative price = £3.68
baguettes 350 gram (ACBS) - NHS indicative price = £3.51

Glutafin® Select Rolls
GLUTEN-FREE

Glutafin gluten free (Dr Schar UK Ltd)
4 long rolls, white rolls 150 gram (ACBS) - NHS indicative price = £2.81
4 white rolls 200 gram (ACBS) - NHS indicative price = £3.68

Juvela® Rolls
GLUTEN-FREE

Juvela gluten free bread rolls (Hero UK Ltd)
425 gram (ACBS) - NHS indicative price = £4.77

Juvela gluten free fibre bread rolls (Hero UK Ltd)
425 gram (ACBS) - NHS indicative price = £4.77

Juvela gluten free fresh (Hero UK Ltd)
fibre rolls, white rolls 425 gram (ACBS) - NHS indicative price = £4.42

Juvela gluten free part baked (Hero UK Ltd)
white bread rolls 375 gram (ACBS) - NHS indicative price = £4.94

FlavourPac oral powder 4g sachets (Vitalfio International Ltd)
blackcurrant, lemon, orange, raspberry, tropical 30 sachet (ACBS) - NHS indicative price = £15.64

1280  Foods for special diets
Foods for special diets

Lifestyle® Rolls
GLUTEN-FREE
Lifestyle gluten free (Ultrapharm Ltd)
brown bread rolls, high fibre bread rolls, white bread rolls
400 gram (ACBS) · NHS indicative price = £2.82
Livwell® Baguettes, buns and rolls
GLUTEN-FREE
Livwell gluten free (Livwell Ltd)
toasting bread buns 180 gram (ACBS) · NHS indicative price = £2.40
white rolls 240 gram (ACBS) · NHS indicative price = £2.25
white baguettes 140 gram (ACBS) · NHS indicative price = £2.15
part baked square dinner rolls 160 gram (ACBS) · NHS indicative price = £2.09
Procell® baguettes, buns and rolls
GLUTEN-FREE
Procell gluten free (Ambe Ltd)
part baked baguettes 250 gram (ACBS) · NHS indicative price = £3.24
white lunch rolls 270 gram (ACBS) · NHS indicative price = £3.26
Warburtons® Baguettes and rolls
GLUTEN-FREE
Warburtons gluten free (Warburtons Ltd)
brown rolls, white rolls 220 gram (ACBS) · NHS indicative price = £2.55
baguettes 150 gram (ACBS) · NHS indicative price = £2.86
Wellfoods® Buns and rolls
GLUTEN-FREE
Wellfoods gluten free (Wellfoods Ltd)
burger buns 380 gram (ACBS) · NHS indicative price = £3.95
rolls 360 gram (ACBS) · NHS indicative price = £3.65
SPECIALITY BREADS
Livwell® Flat bread
GLUTEN-FREE
Livwell gluten free (Livwell Ltd)
tear drop flat bread 180 gram (ACBS) · NHS indicative price = £3.00
flat bread 220 gram (ACBS) · NHS indicative price = £3.00
Cereals
Juvela® Fibre flakes and oats
GLUTEN-FREE
Juvela gluten free (Hero UK Ltd)
fibre flakes, flakes 500 gram (ACBS) · NHS indicative price = £2.78
pure oats 500 gram (ACBS) · NHS indicative price = £2.78
Nairns® Porridge
GLUTEN-FREE
Nairn's gluten free oat porridge (Nairn's Oatcakes Ltd)
500 gram (ACBS) · NHS indicative price = £3.05
Cookies and biscuits
Barkat® Biscuits
GLUTEN-FREE
Barkat gluten free (Gluten Free Foods Ltd)
digestive biscuits 175 gram (ACBS) · NHS indicative price = £2.61
coffee biscuits 200 gram (ACBS) · NHS indicative price = £3.58
Ener-G® Cookies
GLUTEN-FREE
Ener-G gluten free vanilla cookies (General Dietary Ltd)
435 gram (ACBS) · NHS indicative price = £6.16
Glutafin® Cookies and biscuits
GLUTEN-FREE
Glutafin gluten free (Dr Schar UK Ltd)
digestive biscuits, sweet biscuits 150 gram (ACBS) · NHS indicative price = £2.15
tea biscuits 150 gram (ACBS) · NHS indicative price = £2.09
biscuits 200 gram (ACBS) · NHS indicative price = £4.14
savoury short biscuits 130 gram (ACBS) · NHS indicative price = £2.80
shortbread biscuits 100 gram (ACBS) · NHS indicative price = £1.73
Juvela® Biscuits
GLUTEN-FREE
Juvela gluten free (Hero UK Ltd)
sweet biscuits 150 gram (ACBS) · NHS indicative price = £2.88
digestive biscuits, tea biscuits 150 gram (ACBS) · NHS indicative price = £3.05
savoury biscuits 150 gram (ACBS) · NHS indicative price = £3.82
Crackers, crispbreads, and breadsticks
Barkat® Crackers
GLUTEN-FREE
Barkat gluten free matzo crackers (Gluten Free Foods Ltd)
200 gram (ACBS) · NHS indicative price = £3.52
Glutafin® Crackers
GLUTEN-FREE
Glutafin gluten free (Dr Schar UK Ltd)
mini crackers 175 gram (ACBS) · NHS indicative price = £2.96
crackers 200 gram (ACBS) · NHS indicative price = £3.46
high fibre crackers 200 gram (ACBS) · NHS indicative price = £2.90
Juvela® Crispbread
GLUTEN-FREE
Juvela gluten free crispbread (Hero UK Ltd)
200 gram (ACBS) · NHS indicative price = £4.64
Warburtons® Crackers
GLUTEN-FREE
Warburtons gluten free (Warburtons Ltd)
150 gram (ACBS) · NHS indicative price = £2.54
Flour mixes and xanthan gum
FLOUR MIXES
Barkat® Flour mix
GLUTEN-FREE
Barkat gluten free (Gluten Free Foods Ltd)
bread mix 500 gram (ACBS) · NHS indicative price = £6.81
flour mix 750 gram (ACBS) · NHS indicative price = £6.98
Finax® Flour mix
GLUTEN-FREE
Finax gluten free (Drossa Ltd)
crude flour mix, flour mix 900 gram (ACBS) · NHS indicative price = £8.66
fibre bread mix 1000 gram (ACBS) · NHS indicative price = £9.92
Glutafin® Flour mix
GLUTEN-FREE
Glutafin Select® Flour mix
GLUTEN-FREE
Glutafin gluten free Select bread mix (Dr Schar UK Ltd)
500 gram (ACBS) · NHS indicative price = £6.66
Glutafin gluten free Select fibre bread mix (Dr Schar UK Ltd)
500 gram (ACBS) · NHS indicative price = £6.66
Glutafin gluten free Select multipurpose (Dr Schar UK Ltd)
fibre mix, white mix 500 gram (ACBS) · NHS indicative price = £6.66
Glutafin gluten free multipurpose white mix (Dr Schar UK Ltd)
500 gram (ACBS) · NHS indicative price = £6.66
Heron Foods® Flour mix
GLUTEN-FREE
Heron Hi-Fibre gluten free (Gluten Free Foods Ltd)
organic bread mix, wheat free organic bread mix 500 gram (ACBS) · NHS indicative price = £8.96
Juvela® Flour mix
GLUTEN-FREE
Juvela gluten free (Hero UK Ltd)
- fibre mix, harvest mix, mix 500 gram (ACBS) - NHS indicative price = £7.35

Mrs Crimble's gluten free mixes
GLUTEN-FREE

Mrs Crimble's gluten free (Stiletto Foods (UK) Ltd)
- pastry mix 200 gram (ACBS) - NHS indicative price = £1.09
- bread mix 275 gram (ACBS) - NHS indicative price = £1.09

Orgran® Flour mix
GLUTEN-FREE

Orgran gluten free (Naturally Good Food Ltd)
- pizza & pastry mix 575 gram (ACBS) - NHS indicative price = £3.80
- all purpose flour 500 gram (ACBS) - NHS indicative price = £3.10

Proceli® Flour mix
GLUTEN-FREE

Proceli gluten free white plain flour (Ambe Ltd)
- 1000 gram (ACBS) - NHS indicative price = £9.95

Tobia® Flour mix
GLUTEN-FREE

Tobia Teff gluten free (Tobia Teff (UK) Ltd)
- brown teff flour, white teff flour 1000 gram (ACBS) - NHS indicative price = £3.55

Tritamyl® Flour mix
GLUTEN-FREE

Tritamyl gluten free (Gluten Free Foods Ltd)
- brown bread mix 1000 gram (ACBS) - NHS indicative price = £7.10
- flour mix, white bread mix 2000 gram (ACBS) - NHS indicative price = £14.26

Wellfoods® Flour mix
GLUTEN-FREE

Wellfoods gluten free flour alternative (Wellfoods Ltd)
- 1000 gram (ACBS) - NHS indicative price = £7.65

Xanthan Gum

Ener-G® Xanthan gum
GLUTEN-FREE

Ener-G xanthan gum (General Dietary Ltd)
- 170 gram (ACBS) - NHS indicative price = £8.53

Pure® Xanthan gum
GLUTEN-FREE

Innovative Solutions Pure xanthan gum (Innovative Solutions (UK) Ltd)
- 100 gram (ACBS) - NHS indicative price = £6.85

Pasta

Barkat® Pasta
GLUTEN-FREE

- macaroni (Gluten Free Foods Ltd)
  - 500 gram (ACBS) - NHS indicative price = £5.88
- spaghetti (Gluten Free Foods Ltd)
  - 500 gram (ACBS) - NHS indicative price = £5.88
- spirals (Gluten Free Foods Ltd)
  - 500 gram (ACBS) - NHS indicative price = £5.88
- tagliatelle (Gluten Free Foods Ltd)
  - 500 gram (ACBS) - NHS indicative price = £5.88
- Barkat gluten free pasta animal shapes (Gluten Free Foods Ltd)
  - 500 gram (ACBS) - NHS indicative price = £5.88
- Barkat gluten free pasta buckwheat (Gluten Free Foods Ltd)
  - penne, spirals 250 gram (ACBS) - NHS indicative price = £2.95

BiAlimenta® Pasta
GLUTEN-FREE

- BiAlimenta gluten free Pasta (Drossa Ltd)
  - spirals, sagnette 500 gram (ACBS) - NHS indicative price = £5.97

Glutfain® Pasta
GLUTEN-FREE

Glutfain gluten free pasta (Dr Schar UK Ltd)
- lasagne, tagliatelle nests 250 gram (ACBS) - NHS indicative price = £5.53
- fibre spaghetti 500 gram (ACBS) - NHS indicative price = £5.74
- macaroni penne, shells, spirals, long-cut spaghetti 500 gram (ACBS) - NHS indicative price = £6.73

Juvela® Pasta
GLUTEN-FREE

Juvela gluten free fibre penne (Hero UK Ltd)
- 500 gram (ACBS) - NHS indicative price = £6.61

Juvela gluten free pasta (Hero UK Ltd)
- tagliatelle 250 gram (ACBS) - NHS indicative price = £3.47
- fusilli, macaroni, spaghetti 500 gram (ACBS) - NHS indicative price = £7.21
- lasagne 250 gram (ACBS) - NHS indicative price = £3.68

Orgran® Pasta
GLUTEN-FREE

Orgran gluten free pasta brown rice spirals (Naturally Good Food Ltd)
- 250 gram (ACBS) - NHS indicative price = £2.42

Orgran gluten free pasta buckwheat spirals (Naturally Good Food Ltd)
- 250 gram (ACBS) - NHS indicative price = £2.42

Orgran gluten free pasta corn spirals (Naturally Good Food Ltd)
- 250 gram (ACBS) - NHS indicative price = £2.42

Orgran gluten free pasta rice & corn (Naturally Good Food Ltd)
- macaroni, spirals 250 gram (ACBS) - NHS indicative price = £2.42
- lasagne 200 gram (ACBS) - NHS indicative price = £3.13

Orgran gluten free pasta rice & millet spirals (Naturally Good Food Ltd)
- 250 gram (ACBS) - NHS indicative price = £2.42

Rizopia® Pasta
GLUTEN-FREE

Rizopia gluten free organic brown rice pasta (PGR Health Foods Ltd)
- lasagne 375 gram (ACBS) - NHS indicative price = £2.72
- fusilli, penne, spaghetti 500 gram (ACBS) - NHS indicative price = £2.72

Pizza bases

Barkat®, Pizza crust
GLUTEN-FREE

Barkat gluten free (Gluten Free Foods Ltd)
- brown rice pizza crust, white rice pizza crust 150 gram (ACBS) - NHS indicative price = £5.00

Glutafin® Pizza base
GLUTEN-FREE

Glutafin gluten free pizza base (Dr Schar UK Ltd)
- 300 gram (ACBS) - NHS indicative price = £6.56

Juvela® Pizza base
GLUTEN-FREE

Juvela gluten free pizza base (Hero UK Ltd)
- 360 gram (ACBS) - NHS indicative price = £8.78

Proceli® Pizza base
GLUTEN-FREE

Proceli gluten free pizza base (Ambe Ltd)
- 250 gram (ACBS) - NHS indicative price = £3.90

Ultra® Pizza base
GLUTEN-FREE

Wellfoods® Pizza base
GLUTEN-FREE

Wellfoods gluten free pizza base (Wellfoods Ltd)
- 600 gram (ACBS) - NHS indicative price = £8.95
Gluten- and wheat-free foods

ACBS indications: established gluten-sensitive enteropathies with coexisting established wheat sensitivity only.

Ener-G® (General Dietary Ltd)
Gluten-free, wheat-free. Rolls, Seattle brown, round (hamburger) 4 x 80 gram (ACBS) - NHS indicative price = £4.08
long (hot dog) 4 x 80 gram (ACBS) - NHS indicative price = £4.08
Pizza base 3 x 124 gram (ACBS) - NHS indicative price = £4.74
Glutafin® (Dr Schar UK Ltd)
Gluten-free, wheat-free. Flour mix, bread, fibre 500 gram (ACBS) - NHS indicative price = £6.66
Crispbread 150 gram (ACBS) - NHS indicative price = £8.96
Bread and cake mix 500 gram (ACBS) - NHS indicative price = £8.96

Low-protein foods

ACBS indications: inherited metabolic disorders, renal or liver failure, requiring a low-protein diet

Bread

Ener-G® Rice bread
LOW PROTEIN
400 gram (ACBS) - NHS indicative price = £5.54

Juvela® Loaf and rolls
LOW PROTEIN
Juvela gluten free loaf sliced (Hero UK Ltd) 400 gram (ACBS) - NHS indicative price = £3.54
Juvela low protein loaf (Hero UK Ltd) 400 gram (ACBS) - NHS indicative price = £3.64
bread rolls 350 gram (ACBS) - NHS indicative price = £4.52

Loprofin® Bread
LOW-PROTEIN
Loprofin low protein part baked (Nutricia Ltd) loaf sliced 400 gram (ACBS) - NHS indicative price = £3.91
bread rolls 260 gram (ACBS) - NHS indicative price = £4.12

PK Foods® Loaf
LOW PROTEIN
PK Foods low protein white bread sliced (Gluten Free Foods Ltd) 550 gram (ACBS) - NHS indicative price = £4.75

Cake, biscuits, and snacks

Juvela® cookies
LOW-PROTEIN
Juvela low protein loaf (Hero UK Ltd) chocolate chip cookies 110 gram (ACBS) - NHS indicative price = £7.62
biscuits, organic, bread, fibre 500 gram (ACBS) - NHS indicative price = £7.62

Loprofin® Wafers
LOW-PROTEIN
Loprofin low protein (Nutricia Ltd) chocolate cream wafers, vanilla cream wafers 100 gram (ACBS) - NHS indicative price = £2.53

PK Foods® Biscuits
LOW-PROTEIN
PK Foods Aminex low protein (Gluten Free Foods Ltd) biscuits, rusks 200 gram (ACBS) - NHS indicative price = £5.04
cookies 150 gram (ACBS) - NHS indicative price = £5.04

PK Foods low protein (Gluten Free Foods Ltd) crispbread 75 gram (ACBS) - NHS indicative price = £2.42
chocolate chip cookies, cinnamon cookies, orange cookies 150 gram (ACBS) - NHS indicative price = £5.04

Promin® Cooked and flavoured pasta snax
LOW-PROTEIN

Promin low protein (Firstplay Dietary Foods Ltd)

Snax salt & vinegar 25g sachets, Snax ready salted 25g sachets, Snax cheese & onion 25g sachets 3 sachet

Taranis® Cake bars
LOW-PROTEIN

Taranis low protein (Firstplay Dietary Foods Ltd)

apricot cake, lemon cake, pear cake 240 gram (ACBS) - NHS indicative price = £6.08

Vita Bite®
Not recommended for any child under 1 year.

VitaBite bar (Vitaflo International Ltd)
175 gram (ACBS) - NHS indicative price = £8.52

Vitaflo Choices® Mini crackers
LOW-PROTEIN

Vitaflo Choices mini crackers (Vitaflo International Ltd) 40 gram (ACBS) - NHS indicative price = £0.84

Cereals

Loprofin® Breakfast cereal
LOW-PROTEIN
375 gram (ACBS) - NHS indicative price = £8.12

Loprofin low protein breakfast cereal flakes (Nutricia Ltd) apple, chocolate, strawberry 375 gram (ACBS) - NHS indicative price = £7.85

Promin® Hot breakfast
LOW-PROTEIN

Promin low protein hot breakfast powder sachets (Firstplay Dietary Foods Ltd) apple & cinnamon, banana, chocolate 342 gram (ACBS) - NHS indicative price = £8.09

Original 336 gram (ACBS) - NHS indicative price = £8.09

Desserts

Loprofin® Powder
LOW-PROTEIN

Loprofin low protein dessert (Nutricia Ltd) mix chocolate, mix strawberry, mix vanilla 150 gram (ACBS) - NHS indicative price = £4.79

PK Foods® Jelly
LOW-PROTEIN

PK Foods low protein jelly mix dessert (Gluten Free Foods Ltd) cherry, orange 320 gram (ACBS) - NHS indicative price = £8.03

Promin® Desserts
LOW-PROTEIN

Promin low protein imitation rice pudding (Firstplay Dietary Foods Ltd) apple, banana, original, strawberry 276 gram (ACBS) - NHS indicative price = £6.33

Flour mixes and egg substitutes

Ener-G® Egg replacer
LOW-PROTEIN

Ener-G low protein egg replacer (General Dietary Ltd) 454 gram (ACBS) - NHS indicative price = £5.11

Fate® Flour mix
LOW PROTEIN

Fate low protein (Fate Special Foods) all purpose mix, chocolate cake mix, plain cake mix 500 gram (ACBS) - NHS indicative price = £6.97

Juvela® Mix
LOW-PROTEIN
Juvela low protein mix (Hero UK Ltd) 500 gram (ACBS) - NHS indicative price = £7.79
Loprofin® Flour mixes and egg substitutes LOW-PROTEIN
mix (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £8.27
Loprofin low protein cake (Nutricia Ltd) mix lemon, mix chocolate 500 gram (ACBS) - NHS indicative price = £8.76
Loprofin low protein egg (Nutricia Ltd) white replacement 100 gram (ACBS) - NHS indicative price = £9.79
replacer 500 gram (ACBS) - NHS indicative price = £15.22
PK Foods® Flour mix and egg substitute LOW-PROTEIN
PK Foods low protein (Gluten Free Foods Ltd) egg replacer 200 gram (ACBS) - NHS indicative price = £4.08
Flour mix 750 gram (ACBS) - NHS indicative price = £10.71
Pasta
Loprofin® Pasta LOW-PROTEIN
rice (Nutricia Ltd) 500 gram
Loprofin low protein pasta (Nutricia Ltd) penne, long cut spaghetti 500 gram (ACBS) - NHS indicative price = £8.66
animal shapes 500 gram (ACBS) - NHS indicative price = £8.33
tagliatelle, macaroni elbows 250 gram (ACBS) - NHS indicative price = £4.16
lasagne 250 gram (ACBS) - NHS indicative price = £4.21
Promin® Pasta LOW-PROTEIN
Promin Plus low protein pasta (Firstplay Dietary Foods Ltd) macaroni, flat noodles 500 gram (ACBS) - NHS indicative price = £6.99
Promin low protein imitation rice (Firstplay Dietary Foods Ltd) 500 gram (ACBS) - NHS indicative price = £6.99
Promin low protein lasagne sheets (Firstplay Dietary Foods Ltd) 200 gram (ACBS) - NHS indicative price = £3.03
Promin low protein pasta (Firstplay Dietary Foods Ltd) alphabets, shells, short cut spaghetti, spirals 500 gram (ACBS) - NHS indicative price = £6.99
Promin low protein tricolour pasta (Firstplay Dietary Foods Ltd) spirals, alphabets, shells 500 gram (ACBS) - NHS indicative price = £6.99
Promin Plus low protein pasta spirals (Firstplay Dietary Foods Ltd) 500 gram (ACBS) - NHS indicative price = £6.99
Promin low protein X-Pot (Firstplay Dietary Foods Ltd) all day scramble, beef & tomato, chip shop curry, rogan style curry 240 gram (ACBS) - NHS indicative price = £20.94
Promin low protein burger mix (Firstplay Dietary Foods Ltd) 124 gram (ACBS) - NHS indicative price = £6.36
Promin low protein cous cous (Firstplay Dietary Foods Ltd) 500 gram (ACBS) - NHS indicative price = £6.99
Promin low protein lamb and mint burger mix (Firstplay Dietary Foods Ltd) 124 gram (ACBS) - NHS indicative price = £6.56
Promin low protein pasta in (Firstplay Dietary Foods Ltd) cheese and broccoli sauce 264 gram (ACBS) - NHS indicative price = £8.31
tomato, pepper and herb sauce 288 gram (ACBS) - NHS indicative price = £8.31
Promin low protein pasta spirals in Moroccan sauce (Firstplay Dietary Foods Ltd) 288 gram (ACBS) - NHS indicative price = £8.31
Promin low protein potato pot (Firstplay Dietary Foods Ltd) onion, cabbage & bacon, sausage 200 gram (ACBS) - NHS indicative price = £16.40
Promin low protein sausage (Firstplay Dietary Foods Ltd) mix apple and sage, mix original, mix tomato and basil 120 gram (ACBS) - NHS indicative price = £7.15
Spreads
Taranis® Spread LOW-PROTEIN
Taranis low protein hazelnut spread (Firstplay Dietary Foods Ltd) 250 gram (ACBS) - NHS indicative price = £7.87

Nutritional supplements for metabolic diseases
Glutaric aciduria (type 1)

GAI Anamix® Infant
- Nutritional supplement for the dietary management of proven glutaric aciduria (type 1) in children from birth to 3 years.
- POWDER, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

GA Gel®
- Nutritional supplement for dietary management of type 1 glutaric aciduria in children 6 months–10 years.
- GEL, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 10 g, carbohydrate 10.3 g, fat trace, energy 339 kJ (81 kcal)/24 g, with vitamins, minerals, and trace elements.

GA gel oral powder 24g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £210.12

XLYS, Low TRY, Maxamaid®
- Nutritional supplement for the dietary management of type 1 glutaric aciduria.
- POWDER, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements.

XLYS LOW TRY Maxamaid powder (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £96.40

XLYS, TRY Glutaridon®
- Nutritional supplement for the dietary management of type 1 glutaric aciduria in children and adults; requires additional source of vitamins, minerals, and trace elements.
- POWDER, protein equivalent (essential and non-essential amino acids except lysine and tryptophan) 79 g, carbohydrate 4 g, energy 1411 kJ (352 kcal)/100 g.

XLYS TRY Glutaridon powder (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £182.61
Nutritional supplements for metabolic diseases

Glycogen storage disease

Corn flour and corn starch
For glycogen storage disease

Glycosade®
- A nutritional supplement for use in the dietary management of glycogen storage disease and other metabolic conditions where a constant supply of glucose is essential. Not suitable for use in children under 2 years.
POWDER, protein 200mg, carbohydrate (maize starch) 47.6g, fat 100mg, fibre less than 600mg, energy 805kJ (192 kcal)/60g.
Glycosade oral powder 60g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £110.44

Homocystinuria or hypermethioninaemia

HCU Anamix Infant
- Nutritional supplement for the dietary management of proven vitamin B6 non-responsive homocystinuria or hypermethioninaemia in children from birth to 3 years.
POWDER, protein equivalent (essential and non-essential amino acids except methionine) 15.1g, carbohydrate 49.5g, fat 23g, fibre 5.3g, energy 1915kJ (457 kcal)/100g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2g, carbohydrate 7.4g, fat 3.5g, fibre 0.8mg, energy 287kJ (69 kcal)/100mL.
HCU express 20 Oral powder 34g sachets (Nutricia Ltd) 416kJ (99 kcal)/34g with vitamins, minerals, and trace elements.
HCU Lophlex 20 Oral powder 27.8g sachets (Nutricia Ltd) 416kJ (99 kcal)/27.8g sachet, with vitamins, minerals, and trace elements.

HCU LV®
- Nutritional supplement for the dietary management of hypermethioninaemia or vitamin B6 non-responsive homocystinuria in children over 8 years.
POWDER, protein (essential and non-essential amino acids except methionine) 20g, carbohydrate 2.5g, fat 190mg, energy 390kJ (92 kcal)/27.8g sachet, with vitamins, minerals, and trace elements.

HCU-LV Anamix Infant powder 800mg, energy 287kJ (69 kcal)/100mL.

HCU Lophlex®
- Nutritional supplement for the dietary management of hypermethioninaemia or homocystinuria in children over 8 years.
POWDER, protein equivalent (essential and non-essential amino acids except methionine) 77g, carbohydrate 4.5g, fat 51g, energy 1536kJ (362 kcal)/100g.

HCU LV®
- Nutritional supplement for the dietary management of hypermethioninaemia or homocystinuria in children and adults.
POWDER, protein equivalent (essential and non-essential amino acids except methionine) 77g, carbohydrate 4.5g, fat 51g, energy 1536kJ (362 kcal)/100g.

HCU LV Anamix Infant powder 800mg, energy 287kJ (69 kcal)/100mL.

HCU LV Anamix Infant powder 800mg, energy 287kJ (69 kcal)/100mL.

Hyperlysinaemia

HYPER LYS Anamix Infant
- Nutritional supplement for the dietary management of proven hyperlysinaemia in children from birth to 3 years.
POWDER, protein equivalent (essential and non-essential amino acids except lysine) 15.1g, carbohydrate 49.5g, fat 23g, fibre 5.3g, energy 1915kJ (457 kcal)/100g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2g, carbohydrate 7.4g, fat 3.5g, fibre 0.8mg, energy 287kJ (69 kcal)/100mL.

HYPER LYS Anamix Infant powder 800mg, energy 287kJ (69 kcal)/100mL.

HYPER LYS Anamix Infant powder 800mg, energy 287kJ (69 kcal)/100mL.

HYPER LYS Anamix Infant powder 800mg, energy 287kJ (69 kcal)/100mL.
Isovaleric acidaemia
IVA Anamix® Infant
- Nutritional supplement for the dietary management of proven isovaleric acidaemia or other proven disorders of leucine metabolism in children from birth to 3 years.
POWDER, protein equivalent (essential and non-essential amino acids except leucine) 15.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.5 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.
IVA Anamix Infant powder (Nutricia Ltd)
400 gram (ACBS) - NHS indicative price = £38.18

XLEU Faladon®
- Nutritional supplement for the dietary management of isovaleric acidaemia.
POWDER, protein equivalent (essential and non-essential amino acids except leucine) 77 g, carbohydrate 4.5 g, fat nil, energy 1586 kJ (326 kcal)/100 g.

XLEU Maxamaid®
- Nutritional supplement for the dietary management of isovaleric acidaemia.
POWDER, protein equivalent (essential and non-essential amino acids except leucine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1531 kJ (309 kcal)/100 g with vitamins, minerals, and trace elements.

XLEU Maxamaid powder (Nutricia Ltd)
500 gram (ACBS) - NHS indicative price = £96.40

Maple syrup urine disease
MSUD Aid III®
- Nutritional supplement for the dietary management of maple syrup urine disease and related conditions in children and adults where it is necessary to limit the intake of branched chain amino acids.
POWDER, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 77 g, carbohydrate 4.5 g, fat nil, energy 1586 kJ (326 kcal)/100 g.

MSUD Aid III powder (Nutricia Ltd)
500 gram (ACBS) - NHS indicative price = £182.61

MSUD Anamix® Infant
- Nutritional supplement for the dietary management of proven maple syrup urine disease in children from birth to 3 years.
POWDER, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 15.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.5 g, energy 1915 [kJ (457 kcal)/100 g with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.
MSUD Anamix Infant powder (Nutricia Ltd)
400 gram (ACBS) - NHS indicative price = £58.18

MSUD Anamix® Junior
- Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
POWDER, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 8.4 g, carbohydrate 11 g, fat 3.9 g, energy 474 kJ (113 kcal)/29 g sachet, with vitamins, minerals, and trace elements.
MSUD Anamix Junior oral powder 29g sachets (Nutricia Ltd)
50 sachet (ACBS) - NHS indicative price = £204.00

MSUD Anamix® Junior LQ
- Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
LIQUID, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free.
MSUD Anamix Junior LQ liquid (Nutricia Ltd)
125 ml (ACBS) - NHS indicative price = £8.85
Nutritional supplements for metabolic diseases

Methylmalonic or propionic acidaemia

MMA/PA Anamix® Infant
- Nutritional supplement for the dietary management of proven methylmalonic acidaemia or propionic acidaemia in children from birth to 3 years.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 15.1 g, carbohydrate 49.5 g, fat 25 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.
- MMA PA Anamix Infant powder (Nutricia Ltd) 400 gram (ACBS) - NHS indicative price = £38.18

XMTVI Asadon®
- Nutritional supplement for the dietary management of methylmalonic acidaemia or propionic acidaemia in children and adults.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 77 g, carbohydrate 4.5 g, fat nil, energy 1586 kJ (352 kcal)/100 g.
- XMTVI Asadon powder (Nutricia Ltd) 200 gram (ACBS) - NHS indicative price = £73.04

XMTVI Maxamaid®
- Nutritional supplement for the dietary management of methylmalonic acidaemia or propionic acidaemia.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1511 kJ (359 kcal)/100 g, with vitamins, minerals, and trace elements.
- XMTVI Maxamaid powder (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £96.40

XMTVI Maxamum®
- Nutritional supplement for the dietary management of methylmalonic acidaemia or propionic acidaemia.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 39 g, carbohydrate 34 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements.
- XMTVI Maxamum powder (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £154.52

Other inborn errors of metabolism

Isoleucine50®
- Nutritional supplement for use in the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
- POWDER, isoleucine 50 mg, carbohydrate 3.8 g, fat nil, energy 63 kJ (15 kcal)/4 g

Isoleucine50 oral powder 4g sachets (Vitaflor International Ltd) 30 sachet (ACBS) - NHS indicative price = £53.38

KeyOmega®
- Nutritional supplement for the dietary management of inborn errors of metabolism.
- POWDER, protein (cows’ milk, soya) 170 mg, carbohydrate 2.8 g, fat 800 mg (of which arachidonic acid 200 mg), docosahexaenoic acid 100 mg), energy 80 kJ (19 kcal)/4 g

KeyOmega oral powder 4g sachets (Vitaflor International Ltd) 30 sachet (ACBS) - NHS indicative price = £39.50

Leucine100®
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
- POWDER, leucine 100 mg, carbohydrate 3.7 g, fat nil, energy 63 kJ (15 kcal)/4 g

Leucine100 oral powder sachets (Vitaflor International Ltd) 30 sachet (ACBS) - NHS indicative price = £53.38

Low protein drink
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children over 1 year.
- POWDER, protein (cows’ milk) 4.5 g (phenylalanine 100 mg), carbohydrate 59.5 g, fat 29.9 g, fibre nil, energy 2194 kJ (528 kcal)/100 g, with vitamins, minerals, and trace elements. Contains lactose.

Milkup LP drink (Nutricia Ltd) 400 gram (ACBS) - NHS indicative price = £9.06

Phenylalanine50®
- Nutritional supplement for use in the dietary management of inborn errors of metabolism in adults and children from birth.
- POWDER, phenylalanine 50 mg, carbohydrate 5.8 g, fat nil, energy 65 kJ (15 kcal)/4 g

Phenylalanine50 oral powder sachets (Vitaflor International Ltd) 30 sachet (ACBS) - NHS indicative price = £51.83

ProZero®
- A protein-free nutritional supplement for the dietary management of inborn errors of metabolism in children over 6 months and adults.
- LIQUID, carbohydrate 8.1 g (of which sugars 3.5 g), fat 3.8 g, energy 278 kJ (66 kcal)/100 mL. Contains lactose.
- ProZero liquid (Vitaflor International Ltd) 250 ml (ACBS) - NHS indicative price = £1.42 | 1000 ml (ACBS) - NHS indicative price = £5.68

Tyrosine100®
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
- POWDER, tyrosine 1 g, carbohydrate 2.9 g, fat nil, energy 65 kJ (15 kcal)/4 g sachet.

Tyrosine100 oral powder 4g sachets (Vitaflor International Ltd) 30 sachet (ACBS) - NHS indicative price = £4.89

Valine50®
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
- POWDER, valine 50 mg, carbohydrate 5.8 g, fat nil, energy 65 kJ (15 kcal)/4 g

Valine50 oral powder 4g sachets (Vitaflor International Ltd) 30 sachet (ACBS) - NHS indicative price = £53.38
Phenylketonuria

Add-ins®
> Nutritional supplement for the dietary management of proven phenylketonuria. Not suitable for children under 4 years.

**Powder,** protein equivalent (containing essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate nil, fat 5.1 g, energy 359 kJ (86 kcal)/18.2 g sachet, with vitamins, minerals, and trace elements.

**Add Ins oral powder 18.2g sachets (Nutricia Ltd)**
60 sachet (ACBS) - NHS Indicative price = £568.40

**Easiphën®**
> Nutritional supplement for the dietary management of proven phenylketonuria. Not suitable for children under 8 years.

**Liquid,** protein equivalent (containing essential and non-essential amino acids except phenylalanine) 6.7 g, carbohydrate 5.1 g, fat 2 g, energy 275 kJ (65 kcal)/100 mL with vitamins, minerals, and trace elements.

**Easiphën liquid (Nutricia Ltd)**
250 ml (ACBS) - NHS Indicative price = £9.47

**Lophlex**
> Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years and adults including pregnant women.

**Powder,** protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 2.5 g, fat 60 mg, fibre 220 mg, energy 585 kJ (137 kcal)/27.8 g sachet, with vitamins, minerals, and trace elements.

**Lophlex powder 27.8g sachets (Nutricia Ltd)**
berry, orange, unflavoured 30 sachet (ACBS) - NHS Indicative price = £284.40

**Loprofin PKU Drink**
> Nutritional supplement for the dietary management of phenylketonuria in children over 1 year and adults.

**Liquid,** protein (cows’ milk) 400 mg (phenylalanine 10 mg), lactose 9.4 g, fat 2 g, energy 165 kJ (40 kcal)/100 mL.

**Loprofin PKU drink (Nutricia Ltd)**
200 ml (ACBS) - NHS Indicative price = £0.74

**Loprofin® Sno-Pro**
> Nutritional supplement for the dietary management of phenylketonuria, chronic renal failure and other inborn errors of amino acid metabolism.

**Liquid,** protein (cows’ milk) 220 mg (phenylalanine 12.5 mg), carbohydrate 8 g, fat 5.8 g, energy 273 kJ (65 kcal)/100 mL.

**Loprofin PKU drink (Nutricia Ltd)**
200 ml (ACBS) - NHS Indicative price = £1.25

**Milupa PKU 2-prima®**
> Nutritional supplement for the dietary management of phenylketonuria in children 1-8 years.

**Powder,** protein equivalent (essential and non-essential amino acids except phenylalanine) 60 g, carbohydrate 10 g, fat nil, energy 1190 kJ (280 kcal)/100 g, with vitamins, minerals, and trace elements.

**Milupa PKU 2 Prima powder (Nutricia Ltd)**
500 gram (ACBS) - NHS Indicative price = £153.73

**Milupa PKU 2-secunda®**
> Nutritional supplement for the dietary management of phenylketonuria in children 9-15 years.

**Powder,** protein equivalent (essential and non-essential amino acids except phenylalanine) 70 g, carbohydrate 6.8 g, fat nil, energy 1306 kJ (307 kcal)/100 g, with vitamins, minerals, and trace elements.

**Milupa PKU 2 Secunda powder (Nutricia Ltd)**
500 gram (ACBS) - NHS Indicative price = £179.34

**Milupa PKU 3-advanta®**
> Nutritional supplement for the dietary management of phenylketonuria in children over 15 years.

**Powder,** protein equivalent (essential and non-essential amino acids except phenylalanine) 70 g, carbohydrate 4.7 g, fat nil, energy 1270 kJ (299 kcal)/100 g, with vitamins, minerals, and trace elements.

**Milupa PKU 3 Advanta powder (Nutricia Ltd)**
500 gram (ACBS) - NHS Indicative price = £179.34

**Phlexy-10® Exchange System**
> Nutritional supplement for the dietary management of phenylketonuria.

**Capsules,** protein equivalent (essential and non-essential amino acids except phenylalanine) 416.5 mg/capsule.

**Phlexy-10 500mg capsules (Nutricia Ltd)**
200 capsule (ACBS) - NHS Indicative price = £42.00

**DrinK mix,** powder, protein equivalent (essential and non-essential amino acids except phenylalanine) 8.35 g, carbohydrate 8.8 g/20-g sachet.

**Phlexy-10 drink (Nutricia Ltd)**
mix apple & blackcurrant, mix citrus burst, mix tropical surprise 600 gram (ACBS) - NHS Indicative price = £126.00

**TABLETS,** protein equivalent (essential and non-essential amino acids except phenylalanine) 835 mg tablet.

**tablets (Nutricia Ltd)**
75 tablet (ACBS) - NHS Indicative price = £27.00

**Phlexy-Vits®**
> For use as a vitamin and mineral component of restricted therapeutic diets in children over 11 years and adults with phenylketonuria and similar amino acid abnormalities.

**Powder,** vitamins, minerals, and trace elements.

**Phlexy-Vits (Nutricia Ltd)**
powder 210 gram (ACBS) - NHS Indicative price = £70.20

**Phlexy-Vits (Nutricia Ltd)**
tables 180 tablet (ACBS) - NHS Indicative price = £79.20

**PK Aid®**
> Nutritional supplement for the dietary management of phenylketonuria in children and adults.

**Powder,** protein equivalent (essential and non-essential amino acids except phenylalanine) 79 g, carbohydrate 4.5 g, fat nil, energy 1420 kJ (334 kcal)/100 g.

**PK Aid® powder (Nutricia Ltd)**
500 gram (ACBS) - NHS Indicative price = £140.37

**PKU Anamix® Infant**
> Nutritional supplement for the dietary management of proven phenylketonuria in children from birth to 3 years.

**Powder,** protein equivalent (essential and non-essential amino acids except phenylalanine) 15.1 g, carbohydrate 49.5 g, fat 25 g, fibre 5.5 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

**PKU Anamix Infant powder (Nutricia Ltd)**
400 gram (ACBS) - NHS Indicative price = £34.70

**PKU Anamix® Junior**
> Nutritional supplement for the dietary management of phenylketonuria in children 1–10 years.

**Powder,** protein equivalent (essential and non-essential amino acids except phenylalanine) 8.4 g, carbohydrate 9.9 g, fat 3.9 g, energy 455 kJ (108 kcal)/29-g sachet, with vitamins, minerals, and trace elements.

**PKU Anamix Junior powder (Nutricia Ltd)**
chocolate, neutral 870 gram (ACBS) - NHS Indicative price = £123.90

1080 gram (ACBS) - NHS Indicative price = £123.90

**PKU Anamix® Junior LQ**
> Nutritional supplement for the dietary supplement of phenylketonuria in children 1–10 years.

**Liquid,** protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free.

**PKU Anamix Junior LQ lipid (Nutricia Ltd)**
berry, orange 125 ml (ACBS) - NHS Indicative price = £5.51
### Nutritional supplements for metabolic diseases

**PKU cooler10®**
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years. **LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 5.1 g, energy 258 kJ (62 kcal)/87-mL pouch, with vitamins, minerals, and trace elements.
- **PKU** (Vitaflo International Ltd) orange cooler 10 liquid, purple cooler 10 liquid, red cooler 10 liquid, white cooler 10 liquid 87 ml (ACBS) - NHS indicative price = £4.51

**PKU cooler15®**
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years. **LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 15 g, carbohydrate 7.8 g, energy 386 kJ (92 kcal)/150-mL pouch, with vitamins, minerals, and trace elements.
- **PKU** (Vitaflo International Ltd) orange cooler 15 liquid, purple cooler 15 liquid, red cooler 15 liquid, white cooler 15 liquid 150 ml (ACBS) - NHS indicative price = £6.72

**PKU cooler20®**
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years. **LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 10.2 g, energy 517 kJ (124 kcal)/174-mL pouch, with vitamins, minerals, and trace elements.
- **PKU** (Vitaflo International Ltd) orange cooler 20 liquid, purple cooler 20 liquid, red cooler 20 liquid, white cooler 20 liquid 174 ml (ACBS) - NHS indicative price = £9.02

**PKU express15®**
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years. **POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 15 g, carbohydrate 2.4 g, energy 293 kJ (70 kcal)/25 g, with vitamins, minerals, and trace elements.
- **PKU express 15 powder** (Vitaflo International Ltd) lemon, orange, tropical, unflavoured 750 gram (ACBS) - NHS indicative price = £197.82

**PKU express20®**
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years. **POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 3.5 g, energy 389 kJ (95 kcal)/34 g, with vitamins, minerals, and trace elements.
- **PKU express 20 powder** (Vitaflo International Ltd) lemon, orange, tropical, unflavoured 1020 gram (ACBS) - NHS indicative price = £255.58

**PKU gel®**
- **POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 8.9 g, fat less than 100 mg, energy 518 kJ (76 kcal)/24 g, with vitamins, minerals, and trace elements.
- **PKU gel powder** (Vitaflo International Ltd) orange, raspberry, unflavoured 720 gram (ACBS) - NHS indicative price = £136.86

**PKU Lophlex® LQ 10**
- Nutritional supplement for the dietary management of phenylketonuria in children over 4 years and adults including pregnant women. **LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 4.4 g, fibre 250 mg, energy 245 kJ (58 kcal)/62.5 mL, with vitamins, minerals, and trace elements.
- **PKU Lophlex LQ 10 liquid juicy** (Nutricia Ltd) berries, orange 62.5 ml (ACBS) - NHS indicative price = £5.08

**PKU Lophlex® LQ 20**
- Nutritional supplement for the dietary management of phenylketonuria in children over 4 years and adults including pregnant women. **LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 8.8 g, fibre 340 mg, energy 490 kJ (115 kcal)/125 mL, with vitamins, minerals, and trace elements.
- **PKU Lophlex LQ 20 liquid** (Nutricia Ltd) berry, juicy berries, orange 125 ml (ACBS) - NHS indicative price = £10.14

**PKU Lophlex® sensation 20**
- Nutritional supplement for the dietary management of phenylketonuria in children under 3 years. **LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 22.5 g, fat 500 mg, energy 565 kJ (135 kcal)/85 g, with vitamins, minerals, and trace elements.
- **PKU Lophlex Sensation 20** (Nutricia Ltd) berry, orange, lemon, unflavoured 2550 gram (ACBS) - NHS indicative price = £150.84

**L-Tyrosine**
- **POWDER**, L-tyrosine 20 g, carbohydrate 76.8 g, fat nil, energy 1612 kJ (379 kcal)/100 g.

**L-Tyrosine powder** (Nutricia Ltd)
- XP Maxamaid powder 50g sachets 100 gram (ACBS) - NHS indicative price = £21.50

**XP Maxamaid®**
- Nutritional supplement for the dietary management of phenylketonuria in children aged 1–8 years. **POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1511 kJ (369 kcal)/100 g, with vitamins, minerals, and trace elements.
- **XP Maxamaid powder** (Nutricia Ltd) orange, unflavoured 500 gram (ACBS) - NHS indicative price = £57.03

**XP Maxum®**
- Nutritional supplement for the dietary management of phenylketonuria in children under 8 years and adults. **POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 39 g, carbohydrate 54 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements.
- **XP Maxum oral powder 50g sachets** (Nutricia Ltd) orange, unflavoured 30 sachet (ACBS) - NHS indicative price = £264.45

**Tyrrosinaemia**

**Methionine-free TYR Anamix® Infant**
- Nutritional supplement for the dietary management of proven tyrrosinaemia type 1 in children from birth to 3 years.
POWDER, protein equivalent (essential and non-essential amino acids except methionine, phenylalanine, and tyrosine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

TYR Anamix Infant methionine free powder (Nutricia Ltd) 400 gram (ACBS) - NHS indicative price = £38.18

TYR Anamix® Infant
- Nutritional supplement for the dietary management of proven tyrosinaemia where plasma-methionine concentrations are normal in children from birth to 3 years.
- POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 15.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

TYR Anamix Infant (Nutricia Ltd) methionine free powder, powder 400 gram (ACBS) - NHS indicative price = £38.18

TYR Anamix® Junior
- Nutritional supplement for the dietary management of proven tyrosinaemia in children 1–10 years.
- POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 8.4 g, carbohydrate 11 g, fat 5.9 g, energy 475 kJ (115 kcal)/29 g sachet, with vitamins, minerals, and trace elements.

TYR Anamix Junior oral powder 29g sachets (Nutricia Ltd) 30 sachet (ACBS) - NHS Indicative price = £202.50

TYR Anamix® Junior LQ
- Nutritional supplement for the dietary management of tyrosinaemia type I (when nitisinone (NTBC) is used, see type II, and type III, in children over 1 year).
- LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 10 g, carbohydrate 8.8 g, fat 4.6 g, fibre 510 mg, energy 500 kJ (121 kcal)/125 mL, with vitamins, minerals and trace elements.

TYR Anamix Junior LQ liquid (Nutricia Ltd) 125 ml (ACBS) - NHS Indicative price = £8.85

TYR cooler® 15
- Nutritional supplement for the dietary management of tyrosinaemia in children over 3 years and adults.
- LIQUID, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 15 g, carbohydrate 7 g, fat 500 mg, energy 395 kJ (92 kcal)/150 mL, with vitamins, minerals, and trace elements.

TYR orange cooler 15 liquid (Vitaflo International Ltd) 130 ml (ACBS) - NHS indicative price = £11.09

TYR red cooler (Vitaflo International Ltd) 15 liquid 130 ml (ACBS) - NHS indicative price = £11.09

TYR express®
- Nutritional supplement for the dietary management of tyrosinaemia in children over 8 years and adults.
- POWDER, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 15 g, carbohydrate 3.4 g, fat less than 100 mg, energy 310 kJ (74 kcal)/25 g, with vitamins, minerals, and trace elements.

TYR express 15 oral powder 25g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £326.30

TYR express®20
- Nutritional supplement for the dietary management of tyrosinaemia. Not recommended for children under 8 years.
- POWDER, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 20 g, carbohydrate 4.7 g, fat less than 100 mg, energy 416 kJ (99 kcal)/54 g, with vitamins, minerals, and trace elements.

TYR express 20 oral powder 34g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £421.57

TYR Gel®
- Nutritional supplement for the dietary management of tyrosinaemia in children 1–10 years.
- POWDER, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 10 g, carbohydrate 10.5 g, fat less than 100 mg, energy 359 kJ (81 kcal)/24 g, with vitamins, minerals, and trace elements.

TYR gel oral powder 24g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £210.07

TYR Lophlex® LQ 20
- Nutritional supplement for the dietary management of tyrosinaemia in children over 3 years and adults.
- LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 20 g, carbohydrate 8.8 g, fat less than 500 mg, fibre 500 mg, energy 509 kJ (120 kcal)/125 mL, with vitamins, minerals, and trace elements.

TYR Lophlex LQ 20 liquid (Nutricia Ltd) 125 ml (ACBS) - NHS indicative price = £15.75

XPHEN TYR Maxamaid®
- Nutritional supplement for the dietary management of tyrosinaemia in children 1–8 years.
- POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1511 kJ (362 kcal)/100 g, with vitamins, minerals, and trace elements.

XPHEN TYR Tyrosidon Free AA Mix powder (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £96.40

XPHEN TYR Tyrosidon®
- Nutritional supplement for the management of tyrosinaemia in children and adults where plasma-methionine concentrations are normal.
- POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (330 kcal)/100 g.

XPHEN TYR Tyrosidon Free AA Mix powder (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £182.61

XPTM Tyrosidon®
- Nutritional supplement for the dietary management of tyrosinaemia type I in children and adults where plasma-methionine concentrations are above normal.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine, phenylalanine, and tyrosine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g.

XPTM Tyrosidon powder (Nutricia Ltd) 500 gram (ACBS) - NHS indicative price = £91.31
Appendix 3

Cautionary and advisory labels for dispensed medicines

Guidance for cautionary and advisory labels

Medicinal forms within BNF publications include code numbers of the cautionary labels that pharmacists are recommended to add when dispensing. It is also expected that pharmacists will counsel patients and carers when necessary.

Counselling needs to be related to the age, experience, background, and understanding of the individual patient or carer. The pharmacist should ensure understanding of how to take or use the medicine and how to follow the correct dosage schedule. Any effects of the medicine on co-ordination, performance of skilled tasks (e.g. driving or work), any foods or medicines to be avoided, and what to do if a dose is missed should also be explained. Other matters, such as the possibility of staining of the clothes or skin, or discolouration of urine or stools by a medicine should also be mentioned.

For some medicines there is a special need for counselling, such as an unusual method or time of administration or a potential interaction with a common food or domestic remedy, and this should be mentioned where necessary.

Original packs

Most preparations are dispensed in unbroken original packs that include further advice for the patient in the form of patient information leaflets. Label 10 may be of value where appropriate. More general leaflets advising on the administration of preparations such as eye drops, eye ointments, inhalers, and suppositories are also available.

Scope of labels

In general no label recommendations have been made for injections on the assumption that they will be administered by a healthcare professional or a well-instructed patient. The labelling is not exhaustive and pharmacists are recommended to use their professional discretion in labelling new preparations and those for which no labels are shown.

Individual labelling advice is not given on the administration of the large variety of antacids. In the absence of instructions from the prescriber, and if on enquiry the patient has had no sense of the original.

It is the usual practice for patients to take standard tablets with water or other liquid and for this reason no separate label has been recommended.

The label wordings recommended by the BNF apply to medicines dispensed against a prescription. Patients should be aware that a dispensed medicine should never be taken by, or shared with, anyone other than for whom the prescriber intended it. Therefore, the BNF does not include warnings against the use of a dispensed medicine by persons other than for whom it was specifically prescribed.

The label or labels for each preparation are recommended after careful consideration of the information available. However, it is recognised that in some cases this information may be either incomplete or open to a different interpretation. The BNF will therefore be grateful to receive any constructive comments on the labelling suggested for any preparation.

Recommended label wordings

For BNF 61 (March 2011), a revised set of cautionary and advisory labels were introduced. All of the existing labels were user-tested, and the revised wording selected reflects terminology that is better understood by patients.

Wordings which can be given as separate warnings are labels 1–19, 29–30, and 32. Wordings which can be incorporated in an appropriate position in the directions for dosage or administration are labels 21–28. A label has been omitted for number 20; labels 51 and 33 no longer apply to any medicines in the BNF and have therefore been deleted.

If separate labels are used it is recommended that the wordings be used without modification. If changes are made to suit computer requirements, care should be taken to retain the sense of the original.

Labels

1 Warning: This medicine may make you sleepy

To be used on preparations for children containing antihistamines, or other preparations given to children where the warnings of label 2 on driving or alcohol would not be appropriate.

2 Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines. Do not drink alcohol

To be used on preparations for adults that can cause drowsiness, thereby affecting coordination and the ability to drive and operate hazardous machinery; label 1 is more appropriate for children. It is an offence to drive while under the influence of drink or drugs.

Some of these preparations only cause drowsiness in the first few days of treatment and some only cause drowsiness in higher doses. In such cases the patient should be told that the advice applies until the effects have worn off. However many of these preparations can produce a slowing of reaction time and a loss of mental concentration that can have the same effects as drowsiness.

Avoidance of alcoholic drink is recommended because the effects of CNS depressants are enhanced by alcohol. Strict prohibition however could lead to some patients not taking the medicine. Pharmacists should therefore explain the risk and encourage compliance, particularly in patients who may think they already tolerate the effects of alcohol (see also label 3). Queries from patients with epilepsy regarding fitness to drive should be referred back to the patient’s doctor.
Side-effects unrelated to drowsiness that may affect a patient’s ability to drive or operate machinery safely include blurred vision, dizziness, or nausea. In general, no label has been recommended to cover these cases, but the patient should be suitably counselled.

3 Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines.
   To be used on preparations containing monoamine-oxidase inhibitors; the warning to avoid alcohol and dealkoholised (low alcohol) drink is covered by the patient information leaflet. Also to be used as for label 2 but where alcohol is not an issue.

4 Warning: Do not drink alcohol.
   To be used on preparations where a reaction such as flushing may occur if alcohol is taken (e.g. metronidazole). Alcohol may also enhance the hypoglycaemia produced by some oral antidiabetic drugs but routine application of a warning label is not considered necessary. Patients should be advised not to drink alcohol for as long as they are receiving/using a course of medication, and in some cases for a period of time after the course is finished.

5 Do not take indigestion remedies 2 hours before or after you take this medicine.
   To be used with label 25 on preparations coated to resist gastric acid (e.g. enteric-coated tablets). This is to avoid the possibility of premature dissolution of the coating in the presence of an alkaline pH. Label 5 also applies to drugs such as gabapentin where the absorption is significantly affected by antacids. Pharmacists will be aware (from a knowledge of physiology) that the usual time during which indigestion remedies should be avoided is at least 2 hours before and after the majority of medicines have been taken; when a manufacturer advises a different time period, this can be followed, and should be explained to the patient.

6 Do not take indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine.
   To be used on preparations containing ofloxacin and some other quinolones, doxycycline, lymecycline, minocycline, and penicillin. These drugs chelate calcium, iron, and zinc and are less well absorbed when taken with calcium-containing antacids or preparations containing iron or zinc. Pharmacists will be aware (from a knowledge of physiology) that these incompatible preparations should be taken at least 2 hours apart for the majority of medicines; when a manufacturer advises a different time period, this can be followed, and should be explained to the patient.

7 Do not take milk, indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine.
   To be used on preparations containing ciprofloxacin, norfloxacin, or tetracyclines that chelate calcium, iron, magnesium, and zinc, and are thus less available for absorption. Pharmacists will be aware (from a knowledge of physiology) that these incompatible preparations should be taken at least 2 hours apart for the majority of medicines; when a manufacturer advises a different time period, this can be followed, and should be explained to the patient.

8 Warning: Do not stop taking this medicine unless your doctor tells you to stop.
   To be used on preparations that contain a drug which is required to be taken over long periods without the patient necessarily perceiving any benefit (e.g. antituberculous drugs). Also to be used on preparations that contain a drug whose withdrawal is likely to be a particular hazard (e.g. clonidine for hypertension). Label 10 (see below) is more appropriate for corticosteroids.

9 Space the doses evenly throughout the day. Keep taking this medicine until the course is finished, unless you are told to stop.
   To be used on preparations where a course of treatment should be completed to reduce the incidence of relapse or failure of treatment.

10 Warning: Read the additional information given with this medicine.
   To be used particularly on preparations containing anticoagulants, lithium, and oral corticosteroids. The appropriate treatment label should be given to the patient and any necessary explanations given.

11 Protect your skin from sunlight—even on a bright but cloudy day. Do not use sunbeds.
   To be used on preparations that may cause phototoxic or photoallergic reactions if the patient is exposed to ultraviolet radiation. Many drugs other than those listed in Appendix 3 (e.g. phenothiazines and sulfonamides) may, on rare occasions, cause reactions in susceptible patients. Exposure to high intensity ultraviolet radiation from sunray lamps and sunbeds is particularly likely to cause reactions.

12 Do not take anything containing aspirin while taking this medicine.
   To be used on preparations containing sulfinpyrazone whose activity is reduced by aspirin.
   Label 12 should not be used for anticoagulants since label 10 is more appropriate.

13 Dissolve or mix with water before taking.
   To be used on preparations that are intended to be dissolved in water (e.g. soluble tablets) or mixed with water (e.g. powders, granules) before use. In a few cases other liquids such as fruit juice or milk may be used.

14 This medicine may colour your urine. This is harmless.
   To be used on preparations that may cause the patient’s urine to turn an unusual colour. These include triamterene (blue under some lights), levodopa (dark reddish), and rifampicin (red).

15 Caution: flammable. Keep your body away from fire or flames after you have put on the medicine.
   To be used on preparations containing sufficient flammable solvent to render them flammable if exposed to a naked flame.

16 Dissolve the tablet under your tongue—do not swallow.
   To be used particularly on preparations where a course of treatment is required to reduce the incidence of relapse or failure of treatment.

17 Do not take more than... in 24 hours.
   To be used on preparations for the treatment of acute migraine except those containing ergotamine, for which label 18 is used. The dose form should be specified, e.g. tablets or capsules. It may also be used on preparations for which no dose has been specified by the prescriber.

18 Do not take more than... in 24 hours. Also, do not take more than... in any one week.
   To be used on preparations containing ergotamine. The dose form should be specified, e.g. tablets or suppositories.

19 Warning: This medicine makes you sleepy. If you still feel sleepy the next day, do not drive or use tools or machines. Do not drink alcohol.
   To be used on preparations containing hypnotics (or some other drugs with sedative effects) prescribed to be taken at night. On the rare occasions when hypnotics are prescribed...
for daytime administration (e.g. nitrazepam in epilepsy),
this label would clearly not be appropriate. Also to be used
as an alternative to the label 2 wording (the choice being at
the discretion of the pharmacist) for anxiolytics prescribed to
be taken at night.
It is hoped that this wording will convey adequately the
problem of residual morning sedation after taking ‘sleeping
tablets’.

21 Take with or just after food, or a meal
   To be used on preparations that are liable to cause gastric
   irritation, or those that are better absorbed with food.
   Patients should be advised that a small amount of food is
   sufficient.

22 Take 30 to 60 minutes before food
   To be used on some preparations whose absorption is
   thereby improved.
   Most oral antibacterials require label 23 instead (see
   below).

23 Take this medicine when your stomach is empty. This
   means an hour before food or 2 hours after food
   To be used on oral antibacterials whose absorption may be
   reduced by the presence of food and acid in the stomach.

24 Suck or chew this medicine
   To be used on preparations that should be sucked or
   chewed. The pharmacist should use discretion as to which
   of these words is appropriate.

25 Swallow this medicine whole. Do not chew or crush
   To be used on preparations that are enteric-coated or
   designed for modified-release.
   Also to be used on preparations that taste very unpleasant or
   may damage the mouth if not swallowed whole.
   Patients should be advised (where relevant) that some
   modified-release preparations can be broken in half, but
   that the halved tablet should still be swallowed whole, and
   not chewed or crushed.

26 Dissolve this medicine under your tongue
   To be used on preparations designed for sublingual use.
   Patients should be advised to hold under the tongue and
   avoid swallowing until dissolved. The buccal mucosa
   between the gum and cheek is occasionally specified by the
   prescriber.

27 Take with a full glass of water
   To be used on preparations that should be well diluted (e.g.
   chloral hydrate), where a high fluid intake is required (e.g.
   sulfonamides), or where water is required to aid the action
   (e.g. methylcellulose). The patient should be advised that
   ‘a full glass’ means at least 150 mL. In most cases fruit
   juice, tea, or coffee may be used.

28 Spread thinly on the affected skin only
   To be used on external preparations that should be
   applied sparingly (e.g. corticosteroids, dithranol).

29 Do not take more than 2 at any one time. Do not take
   more than 8 in 24 hours
   To be used on containers of dispensed solid dose
   preparations containing paracetamol for adults when the
   instruction on the label indicates that the dose can be taken on
   an ‘as required’ basis. The dose form should be specified,
   e.g. tablets or capsules.
   This label has been introduced because of the serious
   consequences of overdosage with paracetamol.

30 Contains paracetamol. Do not take anything else
   containing paracetamol while taking this medicine. Talk
   to a doctor at once if you take too much of this medicine,
   even if you feel well.
   To be used on all containers of dispensed preparations
   containing paracetamol.

32 Contains aspirin. Do not take anything else containing
   aspirin while taking this medicine
   To be used on containers of dispensed preparations
   containing aspirin when the name on the label does not
   include the word ‘aspirin’.
Appendix 4

Wound management products and elasticated garments

The correct dressing for wound management depends not only on the type of wound but also on the stage of the healing process. The principal stages of healing are: cleansing, removal of debris; granulation, vascularisation; epithelialisation. The ideal dressing for moist wound healing needs to ensure that the wound remains: moist with exudate, but not macerated; free of clinical infection and excessive slough; free of toxic chemicals, particles or fibres; at the optimum temperature for healing; undisturbed by the need for frequent changes; at the optimum pH value. As wound healing passes through its different stages, different types of dressings may be required to satisfy better one or other of these requirements. Under normal circumstances, a moist environment is a necessary part of the wound healing process; exudate provides a moist environment and promotes healing, but excessive exudate can cause maceration of the wound and surrounding healthy tissue. The volume and viscosity of exudate changes as the wound heals. There are certain circumstances where moist wound healing is not appropriate (e.g. gangrenous toes associated with vascular disease). Advanced wound dressings, p. 1297 are designed to control the environment for wound healing, for example to donate fluid (hydrogels), maintain hydration (hydrocolloids), or to absorb wound exudate (alginites, foams). Practices such as the use of irritant cleansers and desloughing agents may be harmful and are largely obsolete; removal of debris and dressing remnants should need minimal irrigation with lukewarm sterile sodium chloride 0.9% solution or water. Hydrogel, hydrocolloid, and medical grade honey dressings can be used to deslough wounds by promoting autolytic debridement; there is insufficient evidence to support any particular method of debridement for difficult-to-heal surgical wounds. Sterile larvae (maggots) are also available for biosurgical removal of wound debris. There have been few clinical trials able to establish a clear advantage for any particular product. The choice between different dressings depends not only on the type and stage of the wound, but also on patient preference or tolerance, site of the wound, and cost. For further information, see Buyers’ Guide: Advanced wound dressings (October 2008); NHS Purchasing and Supply Agency, Centre for Evidence-based Purchasing. Prices quoted in Appendix 4 are basic NHS net prices; for further information see Prices in the BNF. The table below gives suggestions for choices of primary dressing depending on the type of wound (a secondary dressing may be needed in some cases).

### Basic wound contact dressings

Low adherence dressings

Low adherence dressings are used as interface layers under secondary absorbent dressings. Placed directly on the wound bed, non-absorbent, low adherence dressings are suitable for clean, granulating, lightly exuding wounds without necrosis, and protect the wound bed from direct contact with secondary dressings. Care must be taken to avoid granulation tissue growing into the weave of these dressings.

Tulle dressings are manufactured from cotton or viscose fibres which are impregnated with white or yellow soft paraffin to prevent the fibres from sticking, but this is only
### Wound contact material for different types of wounds

#### Wound PINK (epitheliasing)

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence p. 1294</td>
<td>Soft polymer p. 1300</td>
<td>Foam with extra absorbency p. 1302</td>
</tr>
<tr>
<td>Vapour-permeable film p. 1298</td>
<td>Foam, low absorbent p. 1302</td>
<td>Hydrocolloid-fibrous p. 1301</td>
</tr>
<tr>
<td>Soft polymer p. 1300</td>
<td>Alginate p. 1304</td>
<td>Alginate p. 1304</td>
</tr>
<tr>
<td>Hydrocolloid p. 1301</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Wound RED (granulating)

Symptoms or signs of infection, see Wounds with signs of infection

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence p. 1294</td>
<td>Hydrocolloid-fibrous p. 1301</td>
<td>Foam with extra absorbency p. 1302</td>
</tr>
<tr>
<td>Soft polymer p. 1300</td>
<td>Foam p. 1302</td>
<td>Hydrocolloid-fibrous p. 1301</td>
</tr>
<tr>
<td>Hydrocolloid p. 1301</td>
<td>Alginate p. 1304</td>
<td>Alginate p. 1304</td>
</tr>
<tr>
<td>Foam, low absorbent p. 1302</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Wound YELLOW (Sloughy) (granulating)

Symptoms or signs of infection, see Wounds with signs of infection

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogel p. 1297</td>
<td>Hydrocolloid-fibrous p. 1301</td>
<td>Hydrocolloid-fibrous p. 1301</td>
</tr>
<tr>
<td>Hydrocolloid p. 1301</td>
<td>Alginate p. 1304</td>
<td>Alginate p. 1304</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capillary-action p. 1305</td>
</tr>
</tbody>
</table>

#### Wound BLACK (Necrotic/Eschar)

Consider mechanical debridement alongside autolytic debridement

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogel p. 1297</td>
<td>Hydrocolloid p. 1301</td>
<td>Seek advice from wound care specialist</td>
</tr>
<tr>
<td>Hydrocolloid p. 1301</td>
<td>Hydrocolloid-fibrous p. 1301</td>
<td>Foam p. 1302</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Wounds with signs of infection

Consider systemic antibacterials if appropriate; also consider odour-absorbent dressings. For malodorous wounds with slough or necrotic tissue, consider mechanical or autolytic debridement.

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence with honey p. 1306</td>
<td>Hydrocolloid-fibrous with silver p. 1308</td>
<td>Hydrocolloid-fibrous with silver p. 1308</td>
</tr>
<tr>
<td>Low adherence with iodine p. 1306</td>
<td>Foam with silver p. 1308</td>
<td>Foam extra absorbent, with silver p. 1308</td>
</tr>
<tr>
<td>Low adherence with silver p. 1308</td>
<td>Alginate with silver p. 1307</td>
<td>Alginate with silver p. 1306</td>
</tr>
<tr>
<td>Honey-topical p. 1306</td>
<td>Honey-topical p. 1306</td>
<td>Cadexomer-iodine p. 1306</td>
</tr>
</tbody>
</table>

**Note:** In each section of this table, the dressings are listed in order of increasing absorbency. Some wound contact (primary) dressings require a secondary dressing.

Partly successful and it may be necessary to change the dressings frequently. The paraffin reduces absorbency of the dressing. Dressings with a reduced content (light loading) of soft paraffin are less liable to interfere with absorption; dressings with ‘normal loading’ (such as Jelonet®) have been used for skin graft transfer.

Knitted viscose primary dressing is an alternative to tulle dressings for exuding wounds; it can be used as the initial layer of multi-layer compression bandaging in the treatment of venous leg ulcers.

**Knitted polyester primary dressing**

**Atrauman**

Non-adherent knitted polyester primary dressing impregnated with neutral triglycerides

**Atrauman dressing** (Paul Hartmann Ltd) 10cm x 20cm = £0.63, 20cm x 30cm = £1.72, 5cm x 5cm = £0.27, 7.5cm x 10cm = £0.28

**Knitted viscose primary dressing**

**N-A Dressing**

Warp knitted fabric manufactured from a bright viscose monofilament.

N-A dressing (Systagenix Wound Management Ltd) 19cm x 9.5cm = £0.67, 9.5cm x 9.5cm = £0.35

**N-A Ultra**

Warp knitted fabric manufactured from a bright viscose monofilament.

N-A Ultra dressing (Systagenix Wound Management Ltd) 19cm x 9.5cm = £0.63, 9.5cm x 9.5cm = £0.33

**Profore**

Warp knitted fabric manufactured from a bright viscose monofilament.

Profore (Smith & Nephew Healthcare Ltd) wound contact layer 14cm x 20cm = £0.32

**Tricotex**

Warp knitted fabric manufactured from a bright viscose monofilament.

Tricotex dressing (Smith & Nephew Healthcare Ltd) 9.5cm x 9.5cm = £0.34

**Paraffin Gauze Dressing**

**Cuticell**

(Tulle Gras). Fabric of leno weave, wool and mohair of cotton and/or viscose yarn, impregnated with white or yellow paraffin

Cuticell (BSN medical Ltd) Classic dressing 10cm x 10cm = £0.29

**Jelonet**

(Tulle Gras). Fabric of leno weave, wool and mohair of cotton and/or viscose yarn, impregnated with white or yellow paraffin

Jelonet dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm = £0.41

**Neotulle**

(Tulle Gras). Fabric of leno weave, wool and mohair of cotton and/or viscose yarn, impregnated with white or yellow paraffin

Neotulle (Neomedic Ltd) dressing 10cm x 10cm = £0.29
Paragauze (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin.

Paragauze (C D Medical Ltd) dressing 10cm x 10cm = £0.28

Paramet (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin.

Paramet (Synergy Health Plc) dressing 10cm x 10cm = £0.25

Absorbent dressings
Perforated film absorbent dressings are suitable only for wounds with mild to moderate amounts of exudate; they are not appropriate for leg ulcers or for other lesions that produce large quantities of viscous exudate. Dressings with an absorbent cellulose or polymer wadding layer are suitable for use on moderately to heavily exuding wounds.

Absorbent cellulose dressing

CelluDress
Absorbent Cellulose Dressing with Fluid Repellent Backing

CelluDress dressing (Medicareplus international Ltd) 10cm x 10cm = £0.19, 10cm x 15cm = £0.20, 10cm x 20cm = £0.22, 15cm x 20cm = £0.30, 20cm x 25cm = £0.40, 20cm x 30cm = £0.45

Eclypse
Absorbent Cellulose Dressing with Fluid Repellent Backing

Eclypse (Advancis Medical) Root dressing 60cm x 70cm = £13.78, dressing 15cm x 15cm = £0.97, 20cm x 30cm = £2.14, 60cm x 40cm = £8.15,

Exu-Dry
Absorbent Cellulose Dressing with Fluid Repellent Backing

Exu-Dry dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm = £1.12, 15cm x 23cm = £2.29, 23cm x 38cm = £5.32

Mesorb
Cellulose wadding pad with gauze wound contact layer and non-woven repellent backing

Mesorb dressing (Mohlyche Health Care Ltd) 10cm x 10cm = £0.62, 10cm x 15cm = £0.81, 10cm x 20cm = £1.00, 15cm x 20cm = £1.42, 20cm x 25cm = £2.24, 20cm x 30cm = £2.54

Telfa Max
Absorbent Cellulose Dressing with Fluid Repellent Backing

Zetuvit E
Absorbent Cellulose Dressing with Fluid Repellent Backing; sterile or non-sterile

Zetuvit E (Paul Hartmann Ltd) non-sterile dressing 10cm x 10cm = £0.07, 10cm x 20cm = £0.09, 20cm x 20cm = £0.14, 20cm x 40cm = £0.27, sterile dressing 10cm x 10cm = £0.21, 10cm x 20cm = £0.25, 20cm x 20cm = £0.39, 20cm x 40cm = £1.10,

Absorbent perforated dressing

Adpro
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Adpro dressing (Medicareplus International Ltd) 10cm x 10cm = £0.10, 10cm x 15cm = £0.16, 10cm x 20cm = £0.30, 15cm x 25cm = £0.34, 10cm x 30cm = £0.42, 10cm x 35cm = £0.50, 7cm x 8cm = £0.08

Cosmopore E
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Cosmopore E dressing (Paul Hartmann Ltd) 10cm x 20cm = £0.45, 10cm x 25cm = £0.56, 10cm x 35cm = £0.78, 5cm x 7.2cm = £0.08, 8cm x 10cm = £0.17, 8cm x 15cm = £0.28

Cutiplast Steril
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Cutiplast Steril dressing (Smith & Nephew Healthcare Ltd) 10cm x 20cm = £0.31, 10cm x 25cm = £0.32, 10cm x 30cm = £0.42, 8cm x 10cm = £0.11, 8cm x 15cm = £0.24

Leukomed
Low-adenhence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Leukomed dressing (Bsn medical Ltd) 10cm x 20cm = £0.43, 10cm x 25cm = £0.48, 10cm x 30cm = £0.62, 10cm x 35cm = £0.72, 5cm x 7.2cm = £0.09, 8cm x 10cm = £0.18, 8cm x 15cm = £0.32

Medipore + Pad
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Medipore + Pads dressing (3M Health Care Ltd) 10cm x 10cm = £0.15, 10cm x 15cm = £0.25, 10cm x 20cm = £0.37, 10cm x 25cm = £0.46, 10cm x 35cm = £0.64, 5cm x 7.2cm = £0.07

Medisafe
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Medisafe dressing (Neomedic Ltd) 6cm x 8cm = £0.08, 8cm x 10cm = £0.13, 8cm x 12cm = £0.23, 9cm x 15cm = £0.29, 9cm x 25cm = £0.34, 9cm x 25cm = £0.36

Mepore
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Mepore dressing (Möllycke Health Care Ltd) 10cm x 11cm = £0.22, 11cm x 15cm = £0.36, 7cm x 8cm = £0.11, 8cm x 20cm = £0.44, 9cm x 25cm = £0.61, 9cm x 30cm = £0.70, 9cm x 35cm = £0.76

PremierPore
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

PremierPore dressing (Shermond) 10cm x 10cm = £0.12, 10cm x 15cm = £0.18, 10cm x 20cm = £0.32, 10cm x 25cm = £0.36, 10cm x 30cm = £0.45, 10cm x 35cm = £0.52, 5cm x 7cm = £0.05

Primapore
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Primapore dressing (Smith & Nephew Healthcare Ltd) 10cm x 20cm = £0.43, 10cm x 25cm = £0.50, 10cm x 30cm = £0.62, 10cm x 35cm = £0.96, 6cm x 8.3cm = £0.18, 8cm x 10cm = £0.19, 8cm x 15cm = £0.33

Softpore
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Softpore dressing (Richardson Healthcare Ltd) 10cm x 10cm = £0.13, 10cm x 15cm = £0.20, 10cm x 20cm = £0.35, 10cm x 25cm = £0.40, 10cm x 30cm = £0.49, 10cm x 35cm = £0.58, 6cm x 7cm = £0.06

Sterifix
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Sterifix dressing (Paul Hartmann Ltd) 10cm x 14cm = £0.52, 7cm x 7cm = £0.28, 7cm x 10cm = £0.32

Telfa Island
Low-adeherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Telfa Island dressing (Aria Medical Ltd) 10cm x 12.5cm = £0.27, 10cm x 20cm = £0.35, 10cm x 25cm = £0.45, 10cm x 35cm = £0.62, 5cm x 10cm = £0.08

Absorbent perforated plastic film faced dressing

Absopad
Low-adeherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Absopad dressing (Medicareplus International Ltd) 10cm x 10cm = £0.13, 20cm x 10cm = £0.28

Askinga Pad
Low-adeherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Askinga (B.Braun Medical Ltd) Pad dressing 10cm x 10cm = £0.21

Melolin
Low-adeherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Melolin dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm = £0.27, 20cm x 10cm = £0.53, 5cm x 5cm = £0.17
Hydrogel dressings

Hydrogel dressings are most commonly supplied as an amorphous, cohesive topical application that can take up the shape of a wound. A secondary, non-absorbent dressing is needed. These dressings are generally used to capture liquid to dry sloughy wounds and facilitate autolytic debridement of necrotic tissue; some also have the ability to absorb very small amounts of exudate. Hydrogel products that do not contain propylene glycol should be used if the wound is to be treated with larval therapy. Hydrogel sheets have a fixed structure and limited fluid-handling capacity; hydrogel sheet dressings are best avoided in the presence of infection, and are unsuitable for heavily exuding wounds.

Hydrogel application (amorphous)

**ActivHeal Hydrogel**
Hydrogel containing guar gum and propylene glycol
**ActivHeal (Advanced Medical Solutions Ltd)** Hydrogel dressing = £1.41

**Aquaform**
Hydrogel containing modified starch copolymer
**AquaForm (Aspen Medical Europe Ltd)** Hydrogel dressing = £2.02

**Askina Gel**
Hydrogel containing modified starch and glycerol
**Askina (B.Braun Medical Ltd)** Gel dressing = £2.00

**Cutimed Hydrogel**
**Cutimed (BSN medical Ltd)** Gel dressing = £2.99

**Flexigran**
Hydrogel containing modified starch and glycerol
**Flexigran (A1 Pharmaceuticals)** Gel dressing = £1.90

**GranuGel**
Hydrogel containing carboxymethylcellulose, pectin and propylene glycol
**GranuGel (Convatec Ltd)** Hydrocolloid Gel dressing = £2.32

**Intrasite Gel**
Hydrogel containing modified carmellose polymer and propylene glycol
**IntraSite (Smith & Nephew Healthcare Ltd)** Gel dressing = £3.57

**Nu-Gel**
Hydrogel containing alginate and propylene glycol
**Nu-Gel (Systagenix Wound Management Ltd)** dressing = £2.09

**Purilon Gel**
Hydrogel containing carboxymethylcellulose and calcium alginate
**Purilon (Coloplast Ltd)** Gel dressing = £2.26

**Hydrogel sheet dressings**

**ActiFormCool**
Hydrogel dressing
**ActiFormCool sheet (Activa Healthcare Ltd)** 10cm x 10cm square = £2.63, 10cm x 15cm rectangular = £3.79, 20cm x 20cm square = £7.93, 5cm x 6.5cm rectangular = £1.79

**Aquaflo**
Hydrogel dressing
**Aquaflo (Covidien (UK) Commercial Ltd)** sheet 7.5cm discs = £2.60

**Coolie**
Hydrogel dressing (without adhesive border)
**Coolie (Zeroderm Ltd)** sheet 7cm discs = £1.96

**Gel FX**
Hydrogel dressing (without adhesive border)
**Gel FX sheet (Synergy Health Plc)** 8cm x 10cm square = £1.60, 5cm x 15cm square = £3.20

**Geliperm**
Hydrogel sheets
**Geliperm (Geistlich Sons Ltd)** sheet 10cm x 10cm square = £2.53

**Hydrosorb**
Absorbent, transparent, hydrogel sheets containing polyurethane polymers covered with a semi-permeable film
**Hydrosorb sheet (Paul Hartmann Ltd)** 10cm x 10cm square = £2.24, 20cm x 20cm square = £6.71, 5cm x 7.5cm rectangular = £1.56
Wound management products and elasticated garments

Hydrosorb Comfort
Absorbent, transparent, hydrogel sheets containing polyurethane polymers covered with a semi-permeable film (with adhesive border, waterproof)

Hydrosorb Comfort sheet (Paul Hartmann Ltd) 12.5cm x 12.5cm square = £3.58, 4.5cm x 6.5cm rectangular = £1.85, 7.5cm x 10cm rectangular = £2.46

Intrasite Conformable
Soft non-woven dressing impregnated with Intrasite gel

Intrasite Conformable dressing 10cm x (Smith & Nephew Healthcare Ltd) 10cm square = £1.80, 20cm rectangular = £2.42, 40cm rectangular = £4.33

Novogel
Glycerol-based hydrogel sheets (standard or thin)

Novogel sheet (Ford Medical Associates Ltd) 10cm x 10cm square = £3.15, 15cm x 20cm rectangular = £6.07, 20cm x 40cm rectangular = £11.56, 30cm x 30cm (0.25cm thickness) square = £12.71, (0.30cm thickness) square = £13.47, 5cm x 7.5cm rectangular = £1.99, 7.5cm diameter circular = £2.89,

Sanoskin NET
Hydrogel sheet (without adhesive border)

Sanoskin (Ideal Medical Solutions Ltd) NET sheet 8.5cm x 12cm rectangular = £2.28

Vacunet
Non-adherent, hydrogel coated polyester net dressing

Vacunet dressing 10cm x 1 (Pro-Tex Capillary Dressings Ltd) 10cm square = £1.93, 5cm rectangular = £2.86

Sodium hyaluronate dressings
The hydrating properties of sodium hyaluronate promote wound healing, and dressings can be applied directly to the wound, or to a primary dressing (a secondary dressing should also be applied). The iodine and potassium iodide in these dressings prevent the bacterial decay of sodium hyaluronate in the wound.

Hyiodine® should be used with caution in thyroid disorders.

Hyiodine
Sodium hyaluronate 1.5%, potassium iodide 0.15%, iodine 0.1%, in a viscous solution

Hyiodine (H & R Healthcare Ltd) dressing = £35.00

Vapour-permeable films and membranes
Vapour-permeable films and membranes allow the passage of water vapour and oxygen but are impermeable to water and micro-organisms, and are suitable for lightly exuding wounds. They are highly conformable, provide protection, and a moist healing environment; transparent film dressings permit constant observation of the wound. Water vapour loss can occur at a slower rate than exudate is generated, so that fluid accumulates under the dressing, which can lead to tissue maceration and to wrinkling at the adhesive contact site (with risk of bacterial entry). Newer versions of these dressings have increased moisture vapour permeability. Despite these advances, vapour-permeable films and membranes are unsuitable for infected, large heavily exuding wounds, and chronic leg ulcers.

Vapour-permeable films and membranes are suitable for partial-thickness wounds with minimal exudate, or wounds with eschar. Most commonly, they are used as a secondary dressing over alginates or hydrogels; film dressings can also be used to protect the fragile skin of patients at risk of developing minor skin damage caused by friction or pressure.

Non-woven fabric dressing with viscose-rayon pad

Niko Fix
For intravenous and subcutaneous catheter sites

Niko (Unomedical Ltd) Fix dressing 7cm x 8.5cm = £0.19

Vapour-permeable Adhesive Film Dressing (Semi-permeable Adhesive Dressing)
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces.

Askina Derm
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Askina Derm dressing (Braun Medical Ltd) 10cm x 12cm = £1.08, 15cm x 20cm = £2.05, 15cm x 20cm = £2.49, 20cm x 30cm = £4.44, 6cm x 7cm = £0.37

Bioclusive
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Bioclusive (Systagenix Wound Management Ltd) dressing 10.2cm x 12.7cm = £1.54

C-View
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

C-View dressing (Aspen Medical Europe Ltd) 10cm x 12cm = £1.02, 12cm x 12cm = £1.09, 15cm x 20cm = £2.36, 6cm x 7cm = £0.38

Dressfilm
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Dressfilm dressing (St Georges Medical Ltd) 12cm x 12cm = £0.93, 15cm x 20cm = £1.90, 6cm x 7cm = £0.30

Hydrofilm
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Hydrofilm dressing (Paul Hartmann Ltd) 10cm x 12.5cm = £0.42, 10cm x 15cm = £0.52, 10cm x 25cm = £0.81, 12cm x 25cm = £0.86, 15cm x 20cm = £0.96, 20cm x 30cm = £1.60, 6cm x 7cm = £0.22

Hypafix Transparent
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Hypafix Transparent (BSN medical Ltd) dressing 10cm x 2m = £8.71

Leukomed T
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Leukomed T dressing (BSN medical Ltd) 10cm x 12.5cm = £1.01, 11cm x 14cm = £1.23, 15cm x 20cm = £2.35, 15cm x 25cm = £2.51, 7.2cm x 5cm = £0.37, 8cm x 10cm = £0.69

Mepitel Film
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Mepitel Film dressing (Molnlycke Health Care Ltd) 10.5cm x 12cm = £1.31, 10.5cm x 25cm = £2.55, 15.5cm x 20cm = £3.24, 6.5cm x 7cm = £0.49

Mepore Film
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Mepore Film dressing (Molnlycke Health Care Ltd) 10cm x 12cm = £1.23, 10cm x 25cm = £2.39, 15cm x 20cm = £3.04, 6cm x 7cm = £0.46

OpSite Flexifix
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

OpSite Flexifix dressing (Smith & Nephew Healthcare Ltd) 10cm x 1m = £6.57, 5cm x 1m = £3.89

OpSite Flexigrid
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

OpSite Flexigrid dressing (Smith & Nephew Healthcare Ltd) 12cm x 12cm = £1.12, 15cm x 20cm = £2.84, 6cm x 7cm = £0.40
**Wound management products and elasticated garments** 1299

**PolySkin II**  
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces.

**Kendall Film dressing** (Aria Medical Ltd) 10cm x 12cm = £1.03, 10cm x 20cm = £2.04, 15cm x 20cm = £2.35, 20cm x 25cm = £4.11, 4cm x 4cm = £0.36, 5cm x 7cm = £0.40.

**ProtectFilm**  
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces.

**ProtectFilm dressing** (Wallace, Cameron & Company Ltd) 10cm x 12cm = £0.20, 15cm x 20cm = £0.40, 6cm x 7cm = £0.11.

**Vapour-permeable Adhesive Film Dressing with absorbent pad**  
Vellafilm dressing 1 (Lohmann & Rauscher (UK) Ltd) 10cm x 12cm = £0.80, 15cm x 20cm = £2.50, 5cm x 7cm = £0.33.

**Tegaderm**  
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces.

**Tegaderm Film dressing** (3M Health Care Ltd) 12cm x 12cm = £1.11, 15cm x 20cm = £2.41, 6cm x 7cm = £0.39.

**Pharmapore-PU dressing**  
Film dressing with acetate film backing. Supplied in single-use pieces.

**Mepore Ultra dressing**  
Film dressing with absorbent pad.

**Mepore Ultra dressing** (Molnlycke Health Care Ltd) 4cm x 5cm = £0.24, 5cm x 7cm = £0.24, 6cm x 10cm = £0.62, 7cm x 15cm = £0.92, 9cm x 20cm = £1.36, 9cm x 25cm = £1.50, 9cm x 30cm = £2.00, 9cm x 35cm = £2.49.

**OpSite Plus**  
Film dressing with absorbent pad.

**OpSite Plus dressing** (Smith & Nephew Healthcare Ltd) 10cm x 12cm = £1.19, 10cm x 20cm = £2.01, 10cm x 35cm = £3.33, 6.5cm x 5cm = £0.32, 8.5cm x 9.5cm = £0.88.

**Pharmapore-PU dressing**  
Film dressing with acetate film backing. Supplied in single-use pieces.

**PremierPore VP**  
Film dressing with absorbent pad.

**PremierPore VP dressing** (Shermon) 10cm x 10cm = £0.16, 10cm x 15cm = £0.24, 10cm x 20cm = £0.36, 10cm x 25cm = £0.38, 10cm x 30cm = £0.57, 10cm x 35cm = £0.69, 5cm x 7cm = £0.13.

**Tegaderm**  
Film dressing with absorbent pad.

**Tegaderm + Pad dressing** (3M Health Care Ltd) 5cm x 7cm = £0.26, 9cm x 10cm = £0.65, 9cm x 15cm = £0.95, 9cm x 20cm = £1.40, 9cm x 25cm = £1.57, 9cm x 35cm = £2.60.

**Tegaderm Absorbent Clear**  
Film dressing with clear acrylic polymer oval-shaped pad or rectangular-shaped pad.

**Tegaderm Absorbent Clear Acrylic dressing** (3M Health Care Ltd) 11.1cm x 12.7cm oval = £4.11, 14.2cm x 15.8cm oval = £5.78, 14.9cm x 15.2cm rectangular = £8.66, 16.8cm x 19cm sacral = £10.37, 20cm x 20cm rectangular = £13.91, 7.6cm x 9.5cm oval = £3.17.

**Vapour-permeable transparent film dressing with adhesive foam border.**

**Central Gard**  
For intravenous and subcutaneous catheter sites.

**East-V**  
For intravenous and subcutaneous catheter sites.

**East-V** (Convatec Ltd) dressing 7cm x 7.5cm = £0.38.

**Vapour-permeable transparent, adhesive film dressing.**

**Hydrofilm I.V. Control**  
For intravenous and subcutaneous catheter sites.

**IV3000**  
For intravenous and subcutaneous catheter sites.

**IV3000 dressing** (Smith & Nephew Healthcare Ltd) 10cm x 12cm = £1.39, 5cm x 6cm = £0.42, 6cm x 7cm = £0.55, 7cm x 9cm = £0.73, 9cm x 12cm = £1.44.
**Wound management**

**Pharmapoe-PU IV**
For intravenous and subcutaneous catheter sites

**Pharmapoe-PU-LV dressing** (Wallace, Cameron & Company Ltd) 6cm x 7cm = £0.08, 7cm x 8.5cm = £0.07, 7cm x 9cm = £0.17

**Tegaderm IV**
For intravenous and subcutaneous catheter sites
Tegaderm IV dressing with securing tapes (3M Health Care Ltd) 10cm x 15.5cm = £1.67, 7cm x 8.5cm = £0.59, 8.5cm x 10.5cm = £1.16

**Soft polymer dressings**
Dressings with soft polymer, often a soft silicone polymer, in a non-adherent or gently adherent layer are suitable for use on lightly to moderately exuding wounds. For moderately to heavily exuding wounds, an absorbent secondary dressing can be added, or a soft polymer dressing with an absorbent pad can be used. Wound contact dressings coated with soft silicone have gentle adhesive properties and can be used on fragile skin areas or where it is beneficial to reduce the frequency of primary dressing changes. Soft polymer dressings should not be used on heavily bleeding wounds; blood clots can cause the dressing to adhere to the wound surface. For silicone keloid dressings see p. 1309.

**Cellulose dressings**

**Sorbion Sachet Border**
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope, with adhesive border sorbion sachet border dressing (H & R Healthcare Ltd) 10cm x 10cm square = £2.95, 15cm x 15cm square = £4.49, 25cm x 15cm rectangular = £6.99

**Sorbion Sachet EXTRA**
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope sorbion sachet EXTRA dressing (H & R Healthcare Ltd) 10cm x 10cm = £2.35, 10cm x 20cm = £3.73, 20cm x 20cm = £7.00, 30cm x 20cm = £9.99, 5cm x 5cm = £1.45, 7.5cm x 7.5cm = £1.78

**Sorbion Sachet Multi Star**
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope sorbion sachet multi star dressing (H & R Healthcare Ltd) 14cm x 14cm = £4.89, 8cm x 8cm = £2.99

**Sorbion Sachet 5 Drainage**
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope (‘Y’ shaped dressing) sorbion (H & R Healthcare Ltd) sacchet 5 drainage dressing 10cm x 10cm = £2.64

**Suprasorb X**
 Biosynthetic cellulose fibre dressing Suprasorb X dressing (Lohmann & Rauscher (UK) Ltd) 14cm x 20cm rectangular = £8.38, 2cm x 21cm rope = £6.51, 5cm x 5cm square = £2.03, 9cm x 9cm square = £4.23

**With absorbent pad**

**Advazorb Border**
Soft silicone wound contact dressing with polyurethane foam film backing and adhesive border Advazorb Border dressing (Advancis Medical) 10cm x 10cm = £2.10, 10cm x 20cm = £2.95, 20cm x 20cm = £4.25, 12.5cm x 12.5cm = £2.58, 15cm x 15cm = £3.15, 20cm x 20cm = £5.46, 7.5cm x 7.5cm = £1.19

**Advazorb Border Lite**
Soft silicone wound contact dressing with polyurethane foam film backing and adhesive border Advazorb Border Lite dressing (Advancis Medical) 10cm x 10cm = £1.89, 10cm x 20cm = £2.61, 10cm x 30cm = £3.83, 12.5cm x 12.5cm = £2.32, 15cm x 15cm = £2.84, 20cm x 20cm = £4.91, 7.5cm x 7.5cm = £1.07

**Advazorb Silfix**
Soft silicone wound contact dressing with polyurethane foam film backing Advazorb Silfix dressing (Advancis Medical) 10cm x 10cm = £1.85, 10cm x 20cm = £3.18, 12.5cm x 12.5cm = £2.59, 15cm x 15cm = £3.36, 20cm x 20cm = £4.98, 7.5cm x 7.5cm = £0.99

**Advazorb Silfix Lite**
Soft silicone wound contact dressing with polyurethane foam film backing Advazorb Silfix Lite dressing (Advancis Medical) 10cm x 10cm = £1.67, 10cm x 20cm = £2.86, 12.5cm x 12.5cm = £3.33, 15cm x 15cm = £3.02, 20cm x 20cm = £4.48, 7.5cm x 7.5cm = £0.89

**Allevyn Gentle**
Soft gel wound contact dressing, with polyurethane foam film backing Allevyn Gentle dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm = £2.49, 10cm x 20cm = £4.01, 15cm x 15cm = £4.18, 20cm x 20cm = £6.68, 5cm x 5cm = £1.26

**Allevyn Gentle Border**
 Silicone gel wound contact dressing, with polyurethane foam film backing Allevyn Gentle Border dressing (Smith & Nephew Healthcare Ltd) Heel dressing 23cm x 23.2cm = £9.59, dressing 10cm x 10cm = £2.18, 12.5cm x 12.5cm = £2.67, 17.5cm x 17.5cm = £5.26, 7.5cm x 7.5cm = £1.48

**Allevyn Gentle Border Lite**
 Silicone gel wound contact dressing, with polyurethane foam film backing Allevyn Gentle Border Lite dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm = £2.15, 15cm x 15cm = £3.79, 5.5cm x 12cm = £1.84, 5cm x 5cm = £0.89, 9cm x 15cm = £3.41

**Allevyn Life**
Soft silicone wound contact dressing, with central mesh screen, polyurethane foam film backing and adhesive border Allevyn Life dressing (Smith & Nephew Healthcare Ltd) 10.3cm x 10.3cm = £1.68, 12.9cm x 12.9cm = £2.47, 15.4cm x 15.4cm = £3.02, 21cm x 21cm = £5.95

**Cutimed Siltec**
Soft silicone wound contact dressing, with polyurethane foam film backing Cutimed Siltec (BSN medical Ltd) Heel dressing 16cm x 24cm = £7.15, Sacrum dressing 17.5cm x 17.5cm = £4.55, 23cm x 23cm = £7.29, dressing 10cm x 10cm = £2.46, 18cm x 20cm = £4.06, 15cm x 15cm = £4.59, 20cm x 20cm = £6.97, 5cm x 6cm = £3.11,

**Cutimed Siltec B**
Soft silicone wound contact dressing, with polyurethane foam film backing, with adhesive border, for lightly to moderately exuding wounds Cutimed Siltec B dressing (BSN medical Ltd) 12.5cm x 12.5cm = £2.24, 15cm x 15cm = £4.36, 17.5cm x 17.5cm = £5.35, 22.5cm x 22.5cm = £8.47, 7.5cm x 7.5cm = £1.53

**Cutimed Siltec L**
Soft silicone wound contact dressing, with polyurethane foam film backing, for lightly to moderately exuding wounds Cutimed Siltec L dressing (BSN medical Ltd) 10cm x 10cm = £2.12, 15cm x 15cm = £3.48, 5cm x 6cm = £1.05

**Eclipse Adherent**
Soft silicone wound contact layer with absorbent pad and film backing Eclipse Adherent dressing (Advancis Medical) 10cm x 10cm = £2.99, 10cm x 20cm = £3.75, 15cm x 15cm = £4.99, 20cm x 20cm = £9.99, 17cm x 19cm sacral = £3.76, 22cm x 23cm sacral = £6.23,

**Flivisorb**
Absorbent polymer dressing with non-adherent wound contact layer Flivisorb dressing (Lohmann & Rauscher (UK) Ltd) 10cm x 10cm square = £5.88, 10cm x 20cm rectangular = £1.05, 20cm x 20cm square = £1.86, 20cm x 30cm rectangular = £2.35

**Flivisorb Adhesive**
Absorbent polymer dressing with non-adherent wound contact layer and adhesive border Flivisorb Adhesive dressing (Lohmann & Rauscher (UK) Ltd) 2cm x 12cm square = £3.32, 5cm x 15cm square = £4.54

**Mepilex**
Absorbent soft silicone dressing with polyurethane foam film backing
Mepilex (Molnlycke Health Care Ltd) Heel dressing 13cm x 20cm = £5.41, 15cm x 22cm = £6.22, XT dressing 10cm x 11cm = £2.66, 11cm x 20cm = £4.39, 15cm x 16cm = £4.82, 20cm x 21cm = £7.28, dressing 5cm x 5cm = £1.21.

Mepilex Border Absorbent soft silicone dressing with polyurethane foam film backing and adhesive border.

Mepilex Border (Molnlycke Health Care Ltd) Heel dressing 18.5cm x 24cm = £6.63, Sacrum dressing 18cm x 18cm = £4.85, 23cm x 23cm = £7.91, dressing 10cm x 12.5cm = £2.72, 10cm x 20cm = £3.69, 10cm x 30cm = £5.55, 15cm x 17.5cm = £4.74, 17cm x 20cm = £5.07.

Mepilex Border Lite Thin absorbent soft silicone dressing with polyurethane foam film backing and adhesive border.

Mepilex Border Lite dressing (Molnlycke Health Care Ltd) 10cm x 10cm = £2.53, 15cm x 15cm = £4.13, 4cm x 5cm = £0.92, 5cm x 12.5cm = £2.51, 7.5cm x 7.5cm = £1.39.

Mepilex Lite Thin absorbent soft silicone dressing with polyurethane foam film backing.

Mepilex Lite dressing (Molnlycke Health Care Ltd) 10cm x 10cm = £2.17, 15cm x 15cm = £4.42, 20cm x 20cm = £26.66, 6cm x 8.5cm = £1.82.

Mepilex Transfer Soft silicone exudate transfer dressing.

Mepilex Transfer dressing (Molnlycke Health Care Ltd) 10cm x 12cm = £3.51, 15cm x 20cm = £10.64, 20cm x 30cm = £27.20, 7.5cm x 8.5cm = £2.23.

Sorbon Sana Non-adherent polyethylene wound contact dressing with absorbent core.

sorbon sana gentle dressing (H & R Healthcare Ltd) 12cm x 12cm = £2.49, 12cm x 22cm = £4.49, 22cm x 22cm = £7.99, 8.5cm x 8.5cm = £1.99.

Urgotol Duo Non-adherent soft polyester wound contact dressing with absorbent pad.

Urgotol Duo dressing (Urgo Ltd) 10cm x 12cm = £3.85, 15cm x 20cm = £8.35, 5cm x 10cm = £2.26.

Without absorbant pad

Adaptic Touch Non-adherent soft silicone wound contact dressing.

Adaptic Touch dressing (Systagenix Wound Management Ltd) 12.7cm x 15cm = £4.65, 20cm x 32cm = £12.50, 5cm x 7.5cm = £1.13, 7.5cm x 11cm = £2.25.

Askina SilNet Soft silicone-coated wound contact dressing.

Askina SilNet dressing (B.Braun Medical Ltd) 10cm x 18cm = £4.98, 20cm x 30cm = £12.20, 5cm x 7.5cm = £1.13, 7.5cm x 10cm = £2.28.

Meptel Soft silicone, semi-transparent wound contact dressing.

Meptel dressing (Molnlycke Health Care Ltd) 12cm x 15cm = £6.45, 5cm x 7cm = £1.59, 8cm x 10cm = £2.19.

Meptel One Soft silicone, thin, transparent wound contact dressing.

Meptel One dressing (Molnlycke Health Care Ltd) 13cm x 15cm = £6.45, 24cm x 27.5cm = £17.38, 6cm x 7cm = £1.59, 9cm x 10cm = £3.19.

Physiotulle Non-adherent soft polyester wound contact dressing.

Physiotulle dressing 1 (Coloplast Ltd) 0cm x 10cm = £2.25, 5cm x 20cm = £6.86.

Siflex Soft coated polyester wound contact dressing.

Siflex dressing (Advancis Medical) 12cm x 15cm = £4.58, 20cm x 30cm = £11.79, 35cm x 60cm = £39.54, 5cm x 7cm = £1.11, 8cm x 10cm = £2.27.

Silon-TSR Soft silicone polymer wound contact dressing.

Silon-TSR dressing (Bio Med Sciences) 13cm x 13cm = £3.52, 13cm x 25cm = £5.47, 28cm x 30cm = £7.37.

Sobion Contact Non-adherent soft polyurethane foam contact dressing.

sobion contact dressing (H & R Healthcare Ltd) 10cm x 10cm = £1.99, 10cm x 20cm = £3.39, 20cm x 20cm = £6.59, 20cm x 30cm = £9.99, 7.5cm x 7.5cm = £1.49.

Tegaderm Contact Non-adherent soft polyurethane wound contact dressing.

Tegaderm Contact dressing (3M Health Care Ltd) 20cm x 25cm = £10.86, 7.5cm x 10cm = £2.27, 7.5cm x 20cm = £4.46.

Urgotol Non-adherent soft polyurethane wound contact dressing.

Urgotol dressing (Urgo Ltd) 10cm x 10cm = £3.06, 10cm x 40cm = £10.29, 15cm x 15cm = £5.50, 15cm x 20cm = £8.66, 20cm x 30cm = £13.92, 5cm x 5cm = £1.53.

Hydrocolloid dressings

Hydrocolloid dressings are usually presented as a hydrocolloid layer on a vapour-permeable film or foam pad. Semi-permeable to water vapour and oxygen, these dressings form a gel in the presence of exudate to facilitate rehydration in lightly to moderately exuding wounds and promote autolytic debridement of dry, sloughy, or necrotic wounds; they are also suitable for promoting granulation. Hydrocolloid-fibrous dressings made from modified carmellose fibres resemble alginate dressings; hydrocolloid-fibrous dressings are more absorptive and suitable for moderately to heavily exuding wounds.

Hydrocolloid-fibrous dressings

Aquacel Soft non-woven pad containing hydrocolloid-fibres.

Aquacel (Convatec Ltd) Ribbon dressing 1cm x 45cm = £1.83, 2cm x 45cm = £2.44, dressing 10cm x 10cm square = £2.41, 15cm x 15cm square = £4.53, 4cm x 10cm rectangular = £1.30, 4cm x 20cm rectangular = £1.91, 4cm x 30cm rectangular = £2.88, 5cm x 5cm square = £1.01.

Aquacel Foam Soft non-woven pad containing hydrocolloid-fibres with foam layer; with or without adhesive border.

Aquacel Foam dressing (Convatec Ltd) adhesive 10cm x 10cm = £2.34, 12.5cm x 12.5cm = £2.65, 17.5cm x 17.5cm = £5.30, 19.8cm x 14cm heel = £5.43, 20cm x 16.9cm sacral = £4.87, 21cm x 21cm = £7.76, 25cm x 30cm = £10.05, 8cm x 6cm = £1.38, non-adhesive 10cm x 10cm = £2.53, 15cm x 15cm = £4.25, 15cm x 20cm = £5.81, 20cm x 20cm = £6.94.

UrgoClean Pad Pad, hydrocolloid fibres coated with soft-adherent lipo-colloidal wound contact layer.

UrgoClean Pad dressing (Urgo Ltd) 10cm x 10cm square = £2.11, 20cm x 15cm rectangular = £3.96, 6cm x 6cm square = £0.95.

UrgoClean Rope Rope, non-woven rope containing hydrocolloid fibres.

UrgoClean rope dressing (Urgo Ltd) 2.5cm x 40cm = £2.37, 5cm x 40cm = £3.14.

Versiva XC, non-adhesive

Hydrocolloid gelling foam dressing; with or without adhesive border.

Versiva XC dressing (Convatec Ltd) 10cm x 10cm square = £2.50, 11cm x 11cm square = £2.44, 14cm x 14cm square = £3.16, 15cm x 15cm square = £4.50, 18cm x 19cm square = £5.37, 20cm x 20cm square = £6.73, 21cm x 25cm sacral = £6.46, 22cm x 22cm square = £5.97, 7.5cm x 7.5cm square = £1.47.

Polyurethan matrix dressing

Cutinova Hydro Polyurethane matrix with absorbent particles and waterproof polyurethane film.

Cutinova Hydro dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £2.53, 15cm x 20cm rectangular = £5.36, 5cm x 6cm rectangular = £1.26.
### With adhesive border

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Shape</th>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biatain Super</strong></td>
<td>Semi-permeable hydrocolloid dressing; without adhesive border</td>
<td>10cm x 10cm</td>
<td>£2.16, 12.5cm x 12.5cm</td>
</tr>
<tr>
<td><strong>Granuflex Border</strong></td>
<td>Hydrocolloid wound contact layer bonded to plastic foam layer, with outer semi-permeable polyurethane film</td>
<td>10cm x 10cm</td>
<td>£3.32, 10cm x 18cm triangular</td>
</tr>
<tr>
<td><strong>Hydrocoll Border</strong></td>
<td>Hydrocolloid dressing with adhesive border and absorbent wound contact pad</td>
<td>10cm x 10cm</td>
<td>£4.53, 5cm x 5cm square</td>
</tr>
<tr>
<td><strong>Tegaderm Hydrocolloid</strong></td>
<td>Hydrocolloid dressing with adhesive border; normal or thin</td>
<td>10cm x 12cm oval</td>
<td>£1.55, 13cm x 15cm oval</td>
</tr>
<tr>
<td><strong>Ultec Pro</strong></td>
<td>Semi-permeable hydrocolloid dressing with adhesive border</td>
<td>15cm x 18cm sacral</td>
<td>£3.30, 19.5cm x 23cm sacral</td>
</tr>
<tr>
<td><strong>Hydrocoll (bevelled edge) dressing</strong></td>
<td>(Paul Hartmann Ltd)</td>
<td>10cm x 10cm</td>
<td>£2.07, 20cm x 20cm square</td>
</tr>
<tr>
<td><strong>Biatain Super</strong></td>
<td>Semi-permeable, hydrocolloid film dressing without adhesive border</td>
<td>10cm x 10cm</td>
<td>£2.16, 12.5cm x 12.5cm square</td>
</tr>
<tr>
<td><strong>Comfeel Plus Contour</strong></td>
<td>Hydrocolloid dressings containing carmellose sodium and calcium alginate</td>
<td>6cm x 8cm</td>
<td>£2.19, 9cm x 11cm</td>
</tr>
<tr>
<td><strong>Comfeel Plus Pressure Relieving</strong></td>
<td>Hydrocolloid dressings containing carmellose sodium and calcium alginate</td>
<td>10cm diameter circular</td>
<td>£4.59, 15cm diameter circular</td>
</tr>
<tr>
<td><strong>Comfeel Plus Transparent</strong></td>
<td>Hydrocolloid dressings containing carmellose sodium and calcium alginate</td>
<td>10cm x 10cm</td>
<td>£3.30, 15cm x 15cm square</td>
</tr>
</tbody>
</table>

### Without adhesive border

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Shape</th>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biatain Super</strong></td>
<td>Semi-permeable hydrocolloid dressing</td>
<td>10cm x 10cm</td>
<td>£2.16, 12.5cm x 12.5cm square</td>
</tr>
<tr>
<td><strong>Granuflex Border</strong></td>
<td>Hydrocolloid wound contact layer bonded to plastic foam layer, with outer semi-permeable polyurethane film</td>
<td>10cm x 10cm</td>
<td>£3.32, 10cm x 18cm triangular</td>
</tr>
<tr>
<td><strong>Hydrocoll Border</strong></td>
<td>Hydrocolloid dressing with adhesive border and absorbent wound contact pad</td>
<td>10cm x 10cm</td>
<td>£4.53, 5cm x 5cm square</td>
</tr>
<tr>
<td><strong>Tegaderm Hydrocolloid</strong></td>
<td>Hydrocolloid dressing with adhesive border; normal or thin</td>
<td>10cm x 12cm oval</td>
<td>£1.55, 13cm x 15cm oval</td>
</tr>
<tr>
<td><strong>Ultec Pro</strong></td>
<td>Semi-permeable hydrocolloid dressing with adhesive border</td>
<td>15cm x 18cm sacral</td>
<td>£3.30, 19.5cm x 23cm sacral</td>
</tr>
<tr>
<td><strong>Hydrocoll (bevelled edge) dressing</strong></td>
<td>(Paul Hartmann Ltd)</td>
<td>10cm x 10cm</td>
<td>£2.07, 20cm x 20cm square</td>
</tr>
<tr>
<td><strong>Biatain Super</strong></td>
<td>Semi-permeable, hydrocolloid film dressing without adhesive border</td>
<td>10cm x 10cm</td>
<td>£2.16, 12.5cm x 12.5cm square</td>
</tr>
<tr>
<td><strong>Comfeel Plus Contour</strong></td>
<td>Hydrocolloid dressings containing carmellose sodium and calcium alginate</td>
<td>6cm x 8cm</td>
<td>£2.19, 9cm x 11cm</td>
</tr>
<tr>
<td><strong>Comfeel Plus Pressure Relieving</strong></td>
<td>Hydrocolloid dressings containing carmellose sodium and calcium alginate</td>
<td>10cm diameter circular</td>
<td>£4.59, 15cm diameter circular</td>
</tr>
<tr>
<td><strong>Comfeel Plus Transparent</strong></td>
<td>Hydrocolloid dressings containing carmellose sodium and calcium alginate</td>
<td>10cm x 10cm</td>
<td>£3.30, 15cm x 15cm square</td>
</tr>
</tbody>
</table>

### Nu-Derm

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Shape</th>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nu-Derm dressing</strong></td>
<td>(Sytangenix Wound Management Ltd)</td>
<td>10cm x 10cm</td>
<td>£1.56, 15cm x 15cm square</td>
</tr>
<tr>
<td><strong>Tegaderm Hydrocolloid</strong></td>
<td>Hydrocolloid dressing without adhesive border; normal and thin</td>
<td>10cm x 10cm</td>
<td>£1.55, dressing 10cm x 10cm square</td>
</tr>
<tr>
<td><strong>Ultec Pro</strong></td>
<td>Semi-permeable hydrocolloid dressing; without adhesive border</td>
<td>10cm x 10cm</td>
<td>£2.28, 15cm x 15cm square</td>
</tr>
</tbody>
</table>

### Foam dressings

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Shape</th>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Foam dressings</strong></td>
<td>Dressings containing hydrophilic polyurethane foam (adhesive or non-adhesive), with or without plastic film-backing, are suitable for all types of exuding wounds, but not for dry wounds; some foam dressings have a moisture-sensitive film backing with variable permeability dependant on the level of exudate.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Foam dressings vary in their ability to absorb exudate; some are suitable only for lightly to moderately exuding wounds, others have greater fluid-handling capacity and are suitable for heavily exuding wounds. Saturated foam dressings can cause maceration of healthy skin if left in contact with the wound. Foam dressings can be used in combination with other primary wound contact dressings. If used under compression bandaging or compression garments, the fluid-handling capacity of the foam dressing may be reduced. Foam dressings can also be used to provide a protective cushion for fragile skin. A foam dressing containing ibuprofen is available and may be useful for treating painful exuding wounds.

Cavi-Care

Soft, conforming cavity wound dressing prepared by mixing thoroughly for 15 seconds immediately before use and allowing to expand its volume within the cavity.

Polyurethane Foam Dressing

Kendall

Kendall Foam dressing (Aria Medical Ltd) 10cm x 10cm square = £1.06, 10cm x 20cm rectangular = £2.05, 12.5cm x 12.5cm square = £1.80, 15cm x 15cm square = £2.60, 20cm x 20cm square = £3.01, 5cm x 5cm square = £0.71, 7.5cm x 7.5cm square = £1.21, 8.5cm x 7.5cm rectangular (fenestrated) = £0.91

Polyurethane Foam Film Dressing with Adhesive Border

ActivHeal Foam Adhesive

ActivHeal Foam Adhesive dressing (Advanced Medical Solutions Ltd) 10cm x 10cm square = £1.63, 12.5cm x 12.5cm square = £1.68, 15cm x 15cm square = £2.15, 20cm x 20cm square = £4.50, 7.5cm square = £1.18

Allevyn Adhesive

Allevyn Adhesive dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £2.17, 12.5cm x 12.5cm square = £2.66, 12.5cm x 22.5cm rectangular = £4.14, 17.5cm x 17.5cm square = £5.25, 17cm x 17cm anatomically shaped sacral = £3.94, 22.5cm x 22.5cm square = £7.64, 22cm x 22cm anatomically shaped sacral = £5.68, 7.5cm x 7.5cm square = £1.48

Allevyn Plus Adhesive

Allevyn Plus Adhesive dressing (Smith & Nephew Healthcare Ltd) 12.5cm x 12.5cm square = £3.34, 12.5cm x 22.5cm rectangular = £5.91, 17cm x 17cm square = £6.44, 17cm x 17cm anatomically shaped sacral = £4.87, 22cm x 22cm anatomically shaped sacral = £7.04

Biatain Adhesive

Biatain Adhesive dressing (Coloplast Ltd) 10cm x 10cm square = £1.74, 12.5cm x 12.5cm square = £2.54, 17cm diameter contour = £4.94, 18cm x 18cm square = £5.13, 18cm x 28cm rectangular = £7.60, 15cm x 20cm heel = £5.13, 23cm x 23cm sacral = £4.39

Biatain Silicone

Biatain Silicone dressing (Coloplast Ltd) 7.5cm x 7.5cm = £1.45, 10cm x 10cm = £2.13, 12.5cm x 12.5cm = £2.60, 15cm x 15cm = £3.86, 17.5cm x 17.5cm = £5.13

Kendall Island

Kendall Foam Island dressing (Aria Medical Ltd) 10cm x 10cm square = £1.54, 15cm x 15cm square = £2.90, 20cm x 20cm square = £5.46

PermaFoam

PermaFoam dressing (Paul Hartmann Ltd) 16.5cm x 18cm concave = £0.42, 18cm x 18cm sacral = £3.31, 22cm x 22cm sacral = £3.80

PermaFoam Comfort

PermaFoam Comfort dressing (Paul Hartmann Ltd) 10cm x 20cm rectangular = £3.35, 11cm x 11cm square = £2.12, 15cm x 15cm square = £3.46, 20cm x 20cm square = £5.03, 8cm x 8cm square = £1.12
rectangular = £3.44, 20cm x 20cm = £5.75, Heel dressing 12cm x 20cm = £4.66.

**Biatain-Ibu Non-Adhesive**
- Biatain-Ibu Non-Adhesive dressing (Coloplast Ltd) 10cm x 12cm rectangular = £3.29, 10cm x 22.5cm rectangular = £5.18, 15cm x 15cm square = £5.18, 20cm x 20cm square = £8.81, 5cm x 7cm rectangular = £1.71

**Biatain-Ibu Soft-Hold**
- Biatain-Ibu Soft-Hold dressing (Coloplast Ltd) 5cm x 12cm rectangular = £3.29, 0cm x 22.5cm rectangular = £5.18, 5cm x 15cm square = £5.18

**Biatain Non-Adhesive**
- Biatain Non-Adhesive dressing (Coloplast Ltd) 10cm x 10cm square = £2.37, 10cm x 20cm rectangular = £3.91, 15cm x 15cm square = £4.36, 20cm x 20cm square = £6.47, 5cm x 7cm rectangular = £1.30

**Biatain Soft-Hold**
- Biatain Soft-Hold dressing (Coloplast Ltd) 10cm x 10cm square = £2.57, 10cm x 20cm rectangular = £3.91, 15cm x 15cm square = £4.28, 5cm x 7cm rectangular = £1.30

**Kendall Plus**
- Kendall Foam Plus dressing (Aria Medical Ltd) 10cm x 10cm square = £1.47, 10cm x 20cm rectangular = £2.69, 15cm x 15cm square = £3.38, 20cm x 20cm square = £4.04, 5cm x 5cm square = £0.82, 7.5cm x 7.5cm square = £1.42, 8.5cm x 7.5cm rectangular = £1.24

**Kerrahel**
- Kerrahel (Crawford Healthcare Ltd) dressing 12cm x 20cm heel = £4.61

**Lyfoam Max**
- Lyfoam Max dressing (Monelycke Health Care Ltd) 10cm x 10cm square = £1.14, 10cm x 20cm rectangular = £2.01, 15cm x 15cm square = £2.15, 15cm x 20cm rectangular = £2.71, 20cm x 20cm square = £3.99, 7.5cm x 8.5cm rectangular = £1.09

**PermaFoam**
- PermaFoam (Paul Hartmann Ltd) Cavity dressing 10cm x 10cm = £2.01, dressing (non-adhesive) 10cm x 10cm square = £2.12, 10cm x 20cm rectangular = £3.63, 15cm x 15cm square = £4.02, 20cm x 20cm square = £6.15, 6cm diameter circular = £1.10, 9cm x 8cm square (fenestrated) = £1.25

**PolyMem**
- PolyMem dressing (Aspen Medical Europe Ltd) 7cm x 7cm tube = £1.72, 9cm x 9cm tube = £2.17, finger/toe size 1 = £2.50, 2 = £2.50, 3 = £2.50,
- PolyMem dressing (non-adhesive) (Aspen Medical Europe Ltd) 10cm x 10cm square = £2.47, 10cm x 26cm rectangular = £13.10, 13cm x 13cm square = £4.12, 17cm x 19cm rectangular = £6.08, 20cm x 60cm rectangular = £30.90, 8cm x 8cm square = £1.59

**PolyMem Max**
- PolyMem Max dressing (Aspen Medical Europe Ltd) 11cm x 11cm square = £2.97, 20cm x 20cm square = £11.68

**PolyMem WIC**
- PolyMem (Aspen Medical Europe Ltd) WIC dressing 8cm x 8cm = £3.69

**Tegaderm Foam**
- Tegaderm Foam dressing (3M Health Care Ltd) 10cm x 10cm square = £2.19, 10cm x 20cm rectangular = £3.71, 10cm x 60cm rectangular = £12.54, 20cm x 20cm square = £5.92, 8.8cm x 8.8cm square (fenestrated) = £2.23

**Tiele Xtra**
- Tiele Xtra dressing (15) (Syntagenix Wound Management Ltd) 1cm x 11cm square = £2.24, 5cm x 15cm square = £3.37, 5cm x 20cm rectangular = £5.51

**Transorbent**
- Transorbent dressing (adhesive) (B.Braun Medical Ltd) 10cm x 10cm square = £1.98, 15cm x 15cm square = £3.63, 20cm x 20cm square = £5.80, 5cm x 7cm rectangular = £1.05

**Trufoam NA**
- Trufoam Non Adhesive dressing (Aspen Medical Europe Ltd) 10cm x 10cm square = £1.34, 15cm x 15cm square = £2.63, 5cm x 5cm square = £0.71

**UrgoCell TLC**
- UrgoCell TLC dressing (Urgo Ltd) 10cm x 10cm = £2.67, 15cm x 20cm = £2.06, 6cm x 6cm = £1.84, 12cm x 10cm heel = £4.77,

**Alginale dressings**
- Non-woven or fibrous, non-occlusive, alginate dressings, made from calcium alginate, or calcium sodium alginate, derived from brown seaweed, form a soft gel in contact with wound exudate. Alginate dressings are highly absorbent and suitable for use on exuding wounds, and for the promotion of autolytic debridement of debris in very moist wounds. Alginate dressings also act as a haemostatic, but caution is needed because blood clots can cause the dressing to adhere to the wound surface. Alginate dressings should not be used if bleeding is heavy and extreme caution is needed if used for tumours with friable tissue. Alginate sheets are suitable for use as a wound contact dressing for moderately to heavily exuding wounds and can be layered into deep wounds; alginate rope can be used in sinus and cavity wounds to improve absorption of exudate and prevent maceration. If the dressing does not have an adhesive border or integral adhesive plastic film backing, a secondary dressing will be required.

**ActiveHeal Alginate**
- Calcium sodium alginate dressing
- ActiveHeal Alginate dressing (Advanced Medical Solutions Ltd) 10cm x 10cm = £1.15, 10cm x 20cm = £2.83, 5cm x 5cm = £0.59

**ActiveHeal Aquafiber**
- Non-woven, calcium sodium alginate dressing

**Algite M**
- Calcium alginate fibre, non-woven dressing

**Algoterol**
- Calcium alginate dressing

**Biatain Alginate**
- Alginate and carboxymethylcellulose dressing, highly absorbent, gelling dressing

**Biatain Alginate dressing** (Coloplast Ltd) 10cm x 10cm = £2.30, 15cm x 15cm = £4.36, 44cm = £7.21, 5cm x 5cm = £0.97

**Cutimed Alginate**
- Calcium sodium alginate dressing

**Kaltostat**
- Calcium alginate fibre, non-woven

**Kaltostat dressing** (Convatec Ltd) 10cm x 20cm = £4.06, 15cm x 25cm = £6.98, 2g = £3.81, 5cm x 5cm = £0.95, 7.5cm x 12cm = £2.07

**Kendall**
- Calcium alginate dressing

**Kendall Calcium Alginate** (Aspen Medical Ltd) Rope dressing 30cm = £2.89, 61cm = £5.07, 91cm = £5.46, dressing 10cm x 10cm = £1.52, 10cm x 14cm = £2.45, 10cm x 20cm = £2.98, 15cm x 25cm = £5.25, 30cm x 61cm = £27.56, 5cm x 5cm = £0.72.

**Kendall Plus**
- Calcium alginate dressing

**Kendall (Aspen Medical Ltd) Foam Plus dressing 10cm x 10cm square = £1.47**
Melgisorb
Calcium sodium alginate fibre, highly absorbent, gelling dressing, non-woven

Melgisorb (Mohnlycke Health Care Ltd) Cavity dressing 2.2cm x 32cm = £3.55, dressing 10cm x 10cm = £1.88, 10cm x 20cm = £3.52, 5cm x 5cm = £0.90.

Sorbalan
Calcium alginate dressing

Sorbalan (Paul Hartmann Ltd) T dressing 2g = £3.47, dressing 10cm x 10cm = £1.70, 5cm x 5cm = £0.81.

Sorbasan Flat
Calcium alginate fibre, highly absorbent, flat non-woven pads

Sorbasan Flat dressing (Aspen Medical Europe Ltd) 10cm x 10cm = £1.71, 10cm x 20cm = £3.20, 5cm x 5cm = £0.81.

Sorbasan Plus
Alginate dressing bonded to a secondary absorbent viscose pad

Sorbasan Plus dressing (Aspen Medical Europe Ltd) 10cm x 10cm = £3.10, 10cm x 20cm = £3.96, 15cm x 20cm = £5.49, 7.5cm x 10cm = £1.76.

Sorbasan Ribbon
Alginate dressing bonded to a secondary absorbent viscose pad

Sorbasan (Aspen Medical Europe Ltd) Ribbon dressing 40cm = £2.04.

Sorbasan Surgical Packing
Alginate dressing bonded to a secondary absorbent viscose pad

Sorbasan (Aspen Medical Europe Ltd) Packing dressing 2g = £3.47.

Suprasorb A
Calcium alginate dressing

Suprasorb A (Lohmann & Rauscher (UK) Ltd) alginate dressing 10cm x 10cm = £1.22, 5cm x 5cm = £0.62, cavity dressing 2g = £2.26.

Tegaderm Alginate
Calcium alginate dressing

Tegaderm Alginate dressing (3M Health Care Ltd) 10cm x 10cm = £1.72, 2cm x 30.4cm = £0.87, 5cm x 5cm = £0.81.

Urgosorb
Alginate and carboxymethylcellulose dressing without adhesive border

Urgosorb (Urgo Ltd) Pad dressing 10cm x 10cm = £2.10, 10cm x 20cm = £3.85, 5cm x 5cm = £0.87, Rope dressing 30cm = £2.75.

Capillary-action dressings
Capillary-action dressings consist of an absorbent core of hydrophilic fibres sandwiched between two low-adherent wound-contact layers to ensure no fibres are shed on to the wound surface. Wound exudate is taken up by the dressing and retained within the highly absorbent central layer. The dressing may be applied to relatively superficial areas, but for deeper wounds or cavities it may be cut to shape to ensure good contact with the wound base. Multiple layers may be applied to heavily exuding wounds to further increase the fluid-absorbing capacity of the dressing. A secondary adhesive dressing is necessary. Capillary-action dressings are suitable for use on all types of exuding wounds, but particularly on sloughy wounds where removal of fluid from the wound aids debridement; capillary-action dressings are contra-indicated for heavily bleeding wounds or arterial bleeding.

Advadraw
Non-adherent dressing consisting of a soft viscose and polyester absorbent pad with central wicking layer between two perforated permeable wound contact layers

Advadraw dressing (Advancis Medical) 10cm x 10cm = £0.88, 10cm x 15cm = £1.19, 15cm x 15cm = £1.57, 5cm x 7.5cm = £0.57.

Advadraw Spiral
Advadraw (Advancis Medical) Spiral dressing 0.5cm x 40cm = £0.82.

Cerdak Aerocloth
Non-adhesive wound contact sachet containing ceramic spheres, with non-woven fabric adhesive backing

Cerdak Aerocloth dressing 5cm x (Apollo Medical Products Ltd) 10cm = £1.94, 5cm = £1.37.

Cerdak Aerofilm
Non-adhesive wound contact sachet containing ceramic spheres, with waterproof transparent adhesive film backing

Cerdak Aerofilm dressing 5cm x (Apollo Medical Products Ltd) 10cm = £2.07, 5cm = £1.51.

Cerdak Basic
Non-adhesive wound contact sachet containing ceramic spheres

Cerdak Basic dressing (Apollo Medical Products Ltd) 10cm x 10cm = £1.56, 10cm x 15cm = £2.08, 5cm x 5cm = £0.70.

Sumar Lite
Sumar Lite dressing (Lantor (UK) Ltd) 10cm x 10cm = £1.59, 10cm x 15cm = £2.12, 5cm x 5cm = £0.93.

Sumar Max
Sumar Max dressing (Lantor (UK) Ltd) 10cm x 10cm = £1.61, 10cm x 15cm = £2.15, 5cm x 5cm = £0.95.

Sumar Spiral
Sumar (Lantor (UK) Ltd) Spiral dressing 0.5cm x 40cm = £1.57.

Vacutex
Low-adherent dressing consisting of two external polyester wound contact layers with central wicking polyester/cotton mix absorbent layer

Vacutex dressing (Pro-Tex Capillary Dressings Ltd) 10cm x 10cm = £1.66, 10cm x 15cm = £2.23, 15cm x 20cm = £2.68, 15cm x 20cm = £3.14, 20cm x 20cm = £4.28, 5cm x 5cm = £0.94.

Odour absorbent dressings
Dressings containing activated charcoal are used to absorb odour from wounds. The underlying cause of wound odour should be identified. Wound odour is most effectively reduced by debridement of slough, reduction in bacterial levels, and frequent dressing changes. Fungating wounds and chronic infected wounds produce high volumes of exudate which can reduce the effectiveness of odour absorbent dressings. Many odour absorbent dressings are intended for use in combination with other dressings; odour absorbent dressings with a suitable wound contact layer can be used as a primary dressing.

Askina Carbosorb
Activated charcoal and non-woven viscose rayon dressing

Askina Carbosorb dressing 10cm x (B.Braun Medical Ltd) 10cm = £2.88, 20cm = £3.56.

CarboFLEX
Dressing in 5 layers: wound-facing absorbent layer containing alginate and hydrocolloid; water-resistant second layer; third layer containing activated charcoal; non-woven absorbent fourth layer; water-resistant backing layer

CarboFLEX dressing (ConvaTec Ltd) 10cm x 10cm = £3.18, 15cm x 20cm = £7.23, 8cm x 15cm oval = £3.82.

Carbopod VC
Activated charcoal non-absorbent dressing

Carbopod VC dressing 10cm x (Synergy Health Plc) 10cm = £1.62, 20cm = £2.19.

CliniSorb Odour Control Dressings
Activated charcoal cloth enclosed in viscose rayon with outer polyamide coating

CliniSorb dressing 1 (CliniMed Ltd) 5cm x 10cm = £1.88, 10cm x 20cm = £2.50, 5cm x 25cm = £4.03.

Sorbasan Plus Carbon
Alginate dressing with activated carbon

Sorbasan Plus Carbon dressing (Aspen Medical Europe Ltd) 10cm x 15cm = £4.96, 10cm x 20cm = £5.94, 15cm x 20cm = £6.84, 7.5cm x 10cm = £2.56.

Antimicrobial dressings
Spreading infection at the wound site requires treatment with systemic antibacterials. For local wound infection, a topical antimicrobial dressing can be used to reduce the level of bacteria at the wound

BNF 70 Wound management products and elasticated garments 1305
surface but will not eliminate a spreading infection. Some
dressings are designed to release the antimicrobial into the
wound, others act upon the bacteria after absorption from
the wound. The amount of exudate present and the level of
infection should be taken into account when selecting an
antimicrobial dressing.
Medical grade honey below, has antimicrobial and anti-
inflammatory properties. Dressings impregnated with iodine
below, can be used to treat clinically infected wounds.
Dressings containing silver p. 1307, should be used only
when clinical signs or symptoms of infection are present.
Dressings containing other antimicrobials p. 1308 such as
polihexanide (polyhexamethylene biguanide) or
dialkylcarbamoyl chloride are available for use on infected
wounds. Although hypersensitivity is unlikely with
chlorhexidine impregnated tulle dressing, the antibacterial
efficacy of these dressings has not been established.

Honey
Medical grade honey has antimicrobial and anti-
inflammatory properties and can be used for acute or
chronic wounds. Medical grade honey has osmotic
properties, producing an environment that promotes
autolytic debridement; it can help control wound malodour.
Honey dressings should not be used on patients with
extreme sensitivity to honey, bee stings or bee products.
Patients with diabetes should be monitored for changes in
blood-glucose concentrations during treatment with topical
honey or honey-impregnated dressings. For Activon Tulle®,
where no size is stated by the prescriber the 5 cm size is to
be supplied. Medihoney® Antimicrobial Wound Gel is not
recommended for use in deep wounds or body cavities
where removal of waxes may be difficult.

Honey-based topical application
Activon Honey
Medical grade manuka honey
L-Mesitran SOFT ointment dressing
Honey (medical grade) 40%
L-Mesitran (Aspen Medical Europe Ltd) SOFT ointment dressing = £3.59
MANUKApil Honey
Medical grade manuka honey
MANUKApil (Manuka Medical Ltd) dressing = £5.90
Medihoney Antibacterial Medical Honey
Medical grade, Leptospermum sp.
Medihoney (Derma Sciences Europe, Ltd) Antibacterial Medical Honey dressing = £9.90
Medihoney Antibacterial Wound Gel
Medical grade, Leptospermum sp. 80% in natural waxes and oils
Medihoney (Derma Sciences Europe, Ltd) Antibacterial Wound Gel dressing = £4.02
Melladerm Plus Honey
Medical grade; Bulgarian, mountain flower) 45% in basis
containing polyethylene glycol
Mesitran Ointment
Honey (medical grade) 47% Excipients include lanolin
Mesitran (Aspen Medical Europe Ltd) ointment dressing = £9.90
Sheet dressing
Actilite
Knitted viscose impregnated with medical grade manuka honey and manuka oil
Actilite gauze dressing (Advancis Medical) 10cm x 10cm = £0.98, 10cm x 20cm = £1.90, 5cm x 5cm = £0.57
Activon Tulle
Knitted viscose impregnated with medical grade manuka honey
Activon Tulle gauze dressing (Advancis Medical) 10cm x 10cm = £2.97, 5cm x 5cm = £1.80

Algivon
Absorbtent, non-adherent calcium alginate dressing impregnated with medical grade manuka honey
Algivon dressing (Advancis Medical) 10cm x 10cm = £3.40, 5cm x 5cm = £1.98
Algivon Plus
Reinforced calcium alginate dressing impregnated with medical grade manuka honey
Algivon Plus (Advancis Medical) Ribbon dressing 2.5cm x 20cm = £3.36, dressing 10cm x 10cm = £3.36, 5cm x 5cm = £1.96,
L-Mesitran Border
Hydrogel, semi-permeable dressing impregnated with medical grade honey, with adhesive border
L-Mesitran (Aspen Medical Europe Ltd) Border sheet 10cm x 10cm square = £2.74
L-Mesitran Hydro
Hydrogel, semi-permeable dressing impregnated with medical grade honey, without adhesive border
L-Mesitran Hydro sheet 1 (Aspen Medical Europe Ltd) 0cm x 10cm square = £2.63, 5cm x 20cm rectangular = £5.48
L-Mesitran Net
Hydrogel, non-adherent wound contact layer, without adhesive border
L-Mesitran (Aspen Medical Europe Ltd) Net sheet 10cm x 10cm square = £2.53
Medihoney Antibacterial Honey Apinate
Non-adherent calcium alginate dressing, impregnated with medical grade honey
Medihoney Antibacterial Honey Apinate (Derma Sciences Europe, Ltd) dressing 10cm x 10cm square = £3.40, 5cm x 5cm square = £2.00, rope dressing 1.9cm x 30cm = £4.20,
Medihoney Antibacterial Honey Tulle
Woven fabric impregnated with medical grade manuka honey
Medihoney (Derma Sciences Europe, Ltd) Tulle dressing 10cm x10cm = £2.98
Medihoney Gel sheet
Sodium alginate dressing impregnated with medical grade honey
Medihoney Gel Sheet dressing (Derma Sciences Europe, Ltd) 10cm x 10cm = £4.20, 5cm x 5cm = £1.75
MelMax
Acetate wound contact layer impregnated with buckwheat honey 75% in ointment basis
MelMax dressing (CliniMed Ltd) 5cm x 6cm rectangular = £4.82, 8cm x 10cm rectangular = £9.90, 8cm x 20cm rectangular = £19.79
Melladerm Plus Tulle
Knitted viscose impregnated with medical grade honey (Bulgarian, mountain flower) 45% in a basis containing
polyethylene glycol
Melladerm (SanoMed Manufacturing BV) Plus Tulle dressing 10cm x 10cm = £2.10

Iodine
Cadeoximer–iodine, like povidone–iodine, releases free
iodine when exposed to wound exudate. The free iodine acts
as an antiseptic on the wound surface, the cadexomer
absorbs wound exudate and encourages de-sloughing.
Two-component hydrogel dressings containing glucose
oxidase and iodide ions generate a low level of free iodine in
the presence of moisture and oxygen.
Povidone–iodine fabric dressing is a knitted viscose
dressing with povidone–iodine incorporated in a
hydrophilic polyethylene glycol basis; this facilitates
diffusion of the iodine into the wound and permits removal
of the dressing by irrigation. The iodine has a wide
spectrum of antimicrobial activity but it is rapidly
deactivated by wound exudate.
Systemic absorption of iodine may occur, particularly from
large wounds or with prolonged use.
Iodoflex® and Iodosorb® are used for the treatment of chronic exuding wounds; max. single application 50 g, max. weekly application 150 g; max. duration up to 3 months in any single course of treatment. They are contra-indicated in patients receiving lithium, in thyroid disorders, in pregnancy and breast feeding, and in children; they should be used with caution in patients with severe renal impairment or history of thyroid disorder. Iodozyme® is an antimicrobial dressing used for lightly to moderately exuding wounds. It is contra-indicated in thyroid disorders and in patients receiving lithium; it should be used with caution in children and in women who are pregnant or breast-feeding. Oxozyme® is used for non-infected, dry to moderately exuding wounds. It is contra-indicated in thyroid disorders and in patients receiving lithium; it should be used with caution in children and in women who are pregnant or breast-feeding. Povidone-iodine Fabric Dressing is used as a wound contact layer for abrasions and superficial burns. It is contra-indicated in patients with severe renal impairment and in women who are pregnant or breast-feeding; it should be used with caution in patients with thyroid disease and in children under 6 months.

Iodosorb Paste
Iodine 0.9% as cadexomer–iodine in a paste basis with gauze backing

Iodosorb Ointment
Iodine 0.9% as cadexomer–iodine in an ointment basis

Iodosorb Powder
Iodine 0.9% as cadexomer–iodine microbeads, 3-g sachet

Iodozyme Hydrogel
Hydrogel (two-component dressing containing glucose oxidase and iodide ions)

Oxozyme Hydrogel
Hydrogel (two-component dressing containing glucose oxidase and iodide ions)

Povidone-iodine fabric dressing

Inadine
(Drug Tariff specification 43). Knitted viscose primary dressing impregnated with povidone–iodine ointment 10%

Silver
Antimicrobial dressings containing silver should be used only when infection is suspected as a result of clinical signs or symptoms (see also notes above). Silver ions exert an antimicrobial effect in the presence of wound exudate; the volume of wound exudate as well as the presence of infection should be considered when selecting a silver-containing dressing. Silver-impregnated dressings should not be used routinely for the management of uncomplicated ulcers. It is recommended that these dressings should not be used on acute wounds as there is some evidence to suggest they delay wound healing. Dressings impregnated with silver sulfaazidine have broad antimicrobial activity; if silver sulfaazidine is applied to large areas, or used for prolonged periods, there is a risk of blood disorders and skin discoloration (see p. 1010). The use of silver sulfaazidine-impregnated dressings is contra-indicated in neonates, in pregnancy, and in patients with significant renal or hepatic impairment, sensitivity to sulfonamides, or G6PD deficiency. Large amounts of silver sulfaazidine applied topically may interact with other drugs—see Appendix 1 (sulfonamides).

Alginate dressings

Aciticoat Absorbent
Calcium alginate dressing with a silver coated antimicrobial barrier

Aciticoat Absorbent (Smith & Nephew Healthcare Ltd) cavity dressing 2 cm x 3 cm = £12.87, dressing 10 cm x 12.5 cm rectangular = £12.79, 5 cm x 5 cm square = £5.33.

Algisite Ag
Calcium alginate dressing, with silver

Algisite Ag dressing (Smith & Nephew Healthcare Ltd) 10 cm x 10 cm = £4.12, 10 cm x 20 cm = £7.57, 2 g = £5.69, 5 cm x 5 cm = £1.65

Askina Calgitrol Ag
Calcium alginate and silver alginate dressing with polysulphone foam backing

Askina Calgitrol Ag dressing (B. Braun Medical Ltd) 10 cm x 10 cm square = £3.21, 15 cm x 15 cm square = £6.21, 20 cm x 20 cm square = £14.48

Askina Calgitrol Thin
Calcium alginate and silver alginate matrix, for use with absorptive secondary dressings

Askina Calgitrol Thin dressing (B. Braun Medical Ltd) 10 cm x 10 cm = £4.06, 15 cm x 15 cm = £9.12, 20 cm x 20 cm = £16.11, 5 cm x 5 cm square = £1.96

Melpisorb Ag
Alginate and carboxymethylcellulose dressing, with ionic silver

Melpisorb Ag (Molnlycke Health Care Ltd) Cavity dressing 3 cm x 4 cm = £4.47, dressing 10 cm x 10 cm = £3.59, 15 cm x 15 cm = £7.60, 5 cm x 5 cm = £1.79.

Silvercel
Alginate and carboxymethylcellulose dressing impregnated with silver

Silvercel dressing (Systagenix Wound Management Ltd) 10 cm x 20 cm rectangular = £7.68, 11 cm x 11 cm square = £4.14, 2.5 cm x 30.5 cm rectangular = £4.45, 5 cm x 5 cm square = £1.68

Silvercel Non-adherent
Alginate and carboxymethylcellulose dressing with film wound contact layer, impregnated with silver

Silvercel Non-Adherent (Systagenix Wound Management Ltd) cavity dressing 2.5 cm x 30.5 cm = £3.94, dressing 10 cm x 20 cm rectangular = £7.25, 11 cm x 11 cm square = £3.89, 5 cm x 5 cm square = £1.62.

Sorbsan Silver Flat
Calcium alginate fibre, highly absorbent, flat non-woven pads, with silver

Sorbsan Silver Flat dressing (Aspen Medical Europe Ltd) 10 cm x 10 cm = £3.97, 10 cm x 20 cm = £7.26, 5 cm x 5 cm = £1.57

Sorbsan Silver Plus
Calcium alginate dressing with absorbent backing, with silver

Sorbsan Silver Plus dressing (Aspen Medical Europe Ltd) 10 cm x 15 cm = £5.56, 10 cm x 20 cm = £6.77, 15 cm x 20 cm = £9.08, 7.5 cm x 10 cm = £3.35

Sorbsan Silver Plus SA
Calcium alginate dressing with absorbent backing and adhesive border, with silver

Sorbsan (Aspen Medical Europe Ltd) Silver Plus SA dressing 11.5 cm x 14 cm = £3.44

Sorbsan Silver Ribbon
With silver

Sorbsan (Aspen Medical Europe Ltd) Silver Ribbon dressing 1 g = £4.15

Sorbsan Silver Surgical Packing
With silver

Sorbsan (Aspen Medical Europe Ltd) Silver Packing dressing 2 g = £5.76

Suprasorb A + Ag
Calcium alginate dressing, with silver
Suprasorb A + Ag (Lohmann & Rauscher (UK) Ltd) dressing 10cm x 10cm = £4.07, 10cm x 20cm = £7.52, 5cm x 5cm = £1.62, rope dressing 2g = £0.02.

Tegaderm Alginate Ag
Calcium alginate and carboxymethylcellulose dressing, with silver
Tegaderm Alginate Ag dressing (3M Health Care Ltd) 10cm x 10cm = £1.24, 3cm x 30cm = £3.70, 5cm x 5cm = £1.39

Urgosorb Silver
Alginate and carboxymethylcellulose dressing, impregnated with silver
Urgosorb Silver (Urgo Ltd) Rope dressing 2.5cm x 30cm = £3.65, dressing 10cm x 10cm = £3.63, 10cm x 20cm = £6.85, 5cm x 5cm = £1.52.

Foam dressings

Acticoat Moisture Control
Three-layer polyurethane dressing consisting of a silver coated layer, a foam layer, and a waterproof layer
Acticoat Moisture Control dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £16.70, 10cm x 20cm rectangular = £22.55, 5cm x 5cm square = £7.14.

Allevyn Ag
Silver sulfadiazine impregnated polyurethane foam film dressing with or without adhesive border
Allevyn Ag (Smith & Nephew Healthcare Ltd) Adhesive dressing 10cm x 10cm square = £5.45, 12.5cm x 12.5cm square = £7.16, 17.5cm x 17.5cm square = £13.77, 17cm x 17cm sacral = £10.75, 22cm x 22cm sacral = £14.40, 7.5cm x 7.5cm square = £3.46, Heel Non-Adhesive dressing 10.5cm x 13.5cm = £10.66, Non-Adhesive dressing 10cm x 10cm square = £6.08, 15cm x 15cm square = £11.53, 20cm x 20cm square = £16.88, 5cm x 5cm square = £3.23.

Blatain Ag
Silver impregnated polyurethane foam film dressing, with or without adhesive border
Blatain Ag (Coloplast Ltd) cavity dressing 5cm x 8cm = £4.01, dressing 10cm x 10cm square = £8.04, 10cm x 20cm rectangular = £14.78, 12.5cm x 12.5cm square = £9.20, 15cm x 15cm square = £16.14, 18cm x 18cm square = £18.45, 19cm x 20cm heel = £18.20, 20cm x 20cm square = £22.76, 22cm x 22cm sacral = £19.34, 5cm x 7cm rectangular = £3.30.

PolyMem Silver
Silver impregnated polyurethane foam film dressing, with or without adhesive border
PolyMem Silver (Aspen Medical Europe Ltd) WIC dressing 8cm x 8cm = £7.05, dressing 10.8cm x 10.8cm oval = £8.06, 12.7cm x 8.8cm oval = £5.60, 17cm x 19cm rectangular = £17.76, 5cm x 7cm oval = £2.27.

UrgeCell Silver
Non-adherent, polyurethane foam film dressing with silver in wound contact layer
UrgeCell Silver dressing (Urgo Ltd) 10cm x 10cm = £5.86, 15cm x 20cm = £10.74, 6cm x 6cm = £4.26.

Hydrocolloid dressings

Aquadel Ag
Soft non-woven pad containing hydrocolloid fibres, (silver impregnated),
Aquadel Ag (Convatec Ltd) Ribbon dressing 1cm x 45cm = £3.08, 2cm x 45cm = £4.71, dressing 10cm x 10cm square = £4.69, 15cm x 15cm square = £8.82, 20cm x 30cm rectangular = £21.89, 4cm x 10cm rectangular = £2.85, 4cm x 20cm rectangular = £3.72, 4cm x 30cm rectangular = £5.57.

Physiostulle Ag
Non-adherent polyester fabric with hydrocolloid and silver sulfadiazine
Physiostulle (Coloplast Ltd) dressing 10cm x 10cm = £2.25

Low-adherence dressings

Acticoat
Three-layer antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 3-day wear)

Acticoat dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £8.52, 10cm x 20cm rectangular = £13.33, 20cm x 40cm rectangular = £45.60, 5cm x 5cm square = £3.49.

Acticoat
Five-layer antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh for 7-day wear

Acticoat dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £8.56, 10cm x 20cm rectangular = £13.37, 20cm x 40cm rectangular = £45.77, 5cm x 5cm square = £3.50.

Acticoat Flex
Conformable antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 3-day wear)

Acticoat Flex dressing (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £8.56, 10cm x 20cm rectangular = £13.37, 20cm x 40cm rectangular = £45.77, 5cm x 5cm square = £3.50.

Atrauman Ag
Non-adherent polyamide fabric impregnated with silver and neutral triglycerides
Atrauman Ag dressing (Paul Hartmann Ltd) 10cm x 10cm = £1.25, 10cm x 20cm = £2.45, 5cm x 5cm = £0.51.

Soft polymer dressings

Allevyn Ag Gentle
Soft polymer wound contact dressing, with silver sulfadiazine impregnated polyurethane foam layer, with or without adhesive border
Allevyn Ag Gentle (Smith & Nephew Healthcare Ltd) Border dressing 10cm x 10cm = £6.33, 12.5cm x 12.5cm = £8.14, 17.5cm x 17.5cm = £15.51, 7.5cm x 7.5cm = £4.21, dressing 10cm x 10cm = £6.15, 10cm x 20cm = £10.16, 15cm x 15cm = £11.44, 20cm x 20cm = £16.94, 5cm x 5cm = £3.39.

Mepilex Ag
Soft silicone wound contact dressing with polyurethane foam film backing, with silver, with or without adhesive border
Mepilex (Molnlycke Health Care Ltd) Ag dressing 10cm x 10cm = £6.12, 10cm x 20cm = £10.09, 15cm x 15cm = £11.36, 20cm x 20cm = £16.94, 20cm x 50cm = £63.20, Border Ag dressing 10cm x 12.5cm = £6.16, 10cm x 20cm = £8.97, 10cm x 30cm = £13.46, 15cm x 17.5cm = £11.31, 17cm x 20cm = £14.66, 7cm x 7cm = £3.41, Border Sacrum Ag dressing 18cm x 18cm = £11.83, 20cm x 20cm = £14.38, 23cm x 23cm = £18.89, Heel Ag dressing 13cm x 20cm = £12.78, 15cm x 22cm = £14.32.

Urgotol 550
Non-adherent, soft polymer wound contact dressing, with silver sulfadiazine

Urgotol Silver
Non-adherent soft polymer wound contact dressing, with silver
Urgotol Silver dressing 1 (Urgo Ltd) 5cm x 12cm = £3.53, 5cm x 20cm = £9.61.

With charcoal

Actisorb Silver 220
Knitted fabric of activated charcoal, with one-way stretch, with silver residues, within spun-bonded nylon sleeve
Actisorb Silver 220 dressing (Syntagenix Wound Management Ltd) 10.5cm x 10.5cm = £2.58, 10.5cm x 19cm = £4.70, 6.5cm x 9.5cm = £1.64.

Other antimicrobials

Cuthmed Siltex Sorbate
Polyurethane foam dressing with acetate fabric coated with diallylcarbamoyl chloride, with adhesive border
Cutimed Siltec Sorbact dressing (BSN medical ltd) 12.5cm x 12.5cm = £6.38, 15cm x 15cm = £7.91, 17.5cm x 17.5cm = £11.06, 22.5cm x 22.5cm = £16.83, 7.5cm x 7.5cm = £2.49, 17.5cm x 17.5cm sacral = £8.00, 23cm x 23cm sacral = £12.02.

Cutimed Sorbact
Low adherence acetate tissue impregnated with dialkylcarbamoyl chloride; dressign pad, swabs, round swabs or ribbon gauze, cotton
Cutimed Sorbact (BSN medical ltd) Ribbon dressing 2cm x 50cm = £4.00, 5cm x 200cm = £7.87. Round swab 3cm = £3.27, dressing pad 10cm x 10cm = £5.45, 10cm x 20cm = £8.49, 7cm x 9cm = £3.49, swab 4cm x 6cm = £1.63, 7cm x 9cm = £2.72.

Cutimed Sorbact Gel
Hydrogel dressing impregnated with dialkylcarbamoyl chloride
Cutimed Sorbact Gel dressing 7.5cm x (BSN medical ltd) 15cm rectangular = £4.42, 7.5cm square = £2.63.

Cutimed Sorbact Hydroactive
Non-adhesive gel dressing with hydropolymer matrix and acetate fabric coated with dialkylcarbamoyl chloride.
Cutimed Sorbact Hydroactive dressing (BSN medical ltd) 14cm x 14cm = £5.31, 14cm x 24cm = £8.52, 19cm x 19cm = £10.01, 24cm x 24cm = £15.17, 7cm x 8.5cm = £3.74.

Cutimed Sorbact Hydroactive B
Gel dressing with hydropolymer matrix and acetate fabric coated with dialkylcarbamoyl chloride, with adhesive border
Cutimed Sorbact Hydroactive B dressing (BSN medical ltd) 10cm x 10cm = £7.02, 20cm x 20cm = £11.24, 15cm x 15cm = £13.21, 20cm x 20cm = £20.02, 5cm x 6.5cm = £3.94.

Flaminal Forte Gel
Alginate with glucose oxidase and lactoperoxidase, for moderately to heavily exuding wounds
Flaminal Hydro gel
Alginate with glucose oxidase and lactoperoxidase, for lightly to moderately exuding wounds

Kendall AMD
Foam dressing with polyhexamidine, without adhesive border
Kendall AMD Antimicrobial foam dressing (Aria Medical ltd) 10cm x 10cm square = £4.71, 10cm x 20cm rectangular = £8.92, 15cm x 15cm square = £8.92, 20cm x 20cm square = £13.07, 5cm x 5cm square = £2.59, 8.8cm x 7.5cm rectangular (fenestrated) = £4.23.

Kendall AMD Plus
Foam dressing with polyhexamidine, without adhesive border
Kendall AMD Antimicrobial Plus foam dressing (Aria Medical ltd) 10cm x 10cm square = £4.94, 8.8cm x 7.5cm rectangular (fenestrated) = £4.43.

Octenilin Wound gel
Wound gel, hydroxyethylcellulose and propylene glycol, with octenidine hydrochloride

Promotan Wound Gel
Wound gel, containing betaine surfactant and polyhexamidine

Suprasorb X + PHMB
Biosynthetic cellulose fibre dressing with polyhexamidine
Suprasorb X + PHMB dressing (Lohmann & Rauscher (UK) Ltd) 14cm x 20cm rectangular = £11.53, 2cm x 21cm rope = £7.18, 5cm x 5cm square = £2.59, 8cm x 8cm rectangular (fenestrated) = £5.07.

Telfa AMD
Low adherence absorbent perforated plastic film faced dressing with polyhexamidine
Telfa AMD dressing (Aria Medical ltd) 10cm x 7.5cm = £0.18, 20cm x 7.5cm = £0.28.

Telfa AMD Island
Low adherence dressing with adhesive border and absorbent pad, with polyhexamidine
Telfa AMD Island dressing 10cm x (Aria Medical ltd) 12.5cm = £0.59, 20cm = £0.86, 25.5cm = £0.98, 35cm = £1.22.

Chlorhexidine gauze dressing
Bactigras
Fabric of leno weave, wool and warp threads of cotton and/or viscose yarn, impregnated with ointment containing chlorhexidine acetate
Bactigras gauze dressing (Smith & Nephew Healthcare ltd) 5cm x 5cm = 28p, 10cm x 10cm = 58p.

Irrigation fluids
Octenilin Wound irrigation solution
Aqueous solution containing glycerol, ethylhexyglycerin and octenidine hydrochloride

Prontosan Wound Irrigation Solution
Aqueous solution containing betaine surfactant and polyhexamidine

Specialised dressings
Protease-modulating matrix dressings
Cadesorb Ointment
Cadesorb (Smith & Nephew Healthcare ltd) ointment = £9.18.

Catrix
Catrix dressing (Cranage Healthcare ltd) sachets = £3.80.

Promogran
Collagen and oxidised regenerated cellulose matrix, applied directly to wound and covered with suitable dressing
Promogran dressing (Systagenix Wound Management ltd) 123 square cm = £15.62, 28 square cm = £5.19.

Promogran Prisma Matrix
Collagen, silver and oxidised regenerated cellulose matrix, applied directly to wound and covered with suitable dressing
Promogran Prisma dressing (Systagenix Wound Management ltd) 123 square cm = £17.98, 28 square cm = £6.31.

Tegaderm Matrix
Cellulose acetate matrix, impregnated with polyhydrated ionogens ointment in polyethylene glycol basis

UrgoStart
Soft adherent polymer matrix containing nano-oigosaccharide factor (NOSF), with polyurethane foam film backing
UrgoStart dressing (Urgo ltd) 10cm x 10cm = £6.07, 15cm x 20cm = £10.92, 6cm x 6cm = £4.39, 12cm x 19cm heel = £8.36.

UrgoStart Contact
Non-adherent soft polymer wound contact dressing containing nano-oigosaccharide factor (NOSF)
UrgoStart (Urgo ltd) Contact dressing 5cm x 7cm = £2.96.

Silicone keloid dressings
Silicone gel and gel sheets are used to reduce or prevent hypertrophic and keloid scarring. They should not be used on open wounds. Application times should be increased gradually. Silicone sheets can be washed and reused.

Silicone gel
Bapscarcare
Silicone gel
Bapscarcare (BAP Medical Ltd) gel = £17.00.

Ciltech
Silicone gel
Ciltech (Su-Med International (UK) Ltd) gel = £50.00.

Dermafix
Silicone gel
Dermafix gel (Meda Pharmaceuticals Ltd) = £60.53.

Kelo-cote UV
Silicone gel with SPF 30 UV protection
Kelo-cote (Sinclair IS Pharma Plc) UV gel = £17.88.

Kelo-cote gel
Silicone gel
Wound management

Kelo-cote (Sinclair IS Pharma Plc) gel = £51.00
Kelo-cote spray
Silicone spray
Kelo-cote (Sinclair IS Pharma Plc) spray = £51.00
NewGel®E
Silicone gel with vitamin E
NewGel®E (Advancell Surgical Ltd) gel = £17.70
Scarsil
Silicone gel
Scarsil (Jobskin Ltd) gel = £15.19
Siligel STC-SE
Silicone gel
Siligel (Nagor Ltd) STC-SE gel = £19.00
Silicone sheets
Advasil Conform
Self-adhesive silicone gel sheet with polyurethane film backing
Advasil Conform sheet (Advancell Medical) 10cm x 10cm square = £5.20, 5cm x 10cm rectangular = £9.17
Bapscarcare T
Self-adhesive silicone gel sheet
Bapscarcare T sheet (BAP Medical UK Ltd) 10cm x 15cm rectangular = £9.00, 5cm x 30cm rectangular = £9.00, 5cm x 7cm rectangular = £3.15
Cica-Care
Soft, self-adhesive, semi-occlusive silicone gel sheet with backing
Cica-Care sheet (Smith & Nephew Healthcare Ltd) 15cm x 12cm rectangular = £28.40, 6cm x 12cm rectangular = £14.57
Ciltech
Silicone gel sheet
Ciltech sheet 1 (Su-Med International (UK) Ltd) 10cm x 10cm square = £7.50, 0cm x 20cm rectangular = £12.50, 5cm x 15cm square = £14.00
DermaTec
Self-adhesive silicone gel sheet (clear- or fabric-backed)
DermaTec (Meda Pharmaceuticals Ltd) Clear sheet 13cm x 13cm square = £15.79, 13cm x 25cm rectangular = £28.53, 20cm x 30cm rectangular = £51.97, 4cm x 13cm rectangular = £8.68. Fabric sheet 13cm x 13cm square = £15.79, 13cm x 25cm rectangular = £28.53, 20cm x 30cm rectangular = £51.97, 4cm x 13cm rectangular = £6.68,
Mepiform
Self-adhesive silicone gel sheet with polyurethane film backing
Mepiform sheet (Molnlycke Health Care Ltd) 4cm x 31cm rectangular = £10.80, 5cm x 7cm rectangular = £3.42, 9cm x 18cm rectangular = £13.37
Scar FX
Self-adhesive, transparent, silicone gel sheet
Scar FX sheet (Jobskin Ltd) 10cm x 20cm rectangular = £16.00, 22.5cm x 14.5cm shaped = £12.00, 25.5cm x 30.5cm rectangular = £60.00, 3.75cm x 22.5cm rectangular = £12.00, 7.5cm diameter shaped = £8.50
Siligel
Silicone gel sheet
Siligel (Nagor Ltd) 10cm x 10cm square = £13.50, 10cm x 30cm rectangular = £31.50, 10cm x 5cm rectangular = £7.50, 15cm x 10cm rectangular = £19.50, 20cm x 20cm square = £40.00, 25cm x 15cm shaped = £21.12, 30cm x 5cm rectangular = £19.50, 40cm x 40cm square = £144.00, 46cm x 8.5cm shaped = £39.46, 5.5cm diameter shaped = £4.00

Adjunct dressings and appliances

Surgical absorbents
Surgical absorbents applied directly to the wound have many disadvantages—dehydration of and adherence to the wound, shedding of fibres, and the leakage of exudate (‘strike through’) with an associated risk of infection. Gauche and cotton absorbent dressings can be used as secondary layers in the management of heavily exuding wounds (but see also Capillary-action dressings, p. 1305). Absorbent cotton gauze fabric can be used for swabbing and cleaning skin. Ribbon gauze can be used post-operatively to pack wound cavities, but adherence to the wound bed will cause bleeding and tissue damage on removal of the dressing—an advanced wound dressing (e.g. hydrocolloid-fibrous p. 1301, foam p. 1302, or alginate p. 1304) layered into the cavity is often more suitable.

Cotton
Absorbent Cotton, BP
Carded cotton fibres of not less than 10 mm average staple length, available in rolls and balls
Absorbent (Robert Bailey & Son Plc) cotton BP 1988
Absorbent Cotton, Hospital Quality
As for absorbent cotton but lower quality materials, shorter staple length etc.
Absorbent (Robert Bailey & Son Plc) cotton hospital quality
Gauze and cotton tissue
Ganggee Tissue (blue)
Consists of absorbent cotton enclosed in absorbent cotton gauze type 2 or absorbent cotton and viscose gauze type 2
Ganggee (Robinson Healthcare) tissue blue label
Ganggee Tissue (pink)
Consists of absorbent cotton enclosed in absorbent cotton gauze type 2 or absorbent cotton and viscose gauze type 2
Ganggee (Robinson Healthcare) tissue pink label DT
Gauze and tissue
Absorbent Cotton Gauze, BP 1988
Cotton fabric of plain weave, in rolls and as swabs (see below), usually Type 13 light, sterile
Absorbent (Robert Bailey & Son Plc) cotton BP 1988
Alvita (Alliance Healthcare (Distribution) Ltd) absorbent cotton BP 1988
Clini (Clinisupplies Ltd) absorbent cotton BP 1988
Vermaid (Synergy Health Plc) absorbent cotton BP 1988
Absorbent Cotton and Viscose Ribbon Gauze, BP 1988
Woven fabric in ribbon form with fast selvedge edges, warp threads of cotton, weft threads of viscose or combined cotton and viscose yarn, sterile
Vermaid Fast Edge ribbon gauze sterile (Synergy Health Plc) 1.25cm, 2.5cm
Lint
Absorbent Lint, BPC
Cotton cloth of plain weave with nap raised on one side from warp yarns
Absorbent (Robinson Healthcare) lint
Alvita (Alliance Healthcare (Distribution) Ltd) absorbent lint BPC
Clini (Clinisupplies Ltd) absorbent lint BPC

Pads
Drisorb
Absorbent Dressing Pads, Sterile
Drisorb (Synergy Health Plc) dressing pad 10cm x 20cm = £0.17
PremierPad
Absorbent Dressing Pads, Sterile
PremierPad dressing pad (Shermond) 10cm x 20cm = £0.18, 20cm x 20cm = £0.25
XuPad
Absorbent Dressing Pads, Sterile
Xu pad dressing pad (Richardson Healthcare Ltd) 10cm x 20cm = £0.17, 20cm x 20cm = £0.28, 20cm x 40cm = £0.40

Wound drainage pouches
Wound drainage pouches can be used in the management of wounds and fistulas with significant levels of exudate.
Biotrol Draina S
Wound drainage pouch
Biotrol Draina S wound drainage bag (B.Braun Medical Ltd) large (Transparent) = £94.55, medium (Transparent) = £76.86, mini (Transparent) = £77.11
Wound management products and elasticated garments

Biotrol Draina S Vision
Wound drainage pouch
Draina S Vision (B.Braun Medical Ltd) 100 wound drainage bag = £123.38, 50 wound drainage bag = £100.66, 75 wound drainage bag = £106.34

Eakin Access window
For use with Eakin pouches
Eakin (Pelican Healthcare Ltd) access window = £37.39

Eakin Wound pouch, bung closure
Wound pouch, bung closure
Eakin wound drainage bag with bung closure (Pelican Healthcare Ltd), large = £160.48, medium = £147.78, small = £133.41, and access window for horizontal wounds, extra large = £101.48, for horizontal wounds, extra large = £90.80, for vertical incision wounds, extra large = £90.80, wounds, extra large = £90.80

Option Wound Manager
Wound pouch, fold and tuck closure
Eakin wound drainage bag with fold and tuck closure, (Pelican Healthcare Ltd) large = £80.70, medium = £69.44, small = £46.07, extra large = £80.12

Option Wound Manager bag
Option wound drainage bag, with access port
Option wound manager bag (Oakeled Ltd) large = £158.71, medium = £133.16, small = £130.26, square = £138.95, extra small = £131.12

Option Wound Manager with access port
Wound drainage bag, with access port
Option wound manager bag with access port, (Oakeled Ltd) large = £169.65, medium = £138.95, small = £136.05, square = £144.74, extra small = £128.06

Option Wound Manager, cut to fit
Wound drainage bag, cut to fit
Option wound manager bag (Oakeled Ltd) large = £83.44, medium = £79.66, small = £71.91

Welland Fistula bag
Wound drainage bag, cut-to-fit
Welland (Welland Medical Ltd) Fistula wound drainage bag = £81.29

Physical debridement pads
Debrisoft® is a pad that is used for the debridement of superficial wounds containing loose slough and debris, and for the removal of hyperkeratosis from the skin. Debrisoft® must be fully moistened with a wound cleansing solution before use and is not appropriate for use as a wound dressing.

Debrisoft Pad
Polyester fibres with bound edges and knitted outer surface coated with polyacrylate
Debrisoft (Activa Healthcare Ltd) pad 10cm x 10cm = £6.39

Complex adjunct therapies
Topical negative pressure therapy
Accessories
Renasys
Soft port and connector
Renasys (Smith & Nephew Healthcare Ltd) Soft Port = £11.11, connector for use with soft port = £3.24

V.A.C.
Drape, gel for canister, Sensa T.R.A.C. Pad
SensaT.R.A.C. (KCI Medical Ltd) pad = £10.95
T.R.A.C. (KCI Medical Ltd) connector = £3.13
V.A.C. (KCI Medical Ltd) drape = £9.39, gel strips = £3.76

Venturi
Gel patches, adhesive, and connector
Venturi (Talley Group Ltd) adhesive gel patch = £15.00, connector = £15.00

WoundASSIST gel strip
WoundASSIST (Huntleigh Healthcare Ltd) TNP gel strip = £3.37

Vacuum assisted closure products
Exsu-Fast kit 1
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 1 = £28.04
Exsu-Fast kit 2
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 2 = £35.83
Exsu-Fast kit 3
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 3 = £35.83
Exsu-Fast kit 4
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 4 = £28.04

V.A.C GranuFoam
Polyurethane foam dressing (with adhesive drapes and pad connector); with or without silver
V.A.C. GranuFoam (KCI Medical Ltd) Bridge dressing kit = £32.04
Silver with SensaT.R.A.C dressing kit medium = £36.04, small = £32.76, dressing kit large = £31.70, medium = £27.32, small = £22.95

V.A.C Simplace
Spiral-cut polyurethane foam dressings, vapour-permeable adhesive film dressings (with adhesive drapes and pad connector)
V.A.C. Simplace EX dressing kit (KCI Medical Ltd) medium = £30.58, small = £26.60

V.A.C WhiteFoam
Polyvinyl alcohol foam dressing or dressing kit
V.A.C. WhiteFoam dressing (KCI Medical Ltd) large = £17.04, small = £10.64, kit large = £33.54, small = £25.91

Venturi
Wound sealing kit, flat drain; with or without channel drain
Venturi wound sealing kit with (Talley Group Ltd) channel drain = £15.00, flat drain, large = £17.50, standard = £15.00

WoundASSIST
Wound pack and channel drain
WoundASSIST TNP dressing pack (Huntleigh Healthcare Ltd) medium/large = £23.85, small/medium = £20.81, channel drain medium/large = £23.85, small/medium = £20.81, extra large = £34.05

Wound drainage collection devices
ActiV.A.C.
Canister with gel
ActiV.A.C. (KCI Medical Ltd) canister with gel = £28.42

S-Canister
Canister kit
S-Canister (Smith & Nephew Healthcare Ltd) kit = £19.00

V.A.C Freedom
Canister with gel
V.A.C. (KCI Medical Ltd) Freedom Canister with gel = £28.85

Venturi
Canister kit with solidifier
Venturi (Talley Group Ltd) Compact canister kit = £12.50, canister kit = £12.50

WoundASSIST wound pack
Canister
WoundASSIST (Huntleigh Healthcare Ltd) TNP canister = £20.30

Wound care accessories
Dressing packs
The role of dressing packs is very limited. They are used to provide a clean or sterile working surface; some packs shown below include cotton wool balls, which are not recommended for use on wounds.

Multiple Pack Dressing No. 1
Contains absorbent cotton, absorbent cotton gauze type 13 light (sterile), open-wove bandages (banded)
Vernaid (Synergy Health Plc) multiple pack dressing
Non-drug tariff specification sterile dressing packs

Dressit
Vitrex gloves, large apron, disposable bag, paper towel, soft swabs, adsorbent pad, sterile field
Dressit sterile dressing pack with (Richardson Healthcare Ltd)
medium/large gloves = £0.60, small/medium gloves = £0.60
Nurse It
Contains latex-free, powder-free nitrile gloves, sterile
laminated paper sheet, large apron, non-sterile swabs,
paper towel, disposable bag, compartmented tray,
disposable forceps, paper measuring tape
Nurse It sterile dressing pack with (Medicareplus International Ltd)
medium/large gloves = £0.54, small/medium gloves = £0.54
Polyfield Nitrile Patient Pack
Contains powder-free nitrile gloves, laminate sheet, non-woven
swabs, towel, polythene disposable bag, apron
Polyfield Nitrile Patient Pack with (Shermond) large gloves = £0.52,
medium gloves = £0.52, small gloves = £0.52
Sterile Dressing Pack with Non-Woven Pads
Vernaid
(Drug Tariff specification 35). Contains non-woven fabric
covered dressing pad, non-woven fabric swabs, absorbent
cotton wool balls, absorbent paper towel, water repellent
inner wrapper
Vernaid (Synergy Health Plc) sterile dressing pack with non-woven
pads
Sterile dressing packs
Vernaid
(Drug Tariff specification 10). Contains gauze and cotton
tissue pad, gauze swabs, absorbent cotton wool balls,
absorbent paper towel, water repellent inner wrapper
Vernaid (Synergy Health Plc) sterile dressing pack
Woven and fabric swabs
Gauze Swab, PB 1988
Consists of absorbent cotton gauze type 13 light or absorbent
cotton and viscose gauze type 1 folded into
squares or rectangles of 8-ply with no cut edges exposed,
sterile or non-sterile
Alvita gauze swab 8ply (Alliance Healthcare (Distribution) Ltd) non-
sterile 10cm x 10cm, sterile 7.5cm x 7.5cm
CS (Clinisupplies Ltd) gauze swab 8ply non-sterile 10cm x 10cm
Clini gauze swab 8ply (Clinisupplies Ltd) non-sterile 10cm x 10cm,
sterile 7.5cm x 7.5cm
Gauze (Robert Bailey & Son Plc) swab 8ply non-sterile 10cm x 10cm
MeCobo gauze swab 8ply (MeCobo Ltd) non-sterile 10cm x 10cm,
sterile 7.5cm x 7.5cm
Propax gauze (BSN medical Ltd) swab 8ply sterile 7.5cm x 7.5cm
Sovereign (Waymade Healthcare Plc) gauze swab sterile 7.5cm x
7.5cm
Steraid (Robert Bailey & Son Plc) gauze swab 8ply sterile 7.5cm x
7.5cm
Vernaid gauze swab 8ply (Synergy Health Plc) non-sterile 10cm x
10cm, sterile 7.5cm x 7.5cm
Non-woven Fabric Swab
(Drug Tariff specification 28). Consists of non-woven fabric
folded 4-ply; alternative to gauze swabs, type 13 light,
sterile or non-sterile
CS (Clinisupplies Ltd) non-woven fabric swab 4ply non-sterile
10cm x 10cm
Clini non-woven fabric swab 4ply (Clinisupplies Ltd) non-sterile
10cm x 10cm, sterile 7.5cm x 7.5cm
CliniMed (CliniMed Ltd) non-woven fabric swab 4ply non-sterile
10cm x 10cm
MeCobo (MeCobo Ltd) non-woven fabric swab 4ply non-sterile
10cm x 10cm
Multisorb (BSN medical Ltd) non-woven fabric swab 4ply sterile
7.5cm x 7.5cm
SofoSorb non-woven fabric swab 4ply (Synergy Health Plc) non-
sterile 10cm x 10cm, sterile 7.5cm x 7.5cm
SoftSwab non-woven fabric swab 4ply (Richardson Healthcare Ltd)
non-sterile 10cm x 10cm, sterile 7.5cm x 7.5cm
Topper 8 non-woven fabric swab 4ply (Sytagenix Wound Management
Ltd) non-sterile 10cm x 10cm, sterile 7.5cm x 7.5cm
Filamented gauze swabs
Cofil
As for Gauze Swab, but with thin layer of Absorbent Cotton
enclosed within, non-sterile
Cofil (Synergy Health Plc) filamented gauze swab 8ply non-sterile
10cm x 10cm
Filamented non-woven Fabric Swab
Regal
(Drug Tariff specification 29). Film of viscose fibres enclosed
within non-sterile viscose fabric folded 8-ply, non-sterile
Regal (Sytagenix Wound Management Ltd) filamented swab 8ply 10cm
x 10cm
Surgical adhesive tapes
Adhesive tapes are useful for retaining dressings on joints
or awkward body parts. These tapes, particularly those
containing rubber, can cause irritant and allergic reactions
in susceptible patients; synthetic adhesives have been
developed to overcome this problem, but they, too, may
sometimes be associated with reactions. Synthetic adhesive,
or silicon adhesive, tapes can be used for patients with skin
reactions to plasters and strapping containing rubber, or
undergoing prolonged treatment. Adhesive tapes that are
occlusive may cause skin maceration. Care is needed not to apply these tapes under
tension, to avoid creating a touriquet effect. If applied over
joints they need to be orientated so that the area of
maximum extensibility of the fabric is in the direction of
movement of the limb.
Occlusive adhesive tapes
Blenderm
(Impermeable Plastic Adhesive Tape, BP 1988). Extensible
water-impermeable plastic film spread with a
polymeric adhesive mass
Blenderm tape (3M Health Care Ltd) 2.5cm = £1.77, 5cm = £3.37
Sleek
(Impermeable Plastic Adhesive Tape, BP 1988). Extensible
water-impermeable plastic film spread with an adhesive
mass
Leukoplast Sleek tape (BSN medical Ltd) 2.5cm, 5cm, 7.5cm
Permeable adhesive tapes
3M Kid Removal Silicone Tape
Soft silicone, water-resistant, knitted fabric, polyurethane
film adhesive tape
3M Kid removal tape (3M Health Care Ltd) 2.5cm = £3.58, 5cm =
£6.48
Chemifix
(Permeable, Apertured Non-Woven Synthetic Adhesive
Tape, BP 1988). Non-woven fabric with a polyacrylate
adhesive
Chemifix tape (Medicareplus International Ltd) 10cm = £2.10, 2.5cm =
£0.90, 5cm = £1.40
Chemipore
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988).
Backed of paper-based or non-woven textile material
spread with a polymeric adhesive mass
Chemipore tape (Medicareplus International Ltd) 1.25cm = £0.27,
2.5cm = £0.70, 5cm = £0.95
Clinipore
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988).
Backed of paper-based or non-woven textile material
spread with a polymeric adhesive mass
Clinipore tape (Clinisupplies Ltd) 1.25cm = £0.35, 2.5cm = £0.73, 5cm =
£0.99
Elastoplast
(Elastic Adhesive Tape, BP 1988). Woven fabric, elastic in
warp (crepe-twisted cotton threads), weft of cotton and/or
viscose threads, spread with adhesive mass containing zinc
oxide
Tensoplast (BSN medical Ltd) elastic adhesive tape 2.5cm

Hypafix tape (BSN medical Ltd) 10cm = £4.63, 15cm = £6.86, 2.5cm = £1.67, 5cm = £9.10, 30cm = £13.15, 5cm = £2.65

Insil
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape

Insil tape (Insight Medical Products Ltd) 2cm = £5.77, 4cm = £5.77

Leukofix
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass

Leukofix tape (BSN medical Ltd) 1.25cm = £0.55, 2.5cm = £0.89, 5cm = £1.55

Leukopor
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass

Leukopor tape (BSN medical Ltd) 1.25cm = £0.49, 2.5cm = £0.76, 5cm = £1.34

Mediplast
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass

Mediplast tape (Neomedic Ltd) 1.25cm = £0.30, 2.5cm = £0.50

Mediplast
Fabric, plain weave, warp and weft of cotton and/or viscose, spread with an adhesive containing zinc oxide

Mediplast Zinc Oxide plaster (Neomedic Ltd) 1.25cm = £0.82, 2.5cm = £1.19, 5cm = £1.99, 7.5cm = £2.99

Mefix

Mefix tape (Molnlycke Health Care Ltd) 10cm = £2.89, 15cm = £3.94, 2.5cm = £1.02, 20cm = £5.04, 30cm = £7.24, 5cm = £1.81

Mepitac
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape

Mepitac tape (Molnlycke Health Care Ltd) 2cm = £0.93, 4cm = £6.93

Micropore
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass

Micropore tape (3M Health Care Ltd) 1.25cm = £0.62, 2.5cm = £0.92, 5cm = £1.62

Omnifix

Omnifix tape (Paul Hartmann Ltd) 10cm = £4.04, 15cm = £5.97, 5cm = £2.40

OpSite Flexifix Gentle
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape

OpSite Flexifix Gentle tape (Smith & Nephew Healthcare Ltd) 2.5cm = £10.20, 5cm = £19.13

Primafix

Primafix tape (Smith & Nephew Healthcare Ltd) 10cm = £2.32, 15cm = £3.43, 20cm = £4.22, 5cm = £1.58

Scanpor
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass

Scanpor tape (Bio-Diagnositci Ltd) 1.25cm = £0.55, 2.5cm = £0.92, 5cm = £1.75, 7.5cm = £2.56

Siltape
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape

Siltape (Advanics Medical) 2cm = £5.60, 4cm = £5.60

Strappal
Fabric, plain weave, warp and weft of cotton and/or viscose, spread with an adhesive containing zinc oxide

Strappal adhesive tape (BSN medical Ltd) 2.5cm = £1.37, 5cm = £2.32, 7.5cm = £3.49

Transpore
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass

Transpore tape (3M Health Care Ltd) 1.25cm = £0.52, 2.5cm = £0.84, 5cm = £1.48

Zinc Oxide Adhesive Tape, BP 1988
Fabric, plain weave, warp and weft of cotton and/or viscose, spread with an adhesive containing zinc oxide

Fast Aid zinc oxide adhesive tape (Robinson Healthcare) 1.25cm, 2.5cm, 5cm, 7.5cm

Skin closure dressings
Skin closure strips are used as an alternative to sutures for minor cuts and lacerations. Skin tissue adhesive can be used for closure of minor skin wounds and for additional suture support.

Skin closure strips, sterile

Leukostrip
Drug Tariff specifies that these are specifically for personal administration by the prescriber

Leukostrip (Smith & Nephew Healthcare Ltd) skin closure strips 6.4mm x 76mm = £6.28

Omnistrip
Drug Tariff specifies that these are specifically for personal administration by the prescriber

Omnistrip (Paul Hartmann Ltd) skin closure strips sterile 6mm x 76mm = £24.11

Steri-strip
Drug Tariff specifies that these are specifically for personal administration by the prescriber

Steri-strip (3M Health Care Ltd) skin closure strips 6mm x 75mm = £8.77

Bandages

Non-extensible bandages
Skin closure strips are used as an alternative to sutures for minor cuts and lacerations. Skin tissue adhesive can be used for closure of minor skin wounds and for additional suture support.

Open-wound Bandage, Type 1 BP 1988
Cotton cloth, plain weave, warp of cotton, weft of cotton, viscose, or combination, one continuous length

Clni open wave bandage Type 1 BP 1988 (CliniSupplies Ltd) 10cm x 5m, 2.5cm x 5m, 5cm x 5m, 7.5cm x 5m

Vernaid white open wave bandage (Synergy Health Plc) 10cm x 5m, 2.5cm x 5m, 5cm x 5m, 7.5cm x 5m

White open wave bandage (Robert Bailey & Son Plc) 10cm x 5m, 2.5cm x 5m, 5cm x 5m, 7.5cm x 5m

Triangular Calico Bandage, BP 1980
Unbleached calico right-angled triangle

Clni (CliniSupplies Ltd) triangular calico bandage BP 1980 90cm x 127cm

Triangular (BSN medical Ltd) calico bandage 90cm x 127cm

Light-weight conforming bandages
Lightweight conforming bandages are used for dressing retention, with the aim of keeping the dressing close to the wound without inhibiting movement or restricting blood flow. The elasticity of conforming-stretch bandages (also termed contour bandages) is greater than that of cotton conforming bandages.
Acti-Wrap
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Acti-Wrap (cohesive/latex free) bandage (Activa Healthcare Ltd) 10cm x 4m = £0.60, 6cm x 4m = £0.46, 8cm x 4m = £0.66

Cotton Conforming Bandage, BP 1988
Cotton fabric, plain weave, treated to impart some elasticity to warp and weft

Easifix CrinX bandage (BSN medical Ltd) 10cm x 3.5m = £1.60, 15cm x 3.5m = £1.39, 5cm x 3.5m = £0.68, 7.5cm x 3.5m = £0.83

Easifix
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Easifix bandage (BSN medical Ltd) 10cm x 4m = £0.50, 15cm x 4m = £0.85, 5cm x 4m = £0.35, 7.5cm x 4m = £0.42

Easifix K
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Easifix K bandage (6N medical Ltd) 10cm x 4m = £0.18, 15cm x 4m = £0.32, 2.5cm x 4m = £0.10, 5cm x 4m = £0.11, 7.5cm x 4m = £0.16

Hospiform
Fabric, plain weave, warp of polyamide, weft of viscose

Hospiform bandage (Paul Hartmann Ltd) 10cm x 4m = £0.19, 12cm x 4m = £0.23, 6cm x 4m = £0.13, 8cm x 4m = £0.17

K-Band
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

K-Band bandage (Urgo Ltd) 10cm x 4m = £0.28, 15cm x 4m = £0.49, 5cm x 4m = £0.20, 7cm x 4m = £0.26

Knit Fix
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched

Knit Fix bandage (Robert Bailey & Son Plc) 10cm x 4m = £0.17, 15cm x 4m = £0.33, 5cm x 4m = £0.12, 7cm x 4m = £0.17

Knit-Band
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Knit-Band bandage (CliniSupplies Ltd) 10cm x 4m = £0.17, 15cm x 4m = £0.30, 5cm x 4m = £0.10, 7cm x 4m = £0.15

Kontour
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Kontour bandage (Easigrip Ltd) 10cm x 4m = £0.40, 15cm x 4m = £0.66, 5cm x 4m = £0.28, 7.5cm x 4m = £0.35

Molelast
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Molelast (Lohmann & Rauscher (UK) Ltd) bandage 4cm x 4m = £0.30

Peha-haft
Polyamide and Cellulose Contour Bandage, cohesive, latex-free

Peha-haft bandage (Paul Hartmann Ltd) 10cm x 4m = £0.76, 12cm x 4m = £0.90, 2.5cm x 4m = £0.73, 4cm x 4m = £0.47, 6cm x 4m = £0.56, 8cm x 4m = £0.66

PremierBand
Polyamide and Cellulose Contour Bandage

PremierBand bandage (Sherwood) 10cm x 4m = £0.17, 15cm x 4m = £0.25, 2.5cm x 4m = £0.12, 7.5cm x 4m = £0.14

Slinky
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Slinky bandage (Molnycke Health Care Ltd) 10cm x 4m = £0.71, 15cm x 4m = £1.02, 7.5cm x 4m = £0.59

Stayform
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Stayform bandage (Robinson Healthcare) 10cm x 4m = £0.40, 15cm x 4m = £0.68, 5cm x 4m = £0.29, 7.5cm x 4m = £0.36

Tubular bandages and garments
Tubular bandages are available in different forms, according to the function required of them. Some are used under orthopaedic casts and some are suitable for protecting areas to which creams or ointments (other than those containing potent corticosteroids) have been applied. The conformability of the elasticated versions makes them particularly suitable for retaining dressings on difficult parts of the body or for soft tissue injury, but their use as the only means of applying pressure to an oedematous limb or to a varicose ulcer is not appropriate, since the pressure they exert is inadequate. Compression hosiery reduces the recurrence of venous leg ulcers and should be considered for use after wound healing.

Silk clothing is available as an alternative to elasticated viscose stockinette garments, for use in the management of severe eczema and allergic skin conditions.

Elasticated Surgical Tubular Stockinette, Foam padded is used for relief of pressure and elimination of friction in relevant area; porosity of foam lining allows normal water loss from skin surface.

For Elasticated Tubular Bandage, BP 1993, where no size stated by the prescriber, the 30 cm length should be supplied and width endorsed. Non-elasticated Cotton Stockinette, Bleached, BP 1988 1m lengths is used as basis (with wadding) for Plaster of Paris bandages etc.; 6 m length, compression bandage.

For Non-elasticated Ribbed Cotton and Viscose Surgical Tubular Stockinette, BP 1988, the Drug Tariff specifies various combinations of sizes to provide sufficient material for part or full body coverage. It is used as protective dressings with tar-based and other steroid ointments.

Elasticated

Acti-Fast
(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage

Acti-Fast 2-way stretch stockinette (Activa Healthcare Ltd) 10.75cm = £6.04, 17.5cm = £1.83, 20cm = £3.20, 3.5cm = £0.56, 5cm = £0.58, 7.5cm = £0.77

Clinfast
(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes

Clinfast stockinette (CliniSupplies Ltd) 10.75cm = £6.04, 17.5cm = £1.83, 3.5cm = £0.56, 5cm = £0.58, 7.5cm = £0.57

Molelast (Lohmann & Rauscher (UK) Ltd) bandage 4cm x 4m = £0.30

Peha-haft
Polyamide and Cellulose Contour Bandage, cohesive, latex-free

Peha-haft bandage (Paul Hartmann Ltd) 10cm x 4m = £0.76, 12cm x 4m = £0.90, 2.5cm x 4m = £0.73, 4cm x 4m = £0.47, 6cm x 4m = £0.56, 8cm x 4m = £0.66

PremierBand
Polyamide and Cellulose Contour Bandage

PremierBand bandage (Sherwood) 10cm x 4m = £0.17, 15cm x 4m = £0.25, 2.5cm x 4m = £0.12, 7.5cm x 4m = £0.14

Slinky
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Slinky bandage (Molnycke Health Care Ltd) 10cm x 4m = £0.71, 15cm x 4m = £1.02, 7.5cm x 4m = £0.59

Stayform
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all)

Stayform bandage (Robinson Healthcare) 10cm x 4m = £0.40, 15cm x 4m = £0.68, 5cm x 4m = £0.29, 7.5cm x 4m = £0.36
Comfifast Multistretch (Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes.

- Beige, Blue, Ecru, Grey, Pink
Wound management products and elasticated garments

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Sizes</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alvita crepe bandage</td>
<td>(Alliance Healthcare (Distribution) Ltd)</td>
<td>10cm x 4.5m, 15cm x 4.5m, 5cm x 4.5m, 7.5cm x 4.5m</td>
<td>£0.91, £0.50, £0.54, £0.73</td>
</tr>
<tr>
<td>Clinicrepe bandage</td>
<td>(Clinisupplies Ltd)</td>
<td>10cm x 4.5m, 15cm x 4.5m, 5cm x 4.5m, 7.5cm x 4.5m</td>
<td>£0.91, £0.50, £0.54, £0.73</td>
</tr>
<tr>
<td>Crepe bandage</td>
<td>(Romula Bailey &amp; Son)</td>
<td>10cm x 4.5m, 15cm x 4.5m, 5cm x 4.5m, 7.5cm x 4.5m</td>
<td>£0.91, £0.50, £0.54, £0.73</td>
</tr>
<tr>
<td>Propax crepe bandage</td>
<td>(Bsn medical ltd)</td>
<td>10cm x 4.5m, 15cm x 4.5m, 5cm x 4.5m, 7.5cm x 4.5m</td>
<td>£0.91, £0.50, £0.54, £0.73</td>
</tr>
<tr>
<td>Vernon crepe bandage</td>
<td>(Synergy Health plc)</td>
<td>10cm x 4.5m, 15cm x 4.5m, 5cm x 4.5m, 7.5cm x 4.5m</td>
<td>£0.91, £0.50, £0.54, £0.73</td>
</tr>
</tbody>
</table>

Elastofit

- Knitted fabric, viscose and elastomer yarn. Type 2 (light support bandage) | £2.19

Hospicrepe 233

- Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton threads; stretch bandage, lighter than cotton crepe, 4.5 m stretched (all) | £2.19

K-Lite

- Knitted fabric, viscose and elastomer yarn. Type 2 (light support bandage) | £2.19

Knit-Firm

- Knitted fabric, viscose and elastomer yarn. Type 2 (light support bandage) | £2.19

Neosporin

- Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all) | £2.19

PremierBand

- Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton threads; stretch bandage, lighter than cotton crepe, 4.5 m stretched (all) | £2.19

Profore #3

- Knitted fabric, viscose and elastomer yarn. Type 2 (light support bandage) | £2.19

Setocrepe

- Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all) | £2.19

**Support bandages**

- Light support bandages, which include the various forms of crepe bandages, are used in the prevention of oedema; they are also used to provide support for mild sprains and joints but their effectiveness has not been proven for this purpose. For a warning against injudicious compression see p. 1317.

**Clinilite**

- Knitted fabric, viscose and elastomer yarn. Type 2 (light support bandage) | £2.19

**Clinilite bandage** (Clinisupplies Ltd) 10cm x 4.5m = £0.80, 15cm x 4.5m = £1.16, 5cm x 4.5m = £0.44, 7.5cm x 4.5m = £0.61

**Cliniplus**

- Knitted fabric, viscose and elastomer yarn. Type 2 (light support bandage) | £2.19

**Cliniplus** (Clinisupplies Ltd) bandage 10cm x 8.7m = £1.80

**Cotton Crepe Bandage**

- Light support bandage, 4.5 m stretched (all) | £2.19

**Hospicrepe 2** (Paul Hartmann Ltd) 29 bandage 10cm x 4.5m = £0.81, 15cm x 4.5m = £1.18, 2.5cm x 4.5m = £0.46, 7.5cm x 4.5m = £0.62, 39 bandage 10cm x 4.5m = £0.80, 15cm x 4.5m = £1.17, 5cm x 4.5m = £0.44, 7.5cm x 4.5m = £0.62

**Cotton Crepe Bandage, BP 1988**

- Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton and/or viscose threads; stretch bandage. 4.5 m stretched (both) | £2.19

**Elastocrepe bandage** (Bsn medical ltd) 10cm x 4.5m, 7.5cm x 4.5m | £2.19

**Flexocrepe bandage** (Robinson Healthcare) 10cm x 4.5m, 7.5cm x 4.5m | £2.19

**Sterocrepe bandage** (Steroplast Healthcare Ltd) 10cm x 4.5m, 7.5cm x 4.5m | £2.19

**Cotton Suspensory Bandage** (Drug Tarif). Type 1: cotton net bag with draw tapes and webbing waistband; small, medium, and large (all) | £2.19

**Crepe Bandage, BP 1988**

- Fabric, plain weave, warp of wool threads and crepe-twisted cotton threads, weft of cotton threads; stretch bandage; 4.5 m stretched | £2.19
Setocrep (Molnlycke Health Care Ltd) bandage 10cm x 4.5m = £1.18

Soffcrepe
Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all) Soffcrepe bandage (BSN medical Ltd) 10cm x 4.5m = £1.23, 15cm x 4.5m = £1.79, 5cm x 4.5m = £0.69, 7.5cm x 4.5m = £0.97

Adhesive bandages
Elastic adhesive bandages are used to provide compression in the treatment of varicose veins and for the support of injured joints; they should no longer be used for the support of fractured ribs and clavicles. They have also been used with zinc paste bandage in the treatment of venous ulcers, but they can cause skin reactions in susceptible patients and may not produce sufficient pressures for healing (significantly lower than those provided by other compression bandages).

Elastic Adhesive Bandage, BP 1993
Woven fabric, elastic in warp (crepe-twisted cotton threads), weft of cotton and/or viscose threads spread with adhesive mass containing zinc oxide. 4.5 m stretched Tensoplast bandage (BSN medical Ltd) 10cm x 4.5m, 5cm x 4.5m, 7.5cm x 4.5m

Cohesive bandages
Cohesive bandages adhere to themselves, but not to the skin, and are useful for providing support for sports use where ordinary stretch bandages might become displaced and adhesive bandages are inappropriate. Care is needed in their application, however, since the loss of ability for movement between turns of the bandage to equalise local skin tension carries the potential for creating a tourniquet effect. Cohesive bandages can be used to support sprained joints and as an outer layer for multi-layer compression bandaging; they should not be used if arterial disease is suspected.

Cohesive extensible bandages
Coban
Bandage
Coban (3M Health Care Ltd) self-adherent bandage 10cm x 6m = £2.93

K Press
Bandage
K Press bandage (Urgo Ltd) 10cm x 6.5m = £2.89, 10cm x 7.5m = £3.37, 12cm x 7.5m = £4.25, 8cm x 7.5cm = £3.18

Profore #4
Bandage
Profore #4 (Smith & Nephew Healthcare Ltd) bandage 10cm x 2.5m = £3.23, latex free bandage 10cm x 2.5m = £3.51

Ultra Fast
Bandage
Ultra (Robinson Healthcare) Fast cohesive bandage 10cm x 6.3m = £2.59

Compression bandages
High compression products are used to provide the high compression needed for the management of gross varices, post-thrombotic venous insufficiency, venous leg ulcers, and gross oedema in average-sized limbs. Their use calls for an expert knowledge of the elastic properties of the products and experience in the technique of providing careful graduated compression. Incorrect application can lead to uneven and inadequate pressures or to hazardous levels of pressure. In particular, injudicious use of compression in limbs with arterial disease has been reported to cause severe skin and tissue necrosis (in some instances calling for amputation). Doppler testing is required before treatment with compression. Oral pentoxifylline, p. 207 can be used as adjunct therapy if a chronic venous leg ulcer does not respond to compression bandaging (unlicensed indication).

High compression bandages
High Compression Bandage
Cotton, viscose, nylon, and Lycra extensible bandage, 3 m (unstretched)
K-Three (Urgo Ltd) bandage 10cm x 3m = £2.81
SurePress (Convatec Ltd) bandage 10cm x 3m = £3.61

PEC High Compression Bandages
Polyamide, elastane, and cotton compression (high) extensible bandage, 3.5 m unstretched
Setopress (Molnlycke Health Care Ltd) bandage 10cm x 3.5m = £3.50
VEC High Compression Bandages
Viscose, elastane, and cotton compression (high) extensible bandage, 3 m unstretched (both)
Tensoplast bandage (BSN medical Ltd) 10cm x 3m = £3.43, 7.5cm x 3m = £2.67

Short stretch compression bandages
Actico
Bandage
Actico bandage (Activa Healthcare Ltd) 10cm x 6m = £3.33, 12cm x 6m = £4.24, 4cm x 6m = £2.38, 6cm x 6m = £2.79, 8cm x 6m = £3.21

Comprilan
Bandage
Comprilan bandage (BSN medical Ltd) 10cm x 5m = £3.36, 12cm x 5m = £4.09, 6cm x 5m = £2.66, 8cm x 5m = £3.12

Rosidal K
Bandage
Rosidal K bandage (Lohmann & Rauscher (UK) Ltd) 10cm x 10m = £5.97, 10cm x 5m = £3.43, 12cm x 5m = £4.16, 6cm x 5m = £2.63, 8cm x 5m = £3.14

Sub-compression wadding bandage
Cellona Undercast Padding
Padding
Cellona Undercast padding bandage (Lohmann & Rauscher (UK) Ltd) 10cm x 2.75m = £0.47, 15cm x 2.75m = £0.60, 5cm x 2.75m = £0.30, 7.5cm x 2.75m = £0.38

Flexi-Ban
Padding
Flexi-Ban (Activa Healthcare Ltd) bandage 10cm x 3.5m = £0.50

K Tech Reduced
Padding
K Tech Reduced bandage 10cm x (Urgo Ltd) 6m = £4.68, 7.3m = £5.11

K-Soft
Padding
K-Soft (Urgo Ltd) Long bandage 10cm x 4.5m = £0.56, bandage 10cm x 3.5m = £0.45

K-Tech (K Tech in DMD)
Padding
K Tech (Urgo Ltd) Reduced bandage 10cm x 7.3m = £5.11, bandage 10cm x 5m = £3.90, 10cm x 6m = £4.68, 12cm x 6m = £5.91, 12cm x 7.3m = £6.45, 8cm x 6m = £4.42, 8cm x 7.3m = £4.82,

Ortho-Band Plus
Padding
Ortho-Band (Millpledge Healthcare) Plus bandage 10cm x 3.5m = £0.37

Profore #1
Padding
Profore #1 (Smith & Nephew Healthcare Ltd) bandage 10cm x 3.5m = £0.70, latex free bandage 10cm x 3.5m = £0.76

Softex
Padding
Softex (Molnlycke Health Care Ltd) bandage 10cm x 3.5m = £0.62

SurePress
Padding
SurePress (Convatec Ltd) bandage 10cm x 3m = £3.61

Ultra Soft
Padding
Ultra (Robinson Healthcare) Soft wadding bandage 10cm x 3.5m = £0.39
Wound management products and elasticated garments

**Velband**
Padding

**Velband** (BSN medical Ltd) absorbent padding bandage 10cm x 4.5m = £0.72

**Multi-layer compression bandaging**
Multi-layer compression bandaging systems are an alternative to High Compression Bandages for the treatment of venous leg ulcers. Compression is achieved by the combined effects of two or three extensible bandages applied over a layer of orthopaedic wadding and a wound contact dressing.

**Four layer systems**

- **K-Four** Padding

  **K-Four** (Ferndale) Reduced Compression multi-layer compression bandage kit = £4.45, multi-layer compression bandage kit 18cm-25cm ankle circumference = £6.80, 25cm-30cm ankle circumference = £6.80, greater than 30cm ankle circumference = £9.36, less than 18cm ankle circumference = £7.11.

- **Profore** Wound contact layer

  **Profore** Multi-layer compression bandaging kit, four layer system

  **Profore** (Smith & Nephew Healthcare Ltd) Lite latex free multi-layer compression bandage kit = £5.91, multi-layer compression bandage kit 18cm-25cm ankle circumference = £10.07, multi-layer compression bandage kit 18cm-25cm ankle circumference = £9.42, 25cm-30cm ankle circumference = £7.82, above 30cm ankle circumference = £11.71, up to 18cm ankle circumference = £10.11.

- **Ultra Four** Wound contact layer

  **Ultra Four** Multi-layer compression bandaging kit, four layer system

  **Ultra Four** (Robinson Healthcare) Reduced Compression multi-layer compression bandage kit = £8.44, latex free multi-layer compression bandage kit 18cm-25cm ankle circumference = £9.67, up to 18cm ankle circumference = £6.41.

**Two layer systems**

- **Coban 2** Multi-layer compression bandaging kit, two layer system (latex-free, foam bandage and cohesive compression bandage)

  **Coban 2** (3M Health Care Ltd) Lite multi-layer compression bandage kit = £8.24, multi-layer compression bandage kit = £8.24

- **K Two** Multi-layer compression bandaging kit, two layer system

  **K Two** (Urgo Ltd) Reduced latex free multi-layer compression bandage kit (10cm) 18cm-25cm ankle circumference = £8.55, 25cm-32cm ankle circumference = £9.34, Reduced multi-layer compression bandage kit 18cm-25cm ankle circumference = £8.05, 25cm-32cm ankle circumference = £8.80, latex free multi-layer compression bandage kit (10cm) 18cm-25cm ankle circumference = £8.55, 25cm-32cm ankle circumference = £9.34, multi-layer compression bandage kit (12cm) 18cm-25cm ankle circumference = £8.05, 25cm-32cm ankle circumference = £8.80, multi-layer compression bandage kit (12cm) 18cm-25cm ankle circumference = £10.15, 25cm-32cm ankle circumference = £11.10, multi-layer compression bandage kit (8cm) 18cm-25cm ankle circumference = £7.60, 25cm-32cm ankle circumference = £8.26, multi-layer compression bandage kit size 6 short 18cm-25cm ankle circumference = £6.79.

**Medicated bandages**
Zinc Paste Bandage has been used with compression bandaging for the treatment of venous leg ulcers. However, paste bandages are associated with hypersensitivity reactions and should be used with caution. Zinc paste bandages are also used with coal tar or ichthammol in chronic lichenified skin conditions such as chronic eczema (ichthammol often being preferred since its action is considered to be milder). They are also used with calamine in milder eczematous skin conditions.

**Steripaste**
Cotton fabric, selvedge weave impregnated with paste containing zinc oxide (requires additional bandaging) Excipients include polysorbate 80

**Steripaste (Mohyleve Health Care Ltd)** bandage 7.5cm x 6m = £3.24

**Zinc Paste Bandage, BP 1993**
Cotton fabric, plain weave, impregnated with suitable paste containing zinc oxide; requires additional bandaging Excipients: may include cetoestearyl alcohol, hydroxybenzoates

**Viscopaste (Smith & Nephew Healthcare Ltd)** bandage 7.5cm x 6m = £3.63

**Zinc Paste and Ichthammol Bandage, BP 1993**
Cotton fabric, plain weave, impregnated with suitable paste containing zinc oxide and ichthammol; requires additional bandaging Excipients: may include cetoestearyl alcohol

**Ichthopaste (Smith & Nephew Healthcare Ltd)** bandage 7.5cm x 6m = £3.67

**Medicated stocking**

- **Zipzoc**
  
  Sterile rayon stocking impregnated with ointment containing zinc oxide 20%  
  
  **Zipzoc** (Smith & Nephew Healthcare Ltd) stockings = £31.26

**Compression hosiery and garments**
Compression (elastic) hosiery is used to treat conditions associated with chronic venous insufficiency, to prevent recurrence of thrombosis, or to reduce the risk of further venous ulceration after treatment with compression bandaging. Doppler testing to confirm arterial sufficiency is required before recommending the use of compression hosiery.

Before elastic hosiery can be dispensed, the quantity (single or pair), article (including accessories), and compression class must be specified by the prescriber. There are different compression values for graduated compression hosiery and lymphoedema garments (see table below). All dispensed elastic hosiery articles must state on the packaging that they conform with Drug Tariff technical specification No. 40, for further details see Drug Tariff.

Graduated Compression hosiery, Class 1 Light Support is used for superficial or early varices, varicosis during pregnancy.

Graduated Compression hosiery, Class 2 Medium Support is used for varices of medium severity, ulcer treatment and prophylaxis, mild oedema, varicosis during pregnancy. Graduated Compression hosiery, Class 3 Strong Support is used for gross varices, post thrombotic venous insufficiency, gross oedema, ulcer treatment and prophylaxis.

**Compression values for hosiery and lymphoedema garments**
Class 1: Compression hosiery (British standard) 14–17 mmHg, lymphoedema garments (European classification) 18–21 mmHg; Class 2 Compression hosiery (British standard) 18–24 mmHg, lymphoedema garments (European classification) 23–32 mmHg; Class 3 Compression hosiery (British standard) 25–35 mmHg, lymphoedema garments (European classification) 34–46 mmHg; Class 4 Compression hosiery (British standard)—not available, lymphoedema garments (European classification) 49–70 mmHg; Class 4 super Compression hosiery (British standard)—not available, lymphoedema garments (European classification) 60–90 mmHg.
Graduated compression hosiery

**Class 1 Light Support**
Hosiery, compression at ankle 14–17 mmHg, thigh length or below knee with knitted in heel

**Class 2 Light Support**
Hosiery, compression at ankle 14–17 mmHg, thigh length or below knee with knitted in heel

**Accessories**
**Suspenders**
Suspenders, for thigh stockings

**Anklets**
**Class 2 Medium Support**
Anklets, compression 18–24 mmHg, circular knit (standard and made-to-measure),

**Class 3 Strong Support**
Anklets, compression 18–24 mmHg, circular knit (standard and made-to-measure),

**Knee caps**
**Class 2 Medium Support**
Kneecaps, compression 18–24 mmHg, circular knit (standard and made-to-measure)

**Class 3 Strong Support**
Kneecaps, compression 18–24 mmHg, circular knit (standard and made-to-measure)

**Lymphoedema garments**
Lymphoedema compression garments are used to maintain limb shape and prevent additional fluid retention. Either flat-bed or circular knitting methods are used in the manufacture of elasticated compression garments. Seamless, circular-knitted garments (in standard sizes) can be used to prevent swelling if the lymphoedema is well controlled and if the limb is in good shape and without skin folds. Flat-knitted garments (usually made-to-measure) with a seam, provide greater rigidity and stiffness to maintain reduction of lymphoedema following treatment with compression bandages.

A standard range of light, medium, or high compression garments are available, as well as low compression (12–16 mmHg) armsleeves, made-to-measure garments up to compression 90 mmHg, and accessories—see Drug Tariff for details. Note There are different compression values for lymphoedema garments and graduated compression hosiery, see above.
Dental Practitioners’ Formulary

List of Dental Preparations

The following list has been approved by the appropriate Secretaries of State, and the preparations therein may be prescribed by dental practitioners on form FP10D (GP14 in Scotland, WP10D in Wales).

Licensed sugar-free versions, where available, are preferred. Licensed alcohol-free mouthwashes, where available, are preferred.

Artificial Saliva Substitute Spray, DPF
Artificial Saliva Pastilles, DPF
Artificial Saliva Oral Spray, DPF
Artificial Saliva Protective Spray, DPF

Artificial Saliva Substitutes as listed below (to be prescribed only for indications approved by ACBS (patients suffering from dry mouth as a result of having or having undergone, radiotherapy or sicca syndrome):
- BioXtra® Gel Mouthspray
- BioXtra® Moisturising Gel
- Glandosane®
- Salvez®

Artificial Saliva Substitute Spray, DPF
Aspirin Tablets, Dispensable, BP
Azithromycin Capsules, 250 mg, DPF
Azithromycin Oral Suspension, 200 mg/5 mL, DPF
Azithromycin Tablets, 250 mg, DPF
Azithromycin Tablets, 500 mg, DPF
Beclometasone Pressurised Inhalation, BP, 50 micrograms/metered inhalation, CFC-free, as:
- Clen Modulite®
- BioModult™

Benzydamine Mouthwash, BP 0.15%
Benzydamine Oromucosal Spray, BP 0.15%
Betamethasone Soluble Tablets, 500 micrograms, DPF
Carbamazepine Tablets, BP
Cefalexin Capsules, BP
Cefalexin Oral Suspension, BP
Cefalexin Tablets, BP
Cefadroxil Capsules, BP
Cefadroxil Oral Solution, BP, 5 mg/5 mL
Cefazolin Tablets, BP, 10 mg
Chlorhexidine Gluconate Gel, BP
Chlorhexidine Mouthwash, BP
Chlorhexidine Oral Spray, DPF
Chlorphenamine Oral Solution, BP
Chlorphenamine Tablets, BP
Choline Salicylate Dental Gel, BP
Clarithromycin Oral Suspension, 125 mg/5 mL, DPF
Clarithromycin Oral Suspension, 250 mg/5 mL, DPF
Clarithromycin Tablets, BP
Clindamycin Capsules, BP
Co-amoxiclav Tablets, BP, 250/125 (amoxicillin 250 mg as trihydrate, clavulanic acid 125 mg as potassium salt)
Co-amoxiclav Oral Suspension, BP, 125/31 (amoxicillin 125 mg as trihydrate, clavulanic acid 31.25 mg as potassium salt)/5 mL
Co-amoxiclav Oral Suspension, BP, 250/62 (amoxicillin 250 mg as trihydrate, clavulanic acid 62.5 mg as potassium salt)/5 mL
Diazepam Oral Solution, BP, 2 mg/5 mL
Diazepam Tablets, BP
Diclofenac Sodium Tablets, Gastro-resistant, BP
Dihydrocodeine Tablets, BP, 30 mg
Doxycline Tablets, Dispersible, BP
Doxycline Capsules, BP, 100 mg
Doxycline Tablets, 20 mg, DPF
Ephedrine Nasal Drops, BP
Erythromycin Ethyl Succinate Oral Suspension, BP
Erythromycin Ethyl Succinate Tablets, BP
Erythromycin Stearate Tablets, BP
Erythromycin Tablets, Gastro-resistant, BP
Fluconazole Capsules, 50 mg, DPF
Fluconazole Oral Suspension, 50 mg/5 mL, DPF
Hydrocortisone Cream, BP, 1%
Hydrocortisone Oromucosal Tablets, BP
Hydrogen Peroxide Mouthwash, BP, 6%
Ibuprofen Oral Suspension, BP, sugar-free
Ibuprofen Tablets, BP
Lansoprazole Capsules, Gastro-resistant, BP
Lidocaine Ointment, BP, 5%
Lidocaine Spray 10%, DPF
Loratadine Syrup, 5 mg/5 mL, DPF
Loratadine Tablets, BP, 10 mg
Menthol and Eucalyptus Inhalation, BP 1980
Metronidazole Oral Suspension, BP
Metronidazole Tablets, BP
Miconazole Cream, BP
Miconazole Oromucosal Gel, BP
Miconazole and Hydrocortisone Cream, BP
Miconazole and Hydrocortisone Ointment, BP
Nystatin Oral Suspension, BP
Omeprazole Capsules, Gastro-resistant, BP
Oxytetracycline Tablets, BP
Paracetamol Oral Suspension, BP
Paracetamol Tablets, BP
Paracetamol Tablets, Soluble, BP
Phenoxymethylpenicillin Oral Solution, BP
Phenoxymethylpenicillin Tablets, BP
Promethazine Hydrochloride Tablets, BP
Promethazine Oral Solution, BP
Saliva Stimulating Tablets, DPF
Sodium Chloride Mouthwash, Compound, BP
Sodium Fluoride Toothpaste
Sodium Fluoride Tablets, BP
Sodium Fluoride Oral Drops, BP
Sodium Fluoride Tablets, BP
Sodium Fluoride Toothpaste 0.619%, DPF
Sodium Fluoride Toothpaste 1.1%, DPF
Sodium Fusicide Ointment, BP
Temazepam Oral Solution, BP
Temazepam Tablets, BP
Tetracycline Tablets, BP

Preparations in this list which are not included in the BP or BPC are described under Details of DPF preparations.

For details of preparations that can be prescribed, see individual entries under the relevant drug monographs throughout the BNF publications.

Details of DPF preparations

Preparations on the List of Dental Preparations which are specified as DPF are described as follows in the DPF.

Although brand names have sometimes been included for identification purposes, preparations on the list should be prescribed by non-proprietary name.

Amoxicillin Oral Powder
- amoxicillin (as trihydrate) 3 g sachet
Artificial Saliva Gel
(proprietary product: *Biotene Oralbalance*), lactoperoxidase, lactoferrin, lysozyme, glucose oxidase, xylitol in a gel basis

Artificial Saliva Oral Spray
(proprietary product: *Xerotin*) consists of water, sorbitol, carmelllose (carboxymethylcellulose), potassium chloride, sodium chloride, potassium phosphate, magnesium chloride, calcium chloride and other ingredients, pH neutral

Artificial Saliva Pastilles
(proprietary product: *Salivix*), consists of acacia, malic acid, and other ingredients

Artificial Saliva Protective Spray
(proprietary product: *Aquoral*) consists of oxidised glycerol triesters, silicon dioxide, flavouring agents, aspartame

Artificial Saliva Substitute Spray
(proprietary product: *AS Saliva Orthana Spray*) consists of mucin, methylparaben, benzalkonium chloride, EDTA, xylitol, peppermint oil, spearmint oil, mineral salts

Azithromycin Capsules
azithromycin 250 mg

Azithromycin Oral Suspension 200 mg/5 mL
azithromycin 200 mg/5 mL when reconstituted with water

Azithromycin Tablets
azithromycin 250 mg and 500 mg

Betamethasone Soluble Tablets 500 micrograms
betamethasone (as sodium phosphate) 500 micrograms

Chlorhexidine Oral Spray
(proprietary product: *Corsodyl Oral Spray*), chlorhexidine gluconate 0.2%

Clarithromycin Oral Suspension 125 mg/5 mL
clarithromycin 125 mg/5 mL when reconstituted with water

Clarithromycin Oral Suspension 250 mg/5 mL
clarithromycin 250 mg/5 mL when reconstituted with water

Doxycycline Tablets 20 mg
(proprietary product: *Periostat*), doxycycline (as hyclate) 20 mg

Fluconazole Capsules 50 mg
fluconazole 50 mg

Fluconazole Oral Suspension 50 mg/5 mL
(proprietary product: *Diflucan*), fluconazole 50 mg/5 mL when reconstituted with water

Lidocaine Spray 10%
(proprietary product: *Xylocaine Spray*), lidocaine 10%
supplying 10 mg lidocaine/spray

Loratadine Syrup 5 mg/5 mL
loratadine 5 mg/5 mL

Saliva Stimulating Tablets
(proprietary product: SST), citric acid, malic acid and other ingredients in a sorbitol base

Sodium Fluoride Toothpaste 0.619%
(proprietary product: *Duraphat '2800 ppm' Toothpaste*), sodium fluoride 0.619%

Sodium Fluoride Toothpaste 1.1%
(proprietary product: *Duraphat '5000 ppm' Toothpaste*), sodium fluoride 1.1%
Nurse Prescribers’ Formulary

Nurse Prescribers’ Formulary for Community Practitioners

Nurse Prescribers’ Formulary Appendix (Appendix NPF).
List of preparations approved by the Secretary of State which may be prescribed on form FP10P (form HS21(N) in Northern Ireland, forms WP10CN and WP10PN in Wales) by Nurses for National Health Service patients.
Community practitioners who have completed the necessary training may only prescribe items appearing in the nurse prescribers’ list set out below. Community Practitioner Nurse Prescribers are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved generic name.

Medicinal Preparations
Preparations on this list which are not included in the BP or BPC are described on p. 1323.
Almond Oil Ear Drops, BP
Arachis Oil Enema, NPF
Aspirin Tablets, Dispersible, 300 mg, BP (max. 96 tablets; max. pack size 32 tablets)
Bisacodyl Suppositories, BP (includes 5-mg and 10-mg strengths)
Bisacodyl Tablets, BP
Catheter Maintenance Solution, Sodium Chloride, NPF
Catheter Maintenance Solution, ‘Solution G’, NPF
Catheter Maintenance Solution, ‘Solution R’, NPF
Chlorhexidine Gluconate Aqueous Solutions containing at least 0.05%
Chlorhexidine Gluconate Alcoholic Solutions containing at least 0.05%
Choline Salicylate Dental Gel, BP
Clotrimazole Cream 1%, BP
Co-danthramer Capsules, NPF
Co-danthramer Capsules, Strong, NPF
Co-danthramer Oral Suspension, NPF
Co-danthramer Oral Suspension, Strong, NPF
Co-danthrusate Capsules, BP
Co-danthrusate Oral Suspension, NPF
Crotamiton Cream, BP
Crotamiton Lotion, BP
Dimeticone barrier creams containing at least 10%
Dimeticone Lotion, NPF
Docusate Capsules, BP
Docusate Enema, NPF
Docusate Oral Solution, BP
Docusate Oral Solution, Paediatric, BP
Econazole Cream 1%, BP
Emollients as listed below:
Aquadrate® 10% w/w Cream
Arachis Oil, BP
Balneum® Plus Cream
Cetraben® Emollient Cream
Dermafast®
Diprobase® Cream
Diprobase® Ointment
Doublebase®
Doublebase® Dayleve Gel
E45® Cream
E45® Itch Relief Cream
Emulsifying Ointment, BP
Eucerin® Intensive 10% w/w Urea Treatment Cream
Eucerin® Intensive 10% w/w Urea Treatment Lotion
Hydromol® Cream
Hydromol® Intensive
Hydrous Ointment, BP
Lipobase®
Liquid and White Soft Paraffin Ointment, NPF
Neutrogena® Norwegian Formula Dermatological Cream
Nutraplus® Cream
Oilatum® Cream
Oilatum® Junior Cream
Paraffin, White Soft, BP
Paraffin, Yellow Soft, BP
Ultrasal®
Unguentum M®
Emollient Bath and Shower Preparations as listed below:
Aqueous Cream, BP
Balneum® (except pack sizes that are not to be prescribed under the NHS (see Part XVIIIA of the Drug Tariff, Part XI of the Northern Ireland Drug Tariff))
Balneum Plus® Bath Oil (except pack sizes that are not to be prescribed under the NHS (see Part XVIIIA of the Drug Tariff, Part XI of the Northern Ireland Drug Tariff))
Cetraben® Emollient Bath Additive
Dermalo® Bath Emollient
Doublebase® Emollient Bath Additive
Doublebase® Emollient Shower Gel
Doublebase® Emollient Wash Gel
Hydromol® Bath and Shower Emollient
Oilatum® Emollient
Oilatum® Gel
Oilatum® Junior Bath Additive
Zerolatum® Emollient Medicinal Bath Oil
Folic Acid Tablets 400 micrograms, BP
Glycerol Suppositories, BP
Ibuprofen Oral Suspension, BP (except for indications and doses that are PoM)
Ibuprofen Tablets, BP (except for indications and doses that are PoM)
Ispaghula Husk Granules, BP
Ispaghula Husk Granules, Effervescent, BP
Ispaghula Husk Oral Powder, BP
Lactulose Solution, BP
Lidocaine Ointment, BP
Lidocaine and Chlorhexidine Gel, BP
Macrogol Oral Liquid, Compound, NPF
Macrogol Oral Powder, Compound, NPF
Macrogol Oral Powder, Compound, Half-strength, NPF
Magnesium Hydroxide Mixture, BP
Magnesium Sulfate Paste, BP
Malathion aqueous lotions containing at least 0.5%
Mebendazole Oral Suspension, NPF
Mebendazole Tablets, NPF
Methylcellulose Tablets, BP
Miconazole Cream 2%, BP
Miconazole Oromucosal Gel, BP
Mouthwash Solution-tablets, NPF
Nicotine Inhalation Cartridge for Oromucosal Use, NPF
Nicotine Lozenge, NPF
Nicotine Medicated Chewing Gum, NPF
Nicotine Nasal Spray, NPF
Nicotine Oral Spray, NPF
Nicotine Sublingual Tablets, NPF
Nicotine Transdermal Patches, NPF
Nystatin Oral Suspension, BP
Olive Oil Ear Drops, BP

Nurse Prescribers’ Formulary for Community Practitioners

Nurse Prescribers’ Formulary Appendix (Appendix NPF).
List of preparations approved by the Secretary of State which may be prescribed on form FP10P (form HS21(N) in Northern Ireland, forms WP10CN and WP10PN in Wales) by Nurses for National Health Service patients.
Community practitioners who have completed the necessary training may only prescribe items appearing in the nurse prescribers’ list set out below. Community Practitioner Nurse Prescribers are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved generic name.

Medicinal Preparations
Preparations on this list which are not included in the BP or BPC are described on p. 1323.
Almond Oil Ear Drops, BP
Arachis Oil Enema, NPF
Aspirin Tablets, Dispersible, 300 mg, BP (max. 96 tablets; max. pack size 32 tablets)
Bisacodyl Suppositories, BP (includes 5-mg and 10-mg strengths)
Bisacodyl Tablets, BP
Catheter Maintenance Solution, Sodium Chloride, NPF
Catheter Maintenance Solution, ‘Solution G’, NPF
Catheter Maintenance Solution, ‘Solution R’, NPF
Chlorhexidine Gluconate Aqueous Solutions containing at least 0.05%
Chlorhexidine Gluconate Alcoholic Solutions containing at least 0.05%
Choline Salicylate Dental Gel, BP
Clotrimazole Cream 1%, BP
Co-danthramer Capsules, NPF
Co-danthramer Capsules, Strong, NPF
Co-danthramer Oral Suspension, NPF
Co-danthramer Oral Suspension, Strong, NPF
Co-danthrusate Capsules, BP
Co-danthrusate Oral Suspension, NPF
Crotamiton Cream, BP
Crotamiton Lotion, BP
Dimeticone barrier creams containing at least 10%
Dimeticone Lotion, NPF
Docusate Capsules, BP
Docusate Enema, NPF
Docusate Oral Solution, BP
Docusate Oral Solution, Paediatric, BP
Econazole Cream 1%, BP
Emollients as listed below:
Aquadrate® 10% w/w Cream
Arachis Oil, BP
Balneum® Plus Cream
Cetraben® Emollient Cream
Dermafast®
Diprobase® Cream
Diprobase® Ointment
Doublebase®
Doublebase® Dayleve Gel
E45® Cream
E45® Itch Relief Cream
Emulsifying Ointment, BP
Eucerin® Intensive 10% w/w Urea Treatment Cream
Eucerin® Intensive 10% w/w Urea Treatment Lotion
Hydromol® Cream
Hydromol® Intensive
Hydrous Ointment, BP
Lipobase®
Liquid and White Soft Paraffin Ointment, NPF
Neutrogena® Norwegian Formula Dermatological Cream
Nutraplus® Cream
Oilatum® Cream
Oilatum® Junior Cream
Paraffin, White Soft, BP
Paraffin, Yellow Soft, BP
Ultrasal®
Unguentum M®
Emollient Bath and Shower Preparations as listed below:
Aqueous Cream, BP
Balneum® (except pack sizes that are not to be prescribed under the NHS (see Part XVIIIA of the Drug Tariff, Part XI of the Northern Ireland Drug Tariff))
Balneum Plus® Bath Oil (except pack sizes that are not to be prescribed under the NHS (see Part XVIIIA of the Drug Tariff, Part XI of the Northern Ireland Drug Tariff))
Cetraben® Emollient Bath Additive
Dermalo® Bath Emollient
Doublebase® Emollient Bath Additive
Doublebase® Emollient Shower Gel
Doublebase® Emollient Wash Gel
Hydromol® Bath and Shower Emollient
Oilatum® Emollient
Oilatum® Gel
Oilatum® Junior Bath Additive
Zerolatum® Emollient Medicinal Bath Oil
Folic Acid Tablets 400 micrograms, BP
Glycerol Suppositories, BP
Ibuprofen Oral Suspension, BP (except for indications and doses that are PoM)
Ibuprofen Tablets, BP (except for indications and doses that are PoM)
Ispaghula Husk Granules, BP
Ispaghula Husk Granules, Effervescent, BP
Ispaghula Husk Oral Powder, BP
Lactulose Solution, BP
Lidocaine Ointment, BP
Lidocaine and Chlorhexidine Gel, BP
Macrogol Oral Liquid, Compound, NPF
Macrogol Oral Powder, Compound, NPF
Macrogol Oral Powder, Compound, Half-strength, NPF
Magnesium Hydroxide Mixture, BP
Magnesium Sulfate Paste, BP
Malathion aqueous lotions containing at least 0.5%
Mebendazole Oral Suspension, NPF
Mebendazole Tablets, NPF
Methylcellulose Tablets, BP
Miconazole Cream 2%, BP
Miconazole Oromucosal Gel, BP
Mouthwash Solution-tablets, NPF
Nicotine Inhalation Cartridge for Oromucosal Use, NPF
Nicotine Lozenge, NPF
Nicotine Medicated Chewing Gum, NPF
Nicotine Nasal Spray, NPF
Nicotine Oral Spray, NPF
Nicotine Sublingual Tablets, NPF
Nicotine Transdermal Patches, NPF
Nystatin Oral Suspension, BP
Olive Oil Ear Drops, BP
Paracetamol Oral Suspension, BP (includes 120 mg/5 mL and 250 mg/5 mL strengths—both of which are available as sugar-free formulations)
Paracetamol Tablets, BP (max. 96 tablets; max. pack size 32 tablets)
Paracetamol Tablets, Soluble, BP (includes 120- and 500-mg tablets); (max. 96 tablets; max. pack size 32 tablets)
Permethrin Cream, NPF
Phosphates Enema, BP
Povidone–Iodine Solution, BP
Senna Oral Solution, NPF
Senna Tablets, BP
Senna and Ispaghula Granules, NPF
Sodium Chloride Solution, Sterile, BP
Sodium Citrate Compound Enema, NPF
Sodium Chloride Solution, Sterile, BP
Sodium Chloride Solution, Sterile, BP
Sodium Picosulphate Elixir, NPF
Spermicidal contraceptives as listed below:
   - Gyge® Contraceptive Jelly
   - Sterculia Granules, NPF
   - Sterculia and Frangula Granules, NPF
   - Titanium Ointment, BP
   - Water for Injections, BP
   - Zinc and Castor Oil Ointment, BP
   - Zinc Oxide and Dimeticonic Spray, NPF
   - Zinc Oxide Impregnated Medicated Bandage, NPF
   - Zinc Oxide Impregnated Medicated Stocking, NPF
   - Zinc Paste Bandage, BP 1993
   - Zinc Paste and Ichthammol Bandage, BP 1993

**Appliances and Reagents (including Wound Management Products)**
Community Practitioner Nurse Prescribers in England, Wales and Northern Ireland can prescribe any appliance or reagent in the relevant Drug Tariff. In the Scottish Drug Tariff, Appliances and Reagents which may not be prescribed by Nurses are annotated *N*.

**Appliances** (including Contraceptive Devices—where it is not appropriate for nurse prescribers in family planning clinics to prescribe contraceptive devices using form FP10(P) (forms WP10CN and WP10PN in Wales), they may prescribe using the same system as doctors in the clinic) as listed in Part IXA of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 3 (Appliances) and Part 2 (Dressings) of the Scottish Drug Tariff).

**Incontinence Appliances** as listed in Part IXB of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 5 of the Scottish Drug Tariff).

**Stoma Appliances and Associated Products** as listed in Part IXC of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 6 of the Scottish Drug Tariff).

**Chemical Reagents** as listed in Part IXR of the Drug Tariff (Part II of the Northern Ireland Drug Tariff, Part 9 of the Scottish Drug Tariff).

The Drug Tariffs can be accessed online at:
- National Health Service Drug Tariff for England and Wales: [www.ppa.org.uk/ppa/edt_intro.htm](http://www.ppa.org.uk/ppa/edt_intro.htm)

**Details of NPF preparations**
Preparations on the Nurse Prescribers’ Formulary which are not included in the BP or BPC are described as follows in the Nurse Prescribers’ Formulary.

Although brand names have sometimes been included for identification purposes, it is recommended that non-proprietary names should be used for prescribing medicinal preparations in the NPF except where a non-proprietary name is not available.

**Arachis Oil Enema**
arachis oil 100%  
**Catheter Maintenance Solution, Sodium Chloride** (proprietary products: OptiFlo S; Uro-Tainer Sodium Chloride; Uriflex-S), sodium chloride 0.9%

**Catheter Maintenance Solution, ‘Solution G’** (proprietary products: OptiFlo G; Uro-Tainer Saby G; Uriflex G), citric acid 3.23%, magnesium oxide 0.38%, sodium bicarbonate 2.8%, disodium edetate 0.01%

**Catheter Maintenance Solution, ‘Solution R’** (proprietary products: OptiFlo R; Uro-Tainer Solution R; Uriflex R), citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%

**Chlorhexidine gluconate alcoholic solutions** (proprietary product: Unisept) chlorhexidine gluconate in alcoholic solution

**Chlorhexidine gluconate aqueous solutions** (proprietary product: Unisept) chlorhexidine gluconate in aqueous solution

**Co-danthramer Capsules** (P) co-danthramer 25/200 (dantron 25 mg, poloxamer ‘188’ 200 mg)

**Co-danthramer Capsules, Strong** (P) co-danthramer 37.5/500 (dantron 37.5 mg, poloxamer ‘188’ 500 mg)

**Co-danthramer Oral Suspension** (P) (proprietary product: Codalax), co-danthramer 25/200 in 5 mL (dantron 25 mg, poloxamer ‘188’ 200 mg/5 mL)

**Co-danthramer Oral Suspension, Strong** (P) (proprietary product: Codalax Forte), co-danthramer 75/1000 in 5 mL (dantron 75 mg, poloxamer ‘188’ 1.5 g/5 mL)

**Co-danthrusate Oral Suspension** (P) (proprietary product: Normal), co-danthrusate 50/60 (dantron 50 mg, docusate sodium 60 mg/5 mL)

**Dimebonium barrier creams** (proprietary products: Conotrane Cream, dimebonium ‘350’ 22%; Sispel Barrier Cream, dimebonium ‘1000’ 10%), dimebonium 10–22%

**Dimebonium Lotion** (proprietary product: Hedrin), dimebonium 4%

**Docusate Enema** (proprietary product: Noragal Micro-encema) docusate sodium 120 mg in 10 g

**Liquid and White Soft Paraffin Ointment** liquid paraffin 50%, white soft paraffin 50%

**Macrogol Oral Liquid, Compound** (proprietary product: Movicol Liquid), macrogol ‘3350’ (polyethylene glycol ‘3350’) 13.125 g, sodium bicarbonate 178.5 mg, sodium chloride 350.7 mg, potassium chloride 46.6 mg/25 mL

**Macrogol Oral Powder, Compound** (proprietary products: Laxido Orange, Molosao, Movicol) macrogol ‘3350’ (polyethylene glycol ‘3350’) 13.125 g, sodium bicarbonate 178.5 mg, sodium chloride 350.7 mg, potassium chloride 46.6 mg/sachet

Note: Amount of potassium chloride varies according to flavour of Movicol® as follows: plain-flavour (sugar-free) = 50.2 mg/sachet; lime and lemon flavour = 46.6 mg/sachet; chocolate flavour = 31.7 mg/sachet. 1 sachet when reconstituted with 125 mL water provides K+ 5.4 mmol/litre

**Macrogol Oral Powder, Compound, Half-strength** (proprietary product: Movicol-Half), macrogol ‘3350’ (polyethylene glycol ‘3350’) 6.563 g, sodium bicarbonate 89.3 g, sodium chloride 175.4 mg, potassium chloride 23.3 mg/sachet
Malathion aqueous lotions
(proprietary products: Derbac-M Liquid), malathion 0.5% in an aqeous basis

Mebendazole Oral Suspension
(proprietary product: Vermox), mebendazole 100 mg/5 mL

Mebendazole Tablets
(proprietary products: Ovex, Vermox), mebendazole 100 mg

Mouthwash Solution-tablets
consist of tablets which may contain antimicrobial, colouring and flavouring agents in a suitable soluble effervescent basis to make a mouthwash

Nicotine Inhalation Cartridge for Oromucosal Use
(for use with inhalation mouthpiece; to be prescribed as either a starter pack (6 cartridges with inhalator device and holder) or refill pack (42 cartridges with inhalator device))
(proprietary products: NicAssist Inhalator, Nicorette Inhalator), nicotine 10 mg or 15 mg

Nicotine Lozenge
nicotine (as bitartrate) 1 mg or 2 mg (proprietary product: Nicorette Mint Lozenge, Nicotinell Mint Lozenge), or nicotine (as resinate) 1.5 mg, 2 mg, or 4 mg (proprietary product: NiQuitin Lozenges, NiQuitin Minis, NiQuitin Pre-quit)

Nicotine Medicated Chewing Gum
(proprietary products: NicAssist Gum, Nicorette Gum, Nicotinell Gum, NiQuitin Gum), nicotine 2 mg or 4 mg

Nicotine Nasal Spray
(proprietary product: NicAssist Nasal Spray, Nicorette Nasal Spray), nicotine 500 micrograms/metered spray

Nicotine Oral Spray
(proprietary product: Nicorette Quickmist), nicotine 1 mg/metered spray

Nicotine Sublingual Tablets
(to be prescribed as either a starter pack (2 × 15-tablet discs with dispenser) or refill pack (7 × 15-tablet discs))
(proprietary product: NicAssist Microtab, Nicorette Microtab), nicotine (as a cyclodextrin complex) 2 mg

Nicotine Transdermal Patches
(prescriber should specify the brand to be dispensed) releasing in each 16 hours, nicotine approx. 5 mg, 10 mg, or 15 mg (proprietary products: Boots NicAssist Patch, Nicorette Patch) or releasing in each 16 hours approx. 10 mg, 15 mg, or 25 mg (proprietary products: NicAssist Translucent Patch, Nicorette Invisi Patch), or releasing in each 24 hours nicotine approx. 7 mg, 14 mg, or 21 mg (proprietary products: Nicopatch, Nicotinell TTS, NiQuitin, NiQuitin Clear)

Permethrin Cream
(proprietary product: Lyclear Dermal Cream), permethrin 5%

Senna Oral Solution
(proprietary product: Senokot Syrup), sennosides 7.5 mg/5 mL

Senna and Ispaghula Granules
(proprietary product: Manevac Granules), senna fruit 12.4%, ispaghula 54.2%

Sodium Citrate Compound Enema
(proprietary products: Micolette Micro-enema; Micralax Micro-enema; Relaxit Micro-enema), sodium citrate 450 mg with glycerol, sorbitol and an anionic surfactant

Sodium Picosulfate Capsules
(proprietary products: Dulcolax Perles), sodium picosulfate 2.5 mg

Sodium Picosulfate Elixir
(proprietary products: Dulcolax Liquid), sodium picosulfate 5 mg/5 mL

Sterculia Granules
(proprietary product: Normacol Granules), sterculia 62%
Non-medical prescribing

A range of non-medical healthcare professionals can prescribe medicines for patients as either Independent or Supplementary Prescribers. Independent prescribers are practitioners responsible and accountable for the assessment of patients with previously undiagnosed or diagnosed conditions and for decisions about the clinical management required, including prescribing. They are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved non-proprietary name. Supplementary prescribing is a partnership between an independent prescriber (a doctor or a dentist) and a supplementary prescriber to implement an agreed Clinical Management Plan for an individual patient with that patient’s agreement. Independent and Supplementary Prescribers are identified by an annotation next to their name in the relevant professional register. Information and guidance on non-medical prescribing is available on the Department of Health website at www.dh.gov.uk/health/2012/04/prescribing-change.

For information on the mixing of medicines by Independent and Supplementary Prescribers, see Mixing of medicines prior to administration in clinical practice—responding to legislative changes, National Prescribing Centre, May 2010 (available at www.npc.nhs.uk/improving_safety/mixing_meds/resources/mixing_of_medicines.pdf).

For information on the supply and administration of medicines to groups of patients using Patient Group Directions see Guidance on prescribing p. 1.

Nurses
Nurse Independent Prescribers (formerly known as Extended Formulary Nurse Prescribers) are able to prescribe any medicine for any medical condition. Nurse Independent Prescribers are able to prescribe, administer, and give directions for the administration of Schedule 2, 3, 4, and 5 Controlled Drugs. This extends to diamorphine, dipipanone, or cocaine for treating organic disease or injury, but not for treating addiction. Nurse Independent Prescribers must work within their own level of professional competence and expertise. The Nurse Prescribers’ Formulary p. 1322 for Community Practitioners provides information on prescribing.

Pharmacists
Pharmacist Independent Prescribers can prescribe any medicine for any medical condition. They are also able to prescribe, administer, and give directions for the administration of Schedule 2, 3, 4, and 5 Controlled Drugs. This extends to diamorphine, dipipanone, or cocaine for treating organic disease or injury, but not for treating addiction. Pharmacist Independent Prescribers must work within their own level of professional competence and expertise.

Optometrists
Optometrist Independent Prescribers can prescribe any licensed medicine for ocular conditions affecting the eye and the tissues surrounding the eye, except Controlled Drugs or medicines for parenteral administration. Optometrist Independent Prescribers must work within their own level of professional competence and expertise.
The following is an alphabetical list of manufacturers and other companies referenced in the BNF, with their medicines information or general contact details. For information on ‘special-order’ manufacturers and specialist importing companies see ‘Special-order manufacturers’.

3M
3M Health Care Ltd
Tel: (01509) 611 611

A&H
Allen & Hanburys Ltd
Tel: 0800 221 441
customercontactuk@gsk.com

A1 Pharmaceuticals
A1 Pharmaceuticals Plc
Tel: (01708) 528 900
sales@a1plc.co.uk

Abbott
Tel: (01628) 773 355
Abbott Healthcare
Abbott Healthcare Products Ltd
Tel: (01628) 773 355
medinfo.shl@abbott.com

AbbVie
AbbVie Ltd
Tel: (01628) 561 090
ukmedinfo@abbvie.com

Abrasix
Abraxis BioScience Ltd
Tel: (020) 7081 0850
abrasixmedical@idispharma.com

Acorus
Acorus Therapeutics Ltd
Tel: (01244) 625 152

Actavis
Actavis UK Ltd
Tel: (01271) 311 257
medinfo@actavis.co.uk

Actelion
Actelion Pharmaceuticals UK Ltd
Tel: (020) 8987 3333
medinfo.uk@actelion.com

Activa
Activa Healthcare
Tel: 0845 060 6707
advcie@activahealthcare.co.uk

Adienne
Adienne Pharma and Biotech
Tel: 0039 (0) 335 873 8731

ADI Medical
ADI Medical UK
Tel: (01628) 485159
info@adimedical.co.uk

Advanced Medical Solutions
Advanced Medical Solutions Group Plc
Tel: (01606) 863 500

Advancis
Advancis Medical Ltd
Tel: (01623) 751 500
info@advancis.co.uk

Advantech Surgical
Advantech Surgical Ltd
Tel: 0845 130 5866
customerservice@newgel.co.uk

Aegerion
Aegerion Pharmaceuticals Ltd
Tel: 08000 2343 7466
medinfo.emea@aegerion.com

Agematrix
Agerma Matrix Europe Ltd
Tel: (01235) 838 639
info@wavesense.co.uk

Agepha
Agepha GmbH
Tel: (020) 3239 6241
uk@agepha.com

Aguettant
Aguettant Ltd
Tel: (01934) 835 694
info@aguettant.co.uk

Air Products
Air Products plc
Tel: 0800 373 580

Alan Pharmaceuticals
Alan Pharmaceuticals
Tel: (020) 7284 2887
info@alanpharmaceuticals.com

Alcon
Alcon Laboratories (UK) Ltd
Tel: 0345 266 9363
gbmedicaldepartment@alcon.com

Alexion
Alexion Pharma UK Ltd
Tel: (01932) 359 220
alexion.uk@alxn.com

Alimera
Alimera Sciences Limited
Tel: 0800 019 1253
medicalinformation@alimera-sciences.com

Allia
Allia Healthcare
Tel: (01489) 80 759
enquiries@alliahealthcare.com

ALK-Abelló
ALK-Abelló (UK) Ltd
Tel: (0118) 903 7940
info@uk.alk-abelló.com

Alkopharma
Alkopharma Sarl
Tel: (0041) 277 206 969
regulatory@alkopharma.com

Allergan
Allergan Ltd
Tel: (01628) 494 026

Allergy
Allergy Therapeutics Ltd
Tel: (01903) 844 702

Alliance
Alliance Pharmaceuticals Ltd
Tel: (01249) 466 966
info@alliancepharma.co.uk

Almirall
Almirall Ltd
Tel: 0800 008 7399
medinfo@alamirall.com

Altacor
Altacor Ltd
Tel: (01223) 421 411
info@altracor-pharma.com

AMCo
Andipharm Mercury Company Ltd
Tel: 08700 70 30 33
medicalinformation@amcolimited.com

Amgen
Amgen Ltd
Tel: (01223) 420 305
gbinfo@amgen.com

AMO
Abot Medical Optics
Tel: 0800 376 7950

Amred
Amred Healthcare Ltd
Tel: (0330) 333 0079
info@amredhealthcare.com

Apollo Medical
Apollo Medical Technologies Ltd
Tel: (01636) 831 201
supercheck2@btinternet.com

Archimed
Archimed
Tel: 0800 756 9951
enquiries@archimed.co.uk

Archimeides
Archimedes Pharma UK Ltd
Tel: (0118) 931 5094
medicalinformationuk@archimedespharma.com

Arctic Medical
Arctic Medical Ltd
Tel: (01303) 277 751
sales@arcticmedical.co.uk

Ardana
Ardana Bioscience Ltd
Tel: (0131) 226 8550

ARIAD
ARIAD Pharma UK Ltd
Tel: 0800 0002 7423
eumedinfo@ariad.com

Ark Therapeutics
Ark Therapeutics Group Plc
Tel: (020) 7388 7722
info@arktherapeutics.com

Aspen
Aspen
Tel: 0800 008 7392
aspenmedinfo@professionalinformation.co.uk

Aspen Medical
Aspen Medical Europe Ltd
Tel: (01527) 587 728
customers@aspenmedical-europe.com

AS Pharma
AS Pharma Ltd
Tel: 0870 066 4117
info@aspharma.co.uk
Index of proprietary manufacturers

Aspire
Aspire Pharma Ltd
Tel: (01730) 231 148
info@aspirepharma.co.uk

Astellas
Astellas Pharma Ltd
Tel: (020) 3379 8000
medinfo.gb@astellas.com

AstraZeneca
AstraZeneca UK Ltd
Tel: 0800 783 0033
medical.informationuk@astraZeneca.com

Auden Mckenzie
Auden Mckenzie (Pharma Division) Ltd
Tel: (01895) 627 420

Auxilium
Auxilium
Tel: 0845 017 2315
auxilium@pilglobal.com

Axcan
Axcan Pharma SA
Tel: (0033) 130 461 900

AYMES
AYMES International Ltd
Tel: 0845 6805 496
info@aymes.com

Ayrton Saunders
Ayrton Saunders Ltd
Tel: (0151) 709 2074
info@ayrtons.com

BAP
BAP Medical UK Ltd
Tel: 0844 879 7689

Bard
Bard Ltd
Tel: (01293) 527 888

Basilea
Basilea Pharmaceutica Ltd
Tel: (01483) 790 023
ukmedinfo@basilea.com

Bausch & Lomb
Bausch & Lomb UK Ltd
Tel: (01748) 628 864
medicalinformationuk@bausch.com

Baxter
Baxter Healthcare Ltd
Tel: (01635) 206 345
surecall@baxter.com

Bayer
Bayer Healthcare Pharmaceuticals
Tel: (01635) 563 000
medical.information@bayer.co.uk

Bayer Consumer Care
Bayer Healthcare Pharmaceuticals
Tel: (01635) 563 000
medical.information@bayer.co.uk

Bayer Diabetes Care
Bayer Healthcare Pharmaceuticals
Tel: (01635) 563 000
medical.information@bayer.co.uk

Bayer Diagnostics
Bayer Healthcare Pharmaceuticals
Tel: (01635) 563 000
medical.information@bayer.co.uk

BBI Healthcare
BBI Healthcare
Tel: (01792) 229 333
info@bbihealthcare.com

B. Braun
B. Braun Medical Ltd
Tel: (0114) 225 9000
info.bbraun@bbraun.com

Beacon
Beacon Pharmaceuticals Ltd
Tel: (01892) 600 930
info@beaconpharma.co.uk

Beiersdorf
Beiersdorf UK Ltd
Tel: (0121) 329 8800

Besoins
Besoins Healthcare (UK) Ltd
Tel: (01748) 828 789
information@besoins-healthcare.com

BHR
BHR Pharmaceuticals Ltd
Tel: (024) 7637 7210
info@bhr.co.uk

Biogen
Biogen Idec Ltd
Tel: 0800 008 7401

Biotec
Biotec Pharma Ltd
Tel: (00353) 1463 7415

BioMarin
BioMarin Europe Ltd
Tel: (020) 7420 0800
biomarin-europe@bmnr.com

BioMond
BioMond
Tel: 0845 230 1810
info@biomonde.com

Biotest UK
Biotest (UK) Ltd
Tel: (0121) 733 3393
medicinesinformation@biotestuk.com

Blackwell
Blackwell Supplies Ltd
Tel: (01634) 877 620

BOC
BOC Medical
Tel: 0800 111 333

Boehringer Ingelheim
Boehringer Ingelheim Ltd
Tel: (01344) 424 600
info@bra.boehringer-ingelheim.com

Boots
The Boots Company PLC
Tel: (0115) 955 5165

BPC 100
BPC 100 Ltd
Tel: 01942 852085

BPL
Bio Products Laboratory Ltd
Tel: (020) 8957 2255
medinfo@bpl.co.uk

Bray
Bray Healthcare
Tel: (01367) 240 736
info@bray-healthcare.com

Bristol-Myers Squibb
Bristol-Myers Squibb Pharmaceuticals Ltd
Tel: (01895) 523 000
medical.information@bms.com

Britannia
Britannia Pharmaceuticals
Tel: 0870 851 0207
enquiries@medinformation.co.uk

BSN Medical
BSN Medical Ltd
Tel: 0845 122 3600

BTG
BTG International Ltd
Tel: (0207) 575 0000
medical.services@btgplc.com

Bullen
Bullen Healthcare
Tel: 0800 269 327

Cambridge Medical Aesthetics
Cambridge Medical Aesthetics Ltd
Tel: (01733) 396 171
info@cambridgedermalaeesthetics.com

Cambridge Sensors
Cambridge Sensors Ltd
Tel: (01480) 482 920
sales-orders@cs-limited.co.uk

CareFusion
CareFusion UK 244 Ltd
Tel: 0800 043 7546
enquiries@chloraprep.co.uk

Casen-Fleet
Casen-Fleet
Tel: (0034) 913 518 800

C D Medical
C D Medical Ltd
Tel: (01942) 816 184

Celgene
Celgene Ltd
Tel: 0844 801 0045
medinfo.uk.ire@celgene.com

Chanelle Medical
Chanelle Medical UK Ltd
Tel: (01233) 822 297

Chattem UK
Chattem UK Ltd
Tel: (01256) 844 144

Chefaro UK
Chefaro UK Ltd
Tel: (01748) 828 860
info@omegapharma.co.uk

Chemidex
Chemidex Pharma Ltd
Tel: (01784) 477 167
info@chemidex.co.uk

Chiesi
Chiesi Ltd
Tel: (0161) 488 5555
medinfo.uk@chiesi.com

CHS
CHS Cambridge Healthcare Supplies Ltd
Tel: (01953) 607 856
customerservices@cambridge-healthcare.co.uk

Chugai
Chugai Pharma UK Ltd
Tel: (020) 8987 5680

Clement Clarke
Clement Clarke International Ltd
Tel: (01279) 414 969
resp@clement-clarke.com

Clinigen
Clinigen Group Plc
Tel: (01748) 828 375
clinigen@professionalinformation.co.uk

Clinimed
Clinimed Ltd
Tel: (01628) 535 250
| **Clinisupplies** | Clinisupplies Ltd | Tel: (020) 8863 4168 | info@clinisupplies.co.uk |
| **Colgate-Palmolive** | Colgate-Palmolive Ltd | Tel: (01483) 302 222 |
| **Coloplast** | Coloplast Ltd | Tel: (01733) 392 000 |
| **Community** | Community Foods Ltd | Tel: (020) 8450 9411 | email@communityfoods.co.uk |
| **Danetre** | Danetre Health Products Ltd | Tel: (01327) 310 909 | enquiries@danetrehealthproducts.com |
| **DDD** | DDD Ltd | Tel: (01923) 229 251 |
| **Dee** | Dee Pharmaceuticals Ltd | Tel: (01978) 661993 | enquiries@deepeharmaceuticals.co.uk |
| **Dental Health** | Dental Health Products Ltd | Tel: (01622) 749 222 |
| **Dentsply** | Dentsply Ltd | Tel: (01932) 837 279 |
| **Dermal** | Dermal Laboratories Ltd | Tel: (01462) 458 866 |
| **Derma Logical** | Derma Logical Ltd | Tel: (0208) 449 2931 | enquiries@aqua-max.co.uk |
| **Dermatronics** | Dermatronics Ltd | Tel: (01480) 462 910 | sales@dermatronics.co.uk |
| **Derma Sciences Europe** | Derma Sciences Europe Ltd | Tel: (01628) 625 916 | cs@dermasciences.com |
| **Derma UK** | Derma UK Ltd | Tel: (01462) 733 500 | info@dermauk.co.uk |
| **Desitin** | Desitin Pharma Ltd | Tel: (01483) 688 240 | medinfo@desitin.co.uk |
| **Devilbiss** | Devilbiss Healthcare UK Ltd | Tel: (01384) 446 688 |
| **Dexcel** | Dexcel-Pharma Ltd | Tel: (01327) 312 266 | office@dexcelpharma.co.uk |
| **DHP Healthcare** | DHP Healthcare Ltd | Tel: (01622) 749 222 | sales@dhphealthcare.co.uk |
| **DiME** | DiME Ltd | Tel: (01483) 715 008 | info@dime-med.com |
| **Dreamkin** | Dreamkin Health Ltd | Tel: (01707) 228 688 |
| **Dr Falk** | Dr Falk Pharma UK Ltd | Tel: (01628) 536 600 |
| **Drossa** | Drossa Ltd | Tel: (020) 3393 0859 | info@drossa.co.uk |
| **Dubin** | Dubin Ltd | Tel: (020) 8869 6500 | info@dubin.co.uk |
| **Eakin** | T G Eakin | Tel: (028) 9187 1000 | mail@eakin.co.uk |
| **Easigrip** | Easigrip Ltd | Tel: (01926) 497 108 | enquiry@easigrip.co.uk |
| **Ecolab** | Ecolab UK | Tel: (0113) 232 0066 | info.healthcare@ecolab.co.uk |
| **Egis** | Egis Pharmaceuticals UK Ltd | Tel: (020) 7266 2669 | enquiries@medimpexuk.com |
| **Eisai** | Eisai Ltd | Tel: (020) 8600 1400 | eumedinfo@eisai.net |
| **Encysive** | Encysive (UK) Ltd | Tel: (01895) 876 168 |
| **Entra Health** | Entra Health Systems | Tel: (0113) 815 5108 |
| **Espere** | Espere Healthcare Ltd | Tel: (01462) 346 100 | info@esperehealth.co.uk |
| **Essential** | Essential Pharmaceuticals Ltd | Tel: (01784) 477 167 | info@essentialpharmaceuticals.com |
| **Ethicon** | Ethicon Ltd | Tel: (01506) 594 500 |
| **Eumedica** | Eumedica S.A. | Tel: (020) 8444 3377 | enquiries@eumedica.com |
| **European Pharma** | European Pharma Group | Tel: 003 (0) 20 316 0140 | info@insujet.com |
| **EUSA Pharma** | EUSA Pharma (Europe) Ltd | Tel: (01438) 740 720 | medinfo-uk@eusapharma.com |
| **Fabre** | Pierre Fabre Ltd | Tel: (01962) 874 435 | medicalinformation@pierre-fabre.co.uk |
| **Fate** | Fate Special Foods | Tel: (01215) 224 433 |
| **Fenton** | Fenton Pharmaceuticals Ltd | Tel: (020) 7224 1388 | mail@fentonpharm.co.uk |
| **Ferndale** | Ferndale Pharmaceuticals Ltd | Tel: (01937) 541 122 | info@ferndalepharma.co.uk |
| **Ferring** | Ferring Pharmaceuticals (UK) | Tel: 0844 931 0050 | medical@ferring.com |
| **Firstplay Dietary** | Firstplay Dietary Foods Ltd | Tel: (0161) 474 7576 |
| **Flynn** | Flynn Pharma Ltd | Tel: (01438) 727 822 | medinfo@flynnpharma.com |
Index of proprietary manufacturers 1329

Focus
Focus Pharmaceuticals Ltd
Tel: (01283) 495 280
medinfo@focuspharma.co.uk

Foodlink
Foodlink (UK) Ltd
Tel: (01752) 344 544
info@foodlinkltd.co.uk

Ford
Ford Medical Associates Ltd
Tel: (01233) 633 224
enquiries@fordmedical.co.uk

Geistlich
Geistlich Pharma
Tel: (01494) 234 2664
info@genopharm.eu

Genus
Genus Pharmaceuticals
Tel: (01635) 568 400
info@genuspharma.com

Gennzyme
Gennzyme Therapeutics
Tel: (01865) 405 200
ukmedinfo@gennzyme.com

GFF Trade
GF Foods Ltd
Tel: (01757) 289 207
admin@gffdirect.co.uk

Gilead
Gilead Sciences Ltd
Tel: 0800 011 3700
ukmedinfo@gilead.com

Glenwood
Glenwood GmbH
Tel: (0049) 815 199 8790
info@glenwood.de

Glucorx
Glucorx Ltd
Tel: (01483) 755 133
info@glucorx.co.uk

Gluten Free Foods
Gluten Free Foods Ltd
Tel: (020) 8953 4444
info@glutenfree-foods.co.uk

GP Pharma
Derma Pharma Ltd
Tel: (01462) 733 500
info@dermauk.co.uk

Grifols
Grifols UK Ltd
Tel: (01223) 395 700
medinfo.uk@grifols.com

Grüntenthal
Grüntenthal Ltd
Tel: 0870 351 8960
medicalinformationuk@grunental.com

GSK
GSK Consumer Healthcare
Tel: 0800 221 441
customerrelations@gsk.com

H+R
H+R Healthcare Ltd
Tel: 01482 631 606
info@hrhealthcare.co.uk

Hartmann
Paul Hartmann Ltd
Tel: (01706) 363 200
info@uk.hartmann.info

Henleys
Henleys Medical Supplies Ltd
Tel: (01707) 333 164

Hennig Arzneimittel
Hennig Arzneimittel GmbH & Co.
Tel: 0844 504 0866

HFA Healthcare
HFA Healthcare Ltd
Tel: 0844 335 8270

HK Pharma
HK Pharma Ltd
Tel: 0845 519 1609

Hollister
Hollister Ltd
Tel: (0118) 989 5000

Hospira
Hospira UK Ltd
Tel: 0800 088 5133
hospirami@pi-arm.co.uk

HRA Pharma
HRA Pharma UK & Ireland Ltd
Tel: 0800 917 9548
med.info.uk@hra-pharma.com

Huntleigh
Huntleigh Healthcare Ltd
Tel: (01582) 413 104

Huxley
Huxley Europe Ltd
Tel: (0161) 773 0485

Idis
Idis Ltd
Tel: (01932) 824 000
mi@idispharma.com

iMed
iMed Systems Ltd
Tel: (0203) 397 8020
emerade@imed-systems.com

INCA-Pharm
INCA-Pharm UK
Tel: (01748) 828 812
info@inca- pharm.com

Infai
Infai UK Ltd
Tel: (01904) 435 228
info@infai.co.uk

Injex UK
Injex UK Ltd
Tel: 0845 126 8900
enquiries@injexuk.com

Innovative
Innovative Solutions UK Ltd
Tel: (01706) 746 713
enquiries@innovative-solutions.org.uk

Insight
Insight Medical Products Ltd
Tel: (01666) 500 055
info@insightmedical.net

InterMune
InterMune
Tel: (03308) 080 960
med-info@intermune.co.uk

Internis
Internis Pharmaceuticals Ltd
Tel: (020) 8346 5588
regulatory@jensoングroup.com

Intrapharm
Intrapharm Laboratories Ltd
Tel: (01628) 771 800
sales@intrapharmlabs.com

Ipsen
Ipsen Ltd
Tel: (01753) 627 777
medical.information.uk@ipsen.com
<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iroko</td>
<td>Iroko Cardio GmbH</td>
</tr>
<tr>
<td></td>
<td>Tel: (020) 3002 8114 <a href="mailto:info@irokocardio.com">info@irokocardio.com</a></td>
</tr>
<tr>
<td>IS Pharmaceuticals</td>
<td>Sinclair IS</td>
</tr>
<tr>
<td></td>
<td>Tel: (01244) 652 152 <a href="mailto:enquiries@ispharma.plc.uk">enquiries@ispharma.plc.uk</a></td>
</tr>
<tr>
<td>IVAX</td>
<td>TEVA UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0870 502 0304 <a href="mailto:medinfo@tevauk.com">medinfo@tevauk.com</a></td>
</tr>
<tr>
<td>J &amp; J</td>
<td>Johnson &amp; Johnson Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01628) 822 222 <a href="mailto:medinfo@congb.jnj.com">medinfo@congb.jnj.com</a></td>
</tr>
<tr>
<td>Janssen</td>
<td>Janssen-Cilag Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0800 731 8450 <a href="mailto:medinfo@janssen-cilag.co.uk">medinfo@janssen-cilag.co.uk</a></td>
</tr>
<tr>
<td>Jobskin</td>
<td>Jobskin Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (0115) 973 4300 <a href="mailto:dw@jobskin.co.uk">dw@jobskin.co.uk</a></td>
</tr>
<tr>
<td>Juvela</td>
<td>Juvela (Hero UK) Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (0151) 432 5300 <a href="mailto:info@juvela.co.uk">info@juvela.co.uk</a></td>
</tr>
<tr>
<td>K/L</td>
<td>K/L Pharmaceuticals Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01294) 215 951</td>
</tr>
<tr>
<td>KCI Medical</td>
<td>KCI Medical Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01865) 840 600</td>
</tr>
<tr>
<td>Kestrel Ophthalmics</td>
<td>Kestrel Ophthalmics Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01202) 658 444 <a href="mailto:info@kestrelophthalmics.co.uk">info@kestrelophthalmics.co.uk</a></td>
</tr>
<tr>
<td>King</td>
<td>King Pharmaceuticals Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01438) 356 924</td>
</tr>
<tr>
<td>Kora</td>
<td>KoRa Healthcare Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0845 303 8631 <a href="mailto:info@kora.ie">info@kora.ie</a></td>
</tr>
<tr>
<td>Labopharm</td>
<td>Labopharm Europe Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0880 028 0037 <a href="mailto:medinfo@paladin-labs.com">medinfo@paladin-labs.com</a></td>
</tr>
<tr>
<td>LaCorium</td>
<td>LaCorium Health (UK) Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0800 158 8233 <a href="mailto:ukinfo@flexitol.com">ukinfo@flexitol.com</a></td>
</tr>
<tr>
<td>Lantor</td>
<td>Lantor UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01204) 855 000 <a href="mailto:help@lantor.co.uk">help@lantor.co.uk</a></td>
</tr>
<tr>
<td>LEO</td>
<td>LEO Laboratories Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01844) 347 333 <a href="mailto:medical-info.uk@leo-pharma.com">medical-info.uk@leo-pharma.com</a></td>
</tr>
<tr>
<td>LifeScan</td>
<td>LifeScan</td>
</tr>
<tr>
<td></td>
<td>Tel: 0800 001 210</td>
</tr>
<tr>
<td>Lilly</td>
<td>Eli Lilly &amp; Co Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01256) 315 000 <a href="mailto:ukmedinfo@lilly.com">ukmedinfo@lilly.com</a></td>
</tr>
<tr>
<td>Lincoln Medical</td>
<td>Lincoln Medical Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01722) 742 900 <a href="mailto:info@lincolnmicdical.co.uk">info@lincolnmicdical.co.uk</a></td>
</tr>
<tr>
<td>Lindera</td>
<td>Lindera Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01942) 816 184 <a href="mailto:linderaa@virgin.ne">linderaa@virgin.ne</a></td>
</tr>
<tr>
<td>Lipomed</td>
<td>Lipomed GmbH</td>
</tr>
<tr>
<td></td>
<td>Tel: (0041) 6170 20200 <a href="mailto:save@lipomed.com">save@lipomed.com</a></td>
</tr>
<tr>
<td>Livwell</td>
<td>Livwell Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0845 120 0038 <a href="mailto:info@livwell.eu">info@livwell.eu</a></td>
</tr>
<tr>
<td>LogixX</td>
<td>LogixX Pharma Solutions Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01189) 011 747 <a href="mailto:medinfo@logixxpharma.com">medinfo@logixxpharma.com</a></td>
</tr>
<tr>
<td>Lornamead</td>
<td>Lornamead Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01276) 674000 <a href="mailto:lornamead@dhl.com">lornamead@dhl.com</a></td>
</tr>
<tr>
<td>LPC</td>
<td>LPC Pharmaceuticals Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01582) 560 393 <a href="mailto:info@lpcharma.com">info@lpcharma.com</a></td>
</tr>
<tr>
<td>Lucane</td>
<td>Lucane Pharma</td>
</tr>
<tr>
<td></td>
<td>Tel: 0033 (0) 153 868 750 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Lundbeck</td>
<td>Lundbeck Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01908) 649 966 <a href="mailto:ukmedicalinformation@lundbeck.com">ukmedicalinformation@lundbeck.com</a></td>
</tr>
<tr>
<td>L’Oreal Active</td>
<td>L’Oreal Active Cosmetics UK</td>
</tr>
<tr>
<td></td>
<td>Tel: 0800 055 6822</td>
</tr>
<tr>
<td>M &amp; A Pharmachem</td>
<td>M &amp; A Pharmachem Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01942) 816 184</td>
</tr>
<tr>
<td>Manuka Medical</td>
<td>Manuka Medical</td>
</tr>
<tr>
<td></td>
<td>Tel: (01623) 600 669</td>
</tr>
<tr>
<td>Manx</td>
<td>Manx Healthcare</td>
</tr>
<tr>
<td></td>
<td>Tel: (01926) 462 511 <a href="mailto:info@manxhealthcare.com">info@manxhealthcare.com</a></td>
</tr>
<tr>
<td>Marlborough</td>
<td>Marlborough Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Tel: (01279) 406 759 <a href="mailto:info@marlborough-pharma.co.uk">info@marlborough-pharma.co.uk</a></td>
</tr>
<tr>
<td>Martindale</td>
<td>Martindale Pharma</td>
</tr>
<tr>
<td></td>
<td>Tel: (01277) 266 600 <a href="mailto:medinfo@martindalepharma.co.uk">medinfo@martindalepharma.co.uk</a></td>
</tr>
<tr>
<td>MARTA</td>
<td>MARTA</td>
</tr>
<tr>
<td></td>
<td>Tel: (0113) 238 7500 <a href="mailto:medical@marta.org">medical@marta.org</a></td>
</tr>
<tr>
<td>McNeil</td>
<td>McNeil Products Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01628) 822 222</td>
</tr>
<tr>
<td>MED</td>
<td>Medical Diagnostics Europe Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0845 370 8077 <a href="mailto:info@medediatric.co.uk">info@medediatric.co.uk</a></td>
</tr>
<tr>
<td>Medac</td>
<td>Medac</td>
</tr>
<tr>
<td></td>
<td>Medac (UK)</td>
</tr>
<tr>
<td></td>
<td>Tel: (01786) 458 086 <a href="mailto:info@medac-uk.co.uk">info@medac-uk.co.uk</a></td>
</tr>
<tr>
<td>Medical Developments</td>
<td>Medical Developments UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0870 850 1234 <a href="mailto:enquiries@ashfieldin2focus.com">enquiries@ashfieldin2focus.com</a></td>
</tr>
<tr>
<td>Medicare</td>
<td>Medicare</td>
</tr>
<tr>
<td></td>
<td>Medicare Plus International Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (020) 8810 8811 <a href="mailto:info@medicare-plus.com">info@medicare-plus.com</a></td>
</tr>
<tr>
<td>Medicon</td>
<td>Medicon</td>
</tr>
<tr>
<td></td>
<td>Medicon Healthcare Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01489) 574 119 <a href="mailto:info@mediconhealthcare.com">info@mediconhealthcare.com</a></td>
</tr>
<tr>
<td>Medipheny</td>
<td>Medipheny (Europe) Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0800 071 3912</td>
</tr>
<tr>
<td>Medisana</td>
<td>Medisana</td>
</tr>
<tr>
<td></td>
<td>Tel: +49 (0) 2131/36 68 0</td>
</tr>
<tr>
<td>Medlock</td>
<td>Medlock</td>
</tr>
<tr>
<td></td>
<td>Medlock Medical Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (0161) 621 2100</td>
</tr>
<tr>
<td>MedLogic</td>
<td>MedLogic Global Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01752) 209 955 <a href="mailto:enquiries@mlgl.co.uk">enquiries@mlgl.co.uk</a></td>
</tr>
<tr>
<td>Menarini A</td>
<td>Menarini A</td>
</tr>
<tr>
<td>Menarini C</td>
<td>Menarini C</td>
</tr>
<tr>
<td>Menarini Diagnostics</td>
<td>Menarini Diagnostics</td>
</tr>
<tr>
<td></td>
<td>Tel: (0118) 944 4100</td>
</tr>
<tr>
<td>Merck Serono</td>
<td>Merck Serono Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (020) 8818 7200 <a href="mailto:medinfo.uk@merckserono.net">medinfo.uk@merckserono.net</a></td>
</tr>
<tr>
<td>Merus</td>
<td>Merus Labs</td>
</tr>
<tr>
<td></td>
<td>Tel: 00352 (0) 2637 5878 <a href="mailto:qchs.mi@quintiles.com">qchs.mi@quintiles.com</a></td>
</tr>
<tr>
<td>Merz</td>
<td>Merz</td>
</tr>
<tr>
<td></td>
<td>Merz Pharma UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (020) 8236 0000 <a href="mailto:info@merzpharma.co.uk">info@merzpharma.co.uk</a></td>
</tr>
<tr>
<td>Micro Medical</td>
<td>Micro Medical</td>
</tr>
<tr>
<td></td>
<td>Micro Medical Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01634) 893 500</td>
</tr>
<tr>
<td>Milupa</td>
<td>Milupa Aptamil</td>
</tr>
<tr>
<td></td>
<td>Tel: 0845 762 3676 <a href="mailto:caroline@aptamil4hcpps.co.uk">caroline@aptamil4hcpps.co.uk</a></td>
</tr>
<tr>
<td>Mitsubishi</td>
<td>Mitsubishi</td>
</tr>
<tr>
<td></td>
<td>Mitsubishi Pharma</td>
</tr>
<tr>
<td></td>
<td>Tel: (0207) 382 9000 <a href="mailto:medinfo@mitsubishi-pharma.eu">medinfo@mitsubishi-pharma.eu</a></td>
</tr>
</tbody>
</table>
Index of proprietary manufacturers

Mölnlycke
Mölnlycke Health Care Ltd
Tel: (0161) 777 2628
info.uk@molnlycke.net

Nordic
Nordic Pharma UK Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Norgine
Norgine Pharmaceuticals Ltd
Tel: (01895) 826 600
medinfo@norgine.com

Nya Kallio Ventures
Medinfo@norgine.com

Novartis
Novartis Consumer Health
Tel: (0276) 687 202
medicalaffairs.uk@novartis.com

Novartis Vaccines
Novartis Vaccines Ltd
Tel: 0845 745 1500
service.uk@novartis.com

Novo Nordisk
Novo Nordisk Ltd
Tel: (01293) 613 555
nspirehealth.com

Nutricia
Nutricia Ltd
Tel: (01225) 751 098
resourcecentre@nutricia.com

Nutrinovo
Nutrinovo Ltd
Tel: (01304) 829 068
info@nutrinovo.com

Nutilact
Nutilact Ltd
Tel: 0808 101 0926
support@nutilact.co.uk

Nunivie
Nunivie Ltd
Tel: (0113) 620 7000

Nestlé
Nestlé UK
Tel: (0845) 745 1500
service.uk@novartis.com

Nutricia
Nutricia Ltd
Tel: (01225) 751 098
resourcecentre@nutricia.com

Nutrinovo
Nutrinovo Ltd
Tel: (01304) 829 068
info@nutrinovo.com

Nutrition Point
Nutrition Point Ltd
Tel: (07041) 544 044
info@nutritionpoint.co.uk

Nycomed
Nycomed (UK) Ltd
Tel: (01628) 646 4397
medinfo@nycomed.com

Oakmed
Oakmed Ltd
Tel: 0800 592 786
orders@oakmed.co.uk

Octapharma
Octapharma Ltd
Tel: (0161) 837 3770
octapharma@octapharma.co.uk

Omega Pharma
Omega Pharma
Tel: (01748) 828 860
omega@professionalinformation.co.uk

Omsen
Omsen Ltd
Tel: 0800 592 786
orders@oakmed.co.uk

Orphan Europe
Orphan Europe (UK) Ltd
Tel: (01491) 414 333
info@orphan-europe.com

Otsuka
Otsuka Pharmaceuticals (UK) Ltd
Tel: (020) 3747 5300
ukmedinfo@otsuka.co.uk

Otsuka Novel
Otsuka Novel Products GmbH
Tel: (0049) 892 0602 0500
medical@otsuka-ongp.com

Ovation
Ovation Healthcare International Ltd
Tel: (00353) 1613 9707

Owen Mumford
Owen Mumford Ltd
Tel: (01993) 812 021
customerservices@owenmumford.co.uk

Oxford Nutrition
Oxford Nutrition Ltd
Tel: (01262) 832 067
info@nutrinox.com

Pari
PARI Medical Ltd
Tel: (0132) 341 122
info@pari.de

Parkside
Parkside Healthcare
Tel: (0161) 795 2792

Peckforton
Peckforton Pharmaceuticals Ltd
Tel: (01270) 582 255
info@peckforton.com

Pfizer
Pfizer Ltd
Tel: (01304) 616 161
eumedinfo@pfizer.com

PGI Health Foods
PGI Health Foods Ltd
Tel: (01992) 581 715
info@pgihealthfoods.co.uk

Pharmacy
Pharmacy Ltd
Tel: (01304) 616 161
eumedinfo@pfizer.com

Pharmacosmos
Pharmacosmos UK Ltd
Tel: (01844) 269 007
info@vitalineuk.co.uk

Pharmacy
Pharmacy Ltd
Tel: (0132) 341 122
info@pari.de

Pharma Nord
Pharma Nord (UK) Ltd
Tel: (01670) 519 989
uksales@pharmanord.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nordic
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nordic
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nord Ltd
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nordic
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Pharma Nordic
Tel: (0118) 929 6233
info@nordicpharma.co.uk

Pharma Nord
Index of proprietary manufacturers

Pharmasure
Pharmasure Ltd
Tel: (01923) 233 466
info@pharmasure.co.uk

Pharmaxis
Pharmaxis Pharmaceuticals Ltd
Tel: (01628) 902 053
med.info@pharmaxis.com.au

PharSafer
PharSafer Associates Ltd
Tel: 01483 212151
mediafouquiries@pharsafer.com

Phoenix
Phoenix Labs
Tel: (00353) 1468 8917
medicalinformation@phoenixlabs.ie

Pinewood
Pinewood Healthcare
Tel: (00353) 523 6253
info@pinewood.ie

Pinnacle
Pinnacle Biologics Inc.
Tel: 1-866-248-2039
pinnaclemedinfo@optum.com

Potters
Potters Herbal Medicines
Tel: (01942) 219 960

Procei
Procei
Tel: (01226) 713 044
admin@procei.co.uk

Procter & Gamble
Procter & Gamble (Health and Beauty Care) Ltd
Tel: (0191) 297 5000

Profile
Profile Pharma Ltd
Tel: 0800 1300 855
info@profilepharma.com

ProStrakan
ProStrakan Ltd
Tel: (01896) 664 000
medinfo@prostrakan.com

Protex
Protex Healthcare (UK) Ltd
Tel: 0870 011 4112
orders@protexhealthcare.co.uk

Qdem
Qdem
Tel: (01223) 426 929
medicalinformation@qdem.co.uk

Ranbaxy
Ranbaxy UK Ltd
Tel: (020) 8280 1986
medinfoeurope@ranbaxy.com

Ransom
Ransom Consumer Healthcare
Tel: (01462) 437 615
info@williamransom.com

Ratiopharm UK
Ratiopharm UK Ltd
Tel: (023) 9221 3592
info@ratiopharm.co.uk

Reckitt Benckiser
Reckitt Benckiser Healthcare
Tel: (01482) 326 151
info.mi@reckittbenckiser.com

Recordati
Recordati Pharmaceuticals Ltd
Tel: (01491) 576 336
medinfo@recordati.co.uk

ReSource Medical
ReSource Medical UK Ltd
Tel: (01484) 531 489
info@resource-medical.co.uk

Respirronics
Philips Respirronics (UK) Ltd
Tel: 0800 130 0840
rukmketing@respironics.co.uk

RF Medical
RF Medical Supplies Ltd
Tel: (0151) 493 1473
enquiries@rfmedicalsupplies.co.uk

Richardson
Richardson Healthcare Ltd
Tel: 0800 170 1126
info@richardsonhealthcare.com

Riemser
Riemser Arzneimittel AG
Tel: (0694) 383 517 6679
info@riemser.de

RIS Products
RIS Products Ltd
Tel: (01438) 840 135

Robinsons
Robinson Healthcare Ltd
Tel: (01909) 735 064
enquiry@robinsonhealthcare.com

Roche
Roche Products Ltd
Tel: 0800 328 1629
medinfo.uk@roche.com

Roche Diagnostics
Roche Diagnostics Ltd
Tel: (01444) 256 000

Rosemont
Rosemont Pharmaceuticals Ltd
Tel: 0800 919 312
infodesk@rosemontpharma.com

Rowa
Rowa Pharmaceuticals Ltd
Tel: (00353) 275 0077
rowa@rowa-pharma.ie

RPH
RPH Pharmaceuticals
Tel: (01483) 212 151
medinfoenquiries@pharsafer.com

S & N Hlth.
Smith & Nephew Healthcare Ltd
Tel: (01482) 222 200
advice@smith-nephew.com

Sallis
Sallis Healthcare Ltd
Tel: (0115) 978 7841

Sandoz
Sandoz Ltd
Tel: (01276) 698 020
sandoz@professionalinformation.co.uk

Sanovia
Sanovia Diagnostics UK Ltd
Tel: (0117) 906 3562

Sanofi-Aventis
Sanofi-Aventis Ltd
Tel: 0845 372 7101
uk-medicalinformation@sanofi-aventis.com

Sanofi Pasteur
Sanofi Pasteur MSD Ltd
Tel: (01628) 785 291

SanoMed
SanoMed Manufacturing bv
Tel: +32 503 93627
info@sanoemed.nl

Schering-Plough
Merck Sharp & Dohme Ltd
Tel: (01992) 467 272
medicalinformationuk@merck.com

Schuco
Schuco International Ltd
Tel: (020) 8368 1642
sales@schuco.co.uk

Schülke
Schülke UK
Tel: (0114) 254 3500
mail.uk@schuelke.de

Scope Ophthalmics
Scope Ophthalmics Ltd
Tel: (01293) 897 209
info@scopeophthalmics.com

SD Biosensor
SD Biosensor, Inc.
Tel: 0082 31 300 0475
sales@sbiosensor.com

SD Healthcare
SD Healthcare
Tel: (0161) 776 7626
sales@sdhealthcare.com

Seahorse
Seahorse Laboratories Ltd
Tel: (020) 8257 8412
info@seahorse-labs.com

Septodont
Septodont Ltd
Tel: (01622) 695 520

Servier
Servier Laboratories Ltd
Tel: (01753) 666 409
medical.information@uk.netgrs.com

Seven Seas
Seven Seas Ltd
Tel: (01482) 375 234

Shermond
Shermond
Tel: 0870 242 7701
sales@shermond.com

Shire
Shire Pharmaceuticals Ltd
Tel: 0800 055 6614
medinfo@shire.com

Shire HGT
Shire Human Genetic Therapies
Tel: (01256) 894 000
htgmmedcomm@shire.com

SIS
SIS International Ltd
Tel: (0151) 228 8161

Siemens
Siemens Healthcare Diagnostics Ltd
Tel: 0845 600 1966
dx-diag-sales-uk.med@siemens.com

Sigma-Tau
Sigma-Tau Pharma Ltd (UK)
Tel: 0800 043 1269
medical.information@sigttau.co.uk

SilDerm
SilDerm Ltd
Tel: (01260) 271 666
Index of proprietary manufacturers

Sinclair IS
Sinclair IS Pharma
Tel: (01244) 625 152
enquiries@ispharma.plc.uk

Skin Camouflage Co.
The Skin Camouflage Company Ltd
Tel: (01507) 343 091
smcovermark@aol.com

Skinny's
Skinny's UK
Tel: (01562) 546 123
info@skinnyssuk.com

SLO Drinks
SLO Drinks Ltd
Tel: 0845 222 2205
info@slodrinks.com

SMA Nutrition
Wyeth Pharmaceuticals
Tel: (01628) 604 377
eumedinfo@pfizer.com

SNBTS
Scottish National Blood Transfusion Service
Tel: (0131) 536 5700
contact.plc@snbts.csascot.nhs.uk

Sound Opinion
Spectrum Thea
Tel: (01895) 523 000
medical.information@bms.com

SPEPharm
SpePharm UK Ltd
Tel: 0844 800 7579
medinfo.uk@spepharm.com

Spectrum Thea
Spectrum Thea Pharmaceuticals
Tel: 0870 192 3283
thesupport@spectrum-thea.co.uk

SpePharm
SpePharm UK Ltd
Tel: 0844 800 7579
medinfo.uk@spepharm.com

Spirit
Spirit Healthcare Ltd
Tel: 0800 881 5423
cs@spirit-healthcare.co.uk

Squibb
Bristol-Myers Squibb Pharmaceuticals Ltd
Tel: (01895) 523 000
medical.information@bms.com

SSL
SSL International plc
Tel: 0870 122 2690

Stanningley
Stanningley Pharma Ltd
Tel: (01159) 124 253
medinfo@stanningleypharma.co.uk

STD Pharmaceuticals
STD Pharmaceutical Products Ltd
Tel: (01432) 373 555
enquiries@stdpharm.co.uk

Steraid
Steraid (Gainsborough) Ltd
Tel: (01427) 677 559

St George's Medical
St George's Medical
Tel: (020) 7582 1015

Stiefel (a GSK company)
Tel: 0800 221 441

Stiellito Foods
Stiellito Foods UK Ltd
Tel: 0845 130 0869

Stragen
Stragen UK Ltd
Tel: 0870 351 8744
info@stragenuk.com

Sucampo
Sucampo Pharma
Tel: 0800 756 3416
infoeu@sucampo.com

Su-Med
Su-Med International UK Ltd
Tel: (01457) 890 980
sales@sumed.co.uk

Sunovion
Sunovion Pharmaceuticals Europe Ltd
Tel: (020) 7821 2840
medinfo@sunovion.eu

Sutherland
Sutherland Health Ltd
Tel: (01635) 874 488

Swedish Orphan
Swedish Orphan Biovitrum Ltd
Tel: (01638) 722 380
medical.info@sobi.com

Synergy Healthcare
Synergy Healthcare (UK) Ltd
Tel: (0161) 624 5641
healthcaresolutions@synergyhealthplc.com

Syner-Med
Syner-Med (Pharmaceutical Products) Ltd
Tel: 0845 634 2100
mail@syner-med.com

Systagenix
Systagenix Wound Management
Tel: (01293) 842 000

Takeda
Takeda UK Ltd
Tel: (01628) 537 900
medinfo@takeda.co.uk

Talley
Talley Group Ltd
Tel: (01794) 503 500

Taro
Taro Pharmaceuticals (UK) Ltd
Tel: 0870 736 9544
customerservice@taropharma.co.uk

Teofarma
Teofarma S.r.l.
servizioclienti@teofarma.it

Teva
TEVA UK Ltd
Tel: 0870 502 0304
medinfo@tevauk.com

TEVA UK
TEVA UK Ltd
Tel: (020) 7540 7117
medinfo@tevauk.com

The Medicines Company
The Medicines Company
Tel: 0800 8436 3326
medical.information@themedicom.com

Therabel
Therabel Pharma UK Ltd
Tel: 0800 066 5446
info@therabel.co.uk

The Urology Co.
The Urology Company Ltd
Tel: (020) 3077 5411
info@theurologyco.com

Thomas Blake
Thomas Blake Cosmetic Creams Ltd
Tel: (01207) 272 311
sales@veilcover.com

Thornton & Ross
Thornton & Ross Ltd
Tel: (01484) 842 217

Tillomed
Tillomed Laboratories Ltd
Tel: (01480) 402 400
info@tillomed.co.uk

Tillotts
Tillotts Pharma UK Ltd
Tel: 0845 034 4476

TMC
TMC Pharma Services Ltd
Tel: (01252) 842 255
info@tmcpharma.com

Tobia Teff
Tobia Teff UK Ltd
Tel: (020) 7328 2045
info@tobiateff.co.uk

Torbet
Torbet Laboratories Ltd
Tel: (01953) 607 856
customerservices@cambridge-healthcare.co.uk

Transdermal
Transdermal Ltd
Tel: (020) 8654 2251
info@transdermal.co.uk

TRB Chemedica
TRB Chemedica (UK) Ltd
Tel: 0845 330 7556

Typharm
Typharm Ltd
Tel: (01603) 722 480
customerservices@typharm.com

UCB Pharma
UCB Pharma Ltd
Tel: (01753) 534 655
medicalinformationuk@ucb.com

Ultrapharm
Ultrapharm Ltd
Tel: (01491) 578 016

Univar
Univar Ltd
Tel: (01908) 362 200
trietine@univareurope.com

Unomedical
Unomedical Ltd
Tel: (01527) 587 700

Urgo
Urgo Ltd
Tel: (01509) 502 051
woundcare@uk.urgocom

Vegenat
c/o Archealis Ltd
Tel: 0870 803 2484

Vertex
Vertex Pharmaceuticals (UK) Ltd
Tel: 0800 028 2616
eumedicalinfo@VRTX.com
<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vifor</td>
<td>Vifor Pharma UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01276) 853 633</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medicalinfo.uk@viforpharma.com">medicalinfo.uk@viforpharma.com</a></td>
</tr>
<tr>
<td>Viiv</td>
<td>Viiv Healthcare UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: 0800221441</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:customercontactuk@gsk.com">customercontactuk@gsk.com</a></td>
</tr>
<tr>
<td>Viridian</td>
<td>Viridian Pharma Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01633) 400 335</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@viridianpharma.co.uk">info@viridianpharma.co.uk</a></td>
</tr>
<tr>
<td>ViroPharma</td>
<td>ViroPharma Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (020) 7572 1222</td>
</tr>
<tr>
<td>Vitaflo</td>
<td>Vitaflo International Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (0151) 709 9020</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:vitaflo@vitaflo.co.uk">vitaflo@vitaflo.co.uk</a></td>
</tr>
<tr>
<td>Vitalograph</td>
<td>Vitalograph Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01280) 827 110</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:sales@vitalograph.co.uk">sales@vitalograph.co.uk</a></td>
</tr>
<tr>
<td>Wallace Cameron</td>
<td>Wallace Cameron Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01698) 354 600</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:sales@wallacecameron.com">sales@wallacecameron.com</a></td>
</tr>
<tr>
<td>Wallace Mfg</td>
<td>Wallace Manufacturing Chemists Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01235) 538 700</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@alinter.co.uk">info@alinter.co.uk</a></td>
</tr>
<tr>
<td>Warburtons</td>
<td>Warburtons</td>
</tr>
<tr>
<td></td>
<td>Tel: (01204) 513 004</td>
</tr>
<tr>
<td>Warner Chilcott</td>
<td>Warner Chilcott UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01932) 824 700</td>
</tr>
<tr>
<td>WBS</td>
<td>Welsh Blood Service</td>
</tr>
<tr>
<td></td>
<td>Tel: (01443) 622 000</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:donor.care@wales.nhs.uk">donor.care@wales.nhs.uk</a></td>
</tr>
<tr>
<td>Wellfoods</td>
<td>Wellfoods Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01226) 381 712</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:wellfoods@wellfoods.co.uk">wellfoods@wellfoods.co.uk</a></td>
</tr>
<tr>
<td>Williams</td>
<td>Williams Medical Supplies Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01685) 844 739</td>
</tr>
<tr>
<td>Wockhardt</td>
<td>Wockhardt UK Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01978) 661 261</td>
</tr>
<tr>
<td>Wyeth</td>
<td>Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Tel: (01628) 604 377</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:eumedinfo@pfizer.com">eumedinfo@pfizer.com</a></td>
</tr>
<tr>
<td>Wynlit</td>
<td>Wynlit Laboratories</td>
</tr>
<tr>
<td></td>
<td>Tel: (07903) 370 130</td>
</tr>
<tr>
<td>Wyvern</td>
<td>Wyvern Medical Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01531) 631 105</td>
</tr>
<tr>
<td>Zentiva</td>
<td>Zentiva</td>
</tr>
<tr>
<td></td>
<td>Tel: (01483) 554 101</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:gb-zentivamedicalinformation@sanofi.com">gb-zentivamedicalinformation@sanofi.com</a></td>
</tr>
<tr>
<td>Zeroderma</td>
<td>Zeroderma Ltd</td>
</tr>
<tr>
<td></td>
<td>Tel: (01858) 525 643</td>
</tr>
</tbody>
</table>
Unlicensed medicines are available from 'special-order' manufacturers and specialist-importing companies; the MHRA maintains a register of these companies at tinyurl.com/cdiskk.

Licensed hospital manufacturing units also manufacture 'special-order' products as unlicensed medicines, the principal NHS units are listed below. A database (Pro-File; www.pro-file.nhs.uk) provides information on medicines manufactured in the NHS; access is restricted to NHS pharmacy staff.

The Association of Pharmaceutical Specials Manufacturers may also be able to provide further information about commercial companies (www.apsm-uk.com).

The MHRA recommends that an unlicensed medicine should only be used when a patient has special requirements that cannot be met by use of a licensed medicine.

As well as being available direct from the hospital manufacturer(s) concerned, many NHS-manufactured Specials may be bought from the Oxford Pharmacy Store, owned and operated by Oxford Health NHS Foundation Trust.

England

London

Barts and the London NHS Trust
Mr J. Singh, Head of PMU
Barts Health NHS Trust
Royal London Hospital
Pathology and Pharmacy Building
80 Newark St
Whitechapel
London E1 2ES
Tel: (020) 3246 0274 (order)
Tel: (020) 3246 0399 (enquiry)
jasdeep.singh@bartshealth.nhs.uk

Guy’s and St. Thomas’ NHS Foundation Trust
Mr P. Forsay, Associate Chief Pharmacist
Guy’s and St. Thomas’ NHS Foundation Trust
Guy’s Hospital
Pharmacy Department
Great Maze Pond
London SE1 9RT
Tel: (020) 7188 4992 (order)
Tel: (020) 7188 5003 (enquiry)
Tel: (020) 7188 5013
paul.forsay@gstt.nhs.uk

Moorfields Pharmaceuticals
Mr. N. Precious, Technical Director
Moorfields Pharmaceuticals
34 Nile St
London N1 7TP
Tel: (020) 7684 9090 (order)
Tel: (020) 7684 8574 (enquiry)
Fax: (020) 7502 2332
nick.precious@moorfields.nhs.uk

North West London Hospitals NHS Trust
Dr K. Middleton,
North West London Hospitals NHS Trust
Northwick Park Hospital
Watford Rd
Harrow
Middlesex HA1 3UJ
Tel: (020) 8869 2295 (order)
Tel: (020) 8869 2204/2223 (enquiry)
keith.middleton@nwlht.nhs.uk

Royal Free Hampstead NHS Trust
Ms C. Trehane, Production Manager
Royal Free Hampstead NHS Trust
Pond St
London NW3 2QG
Tel: (020) 7830 2424 (order)
Tel: (020) 7830 2282 (enquiry)
Fax: (020) 7794 1875
christine.trehane@nhs.net

St George’s Healthcare NHS Trust
Mr V. Kumar, Assistant Chief Pharmacist
St George’s Hospital
Technical Services
Blackshaw Rd
Tooting
London SW17 0QT
Tel: (020) 8725 1770/1768
Fax: (020) 8725 3947
vinodh.kumar@stgeorges.nhs.uk

University College Hospital NHS Foundation Trust
Mr T. Murphy, Production Manager
University College Hospital
235 Euston Rd
London NW1 2BU
Tel: (020) 7380 9723 (order)
Tel: (020) 7380 9472 (enquiry)
Fax: (020) 7380 9726
tony.murphy@UCH.nhs.uk

Midlands and Easterns

Barking, Havering and Redbridge University Trust
Mr N. Fisher, Senior Principal Pharmacist
Queen’s Hospital
Pharmacy Department
Romford
Essex RM7 0AG
Tel: (01708) 435 463 (order)
Tel: (01708) 435 042 (enquiry)
nigel.fisher@bhrhospitals.nhs.uk

Burton Hospitals NHS Trust
Mr P. Williams, Pharmacy Technical and Support Services Manager
Queens Hospital
Burton Hospitals NHS Trust
Pharmacy Manufacturing Unit
Belvedere Rd
Burton-on-Trent DE13 0RB
Tel: (01283) 511 511 (or 566 333)
ext:5115 (order) 5138 (enquiry)
Fax: (01283) 593 036
paul.williams@burtonh-tr.wmids.nhs.uk

Colchester University Hospital NHS Foundation Trust
Mrs A. Reynolds, Pharmacy Business Manager
Colchester General Hospital
Pharmacy Support Unit
Turner Rd
Colchester CO4 5J
Tel: (01206) 742 007 (order)
Tel: (01206) 746 148 (enquiry)
Fax: (01206) 241 249
pharmacy.stores@colchesterhospital.nhs.uk (order)
pseuqueries@colchesterhospital.nhs.uk (enquiries)

Ipswich Hospital NHS Trust
Dr J. Harwood, Production Manager
Ipswich Hospital NHS Trust
Pharmacy Manufacturing Unit
Heath Rd
Ipswich, IP4 5PP
Tel: (01473) 703 440 (order)
Tel: (01473) 703 603 (enquiry)
Fax: (01473) 703 609
john.harwood@ipswichhospital.nhs.uk

Nottingham University Hospitals NHS Trust
Ms J. Kendall, Assistant Head of Pharmacy, Technical and Logistical Services
Nottingham University Hospitals NHS Trust
Pharmacy Production Units
Queens Medical Centre Campus
Nottingham NG7 2UH
Tel: (0115) 875 4521 (order)
Tel: (0115) 924 9524 ext: 64177 (enquiry)
Fax: (0115) 970 9780
jeannette.kendall@nuh.nhs.uk

University Hospital of North Staffordshire NHS Trust
Ms K. Ferguson, Chief Technician
University Hospital of North Staffordshire NHS Trust
Pharmacy Technical Services
City General Site
Stoke-on-Trent ST4 6QG
Tel: (01782) 674 568 (order)
Tel: (01782) 674 568 (enquiry)
Fax: (01782) 674 575
jeannette.kendall@nuh.nhs.uk

North East

The Newcastle upon Tyne Hospitals NHS Foundation Trust
Mr Y. Hunter-Blair, Production Manager
Royal Victoria Infirmary
Newcastle Specials
Pharmacy Production Unit
Queen Victoria Rd
Newcastle-upon-Tyne NE1 4LP
Tel: (0191) 282 0395 (order)
Tel: (0191) 282 0389 (enquiry)
Fax: (0191) 282 0469
yan.hunter-blair@nuth.nhs.uk

Salford Royal NHS Foundation Trust
Mr P. Williams, Pharmacy Technical and Support Services Manager
Salford Royal
Pharmacy Department
Salford Royal
Moss Lane, Eccles
Manchester M30 9RN
Tel: (0161) 827 1515 (order)
Tel: (0161) 827 1516 (enquiry)
Fax: (0161) 827 1234
paul.williams@salfordroyal.nhs.uk
North West
Preston Pharmaceuticals
Ms A. Nutman, Assistant Director of Pharmacy
Preston Pharmaceuticals
Royal Preston Hospital
Fulwood
Preston PR2 9HT
Tel: (01772) 523 617 (order)
Tel: (01772) 522 593 (enquiry)
Fax: (01772) 523 645
angela.nutman@lthtr.nhs.uk
Stockport Pharmaceuticals
Mrs S. Miller, Production Manager
Stepping Hill Hospital
Stockport Pharmaceuticals
Pharmacy Department
Stockport SK2 7JE
Tel: (0161) 419 5666 (order)
Tel: (0161) 419 5657 (enquiry)
Fax: (0161) 419 5426
sally.miller@stockport.nhs.uk

South
Portsmouth Hospitals NHS Trust
Mr R. Lucas, Product Development Manager
Portsmouth Hospitals NHS Trust
Pharmacy Manufacturing Unit
Unit D2, Railway Triangle Industrial Estate
Walton Road
Farlington
Portsmouth PO6 1TF
Tel: (02392) 389 078 (order)
Tel: (02392) 316 312 (enquiry)
Fax: (02392) 316 316
robert.lucas@porthosp.nhs.uk

South East
East Sussex Healthcare NHS Trust
Mr P. Keen, Business Manager
Eastbourne District General Hospital
East Sussex Hospitals NHS Trust
Eastbourne Pharmaceuticals
Kings Drive
Eastbourne BN21 2UD
Tel: (01323) 414 906 (order)
Tel: (01323) 417 400 ext: 3076 (enquiry)
Fax: (01323) 414 931
paul.keen@esht.nhs.uk

South West
Torbay PMU
Mr P. Bendell, Pharmacy Manufacturing Services Manager
South Devon Healthcare NHS Foundation Trust
Torbay PMU
Kemmings Close, Long Rd
Paignton TQ4 7TW
Tel: (01803) 664 707
Fax: (01803) 664 354
phil.bendell@nhs.net

Yorkshire
Calderdale and Huddersfield NHS Foundation Trust
Director
Dr S. Langford, Pharmacy Production
Huddersfield Royal Infirmary
Pharmacy Manufacturing Unit
Gate 2, Acre Mills, School St
Lindley
Huddersfield HD3 3ET
Tel: (01484) 355 388 (order)
Tel: (01484) 355 371 (enquiry)
Fax: (01484) 355 377
stephen.langford@cht.nhs.uk

Northern Ireland
Victoria Pharmaceuticals
Ms C. McBride, Production Manager
Victoria Pharmaceuticals
Royal Hospitals Plenum Building
Grosvenor Road
Belfast BT12 6BA
Tel: (028) 9263 0070 (order/enquiry)
Fax: (028) 9063 5282 (order/enquiry)
colettemcbride@belfasttrust.hscni.net

Scotland
NHS Greater Glasgow and Clyde
Mr G. Conkie, Production Manager
Western Infirmary
Dumbarton Rd
Glasgow G11 6NT
Tel: (0141) 211 2754 (order)
Tel: (0141) 211 2882 (enquiry)
Fax: (0141) 211 1967
graham.conkie@ggc.scot.nhs.uk

Tayside Pharmaceuticals
Dr B. Millar, General Manager
Ninewells Hospital
Tayside Pharmaceuticals
Dundee DD1 9SY
Tel: (01382) 632 052 (order)
Tel: (01382) 632 183 (enquiry)
Fax: (01382) 632 060
baxter.millar@nhs.net

Wales
Cardiff and Vale University Health Board
(Production)
Mr P. Spark, Principal Pharmacist
Cardiff and Vale University Health Board
20 Fieldway
Cardiff CF14 4HY
Tel: (029) 2074 8120
Fax: (029) 2074 8130
paul.spark@wales.nhs.uk
Index

Alogliptin, 596
Alogliptin with metformin, 596
Alomide, 946
Alori, 351
Alp, 672
Alphadern, 1031
Alphagan, 964
Alphamethylin, 96
Alpha tocopherol, 888
Alpha tocopheryl acetate, 888
Amiloride with hydrochlorothiazide and simeticone, 73
Amiloride hydrochloride, 976
Amisulpride, 88
Amiodarone hydrochloride, 230
Aminosalicylic acid, 1123
Aminophylline, 447
Amikin, 1042
Amifostine, 888
Amfostel, 596
Amfutab, 1009
Amefostine, 888
Amfutacine, 1042
Amfutop, 1122
Amfutubone, see Bupropion hydrochloride, 125
Amifampridine, 911
Amikacin, 450
Amikacin, 450
Amilamone, 203
Amiloride hydrochloride, 203
Amiloride hydrochloride with furosemide, 203
Amiloride hydrochloride with hydrochlorothiazide, see Co-amilozide
Amiloride with bumetanide, 203
Amiloride with cyclopenthiazide, 160
Amiloride with hydrochlorothiazide and timolol, 147
Aminoglycosides, 449
Aminophylline, 237
Amnion, 237
Chronic obstructive pulmonary disease, 214
Aminosalicylates
Class monograph, 34
Inflammatory bowel disease, 32
Aminosaliclyc acid, 503
Amiodarone hydrochloride, 88
Arrhythmias, 64
Amisulpiride, 312
Psychoses and related disorders, 300
 Amitiza, 46
Amitriptyline hydrochloride, 292
Neuropathic pain, 382
Amitriptyline with perphenazine, 293
Amlodipine, 148
Amlodipine with hydrochlorothiazide and olmesartan, 135
Amlodipine with olmesartan, 135
Amlodipine with valsartan, 149
Amotest, 149
Ammonaps, 872
Amorolfine, 1012
Amoxicillin, 483
Ear infections, bacterial, 444
Nose infections, bacterial, 446
Oral bacterial infections, 446
Oropharynx infections, bacterial, 995
Respiratory system infections, bacterial, 447
Urinary-tract infections, 510
Amoxicillin with clavulanic acid, see Co-amoxiclav
Amoxil, 483
Amoxycillin, see Amoxicillin
Amphero XL, 290
Amphotericin B, 517
Amphotericin, 517
Amphotericin B, see Amphotericin
Amipril, 483
Amipril with fluocoxacinil, see Co-flumapicil
Anpeps, 1155
Anubact, 1009
Anaemia, 822
Anaesthesia, sedation, and resuscitation in dental practice, 1094
Anfranil SR, 295
Anagrelide, 483
Anakinra, 897
Anal fissures, 78
Analgesics
Emergency treatment of poisoning, 1123
Stoma care, 83
Anamix, 1284, 1285, 1286, 1287, 1288, 1289
Anastrozole, 792
Ancoct, 522
Androcort, 663
Androgenetic alopecia, 1048
Androgens, 660
Aneuctine, 1103
Anethol with borneol, camphene, cineole, fenchone and pinene, 663
Angitil XL, 295
Angiox, 151
Antacids, 1078
Antianginal drugs, 182
Antibacterial drugs, 54
Antibacterial policies, 439
Antibacterials, principles of therapy, 458
Antibacterials, use for prophylaxis, 439
Antibacterial therapy for
Animal and human bites, 448
Bacterial vaginosis, 445
Biliary-tract infection, 445
Campylobacter enteritis, 445
Cellulitis, 448
Chronic bronchitis: acute exacerbations, 447
Clostridium difficile infection, 445
Early syphilis (infection of less than 2 years), 446
Endocarditis caused by enterococci, 445
Endocarditis caused by fully-sensitive streptococci, 445
Endocarditis caused by Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella species (‘HACEK’ micro-organisms), 444
Endocarditis caused by less-sensitive streptococci, 443
Endocarditis: initial ‘blind’ therapy, 443
Erysipelas, 448
Gastro-enteritis, 445
Gingivitis: acute necrotising ulcerative, 995
 Gonorrhoea: uncomplicated, 445
Haemophilus influenzae epiglottitis, 447
Impetigo: small areas of skin infected, 445
Late latent syphilis (asymptomatic infection of more than 2 years), 446
Lower urinary-tract infections, 511
Mastitis during breast-feeding, 449
Meningitis caused by Haemophilus influenzae, 444
Meningitis caused by Listeria, 444
Meningitis caused by meningococci, 444
Meningitis caused by pneumococci, 444
Meningitis: initial empirical therapy, 444
Native-valve endocarditis caused by staphylococci, 445
Osteomyelitis, 446
Otis externa, 444
Otis media, 444
Pelvic inflammatory disease, 446
Periperal or periportal abscess, 995
Pericoronitis, 995
Peritonitis, 995
Peritonitis: peri toneal dialysis-associated, 445
Pneumonia: high-severity community-acquired, 448
Pneumonia: hospital-acquired, 448
Pneumonia: low-severity community-acquired, 447
Pneumonia: moderate-severity community-acquired, 447
Pneumonia possibly caused by atypical pathogens, 448
Prosthetic valve endocarditis caused by staphylococci, 443
Purulent conjunctivitis, 445
Salmonella (non-typoid), 445
Septicaemia: community-acquired, 442
Septicaemia: hospital-acquired, 442
Septic arthritis, 446
Shigellosis, 445
Sinusitis, 446
Throat infections, 995
Typhoid fever, 445
Uncomplicated genital chlamydial infection, non-gonococcal urethritis, and non-specific genital infection, 445
Upper urinary-tract infections, 510
Anticholinesterases, 912
Anticoagulants, 102, 104, 529
Antidepressants, 1127
Antidiarrhoeals, 83
Anti-d (rhD) immunoglobulin, 1061
Antiepileptic drugs, 383
Antiepileptic hypersensitivity syndrome, 384
Anti-lymphocyte monoclonal antibodies, 751
Antimalarials, 1123
Antimicrobial dressings, 1305
Antimotility drugs, 54
Antimuscarinic drugs used in parkinsonism, 324
Antimuscarinics (eye), 949
Antimuscarinics (inhaled), 217
Antimuscarinics (systemic), 668
Antiplaquette drugs, 103
Antiplaquette drugs and coronary stents, 103
Antipsychotic depot injections, 300
Antipsychotic drugs, 300
Class monograph, 303
Psychoses and related disorders, 300
Antiseptic mouthwashes, 992
Antispasmodics, 54
Antithymocyte immunoglobulin (rabbit), 723
Antituberculosis drugs, 501
Tuberculosis, 501
Antivariella-zoster Immunoglobulin, see Variella-zoster immunoglobulin
Apergan, 40
Apira, 606
Apira SoloStar, 606
Apixaban, 108
Apodespan PR, 331
Apo-go, 333
Apo-go Pen, 333
Apo-go PFS, 333
Apomorphine hydrochloride, 333
Parkinson’s disease and related disorders, 324
Approximate Conversions and Units, inside back cover
Apromedone, 963
Glucocorticoids, 962
Aprepitant, 351
Apreprost, 158
Aprokon, 159
Aprokam, 955
Aprovel, 134
Aptivus, 571
Aqua-cool, 1041
Aquadrate, 1005
Aquamol, 1004
AquaSoothe, 1041
Arachis oil, 51
Arachis oil of coal tar with cade oil, coal tar, light liquid paraffin and tar, 1035
Arachis oil with chlorobutanol, 980
Arachis oil with extract of coal tar, 1036
Aradam, 1064
Aranesp, 826
Aranesp SureClick, 826
Arava, 895
Arcocita, 925
Aredia, 624
Argatroban monohydrate, 116
Aricept, 263
Aricept Eves, 263
Arimidex, 792
Aripiprazole, 312
Psychoses and related disorders, 300
Arivra, 105
Arjun, 1041
Arlomol, 516
Arlevert, 343
Aromasin, 792
Aromatic inhalations, cough preparations and systemic nasal decongestants, 258
Aripicin, 326
Arrangements for supplying oxygen, 214
Arrhythmias, 884
Arrhythmias after myocardial infarction, 84
Arsenic trioxide, 776
Artelac, 952
Artelac Nighttime, 951
Artelac Rebalance, 953
ArtelacSplash, 953
Artemether with lumefantrine, 334
Arteminol with piperaquine phosphate, 333
Arthritis, 891
Arthrocare, 924
Articaine hydrochloride with adrenaline, see Adrenaline with articaine hydrochloride
Artificial saliva products, 987
Arthromol, 93
Arzerra, 740
Asacol, 36
Asacol MR, 36
Asasantin Retard, 107
Ascaricides (common roundworm infections), 524
Ascorbic acid, 884
Asenapine, 276
Psychoses and related disorders, 300
Asmaclear, 228
Asmanex Twisthaler, 232
Asmanex Clickhaler, 224
Asmavent, 224
Aspirin
Drug monograph, 104
Acute coronary syndromes, 186
Antiplaquette drugs, 103
Arrhythmias, 84
Emergency treatment of poisoning, 1123
Gout, 908
Hypertension, 121
Management of stroke, 101
Aspirin with codeine, 354
Aspirin with dipyriramol, 107
Aspirin with metoclopamid, 381
Asplenia, 528
Asma Airways disease, use of corticosteroids, 226
Treatment summary, 210
Asymptomatic contacts of patients with infectious syphilis, 445
AT10, 887
Atarax, 248
Atazanavir, 567
Atenolol, 141
Atenolol with chlortalidone, see Co-tenantide
Atenolol with nifedipine, 141
Atimos Modular, 221
Ativan, 414
Atmoxetine, 272
Atopic and tonic seizures, 383
Atorvastatin, 179
Atosiban, 708
Atovaquone, 523
Pneumocystis pneumonia, 522
Atovaquone with proguanil hydrochloride, 536
Atracurium besilate, 1103
Atracurium besilate, see Atracurium besilate
Atrial fibrillation, 84
Atrial flutter, 84
Atriance, 764
Atripla, 565
Atriplak XL, 319
Atropine sulfate, 950, 1099
Cardiopulmonary resuscitation, 195
Emergency treatment of poisoning, 1123
Atropine sulfate with diphenoxylate hydrochloride, see Co-phenotrope
Atrovent, 218
Atrovent UDV, 218
Attention deficit hyperactivity disorder, 270
Attia, 107
Aubagio, 734
Audastrate, 1023
Aumanol, 75
Augmentin, 485
Augmentin-Duo, 485
Augmentin Intravenous, 485
Aureocort, 1032
Avamys, 985
Avanafl, 698
Avastin, 737
Avaxim, 1082
Avex, 493
Avitocil, 886
Avloclor, 537
Avoca, 1057
Avordart, 676
Avomine, 252
Avonex, 730
Axitinib, 802
Axorid, 932
Axissin, 383
Aynes Shake, 1266
Azacitidine, 757
Azactam, 474
Azapress, 717
Azargia, 966
Azathioprine, 716
Inflammatory bowel disease, 32
Azelaic acid, 1043
Rosacea and Acne, 1041
Azelaic acid hydrochloride, 945
Azelaic acid with fluticasone, 985
Azidothymidine, see Zidovudine
Azilect, 340
Azilsartan medoxomil, 132
Azithromycin, 469, 955
Genital system infections, bacterial, 445
Azopt, 966
Aztreomam, 474
AZT, see Zidovudine
**Beacita**, 300

**Bendroflumethiazide**, 159

**Benzodiazepines**, 725

**Benlysta**, 243

**Benerva**, 603

**Bendroflumethiazide with timolol**, 725

**Bisacodyl**, 324

**Bisoprolol fumarate**, 142

**Bisphosphonates**, 620

**Bivalirudin**, 116

**Bladder cancer**, 678

**Bladder infection**, 678

**Bladder instillations and urological surgery**, 678

**Bleo-Kyowa**, 767

**Bleomycin**, 766

**Blephagel**, 951

**Blerone XL**, 671

**Blink Intensive**, 953

**Blood infections**, 442

**Boceprevir**, 547

**Bocouture**, 324

**Bolant-SR**, 595

**Bonderon**, 623

**Bonefos**, 625

**Bone metabolism**, 619

**Bonek**, 965

**Bonviiva**, 36, 36

**Boostrix-IPV**, 1080

**Boric acid with salicylic acid and tannic acid**, 1013

**Borneol with camphene, cineole, menthol, menthone and pinene**, 76

**Bortezomib**, 801

**Bosentan**, 163

**Bosulf**, 803

**Boutinib**, 803

**Botox**, 324

**Botulinum toxin type A**, 322

**Botulinum toxin type B**, 324

**Botulinum toxin type C**, 1044

**Bovine blood cleansing preparations**, 43

**Bromitod**, 452

**Brasilvol**, 1042

**Bravelle**, 642

**Brealy**, 365

**Breast feeding**

**Epilepsy**, 383

**HIV infection**, 555

**Malaria, prophylaxis**, 528

**Breast pain (mastalgia)**, 631

**Brentuximab vedotin**, 737

**Brevibloc**, 143

**Brevinor**, 688

**Brevoxyl**, 1044

**Bricanyl**, 226

**Bricanyl Resuples**, 226

**Bricanyl Turbulator**, 226

**Brizend**, 1106

**Brilique**, 189

**Bromidine tartrate**, 963, 1048

**Glaucoma**, 962

**Rosacea and Acne**, 1041

**Brimonidine with timolol**, 964

**Brinzolamide**, 966

**Glaucoma**, 962

**Brinzolamide with timolol**, 966

**BritLofex**, 434

**Broad-spectrum penicillins**, 478

**Brochilor**, 955

**Brolene**, 957

**Bromfenac**, 961

**Bromocriptine**, 1044

**Bromhexine hydrochloride with codeine phosphate and paracetamol**, 375

**Budelin Novolizer**, 229

**Budenoside**, 31, 228, 394

**Budeprone with clindamycin**, 1044
Calcium carbonate, 857
Calcium lactate gluconate with calcium carbonate, see Calcium carbonate with calcium lactate gluconate
Calcium lactate with calcium phosphate and ergocalciferol, see Ergocalciferol with calcium lactate and calcium phosphate
Calcium phosphate with calcium lactate and ergocalciferol, see Ergocalciferol with calcium lactate and calcium phosphate
Calcium phosphate with colecalciferol, 887
Calcium polystyrene sulfonate, 862
Calcium Resonium, 862
Calcium salts, 856
Calcitriol, 1037
Calciferol, see Calcichew D3 Forte
Calcichew D3
Calcichew
Calcichew D3 Forte, 887
Calciferol, see Ergocalciferol
Calcipotriol, 1036
Calcitril, 1037
Calcitonin with betamethasone, 1037
Calcitriol, 1036
Calcitriol, 885, 1037
Calcitonin (salmon)/salcatonin, 627
Calcium carbonate with colecalciferol, 886
Calcium carbonate with colecalciferol and risedronate, 624
Calcium carbonate with sodium alginate and sodium bicarbonate, 58
Calcium-channel blockers, 148
Emergency treatment of poisoning, 1125
Calcium chloride, 857
Calcium chloride dihydrate with potassium chloride and sodium chloride, see Potassium chloride with calcium chloride dihydrate and sodium chloride, 849
Calcium chloride with potassium chloride and sodium chloride, see Potassium chloride with calcium chloride, sodium chloride and sodium lactate, 850
Calcium gluconate, 857
Coal tar with calamine, 1035
Coal tar with coconut oil and salicylic acid, 1035
Coal tar with dithranol and salicylic acid, 1035
Coal tar with lecithin, 1035
Coal tar with salicylic acid, 1035
Coal tar with salicylic acid and precipitated sulfur, 1036
Coal tar with zinc oxide, 1036
Co-amilofruse, 200
Co-amiloide, 160
Co-amoxiclav, 484
Antibacterials, used for prophylaxis, 439
Oral bacterial infections, 446
Skin infections, bacterial, 448
CoAprovel, 134
Cobalamin, 838
Co-beneldopa, 328
Cobicistat, 567
HIV infection, 555
Cobicistat with elvitegravir, emtricitabine and tenofovir, 565
Cocaine, 1128
Co-careldopa, 329
Cockcroft and Gault Formula, 18
Co-codamol, 358
Cocois, 1036
Coconut oil with coal tar and salicylic acid, see Coal tar with coconut oil and salicylic acid
Co-cyprindiol, 1042
Rosacea and Acne, 1041
Scalp and hair conditions, 1048
Co-danthramer, 52
Co-danthrusate, 51
Codeine phosphate, 360
Aromatic inhalations, cough preparations and systemic nasal decongestants, 258
Codeine phosphate with buclizine hydrochloride and paracetamol, see Buclizine hydrochloride with codeine phosphate and paracetamol
Codeine phosphate with paracetamol, see Co-codamol
Codeine with aspirin, see Aspirin with codeine
Co-Dian, 137
Codipar, 359
Codis, 354
Co-dydramol, 359
Coeliac disease, 880
Co-flumicil, 485
Co-flumactone, 168
Cohesive extensible bandages, 1317
Colazide, 34
Colchicine, 908
Gout, 908
Colecalficiferol, 886
Colecalficiferol with alendronic acid, see Alendronic acid with colecalciferyl
Colecalficiferol with calcium carbonate, 886
Colecalficiferol with calcium phosphate, 887
Colesevelam hydrochloride, 172
Colestrid, 173
Colestipol hydrochloride, 173
Colestyreidine, 173
Acute diarrhoea, 54
Biliary disorders, 75
Colgate Duraphat, 991, 992
Colfoam, 584
Colistimethate sodium, 489
Colistin sulfomethate sodium, see Colistimethate sodium
Collagenase, 941
Soft-tissue disorders, 940
Collodion with castor oil and colcholony, see Castor oil with colloid and colcholony
Colobrate, 490
Colofuc, 75
Colofuc MB, 75
Colomycin, 489
Colophony with castor oil and colloid, see Castor oil with colloid and colcholony
Conjugate, 40
Co-magaldrox, 59
Combigan, 964
Combivir, 218
Combivir, 567
Combodart, 675
Combret, 804
Competact, 614
Complan Shake, 1470
Compound haemorrhoidal preparations with corticosteroids, 78
Compound sodium lactate (Hartmann’s), 845
Compound topical preparations, 1006
Compression bandages, 1317
Compression hosiery and garments, 1318
Comtess, 327
Concerta XL, 274
Condylone, 1056
Conestat alfa, 255
Congescor, 142
Conjugated oestrogens (equine), 647
Conjugated oestrogens with medroxyprogesterone, 648
Conjugated oestrogens with norgestrel, 648
Contraceptives, vaginal, see Vaginal contraceptives
Controlled drugs and drug dependence, 7
Control of microbial contamination, 943
Control of the epilepsies, 383
Convulsions, 1123
Convulsive status epilepticus, 383
Copaxone, 729
Copetax, 546
Co-phentotope, 55
Coracten SR, 156
Coracten XL, 156
Cordareone X, 89
Corgad, 145
Cortifollitropin alfa, 639
Cortisol, 990
Corticosteroid-induced osteoporosis, 619
Corticosteroids
General use, 577
Inhaled, 227
Intranasal, 983
Nose, 980
Oral ulceration and inflammation, 992
Replacement therapy, 578
Systemic, 579
Topical, 1022
Tuberculosis, 501
Cortiment, 39
Co-simalcite, 59
Costaux, 675
CosmoCol, 49
Cosmofer, 83
Cosopt, 967
Co-tenidone, 145
Co-triamterzide, 204
Co-trimoxazole, 461
Pneumocystis pneumonia, 522
Cough suppressants, 258
Coversyl Arginine, 129
Coversy Arginine Plus, 130
Covonia Dry Cough, 259
Cozaar, 154
Cyclosporin, 135
Cyco-Cap, 135
Cyco-dicapt, 127
Grab lice, 1008
Creon, 82
Creator, 181
Crisiantaspase, 776
Crisivan, 569
Crisolitinib, 804
Cromolyn, 946
Crotamiton, 1040
Group, 209
Crystacide, 1052
CS Spray, 1129
Cubicin, 468
Cubicide D5, 866
Cuplex, 1058
Cuprofen, 929
Curanall, 1012
Curasept, 990
Curcumin, 1038
Cushing’s Syndrome, 587
Cutivate, 1029
Cyamides, 1123
Cyanocobalamin, 837
Cyclamex, 838
Cyclimorph, 369
Cyclizine, 345
Cyclizine with dipipanone hydrochloride, see Dipipanone hydrochloride with cyclizine
Cyclizine with morphine, 369
Cyclogest, 659
Cyclophosphamide, 204
Cyclophosphamide with amiloride, 160
Cyclophosphatol hydrochloride, 950
Cyclophosphamide, 750
Cyclo-Progynova, 655
Cycloserine, 504
Cyclosporin, see Ciclosporin
Cyclokapron, 95
Cymalon (sodium citrate), 677
Cymbalta, 289
Cymeven, 554
Cyproheptadine hydrochloride, 246
Cyprostat, 665
Cyproterone acetate, 662
Cyproterone acetate with ethinylestradiol, see Co-cyprindiol
Cystandine, 868
Cystagon, 870
Cysteamine, see Mercaptamine
Cystocarm, 677
Cystin, 670
Cytacol, 837
Cytamen, 837
Cytarabine, 759
Cytokine modulators, 34, 892
Cytomegalovirus infection, 549
Cytotec, 710
Dabigatran etexilate, 117
Dabrafenib, 805
Dacavis MR, 612
Dacarbazine, 751
Daclatasvir, 544
Hepatitis, 541
Dacogen, 760
Daklinza, 545
Daktacort, 1031
Daktarin, 713, 997, 1012
Daktarin Gold, 1011
Dalcin, 476, 711
Dalcin C, 467, 468
Dalcin T, 468
Dalmane, 418
Deltaparin sodium, 112
Danaparoid sodium, 111
Danazol, 636
Gonadotrophins, 631
Danrod, 1011
Danol, 637
Dantrium, 1101
Dantrolene sodium, 1101
General anaesthesia, 1093
Dantron with docusate sodium, see Co-danthrane
Dantron with polyoxamer 188, see Co-danthrane
Dapagliflozin, 609
Dapagliflozin with metformin, 610
Dapoxetine, 703
Dapsone, 500
Daptomycin, 468
Dapagliflozin, 540
Darbeopenol alfa, 825
Nicardipine, 822
Dexamethasone, 1097
General anaesthesia, 1093
Dextorp, 397
Desloraditain, 247
Desmolit, 576
Desmopressin, 574
Urinary frequency, enuresis and incontinence, 667
Desmopressin, 576
Desmogestrel, 691
Desogestrel with ethinylestradiol, 685
Desomono, 692
Desmotril, 76
Desunil, 886
Dextranorm, 670
Dextranorm XL, 670
Dextran in, 671
Dextran XL, 671
Dexafree, 948
Dexemethasone, 581
Corticosteroids, general use, 577
Eye, 947
Dexemethasone with framycetin sulfate and neomycin, 948
Dexemethasone with glacial acetic acid and neomycin sulfate, 979
Dexemethasone with hydropromellose, neomycin and polymyxin B sulfate, 948
Dexemethasone with tobramycin, 948
Dexemethasone sulfate, 270
Dexmethasone sulfate, see Desmethasone sulfate
Dexor, 1110
Dexibuprofen, 919
Dexime, 719
Decetropen, 919
Decedemodimidine, 1110
Dexrazoxane, 782
Dexaprazine, 782
Soft-tissue disorders, 940
Desacol, 582
Dextan 70 with hydropromellose, 952
Dextan 70 with sodium chloride, 853
Dextro Energy, 951
Dextrogel, 618
Dextrose Monohydrate, see Glucose
DF 118, 362
D-Gam, 1062
DHC Continus, 362
Diabact UBT, 72

Diabetes
Psychoses and related disorders, 300
Diabetes mellitus, diagnostic and monitoring devices, 614
Diabetic ketoacidosis, management, 590
Diabetic nephropathy, 588
Diabetic neuropathy, 588
Diaz, 852
Diphenylcyclopropyl, 595
Diamidine, 1276
Diamonil, 612
Diamicron MR, 612
Diamorphine hydrochloride, 361
Aromatic inhalations, cough preparations and systemic nasal decongestants, 258
Diamox, 966
Diamox SR, 966
Dianette, 1043
Diazepine, 56
Diazemuls, 269
Diazepam, 267
Anaesthesia, sedation, and resuscitation in dental practice, 1094
Diazoxide, 619
Hypoglycaemia, 618
Diclofenac potassium, 920
Diclofenac sodium, 921, 961
Diclofenac sodium with misoprostol, 925
Dicloflex, 923
Dicloflex Retard, 923
Dicloflex SR, 923
Dicloflex Retard, 923
Diclomax SR, 923
Dichobalt edetate, 1131
Emergency treatment of poisoning, 1133
Dicyclomine hydrochloride, see Dicyclomine hydrochloride
Dicyclomine hydrochloride, 73
Didanosine, 362
Diensogest with estradiol valerate, 685
Diethylcarbamazine, 525
Diethyl phthalate with methyl salicylate, 1053
Diethylstilbestrol, 788
Differin, 1045
Diflalm, 994
Diflunoxol XL, 675
Diflucin, 469
Diflucan, 519
Diflucortolone valerate, 1026
DigiFab, 1133
Diginox, 94
Arrhythmias, 84
Heart failure, 167
Stoma care, 83
Diginox-specific antibody, 1132
Dihydrocodeine tartrate, 362
Dihydrocodeine with paracetamol, see Co-dydramol
Dihydrotachysterol, 887
1,25-Dihydroxycholecalciferol, see Calcitriol
Dilacort, 586
Dilacort SR, 515
Diloxanide furoate, 438
Diltiazem hydrochloride, 149
Acute coronary syndromes, 186
Diltiazem hydrochloride, 149
Acute coronary syndromes, 186
Diltiazem hydrochloride, 149
Acute coronary syndromes, 186
Diltiazem hydrochloride, 149
Acute coronary syndromes, 186
Dimethyl sulfoxide, 679
Dimeticone, 1014
Skin infections, 1006
Dimeticone with benzalkonium chloride, hydrocortisone and nystatin, see Hydrocortisone with benzalkonium chloride, dimeticone and nystatin
Dinoprostone, 706
Diethyl, 52
Diethyl sulphonesuccinate, see Docosate sodium
Dioderm, 1029
Dioralyte, 849
Dioralyte Relief, 849
Dipot, 137
Dipeptiven, 879
Diphenoxylate hydrochloride with atropine sulfate, see Co-phenotrope
Diphenyl antitoxin, 1066
Diptheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus, 1079
Diptheria with pertussis, poliomyelitis vaccine and tetanus, 1080
Diptheria with poliomyelitis and tetanus vaccine, 1080
Dipipanone hydrochloride with cyclizine, 362
Dipirone, 1096
Diprosalic, 1025
Diprosone, 1023
Dip/Ser, see Diptheria antitoxin
Dipyridamole, 107
Antiplatelet drugs, 105
Dipyridamole with aspirin, see Aspirin with dipyridamole
Dispal, 326
Disodium hydrogen citrate with glucose, potassium chloride and sodium chloride, 849
Disopyramide, 89
Arrhythmias, 84
Disulfiram, 356
Dissolution of blood clots, 678
Distacol, 456
Distacol MR, 456
Distamine, 896
Disulfiram, 428
Substance dependence, 425
Dithranol, 1018
Psoriasis, 1017
Dithranol with coal tar and salicylic acid, see Coal tar with dithranol and salicylic acid
Dithranol with salicylic acid and zinc oxide, 1019
Dithrocream, 1019
Disopropanol, 670
Disodium K Continus, 201
Diureasol, 201
Diuretics, 83
Diurexan, 205
Diverticular disease, 32
Dixarin, 138
DLax, 886
D-Max, 886
Dobutamine, 193
Docetaxel, 770
DocOmega, 1287
Docosate sodium, 52, 980
Constipation, 45
Ear, 976
Docosate sodium with dantron, see Candenhusate
Docecol, 52
Dolenio, 894
Dolmatil, 310
Dolutegravir, 557
HIV infection, 555
Dolutegravir with abacavir and lamivudine, see Abacavir with dolutegravir and lamivudine
Domiciliary oxygen, 214
Domperidone, 346
Donepezil hydrochloride, 262
Dopcard, 170
Dopamine hydrochloride, 165
Dopamine-receptor agonists, 324
Dopaminergic drugs used in Parkinson’s disease, 324
Dopexamet hydrochloride, 170
Doralene Tiltab, 674
Dorisin XL, 180
Dornase alfa, 256
Mucolytics, 256
Dorzolamide, 967
Glaucoma, 962
Dorzolamide with timolol, 967
Dostinex, 356
Doxepin hydrochloride, 295
Doxinop, 170
Doxepin, 296, 1040
Doxorubicin hydrochloride, 754
Doxorubicin, 755
Doxycycline, 496, 995
Genital system infections, bacterial, 445
Lyme disease, 500
Malaria, prophylaxis, 528
Oral bacterial infections, 446
Oral ulceration and inflammation, 992
Rosacea and Acne, 1041
Dozogen XL, 673
Drupoline, 999
Dressing packs, 1311
Dressings and appliances, adjacent, see Adjunct dressings and appliances
Dressings, antimicrobial, see Antimicrobial dressings
Dressings, basic contact dressings, see Basic wound contact dressings
Dressings, specialised, see Specialised dressings
Dretine, 686
Driclor, 1038
Dried prothrombin complex, 96
Driving
Diabetes, 588
Epilepsy, 383
Dronedarone, 90
Droperidol, 345
Dropodex, 948
Drospirenone with estradiol, 652
Drospirenone with ethinylestradiol, 686
Drugs affecting biliary composition and flow, 75
Drugs affecting gonadotrophins, 631
Drugs affecting the immune response, 32
Drugs and sport, 26
Drugs for arrhythmias, 84
Drugs for cutaneous larva migrans (creeping eruption), 524
Drugs for HIV infection, 555
Drugs for hookworms, 524
Drugs for strongyloidiases, 524
Drugs for tapeworm infections, 524
Drugs for threadworms, 524
Drugs for urinary retention, 672
Drugs unsafe for use in acute porphyrias, 864
Drugs used for intravenous anaesthesia, 1079
Drugs used for mania and hypomania, 274
Drugs used in alcohol dependence, 425
Drugs used in chronic bowel disorders, 32
Drugs used in essential tremor, chorea, tics, and related disorders, 324
Drugs used in hypoplastic, haemolytic, and renal anaemias, 822
Drugs used in nasal allergy, 980
Drugs used in opharyngeal candidiasis, 996
Drugs with definite risk of haemolysis in most G6PD-deficient individuals, 822
Drugs with possible risk of haemolysis in some G6PD-deficient individuals, 822
Dry eye, 950
Drytec saline, 289
DfT, see Stavudine
Duac, 1045
Dualitis, 178
Dukoral, 1079
Dulco-Lax, 52, 54
Duloxetine, 288
Diabetes, 588
Urinary frequency, enuresis and incontinence, 667
Duocit, 1275
Duodopa, 331
Duofilm, 1058
Duosp Respiromax, 230
DuoTran, 971
Duperite, 47
Durogesic DTrans, 366
Dutasteride, 676
Drugs for urinary retention, 672
Dutasteride with tamsulosin, 675
Dyazide, 204
Dydrogesterone with estradiol, 652
Dysloject, 923
Dymista, 985
Dynamin XL, 193
Dynumatin, 1108
Dysport, 324

E
E45, 1002, 1004, 1006
Ear, 976
Ear infections, bacterial, 444
Earol, 980
Easiphen, 1288
Ebesque XL, 319
Ebita, 265
Ecalta, 515
Ecoclopect, 924
Ecloferol, 901
Econac, 923
Econac SR, 923
Econac XL, 923
Econazole nitrate, 1011
Ecopace, 126
Ecstasy, 1123
Ecotropic viruses, 84
Eculizumab, 830
Eczema, 1016
Eczmol, 1051
Ethinylestradiol with desogestrel,
Exenatide,
Evorel Conti
Eudemine
Etodolac,
Ethinyloestradiol,
Etanercept,
Estriol with estrone and estradiol,
Ethinylestradiol with etonogestrel
Desogestrel with ethinylestradiol
Ethinylestradiol with drospirenone, see Drosiprenone with ethinylestradiol
Ethinylestradiol
With etonogestrel, 686
With gestodene, 687
With levonorgestrel, 687
With norelgestromin, 688
With norethisterone, 688
With norgestimate, 688
Ethinylestradiol, see Ethinylestradiol
Ethosuximide, 390
Epilepsy, 383
Ethylene glycol and methanol, 1123
Etodolac, 924
Etomate, 1095
General anaesthesia, 1093
Etonogestrel, 695
Etonogestrel with ethinylestradiol, see Ethinylestradiol with etonogestrel
Etopan XL, 924
Etopophos, 777
Etoposide, 777
EToricubt, 925
Etravirine, 559
HIV infection, 555
Etritec, 1025
Eucalyptus with menthol, 259
Aromatic inhalations, cough preparations and systemic nasal decongestants, 258
Eucerin, 1005
Eucrase, 599
Eudamine, 619
Eumocream, 945
Eumon XL, 193
Eumovate, 1026
Eurartesin, 556
Eurax, 1040
European viper snake venom antiserum, 1136
Emergency treatment of poisoning, 1123
Evacal DS, 887
Everolimus, 808
Eviplera, 556
Evista, 659
Evoitra, 759
Evoer, 652
Evoer Conti, 655
Evoer Sequi, 655
Evool, 492
Evra, 689
Excipients and sensitisation, 998
Exelon, 264, 265
Exemol, 116
Exemestane, 792
Exenatide, 599
Exforge, 149
Exide, 839
Exocin, 957
Exorex, 1035
Estatin, 730
Exterol, 980
Extracorporeal circuits, 100
Extract of coal tar with arachis oil, see Arachis oil with extract of coal tar
Extravasation, 940
Eye drops and eye ointments, 945
Eye infections, bacterial, 445
Eye lotions, 943
Eye, 972
Ezymex, 966
Exetimibe, 173
Exetimibe with simvastatin, 182
Exetrol, 174
F
Fabrazyme, 867
Factor ix fraction, dried, 96
Factor via (recombinant), 97
Factor viii fraction, dried, 97
Factor viii inhibitor bypassing fraction, 97
Factor xiii fraction, dried, 98
Faecal softeners, 43
Falciparum malaria (treatment), 529
Famciclovir, 552
Herpesvirus infections, 549
Famotidine, 65
Fampridine, 726
Famprysa, 991
Famei, 552
Fanbdh, 97
Farmals, 675
Fareston, 792
Fasigyn, 477
Fasolax, 791
Fasturate, 784
Fate, 1283
Faverin, 287
Fenacola, 692
Fehrie convulsions, 383
Fexinostat, 910
Gout, 908
Felbzn XL, 471
Fefol Spansules, 835
FEIBA Immuno, 98
Felhina, 925
Feldene, 937
Feldene Melt, 937
Feldenil XL, 152
Feldolipine, 131
Feldolipine with ramipril, 131
Felenix XL, 152
Feltolens XL, 152
Felypressin with prilocaine, 1121
Fenara, 793
Feminax Express, 929
Feminax Ultra, 935
Femodene, 687
Femodette, 687
Femoston 1/0, 653
Femoston 2/10, 653
Femoston-conti, 653
FemSeven, 652
FemSeven Conti, 653
FemSeven Sequi, 653
FemSeven Sequi Phase 1, 652
Fenacol, 923
Fenacol Retard, 923
Fenacol SR, 923
Fenbid, 929
Fenchone with anethol, borneol, camphene, cineole and pinene, see Anethol with borneol, camphene, cineole, fenchone and pinene
Fenclor, 366
Fendix, 1085
Fenolflate, 175
Fenoprofen, 926
Fenpro, 926
Fentals, 366
Fentanyl, 362
Fentanyl with bupivacaine, see Bupivacaine with fentanyl
Fenticonazole nitrate, 713
Fenugreek Spansules, 835
Ferinject, 832
Ferric carboxymaltose, 831
Ferrimox, 839
Ferograd, 834
Ferograd C, 835
Ferograd Folic, 835
Ferrous fumarate, 833
Ferrous fumarate with folic acid, 834
Ferrous gluconate, 834
Ferrous sulfate, 834
Ferrous sulfate with ascorbic acid, see Ascorbic acid with ferrous sulfate
Ferrous sulfate with folic acid, 835
Fersaday, 835
Fesoterodine fumarate, 668
Fexofenadine hydrochloride, 247
Fibrinase XL, 174
Fibrinogen, dried, 98
Fibrinolitics, 194
Fibrogammin P, 98
Fibro-Vein, 208
Fidaxamicin, 468
Filarmicide, 524
Filigrastim, 841
Filminated gauze swabs, 1312
Filminated non-woven Fabric Swab, 1312
Fimec, 1043
Finaestride, 676
Scalp and hair conditions, 1048
Fingolimod, 727
Firazyr, 255
Firlaput, 1122
Firtunon, 788
First-generation antipsychotic drugs, 301
Fistulating Crohn’s disease, 33
Flagyl, 476
Flamazine, 1030
Flumase SR, 923
FlavourPac, 1279
Flavoxate hydrochloride, 669
Urinary frequency, enuresis and incontinence, 667
Flbogammadif, 1064
Flecainide acetate, 91
Arrhythmias, 84
Flectone XL, 675
Fleet Phospho-soda, 50
Fleet Ready-to-use, 50
Flexbumin, 853
Flexitol, 1005
Flexonase, 595
Flibotid Acidulator, 231
Flibotid Exhulator, 230
Flibotid Nebule, 231
Fidol, 100
Flomax MR, 675
Flomastra XL, 675
Florinef, 583
Flotros, 671
Floxapen, 487
Fluvoxol, 305
Glucose with sodium chloride,
Glycopyrronium bromide,
Glandosane,
Glycine,
Glyceryl trinitrate,
see 1056
Glusartel
893
Glucobay
618
Glivec
612
Glidipion
611
Glatiramer acetate,
Gentamicin,
450
Gemzar
Tegafur with gimeracil and oteracil
Dexamethasone with glacial acetic acid
1105
phenol,
see BNF
70
Constipation,
43
Fluids and electrolytes,
Hypoglycaemia,
Fluids and electrolytes,
891
,
728
,
894
,
913
,
622
,
908
Graduated compression hosiery, 1319
Gramicidin with dexamethasone and sodium lactate
Gonadorelin analogues,
GnRH,
Glytrin
77
Glycoprotein lH/IIa inhibitors, 103
Glycopyrrolate, see Glycopyrronium bromide
Glycopyrronium bromide, 217, 1038, 1100
Glycopyrronium bromide with neostigmine, 1105
Glycyrrhiza, 77
Glycyrin, 191
GnRH, see Gonadorelin
Golimumab, 904
Inflammatory bowel disease, 32
Gonadorelin, 639
Gonadorelin analogues, 631
Gondotrophin-releasing hormone, see Gonadorelin
Gondotrophins, 631
Gonad-f, 640
Gonapeptil Depot, 636
Gosachev, 894
Gosaveg, 913
Goserelin, 622
Gout, 908
Granisetron,
348
Granucyte, 842
Granulocyte-colony stimulating factors, 840
Granupas, 503
Grass pollen extract, 253
Grazax, 253
Grepid, 106
Griseofulvin, 514, 1012
Grisol AF, 520
Guaniethidine monosulfate, 162
Guidance on intravenous infusions, 14
Guidance on prescribing, 1
Gygel, 697
Gyno-Daktarin, 713, 1012
Gyno-Pevaryl, 1011
Gynokin, 713
Haelan, 1027
Haea arginina, 865
Acute porphyrias, 864
Haemophilus influenzae type B with meningococcal group C vaccine, 1080
Haemophilus influenzae with diphtheria with pertussis with poliomyelitis and tetanus, see Diphtheria with haemophilus influenzae type B vaccine, pertussis, poliomyelitis and tetanus
Haemorrhage, 100
Halaven, 777
Halodol, 307
Halodol decanoate, 308
Half Beta-Propranol, 147
Holf Scurox, 157
Holf Sinemet CR, 331
Haliborange Halibonbons, 884
Haliborange High Strength Vitamin C, 884
Haloperidol, 306
Parkinson's disease and related disorders, 324
Haloperidol decanoate, 307
Hapactin, 456
Hapinose, 1080
Hartmann's Solution for Injection, see Calcium chloride with potassium chloride and sodium chloride and sodium lactate
Hartmann's Solution for Injection, see Potassium chloride
Havrix, 1082
Hayeve, 246
HBVAXPRO, 1085
He4S, 1029
HCG, see Chorionic gonadotrophin
HCU Cooler, 1285
HCU express, 1285
HCU Lophlex LQ, 1285
Head lice, 1006
Heart failure, 167
Heavy metals, 1123
 Hedrin, 1015
Helicobacter pylori infection, 61
Helixate NexGen, 97
Heliminth infections, 524
Hemabate, 706
Heparinoid, 1055
Heparins, 111
Heparin (unfractionated), 114
Venous thromboembolism, 100
Hepcinat, 1271
Hepatex CP, 1062
Hepatitis, 541
Hepatitis A and B vaccine, 1082
Hepatitis A vaccine, 1081
Hepatitis A with typhoid vaccine, 1082
Hepatitis B and A vaccine, see Hepatitis a and b vaccine
Hepatitis B immunoglobulin, 1062
Hepatitis B vaccine, 1083
Hepatyc, 1083
Hepsera, 544
Hepcceptin, 744
Heroin hydrochloride, see Diamorphine hydrochloride
Herpes labialis, 1006
Herpes simplex and varicella–zoster infection, 549
Herpes simplex infections, 549
Herpesvirus infections, 549
Hexamidine hupprurate, see Methenamine hupprurate
Hexetidine, 990
Hexigal, 206
Hibi, 1051
HibiScrub, 1051
Hibitane, 1051
HibiTane Plus, 1051
Hibisasec, 57
High compression handages, 1317
High-dose inhaled corticosteroids, 210
High lower-limb amputation, 439
Hiprex, 513
Hirsutism, 1048
HIRUDOID, 1055
Histamine dihydrochloride, 794
HIV infection, 555
Hizentra, 1064
Homatropine hydrobromide, 950
Honey, 1306
Honey-based topical application, 1306
Hormone treatment for acne, 1041
Hormonin, 653
How BNF publications are constructed, ix
How to use BNF publications, xi
H2 receptor antagonists, 64
Humalog, 606
Humalog KwiiPen, 606
Humalog Mix25, 606
Humalog Mix30, 603
Humalog Mix25 KwiiPen, 603
Humalog Mix50 KwiiPen, 603
Human Albumin Solution, see Albumin solution
Human Chorionic Gonadotrophin, see Chorionic gonadotrophin
Human chorionic gonadotrophin, see Chorionic gonadotrophin
Human Chorionic gonadotrophin alfa
Human Coagulation Factor VIII, Dried, see Factor viii fraction, dried
Human Fibrinogen, see Fibrinogen, dried
Index

Human Fibrin-stabilising Factor, Dried, see Factor xii fraction, dried
Human hemin, see Haem arginate
Human papillomavirus vaccines, 1085
Human Prothrombin Complex, see Dried prothrombin complex
Human recombinant parathyroid hormone, see Parathyroid hormone
Humatrope, 644
Humira, 902
Humulin I, 607
Humulin I KwikPen, 607
Humulin M3, 603
Humulin M3 KwikPen, 603
Humulin S, 604
Hux D3, 886
Hyabak, 953
Hyalgan, 891
Hyaluronidase, 941
Soft-tissue disorders, 940
Hydacin, 775
Hycozan, 953
Hydatid disease, 524
Hydralazine hydrochloride, 157
Hydrafed, 953
Hydrea, 778
Hydrex, 1051
Hydrochlorothiazide, 160
Hydrochlorothiazide with amiloride and timolol, see Amiloride with hydrochlorothiazide and timolol
Hydrochlorothiazide with amiloride hydrochloride, see Co-amiloride
Hydrochlorothiazide with amiodipine and olmesartan, see Amlodipine with hydrochlorothiazide and olmesartan
Hydrochlorothiazide with captopril, see Co-zidacapt
Hydrochlorothiazide with enalapril, see Enalapril with hydrochlorothiazide
Hydrochlorothiazide
With irbesartan, 134
With lisinopril, 129
With losartan, 135
With olmesartan, 136
With quinapril, 131
With telmisartan, 136
With valsartan, 137
Hydrochlorothiazide with triamterene, see Co-triamteride
Hydrocodone dressings, 1301, 1308
Hydrocortisone, 583, 993
Airways disease, use of corticosteroids, 226
Oral ulceration and inflammation, 992
Soft-tissue disorders, 940
Hydrocortisone and clotrimazole, see Clotrimazole with hydrocortisone
Hydrocortisone butyrate, 1029
Hydrocortisone with benzalkonium chloride, dimeticone, and nystatin, see Benzalkonium chloride with dimeticone, hydrocortisone and nystatin
Hydrocortisone with chlorhexidine hydrochloride and nystatin, see Chlorhexidine hydrochloride with hydrocortisone and nystatin
Hydrocortisone with cinnchonine, see Cinchonine with hydrocortisone
Hydrocortisone with fusidic acid, 1031
Hydrocortisone with gentamicin, see Gentamicin with hydrocortisone

Hydrocortisone
With lidocaine, 80
With miconazole, 1031
With oxytetracycline, 1031
With promocaine, 81
With urea, 1031
Hydrocortisol, 584
Hydroflumethiazide with spironolactone, see Co-flumactone
Hydrogencap (amorphous), 1297
Hydrogel dressings, 1297
Hydrogel sheet dressings, 1297
Hydrogen peroxide, 990, 1052
Hydromol Intensive, 1006
Hydrogulsion, 952
Hydromorphine hydrochloride, 366
Hydrotalcite with simeticone, see Co-simeticone
Hydroxychloroquine, 837
Anemia, 838
Emergency treatment of poisoning, 1123
Hydroxypropyl methylcellulose, 577
Sickle-cell disease, 822
Hydroxyquinolone sulfate, 894
1α-Hydroxylcholecalciferol, see Alfacalcidol
Hydroxyurea, see Hydroxyuremic
Hydroxyuremic
Hydroxyurea, 951
Hydroxypropyl guar with polyethylene glycol and propylene glycol, 951
Hydroxyurea, see Hydroxyuremic
Hydroxyuremic
Hydroxyuremic
Hydroxychloroquine, 951
Hypoglycaemia, 591
Hypoprolactinaemia, 591
Hyposial, 953
Hypertension, 121
In diabetes, 121
In pregnancy, 121
In renal disease, 121
In the elderly, 121
Hypertensive crises, 123
Hypomagnesaemia, 1097
Hynovel, 416
Hypodermic insulin injection pen, 617
Hypoglycaemia, 618
Hypotension and interference with temperature regulation, 300
Hypovase, 674
Hypromellose, 952
Dry eye, 950
Hypromellose with dexamethasone, see Dexamethasone with hypromellose
Dexamethasone with hypromellose
Hypromellose with dextran 70, see Dextran 70 with hypromellose
Hypromellose, 952
Hypurin Bovine Isophane, 607
Hypurin Bovine Lente, 607
Hypurin Bovine Neutral, 604
Hypurin Bovine Proamine Zinc, 607
Hypurin Porcine Isophane, 607
Hypurin Porcine 30/70 Mix, 603
Hypurin Porcine Neutral, 604
Hysterectomy, 439
Hytrin, 439
Iasibon, 623
Ibandronic acid, 622
Ibrutinib, 809
Ibucalm, 929
Ibugal, 929
Ibuleve, 929
Ibumousse, 929
Ibuprofen, 927
Ibuspray, 929
Icatibant, 255
Ichthammol, 1019
Ichthammol with zinc oxide, 1019
Iclusig, 815
Idarubicin hydrochloride, 756
Idelalisib, 810
Idursulfase, 868
Iftin, 134
Ifosfamide, 751
Iloré, 185
Ilaris, 724
Ixarten, 244
Iloprost, 164
Ilube, 951
Iluvien, 975
Imatinib, 810
Imbruvica, 810
Imdur, 192
Imidapril hydrochloride, 128
Imiglucerase, 867
Imigran, 380
Imizol Subject, 380
Imipenem with cilastatin, 454
Imipramine hydrochloride, 296
Imiquimod, 1057
ImmuCyst, 794
Imukturin, 795
Immune interferon, see Interferon gamma-1b
Immune reconstitution syndrome, 555
Immunocompromised patients
Oropharynx infections, fungal, 996
Tuberculosis, 501
Immunosuppression and indwelling intraperitoneal catheters, 439
Innovid, 799
Imodium, 56
Imodium Plus, 56
Ino LA, 193
Impetigo: widespread infection, 448
Imunovir, 530
Imuran, 717
Imuvac, 1086
Imudine, 1053
Incivo, 549
Inconex XL, 671
Incursol Ellipta, 219
Indacaterol, 221
Chronic obstructive pulmonary disease, 214
Indapamide, 160
Indapamide with perindopril arginate, 130
Index of proprietary manufacturers, 1326
Indinavir, 569
HIV infection, 555
Indipam XL, 161
Indiniva, 654
Indocid, 930
Indolar SR, 930
Indometacin, 929
Indomethacin, see Indometacin
Indoramin, 673
Industrial methylated spirit, 1050
Inergy, 182
Infacol, 60
Infanrix-IPV, 1080
Infanrix-IPV + Hib, 1079
Infection, 458
L
Leacyflora MR, 612
Labetalol hydrochloride, 143
Hypertension, 121
Lacidipine, 152
Lacosamide, 393
Lacri-Lube, 954
Lactic acid, 439
Lactic acid with salicylic acid, 1058
Lactugal, 47
Lactulose, 47
Constipation, 43
Lamictal, 395
Lamisil, 515, 1013
Lamivudine, 563
Lamivudine with abacavir and dolutegravir, see Abacavir with dolutegravir and lamivudine
Lamivudine with abacavir and zidovudine, see Abacavir with lamivudine and zidovudine
Lamivudine with abacavir, see Abacavir with lamivudine
Lamivudine with zidovudine, 567
Lamotrigine, 394
Epilepsy, 383
Lanacort, 1029
Lanoxin, 95
Lanreotide, 789
Lansoprazole, 69
With amoxicillin + clarithromycin, 69
With amoxicillin + metronidazole, 69
With clarithromycin + metronidazole, 69
With amoxicillin + clarithromycin, 69
With amoxicillin + metronidazole, 69
With tetracaine, 69
Life-threatening acute asthma, 1313
Lanreotide, 201
Latanoprost, 969
Latanoprost with timolol, 969
Lattitude, 315
Laxatives, 83
Laxido, 49
Lecado, 331
Lecent, 401
Lecithin with coal tar, see Coal tar with lecithin
Leflunomide, 895
Lemtrada, 732
Lenalidomide, 796
Length of prophylaxis, 528
Lenograsitam, 842
Leprosy, 499
Lercanidipine hydrochloride, 153
Lescol, 180
Lescol XL, 180
Lestranyl, 686
Letrozole, 793
Leuprorelin acetate, 633
Levat, 759
Levat, 748
Levamisol, 525
Helminth infections, 524
Levemir FlexPen, 605
Levonelle, 605
Levemir Penfill, 605
Levest, 687
Levetiracetam
Drug monograph, 396
Epilepsy, 383
Levaxin, 346
Levitra, 701
Levobunolol hydrochloride, 964
Levodopa, 315
Levodopa with carbidopa, 688
Levodopa with carbidopa and entacapone, see Carbendopa
Levodopa with entacapone and levodopa
Levodopa with carbipedia and entacapone, see Carbendopa
Levodopa with carbipedia, see Carbendopa
Levodopa with levofolinic acid, 394, 967
With amoxicillin + clarithromycin, 394
With amoxicillin + metronidazole, 394
With clarithromycin + metronidazole, 394
Lanthanum, 860
Lantus, 605
Lapatinib, 812
Larafenib CR, 952
Larbitex XL, 673
Largactil, 305
Lariam, 538
Laronidase, 869
Lasilactone, 201
Lasix, 201
Latanoprost, 969
Latanoprost with timolol, 969
Lattitude, 315
Laxatives, 83
Laxido, 49
Lecado, 331
Lecent, 401
Lecithin with coal tar, see Coal tar with lecithin
Leflunomide, 895
Lemtrada, 732
Lenalidomide, 796
Linezolid, 477
MRSA, 501
Lint, 1310
Lioresal, 914
Lithothrytone sodium, 666
Lipantil Micro, 175
Lipegfilgrastim, 842
Lipitor, 179
Lipobase, 1004
Lipodystrophy syndrome, 556
Lipstatin, 180
LiquaMag GP, 858
Liquid paraffin, 49
Constipation, 44
Liquid paraffin with magnesium hydroxide, 49
Liquid paraffin with white soft paraffin and wool alcohols, 953
Liquifilm Tears, 952
Liquid, 1274
Liquivisc, 951
Liraglutide, 600
Liraglutide with insulin degludec, see Insulin degludec with liraglutide
Lisdexametamfetamine mesilate, 271
Lisinopril, 128
Lisinopril with hydrochlorothiazide, see Hydrochlorothiazide with lisinopril
Lidokain, 279
Litak, 759
Lithium
Emergency treatment of poisoning, 1128
Psychoses and related disorders, 275
Lithium carbonate, 277
Lithium citrate, 279
Lithium salts, 276
Livial, 647
Lizisenatide, 601
Lizinia, 688
LMX 4, 1118
Local analgesics, 992
Lodrin, 1012
Locoid, 1029
Locoid Crelo, 1029
Locoid Lipocream, 1029
Lodine SR, 924
Lodotra, 586
Lodoxamide, 946
Loestrin 20, 688
Loestrin 30, 688
Loferpramine, 297
Lofexidine hydrochloride, 428
Lofexidine, 1040
Lifexpram, 297
Lipidzone, 428
Lipofen, 425
Lipoxin, 425
Lipoxin hydrochloride, 434
Substance dependence, 425
Lojixta, 177
Lomikapide, 176
Lomont, 298
Lomustine, 752
Long-term oxygen therapy, 214
Loniten, 158
Lonquex, 688
Loop diuretics, 199
Loperamide hydrochloride, 56
Acute diarrhoea, 54
Chronic bowel disorders, 32
Loperamide with simeticone, 56
Lophex, 1288, 1289
Lopid, 176
Lopinavir with ritonavir, 569
Loprazolam, 418
Lopresor, 145
Lopresor SR, 145
Loratadine, 250
Lorazepam, 412
Lormetazepam, 419
Magnesium hydroxide with aluminium hydroxide and simeticone, see Aluminium hydroxide with magnesium hydroxide and simeticone
Magnesium hydroxide with aluminium hydroxide, see Co-magaldrox
Magnesium hydroxide with liquid paraffin, see Liquid paraffin with magnesium hydroxide
Magnesium sulphate, 858
Magnesium sulphate with glycerol and phenol, see Glycerol with magnesium sulphate and phenol
Magnesium trisilicate, 61
Magnesium trisilicate with sodium bicarbonate and magnesium carbonate, see Magnesium carbonate with aluminium hydroxide and simeticone, Magnesium carbonate with aluminium hydroxide, Magnesium hydroxide with aluminium hydroxide, Magnesium hydroxide, Magnesium carbonate, Magnesite, 60
Magnesium carbonate with calcium acetate, see Calcium acetate with magnesium carbonate
Magnesium carbonate with citric acid, see Citric acid with magnesium carbonate
Magnesium carbonate with magnesium trisilicate and sodium bicarbonate, 61
Magnesium citrate with sodium picosulphate, 102
Magnesium glycerophosphate, 858
Magnesium hydroxide, 46, 54
Maxitram SR, 374
Maxitrol, 948
Maxolon, 348
Maxtex, 764
MCT Procal, 1277
Measles, mumps and rubella vaccine, live, 1087
Measurement of HbA1c, 589
Mebendazole, 526
Mebendazole with albendazole, 524
Mebeverine hydrochloride, 75
Mebeverine with ispaghula husk, see Ispaghula husk with mebeverine
Medicated bandages, 1318
Medicated sock, 1318
Medihoney, 1306
Medikinet, 274
Medikinet XL, 274
Medrone, 584
Medroxyprogesterone acetate, 695
Medroxyprogesterone with conjugated oestrogens, see Conjugated oestrogens with medroxyprogesterone
Medroxyprogesterone with estradiol, see Estradiol with medroxyprogesterone
Mefenamic acid, 315
Mefloquine, 537
Menotrophin, 537
Menopur, 536
Menopause, 1015
Menopausal symptoms, 1094
Menstrual symptoms, 1094
Menstruation, 1094
Meningococcal groups A with C and Y vaccine, see Meningococcal groups A, C, Y and W135 vaccine
Meningococcal groups A, C, Y and W135 vaccine, 1088
Meningococcal groups B vaccine (DNA, component, adsorbed), 1088
Meningococcal groups C vaccine, 1088
Meningococcal groups D with C and W135 and Y vaccine, 1089
Meningococcal septicaemia, 443
Menitrix, 1081
Menjugate, 1088
Mephradec, 641
Menthol, 641
Menthol with eucalyptus, see Eucalyptus with menthol
Menthol with eucalyptus, 438
Mepradec, 794
Meperidine, 836
Mepivacaine with adrenaline, see Adrenaline with mepivacaine
Mepivacaine, 1119
Mepivacaine hydrochloride, 438
Mepivacaine with adrenaline, see Adrenaline with mepivacaine
Mepredade, 70
Meprobamate, 265
Meprocin, 367
Mepitid, 367
Mercaptamine, 689
Mercaptopurine, 762
6-Mercaptopurine, see Mercaptopurine
Mercilon, 686
Merton, 641
Meropen, 454
Meropen, 454
Mesalazine, 34
Mesalin, 1306
Mesna, 783
Mesterolone, 661
Mestinon, 913
Mestranol with norethisterone, 689
Metabet SR, 595
Metalyse, 195
Metamandin, 165
Meters and test strips, 614
Metformin hydrochloride, 594
Metformin with alogliptin, see Alogliptin with metformin
Metformin with canagliflozin, see Canagliflozin with metformin
Metformin with dapagliflozin, see Dapagliflozin with metformin
Metformin with linagliptin, see Linagliptin with metformin
Metformin with pioglitazone, 614
Metformin with saxagliptin, 597
Methyldopa, 138
Metformin with vildagliptin, 599
Methadone, 425
Methadone hydrochloride, 436
Aromatic inhalations, cough preparations and systemic nasal decongestants, 258
Substance dependence, 425
Methodone, 437
Methaemoglobinemia, 1123
Metharose, 437
Menethamine hupurate, 511
Urinary-tract infections, 510
Methoctramol, 915
Methotrexate, 762
Inflammatory bowel disease, 32
Methotrimprazine, see Levomepromazine
Methoxy polyethylene glycol-epoetin beta, 824
Anemias, 823
Methylcellulose, 45
Constipation, 45
Obesity, 77
Methyl dopa, 138
Hypertension, 121
Methylene blue, see Methylene blue chloride
Methynaltrexone bromide, 47
Mephenytoin hydrochloride, 273
Attention deficit hyperactivity disorder, 270
Methylprednisolone, 584
Methylprednisolone with lidocaine, see Lidocaine with methylprednisolone
Methyl salicylate with diethyl phthalate, see Diethyl phthalate with methyl salicylate
Methylthioninium chloride, 1155
Emergency treatment of poisoning, 1123
Metoclopramide hydrochloride, 347
Metoclopramide with aspirin, see Aspirin with metoclopramide
Metoclopramide with paracetamol, 375
Metoprolol PEN, 764
Metolazone, 205
Metoprolol, 588
Metoprolol tartrate, 144
Metoxy, 1028
Metronidazole, 712, 1008
Inflammatory bowel disease, 32
Oral bacterial infections, 446
Oropharyngeal bacterial infections, 995
Skin infections, 1006
Vaginal and vulval conditions, 710
Metronidazole and tinidazole, 446
Metroga, 1009
Metyparone, 588
Cushing’s Syndrome, 587
Mezavant XL, 36
Mezopram, 70
Miaclalcic, 627
Miaotin hydrochloride, 290
Mictag, 516
Micin, 1019
Micards, 136
MicardsPlus, 136
Micolette Micro-emama, 678
Miconazole, 713, 997, 1011
Oropharyngeal fungal infections, 996
Skin infections, 1006
Micralax Micro-emama, 678
Microgynon 30, 687
Micronor, 658
Micropirin, 105
Midazolam, 414
Diabetes, 588
Mifamurtide, 793
Mife, 709
Mifepristone, 708
Migard, 378
Migliustat, 870
Migrante, 380
Migrate, 375
Migraine Pink, 375
Migraine Yellow, 359
MigraMax, 381
Migrel, 577
Midilson Lipocream, 1029
Millina, 687
Milirontone, 169
Milupa, 1287, 1288
Mimpara, 856
Mineralocorticoid side effects, 577
Minerals with vitamins and trace elements, see Vitamins and minerals and trace elements
Minirant, 191
Minocin MR, 498
Minocycline, 498
Rosacea and Acne, 1041
Monodih, 612
Minoxidil, 158, 1049
Mintec, 40
Mintrel XL, 519
Miochol-E, 959
Miotics, 962
Miphel, 959
Mirabegron, 671
Urinary frequency, incontinence, 667
Mirapectin, 337, 338
Mircera, 824
Mirena, 694
Mirtazapine, 291
Mivasaos, 1048
Misofern, 924
Misoprostol, 709
Misoprostol with diclofenac sodium, see Diclofenac sodium with misoprostol
Misoprostol with naproxen, 955
Mitomycin, 767
Mitotane, 778
Mitoxantrone, 778
Mitoxantrone, see Mitoxantrone
Miveron, 1104
Mivacuvir, 1104
Mizolastine, 250
Mizellen, 251
M-M-RVAXPRO, 1088
Mobil, 938
Mocllobemide, 283
Mocfam, 424
Moderate, 306
Moderate acute asthma, 210
Modigraf, 723
Modisol XL, 193
Modrasone, 1023
Modulin IBQ, 1272
Moduret, 160
Moduretic, 160
Moxepin hydrochloride, 129
Mogadon, 420
Molap, 153
Moloc, 49
Molcer, 980
Molipaxin, 292
Molita, 107
Mometasone furoate, 232, 986, 1031
Mongen XL, 194
Monoamine-oxidase-B inhibitors, 324
Monoamine-oxidase inhibitors, 282
Monodril, 832
Monoxam SR, 193
Monoxam XL, 193
Mononil XL, 193
Monoxide, 96
Monopost, 969
Monoxor XL, 193
Monotrin, 463
Montelukast, 233
Nose, 980
Morphesic SR, 369
Morphine, 367
Morphine with cyclizine, see Cyclizine with morphine
Morphine with kaolin, see Kaolin with morphine
Morten, 153
Motifen, 923
Motilium, 347
Mouthwashes and other preparations for oropharyngeal use, 998
Mouthwashes, gargles, and dentifrices, 989
Movicof, 49
Moviprep, 42
Moxifloxacin, 492, 957
Moxisylyte, 205
Moxivig, 957
Moxomidine, 138
Mozobil, 564
MRSA, 501
MST Continus, 369
MSUD, 1286, 1286
MSUD Moxiplex LQ, 1286
MSUD Maxatum, 1286
MucoClear, 240
Mucodyne, 256
Mucogel, 59
Mucolytics, 256
Multaq, 90
Multi-layer compression bandaging, 1318
Munalea, 686
Mupirocin, 987, 1009
Skin infections, 1006
Musculoskeletal system infections, 446
Muse, 703
MXT, 369
Mycanrine, 516
Mycofloc K, 471
Mycobutin, 508
Mycoprophene mofetil, 725
Mydricyl, 958
Naltrexone hydrochloride, 959
Mydriate, 950
Myferax, 726
Myfortic, 726
Myleran, 749
Myocet, 756
Myoclonic seizures, 383
Myocisn, 897
Myotone, 676
Myzam, 870
Myxodelle, 710

Nabilone, 346
Nabumetone, 934
Nacex, 692
Nadolol, 145
Nafarelin, 634
Naftidrofuryl oxalate, 206
Peripheral vascular disease, 205
Napflazine, 868
Nalcom, 235
Nalidixic acid, 493
Nalmefene, 429
Substance dependence, 425
Nalox, 430
Naloxone hydrochloride, 1133
Naloxone with buprenorphine, see Buprenorphine with naloxone
Naloxone with oxycodone, see Oxycodone with naloxone
Naltrexone hydrochloride, 430
Substance dependence, 425
Nandrolone, 620
Napratec, 936
Naproxen, 935
Naproxen EC, 935
Naproxen, 934
Naproxen with esomeprazole, see Esomeprazole with naproxen
Naproxen with misoprostol, see Misoprostol with naproxen

Namaig, 579
Naratriptan, 378
Nardil, 283
Naropin, 1122
Nasacort, 986
Nasal polyps, 980
Nasal preparations for infection, 980
Nasal staphylococci, 383
Naseptin, 987
Nasocid, 984
Nasocon, 985
Nasox, 986
Natalizumab, 732
Natalc, 887
Nateglinide, 607
Nataril, 161
Nataril SR, 161
Natzon, 436
Navelbine, 775, 776
Navirex, 204
Navispare, 160
Naxodol MR, 612
Nebbico, 178
Nebcin, 452
Nebido, 662
Nebilet, 145
Nebivolol, 145
Nebuliser diluent, 209
Nebulisers, 209
Nebuliser solutions, 240
Nebusol, 240
Nedrotol XL, 671
Nedocromil sodium, 234, 946

Needle free Insulin delivery systems, 617
Nefopam hydrochloride, 356
Nebaban, 488
NeisVac-C, 1088
Nelarabine, 764
Nemdatine, 265
Neocaridin, 247
Neo-Cytam, 838
Neoel XL, 152
Nexify, 889
Neomycin sulfate, 451, 1009
Neomycin sulfate with clobetasol propionate and nystatin, see Clobetasol propionate with neomycin sulfate and nystatin
Neomycin sulfate with dexamethasone and glacial acetic acid, see Dexamethasone with glacial acetic acid and neomycin sulfate
Neomycin with betamethasone, see Betamethasone with neomycin
Neomycin with chlorhexidine, see Chlorhexidine with neomycin
Neomycin with dexamethasone, hypermellose and polymyxin B sulfate, see Dexamethasone with hypermellose, neomycin and polymyxin B sulfate
Neomycin with fluocinolone, see Fluocinolone acetonide with neomycin
Neo-Nexul, 160
Neoral, 719
Neorecormon, 829
Neostigmine, 912
Neostigmine and glycopyrronium bromide, see Glycopyrronium bromide with neostigmine
Neostigmine methylsulfate, see Neostigmine
Neotigason, 1035
Neouvent, 222
Neozpine XL, 155
Nepafan, 961
Nepro, 1277
Nerisone, 1027
Nerve agents, 1123
Neulasta, 843
Neupogen, 842
Neupogen Singleject, 842
Neo, 540
Neural tube defects (prevention in pregnancy), 980
NeuroBloc, 324
Neuroleptic malignant syndrome, 300
Neurontin, 393
Neuropathic pain, 382
Neutral Insulin, see Insulin
Neutrogena T/Gel Therapeutic, 1034
Nevanac, 962
Nevirapine, 560
HIV infection, 555
NewGel-E, 1310
Nexavir, 817
Nexum, 68
Nexplanon, 695
Nicam, 1048
Nicardipine hydrochloride, 153
Nicel, 458
Nicorandil, 185
Stable angina, 182
Nichette, 432
Nicrorette Icy White, 432
Nicrorette inves, 432
Nicrorette Microtab, 432
Nicrorette QuickMist, 432
Nicotinamide, 1048

Nicotine, 430
Substance dependence, 425
Nicotine dependence, 425
Nicotinell, 432
Nicotinell TTS, 432
Nicotine replacement therapy, 425
Nicotinic acid, 177
Nicoumalone, see Acenocoumarol
Nifeplex, 154
Peripheral vascular disease, 205
Niferidipine with atenolol, see Atenolol with nifeplex
Nifedipress MR, 155
Nifext, 835
Nifopress Retard, 154
Nilotinib, 812
Nimex, 1104
Nimenrix, 1089
Nimodipine, 99
Nimotop, 99
Nivastid, 264
Niprat, 700
Nipent, 779
Niquitin, 432
Niquitin Clear, 432
Nitisinone, 871
Nitrates, 189
Nitrazepam, 419
Nitrocin, 191
Nitro-Dur, 160
Nitrofurantoin, 512
Urinary-tract infections, 510
Nitrolingual, 191
Nitromin, 191
Nitronal, 191
Nitrous oxide, 1096
General anaesthesia, 1093
Nivestim, 842
Nizatidine, 65
Nizoral, 713, 1011
Nocturnal enuresis in children, 667
Nocturnal leg cramps, 913
Nomegestrol with estradiol, see Estradiol with nomegestrol
Non-convulsive status epilepticus, 383
Non-depolarising neuromuscular blocking drugs, 1103
Non-drug tariff specification sterile dressing packs, 1311
Non-extensible bandages, 1313
Non-falciparum malaria (treatment), 529
Non-hormonal preparations for vaginal atrophy, 710
Non-medical prescribing, 1325
Nonoxinol, 697
Non-woven fabric dressing with viscose-rayon pad., 1298
Nootropil, 521
Noradrenaline/norepinephrine, 166
Noracron, 1105
Noradropin Nordiflex, 643
Noradropin SimpleXx, 643
Norgestomarin with ethinylestradiol, see Ethinylestradiol with norgestomarin
Norethisterone, 656
Norethisterone with estradiol, see Estradiol with norethisterone
Norethisterone with ethinylestradiol, see Ethinylestradiol with norethisterone
Norethisterone with mestranol, see Mestranol with norethisterone
Nortrolac, 493
Norgalax, 52
Norgestrol with estradiol, see Estradiol with norgestrel
Index

Norgestimate with ethinylestradiol, see Ethinylestradiol with norgestimate
Norgestrom, 694
Norgestrel with conjugated oestrogens, see Conjugated oestrogens with norgestrel
Norday, 658
Norimin, 688
Norinyl-1, 689
Noristerat, 658
Noracal, 46
Normal immunoglobulin, 1063
Normosal, 1053
Normax, 51
Normsang, 865
Novoprolac, 631
Nortriptyline, 298
Diabetes, 588
Nurse Prescribers, 1461
Nurofen Back Pain SR
Nurofen
Nulojix
Nucleoside reverse transcriptase
see NTBC, 997
Noxafil
NovoSeven
NovoRapid PumpCart
NovoRapid FlexTouch
NovoRapid FlexPen, 604
NovoRapid PumpCart, 604
NovoSeven, 97
Naxipil, 521
Noxious gases, 1123
Noyada, 126
Nozinan, 346
Nplate, 845
NSAID-associated ulcers, 61
NTBC, see Nitisinone
Nucleoside reverse transcriptase inhibitors, 561
Nuelin SA, 239
Nulofix, 726
Nurofen, 929
Nurofen Back Pain SR, 929
Nurofen Express, 929
Nurofen Meltlets, 929
Nurofen Migraine Pain, 929
Nurofen Tension Headache, 929
Nurse Prescribers’ Advisory Group 2015–2016, viii
Nut-Seals, 105
Nutilis, 1268, 1270, 1279
Nutraplus, 1006
Nutricrem, 1270
Nutripilen, 1268, 1270
Nutriprem, 1461
Nutrison, 1262, 1263, 1264, 1265
Nutrizym, 82
Nutropin, 643
Nuvaraing, 687
Nvelle TS Phase I, 652
Nystaform, 1014
Nystaform HC, 1030
Nytran, 997
Nytran, 997

Orophraryngeal fungal infections, 996
Nystatin with benzalkonium chloride, dimeticone and hydrocortisone, see Benzalkonium chloride with dimeticone, hydrocortisone and nystatin
Nystatin with chlorhexidine hydrochloride and hydrocortisone, see Chlorhexidine hydrochloride with hydrocortisone and nystatin
Nystatin with chlorhexidine, see Chlorhexidine with nystatin
Nystatin with clindamycin propionate and neomycin sulfate, see Clindamycin propionate with neomycin sulfate and nystatin
Nystatin with clotrimazole butyrate and oxymetazoline, see Clotrimazole butyrate with nystatin and oxymetazoline

O
Obesity, 77
Obinutuzumab, 739
Occlusal, 1058
Oclusive adhesive tapes, 1312
Ocriplasmin, 975
Octagam
Octanax, 494, 957
Octaqué, 957
Olatinum Plus, 1000
Olanzapine, 315
Psychoses and related disorders, 300
Olanzapine embonate, 316
Olanzapine Pamoate, see Olanzapine embonate
Olbetam, 177
Oldaram, 374
Olena, 286
Olive oil, 980
Olmesartan medoxomil, 135
Olmesartan with amlodipine and hydrochlorothiazide, see Amlodipine with hydrochlorothiazide and olmesartan
Olmesartan with amlodipine, see Amlodipine with olmesartan
Olmesartan with hydrochlorothiazide, see Hydrochlorothiazide with olmesartan
Olmetec, 135
Olmetec Plus, 136
Olodaterol, 222
Olapatadine, 946
Olsalazine sodium, 946
Olsiposio, 548
Onmacor, 178
Omalizumab, 235
Omega-3-acid ethyl esters, 235
Omeprazole, 69
Gastro-oesophageal reflux disease, 72
Peptic ulceration, 61
With amoxicillin + clarithromycin, 61
With amoxicillin + metronidazole, 61
With clarithromycin + metronidazole, 61
With ketoprofen, see Ketoprofen with omeprazole
Onmicur, 1012
Omnitrope Pen, 643
Omnitrope SurePal, 643
Ondreex Brezchuler, 221
OnciTICE, 794
Ondansetron, 349
Ondemet, 350
One-Alph, 885
Onglyza, 597
Onkotone, 779
Opatanol, 946
Ophthalmic Specials, 943
Oplon, 205
Opiodur, 366
Opioid dependence, 425
Opioid-receptor antagonists, 425
Opioids, 357
Opioid substitution therapy, 425
During breastfeeding, 425
During pregnancy, 425
Opizone, 430
Oralan, 337, 338
Opsumin, 163
Optaflu, 1086
Opticron, 946
OptiFlo S, 679
Optilast, 945
Optive Fusion, 953
Optrex Allergy, 946
Optrex Infected Eyes, 955
Oral bacterial infections, 446
Oral bicarbonate, 845
Oral corticosteroids
Airways disease, use of corticosteroids, 126
Oraledene, 990
Oral glucose tolerance test, 614
Oral iron, 830
Oral potassium, 845
Oral preparations for acne, 1041
Oral preparations for fluid and electrolyte imbalance, 845
Oral rehydration therapy (ORT), 845
Oral retinoid for acne, 1041
Oral sodium and water, 845
Oral ulceration and inflammation, 992
Oranorph, 369
Orbifen, 929
Orecina, 900,
Oral-par, 871
Orgalutran, 636
Organophosphorus insecticides, 1123
Orgaran, 111
Orlilast, 78
Obesity, 77
Orophrarynx infections, bacterial, 995
Oropharynx infections, fungal, 996
Orphenadrine hydrochloride, 325
Ourviol, 952
Ouelamivir, 571
Influenza, 571
Osmanil, 366
Osmolite, 1262, 1264
Osmotic laxatives, 45
Osteoarthritis and soft-tissue disorders, 891
OsteoCaps DS, 886
Osteonecrosis, 555
Osteoporosis, 619
Ostial, 659
Oteracil with tegafur and gimeracil, see Tegafur with gimeracil and oteracil
Otex, 980
Otitis externa, 976
Otitis media, 976
With effusion, 976
Otomize, 979,
Otrive, 983
Otrive Antistin, 945
Ovestin, 714
Oxex, 526
Oxitelle, 639
Ovanette, 687
Oxiprenolol hydrochloride, 688
Oxactin, 286
Oxalatilinum, 768
Oxazepam, 420
Oxcarbazepine, 597
Epilepsy, 383
Oxeltra, 370
Oxbenzetin, 206
Oxithrorbital, 221
Oxphenylypiridine, see Pentoxifylline
Oxrenolol hydrochloride, 145
Oxyl, 953
Oxypropanoic hydrochloride, 960
Oxybutynin hydrochloride, 669
Urinary frequency, enuresis and incontinence, 667
Oxycodone hydrochloride, 369
Oxycodone with naloxone, 370
Oxycodone, 370
Oxymethalone, 823
Oxynorm, 370, 498
Oxycycline, 498
Oxycycline with clobetasone butyrate and nystatin, see Clobetasone butyrate with nystatin and oxycycline
Oxytocin, 705
Oxytocin with ergometrine, see Ergometrine with oxytocin
Ozurdex, 948

P
Pabal, 706
Pabrinex Intramuscular High Potency, 883
Pabrinex Intravenous High Potency, 885
Paclitaxel, 771
Palexia, 372
Palexia SR, 372
Palifermin, 783
Paliperidone, 317
Palladone, 366
Palladone SR, 366
Palliative care, 258
Palonosetron, 350
Paludrine, 539
Pamidronate disodium, 623
Pamidronate disodium was formerly called aminohydroxypropyldiene-diphosphonate disodium (ADP), see Pamidronate disodium
Pamsuxal XI, 675
Panadol, 355
Panadol Ultra, 359
Pancrease, 82
Pancreatin, 81
Biliary disorders, 75
Pancrex, 82
Pancuronium bromide, 1104
Pandermis HIN1, 1086
Panitumumab, 741
Pantoloc, 1044
Pantoloc Aegagel, 1044
Pantoloc Control, 71
Pantoprazole, 71
Pantoprazole with amoxicillin + clarithromycin, 61
Pantoprazole with clarithromycin + metronidazole, 61
Papaveretum, 371

Paracetamol, 354
Emergency treatment of poisoning, 1123
Oxyprenolol hydrochloride and codeine phosphate, see Buclozine hydrochloride with codeine phosphate and paracetamol
Paracetamol with codeine phosphate, see Co-codamol
Paracetamol with dihydrocodeine, see Co-dydramol
Paracetamol with methoclopramide, see Metoclopramide with paracetamol
Paracetamol with tramadol, 356
Paracodon, 359
Paraffin Gauze Dressing, 1295
Paraffin, yellow, soft, 954
Parama, 376
Parasitidical preparations, 1007
Parasymptomathematics, 672
Parathyroid hormone, 629
Parecoxib, 1108
Parenteral corticosteroids, 227
Parenteral iron, 831
Parenteral nutrition supplements, 878
Parenteral preparations for fluid and electrolyte imbalance, 846
Paricalcitol, 888
Pariet, 72
Parkinson’s disease, 324
Parkinson’s disease and related disorders, 324
Parodol, 334
Parmid XL, 152
Paroven, 206
Paroxetine, 287
Paroxysmal atrial fibrillation, 85
Paroxysmal supraventricular tachycardia, 85
Parvolex, 1135
Parsireotide, 790
Pavacol-D, 259
Pazopanib, 813
Peak flow meters
Asthma, 213
Medical device, 240
PreFent, 364
Pedea, 929
Pediace, 1079
Peditrace, 879
Pegaptanib sodium, 972
Pegans, 542
Pegfilgrastim, 842
Peginterferon alfa, 542
Hepatitis, 541
Peginterferon beta-1a, 730
Pegvisomant, 642
Peglated recombinant methionyl human granulocyte-colony stimulating factor, see Pegfilgrastim
Pemetrexed, 765
Penbritin, 484
Penicillamine, 896
Penicillin G, see Benzylpenicillin sodium
Penicillins
Class monograph, 478
Oxycycline with clindamycin, 61
Penicillin with tetracycline + amoxicillin + clarithromycin, 61
Penicillin with tetracycline + metronidazole, 61
Penprostatum, 371

Pentoxifylline, 207
Peripheral vascular disease, 205
Peppermint oil, 40
Peptac, 58
Peptamin, 1263, 1265
Peptic ulceration, 61
Peptisorb, 1263
Perampanel, 598
Perative, 1265
Perioperative endoscopic gastroscopy or jejunoscopy, 441
Peridol, 191
Perlix, 129
Perflugan, 356
Perivan, 104
Pergolide, 336
Pergoveris, 640
Pertactin, 247
Percyazine, see Pericyazine 508
Pericyazine, 308
Perinal, 81
Perindopril arginine, 129
Perindopril arginine with indapamide, see Indapamide with perindopril arginine
Perindopril erbumine, 130
Periodontitis, 992
Pentostatin, 996
Peripheral vascular disease, 205
Perjeta, 742
Permeable adhesive tapes, 1312
Permethrin, 1015
Skin infections, 1006
Permitabs, 1095
Peroxyl, 991
Perphenazine, 308
Perphenazine with amitriptyline, see Amitriptyline with perphenazine
Persantin, 107
Persantin Retard, 107
Pertussis with diptheria with haemophilus influenza with poliomyelitis and tetanus, see Diphtheria with haemophilus influenza type b vaccine, pertussis, poliomyelitis and tetanus
Pertussis with diptheria with poliomyelitis and tetanus, see Diphtheria with pertussis, poliomyelitis vaccine and tetanus
Pertuzumab, 741
Pesticides, 1129
Pethidine hydrochloride, 372
Peyme MR, 675
Pevanti, 586
Pevaryl, 1011
Phaeochromocytoma, 123
Pharmacollicin, 756
Pheburene, 872
Phenelzine, 283
Phenergan, 251, 252
Phenindione, 120
Phenobarbital, 409
Epilepsy, 383, 414
Phenobarbitone, see Phenobarbital
Phenol, 78, 81
Phenol with Glycerol and magnesium sulphate, see Glycerol with magnesium sulphate and phenol
Phenothiazines and related drugs, 1127
Phenylbutazone hydrochloride, 161
Hypertension, 121
Phenoxymethylpenicillin, 481
Antibacterials, use for prophylaxis, 459
Oral bacterial infections, 446
index

Oropharynx infections, bacterial, 995
Phentolamine mesilate, 161
Hypertension, 121
Phenytoine hydrochloride, 166, 959
Phenytoine with lidocaine, see Lidocaine with phenytoine
Phenytoine with tropicamide, 958
Phenylketonuria, 879
Phenyltoine, 398
Epilepsy, 383, 414
Pholcodine, 259
Phorpin, 929
Phos, 860
PhosLo, 860
Phosphate, 861
Phosphate Sandoz, 862
Phosphorylated glycosylated recombinant human deoxyribonuclease 1 (DHase), see Dornase alfa
Phenofrin, 800
Phototherapy, 1018
Phytocontin Continus, 238
Physeptone, 457
Physical debridement pads, 1311
Physiostatin, 139
Phyex, 1014
Phytomenadione, 889
Picato, 1039
Pickles, 1058
Picolax, 45
Pilocarpine, 967, 988
Glaucoma, 962
Treatment of dry mouth, 987
Pimecrolimus, 619
Pimodalez, 1019
Psoriasis, 1017
Pimozide, 308
Pindolol, 146
Pindolol with clopamide, see Clopamide with pindolol
Pinefed XL, 152
Pineex PR, 675
Pinnactil, 180
Pilorgan, 613
Pilorgan with metformin, see Metformin with piloglatazone
Piperacillin with tazobactam, 479
Piperaccline phosphate with artensinol, see Artensinol with piperaccline phosphate
Piperaccline tetra phosphate with dihydroartemisinin, see Artensinol with piperaccline phosphate
Piptoazine palmitate, see Pipotiazine palmitate
Pipotiazine palmitate, 314
Piracetam, 521
Epilepsy, 383, 414
Parkinson’s disease and related disorders, 324
Pirfenidone, 260
Pirimase Hayward, 985
Piriton, 246
Piroxicam, 936
Pityriasis versicolor, 1007
Pivmecillinam hydrochloride, 486
Pixintrone, 779
Pizol, 850
Pizotifin, 376
Pivacaine, 895
Plasma and plasma substitutes, 845
Plavix, 106
Plag, 731
Plenaloch, 886
Pleodren, 584
Pendi, 152
Plerixafor, 840
Pletal, 207
Plagalis, 1119
Pneumococcal vaccine, 1089
Pneumocystis pneumonia, 522
Podophyllotoxin, 1056
Polymyositis with diptheria and tetanus, see Diptheria with polymyositis and tetanus vaccine
Polymyositis with diptheria with haemophilus influenzae type b vaccine, pertussis, polymyositis and tetanus
Polymyositis with diptheria with pertussis and tetanus, see Diptheria with polymyositis vaccine and tetanus
Politid XL, 290
Pollenase, 246, 946, 984
Pollenshield, 245
Pollines Grasses + Rye, 253
Pollines Trees, 254
Poloxamer 188 with dantron, see Dantron with poloxamer 188
Poloxamer 188, 330
Pollinex Grasses + Rye, 290
Pollenshield, 290
Polyacrylic acid, see Carbomer
Polyca, 1273
Polyfax, 1008
Polymyxin B with bacitracin, see Bacitracin with polymyxin b
Polymyxin B sulfate with danthromer, see Danthromer with polymyxin b sulfate
Polymyxin B sulfate, 1303
Polyurethan matrix dressing, 1301
Polyvinyl alcohol, 952
Dry eye, 950
Pomalidomide, 797
Potentia, 814
Ponstan, 933
Potassium supplements, see Potassium supplements
Potassium bicarbonate, see Potassium bicarbonate
Potassium bicarbonate and precipitated sulfur, see Precipitated sulfur with coal tar and salicylic acid, see Coal tar with salicylic acid and precipitated sulfur
Pred Forte, 949
Prednisolone, 585, 949, 979
Prednisolone with cinchocaine, see Cinchocaine with prednisolone
Prednison, 586
Predsol, 586
Preface, iii
Preltin, 436
Prebalbin, 400
Epilepsy, 383
Pregaday, 834
Pregestimil, 1475
Pregnancy
Constipation, 43
Epilepsy, 383
Gastro-oesophageal reflux disease, 72
HIV infection, 555
Malaria, prophylaxis, 528
Malaria, treatment, 529
Urinary-tract infections, 510
Pregnancy and breast-feeding
Asthma, 210
Tuberculosis, 501
Pregnyl, 639
Premarin, 648
Premique, 648
Premjact, 1118
Prenoxad, 649
Preparations for vaginal and vulval changes, 710
Prescribing for children, 16
Prescribing for the elderly, 25
Psychoses and related disorders, 300
Prescribing in
Breast-feeding, 19
Dental practice, 27
Hepatic impairment, 17
Palliative care, 20
Pregnancy, 19
Renal impairment, 17
Prescription writing, 4
Preservatives and sensitisers, 943
Preservex, 917
Prestim, 147
Prestylon, 178
Prevenar, 1089
Prevention of
Cardiovascular events, 186
Diabetic complications, 588
Early-onset neonatal infection, 439
Entrophtis, 459
Extravasation, 940
Infection from animal and human bites, 459
Infection in cardiology procedures, 439
Infection in gastro-intestinal procedures, 439
Infection in obstetric and gynaecological surgery, 439
Infection in orthopaedic surgery, 439
Infection in urological procedures, 439
Infection in vascular surgery, 439
Pertussis, 439
Pneumococcal infection in asplenia or in patients with sickle-cell disease, 439
Recurrence of rheumatic fever, 439
Secondary case of diphtheria in non-immune patient, 439
Secondary case of Haemophilus influenzae type b disease, 439
Secondary case of invasive group A streptococcal infection, 439
Secondary case of meningococcal meningitis, 439
Tuberculosis, 501
Tuberculosis in susceptible close contacts or those who have become tuberculin positive, 439
Prezista, 568
Priadel, 279
Priligy, 704
Prilocaine hydrochloride, 1120
Prilocaine with felypressin, see Felypressin with prilocaine
Prilocaine with lidocaine, see Lidocaine with prilocaine
Prilotalkal, 1121
Primacor, 170
Primaxin, 538
Primaxin L.V., 454
Primidone, 401
Epilepsy, 383
Parkinson’s disease and related disorders, 324
Primolut N, 658
Prioxx, 1088
Privigen, 1064
Pro-Banthine, 74
Procarbazine, 780
Prochlorperazine, 309
Procoralan, 186
Proctofoam HC, 81
Proctosedyl, 80
Procyclidine hydrochloride, 326
Paxil, 780
Parkinson’s disease and related disorders, 324
Pro D3, 886
Pro-Epanutin, 591
Proflavine, 1052
Progesterone, 658
Prograf, 723
Progynon, 539
Progestin hydrochloride, see atovaquone, see Atovaquone with proguanil hydrochloride
Proguanil with chloroquine, see Chloroquine with proguanil
Progynova, 651
Progynova TS, 652
Proleukin, 796
Procain, 629
Promazine hydrochloride, 320
Prometazin, 265
Prostaglandin hydrochloride, 251
Promethazine teoclate, 252
Promixin, 490
Propanafen hydrochloride, 92
Arrhythmias, 84
Propamidine isetionate, 957
Propantheline bromide, 74
Urinary frequency, enuresis and incontinence, 667
Propecia, 677
Propess, 707
Prophylaxis
Pneumocystis pneumonia, 522
Venous thromboembolism, 100
Propiverine hydrochloride, 670
Propofol, 1095
General anaesthesia, 1093
Propanolol hydrochloride, 146
Parkinson’s disease and related disorders, 524
Propylthiouracil, 664
Proscar, 677
ProSource, 1275, 1276
Prostacyclin, see Epoprostenol
Prostaglandin analogues and prostamides, 962
Prostap 3 DCS, 634
Prostap SR DCS, 654
ProSure, 1272
Prosurin XL, 675
Promazine sulfate, 1133
Promazine zinc insulin, 607
Promazine Zinc Insulin Injection—long acting, see Promazine zinc insulin
Protease inhibitors, 567
Protease-modulating matrix dressings, 1309
Protein C concentrate, 98
Protosol, 627
Prothrombin, 296
Protifilar, 1275
Protium, 71
Proton pump inhibitors, 67
Protopic, 1021
Provera, 697
Provigil, 425
Pro-Viron, 661
Proxymecatina hydrochloride, 960
Prozac, 287
Prozep, 287
ProZerol, 1287
Prucalopride, 30
Constipation, 43
Pseudoephedrine hydrochloride, 982
Aromatic inhalations, cough preparations and systemic nasal decongestants, 438
Psoriasis, 1017
Psychoses and related disorders, 300
Psytotal, 305
Publication information, ii
Salicylic acid with zinc oxide,
Salicylic acid with lactic acid,
Salicylic acid with dithranol and zinc
Salicylic acid with coal tar,
Salicylic acid with coal tar and coconut
Salicylic acid with benzoic acid,
Salbutamol with ipratropium,
Salazopyrin EN
Salamol Steri-Neb
Salamol Easi-Breathe
Salamol
Salagen
Salicylic acid with rhubarb extract,
Scandonest special
Scandishake,
Scalp and hair conditions,
Saxagliptin with metformin,
Saxagliptin,
Savlon Dry
Savlon disinfectant
Sastravi
Sapropterin dihydrochloride,
Sandostatin
Sando-K
Sandocal
Sandimmun
Sancuso
Samsca
Salvacyl
Salmeterol with fluticasone,
Salmeterol,
Salivix,
Salicylic acid with salicylic acid
Coal tar with dithranol and salicylic
Coal tar with coconut oil and
Salicylic acid
Rhubarb extract with salicylic acid
Boric acid with salicylic acid
Coal tar with benzonic acid,
Benzoic acid with salicylic acid
Salicylic acid with betamethasone, see
Betamethasone with salicylic acid
Salicylic acid with boric acid and tannic
acid, see Boric acid with salicylic acid
tannic acid
Salicylic acid with coal tar and coconut
oil, see Coal tar with coconut oil and salicylic
acid
Salicylic acid with coal tar and dithranol,
see Coal tar with dithranol and salicylic
acid
Salicylic acid with coal tar and precipitated sulfur, see Coal tar with salicylic acid and precipitated sulfur
Salicylic acid with coal tar, see Coal tar with salicylic acid
Salicylic acid with dithranol and zinc
oxide, see Dithranol with salicylic acid and zinc oxide
Salicylic acid with fluorouracil, see
Fluorouracil with salicylic acid
Salicylic acid with lactic acid, see Lactic
acid with salicylic acid
Salicylic acid with zinc oxide, 1034
Salix, 988
Salix, 988
Salmeterol, 122
Salmeterol with fluticasone, see
Fluticasone with salmeterol
Salofalk, 36
Salcabyl, 636
Sample prescription, 4
Samsca, 577
Sancuso, 349
Sandimmun, 719
Sandocyl, 856
Sando-K, 850
Sandostatin LAR, 790
Sandrena, 652
Sanomigran, 376
Santizor XL, 671
Sapropterin dihydrochloride, 880
Nutrition in special diets, 880
Saqvinavir, 570
Sastravi, 351
Sativex, 914
Savene, 783
Savlon disinfectant, 1054
Savlon Dry, 1053
Saxagliptin, 597
Saxagliptin with metformin, see
Metformin with saxagliptin
Sayana Press, 697
Scabies, 1007
Scalp and hair conditions, 1048
Scandishake, 1277
Scandosen PAIN, 1120
Scandosen special, 1120
ScarSil, 1310
Scheriproc, 80
Schistosomiasis (bilharziasis), 524
Schizophrenia, 300
Scoll Corn Removal, 1058
Scopol memorable, 345
Scopolamine hydrobromide, see Hyoscine
hydrobromide
Sefico, 1056
Selhio, 544
Seborrhoeic dermatitis, 1017
Second-generation antipsychotic drugs
Emergency treatment of poisoning,
1127
Psychooses and related disorders, 300
Secratul, 141
Securon, 157
Securon SR, 157
Seerhi Breechaler, 217
Selective beta, agonists, 219
Selective serotonin re-uptake inhibitors,
284
Selegeline hydrochloride, 340
Selenase, 873
Selenium, 873, 1049
Selenoprecise, 873
Seluxid, 486
Selintron, 430
Selsan, 1049
Senna, 53
Senna with ispaghula husk, see Ispaghula
husk with senna
Sensokot, 54
Seotiapim XL, 319
Septanest, 1113
Septicaemia related to vascular catheter,
443
Septin, 46
Sevuctil, 919
Seravit, 1278
Serc, 352
Serena, 307
Seretide Accuhaler, 232
Seretide Evohaler, 232
Serevent Accuhaler, 222
Serevent Evohaler, 222
Seroquel, 319
Seroxat, 319
Serowat, 287, 288
Sertraline, 288
Setofil, 350
Sevelamer, 861
Severe acute asthma, 210
Severe refractory eczema, 1016
Sekvar, 135
Sekvar HCT, 135
Sevoflurane, 1098
General anaesthesia, 1093
Seredol, 368
Sexual dysfunction and prolactin, 302
Sheet dressing, 1306
Short-circuit oxygen therapy, 214
Shortec, 370
Short stretch compression bandages,
1317
Sickle-cell disease,
Side-effects of specific nicotine
preparations, 427
Sideromal, 834
Signifor, 790
Sikkos, 778
Sildenafil, 698
Silegel, 1510
Silicone gel, 1309
Silicone keloid dressings, 1309
Silicone sheets, 1310
Silk Clothing, 1315
Silvutimab, 742
Silver, 1307
Silver nitrate, 1056
Silver sulfadiazine, 1010
Skin infections, 1006
Simprevir, 548
Hepatitis, 541
Simicome, 60
Simeticone with hydrotalcite, see
Cocamalite
Simeticone with loperamide, see
Loperamide with simeticone
Simple linctus, see Citric acid
Simple mouthwashes, 992
Simpson, 906
Simulect, 724
Simvadon, 182
Simvastatin, 181
Simvastatin with ezetimibe, see
Ezetimibe with simvastatin
Simret, 330
Simret CR, 331
Simret Plus, 330
Singular, 233
Synthrome, 120
Sinusitis and oral pain, 981
Stope, 999
Sirolimus, 719
Siruto, 504
Sitagliptin, 598
Sitagliptin with metformin, see
Metformin with sitagliptin
Skin adhesives, 1054
Skin closure dressings, 1313
Skin closure strips, sterile, 1313
Skin infections, 1006
Skin infections, bacterial, 448
Skinorin, 1043
Slocnix XL, 673
SLO Drink, 1279
Slo-Phylarin, 239
Slow Sodium, 851
Slow-Trasicor, 146
Slosem, 151
Snake bites and animal stings, 1136
Sno-Pro, 1288
Sno Tears, 952
Sodirol, 782
Sodium acid phosphate with sodium
phosphate, 49
Sodium alginat with calcium carbonate
and sodium bicarbonate, see Calcium
carbonate with sodium alginate and
sodium bicarbonate
Sodium alginat with potassium
bicarbonate, see Potassium bicarbonate
with sodium alginate
Sodium aurothiomolate, 897
Sodium bicarbonate, 848, 979
Fluids and electrolytes, 845
Urological pain, 677
Sodium Bicarbonate 1.26%, 848
Sodium Bicarbonate 8.4% for cardiac
arrest, 847
Sodium bicarbonate with calcium
carbonate and sodium alginate, see
Calcium carbonate with sodium
alginate and sodium bicarbonate
Sodium bicarbonate with glucose with
potassium chloride and sodium
chloride, see Glucose with potassium
chloride, sodium bicarbonate and
sodium chloride
Sodium bicarbonate with magnesium carbonate and magnesium trisilicate, see Magnesium carbonate with magnesium trisilicate and sodium bicarbonate
Sodium bicarbonate with sodium chloride, 991
Sodium chloride, 851, 953
Dry eye, 950
Fluids and electrolytes, 845
Nose, 980
Sodium chloride with dextran 70, see Dextran 70 with sodium chloride
Sodium chloride with glucose and potassium chloride, see Glucose with potassium chloride and sodium chloride
Sodium chloride with glucose, see Glucose with sodium chloride
Sodium chloride with potassium chloride, see Potassium chloride with sodium chloride
Sodium chloride with sodium bicarbonate, see Sodium bicarbonate with sodium chloride
Sodium citrate, 677
Sodium clonodenate, 625
Sodium cromoglicate, 693
Arthritis, 891
Dry eye, 950
Sodium hyaluronate, 1953
Sodium ironedetate, see Sodium feredetate
Sodium Lactate (m/6), see Sodium chloride, bicarbonate
Sodium Lactate Intravenous Infusion, Compound, see Calcium chloride with potassium chloride and sodium chloride and sodium lactate
Sodium Lactate Intravenous Infusion, Compound, see Potassium chloride
Sodium Lactate (m/6), 847
Sodium nitrite, 1131
Sodium nitroprusside, 161
Sodium oxybate, 425
Sodium phenylbutrate, 871
Sodium phosphate with sodium acid phosphate, see Sodium acid phosphate with sodium phosphate
Sodium picosulfate, 54
Sodium picosulfate with magnesium citrate, see Magnesium citrate with sodium picosulfate
Sodium polystyrene sulfonate, 862
Sodium stibogluconate, 527
Sodium tetracycl sulfate, 208
Sodium thiosulfate, 1131
Sodium valproate, 403
Epilepsy, 383
Saffin, 1004
Safloxabir, 546
Hepatitis, 541
Sofradex, 978
Soft Drops, 952
Soft polymer dressings, 1300, 1308
Soft-tissue disorders, 940
Solaraze, 923
Solian, 312
Solfenacin succinate, 670
Solfenacin with tamsulosin, 675
Soloris, 830
Soliveto N, 879
Solpadeine Max, 359
Solpadol, 359
Solfastax, 791
Soluble Insulin, see Insulin
Sola-Cortef, 584
Solu-Medrone, 584
Solvaset, 873
Somatostatin analogues, 788
Somatropin, 642
Somatoline Autogel, 789
Somatostatin LA, 789
Somavert, 642
Somatrem, 365
Sonata, 423
Sondale XL, 319
Sothing haemorrhoidal preparations, 78
Sorafenib, 816
Sorbitest, 862
S.O.S., 1274
Sotacor, 93
Sotalol hydrochloride, 93
Sovald, 547
Soybean oil, 953
Spacer devices, 209
Spacern, 240
Spasmonal, 75
Spatone Iron-Plus, 835
Specialised dressings, 1309
Special-order Manufacturers, 1335
Sperda, 698
Spirit, 219
Spiriva Respimat, 218
Spiroco XL, 339
Spirolactone, 168
Spirolactone with furosemide, see Furosemide with spirolactone
Spirolactone with hydroflumethiazide, see Co-flumactone
Sporanox, 520
SportVia, 852
Sprilone, 1000
Sprycl, 807
SS, 988
Stable angina, 182
Stalevo, 331
Stamaril, 1092
Standard-dose inhaled corticosteroids, 712
Stanek, 331
Starlix, 608
Statins, 178
Status epilepticus, 383, 387
Stavudine, 564
Steflavin XL, 180
Stelara, 899
Stemetil, 309, 310
Sterculia, 46
Sterites Tisept, 1054
Sterilens, 1054
Sterile dressing packs, 1312
Sterile Dressing Pack with Non-Woven Pads, 1312
Steripaste, 1318
Stesolid, 269
Stexerol-DS, 886
Stimovin, 1044
Stillboestrol, see Diethylstilboestrol
Stilnoct, 423
Stimulant laxatives, 42
Stivarga, 816
Stoma care, 83
Strattera, 272
Strefen, 994
Streptokinase, 195
Streptomycin, 451
Tuberculosis, 501
Triludin, 365
Triverdi Respimat, 222
Stroke prevention, 85
Strontium ranelate
Bone metabolism, 619
Drug monograph, 626
ST-segment elevation myocardial infarction (STEMI), 186
Stud 100, 1118
Stugeron, 343
Sub-compression wadding bandage, 1317
Subfoveal choroidal neovascularisation, 971
Subgum, 1063
Sublunoxe, 366
Suboxone, 436
Substance dependence, 425
Subutex, 436
Succinylcholine chloride, see Succinylcholine chloride
Sucralfate, see Sucralfate
Sunyl, 37
Surgical adhesive tapes, 939
Surgam, 1063
Sulfonylureas, 611
Sulfadiazine, see Sulphasalazine
Sulfadiazine
Sulfadoxine and pyrimethamine, see Pyrimethamine with sulfadoxine
Sulfamethoxazole with trimethoprim, see Co-trimoxazole
Sulfasalazine, 37
Inflammatory bowel disease, 32
Sulfamiprazone, 909
Gout, 908
Sulfonamides, 611
Sulfur dioxide, chlorines, phosgene, ammonia, 1129
Sulindac, 937
Sulphadiazine, see Sulfasalazine
Sulphasalazine, see Sulphasalazine
Sulphapyrazine, see Sulfapyrazine
Sulpiride, 310
Sulpur, 310
Sunmarine, 379
Sunstinen, 817
Sunvenix XL, 289
SunVit DS, 886
Sunsy, 687
Super absorbent cellulose and polymer primary dressing, 1297
Super absorbent hydroconductive dressing, 1297
Superinfection, 439
Supervised treatment, 501
Support bandages, 1316
Supralip, 175
Suprane, 1097
Supraventricular and ventricular arrhythmias, 86
Suprax, 457
Suprecur, 632
Supralfact, 652
Surgam, 939
Surgery and long-term medication, 1094
Surgical absorbents, 1310
Surgical adhesive tapes, 1312
Survived ODP, 1263
Sustanon, 662
<table>
<thead>
<tr>
<th><strong>Index 1363</strong></th>
</tr>
</thead>
</table>

- **Susivu**, 559
- **Sutent**, 818
- **Suxamethonium chloride**, 1102
- **General anaesthesia**, 1093
- **Systag**, 276
- **Sylvert**, 742
- **Symboct Turbohaler**, 230
- **Symptomometrics**, 962
- **Synachten**, 638
- **Synachten Depot**, 638
- **Synalar**, 1027
- **Synalar C**, 1028
- **Synalar N**, 1028
- **Synarel**, 634
- **Synastone**, 457
- **Syner-KINASE**, 119
- **Syrner-Vit-DS**, 886
- **Synflorx**, 1089
- **Synotoxin**, 706
- **Symmetrine**, 708
- **Syprol**, 147
- **Systane**, 952
- **Systemic nasal decongestants**, 258
- **Sytron**, 836

<table>
<thead>
<tr>
<th>T</th>
</tr>
</thead>
</table>
- **Taphryn MR**, 675
- **Tacalcitol**, 1037
- **Tacrolimus**, 720, 1020
- **Tadalafil**, 700
- **Drugs for urinary retention**, 672
- **Taenicide**, 524
- **Tafamidis**, 322
- **Tafinlar**, 806
- **Tafduprost**, 969
- **Tagamet**, 65
- **Talidex**, 799
- **Tambocor**, 91
- **Tambocor XL**, 91
- **Tamfrev XL**, 675
- **Tamiflu**, 573
- **Tamafoxin**, 791
- **Gonadotrophins**, 651
- **Tamsulosin hydrochloride**, 674
- **Tamsulosin with dutasteride**, see **Dutasteride** and **Tamsulosin**
- **Tamsulosin with solifenacin**, see **Solifenacin with tamsulosin**
- **Tamurex**, 675
- **Tanatril**, 128
- **Tannic acid with boric acid and salicylic acid**, see **Boric acid with salicylic acid** and **Tannic acid**
- **Tapclob**, 411
- **Tapentadol**, 372
- **Tarceva**, 808
- **Tardicid XL**, 193
- **Targetax**, 495
- **Targinact**, 371
- **Targocid**, 464
- **Targetelt**, 769
- **Tarivid**, 494
- **Tasigna**, 813
- **Tasmar**, 528
- **Tavanic**, 492
- **Tavegyl**, 246
- **Taxaceus**, 771
- **Taxotere**, 771
- **Taxotere**, 1034
- **Psorias**, 1017
- **Taxobactam with piperacillin**, see **Piperacillin with tazobactam**
- **Tazocin**, 480
- **3TC, lamivudine**
- **Tear deficiency, ocular lubricants, and astringents**, 950
- **Tear-Lac**, 952
- **Tears Naturale**, 952
- **Tecfidera**, 727
- **Tegafur with gimeracil and oteracil**, 765
- **Tegretol**, 389
- **Tegretol Cheptabs**, 389
- **Tegretol Retard**, 389
- **Teicoplanin**, 464
- **Telaprevir**, 548
- **Telavancin**, 464
- **Teltubidine**, 544
- **Telfast**, 248
- **Telithromycin**, 473
- **Telmisartan**, 136
- **Telzir**, 589
- **Temazepam**, 420
- **Tengesic**, 436
- **Temocillin**, 487
- **Temodar**, 753
- **Temodomed**, 753
- **Temoporfin**, 800
- **Temozolomide**, 753
- **Temirolimus**, 818
- **Tenecteplase**, 195
- **Tenif**, 142
- **Tenofovir disoproxil**, 564
- **Hepatitis**, 541
- **Tenofovir with cobicistat, elvitegravir, and emtricitabine**, see **Cobicistat with elvitegravir, emtricitabine and tenofovir**
- **Tenofovir with efavirenz and emtricitabine**, see **Efavirenz with emtricitabine and tenofovir**
- **Tenofovir with emtricitabine and rilpivirine**, see **Emtricitabine with rilpivirine and tenofovir**
- **Tenofovir with emtricitabine**, see **Emtricitabine with tenofovir**
- **Tenor, 145**
- **Teneretic**, 143
- **Tenormin**, 141
- **Tenoxicam**, 937
- **Tenprolide XI**, 319
- **Tensaid XI**, 161
- **Tensiprine MR**, 155
- **Teoptic**, 964
- **Tepudina**, 754
- **Tephrine**, 456
- **Terazosin**, 675
- **Terbinafine**, 514, 1013
- **Skin infections**, 513
- **Terbutaline sulfate**, 225
- **Teriflunomide**, 735
- **Teriparatide**, 629
- **Bone metabolism**, 619
- **Toleripressin acetate**, 77
- **Termination of pregnancy**, 708
- **Teroreg**, 178
- **Terra-Cotrin**, 1031
- **Test for Helicobacter pylori**, 62
- **Testim**, 661
- **Testogel**, 661
- **Testosterone**, 661
- **Testosterone decanoate, isocaproate, phenylpropionate and propionate**, 662
- **Testosterone enantate**, 661
- **Testosterone propionate**, 662
- **Testosterone undecanoate**, 662
- **Tetanus and diphtheria with poliomyelitis**, see **Diphtheria with poliomyelitis and tetanus vaccine**
- **Tetanus immunoglobulin**, 1065
- **Tetanus with diphtheria with haemophilus influenza with pertussis and poliomyelitis**, see **Diphtheria with haemophilus influenza type B vaccine, pertussis, poliomyelitis and tetanus**
- **Tetanus with diphtheria with pertussis and diphtheria**, see **Diphtheria with pertussis, poliomyelitis vaccine and tetanus**
- **Tetralog**, 322
- **Tetrabenazine**, 321
- **Parkinson’s disease and related disorders**, 324
- **Tetracaine**, 961, 1122
- **Tetracaine with lidocaine, see Lidocaine with tetracaine**
- **Tetracosactide**, 638
- **Tetracosactrin, see Tetracosactide**
- **Tetracycline**, 498
- **Tetracyclines**
- **Class monograph**, 496
- **Oral bacterial infections**, 446
- **Tetracythal**, 497
- **Tetratarch**, 854
- **Teveten**, 133
- **Teysonu**, 766
- **Thalidomide**, 798
- **Lexapro**, 499
- **TheCai-DS**, 887
- **Theophylline**
- **Drug monograph**, 238
- **Emergency treatment of poisoning**, 1123
- **Thiamine**, 882
- **Thiazides and related diuretics**, 159
- **Thick & Easy**, 1279
- **Thioguanine, see Thioguanine**
- **Thiotepal sodium**, 412
- **General anaesthesia**, 1093
- **Thiopentone sodium, see Thiopental sodium**
- **Thiopa**, 753
- **Thio-D, 1279**
- **Thoren**, 886
- **Thrusul**, 996
- **Thymoglobulin**, 724
- **Thymoxamine, see Moxisylyte**
- **Thyrogen**, 663
- **Thyrotropin alfa**, 663
- **Thyroxine sodium, see Levothyroxine sodium**
- **Thioguanine, 406**
- **Tiaprofenic acid**, 938
- **Tibolone**, 646
- **Ticagrelor**, 188
- **Acute coronary syndromes**, 186
- **Antiplatelet drugs**, 103
- **Ticarcillin with clavulanic acid**, 480
- **Tockborne encephalitis vaccine, inactivated**, 1091
- **TicoVac, 1091**
- **Tigecycline**, 466
- **MRSA**, 501
- **Tilade**, 234
- **Tildem**, 151
- **Tildem LA, 151**
- **Tildem Retard, 151**
- **Tildol SR**, 374
- **Tilofyl**, 366
- **Tiloket**, 931
- **Tiloket CR, 932**
- **Tilorex, 473, 1044**
- **Timentin**, 480
- **Tinodine**, 1030
- **Timolol and dorzolamide, see**
- **Dorzolamide with timolol**
- **Timolol maleate, 147, 965**
- **Timolol with amiloride and hydrochlorothiazide, see Amiloride with hydrochlorothiazide and timolol**
Timolol with bendroflumethiazide, see Bendroflumethiazide with timolol
Timolol with bimatoprost, see Bimatoprost with timolol
Timolol with brimonidine, see Brimonidine with timolol
Timolol with brinzolamide, see Brinzolamide with timolol
Timolol with lantanoprost, see Lantanoprost with timolol
Timolol with travoprost, 970
Timoptol, 965
Timoptol-LA, 965
Tinidazole, 476
Tobramycin with dexamethasone, 452
Tobramycin with dexamethasone, see Dexamethasone with tobramycin
Tobramycin, 452, 957
Tobramycin with desamethasone, see Desamethasone with tobramycin
Tobracid, 958
Tocolizumab, 898
Tocopherol, see Alpha tocopherol
Tocopherol, see Alpha tocopheryl acetate
Tocol, 1034
Tolbutamide, 613
Tolcapon, 327
Tolperone, 381
Tolcump, 136
Tolbutamide, 613
Tolvaptan, 577
Tonalde, 780
Tonic-clonic seizures, 385
Topinat XL, 290
Topamax, 407
Topical antibacterials for acne, 1041
Topical nasal decongestants, 510
Topical negative pressure therapy, 1311
Topical NSAIDs, 941
Topical preparations for acne, 1041
Topical retinoids and related preparations for acne, 1041
Topiramate, 406
Epilepsy, 383
Topogyn, 710
Topotecan, 772
Toradol, 1107
Torasemide, 202
Torem, 202
Toremen, 791
Torsel, 618
Torsade de pointes, 86
Torsion dystonia and other involuntary movements, 325
Tosan, 661
Total intravenous anaesthesia, 1093
Toviaz, 669
Trabectedin, 780
Trace elements with vitamins and minerals, see Vitamins with minerals and trace elements
Tracleer, 163
Tracrium, 1104
Tractocile, 708
Tracut, 879
Tradefor XL, 374
Traluent, 596
Tramacet, 356
Tramadol hydrochloride, 373
Diabetes, 588
Neuropathic pain, 382
Tramadol with paracetamol, see Paracetamol with tramadol
Tranquix SR, 374
Tranudil SR, 374
Trandate, 144
Trandolapril, 132
Tranexamic acid, 95
Trangina XL, 193
Tranquil, 274
Transderm-Nitro, 191
Transient ischaemic attack, 101
Transrectal prostate biopsy, 441
Transester resection of prostate, 441
Tranlycypromine, 283
Trastuzumab, 743
Trastuzumab emtansine, 744
Travo, 970
Travel Calm, 344
Travoprost, 970
Travoprost with timolol, see Timolol with travoprost
Traxa, 926
Traxodone hydrochloride, 291
Treatment of Pneumocystis pneumonia, 522
Treatment of Acute ulcerative colitis and Crohn's disease, 32
Diabetes, 588
Dry mouth, 987
Hypoglycaemia, 618
Malaria, 529
Venous thromboembolism, 100
Treclin, 1047
Tree pollen extract, 253
Trental, 207
Tresiba FlexTouch, 754
Tresiba FlexTouch, 604
Tresiba Penfill, 605
Tretinoin, 769
Tretinoin with clindamycin, see Clindamycin with tretinoin
Tretinoin with erythromycin, see Erythromycin with tretinoin
Triamcinolone acetonide, 587, 986
Triamcinolone hexacetonide, 940
Triamcinolone with chlorotetracycline, see Chlorotetracycline with triamcinolone
Triamterene, 203
Triamterene with chlortalidone, see Chlortalidone with triamterene
Triamterene with furosemide, see Furosemide with triamterene
Triamterene with hydrochlorothiazide, see Co-trimaterzide
Triapin, 132
Tribarin, see Ribavirin
Tricyclic and related antidepressants, 281
Trilud, 654
Trientine dihydrochloride, 872
Trifluoperazine, 310
Trigeminal neuralgia, 382
Trihexyphenidyl hydrochloride, 326
Parkinson's disease and related disorders, 324
Trileptal, 398
Trimipramine tartrate, see Alimemazine tartrate
Trimeprazine tartrate, 462
Rosacea and Acne, 1041
Urinary-tract infections, 510
Trimethoprim with sulfamethoxazole, see Co-trimoxazole
Trimipramine, 299
Trimovate, 1026
Triparentic dicitratobismuthate, 63
Triparentic, 293
Triptorelin, 635
Trenox, 776
Trisequens, 655
Triferix, 1091
Triuniver, 562
Trizivir, 562
Trobot, 402
Tropicamide, 958
Tropicamide with phenylephrine, see Phenylephrine with tropicamide
Tropium chloride, 671
Trosyl, 1012
Trusopt, 967
Truvada, 566
Tuberculin PPD, see Tuberculin purified protein derivative
Tuberculin purified protein derivative, 1086
Tuberculosis, 501
Tubular bandages and garments, 1314
Twinrix, 1082
TwoCal, 1266
Two layer systems, 1318
Tybost, 567
Tygacil, 466
Tylenol, 359
Tymbrineb, 452
Tymphim Vi, 1091
Typhoid vaccine, 1091
Typhoid with hepatitis A vaccine, see Hepatitis A with typhoid vaccine
TYR, 1290
TYR Anamix Junior LQ, 1290
TYR Lophlex LQ, 1290
Typhus, 733
Tyver, 883
Tyverb, 812

U
Uard XL, 151
Ucerax, 248
Ulcera, 128
Ulcereation and inflammation, 992
Ulipristal acetate, 691
Ultiva, 1109
Ultralanum Plain, 1028
Ultraproct, 79, 80
Ultrasonic nebulisers, 274
Umeclidinium, 219
Umeclidinium with vilanterol, 219
Undecenoic acid with cetrimide, see Cetrimide with undecenoic acid
Undecenoic acid with zinc undecenoate, 1014
Unguentum M, 1004
Uniphyllin Continus, 239
Unioil HC, 80
Univer, 157
Unsafe Drug Groups (porphyria), 864
Unsafe Drugs (porphyria), 864
Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), 186
Upostelle, 694
Urarep, 671
Urea (13C), 72
Urea hydrogen peroxide, 980
Uricto, 910
Urinalysis, 614
Urinary analysis reagent strips, 618
Urinary frequency and incontinence, 667
Urinary tract infections, 510
Urspax, 669
Urofolitropin, 641
Urokinease, 119
Urological pain, 677
Urological surgery, 678
Uro-Tainer, 899
Ustekinumab, 612
Use and care of spacer devices, 684
Ursofalk, 612
Urological surgery, 678
Urokinase, 641
Urinary-tract infections, 667
Urinary frequency and incontinence, 667
Urinary tract infections, 510
Urinary-tract infections, 667
V
Vaccines, 1077
Vacuum assisted closure products, 1311
Vagifem, 819
Vandetanib, 935
Vancomycin, 641
Vancocin, 757
Vamju, 658
Valsartan with amlodipine, 136
Valproate, 555
Valcyte, 552
Vapour-permeable Adhesive Film Dressing (Semi-permeable Adhesive Dressing), 1298
Vapour-permeable Adhesive Film Dressing with absorbent pad, 1299
Vapour-permeable films and membranes, 1298
Vapour–permeable transparent, adhesive film dressing, 1299
Vapour–permeable transparent film dressing with adhesive foam border., 1299
VAQTA, 1082
Vardenafil, 701
Varenicline, 432
Varicella-zoster immunoglobulin, 1065
Varicella-zoster infections, 549
Varicella-zoster vaccine, 1092
Varilrix, 1092
Variguel, 77
Varivax, 1092
Vasculapha, 152
Vaseline, 683
Vasopressin, 576
Vasrfan XL, 673
Vecibix, 741
Vecuronium bromide, 1105
Vedolizumab, 39
Inflammatory bowel disease, 32
Vedrop, 888
Vehicles, 998
Velasculase alfa, 867
Velandase, 801
Velvetri, 100
Vemurafenib, 407
Vindelac, 1058
Vinee, 1105
Venous thromboembolism, 100
Vensir XL, 673
Ventavis, 164
Ventmax SR, 224
Ventolin, 224
Ventolin Accuhaler, 224
Ventolin Evohaler, 224
Ventolin Nebules, 224
Ventricular arrhythmias, 224
Venlalic XL, 290
Venlafaxine, 289
Venlalic XL, 290
Venofer, 618
Venlalic XL, 1033
Venoloid, 1057
Venous thromboembolism, 100
Vensir XL, 673
Ventavis, 164
Ventmax SR, 224
Ventolin, 224
Ventolin Accuhaler, 224
Ventolin Evohaler, 224
Ventolin Nebules, 224
Ventricular arrhythmias, 84
Ventricular tachycardia, 84
Vepesid, 777
Veracur, 1057
Verapamil hydrochloride, 156
Arrhythmias, 84
Verapress MR, 157
Vera-Til SR, 157
Vernox, 526
Verrugon, 1058
Versatail, 1118
Vertab SR, 157
Verteporfin, 971
Vertine, 222
Vescicare, 670
Vesosom, 675
Vexalin XR, 290
Vexol, 949
VFEND, 522
Viagra, 699
VIATIM, 1083
Viazem XL, 151
Vibativ, 465
Vibramycin-D, 996
Vibron, 497
Victantyl, 366
Victoza, 601
Vidrelis, 548
Vidaza, 757
Videne, 1053
Videx, 563
Videon, 563
Videon, 563
ViePax, 289
ViePax XL, 290
Vigabatrin, 407
Vigam, 1064
Vilanterol with fluticasone, see Fluticasone with vilanterol
Vilanterol with umecclidinium, see Umeclidinium with vilanterol
Vilaglaptin, 598
Vilaglaptin with metformin, see Metformin with vilaglaptin
Vinovo, 935
Vinpatt, 394
Vinblastine sulfate, 773
Vincristine sulfate, 773
Vindesine sulfate, 774
Vinflunine, 774
Vinorelbine, 773
Vipidom, 596
Vipidia, 596
ViraferonPeg, 543
Viramune, 560
Viread, 565
Virgan, 958
Viridil, 703
Viscotears, 951
Vistalog, 146
Visten, 146
Vismed, 953
Visnogidegib, 800
Vistamethasone, 947, 979, 984
Visudyne, 993
VitaBite, 1283
Vitajoule, 1274
Vitamin A, 880
Vitamin B complex, 883
Vitamin B6, see Pyridoxine hydrochloride
Vitamin B1, see Thiamine
Vitamin B substances with ascorbic acid, 883
Vitamin C, see Ascorbic acid
Vitamin D and analogues (systemic), 884
Vitamin D5, see Colecalciferol
Vitamin D2, see Ergocalciferol
Vitamin K antagonists, 119
Vitamin K1, see Phytomenadione
Vitamins A and D, 881
Vitamins A, C and D, 881
Vitamins with minerals and trace elements, 884
VITA-POS, 953
Vitaquick, 1279
Vitaros, 703
Vitasavoury, 1178
Vitilipid N Adult, 881
Vitilipid N Infant, 881
Vivax, 723
Vivitrol, 946
Vivotif, 1091
Vizarsin, 699
Vokanamet, 609
Volatile liquid anaesthetics
Class monograph, 1097
General anaesthesia, 1093
Volece, 265
Vollbris, 163
Volplex, 854
Voxaid Retard, 923
Voltarol, 1923
Voltarol Opitha, 961
Voltarol Opitha Multidose, 961
Voltarol Rapid, 921
Voltarol Retard, 923
Voltarol SR, 923
Volulyte, 854
Volvhen, 855
Voractiv, 510
Vorconazole, 521
Votrient, 814
X

Xagrid, 843
Xailin, 951
Xailin H₄, 953
Xailin Hydrate, 952
Xalacom, 969
Xalatan, 969
Xalkori, 805
Xalasprine, 762
Xanax, 266
Xarelto, 111
Xatral, 672
Xatral XL, 673
Xeloda, 758
Xenazine, 322
Xenical, 78
Xenidate XL, 274
Xezomin, 324
Xepin, 1040
Xepthon, 518
Xerotin, 988
Xgeva, 629
Xiapex, 941
Xifaxantin, 495
Xigduo, 610
Xipamide, 205
Xismox XL, 193
XLEU, 1286
XLYS, 1284, 1285
XLYS TRY Glutardon, 1284
XMET, 1285
XMTVI, 1287
Xolar, 236
Xomolix, 345
XP - brand group, 1289
XPHEN TYR, 1290
XPTM, 1290
Xtandi, 787
Xulotroph, 605
Xylocaine, 994, 1118
Xylocaine with Adrenaline, 1118
Xylometazoline hydrochloride, 983

Y

Yasmin, 686
Yellow fever vaccine, live, 1092
Yellox, 961
Yentree, 289
Yervoy, 759
Yondelis, 781

Z

Zacin, 383
Zaditen, 249, 946
Zafirlukast, 233
Zolasta, 316
Zaleplon, 422
Zaltrap, 821
Zaluran XL, 319
Zamadol, 374
Zamadol 24hr, 374
Zamadol Melt, 373
Zamadol SR, 374
Zanaflex, 913
Zanamivir, 573
Influenza, 571
Zanidip, 153
Zantac, 67
Zaprin, 335
Zaronex, 315
Zarontin, 391
Zarzio, 842
Zavedos, 757
Zavesca, 870
Zebini, 390
Zebbac, 470
Zefix, 564
Zelapar, 341
Zelbora, 820
Zoleta, 692
Zemon XL, 193
Zemplar, 888
Zemret XL, 151
Zentaur XL, 151
Zenal, 853
Zenoxone, 1029
Zeridame SR, 374
Zerr, 564
Zerelda, 626
ZerAQS, 1004
Zerobase, 1004
Zerodouble, 1002
Zerguent, 1004
Zerolatum, 1002
Zeroneum, 1003
Zestoretic 10, 129
Zestoretic 20, 129
Zestril, 128
Ziguen, 562
Zileasag, 612
Zicron, 612
Zidovudine, 566
Zidovudine with abacavir and lamivudine, see Abacavir with lamivudine and zidovudine
Zidovudine with lamivudine, see Lamivudine with zidovudine
Zimovane, 424
Zinacef, 461
Zinamid, 507
Zinc acetate, 872
Zinc acetate with erythromycin, see Erythromycin with zinc acetate
Zinc oxide with coal tar, see Coal tar with zinc oxide
Zinc oxide with dithranol and salicylic acid, see Dithranol with salicylic acid and zinc oxide
Zinc oxide with ichthammol, see Ichthammol with zinc oxide
Zinc oxide with salicylic acid, see Salicylic acid with zinc oxide
Zinc sulfate, 873
Zinc undecenoate with undecenoic acid, see Undecenoic acid with zinc undecanoate
Zindecilin, 468
Zineryt, 1044
Zinforo, 458
Zinnat, 461
Zirtek, 245
Zispin SolTab, 291
Zithromax, 470
Zocor, 182
Zoely, 686
Zofran, 350
Zofran Flexi-amp, 350
Zofran Melt, 350
Zoladex, 633
Zoladex LA, 633
Zoledronic acid, 625
Zolmitraptan, 380
Zolpidem tartrate, 423
Zolvera, 157
Zomacton, 644
Zomet, 626
Zomig, 381
Zomig RapiMelt, 381
Zonapharm, 369
Zonegran, 409
Zonisamide, 408
Epilepsy, 383
Zopiclone, 423
Zorac, 1034
Zoton FasTab, 69
Zovirax, 551, 552, 958, 1016
Zuclopenthixol, 311
Zuclopenthixol decanoate, 311
Psychoses and related disorders, 300
Zumenon, 651
Zutectra, 1062
Zyban, 433
Zyclara, 1057
Zydelig, 810
Zydol, 373
Zydol SR, 374
Zydol XL, 374
Zylocin, 910
Zyomet, 1009
Zypadhera, 317
Zyprexa, 316
Zyprexa Velotabs, 316
Zytila, 786
Zyvox, 478
REPORT OF SUSPECTED ADVERSE DRUG REACTIONS

If you suspect an adverse reaction may be related to one or more drugs/vaccines/complementary remedies, please complete this Yellow Card. See 'Adverse reactions to drugs' section in BNF or www.mhra.gov.uk/yellowcard for guidance. Do not be put off reporting because some details are not known.

PATIENT DETAILS

<table>
<thead>
<tr>
<th>Patient Initials</th>
<th>Sex: M / F</th>
<th>Is the patient pregnant? Y / N</th>
<th>Ethnicity:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age (at time of reaction):</th>
<th>Weight (kg):</th>
<th>Identification number (e.g. Practice or Hospital Ref):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SUSPECTED DRUG(S)/VACCINE(S)

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SUSPECTED REACTION(S)

Please describe the reaction(s) and any treatment given. (Please attach additional pages if necessary):

Outcome

- Recovered
- Recovering
- Continuing
- Other

Date reaction(s) started: ____________ Date reaction(s) stopped: ____________

Do you consider the reactions to be serious? Yes / No

If yes, please indicate why the reaction is considered to be serious (please tick all that apply):
- Patient died due to reaction
- Life threatening
- Congenital abnormality
- Involved or prolonged inpatient hospitalisation
- Involved persistent or significant disability or incapacity
- Medically significant; please give details:

If the reactions were not serious according to the categories above, how bad was the suspected reaction?
- Mild
- Unpleasant, but did not affect everyday activities
- Bad enough to affect everyday activities
It's easy to report online: www.mhra.gov.uk/yellowcard

OTHER DRUG(S) (including self-medication and complementary remedies)

Did the patient take any other medicines/vaccines/complementary remedies in the last 5 months prior to the reaction? Yes / No
If yes, please give the following information if known:

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional relevant information e.g. medical history, test results, known allergies, rechallenge (if performed). For reactions relating to use of a medicine during pregnancy please state all other drugs taken during pregnancy, the last menstrual period, information on previous pregnancies, ultrasound scans, any delivery complications, birth defects or developmental concerns.

Please list any medicines obtained from the internet:

REPORTER DETAILS
Name and Professional Address:

<table>
<thead>
<tr>
<th>Postcode:</th>
<th>Tel No:</th>
<th>Email:</th>
<th>Speciality:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CLINICIAN (if not the reporter)
Name and Professional Address:

<table>
<thead>
<tr>
<th>Postcode:</th>
<th>Tel No:</th>
<th>Email:</th>
<th>Speciality:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Information on adverse drug reactions received by the MHRA can be downloaded at www.mhra.gov.uk/daps
Stay up-to-date on the latest advice for the safe use of medicines with our monthly bulletin Drug Safety Update at: www.mhra.gov.uk/drugsafetyupdate

Please attach additional pages if necessary. Send to: FREEPOST YELLOW CARD (no other address details required)
# Yellow Card

**COMMISSION ON HUMAN MEDICINES (CHM)**

**REPORT OF SUSPECTED ADVERSE DRUG REACTIONS**

If you suspect an adverse reaction may be related to one or more drugs/vaccines/complementary remedies, please complete this Yellow Card. See 'Adverse reactions to drugs' section in BNF or www.mhra.gov.uk/yellowcard for guidance. Do not be put off reporting because some details are not known.

**PATIENT DETAILS**

- Patient Initials: __________
- Sex: M / F
- Is the patient pregnant? Y / N
- Ethnicity: __________
- Age (at time of reaction): __________
- Weight (kg): __________
- Identification number (e.g. Practice or Hospital Ref): __________

**SUSPECTED DRUG(S)/VACCINE(S)**

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SUSPECTED REACTION(S)**

Please describe the reaction(s) and any treatment given. (Please attach additional pages if necessary):

- Outcome
  - Recovered
  - Recovering
  - Continuing
  - Other

- Data reaction(s) started: __________
- Date reaction(s) stopped: __________

- Do you consider the reactions to be serious? Yes / No

  - If yes, please indicate why the reaction is considered to be serious (please tick all that apply):
    - Patient died due to reaction
    - Life threatening
    - Congenital abnormality
    - Involved or prolonged inpatient hospitalisation
    - Involved persistent or significant disability or incapacity
    - Medically significant; please give details:

- If the reactions were not serious according to the categories above, how bad was the suspected reaction?
  - Mild
  - Unpleasant, but did not affect everyday activities
  - Bad enough to affect everyday activities
It's easy to report online: www.mhra.gov.uk/yellowcard

OTHER DRUG(S) (including self-medication and complementary remedies)

Did the patient take any other medicines/vaccines/complementary remedies in the last 3 months prior to the reaction? Yes / No
If yes, please give the following information if known:

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional relevant information e.g. medical history, test results, known allergies, rechallenge (if performed). For reactions relating to use of a medicine during pregnancy please state all other drugs taken during pregnancy, the last menstrual period, information on previous pregnancies, ultrasound scans, any delivery complications, birth defects or developmental concerns.

Please list any medicines obtained from the internet:

REPORTER DETAILS
Name and Professional Address:

Postcode:__________ Tel No:__________ Email:__________ Speciality:__________ Signature:__________ Date:__________

CLINICIAN (if not the reporter)
Name and Professional Address:

Postcode:__________ Tel No:__________ Email:__________ Speciality:__________ Date:__________

Information on adverse drug reactions received by the MHRA can be downloaded at www.mhra.gov.uk/daps
Stay up-to-date on the latest advice for the safe use of medicines with our monthly bulletin Drug Safety Update at: www.mhra.gov.uk/drugsafetyupdate

Please attach additional pages if necessary. Send to: FREEPOST YELLOW CARD (no other address details required)
Adult Advanced Life Support Algorithm

Unresponsive?
Not breathing or only occasional gasps

Call Resuscitation Team

CPR 30:2
Attach defibrillator/monitor
Minimise interruptions

Assess rhythm

Shockable
(VF/pulseless VT)

Non-shockable
(PEA/Asystole)

Return of spontaneous circulation

1 Shock
Immediately resume CPR for 2 mins
Minimise interruptions

Immediate post cardiac arrest treatment
- Use ABCDE approach
- Controlled oxygenation and ventilation
- 12-lead ECG
- Treat precipitating cause
- Temperature control / therapeutic hypothermia

During CPR
- Ensure high-quality CPR: rate, depth, recoil
- Plan actions before interrupting CPR
- Give oxygen
- Consider advance airway and capnography
- Continuous chest compressions when advanced airway in place
- Vascular access (intravenous, intraosseous)
- Give adrenaline every 3-5 min
- Correct reversible causes

Reversible causes
- Hypoxia
- Hypovolaemia
- Hypo- / hyperkalaemia / metabolic
- Hypothermia
- Thrombosis – coronary or pulmonary
- Tamponade – cardiac
- Toxins
- Tension pneumothorax

Immediately resume CPR for 2 mins
Minimise interruptions

Adapted with the kind permission of the Resuscitation Council (UK) from Resuscitation Guidelines, October 2010
Medical emergencies in the community

Drug treatment outlined below is intended for use by appropriately qualified healthcare professionals. Only drugs that are used for immediate relief are shown, advice on supporting care is not given. Where the patient’s condition requires investigation and further treatment, the patient should be transferred to hospital promptly.

Acute coronary syndromes

- **ANGINA: UNSTABLE**
  - Aspirin dispersible tablets p. 104 (75 mg, 300 mg)
    - By mouth (dispersed in water or chewed)
      - Adult: 300 mg
  - **PLUS**
    - **EITHER** Glyceryl trinitrate aerosol spray p. 190 (400 micrograms/metered dose)
      - Sublingually
      - Adult: 1–2 sprays, repeated as required
    - **OR** Glyceryl trinitrate tablets p. 190 (300 micrograms, 500 micrograms, 600 micrograms)
      - Sublingually
      - Adult: 0.3–1 mg, repeated as required

- **MYOCARDIAL INFARCTION: NON-ST-SEGMENT ELEVATION**
  - Treat as for Angina: unstable
  - Aspirin dispersible tablets p. 104 (75 mg, 300 mg)
    - By mouth (dispersed in water or chewed)
      - Adult: 300 mg
  - Glyceryl trinitrate aerosol spray p. 190 (400 micrograms/metered dose)
    - Sublingually
    - Adult: 1–2 sprays, repeated as required
  - **OR** Glyceryl trinitrate tablets p. 190 (300 micrograms, 500 micrograms, 600 micrograms)
    - Sublingually
    - Adult: 0.3–1 mg, repeated as required

- **MYOCARDIAL INFARCTION: ST-SEGMENT ELEVATION**
  - Aspirin dispersible tablets p. 104 (75 mg, 300 mg)
    - By mouth (dispersed in water or chewed)
      - Adult: 300 mg
  - Glyceryl trinitrate aerosol spray p. 190 (400 micrograms/metered dose)
    - Sublingually
    - Adult: 1–2 sprays, repeated as required
  - **OR** Glyceryl trinitrate tablets p. 190 (300 micrograms, 500 micrograms, 600 micrograms)
    - Sublingually
    - Adult: 0.3–1 mg, repeated as required

- **METOCLOPRAMIDE HYDROCHLORIDE INJECTION p. 347 (5 mg/mL)**
  - By intravenous injection
    - Adult (under 60 kg) 18-19 years: 5 mg
    - Adult (over 60 kg) 18-19 years: 10 mg
    - Adult over 19 years: 10 mg

- **DIAMORPHINE HYDROCHLORIDE INJECTION p. 361 (5 mg powder for reconstitution)**
  - By slow intravenous injection (1-2 mg/minute)
    - Adult: 5 mg followed by a further 2.5–5 mg if necessary
    - Elderly or frail patients: reduce dose by half

- **MORPHINE SULPHATE INJECTION p. 367 (10 mg/mL)**
  - By slow intravenous injection (1-2 mg/minute)
    - Adult: 5–10 mg followed by a further 5–10 mg if necessary
    - Elderly or frail patients: reduce dose by half

- **OXYGEN**, if appropriate

Airways disease, obstructive

- **ASTHMA: ACUTE**
  - Regard each emergency consultation as being for severe acute asthma until shown otherwise; failure to respond adequately at any time requires immediate transfer to hospital

- **EITHER** Salbutamol aerosol inhaler p. 222 (100 micrograms/metered inhalation)
  - By aerosol inhalation via large-volume spacer (and a close-fitting face mask if child under 3 years)
    - Adult and child: 2–10 puffs each inhaled separately, repeated every 10–20 minutes or as necessary

- **OR** Salbutamol nebuliser solution p. 222 (1 mg/mL, 2 mg/mL)
  - By inhalation of nebulised solution (via oxygen-driven nebuliser if available)
    - Child 4 years and below: 2.5 mg every 20–30 minutes or as necessary
    - Child 5-11 years: 2.5–5 mg every 20–30 minutes or as necessary
    - Child 12-17 years: 5 mg every 20–30 minutes or as necessary
    - Adult: 5 mg every 20–30 minutes or as necessary

- **OR** Terbutaline sulfate nebuliser solution p. 225 (2.5 mg/mL)
  - By inhalation of nebulised solution (via oxygen-driven nebuliser if available)
    - Child 4 years and below: 5 mg every 20–30 minutes or as necessary
    - Child 5-11 years: 5–10 mg every 20–30 minutes or as necessary
    - Child 12-17 years: 10 mg every 20–30 minutes or as necessary
    - Adult: 10 mg every 20–30 minutes or as necessary

- **PLUS (in all cases)**
  - **EITHER** Prednisolone tablets p. 585 (or prednisolone soluble tablets) (5 mg)
    - By mouth
      - Child 11 years and below: 1–2 mg/kg (max. 40 mg) once daily for up to 3 days or longer if necessary; if child has been taking an oral corticosteroid for more than a few days, give prednisolone 2 mg/kg (max. 60 mg) once daily
      - Child 12-17 years: 40–50 mg once daily for at least 5 days
      - Adult: 40–50 mg once daily for at least 5 days
  - **OR** Hydrocortisone (preferably as sodium succinate) p. 583
    - By intravenous injection
      - Child 17 years and below: 4 mg/kg (max. 100 mg) every 6 hours until conversion to oral prednisolone is possible; alternative dose if weight unavailable:
        - Child 1 year and below: 25 mg
        - Child 2-4 years: 50 mg
        - Child 5-17 years: 100 mg
      - Adult: 100 mg every 6 hours until conversion to oral prednisolone is possible

  - High-flow oxygen should be given if available (via face mask in children)

  - Monitor response 15 to 30 minutes after nebulisation; if any signs of acute asthma persist, arrange hospital admission. While awaiting ambulance, repeat nebulised beta, agonist (as above) and give with

  - Ipratropium bromide nebuliser solution p. 217 (250 micrograms/mL)
    - By inhalation of nebulised solution (via oxygen-driven nebuliser if available)
      - Child 11 years and below: 250 micrograms, repeated every 20–30 minutes for the first 2 hours, then every 4–6 hours as necessary
      - Child 12-17 years: 500 micrograms every 4–6 hours as necessary
      - Adult: 500 micrograms every 4–6 hours as necessary
CROUP
Dexamethasone oral solution p. 581 (2 mg/5 mL)
BY MOUTH
» Child 1 month-2 years: 150 micrograms/kg as a single dose

Anaphylaxis

Adrenaline/epinephrine injection p. 196 (1 mg/mL (1 in 1000))
BY INTRAMUSCULAR INJECTION
» Child 5 years and below: 150 micrograms (0.15 mL), repeated every 5 minutes if necessary
» Child 6-11 years: 300 micrograms (0.3 mL), repeated every 5 minutes if necessary
» Child 12-17 years: 500 micrograms (0.5 mL), repeated every 5 minutes if necessary; 300 micrograms (0.3 mL) should be given if child is small or prepubertal
» Adult: 500 micrograms (0.5 mL), repeated every 5 minutes if necessary

High-flow oxygen and intravenous fluids should be given as soon as available.

Chlorphenamine maleate injection p. 245
BY INTRAMUSCULAR OR INTRAVENOUS INJECTION may help counter histamine-mediated vasodilation and bronchoconstriction.

Hydrocortisone (preferably as sodium succinate) p. 583
BY INTRAVENOUS INJECTION has delayed action but should be given to severely affected patients to prevent further deterioration.

Bacterial infection

Meningococcal disease
Benzy1penicillin sodium injection p. 480 (600 mg, 1.2 g)
BY INTRAVENOUS INJECTION (OR BY INTRAMUSCULAR INJECTION IF VENOUS ACCESS NOT AVAILABLE)
» Neonate: 300 mg
» Child 1 month-11 months: 300 mg
» Child 1-9 years: 600 mg
» Child 10-17 years: 1.2 g
» Adult: 1.2 g
Note A single dose should be given before urgent transfer to hospital, so long as this does not delay the transfer.

OR if history of allergy to penicillin

Cefotaxime injection p. 457 (1 g)
BY INTRAVENOUS INJECTION (OR BY INTRAMUSCULAR INJECTION IF VENOUS ACCESS NOT AVAILABLE)
» Neonate: 50 mg/kg
» Child 1 month-11 years: 50 mg/kg (max. 1 g)
» Child 12-17 years: 1 g
» Adult: 1 g
Note A single dose can be given before urgent transfer to hospital, so long as this does not delay the transfer.

OR if history of immediate hypersensitivity reaction (including anaphylaxis, angioedema, urticaria, or rash immediately after administration) to penicillin or to cephalosporins

Chloramphenicol injection p. 452 (1 g)
BY INTRAVENOUS INJECTION
» Child 1 month-17 years: 12.5–25 mg/kg
» Adult: 12.5–25 mg/kg
Note A single dose can be given before urgent transfer to hospital, so long as this does not delay the transfer.

See also Central nervous system infections, bacterial p. 444

Hypoglycaemia

Diabetic hypoglycaemia
Glucose or sucrose
BY MOUTH
» Adult and child over 2 years: approx. 10–20 g (55–110 mL
Lucozade® Energy Original or 100–200 mL Coca-Cola®—both non-diet versions or 2–4 teaspoonfuls of sugar or 3–6 sugar lumps) repeated after 10–15 minutes if necessary

OR if hypoglycaemia unresponsive or if oral route cannot be used
Glucagon injection p. 618 (1 mg/mL)
BY SUBCUTANEOUS OR INTRAMUSCULAR INJECTION
» Child body-weight under 25 kg: 500 micrograms (0.5 mL)
» Child body-weight over 25 kg: 1 mg (1 mL)
» Adult: 1 mg (1 mL)

OR if hypoglycaemia prolonged or unresponsive to glucagon after 10 minutes
Glucose intravenous infusion p. 852 (10%)
BY INTRAVENOUS INJECTION INTO LARGE VEIN
» Child 1 month-17 years: 5 mL/kg (glucose 500 mg/kg)

Glucose intravenous infusion p. 852 (20%)
BY INTRAVENOUS INJECTION INTO LARGE VEIN
» Adult: 50 mL

Seizures

Convulsive (including febrile) seizures lasting longer than 5 minutes

Either Diazepam rectal solution p. 267 (2 mg/mL, 4 mg/mL) BY RECTUM
» Neonate: 1.25–2.5 mg, repeated once after 10–15 minutes if necessary
» Child 1 month-1 years: 5 mg, repeated once after 10–15 minutes if necessary
» Child 2-11 years: 5–10 mg, repeated once after 10–15 minutes if necessary
» Child 12-17 years: 10–20 mg, repeated once after 10–15 minutes if necessary
» Adult: 10–20 mg, repeated once after 10–15 minutes if necessary
» Elderly 65 years and over: 10 mg, repeated once after 10–15 minutes if necessary

OR Midazolam oromucosal solution p. 414
BY BUCCAL ADMINISTRATION, REPEATED EVERY 5 MINUTES IF NECESSARY
» Neonate: 300 micrograms/kg [unlicensed]
» Child 1-2 months: 300 micrograms/kg (max. 2.5 mg) [unlicensed]
» Child 3 months-11 months: 2.5 mg
» Child 1-4 years: 5 mg
» Child 5-9 years: 7.5 mg
» Child 10-17 years: 10 mg
» Adult: 10 mg [unlicensed]

See also Central nervous system infections, bacterial p. 444
Approximate Conversions and Units

### Conversion of pounds to kilograms

<table>
<thead>
<tr>
<th>lb</th>
<th>kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.45</td>
</tr>
<tr>
<td>2</td>
<td>0.91</td>
</tr>
<tr>
<td>3</td>
<td>1.36</td>
</tr>
<tr>
<td>4</td>
<td>1.81</td>
</tr>
<tr>
<td>5</td>
<td>2.27</td>
</tr>
<tr>
<td>6</td>
<td>2.72</td>
</tr>
<tr>
<td>7</td>
<td>3.18</td>
</tr>
<tr>
<td>8</td>
<td>3.63</td>
</tr>
<tr>
<td>9</td>
<td>4.08</td>
</tr>
<tr>
<td>10</td>
<td>4.54</td>
</tr>
<tr>
<td>11</td>
<td>4.99</td>
</tr>
<tr>
<td>12</td>
<td>5.44</td>
</tr>
<tr>
<td>13</td>
<td>5.90</td>
</tr>
<tr>
<td>14</td>
<td>6.35</td>
</tr>
</tbody>
</table>

### Conversion of stones to kilograms

<table>
<thead>
<tr>
<th>stones</th>
<th>kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.35</td>
</tr>
<tr>
<td>2</td>
<td>12.70</td>
</tr>
<tr>
<td>3</td>
<td>19.05</td>
</tr>
<tr>
<td>4</td>
<td>25.40</td>
</tr>
<tr>
<td>5</td>
<td>31.75</td>
</tr>
<tr>
<td>6</td>
<td>38.10</td>
</tr>
<tr>
<td>7</td>
<td>44.45</td>
</tr>
<tr>
<td>8</td>
<td>50.80</td>
</tr>
<tr>
<td>9</td>
<td>57.15</td>
</tr>
<tr>
<td>10</td>
<td>63.50</td>
</tr>
<tr>
<td>11</td>
<td>69.85</td>
</tr>
<tr>
<td>12</td>
<td>76.20</td>
</tr>
<tr>
<td>13</td>
<td>82.55</td>
</tr>
<tr>
<td>14</td>
<td>88.90</td>
</tr>
<tr>
<td>15</td>
<td>95.25</td>
</tr>
</tbody>
</table>

### Conversion from millilitres to fluid ounces

<table>
<thead>
<tr>
<th>mL</th>
<th>fl oz</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>1.8</td>
</tr>
<tr>
<td>100</td>
<td>3.5</td>
</tr>
<tr>
<td>150</td>
<td>5.3</td>
</tr>
<tr>
<td>200</td>
<td>7.0</td>
</tr>
<tr>
<td>500</td>
<td>17.6</td>
</tr>
<tr>
<td>1000</td>
<td>35.2</td>
</tr>
</tbody>
</table>

### Mass

- 1 kilogram (kg) = 1000 grams (g)
- 1 gram (g) = 1000 milligrams (mg)
- 1 milligram (mg) = 1000 micrograms
- 1 microgram = 1000 nanograms
- 1 nanogram = 1000 picograms

### Volume

- 1 litre (L) = 1000 millilitres (mL)
- 1 millilitre (1 mL) = 1000 microlitres

### Other units

- 1 kilocalorie (kcal) = 4186.8 joules (J)
- 1000 kilocalories (kcal) = 4,186.8 megajoules (MJ)
- 1 megajoule (MJ) = 238.8 kilocalories (kcal)
- 1 millimetre of mercury (mmHg) = 133.3 pascals (Pa)
- 1 kilopascal (kPa) = 7.5 mmHg (pressure)

### Plasma-drug concentrations

Plasma-drug concentrations in BNF publications are expressed in mass units per litre (e.g. mg/litre). The approximate equivalent in terms of amount of substance units (e.g. micromol/litre) is given in brackets.

### Prescribing for children: weight, height, and gender

The table below shows the mean values for weight, height, and gender by age; these values have been derived from the UK-WHO growth charts 2009 and UK1990 standard centile charts, by extrapolating the 50th centile, and may be used to calculate doses in the absence of measurements. However, an individual’s weight and height might vary considerably from the values in the table and it is important to ensure that the value chosen is appropriate. In most cases the actual measurement should be obtained as soon as possible and the dose re-calculated.

<table>
<thead>
<tr>
<th>Age</th>
<th>Weight (kg)</th>
<th>Height (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-term neonate</td>
<td>3.5</td>
<td>51</td>
</tr>
<tr>
<td>1 month</td>
<td>4.3</td>
<td>55</td>
</tr>
<tr>
<td>2 months</td>
<td>5.4</td>
<td>58</td>
</tr>
<tr>
<td>3 months</td>
<td>6.1</td>
<td>61</td>
</tr>
<tr>
<td>4 months</td>
<td>6.7</td>
<td>63</td>
</tr>
<tr>
<td>6 months</td>
<td>7.6</td>
<td>67</td>
</tr>
<tr>
<td>1 year</td>
<td>9</td>
<td>75</td>
</tr>
<tr>
<td>3 years</td>
<td>14</td>
<td>96</td>
</tr>
<tr>
<td>5 years</td>
<td>18</td>
<td>109</td>
</tr>
<tr>
<td>7 years</td>
<td>23</td>
<td>122</td>
</tr>
<tr>
<td>10 years</td>
<td>32</td>
<td>138</td>
</tr>
<tr>
<td>12 years</td>
<td>39</td>
<td>149</td>
</tr>
<tr>
<td>14 year-old boy</td>
<td>49</td>
<td>163</td>
</tr>
<tr>
<td>14 year-old girl</td>
<td>50</td>
<td>159</td>
</tr>
<tr>
<td>Adult male</td>
<td>68</td>
<td>176</td>
</tr>
<tr>
<td>Adult female</td>
<td>58</td>
<td>164</td>
</tr>
</tbody>
</table>

### Length

- 1 metre (m) = 1000 millimetres (mm)
- 1 centimetre (cm) = 10 mm
- 1 inch (in) = 25.4 mm
- 1 foot (ft) = 12 inches
- 12 inches = 304.8 mm
Recommended wording of cautionary and advisory labels

For details please see p. 1291

1. Warning: This medicine may make you sleepy
2. Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines.
3. Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines.
4. Warning: Do not drink alcohol
5. Do not take indigestion remedies 2 hours before or after you take this medicine
6. Do not take indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine
7. Do not take milk, indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine
8. Warning: Do not stop taking this medicine unless your doctor tells you to stop
9. Space the doses evenly throughout the day. Keep taking this medicine until the course is finished, unless you are told to stop
10. Warning: Read the additional information given with this medicine
11. Protect your skin from sunlight—even on a bright but cloudy day. Do not use sunbeds
12. Do not take anything containing aspirin while taking this medicine
13. Dissolve or mix with water before taking
14. This medicine may colour your urine. This is harmless
15. Caution: flammable. Keep your body away from fire or flames after you have put on the medicine
16. Dissolve the tablet under your tongue—do not swallow.
   Store the tablets in this bottle with the cap tightly closed.
   Get a new supply 8 weeks after opening
17. Do not take more than... in 24 hours
18. Do not take more than... in 24 hours. Also, do not take more than... in any one week
19. Warning: This medicine makes you sleepy. If you still feel sleepy the next day, do not drive or use tools or machines.
   Do not drink alcohol
21. Take with or just after food, or a meal
22. Take 30 to 60 minutes before food
23. Take this medicine when your stomach is empty. This means an hour before food or 2 hours after food
24. Suck or chew this medicine
25. Swallow this medicine whole. Do not chew or crush
26. Dissolve this medicine under your tongue
27. Take with a full glass of water
28. Spread thinly on the affected skin only
29. Do not take more than 2 at any one time. Do not take more than 8 in 24 hours
30. Contains paracetamol. Do not take anything else containing paracetamol while taking this medicine. Talk to a doctor at once if you take too much of this medicine, even if you feel well
32. Contains aspirin. Do not take anything else containing aspirin while taking this medicine
Abbreviations and Symbols

Internationally recognised units and symbols are used in the BNF publications where possible.

ACBBS Advisory Committee on Borderline Substances, see Borderline Substances
ACE Angiotensin-converting enzyme
ADHD Attention deficit hyperactivity disorder
AIDS Acquired immunodeficiency syndrome
approx. approximately
AV atrioventricular
BAN British Approved Name
BMI body mass index
BP British Pharmacopoeia 2013, unless otherwise stated
BPC British Pharmaceutical Codex 1973 and Supplement 1976, unless otherwise stated
CAPD Continuous ambulatory peritoneal dialysis
CD1 preparation in Schedule 1 of the Misuse of Drugs Regulations 2001 (and subsequent amendments). For regulations see Controlled drugs and drug dependence p. 7.
CD2 preparation in Schedule 2 of the Misuse of Drugs Regulations 2001 (and subsequent amendments). For regulations see Controlled drugs and drug dependence p. 7.
CD3 preparation in Schedule 3 of the Misuse of Drugs Regulations 2001 (and subsequent amendments). For regulations see Controlled drugs and drug dependence p. 7.
CD4-1 preparation in Schedule 4 (Part I) of the Misuse of Drugs Regulations 2001 (and subsequent amendments). For regulations see Controlled drugs and drug dependence p. 7.
CD4-2 preparation in Schedule 4 (Part II) of the Misuse of Drugs Regulations 2001 (and subsequent amendments). For regulations see Controlled drugs and drug dependence p. 7.
CHM Commission on Human Medicines
CHMP Committee for Medicinal Products for Human Use
CNS central nervous system
CSM Committee on Safety of Medicines (now subsumed under Commission on Human Medicines)
d. c. direct current
DMARD Disease-modifying antirheumatic drug
DPF Dental Practitioners’ Formulary
e/c enteric-coated (term gastro-resistant in BP)
ECG electrocardiogram
EEG electro-encephalogram
eGFR estimated glomerular filtration rate, see Prescribing in renal impairment p. 17
f/c film-coated
G6PD glucose 6-phosphate dehydrogenase
HIV Human immunodeficiency virus
HRT Hormone replacement therapy
i/m intramuscular
i/v intravenous
INR international normalised ratio
MAOI Monoamine-oxidase inhibitor
max. maximum
MHRA Medicines and Healthcare products Regulatory Agency
modified-release
NCL no cautionary labels, see Guidance for cautionary and advisory labels Appendix 3
NHS National Health Service
NMP not prescribable under National Health Service (NHS) treatment
NICE National Institute for Health and Care Excellence
NPF Nurse Prescribers’ Formulary
NSAID Non-steroidal anti-inflammatory drug
NSTEMI non-ST-segment elevation myocardial infarction
PGD patient group direction
PHE Public Health England (formerly Health Protection Agency (HPA))

The following is a list of appropriate abbreviations. It should be noted that the English version is not always an exact translation.

a. c. = ante cibum (before food)
b. d. = bis die (twice daily)
o. d. = omni die (every day)
o. m. = omni mane (every morning)
o. n. = omni nocte (every night)
p. c. = post cibum (after food)
p. r. n. = pro re nata (when required)
q. d. s. = quater die sumendum (to be taken four times daily)
q. q. h. = quarta quaque hora (every four hours)
stat. = immediately
t. d. s. = ter die sumendum (to be taken three times daily)
t. i. d. = in die (three times daily)

E numbers

The following is a list of common E numbers and the inactive ingredients to which they correspond.

E102 Tartrazine
E211 Sodium Benzoate
E104 Quinoline Yellow
E223 Sodium Metabisulphite
E110 Sunset Yellow FCF
E320 Butylated Hydroxyanisole
E123 Amaranth
E321 Butylated Hydroxytoluene
E124ponceau 4R
E322 Lecithins
E127 Erythrosine BS
E420 Sorbitol
E132 Indigo Carmine
E421 Mannitol
E142 Green S
E422 Glycerol
E171 Titanium Dioxide
E901 Beeswax (white and yellow)
E172 Iron oxides, iron hydroxides
E1520 Propylene Glycol
E200 Sorbic Acid

Latin abbreviations

Directions should be in English without abbreviation. However, Latin abbreviations have been used when prescribing.

The following is a list of appropriate abbreviations. It should be noted that the English version is not always an exact translation.

s/c sugar-coated
SLS Selected List Scheme
SMC Scottish Medicines Consortium
SPC Summary of Product Characteristics
spp. species
SSRI Selective serotonin reuptake inhibitor
STEMI ST-segment elevation myocardial infarction
UK United Kingdom
Units for SI units see Prescription writing p. 4
WHO World Health Organization

limited experience of the use of this product and the MHRA requests that all suspected adverse reactions should be reported, see Adverse reactions to drugs p. 11
GSL general sales list
F pharmacy only medicine